<SEC-DOCUMENT>0000078003-20-000014.txt : 20200227
<SEC-HEADER>0000078003-20-000014.hdr.sgml : 20200227
<ACCEPTANCE-DATETIME>20200227141512
ACCESSION NUMBER:		0000078003-20-000014
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		223
CONFORMED PERIOD OF REPORT:	20191231
FILED AS OF DATE:		20200227
DATE AS OF CHANGE:		20200227

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PFIZER INC
		CENTRAL INDEX KEY:			0000078003
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				135315170
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-03619
		FILM NUMBER:		20660897

	BUSINESS ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017
		BUSINESS PHONE:		2125732323

	MAIL ADDRESS:	
		STREET 1:		235 E 42ND ST
		CITY:			NEW YORK
		STATE:			NY
		ZIP:			10017

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	PFIZER CHARLES & CO INC
		DATE OF NAME CHANGE:	19710908
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>pfe-12312019x10kshell.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:50401aaac9ea4bc98e3dd1226080ffa1,x:e20175334ceb41ffbd73f8b83fd01f02-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:pfe="http://www.pfizer.com/20191231" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Document</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:AmendmentFlag" id="Fact-2B657D43D8938771F232801F7F5CD86D-wk-Fact-2B657D43D8938771F232801F7F5CD86D" format="ixt:booleanfalse">false</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:CurrentFiscalYearEndDate" id="Fact-FDAD72B0C6D4E294BFE4801F7F5E799B-wk-Fact-FDAD72B0C6D4E294BFE4801F7F5E799B">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalPeriodFocus" id="Fact-0AF5AB95C5E316F58D8A801F7F4CEA86-wk-Fact-0AF5AB95C5E316F58D8A801F7F4CEA86">FY</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentFiscalYearFocus" id="Fact-3EDCF98D3543816108FA801F7F5D9A85-wk-Fact-3EDCF98D3543816108FA801F7F5D9A85">2019</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:EntityCentralIndexKey" id="Fact-A9C087689D4F948E379E801F7F5D9FC6-wk-Fact-A9C087689D4F948E379E801F7F5D9FC6">0000078003</ix:nonNumeric><ix:nonFraction decimals="-8" unitRef="usd" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TopNineProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" name="pfe:ConcentrationRiskAmount" id="Fact-08663DB808564A9164DF801F7EFCD207-wk-Fact-08663DB808564A9164DF801F7EFCD207">1000000000</ix:nonFraction><ix:nonFraction decimals="-8" unitRef="usd" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TopTenProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" name="pfe:ConcentrationRiskAmount" id="Fact-33192B704B3D1FC9AC37801F7EFDC507-wk-Fact-33192B704B3D1FC9AC37801F7EFDC507">1000000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="Country" contextRef="FI2017Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" name="pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries" id="Fact-07B7861ECCCF49CF9868D91F8AA0B6BC-wk-Fact-07B7861ECCCF49CF9868D91F8AA0B6BC">11</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="Country" contextRef="FI2018Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" name="pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries" id="Fact-2FD12D144CF5F0BCA9F0801F7EA63D72-wk-Fact-2FD12D144CF5F0BCA9F0801F7EA63D72">11</ix:nonFraction><ix:nonNumeric contextRef="D2017Q2Jun01-Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-CE9D7C462BF5775EE0E60172459C0EFD-wk-Fact-CE9D7C462BF5775EE0E60172459C0EFD">P9Y</ix:nonNumeric><ix:nonNumeric contextRef="D2017Q3Aug01-Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-B34FA96F5D29BF16F8E90171DB2837FD-wk-Fact-B34FA96F5D29BF16F8E90171DB2837FD">P9Y</ix:nonNumeric><ix:nonNumeric contextRef="D2017Q4Dec01-Dec31_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-5B2E909BB7EB119FE74D01700E6A1601-wk-Fact-5B2E909BB7EB119FE74D01700E6A1601">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="D2018Q2Apr01-Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-25869237F7D2F57A1A0C0C106D287EAC-wk-Fact-25869237F7D2F57A1A0C0C106D287EAC">P10Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BesponsaMember" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-18AC9D0320158F920D920CBB1E7659E2-wk-Fact-18AC9D0320158F920D920CBB1E7659E2">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" id="Fact-865416170C3E90E5A5220CBB38A610BB-wk-Fact-865416170C3E90E5A5220CBB38A610BB">P8Y</ix:nonNumeric><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" id="Fact-F05521051C8C3FD2AFED801F7EE47945-wk-Fact-F05521051C8C3FD2AFED801F7EE47945">1</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" id="Fact-23D45D4F9652521A040F801F7EE0019B-wk-Fact-23D45D4F9652521A040F801F7EE0019B">3</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" id="Fact-63DC8ECD22B4D3148FFF801F7EE1EF8F-wk-Fact-63DC8ECD22B4D3148FFF801F7EE1EF8F">1</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" id="Fact-360680CD5A0D33FD8939801F7EE0D449-wk-Fact-360680CD5A0D33FD8939801F7EE0D449">3</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod" id="Fact-0B400448D25558A313A71217CF67418B-wk-Fact-0B400448D25558A313A71217CF67418B">P1Y</ix:nonNumeric><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-DBA38F5FA084593399643607C04AC75E-wk-Fact-DBA38F5FA084593399643607C04AC75E">541000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent" id="Fact-07091715647256CDB4AD8057DCE577E8-wk-Fact-07091715647256CDB4AD8057DCE577E8">527000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2018Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-B0ADFA04558E26682149801F804BAD07-wk-Fact-B0ADFA04558E26682149801F804BAD07">0.05</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usdPerShare" contextRef="FI2019Q4" name="us-gaap:CommonStockParOrStatedValuePerShare" id="Fact-37E466B377E093574704801F823ADEB7-wk-Fact-37E466B377E093574704801F823ADEB7">0.05</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-516E2DBFF137FF395442801F824C52D5-wk-Fact-516E2DBFF137FF395442801F824C52D5">12000000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesAuthorized" id="Fact-00B42AB6C63D4D47D995801F8250336C-wk-Fact-00B42AB6C63D4D47D995801F8250336C">12000000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-9426C78F4864E19099BE801F824ECFDE-wk-Fact-9426C78F4864E19099BE801F824ECFDE">9332000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:CommonStockSharesIssued" id="Fact-43A568A1B2F110213B88801F806FD23A-wk-Fact-43A568A1B2F110213B88801F806FD23A">9369000000</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" name="us-gaap:ConcentrationRiskPercentage1" id="Fact-2D6BDB639B30D9971A39801F7EC66802-wk-Fact-2D6BDB639B30D9971A39801F7EC66802">0.08</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" name="us-gaap:ConcentrationRiskPercentage1" id="Fact-A8F6BC46C9DE51BCA5D7801F7EEA5272-wk-Fact-A8F6BC46C9DE51BCA5D7801F7EEA5272">0.1</ix:nonFraction><ix:nonFraction decimals="2" unitRef="number" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" name="us-gaap:ConcentrationRiskPercentage1" id="Fact-FA8C73E73D60150B05E2801F7EC90777-wk-Fact-FA8C73E73D60150B05E2801F7EC90777">0.08</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" name="us-gaap:ConcentrationRiskPercentage1" id="Fact-2B0B9AC8F3B089659683801F7EEB5D61-wk-Fact-2B0B9AC8F3B089659683801F7EEB5D61">0.1</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="usd" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentFaceAmount" id="Fact-502EBE080DE28256D76B801F7E07D4E4-wk-Fact-502EBE080DE28256D76B801F7E07D4E4">1800000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-63A97B54CDA8AA2AC3A8801F7E06374A-wk-Fact-63A97B54CDA8AA2AC3A8801F7E06374A">0.02735</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-7501CCEC7B4D0192DEEF801F81E84FD3-wk-Fact-7501CCEC7B4D0192DEEF801F81E84FD3">0.04</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-2CBB41D064359126314C801F82CC8933-wk-Fact-2CBB41D064359126314C801F82CC8933">0.0345</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-DF805AE36913A86A1B9C801F81E89568-wk-Fact-DF805AE36913A86A1B9C801F81E89568">0.039</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-38352E73A1AC3A38585F801F81E7E0C5-wk-Fact-38352E73A1AC3A38585F801F81E7E0C5">0.028</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" id="Fact-666BF4CEF70690419B91801F81E7FF4C-wk-Fact-666BF4CEF70690419B91801F81E7FF4C">0.0295</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-EF7AF87778B8BF220999801F81CDFFA1-wk-Fact-EF7AF87778B8BF220999801F81CDFFA1">0.034</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-871845D615D6741D412B801F81BA2DA1-wk-Fact-871845D615D6741D412B801F81BA2DA1">0.003</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-71B06D495A3D578308EE801F81CC9DA9-wk-Fact-71B06D495A3D578308EE801F81CC9DA9">0.038</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-642D5A87658829931DEB801F81C28AD1-wk-Fact-642D5A87658829931DEB801F81C28AD1">0.044</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-38C5A1566BA31025F756801F81C7A7E0-wk-Fact-38C5A1566BA31025F756801F81C7A7E0">0.060</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-F1A4832E4D5F6041A612801F81C06ABC-wk-Fact-F1A4832E4D5F6041A612801F81C06ABC">0.042</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-BE07C1C52CE5A7D41240801F81C8FBE9-wk-Fact-BE07C1C52CE5A7D41240801F81C8FBE9">0.013</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-27232A0FA21D95C62103801F81CD890F-wk-Fact-27232A0FA21D95C62103801F81CD890F">0.007</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-E3F9F325914858818975801F81CDD56D-wk-Fact-E3F9F325914858818975801F81CDD56D">0.010</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-E253864A1112EAD0DDE2801F824B2E5D-wk-Fact-E253864A1112EAD0DDE2801F824B2E5D">0.037</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-56003317C811A762BCE6801F81C691E0-wk-Fact-56003317C811A762BCE6801F81C691E0">0.039</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-B29CF7EA6EBA8F9EB379801F81BD2934-wk-Fact-B29CF7EA6EBA8F9EB379801F81BD2934">0.033</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-81623C201F9DA92074C8801F81CA98F9-wk-Fact-81623C201F9DA92074C8801F81CA98F9">0.065</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-DA12961832EB1C963A31801F81CCCBD2-wk-Fact-DA12961832EB1C963A31801F81CCCBD2">0.058</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-7D484FBD1E68D916F0AF801F81BCEB31-wk-Fact-7D484FBD1E68D916F0AF801F81BCEB31">0.035</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-9297627A69595560275B801F81CC162E-wk-Fact-9297627A69595560275B801F81CC162E">0.041</ix:nonFraction><ix:nonFraction decimals="3" unitRef="number" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" name="us-gaap:DebtWeightedAverageInterestRate" id="Fact-27D7795FCD321467BE07801F81BCD4A5-wk-Fact-27D7795FCD321467BE07801F81BCD4A5">0.012</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-53CB1A49574D5CE257FC801F818882B4-wk-Fact-53CB1A49574D5CE257FC801F818882B4">0.1</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-17913D5BA00FFB4127B5801F80F3DC70-wk-Fact-17913D5BA00FFB4127B5801F80F3DC70">0.10</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-36CFDFF82E0CB7B2841F801F81A7DA64-wk-Fact-36CFDFF82E0CB7B2841F801F81A7DA64">0.05</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-7FCB72B2BDFEFCCC5B37801F81048B8C-wk-Fact-7FCB72B2BDFEFCCC5B37801F81048B8C">0.5500</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-11DD842422E9A0F2A3DE801F8102E0D1-wk-Fact-11DD842422E9A0F2A3DE801F8102E0D1">0.40</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-3C3F9BCACFE22DCF06DA801F810484FE-wk-Fact-3C3F9BCACFE22DCF06DA801F810484FE">0.53</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-0B960140FF9DAC00DD8E801F81887BC6-wk-Fact-0B960140FF9DAC00DD8E801F81887BC6">0.60</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-8F3483B4DE3FA66058B3801F81BA4C9C-wk-Fact-8F3483B4DE3FA66058B3801F81BA4C9C">0.20</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-4C4FEF80804DE4BD33B3801F8194D45A-wk-Fact-4C4FEF80804DE4BD33B3801F8194D45A">0.35</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-C84FC8BF46E630041A72801F81174C9F-wk-Fact-C84FC8BF46E630041A72801F81174C9F">1</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-87C0C6806493E29D6238801F80EE5176-wk-Fact-87C0C6806493E29D6238801F80EE5176">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-D8A598710B92EDB2594A801F80F4F418-wk-Fact-D8A598710B92EDB2594A801F80F4F418">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-93C88483D18B83B0BEE5801F81968492-wk-Fact-93C88483D18B83B0BEE5801F81968492">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-876A47F0039172E0C563801F81B8D5E8-wk-Fact-876A47F0039172E0C563801F81B8D5E8">0.35</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-1D33269243E8BFFC198B801F8110C571-wk-Fact-1D33269243E8BFFC198B801F8110C571">0.20</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-9957215E4BDF713E4784801F80EC4A69-wk-Fact-9957215E4BDF713E4784801F80EC4A69">0.28</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-08DEA385BD5A96B817D2801F80F34999-wk-Fact-08DEA385BD5A96B817D2801F80F34999">0.35</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-149F3B0F304C8FC2DD56801F818A1A56-wk-Fact-149F3B0F304C8FC2DD56801F818A1A56">0.05</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-F9D716E92CB45B192770801F8101D592-wk-Fact-F9D716E92CB45B192770801F8101D592">0.10</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-040F1EC048A6CC10E966801F810641F6-wk-Fact-040F1EC048A6CC10E966801F810641F6">0.95</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-860B3E24E16561D80A9C801F8102C4C5-wk-Fact-860B3E24E16561D80A9C801F8102C4C5">0</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="number" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" id="Fact-65A04078CF26655074A5801F8104D5D8-wk-Fact-65A04078CF26655074A5801F8104D5D8">0</ix:nonFraction><ix:nonFraction decimals="-8" unitRef="usd" contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" name="us-gaap:ExtinguishmentOfDebtAmount" id="Fact-3130505587C151D09D4B801F7E062A88-wk-Fact-3130505587C151D09D4B801F7E062A88">1100000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2018Q4" name="us-gaap:LongTermDebtCurrent" id="Fact-C13CFC3CB21F52099D562C221C465A73-wk-Fact-C13CFC3CB21F52099D562C221C465A73">4776000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="usd" contextRef="FI2019Q4" name="us-gaap:LongTermDebtCurrent" id="Fact-7414237C2DE558C2A570279D3852E356-wk-Fact-7414237C2DE558C2A570279D3852E356">1462000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-B1B9FBB3E65B02DB442A801F8086325E-wk-Fact-B1B9FBB3E65B02DB442A801F8086325E">27000000</ix:nonFraction><ix:nonFraction decimals="INF" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesAuthorized" id="Fact-61D00E77EE76E65E4F9F801F823CCE99-wk-Fact-61D00E77EE76E65E4F9F801F823CCE99">27000000</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-B3981B3D44CB5A0D36C3801F8253C52A-wk-Fact-B3981B3D44CB5A0D36C3801F8253C52A">478</ix:nonFraction><ix:nonFraction decimals="0" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:PreferredStockSharesIssued" id="Fact-9D817CFBE8E27DFE8D7A801F80886593-wk-Fact-9D817CFBE8E27DFE8D7A801F80886593">431</ix:nonFraction><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-F0FEE16982B3DD9280F3801F7E7BB2D3-wk-Fact-F0FEE16982B3DD9280F3801F7E7BB2D3">P50Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-F998F6CFFEA92A32DD15801F7E7A91D9-wk-Fact-F998F6CFFEA92A32DD15801F7E7A91D9">P12Y6M</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-557A5D82EB3A050CC7AE801F7E7BC830-wk-Fact-557A5D82EB3A050CC7AE801F7E7BC830">P20Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-90776A5E9858FF074F59801F7E7A1869-wk-Fact-90776A5E9858FF074F59801F7E7A1869">P33Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-9F29060FFD5AC29F8FC6801F7E78605F-wk-Fact-9F29060FFD5AC29F8FC6801F7E78605F">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="Fact-21E6539C99EA15E24D5B801F7E7A74D8-wk-Fact-21E6539C99EA15E24D5B801F7E7A74D8">P8Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-42A6B4CC4728DCFCF8D71214EEA5550F-wk-Fact-42A6B4CC4728DCFCF8D71214EEA5550F">P5Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Fact-ED5E433E1E4A6F191CB912189D887EDC-wk-Fact-ED5E433E1E4A6F191CB912189D887EDC">P3Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact-4BB44F61DD66844E4DB20CAE9E2A3888-wk-Fact-4BB44F61DD66844E4DB20CAE9E2A3888">P7Y</ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="Fact-EAF0B2177CC3A35A89CC0CAE49EA87B5-wk-Fact-EAF0B2177CC3A35A89CC0CAE49EA87B5">P5Y</ix:nonNumeric><ix:nonFraction decimals="-6" unitRef="shares" contextRef="FI2018Q4" name="us-gaap:TreasuryStockShares" id="Fact-B2C06C2292CD5F05AEAF801F825BDEAA-wk-Fact-B2C06C2292CD5F05AEAF801F825BDEAA">3615000000</ix:nonFraction><ix:nonFraction decimals="-6" unitRef="shares" contextRef="FI2019Q4" name="us-gaap:TreasuryStockShares" id="Fact-BFE1E325EAE23FB57CC7801F82423AA9-wk-Fact-BFE1E325EAE23FB57CC7801F82423AA9">3835000000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:href="pfe-20191231.xsd" xlink:type="simple"></link:schemaRef></ix:references><ix:resources><xbrli:context id="FD2019Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q2">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2020Q1Feb25">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-02-25</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20200.000Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20200.000Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_OncologyVaccinesStartUpMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:OncologyVaccinesStartUpMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelTherapeuticsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_U.K.PoundDenominatedDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:U.K.PoundDenominatedDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Jan01-Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TopTenProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopTenProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-30</xbrli:startDate>
			<xbrli:endDate>2019-07-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-12-22</xbrli:startDate>
			<xbrli:endDate>2016-12-22</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-07-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:AkceaAndIonisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-09-30</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TopEightProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopEightProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_us-gaap_LeaseArrangementTypeAxis_pfe_OfficeBuildingInNewYorkCityMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">pfe:OfficeBuildingInNewYorkCityMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_srt_OwnershipAxis_pfe_UpjohnAndMylanMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:UpjohnAndMylanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jan01-Jul02_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2019-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TopNineProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopNineProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-03</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2020Q2_dei_LegalEntityAxis_pfe_MylanMember_srt_OwnershipAxis_pfe_UpjohnAndMylanMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:MylanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:UpjohnAndMylanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2020-06-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-01</xbrli:startDate>
			<xbrli:endDate>2019-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul31-Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-31</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q4Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-11-10</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-28</xbrli:startDate>
			<xbrli:endDate>2016-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-02</xbrli:startDate>
			<xbrli:endDate>2018-07-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2014Q4QTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-09-29</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BionTechMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q1_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:RPIFinanceTrustMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BainCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-03</xbrli:startDate>
			<xbrli:endDate>2017-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q1Jan2016_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:RPIFinanceTrustMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsDevelopedTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-30</xbrli:startDate>
			<xbrli:endDate>2019-07-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct01-Oct31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2013Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_BalanceSheetLocationAxis_pfe_DeferredRevenueMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredRevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-01-01</xbrli:startDate>
			<xbrli:endDate>2013-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q4Oct31_dei_LegalEntityAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-10-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2014Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CellectisMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CellectisMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Oct06_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-10-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-28</xbrli:startDate>
			<xbrli:endDate>2016-09-28</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BionTechMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-02</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsDevelopedTechnologyMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov10-Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-10</xbrli:startDate>
			<xbrli:endDate>2017-11-10</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BionTechMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-09-30</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:RPIFinanceTrustMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Jan01-Jan31_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2014Q4QTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_pfe_CollaborativeArrangementUpfrontCashPaymentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pfe:CollaborativeArrangementUpfrontCashPaymentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-09-29</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2012Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2012-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-02</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-01-01</xbrli:startDate>
			<xbrli:endDate>2016-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr01-Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-02</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_NeuroscienceAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BainCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:NeuroscienceAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_srt_OwnershipAxis_pfe_CerevelTherapeuticsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:CerevelTherapeuticsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-09-28</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MylanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-22</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Jun30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul31_dei_LegalEntityAxis_pfe_GSKMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_BalanceSheetLocationAxis_pfe_DeferredRevenueMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredRevenueMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2016Q2Apr01-Apr30_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-04-01</xbrli:startDate>
			<xbrli:endDate>2016-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jan1-Jul31_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-07-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-02</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsTechnologyInDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsTechnologyInDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q2_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-07-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr01-Apr30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-02</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-07-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-03</xbrli:startDate>
			<xbrli:endDate>2017-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-09-30</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IncomeStatementLocationAxis_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Nov1-30_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:AkceaAndIonisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-11-01</xbrli:startDate>
			<xbrli:endDate>2019-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-30</xbrli:startDate>
			<xbrli:endDate>2019-07-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-04-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-07-01</xbrli:startDate>
			<xbrli:endDate>2019-09-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Sept-Dec2017_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2016-09-29</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:RPIFinanceTrustMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_OtherActivitiesMember_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:OtherActivitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q2QTD">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_GeneTherapiesMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GeneTherapiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SterileInjectablePainRelieverMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SterileInjectablePainRelieverMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:InnoPharmaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TreatmentForToenailFungusMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TreatmentForToenailFungusMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentMatterMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MultiAntigenVaccineForSpinalFusionSurgeryMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-04-01</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AMPharmaBVMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AMPharmaBVMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TreatmentOfAttentionHyperactivityDisorderMember_us-gaap_BusinessAcquisitionAxis_pfe_NextWaveMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TreatmentOfAttentionHyperactivityDisorderMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:NextWaveMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:InnoPharmaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BainCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenericInjectablePainRelieverMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericInjectablePainRelieverMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CortexymeInc.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_DeferredTaxLiabilitiesNetNoncurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredTaxLiabilitiesNetNoncurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_DeferredTaxLiabilitiesNetNoncurrentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredTaxLiabilitiesNetNoncurrentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_CurrentTaxAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:CurrentTaxAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q2Apr01-Apr30">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-04-01</xbrli:startDate>
			<xbrli:endDate>2019-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_CurrentTaxAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:CurrentTaxAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_pfe_CreditFacilityExpiring2024Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:CreditFacilityExpiring2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_pfe_FacilityExpiringSeptember2020Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:FacilityExpiringSeptember2020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2034Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20262029Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20462049Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2020Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2021Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20362040Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20362040Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20432044Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2034Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20432044Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20262029Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2021Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20462049Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2023Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointEightPercentDue2022Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtThreePointNinePercentDue2039Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtFourPercentDue2049Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-01-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Mar31_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2047Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Mar31_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-03-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-09-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q1QTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q3Aug31_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q3QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-07-02</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-04-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q2Jun30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q2Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-06-30</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q3Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-08-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Jun01-Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-06-01</xbrli:startDate>
			<xbrli:endDate>2017-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec01-Dec31_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Apr01-Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-04-02</xbrli:startDate>
			<xbrli:endDate>2018-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q3Aug01-Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-08-01</xbrli:startDate>
			<xbrli:endDate>2017-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:FinancialServicesSectorMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-03</xbrli:startDate>
			<xbrli:endDate>2017-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-04-03</xbrli:startDate>
			<xbrli:endDate>2017-07-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Jan01">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-01-01</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q4Jun29-Dec31_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-06-29</xbrli:startDate>
			<xbrli:endDate>2020-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_pfe_OpenMarketPurchasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:OpenMarketPurchasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:PreferredEmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-06</xbrli:startDate>
			<xbrli:endDate>2017-02-06</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Feb12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Mar12-Mar12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-12</xbrli:startDate>
			<xbrli:endDate>2018-03-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep07-Sep07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-07</xbrli:startDate>
			<xbrli:endDate>2018-09-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:PreferredEmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-06</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q3Aug05-Aug05_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-08-05</xbrli:startDate>
			<xbrli:endDate>2019-08-05</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2015Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2015StockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2015StockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2015-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Mar12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-12</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Feb07-Feb07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-07</xbrli:startDate>
			<xbrli:endDate>2019-02-07</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Feb02-Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-02</xbrli:startDate>
			<xbrli:endDate>2017-02-02</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:PreferredEmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2017StockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2017StockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Feb12-Feb12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-02-12</xbrli:startDate>
			<xbrli:endDate>2019-02-12</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Mar14-Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-03-14</xbrli:startDate>
			<xbrli:endDate>2018-03-14</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2May19-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-05-19</xbrli:startDate>
			<xbrli:endDate>2017-05-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Feb06-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-06</xbrli:startDate>
			<xbrli:endDate>2017-05-19</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2019Q1Feb07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-02-07</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-02-02</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredESOPPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:PreferredESOPPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2018Q1Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-03-14</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_pfe_OpenMarketPurchasesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:OpenMarketPurchasesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="I2014Q4Oct23-2014">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2014-10-23</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2018StockPurchasePlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2018StockPurchasePlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec29-Dec29_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec29-Dec29_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ManagementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Dec29-Dec29_srt_TitleOfIndividualAxis_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pfe:GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-12-29</xbrli:startDate>
			<xbrli:endDate>2017-12-29</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:DirectorsCompensationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:DirectorsCompensationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:DirectorsCompensationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q4Dec31-31_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusFreseniusKabjUSALLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-12-31</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-02-01</xbrli:startDate>
			<xbrli:endDate>2017-04-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusAmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Nov2017">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-11-01</xbrli:startDate>
			<xbrli:endDate>2017-11-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusAmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Oct01-Oct31_srt_LitigationCaseAxis_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_srt_ProductOrServiceAxis_pfe_DocetaxelMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-10-01</xbrli:startDate>
			<xbrli:endDate>2018-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_EpiPenMember_srt_RangeAxis_srt_MinimumMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusAjantaMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusAjantaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2020Q1Jan1-31_srt_LitigationCaseAxis_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusViwitPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2020-01-01</xbrli:startDate>
			<xbrli:endDate>2020-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2016Q4_srt_ProductOrServiceAxis_pfe_PhenytoinSodiumCapsulesMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_ViolationofAntitrustLawsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PhenytoinSodiumCapsulesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:ViolationofAntitrustLawsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2016-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2013-03-01</xbrli:startDate>
			<xbrli:endDate>2013-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusFreseniusKabjUSALLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2014Q4YTD_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusAmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2014-01-01</xbrli:startDate>
			<xbrli:endDate>2014-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusZydusMember_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-03-01</xbrli:startDate>
			<xbrli:endDate>2017-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q3Sep01-Sep30_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-09-01</xbrli:startDate>
			<xbrli:endDate>2018-09-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q3Aug1-31_srt_LitigationCaseAxis_pfe_HospiraVersusParMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusParMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-08-01</xbrli:startDate>
			<xbrli:endDate>2015-08-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-10-01</xbrli:startDate>
			<xbrli:endDate>2017-10-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusGenericCompaniesMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusGenericCompaniesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-03-01</xbrli:startDate>
			<xbrli:endDate>2019-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q4Dec1-31_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusFreseniusKabjUSALLCMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-12-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q2Jun01-Jun30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-06-01</xbrli:startDate>
			<xbrli:endDate>2018-06-30</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusParMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusParMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-01-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2015-03-01</xbrli:startDate>
			<xbrli:endDate>2015-03-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BesponsaMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XanaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DiflucanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZosynTazocinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZosynTazocinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XanaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DiflucanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DiflucanMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:HISProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:HISProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XanaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:HISProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZosynTazocinMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2019Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2019-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BainCapitalMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2019-01-01</xbrli:startDate>
			<xbrli:endDate>2019-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2017Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2017-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FI2018Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:instant>2018-12-31</xbrli:instant>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2018-01-01</xbrli:startDate>
			<xbrli:endDate>2018-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
		<xbrli:entity>
			<xbrli:identifier scheme="http://www.sec.gov/CIK">0000078003</xbrli:identifier>
			<xbrli:segment>
				<xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
				<xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
			</xbrli:segment>
		</xbrli:entity>
		<xbrli:period>
			<xbrli:startDate>2017-01-01</xbrli:startDate>
			<xbrli:endDate>2017-12-31</xbrli:endDate>
		</xbrli:period>
	</xbrli:context><xbrli:unit id="Accounting_standard">
		<xbrli:measure>pfe:Accounting_standard</xbrli:measure>
	</xbrli:unit><xbrli:unit id="number">
		<xbrli:measure>xbrli:pure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Operating_Segment">
		<xbrli:measure>pfe:Operating_Segment</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usd">
		<xbrli:measure>iso4217:USD</xbrli:measure>
	</xbrli:unit><xbrli:unit id="shares">
		<xbrli:measure>xbrli:shares</xbrli:measure>
	</xbrli:unit><xbrli:unit id="usdPerShare">
		<xbrli:divide>
			<xbrli:unitNumerator>
				<xbrli:measure>iso4217:USD</xbrli:measure>
			</xbrli:unitNumerator>
			<xbrli:unitDenominator>
				<xbrli:measure>xbrli:shares</xbrli:measure>
			</xbrli:unitDenominator>
		</xbrli:divide>
	</xbrli:unit><xbrli:unit id="iso4217_EUR">
		<xbrli:measure>iso4217:EUR</xbrli:measure>
	</xbrli:unit><xbrli:unit id="gbp">
		<xbrli:measure>iso4217:GBP</xbrli:measure>
	</xbrli:unit><xbrli:unit id="pension_plan">
		<xbrli:measure>pfe:pension_plan</xbrli:measure>
	</xbrli:unit><xbrli:unit id="employee_stock_ownership_plan">
		<xbrli:measure>pfe:employee_stock_ownership_plan</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Country">
		<xbrli:measure>pfe:Country</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Defendant">
		<xbrli:measure>pfe:Defendant</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Employee">
		<xbrli:measure>pfe:Employee</xbrli:measure>
	</xbrli:unit><xbrli:unit id="measure">
		<xbrli:measure>pfe:measure</xbrli:measure>
	</xbrli:unit><xbrli:unit id="class_action">
		<xbrli:measure>pfe:class_action</xbrli:measure>
	</xbrli:unit><xbrli:unit id="lawsuit">
		<xbrli:measure>pfe:lawsuit</xbrli:measure>
	</xbrli:unit><xbrli:unit id="trading_day">
		<xbrli:measure>pfe:trading_day</xbrli:measure>
	</xbrli:unit><xbrli:unit id="lagoon">
		<xbrli:measure>pfe:lagoon</xbrli:measure>
	</xbrli:unit><xbrli:unit id="Patent">
		<xbrli:measure>pfe:Patents</xbrli:measure>
	</xbrli:unit><xbrli:unit id="period">
		<xbrli:measure>pfe:period</xbrli:measure>
	</xbrli:unit><xbrli:unit id="manufacturer">
		<xbrli:measure>pfe:manufacturer</xbrli:measure>
	</xbrli:unit><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2168-wk-Fact-0035B9C9DB225A72A990E1262460243C d34523018e1616-wk-Fact-0035B9C9DB225A72A990E1262460243C" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3144-wk-Fact-0065C22DDD425D5EB99735A6E835EC0F" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11445-wk-Fact-00777F633E4D23DFB02C801F81EE6F40" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2442-wk-Fact-00B28A85A0415720B146A31F5401E641" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-00B42AB6C63D4D47D995801F8250336C-wk-Fact-00B42AB6C63D4D47D995801F8250336C" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20421-wk-Fact-00B706497805EC20E4D4801F80E92761" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1609-wk-Fact-00FA4D10D2645A50AEDEE8302484A6D5" toRefs="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1609-wk-Fact-00FA4D10D2645A50AEDEE8302484A6D5" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20893-wk-Fact-01207FB539212ED3CB3B801F810048DB" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e20893-wk-Fact-01207FB539212ED3CB3B801F810048DB" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1718-wk-Fact-01A8C48E01D25B3EAFDAC449EB4857D2" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10438-wk-Fact-0239ED48FEE8F23ED2EC801F81FB9BC5" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9572-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB d34661879e11542-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34523018e2616-wk-Fact-027BA945C36E755C6E0D801F8147CCD2" toRefs="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7487-wk-Fact-02E59B78118A5E36927E6E9D343F80C1" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6203-wk-Fact-0330CAF6E36D229B5BC3801F7E8C2429" toRefs="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9831-wk-Fact-0396A14A962557AD9B92CF1A5FBBC4F5" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6860-wk-Fact-0451479DAEAC08A2B0C5801F820E384C" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e9131-wk-Fact-04675E47A2C7545A8AB05010E81694A0" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63" toRefs="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1604-wk-Fact-0489780C77A658BF8868E1551D1C625D" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1604-wk-Fact-0489780C77A658BF8868E1551D1C625D" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2938-wk-Fact-048CE44A39F6A1095A80801F80E770F3" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11011-wk-Fact-04C938F3AC685E7389C0CF59D2959913" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20222-wk-Fact-050ACDA8F1A6426D3F26801F7FFAD77E" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2696-wk-Fact-05108BE54FE052919D68B32B6466B9DF" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e4513-wk-Fact-0584C0E58CA0A6B96247801F7EC7A79A" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4513-wk-Fact-0584C0E58CA0A6B96247801F7EC7A79A" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2597-wk-Fact-05A1EA23D34141CA08B0801F825F2A0B" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3301-wk-Fact-05D8B303E9C377506BB9801F81963C22" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e12171-wk-Fact-05EFB7BDD97ED86D525A801F8161A33D" toRefs="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1909-wk-Fact-0612C9171BB1563BAA0D97F47098AC20" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5634-wk-Fact-0688D8F87F0B5FFEBC9B4EB51F7A9A52" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e6816-wk-Fact-06AF0A8C537DC59A1463801F827D4A6F" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6816-wk-Fact-06AF0A8C537DC59A1463801F827D4A6F" toRefs="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-07091715647256CDB4AD8057DCE577E8-wk-Fact-07091715647256CDB4AD8057DCE577E8" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3189-wk-Fact-07104F174ED656CF8AABB4441FC28486" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10207-wk-Fact-0746CE99B3EAB2B6BC0D801F8173BC3D" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7228-wk-Fact-075B080714B45D30944D97942F14A858" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2136-wk-Fact-07A3726E8AD3C897B843CF6EF6032DBA" toRefs="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4345-wk-Fact-07AD3C926A5E57D3A3F93B11BDBF155E" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2644-wk-Fact-07EEAB5D75BE5733BBE5DDB62C46DAC9" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7209-wk-Fact-07FAC1C1243E5138A0C37BBBC348368F" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11852-wk-Fact-080B5520FFBB5986BB0E2FAA190C849C" toRefs="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2447-wk-Fact-08237D5DF91153BBBDE19A688EC551B8 d34523018e1950-wk-Fact-08237D5DF91153BBBDE19A688EC551B8" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2861-wk-Fact-084878331CAE5F50893848F4E5725E12" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23067-wk-Fact-084E62D562F5DB1E17D2801F8025171B" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1889-wk-Fact-0861F3F4D28BB35D854E801F80ADCAA4" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1889-wk-Fact-0861F3F4D28BB35D854E801F80ADCAA4" toRefs="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11401-wk-Fact-08FCBF9B923C5EC484E72D471007E0A6" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7635-wk-Fact-09097F7E24E55CE185B3A8241786D001" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2584-wk-Fact-09366D0018503E3621D1801F819C0D25" toRefs="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e3372-wk-Fact-09473C310A80FA565C36801F7F16DCBB d34523018e2550-wk-Fact-09473C310A80FA565C36801F7F16DCBB" toRefs="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3372-wk-Fact-09473C310A80FA565C36801F7F16DCBB d34523018e2550-wk-Fact-09473C310A80FA565C36801F7F16DCBB" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5738-wk-Fact-0951D465F2EAA589DB57801F7EA951E3" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7219-wk-Fact-096BFE17591BD0B2DDDC801F823E3221" toRefs="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4045-wk-Fact-09761C58BD65590B9D0A94898AC11853" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2014-wk-Fact-09785B23D3307BE69A79801F8181F4E8" toRefs="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3227-wk-Fact-098C50B89DAF5EB9A094993C8FEEA183" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34496162e5534-wk-Fact-09A4B51093258130F5FD023AB0BF7398" toRefs="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2185-wk-Fact-09EB80731D7155BD844BFECD417399D3" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e16217-wk-Fact-0A0820F3891084F2D3BC801F822ACC1A" toRefs="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5156-wk-Fact-0A18106D10AC563B54F9801F7F18F45F" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e9112-wk-Fact-0A2EFD43015A58319E9B6A5301E68F22" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2367-wk-Fact-0AA2D540FDE353DF84FFCE6640225D60" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2730-wk-Fact-0ABC054ABD705474B81B86310757E0CC" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3750-wk-Fact-0AFCCC455878510D879042E7F8FF809D" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3143-wk-Fact-0B0BC391D4C7298B505D801F82CD3D11" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5266-wk-Fact-0B2C9A8A17225E17979E8C6A9A7A0472" toRefs="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2489-wk-Fact-0B4B7D09A234587DBD0FEB3766ED94BB" toRefs="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2807-wk-Fact-0B920E93F75F59F63ECE801F80F39A24" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e1988-wk-Fact-0CDCE653A5E45D5BA0F60BE9927B384C" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4356-wk-Fact-0CDEC0D247EB505292D3E60E677BC871" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D" toRefs="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2606-wk-Fact-0CE5B6DDA0365CB096E454B209F9983E" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1992-wk-Fact-0D4501C3F382F4D74FB6801F80B5B5B4" toRefs="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8296-wk-Fact-0D6DA45C2A7C59239CB62D356266BA2F" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4980-wk-Fact-0D7980FB1A19BDA52E10801F8004B06B" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3664-wk-Fact-0DABBE66E4D8805F212A801F7F93FAD2" toRefs="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e4035-wk-Fact-0DC222C12EB155DBBE6BAFA5807A4EE1" toRefs="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2810-wk-Fact-0DCDEA0AFFF95ED982FB39EAA2FBC94A" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22325-wk-Fact-0DD70E539B87F2FB041C801F8112B0EF" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e16318-wk-Fact-0DEFE5C159BAEC795B00801F82386F80" toRefs="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5351-wk-Fact-0DFBEF6B024C671D2CCB801F80B50D92" toRefs="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34523018e2708-wk-Fact-0E154CA77D6B55F38225A9B701605CD5" toRefs="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2139-wk-Fact-0E93D2D6EF205317999004B109639A0A" toRefs="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2139-wk-Fact-0E93D2D6EF205317999004B109639A0A" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2556-wk-Fact-0E9DF21E8B8D568689FB453465570C12" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4461-wk-Fact-0F12AD78F79C5102A8E62FEDCC592E95" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20086-wk-Fact-0F1DB5BD6CE9D70B16BE801F812DE5BC" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3994-wk-Fact-0F2EB7A6D4B3040B6027E3C58F8C7591" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4234-wk-Fact-0F427D37984EF6A14C01801F80833398" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11298-wk-Fact-0F4B80AB484F70EADA00801F822053F3" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1925-wk-Fact-0F5337E2D08EAAB68D68801F80EB1026" toRefs="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1855-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE d34496162e9168-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e1929-wk-Fact-0FFA20352D33594482BE61F2516C104D d34468079e3597-wk-Fact-0FFA20352D33594482BE61F2516C104D" toRefs="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10662-wk-Fact-101EC636E37E5D65C52C801F81EB2366" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4289-wk-Fact-105EFED9824651F6ABA05E9CA04F453B" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3366-wk-Fact-10B388DAE9985C6E9C8A0D8BD38AD150" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2725-wk-Fact-111ED69E468B22889D50801F81BB10E7" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2130-wk-Fact-11293434603BE982F98F801F80B2BCE9" toRefs="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961" toRefs="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11273-wk-Fact-11BAC5EE7A45CC2D5AFAD082FDAA0EF1" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34496162e5476-wk-Fact-1260CCD84F5EAA993014023A45379D65" toRefs="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21293-wk-Fact-12704F96F376D4121D69801F80E15138" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21293-wk-Fact-12704F96F376D4121D69801F80E15138" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7114-wk-Fact-12773FEDE0EF5957B1201377DC9142AE" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22041-wk-Fact-129BCA5EF7E3C4047DF8801F807EBD37" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5748-wk-Fact-12B293ED1A777402AC1F801F7ECA154F" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2135-wk-Fact-13109FFF8177575B8F1774DB9B952255" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4706-wk-Fact-1317FDFBDCC45E05A5F89D304C128317" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2854-wk-Fact-13191F129DFB57EB8DE4693D33017900" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20621-wk-Fact-131B4259055DC4154011801F7E6A5E45" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e8571-wk-Fact-1358C7993E24C71EC31CDE2099C357C1" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8571-wk-Fact-1358C7993E24C71EC31CDE2099C357C1" toRefs="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4329-wk-Fact-1374505693265BF17B2B801F82AB7A82" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e4846-wk-Fact-137CA28F27F7A870C810801F81C79E37" toRefs="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4796-wk-Fact-1381E356C11529474B50801F7FE67AD8" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6920-wk-Fact-13974E7B4E179154410C801F7E5B86C1" toRefs="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5718-wk-Fact-13A50261D17557B8A175FB539D8C549E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3836-wk-Fact-13B8F46793BB5B219C40DD3378500D40" toRefs="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23113-wk-Fact-13C4C66382AC9F3D31ED801F7E1DF337" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23113-wk-Fact-13C4C66382AC9F3D31ED801F7E1DF337" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21111-wk-Fact-13CB94F03E493E18A76F801F8065B591" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8157-wk-Fact-13DACBE475EF4ADD4FF8801F828BECB3" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2663-wk-Fact-13DF08A1DA2702456A68801F7E99FA8D" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22912-wk-Fact-13F5E48EBC5CD653F364801F81489ED5" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e7059-wk-Fact-13FB97E7671458A9E0F4801F7EBCE117" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7059-wk-Fact-13FB97E7671458A9E0F4801F7EBCE117" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2394-wk-Fact-13FBCE16090D77486260801F80AF4E2A" toRefs="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2115-wk-Fact-142A53BD92AA56EB8F30C720D04947B1" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e7082-wk-Fact-1431F69E27412BDBF397801F7E6A58E6" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e7082-wk-Fact-1431F69E27412BDBF397801F7E6A58E6" toRefs="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9870-wk-Fact-14994130FABC5D73BECDDC06FF0B8749" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5195-wk-Fact-14ADBD55BE745ADEBD77EA9D5312ED22" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5195-wk-Fact-14ADBD55BE745ADEBD77EA9D5312ED22" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e6835-wk-Fact-14B110795751DD5A5119801F7E469842" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6835-wk-Fact-14B110795751DD5A5119801F7E469842" toRefs="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2462-wk-Fact-14F1C2A6A168BD044F0E801F802AA8F2" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6215-wk-Fact-14FD69433DA24328385A801F7DF3375A" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e8057-wk-Fact-150B8237E6AC43FC08DF801F7E45E25C" toRefs="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2215-wk-Fact-1526F7310FFB6F8E8B4BCB2DE56B079F" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4190-wk-Fact-154E2A860FA2D40C9895801F828D41CB" toRefs="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e3767-wk-Fact-1561A8609FA608E10A98801F80706999" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3767-wk-Fact-1561A8609FA608E10A98801F80706999" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2816-wk-Fact-1579B10788C733E8AAC8801F828B55EB" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3080-wk-Fact-158D3A6B6505E95558B1801F81DBB22C" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5793-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7 d34545404e5968-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10643-wk-Fact-15BADC559EFA5E2148B7801F8234494C" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1672-wk-Fact-15E210D3DD0D5FB08B54D80504EBC060" toRefs="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1672-wk-Fact-15E210D3DD0D5FB08B54D80504EBC060" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3139-wk-Fact-1607AE44D7025E1EB5295964DC39F488" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8450-wk-Fact-1618790FEEDB5D8FA14CCFA4F0B219DF" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20543-wk-Fact-162134FF808D683214CB801F80F133F9" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2944-wk-Fact-1645F7BA211F13D895DB801F821CDBB9 d34661879e9809-wk-Fact-1645F7BA211F13D895DB801F821CDBB9" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3158-wk-Fact-166D37DCD0615EB59DA9AF177DA4F7E9" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22524-wk-Fact-16D5C33B23D96F298EA6801F7E18070A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5445-wk-Fact-16DA44395D73061538E3801F81E5A68D" toRefs="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e1976-wk-Fact-1720732DC86856B0BBAA3408390B34EC" toRefs="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21131-wk-Fact-1784E446F9B0340EF1E7801F80F5F65A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1905-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962 d34501946e4265-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962" toRefs="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e1905-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962 d34501946e4265-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962" toRefs="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2155-wk-Fact-17A18791930ECAD2DCEB801F82A24FA8" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10393-wk-Fact-1855B6419A7F5D4AE722801F81FE1A9A" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11234-wk-Fact-1869D81D977F534390770DD20D262AB7" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2747-wk-Fact-1878ED88AD3662670B3D801F82BFC1A3" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1737-wk-Fact-1879B130A48A521A91B25AA7A433481D" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e1626-wk-Fact-18A55E3A510C5C5B3112801F7ED70A08" toRefs="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11052-wk-Fact-18D66D9FD2EF5E4071F3801F820F2C81" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e2109-wk-Fact-18D776DBF49C5BD0821AEAF95ADFD3B6" toRefs="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3857-wk-Fact-18E37EACB23652878A34A31EF09685A7" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e3857-wk-Fact-18E37EACB23652878A34A31EF09685A7" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3944-wk-Fact-190D7B7514575574AE1769D904D6CA82" toRefs="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4615-wk-Fact-192DA984185DD0ED8BF0801F803D17EF" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2213-wk-Fact-19548AB61F0E5995A6CDA20B4FE892D2" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3526-wk-Fact-1967B402D8BE56648C1FED785998B3C6" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9329-wk-Fact-1975D34B81EE58A99F75AD822E7EA8D7" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2158-wk-Fact-19792256C9155CD4A4B30F1FFD71D2BF" toRefs="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4376-wk-Fact-197F4485B7325617ACD30B3E17928D84" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23448-wk-Fact-19AE6BF04D8CC5A87EEA801F7E12AE32" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e1956-wk-Fact-19AEA7C81E205D2B0C4DCB55FB59380E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1956-wk-Fact-19AEA7C81E205D2B0C4DCB55FB59380E" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9969-wk-Fact-19B551E7615E5B2D61BB801F81EC6B71" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4318-wk-Fact-19D10F7FBBB55166B828C57515F0E5DC" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7181-wk-Fact-1A163CFC61DB374C9859801F82396806" toRefs="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2448-wk-Fact-1A17F756201A26636A56801F825B0538" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21048-wk-Fact-1A3B6926FC4FE6AFF9C8801F807EB040" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21048-wk-Fact-1A3B6926FC4FE6AFF9C8801F807EB040" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2509-wk-Fact-1A6E3FA2203C5CDDA2BD99ED3CEEEA51" toRefs="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e3801-wk-Fact-1A7E3821C23A4DED79AC801F7E1FD112" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3801-wk-Fact-1A7E3821C23A4DED79AC801F7E1FD112" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4737-wk-Fact-1A7FFDC660ABEFAC6697801F7ECAA2B8" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19796-wk-Fact-1A8B2C6C459DCC13D002801F7FD5858E" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8345-wk-Fact-1AA27963C1EA03D86E56DE208FA6FEF4" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5125-wk-Fact-1AAB635BCEF5567C8400CCFFA9F211E9" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5125-wk-Fact-1AAB635BCEF5567C8400CCFFA9F211E9" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3208-wk-Fact-1B23844B5232538ABD87C7C1814A1CF1" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3663-wk-Fact-1B60D667972BE02E235D801F8128BBC9" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9514-wk-Fact-1BB3443744FA4A3A8997801F822C8818" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9950-wk-Fact-1BCCBE0EAF7ECB6D503C801F821CEE76" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14639-wk-Fact-1BDD07D787E81176926F801F7F11CAEA" toRefs="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6406-wk-Fact-1C0A16C44A2B5C6AAE89B204324775E1" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6406-wk-Fact-1C0A16C44A2B5C6AAE89B204324775E1" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3363-wk-Fact-1C1A48D8D8FB59F484CD69BF32113D2E" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2961-wk-Fact-1C6A9F20611E5E39AE756F72080F3817" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7227-wk-Fact-1C89FA66D1ECFDF67F72801F8179DC33" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1630-wk-Fact-1C949239FD4407E55222801F7FD72F26" toRefs="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1630-wk-Fact-1C949239FD4407E55222801F7FD72F26" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997 d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997 d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997" toRefs="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997 d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997 d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997 d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997 d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7175-wk-Fact-1CA134AD576458FCA79E9C753A5EF8FD" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4922-wk-Fact-1CD88F40E9218841E1F5801F7F82CECD" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10028-wk-Fact-1CFEC5FF204858E76294801F8228D349" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e4865-wk-Fact-1D05AD6F6F2D8CB837F3801F81CB438D" toRefs="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7526-wk-Fact-1D1D9E822C1094BF0A35801F7E86E0C0" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6090-wk-Fact-1D437AF9323714A08390801F7E93DC39" toRefs="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7262-wk-Fact-1D47F48F7F3554A78127DAFE590E794E" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e4843-wk-Fact-1D9607EC2BA2B2BE84B8801F807C0925" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4843-wk-Fact-1D9607EC2BA2B2BE84B8801F807C0925" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2616-wk-Fact-1D9D8C11D13199ACE522801F82C58824" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e1780-wk-Fact-1E3FF9437BEA5C5E903FC608EF1570C3" toRefs="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11872-wk-Fact-1E63E1B1645BA0E7748B801F818279BE" toRefs="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5327-wk-Fact-1EA1B7699985D7A7899C801F7E93B603" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5327-wk-Fact-1EA1B7699985D7A7899C801F7E93B603" toRefs="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E" toRefs="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2871-wk-Fact-1F2788F8C7EAC31BDBAF801F7E00C985" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5116-wk-Fact-1F4672D432636FBAB1D9801F811E4A03" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22442-wk-Fact-1F4D93C2F9904F6D73B7801F7FFAD79C" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14782-wk-Fact-1F63287DE71910139202801F7F087DC5" toRefs="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3007-wk-Fact-1F6DDFC5F407544BA48EE7A820F1CB06" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34512803e1675-wk-Fact-1F6DFBB307AD56A78E5BB87151D63936" toRefs="TextSelection-99ECE6937087FF439970801F831B2740-0-wk-Footnote-99ECE6937087FF439970801F831B2740_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6184-wk-Fact-1F8E1E5AC854059418AF801F7E7A53FB" toRefs="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14504-wk-Fact-1FABDAEE54CD68890F1E801F7F0BED57" toRefs="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4052-wk-Fact-1FB0890125B2E2F568A0801F82580255" toRefs="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4052-wk-Fact-1FB0890125B2E2F568A0801F82580255" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24717-wk-Fact-1FD036A003F66D196001801F80EDBF09" toRefs="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10981-wk-Fact-1FE49E27774BBC4F7DE7801F7E5B14A7" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6368-wk-Fact-2022231E382951F7A5219EA645136F0E" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6368-wk-Fact-2022231E382951F7A5219EA645136F0E" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3883-wk-Fact-204C8AF80ED25BDE9A77B2C926C838B9" toRefs="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14850-wk-Fact-2062BC7C0DF48822A1BA801F7F02D514" toRefs="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11530-wk-Fact-2091B860985E526EACD15CD4A5669CD5" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1864-wk-Fact-20A55537F0675518894025A232665AAA d34468079e2125-wk-Fact-20A55537F0675518894025A232665AAA" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e16298-wk-Fact-20C1F8EC97D87AA8FE1C801F822F40EA" toRefs="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2325-wk-Fact-2101798BE4EDF6E78C8F801F803DE4E4" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3177-wk-Fact-211494DFE1B65B998EAAA38B4550E8C1" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3921-wk-Fact-213E32B8B2FE51C690B80D561FAEFE40" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e3921-wk-Fact-213E32B8B2FE51C690B80D561FAEFE40" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e6097-wk-Fact-2169B9839E1C354CF47B801F7F1FEF95" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6097-wk-Fact-2169B9839E1C354CF47B801F7F1FEF95" toRefs="TextSelection-B6A3FF5187C02063A75F801F8312B48A-0-wk-Footnote-B6A3FF5187C02063A75F801F8312B48A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22602-wk-Fact-21757F62AEF00E5BF73F801F7EA5E973" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22621-wk-Fact-21863FBD06730CC6F0CE801F8133FD38" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2673-wk-Fact-218AEF14B977A83E4A06801F7EFF265B" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23171-wk-Fact-21E0043926A006FDE718801F80EA1DF6" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23171-wk-Fact-21E0043926A006FDE718801F80EA1DF6" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9475-wk-Fact-2227E15F117DFBBA6CDF801F823CAC01" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10092-wk-Fact-225081F555A03A27E808801F8232C488" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9591-wk-Fact-22F449DB433F0BD91E88801F8227AC5A" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6787-wk-Fact-22F8C804B14DB17BB996801F7E35F6F2" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1747-wk-Fact-22FC256F29955A5AAC465714927146A3" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11379-wk-Fact-236A48C44D219DB1205A801F8231D63E" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10786-wk-Fact-23DB84919E70B73B1647801F8249C9E2" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6137-wk-Fact-2409EE5D9DDE703FA11B801F7E7C5AAF" toRefs="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4030-wk-Fact-241AF0F5CD243F91D7E3801F81BCFDF4" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5379-wk-Fact-246CB21BC49B5BF7A871DD3D4BFCC13C" toRefs="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81" toRefs="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14581-wk-Fact-248A8F8CD6CA4B37A1DD801F7F0C957E" toRefs="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e6277-wk-Fact-24A404127FF2306D6A2E801F7FC76C30" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6277-wk-Fact-24A404127FF2306D6A2E801F7FC76C30" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2546-wk-Fact-24AE793F7AF5A0FFC713801F81A5B87D" toRefs="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e5623-wk-Fact-24C3D095E2CC3CF22E410211B6D446C8" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5623-wk-Fact-24C3D095E2CC3CF22E410211B6D446C8" toRefs="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3624-wk-Fact-2575FD938424E6650896801F80D24265" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8007-wk-Fact-25FC84B343C1A318CA97DE1AB610DB22" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7674-wk-Fact-26023C9A152437741F6FDE1A28B16CBA" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3814-wk-Fact-264673D948622D0AA0A4801F7F4D3D67" toRefs="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4102-wk-Fact-2648C18B67135722AC996F7545880D80" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3525-wk-Fact-265DAD9E00B9993A01D4801F81574A5A" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3525-wk-Fact-265DAD9E00B9993A01D4801F81574A5A" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4732-wk-Fact-267B1096BA37527F9F57BD86C5CF0ACF" toRefs="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3693-wk-Fact-268578D08E27C197EEE6801F8149CC9C" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3693-wk-Fact-268578D08E27C197EEE6801F8149CC9C" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e3882-wk-Fact-27063B77FAD0699D0962801F7E91ACE2" toRefs="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3882-wk-Fact-27063B77FAD0699D0962801F7E91ACE2" toRefs="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2069-wk-Fact-270C12BCCD80680CE432CB2DE5F8DC92" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7457-wk-Fact-2735403E9898D9DCFDE4DE1919D0AF5E" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2309-wk-Fact-274A4E3678CE5C1E9A3DE2C7A5DF6A4D" toRefs="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5176-wk-Fact-276A8A35EE68509F999B815A3BCBFE8E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5176-wk-Fact-276A8A35EE68509F999B815A3BCBFE8E" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2906-wk-Fact-276AE48F003C5B94964313479CA47CC4" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20401-wk-Fact-278022090600AF2B386D801F811D7324" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19100-wk-Fact-27B7F1F490681634429E801F80F1F370" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1819-wk-Fact-27CD0201DE5939C1D6C9801F7F2B2695" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4777-wk-Fact-27E943B33C7E2180DED5801F807FD2B1" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7806-wk-Fact-28116B03F1F1501FA19804A781E93B54" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228" toRefs="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e12058-wk-Fact-2846B8E6B6B05D109C0045899F1AADE9" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9553-wk-Fact-28AB86F70D2CD4381B5F801F81FA1B6D" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1585-wk-Fact-28DD1757DF955D578E13DE8351B692BB" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1585-wk-Fact-28DD1757DF955D578E13DE8351B692BB" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2270-wk-Fact-28E378BA49F05856958E09125890B46D" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2513-wk-Fact-28FF4AB5B22B53EA235C801F82B2C028" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2397-wk-Fact-2955D81BA66657739DD6267CF9D38630" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23210-wk-Fact-296077A478766CD8DCE5801F8128127D" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23210-wk-Fact-296077A478766CD8DCE5801F8128127D" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1670-wk-Fact-29CC16548E2E546280762B10A285EBB3" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1670-wk-Fact-29CC16548E2E546280762B10A285EBB3" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3139-wk-Fact-29D31CFA7A6550EBAA66F5ACE1A10761" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5031-wk-Fact-29D9AEE0EF874B7D2804801F810F970F" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8732-wk-Fact-2A00978854A95D9F943FA975DD0E0D7C" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22505-wk-Fact-2A45E23937B1E03B0AA9801F816FD16A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6328-wk-Fact-2A9ACB09597856F4AD1723B635334EC2" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2335-wk-Fact-2AA90167164D2E1A59FA801F7E8DBF9F" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3079-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495 d34661879e9906-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1554-wk-Fact-2B2A9C8657C8CAF5F992801F80CD8F28" toRefs="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10951-wk-Fact-2B8A551F74454F44A11F801F8230140D" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3318-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F d34519344e2140-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4682-wk-Fact-2BBF90C0E0ACDECC1704801F80243029" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7287-wk-Fact-2C386152CD1597FBF4FA801F82A1CFF0" toRefs="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19196-wk-Fact-2C64274CCAA479E1D7CD801F7E6C51E8" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11160-wk-Fact-2C95573C6F895F6892E174F65C10E575" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4603-wk-Fact-2CA2DA51FA5858A080A8149D1EF99AE3" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24037-wk-Fact-2CA6288317D80D709922801F8147D1CB" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24037-wk-Fact-2CA6288317D80D709922801F8147D1CB" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5027-wk-Fact-2CA67D7D788BA11D095F801F7FD36422" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2901-wk-Fact-2CB4512C4635516E90761E4D85A4869E" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-2CBB41D064359126314C801F82CC8933-wk-Fact-2CBB41D064359126314C801F82CC8933" toRefs="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6767-wk-Fact-2D59B5E05ED9F368C224801F80B95B6D" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4175-wk-Fact-2D81E359A3F32671B09D801F7F331769" toRefs="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7005-wk-Fact-2D99B1124ACE12540611801F82B4994F" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e10041-wk-Fact-2DA2C6E810E554E8A093A9328B417C64" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10041-wk-Fact-2DA2C6E810E554E8A093A9328B417C64" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e2714-wk-Fact-2EFB3D5BD681B11EF065801F7F7EB754" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1623-wk-Fact-2F12F18AD8251A365397801F7F1D63C2" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1623-wk-Fact-2F12F18AD8251A365397801F7F1D63C2" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11771-wk-Fact-2F3A89C4B2BD5133ACFBE4229DDE6CC5" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2970-wk-Fact-2F3CA3A3FAD45C6BBFFA9AF52B012B5D" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10866-wk-Fact-2FA5505B9C078F2C7287801F821DF04C" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5247-wk-Fact-2FA734C3E6F851F3A59F806EDB8CEAFE" toRefs="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2929-wk-Fact-30AD1982C6115A29A36BF68B59AEDB47" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6561-wk-Fact-30D9418081FBA848CBA2801F7ECCAB71" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23836-wk-Fact-31101E0D5A9F589C42B9801F7EDE61BF" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23836-wk-Fact-31101E0D5A9F589C42B9801F7EDE61BF" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5833-wk-Fact-3156136D7E33FEA3D6A7801F7F106890 d34545404e6008-wk-Fact-3156136D7E33FEA3D6A7801F7F106890" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2122-wk-Fact-316CD294736155A2BF815F488E7DB6E0 d34545404e3133-wk-Fact-316CD294736155A2BF815F488E7DB6E0" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11523-wk-Fact-3172D79ECC315BEBFB19801F822ED289" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2290-wk-Fact-31991F01AC86E4619B23801F800998F2" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34523018e2578-wk-Fact-31994C39581B5B71BDDB9AE8FC22964B" toRefs="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2411-wk-Fact-31D197A179335FA6BF6A7BC5D0D64EA2" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9231-wk-Fact-31D3680708335B049E798A2ECB5508B4" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e16237-wk-Fact-31E13FD9B07B11996B5E801F8233F654" toRefs="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3708-wk-Fact-31E5ACFB46A559DC7083801F81586817" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3708-wk-Fact-31E5ACFB46A559DC7083801F81586817" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2243-wk-Fact-31EE472AE3C7503BA361B44F0445BA6E" toRefs="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7353-wk-Fact-31F361F21F2837AACE1C801F82A5E94F" toRefs="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e6734-wk-Fact-3211B659D4CE729821B4801F7F0D704F" toRefs="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14891-wk-Fact-324241AD63CEF2D77B12801F7F01BBA9" toRefs="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5669-wk-Fact-324D6E1724EEC6BE2FE9801F7DF40048" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2428-wk-Fact-324E930EA3FE51309DAF874C15316ACB d34523018e1931-wk-Fact-324E930EA3FE51309DAF874C15316ACB" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23875-wk-Fact-32850438677456DE85D2801F80EF43A5" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23875-wk-Fact-32850438677456DE85D2801F80EF43A5" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23902-wk-Fact-32BE2AC3AB258DAE14BA801F815D5109" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11257-wk-Fact-32E1EBDBF1BACBF6E103801F8241B168" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7339-wk-Fact-32EF9B5301DDDEC38EC0801F829FDB14" toRefs="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20990-wk-Fact-32F10B48A55F1AE6E300801F813AC7A0" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e20990-wk-Fact-32F10B48A55F1AE6E300801F813AC7A0" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3080-wk-Fact-33025D2CE7995F16A707BC65C2D0FAA0" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1590-wk-Fact-3328F0DAC738681A6D21801F7ECF7D37" toRefs="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1590-wk-Fact-3328F0DAC738681A6D21801F7ECF7D37" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10273-wk-Fact-3332CC39DDDB775F98DD801F82319453" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4065-wk-Fact-333989DFC77B15A1F172801F7E787CBF" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4369-wk-Fact-33AFDD4662101709F692801F7E18C5FF" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e3417-wk-Fact-33F90922FE92534B8F84E80D9633CDA7 d34523018e2661-wk-Fact-33F90922FE92534B8F84E80D9633CDA7" toRefs="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3417-wk-Fact-33F90922FE92534B8F84E80D9633CDA7 d34523018e2661-wk-Fact-33F90922FE92534B8F84E80D9633CDA7" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e4016-wk-Fact-34056A88C0D75E6C9FEE2D3BDD894FE8" toRefs="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3939-wk-Fact-341D9ED90C94596BB9FAE98E1294E451" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e3939-wk-Fact-341D9ED90C94596BB9FAE98E1294E451" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21228-wk-Fact-341E870038AF69B1EEA5801F813FD1D5" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2401-wk-Fact-3428A9878F8D11970A11801F7E90E64E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11154-wk-Fact-3436CB2133E67A0CED9C801F8220C53D" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14870-wk-Fact-346579D6E7C0E2843401801F7F121ACE" toRefs="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7822-wk-Fact-34727ACB136D8931558B801F7E88E0C5" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5051-wk-Fact-347BAF696A1993925737801F8131C37D" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1717-wk-Fact-3482AAEFC33858968E580ACA1EF44907" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1717-wk-Fact-3482AAEFC33858968E580ACA1EF44907" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7580-wk-Fact-34A07B3634CE5849A713202F3645E2BC" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5575-wk-Fact-34AD8E413C695FBD8469975721FFB0F6" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10477-wk-Fact-34CCCF8B6B98C5A6827D801F8243C77E" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e2206-wk-Fact-34FF2F3BFE615D19B8D425D5797E438A" toRefs="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3892-wk-Fact-3503C852F9E4ADA0D97B801F7FA9C9D8" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9931-wk-Fact-3550225B14CDA4F396FD801F81FC93AD" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6020-wk-Fact-35607E33C1EA7F8BC8EF801F7E4B3C15" toRefs="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8475-wk-Fact-356826AC764E5F1AB122D61B135DA970" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e16196-wk-Fact-3575E2B197DFFB710849801F822BF3AD" toRefs="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21613-wk-Fact-3582128093A73BF0EBD0801F80323008" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4234-wk-Fact-35B362807E1AE86654F9801F811F7FF8" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e4234-wk-Fact-35B362807E1AE86654F9801F811F7FF8" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9851-wk-Fact-35D3A5D66469542E865E5AA0C2D06B43" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4701-wk-Fact-35E0049DFF2E76A140E3801F8089CAA6" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2686-wk-Fact-360249B3A006541E93860494E7664450" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4364-wk-Fact-36071102556E5A8BB41605B5E0E61960" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1820-wk-Fact-3608CBE3F82FCEC11A98801F7EB42466" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e9657-wk-Fact-364B4EF7858D52F1B60FF23BA7D7CA9F" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9657-wk-Fact-364B4EF7858D52F1B60FF23BA7D7CA9F" toRefs="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1885-wk-Fact-364D49347A25577A9FDDC9569F869ED0 d34501946e4245-wk-Fact-364D49347A25577A9FDDC9569F869ED0" toRefs="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e1885-wk-Fact-364D49347A25577A9FDDC9569F869ED0 d34501946e4245-wk-Fact-364D49347A25577A9FDDC9569F869ED0" toRefs="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5557-wk-Fact-365F3C6454AE5427308D801F8123E06B" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6577-wk-Fact-3699E726612D593C213A801F7E0FB736" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34524436e1715-wk-Fact-36C4BF558BFA7F0626F6801F8284052E" toRefs="TextSelection-38BDAE166DE9044C0E60801F8347D176-0-wk-Footnote-38BDAE166DE9044C0E60801F8347D176_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4877-wk-Fact-36EFF26A70BF5280BEBB3D0AA77CBFFB" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3894-wk-Fact-3706D36BE0715C4B909C295C63B57B4F" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2290-wk-Fact-372575356B8E57CCAFE65ACA01B572B8" toRefs="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10190-wk-Fact-378CC18954DCD2BE6AD2801F8208C07A" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3653-wk-Fact-378E7CFB0C3366BE1636801F7F982A6D" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e3653-wk-Fact-378E7CFB0C3366BE1636801F7F982A6D" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2743-wk-Fact-37BB967598E60C472CDF801F80B12AD6" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20524-wk-Fact-37C2E96F0C06B8BE58DC801F81379E3A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-37E466B377E093574704801F823ADEB7-wk-Fact-37E466B377E093574704801F823ADEB7" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6074-wk-Fact-380993016EC856A5A43F951D0C773A80" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-38352E73A1AC3A38585F801F81E7E0C5-wk-Fact-38352E73A1AC3A38585F801F81E7E0C5" toRefs="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8194-wk-Fact-385EDBE1A04BC6E2A680801F829EC2AC" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23048-wk-Fact-386DE871FDE603DE0A0C801F7E75C64F" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2177-wk-Fact-38838F053717CF5598FFCF6EFFF59BAF" toRefs="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5453-wk-Fact-3886E93F27E98EE28D2C801F7F4E0594" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3247-wk-Fact-388802394B995CDECA90801F7F4A337B" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1899-wk-Fact-38B878301DB957B297D2601592AD511A d34496162e9129-wk-Fact-38B878301DB957B297D2601592AD511A" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11407-wk-Fact-390B954ED7FDBB67E7CD801F8201DB61" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e2003-wk-Fact-393C1336661B5502A717C267B3C8D41C" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2003-wk-Fact-393C1336661B5502A717C267B3C8D41C" toRefs="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24076-wk-Fact-3993C9034191C03D601B801F7EDE39F5" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24076-wk-Fact-3993C9034191C03D601B801F7EDE39F5" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3844-wk-Fact-39A51FF36D53F8FAFD27801F828948C3" toRefs="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3659-wk-Fact-39D10B011D5484305F0B801F814829A7" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3659-wk-Fact-39D10B011D5484305F0B801F814829A7" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3255-wk-Fact-3A0EED0F100854319344F954D1578C77" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11359-wk-Fact-3A17F7C7D9A8C3BFB338801F82230016" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2643-wk-Fact-3A431FAAB1251C8B2F11801F7EAD8859" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8531-wk-Fact-3A992D3D837957AFBC4539641549FE54" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6678-wk-Fact-3AD0784E9548664647E8801F7EFA79D4" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6000-wk-Fact-3AD6F4B4A41632FD0B68801F817F1B4F" toRefs="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3452-wk-Fact-3AE7E9A85D765783A134E8B901625365" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2660-wk-Fact-3B3FED2A33115ED2B476EFD5B5811F3E" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23739-wk-Fact-3B84715E11DB37BB7F37801F7E1EFCF3" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23739-wk-Fact-3B84715E11DB37BB7F37801F7E1EFCF3" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2516-wk-Fact-3BADC091FCBEA9D91D08801F819B12FC" toRefs="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22021-wk-Fact-3C503682A37762C63BE1801F8147265C" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1574-wk-Fact-3C5E1456EFEB580EB0B057546407A424" toRefs="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14620-wk-Fact-3C628A0CB0E19BD342B2801F7F090262" toRefs="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2337-wk-Fact-3C80ECF87216CAD55440801F7F4B62D4" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1571-wk-Fact-3C889F3A20C0530CB57A37DDC3BC5CFD" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1595-wk-Fact-3C9472B7B150D7664833801F80B066CF" toRefs="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2196-wk-Fact-3CE8EBCFF7A37827A78B801F80EE18A9" toRefs="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8256-wk-Fact-3D222D29334A51ED9477C50D604F7F80" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2478-wk-Fact-3DAD4CB2028224ADCA3A801F819615A2" toRefs="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7437-wk-Fact-3DB102BD4155797B5C71DE18EDD8B9B9" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e27708-wk-Fact-3DE297FCB202AC8DCCF7801F7E992601" toRefs="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5529-wk-Fact-3E8F06EF234D88E987EF801F821B72E3" toRefs="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2493-wk-Fact-3EB348FE8DB4F3058FEF801F81A6D04E" toRefs="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11253-wk-Fact-3EBD6C7A46BD54608DC97B7D5BC28BC5" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e5088-wk-Fact-3EF2B8E9997739EA3A5F801F7FF78369" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2378-wk-Fact-3F54F0E033DA5F4EB9E1DB8292AC5F35" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3615-wk-Fact-3F59543875025E468AEF3F683189F304" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e3615-wk-Fact-3F59543875025E468AEF3F683189F304" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23268-wk-Fact-3F72EA523C34D3EBBCF1801F80C7CC92" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23268-wk-Fact-3F72EA523C34D3EBBCF1801F80C7CC92" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2900-wk-Fact-3FA833AC5BE1008431CF801F80F4EAAE" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11135-wk-Fact-3FAA9033222E4A62E69F801F822B103B" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2709-wk-Fact-3FAC1D7D150D5D3693952644AB014570" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2977-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC d34545404e9313-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC" toRefs="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2977-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC d34545404e9313-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e5501-wk-Fact-3FDB29B576C0C8FDA061801F7FF11DF2" toRefs="TextSelection-C075792364F3F1E4361D801F8348FF26-0-wk-Footnote-C075792364F3F1E4361D801F8348FF26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6916-wk-Fact-3FE2875CC05E5AF0955E1F16A4747D4E" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34524436e1784-wk-Fact-406980FB36901507CFF4801F8284BFE7" toRefs="TextSelection-38BDAE166DE9044C0E60801F8347D176-0-wk-Footnote-38BDAE166DE9044C0E60801F8347D176_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e2753-wk-Fact-40815EB793804FE4A834801F7EBFA646" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4011-wk-Fact-4092AEA9F2F669BF51ECD083C021CD3C" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5214-wk-Fact-40C3E909042539E5B10F801F7E98C05E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5214-wk-Fact-40C3E909042539E5B10F801F7E98C05E" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8403-wk-Fact-40C546EC33A35AFE9BEEFE176817495B" toRefs="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e9697-wk-Fact-40E0EB9593AE56E6ABE3328268CD2D11" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9697-wk-Fact-40E0EB9593AE56E6ABE3328268CD2D11" toRefs="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5859-wk-Fact-40EBEAFCE6C7703C624E801F7F333340" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10961-wk-Fact-414C030E79B750E3A44270BCED97927B" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2559-wk-Fact-4158106AA31D76C528FD801F7F58702B" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2070-wk-Fact-416C8D02D1AC53CF8E7B9B0BE22D3ECD" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1766-wk-Fact-41F671B8835D59FE8632B22D5D005E66" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10992-wk-Fact-420050CC9AF1183EA21D801F82478087" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2846-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A d34661879e9746-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2846-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A d34661879e9746-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81 d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81 d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81 d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14661-wk-Fact-42DC91E16F73927C464F801F7F0DDD4E" toRefs="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e3867-wk-Fact-42EBCBC4C248331A0BFD801F82753FD6" toRefs="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3867-wk-Fact-42EBCBC4C248331A0BFD801F82753FD6" toRefs="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4195-wk-Fact-43172D93073829A17FB6801F82AF4ECB d34594690e8605-wk-Fact-43172D93073829A17FB6801F82AF4ECB" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23249-wk-Fact-4324A26D75595331CCFC801F81546900" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23249-wk-Fact-4324A26D75595331CCFC801F81546900" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3334-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B d34523018e2512-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B" toRefs="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e3334-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B d34523018e2512-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3169-wk-Fact-43647EACB2365019AF739809E6A7AA33" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-43A568A1B2F110213B88801F806FD23A-wk-Fact-43A568A1B2F110213B88801F806FD23A" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2842-wk-Fact-43B675EB3B86596CAC5E7949E794E330" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23409-wk-Fact-43D0EA4505ACE6E465E2801F7FD72974" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2422-wk-Fact-43F9860B2E4FABD39FD0801F824B7F7B" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5286-wk-Fact-44258E2A7EC67FA448C2801F81E421B4" toRefs="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2728-wk-Fact-44E9A00560B253F9B13272B4DADC5EE7" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2381-wk-Fact-44EF20E31F87512BB82C3578F60D84E2" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e9562-wk-Fact-455D7F50A78999F57E0BE7AEB28EE379" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9562-wk-Fact-455D7F50A78999F57E0BE7AEB28EE379" toRefs="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10293-wk-Fact-45B18C9F6F2875D22AB6801F81F7973B" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9821-wk-Fact-45E0D791242D55AC81FC3EFB761F9C00" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8902-wk-Fact-4621E7DDA21358AB9B0293A23E1E94CC" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9777-wk-Fact-4638B594C90A5D0FB3648867A34E71BB" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3644-wk-Fact-464A486895AEEBF8EC5F801F7FA5F9F7" toRefs="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e6445-wk-Fact-46A676894226F74F6BFC801F7EFC1911" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6445-wk-Fact-46A676894226F74F6BFC801F7EFC1911" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e4589-wk-Fact-46AB28E4CC157C45741A801F823EEFDA" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4589-wk-Fact-46AB28E4CC157C45741A801F823EEFDA" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5308-wk-Fact-46C48E9C21AF899B9CBE801F824C920A" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5308-wk-Fact-46C48E9C21AF899B9CBE801F824C920A" toRefs="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7059-wk-Fact-46F27B55B27B54EA8DB9649561CE42BB" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e5643-wk-Fact-47070BCAA8F0873AE2800210CE266E9B" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5643-wk-Fact-47070BCAA8F0873AE2800210CE266E9B" toRefs="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1870-wk-Fact-4752641D09C957ACBC4D5CB0E30EFE1F" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1870-wk-Fact-4752641D09C957ACBC4D5CB0E30EFE1F" toRefs="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4380-wk-Fact-478A747253E5F8B23E49801F81C71589" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7302-wk-Fact-479F4E8A21C856B284E67E3F6C120C46" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8976-wk-Fact-47C32F6B4940C65CF511DE20FEBC9F1E" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1659-wk-Fact-47C637A51CEE5EF080D18BCE1B38E7DA" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e2668-wk-Fact-47EFFB693B37262CF809801F82673E4B" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e2734-wk-Fact-48209B5C749FB96707F8801F82806943" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34423000e3477-wk-Fact-48600923F2B454478E9D06C9836F179C d34458032e9930-wk-Fact-48600923F2B454478E9D06C9836F179C" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3477-wk-Fact-48600923F2B454478E9D06C9836F179C d34458032e9930-wk-Fact-48600923F2B454478E9D06C9836F179C" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4760-wk-Fact-48A2AF59E0EAFF0A6B26801F81171029" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4760-wk-Fact-48A2AF59E0EAFF0A6B26801F81171029" toRefs="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3236-wk-Fact-48F3227EB91F519693B62AAB048CF3C2" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9015-wk-Fact-48F70FD623656D97865CDE21089CEB52" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2352-wk-Fact-48FBE878E867A2126357801F828892B1" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21332-wk-Fact-4924E685A3ACAA7EBD6E801F7FD67A92" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21332-wk-Fact-4924E685A3ACAA7EBD6E801F7FD67A92" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9220-wk-Fact-494DF9151E065567834DBAE4E1B562F9" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34523018e2727-wk-Fact-496231284B82551EA3C09B63129DD116" toRefs="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2051-wk-Fact-49C7F7BFD94F58259E8F91521C863A5D" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5265-wk-Fact-4A34A51B3998F315A6C3801F81061EB9" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2119-wk-Fact-4A424945B16E50C896282B201E79955C d34519344e1948-wk-Fact-4A424945B16E50C896282B201E79955C" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e27689-wk-Fact-4A576DD84E72BF694DFE801F7E989595" toRefs="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2587-wk-Fact-4B1590ADE87B568D8CC8C86F0B307CF0" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3789-wk-Fact-4B742D12220955FCB8512E0C28478091" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20640-wk-Fact-4B8271E7A0E5A3CF5E04801F7EC8BD2A" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4121-wk-Fact-4BC04F50F859575786CDEB42846504B3" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2236-wk-Fact-4BF8867A9673AACA0E31CB2DE4C160C4" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2663-wk-Fact-4D09902765CD56939721BF43E88C545F" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11717-wk-Fact-4D849F31F84479F6D413D0834B8AEBFC" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1850-wk-Fact-4D8CEC7EA9FB5F60A15FD79906165FE2" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1850-wk-Fact-4D8CEC7EA9FB5F60A15FD79906165FE2" toRefs="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9724-wk-Fact-4DE63B25DF8F54C98BE8801F7DD138D7" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e7600-wk-Fact-4E0DBFBB79A3239D00CC801F7F5FBA6F" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2159-wk-Fact-4E0F3852D83E28ABDBED801F7ECDFF6C" toRefs="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2159-wk-Fact-4E0F3852D83E28ABDBED801F7ECDFF6C" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3123-wk-Fact-4E6373F9AE145393977B4D50CD0C3C97" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3829-wk-Fact-4E680D94DBBF677FF299801F7EAAEC74" toRefs="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3685-wk-Fact-4EC473580DFC97201347801F7F618775" toRefs="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19719-wk-Fact-4ED0DD3E047FEF605271801F7E880A91" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2862-wk-Fact-4F41970AB5AF5A55B4EA05E37BD7A829" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e6854-wk-Fact-4F592E77B2B5EA96F0FA801F7EF1FA0F" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6854-wk-Fact-4F592E77B2B5EA96F0FA801F7EF1FA0F" toRefs="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4383-wk-Fact-4F6A9D76BC23A664699C801F8033D7FF" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7283-wk-Fact-5000F0EEE05D5658998A06FB2C356390" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6387-wk-Fact-50286E7377FA596E859503D29B20ABBF" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6387-wk-Fact-50286E7377FA596E859503D29B20ABBF" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21312-wk-Fact-5051258CEF279EAE4904801F8082EB61" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21312-wk-Fact-5051258CEF279EAE4904801F8082EB61" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2224-wk-Fact-50686A372E736C0F5647801F82939361" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2600-wk-Fact-50C71B602D558F20976C801F828D6F53" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1973-wk-Fact-50D8069E0C6A50D989482D5B5834E63D" toRefs="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3477-wk-Fact-50F041F28B665D836084801F81547F30" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3477-wk-Fact-50F041F28B665D836084801F81547F30" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6616-wk-Fact-5131EE518687D3BFD19B801F7E64723A d34545404e7173-wk-Fact-5131EE518687D3BFD19B801F7E64723A" toRefs="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6426-wk-Fact-516913B914BB588F94ACCEBA9291FDAD" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6426-wk-Fact-516913B914BB588F94ACCEBA9291FDAD" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-516E2DBFF137FF395442801F824C52D5-wk-Fact-516E2DBFF137FF395442801F824C52D5" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19738-wk-Fact-516E83BACCC191ED5F55801F7E89AB76" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2012-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927 d34471435e2600-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2275-wk-Fact-51AF8A24F6320B3DD4D9CB2DE5470BE9" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10583-wk-Fact-51C0100384A147990743801F81EB9934" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7802-wk-Fact-51CBEE775FF5588DB0D7DCEC07FF57B0" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1948-wk-Fact-51D5CD0734BBD4CF6AB0CB00E2C1C110" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3762-wk-Fact-51E697B313F65177AA951CD8E64EC1C9" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2386-wk-Fact-52056BFD52B55AD7B0B223B4DB2C6129" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e2148-wk-Fact-523DC6B2EC505EFFBFCB4D7A7C5179A9" toRefs="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2141-wk-Fact-5244EF9D70AB4BF20E72CB2DE505A72E" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10537-wk-Fact-5265E1D654B7823D4E63801F82280344" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e10022-wk-Fact-52734113DA315C5EB0822EA6C1F6019D" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10022-wk-Fact-52734113DA315C5EB0822EA6C1F6019D" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1817-wk-Fact-528109C6117952069FCC0A02E9E0964C" toRefs="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5616-wk-Fact-52CE05D4D58AA63DFD75801F8215C3D3" toRefs="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2336-wk-Fact-5326AFF91A2251119CB3EA737ED72B03" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2530-wk-Fact-532861FAECEE50D0A6F6D5AEF071E5B9" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8325-wk-Fact-532A8105F0605BF7A90B026D9DC3C86C" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3895-wk-Fact-5344A287AEC4338D220DE3C58F9727B5" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4399-wk-Fact-535FEE135E2ABD4ECB45801F81937510" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3998-wk-Fact-536D379D583EEC0E6BB0801F7E8674D3" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2693-wk-Fact-538AD0D1FEAC9B9942E5801F80805FA6" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5374-wk-Fact-539977E9F571B801F8F2801F82CC3FC2" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5374-wk-Fact-539977E9F571B801F8F2801F82CC3FC2" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4815-wk-Fact-53A4C5E0F7DCF0473DB8801F8250BB73" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34529301e2317-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41 d34529301e3063-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2317-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41 d34529301e3063-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e2128-wk-Fact-53FADFD5082D5F7483E92BF38D157660" toRefs="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e6056-wk-Fact-540977569490C9755BD3801F7F1FE236" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6056-wk-Fact-540977569490C9755BD3801F7F1FE236" toRefs="TextSelection-B6A3FF5187C02063A75F801F8312B48A-0-wk-Footnote-B6A3FF5187C02063A75F801F8312B48A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6948-wk-Fact-540CAB81FBF19E5166CE801F82251FFC" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e3897-wk-Fact-540F98E963893D555BBC801F8251C495" toRefs="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3897-wk-Fact-540F98E963893D555BBC801F8251C495" toRefs="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2464-wk-Fact-54104279652F5BA598DF82A20E111838" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2942-wk-Fact-54259B5ADCDB523D95E357958F32EAA5" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3996-wk-Fact-5438260A5AB3500C8619EA7A64AD5E8B" toRefs="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7857-wk-Fact-5472417927D753EEBBB1072B6B105F5F" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2788-wk-Fact-547A9426B8FEDD3D980A801F821CD025 d34661879e9708-wk-Fact-547A9426B8FEDD3D980A801F821CD025" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2788-wk-Fact-547A9426B8FEDD3D980A801F821CD025 d34661879e9708-wk-Fact-547A9426B8FEDD3D980A801F821CD025" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e2688-wk-Fact-54AA553FEEBE8772CC50801F7F6E0504" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23331-wk-Fact-54BB374F531662E67301801F8151A7BD" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9802-wk-Fact-54CC08145C9B5A5BA23B67DFBAD4AE0E" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23370-wk-Fact-55065D7329FC0CE09063801F8127D52D" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4077-wk-Fact-552B0DEF974EB94D62FC801F81213B84" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4001-wk-Fact-556CBCAD88F04EADEC0B01C7EFA1BB3D" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7153-wk-Fact-5582142AF8CAFB1642B1801F8152C802" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2042-wk-Fact-559668800F8D5F39871CB0D8FAB473CD" toRefs="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3457-wk-Fact-55A2404E40890D14A72D801F8159A9F4" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3457-wk-Fact-55A2404E40890D14A72D801F8159A9F4" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5813-wk-Fact-55BA3A8CA443922DFC21801F812BB48D" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5549-wk-Fact-55FAF1E14383FE9A5716801F81DC7AAF" toRefs="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34529301e2852-wk-Fact-561E433B6B30525EBA77DD0C09816B40 d34529301e2892-wk-Fact-561E433B6B30525EBA77DD0C09816B40" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2852-wk-Fact-561E433B6B30525EBA77DD0C09816B40 d34529301e2892-wk-Fact-561E433B6B30525EBA77DD0C09816B40" toRefs="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3253-wk-Fact-562D6F8F14805BDBA1EEB5EC76E5A656" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4819-wk-Fact-563A84C808D48A91680F801F7F11733F" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4819-wk-Fact-563A84C808D48A91680F801F7F11733F" toRefs="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1692-wk-Fact-563BB6FEBF5717E60D97CB0A84CDFE98" toRefs="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1692-wk-Fact-563BB6FEBF5717E60D97CB0A84CDFE98" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3987-wk-Fact-565E3B0013E83A6400DF01C7EED4523E" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3021-wk-Fact-56AC0425594EB6B614D8801F82235863 d34661879e9868-wk-Fact-56AC0425594EB6B614D8801F82235863" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9985-wk-Fact-56B05001ED9BC8F7B322801F8171F6EF" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11050-wk-Fact-56B658880869AEACE541801F8187F9A3" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2705-wk-Fact-56CA584C4B365E4B845856D506783484" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2519-wk-Fact-56CDBBCBD4E37D7B159C801F7FF5592A" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7249-wk-Fact-56D7F8DD1BDAEA1F8A93801F82A07FA6" toRefs="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5698-wk-Fact-570F688A036C517B8DC6519B9EEC35DC" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8174-wk-Fact-574622BD96AD5C9083C68ABC1F23BDDF" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5280-wk-Fact-5763263A0462B65542D3801F82B1A33F" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5280-wk-Fact-5763263A0462B65542D3801F82B1A33F" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9872-wk-Fact-5771636556985C87BC8C3CB410CC66F7" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10885-wk-Fact-578D671C8F705BCD1B24801F82058BDF" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21390-wk-Fact-57959C448E7CB9BAE6F1801F81494C11" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21390-wk-Fact-57959C448E7CB9BAE6F1801F81494C11" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3991-wk-Fact-57987F1F001AA9CC9C56801F812C5B39" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3060-wk-Fact-57F6BF74720C5F8388DA1CC92604AB69" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1498-wk-Fact-5800B99789A546352282801F7F2D7923 d34586122e4303-wk-Fact-5800B99789A546352282801F7F2D7923 d34586122e5487-wk-Fact-5800B99789A546352282801F7F2D7923 d34586122e6786-wk-Fact-5800B99789A546352282801F7F2D7923" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e7562-wk-Fact-58349156F701DBD2FAE9801F7F55CCA1" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e7153-wk-Fact-583AA105D95E04AFAC9B801F7E2BE5D7" toRefs="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10254-wk-Fact-587F4F874523BF22E7AF801F823BD65E" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1974-wk-Fact-58A10D106477541896C64514721528B2 d34471435e2561-wk-Fact-58A10D106477541896C64514721528B2" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1590-wk-Fact-58A9D592472E54ACB181BBAE9BC91E05" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23191-wk-Fact-58CB03993CECC3B620EC801F7EDEE43C" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2021-wk-Fact-58D64728C9445B32B7001C141E840546" toRefs="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1615-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9 d34512803e1629-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34423000e1615-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9 d34512803e1629-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9" toRefs="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2842-wk-Fact-5947CFACA921556B9FFF58244C1A10F0" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9070-wk-Fact-5955DF531022E6A702C4801F82A42A3E" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8996-wk-Fact-5971AF67CC945F6EA0252DF12812F82F" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6636-wk-Fact-597816EBBEA9C653591F801F7EEC46E1 d34545404e7194-wk-Fact-597816EBBEA9C653591F801F7EEC46E1" toRefs="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2381-wk-Fact-5978204D04A9412FC943801F82AB9CA2" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7896-wk-Fact-5994144D551B14BACEFF801F7E7863C5" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2182-wk-Fact-599EFC3C5A9B585D8082B26EDB29D9AA" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1801-wk-Fact-59B0AF76AAAA5B66B8EF1D2F0CE5B1EC" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21208-wk-Fact-59B1E65891137B9A016D801F7ED92BBC" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2088-wk-Fact-59C2713351C3718503CECB2DE492EDAD" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4941-wk-Fact-59FCEED3F6055C9A869BCCC59046D785" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2862-wk-Fact-5A1858B72D840CA48B81801F8088EC92" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2531-wk-Fact-5A1DD2370C1F985FBB91801F81A8925B" toRefs="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19699-wk-Fact-5A20A9FE6AC6B79177A4801F8146DDEB" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4966-wk-Fact-5A2A15D93FBF9DBC472E801F7F42D616" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4966-wk-Fact-5A2A15D93FBF9DBC472E801F7F42D616" toRefs="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11456-wk-Fact-5A942695EAC354C8809AF1522CA91E6D" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1781-wk-Fact-5ABF4791BE6951B3BD213F08FF302F41" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8827-wk-Fact-5AE29E30628550D4AAC86546A2DDB7C3" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e7393-wk-Fact-5AE5207BC2F85C839F3BD7D293D59B4E" toRefs="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10683-wk-Fact-5B79851311CC6FFAB3EF801F820E9581" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14562-wk-Fact-5BFD4CE5B0EB344F1A4A801F7F0AA68E" toRefs="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8754-wk-Fact-5C0064D89F285BDD8A146792BE0F3384" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e1799-wk-Fact-5C1105B34A8A5168A29CDA6A58BEDCE8" toRefs="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e1995-wk-Fact-5C6CEA6ACFCD5D859F39208DA973ACEC" toRefs="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4050-wk-Fact-5CA5DCE2265634E3F870801F81D69ABB" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3802-wk-Fact-5D06811EF4C34003FE7FAB460A240C38" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10133-wk-Fact-5D359C48EE073DF7C9CD801F817AF13E" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3817-wk-Fact-5D65BE3231925A3690D7162CD4FAA218" toRefs="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8751-wk-Fact-5E2F8A36DD7104849060801F7E8B4BB0" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1722-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD d34519344e1823-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3583-wk-Fact-5EB5DEEFDF475D0D875609F4CEF1710B" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3798-wk-Fact-5F0D40017013586D8F17BC834125A378" toRefs="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5219-wk-Fact-5F191F9F323C685F3993801F7DCDF586" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e7135-wk-Fact-5F2D4ADDF8FF1844A040801F7E00C1DC" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7135-wk-Fact-5F2D4ADDF8FF1844A040801F7E00C1DC" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e3088-wk-Fact-5F457A9009553F04B717801F7FB266B9 d34458032e2731-wk-Fact-5F457A9009553F04B717801F7FB266B9" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3088-wk-Fact-5F457A9009553F04B717801F7FB266B9 d34458032e2731-wk-Fact-5F457A9009553F04B717801F7FB266B9" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10846-wk-Fact-5F786390C2E8481D63AB801F820FDD80" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3770-wk-Fact-5FCA9B06E5F243C62A7E801F7F95C2A9" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9090-wk-Fact-5FF17F954895E52A550DDE22B9D0BED2" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4214-wk-Fact-60449F03FF9FEEB388F5801F81D5F45D" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e4214-wk-Fact-60449F03FF9FEEB388F5801F81D5F45D" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4025-wk-Fact-606A9D26C4D35A40A035883CAA24CCE7" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e4885-wk-Fact-6077434EDCF327AE1499801F81D5A9C4" toRefs="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e7270-wk-Fact-6081521688175CC5A7553A80707D9EAC" toRefs="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6719-wk-Fact-608268E446BF53A67800801F7ECCEFB9" toRefs="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1800-wk-Fact-60979D16D8DE563EA2F73F6D211A9A3F" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3305-wk-Fact-60CD4D80F7AE528A9A1801629A9AD807" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3913-wk-Fact-60E259DD84E55069AE8582467CCBEEF4" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e7152-wk-Fact-60FB429DDE645C968BD3DD43109F92F8" toRefs="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23720-wk-Fact-61637C3FAD1A1EBEC396801F7E02E832" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23720-wk-Fact-61637C3FAD1A1EBEC396801F7E02E832" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3164-wk-Fact-6178D606D0576009E7D8801F800B47C5" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11193-wk-Fact-61950C831388E08B6286801F81EDD259" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-61D00E77EE76E65E4F9F801F823CCE99-wk-Fact-61D00E77EE76E65E4F9F801F823CCE99" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e2186-wk-Fact-61E9846E1AC95B2E9188CB7391BD7711" toRefs="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1845-wk-Fact-61EEF037EA245BC58651F6491A13B057 d34468079e2106-wk-Fact-61EEF037EA245BC58651F6491A13B057" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e4024-wk-Fact-6218C747DBEE55A9AF76EE26E178A31C" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3394-wk-Fact-6221149E08DD0A17F14B801F8152992D" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3394-wk-Fact-6221149E08DD0A17F14B801F8152992D" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23028-wk-Fact-624D9122625475A0C346801F810535CB" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23152-wk-Fact-6259E894CBE6FA9FB71A801F7E0FCAAB" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23152-wk-Fact-6259E894CBE6FA9FB71A801F7E0FCAAB" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7079-wk-Fact-62650662D7DD8D7E8080801F82C35669" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e2167-wk-Fact-626CCC40E7795A0A83CE3935A24DFAFC" toRefs="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e4043-wk-Fact-62C2FD859415581FBF973FCE94B77BC7" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6869-wk-Fact-62C88B2989C62E56687F801F7DE4D234" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6222-wk-Fact-62D20C34C95D577873AD801F7E784708" toRefs="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1802-wk-Fact-6325E2F134D45571A3E0DD3C60FB9C6F" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23009-wk-Fact-6343757AF4A26430D7A1801F7DD0CC07" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2273-wk-Fact-6353F406AD7D5730BA1BF2FBE27EFAE9" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4204-wk-Fact-636FAEFED881C9A536B7801F7EB61207" toRefs="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4130-wk-Fact-638270EA30AE2FE9D14C801F7E7BF6D8" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14741-wk-Fact-63A8380FD8882B8BF33C801F7F0B001F" toRefs="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11623-wk-Fact-63FD058F80E55C109E636F60FC6CA539" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11308-wk-Fact-6428270E830C52D8A83D9D78EC21F20E" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3868-wk-Fact-643BD36B0A7BD2A450F4801F8291FACD" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34529301e2795-wk-Fact-643D9E90F2225078A9387D3F21E73814 d34529301e2832-wk-Fact-643D9E90F2225078A9387D3F21E73814" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2795-wk-Fact-643D9E90F2225078A9387D3F21E73814 d34529301e2832-wk-Fact-643D9E90F2225078A9387D3F21E73814" toRefs="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2356-wk-Fact-644EBFAF34BD5FBA9B1CF394FD689FBB" toRefs="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3395-wk-Fact-64527C0F87BA22A2495F801F7FFC6A1A" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2788-wk-Fact-648F7B6A7F165EE0A40B6056F82B93C7" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e5107-wk-Fact-6490FB80A4F21290128A801F7FC0275E" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e4175-wk-Fact-64B6841D8A9647CC861B801F81B47923" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4175-wk-Fact-64B6841D8A9647CC861B801F81B47923" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5594-wk-Fact-64DE649A1DC85272824F592AAE2FEBD3" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5689-wk-Fact-65066DE8900A50DCDF11801F7F0E6375" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787 d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787 d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787 d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3535-wk-Fact-654FE5FF7865D1DED1CD801F815171FE" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3535-wk-Fact-654FE5FF7865D1DED1CD801F815171FE" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4262-wk-Fact-6556B2C27E285E515E05801F82C1264D" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4629-wk-Fact-6586B6AD1EA296008717801F7EBC80FD" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3120-wk-Fact-65AD28ADEA625EEBBB3613A384127FAA" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19578-wk-Fact-65B741C45407AAE78B32801F815BCE12" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-666BF4CEF70690419B91801F81E7FF4C-wk-Fact-666BF4CEF70690419B91801F81E7FF4C" toRefs="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4396-wk-Fact-6675DE4C808280B705BC801F825EB10F" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3343-wk-Fact-66EE9ACDD29C54A495F8D48FB257E0D9" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34509238e2027-wk-Fact-67276C3C3805655E626C801F80B6FF7C" toRefs="TextSelection-1B6D1520B957E6708C32801F8318DAAD-0-wk-Footnote-1B6D1520B957E6708C32801F8318DAAD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10151-wk-Fact-6734B0CCF706755370DC801F82248099" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e9146-wk-Fact-67635FDCF78A5B1F882CF82F5CDD09D7" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9146-wk-Fact-67635FDCF78A5B1F882CF82F5CDD09D7" toRefs="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5774-wk-Fact-678AA5395AAB27D2692D801F7F41983A" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8155-wk-Fact-67C37AC357CC578E8A2CE9AD15A0F5DE" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20125-wk-Fact-67EBD4339740E27DDD1E801F7FFC6246" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3119-wk-Fact-681CAA08E088E04EA79E801F7ECB79CF" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2194-wk-Fact-6828C32532055C2D9F9FCA7D73FE1813" toRefs="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9296-wk-Fact-685DE43906F252099A21B0122F5E2271" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e4154-wk-Fact-6861B27FF0E359E495FAE4664EA2AD95" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4154-wk-Fact-6861B27FF0E359E495FAE4664EA2AD95" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2926-wk-Fact-68A35B6201B05F6791E934C35C4FF3BB" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2823-wk-Fact-68C3B0FD2C4751708C56BFF9C8FF5735" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5398-wk-Fact-68EA97346488548597981D4BC7C4FA17" toRefs="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4584-wk-Fact-691D5136507A5CF6B58B87FA8C2DFF67" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2692-wk-Fact-6933FD29A03F60C5C1DB801F8037A1E9" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2692-wk-Fact-6933FD29A03F60C5C1DB801F8037A1E9" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e7097-wk-Fact-694C315E46A521BE92D5801F7DD0578A" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7097-wk-Fact-694C315E46A521BE92D5801F7DD0578A" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5493-wk-Fact-6955E2160BED229E172F801F7F0EBB71" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34523018e2746-wk-Fact-699213AA4BB320044F47801F81563F2E" toRefs="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7336-wk-Fact-6A1D5D6AF4EC5CA8BE48BCBA53E3E2A8" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11199-wk-Fact-6A5565AC16FAF0E46BF3801F818756A4" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8046-wk-Fact-6A654FC14177C9A6479ADE1ABFE4C4D9" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7554-wk-Fact-6B459265E6775C47B37741B8BA18E170" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22002-wk-Fact-6B515B4176DA3F1E487E801F7E934F57" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3847-wk-Fact-6B869F58FEDE17E7F0E5801F81D500ED" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9796-wk-Fact-6B8B35F0C5A25612B8D5FB3898261F5D" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1768-wk-Fact-6B8F488463125E46B584902709E619F5" toRefs="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5653-wk-Fact-6C6813303FAB516E9EF5ED555B6EFC07" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20324-wk-Fact-6C6A4F5106ED00592CB9801F80B9D6FC" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2543-wk-Fact-6C6D242FEDF05A7CADA10BE9ECFC67DD" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6966-wk-Fact-6C731063DF07515B8278EAAAF41E82F5" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7600-wk-Fact-6C990DD2B2AD4FB4F7BA801F82BE5EDE" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5459-wk-Fact-6CFCA119539F5C0D846D537B1FB079D6" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5459-wk-Fact-6CFCA119539F5C0D846D537B1FB079D6" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2539-wk-Fact-6D3E645E9EBC03EFCF4B801F82A9D31C" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2328-wk-Fact-6D614FEC811C0CB49DA6801F823ECDD2" toRefs="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3876-wk-Fact-6D7C9A2836915BA9A1C8765EC5343BEF" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e3876-wk-Fact-6D7C9A2836915BA9A1C8765EC5343BEF" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14680-wk-Fact-6D8465E75F36770F95BA801F7F0AFDCF" toRefs="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10419-wk-Fact-6D9D6801D8F49E72AC9F801F8247BF37" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3731-wk-Fact-6DB8EEE5D9865BED9C6C65D55477AD7B" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e1984-wk-Fact-6DBE94D819C45C32A44ABAD8E234B1BA" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1984-wk-Fact-6DBE94D819C45C32A44ABAD8E234B1BA" toRefs="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2917-wk-Fact-6DF270940FC65894A5CA91BBF63EB321 d34519344e2076-wk-Fact-6DF270940FC65894A5CA91BBF63EB321" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e12132-wk-Fact-6E43981A243F593FB97D9CA3CEB76E6D" toRefs="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66" toRefs="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e8161-wk-Fact-6E8F52F802E68107D2ED801F7E65A2D6" toRefs="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E" toRefs="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2012-wk-Fact-6EE57D419E98505BB872CDF37DAACD72 d34529301e4965-wk-Fact-6EE57D419E98505BB872CDF37DAACD72" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1736-wk-Fact-6EED17ECA25F58D092D7F74CB80AA63D" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1736-wk-Fact-6EED17ECA25F58D092D7F74CB80AA63D" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6909-wk-Fact-6F45B7B7D9041F4DACD1801F7DC65341" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21009-wk-Fact-6F6B7321CCFF4B9C9028801F7EBC6553" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21009-wk-Fact-6F6B7321CCFF4B9C9028801F7EBC6553" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e3047-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5 d34458032e7826-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3047-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5 d34458032e7826-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10622-wk-Fact-707FF8E8FE2A2798AEDA801F8220322D" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916 d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916 d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916 d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916 d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916 d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916 d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2299-wk-Fact-70A89F04606E5C478C49B14416D6CE2D" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24365-wk-Fact-70AB9AE43B82A35609DD801F7EC60B58" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2578-wk-Fact-70AE538A79495076EEEF801F82A94AED" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9277-wk-Fact-710F79BB7E78505B80B3DD29D470A8D7" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3118-wk-Fact-717E35B044362C67F868801F81BDF57D" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21497-wk-Fact-71ACBA717F716B8607A4801F80F2069A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4461-wk-Fact-721F3FC462E1384F6A25801F7EB6DE98" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4337-wk-Fact-722AC42D560351C29546696AF2E1458D" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1" toRefs="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2880-wk-Fact-7249016752645521B4A449214872FA3C" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5644-wk-Fact-725EA7A18943A5F5A993801F8216D9F7" toRefs="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2213-wk-Fact-726DD7EC40B27F8510DA801F81EF7AF4" toRefs="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21448-wk-Fact-72790138A19EAC31CA09801F807E33DE" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21448-wk-Fact-72790138A19EAC31CA09801F807E33DE" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2455-wk-Fact-729C012AD2435DBEB3A6986C8E3F0F60" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4136-wk-Fact-72DE426063852BE9262D801F7E146126" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7161-wk-Fact-72F12325846A255A2934801F823A73B8" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9911-wk-Fact-72FA6A6777398A051E57801F7E7966A0" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20971-wk-Fact-732BFC75898DC67D4551801F7E2006BB" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4817-wk-Fact-7331B3996B7156028ABA17B0B6F034DA" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9495-wk-Fact-73596D19D7B15B05E6A9801F820D7E85 d34661879e11465-wk-Fact-73596D19D7B15B05E6A9801F820D7E85" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e1963-wk-Fact-73675557E3290275CFB2801F8179DBF8" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7166-wk-Fact-73C56959049A2D57F4C1801F82A49C55" toRefs="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-7414237C2DE558C2A570279D3852E356-wk-Fact-7414237C2DE558C2A570279D3852E356" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2467-wk-Fact-74710073FCDBB8BA38A9AB460A554FBE" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3867-wk-Fact-74BDF519ACFF7C0C48A3801F819B32C2" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3970-wk-Fact-74C1614E6C935CA08B5422036CFAC156" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2284-wk-Fact-74D8FB512BB0C16FBCA9801F7F9F040A" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-7501CCEC7B4D0192DEEF801F81E84FD3-wk-Fact-7501CCEC7B4D0192DEEF801F81E84FD3" toRefs="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2419-wk-Fact-752CABA8E508F4880C7C801F81391188" toRefs="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2419-wk-Fact-752CABA8E508F4880C7C801F81391188" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24736-wk-Fact-753465D7A627C0C6C864801F7E922133" toRefs="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24736-wk-Fact-753465D7A627C0C6C864801F7E922133" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4507-wk-Fact-753BABE650466031F517AB460A3BD22C d34458036e4596-wk-Fact-753BABE650466031F517AB460A3BD22C" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e27650-wk-Fact-753DD635276562AAADD0801F7E9ACA47" toRefs="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14523-wk-Fact-759056D49537AAD9E899801F7F0EAFC2" toRefs="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e8401-wk-Fact-759DF68F819A59389A4AC00C6D1F61C6" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8401-wk-Fact-759DF68F819A59389A4AC00C6D1F61C6" toRefs="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11678-wk-Fact-75D45301C70951D3867054250941F9AE" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2898-wk-Fact-75F7E84A031750E0A49F77B3AEF45671" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e3901-wk-Fact-760E7E634C39F63FC233801F7E0F6B98" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3901-wk-Fact-760E7E634C39F63FC233801F7E0F6B98" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2149-wk-Fact-7613A3BE7B3C52548720187D3E9B29CB" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22951-wk-Fact-761A045667090BCC60CB801F7E75C1C9" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22422-wk-Fact-7658020187599961F4A5801F80F4D671" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10942-wk-Fact-76700083BB585619B1B78E77F16D4429" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e3436-wk-Fact-769F1280EBF192E593C5801F7F419E21 d34523018e2680-wk-Fact-769F1280EBF192E593C5801F7F419E21" toRefs="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3436-wk-Fact-769F1280EBF192E593C5801F7F419E21 d34523018e2680-wk-Fact-769F1280EBF192E593C5801F7F419E21" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11643-wk-Fact-76BFF3E0ECCB06EAD23D801F82CA7536" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e12151-wk-Fact-772A4F70D4985AACB86E028464DB65E7" toRefs="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3273-wk-Fact-7747152390E65C85B0029AEB713C8F55" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2474-wk-Fact-77801D3C57905C8C93FABB42EA4BACE1" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8495-wk-Fact-778F76F534866B4C274BDE209664FDB1" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5350-wk-Fact-783053BF5BCEAF088BA3801F7F1B9FD6" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e5350-wk-Fact-783053BF5BCEAF088BA3801F7F1B9FD6" toRefs="TextSelection-90990489192C50447F2C801F831133E5-0-wk-Footnote-90990489192C50447F2C801F831133E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e1606-wk-Fact-7891E4C59FB8C240ECF8801F7ED8C974" toRefs="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3032-wk-Fact-789D85DCBD5CAAFAC780801F7E9C6FBB" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1883-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409 d34468079e2144-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2355-wk-Fact-78EA4E1EB168C708F8A0801F7E99078A" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21371-wk-Fact-7901A59E0B6D8AB6EE3A801F81370C3C" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4096-wk-Fact-7918FE9F0C5FFB8CDA07801F8037553C" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10517-wk-Fact-791EAF9C41A719B8AE07801F821A4C3E" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2070-wk-Fact-7952617F186F5E01B2B1132FE8B404CC" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2070-wk-Fact-7952617F186F5E01B2B1132FE8B404CC" toRefs="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9130-wk-Fact-798874FBBD7A57AD8D423B83A189AC62" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e1903-wk-Fact-798B7A350A5E13556B82801F82A90157" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2442-wk-Fact-7993C88B8674482BA763E3D78533039D" toRefs="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2031-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04 d34529301e4705-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D" toRefs="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2683-wk-Fact-7A0B0B97234568FCF5ED801F8263730F" toRefs="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2683-wk-Fact-7A0B0B97234568FCF5ED801F8263730F" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2679-wk-Fact-7A1567D519C2CFE241FC801F7EDF7AAB" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e7877-wk-Fact-7A6A6BE7AC6954D4AA27EA74C266AF79" toRefs="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3958-wk-Fact-7A6C38FEB7545F758C160BD056416478" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2110-wk-Fact-7A7351669AE1529E97E70E745B581A4A" toRefs="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2206-wk-Fact-7AB6A34649A53C89765A801F808558FA d34523018e1655-wk-Fact-7AB6A34649A53C89765A801F808558FA" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2116-wk-Fact-7B2716E1C24FE2422E5FCF6EF0CCB67A" toRefs="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3227-wk-Fact-7B3EE432FBB3579996CA5926DC51D999" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e2988-wk-Fact-7BA94F9ED2EC5F1A966CB3304B53AF56" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3427-wk-Fact-7BB330D73286C9EA44FD801F8148FF86" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3427-wk-Fact-7BB330D73286C9EA44FD801F8148FF86" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2265-wk-Fact-7BBA68F22C4A3BB9286A801F7F95841D" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34498941e1559-wk-Fact-7BD53D154D3451E59F8DCFF457C25E21" toRefs="TextSelection-80773A0CFA5531791DCE801F8317B622-0-wk-Footnote-80773A0CFA5531791DCE801F8317B622_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2833-wk-Fact-7C5CEEA458045143ABEBEAB70E5E4CE1" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1678-wk-Fact-7C95FE45B026572C9C6575056E409438" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4163-wk-Fact-7CA1E8DB0EEA61585658801F8257D851" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3787-wk-Fact-7CE1E0EF766B581893CBC5A1DB76D621" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11604-wk-Fact-7CFB7F412548587F896D99F507DBCD19" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14830-wk-Fact-7D0DED212B5AD84E6737801F7F10668E" toRefs="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6705-wk-Fact-7D359D4DCFEB1E002351801F7DEFB4FE" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24200-wk-Fact-7D93FC3424C9D543074F801F7E17454A" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24200-wk-Fact-7D93FC3424C9D543074F801F7E17454A" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7709-wk-Fact-7DD40C3C0E31507482EEDE2CEC4E867A" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2375-wk-Fact-7DDB8A53183E908A30E5801F80CDA452 d34586122e4719-wk-Fact-7DDB8A53183E908A30E5801F80CDA452" toRefs="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8957-wk-Fact-7DFD68914530594697567F87F6C1044E" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e2023-wk-Fact-7E730D2AED1D0795DF3D801F82A5E242" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2023-wk-Fact-7E730D2AED1D0795DF3D801F82A5E242" toRefs="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8713-wk-Fact-7F748C891A4E562C8DD5B4D163881419" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1943-wk-Fact-7F7E046052F852439B2A0884F029C60C d34514486e1927-wk-Fact-7F7E046052F852439B2A0884F029C60C d34586122e6272-wk-Fact-7F7E046052F852439B2A0884F029C60C" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34423000e1943-wk-Fact-7F7E046052F852439B2A0884F029C60C d34514486e1927-wk-Fact-7F7E046052F852439B2A0884F029C60C d34586122e6272-wk-Fact-7F7E046052F852439B2A0884F029C60C" toRefs="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4037-wk-Fact-7F97E24FF7E81A914961801F825D5D9B" toRefs="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4037-wk-Fact-7F97E24FF7E81A914961801F825D5D9B" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4601-wk-Fact-7F9C57983A364C82C7B8D85DDABE68FA" toRefs="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4960-wk-Fact-7FAB76E95E2266217B40801F7FD40652" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5708-wk-Fact-7FCA3EEAD1E583C6014B801F7F1DA91D" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e1948-wk-Fact-7FFA047BAF9ADE9DA824801F81229B16" toRefs="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2500-wk-Fact-80135A3F2616CE4B3FFE801F7E2617E5" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9201-wk-Fact-801912F69D61590398C5CEEE0D4764FE" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e6695-wk-Fact-8027040D1DF4721D6272801F7F0F7A3C" toRefs="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2990-wk-Fact-80382989DBE2B2A99A05801F7F3B9C46" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e7548-wk-Fact-8060BA9EC76EA962A052801F7EFC1E79" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843" toRefs="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3782-wk-Fact-80E620F0079F9C476673AB460A2BDC83" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9910-wk-Fact-80FEC9DEE7D7156F2215801F8243459B" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e9127-wk-Fact-810B1FD04766529CA8FCD18FC3883D4B" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9127-wk-Fact-810B1FD04766529CA8FCD18FC3883D4B" toRefs="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8941-wk-Fact-813264E7C289A5D5ECB7DE20AAB91829" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1656-wk-Fact-813E0BD933FADF623E45801F80DB191F" toRefs="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5509-wk-Fact-81475F9812C2036C8F54801F821721D4" toRefs="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9240-wk-Fact-81945090A4FFE403DEA2DE22C004E729" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24756-wk-Fact-81BF9447839E6277781D801F8110D158" toRefs="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24756-wk-Fact-81BF9447839E6277781D801F8110D158" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2122-wk-Fact-81C7586111FF1F4FF011CB2DE6212D3A" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11421-wk-Fact-821C54ED7C862C84B170801F7E88C49D" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2886-wk-Fact-823CFC536B2415CC760F801F821963E0 d34661879e9771-wk-Fact-823CFC536B2415CC760F801F821963E0" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2886-wk-Fact-823CFC536B2415CC760F801F821963E0 d34661879e9771-wk-Fact-823CFC536B2415CC760F801F821963E0" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23428-wk-Fact-825A924821B029DD3CBD801F7E981ACD" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2233-wk-Fact-8266B3DB731A5825ABEED6BC4888318C" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3274-wk-Fact-82DF9C203377249F2601AB460A6EF1A6" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3932-wk-Fact-82F8E32880CAD288D376801F7EB6D6B3" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e5040-wk-Fact-831DB9576209A9ACB46A801F7FE98854" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3698-wk-Fact-8322EE49CD6D5BD6A6C9E81023F930D3" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24852-wk-Fact-83666425473B48E80163801F7E7455A0" toRefs="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24852-wk-Fact-83666425473B48E80163801F7E7455A0" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2177-wk-Fact-8376203D932F5639A955E3156349142D" toRefs="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11929-wk-Fact-83D643576F2E4A880436DE3EC9DE5D5D" toRefs="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1689-wk-Fact-83E1143E04F5A91F1232801F80AB7507" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1689-wk-Fact-83E1143E04F5A91F1232801F80AB7507" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3013-wk-Fact-8413E641C55A4976D254801F7EBA5C58" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11125-wk-Fact-841D58224C20C05AA3AF801F82B7E834" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24384-wk-Fact-846B26327BEE6C94A307801F8102D6F8" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e10061-wk-Fact-8479D37C35D17BB7F483DE31473AEC66" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10061-wk-Fact-8479D37C35D17BB7F483DE31473AEC66" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3160-wk-Fact-84A9A3C57D9468DD47C4801F80615D38" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21633-wk-Fact-84CFAE8D822C91DEF42D801F80EA8284" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22970-wk-Fact-851A65644168F7A09FFC801F80C5042F" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3717-wk-Fact-855EC1B85F5A5E84B3ACFB91DAA41FBE" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3299-wk-Fact-856AC81ACCEC5011ACDEA26123CED5EE" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e7120-wk-Fact-85827D800B7F9E2973DA801F80DC2984" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e7120-wk-Fact-85827D800B7F9E2973DA801F80DC2984" toRefs="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1478-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E d34586122e4283-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E d34586122e5467-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E d34586122e6766-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD" toRefs="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10457-wk-Fact-85CA80585D2874D45B54801F82219616" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9946-wk-Fact-85E9E7AA5D595959A86313A1C0CA3A83" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1737-wk-Fact-860CFBCF363653FC86BC0095D64D864D" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3957-wk-Fact-86415D4CAB5E59DBBD55EC735E24E7F2" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e3957-wk-Fact-86415D4CAB5E59DBBD55EC735E24E7F2" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2487-wk-Fact-8641DEB0F388E97194C5801F8260F41E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5597-wk-Fact-868049DF95AAA71CE427801F81DEE776" toRefs="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3545-wk-Fact-86C1962CA09E5E038A8356A346B1940A" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19119-wk-Fact-86DEF6460514D6862E92801F80F116B8" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2102-wk-Fact-86FCF4A9AC35C93C9512CB2DE640F043" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9464-wk-Fact-871389EB45915ACC83623B1FF4BA7915" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5898-wk-Fact-87316DD24D8C6C196E84801F813793DC" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11347-wk-Fact-8784FEB4B63967D223B8D083004C1A1D" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11495-wk-Fact-87951FBDF4C375B6753E801F81755F3D" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2533-wk-Fact-879A192382A7330D4759801F7E97C8E7" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6118-wk-Fact-87ADA00DA5C5D3DB1F1C801F7E7826DD" toRefs="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4968-wk-Fact-87DF5DD60C52EBFDCA12801F7F002312" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6071-wk-Fact-87E59A336B0A618A1F1D801F7E8AD801" toRefs="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7748-wk-Fact-8806516F8B0543D58C87801F7DEE6452" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1782-wk-Fact-8812B04713F051B0AF0A1F76A2EBAA85" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9891-wk-Fact-881709D18F145B4CB609A31E6FB0D982" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5728-wk-Fact-8837BD3A347667C998B0801F7F1627AE" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e1818-wk-Fact-8847B6BEC2EEE8F6B106801F81DD12BF" toRefs="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19500-wk-Fact-885642E3FF5078D7E180801F8136338F" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6936-wk-Fact-8882814ACBF86601CC36801F7E885BFB" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14601-wk-Fact-88C4C82D6AD7A0143C97801F7F066B14" toRefs="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10170-wk-Fact-88DB7F79687BCA54F881801F82414571" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8828-wk-Fact-88ED49AD8223552FBECDEDC3724ABA7A" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1811-wk-Fact-88F8256AB81452CCA864D49A834C7EC7" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21652-wk-Fact-8901B45EE693D1A5A42B801F7ECF7B1B" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23132-wk-Fact-891D6E78C37A848AAD66801F8103A7FC" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23132-wk-Fact-891D6E78C37A848AAD66801F8103A7FC" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4879-wk-Fact-8927DC5325C709371727801F81339286" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10703-wk-Fact-893F257BDBDAF32100A5801F81FC6EC8" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3978-wk-Fact-89458B2935BE5CA5AF20EE141CB4DDAE" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2873-wk-Fact-897222CA063B5438BA0EAAE6C107C7B6" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4178-wk-Fact-89A0361AA02CC1515879801F8245AD29" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4663-wk-Fact-89C1C2FF8BAE35AB2220801F7FC7C2B0" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6720-wk-Fact-89DB22A158608FA629D2801F8240115D" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8256-wk-Fact-89FA221AF605553CA7321BB43DD73142" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3828-wk-Fact-8A13EF2DD2417F08F8E0D083BFECB190" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2355-wk-Fact-8A1F93452E32511246DC801F7F0CF497" toRefs="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2355-wk-Fact-8A1F93452E32511246DC801F7F0CF497" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2550-wk-Fact-8A35E5331DDD75689E2C801F829E69B4" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3977-wk-Fact-8A3D3D8306295DD7A9624AA8071C2632" toRefs="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4526-wk-Fact-8A5BA32EB90D3260C033801F82C4798C" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34496162e5553-wk-Fact-8A8CC7E111309130A3F9023AB1C2B87A" toRefs="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2730-wk-Fact-8ACD50A587CEC7867541801F81EBAED4 d34661879e9669-wk-Fact-8ACD50A587CEC7867541801F81EBAED4" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2730-wk-Fact-8ACD50A587CEC7867541801F81EBAED4 d34661879e9669-wk-Fact-8ACD50A587CEC7867541801F81EBAED4" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20304-wk-Fact-8ADF784CF3544B521652801F7DE5428D" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6832-wk-Fact-8AF87FC965702ACF9270801F80DB9038" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e9677-wk-Fact-8B4254960B2E50548FD24AC21D991E6A" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9677-wk-Fact-8B4254960B2E50548FD24AC21D991E6A" toRefs="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3713-wk-Fact-8B63FA0079F150DF8891946F5AC894DF" toRefs="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2217-wk-Fact-8B8742C522CFC603BD73CF6F077A96B2" toRefs="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24423-wk-Fact-8C4DF439940F0708B5F7801F7E87B8C4" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2022-wk-Fact-8C7EA7D7F43807E0390D801F7ECD3AD1" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2783-wk-Fact-8D2F59DA09B7FE8B09E6801F8148C80C" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9757-wk-Fact-8D841CA3F88A9E41A873801F823E6F2C" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2769-wk-Fact-8E28EFA6EB215BD0993C634ED8262AFF" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3099-wk-Fact-8E4ECE37A9934A1B313CD083BFE52A99" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19216-wk-Fact-8E57072868D5458BD30A801F7EA6C7E3" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11174-wk-Fact-8EA2843D9C6DF208E5AC801F820B737B" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e9151-wk-Fact-8EA5960B76BF5C90C28C801F7E3E9349" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3435-wk-Fact-8EAE4EB5674D9D1095E0801F7FEA5B11" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4756-wk-Fact-8F27495BD68561A9487C801F7DC77927" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD" toRefs="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10008-wk-Fact-8FB2D62A8EBEF9B34218801F8228C56A" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2724-wk-Fact-901416E0C584524B87DD0ACFD655A517" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6061-wk-Fact-9050CF9D6C997910CB96801F7E3C9CE2" toRefs="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5144-wk-Fact-90C896B3582A49B87DFDE5206F18DC24" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5144-wk-Fact-90C896B3582A49B87DFDE5206F18DC24" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34496162e5514-wk-Fact-9120BAFF50D1AEC6196F023AB29B9891" toRefs="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e2565-wk-Fact-9148FA2E247D578D82EBB7DE0DEF4259" toRefs="TextSelection-CE8D3299C54E02D979FA801F8303D076-0-wk-Footnote-CE8D3299C54E02D979FA801F8303D076_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e6714-wk-Fact-9179C071F6FA44A44864801F7F0CC3E4" toRefs="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7786-wk-Fact-91841B5580A65F1AB688FCF8F5511CF9" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23312-wk-Fact-91858568C939C7AE738C801F80EC0790" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4927-wk-Fact-91D4D1D5754CB771E91B801F7F1DC0E3" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4927-wk-Fact-91D4D1D5754CB771E91B801F7F1DC0E3" toRefs="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1507-wk-Fact-92028286814C58C496DAD3D9CE00EA8A" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6052-wk-Fact-921D990124AD87101C23801F7E92DAFD" toRefs="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2616-wk-Fact-923B7EF4CCA59EE61341801F7F2C1401" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9841-wk-Fact-92524ACC782CD4CDC985801F7E45AECD" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2318-wk-Fact-92574249FA1B5792A5D2D0D169042981" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e1864-wk-Fact-925E28131BC6D032A9E6801F827FCD84" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5412-wk-Fact-9281B6AE49D7C2B2BA97801F825215AE" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5412-wk-Fact-9281B6AE49D7C2B2BA97801F825215AE" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2677-wk-Fact-92CFAEDA1D275CCFA954DF7DFEDFAB50" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22403-wk-Fact-92F2D29881335576C0FD801F7E7CED30" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3673-wk-Fact-931C9AE7EA695C8789803ED34BF3218D" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2051-wk-Fact-93625872A9D656368D7E152DE8C08019" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2051-wk-Fact-93625872A9D656368D7E152DE8C08019" toRefs="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6747-wk-Fact-936D6A2CF388244CD289801F80ED7BAA" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8456-wk-Fact-937F899827ED53BF9733BC0E5A2C276B" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2744-wk-Fact-93A83F7AF2C8708F880AD083C00A9C02" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20504-wk-Fact-93B234B3231C3F13BFA0801F813200A4" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e3015-wk-Fact-93DDC1938188F9E00A7E801F808A913C d34545404e9352-wk-Fact-93DDC1938188F9E00A7E801F808A913C" toRefs="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3015-wk-Fact-93DDC1938188F9E00A7E801F808A913C d34545404e9352-wk-Fact-93DDC1938188F9E00A7E801F808A913C" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8793-wk-Fact-93F788C458704E75C6BDDE20A3FD7BC2" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34529301e2376-wk-Fact-940CD216AF3B5681959A8635C41B9FA0 d34529301e3122-wk-Fact-940CD216AF3B5681959A8635C41B9FA0" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2376-wk-Fact-940CD216AF3B5681959A8635C41B9FA0 d34529301e3122-wk-Fact-940CD216AF3B5681959A8635C41B9FA0" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-9426C78F4864E19099BE801F824ECFDE-wk-Fact-9426C78F4864E19099BE801F824ECFDE" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3923-wk-Fact-942BEE47CDD75096A0AEFEFF55769ACA" toRefs="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3828-wk-Fact-945DBFC591102C8BB117801F803ED887" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3138-wk-Fact-94EEAC12B164219871FE801F8106C475" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2197-wk-Fact-95156657E2A6B44ABF2BCF6F034F6554" toRefs="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8719-wk-Fact-953503D0D518BB2D4A20DE20A0816CCB" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24326-wk-Fact-9560997241A91E7FCCDC801F7E780256" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5682-wk-Fact-95B614941C4A9D8BE504801F81DF6C76" toRefs="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e6346-wk-Fact-95C3D7179E1C7455799D801F7EC9AC19" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6346-wk-Fact-95C3D7179E1C7455799D801F7EC9AC19" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20285-wk-Fact-9667992F4720EEBE8507801F7E9223CD" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9273-wk-Fact-9672E748D5A35A1AB1475BEE8450A06D" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2829-wk-Fact-96A8E9E0E31B5853A1D087253B1B6301" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2383-wk-Fact-96EE1FC21874513CAC2C4A3E7FCA2B60" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5164-wk-Fact-9703446C4160595B906FE4A04D8E2262" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5164-wk-Fact-9703446C4160595B906FE4A04D8E2262" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2007-wk-Fact-9727ED04B3395B12A9B3B5A9C5599258" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4" toRefs="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e4551-wk-Fact-97A49B0ECEA9517FFBB7801F7E06BC9B" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4551-wk-Fact-97A49B0ECEA9517FFBB7801F7E06BC9B" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11105-wk-Fact-982E769D9AA15AF18F31878D9A3BFD37" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3500-wk-Fact-987B313113ED573B8A810513702726B3" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e27669-wk-Fact-98BFF5893FA87300516A801F7E8D015A" toRefs="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24018-wk-Fact-98EC241C0428BD0AE10C801F7E1180B1" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24018-wk-Fact-98EC241C0428BD0AE10C801F7E1180B1" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4565-wk-Fact-98F2A54AC46334361761E5206F313F68" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1459-wk-Fact-99447C56530B57BB99F3272D91D61246 d34586122e4264-wk-Fact-99447C56530B57BB99F3272D91D61246 d34586122e5448-wk-Fact-99447C56530B57BB99F3272D91D61246 d34586122e6747-wk-Fact-99447C56530B57BB99F3272D91D61246" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4309-wk-Fact-9967D5B336225ACF8C7C4F042D7A1102" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7281-wk-Fact-999640AF0F3A5772A546D4FCE619DC98" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e16278-wk-Fact-99AD0A449205CDDA0508801F827E53C0" toRefs="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e3786-wk-Fact-99C23B4E5EC579EA4F26801F7DF197AB" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3786-wk-Fact-99C23B4E5EC579EA4F26801F7DF197AB" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20382-wk-Fact-99C3C972AE8486FA89F4801F7E139ECD" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23351-wk-Fact-99E09AD183E83160CC87801F7E8A836A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4441-wk-Fact-99F422E9BA7958F2846EA6E7D03791DC" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7301-wk-Fact-9A23FE915E5D4E701F2A801F8173E1A9" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6195-wk-Fact-9A4592A1FACA84D5869A801F8024E489" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5672-wk-Fact-9A5FE66D958474E62B0B801F7E97F314" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2882-wk-Fact-9AFB6DAE6BF5A7027999801F7ED8C9BD" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8842-wk-Fact-9B1DCEF966A955A2B00217967C88ACDA" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7133-wk-Fact-9BBA998B2CFF5DED95D8D386714FFE6A" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2028-wk-Fact-9C0330EE00BC595DB7D0BE5577BD9383" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5393-wk-Fact-9C12B5D1FDF6DC56A5B8801F7E7A2727" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5393-wk-Fact-9C12B5D1FDF6DC56A5B8801F7E7A2727" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3669-wk-Fact-9C15C23B033F2F07DF6B801F823D2E2E" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10603-wk-Fact-9C416A8427655856201B801F81FBE3C5" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9533-wk-Fact-9C92BDF888590B6AA55E801F82481AA2 d34661879e11504-wk-Fact-9C92BDF888590B6AA55E801F82481AA2" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3099-wk-Fact-9CA9F5D6598257E8B08FB6226CA68B1F" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1836-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F d34496162e9149-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8138-wk-Fact-9CF783F2B69B5D93A482F2C929ED1566" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e1937-wk-Fact-9D26812D16985C8A83C043FBACDEB01A" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1937-wk-Fact-9D26812D16985C8A83C043FBACDEB01A" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e4863-wk-Fact-9D37210D257EF686844E801F800CB2CA" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4863-wk-Fact-9D37210D257EF686844E801F800CB2CA" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21092-wk-Fact-9D5C193DFCEF155D2BA5801F8158E97D" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14721-wk-Fact-9D6C46A96E8CE95D147B801F7F0D5028" toRefs="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-9D817CFBE8E27DFE8D7A801F80886593-wk-Fact-9D817CFBE8E27DFE8D7A801F80886593" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23979-wk-Fact-9D87527D8A9492D75841801F7EA8D8E9" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23979-wk-Fact-9D87527D8A9492D75841801F7EA8D8E9" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2416-wk-Fact-9EBE45B86EF3A4ED4BB6801F7E8624C1" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3200-wk-Fact-9EC5142FF1350AFCC36A801F7FDF5605" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4195-wk-Fact-9EE24B8CE46E4AFB1CAED083C012D553" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e4195-wk-Fact-9EE24B8CE46E4AFB1CAED083C012D553" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8880-wk-Fact-9EED0554CF1857D8B1887EDCD838B377" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2625-wk-Fact-9F4115E6A91F5D5A8F7DBFD6C8FE97D2" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8680-wk-Fact-9F9BFF3F49E4598B845CC5FD385C80FE" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4687-wk-Fact-A0164F459FB4FEDAE7F5E5206F2A0E3C" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1936-wk-Fact-A0580F12FEFB5184AF83F23E7628F9E3" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e1929-wk-Fact-A089F24D480155BE84E9E384AAB61EDF" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3520-wk-Fact-A08B5E2989AB58B0A8139571535F4EFB" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3144-wk-Fact-A0AE51B2124A549B9B82AE9C29097AF0" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2924-wk-Fact-A1514905E048F0FFA68C801F800B7A4F" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5465-wk-Fact-A161DD024D9F78FE3297801F82161F7E" toRefs="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22544-wk-Fact-A16FEE27FC5491A49909801F81596307" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7506-wk-Fact-A1A886242BD55B97B9C6B7AE43B77A3F" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21029-wk-Fact-A1CED4074FA1FDF7A5FC801F8022EF72" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21029-wk-Fact-A1CED4074FA1FDF7A5FC801F8022EF72" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3282-wk-Fact-A1E2DBD4AD5154A27F57D083C01AB381" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2599-wk-Fact-A1E8D06C4BADD1A6A43D801F819A99BD" toRefs="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5136-wk-Fact-A26746429C1908FDD4E5801F7F1B893B" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20202-wk-Fact-A2751CB79E5C657710FC801F7E6BAF40" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11212-wk-Fact-A2924772A01FADBA0AFC801F8209EC9B" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14762-wk-Fact-A2A4CC4306DEA373350A801F7F0B3827" toRefs="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34496162e8665-wk-Fact-A2C8D5C7533E515EB203A3E9F7008E7C" toRefs="TextSelection-00B1F244805F23E229ECE4C97135F977-0-wk-Footnote-00B1F244805F23E229ECE4C97135F977_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e9166-wk-Fact-A2F4496694D82FBCD30CDE22BCA5386D" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9166-wk-Fact-A2F4496694D82FBCD30CDE22BCA5386D" toRefs="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20105-wk-Fact-A320D830DB302CFA5F67801F7E9BA879" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9989-wk-Fact-A339E48382383D402CC3801F81FAD97A" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22660-wk-Fact-A349362A7F0F24D7725D801F8161CBEA" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1488-wk-Fact-A3B4914B172C5BC59639B98C6FB3F588" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e2648-wk-Fact-A3F4A2E507D5855FCA57801F7FA5036E" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB" toRefs="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB" toRefs="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e8087-wk-Fact-A41309C827BD3760EAD4801F7E667623" toRefs="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e8087-wk-Fact-A41309C827BD3760EAD4801F7E667623" toRefs="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2641-wk-Fact-A42CFC7A5BC659D7A3189F4AF6F5EC83" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22306-wk-Fact-A43617795041B30B05CB801F7ECAF0A6" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10825-wk-Fact-A4C2A6D0663F5845176B801F81F80E32" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2303-wk-Fact-A51B51A828275272A7C573C440BF63F4 d34498941e1766-wk-Fact-A51B51A828275272A7C573C440BF63F4" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20951-wk-Fact-A543C6B15A6318DF95B8801F7E694554" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e20951-wk-Fact-A543C6B15A6318DF95B8801F7E694554" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8995-wk-Fact-A561864E833387BD903CDE210367E099" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3829-wk-Fact-A591E3AF789D5180A58CDB8F61EA51D0" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9953-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639 d34523018e2837-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21351-wk-Fact-A621438BD8C8D4F1F9D1801F7E16B826" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21351-wk-Fact-A621438BD8C8D4F1F9D1801F7E16B826" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5266-wk-Fact-A63F83E6394508389223801F8216DDFD" toRefs="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e3353-wk-Fact-A641170D49AD547A8914C2CE48D6E64F d34523018e2531-wk-Fact-A641170D49AD547A8914C2CE48D6E64F" toRefs="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3353-wk-Fact-A641170D49AD547A8914C2CE48D6E64F d34523018e2531-wk-Fact-A641170D49AD547A8914C2CE48D6E64F" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21274-wk-Fact-A66838ACCE990B7D1974801F80F24A8B" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3920-wk-Fact-A684767625371E2C2BE9801F82707B93" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1703-wk-Fact-A68C33E581015A07BF02867B616768F9" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7040-wk-Fact-A6B4F6B324375D53B10094F17B3C65B3" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5310-wk-Fact-A6CC259B83A6C2A0E036801F81DB019C" toRefs="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4899-wk-Fact-A6D28E13D65A157B5F67801F81407A21" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e7629-wk-Fact-A6FC51038FA814464645801F81FD9227" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19597-wk-Fact-A730E8A1EA686A58B9A9801F812B26B3" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11382-wk-Fact-A794165CEA5A51B0A3B6004B3D79A885" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2683-wk-Fact-A7D8A59FD536FC537EA7801F82CDAF6E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3563-wk-Fact-A80502CBDD0A15BE22F7801F812601A0" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e7933-wk-Fact-A80D878425B55E7DB0E92B5480994305" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7933-wk-Fact-A80D878425B55E7DB0E92B5480994305" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2333-wk-Fact-A80DE1A520AD557392F9597D3D60F83A" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14802-wk-Fact-A816C66465B359E5274A801F7F026BDF" toRefs="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23960-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961 d34661879e26031-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23960-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961 d34661879e26031-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7207-wk-Fact-A83EDCFE0B465D95A739D4248C9470C0" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34423000e3496-wk-Fact-A856A5C9461154769813BC75D3DBEF25 d34458032e7361-wk-Fact-A856A5C9461154769813BC75D3DBEF25" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3496-wk-Fact-A856A5C9461154769813BC75D3DBEF25 d34458032e7361-wk-Fact-A856A5C9461154769813BC75D3DBEF25" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3320-wk-Fact-A866155102FA518DAD8A3AC3849A29ED" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8237-wk-Fact-A8B53B0AF0215974918EFB048833F5CB" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2951-wk-Fact-A8B9CC29B1BD5DCCB10156807AFD46CF" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1783-wk-Fact-A8ECAB64FC345D158EED4CF5EB8D3C49" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5285-wk-Fact-A96A62C6E678423BC122801F80CEE810" toRefs="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6809-wk-Fact-A97915E9582AC1C02322801F80D9D022" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9965-wk-Fact-A982B6EE13215444830BADC0E2C52ACD" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34498941e1513-wk-Fact-A98C87D2BA285EA58206340681E8AC55" toRefs="TextSelection-A750B31D2CDA1870AFBA801F8317F8FF-0-wk-Footnote-A750B31D2CDA1870AFBA801F8317F8FF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e7952-wk-Fact-A9B6D8B90E4D5AC4A32D4CCEFCEEBE96" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7952-wk-Fact-A9B6D8B90E4D5AC4A32D4CCEFCEEBE96" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2305-wk-Fact-AA09423469405CACDD8C801F7F53FDB0" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7728-wk-Fact-AA23783A2EF0547FB95205FE30FF67FA" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3683-wk-Fact-AA448E5E8130401937D9801F80FB6261" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e1969-wk-Fact-AA8CABF2F570588CA468DCE619BE951F" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3241-wk-Fact-AAAC7E6A61915A9AB289BFF791014433" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5260-wk-Fact-AAADFB48294C3599DB10801F82605B2C" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2245-wk-Fact-AAFD78C12C113C0D686D801F8281F391" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2056-wk-Fact-AB13686A614A540891E5DB6A56F3428E" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3873-wk-Fact-AB1A5D7154D55524B1896C7D13EEE1BE" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11237-wk-Fact-AB51FFA5E25BF090B8E4801F821615F8" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24872-wk-Fact-AB5ECEED024AF101A1AC801F8151B0F7" toRefs="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24872-wk-Fact-AB5ECEED024AF101A1AC801F8151B0F7" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1651-wk-Fact-AB74A10364F359F29349BB0B21ECB2F3" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1651-wk-Fact-AB74A10364F359F29349BB0B21ECB2F3" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9191-wk-Fact-AB82307C2179145E356A801F824B4798" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24103-wk-Fact-ABB7C1831B6036A1961D801F8111BCF2" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24103-wk-Fact-ABB7C1831B6036A1961D801F8111BCF2" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5388-wk-Fact-AC840D295965D51F3AEB801F7F1296E1" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e5388-wk-Fact-AC840D295965D51F3AEB801F7F1296E1" toRefs="TextSelection-90990489192C50447F2C801F831133E5-0-wk-Footnote-90990489192C50447F2C801F831133E5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1924-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD d34514486e1908-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD d34586122e6253-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34423000e1924-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD d34514486e1908-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD d34586122e6253-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD" toRefs="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11549-wk-Fact-AD6A89B15A765F7DA13013F765D9BCCE" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3344-wk-Fact-AD91E61606B3F9D31977801F7FE885E5" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5902-wk-Fact-ADB247F63E15672E1A7D801F7DC78C20" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3208-wk-Fact-ADE382A1D3945AC3B461E0B1B11CBDE7" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19816-wk-Fact-ADFD09EFBAAE17E76B8C801F812CED5A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7561-wk-Fact-AE2B016013A759EB976F0B6B8F4C219E" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3300-wk-Fact-AE4BE372D7E0566CA33FCE7A63C55830" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2176-wk-Fact-AEFB6F4B2F0FF7051095CB2DE528EDFE" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5440-wk-Fact-AF2E68BBA8025433B3103D89BFF2ABC1" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5440-wk-Fact-AF2E68BBA8025433B3103D89BFF2ABC1" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23921-wk-Fact-AF3B835BA88A5AF10D40801F814757D9" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23921-wk-Fact-AF3B835BA88A5AF10D40801F814757D9" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e16176-wk-Fact-AF3CA0CEC8AD61474DDB801F82306D75" toRefs="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e8551-wk-Fact-AF503AE62454526EB03769AE56899F54" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8551-wk-Fact-AF503AE62454526EB03769AE56899F54" toRefs="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3086-wk-Fact-AF6AA38DDBAD57078BE06AFBF6047957" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2797-wk-Fact-AF85C0A522725220A32AC451BBAD97DA" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6094-wk-Fact-AF8B407E154F54148E312BE4E9BB335A" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2866-wk-Fact-AFB9A55388F572AD8D2E801F7FC2597A" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23094-wk-Fact-B027583F189DF18A6C25801F81488DCF" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21555-wk-Fact-B0690B2915B8FC4A125C801F80217B36" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11096-wk-Fact-B06D18314819524CDB53801F8224ECF4" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-B0ADFA04558E26682149801F804BAD07-wk-Fact-B0ADFA04558E26682149801F804BAD07" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9258-wk-Fact-B0C3BCD9194159029B0449658B7BCFBA" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2963-wk-Fact-B14453A638517C4D7C51801F82449662 d34661879e9829-wk-Fact-B14453A638517C4D7C51801F82449662" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11949-wk-Fact-B14A778A0529F4E56FC1DE3ECD2EE7E6" toRefs="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5097-wk-Fact-B17BA65FC5E9803F8ED2801F8133E381" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-B1B9FBB3E65B02DB442A801F8086325E-wk-Fact-B1B9FBB3E65B02DB442A801F8086325E" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11475-wk-Fact-B1C55F4CB7D652428FCC68218AAE6DD5" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2222-wk-Fact-B1E7467675494F8418B3801F82B05100" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23229-wk-Fact-B1F66149E5D30EF98A05801F81603EA8" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23229-wk-Fact-B1F66149E5D30EF98A05801F81603EA8" toRefs="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4419-wk-Fact-B1FE1F215AFFABD9B609801F81378823" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1792-wk-Fact-B2196219F55E53698D0DA829DF1E2B27" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10114-wk-Fact-B2445D4B47D85E9CBA4A74E1190125C3" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6897-wk-Fact-B24D04AD1CFE5421B8AAB5E1AE97DC0A" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3177-wk-Fact-B281E1948A327D1F074D801F7F417F9A" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-B2C06C2292CD5F05AEAF801F825BDEAA-wk-Fact-B2C06C2292CD5F05AEAF801F825BDEAA" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8765-wk-Fact-B337B62ABBFB5C5696C49995587C6B7B" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8921-wk-Fact-B344BD9ABF6754369FCF350AF52DE418" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e3067-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A d34458032e5280-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3067-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A d34458032e5280-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11033-wk-Fact-B37B6F505700BFB86614801F8217AF5C" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-B3981B3D44CB5A0D36C3801F8253C52A-wk-Fact-B3981B3D44CB5A0D36C3801F8253C52A" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6985-wk-Fact-B3E66210D48550AA9926F625E4EBBAD4" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34512803e1694-wk-Fact-B3F7F06F30815B7EB3DF94113CFBD851" toRefs="TextSelection-99ECE6937087FF439970801F831B2740-0-wk-Footnote-99ECE6937087FF439970801F831B2740_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1955-wk-Fact-B3FD5671955A957CB3C8801F7ECD2BE6" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34524436e1804-wk-Fact-B41D8C40DC9E96021764801F82858FF5" toRefs="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-0-wk-Footnote-4ABFC5BADBDD92BDEF6F801F83478C48_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5247-wk-Fact-B43EBF08C38CF8025BE1801F81E33B35" toRefs="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e9456-wk-Fact-B46984BEC265F2CB3433801F822E334D d34661879e11426-wk-Fact-B46984BEC265F2CB3433801F822E334D" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0 d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0 d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0" toRefs="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0 d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14543-wk-Fact-B51A8E65B32A1B7A347F801F7F099B83" toRefs="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2156-wk-Fact-B51D44885CA609BBF357CF6EFC35BB67" toRefs="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2643-wk-Fact-B56F71AB068951F5B6B9C531420B33FC" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11327-wk-Fact-B57EC914CEEC57AD9AEC75DF29FD04C2" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4035-wk-Fact-B5FF23DD831E759A71FF801F7DE6500E" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7765-wk-Fact-B5FF4C264E8259AB8C76122637225C36" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23467-wk-Fact-B6002D168EA0157D8AFF801F80E23E6D" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22563-wk-Fact-B61033E055581DA45EB7801F80C6CBA8" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5614-wk-Fact-B655A10CD6EE090891E7801F82B1C3E5" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e6330-wk-Fact-B657D1ACB72B0C617B94801F7ECE5765" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6330-wk-Fact-B657D1ACB72B0C617B94801F7ECE5765" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4840-wk-Fact-B6A199DD0727BCEC4725801F7F2F06A4" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1755-wk-Fact-B6E23DD26A27DC66F8C3CAFFFD2CBF22" toRefs="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e1755-wk-Fact-B6E23DD26A27DC66F8C3CAFFFD2CBF22" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5981-wk-Fact-B6F40B75323EE6EF4FC4801F7DF547A2" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8081-wk-Fact-B703DA942F77EDFDF491DE1AC4EE74EA" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3041-wk-Fact-B707042704E051E094DA0C2D5A4B4F2B" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3047-wk-Fact-B708802DEAF9567DBA106E1C0C84390C" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2224-wk-Fact-B70F6FAB9C4E502489A9A03753771E32" toRefs="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1857-wk-Fact-B712982E5A7317455650801F80ECC2E5" toRefs="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19835-wk-Fact-B782F5C9086BF99E0D5C801F80CEC6DC" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5240-wk-Fact-B7BD42B10C099A6A26D1801F7FD5AF39" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5261-wk-Fact-B7FAC3FC55D55C4A8390CDA9B27086EE" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5261-wk-Fact-B7FAC3FC55D55C4A8390CDA9B27086EE" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="4" fromRefs="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096 d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3262-wk-Fact-B844E6AF354E6B90FBC0D083BFDF0319" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2664-wk-Fact-B84B5B2E9880B8DB72EA801F7F15BA80" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4824-wk-Fact-B85C9CC9D293576C909EA9314FC824EE" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e4824-wk-Fact-B85C9CC9D293576C909EA9314FC824EE" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2422-wk-Fact-B86C473D53F433E01138E3D722277F0D" toRefs="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e1587-wk-Fact-B879D2FCD0A23F2045A2801F7ED7E9E3" toRefs="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8215-wk-Fact-B8848B5AC5765E01A8796908F66409AA" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10187-wk-Fact-B891103106B358EFB566B38D67137E32" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2808-wk-Fact-B8932CAFC2CF99FDC067801F7FD54D8F" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8423-wk-Fact-B8C0D0C18DFF193C78E9801F81F22825" toRefs="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19520-wk-Fact-B8D531637E8DF54F3F7E801F80AB0923" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2100-wk-Fact-B8D6B5CC80C55A49A1EE3141CCBD5ACE" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10333-wk-Fact-B8EF963B8EAAA02A9097801F82143358" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2" toRefs="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8276-wk-Fact-B9634D3CD51FCF12B7F1DE1F7DE2E34F" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e8382-wk-Fact-B9796D68B7845314B40EE00253EDFE48" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8382-wk-Fact-B9796D68B7845314B40EE00253EDFE48" toRefs="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2314-wk-Fact-B984EC8BD3C15978AA373038C05C04C3" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3442-wk-Fact-B9A985D5E312D61B9E03801F81513582" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3442-wk-Fact-B9A985D5E312D61B9E03801F81513582" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34524436e1734-wk-Fact-B9B68A9EF2D595760795801F82827C2E" toRefs="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-0-wk-Footnote-4ABFC5BADBDD92BDEF6F801F83478C48_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2252-wk-Fact-B9EEDF4C478F5FE399BD8F88FA3C4292" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3732-wk-Fact-B9F8D9C900D35DCE8A6D80AA6FAD17C8" toRefs="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22345-wk-Fact-BA2C0B3B568CB294D55A801F7E0CA046" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2973-wk-Fact-BA711E164C3C5AA1A6F841BD16FF39C7" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11318-wk-Fact-BA7C888E080F79CDEA22801F8225858E" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5220-wk-Fact-BA7D87048EFE8B8832B0801F812594B2" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34498941e1532-wk-Fact-BA94151A8C0D50BF9AA027BBFC277D06" toRefs="TextSelection-A750B31D2CDA1870AFBA801F8317F8FF-0-wk-Footnote-A750B31D2CDA1870AFBA801F8317F8FF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23856-wk-Fact-BAB81DA4890D0987B01F801F7EBE147E" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23856-wk-Fact-BAB81DA4890D0987B01F801F7EBE147E" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3321-wk-Fact-BAB8B49654C57E704233801F8111DFBB" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3848-wk-Fact-BAD831174C94566A924C53EC67145618" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2575-wk-Fact-BAD8CA6C4B6A5AE88554A9B88D8A8209" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1821-wk-Fact-BAE279F5EB71087D83F2801F7EE05475" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2204-wk-Fact-BAF546B82D94528D8306C20351599D86" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34529301e3044-wk-Fact-BB4D97BFDF50513BAE0BF29E98F95690" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e3044-wk-Fact-BB4D97BFDF50513BAE0BF29E98F95690" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6809-wk-Fact-BB8EECA4B442C1A654CD801F7DF0331C" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1954-wk-Fact-BB9B4543336C561697FD0F59A7D23B67" toRefs="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3935-wk-Fact-BB9E538422B53CC7D9FE801F82463C58" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4946-wk-Fact-BBB1AC598EA163A20CDE801F7F453119" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4946-wk-Fact-BBB1AC598EA163A20CDE801F7F453119" toRefs="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3539-wk-Fact-BC04211B3B4E671AA2DC801F82A46721" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e4135-wk-Fact-BC0C1F861F85562394C153BA53C5058B" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4135-wk-Fact-BC0C1F861F85562394C153BA53C5058B" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2946-wk-Fact-BC27D7DE57C7FCDFEA06801F82A12BD1" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2061-wk-Fact-BC2A634BA20E3AB6E549801F823C4316" toRefs="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e6406-wk-Fact-BC35357C49C864E19515801F7EFFF359" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6406-wk-Fact-BC35357C49C864E19515801F7EFFF359" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2705-wk-Fact-BC7E0D00B21FF35D771B801F81A9F967" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2529-wk-Fact-BCF75818718DFBE05AB3801F80FDBB16" toRefs="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14972-wk-Fact-BCFF3D61A9114065510B801F7F0C89BE" toRefs="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7355-wk-Fact-BD0B6B5222EF5CB6A5FCC1C812C3C334" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10806-wk-Fact-BD46B1A4E13BB0CD2D7F801F81EA9171" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3040-wk-Fact-BD795F9219995817AC05CE7BBCBF719E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4092-wk-Fact-BD8A72C249F655DE8F2BC9B4F95D1DCA" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4581-wk-Fact-BD96EFDCEF39E408FD37D85DDBD98655" toRefs="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e21429-wk-Fact-BDDDC33CB2AC40243C72801F7E12971A" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21429-wk-Fact-BDDDC33CB2AC40243C72801F7E12971A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3973-wk-Fact-BE07CE4FFFBA7AA6551D01C7EE81842C" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e8421-wk-Fact-BE0EABAA50D96FFC3507DE2093101A4D" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8421-wk-Fact-BE0EABAA50D96FFC3507DE2093101A4D" toRefs="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4859-wk-Fact-BE134C05DCF6ADAF9FBF801F7F4DDC1B" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4770-wk-Fact-BE4C23E3208BEB55E46ED85E8DBE2AC5" toRefs="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4584-wk-Fact-BE88CEC570F652B19EAF84B100B1E47E" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2905-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000 d34661879e9790-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2905-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000 d34661879e9790-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4779-wk-Fact-BEE8E31AD112200FA011801F7F3392D2" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4779-wk-Fact-BEE8E31AD112200FA011801F7F3392D2" toRefs="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e6156-wk-Fact-BEEC85B5E0F398A0DE71801F7E7B685A" toRefs="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2168-wk-Fact-BF946A4349E2545BA4A121AADE5B3A9D" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23759-wk-Fact-BFCA8568A70BD9B17120801F7E0B201D" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23759-wk-Fact-BFCA8568A70BD9B17120801F7E0B201D" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6348-wk-Fact-BFDC8661881B55B6A476783E59E9740E" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-BFE1E325EAE23FB57CC7801F82423AA9-wk-Fact-BFE1E325EAE23FB57CC7801F82423AA9" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3644-wk-Fact-C023DBBE72C11C46F64CD083BFF55D24" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e5337-wk-Fact-C09AF6E13F933AFF10EF801F7FC152C9" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2882-wk-Fact-C0A19D1D9DC45DD6801580B6A3ACBEA6" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e12095-wk-Fact-C0BF06F9A6D60B722450801F82C0AE3B" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2342-wk-Fact-C0D03D29D7BD5A5094E94025EADCF408" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7194-wk-Fact-C0D2C058A53A516D89F67516151CA125" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6638-wk-Fact-C12C1FBA8458EC3FD4D1801F7E041A29" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1652-wk-Fact-C13328F655305F8CB43D006E17681322" toRefs="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e1652-wk-Fact-C13328F655305F8CB43D006E17681322" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-C13CFC3CB21F52099D562C221C465A73-wk-Fact-C13CFC3CB21F52099D562C221C465A73" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1634-wk-Fact-C16D2F781E815917AC4E583A6245970B d34512803e1648-wk-Fact-C16D2F781E815917AC4E583A6245970B" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34423000e1634-wk-Fact-C16D2F781E815917AC4E583A6245970B d34512803e1648-wk-Fact-C16D2F781E815917AC4E583A6245970B" toRefs="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3196-wk-Fact-C1EB256C91145D3BB9F80464D5790C53" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3119-wk-Fact-C2867733F38A06F7227D801F7F30AEAD" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10168-wk-Fact-C29B3A689BD4584B967AF3ABE0A9C9D3" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e5317-wk-Fact-C2A34D3ABFB1A91EA818801F7FB1393F" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2402-wk-Fact-C2C7E920844E64417EE0801F7F43A1D0" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857 d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857 d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857" toRefs="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857 d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2579-wk-Fact-C3564D2578C699EB2759801F8289A914" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10972-wk-Fact-C356BA78C171B344C1E7801F823FA26C" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1929-wk-Fact-C36972272EBF57F09D3E0A0B47D781D3" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3634-wk-Fact-C3D0942856A1581EAF48531154A4786E" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e3634-wk-Fact-C3D0942856A1581EAF48531154A4786E" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7342-wk-Fact-C3D92DAFDA945B9CB8FF4887D799EB18" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9743-wk-Fact-C3DE40879A16565EBD6E29F02FEBF113" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4751-wk-Fact-C45B07370E9D1070339E801F7FB12D9A" toRefs="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3649-wk-Fact-C481ECF3EFBB0708C01D801F7EFDD582" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3183-wk-Fact-C48222126B9050F9BFAC0CB6B70D58A1" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6795-wk-Fact-C4A0AC65971AD463ED33801F81E8AD2D" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2317-wk-Fact-C51C12B9003E560B915ACD09B3E99840" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2141-wk-Fact-C55A09F5044EA944EC43801F7F3390E1 d34545404e3153-wk-Fact-C55A09F5044EA944EC43801F7F3390E1" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8896-wk-Fact-C5A4FB3948D259AA97E130C3BE069EA0" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24462-wk-Fact-C5DF68B00988C4249D4D801F81707342" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14911-wk-Fact-C5F159D4AD69FB122084801F7F082E6A" toRefs="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2364-wk-Fact-C602001194365B76BEA91037F0F0DB98" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2480-wk-Fact-C61A53394E697A7EF8C6801F7E98760D" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e7101-wk-Fact-C66ABB169512D5FA96F6801F7EE94810" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e7101-wk-Fact-C66ABB169512D5FA96F6801F7EE94810" toRefs="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3386-wk-Fact-C6871A6C06945BFABCFCA1C5346E9560" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2949-wk-Fact-C691D683EBCB98306D23801F7F16756B" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2852-wk-Fact-C6ADF4DB93D254E5BD23EA5C35CC303C" toRefs="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5134-wk-Fact-C6E28D0783BF5F14B7C1F693DE2205FC" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5134-wk-Fact-C6E28D0783BF5F14B7C1F693DE2205FC" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7514-wk-Fact-C787510F91375F8DA60A77279DBC12D7" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3950-wk-Fact-C7C4AE8978C55E58ADD8D2CE87F7F6ED" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1618-wk-Fact-C811C044F93768A92542801F80F5DB92" toRefs="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2596-wk-Fact-C815B28EFCEB57A091D4DD245EBDE146" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23817-wk-Fact-C81AF605318FDAE7E9A8801F813229BB" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23817-wk-Fact-C81AF605318FDAE7E9A8801F813229BB" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34498941e1578-wk-Fact-C822D3E8545E59F38E6D05A0A14FFE9D" toRefs="TextSelection-80773A0CFA5531791DCE801F8317B622-0-wk-Footnote-80773A0CFA5531791DCE801F8317B622_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3216-wk-Fact-C8753C9584514B8878AE801F81306F2E" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19777-wk-Fact-C8943A121EEDA141FD9B801F7DF3C7FA" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5663-wk-Fact-C89921B0CDF57E82D509801F81DD2CD9" toRefs="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4622-wk-Fact-C8A8BF249D3C3080DE9D801F803E1DD7" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e4096-wk-Fact-C8B439FC676AA180BB18801F8196982F" toRefs="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4242-wk-Fact-C8B9E3934BFD630207B2AB460A1A7731" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3853-wk-Fact-C8FEE220A6AD511B90AEDFED4C8522CE" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10229-wk-Fact-C92813FC360B292546D9801F821F48E6" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6041-wk-Fact-C92D70667288365FCFEA801F82243A1E" toRefs="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e16257-wk-Fact-C971B93D19C9DBDCC70B801F827FFB9E" toRefs="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21189-wk-Fact-C987C1B42EE95EB272F6801F7DFFD049" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4222-wk-Fact-C99D0BA3F6095B8AB635F01DBE0D4EF8" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2400-wk-Fact-CA434D2888FB588EB4655963352B2A4D" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9810-wk-Fact-CA576382E824210D03C9801F7EFD8AAC" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7573-wk-Fact-CA6EF8716A5E5BD1809B42697B1223C5" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2250-wk-Fact-CAA3EF8F2067516F9B2E0F85B4BF5AD0" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6774-wk-Fact-CAB1BA2F9C800F5BD664801F825C70B5" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9316-wk-Fact-CAF98663333909A19E50DE22C3E7514B" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5949-wk-Fact-CB369BD69160A09C5DFC801F7F340DDE" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3771-wk-Fact-CB5261FF2DCF567B98B84D4EEBACC61C" toRefs="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4648-wk-Fact-CB5E098B3EA566270808801F7E0EF978" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10557-wk-Fact-CB5E2C6E53AA4E02F333801F82392BCB" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e8076-wk-Fact-CB7E2DB668A75D5161C1801F7E45DB8D" toRefs="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20183-wk-Fact-CB978D333D218C3AA504801F81620995" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2080-wk-Fact-CBD997DC56489F4D822B801F818B8507" toRefs="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7783-wk-Fact-CBED98872E6D5AD683F5F65CF970FCE1" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2483-wk-Fact-CBF9C7A23687212604C8801F829129F8" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4790-wk-Fact-CC09067F9E93539BA598F5986D30A0D2" toRefs="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6311-wk-Fact-CC0C0ECD3677090B8283801F80884BB4" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e6311-wk-Fact-CC0C0ECD3677090B8283801F80884BB4" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e3733-wk-Fact-CC66745CDAB046F9CA50801F7EC633DE" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3733-wk-Fact-CC66745CDAB046F9CA50801F7EC633DE" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34496162e5573-wk-Fact-CC98EE15F05729F82BC1023AB01871BC" toRefs="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11833-wk-Fact-CCBB2BC438EC5A9B8250ABDDBE53A9E1" toRefs="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7263-wk-Fact-CCCD894D3B3A5080B54BA18BB185ECA4" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7196-wk-Fact-CD039103D85D7763C03A801F82921CA3" toRefs="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3164-wk-Fact-CD12D99291BD50F3BBC6B2BCAA5E89C9" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5313-wk-Fact-CD1DAE84A7D8575096A679F1CD7AEBB1" toRefs="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11339-wk-Fact-CD4577912E966CBCE234801F821708AE" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5303-wk-Fact-CDADF0B40C985D2FD733801F814361A2" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11910-wk-Fact-CDC99316A1F49B8343F1DE3EC68E31D9" toRefs="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3818-wk-Fact-CDFA015BEFBB5917ADD08A5A17C5EE6F" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e3818-wk-Fact-CDFA015BEFBB5917ADD08A5A17C5EE6F" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11179-wk-Fact-CE019DDF6C655A12B3EDF80392CD6DCA" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3060-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C d34661879e9887-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23940-wk-Fact-CEA719F9B7E460A69C70801F7ECBC889" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23940-wk-Fact-CEA719F9B7E460A69C70801F7ECBC889" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2155-wk-Fact-CEBB6ABAEC10A6B4CDAFCB2DE5909958" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23701-wk-Fact-CEFD277C9DD70587E852801F80CE0B4F" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2089-wk-Fact-CF0794E1A8A3CA0BB480801F7F0C5847" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2089-wk-Fact-CF0794E1A8A3CA0BB480801F7F0C5847" toRefs="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e5663-wk-Fact-CF3BF8A51EB1AF804C9D0215472652F8" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5663-wk-Fact-CF3BF8A51EB1AF804C9D0215472652F8" toRefs="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3389-wk-Fact-CF4BCD6471CF5A67AD13EFC0CB141620" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4176-wk-Fact-CF6EA013BF1855E39D139D5A4C827484 d34594690e8585-wk-Fact-CF6EA013BF1855E39D139D5A4C827484" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5154-wk-Fact-CF81983A611C3D14907CCB572FBC8D5D" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5154-wk-Fact-CF81983A611C3D14907CCB572FBC8D5D" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11086-wk-Fact-D010F52EA88A56D0A3A81F17EB5D38DC" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4111-wk-Fact-D017797EF627548D8B995B4200D51DEC" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7375-wk-Fact-D025766C2E67D378C102801F81229E63" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11013-wk-Fact-D02BC6C959B70F0C42F4801F81EA9247" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8606-wk-Fact-D06ED7D632E3530D9D350CF38120C535" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11697-wk-Fact-D0B09E4190DD536D8D7A0B352A916E5F" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10496-wk-Fact-D1066964CCBB2F06D211801F8229BFCC" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4717-wk-Fact-D132FA43C9BCB6877BE6801F802DED15" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5417-wk-Fact-D134462A8015E9052612801F81B8005A" toRefs="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1637-wk-Fact-D1493B6B95195AACB13FF4316F418040" toRefs="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4800-wk-Fact-D15932B9102F00678306801F7F4183A3" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4800-wk-Fact-D15932B9102F00678306801F7F4183A3" toRefs="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3837-wk-Fact-D197856ADE315AF9B1BD0141D8126013" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e3837-wk-Fact-D197856ADE315AF9B1BD0141D8126013" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e3398-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027 d34523018e2642-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2544-wk-Fact-D1EEE24D840C1A7260A5801F823B70E3" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2562-wk-Fact-D213F8E63BD05CEBBE34196677D85307" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985" toRefs="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21536-wk-Fact-D2A4F992E497F4962F79801F7ECCF7C9" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2740-wk-Fact-D2AF16FAEA7B5A13BDB49C7D1827AC2B" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6781-wk-Fact-D2DF1C2AD15035E416EB801F7FC07A27" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2461-wk-Fact-D3148F133483360760CAE3D7A356B4E2" toRefs="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10931-wk-Fact-D327E219A54033D54A8F801F82396897" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3274-wk-Fact-D358FB74D462C490D295801F7FC14EB5" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e7858-wk-Fact-D363B0E0565C5479A3956F6F31D775C9" toRefs="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5012-wk-Fact-D379165107988FEE1AB7801F7F399F8C" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6901-wk-Fact-D3921F90DA63770751B7801F7F0233BF" toRefs="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e3976-wk-Fact-D3A3B59227395C7B84054756B56717E7" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34471435e3976-wk-Fact-D3A3B59227395C7B84054756B56717E7" toRefs="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3692-wk-Fact-D3F2DE5872EC5230B439CD011DA01871" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2525-wk-Fact-D3FD2148011D5F65AD0C27F9F1F55576" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e1948-wk-Fact-D40799FE54FE50768D7FC07B9F31BF58" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1748-wk-Fact-D46423C593ED51E19EFC3DB182C18357" toRefs="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20874-wk-Fact-D487984B48B22F1A5D80801F7E671411" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34519344e4935-wk-Fact-D4A071180EDE5CEF82B5ECC8A1B682B0" toRefs="TextSelection-13B98780E3A32428D56ECDA99D9FF8D0-0-wk-Footnote-13B98780E3A32428D56ECDA99D9FF8D0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e2969-wk-Fact-D4B1E0BBE3F058D3B98806E9C6B99CAF" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21925-wk-Fact-D51127B4DF5263E26631801F80FC4240" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2041-wk-Fact-D580F9F59A215E69A2F8C8CF9897A050" toRefs="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2284-wk-Fact-D592F35F847457ABB1C2D0D22ED64864 d34498941e1747-wk-Fact-D592F35F847457ABB1C2D0D22ED64864" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2510-wk-Fact-D5EB172CCBCC5F4D8D27B6F5728E0EBD" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2120-wk-Fact-D5F5556E181E5148B38700A64385FDDC" toRefs="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2120-wk-Fact-D5F5556E181E5148B38700A64385FDDC" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e9617-wk-Fact-D5FAE833F4155DD697072C1983D12DD3" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9617-wk-Fact-D5FAE833F4155DD697072C1983D12DD3" toRefs="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e5019-wk-Fact-D61DE1C8D5314D9446A3801F7FA8246B" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5115-wk-Fact-D632D615CB115AE398552F0296C267F2" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5115-wk-Fact-D632D615CB115AE398552F0296C267F2" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3078-wk-Fact-D6D3D533E39ABD216739AB460AAB7F32" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e1883-wk-Fact-D71CC752F8554F4A326D801F7F9F4E99" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2445-wk-Fact-D72EAE58B45655088BE6DF720737CDA8" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e6846-wk-Fact-D7952502BA2F1E69FE54801F820C8790" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2202-wk-Fact-D7F3CECA708D58BE9F756B50300BDB3F" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7247-wk-Fact-D7F3F8AF036E5D0FB8EF97E397FAB8AF" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11030-wk-Fact-D8245C971D9C5E578F90851085D1B795" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5104-wk-Fact-D82E84CD29B95374845A78E05E6E431A" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5104-wk-Fact-D82E84CD29B95374845A78E05E6E431A" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2594-wk-Fact-D83DE49486164AB0AD35801F7F32BB1B" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e12076-wk-Fact-D8583C2532635E7E884D51C71C684B47" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6680-wk-Fact-D8BAB29A7AEA2D495984801F80E9FBD5" toRefs="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2769-wk-Fact-D8C072D06B49773A72EE801F81FC0B93 d34661879e9688-wk-Fact-D8C072D06B49773A72EE801F81FC0B93" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2769-wk-Fact-D8C072D06B49773A72EE801F81FC0B93 d34661879e9688-wk-Fact-D8C072D06B49773A72EE801F81FC0B93" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3808-wk-Fact-D8C77E7DECB85CFDA69FCED349A74F3B" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3236-wk-Fact-D8D3C4F5774A56769436D861E4EEF751" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2061-wk-Fact-D8F202BB5B6A5B28A9A31C0EB79F405E" toRefs="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1757-wk-Fact-D92D96928692FE5AFF2B801F7F150711" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34524436e1696-wk-Fact-D95C333A77FF51D2367A801F8284E06B" toRefs="TextSelection-02E52614EBB7CDE55C93801F8347287F-0-wk-Footnote-02E52614EBB7CDE55C93801F8347287F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3105-wk-Fact-D993A80C463256F1AA201062DD098CB4" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4857-wk-Fact-D9E19CB4E10F040A89ABD85E8FD4E4A8" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5989-wk-Fact-D9F7707EF4A74E9CF2A9801F812F89DC" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6988-wk-Fact-DA36ACA13488CC4953E0801F822DA219" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3408-wk-Fact-DA95F5D557CD51E498E32E8F9370AC31" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2569-wk-Fact-DACC4B795F2137AD8A42801F81A81F11" toRefs="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e8019-wk-Fact-DAD0CA8E455F2B5DC7FA801F7E585E15" toRefs="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2766-wk-Fact-DB90E025117E5EE7A0F72EE7BD31627B" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2827-wk-Fact-DB9558D1E67DB9DBC296801F821D4332 d34661879e9727-wk-Fact-DB9558D1E67DB9DBC296801F821D4332" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2827-wk-Fact-DB9558D1E67DB9DBC296801F821D4332 d34661879e9727-wk-Fact-DB9558D1E67DB9DBC296801F821D4332" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-DBA38F5FA084593399643607C04AC75E-wk-Fact-DBA38F5FA084593399643607C04AC75E" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4488-wk-Fact-DBDD38161F5354477BEEAB460A4A0822 d34458036e4576-wk-Fact-DBDD38161F5354477BEEAB460A4A0822" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2499-wk-Fact-DC09811A83505392B3800EEDE627AFCD" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3059-wk-Fact-DC14423F4FD126343D5EAB460A5E402A" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4621-wk-Fact-DC29F3E24AC4E1D31CB3D85DDB384CCC" toRefs="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2091-wk-Fact-DCBD066B5B3F57A98C5A6477D74A4C3D" toRefs="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7418-wk-Fact-DCCC9223184B56788CBE0DB3BD4499E3" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2323-wk-Fact-DCCF1CBB1A0259B4B4B8B56A33FFAE88" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11484-wk-Fact-DCDE7C80F284CDA4BB90801F823D07A2" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3050-wk-Fact-DCF7E4E72A2BD2587C67801F7EA7706F" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8847-wk-Fact-DD01A36819E15802AFBF1E72FE27BC50" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8861-wk-Fact-DD18335422DB5858902DCD3895050F71" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e8043-wk-Fact-DD2FFFF9189C3FA5A3DB801F7E4AF4C6" toRefs="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2778-wk-Fact-DD92E4AF9BD15F60838130DCE8A678BE" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7234-wk-Fact-DDA3C772DD5D6A9CF860801F82921818" toRefs="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1982-wk-Fact-DDD211C8993350B79EF8D3FEBE1A053B" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3624-wk-Fact-DDF2C025AF9CF365CD89801F7F653ACA" toRefs="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24346-wk-Fact-DE1F7A8483528CB9F99C801F7DF38979" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2576-wk-Fact-DE50E7770F245761B8991D27CD7FA8EE" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10911-wk-Fact-DEAEDE0078E36DBB07CB801F82112993" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3505-wk-Fact-DED528DDB914A2BDEF0A801F81463977" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3505-wk-Fact-DED528DDB914A2BDEF0A801F81463977" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10131-wk-Fact-DEDF8AC547B275C98BB2801F81FE5559" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7654-wk-Fact-DF1B3BD729A55AC0A504DFD9608FFB96" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3736-wk-Fact-DF223CDEB60EF38BA68C801F829307E6" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e3748-wk-Fact-DF31EFE36B91F582343D801F80809133" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3748-wk-Fact-DF31EFE36B91F582343D801F80809133" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3433-wk-Fact-DF4C7D7A1BC15C8FB52ACDC98F4B191B" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8026-wk-Fact-DF4D7D64D34A7D6D90A6DE1ABA698DA3" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9891-wk-Fact-DF536431A96ABD94CF42801F825CE145" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="Fact-DF805AE36913A86A1B9C801F81E89568-wk-Fact-DF805AE36913A86A1B9C801F81E89568" toRefs="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2466-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F d34523018e1969-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10066-wk-Fact-DFBA5F50241AD6477837801F820D9779" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66" toRefs="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2430-wk-Fact-DFC5C4232A535405BE8E98D62FCA6018" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2255-wk-Fact-DFD2BE3FC86FDFD923FDCB2DE4E53FC7" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e7577-wk-Fact-E02ED63B97645048DC3D801F80ED740C" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8491-wk-Fact-E04CC84099F25E25851523F603002A2A" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1788-wk-Fact-E0737BFD19C0100A5FE8801F80CB7FAE" toRefs="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14932-wk-Fact-E0B910DD31466DB4F6A3801F7F105131" toRefs="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e5068-wk-Fact-E12E0298D04CBB2C3A47801F7F8D79BA" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5486-wk-Fact-E188FF1B79A2458CF37A801F81E69759" toRefs="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e5357-wk-Fact-E19185551DC6EBA76F10801F8027D89E" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3808-wk-Fact-E19218AE39D843301427801F81BB5A43" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4902-wk-Fact-E197FC2A851A0D8F91E2801F7FC6EAB4" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6968-wk-Fact-E1A13D9EA58071BA48AC801F8231AA2E" toRefs="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2506-wk-Fact-E1D5C5643E20593EBC9062EA4C0879C4" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09" toRefs="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09" toRefs="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09" toRefs="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4561-wk-Fact-E2D26B3B9514260520BAD85DDAA659BB" toRefs="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2750-wk-Fact-E2FFF18A87ED82A265A1801F8065BD9A" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105" toRefs="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105" toRefs="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105" toRefs="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10111-wk-Fact-E31F7F0602F984C69606801F822B89AD" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4986-wk-Fact-E33B08E22E8C41C41495801F7F33C2F5" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4986-wk-Fact-E33B08E22E8C41C41495801F7F33C2F5" toRefs="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21905-wk-Fact-E34AFABD364472579390801F7DF5BC3B" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7302-wk-Fact-E385705FB7C3A2995158801F82A7D035" toRefs="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2920-wk-Fact-E3D918CD118292C5AA27801F802986E2" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1546-wk-Fact-E3E97336ACA652838D81F531EE99F43B d34496162e8816-wk-Fact-E3E97336ACA652838D81F531EE99F43B" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3255-wk-Fact-E3F086AF3830512484E4717330E2CA08" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11277-wk-Fact-E3F7F347B26B1F422343801F81F13EF8" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2785-wk-Fact-E3FD9DF1F7065B2BAFE310C3379623D1" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808 d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808 d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808 d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34529301e3103-wk-Fact-E4D712528036514CA1CCFB0C4C138D8D" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e3103-wk-Fact-E4D712528036514CA1CCFB0C4C138D8D" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2196-wk-Fact-E54EE12FB1C1E89110A9CB2DE5B4B413" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e9051-wk-Fact-E562078593EEE80AC567801F8179DDAD" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10209-wk-Fact-E5C179E74FC2148A9039801F81F8B818" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e7897-wk-Fact-E60F964DE99E4B40AE50801F7ECFCAC9" toRefs="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7188-wk-Fact-E6122F9BEB87535189F2629012724D92" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2075-wk-Fact-E658F74A5A8852C19F682FC523E87C64 d34519344e1883-wk-Fact-E658F74A5A8852C19F682FC523E87C64" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e3950-wk-Fact-E6A475BF77FF3BDAAABB801F825FD297" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1880-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC d34496162e9110-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e5482-wk-Fact-E6EDC6EB8DF84B60CE5A801F80D3642D" toRefs="TextSelection-C075792364F3F1E4361D801F8348FF26-0-wk-Footnote-C075792364F3F1E4361D801F8348FF26_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2710-wk-Fact-E6FC35E4FFF354B58F58E4CFFF29DCB8" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1756-wk-Fact-E70CA54923CC1FAD4F80801F7E7CC351" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4441-wk-Fact-E71BAB60F8F54CE72E1EAB460A620A61" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8699-wk-Fact-E7318B73FA0358F7AAB3343146AFB749" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19617-wk-Fact-E73373912ABEFE585146801F81629B0E" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0" toRefs="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3125-wk-Fact-E756524CD9B052E3BC12448706C676DB" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21594-wk-Fact-E7F460C957BC5FCAA01E801F7E03BE66" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4269-wk-Fact-E826CDDD3780AEBA80B0CB2DE5D9E519" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3104-wk-Fact-E83DC31A66C95716944B69D6571C0712" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961 d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961 d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961 d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961 d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961" toRefs="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961 d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961 d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961" toRefs="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e7614-wk-Fact-E880D275F9E61ED56A76801F7EE80BBC" toRefs="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10373-wk-Fact-E89A524C2D8E94D7B82F801F820D0235" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5071-wk-Fact-E89AA763E81D428EDA17801F811E14C7" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2315-wk-Fact-E8B4FB59DE0025523471801F82937FF6" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3406-wk-Fact-E8C1F0E054CC0BFAC98F801F7EA87952" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23798-wk-Fact-E8F433CDF6DA732D6EF5801F7E697BF0" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3124-wk-Fact-E90985269B2154239A430851FD659027" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3339-wk-Fact-E926E550228AFBDF79A3801F7EAA2096" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4422-wk-Fact-E9440844908157FB84B59804D5572F92" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8306-wk-Fact-E9743691F65857D4AA21DEFCE49F0F66" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e8532-wk-Fact-E97AA6E5D4FA5F64AFB7FBD507DC3DB7" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8532-wk-Fact-E97AA6E5D4FA5F64AFB7FBD507DC3DB7" toRefs="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2193-wk-Fact-E9E2C2D229FB5FD08F618AA417F7A246" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8645-wk-Fact-EA467189B34B25F5663DDE209D44E894" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3354-wk-Fact-EA60695FBD38F2408E8C801F7EC802D2" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2721-wk-Fact-EAC2A8EBA0265A18879BA13F53119C66" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4999-wk-Fact-EADEAA54DF8A5541A925A32BD98FDB78" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e24057-wk-Fact-EAE26AAB2C1914749716801F81E7B60A d34661879e25527-wk-Fact-EAE26AAB2C1914749716801F81E7B60A d34661879e26050-wk-Fact-EAE26AAB2C1914749716801F81E7B60A" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24057-wk-Fact-EAE26AAB2C1914749716801F81E7B60A d34661879e25527-wk-Fact-EAE26AAB2C1914749716801F81E7B60A d34661879e26050-wk-Fact-EAE26AAB2C1914749716801F81E7B60A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e1917-wk-Fact-EB399C3D7F4B5217B1ECA17E1450C7CB" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1917-wk-Fact-EB399C3D7F4B5217B1ECA17E1450C7CB" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4140-wk-Fact-EB4AB9F6D4F4A8E5149B801F8025CB18" toRefs="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10313-wk-Fact-EBE912A2B8B787111E58801F81ECF50B" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e5604-wk-Fact-EC03DB407E47C12F595C02108AD6FC21" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5604-wk-Fact-EC03DB407E47C12F595C02108AD6FC21" toRefs="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5008-wk-Fact-EC11057FA838BD75D525801F824F6767" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2089-wk-Fact-EC38E965C828B3438D45801F82AD8435" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e1942-wk-Fact-EC3C848AE6A9CBDEC522801F7E7CD417" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19481-wk-Fact-EC53E968779C6028ED9C801F7EC737F6" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3903-wk-Fact-ECAA0C7EF7645E87A5DF7782CF068255" toRefs="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5348-wk-Fact-ECECA9DC935CC99E3524801F82146F62" toRefs="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5710-wk-Fact-ED209CAAD0144B632B7B801F7DF7158B" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3209-wk-Fact-ED884752BC3FCC09AA86801F82ADF8F8" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e3324-wk-Fact-EDB5A19EC991587EA94D6F34F8FC39F7" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4157-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0 d34594690e8566-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5182-wk-Fact-EDC9BC9984C3F470119D801F8127899E" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24442-wk-Fact-EDDE1FED2572278FFC6B801F7EC0F70A" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20601-wk-Fact-EDE6AA3E50AC798E1DBE801F7DF2E87B" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22641-wk-Fact-EDF3B6B8EE0203C0AE3F801F80E9D531" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8384-wk-Fact-EE402418A54D574CB441079C7682C003" toRefs="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4329-wk-Fact-EE63D6A60A1762912BF4801F8259FD6E" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e6292-wk-Fact-EE6CC8909F1494988B7A801F7DF1C8F7" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e6292-wk-Fact-EE6CC8909F1494988B7A801F7DF1C8F7" toRefs="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7325-wk-Fact-EE8C91D96F98673768FF801F82A21974" toRefs="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10748-wk-Fact-EEAFCF15A92A73FE4BC1801F820BA9BC" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24481-wk-Fact-EEDDB06313F61B23BAEB801F7EC79AC8" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10353-wk-Fact-EF1120B81FCABC3479FE801F81EE2ED4" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5346-wk-Fact-EF43F96DEFFEE9BA1C18801F82C1C357" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5346-wk-Fact-EF43F96DEFFEE9BA1C18801F82C1C357" toRefs="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6700-wk-Fact-EF6483D67C1CC41F73AB801F8280AE16" toRefs="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e5943-wk-Fact-EFC8C046FEC7E568BE67801F803C6F71" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2002-wk-Fact-EFFB4E372D675AF89AAD0163ED875CE2" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21944-wk-Fact-F02B4A8F59412D2599F9801F7EBEBAF8" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8773-wk-Fact-F0DD6FB9D7D65FF7A33085989120CCED" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e1923-wk-Fact-F0E9225B40E6D9F21243801F7E9BDD39" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3067-wk-Fact-F1667F5FCAC154B8954BDD808EA7CF01" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e4063-wk-Fact-F16E0A41BA8953F7AFA1ACB2D90C1AB8" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e28318-wk-Fact-F1841F95F4C2B39FD6AF1B677F253E82" toRefs="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19680-wk-Fact-F1A609A7255A0AC15A90801F8171F6C4" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3767-wk-Fact-F1DA5A74EBBE5412A2A5D4960C73D7D2" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC" toRefs="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e1916-wk-Fact-F2276591896D5AF8B95530B8937AAC4D" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e6882-wk-Fact-F23CE49E146AE8ABD01E801F80CDC5E3" toRefs="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e3751-wk-Fact-F2E147AA2E8654AB8038D339B5F38F4E" toRefs="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2461-wk-Fact-F2F4F04B9714562C8431CD66A86B0259" toRefs="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e2262-wk-Fact-F2F93F5F2FC3C51352FB801F80F4AFFE" toRefs="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e2463-wk-Fact-F35741687D18E3B4878F801F81982A44" toRefs="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9114-wk-Fact-F3755FEC2162588F811E0BE706D54E9C" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e4019-wk-Fact-F3866D134A97F71188EB801F7E1851F4" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e4837-wk-Fact-F3A34AC6947D589C87DC5D125305250F" toRefs="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10767-wk-Fact-F3A9A889D5F803CEA915801F81FC88F0" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3603-wk-Fact-F3F4B1BA315C571D94BD569F67709BC4" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20582-wk-Fact-F412DE60776769E48B4D801F8102E063" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34594690e7272-wk-Fact-F46555EB6318EAAE369C801F8291F711" toRefs="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34545404e4023-wk-Fact-F48375E1B07289C166E7801F7E895D8F" toRefs="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e4023-wk-Fact-F48375E1B07289C166E7801F7E895D8F" toRefs="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3002-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2 d34661879e9848-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10047-wk-Fact-F507F3DBBA00388E5CD9801F820B8A6C" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e3221-wk-Fact-F510E0B5E23456BCA1F3AB0787E1A55F" toRefs="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e3712-wk-Fact-F538ACACF4943B2112FE801F7FAADCE2" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34496162e8684-wk-Fact-F57AC8E1967F55269DC8AFBFE79580C5" toRefs="TextSelection-00B1F244805F23E229ECE4C97135F977-0-wk-Footnote-00B1F244805F23E229ECE4C97135F977_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e24814-wk-Fact-F588B19D0C5C6EC9C734801F7FE99D83" toRefs="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e1993-wk-Fact-F590D4C627155C828C90476F227A1511 d34471435e2580-wk-Fact-F590D4C627155C828C90476F227A1511" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8867-wk-Fact-F5C4DA82D51CF805497FDE20A789D463" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e3164-wk-Fact-F60C602F8EF1574C98B984D666B6FDE3" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e2175-wk-Fact-F6552983FEE057A7B0758F714B47B201" toRefs="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2996-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C d34545404e9332-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C" toRefs="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2996-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C d34545404e9332-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11569-wk-Fact-F6AEFE5F18DC80AFD6EE801F81742ECC" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e10096-wk-Fact-F6B75BABBAB55FA999FDCDEA743AF12B" toRefs="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e21517-wk-Fact-F6CAFC8B9758DAA23D9B801F80F1603E" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14952-wk-Fact-F6F791A5DBF42B041441801F7F0A62EE" toRefs="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e20932-wk-Fact-F7341069EEF19CA78430801F7ECE7A09" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e20932-wk-Fact-F7341069EEF19CA78430801F7ECE7A09" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e5332-wk-Fact-F774D66B39E3548293A7768C17FCC7C8" toRefs="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e2711-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F d34661879e9649-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e2711-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F d34661879e9649-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F" toRefs="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2993-wk-Fact-F7A1A47C403158F4A0050A07FD1FD932" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e9424-wk-Fact-F7BF280E6470537B8D74D0E1C2349E3E" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8625-wk-Fact-F7DF3FA519E05ABBB36AF2BDC1C1D5E2" toRefs="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2187-wk-Fact-F7E834DB2C365543A0147187D74A1E82 d34523018e1635-wk-Fact-F7E834DB2C365543A0147187D74A1E82" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e1718-wk-Fact-F7E8D2F6BA545C88B2145BBF4BB71213" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5478-wk-Fact-F803761CFD33D77A1C43801F82624A72" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5478-wk-Fact-F803761CFD33D77A1C43801F82624A72" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2552-wk-Fact-F8064D62E55D3D14B6F5801F82AA72CC" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11791-wk-Fact-F82E69C6D1AF9AB5F0E1801F7E7C93ED" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2763-wk-Fact-F84C8C614DC11C920600801F81CCF916" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34509238e2046-wk-Fact-F86E93B23C3F1D21812D801F7FA074B1" toRefs="TextSelection-1B6D1520B957E6708C32801F8318DAAD-0-wk-Footnote-1B6D1520B957E6708C32801F8318DAAD_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23778-wk-Fact-F8768CC4E46B6B99211A801F7EE08C5B" toRefs="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34661879e23778-wk-Fact-F8768CC4E46B6B99211A801F7EE08C5B" toRefs="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5329-wk-Fact-F887DA1F92BAA8B8385A801F81DC8EFC" toRefs="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e2421-wk-Fact-F8A9B839E0BCBA875A7D801F82AD2263" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2919-wk-Fact-F917EC74CAF8798A2465D083C001D773" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e4883-wk-Fact-F926238DB44A5C97B1224C96A9C8141E" toRefs="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2712-wk-Fact-F98321594AC5D5415DB0801F825F0776" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="3" fromRefs="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E" toRefs="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e4557-wk-Fact-F9953003974753B0A6C247B19A717620" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458036e5242-wk-Fact-F99E6C3DC2CC5F62AF63CD1ED043A574" toRefs="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458036e5242-wk-Fact-F99E6C3DC2CC5F62AF63CD1ED043A574" toRefs="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34523018e2597-wk-Fact-F9C9FEE2CCBF5BBAB626316FA2913D2A" toRefs="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5519-wk-Fact-F9D55A1BA8C4FB2C64FC801F7F4A5D64" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e11752-wk-Fact-FA19F775D49E5417994497ED45F8B1B7" toRefs="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34506804e5578-wk-Fact-FA33375103F0D9AB7DC6801F81DED8EA" toRefs="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34458032e3862-wk-Fact-FA5370553D0E753807A4801F800C2D97" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e3862-wk-Fact-FA5370553D0E753807A4801F800C2D97" toRefs="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e2958-wk-Fact-FA6F8F4B8C07145CBB9E801F8194C1D3" toRefs="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34586122e7972-wk-Fact-FA8027A58E5CA9651A05801F82B7CF8D" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7972-wk-Fact-FA8027A58E5CA9651A05801F82B7CF8D" toRefs="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11077-wk-Fact-FAED8312CB6DE3371555801F822F66EF" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34501946e3028-wk-Fact-FB08398EDEE850A395E7D7BAD4CE39AD" toRefs="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34468079e1910-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3 d34468079e3856-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3" toRefs="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34468079e1910-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3 d34468079e3856-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3" toRefs="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e10723-wk-Fact-FB2A542C8BE81796CCFD801F824281CD" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34524436e1765-wk-Fact-FB3538E362BC65E9A4AD801F8283AB6A" toRefs="TextSelection-02E52614EBB7CDE55C93801F8347287F-0-wk-Footnote-02E52614EBB7CDE55C93801F8347287F_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e1837-wk-Fact-FB53920211195F4191C78C4B2EA1ECDE" toRefs="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="2" fromRefs="d34428379e2750-wk-Fact-FB5AEC684D9BF5EB4428801F8178F643" toRefs="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2750-wk-Fact-FB5AEC684D9BF5EB4428801F8178F643" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e5748-wk-Fact-FBAE50428F678875E52F801F7F51C451" toRefs="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e2518-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31 d34519344e2012-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34430544e2103-wk-Fact-FC65E982593353C58EDD19521634B9BF d34545404e3114-wk-Fact-FC65E982593353C58EDD19521634B9BF" toRefs="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e14700-wk-Fact-FC73D9D20F903DB9A545801F7F1031E7" toRefs="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34423000e1527-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6 d34496162e8797-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6" toRefs="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e7876-wk-Fact-FD3ADF5E45AC5ABC941EDCA88225428B" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e7323-wk-Fact-FD92DBC7FD8183249D6D801F80213CFC" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34496162e5495-wk-Fact-FE5FA64237140370947E0C1E584B0DA8" toRefs="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e23999-wk-Fact-FE6953A187622C643914801F80E89DAA" toRefs="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e22931-wk-Fact-FE7BED24ED2F7DF891B2801F80642BB5" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19177-wk-Fact-FF00362B6AD5984309B1801F80812477" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e2481-wk-Fact-FF2092BE1BF7CB316625801F7E1E3368" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34586122e8120-wk-Fact-FF2D62AF2B56AC1092D2DE1ACB8DAAEA" toRefs="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34529301e2174-wk-Fact-FF4615007CC653C7B1758F53F75C3121" toRefs="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34471435e4082-wk-Fact-FF50DEB8A335501E80F11891D08A50FF" toRefs="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34545404e8119-wk-Fact-FF8055EC7C995980A43AA0986DC6DBB3" toRefs="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34458032e8745-wk-Fact-FFA1CCE628C152E085CCD1B102488E00" toRefs="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e19080-wk-Fact-FFA28E99A41E4CCC026F801F803FFF5D" toRefs="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34661879e11115-wk-Fact-FFA2D2947052B95B9E66801F822852A2" toRefs="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34428379e2909-wk-Fact-FFE4B8C9C5A45A3BB02F23579673DDAA" toRefs="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"></ix:relationship><ix:relationship arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote" linkRole="http://www.xbrl.org/2003/role/link" order="1" fromRefs="d34460716e2346-wk-Fact-FFFCC0F0F24614B44437801F828D0336" toRefs="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"></ix:relationship></ix:resources></ix:header></div><div><a id="s987665DA13425B8FACCB16E85A20A1F7"></a></div><div style="line-height:120%;text-align:center;font-size:10.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:533px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:533px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;font-weight:bold;">UNITED STATES SECURITIES AND EXCHANGE COMMISSION</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Washington, D.C. 20549</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10.5pt;"><span style="font-family:Arial;font-size:10.5pt;font-weight:bold;">FORM </span><span style="font-family:Arial;font-size:10.5pt;font-weight:bold;"><span><ix:nonNumeric id="d34666028e513-wk-Fact-0DE47614AD1F7C218E5B1A605CB4DB2B" name="dei:DocumentType" contextRef="FD2019Q4YTD">10-K</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:10.5pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:533px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:533px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:708px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:66px;"></td><td style="width:641px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(Mark One)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial Unicode MS;font-size:7.5pt;"><span><ix:nonNumeric id="d34666028e555-wk-Fact-E92CA8A0CBDB1D49653BD7555A2B223B" name="dei:DocumentAnnualReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9746;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE&#160;ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">For the fiscal year ended </span><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><span style="white-space:nowrap"><ix:nonNumeric id="d34666028e565-wk-Fact-AE3A07A803AAEE6BBA631A6117870CEE" name="dei:DocumentPeriodEndDate" contextRef="FD2019Q4YTD" format="ixt:datemonthdayyearen">December 31, 2019</ix:nonNumeric></span></span></span><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"> </span></div><div style="line-height:120%;text-align:center;font-size:7.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:708px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:66px;"></td><td style="width:641px;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial Unicode MS;font-size:7.5pt;"><span><ix:nonNumeric id="d34666028e582-wk-Fact-DC1C87A0E7539A399A28D757139C85E3" name="dei:DocumentTransitionReport" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox">&#9744;</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">For the transition period from</span><span style="font-family:Arial;font-size:7.5pt;">             </span><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">to           </span></div><div style="line-height:120%;padding-top:6px;text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;text-decoration:underline;">Commission file number </span><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;text-decoration:underline;"><span><ix:nonNumeric id="d34666028e599-wk-Fact-9576174C12745AD7B04072F87B5CE0F2" name="dei:EntityFileNumber" contextRef="FD2019Q4YTD">1-3619</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;text-align:center;"><img src="pfizercoverlogoa01.jpg" alt="pfizercoverlogoa01.jpg" style="height:60px;width:102px;"></img></div><div style="line-height:120%;text-align:center;font-size:16pt;"><span style="font-family:Arial;font-size:16pt;font-weight:bold;"><span><ix:nonNumeric id="d34666028e606-wk-Fact-924554071C555A81B9AD8B8963A6EFF6" name="dei:EntityRegistrantName" contextRef="FD2019Q4YTD">PFIZER INC</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:16pt;font-weight:bold;">.</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Exact name of registrant as specified in its charter)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.54838709677419%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34666028e627-wk-Fact-E7762A4376DC5B6CBED86E223B486A55" name="dei:EntityIncorporationStateCountryCode" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen">Delaware</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34666028e632-wk-Fact-ADC05CA6FA1B5C05B7CB5D0163D37541" name="dei:EntityTaxIdentificationNumber" contextRef="FD2019Q4YTD">13-5315170</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(State or other jurisdiction of incorporation or organization)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(I.R.S. Employer Identification Number)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e648-wk-Fact-824BC2808993F1D647251A64A58D58B5" name="dei:EntityAddressAddressLine1" contextRef="FD2019Q4YTD">235 East 42nd Street</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e652-wk-Fact-A286BFAA6693510082A67B33B9DEEA7F" name="dei:EntityAddressCityOrTown" contextRef="FD2019Q4YTD">New York</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e656-wk-Fact-4508AA3B089055F9BABF1E5C4CCC91CD" name="dei:EntityAddressStateOrProvince" contextRef="FD2019Q4YTD" format="ixt-sec:stateprovnameen">New York</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;">  </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e660-wk-Fact-6D9F28CF77D25E7DB1ED323F5AB0729B" name="dei:EntityAddressPostalZipCode" contextRef="FD2019Q4YTD">10017</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Address of principal executive offices)  (zip code)</span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(</span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e670-wk-Fact-A8F59C52B0D25235B53B9CC43A7E7B30" name="dei:CityAreaCode" contextRef="FD2019Q4YTD">212</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;">) </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e674-wk-Fact-2FC696AFEDA15E708F1E6C13D033F657" name="dei:LocalPhoneNumber" contextRef="FD2019Q4YTD">733-2323</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Registrant&#8217;s telephone number, including area code)</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.54838709677419%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:29%;"></td><td style="width:36%;"></td></tr><tr><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #acacac;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Title of each class</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Trading Symbol(s)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Name&#160;of&#160;each&#160;exchange on which registered</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e727-wk-Fact-C0663720DFCC5BBF8748AF7E30ADB7B4" name="dei:Security12bTitle" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">Common Stock, $.05 par value</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e732-wk-Fact-4DCF02DE9FCD5311A11F6F1DBBB5411E" name="dei:TradingSymbol" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">PFE</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e737-wk-Fact-BD3D554CEF44594D9687B580217D371E" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e743-wk-Fact-A7C96037DE0858978100C564955F8913" name="dei:Security12bTitle" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20200.000Member">0.000% Notes due 2020</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e748-wk-Fact-16123E0663B45490B33BE7F7EDFBF57D" name="dei:TradingSymbol" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20200.000Member">PFE20A</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e753-wk-Fact-38EA800BC5C15FF39221569997E29414" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20200.000Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e759-wk-Fact-CC4EC4DF8CD157A18C4E86288502B7D3" name="dei:Security12bTitle" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member">0.250% Notes due 2022</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e764-wk-Fact-F1BEFEBBCA255DC1AA1056BEA6513E6C" name="dei:TradingSymbol" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member">PFE22</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e769-wk-Fact-CB148444D4C655A59A016B49B0F911AC" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e775-wk-Fact-769591A72C41593FB46221C0CEB26D96" name="dei:Security12bTitle" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member">1.000% Notes due 2027</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e780-wk-Fact-BAA8AAFC057A5693865364DF4522B448" name="dei:TradingSymbol" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member">PFE27</ix:nonNumeric></span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34666028e785-wk-Fact-7C0690AFE7B65DBCAEB584CF885946C5" name="dei:SecurityExchangeName" contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member" format="ixt-sec:exchnameen">New York Stock Exchange</ix:nonNumeric></span></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:368px;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:368px;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Securities registered pursuant to Section&#160;12(g) of the Act: </span><span style="font-family:Arial;font-size:8pt;">None</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. &#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d34666028e806-wk-Fact-4D4E1222DF067BD0609AD7584777B4A7" name="dei:EntityWellKnownSeasonedIssuer" contextRef="FD2019Q4YTD"><span style="font-family:Arial;font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.&#160;&#160;&#160;Yes&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span><span style="font-family:Arial;font-size:7pt;">&#160;&#160;</span><span style="font-family:Arial;font-size:8pt;">&#160;  </span><span><ix:nonNumeric id="d34666028e826-wk-Fact-75518DC909E5C9437CBCD758D0272473" name="dei:EntityVoluntaryFilers" contextRef="FD2019Q4YTD"><span style="font-family:Arial;font-size:8pt;">No</span></ix:nonNumeric></span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d34666028e836-wk-Fact-C5DD8A1E7155F9C4A5ABD7592DE303DC" name="dei:EntityCurrentReportingStatus" contextRef="FD2019Q4YTD"><span style="font-family:Arial;font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:Wingdings 2;font-size:10pt;"> </span><span style="font-family:Arial;font-size:8pt;">No&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files.)&#160;&#160;&#160;&#160;</span><span><ix:nonNumeric id="d34666028e853-wk-Fact-5A64DFA7C18879E7BB21D75990CBAB64" name="dei:EntityInteractiveDataCurrent" contextRef="FD2019Q4YTD"><span style="font-family:Arial;font-size:8pt;">Yes</span></ix:nonNumeric></span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9746;</span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;&#160;No&#160;&#160;</span><span style="font-family:Arial Unicode MS;font-size:8pt;">&#9744;</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;text-align:left;font-size:8pt;"><span><ix:nonNumeric id="d34666028e870-wk-Fact-DC94FCCB6B808F6B10A9D784C460A8B2" name="dei:EntityFilerCategory" contextRef="FD2019Q4YTD" format="ixt-sec:entityfilercategoryen"><span style="font-family:Arial;font-size:8pt;">Large Accelerated filer</span></ix:nonNumeric></span><span style="font-family:Arial;font-size:7.5pt;">  </span><span style="font-family:Arial;font-size:8pt;">&#9746;</span><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:Arial;font-size:8pt;">&#160;Accelerated filer</span><span style="font-family:Arial;font-size:7.5pt;">  </span><span style="font-family:Arial;font-size:8pt;">&#9744;</span><span style="font-family:Arial;font-size:7.5pt;"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:Arial;font-size:8pt;">Non-accelerated filer</span><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span><span style="font-family:Arial;font-size:8pt;">&#9744;</span><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="font-family:Arial;font-size:8pt;">Smaller reporting company</span><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span><span><ix:nonNumeric id="d34666028e900-wk-Fact-26E48308B17947822A14D7850FA0B506" name="dei:EntitySmallBusiness" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial;font-size:8pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Arial;font-size:7.5pt;">         </span><span style="font-family:Arial;font-size:8pt;">Emerging growth company</span><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span><span><ix:nonNumeric id="d34666028e909-wk-Fact-C311D3C4CFCACD97C6BCD785681FDAF4" name="dei:EntityEmergingGrowthCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial;font-size:8pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Arial;font-size:7.5pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;   &#9744;</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;</span><span><ix:nonNumeric id="d34666028e922-wk-Fact-AFEDBD89AE868CF5238AD75A0CDEB96B" name="dei:EntityShellCompany" contextRef="FD2019Q4YTD" format="ixt-sec:boolballotbox"><span style="font-family:Arial;font-size:8pt;">&#9744;</span></ix:nonNumeric></span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;&#160;&#160;No&#160;&#160;&#9746;</span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The aggregate market value of the voting stock held by non-affiliates of the registrant, computed by reference to the closing price as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter, </span><span style="font-family:Arial;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:Arial;font-size:8pt;">, was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34666028e934-wk-Fact-39CD82BC0F711C8BD8051A64D31AE13E" name="dei:EntityPublicFloat" contextRef="FI2019Q2" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">241</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">. This excludes shares of common stock held by directors and executive officers at </span><span style="font-family:Arial;font-size:8pt;">June&#160;30, 2019</span><span style="font-family:Arial;font-size:8pt;">. Exclusion of shares held by any person should not be construed to indicate that such person possesses the power, directly or indirectly, to direct or cause the direction of the management or policies of the registrant, or that such person is controlled by or under common control with the registrant. The registrant has no non-voting common stock. </span></div><div style="line-height:120%;padding-bottom:1px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The number of shares outstanding of the registrant&#8217;s common stock as of </span><span style="font-family:Arial;font-size:8pt;">February&#160;25, 2020</span><span style="font-family:Arial;font-size:8pt;"> was </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34666028e949-wk-Fact-4F66DC7318685148819BD0F1BEC68760" name="dei:EntityCommonStockSharesOutstanding" contextRef="I2020Q1Feb25" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">5,547,639,005</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> shares of common stock, all of one class.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="TextSelection-AE0128151DF5C78FF5FAD77E81B27A7D-0-wk-Fact-E13451DE98FB5847FE6FD77E8E654B2E" escape="true"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:653px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:532px;"></td><td style="width:121px;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Portions of the 2019 Annual Report to Shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Parts&#160;I,&#160;II&#160;and&#160;IV</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Portions of the Proxy Statement for the 2020 Annual Meeting of Shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Part III</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div></ix:nonNumeric><div><br/></div><hr style="page-break-after:always"></hr><div><a id="sCD6DED064D4B590AA026733F024E7C1F"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:33.15412186379928%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px dotted #006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #006ebf;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">TABLE OF CONTENTS</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.56630824372759%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:95%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">&#160;</span><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;color:#00497f;font-weight:bold;">Page</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;" href="#s02DA1DE6CEE55FDDBA2B21A2B62C7BD1"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;">PART I</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s02DA1DE6CEE55FDDBA2B21A2B62C7BD1">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s577633ABD1A051B7A8B00E90BCC676AC"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;1. BUSINESS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s577633ABD1A051B7A8B00E90BCC676AC">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#s51043C8A7B4C55538463158F883F7D26"><span style="font-family:Arial;font-size:9pt;">About Pfizer</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s51043C8A7B4C55538463158F883F7D26">1</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s29689FBFF72654DDBA85E019CBE58822"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Available Information and Pfizer Website</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s29689FBFF72654DDBA85E019CBE58822">2</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s7CAA23F1D5715084916CF86D946D5810"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Commercial Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s7CAA23F1D5715084916CF86D946D5810">3</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#s5545E9AE019053FCBD035AEF266AC6F5"><span style="font-family:Arial;font-size:9pt;">Pfizer Biopharmaceuticals Group (Biopharma)</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s5545E9AE019053FCBD035AEF266AC6F5">4</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#s14B27B8472785915B895CCBE82296593"><span style="font-family:Arial;font-size:9pt;">Upjohn</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s14B27B8472785915B895CCBE82296593">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#s14E3615AAA885E3FAB4992117F87E67A"><span style="font-family:Arial;font-size:9pt;">Collaboration and Co-Promotion Agreements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s14E3615AAA885E3FAB4992117F87E67A">5</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s3BE135625FA753D382C094E8A20E5AB2"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Research and Development</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s3BE135625FA753D382C094E8A20E5AB2">6</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s9C32A8F6EF6E59B79ABBB82C4A35DD83"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">International Operations</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s9C32A8F6EF6E59B79ABBB82C4A35DD83">8</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s004BD76FDBD357B0BA6137FF962A1E71"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Marketing</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s004BD76FDBD357B0BA6137FF962A1E71">8</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s50BFE339300B57BF9CBAD0E9E41AF305"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Patents and Other Intellectual Property Rights</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s50BFE339300B57BF9CBAD0E9E41AF305">9</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#s6A4B83F647685F0AB7680E53CD7F4421"><span style="font-family:Arial;font-size:9pt;">Competition</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s6A4B83F647685F0AB7680E53CD7F4421">12</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#s800FAAB7988D56C08B93517F18958040"><span style="font-family:Arial;font-size:9pt;">Raw Materials</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s800FAAB7988D56C08B93517F18958040">13</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#sB238C4365E0D54E6B1E6BADD068EB983"><span style="font-family:Arial;font-size:9pt;">Government Regulation and Price Constraints</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sB238C4365E0D54E6B1E6BADD068EB983">14</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s6FC770942FED549E9A3BEDDB7CE0170A"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Environmental Matters</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s6FC770942FED549E9A3BEDDB7CE0170A">20</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s9F0B107560D05C65B113FCD92A000480"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Tax Matters</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s9F0B107560D05C65B113FCD92A000480">20</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sC12D192ABFC15E599A3FF5A7C2797E6E"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Employees</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sC12D192ABFC15E599A3FF5A7C2797E6E">20</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sE3A373D11EBE5700B8D4083AE7C00167"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Disclosure Pursuant to Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sE3A373D11EBE5700B8D4083AE7C00167">20</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s22DE39E5F1A25F3ABB694A5B673BED2B"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;1A. RISK FACTORS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s22DE39E5F1A25F3ABB694A5B673BED2B">21</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sB98CBE8A8A615666B5C535AE350D46B0"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;1B. UNRESOLVED STAFF COMMENTS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sB98CBE8A8A615666B5C535AE350D46B0">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sA65061D3D52D5828A75D50F1B1ACB477"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;2. PROPERTIES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sA65061D3D52D5828A75D50F1B1ACB477">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s0D3A3EECAB8D5DAAABEA3A430CC77ABF"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;3. LEGAL PROCEEDINGS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s0D3A3EECAB8D5DAAABEA3A430CC77ABF">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s20443CE278E4546E95B7C03120269A52"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;4. MINE SAFETY DISCLOSURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s20443CE278E4546E95B7C03120269A52">37</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#sFD44FC0862BC5DC5988EE9485D1B45BD"><span style="font-family:Arial;font-size:9pt;">INFORMATION ABOUT OUR EXECUTIVE OFFICERS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sFD44FC0862BC5DC5988EE9485D1B45BD">38</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;" href="#sED3D006782A65B7AAF85A448A45572BF"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;">PART II</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sED3D006782A65B7AAF85A448A45572BF">40</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s0F5AA24F4EB65B5FAA1EAB09D430CF50"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160; 5. MARKET FOR THE COMPANY&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s0F5AA24F4EB65B5FAA1EAB09D430CF50">40</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s227808A6FAA05DCFBE13F365162E4B5A"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;6. SELECTED FINANCIAL DATA</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s227808A6FAA05DCFBE13F365162E4B5A">41</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s47D06050A00C5F5EB81E6674B675DAE1"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160; 7. MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s47D06050A00C5F5EB81E6674B675DAE1">41</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s377D5C48E6D7540AB92254D3AFF8A41C"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;7A. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s377D5C48E6D7540AB92254D3AFF8A41C">41</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s2E8F226DCAB35200A069D4A32F1F75B7"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s2E8F226DCAB35200A069D4A32F1F75B7">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sBBB73A0ABDC95CB8B4C4D93D33D6AF9D"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;9. CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sBBB73A0ABDC95CB8B4C4D93D33D6AF9D">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sDA303666ECC751399D9DF91C4B027B6F"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;9A. CONTROLS AND PROCEDURES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sDA303666ECC751399D9DF91C4B027B6F">42</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s1AF8C25F34745A5FBDAF296DEA3109A1"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;9B. OTHER INFORMATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s1AF8C25F34745A5FBDAF296DEA3109A1">42</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;" href="#sBAFDD9F5AF4A5894AD49D3681101911D"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;">PART III</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sBAFDD9F5AF4A5894AD49D3681101911D">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sF068F019C94A504F8F17A818A20D0CB8"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;10. DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sF068F019C94A504F8F17A818A20D0CB8">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s15633F5448C25D9680F3D4D3E62E723E"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;11. EXECUTIVE COMPENSATION</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s15633F5448C25D9680F3D4D3E62E723E">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s9C00A14D506E5713B6EAC924A49B3CF3"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;12. SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s9C00A14D506E5713B6EAC924A49B3CF3">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s259FD2EB1F8658DBA346B40ACEF7A9B5"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;13. CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s259FD2EB1F8658DBA346B40ACEF7A9B5">43</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s6B150B86AF6B5AE480C3617B7EDB145E"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;14. PRINCIPAL ACCOUNTING FEES AND SERVICES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s6B150B86AF6B5AE480C3617B7EDB145E">43</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;" href="#s555F1C56F7FA51D99AE4C64AF525DE63"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;">PART IV</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s555F1C56F7FA51D99AE4C64AF525DE63">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sAB9622F45ECA5CCFAF58170719917F9C"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">ITEM&#160;15. EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sAB9622F45ECA5CCFAF58170719917F9C">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s72097BE09AA95E2FB7F67AD81F21380B"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">15(a)(1) Financial Statements</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s72097BE09AA95E2FB7F67AD81F21380B">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#sD10AEFD41437504E8AE91E8A76D372A3"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">15(a)(2) Financial Statement Schedules</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#sD10AEFD41437504E8AE91E8A76D372A3">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="font-family:Arial;font-size:9pt;text-decoration:underline;" href="#s60FF4F741B195321AF6B1B1CDC92D24E"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">15(a)(3) Exhibits</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s60FF4F741B195321AF6B1B1CDC92D24E">44</a></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;" href="#s0CCC93D8C6DE5D9C9FB6ABA7AB766AE5"><span style="font-family:Arial;font-size:9pt;">ITEM 16. FORM 10-K SUMMARY</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;text-decoration:none;" href="#s0CCC93D8C6DE5D9C9FB6ABA7AB766AE5">48</a></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">i</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s1D641C41D13B53F7A8EE2BE873D50012"></a></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px dotted #006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #006ebf;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">DEFINED TERMS</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Unless the context requires otherwise, references to &#8220;Pfizer,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K, most of which are explained or defined below.</span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:20%;"></td><td style="width:80%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">2019 Financial Report</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exhibit 13 to this 2019 Form 10-K</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">This Annual Report on Form 10-K for the fiscal year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">2020 Proxy Statement</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Proxy Statement for the 2020 Annual Meeting of Shareholders</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">ACA</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Alliance revenues</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Akcea</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Akcea Therapeutics, Inc. </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Array</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Array BioPharma Inc.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Astellas</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Biopharma</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Biopharmaceuticals Group</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">BMS</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Bristol-Myers Squibb Company</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">cGMPs</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">current Good Manufacturing Practices </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">DEA</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Drug Enforcement Agency</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Developed Markets</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and New Zealand</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">EMA</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">European Medicines Agency</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Emerging Markets</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">EU</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">European Union</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Exchange Act</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Securities Exchange Act of 1934, as amended</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">FCPA</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Foreign Corrupt Practices Act</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">FDA</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Food and Drug Administration</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">FFDCA</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Federal Food, Drug and Cosmetic Act</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">GPD</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Global Product Development organization</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">GSK</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">GlaxoSmithKline plc</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Hospira</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Hospira, Inc.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Ionis</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ionis Pharmaceuticals, Inc.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">IPR&amp;D</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In-process Research and Development</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">LIBOR</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">London Interbank Offered Rate</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">LOE</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Loss of Exclusivity</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">MCO</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Managed Care Organization</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Mylan</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mylan N.V.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">NMPA</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">National Medical Product Administration in China</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">NYSE</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">New York Stock Exchange</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">OTC</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">over-the-counter</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">PBM</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pharmacy Benefit Manager</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;border-bottom:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">PGS</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;border-bottom:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Global Supply</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">ii</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:20%;"></td><td style="width:80%;"></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">PMDA</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pharmaceuticals and Medical Device Agency in Japan</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">QCE</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">quality consistency evaluation in China</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">R&amp;D</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">research and development</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">SEC</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. Securities and Exchange Commission</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #acacac;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">Teva</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Teva Pharmaceuticals USA, Inc.</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">U.K.</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">United Kingdom</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">U.S.</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">United States</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">VAI</span></div></td><td style="vertical-align:middle;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Voluntary Action Indicated</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #acacac;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">VBP</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">volume-based procurement in China</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #acacac;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#2c2c2c;font-style:italic;">WRDM</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #acacac;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #acacac;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Worldwide Research, Development and Medical</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:30px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">iii</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s2CECBB09A771532BBC8CFEFEDF1DC7FE"></a></div><div><br/></div><div style="line-height:120%;text-align:center;-sec-extract:summary;font-size:22pt;"><img src="tagline_1.jpg" alt="tagline_1.jpg" style="height:68px;width:558px;"></img><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:653px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:88px;"></td><td style="width:565px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:center;"><img src="marketgrowth.jpg" alt="marketgrowth.jpg" style="height:65px;width:65px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="text-decoration:none;color:#0000FF;font-size:22pt;font-weight:bold;-sec-extract:exhibit;" href="pfe-exhibit13x12312019.htm"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">~$51.8 Billion</span></a><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;">&#160;</span><span style="font-family:Arial;font-size:14pt;color:#0093d0;">in Revenues in 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="pharmapill.jpg" alt="pharmapill.jpg" style="height:64px;width:64px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="text-decoration:none;color:#0000FF;font-size:22pt;font-weight:bold;-sec-extract:exhibit;" href="pfe-exhibit13x12312019.htm"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">8</span></a><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;">&#160;</span><span style="font-family:Arial;font-size:14pt;color:#0093d0;">Products with Direct Product and/or Alliance Revenues of Greater than $1 Billion in 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="structure.jpg" alt="structure.jpg" style="height:62px;width:62px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;" href="#s7CAA23F1D5715084916CF86D946D5810"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">3</span></a><span style="font-family:Arial;font-size:14pt;color:#0093d0;">&#160;Distinct Businesses in 2019* </span><span style="font-family:Arial;font-size:10pt;color:#0093d0;">&#8212;</span><span style="font-family:Arial;font-size:14pt;color:#0093d0;">&#160;&#160;</span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#0093d0;">Pfizer Biopharmaceuticals Group (Biopharma) </span><span style="font-family:Arial;font-size:10pt;color:#0093d0;font-style:italic;">(~$39.4 Billion 2019 Revenues) / </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#0093d0;">Upjohn </span><span style="font-family:Arial;font-size:10pt;color:#0093d0;font-style:italic;">(~$10.2 Billion 2019 Revenues) / </span><span style="font-family:Arial;font-size:10pt;color:#0093d0;">Consumer Healthcare</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="prescription.jpg" alt="prescription.jpg" style="height:65px;width:65px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;" href="#s5545E9AE019053FCBD035AEF266AC6F5"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">6</span></a><span style="font-family:Arial;font-size:14pt;color:#0093d0;">&#160;Primary Therapeutic Areas in Biopharma </span><span style="font-family:Arial;font-size:10pt;color:#0093d0;">&#8212; </span></div><div style="text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;color:#0093d0;">Internal Medicine, Oncology, Hospital, Vaccines, Inflammation &amp; Immunology and Rare Disease </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="syringe.jpg" alt="syringe.jpg" style="height:65px;width:65px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;" href="#s14B27B8472785915B895CCBE82296593"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">20</span></a><span style="font-family:Arial;font-size:14pt;color:#0093d0;">&#160;Globally Recognized Brands and the Greenstone generics platform in Upjohn </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="globe.jpg" alt="globe.jpg" style="height:65px;width:65px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="padding-bottom:13px;text-align:left;font-size:22pt;"><a style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;" href="#s9C32A8F6EF6E59B79ABBB82C4A35DD83"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">&gt;125</span></a><span style="font-family:Arial;font-size:14pt;color:#0093d0;">&#160;Countries Where We Sell Our Products</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="microscope.jpg" alt="microscope.jpg" style="height:65px;width:65px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;" href="#s3BE135625FA753D382C094E8A20E5AB2"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">95</span></a><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;">&#160;</span><span style="font-family:Arial;font-size:14pt;color:#0093d0;">Projects in Clinical Research &amp; Development**</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="testtubes.jpg" alt="testtubes.jpg" style="height:65px;width:65px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="text-decoration:none;color:#0000FF;font-size:22pt;font-weight:bold;-sec-extract:exhibit;" href="pfe-exhibit13x12312019.htm"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">~$8.7 Billion</span></a><span style="font-family:Arial;font-size:14pt;color:#0093d0;">&#160;2019 R&amp;D Expense</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="pharmapack.jpg" alt="pharmapack.jpg" style="height:65px;width:65px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;" href="#sA65061D3D52D5828A75D50F1B1ACB477"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">42</span></a><span style="font-family:Arial;font-size:14pt;color:#0093d0;">&#160;Manufacturing Sites Worldwide Operated by PGS; </span></div><div style="text-align:left;font-size:22pt;"><a style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;" href="#sA65061D3D52D5828A75D50F1B1ACB477"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">7</span></a><span style="font-family:Arial;font-size:14pt;color:#0093d0;">&#160;Manufacturing Sites Worldwide Operated by Upjohn</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="team.jpg" alt="team.jpg" style="height:65px;width:65px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px dotted #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:22pt;"><a style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;" href="#sC12D192ABFC15E599A3FF5A7C2797E6E"><span style="font-family:Arial;font-size:22pt;color:#0093d0;font-weight:bold;text-decoration:none;">~88,300</span></a><span style="font-family:Arial;font-size:14pt;color:#0093d0;font-weight:bold;">&#160;</span><span style="font-family:Arial;font-size:14pt;color:#0093d0;">Employees Globally</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:8px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;color:#616365;font-style:italic;font-weight:bold;">Unless indicated otherwise, the information contained in this summary is as of </span><span style="font-family:Arial;font-size:7pt;color:#616365;font-style:italic;font-weight:bold;">December&#160;31, 2019</span><span style="font-family:inherit;font-size:7pt;color:#616365;font-style:italic;font-weight:bold;">.</span><span style="font-family:Arial;font-size:7pt;color:#616365;font-style:italic;font-weight:bold;"> This summary does not include information that will be incorporated by reference into Part III of this </span><span style="font-family:Arial;font-size:7pt;color:#616365;font-style:italic;font-weight:bold;">2019</span><span style="font-family:Arial;font-size:7pt;color:#616365;font-style:italic;font-weight:bold;"> Form 10-K from our </span><span style="font-family:Arial;font-size:7pt;color:#616365;font-style:italic;font-weight:bold;">2020</span><span style="font-family:Arial;font-size:7pt;color:#616365;font-style:italic;font-weight:bold;"> Proxy Statement.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;color:#616365;">* On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. On July&#160;31, 2019, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see the</span><span style="font-family:Arial;font-size:7pt;color:#616365;font-style:italic;"> Item 1. Business&#8212;About Pfizer</span><span style="font-family:Arial;font-size:7pt;color:#616365;"> section in this 2019 Form 10-K.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;color:#616365;">** As of January 28, </span><span style="font-family:Arial;font-size:7pt;color:#616365;">2020</span><span style="font-family:Arial;font-size:7pt;color:#616365;"> </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">iv</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s02DA1DE6CEE55FDDBA2B21A2B62C7BD1"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px dotted #006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #006ebf;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PART I</span></div></td></tr></table></div></div><div><a id="s577633ABD1A051B7A8B00E90BCC676AC"></a></div><div style="line-height:120%;padding-bottom:8px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;1.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">BUSINESS</span></div></td></tr></table></div></div><div><a id="s51043C8A7B4C55538463158F883F7D26"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><img src="pfizerlogo.jpg" alt="pfizerlogo.jpg" style="height:29px;width:50px;"></img><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;"> ABOUT PFIZER </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Inc. is a research-based, global biopharmaceutical company. </span><span style="font-family:Arial;font-size:9pt;">We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture and distribution of healthcare products, including innovative medicines and vaccines. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us</span><span style="font-family:Arial;font-size:9pt;">. The majority of our revenues come from the manufacture and sale of biopharmaceutical products. The Company was incorporated under the laws of the State of Delaware on June 2, 1942. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our Company&#8217;s purpose: </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Breakthroughs that change patients&#8217; lives</span><span style="font-family:Arial;font-size:9pt;">. By doing so, we expect to create value for the patients we serve and for our colleagues and shareholders.</span><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">With the formation of the GSK Consumer Healthcare joint venture and the pending combination of Upjohn with Mylan, which are further discussed below, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities.</span><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our significant recent business development activities include:</span></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">License Agreement with Akcea Therapeutics, Inc.</span><span style="font-family:Arial;font-size:9pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;">In October 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. The transaction closed in November 2019 and we made an upfront payment of</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;">$250 million</span><span style="font-family:Arial;font-size:9pt;"> to Akcea and Ionis. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Formation of a New Consumer Healthcare Joint Venture</span><span style="font-family:Arial;font-size:9pt;">&#8212;On July&#160;31, 2019, </span><span style="font-family:Arial;font-size:9pt;">we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name.</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;">The joint venture is a category leader in pain relief, respiratory and vitamins, minerals and supplements, and therapeutic oral health and is the largest global OTC consumer healthcare business.</span><span style="font-family:Arial;font-size:9pt;"> In exchange for contributing our Consumer Healthcare business to the joint venture, we received a </span><span style="font-family:Arial;font-size:9pt;">32%</span><span style="font-family:Arial;font-size:9pt;"> equity stake in the new company and GSK owns the remaining </span><span style="font-family:Arial;font-size:9pt;">68%</span><span style="font-family:Arial;font-size:9pt;">. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Acquisition of Array BioPharma Inc.</span><span style="font-family:Arial;font-size:9pt;">&#8212;On July&#160;30, 2019, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for $48 per share in cash. The total fair value of the consideration transferred for Array was approximately $11.2 billion ($10.9 billion, net of cash acquired). </span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Agreement to Combine Upjohn with Mylan N.V.</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;">On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun off or split off to Pfizer&#8217;s shareholders and, immediately thereafter, combined with Mylan.</span><span style="font-family:Arial;font-size:9pt;"> Pfizer shareholders would own 57% of the combined new company, and former Mylan shareholders would own 43%. The transaction is expected to be tax free to Pfizer and Pfizer shareholders. </span><span style="font-family:Arial;font-size:9pt;">The transaction is anticipated to close in mid-2020, subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals.</span><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">1</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Acquisition of Therachon Holding AG</span><span style="font-family:Arial;font-size:9pt;">&#8212;On July 1, 2019, we acquired all the remaining shares of Therachon Holding AG, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for $340 million upfront, plus potential milestone payments of up to $470 million, contingent on the achievement of key milestones in the development and commercialization of the lead asset.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For a further discussion of our strategy and our business development initiatives, see the</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Our Business Development Initiatives</span><span style="font-family:Arial;font-size:9pt;"> and &#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Our Strategy</span><span style="font-family:Arial;font-size:9pt;"> sections and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 2</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our businesses are heavily regulated in most of the countries in which we operate. In the U.S., the principal authority regulating our operations is the FDA. The FDA regulates the safety and efficacy of the products we offer and our research, quality, manufacturing processes, product promotion, advertising and product labeling. Similar regulations exist in most other countries, and in many countries the government also regulates our prices. In the EU, the EMA conducts the scientific evaluation, supervision and safety monitoring of our products, and employs a centralized procedure for approval of medicines for the EU and the European Economic Area countries. In China, the NMPA is the primary regulatory authority for approving and supervising medicines. In Japan, the PMDA is involved in a wide range of regulatory activities, including clinical studies, approvals, post-marketing reviews and pharmaceutical safety. Health authorities in many middle and lower income countries require marketing approval by a recognized regulatory authority (i.e., similar to the authority of the FDA or EMA) before they begin to conduct their application review process and/or issue their final approval. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Some amounts in this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K may not add due to rounding. All percentages have been calculated using unrounded amounts. All trademarks in this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K are the property of their respective owners.</span></div><div><a id="s29689FBFF72654DDBA85E019CBE58822"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;" href="#s29689FBFF72654DDBA85E019CBE58822"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;">AVAILABLE INFORMATION AND PFIZER WEBSITE</span></a></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our website is located at </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">www.pfizer.com</span><span style="font-family:Arial;font-size:9pt;">. This </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K, and amendments to those reports filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act, are, or will be, available (free of charge) on our website, in text format and, where applicable, in interactive data file format</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">,</span><span style="font-family:Arial;font-size:9pt;"> as soon as reasonably practicable after we electronically file this material with, or furnish it to, the SEC.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Throughout this </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K, we &#8220;incorporate by reference&#8221; certain information from other documents filed or to be filed with the SEC, including our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement and our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report, portions of which are filed as Exhibit 13 to this </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K, and which also will be contained in Appendix A to our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. The SEC allows us to disclose important information by referring to it in that manner. Please refer to this information. Our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Annual Report to Shareholders consists of our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report and the Corporate and Shareholder Information attached to the </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. Our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report will be available on our website on or about February 27, 2020. Our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement will be available on our website on or about March 13, 2020.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We may use our website as a means of disclosing material information and for complying with our disclosure obligations under Regulation Fair Disclosure promulgated by the SEC. These disclosures are included on our website in the &#8220;Investors&#8221; or &#8220;News&#8221; sections. Accordingly, investors should monitor these portions of our website, in addition to following Pfizer&#8217;s press releases, SEC filings, public conference calls and webcasts, as well as Pfizer&#8217;s social media channels (Pfizer&#8217;s Facebook, YouTube and LinkedIn pages and Twitter accounts (</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">@Pfizer </span><span style="font-family:Arial;font-size:9pt;">and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">@Pfizer_News</span><span style="font-family:Arial;font-size:9pt;">)).</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information relating to corporate governance at Pfizer, including our Corporate Governance Principles; Director Qualification Standards; Pfizer Policies on Business Conduct (for all of our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer); Code of Business Conduct and Ethics for Members of the Board of Directors; information concerning our Directors; ways to communicate by e-mail with our Directors; Board Committees; Committee Charters; Charter of the Lead Independent Director; and transactions in Pfizer securities by Directors and Officers are available on our website. We will provide any of the foregoing information without charge upon written request to our Corporate Secretary, Pfizer Inc., 235 East 42nd Street, New York, NY 10017. We will disclose any future amendments to, or waivers from, provisions of the Pfizer Policies on Business Conduct affecting our Chief Executive Officer, Chief Financial Officer and Controller on our website as promptly as practicable, as may be required under applicable SEC and NYSE rules. Information relating to shareholder services, including the Computershare Investment Program, book-entry share ownership and direct deposit of dividends, is also available on our website.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The information contained on our website, our Facebook, YouTube and LinkedIn pages or our Twitter accounts is not incorporated by reference into this </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K. Pfizer&#8217;s references to the URLs for websites are intended to be inactive textual references only.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">2</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s7CAA23F1D5715084916CF86D946D5810"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><a style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;" href="#s7CAA23F1D5715084916CF86D946D5810"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:none;">COMMERCIAL OPERATIONS</span></a></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three businesses&#8212;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through July 31, 2019, Consumer Healthcare, each led by a single manager. We have revised prior-period segment information in our 2019 Form 10-K to reflect the 2019 reorganization. Biopharma and Upjohn are the only reportable segments. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For additional information regarding the 2019 reorganization, as well as our Organizing for Growth initiative, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Strategy&#8211;&#8211;Organizing for Growth</span><span style="font-family:Arial;font-size:9pt;"> section and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 17. Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:9pt;"> in our 2019 Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On July 31, 2019, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture in which we own a 32% equity stake. For additional information, see the Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;Note 1A.</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies: Basis of Presentation </span><span style="font-family:Arial;font-size:9pt;">and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 2C. Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements: Equity-Method Investments and Assets and Liabilities Held for Sale</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in our 2019 Financial Report</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:9%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Some additional information about our Biopharma and Upjohn business segments follows:</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="pfizerlogo2816.jpg" alt="pfizerlogo2816.jpg" style="height:34px;width:60px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Pfizer </span></div><div style="text-align:left;font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Biopharmaceuticals </span></div><div style="text-align:left;font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Group</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="upjohnlogoa02.jpg" alt="upjohnlogoa02.jpg" style="height:82px;width:215px;"></img></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Biopharma is a science-based medicines business that includes six business units &#8211; Oncology, Inflammation &amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer&#8217;s contract manufacturing operation, Pfizer CentreOne. At the beginning of our 2019 fiscal year, we also incorporated our biosimilar portfolio into the Oncology and Inflammation &amp; Immunology business units and certain legacy established products into the Internal Medicine business unit. Each business unit is committed to delivering breakthroughs that change patients&#8217; lives.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:3px double #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:Arial;font-size:9pt;">- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Prevnar 13/Prevenar 13<br/>- Ibrance<br/></span><span style="font-family:Arial;font-size:9pt;">- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Eliquis<br/></span><span style="font-family:Arial;font-size:9pt;">- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Xeljanz<br/></span><span style="font-family:Arial;font-size:9pt;">- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Enbrel </span><span style="font-family:Arial;font-size:9pt;">(outside the U.S. and Canada)<br/>- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Chantix/Champix<br/></span><span style="font-family:Arial;font-size:9pt;">- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Sutent<br/>- Xtandi<br/></span><span style="font-family:Arial;font-size:9pt;font-style:italic;">- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #0093d0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="padding-top:2px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:Arial;font-size:9pt;">- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Lyrica<br/>- Lipitor<br/>- Norvasc<br/>- Celebrex<br/>- Viagra<br/></span><span style="font-family:Arial;font-size:9pt;">- </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Certain generic medicines</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;Our Business Development Initiatives </span><span style="font-family:Arial;font-size:9pt;">and</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> &#8212;Our Strategy</span><span style="font-family:Arial;font-size:9pt;">&#160;sections in our 2019 Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For a further discussion of these operating segments, see the</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Pfizer Biopharmaceuticals Group (Biopharma) </span><span style="font-family:Arial;font-size:9pt;">and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Upjohn</span><span style="font-family:Arial;font-size:9pt;"> sections in this 2019 Form 10-K, the table captioned </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues by Operating Segment and Geography</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of the Consolidated Statements of Income</span><span style="font-family:Arial;font-size:9pt;"> section and</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 17. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:9pt;">, including the tables therein captioned </span><span style="font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Selected Income Statement Information</span><span style="font-family:Arial;font-size:9pt;">,</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Geographic Information</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Significant Product Revenues</span><span style="font-family:Arial;font-size:9pt;">, in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report, which are incorporated by reference.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s5545E9AE019053FCBD035AEF266AC6F5"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The key therapeutic areas comprising our Biopharma business segment include:</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:19%;"></td><td style="width:42%;"></td><td style="width:39%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #00497f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-right:1px dotted #80c9ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">Therapeutic Area</span></div></td><td style="vertical-align:top;border-bottom:1px solid #00497f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">Description</span></div></td><td style="vertical-align:top;border-bottom:1px solid #00497f;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">Key Products</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;font-weight:bold;">Internal Medicine</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes innovative brands from two therapeutic areas, Cardiovascular Metabolic and Pain, as well as regional brands.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Eliquis, Chantix/Champix and Premarin family</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;font-weight:bold;">Oncology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes innovative oncology brands of biologics, small molecules, immunotherapies, and biosimilars across a wide range of cancers. </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ibrance, Sutent, Xtandi, Xalkori, Inlyta and Braftovi + Mektovi</span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;font-weight:bold;">Hospital</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-right:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes our global portfolio of sterile injectable and anti-infective medicines, as well as Pfizer CentreOne, our contract manufacturing and active pharmaceutical ingredient sales operation.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sulperazon, Medrol, Vfend and Zithromax</span></div><div style="padding-bottom:4px;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;padding-left:12px;font-size:11pt;"><span style="font-family:Arial;font-size:9pt;">Includes innovative vaccines brands across all ages&#8212;infants, adolescents and adults&#8212;in pneumococcal disease, Meningococcal disease</span><span style="font-family:inherit;font-size:11pt;">&#160;</span><span style="font-family:Arial;font-size:9pt;">and tick-borne encephalitis, with a pipeline focus on healthcare-acquired infections and maternal health.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prevnar 13/Prevenar 13 (pediatric/adult), FSME-IMMUN, Nimenrix and Trumenba </span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;font-weight:bold;">Inflammation and Immunology</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes innovative brands and biosimilars for chronic immune and inflammatory diseases. </span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Xeljanz, Enbrel (outside the U.S. and Canada), Inflectra and Eucrisa</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="padding-bottom:8px;padding-top:8px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Includes innovative brands for a number of therapeutic areas with rare diseases, including amyloidosis, hemophilia, and endocrine diseases.</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #80c9ff;border-top:1px dotted #0093d0;"><div style="padding-bottom:4px;text-align:left;padding-left:12px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vyndaqel/Vyndamax, BeneFIX, Genotropin and Refacto AF/Xyntha</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We recorded direct product and/or alliance revenues of more than $1 billion for each of six Biopharma products in </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;">, seven Biopharma products in </span><span style="font-family:Arial;font-size:9pt;">2018</span><span style="font-family:Arial;font-size:9pt;"> and six Biopharma products in </span><span style="font-family:Arial;font-size:9pt;">2017</span><span style="font-family:Arial;font-size:9pt;">: </span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.1484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:3%;"></td><td style="width:32%;"></td><td style="width:3%;"></td><td style="width:32%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Biopharma $1 Billion+ Products</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prevnar 13/Prevenar 13</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ibrance</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ibrance</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ibrance</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Eliquis*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Eliquis</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">*</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Eliquis</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">*</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Xeljanz</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Enbrel</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Enbrel</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Enbrel</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Xeljanz</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Xeljanz</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chantix/Champix</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chantix/Champix</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sutent</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sutent</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="5" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">* </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Eliquis</span><span style="font-family:Arial;font-size:8pt;">&#160;includes alliance revenues and direct sales in 2019, 2018 and 2017.</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For a discussion of certain Biopharma products and additional information regarding collaboration and/or co-promotion agreements involving certain of these Biopharma products, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Collaboration and Co-Promotion Agreements </span><span style="font-family:Arial;font-size:9pt;">and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;Patents and Other Intellectual Property Rights </span><span style="font-family:Arial;font-size:9pt;">sections of this 2019 Form 10-K; for additional information regarding the revenues of our Biopharma business, including revenues by geography and of significant Biopharma products, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of the Consolidated Statements of Income</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview,</span><span style="font-family:Arial;font-size:9pt;"> &#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues by Operating Segment and Geography</span><span style="font-family:Arial;font-size:9pt;"> and &#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues&#8212;Selected Product Discussion</span><span style="font-family:Arial;font-size:9pt;"> sections and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 17. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report; and for additional information on the key operational revenue drivers of our Biopharma business, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of Operating Segment Information</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Biopharma Operating Segment</span><span style="font-family:Arial;font-size:9pt;"> section in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report. For a discussion of the risks associated with our dependence on certain of our major products, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Dependence on Key In-Line Products</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">4</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s14B27B8472785915B895CCBE82296593"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">UPJOHN</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Upjohn&#8217;s products are used to treat non-communicable diseases across a broad range of therapeutic areas, including:</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cardiovascular (Lipitor, Norvasc and Revatio); </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pain and neurology (Lyrica and Celebrex);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Psychiatry (Effexor, Zoloft and Xanax); </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Urology (Viagra); and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ophthalmology (Xalatan/Xalacom).</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We recorded direct product revenues of more than $1 billion for two Upjohn products in </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;">, three Upjohn products in </span><span style="font-family:Arial;font-size:9pt;">2018</span><span style="font-family:Arial;font-size:9pt;">, and three Upjohn products in </span><span style="font-family:Arial;font-size:9pt;">2017</span><span style="font-family:Arial;font-size:9pt;">:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:77.1484375%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:30%;"></td><td style="width:3%;"></td><td style="width:32%;"></td><td style="width:3%;"></td><td style="width:32%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Upjohn $1 Billion+ Products</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lyrica</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lyrica</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lyrica</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lipitor</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Norvasc</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Viagra</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For a discussion of certain Upjohn products and additional information regarding the revenues of our Upjohn business, including revenues by geography and of significant Upjohn products, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of the Consolidated Statements of Income</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview,</span><span style="font-family:Arial;font-size:9pt;"> &#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues by Operating Segment and Geography</span><span style="font-family:Arial;font-size:9pt;"> and &#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues&#8212;Selected Product Discussion</span><span style="font-family:Arial;font-size:9pt;"> sections and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 17. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report; and for additional information on the key operational revenue drivers of our Upjohn business, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of Operating Segment Information</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Upjohn Operating Segment</span><span style="font-family:Arial;font-size:9pt;"> section in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report. For a discussion of the risks associated with our dependence on certain of our major products, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Dependence on Key In-Line Products</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K.  </span></div><div><a id="s14E3615AAA885E3FAB4992117F87E67A"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">COLLABORATION AND CO-PROMOTION AGREEMENTS</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We are party to collaboration and/or co-promotion agreements relating to certain biopharmaceutical products, including, among others, Eliquis, Xtandi and Bavencio. Revenues from Eliquis (except in certain markets where we have direct sales)</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">, </span><span style="font-family:Arial;font-size:9pt;">Xtandi and Bavencio are included in alliance revenues. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Eliquis has been jointly developed and is commercialized by Pfizer and BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMS compensation based on a percentage of net sales. We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plus a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant market; the agents in this class were developed as alternative treatment options to warfarin in appropriate patients.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Xtandi is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related to U.S. net sales of Xtandi. Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S. market. In addition, Pfizer and Astellas share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of international Xtandi net sales (recorded in </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:9pt;">). Xtandi is an androgen receptor inhibitor that blocks multiple steps in the androgen receptor signaling pathway within tumor cells. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Bavencio (avelumab) is being developed and commercialized in collaboration with Merck KGaA. </span><span style="font-family:Arial;font-size:9pt;">Both companies jointly fund the majority of development and commercialization costs, and split equally any profits related to net sales generated from selling any products containing avelumab from this collaboration.</span><span style="font-family:Arial;font-size:9pt;"> Bavencio is a human anti-programmed death ligand-1 (PD-L1) antibody. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">5</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s3BE135625FA753D382C094E8A20E5AB2"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">RESEARCH AND DEVELOPMENT</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Innovation is critical to the success of our Company, and drug discovery and development are time-consuming, expensive and unpredictable.</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;">Pfizer&#8217;s purpose is to deliver breakthroughs that change patients&#8217; lives.</span><span style="font-family:Arial;font-size:9pt;"> R&amp;D is at the heart of fulfilling Pfizer&#8217;s purpose as we work to translate advanced science and technologies into the therapies that matter most. </span></div><div style="line-height:120%;padding-top:12px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;text-decoration:underline;">Our R&amp;D Priorities and Strategy</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our R&amp;D priorities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">delivering a pipeline of highly differentiated medicines and vaccines where Pfizer has a unique opportunity to bring the most important new therapies to patients in need;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">advancing our capabilities that can position Pfizer for long-term R&amp;D leadership; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">advancing new models for partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">To that end, our R&amp;D primarily focuses on:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Oncology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inflammation and Immunology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vaccines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Internal Medicine;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rare Diseases;</span><span style="font-family:Arial;font-size:9pt;"> and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Hospital</span><span style="font-family:Arial;font-size:9pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">While a significant portion of R&amp;D is done internally, we continue to seek out promising chemical and biological lead molecules and innovative technologies developed by third parties to incorporate into our discovery and development processes or projects, as well as our product lines. We do so by entering into collaboration, alliance and license agreements with other companies, as well as leveraging acquisitions and equity- or debt-based investments. These agreements enable us to co-develop, license or acquire promising compounds, technologies and/or capabilities. We also enter into agreements pursuant to which a third party agrees to fund a portion of the development costs of one or more of our pipeline products in exchange for rights to receive potential milestone payments, revenue sharing payments, profit sharing payments and/or royalties. Collaboration, alliance, license and funding agreements and equity- or debt-based investments allow us to share risk and cost. They also enable us to access external scientific and technological expertise, as well as provide us the opportunity to advance our own products and in-licensed or acquired products.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For additional information, see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 2</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;text-decoration:underline;">Our R&amp;D Operations</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We conduct R&amp;D internally and also through contracts with third parties, through collaborations with universities and biotechnology companies and in cooperation with other pharmaceutical firms. </span><span style="font-family:Arial;font-size:9pt;">In 2019, we continued to strengthen our global R&amp;D organization and pursue strategies intended to improve innovation and overall productivity in R&amp;D to achieve a sustainable pipeline that is positioned to deliver value in the near term and over time.</span><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our R&amp;D spending is conducted through a number of matrix organizations:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Research Units within our WRDM organization are generally responsible for research and early-stage development assets for our Biopharma business (assets that have not yet achieved proof-of-concept). Our Research Units are organized by therapeutic area to enhance flexibility, cohesiveness and focus. Because of our structure, we are able to rapidly redeploy resources within a Research Unit between various projects as necessary because in many instances the workforce shares similar skills, expertise and/or focus.</span><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our science-based and other platform-services organizations provide technical expertise and other services to the various R&amp;D projects, and are organized into science-based functions (which are part of our WRDM organization), such as Pharmaceutical Sciences, Medicine Design, and non-science-based functions, such as Facilities, Digital and Finance. Within each of these functions, we are able to migrate resources among projects, candidates and/or targets in any therapeutic area and in most phases of development, allowing us to react quickly in response to evolving needs. In addition, the Worldwide Medical and Safety group, within WRDM, ensures that Pfizer provides all stakeholders</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;">including patients, healthcare providers, pharmacists, payers and health authorities</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;">with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span><span style="font-family:Arial;font-size:9pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our R&amp;D organization within Upjohn supports the off-patent branded and generic established medicines and helps to develop product enhancements, new indications and new market registrations for these medicines.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">6</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our Global Product Development (GPD) organization </span><span style="font-family:Arial;font-size:9pt;">is a unified center for clinical development and regulatory activities that is generally responsible for the clinical development strategy and operational execution of clinical trials for both early-stage assets in the WRDM portfolio as well as late-stage assets in the Biopharma portfolio. </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We manage R&amp;D operations on a total-company basis through our matrix organizations described above. Specifically, the Portfolio Strategy &amp; Investment committee, comprised of senior executives, is accountable for aligning resources among all of our WRDM, GPD and Biopharma R&amp;D projects and for seeking to ensure optimal capital allocation across the innovative R&amp;D portfolio. We believe that this approach also serves to maximize accountability and flexibility. Our Upjohn R&amp;D organization manages its resources separately from the WRDM and GPD organizations, with operational support from GPD for select clinical development regulatory activities and from WRDM for clinical supply operations and global pharmacovigilance processing.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Generally, we do not disaggregate total R&amp;D expense by development phase or by therapeutic area since, as described above, we do not manage our R&amp;D operations by development phase or by therapeutic area. Further, as we are able to adjust a significant portion of our spending quickly, we believe that any prior-period information about R&amp;D expense by development phase or by therapeutic area would not necessarily be representative of future spending.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For additional information on our R&amp;D operations and expenses, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Costs and Expenses</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Research and Development (R&amp;D) Expenses</span><span style="font-family:Arial;font-size:9pt;"> section in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;text-decoration:underline;">Our R&amp;D Pipeline and Competition</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The discovery and development of safe, effective new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our businesses. Drug candidates can fail at any stage of the process, and candidates may not receive regulatory approval even after many years of research and development. The process from discovery to development to regulatory approval can take more than ten years. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:100%;padding-top:4px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of </span><span style="font-family:Arial;font-size:9pt;">January&#160;28, 2020</span><span style="font-family:Arial;font-size:9pt;">, we had the following number of projects in various stages of R&amp;D: </span></div><div style="line-height:100%;padding-top:4px;"><img src="pfizerpipeline2020a02.jpg" alt="pfizerpipeline2020a02.jpg" style="height:185px;width:682px;"></img></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Development of a single compound is often pursued as part of multiple programs. While these drug candidates may or may not eventually receive regulatory approval, new drug candidates entering clinical development phases are the foundation for future products. In addition to discovering and developing new products, our R&amp;D efforts seek to add value to our existing products by improving their effectiveness, enhancing ease of dosing and by discovering potential new indications for them.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information concerning several of our drug candidates in development, as well as supplemental filings for existing products, is set forth in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of the Consolidated Statements of Income</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Product Developments&#8211;&#8211;Biopharmaceutical</span><span style="font-family:Arial;font-size:9pt;"> section in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report, which is incorporated by reference.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our competitors also devote substantial funds and resources to R&amp;D. We also compete against numerous small biotechnology companies in developing potential drug candidates. The extent to which our competitors are successful in their research could result in erosion of the sales of our existing products and potential sales of products in development, as well as unanticipated product obsolescence. In addition, several of our competitors operate without large R&amp;D expenses and make a regular practice of challenging our product patents before their expiration. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Competition</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Competitive Products</span><span style="font-family:Arial;font-size:9pt;"> sections in this 2019 Form 10-K.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s9C32A8F6EF6E59B79ABBB82C4A35DD83"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">INTERNATIONAL OPERATIONS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We have significant operations outside the U.S. In 2019, operations in developed and emerging markets were managed through our business segments: Biopharma, Upjohn and, through July 31, 2019, Consumer Healthcare. Emerging markets are an important component of our strategy for global leadership, and our commercial structure recognizes that the demographics and rising economic power of the fastest-growing emerging markets are becoming more closely aligned with the profile found within developed markets. Urbanization and the rise of the middle class in emerging markets, particularly in Asia, provide growth opportunities for our medicines. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We sell our products in over 125 countries. Revenues from operations outside the U.S. of </span><span style="font-family:Arial;font-size:9pt;">$27.9 billion</span><span style="font-family:Arial;font-size:9pt;"> accounted for </span><span style="font-family:Arial;font-size:9pt;">54%</span><span style="font-family:Arial;font-size:9pt;"> of our total revenues in </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;">. Revenues exceeded $500 million in each of&#160;eleven countries outside the U.S. in 2019, 2018 and 2017. By total revenues, China and Japan are our two largest national markets outside the U.S. For a geographic breakdown of revenues, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of the Consolidated Statements of Income</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Overview</span><span style="font-family:Arial;font-size:9pt;"> and</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues by Operating Segment and Geography</span><span style="font-family:Arial;font-size:9pt;"> sections and the table captioned </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Geographic Information</span><span style="font-family:Arial;font-size:9pt;"> in the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 17. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report. </span></div><div style="line-height:120%;text-align:center;text-indent:32px;"><img src="revbynatlmrkt2017-2019.jpg" alt="revbynatlmrkt2017-2019.jpg" style="height:250px;width:522px;"></img></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our international operations are subject, in varying degrees, to a number of risks inherent in carrying on business in other countries, including, among other things, currency fluctuations, capital and exchange control regulations and expropriation and other restrictive government actions. See the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">International Operations</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K. Our international businesses are also subject to government-imposed constraints, including laws and regulations on pricing, reimbursement, and access to our products. See the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="color:#000000;font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Outside the United States</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K for a discussion of these matters.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;">Depending on the direction of change relative to the U.S. dollar, foreign currency values can increase or decrease the reported dollar value of our net assets and results of operations. While we cannot predict with certainty future changes in foreign exchange rates or the effect they will have on us, we attempt to mitigate their impact through operational means and by using various financial instruments, depending upon market conditions. For additional information, see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 7</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">F</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Financial Instruments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Derivative Financial Instruments and Hedging Activities</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report, which is incorporated by reference, as well as </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Financial Risk Management</span><span style="font-family:Arial;font-size:10pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">section</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in this 2019 Form 10-K.</span></div><div><a id="s004BD76FDBD357B0BA6137FF962A1E71"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">MARKETING</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In our global biopharmaceutical businesses, we promote our products to healthcare providers and patients. Through our marketing organizations, we explain the approved uses, benefits and risks of our products to healthcare providers, such as doctors, nurse practitioners, physician assistants and pharmacists; MCOs that provide insurance coverage, such as hospitals, Integrated Delivery Systems, PBMs and health plans; and employers and government agencies who hire MCOs to provide health benefits to their employees. We also market directly to consumers in the U.S. through direct-to-consumer advertising that seeks to communicate the approved uses, benefits and risks of our products while motivating people to have meaningful conversations with their doctors. In addition, we sponsor general advertising to educate the public on disease awareness, prevention and wellness, important public health issues, and our patient assistance programs.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our prescription pharmaceutical products are sold principally to wholesalers, but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccines products in the U.S., we primarily sell directly to the U.S. Centers for Disease Control and Prevention, wholesalers, individual provider offices, retail pharmacies, and integrated delivery networks. We seek to gain access for our products on healthcare authority and PBM formularies, which are lists of approved medicines available to members of the PBMs. PBMs use various benefit designs, such as tiered co-pays for formulary </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">8</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">products, to drive utilization of products in preferred formulary positions. We may also work with payers on disease management programs that help to develop tools and materials to educate patients and physicians on key disease areas.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;">, our top three biopharmaceutical wholesalers accounted for approximately </span><span style="font-family:Arial;font-size:9pt;">37%</span><span style="font-family:Arial;font-size:9pt;"> of our total revenues (and approximately </span><span style="font-family:Arial;font-size:9pt;">79%</span><span style="font-family:Arial;font-size:9pt;"> of our total U.S. revenues).</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">% of </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"> Total Revenues and U.S. Revenues from </span></div><div style="line-height:120%;text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Major Biopharmaceutical Wholesalers and Other Customers</span></div><div style="line-height:120%;text-align:center;"><img src="totalrevbycustomer.jpg" alt="totalrevbycustomer.jpg" style="height:216px;width:306px;"></img><img src="totandusrevbiowhlslrs2019.jpg" alt="totandusrevbiowhlslrs2019.jpg" style="height:216px;width:306px;"></img></div><div><a id="s50BFE339300B57BF9CBAD0E9E41AF305"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PATENTS AND OTHER INTELLECTUAL PROPERTY RIGHTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our products are sold around the world under brand-name, logo and certain product design trademarks that we consider, in the aggregate, to be of material importance to Pfizer. Trademark protection continues in some countries for as long as the mark is used and, in other countries, for as long as it is registered. Registrations generally are for fixed, but renewable, terms.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We own or license a number of U.S. and foreign patents. These patents cover pharmaceutical and other products and their uses, pharmaceutical formulations, product manufacturing processes and intermediate chemical compounds used in manufacturing.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Patents for individual products extend for varying periods according to the date of patent filing or grant and the legal term of patents in the various countries where patent protection is obtained. The actual protection afforded by a patent, which can vary from country to country, depends upon the type of patent, the scope of its coverage and the availability of legal remedies in the country. Further, patent term extension may be available in many major countries to compensate for a regulatory delay in approval of the product. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="color:#000000;font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Outside the United States</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Intellectual Property</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In various markets, a period of regulatory exclusivity may be provided to certain drugs upon approval. The scope and term of such exclusivity will vary but, in general, the period of regulatory exclusivity will run concurrently with the term of any existing patent rights associated with the drug at the time of approval.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In the aggregate, our patent and related rights are of material importance to our businesses in the U.S. and most other countries. Based on current product sales, and considering the vigorous competition with products sold by our competitors, the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires (including, where applicable, grant of an additional six-month pediatric extension and/or the granted patent term extension in the U.S. and Japan and Supplementary Patent Certificate in Europe), are those for the medicines set forth in the table below. Unless otherwise indicated, the years set forth in the table below pertain to the basic product patent expiration for the respective products. Patent term extensions, supplementary protection certificates and pediatric exclusivity periods are not reflected in the expiration dates listed in the table below, unless they have been granted by the issuing authority. In some instances, there are later-expiring patents relating to our products directed to particular forms or compositions, to methods of manufacturing, or to use of the drug in the treatment of particular diseases or conditions. However, in some cases, such patents may not protect our drug from generic or, as applicable, biosimilar competition after the expiration of the basic patent.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:24%;"></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Drug</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">U.S. Basic Product Patent Expiration Year&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Major EU Basic Product Patent Expiration Year</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Japan Basic Product Patent Expiration Year</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lyrica</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(1)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2014</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(2)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(3)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2028</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2026</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2026</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2025</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2025</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2028</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(4)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2025</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2026</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">__(5)</sup>&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2029</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Eliquis</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(6)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2026</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2026</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2026</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Xtandi</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(7)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(7)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(7)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2029</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2027</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2028</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Besponsa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2030</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2028</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2028</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(8)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Braftovi</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2031</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mektovi</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2031</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(10)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(9)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Bavencio</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(11)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2033</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2032</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #828282;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2033</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(1)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lyrica</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019.  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(2)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lyrica</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">regulatory exclusivity in the EU expired in July 2014.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(3)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lyrica is covered by a Japanese method-of-use patent which expires in 2022. The patent is currently subject to an invalidation action.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(4)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Xeljanz EU expiry is provided by regulatory exclusivity.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(5)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The EU patent that covers the combination of the 13 serotype conjugates of Prevenar</span><span style="font-family:Arial;font-size:8pt;color:#1f497d;"> </span><span style="font-family:Arial;font-size:8pt;">13 was revoked following an opposition and has now been withdrawn. There are other EU patents and pending applications covering the formulation, various aspects of the manufacturing process, and the combination of serotype conjugates of Prevenar</span><span style="font-family:Arial;font-size:8pt;color:#1f497d;"> </span><span style="font-family:Arial;font-size:8pt;">13 that remain in force.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(6)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Eliquis was developed and is being commercialized in collaboration with BMS.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(7)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Xtandi is being developed and commercialized in collaboration with Astellas, which has exclusive commercialization rights for Xtandi outside the U.S. Pfizer receives tiered royalties as a percentage of international Xtandi net sales.&#160;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(8)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Besponsa</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">Japan expiry is provided by regulatory exclusivity.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(9)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer has exclusive rights to Braftovi and Mektovi in the U.S. The Pierre Fabre Group has exclusive rights to commercialize both products in Europe and Ono Pharmaceutical Co., Ltd. has exclusive rights to commercialize both products in Japan. Pfizer receives royalties from The Pierre Fabre Group and Ono Pharmaceutical Co., Ltd. on sales of Braftovi and Mektovi outside the U.S.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(10)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The U.S. expiration date in the table for Mektovi is provided by a method-of-use patent.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(11)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Bavencio is being developed and commercialized in collaboration with Merck KGaA.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:-18px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a significant adverse effect on our revenues. Many of our branded products have multiple patents that expire at varying dates, thereby strengthening our overall patent protection. However, once patent protection has expired or has been lost prior to the expiration date as a result of a legal challenge, we typically lose exclusivity on these products, and generic and biosimilar pharmaceutical manufacturers generally produce identical or highly similar products and sell them for a lower price. The date at which generic or biosimilar competition commences may be different from the date that the patent or regulatory exclusivity expires. However, when generic or biosimilar competition does commence, the resulting price competition can substantially decrease our revenues for the impacted products, often in a very short period of time. In some cases, however, we can continue to obtain commercial benefits from product manufacturing trade secrets; patents on uses for products; patents on processes and intermediates for the economical manufacture of the active ingredients; patents for special formulations of the product or delivery mechanisms; or conversion of the active ingredient to OTC products.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Also, if one of our patents is found to be invalid by judicial, court or administrative proceedings, such as inter partes</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Patent Protection</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Companies have filed applications with the FDA seeking approval of product candidates that such companies claim either do not infringe our patents or our patents are invalid; these include candidates that would compete with, among other products, Eliquis, Ibrance and Xeljanz. We will continue to aggressively defend our patent rights whenever we deem appropriate. For additional </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">10</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">information, see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 16</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">A1</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Legal Proceedings&#8211;&#8211;Patent Litigation</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;">Recent Losses and Expected Losses of Product Exclusivity</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certain of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face significantly increased generic competition over the next few years.</span><span style="font-family:Arial;font-size:9pt;"> For example, as a result of a patent litigation settlement, Teva launched a generic version of Viagra in the U.S. in December 2017. Lyrica lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019. Also, the basic product patent for Chantix in the U.S. will expire in November 2020. See the table above for the basic product patent expiries of our most significant products.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We expect the impact of reduced revenues due to patent expiries will be significant in 2020, then moderating downward to a much lower level from 2021 through 2025.</span><span style="font-family:Arial;font-size:9pt;"> For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Dependence on Key In-Line Products</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">section</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in this 2019 Form 10-K. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table provides information about certain products recently experiencing, or expected to experience in </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;">, patent expirations or loss of regulatory exclusivity in the U.S., Europe or Japan. Our financial results in </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> and our financial guidance for 2020 reflect the impact of the loss of exclusivity of various products discussed below:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Product Revenues in Markets Impacted</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Products</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Key Dates</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Markets Impacted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Viagra</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:4px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">June 2013<br/>May 2014<br/>December 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Major European markets<br/>Japan<br/>U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">134</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">274</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">$</span></div></td><td style="vertical-align:top;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">850</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lyrica</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">July 2014</span></div><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">June 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Major European markets</span></div><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">2,208</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">3,852</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">3,901</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pristiq</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">March 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">42</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">71</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">133</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chantix</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(e)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">November 2020</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S.</span></div><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">899</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">838</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">742</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unless otherwise noted, &#8220;Key Dates&#8221; indicate patent-based expiration dates.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a result of a patent litigation settlement, Teva launched a generic version of Viagra in the U.S. in December 2017.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lyrica</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019.  </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a result of a patent litigation settlement with several generic manufacturers, generic versions of Pristiq launched in the U.S. in March 2017.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The basic product patent for Chantix in the U.S. will expire in November 2020, which includes the FDA&#8217;s grant of pediatric exclusivity that extended the period of market exclusivity in the U.S. for Chantix for an additional six months from May 2020.</span></div></td></tr></table><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;">Biologic Products</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our biologic products, including BeneFIX, ReFacto, Xyntha, Bavencio, Prevnar 13/Prevenar 13 and Enbrel (we market Enbrel outside the U.S. and Canada), already face, or may face in the future, competition from biosimilars (also referred to as follow-on biologics).</span><span style="font-family:Arial;font-size:9pt;"> In the U.S., such biosimilars would reference our originator biologic products approved under the U.S. Public Health Service Act. Additionally, the FDA has approved a follow-on recombinant human growth hormone that referenced our biotechnology product, Genotropin, that was approved under the FFDCA.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Biosimilars are versions of biologic medicines that have been developed and proven to be highly similar to the original biologic in terms of safety and efficacy and that have no clinically meaningful differences in safety, purity or potency. Biosimilars have the potential to offer high-quality, lower-cost alternatives to biologic medicines. Abbreviated legal pathways for the approval of biosimilars exist in certain international markets and, since the passage of the ACA in 2010, a framework for such approval exists in the U.S. In Europe, the European Commission grants marketing authorizations for biosimilars pursuant to a set of general and product class-specific guidelines for biosimilar approvals. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;">As part of our business strategy, we are capitalizing on our expertise in biologics manufacturing, as well as our regulatory and commercial strengths, to develop and commercialize biosimilar medicines. Some of the biosimilars that we currently market include Inflectra, Nivestym, Retacrit, Zirabev, Ruxience and Trazimera in the U.S.; Inflectra, Retacrit, Nivestim and Trazimera in the EU; and Ixifi, Trazimera, Zirabev and Ruxience in Japan.</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:9pt;">See the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Biosimilars</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We may face litigation with respect to the validity and/or scope of patents relating to our biologic products. Likewise, as we develop, manufacture and seek to launch biosimilars, patents may be asserted against us.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;">International</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">One of the main limitations on our operations in some countries outside the U.S. is the lack of effective intellectual property protection for our products. Under international and U.S. free trade agreements in recent years, we have seen some improvement in global protection of intellectual property rights. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="color:#000000;font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Outside the United States</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="color:#000000;font-family:Arial;font-size:9pt;font-style:italic;">Intellectual Property</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K.</span></div><div><a id="s6A4B83F647685F0AB7680E53CD7F4421"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">COMPETITION</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our businesses are conducted in intensely competitive and often highly regulated markets. </span><span style="font-family:Arial;font-size:9pt;">Many of our prescription pharmaceutical products face competition in the form of branded or generic drugs or biosimilars that treat similar diseases or indications.</span><span style="font-family:Arial;font-size:9pt;"> The principal forms of competition include efficacy, safety, ease of use, and cost effectiveness. Though the means of competition vary among product categories and business groups, demonstrating the value of our products is a critical factor for success in all of our principal businesses.</span></div><div style="line-height:120%;text-indent:30px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our competitors include other worldwide research-based biopharmaceutical companies, smaller research companies with more limited therapeutic focus and generic and biosimilar drug manufacturers. We compete with other companies that manufacture and sell products that treat diseases or indications similar to those treated by our major products.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">This competition affects our core product business, which is focused on applying innovative science to discover and market products that satisfy unmet medical needs and provide therapeutic improvements. Our emphasis on innovation is underscored by our multi-billion-dollar investment in R&amp;D, as well as our business development transactions, both designed to result in a strong product pipeline. Our investment in research does not stop with drug approval; we continue to invest in further demonstrating the value of our products for the conditions they treat, as well as potential new applications. We seek to protect the health and well-being of patients by striving to ensure that medically sound knowledge of the benefits and risks of our medicines is understood and communicated to patients, physicians, payers and global health authorities. We also seek to continually enhance the organizational effectiveness of all of our biopharmaceutical functions, including coordinating support for our efforts to accurately and ethically launch and promote our products to our customers.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Operating conditions have become more challenging under mounting global pressures of competition, industry regulation and cost containment. We continue to take measures to evaluate, adapt and improve our organization and business practices to better meet customer and public needs. We believe that we have taken an industry-leading role in evolving our approaches to U.S. direct-to-consumer advertising, interactions with, and payments to, healthcare professionals, and medical education grants. We also continue to sponsor programs to address patient affordability and access barriers, as we strive to advance fundamental health system change through support for better healthcare solutions.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our vaccines business may face competition from the introduction of alternative vaccines. For example, Prevnar 13 may face competition in the form of competitor vaccines, including vaccines with additional serotypes or &#8220;next-generation&#8221; pneumococcal conjugate vaccines prior to or after the expiration of its patents, which may adversely affect our future results.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our generics and biosimilars businesses compete with branded products from competitors, as well as other generics and biosimilars manufacturers. Globally, Pfizer sells generic versions of Pfizer&#8217;s, as well as certain competitors&#8217;, solid oral dose and sterile injectable pharmaceutical products. We also sell biosimilars of certain inflammation &amp; immunology and oncology biologic medicines globally. We seek to maximize the opportunity to establish a &#8220;first-to-market&#8221; or early market position for our generic injectable drugs and biosimilars, as a &#8220;first-to-market&#8221; position provides customers a lower-cost alternative immediately when available and also may provide us with potentially higher levels of sales and profitability until other generic or biosimilar competitors enter the market. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;">Managed Care Organizations</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The evolution of managed care in the U.S. has been a major factor in the competitive makeup of the healthcare marketplace. Approximately 300 million people in the U.S. now have some form of health insurance coverage. Due to the expansion of health insurance coverage (see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="color:#000000;font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">In the United States</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K), the marketing of prescription drugs to both consumers and the entities that manage this expanded coverage in the U.S. continues to grow in importance.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The influence of MCOs has increased in recent years due to the growing number of patients receiving coverage through MCOs. At the same time, those organizations have been consolidating into fewer, even larger entities. This consolidation enhances both their ability to negotiate, as well as their importance to Pfizer.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The growth of MCOs has increased pressure on drug prices as well as revenues. One objective of MCOs is to contain and, where possible, reduce healthcare expenditures. MCOs typically negotiate prices with pharmaceutical providers by using </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">12</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">formularies (which are lists of approved medicines available to members of the MCOs), clinical protocols (requiring prior authorization for a branded product if a generic product is available or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine), volume purchasing, long-term contracts and their ability to influence volume and market share of prescription drugs. In addition, by placing branded medicines on higher-tier status in their formularies (leading to higher patient co-pays) or non-preferred tier status, MCOs transfer a portion of the cost of the medicine to the patient, resulting in significant out-of-pocket expenses for the patient, especially for chronic treatments. This financial disincentive is a tool for MCOs to manage drug costs and channel patients to medicines preferred by the MCOs. MCOs also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing and &#8220;copay accumulator&#8221; programs to improve their cost containment efforts. We are closely monitoring these newer approaches and developing appropriate strategies to respond to them.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Due to their generally lower cost, generic medicines typically are placed in lowest cost tiers of MCO formularies. The breadth of the products covered by formularies can vary considerably from one MCO to another, and many formularies include alternative and competitive products for treatment of particular medical problems. </span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exclusion of a product from a formulary or other MCO-implemented restrictions can significantly impact drug usage in the MCO patient population and beyond. Consequently, pharmaceutical companies compete to gain access to formularies for their products. Unique product features, such as greater efficacy, better patient ease of use, or fewer side effects, are generally beneficial to achieving access to formularies. However, lower overall cost of therapy is also an important factor. We have been generally, although not universally, successful in having our major products included on MCO formularies. However, increasingly our branded products are being placed on the higher tiers or in a non-preferred status. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">MCOs also emphasize primary and preventive care, out-patient treatment and procedures performed at doctors&#8217; offices and clinics as another way to manage costs. Hospitalization and surgery, typically the most expensive forms of treatment, are carefully managed. Since the use of certain drugs can reduce the need for hospitalization, professional therapy, or even surgery, such drugs can become favored first-line treatments for certain diseases. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The ACA has accelerated payment reform by distributing risk across MCOs and other stakeholders in care delivery with the intent of improving quality while reducing costs, which creates pressure on MCOs to tie reimbursement to defined outcomes. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">In the United States&#8212;Healthcare Reform</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;">Generic Products</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">One of the biggest competitive challenges that our branded products face is from generic pharmaceutical manufacturers. Upon the expiration or loss of patent protection for a product, especially a small molecule product, we can lose the major portion of revenues for that product in a very short period of time. Several competitors make a regular practice of challenging our product patents before their expiration. Generic competitors often operate without large R&amp;D expenses, as well as without costs of conveying medical information about products to the medical community. In addition, the FDA approval process exempts generics from costly and time-consuming clinical trials to demonstrate their safety and efficacy, allowing generic manufacturers to rely on the safety and efficacy data of the innovator product. Generic competitors can market a competing version of our product after the expiration or loss of our patent and often charge much less. In China, for example, we are expected to face further intensified competition by certain generic manufacturers in 2020, which may result in price cuts and volume loss of some of our products.&#160;</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition, our patent-protected products can face competition in the form of generic versions of competitors&#8217; branded products that lose their market exclusivity.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As noted above, MCOs that focus primarily on the immediate cost of drugs often favor generics over brand-name drugs. Many governments also encourage the use of generics as alternatives to brand-name drugs in their healthcare programs, including Medicaid in the U.S. Laws in the U.S. generally allow, and in some cases require, pharmacists to substitute, for brand-name drugs, generic drugs that have been rated under government procedures to be chemically and therapeutically equivalent to brand-name drugs. In a small subset of states, prescribing physicians are able to expressly prevent such substitution. Favoring generics may reduce sales of our branded products.</span></div><div><a id="s800FAAB7988D56C08B93517F18958040"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">RAW MATERIALS</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Raw materials essential to our businesses are purchased worldwide in the ordinary course of business from numerous suppliers. In general, these materials are available from multiple sources. In </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;">, we experienced periodic shortages of select materials due to constrained capacity or operational challenges with the associated suppliers. Supplier management activities are ongoing to work to ensure the necessary supply to meet our requirements for these materials. No significant impact to our operations is anticipated in 2020.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sB238C4365E0D54E6B1E6BADD068EB983"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">GOVERNMENT REGULATION AND PRICE CONSTRAINTS</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pharmaceutical companies are subject to extensive regulation by government authorities in the countries in which they do business. Certain laws and regulations that govern Pfizer&#8217;s business are discussed below.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">General</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">.</span><span style="font-family:Arial;font-size:9pt;"> Our business has been and will continue to be subject to numerous laws and regulations. Failure to comply with these laws and regulations, including those governing the manufacture and marketing of our products, could subject us to administrative and legal proceedings and actions by various governmental bodies. For additional information on these proceedings and actions, see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 16</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">A</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Legal Proceedings</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report. Criminal charges, substantial fines and/or civil penalties, warning letters and product recalls or seizures, delays in product approvals, as well as limitations on our ability to conduct business in applicable jurisdictions, could result from such proceedings and actions.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="color:#006ebf;font-family:Arial;font-size:9pt;font-style:italic;text-decoration:underline;">In the United States</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Drug Regulation</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">.</span><span style="font-family:Arial;font-size:9pt;"> In the U.S., biopharmaceutical products are subject to extensive pre- and post-market regulation by the FDA, including regulations that govern, among other things, the safety and efficacy of our medicines, clinical trials, advertising and promotion, manufacturing, labeling and record keeping. Our products are also subject to post-market surveillance under the FFDCA and its implementing regulations with respect to drugs, as well as the Public Health Service Act and its implementing regulations with respect to biologics. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other U.S. federal agencies, including the DEA, also regulate certain of our products. Many of our activities also are subject to the jurisdiction of the SEC. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Biopharmaceutical companies seeking to market a product in the U.S. must first test the product to demonstrate that it is safe and effective for its intended use. If, after evaluation, the FDA determines the product is safe (i.e., its benefits outweigh its known risks) and effective, then the FDA will approve the product for marketing, issuing a New Drug Application or Biologics License Application, as appropriate. Companies seeking to market a generic prescription drug must scientifically demonstrate that the generic drug is bioequivalent to the innovator drug. The Abbreviated New Drug Application, or generic drug application, must show, among other things, that the generic drug is pharmaceutically equivalent to the brand, the manufacturer is capable of making the drug correctly, and the proposed label is the same as that of the innovator/brand drug&#8217;s label. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Even after a drug or biologic is approved for marketing, it may still be subject to postmarketing commitments or postmarketing requirements. Postmarketing commitments are studies or clinical trials that the drug or biologic sponsor has agreed to conduct, but are not required by law and/or regulation. Postmarketing requirements include studies and clinical trials that sponsors are required to conduct, by law and/or regulation, as a condition of approval. Postmarketing studies or clinical trials can be required in order to assess a known risk or demonstrate clinical benefit for drugs or biologics approved pursuant to accelerated approval. If a company fails to meet its postmarketing requirements, the FDA may assess a civil monetary penalty, issue a warning letter or deem the drug or biologic misbranded. Once a drug or biologic is approved, the FDA must be notified of any modifications to the product and the FDA may also require a manufacturer to submit additional studies or conduct clinical trials. In addition, we are also required to report adverse events and comply with cGMPs, as well as advertising and promotion regulations. Failure to comply with the FFDCA may subject us to administrative and/or judicial sanctions, including warning letters, product recalls, seizures, delays in product approvals, injunctions, fines, civil penalties and/or criminal prosecution.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Biosimilar Regulation.</span><span style="font-family:Arial;font-size:9pt;"> The ACA created a framework for the approval of biosimilars (also known as follow-on biologics) following the expiration of 12 years of exclusivity for the innovator biologic, with a potential six-month pediatric extension. Under the ACA, biosimilar applications may not be submitted until four years after the approval of the reference innovator biologic. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The FDA is responsible for implementation of the legislation and approval of new biosimilars. Through FDA approvals and the issuance of draft and final guidance, the FDA has addressed a number of issues related to the biosimilars approval pathway, such as the labeling expectations for biosimilars. For example, in 2019, the FDA issued final guidance regarding the standards for demonstrating interchangeability with a U.S.-licensed reference product. In addition, in 2017, the Biosimilar User Fee Act was reauthorized for a five-year period, which led to a significant increase in the FDA&#8217;s biosimilar user fee revenues, thereby providing the FDA with additional resources to process biosimilar applications. For example, since the enactment of the newly authorized fee structure, the FDA estimates its revenues from biosimilar user fees generally will exceed $40 million.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Sales and Marketing Laws and Regulations</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">.</span><span style="font-family:Arial;font-size:9pt;"> The marketing practices of U.S. biopharmaceutical companies are generally subject to various federal and state healthcare laws that are intended, among other things, to prevent fraud and abuse in the healthcare industry and to protect the integrity of government healthcare programs. These laws include anti-kickback laws and false claims laws. Anti-kickback laws generally prohibit a biopharmaceutical company from soliciting, offering, receiving, or paying anything of value to generate business, including purchasing or prescribing of a particular product. False claims laws generally prohibit anyone from knowingly and willingly presenting, or causing to be presented, any claims for payment for goods (including drugs or biologics) or services to third-party payers (including Medicare and Medicaid) that are false or fraudulent and generally treat claims generated through kickbacks as false or fraudulent. Violations of fraud and abuse laws may be punishable by criminal or civil sanctions and/or exclusion from federal healthcare programs (including Medicare and Medicaid). The federal government </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">14</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">and various states also have enacted laws to regulate the sales and marketing practices of pharmaceutical companies. The laws and regulations generally limit financial interactions between manufacturers and healthcare providers, require disclosure to the federal or state government and the public of such interactions, and/or require the adoption of compliance standards or programs. Many of these laws and regulations contain ambiguous requirements or require administrative guidance for implementation. Individual states, acting through their attorneys general, have become active as well, seeking to regulate the marketing of prescription drugs under state consumer protection and false advertising laws. Given the lack of clarity in laws and their implementation, our activities could be subject to the penalties under the pertinent laws and regulations.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Pricing and Reimbursement</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">.</span><span style="font-family:Arial;font-size:9pt;"> Pricing and reimbursement for our pharmaceutical products depends in part on government regulation. Pfizer must offer discounted pricing or rebates on purchases of pharmaceutical products under various federal and state healthcare programs, such as the Medicaid Drug Rebate Program, the &#8220;federal ceiling price&#8221; drug pricing program, the 340B drug pricing program and the Medicare Part D Program. Pfizer must also report specific prices to government agencies under healthcare programs, such as the Medicaid Drug Rebate Program and Medicare Part B. The calculations necessary to determine the prices reported are complex and the failure to report prices accurately may expose Pfizer to penalties. See the discussion regarding rebates in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of the Consolidated Statements of Income</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Revenues</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Overview</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">section and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 1</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">G</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Revenues and Trade Accounts Receivable</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report, which are incorporated by reference.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Government and private third-party payers routinely seek to manage utilization and control the costs of our products. Efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including proposed action on drug importation, could adversely affect our business if implemented. There continues to be considerable public and government scrutiny of pharmaceutical pricing, and measures to address the perceived high cost of pharmaceuticals are being considered by Congress, the Presidential Administration and select states. For example, recent legislation revised how manufacturers calculate the average manufacturer price on branded drugs with authorized generics under the Medicaid drug rebate program, which the Congressional Budget Office has estimated will reduce Medicaid costs by over $3 billion over the next decade. Proposals for even more far-reaching reform, such as immediately eliminating or phasing out private health insurance, are being proposed by some Democratic candidates for U.S. President. In particular, several states have enacted or are considering transparency laws that require prescription drug manufacturers to report to the state and make public price increases, and sometimes to provide a written justification for the increase. In addition to new state transparency laws and the introduction of several Federal pricing bills, we have also seen the Presidential Administration introduce proposals related to importation and express interest in international reference pricing in Medicare Part B. We expect to see continued focus in regulating pricing resulting in additional legislation and regulation that could adversely impact revenue. In addition, U.S. government action to reduce federal spending on entitlement programs including Medicare and Medicaid may affect payment for our products or services associated with the provision of our products. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">U.S. Entitlement Reform</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K. Also, the majority of states use preferred drug lists to restrict access to certain pharmaceutical products under Medicaid. Restrictions exist for some Pfizer products under certain state Medicaid programs. As another example, access to our products under the Medicaid managed care program is typically determined by the health plans with which state Medicaid agencies contract to provide services to Medicaid beneficiaries. States continue to explore options for controlling healthcare costs related to Medicaid and other state healthcare programs, including the implementation of supplemental rebate agreements under the Medicaid drug rebate program that are tied to patient outcomes. In addition, we expect that consolidation and integration among pharmacy chains and wholesalers, who collectively are the primary purchasers of our pharmaceutical products in the U.S., and PBMs will increase pricing pressures on pharmaceutical manufacturers, including us. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Managed Care Trends</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The potential for additional pricing and access pressures in the commercial sector continues to be significant. Many employers have adopted high deductible health plans, which can increase out-of-pocket costs for medicines. This is a trend that is likely to continue. Private third-party payers, such as health plans, increasingly challenge pharmaceutical product pricing, which could result in lower prices, lower reimbursement rates and a reduction in demand for our products. Pricing pressures for our products may occur as a result of highly competitive insurance markets. Healthcare provider purchasers, directly or through group purchasing organizations, are seeking enhanced discounts or implementing more rigorous bidding or purchasing review processes.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Overall, there is increasing pressure on U.S. providers to deliver healthcare at a lower cost and to ensure that those expenditures deliver demonstrated value in terms of health outcomes. Longer term, we are seeing a shift in focus away from fee-for-service payments towards outcomes-based payments and risk-sharing arrangements that reward providers for cost reductions and improved patient outcomes. These new payment models can, at times, lead to lower prices for, and restricted access to, new medicines. At the same time, these models can also promote utilization of drugs by encouraging physicians to screen and diagnose and consider drugs as a means of forestalling more costly medical interventions.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We believe medicines are the most efficient and effective use of healthcare dollars based on the value they deliver to the overall healthcare system. We work with law makers and advocate for solutions that effectively improve patient health outcomes, lower costs to the healthcare system, and ensure access to medicines within an efficient and affordable healthcare system. In addition, in response to the evolving U.S. and global healthcare spending landscape, we work with health authorities, health technology assessment and quality measurement bodies and major U.S. payers throughout the product-development process to better </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">understand how these entities value our compounds and products. Further, we seek to develop stronger internal capabilities focused on demonstrating the value of the medicines that we discover or develop, register and manufacture, by recognizing patterns of usage of our medicines and competitor medicines along with patterns of healthcare costs</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Healthcare Reform.</span><span style="font-family:Arial;font-size:9pt;"> There have been significant efforts at the federal and state levels to reform the healthcare system by enhancing access to healthcare, improving the delivery of healthcare and further rationalizing payment for healthcare. We face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. There is additional uncertainty given the ruling in December 2019 by the U.S. Circuit Court of Appeals for the Fifth Circuit in </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Texas v. Azar </span><span style="font-family:Arial;font-size:9pt;">that the individual mandate, which is a significant provision of the ACA, is unconstitutional. The case has been remanded to a lower court to determine whether the individual mandate is inseparable from the entire ACA, in which case the ACA as a whole would be rendered unconstitutional. In the meantime, the remaining provisions of the law remain in effect. The revenues generated for Pfizer by the health insurance exchanges and Medicaid expansion under the ACA are not material, so the impact of full invalidation of the law is expected to be limited. However, any future replacement for the ACA may adversely affect our business and financial results, particularly if the legislation reduces incentives for employer-sponsored insurance coverage or dramatically increases industry taxes and fees. Any future healthcare reform efforts may adversely affect our business and financial results.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Anti-Corruption. </span><span style="font-family:Arial;font-size:9pt;">The FCPA prohibits U.S. corporations and their representatives from offering, promising, authorizing or making payments to any foreign government official, government staff member, political party or political candidate in an attempt to obtain or retain business abroad. The scope of the FCPA includes interactions with certain healthcare professionals in many countries. Other countries have enacted similar anti-corruption laws and/or regulations.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Data Privacy. </span><span style="font-family:Arial;font-size:9pt;">Pfizer collects personal data as part of its regular business activities. The collection and use of this data is subject to privacy and data security laws and regulations, including oversight by various regulatory or other governmental bodies. For example, we are subject to the California Consumer Privacy Act (CCPA). The CCPA, which came into effect on January 1, 2020, imposes numerous obligations on us, including a duty to disclose the categories of personal data that we collect, sell, or share about California consumers, and gives those consumers rights regarding their personal data. Noncompliance with any of these laws could result in the imposition of fines, penalties, or orders to stop non-compliant activities, and could damage our reputation and harm our business.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="color:#006ebf;font-family:Arial;font-size:9pt;font-style:italic;text-decoration:underline;">Outside the United States</span><span style="font-family:Arial;font-size:9pt;color:#006ebf;font-style:italic;text-decoration:underline;"> </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We encounter similar regulatory and legislative issues in most countries outside the U.S. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">New Drug Approvals.</span><span style="font-family:Arial;font-size:9pt;"> In the EU, the approval of new drugs may be achieved using the Mutual Recognition Procedure, the Decentralized Procedure or the EU Centralized Procedure. These procedures apply in the EU member states, plus the European Economic Area countries, Norway, Iceland and Liechtenstein. The Centralized Procedure, managed by the EMA, results in one single authorization for the whole EU, which provides the most rapid and efficient means of gaining approval across the EU and is the one most commonly used for new products.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In China, the regulatory system historically presented numerous challenges for the pharmaceutical industry, as its requirements for drug development and registration were often inconsistent with U.S. or other international standards. In recent years, however, China has introduced reforms and draft reforms, which are discussed in more detail below, that attempt to address these challenges. Furthermore, in 2017, the China regulatory authority, the National Medical Products Administration (NMPA), became a member of the International Council for Harmonization (ICH), which has resulted in greater adoption of international technical guidelines and practices by the government. 2019 was another active year in this respect, with a number of reforms coming into effect, and more proposals and drafts being issued for consultation.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In Japan, the PMDA is the point of entry for businesses looking to sell drugs in the country. The PMDA, which is involved in a wide range of regulatory activities, including clinical studies, approvals, postmarketing reviews and pharmaceuticals safety, must approve an application before a new drug product may be marketed in Japan. The PMDA also offers consultations on clinical trials of new drugs and provides advice on product classifications and approvals.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Health authorities in many middle and lower income countries require marketing approval by a recognized regulatory authority (i.e., similar to the authority of the FDA or the EMA) before they begin to conduct their application review process and/or issue their final approval. Many authorities also require local clinical data in the country&#8217;s population in order to receive final marketing approval. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Pharmacovigilance.</span><span style="font-family:Arial;font-size:9pt;color:#00497f;"> </span><span style="font-family:Arial;font-size:9pt;">In the EU, the EMA&#8217;s Pharmacovigilance Risk Assessment Committee has the responsibility for reviewing and making recommendations on product safety issues for the EU authorities. EU regulators may require pharmaceutical companies to conduct post-authorization safety and efficacy studies at the time of approval, or at any time afterwards in light of scientific developments. There are also additional extensive requirements regarding adverse drug reaction reporting and additional monitoring of products. Outside developed markets such as the EU and Japan, pharmacovigilance requirements vary and are generally not as extensive, but there is a trend toward increasing regulation.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">16</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Pricing and Reimbursement</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">. </span><span style="font-family:Arial;font-size:9pt;">Certain governments, including the different EU member states, the U.K., China, Japan, Canada, South Korea and some other international markets, provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power as large single payers to regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global financing pressures.</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;">Governments may use a variety of cost-containment measures for our pharmaceutical products, including price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, &#8220;international reference pricing&#8221; (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement.</span><span style="font-family:Arial;font-size:9pt;"> In addition, the international patchwork of price regulation and differing economic conditions and incomplete value assessments across countries has led to varying access to quality medicines in many markets and some third-party trade in our products between countries.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In particular, international reference pricing adds to the regional impact of price cuts in individual countries and hinders patient access and innovation. Price variations, exacerbated by international reference pricing systems, also have resulted from exchange rate fluctuations. The downward pricing pressure resulting from this dynamic can be expected to continue as a result of reforms to international reference pricing policies and measures targeting pharmaceuticals in some European countries.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition, several important multilateral organizations, such as the United Nations, including the World Health Organization (WHO), and the Organization for Economic Cooperation and Development, are increasing scrutiny of international pharmaceutical pricing through issuing reports and policy recommendations. In 2019, the WHO continued exerting pressure on pharmaceutical pricing practices by supporting strategies to reduce medicine prices, including calling for greater transparency around the cost of research and development and production of medicines, as well as disclosure of net prices.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In Japan, the pricing environment for innovative medicines further deteriorated in 2019 with the introduction of a health technology assessment (HTA) system to inform price adjustments of healthcare technologies after launch. Expansion of this system for reimbursement decisions, as seen in other HTA markets, remains a risk. While significant challenges remain, the 2020 Drug Pricing Reform Package, unlike the last reform package in 2018, is not expected to fundamentally change the access landscape. Furthermore, the eligibility criteria for the Price Maintenance Premium, a key policy that protects against price erosion for certain products, is expected to be somewhat enhanced while expedited regulatory pathways are codified in law. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In Canada, the Patented Medicine Prices Review Board (PMPRB) released draft guidelines to implement new pricing regulations in November 2019, which will go into force in July 2020. These regulations drop the U.S. from the reference basket of countries used to determine price and add economic factors for setting ceiling prices for new medicines. An initial analysis of the potential impact of these proposed changes to the PMPRB regulations estimated an approximately $26 billion reduction in industry revenues over the next decade.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">China Pricing Pressures</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">. </span><span style="font-family:Arial;font-size:9pt;">In China, healthcare is largely driven by a public payer system, with public medical insurance as the largest single payer for pharmaceuticals, and pricing pressures have increased in recent years. Government officials have consistently emphasized the importance of improved health outcomes, the need for healthcare reform and decreased drug prices as key indicators of progress towards reform. While the government provides basic health insurance for the vast majority of Chinese citizens, that insurance is not adequate to cover many innovative medicines, and alternative funding sources for innovative medicines remain suboptimal.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In 2019, China&#8217;s government negotiated with companies to add approximately 90 innovative drugs (mainly oncology medicines) to the National Reimbursement Drug List. This builds on 60 drugs already added through negotiation in 2017 and 2018. Prices for drugs have been reduced dramatically through this government-led process. While these negotiations have included a path to access for companies, market access is not assured. In addition, significant questions about the processes and negotiations for provincial tendering remain, as well as the need for multi-layered negotiations across provincial, municipal and hospital levels.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In the off-patent space, in 2013, China began to implement a quality consistency evaluation (QCE) process in order to improve the quality of domestically-manufactured generic drugs, primarily by requiring such drugs to pass a test to assess their bioequivalence to a qualified reference drug (typically the originator drug). In 2018, numerous local generics were officially deemed bioequivalent under QCE. A pilot project for centralized volume-based procurement (VBP) was then initiated including 25 molecules of drugs covering 11 major Chinese cities. Under this procurement model, a tender process has been established where a certain portion of included molecule volumes are guaranteed to tender winners. The program is intended to contain healthcare costs by driving utilization of generics that have passed QCE, which has resulted in dramatic price cuts for off-patent medicines.</span><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Upjohn and most off-patent originators were not successful in the first bidding process under this pilot, which was finalized in December 2018 and implemented in March 2019, and most contracts went to local generic companies. The first bidding process resulted in significant price cuts by the successful bidders, with some bidders reducing the price of their products by as much as 96 percent, as companies attempted to secure volumes on the Chinese pharmaceutical market. The drugs that lost the bidding were also requested to reduce their selling price up to 30 percent based on the price difference with the successful bidder. China&#8217;s government began nationwide expansion of the VBP pilot in December 2019. The expanded model, which is being implemented nationwide, applies to certain drugs that are purchased for public hospitals as well as some military and private medical institutions. As in the first bidding process, our Upjohn business unit and most originator brands were not successful in </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">the bidding process for this nationwide expansion, and those contracts mostly went to local Chinese generic companies. The QCE-qualified generic makers of atorvastatin and amlodipine bid aggressively, lowering prices even further from the March 2019 tender. Our Upjohn business unit continues to take steps to mitigate the revenue impact of these initiatives but anticipates that they will continue to affect our Upjohn business in China in the future. We expect to utilize our presence in the retail channel, private hospitals and tendering capabilities to mitigate some of these pricing pressures. In addition, we believe that our geographic expansion to under-penetrated and lower-tiered cities and counties and additional focus on non-tendered products will increase sales volumes in greater China and partially mitigate pressures from QCE.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In late 2019, China announced another round of expansion of the national VBP program, which covers 33 new molecules, including Biopharma&#8217;s Zithromax tablets and Diflucan tablets and no Upjohn products. Biopharma was not successful in the bidding process for this expansion.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Furthermore, the Chinese government has discussed moving toward efforts to unify the reimbursement price between QCE-approved generic medicines and the applicable original medicines. The government currently plans to implement this universal reimbursement price initiative within the next two to three years. If this policy is implemented, the new reimbursement level for Upjohn&#8217;s products will likely be lower than the current reimbursement level, placing additional pressures on price and/or patient copays. There remains uncertainty as to whether, when and how this policy may be officially implemented. The Chinese government could also enact other policies that may increase pricing pressures or have the effect of reducing the volume of sales available to Upjohn&#8217;s products. This potential policy, and any other policies like it that could increase pricing and copay pressures on Upjohn&#8217;s drug products in China, could have an adverse effect on our business, financial condition and results of operations. The government has indicated that additional post-LOE drugs could be subjected to QCE qualification in future rounds, which could also be tied to volume-based procurement. The scope of future QCE products and timing of any program expansion is currently unknown, making it difficult to determine the impact on Pfizer&#8217;s business and financial condition. We will continue to monitor the market for developments.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">EU Regulatory Changes</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">.</span><span style="font-family:Arial;font-size:9pt;"> The EU adopted a new Clinical Trials Regulation in May 2014, but its implementation has been delayed by the need for the EU authorities to establish new technical systems. This regulation is aimed at simplifying and harmonizing the administrative processes and governance of clinical trials in the EU and will require increased public posting of clinical trial results. It is currently not anticipated to be fully implemented until the first half of 2022 at the earliest.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Brexit</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;">In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as &#8220;Brexit&#8221;.</span><span style="font-family:Arial;font-size:9pt;"> The </span><span style="font-family:Arial;font-size:9pt;">U.K. left the EU on January 31, 2020 with status quo arrangements through a transition period scheduled to end on December 31, 2020.</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;">The consequences of the U.K. leaving the EU and the terms of the future trading relationship continue to be highly uncertain, which may pose certain implications to our research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products.</span><span style="font-family:Arial;font-size:9pt;"> However, both the U.K. and the EU have issued detailed guidance for the industry on how medicines, medical devices and clinical trials will be separately regulated in their respective territories. Pfizer has substantially completed its preparations for Brexit, having made the changes necessary to meet relevant regulatory requirements in the EU and the U.K., through the transition period and afterwards, especially in the regulatory, research, manufacturing and supply chain areas. Between 2018 and 2021, we expect to spend up to approximately $60 million in one-time costs to make these adaptations.</span><span style="font-family:Arial;font-size:9pt;"> For additional information on Brexit, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">The Global Economic Environment</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">section</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">China Regulatory Changes</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">.</span><span style="font-family:Arial;font-size:9pt;"> In an effort to encourage drug innovation and reduce backlogs for existing applications for drug approval, in recent years, the NMPA has unveiled numerous reform initiatives for China&#8217;s drug approval system and engaged in significant efforts to build its capabilities. The NMPA divides drugs into new drugs and generics, with the definition for new drugs changed from &#8220;China New&#8221; to &#8220;Global New.&#8221; This means that drugs previously approved in other markets (such as the U.S. or Europe) are not considered new drugs under China&#8217;s regulatory regime. This change in definition creates more opportunities for China&#8217;s domestic drug manufacturers than for multinational firms, because multinational firms have historically had significant competitive advantage in successfully achieving regulatory approvals for drugs first approved outside of China. Revisions in 2019 made clear, however, that regulatory approval from the FDA or the EMA would no longer be required for approval of imported drugs, though a notable exception persists for imported vaccines, which still require prior approval from a reference regulatory agency such as the FDA. In 2019, China published a revision to its Drug Administration Law and introduced a &#8220;marketing authorization holder&#8221; system, which grants the NMPA more authority over regulating manufacturers and provides manufacturers more flexibility in contract manufacturing arrangements and manufacturing site transfers.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">While challenges remain, a number of other policy changes are streamlining and accelerating approvals of domestic and imported drugs in China. These reforms, along with China&#8217;s June 2018 elevation to the ICH Management Committee, are expected to pave the way for integration of Chinese regulations with global practices. These changes include introducing more streamlined processes for maintaining renewal of product registrations, reduction in importing testing requirements, and establishing an expedited registration pathway for drugs to treat rare diseases and serious, life-threatening illnesses with no effective treatment. Though certain details on implementation are unclear (e.g., evolving list of qualified rare diseases and no guidance on what qualifies as serious, life threatening), the NMPA aims to build expedited pathways for certain categories of products similar to the U.S. and European regulatory systems. Additionally, the NMPA published changes to China&#8217;s registration requirements that align more with international practices, including a 60-day review timeline for clinical trial authorizations and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">18</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">guidance for acceptance of foreign clinical data and the utilization of real world data in drug development and regulatory decision making.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Although a number of regulatory changes better support China&#8217;s inclusion in simultaneous global drug development, unique regulatory requirements continue to pose challenges for multinational companies, including China&#8217;s Human Genetic Resources process for exporting clinical trial samples (which adds months to starting a clinical trial in China); mismatched China Pharmacopoeia and manufacturing data requirements that require standards exceeding acceptable practices in the U.S., EU, and Japan; and unpredictable and inconsistent clinical trial inspection practices.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Healthcare Provider Transparency and Disclosures.</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">A number of countries have implemented laws requiring (or their industry associations have recommended) disclosure of transfers of value made by pharmaceutical companies to healthcare providers. For example, the European Federation of Pharmaceutical Industries and Associations&#8217; disclosure code requires all members, including Pfizer, to disclose transfers of value to healthcare professionals and healthcare organizations. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="color:#00497f;font-family:Arial;font-size:9pt;font-style:italic;">Intellectual Property</span><span style="font-family:Arial;font-size:9pt;color:#00497f;">.</span><span style="font-family:Arial;font-size:9pt;"> The World Trade Organization Agreement on Trade Related Aspects of Intellectual Property Rights (WTO-TRIPS) required participant countries to amend their intellectual property laws to provide patent protection for pharmaceutical products by 2005, with an extension until 2033 for least-developed countries. While we still face patent grant, enforcement and other intellectual property challenges around the world, some countries have made improvements. We include stronger patent protection among the factors we consider for continued business expansion in other participant countries. </span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">While the global intellectual property environment has generally improved following WTO-TRIPS and bilateral/multilateral trade agreements, our future business growth depends on further progress in intellectual property protection. In emerging market countries in particular, governments have used intellectual property policies as a tool to force innovators to accept less than fair value for medicines, as well as to protect their local pharmaceutical industries. Considerable political and economic pressure exists to weaken current intellectual property protection and resist implementation of any further protection, which has led to policies such as more restrictive standards for obtaining patents and more difficult procedures for patenting biopharmaceutical inventions, restrictions on patenting certain types of inventions (e.g., new medical treatment methods), revocation of patents, laws or regulations that promote or provide broad discretion to issue a compulsory license, weak intellectual property enforcement and failure to implement effective regulatory data protection. Our industry advocacy efforts focus on seeking a more balanced business environment for foreign manufacturers, as well as on underscoring the importance of strong intellectual property systems for local innovative industries and helping improve patients&#8217; access to innovative medicines. In developed countries as well, including the EU, we are facing an increasingly challenging intellectual property environment.</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As part of the Canada/EU Comprehensive Economic &amp; Trade Agreement (CETA), Canada now provides </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">sui generis</span><span style="font-family:Arial;font-size:9pt;"> protection, commonly referred to as patent term restoration, for patent term extensions for basic patents; however, the extension is capped at two years, whereas the international norm is five years. In addition, the implementing regulations may create obstacles for patentees applying for patent term restoration via a Certificate of Supplementary Protection (CSP), and Canada&#8217;s proposed drug pricing reforms may negatively impact the benefit of a CSP. Furthermore, the United States-Mexico-Canada Agreement (USMCA) will, when implemented, require Canada and Mexico to make certain improvements to their current intellectual property regimes, including the establishment of patent term adjustment for unreasonable delays in the grant of patents.</span></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In China, the intellectual property environment has improved in recent years, although effective enforcement and adequate legal remedies remain areas of concern. The government has taken steps to protect intellectual property rights in conformity with World Trade Organization provisions, although China remained on the U.S. Trade Representative&#8217;s Priority Watch List for 2019 due to ongoing enforcement challenges and China&#8217;s failure to make certain structural reforms. Further, the standards for patentability in China remain more restrictive than in other major markets, including the U.S., Europe and Japan. Also, while a framework exists for protecting patents for 20 years, enforcement mechanisms are often lacking or inconsistent. For example, the absence of effective patent linkage mechanisms and preliminary injunctions, impractical evidentiary burdens, and heightened sufficiency standards have been used to invalidate patents at the enforcement stage. In 2019, the regulatory authority granted marketing approval to generic products while the reference product in each case are still subject to patent protection, and there is no effective legal means to resolve patent disputes prior to the marketing of those infringing drugs. The U.S. and China recently signed an initial agreement in which China has committed to address some patent-related concerns, and both governments have indicated that they will continue bilateral discussions on implementation of these commitments and other intellectual property issues in 2020.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In Brazil and other Latin American countries, the role of health regulatory authorities in reviewing patents (e.g., National Health Surveillance Agency in Brazil), restrictive patentability rules, ambiguity regarding the term of certain patents and backlogs at patent agencies may limit our ability to protect our products through patents. The lack of regulatory data protection and difficulties in protecting certain types of inventions, such as new medical uses of drug products, may limit the commercial lifespan of some pharmaceutical products. Additionally, an increased threat of issuance of compulsory licenses for biopharmaceutical products exists, which adds to business uncertainty.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In India, we have seen some progress in terms of expediting patent approval processes to reduce pendency rates and implementing training programs to enhance enforcement. Despite these positive steps, gaps remain in terms of addressing longstanding intellectual property concerns. For example, policies favoring compulsory licensing of patents, the tendency of the </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indian Patent Office to revoke pharmaceutical patents in opposition proceedings (both pre- and post-grant), and restrictive standards for patentability of pharmaceutical products have made it difficult to safeguard many of our inventions and our investments in innovation. These policies heighten the risk of additional patent challenges targeting innovative pharmaceutical products, especially in areas perceived as being important to the public health of the population. Challenges against Pfizer patents in India are ongoing.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-style:italic;">Data Privacy. </span><span style="font-family:Arial;font-size:9pt;">Outside of the U.S., many countries where we conduct business, including the EU, have privacy and data security laws and regulations concerning the collection and use of personal data, and we must comply with these laws and regulations as well. One applicable law is the EU&#8217;s General Data Protection Regulation (GDPR). The GDPR imposes detailed obligations on companies that collect, use, or otherwise process personal data and penalties for noncompliance may include fines of up to 4 percent of the company&#8217;s global annual revenue. Additionally, the legislative and regulatory framework for privacy and data protection issues worldwide is rapidly evolving as countries continue to adopt privacy and data security laws. Any inability to comply with applicable laws, regulations, policies, industry standards or other legal obligations regarding data protection or privacy could result in additional costs and liability to Pfizer as well as reputational harm and may adversely affect our business.</span></div><div><a id="s6FC770942FED549E9A3BEDDB7CE0170A"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">ENVIRONMENTAL MATTERS</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Most of our operations are affected by national, state and/or local environmental laws. We have made, and intend to continue to make, the expenditures necessary for compliance with applicable laws. We also are cleaning up environmental contamination from past industrial activity at certain sites. See the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 16</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">A3</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report. As a result, we incurred capital and operational expenditures in </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> for environmental compliance purposes and for the clean-up of certain past industrial activity as follows:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">environment-related capital expenditures&#8212; </span><span style="font-family:Arial;font-size:9pt;">$31 million</span><span style="font-family:Arial;font-size:9pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:42px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:24px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">other environment-related expenses&#8212; </span><span style="font-family:Arial;font-size:9pt;">$136 million</span><span style="font-family:Arial;font-size:9pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">While capital expenditures or operating costs for environmental compliance cannot be predicted with certainty, we do not currently anticipate they will have a material effect on our capital expenditures or competitive position.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Climate change presents risks to our operations, including the potential for additional regulatory requirements and associated costs, and the potential for more frequent and severe weather events and water availability challenges that may impact our facilities and those of our suppliers. For example, in 2017, our manufacturing and commercial operations in Puerto Rico were impacted by hurricanes as our three manufacturing sites in Puerto Rico sustained damage and became inoperable due to issues impacting Puerto Rico overall. All three sites resumed operations, and remediation activities were completed in 2018. We cannot provide assurance that physical risks to our facilities and supply chain due to climate change will not occur in the future; however, we have a program for reviewing our vulnerability to potential weather-related risks and other natural disasters and we update our assessments periodically. To date, we have concluded that, because of our facility locations, our existing distribution networks and our controls, we do not anticipate that these risks will have a material impact on Pfizer in the near term.</span></div><div><a id="s9F0B107560D05C65B113FCD92A000480"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">TAX MATTERS</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The discussion of tax-related matters in the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 5</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Tax Matters</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report is incorporated by reference.</span></div><div><a id="sC12D192ABFC15E599A3FF5A7C2797E6E"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">EMPLOYEES</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In our innovation-intensive business, our employees are vital to our success. We generally believe we have good relationships with our employees. As of December 31, </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;">, we employed approximately </span><span style="font-family:Arial;font-size:9pt;">88,300</span><span style="font-family:Arial;font-size:9pt;"> people in our operations throughout the world.</span></div><div><a id="sE3A373D11EBE5700B8D4083AE7C00167"></a></div><div style="line-height:120%;padding-top:16px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">DISCLOSURE PURSUANT TO SECTION 219 OF THE IRAN THREAT REDUCTION AND SYRIA HUMAN RIGHTS ACT OF 2012</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 (ITRSHRA) requires disclosure by public companies of certain transactions involving the Government of Iran, as well as entities and individuals designated under Executive Order 13382 and Executive Order 13224. </span></div><div style="line-height:120%;text-align:left;padding-left:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As a global biopharmaceutical company, we conduct business in multiple jurisdictions throughout the world. During </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;">, our activities included supplying medicine and medical products (Pfizer products) for patient and consumer use in Iran. We ship Pfizer products to Iran, and conduct related activities, in accordance with licenses issued by the U.S. Department of the Treasury&#8217;s Office of Foreign Assets Control and other U.S. and non-U.S. governmental entities, and in line with our corporate policies. We will continue our global activities to improve the health and well-being of patients and consumers in a manner consistent with applicable laws and our corporate policies. To our knowledge, none of our activities during </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> are required to be disclosed pursuant to ITRSHRA.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">20</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s22DE39E5F1A25F3ABB694A5B673BED2B"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;1A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">RISK FACTORS</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The statements in this Section describe the major risks to our business and should be considered carefully. In addition, these statements constitute our cautionary statements under the Private Securities Litigation Reform Act of 1995.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">Our disclosure and analysis in this </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Form 10-K and in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Annual Report to Shareholders contain forward-looking statements. From time to time, we also provide forward-looking statements in other materials we release to the public, as well as oral forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek&#8221; and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, plans for and prospects of our acquisitions and other business-development activities, benefits anticipated from the reorganization of our commercial operations in 2019, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, government regulation, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends. In particular, these include statements relating to future actions, including, among others, the expected timing, benefits, charges and/or costs in connection with our agreement to combine Upjohn with Mylan to create a new global pharmaceutical company, Viatris, set forth in the Item 1. Business&#8211;&#8211;About Pfizer and Item 1A. Risk Factors&#8211;&#8211;Pending Combination of Upjohn with Mylan sections in this </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Form 10-K and the Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business Development Initiatives and &#8211;&#8211;Our Strategy sections and the Notes to Consolidated Financial Statements&#8212;Note 1A. Basis of Presentation and Significant Accounting Policies&#8211;&#8211;Basis of Presentation in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the expected impact of patent expiries on our business set forth in the Item 1. Business&#8211;&#8211;Patents and Other Intellectual Property Rights section in this </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Form 10-K and in the Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Operating Environment&#8211;&#8211;Industry-Specific Challenges&#8211;&#8211;Intellectual Property Rights and Collaboration/Licensing Rights section in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the expected competition from certain generic manufacturers in China in the Item 1. Business&#8211;&#8211;Competition&#8211;&#8211;Generic Products and Item 1A. Risk Factors&#8211;&#8211;Generic Competition sections in this 2019 Form 10-K; the anticipated costs related to our preparations for Brexit set forth in the Item 1. Business&#8211;&#8211;Government Regulation and Price Constraints&#8211;&#8211;Outside the United States&#8211;&#8211;Brexit section in this </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Form 10-K and the Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment section in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the availability of raw materials for 2020 set forth in Item 1. Business&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Raw Materials</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> in this </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Form 10-K; the expected pricing pressures on our products in the U.S. and internationally and the anticipated impact to our business set forth in the Item 1. Business&#8211;&#8211;Government Regulation and Price Constraints and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;Pricing and Reimbursement sections in this </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Form 10-K; the anticipated impact of climate change on Pfizer set forth in Item 1. Business&#8211;&#8211;Environmental Matters in this </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Form 10-K; the expected demerger of the GSK Consumer Healthcare joint venture set forth in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;Consumer Healthcare Joint Venture with GSK section in this </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Form 10-K; the benefits expected from the reorganization of our commercial operations in 2019 and our expectations regarding growth set forth in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Our Strategy</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Organizing for Growth</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> section in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; our anticipated liquidity position set forth in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">The Global Economic Environment</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> and the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of Financial Condition, Liquidity and Capital Resources</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> sections in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the anticipated costs and savings from certain of our initiatives, including Transforming to a More Focused Company initiative, set forth in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;Transforming to a More Focused Company and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Costs and Expenses</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> sections and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> in our 2019 Financial Report; our plans for increasing investment in the U.S. set forth in the Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Strategy&#8211;&#8211;Capital Allocation and Expense Management&#8211;&#8211;Increasing Investment in the U.S. section in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the financial guidance set forth in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Our Financial Guidance for</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2020</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> section in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the expected impact of the Advisory Committee on Immunization Practices recommendation for Prevnar 13 for adults 65 and older on Prevnar 13&#8217;s revenues set forth in the Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8211;&#8211;Prevnar 13/Prevenar 13 (Biopharma) section in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the expected impact of updates to the prescribing information for Xeljanz on its growth set forth in the Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8211;&#8211;Xeljanz (Biopharma) section in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the benefits expected from our business development transactions; the planned capital spending set forth in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of Financial Condition, Liquidity and Capital Resources</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Selected Measures of Liquidity and Capital Resources</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Contractual Obligations</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> section in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report; the expected payments to our unfunded U.S. supplemental (non-qualified) pension plans, postretirement plans and deferred compensation plans and expected funding obligations set forth in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of Financial Condition, Liquidity and Capital Resources</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Selected Measures of Liquidity and Capital Resources</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Contractual Obligations</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> section; and the voluntary contribution we expect to make during 2020 for the U.S. qualified plans set forth in the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Pension and Postretirement Benefit Plans and Defined Contribution Plans</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> in our </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2019</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Financial Report.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize, or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. You should bear this in mind as you consider forward-looking statements, and you are cautioned not to put undue reliance on forward-looking statements.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects. Also note that we provide the following cautionary discussion of risks, uncertainties and possibly inaccurate assumptions relevant to our businesses. These are factors that, individually or in the aggregate, may cause our actual results to differ materially from expected, projected or historical results. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider the following to be a complete discussion of all potential risks or uncertainties.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:underline;">RISKS RELATED TO OUR BUSINESS, INDUSTRY AND OPERATIONS</span><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">MANAGED CARE TRENDS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Private third-party payers, such as health plans, and other managed care entities, such as PBMs, continue to take action to manage the utilization of drugs and control the cost of drugs. Consolidation among MCOs has increased the negotiating power of MCOs and other private third-party payers. Private third-party payers, as well as governments, increasingly employ formularies to control costs by taking into account discounts in connection with decisions about formulary inclusion or favorable formulary placement. Failure to obtain or maintain timely or adequate pricing or favorable formulary placement for our products, or failure to obtain such formulary placement at favorable pricing, could adversely impact revenue. Private third-party payers often implement formularies with copayment tiers to encourage utilization of certain drugs and have also been raising co-payments required from beneficiaries, particularly for branded pharmaceuticals and biotechnology products. Private third-party payers are also implementing new initiatives like so-called &#8220;copay accumulators&#8221; (policies that provide that the value of copay assistance does not count as out-of-pocket costs that are applied toward deductibles) that can shift more of the cost burden to manufacturers and patients. This cost shifting has increased consumer interest and input in medication choices, as they pay for a larger portion of their prescription costs and may cause consumers to favor lower cost generic alternatives to branded pharmaceuticals. Third-party payers also use additional measures such as new-to-market blocks, exclusion lists, indication-based pricing, and value-based pricing/contracting to improve their cost containment efforts, and are also increasingly imposing utilization management tools, such as clinical protocols, requiring prior authorization for a branded product if a generic product is available or requiring the patient to first fail on one or more generic products before permitting access to a branded medicine. As the U.S. private third-party payer market consolidates further and as more drugs become available in generic form, biopharmaceutical companies may face greater pricing pressure from private third-party payers, who will continue to drive more of their patients to use lower cost generic alternatives.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">GENERIC COMPETITION</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Competition from manufacturers of generic drugs is a major challenge for our branded products around the world, and the loss or expiration of intellectual property rights can have a significant adverse effect on our revenues. In addition, our patented products may face generic competition before patent exclusivity expires, including upon the &#8220;at-risk&#8221; launch (despite pending patent infringement litigation against the generic product) by a manufacturer of a generic version of one of our patented products. Generic competition could lead to our loss of a major portion of revenues for that product in a very short period of time. A number of our products have experienced significant generic competition over the last few years. For example, Lyrica (a product in our Upjohn business) lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019. Also, the basic product patent for Chantix in the U.S. will expire in November 2020. In China, we are expected to face further intensified competition by certain generic manufacturers, which may result in price cuts and volume loss of some of our products.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Also, generic manufacturers have filed applications with the FDA seeking approval of product candidates that such companies claim do not infringe our patents or that our patents are not valid; these include candidates that would compete with, among other products, Eliquis, Ibrance and Xeljanz. Our licensing and collaboration partners also face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. In addition, our patent-protected products may face competition in the form of generic versions of competitors&#8217; branded products that lose their market exclusivity.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">22</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">COMPETITIVE PRODUCTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We cannot predict with accuracy the timing or impact of the introduction of competitive products, including new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates. The introduction of competitive products can result in erosion of the sales of our existing products and potential sales of products in development, as well as unanticipated product obsolescence. Competitive product launches have occurred in recent years, and certain potentially competitive products are in various stages of development. Some of these have been filed for approval with the FDA and with regulatory authorities in other countries.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We also produce generic and biosimilar pharmaceutical products that compete with products from competitors, including other generic and biosimilar manufacturers. The ability to launch a generic or biosimilar pharmaceutical product at or before the anticipated formation of the generic or biosimilar marketplace is important to that product&#8217;s profitability. With increasing competition in the generic or biosimilar product markets, our success will depend on our ability to bring new products to market quickly. The FDA, along with other regulatory agencies around the world, has been experiencing a backlog of generic drug applications, which may result in delayed approvals of new generic products over the next few years. Also, we may face access challenges for our biosimilar products where our product may not receive appropriate coverage/reimbursement access or remains in a disadvantaged position relative to the innovator product. For example, Inflectra has experienced access challenges among commercial payers. In September 2017, Pfizer filed suit in the U.S. District Court for the Eastern District of Pennsylvania against Johnson &amp; Johnson (J&amp;J) alleging that J&amp;J&#8217;s exclusionary contracts and other anticompetitive practices concerning Remicade</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">&#174;</sup></span><span style="font-family:Arial;font-size:9pt;"> (infliximab) violate federal antitrust laws.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">DEPENDENCE ON KEY IN-LINE PRODUCTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We recorded direct product and/or alliance revenues of more than $1 billion for each of eight biopharmaceutical products in 2019: Prevnar 13/Prevenar 13, Ibrance, Eliquis, Lyrica, Xeljanz, Lipitor, Enbrel and Chantix/Champix. Those products accounted for </span><span style="font-family:Arial;font-size:9pt;">49%</span><span style="font-family:Arial;font-size:9pt;"> of our total revenues in </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;">. If these products or any of our other major products were to become subject to problems such as loss of patent protection (if applicable), changes in prescription growth rates, material product liability litigation, unexpected side effects, regulatory proceedings, publicity affecting doctor or patient confidence, pressure from existing competitive products, changes in labeling, pricing and access pressures, supply shortages or, if a new, more effective treatment should be introduced, the adverse impact on our revenues could be significant. A number of our products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and patents covering a number of our best-selling medicines are, or have been, the subject of pending legal challenges. For example, as a result of a patent litigation settlement, Teva Pharmaceuticals USA, Inc. launched a generic version of Viagra (a product in our Upjohn business) in the U.S. in December 2017. In addition, Lyrica (a product in our Upjohn business) lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019. Also, the basic product patent for Chantix in the U.S. will expire in November 2020. In addition, our revenues could be significantly impacted by the timing and rate of commercial acceptance of key new products. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business&#8211;&#8211;Patents and Other Intellectual Property Rights </span><span style="font-family:Arial;font-size:9pt;">section in this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K. Further, our Alliance revenues will be adversely affected by the termination or expiration of collaboration and co-promotion agreements that we have entered into and that we may enter into from time to time. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">RESEARCH AND DEVELOPMENT INVESTMENT</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The discovery and development of safe, effective new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our businesses. Our product lines must be replenished over time in order to offset revenue losses when products lose their market exclusivity, as well as to provide for earnings growth. Our growth potential depends in large part on our ability to identify and develop new products or new indications for existing products that address unmet medical needs and receive reimbursement from payers, either through internal R&amp;D or through collaborations, acquisitions, joint ventures or licensing or other arrangements with third parties. However, balancing current growth, investment for future growth and the delivery of shareholder return remains a major challenge. The average costs of product development continue to rise, as do the regulatory requirements in many therapeutic areas, which may affect the number of candidates funded as well as the sustainability of the R&amp;D portfolio. Our ongoing investments in new product introductions and in R&amp;D for new products and existing product extensions could exceed corresponding sales growth.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Additionally, our R&amp;D investment plans and resources may not be correctly matched between science and markets, and failure to invest in the right technology platforms, therapeutic segments, product classes, geographic markets and/or in-licensing and out-licensing opportunities could adversely impact the productivity of our pipeline. Further, even if the areas with the greatest market attractiveness are identified, the scientific approach may not succeed for any given program despite the significant investment required for R&amp;D, and the commercial potential of the product may not be as competitive as expected because of the highly dynamic market environment and the hurdles in terms of access and reimbursement.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We continue to strengthen our global R&amp;D organization and pursue strategies intended to improve innovation and overall productivity in R&amp;D to achieve a sustainable pipeline that is positioned to deliver value in the near-term and over time. These strategies may not deliver the desired result, which could affect growth and profitability in the future.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">BIOSIMILARS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Abbreviated legal pathways for the approval of biosimilars exist in many international markets and, since the passage of the ACA, a framework for such approval exists in the U.S. If competitors are able to obtain marketing approval for biosimilars referencing our biologic products, our biologic products may become subject to competition from these biosimilars, with attendant competitive pressure, and price reductions could follow. For example, Enbrel faces ongoing biosimilar competition in most European markets. The loss of patent rights, due to patent expiration or litigation, could trigger competition.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We are developing and commercializing biosimilar medicines. Risks related to our commercialization of biosimilars include the potential for steeper than anticipated price erosion due to increased competitive intensity, coupled with intellectual property challenges that may preclude timely commercialization of our potential biosimilar products. There is also a risk of lower uptake for biosimilars due to various factors that may vary for different biosimilars (e.g., anti-competitive practices, physician reluctance to prescribe biosimilars for existing patients taking the originator product, or misaligned financial incentives). See also the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Competitive Products </span><span style="font-family:Arial;font-size:9pt;">risk factor above.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">RESEARCH STUDIES</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Decisions about research studies made early in the development process of a drug or vaccine candidate can have a substantial impact on the marketing strategy and payer reimbursement possibilities if it receives regulatory approval. For example, a wider range of studies can lead to approval for a broader set of indications that may impact the marketing and payer reimbursement process. However, each additional indication and its reimbursement potential must be balanced against the time and resources required to demonstrate benefit, the increased complexity of development and manufacturing and the potential delays to approval of the lead indication. We try to plan clinical trials prudently and to reasonably anticipate and address challenges, but there is no guarantee that an optimal balance between trial conduct, speed and desired outcome will be achieved each time. The degree to which such potential challenges are foreseen and adequately addressed could affect our future results.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">INTERNATIONAL OPERATIONS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our international operations could be affected by currency fluctuations, capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, trade regulations and procedures and actions affecting approval, production, pricing, and marketing of, reimbursement for and access to our products, as well as by political unrest, unstable governments and legal systems and inter-governmental disputes. Any of these changes could adversely affect our business.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Many emerging markets have experienced growth rates in excess of developed markets, leading to an increased contribution to the industry&#8217;s global performance. As a result, we have been employing strategies to grow in emerging markets. However, our strategies in emerging markets may not be successful and these countries may not continue to sustain these growth rates. For example, even though China is growing faster than most emerging markets, we face certain challenges in China due to government imposed pricing controls affecting certain Pfizer medicines. In addition, some emerging market countries may be particularly vulnerable to periods of financial or political instability or significant currency fluctuations or may have limited resources for healthcare spending. Even though we constantly monitor the evolving emerging markets for any unanticipated risk to Pfizer, certain financial or political events in such markets can adversely affect our results.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">SPECIALTY PHARMACEUTICALS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Specialty pharmaceuticals are medicines that treat rare or life-threatening conditions that typically have smaller patient populations. The growing availability and use of innovative specialty pharmaceuticals, combined with their relative higher cost as compared to other types of pharmaceutical products, has generated payer interest in developing cost-containment strategies targeted to this sector. The impact of payers&#8217; efforts to control access to and pricing of specialty pharmaceuticals is increasing. A number of factors create a more challenging paradigm for Pfizer given our growing specialty business portfolio such as formulary restrictions and increasing use of utilization management tools such as step edits, which can lead to higher negotiated rebates or discounts to health plans and PBMs in the U.S., as well as the increasing use of health technology assessments and government pressures in markets around the world.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PRODUCT MANUFACTURING, SALES AND MARKETING RISKS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Difficulties or delays in product manufacturing, sales or marketing could affect future results through regulatory actions, shut-downs, work stoppages or strikes, approval delays, withdrawals, recalls, penalties, supply disruptions, shortages or stock-outs, reputational harm, product liability or unanticipated costs. Examples of such difficulties or delays include, but are not limited to, the inability to increase production capacity commensurate with demand; the failure to predict market demand for, or to gain market acceptance of, approved products; the possibility that the supply of component materials is delayed or unavailable and that the quality of such materials are substandard and not detected; the possibility that we may fail to maintain appropriate quality standards throughout our internal and external supply network and/or comply with cGMPs and other applicable regulations such as serialization (which allows for track and trace of products in the supply chain to enhance patient safety); </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">24</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">risks to supply chain continuity and commercial operations as a result of natural (including hurricanes, earthquakes and floods) or man-made disasters (including arson or terrorist attacks) at our facilities or at a supplier or vendor, including those that may be related to climate change; failure to maintain the integrity of our supply chains against economic adulteration, product diversion, product theft, counterfeit goods and cyberattacks. As an example, we have been experiencing production issues with Genotropin that will decrease revenue from that product.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Regulatory agencies periodically inspect our drug manufacturing facilities to evaluate compliance with cGMP or other applicable requirements. Failure to comply with these requirements may subject us to possible legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, recall of a product, delays or denials of product approvals, import bans or denials of import certifications, any of which could have a material adverse effect on our business, financial condition and results of operations. In February 2017, for example, we received a warning letter from the FDA communicating the FDA&#8217;s view that certain violations of cGMP regulations exist at Hospira&#8217;s manufacturing facility in McPherson, Kansas. We undertook corrective actions to address the concerns raised by the FDA. In January 2018, the FDA upgraded the status of Pfizer&#8217;s McPherson manufacturing facility to VAI based on an October 2017 inspection. The change to VAI status lifted the compliance hold that the FDA placed on approval of pending applications. In June 2018, the FDA informed us that it had completed an evaluation of corrective actions and closed out the February 2017 warning letter issued to our McPherson manufacturing facility after determining that we had addressed the violations contained in the warning letter. In July-August 2018, the FDA conducted a follow-up inspection of our McPherson facility and issued an inspection report noting several findings. Pfizer responded to the FDA&#8217;s findings, and is in the process of implementing a corrective and preventive action plan to address the FDA&#8217;s concerns. On the basis of the July-August 2018 FDA inspection, the FDA changed the inspection classification of the McPherson site to Official Action Indicated (OAI). Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections implemented at the site. Communication with the FDA on the status of the McPherson site is ongoing. As a result of the current OAI classification, the FDA may refuse to grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufactured at our McPherson site until the site status is upgraded, which upgrade would be based on a re-inspection by the FDA. We have been experiencing shortages of products from the legacy Hospira portfolio, among others, largely driven by capacity constraints, technical issues, supplier quality concerns or unanticipated increases in demand. We have made considerable progress in remediating issues at legacy Hospira facilities manufacturing sterile injectables and have substantially improved supply from most of these sites. Continuing product shortage interruption at these manufacturing facilities could negatively impact our financial results.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition, in September 2017, Meridian Medical Technologies, Inc., a subsidiary of Pfizer Inc., received a warning letter from the FDA asserting the FDA&#8217;s view that certain violations of cGMP and Quality System Regulations exist at Meridian&#8217;s manufacturing sites in St. Louis, Missouri and classifying the site as OAI. Meridian responded to the warning letter and committed to making improvements across the sites. We have made considerable progress addressing the concerns raised by the FDA, and communication with the FDA is ongoing. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections implemented at the site. As a result of the OAI classification, the FDA may refuse to grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufactured at our St. Louis sites.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="color:#00497f;font-family:Arial;font-size:9pt;font-weight:bold;">COLLABORATIONS AND OTHER RELATIONSHIPS WITH THIRD PARTIES</span><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;"> </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We depend on third-party collaborators, service providers, and others in the research, development, manufacturing and commercialization of our products and product candidates and also enter into joint ventures and other business development transactions in connection with our business. To achieve expected longer term benefits, we may make substantial upfront payments in such transactions, which may negatively impact our reported earnings. We rely heavily on these parties for multiple aspects of our drug development, manufacturing and commercialization activities, but we do not control many aspects of those activities. We also outsource certain services to other parties, including transaction processing, accounting, information technology, manufacturing, clinical trial recruitment and execution, clinical lab services, non-clinical research, safety services, integrated facilities management and other areas. Failure by one or more of these third parties to complete activities on schedule or in accordance with our expectations; failure by one or more of these parties to meet their contractual or other obligations to Pfizer; failure of one or more of these parties to comply with applicable laws or regulations; or any disruption in the relationships between Pfizer and one or more of these third parties, could delay or prevent the development, approval, manufacturing or commercialization of our products and product candidates, could expose us to suboptimal quality of service delivery or deliverables, could result in repercussions such as missed deadlines or other timeliness issues, erroneous data and supply disruptions, and could also result in non-compliance with legal or regulatory requirements or industry standards or reputational harm, all with potential negative implications for our product pipeline and business.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">BIOPHARMACEUTICAL WHOLESALERS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;">, our largest biopharmaceutical wholesaler accounted for approximately </span><span style="font-family:Arial;font-size:9pt;">16%</span><span style="font-family:Arial;font-size:9pt;"> of our total revenues (and approximately </span><span style="font-family:Arial;font-size:9pt;">32%</span><span style="font-family:Arial;font-size:9pt;"> of our total U.S. revenues), and our top three biopharmaceutical wholesalers accounted for approximately </span><span style="font-family:Arial;font-size:9pt;">37%</span><span style="font-family:Arial;font-size:9pt;"> of our total revenues (and approximately </span><span style="font-family:Arial;font-size:9pt;">79%</span><span style="font-family:Arial;font-size:9pt;"> of our total U.S. revenues). If one of our significant biopharmaceutical wholesalers should encounter financial or other difficulties, such wholesaler might decrease the amount of business that it does with us, and we might be unable to collect all the amounts that the wholesaler owes us on a timely basis or at all, which could negatively impact </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">our results of operations. In addition, we expect that consolidation and integration of pharmacy chains and wholesalers will increase competitive and pricing pressures on pharmaceutical manufacturers, including us.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">BUSINESS DEVELOPMENT ACTIVITIES</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We expect to continue to enhance our in-line products and product pipeline through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, divestments, mergers and acquisitions. However, these enhancement plans are subject to the availability and cost of appropriate opportunities, competition from other pharmaceutical companies that are seeking similar opportunities and our ability to successfully identify, structure and execute transactions, including the ability to satisfy the conditions to closing of announced transactions in the anticipated timeframes or at all, and successfully integrate acquisitions. Pursuing these opportunities may require us to obtain additional equity or debt financing, and could result in increased leverage and/or a downgrade of our credit ratings. Where we acquire debt or equity securities as all or part of the consideration for business development activities, such as in connection with our contribution agreement entered into with Allogene Therapeutics, Inc., the value of those securities will fluctuate, and may depreciate in value. We may not control the company in which we acquire securities, such as in connection with a divestiture or collaborative arrangement, and as a result, we will have limited ability to determine its management, operational decisions and policies. Further, while we seek to mitigate risks and liabilities of such transactions through, among other things, due diligence, there may be risks and liabilities that such due diligence efforts fail to discover, that are not disclosed to us, or that we inadequately assess. Legal proceedings or regulatory issues often arise as a result of activities that occurred at acquired companies, their partners and other third parties. In 2016, for example, we paid $784.6 million to resolve allegations related to Wyeth&#8217;s reporting of prices to the government with respect to Protonix for activities that occurred prior to our acquisition of Wyeth. For these and other reasons, we may not realize the anticipated benefits of such transactions, and expected synergies and accretion may not be realized within the expected timeframes, or at all. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">COUNTERFEIT PRODUCTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">A counterfeit medicine is one that has been deliberately and fraudulently mislabeled as to its identity and source. A counterfeit Pfizer medicine, therefore, is one manufactured by someone other than Pfizer, but which appears to be the same as an authentic Pfizer medicine. The prevalence of counterfeit medicines is a significant and growing industry-wide issue due to a variety of factors, including, but not limited to, the following: the widespread use of the Internet, which has greatly facilitated the ease by which counterfeit medicines can be advertised, purchased and delivered to individual patients; the availability of sophisticated technology that makes it easier for counterfeiters to make counterfeit medicines; the growing involvement in the medicine supply chain of under-regulated wholesalers and repackagers; the lack of adequate inspection at certain international postal facilities as counterfeit medicines are increasingly delivered direct to customers in small parcel packages; the tendency to misuse and abuse medicines; and the relatively modest risk of penalties faced by counterfeiters compared to the large profits that can be earned by them from the sale of counterfeit medicines. Further, laws against pharmaceutical counterfeiting vary greatly from country to country, and the enforcement of existing law varies greatly from jurisdiction to jurisdiction. For example, in some countries, pharmaceutical counterfeiting is not a crime; in others, it may result in only minimal sanctions. In addition, those involved in the distribution of counterfeit medicines use complex transport routes in order to evade customs controls by disguising the true source of their products.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer&#8217;s global reputation makes its medicines prime targets for counterfeiting organizations. Counterfeit medicines continue to pose a significant risk to patient health and safety because of the conditions under which they are manufactured&#8212;often in unregulated, unlicensed, uninspected and unsanitary sites&#8212;as well as the lack of regulation of their contents. Counterfeiters have been recently evolving to counterfeit life sustaining medications such as oncology medicines. This shift significantly increases the risk to patients who, for instance, unsuspectingly purchase counterfeit oncology medications from illicit online &#8220;pharmacies&#8221; operated by criminal counterfeiting organizations. Failure to mitigate this new threat posed by counterfeit biopharma medicines could adversely impact our business, by, among other things, causing the loss of patient confidence in the Pfizer name and in the integrity of our medicines, potentially resulting in lost sales, product recalls, and an increased threat of litigation.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We have an enterprise-wide strategy to counteract the threats associated with counterfeit medicines, and focused on educating patients and health care providers to reduce demand through awareness; increasing engagement and education of global law enforcement, customs and regulatory agencies about the growing prevalence of counterfeit life sustaining medicines; enhancing online identification and disruption efforts in partnership with pharmaceutical associations to optimize resources and impact; educating legislators about the risk to the security of the international drug supply chain by illicit manufacturing and distribution networks operated by transnational criminal organizations; supporting efforts by law enforcement authorities to prosecute counterfeiters; assessing new and existing technologies to seek to make it more difficult for counterfeiters to copy our products and easier for patients and healthcare providers to distinguish authentic from counterfeit medicines; and using data analytics and risk assessment tools to better target the factors that give rise to the counterfeiting problem in the first place. However, our efforts and the efforts of others may not be entirely successful, and the presence of counterfeit medicines may continue to increase.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">26</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:underline;">RISKS RELATED TO GOVERNMENT REGULATION AND LEGAL PROCEEDINGS</span><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PRICING AND REIMBURSEMENT</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">U.S. and international governmental regulations that mandate price controls and limitations on patient access to our products or establish prices paid by government entities or programs for our products impact our business, and our future results could be adversely affected by changes in such regulations or policies. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In the U.S., many of our products are subject to increasing pricing pressures. Pharmaceutical product pricing is subject to enhanced government and public scrutiny and calls for reform. Some states have implemented, and other states are considering, pharmaceutical price controls or patient access constraints under the Medicaid program, and some states are considering price-control regimes that would apply to broader segments of their populations that are not Medicaid-eligible. There have also been recent state legislative efforts to address drug costs, which generally have focused on increasing transparency around drug costs or limiting drug prices. Efforts by government officials or legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation, could adversely affect our business if implemented. See the discussion regarding pricing and reimbursement in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="color:#000000;font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">In the United States</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Pricing and Reimbursement </span><span style="font-family:Arial;font-size:9pt;">section</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We encounter similar regulatory and legislative issues in most other countries. In certain international markets, such as the different EU member states, the U.K., China, Japan, Canada and South Korea, governments have significant power as large single payers to regulate prices, access criteria (e.g., through public or private health technology assessments), or other means of cost control, particularly under recent global financing pressures. As a result, we expect that pressures on the pricing component of operating results will continue. For example, China, in 2013, began to implement a QCE process, under which numerous local generics have officially been deemed bioequivalents of a qualified reference drug. China&#8217;s government subsequently initiated a pilot project for centralized VBP in 2018, which included 25 molecules of drugs and covered 11 major Chinese cities. Under this procurement model, a tender process was established whereby a certain portion of included molecule volumes were guaranteed to tender winners. This tender process was intended to contain healthcare costs by driving utilization of generics and bioequivalents that had passed QCE, and has resulted in dramatic price cuts for off-patent medicines. China&#8217;s government began nationwide expansion of the VBP pilot in December 2019. See the discussion regarding these government initiatives in China in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Outside the United States</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">China Pricing Pressures</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K. We anticipate that these initiatives will continue to increase pricing pressures on our drug products in China in the future.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The adoption of restrictive price controls in new jurisdictions or more restrictive ones in existing jurisdictions or the failure to obtain or maintain timely or adequate pricing could also adversely impact revenue. In our vaccines business, we participate in a tender process in many countries for participation in national immunization programs. Failure to secure participation in national immunization programs or to obtain acceptable pricing in the tender process could adversely affect our business. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">U.S. HEALTHCARE REFORM</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The U.S. healthcare industry is highly regulated and subject to frequent and substantial changes. For example, the ACA was enacted by Congress in March 2010 and established a major expansion of healthcare coverage, financed in part by a number of new rebates, discounts, and taxes that had a significant effect on our expenses and profitability. See the discussion in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1. Business</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Government Regulation and Price Constraints</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="color:#000000;font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">In the United States</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K. We face uncertainties due to federal legislative and administrative efforts to repeal, substantially modify or invalidate some or all of the provisions of the ACA. There is additional uncertainty given the ruling in December 2019 by the U.S. Circuit Court of Appeals for the Fifth Circuit in </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Texas v. Azar</span><span style="font-family:Arial;font-size:9pt;"> that the individual mandate, which is a significant provision of the ACA, is unconstitutional. The case has been remanded to a lower court to determine whether the individual mandate is inseparable from the entire ACA, in which case the ACA as a whole would be rendered unconstitutional. In the meantime, the remaining provisions of the law remain in effect. The revenues generated for Pfizer by the health insurance exchanges and Medicaid expansion under the ACA are not material, so the impact of full invalidation of the law is expected to be limited. However, any future replacement of the ACA may adversely affect our business and financial results, particularly if the legislation reduces incentives for employer-sponsored insurance coverage or dramatically increases industry taxes and fees. Any future healthcare reform efforts may adversely affect our business and financial results.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Other U.S. federal or state legislative or regulatory action and/or policy efforts could adversely affect our business, including, among others, general budget control actions, changes in patent laws, the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries (which is among the U.S. Presidential Administration&#8217;s policy proposals), revisions to reimbursement of biopharmaceuticals under government programs (such as the implementation of international reference pricing for Medicare Part B drugs, or changes to protected class criteria for Part D drugs), restrictions on U.S. direct-to-consumer advertising, limitations on interactions with healthcare professionals, or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">U.S. ENTITLEMENT REFORM</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In the U.S., government action to reduce federal spending on entitlement programs including Medicare and Medicaid may affect payment for our products or services provided using our products. The Congressional Budget Office routinely releases options for reducing federal spending, and the December 2018 release includes proposals to cap federal Medicaid payments to the states, and to require manufacturers to pay a minimum rebate on drugs covered under Medicare Part D for low-income beneficiaries. Significant Medicare reductions could also result if, for example, Congress proceeds with certain proposals to convert the Medicare fee-for-service program into a premium support program, or Congress chooses to implement the recommendations made annually by the Medicare Payment Advisory Commission, which are primarily intended to extend the fiscal solvency of the Medicare program. These and any other significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs that may be implemented could have an adverse impact on our results of operations.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">SUBSTANTIAL REGULATION</span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We are subject to extensive, complex, costly and evolving regulation by federal and state governmental authorities in the U.S., principally by the FDA and the DEA, and foreign regulatory authorities. Failure to comply with all applicable regulatory requirements may subject us to operating restrictions and criminal prosecution, monetary penalties and other disciplinary actions, including, sanctions, warning letters, product seizures, recalls, fines, injunctions, suspension, revocation of approvals, corporate integrity or deferred prosecution agreements or exclusion from future participation in government healthcare programs, as well as reputational harm.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">DEVELOPMENT, REGULATORY APPROVAL AND MARKETING OF PRODUCTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Innovation is critical to the success of our Company, and drug discovery and development are time-consuming, expensive and unpredictable.</span><span style="font-family:Arial;font-size:9pt;"> The outcome of the lengthy and complex process of identifying new compounds and developing new products is inherently uncertain and involves a high degree of risk and cost. The process from early discovery to design and adequate implementation of clinical trials to regulatory approval can take many years. Drug candidates can and do fail at any stage of the process, including as the result of unfavorable pre-clinical and clinical trial results, or unfavorable new clinical data and further analyses of existing clinical data, including results that may not support further clinical development of the applicable product candidate or indication. We may not be able to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates. Similarly, we may not be able to successfully address all of the comments received from regulatory authorities such as the FDA and the EMA, or obtain approval from regulators. Regulatory approval of drug or biologic products depends on myriad factors, including a regulator making a determination as to whether a product&#8217;s benefits outweigh its known risks and a determination of the product&#8217;s efficacy. Additionally, clinical trial data are subject to differing interpretations and assessments by regulatory authorities. Even after a drug or biologic is approved, it could be adversely affected by regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters. We may not be able to receive or maintain favorable recommendations by technical or advisory committees, such as the Advisory Committee on Immunization Practices that may impact the use of our vaccines. Further, claims and concerns that may arise regarding the safety and efficacy of in-line products and product candidates can result in a negative impact on product sales, product recalls or withdrawals, and/or consumer fraud, product liability and other litigation and claims. Increasing regulatory scrutiny of drug safety and efficacy, with regulatory authorities increasingly focused on product safety and the risk/benefit profile of products as they relate to already-approved products, has resulted in a more challenging, expensive and lengthy regulatory approval process due to requests for, among other things, additional or more extensive clinical trials prior to granting approval or increased post-approval requirements. For these and other reasons discussed in </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1A. Risk Factors</span><span style="font-family:Arial;font-size:9pt;">, we may not obtain the approvals we expect within the timeframe we anticipate, or at all. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">POST-APPROVAL DATA</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these Phase 4 trials could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of a product. Regulatory agencies in countries outside the U.S. often have similar authority and may impose comparable requirements. For example, in July and December 2019, the FDA updated the U.S. prescribing information for Xeljanz to include three additional boxed warnings as well as changes to the indication and dosing for ulcerative colitis. In January 2020, the EMA revised the summary of product characteristics (SmPC) for Xeljanz to include new warnings and recommendations for use of Xeljanz due to an increased risk of venous thromboembolism and, due to an increased risk of infections, revised warnings in patients older than 65 years of age. These updates were based on the FDA&#8217;s and EMA&#8217;s review of data from the ongoing post-marketing requirement rheumatoid arthritis study A3921133. Postmarketing studies, whether conducted by us or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect the availability or commercial potential of our products. Further, the discovery of significant problems with a product similar to one of our products could implicate the entire class of products; and this, in turn, could have an adverse effect on the availability or commercial viability of our product(s) as well as other products in the class. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">28</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">INTERACTIONS WITH HEALTHCARE PROFESSIONALS AND GOVERNMENT OFFICIALS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Risks and uncertainties apply if we provide, offer, or promise something of value to a healthcare professional, other healthcare provider and/or government official. Requirements or industry standards in the U.S. and certain jurisdictions abroad that require pharmaceutical manufacturers to track and disclose financial interactions with healthcare professionals and healthcare providers increase government and public scrutiny of such financial interactions. If an interaction is found to be improper, government enforcement actions and penalties could result. These risks may increase as both U.S. and foreign enforcement agencies adopt or increase enforcement efforts in respect of existing and new laws and regulations governing product promotion, marketing, anti-bribery and kickbacks, industry regulations, and codes of conduct. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">CHANGES IN LAWS AND ACCOUNTING STANDARDS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our future results could be adversely affected by changes in interpretations of existing laws and regulations, or changes in laws and regulations, including, among others, changes in accounting standards, taxation requirements (including tax rate changes, new tax laws, changes to existing tax laws and revised tax law and regulatory clarifications and/or interpretations, including changes affecting the taxation by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals, including further clarifications and/or interpretations of or changes to the U.S. Tax Cuts and Jobs Act of 2017), competition laws, privacy laws and environmental laws in the U.S. and other countries. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Provision/(Benefit) for Taxes on Income</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;text-decoration:none;">Changes in Tax Laws</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">New Accounting Standards</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">sections, and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 1</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">B.</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Adoption of New Accounting Standards in 2019</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">LEGAL PROCEEDINGS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We and certain of our subsidiaries are involved in various legal proceedings, including patent litigation, such as claims that our patents are invalid and/or do not cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment, tax litigation and other legal proceedings, including various means for resolving asbestos litigation, that arise from time to time in the ordinary course of our business. Litigation is inherently unpredictable, and excessive verdicts do occur. Although we believe that our claims and defenses in matters in which we are a defendant are substantial, we could in the future incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Claims against our patents include challenges to the coverage and/or validity of our patents on various products or processes. Although we believe we have substantial defenses to these challenges with respect to all of our material patents, there can be no assurance as to the outcome of these matters, and a loss in any of these cases could result in a loss of patent protection for the product at issue, which could lead to a significant loss of sales of that product and could materially affect future results of operations.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.</span><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our activities relating to the sale and marketing and the pricing of our products are subject to extensive regulation under the FFDCA, the Medicaid Drug Rebate Program, the FCPA and other federal and state statutes, including those discussed elsewhere in this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K, as well as anti-kickback and false claims laws, and similar laws in international jurisdictions. Like many companies in our industry, we have from time to time received inquiries and subpoenas and other types of information demands from government authorities, and been subject to claims and other actions related to our business activities brought by governmental authorities, as well as by consumers and private payers. In some instances, we have incurred significant expense, civil payments, fines and other adverse consequences as a result of these claims, actions and inquiries. For example, these claims, actions and inquiries may relate to alleged failures to accurately interpret or identify or prevent non-compliance with the laws and regulations associated with the dissemination of product information (approved and unapproved), potentially resulting in government enforcement and damage to our reputation. This risk may be heightened by digital marketing, including social media, mobile applications and blogger outreach.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In connection with the resolution of a U.S. government investigation concerning independent copay assistance organizations that provide financial assistance to Medicare patients, in May 2018, we entered into a Corporate Integrity Agreement (CIA) with the Office of the Inspector General of the U.S. Department of Health and Human Services, which is effective for a period of five </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">years. In the CIA, we agreed to implement and/or maintain certain compliance program elements to promote compliance with federal healthcare program requirements. Breaches of the CIA could result in severe sanctions against us.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For additional information, including information regarding certain legal proceedings in which we are involved in, see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 16</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">A</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Legal Proceedings</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">ENVIRONMENTAL CLAIMS AND PROCEEDINGS</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business relating to environmental claims and proceedings. </span><span style="font-family:Arial;font-size:9pt;">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span><span style="font-family:Arial;font-size:9pt;"> While we have accrued for worldwide environmental liabilities, there is no guarantee that additional costs will not be incurred beyond the amounts accrued. If we fail to properly manage the safety of our facilities and the environmental risks associated therewith or if we are required to increase our accruals for contingencies for environmental claims and proceedings in the future, it could potentially have an adverse effect on our results of operations.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:underline;">RISKS RELATED TO INTELLECTUAL PROPERTY</span><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PATENT PROTECTION</span></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our long-term success largely depends on our ability to market technologically competitive products. We rely and expect to continue to rely on a combination of intellectual property, including patent, trademark, trade dress, copyright, trade secret and domain name protection laws, as well as confidentiality and license agreements, to protect our intellectual property and proprietary rights. If we fail to obtain and maintain adequate intellectual property protection, we may not be able to prevent third parties from launching generic or biosimilar versions of our branded products, using our proprietary technologies or from marketing products that are very similar or identical to ours. Our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis. Similarly, any term extensions that we seek may not be granted on a timely basis, if at all. In addition, our issued patents may not contain claims sufficiently broad to protect us against third parties with similar technologies or products or provide us with any competitive advantage, including exclusivity in a particular product area. The scope of our patent claims also may vary between countries, as individual countries have distinct patent laws. We may be subject to challenges by third parties regarding our intellectual property, including, among others, claims regarding validity, enforceability, scope and effective term. </span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our ability to enforce our patents also depends on the laws of individual countries and each country&#8217;s practice with respect to enforcement of intellectual property rights, and the extent to which certain sovereigns may seek to engage in policies or practices that may weaken its intellectual property framework (e.g., laws or regulations that promote or provide broad discretion to issue a compulsory license). In countries that provide some form of regulatory exclusivity, mechanisms exist permitting some form of challenge to our patents by competitors or generic drug marketers prior to or immediately following the expiration of such regulatory exclusivity, and generic companies are increasingly employing aggressive strategies, such as &#8220;at risk&#8221; launches that challenge our patent rights. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Independent actions have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. Such claims may also be brought as counterclaims to actions we bring to enforce our patents. We are also party to other patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for alleged delay of generic entry. We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others. Also, if one of our patents is found to be invalid in such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to </span><span style="font-family:Arial;font-size:9pt;">two</span><span style="font-family:Arial;font-size:9pt;"> patents. In June 2018, the PTAB ruled on another patent, holding that one claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision. In November 2019, the Federal Circuit vacated the PTAB&#8217;s ruling and requested that the PTAB redecide the challenge. In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We have appealed. Challenges to other patents remain pending in jurisdictions outside the U.S. The invalidation of all of these patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. Further, if we are unable to maintain our existing license agreements or other agreements pursuant to which third parties grant us rights to intellectual property, including because such agreements expire or are terminated, our operating results and financial condition could be materially adversely affected. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Likewise, in the U.S. and other countries, we currently hold issued trademark registrations and have trademark applications pending, any of which may be the subject of a governmental or third-party objection, which could prevent the maintenance or issuance of the trademark. As our products mature, our reliance on our trademarks and trade dress to differentiate us from our competitors increases and as a result, if we are unable to prevent third parties from adopting, registering or using trademarks </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">30</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">and trade dress that infringe, dilute or otherwise violate our trademark rights, our business could be materially adversely affected. We actively seek to protect our proprietary information, including our trade secrets and proprietary know-how, by requiring our employees, consultants, other advisors and other third parties to execute proprietary information and confidentiality agreements upon the commencement of their employment, engagement or other relationship. Despite these efforts and precautions, we may be unable to prevent a third party from copying or otherwise obtaining and using our trade secrets or our other intellectual property without authorization, and legal remedies in some countries may not adequately compensate us for the damages caused by such unauthorized use. Further, others may independently and lawfully develop substantially similar or identical products that circumvent our intellectual property by means of alternative designs or processes or otherwise.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">THIRD PARTY INTELLECTUAL PROPERTY CLAIMS</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">A properly functioning intellectual property regime is essential to our business model. We are committed to respecting the valid intellectual property rights of other companies, but the patent granting process is imperfect. Accordingly, </span><span style="font-family:Arial;font-size:9pt;">the pursuit of valid business opportunities may require us to challenge intellectual property rights held by other companies that we believe were improperly granted. Such challenges may include negotiation and litigation, which may not always be successful.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Part of our business depends upon successfully identifying generic pharmaceutical product and biosimilar opportunities and launching products to take advantage of those opportunities, which may involve litigation, associated costs and time delays, and may ultimately not be successful. These opportunities may arise in situations where patent protection of equivalent branded products has expired, where patents have been declared invalid, or where products do not infringe the patents of others, and in some circumstances we may take action, such as litigation, asserting that our products do not infringe patents of existing products or that those patents are invalid or unenforceable in order to achieve a &#8220;first-to-market&#8221; or early market position for our products.</span></div><div style="line-height:120%;text-align:left;text-indent:30px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Third parties may claim that our products infringe one or more patents owned or controlled by the third party. Claims of intellectual property infringement can be costly and time-consuming to resolve, may delay or prevent product launches, and may result in significant damages. We are involved in patent-related disputes with third parties over our attempts to market generic pharmaceutical products and biosimilars. Once we have final regulatory approval of the related generic pharmaceuticals products or biosimilars, we may decide to commercially market these products even though associated legal proceedings (including any appeals) have not been resolved (i.e., &#8220;at-risk&#8221; launch). </span><span style="font-family:Arial;font-size:9pt;">If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.</span><span style="font-family:Arial;font-size:9pt;"> Any of these adverse consequences could have a material adverse effect on our profitability and financial condition.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:underline;">RISK RELATED TO TECHNOLOGY</span><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">INFORMATION TECHNOLOGY AND SECURITY </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Significant disruptions of information technology systems or breaches of information security could adversely affect our businesses. We rely to a large extent upon sophisticated information technology systems to operate our businesses. In the ordinary course of business, we collect, store and transmit large amounts of confidential information (including, but not limited to, personal information and intellectual property), and we deploy and operate an array of technical and procedural controls to maintain the confidentiality and integrity of such confidential information. We also have outsourced significant elements of our operations to third parties, including significant elements of our information technology infrastructure and, as a result, we are managing many independent vendor relationships with third parties who may or could have access to our confidential information. The size and complexity of our information technology and information security systems, and those of our third-party vendors with whom we contract (and the large amounts of confidential information that is present on them), make such systems potentially vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees or vendors, or from attacks by malicious third parties. Such attacks are of ever-increasing levels of sophistication and are made by groups and individuals with a wide range of motives (including, but not limited to, industrial espionage) and expertise, including organized criminal groups, &#8220;hacktivists,&#8221; nation states and others. As a global pharmaceutical company, our systems are subject to frequent attacks. Due to the nature of some of these attacks, there is a risk that they may remain undetected for a period of time. While we have invested in the protection of data and information technology, our efforts may not prevent service interruptions or security breaches. Any such interruption or breach of our systems could adversely affect our business operations and/or result in the loss of critical or sensitive confidential information or intellectual property, and could result in financial, legal, business and reputational harm to us. We maintain cyber liability insurance; however, this insurance may not be sufficient to cover the financial, legal, business or reputational losses that may result from an interruption or breach of our systems.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:underline;">RISKS RELATED TO OUR STRATEGIC TRANSACTIONS</span><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">STRATEGIC ACQUISITIONS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The success of any of our strategic acquisitions will depend, in large part, on our ability to realize anticipated benefits from combining these businesses with Pfizer. We, for example, may fail to achieve cost savings anticipated with certain of these acquisitions, or such cost savings within the expected time frame. Similarly, the accretive impact anticipated from certain of these acquisitions may not be realized or may be delayed. Integration of these businesses may result in the loss of key employees, the disruption of ongoing business, including third-party relationships, or inconsistencies in standards, controls, procedures and policies. We also may fail to generate the revenue growth for the acquired business that we expected at the time of entering into the transaction. Expected revenue from acquired products and product candidates also may be constrained by developments outside of our control. Unsuccessful clinical trials, regulatory hurdles and commercialization challenges may adversely impact revenue and income contribution from products and product candidates, including those acquired in these acquisitions. Hospira, for example, has experienced manufacturing disruptions and substantial regulatory scrutiny due to quality issues. Manufacturing problems, as well as any corrective actions and their operational implementation, could adversely impact the revenue we generate from products acquired from Hospira and result in substantial unanticipated costs. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Our Business Development Initiatives</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">section in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PENDING COMBINATION OF UPJOHN WITH MYLAN</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;font-style:italic;font-weight:bold;">Pfizer, Mylan and Upjohn may be unable to satisfy the conditions or obtain the approvals required to complete the combination of Upjohn with Mylan (the Combination), and regulatory agencies may delay or impose conditions on approval of the Combination, which may diminish the anticipated benefits of the Combination. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;">The consummation of the Combination is subject to numerous conditions, including the receipt by Pfizer of an Internal Revenue Service ruling and an opinion of its tax counsel to the effect that, among other things, certain transactions related to the Combination and certain related transactions will constitute a tax-free &#8220;reorganization&#8221; within the meaning of Section 368(a)(1)(D) of the Internal Revenue Code, the approval of the Combination by Mylan shareholders, and other customary conditions, certain of which are dependent upon the actions of third parties. As a result of such conditions, Pfizer cannot make any assurances that the Combination will be consummated on the terms or timeline currently contemplated, or at all.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;">Completion of the Combination is also conditioned upon the receipt of certain required government consents and approvals, including certain approvals required from regulatory agencies. While Pfizer, Mylan and Upjohn intend to pursue vigorously all required governmental approvals, the requirement to receive these approvals prior to the consummation of the Combination could delay the completion of the Combination, possibly for a significant period of time. Any delay in the completion of the Combination could diminish the anticipated benefits of the Combination or result in additional transaction costs, loss of revenue or other effects associated with uncertainty about the Combination, including delaying Pfizer&#8217;s ability to capitalize on its strategy of becoming a more focused, innovative company as well as Upjohn&#8217;s ability to optimize the execution of its growth strategies.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;">Pfizer may be subject to shareholder lawsuit, or other actions filed in connection with or in opposition to the Combination or any related transactions. Such litigation could have an adverse effect on the business, financial condition and results of operations of Pfizer and could prevent or delay the consummation of the Combination. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;">Pfizer has expended and will continue to expend significant management time and resources and has incurred and will continue to incur significant expenses due to legal, advisory, printing and financial services fees related to the Combination, including costs required to obtain the required government consents or defend or settle actions noted above. We expect to incur costs of approximately $500 million in connection with fully separating Upjohn, inclusive of </span><span style="font-family:Arial;font-size:9pt;color:#212529;">$145 million</span><span style="font-family:Arial;font-size:9pt;color:#212529;"> incurred in 2019. Such charges will include costs and expenses related to separation of legal entities and anticipated transaction costs. Many of these expenses must be paid regardless of whether the Combination is consummated, and even if the expected benefits of the Combination are not achieved. Additionally, the completion of the Combination, including for example, obtaining regulatory approvals, will require significant time and attention from Pfizer management and may divert attention from the day-to-day operations of our business.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;font-style:italic;font-weight:bold;">Even if the Combination is completed as anticipated, Pfizer may not realize some or all of the expected benefits. Furthermore, Upjohn may experience operational challenges in integrating the Upjohn and Mylan businesses, which may also diminish the anticipated benefits of the Combination.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;">Even if the Combination is completed, the anticipated operational, financial, strategic and other benefits of the Combination may not be achieved. There are many factors that could impact the anticipated benefits from the Combination, including, among others, strategic adjustments required to reflect the nature of our business following the Combination, any negative reaction to the Combination by our customers and business partners, and increased risks resulting from Pfizer becoming a company that is more focused on innovative medicines. In addition, Pfizer has agreed to provide certain transition services to the combined company, generally for an initial period of 24 months following the completion of the Combination (with certain possibilities for extension). These obligations under the transition agreements may result in additional expenses and may divert </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">32</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;">Pfizer&#8217;s focus and resources that would otherwise be invested into maintaining or growing Pfizer&#8217;s business. An inability to realize the full extent of the anticipated benefits of the Combination, as well as any delays encountered in the process, could have an adverse effect on the revenues, level of expenses and operating results of our business.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#212529;">Furthermore, the Combination is a complex, costly and time-consuming process. Even if Upjohn and Mylan successfully integrate, Pfizer, Upjohn and Mylan cannot predict with certainty if or when the anticipated synergies, growth opportunities and benefits resulting from the Combination will occur, or the extent to which they actually will be achieved. For example, the benefits from the Combination may be offset by costs incurred in integrating the companies or by required capital expenditures related to the combined businesses. In addition, the quantification of synergies expected to result from the Combination is based on significant estimates and assumptions that are subjective in nature and inherently uncertain. Realization of any benefits and synergies could be affected by a number of factors beyond Pfizer&#8217;s, Mylan&#8217;s, Upjohn&#8217;s or the combined company&#8217;s control, including, without limitation, general economic conditions, increased operating costs, regulatory developments and the other risks described in these risk factors. The amount of synergies actually realized in the Combination, if any, and the time periods in which any such synergies are realized, could differ materially from the synergies anticipated to be realized, regardless of whether the two business operations are combined successfully. If the integration is unsuccessful or if the combined company is unable to realize the anticipated synergies and other benefits of the Combination, there could be a material adverse effect on the combined company&#8217;s share price, business, financial condition and results of operations.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">CONSUMER HEALTHCARE JOINT VENTURE WITH GSK</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On July 31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. Following the integration of the combined business, GSK intends to separate the joint venture as an independent company via a demerger of its equity interest to its shareholders and a listing of the combined business on the U.K. equity market. In February 2020, GSK announced the initiation of a two-year program to prepare for the separation of GSK into two companies, including a standalone Consumer Healthcare company. Until the fifth anniversary of the closing of the transaction, GSK will have the sole right to decide whether and when to initiate a separation and listing, and may also sell all or part of its stake in the joint venture in a contemporaneous initial public offering. Should a separation and listing occur during the first five years after closing, Pfizer has the option to participate through the distribution of some or all of its equity interest in the joint venture to its shareholders. Following a separation or listing, and subject to customary lock-up or similar restrictions, Pfizer will also have the ability to sell its equity interest in the joint venture through the capital markets. After the fifth anniversary of the closing of the transaction, both GSK and Pfizer will have the right to decide whether and when to initiate a separation and public listing of the joint venture. The planned separation and public listing transactions may not be initiated or completed within the expected time periods or at all, and both the timing and success of any separation and public listing transaction, as well as the value generated for Pfizer or its shareholders in any such transaction, will be subject to prevailing market conditions and other factors at the time of such transaction. Although Pfizer is entitled to participate in any separation and listing transaction initiated by GSK prior to the fifth anniversary of the closing, it is not required to do so, and any future distribution or sale of Pfizer&#8217;s equity stake in the joint venture will similarly be subject to prevailing market conditions and other factors at the time of such transaction. Pfizer&#8217;s ability to complete any such future distribution or sale may also be impacted by the size of Pfizer&#8217;s retained equity stake at the time. The uncertainty relating to the separation and public listing transactions, their implementation, their timing and their yet to be determined effects on the joint venture&#8217;s business may subject us and the joint venture to risks and uncertainties that may adversely affect our business and financial results.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Moreover, although we have certain consent, board representation and other governance rights with respect to the joint venture, Pfizer is a minority owner of the joint venture. As a result, Pfizer does not have control over the joint venture, its management or its policies and we may have business interests, strategies and goals that differ in certain respects from those of GSK or the joint venture.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition, the joint venture will be subject to the risks associated with the joint venture&#8217;s consumer healthcare business, and the business, financial condition and results of operations of the joint venture may be affected by factors that are different from or in addition to those that previously affected the business, financial condition and results of operations of Pfizer&#8217;s historical consumer healthcare business. Many of these factors are outside of our and the joint venture&#8217;s control, and could materially impact the business, financial condition and results of operations of the joint venture. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The success of the transaction will also depend, in part, on the joint venture&#8217;s ability to realize the anticipated benefits and cost synergies from the transaction. These anticipated benefits and cost savings may not be realized or may not be realized within the expected time period. The joint venture&#8217;s integration of Pfizer&#8217;s and GSK&#8217;s historic consumer healthcare businesses may result in material unanticipated problems, costs, expenses, liabilities, competitive responses, and loss of customer and other business relationships. Any material unanticipated issues arising from the integration process could negatively impact our stock price and our or the joint venture&#8217;s future business and financial results</span><span style="font-family:inherit;font-size:9pt;">.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;text-decoration:underline;">OTHER RISKS:</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">THE GLOBAL ECONOMIC ENVIRONMENT</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Like all businesses of our size, we are exposed to both global and industry-specific economic conditions. </span><span style="font-family:Arial;font-size:9pt;">Governments, corporations, and insurance companies, which provide insurance benefits to patients, have implemented increases in cost-sharing and restrictions on access to medicines, potentially causing patients to switch to generic or biosimilar products, delay treatments, skip doses or use less effective treatments. As discussed above, government financing pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through public or private health technology assessments), or other means of cost control. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The global economic environment has not had, nor do we anticipate that it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving economic conditions, but there can be no guarantee that changes in global financial markets and global economic conditions will not affect our liquidity or capital resources or impact our ability to obtain financing in the future. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We continue to monitor credit, capital restrictions and economic situations in volatile regions and markets, especially where the ability to obtain U.S. dollars for local currency is unpredictable and challenging. We cannot predict the likelihood of future changes in these economic conditions, or what impact they may have on our results of operations, financial condition or business.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition, given that a significant portion of our business is conducted in the EU, including the U.K., the formal change in the relationship between the U.K. and the EU caused by Brexit may pose certain implications for our research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products. Details on how Brexit will be finally executed and the impact on the remaining EU countries will dictate how and whether the broader EU will be impacted and what the resulting impact on our business may be. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">The Global Economic Environment</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">section in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Public health epidemics or outbreaks could adversely impact our business.&#160;In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:9pt;">&#160;While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.&#160;The extent to which the coronavirus impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In particular, the continued spread of the coronavirus globally could adversely impact our operations, including among others, our manufacturing and supply chain, sales and marketing and clinical trial operations and could have an adverse impact on our business and our financial results.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:inherit;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We also continue to monitor the global trade environment and potential trade conflicts and impediments. If trade restrictions or tariffs reduce global economic activity, or if other factors lead to a general economic downturn, potential impacts could include declining sales; increased costs; volatility in foreign exchange rates; a decline in the value of our financial assets and pension plan investments; required increases of our pension funding obligations; increased government cost control efforts; delays or failures in the performance of customers, suppliers, and other third parties on whom we may depend for the performance of our business; and the risk that our allowance for doubtful accounts may not be adequate. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">FOREIGN EXCHANGE AND INTEREST RATE RISK</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. </span><span style="font-family:Arial;font-size:9pt;">54%</span><span style="font-family:Arial;font-size:9pt;"> of our total </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> revenues were derived from international operations, including </span><span style="font-family:Arial;font-size:9pt;">21%</span><span style="font-family:Arial;font-size:9pt;"> from Europe and </span><span style="font-family:Arial;font-size:9pt;">24%</span><span style="font-family:Arial;font-size:9pt;"> from China, Japan and the rest of Asia. As we operate in multiple foreign currencies, including the euro, the Chinese renminbi, the Japanese yen, the Canadian dollar, the U.K. pound and approximately 100 other currencies, changes in those currencies relative to the U.S. dollar will impact our revenues and expenses. If the U.S. dollar were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the U.S. dollar were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The impact of possible currency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including Venezuela and Argentina, can impact our results and financial guidance</span><span style="font-family:Arial;font-size:9pt;">. For additional information about our exposure to foreign currency risk, see the&#160;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk&#8212;Foreign Exchange Risk</span><span style="font-family:Arial;font-size:9pt;">&#160;section in this 2019 Form 10-K and the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">34</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-style:italic;">Outlook</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Our Financial Guidance for</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2020</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of Financial Condition, Liquidity and Capital Resources</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">sections in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition, our interest-bearing investments and borrowings, and our pension benefit obligations, net, and our postretirement benefit obligations, net, are subject to risk from changes in interest rates and foreign exchange rates. These risks related to interest-bearing investments and borrowings and the measures we have taken to help contain them are discussed in the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Financial Risk Management</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K. For additional details, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8211;&#8211;Benefit Plans</span><span style="font-family:Arial;font-size:9pt;"> section and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 7</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">F</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Financial Instruments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Derivative Financial Instruments and Hedging Activities</span><span style="font-family:Arial;font-size:9pt;"> and &#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Pension and Postretirement Benefit Plans and Defined Contribution Plans</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report, which are incorporated by reference.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">From time to time, we issue variable rate debt based on LIBOR, or undertake interest rate swaps that contain a variable element based on LIBOR. The U.K. Financial Conduct Authority announced in July 2017 that it will no longer compel banks to submit rates that are currently used to calculate LIBOR after 2021. Various governing parties, including government agencies, are working on a benchmark transition plan for LIBOR (and other interbank offered rates globally)</span><span style="font-family:inherit;font-size:9pt;">.</span><span style="font-family:Arial;font-size:9pt;"> We are monitoring their progress, and we will likely amend contracts to accommodate any replacement rate where it is not already provided. As a result, our interest expense could increase and our available cash flow for general corporate requirements may be adversely affected. Additionally, uncertainty as to the nature of a potential discontinuance, modification, alternative reference rates or other reforms may materially adversely affect the trading market for securities linked to such benchmarks.&#160;For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Analysis of Financial Condition, Liquidity and Capital Resources</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Selected Measures of Liquidity and Capital Resources</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">LIBOR</span><span style="font-family:Arial;font-size:9pt;"> section in our 2019 Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notwithstanding our efforts to foresee and mitigate the effects of changes in external fiscal circumstances, we cannot predict with certainty changes in currency and interest rates, inflation or other related factors affecting our businesses.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">MARKET FLUCTUATIONS IN OUR EQUITY INVESTMENTS</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In 2018, we adopted a new accounting standard whereby certain equity investments are measured at fair value with changes in fair value now recognized in net income. We expect the adoption of this new accounting standard may increase the volatility of our income in future periods due to changes in the fair value of certain equity investments. For additional information, see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 4. Other (Income)/Deductions</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Net </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report and the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 7A. Quantitative and Qualitative Disclosures About Market Risk</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">Financial Risk Management</span><span style="font-family:Arial;font-size:9pt;"> section in this 2019 Form 10-K. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our pension benefit obligations and postretirement benefit obligations, net of our plan assets, are subject to volatility from changes in fair value of equity investments and other investment risk. For additional information, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Benefit Plans </span><span style="font-family:Arial;font-size:9pt;">section and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 11. Pension and Postretirement Benefit Plans and Defined Contribution Plans </span><span style="font-family:Arial;font-size:9pt;">in our 2019 Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">COST AND EXPENSE CONTROL/UNUSUAL EVENTS/FAILURE TO REALIZE THE ANTICIPATED BENEFITS OF STRATEGIC INITIATIVES AND ACQUISITIONS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Growth in costs and expenses, changes in product, segment and geographic mix and the impact of acquisitions, divestitures, restructurings, internal reorganizations, product withdrawals, recalls and other unusual events that could result from evolving business strategies, evaluation of asset realization and organizational restructuring could adversely affect future results. Such risks and uncertainties include, in particular, our ability to realize the projected benefits of (i) our cost-reduction and productivity initiatives; (ii) the reorganization of our commercial operations in 2019; (iii) any other corporate strategic initiatives; and (iv) any acquisitions, divestitures or other initiatives, such as our agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, which is anticipated to close in mid-2020, our acquisition of Array and the formation of the new consumer healthcare joint venture with GSK.</span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">INTANGIBLE ASSETS, GOODWILL AND EQUITY-METHOD INVESTMENTS</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our consolidated balance sheet contains significant amounts of intangible assets, including goodwill. For IPR&amp;D assets, the risk of failure is significant, and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and requires that we invest in a large number of projects in an effort to achieve a successful portfolio of approved products. Our ability to realize value on these significant investments is often contingent upon, among other things, regulatory approvals and market acceptance. As such, we expect that many of these IPR&amp;D assets will become impaired and be written off at some time in the future. If the associated R&amp;D effort is abandoned, the related IPR&amp;D assets will likely be written-off, and we will record an impairment charge. For goodwill, all reporting units can confront events and circumstances that can lead to a goodwill impairment charge (such as, among other things, unanticipated competition, an adverse action or assessment by a regulator, a significant adverse change in legal matters or in the business climate and/or a failure to replace the contributions of products that lose exclusivity). Any such charge may be significant. Our other intangible </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">assets, including developed technology rights and brands, face similar risks for impairment and charges related to such assets may be significant as well. For additional details, see the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span><span style="font-family:Arial;font-size:9pt;"> section in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We also regularly review our equity-method investments for impairment. An impairment charge may result from the occurrence of unexpected adverse events or management decisions that impact our estimates of expected cash flows to be generated from these investments. We may recognize impairment charges as a result of a weak economic environment, events related to particular customers or asset types, challenging market conditions or decisions by management.</span></div><div style="line-height:120%;text-align:left;text-indent:29px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">TERRORIST ACTIVITY</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our future results could be adversely affected by changes in business, political and economic conditions, including the cost and availability of insurance, due to the threat of terrorist activity in the U.S. and other parts of the world and related U.S. military action overseas.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">36</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sB98CBE8A8A615666B5C535AE350D46B0"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;1B.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">UNRESOLVED STAFF COMMENTS</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Not applicable.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="sA65061D3D52D5828A75D50F1B1ACB477"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;2.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">PROPERTIES</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of December 31, </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;">, we had 453 owned and leased properties, amounting to approximately 47 million square feet.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In 2019, we reduced the number of properties in our portfolio by 45 sites and 6 million square feet, which reflects the divestment of properties in connection with the formation of the GSK Consumer Healthcare joint venture and the addition of properties in connection with the acquisition of Array.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer continues to own and lease space around the world for sales and marketing, customer service, regulatory compliance, R&amp;D, manufacturing and distribution, and administrative support functions. In many locations, business lines and operations are co-located to achieve synergy and operational efficiencies. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer&#8217;s corporate headquarters are in New York City and Pfizer&#8217;s properties extend internationally to approximately 90 countries.  </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In April 2018, we entered an agreement to lease space at the Spiral, an office building in the Hudson Yards neighborhood of New York City. We will relocate our global headquarters to this property with occupancy expected beginning in 2022. In July 2018, we completed the sale of our current headquarters in New York City. We remain in a lease-back arrangement with the buyer while we complete our relocation. We continue to advance our global workplace strategy to provide workplaces that enable collaboration and foster innovation.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We have numerous facilities across the world to support our R&amp;D organizations, with a heavy concentration in North America. In 2019, we operationalized the new R&amp;D facilities in St. Louis, Missouri and Andover, Massachusetts. We also purchased an R&amp;D property in Durham, North Carolina in 2019 and expect to renovate and fit out the space over the next several years. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our PGS division is headquartered in various locations, with leadership teams primarily in New York City, New York and in Peapack, New Jersey. As of December 31, </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;">, PGS had responsibility for 42 plants around the world, which manufacture products for our commercial divisions. Locations with major manufacturing facilities include Belgium, China, Germany, India, Ireland, Italy, Japan, Singapore and the U.S. Our PGS division&#8217;s plant network strategy is expected to result in the exit of two of these sites over the next several years. PGS also operates multiple distribution facilities around the world. In 2019, seven manufacturing plants transferred from PGS&#8217;s responsibility to Upjohn&#8217;s responsibility, and an additional two plants are expected to be fully migrated from PGS&#8217;s responsibility to Upjohn&#8217;s responsibility over the next several years.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In general, we believe that our properties are well-maintained, adequate and suitable for their current requirements and for our operations in the foreseeable future. See the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 9</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Property, Plant and Equipment</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report, which provides amounts invested in land, buildings and equipment and which is incorporated by reference. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s0D3A3EECAB8D5DAAABEA3A430CC77ABF"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;3.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">LEGAL PROCEEDINGS</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certain legal proceedings in which we are involved are discussed in the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 16</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">A</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Legal Proceedings</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report, which is incorporated by reference.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s20443CE278E4546E95B7C03120269A52"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;4.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">MINE SAFETY DISCLOSURES</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Not applicable.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sFD44FC0862BC5DC5988EE9485D1B45BD"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">INFORMATION ABOUT OUR EXECUTIVE OFFICERS </span></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The executive officers of the Company are set forth in this table. Each holds the office or offices indicated until his or her successor is chosen and qualified at the regular meeting of the Board of Directors to be held on the date of the </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Annual Meeting of Shareholders, or until his or her earlier death, resignation or removal. Each of the executive officers is a member of the Pfizer Executive Leadership Team.</span></div><div style="line-height:120%;text-align:left;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:70%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Age</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Position</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:9px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Albert Bourla</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">58</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chairman of the Board since January 2020 and Chief Executive Officer since January 2019. Chief Operating Officer from January 2018 until December 2018; Group President, Pfizer Innovative Health from June 2016 until December 2017; Group President, Global Innovative Pharma Business (responsible for Vaccines, Oncology and Consumer Healthcare since 2014) from February 2016 until June 2016. President and General Manager of Established Products Business Unit from December 2010 until December 2013. Our Director since February 2018. Board member of Pharmaceutical Research and Manufacturers of America (PhRMA). Board member of the Pfizer Foundation, which promotes access to quality healthcare. Member of the Board of Directors of the Partnership for New York City and Catalyst, a global non-profit organization accelerating progress for the advancement of women into leadership.</span></div><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Frank A. D&#8217;Amelio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">62</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Financial Officer, Executive Vice President, Business Operations and Global Supply since November 2018. Executive Vice President, Business Operations and Chief Financial Officer from December 2010 until October 2018. Senior Vice President and Chief Financial Officer from September 2007 until December 2010. Director of Zoetis Inc. and Humana Inc. and Chair of the Humana Inc. Board of Directors&#8217; Audit Committee. Director of the Independent College Fund of New Jersey.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Mikael Dolsten</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">61</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Scientific Officer, President, Worldwide Research, Development and Medical since January 2019. President of Worldwide Research and Development from December 2010 until December 2018. Senior Vice President; President of Worldwide Research and Development from May 2010 until December 2010. Senior Vice President; President of Pfizer BioTherapeutics Research &amp; Development Group from October 2009 until May 2010. He was Senior Vice President of Wyeth and President, Wyeth Research from June 2008 until October 2009. Director of Karyopharm Therapeutics Inc. Chairman of the Translational Advisory Board of Apple Tree Partners from 2016 to 2017.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Lidia Fonseca</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">51</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Digital and Technology Officer, Executive Vice President since January 2019. Chief Information Officer and Senior Vice President of Quest Diagnostics Incorporated from 2014 to 2018. Senior Vice President of Laboratory Corporation of America Holdings from 2008 until March 2013. Director of Tegna, Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Angela Hwang</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">54</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Group President, Pfizer Biopharmaceuticals Group since January 2019. Group President, Pfizer Essential Health from January 2018 until December 2018. Global President, Pfizer Inflammation and Immunology from January 2016 until December 2017. Regional Head, U.S. Vaccines from January 2014 until December 2015. Vice President, Emerging Markets for the Primary Care business from September 2011 until December 2013. Vice President, U.S. Brands business within Essential Health from October 2009 until August 2011.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Rady A. Johnson</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">58</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Compliance, Quality and Risk Officer, Executive Vice President since January 2019. Executive Vice President, Chief Compliance and Risk Officer from December 2013 until December 2018. Senior Vice President and Associate General Counsel from October 2006 until December 2013.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Douglas M. Lankler</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">54</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">General Counsel, Executive Vice President since December 2013. Corporate Secretary from January 2014 until February 2014. Executive Vice President, Chief Compliance and Risk Officer from February 2011 until December 2013. Executive Vice President, Chief Compliance Officer from December 2010 until February 2011. Senior Vice President and Chief Compliance Officer from January 2010 until December 2010. Senior Vice President, Deputy General Counsel and Chief Compliance Officer from August 2009 until January 2010. </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">38</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;padding-left:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:70%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Name</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Age</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Position</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">A. Rod MacKenzie</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">60</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Development Officer, Executive Vice President since June 2016. Senior Vice President, Chief Development Officer from March 2016 until June 2016. Group Senior Vice President and Head, Pharma Therapeutics Research and Development from 2010 until March 2016. Dr. MacKenzie represents Pfizer as a member of the Board of Directors of ViiV Healthcare Limited, TransCelerate Biopharma Inc. and the National Health Council.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dawn Rogers</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">55</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Human Resources Officer, Executive Vice President since January 2019. Executive Vice President, Worldwide Human Resources from June 2018 until December 2018. Senior Vice President, Human Resources for the Chief Operating Officer from November 2017 until May 2018. Senior Vice President of Human Resources for Pfizer Essential Health, Global Product Development, and the Legal and Compliance Divisions from 2016 until November 2017. Senior Vice President of Human Resources for the Global Innovative Pharma Business from 2013 until 2016. Senior Vice President of Human Resources for the Primary Care Business Unit from 2011 until 2013. Senior Vice President of Human Resources for Worldwide Research and Development from 2008 until 2011.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sally Susman</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">58</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Corporate Affairs Officer, Executive Vice President since January 2019. Executive Vice President, Corporate Affairs (formerly Policy, External Affairs and Communications) from December 2010 until December 2018. Senior Vice President, Policy, External Affairs and Communications from December 2009 until December 2010. Director of WPP plc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">John D. Young</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">55</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Business Officer, Group President since January 2019. Group President, Pfizer Innovative Health from January 2018 until December 2018. Group President, Pfizer Essential Health from June 2016 until December 2017; Group President, Global Established Pharma Business from January 2014 until June 2016. President and General Manager, Pfizer Primary Care from June 2012 until December 2013. Primary Care Business Unit&#8217;s Regional President for Europe and Canada from 2009 until June 2012. Director of Johnson Controls International plc. Mr. Young represents Pfizer as a member of the Board of Directors of the GSK Consumer Healthcare joint venture.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sED3D006782A65B7AAF85A448A45572BF"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px dotted #006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #006ebf;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PART II</span></div></td></tr></table></div></div><div><a id="s0F5AA24F4EB65B5FAA1EAB09D430CF50"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;5.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">MARKET FOR THE COMPANY&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The principal market for our common stock is the NYSE. Our common stock currently trades on the NYSE under the symbol &#8220;PFE&#8221;. As of </span><span style="font-family:Arial;font-size:9pt;">February&#160;25, 2020</span><span style="font-family:Arial;font-size:9pt;">, there were </span><span style="font-family:Arial;font-size:9pt;">142,524</span><span style="font-family:Arial;font-size:9pt;"> holders of record of our common stock. Additional information required by this item is incorporated by reference from the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Selected Quarterly Financial Data</span><span style="font-family:Arial;font-size:9pt;"> </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">(Unaudited)</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Peer Group Performance Graph </span><span style="font-family:Arial;font-size:9pt;">sections in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following table provides certain information with respect to our purchases of shares of the Company&#8217;s common stock during the fourth fiscal quarter of </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;">:</span></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Issuer Purchases of Equity Securities</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:37%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Period</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Total&#160;Number</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">of Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Purchased</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Average Price</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Paid&#160;per</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;Share</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;&#160;</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Total&#160;Number&#160;of</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Shares&#160;Purchased&#160;as</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Part of Publicly</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;Announced&#160;Plan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Approximate Dollar Value of Shares</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">that May Yet Be Purchased</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;&#160;&#160;&#160;Under&#160;the&#160;Plan</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:8pt;">&#160;&#160;&#160;</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">September 30, 2019 through October 27, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">32,848</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">36.06</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,292,881,709</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">October 28, 2019 through November 30, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">13,399</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">37.50</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,292,881,709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 1, 2019 through December 31, 2019</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">67,767</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">38.86</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,292,881,709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">114,014</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">37.89</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information, see the Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 12</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Equity</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">in our </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report, which is incorporated by reference.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">These columns represent (i) </span><span style="font-family:Arial;font-size:8pt;">108,367</span><span style="font-family:Arial;font-size:8pt;"> shares of common stock surrendered to the Company to satisfy tax withholding obligations in connection with the vesting of awards under our long-term incentive programs and (ii) the open market purchase by the trustee of </span><span style="font-family:Arial;font-size:8pt;">5,647</span><span style="font-family:Arial;font-size:8pt;"> shares of common stock in connection with the reinvestment of dividends paid on common stock held in trust for employees who were granted performance share awards and who deferred receipt of such awards.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">40</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s227808A6FAA05DCFBE13F365162E4B5A"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;6.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">SELECTED FINANCIAL DATA</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information required by this item is incorporated by reference from the discussion under the heading </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Financial Summary</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s47D06050A00C5F5EB81E6674B675DAE1"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;7.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information required by this item is incorporated by reference from the discussion under the heading </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Financial Review</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s377D5C48E6D7540AB92254D3AFF8A41C"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;7A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Financial Risk Management</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The objective of our financial risk management program is to minimize the impact of foreign exchange rate movements and interest rate movements on our earnings. We manage these financial exposures through operational means and through the use of third-party instruments. These practices may change as economic conditions change.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Foreign Exchange Risk</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We operate globally and, as such, we are subject to foreign exchange risk in our commercial operations, as well as in our financial assets (investments) and liabilities (borrowings). Our net investments in foreign subsidiaries are also subject to currency risk.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">On the commercial side, a significant portion of our revenues and earnings is exposed to changes in foreign exchange rates. See the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;font-weight:normal;text-decoration:none;">The Global Economic Environment</span><span style="font-family:Arial;font-size:9pt;"> section in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report for the key currencies in which we operate. We seek to manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Where foreign exchange risk cannot be mitigated via operational means, we may use foreign currency forward-exchange contracts and/or foreign currency swaps to manage that risk. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">With respect to our financial assets and liabilities, our primary foreign exchange exposure arises predominantly from short-term and long-term intercompany receivables and payables, and, to a lesser extent, from short-term and long-term investments and debt, where the assets and/or liabilities are denominated in currencies other than the functional currency of the business entity.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We also hedge some forecasted intercompany sales denominated in euro, Japanese yen, Chinese renminbi, U.K. pound, Canadian dollar, and Australian dollar to protect against longer-term movements.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">In addition, under certain market conditions, we may seek to protect against possible declines in the reported net investments of our foreign business entities. In these cases, we may use foreign currency swaps, foreign currency forward-exchange contracts and/or foreign currency debt.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For details about these and other financial instruments, including fair valuation methodologies, see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 7A. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Financial Instruments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report. </span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to foreign exchange rate changes. In this sensitivity analysis, holding all other assumptions constant and assuming that a change in one currency&#8217;s rate relative to the U.S. dollar would not have any effect on another currency&#8217;s rates relative to the U.S. dollar, if the dollar were to appreciate against all other currencies by 10%, as of </span><span style="font-family:Arial;font-size:9pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:9pt;">, the expected adverse impact on our net income would not be significant.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Interest Rate Risk</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We are subject to interest rate risk on our investments and on our borrowings. We manage interest rate risk in the aggregate, while focusing on Pfizer&#8217;s immediate and intermediate liquidity needs.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. Our floating-rate assets are subject to the risk that short-term interest rates may fall and, as a result, the investments would generate less interest income. Fixed-rate investments provide a known amount of interest income regardless of a change in interest rates. We sometimes use interest rate swaps in our financial investment portfolio.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">For details about these and other financial instruments, including fair valuation methodologies, see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Note 7A. </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Financial Instruments</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Fair Value Measurements</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report. </span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The fair values of our financial instrument holdings are analyzed at year-end to determine their sensitivity to interest rate changes. In this sensitivity analysis, holding all other assumptions constant and assuming a parallel shift in the interest rate curve for all maturities and for all instruments, if there were a one hundred basis point increase in interest rates as of </span><span style="font-family:Arial;font-size:9pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:9pt;">, the expected adverse impact on our net income would not be significant.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Equity Price Risk</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We hold equity securities with readily determinable fair values in life science companies as a result of certain business development transactions. While we are holding such securities, we are subject to equity price risk, and this may increase the volatility of our income in future periods due to changes in the fair value of equity investments. From time to time, we will sell such equity securities based on our business considerations, which may include limiting our price risk.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our equity securities with readily determinable fair values are analyzed at year-end to determine their sensitivity to equity price rate changes. In this sensitivity analysis, the expected adverse impact on our net income would not be significant.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s2E8F226DCAB35200A069D4A32F1F75B7"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;8.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information required by this item is incorporated by reference from the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Report of Independent Registered Public Accounting Firm </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report and from the consolidated financial statements, related notes and supplementary data in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="sBBB73A0ABDC95CB8B4C4D93D33D6AF9D"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;9.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">None.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="sDA303666ECC751399D9DF91C4B027B6F"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;9A.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">CONTROLS AND PROCEDURES</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Disclosure Controls</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">As of the end of the period covered by this </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K, we carried out an evaluation, under the supervision and with the participation of our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures (as such term is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act). Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures are effective in alerting them in a timely manner to material information required to be disclosed in our periodic reports filed with the SEC.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Internal Control over Financial Reporting</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Management&#8217;s report on the Company&#8217;s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act), and the related report of our independent registered public accounting firm, are included in our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report under the headings </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Management&#8217;s Report on Internal Control Over Financial Reporting</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting</span><span style="font-family:Arial;font-size:9pt;">, respectively, and are incorporated by reference.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Changes in Internal Controls</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">During our most recent fiscal quarter, there has not been any change in the Company&#8217;s internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) that has materially affected, or is reasonably likely to materially affect, the Company&#8217;s internal control over financial reporting.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s1AF8C25F34745A5FBDAF296DEA3109A1"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:12%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;9B.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">OTHER INFORMATION</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Not applicable.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">42</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sBAFDD9F5AF4A5894AD49D3681101911D"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px dotted #006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #006ebf;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PART III</span></div></td></tr></table></div></div><div><a id="sF068F019C94A504F8F17A818A20D0CB8"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;10.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information about our Directors is incorporated by reference from the discussion under the heading </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Election of Directors</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. Information about the Pfizer Policies on Business Conduct governing our employees, including our Chief Executive Officer, Chief Financial Officer and Principal Accounting Officer, and the Code of Business Conduct and Ethics for Members of the Board of Directors, is incorporated by reference from the discussions under the headings </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Governance</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Pfizer Policies on Business Conduct </span><span style="font-family:Arial;font-size:9pt;">and &#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Code of Conduct for Directors</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. Information regarding the procedures by which our shareholders may recommend nominees to our Board of Directors is incorporated by reference from the discussion under the headings </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 1</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Election of Directors</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Criteria for Board Membership</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Submitting Proxy Proposals and Director Nominations for the </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">2021</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Annual Meeting </span><span style="font-family:Arial;font-size:9pt;">in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. Information about our Audit Committee, including the members of the Committee, and our Audit Committee financial experts, is incorporated by reference from the discussion under the heading </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Governance</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Board Information&#8212;Board and Committee Information</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Board Committees&#8212;The Audit Committee</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. The balance of the information required by this item is contained in the discussion entitled </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Information about Our Executive Officers</span><span style="font-family:Arial;font-size:9pt;"> in Part I of this </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s15633F5448C25D9680F3D4D3E62E723E"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;11.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">EXECUTIVE COMPENSATION</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information about Director and executive compensation is incorporated by reference from the discussion under the headings </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Non-Employee Director Compensation</span><span style="font-family:Arial;font-size:9pt;">;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> Executive Compensation</span><span style="font-family:Arial;font-size:9pt;">; and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Governance&#8212;Board Information&#8212;Board and Committee Information&#8212;Board Committees</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">The Compensation Committee</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Compensation Committee Interlocks and Insider Participation</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s9C00A14D506E5713B6EAC924A49B3CF3"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;12.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information required by this item is incorporated by reference from the discussion under the headings </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Executive Compensation</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Compensation Tables&#8212;Equity Compensation Plan Information</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Securities Ownership</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s259FD2EB1F8658DBA346B40ACEF7A9B5"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;13.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information about certain relationships and transactions with related parties is incorporated by reference from the discussion under the headings </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Related Person Transactions and Indemnification</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Transactions with Related Persons</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. Information about director independence is incorporated by reference from the discussion under the heading </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Governance</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Other Governance Practices and Policies</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Director Independence</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><a id="s6B150B86AF6B5AE480C3617B7EDB145E"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;14.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">PRINCIPAL ACCOUNTING FEES AND SERVICES</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:32px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Information about the fees for professional services rendered by our independent registered public accounting firm in </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> and </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:9pt;"> is incorporated by reference from the discussion under the heading </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 2</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Ratification of Selection of Independent Registered Public Accounting Firm</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Audit and Non-Audit Fees</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. Our Audit Committee&#8217;s policy on pre-approval of audit and permissible non-audit services of our independent registered public accounting firm is incorporated by reference from the discussion under the heading </span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Item 2</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Ratification of Selection of Independent Registered Public Accounting Firm</span><span style="font-family:Arial;font-size:9pt;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-style:italic;">Policy on Audit Committee Pre-Approval of Audit and Permissible Non-Audit Services of Independent Registered Public Accounting Firm</span><span style="font-family:Arial;font-size:9pt;"> in our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. </span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s555F1C56F7FA51D99AE4C64AF525DE63"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:36.1328125%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px dotted #006ebf;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #006ebf;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">PART IV</span></div></td></tr></table></div></div><div><a id="sAB9622F45ECA5CCFAF58170719917F9C"></a></div><div style="line-height:120%;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;15.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</span></div></td></tr></table></div></div><div><a id="s72097BE09AA95E2FB7F67AD81F21380B"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">15(a)(1) Financial Statements.</span><span style="font-family:Arial;font-size:9pt;"> The following consolidated financial statements, related notes, report of independent registered public accounting firm and supplementary data from our </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Financial Report are incorporated by reference into Item 8 of Part II of this </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Report of Independent Registered Public Accounting Firm on the Consolidated Financial Statements</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Consolidated Statements of Income</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Consolidated Statements of Comprehensive Income</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Consolidated Balance Sheets</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Consolidated Statements of Equity</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Consolidated Statements of Cash Flows</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Notes to Consolidated Financial Statements</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:8px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:48px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Selected Quarterly Financial Data (Unaudited)</span></div></td></tr></table><div><a id="sD10AEFD41437504E8AE91E8A76D372A3"></a></div><div style="line-height:120%;padding-top:16px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">15(a)(2) Financial Statement Schedules.</span><span style="font-family:Arial;font-size:9pt;"> Schedules are omitted because they are not required or because the information is provided elsewhere in the financial statements. The financial statements of unconsolidated subsidiaries are omitted because, considered in the aggregate, they would not constitute a significant subsidiary.</span></div><div><a id="s60FF4F741B195321AF6B1B1CDC92D24E"></a></div><div style="line-height:120%;padding-top:16px;-sec-extract:summary;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">15(a)(3) Exhibits.</span><span style="font-family:Arial;font-size:9pt;"> These exhibits are available upon request. Requests should be directed to our Corporate Secretary, Pfizer Inc., 235 East 42nd Street, New York, New York 10017. The exhibit numbers preceded by an asterisk (*) indicate exhibits filed with this </span><span style="font-family:Arial;font-size:9pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K. All other exhibit numbers indicate exhibits filed by incorporation by reference. Exhibit numbers 10.1 through 10.38 are management contracts or compensatory plans or arrangements.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit22x12312018x10k.htm"><span style="font-family:Arial;font-size:9pt;">2.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Stock and Asset Purchase Agreement, dated December 19, 2018, by and among Pfizer Inc., GlaxoSmithKline plc and GlaxoSmithKline Consumer Healthcare Holdings Limited is incorporated by reference from our 2018 Annual Report on Form 10-K (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Stock and Asset Purchase Agreement.)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312519204818/d769805dex21.htm"><span style="font-family:Arial;font-size:9pt;">2.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Business Combination Agreement, dated July 29, 2019, by and among Pfizer Inc., Upjohn Inc., Utah Acquisition Sub Inc., Mylan N.V., Mylan I B.V. and Mylan II B.V. is incorporated by reference from our Current Report on Form 8-K filed on July 29, 2019 (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Business Combination Agreement.)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312519204818/d769805dex22.htm"><span style="font-family:Arial;font-size:9pt;">2.3</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Separation and Distribution Agreement, dated as of July 29, 2019, by and between Pfizer Inc. and Upjohn Inc. is incorporated by reference from our Current Report on Form 8-K filed on July 29, 2019 (File No. 001-03619). (Pursuant to Item 601(b)(2) of Regulation S-K, the registrant hereby agrees to supplementally furnish to the Securities and Exchange Commission upon request any omitted schedule or exhibit to the Separation and Distribution Agreement.)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exhibit24x12312019.htm"><span style="font-family:Arial;font-size:9pt;">2.4</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 1 to the Separation and Distribution Agreement, dated as of February 18, 2020, by and between Pfizer Inc. and Upjohn Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800304000132/ex-3_1.htm"><span style="font-family:Arial;font-size:9pt;">3.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended March 28, 2004 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800306000203/aex030501.htm"><span style="font-family:Arial;font-size:9pt;">3.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment dated May 1, 2006 to Restated Certificate of Incorporation dated April 12, 2004, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended July 2, 2006 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800317000057/exh31_by-laws20171.htm"><span style="font-family:Arial;font-size:9pt;">3.3</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Our By-laws, as amended December 18, 2017, are incorporated by reference from our Current Report on Form 8-K filed on December 21, 2017 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000091412101000106/0000914121-01-000106-0002.txt"><span style="font-family:Arial;font-size:9pt;">4.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indenture, dated as of January 30, 2001, between us and The Chase Manhattan Bank, is incorporated by reference from our Current Report on Form 8-K filed on January 30, 2001 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000115752309005774/a6022539ex4-1.htm"><span style="font-family:Arial;font-size:9pt;">4.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">First Supplemental Indenture, dated as of March 24, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 28, 2009 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">44</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800309000122/ex0603x.htm"><span style="font-family:Arial;font-size:9pt;">4.3</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Second Supplemental Indenture, dated as of June 2, 2009, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2009 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312513245261/d547019dex42.htm"><span style="font-family:Arial;font-size:9pt;">4.4</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Third Supplemental Indenture, dated as of June 3, 2013, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K filed on June 3, 2013 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312514201187/d727538dex42.htm"><span style="font-family:Arial;font-size:9pt;">4.5</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fourth Supplemental Indenture, dated as of May 15, 2014, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on May 15, 2014 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312515338599/d37576dex42.htm"><span style="font-family:Arial;font-size:9pt;">4.6</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fifth Supplemental Indenture, dated as of October 5, 2015, between us and The Bank of New York Mellon (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank)), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on October 6, 2015 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312516612635/d193755dex43.htm"><span style="font-family:Arial;font-size:9pt;">4.7</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sixth Supplemental Indenture, dated as of June 3, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on June 3, 2016 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000110465916158373/a16-21499_7ex4d2.htm"><span style="font-family:Arial;font-size:9pt;">4.8</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seventh Supplemental Indenture, dated as of November 21, 2016, between us and The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on November 21, 2016 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312517087159/d347858dex42.htm"><span style="font-family:Arial;font-size:9pt;">4.9</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Eighth Supplemental Indenture, dated as of March 17, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (successor to the Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on March 17, 2017 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312517071809/d335900dex42.htm"><span style="font-family:Arial;font-size:9pt;">4.10</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Ninth Supplemental Indenture, dated as of March 6, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent and calculation agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on March 6, 2017 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312517373738/d476089dex42.htm"><span style="font-family:Arial;font-size:9pt;">4.11</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Tenth Supplemental Indenture, dated as of December 19, 2017, among us, The Bank of New York Mellon (formerly The Bank of New York (successor to JPMorgan Chase Bank, N.A. (formerly JPMorgan Chase Bank, formerly The Chase Manhattan Bank (National Association)))), as trustee, and The Bank of New York Mellon, London Branch, as paying agent, to Indenture dated as of January 30, 2001, is incorporated by reference from our Current Report on Form 8-K report filed on December 19, 2017 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/5187/0000950112-95-000091.txt"><span style="font-family:Arial;font-size:9pt;">4.12</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indenture, dated as of April 10, 1992, between Wyeth (formerly American Home Products Corporation) and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s Registration Statement on Form&#160;S-3 (File No.&#160;33-57339), filed on January 18, 1995.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/5187/0000950112-95-000091.txt"><span style="font-family:Arial;font-size:9pt;">4.13</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Supplemental Indenture, dated as of October 13, 1992, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s Registration Statement on Form&#160;S-3 (File No. 33-57339), filed on January 18, 1995.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/5187/000000518704000048/indent5.txt"><span style="font-family:Arial;font-size:9pt;">4.14</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Fifth Supplemental Indenture, dated as of December 16, 2003, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s 2003 Annual Report on Form 10-K (File No. 001-01225).</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/5187/000000518705000060/y14795.htm"><span style="font-family:Arial;font-size:9pt;">4.15</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Sixth Supplemental Indenture, dated as of November 14, 2005, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s Current Report on Form 8-K filed on November 15, 2005 (File No. 001-01225).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/5187/000119312507067406/dex41.htm"><span style="font-family:Arial;font-size:9pt;">4.16</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Seventh Supplemental Indenture, dated as of March 27, 2007, between Wyeth and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, N.A.), as trustee, is incorporated by reference from Wyeth&#8217;s Current Report on Form 8-K filed on March 28, 2007 (File No. 001-01225).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/5187/000091412109001203/pf17591951-ex4_1.htm"><span style="font-family:Arial;font-size:9pt;">4.17</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Eighth Supplemental Indenture, dated as of October 30, 2009, between Wyeth, us and The Bank of New York Mellon (as successor to JPMorgan Chase Bank, formerly The Chase Manhattan Bank), as trustee, to Indenture dated as of April 10, 1992 (as amended on October 13, 1992), is incorporated by reference from our Current Report on Form 8-K filed on November 3, 2009 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312518269276/d618110dex41.htm"><span style="font-family:Arial;font-size:9pt;">4.18</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on September 7, 2018 (File No. 001-03619). </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312518269276/d618110dex42.htm"><span style="font-family:Arial;font-size:9pt;">4.19</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">First Supplemental Indenture, dated as of September 7, 2018, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on September 7, 2018 (File No. 001-03619). </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312519070967/d720336dex42.htm"><span style="font-family:Arial;font-size:9pt;">4.20</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Second Supplemental Indenture, dated as of March 11, 2019, between us and The Bank of New York Mellon, as trustee, is incorporated by reference from our Current Report on Form 8-K filed on March 11, 2019 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exhibit421x123119x.htm"><span style="font-family:Arial;font-size:9pt;">4.21</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Description of Pfizer&#8217;s Securities. </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">4.22</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Except as set forth in Exhibits 4.1-21 above, the instruments defining the rights of holders of long-term debt securities of the Company and its subsidiaries have been omitted.</span><span style="font-family:Arial;font-size:9pt;"><sup style="vertical-align:top;line-height:120%;font-size:6pt">1</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000093041301500008/c19779-def14a.htm"><span style="font-family:Arial;font-size:9pt;">10.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">2001 Stock and Incentive Plan is incorporated by reference from our Proxy Statement for the 2001 Annual Meeting of Shareholders (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312512085703/d278590dex102.htm"><span style="font-family:Arial;font-size:9pt;">10.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Inc. 2004 Stock Plan, as Amended and Restated is incorporated by reference from our 2011 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000093041314001277/c76328_def14a.htm"><span style="font-family:Arial;font-size:9pt;">10.3</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Inc. 2014 Stock Plan is incorporated by reference from our Proxy Statement for the 2014 Annual Meeting of Shareholders (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit104x1231201.htm"><span style="font-family:Arial;font-size:9pt;">10.4</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Form of Acknowledgment and Consent and Summary of Key Terms for Stock Option Grants, RSUs and TSRUs is incorporated by reference from our 2017 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800316000077/pfe-12312015x10kexhibit105.htm"><span style="font-family:Arial;font-size:9pt;">10.5</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Form of Executive Grant Letter is incorporated by reference from our 2015 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit106x1231201.htm"><span style="font-family:Arial;font-size:9pt;">10.6</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2017 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit107x12312018x10k.htm"><span style="font-family:Arial;font-size:9pt;">10.7</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 1 to the Pfizer Consolidated Supplemental Pension Plan for United States and Puerto Rico Employees is incorporated by reference from our 2018 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800316000096/pfe-4032016x10qexhibit101.htm"><span style="font-family:Arial;font-size:9pt;">10.8</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2016 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800317000049/pfe-10012017x10qexhibit101.htm"><span style="font-family:Arial;font-size:9pt;">10.9</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 1 to the Pfizer Supplemental Savings Plan (Amended and Restated as of January 1, 2016), is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended October 1, 2017 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit109x1231201.htm"><span style="font-family:Arial;font-size:9pt;">10.10</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 2 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2017 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000091/pfe-930201810qxexhibit101.htm"><span style="font-family:Arial;font-size:9pt;">10.11</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 3 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended September 30, 2018 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit1012x12312018x1.htm"><span style="font-family:Arial;font-size:9pt;">10.12</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 4 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit1013x12312018x1.htm"><span style="font-family:Arial;font-size:9pt;">10.13</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 5 to the Pfizer Supplemental Savings Plan is incorporated by reference from our 2018 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000064/pfe-630201910qxexh101.htm"><span style="font-family:Arial;font-size:9pt;">10.14</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 6 to the Pfizer Supplemental Savings Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended June 30, 2019 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-ex1015x12312019xk.htm"><span style="font-family:Arial;font-size:9pt;">10.15</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 7 to the Pfizer Supplemental Savings Plan.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800317000049/pfe-10012017x10qexhibit102.htm"><span style="font-family:Arial;font-size:9pt;">10.16</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Inc. Global Performance Plan is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended October 1, 2017 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800313000006/pfe-12312012xex108.htm"><span style="font-family:Arial;font-size:9pt;">10.17</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Executive Annual Incentive Plan is incorporated by reference from our 2012 Annual Report on Form 10-K (File No. 001-03619). </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800313000006/pfe-12312012xex109.htm"><span style="font-family:Arial;font-size:9pt;">10.18</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amended and Restated Deferred Compensation Plan is incorporated by reference from our 2012 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000018/pfe-12312013xex1011.htm"><span style="font-family:Arial;font-size:9pt;">10.19</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment to Amended and Restated Deferred Compensation Plan, dated June 20, 2013, is incorporated by reference from our 2013 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800316000105/pfe-07032016x10qexhibit101.htm"><span style="font-family:Arial;font-size:9pt;">10.20</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 2 to Amended and Restated Deferred Compensation Plan, dated April 27, 2016, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended July 3, 2016 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000018/pfe-12312013xex1014.htm"><span style="font-family:Arial;font-size:9pt;">10.21</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Wyeth 2005 (409A) Deferred Compensation Plan (frozen as of January 2012), together with all material Amendments, is incorporated by reference from our 2013 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">1 </sup></span><span style="font-family:Arial;font-size:8pt;">We agree to furnish to the Securities and Exchange Commission, upon request, a copy of each instrument with respect to issuances of long-term debt of the Company and its subsidiaries.</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">46</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312512085703/d278590dex1011.htm"><span style="font-family:Arial;font-size:9pt;">10.22</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amended and Restated Wyeth Supplemental Employee Savings Plan (effective as of January 1, 2005 and frozen as of January 2012), together with all material Amendments is incorporated by reference from our 2011 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000018/pfe-12312013xex1016.htm"><span style="font-family:Arial;font-size:9pt;">10.23</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment to Amended and Restated Wyeth Supplemental Employee Savings Plan, dated June 20, 2013, is incorporated by reference from our 2013 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/0000950116-97-000605.txt"><span style="font-family:Arial;font-size:9pt;">10.24</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The form of Indemnification Agreement with each of our non-employee Directors is incorporated by reference from our 1996 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/0000940180-98-000332.txt"><span style="font-family:Arial;font-size:9pt;">10.25</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The form of Indemnification Agreement with each of the Named Executive Officers identified in our Proxy Statement for the 2019 Annual Meeting of Shareholders is incorporated by reference from our 1997 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800307000213/ex101822.htm"><span style="font-family:Arial;font-size:9pt;">10.26</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Letter to Frank A. D&#8217;Amelio regarding replacement pension benefit dated August 22, 2007 is incorporated by reference from our Current Report on Form 8-K filed on August 22, 2007 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800309000024/exhf09.htm"><span style="font-family:Arial;font-size:9pt;">10.27</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Inc. Executive Severance Plan is incorporated by referenced from our Current Report on Form 8-K filed on February 20, 2009 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit1026x12312018x1.htm"><span style="font-family:Arial;font-size:9pt;">10.28</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 1 to the Pfizer Inc. Executive Severance Plan is incorporated by reference from our 2018 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh1029x12312019x1.htm"><span style="font-family:Arial;font-size:9pt;">10.29</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Amendment No. 2 to the Pfizer Inc. Executive Severance Plan.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312509040568/dex1022.htm"><span style="font-family:Arial;font-size:9pt;">10.30</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Annual Retainer Unit Award Plan (for Non-Employee Directors) (frozen as of March 1, 2006) as amended, is incorporated by reference from our 2008 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800314000046/pfe-9282014x10qexhibit102.htm"><span style="font-family:Arial;font-size:9pt;">10.31</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Nonfunded Deferred Compensation and Unit Award Plan for Non-Employee Directors, as amended, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended September 28, 2014 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800309000235/ex1009.htm"><span style="font-family:Arial;font-size:9pt;">10.32</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Form of Special Award Letter Agreement is incorporated by reference from our Current Report on Form 8-K filed on October 28, 2009 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000115752311003088/a6715256ex10-1.htm"><span style="font-family:Arial;font-size:9pt;">10.33</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Offer Letter to G. Mikael Dolsten, dated April 6, 2009, is incorporated by reference from our Quarterly Report on Form 10-Q for the period ended April 3, 2011 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit1026x123120.htm"><span style="font-family:Arial;font-size:9pt;">10.34</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Form of Special Performance-Based Incentive Award Letter is incorporated by reference from our 2017 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800318000027/pfe-exhibit1027x123120.htm"><span style="font-family:Arial;font-size:9pt;">10.35</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Form of Special Performance-Based Incentive Grant Letter is incorporated by reference from our 2017 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000093041319000953/c93082_def14a.htm#x2_c93082a060"><span style="font-family:Arial;font-size:9pt;">10.36</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Pfizer Inc. 2019 Stock Plan is incorporated by reference from our Proxy Statement for the 2019 Annual Meeting of Shareholders (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000007800319000015/pfe-exhibit1033x12312018x1.htm"><span style="font-family:Arial;font-size:9pt;">10.37</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Time Sharing Agreement, dated December 17, 2018, by and between Pfizer Inc. and Ian C. Read is incorporated by reference from our 2018 Annual Report on Form 10-K (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="http://www.sec.gov/Archives/edgar/data/78003/000119312519319205/d599655dex101.htm"><span style="font-family:Arial;font-size:9pt;">10.38</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Consulting Agreement, dated December 13, 2019, between Ian C. Read and Pfizer Inc. is incorporated by reference from our Current Report on Form 8-K filed on December 19, 2019 (File No. 001-03619).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exhibit13x12312019.htm"><span style="font-family:Arial;font-size:9pt;">13</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Portions of the 2019 Financial Report, which, except for those sections incorporated by reference, are furnished solely for the information of the SEC and are not to be deemed &#8220;filed.&#8221;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exhibit21x12312019.htm"><span style="font-family:Arial;font-size:9pt;">21</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Subsidiaries of the Company.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exhibit23x12312019.htm"><span style="font-family:Arial;font-size:9pt;">23</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Consent of Independent Registered Public Accounting Firm.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="font-family:Arial;font-size:9pt;" href="#s04549B44969F5EEB9DF3B65DC67F53F3"><span style="font-family:Arial;font-size:9pt;">24</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Power of Attorney (included as part of signature page).</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh311x1231201910k.htm"><span style="font-family:Arial;font-size:9pt;">31.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certification by the Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh312x1231201910k.htm"><span style="font-family:Arial;font-size:9pt;">31.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certification by the Chief Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh321x1231201910k.htm"><span style="font-family:Arial;font-size:9pt;">32.1</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*</span><a style="text-decoration:underline;color:#0000FF;-sec-extract:exhibit;" href="pfe-exh322x1231201910k.htm"><span style="font-family:Arial;font-size:9pt;">32.2</span></a></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Exhibit 101:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*101.INS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*101.SCH</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inline XBRL Taxonomy Extension Schema</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*101.CAL</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inline XBRL Taxonomy Extension Calculation Linkbase</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:88%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*101.LAB</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inline XBRL Taxonomy Extension Label Linkbase</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*101.PRE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inline XBRL Taxonomy Extension Presentation Linkbase</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">*101.DEF</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Inline XBRL Taxonomy Extension Definition Document</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">104</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Cover Page Interactive Data File - the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.</span></div></td></tr></table></div></div><div><a id="s0CCC93D8C6DE5D9C9FB6ABA7AB766AE5"></a></div><div style="line-height:120%;padding-top:12px;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:11%;"></td><td style="width:89%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">ITEM&#160;16.</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">FORM 10-K SUMMARY</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">A Form 10-K summary is provided at the beginning of this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K, with hyperlinked cross-references. This allows users to easily locate the corresponding items in this </span><span style="font-family:Arial;font-size:9pt;">2019</span><span style="font-family:Arial;font-size:9pt;"> Form 10-K, where the disclosure is fully presented. The summary does not include certain Part III information that is incorporated by reference from our </span><span style="font-family:Arial;font-size:9pt;">2020</span><span style="font-family:Arial;font-size:9pt;"> Proxy Statement. </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:9pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:615px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:284px;"></td><td style="width:104px;"></td><td style="width:226px;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #0093d0;"><div style="text-align:right;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">Pfizer Inc.</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:center;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;">2019 Form 10-K</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px dotted #0093d0;border-top:1px dotted #0093d0;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;color:#00497f;font-weight:bold;">48</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s04549B44969F5EEB9DF3B65DC67F53F3"></a></div><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">SIGNATURES</span></div><div style="line-height:120%;text-indent:32px;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Under the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, this report was signed on behalf of the Registrant by the authorized person named below.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:56%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Pfizer Inc.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Dated: February 27, 2020</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">By:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">/S/&#160;&#160;&#160;&#160;MARGARET M. MADDEN</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Margaret M. Madden</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Senior Vice&#160;President&#160;and&#160;Corporate&#160;Secretary</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Chief Governance Counsel</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">We, the undersigned directors and officers of Pfizer Inc., hereby severally constitute Douglas M. Lankler and Margaret M. Madden, and each of them singly, our true and lawful attorneys with full power to them and each of them to sign for us, in our names in the capacities indicated below, any and all amendments to this Annual Report on Form 10-K filed with the Securities and Exchange Commission.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Under the requirements of the Securities Exchange Act of 1934, this report was signed by the following persons on behalf of the Registrant and in the capacities and on the date indicated.</span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Signature</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Title</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;ALBERT BOURLA</span></div><div style="text-align:start;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Albert Bourla</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chairman and Chief Executive Officer</span></div><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">(Principal Executive Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;FRANK A. D&#8217;AMELIO</span></div><div style="text-align:start;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Frank A. D&#8217;Amelio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Chief Financial Officer, Executive Vice President, Business Operations and Global Supply</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;">&#160;</span><span style="font-family:Arial;font-size:9pt;">(Principal Financial Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:start;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;LORETTA V. CANGIALOSI</span></div><div style="text-align:start;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Loretta V. Cangialosi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Senior Vice President&#8212;Controller</span></div><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">(Principal Accounting Officer)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;RONALD E. BLAYLOCK<br/></span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Ronald E. Blaylock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;W. DON CORNWELL<br/></span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">W. Don Cornwell</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:18px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;JOSEPH J. ECHEVARRIA</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Joseph J. Echevarria</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;SCOTT GOTTLIEB</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Scott Gottlieb</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;HELEN H. HOBBS</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Helen H. Hobbs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:30px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><a style="font-family:Arial;font-size:8pt;color:#0093d0;" href="#sCD6DED064D4B590AA026733F024E7C1F"><span style="font-family:Arial;font-size:8pt;color:#0093d0;">TABLE OF CONTENTS</span></a></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:26%;"></td><td style="width:1%;"></td><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:16%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Signature</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Title</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Date</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;JAMES M. KILTS</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">James M. Kilts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;DAN R. LITTMAN</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Dan R. Littman</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;SHANTANU NARAYEN</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Shantanu Narayen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;SUZANNE NORA JOHNSON</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Suzanne Nora Johnson</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">/S/&#160;&#160;&#160;&#160;JAMES C. SMITH</span></div><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">James C. Smith</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">Director</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">February 25, 2020</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div><br/></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-2.4
<SEQUENCE>2
<FILENAME>pfe-exhibit24x12312019.htm
<DESCRIPTION>EXHIBIT 2.4
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFBDB76F261B7E13742B8EE0DC1830F58"></a></div><div><div style="line-height:120%;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 2.4</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">AMENDMENT NO. 1 TO THE <br>SEPARATION AND DISTRIBUTION AGREEMENT</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This Amendment No. 1 (this &#8220;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Amendment</font><font style="font-family:Arial;font-size:9pt;">&#8221;) to the Separation and Distribution Agreement, dated as of July 29, 2019 (the &#8220;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Agreement</font><font style="font-family:Arial;font-size:9pt;">&#8221;), is made as of February 18, 2020, by and between Pfizer Inc., a Delaware corporation (&#8220;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Pfizer</font><font style="font-family:Arial;font-size:9pt;">&#8221;), and Upjohn Inc., a Delaware corporation and wholly owned Subsidiary of Pfizer (&#8220;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Upjohn</font><font style="font-family:Arial;font-size:9pt;">&#8221;, and together with Pfizer, the &#8220;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Parties</font><font style="font-family:Arial;font-size:9pt;">&#8221;, and each, a &#8220;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Party</font><font style="font-family:Arial;font-size:9pt;">&#8221;). </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">WHEREAS, the Parties entered into the Agreement on July 29, 2019; </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">WHEREAS, in accordance with the terms and conditions of the Agreement, the Parties now wish to amend the Agreement in the manner set forth in this Amendment; and</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">WHEREAS, in accordance with Section 10.03 of the Agreement, the Parties have obtained the prior written consent of Mylan N.V., a public company with limited liability incorporated under the laws of the Netherlands, to amend the Agreement as set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">NOW, THEREFORE, in consideration of the foregoing recitals and other good and valuable consideration, the receipt, adequacy and sufficiency of which is hereby acknowledged by each Party, the Parties hereto agree as follows:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:16px;text-align:left;text-indent:96px;"><font style="padding-bottom:16px;text-align:left;font-family:Arial;font-size:9pt;padding-right:96px;">SECTION 1.  </font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Definitions</font><font style="font-family:Arial;font-size:9pt;">. Capitalized terms used in this Amendment but not defined herein shall have the meanings given to them in the Agreement.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SECTION 2.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Amendment to the Agreement</font><font style="font-family:Arial;font-size:9pt;">. Section 1.01 of the Agreement is hereby amended to replace the definition of the term &#8220;Closing Working Capital Target&#8221; with the following: </font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;padding-left:144px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">&#8220;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Closing Working Capital Target</font><font style="font-family:Arial;font-size:9pt;">&#8221; means $902,000,000.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SECTION 3.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Limited Amendment</font><font style="font-family:Arial;font-size:9pt;">. Each Party acknowledges and agrees that this Amendment constitutes an instrument in writing duly signed by the Parties under Section 10.03 of the Agreement. Except as specifically amended hereby, the Agreement shall continue in full force and effect in accordance with the provisions thereof as in existence on the date hereof. From and after the date hereof, all references to the Agreement, and each reference in the Agreement to &#8220;this Agreement,&#8221; &#8220;hereof,&#8221; &#8220;herein,&#8221; &#8220;hereby,&#8221; &#8220;hereto,&#8221; &#8220;herewith,&#8221; &#8220;hereunder&#8221; and derivative or similar words, shall refer to the Agreement as amended hereby. Each reference in the Agreement, as amended hereby, to &#8220;the date of this Agreement&#8221; or any similar reference, shall continue to refer to July 29, 2019.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SECTION 4.  </font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">Miscellaneous</font><font style="font-family:Arial;font-size:9pt;">. The provisions of Article VII and Article X of the Agreement shall apply to this Amendment, </font><font style="font-family:Arial;font-size:9pt;font-style:italic;">mutatis mutandis</font><font style="font-family:Arial;font-size:9pt;">, and are incorporated by reference as if fully set forth herein.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">[</font><font style="font-family:Arial;font-size:9pt;font-style:italic;">Signature page follows</font><font style="font-family:Arial;font-size:9pt;">]</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-bottom:16px;text-align:left;text-indent:96px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">IN WITNESS WHEREOF, the Parties have duly executed this Amendment, all as of the day and year first above written.</font></div><div style="line-height:120%;padding-bottom:16px;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:55.98290598290598%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:16%;"></td><td style="width:84%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">PFIZER INC. </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">By:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ DOUGLAS E. GIORDANO</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Name: Douglas E. Giordano</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Title:   Senior Vice President, Worldwide Business Development</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:right;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;text-align:-moz-right;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:55.98290598290598%;border-collapse:collapse;text-align:left;margin-left:auto;margin-right:0;"><tr><td colspan="2"></td></tr><tr><td style="width:16%;"></td><td style="width:84%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">UPJOHN INC. </font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">By:</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">/s/ BRYAN A. SUPRAN</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Name: Bryan A. Supran</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Title:   Vice President</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.21
<SEQUENCE>3
<FILENAME>pfe-exhibit421x123119x.htm
<DESCRIPTION>EXHIBIT 4.21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s5CAAE0A28D3D2939FD3D603C834EE9B0"></a></div><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 4.21</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DESCRIPTION OF THE REGISTRANT&#8217;S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As of February 27, 2020, Pfizer Inc. has common stock, the 0.000% Notes due 2020 (the 2020 notes), the 0.250% Notes due 2022 (the 2022 notes) and the 1.000% Notes due 2027 (the 2027 notes and together with the 2020 notes and the 2022 notes, the notes) registered under Section 12 of the Securities Exchange Act of 1934, as amended. The following descriptions of our common stock and the notes are summaries and do not purport to be complete. The description of our common stock is subject to and qualified in its entirety by reference to our restated certificate of incorporation, as amended (the Certificate of Incorporation), and our bylaws, as amended (the Bylaws), and the description of the notes is subject to and qualified in its entirety by reference to the base indenture (as defined below) and the ninth supplemental indenture (as defined below), each of which are incorporated by reference as an exhibit to the Annual Report on Form 10-K of which this Exhibit 4.21 is a part. We encourage you to read our Certificate of Incorporation, our Bylaws, the applicable provisions of the Delaware General Corporation Law (the DGCL), the base indenture and the ninth supplemental indenture for additional information. References in this section to &#8220;Pfizer,&#8221; &#8220;we,&#8221; &#8220;us&#8221; and &#8220;our&#8221; are to Pfizer Inc., unless otherwise stated or the context so requires.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DESCRIPTION OF CAPITAL STOCK</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Common Stock</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the Certificate of Incorporation, we are authorized to issue up to 12&#160;billion shares of common stock, par value $0.05 per share. The common stock is not redeemable, does not have any conversion rights and is not subject to call. Holders of shares of common stock have no preemptive rights to maintain their percentage of ownership in future offerings or sales of our stock. Holders of shares of common stock have one vote per share in all elections of Directors and on all other matters submitted to a vote of our stockholders. The holders of common stock are entitled to receive dividends, if any, as and when may be declared from time to time by our Board of Directors, out of funds legally available therefor. Upon liquidation, dissolution or winding up of our affairs, the holders of common stock will be entitled to participate equally and ratably, in proportion to the number of shares held, in our net assets available for distribution to holders of common stock. The shares of common stock currently outstanding are fully paid and nonassessable. The common stock is traded on the New York Stock Exchange under the trading symbol &#8220;PFE.&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Preferred Stock</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the Certificate of Incorporation, we are authorized to issue up to 27&#160;million shares of preferred stock, without par value, of which 7,500&#160;shares of preferred stock have been designated Series A convertible perpetual preferred stock. The preferred stock may be issued in one or more series, and the Board of Directors of Pfizer is expressly authorized (i)&#160;to fix the descriptions, powers, preferences, rights, qualifications, limitations, and restrictions with respect to any series of preferred stock and (ii)&#160;to specify the number of shares of any series of preferred stock. </font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Series&#160;A Convertible Perpetual Preferred Stock</font><font style="font-family:Arial;font-size:10pt;">. Our Series&#160;A convertible perpetual preferred stock is held by an Employee Stock Ownership Plan (Preferred ESOP) Trust and provides dividends in an amount not </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">to exceed 6.25% of the stated value, which are paid quarterly. The stated value is $40,300 per share, and the Series A convertible perpetual preferred stock ranks senior to our common stock and junior to all other preferred stock as to dividends and liquidation rights, unless designated as ranking senior or on a parity with the new preferred stock. Each share is convertible, at the holder&#8217;s option, at a conversion rate initially equivalent to 2,574.8685&#160;shares of our common stock for each preferred share converted, subject to adjustment. Each share of Series&#160;A convertible perpetual preferred stock is entitled to a number of votes equal to the number of shares of common stock into which such convertible perpetual preferred stock could be converted on the record date for determining the stockholders entitled to vote in any matter submitted to the stockholders to vote. The holders of Series&#160;A convertible perpetual preferred stock are entitled to vote on all matters submitted to a vote of the stockholders, voting together with the holders of common stock as one class. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the Series&#160;A convertible perpetual preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of $40,300 per share, plus any accrued and unpaid dividends to the redemption date. We will also redeem the Series&#160;A convertible perpetual preferred stock in cash, or at our election, in shares of common stock, or a combination of any shares of common stock to be valued at their fair market value, at a price of $40,300 per share, upon certification of the holder to us of certain events. Holders of Series&#160;A convertible perpetual preferred stock have no preemptive rights to maintain their percentage of ownership in future offerings or sales of our stock.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Anti-takeover Effects of the Certificate of Incorporation,&#160;By-laws&#160;and Delaware Law</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Certificate of Incorporation and&#160;Bylaws</font><font style="font-family:Arial;font-size:10pt;">. Various provisions contained in the Certificate of Incorporation and the&#160;Bylaws&#160;could delay or discourage some transactions involving an actual or potential change in control of us or a change in our management and may limit the ability of our stockholders to remove current management or approve transactions that our stockholders may deem to be in their best interests. Among other things, these provisions:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">limit the right of stockholders to call special meetings of stockholders to holders of at least 10% of the total number of shares of stock entitled to vote on the matter to be brought before the proposed special meeting;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">authorize our Board of Directors to establish one or more series of preferred stock without stockholder approval;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">authorize the Board to issue dividends in the form of stock purchase or similar rights, including rights that would have the effect of making an attempt to acquire us more costly;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">grant to the Board of Directors, and not to the stockholders, the sole power to set the number of Directors;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">require that any action required or permitted to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and may not be effected by any consent in writing; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">subject to the rights of the holders of any one or more series of preferred stock then outstanding, allow our Directors, and not our stockholders, to fill vacancies on our Board of </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-left:72px;padding-bottom:16px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">Directors, including vacancies resulting from the removal of one or more Directors or an increase in the number of Directors constituting the whole Board of Directors.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Delaware Law</font><font style="font-family:Arial;font-size:10pt;">. We are a Delaware corporation and consequently are also subject to certain anti-takeover provisions of the DGCL. Subject to certain exceptions, Section&#160;203 of the DGCL prevents a publicly-held Delaware corporation from engaging in a &#8220;business combination&#8221; with any &#8220;interested stockholder&#8221; for three years following the date that the person became an interested stockholder, unless (a)&#160;the interested stockholder attained such status with the approval of the corporation&#8217;s board of directors, (b)&#160;upon consummation of the transaction that resulted in the stockholder becoming an interested stockholder, the interested stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, exclusive of shares owned by directors who are also officers and by certain employee stock plans or (c)&#160;at or subsequent to such time, the business combination is approved by the board of directors and authorized by the affirmative vote at a stockholders&#8217; meeting, and not by written consent, of at least 66-2/3% of the outstanding voting stock which is not owned by the interested stockholder. A &#8220;business combination&#8221; includes, among other things, a merger or consolidation involving the corporation and the &#8220;interested stockholder&#8221; and the sale of more than 10% of the corporation&#8217;s assets. In general, an &#8220;interested stockholder&#8221; is any entity or person beneficially owning 15% or more of the corporation&#8217;s outstanding voting stock, and any entity or person affiliated with or controlling or controlled by such entity or person. Section&#160;203 makes it more difficult for an interested stockholder to effect various business combinations with a corporation for a three-year period. This statute could prohibit or delay mergers or other takeover or change in control attempts not approved in advance by our Board of Directors, and, as a result, could discourage attempts to acquire us, which could depress the market price of our common stock.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">DESCRIPTION OF DEBT SECURITIES</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Reference should be made to the indenture dated as of January 30, 2001, between Pfizer and The Bank of New York Mellon (formerly known as The Bank of New York), as successor to JPMorgan Chase Bank (formerly known as The Chase Manhattan Bank), as trustee, which we refer to as the &#8220;base indenture,&#8221; as supplemented by the ninth supplemental indenture dated as of March 6, 2017, among Pfizer Inc., The Bank of New York Mellon, as trustee, and The Bank of New York Mellon, London Branch, as paying agent, which we refer to as the &#8220;ninth supplemental indenture.&#8221; When we refer to the &#8220;indenture,&#8221; we mean the base indenture, as supplemented by the ninth supplemental indenture. The following description is a summary of selected portions of the base indenture and the ninth supplemental indenture. It does not restate the base indenture or the ninth supplemental indenture, and those documents, not this description, define the rights of a holder of the notes.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Principal, Maturity and Interest</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The 2020 notes were limited to &#8364;1,000,000,000 aggregate principal amount, the 2022 notes were limited to &#8364;1,000,000,000 aggregate principal amount and the 2027 notes were limited to &#8364;750,000,000 aggregate principal amount. The 2020 Notes will mature on March 6, 2020, the 2022 notes will mature on March 6, 2022 and the 2027 notes will mature on March 6, 2027. We issued the notes in denominations of &#8364;100,000 and in integral multiples of &#8364;1,000 in excess thereof.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Interest on the 2020 notes accrues at the annual rate of 0.000%, interest on the 2022 notes accrues at the annual rate of 0.250% and interest on the 2027 notes accrues at the annual rate of 1.000%. Interest on the notes is payable on March 6 of each year. Interest on the notes is computed on the basis of the </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">actual number of days in the period for which interest is being calculated and the actual number of days from and including the last date on which interest was paid on the notes to, but excluding, the next scheduled interest payment date. This payment convention is referred to as ACTUAL/ACTUAL (ICMA) (as defined in the rulebook of the International Capital Market Association).</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We make each interest payment to the holders of record of the notes at the close of business on the 15th calendar day (whether or not a business day) preceding the relevant interest payment date.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Bank of New York Mellon, London Branch, acts as our paying agent with respect to the notes. Upon notice to the trustee, we may change any paying agent. Payments of principal, interest and premium, if any, will be made by us through the paying agent to Euroclear Bank S.A./N.V. (the &#8220;Euroclear Operator&#8221;), as operator of the Euroclear System (&#8220;Euroclear&#8221;) and/or Clearstream Banking, Soci&#233;t&#233; Anonyme, Luxembourg (&#8220;Clearstream&#8221;) as described under &#8220;&#8212;Book-Entry.&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Issuance in Euros</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Principal, premium, if any, and interest payments and additional amounts, if any, in respect of the notes are payable in euros.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If the euro is unavailable to us due to the imposition of exchange controls or other circumstances beyond our control or the euro is no longer used by the then member states of the European Monetary Union that have adopted the euro as their currency or for the settlement of transactions by public institutions within the international banking community, then all payments in respect of the notes will be made in U.S. dollars until the euro is again available to us or so used. In such circumstances, the amount payable on any date in euros will be converted to U.S. dollars on the basis of the most recently available market exchange rate for euros, as determined by us in our sole discretion. Any payment in respect of the notes so made in U.S. dollars does not constitute an event of default under the indenture or the notes. Neither the trustee nor the paying agent is responsible for obtaining exchange rates, effecting conversions or otherwise handling redenominations.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Payment of Additional Amounts</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">All payments in respect of the notes are made by or on behalf of us without withholding or deduction for, or on account of, any present or future taxes, duties, assessments or governmental charges of whatever nature, imposed or levied by the United States or any taxing authority thereof or therein, unless such withholding or deduction is required by law. If such withholding or deduction is required by law, we pay to a beneficial owner who is not a United States person such additional amounts on the notes as are necessary in order that the net payment of the principal of, and premium or redemption price, if any, and interest on, such notes to such beneficial owner, after such withholding or deduction (including any withholding or deduction on such additional amounts), will not be less than the amount provided in such notes to be then due and payable; provided, however, that the foregoing obligation to pay additional amounts will not apply:</font></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;"><font style="padding-bottom:16px;padding-top:16px;text-align:left;font-family:Arial;font-size:10pt;padding-right:48px;">(a)</font><font style="font-family:Arial;font-size:10pt;">to any tax, assessment or other governmental charge that would not have been imposed but for the beneficial owner, or a fiduciary, settlor, beneficiary, member or shareholder of the beneficial owner if the beneficial owner is an estate, trust, partnership or corporation, or a person holding a power over an estate or trust administered by a fiduciary holder, being considered as (i) having a current or former connection with the United States (other than a connection arising solely as a result of the </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-left:0px;padding-bottom:16px;padding-top:16px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">ownership of such notes, the receipt of any payment or the enforcement of any rights thereunder), including being or having been a citizen or resident of the United States, or being or having been engaged in a trade or business in the United States or having or having had a permanent establishment in the United States; (ii) being a controlled foreign corporation related to Pfizer directly, indirectly or constructively through stock ownership for U.S. federal income tax purposes; (iii) being an owner of a 10% or greater interest in voting stock of Pfizer within the meaning of Section 871(h)(3) of the U.S. Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) or any successor provision; or (iv) being a bank receiving payments on an extension of credit made pursuant to a loan agreement entered into in the ordinary course of its trade or business;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(b)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any holder that is not the sole beneficial owner of such notes, or a portion of such notes, or that is a fiduciary, partnership or limited liability company, but only to the extent that a beneficiary or settlor with respect to the fiduciary, a beneficial owner or a member of the partnership or limited liability company would not have been entitled to the payment of an additional amount had the beneficiary, settlor, beneficial owner or member received directly from Pfizer its beneficial or distributive share of the payment;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(c)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any tax, assessment or other governmental charge imposed by reason of the holder&#8217;s or beneficial owner&#8217;s past or present status as a passive foreign investment company, a controlled foreign corporation, a foreign tax exempt organization or a personal holding company with respect to the United States or as a corporation that accumulates earnings to avoid U.S. federal income tax;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(d)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any tax, assessment or other governmental charge that would not have been imposed but for the failure of the holder or beneficial owner of the applicable notes to comply with any applicable certification, identification or information reporting requirements concerning the nationality, residence, identity or connection with the United States of the holder or beneficial owner of such notes, if compliance is timely requested by Pfizer and required by statute, by regulation of the United States or any taxing authority therein or by an applicable income tax treaty to which the United States is a party as a precondition to exemption from such tax, assessment or other governmental charge;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(e)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any tax, assessment or other governmental charge that is imposed otherwise than by withholding or deducting from the payment;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(f)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any estate, inheritance, gift, sales, transfer, wealth, capital gains or personal property tax or similar tax, assessment or other governmental charge;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(g)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any tax, assessment or other governmental charge required to be withheld by any paying agent from any payment of principal of or interest on any such note, if such payment can be made without such withholding by at least one other paying agent in a Member State of the European Union;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(h)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any tax, assessment or other governmental charge that is imposed or withheld solely by reason of a change in law, regulation, or administrative or judicial interpretation that becomes effective more than 15 days after the payment becomes due or is duly provided for, whichever occurs later;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(i)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any tax, assessment or other governmental charge that would not have been imposed but for the presentation by the holder of any note, where presentation is required, for payment on a date more than 30 days after the date on which payment became due and payable or the date on which payment thereof is duly provided for, whichever occurs later, except to the extent that the holder or </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">beneficial owner thereof would have been entitled to additional amounts had the note been presented for payment on the last day of such 30 day period;</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(j)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">to any withholding or deduction that is imposed on a payment pursuant to Sections 1471 through 1474 of the Code and related Treasury regulations and pronouncements or any successor provisions thereto (that are substantively comparable and not materially more onerous to comply with) and any regulations or official law, agreement or interpretations thereof in any jurisdiction implementing an intergovernmental approach thereto; or</font></div><div style="line-height:138%;padding-bottom:16px;padding-top:16px;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">(k)</font><font style="font-family:inherit;font-size:10pt;">&#160;&#160;&#160;&#160;</font><font style="font-family:Arial;font-size:10pt;">in the case of any combination of the above listed items.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Except as specifically provided under this heading &#8220;&#8212;Payment of Additional Amounts,&#8221; we are not required to make any payment for any tax, duty, assessment or governmental charge of whatever nature imposed by any government or a political subdivision or taxing authority of or in any government or political subdivision.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As used under this heading &#8220;&#8212;Payment of Additional Amounts&#8221; and under the heading &#8220;&#8212;Optional Redemption of 2022 Notes and 2027 Notes; Redemption for Tax Reasons; No Sinking Fund,&#8221; the term &#8220;United States&#8221; means the United States of America, any state thereof, and the District of Columbia, and the term &#8220;United States person&#8221; means (i) any individual who is a citizen or resident of the United States for U.S. federal income tax purposes, (ii) a corporation, partnership or other entity created or organized in or under the laws of the United States, any state thereof or the District of Columbia (other than a partnership that is not treated as a United States person for U.S. federal income tax purposes), (iii) any estate the income of which is subject to U.S. federal income taxation regardless of its source, or (iv) any trust if a U.S. court can exercise primary supervision over the administration of the trust and one or more United States persons can control all substantial trust decisions, or if a valid election is in place to treat the trust as a United States person.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Ranking</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The notes are unsecured general obligations of Pfizer and rank equally with all other unsecured and unsubordinated indebtedness of Pfizer from time to time outstanding.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Listing</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The notes are listed on the NYSE. We have no obligation to maintain such listing, and we may delist the notes at any time.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Covenants</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The indenture contains a provision that restricts our ability to consolidate with or merge into any other person or convey or transfer our properties and assets as an entirety or substantially as an entirety to any other person. The indenture does not restrict our ability to convey or transfer our properties and assets other than as an entirety or substantially as an entirety to any other person. See &#8220;Article VIII - Consolidation, Merger, Conveyance or Transfer&#8221; in the base indenture. The indenture contains no other restrictive covenants, including those that would afford holders of the notes protection in the event of a highly-leveraged transaction involving Pfizer or any of its affiliates or other events involving us that may adversely affect our creditworthiness or the value of the notes. The indenture also does not contain any </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">covenants relating to total indebtedness, interest coverage, stock repurchases, recapitalizations, dividends and distributions to shareholders, current ratios or acquisitions and divestitures. The notes do not have the benefit of covenants that relate to subsidiary guarantees, liens and sale leaseback transactions that apply to other of our existing unsecured and unsubordinated notes.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer may, without the consent of the holders of notes of any series, issue additional notes having the same ranking and the same interest rate, maturity and other terms as the notes of any series (except for the issue date and the public offering price). Any additional notes having such similar terms, together with the notes of the applicable series, will constitute a single series of debt securities under the indenture. No additional notes of any series may be issued if an event of default has occurred with respect to the notes of that series. Pfizer will not issue any additional notes intended to form a single series with the notes of any series, unless such further notes will be fungible with all notes of the same series for U.S. federal income tax purposes.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Optional Redemption of 2022 Notes and 2027 Notes; Redemption for Tax Reasons; No Sinking Fund</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At our option, we may redeem the 2022 notes or the 2027 notes (together, the redemption notes), in whole, at any time, or in part, from time to time, prior to February 6, 2022 (one month prior to the maturity date) with respect to the 2022 notes and December 6, 2026 (three months prior to the maturity date) with respect to the 2027 notes. The redemption price will be equal to the greater of the following amounts:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">100% of the principal amount of the redemption notes being redeemed on the redemption date; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the sum of the present values of the remaining scheduled payments of principal and interest on the redemption notes being redeemed on that redemption date (not including the amount, if any, of accrued and unpaid interest to, but excluding, the redemption date) discounted to the redemption date on an annual basis at a rate equal to the sum of the Comparable Government Bond Rate plus (a) 15 basis points in the case of the 2022 notes and (b) 15 basis points in the case of the 2027 notes;</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">plus, in each case, accrued and unpaid interest on the redemption notes being redeemed to, but excluding, the redemption date.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">At any time on or after February 6, 2022 (one month prior to the maturity date) with respect to the 2022 notes and December 6, 2026 (three months prior to the maturity date) with respect to the 2027 notes, we may redeem such series of redemption notes, in whole or in part, at a redemption price equal to 100% of the principal amount of the redemption notes to be redeemed, plus in each case, accrued and unpaid interest on the redemption notes being redeemed to, but excluding, the redemption date.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Notwithstanding the foregoing, installments of interest on the applicable redemption notes that are due and payable on interest payment dates falling on or prior to a redemption date will be payable on the interest payment date to the registered holders as of the close of business on the relevant record date according to the applicable redemption notes and the indenture. The redemption prices for the redemption notes will be calculated on the basis of a 365-day year or a 366-day year, as applicable, and the actual number of days elapsed.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We will mail notice of any redemption at least 10 days, but not more than 60 days, before the redemption date to each registered holder of the redemption notes to be redeemed. Once notice of redemption is mailed, the redemption notes called for redemption will become due and payable on the redemption date at the applicable redemption price, plus accrued and unpaid interest applicable to such redemption notes to, but excluding, the redemption date.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;Comparable Government Bond&#8221; means, in relation to any Comparable Government Bond Rate calculation, at the discretion of an Independent Investment Banker, a German government bond whose maturity is closest to the maturity of the redemption notes to be redeemed, or if such independent investment bank in its discretion determines that such similar bond is not in issue, such other German government bond as such Independent Investment Banker may, with the advice of three brokers of, and/or market makers in, German government bonds selected by us, determine to be appropriate for determining the Comparable Government Bond Rate. </font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;Comparable Government Bond Rate&#8221; means the price, expressed as a percentage (rounded to three decimal places, with 0.0005 being rounded upwards), at which the gross redemption yield on the fixed rate notes to be redeemed, if they were to be purchased at such price on the third business day prior to the date fixed for redemption, would be equal to the gross redemption yield on such business day of the Comparable Government Bond on the basis of the middle market price of the Comparable Government Bond prevailing at 11:00 a.m. (London time) on such business day as determined by an Independent Investment Banker.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;Independent Investment Banker&#8221; means one of the Reference Treasury Dealers appointed by us to act as the &#8220;Independent Investment Banker.&#8221;</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">&#8220;Reference Treasury Dealer&#8221; means each of Barclays Bank PLC, BNP Paribas, Goldman, Sachs &amp; Co. and J.P. Morgan Securities plc (or their respective affiliates that are Primary Treasury Dealers), and their respective successors; provided, however, that if any of the foregoing shall cease to be a broker or dealer of, and/or market maker in, German government bonds (a &#8220;Primary Treasury Dealer&#8221;), we will substitute therefor another Primary Treasury Dealer.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">On and after the redemption date, interest will cease to accrue on the redemption notes or any portion of the redemption notes called for redemption (unless we default in the payment of the redemption price and accrued and unpaid interest). On or before the redemption date, we will deposit with a paying agent (or the trustee) money sufficient to pay the redemption price of and accrued and unpaid interest on the redemption notes to be redeemed on that date. If fewer than all of the redemption notes of any series are to be redeemed, the redemption notes to be redeemed shall be selected by Euroclear and/or Clearstream, in the case of redemption notes represented by a global security, or by the trustee by a method the trustee deems to be fair and appropriate, in the case of redemption notes that are not represented by a global security.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The notes are not entitled to the benefit of a sinking fund.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Redemption for Tax Reasons</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If, as a result of any change in, or amendment to, the laws (or any regulations or rulings promulgated under the laws) of the United States (or any taxing authority thereof or therein), or any change in, or amendments to, an official position regarding the application or interpretation of such laws, regulations or </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">rulings, which change or amendment is announced or becomes effective on or after February 28, 2017, we become or, based upon a written opinion of independent tax counsel of recognized standing selected by us, will become obligated to pay additional amounts as described herein under the heading &#8220;&#8212;Payment of Additional Amounts&#8221; with respect to any series of the notes, then we may at our option, having given not less than 10 nor more than 60 days prior notice to holders, redeem, in whole, but not in part, the applicable series of notes at a redemption price equal to 100% of the principal amount, together with accrued and unpaid interest (including any additional amounts) on such notes to, but excluding, the redemption date.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Book-Entry</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Global Clearance and Settlement</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The notes of each series were issued in the form of one or more global notes in fully registered form, without coupons, and are deposited with, or on behalf of, a common depositary, and registered in the name of the nominee of the common depositary, for, and in respect of interests held through, Euroclear and Clearstream. Except as described herein, certificates will not be issued in exchange for beneficial interests in the global notes representing the notes.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Except as set forth below, the global notes representing the notes may be transferred, in whole and not in part, only to Euroclear or Clearstream or their respective nominees.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Beneficial interests in the global notes representing the notes are represented, and transfers of such beneficial interests are effected, through accounts of financial institutions acting on behalf of beneficial owners as direct or indirect participants in Euroclear or Clearstream. Those beneficial interests are in denominations of &#8364;100,000 and integral multiples of &#8364;1,000 in excess thereof. Investors may hold the notes directly through Euroclear or Clearstream, if they are participants in such systems, or indirectly through organizations that are participants in such systems.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">For so long as any series of the notes is represented by a global note deposited with, and registered in the name of a nominee for, a common depositary for Euroclear and/or Clearstream, each person (other than Euroclear or Clearstream) who is for the time being shown in the records of Euroclear or of Clearstream as the holder of a particular nominal amount of the notes (in which regard any certificate or other document issued by Euroclear or Clearstream as to the nominal amount of the notes standing to the account of any person shall be conclusive and binding for all purposes save in the case of manifest error) shall upon their receipt of a certificate or other document be treated by Pfizer and the trustee as the holder of such nominal amount of the notes and the registered holder of the global note representing such notes shall be deemed not to be the holder for all purposes other than with respect to the payment of principal or interest on such nominal amount of the notes, for which purpose the registered holder of the relevant global note shall be treated by Pfizer and the trustee as the holder of such nominal amount of notes in accordance with and subject to the terms of the global note representing the notes, and the expressions &#8220;noteholder&#8221; and &#8220;holder of notes&#8221; and related expressions shall be construed accordingly.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The information in this section concerning Euroclear and Clearstream Banking and their book-entry systems and procedures has been obtained from sources that we believe to be reliable. We are not responsible for the accuracy or completeness of this information.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We have been advised by Clearstream and Euroclear, respectively, as follows:</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clearstream has advised that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It is incorporated under the laws of Luxembourg and licensed as a bank and professional depositary. Clearstream holds securities for its participating organizations and facilitates the clearance and settlement of securities transactions among its participants through electronic book-entry changes in accounts of its participants, thereby eliminating the need for physical movement of certificates.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clearstream provides to its participants, among other things, services for safekeeping, administration, clearance and settlement of internationally traded securities and securities lending and borrowing. Clearstream interfaces with domestic markets in several countries.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clearstream has established an electronic bridge with the Euroclear Operator to facilitate the settlement of trades between the nominees of Clearstream and Euroclear.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">As a registered bank in Luxembourg, Clearstream is subject to regulation by the Luxembourg Commission for the Supervision of the Financial Sector.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clearstream customers are recognized financial institutions around the world, including underwriters, securities brokers and dealers, banks, trust companies, clearing corporations and certain other organizations and may include the underwriters. Indirect access to Clearstream is also available to others, such as banks, brokers, dealers and trust companies that clear through, or maintain a custodial relationship with, a Clearstream participant, either directly or indirectly.</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distributions with respect to the notes held beneficially through Clearstream will be credited to cash accounts of Clearstream participants in accordance with its rules and procedures.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Euroclear has advised that:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">It was created in 1968 to hold securities for its participants and to clear and settle transactions between Euroclear participants through simultaneous electronic book-entry delivery against payment, thereby eliminating the need for physical movement of certificates and any risk from lack of simultaneous transfers of securities and cash.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Euroclear includes various other services, including securities lending and borrowing and interfaces with domestic markets in several countries.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Euroclear is operated by the Euroclear Operator. All operations are conducted by the Euroclear Operator, and all Euroclear securities clearance accounts and Euroclear cash accounts are accounts with the Euroclear Operator.</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Securities clearance accounts and cash accounts with the Euroclear Operator are governed by the Terms and Conditions Governing Use of Euroclear and the related operating procedures of Euroclear, and applicable Belgian law (collectively, the &#8220;Terms and Conditions&#8221;). The Terms and Conditions govern transfers of securities and cash within Euroclear, withdrawals of securities and cash from Euroclear, and receipts of payments with respect to securities in Euroclear. All securities in Euroclear are held on a fungible basis without attribution of specific certificates to specific securities clearance accounts. The </font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-left:72px;padding-bottom:16px;text-align:left;"><font style="font-family:Arial;font-size:10pt;">Euroclear Operator acts under the Terms and Conditions only on behalf of Euroclear participants, and has no records of or relationship with persons holding through Euroclear participants.</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Euroclear participants include banks (including central banks), securities brokers and dealers and other professional financial intermediaries and may include the underwriters. Indirect access to Euroclear is also available to other firms that clear through or maintain a custodial relationship with a Euroclear participant, either directly or indirectly.</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distributions with respect to the notes held beneficially through Euroclear will be credited to the cash accounts of Euroclear participants in accordance with the Terms and Conditions.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Euroclear and Clearstream Arrangements</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">So long as Euroclear or Clearstream or their nominee or their common depositary is the registered holder of the global notes representing the notes, Euroclear, Clearstream or such nominee, as the case may be, will be considered the sole owner or holder of the notes represented by such global notes for all purposes under the indenture and the notes. Payments of principal, interest and additional amounts, if any, in respect of the global notes representing the notes are made to Euroclear, Clearstream, such nominee or such common depositary, as the case may be, as registered holder thereof. Neither Pfizer nor the trustee, or any affiliate of any of the above or any person by whom any of the above is controlled (as such term is defined in the Securities Act) has any responsibility or liability for any records relating to or payments made on account of beneficial ownership interests in the global notes representing the notes or for maintaining, supervising or reviewing any records relating to such beneficial ownership interests.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distributions of principal, premium, if any, and interest with respect to the global notes representing the notes are credited in euros to the extent received by Euroclear or Clearstream from the paying agent to the cash accounts of Euroclear or Clearstream customers in accordance with the relevant system&#8217;s rules and procedures.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because Euroclear and Clearstream can only act on behalf of participants, who in turn act on behalf of indirect participants, the ability of a person having an interest in the global notes representing the notes to pledge such interest to persons or entities which do not participate in the relevant clearing system, or otherwise take actions in respect of such interest, may be affected by the lack of a physical certificate in respect of such interest.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Secondary Market Trading</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Because the purchaser determines the place of delivery, it is important to establish at the time of trading of any notes where both the purchaser&#8217;s and seller&#8217;s accounts are located to ensure that settlement can be made on the desired value date.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We understand that secondary market trading between Clearstream and/or Euroclear participants occurs in the ordinary way following the applicable rules and operating procedures of Clearstream and Euroclear. Secondary market trading is settled using procedures applicable to conventional eurobonds in global registered form.</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The holder of the notes should be aware that investors are only able to make and receive deliveries, payments and other communications involving the notes through Clearstream and Euroclear on days when those systems are open for business. Those systems may not be open for business on days when banks, brokers and other institutions are open for business in the United States.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In addition, because of time-zone differences, there may be problems with completing transactions involving Clearstream and Euroclear on the same business day as in the United States. U.S. investors who wish to transfer their interests in the notes, or to make or receive a payment or delivery of the notes, on a particular day, may find that the transactions  are not performed until the next business day in Luxembourg or Brussels, depending on whether Clearstream or Euroclear is used.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clearstream or Euroclear credits payments to the cash accounts of Clearstream customers or Euroclear participants, as applicable, in accordance with the relevant system&#8217;s rules and procedures, to the extent received by its depositary. Clearstream or the Euroclear Operator, as the case may be, takes any other action permitted to be taken by a holder under the indenture on behalf of a Clearstream customer or Euroclear participant only in accordance with its relevant rules and procedures.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Clearstream and Euroclear have agreed to the foregoing procedures in order to facilitate transfers of the notes among participants of Clearstream and Euroclear. However, they are under no obligation to perform or continue to perform those procedures, and they may discontinue those procedures at any time.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-style:italic;">Exchange of Global Notes for Certificated Notes</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Subject to certain conditions, the notes represented by the global notes are exchangeable for certificated notes in definitive form of like tenor in minimum denominations of &#8364;100,000 principal amount and multiples of &#8364;1,000 in excess thereof if:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the common depositary notifies us that it is no longer willing or able to act as a depositary for such global notes or ceases to be a clearing agency registered under the Exchange Act and we fail to appoint a successor common depositary within 90 days;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">an event of default has occurred and is continuing and the common depositary requests the issuance of certificated notes; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we determine not to have the notes represented by a global note.</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">In all cases, certificated notes delivered in exchange for any global note or beneficial interest therein will be registered in the names, and issued in any approved denominations, requested by or on behalf of the common depositary (in accordance with its customary procedures).</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Payments (including principal, premium and interest) and transfers with respect to the notes in certificated form may be executed at the office or agency maintained for such purpose in London (initially the corporate trust office of the paying agent) or, at our option, by check mailed to the holders thereof at the respective addresses set forth in the register of holders of the notes (maintained by the registrar), provided that all payments (including principal, premium and interest) on the notes in certificated form, for which the holders thereof have given wire transfer instructions, are required to be made by wire transfer of immediately available funds to the accounts specified by the holders thereof. No service charge is </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">made for any registration of transfer, but payment of a sum sufficient to cover any tax or governmental charge payable in connection with such registration may be required.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Modification of Indenture</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Under the indenture, the rights of the holders of the notes may be modified through a supplemental indenture if the holders of a majority in aggregate principal amount of the outstanding notes of all series affected by the modification (voting as one class) consent to it. No modification of the maturity date or principal or interest payment terms, no modification of the currency for payment, no impairment of the right to sue for the enforcement of payment at the maturity of the debt security, no modification of any conversion rights, no modification reducing the percentage required for any such supplemental indenture or the percentage required for the waiver of certain defaults, and no modification of the foregoing provisions or any other provisions relating to the waiver of past defaults or the waiver of certain covenants, is effective against any holder without its consent.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Events of Default</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Each of the following will constitute an Event of Default under the indenture with respect to the notes of the applicable series:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we fail to make the principal or any premium payment on any note of such series when due;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we fail to make any sinking fund payment for 60 days after payment was due by the terms of any note of such series;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we fail to pay interest on any note of such series for 60 days after payment was due;</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we fail to perform any other covenant in the indenture and this failure continues for 90 days after we receive written notice of it; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we, or a court, take certain actions relating to the bankruptcy, insolvency or reorganization of our company.</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">A default under our other indebtedness will not be a default under the indenture for the notes, and a default under one series of the notes will not necessarily be a default under another series. The trustee may withhold notice to the holders of notes of the applicable series of any default (except for defaults that involve our failure to pay principal or interest) if it considers such withholding of notice to be in the best interests of the holders.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If an Event of Default with respect to outstanding notes of any series occurs and is continuing, then the trustee or the holders of at least 33% in principal amount of outstanding  notes of that series may declare, in a written notice, the principal amount (or, if any of the notes of that series are original issue discount securities, such portion of the principal amount of such notes) plus accrued and unpaid interest on all notes of that series to be immediately due and payable. At any time after a declaration of acceleration with respect to notes of any series has been made, the holders of a majority in principal amount of the outstanding notes of such series may rescind and annul the acceleration if:</font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">the holders act before the trustee has obtained a judgment or decree for payment of the money due;</font></div></td></tr></table><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div></div><div><br></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we have paid or deposited with the trustee a sum sufficient to pay overdue interest and overdue principal other than the accelerated interest and principal; and</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we have cured or the holders have waived all Events of Default, other than the non-payment of accelerated principal and interest with respect to notes of that series, as provided in the indenture.</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">If a default in the performance or breach of the indenture shall have occurred and be continuing, the holders of not less than a majority in principal amount of the outstanding notes of all series affected thereby, by notice to the trustee, may waive any past Event of Default or its consequences under the indenture. However, an Event of Default cannot be waived with respect to any series of notes in the following two circumstances: </font></div><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a failure to pay the principal of, and premium, if any, or interest on any security or in the payment of any sinking fund installment; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:16px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:72px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:48px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">a covenant or provision that cannot be modified or amended without the consent of each holder of outstanding notes of that series.</font></div></td></tr></table><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Other than its duties in case of a default, the trustee is not obligated to exercise any of its rights or powers under the indenture at the request, order or direction of any holders, unless the holders offer the trustee reasonable indemnity. Holders of a majority in principal amount outstanding of any series of notes may, subject to certain limitations, direct the time, method and place of conducting any proceeding or any remedy available to the trustee, or exercising any power conferred upon the trustee, for such applicable series of notes.</font></div><div style="line-height:138%;padding-bottom:13px;padding-top:16px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">We are required to deliver an annual officers&#8217; certificate to the trustee, stating whether we are in default in the performance and observance of any of the terms, provisions and conditions of the indenture, and, if we are in default, specifying all such defaults and the nature and status thereof.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Defeasance</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">When we use the term defeasance, we mean discharge from some or all of our obligations under the indenture. Subject to certain additional conditions, if we irrevocably deposit with the trustee sufficient cash or government securities to pay the principal, interest, any premium and any other sums due to the stated maturity date or a redemption date of the notes of a particular series, then at our option:</font></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we will be discharged from our obligations with respect to the notes of such series; or</font></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:48px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:138%;font-size:10pt;padding-left:24px;"><font style="font-family:inherit;font-size:10pt;">&#8226;</font></div></td><td style="vertical-align:top;"><div style="line-height:138%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">we will no longer be under any obligation to comply with certain restrictive covenants under the indenture, and certain events of default will no longer apply to us.</font></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:6pt;"><font style="font-family:Arial;font-size:6pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">To exercise our defeasance option, we must deliver to the trustee an officer&#8217;s certificate and an opinion of counsel, each stating that all conditions precedent related to the defeasance have been complied with.</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.15
<SEQUENCE>4
<FILENAME>pfe-ex1015x12312019xk.htm
<DESCRIPTION>EXHIBIT 10.15
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s89910638C8A5097E018FD41FE744AA06"></a></div><div><div style="line-height:120%;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 10.15</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;text-decoration:underline;">Amendment No. 7</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;text-decoration:underline;">Pfizer Supplemental Savings Plan (the &#8220;PSSP&#8221;)</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;">(Amended and Restated as of January 1, 2016)</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-weight:bold;text-decoration:underline;">*  *  *</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;font-style:italic;text-decoration:underline;">(New material underlined; deletions crossed out)</font></div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:14pt;"><font style="font-family:inherit;font-size:14pt;"><br></font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1.  Section 3.3 shall be amended to read as follows:  </font></div><div style="line-height:138%;padding-bottom:16px;text-align:left;text-indent:312px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;">3.3&#160;&#160;&#160;&#160;</font><font style="font-family:inherit;font-size:11pt;text-decoration:underline;">Amendment or Suspension of Election</font><font style="font-family:inherit;font-size:11pt;">. Except as otherwise provided in this Section 3.3, once made, a Member may not change his or her existing Excess Regular Earnings Deferrals election under this Plan during the Plan Year until the next Annual Enrollment. Notwithstanding the foregoing, if a Member </font><font style="font-family:inherit;font-size:11pt;text-decoration:line-through;">receives a hardship withdrawal under the Qualified Plan,</font><font style="font-family:inherit;font-size:11pt;">&#32;incurs a Disability or obtains a distribution under Section 6.4 on account of an Unforeseeable Emergency during a year, his or her Excess Regular Earnings Deferral election shall be cancelled.</font></div><div style="line-height:138%;padding-bottom:13px;text-align:left;padding-left:48px;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div><div><br></div><div><div style="line-height:120%;text-align:left;font-size:11pt;"><font style="font-family:inherit;font-size:11pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>5
<FILENAME>pfe-exh1029x12312019x1.htm
<DESCRIPTION>EXHIBIT 10.29
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFEFA00D5B31911DF68D8D426541B3BE5"></a></div><div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div></div><div><br></div><div style="line-height:138%;padding-bottom:13px;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 10.29</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Amendment No.2 to the</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Pfizer Inc. Executive Severance Plan</font></div><div style="line-height:120%;padding-bottom:13px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">*     *     *</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-style:italic;text-decoration:underline;">(New material underlined; deletions crossed out)</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Section 2.1(c) of Appendix A of the Pfizer Inc. Executive Severance Plan is amended to read as follows:</font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(c)&#160;&#160;&#160;&#160;His or her Official Notification Date is on or after December 21, 2018 and on or before </font><font style="font-family:Arial;font-size:9pt;text-decoration:line-through;">October 25, 2019</font><font style="font-family:Arial;font-size:9pt;">&#32;</font><font style="font-family:Arial;font-size:9pt;text-decoration:underline;">October 23, 2020. &#8220;Official Notification Date&#8221; means the date an eligible employee&#8217;s Notice Period begins</font><font style="font-family:Arial;font-size:9pt;">.</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:180%;padding-bottom:16px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div><div><div style="line-height:138%;padding-bottom:13px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">1</font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-13
<SEQUENCE>6
<FILENAME>pfe-exhibit13x12312019.htm
<DESCRIPTION>EXHIBIT 13
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!--p:50401aaac9ea4bc98e3dd1226080ffa1,x:e20175334ceb41ffbd73f8b83fd01f02-->
<!-- Document created using Wdesk  -->
<!-- Copyright 2020 Workiva -->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:schedoi-fednote="http://fasb.org/dis/schedoi-fednote/2019-01-31" xmlns:fs-interest="http://fasb.org/dis/fs-interest/2019-01-31" xmlns:sfp-ibo="http://fasb.org/stm/sfp-ibo/2019-01-31" xmlns:sfp-sbo="http://fasb.org/stm/sfp-sbo/2019-01-31" xmlns:sic-std="http://xbrl.sec.gov/sic-std/2011-01-31" xmlns:stpr-std="http://xbrl.sec.gov/stpr-std-std-std/2018-01-31" xmlns:currency-ent-std="http://xbrl.sec.gov/currency-ent-std/2019-01-31" xmlns:lea="http://fasb.org/dis/lea/2019-01-31" xmlns:ctbl="http://fasb.org/dis/ctbl/2019-01-31" xmlns:guar="http://fasb.org/dis/guar/2019-01-31" xmlns:ru="http://fasb.org/dis/ru/2019-01-31" xmlns:stpr-all="http://xbrl.sec.gov/stpr-all-all-all/2018-01-31" xmlns:leas="http://fasb.org/dis/leas/2019-01-31" xmlns:sfp-clreo="http://fasb.org/stm/sfp-clreo/2019-01-31" xmlns:iaoi="http://fasb.org/dis/iaoi/2019-01-31" xmlns:soi-ins="http://fasb.org/stm/soi-ins/2019-01-31" xmlns:country-ent-std="http://xbrl.sec.gov/country-ent-std/2017-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:fs-insa="http://fasb.org/dis/fs-insa/2019-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:cce="http://fasb.org/dis/cce/2019-01-31" xmlns:inv="http://fasb.org/dis/inv/2019-01-31" xmlns:naics-ent-std="http://xbrl.sec.gov/naics-ent-std/2017-01-31" xmlns:srt-std="http://fasb.org/srt-std/2019-01-31" xmlns:stpr-ent-all="http://xbrl.sec.gov/stpr-ent-all-all-all/2018-01-31" xmlns:stpr-ent-std="http://xbrl.sec.gov/stpr-ent-std-std-std/2018-01-31" xmlns:schedoi-iiaa="http://fasb.org/dis/schedoi-iiaa/2019-01-31" xmlns:us-arcroles="http://fasb.org/us-arcroles/2019-01-31" xmlns:dccpoa="http://fasb.org/dis/dccpoa/2019-01-31" xmlns:soi-sbi="http://fasb.org/stm/soi-sbi/2019-01-31" xmlns:us-gaap-all="http://fasb.org/us-gaap-all/2019-01-31" xmlns:scf-sd="http://fasb.org/stm/scf-sd/2019-01-31" xmlns:ceclcalc3l="http://fasb.org/dis/ceclcalc3l/2019-01-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei-ent-all="http://xbrl.sec.gov/dei-ent-all/2019-01-31" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:deprecated="http://www.xbrl.org/2009/arcrole/deprecated" xmlns:naics-all="http://xbrl.sec.gov/naics-all/2017-01-31" xmlns:re="http://fasb.org/dis/re/2019-01-31" xmlns:srt-types="http://fasb.org/srt-types/2019-01-31" xmlns:reorg="http://fasb.org/dis/reorg/2019-01-31" xmlns:invco="http://fasb.org/dis/invco/2019-01-31" xmlns:currency-ent-all="http://xbrl.sec.gov/currency-ent-all/2019-01-31" xmlns:currency-std="http://xbrl.sec.gov/currency-std/2019-01-31" xmlns:currency-ent-dep="http://xbrl.sec.gov/currency-ent-dep/2019-01-31" xmlns:aro="http://fasb.org/dis/aro/2019-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2019-01-31" xmlns:ocpfs="http://fasb.org/dis/ocpfs/2019-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31" xmlns:naics-std="http://xbrl.sec.gov/naics-std/2017-01-31" xmlns:srt-all="http://fasb.org/srt-all/2019-01-31" xmlns:codification-part="http://fasb.org/codification-part/2019-01-31" xmlns:srt="http://fasb.org/srt/2019-01-31" xmlns:deprecated1="http://www.xbrl.org/2009/role/deprecated" xmlns:sec-re="http://fasb.org/dis/sec-re/2019-01-31" xmlns:soi-int="http://fasb.org/stm/soi-int/2019-01-31" xmlns:emjv="http://fasb.org/dis/emjv/2019-01-31" xmlns:sec-suppc="http://fasb.org/dis/sec-suppc/2019-01-31" xmlns:equity="http://fasb.org/dis/equity/2019-01-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:se="http://fasb.org/dis/se/2019-01-31" xmlns:crcrb="http://fasb.org/dis/crcrb/2019-01-31" xmlns:edco="http://fasb.org/dis/edco/2019-01-31" xmlns:te="http://fasb.org/dis/te/2019-01-31" xmlns:dei-all="http://xbrl.sec.gov/dei-all/2019-01-31" xmlns:fs-bd="http://fasb.org/dis/fs-bd/2019-01-31" xmlns:invest-all="http://xbrl.sec.gov/invest-all/2013-01-31" xmlns:hco="http://fasb.org/dis/hco/2019-01-31" xmlns:fs-bt="http://fasb.org/dis/fs-bt/2019-01-31" xmlns:us-roles="http://fasb.org/us-roles/2019-01-31" xmlns:dr="http://fasb.org/dis/dr/2019-01-31" xmlns:ero="http://fasb.org/dis/ero/2019-01-31" xmlns:country-ent-all="http://xbrl.sec.gov/country-ent-all/2017-01-31" xmlns:schedoi-oocw="http://fasb.org/dis/schedoi-oocw/2019-01-31" xmlns:cecl="http://fasb.org/dis/cecl/2019-01-31" xmlns:rpd="http://fasb.org/dis/rpd/2019-01-31" xmlns:schedoi-sumhold="http://fasb.org/dis/schedoi-sumhold/2019-01-31" xmlns:ceclcalc2="http://fasb.org/dis/ceclcalc2/2019-01-31" xmlns:othliab="http://fasb.org/dis/othliab/2019-01-31" xmlns:soi-egm="http://fasb.org/stm/soi-egm/2019-01-31" xmlns:pfe="http://www.pfizer.com/20191231" xmlns:schedoi-shorthold="http://fasb.org/dis/schedoi-shorthold/2019-01-31" xmlns:soi="http://fasb.org/stm/soi/2019-01-31" xmlns:diha="http://fasb.org/dis/diha/2019-01-31" xmlns:debt="http://fasb.org/dis/debt/2019-01-31" xmlns:schedoi-hold="http://fasb.org/dis/schedoi-hold/2019-01-31" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:invest-std="http://xbrl.sec.gov/invest-std/2013-01-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:us-gaap-ent-std="http://fasb.org/us-gaap-ent-std/2019-01-31" xmlns:bc="http://fasb.org/dis/bc/2019-01-31" xmlns:sic-ent-all="http://xbrl.sec.gov/sic-ent-all/2011-01-31" xmlns:exch-ent-std="http://xbrl.sec.gov/exch-ent-std/2019-01-31" xmlns:invest-ent-all="http://xbrl.sec.gov/invest-ent-all/2013-01-31" xmlns:rcc="http://fasb.org/dis/rcc/2019-01-31" xmlns:rd="http://fasb.org/dis/rd/2019-01-31" xmlns:sfp-ucreo="http://fasb.org/stm/sfp-ucreo/2019-01-31" xmlns:eui="http://fasb.org/dis/eui/2019-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31" xmlns:ap="http://fasb.org/dis/ap/2019-01-31" xmlns:soi-reit="http://fasb.org/stm/soi-reit/2019-01-31" xmlns:fs-mort="http://fasb.org/dis/fs-mort/2019-01-31" xmlns:sec-reins="http://fasb.org/dis/sec-reins/2019-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:sec-cndfir="http://fasb.org/dis/sec-cndfir/2019-01-31" xmlns:sr="http://fasb.org/dis/sr/2019-01-31" xmlns:currency-all="http://xbrl.sec.gov/currency-all/2019-01-31" xmlns:scf-dbo="http://fasb.org/stm/scf-dbo/2019-01-31" xmlns:fs-fhlb="http://fasb.org/dis/fs-fhlb/2019-01-31" xmlns:crcpb="http://fasb.org/dis/crcpb/2019-01-31" xmlns:dei-ent-std="http://xbrl.sec.gov/dei-ent-std/2019-01-31" xmlns:us-types="http://fasb.org/us-types/2019-01-31" xmlns:scf-inv="http://fasb.org/stm/scf-inv/2019-01-31" xmlns:scf-indira="http://fasb.org/stm/scf-indira/2019-01-31" xmlns:bsoff="http://fasb.org/dis/bsoff/2019-01-31" xmlns:exch-ent-all="http://xbrl.sec.gov/exch-ent-all/2019-01-31" xmlns:oi="http://fasb.org/dis/oi/2019-01-31" xmlns:soi-indira="http://fasb.org/stm/soi-indira/2019-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:schedoi-otsh="http://fasb.org/dis/schedoi-otsh/2019-01-31" xmlns:sfp-dbo="http://fasb.org/stm/sfp-dbo/2019-01-31" xmlns:cc="http://fasb.org/dis/cc/2019-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:crcsbp="http://fasb.org/dis/crcsbp/2019-01-31" xmlns:disops="http://fasb.org/dis/disops/2019-01-31" xmlns:reference="http://www.xbrl.org/2009/role/reference" xmlns:cn-part="http://fasb.org/cn-part/2019-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31" xmlns:srt-roles="http://fasb.org/srt-roles/2019-01-31" xmlns:country-std="http://xbrl.sec.gov/country-std/2017-01-31" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:scf-indir="http://fasb.org/stm/scf-indir/2019-01-31" xmlns:rlnro="http://fasb.org/dis/rlnro/2019-01-31" xmlns:ts="http://fasb.org/dis/ts/2019-01-31" xmlns:us-gaap-std="http://fasb.org/us-gaap-std/2019-01-31" xmlns:naics-ent-all="http://xbrl.sec.gov/naics-ent-all/2017-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:scf-dir="http://fasb.org/stm/scf-dir/2019-01-31" xmlns:dei-std="http://xbrl.sec.gov/dei-std/2019-01-31" xmlns:ni="http://fasb.org/dis/ni/2019-01-31" xmlns:sec-mort="http://fasb.org/dis/sec-mort/2019-01-31" xmlns:fifvd="http://fasb.org/dis/fifvd/2019-01-31" xmlns:otherexp="http://fasb.org/dis/otherexp/2019-01-31" xmlns:scf-re="http://fasb.org/stm/scf-re/2019-01-31" xmlns:sec-vq="http://fasb.org/dis/sec-vq/2019-01-31" xmlns:sec-sum="http://fasb.org/dis/sec-sum/2019-01-31" xmlns:exch-std="http://xbrl.sec.gov/exch-std/2019-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:ir="http://fasb.org/dis/ir/2019-01-31" xmlns:sheci="http://fasb.org/stm/sheci/2019-01-31" xmlns:foct="http://fasb.org/dis/foct/2019-01-31" xmlns:soc="http://fasb.org/stm/soc/2019-01-31" xmlns:scf-sbo="http://fasb.org/stm/scf-sbo/2019-01-31" xmlns:inctax="http://fasb.org/dis/inctax/2019-01-31" xmlns:ppe="http://fasb.org/dis/ppe/2019-01-31" xmlns:country-all="http://xbrl.sec.gov/country-all/2017-01-31" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:con="http://fasb.org/dis/con/2019-01-31" xmlns:sic-ent-std="http://xbrl.sec.gov/sic-ent-std/2011-01-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:invest-ent-std="http://xbrl.sec.gov/invest-ent-std/2013-01-31" xmlns:fs-ins="http://fasb.org/dis/fs-ins/2019-01-31" xmlns:eps="http://fasb.org/dis/eps/2019-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2018-01-31" xmlns:iago="http://fasb.org/dis/iago/2019-01-31" xmlns:pay="http://fasb.org/dis/pay/2019-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:tin-part="http://fasb.org/tin-part/2019-01-31" xmlns:acec="http://fasb.org/dis/acec/2019-01-31" xmlns:us-gaap-entryPoint-all="http://fasb.org/us-gaap-entryPoint-all/2019-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:nt="http://fasb.org/dis/nt/2019-01-31" xmlns:spc="http://fasb.org/stm/spc/2019-01-31" xmlns:exch-all="http://xbrl.sec.gov/exch-all/2019-01-31" xmlns:ides="http://fasb.org/dis/ides/2019-01-31" xmlns:sec-supins="http://fasb.org/dis/sec-supins/2019-01-31" xmlns:sic-all="http://xbrl.sec.gov/sic-all/2011-01-31" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:regop="http://fasb.org/dis/regop/2019-01-31" xmlns:sfp-cls="http://fasb.org/stm/sfp-cls/2019-01-31" xmlns:com="http://fasb.org/stm/com/2019-01-31" xmlns:soi-re="http://fasb.org/stm/soi-re/2019-01-31" xmlns:crcgen="http://fasb.org/dis/crcgen/2019-01-31" xmlns:exch-ent-dep="http://xbrl.sec.gov/exch-ent-dep/2019-01-31" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:ei="http://fasb.org/dis/ei/2019-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
	<head>
		<meta http-equiv="Content-Type" content="text/html" />
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a id="s80692534D5665CFBBAB9E9501EEA06B9"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 13</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:22pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:82%;"></td><td style="width:18%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:right;font-size:22pt;"><span style="font-family:Arial;font-size:22pt;font-weight:bold;">Pfizer Inc.                                           2019 Financial Report</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;"><img src="pfizercoverlogoa01.jpg" alt="pfizercoverlogoa01.jpg" style="height:78px;width:137px;"></img></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="overflow:hidden;height:493px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div><br/></div><hr style="page-break-after:always"></hr><div><a id="s7520AECCF82251358C77231816864619"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:8.5pt;"><span style="font-family:Arial;font-size:8.5pt;font-weight:bold;">GLOSSARY OF DEFINED TERMS</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unless the context requires otherwise, references to &#8220;Pfizer,&#8221; &#8220;the Company,&#8221; &#8220;we,&#8221; &#8220;us&#8221; or &#8220;our&#8221; in this </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report (defined below) refer to Pfizer Inc. and its subsidiaries. We also have used several other terms in this </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report, most of which are explained or defined below:</span></div><div style="line-height:120%;text-align:center;font-size:7.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">2018 Financial Report</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Financial Report for the fiscal year ended December 31, 2018, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2018</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">2019 Financial Report</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This Financial Report for the fiscal year ended December 31, 2019, which was filed as Exhibit 13 to the Annual Report on Form 10-K for the fiscal year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">2019 Form 10-K</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Annual Report on Form 10-K for the fiscal year ended December 31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">ABO</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Accumulated benefit obligation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">ACA (Also referred to as U.S. Healthcare Legislation)</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">ACIP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Advisory Committee on Immunization Practices</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">ALK</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">anaplastic lymphoma kinase</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Allergan</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Allergan plc</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Alliance revenues</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Revenues from alliance agreements under which we co-promote products discovered or developed by other companies or us</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Allogene</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Allogene Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Akcea</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Akcea Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">AMPA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#945;-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Anacor</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Anacor Pharmaceuticals, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">AOCI</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Accumulated Other Comprehensive Income</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Array</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Array BioPharma Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Astellas</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Astellas Pharma Inc., Astellas US LLC and Astellas Pharma US, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">ATM-AVI</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">aztreonam-avibactam</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Bain Capital</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Bain Capital Private Equity and Bain Capital Life Sciences</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Bamboo</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Bamboo Therapeutics, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Biogen</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Biogen Inc.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Biopharma</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Pfizer Biopharmaceuticals Group</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">BMS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Bristol-Myers Squibb Company</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">BRCA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">BReast CAncer susceptibility gene</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">CAR T</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">chimeric antigen receptor T cell</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">CDC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">U.S. Centers for Disease Control and Prevention</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Cellectis</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Cellectis S.A.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Cerevel</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Cerevel Therapeutics, LLC</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">CHMP</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Committee for Medicinal Products for Human Use</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">CIAS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">cognitive impairment associated with schizophrenia</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Citibank</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Citibank, N.A.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">CML</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">chronic myelogenous leukemia</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Developed Markets</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and New Zealand</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">EC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">European Commission</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">EGFR</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">epidermal growth factor receptor</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">EH</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Essential Health</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">EMA</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">European Medicines Agency</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Emerging Markets</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">EPS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">earnings per share</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">EU</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">European Union</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">FASB</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Financial Accounting Standards Board</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">FDA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">U.S. Food and Drug Administration</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">GAAP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Generally Accepted Accounting Principles</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">GIST</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">gastrointestinal stromal tumors</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">GPD</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Global Product Development organization</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">GSK</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">GlaxoSmithKline plc</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">GS&amp;Co.</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Goldman, Sachs &amp; Co. LLC</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">HER2-</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">human epidermal growth factor receptor 2-negative</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="padding-top:6px;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">hGH-CTP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">human growth hormone</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">HIS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Hospira Infusion Systems </span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Hisun</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Zhejiang Hisun Pharmaceuticals Co., Ltd.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Hisun Pfizer</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Hisun Pfizer Pharmaceuticals Company Limited</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Hospira</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Hospira, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">HR+</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">hormone receptor-positive</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">IBT</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Income before tax</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">ICU Medical</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">ICU Medical, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">IH</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Innovative Health</span></div></td></tr></table></div></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">i</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:7.5pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Ionis</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Ionis Pharmaceuticals, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">InnoPharma</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">InnoPharma, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">IPR&amp;D</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">in-process research and development</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">IRC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Internal Revenue Code</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">IRS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">U.S. Internal Revenue Service</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">IV</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">intravenous</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Janssen</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Janssen Biotech, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">J&amp;J</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Johnson &amp; Johnson</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">JV</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">joint venture</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">King</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">King Pharmaceuticals LLC (formerly King Pharmaceuticals, Inc.)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">LDL</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">low density lipoprotein</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">LEP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Legacy Established Products</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">LIBOR</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">London Interbank Offered Rate</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Lilly</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Eli Lilly and Company</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">LOE</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">loss of exclusivity</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">MCC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Merkel Cell Carcinoma</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">MCO</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Managed Care Organization</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">mCRC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">metastatic colorectal cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Medivation</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Medivation, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Merck</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Merck &amp; Co., Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Meridian</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Meridian Medical Technologies, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Moody&#8217;s</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Moody&#8217;s Investors Service</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Mylan</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Mylan N.V.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">NAV</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net asset value</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">NDA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">new drug application</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">NovaQuest</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">NovaQuest Co-Investment Fund II, L.P. or NovaQuest Co-Investment Fund V, L.P., as applicable</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">NSCLC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">non-small cell lung cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">NYSE</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">New York Stock Exchange</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">OPKO</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">OPKO Health, Inc.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">OTC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">over-the-counter</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">PARP</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">poly ADP ribose polymerase</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">PBM</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Pharmacy Benefit Manager</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">PBO</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Projected benefit obligation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Pharmacia</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Pharmacia Corporation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">PPS</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Portfolio Performance Shares</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">PP&amp;E</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Property, plant &amp; equipment</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">PSAs</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Performance Share Awards</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">PsA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">psoriatic arthritis</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">PTSRUs</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Performance Total Shareholder Return Units</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">PTUs</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Profit Units</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">RA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">rheumatoid arthritis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">RCC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">renal cell carcinoma</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">R&amp;D</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">research and development</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">ROU</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">right of use</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">RPI</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">RPI Finance Trust</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">RSUs</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Restricted Stock Units</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Sandoz</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Sandoz, Inc., a division of Novartis AG</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">SEC</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">U.S. Securities and Exchange Commission</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Servier</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Les Laboratoires Servier SAS</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">SFJ</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">SFJ Pharmaceuticals</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Shire</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Shire International GmbH</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">SI&amp;A</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Selling, informational and administrative</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">S&amp;P</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Standard and Poor&#8217;s</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">SIP</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Sterile Injectable Pharmaceuticals</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Tax Cuts and Jobs Act or TCJA</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Legislation commonly referred to as the U.S. Tax Cuts and Jobs Act of 2017</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Teuto</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Laborat&#243;rio Teuto Brasileiro S.A.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">Therachon</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Therachon Holding AG</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">TSR</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total Shareholder Return</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">TSRUs</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total Shareholder Return Units</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">UC</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">ulcerative colitis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">U.K.</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">United Kingdom</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">U.S.</span></div></td><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">United States</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">VBP</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">volume-based procurement in China</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">ViiV</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">ViiV Healthcare Limited</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;color:#2c2c2c;font-style:italic;">WRDM</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #acacac;border-right:1px solid #acacac;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Worldwide Research, Development and Medical</span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">ii</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s84191E15595151D98E257B256B01D6AA"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">INTRODUCTION</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See the Glossary of Defined Terms at the beginning of this </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report for terms used throughout this </span><span style="font-family:Arial;font-size:8pt;">Financial Review</span><span style="font-family:Arial;font-size:8pt;">. Our Financial Review is provided to assist readers in understanding the results of operations, financial condition and cash flows of Pfizer Inc. and its subsidiaries (the Company). It should be read in conjunction with the consolidated financial statements and Notes to Consolidated Financial Statements. The discussion in this Financial Review contains forward-looking statements that involve substantial risks and uncertainties. Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, such as those discussed in Part 1, Item&#160;1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K and in the &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221;, &#8220;Our Operating Environment&#8221;, "The Global Economic Environment" and &#8220;Our Strategy&#8221; sections of this Financial Review.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All trademarks in this Financial Report are the property of their respective owners.</span></div><div style="line-height:120%;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Financial Review is organized as follows:</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:95.23809523809523%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:27%;"></td><td style="width:17%;"></td><td style="width:17%;"></td><td style="width:18%;"></td><td style="width:17%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#sDDD218ACA4FA588B9FB6D424BCEDAB92"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#sDDD218ACA4FA588B9FB6D424BCEDAB92">2</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This section provides information about the following: Financial Highlights; Our Business; Our Business Development Initiatives; Our 2019 Performance; Our Operating Environment; The Global Economic Environment; Our Strategy; and Our Financial Guidance for 2020.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#sDC26669E742C5B4980C39F8C41F279E2"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Significant Accounting Policies and Application of Critical Accounting Estimates and Assumptions</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#sDC26669E742C5B4980C39F8C41F279E2">12</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This section discusses those accounting policies and estimates that we consider important in understanding our consolidated financial statements. For additional discussion of our accounting policies, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Note 1. Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:7.5pt;">.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s8E16A31A844757AB8D0858DD5E468A4D"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Analysis of the Consolidated Statements of Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s8E16A31A844757AB8D0858DD5E468A4D">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This section includes the following sub-sections:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">&#9675;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">&#160;</span><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s99E866B0537D5F9BA35439015AE2B430"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Revenues&#8212;Overview</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s99E866B0537D5F9BA35439015AE2B430">16</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This sub-section provides a high-level summary of our revenues, including revenue deductions.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">&#9675;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">&#160;</span><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s8634af04bf7f41d2879e226b286dd782"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Revenues by Operating Segment and Geography</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s8634af04bf7f41d2879e226b286dd782">18</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This sub-section provides an overview of revenues by segment and geography.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">&#9675;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s30E446CEB79F5B14A78819C791FF5CB2"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Revenues&#8211;&#8211;Selected Product Discussion</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s30E446CEB79F5B14A78819C791FF5CB2">21</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This sub-section provides an overview of several of our biopharmaceutical products.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">&#9675;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#sD19EB0840C59585BB8015C765A050CB8"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Product Developments&#8211;&#8211;Biopharmaceutical</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#sD19EB0840C59585BB8015C765A050CB8">26</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This sub-section provides an overview of important biopharmaceutical product developments.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">&#9675;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">&#160;</span><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s2A103E6709085297913858D0A1DA36F8"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Costs and Expenses</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s2A103E6709085297913858D0A1DA36F8">30</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This sub-section provides a discussion about our costs and expenses. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">&#9675;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">&#160;</span><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s6238E702502F576EB2522FA72BCA244C"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Provision/(Benefit) for Taxes on Income</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s6238E702502F576EB2522FA72BCA244C">33</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:2px;text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This sub-section provides a discussion of items impacting our tax provisions.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">&#9675;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">&#160;</span><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#sBF11949AB6815BB4A94F2CD4EC7CF550"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Non-GAAP Financial Measure (Adjusted Income)</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#sBF11949AB6815BB4A94F2CD4EC7CF550">34</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This sub-section provides a discussion of an alternative view of performance used by management.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s31E255B2392A5B05B4CC0CE0F5376674"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Analysis of Operating Segment Information</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s31E255B2392A5B05B4CC0CE0F5376674">39</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:7.5pt;">This section provides a discussion of</span><span style="font-family:Arial;font-size:8pt;">&#160;the </span><span style="font-family:Arial;font-size:7.5pt;">performance of each of our operating segments.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s0A824E089CFE53B8AD5C7389F03876AD"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Analysis of the Consolidated Statements of Cash Flows</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s0A824E089CFE53B8AD5C7389F03876AD">48</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This section provides an analysis of our consolidated cash flows for the three years ended December&#160;31, 2019.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#sEAE1570191A356DF83AA012DDD05940C"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Analysis of Financial Condition, Liquidity and Capital Resources</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#sEAE1570191A356DF83AA012DDD05940C">49</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This section provides an analysis of selected measures of our liquidity and of our capital resources as of December&#160;31, 2019 and December&#160;31, 2018, as well as a discussion of our outstanding debt and other commitments that existed as of December&#160;31, 2019 and December 31, 2018. Included in the discussion of outstanding debt is a discussion of the amount of financial capacity available to help fund Pfizer&#8217;s future activities.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#s527AD00D04ED5487BE6FAE5909AF1405"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">New Accounting Standards</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#s527AD00D04ED5487BE6FAE5909AF1405">54</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This section discusses accounting standards that we have recently adopted, as well as those that recently have been issued, but not yet adopted.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#9679;</span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><a style="font-family:Arial;font-size:7.5pt;font-style:italic;" href="#sE89660235E295CF4BD6750A0E51F3765"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Forward-Looking Information and Factors That May Affect Future Results</span></a></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:20px;text-indent:-18px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Beginning on page </span><a style="font-family:Arial;font-size:7.5pt;" href="#sE89660235E295CF4BD6750A0E51F3765">55</a></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">This section provides a description of the risks and uncertainties that could cause actual results to differ materially from those discussed in forward-looking statements presented in this Financial Review. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:2px;padding-left:30px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain amounts in our Financial Review may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">1</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sDDD218ACA4FA588B9FB6D424BCEDAB92"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">OVERVIEW OF OUR PERFORMANCE, OPERATING ENVIRONMENT, STRATEGY AND OUTLOOK</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Financial Highlights</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following charts provide a summary of certain financial performance (in billions, except per share data):</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:336px;"></td><td style="width:336px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Total Revenues&#8211;&#8211;$51.8 billion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Net Cash Flow from Operations&#8211;&#8211;$12.6 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A decrease of 4% compared to 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A decrease of 20% compared to 2018</span></div></td></tr></table></div><img src="totalrev2019.jpg" alt="totalrev2019.jpg" style="height:138px;width:336px;"></img><img src="netcashflowfromops2019.jpg" alt="netcashflowfromops2019.jpg" style="height:138px;width:336px;"></img></div><div style="line-height:120%;text-align:left;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:672px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:336px;"></td><td style="width:336px;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Reported Diluted EPS&#8211;&#8211;$2.87</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Adjusted Diluted EPS (Non-</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">GAAP</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)&#8211;&#8211;$2.95*</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">An increase of 54% compared to 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">An increase of 1% compared to 2018</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;"><img src="reporteddilutedeps2019.jpg" alt="reporteddilutedeps2019.jpg" style="height:138px;width:336px;"></img><img src="adjdilutedeps-nongaap2019.jpg" alt="adjdilutedeps-nongaap2019.jpg" style="height:138px;width:336px;"></img></div><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:6px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For additional information regarding Adjusted diluted EPS (which is a non-GAAP financial measure), including reconciliations of certain GAAP reported to non-GAAP adjusted information, see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this Financial Review. We have revised 2018 and 2017 Adjusted diluted EPS to conform with our 2019 presentation (see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8211;&#8211;Certain Significant Items)&#8221; section of this Financial Review).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Business</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture and distribution of healthcare products, including innovative medicines and vaccines. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. Our revenues are derived from the sale of our products and, to a much lesser extent, from alliance agreements, under which we co-promote products discovered or developed by other companies or us</span><span style="font-family:Arial;font-size:8pt;"> (Alliance revenues).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments&#8211;&#8211;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. For additional information about this operating structure, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17A. Segment, Geographic and Other Revenue Information: Segment Information.</span><span style="font-family:Arial;font-size:8pt;"> See the &#8220;Our Strategy&#8211;&#8211;Organizing for Growth&#8221; section of this Financial Review below and the &#8220;Commercial Operations&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K for additional information.</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The majority of our revenues come from the manufacture and sale of biopharmaceutical products. The biopharmaceutical industry is highly competitive and highly regulated. As a result, we face a number of industry-specific factors and challenges, which can significantly impact our results. These factors include, among others: the loss or expiration of intellectual property rights and the expiration of co-promotion and licensing rights, the ability to replenish innovative biopharmaceutical products, healthcare legislation, pipeline productivity, the regulatory environment, pricing and access pressures and competition. We also face challenges as a result of the global economic environment. For additional information about these factors and challenges, see the &#8220;Our Operating Environment&#8221; and &#8220;The Global Economic Environment&#8221; sections of this Financial Review and Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The financial information included in our consolidated financial statements for our subsidiaries operating outside the U.S. is as of and for the year ended November&#160;30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">2</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.13176007866274%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:49%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">References to developed and emerging markets in this Financial Review include:</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S., Western Europe, Japan, Canada, South Korea, Australia, Scandinavian countries, Finland and New Zealand</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging markets (include, but are not limited to)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">References to operational variances in this Financial Review pertain to period-over-period growth rates that exclude the impact of foreign exchange. The operational variances are determined by multiplying or dividing, as appropriate, our current year U.S. dollar results by the current year average foreign exchange rates and then multiplying or dividing, as appropriate, those amounts by the prior-year period average foreign exchange rates. Although exchange rate changes are part of our business, they are not within our control. Exchange rate changes, however, can mask positive or negative trends in the business; therefore, we believe presenting operational variances provides useful information to evaluate the results of our business.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On December 22, 2017, the U.S. enacted significant changes to U.S. tax law following the passage and signing of the TCJA. The TCJA is complex and significantly changes the U.S. corporate income tax system by, among other things, reducing the U.S. Federal corporate tax rate from 35% to 21%, transitioning U.S. international taxation from a worldwide tax system to a territorial tax system and imposing a repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries.</span><span style="font-family:Arial;font-size:8pt;"> For information on the TCJA, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Tax Matters: Taxes on Income from Continuing Operations.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Business Development Initiatives</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. We view our business development activity as an enabler of our strategies, and we seek to generate earnings growth and enhance shareholder value by pursuing a disciplined, strategic and financial approach to evaluating business development opportunities.</span><span style="font-family:Arial;font-size:8pt;"> We continue to evaluate business development transactions that have the potential to strengthen our businesses and their capabilities, such as our acquisitions of Array, Therachon, Hospira, Medivation, Anacor and AstraZeneca&#8217;s small molecule anti-infectives business, as well as collaborations, and alliance and license agreements with other companies. We assess our businesses, assets and scientific capabilities/portfolio as part of our regular, ongoing portfolio review process and also continue to consider business development activities that will advance our businesses.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our significant recent business development activities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">License Agreement with Akcea Therapeutics, Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">In October 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. The transaction closed in November 2019 and we made an upfront payment of</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$250 million</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">to Akcea and Ionis, which was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:8pt;">in our fiscal fourth quarter of 2019. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Formation of a New Consumer Healthcare Joint Venture</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">The joint venture is a category leader in pain relief, respiratory and vitamins, minerals and supplements, and therapeutic oral health and is the largest global OTC consumer healthcare business.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">In accordance with our domestic and international reporting periods, our financial results, and our Consumer Healthcare segment&#8217;s operating results, for 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018.</span><span style="font-family:Arial;font-size:8pt;"> See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Basis of Presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of Array BioPharma Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On </span><span style="font-family:Arial;font-size:8pt;">July&#160;30, 2019</span><span style="font-family:Arial;font-size:8pt;">, we acquired Array for </span><span style="font-family:Arial;font-size:8pt;">$48</span><span style="font-family:Arial;font-size:8pt;"> per share in cash. The total fair value of the consideration transferred for Array was approximately </span><span style="font-family:Arial;font-size:8pt;">$11.2 billion</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;">$10.9 billion</span><span style="font-family:Arial;font-size:8pt;">, net of cash acquired). </span><span style="font-family:Arial;font-size:8pt;">Our financial statements for 2019 reflect the assets, liabilities, operating results and cash flows of Array, commencing from the acquisition date</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Agreement to Combine Upjohn with Mylan N.V.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun off or split off to Pfizer&#8217;s shareholders and, immediately thereafter, combined with Mylan.</span><span style="font-family:Arial;font-size:8pt;"> Pfizer shareholders would own </span><span style="font-family:Arial;font-size:8pt;">57%</span><span style="font-family:Arial;font-size:8pt;"> of the combined new company, and former Mylan shareholders would own </span><span style="font-family:Arial;font-size:8pt;">43%</span><span style="font-family:Arial;font-size:8pt;">. The transaction is expected to be tax free to Pfizer and Pfizer shareholders. </span><span style="font-family:Arial;font-size:8pt;">The transaction is anticipated to close in mid-2020, subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals.</span><span style="font-family:Arial;font-size:8pt;"> We expect to incur costs of approximately $500 million in connection with fully separating Upjohn, inclusive of </span><span style="font-family:Arial;font-size:8pt;">$145 million</span><span style="font-family:Arial;font-size:8pt;"> incurred in 2019. Such charges will include costs and expenses related to separation of legal entities and anticipated transaction costs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of Therachon Holding AG</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On July 1, 2019, we acquired all the remaining shares of Therachon for </span><span style="font-family:Arial;font-size:8pt;">$340 million</span><span style="font-family:Arial;font-size:8pt;"> upfront, plus potential milestone payments of up to </span><span style="font-family:Arial;font-size:8pt;">$470 million</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">contingent on the achievement of key milestones in the development and commercialization of the lead asset. The total fair value of the consideration transferred for Therachon was approximately</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$322 million</span><span style="font-family:Arial;font-size:8pt;">. </span><span style="font-family:Arial;font-size:8pt;">Our financial statements for 2019 reflect the assets, liabilities, operating results and cash flows of Therachon, commencing from the acquisition date and, in accordance with our international reporting period, reflect five months of Therachon operations and cash flows.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">On February 3, 2017, we completed the sale of Pfizer&#8217;s global infusion systems net assets, HIS, to ICU Medical for up to approximately</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$900 million</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">composed of cash and contingent cash consideration, ICU Medical common stock (all of which we sold during 2018) and seller financing</span><span style="font-family:Arial;font-size:8pt;">. The operating results of HIS are included in our consolidated statement of income through February 2, 2017 and, therefore, our financial results for 2017 reflect one month of HIS domestic operations and two months of HIS international operations. Our financial results for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> do not reflect any contribution from HIS global operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of AstraZeneca&#8217;s Small Molecule Anti-Infectives Business</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, </span><span style="font-family:Arial;font-size:8pt;">we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">3</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:8pt;">business, primarily outside the U.S.</span><span style="font-family:Arial;font-size:8pt;"> for approximately </span><span style="font-family:Arial;font-size:8pt;">$1.0 billion</span><span style="font-family:Arial;font-size:8pt;">, composed of cash and contingent consideration. </span><span style="font-family:Arial;font-size:8pt;">Our financial statements reflect the assets, liabilities, operating results and cash flows of this business, commencing from the acquisition date and, in accordance with our international reporting period, for 2017 reflect approximately 11 months of the small molecule anti-infectives business operations and cash flows acquired from AstraZeneca.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Our </span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-align:center;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"> Performance</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Revenues&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;text-align:center;text-decoration:underline;">2019</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$1.9 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">4%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$51.8 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$53.6 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, reflecting an operational </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">$545 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;">an unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">$1.4 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">3%</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following graph illustrates the components of the net </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in revenues in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;padding-top:4px;text-align:center;"><img src="revenuedecreasein2019.jpg" alt="revenuedecreasein2019.jpg" style="height:206px;width:684px;"></img></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">**</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">On </span><span style="font-family:Arial;font-size:7pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;">we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name.</span><span style="font-family:Arial;font-size:7pt;"> For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following provides an analysis of the changes in revenues in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.11504424778761%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:82%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018 </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53,647</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Continued growth from certain key brands</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,495</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenues from continued growth of anti-infective products in China, driven by increased demand for Sulperazon and new launches, the 2018 U.S. launches of immune globulin intravenous products (Panzyga and Octagam) and certain anti-infective launches in international developed and other emerging markets, all in the Hospital products business, higher revenues primarily in the U.S. for Inlyta, Biosimilars, and rare disease products driven by Vyndaqel/Vyndamax and volume-driven growth from Celebrex and Effexor, primarily in Japan and China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,067</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Declines from Lyrica, primarily in the U.S., reflecting significantly lower volume associated with multi-source generic competition that began in July 2019, other Hospital products, Enbrel internationally, Viagra and Upjohn&#8217;s authorized generic for Viagra primarily in the U.S., Revatio and Relpax primarily in the U.S., and Norvasc and Lipitor primarily in China and Japan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(2,728</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline from Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,436</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">57</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operational decline, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(545</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operational revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">53,102</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,352</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019 </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">51,750</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain key brands represent Ibrance, Eliquis, Xeljanz and Prevnar 13/Prevenar 13. See the &#8220;Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion" section of this Financial Review for product analysis information.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For worldwide revenues and revenues by geography, for selected products, see the discussion in the &#8220;Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8221; section of this Financial Review. For additional information regarding the primary indications or class of certain products, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17C. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Other Revenue Information</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">4</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See the &#8220;Analysis of the Consolidated Statements of Income</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">Revenues</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">Overview&#8221; and &#8220;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-weight:normal;text-decoration:none;">Revenues by Operating Segment and Geography</span><span style="font-family:Arial;font-size:8pt;">&#8221; sections of this Financial Review for more information, including a discussion of key drivers of our revenue performance.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Income from Continuing Operations Before Provision/(Benefit) for Taxes on Income&#8211;&#8211;</span><span style="font-family:Arial;font-size:9pt;text-align:center;text-decoration:underline;">2019</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following provides an analysis of the </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.11504424778761%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:86%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income </span><span style="font-family:Arial;font-size:8pt;">for the year ended December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,885</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unfavorable change in revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,897</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Favorable/(Unfavorable) changes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gain on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,086</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#160;Cost of sales</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,029</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, information and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">105</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(644</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">283</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">296</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower certain asset impairments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">272</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher royalty-related income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">154</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Favorable change in the fair value of contingent consideration</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">153</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-recurrences of net realized losses on sales of investments in debt securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">141</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from insurance recoveries related to Hurricane Maria</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">50</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher charges for certain legal matters</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(397</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher net interest expense</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(365</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impact of net periodic benefit costs/(credits) other than service costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(352</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-recurrence of gain on equity investment in Cerevel</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(343</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(320</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher business and legal entity alignment costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(275</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher net losses on early retirement of debt</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(134</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower net gains recognized during the period on equity securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(132</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-recurrence of gain on the contribution of Pfizer&#8217;s CAR T assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(50</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other items, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">138</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income </span><span style="font-family:Arial;font-size:8pt;">for the year ended December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">17,682</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Cost of Sales&#8221; section of this Financial Review.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Selling, Informational and Administrative (SI&amp;A) Expenses&#8221; section of this Financial Review.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Research and Development (R&amp;D) Expenses&#8221; section of this Financial Review.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See the &#8220;Costs and Expenses&#8211;&#8211;Amortization of Intangible Assets</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8221; </span><span style="font-family:Arial;font-size:7pt;">section of this Financial Review.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See the &#8220;Costs and Expenses&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;">&#8221; and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:7pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See the Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Other (Income)/Deductions&#8212;Net</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For information on our tax provision and effective tax rate see the &#8220;Provision/(Benefit) for Taxes on Income&#8221; section of this Financial Review and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Tax Matters: Taxes on Income from Continuing Operations.</span></div><div style="line-height:120%;padding-bottom:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Operating Environment</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;font-weight:bold;text-decoration:underline;">Industry-Specific Challenges</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Intellectual Property Rights and Collaboration/Licensing Rights</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The loss, expiration or invalidation of intellectual property rights, patent litigation settlements with manufacturers and the expiration of co-promotion and licensing rights can have a significant adverse effect on our revenues. </span><span style="font-family:Arial;font-size:8pt;">Certain of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face significantly increased generic competition over the next few years.</span><span style="font-family:Arial;font-size:8pt;"> For example, Lyrica lost patent protection in the U.S. in June 2019 and multi-source generic competition began in July 2019. Also, the basic product patent for Chantix in the U.S. will expire in November 2020. </span><span style="font-family:Arial;font-size:8pt;">We expect the impact of reduced revenues due to patent expiries will be significant in 2020, then moderating downward to a much lower level from 2021 through 2025.</span></div><div style="line-height:120%;font-size:3pt;"><span style="font-family:Arial;font-size:3pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information, including the patent rights we consider most significant in relation to our business as a whole, together with the year in which the basic product patent expires and recent and expected losses of product exclusivity, see the &#8220;Patents and Other Intellectual Property Rights&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">5</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We will continue to aggressively defend our patent rights whenever we deem appropriate. For a discussion of certain recent developments with respect to patent litigation, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16A1. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Legal Proceedings</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Patent Litigation</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Regulatory Environment/Pricing and Access&#8211;&#8211;U.S. Healthcare Legislation</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2010, the ACA was enacted in the U.S. For additional information, see the &#8220;Government Regulation and Price Constraints&#8221; section in Part I, Item 1, &#8220;Business&#8221;, of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.11504424778761%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We recorded the following amounts as a result of the U.S. Healthcare Legislation:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reduction to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">, related to the Medicare &#8220;coverage gap&#8221; discount provision</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">934</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">674</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">450</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, related to the fee payable to the federal government (which is not deductible for U.S. income tax purposes), based on our prior-calendar-year share relative to other companies of branded prescription drug sales to specified government programs. 2018 reflected a favorable true-up associated with the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods.</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">247</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">184</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">307</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Regulatory Environment/Pricing and Access&#8211;&#8211;Government and Other Payer Group Pressures</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The pricing of medicines by pharmaceutical manufacturers and the cost of healthcare, which includes medicines, medical services and hospital services, continues to be important to payers, governments, patients, and other stakeholders. Governments, MCOs and other payor groups continue to seek increasing discounts on our products through a variety of means and could have an adverse impact on our results of operations. We believe that medicines are amongst the most powerful tools for patients in curing, treating and preventing illness and disability, and that all patients should have appropriate access to the medicines their doctors prescribe. We may consider a number of factors when determining a medicine&#8217;s price, including, for example, its impact on patients and their disease, other available treatments, the medicine&#8217;s potential to reduce other healthcare costs (such as hospital stays), and affordability. Within the U.S., in particular, we may also engage with patients, doctors and healthcare plans regarding their views. We also negotiate with insurers, including PBMs and MCOs, often providing significant discounts to them from the list price. The price that patients pay in the U.S. for the medicines their physicians prescribe is ultimately set by healthcare providers and insurers. On average, in the U.S., insurers impose a of higher out-of-pocket burden on patients for prescription medicines than for comparably-priced medical services. We will continue to work with insurance providers, governments and others to improve access to today&#8217;s innovative treatments. </span><span style="font-family:Arial;font-size:8pt;">Certain governments, including the different EU member states, the U.K., China, Japan, Canada, South Korea and some other international markets, provide healthcare at low-to-zero direct cost to consumers at the point of care and have significant power as large single payers to regulate pharmaceutical prices or patient reimbursement levels to control costs for the government-sponsored healthcare system, particularly under recent global financing pressures.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">Governments may use a variety of cost-containment measures for our pharmaceutical products, including price cuts, mandatory rebates, health technology assessments, forced localization as a condition of market access, &#8220;international reference pricing&#8221; (i.e., the practice of a country linking its regulated medicine prices to those of other countries), quality consistency evaluation processes and volume-based procurement.</span><span style="font-family:Arial;font-size:8pt;"> For additional information, see the &#8220;Government Regulation and Price Constrains&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Regulatory Environment&#8211;&#8211;Pipeline Productivity</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The discovery and development of safe, effective new products, as well as the development of additional uses for existing products, are necessary for the continued strength of our businesses. We have encountered increasing regulatory scrutiny of drug safety and efficacy, even as we continue to gather safety and other data on our products, before and after the products have been launched. Our product lines must be replenished over time in order to offset revenue losses when products lose their market exclusivity, as well as to provide for earnings growth. We devote considerable resources to R&amp;D activities. These activities involve a high degree of risk and cost and may take many years, and with respect to any specific R&amp;D project, there can be no assurance that the development of any particular product candidate or new indication for an in-line product will achieve the desired clinical endpoints and safety profile, will be approved by regulators or will be successful commercially.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">During the development of a product, we conduct clinical trials to provide data on the drug&#8217;s safety and efficacy to support the evaluation of its overall benefit-risk profile for a particular patient population. In addition, after a product has been approved and launched, we continue to monitor its safety as long as it is available to patients, and postmarketing trials may be conducted, including trials requested by regulators and trials that we do voluntarily to gain additional medical knowledge. For the entire life of the product, we collect safety data and report safety information to the FDA and other regulatory authorities. The FDA and regulatory authorities in other jurisdictions may evaluate potential safety concerns related to a product or a class of products and take regulatory actions in response, such as updating a product&#8217;s labeling, restricting the use of a product, communicating new safety information to the public, or, in rare cases, removing a product from the market.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Product Manufacturing</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We periodically encounter difficulties or delays in manufacturing, including due to suspension of manufacturing or recall of a product, or legal or regulatory actions such as warning letters. For example, Hospira&#8217;s manufacturing facility in McPherson, Kansas is currently under the FDA inspection classification of Official Action Indicated (OAI). As a result of this classification, the FDA may refuse to grant premarket approval of applications and/or the FDA may refuse to grant export certificates related to products manufactured at our McPherson site until the site status is upgraded, which upgrade would be based on a re-inspection by the FDA. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of corrections implemented at the site. Communication with the FDA on the status of the McPherson site is </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">6</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ongoing. For additional information regarding the FDA inspection of the McPherson site, see Part I, Item 1A, &#8220;Risk Factors&#8211;&#8211;Product Manufacturing, Sales and Marketing Risks&#8221; of our 2019 Form 10-K.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have been experiencing product shortages for products from the legacy Hospira portfolio, among others, largely driven by capacity constraints, technical issues, supplier quality concerns or unanticipated demand. We have made considerable progress remediating issues at legacy Hospira facilities manufacturing sterile injectables and have substantially improved supply from most of these sites. Continuing product shortage interruption at these and other manufacturing facilities could negatively impact our financial results.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Competition</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Many of our prescription pharmaceutical products face competition in the form of branded or generic drugs or biosimilars that treat similar diseases or indications.</span><span style="font-family:Arial;font-size:8pt;"> For additional information, see the &#8220;Competition&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">The Global Economic Environment</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition to the industry-specific factors discussed above, we, like other businesses of our size, are exposed to the economic cycle, which impacts our biopharmaceutical operations globally. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Governments, corporations, and insurance companies, which provide insurance benefits to patients, have implemented increases in cost-sharing and restrictions on access to medicines, potentially causing patients to switch to generic or biosimilar products, delay treatments, skip doses or use less effective treatments. As discussed above, government financing pressures can lead to negative pricing pressure in various markets where governments take an active role in setting prices, access criteria (e.g., through public or private health technology assessments), or other means of cost control. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Significant portions of our revenues, costs and expenses, as well as our substantial international net assets, are exposed to changes in foreign exchange rates. We seek to manage our foreign exchange risk in part through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. Depending on market conditions, foreign exchange risk also is managed through the use of derivative financial instruments and foreign currency debt. As we operate in multiple foreign currencies, including the euro, the Chinese renminbi, the Japanese yen, the Canadian dollar, the U.K. pound and approximately 100 other currencies, changes in those currencies relative to the U.S. dollar will impact our revenues and expenses. If the U.S. dollar were to weaken against another currency, assuming all other variables remained constant, our revenues would increase, having a positive impact on earnings, and our overall expenses would increase, having a negative impact on earnings. Conversely, if the U.S. dollar were to strengthen against another currency, assuming all other variables remained constant, our revenues would decrease, having a negative impact on earnings, and our overall expenses would decrease, having a positive impact on earnings. Therefore, significant changes in foreign exchange rates can impact our results and our financial guidance. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The impact of possible currency devaluations in countries experiencing high inflation rates or significant exchange fluctuations, including Venezuela and Argentina, can impact our results and financial guidance</span><span style="font-family:Arial;font-size:8pt;">. For additional information about our exposure to foreign currency risk, see the &#8220;Our Financial Guidance for </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;">&#8221; and the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; sections of this Financial Review.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In June 2016, the U.K. electorate voted in a referendum to leave the EU, which is commonly referred to as &#8220;Brexit&#8221;.</span><span style="font-family:Arial;font-size:8pt;"> In March 2017, the U.K. government formally notified the European Council of its intention to leave the EU after it triggered Article 50 of the Lisbon Treaty to begin the two-year negotiation process establishing the terms of the exit and outlining the future relationship between the U.K. and the EU. Formal negotiations officially started in June 2017. Following the General Election in December 2019, the new U.K. parliament approved the negotiated withdrawal agreement and the </span><span style="font-family:Arial;font-size:8pt;">U.K. left the EU on January 31, 2020 with status quo arrangements through a transition period scheduled to end on December 31, 2020.</span><span style="font-family:Arial;font-size:8pt;"> The transition period will be used to negotiate future trade arrangements between the U.K. and the EU. </span><span style="font-family:Arial;font-size:8pt;">The consequences of the U.K. leaving the EU and the terms of the future trading relationship continue to be highly uncertain, which may pose certain implications to our research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products.</span><span style="font-family:Arial;font-size:8pt;"> At present, it is still unclear whether and to what extent the U.K. will remain within or aligned to the EU system of medicines regulation, after the end of the transition period.</span><span style="font-family:Arial;font-size:8pt;"> However, both the U.K. and the EU have issued detailed guidance for the industry on how medicines, medical devices and clinical trials will be separately regulated in their respective territories. Pfizer has substantially completed its preparations for Brexit, having made the changes necessary to meet relevant regulatory requirements in the EU and the U.K., through the transition period and afterwards, especially in the regulatory, research, manufacturing and supply chain areas. Between 2018 and 2021, we expect to spend up to approximately $60 million in one-time costs to make these adaptations.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We generated approximately </span><span style="font-family:Arial;font-size:8pt;">2%</span><span style="font-family:Arial;font-size:8pt;"> of our worldwide revenues from the U.K. in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> including the foreign currency exchange impact from the weakening U.K. pound relative to the U.S. dollar to date.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Public health epidemics or outbreaks could adversely impact our business.&#160;In December 2019, a novel strain of coronavirus (COVID-19) emerged in Wuhan, Hubei Province, China.&#160;While initially the outbreak was largely concentrated in China and caused significant disruptions to its economy, it has now spread to several other countries and infections have been reported globally.&#160;The extent to which the coronavirus impacts our operations will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the duration of the outbreak, new information which may emerge concerning the severity of the coronavirus and the actions to contain the coronavirus or treat its impact, among others. In particular, the continued spread of the coronavirus globally could adversely impact our operations, including among others, our manufacturing and supply chain, sales and marketing and clinical trial operations and could have an adverse impact on our business and our financial results.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer maintains a strong financial position while operating in a complex global environment. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. Our long-term debt is rated high quality by both S&amp;P and Moody&#8217;s. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified, </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">7</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">available-for-sale debt securities. For further discussion of our financial condition and credit ratings, see the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this Financial Review.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">These and other industry-wide factors that may affect our businesses should be considered along with information presented in the &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; section of this Financial Review and in Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Strategy</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We believe that our medicines provide significant value for both healthcare providers and patients, not only from the improved treatment of diseases but also from a reduction in other healthcare costs, such as emergency room or hospitalization costs, as well as improvements in health, wellness and productivity. We continue to actively engage in dialogues about the value of our medicines and how we can best work with patients, physicians and payers to prevent and treat disease and improve outcomes. We continue to work within the current legal and pricing structures, as well as continue to review our pricing arrangements and contracting methods with payers, to maximize patient access and minimize any adverse impact on our revenues. We remain firmly committed to fulfilling our Company&#8217;s purpose: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Breakthroughs that change patients&#8217; lives</span><span style="font-family:Arial;font-size:8pt;">. By doing so, we expect to create value for the patients we serve and for our colleagues and shareholders.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Organizing for Growth</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We believe we have one of the strongest pipelines we have had in over a decade, and believe we are well positioned for future growth. Additional patent expiries will continue over several years, and we expect the impact of reduced revenues due to patent expiries will be significant in 2020, then moderating downward to a much lower level from 2021 through 2025. This confluence of events has provided us an opportunity to look at and refine how we organize our business to best achieve sustainable growth and to deliver our medicines and vaccines to the maximum number of people who need them.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At the beginning of our fiscal year 2019, we began to manage our commercial operations through a new global structure consisting of three businesses, each led by a single manager&#8212;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through July 31, 2019, Pfizer&#8217;s Consumer Healthcare business. We designed this new global structure to take advantage of new growth opportunities driven by the evolving and unique dynamics of relevant markets.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information about each business, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17A. Segment, Geographic and Other Revenue Information: Segment Information.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We also reorganized our R&amp;D operations as part of our Organizing for Growth reorganization:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The former Worldwide Research and Development organization is renamed Worldwide Research, Development and Medical (WRDM) as we have created a new Worldwide Medical &amp; Safety organization in WRDM that incorporates the former Chief Medical Office as well as the Worldwide Safety function;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The R&amp;D organization within our former Essential Health business has been integrated into the WRDM, GPD and Upjohn organizations, including moving biosimilars into WRDM and GPD and realigning them with the relevant therapeutic areas (e.g., Oncology and Inflammation &amp; Immunology);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Regulatory function has been moved from the WRDM organization into the GPD organization; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Late-stage portfolio spend has been moved from our former Innovative Health business to GPD and from our former Essential Health business to GPD and Upjohn.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We re-aligned our commercial operations in 2019 for a number of reasons, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Bringing biosimilars into our Oncology and Inflammation &amp; Immunology therapeutic categories gives us the potential to leverage our R&amp;D, regulatory and commercial infrastructure within the Biopharma business to more efficiently bring those assets to market;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Creating a business unit (i.e., the Hospital unit within Biopharma) that is solely focused on medicines that are used in hospitals can potentially bring greater focus and attention to serving those customers and developing those relationships;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Giving Upjohn more autonomy with a focus on maximizing the value of its products, particularly in emerging markets, provides it the opportunity to operate as a standalone business within Pfizer with the potential for sustainable modest growth; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We believe this new structure better positions each business to achieve its growth potential as we transition to a period post-2020 where we expect higher and more sustained revenue growth due to declining LOEs and the potential of our late-stage pipeline.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma seeks to leverage a strong pipeline, organize around operational growth drivers, and capitalize on trends creating long-term growth opportunities, including:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an aging global population that is generating increased demand for innovative medicines that address patients&#8217; unmet needs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">advances in both biological science and digital technology that are enhancing the delivery of breakthrough new medicines; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the increasingly significant role of hospitals in healthcare systems.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Urbanization and the rise of the middle class in emerging markets, particularly in Asia, provide growth opportunities for the Upjohn business. Our ability to work collaboratively within local markets and to be fast, focused and flexible is intended to position this business to seize these opportunities. Upjohn has distinct and dedicated manufacturing, marketing, regulatory and, subject to limited exceptions, enabling functions that report directly into the business providing autonomy and positioning Upjohn to operate as a true stand-alone division. We created this new structure to, among other things, position Upjohn to optimize its distinct growth potential and provide us with the flexibility to access further opportunities to enhance value.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Subsequent to the re-alignment of our commercial operations in 2019, on July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. For additional information, see the &#8220;Our Business Development Initiatives&#8221; section above in this Financial Review. We believe the new company will transform and accelerate Upjohn&#8217;s </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">8</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">and Mylan&#8217;s ability to serve patients&#8217; needs and expand their capabilities across more than 165 markets. The combination will drive a sustainable, diverse and differentiated portfolio of prescription medicines, complex generics, over-the-counter products and biosimilars supported by commercial and regulatory expertise, established infrastructure, R&amp;D capabilities and manufacturing and supply chain excellence.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As we prepare for expected growth, we are focused on creating a simpler, more efficient organization by streamlining structures, processes and governance within each business and the functions that support them. As our innovative pipeline matures based on anticipated progression of current trials and the initiation of new pivotal trials, including new trials for medicines we may acquire or in-license, we will need to increase our R&amp;D investments. In addition, as our pipeline potentially delivers new commercialization opportunities, we will need to increase our investments in new-market-creation activities. We have initiated an enterprise-wide digital effort to accelerate drug development, enhance experiences (patient and physician) and access and leverage technology and robotics to simplify and automate our processes.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the fourth quarter of 2018, we took steps to simplify the organization, increase spans of control and reduce organizational layers, which impacted some managerial roles and responsibilities. We also offered enhancements to certain employee benefits for a short period of time. The expenses related to these enhancements for certain employee benefits did not have a material impact on our 2018 and 2019 results of operations.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Transforming to a More Focused Company</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">With the formation of the GSK Consumer Healthcare venture and the pending combination of Upjohn with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began, in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base, which is expected to be 20% less (based on the midpoint of the range for 2020 New Pfizer revenue guidance (see the &#8220;Our Financial Guidance for 2020&#8221; section of this Financial Review), compared to 2019 total company reported revenue) as a result of both the completed Consumer Healthcare and expected Upjohn transactions.&#160;While certain direct costs have transferred or will transfer to the Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;D, Manufacturing and Commercial.&#160;</span><span style="font-family:Arial;font-size:8pt;">For additional information, see the &#8220;Costs and Expenses&#8211;&#8211; </span><span style="font-family:Arial;font-size:8pt;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:8pt;">&#8221; section of this Financial Review.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Commercial Operations</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As discussed under &#8220;Organizing for Growth&#8221;, at the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of three business segments&#8211;&#8211;Biopharma, Upjohn and, through July&#160;31, 2019, Consumer Healthcare, each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn, and through July 31, 2019, Consumer Healthcare are responsible for their own R&amp;D activities while Biopharma receives its R&amp;D services from GPD and WRDM. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets.</span><span style="font-family:Arial;font-size:8pt;"> For additional information on our Commercial Operations, see the &#8220;Commercial Operations&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K. For additional information about our operating structure, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17A. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Segment Information. </span><span style="font-family:Arial;font-size:8pt;">For additional information about the </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> performance of each of our operating segments, see the &#8220;Analysis of Operating Segment Information&#8221; section of this Financial Review.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Description of Research and Development Operations</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Innovation is critical to the success of our Company, and drug discovery and development are time-consuming, expensive and unpredictable.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:normal;">Pfizer&#8217;s purpose is to deliver breakthroughs that change patients&#8217; lives.</span><span style="font-family:Arial;font-size:8pt;"> R&amp;D is at the heart of fulfilling Pfizer&#8217;s purpose as we work to translate advanced science and technologies into the therapies that matter most. </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our R&amp;D priorities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">delivering a pipeline of highly differentiated medicines and vaccines where Pfizer has a unique opportunity to bring the most important new therapies to patients in need;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:8pt;">advancing our capabilities that can position Pfizer for long-term R&amp;D leadership; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:9pt;padding-left:0px;"><span style="font-family:Arial;font-size:9pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:9pt;text-indent:-12px;"><span style="font-family:Arial;font-size:8pt;">advancing new models for partnerships with creativity, flexibility and urgency to deliver innovation to patients as quickly as possible.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">To that end, our R&amp;D primarily focuses on:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oncology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Inflammation and Immunology;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Vaccines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Internal Medicine;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rare Diseases;</span><span style="font-family:Arial;font-size:8pt;"> and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hospital</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information about R&amp;D, see the &#8220;Research and Development&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K. For additional information about R&amp;D by operating segment, see the &#8220;Analysis of Operating Segment Information&#8221; section of this Financial Review. </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information about our pending new drug applications and supplemental filings, see the &#8220;Analysis of the Consolidated Statements of Income&#8211;&#8211;Product Developments&#8211;&#8211;Biopharmaceutical&#8221; section of this Financial Review.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information about recent transactions and strategic investments that we believe have the potential to advance our pipeline, see the &#8220;Our Business Development Initiatives&#8221; section of this Financial Review above.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">9</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Intellectual Property Rights</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We continue to vigorously defend our patent rights against increasingly aggressive infringement, and we will continue to support efforts that strengthen worldwide recognition of patent rights while taking necessary steps to ensure appropriate patient access. In addition, we will continue to employ innovative approaches designed to prevent counterfeit pharmaceuticals from entering the supply chain and to achieve greater control over the distribution of our products, and we will continue to participate in the generics market whenever appropriate. Also, </span><span style="font-family:Arial;font-size:8pt;">the pursuit of valid business opportunities may require us to challenge intellectual property rights held by other companies that we believe were improperly granted. Such challenges may include negotiation and litigation, which may not always be successful.</span><span style="font-family:Arial;font-size:8pt;"> For additional information about our current efforts to enforce our intellectual property rights and certain other patent proceedings, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16A1. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Legal Proceedings</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Patent Litigation. </span><span style="font-family:Arial;font-size:8pt;">For information on risks related to patent protection and intellectual property claims by third parties, see Part I, Item 1A, &#8220;Risk Factors&#8211;&#8211;Risks Related to Intellectual Property&#8221; in our </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Capital Allocation and Expense Management</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We seek to maintain a strong balance sheet and robust liquidity so that we continue to have the financial resources necessary to take advantage of prudent commercial, research and business development opportunities and to directly enhance shareholder value through share repurchases and dividends. For additional information about our financial condition, liquidity, capital resources, share repurchases (including accelerated share repurchases) and dividends, see the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this Financial Review. For additional information about our recent business development activities, see the &#8220;Our Business Development Initiatives&#8221; section of this Financial Review above.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December&#160;</span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, our Board of Directors declared a first-quarter </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;"> dividend of </span><span style="font-family:Arial;font-size:8pt;">$0.38</span><span style="font-family:Arial;font-size:8pt;"> per share, an increase from the </span><span style="font-family:Arial;font-size:8pt;">$0.36</span><span style="font-family:Arial;font-size:8pt;"> per-share quarterly dividend paid during </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">. For additional information, see the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section of this Financial Review</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We remain focused on achieving an appropriate cost structure for our company. For additional information about our various initiatives, see the &#8220;Our Strategy&#8211;&#8211;Transforming to a More Focused Company&#8221; and &#8220;Costs and Expenses&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:8pt;">&#8221; sections of this Financial Review and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 3</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Increasing Investment in the U.S.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;After evaluating the expected positive net impact the TCJA will have on us, in early 2018, we decided to take several actions:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Over the five-year period from 2018 through 2022, we plan to invest approximately $5.0 billion in capital projects in the U.S., including the strengthening of our manufacturing presence in the U.S. As part of this plan:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">in July 2018, we announced that we will increase our commitment to U.S. manufacturing with a $465 million investment to build one of the most technically advanced sterile injectable pharmaceutical production facilities in the world in Portage, Michigan. This U.S. investment will strengthen our capability to produce and supply critical, life-saving injectable medicines for patients around the world, creating an estimated 450 new jobs over the next several years; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">in August 2019, we announced an additional half billion dollar investment for the construction of a state-of-the-art gene therapy manufacturing facility in Sanford, North Carolina. This facility is anticipated to support our continuing investment in gene therapy R&amp;D, similar to Pfizer&#8217;s Chapel Hill and Kit Creek, North Carolina R&amp;D sites. This facility would expand our presence in North Carolina. The expanded facility is projected to add approximately 300 new jobs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We made a $500 million voluntary contribution to the U.S. Pfizer Consolidated Pension Plan in February 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the first quarter of 2018, we paid a special, one-time bonus to virtually all Pfizer colleagues, excluding executives, of </span><span style="font-family:Arial;font-size:8pt;">$119 million</span><span style="font-family:Arial;font-size:8pt;"> in the aggregate.</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Our Business Development Initiatives</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As part of our strategy, we are also committed to capitalizing on growth opportunities by advancing our own pipeline and maximizing the value of our in-line products, as well as through various forms of business development, which can include alliances, licenses, joint ventures, collaborations, equity- or debt-based investments, dispositions, mergers and acquisitions. For additional information see the &#8220;Our Business Development Initiatives&#8221; section of this Financial Review above and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">10</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Our Financial Guidance for</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"> </span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">2020</span></div><div style="line-height:120%;padding-top:10px;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">2020 Financial Guidance for Total Company</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.11504424778761%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><span style="font-family:Arial;font-size:8pt;">2020 financial guidance for Total Company is presented below</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span><span style="font-family:inherit;font-size:9pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$48.5 to $50.5 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted cost of sales as a percentage of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19.9% to 20.9%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$12.0 to $13.0 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$8.1 to $8.5 billion</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted other (income)/deductions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Approximately $800 million of income</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effective tax rate on adjusted income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Approximately 15.0%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted diluted EPS</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$2.82 to $2.92</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The </span><span style="font-family:Arial;font-size:7pt;">2020</span><span style="font-family:Arial;font-size:7pt;"> financial guidance for Total Company reflects the following:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Reflects a full year of revenue and expense contributions from Biopharma and Upjohn</span><span style="font-family:Arial;font-size:8pt;">,</span><span style="font-family:Arial;font-size:7pt;"> and excludes any impact from the pending Upjohn combination with Mylan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Does not assume the completion of any business development transactions&#160;not completed as of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:8pt;">i</span><span style="font-family:Arial;font-size:7pt;">ncluding any one-time upfront payments associated with such transactions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes Pfizer&#8217;s pro rata share of the Consumer Healthcare joint venture anticipated earnings, which is recorded in Adjusted other (income)/deductions on a one-quarter lag. Therefore, 2020 financial guidance for Adjusted other (income)/deductions and Adjusted diluted EPS reflects Pfizer&#8217;s share of the joint venture&#8217;s earnings that were generated in the fourth quarter of 2019 (to be recorded by Pfizer in the first quarter of 2020) as well as Pfizer&#8217;s share of the joint venture&#8217;s projected earnings during the first three quarters of 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Reflects an anticipated negative revenue impact of </span><span style="font-family:Arial;font-size:7pt;">$2.4 billion</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;">due to recent and expected generic and biosimilar competition for certain products that have recently lost or are anticipated to soon lose patent protection. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Exchange rates assumed are as of mid-January 2020. Reflects the anticipated unfavorable impact of approximately </span><span style="font-family:Arial;font-size:7pt;">$0.2 billion</span><span style="font-family:Arial;font-size:7pt;"> on revenues and approximately </span><span style="font-family:Arial;font-size:7pt;">$0.01</span><span style="font-family:Arial;font-size:7pt;"> on adjusted diluted EPS </span><span style="font-family:Arial;font-size:7pt;">as a result of changes in foreign exchange rates relative to the U.S. dollar compared to foreign exchange rates from 2019.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Guidance for adjusted diluted EPS assumes diluted weighted-average shares outstanding of approximately </span><span style="font-family:Arial;font-size:7pt;">5.65</span><span style="font-family:Arial;font-size:7pt;"> billion shares, </span><span style="font-family:Arial;font-size:7pt;">which assumes no share repurchases in 2020</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information regarding an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this Financial Review.</span></div></td></tr></table><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in 2020, Upjohn began managing Pfizer&#8217;s Meridian subsidiary, the manufacturer of EpiPen and other auto-injector products, and the Mylan-Japan collaboration for generic drugs in Japan (established in 2012) (Mylan-Japan). As a result, revenues and expenses associated with Meridian and Mylan-Japan will be reported in Pfizer&#8217;s Upjohn business beginning in the first quarter of 2020. In 2019, revenues from Meridian and Mylan-Japan were recorded in Pfizer&#8217;s Biopharma business and totaled </span><span style="font-family:Arial;font-size:8pt;">$598</span><span style="font-family:Arial;font-size:8pt;"> million, flat operationally, compared with full-year 2018.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer, Upjohn and Mylan are in the process of negotiating the terms on which Pfizer would transfer the Meridian business and/or certain Pfizer assets that currently form part of the Mylan-Japan collaboration&#160;to Viatris&#160;following the completion of the proposed combination of Upjohn and Mylan.&#160;There can be no&#160;assurance&#160;that any&#160;agreement&#160;or transaction will result from these negotiations and if the parties are unsuccessful in their efforts to negotiate the terms of such potential transactions, the Meridian business and/or the Pfizer assets that currently form part of the Mylan-Japan collaboration will remain with Pfizer.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">2020 Financial Guidance for New Pfizer</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.11504424778761%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020 financial guidance for New Pfizer is presented below</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$40.7 to $42.3 billion</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted IBT Margin</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Approximately 37.0%</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted Diluted EPS</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$2.25 to $2.35</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating Cash Flow</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$11.0 to $12.0 billion</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Financial guidance for New Pfizer reflects a full-year 2020 pro-forma view of the company assuming the pending Upjohn combination with Mylan was completed at the beginning of 2020. Therefore, New Pfizer reflects contributions from the Biopharma business as it is presently being managed, which excludes contributions from Pfizer&#8217;s Meridian subsidiary and the Pfizer-Mylan strategic collaboration in Japan (Mylan-Japan). Pfizer&#8217;s Meridian subsidiary and Mylan-Japan were managed by Pfizer&#8217;s Biopharma business in 2019. Financial guidance for New Pfizer also includes the full-year effect of the following items that assume the completion of the Upjohn combination with Mylan: (i) $12 billion of net proceeds from Upjohn to be retained by Pfizer, which Pfizer will use to repay its own existing indebtedness; and (ii) other transaction-related items, such as income from transition services agreements between Pfizer and Viatris. In addition, 2020 financial guidance for New Pfizer Adjusted IBT Margin and Adjusted diluted EPS reflects Pfizer&#8217;s share of the earnings generated by the Consumer Healthcare joint venture in fourth-quarter 2019 (to be recorded by Pfizer in first-quarter 2020) as well as Pfizer&#8217;s share of the Consumer Healthcare joint venture&#8217;s projected earnings during the first three quarters of 2020.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For additional information regarding an understanding of Adjusted income and its components and Adjusted diluted EPS (all of which are non-GAAP financial measures), see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this Financial Review.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Adjusted income before tax margin (Adjusted IBT margin) is defined as revenue less the sum of Adjusted cost of sales, Adjusted SI&amp;A expenses, Adjusted R&amp;D expenses, Adjusted amortization of intangible assets and Adjusted other (income)/deductions as a percentage of revenue. Adjusted IBT Margin is presented because management believes this performance measure supplements investors&#8217; and other readers&#8217; understanding and assessment of the financial performance of New Pfizer. Adjusted IBT margin is not, and should not be viewed as, a substitute for U.S. GAAP income before tax margin.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Does not include our planned </span><span style="font-family:Arial;font-size:7pt;">$1.25 billion</span><span style="font-family:Arial;font-size:7pt;"> voluntary contribution to the U.S. qualified pension plans in the second half of 2020.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">2020 Financial Guidance for Upjohn</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020 financial guidance for Upjohn now reflects the inclusion of revenues and expenses associated with Meridian and Mylan-Japan, which were previously recorded in Pfizer&#8217;s Biopharma business. Except for the shift of Meridian and Mylan-Japan from Biopharma to Upjohn, there are no operational changes to Upjohn&#8217;s 2020 financial guidance compared with the preliminary financial targets that were provided in July 2019.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">11</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.11504424778761%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:50%;"></td><td style="width:50%;"></td></tr><tr><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020 financial guidance for Upjohn is presented below</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$8.0 to $8.5 billion</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted EBITDA</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$3.8 to $4.2 billion</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Financial guidance for Upjohn assumes a full-year 2020 contribution from the Upjohn business as it is presently being managed, which includes contributions from Pfizer&#8217;s Meridian subsidiary and Mylan-Japan.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Adjusted Earnings Before Interest, Tax, Depreciation and Amortization (EBITDA) is defined as reported U.S. GAAP net income/(loss), and its components, adjusted for interest expense, provision/(benefit) for taxes on income/(loss) and depreciation and amortization, further adjusted to exclude purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items (some of which may recur, such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on equity securities, but which management does not believe are reflective of ongoing core operations). Adjusted EBITDA is presented because management believes this performance measure supplements investors&#8217; and other readers&#8217; understanding and assessment of the financial performance of Upjohn. Adjusted EBITDA as defined is not a measurement of financial performance under GAAP, and should not be considered as an alternative to net income/(loss) or cash flow from operations determined in accordance with GAAP.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:1px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer does not provide guidance for GAAP Reported financial measures (other than revenues) or a reconciliation of forward-looking non-GAAP financial measures to the most directly comparable GAAP Reported financial measures on a forward-looking basis because it is unable to predict with reasonable certainty the ultimate outcome of pending litigation, unusual gains and losses, acquisition-related expenses, net gains or losses on investments in equity securities and potential future asset impairments without unreasonable effort. These items are uncertain, depend on various factors, and could have a material impact on GAAP Reported results for the guidance period.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For information about our actual costs and anticipated costs and cost savings associated with our various initiatives, see the &#8220;Costs and Expenses&#8211;&#8211;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&#8221; section of this Financial Review and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;"> financial guidance is subject to a number of factors and uncertainties as described in the &#8220;Our Operating Environment&#8221;, &#8220;The Global Economic Environment&#8221;, &#8220;Our Strategy&#8221; and &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; sections of this Financial Review; and Part I, Item 1A, &#8220;Risk Factors&#8221; of our </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div><a id="sDC26669E742C5B4980C39F8C41F279E2"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">SIGNIFICANT ACCOUNTING POLICIES AND APPLICATION OF CRITICAL ACCOUNTING ESTIMATES AND ASSUMPTIONS</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For a description of our significant accounting policies, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1. Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:8pt;">. Of these policies, the following are considered critical to an understanding of our consolidated financial statements as they require the application of the most subjective and the most complex judgments: Acquisitions (Note 1D);&#160;Fair Value (Note 1E); Revenues (Note 1G);&#160;Asset Impairments (Note 1L);&#160;Tax Assets and Liabilities and</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">Income Tax Contingencies (Note 1P);&#160;Pension and Postretirement Benefit Plans (Note 1Q); and Legal and Environmental Contingencies (Note 1R). </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Following is a discussion about the critical accounting estimates and assumptions impacting our consolidated financial statements. See also Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C. Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions</span><span style="font-family:Arial;font-size:8pt;"> for a discussion about the risks associated with estimates and assumptions.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Acquisitions and Fair Value</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For a discussion about the application of fair value to our recent acquisitions, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2A. Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements: Acquisitions</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For a discussion about the application of fair value to our investments, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7A. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Financial Instruments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Fair Value Measurements</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For a discussion about the application of fair value to our benefit plan assets, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 11D. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Pension and Postretirement Benefit Plans and Defined Contribution Plans</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Plan Assets</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For a discussion about the application of fair value to our asset impairment reviews, see &#8220;Asset Impairment Reviews&#8221; below.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenues</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends.</span><span style="font-family:Arial;font-size:8pt;"> If any of our ratios, factors, assessments, experiences or judgments are not indicative or accurate predictors of our future experience, our results could be materially affected. The sensitivity of our estimates can vary by program, type of customer and geographic location. However, estimates associated with U.S. Medicare, Medicaid and performance-based contract rebates are most at risk for material adjustment because of the extensive time delay between the recording of the accrual and its ultimate settlement, an interval that can generally range up to one year. Because of this time lag, in any given quarter, our adjustments to actual can incorporate revisions of several prior quarters.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">12</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Asset Impairment Reviews</span><span style="font-family:Arial;font-size:9pt;"> </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets. Our impairment review processes are described in the Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1L. Basis of Presentation and Significant Accounting Policies: Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Examples of events or circumstances that may be indicative of impairment include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A significant adverse change in legal factors or in the business climate that could affect the value of the asset. For example, a successful challenge of our patent rights would likely result in generic competition earlier than expected.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A significant adverse change in the extent or manner in which an asset is used. For example, restrictions imposed by the FDA or other regulatory authorities could affect our ability to manufacture or sell a product.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A projection or forecast that indicates losses or reduced profits associated with an asset. This could result, for example, from a change in a government reimbursement program that results in an inability to sustain projected product revenues and profitability. This also could result from the introduction of a competitor&#8217;s product that results in a significant loss of market share or the inability to achieve the previously projected revenue growth, as well as the lack of acceptance of a product by patients, physicians and payers. For IPR&amp;D projects, this could result from, among other things, a change in outlook based on clinical trial data, a delay in the projected launch date or additional expenditures to commercialize the product.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Identifiable Intangible Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a result of our identifiable intangible asset impairment review work, we recognized a number of impairments of identifiable intangible assets for the years ended </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4. Other (Income)/Deductions</span><span style="font-family:Arial;font-size:8pt;">&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Net.</span></div><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">When we are required to determine the fair value of intangible assets other than goodwill, we use an income approach, specifically the discounted cash flow method. We start with a forecast of all the expected net cash flows associated with the asset, which includes the application of a terminal value for indefinite-lived assets, and then we apply an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the projections and the impact of technological risk associated with IPR&amp;D assets, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">While all intangible assets other than goodwill can face events and circumstances that can lead to impairment, in general, intangible assets other than goodwill that are most at risk of impairment include IPR&amp;D assets (approximately </span><span style="font-family:Arial;font-size:8pt;">$5.9 billion</span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">) and newly acquired or recently impaired indefinite-lived brand assets. IPR&amp;D assets are high-risk assets, as R&amp;D is an inherently risky activity. Newly acquired and recently impaired indefinite-lived assets are more vulnerable to impairment as the assets are recorded at fair value and are then subsequently measured at the lower of fair value or carrying value at the end of each reporting period. As such, immediately after acquisition or impairment, even small declines in the outlook for these assets can negatively impact our ability to recover the carrying value and can result in an impairment charge.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Goodwill</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a result of our goodwill impairment review work, we concluded that none of our goodwill was impaired as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, and we do not believe the risk of impairment is significant at this time.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying amount. Qualitative factors that we consider include, for example, macroeconomic and industry conditions, overall financial performance and other relevant entity-specific events. If we conclude that it is more likely than not that the fair value of a reporting unit is less than its carrying value, we then perform a quantitative fair value test.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">When we are required to determine the fair value of a reporting unit, as appropriate for the individual reporting unit, we mainly use the income approach but we may also use the market approach, or a weighted-average combination of both approaches.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:5px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The income approach is a forward-looking approach to estimating fair value and relies primarily on internal forecasts. Within the income approach, the method that we use is the discounted cash flow method. We start with a forecast of all the expected net cash flows associated with the reporting unit, which includes the application of a terminal value, and then we apply a reporting unit-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of technological risk and competitive, legal and/or regulatory forces on the projections, as well as the selection of a long-term growth rate; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The market approach is a historical approach to estimating fair value and relies primarily on external information. Within the market approach are two methods that we may use:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Guideline public company method&#8212;this method employs market multiples derived from market prices of stocks of companies that are engaged in the same or similar lines of business and that are actively traded on a free and open market and the application of the identified multiples to the corresponding measure of our reporting unit&#8217;s financial performance.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">13</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Guideline transaction method&#8212;this method relies on pricing multiples derived from transactions of significant interests in companies engaged in the same or similar lines of business and the application of the identified multiples to the corresponding measure of our reporting unit&#8217;s financial performance.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:4px;text-align:left;padding-left:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The market approach is only appropriate when the available external information is robust and deemed to be a reliable proxy for the specific reporting unit being valued; however, these assessments may prove to be incomplete or inaccurate. Some of the more significant estimates and assumptions inherent in this approach include: the selection of appropriate guideline companies and transactions and the determination of applicable premiums and discounts based on any differences in ownership percentages, ownership rights, business ownership forms or marketability between the reporting unit and the guideline companies and transactions.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For all of our reporting units, there are a number of future events and factors that may impact future results and that could potentially have an impact on the outcome of subsequent goodwill impairment testing. For a list of these factors, see the &#8220;Forward-Looking Information and Factors That May Affect Future Results&#8221; section of this Financial Review and Part I, Item 1A, &#8220;Risk Factors&#8221; in our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Benefit Plans</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The accounting for benefit plans is highly dependent on actuarial estimates, assumptions and calculations, which can result from a complex series of judgments about future events and uncertainties. The assumptions and actuarial estimates required to estimate the net employee benefit obligations for the defined benefit and postretirement plans include the discount rate; expected salary increases; certain employee-related factors, such as turnover, retirement age and mortality (life expectancy); and healthcare cost trend rates.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effective January 1, 2018, accruals for future benefits under the Pfizer Consolidated Pension Plan (our largest U.S. defined benefit plan) and the defined benefit section of the Pfizer Group Pension Scheme (our largest pension plan in the U.K.) were frozen and resulted in elimination of future service costs for the plans. The Pfizer defined contribution savings plan provides additional annual contributions to those previously accruing benefits under the Pfizer Consolidated Pension Plan and active members of the Pfizer Group Pension Scheme started accruing benefits under the defined contribution section of that plan.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, the noncurrent portion of our pension benefit obligations, net, increased by approximately </span><span style="font-family:Arial;font-size:8pt;">$326 million</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">. The increase reflects, among other things, a decrease in the discount rate used in the measurement of plan obligations, partially offset by an increase in the actual returns on plan assets. As of December 31, 2019, the noncurrent portion of our postretirement benefit obligations, net decreased by approximately </span><span style="font-family:Arial;font-size:8pt;">$247 million</span><span style="font-family:Arial;font-size:8pt;">, compared to December 31, 2018. The decrease reflects, among other things, plan amendments related to the prescription drug coverage in our U.S. and Puerto Rico Postretirement Plans and changes to the claim cost assumptions, partially offset by the decrease in discount rate. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 11C. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Pension and Postretirement Benefit Plans and Defined Contribution Plans</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Obligations and Funded Status</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our assumptions reflect our historical experiences and our judgment regarding future expectations that have been deemed reasonable by management. The judgments made in determining the costs of our benefit plans can materially impact our results of operations.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides (i) at the end of each year, the expected annual rate of return on plan assets for the following year, (ii) the actual annual rate of return on plan assets achieved in each year, and (iii) the weighted-average discount rate used to measure the benefit obligations at the end of each year for our U.S. qualified pension plans and our international pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">U.S. Qualified Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected annual rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7.0</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actual annual rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">22.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(5.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">16.2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate used to measure the plan obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3.3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">International Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected annual rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4.4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actual annual rate of return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(0.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">10.3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate used to measure the plan obligations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For detailed assumptions associated with our benefit plans, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11B. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Actuarial Assumptions.</span></div></td></tr></table><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Expected Annual Rate of Return on Plan Assets</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The assumptions for the expected annual rate of return on all of our plan assets reflect our actual historical return experience and our long-term assessment of forward-looking return expectations by asset classes, which is used to develop a weighted-average expected return based on the implementation of our targeted asset allocation in our respective plans. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The expected annual rate of return on plan assets for our U.S. plans and the majority of our international plans is applied to the fair value of plan assets at each year-end and the resulting amount is reflected in our net periodic benefit costs in the following year.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">14</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:18%;"></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table illustrates the sensitivity of net periodic benefit costs to a 50 basis point decline in our assumption for the expected annual rate of return on plan assets, holding all other assumptions constant (in millions, pre-tax):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Assumption</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase in 2020 Net Periodic Benefit Costs</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected annual rate of return on plan assets</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">50 basis point decline</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$110</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The actual return on plan assets was approximately </span><span style="font-family:Arial;font-size:8pt;">$3.7 billion</span><span style="font-family:Arial;font-size:8pt;"> during </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Discount Rate Used to Measure Plan Obligations</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The weighted-average discount rate used to measure the plan obligations for our U.S. defined benefit plans is determined at least annually and evaluated and modified, as required, to reflect the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better, that reflect the rates at which the pension benefits could be effectively settled. The discount rate used to measure the plan obligations for our international plans is determined at least annually by reference to investment grade corporate bonds, rated AA/Aa or better, including, when there is sufficient data, a yield-curve approach. These discount rate determinations are made in consideration of local requirements.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The measurement of the plan obligations at the end of the year will affect the amount of service cost, interest cost and amortization expense reflected in our net periodic benefit costs in the following year. </span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:50%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td colspan="7" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table illustrates the sensitivity of net periodic benefit costs and benefit obligations to a 10 basis point decline in our assumption for the discount rate, holding all other assumptions constant (in millions, pre-tax):</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Assumption</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Change</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase in 2020 Net Periodic Benefit Costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019 Benefit Obligations</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">10 basis point decline</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$461</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The change in the discount rates used in measuring our plan obligations as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> resulted in </span><span style="font-family:Arial;font-size:8pt;">an increase</span><span style="font-family:Arial;font-size:8pt;"> in the measurement of our aggregate plan obligations by approximately </span><span style="font-family:Arial;font-size:8pt;">$3.2 billion</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Income Tax Assets and Liabilities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including (i) the impact on deferred tax assets and liabilities from the reduction in the U.S. Federal corporate tax rate from 35% to </span><span style="font-family:Arial;font-size:8pt;">21%</span><span style="font-family:Arial;font-size:8pt;">, (ii) the impact on valuation allowances and other state income tax considerations, (iii) a repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026, and (iv) deferred taxes on basis differences expected to give rise to future taxes on global intangible low-taxed income. In addition, we had provided deferred tax liabilities in the past on foreign earnings that were not indefinitely reinvested. As a result of the TCJA, in the fourth quarter of 2017, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to the territorial tax system.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accounting for Global Intangible Low-Taxed Income</span><span style="font-family:Arial;font-size:8pt;">, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years. We were able to make a reasonable estimate of the deferred taxes on the temporary differences expected to reverse in the future and provided a provisional deferred tax liability as of December 31, 2017.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2018, we finalized our provisional accounting for the tax effects of the TCJA based on our best estimates of available information and data, and reported and disclosed the impacts within the applicable measurement period, in accordance with guidance issued by the SEC. We believe that there may be additional interpretations, clarifications and guidance from the U.S. Department of Treasury. Any change to our calculations resulting from such additional interpretations, clarifications and guidance would be reflected in the period of issuance. In addition, our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. The current portion of the aforementioned repatriation tax liability is reported in current </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable </span><span style="font-family:Arial;font-size:8pt;">in our consolidated balance sheet as of December 31, 2019 (approximately $600 million due in April 2020) and the remaining liability is reported in noncurrent </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable </span><span style="font-family:Arial;font-size:8pt;">in our consolidated balance sheet as of December 31, 2019. The first installment of $750 million was paid in April 2019.</span></div><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income tax assets and liabilities also include income tax valuation allowances and accruals for uncertain tax positions. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies: Estimates and Assumptions</span><span style="font-family:Arial;font-size:8pt;">; </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1P. Basis of Presentation and Significant Accounting Policies: Tax Assets and Liabilities and Income Tax Contingencies </span><span style="font-family:Arial;font-size:8pt;">and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A. Tax Matters: Taxes on Income from Continuing Operations, </span><span style="font-family:Arial;font-size:8pt;">as well as the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8211;&#8211;Selected Measures of Liquidity and Capital Resources&#8212;Contractual Obligations&#8221; section of this Financial Review</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">15</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Contingencies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations, and guarantees and indemnifications, as well as for tax matters. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1P. Basis of Presentation and Significant Accounting Policies: Tax Assets and Liabilities and Income Tax Contingencies, Note 1R. Basis of Presentation and Significant Accounting Policies: Legal and Environmental Contingencies, Note 5D. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Tax Matters</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Tax Contingencies</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div><a id="s8E16A31A844757AB8D0858DD5E468A4D"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF THE CONSOLIDATED STATEMENTS OF INCOME</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of the consolidated statements of income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:36px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18/17</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">51,750</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53,647</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">52,546</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,219</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,248</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,228</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,350</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,455</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,804</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">27.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">26.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">28.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,650</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8,006</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,683</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,610</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,893</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,758</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8.9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9.1</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">747</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,044</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(28</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(8,086</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">15.6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8212;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,578</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,116</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,416</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">69</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">49</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">17,682</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,885</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12,305</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">49</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">34.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">22.2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">23.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,384</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">706</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(9,049</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">96</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effective tax rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7.8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5.9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(73.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16,298</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,179</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21,353</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">46</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(48</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">31.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20.8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">40.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(61</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16,302</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,188</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21,355</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">46</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(48</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">31.5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20.9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">40.6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">29</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">36</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">47</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(18</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(24</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16,273</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,153</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21,308</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">46</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(48</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">31.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">40.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Indicates calculation not meaningful or result is equal to or greater than 100%.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Excludes amortization of intangible assets, except as disclosed in Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 10</span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">A</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Identifiable Intangible Assets and Goodwill</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Identifiable Intangible Assets</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><div><a id="s99E866B0537D5F9BA35439015AE2B430"></a></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenues</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">&#8212;</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Overview</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total revenues in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> compared to </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> reflects an operational </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">$545 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;">an unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">$1.4 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">3%</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> compared to </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total revenues in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> reflects an operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">$791 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">2%</span><span style="font-family:Arial;font-size:8pt;">, and the </span><span style="font-family:Arial;font-size:8pt;">favorable</span><span style="font-family:Arial;font-size:8pt;"> impact of foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">$310 million</span><span style="font-family:Arial;font-size:8pt;">, or less than </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;">, in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See the &#8220;Revenues by Segment and Geography&#8221; and &#8220;Revenues&#8212;Selected Product Discussion&#8221; sections of this Financial Review for additional analyses.</span></div><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain of our current products have experienced patent-based expirations or loss of regulatory exclusivity in certain markets in the last few years, and we expect certain products to face significantly increased generic competition over the next few years.</span><span style="font-family:Arial;font-size:8pt;"> For additional information, see the &#8220;Patents and Other Intellectual Property Rights&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have significant operations outside the U.S., with revenues exceeding $500 million in eleven countries in each of 2019, 2018 and 2017.</span></div><div style="line-height:120%;text-align:center;text-indent:32px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">16</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">By total revenues, the U.S., China and Japan are our three largest national markets:</span></div><div style="line-height:120%;text-align:center;text-indent:32px;"><img src="revbynatlmarket2017-2019.jpg" alt="revbynatlmarket2017-2019.jpg" style="height:197px;width:672px;"></img></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Inventory Stocking</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our policy relating to the supply of pharmaceutical inventory at domestic wholesalers, and in major international markets, is to generally maintain stocking levels under one month on average and to keep monthly levels consistent from year to year based on patterns of utilization. We historically have been able to closely monitor these customer stocking levels by purchasing information from our customers directly or by obtaining other third-party information. We believe our data sources to be directionally reliable but cannot verify their accuracy. Further, as we do not control this third-party data, we cannot be assured of continuing access. Unusual buying patterns and utilization are promptly investigated.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Revenue Deductions</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of related obligations and, as such, knowledge and judgment are required when estimating the impact of these revenue deductions on gross sales for a reporting period. </span><span style="font-family:Arial;font-size:8pt;">Historically, our adjustments of estimates, to reflect actual results or updated expectations, have not been material to our overall business. On a quarterly basis, our adjustments of estimates to reflect actual results generally have been less than 1% of revenues, and have resulted in either a net increase or a net decrease in revenues. Product-specific rebates, however, can have a significant impact on year-over-year individual product growth trends.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information about revenue deductions:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Medicare rebates</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,306</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,706</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,316</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Medicaid and related state program rebates</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,936</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,969</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,860</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Performance-based contract rebates</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,767</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,377</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,245</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Chargebacks</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,588</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,461</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,047</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Sales allowances</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,678</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,592</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,165</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Sales returns and cash discounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,315</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,522</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,493</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19,589</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20,627</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19,126</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Rebates are product-specific and, therefore, for any given year are impacted by the mix of products sold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Performance-based contract rebates include contract rebates with MCOs within the U.S., including health maintenance organizations and PBMs, who receive rebates based on the achievement of contracted performance terms and claims under these contracts. Outside the U.S., performance-based contract rebates include rebates to wholesalers/distributors based on achievement of contracted performance for specific products or sales milestones.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Chargebacks primarily represent reimbursements to U.S. wholesalers for honoring contracted prices to third parties.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Sales allowances primarily represent price reductions that are contractual or legislatively mandated outside the U.S., discounts and distribution fees.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, associated with the following segments: Biopharma (</span><span style="font-family:Arial;font-size:7pt;">$12.0 billion</span><span style="font-family:Arial;font-size:7pt;">), Upjohn (</span><span style="font-family:Arial;font-size:7pt;">$7.2 billion</span><span style="font-family:Arial;font-size:7pt;">) and Other (</span><span style="font-family:Arial;font-size:7pt;">$0.4 billion</span><span style="font-family:Arial;font-size:7pt;">). For </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, associated with the following segments: Biopharma (</span><span style="font-family:Arial;font-size:7pt;">$10.2 billion</span><span style="font-family:Arial;font-size:7pt;">), Upjohn (</span><span style="font-family:Arial;font-size:7pt;">$9.7 billion</span><span style="font-family:Arial;font-size:7pt;">) and Other (</span><span style="font-family:Arial;font-size:7pt;">$0.7 billion</span><span style="font-family:Arial;font-size:7pt;">). For </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, associated with the following segments: Biopharma (</span><span style="font-family:Arial;font-size:7pt;">$9.2 billion</span><span style="font-family:Arial;font-size:7pt;">), Upjohn (</span><span style="font-family:Arial;font-size:7pt;">$9.2 billion</span><span style="font-family:Arial;font-size:7pt;">) and Other (</span><span style="font-family:Arial;font-size:7pt;">$0.7 billion</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total revenue deductions for </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">5%</span><span style="font-family:Arial;font-size:8pt;"> compared to </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, primarily as a result of:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a decrease in chargebacks primarily related to Upjohn products, including Viagra and Lyrica; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a decrease in Medicare rebates, driven by a significant decrease in Lyrica sales in the U.S. due to multi-source generic competition that began in July 2019,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an increase in performance-based contract rebates, primarily in the U.S. due to increased sales of certain Biopharma products, slightly offset by decreased Lyrica sales.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For information on our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts, including the balance sheet classification of these accruals, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1G. Basis of Presentation and Significant Accounting Policies: Revenues and Trade Accounts Receivable</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">17</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s8634af04bf7f41d2879e226b286dd782"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenues by Operating Segment and Geography</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;">The following graphs show revenues by operating segment and geography:</span></div><div style="line-height:120%;text-align:center;"><img src="revbyopsegment-geography2019.jpg" alt="revbyopsegment-geography2019.jpg" style="height:197px;width:369px;"></img></div><div style="line-height:120%;padding-top:4px;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:297px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:182px;"></td><td style="width:5px;"></td><td style="width:109px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019 Revenues by Geography</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">46%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">54%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;"><img src="revbyopsegment-geography2018.jpg" alt="revbyopsegment-geography2018.jpg" style="height:197px;width:369px;"></img></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:297px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:182px;"></td><td style="width:5px;"></td><td style="width:109px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018 Revenues by Geography</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">47%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53%</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;"><img src="revbyopsegment-geography2017.jpg" alt="revbyopsegment-geography2017.jpg" style="height:197px;width:369px;"></img></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:297px;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:182px;"></td><td style="width:5px;"></td><td style="width:109px;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017 Revenues by Geography</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of Total</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">50%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">50%</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">18</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s303F47D607385D47B7D496ED5BABA3F4"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="54"></td></tr><tr><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td></tr><tr><td colspan="54" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides worldwide revenues by operating segment and geography:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="16" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">18/17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">18/17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">18/17</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Operating Segments</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:7pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">39,419</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">37,558</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">35,530</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">19,605</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">18,243</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">17,961</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">19,814</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">19,315</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">17,569</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">6</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">3</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">10</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">10,233</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">12,484</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">13,447</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">3,259</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">5,209</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">6,150</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">6,974</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">7,275</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">7,297</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(18</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(37</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">(15</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">2,098</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">3,605</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">3,472</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">988</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">1,877</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">1,851</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">1,110</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">1,728</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">1,621</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(42</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(47</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(36</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">7</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">97</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">64</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">33</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">51,750</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">53,647</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">52,546</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">23,852</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">25,329</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">26,026</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">27,898</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">28,318</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">26,519</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">(3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">(1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial Narrow;font-size:7pt;">7</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Indicates the calculation is not meaningful or results are equal to or greater than 100%. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information about each operating segment, see the &#8220;Commercial Operations&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> Form 10-K, the &#8220;Analysis of Operating Segment Information&#8221; section of this Financial Review and Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 17A. Segment, Geographic and Other Revenue Information: Segment Information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents HIS revenues through February 2, 2017. On February 3, 2017, we completed the sale of HIS to ICU Medical. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:7pt;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:7pt;">: </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We recorded direct product and/or alliance revenues of more than $1 billion for each of: </span><span style="font-family:Arial;font-size:8pt;">eight</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">ten</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">nine</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:32%;"></td><td style="width:1%;"></td><td style="width:33%;"></td><td style="width:1%;"></td><td style="width:33%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Direct Product And/Or Alliance Revenues of More Than $1 Billion</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Prevnar 13/Prevenar 13</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Lyrica</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Lyrica</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Eliquis*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Ibrance</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Lyrica</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Eliquis*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Eliquis*</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Enbrel</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Enbrel</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Lipitor</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Enbrel</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Xeljanz</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Viagra</span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Sutent</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Norvasc</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">* </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Eliquis</span><span style="font-family:Arial;font-size:7pt;">&#160;includes alliance revenues and direct sales in 2019, 2018 and 2017.</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">These direct product sales and/or alliance product revenues represent </span><span style="font-family:Arial;font-size:8pt;">49%</span><span style="font-family:Arial;font-size:8pt;"> of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">51%</span><span style="font-family:Arial;font-size:8pt;"> of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">46%</span><span style="font-family:Arial;font-size:8pt;color:#ffffff;"> </span><span style="font-family:Arial;font-size:8pt;">of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. See the &#8220;Analysis of the Consolidated Statements of Income&#8212;Revenues&#8212;Selected Product Discussion&#8221;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">section of this Financial Review for additional information.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">19</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">The following provides an analysis of the change in worldwide revenues by geographic areas in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Continued growth from certain key brands</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,495</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">914</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,581</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenue from continued growth of anti-infective products in China, driven by increased demand for Sulperazon and new launches, the 2018 U.S. launches of our immune globulin intravenous products (Panzyga and Octagam) and the launches of certain anti-infectives products (Zavicefta, Zinforo and Cresemba) in international developed and emerging markets, all in the Hospital products business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">472</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">174</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">298</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenues for Inlyta, primarily in the U.S. driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">190</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">175</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenues for Biosimilars, primarily in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">168</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">185</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(17</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenues for rare disease products driven by the U.S. launches in May 2019 of Vyndaqel and in September 2019 of Vyndamax, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM); and in international markets, primarily driven by continued uptake for the transthyretin amyloid polyneuropathy indication, primarily in developed Europe, as well as the March 2019 launch of the ATTR-CM indication in Japan, partially offset by lower revenues for certain rare disease products, including the hemophilia franchises (Refacto AF/Xyntha and BeneFIX), primarily due to competitive pressures, and Genotropin in developed markets, mainly due to unfavorable channel mix in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">159</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">108</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">51</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Volume-driven growth from Celebrex and Effexor, primarily in Japan and China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">78</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">87</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in July 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,628</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,582</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(46</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Consumer Healthcare reflecting the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK. As a result, 2019 revenues reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,436</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(889</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(547</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues from other Hospital products, primarily reflecting declines in developed markets, mostly due to the continued expected negative impact from generic competition for products that have previously lost marketing exclusivity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(447</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(200</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(247</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Enbrel internationally, reflecting continued biosimilar competition in most developed Europe markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(292</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(292</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Viagra and Upjohn's authorized generic for Viagra in the U.S. resulting from increased generic competition following Viagra's December 2017 patent expiration, partially offset by increased retail demand growth in China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(171</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(193</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">21</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to a recent generic entry, and for Relpax, driven by continued generic competition across developed markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(149</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(110</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(39</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in Norvasc and Lipitor due to pricing pressures from the implementation of the VBP in certain cities in China and lower volumes in Japan, partially offset by overall increased demand in China in the first quarter of 2019 and continued geographic expansion in China during the second half of 2019 in provinces where the VBP had not yet been implemented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(40</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(36</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">57</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(47</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">104</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operational growth/(decline), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(545</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,477</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">932</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,352</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,352</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">&#160;decrease</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,897</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,477</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(420</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Certain key brands represent Ibrance, Eliquis, Xeljanz and Prevnar 13/Prevenar 13. See the &#8220;Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion" section of this Financial Review for product analysis information.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging markets revenues </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$82 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;">, in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;">$12.7 billion</span><span style="font-family:Arial;font-size:8pt;">, reflecting an operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">$877 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">7%</span><span style="font-family:Arial;font-size:8pt;">. Foreign exchange had an </span><span style="font-family:Arial;font-size:8pt;">unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of approximately </span><span style="font-family:Arial;font-size:8pt;">6%</span><span style="font-family:Arial;font-size:8pt;"> on emerging markets revenues. The operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in emerging markets was primarily driven by Prevenar 13, Ibrance and Eliquis in our Biopharma segment and Zoloft, Viagra, Celebrex and Lipitor in our Upjohn segment.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">20</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">The following provides an analysis of the change in worldwide revenues by geographic areas in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">:</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Continued growth from certain key brands</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,715</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,696</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Growth from Biosimilars, primarily from Inflectra in certain channels in the U.S. and developed Europe markets<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">217</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">147</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">69</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Growth from recently launched products, including Eucrisa in the U.S., as well as Besponsa and Bavencio, primarily in the U.S. and developed Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">195</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">158</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">37</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenues for Lipitor and Norvasc primarily due to increased demand in China, partially offset by pricing pressures in China and lower volumes in Japan for Lipitor and Norvasc and the non-recurrence of favorable U.S. rebates for Lipitor that occurred in 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">182</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(52</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">234</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Growth in our Consumer Healthcare business across all markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">107</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">26</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">81</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Viagra in the U.S. resulting from the loss of exclusivity in December 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(572</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(572</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in the Hospital products business, driven by lower revenues in developed markets, primarily due to increased competition across the portfolio and continued legacy Hospira product shortages in the U.S., partially offset by an increase in emerging markets, primarily in China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(482</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(703</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">221</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar competition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(350</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(350</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in Greenstone, Upjohn's solid oral dose generics subsidiary, due to additional generic competition in the U.S. and decline in Relpax, primarily due to loss of exclusivity in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(318</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(310</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for the Premarin family of products and Pristiq primarily driven by generic competition in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(241</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(201</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(40</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in revenues for Lyrica, primarily driven by losses of exclusivity in developed Europe markets and Australia, partially offset by growth in the U.S. and growth in the orally dissolving tablet formulation in Japan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(115</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">131</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(246</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues from the hemophilia portfolio (BeneFIX and Refacto AF/Xyntha), primarily in developed Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(13</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(88</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in revenues for Celebrex, primarily driven by the non-recurrence of favorable U.S. rebates that occurred in 2017 and lower volumes in the U.S.<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(99</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(99</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impact on financial results from the sale of HIS in February 2017. 2018 does not reflect any contribution from HIS global operations, compared to approximately one month of HIS domestic operations and approximately two months of HIS international operations in the same period in 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(97</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(64</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(33</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(251</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(166</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(84</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operational growth/(decline), net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">791</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(698</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,489</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Favorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">310</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">310</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues increase/(decrease)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,101</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(698</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,799</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Certain k</span><span style="font-family:Arial;font-size:7pt;text-align:center;">ey brands </span><span style="font-family:Arial;font-size:7pt;">represent Ibrance, </span><span style="font-family:Arial;font-size:7pt;text-align:center;">Eliquis, </span><span style="font-family:Arial;font-size:7pt;">Xeljanz, Prevnar/Prevenar 13, Xtandi and Chantix/Champix. See the &#8220;Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion" section of this Financial Review for product analysis information.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging markets revenues </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$1.3 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">11%</span><span style="font-family:Arial;font-size:8pt;">, in 2018 to </span><span style="font-family:Arial;font-size:8pt;">$12.7 billion</span><span style="font-family:Arial;font-size:8pt;">, from </span><span style="font-family:Arial;font-size:8pt;">$11.4 billion</span><span style="font-family:Arial;font-size:8pt;"> in 2017, reflecting an operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">$1.5 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">13%</span><span style="font-family:Arial;font-size:8pt;">. Foreign exchange had an </span><span style="font-family:Arial;font-size:8pt;">unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of approximately </span><span style="font-family:Arial;font-size:8pt;">2%</span><span style="font-family:Arial;font-size:8pt;"> on emerging markets revenues. The operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in emerging markets was primarily driven by Prevenar 13, Sulperazon, Ibrance and Eliquis in our Biopharma segment and Lipitor and Norvasc in our Upjohn segment.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information about operating segment revenues, see the &#8220;Analysis of Operating Segment Information&#8221; section of this Financial Review.</span></div><div><a id="s30E446CEB79F5B14A78819C791FF5CB2"></a></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenues&#8212;Selected Product Discussion</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The tables below provide worldwide revenues and revenues by geography, for selected products. References to total change pertain to period-over-period growth rates that include foreign exchange. The difference between the total change and operational change represents the impact of foreign exchange. Amounts may not add due to rounding. All percentages have been calculated using unrounded amounts. An asterisk (*) indicates the calculation is not meaningful or results are equal to or greater than 100%.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">21</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Prevnar 13/Prevenar 13</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma): </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,209</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,360</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,638</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,443</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,847</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,802</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. primarily reflects the continued decline in revenues for the adult indication due to a high initial capture rate of the eligible population following its successful fourth-quarter 2014 launch, which resulted in a smaller remaining &#8220;catch up&#8221; opportunity (i.e., the opportunity to reach adults aged 65 years and older who have not been previously vaccinated with Prevnar 13) as well as lower government purchases for the pediatric indication.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> internationally was primarily driven by the pediatric indication due to higher volumes reflecting continued uptake in China, favorable impact of timing and increased volumes associated with government purchases for the pediatric indication in certain emerging markets and higher volumes resulting from increased shipments associated with Gavi, the Vaccine Alliance.</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2014, the ACIP voted to recommend Prevnar 13 for routine use to help protect adults aged 65 years and older against pneumococcal disease, which for adults includes pneumonia caused by the 13 pneumococcal serotypes included in the vaccine. These ACIP recommendations were subsequently approved by the directors at the CDC and U.S. Department of Health and Human Services, and were published in the Morbidity and Mortality Weekly Report in September 2014 by the CDC. The CDC regularly monitors the impact of vaccination and reviews the recommendations. During the February 2019 ACIP meeting, the CDC presented a formal evaluation of evidence to the recommendation framework (grading) for ACIP&#8217;s input. On June 26, 2019, the ACIP voted to revise the pneumococcal vaccination guidelines and recommend Prevnar 13 for adults 65 and older based on the shared clinical decision making of the provider and patient, which means the decision to vaccinate should be made at the individual level between health care providers and their patients, maintaining reimbursement. The recommendation reaffirms that there remains vaccine preventable pneumococcal disease in the population of adults 65 years or older, which may be prevented through direct vaccination. The ACIP&#8217;s recommendation was approved by the directors at the CDC and U.S. Department of Health and Human Services, and published by the CDC in the Morbidity and Mortality Weekly Report in the fourth quarter of 2019. While the ACIP&#8217;s latest recommendation did not have an impact on Prevnar 13 revenues in 2019, due to timing of the Morbidity and Mortality Weekly Report publication, we expect Prevnar 13 revenues from the adult indication to continue to decline in 2020 and beyond.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Ibrance</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,250</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,922</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,710</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,196</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">43</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,961</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,118</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">23</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> in international markets reflects the continued strong uptake in developed Europe and Japan as well as in certain emerging markets following launches, partially offset by pricing pressure primarily in certain developed Europe markets beginning in the fourth quarter of 2019. The </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. was mainly driven by cyclin-dependent kinase (CDK) class share growth and Ibrance&#8217;s continued CDK class share leadership in its approved metastatic breast cancer indications.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Eliquis alliance revenues and direct sales </span><span style="font-family:Arial;font-size:8pt;">(Biopharma): Eliquis has been jointly developed and is commercialized by Pfizer and BMS. Pfizer funds between 50% and 60% of all development costs depending on the study. Profits and losses are shared equally on a global basis, except in certain countries where Pfizer commercializes Eliquis and pays BMS compensation based on a percentage of net sales. We have full commercialization rights in certain smaller markets. BMS supplies the product to us at cost plus a percentage of the net sales to end-customers in these markets. Eliquis is part of the Novel Oral Anticoagulant market; the agents in this class were developed as alternative treatment options to warfarin in appropriate patients.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,343</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,849</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">27</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,877</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,585</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">24</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,220</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,434</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">23</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">26</span></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was mostly driven by continued increased adoption in non-valvular atrial fibrillation, as well as oral anti-coagulant market share gains, partially offset by a higher Medicare &#8220;coverage gap&#8221; discount provision on U.S. revenues compared to the prior year.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">22</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Lyrica</span><span style="font-family:Arial;font-size:8pt;"> (Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:9.5pt;"><span style="font-family:Arial;font-size:9.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,012</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,594</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(44</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,308</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,375</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,321</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,970</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(33</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(33</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;">s in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. were due to the expected significantly lower volumes driven by multi-source generic competition which began in July 2019.</span></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The operational </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> internationally in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was primarily due to generic competition in developed Europe markets and pricing pressures across international markets, partially offset by increased volumes in Japan attributable to growth in the orally dissolving tablet formulation, and increased volumes in Russia and China.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Xeljanz </span><span style="font-family:Arial;font-size:8pt;">(Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,636</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,394</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">17</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">606</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">380</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">59</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">70</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,242</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,774</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">26</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">29</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was primarily due to continued growth in the RA indication driven by access improvements, and by volume growth from the launches of the UC and PsA indications in 2018, partially offset by higher rebating from new commercial contracts.</span></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> internationally in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was mainly driven by continued uptake in the RA indication in developed Europe, emerging markets, Japan and Canada as well as from the recent launch of the UC indication in certain developed markets.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In July and December 2019, the FDA updated the U.S. prescribing information for Xeljanz to include three additional boxed warnings as well as changes to the indication and dosing for UC. In January 2020, the EC revised the summary of product characteristics (SmPC) for Xeljanz to include new warnings&#160;and recommendations for use of Xeljanz due to an increased risk of venous thromboembolism, and, due to an increased risk of infections, revised warnings in patients older than 65 years of age.</span><span style="font-family:Arial;font-size:8pt;color:#ff0000;"> </span><span style="font-family:Arial;font-size:8pt;">These updates were based on the FDA&#8217;s and EMA&#8217;s review of 10 mg data from the ongoing post-marketing requirement RA study A3921133. We expect these updates to moderate growth. See the &#8220;Analysis of Consolidated Statements of Income&#8212;Product Development&#8212;Biopharmaceuticals&#8221; section of this Financial Review.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Lipitor </span><span style="font-family:Arial;font-size:8pt;">(Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">104</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">110</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,870</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,952</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,973</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,062</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational revenue was flat in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> mostly due to overall increased demand in China in the first quarter of 2019 and continued geographic expansion during the second half of 2019 in provinces where the VBP program had not yet been implemented, offset by pricing pressures in China resulting from the VBP implementation in certain cities, discontinued sales in Saudi Arabia and lower volumes in Japan.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Enbrel </span><span style="font-family:Arial;font-size:8pt;">(Biopharma, outside the U.S. and Canada):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,699</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,112</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(20</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(14</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,699</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,112</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(20</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(14</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was primarily due to ongoing biosimilar competition in most developed Europe markets, which is expected to continue.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">23</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Chantix/Champix</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">899</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">838</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">208</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">247</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,107</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,085</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was primarily due to stronger demand. The operational </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> internationally in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was mainly driven by generic entry in South Korea and Canada.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Norvasc </span><span style="font-family:Arial;font-size:8pt;">(Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">39</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">36</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">911</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">992</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">950</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,029</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was primarily due to pricing pressures in China resulting from the VBP implementation in certain cities and lower volumes in Japan, partially offset by overall increased demand in China in the first quarter of 2019 and continued geographic expansion during the second half of 2019 in provinces where the VBP had not yet been implemented.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Sutent</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">283</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">357</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(21</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">653</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">692</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">936</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,049</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(11</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> reflects continued erosion as a result of increased competition in the U.S. and key developed markets, partially offset by growth in certain emerging markets.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Xtandi alliance revenues </span><span style="font-family:Arial;font-size:8pt;">(Biopharma): Xtandi is being developed and commercialized through a collaboration with Astellas. The two companies share equally in the gross profits (losses) related to U.S. net sales of Xtandi. Subject to certain exceptions, Pfizer and Astellas also share equally all Xtandi commercialization costs attributable to the U.S. market. Pfizer and Astellas also share certain development and other collaboration expenses, and Pfizer receives tiered royalties as a percentage of international Xtandi net sales (recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;">).</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">838</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">699</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">838</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">699</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was primarily driven by increased demand for Xtandi in metastatic (mCRPC) and non-metastatic (nmCRPC) castration-resistant prostate cancer. Revenues continue to be unfavorably impacted by patient assistance programs (PAP) utilization.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Premarin</span><span style="font-family:Arial;font-size:8pt;"> family of products (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">690</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">783</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(12</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">44</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">49</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">734</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">832</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(12</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(12</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was primarily driven by continued competitive pressures in the U.S., which is expected to continue.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">24</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Celebrex </span><span style="font-family:Arial;font-size:8pt;">(Upjohn):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">58</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">65</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(11</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">661</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">621</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">719</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">686</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was mainly due to higher volumes in China, driven by investments in geographic expansion, and higher volumes in Japan, partially offset by pricing pressures in certain emerging markets. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Sulperazon</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">684</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">613</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">17</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">684</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">613</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">17</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The international operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was mostly due to increased demand in China.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Inflectra/Remsima </span><span style="font-family:Arial;font-size:8pt;">(Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">300</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">259</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">16</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">325</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">383</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(15</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">625</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">642</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide operational revenues were relatively flat in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> due to continued volume growth in the U.S., as well as in certain developed markets in Europe and Canada, offset by pricing pressures globally as well as competitive pressures internationally.</span></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. in 2019 was primarily driven by demand in open systems, partially offset by price erosion. While Inflectra has achieved parity access to Remicade</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:8pt;"> (infliximab) in Medicare Part B, nearly half of all commercial patients are not able to access Inflectra due to exclusionary contracting practices by J&amp;J. In September 2017, Pfizer filed suit in the U.S. District Court for the Eastern District of Pennsylvania against J&amp;J alleging that J&amp;J&#8217;s exclusionary contracts and other anticompetitive practices concerning Remicade violate federal antitrust laws. In June 2019, Pfizer received a Civil Investigative Demand from the Federal Trade Commission (FTC) seeking documents and information relating to the alleged conduct and market conditions at issue in Pfizer&#8217;s lawsuit against J&amp;J. Pfizer understands that the FTC&#8217;s investigation is focused on J&amp;J&#8217;s alleged conduct at issue in Pfizer&#8217;s lawsuit against J&amp;J.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Xalkori </span><span style="font-family:Arial;font-size:8pt;">(Biopharma):</span></div></td></tr></table><div style="line-height:120%;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">149</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">158</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">381</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">366</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">530</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">524</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> primarily resulted from growth in China, following the impact of inclusion of Xalkori in the 2019 National Reimbursement Drug Listing, partially offset by erosion due to competition in developed Europe and in the U.S.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Viagra </span><span style="font-family:Arial;font-size:8pt;">(Upjohn)</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">75</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">217</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(65</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">422</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">419</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">497</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">636</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(19</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was driven by the loss of exclusivity in December 2017. The operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> internationally in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;text-align:center;"> </span><span style="font-family:Arial;font-size:8pt;">was mostly due to increased retail demand growth in China, partially offset by pricing pressures in China and lower volumes across certain developed and certain emerging markets.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">25</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Inlyta</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">295</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">119</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">182</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">178</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">477</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">298</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">60</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">64</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;text-align:center;"> </span><span style="font-family:Arial;font-size:8pt;">was primarily due to increased demand in the U.S. as a result of the FDA approvals in the second quarter of 2019 for combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC. </span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vyndaqel/Vyndamax</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">191</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">282</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">148</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">91</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">96</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">473</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">148</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">*</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. was driven by the launches in May 2019 of Vyndaqel and in September 2019 of Vyndamax, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM). The operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in international markets was primarily driven by continued uptake for the transthyretin amyloid polyneuropathy indication, primarily in developed Europe, as well as the March 2019 launch of the ATTR-CM indication in Japan.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Eucrisa </span><span style="font-family:Arial;font-size:8pt;">(Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">134</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">147</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">138</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">147</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">decline</span><span style="font-family:Arial;font-size:8pt;"> in the U.S. in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was primarily driven by higher rebating and unfavorable channel mix, in addition to favorable rebate adjustments in 2018, partially offset by volume growth.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Alliance revenues</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma):</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:18px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.42063492063492%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Oper.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,208</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,576</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">25</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,440</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,263</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Worldwide revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,648</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,838</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">23</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:4px;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The worldwide operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> was mainly due to increases in Eliquis and Xtandi alliance revenues included in the above discussion.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:18px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Bavencio</span><span style="font-family:Arial;font-size:8pt;"> (Biopharma) is being developed and commercialized in collaboration with Merck KGaA. </span><span style="font-family:Arial;font-size:8pt;">Both companies jointly fund the majority of development and commercialization costs, and split equally any profits related to net sales generated from selling any products containing avelumab from this collaboration.</span><span style="font-family:Arial;font-size:8pt;"> Bavencio is currently approved in metastatic MCC in the U.S., the EU, Japan and select other markets; the second-line treatment of locally advanced or metastatic urothelial carcinoma in the U.S. and select other markets; and first-line treatment of patients with advanced RCC in combination with Inlyta in the U.S., the EU, Japan and select other markets.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17C.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:8pt;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Other Revenue Information</span><span style="font-family:Arial;font-size:8pt;"> for additional information regarding the primary indications or class of the selected products discussed above.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See the &#8220;Patents and Other Intellectual Property Rights&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K for information regarding the expiration of various patent rights.</span></div><div style="line-height:120%;font-size:3pt;"><span style="font-family:Arial;font-size:3pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;"> for a discussion of recent developments concerning patent and product litigation relating to certain of the products discussed above.</span></div><div><a id="sD19EB0840C59585BB8015C765A050CB8"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">PRODUCT DEVELOPMENTS&#8212;BIOPHARMACEUTICAL</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We continue to invest in R&amp;D to provide potential future sources of revenues through the development of new products, as well as through additional uses for in-line and alliance products. Notwithstanding our efforts, there are no assurances as to when, or if, we will receive regulatory approval for additional indications for existing products or any of our other products in development.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">26</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We continue to strengthen our global R&amp;D organization and pursue strategies intended to improve innovation and overall productivity in R&amp;D to achieve a sustainable pipeline that will deliver value in the near term and over time. </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information about our R&amp;D organization, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;Our Strategy&#8212;Organizing for Growth&#8221; and &#8220;&#8212;Description of Research and Development Operations&#8221; sections of this Financial Review. </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A comprehensive update of Pfizer&#8217;s development pipeline was published as of </span><span style="font-family:Arial;font-size:8pt;">January&#160;28, 2020</span><span style="font-family:Arial;font-size:8pt;"> and is available at www.pfizer.com/science/drug-product-pipeline. It includes an overview of our research and a list of compounds in development with targeted indication and phase of development, as well as mechanism of action for some candidates in Phase 1 and all candidates from Phase 2 through registration.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following series of tables provides information about significant regulatory actions by, and filings pending with, the FDA and regulatory authorities in the EU and Japan, as well as additional indications and new drug candidates in late-stage development.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:58%;"></td><td style="width:16%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">RECENT FDA APPROVALS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">INDICATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">DATE APPROVED</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of metastatic castration-sensitive prostate cancer, which is being developed through a collaboration with Astellas</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Abrilada</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;</sup></span><span style="font-family:Arial;font-size:7pt;">(adalimumab-afzb)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A biosimilar to Humira</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174; </sup></span><span style="font-family:Arial;font-size:7pt;">(adalimumab) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult Crohn's disease, ulcerative colitis and plaque psoriasis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">November 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Ruxience (rituximab-pvvr)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A biosimilar to Rituxan</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(rituximab) for the treatment of adult patients with non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, and granulomatosis with polyangiitis and microscopic polyangiitis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">July 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Zirabev (bevacizumab-bvzr)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A biosimilar to Avastin</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(bevacizumab) for the treatment of mCRC; unresectable, locally advanced, recurrent or metastatic NSCLC; recurrent glioblastoma; metastatic RCC; and persistent, recurrent or metastatic cervical cancer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">June 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of patients with advanced RCC, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">May 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vyndaqel (tafamidis meglumine)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">May 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vyndamax (tafamidis)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of the cardiomyopathy of wild-type or hereditary ATTR-CM in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">May 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:1px;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Trazimera (trastuzumab-qyyp)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-top:3px;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A biosimilar to Herceptin</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(trastuzumab) for all eligible indications of the reference product</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">March 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Daurismo (glasdegib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of newly-diagnosed acute myeloid leukemia in adult patients who are 75 years or older or who have comorbidities that preclude use of intensive induction chemotherapy</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">November 2018</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Lorbrena (lorlatinib)</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of patients with ALK-positive metastatic NSCLC whose disease has progressed on crizotinib and at least one other ALK inhibitor for metastatic disease; or whose disease has progressed on alectinib or ceritinib as the first ALK inhibitor therapy for metastatic disease</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">November 2018</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Humira</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;"> is a registered trademark of AbbVie Biotechnology Ltd. Pfizer is working to make Abrilada available to U.S. patients as soon as feasible based on the terms of its agreement with AbbVie. Current plans are to launch Abrilada in 2023.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Rituxan</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;"> is a registered trademark of Biogen MA Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Avastin</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;"> is a registered trademark of Genentech, Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Herceptin</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;"> is a registered trademark of Genentech, Inc.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:58%;"></td><td style="width:16%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">PENDING U.S. NDAs AND SUPPLEMENTAL FILINGS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">PROPOSED INDICATION</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">DATE FILED*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Braftovi (encorafenib)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Braftovi (encorafenib) in combination with Erbitux</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(cetuximab) for the treatment of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">BRAF</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</sup></span><span style="font-family:Arial;font-size:7pt;">-mutant metastatic colorectal cancer after prior therapy</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">PF-06881894</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A potential biosimilar to Neulasta</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(pegfilgrastim)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">August 2019</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vyndaqel (tafamidis meglumine)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of transthyretin familial amyloid polyneuropathy</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">February 2012</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:Arial;font-size:7.5pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">The dates set forth in this column are the dates on which the FDA accepted our submissions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Erbitux</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174; </sup></span><span style="font-family:Arial;font-size:7pt;">is a registered trademark of ImClone LLC.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Neulasta</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174; </sup></span><span style="font-family:Arial;font-size:7pt;">is a registered U.S. trademark of Amgen Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In May 2012, the FDA&#8217;s Peripheral and Central Nervous System Drugs Advisory Committee voted that the tafamidis meglumine data provide substantial evidence of efficacy for a surrogate endpoint that is reasonably likely to predict a clinical benefit. In June 2012, the FDA issued a &#8220;complete response&#8221; letter with respect to this tafamidis NDA. The FDA has requested the completion of a second efficacy study, and also has asked for additional information on the data within the current tafamidis NDA. Pfizer has completed study B3461028, a global Phase 3 study to support the new indication of transthyretin amyloid cardiomyopathy, which includes patients with wild type and variant transthyretin. We are working with the FDA to identify next steps.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">27</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:21%;"></td><td style="width:51%;"></td><td style="width:14%;"></td><td style="width:14%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">REGULATORY APPROVALS AND FILINGS IN THE EU AND JAPAN</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">DESCRIPTION OF EVENT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">DATE APPROVED</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">DATE FILED*</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vyndaqel (tafamidis free acid)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in the EU for </span><span style="font-family:Arial;font-size:7pt;color:#333333;">a once-daily 61 mg oral capsule, for the treatment of wild-type or hereditary transthyretin amyloidosis in adult patients with cardiomyopathy</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">February 2020</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amsparity (adalimumab)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in the EU for a biosimilar to Humira</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(adalimumab) for the treatment of certain patients with rheumatoid arthritis, juvenile idiopathic arthritis, axial spondyloarthritis, psoriatic arthritis, psoriasis, hidradenitis suppurativa, Crohn&#8217;s disease, ulcerative colitis, uveitis, and pediatric plaque psoriasis</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">February 2020</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in the EU for Xeljanz (tofacitinib) 11 mg prolonged release tablets in combination with methotrexate&#160;for the treatment of moderate to severe active rheumatoid arthritis&#160;in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs </span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in Japan for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of advanced RCC, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December 2019</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Braftovi (encorafenib) and Mektovi (binimetinib)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application filed in the EU for second-or-third-line treatment of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">BRAF-</span><span style="font-family:Arial;font-size:7pt;">mutant mCRC in patients who have received prior systemic therapy, which is being developed in collaboration with the Pierre Fabre Group</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">November 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in the EU for Bavencio (avelumab) in combination with Inlyta (axitinib) for the first-line treatment of advanced RCC, which is being developed in collaboration with Merck KGaA, Germany</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">October 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">PF-06881894</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application filed in the EU for a potential biosimilar to Neulasta&#174; (pegfilgrastim)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">October 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Rituximab Pfizer (rituximab)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in Japan for a biosimilar to Rituxan</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(rituximab) for the treatment of CD20-positive, B-cell non-Hodgkin&#8217;s Lymphoma, CD20-positive, B-cell lymphoproliferative disease under immunosuppression, and Granulomatosis with polyangiitis, and microscopic polyangiitis</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">September 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bosulif (bosutinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application filed in Japan for the treatment of chronic myelogenous leukemia (CML), which is being developed in collaboration with Avillion LLP</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">July 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application filed in the EU for the treatment of metastatic hormone-sensitive prostate cancer, which is being developed through a collaboration with Astellas</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">July 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Talzenna (talazoparib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in the EU for monotherapy for the treatment of adult patients with germline breast cancer susceptibility gene (g</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">BRCA</span><span style="font-family:Arial;font-size:7pt;">)1/2-mutations, who have HER2- locally advanced or metastatic breast cancer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">June 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bevacizumab Pfizer (bevacizumab)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in Japan for a biosimilar to Avastin</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(bevacizumab) for the treatment of metastatic colorectal cancer</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">June 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Daurismo (glasdegib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application filed in the EU for treatment of newly-diagnosed acute myeloid leukemia in adult patients who are 75 years or older or who have co-morbidities that preclude use of intensive induction chemotherapy</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">May 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Lorviqua (lorlatinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in the EU as monotherapy, for the treatment of adult patients with ALK- positive advanced non-small cell lung cancer whose disease has progressed after:</span></div><div><div style="float:left; width:12px; padding-left:6px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div><span style=""><span style="font-family:Arial;font-size:7pt;">alectinib or ceritinib as the first ALK tyrosine kinase inhibitor (TKI) therapy; or</span></span></div><div><div style="float:left; width:12px; padding-left:6px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div><span style=""><span style="font-family:Arial;font-size:7pt;">crizotinib and at least one other ALK TKI</span></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">May 2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vizimpro (dacomitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in the EU as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with EGFR activating mutations, which is being developed in collaboration with SFJ</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">April 2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vyndaqel (tafamidis meglumine)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in Japan for treatment of transthyretin amyloid cardiomyopathy</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">March 2019</span></div></td><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Zirabev</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in the EU for a biosimilar to Avastin</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(bevacizumab) for the treatment of metastatic carcinoma of the colon or rectum, metastatic breast cancer, unresectable advanced, metastatic or recurrent NSCLC, advanced and/or metastatic renal cell cancer and persistent, recurrent, or metastatic carcinoma of the cervix</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">February 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vizimpro (dacomitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application approved in Japan for the treatment of patients with locally advanced or metastatic non-small cell lung cancer with EGFR mutations, which is being developed in collaboration with SFJ</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">January 2019</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">PF-05280586</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application filed in the EU for a potential biosimilar to MabThera</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">&#160;(rituximab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">August 2018</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">crisaborole</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Application filed in the EU for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients from 2&#160;years of age with &#8804;&#160;40% body surface area (BSA) affected</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">May 2018</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For applications in the EU, the dates set forth in this column are the dates on which the EMA validated our submissions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Humira</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;"> is a registered trademark of AbbVie Biotechnology Ltd. Pfizer does not currently plan to commercialize Amsparity in the EU due to unfavorable market conditions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Neulasta</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;"> is a registered trademark of Amgen Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Rituxan</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;"> is a registered trademark of Biogen MA Inc. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Avastin</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;"> is a registered trademark of Genentech, Inc.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">MabThera&#174; is a registered trademark of Roche, Inc. In January 2020, the EMA&#8217;s CHMP adopted a positive opinion recommending the approval of PF-05280586 as a potential biosimilar to MabThera&#174; (rituximab) for the treatment of non-Hodgkin&#8217;s lymphoma, chronic lymphocytic leukemia, RA, granulomatosis with polyangiitis and microscopic polyangiitis, and pemphigus vulgaris.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In January 2020, the EMA&#8217;s CHMP adopted a positive opinion recommending the approval of Staquis (crisaborole) for the treatment of mild to moderate atopic dermatitis in adults and pediatric patients from 2 years of age with &#8804; 40% BSA affected.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">28</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">LATE-STAGE CLINICAL PROGRAMS FOR ADDITIONAL USES AND DOSAGE FORMS<br/>FOR IN-LINE AND IN-REGISTRATION PRODUCTS</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">PROPOSED INDICATION</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A monoclonal antibody that inhibits PD-L1 for the first-line treatment of stage IIIb/IV non-small cell lung cancer, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A monoclonal antibody that inhibits PD-L1 for maintenance treatment, in the first-line setting, for patients with urothelial cancer, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Bavencio (avelumab)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A monoclonal antibody that inhibits PD-L1 for treatment of locally advanced squamous cell carcinoma of the head and neck, which is being developed in collaboration with Merck KGaA, Germany</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Daurismo (glasdegib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A smoothened inhibitor, in combination with azacitidine, for the treatment of acute myeloid leukemia</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of HER2+ advanced breast cancer, in collaboration with the Alliance Foundation Trials, LLC</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of high-risk early breast cancer, in collaboration with the German Breast Group</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Ibrance (palbociclib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of HR+ early breast cancer, in collaboration with the Alliance Foundation Trials, LLC, and the Austrian Breast Colorectal Cancer Study Group</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Lorbrena (lorlatinib)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of patients with metastatic non-small cell lung cancer whose tumors are ALK-positive as detected by an FDA-approved test</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Xeljanz (tofacitinib)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of ankylosing spondylitis</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Xtandi (enzalutamide)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Treatment of non-metastatic hormone-sensitive prostate cancer, which is being developed through a collaboration with Astellas</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Talzenna (talazoparib)</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">An oral PARP inhibitor, in combination with Xtandi (enzalutamide), for the treatment of metastatic castration-resistant prostate cancer</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In November 2019, we and our partner Merck KGaA, Germany, announced the topline results of the Phase III JAVELIN Gastric 100 study evaluating avelumab as first-line maintenance therapy following induction chemotherapy in patients with unresectable, locally advanced or metastatic HER2-negative gastric or gastroesophageal junction cancer versus continuation of chemotherapy or best supportive care. While the study showed clinical activity for avelumab in this setting, it did not meet the primary endpoints of superior overall survival compared with the standard of care in the overall intent-to-treat population. No new safety signals were observed, and the safety profile for avelumab in this trial was consistent with that observed in the overall JAVELIN clinical development program.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February 2019, the company took steps to transition rheumatoid arthritis study patients who were on tofacitinib 10 mg twice daily to tofacitinib 5 mg twice daily in the ongoing FDA post-marketing requirement study A3921133, a study performed in patients considered to be at high risk for certain side effects. This action was taken as the result of notification from the tofacitinib Rheumatology Data Safety Monitoring Board of a safety signal regarding the tofacitinib 10 mg twice daily treatment arm in study A3921133. The 5 mg twice daily dose is the FDA approved dose in the U.S. for adult patients with moderate to severe rheumatoid arthritis. In July 2019, the FDA updated the U.S. prescribing information for Xeljanz to include two additional boxed warnings as well as changes to the indication and dosing for UC. These updates were based on the FDA&#8217;s review of data from the ongoing post-marketing requirement RA study A3921133. In January 2020, the EC revised the summary of product characteristics (SmPC) for Xeljanz to include new warnings and recommendations for use of Xeljanz due to an increased risk of venous thromboembolism and, due to an increased risk of infections, revised warnings in patients older than 65 years of age. These updates were based on the FDA&#8217;s and EMA&#8217;s review of data from the ongoing post-marketing requirement rheumatoid arthritis study A3921133.</span></div><div style="line-height:120%;text-align:left;font-size:11pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:22%;"></td><td style="width:78%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">NEW DRUG CANDIDATES IN LATE-STAGE DEVELOPMENT</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">CANDIDATE</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">PROPOSED INDICATION</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">aztreonam-avibactam <br/>(PF-06947387)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A beta lactam/beta lactamase inhibitor for the treatment of patients with infections caused by Gram-negative bacteria, including those that produce metallo-beta-lactamases, for which there are limited or no treatment options</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">fidanacogene elaparvovec (PF-06838435)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">An investigational gene therapy for the treatment of hemophilia B</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">PF-06482077</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A 20-Valent pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease and pneumonia caused by </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Streptococcus pneumoniae</span><span style="font-family:Arial;font-size:7pt;">&#160;serotypes covered by the vaccine in adults 18 years of age and older</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">PF-06651600</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A selective dual Janus kinase 3 (JAK3) and Tyrosine kinase Expressed in hepatocellular Carcinoma (TEC) family inhibitor for the treatment of patients with moderate to severe alopecia areata</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">abrocitinib (PF-04965842)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A Janus kinase 1 (JAK1) inhibitor for the treatment of moderate-to-severe atopic dermatitis</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">PF-06425090</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:11pt;"><span style="font-family:Arial;font-size:7pt;">A prophylactic vaccine for prevention of primary clostridioides</span><span style="font-family:inherit;font-size:11pt;font-style:italic;">&#160;</span><span style="font-family:Arial;font-size:7pt;">difficile infection (CDI) in individuals</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">PF-07265803</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">An oral inhibitor of p38 mitogen-activated protein kinase for the treatment of patients with symptomatic dilated cardiomyopathy due to a Lamin A/C gene mutation</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">PF-06801591</span></div><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A monoclonal antibody that inhibits PD-1, in combination with Bacillus Calmette-Guerin (BCG), for the treatment of non-muscle invasive bladder cancer</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">somatrogon (PF-06836922)</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A long-acting hGH-CTP for the treatment of growth hormone deficiency in children, which is being developed in collaboration with OPKO</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">somatrogon (PF-06836922)</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">A long-acting hGH-CTP for the treatment of growth hormone deficiency in adults, which is being developed in collaboration with OPKO</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">tanezumab</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-right:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">An anti-nerve growth factor monoclonal antibody for the treatment of pain, which is being developed in collaboration with Lilly</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2019, we announced that the Phase 3 Rivipansel (GMI-1070): Evaluating Safety, Efficacy and Time to Discharge (RESET) pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease (SCD) who were hospitalized for a vaso-occlusive crisis (VOC) and required treatment with IV opioids. We plan to share the study data in a publication or scientific meeting presentation in the near future, as we want to ensure the learnings from this trial help inform future sickle cell programs that aim to improve care for SCD disease patients experiencing a </span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">29</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">VOC. In February 2020, we notified GlycoMimetics, Inc. that we were discontinuing further development of rivipansel and will transfer the program back to them.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Additional product-related programs are in various stages of discovery and development.</span></div><div><a id="s2A103E6709085297913858D0A1DA36F8"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">COSTS AND EXPENSES</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The changes in expenses below reflect, among other things, a decline in expenses resulting from the July 31, 2019 completion of the Consumer Healthcare JV transaction with GSK. Our financial results, and our Consumer Healthcare segment&#8217;s operating results, for 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Basis of Presentation.</span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Cost of Sales</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18/17</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,219</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,248</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,228</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(9</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a percentage of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21.0</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21.4</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decreased</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$1.0 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">9%</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture transaction with GSK;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">$279 million</span><span style="font-family:Arial;font-size:8pt;">; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of hedging activity on intercompany inventory of </span><span style="font-family:Arial;font-size:8pt;">$261 million</span><span style="font-family:Arial;font-size:8pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">lower royalty expense for Lyrica due to the patent expiration,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an unfavorable change in product mix.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> as a percentage of revenues in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, was primarily due to all of the factors discussed above, as well an increase in alliance revenues, which have no associated cost of sales, partially offset by lower Lyrica revenues in developed markets, due to U.S. multi-source generic competition that began in July 2019.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">increased</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$21 million</span><span style="font-family:Arial;font-size:8pt;">, or were relatively flat, in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, primarily due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased sales volumes mostly related to key products within our product portfolio; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">higher costs across the legacy SIP portfolio, as a result of the complexity of high quality product manufacture across the legacy Hospira plants, which was partially offset by decreases in other costs across various markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an increase in royalty expenses based on the mix of products sold; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the unfavorable impact of hedging activity on intercompany inventory of $65 million,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">lower volumes from the legacy SIP portfolio, in developed markets, primarily due to increased competition across the legacy SIP portfolio and continued legacy Hospira product shortages in the U.S.;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-recurrence of $195 million in inventory losses, overhead costs, and incremental costs related to the period in 2017 during which our Puerto Rico plants were not operational due to hurricanes; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of foreign exchange of $153 million;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-recurrence of charges related to a product recall that occurred in 2017; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of the sale of HIS of $35 million.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> as a percentage of revenues in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, was mainly due to all of the factors discussed above, as well as an increase in alliance revenues, which have no associated cost of sales.</span></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Selling, Informational and Administrative (SI&amp;A) Expenses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18/17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,350</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,455</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,804</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a percentage of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">27.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">26.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">28.2</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">SI&amp;A expenses </span><span style="font-family:Arial;font-size:8pt;">decreased</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$105 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;">, in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, mostly due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture with GSK;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">30</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">reduction in field force expense as well as advertising and promotion expenses in developed markets, primarily related to Lyrica in the U.S.; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of foreign exchange of $291 million,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">additional Biopharma investment in emerging markets; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">separation costs of </span><span style="font-family:Arial;font-size:8pt;">$127 million</span><span style="font-family:Arial;font-size:8pt;"> associated with our planned Upjohn transaction with Mylan;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">additional investment in the Oncology portfolio in developed markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased employee deferred compensation as a result of savings plan gains;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an increase due to the timing of expenses (i.e., insurance recoveries and product donations);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">marketing and promotional expenses associated with the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">costs to separate Consumer Healthcare;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased healthcare reform expenses; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn investments in China across key brands.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">SI&amp;A expenses </span><span style="font-family:Arial;font-size:8pt;">decreased</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$350 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">2%</span><span style="font-family:Arial;font-size:8pt;">, in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, mainly due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">lower advertising, promotional and field force expenses, as well as general and administrative expenses, reflecting the benefits of cost-reduction and productivity initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-recurrence of a $200 million charitable contribution to the Pfizer Foundation;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">decreased investment across several of our key products, primarily Viagra and Enbrel; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">lower healthcare reform expenses as a result of a true up of the prior year amount,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">additional investment across several of our key products, primarily, Xeljanz, Ibrance, Eucrisa and Prevnar 13/Prevenar 13;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">additional investments in China; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, of </span><span style="font-family:Arial;font-size:8pt;">$119 million</span><span style="font-family:Arial;font-size:8pt;">, in the aggregate, in the first quarter of 2018.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Research and Development (R&amp;D) Expenses</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18/17</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,650</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8,006</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,683</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a percentage of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16.7</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14.6</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">R&amp;D expenses </span><span style="font-family:Arial;font-size:8pt;">increased</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$644 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">8%</span><span style="font-family:Arial;font-size:8pt;">, in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, mainly due to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">upfront payments to Therachon and Akcea (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;">);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased investments towards building new capabilities and driving automation; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased spending on our Inflammation &amp; Immunology and Rare Disease portfolios due to several Phase 3 programs and </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">investment in gene therapy;</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased spending related to assets acquired from Array; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased medical spend for new and growing products, </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">decreased spending across the Oncology, Vaccines and Internal Medicine portfolios, as select programs have reached completion;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a decrease in the value of the portfolio performance share grants reflecting changes in the price of Pfizer&#8217;s common stock, as well as management&#8217;s assessment of the probability that the specified performance criteria will be achieved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the discontinuation of the Staphylococcus aureus vaccine trial;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of the July 31, 2019 completion of the Consumer Healthcare joint venture with GSK; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable impact of foreign exchange.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">R&amp;D expenses </span><span style="font-family:Arial;font-size:8pt;">increased</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$322 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">4%</span><span style="font-family:Arial;font-size:8pt;">, in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, mainly due to: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased costs associated with our Phase 3 clinical trials related to our JAK1 inhibitor (which was initiated in December 2017) and the </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">C. difficile</span><span style="font-family:Arial;font-size:8pt;"> vaccine program (which was initiated in March 2017) as well as increased spending for our 20 valent pneumococcal conjugate vaccine candidate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">increased costs associated with the Bavencio program; and</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">31</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an increase in the value of the portfolio performance share grants reflecting changes in the price of Pfizer&#8217;s common stock, as well as management&#8217;s assessment of the probability that the specified performance criteria will be achieved,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">decreased spending for biosimilars as several programs have reached completion; and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of our decision to end internal neuroscience discovery and early development efforts.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information on Cost of sales, SI&amp;A and R&amp;D expenses by operating segment, see the &#8220;Analysis of Operating Segment Information&#8221; section of this Financial Review.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Amortization of Intangible Assets</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="18"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18/17</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,610</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,893</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,758</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a percentage of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9.1</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets </span><span style="font-family:Arial;font-size:8pt;">decreased</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$283 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">6%</span><span style="font-family:Arial;font-size:8pt;">, in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, mainly due to the non-recurrence of amortization expense as a result of the impairment of sterile injectable products in the fourth quarter of 2018 (recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">), fully amortized assets and the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK, partially offset by an increase in amortization expense related to assets recorded as a result of the approval of Xtandi in the U.S. for the treatment of non-metastatic castration-resistant prostate cancer in July of 2018 and amortization of intangible assets as a result of our acquisition of Array.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets </span><span style="font-family:Arial;font-size:8pt;">increased</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">$135 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">3%</span><span style="font-family:Arial;font-size:8pt;">, in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, primarily due to amortization expense of approximately $151 million (pre-tax) in 2018 associated with the approval of Xtandi in the U.S. for the treatment of non-metastatic castration-resistant prostate cancer. The U.S. approval resulted in the transfer of </span><span style="font-family:Arial;font-size:8pt;">$2.7 billion</span><span style="font-family:Arial;font-size:8pt;"> from an indefinite-lived </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">IPR&amp;D </span><span style="font-family:Arial;font-size:8pt;">intangible asset to a finite-lived </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights </span><span style="font-family:Arial;font-size:8pt;">intangible asset.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2A.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Acquisitions, </span><span style="font-family:Arial;font-size:8pt;">&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2C. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Equity-Method Investment and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Assets and Liabilities Held for Sale</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">and &#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 10A. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Identifiable Intangible Assets and Goodwill</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Identifiable Intangible Assets</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">18/17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Restructuring charges/(credits)&#8211;&#8211;acquisition-related costs</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(192</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">37</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">105</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">(64</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Restructuring charges/(credits)&#8211;&#8211;cost reduction initiatives</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">565</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">745</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">(75</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(24</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Restructuring charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">373</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">782</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">30</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(52</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Transaction costs</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">63</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">(62</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Integration costs and other</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">311</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">260</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">317</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">20</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">(18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">747</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">1,044</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">351</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(28</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net periodic benefit costs</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">23</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">146</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">136</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(84</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">38</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">50</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">91</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(24</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">(45</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">158</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">194</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">227</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(18</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">(15</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Costs associated with acquisitions and cost-reduction/productivity initiatives</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">967</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">1,434</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">805</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">(33</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">78</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Restructuring charges/(credits)&#8211;&#8211;acquisition-related costs include employee termination costs, asset impairments and other exit costs associated with business combinations. Credits for 2019 were mostly due to the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of an IRS audit for multiple tax years. See Notes Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5D. Tax Matters: Tax Contingencies. </span><span style="font-family:Arial;font-size:7pt;">Charges for 2018 </span><span style="font-family:Arial;font-size:7pt;">were mainly due to asset write downs, partially offset by the reversal of previously recorded accruals for employee termination costs related to our acquisition of Hospira</span><span style="font-family:Arial;font-size:7pt;">. Restructuring charges for 2017 mainly related to our acquisitions of Hospira and Medivation and were primarily due to asset write-downs, partially offset by the reversal of previously recorded accruals for employee termination costs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Restructuring charges/(credits)&#8211;&#8211;cost reduction initiatives relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions. For 2019, </span><span style="font-family:Arial;font-size:7pt;">the charges were mostly related to employee termination costs</span><span style="font-family:Arial;font-size:7pt;">. For 2018, </span><span style="font-family:Arial;font-size:7pt;">the charges were mostly related to employee termination costs and asset write downs. </span><span style="font-family:Arial;font-size:7pt;">The employee termination costs for 2019 and 2018 were primarily associated with our improvements to operational effectiveness as part of the realignment of our organizational structure, and for 2019, also includes employee termination costs associated with the Transforming to a More Focused Company initiative.</span><span style="font-family:Times New Roman;font-size:8pt;"> </span><span style="font-family:Arial;font-size:7pt;">For 2017, the credits were mostly related to the reversal of previously recorded accruals for employee termination costs, partially offset by asset write downs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Comprises </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:7pt;"> as well as costs associated with our cost-reduction/productivity initiatives included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:7pt;"> and/or </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">as appropriate. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">32</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Indicates calculation not meaningful or result is equal to or greater than 100%.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">2017-2019 Initiatives and Organizing for Growth</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">During 2018, we determined that at the start of our 2019 fiscal year, we would begin operating under our new commercial structure, which reorganized our operations into three businesses</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">Biopharma,</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">a science-based innovative medicines business; Upjohn, a global, primarily off-patent branded and generic established medicines business; and through July 31, 2019, a Consumer Healthcare business. To operate effectively in this structure and position ourselves for future growth, we focused on creating a simpler, more efficient operating structure within each business as well as the functions that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new structure and combined the 2017-2019 initiatives with our current Organizing for Growth initiatives to form one cohesive plan. For the combined programs, we achieved savings of approximately </span><span style="font-family:Arial;font-size:8pt;">$1.6 billion</span><span style="font-family:Arial;font-size:8pt;"> and incurred approximately </span><span style="font-family:Arial;font-size:8pt;">$2.1 billion</span><span style="font-family:Arial;font-size:8pt;"> in costs over the three-year period 2017-2019. Savings of approximately </span><span style="font-family:Arial;font-size:8pt;">$500 million</span><span style="font-family:Arial;font-size:8pt;"> were reinvested in our R&amp;D pipeline and in selling and marketing to support our current and recently launched products and indications.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Transforming to a More Focused Company</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">With the formation of the GSK Consumer Healthcare venture and the pending combination of Upjohn with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began, in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base, which is expected to be 20% less (based on the midpoint of the range for 2020 New Pfizer revenue guidance (see the &#8220;Our Financial Guidance for 2020&#8221; section of this Financial Review), compared to 2019 total company reported revenue) as a result of both the completed Consumer Healthcare and expected Upjohn transactions.&#160;While certain direct costs have transferred or will transfer to the Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;D, Manufacturing and Commercial.&#160;</span><span style="font-family:Arial;font-size:8pt;">We expect the costs associated with this multi-year effort to continue through 2022 and to total approximately </span><span style="font-family:Arial;font-size:8pt;">$1.4 billion</span><span style="font-family:Arial;font-size:8pt;"> on a pre-tax basis and approximately </span><span style="font-family:Arial;font-size:8pt;">10%</span><span style="font-family:Arial;font-size:8pt;"> of this to be non-cash.&#160;Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs are currently in development but will include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We expect net cost savings of about </span><span style="font-family:Arial;font-size:8pt;">$1.0 billion</span><span style="font-family:Arial;font-size:8pt;"> to be achieved over the three-year period 2020-2022. Certain qualifying costs associated with this program were recorded in the fourth quarter of 2019 and are reflected as Certain Significant Items and excluded from our non-GAAP measure of Adjusted Income. See the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this Financial Review for&#160;additional information.&#160;These savings are expected to be realized primarily in procurement and in enabling functions (as described in the Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17A. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Segment, Geographic and Other Revenue Information</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Segment Information</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information about this program and expected and actual total costs, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 3. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition to these major initiatives, we continuously monitor our operations for cost reduction and/or productivity opportunities, especially in light of the losses of exclusivity and the expiration of collaborative arrangements for various products.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8211;&#8211;Net</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">18/17</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Other (income)/deductions&#8212;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">3,578</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2,116</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">1,416</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">69</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">49</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:6px;text-indent:-6px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For information about the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;">, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4. Other (Income)/Deductions&#8212;Net.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See also the &#8220;Analysis of Operating Segment Information&#8221; section of this Financial Review.</span></div><div><a id="s6238E702502F576EB2522FA72BCA244C"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">PROVISION/(BENEFIT) FOR TAXES ON INCOME</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:11%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18/17</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,384</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">706</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(9,049</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">96</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effective tax rate on continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7.8</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5.9</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(73.5</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Indicates calculation not meaningful or result is equal to or greater than 100%.</span></div></td></tr></table><div style="line-height:120%;padding-top:1px;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">higher</span><span style="font-family:Arial;font-size:8pt;"> effective tax rate in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> compared to </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> was mainly the result of:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the tax expense of approximately </span><span style="font-family:Arial;font-size:8pt;">$2.7 billion</span><span style="font-family:Arial;font-size:8pt;"> associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-recurrence of certain tax initiatives and favorable adjustments to the provisional estimate of the TCJA,</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">33</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an increase in tax benefits associated with the resolution of certain tax positions pertaining to prior years, primarily due to a benefit of </span><span style="font-family:Arial;font-size:8pt;">$1.4 billion</span><span style="font-family:Arial;font-size:8pt;">, representing tax and interest, resulting from the favorable settlement of a U.S. IRS audit;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">benefits related to certain tax initiatives associated with the implementation of our new organizational structure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the tax benefit recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the enactment of the TCJA; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">higher</span><span style="font-family:Arial;font-size:8pt;"> effective tax rate in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> was primarily the result of:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-recurrence of a $10.7 billion tax benefit recorded in 2017 to reflect the enactment of the TCJA,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits related to the TCJA, including certain 2018 tax initiatives as well as favorable adjustments to the provisional estimate of the impact of the legislation, reported and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business; as well as</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an increase in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations. </span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For details about discrete elements that impacted our tax provisions, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A. Tax Matters: Taxes on Income from Continuing Operations</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Changes in Tax Laws</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On December 22, 2017, the U.S. enacted significant changes to U.S. tax law following the passage and signing of the TCJA. The TCJA is complex and significantly changes the U.S. corporate income tax system by, among other things, reducing the U.S. Federal corporate tax rate from 35% to 21%, transitioning U.S. international taxation from a worldwide tax system to a territorial tax system and imposing a repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries.</span><span style="font-family:Arial;font-size:8pt;"> In accordance with guidance issued by the SEC we recorded provisional estimates of the legislation in the fourth-quarter 2017. In 2018, we finalized our provisional accounting for the tax effects of the TCJA based on our best estimates of available information and data, and have reported and disclosed the impacts within the applicable measurement period, in accordance with guidance issued by the SEC. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A. Tax Matters: Taxes on Income from Continuing Operations </span><span style="font-family:Arial;font-size:8pt;">and the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8211;&#8211;Selected Measures of Liquidity and Capital Resources&#8212;Contractual Obligations&#8221; section of this Financial Review.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On January 23, 2017, the Governor of Puerto Rico signed into law Act No. 3-2017, amending Section 2101 of the Puerto Rico Internal Revenue Code of 1994, which imposes an excise tax that was effective beginning in 2011 (Act 154). The excise tax is imposed on the purchase of products by multinational corporations and their affiliates from their Puerto Rico affiliates. As originally adopted, the excise tax was to be in effect from 2011 through 2016 and the tax rate was to decline over time from 4% in 2011 to 1% in 2016. Act No. 2-2013 extended the excise tax through 2017 and, effective July 1, 2013, increased the tax rate to 4% for all years through 2017. Act No. 3-2017 further extended the excise tax for all years through 2027 at a rate of 4%. The excise tax has been recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> and</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Provision/(benefit) for taxes on income, </span><span style="font-family:Arial;font-size:8pt;">as appropriate. All expected impacts in </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;"> have been reflected in our financial guidance for </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div><a id="sBF11949AB6815BB4A94F2CD4EC7CF550"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">NON-GAAP FINANCIAL MEASURE (ADJUSTED INCOME)</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">General Description of Non-GAAP Financial Measure (Adjusted Income)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted income is an alternative view of performance used by management. We measure the performance of the overall Company on this basis in conjunction with other performance metrics. Because Adjusted income is an important internal measurement for Pfizer, we believe that investors&#8217; understanding of our performance is enhanced by disclosing this performance measure. We report Adjusted income, certain components of Adjusted income, and Adjusted diluted earnings per share in order to portray the results of our major operations&#8211;&#8211;the discovery, development, manufacture, marketing and sale of prescription medicines and vaccines&#8211;&#8211;prior to considering certain income statement elements. We have defined Adjusted income as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Net income attributable to Pfizer Inc.</span><span style="font-family:Arial;font-size:8pt;"> before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items, which are described below. Similarly, we have defined the Adjusted income components as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses, Research and development expenses, Amortization of intangible assets </span><span style="font-family:Arial;font-size:8pt;">and</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> each before the impact of purchase accounting for acquisitions, acquisition-related costs and certain significant items. We have defined Adjusted diluted earnings per share as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span><span style="font-family:Arial;font-size:9pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">before the impact of purchase accounting for acquisitions, acquisition-related costs, discontinued operations and certain significant items. The Adjusted income measure, the Adjusted income component measures and the Adjusted diluted earnings per share measure are not, and should not be viewed as, substitutes for U.S. GAAP net income, U.S. GAAP net income components or U.S. GAAP diluted earnings per share. </span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following are examples of how the Adjusted income and Adjusted diluted earnings per share measures are utilized:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">senior management receives a monthly analysis of our operating results that is prepared on an Adjusted income and Adjusted diluted earnings per share basis;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">our annual budgets are prepared on an Adjusted income and Adjusted diluted earnings per share basis; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">senior management&#8217;s annual compensation is derived, in part, using Adjusted income and Adjusted diluted earnings per share measures. The bonus plans for virtually all bonus-eligible, non-sales-force employees worldwide, including the Executive Leadership Team members </span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">34</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-left:12px;padding-top:4px;text-align:left;"><span style="font-family:Arial;font-size:8pt;">and other members of senior management, are funded from a pool based on the performance measured by three financial metrics, including Adjusted diluted earnings per share, which is derived from Adjusted income. This metric accounts for 40% of the bonus pool funding. In addition, effective in 2019, Adjusted net income, which is derived from Adjusted income, is one of the measures utilized to determine payout for PSAs and is used for performance years starting in 2019, except for the 2017 PSA grant that used the previous metric, Adjusted operating income.</span></div><div style="line-height:120%;padding-left:4px;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted income and its components and Adjusted diluted earnings per share are non-GAAP financial measures that have no standardized meaning prescribed by U.S. GAAP and, therefore, are limited in their usefulness to investors. Because of their non-standardized definitions, Adjusted income and its components (unlike U.S. GAAP net income and its components) and Adjusted diluted earnings per share (unlike U.S. GAAP diluted earnings per share) may not be comparable to the calculation of similar measures of other companies. Adjusted income and its components and Adjusted diluted earnings per share are presented solely to permit investors to more fully understand how management assesses performance.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We also recognize that, as internal measures of performance, the Adjusted income and its components and Adjusted diluted earnings per share measures have limitations, and we do not restrict our performance-management process solely to these metrics. A limitation of these measures is that they provide a view of our operations without including all events during a period, such as the effects of an acquisition or amortization of purchased intangibles, and do not provide a comparable view of our performance to other companies in the biopharmaceutical industry. We also use other specifically tailored tools designed to achieve the highest levels of performance. For example, our R&amp;D organization has productivity targets, upon which its effectiveness is measured. In addition, total shareholder return, both on an absolute basis and relative to a publicly traded pharmaceutical index, plays a significant role in determining payouts under certain of Pfizer&#8217;s long-term incentive compensation plans.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See the accompanying reconciliations of certain GAAP reported to non-GAAP adjusted information for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> below.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Purchase Accounting Adjustments</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted income is calculated prior to considering certain significant purchase accounting impacts resulting from business combinations and net asset acquisitions. These impacts, primarily associated with Wyeth (acquired in 2009), Hospira (acquired in 2015), Anacor (acquired in 2016) and Medivation (acquired in 2016), can include the incremental charge to cost of sales from the sale of acquired inventory that was written up to fair value, amortization related to the increase in fair value of the acquired finite-lived intangible assets, and to a much lesser extent, depreciation related to the increase/decrease in fair value of the acquired fixed assets (primarily manufacturing facilities), amortization related to the increase in fair value of acquired debt, and the fair value changes associated with contingent consideration. Therefore, the Adjusted income measure includes the revenues earned upon the sale of the acquired products without considering the acquisition cost of those products.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain of the purchase accounting adjustments can occur through 20 or more years, but this presentation provides an alternative view of our performance that is used by management to internally assess business performance. We believe the elimination of amortization attributable to acquired intangible assets provides management and investors an alternative view of our business results by trying to provide a degree of parity to internally developed intangible assets for which R&amp;D costs previously have been expensed.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">However, a completely accurate comparison of internally developed intangible assets and acquired intangible assets cannot be achieved through Adjusted income. This component of Adjusted income is derived solely from the impacts of the items listed in the first paragraph of this section. We have not factored in the impacts of any other differences in experience that might have occurred if we had discovered and developed those intangible assets on our own, and this approach does not intend to be representative of the results that would have occurred in those circumstances. For example, our R&amp;D costs in total, and in the periods presented, may have been different; our speed to commercialization and resulting sales, if any, may have been different; or our costs to manufacture may have been different. In addition, our marketing efforts may have been received differently by our customers. As such, in total, there can be no assurance that our Adjusted income amounts would have been the same as presented had we discovered and developed the acquired intangible assets.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Acquisition-Related Costs</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted income is calculated prior to considering transaction, integration, restructuring charges and additional depreciation costs associated with business combinations because these costs are unique to each transaction and represent costs that were incurred to restructure and integrate two businesses as a result of the acquisition decision. For additional clarity, only transaction costs, additional depreciation and restructuring and integration activities that are associated with a business combination or a net-asset acquisition are included in acquisition-related costs. We have made no adjustments for the resulting synergies.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We believe that viewing income prior to considering these charges provides investors with a useful additional perspective because the significant costs incurred in connection with a business combination result primarily from the need to eliminate duplicate assets, activities or employees&#8211;&#8211;a natural result of acquiring a fully integrated set of activities. For this reason, we believe that the costs incurred to convert disparate systems, to close duplicative facilities or to eliminate duplicate positions (for example, in the context of a business combination) can be viewed differently from those costs incurred in other, more normal, business contexts.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The integration and restructuring costs associated with a business combination may occur over several years, with the more significant impacts typically ending within three years of the transaction. Because of the need for certain external approvals for some actions, the span of time needed to achieve certain restructuring and integration activities can be lengthy. For example, due to the highly regulated nature of the pharmaceutical business, the closure of excess facilities can take several years, as all manufacturing changes are subject to extensive validation and testing and must be approved by the FDA and/or other global regulatory authorities.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">35</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Discontinued Operations</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted income is calculated prior to considering the results of operations included in discontinued operations, as well as any related gains or losses on the disposal of such operations. We believe that this presentation is meaningful to investors because, while we review our businesses and product lines for strategic fit with our operations, we do not build or run our businesses with the intent to sell them. Restatements due to discontinued operations do not impact compensation or change the Adjusted income measure for the compensation in respect of the restated periods, but are presented for consistency across all periods.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Certain Significant Items</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted income is calculated prior to considering certain significant items. Certain significant items represent substantive and/or unusual items that are evaluated on an individual basis. Such evaluation considers both the quantitative and the qualitative aspects of their nature. Certain significant items may be highly variable and difficult to predict. Furthermore, in some cases it is reasonably possible that they could reoccur in future periods. For example, major non-acquisition-related cost-reduction programs stand on their own as they are specific to an event or goal with a defined term, but we may have subsequent programs based on reorganizations of the business, cost productivity or in response to loss of exclusivity or economic conditions. Legal charges to resolve litigation are also related to specific cases, which are facts and circumstances specific and, in some cases, may also be the result of litigation matters at acquired companies that were inestimable, not probable or unresolved at the date of acquisition. Unusual items may represent items that are not part of our ongoing business; items that, either as a result of their nature or size, we would not expect to occur as part of our normal business on a regular basis; items that would be non-recurring; or items that relate to products we no longer sell. While not all-inclusive, examples of items that could be included as certain significant items would be gains on the completion of joint venture transactions such as the gain on the completion of the Consumer Healthcare joint venture transaction discussed in Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2C. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Equity-Method Investment and Assets and Liabilities Held for Sale</span><span style="font-family:Arial;font-size:8pt;">, a major non-acquisition-related restructuring charge and associated implementation costs; amounts related to certain disposals of businesses, products or facilities that do not qualify as discontinued operations under U.S. GAAP; certain intangible asset impairments; adjustments related to the resolution of certain tax positions; the impact of adopting certain significant, event-driven tax legislation, such as the TCJA discussed in Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A. Tax Matters: Taxes on Income from Continuing Operations</span><span style="font-family:Arial;font-size:8pt;"> or charges related to certain legal matters, such as certain of those discussed in Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16A. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Legal Proceedings </span><span style="font-family:Arial;font-size:8pt;">and in Part II, Item 1, &#8220;Legal Proceedings&#8221; in our Quarterly Reports on Form 10-Q. Normal, ongoing defense costs of the Company or settlements of and accruals for legal matters made in the normal course of our business would not be considered certain significant items.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:1px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in 2019, we exclude the gains and losses from equity securities from our measure of Adjusted income because of their inherent volatility, which we do not control and cannot predict with any level of certainty and because we do not believe that including these gains and losses assists investors in understanding our business or is reflective of our core operations and business. For example, in 2018, we contributed assets related to our allogeneic CAR T therapy to Allogene and received equity securities. We have revised Adjusted income and Adjusted diluted EPS for prior periods for consistency with our 2019 presentation.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Reconciliation of GAAP Reported to Non-GAAP Adjusted Information&#8211;&#8211;Certain Line Items</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Purchase Accounting Adjustments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisition-Related Costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Operations</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain Significant Items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">51,750</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">51,750</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,219</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(208</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">10,030</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,350</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(309</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,041</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,650</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(666</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,988</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,610</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4,339</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">271</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">747</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(183</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(565</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(8,086</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8,086</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,578</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(21</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3,858</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(300</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">17,682</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,333</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">185</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2,481</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19,720</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,384</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">848</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">59</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">667</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,958</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16,298</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,485</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">126</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3,148</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">16,762</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">29</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">29</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16,273</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,485</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">126</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3,148</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">16,733</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2.87</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.61</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.02</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(0.55</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.95</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See end of tables for notes </span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span><span style="font-family:Arial;font-size:7pt;">.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">36</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Purchase Accounting Adjustments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisition-Related Costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Operations</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain Significant Items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">53,647</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53,647</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11,248</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(110</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,130</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,455</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(222</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,232</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,006</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(47</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,962</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,893</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4,612</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">281</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,044</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(299</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(745</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,116</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(182</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2,595</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(667</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11,885</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,786</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">318</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,719</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20,709</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">706</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">915</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">54</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,520</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,196</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11,179</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,871</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">264</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,199</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">17,513</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">36</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">36</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11,153</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,871</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">264</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(10</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,199</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">17,477</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1.87</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.65</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.04</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.37</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.92</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">IN MILLIONS, EXCEPT PER COMMON SHARE DATA</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Purchase Accounting Adjustments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisition-Related Costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Operations</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain Significant Items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-GAAP Adjusted</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">52,546</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">52,546</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11,228</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(47</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(39</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(363</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">10,778</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,804</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(16</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(299</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,489</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,683</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(38</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,653</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,758</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4,565</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">193</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(426</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">75</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,416</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(138</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1,796</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(509</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">12,305</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,758</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">456</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,423</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19,941</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(9,049</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,331</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">173</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,506</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,962</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">21,353</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,426</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">283</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(9,083</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">15,980</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">47</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">47</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">21,308</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,426</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">283</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(9,083</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">15,933</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings per common share attributable to Pfizer Inc.&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3.52</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.57</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.05</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1.50</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.63</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For details of adjustments, see &#8220;Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income&#8221; below.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The effective tax rate on Non-GAAP Adjusted income was </span><span style="font-family:Arial;font-size:7pt;">15.0%</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;">15.4%</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;">19.9%</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. The decrease in the effective tax rate on Non-GAAP Adjusted income for 2019, compared with 2018, was primarily due to a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business, partially offset by a decrease in tax benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities. The decrease in the effective tax rate on Non-GAAP Adjusted income for 2018 compared with 2017 was primarily due to tax benefits associated with the December 2017 enactment of the TCJA, a favorable change in the jurisdictional mix of earnings as a result of operating fluctuations in the normal course of business, as well as an increase in benefits associated with the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations. </span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">37</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Details of Income Statement Items Included in GAAP Reported but Excluded from Non-GAAP Adjusted Income</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adjusted income, as shown above, excludes the following items:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended&#160;December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization, depreciation and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,353</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,789</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,711</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(19</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">47</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total purchase accounting adjustments&#8212;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,333</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,786</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,758</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income taxes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(848</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(915</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1,331</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total purchase accounting adjustments&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,485</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,871</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,426</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges/(credits)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(192</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">37</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">105</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Transaction costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">63</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Integration costs and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">311</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">260</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">317</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit costs/(credits) other than service costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(9</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Additional depreciation&#8212;asset restructuring</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">39</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total acquisition-related costs&#8212;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">185</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">318</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">456</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income taxes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(59</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(54</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(173</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total acquisition-related costs&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">126</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">264</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">283</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Discontinued operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total discontinued operations&#8212;net of tax, attributable to Pfizer Inc.</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Certain significant items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges/(credits)</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">cost reduction initiatives</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">565</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">745</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(75</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Implementation costs and additional depreciation&#8212;asset restructuring</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">194</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">232</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">279</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain legal matters, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">543</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">157</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">237</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain asset impairments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,798</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,101</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">379</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Business and legal entity alignment costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">495</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">63</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">71</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net gains recognized during the period on equity securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(415</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(586</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(224</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(8,086</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net losses on early retirement of debt</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">138</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">999</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(m)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,289</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">756</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total certain significant items&#8212;pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(2,481</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,719</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,423</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income taxes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(n)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(667</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1,520</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(11,506</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total certain significant items&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(3,148</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,199</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(9,083</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items&#8212;net of tax, attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">460</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,324</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(5,376</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Included primarily in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:7pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income. </span><span style="font-family:Arial;font-size:7pt;">Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate. Income taxes recorded in 2017 do not reflect any changes associated with the enactment of the TCJA. These changes resulting from the TCJA have been reflected in the line item, Certain significant items &#8220;Income taxes&#8221;.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:7pt;">. Restructuring charges/(credits) include employee termination costs, asset impairments and other exit costs associated with business combinations. Transaction costs represent external costs for banking, legal, accounting and other similar services. Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes and certain other qualifying costs. For additional information, see the &#8220;Costs and Expenses&#8212;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8221; </span><span style="font-family:Arial;font-size:7pt;">section of this Financial Review and Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 3</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net. </span><span style="font-family:Arial;font-size:7pt;">The credits in 2017 included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. See Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Pension and Postretirement Benefit Plans and Defined Contribution Plans</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In 2019, primarily included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses. </span><span style="font-family:Arial;font-size:7pt;">In 2018 and 2017, primarily included in C</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">ost of sales. </span><span style="font-family:Arial;font-size:7pt;">Represents the impact of changes in estimated useful lives of assets involved in restructuring actions related to acquisitions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income. </span><span style="font-family:Arial;font-size:7pt;">Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate. 2019 includes the impact of the non-taxable reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. Income taxes recorded in 2017 do not reflect any changes associated with the December 2017 enactment of the TCJA. These changes resulting from the TCJA have been reflected in Certain significant items &#8220;Income taxes&#8221;. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Discontinued operations&#8211;&#8211;net of tax. </span><span style="font-family:Arial;font-size:7pt;">For all years presented, represents post-close adjustments.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">38</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts relate to employee termination costs, asset impairments and other exit costs not associated with acquisitions, which are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:7pt;"> (see the &#8220;Costs and Expenses&#8212;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8221; </span><span style="font-family:Arial;font-size:7pt;">section of this Financial Review and Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 3</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">).</span><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts relate to our cost-reduction/productivity initiatives not related to acquisitions (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;">). For </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;">$90 million</span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;">$74 million</span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;">$30 million</span><span style="font-family:Arial;font-size:7pt;">). For </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$121 million</span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$72 million</span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$39 million</span><span style="font-family:Arial;font-size:7pt;">). For </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$170 million</span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$71 million</span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$38 million</span><span style="font-family:Arial;font-size:7pt;">). </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:7pt;"> (see the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4. Other (Income)/Deductions&#8212;Net</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In 2019, primarily included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$15 million</span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$139 million</span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$338 million</span><span style="font-family:Arial;font-size:7pt;">) and represents (i) incremental costs of </span><span style="font-family:Arial;font-size:7pt;">$350 million</span><span style="font-family:Arial;font-size:7pt;"> associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services and (ii) separation costs of </span><span style="font-family:Arial;font-size:7pt;">$145 million</span><span style="font-family:Arial;font-size:7pt;"> associated with our planned Upjohn transaction with Mylan and mainly includes consulting, legal, tax and advisory services</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:7pt;">In full-year 2018, primarily included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">and mainly represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Gain) on completion of Consumer Healthcare JV transaction </span><span style="font-family:Arial;font-size:7pt;">(see notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:7pt;">:</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Equity-Method Investments and Assets and Liabilities Held for Sale</span><span style="font-family:Arial;font-size:7pt;">).</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(m)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$103 million</span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$96 million</span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$632 million</span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$457 million</span><span style="font-family:Arial;font-size:7pt;">). For </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;">$10 million</span><span style="font-family:Arial;font-size:7pt;"> income), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$151 million</span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$8 million</span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;">$143 million</span><span style="font-family:Arial;font-size:7pt;"> income). For </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$193 million</span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses (</span><span style="font-family:Arial;font-size:7pt;">$229 million</span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$334 million</span><span style="font-family:Arial;font-size:7pt;">). For </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> includes, among other things, (i) an upfront license fee payment of </span><span style="font-family:Arial;font-size:7pt;">$250 million</span><span style="font-family:Arial;font-size:7pt;"> to Akcea, which was recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses, </span><span style="font-family:Arial;font-size:7pt;">(ii) charges of </span><span style="font-family:Arial;font-size:7pt;">$112 million</span><span style="font-family:Arial;font-size:7pt;"> recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the Consumer Healthcare joint venture, (iii) a </span><span style="font-family:Arial;font-size:7pt;">$337 million</span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:7pt;"> related to our acquisition of Therachon, (iv) a </span><span style="font-family:Arial;font-size:7pt;">$99 million</span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">related to rivipansel, primarily for inventory manufactured for expected future sale and (v) charges of </span><span style="font-family:Arial;font-size:7pt;">$240 million</span><span style="font-family:Arial;font-size:7pt;">, primarily in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$87 million</span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;">$152 million</span><span style="font-family:Arial;font-size:7pt;">), for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For 2018, includes, among other things, (i) a non-cash </span><span style="font-family:Arial;font-size:7pt;">$343 million</span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system, (ii) a </span><span style="font-family:Arial;font-size:7pt;">$119 million</span><span style="font-family:Arial;font-size:7pt;"> charge, in the aggregate, in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the legislation commonly referred to as the TCJA and (iii) a non-cash </span><span style="font-family:Arial;font-size:7pt;">$50 million</span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the contribution of our allogeneic chimeric antigen receptor T cell therapy development program assets in connection with our contribution agreement entered into with Allogene (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B.</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">: Divestitures</span><span style="font-family:Arial;font-size:7pt;">). For 2017, includes, among other things, (i) a charitable contribution to the Pfizer Foundation of </span><span style="font-family:Arial;font-size:7pt;">$200 million</span><span style="font-family:Arial;font-size:7pt;">, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:7pt;">; (ii) </span><span style="font-family:Arial;font-size:7pt;">$195 million</span><span style="font-family:Arial;font-size:7pt;"> in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;">; (iii) an </span><span style="font-family:Arial;font-size:7pt;">$81 million</span><span style="font-family:Arial;font-size:7pt;"> loss related to the sale of our former 49% equity share in Hisun Pfizer, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">; (iv) charges of $55 million in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and (v) a net loss of </span><span style="font-family:Arial;font-size:7pt;">$30 million</span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;">40%</span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining 60% ownership interest, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(n)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income. </span><span style="font-family:Arial;font-size:7pt;">Income taxes includes the tax effect of the associated pre-tax amounts, calculated by determining the jurisdictional location of the pre-tax amounts and applying that jurisdiction&#8217;s applicable tax rate. Also included is the effect of certain U.S. tax consequences. The amount in 2019 was favorably impacted by a benefit of </span><span style="font-family:Arial;font-size:7pt;">$1.4 billion</span><span style="font-family:Arial;font-size:7pt;">, representing tax and interest, resulting from the favorable settlement of a U.S. IRS audit for multiple tax years, the benefits related to certain tax initiatives associated with the implementation of our new organizational structure, as well as the tax benefit recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the TCJA and unfavorably impacted by the tax expense of approximately </span><span style="font-family:Arial;font-size:7pt;">$2.7 billion</span><span style="font-family:Arial;font-size:7pt;"> associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK. The amount in 2018 was favorably impacted primarily by tax benefits related to the TCJA, including certain 2018 tax initiatives as well as adjustments to the provisional estimate of the legislation, reported and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC. The amount in 2017 was favorably impacted by tax benefits primarily associated with the remeasurement of deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries associated with the TCJA. See Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Tax Matters</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">: Taxes on Income from Continuing Operations</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div><a id="s31E255B2392A5B05B4CC0CE0F5376674"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF OPERATING SEGMENT INFORMATION</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following tables and associated notes provide additional information about the performance of each of our two reportable operating segments for the periods presented&#8212;Biopharma and Upjohn, and our Consumer Healthcare operating segment through July 31, 2019. For additional information about each operating segment, see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8212;Our Strategy&#8212;Organizing for Growth&#8221; section of this Financial Review, Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17. Segment, Geographic and Other Revenue Information </span><span style="font-family:Arial;font-size:8pt;">and the &#8220;Commercial Operations&#8221; section in Part I, Item 1, &#8220;Business&#8221; of our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Form 10-K</span><span style="font-family:Arial;font-size:8pt;text-align:center;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As described in Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A. Basis of Presentation and Significant Accounting Policies: Basis of Presentation</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in 2019 and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">39</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following tables provide revenue and cost information by reportable operating segment and a reconciliation of that information to our consolidated statements of income:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reconciling Items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">39,419</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,233</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,098</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">51,750</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">51,750</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,579</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,724</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">727</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,030</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">189</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,219</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19.2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16.8</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19.4</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19.7</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,492</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,549</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,041</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">309</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,350</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,047</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">236</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">6,705</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,988</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">661</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,650</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">271</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">271</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,339</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,610</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">747</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">747</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(8,086</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(8,086</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(993</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">698</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(300</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,878</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,578</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">24,517</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">6,785</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(11,582</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19,720</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(2,037</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">17,682</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">See end of tables for notes (a) through (d).</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reconciling </span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">37,558</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12,484</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,605</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53,647</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">53,647</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,147</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,964</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,130</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">118</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11,248</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">15.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">21.0</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,678</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,668</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,886</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,232</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">223</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,455</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">907</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">233</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,822</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,962</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">43</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,006</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">235</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">45</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">281</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,612</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,893</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,044</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,044</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1,148</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">499</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(667</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,784</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,116</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">23,738</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8,636</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(11,666</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20,709</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(8,823</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11,885</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-GAAP<br/>Adjusted</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reconciling Items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">GAAP Reported</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">35,530</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">13,447</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,569</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">52,546</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">52,546</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,012</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,919</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,847</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">10,778</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">449</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11,228</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">% of revenue</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19.7</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14.3</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20.5</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">21.4</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,487</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,913</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,089</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,489</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">316</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,804</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">847</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">275</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,653</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">31</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,683</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">149</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">44</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">193</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,565</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,758</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">351</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1,159</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(8</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">658</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(509</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,925</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,416</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">22,194</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9,348</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(11,600</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">19,941</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(7,637</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">12,305</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Indicates calculation not meaningful or result is equal to or greater than 100%.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a) </sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts represent the revenues and costs managed by each of the Biopharma and Upjohn reportable operating segments for the periods presented. The expenses generally include only those costs directly attributable to the operating segment.</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">40</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Other comprises the revenues and costs included in our Adjusted income components (see footnote (c) below)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span><span style="font-family:Arial;font-size:7pt;">that are managed outside Biopharma and Upjohn and includes the following:</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.21428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">GPD</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Corporate and Other <br/>Unallocated</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,098</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,098</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">663</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">62</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">727</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">146</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,218</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,185</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,549</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,398</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,311</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">89</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">908</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">6,705</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(6</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">704</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">698</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(2,538</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(3,313</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">128</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(5,859</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(11,582</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.21428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">GPD</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Corporate and Other <br/>Unallocated</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,605</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,605</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,211</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">807</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">159</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,753</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,974</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,886</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,319</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,359</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">179</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">965</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,822</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">45</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">45</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(127</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(18</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">637</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">499</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2,352</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3,341</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">410</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(6,383</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(11,666</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;padding-left:12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.21428571428571%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:43%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other Business Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">GPD</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Corporate and Other <br/>Unallocated</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iv)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,472</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">97</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,569</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,192</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">653</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,847</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">143</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,741</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,204</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,089</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,363</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,151</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">176</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">840</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,531</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">44</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">44</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(49</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">15</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">698</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">658</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(2,457</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(3,148</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">304</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(6,299</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(11,600</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">WRDM&#8212;the R&amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#8211;&#8211;including patients, healthcare providers, pharmacists, payers and health authorities&#8211;&#8211;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">41</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">GPD&#8211;&#8211;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other&#8212;the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iv)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate and Other Unallocated&#8212;the costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;padding-left:24px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We recognized the following amounts in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;"> related to forward-exchange contracts designated as cash flow hedges of a portion of our foreign exchange-denominated forecasted intercompany inventory sales: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:24px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">a </span><span style="font-family:Arial;font-size:7pt;">$247 million</span><span style="font-family:Arial;font-size:7pt;"> net </span><span style="font-family:Arial;font-size:7pt;">gain</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:24px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">a </span><span style="font-family:Arial;font-size:7pt;">$13 million</span><span style="font-family:Arial;font-size:7pt;"> net </span><span style="font-family:Arial;font-size:7pt;">loss</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:24px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">a </span><span style="font-family:Arial;font-size:7pt;">$52 million</span><span style="font-family:Arial;font-size:7pt;"> net </span><span style="font-family:Arial;font-size:7pt;">gain</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7F. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Financial Instruments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Derivative Financial Instruments and Hedging Activities</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For information purposes only, the following tables present reconciliations of the Biopharma segment operating results and Upjohn segment operating results to Biopharma and Upjohn operating results including estimated Other costs generally associated with the Biopharma and Upjohn operating segments for </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">. While we do not manage our segments or have performance goals under such an allocated manner, we believe that some investors may find this information useful in their analyses. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The estimated Other costs generally associated with our operating segments do not purport to reflect the additional amounts that each of our operating segments would have incurred had each segment operated as a standalone company during the period presented. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For information purposes only, for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, we estimate that Other costs attributable to our Biopharma and Upjohn segments, as described above, for combined WRDM, GPD and other business activities costs are </span><span style="font-family:Arial;font-size:8pt;">$6.4 billion</span><span style="font-family:Arial;font-size:8pt;">, and combined Corporate and Other Unallocated costs are </span><span style="font-family:Arial;font-size:8pt;">$4.8 billion</span><span style="font-family:Arial;font-size:8pt;">, which excludes income and costs associated with our Consumer Healthcare business. The combined Corporate and Other Unallocated costs also exclude (i) net interest-related expense not attributable to an operating segment included in Corporate (approximately </span><span style="font-family:Arial;font-size:8pt;">$1.4 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">); and (ii) net income from investments and other assets not attributable to an operating segment included in Corporate (approximately </span><span style="font-family:Arial;font-size:8pt;">$318 million</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">(income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">). The remaining costs have been attributed to our Biopharma and Upjohn operating segments, as follows:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Estimated Other Costs Associated with Biopharma</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma Non-GAAP Adjusted</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i), (iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Estimated WRDM/GPD/Other Business Activities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Estimated Corporate/Other Unallocated</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma with Estimated Other Costs Associated with<br/>Biopharma<br/>Non-GAAP Adjusted</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii),</sup></span><span style="font-family:Arial;font-size:8pt;">&#160;</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">39,419</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">39,419</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,579</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">55</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,635</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,000</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">611</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,268</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,879</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,047</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,721</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">873</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,640</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">271</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">271</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(993</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(275</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,273</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">24,517</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(6,329</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(3,921</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">14,267</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">42</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Estimated Other Costs Associated with Upjohn</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn <br/>Non-GAAP Adjusted</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i), (iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Estimated WRDM/GPD/Other Business Activities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Estimated Corporate/Other Unallocated</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn with Estimated Other Costs Associated with Upjohn<br/>Non-GAAP Adjusted</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii), (iii)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,233</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,233</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,724</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(14</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,710</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,492</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">34</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">753</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,280</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">236</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">21</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">262</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(5</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(46</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(51</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">6,785</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(39</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(714</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">6,031</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:6px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amount represents the revenues and costs managed by each of our operating segments. The expenses generally include only those costs directly attributable to the operating segment. See note (a) above for more information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:6px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(ii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Represents costs not assessed to an operating segment, as business unit (segment) management does not manage these costs. For a description of these other costs and business activities, see note (b) above.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:18px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">WRDM/GPD/Other Business Activities</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;">The information provided for WRDM, GPD and Other Business Activities was substantially all derived from our estimates of the costs incurred in connection with the R&amp;D projects associated with the Biopharma and Upjohn operating segment.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:30px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:18px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate/Other Unallocated</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;">The information provided for Corporate and Other Unallocated was derived mainly using proportional allocation methods based on global, regional or country revenues or global, regional or country headcount, as well as certain cost metrics, as appropriate, such as those derived from R&amp;D and manufacturing costs, and, to a lesser extent, specific identification and estimates. Management believes that the allocations of Corporate and Other Unallocated costs are reasonable.</span></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:30px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The estimated Other costs generally associated with our Biopharma and Upjohn operating segments do not purport to reflect the additional amounts that each of our operating segments would have incurred had each segment operated as a standalone company during the period presented.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:6px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(iii)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See note (c) below for an explanation of our Non-GAAP Adjusted financial measure.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">See the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this Financial Review for a definition of these &#8220;Adjusted Income&#8221; components.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Includes costs associated with (i) purchase accounting adjustments; (ii) acquisition-related costs; and (iii) certain significant items, which are substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investment in equity securities), that are evaluated on an individual basis by management. For additional information about these reconciling items and/or our Non-GAAP adjusted measure of performance, see the &#8220;Non-GAAP Financial Measure (Adjusted Income)&#8221; section of this Financial Review.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Biopharma Operating Segment</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-align:center;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> vs. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-align:center;text-decoration:underline;">2018</span></div><div style="line-height:120%;text-align:left;font-size:3pt;"><span style="font-family:Arial;font-size:3pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$1.9 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">5%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$39.4 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$37.6 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, reflecting an operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">$2.9 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">8%</span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;">an unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">$1.0 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">3%</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following graph illustrates the components of the net </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;"><img src="biopharmrevincrease2018-2019.jpg" alt="biopharmrevincrease2018-2019.jpg" style="height:196px;width:684px;"></img></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">43</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following provides an analysis of the </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in Biopharma worldwide </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">37,558</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Continued growth from certain key brands</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,495</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenue from continued growth of anti-infective products in China, driven by increased demand for Sulperazon and new launches, the 2018 U.S. launches of our immune globulin intravenous products (Panzyga and Octagam) and the launches of certain anti-infectives products (Zavicefta, Zinforo and Cresemba) in international developed and emerging markets, all in the Hospital products business</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">472</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenues for Inlyta, primarily in the U.S. driven by increased demand resulting from the second quarter of 2019 U.S. FDA approvals for the combinations of certain immune checkpoint inhibitors plus Inlyta for the first-line treatment of patients with advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">190</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Growth from Biosimilars, primarily in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">168</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenues for rare disease products driven by the U.S. launches in May 2019 of Vyndaqel and in September 2019 of Vyndamax, for the treatment of transthyretin amyloid cardiomyopathy (ATTR-CM); and in international markets, primarily driven by continued uptake for the transthyretin amyloid polyneuropathy indication, primarily in developed Europe, as well as the March 2019 launch of the ATTR-CM indication in Japan, partially offset by lower revenues for certain rare disease products, including the hemophilia franchises (Refacto AF/Xyntha and BeneFIX), primarily due to competitive pressures, and Genotropin in developed markets, mainly due to unfavorable channel mix in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">159</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues from other Hospital products, primarily reflecting declines in developed markets, mostly due to the continued expected negative impact from generic competition for products that have previously lost marketing exclusivity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(447</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Enbrel internationally, reflecting continued biosimilar competition in most developed Europe markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(292</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">150</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operational growth, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,894</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,033</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">&#160;increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,862</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">39,419</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain key brands represent Ibrance, Eliquis, Xeljanz and Prevnar 13/Prevenar 13. See the &#8220;Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion" section of this Financial Review for product analysis information.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Biopharma revenues from emerging markets </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$539 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">7%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$8.2 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$7.7 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, reflecting a </span><span style="font-family:Arial;font-size:8pt;">14%</span><span style="font-family:Arial;font-size:8pt;"> operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">. Foreign exchange had an </span><span style="font-family:Arial;font-size:8pt;">unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of </span><span style="font-family:Arial;font-size:8pt;">7%</span><span style="font-family:Arial;font-size:8pt;"> on total Biopharma revenues from emerging markets. The operational increase in emerging markets was primarily driven by Prevenar 13, Ibrance and Eliquis.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:8pt;">as a percentage of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">was relatively flat.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:8pt;">of </span><span style="font-family:Arial;font-size:8pt;">6%</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">was mainly driven by an unfavorable change in product mix, an increase in royalty expenses based on the mix of products sold, and an increase in sales volumes for various products within our product portfolio, partially offset by a favorable impact of foreign exchange.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">expenses</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">5%</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">was mostly driven by additional investment in emerging markets, the Oncology portfolio in developed markets, and for marketing and promotional expenses associated with the U.S. launches of Vyndaqel in May 2019 and Vyndamax in September 2019, as well as an increase in healthcare reform expenses, partially offset by a favorable impact of foreign exchange.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">expenses</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">15%</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">was mainly related to the Array acquisition, as well as an increase in medical spend for new and growing products.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">unfavorable</span><span style="font-family:Arial;font-size:8pt;"> change in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">primarily reflects a </span><span style="font-family:Arial;font-size:8pt;">$246 million</span><span style="font-family:Arial;font-size:8pt;"> decrease in income from collaborations, out-licensing arrangements and sales of compound/product rights and a </span><span style="font-family:Arial;font-size:8pt;">$33 million</span><span style="font-family:Arial;font-size:8pt;"> decrease in dividend income from our investment in ViiV, partially offset by an increase in royalty-related income mainly due to a one-time favorable resolution in the second quarter of 2019 of a legal dispute for </span><span style="font-family:Arial;font-size:8pt;">$82 million</span><span style="font-family:Arial;font-size:8pt;">, as well as a favorable impact of foreign exchange.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-align:center;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> vs. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$2.0 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">6%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$37.6 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$35.5 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, reflecting an operational increase of </span><span style="font-family:Arial;font-size:8pt;">$1.9 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">5%</span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;">a favorable</span><span style="font-family:Arial;font-size:8pt;"> impact of foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">$168 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;">. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">44</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following graph illustrates the components of the net </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;"><img src="biopharmrevincrease2018v2017.jpg" alt="biopharmrevincrease2018v2017.jpg" style="height:196px;width:684px;"></img></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following provides an analysis of the </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues,</span><span style="font-family:Arial;font-size:8pt;">&#160;2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">35,530</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Continued growth from certain key brands</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,715</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Growth from Biosimilars, primarily from Inflectra in certain channels in the U.S. and developed Europe markets<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">217</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Growth from recently launched products, including Eucrisa in the U.S., as well as Besponsa and Bavencio, primarily in the U.S. and developed Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">195</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in the Hospital products business, driven by lower revenues in developed markets, primarily due to increased competition across the portfolio and continued legacy Hospira product shortages in the U.S., partially offset by an increase in emerging markets, primarily in China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(482</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Enbrel, primarily in most developed Europe markets due to continued biosimilar competition</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(350</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for the Premarin family of products and Pristiq primarily driven by generic competition in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(241</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues from the hemophilia portfolio (BeneFIX and Refacto AF/Xyntha), primarily in developed Europe</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(100</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:6px;text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(93</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operational growth, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,860</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Favorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">168</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">&#160;increase</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,028</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues, </span><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">37,558</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Certain key brands represent Ibrance, Eliquis, Xeljanz, Prevnar 13/Prevenar 13, Xtandi and Chantix/Champix.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Biopharma revenues from emerging markets </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$878 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">13%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$7.7 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$6.8 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, reflecting a </span><span style="font-family:Arial;font-size:8pt;">16%</span><span style="font-family:Arial;font-size:8pt;"> operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">. Foreign exchange had an </span><span style="font-family:Arial;font-size:8pt;">unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of </span><span style="font-family:Arial;font-size:8pt;">3%</span><span style="font-family:Arial;font-size:8pt;"> on total Biopharma revenues from emerging markets. The operational increase in emerging markets was primarily driven by Prevenar 13, Sulperazon, Ibrance and Eliquis.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> as a percentage of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">0.7</span><span style="font-family:Arial;font-size:8pt;"> percentage points mainly driven by a favorable change in product mix, which includes an increase in alliance revenue which has no associated cost of sales, and a favorable impact of foreign exchange, partially offset by an increase in royalty expenses based on the mix of products sold.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:8pt;">of </span><span style="font-family:Arial;font-size:8pt;">2%</span><span style="font-family:Arial;font-size:8pt;"> was mostly driven by an increase in royalty expenses based on the mix of products sold, an unfavorable change in product mix, and an increase in sales volumes for various products within our product portfolio, partially offset by a favorable impact of foreign exchange.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">expenses</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">3%</span><span style="font-family:Arial;font-size:8pt;"> was mainly driven by additional investment across several of our products, primarily Xeljanz, Ibrance, Eucrisa and Prevnar 13/Prevenar 13 (pediatric indication), partially offset by lower marketing, advertising and promotion expenses, reflecting the benefits of cost-reduction and productivity initiatives.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">7%</span><span style="font-family:Arial;font-size:8pt;"> was driven by an increase in medical spend, mostly in Oncology (including Ibrance, as well as investments for new global capabilities) and expenses associated with the creation of new business units, as well as support for recently launched assets (including Talzenna), partially offset by a decrease in spend on products transferred from EH to Internal Medicine and on Hospital products.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> was relatively unchanged.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">45</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">Upjohn Operating Segment</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-align:center;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> vs. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-align:center;text-decoration:underline;">2018</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$2.3 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">18%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$10.2 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$12.5 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, reflecting an operational </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">$2.0 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">16%</span><span style="font-family:Arial;font-size:8pt;">, and an </span><span style="font-family:Arial;font-size:8pt;">unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">$249 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">2%</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following graph illustrates the components of the </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;"><img src="upjohnrevdecrease2018-2019.jpg" alt="upjohnrevdecrease2018-2019.jpg" style="height:196px;width:684px;"></img></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following provides an analysis of the </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in worldwide Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12,484</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower worldwide revenues for Lyrica, primarily in the U.S., reflecting the expected significantly lower volumes associated with multi-source generic competition that began in July 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,628</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Viagra and Upjohn's authorized generic for Viagra in the U.S. resulting from increased generic competition following Viagra's December 2017 patent expiration, partially offset by increased retail demand growth in China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(171</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in revenues for Revatio driven by lower U.S. Oral Suspension formulation sales and pricing pressures due to a recent generic entry, and for Relpax, driven by continued generic competition across developed markets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(149</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in Norvasc and Lipitor due to pricing pressures from the implementation of the VBP in certain cities in China and lower volumes in Japan, partially offset by overall increased demand in China in the first quarter of 2019 and continued geographic expansion in China during the second half of 2019 in provinces where the VBP had not yet been implemented</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(40</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Volume-driven growth from Celebrex and Effexor, primarily in Japan and China</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">78</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(92</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operational decline, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(2,002</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unfavorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(249</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues </span><span style="font-family:Arial;font-size:8pt;">decrease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(2,251</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,233</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">Total Upjohn revenues from emerging markets </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$128 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">3%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$3.9 billion</span><span style="font-family:inherit;font-size:10pt;"> </span><span style="font-family:Arial;font-size:8pt;">in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$4.0 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, reflecting </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;"> operational </span><span style="font-family:Arial;font-size:8pt;">growth</span><span style="font-family:Arial;font-size:8pt;"> more than offset by the </span><span style="font-family:Arial;font-size:8pt;">unfavorable</span><span style="font-family:Arial;font-size:8pt;"> impact of foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">5%</span><span style="font-family:Arial;font-size:8pt;"> on total Upjohn revenues from emerging markets. The operational increase in emerging markets was primarily driven by Zoloft, Viagra, Celebrex and Lipitor.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:8pt;">as a percentage of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">1.1</span><span style="font-family:Arial;font-size:8pt;"> percentage points, </span><span style="font-family:Arial;font-size:8pt;">driven by lower Lyrica revenues in developed markets, primarily in the U.S. due to multi-source generic competition that began in July 2019, partially offset by lower royalty expense for Lyrica due to the patent expiration.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">12%</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="color:#000000;font-family:Arial;font-size:8pt;font-style:normal;font-weight:normal;text-decoration:none;">was mainly driven by lower royalty expense due to the Lyrica patent expiration and multi-source generic competition that began in July 2019, as well as a favorable impact of foreign exchange.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">expenses</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">11%</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">driven by a reduction in field force expense as well as advertising and promotion expenses in developed markets, primarily related to Lyrica in the U.S., as well as a favorable impact of foreign exchange, </span><span style="color:#2c2c2c;font-family:Arial;font-size:8pt;">partially offset by</span><span style="font-family:Arial;font-size:8pt;"> the non-recurrence of one-time general and administrative expense reversals in the second and third quarters of 2018, and </span><span style="color:#2c2c2c;font-family:Arial;font-size:8pt;">investments in China across key brands</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">expenses</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">were relatively unchanged.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-align:center;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> vs. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$963 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">7%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$12.5 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$13.4 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, reflecting an operational </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;">$1.1 billion</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">8%</span><span style="font-family:Arial;font-size:8pt;">, and </span><span style="font-family:Arial;font-size:8pt;">a favorable</span><span style="font-family:Arial;font-size:8pt;"> impact from foreign exchange of </span><span style="font-family:Arial;font-size:8pt;">$116 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;">. </span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">46</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following graph illustrates the components of the net </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;"><img src="upjohnrevdecrease2018v2017.jpg" alt="upjohnrevdecrease2018v2017.jpg" style="height:196px;width:684px;"></img></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">LOE generally pertains to period-over-period revenue impacts for products across our portfolios experiencing patent expirations or loss of regulatory exclusivity in certain developed markets.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following provides an analysis of the </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">:</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:85%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">13,447</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operational growth/(decline):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lower revenues for Viagra in the U.S. resulting from the loss of exclusivity in December 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(572</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in Greenstone, Upjohn's solid oral dose generics subsidiary, due to additional generic competition in the U.S. and decline in Relpax, primarily due to loss of exclusivity in the U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(318</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in revenues for Lyrica, primarily driven by losses of exclusivity in developed Europe markets and Australia, partially offset by growth in the U.S. and growth in the orally dissolving tablet formulation in Japan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(115</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decline in revenues for Celebrex, primarily driven by the non-recurrence of favorable U.S. rebates that occurred in 2017 and lower volumes in the U.S.<br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(99</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher revenues for Lipitor and Norvasc primarily due to increased demand in China, partially offset by pricing pressures in China and lower volumes in Japan for Lipitor and Norvasc and the non-recurrence of favorable U.S. rebates for Lipitor that occurred in 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">182</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other operational factors, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(158</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operational decline, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1,079</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Favorable impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">116</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">&#160;decrease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(963</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues,</span><span style="font-family:Arial;font-size:8pt;">&#160;2018</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12,484</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Upjohn revenues from emerging markets </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">$352 million</span><span style="font-family:Arial;font-size:8pt;">, or </span><span style="font-family:Arial;font-size:8pt;">10%</span><span style="font-family:Arial;font-size:8pt;">, to </span><span style="font-family:Arial;font-size:8pt;">$4.0 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> from </span><span style="font-family:Arial;font-size:8pt;">$3.7 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, reflecting a </span><span style="font-family:Arial;font-size:8pt;">9%</span><span style="font-family:Arial;font-size:8pt;"> operational </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">. Foreign exchange had a </span><span style="font-family:Arial;font-size:8pt;">favorable</span><span style="font-family:Arial;font-size:8pt;"> impact of </span><span style="font-family:Arial;font-size:8pt;">1%</span><span style="font-family:Arial;font-size:8pt;">. The operational increase in emerging markets was primarily driven by Lipitor and Norvasc growth in China. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Costs and Expenses</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:8pt;">as a percentage of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">1.5</span><span style="font-family:Arial;font-size:8pt;"> percentage points driven by lower revenues for Viagra in the U.S. resulting from the loss of exclusivity in December 2017, as well as increased manufacturing plant costs in Puerto Rico due to hurricane-related recovery expenses, partially offset by a favorable impact of foreign exchange. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:8pt;">of</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">2%</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">was mostly driven by higher sales volume of Lyrica in the U.S. and Japan, as well as key products in China, partially offset by a favorable impact of foreign exchange.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">expenses</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">13%</span><span style="font-family:Arial;font-size:8pt;">, primarily driven by a reduction in field force expense as well as advertising and promotion expenses in developed markets, mainly related to Viagra and Lyrica in the U.S., as well as one-time general and administrative expense reversals in the second and third quarters of 2018, partially offset by additional investments in China across key brands.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">expenses</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;">d </span><span style="font-family:Arial;font-size:8pt;">15%</span><span style="font-family:Arial;font-size:8pt;"> mostly due to decreased spending for post-approval commitment activities for Lyrica and Celebrex.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">were relatively unchanged.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">47</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s0A824E089CFE53B8AD5C7389F03876AD"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF THE CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="19"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December&#160;31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%&#160;Change</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">19/18</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18/17</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash provided by/(used in):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">12,588</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">15,827</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">16,802</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(20</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(6</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(3,945</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,525</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(4,740</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(8,485</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(20,441</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(13,350</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(58</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(32</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(116</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(73</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net increase/(decrease) in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">125</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(205</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1,235</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">*</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(83</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Indicates calculation not meaningful or result is equal to or greater than 100%.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the consolidated statements of cash flows, the line item, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other changes in assets and liabilities, net of acquisitions and divestitures</span><span style="font-family:Arial;font-size:8pt;">, is presented excluding the effects of changes in foreign currency exchange rates, as these changes do not reflect actual cash inflows or outflows, and excluding any other significant non-cash movements. Accordingly, the amounts shown will not necessarily agree with the changes in the assets and liabilities that are presented in our consolidated balance sheets.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Operating Activities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our net cash provided by operating activities was </span><span style="font-family:Arial;font-size:8pt;">$12.6 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">$15.8 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">. The </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in net cash provided by operating activities reflects the timing of receipts from customers and payments to vendors in the ordinary course of business, the upfront cash payment associated with our acquisition of Therachon, and the upfront cash payment associated with our licensing agreement with Akcea (see Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;Note 2A. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Acquisitions</span><span style="font-family:Arial;font-size:8pt;">), partially offset by an </span><span style="font-family:Arial;font-size:8pt;">increase</span><span style="font-family:Arial;font-size:8pt;"> in net income and a decrease in benefit plan contributions.</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, the change in the line item </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other adjustments, net</span><span style="font-family:Arial;font-size:8pt;"> primarily reflects, among other items:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-recurrence of a non-cash gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets in 2018 (see Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2</span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">A</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Acquisitions</span><span style="font-family:Arial;font-size:8pt;">); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-recurrence of a non-cash gain on the contribution of Pfizer&#8217;s allogeneic CAR T developmental program assets, in connection with our contribution agreement with Allogene in 2018 (see Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2</span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">B</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Divestitures</span><span style="font-family:Arial;font-size:8pt;">), </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">net gains on foreign exchange contracts hedging a portion of our forecasted intercompany inventory sales (that fixes the cost of inventory sold later to customers).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, the line item </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other changes in assets and liabilities, net of acquisitions and divestitures,</span><span style="font-family:Arial;font-size:8pt;"> primarily reflects changes, in the normal course of business, in trade accounts receivable, inventories, other current assets, other noncurrent assets, trade accounts payable, accrued compensation, other current and noncurrent liabilities, as well as in 2019, the adjustment necessary to reflect the non-cash nature of a favorable settlement of a U.S. IRS audit for multiple tax years (see Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;Note 5A. Tax Matters: Taxes on Income from Continuing Operations</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;color:#000000;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;color:#000000;font-style:italic;text-decoration:underline;">2017</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our net cash provided by operating activities was </span><span style="font-family:Arial;font-size:8pt;">$15.8 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">$16.8 billion</span><span style="font-family:Arial;font-size:8pt;"> in 2017. The </span><span style="font-family:Arial;font-size:8pt;">decrease</span><span style="font-family:Arial;font-size:8pt;"> in net cash provided by operating activities reflects a decrease in net cash generated from net income. The net cash generated reflects the timing of receipts from customers and payments to vendors in the ordinary course of business. </span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, the change in the line item </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other adjustments, net</span><span style="font-family:Arial;font-size:8pt;"> primarily reflects, among other items:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-recurrence of a non-cash net loss on early retirement of debt under an exchange offer in 2017;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">unrealized net gains on equity securities resulting from the adoption of a new accounting standard on January 1, 2018, related to the recognition and measurement of financial assets and liabilities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a decrease in debt extinguishment costs in 2018 related to early retirement of debt under an exchange offer in 2017, which had been reclassified from operating to financing activities in 2018 and 2017 in accordance with our implementation of a new accounting standard on January 1, 2018 related to the classification of debt prepayment and extinguishment costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a non-cash gain associated with our transaction with Bain Capital to create a new biopharmaceutical company to continue development of a portfolio of clinical and preclinical stage neuroscience assets (see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2B. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Divestitures</span><span style="font-family:Arial;font-size:8pt;">); and</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">48</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a non-cash gain on the contribution of Pfizer&#8217;s allogeneic CAR T developmental program assets, in connection with our contribution agreement with Allogene (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2B. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Divestitures</span><span style="font-family:Arial;font-size:8pt;">),</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">decreases in net realized gains on sales of investments in debt and equity securities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">net losses on foreign exchange contracts hedging a portion of our forecasted intercompany inventory sales (that fixes the cost of inventory later sold to customers); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a decrease in gains on the sale of property, plant and equipment.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the line item </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other changes in assets and liabilities, net of acquisitions and divestitures,</span><span style="font-family:Arial;font-size:8pt;"> primarily reflects changes, in the normal course of business, in trade accounts receivable, inventories, other current assets, other noncurrent assets, trade accounts payable, accrued compensation and other current and noncurrent liabilities.</span></div><div style="line-height:120%;padding-top:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Investing Activities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our net cash used in investing activities was </span><span style="font-family:Arial;font-size:8pt;">$3.9 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, compared to net cash provided by investing activities of </span><span style="font-family:Arial;font-size:8pt;">$4.5 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">. The change in net cash used in/provided by investing activities was primarily attributable to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">cash used for the acquisition of Array, net of cash acquired, of </span><span style="font-family:Arial;font-size:8pt;">$10.9 billion</span><span style="font-family:Arial;font-size:8pt;"> in 2019,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an increase in net proceeds generated from the sale of investments of </span><span style="font-family:Arial;font-size:8pt;">$2.9 billion</span><span style="font-family:Arial;font-size:8pt;"> for cash needs, including financing the acquisition of Array (see Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2A. Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements: Acquisitions</span><span style="font-family:Arial;font-size:8pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our net cash provided by investing activities was </span><span style="font-family:Arial;font-size:8pt;">$4.5 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to net cash used in investing activities of </span><span style="font-family:Arial;font-size:8pt;">$4.7 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. The change in net cash provided by/(used in) investing activities was primarily attributable to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">an increase in net proceeds generated from the sale of investments of </span><span style="font-family:Arial;font-size:8pt;">$8.6 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> for cash needs; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">a decrease in cash used for acquisitions, net of cash acquired of </span><span style="font-family:Arial;font-size:8pt;">$1.0 billion</span><span style="font-family:Arial;font-size:8pt;"> due to the acquisition of the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business and substantially all of the remaining consideration for the Medivation acquisition in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2017</span><span style="font-family:Arial;font-size:8pt;"> (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2A. Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements: Acquisitions</span><span style="font-family:Arial;font-size:8pt;">)</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Financing Activities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our net cash used in financing activities was </span><span style="font-family:Arial;font-size:8pt;">$8.5 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">$20.4 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">. The decrease in net cash used in financing activities was primarily attributable to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$10.6 billion</span><span style="font-family:Arial;font-size:8pt;"> net proceeds raised from short-term borrowings in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;text-align:center;">, </span><span style="font-family:Arial;font-size:8pt;">primarily in connection with the acquisition of Array, compared to net payments on short-term borrowings of </span><span style="font-family:Arial;font-size:8pt;">$2.3 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;text-align:center;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">lower purchases of common stock of </span><span style="font-family:Arial;font-size:8pt;">$3.3 billion</span><span style="font-family:Arial;font-size:8pt;text-align:center;">,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">higher repayments on long-term debt of </span><span style="font-family:Arial;font-size:8pt;">$3.2 billion</span><span style="font-family:Arial;font-size:8pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">lower proceeds from the exercise of stock options of </span><span style="font-family:Arial;font-size:8pt;">$864 million</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;"> v. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-decoration:underline;">2017</span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our net cash used in financing activities was </span><span style="font-family:Arial;font-size:8pt;">$20.4 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">$13.3 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. The increase in net cash used in financing activities was primarily attributable to:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$2.3 billion</span><span style="font-family:Arial;font-size:8pt;"> less proceeds raised from short-term borrowings in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, compared to </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">higher purchases of common stock of </span><span style="font-family:Arial;font-size:8pt;">$7.2 billion</span><span style="font-family:Arial;font-size:8pt;">,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">lower repayments on long-term debt of </span><span style="font-family:Arial;font-size:8pt;">$2.6 billion</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><div><a id="sEAE1570191A356DF83AA012DDD05940C"></a></div><div style="line-height:120%;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">ANALYSIS OF FINANCIAL CONDITION, LIQUIDITY AND CAPITAL RESOURCES</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We rely largely on operating cash flows, short-term investments, short-term commercial paper borrowings and long-term debt to provide for our liquidity requirements. We continue our efforts to improve cash inflows through working capital efficiencies. We target specific areas of focus including accounts receivable, inventories, accounts payable, and other working capital, which allows us to optimize our operating cash flows.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">49</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Due to our significant operating cash flows as well as our financial assets, access to capital markets and available lines of credit and revolving credit agreements, we believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future, which include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the working capital requirements of our operations, including our R&amp;D activities;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">investments in our business;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">dividend payments and potential increases in the dividend rate;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">share repurchases;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the cash requirements associated with our cost-reduction/productivity initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">paying down outstanding debt;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">contributions to our pension and postretirement plans; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">business-development activities.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our long-term debt is rated high-quality by both S&amp;P and Moody&#8217;s. See the &#8220;Credit Ratings&#8221; section below. As market conditions change, we continue to monitor our liquidity position. We have taken and will continue to take a conservative approach to our financial investments. Both short-term and long-term investments consist primarily of high-quality, highly liquid, well-diversified available-for-sale debt securities.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Selected Measures of Liquidity and Capital Resources</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.11504424778761%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides certain relevant measures of our liquidity and capital resources:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT RATIOS AND PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selected financial assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1,305</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,139</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,525</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">17,694</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Long-term investments, excluding private equity securities at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2,258</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,823</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">12,088</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">20,656</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Debt:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16,195</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8,831</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">35,955</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">32,909</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">52,150</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">41,740</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selected net financial liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(40,062</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(21,084</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Working capital</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(4,501</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">18,068</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Ratio of current assets to current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.88:1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.57:1</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Pfizer Inc. shareholders&#8217; equity per common share</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">11.41</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11.09</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7. Financial Instruments</span><span style="font-family:Arial;font-size:7pt;"> for a description of certain assets held and for a description of credit risk related to our financial instruments held.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The </span><span style="font-family:Arial;font-size:7pt;">increase</span><span style="font-family:Arial;font-size:7pt;"> in selected net financial liabilities was primarily driven by a decrease in short-term investments and net increase in short-term debt, mainly as a result of cash paid for the acquisition of Array (see Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A. Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements: Acquisitions</span><span style="font-family:Arial;font-size:7pt;">). We retain a strong financial liquidity position as a result of our net cash provided by operating activities, our high-quality financial asset portfolio and access to capital markets. For additional information, see the &#8220;Credit Ratings&#8221; section of this Financial Review.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The </span><span style="font-family:Arial;font-size:7pt;">decrease</span><span> </span><span style="font-family:Arial;font-size:7pt;">in working capital was primarily due to:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">financing requirements for the acquisition of Array, share repurchase activities, dividend payments, capital expenditures and debt repayment, partially offset by operating cash flow generation, cash from employee stock option exercises and the March 2019 long-term debt issuance discussed below;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">the impact of the deconsolidation of the Consumer Healthcare business as a result of the completion of the joint venture transaction; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">the net impact of foreign currency exchange,</span></div></td></tr></table><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">the timing of accruals, cash receipts and payments in the ordinary course of business; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">an increase in inventory for certain products, including inventory build for new product launches, supply recovery, and market demand, partially offset by a charge related to rivipansel, primarily for inventory manufactured for expected future sale (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">for additional information).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents total Pfizer Inc. shareholders&#8217; equity divided by the actual number of common shares outstanding (which excludes treasury stock).</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On February 11, 2020, we issued a notice for the redemption in full of all </span><span style="font-family:Arial;font-size:8pt;">$1.065 billion</span><span style="font-family:Arial;font-size:8pt;"> principal amount of senior unsecured notes due 2047. The notes will be redeemed on March 17, 2020 at par as set forth in the indenture agreement. We do not expect this redemption to have a material impact on our consolidated financial statements.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2019, we completed a public offering of </span><span style="font-family:Arial;font-size:8pt;">$5.0 billion</span><span style="font-family:Arial;font-size:8pt;"> aggregate principal amount of senior unsecured notes with a weighted average effective interest rate of </span><span style="font-family:Arial;font-size:8pt;">3.57%</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Notes to Consolidated Financial Statements&#8211;&#8211;Note 7D. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Financial Instruments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Long-Term Debt</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information about the sources and uses of our funds, see the </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8220;</span><span style="font-family:Arial;font-size:8pt;">Analysis of the Consolidated Statements of Cash Flows</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8221;</span><span style="font-family:Arial;font-size:8pt;"> section of this Financial Review.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">50</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Domestic and International Selected Financial Assets</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Many of our operations are conducted outside the U.S., and significant portions of our selected financial assets are held internationally. The amount of funds held in U.S. tax jurisdictions can fluctuate due to the timing of receipts and payments in the ordinary course of business and due to other reasons, such as business-development activities. As part of our ongoing liquidity assessments, we regularly monitor the mix of domestic and international cash flows (both inflows and outflows). The changes in tax law under the TCJA, which includes transitioning U.S. international taxation from a worldwide tax system to a territorial tax system, will also allow us to more easily access our selected financial assets globally. The majority of our cash we held internationally as of year-end 2017 was repatriated in 2018.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Agreement to Combine Upjohn with Mylan</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with the recently-announced agreement to combine Upjohn with Mylan discussed in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business Development Initiatives&#8221; section of this Financial Review, Upjohn will incur approximately $12 billion of debt prior to the closing of the transaction. Immediately prior to the separation, Upjohn will make a cash distribution of $12 billion to Pfizer, which will be funded by the proceeds of such debt. Following the separation, Upjohn will remain the obligor with respect to the debt.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Credit Ratings</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Two major corporate debt-rating organizations, Moody&#8217;s and S&amp;P, assign ratings to our short-term and long-term debt. A security rating is not a recommendation to buy, sell or hold securities and the rating is subject to revision or withdrawal at any time by the rating organization. Each rating should be evaluated independently of any other rating. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In June 2019, S&amp;P placed Pfizer on &#8220;CreditWatch Negative&#8221; following the announcement of Pfizer&#8217;s intention to acquire Array. The CreditWatch placement was resolved with a one-notch downgrade of Pfizer&#8217;s debt rating to &#8216;AA-&#8217; upon the consummation of the transaction. In July 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, which resulted in actions from both Moody&#8217;s and S&amp;P.&#160;Moody&#8217;s placed Pfizer&#8217;s long-term rating under review for downgrade (limited to one-notch, or &#8216;A2&#8217; upon close of the Mylan transaction) while S&amp;P lowered Pfizer&#8217;s rating to &#8216;AA-&#8217; (as a result of the Array transaction) and confirmed it will still remain on CreditWatch Negative (with the expectation the rating will be lowered one additional notch to &#8216;A+&#8217; upon close of the Mylan transaction).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:23%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the current ratings assigned by these rating agencies to our commercial paper and senior unsecured long-term debt:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">NAME OF RATING AGENCY</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer </span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Commercial Paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Long-Term Debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Outlook</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Date of Last Rating Change</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rating</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Moody&#8217;s</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">P-1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Under Review for Downgrade</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">October 2009</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">S&amp;P</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A-1+</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">AA-</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">CreditWatch Negative</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">July 2019</span></div></td></tr></table></div></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Debt Capacity&#8211;&#8211;Lines of Credit</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have available lines of credit and revolving credit agreements with a group of banks and other financial intermediaries. We typically maintain cash and cash equivalent balances and short-term investments which, together with our available revolving credit facilities, are in excess of our commercial paper and other short-term borrowings. As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had access to a total of </span><span style="font-family:Arial;font-size:8pt;">$15 billion</span><span style="font-family:Arial;font-size:8pt;"> in U.S. revolving credit facilities consisting of a </span><span style="font-family:Arial;font-size:8pt;">$7 billion</span><span style="font-family:Arial;font-size:8pt;"> facility expiring in 2024 and an </span><span style="font-family:Arial;font-size:8pt;">$8 billion</span><span style="font-family:Arial;font-size:8pt;"> facility expiring in September 2020, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional </span><span style="font-family:Arial;font-size:8pt;">$537 million</span><span style="font-family:Arial;font-size:8pt;"> in lines of credit, of which </span><span style="font-family:Arial;font-size:8pt;">$508 million</span><span style="font-family:Arial;font-size:8pt;"> expire within one year. Of these total lines of credit, </span><span style="font-family:Arial;font-size:8pt;">$15.5 billion</span><span style="font-family:Arial;font-size:8pt;"> were unused on </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. In connection with the recently-announced agreement to combine Upjohn with Mylan discussed in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business Development Initiatives&#8221; section of this Financial Review, Upjohn entered into a fully underwritten, 364-day senior unsecured bridge facility for up to $12 billion. This bridge facility is expected to terminate upon the issuance of approximately $12 billion of debt securities, loans or a combination of the two by Upjohn prior to the transaction close.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">LIBOR</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">From time to time, we issue variable rate debt based on LIBOR, or undertake interest rate swaps that contain a variable element based on LIBOR. The U.K. Financial Conduct Authority announced in July 2017 that it will no longer compel banks to submit rates that are currently used to calculate LIBOR after 2021. Various governing parties, including government agencies, are working on a benchmark transition plan for LIBOR (and other interbank offered rates globally). We are monitoring their progress, and we will likely amend contracts to accommodate any replacement rate where it is not already provided. We do not expect the transition to an alternative rate to have a material impact on our liquidity or financial resources. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Global Economic Conditions&#8211;&#8211;General</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The global economic environment has not had, nor do we anticipate it will have, a material impact on our liquidity or capital resources. Due to our significant operating cash flows, financial assets, access to capital markets and available lines of credit and revolving credit agreements, we continue to believe that we have, and will maintain, the ability to meet our liquidity needs for the foreseeable future. We monitor our liquidity position continuously in the face of evolving economic conditions.</span><span style="font-family:Arial;font-size:8pt;"> For additional information see the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221; section in this Financial Review.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">51</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Global Economic Conditions&#8211;&#8211;Venezuela Operations and Argentina Operations</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our Venezuela and Argentina operations function in hyperinflationary economies. The impact to Pfizer is not considered material.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Contractual Obligations</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Payments due under contractual obligations as of December&#160;31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, mature as follows:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.11504424778761%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:45%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Years</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021-2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023-2024</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Thereafter</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Long-term debt, including current portion</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">37,417</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,462</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,769</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">5,274</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">25,912</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest payments on long-term debt obligations</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21,612</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,403</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,701</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,436</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">15,073</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other long-term liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,521</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">427</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">534</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">483</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,078</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating leases</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,280</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">323</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">512</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">433</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,012</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Purchase obligations and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,534</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">711</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">994</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">485</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">344</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other taxes payable</span><span style="font-family:inherit;font-size:7pt;">&#8212;</span><span style="font-family:Arial;font-size:8pt;">deemed repatriated accumulated post-1986 earnings of foreign subsidiaries</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9,650</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">600</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1,700</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2,400</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,950</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Uncertain tax positions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">130</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">130</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Long-term debt consists of senior unsecured notes (including fixed and floating rate, foreign currency denominated, and other notes), carried at historical proceeds, as adjusted (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7. Financial Instruments</span><span style="font-family:Arial;font-size:7pt;">). Commitments under financing leases are not significant.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Our calculations of expected interest payments incorporate only current period assumptions for interest rates, foreign currency translation rates and hedging strategies (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7. Financial Instruments</span><span style="font-family:Arial;font-size:7pt;">), and assume that interest is accrued through the maturity date or expiration of the related instrument.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Includes expected payments relating to our unfunded U.S. supplemental (non-qualified) pension plans, postretirement plans and deferred compensation plans. Excludes amounts relating to our U.S. qualified pension plans and international pension plans, all of which have a substantial amount of plan assets, because the required funding obligations are not expected to be material and/or because such liabilities do not necessarily reflect future cash payments, as the impact of changes in economic conditions on the fair value of the pension plan assets and/or liabilities can be significant. Also, excludes </span><span style="font-family:Arial;font-size:7pt;">$3.9 billion</span><span style="font-family:Arial;font-size:7pt;"> of liabilities related to  the fair value of derivative financial instruments, legal matters and employee terminations, among other liabilities, most of which do not represent contractual obligations. See also our liquidity discussion above in this &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; section, as well as the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3. Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives, Note 7A. Financial Instruments: Fair Value Measurements, Note 11E. Pension and Postretirement Benefit Plans and Defined Contribution Plans: Cash Flows, </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 16. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Includes future minimum rental commitments under non-cancelable operating leases. These amounts include an agreement we entered in April 2018 to lease space in an office building in New York City. We expect to take control of the property in 2021 and relocate our global headquarters to this new office building in 2022. Our future minimum rental commitment under this 20-year lease is approximately </span><span style="font-family:Arial;font-size:7pt;">$1.7 billion</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Includes agreements to purchase goods and services that are enforceable and legally binding and includes amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur. Also includes obligations to make guaranteed fixed annual payments over the next 7 years in connection with the U.S. and EU approvals for Besponsa (</span><span style="font-family:Arial;font-size:7pt;">$412 million</span><span style="font-family:Arial;font-size:7pt;">) and an obligation to make guaranteed fixed annual payments over the next 8 years for Bosulif (</span><span style="font-family:Arial;font-size:7pt;">$217 million</span><span style="font-family:Arial;font-size:7pt;">), both associated with R&amp;D arrangements. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7E. Financial Instruments: Other Noncurrent Liabilities </span><span style="font-family:Arial;font-size:7pt;">and &#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 16C. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">: Certain Commitments</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents estimated cash payments related to the TCJA repatriation tax for which we elected with the filing of our 2018 U.S. Federal Consolidated Income Tax Return to pay in annual installments over eight years through 2026 (with the next installment due in April 2020). Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A. Tax Matters: Taxes on Income from Continuing Operations</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5C. Tax Matters: Deferred Taxes.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Includes only income tax amounts currently payable. We are unable to predict the timing of tax settlements related to our noncurrent obligations for uncertain tax positions as tax audits can involve complex issues and the resolution of those issues may span multiple years, particularly if subject to negotiation or litigation.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The above table includes amounts for potential milestone payments under collaboration, licensing or other arrangements, if the payments are deemed reasonably likely to occur. Payments under these agreements generally become due and payable only upon the achievement of certain development, regulatory and/or commercialization milestones, which may span several years and which may never occur.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;">, we expect to spend approximately </span><span style="font-family:Arial;font-size:8pt;">$2.4 billion</span><span style="font-family:Arial;font-size:8pt;"> on property, plant and equipment. We rely largely on operating cash flows to fund our capital investment needs. Due to our significant operating cash flows, we believe we have the ability to meet our capital investment needs and anticipate no delays to planned capital expenditures.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Off-Balance Sheet Arrangements</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with a transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnification obligations generally are subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, the estimated fair value of our indemnification obligations was not significant.</span></div><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain of our co-promotion or license agreements give our licensors or partners the rights to negotiate for, or in some cases to obtain under certain financial conditions, co-promotion or other rights in specified countries with respect to certain of our products.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">52</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Share-Purchase Plans and Accelerated Share Repurchase Agreements</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 12. Equity </span><span style="font-family:Arial;font-size:8pt;">for information on the shares of our common stock purchased and the cost of purchases under our publicly announced share-purchase plans, including our accelerated share repurchase agreements. At December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, our remaining share-purchase authorization was approximately </span><span style="font-family:Arial;font-size:8pt;">$5.3 billion</span><span style="font-family:Arial;font-size:8pt;">, with no repurchases currently planned in 2020.</span></div><div style="line-height:120%;padding-top:6px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Dividends on Common Stock</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We paid dividends on our common stock of </span><span style="font-family:Arial;font-size:8pt;">$8.0 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">$8.0 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">$7.7 billion</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. In December </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, our Board of Directors declared a first-quarter 2020 dividend of </span><span style="font-family:Arial;font-size:8pt;">$0.38</span><span style="font-family:Arial;font-size:8pt;"> per share, payable on March&#160;6, </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;">, to shareholders of record at the close of business on January 31, </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;">. The first-quarter </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;"> cash dividend will be our 325</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">th </sup></span><span style="font-family:Arial;font-size:8pt;">consecutive quarterly dividend.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our current and projected dividends provide a return to shareholders while maintaining sufficient capital to invest in growing our businesses. Our dividends are not restricted by debt covenants. While the dividend level remains a decision of Pfizer&#8217;s Board of Directors and will continue to be evaluated in the context of future business performance, we currently believe that we can support future annual dividend increases, barring significant unforeseen events. Pfizer also expects that immediately following the closing of the proposed transaction to combine Upjohn with Mylan, the combined dividend dollar amount received by Pfizer shareholders in the event the equity distribution is structured as a spinoff, based upon the combination of continued Pfizer ownership and an expected 0.12 shares of the new company granted for each Pfizer share, will equate to Pfizer&#8217;s dividend amount in effect immediately prior to closing.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">53</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s527AD00D04ED5487BE6FAE5909AF1405"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-bottom:6px;padding-top:10px;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">NEW ACCOUNTING STANDARDS</span></div><div style="line-height:120%;padding-bottom:6px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Recently Adopted Accounting Standards</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:38%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:41%;"></td></tr><tr><td colspan="5" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Recently Issued Accounting Standards, Not Adopted as of December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Standard/Description</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effective Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effect on the Financial Statements or Other Significant Matters</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In June 2016, the FASB issued new guidance on accounting for </span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">credit losses of financial instruments</span><span style="font-family:Arial;font-size:8pt;">. The new guidance and related amendments replace the probable initial recognition threshold for incurred loss estimates in current GAAP with a methodology that reflects expected credit loss estimates.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="padding-top:1px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This standard includes our financial instruments, such as accounts receivable, and investments that are generally of high credit quality.</span></div><div style="padding-top:1px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Previously, when credit losses were measured under GAAP, an entity generally only considered past events and current conditions in measuring the incurred loss.</span></div><div style="padding-top:1px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The new guidance requires us to identify, analyze, document and support new methodologies for quantifying expected credit loss estimates for our financial instruments, using information such as historical experience and current economic conditions, plus the use of reasonable supportable forecast information. We do not expect this new guidance to have a material impact on our consolidated financial statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In January 2017, the FASB issued new guidance for </span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">goodwill impairment testing</span><span style="font-family:Arial;font-size:8pt;">. The new guidance eliminates the requirement to perform a hypothetical purchase price allocation to measure goodwill impairment. Under the new guidance the goodwill impairment test is performed by comparing the fair value of a reporting unit with its carrying amount, and recognizing an impairment charge for the amount by which the carrying amount of the reporting unit exceeds its fair value, although it cannot exceed the total amount of goodwill allocated to that reporting unit. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We do not expect this new guidance to have a material impact on our consolidated financial statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2018, the FASB issued new guidance related to </span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">customers&#8217; accounting for implementation costs incurred in a cloud computing arrangement that is considered a service contract</span><span style="font-family:Arial;font-size:8pt;">. The new guidance aligns the requirements for capitalizing implementation costs in such arrangements with the requirements for capitalizing implementation costs incurred to develop or obtain internal-use software. The new guidance can be adopted either prospectively or retrospectively.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We do not expect this new guidance to have a material impact on our consolidated financial statements.</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In November 2018, the FASB issued new guidance clarifying the interaction between the accounting guidance for </span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">collaboration agreements </span><span style="font-family:Arial;font-size:8pt;">and</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;revenue from contracts with customers</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2020. </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We do not expect this new guidance to have a material impact on our consolidated financial statements.</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2019, the FASB issued new guidance that simplifies the </span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">accounting for income taxes</span><span style="font-family:Arial;font-size:8pt;">&#160;by eliminating certain exceptions to the guidance related to the approach for intraperiod tax allocation, the methodology for calculating income taxes in an interim period and the recognition of deferred tax liabilities for outside basis differences. The new guidance also simplifies aspects of the accounting for franchise taxes and enacted changes in tax laws or rates and clarifies the accounting for transactions that result in a step-up in the tax basis of goodwill. </span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2021. Early adoption is permitted.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are assessing the impact of the provisions of this new guidance on our consolidated financial statements. </span></div></td></tr></table></div></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">54</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sE89660235E295CF4BD6750A0E51F3765"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">FORWARD-LOOKING INFORMATION AND FACTORS THAT MAY AFFECT FUTURE RESULTS</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This report and other written or oral statements that we make from time to time contain forward-looking statements. Such forward-looking statements involve substantial risks and uncertainties. We have tried, wherever possible, to identify such statements by using words such as &#8220;will,&#8221; &#8220;may,&#8221; &#8220;could,&#8221; &#8220;likely,&#8221; &#8220;ongoing,&#8221; &#8220;anticipate,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;project,&#8221; &#8220;intend,&#8221; &#8220;plan,&#8221; &#8220;believe,&#8221; &#8220;assume,&#8221; &#8220;target,&#8221; &#8220;forecast,&#8221; &#8220;guidance,&#8221; &#8220;goal,&#8221; &#8220;objective,&#8221; &#8220;aim,&#8221; &#8220;seek&#8221; and other words and terms of similar meaning or by using future dates in connection with any discussion of, among other things, our anticipated operating and financial performance, business plans and prospects, expectations for our product pipeline, in-line products and product candidates, including anticipated regulatory submissions, data read-outs, study starts, approvals, revenue contribution, growth, performance, timing of exclusivity and potential benefits, strategic reviews, capital allocation objectives, plans for and prospects of our acquisitions and other business-development activities, benefits anticipated from the reorganization of our commercial operations in 2019, sales efforts, expenses, interest rates, foreign exchange rates, the outcome of contingencies, such as legal proceedings, government regulation, our ability to successfully capitalize on growth opportunities or prospects, manufacturing and product supply and plans relating to share repurchases and dividends. In particular, these include statements relating to future actions, including, among others, the expected timing, benefits, charges and/or costs in connection with our agreement to combine Upjohn with Mylan to create a new global pharmaceutical company, Viatris, set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Business Development Initiatives&#8221; and &#8220;&#8211;&#8211;Our Strategy&#8221; sections and the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A. Basis of Presentation and Significant Accounting Policies&#8211;&#8211;Basis of Presentation </span><span style="font-family:Arial;font-size:8pt;">of this Financial Review, the expected impact of patent expiries on our business set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Operating Environment&#8211;&#8211;Industry-Specific Challenges&#8211;&#8211;Intellectual Property Rights and Collaboration/Licensing Rights&#8221; section of this Financial Review, the benefits expected from the reorganization of our commercial operations in 2019 and our expectations regarding growth set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Strategy&#8211;&#8211;Organizing for Growth&#8221; section of this Financial Review, the anticipated costs related to our preparations for Brexit set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221; section of this Financial Review, our anticipated liquidity position set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;The Global Economic Environment&#8221; and the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8221; sections of this Financial Review, the anticipated costs and savings from certain of our initiatives, including the Transforming to a More Focused Company initiative, set forth in the &#8220;</span><span style="font-family:Arial;font-size:8pt;">Overview of Our Performance, Operating Environment, Strategy and Outlook</span><span style="font-family:Arial;font-size:8pt;">&#8212;Transforming to a More Focused Company&#8221; and &#8220;</span><span style="font-family:Arial;font-size:8pt;">Costs and Expenses</span><span style="font-family:Arial;font-size:8pt;">&#8212;</span><span style="font-family:Arial;font-size:8pt;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:8pt;">&#8221; sections of this Financial Review and in the Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:8pt;">, our plans for increasing investment in the U.S. set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Strategy&#8211;&#8211;Capital Allocation and Expense Management&#8211;&#8211;Increasing Investment in the U.S.&#8221; section of this Financial Review, the financial guidance set forth in the &#8220;Overview of Our Performance, Operating Environment, Strategy and Outlook&#8211;&#8211;Our Financial Guidance for </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;">&#8221; section of this Financial Review, the expected impact of ACIP&#8217;s recommendation for Prevnar 13 for adults 65 and older on Prevnar 13&#8217;s revenues set forth in the &#8220;Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8211;&#8211;Prevnar 13/Prevenar 13 (Biopharma)&#8221; section of this Financial Review, the expected impact of updates to the prescribing information for Xeljanz on its growth set forth in the &#8220;Analysis of the Consolidated Statements of Income&#8211;&#8211;Revenues&#8211;&#8211;Selected Product Discussion&#8211;&#8211;Xeljanz (Biopharma)&#8221; section of this Financial Review, the benefits expected from our business development transactions, the planned capital spending set forth in the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8211;&#8211;Selected Measures of Liquidity and Capital Resources&#8211;&#8211;Contractual Obligations&#8221; section of this Financial Review, the expected payments to our unfunded U.S. supplemental (non-qualified) pension plans, postretirement plans and deferred compensation plans and expected funding obligations set forth in the &#8220;Analysis of Financial Condition, Liquidity and Capital Resources&#8211;&#8211;Selected Measures of Liquidity and Capital Resources&#8211;&#8211;Contractual Obligations&#8221; section of this Financial Review, and the voluntary contribution we expect to make during 2020 for the U.S. qualified plans set forth in Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 11. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Pension and Postretirement Benefit Plans and Defined Contribution Plans</span><span style="font-family:Arial;font-size:8pt;">. Among the factors that could cause actual results to differ materially from past results and future plans and projected future results are the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the outcome of R&amp;D activities, including, without limitation, the ability to meet anticipated pre-clinical or clinical endpoints, commencement and/or completion dates for our pre-clinical or clinical trials, regulatory submission dates, regulatory approval dates and/or launch dates, as well as the possibility of unfavorable pre-clinical and clinical trial results, including the possibility of unfavorable new clinical data and further analyses of existing clinical data;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the risk we may not be able to successfully address all of the comments received from regulatory authorities such as the FDA or the EMA, or obtain approval from regulators, which will depend on myriad factors, including such regulator making a determination as to whether a product&#8217;s benefits outweigh its known risks and a determination of the product&#8217;s efficacy; regulatory decisions impacting labeling, manufacturing processes, safety and/or other matters; and recommendations by technical or advisory committees, such as ACIP, that may impact the use of our vaccines;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the speed with which regulatory authorizations, pricing approvals and product launches may be achieved;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">claims and concerns that may arise regarding the safety or efficacy of in-line products and product candidates, including claims and concerns that may arise from the outcome of post-approval clinical trials, which could result in the loss of marketing approval, changes in product labeling, and/or new or increased concerns about the side effects or efficacy of, a product that could affect its availability or commercial potential, such as the update to the U.S. and EU prescribing information for Xeljanz;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the success of external business-development activities, including the ability to identify and execute on potential business development opportunities, the ability to satisfy the conditions to closing of announced transactions in the anticipated time frame or at all, the ability to realize the anticipated benefits of any such transactions, and the potential need to obtain additional equity or debt financing to pursue these opportunities, which could result in increased leverage and impact our credit ratings;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">competitive developments, including the impact on our competitive position of new product entrants, in-line branded products, generic products, private label products, biosimilars and product candidates that treat diseases and conditions similar to those treated by our in-line drugs and drug candidates;</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">55</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the implementation by the FDA and regulatory authorities in certain countries of an abbreviated legal pathway to approve biosimilar products, which could subject our biologic products to competition from biosimilar products, with attendant competitive pressures, after the expiration of any applicable exclusivity period and patent rights;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">risks related to our ability to develop and commercialize biosimilars, including risks associated with &#8220;at risk&#8221; launches, defined as the marketing of a product by Pfizer before the final resolution of litigation (including any appeals) brought by a third party alleging that such marketing would infringe one or more patents owned or controlled by the third party, and access challenges for our biosimilar products where our product may not receive appropriate formulary access or remains in a disadvantaged position relative to the innovator product;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the ability to meet competition from generic, branded and biosimilar products after the loss or expiration of patent protection for our products or competitor products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the ability to successfully market both new and existing products domestically and internationally;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">difficulties or delays in manufacturing, sales or marketing, including delays caused by natural events, such as hurricanes; supply disruptions, shortages or stock-outs at our facilities; and legal or regulatory actions, such as warning letters, suspension of manufacturing, seizure of product, injunctions, debarment, recall of a product, delays or denials of product approvals, import bans or denial of import certifications; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of public health epidemics or outbreaks on our operations (such as the novel strain of coronavirus impacting China and several other countries);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">trade buying patterns;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of existing and future legislation and regulatory provisions on product exclusivity;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">trends toward managed care and healthcare cost containment, and our ability to obtain or maintain timely or adequate pricing or favorable formulary placement for our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of any significant spending reductions or cost controls affecting Medicare, Medicaid or other publicly funded or subsidized health programs or changes in the tax treatment of employer-sponsored health insurance that may be implemented;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226; </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of any U.S. healthcare reform or legislation, including any replacement, repeal, modification or invalidation of some or all of the provisions of the U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226; </span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. federal or state legislation or regulatory action and/or policy efforts affecting, among other things, pharmaceutical product pricing, intellectual property, reimbursement or access, including under Medicaid, Medicare and other publicly funded or subsidized health programs; patient out-of-pocket costs for medicines, manufacturer prices and/or price increases that could result in new mandatory rebates and discounts or other pricing restrictions; general budget control actions; the importation of prescription drugs from outside the U.S. at prices that are regulated by governments of various foreign countries; revisions to reimbursement of biopharmaceuticals under government programs; restrictions on U.S. direct-to-consumer advertising; limitations on interactions with healthcare professionals; or the use of comparative effectiveness methodologies that could be implemented in a manner that focuses primarily on the cost differences and minimizes the therapeutic differences among pharmaceutical products and restricts access to innovative medicines; as well as pricing pressures for our products as a result of highly competitive insurance markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">legislation or regulatory action in markets outside the U.S., including China, affecting pharmaceutical product pricing, intellectual property, reimbursement or access, including, in particular, continued government-mandated reductions in prices and access restrictions for certain biopharmaceutical products to control costs in those markets;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the exposure of our operations outside the U.S. to possible capital and exchange controls, economic conditions, expropriation and other restrictive government actions, changes in intellectual property legal protections and remedies, as well as political unrest, unstable governments and legal systems and inter-governmental disputes;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">contingencies related to actual or alleged environmental contamination;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">any significant breakdown, infiltration or interruption of our information technology systems and infrastructure;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">legal defense costs, insurance expenses and settlement costs;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the risk of an adverse decision or settlement and the adequacy of reserves related to legal proceedings, including patent litigation, such as claims that our patents are invalid and/or do not cover the product of the generic drug manufacturer or where one or more third parties seeks damages and/or injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities, product liability and other product-related litigation, including personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, commercial, environmental, government investigations, employment and other legal proceedings, including various means for resolving asbestos litigation, as well as tax issues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the risk that our currently pending or future patent applications may not result in issued patents, or be granted on a timely basis, or any patent-term extensions that we seek may not be granted on a timely basis, if at all;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">our ability to protect our patents and other intellectual property, both domestically and internationally;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">interest rate and foreign currency exchange rate fluctuations, including the impact of possible currency devaluations in countries experiencing high inflation rates;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">governmental laws and regulations affecting domestic and foreign operations, including, without limitation, tax obligations and changes affecting the tax treatment by the U.S. of income earned outside the U.S. that may result from pending and possible future proposals, including further clarifications and/or interpretations of or changes to the TCJA enacted in 2017;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">any significant issues involving our largest wholesale distributors, which account for a substantial portion of our revenues;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the possible impact of the increased presence of counterfeit medicines in the pharmaceutical supply chain on our revenues and on patient confidence in the integrity of our medicines;</span></div></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">56</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Review</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">uncertainties based on the formal change in relationship between the U.K. government and the EU, which could have implications on our research, commercial and general business operations in the U.K. and the EU, including the approval and supply of our products;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">any significant issues that may arise related to the outsourcing of certain operational and staff functions to third parties, including with regard to quality, timeliness and compliance with applicable legal or regulatory requirements and industry standards;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">any significant issues that may arise related to our joint ventures and other third-party business arrangements;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">further clarifications and/or changes in interpretations of existing laws and regulations, or changes in laws and regulations, in the U.S. and other countries, including changes in U.S. generally accepted accounting principles;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">uncertainties related to general economic, political, business, industry, regulatory and market conditions including, without limitation, uncertainties related to the impact on us, our customers, suppliers and lenders and counterparties to our foreign-exchange and interest-rate agreements of challenging global economic conditions and recent and possible future changes in global financial markets; the related risk that our allowance for doubtful accounts may not be adequate; and the risks related to volatility of our income due to changes in the market value of equity investments;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">any changes in business, political and economic conditions due to actual or threatened terrorist activity in the U.S. and other parts of the world, and related U.S. military action overseas;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">growth in costs and expenses;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">changes in our product, segment and geographic mix; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of purchase accounting adjustments, acquisition-related costs, discontinued operations and certain significant items;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of product recalls, withdrawals and other unusual items;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the risk of an impairment charge related to our intangible assets, goodwill or equity-method investments; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of, and risks and uncertainties related to, acquisitions and divestitures, such as the acquisition of Array, our transaction with GSK which combined our respective consumer healthcare businesses into a new consumer healthcare joint venture and our agreement to comb</span><span style="font-family:Arial;font-size:8pt;color:#0000ff;">i</span><span style="font-family:Arial;font-size:8pt;">ne Upjohn with Mylan to create a new global pharmaceutical company, Viatris, including, among other things, risks related to the satisfaction of the conditions to closing to any pending transaction (including the failure to obtain any necessary shareholder and regulatory approvals) in the anticipated timeframe or at all and the possibility that such transaction does not close; the ability to realize the anticipated benefits of those transactions, including the possibility that the expected cost savings and/or accretion from certain of those transactions will not be realized or will not be realized within the expected time frame; the risk that the businesses will not be integrated successfully; negative effects of the announcement or the consummation of the transaction on the market price of Pfizer&#8217;s common stock, Pfizer&#8217;s credit ratings and/or Pfizer&#8217;s operating results; disruption from the transactions making it more difficult to maintain business and operational relationships; risks related to our ability to grow revenues for certain acquired products; significant transaction costs; unknown liabilities; the risk of litigation and/or regulatory actions related to the transaction, other business effects, including the effects of industry, market, economic, political or regulatory conditions, future exchange and interest rates, changes in tax and other laws, regulations, rates and policies, future business combinations or disposals; competitive developments; and as it relates to the Consumer Healthcare JV with GSK, the possibility that a future separation of the joint venture as an independent company via a demerger of GSK&#8217;s equity interest to GSK&#8217;s shareholders and a listing of the joint venture on the U.K. equity market may not occur; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the impact of, and risks and uncertainties related to, restructurings and internal reorganizations, including the reorganization of our commercial operations in 2019, as well as any other corporate strategic initiatives, and cost-reduction and productivity initiatives, each of which requires upfront costs but may fail to yield anticipated benefits and may result in unexpected costs or organizational disruption</span><span style="font-family:Times New Roman;font-size:8pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We cannot guarantee that any forward-looking statement will be realized. Achievement of anticipated results is subject to substantial risks, uncertainties and inaccurate assumptions. Should known or unknown risks or uncertainties materialize or should underlying assumptions prove inaccurate, actual results could vary materially from past results and those anticipated, estimated or projected. Investors should bear this in mind as they consider forward-looking statements, and are cautioned not to put undue reliance on forward-looking statements.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We undertake no obligation to publicly update forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law or by the rules and regulations of the SEC. You are advised, however, to consult any further disclosures we make on related subjects.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain risks, uncertainties and assumptions are discussed here and under the heading entitled &#8220;Risk Factors&#8221; in Part I, Item&#160;1A. of our Form 10-K for the year ended </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. We note these factors for investors as permitted by the Private Securities Litigation Reform Act of 1995. You should understand that it is not possible to predict or identify all such factors. Consequently, you should not consider any such list to be a complete set of all potential risks or uncertainties.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The operating segment information provided in this report does not purport to represent the revenues, costs and income from continuing operations before provision for taxes on income that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">This report includes discussion of certain clinical studies relating to various in-line products and/or product candidates. These studies typically are part of a larger body of clinical data relating to such products or product candidates, and the discussion herein should be considered in the context of the larger body of data. In addition, clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety and/or effectiveness of a product candidate or a new indication for an in-line product, regulatory authorities may not share our views and may require additional data or may deny approval altogether.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">57</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s25609F0C8BAB54DB95F45F92A401A919"></a></div><div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:11.75pt;"><span style="font-family:Arial;font-size:11.75pt;font-weight:bold;">Management&#8217;s Report on Internal Control Over Financial Reporting</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Management&#8217;s Report</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We prepared and are responsible for the financial statements that appear in our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report. These financial statements are in conformity with accounting principles generally accepted in the United States of America and, therefore, include amounts based on informed judgments and estimates. We also accept responsibility for the preparation of other financial information that is included in this document.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Report on Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The management of the Company is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934. The Company&#8217;s internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles in the United States of America. The Company&#8217;s internal control over financial reporting includes those policies and procedures that: (i) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the Company; (ii) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles and that receipts and expenditures of the Company are being made only in accordance with authorizations of management and directors of the Company; and (iii) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the Company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions or that the degree of compliance with the policies or procedures may deteriorate. Management assessed the effectiveness of the Company&#8217;s internal control over financial reporting as of December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Internal Control&#8212;Integrated Framework</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">(2013)</span><span style="font-family:Arial;font-size:8pt;">. Based on our assessment and those criteria, management believes that the Company maintained effective internal control over financial reporting as of December&#160;31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Company&#8217;s independent auditors have issued their auditors&#8217; report on the Company&#8217;s internal control over financial reporting. That report appears in our </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report under the heading, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Report of Independent Registered Public Accounting Firm on Internal Control Over Financial Reporting</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:3%;"></td><td style="width:62%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="albertbourlasignatureq42019.jpg" alt="albertbourlasignatureq42019.jpg" style="height:45px;width:164px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Albert Bourla</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Chairman and Chief Executive Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;text-indent:96px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">    </span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:35%;"></td><td style="width:3%;"></td><td style="width:62%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="franksignatureq42019.jpg" alt="franksignatureq42019.jpg" style="height:45px;width:217px;"></img></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:53px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div><img src="lorettasignatureq42019.jpg" alt="lorettasignatureq42019.jpg" style="height:45px;width:140px;"></img></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Frank D&#8217;Amelio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Loretta Cangialosi</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Principal Financial Officer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Principal Accounting Officer</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">February&#160;27, 2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">58</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s5F47B03C85B35EDEA139CB29CD40B156"></a></div><div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Audit Committee Report</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Audit Committee reviews Pfizer&#8217;s financial reporting process on behalf of the Board of Directors. Management has the primary responsibility for the financial statements and the reporting process, including the system of internal controls.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Committee met and held discussions with management and the independent registered public accounting firm regarding the fair and complete presentation of Pfizer&#8217;s results and the assessment of Pfizer&#8217;s internal control over financial reporting. We discussed significant accounting policies applied in Pfizer&#8217;s financial statements, as well as, when applicable, alternative accounting treatments, and critical audit matters addressed during the audit. Management represented to the Committee that the consolidated financial statements were prepared in accordance with accounting principles generally accepted in the United States of America, and the Committee reviewed and discussed the consolidated financial statements with management and the independent registered public accounting firm. The Committee discussed with the independent registered public accounting firm matters required to be discussed under applicable Public Company Accounting Oversight Board (PCAOB) and U.S. Securities and Exchange Commission standards.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition, the Committee reviewed and discussed with the independent registered public accounting firm the auditor&#8217;s independence from Pfizer and its management. As part of that review, we received the written disclosures and the letter required by applicable requirements of the PCAOB regarding the independent registered public accounting firm&#8217;s communications with the Audit Committee concerning independence, and the Committee discussed the independent registered public accounting firm&#8217;s independence from Pfizer.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We also considered whether the independent registered public accounting firm&#8217;s provision of non-audit services to Pfizer is compatible with the auditor&#8217;s independence. The Committee concluded that the independent registered public accounting firm is independent from Pfizer and its management.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As part of our responsibilities for oversight of Pfizer&#8217;s Enterprise Risk Management process, we reviewed and discussed company policies with respect to risk assessment and risk management, including discussions of individual risk areas, as well as an annual summary of the overall process.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Committee discussed with Pfizer&#8217;s Internal Audit Department and independent registered public accounting firm the overall scope of and plans for their respective audits. The Committee meets with the Chief Internal Auditor, Chief Compliance, Quality and Risk Officer and representatives of the independent registered public accounting firm, in regular and executive sessions, to discuss the results of their examinations, the evaluations of Pfizer&#8217;s internal controls, and the overall quality of Pfizer&#8217;s financial reporting and compliance programs.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In reliance on the reviews and discussions referred to above, the Committee has recommended to the Board of Directors, and the Board has approved, that the audited financial statements be included in Pfizer&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, for filing with the U.S. Securities and Exchange Commission. The Committee has selected, and the Board of Directors has ratified, the selection of Pfizer&#8217;s independent registered public accounting firm for </span><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:center;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">The Audit Committee</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Suzanne Nora Johnson, Chair</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Ronald E. Blaylock</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Joseph J. Echevarria</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">James C. Smith</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">February&#160;27, 2020</span></div></td></tr></table></div></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">The Audit Committee Report does not constitute soliciting material, and shall not be deemed to be filed or incorporated by reference into any Company filing under the Securities Act of 1933, as amended, or the Securities Exchange Act of 1934, as amended, except to the extent that the Company specifically incorporates the Audit Committee Report by reference therein.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">59</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s7101D9235F635546873A2383A0B4038D"></a></div><div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">To the Board of Directors and Shareholders of Pfizer Inc.:</span></div><div style="line-height:120%;padding-top:13px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Opinion on the Consolidated Financial Statements</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have audited the accompanying consolidated balance sheets of Pfizer Inc. and Subsidiary Companies (the Company) as of December 31, </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, and the results of its operations and its cash flows for each of the years in the three-year period ended December 31, </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, in conformity with U.S. generally accepted accounting principles.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company&#8217;s internal control over financial reporting as of December 31, </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, based on criteria established in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Internal Control </span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Integrated Framework (2013) </span><span style="font-family:Arial;font-size:8pt;">issued by the Committee of Sponsoring Organizations of the Treadway Commission, and our report dated </span><span style="font-family:Arial;font-size:8pt;">February&#160;27, 2020</span><span style="font-family:Arial;font-size:8pt;"> expressed an unqualified opinion on the effectiveness of the Company&#8217;s internal control over financial reporting.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Basis for Opinion</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">These consolidated financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Critical Audit Matters</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The critical audit matters communicated below are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the consolidated financial statements, taken as a whole, and we are not, by communicating the critical audit matters below, providing separate opinions on the critical audit matters or on the accounts or disclosures to which they relate.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Evaluation of certain assumptions impacting the U.S. Medicare, Medicaid, and performance-based contract rebates accrual</span></div><div style="line-height:120%;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As discussed in Note 1G to the consolidated financial statements, the Company records estimated deductions for Medicare, Medicaid, and performance-based contract rebates (collectively, U.S. rebates) as a reduction to gross product revenues. The accrual for U.S. rebates is recorded in the same period that the corresponding revenues are recognized. The length of time between when a sale is made and when the U.S. rebate is paid by the Company can be as long as one year, which increases the need for significant management judgment and knowledge of market conditions and practices in estimating the accrual.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:justify;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We identified the evaluation of the U.S. rebates accrual as a critical audit matter because evaluating the product-specific experience ratio assumption underlying the estimate of the accrual involved especially challenging auditor judgment. The product-specific experience ratio assumption relates to estimating which of the Company&#8217;s revenue transactions will ultimately be subject to a related rebate.</span></div><div style="line-height:120%;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The primary procedures we performed to address this critical audit matter included the following. We tested certain internal controls over the Company&#8217;s U.S. rebate accrual process, including controls related to the development of the product-specific experience ratio assumptions. We recalculated the U.S. rebates accrual for a selection of products, based on a combination of Company internal data, historical actual information, and executed third-party contracts. We performed a sensitivity analysis of the Company&#8217;s accrual by recalculating the accrual using our independent assumptions. We evaluated the Company&#8217;s ability to accurately estimate the accrual for U.S. rebates by comparing historically recorded accruals to the actual amount that was ultimately paid by the Company.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Evaluation of gross unrecognized tax benefits</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2019 the Company has recorded gross unrecognized tax benefits, excluding associated interest, of </span><span style="font-family:Arial;font-size:8pt;">$5.4 billion</span><span style="font-family:Arial;font-size:8pt;">. As discussed in Notes 5D and 1P, the Company&#8217;s tax positions are subject to audit by local taxing authorities in each respective tax jurisdiction, and the resolution of such audits may span multiple years. Since tax law is complex and often subject to varied interpretations and judgments, it is uncertain whether some of the Company&#8217;s tax positions will be sustained upon audit.</span></div><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We identified the evaluation of the Company&#8217;s gross unrecognized tax benefits as a critical audit matter because complex auditor judgment is required in evaluating the Company&#8217;s interpretation of tax law and its estimate of the ultimate resolution of its tax positions.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">60</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The primary procedures we performed to address this critical audit matter included the following. We tested certain internal controls over the Company&#8217;s liability for unrecognized tax position process, including (1) interpretation of tax law, (2) evaluation of which of the Company&#8217;s tax positions may not be sustained upon audit, and (3) estimation and recording of the gross unrecognized tax benefits. We involved tax and valuation professionals with specialized skills and knowledge. We evaluated the Company&#8217;s interpretation of tax laws, including the assessment of transfer pricing practices in accordance with applicable tax laws and regulations. We inspected settlements with applicable taxing authorities, including assessing the expiration of statutes of limitations. We tested the calculation of the liability for uncertain tax positions, including an evaluation of the Company&#8217;s assessment of the technical merits of tax positions and estimates of the amount of tax benefits expected to be sustained.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Evaluation of product and other product-related litigation</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As discussed in Notes 1R and 16 to the consolidated financial statements, the Company is involved in product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others. Certain of these pending product and other product-related legal proceedings could result in losses that could be substantial. The accrued liability and/or disclosure for the pending product and other product-related legal proceedings requires a complex series of judgments by the Company about future events, which involves a number of uncertainties.</span></div><div style="line-height:120%;padding-bottom:10px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We identified the evaluation of the accrued liability and/or related disclosures for these legal proceedings as a critical audit matter because the nature of the estimates and assumptions, including judgments about uncertainties and future events, requires challenging auditor judgment.</span></div><div style="line-height:120%;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The primary procedures we performed to address this critical audit matter included the following. We tested certain internal controls over the Company&#8217;s product liability and other product-related litigation processes, including (1) the evaluation of information from external and internal legal counsel, (2) forward-looking expectations, and (3) new legal proceedings, or other legal proceedings not currently reserved or disclosed. We read letters received directly from the Company&#8217;s external and internal legal counsel that described the Company&#8217;s probable or reasonably possible legal contingency to pending product and other product-related legal proceedings. We inspected the Company&#8217;s minutes from meetings of the Audit Committee, which included the status of key litigation matters. We evaluated the Company&#8217;s ability to estimate its monetary exposure to pending product and other product-related legal proceedings by comparing historically recorded liabilities to actual monetary amounts incurred upon resolution of prior legal matters. We analyzed relevant publicly available information about the Company, its competitors, and the industry.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span><img src="kpmgsignatureq42019.jpg" alt="kpmgsignatureq42019.jpg" style="height:49px;width:141px;"></img></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">KPMG LLP</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have not been able to determine the specific year that KPMG and our predecessor firms began serving as the Company&#8217;s auditor, however, we are aware that KPMG and our predecessor firms have served as the Company&#8217;s auditor since at least 1942.</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">New York, New York</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">February&#160;27, 2020</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">61</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s1E560E4B557A546B9BBC397F0B753B2E"></a></div><div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Report of Independent Registered Public Accounting Firm on</span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Internal Control Over Financial Reporting</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">The Board of Directors and Shareholders of Pfizer Inc.:</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Opinion on Internal Control Over Financial Reporting</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have audited Pfizer Inc. and Subsidiary Companies&#8217; (the Company) internal control over financial reporting as of December&#160;31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, based on criteria established in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Internal Control</span><span style="font-family:Arial;font-size:8pt;">&#8212;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Integrated Framework </span><span style="font-family:Arial;font-size:8pt;">(2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, based on criteria established in Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission. </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated balance sheets of Pfizer Inc. and Subsidiary Companies as of December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, and the related consolidated statements of income, comprehensive income, equity, and cash flows for each of the years in the three-year period ended December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, and the related notes (collectively, the consolidated financial statements), and our report dated </span><span style="font-family:Arial;font-size:8pt;">February&#160;27, 2020</span><span style="font-family:Arial;font-size:8pt;"> expressed an unqualified opinion on those consolidated financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Basis for Opinion</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying </span><span style="font-family:Arial;font-size:8pt;">Management&#8217;s Report on Internal Control Over Financial Reporting</span><span style="font-family:Arial;font-size:8pt;">. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, and testing and evaluating the design and operating effectiveness of internal control based on the assessed risk. Our audit also included performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Definition and Limitations of Internal Control Over Financial Reporting </span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="line-height:120%;padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span><img src="kpmgsignatureq42019.jpg" alt="kpmgsignatureq42019.jpg" style="height:53px;width:150px;"></img></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="1"></td></tr><tr><td style="width:100%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">KPMG LLP</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">New York, New York</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:16px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">February&#160;27, 2020</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">62</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s1A77D3F67ADB5496BC5E687FE989186C"></a></div><div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Consolidated Statements of Income</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.61904761904762%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e1459-wk-Fact-99447C56530B57BB99F3272D91D61246" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1478-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53,647</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1498-wk-Fact-5800B99789A546352282801F7F2D7923" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Costs and expenses:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e1585-wk-Fact-28DD1757DF955D578E13DE8351B692BB" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1604-wk-Fact-0489780C77A658BF8868E1551D1C625D" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1623-wk-Fact-2F12F18AD8251A365397801F7F1D63C2" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,228</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e1651-wk-Fact-AB74A10364F359F29349BB0B21ECB2F3" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1670-wk-Fact-29CC16548E2E546280762B10A285EBB3" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1689-wk-Fact-83E1143E04F5A91F1232801F80AB7507" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e1717-wk-Fact-3482AAEFC33858968E580ACA1EF44907" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1736-wk-Fact-6EED17ECA25F58D092D7F74CB80AA63D" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1755-wk-Fact-B6E23DD26A27DC66F8C3CAFFFD2CBF22" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,683</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e1781-wk-Fact-5ABF4791BE6951B3BD213F08FF302F41" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1800-wk-Fact-60979D16D8DE563EA2F73F6D211A9A3F" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,893</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1819-wk-Fact-27CD0201DE5939C1D6C9801F7F2B2695" name="pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e1845-wk-Fact-61EEF037EA245BC58651F6491A13B057" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">747</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1864-wk-Fact-20A55537F0675518894025A232665AAA" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,044</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1883-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34430544e1909-wk-Fact-0612C9171BB1563BAA0D97F47098AC20" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1929-wk-Fact-C36972272EBF57F09D3E0A0B47D781D3" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1948-wk-Fact-51D5CD0734BBD4CF6AB0CB00E2C1C110" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e1974-wk-Fact-58A10D106477541896C64514721528B2" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e1993-wk-Fact-F590D4C627155C828C90476F227A1511" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2012-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations before provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2103-wk-Fact-FC65E982593353C58EDD19521634B9BF" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2122-wk-Fact-316CD294736155A2BF815F488E7DB6E0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34430544e2141-wk-Fact-C55A09F5044EA944EC43801F7F3390E1" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2168-wk-Fact-0035B9C9DB225A72A990E1262460243C" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2187-wk-Fact-F7E834DB2C365543A0147187D74A1E82" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2206-wk-Fact-7AB6A34649A53C89765A801F808558FA" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2299-wk-Fact-70A89F04606E5C478C49B14416D6CE2D" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2318-wk-Fact-92574249FA1B5792A5D2D0D169042981" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34430544e2337-wk-Fact-3C80ECF87216CAD55440801F7F4B62D4" name="us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gain on disposal of discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2364-wk-Fact-C602001194365B76BEA91037F0F0DB98" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2383-wk-Fact-96EE1FC21874513CAC2C4A3E7FCA2B60" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2402-wk-Fact-C2C7E920844E64417EE0801F7F43A1D0" name="us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2428-wk-Fact-324E930EA3FE51309DAF874C15316ACB" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2447-wk-Fact-08237D5DF91153BBBDE19A688EC551B8" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2466-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2556-wk-Fact-0E9DF21E8B8D568689FB453465570C12" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2575-wk-Fact-BAD8CA6C4B6A5AE88554A9B88D8A8209" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2594-wk-Fact-D83DE49486164AB0AD35801F7F32BB1B" name="us-gaap:NetIncomeLossAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2625-wk-Fact-9F4115E6A91F5D5A8F7DBFD6C8FE97D2" name="us-gaap:NetIncomeLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2644-wk-Fact-07EEAB5D75BE5733BBE5DDB62C46DAC9" name="us-gaap:NetIncomeLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2664-wk-Fact-B84B5B2E9880B8DB72EA801F7F15BA80" name="us-gaap:NetIncomeLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;basic</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;text-indent:-30px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2823-wk-Fact-68C3B0FD2C4751708C56BFF9C8FF5735" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2842-wk-Fact-5947CFACA921556B9FFF58244C1A10F0" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2862-wk-Fact-5A1858B72D840CA48B81801F8088EC92" name="us-gaap:IncomeLossFromContinuingOperationsPerBasicShare" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:0px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2882-wk-Fact-C0A19D1D9DC45DD6801580B6A3ACBEA6" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2901-wk-Fact-2CB4512C4635516E90761E4D85A4869E" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2920-wk-Fact-E3D918CD118292C5AA27801F802986E2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e2951-wk-Fact-A8B9CC29B1BD5DCCB10156807AFD46CF" name="us-gaap:EarningsPerShareBasic" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2970-wk-Fact-2F3CA3A3FAD45C6BBFFA9AF52B012B5D" name="us-gaap:EarningsPerShareBasic" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e2990-wk-Fact-80382989DBE2B2A99A05801F7F3B9C46" name="us-gaap:EarningsPerShareBasic" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Earnings per common share&#8211;&#8211;diluted</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:42px;text-indent:-30px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e3080-wk-Fact-33025D2CE7995F16A707BC65C2D0FAA0" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3099-wk-Fact-9CA9F5D6598257E8B08FB6226CA68B1F" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3119-wk-Fact-C2867733F38A06F7227D801F7F30AEAD" name="us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:0px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e3139-wk-Fact-1607AE44D7025E1EB5295964DC39F488" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3158-wk-Fact-166D37DCD0615EB59DA9AF177DA4F7E9" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3177-wk-Fact-B281E1948A327D1F074D801F7F417F9A" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e3208-wk-Fact-ADE382A1D3945AC3B461E0B1B11CBDE7" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">2.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3227-wk-Fact-098C50B89DAF5EB9A094993C8FEEA183" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">1.87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3247-wk-Fact-388802394B995CDECA90801F7F4A337B" name="us-gaap:EarningsPerShareDiluted" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">3.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average shares&#8211;&#8211;basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e3334-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3353-wk-Fact-A641170D49AD547A8914C2CE48D6E64F" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3372-wk-Fact-09473C310A80FA565C36801F7F16DCBB" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average shares&#8211;&#8211;diluted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34430544e3398-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3417-wk-Fact-33F90922FE92534B8F84E80D9633CDA7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34430544e3436-wk-Fact-769F1280EBF192E593C5801F7F419E21" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Exclusive of amortization of intangible assets, except as disclosed in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1L.</span></div></ix:footnote></td></tr></table><ix:footnote id="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-top:1px;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;padding-top:300px;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements, which are an integral part of these statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">63</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s34F040255A715E299488F069B2AC3F70"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Consolidated Statements of Comprehensive Income</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency translation adjustments, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e1590-wk-Fact-3328F0DAC738681A6D21801F7ECF7D37" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e1609-wk-Fact-00FA4D10D2645A50AEDEE8302484A6D5" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e1630-wk-Fact-1C949239FD4407E55222801F7FD72F26" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e1652-wk-Fact-C13328F655305F8CB43D006E17681322" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e1672-wk-Fact-15E210D3DD0D5FB08B54D80504EBC060" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e1692-wk-Fact-563BB6FEBF5717E60D97CB0A84CDFE98" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e1718-wk-Fact-01A8C48E01D25B3EAFDAC449EB4857D2" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e1737-wk-Fact-860CFBCF363653FC86BC0095D64D864D" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">821</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e1757-wk-Fact-D92D96928692FE5AFF2B801F7F150711" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unrealized holding gains/(losses) on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e1783-wk-Fact-A8ECAB64FC345D158EED4CF5EB8D3C49" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">476</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e1802-wk-Fact-6325E2F134D45571A3E0DD3C60FB9C6F" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e1821-wk-Fact-BAE279F5EB71087D83F2801F7EE05475" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for (gains)/losses included in net income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e1850-wk-Fact-4D8CEC7EA9FB5F60A15FD79906165FE2" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e1870-wk-Fact-4752641D09C957ACBC4D5CB0E30EFE1F" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e1889-wk-Fact-0861F3F4D28BB35D854E801F80ADCAA4" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">520</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e1916-wk-Fact-F2276591896D5AF8B95530B8937AAC4D" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e1936-wk-Fact-A0580F12FEFB5184AF83F23E7628F9E3" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e1955-wk-Fact-B3FD5671955A957CB3C8801F7ECD2BE6" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unrealized holding gains/(losses) on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e1982-wk-Fact-DDD211C8993350B79EF8D3FEBE1A053B" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2002-wk-Fact-EFFB4E372D675AF89AAD0163ED875CE2" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2022-wk-Fact-8C7EA7D7F43807E0390D801F7ECD3AD1" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">818</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for (gains)/losses included in net income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e2051-wk-Fact-93625872A9D656368D7E152DE8C08019" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2070-wk-Fact-7952617F186F5E01B2B1132FE8B404CC" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2089-wk-Fact-CF0794E1A8A3CA0BB480801F7F0C5847" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for unrealized gains included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e2120-wk-Fact-D5F5556E181E5148B38700A64385FDDC" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2139-wk-Fact-0E93D2D6EF205317999004B109639A0A" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2159-wk-Fact-4E0F3852D83E28ABDBED801F7ECDFF6C" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e2185-wk-Fact-09EB80731D7155BD844BFECD417399D3" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2204-wk-Fact-BAF546B82D94528D8306C20351599D86" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">522</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2224-wk-Fact-50686A372E736C0F5647801F82939361" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit plans: actuarial losses, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e2250-wk-Fact-CAA3EF8F2067516F9B2E0F85B4BF5AD0" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2270-wk-Fact-28E378BA49F05856958E09125890B46D" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">649</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2290-wk-Fact-31991F01AC86E4619B23801F800998F2" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e2317-wk-Fact-C51C12B9003E560B915ACD09B3E99840" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2336-wk-Fact-5326AFF91A2251119CB3EA737ED72B03" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2355-wk-Fact-8A1F93452E32511246DC801F7F0CF497" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e2381-wk-Fact-44EF20E31F87512BB82C3578F60D84E2" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2400-wk-Fact-CA434D2888FB588EB4655963352B2A4D" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2419-wk-Fact-752CABA8E508F4880C7C801F81391188" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">117</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e2445-wk-Fact-D72EAE58B45655088BE6DF720737CDA8" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2464-wk-Fact-54104279652F5BA598DF82A20E111838" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2483-wk-Fact-CBF9C7A23687212604C8801F829129F8" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e2510-wk-Fact-D5EB172CCBCC5F4D8D27B6F5728E0EBD" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">289</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2530-wk-Fact-532861FAECEE50D0A6F6D5AEF071E5B9" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2550-wk-Fact-8A35E5331DDD75689E2C801F829E69B4" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit plans: prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e2576-wk-Fact-DE50E7770F245761B8991D27CD7FA8EE" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2596-wk-Fact-C815B28EFCEB57A091D4DD245EBDE146" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2616-wk-Fact-923B7EF4CCA59EE61341801F7F2C1401" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e2643-wk-Fact-B56F71AB068951F5B6B9C531420B33FC" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2663-wk-Fact-4D09902765CD56939721BF43E88C545F" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2683-wk-Fact-7A0B0B97234568FCF5ED801F8263730F" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to curtailments of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e2710-wk-Fact-E6FC35E4FFF354B58F58E4CFFF29DCB8" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2730-wk-Fact-0ABC054ABD705474B81B86310757E0CC" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2750-wk-Fact-FB5AEC684D9BF5EB4428801F8178F643" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e2778-wk-Fact-DD92E4AF9BD15F60838130DCE8A678BE" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2797-wk-Fact-AF85C0A522725220A32AC451BBAD97DA" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2816-wk-Fact-1579B10788C733E8AAC8801F828B55EB" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e2842-wk-Fact-43B675EB3B86596CAC5E7949E794E330" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2862-wk-Fact-4F41970AB5AF5A55B4EA05E37BD7A829" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">207</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2882-wk-Fact-9AFB6DAE6BF5A7027999801F7ED8C9BD" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other comprehensive income/(loss), before tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e2909-wk-Fact-FFE4B8C9C5A45A3BB02F23579673DDAA" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e2929-wk-Fact-30AD1982C6115A29A36BF68B59AEDB47" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2949-wk-Fact-C691D683EBCB98306D23801F7F16756B" name="us-gaap:OtherComprehensiveIncomeLossBeforeTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax provision/(benefit) on other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e2977-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e2996-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e3015-wk-Fact-93DDC1938188F9E00A7E801F808A913C" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other comprehensive income/(loss) before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34428379e3047-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34428379e3067-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e3088-wk-Fact-5F457A9009553F04B717801F7FB266B9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Comprehensive income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e3177-wk-Fact-211494DFE1B65B998EAAA38B4550E8C1" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,926</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e3196-wk-Fact-C1EB256C91145D3BB9F80464D5790C53" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e3216-wk-Fact-C8753C9584514B8878AE801F81306F2E" name="us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,085</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Comprehensive income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e3236-wk-Fact-D8D3C4F5774A56769436D861E4EEF751" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e3255-wk-Fact-E3F086AF3830512484E4717330E2CA08" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e3274-wk-Fact-D358FB74D462C490D295801F7FC14EB5" name="us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Comprehensive income attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34428379e3305-wk-Fact-60CD4D80F7AE528A9A1801629A9AD807" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,908</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e3324-wk-Fact-EDB5A19EC991587EA94D6F34F8FC39F7" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34428379e3344-wk-Fact-AD91E61606B3F9D31977801F7FE885E5" name="us-gaap:ComprehensiveIncomeNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,023</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts in 2019 include a gain of approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34428379e3358-wk-Fact-BD803F6CBE8619C04B2F16E6F1410DC8" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34428379e3362-wk-Fact-7585EA770858DD8F140716EB02CF3463" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">978</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> after-tax) related to foreign currency translation adjustments attributable to our equity method investment in the GSK Consumer Healthcare joint venture (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2C</span><span style="font-family:Arial;font-size:7pt;">), partially offset by the strengthening of the U.S. dollar against the euro and the Australian dollar, and the results of our net investment hedging program. In 2018, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Foreign currency translation adjustments, net</span><span style="font-family:Arial;font-size:7pt;">, primarily reflects the strengthening of the U.S. dollar against the euro, U.K. pound and Chinese renminbi, In 2017, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Foreign currency translation adjustments, net</span><span style="font-family:Arial;font-size:7pt;">, primarily reflects the weakening of the U.S. dollar against the euro, U.K. pound and the Canadian dollar.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-1"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For the year ended December 31, 2019, the foreign currency translation adjustments are primarily reclassified into </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">(Gain) on completion of Consumer Healthcare JV transaction </span><span style="font-family:Arial;font-size:7pt;">in the consolidated statement of income as a result of the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK.</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C.</span><span style="font-family:Arial;font-size:7pt;"> For the year ended December 31, 2017, the foreign currency translation adjustments reclassified into </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:Arial;font-size:7pt;">in the consolidated statement of income primarily result from the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34428379e3409-wk-Fact-CACD50923894EDD99872801F80B0B6C2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto and the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34428379e3414-wk-Fact-C1577C38066176D10EAC801F80EADEC6" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;">-owned equity method investment in Hisun Pfizer. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"><ix:continuation id="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-1"></ix:continuation>(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Reclassified into </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income. For additional information on amounts reclassified into </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales,</span><span style="font-family:Arial;font-size:7pt;"> see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7F.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For additional information, see Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8212;Note 1B</span><span style="font-family:Arial;font-size:7pt;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information. see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5E. </span></div></ix:footnote></td></tr></table><ix:footnote id="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-top:2px;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;padding-top:140px;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements, which are an integral part of these statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">64</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s6FE0DE3BEAD65845B6664F089DE03CA9"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Consolidated Balance Sheets</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS, EXCEPT PREFERRED STOCK ISSUED AND PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1488-wk-Fact-A3B4914B172C5BC59639B98C6FB3F588" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1507-wk-Fact-92028286814C58C496DAD3D9CE00EA8A" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1527-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1546-wk-Fact-E3E97336ACA652838D81F531EE99F43B" name="us-gaap:ShortTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Trade accounts receivable, less allowance for doubtful accounts: 2019&#8212;$527; 2018&#8212;$541</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1571-wk-Fact-3C889F3A20C0530CB57A37DDC3BC5CFD" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,724</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1590-wk-Fact-58A9D592472E54ACB181BBAE9BC91E05" name="us-gaap:AccountsReceivableNetCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1615-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1634-wk-Fact-C16D2F781E815917AC4E583A6245970B" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,508</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1659-wk-Fact-47C637A51CEE5EF080D18BCE1B38E7DA" name="pfe:OtherTaxAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,344</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1678-wk-Fact-7C95FE45B026572C9C6575056E409438" name="pfe:OtherTaxAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1703-wk-Fact-A68C33E581015A07BF02867B616768F9" name="us-gaap:OtherAssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1722-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD" name="us-gaap:OtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1747-wk-Fact-22FC256F29955A5AAC465714927146A3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1766-wk-Fact-41F671B8835D59FE8632B22D5D005E66" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1792-wk-Fact-B2196219F55E53698D0DA829DF1E2B27" name="us-gaap:AssetsCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32,803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1811-wk-Fact-88F8256AB81452CCA864D49A834C7EC7" name="us-gaap:AssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49,926</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1836-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1855-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1880-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC" name="us-gaap:LongTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1899-wk-Fact-38B878301DB957B297D2601592AD511A" name="us-gaap:LongTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment, less accumulated depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1924-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,967</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1943-wk-Fact-7F7E046052F852439B2A0884F029C60C" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Identifiable intangible assets, less accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2012-wk-Fact-6EE57D419E98505BB872CDF37DAACD72" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2031-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2056-wk-Fact-AB13686A614A540891E5DB6A56F3428E" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2075-wk-Fact-E658F74A5A8852C19F682FC523E87C64" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2100-wk-Fact-B8D6B5CC80C55A49A1EE3141CCBD5ACE" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,450</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2119-wk-Fact-4A424945B16E50C896282B201E79955C" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2149-wk-Fact-7613A3BE7B3C52548720187D3E9B29CB" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167,489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2168-wk-Fact-BF946A4349E2545BA4A121AADE5B3A9D" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">159,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Liabilities and Equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Short-term borrowings, including current portion of long-term debt: 2019&#8212;$1,462; 2018&#8212;$4,776</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2284-wk-Fact-D592F35F847457ABB1C2D0D22ED64864" name="us-gaap:DebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2303-wk-Fact-A51B51A828275272A7C573C440BF63F4" name="us-gaap:DebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2323-wk-Fact-DCCF1CBB1A0259B4B4B8B56A33FFAE88" name="us-gaap:AccountsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2342-wk-Fact-C0D03D29D7BD5A5094E94025EADCF408" name="us-gaap:AccountsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,674</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Dividends payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2367-wk-Fact-0AA2D540FDE353DF84FFCE6640225D60" name="us-gaap:DividendsPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,104</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2386-wk-Fact-52056BFD52B55AD7B0B223B4DB2C6129" name="us-gaap:DividendsPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,047</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2411-wk-Fact-31D197A179335FA6BF6A7BC5D0D64EA2" name="us-gaap:TaxesPayableCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">980</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2430-wk-Fact-DFC5C4232A535405BE8E98D62FCA6018" name="us-gaap:TaxesPayableCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,265</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrued compensation and related items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2455-wk-Fact-729C012AD2435DBEB3A6986C8E3F0F60" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2474-wk-Fact-77801D3C57905C8C93FABB42EA4BACE1" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,397</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2499-wk-Fact-DC09811A83505392B3800EEDE627AFCD" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,083</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2518-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liabilities held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2543-wk-Fact-6C6D242FEDF05A7CADA10BE9ECFC67DD" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2562-wk-Fact-D213F8E63BD05CEBBE34196677D85307" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2587-wk-Fact-4B1590ADE87B568D8CC8C86F0B307CF0" name="us-gaap:LiabilitiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2606-wk-Fact-0CE5B6DDA0365CB096E454B209F9983E" name="us-gaap:LiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,858</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2677-wk-Fact-92CFAEDA1D275CCFA954DF7DFEDFAB50" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2696-wk-Fact-05108BE54FE052919D68B32B6466B9DF" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2721-wk-Fact-EAC2A8EBA0265A18879BA13F53119C66" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2740-wk-Fact-D2AF16FAEA7B5A13BDB49C7D1827AC2B" name="us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2766-wk-Fact-DB90E025117E5EE7A0F72EE7BD31627B" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2785-wk-Fact-E3FD9DF1F7065B2BAFE310C3379623D1" name="us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2810-wk-Fact-0DCDEA0AFFF95ED982FB39EAA2FBC94A" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2829-wk-Fact-96A8E9E0E31B5853A1D087253B1B6301" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2854-wk-Fact-13191F129DFB57EB8DE4693D33017900" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2873-wk-Fact-897222CA063B5438BA0EAAE6C107C7B6" name="us-gaap:LiabilityForUncertainTaxPositionsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2898-wk-Fact-75F7E84A031750E0A49F77B3AEF45671" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2917-wk-Fact-6DF270940FC65894A5CA91BBF63EB321" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e2942-wk-Fact-54259B5ADCDB523D95E357958F32EAA5" name="us-gaap:Liabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">104,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e2961-wk-Fact-1C6A9F20611E5E39AE756F72080F3817" name="us-gaap:Liabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Commitments and Contingencies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3032-wk-Fact-789D85DCBD5CAAFAC780801F7E9C6FBB" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2019Q4" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3050-wk-Fact-DCF7E4E72A2BD2587C67801F7EA7706F" name="us-gaap:CommitmentsAndContingencies" contextRef="FI2018Q4" unitRef="usd" xsi:nil="true" scale="0" format="ixt:nocontent"></ix:nonFraction></span><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2019&#8212;431; 2018&#8212;478</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e3120-wk-Fact-65AD28ADEA625EEBBB3613A384127FAA" name="us-gaap:PreferredStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3139-wk-Fact-29D31CFA7A6550EBAA66F5ACE1A10761" name="us-gaap:PreferredStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Common stock, $0.05 par value; 12,000 shares authorized; issued: 2019&#8212;9,369; 2018&#8212;9,332</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e3164-wk-Fact-F60C602F8EF1574C98B984D666B6FDE3" name="us-gaap:CommonStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3183-wk-Fact-C48222126B9050F9BFAC0CB6B70D58A1" name="us-gaap:CommonStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Additional paid-in capital</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e3208-wk-Fact-1B23844B5232538ABD87C7C1814A1CF1" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3227-wk-Fact-7B3EE432FBB3579996CA5926DC51D999" name="us-gaap:AdditionalPaidInCapital" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Treasury stock, shares at cost: 2019&#8212;3,835; 2018&#8212;3,615</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34423000e3253-wk-Fact-562D6F8F14805BDBA1EEB5EC76E5A656" name="us-gaap:TreasuryStockValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34423000e3273-wk-Fact-7747152390E65C85B0029AEB713C8F55" name="us-gaap:TreasuryStockValue" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">101,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Retained earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e3299-wk-Fact-856AC81ACCEC5011ACDEA26123CED5EE" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3318-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accumulated other comprehensive loss</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34423000e3343-wk-Fact-66EE9ACDD29C54A495F8D48FB257E0D9" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34423000e3363-wk-Fact-1C1A48D8D8FB59F484CD69BF32113D2E" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Pfizer Inc. shareholders&#8217; equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e3389-wk-Fact-CF4BCD6471CF5A67AD13EFC0CB141620" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3408-wk-Fact-DA95F5D557CD51E498E32E8F9370AC31" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e3433-wk-Fact-DF4C7D7A1BC15C8FB52ACDC98F4B191B" name="us-gaap:MinorityInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3452-wk-Fact-3AE7E9A85D765783A134E8B901625365" name="us-gaap:MinorityInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e3477-wk-Fact-48600923F2B454478E9D06C9836F179C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3496-wk-Fact-A856A5C9461154769813BC75D3DBEF25" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total liabilities and equity</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34423000e3526-wk-Fact-1967B402D8BE56648C1FED785998B3C6" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167,489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-bottom:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34423000e3545-wk-Fact-86C1962CA09E5E038A8356A346B1940A" name="us-gaap:LiabilitiesAndStockholdersEquity" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">159,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><ix:footnote id="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;padding-top:60px;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements, which are an integral part of these statements.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">65</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s5CDC00621FB15E6399D4962F5A9D45FB"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Consolidated Statements of Equity</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;padding-bottom:13px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:6px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.44444444444444%;border-collapse:collapse;text-align:left;"><tr><td colspan="46"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:2%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td></tr><tr><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="36" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">PFIZER INC. SHAREHOLDERS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#160;</span></div></td></tr><tr><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Preferred Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Common Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Treasury Stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">(MILLIONS,&#160;EXCEPT PREFERRED SHARES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Stated Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Par Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Add&#8217;l</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Paid-In</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Capital</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Shares</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Retained Earnings</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Accum.</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Other</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Comp. Loss</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Share -</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">holders&#8217;</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Equity</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Non-controlling Interests</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Total</span></div><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Equity</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Balance, January&#160;1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2069-wk-Fact-270C12BCCD80680CE432CB2DE5F8DC92" name="us-gaap:SharesIssued" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2088-wk-Fact-59C2713351C3718503CECB2DE492EDAD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2102-wk-Fact-86FCF4A9AC35C93C9512CB2DE640F043" name="us-gaap:SharesIssued" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2122-wk-Fact-81C7586111FF1F4FF011CB2DE6212D3A" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2141-wk-Fact-5244EF9D70AB4BF20E72CB2DE505A72E" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82,685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e2155-wk-Fact-CEBB6ABAEC10A6B4CDAFCB2DE5909958" name="us-gaap:SharesIssued" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e2176-wk-Fact-AEFB6F4B2F0FF7051095CB2DE528EDFE" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">84,364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2196-wk-Fact-E54EE12FB1C1E89110A9CB2DE5B4B413" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e2215-wk-Fact-1526F7310FFB6F8E8B4BCB2DE56B079F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2236-wk-Fact-4BF8867A9673AACA0E31CB2DE4C160C4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2255-wk-Fact-DFD2BE3FC86FDFD923FDCB2DE4E53FC7" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2275-wk-Fact-51AF8A24F6320B3DD4D9CB2DE5470BE9" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59,840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2422-wk-Fact-43F9860B2E4FABD39FD0801F824B7F7B" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2462-wk-Fact-14F1C2A6A168BD044F0E801F802AA8F2" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2481-wk-Fact-FF2092BE1BF7CB316625801F7E1E3368" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2673-wk-Fact-218AEF14B977A83E4A06801F7EFF265B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2693-wk-Fact-538AD0D1FEAC9B9942E5801F80805FA6" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2712-wk-Fact-F98321594AC5D5415DB0801F825F0776" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e2731-wk-Fact-5F457A9009553F04B717801F7FB266B9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Cash dividends declared:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Common stock </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3119-wk-Fact-681CAA08E088E04EA79E801F7ECB79CF" name="us-gaap:DividendsCommonStockCash" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3160-wk-Fact-84A9A3C57D9468DD47C4801F80615D38" name="us-gaap:DividendsCommonStockCash" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3200-wk-Fact-9EC5142FF1350AFCC36A801F7FDF5605" name="us-gaap:DividendsCommonStockCash" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3354-wk-Fact-EA60695FBD38F2408E8C801F7EC802D2" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3395-wk-Fact-64527C0F87BA22A2495F801F7FFC6A1A" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3435-wk-Fact-8EAE4EB5674D9D1095E0801F7FEA5B11" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3649-wk-Fact-C481ECF3EFBB0708C01D801F7EFDD582" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3669-wk-Fact-9C15C23B033F2F07DF6B801F823D2E2E" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Share-based payment transactions</span><span style="font-family:Arial;font-size:6pt;"><sup style="vertical-align:top;line-height:120%;font-size:4pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e3733-wk-Fact-CC66745CDAB046F9CA50801F7EC633DE" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e3748-wk-Fact-DF31EFE36B91F582343D801F80809133" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e3767-wk-Fact-1561A8609FA608E10A98801F80706999" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,597</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e3786-wk-Fact-99C23B4E5EC579EA4F26801F7DF197AB" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e3801-wk-Fact-1A7E3821C23A4DED79AC801F7E1FD112" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e3862-wk-Fact-FA5370553D0E753807A4801F800C2D97" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e3901-wk-Fact-760E7E634C39F63FC233801F7E0F6B98" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4019-wk-Fact-F3866D134A97F71188EB801F7E1851F4" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4035-wk-Fact-B5FF23DD831E759A71FF801F7DE6500E" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4096-wk-Fact-7918FE9F0C5FFB8CDA07801F8037553C" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4136-wk-Fact-72DE426063852BE9262D801F7E146126" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Preferred stock conversions and redemptions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4163-wk-Fact-7CA1E8DB0EEA61585658801F8257D851" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4178-wk-Fact-89A0361AA02CC1515879801F8245AD29" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4234-wk-Fact-0F427D37984EF6A14C01801F80833398" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4269-wk-Fact-E826CDDD3780AEBA80B0CB2DE5D9E519" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4329-wk-Fact-EE63D6A60A1762912BF4801F8259FD6E" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4369-wk-Fact-33AFDD4662101709F692801F7E18C5FF" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4513-wk-Fact-0584C0E58CA0A6B96247801F7EC7A79A" name="us-gaap:StockholdersEquityOther" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4551-wk-Fact-97A49B0ECEA9517FFBB7801F7E06BC9B" name="us-gaap:StockholdersEquityOther" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4589-wk-Fact-46AB28E4CC157C45741A801F823EEFDA" name="us-gaap:StockholdersEquityOther" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Balance, December&#160;31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4615-wk-Fact-192DA984185DD0ED8BF0801F803D17EF" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4629-wk-Fact-6586B6AD1EA296008717801F7EBC80FD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4648-wk-Fact-CB5E098B3EA566270808801F7E0EF978" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4663-wk-Fact-89C1C2FF8BAE35AB2220801F7FC7C2B0" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4682-wk-Fact-2BBF90C0E0ACDECC1704801F80243029" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4701-wk-Fact-35E0049DFF2E76A140E3801F8089CAA6" name="us-gaap:SharesIssued" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4717-wk-Fact-D132FA43C9BCB6877BE6801F802DED15" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">89,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4737-wk-Fact-1A7FFDC660ABEFAC6697801F7ECAA2B8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85,291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e4756-wk-Fact-8F27495BD68561A9487C801F7DC77927" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4777-wk-Fact-27E943B33C7E2180DED5801F807FD2B1" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4796-wk-Fact-1381E356C11529474B50801F7FE67AD8" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4815-wk-Fact-53A4C5E0F7DCF0473DB8801F8250BB73" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2017Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71,656</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e4968-wk-Fact-87DF5DD60C52EBFDCA12801F7F002312" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e5008-wk-Fact-EC11057FA838BD75D525801F824F6767" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e5027-wk-Fact-2CA67D7D788BA11D095F801F7FD36422" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5219-wk-Fact-5F191F9F323C685F3993801F7DCDF586" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5240-wk-Fact-B7BD42B10C099A6A26D1801F7FD5AF39" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5260-wk-Fact-AAADFB48294C3599DB10801F82605B2C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5280-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,975</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Cash dividends declared:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Common stock </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5669-wk-Fact-324D6E1724EEC6BE2FE9801F7DF40048" name="us-gaap:DividendsCommonStockCash" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5710-wk-Fact-ED209CAAD0144B632B7B801F7DF7158B" name="us-gaap:DividendsCommonStockCash" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5748-wk-Fact-12B293ED1A777402AC1F801F7ECA154F" name="us-gaap:DividendsCommonStockCash" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5902-wk-Fact-ADB247F63E15672E1A7D801F7DC78C20" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5943-wk-Fact-EFC8C046FEC7E568BE67801F803C6F71" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e5981-wk-Fact-B6F40B75323EE6EF4FC4801F7DF547A2" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6195-wk-Fact-9A4592A1FACA84D5869A801F8024E489" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6215-wk-Fact-14FD69433DA24328385A801F7DF3375A" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Share-based payment transactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e6277-wk-Fact-24A404127FF2306D6A2E801F7FC76C30" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e6292-wk-Fact-EE6CC8909F1494988B7A801F7DF1C8F7" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e6311-wk-Fact-CC0C0ECD3677090B8283801F80884BB4" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6330-wk-Fact-B657D1ACB72B0C617B94801F7ECE5765" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e6346-wk-Fact-95C3D7179E1C7455799D801F7EC9AC19" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e6406-wk-Fact-BC35357C49C864E19515801F7EFFF359" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e6445-wk-Fact-46A676894226F74F6BFC801F7EFC1911" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6561-wk-Fact-30D9418081FBA848CBA2801F7ECCAB71" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6577-wk-Fact-3699E726612D593C213A801F7E0FB736" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6638-wk-Fact-C12C1FBA8458EC3FD4D1801F7E041A29" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6678-wk-Fact-3AD0784E9548664647E8801F7EFA79D4" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Preferred stock conversions and redemptions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6705-wk-Fact-7D359D4DCFEB1E002351801F7DEFB4FE" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6720-wk-Fact-89DB22A158608FA629D2801F8240115D" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6774-wk-Fact-CAB1BA2F9C800F5BD664801F825C70B5" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e6809-wk-Fact-BB8EECA4B442C1A654CD801F7DF0331C" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6869-wk-Fact-62C88B2989C62E56687F801F7DE4D234" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e6909-wk-Fact-6F45B7B7D9041F4DACD1801F7DC65341" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Other</span><span style="font-family:Arial;font-size:6pt;"><sup style="vertical-align:top;line-height:120%;font-size:4pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7059-wk-Fact-13FB97E7671458A9E0F4801F7EBCE117" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7097-wk-Fact-694C315E46A521BE92D5801F7DD0578A" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7135-wk-Fact-5F2D4ADDF8FF1844A040801F7E00C1DC" name="us-gaap:StockholdersEquityOther" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">Balance, December&#160;31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7161-wk-Fact-72F12325846A255A2934801F823A73B8" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7175-wk-Fact-1CA134AD576458FCA79E9C753A5EF8FD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7194-wk-Fact-C0D2C058A53A516D89F67516151CA125" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7209-wk-Fact-07FAC1C1243E5138A0C37BBBC348368F" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">467</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7228-wk-Fact-075B080714B45D30944D97942F14A858" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86,253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e7247-wk-Fact-D7F3F8AF036E5D0FB8EF97E397FAB8AF" name="us-gaap:SharesIssued" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,615</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e7263-wk-Fact-CCCD894D3B3A5080B54BA18BB185ECA4" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">101,610</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7283-wk-Fact-5000F0EEE05D5658998A06FB2C356390" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span>(<ix:nonFraction id="d34458032e7302-wk-Fact-479F4E8A21C856B284E67E3F6C120C46" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7323-wk-Fact-FD92DBC7FD8183249D6D801F80213CFC" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7342-wk-Fact-C3D92DAFDA945B9CB8FF4887D799EB18" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><span><ix:nonFraction id="d34458032e7361-wk-Fact-A856A5C9461154769813BC75D3DBEF25" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e7514-wk-Fact-C787510F91375F8DA60A77279DBC12D7" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e7554-wk-Fact-6B459265E6775C47B37741B8BA18E170" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e7573-wk-Fact-CA6EF8716A5E5BD1809B42697B1223C5" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Other&#160;comprehensive income/(loss), net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e7765-wk-Fact-B5FF4C264E8259AB8C76122637225C36" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e7786-wk-Fact-91841B5580A65F1AB688FCF8F5511CF9" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e7806-wk-Fact-28116B03F1F1501FA19804A781E93B54" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e7826-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">376</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Cash dividends declared:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Common stock </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8215-wk-Fact-B8848B5AC5765E01A8796908F66409AA" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8256-wk-Fact-89FA221AF605553CA7321BB43DD73142" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8296-wk-Fact-0D6DA45C2A7C59239CB62D356266BA2F" name="us-gaap:DividendsCommonStockCash" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,174</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Preferred stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8450-wk-Fact-1618790FEEDB5D8FA14CCFA4F0B219DF" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8491-wk-Fact-E04CC84099F25E25851523F603002A2A" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8531-wk-Fact-3A992D3D837957AFBC4539641549FE54" name="us-gaap:DividendsPreferredStockCash" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8745-wk-Fact-FFA1CCE628C152E085CCD1B102488E00" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8765-wk-Fact-B337B62ABBFB5C5696C49995587C6B7B" name="us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Share-based payment transactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e8827-wk-Fact-5AE29E30628550D4AAC86546A2DDB7C3" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e8842-wk-Fact-9B1DCEF966A955A2B00217967C88ACDA" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e8861-wk-Fact-DD18335422DB5858902DCD3895050F71" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8880-wk-Fact-9EED0554CF1857D8B1887EDCD838B377" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e8896-wk-Fact-C5A4FB3948D259AA97E130C3BE069EA0" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e8957-wk-Fact-7DFD68914530594697567F87F6C1044E" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">894</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e8996-wk-Fact-5971AF67CC945F6EA0252DF12812F82F" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">894</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9114-wk-Fact-F3755FEC2162588F811E0BE706D54E9C" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9130-wk-Fact-798874FBBD7A57AD8D423B83A189AC62" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9191-wk-Fact-AB82307C2179145E356A801F824B4798" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9231-wk-Fact-31D3680708335B049E798A2ECB5508B4" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Preferred stock conversions and redemptions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9258-wk-Fact-B0C3BCD9194159029B0449658B7BCFBA" name="pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9273-wk-Fact-9672E748D5A35A1AB1475BEE8450A06D" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9329-wk-Fact-1975D34B81EE58A99F75AD822E7EA8D7" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9424-wk-Fact-F7BF280E6470537B8D74D0E1C2349E3E" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9464-wk-Fact-871389EB45915ACC83623B1FF4BA7915" name="pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Other</span><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:4pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9562-wk-Fact-455D7F50A78999F57E0BE7AEB28EE379" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9617-wk-Fact-D5FAE833F4155DD697072C1983D12DD3" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9657-wk-Fact-364B4EF7858D52F1B60FF23BA7D7CA9F" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9677-wk-Fact-8B4254960B2E50548FD24AC21D991E6A" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9697-wk-Fact-40E0EB9593AE56E6ABE3328268CD2D11" name="us-gaap:StockholdersEquityOther" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">Balance, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9724-wk-Fact-4DE63B25DF8F54C98BE8801F7DD138D7" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="shares" decimals="0" scale="0" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9743-wk-Fact-C3DE40879A16565EBD6E29F02FEBF113" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9757-wk-Fact-8D841CA3F88A9E41A873801F823E6F2C" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">9,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9777-wk-Fact-4638B594C90A5D0FB3648867A34E71BB" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9796-wk-Fact-6B8B35F0C5A25612B8D5FB3898261F5D" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87,428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9810-wk-Fact-CA576382E824210D03C9801F7EFD8AAC" name="us-gaap:SharesIssued" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">3,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9831-wk-Fact-0396A14A962557AD9B92CF1A5FBBC4F5" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">110,801</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9851-wk-Fact-35D3A5D66469542E865E5AA0C2D06B43" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97,670</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458032e9870-wk-Fact-14994130FABC5D73BECDDC06FF0B8749" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9891-wk-Fact-DF536431A96ABD94CF42801F825CE145" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9910-wk-Fact-80FEC9DEE7D7156F2215801F8243459B" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;font-weight:bold;"><span><ix:nonFraction id="d34458032e9930-wk-Fact-48600923F2B454478E9D06C9836F179C" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">2017 treasury shares include the effect of the modification for a commitment to pay </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34458032e9953-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">15.2</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily represents the cumulative effect of the adoption of new accounting standards in the first quarter of 2018 for revenues, financial assets and liabilities, income tax accounting, and the reclassification of certain tax effects from </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Accumulated other comprehensive income</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018</span><span style="font-family:Arial;font-size:7pt;"> in our 2018 Financial Report.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The increase to </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:7pt;"> in 2019 includes the cumulative effect of the adoption of a new accounting standard for leases in the first quarter of 2019. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B.</span><span style="font-family:Arial;font-size:7pt;"> The decrease in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Equity attributable to noncontrolling interests </span><span style="font-family:Arial;font-size:7pt;">resulted from the deconsolidation of our Consumer Healthcare business in connection with the formation of the GSK Consumer Healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C.</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"> </sup></span><span style="font-family:Arial;font-size:7pt;">The decrease in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Additional paid in capital</span><span style="font-family:Arial;font-size:7pt;"> relates to our buyout of the remaining </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34458032e10027-wk-Fact-8948518703BA8CF15EC216EE4CBB53B8" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_OncologyVaccinesStartUpMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">50</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;"> of noncontrolling interests in an oncology vaccines start up, which has historically been consolidated by us.</span></div></ix:footnote></td></tr></table><ix:footnote id="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-top:2px;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;padding-top:164px;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements, which are an integral part of these statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">66</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s91A92AB78D185166B17C4EBD27868423"></a></div><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;text-decoration:underline;">Operating Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net income before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D" name="us-gaap:ProfitLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F" name="us-gaap:ProfitLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096" name="us-gaap:ProfitLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Depreciation and amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e1718-wk-Fact-F7E8D2F6BA545C88B2145BBF4BB71213" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,010</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e1737-wk-Fact-1879B130A48A521A91B25AA7A433481D" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e1756-wk-Fact-E70CA54923CC1FAD4F80801F7E7CC351" name="pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Asset write-offs and impairments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e1782-wk-Fact-8812B04713F051B0AF0A1F76A2EBAA85" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e1801-wk-Fact-59B0AF76AAAA5B66B8EF1D2F0CE5B1EC" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e1820-wk-Fact-3608CBE3F82FCEC11A98801F7EB42466" name="pfe:AssetWriteOffsAndAssetImpairmentCharges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">TCJA impact</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">323</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10,660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e1917-wk-Fact-EB399C3D7F4B5217B1ECA17E1450C7CB" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e1937-wk-Fact-9D26812D16985C8A83C043FBACDEB01A" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e1956-wk-Fact-19AEA7C81E205D2B0C4DCB55FB59380E" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Deferred taxes from continuing operations</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e1984-wk-Fact-6DBE94D819C45C32A44ABAD8E234B1BA" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2003-wk-Fact-393C1336661B5502A717C267B3C8D41C" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2023-wk-Fact-7E730D2AED1D0795DF3D801F82A5E242" name="us-gaap:DeferredIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,410</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e2051-wk-Fact-49C7F7BFD94F58259E8F91521C863A5D" name="us-gaap:ShareBasedCompensation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2070-wk-Fact-416C8D02D1AC53CF8E7B9B0BE22D3ECD" name="us-gaap:ShareBasedCompensation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2089-wk-Fact-EC38E965C828B3438D45801F82AD8435" name="us-gaap:ShareBasedCompensation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Benefit plan contributions in excess of expense/income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e2115-wk-Fact-142A53BD92AA56EB8F30C720D04947B1" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2135-wk-Fact-13109FFF8177575B8F1774DB9B952255" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,095</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2155-wk-Fact-17A18791930ECAD2DCEB801F82A24FA8" name="pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other adjustments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e2182-wk-Fact-599EFC3C5A9B585D8082B26EDB29D9AA" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,086</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2202-wk-Fact-D7F3CECA708D58BE9F756B50300BDB3F" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2222-wk-Fact-B1E7467675494F8418B3801F82B05100" name="us-gaap:OtherNoncashIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other changes in assets and liabilities, net of acquisitions and divestitures:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Trade accounts receivable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e2315-wk-Fact-E8B4FB59DE0025523471801F82937FF6" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">742</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2335-wk-Fact-2AA90167164D2E1A59FA801F7E8DBF9F" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2355-wk-Fact-78EA4E1EB168C708F8A0801F7E99078A" name="us-gaap:IncreaseDecreaseInAccountsReceivable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e2381-wk-Fact-5978204D04A9412FC943801F82AB9CA2" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,050</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2401-wk-Fact-3428A9878F8D11970A11801F7E90E64E" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">717</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2421-wk-Fact-F8A9B839E0BCBA875A7D801F82AD2263" name="us-gaap:IncreaseDecreaseInInventories" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">357</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e2448-wk-Fact-1A17F756201A26636A56801F825B0538" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2467-wk-Fact-74710073FCDBB8BA38A9AB460A554FBE" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2487-wk-Fact-8641DEB0F388E97194C5801F8260F41E" name="us-gaap:IncreaseDecreaseInOtherOperatingAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e2513-wk-Fact-28FF4AB5B22B53EA235C801F82B2C028" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2533-wk-Fact-879A192382A7330D4759801F7E97C8E7" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2552-wk-Fact-F8064D62E55D3D14B6F5801F82AA72CC" name="us-gaap:IncreaseDecreaseInAccountsPayableTrade" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e2578-wk-Fact-70AE538A79495076EEEF801F82A94AED" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">267</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2597-wk-Fact-05A1EA23D34141CA08B0801F825F2A0B" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2616-wk-Fact-1D9D8C11D13199ACE522801F82C58824" name="us-gaap:IncreaseDecreaseInOtherOperatingLiabilities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other tax accounts, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e2643-wk-Fact-3A431FAAB1251C8B2F11801F7EAD8859" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,737</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2663-wk-Fact-13DF08A1DA2702456A68801F7E99FA8D" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2683-wk-Fact-A7D8A59FD536FC537EA7801F82CDAF6E" name="us-gaap:IncreaseDecreaseInAccruedTaxesPayable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,446</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net cash provided by operating activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e2709-wk-Fact-3FAC1D7D150D5D3693952644AB014570" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2728-wk-Fact-44E9A00560B253F9B13272B4DADC5EE7" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,827</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e2747-wk-Fact-1878ED88AD3662670B3D801F82BFC1A3" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,802</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;text-decoration:underline;">Investing Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchases of property, plant and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e2906-wk-Fact-276AE48F003C5B94964313479CA47CC4" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2926-wk-Fact-68A35B6201B05F6791E934C35C4FF3BB" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2946-wk-Fact-BC27D7DE57C7FCDFEA06801F82A12BD1" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,956</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchases of short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e2973-wk-Fact-BA711E164C3C5AA1A6F841BD16FF39C7" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,835</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e2993-wk-Fact-F7A1A47C403158F4A0050A07FD1FD932" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3013-wk-Fact-8413E641C55A4976D254801F7EBA5C58" name="us-gaap:PaymentsToAcquireShortTermInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Proceeds from redemptions/sales of short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e3040-wk-Fact-BD795F9219995817AC05CE7BBCBF719E" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3059-wk-Fact-DC14423F4FD126343D5EAB460A5E402A" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3078-wk-Fact-D6D3D533E39ABD216739AB460AAB7F32" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e3104-wk-Fact-E83DC31A66C95716944B69D6571C0712" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,925</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3123-wk-Fact-4E6373F9AE145393977B4D50CD0C3C97" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,917</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3143-wk-Fact-0B0BC391D4C7298B505D801F82CD3D11" name="us-gaap:PaymentsForProceedsFromShortTermInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchases of long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e3169-wk-Fact-43647EACB2365019AF739809E6A7AA33" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3189-wk-Fact-07104F174ED656CF8AABB4441FC28486" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3209-wk-Fact-ED884752BC3FCC09AA86801F82ADF8F8" name="us-gaap:PaymentsToAcquireMarketableSecurities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,537</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Proceeds from redemptions/sales of long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e3236-wk-Fact-48F3227EB91F519693B62AAB048CF3C2" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3255-wk-Fact-3A0EED0F100854319344F954D1578C77" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,244</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3274-wk-Fact-82DF9C203377249F2601AB460A6EF1A6" name="us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,579</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Acquisitions of businesses, net of cash acquired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e3300-wk-Fact-AE4BE372D7E0566CA33FCE7A63C55830" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,861</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3320-wk-Fact-A866155102FA518DAD8A3AC3849A29ED" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3339-wk-Fact-E926E550228AFBDF79A3801F7EAA2096" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Acquisitions of intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e3366-wk-Fact-10B388DAE9985C6E9C8A0D8BD38AD150" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">418</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3386-wk-Fact-C6871A6C06945BFABCFCA1C5346E9560" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3406-wk-Fact-E8C1F0E054CC0BFAC98F801F7EA87952" name="us-gaap:PaymentsToAcquireIntangibleAssets" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other investing activities, net</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b), (d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E" name="us-gaap:PaymentsForProceedsFromOtherInvestingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">671</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net cash provided by/(used in) investing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e3500-wk-Fact-987B313113ED573B8A810513702726B3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3520-wk-Fact-A08B5E2989AB58B0A8139571535F4EFB" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3539-wk-Fact-BC04211B3B4E671AA2DC801F82A46721" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,740</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;text-decoration:underline;">Financing Activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Proceeds from short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e3698-wk-Fact-8322EE49CD6D5BD6A6C9E81023F930D3" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,455</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3717-wk-Fact-855EC1B85F5A5E84B3ACFB91DAA41FBE" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3736-wk-Fact-DF223CDEB60EF38BA68C801F829307E6" name="us-gaap:ProceedsFromShortTermDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Principal payments on short-term borrowings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e3762-wk-Fact-51E697B313F65177AA951CD8E64EC1C9" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3782-wk-Fact-80E620F0079F9C476673AB460A2BDC83" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3802-wk-Fact-5D06811EF4C34003FE7FAB460A240C38" name="us-gaap:RepaymentsOfShortTermDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e3829-wk-Fact-A591E3AF789D5180A58CDB8F61EA51D0" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3848-wk-Fact-BAD831174C94566A924C53EC67145618" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,617</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3868-wk-Fact-643BD36B0A7BD2A450F4801F8291FACD" name="us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,422</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Proceeds from issuance of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e3894-wk-Fact-3706D36BE0715C4B909C295C63B57B4F" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3913-wk-Fact-60E259DD84E55069AE8582467CCBEEF4" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,974</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e3932-wk-Fact-82F8E32880CAD288D376801F7EB6D6B3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Principal payments on long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e3958-wk-Fact-7A6C38FEB7545F758C160BD056416478" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,806</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3978-wk-Fact-89458B2935BE5CA5AF20EE141CB4DDAE" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e3998-wk-Fact-536D379D583EEC0E6BB0801F7E8674D3" name="us-gaap:RepaymentsOfLongTermDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchases of common stock</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e4025-wk-Fact-606A9D26C4D35A40A035883CAA24CCE7" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4045-wk-Fact-09761C58BD65590B9D0A94898AC11853" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4065-wk-Fact-333989DFC77B15A1F172801F7E787CBF" name="us-gaap:PaymentsForRepurchaseOfCommonStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Cash dividends paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e4092-wk-Fact-BD8A72C249F655DE8F2BC9B4F95D1DCA" name="us-gaap:PaymentsOfOrdinaryDividends" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4111-wk-Fact-D017797EF627548D8B995B4200D51DEC" name="us-gaap:PaymentsOfOrdinaryDividends" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,978</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4130-wk-Fact-638270EA30AE2FE9D14C801F7E7BF6D8" name="us-gaap:PaymentsOfOrdinaryDividends" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Proceeds from exercise of stock options</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e4157-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e4176-wk-Fact-CF6EA013BF1855E39D139D5A4C827484" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e4195-wk-Fact-43172D93073829A17FB6801F82AF4ECB" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other financing activities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e4222-wk-Fact-C99D0BA3F6095B8AB635F01DBE0D4EF8" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">736</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4242-wk-Fact-C8B9E3934BFD630207B2AB460A1A7731" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">588</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4262-wk-Fact-6556B2C27E285E515E05801F82C1264D" name="us-gaap:ProceedsFromPaymentsForOtherFinancingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">611</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net cash used in financing activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e4289-wk-Fact-105EFED9824651F6ABA05E9CA04F453B" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8,485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4309-wk-Fact-9967D5B336225ACF8C7C4F042D7A1102" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20,441</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4329-wk-Fact-1374505693265BF17B2B801F82AB7A82" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-24px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e4356-wk-Fact-0CDEC0D247EB505292D3E60E677BC871" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4376-wk-Fact-197F4485B7325617ACD30B3E17928D84" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e4396-wk-Fact-6675DE4C808280B705BC801F825EB10F" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e4422-wk-Fact-E9440844908157FB84B59804D5572F92" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4441-wk-Fact-E71BAB60F8F54CE72E1EAB460A620A61" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">205</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e4461-wk-Fact-721F3FC462E1384F6A25801F7EB6DE98" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,235</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e4488-wk-Fact-DBDD38161F5354477BEEAB460A4A0822" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e4507-wk-Fact-753BABE650466031F517AB460A3BD22C" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e4526-wk-Fact-8A5BA32EB90D3260C033801F82C4798C" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,666</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e4557-wk-Fact-F9953003974753B0A6C247B19A717620" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,350</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e4576-wk-Fact-DBDD38161F5354477BEEAB460A4A0822" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e4596-wk-Fact-753BABE650466031F517AB460A3BD22C" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" contextRef="FI2017Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,431</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:10px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">- Continued -</span></div></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;height:13px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">67</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Consolidated Statements of Cash Flows</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;text-decoration:underline;">Supplemental Cash Flow Information</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Non-cash transactions:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">32% equity-method investment in GSK Consumer Healthcare JV in exchange for contributing Pfizer&#8217;s Consumer Healthcare business</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e5115-wk-Fact-D632D615CB115AE398552F0296C267F2" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,711</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5134-wk-Fact-C6E28D0783BF5F14B7C1F693DE2205FC" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5154-wk-Fact-CF81983A611C3D14907CCB572FBC8D5D" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Equity investment in Cerevel Therapeutics, Inc. in exchange for Pfizer&#8217;s portfolio of clinical and preclinical neuroscience assets</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e5176-wk-Fact-276A8A35EE68509F999B815A3BCBFE8E" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5195-wk-Fact-14ADBD55BE745ADEBD77EA9D5312ED22" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5214-wk-Fact-40C3E909042539E5B10F801F7E98C05E" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Equity investment in Allogene received in exchange for Pfizer's allogeneic CAR T developmental program assets</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e5242-wk-Fact-F99E6C3DC2CC5F62AF63CD1ED043A574" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5261-wk-Fact-B7FAC3FC55D55C4A8390CDA9B27086EE" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5280-wk-Fact-5763263A0462B65542D3801F82B1A33F" name="pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Exchange of $1.1 billion net book value 6.50% U.K. pound-denominated bonds maturing in 2038 for $1.8 billion of new 2.735% U.K. pound-denominated bonds maturing in 2043, resulting in a debt extinguishment loss of $747 million</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e5308-wk-Fact-46C48E9C21AF899B9CBE801F824C920A" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5327-wk-Fact-1EA1B7699985D7A7899C801F7E93B603" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5346-wk-Fact-EF43F96DEFFEE9BA1C18801F82C1C357" name="us-gaap:DebtConversionConvertedInstrumentAmount1" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,848</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Receipt of ICU Medical common stock</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e5374-wk-Fact-539977E9F571B801F8F2801F82CC3FC2" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5393-wk-Fact-9C12B5D1FDF6DC56A5B8801F7E7A2727" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5412-wk-Fact-9281B6AE49D7C2B2BA97801F825215AE" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">428</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Promissory note from ICU Medical</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e5440-wk-Fact-AF2E68BBA8025433B3103D89BFF2ABC1" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5459-wk-Fact-6CFCA119539F5C0D846D537B1FB079D6" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5478-wk-Fact-F803761CFD33D77A1C43801F82624A72" name="pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Cash paid (received) during the period for:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e5575-wk-Fact-34AD8E413C695FBD8469975721FFB0F6" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5594-wk-Fact-64DE649A1DC85272824F592AAE2FEBD3" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,655</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5614-wk-Fact-B655A10CD6EE090891E7801F82B1C3E5" name="us-gaap:IncomeTaxesPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34458036e5634-wk-Fact-0688D8F87F0B5FFEBC9B4EB51F7A9A52" name="us-gaap:InterestPaidNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,587</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5653-wk-Fact-6C6813303FAB516E9EF5ED555B6EFC07" name="us-gaap:InterestPaidNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34458036e5672-wk-Fact-9A5FE66D958474E62B0B801F7E97F314" name="us-gaap:InterestPaidNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Interest rate hedges</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34458036e5698-wk-Fact-570F688A036C517B8DC6519B9EEC35DC" name="pfe:InterestPaidInterestRateHedges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e5718-wk-Fact-13A50261D17557B8A175FB539D8C549E" name="pfe:InterestPaidInterestRateHedges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34458036e5738-wk-Fact-0951D465F2EAA589DB57801F7EA951E3" name="pfe:InterestPaidInterestRateHedges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As a result of the enactment of the TCJA in December 2017, Pfizer&#8217;s </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;"> (i) for the year ended December 31, 2017 was favorably impacted by approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5773-wk-Fact-4AB2319F04C6B9C93D3ACB57A40C195C" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">10.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">, primarily reflecting the remeasurement of U.S. deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries, (ii) for the year ended December 31, 2018 was favorably impacted by approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5777-wk-Fact-07D7749619A14DC9F0CF801F7F3C1F9A" name="pfe:TaxCutsAndJobsActIncomeTaxBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, primarily related to certain tax initiatives associated with the TCJA, as well as favorable adjustments to the provisional estimates of the legislation and (iii) for the year ended December 31, 2019 was favorably impacted by approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">323</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, primarily as a result of additional guidance issued by the U.S. Department of Treasury. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 5</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">A.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5803-wk-Fact-A057140022E852CCB9A6C67AE43A9EB2" name="pfe:DeconsolidationGainLossAmountNetOfCashConveyed" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</span><span style="font-family:Arial;font-size:7pt;"> reflects the receipt of a </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34458036e5811-wk-Fact-57A1AFBB73FE59E08A57E18D20754A66" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;"> equity-method investment in the new company initially valued at </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5815-wk-Fact-864ED6D8892F5C49A719105F87AE47B5" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">15.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> in exchange for net assets contributed of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5819-wk-Fact-F5CA5E5BAD9355008E552A9D050A0743" name="pfe:DeconsolidationNetAssetsContributed" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">7.6</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> and is presented in operating activities net of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5824-wk-Fact-40C813D724515B76A8F32C0048A56ABC" name="pfe:DeconsolidationGainLossAmountCashConveyed" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> cash conveyed that is reflected in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other investing activities, net</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2C.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes tax expense of approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5853-wk-Fact-44A0BFD4912753E3ABE6A533D3956A57" name="pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C </span><span style="font-family:Arial;font-size:7pt;">and</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 5</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">A.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For additional information, see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2B.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5891-wk-Fact-191A3FC341F9978F83CF801F81E890B0" name="pfe:GainLossOnExchangeOfDebt" contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_U.K.PoundDenominatedDebtMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">747</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> is included in the net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34458036e5895-wk-Fact-046237D900496E5BF3D0801F81E93368" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">846</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> upon the exchange and early retirement of the U.K. pound-denominated debt. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 7D.</span></div></ix:footnote></td></tr></table><ix:footnote id="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;padding-top:2px;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</span></div></ix:footnote><div style="line-height:120%;padding-top:400px;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See Notes to Consolidated Financial Statements, which are an integral part of these statements.</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">68</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s547B08979AB35FFB9532229BF9E55D19"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><a id="sD1A97F3E496A5A4BBB7A289B3DF01B5C"></a></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 1</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-0-wk-Fact-279D5DA1C29A0403BF5C801F7FEB22AD" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Basis of Presentation and Significant Accounting Policies</span></ix:nonNumeric></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-1" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A.</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> Basis of Presentation</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See the Glossary of Defined Terms at the beginning of this </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report for terms used throughout the consolidated financial statements and related notes in this </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="TextSelection-AE5BFF9C0E5225E61570801F82FAB796-0-wk-Fact-737A33A41F26B0EF78C8801F811185F3" escape="true">The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). </ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ConsolidationPolicyTextBlock" id="TextSelection-DF28F64A56F53AD329E6801F82F9C5D2-0-wk-Fact-3756AF0F79AAE11D26C5801F809AC715" escape="true">The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. </ix:nonNumeric>Beginning on January 1, 2018, only taxes paid on intercompany inventory sales transactions are deferred until recognized upon the sale of the inventory to a third party, reflecting the adoption of a new accounting standard in the first quarter of 2018. Prior to the adoption of this new accounting standard in the first quarter of 2018, taxes paid on intercompany sales transactions were deferred until recognized upon sale of the asset to a third party.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1369-wk-Fact-D17055AF0AB4DC9AC143801F8131E959" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2018Q4YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1373-wk-Fact-E001667F01F95E298014FB8B5A7B8850" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q4YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> business segments&#8211;&#8211;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. We have revised prior-period segment information to reflect the reorganization. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17</span><span style="font-family:Arial;font-size:8pt;">. In addition, certain amounts within </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span><span style="font-family:Arial;font-size:8pt;"> in the December 31, 2018 consolidated balance sheet have been reclassified to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Equity-method investments</span><span style="font-family:Arial;font-size:8pt;"> to conform to the current presentation. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2C.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the first quarter of 2019, as of January 1, 2019, we adopted </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1407-wk-Fact-EF0C3233F7CA5E6898CC271647FD9CD6" name="pfe:NumberOfAccountingStandardsAdopted" contextRef="I2019Q1Jan01" unitRef="Accounting_standard" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> new accounting standards. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1B</span><span style="font-family:Arial;font-size:8pt;"> for further information.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our recent significant business development activities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">License Agreement with Akcea Therapeutics, Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">In October 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. The transaction closed in November 2019 and we made an upfront payment of</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1433-wk-Fact-820E4481EA1BBFE4406DCDC046424C7F" name="pfe:PaymentForLicensingArrangement" contextRef="FD2019Q4QTD_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">to Akcea and Ionis, which was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:8pt;">in our fiscal fourth quarter of 2019. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Formation of a New Consumer Healthcare Joint Venture</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">In accordance with our domestic and international reporting periods, our financial results, and our Consumer Healthcare segment&#8217;s operating results, for 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of Array BioPharma Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On </span><span style="font-family:Arial;font-size:8pt;">July&#160;30, 2019</span><span style="font-family:Arial;font-size:8pt;">, we acquired Array for </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1476-wk-Fact-87A73243BF595DD18C64026B1A594F00" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">48</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share in cash. The total fair value of the consideration transferred for Array was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1480-wk-Fact-661D03E21572543CB5AFEBAECACF8E2B" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1484-wk-Fact-AA9C766FC51A56248B8278DB552969BB" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">10.9</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, net of cash acquired). </span><span style="font-family:Arial;font-size:8pt;">Our financial statements for 2019 reflect the assets, liabilities, operating results and cash flows of Array, commencing from the acquisition date</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Agreement to Combine Upjohn with Mylan N.V.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun off or split off to Pfizer&#8217;s shareholders and, immediately thereafter, combined with Mylan.</span><span style="font-family:Arial;font-size:8pt;"> Pfizer shareholders would own </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1506-wk-Fact-77A45F205D1B51C0BEAB73201E304C18" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="FI2020Q2_srt_OwnershipAxis_pfe_UpjohnAndMylanMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">57</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of the combined new company, and former Mylan shareholders would own </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1510-wk-Fact-853CDBE591765273B550231BC64EAA86" name="us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners" contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_MylanMember_srt_OwnershipAxis_pfe_UpjohnAndMylanMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">43</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">.  Closing of the transaction is subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of Therachon Holding AG</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On July 1, 2019, we acquired all the remaining shares of Therachon for </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1523-wk-Fact-D4613DCD361C587C8CEC0BB4595ED1E7" name="pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment" contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront, plus potential milestone payments of up to </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1527-wk-Fact-F4590EEA4BAF5B65B61201FB5AB77321" name="pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">contingent on the achievement of key milestones in the development and commercialization of the lead asset. The total fair value of the consideration transferred for Therachon was approximately</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1535-wk-Fact-E471A84C0B3850C393C12C737086419C" name="pfe:AssetAcquisitionConsiderationTransferred" contextRef="D2019Q3Jan01-Jul02_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">322</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">. </span><span style="font-family:Arial;font-size:8pt;">Our financial statements for 2019 reflect the assets, liabilities, operating results and cash flows of Therachon, commencing from the acquisition date and, in accordance with our international reporting period, reflect five months of Therachon operations and cash flows.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical for up to approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1551-wk-Fact-1322BD020F41F6AA79BF801F7F42DBE6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">900</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, composed of cash and contingent cash consideration, ICU Medical common stock (all of which we sold during 2018) and seller financing. HIS includes IV pumps, solutions and devices. The operating results of HIS are included in our consolidated statement of income through February 2, 2017 and, therefore, our financial results for 2017 reflect one month of HIS domestic operations and two months of HIS international operations. Our financial results for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> do not reflect any contribution from HIS global operations.</span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">69</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-2" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-3"><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:8pt;text-indent:-12px;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of AstraZeneca&#8217;s Small Molecule Anti-Infectives Business</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S. for approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1572-wk-Fact-AE69E3A5F2E6833E0DD1801F7F120629" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, composed of cash and contingent consideration. </span><span style="font-family:Arial;font-size:8pt;">Our financial statements reflect the assets, liabilities, operating results and cash flows of this business, commencing from the acquisition date and, in accordance with our international reporting period, for 2017 reflect approximately 11 months of the small molecule anti-infectives business operations and cash flows acquired from AstraZeneca.</span><span style="font-family:Arial;font-size:8pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B.</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="TextSelection-26D19012E03173D569AB801F8302F7ED-0-wk-Fact-D4D50358F1EC83E9AF72801F7F300322" continuedAt="TextSelection-26D19012E03173D569AB801F8302F7ED-1" escape="true"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Adoption of New Accounting Standards in 2019</span></ix:nonNumeric></div><ix:continuation id="TextSelection-26D19012E03173D569AB801F8302F7ED-1"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On January 1, 2019, we adopted </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1612-wk-Fact-EF0C3233F7CA5E6898CC271647FD9CD6" name="pfe:NumberOfAccountingStandardsAdopted" contextRef="I2019Q1Jan01" unitRef="Accounting_standard" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> new accounting standards.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Leases</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1621-wk-Fact-7D219E92EFD05A6EA6E0DA4E2FA5E1BA" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> and current and noncurrent operating lease liabilities of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1625-wk-Fact-4E411801636956FF8E2A3D3670608235" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"> by </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1633-wk-Fact-8219CF42872D5F67860A4641102A46CD" name="us-gaap:CumulativeEffectOnRetainedEarningsBeforeTax1" contextRef="D2019Q1Jan01-Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> on a pre-tax basis (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e1637-wk-Fact-E63442DE4A725840B73A5D18F5D4D595" name="us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1" contextRef="D2019Q1Jan01-Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="TextSelection-EBAA92A02A869580AA71801F82F924CB-0-wk-Fact-B66E6EAE1AD3F4007BBA801F7F289AFE" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adopting the standard related to leases impacted our prior period consolidated balance sheet as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As Previously Reported Balance at</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect of Change</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher/(Lower)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance at</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1823-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD" name="us-gaap:OtherAssetsCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,461</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34519344e1842-wk-Fact-B0F1DF2EE48E52F0A94EDC5C8D8C5EB2" name="us-gaap:OtherAssetsCurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e1863-wk-Fact-D1DF428DA372513ABF9E3876EB4AB068" name="us-gaap:OtherAssetsCurrent" contextRef="I2019Q1Jan01" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,460</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1883-wk-Fact-E658F74A5A8852C19F682FC523E87C64" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,924</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34519344e1902-wk-Fact-F4AD0B3FF2885637B1AD0ACDBAFDB9B0" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e1922-wk-Fact-DEAB1874587E5D5BB8EFCBEF3E0BF9FC" name="pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" contextRef="I2019Q1Jan01" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e1948-wk-Fact-4A424945B16E50C896282B201E79955C" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e1967-wk-Fact-4E0465F4DDB65B9BB78223A77CFE6EE2" name="us-gaap:OtherAssetsNoncurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e1986-wk-Fact-4EFDDF01BAAE55DF88C3947BA6EB0E02" name="us-gaap:OtherAssetsNoncurrent" contextRef="I2019Q1Jan01" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e2012-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31" name="us-gaap:OtherLiabilitiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2031-wk-Fact-5200EE176D305D8AA059957DCF18B445" name="us-gaap:OtherLiabilitiesCurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2050-wk-Fact-8377E7FB3B4B5E8F8147DEC7AF66B25D" name="us-gaap:OtherLiabilitiesCurrent" contextRef="I2019Q1Jan01" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e2076-wk-Fact-6DF270940FC65894A5CA91BBF63EB321" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2095-wk-Fact-4D0778A972C45D2A9B5ACE0D983EDC3D" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2114-wk-Fact-DB9E42CC42D95101905E3312C16BF1B0" name="us-gaap:OtherLiabilitiesNoncurrent" contextRef="I2019Q1Jan01" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,910</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e2140-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2159-wk-Fact-3EDA657D41A55B7D929ACD659463C508" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2178-wk-Fact-C08349F2EE27559983B1A81217A728C6" name="us-gaap:RetainedEarningsAccumulatedDeficit" contextRef="I2019Q1Jan01" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adoption of the standard related to leases did not have a material impact on our consolidated statements of income or consolidated statements of cash flows in</span><span style="font-family:Arial;font-size:8pt;text-align:center;"> 2019</span><span style="font-family:Arial;font-size:8pt;">. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1T</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Amortization Period for Certain Callable Debt Securities Held at a Premium</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Accounting for Share-Based Payments to Nonemployees</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div></ix:continuation><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:UseOfEstimates" id="TextSelection-2CC1CBFF9C364F35586C801F82FF42BD-0-wk-Fact-ACFAD16F72DE559FC03C801F81050652" continuedAt="TextSelection-2CC1CBFF9C364F35586C801F82FF42BD-1" escape="true">Estimates and Assumptions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-2CC1CBFF9C364F35586C801F82FF42BD-1" continuedAt="TextSelection-2CC1CBFF9C364F35586C801F82FF42BD-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&amp;D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income.</span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">70</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-3" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-4"><ix:continuation id="TextSelection-2CC1CBFF9C364F35586C801F82FF42BD-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For information on estimates and assumptions in connection with the TCJA, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Tax Matters: Taxes on Income from Continuing Operations.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:BusinessCombinationsPolicy" id="TextSelection-AEFF5DF203FBB50D92E9801F830237EB-0-wk-Fact-2F28DC64542A7F10C645801F7FC156F1" continuedAt="TextSelection-AEFF5DF203FBB50D92E9801F830237EB-1" escape="true">Acquisitions</ix:nonNumeric></span></div><ix:continuation id="TextSelection-AEFF5DF203FBB50D92E9801F830237EB-1" continuedAt="TextSelection-AEFF5DF203FBB50D92E9801F830237EB-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16D</span><span style="font-family:Arial;font-size:8pt;">. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-AEFF5DF203FBB50D92E9801F830237EB-2">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</ix:continuation> For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="TextSelection-46B2DA26826D57DD1BED801F8300C51B-0-wk-Fact-00279C1CF2B0246859DD801F812713CE" continuedAt="TextSelection-46B2DA26826D57DD1BED801F8300C51B-1" escape="true">Fair Value</ix:nonNumeric></span></div><ix:continuation id="TextSelection-46B2DA26826D57DD1BED801F8300C51B-1" continuedAt="TextSelection-46B2DA26826D57DD1BED801F8300C51B-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income approach, which is based on the present value of a future stream of net cash flows. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our fair value methodologies depend on the following types of inputs:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-46B2DA26826D57DD1BED801F8300C51B-2">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</ix:continuation> For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">F. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" id="TextSelection-118A7D836807EFE5E5FC801F82FC0212-0-wk-Fact-C36556CB1BF7E1E78909801F7F4BD286" continuedAt="TextSelection-118A7D836807EFE5E5FC801F82FC0212-1" escape="true">Foreign Currency Translation</ix:nonNumeric></span></div><ix:continuation id="TextSelection-118A7D836807EFE5E5FC801F82FC0212-1"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">, and we translate non-monetary items at historical rates.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">71</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-4" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-5"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">G</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="TextSelection-31400FAA85C073F417AD801F8301991B-0-wk-Fact-DA61EB0AF0042B352FFB801F802AD447" continuedAt="TextSelection-31400FAA85C073F417AD801F8301991B-1" escape="true"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenues and Trade Accounts Receivable</span></ix:nonNumeric></div><ix:continuation id="TextSelection-31400FAA85C073F417AD801F8301991B-1" continuedAt="TextSelection-31400FAA85C073F417AD801F8301991B-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We recorded direct product sales and/or alliance revenues of more than </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e2461-wk-Fact-BBCDC3C9165F5704C6C1801F7F32A97B" name="pfe:ConcentrationRiskAmount" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TopEightProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> for each of </span><span style="font-family:Arial;font-size:8pt;">eight</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, for each of </span><span style="font-family:Arial;font-size:8pt;">ten</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and for each of </span><span style="font-family:Arial;font-size:8pt;">nine</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. In the aggregate, these direct products sales and/or alliance product revenues represent </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e2490-wk-Fact-F85FDF185EF539090E35801F7F3B68D3" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TopEightProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e2498-wk-Fact-0B4BF375084A125303CA801F7FB014D7" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TopTenProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">51</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e2507-wk-Fact-CD8C03F1D7453B6FE934801F7FFBE54C" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TopNineProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">46</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;color:#ffffff;"> </span><span style="font-family:Arial;font-size:8pt;">of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17C </span><span style="font-family:Arial;font-size:8pt;">for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business, which was combined with GSK&#8217;s Consumer Healthcare business into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name on July 31, 2019, included OTC brands with a focus on dietary supplements, pain management, gastrointestinal and respiratory and personal care. We sell biopharmaceutical products after patent expiration, and under patent, and, to a much lesser extent, through July 31, 2019, we sold consumer healthcare products worldwide to developed and emerging market countries.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenue Recognition</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Customers</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Customers for our consumer healthcare business, which were part of the business that was combined with GSK&#8217;s Consumer Healthcare business into a new consumer healthcare joint venture on July 31, 2019, included retailers and, to a lesser extent, wholesalers and distributors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Our Sales Contracts</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales</span><span style="font-family:Arial;font-size:8pt;color:#ff0000;"> </span><span style="font-family:Arial;font-size:8pt;">are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of exclusivity, product recalls or a changing competitive environment. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Deductions from Revenues</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Specifically:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managers and legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period&#8217;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#8220;coverage gap,&#8221; also known as the &#8220;doughnut hole,&#8221; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#8217;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.</span></div></td></tr></table></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">72</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-5" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-6"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-31400FAA85C073F417AD801F8301991B-2" continuedAt="TextSelection-42291D1A964B69B993EB801F83012366-0"></ix:continuation>Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e2610-wk-Fact-C66567CD14E95F92AFFC0E08F8683BC1" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e2620-wk-Fact-C5B82205C7F5510AAB55F9B3C6A1D874" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2018Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="TextSelection-412809AC9762DE565764801F82FB9290-0-wk-Fact-1912928CAD6A19BFE86F801F805FBEE4" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:71%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information about the balance sheet classification of these accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reserve against </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2804-wk-Fact-8402D23656C955A385898AA9E62ECD6F" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e2823-wk-Fact-AE11515EF3ED597F8A84C997EBC1D5F1" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrued rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2937-wk-Fact-3468E93B75C15267A94589A1BC13D5C9" name="pfe:AccruedRebates" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,285</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e2956-wk-Fact-276A53E02F1354F58F2FD3DB009E15BE" name="pfe:AccruedRebates" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e2981-wk-Fact-163F9FFCF1335A1996EA5783150DB776" name="pfe:OtherAccruals" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e3000-wk-Fact-67DADA72665A53ED8493A3A1CEDCB3CE" name="pfe:OtherAccruals" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e3071-wk-Fact-8A436208B4215FD58BBA2A089EC34291" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">565</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e3090-wk-Fact-72B28649003C52259374DD039402E60C" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total accrued rebates and other accruals</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e3120-wk-Fact-A3FC32B0BB005D76B9DEF4997F522592" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,689</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e3139-wk-Fact-FBFA31360AAD5FA3BF289C2EA275A636" name="pfe:RebatesAndDiscountsAccrual" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><ix:continuation id="TextSelection-42291D1A964B69B993EB801F83012366-0" continuedAt="TextSelection-A49463E38461F7D2C3F3801F83016362-0"><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">.</span></div></ix:continuation><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ReceivablesPolicyTextBlock" id="TextSelection-678FAF2F794D349E85FF801F82FD3981-0-wk-Fact-82A8DEBB2A29B34926F2801F7F4DF6E1" escape="true"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Trade Accounts Receivable</span><span style="font-family:Arial;font-size:8pt;">&#8212;Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">H. <ix:continuation id="TextSelection-A49463E38461F7D2C3F3801F83016362-0" continuedAt="TextSelection-A49463E38461F7D2C3F3801F83016362-1">Collaborative Arrangements</ix:continuation></span></div><ix:continuation id="TextSelection-A49463E38461F7D2C3F3801F83016362-1"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues,</span><span style="font-family:Arial;font-size:8pt;"> when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable period. The related expenses for selling and marketing these products are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses.</span><span style="font-family:Arial;font-size:8pt;"> In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;">. Royalty payments received from collaboration partners are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reimbursements to or from our collaboration partners for development costs are recorded net in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets&#8212;Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;"> over the development period for the collaboration products, when our performance obligations include providing R&amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;"> immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.</span></div></ix:continuation><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">I. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryPolicyTextBlock" id="TextSelection-3B93404216BFEF1732C7801F82FB11A5-0-wk-Fact-3D4608BC7ECCAC649140801F8099C769" continuedAt="TextSelection-3B93404216BFEF1732C7801F82FB11A5-1" escape="true">Cost of Sales and Inventories</ix:nonNumeric></span></div><ix:continuation id="TextSelection-3B93404216BFEF1732C7801F82FB11A5-1"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.</span></div></ix:continuation><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">J. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock" id="TextSelection-6B3EE57EBD1E8B931B55801F83029006-0-wk-Fact-86FFA8D514F02E2DB623801F7F2FC1CE" continuedAt="TextSelection-6B3EE57EBD1E8B931B55801F83029006-1" escape="true">Selling, Informational and Administrative Expenses</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6B3EE57EBD1E8B931B55801F83029006-1" continuedAt="TextSelection-6B3EE57EBD1E8B931B55801F83029006-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-6B3EE57EBD1E8B931B55801F83029006-2">Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.</ix:continuation> Advertising expenses totaled approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e3307-wk-Fact-744D1DB29E3F183A7ECA801F812FC803" name="us-gaap:AdvertisingExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.6</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e3315-wk-Fact-01D9995CCBE49C7109F9801F8027E29F" name="us-gaap:AdvertisingExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e3323-wk-Fact-0327569D3B2AE41DA377801F7F3CFC98" name="us-gaap:AdvertisingExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs. </span></div><div style="line-height:120%;padding-top:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">K. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="TextSelection-61EBAEF1CDEC87697540801F8300F291-0-wk-Fact-0EB1CE205D8FAD93BA52801F802932F7" continuedAt="TextSelection-61EBAEF1CDEC87697540801F8300F291-1" escape="true">Research and Development Expenses</ix:nonNumeric></span></div><ix:continuation id="TextSelection-61EBAEF1CDEC87697540801F8300F291-1"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">R&amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:8pt;"> and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">73</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-6" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-7"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">L. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Long-lived assets include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="TextSelection-AF5E92C24ADD2F082EC2801F83021985-0-wk-Fact-7D4471CA5742D2F44F36801F7F15740E" escape="true"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Property, plant and equipment, less accumulated depreciation</span><span style="font-family:Arial;font-size:8pt;">&#8212;These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.</span></div></ix:nonNumeric></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-23DF02F084CAE676CC88801F82FAF2E6-0" continuedAt="TextSelection-23DF02F084CAE676CC88801F82FAF2E6-1"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-23DF02F084CAE676CC88801F82FAF2E6-1" continuedAt="TextSelection-23DF02F084CAE676CC88801F82FAF2E6-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:8pt;">&#8212;These acquired assets are recorded at fair value. Intangible assets with finite lives</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined.</span></div></ix:continuation></td></tr></table><ix:continuation id="TextSelection-23DF02F084CAE676CC88801F82FAF2E6-2"><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;">&#8212;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:8pt;"> as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses,</span><span style="font-family:Arial;font-size:8pt;"> as appropriate.</span></div></ix:continuation><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentImpairment" id="TextSelection-D02927152D57FEAE4A89801F83001914-0-wk-Fact-8F15A110E2E2C6609E55801F8049E1A7" escape="true"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div></ix:nonNumeric><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="TextSelection-295BE658210B6EABCB29801F82FAC2DD-0-wk-Fact-17FEC3AA2A6816D304BD801F80890C06" continuedAt="TextSelection-295BE658210B6EABCB29801F82FAC2DD-1" escape="true"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Specifically:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For indefinite-lived intangible assets, such as Brands and IPR&amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.</span></div></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-295BE658210B6EABCB29801F82FAC2DD-1" continuedAt="TextSelection-295BE658210B6EABCB29801F82FAC2DD-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-295BE658210B6EABCB29801F82FAC2DD-2" continuedAt="TextSelection-23DF02F084CAE676CC88801F82FAF2E6-0"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.</span></div></ix:continuation></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">M. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" id="TextSelection-398CA238E0C1691AAF8C801F8301E8E1-0-wk-Fact-5B6E8434952A8A2EF8CD801F7FB385EC" continuedAt="TextSelection-398CA238E0C1691AAF8C801F8301E8E1-1" escape="true">Restructuring Charges and Certain Acquisition-Related Costs</ix:nonNumeric></span></div><ix:continuation id="TextSelection-398CA238E0C1691AAF8C801F8301E8E1-1" continuedAt="TextSelection-398CA238E0C1691AAF8C801F8301E8E1-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:8pt;"> are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-398CA238E0C1691AAF8C801F8301E8E1-2">Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. </ix:continuation>For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">N. Cash Equivalents and Statement of Cash Flows</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="TextSelection-3E2DC8C373CD8F4401C5801F8300AEA3-0-wk-Fact-6D79ECC490DD2580B06D801F7F1B0B95" escape="true"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term investments</span><span style="font-family:Arial;font-size:8pt;">.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DerivativesReportingOfDerivativeActivity" id="TextSelection-17ECBA1B31B86AF0582A801F82F9FCD5-0-wk-Fact-37AEAB810E8BA3AFA8A1801F8060E3FF" escape="true"><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.</span></div></ix:nonNumeric><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">O. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InvestmentPolicyTextBlock" id="TextSelection-6649E9B4FFE282BCBC15801F8302F923-0-wk-Fact-B09123B438D6667F41A0801F80470BB5" continuedAt="TextSelection-6649E9B4FFE282BCBC15801F8302F923-1" escape="true">Investments and Derivative Financial Instruments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-6649E9B4FFE282BCBC15801F8302F923-1" continuedAt="TextSelection-6649E9B4FFE282BCBC15801F8302F923-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our investments are comprised of the following: public equity securities with readily determinable fair values, available-for-sale debt securities, held-to-maturity debt securities (when we have both the positive intent and ability to hold the investment to maturity), private equity securities </span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">74</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-7" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-8"><ix:continuation id="TextSelection-6649E9B4FFE282BCBC15801F8302F923-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">without readily determinable fair values and equity-method investments. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Public equity securities with readily determinable fair values are carried at fair value, with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities are carried at fair value, with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss) </span><span style="font-family:Arial;font-size:8pt;">until realized.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities are carried at amortized cost.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#8217;s income and expenses in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;">. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Realized gains or losses on sales of investments are determined by using the specific identification cost method.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.</span></div></ix:continuation><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DerivativesPolicyTextBlock" id="TextSelection-8CE12F84BDA7436996D7801F82FFE3B4-0-wk-Fact-D5DA0AF32329F55E54F6801F807BA2F5" escape="true"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative financial instruments are carried at fair value in various balance sheet categories (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7A</span><span style="font-family:Arial;font-size:8pt;">), with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Net income</span><span style="font-family:Arial;font-size:8pt;"> or, for derivative financial instruments in certain qualifying hedging relationships, in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss) </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7F</span><span style="font-family:Arial;font-size:8pt;">). </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A single estimate of fair value and impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">P. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxPolicyTextBlock" id="TextSelection-77172E47F9FF78C04BD1801F830066FF-0-wk-Fact-28FD4D961CF125D368E1801F7F1ED4FA" continuedAt="TextSelection-77172E47F9FF78C04BD1801F830066FF-1" escape="true">Tax Assets and Liabilities and Income Tax Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-77172E47F9FF78C04BD1801F830066FF-1" continuedAt="TextSelection-77172E47F9FF78C04BD1801F830066FF-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Tax Assets and Liabilities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current tax assets primarily includes (i) tax effects associated with intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party, as well as (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws, including the impact of the TCJA enacted in December 2017. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet. Amounts recorded for valuation allowances can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other non-current tax assets </span><span style="font-family:Arial;font-size:8pt;">primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:8pt;"> in our consolidated balance sheet as of December 31, 2019 includes liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability on the deemed repatriated accumulated post-1986 foreign earnings recorded in connection with the TCJA for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5D</span><span style="font-family:Arial;font-size:8pt;"> for uncertain tax positions and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;"> for the repatriation tax liability.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Income Tax Contingencies</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#8220;more likely than not&#8221;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and local and foreign income tax filings, statute of limitations expirations, changes and clarification in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the </span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">75</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-8" continuedAt="TextSelection-8F1609EDD8E991CF1022801F82FF407A-9"><ix:continuation id="TextSelection-77172E47F9FF78C04BD1801F830066FF-2" continuedAt="TextSelection-77172E47F9FF78C04BD1801F830066FF-3"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> and are classified on our consolidated balance sheet with the related tax liability.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-77172E47F9FF78C04BD1801F830066FF-3">Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. </ix:continuation>For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Q. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PensionAndOtherPostretirementPlansPolicy" id="TextSelection-0017DA01FC2F0718B450801F8301824C-0-wk-Fact-3B0FF820F4F887E41EF1801F800C84F3" continuedAt="TextSelection-0017DA01FC2F0718B450801F8301824C-1" escape="true">Pension and Postretirement Benefit Plans</ix:nonNumeric></span></div><ix:continuation id="TextSelection-0017DA01FC2F0718B450801F8301824C-1" continuedAt="TextSelection-0017DA01FC2F0718B450801F8301824C-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-0017DA01FC2F0718B450801F8301824C-2">Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</ix:continuation> For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">R. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="TextSelection-EBFF4AA6E70C2B18AD01801F82FF5586-0-wk-Fact-D379C09B7F692F87AFD8801F8021B0E3" continuedAt="TextSelection-EBFF4AA6E70C2B18AD01801F82FF5586-1" escape="true">Legal and Environmental Contingencies</ix:nonNumeric></span></div><ix:continuation id="TextSelection-EBFF4AA6E70C2B18AD01801F82FF5586-1" continuedAt="TextSelection-EBFF4AA6E70C2B18AD01801F82FF5586-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-EBFF4AA6E70C2B18AD01801F82FF5586-2">Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</ix:continuation> For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">S. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="TextSelection-DCE60D5A78F2CCB333F7801F82FC332A-0-wk-Fact-868690B64604F59F72CB801F800303F3" continuedAt="TextSelection-DCE60D5A78F2CCB333F7801F82FC332A-1" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-DCE60D5A78F2CCB333F7801F82FC332A-1" continuedAt="TextSelection-DCE60D5A78F2CCB333F7801F82FC332A-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:continuation><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-DCE60D5A78F2CCB333F7801F82FC332A-2">Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</ix:continuation> For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">T. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeLeasesPolicyTextBlock" id="TextSelection-032647AC333E2273918BCDA467C2A1A0-0-wk-Fact-6BE4C2427D8EA8B28867CDA4ED371538" continuedAt="TextSelection-032647AC333E2273918BCDA467C2A1A0-1" escape="true">Leases</ix:nonNumeric></span></div><ix:continuation id="TextSelection-032647AC333E2273918BCDA467C2A1A0-1"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On January&#160;1, 2019, we adopted a new accounting standard for leases. For further information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1B</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34519344e3955-wk-Fact-02F2C3D3C7D05BF68C223C1E9808C491" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:duryear">1</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34519344e3959-wk-Fact-3DF3199445B252908034E40D3085935A" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">30</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> years, some of which include options to terminate or extend leases for up to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34519344e3963-wk-Fact-F1552967F9435D9D96ED1CA07DE28384" name="pfe:LesseeOperatingLeaseOptionToExtendTerm" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember" format="ixt-sec:duryear">5</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34519344e3967-wk-Fact-C3765EA1D4B354B1B1C0C07B639C33A8" name="pfe:LesseeOperatingLeaseOptionToExtendTerm" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember" format="ixt-sec:duryear">10</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e3971-wk-Fact-4A75EB86316D58CE867E4A4BEED4F2E7" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> for the year ended </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.</span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">76</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-9"><ix:nonNumeric contextRef="FD2019Q4YTD" name="pfe:AssetsAndLiabilitiesLesseeTableTextBlock" id="TextSelection-EF204A16865E7FE4BB3CCDA79F2399BD-0-wk-Fact-71941A4FF67E8B5FA06DCDA7F6B73516" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:54%;"></td><td style="width:1%;"></td><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For operating leases, the ROU assets and liabilities are presented in our consolidated balance sheet as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance at</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance Sheet Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4134-wk-Fact-93FC417D6E65516CB36353AAC42EF2F6" name="us-gaap:OperatingLeaseRightOfUseAsset" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease liabilities (short-term)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4164-wk-Fact-CA151A9102D05D7088F2EE43B5CF948D" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease liabilities (long-term)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4199-wk-Fact-6F319B62FDF25CFA8D0A320A329799AA" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,048</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LeaseCostTableTextBlock" id="TextSelection-53858455EAEA03F0BAF9CDA8516728A8-0-wk-Fact-BCBD4F30354D30A9CD53CDA88A6240FE" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:80%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our total lease costs are as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4321-wk-Fact-102A92581701552CB40498078D34E5C3" name="us-gaap:OperatingLeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Variable lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4341-wk-Fact-4A75EB86316D58CE867E4A4BEED4F2E7" name="us-gaap:VariableLeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34519344e4366-wk-Fact-39C55B542D345ECFBDCE70F6B2EB86DE" name="us-gaap:SubleaseIncome" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4397-wk-Fact-71624EFD7D5450439FF0ADE33112C760" name="us-gaap:LeaseCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:17%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other supplemental information includes the following:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average Remaining Contractual Lease Term (Years) as of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average Discount Rate as of</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34519344e4583-wk-Fact-7ABEE86154625A10920AD28E665C31B3" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" contextRef="FI2019Q4" format="ixt-sec:duryear">6.8</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4593-wk-Fact-BDCDBC9DCEFF5EF1BBF2AABC81D7EE35" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" contextRef="FI2019Q4" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4715-wk-Fact-9D79BFB44E8E5BC78A4220F4C01916F2" name="us-gaap:OperatingLeasePayments" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gains)/losses on sale and leaseback transactions, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34519344e4760-wk-Fact-9955BF04D4B95FF29504B4DD502F74AE" name="us-gaap:SaleAndLeasebackTransactionGainLossNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ROU assets obtained in exchange for new operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4811-wk-Fact-903437B5E0BE5C3BB05954945635C81D" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="TextSelection-AA9B51D843078125692DCDA91F50CFB5-0-wk-Fact-51C20EAD59E06446F1A6CDA97440FBB9" continuedAt="TextSelection-AA9B51D843078125692DCDA91F50CFB5-1" escape="true"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:23%;"></td><td style="width:1%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating Lease Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Next one year</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4935-wk-Fact-D4A071180EDE5CEF82B5ECC8A1B682B0" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">323</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1-2 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4955-wk-Fact-78AA6EF829B550D78A2B4D19A3F5F6AA" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2-3 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e4980-wk-Fact-150C91F824A554F1893E496F70051414" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3-4 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e5005-wk-Fact-5C807D5E2A165038BF0483B7D22FE73F" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4-5 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e5030-wk-Fact-C1CA5A551CAC5F658E17FB58880C4600" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e5055-wk-Fact-1927129FE3AC5361A96E8A5B591FCF9E" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">424</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total undiscounted lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e5080-wk-Fact-87F0A32A2D1C51398079AE5E55E45F50" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e5105-wk-Fact-3D92602F15F05AA49F55A2FBE80F83F0" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">206</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Present value of minimum lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e5131-wk-Fact-AAD4F64B7D4A5E6287C77330CB4E4C2F" name="us-gaap:OperatingLeaseLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,324</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e5156-wk-Fact-CA151A9102D05D7088F2EE43B5CF948D" name="us-gaap:OperatingLeaseLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34519344e5186-wk-Fact-6F319B62FDF25CFA8D0A320A329799AA" name="us-gaap:OperatingLeaseLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,048</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-AA9B51D843078125692DCDA91F50CFB5-1" continuedAt="TextSelection-AA9B51D843078125692DCDA91F50CFB5-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-13B98780E3A32428D56ECDA99D9FF8D0-0-wk-Footnote-13B98780E3A32428D56ECDA99D9FF8D0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-AA9B51D843078125692DCDA91F50CFB5-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Reflects lease payments due within 12 months subsequent to the balance sheet date.</span><span style="font-family:Arial;font-size:8pt;"> </span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, we entered an agreement to lease space in an office building in New York City. We expect to take control of the property in 2021 and relocate our global headquarters to this new office building in 2022. Our future minimum rental commitment under this </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34519344e5207-wk-Fact-5B4FDBBFA36454E0B7045E3ED44E0122" name="us-gaap:LesseeOperatingLeaseTermOfContract" contextRef="I2018Q2Apr30_us-gaap_LeaseArrangementTypeAxis_pfe_OfficeBuildingInNewYorkCityMember" format="ixt-sec:duryear">20</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;">-year lease is approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e5211-wk-Fact-496AB503F40803FDFA8BCE1515E7651E" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDue" contextRef="I2018Q2Apr30_us-gaap_LeaseArrangementTypeAxis_pfe_OfficeBuildingInNewYorkCityMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior to our adoption of the new lease standard, rental expense, net of sublease income, was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e5219-wk-Fact-A8104E75C62D567E9ADC847E6F6A1E2C" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">301</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2018 and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34519344e5223-wk-Fact-E8E07C6373FF5F32AAE2C17FE497989E" name="us-gaap:OperatingLeasesRentExpenseNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">314</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2017.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" id="TextSelection-25B3763D59BF3E461447CDAA1521FE4E-0-wk-Fact-05262257643BCD37850ECDAA6D143F69" escape="true"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">After 2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease commitments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e5531-wk-Fact-175B6519BF8F5665A96150F7C1277CD3" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e5550-wk-Fact-11F23E7E46ED59299C14AA0CEF0CD735" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e5570-wk-Fact-FAD9C7B04BC757218CDAF1BED4984288" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">210</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e5589-wk-Fact-E7AB6DA1C7925147A4F53D065D1E45C7" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">267</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e5608-wk-Fact-BD11FEDCA0075B93AA4F69282B0BD690" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34519344e5628-wk-Fact-2978B8F81ACC5F4B9C547D637D7643F7" name="us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">77</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s37A6CD3DE47C58B4980854C9887DD432"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 2</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-0-wk-Fact-55709442E36C72041BEF801F803DBC16" continuedAt="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span></ix:nonNumeric></div><ix:continuation id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-1" continuedAt="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Acquisitions</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Array BioPharma Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">July&#160;30, 2019</span><span style="font-family:Arial;font-size:8pt;">, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1330-wk-Fact-87A73243BF595DD18C64026B1A594F00" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">48</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share in cash. The total fair value of the consideration transferred for Array was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1334-wk-Fact-661D03E21572543CB5AFEBAECACF8E2B" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1338-wk-Fact-AA9C766FC51A56248B8278DB552969BB" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">10.9</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, net of cash acquired). In addition, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1342-wk-Fact-5162BD37F8C9541ABBF3ACA81FB246B3" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IncomeStatementLocationAxis_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">157</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs </span><span style="font-family:Arial;font-size:8pt;">in the consolidated statement of income in the third quarter of 2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:8pt;">). We financed the majority of the transaction with debt and the balance with existing cash. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Array&#8217;s portfolio includes the approved combined use of Braftovi (encorafenib) and Mektovi (binimetinib) for the treatment of BRAF</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</sup></span><span style="font-family:Arial;font-size:8pt;">- or BRAF</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600K</sup></span><span style="font-family:Arial;font-size:8pt;">-mutant unresectable or metastatic melanoma. The combination therapy has significant potential for long-term growth via expansion into additional areas of unmet need and is currently being investigated in over 30 clinical trials across several solid tumor indications, including in BRAF-mutant mCRC, through collaborations with third parties. In December 2019, the FDA accepted and granted priority review to our supplemental new drug application for Braftovi in combination with Erbitux (cetuximab) (Braftovi Doublet) in BRAF-mutant mCRC. Pfizer has exclusive rights to commercialize Braftovi and Mektovi in the U.S. and Canada. In addition to the combination therapy for BRAF-mutant metastatic melanoma, Array brings a broad pipeline of targeted cancer medicines in different stages of R&amp;D, as well as a portfolio of out-licensed medicines, which may generate milestones and royalties over time.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with this acquisition, we provisionally recorded: (i) </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1373-wk-Fact-ECD43E8C3A0558F781B405A81919ABC0" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">7.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">, consisting of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1381-wk-Fact-48D871521FAD5D3CB39F25B3CDCABD0C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"> with a useful life of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34506804e1389-wk-Fact-C774FEDE0545501F9BB639A8CF466F64" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear">16</ix:nonNumeric> years</span></span><span style="font-family:Arial;font-size:8pt;color:#0000ff;">,</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1396-wk-Fact-BAFC3442AE0D55949C2C6B7CE309CF0F" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">IPR&amp;D </span><span style="font-family:Arial;font-size:8pt;">and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1404-wk-Fact-BEE0EA2666355F388C62D01084A3CB20" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Licensing agreements </span><span style="font-family:Arial;font-size:8pt;">(</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1412-wk-Fact-D6F35499769551BEA123C478BC1A6C46" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsTechnologyInDevelopmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> for technology in development</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">indefinite-lived licensing agreements and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1421-wk-Fact-72B7FF5E1A7E524A93960464DEEF1FB5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> for developed technology</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">finite-lived licensing agreements with a useful life of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34506804e1429-wk-Fact-E87FB5E6A8AF50FBA3ECDA73F9A15DA5" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember" format="ixt-sec:duryear">10</ix:nonNumeric> years</span></span><span style="font-family:Arial;font-size:8pt;">), (ii) </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1433-wk-Fact-12359B4DCB395C95B28A9B9EB3E7A049" name="us-gaap:Goodwill" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;">, (iii) </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1442-wk-Fact-CD8FF14A7B1C59B991937BD3707EA01D" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of net deferred tax liabilities and (iv) </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1446-wk-Fact-865E3F37E167521D80077626A70B91B9" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">451</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of assumed long-term debt, which was paid in full in the third quarter of 2019. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Therachon Holding AG</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1456-wk-Fact-D4613DCD361C587C8CEC0BB4595ED1E7" name="pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment" contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront, plus potential milestone payments of up to </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1460-wk-Fact-F4590EEA4BAF5B65B61201FB5AB77321" name="pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> contingent on the achievement of key milestones in the development and commercialization of the lead asset. In 2018, we acquired approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e1464-wk-Fact-E6FF67223EDB578184BDA6503B4EBD20" name="pfe:AssetAcquisitionPercentageofSharesAcquired" contextRef="FI2018Q4_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">3</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of Therachon&#8217;s outstanding shares for </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1468-wk-Fact-01AD44704E345567B79909ABB7D672A0" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="FD2018Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">. We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1472-wk-Fact-E471A84C0B3850C393C12C737086419C" name="pfe:AssetAcquisitionConsiderationTransferred" contextRef="D2019Q3Jan01-Jul02_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">322</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, which consisted of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1477-wk-Fact-3F87DE71178655C298052D90DCCA243B" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">317</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of cash and our previous </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1481-wk-Fact-01AD44704E345567B79909ABB7D672A0" name="us-gaap:PaymentsToAcquireProductiveAssets" contextRef="FD2018Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> investment in Therachon. Therachon is a wholly-owned subsidiary of Pfizer. In connection with this asset acquisition, we recorded a charge of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1485-wk-Fact-B8FF75B1EBFC518A84B141992E2D3739" name="us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">337</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">AstraZeneca&#8217;s Small Molecule Anti-Infectives Business</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the marketed products Zavicefta&#8482; (ceftazidime-avibactam), Merrem&#8482;/Meronem&#8482; (meropenem) and Zinforo&#8482;&#160;(ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). In 2017, under the terms of the agreement, we made payments of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1497-wk-Fact-664BC8C9F3B14EC1DB76801F7E12B000" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">605</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to AstraZeneca related to the transaction. We made an additional milestone payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1501-wk-Fact-3EF90B540EEF9FA9EE5B801F7E68742B" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in our first fiscal quarter of 2018, we made a deferred payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1505-wk-Fact-ACA67D96ACE081C2E2BA801F7DF2A1D2" name="pfe:BusinessCombinationConsiderationTransferredDeferredPayment" contextRef="D2019Q1Jan01-Jan31_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">175</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to AstraZeneca in January 2019, and we made an additional milestone payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1509-wk-Fact-616ABF59A568AB9DC1DC801F7E740972" name="pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in our third fiscal quarter of 2019. We may make payments of up to </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1513-wk-Fact-400ACAF3BCCDE458A25E801F80898CC4" name="pfe:BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to AstraZeneca if sales of Zavicefta&#8482; exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta&#8482; and ATM-AVI in certain markets for a period ending on the later of 10 years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1518-wk-Fact-A8DCA49065364D6AA9B4801F80094C56" name="pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1522-wk-Fact-D5239ED646294574B776801F7DE2C909" name="pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">542</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">. The total fair value of consideration transferred for AstraZeneca&#8217;s small molecule anti-infectives business was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1526-wk-Fact-AE69E3A5F2E6833E0DD1801F7F120629" name="us-gaap:BusinessCombinationConsiderationTransferred1" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> inclusive of cash paid of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1530-wk-Fact-48BF4859B0A32BA23E7E801F7FD413C0" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">555</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> and the fair value of contingent consideration of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1534-wk-Fact-66B2EA2967DFB66FBE1B801F7DF246E1" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> (which is composed of the fair values of the deferred payment, the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1538-wk-Fact-873A2FCE13E3F7A54D7C801F7DCFDE8B" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment made in the second quarter of 2017, the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1543-wk-Fact-3EF90B540EEF9FA9EE5B801F7E68742B" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment made in our first fiscal quarter of 2018, the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1547-wk-Fact-616ABF59A568AB9DC1DC801F7E740972" name="pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment made in the third quarter of 2019, and the future expected milestone and royalty payments). In connection with this acquisition, we recorded </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1551-wk-Fact-9ABE5A7329F9817A9547801F8039E9C8" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">894</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">, consisting of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1559-wk-Fact-B7E02A378830B1F7BE49801F824C00E6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">728</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1568-wk-Fact-22EF0C4475B2A4AD777C801F7E3C7ED6" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">166</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:Arial;font-size:8pt;">. We also recorded </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1576-wk-Fact-087AFE02EC26F193B1BC801F807D250A" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">92</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current assets</span><span style="font-family:Arial;font-size:8pt;"> related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1584-wk-Fact-B6FE64416F37E28459E5801F7E1E4151" name="us-gaap:Goodwill" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1593-wk-Fact-640C87204CEB4736BE4A801F7E1F3BF2" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Medivation, Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On September 28, 2016, we acquired Medivation for </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1604-wk-Fact-FFA5B333BCCD36025568801F812EB76E" name="us-gaap:BusinessAcquisitionSharePrice" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">81.50</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share. The total fair value of consideration transferred for Medivation was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1608-wk-Fact-00602B0CD59829308488801F7F23C922" name="us-gaap:PaymentsToAcquireBusinessesGross" contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">14.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in cash (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1612-wk-Fact-B394D27B91D0ACE67F00801F7FF7C501" name="us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired" contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">13.9</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, net of cash acquired). Of this consideration, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1616-wk-Fact-DE3E474FC158525238FC801F7E11B4BC" name="pfe:BusinessCombinationConsiderationTransferredAmountPayable" contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">365</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> was not paid as of December 31, 2016, and was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities.</span><span style="font-family:Arial;font-size:8pt;"> The remaining consideration was paid as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2017</span><span style="font-family:Arial;font-size:8pt;">. Medivation is a wholly-owned subsidiary of Pfizer. Medivation is focused on developing and commercializing small molecules for oncology. Medivation&#8217;s portfolio includes Xtandi (enzalutamide). Xtandi is FDA-approved for the treatment of non-metastatic and metastatic castration-resistant </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">78</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-2" continuedAt="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-3"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">prostate cancer as well as metastatic castration sensitive prostate cancer. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. The Medivation portfolio also includes talazoparib, which was approved by the FDA in October 2018, under the trade name Talzenna, for the treatment of adults with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer and is currently in development for other types of cancer. In connection with this acquisition, we recorded </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1632-wk-Fact-1F746802082F744ED275801F7E119565" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">12.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">, primarily consisting of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1640-wk-Fact-DFAD2DD567A64747F364801F8013EB7A" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"> with an average useful life of approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34506804e1648-wk-Fact-3B9263C0723F412B07FB801F7DF75E50" name="us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear">12</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> years and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1653-wk-Fact-946A9DD73966AD8AF05E801F7EA7FC7B" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">IPR&amp;D, </span><span style="font-family:Arial;font-size:8pt;">and recorded </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1661-wk-Fact-CC812ED22CC64D569887801F7E063673" name="us-gaap:Goodwill" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">6.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Goodwill,</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1669-wk-Fact-7C35F09640F10B40702C801F801983DE" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of net income tax liabilities, and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1673-wk-Fact-085A909DD62E24B7BC59801F7DF30D52" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">259</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of assumed contingent consideration of which </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1678-wk-Fact-05F1F7D310362DFE91C5801F7DCA3DF0" name="us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> has been paid through December 31, 2019. In 2017 and 2016, we recorded measurement period adjustments to the estimated fair values initially recorded in 2016, which resulted in a reduction in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;"> of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1686-wk-Fact-FDDF47CA1670EC5067F6801F7E102CF5" name="us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" contextRef="D2017Q4Sept-Dec2017_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> with a corresponding change to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;"> and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The 2017 results included a decrease of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1694-wk-Fact-BDCB3FDB89F9F323D8CB801F7E165A14" name="pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">38</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:8pt;"> which reflected the cumulative pre-tax impact of the measurement period adjustments to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;"> that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Divestitures</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical, a global device manufacturer, agreed to acquire all of our global infusion systems net assets, HIS, for approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1806-wk-Fact-ED1041F6C5DE51F1929F801F7E0DB7A1" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2016Q4Oct06_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in cash and ICU Medical common stock. HIS includes IV pumps, solutions, and devices. As a result of the performance of HIS relative to ICU Medical&#8217;s expectations, on January 5, 2017 we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1810-wk-Fact-1322BD020F41F6AA79BF801F7F42DBE6" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">900</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The revised transaction closed on February 3, 2017. At closing, we received </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e1817-wk-Fact-448F0E07DB88579118FA801F806FAF0C" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">3.2</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1821-wk-Fact-1575B0E58607CCACD1D7801F80322FE0" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">428</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which were reported as equity securities at fair value in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span><span style="font-family:Arial;font-size:8pt;"> on the consolidated balance sheet as of December 31, 2017. Upon the sale of these shares in 2018, we realized a full gain of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1829-wk-Fact-859D36A3E54BEC0F9084801F7E6E2F0B" name="us-gaap:EquitySecuritiesFvNiRealizedGain" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">302</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> on these securities, although our income statement only reflects a gain of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1833-wk-Fact-0DE148F4345D12970895801F800B323E" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> as the balance of the previously unrealized gain was recorded as a cumulative effect adjustment upon the adoption of a new accounting standard. We also received a promissory note in the amount of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1838-wk-Fact-33FAD1E8644FB8E7555A801F7E285732" name="pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, which was repaid in full as of December 31, 2017, and net cash of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1842-wk-Fact-FC643562DEFCD98D4323801F8014EC76" name="us-gaap:ProceedsFromDivestitureOfBusinesses" contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> before customary adjustments for net working capital, which was reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other investing activities, net</span><span style="font-family:Arial;font-size:8pt;"> on the consolidated statement of cash flows for the year-ended December 31, 2017. In addition, we are entitled to receive a contingent amount of up to an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1850-wk-Fact-E673F86D3B6DCD055732801F7E198E89" name="pfe:DisposalGroupIncludingDiscontinuedOperationContingentConsideration" contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in cash based on ICU Medical&#8217;s achievement of certain cumulative performance targets for the combined company through December 31, 2019. The amount of contingent payment we will receive, if any, will be determined during the first half of 2020. We recognized a pre-tax gain of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1854-wk-Fact-32377B62BE4A55EC2219801F7E248AA4" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and a pre-tax loss of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1863-wk-Fact-FD073C40A0E2055928C6801F7E1E419D" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net, </span><span style="font-family:Arial;font-size:8pt;">representing adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell. </span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The sale of the HIS net assets was fully completed in all jurisdictions as of year-end 2018.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily related to administrative services, and were provided for a period of 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Contribution Agreement Between Pfizer and Allogene Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, Pfizer and Allogene announced that the two companies entered into a contribution agreement for Pfizer&#8217;s portfolio of assets related to allogeneic CAR T therapy, an investigational immune cell therapy approach to treating cancer. Under this agreement, Allogene received from Pfizer rights to pre-clinical and clinical CAR T assets, all of which were previously licensed to Pfizer from French cell therapy company, Cellectis, beginning in 2014 and French pharmaceutical company, Servier, beginning in 2015. Allogene assumed responsibility for all potential financial obligations to both Cellectis and Servier. Pfizer continues to participate financially in the development of the CAR T portfolio through an ownership stake in Allogene. Separately, Pfizer continues to maintain its approximate </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e1908-wk-Fact-F3DD7017E52B31896A59801F8022A2B8" name="pfe:InvestmentOwnershipPercentage" contextRef="FD2014Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CellectisMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> ownership stake in Cellectis that was obtained in 2014 as part of the licensing agreement in which Pfizer obtained exclusive rights to pursue the development and commercialization of certain Cellectis CAR T therapies in exchange for an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1912-wk-Fact-A33AE9DFFC0C74A11C01801F7E02E26C" name="pfe:PaymentsToCollaborators" contextRef="FD2014Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CellectisMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, as well as potential future development, regulatory and commercial milestone payments and royalties. In connection with the Allogene transaction, Pfizer recognized a non-cash </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1916-wk-Fact-A5E7D7BC9D54165BB084801F7E2758E6" name="pfe:GainLossFromContributionAgreement" contextRef="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">in the second quarter of 2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">,</span><span style="font-family:Arial;font-size:8pt;"> representing the difference between the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1929-wk-Fact-075EFE0D84976CB138EE801F7E08FB58" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> fair value of the equity investment received and the book value of assets transferred (including an allocation of goodwill) (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2018, Allogene consummated an initial public offering of new shares of its common stock, which resulted in Pfizer&#8217;s preferred stock converting into common stock and a decrease in our ownership percentage from approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e1940-wk-Fact-1176056932330F446070801F8033D073" name="pfe:InvestmentOwnershipPercentage" contextRef="D2018Q2Apr01-Apr30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> to approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e1944-wk-Fact-D787171481B12E3FC3E7801F7E6C1F8C" name="pfe:InvestmentOwnershipPercentage" contextRef="D2018Q4Oct01-Oct31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">18</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> as of December 31, 2018. The closing price on the day of the initial public offering was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1948-wk-Fact-131227EE45E7CC40CFAD801F7DFFF38B" name="us-gaap:SharePrice" contextRef="I2018Q4Oct31_dei_LegalEntityAxis_pfe_AllogeneMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">25</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share. Beginning as of the date of the initial public offering, our investment in Allogene is being measured at fair value with changes in fair value recognized in net income (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">79</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-3" continuedAt="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-4"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, we sold our Phase 2b ready AMPA receptor potentiator for CIAS to Biogen. We received </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1962-wk-Fact-A4F674735729A9F8CD8D801F7E113FE3" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="I2018Q2Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront and have the opportunity to receive up to </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1966-wk-Fact-E306FE4D7394A9BB8A65801F7E0861F3" name="pfe:DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue" contextRef="D2018Q2Apr01-Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">515</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in total development and commercialization milestones, as well as tiered royalties in the low-to-mid-teen percentages. We recognized the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1970-wk-Fact-DF8338F8650651A27C5B801F7E226BB4" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="FI2018Q2_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront payment in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> in the second quarter of 2018 (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">). In the fourth quarter of 2018, we recognized an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e1983-wk-Fact-DE918A1FC21AD25686BB801F7DFB978A" name="pfe:DisposalGroupIncludingDiscontinuedOperationMilestone" contextRef="FD2018Q4QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">4</span><span style="font-family:Arial;font-size:8pt;">).</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">We will record the other milestones and royalties to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> when due, or earlier if we have sufficient experience to determine such amounts are not probable of significant reversal.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Divestiture of Neuroscience Assets</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2018, we and Bain Capital entered into a transaction to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system including Parkinson&#8217;s disease, epilepsy, Alzheimer&#8217;s disease, schizophrenia and addiction. These assets were part of the neuroscience discovery and early development efforts, which we announced we were ending in January 2018. In connection with this transaction, we out-licensed the portfolio to Cerevel in exchange for a </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2014-wk-Fact-9780104E0674E74703FA801F7E8A9CDA" name="pfe:InvestmentOwnershipPercentage" contextRef="D2018Q3Sep01-Sep30_srt_OwnershipAxis_pfe_CerevelTherapeuticsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> ownership stake in Cerevel&#8217;s parent company, Cerevel Therapeutics, Inc., and potential future regulatory and commercial milestone payments and royalties. Bain Capital has committed to invest </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2018-wk-Fact-BBAB3B97A23EB6C69499801F7E757F14" name="pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" contextRef="FI2019Q4_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_NeuroscienceAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">350</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to develop the portfolio, with the potential for additional funding as the assets advance. In connection with the transaction, we recognized a non-cash </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2022-wk-Fact-EC27A4D700FE4C13F119801F7DEEEE80" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">in the third quarter of 2018, representing the fair value of the equity investment received as the assets transferred</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">had a book value of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2035-wk-Fact-1E7359DCA4D652684527801F824E86BA" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="FI2019Q4_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_NeuroscienceAssetsMember" unitRef="usd" decimals="0" scale="0" format="ixt:numdotdecimal">0</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">). Our investment in Cerevel Therapeutics, Inc. is reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments </span><span style="font-family:Arial;font-size:8pt;">on the consolidated balance sheets as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Equity-Method Investments and </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Assets and Liabilities Held for Sale</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Formation of a New Consumer Healthcare Joint Venture</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2072-wk-Fact-78CADF80D88F5D26B975A32DFECE8696" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> equity stake in the new company and GSK owns the remaining </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2076-wk-Fact-3C52A8025F775FF2941B2078743A61DB" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_dei_LegalEntityAxis_pfe_GSKMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">68</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">. Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2080-wk-Fact-6FB83529DF93F0640B1ECEEC0219391B" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2084-wk-Fact-C548F63688345C97AFB500E3F9AE108E" name="pfe:DeconsolidationGainLossAmountNetOfTax" contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, net of tax) in our fiscal third quarter of 2019 in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="font-family:Arial;font-size:8pt;"> for the difference in the fair value of our </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2093-wk-Fact-78CADF80D88F5D26B975A32DFECE8696" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In valuing our investment in GSK Consumer Healthcare, we used discounted cash flow techniques. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long term; the discount rate, which seeks to reflect our best estimate of the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows. As part of the joint venture transaction, we agreed to indemnify GSK with respect to certain tax matters related to periods prior to closing of the transaction as well as certain potential environmental or other legal liabilities associated with the previous operation of our Consumer Healthcare business. We recognized a liability of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2100-wk-Fact-8F92B12236CC501DBD513A872742A01E" name="pfe:EquityMethodInvestmentsTaxIndemnificationLiability" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> with respect to the tax matters indemnification. The value of the environmental and legal indemnifications was not considered to be material.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our investment in GSK Consumer Healthcare is approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2108-wk-Fact-8C19A93F0FA83CD0C952DED514D5992B" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">17.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> and it is reported as a private equity investment in the </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Equity-method investments </span><span style="font-family:Arial;font-size:8pt;">line in our consolidated balance sheet as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. Our consolidated statement of income for 2019 includes revenues and expenses associated with Pfizer&#8217;s Consumer Healthcare business through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. We record our share of earnings from the Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> commencing from August 1, 2019. Therefore, we recorded our share of two months of the joint venture&#8217;s earnings generated in the third quarter of 2019 totaling </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2129-wk-Fact-6964A67E8C8EEAF8CAC7DED7C4577E23" name="us-gaap:IncomeLossFromEquityMethodInvestments" contextRef="FD2019Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in our operating results in the fourth quarter of 2019. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2133-wk-Fact-1BCE009B4C84501F9E6F999405CD2256" name="us-gaap:EquityMethodInvestmentsFairValueDisclosure" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">15.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2137-wk-Fact-78CADF80D88F5D26B975A32DFECE8696" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2141-wk-Fact-8AD421AE1F909925EB9FDED2FE82D234" name="us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">11.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> resulting in an initial basis difference of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2145-wk-Fact-D05BE98D05DD16B17813DED36595C9FF" name="us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.5</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> commencing August 1, 2019. The amortization of these basis differences for two months of the third quarter of 2019 totaling approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2154-wk-Fact-57E21065191F2530367EDEDE0DF1A6DD" name="pfe:EquityMethodInvestmentExcessBasisAmortization" contextRef="FD2019Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is included in our operating results in the fourth quarter of 2019. Amortization of basis differences on inventory and related deferred tax liabilities will be completely recognized by the first quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34506804e2158-wk-Fact-1C54400B4B1EC34C1F20DEE22A08B149" name="pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" format="ixt-sec:duryear">17</ix:nonNumeric> years</span></span><span style="font-family:Arial;font-size:8pt;">. The increase in the value of our investment from the closing date to December 31, 2019 is primarily due to foreign currency translation adjustments (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 6</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">While we have received our full </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2169-wk-Fact-78CADF80D88F5D26B975A32DFECE8696" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">32</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> interest in GSK Consumer Healthcare as of the </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> closing and transferred control of our Consumer Healthcare business to GSK Consumer Healthcare, the contribution of the business was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, we have continued to operate the business for the net economic benefit of GSK Consumer Healthcare, and we are indemnified by GSK Consumer Healthcare against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. We expect the contribution of our </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">80</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-4" continuedAt="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-5"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Consumer Healthcare business in these jurisdictions to be fully completed by the first half of 2021. As such, and as we and GSK Consumer Healthcare are contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with the contribution of our Consumer Healthcare business, we entered into certain transitional agreements designed to facilitate the orderly transition of the business to GSK Consumer Healthcare. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34506804e2185-wk-Fact-0A6EA1E5982E52838384E83BEDB387B3" name="pfe:EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm" contextRef="D2019Q3Jul31-Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" format="ixt-sec:durmonth">24</ix:nonNumeric> months</span></span><span style="font-family:Arial;font-size:8pt;"> after the closing date. We will also manufacture and supply certain consumer products for GSK Consumer Healthcare and GSK Consumer Healthcare will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of up to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34506804e2189-wk-Fact-1E66E90486245B569877E206170888A1" name="pfe:EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm" contextRef="D2019Q3Jul31-Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" format="ixt-sec:durwordsen">six years</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;">. These agreements are not material to Pfizer.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. The Consumer Healthcare business assets held for sale are reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Assets held for sale</span><span style="font-family:Arial;font-size:8pt;"> and Consumer Healthcare business liabilities held for sale are reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Liabilities held for sale </span><span style="font-family:Arial;font-size:8pt;">in the consolidated balance sheet as of December 31, 2018. This includes the Consumer Healthcare business tax assets and liabilities related to fully dedicated consumer healthcare subsidiaries.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" id="TextSelection-CFF910E2FF62DCB0AC97801F83031BD3-0-wk-Fact-9CD41D024D01F6EA1B85801F7E8C51C5" continuedAt="TextSelection-CFF910E2FF62DCB0AC97801F83031BD3-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:84%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Assets Held for Sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2317-wk-Fact-45112D3279E857839DEC7A6FBF8A4B78" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2337-wk-Fact-0FEB8933B5BF5F038DDD2C4EE723E66F" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2362-wk-Fact-173058331C9451B68EE04F3C60505868" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">538</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2387-wk-Fact-FB04B98A18A05FB98DF48C6E99CA5C09" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PP&amp;E</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2412-wk-Fact-AAD1939A887656679721C6629EC48F41" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Identifiable intangible assets, less accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2437-wk-Fact-94487BCDA5AF5703A087551E0D441E3E" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,763</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2462-wk-Fact-9941E434A8F95432B56195B857FA97F5" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,972</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2487-wk-Fact-63D8CE1AFEFE56B4B678B86104AABD73" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2513-wk-Fact-11FA7057DB795D3DA296405EBB97C4FB" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Consumer Healthcare assets held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2538-wk-Fact-2C2C66055C2174B78ED9CEAD4E815BF7" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,678</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other assets held for sale</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2565-wk-Fact-9148FA2E247D578D82EBB7DE0DEF4259" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Assets held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2595-wk-Fact-7F0F129B1B105287B103012D369F6DD3" name="us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Liabilities Held for Sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2698-wk-Fact-6B62E8B0F9115522987359E688076CAE" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2718-wk-Fact-B895AF3FE19B55038A7E4C5E91E7EF8D" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrued compensation and related items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2743-wk-Fact-80F1C64966CE5CBAB434F7BBED0C0160" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2768-wk-Fact-F4FFE05A62A25EF8A58AD8835551D87A" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2794-wk-Fact-48035F8355055AC093FF574AFC27018B" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2819-wk-Fact-0FA16478D17F5FA58D1B86939B9FD680" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2844-wk-Fact-5011C87A900F507FB10ED767D3DE03FD" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2869-wk-Fact-0AF07267B277A8D732FC801F820FE6DA" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Consumer Healthcare liabilities held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e2899-wk-Fact-4C3A29DAD8215858A7BE8022585EBBDD" name="us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-CFF910E2FF62DCB0AC97801F83031BD3-1" continuedAt="TextSelection-CFF910E2FF62DCB0AC97801F83031BD3-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-CE8D3299C54E02D979FA801F8303D076-0-wk-Footnote-CE8D3299C54E02D979FA801F8303D076_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-CFF910E2FF62DCB0AC97801F83031BD3-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other assets held for sale consist of PP&amp;E.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2924-wk-Fact-65723A0397095AF7B007D658D8B043F9" name="pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" contextRef="D2019Q3Jan1-Jul31_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">654</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2932-wk-Fact-2D6A9470E011FF868CCACF28171D66E1" name="pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" contextRef="FD2018Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">977</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2018 and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e2936-wk-Fact-7FE1760824C493E1DA90CF287A95D063" name="pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" contextRef="FD2017Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">863</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2017.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">81</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-5" continuedAt="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-6"><ix:continuation id="TextSelection-0E8B38AFEE4E8265AEE7D81BE460BD0A-0"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the two months ending September 30, 2019, the most recent period available, is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3023-wk-Fact-7CC19C48EE82EF102ECFD80D7DFCC80F" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,505</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3043-wk-Fact-FF1986FCBEF78493C07ED80D980A3DFE" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38,575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3073-wk-Fact-14D2C87FE29379F24D27D80DAF1B2820" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46,081</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3124-wk-Fact-5471ABE4F754CAED1DBCD80DE237C53C" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3144-wk-Fact-4589C988E38A86D5D306D80DFE377500" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,536</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3174-wk-Fact-8E7C13B0B160B2DCD949D80E247CB8D8" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,776</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity attributable to shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3225-wk-Fact-A9EADF74E4566B7583BFD80E6E636780" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3246-wk-Fact-45D5C27D308DA4ADE116D80E8409C05D" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total net equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3276-wk-Fact-296C4C8626AE7E2AAAABD80EA14B01CF" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity" contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"></td></tr><tr><td style="width:77%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For the Two Months Ending</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">September 30,</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3345-wk-Fact-EC0687894B328D5FDE1ED81F5AE06EB0" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue" contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,161</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34506804e3365-wk-Fact-2C2A9C5544FC02D16741D81F91A04579" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3396-wk-Fact-40021FBA838260F57A3DD8226C21BD73" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss" contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3416-wk-Fact-176941966F2340DD8BA0D822EDE82CB0" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems" contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3441-wk-Fact-ED961F99F0225534B213D8234BF734E1" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3466-wk-Fact-5DB361186A428AEBE921D824E9777C48" name="pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Investment in ViiV Healthcare Limited</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e3489-wk-Fact-3607A4CEBF721D5C1C601702F5A24ED3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">11.7</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of ViiV, and we have historically accounted for our investment in ViiV under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e3493-wk-Fact-01F30C5C613FDA5BECF317075137F7FB" name="us-gaap:EquityMethodInvestments" contextRef="FI2016Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="INF" scale="0" format="ixt-sec:numwordsen">zero</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> due to the recognition of cumulative equity method losses and dividends. Since 2016, we have recognized dividends from ViiV as income in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> when earned, including dividends of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e3501-wk-Fact-293451C69DA75DC8A70D7BAEFB4F73E3" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e3510-wk-Fact-99E3F4A21F825B05BD4E31F27E393D8A" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e3518-wk-Fact-D2DD3479116FE8BE100C801F82405EAA" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EquityMethodInvestmentsTextBlock" id="TextSelection-AA13452F640F2A4402C116FD0A41F93E-0-wk-Fact-FE58EF29FF0F2323205716FD25000C0C" continuedAt="TextSelection-AA13452F640F2A4402C116FD0A41F93E-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Summarized financial information for our equity method investee, ViiV, as of December 31, 2019 and 2018 and for the years ending December 31, 2019, 2018, and 2017 is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3700-wk-Fact-756E779A50B370D76DDB17048C17AF4D" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,839</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e3719-wk-Fact-9E1F570561A13A098D9F17019FFED5C9" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3739-wk-Fact-AC975EB9AFA734FABE4A170491C627A3" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e3758-wk-Fact-ED221A0040813B89CAD31701A3FCDB29" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3783-wk-Fact-2674DC1C3C6EAE76FD6E17049763BF13" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e3802-wk-Fact-3BA48703B0F912F98C671701A7FE6627" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3873-wk-Fact-9C99815A057E3FD3227F17049EDF92AF" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,904</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e3892-wk-Fact-FA264AF25D5B00E43CFD1701AEB132B6" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3917-wk-Fact-93A2DF9C04EC633F956A1704A2FB5768" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e3936-wk-Fact-34A2A0583B59667107A01701B294ADC6" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e3961-wk-Fact-4C0B5B4AB6CF615CA4AD1704A777122F" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,765</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e3980-wk-Fact-BBC3C1448ACF2E0C87C71701B84357DA" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total net equity/(deficit) attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34506804e4057-wk-Fact-5FC46DA6CCE6729429741704AD797643" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital" contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,489</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34506804e4077-wk-Fact-A80EDE2381E30C74A3291703F2382BEC" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital" contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-AA13452F640F2A4402C116FD0A41F93E-1" continuedAt="TextSelection-0E8B38AFEE4E8265AEE7D81BE460BD0A-0"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e4254-wk-Fact-534B074DAAB21D5BBD311700E6A35248" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,139</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4273-wk-Fact-65EB10A98B6EF978CBA417009361701B" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4293-wk-Fact-51E80473A79DC3AEFF3916FFA4767128" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34506804e4313-wk-Fact-B3C718AB997933CABE3E1700EA8821BA" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34506804e4333-wk-Fact-E529F0FAE9E040BCD11B170097D4BBC5" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34506804e4353-wk-Fact-12078C1B08741A95310116FFA8556F82" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e4385-wk-Fact-060A22E35788DEEAED791700F090CB0B" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4404-wk-Fact-2B2F44F13A84524A863C17009E7A26C6" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,757</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4424-wk-Fact-7ED1E954F2F455B2E4A616FFAE39BAF4" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e4444-wk-Fact-F7CC2FD80B2F9B0AB9721700F623B56B" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4463-wk-Fact-BF97D05D87738B5EAB081700A4AC907B" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4482-wk-Fact-163253688A67DD27138116FFB21E50F9" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e4508-wk-Fact-675520A1617915B3943F1700FAC4B07D" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4527-wk-Fact-23040D64DF6C7026C0B21700A923E996" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4546-wk-Fact-4FF53142A8833EEDCA3016FFB68822E1" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e4572-wk-Fact-3A5C5B9B69F71A5515501700FFD9F945" name="pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4591-wk-Fact-1E62924188C9559A3A2C1700AF9B134F" name="pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4610-wk-Fact-CB5AB588B9E6BE19EBBC16FFBA195258" name="pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,867</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">82</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-6" continuedAt="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-7"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Investment in Hisun Pfizer Pharmaceuticals Company Limited</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2012, we and Hisun, a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4632-wk-Fact-A69AB67901B1693A06EE801F824F24D4" name="us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity" contextRef="FI2012Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, of which our portion was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4636-wk-Fact-F33B79E8146797F6C84C801F7DF69ED7" name="us-gaap:EquityMethodInvestments" contextRef="FI2012Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-5" scale="6" format="ixt:numdotdecimal">122.5</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">. As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious disease, oncology, mental health and other therapeutic areas.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We accounted for our interest in Hisun Pfizer as an equity-method investment, due to the significant influence we had over the operations of Hisun Pfizer through our board representation, minority veto rights and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4645-wk-Fact-D463C701915DC8589776801F7E38E976" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q4Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> voting interest. Our investment in Hisun Pfizer was reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span><span style="font-family:Arial;font-size:8pt;">, and our share of Hisun Pfizer&#8217;s net income was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On November 10, 2017, we sold our </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4661-wk-Fact-D463C701915DC8589776801F7E38E976" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q4Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> equity share in Hisun Pfizer to Sapphire I (HK) Holdings Limited, an investment fund managed by Hillhouse Capital, for a total of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4665-wk-Fact-FAF0A0AA15AB0F567459801F7FAE3EA9" name="us-gaap:ProceedsFromSaleOfEquityMethodInvestments" contextRef="D2017Q4Nov10-Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in cash which included our carrying value of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4669-wk-Fact-38BA9FA67C5A095962A7801F7E23083D" name="us-gaap:EquityMethodInvestmentSoldCarryingAmount" contextRef="D2017Q4Nov10-Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">270</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in cash plus </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4673-wk-Fact-689DB61425FC2EB1D2B2801F824B9C9E" name="pfe:EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax" contextRef="D2017Q4Nov10-Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to cover certain taxes incurred on the transaction.&#160;As a result of the sale transaction, we recognized a loss of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4677-wk-Fact-CB0BFC52281CFB30A9D4801F7DF61F42" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="FD2017Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in the fourth quarter of 2017 for the recognition in earnings of the currency translation adjustment associated with our investment. After the sale transaction, Hisun Pfizer changed its name but retained its current rights to manufacture, sell and distribute all of Hisun Pfizer&#8217;s currently marketed and pipeline products in China. We are providing technical, manufacturing and regulatory services in connection with a technology transfer process being run by Hisun Pfizer to support Hisun Pfizer&#8217;s objective that the products that we had previously licensed to Hisun Pfizer, will in the future, be manufactured locally in China.&#160;We continue to supply certain products to Hisun Pfizer for a period of time, after the sale transaction, to facilitate a smooth transition.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Investment in Laborat&#243;rio Teuto Brasileiro S.A.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We entered into an agreement on June 30, 2017 to exit our investment in Teuto, a </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4689-wk-Fact-A9A6F91B231257800749801F80B22D2E" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q2Jun30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">-owned generics company in Brazil, and sell our </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4693-wk-Fact-A9A6F91B231257800749801F80B22D2E" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q2Jun30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> interest in Teuto to the majority shareholders. As part of the agreement, we waived our option to acquire the remaining </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4697-wk-Fact-E218FFA8B1BEC0935D45801F7EB5152A" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of Teuto, and Teuto&#8217;s other shareholders have waived their option to sell their </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4701-wk-Fact-E218FFA8B1BEC0935D45801F7EB5152A" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> stake in the company to us. As a result, in the second quarter of 2017, we recognized a net loss of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4705-wk-Fact-EFB9DE03407E9EBADAF5801F7E04ABC8" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="FD2017Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">), which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders&#8217; option to sell their </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4718-wk-Fact-E218FFA8B1BEC0935D45801F7EB5152A" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> stake in the company to us, and the recognition in earnings of the currency translation adjustment associated with the Teuto investment. The transaction closed on August 16, 2017.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Licensing Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Akcea Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. The transaction closed in November 2019 and we made an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4731-wk-Fact-820E4481EA1BBFE4406DCDC046424C7F" name="pfe:PaymentForLicensingArrangement" contextRef="FD2019Q4QTD_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to Akcea and Ionis, which was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:8pt;">in our fiscal fourth quarter of 2019. Under the terms of the agreement, Akcea and Ionis will split equally the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4739-wk-Fact-820E4481EA1BBFE4406DCDC046424C7F" name="pfe:PaymentForLicensingArrangement" contextRef="FD2019Q4QTD_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront license fee. We may be required to make development, regulatory and sales milestone payments of up to </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4743-wk-Fact-1AA439CC811F2AA27273CF41187095B1" name="pfe:LicensingArrangementMilestoneMaximumValue" contextRef="D2019Q4Nov1-30_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> and tiered, double-digit royalties on annual worldwide net sales upon marketing approval of AKCEA-ANGPTL3-LRx and these payments will also be split equally between Akcea and Ionis. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with the ongoing Phase 2 study.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Shire International GmbH</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2016, we out-licensed PF-00547659, an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease, including ulcerative colitis and Crohn&#8217;s disease, to Shire for an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4753-wk-Fact-5C2CDA321DC50E528ED2801F7EB34AB0" name="pfe:ProceedsFromLicensingArrangement" contextRef="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, up to </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4757-wk-Fact-C79D4C2F20F407BD31DE801F8251BB2B" name="pfe:LicensingArrangementMilestoneMaximumValue" contextRef="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">460</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in development and sales-based milestone payments and potential future royalty payments on commercialized products. The </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4761-wk-Fact-5C2CDA321DC50E528ED2801F7EB34AB0" name="pfe:ProceedsFromLicensingArrangement" contextRef="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront payment was initially deferred and recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> ratably through December 2017. In the first quarter of 2018, we recognized </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4769-wk-Fact-9B02DFA06D6C407B8EBA801F7DF39CFD" name="pfe:ProceedsFromLicensingArrangement" contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of ulcerative colitis, and in the third quarter of 2018, we recognized </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4778-wk-Fact-6B9F402AA8B68FB924E1801F7DF7B11B" name="pfe:ProceedsFromLicensingArrangement" contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of Crohn&#8217;s disease (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">BionTech AG</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2018, a multi-year R&amp;D arrangement went into effect between BionTech AG (BionTech), a privately held company, and Pfizer to develop mRNA-based vaccines for prevention of influenza (flu). In September 2018, we made an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4797-wk-Fact-8C08BEB8EA9DA92FF080801F7E02D8C3" name="pfe:PaymentForLicensingArrangement" contextRef="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to BionTech, which was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses, </span><span style="font-family:Arial;font-size:8pt;">and BionTech became eligible to receive up to an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4805-wk-Fact-075CF4B1A5E59C280D9C801F7DFC6B78" name="pfe:LicensingArrangementMilestoneMaximumValue" contextRef="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in future development and sales based milestones and future royalty payments associated with worldwide sales. As part of the transaction, we also purchased </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4809-wk-Fact-D3DF515F4556BD3C6160801F7E05E6FB" name="pfe:LicensingArrangementNumberOfSharesPurchased" contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">169,670</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> newly-issued ordinary shares of BionTech for </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4813-wk-Fact-2F12672D61E0D4EA57ED801F7DE6DA39" name="pfe:LicensingArrangementValueOfSharesPurchased" contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in the third quarter of 2018, which are reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments </span><span style="font-family:Arial;font-size:8pt;">in the consolidated balance sheets as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and December 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Research and Development and Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest would fund up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4842-wk-Fact-95D2F3BC71A15123ABC280C6AB1F298C" name="pfe:ResearchandDevelopmentArrangementMaximumFundingAmount" contextRef="D2016Q2Apr01-Apr30_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">in development costs related to certain Phase 3 clinical trials of Pfizer&#8217;s rivipansel compound and Pfizer would use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest&#8217;s development funding was expected to cover up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4850-wk-Fact-D0A58E872FDE52CE99EF49E0F224B3E7" name="pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" contextRef="D2016Q2Apr01-Apr30_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">of the development </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">83</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-7" continuedAt="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-8"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">costs and was received over approximately 13 quarters from 2016 through the second quarter of 2019 after which Pfizer would be responsible for the remaining development costs. As there was a substantive and genuine transfer of risk to NovaQuest, the development funding was recognized by us as an obligation to perform contractual services and therefore a reduction of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"> as incurred. The funding cap was reached in 2019.</span><span style="font-family:Arial;font-size:8pt;"> The reduction to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and Development expenses </span><span style="font-family:Arial;font-size:8pt;">totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4869-wk-Fact-50241778B655BF8E4796CF4DD205C66A" name="pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> for 2019, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4873-wk-Fact-DCDCB6F3FC9A522970E8801F7E0063AC" name="pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> for 2018 and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4877-wk-Fact-BE6EF9680988B352E583801F8024A94F" name="pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> for 2017.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:8pt;">In August 2019, we announced that the Phase 3 RESET (Rivipansel Evaluating Safety, Efficacy and Time to Discharge)</span><span style="font-family:Arial;font-size:11pt;"> </span><span style="font-family:Arial;font-size:8pt;">pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease who were hospitalized for a vaso-occlusive crisis and required treatment with IV opioids. As a result, in 2019, we recorded a </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4889-wk-Fact-19106036A66C5E329303022952750D15" name="pfe:Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> charge in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:8pt;">related to rivipansel</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">,</span><span style="font-family:Arial;font-size:8pt;"> primarily for inventory manufactured for expected future sale</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">, </span><span style="font-family:Arial;font-size:8pt;">as well as </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4906-wk-Fact-B21500386AC65000A800D0268E9F0B2F" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of anticipated clinical development program close-out costs, which were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development costs </span><span style="font-family:Arial;font-size:8pt;">in the consolidated statement of income. In January 2020, we discontinued development of rivipansel resulting in the termination of the R&amp;D arrangement with NovaQuest. No payments have been or are expected to be received from or paid to NovaQuest as part of the termination of the arrangement.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Research and Development Arrangement with RPI Finance Trust</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI would fund up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4922-wk-Fact-2755488F3B1EC974F719801F7E077AE7" name="pfe:ResearchandDevelopmentArrangementMaximumFundingAmount" contextRef="D2016Q1Jan2016_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember" unitRef="usd" decimals="INF" scale="6" format="ixt:numdotdecimal">300</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">in development costs related to certain Phase 3 clinical trials of Pfizer&#8217;s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI&#8217;s development funding is expected to cover up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e4930-wk-Fact-4F996FA8CF4E161995BD801F824D0ECB" name="pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" contextRef="D2016Q1Jan2016_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">of the costs primarily for the applicable clinical trials until the first quarter of 2020 after which Pfizer will be responsible for the remaining cost of the trials. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"> as incurred. The reduction to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"> totaled</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4947-wk-Fact-448FF7439D9960ADF98BCF5125A3910B" name="pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4956-wk-Fact-60CF78C302DFD56BDE20801F7E67965D" name="pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4964-wk-Fact-42F43048CF5DCD2BFACA801F7E94A1D2" name="pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">76</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:Arial;font-size:8pt;"> If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e4977-wk-Fact-F01BFC5AF4E17BD39321801F7E1C31D1" name="pfe:ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure" contextRef="D2016Q1Jan2016_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:8pt;"> over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> when incurred. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" id="TextSelection-0CD3AB4C217E2BDA80FB801F8303CE8E-0-wk-Fact-41677BE726F33E38899D801F7E148CA9" continuedAt="TextSelection-0CD3AB4C217E2BDA80FB801F8303CE8E-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">&#8212;Revenues</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e5247-wk-Fact-B43EBF08C38CF8025BE1801F81E33B35" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">664</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5266-wk-Fact-A63F83E6394508389223801F8216DDFD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5286-wk-Fact-44258E2A7EC67FA448C2801F81E421B4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenue</span><span style="font-family:Arial;font-size:8pt;">s&#8212;Alliance revenues</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e5310-wk-Fact-A6CC259B83A6C2A0E036801F81DB019C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,648</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5329-wk-Fact-F887DA1F92BAA8B8385A801F81DC8EFC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5348-wk-Fact-ECECA9DC935CC99E3524801F82146F62" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total revenues from collaborative arrangements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e5379-wk-Fact-1AD4FC7E6C5F6201A8F9801F81DE0A32" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5398-wk-Fact-11F06651487134351FBA801F81E22087" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,409</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5418-wk-Fact-1839921A9C96AE08AAC2801F8213BA92" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,533</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34506804e5445-wk-Fact-16DA44395D73061538E3801F81E5A68D" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34506804e5465-wk-Fact-A161DD024D9F78FE3297801F82161F7E" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34506804e5486-wk-Fact-E188FF1B79A2458CF37A801F81E69759" name="us-gaap:CostOfGoodsAndServicesSold" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34506804e5509-wk-Fact-81475F9812C2036C8F54801F821721D4" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34506804e5529-wk-Fact-3E8F06EF234D88E987EF801F821B72E3" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34506804e5549-wk-Fact-55FAF1E14383FE9A5716801F81DC7AAF" name="us-gaap:SellingGeneralAndAdministrativeExpense" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e5578-wk-Fact-FA33375103F0D9AB7DC6801F81DED8EA" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5597-wk-Fact-868049DF95AAA71CE427801F81DEE776" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5616-wk-Fact-52CE05D4D58AA63DFD75801F8215C3D3" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">222</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other income/(deductions)&#8212;net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34506804e5644-wk-Fact-725EA7A18943A5F5A993801F8216D9F7" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">362</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5663-wk-Fact-C89921B0CDF57E82D509801F81DD2CD9" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5682-wk-Fact-95B614941C4A9D8BE504801F81DF6C76" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents sales to our partners of products manufactured by us.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in each of the periods presented reflect increases in alliance revenues from Eliquis and Xtandi.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34506804e5796-wk-Fact-F931C5FC13CE7B1730D4801F7E158B86" name="pfe:CollaborativeArrangementUpfrontAndMilestonePayments" contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34506804e5804-wk-Fact-C208ABE0944AC41B18BE801F7E926471" name="pfe:CollaborativeArrangementUpfrontAndMilestonePayments" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. There were </span><span style="font-family:Arial;font-size:7pt;">no</span><span style="font-family:Arial;font-size:7pt;"> upfront and milestone payments in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">. Our collaboration with Lilly (see below) also includes reimbursements of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34506804e5824-wk-Fact-4459DCA7DE631BFB2D7D801F803878A3" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34506804e5832-wk-Fact-3EF8A54A3B4DC8EBB7BE801F7EAA0046" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">98</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34506804e5841-wk-Fact-13D2E85B97ABBA3D8A1C801F7E310712" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-0CD3AB4C217E2BDA80FB801F8303CE8E-1" continuedAt="TextSelection-0CD3AB4C217E2BDA80FB801F8303CE8E-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-0CD3AB4C217E2BDA80FB801F8303CE8E-2"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to royalties from our collaboration partners. </span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The amounts disclosed in the above table do not include transactions with third parties other than our collaboration partners, or other costs associated with the products under the collaborative arrangements.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition, in connection with our collaborative arrangements, we paid post-approval milestones of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e5891-wk-Fact-E6464EADDEED74D5E50D801F7E79FC67" name="pfe:PrepaymentsandPaymentstoCollaborators" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e5899-wk-Fact-C6F667B7E72C2EE962DACF542D0F85F7" name="pfe:PrepaymentsandPaymentstoCollaborators" contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> related to our collaboration with Merck KGaA (see below). These payments were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights. </span><span style="font-family:Arial;font-size:8pt;">We did not pay post-approval milestones to collaboration partners in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">. We also recorded milestones earned related to (i) our collaboration with Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub&#174;, a generic of Advair Diskus&#174; (fluticasone propionate and salmeterol inhalation powder) of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e5920-wk-Fact-5835DC1A6A915225A9600FFCFE38DEB7" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">) and (ii) our </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">84</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-8"><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">collaboration with Merck (see below) of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e5940-wk-Fact-6F4495CFCE1DF91F84C7801F7E10B364" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2018 in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e5948-wk-Fact-B163B6E925A72E83E353801F7E1248A8" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, substantially all of which was included in the adjustment to increase the opening balance of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"> upon the adoption of a new accounting standard for revenue recognition, effective January 1, 2018.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Collaboration with Merck &amp; Co., Inc.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Under a worldwide collaboration agreement, except for Japan, we collaborated with Merck on the clinical development of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets, which were approved by the FDA in December 2017 and the EC in March 2018 as Steglatro, Segluromet and Steglujan. Merck exclusively promotes Steglatro and the two fixed-dose combination products and we share revenues and certain costs with Merck on a </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5969-wk-Fact-A038863CC52D0D3FE3E9801F7E453EE9" name="pfe:CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">/</span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5973-wk-Fact-B2D96210B463227E337F801F824F3A11" name="pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> basis, with Pfizer having the </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34506804e5977-wk-Fact-B2D96210B463227E337F801F824F3A11" name="pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> share. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the first quarter of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2017</span><span style="font-family:Arial;font-size:8pt;">, we received a </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e5988-wk-Fact-E8A8A1B02F5E6446CF60801F7E175019" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2017Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment from Merck upon the FDA&#8217;s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which, as of December 31, 2017, was deferred and primarily reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities, </span><span style="font-family:Arial;font-size:8pt;">and through December 31, 2017, was being recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> over a multi-year period. As of December 31, 2017, we were due a </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6000-wk-Fact-93A9FCCAB5CDC404537D801F7E7AA5B9" name="pfe:CollaborativeArrangementMilestonePaymentReceivable" contextRef="FI2017Q4_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment from Merck, which we received in the first quarter of 2018, in conjunction with the approval of ertugliflozin by the FDA. As of December 31, 2017, the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6005-wk-Fact-EC4A9E54B7BAF8048F75801F7E4A07C4" name="pfe:CollaborativeArrangementDeferredMilestonePayment" contextRef="FI2017Q4_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> due from Merck was deferred and primarily reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">. In the first quarter of 2018, in connection with the approval of ertugliflozin in the EU, we recognized a </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6013-wk-Fact-CEECCA4D7D7866D636BF801F7E3379BD" name="pfe:CollaborativeArrangementMilestonePaymentReceivable" contextRef="FI2018Q1_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment from Merck in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">). We are eligible for additional payments associated with the achievement of future commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard for revenue recognition, as of January 1, 2018, the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6025-wk-Fact-3BDA3AA292AFCFEA0BF1801F7FFA828D" name="pfe:CollaborativeArrangementDeferredMilestonePayment" contextRef="FI2018Q1_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of deferred income and approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6030-wk-Fact-FC8128034C8C3B9D8145801F7E41D02C" name="pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized" contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6034-wk-Fact-D1271CABBF13B1912B13801F80802437" name="pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized" contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of deferred income associated with the above-mentioned milestone payments were recorded as a cumulative effect adjustment to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Collaboration with Eli Lilly &amp; Company</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer&#8217;s tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. We received a </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6050-wk-Fact-A7DF59A2823657DD7E8D801F807E6427" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2013Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_BalanceSheetLocationAxis_pfe_DeferredRevenueMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which was deferred and primarily reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities, </span><span style="font-family:Arial;font-size:8pt;">and through December 31, 2017, was being recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard for revenue recognition, as of January 1, 2018, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6062-wk-Fact-462950995AE174C0887E801F7DF66066" name="pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized" contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_BalanceSheetLocationAxis_pfe_DeferredRevenueMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of deferred income associated with the above-mentioned upfront payment was recorded as a cumulative effect adjustment to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;">. Approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6071-wk-Fact-90197255FB5636C73542801F7EAAAF7A" name="pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of the upfront payment continues to be deferred, and is reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. This amount is being recognized in</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> over the remaining development period for the product in 2020.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Collaboration with Merck KGaA</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In November 2014, we entered into a collaborative arrangement with Merck KGaA, to jointly develop and commercialize avelumab, currently approved as Bavencio for metastatic MCC in the U.S., the EU, Japan and select other markets, in combination with Inlyta for the first-line treatment of patients with advanced RCC in the U.S., the EU, Japan and select other markets, as well as for the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma in the U.S. and select other markets. Avelumab is also in development as a potential treatment for multiple other types of cancer. We and Merck KGaA are exploring the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with our and Merck KGaA&#8217;s broad portfolio of approved and investigational oncology therapies. Also, as part of the agreement, we gave Merck KGaA certain co-promotion rights for Xalkori in the U.S. and several other key markets. Under the terms of the agreement, in the fourth quarter of 2014, we made an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6095-wk-Fact-1309562FA35D882361EB801F824C9DD7" name="pfe:CollaborativeArrangementUpfrontAndMilestonePayments" contextRef="FD2014Q4QTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_pfe_CollaborativeArrangementUpfrontCashPaymentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">850</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to Merck KGaA and Merck KGaA is eligible to receive regulatory and commercial milestone payments of up to approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6099-wk-Fact-7006CB4ABF913028435E801F824D60AB" name="pfe:CollaborativeArrangementContingentPaymentsMaximumExposure" contextRef="FD2014Q4QTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">. During 2017, we made </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6103-wk-Fact-C6F667B7E72C2EE962DACF542D0F85F7" name="pfe:PrepaymentsandPaymentstoCollaborators" contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in milestone payments to Merck KGaA, which were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights, </span><span style="font-family:Arial;font-size:8pt;">for approvals of avelumab received in 2017 for the MCC indication in the U.S., the EU and Japan, and for the metastatic urothelial carcinoma indication in the U.S. </span><span style="font-family:Arial;font-size:8pt;">Both companies jointly fund the majority of development and commercialization costs, and split equally any profits related to net sales generated from selling any products containing avelumab from this collaboration.</span><span style="font-family:Arial;font-size:8pt;"> In December 2018, both companies amended the collaborative agreement such that Pfizer will be solely responsible for the development and commercialization of its anti PD-1 antibody. Under the terms of the amended agreement, we paid Merck KGaA an up-front payment and we will make a potential milestone and tiered royalty payments should the Pfizer anti PD-1 antibody achieve regulatory and commercial success. We made </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34506804e6216-wk-Fact-E6464EADDEED74D5E50D801F7E79FC67" name="pfe:PrepaymentsandPaymentstoCollaborators" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in milestone payments to Merck KGaA, which were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights,</span><span style="font-family:Arial;font-size:8pt;"> for the U.S. and the EU approvals received in 2019 related to the use of Bavencio in combination with Inlyta for the first-line treatment of patients with advanced RCC.</span></div></ix:continuation><div><a id="s2BF4607041535477BCF02578A8F556A0"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 3</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-0-wk-Fact-56C11D9BB3DA16C398EA801F815764AF" continuedAt="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span></ix:nonNumeric></div><ix:continuation id="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-1" continuedAt="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">85</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-2" continuedAt="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-3"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as groups such as information technology, shared services and corporate operations. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">2017-2019 Initiatives and Organizing for Growth</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">During 2018, we determined that at the start of our 2019 fiscal year, we would begin operating under our new commercial structure, which reorganized our operations into three businesses</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">Biopharma,</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">a science-based innovative medicines business; Upjohn, a global, primarily off-patent branded and generic established medicines business; and through July 31, 2019, a Consumer Healthcare business (See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17</span><span style="font-family:Arial;font-size:8pt;">). To operate effectively in this structure and position ourselves for future growth, we focused on creating a simpler, more efficient operating structure within each business as well as the functions that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new structure and combined the 2017-2019 initiatives with our Organizing for Growth initiatives to form one cohesive plan. Initiatives for the combined program included activities related to the optimization of our manufacturing plant network, the centralization of our corporate and platform functions, and the simplification and optimization of our operating business structure and functions that support them. From 2017 through December 31, 2019, we incurred approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1345-wk-Fact-24F95B4A48115E7D9824550A385C7315" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">921</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with manufacturing optimization, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1349-wk-Fact-7F89C5B8FBA256B399D166B53D1171C4" name="us-gaap:RestructuringAndRelatedCostCostIncurredToDate1" contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_OtherActivitiesMember_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> associated with other activities, and have substantially completed this program.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Transforming to a More Focused Company</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">With the formation of the GSK Consumer Healthcare venture and the pending combination of Upjohn with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base as a result of both the completed Consumer Healthcare and expected Upjohn transactions.&#160;While certain direct costs have transferred or will transfer to the Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;D, Manufacturing and Commercial.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We expect the costs associated with this multi-year effort to continue through 2022 and to total approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1362-wk-Fact-D7AE96CB42E95D9285D30E8FF3BF0F06" name="us-gaap:RestructuringAndRelatedCostExpectedCost1" contextRef="FI2019Q4_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> on a pre-tax basis and approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1366-wk-Fact-EF31A94230125A87BF09B55A8734C3FA" name="pfe:RestructuringandRelatedCostNoncashChargesPercentage" contextRef="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of this to be non-cash. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs are currently in development but will include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Current-Period Key Activities</span></div><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, we incurred costs of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1381-wk-Fact-F0744E01A0FB5DFEA7D16C346630F69E" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">967</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> composed of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1385-wk-Fact-EAF9566A792158DBB4D8F5DB6EAC565F" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">695</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with 2017-2019 Initiatives and Organizing for Growth, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1389-wk-Fact-D366DE5A260059998E345C38D8B662E8" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">288</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the integration of Array, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1393-wk-Fact-1AEBA4704C0C536D87CF3B46F4055CD6" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the integration of Hospira, and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1398-wk-Fact-C827156933C6D7E41FB1DF3BC04EEF1B" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the Transforming to a More Focused Company initiative, partially offset by income of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34468079e1402-wk-Fact-885B1F7F683852998AAB24877643C16E" name="us-gaap:RestructuringAndRelatedCostIncurredCost" contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">197</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, primarily due to the reversal of certain accruals upon the effective favorable settlement of a U.S. IRS audit for multiple tax years and other acquisition-related initiatives.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock" id="TextSelection-C4E60A7004F00BD70FBB801F8306C89A-0-wk-Fact-A5D8D9B6A624D074088B801F7F501A00" continuedAt="TextSelection-C4E60A7004F00BD70FBB801F8306C89A-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges/(credits):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e1718-wk-Fact-BE908F2453EA50FA8150D8F2D27D26EA" name="us-gaap:SeveranceCosts1" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1737-wk-Fact-2B433FF03CAB56B5838157F4075CF704" name="us-gaap:SeveranceCosts1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34468079e1757-wk-Fact-C9D679DF86868316C76A801F7EAE0194" name="us-gaap:SeveranceCosts1" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset impairments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e1780-wk-Fact-1E3FF9437BEA5C5E903FC608EF1570C3" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1799-wk-Fact-5C1105B34A8A5168A29CDA6A58BEDCE8" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1818-wk-Fact-8847B6BEC2EEE8F6B106801F81DD12BF" name="pfe:RestructuringAssetImpairmentCharges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e1844-wk-Fact-8096B46077615DE7AF9036BAB775555D" name="us-gaap:BusinessExitCosts1" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1863-wk-Fact-4B798D68157055D3B944663B4AE87FE6" name="us-gaap:BusinessExitCosts1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1882-wk-Fact-4528BBA3F3476E752AC6801F7F2FFC8F" name="us-gaap:BusinessExitCosts1" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e1910-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1929-wk-Fact-0FFA20352D33594482BE61F2516C104D" name="us-gaap:RestructuringCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1948-wk-Fact-7FFA047BAF9ADE9DA824801F81229B16" name="us-gaap:RestructuringCharges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Transaction costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e1976-wk-Fact-1720732DC86856B0BBAA3408390B34EC" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e1995-wk-Fact-5C6CEA6ACFCD5D859F39208DA973ACEC" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2014-wk-Fact-09785B23D3307BE69A79801F8181F4E8" name="pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Integration costs and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2042-wk-Fact-559668800F8D5F39871CB0D8FAB473CD" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2061-wk-Fact-D8F202BB5B6A5B28A9A31C0EB79F405E" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2080-wk-Fact-CBD997DC56489F4D822B801F818B8507" name="us-gaap:BusinessCombinationIntegrationRelatedCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2106-wk-Fact-61EEF037EA245BC58651F6491A13B057" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">747</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2125-wk-Fact-20A55537F0675518894025A232665AAA" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,044</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2144-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409" name="pfe:RestructuringChargesAndAcquisitionRelatedCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit costs recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2175-wk-Fact-F6552983FEE057A7B0758F714B47B201" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2194-wk-Fact-6828C32532055C2D9F9FCA7D73FE1813" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2213-wk-Fact-726DD7EC40B27F8510DA801F81EF7AF4" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;</sup></span><span style="font-family:Arial;font-size:8pt;">recorded in our consolidated statements of income as follows</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2314-wk-Fact-B984EC8BD3C15978AA373038C05C04C3" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2333-wk-Fact-A80DE1A520AD557392F9597D3D60F83A" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2352-wk-Fact-48FBE878E867A2126357801F828892B1" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2378-wk-Fact-3F54F0E033DA5F4EB9E1DB8292AC5F35" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2397-wk-Fact-2955D81BA66657739DD6267CF9D38630" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2416-wk-Fact-9EBE45B86EF3A4ED4BB6801F7E8624C1" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2442-wk-Fact-00B28A85A0415720B146A31F5401E641" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2461-wk-Fact-F2F4F04B9714562C8431CD66A86B0259" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2480-wk-Fact-C61A53394E697A7EF8C6801F7E98760D" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2506-wk-Fact-E1D5C5643E20593EBC9062EA4C0879C4" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2525-wk-Fact-D3FD2148011D5F65AD0C27F9F1F55576" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2544-wk-Fact-D1EEE24D840C1A7260A5801F823B70E3" name="us-gaap:RestructuringReserveAcceleratedDepreciation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Implementation costs recorded in our consolidated statements of income as follows</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2641-wk-Fact-A42CFC7A5BC659D7A3189F4AF6F5EC83" name="pfe:ImplementationCosts" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2660-wk-Fact-3B3FED2A33115ED2B476EFD5B5811F3E" name="pfe:ImplementationCosts" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2679-wk-Fact-7A1567D519C2CFE241FC801F7EDF7AAB" name="pfe:ImplementationCosts" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2705-wk-Fact-56CA584C4B365E4B845856D506783484" name="pfe:ImplementationCosts" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2724-wk-Fact-901416E0C584524B87DD0ACFD655A517" name="pfe:ImplementationCosts" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2743-wk-Fact-37BB967598E60C472CDF801F80B12AD6" name="pfe:ImplementationCosts" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2769-wk-Fact-8E28EFA6EB215BD0993C634ED8262AFF" name="pfe:ImplementationCosts" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2788-wk-Fact-648F7B6A7F165EE0A40B6056F82B93C7" name="pfe:ImplementationCosts" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2807-wk-Fact-0B920E93F75F59F63ECE801F80F39A24" name="pfe:ImplementationCosts" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2833-wk-Fact-7C5CEEA458045143ABEBEAB70E5E4CE1" name="pfe:ImplementationCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2852-wk-Fact-C6ADF4DB93D254E5BD23EA5C35CC303C" name="pfe:ImplementationCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2871-wk-Fact-1F2788F8C7EAC31BDBAF801F7E00C985" name="pfe:ImplementationCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e2903-wk-Fact-A1E43A2C3B855213AF3B8554389B681D" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">967</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2922-wk-Fact-45894ADF56F25DBEADA95E5BD8039DA0" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e2942-wk-Fact-A2D16AA3017966681D6D801F81781BDA" name="pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">805</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The asset impairment charges for </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> are largely associated with cost reduction initiatives not associated with acquisitions. The asset impairment charges for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are primarily associated with abandoned assets. See (b) below for additional information.</span></div></ix:footnote></td></tr></table></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">86</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-3" continuedAt="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-4"><ix:continuation id="TextSelection-C4E60A7004F00BD70FBB801F8306C89A-1" continuedAt="TextSelection-C4E60A7004F00BD70FBB801F8306C89A-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-13B5F01039B0051B8C7A801F83041E59-1"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5B</span><span style="font-family:Arial;font-size:7pt;">). In 2018, restructuring charges were primarily related to employee termination costs and asset write downs. The employee termination costs for 2019 and 2018 were primarily associated with our improvements to operational effectiveness as part of the realignment of our organizational structure, and for 2019, also includes employee termination costs associated with the Transforming to a More Focused Company initiative. In </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, restructuring charges were primarily associated with our acquisitions of Hospira and Medivation, partially offset by credits associated with cost-reduction and productivity initiatives not associated with acquisitions that mostly related to the reversal of previously recorded accruals for employee termination costs resulting from revisions of our severance benefit estimates. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span></div></ix:footnote></td></tr></table><ix:continuation id="TextSelection-13B5F01039B0051B8C7A801F83041E59-1" continuedAt="TextSelection-13B5F01039B0051B8C7A801F83041E59-2"><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biopharma (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e2999-wk-Fact-64CF7C8E2712CFF754E8DF537C7026EE" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">118</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); Upjohn (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e3003-wk-Fact-14E4EFD0594C358063DEDF53E92DE6CD" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e3007-wk-Fact-83DEF9E24F2573FC1B5BDF53FCF75417" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:18px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate 2018 and 2017 restructuring charges with the new individual segments.</span></div><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities for </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total reportable segments (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e3028-wk-Fact-364749052680DD985FE8DF57BFD46E59" name="us-gaap:RestructuringCharges" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">207</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e3032-wk-Fact-02CBB78F6D9F27211F2EDF584015F818" name="us-gaap:RestructuringCharges" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">575</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge). </span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:24px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-13B5F01039B0051B8C7A801F83041E59-2" continuedAt="TextSelection-13B5F01039B0051B8C7A801F83041E59-3"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-13B5F01039B0051B8C7A801F83041E59-3"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total reportable segments (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e3051-wk-Fact-AE30A8C819EF462FD6DCDF58B3545147" name="us-gaap:RestructuringCharges" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">89</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> credit); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e3055-wk-Fact-A71CF8F00EF366C0B730DF58EDFF80B7" name="us-gaap:RestructuringCharges" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge).</span></div></ix:continuation></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-247A3B89234CB67B20FD801F8304EDFE-1"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services. In 2019, transaction costs relate to our acquisition of Array. In 2017, transaction costs were directly related to our acquisitions of Hospira, Anacor and Medivation.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"><ix:continuation id="TextSelection-247A3B89234CB67B20FD801F8304EDFE-1"></ix:continuation>(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-1D4C65BD347685B92550801F8304BE9A-1"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, integration costs and other mainly related to our acquisitions of Array (including </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e3123-wk-Fact-5162BD37F8C9541ABBF3ACA81FB246B3" name="us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IncomeStatementLocationAxis_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">157</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">)) and Hospira. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, integration costs and other mostly related to our acquisition of Hospira. In 2017, integration costs primarily related to our acquisitions of Hospira and Medivation, as well as a net gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e3135-wk-Fact-DABEA993F2C7DDD92BE0801F7F1190FF" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"><ix:continuation id="TextSelection-1D4C65BD347685B92550801F8304BE9A-1"></ix:continuation>(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-D8566474AE21E37301E8801F8304D0E0-1"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2018, primarily represents the net pension curtailments and settlements included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">upon the adoption of a new accounting standard in the first quarter of 2018. In 2017, mainly represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"><ix:continuation id="TextSelection-D8566474AE21E37301E8801F8304D0E0-1"></ix:continuation>(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></ix:footnote></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-C4E60A7004F00BD70FBB801F8306C89A-2" continuedAt="TextSelection-C4E60A7004F00BD70FBB801F8306C89A-3"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-C4E60A7004F00BD70FBB801F8306C89A-3"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">I<ix:footnote id="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US">mplementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</ix:footnote></span></div></ix:continuation></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock" id="TextSelection-41160BB593BAEABA27A3801F83054962-0-wk-Fact-30C4BC67732AC5FAAC2A801F8179FE0B" continuedAt="TextSelection-41160BB593BAEABA27A3801F83054962-1" escape="true"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Termination</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impairment</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, January 1, 2018 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3461-wk-Fact-1AD523662FC594F56AF7801F7F6374E9" name="us-gaap:RestructuringReserve" contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,039</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3480-wk-Fact-A5BB74C41800892C284F801F7F6D5279" name="us-gaap:RestructuringReserve" contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3500-wk-Fact-B363698564CC60A8F987801F7F83CEF8" name="us-gaap:RestructuringReserve" contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3519-wk-Fact-FB9F815761D4E6FE8EF6801F7F625307" name="us-gaap:RestructuringReserve" contextRef="FI2017Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3539-wk-Fact-07DA85B128480ADDAA18801F7FA181C3" name="us-gaap:RestructuringCharges" contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3558-wk-Fact-17DE2955CFE34577B72B801F7F7E553C" name="us-gaap:RestructuringCharges" contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3577-wk-Fact-85674BF73C1723FE154B801F7F6023E6" name="us-gaap:RestructuringCharges" contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3597-wk-Fact-0FFA20352D33594482BE61F2516C104D" name="us-gaap:RestructuringCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Utilization and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34468079e3624-wk-Fact-DDF2C025AF9CF365CD89801F7F653ACA" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34468079e3644-wk-Fact-464A486895AEEBF8EC5F801F7FA5F9F7" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34468079e3664-wk-Fact-0DABBE66E4D8805F212A801F7F93FAD2" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34468079e3685-wk-Fact-4EC473580DFC97201347801F7F618775" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, December 31, 2018</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3713-wk-Fact-8B63FA0079F150DF8891946F5AC894DF" name="us-gaap:RestructuringReserve" contextRef="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,203</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3732-wk-Fact-B9F8D9C900D35DCE8A6D80AA6FAD17C8" name="us-gaap:RestructuringReserve" contextRef="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3751-wk-Fact-F2E147AA2E8654AB8038D339B5F38F4E" name="us-gaap:RestructuringReserve" contextRef="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34468079e3771-wk-Fact-CB5261FF2DCF567B98B84D4EEBACC61C" name="us-gaap:RestructuringReserve" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Provision</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e3798-wk-Fact-5F0D40017013586D8F17BC834125A378" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">239</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e3817-wk-Fact-5D65BE3231925A3690D7162CD4FAA218" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e3836-wk-Fact-13B8F46793BB5B219C40DD3378500D40" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e3856-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3" name="us-gaap:RestructuringCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Utilization and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34468079e3883-wk-Fact-204C8AF80ED25BDE9A77B2C926C838B9" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">555</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34468079e3903-wk-Fact-ECAA0C7EF7645E87A5DF7782CF068255" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">81</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34468079e3923-wk-Fact-942BEE47CDD75096A0AEFEFF55769ACA" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34468079e3944-wk-Fact-190D7B7514575574AE1769D904D6CA82" name="pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance, December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e3977-wk-Fact-8A3D3D8306295DD7A9624AA8071C2632" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">887</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e3996-wk-Fact-5438260A5AB3500C8619EA7A64AD5E8B" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e4016-wk-Fact-34056A88C0D75E6C9FEE2D3BDD894FE8" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34468079e4035-wk-Fact-0DC222C12EB155DBBE6BAFA5807A4EE1" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes adjustments for foreign currency translation.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e4064-wk-Fact-7AB2F2EE679D5ADC924CD773BACAE5BB" name="us-gaap:RestructuringReserve" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">823</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e4072-wk-Fact-69A2DA9CA81853E1BF49E1F300B9A667" name="us-gaap:RestructuringReserve" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">428</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5D</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></ix:footnote></td></tr></table></ix:nonNumeric></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-41160BB593BAEABA27A3801F83054962-1" continuedAt="TextSelection-41160BB593BAEABA27A3801F83054962-2"><ix:continuation id="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-4" continuedAt="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-5"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-41160BB593BAEABA27A3801F83054962-2"><ix:continuation id="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-5"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other current liabilities </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e4144-wk-Fact-6515848AB69B5943967B3AD5A80D285F" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34468079e4152-wk-Fact-8CE5D6955AF7510A8AC5F2E039DBAF62" name="us-gaap:RestructuringReserve" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">219</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">87</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sFEE07FD238EC532D8F9657697FABE5C9"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 4.</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;"> </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock" id="TextSelection-826105A02755431DA39A801F830ED4AF-0-wk-Fact-2DFC020800236EB46466801F823B863D" continuedAt="TextSelection-826105A02755431DA39A801F830ED4AF-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8212;Net</span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" id="TextSelection-5DB921DE076476C9D7E1801F830E43C0-0-wk-Fact-3A7CE1EDDD2BAED269E6801F80B71CAD" continuedAt="TextSelection-5DB921DE076476C9D7E1801F830E43C0-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34471435e1554-wk-Fact-2B2A9C8657C8CAF5F992801F80CD8F28" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e1574-wk-Fact-3C5E1456EFEB580EB0B057546407A424" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e1595-wk-Fact-3C9472B7B150D7664833801F80B066CF" name="us-gaap:InvestmentIncomeInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest expense</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e1618-wk-Fact-C811C044F93768A92542801F80F5DB92" name="us-gaap:InterestExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e1637-wk-Fact-D1493B6B95195AACB13FF4316F418040" name="us-gaap:InterestExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,316</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e1656-wk-Fact-813E0BD933FADF623E45801F80DB191F" name="us-gaap:InterestExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,270</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e1682-wk-Fact-FA8FA8545A905408BEAE292045650881" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e1701-wk-Fact-9D91736F368753D8933FDDCC4EBA4F82" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e1720-wk-Fact-2BCA4DCC54ACAAB37390801F80D172EF" name="us-gaap:InterestRevenueExpenseNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Royalty-related income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34471435e1748-wk-Fact-D46423C593ED51E19EFC3DB182C18357" name="us-gaap:RoyaltyIncomeNonoperating" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">648</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e1768-wk-Fact-6B8F488463125E46B584902709E619F5" name="us-gaap:RoyaltyIncomeNonoperating" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e1788-wk-Fact-E0737BFD19C0100A5FE8801F80CB7FAE" name="us-gaap:RoyaltyIncomeNonoperating" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">499</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net (gains)/losses on asset disposals</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34471435e1817-wk-Fact-528109C6117952069FCC0A02E9E0964C" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e1837-wk-Fact-FB53920211195F4191C78C4B2EA1ECDE" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e1857-wk-Fact-B712982E5A7317455650801F80ECC2E5" name="us-gaap:GainLossOnDispositionOfAssets1" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net gains recognized during the period on equity securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34471435e1885-wk-Fact-364D49347A25577A9FDDC9569F869ED0" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e1905-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e1925-wk-Fact-0F5337E2D08EAAB68D68801F80EB1026" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net realized (gains)/losses on sales of investments in debt securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e1954-wk-Fact-BB9B4543336C561697FD0F59A7D23B67" name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e1973-wk-Fact-50D8069E0C6A50D989482D5B5834E63D" name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e1992-wk-Fact-0D4501C3F382F4D74FB6801F80B5B5B4" name="us-gaap:DebtSecuritiesRealizedGainLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34471435e2021-wk-Fact-58D64728C9445B32B7001C141E840546" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e2041-wk-Fact-D580F9F59A215E69A2F8C8CF9897A050" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">488</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e2061-wk-Fact-BC2A634BA20E3AB6E549801F823C4316" name="pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit costs/(credits) other than service costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e2091-wk-Fact-DCBD066B5B3F57A98C5A6477D74A4C3D" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e2110-wk-Fact-7A7351669AE1529E97E70E745B581A4A" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2130-wk-Fact-11293434603BE982F98F801F80B2BCE9" name="us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain legal matters, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e2158-wk-Fact-19792256C9155CD4A4B30F1FFD71D2BF" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2177-wk-Fact-8376203D932F5639A955E3156349142D" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">157</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2196-wk-Fact-3CE8EBCFF7A37827A78B801F80EE18A9" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain asset impairments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e2224-wk-Fact-B70F6FAB9C4E502489A9A03753771E32" name="us-gaap:AssetImpairmentCharges" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2243-wk-Fact-31EE472AE3C7503BA361B44F0445BA6E" name="us-gaap:AssetImpairmentCharges" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2262-wk-Fact-F2F93F5F2FC3C51352FB801F80F4AFFE" name="us-gaap:AssetImpairmentCharges" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">395</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Business and legal entity alignment costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e2290-wk-Fact-372575356B8E57CCAFE65ACA01B572B8" name="pfe:BusinessAlignmentCosts" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">338</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2309-wk-Fact-274A4E3678CE5C1E9A3DE2C7A5DF6A4D" name="pfe:BusinessAlignmentCosts" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2328-wk-Fact-6D614FEC811C0CB49DA6801F823ECDD2" name="pfe:BusinessAlignmentCosts" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net losses on early retirement of debt</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e2356-wk-Fact-644EBFAF34BD5FBA9B1CF394FD689FBB" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2375-wk-Fact-7DDB8A53183E908A30E5801F80CDA452" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2394-wk-Fact-13FBCE16090D77486260801F80AF4E2A" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">GSK Consumer Healthcare JV equity method (income)/loss</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34471435e2422-wk-Fact-B86C473D53F433E01138E3D722277F0D" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2442-wk-Fact-7993C88B8674482BA763E3D78533039D" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2461-wk-Fact-D3148F133483360760CAE3D7A356B4E2" name="pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(m)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34471435e2489-wk-Fact-0B4B7D09A234587DBD0FEB3766ED94BB" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">388</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e2509-wk-Fact-1A6E3FA2203C5CDDA2BD99ED3CEEEA51" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">417</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34471435e2529-wk-Fact-BCF75818718DFBE05AB3801F80FDBB16" name="pfe:OtherNonoperatingIncomeExpenseNet" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">328</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e2561-wk-Fact-58A10D106477541896C64514721528B2" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,578</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2580-wk-Fact-F590D4C627155C828C90476F227A1511" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34471435e2600-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927" name="us-gaap:OtherNonoperatingIncomeExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="TextSelection-5DB921DE076476C9D7E1801F830E43C0-1" continuedAt="TextSelection-5DB921DE076476C9D7E1801F830E43C0-2"><ix:continuation id="TextSelection-826105A02755431DA39A801F830ED4AF-1" continuedAt="TextSelection-826105A02755431DA39A801F830ED4AF-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;Interest income decreased primarily driven by a lower investment balance. Interest expense increased mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year period. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;Interest income decreased primarily driven by a lower investment balance. Interest expense increased primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017. Capitalized interest expense totaled </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2636-wk-Fact-5235225ADE188E03402A801F824771B5" name="us-gaap:InterestCostsCapitalized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, $</span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34471435e2644-wk-Fact-F890E2D2FC370D2706C3801F80B6F568" name="us-gaap:InterestCostsCapitalized" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and $</span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34471435e2653-wk-Fact-7FE0123B867DECE583EF801F80ED4EA5" name="us-gaap:InterestCostsCapitalized" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Royalty-related income </span><span style="font-family:Arial;font-size:7pt;">increased</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, primarily due to a one-time favorable resolution in the second quarter of </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> of a legal dispute for </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2689-wk-Fact-B43F7B053D7E59F6B88D8574E3EC4B5C" name="us-gaap:ProceedsFromLegalSettlements" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily included a realized gain on sale of property of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2711-wk-Fact-B57C908DD253153CF24A801F8247C249" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">. In </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, primarily included an </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2719-wk-Fact-E4E691C290056D92F9C5801F80EFA503" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> realized loss related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34471435e2723-wk-Fact-C1577C38066176D10EAC801F80EADEC6" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;">-owned equity-method investment in Hisun Pfizer and a realized net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2728-wk-Fact-334BEB1ABA3E2F123F0F801F7EFEBE74" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34471435e2732-wk-Fact-CACD50923894EDD99872801F80B0B6C2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the then remaining </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34471435e2736-wk-Fact-18D02467A559416641BC801F82423683" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="FI2017Q4_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership interest, partially offset by a realized gain on sale of property of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2740-wk-Fact-69AEF90E3186D6721976801F80E7F6F4" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">. </span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The gains in 2019 include, among other things, unrealized gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2755-wk-Fact-04F60A3E414CD2F241ABE3EFFA0096F9" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">295</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to investments in Cortexyme, Inc. and SpringWorks Therapeutics, Inc. The gains in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> included unrealized gains on equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2766-wk-Fact-A970E59AE1F26ACBAD36801F7F1604B0" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">477</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting the adoption of a new accounting standard in the first quarter of 2018 and were primarily driven by unrealized gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2770-wk-Fact-84F9F87ED8E49B6F0322801F7EFABC9F" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">466</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to our investment in Allogene. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7B</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2018, primarily includes gross realized losses on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2796-wk-Fact-004D224EE01D2948B0B7E3F2CE7152F9" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">402</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2800-wk-Fact-87A4F3641AAEC2B2D8F5E3F322880714" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">18</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities, partially offset by gross realized gains on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2804-wk-Fact-7F49C9F6FD160EA29BA8E3FC2949637C" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">280</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">. Proceeds from the sale of available-for-sale debt securities were </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2808-wk-Fact-46B1D276FC9164CE6226E3FC6462E9EE" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> in 2018. In 2017, primarily includes gross realized gains on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2812-wk-Fact-651B86B3A1644EE8E8DFE3FCA782953B" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">451</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, partially offset by gross realized losses on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2817-wk-Fact-E3B65CD44F857A7FB9C1E3FD0826888C" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2821-wk-Fact-DEB72249336B456167F3E3FF2E934DF7" name="us-gaap:GainLossOnDerivativeInstrumentsNetPretax" contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">120</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debt securities were </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2825-wk-Fact-B889D85343AC5CDC9870E3FF809FDFF6" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> in 2017.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, mainly includes, among other things, </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2846-wk-Fact-5835DC1A6A915225A9600FFCFE38DEB7" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">, a generic of Advair Diskus</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">(fluticasone propionate and salmeterol inhalation powder) and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2858-wk-Fact-485AEAE0E42D5A18A290481FA47A4259" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from multiple licensees. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes, among other things, (i) approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2867-wk-Fact-4F9D6F155F741267B53FE4034C447D72" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">118</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from multiple licensees, (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2871-wk-Fact-761A93B33CF65581E410801F823D8C66" name="pfe:ProceedsFromLicensingArrangement" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone payments received from Shire, of which </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2875-wk-Fact-F4371ABC579CB963235C801F80CF3AE8" name="pfe:ProceedsFromLicensingArrangement" contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of ulcerative colitis and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2879-wk-Fact-6B9F402AA8B68FB924E1801F7DF7B11B" name="pfe:ProceedsFromLicensingArrangement" contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn&#8217;s disease, (iii) an upfront payment to us and a recognized milestone totaling </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2884-wk-Fact-FEB456A1917AB5E671F6801F7EFFEAEE" name="us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration" contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> for the sale of an AMPA receptor potentiator for CIAS to Biogen, (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2888-wk-Fact-3EB7ADBE9CCB7DB05414801F80C9FF93" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" contextRef="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in gains related to sales of compound/product rights and (v) a </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2892-wk-Fact-5CA1811E9BDCF0302608801F8247A337" name="us-gaap:ProceedsFromCollaborators" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2D </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</span><span style="font-family:Arial;font-size:7pt;">. In 2017, primarily includes, among other things, </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2904-wk-Fact-F3E183ABF14138D68140801F80890CE2" name="pfe:ProceedsFromLicensingArrangement" contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">101</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone payments received from multiple licensees and an </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2909-wk-Fact-C2429C6DAA41C84D4FA5801F824887B6" name="us-gaap:GainLossOnDispositionOfIntangibleAssets" contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> gain related to sales of compound/product rights. </span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">I<ix:footnote id="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-1">n 2019, primarily includes settlement losses within the U.S. Pfizer Consolidated Pension Plan related to special restructuring initiatives, a small annuity buyout program and regular lump sum activity. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for </ix:footnote></span><ix:continuation id="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-1"><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to 2017. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">.</span></ix:continuation></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, mostly includes legal reserves for certain pending legal matters. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes legal reserves for certain pending legal matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In 2017, primarily includes a </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2980-wk-Fact-9B54FC0F1D02D181288F801F7EFD355D" name="us-gaap:LitigationSettlementExpense" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which was approved by the court in April 2018, and a </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e2984-wk-Fact-666D4B08682B43C36845801F823F65F5" name="us-gaap:LitigationSettlementExpense" contextRef="FD2017Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge to reflect damages awarded by a jury in a patent matter.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-1"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3012-wk-Fact-410824BC55BD5125B692CC025A3ADB69" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">, mainly composed of: (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3016-wk-Fact-7D859E3866CB3AF41EF9E41D2013CCFE" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.6</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">, related to Eucrisa, a Biopharma finite-lived developed technology right acquired in connection with our acquisition of Anacor, and reflects updated commercial forecasts mainly reflecting competitive pressures; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3020-wk-Fact-120DFFCBD8C55A598D93A678B4F009DE" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_GeneTherapiesMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3024-wk-Fact-66781254418F59FCB02D385D42D0F9E4" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions; (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3029-wk-Fact-9883A55836FE9D7DB1C1E420C6801BDB" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma IPR&amp;D asset, acquired in connection with our acquisition of AstraZeneca&#8217;s anti-infectives business, which reflects updated commercial forecasts; (v) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3033-wk-Fact-4D4CA291BAE458C090F10D6D4CD134FE" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TreatmentForToenailFungusMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the </span></div></ix:footnote></td></tr></table></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">88</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-826105A02755431DA39A801F830ED4AF-2" continuedAt="TextSelection-826105A02755431DA39A801F830ED4AF-3"><ix:continuation id="TextSelection-5DB921DE076476C9D7E1801F830E43C0-2" continuedAt="TextSelection-5DB921DE076476C9D7E1801F830E43C0-3"><ix:continuation id="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-1"><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">U.S. market only, </span><span style="font-family:Arial;font-size:7pt;text-align:center;">and reflects</span><span style="font-family:Arial;font-size:7pt;">, among other things, updated commercial forecasts; and (vi) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3054-wk-Fact-EEAF3F751228C1976BDFE423B8E78A86" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of Innopharma.</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:1px;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3066-wk-Fact-46D0EBEAC481F3E003A8E42584F9BFDE" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">, mainly composed of (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3070-wk-Fact-E3AC35F114D6E5793435E42743531ACB" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.6</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma developed technology rights, </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3074-wk-Fact-DFB4CBF42A1D29C6CD53E427CF66D45C" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">242</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma licensing agreements and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3078-wk-Fact-C9C72BE5E041C8B13BCFE4282FC48AD1" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma IPR&amp;D, all of which relate to our acquisition of Hospira, for generic sterile injectable products associated with various indications; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3083-wk-Fact-BB65CA4C86C88A8ED1ECE42A25FEE224" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">117</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a multi-antigen vaccine IPR&amp;D program for adults undergoing elective spinal fusion surgery; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3087-wk-Fact-EEA91F40C06A2F62FC74E4291EF6DA0E" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to an Biopharma developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus market marketed in the U.S. market only; and (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3091-wk-Fact-63CAACB19640CEF34F5EE42998C91F1D" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of Innopharma. In 2018, the intangible asset impairment charges associated with the generic sterile injectable products reflect, among other things, updated commercial forecasts, reflecting an increased competitive environment as well as higher manufacturing costs, largely stemming from manufacturing and supply issues. The intangible asset impairment charge for the multi-antigen vaccine IPR&amp;D program was the result of the Phase 2b trial reaching futility at a pre-planned interim analysis. </span><span style="font-family:Arial;font-size:7pt;text-align:center;">The intangible asset impairment charge related to the </span><span style="font-family:Arial;font-size:7pt;">Biopharma developed technology right</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> reflects</span><span style="font-family:Arial;font-size:7pt;">, among other things, updated commercial forecasts. .</span></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2017, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3108-wk-Fact-0DB96D89C59B54A8C3EB801F80DC200F" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">337</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3112-wk-Fact-7411695F32DBAB6BEF4E801F80DB6913" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">127</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3116-wk-Fact-529F87DF004170B964DB801F82422BF8" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SterileInjectablePainRelieverMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3120-wk-Fact-60431E4C7A2BDF64B46C801F80B15BEB" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TreatmentOfAttentionHyperactivityDisorderMember_us-gaap_BusinessAcquisitionAxis_pfe_NextWaveMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3124-wk-Fact-459AC32F88910EB0AE27801F7EFFC506" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenericInjectablePainRelieverMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3129-wk-Fact-AFA012CED968899433A6801F8240AD80" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with Biopharma and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3133-wk-Fact-53AD1925EC34AC46119B801F80DEDB85" name="us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AMPharmaBVMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> for an impairment of our AM-Pharma B.V. long-term investment.</span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019 and 2018, mainly represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In 2017, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019 and 2017, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(m)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, includes, among other things, (i) dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3209-wk-Fact-293451C69DA75DC8A70D7BAEFB4F73E3" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, (ii) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3213-wk-Fact-97A07A88B994572FA52511223AB8DBC2" name="pfe:DeconsolidationExternalIncrementalCostsAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3217-wk-Fact-B06F61437C8457F4804C65B8FE9BFC57" name="us-gaap:InsuranceRecoveries" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> of income from insurance recoveries related to Hurricane Maria. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, includes, among other things, (i) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3226-wk-Fact-B92017FC9E90D38A36B6801F7EF53786" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">), (ii) dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3234-wk-Fact-99E3F4A21F825B05BD4E31F27E393D8A" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, (iii) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3238-wk-Fact-AFBF7664142F02703EC6801F80F1B3ED" name="pfe:GainLossFromContributionAgreement" contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain on the contribution of Pfizer&#8217;s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained an ownership stake in Allogene (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">), (iv) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3247-wk-Fact-8ECBDE405C33A1FF9D79801F80B2C01E" name="pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7E</span><span style="font-family:Arial;font-size:7pt;">), (v) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3255-wk-Fact-950F9736F5FA5CA8B49089B7C8C362F1" name="us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">207</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting the change in the fair value of contingent consideration. and (vi) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3259-wk-Fact-2E0E562A8A0E8D216B00E43D608AD298" name="pfe:DeconsolidationExternalIncrementalCostsAmount" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. In 2017, includes, among other things, dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3263-wk-Fact-D2DD3479116FE8BE100C801F82405EAA" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, and income of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34471435e3267-wk-Fact-6C3CC82B8C5AD303C0DF801F80DE21E1" name="pfe:OtherNonoperatingIncomeMiscellaneous" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> from resolution of a contract disagreement. </span></div></ix:footnote></td></tr></table></ix:continuation><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-5DB921DE076476C9D7E1801F830E43C0-3"></ix:continuation>The asset impairment charges included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> are based on estimates of fair value.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock" id="TextSelection-19978966E7FCBD7EB6CD801F830E3FA9-0-wk-Fact-4ADB6E87730BC8EADB47801F80ADC3BF" continuedAt="TextSelection-19978966E7FCBD7EB6CD801F830E3FA9-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides additional information about the intangible assets that were impaired during 2019 in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impairment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets&#8211;&#8211;Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3818-wk-Fact-CDFA015BEFBB5917ADD08A5A17C5EE6F" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3837-wk-Fact-D197856ADE315AF9B1BD0141D8126013" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3857-wk-Fact-18E37EACB23652878A34A31EF09685A7" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3876-wk-Fact-6D7C9A2836915BA9A1C8765EC5343BEF" name="us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3895-wk-Fact-5344A287AEC4338D220DE3C58F9727B5" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,639</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3921-wk-Fact-213E32B8B2FE51C690B80D561FAEFE40" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3939-wk-Fact-341D9ED90C94596BB9FAE98E1294E451" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3957-wk-Fact-86415D4CAB5E59DBBD55EC735E24E7F2" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3976-wk-Fact-D3A3B59227395C7B84054756B56717E7" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e3994-wk-Fact-0F2EB7A6D4B3040B6027E3C58F8C7591" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e4024-wk-Fact-6218C747DBEE55A9AF76EE26E178A31C" name="pfe:IntangibleAssetsFairValueDisclosure" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e4043-wk-Fact-62C2FD859415581FBF973FCE94B77BC7" name="pfe:IntangibleAssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e4063-wk-Fact-F16E0A41BA8953F7AFA1ACB2D90C1AB8" name="pfe:IntangibleAssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e4082-wk-Fact-FF50DEB8A335501E80F11891D08A50FF" name="pfe:IntangibleAssetsFairValueDisclosure" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34471435e4101-wk-Fact-0ED887E0106DA5C62DCAE3C58F9CB840" name="us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1E.</span></div></ix:footnote></td></tr></table></ix:nonNumeric></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-19978966E7FCBD7EB6CD801F830E3FA9-1" continuedAt="TextSelection-19978966E7FCBD7EB6CD801F830E3FA9-2"><ix:continuation id="TextSelection-826105A02755431DA39A801F830ED4AF-3" continuedAt="TextSelection-826105A02755431DA39A801F830ED4AF-4"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-19978966E7FCBD7EB6CD801F830E3FA9-2"><ix:continuation id="TextSelection-826105A02755431DA39A801F830ED4AF-4"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Reflects intangible assets written down to fair value in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><a id="sE5FE983611F7571BA1ECF98F3E2D2E64"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 5</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:IncomeTaxDisclosureTextBlock" id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-0-wk-Fact-B6BEDCBFC51301EE7B3B801F7F5796C4" continuedAt="TextSelection-D37C7FB2A397C20BFB88801F8314877E-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Tax Matters</span></ix:nonNumeric></div><ix:continuation id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-1" continuedAt="TextSelection-D37C7FB2A397C20BFB88801F8314877E-2"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. Taxes on Income from Continuing Operations</span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" id="TextSelection-924CA535A7A2F4010C49801F8313A81F-0-wk-Fact-773A1C92A027F5AE9077801F7F0946EC" continuedAt="TextSelection-924CA535A7A2F4010C49801F8313A81F-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e1556-wk-Fact-1BC519E69BB49056C007801F82245363" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,931</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e1575-wk-Fact-FF3DBEC39977C9767D1A801F8228542C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,403</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e1596-wk-Fact-C82BF6B0380BE44B2200801F82262EBF" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e1617-wk-Fact-D2824C5EC1C4EDDB4263801F822A6B70" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,751</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e1636-wk-Fact-9E2A666D208853B9E414801F822BB433" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e1655-wk-Fact-B8B8CF251AA5B84F90B4801F82328842" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(</sup></span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">a), (b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-924CA535A7A2F4010C49801F8313A81F-1" continuedAt="TextSelection-924CA535A7A2F4010C49801F8313A81F-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-BD7930C49C417519DB99801F830FA1B0-1"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;">The domestic income in 2019 versus domestic loss in 2018 was mainly related to the completion of the Consumer Healthcare joint venture transaction with GSK as well as lower certain asset impairments, partially offset by reduced Lyrica revenues in the U.S., higher business and legal entity </span></div></ix:footnote></td></tr></table></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">89</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-2" continuedAt="TextSelection-D37C7FB2A397C20BFB88801F8314877E-3"><ix:continuation id="TextSelection-BD7930C49C417519DB99801F830FA1B0-1"><ix:continuation id="TextSelection-924CA535A7A2F4010C49801F8313A81F-2" continuedAt="TextSelection-924CA535A7A2F4010C49801F8313A81F-3"><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">alignment costs as well as increased costs related to certain legal matters. The decrease in the international income was primarily related to higher certain asset impairments as well as the write off of assets contributed to the Consumer Healthcare joint venture with GSK.</span></div></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-924CA535A7A2F4010C49801F8313A81F-3" continuedAt="TextSelection-924CA535A7A2F4010C49801F8313A81F-4"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-924CA535A7A2F4010C49801F8313A81F-4"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;">The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on equity securities and increased revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the legacy SIP portfolio. The decrease in international income was primarily related to lower interest income received primarily from intercompany borrowings from Pfizer Inc. and higher charges related to certain cost reduction initiatives, partially offset by increased revenue related to Ibrance and Eliquis.</span></div></ix:continuation></ix:footnote></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-376560E0FBF696AFABDE801F83141D13-0-wk-Fact-D02FFAEFE2515CCAD0A8801F7ECDE705" continuedAt="TextSelection-376560E0FBF696AFABDE801F83141D13-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;">&#160;based on the location of the taxing authorities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e2188-wk-Fact-3F7EC138A0DC0ABC3933801F81ED0CBB" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,641</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2208-wk-Fact-B89F4B544CBB0490F3B8801F7F6AFF52" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2228-wk-Fact-6D7B0BA6A2EC7869C725801F8272AB50" name="us-gaap:CurrentFederalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,267</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e2248-wk-Fact-056CFAFF734D8F7BCDA0801F7F81D397" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2268-wk-Fact-330AC293DD571A8A50E2801F7F60612E" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2287-wk-Fact-B73E8A4817ACDB834A0A801F82518698" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred income taxes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e2380-wk-Fact-2057D665282AC77BBAE1801F7ED735BA" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,258</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2399-wk-Fact-C11FE48D970CBE734C6E801F7F9B5371" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,663</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2419-wk-Fact-8FF6BDE678C111BEDBFD801F7FA28AC1" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,064</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e2446-wk-Fact-F163C7558F8F1B24207F801F818A4A97" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2465-wk-Fact-29AB13F630E825842305801F818B62FE" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2484-wk-Fact-647101E5C54496C433B1801F81A62C65" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total U.S. tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e2511-wk-Fact-3000EF77327890BBB78C801F7F7F63CF" name="pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2531-wk-Fact-DF173E4CA56C50A2CFC7801F7F6EBCC8" name="pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2551-wk-Fact-36DDCC8E8EF16316AAE0801F8248EA9E" name="pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,055</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">TCJA</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e2648-wk-Fact-A3F4A2E507D5855FCA57801F7FA5036E" name="pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2668-wk-Fact-47EFFB693B37262CF809801F82673E4B" name="pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,035</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2688-wk-Fact-54AA553FEEBE8772CC50801F7F6E0504" name="pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e2714-wk-Fact-2EFB3D5BD681B11EF065801F7F7EB754" name="pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2734-wk-Fact-48209B5C749FB96707F8801F82806943" name="pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,439</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2753-wk-Fact-40815EB793804FE4A834801F7EBFA646" name="pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">23,795</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total TCJA tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">323</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">596</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857" name="us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">10,660</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e2914-wk-Fact-9590EF045DCC52CAD89B801F820F27E5" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2933-wk-Fact-D228C3B1EAB94AF6BA3F801F7F629AC6" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e2952-wk-Fact-B81A9D59D04BF20FD6F6801F7F9F288D" name="us-gaap:CurrentForeignTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,709</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e2978-wk-Fact-35CDF23725BF18F025AB801F81D852B4" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e2998-wk-Fact-779B14E06CE1E12EE07A801F81C6F3F6" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e3018-wk-Fact-D8F4169E7E3389CFF4A5801F8199261A" name="us-gaap:DeferredForeignIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total international tax provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e3045-wk-Fact-66C6B89DC7211DDC88F9801F828BA851" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,981</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e3064-wk-Fact-7C37580A0C7C455B1B63801F7EDE8688" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e3083-wk-Fact-D7B843C0B89966AD917F801F8284A242" name="us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e3114-wk-Fact-FC65E982593353C58EDD19521634B9BF" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e3133-wk-Fact-316CD294736155A2BF815F488E7DB6E0" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e3153-wk-Fact-C55A09F5044EA944EC43801F7F3390E1" name="us-gaap:IncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-376560E0FBF696AFABDE801F83141D13-1" continuedAt="TextSelection-376560E0FBF696AFABDE801F83141D13-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-376560E0FBF696AFABDE801F83141D13-2"><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The 2018 current tax benefit and deferred tax expense primarily relate to the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See discussion below and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including (i) the impact on deferred tax assets and liabilities from the reduction in the U.S. Federal corporate tax rate from 35% to </span><span style="font-family:Arial;font-size:8pt;">21%</span><span style="font-family:Arial;font-size:8pt;">, (ii) the impact on valuation allowances and other state income tax considerations, (iii) the </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3201-wk-Fact-4C248E3EED82997E3F30801F818A95A5" name="us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability" contextRef="FI2017Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">15.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 and (iv) deferred taxes on basis differences expected to give rise to future taxes on global intangible low-taxed income. In addition, we had provided deferred tax liabilities in the past on foreign earnings that were not indefinitely reinvested. As a result of the TCJA, in the fourth quarter of 2017, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to the territorial tax system. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2018, we finalized our provisional accounting for the tax effects of the TCJA, based on our best estimates of available information and data, and reported and disclosed the impacts within the applicable measurement period, in accordance with guidance issued by the SEC, and recorded a favorable adjustment of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3208-wk-Fact-8FC80FE596B3F9A11181801F7F60C048" name="us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;">. We believe that there may be additional interpretations, clarifications and guidance from the U.S. Department of Treasury. Any change to our calculations resulting from such additional interpretations, clarifications and guidance would be reflected in the period of issuance. In addition, our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">With respect to the aforementioned repatriation tax liability, our revised estimate is approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3219-wk-Fact-8EF9B5A847D55767BF5A5596B994B8F5" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">15</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, which is reported in current </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:8pt;"> (approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3227-wk-Fact-7574A578AC5453EE80D42498A2BBDAA5" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">) and the remaining liability is reported in noncurrent </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable </span><span style="font-family:Arial;font-size:8pt;">in our consolidated balance sheet as of December 31, 2019. The first installment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3235-wk-Fact-71130497423450AA97DB57267DA5E202" name="pfe:PaymentForRepatriationTax" contextRef="D2019Q2Apr01-Apr30" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> was paid in April 2019. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accounting for Global Intangible Low-Taxed Income</span><span style="font-family:Arial;font-size:8pt;">, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years. In 2017, we provided a provisional deferred tax liability of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3246-wk-Fact-A465ABA143208C4BD9BB801F7F7FB74D" name="pfe:TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability" contextRef="FI2017Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> based on the evaluation of certain temporary differences inside each of our foreign subsidiaries that are expected to reverse as global intangible low-taxed income. In 2018, this estimate was finalized and we provided for an additional deferred tax liability of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3250-wk-Fact-2FD831C8D0DBA5F87C24801F7FA06750" name="pfe:TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, resulting in a deferred tax liability of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3254-wk-Fact-C8453589A84C97B68431801F7E16D271" name="pfe:TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2019, the</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> was impacted by the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax expense of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3275-wk-Fact-3FA3D32052ED5CAE8FF3C5026CEA3C3D" name="pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3286-wk-Fact-2481F3648C7E706F2FDA26BB2077F715" name="us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.6</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years, primarily resulting from a favorable settlement with the IRS (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5D</span><span style="font-family:Arial;font-size:8pt;"> below);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3301-wk-Fact-BD80A7223EB34D352BA926D8AA6958A4" name="pfe:EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">400</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> related to certain tax initiatives associated with the implementation of our new organizational structure; </span></div></td></tr></table></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">90</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-3" continuedAt="TextSelection-D37C7FB2A397C20BFB88801F8314877E-4"><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3312-wk-Fact-AF0F55D57BA4C56267FD26B6D5B4AD11" name="pfe:TaxCutsAndJobsActIncomeTaxBenefit" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the enactment of the TCJA; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3323-wk-Fact-F6269740018EEB425B0426D916F90DF0" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">620</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> related to certain asset impairments.</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2018, the</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> was impacted by the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">estimated U.S. net tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3343-wk-Fact-07D7749619A14DC9F0CF801F7F3C1F9A" name="pfe:TaxCutsAndJobsActIncomeTaxBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the enactment of the TCJA (see discussion above), primarily reflecting:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3354-wk-Fact-F2FB1653C705DD800EBA801F7F58CDD1" name="pfe:TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated primarily with certain 2018 tax initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3366-wk-Fact-8FC80FE596B3F9A11181801F7F60C048" name="us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated with adjustments to our provisional accounting for the tax effects of the TCJA, reported and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC, mainly consisting of:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3375-wk-Fact-585427480B760D39EED4801F7F8CD629" name="pfe:TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">160</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits related to the repatriation tax on deemed repatriated accumulated earnings of foreign subsidiaries; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3384-wk-Fact-138C0E1B6ECE90FC029E801F81988E02" name="pfe:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated with the remeasurement of other U.S. deferred tax liabilities,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-left:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3396-wk-Fact-78FA610E519E881EBF18801F81E147FA" name="pfe:TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax expense related to future taxes on global intangible low-taxed income;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3407-wk-Fact-150DF36522EA02E6063D801F8175182D" name="us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">700</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years mostly with various foreign tax authorities, and the expiration of certain statutes of limitations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3418-wk-Fact-29920DBB462D8E0B8DF2801F82261BFE" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">740</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> related to certain asset impairments.</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2017, the</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> was impacted by the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">estimated U.S. net tax benefits of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3442-wk-Fact-6EF023A8A9E99AB130BB801F7FA7E5E9" name="pfe:TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">10.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the enactment of the TCJA (see discussion above), primarily reflecting:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3451-wk-Fact-A00621752ABDDD277B07801F7F5E3ED3" name="pfe:TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">22.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated with the remeasurement of U.S. deferred tax liabilities on unremitted earnings of foreign subsidiaries (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:8pt;">);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3465-wk-Fact-308CA9CFDD807F36DB5E801F821DAAB2" name="pfe:TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.6</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated with the remeasurement of other U.S. deferred tax liabilities, mainly associated with intangibles (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:8pt;">);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3478-wk-Fact-F12986874994AC3A9E4B801F7EC7895A" name="pfe:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">12.9</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of tax expense related to the repatriation tax on deemed repatriated accumulated pre-2017 post-1986 earnings of foreign subsidiaries; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3487-wk-Fact-B71E12DEDD43B2443728801F8241317A" name="pfe:TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of tax expense related to future taxes on global intangible low-taxed income (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:8pt;">); and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3502-wk-Fact-030584978E6092910AAA801F8187E52B" name="pfe:TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits mostly associated with certain tax initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. tax expense of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3513-wk-Fact-1479E3C7DC19C0A18E23801F822EC363" name="us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> related to the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3524-wk-Fact-2CFB549FFCFF1EEF806E801F7F5F2C76" name="pfe:EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">370</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> related to net losses on early retirement of debt;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3535-wk-Fact-3EB7CE245B545F236D8E801F7F544692" name="us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">150</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-deductibility of a </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e3546-wk-Fact-161FDD6910BA2F5EE807E475101CD09F" name="pfe:FeePayable" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">307</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> fee payable to the federal government as a result of the U.S. Healthcare Legislation. </span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Tax Rate Reconciliation</span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="TextSelection-2F42A64E1F51B8C5C776801F8314DB98-0-wk-Fact-BEC115F614B83A4E5831801F7F93BCF8" continuedAt="TextSelection-2F42A64E1F51B8C5C776801F8314DB98-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The reconciliation of the U.S. statutory income tax rate to our effective tax rate for </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations</span><span style="font-family:Arial;font-size:8pt;">&#160;follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. statutory income tax rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e3761-wk-Fact-90AEB5A2B77DDDF5B25A801F828FE42C" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2019Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e3776-wk-Fact-325C040A07204AD82DA7801F828F2519" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2018Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">21.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e3791-wk-Fact-F5EA8A7C5E11031C2FF8801F826DB301" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" contextRef="FD2017Q4YTD" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">35.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TCJA impact</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e3814-wk-Fact-264673D948622D0AA0A4801F7F4D3D67" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e3829-wk-Fact-4E680D94DBBF677FF299801F7EAAEC74" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e3844-wk-Fact-39A51FF36D53F8FAFD27801F828948C3" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">86.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Taxation of non-U.S. operations</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e3867-wk-Fact-42EBCBC4C248331A0BFD801F82753FD6" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">5.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e3882-wk-Fact-27063B77FAD0699D0962801F7E91ACE2" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">6.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e3897-wk-Fact-540F98E963893D555BBC801F8251C495" name="us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">17.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax settlements and resolution of certain tax positions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e3920-wk-Fact-A684767625371E2C2BE9801F82707B93" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">9.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e3935-wk-Fact-BB9E538422B53CC7D9FE801F82463C58" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">5.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e3950-wk-Fact-E6A475BF77FF3BDAAABB801F825FD297" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Completion of Consumer Healthcare joint venture transaction</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e3973-wk-Fact-BE07CE4FFFBA7AA6551D01C7EE81842C" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">5.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e3987-wk-Fact-565E3B0013E83A6400DF01C7EED4523E" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e4001-wk-Fact-556CBCAD88F04EADEC0B01C7EFA1BB3D" name="us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Healthcare Legislation</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e4023-wk-Fact-F48375E1B07289C166E7801F7E895D8F" name="pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4037-wk-Fact-7F97E24FF7E81A914961801F825D5D9B" name="pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e4052-wk-Fact-1FB0890125B2E2F568A0801F82580255" name="pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. R&amp;D tax credit and manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e4072-wk-Fact-BEF6BECFD4BD3C366DF7801F82740289" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4087-wk-Fact-82FF14169890F771EBF0801F824C9659" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4102-wk-Fact-0FA556A52E26309BA17F801F8287A576" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain legal settlements and charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e4123-wk-Fact-73F70D43DC2CCFC9DBDD801F7F08261D" name="pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4137-wk-Fact-5D5A6E4E5C5269ADAE16801F7F1D9556" name="pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e4152-wk-Fact-9250C6C0BF97305C67CB801F82816E88" name="pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">0.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e4175-wk-Fact-2D81E359A3F32671B09D801F7F331769" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">1.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e4190-wk-Fact-154E2A860FA2D40C9895801F828D41CB" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4204-wk-Fact-636FAEFED881C9A536B7801F7EB61207" name="us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effective tax rate for income from continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e4225-wk-Fact-1795C85B49296663CC88801F82632A48" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2019Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e4240-wk-Fact-53054E0275D8FD11662B801F7F0C1F97" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2018Q4YTD" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">5.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4255-wk-Fact-BC1C58E1C5F3B7C2FE82801F7E9969CF" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" contextRef="FD2017Q4YTD" unitRef="number" decimals="3" scale="-2" sign="-" format="ixt:numdotdecimal">73.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)%</span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-2F42A64E1F51B8C5C776801F8314DB98-1" continuedAt="TextSelection-2F42A64E1F51B8C5C776801F8314DB98-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For a discussion about the enactment of the TCJA, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-5A6821546E16E8AD2DA6801F83101D80-1"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which, for 2017, includes the repatriation tax on deemed repatriated 2017 earnings of foreign subsidiaries discussed in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:7pt;">, changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions,&#8221; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) </span></div></ix:footnote></td></tr></table></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">91</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-4" continuedAt="TextSelection-D37C7FB2A397C20BFB88801F8314877E-5"><ix:continuation id="TextSelection-2F42A64E1F51B8C5C776801F8314DB98-2"><ix:continuation id="TextSelection-5A6821546E16E8AD2DA6801F83101D80-1"><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A </span><span style="font-family:Arial;font-size:7pt;">for the components of pre-tax income and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income, </span><span style="font-family:Arial;font-size:7pt;">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. </span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2045 on income from manufacturing and other operations.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><ix:footnote id="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><span style="font-family:Arial;font-size:7pt;">For a discussion about tax settlements and resolution of certain tax positions, the impact of the gain on the completion of the Consumer Healthcare joint venture transaction and the impact of U.S. Healthcare Legislation, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span></ix:footnote><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The favorable rate impact in 2018 is a result of the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods, as well as certain tax initiatives.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-109807EBE4EECBA09C38801F831279A4-1"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">All other, net in 2019 is primarily due to routine business operations. 2018 is primarily due to routine business operations and the non-recurrence of tax benefits associated with certain tax initiatives. 2017 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business. </span></div></ix:footnote></td></tr></table><ix:continuation id="TextSelection-109807EBE4EECBA09C38801F831279A4-1"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div></ix:continuation></ix:continuation><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Deferred Taxes</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="TextSelection-C475332A5330C86813C8801F831448E3-0-wk-Fact-3296DCFE64606FE2860D801F821A0EC9" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:52%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Deferred Tax*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018 Deferred Tax*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Liabilities)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Liabilities)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prepaid/deferred items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e4760-wk-Fact-48A2AF59E0EAFF0A6B26801F81171029" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e4779-wk-Fact-BEE8E31AD112200FA011801F7F3392D2" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e4800-wk-Fact-D15932B9102F00678306801F7F4183A3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpense" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,655</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4819-wk-Fact-563A84C808D48A91680F801F7F11733F" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">325</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e4840-wk-Fact-B6A199DD0727BCEC4725801F7F2F06A4" name="us-gaap:DeferredTaxAssetsInventory" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e4859-wk-Fact-BE134C05DCF6ADAF9FBF801F7F4DDC1B" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e4879-wk-Fact-8927DC5325C709371727801F81339286" name="us-gaap:DeferredTaxAssetsInventory" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4899-wk-Fact-A6D28E13D65A157B5F67801F81407A21" name="us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e4927-wk-Fact-91D4D1D5754CB771E91B801F7F1DC0E3" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e4946-wk-Fact-BBB1AC598EA163A20CDE801F7F453119" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,099</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e4966-wk-Fact-5A2A15D93FBF9DBC472E801F7F42D616" name="us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e4986-wk-Fact-E33B08E22E8C41C41495801F7F33C2F5" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5012-wk-Fact-D379165107988FEE1AB7801F7F399F8C" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e5031-wk-Fact-29D9AEE0EF874B7D2804801F810F970F" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,226</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5051-wk-Fact-347BAF696A1993925737801F8131C37D" name="us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e5071-wk-Fact-E89AA763E81D428EDA17801F811E14C7" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,011</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5097-wk-Fact-B17BA65FC5E9803F8ED2801F8133E381" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,217</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e5116-wk-Fact-1F4672D432636FBAB1D9801F811E4A03" name="pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5136-wk-Fact-A26746429C1908FDD4E5801F7F1B893B" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e5156-wk-Fact-0A18106D10AC563B54F9801F7F18F45F" name="pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructurings and other charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5182-wk-Fact-EDC9BC9984C3F470119D801F8127899E" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5220-wk-Fact-BA7D87048EFE8B8832B0801F812594B2" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Legal and product liability reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5265-wk-Fact-4A34A51B3998F315A6C3801F81061EB9" name="pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">496</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5303-wk-Fact-CDADF0B40C985D2FD733801F814361A2" name="pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net operating loss/tax credit carryforwards</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5350-wk-Fact-783053BF5BCEAF088BA3801F7F1B9FD6" name="pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,427</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5388-wk-Fact-AC840D295965D51F3AEB801F7F1296E1" name="pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,512</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unremitted earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e5453-wk-Fact-3886E93F27E98EE28D2C801F7F4E0594" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">79</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e5493-wk-Fact-6955E2160BED229E172F801F7F0EBB71" name="us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local tax adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5519-wk-Fact-F9D55A1BA8C4FB2C64FC801F7F4A5D64" name="pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5557-wk-Fact-365F3C6454AE5427308D801F8123E06B" name="pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Investments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5604-wk-Fact-EC03DB407E47C12F595C02108AD6FC21" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e5623-wk-Fact-24C3D095E2CC3CF22E410211B6D446C8" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5643-wk-Fact-47070BCAA8F0873AE2800210CE266E9B" name="us-gaap:DeferredTaxAssetsEquityMethodInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e5663-wk-Fact-CF3BF8A51EB1AF804C9D0215472652F8" name="us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5689-wk-Fact-65066DE8900A50DCDF11801F7F0E6375" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e5708-wk-Fact-7FCA3EEAD1E583C6014B801F7F1DA91D" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5728-wk-Fact-8837BD3A347667C998B0801F7F1627AE" name="us-gaap:DeferredTaxAssetsOther" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e5748-wk-Fact-FBAE50428F678875E52F801F7F51C451" name="us-gaap:DeferredTaxLiabilitiesOther" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5774-wk-Fact-678AA5395AAB27D2692D801F7F41983A" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e5793-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5813-wk-Fact-55BA3A8CA443922DFC21801F812BB48D" name="us-gaap:DeferredTaxAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,576</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e5833-wk-Fact-3156136D7E33FEA3D6A7801F7F106890" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,456</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Valuation allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e5859-wk-Fact-40EBEAFCE6C7703C624E801F7F333340" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e5898-wk-Fact-87316DD24D8C6C196E84801F813793DC" name="us-gaap:DeferredTaxAssetsValuationAllowance" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,068</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total deferred taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e5949-wk-Fact-CB369BD69160A09C5DFC801F7F340DDE" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,288</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e5968-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,988</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e5989-wk-Fact-D9F7707EF4A74E9CF2A9801F812F89DC" name="us-gaap:DeferredTaxAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,508</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e6008-wk-Fact-3156136D7E33FEA3D6A7801F7F106890" name="us-gaap:DeferredIncomeTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,456</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net deferred tax liability</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e6056-wk-Fact-540977569490C9755BD3801F7F1FE236" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,700</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e6097-wk-Fact-2169B9839E1C354CF47B801F7F1FEF95" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,948</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories above. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:7pt;">. </span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-1"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The increase in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> is primarily related to the capitalization of certain R&amp;D-related expenses.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"><ix:continuation id="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-1"></ix:continuation>(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The decrease in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> is primarily the result of amortization of intangible assets and certain impairment charges, mainly offset by deferred tax liabilities established on intangible assets from the acquisition of Array.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-90990489192C50447F2C801F831133E5-0-wk-Footnote-90990489192C50447F2C801F831133E5_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The amounts in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> are reduced for unrecognized tax benefits of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e6195-wk-Fact-B729B37153358FD18E1B801F822A8F9F" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.9</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e6199-wk-Fact-43B0827F2B463BF3D801801F7F58ADAC" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. </span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The increase in 2019 is primarily related to the Consumer Healthcare joint venture with GSK. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B6A3FF5187C02063A75F801F8312B48A-0-wk-Footnote-B6A3FF5187C02063A75F801F8312B48A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e6242-wk-Fact-763A330A97E93835FC39801F7FB32AB4" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">0.9</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">), and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e6250-wk-Fact-086B819F1F2ED9F70CA3801F7F5113A9" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.6</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">). In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e6263-wk-Fact-AF8EA33F5B1812B0D5C3801F7FA2FF9E" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">0.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">), and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e6278-wk-Fact-EEFA2D0875440957E9DB801F82340482" name="us-gaap:DeferredTaxLiabilities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:footnote></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have carryforwards, primarily related to net operating and capital losses, general business credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2020 to 2039. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section&#160;382.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax assets.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we have not made a U.S. tax provision on approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6312-wk-Fact-552EB646EB24B4826935801F822C3FB4" name="us-gaap:UndistributedEarningsOfForeignSubsidiaries" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">29.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is not practicable.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">92</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-5" continuedAt="TextSelection-D37C7FB2A397C20BFB88801F8314877E-6"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Tax Contingencies</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For a description of our accounting policies associated with accounting for income tax contingencies, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1P. </span><span style="font-family:Arial;font-size:8pt;">For a description of the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Uncertain Tax Positions</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6359-wk-Fact-4EDA2F7467F304BE96E9801F7F648CE0" name="pfe:UnrecognizedTaxBenefitsExcludingInterest" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in net unrecognized tax benefits, excluding associated interest and as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">, we had approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6367-wk-Fact-1A17855576752B62383D801F81A43863" name="pfe:UnrecognizedTaxBenefitsExcludingInterest" contextRef="FI2018Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in net unrecognized tax benefits, excluding associated interest.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in </span><span style="font-family:Arial;font-size:8pt;">one</span><span style="font-family:Arial;font-size:8pt;"> tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6386-wk-Fact-F0C58AB0D30FAC60222A801F8127AEF3" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in assets associated with uncertain tax positions. These amounts were included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6394-wk-Fact-B3BAB779A524D76D2E91801F7F5896CF" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">) and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax liabilities (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6401-wk-Fact-B5A08DDC42BCDF95F48A801F8220BDA2" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_DeferredTaxLiabilitiesNetNoncurrentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">). As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">, we had approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6409-wk-Fact-D85749D1C3DF3A5BD572801F7F0012EF" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in assets associated with uncertain tax positions. These amounts were included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6417-wk-Fact-9B6B15AF95D01C886271801F7EE08116" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">) and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax liabilities (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e6424-wk-Fact-9313CA75922B84E732FB801F81D5AEBF" name="pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_DeferredTaxLiabilitiesNetNoncurrentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">128</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. </span></div></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="TextSelection-671A0589A742B88B1FBB801F83146612-0-wk-Fact-87160A3660C682440996801F7DC71A21" continuedAt="TextSelection-671A0589A742B88B1FBB801F83146612-1" escape="true"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e6616-wk-Fact-5131EE518687D3BFD19B801F7E64723A" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e6636-wk-Fact-597816EBBEA9C653591F801F7EEC46E1" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e6657-wk-Fact-F5108EFBE23CA2D3B82E801F7E3D99DB" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2016Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e6680-wk-Fact-D8BAB29A7AEA2D495984801F80E9FBD5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e6700-wk-Fact-EF6483D67C1CC41F73AB801F8280AE16" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e6719-wk-Fact-608268E446BF53A67800801F7ECCEFB9" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increases based on tax positions taken during a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e6747-wk-Fact-936D6A2CF388244CD289801F80ED7BAA" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e6767-wk-Fact-2D59B5E05ED9F368C224801F80B95B6D" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e6787-wk-Fact-22F8C804B14DB17BB996801F7E35F6F2" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decreases based on tax positions taken during a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e6816-wk-Fact-06AF0A8C537DC59A1463801F827D4A6F" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e6835-wk-Fact-14B110795751DD5A5119801F7E469842" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">561</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e6854-wk-Fact-4F592E77B2B5EA96F0FA801F7EF1FA0F" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decreases based on settlements for a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e6882-wk-Fact-F23CE49E146AE8ABD01E801F80CDC5E3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e6901-wk-Fact-D3921F90DA63770751B7801F7F0233BF" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e6920-wk-Fact-13974E7B4E179154410C801F7E5B86C1" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increases based on tax positions taken during the current period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e6948-wk-Fact-540CAB81FBF19E5166CE801F82251FFC" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e6968-wk-Fact-E1A13D9EA58071BA48AC801F8231AA2E" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e6988-wk-Fact-DA36ACA13488CC4953E0801F822DA219" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">753</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e7015-wk-Fact-41F52651DBC455660A50801F7E765F09" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e7034-wk-Fact-4ED079FF22AE813B13E1801F80A2650D" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e7053-wk-Fact-841C7DCDECCC2487454D801F80F3097C" name="pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e7082-wk-Fact-1431F69E27412BDBF397801F7E6A58E6" name="pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e7101-wk-Fact-C66ABB169512D5FA96F6801F7EE94810" name="pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e7120-wk-Fact-85827D800B7F9E2973DA801F80DC2984" name="pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, ending</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e7153-wk-Fact-583AA105D95E04AFAC9B801F7E2BE5D7" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,381</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e7173-wk-Fact-5131EE518687D3BFD19B801F7E64723A" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e7194-wk-Fact-597816EBBEA9C653591F801F7EEC46E1" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2017Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For 2019, primarily related to the acquisition of Array. For 2017, primarily related to the acquisitions of Medivation and Anacor. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to cash payments and reductions of tax attributes.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-671A0589A742B88B1FBB801F83146612-1" continuedAt="TextSelection-671A0589A742B88B1FBB801F83146612-2"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-671A0589A742B88B1FBB801F83146612-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7350-wk-Fact-1816CFFF9458B56DB440801F8248D281" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Current tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7358-wk-Fact-A96C3597D5A3B4CE10D7E487434AA3D2" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_CurrentTaxAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">),</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7367-wk-Fact-FE11DF7FFD9F85DD6032801F82317883" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7375-wk-Fact-090D2A341B752BA7D0E2801F8194027D" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7384-wk-Fact-2F7BCEFE3C8437463BAF801F80471155" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">). In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7396-wk-Fact-FC5189E17EB5AB41ABAB801F8215B782" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Current tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7404-wk-Fact-16CC8D6DB77E99136D81E4884308E0CE" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_CurrentTaxAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">) </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7413-wk-Fact-5F35EAFC34C3D70F3A83801F8253CBA8" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7421-wk-Fact-ECF2C4E26D92FFDF3562801F7F94E038" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34545404e7435-wk-Fact-E61FC398BDF688206289801F7F631802" name="us-gaap:UnrecognizedTaxBenefits" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">). </span></div></ix:continuation></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> in our consolidated statements of income. In </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, we recorded a net decrease in interest of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7466-wk-Fact-97B34122802EC1B4822F801F824E822A" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">564</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, resulting primarily from a settlement with the IRS. In </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, we recorded a net increase in interest of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7474-wk-Fact-F1EE088065A52DCFDC3E801F81CC100F" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">; and in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, we recorded a net increase in interest of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7483-wk-Fact-C7D6C99CFE1CF4603C64801F7F59BD31" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">208</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">. Gross accrued interest totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7487-wk-Fact-A38512BECF9994FC35CB801F8222DA73" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> (reflecting a decrease of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7495-wk-Fact-B5484FFEAFBF4B71E7DF801F81BBD194" name="pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> as a result of cash payments) and gross accrued interest totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7500-wk-Fact-CCF68568819E21598906801F7F4FB19A" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="FI2018Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;"> (reflecting a decrease of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7508-wk-Fact-C2874A4CBCCB26F05DC1801F7F4A5AF7" name="pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> as a result of cash payments). In </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, this amount was included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable </span><span style="font-family:Arial;font-size:8pt;">(</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7520-wk-Fact-BA818087B713C8380E8F801F7EDC0395" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">) and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7529-wk-Fact-AB1361AF52AA3FAECE5D801F7E029EAA" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">465</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">). In </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, this amount was included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable </span><span style="font-family:Arial;font-size:8pt;">(</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7541-wk-Fact-4C6587999EDA433052AEE4833875C94C" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">)</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7554-wk-Fact-5F3BAA22D7842F1B0210801F7F6FE4A4" name="us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">). Accrued penalties are not significant. See also </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">During the second quarter of 2019, Pfizer reached settlement of disputed issues at the IRS Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2009-2010. As a result of settling these years, in the second quarter of 2019 we recorded a benefit of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7576-wk-Fact-820F0AB2E3455B89B1C5D508B0396F53" name="us-gaap:IncomeTaxReconciliationTaxSettlements" contextRef="FD2019Q2QTD" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, representing tax and interest. </span></div></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">93</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-6" continuedAt="TextSelection-D37C7FB2A397C20BFB88801F8314877E-7"><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">With respect to Pfizer, tax years 2011-2015 are currently under audit. Tax years 2016-2019 are open, but not under audit. All other tax years are closed.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2019), Japan (2017-2019), Europe (2011-2019, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2019, primarily reflecting Brazil) and Puerto Rico (2015-2019).</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34545404e7595-wk-Fact-063690F1028046438F4E801F7F0C4E62" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.</span></div><div style="line-height:120%;padding-top:1px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span><ix:nonNumeric contextRef="FD2019Q4YTD" name="pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" id="TextSelection-B457160A54EABE938283801F8315935B-0-wk-Fact-AB670A82CCB5F5E7001B801F7F5EA5A0" continuedAt="TextSelection-B457160A54EABE938283801F8315935B-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:69%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of the </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency translation adjustments, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e7858-wk-Fact-D363B0E0565C5479A3956F6F31D775C9" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e7877-wk-Fact-7A6A6BE7AC6954D4AA27EA74C266AF79" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e7897-wk-Fact-E60F964DE99E4B40AE50801F7ECFCAC9" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unrealized holding gains/(losses) on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e7985-wk-Fact-14EE8427216251379FB2DB35DA22921F" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8004-wk-Fact-1630FC0671C050EF8D9447A8118D6A12" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8023-wk-Fact-9B2D44BD7D665244E7D4801F80F7EF91" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for (gains)/losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e8049-wk-Fact-0E98AA3D93CF556C8B16CFFEA1407271" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8069-wk-Fact-0093ACEC508452AF9A2F82E421DD10DE" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8088-wk-Fact-BF8E217572DBED3A3A5A801F7EE0757F" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e8119-wk-Fact-FF8055EC7C995980A43AA0986DC6DBB3" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8138-wk-Fact-9CF783F2B69B5D93A482F2C929ED1566" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8157-wk-Fact-13DACBE475EF4ADD4FF8801F828BECB3" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e8183-wk-Fact-4ABE41A898CF5A888CADB00DB029A36D" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8203-wk-Fact-3B7B9F399E625C0EBF51C027705482E0" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8222-wk-Fact-CD9CD6315AF805EE110C801F82314B93" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unrealized holding gains/(losses) on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e8249-wk-Fact-5D743E25975C55F698680794C6AAFEF7" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8268-wk-Fact-D910B98A2A495A7F8D104D295E58A27F" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8288-wk-Fact-AB2A09EB63C492976F0D801F7EEB7CDE" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for (gains)/losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e8314-wk-Fact-17B1980D02D45F8CBB7A7EE19E813B6C" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8333-wk-Fact-56219AC4AD4A515C98D6A194CC02DB93" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8352-wk-Fact-F721A594086A30EF7197801F81E88F06" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for tax on unrealized gains from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e8384-wk-Fact-EE402418A54D574CB441079C7682C003" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8403-wk-Fact-40C546EC33A35AFE9BEEFE176817495B" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8423-wk-Fact-B8C0D0C18DFF193C78E9801F81F22825" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e8449-wk-Fact-7D2C105FB948503BAF6CC2609691190E" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8468-wk-Fact-2308D4804BC15820A1BF5683286AA0FE" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8488-wk-Fact-5D53591A115642D67AE0801F7EC62B8C" name="us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit plans: actuarial losses, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e8514-wk-Fact-7551743EA0D951E684816768D46FC02B" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8534-wk-Fact-DA7AAA48051D5116A888E1C05B7AF9B0" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8554-wk-Fact-CA440F669FCEB236B7D8801F7E232594" name="us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e8581-wk-Fact-B996875DBCC5546FAAB96F580C28152A" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8600-wk-Fact-F3FEF704731B57E083E1DC74B4FC2A72" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8619-wk-Fact-905810C790D95874B61F801F7FF91C19" name="us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e8645-wk-Fact-3FC35AF0A0035C01A2C52C65991A37D0" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8664-wk-Fact-7DF52F6B60C351408D7D1B4E6372978E" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8683-wk-Fact-A4B4A3A0512F365E0A32801F7E66E4D9" name="pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e8713-wk-Fact-7F748C891A4E562C8DD5B4D163881419" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8732-wk-Fact-2A00978854A95D9F943FA975DD0E0D7C" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">637</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8751-wk-Fact-5E2F8A36DD7104849060801F7E8B4BB0" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e8777-wk-Fact-1150CC9401495F9D800257EC24C62047" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8797-wk-Fact-C56097F7E7AB54E8AE9F4369097D3551" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8816-wk-Fact-B6A7C6683A702A90E4D1801F8200ACEA" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e8843-wk-Fact-81134306EC6D54A09C274118E4D1C067" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8863-wk-Fact-9F55F08803BF5F45847FA3A824860C15" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8882-wk-Fact-F3FDA88D35E923A114BB801F80DF4B90" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit plans: prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e8908-wk-Fact-DF810DD1097A5410A0DF2B9B68489689" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8928-wk-Fact-DF2E50CD4CA35A2BAD120EF77A9E40B7" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e8947-wk-Fact-78686DD7C3CF2BED3AAC801F80261C1C" name="pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e8973-wk-Fact-417D7502C1BF56A4B101A79DA9D93249" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e8993-wk-Fact-A9FA63273C945D2EBB3A7A4D635ACA5A" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e9013-wk-Fact-2490D79719E94549B951801F825DEFD6" name="us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to curtailments of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e9040-wk-Fact-87C57E77ED2851889371E52CAC0A5B81" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e9060-wk-Fact-40C9BC3950405881AB74766C2652C4E3" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e9080-wk-Fact-80E77E93974A4CCAEF7A801F82C19FF3" name="pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e9112-wk-Fact-0A2EFD43015A58319E9B6A5301E68F22" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e9131-wk-Fact-04675E47A2C7545A8AB05010E81694A0" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e9151-wk-Fact-8EA5960B76BF5C90C28C801F7E3E9349" name="pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e9177-wk-Fact-36227FCE11595F1F9D306583FDE3D074" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e9196-wk-Fact-755F73D7231255828A1000E65ADC951D" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e9215-wk-Fact-125154CCF8A90975CB54801F7EDF647C" name="pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34545404e9241-wk-Fact-D9381AAF79DA5454BE10EDA3EB3EB5B6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e9261-wk-Fact-BCD4F0E137B953A7A2950B6827C5DBB1" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e9281-wk-Fact-C55F5FB0BDA5A6D6BFB9801F7E9B9974" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income/(loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34545404e9313-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34545404e9332-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34545404e9352-wk-Fact-93DDC1938188F9E00A7E801F808A913C" name="us-gaap:OtherComprehensiveIncomeLossTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-B457160A54EABE938283801F8315935B-1" continuedAt="TextSelection-B457160A54EABE938283801F8315935B-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-B457160A54EABE938283801F8315935B-2" continuedAt="TextSelection-B457160A54EABE938283801F8315935B-3"><ix:continuation id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-7" continuedAt="TextSelection-D37C7FB2A397C20BFB88801F8314877E-8"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-B457160A54EABE938283801F8315935B-3"><ix:continuation id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-8"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B</span><span style="font-family:Arial;font-size:7pt;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">94</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s473C2379076D50E7829B7821420ECFDB"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 6. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="TextSelection-C6360B662F97512739DF801F83155286-0-wk-Fact-E3F3B121856F1F639616801F8270F361" continuedAt="TextSelection-C6360B662F97512739DF801F83155286-1" escape="true">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ix:nonNumeric></span></div><ix:continuation id="TextSelection-C6360B662F97512739DF801F83155286-1"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-7E7D74B57003153923E9801F8315CC5F-0-wk-Fact-C534EFF51308BA9974D0801F827478B4" continuedAt="TextSelection-7E7D74B57003153923E9801F8315CC5F-1" escape="true"><div style="line-height:100%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:31%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the changes, net of tax, in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net Unrealized Gain/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Prior Service (Costs)/ Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e1741-wk-Fact-45B677F0CAC7B2BB8E94801F828E270A" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,659</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e1761-wk-Fact-0E1AD8AA858515F533CF801F82A8444C" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e1781-wk-Fact-B35E76F70D28C4AEDAAC801F7F632F3A" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e1801-wk-Fact-A9AB3B70952527329597801F82A8F5C5" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,473</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e1821-wk-Fact-9F0D8940B8C31C6C01B7801F7F946036" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">879</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e1841-wk-Fact-67FB49FA8269AAD714CF801F827EF758" name="us-gaap:StockholdersEquity" contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,036</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e1864-wk-Fact-925E28131BC6D032A9E6801F827FCD84" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e1883-wk-Fact-D71CC752F8554F4A326D801F7F9F4E99" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e1903-wk-Fact-798B7A350A5E13556B82801F82A90157" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e1923-wk-Fact-F0E9225B40E6D9F21243801F7E9BDD39" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e1942-wk-Fact-EC3C848AE6A9CBDEC522801F7E7CD417" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e1963-wk-Fact-73675557E3290275CFB2801F8179DBF8" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,715</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e1988-wk-Fact-C2B9A885BD41E748D726801F7F95A6F9" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2008-wk-Fact-AF4DC105F488A9B76F07801F82809612" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e2028-wk-Fact-12458EC442838137DFE2801F7F5E1492" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2048-wk-Fact-98F0E97021A68E61CFF6801F82888A95" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e2068-wk-Fact-5C11A243F019E5C8E2A9801F7F5E83A9" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2088-wk-Fact-62FC79EF34B6077783F9801F828D4F15" name="us-gaap:StockholdersEquity" contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">9,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss) due to the adoption of new accounting standards</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2116-wk-Fact-7B2716E1C24FE2422E5FCF6EF0CCB67A" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2136-wk-Fact-07A3726E8AD3C897B843CF6EF6032DBA" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2156-wk-Fact-B51D44885CA609BBF357CF6EFC35BB67" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">416</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2177-wk-Fact-38838F053717CF5598FFCF6EFFF59BAF" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">637</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e2197-wk-Fact-95156657E2A6B44ABF2BCF6F034F6554" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2217-wk-Fact-8B8742C522CFC603BD73CF6F077A96B2" name="us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">913</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2245-wk-Fact-AAFD78C12C113C0D686D801F8281F391" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">893</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e2265-wk-Fact-7BBA68F22C4A3BB9286A801F7F95841D" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2284-wk-Fact-74D8FB512BB0C16FBCA9801F7F9F040A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2305-wk-Fact-AA09423469405CACDD8C801F7F53FDB0" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">128</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2325-wk-Fact-2101798BE4EDF6E78C8F801F803DE4E4" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2346-wk-Fact-FFFCC0F0F24614B44437801F828D0336" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2372-wk-Fact-0689B897DFBC5343838A8A7EB0A52E72" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e2392-wk-Fact-DA332392557D5698BA6257EDB819B3ED" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2411-wk-Fact-895D5C0C88E55E1B96A4FA1F22547BAB" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2432-wk-Fact-BBA2A405B9915134881653F29E094498" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34460716e2452-wk-Fact-2CB61C1AD5CE5D859A08D0BA215C1D89" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">728</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34460716e2472-wk-Fact-447ADAC3DD0B55E9A6CBCBA1E1BC0F65" name="us-gaap:StockholdersEquity" contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34460716e2500-wk-Fact-80135A3F2616CE4B3FFE801F7E2617E5" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34460716e2519-wk-Fact-56CDBBCBD4E37D7B159C801F7FF5592A" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34460716e2539-wk-Fact-6D3E645E9EBC03EFCF4B801F82A9D31C" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34460716e2559-wk-Fact-4158106AA31D76C528FD801F7F58702B" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">231</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34460716e2579-wk-Fact-C3564D2578C699EB2759801F8289A914" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34460716e2600-wk-Fact-50C71B602D558F20976C801F828D6F53" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34460716e2631-wk-Fact-06D7A8BC9046570A84EF75C326DEC822" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34460716e2651-wk-Fact-073F8F502DCA5A9A95A692421AEC503D" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34460716e2671-wk-Fact-E3C97EAFCD455D8082781F59E563A366" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34460716e2691-wk-Fact-060AC96DC6AD5934B52935ADA8EC68E5" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34460716e2711-wk-Fact-4666F139A7605E0CA364A6577C1CB991" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34460716e2731-wk-Fact-3C8FFBEEEB0F5A01AE02EF005CAE3929" name="us-gaap:StockholdersEquity" contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11,640</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:100%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34460716e2752-wk-Fact-BF952FA65727E3F2FF24801F827DA355" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> loss in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34460716e2760-wk-Fact-1A7F82C1579D03FCE652801F827D8FD8" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> loss in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34460716e2768-wk-Fact-03AC7888089D910F5F60801F826DDC85" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> income in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. Amounts in 2019 include after-tax gains of approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34460716e2784-wk-Fact-7585EA770858DD8F140716EB02CF3463" name="us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">978</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2C</span><span style="font-family:Arial;font-size:7pt;">), partially offset by the strengthening of the U.S. dollar against the euro and the Australian dollar, and the results of our net investment hedging program.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:100%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-7E7D74B57003153923E9801F8315CC5F-1"></ix:continuation>As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we estimate that we will reclassify into 2020 income the following pre-tax amounts currently held in</span><span style="font-family:Arial;font-size:11pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss:</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34460716e2830-wk-Fact-13A3ADFFD070509FB934DDECF30C0647" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">179</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of unrealized pre-tax net </span><span style="font-family:Arial;font-size:8pt;">gains</span><span style="font-family:Arial;font-size:8pt;"> on derivative financial instruments (which are expected to be offset primarily by net </span><span style="font-family:Arial;font-size:8pt;">losses</span><span style="font-family:Arial;font-size:8pt;"> from foreign currency exchange-denominated forecasted intercompany inventory sales upon the sale of the inventory to a third party); </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34460716e2851-wk-Fact-D723C9396BE2C89E7E25171D9AE5E56B" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">265</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34460716e2855-wk-Fact-1F46739006A073AA9C40171D53707AD7" name="us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">178</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> of prior service credits, primarily related to benefit plan amendments.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">95</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s39FBF131723658B4B1599E831CFDD89A"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-bottom:10px;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 7</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:FinancialInstrumentsDisclosureTextBlock" id="TextSelection-C6E571358FCD4C6B8359801F8316BFE3-0-wk-Fact-EE1A927A3B971A7EEA4B801F7E3F853A" continuedAt="TextSelection-C6E571358FCD4C6B8359801F8316BFE3-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Financial Instruments</span></ix:nonNumeric></div><ix:continuation id="TextSelection-C6E571358FCD4C6B8359801F8316BFE3-1" continuedAt="TextSelection-C6E571358FCD4C6B8359801F8316BFE3-2"><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="TextSelection-97951772D086F2E7D669801F831564D4-0-wk-Fact-49BE2C853E6AF7073601801F7E409B90" continuedAt="TextSelection-97951772D086F2E7D669801F831564D4-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:42%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in </span><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Note 1E</span><span style="font-family:Arial;font-size:7.5pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financial assets measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as equity securities with readily determinable fair values:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2136-wk-Fact-18A31C1027BB58C7AEE2D01F4BAFE1A4" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2155-wk-Fact-EA8F59D151265C778A8BF582D77C5F0F" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2175-wk-Fact-2FAA3D8195A85949B1B7904C1AF5FAEE" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2194-wk-Fact-68FE043C11DF54BC9F0FFE645351BD48" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2213-wk-Fact-F4E96D2D7D3F55B8B9ADE3F7599880D8" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2233-wk-Fact-E79DA86BB814502983E0AD71C67E2D07" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2255-wk-Fact-82A2245601F85681A011C5CF5DC22574" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2274-wk-Fact-CC4D6529B853515DB76F971BB80BD1F7" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2293-wk-Fact-96F4F464AA385AAC8472ED5CE5876AE8" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2313-wk-Fact-F565F733B4BA5FB3ADE3708106F7C196" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2332-wk-Fact-9854A94284F15962BD709C1580BF94CD" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2352-wk-Fact-EF9132C281325EE9AE260DB5D59CEC4A" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2377-wk-Fact-CCB52DE5DD65542F8C2130217B569DED" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2396-wk-Fact-FF683B87604B5AA0BDFF0C60E4A26196" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2415-wk-Fact-1E44D0DF9C955A63A29BB0B87F7FCBF9" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2435-wk-Fact-CEB8B772487B5B06A33B1C9CAF5BD42B" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2454-wk-Fact-26187F0F4DCC5BB49F82A4FF2EFEB8D1" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2474-wk-Fact-BC134874FE23539EB55130C0C5C3883B" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,583</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2627-wk-Fact-C4D233838522D85F276FE492C1893CCB" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2646-wk-Fact-FB348C48D67827AA929FE492C1FC405B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2665-wk-Fact-C288FFF8E55A42068BBBE492C1785EA8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2685-wk-Fact-0F43A348432352809466BA6165ACC781" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,609</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2704-wk-Fact-3A138C1AA4265C5A8C51D5EF397A96D7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2724-wk-Fact-E01927E7540E55609E2F028A9E13CEBA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,609</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2750-wk-Fact-BEB6FA8944B221D5D3ACE4969D2B28CF" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2769-wk-Fact-32AC1CE3A82326390403E496A5FA0032" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2788-wk-Fact-33E26AFC9B29497D5F28E496B2295334" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2808-wk-Fact-0A888C6EA71281096E7EE496BE5BE562" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2827-wk-Fact-A01EB7CCDF98B20D0963E496C8212B0F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2847-wk-Fact-54C311CFC9AB409967BEE496D546A1BA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,437</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2872-wk-Fact-5077E4384E7A561BF943E492C19F9D79" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,013</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2891-wk-Fact-84F716536FFD7461E32FE492C1AF5AD8" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2910-wk-Fact-9D175383CC37B74A3499E492C1D64386" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,013</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2930-wk-Fact-325CA3D29BCC5DFAB11F3EEAD5E9BC5F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2949-wk-Fact-315360939EAA54B1B683FA1723D1E241" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e2969-wk-Fact-704A8BE5CDEA5D89A5BB1DCAEFBA04C5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e2994-wk-Fact-1DC111F71152E373E9A3E492C1ECC35C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3013-wk-Fact-978B9851E588046AB935E492C15A77A9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3032-wk-Fact-587EC5D4D115CF7E6E53E492C1C5CB21" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3052-wk-Fact-1340C63DB9D65E649AA906709DE68608" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3071-wk-Fact-1EAD0055E74C5D478C6750898FAB8A74" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3091-wk-Fact-E7EE26479BEC513FBF2ACA13187EB86F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3116-wk-Fact-935E22FFBF5AAFEE4AF1E492C23879F8" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3135-wk-Fact-86B2386B118EB38735FBE492C2285E2C" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3154-wk-Fact-5B22A20F564EA38D7879E492C212632F" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3174-wk-Fact-8749D47064FB54E9933321CE575E44EC" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,691</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3193-wk-Fact-3A9E58C8B4A85F76B7F283490AD3C962" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3213-wk-Fact-8358C43DF139515D9C21DE64E451060A" name="pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,674</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3494-wk-Fact-D7DF3A09858B55868ECE129A95EFE4FC" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3513-wk-Fact-BA94DEFAE4E6538F965D0700DFFBE9B5" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3532-wk-Fact-DEC9C8E8C4AD5EB79A3AE4083CEF7E09" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3552-wk-Fact-0E03A97C9221553EB38057AA4DD0D52F" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3571-wk-Fact-6DA6B830F80755E9889BD443B66DA5B4" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3591-wk-Fact-0F56928953AD53F2AD1F6EAB148221B9" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3616-wk-Fact-EE086EFDC8FA52CCB471FE8C94E16435" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3635-wk-Fact-CF5518D0FB265AAA939627B794ECEFC5" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3654-wk-Fact-35A8FB07BE6D5A63A2013D50650B7DEA" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3674-wk-Fact-42C381B09D9B518A9A7191BDF380D611" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3693-wk-Fact-DBDBE6E5915C5182B38AF6FDB20D4289" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3713-wk-Fact-5307CF33306B5D62862738025E01DF12" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3738-wk-Fact-8AE409969906556DA1D53C980AC310B0" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3757-wk-Fact-01ACA4F20AB650619B7440B93917DE4C" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3776-wk-Fact-CCECB9974AF95B5F9EE035BF23A75955" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3796-wk-Fact-21DF23FF6C4C59DD9E2D3E728846EBA2" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3815-wk-Fact-D028FF2C08935CD9AE09E6D0E70533FE" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e3835-wk-Fact-CD39609331BC5197B01763529602916E" name="us-gaap:DerivativeAssetsCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">574</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as equity securities with readily determinable fair values</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e3990-wk-Fact-5179B25EF13E5D03A1D07028891DCE31" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4009-wk-Fact-600150099E535A6B80046F755F61C891" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4028-wk-Fact-C57C6FA8EFB95CF381E0002884269AA9" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4048-wk-Fact-8B5032647C685E9F9D6182CF0CECC704" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4067-wk-Fact-6E4007B2C88C5199890DA9C2769B5FEA" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4087-wk-Fact-7458E0BF72155C08BCB5FE5F3AECA0AF" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4241-wk-Fact-A717235A24F9529BA4CAE4A93E01F11F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4260-wk-Fact-6D1C11320F745232A6B45B64ECDF855C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4279-wk-Fact-903BDDA5C92A5EFE9DACA3579B11388C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4299-wk-Fact-03F8CAA92E315BBE84140B697EA81F5B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4318-wk-Fact-9E4A63A2CDDA5380B4E12D11690D3288" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4338-wk-Fact-2D0CE7B602F850499115214B23691F30" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4363-wk-Fact-6FBE889C698B9862CC16E495A2997897" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4382-wk-Fact-B00DE80EAD8FD1FEB4F3E495AE6566B4" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4401-wk-Fact-7B4D458BF2AD62C9C279E495BDE1A56F" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4421-wk-Fact-6B43A18CDC36B0745648E495C8579E94" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4440-wk-Fact-C90053C9FF3B013F818FE495D20C0A20" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4460-wk-Fact-CABF50D72BF9D0D7717CE495DCF152EC" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4485-wk-Fact-DB7E035B52545F9684840ED31FAA73EA" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4504-wk-Fact-305270CD550F5BE4A26F0069121DCBB1" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4523-wk-Fact-BE807AB737D65A628603813AF86048D6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4543-wk-Fact-A941D61E67FC510A89C7BFCD14430154" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4562-wk-Fact-0D65DD0C4BE65C79BB91BA309F46864A" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4582-wk-Fact-6387209973DC50E6B4E4A436C2EED446" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4607-wk-Fact-70C7D977F3BF5855A2CFCAA6F80FA1E7" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4626-wk-Fact-AAEA41CCB0205B50938F2E5C8461493B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4645-wk-Fact-AC369E91E45457C18B876B8FF7A1A832" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4665-wk-Fact-7AA2BA053AA95E74ACA2FC251B8DEB0B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4684-wk-Fact-22A737D942F75227B2ADDDF3B788A91C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4704-wk-Fact-5CC6477F813F52EDA085A9676B88A165" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4729-wk-Fact-9AB951C740D95C2B856C33A24A2DD8A9" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,216</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4748-wk-Fact-750AEC70E0C0589CBE6F8EB2DF3B4686" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e4767-wk-Fact-E004DB8AC02057C89199EC46EF3C60C7" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">354</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4787-wk-Fact-18DEE7C8F0565278872947FD1E794B3D" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,764</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4806-wk-Fact-9479348F703C5D70905D4147AAAAC37F" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,243</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e4826-wk-Fact-637AA01CC45C5CF3A8A73104013714D4" name="pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5107-wk-Fact-CF6FF91EA0C656829B0FE9BCD0F437F1" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5126-wk-Fact-330BA14691C35D85BF0A08554B551678" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5145-wk-Fact-AFCC550826335673871863EA1BF058E3" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5165-wk-Fact-B0FDBB60323852A69746D3D88D52EA2E" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5184-wk-Fact-3CF1EBDAE05A5B9687F1241ECDEA475D" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5204-wk-Fact-FB292FBDF9955A15B2B0826F09654CF6" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5229-wk-Fact-5AEA46F5548F51A9BC889C00FCD90958" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5248-wk-Fact-1F69C9931CB35D6EB11DD36D79F8E4E2" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5267-wk-Fact-28ACC47374E85BE499E3952D62C96425" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5287-wk-Fact-E174AC0DB1515C5F94C362F71A12F7DD" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5306-wk-Fact-3572C66DD48C50C5A5E64A0AB46068D6" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5326-wk-Fact-625FA27659285EF48A9E7E763EFB8313" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5351-wk-Fact-B0DA2F41368A5038BCD9C7AC01BAA2EC" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5370-wk-Fact-E64826395A6151B2931C102DE0198C19" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5389-wk-Fact-1BE30E22F1CA5A9F869BD4C2DFE5DA2B" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5409-wk-Fact-C7F7003A3AD95E89BC3924C47864116F" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5428-wk-Fact-A15C45D042075C208067A211014F6CF0" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5448-wk-Fact-8BE904F401E05C03AD2D4FAE21091311" name="us-gaap:DerivativeAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5476-wk-Fact-1260CCD84F5EAA993014023A45379D65" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5495-wk-Fact-FE5FA64237140370947E0C1E584B0DA8" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5514-wk-Fact-9120BAFF50D1AEC6196F023AB29B9891" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">575</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5534-wk-Fact-09A4B51093258130F5FD023AB0BF7398" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5553-wk-Fact-8A8CC7E111309130A3F9023AB1C2B87A" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5573-wk-Fact-CC98EE15F05729F82BC1023AB01871BC" name="us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">515</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5598-wk-Fact-664194EED949E86811A20230BABF845E" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5617-wk-Fact-3C60B4A7CB4612E88D3C0230BBDA0271" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5636-wk-Fact-896D109D3632C3DC21120230BC07B0C1" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5656-wk-Fact-CEA4DCE70A52E69024AE0230B99E6DCC" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5675-wk-Fact-3575C07F4462677F03940230BA2F6E24" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5695-wk-Fact-69D773C2A27F49B7099C0230BB4E3AAB" name="us-gaap:OtherAssetsNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,082</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5725-wk-Fact-89CE6A1289DA40501E4D801F82A04C25" name="us-gaap:Assets" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5744-wk-Fact-697894D665ED502CB19B801F82A8684A" name="us-gaap:Assets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e5763-wk-Fact-3FBD613AFFFEA2C8FB63801F82B5E5DC" name="us-gaap:Assets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5782-wk-Fact-0E52443F5C76774FA75C801F82B5973B" name="us-gaap:Assets" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20,110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5801-wk-Fact-775862C803513248303E801F7F4E0495" name="us-gaap:Assets" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e5821-wk-Fact-F56E374FB2E1D63FF319801F82A6F4DA" name="us-gaap:Assets" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18,850</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financial liabilities measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6358-wk-Fact-2D068435DD4A5F5295FA0CCC82EE051D" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6377-wk-Fact-6A9EA96081CA5C8E9BAD5DB1CAFD477F" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6397-wk-Fact-D0A3E10B0A4B5A64B5A6B8443F163774" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6416-wk-Fact-EB5CE6232D575639B91CB12849C35E50" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6435-wk-Fact-8F8D54ADCDC959E695062DDC7BE6B922" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6455-wk-Fact-CD0EF8C046065C3A9EC9B8862112C530" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6475-wk-Fact-AD9607E44D0E5BE38E7237F5FFD41AC2" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6494-wk-Fact-CED4F45B846256F098E3A02AF01EBF08" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6513-wk-Fact-03E72CB89EAB50FA894324460D74A640" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6533-wk-Fact-0148A0906CE35EC4A8412EB93331A984" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6552-wk-Fact-8BF17EB8E8705AE79684AF8AD8B57842" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6572-wk-Fact-CE86BCC2D3505DD09A39C0422DD25E0F" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">78</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6597-wk-Fact-5C099920B8B55A4CAFAF9D7169C6D890" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6616-wk-Fact-FE757A0E7E9E57E9B8BA9E594BA25DCC" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6635-wk-Fact-025EF0801C8E5AED84E50FDB8C0A446C" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6655-wk-Fact-279994B1608C5BBF86C5E2B4E0BAED6D" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6674-wk-Fact-0BE5F4B5A42B5CE580832FE51C9E437B" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e6694-wk-Fact-13EC5BB83BC650FF89A60A6223B8AEB5" name="us-gaap:DerivativeLiabilitiesCurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6976-wk-Fact-000D7A7EF4CF591AB16A9C594E15D42C" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e6995-wk-Fact-D77B1AC41096549BB413220935C7618C" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7014-wk-Fact-6A6B94B545F757568AB45A75C118CA9B" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7034-wk-Fact-F8C1B53CA9E45C8490DD20893F3B6ECE" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7053-wk-Fact-1DF13C3541FB5E39AFDF3B3B26D6E8A2" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7073-wk-Fact-75F99BC9FE0557F09AD81513398AE1C9" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">378</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7098-wk-Fact-C4D87CCD51D05F1792598B2E4B0ECC76" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7117-wk-Fact-B7C1638E0DF05D0E8B6219C5B4D6D0F9" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7136-wk-Fact-4C05222BCA8D5C1F975FF29251154B32" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7156-wk-Fact-ED9EBDFE36E15B32AAE1DAE3CE253FBD" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7175-wk-Fact-25F9EDE8D1D25D7CB1F21FADE82504EA" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7195-wk-Fact-79876789308457AF901FB8884DCAF40E" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">564</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7220-wk-Fact-8336B6DD8E085B03B2E3B66852F632AD" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7239-wk-Fact-A4491DE6736452438C71F500E4E3E53E" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7258-wk-Fact-B61D859E15E75D4EA3481D593DEC8612" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7278-wk-Fact-0AA852D7EA865FE28E7DD9FC9ECA6A8D" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7297-wk-Fact-71F9B9B38D7E533981480976FC4071BD" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7317-wk-Fact-36D5848BB3695543A5468FB8D316B7D5" name="us-gaap:DerivativeLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7347-wk-Fact-B1DCB7979801D0C2E1A2801F82C7DB23" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7366-wk-Fact-8D2AC5EEA5E88C141E4C801F829FB355" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e7386-wk-Fact-77EE121F057E517A91C5801F82ABF006" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7405-wk-Fact-3118F0B7D408D547FCA5801F82A1CA5A" name="us-gaap:DerivativeLiabilities" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7424-wk-Fact-5FE26F1BA5B2869602AC801F80F25EC2" name="us-gaap:DerivativeLiabilities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e7444-wk-Fact-406C8008BEAD002ABC34801F82A1EDFE" name="us-gaap:DerivativeLiabilities" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></div><ix:continuation id="TextSelection-97951772D086F2E7D669801F831564D4-1" continuedAt="TextSelection-97951772D086F2E7D669801F831564D4-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, long-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34496162e7462-wk-Fact-9A98CA2603B6ADF2A73F023785E272F4" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. </span><span style="font-family:Arial;font-size:7pt;text-align:center;">As of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;">, short-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34496162e7472-wk-Fact-FD047506F5725CCDBC6185E76C2B8E82" name="pfe:EquitySecuritiesFVNIRestrictedCurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> and long-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34496162e7477-wk-Fact-34920CE8F316DAC9DDA1E4C6BFD9B105" name="pfe:EquitySecuritiesFVNIRestrictedNoncurrent" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">132</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.</span></div></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-97951772D086F2E7D669801F831564D4-2" continuedAt="TextSelection-97951772D086F2E7D669801F831564D4-3"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-97951772D086F2E7D669801F831564D4-3"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4</span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:continuation></ix:footnote></td></tr></table></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">96</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-C6E571358FCD4C6B8359801F8316BFE3-2" continuedAt="TextSelection-44866C7DEE5949D51431801F831767F9-0"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" id="TextSelection-24E6EA3C2C152DC08565801F83151E7C-0-wk-Fact-98E29AD4000D6F8F6756801F7E3DFFE3" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:36%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:bold;">Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Long-term debt, excluding the current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8296-wk-Fact-C18B2B1FFA4D5577BE1E15FA7DB4215D" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8315-wk-Fact-2F306B9ABED5537F91E4E56214919A3B" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8335-wk-Fact-A548C68EC6AF5D8895F5938FC53151B5" name="us-gaap:LongTermDebtFairValue" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e8354-wk-Fact-7D3EA5FDAECD5B7DA616312E9C0CCE69" name="us-gaap:LongTermDebtFairValue" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e8373-wk-Fact-67B03B54AF825D7F962A5FCE5EF3925B" name="us-gaap:LongTermDebtFairValue" contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34496162e8393-wk-Fact-3571C13CA37A50F0B6DC64608D67AF4F" name="us-gaap:LongTermDebtFairValue" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> or </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition, as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, we had long-term receivables whose fair value is based on Level 3 inputs. As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, the differences between the estimated fair values and carrying values of these receivables were not significant.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Total Short-Term and Long-Term Investments and Equity-Method Investments</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:MarketableSecuritiesTextBlock" id="TextSelection-387995A8D4D18DA6834E801F83164548-0-wk-Fact-2AB2C968200FC7012E86801F7E327739" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table represents our investments by classification type:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities with readily determinable fair values</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8665-wk-Fact-A2C8D5C7533E515EB203A3E9F7008E7C" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">705</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e8684-wk-Fact-F57AC8E1967F55269DC8AFBFE79580C5" name="us-gaap:EquitySecuritiesFvNi" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8704-wk-Fact-481D19D52F17581AA778E6FEED4C0D68" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,687</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e8723-wk-Fact-9A66FB2163DA5DAE918ECBCC09D77765" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,091</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8748-wk-Fact-7FCABA1279235052A9F940D43842EFE9" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e8767-wk-Fact-A1BC31C07767581A93AF73531CEB5E54" name="us-gaap:HeldToMaturitySecuritiesCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,003</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Total Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8797-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6" name="us-gaap:ShortTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e8816-wk-Fact-E3E97336ACA652838D81F531EE99F43B" name="us-gaap:ShortTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities with readily determinable fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8933-wk-Fact-B825E1F8270E5073B6C19C6710864302" name="pfe:EquitySecuritiesFVNINoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,902</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e8952-wk-Fact-1B305BDAC1905A55BF6F156149BF8268" name="pfe:EquitySecuritiesFVNINoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e8973-wk-Fact-466FA462BC555C57AE0A89AFA6C53AB5" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e8992-wk-Fact-0461922369945B39A341ADD2D54221CE" name="us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">491</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e9017-wk-Fact-12C700ACAEA5526091725A9A1BD61E05" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e9036-wk-Fact-D986B7B4ED2A5457A00D615881506333" name="us-gaap:HeldToMaturitySecuritiesNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">59</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Private equity securities at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e9061-wk-Fact-491578780A2C5C66A70F92CC76ABE497" name="pfe:PrivateEquityInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e9080-wk-Fact-EE96DEF0DD8B5A6B94DF2AB4D8D613D4" name="pfe:PrivateEquityInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">763</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Total Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e9110-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC" name="us-gaap:LongTermInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e9129-wk-Fact-38B878301DB957B297D2601592AD511A" name="us-gaap:LongTermInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e9149-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F" name="us-gaap:EquityMethodInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,133</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e9168-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE" name="us-gaap:EquityMethodInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term investments and equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e9198-wk-Fact-473FC4853D285A2D884D0B7E2D4AB721" name="pfe:LongtermInvestmentsAndEquityMethodInvestments" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20,147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e9217-wk-Fact-D9709CC6314D535485F61A85A5508983" name="pfe:LongtermInvestmentsAndEquityMethodInvestments" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,767</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34496162e9242-wk-Fact-B73BEBEF348353D2842BA6BE71FDAC31" name="pfe:HeldToMaturityCashEquivalents" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34496162e9261-wk-Fact-C36BF92CAF1E56628AE6498286970DCB" name="pfe:HeldToMaturityCashEquivalents" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">199</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup><ix:footnote id="TextSelection-00B1F244805F23E229ECE4C97135F977-0-wk-Footnote-00B1F244805F23E229ECE4C97135F977_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-00B1F244805F23E229ECE4C97135F977-1">&#160;</ix:footnote></span></div></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-00B1F244805F23E229ECE4C97135F977-1" continuedAt="TextSelection-00B1F244805F23E229ECE4C97135F977-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.</span></div></ix:continuation></td></tr></table><ix:continuation id="TextSelection-00B1F244805F23E229ECE4C97135F977-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Fair Value Methodology</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following inputs and valuation techniques were used to estimate the fair value of our financial assets and liabilities:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities&#8212;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities with readily determinable fair values&#8212;quoted market prices and observable net asset value prices.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative assets and liabilities&#8212;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Money market funds&#8212;observable net asset value prices.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">97</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s48928D0D9E74560C8465583865392294"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-44866C7DEE5949D51431801F831767F9-0" continuedAt="TextSelection-44866C7DEE5949D51431801F831767F9-1"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Investments</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Debt Securities</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="TextSelection-0EC9F2BC7D65E3B08DFC801F8316E68A-0-wk-Fact-0E7BB5B4C26A9B11F078801F7DE53458" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="TextSelection-4E3D455FFC94E05929FC801F8316FA33-0-wk-Fact-B371FA0F786D34DAEE73801F8111B988" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:HeldToMaturitySecuritiesTextBlock" id="TextSelection-B05D83F00BEFD41C6AEE801F83178EDF-0-wk-Fact-29437B32360C22211954801F7DD3953C" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"></td></tr><tr><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">December 31, 2019</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2526-wk-Fact-060DC2337D305CB589C3930B2AD02F4F" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2545-wk-Fact-9CA917534AE450CEAADED4A4F94030D1" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34501946e2565-wk-Fact-A75D5E0D1AE05935941EB4DCE9A667D4" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2585-wk-Fact-9938D6F7107B5482967DACD21E8DAA38" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2604-wk-Fact-030163DFAA6D5539933A8B3F30DAA159" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2624-wk-Fact-DB135AE5378150EFB07A732967B7ED02" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2643-wk-Fact-2590F356B7AE53EB895073F1E2DE7FF6" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e2662-wk-Fact-01D12574EFCE5397BFCE09A29051D331" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,754</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e2682-wk-Fact-A3B04B9190C5524FABA474FDBEC0A1D6" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(<ix:nonFraction id="d34501946e2701-wk-Fact-0593789538C254FB9B922CC6ED28C5BB" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e2721-wk-Fact-18AB1FBD36BF5912B8D2D6ACB0182D0B" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,703</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2746-wk-Fact-76AB23BB530F07D6CB16E4D1534480CF" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2765-wk-Fact-5C34C702ED52A020D19BE4D158B1218F" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34501946e2784-wk-Fact-D7650322FA82EA4D1827267B2561DEEA" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2805-wk-Fact-B00D1C2A51063472DDB3267B2554715C" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2824-wk-Fact-21487183205063A0D95FE4D168620FFE" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">811</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2844-wk-Fact-D3D3F7A5FE587D9647C8E4D16D912ED9" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2863-wk-Fact-37BAC7540AA10942CD9DE4D172DEDF5E" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e2882-wk-Fact-AFF7D1034A7949C4C9F1E4CFF755B236" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,804</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e2902-wk-Fact-532754C7D7DC08C12B1FE4CFFC0446F9" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(<ix:nonFraction id="d34501946e2921-wk-Fact-DA816034E43A7DA06928E4D000CB53F0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e2941-wk-Fact-A5F57A1DF8373D93DDC8E4D0052E96C6" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,782</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Corporate and other</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2969-wk-Fact-D4B1E0BBE3F058D3B98806E9C6B99CAF" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e2988-wk-Fact-7BA94F9ED2EC5F1A966CB3304B53AF56" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34501946e3007-wk-Fact-1F6DDFC5F407544BA48EE7A820F1CB06" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3028-wk-Fact-FB08398EDEE850A395E7D7BAD4CE39AD" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,025</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3047-wk-Fact-B708802DEAF9567DBA106E1C0C84390C" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3067-wk-Fact-F1667F5FCAC154B8954BDD808EA7CF01" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3086-wk-Fact-AF6AA38DDBAD57078BE06AFBF6047957" name="pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3105-wk-Fact-D993A80C463256F1AA201062DD098CB4" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3125-wk-Fact-E756524CD9B052E3BC12448706C676DB" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(<ix:nonFraction id="d34501946e3144-wk-Fact-A0AE51B2124A549B9B82AE9C29097AF0" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3164-wk-Fact-CD12D99291BD50F3BBC6B2BCAA5E89C9" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,097</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3420-wk-Fact-6BC5A5E262B2505AAFEB907075209997" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3439-wk-Fact-4734762739535CD587A0902B5A3B1488" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3458-wk-Fact-04585002970655668AECF04C9BB7B467" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3478-wk-Fact-B62369EB738157BA93A99FB83E03BDCA" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3497-wk-Fact-3EE2CE7C4A3A5E5897773D88C7FC8785" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">498</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3517-wk-Fact-570F53C118FE5E3097E443D45CBF8904" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3536-wk-Fact-0CDB8052D62B5FF0A88AD6BA33BADAEA" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3555-wk-Fact-9814239CCA795853A5E0998F66E96EDE" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3575-wk-Fact-379D8C1E85AB5E9896437DCD5EF28643" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3594-wk-Fact-3426C0EC192658D9A253878122888165" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3613-wk-Fact-4330F174398C5BBE83E439423EE4F668" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">668</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3643-wk-Fact-E33D3AF2318A516B9D5A5C9CA441D6B1" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3662-wk-Fact-4DD1E9425CBF5FCAB26591893C3A6513" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3681-wk-Fact-D545407F7F8D570D89503AD709A9B7AF" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3701-wk-Fact-90286A5BFB335674BA830B962989A1F0" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">803</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3720-wk-Fact-C0D6DB9F21A15096B97726601B96FAD3" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">798</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3740-wk-Fact-3B5526BFEC3151138F0F054A13698657" name="us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3759-wk-Fact-8D61E28CEF0C5E9DB11B9F7A1B506BF8" name="pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3778-wk-Fact-111714A65B915059991385B8F9897C0F" name="us-gaap:HeldToMaturitySecurities" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3798-wk-Fact-B59C18D8450655D8874D7478DDE7BE96" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3817-wk-Fact-B7C16C235F81570C9E1ADA7A5B0B50C4" name="us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e3836-wk-Fact-FFD4B813A0D25F0884657117E53BA608" name="us-gaap:HeldToMaturitySecuritiesFairValue" contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">592</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3868-wk-Fact-C7CB820F9ED75968AD8E30E7D40DD61B" name="pfe:DebtSecuritiesAmortizedCostBasis" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3887-wk-Fact-3B1D9B6888B05CC98299BAD0C52665B6" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34501946e3907-wk-Fact-B2E46496D8EF56EABBD814F260C33030" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3927-wk-Fact-AC0BFF2EA6D959F59969F893CF59CD09" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,340</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3946-wk-Fact-C470477049895AF99CC6FC97EA0B27E4" name="pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3966-wk-Fact-875C26BCE94D541C9463C55E244301C6" name="pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">322</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34501946e3985-wk-Fact-17832A2FC52E599589ECDAD934E52823" name="pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e4004-wk-Fact-0AEF4901D7965A55A4C1D45A592D3711" name="pfe:DebtSecuritiesAmortizedCostBasis" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e4024-wk-Fact-46FFB6099D71532FA46A93F0B309D4FC" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(<ix:nonFraction id="d34501946e4043-wk-Fact-688574457BB35963ABE4860299A7CAFC" name="pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34501946e4063-wk-Fact-B6299971D97B5083B4F8EAFD4F149957" name="us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,842</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily issued by a diverse group of corporations.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Equity Securities</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" id="TextSelection-84945A5AB6E23ACFCFFE801F83162822-0-wk-Fact-0A67D073155EE41A8B90801F7DD3F3D7" continuedAt="TextSelection-84945A5AB6E23ACFCFFE801F83162822-1" escape="true"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:68%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table presents the net unrealized (gains) and losses for the period that relate to equity securities, excluding equity method investments, still held at the reporting date, calculated as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net gains recognized during the period on equity securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34501946e4245-wk-Fact-364D49347A25577A9FDDC9569F869ED0" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34501946e4265-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net gains recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34501946e4286-wk-Fact-EF7F75F88BB456C49FDEB414EDA4D808" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34501946e4306-wk-Fact-8DFAE7CF1D355F33865A28A45027185B" name="us-gaap:EquitySecuritiesFvNiRealizedGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">109</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unrealized gains during the reporting period on equity securities still held at the reporting date</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34501946e4337-wk-Fact-2F8853D15C6E51BAB72642AB190884C3" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">429</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34501946e4357-wk-Fact-E53E9E5C1A0D55788064DA6EAE2FA60D" name="us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div></ix:nonNumeric></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-84945A5AB6E23ACFCFFE801F83162822-1" continuedAt="TextSelection-84945A5AB6E23ACFCFFE801F83162822-2"><ix:continuation id="TextSelection-44866C7DEE5949D51431801F831767F9-1" continuedAt="TextSelection-44866C7DEE5949D51431801F831767F9-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-84945A5AB6E23ACFCFFE801F83162822-2"><ix:continuation id="TextSelection-44866C7DEE5949D51431801F831767F9-2" continuedAt="TextSelection-A26C4738571C66A26768801F8317C69B-0"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The net gains on equity securities are reported in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net.</span><span style="font-family:Arial;font-size:7pt;"> For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><a id="sAB94F2C45EEB5BE58BA0462EAF352E5C"></a></div><ix:continuation id="TextSelection-A26C4738571C66A26768801F8317C69B-0" continuedAt="TextSelection-8F09149D28F82D98F96B801F831885EA-0"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Short-Term Borrowings</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShortTermDebtTextBlock" id="TextSelection-5BE56D549088AB135614801F8317E547-0-wk-Fact-31EFB2431FA0FC2A48E8801F7FA14F9D" continuedAt="TextSelection-5BE56D549088AB135614801F8317E547-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Short-term borrowings include:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Commercial paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34498941e1472-wk-Fact-F5F921B1937655B28A2E8CB3ACD2E6F6" name="us-gaap:CommercialPaper" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34498941e1491-wk-Fact-F4A852513E8B58CDA9569CE187B368C3" name="us-gaap:CommercialPaper" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current portion of long-term debt, principal amount</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34498941e1513-wk-Fact-A98C87D2BA285EA58206340681E8AC55" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,458</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34498941e1532-wk-Fact-BA94151A8C0D50BF9AA027BBFC277D06" name="pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,781</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other short-term borrowings, principal amount</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34498941e1559-wk-Fact-7BD53D154D3451E59F8DCFF457C25E21" name="us-gaap:OtherShortTermBorrowings" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">860</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34498941e1578-wk-Fact-C822D3E8545E59F38E6D05A0A14FFE9D" name="us-gaap:OtherShortTermBorrowings" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">966</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total short-term borrowings, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34498941e1603-wk-Fact-C8AE244F49C55C63878B4951E1449455" name="pfe:ShorttermDebtGross" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34498941e1622-wk-Fact-CB930CFE3CB15C809A3960EE663060A2" name="pfe:ShorttermDebtGross" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34498941e1647-wk-Fact-91CC3EC5DF5C5B229D9F46662E336761" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34498941e1666-wk-Fact-747327EC3AF258B9B09B9F73900E3D87" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34498941e1692-wk-Fact-95A8D8EAFF2057A79B308FFF9869400B" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34498941e1712-wk-Fact-07E994299E79573F8142DD38A281D53E" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span><span style="font-family:Arial;font-size:8pt;">, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34498941e1747-wk-Fact-D592F35F847457ABB1C2D0D22ED64864" name="us-gaap:DebtCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34498941e1766-wk-Fact-A51B51A828275272A7C573C440BF63F4" name="us-gaap:DebtCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,831</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A750B31D2CDA1870AFBA801F8317F8FF-0-wk-Footnote-A750B31D2CDA1870AFBA801F8317F8FF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7D</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-5BE56D549088AB135614801F8317E547-1" continuedAt="TextSelection-5BE56D549088AB135614801F8317E547-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-80773A0CFA5531791DCE801F8317B622-0-wk-Footnote-80773A0CFA5531791DCE801F8317B622_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-5BE56D549088AB135614801F8317E547-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7F</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The weighted-average effective interest rate on commercial paper outstanding was approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34498941e1817-wk-Fact-5FE40B9980006BD32E48801F7F9C39B0" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" contextRef="FI2019Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.92</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34498941e1825-wk-Fact-A2150506C09AEDD8981F801F7FA2F90A" name="us-gaap:ShortTermDebtWeightedAverageInterestRate" contextRef="FI2018Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.42</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had access to a total of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34498941e1840-wk-Fact-3AECDDFC3B75BEE92C95E4DBE4F88D41" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">15</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in U.S. revolving credit facilities consisting of a </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34498941e1844-wk-Fact-94285FDA5DF62BB0436BE4DC06A0DA59" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_pfe_CreditFacilityExpiring2024Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> facility expiring in 2024 and an </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34498941e1848-wk-Fact-21EEE5902AB5540FA72BE4DB2DA9AEA2" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_pfe_FacilityExpiringSeptember2020Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> facility expiring in September 2020, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34498941e1852-wk-Fact-EE5EB8BE1F59F6BEB5DDE4E451D17EAA" name="us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">537</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in lines of credit, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34498941e1857-wk-Fact-4E985C0FD5B521765F09E4DF24FAC57F" name="pfe:LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">508</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> expire within one year. Of these total lines of credit, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34498941e1861-wk-Fact-B69774305BABA06FB0B7E4DB78354020" name="us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity" contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">15.5</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> were unused as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">98</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sF2BADF31E7A05D3894795D33A24C7945"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-8F09149D28F82D98F96B801F831885EA-0" continuedAt="TextSelection-82080E3E729AA432494E801F831878C5-0"><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Long-Term Debt</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">New Issuances</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="TextSelection-1218F39AFD6723DC3AF4801F8318625F-0-wk-Fact-F93E14F1B9F34BC106A0801F7E4414C9" continuedAt="TextSelection-C00CD7E05AE8D007929F801F8318860F-0" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:62%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the first quarter of 2019, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.800% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;11, 2022</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e1462-wk-Fact-D5263DBF4F0653D689363EDF0100721F" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.950% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2024</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e1494-wk-Fact-6BB7FEB12FCA5295BF226B2D59D4A270" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.450% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2029</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e1531-wk-Fact-56A324A412FD5174AE9EB2CCB959DCC2" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.900% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2039</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e1568-wk-Fact-4489672EEE795DBDBE301A22943A4351" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4.000% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2049</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e1605-wk-Fact-E938067A39DA5B6A9EF9220D29E6E1FC" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt issued in the first quarter of 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e1646-wk-Fact-9A07B781512B6DC74011801F80FC2C4F" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,000</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The weighted-average effective interest rate for the notes at issuance was </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34509238e1673-wk-Fact-F386309A598956EE993526A09B54CDE1" name="us-gaap:DebtWeightedAverageInterestRate" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">3.57</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2018, we completed a public offering of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34509238e1712-wk-Fact-E2B34CF4ABAE85C9D525E501A4A07820" name="us-gaap:DebtInstrumentFaceAmount" contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1716-wk-Fact-C4823693F75884F3BC7C801F7E574D18" name="us-gaap:DebtWeightedAverageInterestRate" contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">3.56</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2017, we completed a public offering of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34509238e1723-wk-Fact-574FF2D5FB890E80F40A801F7E24A90C" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2017Q1Mar31_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">1.065</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of senior unsecured notes due 2047 with an interest rate of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1727-wk-Fact-B567A1791E477D503600801F82375E38" name="us-gaap:DebtWeightedAverageInterestRate" contextRef="I2017Q1Mar31_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">4.20</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">, and also in March 2017, we completed a public offering of &#8364;</span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1731-wk-Fact-1E6510C1833D190811AE801F7E779E3D" name="us-gaap:DebtInstrumentFaceAmount" contextRef="I2017Q1Mar31_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="iso4217_EUR" decimals="INF" scale="9" format="ixt:numdotdecimal">4.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of senior unsecured notes with a weighted-average effective interest rate of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1735-wk-Fact-E40D0BE76E944AA41AA0801F7E2CACF7" name="us-gaap:DebtWeightedAverageInterestRate" contextRef="I2017Q1Mar31_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">0.23</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Retirements</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In January 2019, we repurchased all </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;<ix:nonFraction id="d34509238e1745-wk-Fact-FD1441877E4D577081ECD81348D608A5" name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34509238e1749-wk-Fact-16BEC6A7C12856B28778212B2F5A701C" name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, at exchange rates on settlement) principal amount outstanding of the </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1753-wk-Fact-F14B894984A456E3A081F63F8B4AA566" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.75</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> euro-denominated debt that was due June 2021 before the maturity date at a redemption value of </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;<ix:nonFraction id="d34509238e1757-wk-Fact-76ACE1D3EB0D50B29FB6B4B0728CE8AD" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-8" scale="9" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34509238e1761-wk-Fact-42166BFE3C1C5620871B1D3BE4813114" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.5</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, at exchange rates on settlement). As a result, in the first quarter of 2019, we recorded a net loss of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34509238e1766-wk-Fact-526566BDFD6457DF82D7214A82842C7E" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q1QTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">138</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, which included the related termination of cross-currency swaps, and is reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">in the consolidated statements of income (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2017, we exchanged approximately </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;<ix:nonFraction id="d34509238e1784-wk-Fact-DA69EC3C235DC4AD5934801F7E2D3172" name="us-gaap:ExtinguishmentOfDebtAmount" contextRef="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="gbp" decimals="-6" scale="6" format="ixt:numdotdecimal">833</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> and repurchased </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;<ix:nonFraction id="d34509238e1788-wk-Fact-2AE12B62DF94665F3663801F7E6A2AD6" name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="gbp" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of the outstanding </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1792-wk-Fact-DC7954590A15CD344806801F7E10C87C" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.50</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> debt before the maturity date at a redemption value of </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;<ix:nonFraction id="d34509238e1796-wk-Fact-C949C6CEDD3921D0B5F1801F7E37BE01" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="gbp" decimals="-8" scale="9" format="ixt:numdotdecimal">1.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, leaving </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;<ix:nonFraction id="d34509238e1800-wk-Fact-4C6C066F59D043EB915D801F7E585968" name="us-gaap:LongTermDebt" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="gbp" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of the </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1805-wk-Fact-DC7954590A15CD344806801F7E10C87C" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.50</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> debt due 2038 outstanding. Also, in December 2017, we repurchased approximately </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;<ix:nonFraction id="d34509238e1809-wk-Fact-056670FCDF4076E094FD801F7E37CBC7" name="us-gaap:DebtInstrumentRepurchaseAmount" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-6" scale="6" format="ixt:numdotdecimal">834</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of the outstanding </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1813-wk-Fact-C93C3EAA2AA3B5EE6C61801F82399DF7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.75</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> debt before the maturity date at a redemption value of </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;<ix:nonFraction id="d34509238e1817-wk-Fact-A8560D27AAEBCAB664AC801F7E419A48" name="us-gaap:DebtInstrumentRepurchasedFaceAmount" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-8" scale="9" format="ixt:numdotdecimal">1.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">, leaving approximately </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;<ix:nonFraction id="d34509238e1821-wk-Fact-6E30A7AD0F844EF8739D801F8232845C" name="us-gaap:LongTermDebt" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="iso4217_EUR" decimals="-8" scale="9" format="ixt:numdotdecimal">1.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of the </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e1825-wk-Fact-C93C3EAA2AA3B5EE6C61801F82399DF7" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">5.75</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> euro-denominated debt due 2021 outstanding as of December 31, 2017. As a result, we recorded a net loss of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34509238e1830-wk-Fact-046237D900496E5BF3D0801F81E93368" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">846</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34509238e1834-wk-Fact-5DF392EBA37AB264B17D801F7E26D604" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">153</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> upon the exchange and early retirement of the U.K. pound-denominated debt and the early retirement of the euro-denominated debt, respectively, for a net loss on early retirement of debt of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34509238e1838-wk-Fact-9C352E3DD4A785F70BF4801F8231A7DB" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="D2017Q4Dec01-Dec31" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">999</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, which included the related termination of cross-currency swaps, and that were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> in the consolidated statement of income (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><ix:continuation id="TextSelection-C00CD7E05AE8D007929F801F8318860F-0" continuedAt="TextSelection-C00CD7E05AE8D007929F801F8318860F-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:74%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2019 and 2018 by maturity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2020 (1.2%)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2027-wk-Fact-67276C3C3805655E626C801F80B6FF7C" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2046-wk-Fact-F86E93B23C3F1D21812D801F7FA074B1" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,474</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2021 (0.7% and 3.4%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2066-wk-Fact-B03CD7C3B7455EC05821801F7F9FFF54" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2085-wk-Fact-972D3A38CB237CF20087801F809FB547" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,459</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2022 (1.0% and 0.3%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2110-wk-Fact-A424E690D91C218393CB801F7FA7AF24" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,624</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2129-wk-Fact-615A33CB3760FBC7EDBD801F7FA05F61" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2023 (3.7% and 3.8%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2154-wk-Fact-D03913D170D5C40EA459801F7FA292DB" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2173-wk-Fact-ED38E0D5C570B27F5801801F80A250BC" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,892</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2024 (3.9% and 4.4%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2198-wk-Fact-D9C1046CC79564D4CCCD801F80B35532" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2217-wk-Fact-9730CD26A5E9CF8ABB4E801F80ADD397" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2026-2029 (3.3%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2242-wk-Fact-3498CA6D4701B2985288801F809B48C0" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2261-wk-Fact-1890D02F21CDB814AF05801F809CB7CD" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2034 (6.5%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2286-wk-Fact-098DA8FBD6308DE75972801F7F9EA5A9" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2305-wk-Fact-84CCFD6D52B2CE636E5A801F7F9ED404" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2036-2040 (5.8% and 6.0%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2330-wk-Fact-9FDEB71FF42D94FCDD19801F809F3477" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,566</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2349-wk-Fact-1E8E3C18B4297EC24D84801F7FA4FE02" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2043-2044 (3.5%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2375-wk-Fact-DA10C7FC03F893411721801F80998712" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,568</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2394-wk-Fact-96EB7418C24EB73658CC801F80AD96C4" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,509</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2046-2049 (4.1% and 4.2%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2419-wk-Fact-A32CC770EFA1E649CDA4E4E8F88BFF20" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,565</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2438-wk-Fact-357778E4FFB2BFF68161E4E8F884955A" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,315</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2463-wk-Fact-D0B826C952035A20B1FFC436D83EA983" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34,820</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2482-wk-Fact-5F3EB27291CC30BEC668801F7FA9458E" name="us-gaap:DebtInstrumentCarryingAmount" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2507-wk-Fact-BEFE7AE513FF556C97743777B6248C49" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2526-wk-Fact-C7FAB96EE775813977FD801F7FA522FA" name="pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">479</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34509238e2551-wk-Fact-6D5E88C5179C563ABFFAE70C4B2A72C8" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34509238e2571-wk-Fact-F1C73F1DEB6D9381494D801F7FA86824" name="us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2597-wk-Fact-9BBE2B0BC12F5A3DBB215842E824C5E9" name="us-gaap:OtherLongTermDebt" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2616-wk-Fact-99FFB0A353AA4D10E92F801F7FA46C94" name="us-gaap:OtherLongTermDebt" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2646-wk-Fact-0D2E3798CA9654F998CE592D24D1A644" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2665-wk-Fact-A5909D837FBA536A99C7801F80B4572B" name="us-gaap:LongTermDebtNoncurrent" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32,909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34509238e2690-wk-Fact-9A71EE683E7D5DBF8DD77514DFAAF238" name="us-gaap:LongTermDebtCurrent" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,462</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34509238e2709-wk-Fact-8BB6F735B7DE1C3C3269801F80B24346" name="us-gaap:LongTermDebtCurrent" contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,776</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-C00CD7E05AE8D007929F801F8318860F-1" continuedAt="TextSelection-C00CD7E05AE8D007929F801F8318860F-2"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-1B6D1520B957E6708C32801F8318DAAD-0-wk-Footnote-1B6D1520B957E6708C32801F8318DAAD_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-C00CD7E05AE8D007929F801F8318860F-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, the debt issuances have been reclassified to the current portion of long-term debt.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our long-term debt, provided in the above table, is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">99</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s2046684263CE51249DEFFFFF3F5B0026"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-82080E3E729AA432494E801F831878C5-0" continuedAt="TextSelection-81F58C99B28F1592690B801F831946AE-0"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Other Noncurrent Liabilities</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Mylotarg (gemtuzumab ozogamicin)</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, the EU approved Mylotarg for the treatment of acute myeloid leukemia. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">ten</span><span style="font-family:Arial;font-size:8pt;">-year period aggregating </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1309-wk-Fact-163B919565D8A70146E1801F7F00AA31" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">301</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> related to an R&amp;D arrangement. We recorded the estimated net present value of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1313-wk-Fact-00C07AAC561D097B0950801F7E99AA40" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> as a liability and an intangible asset in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"> as of the approval date. In June 2018, we entered into a transaction with the obligee to buyout the remaining liability for the fixed annual payments for a lump sum payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1321-wk-Fact-DDCB2EFD60013E67F003801F7F01E0F0" name="pfe:ResearchandDevelopmentArrangementLiabilityBuyoutAmount" contextRef="I2018Q2Jun30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">224</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">. As a result of the buyout transaction, the liability was extinguished and we recognized a non-cash </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1326-wk-Fact-8ECBDE405C33A1FF9D79801F80B2C01E" name="pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction>&#160;million</span></span><span style="font-family:Arial;font-size:8pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> in the second quarter of 2018 (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Bosulif (bosutinib)</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2017, the FDA approved Bosulif for the treatment of patients with newly-diagnosed chronic-phase Ph+ CML. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">ten</span><span style="font-family:Arial;font-size:8pt;">-year period aggregating </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1348-wk-Fact-C1F815EBAE353BC7AC20801F7E9DB48C" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="FI2017Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">416</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> related to an R&amp;D arrangement. We recorded the estimated net present value of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1352-wk-Fact-E66436555A85696DBF1D801F7EB9218D" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2017Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">364</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> as of the approval date as an intangible asset in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. In August 2018, we entered into a transaction with the obligee to buyout a portion of the remaining liability for the fixed annual payments for a lump sum payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1360-wk-Fact-D617339AAB02E972F970801F7EABC4C2" name="pfe:ResearchandDevelopmentArrangementLiabilityBuyoutAmount" contextRef="I2018Q3Aug31_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">. As a result of the buyout transaction, the liability was reduced and we recognized a non-cash </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1365-wk-Fact-DF87F9BAC5571D656F5D801F7E9D0E33" name="pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> in the third quarter of 2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:8pt;"> The present value of the remaining future payments as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1381-wk-Fact-F2B49F2C13D3BACB39F9801F7EAA213A" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">191</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1385-wk-Fact-21995516ED50C011ADAB801F7F0ABDC0" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1394-wk-Fact-1DD27AE6CAF3A7303888801F7F01F6BF" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">169</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Besponsa (inotuzumab ozogamicin)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2017, the FDA approved Besponsa and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">nine</span><span style="font-family:Arial;font-size:8pt;">-year period aggregating </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1412-wk-Fact-8E9E6C510B365E9FB6C0801F7E998EB8" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="I2017Q3Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">296</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> related to an R&amp;D arrangement. We recorded the estimated net present value of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1416-wk-Fact-CCE7DE2A116A121D3D71801F7EACD200" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="I2017Q3Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">248</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> as of the approval date as an intangible asset in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. The present value of the remaining future payments as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1429-wk-Fact-034930D7B011E36B4E09801F7E9C4E21" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">242</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1433-wk-Fact-B4F4E77C842393826437801F7EAD406D" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1441-wk-Fact-E925D753331636286CA1801F7F00E1DE" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">235</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">nine</span><span style="font-family:Arial;font-size:8pt;">-year period aggregating </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1454-wk-Fact-AC00F9C78BF29D9105A9801F7F090C2F" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="I2017Q2Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> related to an R&amp;D arrangement. We recorded the estimated net present value of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1458-wk-Fact-A559A68BD922DC8D726C801F7EAEABDC" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="I2017Q2Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">123</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> as of the approval date as an intangible asset in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. The present value of the remaining future payments as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1470-wk-Fact-8473DFBA86E608ED81F0801F7EB9F8E7" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1475-wk-Fact-B63C3E37FDF3FE997E9B801F7EB94BBF" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34510350e1483-wk-Fact-586A388A57E0DE309C59801F7F0178AD" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, the differences between&#160;the estimated fair values, using a market approach in the Level 2 fair value hierarchy, and carrying values of these obligations were not significant.</span></div></ix:continuation><div><a id="s58B85FDC902C565896A2AAFEE582E8FC"></a></div><ix:continuation id="TextSelection-81F58C99B28F1592690B801F831946AE-0" continuedAt="TextSelection-81F58C99B28F1592690B801F831946AE-1"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">F</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Derivative Financial Instruments and Hedging Activities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Foreign Exchange Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet. The derivative financial instruments primarily hedge or offset exposures in the </span><span style="font-family:Arial;font-size:8pt;">euro, U.K. pound, Japanese yen, Chinese renminbi and Swedish krona</span><span style="font-family:Arial;font-size:8pt;">. Changes in fair value are reported in earnings or in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">, depending on the nature and purpose of the financial instrument (hedge or offset relationship) and the effectiveness of the hedge relationships, as follows: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Generally, we record in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;"> gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings. For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We record in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;"> the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. For foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For certain foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses on foreign currency exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">100</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-81F58C99B28F1592690B801F831946AE-1" continuedAt="TextSelection-81F58C99B28F1592690B801F831946AE-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted </span><span style="font-family:Arial;font-size:8pt;">euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar</span><span style="font-family:Arial;font-size:8pt;">-denominated intercompany inventory sales expected to occur no more than </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34538474e1371-wk-Fact-5B9755264B5E6ED7A26F0E475E856CDD" name="us-gaap:DerivativeTermOfContract" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember" format="ixt-sec:durwordsen">two years</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> from the date of each hedge. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For 2017, any ineffectiveness was recognized immediately into earnings. There was no significant ineffectiveness for 2017.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Interest Rate Risk</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings, as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We recognize the gains and losses on interest rate contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We also recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk in earnings.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">For 2017, any ineffectiveness was recognized immediately into earnings. There was no significant ineffectiveness for 2017.</span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsTextBlock" id="TextSelection-F7B56E23462F1BE25538801F831A5DA8-0-wk-Fact-EE2E5F1DBCE1A40D4CB9801F7EED2316" continuedAt="TextSelection-F7B56E23462F1BE25538801F831A5DA8-1" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" id="TextSelection-644F6BDED09D6467178C801F831A1D80-0-wk-Fact-B6D1CC995678F82567B2801F7EEC9AEA" continuedAt="TextSelection-644F6BDED09D6467178C801F831A1D80-1" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" id="TextSelection-EDE44C023F3E5F409CF5801F831AA267-0-wk-Fact-C9F10EBB47C17C0C20CB801F7EEF21B1" continuedAt="TextSelection-EDE44C023F3E5F409CF5801F831AA267-1" escape="true"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2109-wk-Fact-18D776DBF49C5BD0821AEAF95ADFD3B6" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25,193</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2128-wk-Fact-53FADFD5082D5F7483E92BF38D157660" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2148-wk-Fact-523DC6B2EC505EFFBFCB4D7A7C5179A9" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">662</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2167-wk-Fact-626CCC40E7795A0A83CE3935A24DFAFC" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,984</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2186-wk-Fact-61E9846E1AC95B2E9188CB7391BD7711" name="us-gaap:DerivativeAssets" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2206-wk-Fact-34FF2F3BFE615D19B8D425D5797E438A" name="us-gaap:DerivativeLiabilities" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2226-wk-Fact-FAB97B3154565FF7ACCDE5926A30648B" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,645</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2245-wk-Fact-10E78B9FC2CB567FA39F57B7F46A3527" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2264-wk-Fact-1D2EE74A6CFE5572B3888D1EB149327B" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2284-wk-Fact-CF35E2A094F2575F8AA3613567A8087C" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2303-wk-Fact-5FA9776EA82D59F491FACA0BC9F26789" name="us-gaap:DerivativeAssets" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2323-wk-Fact-08B759B927FB5CCF8401B6D7A0012D3C" name="us-gaap:DerivativeLiabilities" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2368-wk-Fact-1E8193513ADF509FB28268AD60667A35" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">909</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2387-wk-Fact-6FD3222CDBF95A90B3B10D57B96416B5" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">662</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2427-wk-Fact-B8D69335CB0953BFBDD5D1DCFA2937C8" name="us-gaap:DerivativeAssets" contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,085</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2447-wk-Fact-FEA472EE6FBE5B139E815023CB1EF451" name="us-gaap:DerivativeLiabilities" contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">968</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2733-wk-Fact-A6D7EF46287050348AD6FE8061437BB9" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19,623</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2747-wk-Fact-241ACB57C79A574A94DA7D7DBDA87F6A" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e2766-wk-Fact-15150F20255B56FCA245DF8F8F9516F6" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2791-wk-Fact-35CA45EADD6754889DF3AA5DC2254E4A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2805-wk-Fact-4C94D50EF315552AA69DBA71A7B15845" name="us-gaap:DerivativeAssets" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e2825-wk-Fact-C097E998B9A95CD985D87DA5B76EB616" name="us-gaap:DerivativeLiabilities" contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e3004-wk-Fact-2EA512967C8E54CBBF9C424D590E48B5" name="us-gaap:DerivativeAssets" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e3024-wk-Fact-8F4ABD1ACB045BD49AD9EC7BC62A82E8" name="us-gaap:DerivativeLiabilities" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e3063-wk-Fact-D78D2820B7EA526D95346F88EB4D9FC6" name="us-gaap:DerivativeAssets" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e3083-wk-Fact-9208AEA66AC559878BBF9748FF1C6BB1" name="us-gaap:DerivativeLiabilities" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,024</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-F7B56E23462F1BE25538801F831A5DA8-1" continuedAt="TextSelection-F7B56E23462F1BE25538801F831A5DA8-2"><ix:continuation id="TextSelection-644F6BDED09D6467178C801F831A1D80-1" continuedAt="TextSelection-644F6BDED09D6467178C801F831A1D80-2"><ix:continuation id="TextSelection-EDE44C023F3E5F409CF5801F831AA267-1" continuedAt="TextSelection-EDE44C023F3E5F409CF5801F831AA267-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><ix:continuation id="TextSelection-F7B56E23462F1BE25538801F831A5DA8-2" continuedAt="TextSelection-F7B56E23462F1BE25538801F831A5DA8-3"><ix:continuation id="TextSelection-644F6BDED09D6467178C801F831A1D80-2" continuedAt="TextSelection-644F6BDED09D6467178C801F831A1D80-3"><ix:continuation id="TextSelection-EDE44C023F3E5F409CF5801F831AA267-2" continuedAt="TextSelection-EDE44C023F3E5F409CF5801F831AA267-3"><span style="font-family:Arial;font-size:7pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34538474e3099-wk-Fact-6D2B160F53805A7DAAE8238BDE54594A" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2019Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.9</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34538474e3107-wk-Fact-0ADB280C3A6E575B8FE863989BFF8858" name="us-gaap:DerivativeNotionalAmount" contextRef="FI2018Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.8</ix:nonFraction> billion</span></span></ix:continuation></ix:continuation></ix:continuation><span style="font-family:Arial;font-size:7pt;"><ix:continuation id="TextSelection-F7B56E23462F1BE25538801F831A5DA8-3"><ix:continuation id="TextSelection-644F6BDED09D6467178C801F831A1D80-3"><ix:continuation id="TextSelection-EDE44C023F3E5F409CF5801F831AA267-3"> as of December 31, 2018</ix:continuation></ix:continuation></ix:continuation>.</span></div></ix:footnote></td></tr></table></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">101</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" id="TextSelection-D14AF9D6BD4B90C78D73801F831A4FBB-0-wk-Fact-8F5D88659A92A76AA675801F7EEE2B36" continuedAt="TextSelection-D14AF9D6BD4B90C78D73801F831A4FBB-1" escape="true"><ix:continuation id="TextSelection-81F58C99B28F1592690B801F831946AE-2" continuedAt="TextSelection-81F58C99B28F1592690B801F831946AE-3"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:34%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">525</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e4318-wk-Fact-19D10F7FBBB55166B828C57515F0E5DC" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34538474e4337-wk-Fact-722AC42D560351C29546696AF2E1458D" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34538474e4441-wk-Fact-99F422E9BA7958F2846EA6E7D03791DC" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">900</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e4461-wk-Fact-0F12AD78F79C5102A8E62FEDCC592E95" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e4565-wk-Fact-98F2A54AC46334361761E5206F313F68" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e4584-wk-Fact-BE88CEC570F652B19EAF84B100B1E47E" name="us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e4687-wk-Fact-A0164F459FB4FEDAE7F5E5206F2A0E3C" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34538474e4706-wk-Fact-1317FDFBDCC45E05A5F89D304C128317" name="us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34538474e5104-wk-Fact-D82E84CD29B95374845A78E05E6E431A" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">313</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e5125-wk-Fact-1AAB635BCEF5567C8400CCFFA9F211E9" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">175</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e5144-wk-Fact-90C896B3582A49B87DFDE5206F18DC24" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e5164-wk-Fact-9703446C4160595B906FE4A04D8E2262" name="us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D" name="us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency short-term borrowings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">68</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency long-term debt</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">149</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228" name="pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34538474e6074-wk-Fact-380993016EC856A5A43F951D0C773A80" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e6094-wk-Fact-AF8B407E154F54148E312BE4E9BB335A" name="us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34538474e6328-wk-Fact-2A9ACB09597856F4AD1723B635334EC2" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e6348-wk-Fact-BFDC8661881B55B6A476783E59E9740E" name="us-gaap:DerivativeGainLossOnDerivativeNet" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e6368-wk-Fact-2022231E382951F7A5219EA645136F0E" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e6387-wk-Fact-50286E7377FA596E859503D29B20ABBF" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">688</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e6406-wk-Fact-1C0A16C44A2B5C6AAE89B204324775E1" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">808</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e6426-wk-Fact-516913B914BB588F94ACCEBA9291FDAD" name="pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">OID = Other (income)/deductions&#8212;net,</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#160;</span><span style="font-family:Arial;font-size:7pt;">included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:7pt;"> COS = Cost of Sales, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-74B8B8E30D87649A0146801F83190686-1"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other comprehensive income/(loss)&#8211;&#8211;Unrealized holding gains/(losses) on derivative financial instruments, net</span><span style="font-family:Arial;font-size:7pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other comprehensive income/(loss)&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt"><ix:continuation id="TextSelection-74B8B8E30D87649A0146801F83190686-1"></ix:continuation>(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The amounts reclassified from OCI into COS were a net </span><span style="font-family:Arial;font-size:7pt;">gain</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in 2019 and a net </span><span style="font-family:Arial;font-size:7pt;">loss</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD" name="us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in 2018. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </span><span style="font-family:Arial;font-size:7pt;">gain</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34538474e6515-wk-Fact-EB69CCFC7CC65A8982AD547836C2F1E3" name="us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> within the next 12 months into </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales. </span><span style="font-family:Arial;font-size:7pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34538474e6523-wk-Fact-D369DD04BB2C55228C07E30F70F86B77" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> U.K. pound debt maturing in 2043. </span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">These amounts were reclassified from OCI into OID. </span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Short-term borrowings include foreign currency short-term borrowings with carrying values of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34538474e6551-wk-Fact-021E1E6E160854329B4D39B736D664D5" name="us-gaap:DebtCurrent" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34538474e6559-wk-Fact-A7EED1EE212B5BB4B30051042FFAB771" name="us-gaap:LongTermDebt" contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, which are used as hedging instruments in net investment hedges.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:nonNumeric><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">102</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-81F58C99B28F1592690B801F831946AE-3" continuedAt="TextSelection-38FD6858F07F98A363F8801F831B4211-0"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="TextSelection-83CBBCE91EBE7CE359F0801F8319F56E-0-wk-Fact-65FE9949F00B2F692555801F7EEDC54A" continuedAt="TextSelection-83CBBCE91EBE7CE359F0801F8319F56E-1" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" id="TextSelection-03A9A6352EB6D362933C801F831AA954-0-wk-Fact-847F8D04641F39FF4FEC801F7EEE8165" continuedAt="TextSelection-03A9A6352EB6D362933C801F831AA954-1" escape="true"><ix:continuation id="TextSelection-D14AF9D6BD4B90C78D73801F831A4FBB-1"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:24%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Value Hedging Adjustment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase/(Decrease) to <br/>Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedging</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7152-wk-Fact-60FB429DDE645C968BD3DD43109F92F8" name="us-gaap:HedgedAssetFairValueHedge" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7171-wk-Fact-08B6A3D22C1A50089C120A749928C2BD" name="us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7191-wk-Fact-A44BF54E1F40576DB69A53789CAD540E" name="us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e7210-wk-Fact-D7A2B5A28D785F81AA97C51023C56D44" name="us-gaap:HedgedAssetFairValueHedge" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34538474e7229-wk-Fact-432AB64A13FE55C8A7D98DBD67233F30" name="us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e7250-wk-Fact-3AC24C0C17AC5CEEB4628BA45D979F98" name="us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7270-wk-Fact-6081521688175CC5A7553A80707D9EAC" name="us-gaap:HedgedLiabilityFairValueHedge" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7289-wk-Fact-B5DD5D7C7E2859FCA19283FF4DD6F377" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7308-wk-Fact-EE56520C829954B3B37BD3262F4F7122" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e7328-wk-Fact-43DA714AD1B2538FB19B58AC471FCC10" name="us-gaap:HedgedLiabilityFairValueHedge" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,499</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34538474e7347-wk-Fact-F9C02E38A7885C6DA0C47A9C8CCAFEF4" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e7368-wk-Fact-EF408127DA3553578EB7BE6AF018F5E8" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7393-wk-Fact-5AE5207BC2F85C839F3BD7D293D59B4E" name="us-gaap:HedgedLiabilityFairValueHedge" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,092</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7412-wk-Fact-FC3625E26DF05F378B439729C453FCA2" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34538474e7431-wk-Fact-75CD43D1A6B55A7AA81A0BC872B73E3E" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">690</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e7451-wk-Fact-1D12DA44A07559DC9FEEB6C80CC2BAAA" name="us-gaap:HedgedLiabilityFairValueHedge" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34538474e7470-wk-Fact-EBDA3F55BD2454A2A6CE5D2BD1F8A8B5" name="us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34538474e7491-wk-Fact-DE35A00897A457A09B77F3C527455709" name="us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:nonNumeric></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-83CBBCE91EBE7CE359F0801F8319F56E-1" continuedAt="TextSelection-83CBBCE91EBE7CE359F0801F8319F56E-2"><ix:continuation id="TextSelection-03A9A6352EB6D362933C801F831AA954-1" continuedAt="TextSelection-03A9A6352EB6D362933C801F831AA954-2"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-83CBBCE91EBE7CE359F0801F8319F56E-2"><ix:continuation id="TextSelection-03A9A6352EB6D362933C801F831AA954-2"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain of our derivative financial instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties&#8217; exposure to risk of defaulting on amounts owed by the other party. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, the aggregate fair value of these derivative financial instruments that are in a net liability position was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34538474e7537-wk-Fact-21ADEB1537B054B39B8E1324C8A46177" name="us-gaap:DerivativeNetLiabilityPositionAggregateFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">449</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, for which we have posted collateral of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34538474e7541-wk-Fact-75AE77D361305A62A4114AC5EEE9B19E" name="us-gaap:CollateralAlreadyPostedAggregateFairValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">470</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in the normal course of business. If there had been a downgrade to below an A rating by S&amp;P or the equivalent rating by Moody&#8217;s, we would not have been required to post any additional collateral to our counterparties. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we received cash collateral of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34538474e7553-wk-Fact-B8AF1FCEAC105FF98FB132BD1C7544F8" name="us-gaap:SecuritiesReceivedAsCollateral" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">835</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt.</span></div></ix:continuation><div><a id="s8E102CF7DC225C4BB1D53324D9B149F7"></a></div><ix:continuation id="TextSelection-38FD6858F07F98A363F8801F831B4211-0"><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">G. Credit Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. For additional information about concentrations of credit risk related to certain significant customers, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17C</span><span style="font-family:Arial;font-size:8pt;">. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had amounts due from a well-diversified, high quality group of banks (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34511230e1310-wk-Fact-AC1B73048EA85B86B06D2C3DA8DC9707" name="us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" contextRef="FD2019Q4YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;">) from around the world. For details about our investments, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7B </span><span style="font-family:Arial;font-size:8pt;">above</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7F</span><span style="font-family:Arial;font-size:8pt;"> above.</span></div></ix:continuation><div><a id="sE4DB870128955984AE33D411D5EC717C"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 8. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:InventoryDisclosureTextBlock" id="TextSelection-04E8C12735852B56AD5C801F831C6AEC-0-wk-Fact-1BF268384744A67B7CB3801F8281A143" continuedAt="TextSelection-04E8C12735852B56AD5C801F831C6AEC-1" escape="true">Inventories</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="TextSelection-EEACAA4F6498C625F665801F831BDC68-0-wk-Fact-7870D0A1C712F6576AA7801F828182AF" continuedAt="TextSelection-EEACAA4F6498C625F665801F831BDC68-1" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock" id="TextSelection-B09CE6DB897A1AB29ABF801F831CC68A-0-wk-Fact-2AE72965378337BBF53F801F8283C102" continuedAt="TextSelection-B09CE6DB897A1AB29ABF801F831CC68A-1" escape="true"><ix:continuation id="TextSelection-04E8C12735852B56AD5C801F831C6AEC-1" continuedAt="TextSelection-04E8C12735852B56AD5C801F831C6AEC-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Inventories</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34512803e1495-wk-Fact-BD6370B452D35ABB91099D08BEF75B41" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34512803e1514-wk-Fact-419A5831FB265852854144F3E0A65D0B" name="us-gaap:InventoryFinishedGoodsNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,262</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34512803e1534-wk-Fact-F9BD92BFAD3E54C78BAB5EE118A99C9A" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34512803e1553-wk-Fact-C3A88391A2C858AE96AFCA01DAB816E8" name="us-gaap:InventoryWorkInProcessNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34512803e1578-wk-Fact-D58C1FEECC34507AB139DF2853E0618F" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">790</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34512803e1597-wk-Fact-45EB0661720F55BFAFC6A474125D98EA" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Inventories</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34512803e1629-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9" name="us-gaap:InventoryNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34512803e1648-wk-Fact-C16D2F781E815917AC4E583A6245970B" name="us-gaap:InventoryNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,508</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent inventories not included above</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34512803e1675-wk-Fact-1F6DFBB307AD56A78E5BB87151D63936" name="us-gaap:InventoryNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">714</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34512803e1694-wk-Fact-B3F7F06F30815B7EB3DF94113CFBD851" name="us-gaap:InventoryNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The change from </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;"> reflects increases for certain products, including inventory build for new product launches, supply recovery and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:footnote></td></tr></table></ix:continuation></ix:nonNumeric></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-EEACAA4F6498C625F665801F831BDC68-1" continuedAt="TextSelection-EEACAA4F6498C625F665801F831BDC68-2"><ix:continuation id="TextSelection-B09CE6DB897A1AB29ABF801F831CC68A-1" continuedAt="TextSelection-B09CE6DB897A1AB29ABF801F831CC68A-2"><ix:continuation id="TextSelection-04E8C12735852B56AD5C801F831C6AEC-2" continuedAt="TextSelection-04E8C12735852B56AD5C801F831C6AEC-3"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-99ECE6937087FF439970801F831B2740-0-wk-Footnote-99ECE6937087FF439970801F831B2740_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-EEACAA4F6498C625F665801F831BDC68-2"><ix:continuation id="TextSelection-B09CE6DB897A1AB29ABF801F831CC68A-2"><ix:continuation id="TextSelection-04E8C12735852B56AD5C801F831C6AEC-3"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:Arial;font-size:7pt;">. There are no recoverability issues associated with these amounts.</span></div></ix:continuation></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">103</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sE04ADE6A9CA452068563417FD37F2AB1"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 9</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="TextSelection-EF693C715660F196895C801F833558EF-0-wk-Fact-4F4968FD6524A8A2BD4C801F827F9433" continuedAt="TextSelection-EF693C715660F196895C801F833558EF-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Property, Plant and Equipment</span></ix:nonNumeric></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="TextSelection-3EE67E4834D35F8A7589801F8335D02C-0-wk-Fact-389FEC8CAF30481CBC74801F827E5368" continuedAt="TextSelection-3EE67E4834D35F8A7589801F8335D02C-1" escape="true"><ix:continuation id="TextSelection-EF693C715660F196895C801F833558EF-1" continuedAt="TextSelection-EF693C715660F196895C801F833558EF-2"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of Property, plant and equipment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Useful Lives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Years)&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34514486e1528-wk-Fact-487FEE7950F882D5EFFF801F7EE999FF" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">516</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34514486e1547-wk-Fact-1B3713B8B96882C8BB79801F7EE74AB8" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Buildings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">33-50</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34514486e1577-wk-Fact-165BE26211760ABF4668801F7E70F367" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,068</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34514486e1596-wk-Fact-17D2A084B9127B4205BC801F7E72470A" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,920</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8-20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34514486e1631-wk-Fact-D349C4ABE3A60240D999801F7EE8C9B3" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34514486e1650-wk-Fact-89AFFA89857503D34C30801F7E774504" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,871</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Furniture, fixtures and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3-12 1/2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34514486e1685-wk-Fact-5FD95F1BF2BD85AA0C38801F7E6A97B5" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,930</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34514486e1704-wk-Fact-8AC34551898939EE4337801F7E773DB2" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,693</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34514486e1739-wk-Fact-8B292287F89F655C383B801F7EE4F681" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34514486e1758-wk-Fact-BAB82E487E2040734D6A801F7EE54E34" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34514486e1793-wk-Fact-5A4A1109352F7996D99B801F7E71508D" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30,756</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34514486e1812-wk-Fact-E77A61A440EA6B42BFC0801F7EE6FC71" name="us-gaap:PropertyPlantAndEquipmentGross" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Accumulated depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34514486e1847-wk-Fact-66F574BF6D6B4D7B9CA3801F7E76E8E4" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,789</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34514486e1866-wk-Fact-818B506C032C30CFD6A8801F7EE99D49" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,591</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34514486e1908-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,967</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34514486e1927-wk-Fact-7F7E046052F852439B2A0884F029C60C" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-3EE67E4834D35F8A7589801F8335D02C-1" continuedAt="TextSelection-3EE67E4834D35F8A7589801F8335D02C-2"><ix:continuation id="TextSelection-EF693C715660F196895C801F833558EF-2" continuedAt="TextSelection-EF693C715660F196895C801F833558EF-3"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><ix:continuation id="TextSelection-3EE67E4834D35F8A7589801F8335D02C-2" continuedAt="TextSelection-3EE67E4834D35F8A7589801F8335D02C-3"><ix:continuation id="TextSelection-EF693C715660F196895C801F833558EF-3" continuedAt="TextSelection-EF693C715660F196895C801F833558EF-4"><span style="font-family:Arial;font-size:7pt;">The increase in total property, plant and equipment is mainly due to capital additions, partially offset by depreciation, reductions due to asset impairments largely associated with cost reduction initiatives not associated with acquisitions (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span></ix:continuation></ix:continuation><span style="font-family:Arial;font-size:7pt;"><ix:continuation id="TextSelection-3EE67E4834D35F8A7589801F8335D02C-3"><ix:continuation id="TextSelection-EF693C715660F196895C801F833558EF-4">), and the impact of foreign exchange.</ix:continuation></ix:continuation><ix:footnote id="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"> </ix:footnote></span></div></td></tr></table><div><a id="s97872BCAF1AB52C1B6099A1A4AE893B0"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 10</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="TextSelection-838FF2C77F703A0AD01D801F833686D0-0-wk-Fact-159C7D87F8C9D28A908D801F81A8491B" continuedAt="TextSelection-838FF2C77F703A0AD01D801F833686D0-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Identifiable Intangible Assets and Goodwill</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"> </span></ix:nonNumeric></div><ix:continuation id="TextSelection-838FF2C77F703A0AD01D801F833686D0-1" continuedAt="TextSelection-838FF2C77F703A0AD01D801F833686D0-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Identifiable Intangible Assets</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Balance Sheet Information</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:30%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gross</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accumulated</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Identifiable</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets, less</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accumulated</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Gross</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Carrying</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Accumulated</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Identifiable</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Intangible</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Assets, less</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Accumulated</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e1929-wk-Fact-A089F24D480155BE84E9E384AAB61EDF" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">88,730</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34529301e1948-wk-Fact-D40799FE54FE50768D7FC07B9F31BF58" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63,106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e1969-wk-Fact-AA8CABF2F570588CA468DCE619BE951F" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25,625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e1988-wk-Fact-0CDCE653A5E45D5BA0F60BE9927B384C" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">89,430</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e2007-wk-Fact-9727ED04B3395B12A9B3B5A9C5599258" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58,895</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2028-wk-Fact-9C0330EE00BC595DB7D0BE5577BD9383" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2048-wk-Fact-B57EC916EB03577B91F7FAFE4CBFD72C" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34529301e2067-wk-Fact-C9B6349A00AF54CF9FD25791C74053D6" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">741</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2087-wk-Fact-DD7AC3C2C7A55E84A0C7863FF827A99F" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2107-wk-Fact-B7E1675F707854F0B9ACB50C0CA3FFDD" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">923</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e2126-wk-Fact-4E4551ADFB795B0DA95CA235A2FEBD3B" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">708</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2147-wk-Fact-EB804E5AFF285115BCBB6276A7DB4B48" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2174-wk-Fact-FF4615007CC653C7B1758F53F75C3121" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34529301e2193-wk-Fact-E9E2C2D229FB5FD08F618AA417F7A246" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,191</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2213-wk-Fact-19548AB61F0E5995A6CDA20B4FE892D2" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">582</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2233-wk-Fact-8266B3DB731A5825ABEED6BC4888318C" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,436</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e2252-wk-Fact-B9EEDF4C478F5FE399BD8F88FA3C4292" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2273-wk-Fact-6353F406AD7D5730BA1BF2FBE27EFAE9" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2298-wk-Fact-FBA220C2143D5E3A8C4CA612D459EA25" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91,425</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34529301e2317-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2337-wk-Fact-7793C4E0CE4652AE81162C77F4E13B72" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,387</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2357-wk-Fact-4FE2437D504C55B3B558E838499BAEC5" name="us-gaap:FiniteLivedIntangibleAssetsGross" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91,788</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e2376-wk-Fact-940CD216AF3B5681959A8635C41B9FA0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2397-wk-Fact-C970DDB03A565589B9F58C3B89469AE1" name="us-gaap:FiniteLivedIntangibleAssetsNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,045</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2550-wk-Fact-D0D03595E4C355EA8B97FD0E2AB14588" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2587-wk-Fact-D0D03595E4C355EA8B97FD0E2AB14588" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2607-wk-Fact-E20757D4B07A542F8E595AF676431E1A" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2645-wk-Fact-E20757D4B07A542F8E595AF676431E1A" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,991</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2672-wk-Fact-B2B1CAAC615F5CB290A86932BBE5F716" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2709-wk-Fact-B2B1CAAC615F5CB290A86932BBE5F716" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,919</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2729-wk-Fact-EA2A0D133C2F552A835AAE5BE5CEA71E" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2767-wk-Fact-EA2A0D133C2F552A835AAE5BE5CEA71E" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2795-wk-Fact-643D9E90F2225078A9387D3F21E73814" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2832-wk-Fact-643D9E90F2225078A9387D3F21E73814" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,073</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2852-wk-Fact-561E433B6B30525EBA77DD0C09816B40" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2892-wk-Fact-561E433B6B30525EBA77DD0C09816B40" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2917-wk-Fact-C75772DD1349525E977292533AAEBDD9" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e2954-wk-Fact-C75772DD1349525E977292533AAEBDD9" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,983</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e2974-wk-Fact-78A6E01615AC5CA5AA78BEDF0E5647D2" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e3012-wk-Fact-78A6E01615AC5CA5AA78BEDF0E5647D2" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3044-wk-Fact-BB4D97BFDF50513BAE0BF29E98F95690" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100,408</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34529301e3063-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">65,037</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e3103-wk-Fact-E4D712528036514CA1CCFB0C4C138D8D" name="us-gaap:IntangibleAssetsGrossExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95,954</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e3122-wk-Fact-940CD216AF3B5681959A8635C41B9FA0" name="us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">60,743</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D" name="us-gaap:IntangibleAssetsNetExcludingGoodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-29EE02E10588E0192531801F8336F241-0-wk-Fact-85AC8C1CFEA3C8C75837801F81B7665B" continuedAt="TextSelection-29EE02E10588E0192531801F8336F241-1" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" id="TextSelection-EF6F5828EFAB414A3B3A801F83369516-0-wk-Fact-53E42CCE5976B2998E41801F81BAF02F" continuedAt="TextSelection-EF6F5828EFAB414A3B3A801F83369516-1" escape="true"><span style="font-family:Arial;font-size:8pt;"><br/></span></ix:nonNumeric></ix:nonNumeric></div><ix:continuation id="TextSelection-29EE02E10588E0192531801F8336F241-1" continuedAt="TextSelection-29EE02E10588E0192531801F8336F241-2"><ix:continuation id="TextSelection-EF6F5828EFAB414A3B3A801F83369516-1" continuedAt="TextSelection-EF6F5828EFAB414A3B3A801F83369516-2"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The increase in the gross carrying amount of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">I</span><span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets </span><span style="font-family:Arial;font-size:7pt;text-align:right;">mainly reflects the impact of the acquisition of Array, including the addition of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34529301e3179-wk-Fact-48D871521FAD5D3CB39F25B3CDCABD0C" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;text-align:right;"> of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34529301e3187-wk-Fact-72B7FF5E1A7E524A93960464DEEF1FB5" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">340</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> of</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">finite-lived </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreements, </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34529301e3198-wk-Fact-BAFC3442AE0D55949C2C6B7CE309CF0F" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">IPR&amp;D</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34529301e3206-wk-Fact-D6F35499769551BEA123C478BC1A6C46" name="us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsTechnologyInDevelopmentMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">1.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> of indefinite-lived </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreement</span><span style="font-family:Arial;font-size:7pt;">s</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">(see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">), partially offset by intangible asset impairment charges, primarily for Eucrisa in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:7pt;">. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </span><span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Reflects acquired licensing agreements for technology in development.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The increase in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">I</span><span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:7pt;text-align:right;">, </span><span style="font-family:Arial;font-size:7pt;">is mostly due to the additions noted in (a) above, partially offset by amortization and intangible asset impairment charges, primarily for Eucrisa in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:7pt;">. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </span><span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3466-wk-Fact-29E9C2979F21521B9EC402EC880FB20B" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">99</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3481-wk-Fact-CDAC44F40E515B25B7264AE3B5C51C8C" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3496-wk-Fact-7F417EF288B15C9F87FD23B676E50412" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3516-wk-Fact-5612C284C4185608AD176585068C6961" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3531-wk-Fact-844C37786CAF534396F9FDF10C810FC8" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3545-wk-Fact-6DE44FEB16EA57E58CD89ED2117B86F1" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3565-wk-Fact-903ABB244B4C5D57B66CFE5FEC304D42" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3580-wk-Fact-9B1C3CCD6E1E5C8DA8E36F17D44E57B5" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3595-wk-Fact-D4117B92D54A554FA5A3733B037B745B" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3615-wk-Fact-D790102B2F3F57EFA369326A27D47D8E" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3630-wk-Fact-D689D021180F559A892AC702882DBE27" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3644-wk-Fact-65ABED6A74FF545CBFFD4E8030920025" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3665-wk-Fact-63A31C70A4EB5D59B08B35B2AA4B6BD4" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3680-wk-Fact-4ECE9221166E5692953AFD721C1B6459" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3694-wk-Fact-601110CBEAC158A8938D91FB12927A84" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other, indefinite-lived</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3715-wk-Fact-9284C38811555BD4A1839CE964530C2E" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3730-wk-Fact-2CFDD7F50551528883630C303C4B6D92" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e3744-wk-Fact-B85D149E46075BA8A28D5AE51B33D2EA" name="pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" unitRef="number" decimals="2" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:continuation></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">104</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-838FF2C77F703A0AD01D801F833686D0-2" continuedAt="TextSelection-838FF2C77F703A0AD01D801F833686D0-3"><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;"><ix:continuation id="TextSelection-29EE02E10588E0192531801F8336F241-2"><ix:continuation id="TextSelection-EF6F5828EFAB414A3B3A801F83369516-2"></ix:continuation></ix:continuation>Developed Technology Rights</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Xtandi, Prevnar 13/Prevenar 13 Infant, Braftovi/Mektovi, Eucrisa, Premarin, Prevnar 13/Prevenar 13 Adult, and, to a lesser extent Tygacil, Zavicefta, Pristiq, Refacto AF and Bosulif. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Brands</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protection. The more significant components of indefinite-lived brands are the following (in order of significance): Xanax, Medrol and Depo-Medrol. The more significant components of finite-lived brands are the following (in order of significance): Depo-Provera and Zavedos.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">IPR&amp;D</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">IPR&amp;D assets represent R&amp;D assets that have not yet received regulatory approval in a major market. The significant components of IPR&amp;D at December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> include IPR&amp;D assets acquired in connection with the Array acquisition and the program for the oral PARP inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer acquired as part of the Medivation acquisition. IPR&amp;D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&amp;D effort. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&amp;D and begin amortization. If the associated R&amp;D effort is abandoned, the related IPR&amp;D assets will likely be written-off, and we will record an impairment charge.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For IPR&amp;D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and, as such, we expect that many of these IPR&amp;D assets will become impaired and be written off at some time in the future.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Licensing Agreements</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements for developed technology and licensing agreements for technology in development primarily relate to out-licensing arrangements acquired from third parties, including the Array acquisition. These intangible assets represent the amortized or unamortized cost associated with the license, where Pfizer has acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partner. A significant component of the licensing arrangements at </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> are for out-licensing arrangements with a number of partners for oncology technology in varying stages of development that have not yet received regulatory approval in a major market. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will likely be written-off, and we will record an impairment charge.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Amortization</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The weighted-average life for each of our total finite-lived intangible assets and the largest component, developed technology rights, is approximately </span><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;"><span><ix:nonNumeric id="d34529301e3833-wk-Fact-727D7A8D27B17F862B66801F81A8419A" name="us-gaap:FiniteLivedIntangibleAssetUsefulLife" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember" format="ixt-sec:duryear">9</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;">years.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">Total amortization expense for finite-lived intangible assets was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34529301e3843-wk-Fact-0AC50A34D7CC5E289579E8C791E6DF78" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.7</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;color:#000000;text-decoration:none;"><span>$<ix:nonFraction id="d34529301e3851-wk-Fact-2D211E0C2F355AE4A0A872BB8501DD69" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34529301e3860-wk-Fact-678050803F2269F67D6E801F81B6A225" name="us-gaap:AmortizationOfIntangibleAssets" contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">4.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" id="TextSelection-39120F38C52C37E24B2B801F83363E4D-0-wk-Fact-D8BE298EB7C2ECAAD7BB801F81A92318" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the annual amortization expense expected for the years 2020 through 2024:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4126-wk-Fact-97B7669EBAA1A8397234801F81D529FD" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4145-wk-Fact-522358F6C59BAB94111A801F81CD6DF7" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4165-wk-Fact-4647C2C66537B5556274801F81CE125D" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,151</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4184-wk-Fact-84AD40105039733D4972801F81CEDE1A" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,851</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4203-wk-Fact-0D600E3EFF5EBE564FD6801F81CE55F2" name="us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Goodwill</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior to 2019, we managed our commercial operations through </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4234-wk-Fact-D17055AF0AB4DC9AC143801F8131E959" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2018Q4YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our 2019 fiscal year, we reorganized our commercial operations and our businesses have been managed through </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4238-wk-Fact-E001667F01F95E298014FB8B5A7B8850" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q4YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> different operating segments&#8211;&#8211;Biopharma, Upjohn and through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Pfizer&#8217;s Consumer Healthcare business (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17</span><span style="font-family:Arial;font-size:8pt;"> for further information). Our Consumer Healthcare business was classified as held for sale as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:8pt;"> for further information). Additionally, upon closing of the transaction during the third quarter of 2019, we deconsolidated our Consumer Healthcare business and derecognized Consumer Healthcare goodwill.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a result of the reorganization of our commercial operations, our remaining goodwill was required to be reallocated amongst the then new Biopharma and Upjohn operating segments by determining the fair value of each reporting unit under our old and new management structure and the portions being transferred. We completed this re-allocation based on relative fair value in the second quarter of 2019 and have retrospectively presented goodwill according to the new operating structure.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">105</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfGoodwillTextBlock" id="TextSelection-A96462E6E9EB7A3A8B7F801F83363325-0-wk-Fact-BAA6B1F0437AD4E92B18801F81AC215E" continuedAt="TextSelection-A96462E6E9EB7A3A8B7F801F83363325-1" escape="true"><ix:continuation id="TextSelection-838FF2C77F703A0AD01D801F833686D0-3" continuedAt="TextSelection-838FF2C77F703A0AD01D801F833686D0-4"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4481-wk-Fact-78B0E3B991B3A3C123F8D85DDC02ABB7" name="us-gaap:Goodwill" contextRef="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">43,359</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4500-wk-Fact-E0D2F908D32839362EFAD85DDBA5311D" name="us-gaap:Goodwill" contextRef="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4520-wk-Fact-A6A7CAA05C1DF579FB00D85E8610EE29" name="us-gaap:Goodwill" contextRef="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4539-wk-Fact-28BA1C6C5DA1C76DC680D85DDBC04825" name="us-gaap:Goodwill" contextRef="FI2017Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e4561-wk-Fact-E2D26B3B9514260520BAD85DDAA659BB" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e4581-wk-Fact-BD96EFDCEF39E408FD37D85DDBD98655" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e4601-wk-Fact-7F9C57983A364C82C7B8D85DDABE68FA" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,993</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34529301e4621-wk-Fact-DC29F3E24AC4E1D31CB3D85DDB384CCC" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,541</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4647-wk-Fact-76674072D9805C48BC3A510964694B90" name="us-gaap:Goodwill" contextRef="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4666-wk-Fact-77B10850E22057F2BD7241BFDBA92E2A" name="us-gaap:Goodwill" contextRef="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4685-wk-Fact-4F877B49DAAE56C1C475D85E8A984C1B" name="us-gaap:Goodwill" contextRef="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34529301e4705-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04" name="us-gaap:Goodwill" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Additions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4732-wk-Fact-267B1096BA37527F9F57BD86C5CF0ACF" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4751-wk-Fact-C45B07370E9D1070339E801F7FB12D9A" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4770-wk-Fact-BE4C23E3208BEB55E46ED85E8DBE2AC5" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4790-wk-Fact-CC09067F9E93539BA598F5986D30A0D2" name="us-gaap:GoodwillAcquiredDuringPeriod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,411</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34529301e4817-wk-Fact-7331B3996B7156028ABA17B0B6F034DA" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34529301e4837-wk-Fact-F3A34AC6947D589C87DC5D125305250F" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4857-wk-Fact-D9E19CB4E10F040A89ABD85E8FD4E4A8" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34529301e4877-wk-Fact-36EFF26A70BF5280BEBB3D0AA77CBFFB" name="us-gaap:GoodwillOtherIncreaseDecrease" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4908-wk-Fact-76552E517DE250B9A465A80EEC1B1FED" name="us-gaap:Goodwill" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48,202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4927-wk-Fact-A43F18A2464E5CFCB172C24E0F20C54E" name="us-gaap:Goodwill" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4947-wk-Fact-9467D88470844F708747D85DDAAFF235" name="us-gaap:Goodwill" contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34529301e4965-wk-Fact-6EE57D419E98505BB872CDF37DAACD72" name="us-gaap:Goodwill" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily reflects the reclassification of our Consumer Healthcare business as</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">held for sale (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;">), the impact of foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biopharma additions relate to our acquisition of Array (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table></ix:continuation></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-bottom:10px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-A96462E6E9EB7A3A8B7F801F83363325-1" continuedAt="TextSelection-A96462E6E9EB7A3A8B7F801F83363325-2"><ix:continuation id="TextSelection-838FF2C77F703A0AD01D801F833686D0-4" continuedAt="TextSelection-838FF2C77F703A0AD01D801F833686D0-5"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-A96462E6E9EB7A3A8B7F801F83363325-2"><ix:continuation id="TextSelection-838FF2C77F703A0AD01D801F833686D0-5"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily reflects the impact of foreign exchange.</span></div></ix:continuation></ix:continuation></td></tr></table><div><a id="sCCB147A3418F5EBC9B69E8AC37C8EB38"></a></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 11</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-0-wk-Fact-9C67C68015CFEABC39A9801F8080D7B5" continuedAt="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Pension and Postretirement Benefit Plans and Defined Contribution Plans</span></ix:nonNumeric></div><ix:continuation id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-1" continuedAt="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" id="TextSelection-D3D653DC07673AEE8478801F8345DAE5-0-wk-Fact-58FDE3F84B838840532E801F80CA871A" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td></tr><tr><td colspan="49" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the annual (credit)/cost and changes in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">&#160;for our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="47" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Qualified</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Service cost</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2692-wk-Fact-6933FD29A03F60C5C1DB801F8037A1E9" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e2711-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2730-wk-Fact-8ACD50A587CEC7867541801F81EBAED4" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2750-wk-Fact-E2FFF18A87ED82A265A1801F8065BD9A" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e2769-wk-Fact-D8C072D06B49773A72EE801F81FC0B93" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2788-wk-Fact-547A9426B8FEDD3D980A801F821CD025" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2808-wk-Fact-B8932CAFC2CF99FDC067801F7FD54D8F" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e2827-wk-Fact-DB9558D1E67DB9DBC296801F821D4332" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2846-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2866-wk-Fact-AFB9A55388F572AD8D2E801F7FC2597A" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e2886-wk-Fact-823CFC536B2415CC760F801F821963E0" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">629</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2905-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2924-wk-Fact-A1514905E048F0FFA68C801F800B7A4F" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e2944-wk-Fact-1645F7BA211F13D895DB801F821CDBB9" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2963-wk-Fact-B14453A638517C4D7C51801F82449662" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e2983-wk-Fact-4D7E696D36452A8FBABE801F80035C76" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e3002-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3021-wk-Fact-56AC0425594EB6B614D8801F82235863" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3041-wk-Fact-E9C0E588D60EFF449BEC801F802BF05A" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e3060-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3079-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3099-wk-Fact-9ED0AE1AAFE89D27C637801F7F9951A8" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e3124-wk-Fact-E90985269B2154239A430851FD659027" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">890</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3144-wk-Fact-0065C22DDD425D5EB99735A6E835EC0F" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,040</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3164-wk-Fact-6178D606D0576009E7D8801F800B47C5" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,005</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e3185-wk-Fact-2DBF4D472C975F0AA14D950D65306807" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3204-wk-Fact-76BACCA131EA51D1B5D320A3CF59AF39" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3224-wk-Fact-850543A2F7B16A871226801F7FC88CC3" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e3243-wk-Fact-AB60FFA4D6735ECEAE192A4A707DAC2B" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">317</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3263-wk-Fact-9106EFBD5E1A5015B50F669BF7823045" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3284-wk-Fact-BBD005126C8B7BF17012801F7F829DC1" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e3304-wk-Fact-BACCC5530F605EA1BB11F5908E9CB895" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3324-wk-Fact-8F2397DD8AFC5996996D132715997194" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3345-wk-Fact-38C16925125E7F347AD0801F80703D12" name="us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial losses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e3615-wk-Fact-3F59543875025E468AEF3F683189F304" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3634-wk-Fact-C3D0942856A1581EAF48531154A4786E" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">120</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3653-wk-Fact-378E7CFB0C3366BE1636801F7F982A6D" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">393</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e3673-wk-Fact-931C9AE7EA695C8789803ED34BF3218D" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3692-wk-Fact-D3F2DE5872EC5230B439CD011DA01871" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3712-wk-Fact-F538ACACF4943B2112FE801F7FAADCE2" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e3731-wk-Fact-6DB8EEE5D9865BED9C6C65D55477AD7B" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3750-wk-Fact-0AFCCC455878510D879042E7F8FF809D" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">101</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3770-wk-Fact-5FCA9B06E5F243C62A7E801F7F95C2A9" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e3789-wk-Fact-4B742D12220955FCB8512E0C28478091" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3808-wk-Fact-D8C77E7DECB85CFDA69FCED349A74F3B" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3828-wk-Fact-945DBFC591102C8BB117801F803ED887" name="us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service cost/(credit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e3853-wk-Fact-C8FEE220A6AD511B90AEDFED4C8522CE" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3873-wk-Fact-AB1A5D7154D55524B1896C7D13EEE1BE" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e3892-wk-Fact-3503C852F9E4ADA0D97B801F7FA9C9D8" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e3912-wk-Fact-FB5534AC2119581C97F07FAA8E748328" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3932-wk-Fact-613E0B05B7865D04A43CD9F51978D9DE" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3953-wk-Fact-686319F7B5604E2276BE801F7FE6F206" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e3973-wk-Fact-034EF17B9785562AAB08D4DFF03B6380" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e3993-wk-Fact-D723E7932AD45B5CBA0CD8286F87796C" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e4014-wk-Fact-FA93D99FAC7F7CCD240D801F7F9D9735" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e4034-wk-Fact-6E21A5F3FA86557DA2ADBE81D11BF014" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e4054-wk-Fact-299F68F3E4305B7396AD49A92B1DBD31" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">178</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e4075-wk-Fact-8D966B14A8E40A9AFA58801F80294ADF" name="us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4102-wk-Fact-2648C18B67135722AC996F7545880D80" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4121-wk-Fact-4BC04F50F859575786CDEB42846504B3" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4140-wk-Fact-EB4AB9F6D4F4A8E5149B801F8025CB18" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">13</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4160-wk-Fact-ADD074ED2993574E8FE7A245F23A9D4B" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4179-wk-Fact-6BAF9C5EBA26505A8C43CBAC57E0BE83" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4199-wk-Fact-AE778EF034BB21B505CE801F8013E5BF" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e4218-wk-Fact-18079E34B32C53C996423C831A0FD2B8" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e4238-wk-Fact-BDFDACC2489653DB8B1E70291B40AAAF" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4259-wk-Fact-A9E0EFC1F162C6867416801F7FA92E48" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e4278-wk-Fact-250C34725FF05BB883239FC420341A54" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e4298-wk-Fact-A16A027B92E3524680E14BE5F7592565" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e4319-wk-Fact-41C48699245DA0B3860D801F7FFA7301" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4345-wk-Fact-07AD3C926A5E57D3A3F93B11BDBF155E" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4364-wk-Fact-36071102556E5A8BB41605B5E0E61960" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4383-wk-Fact-4F6A9D76BC23A664699C801F8033D7FF" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4403-wk-Fact-C0B43F53E7035856B1B1655A6BCF5C25" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4422-wk-Fact-0B9C9F05CB1359C9B15B904FBBE01B56" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">26</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4442-wk-Fact-F4700D93FA2B1270B85C801F7FEB6678" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4461-wk-Fact-900B4862554A52598347DDC7EF675D33" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4480-wk-Fact-AEB2DA29464457BA8DD64A5602FF3160" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4500-wk-Fact-EDC2B33055CD699CD5D1801F7FD79DE8" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e4519-wk-Fact-421F0B17A1105BA186D024847A9EBECA" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4539-wk-Fact-6A30FA2A36BB576592292682CE57A8D6" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4559-wk-Fact-6E00A7BE0DEEA1145279801F7F63CF6A" name="us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4584-wk-Fact-691D5136507A5CF6B58B87FA8C2DFF67" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4603-wk-Fact-2CA2DA51FA5858A080A8149D1EF99AE3" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4622-wk-Fact-C8A8BF249D3C3080DE9D801F803E1DD7" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4642-wk-Fact-4CD2842806B75D2987F3D6D6054096C4" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4661-wk-Fact-5BCE1C36478B5183BA92A14694D138F2" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4681-wk-Fact-87F7B018BE7018B441C1801F804B0D50" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4700-wk-Fact-D9CF230D68F550D2B21951B73C9C2B82" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4719-wk-Fact-F3515DDE6FCB5C6F827698B135BF72F5" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4739-wk-Fact-EA99DFE18AC2A9E31A59801F7F7FCB2A" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4758-wk-Fact-8401190048BF54B4B1327C5B7A8B73E7" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4777-wk-Fact-5010E3E80A16592EA0A75F6671DD8D80" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4797-wk-Fact-2D245F010E417F9A342B801F7FB3C282" name="us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit cost/(credit) reported in income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4824-wk-Fact-B85C9CC9D293576C909EA9314FC824EE" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e4843-wk-Fact-1D9607EC2BA2B2BE84B8801F807C0925" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4863-wk-Fact-9D37210D257EF686844E801F800CB2CA" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4883-wk-Fact-F926238DB44A5C97B1224C96A9C8141E" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4902-wk-Fact-E197FC2A851A0D8F91E2801F7FC6EAB4" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4922-wk-Fact-1CD88F40E9218841E1F5801F7F82CECD" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">166</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e4941-wk-Fact-59FCEED3F6055C9A869BCCC59046D785" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4960-wk-Fact-7FAB76E95E2266217B40801F7FD40652" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e4980-wk-Fact-0D7980FB1A19BDA52E10801F8004B06B" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e4999-wk-Fact-EADEAA54DF8A5541A925A32BD98FDB78" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5019-wk-Fact-D61DE1C8D5314D9446A3801F7FA8246B" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5040-wk-Fact-831DB9576209A9ACB46A801F7FE98854" name="us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Credit)/cost reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e5068-wk-Fact-E12E0298D04CBB2C3A47801F7F8D79BA" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5088-wk-Fact-3EF2B8E9997739EA3A5F801F7FF78369" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">361</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5107-wk-Fact-6490FB80A4F21290128A801F7FC0275E" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e5127-wk-Fact-F859D941124BCB940900801F7F8154F3" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5146-wk-Fact-A87F10406B18404F9B51801F7FABCCF6" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5167-wk-Fact-82E209022CD1F47E9F9D801F7F8D9AAD" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e5186-wk-Fact-0A67FC94C1A335307661801F7FD76CCD" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">570</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5205-wk-Fact-60D31D33F54AF44431A9801F7F6208AA" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5225-wk-Fact-AEEF2220D35942CB0DD3801F7F6F13D1" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e5245-wk-Fact-E599ED1AA40A2469EC61801F804BAEDF" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5264-wk-Fact-D0DD8A60AF26952B3CEA801F7FF27C88" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5284-wk-Fact-494803F49419B09647DE801F7F92F83D" name="us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Credit)/cost recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e5317-wk-Fact-C2A34D3ABFB1A91EA818801F7FB1393F" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5337-wk-Fact-C09AF6E13F933AFF10EF801F7FC152C9" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5357-wk-Fact-E19185551DC6EBA76F10801F8027D89E" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e5376-wk-Fact-4CD2A5D18BF6FA6ED4E1801F7F629857" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5395-wk-Fact-87360E241875CDAFD283801F802DFA3B" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5416-wk-Fact-BCD330DBBD645293232E801F806462D8" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e5435-wk-Fact-1F93183F5D4875A34B19801F7F8D1D5D" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">685</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e5454-wk-Fact-CB20215A2101BBDA321C801F7F803B72" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">168</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5474-wk-Fact-8E19A652CCE7A84C8EF2801F7FB2DD1C" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">154</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e5494-wk-Fact-03BF3C273A7FF17CCC1D801F7FD6B64C" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5514-wk-Fact-F0C23B9E8CA41E5682F8801F80498C05" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e5535-wk-Fact-EAFC8BF958C2209A7EF6801F7F845105" name="us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">83</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34661879e5553-wk-Fact-0BDDE461852B17B8365E17245E828279" name="pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">156</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> net pension benefit obligation and recorded a pretax settlement gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34661879e5557-wk-Fact-2F609D849A8B71F42EE4801F8027C25F" name="pfe:DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34661879e5561-wk-Fact-BE24BBF0713388350C6D801F80284F3C" name="pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net </span><span style="font-family:Arial;font-size:7pt;">(see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Effective January 1, 2018, we froze </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e5592-wk-Fact-909C95070CBD74A122F2801F80651727" name="pfe:DefinedBenefitPlanNumberofPensionPlansFrozen" contextRef="I2018Q1Jan01" unitRef="pension_plan" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:7pt;"> significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We adopted an accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> on the consolidated statements of income. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">106</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-2" continuedAt="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-3"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock" id="TextSelection-5EF5C87432873DAB49E1801F83442F97-0-wk-Fact-CBCBABC1710CE6B31FEB801F8021D542" continuedAt="TextSelection-5EF5C87432873DAB49E1801F83442F97-1" escape="true"><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:23%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:20%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">&#160;expected to be amortized into 2020 net periodic benefit costs:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.<br/>Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial (losses)/gains</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e6000-wk-Fact-3AD6F4B4A41632FD0B68801F817F1B4F" name="us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">127</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e6020-wk-Fact-35607E33C1EA7F8BC8EF801F7E4B3C15" name="us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e6041-wk-Fact-C92D70667288365FCFEA801F82243A1E" name="us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6061-wk-Fact-9050CF9D6C997910CB96801F7E3C9CE2" name="us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service credits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6081-wk-Fact-38C75D351712D4A2B7C1801F7E2E26E8" name="us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6100-wk-Fact-8FEDD9FF84373B0F979D801F814907AD" name="us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6119-wk-Fact-6420F2B3E2E088D80671801F82280E75" name="us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6139-wk-Fact-F96B4A04826575457FC4801F7E338884" name="us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e6169-wk-Fact-01331CF69D5828BD374E801F81872799" name="us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e6189-wk-Fact-D80694D39D46BE0892B8801F7E5AED89" name="us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e6210-wk-Fact-B4CE2A5E54FB9489E5A3801F7E4277D0" name="us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">121</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6230-wk-Fact-52B636E2E0FAAEE98365801F7E5698DB" name="us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-5EF5C87432873DAB49E1801F83442F97-1" continuedAt="TextSelection-5EF5C87432873DAB49E1801F83442F97-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-5EF5C87432873DAB49E1801F83442F97-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for </span><span style="font-family:Arial;font-size:7pt;">2020</span><span style="font-family:Arial;font-size:7pt;"> are </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonNumeric id="d34661879e6257-wk-Fact-B15C404893F9FF56B1871727A086D353" name="pfe:DefinedBenefitPlanExpectedAmortizationTerm" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" format="ixt-sec:duryear">24.9</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:7pt;"> years for our U.S. qualified plans, </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonNumeric id="d34661879e6261-wk-Fact-1E8C536F0B87B6FE6D4D172800706240" name="pfe:DefinedBenefitPlanExpectedAmortizationTerm" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" format="ixt-sec:duryear">24.5</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:7pt;"> years for our U.S. supplemental (non-qualified) plans, </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonNumeric id="d34661879e6265-wk-Fact-582F6F0142957E8B541F172887E36FD9" name="pfe:DefinedBenefitPlanExpectedAmortizationTerm" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" format="ixt-sec:duryear">19.4</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:7pt;"> years for our international plans, and </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonNumeric id="d34661879e6269-wk-Fact-9E79A99D16317B9F000C1729038FD591" name="pfe:DefinedBenefitPlanExpectedAmortizationTerm" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" format="ixt-sec:duryear">9.2</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:7pt;"> years for our postretirement plans.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Actuarial Assumptions</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAssumptionsUsedTableTextBlock" id="TextSelection-812178B86602E889B935801F834620AF-0-wk-Fact-66E5D3D1B44E13F6FB7F801F802E8B99" continuedAt="TextSelection-812178B86602E889B935801F834620AF-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average actuarial assumptions of our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">(PERCENTAGES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Weighted-average assumptions used to determine benefit obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e6524-wk-Fact-A10088B30BB98D823A5E801F81FE7834" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6539-wk-Fact-F4E28D1CA67A086FF726801F80DA0F0D" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6554-wk-Fact-FAAD98FCE0138D8F7D42801F81EED701" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e6575-wk-Fact-5AD94F1A4E64A9050C68801F7F5276F1" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6590-wk-Fact-A62E67DC97322F95F554801F81FF775D" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6605-wk-Fact-04C24B36955CEEC5ADDF801F7EEFFC7C" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e6626-wk-Fact-36BA9E860097EF857906801F81FCAC2C" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6641-wk-Fact-A4199A292961EE91C57F801F81EAD662" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6656-wk-Fact-60DF5AEA2E2098724171801F7FC13C14" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e6677-wk-Fact-C5EA9DE67D02F29142D1801F7EFC2CC7" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6692-wk-Fact-640BF9D80D8F5B2A4A9C801F7F6FC900" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6707-wk-Fact-D104EA94EE16D1F1F072801F82031DB4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate of compensation increase:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e6781-wk-Fact-D2DF1C2AD15035E416EB801F7FC07A27" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6795-wk-Fact-C4A0AC65971AD463ED33801F81E8AD2D" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6809-wk-Fact-A97915E9582AC1C02322801F80D9D022" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e6832-wk-Fact-8AF87FC965702ACF9270801F80DB9038" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6846-wk-Fact-D7952502BA2F1E69FE54801F820C8790" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6860-wk-Fact-0451479DAEAC08A2B0C5801F820E384C" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e6882-wk-Fact-7540B045D1F4D34D894E801F7F605756" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6897-wk-Fact-6509BC0AB3F6034C0A1E801F81EFF1E5" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e6912-wk-Fact-F89D862758DBEC9A52D6801F7EFB563E" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Weighted-average assumptions used to determine net periodic benefit cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7035-wk-Fact-324C5DE15600B0537AF6801F821142E3" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7050-wk-Fact-170E5CC230F6DF73ADDD801F7FC98598" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7065-wk-Fact-59266DC078E867B8154A801F81FD879E" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7086-wk-Fact-B7E89B80435FBA9D2015801F80D27F55" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7101-wk-Fact-890110D94E74323B227F801F7EBE5C6A" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7116-wk-Fact-45240A2F103D85093A6F801F8202535A" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7137-wk-Fact-52B29039EB69049E6496801F82067B03" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7152-wk-Fact-9727EBBE51C4177AF65D801F80EDBB10" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7167-wk-Fact-915581A3FD69CD808C17801F80F020E0" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7188-wk-Fact-DD965C2897CAF9EC9175801F820FA09E" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7203-wk-Fact-AB35FA0FC4A6932A38D9801F820E7C5A" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7218-wk-Fact-E0C719691900484E40C2801F820C6B56" name="pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7239-wk-Fact-7705F0E112C1AEE7C1E2801F7EAC8BF2" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7254-wk-Fact-A0602E1C2A395B026AC5801F81EC9E3A" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7269-wk-Fact-5A7DF338890207B47CEB801F8210C59D" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected return on plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7341-wk-Fact-6E5C77D7B3E8F282445E801F7EF190C6" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7356-wk-Fact-2684EE8C5D7ED2DBEBCB801F7EFE7FE4" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7371-wk-Fact-AB3D3D96B4CA7C55B31B801F7F9A4C20" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7392-wk-Fact-6F25380B960D59999C03801F7F585A6D" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7407-wk-Fact-10C102482859A51971D8801F7EB6C89A" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7422-wk-Fact-BEA766E72B254A056073801F81E921D2" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7444-wk-Fact-54D0EDA1C744571877FE801F81E94F9E" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7459-wk-Fact-A9E4C34ED0AA40BD1775801F81FF128A" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">7.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7474-wk-Fact-0238E055F26CEAEA5813801F7EEA6867" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">8.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate of compensation increase:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7548-wk-Fact-8060BA9EC76EA962A052801F7EFC1E79" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7562-wk-Fact-58349156F701DBD2FAE9801F7F55CCA1" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7577-wk-Fact-E02ED63B97645048DC3D801F80ED740C" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7600-wk-Fact-4E0DBFBB79A3239D00CC801F7F5FBA6F" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7614-wk-Fact-E880D275F9E61ED56A76801F7EE80BBC" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7629-wk-Fact-A6FC51038FA814464645801F81FD9227" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7650-wk-Fact-082F937FD346A54D75CA801F82093B2A" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">1.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7665-wk-Fact-1E5F4F807ADB025DD4BD801F7EBAA5CD" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7680-wk-Fact-42064D442E67BDEAE3EA801F80D3D1D2" name="us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-812178B86602E889B935801F834620AF-1" continuedAt="TextSelection-812178B86602E889B935801F834620AF-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-812178B86602E889B935801F834620AF-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#8217; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the net periodic benefit cost for the subsequent fiscal year. Therefore, the assumptions used to determine net periodic benefit cost for each year are established at the end of each previous fiscal year, while the assumptions used to determine benefit obligations are established at each fiscal year-end.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing retirement benefits.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> resulted in lower discount rates as compared to the prior year.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">107</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-3" continuedAt="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-4"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock" id="TextSelection-EBC9083D6D823E93B03B801F83451725-0-wk-Fact-7CD2CAE5FF3A9FD24828801F803C7458" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Healthcare cost trend rate assumed for next year (up to age 65)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7843-wk-Fact-BF66DABEAA11A0AB30A0801F821A0996" name="pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">5.6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7858-wk-Fact-96E9DA0DB9E8401FC29B801F8218381F" name="pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">5.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Healthcare cost trend rate assumed for next year (age 65 and older)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7879-wk-Fact-4674D59AF05EFCB9EABE801F821B62F7" name="pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">6.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7894-wk-Fact-2FE334E874B9704130BF801F8219736C" name="pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">6.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate to which the cost trend rate is assumed to decline</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e7915-wk-Fact-EC5CDE3A9F793BE8E2B4801F821AEC2B" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e7930-wk-Fact-4568EFAA5E7994817813801F821A53A4" name="us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">4.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year that the rate reaches the ultimate trend rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2037</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2037</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock" id="TextSelection-BF361D661E112EC4042B801F83468E60-0-wk-Fact-ACF158D06E311091FDE7801F8023CC61" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"></td></tr><tr><td style="width:76%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the effects as of December 31, 2019 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decrease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect on total service and interest cost components</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e8107-wk-Fact-9A5007514C1F38D9F209801F7EB931AB" name="us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e8126-wk-Fact-04F871BD21ADFD1AACB0801F7EB71A37" name="us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect on postretirement benefit obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e8147-wk-Fact-67710200F4F38C97A16B801F7EB8B6B2" name="us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e8166-wk-Fact-511281176A9BC5953B9B801F7EC9B7E6" name="us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Obligations and Funded Status</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" id="TextSelection-41A0A9F2277C231DD1F6801F8345B719-0-wk-Fact-7FA2337AE374D988BED1801F80245DE7" continuedAt="TextSelection-41A0A9F2277C231DD1F6801F8345B719-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Change in benefit obligation</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit obligation, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9456-wk-Fact-B46984BEC265F2CB3433801F822E334D" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9475-wk-Fact-2227E15F117DFBBA6CDF801F823CAC01" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,702</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9495-wk-Fact-73596D19D7B15B05E6A9801F820D7E85" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9514-wk-Fact-1BB3443744FA4A3A8997801F822C8818" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,495</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9533-wk-Fact-9C92BDF888590B6AA55E801F82481AA2" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9553-wk-Fact-28AB86F70D2CD4381B5F801F81FA1B6D" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,607</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9572-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9591-wk-Fact-22F449DB433F0BD91E88801F8227AC5A" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,028</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9649-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9669-wk-Fact-8ACD50A587CEC7867541801F81EBAED4" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9688-wk-Fact-D8C072D06B49773A72EE801F81FC0B93" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9708-wk-Fact-547A9426B8FEDD3D980A801F821CD025" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9727-wk-Fact-DB9558D1E67DB9DBC296801F821D4332" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9746-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A" name="us-gaap:DefinedBenefitPlanServiceCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9771-wk-Fact-823CFC536B2415CC760F801F821963E0" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">629</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9790-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">598</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9809-wk-Fact-1645F7BA211F13D895DB801F821CDBB9" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9829-wk-Fact-B14453A638517C4D7C51801F82449662" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9848-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9868-wk-Fact-56AC0425594EB6B614D8801F82235863" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9887-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">75</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9906-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495" name="us-gaap:DefinedBenefitPlanInterestCost" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9931-wk-Fact-3550225B14CDA4F396FD801F81FC93AD" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9950-wk-Fact-1BCCBE0EAF7ECB6D503C801F821CEE76" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e9969-wk-Fact-19B551E7615E5B2D61BB801F81EC6B71" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e9989-wk-Fact-A339E48382383D402CC3801F81FAD97A" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10008-wk-Fact-8FB2D62A8EBEF9B34218801F8228C56A" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10028-wk-Fact-1CFEC5FF204858E76294801F8228D349" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10047-wk-Fact-F507F3DBBA00388E5CD9801F820B8A6C" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10066-wk-Fact-DFBA5F50241AD6477837801F820D9779" name="us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10092-wk-Fact-225081F555A03A27E808801F8232C488" name="us-gaap:DefinedBenefitPlanPlanAmendments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10111-wk-Fact-E31F7F0602F984C69606801F822B89AD" name="us-gaap:DefinedBenefitPlanPlanAmendments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10131-wk-Fact-DEDF8AC547B275C98BB2801F81FE5559" name="us-gaap:DefinedBenefitPlanPlanAmendments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10151-wk-Fact-6734B0CCF706755370DC801F82248099" name="us-gaap:DefinedBenefitPlanPlanAmendments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10170-wk-Fact-88DB7F79687BCA54F881801F82414571" name="us-gaap:DefinedBenefitPlanPlanAmendments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10190-wk-Fact-378CC18954DCD2BE6AD2801F8208C07A" name="us-gaap:DefinedBenefitPlanPlanAmendments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10209-wk-Fact-E5C179E74FC2148A9039801F81F8B818" name="us-gaap:DefinedBenefitPlanPlanAmendments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">56</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10229-wk-Fact-C92813FC360B292546D9801F821F48E6" name="us-gaap:DefinedBenefitPlanPlanAmendments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Changes in actuarial assumptions and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10254-wk-Fact-587F4F874523BF22E7AF801F823BD65E" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10273-wk-Fact-3332CC39DDDB775F98DD801F82319453" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,219</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10293-wk-Fact-45B18C9F6F2875D22AB6801F81F7973B" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10313-wk-Fact-EBE912A2B8B787111E58801F81ECF50B" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10333-wk-Fact-B8EF963B8EAAA02A9097801F82143358" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,224</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10353-wk-Fact-EF1120B81FCABC3479FE801F81EE2ED4" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10373-wk-Fact-E89A524C2D8E94D7B82F801F820D0235" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10393-wk-Fact-1855B6419A7F5D4AE722801F81FE1A9A" name="us-gaap:DefinedBenefitPlanActuarialGainLoss" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">122</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange impact</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10419-wk-Fact-6D9D6801D8F49E72AC9F801F8247BF37" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10438-wk-Fact-0239ED48FEE8F23ED2EC801F81FB9BC5" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10457-wk-Fact-85CA80585D2874D45B54801F82219616" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10477-wk-Fact-34CCCF8B6B98C5A6827D801F8243C77E" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10496-wk-Fact-D1066964CCBB2F06D211801F8229BFCC" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10517-wk-Fact-791EAF9C41A719B8AE07801F821A4C3E" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">457</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10537-wk-Fact-5265E1D654B7823D4E63801F82280344" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10557-wk-Fact-CB5E2C6E53AA4E02F333801F82392BCB" name="us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions/divestitures/other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10583-wk-Fact-51C0100384A147990743801F81EB9934" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10603-wk-Fact-9C416A8427655856201B801F81FBE3C5" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10622-wk-Fact-707FF8E8FE2A2798AEDA801F8220322D" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10643-wk-Fact-15BADC559EFA5E2148B7801F8234494C" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10662-wk-Fact-101EC636E37E5D65C52C801F81EB2366" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10683-wk-Fact-5B79851311CC6FFAB3EF801F820E9581" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10703-wk-Fact-893F257BDBDAF32100A5801F81FC6EC8" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10723-wk-Fact-FB2A542C8BE81796CCFD801F824281CD" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10748-wk-Fact-EEAFCF15A92A73FE4BC1801F820BA9BC" name="us-gaap:DefinedBenefitPlanCurtailments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10767-wk-Fact-F3A9A889D5F803CEA915801F81FC88F0" name="us-gaap:DefinedBenefitPlanCurtailments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10786-wk-Fact-23DB84919E70B73B1647801F8249C9E2" name="us-gaap:DefinedBenefitPlanCurtailments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e10806-wk-Fact-BD46B1A4E13BB0CD2D7F801F81EA9171" name="us-gaap:DefinedBenefitPlanCurtailments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10825-wk-Fact-A4C2A6D0663F5845176B801F81F80E32" name="us-gaap:DefinedBenefitPlanCurtailments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10846-wk-Fact-5F786390C2E8481D63AB801F820FDD80" name="us-gaap:DefinedBenefitPlanCurtailments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e10866-wk-Fact-2FA5505B9C078F2C7287801F821DF04C" name="us-gaap:DefinedBenefitPlanCurtailments" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10885-wk-Fact-578D671C8F705BCD1B24801F82058BDF" name="us-gaap:DefinedBenefitPlanCurtailments" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10911-wk-Fact-DEAEDE0078E36DBB07CB801F82112993" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">692</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10931-wk-Fact-D327E219A54033D54A8F801F82396897" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10951-wk-Fact-2B8A551F74454F44A11F801F8230140D" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e10972-wk-Fact-C356BA78C171B344C1E7801F823FA26C" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e10992-wk-Fact-420050CC9AF1183EA21D801F82478087" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e11013-wk-Fact-D02BC6C959B70F0C42F4801F81EA9247" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11033-wk-Fact-B37B6F505700BFB86614801F8217AF5C" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11052-wk-Fact-18D66D9FD2EF5E4071F3801F820F2C81" name="us-gaap:DefinedBenefitPlanSettlementsBenefitObligation" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11077-wk-Fact-FAED8312CB6DE3371555801F822F66EF" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11096-wk-Fact-B06D18314819524CDB53801F8224ECF4" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11115-wk-Fact-FFA2D2947052B95B9E66801F822852A2" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11135-wk-Fact-3FAA9033222E4A62E69F801F822B103B" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11154-wk-Fact-3436CB2133E67A0CED9C801F8220C53D" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11174-wk-Fact-8EA2843D9C6DF208E5AC801F820B737B" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11193-wk-Fact-61950C831388E08B6286801F81EDD259" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11212-wk-Fact-A2924772A01FADBA0AFC801F8209EC9B" name="us-gaap:DefinedBenefitPlanSpecialTerminationBenefits" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e11237-wk-Fact-AB51FFA5E25BF090B8E4801F821615F8" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e11257-wk-Fact-32E1EBDBF1BACBF6E103801F8241B168" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e11277-wk-Fact-E3F7F347B26B1F422343801F81F13EF8" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e11298-wk-Fact-0F4B80AB484F70EADA00801F822053F3" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e11318-wk-Fact-BA7C888E080F79CDEA22801F8225858E" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e11339-wk-Fact-CD4577912E966CBCE234801F821708AE" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e11359-wk-Fact-3A17F7C7D9A8C3BFB338801F82230016" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e11379-wk-Fact-236A48C44D219DB1205A801F8231D63E" name="us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit obligation, ending</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11407-wk-Fact-390B954ED7FDBB67E7CD801F8201DB61" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11426-wk-Fact-B46984BEC265F2CB3433801F822E334D" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11445-wk-Fact-00777F633E4D23DFB02C801F81EE6F40" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11465-wk-Fact-73596D19D7B15B05E6A9801F820D7E85" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11484-wk-Fact-DCDE7C80F284CDA4BB90801F823D07A2" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,059</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11504-wk-Fact-9C92BDF888590B6AA55E801F82481AA2" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,952</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11523-wk-Fact-3172D79ECC315BEBFB19801F822ED289" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,667</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11542-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB" name="us-gaap:DefinedBenefitPlanBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,870</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Change in plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11904-wk-Fact-F970BB89E53DFCDB7ECF801F8244F550" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11923-wk-Fact-19ED68D32560E34AAE3A801F8209EABD" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11942-wk-Fact-9CF470D6794F6C0CCEC7801F81F8A544" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e11962-wk-Fact-10FF72843765F8BB3027801F82271E5C" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e11981-wk-Fact-4117EF0EF57CC9D621F0801F81EFE30E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12001-wk-Fact-7016255C04AF4B9A9ACA801F822C27CF" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,863</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12020-wk-Fact-3A8C22ABE707DD992DEC801F81EB2BCC" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12039-wk-Fact-311D92B89F4214E789BE801F822A0850" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">494</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actual gain/(loss) on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12064-wk-Fact-E5A9EC3B299F57294718801F81ED9CB6" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,760</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e12083-wk-Fact-7E988DB3F16BD0DA91DD801F82219CEC" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12142-wk-Fact-FAEB11DD8DF99633BE69801F821EA34A" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">873</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e12162-wk-Fact-E7F44177B21B50981524801F81FBDA91" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">77</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12182-wk-Fact-CFDB540F996DE5B99D46801F81F03D49" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e12201-wk-Fact-B9AC8307A779D6F09949801F821995B5" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">22</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Company contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12227-wk-Fact-00164FB29E93F021AA7C801F81EF5943" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12246-wk-Fact-06198EDFD387D35B92AE801F82464881" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">500</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12265-wk-Fact-2F4EF0691232172CBE50801F823725C4" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12285-wk-Fact-895FBC55A2C014AE60DB801F822EA4D6" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12304-wk-Fact-5F9A7586AB2C91889EEF801F81FA1407" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12324-wk-Fact-1AEDB7ED4A8DCF189D67801F823C442D" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12343-wk-Fact-4CF49C83803A70FBB008801F820EACE2" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12362-wk-Fact-C14FE55B8A46DB34463B801F82457CA0" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">145</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12387-wk-Fact-0CF957CDB8DB1B8E8BF5801F82103803" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12406-wk-Fact-9DCABAFB274FAF64432B801F82199D36" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12425-wk-Fact-66AB59873DDB47AB89F7801F820EAC51" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12445-wk-Fact-F80314ACBE555E3E9E3B801F82492D5E" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12464-wk-Fact-8F98F1D658D9E120463D801F81EB97FB" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12484-wk-Fact-4E1FE6F7B598C8807AD3801F81EC5BDA" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12503-wk-Fact-90C6D26954260814C1B0801F821DB384" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12522-wk-Fact-677D1FC6A611834BD89C801F821B9488" name="us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange impact</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12547-wk-Fact-C7D9E0717066F0D4B259801F81FC0FA0" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12566-wk-Fact-2405E4B9D661A0DF12B8801F8223FB9F" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12585-wk-Fact-CC7370FF7EA5E47BA51C801F82497BFE" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12605-wk-Fact-6CC25BEC0E1A84069BE2801F8232DF80" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12624-wk-Fact-A032E560DF4882B29B08801F821F0585" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e12644-wk-Fact-C83D9C05172B44F8773E801F822B264A" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">380</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12664-wk-Fact-168A9585B7249F9C82D6801F8230053A" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12683-wk-Fact-001F470AF34EA1EB4561801F8243CC17" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions/divestitures, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12708-wk-Fact-BE53F1DBA31B16AE1779801F82410B8F" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e12785-wk-Fact-ADB4BDBE18F10B2C4ADA801F81F79BF7" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">16</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12806-wk-Fact-22EAF7C9B4B7E34A06D1801F8249E751" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12825-wk-Fact-216A99E53878AF5DAB01801F82482689" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e12844-wk-Fact-B441AEA30237DE1B4AA7801F82269A65" name="pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e12869-wk-Fact-89722D85FCA1B5DF7C7C801F81EF8ED7" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">692</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e12889-wk-Fact-A64428C832FF96F45A86801F822511CE" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e12909-wk-Fact-B5CDD0A07D672D455A6A801F822590FF" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e12930-wk-Fact-E5FCA4E5F636714478C5801F820C7680" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">72</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e12950-wk-Fact-7954C90D77268CFDD706801F81FEE484" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e12971-wk-Fact-96A54F4085DA003D93DD801F821A8215" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e12991-wk-Fact-4ECAFCF00E51EE589F24801F81FD193A" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e13010-wk-Fact-9DD8F0FD0B6AE7A88D34801F81FB074D" name="us-gaap:DefinedBenefitPlanSettlementsPlanAssets" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e13035-wk-Fact-9AC099DABD33C274FD2E801F821F3862" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">544</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e13055-wk-Fact-E7EFDBF2583292D4FFAB801F8229244B" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e13075-wk-Fact-264D65694E907003263E801F82200311" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e13096-wk-Fact-52A30F4A2E33A0CF3492801F8211EF86" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e13116-wk-Fact-14C3A3D1B63D331729AB801F81EBA652" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e13137-wk-Fact-79CBA17C3000A01BA7EF801F82007698" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">373</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e13157-wk-Fact-CB7DB76C64C38F31AE27801F823D303F" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e13177-wk-Fact-0067A36D794EDE2178A3801F8218C6D2" name="us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid" contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets, ending</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e13203-wk-Fact-17659B69964921976360801F821EE135" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e13222-wk-Fact-F970BB89E53DFCDB7ECF801F8244F550" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e13241-wk-Fact-E9371F5D7FA12FFF576E801F820909B8" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e13261-wk-Fact-9CF470D6794F6C0CCEC7801F81F8A544" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e13280-wk-Fact-AB8F832A31C42E104067801F82165415" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,956</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e13300-wk-Fact-4117EF0EF57CC9D621F0801F81EFE30E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e13319-wk-Fact-839D55BF4D8629637604801F822D8BC9" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e13338-wk-Fact-3A8C22ABE707DD992DEC801F81EB2BCC" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e13368-wk-Fact-B1BB4B65E728C0E688B6801F81EE8DEE" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e13388-wk-Fact-310C89B3053C8C2C8E70801F82279E3C" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e13409-wk-Fact-56675EE303722890B7D7801F823F0231" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e13429-wk-Fact-E427FCA54636A4F6EDAF801F823E20D3" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e13449-wk-Fact-DE9C7F290C3856B78A7C801F8218A88B" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e13470-wk-Fact-B622EA29E741BF176CC3801F81EDCC43" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e13490-wk-Fact-9EE216D56140FCED146C801F81EF7937" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e13510-wk-Fact-486A293311150B87248C801F824470AE" name="us-gaap:DefinedBenefitPlanFundedStatusOfPlan" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-41A0A9F2277C231DD1F6801F8345B719-1" continuedAt="TextSelection-41A0A9F2277C231DD1F6801F8345B719-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup><ix:footnote id="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-1">&#160;</ix:footnote></span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-1"><ix:continuation id="TextSelection-41A0A9F2277C231DD1F6801F8345B719-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The PBO represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases. The ABO is similar to the PBO but does not factor in future compensation increases. For the U.S. qualified and supplemental (non-qualified) pension plans, the benefit obligation is the PBO, which is also equal to the ABO. Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#8217; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34661879e13578-wk-Fact-0BB54A71AC3D332E19E3801F804F31BC" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">10.6</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34661879e13586-wk-Fact-C8077BC3D5B73FFE8069801F807CF447" name="us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">9.5</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">. For the postretirement plans, the benefit obligation is the ABO.</span></div></ix:continuation></ix:continuation></td></tr></table></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">108</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-4" continuedAt="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-5"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" id="TextSelection-C6E91E8FCB72BB10FAEE801F8344DBF8-0-wk-Fact-D3BC0E7A467A5994F5E4801F8037F47C" continuedAt="TextSelection-C6E91E8FCB72BB10FAEE801F8344DBF8-1" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information as to how the funded status is recognized in our consolidated balance sheets:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement<br/>Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e14504-wk-Fact-1FABDAEE54CD68890F1E801F7F0BED57" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e14523-wk-Fact-759056D49537AAD9E899801F7F0EAFC2" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e14543-wk-Fact-B51A8E65B32A1B7A347F801F7F099B83" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e14562-wk-Fact-5BFD4CE5B0EB344F1A4A801F7F0AA68E" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e14581-wk-Fact-248A8F8CD6CA4B37A1DD801F7F0C957E" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e14601-wk-Fact-88C4C82D6AD7A0143C97801F7F066B14" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e14620-wk-Fact-3C628A0CB0E19BD342B2801F7F090262" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e14639-wk-Fact-1BDD07D787E81176926F801F7F11CAEA" name="us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e14661-wk-Fact-42DC91E16F73927C464F801F7F0DDD4E" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e14680-wk-Fact-6D8465E75F36770F95BA801F7F0AFDCF" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e14700-wk-Fact-FC73D9D20F903DB9A545801F7F1031E7" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e14721-wk-Fact-9D6C46A96E8CE95D147B801F7F0D5028" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">167</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e14741-wk-Fact-63A8380FD8882B8BF33C801F7F0B001F" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e14762-wk-Fact-A2A4CC4306DEA373350A801F7F0B3827" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e14782-wk-Fact-1F63287DE71910139202801F7F087DC5" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e14802-wk-Fact-A816C66465B359E5274A801F7F026BDF" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e14830-wk-Fact-7D0DED212B5AD84E6737801F7F10668E" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e14850-wk-Fact-2062BC7C0DF48822A1BA801F7F02D514" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,088</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e14870-wk-Fact-346579D6E7C0E2843401801F7F121ACE" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,162</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e14891-wk-Fact-324241AD63CEF2D77B12801F7F01BBA9" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e14911-wk-Fact-C5F159D4AD69FB122084801F7F082E6A" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,526</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e14932-wk-Fact-E0B910DD31466DB4F6A3801F7F105131" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,111</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e14952-wk-Fact-F6F791A5DBF42B041441801F7F0A62EE" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e14972-wk-Fact-BCFF3D61A9114065510B801F7F0C89BE" name="us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,371</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Funded status</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e15003-wk-Fact-8223FA410497BC998CCE801F7F1282DD" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e15023-wk-Fact-34A9429009D83D55259D801F7F10FE12" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e15044-wk-Fact-45798B521425290247CE801F7F09A82E" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e15064-wk-Fact-D330AA4C3284CC10FAE3801F7F138479" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e15084-wk-Fact-45CDA847129743A56995801F7F0713E6" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e15105-wk-Fact-E4467A3E3845B64C6B37801F7F04FDBE" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e15125-wk-Fact-B34B7ED0357C3D7009E4801F7F0DE644" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e15145-wk-Fact-D463454916E58C050165801F7F098A0E" name="us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1,401</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Accrued compensation and related items</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-C6E91E8FCB72BB10FAEE801F8344DBF8-1" continuedAt="TextSelection-C6E91E8FCB72BB10FAEE801F8344DBF8-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-C6E91E8FCB72BB10FAEE801F8344DBF8-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of December 31, 2019, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Pension benefit obligations, net</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Postretirement benefit obligations</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net, </span><span style="font-family:Arial;font-size:7pt;">as appropriate. In 2018, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Pension benefit obligations, net</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Postretirement benefit obligations</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net</span><span style="font-family:Arial;font-size:7pt;">, as well as in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Liabilities held for sale</span><span style="font-family:Arial;font-size:7pt;"> (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;">)</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">, as </span><span style="font-family:Arial;font-size:7pt;">appropriate.</span></div></ix:continuation></ix:footnote></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" id="TextSelection-2CF961F86D484EEB0DC5801F83467D02-0-wk-Fact-4FCD1F496712736AB0C3801F8021F4B6" continuedAt="TextSelection-2CF961F86D484EEB0DC5801F83467D02-1" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"></td></tr><tr><td style="width:25%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the pre-tax components of cumulative amounts recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement<br/>Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial losses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16176-wk-Fact-AF3CA0CEC8AD61474DDB801F82306D75" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,812</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e16196-wk-Fact-3575E2B197DFFB710849801F822BF3AD" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,061</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16217-wk-Fact-0A0820F3891084F2D3BC801F822ACC1A" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e16237-wk-Fact-31E13FD9B07B11996B5E801F8233F654" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16257-wk-Fact-C971B93D19C9DBDCC70B801F827FFB9E" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,921</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e16278-wk-Fact-99AD0A449205CDDA0508801F827E53C0" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,372</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16298-wk-Fact-20C1F8EC97D87AA8FE1C801F822F40EA" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">76</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e16318-wk-Fact-0DEFE5C159BAEC795B00801F82386F80" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">202</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service (costs)/credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16339-wk-Fact-F30596A8A3FB54FFA87F801F826FA947" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e16359-wk-Fact-D52C68581C63DD1029F1801F82712F9C" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e16378-wk-Fact-267B9D4315F3CD2AC3C3801F822D7560" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e16398-wk-Fact-5E9D557ED38FF39C1E62801F8268CE91" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16417-wk-Fact-EAC2389D8A0B2017163F801F822DF567" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e16438-wk-Fact-144F8F48827BD80FA36B801F8275991E" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e16457-wk-Fact-4712309073C4B9708668801F823192E9" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">830</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e16476-wk-Fact-7912AF6308BF77884C6A801F8262DF0A" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">994</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16506-wk-Fact-DAAA3AF9D54C2B5C1782801F8272DE9E" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,814</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e16526-wk-Fact-6A5C67E264C343591301801F826473DD" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,060</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16547-wk-Fact-F46779058B1DFD0DF4B7801F82397B67" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">485</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e16567-wk-Fact-6EC7FC598AC8D15B3ACB801F8233BAFF" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">370</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e16587-wk-Fact-8EA2B9AA06147DC86AAD801F827E82CE" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,942</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e16608-wk-Fact-4AB6619926524113671B801F827DAAED" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,372</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e16628-wk-Fact-5C68B2AB9351FC4AA68B801F823052FD" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">754</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e16647-wk-Fact-67732A5B9D27859B3231801F822F6C7F" name="us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">792</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-2CF961F86D484EEB0DC5801F83467D02-1" continuedAt="TextSelection-2CF961F86D484EEB0DC5801F83467D02-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-2CF961F86D484EEB0DC5801F83467D02-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our PBO, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:7pt;"> and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the average life expectancy of plan participants for frozen plans, primarily using the corridor approach.</span></div></ix:continuation></ix:footnote></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="TextSelection-0A841C966B9019B38DC7801F8344640F-0-wk-Fact-4C9BB48140B666042170801F8027F40C" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" id="TextSelection-D33965E5C3EB09A0ABE8801F8346AE30-0-wk-Fact-BD9FB87B81F01CB58FE9801F803CA726" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information related to the funded status of selected benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension plans with an ABO in excess of plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e17515-wk-Fact-3FCA20C4F2B691E985DA801F7EEC213D" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e17534-wk-Fact-A2A83C6B6FC78D2018CE801F7EF3B0A0" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e17592-wk-Fact-ED1A82E0BD316C6A233B801F7EF4EB6E" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,843</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e17612-wk-Fact-0EEB63BC554165DECA44801F7EE70289" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ABO</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e17632-wk-Fact-EABF1AF3646DE7888489801F7EEBC7DD" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e17651-wk-Fact-2E5E18582EAC2644A3EB801F7EEE1F4A" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e17670-wk-Fact-05C77FED557C785B920F801F7EEB544B" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e17690-wk-Fact-40F08CA7A1EB5A21E509801F7EED05BA" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e17709-wk-Fact-3917675B93724860214B801F7EF24F57" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e17729-wk-Fact-CDE677BC1925643ACFC0801F7EEA30A9" name="us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension plans with a PBO in excess of plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e17882-wk-Fact-929612D77F162F4D628C801F7EEBEE0F" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e17901-wk-Fact-2648CEC07EC5A4DF1ED5801F7EEA138B" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e17959-wk-Fact-0D60EBCAACAFC3567EF4801F7EE8F50C" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,947</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e17979-wk-Fact-3B8EE448C569BD634FBF801F7EEC4C1E" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,432</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PBO</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e18004-wk-Fact-31EA2DC95E21A6C03AF3801F7EEA0948" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,535</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e18023-wk-Fact-9697CE7A634D261B05EC801F7EE78E0F" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15,141</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e18042-wk-Fact-8357A30CF4B85743C57D801F7EEA3193" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,351</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e18062-wk-Fact-91AAB974411866DE09AD801F7EC4E40D" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,280</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e18081-wk-Fact-43A73C31C22675F5778B801F7EEB83CF" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e18101-wk-Fact-286AC20570D3AE7BACA2801F7EEED97C" name="us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,571</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All of our U.S. plans and many of our international plans were underfunded as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">109</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-5" continuedAt="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-6"><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Plan Assets</span></div><ix:continuation id="TextSelection-235024D196CC77C5BAC2801F83455C65-0" continuedAt="TextSelection-235024D196CC77C5BAC2801F83455C65-1"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="41"></td></tr><tr><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:3%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:4%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="41" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">The following table provides the components of plan assets:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair Value</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair Value</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As of<br/>December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Assets Measured at NAV</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of<br/>December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Assets Measured at NAV</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19061-wk-Fact-7F93F5882C266AF7AC03801F7EDE88E2" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">363</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19080-wk-Fact-FFA28E99A41E4CCC026F801F803FFF5D" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">80</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19100-wk-Fact-27B7F1F490681634429E801F80F1F370" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">284</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19119-wk-Fact-86DEF6460514D6862E92801F80F116B8" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19158-wk-Fact-275CC2A0A7045D3DF218801F80FED32D" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">443</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19177-wk-Fact-FF00362B6AD5984309B1801F80812477" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19196-wk-Fact-2C64274CCAA479E1D7CD801F7E6C51E8" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">390</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19216-wk-Fact-8E57072868D5458BD30A801F7EA6C7E3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Global equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19462-wk-Fact-BA8E84FCF063363DC8CB801F7EB43BDE" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,464</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19481-wk-Fact-EC53E968779C6028ED9C801F7EC737F6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19500-wk-Fact-885642E3FF5078D7E180801F8136338F" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19520-wk-Fact-B8D531637E8DF54F3F7E801F80AB0923" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19559-wk-Fact-9CDB5B0698B41567BC37801F7E7B816B" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,156</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19578-wk-Fact-65B741C45407AAE78B32801F815BCE12" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19597-wk-Fact-A730E8A1EA686A58B9A9801F812B26B3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19617-wk-Fact-E73373912ABEFE585146801F81629B0E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19661-wk-Fact-F658713FC86B180E500C801F7EC720B0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19680-wk-Fact-F1A609A7255A0AC15A90801F8171F6C4" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19699-wk-Fact-5A20A9FE6AC6B79177A4801F8146DDEB" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">819</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19719-wk-Fact-4ED0DD3E047FEF605271801F7E880A91" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e19738-wk-Fact-516E83BACCC191ED5F55801F7E89AB76" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">360</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19758-wk-Fact-E5CDD80B41C6B8D81144801F80FD49C0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">933</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19777-wk-Fact-C8943A121EEDA141FD9B801F7DF3C7FA" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19796-wk-Fact-1A8B2C6C459DCC13D002801F7FD5858E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">634</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19816-wk-Fact-ADFD09EFBAAE17E76B8C801F812CED5A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e19835-wk-Fact-B782F5C9086BF99E0D5C801F80CEC6DC" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20067-wk-Fact-739A3CBCA31942929991801F80709576" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,292</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20086-wk-Fact-0F1DB5BD6CE9D70B16BE801F812DE5BC" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20105-wk-Fact-A320D830DB302CFA5F67801F7E9BA879" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20125-wk-Fact-67EBD4339740E27DDD1E801F7FFC6246" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20164-wk-Fact-90597CDC08F5FDEBD38A801F7E8F8D74" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20183-wk-Fact-CB978D333D218C3AA504801F81620995" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20202-wk-Fact-A2751CB79E5C657710FC801F7E6BAF40" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,650</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20222-wk-Fact-050ACDA8F1A6426D3F26801F7FFAD77E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20266-wk-Fact-4380540F36E2ACCC4664801F8126079D" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20285-wk-Fact-9667992F4720EEBE8507801F7E9223CD" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20304-wk-Fact-8ADF784CF3544B521652801F7DE5428D" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,799</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20324-wk-Fact-6C6A4F5106ED00592CB9801F80B9D6FC" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20363-wk-Fact-2F3F139C5086316CC068801F7EBA7D64" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20382-wk-Fact-99C3C972AE8486FA89F4801F7E139ECD" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20401-wk-Fact-278022090600AF2B386D801F811D7324" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,391</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20421-wk-Fact-00B706497805EC20E4D4801F80E92761" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20466-wk-Fact-B11EE53E100C9A594AFF801F7E6AAEE9" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20504-wk-Fact-93B234B3231C3F13BFA0801F813200A4" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20524-wk-Fact-37C2E96F0C06B8BE58DC801F81379E3A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20543-wk-Fact-162134FF808D683214CB801F80F133F9" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20563-wk-Fact-31948D8451621942863C801F7DE7EB90" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20582-wk-Fact-F412DE60776769E48B4D801F8102E063" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20601-wk-Fact-EDE6AA3E50AC798E1DBE801F7DF2E87B" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20621-wk-Fact-131B4259055DC4154011801F7E6A5E45" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20640-wk-Fact-4B8271E7A0E5A3CF5E04801F7EC8BD2A" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">96</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other investments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Partnership investments</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20874-wk-Fact-D487984B48B22F1A5D80801F7E671411" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20893-wk-Fact-01207FB539212ED3CB3B801F810048DB" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20932-wk-Fact-F7341069EEF19CA78430801F7ECE7A09" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e20951-wk-Fact-A543C6B15A6318DF95B8801F7E694554" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20971-wk-Fact-732BFC75898DC67D4551801F7E2006BB" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e20990-wk-Fact-32F10B48A55F1AE6E300801F813AC7A0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21009-wk-Fact-6F6B7321CCFF4B9C9028801F7EBC6553" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21029-wk-Fact-A1CED4074FA1FDF7A5FC801F8022EF72" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21048-wk-Fact-1A3B6926FC4FE6AFF9C8801F807EB040" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,165</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21073-wk-Fact-C3645AC626FE234DB1B2801F7E1F35E3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21092-wk-Fact-9D5C193DFCEF155D2BA5801F8158E97D" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21111-wk-Fact-13CB94F03E493E18A76F801F8065B591" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">196</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21131-wk-Fact-1784E446F9B0340EF1E7801F80F5F65A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21170-wk-Fact-F6026AF8147DEDB6DEB0801F7EAD9085" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21189-wk-Fact-C987C1B42EE95EB272F6801F7DFFD049" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21208-wk-Fact-59B1E65891137B9A016D801F7ED92BBC" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">192</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21228-wk-Fact-341E870038AF69B1EEA5801F813FD1D5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other commingled funds</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21274-wk-Fact-A66838ACCE990B7D1974801F80F24A8B" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,075</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21293-wk-Fact-12704F96F376D4121D69801F80E15138" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21312-wk-Fact-5051258CEF279EAE4904801F8082EB61" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21332-wk-Fact-4924E685A3ACAA7EBD6E801F7FD67A92" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21351-wk-Fact-A621438BD8C8D4F1F9D1801F7E16B826" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,066</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21371-wk-Fact-7901A59E0B6D8AB6EE3A801F81370C3C" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21390-wk-Fact-57959C448E7CB9BAE6F1801F81494C11" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21429-wk-Fact-BDDDC33CB2AC40243C72801F7E12971A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21448-wk-Fact-72790138A19EAC31CA09801F807E33DE" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,021</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21478-wk-Fact-17659B69964921976360801F821EE135" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">14,586</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21497-wk-Fact-71ACBA717F716B8607A4801F80F2069A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,496</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21517-wk-Fact-F6CAFC8B9758DAA23D9B801F80F1603E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,451</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21536-wk-Fact-D2A4F992E497F4962F79801F7ECCF7C9" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21555-wk-Fact-B0690B2915B8FC4A125C801F80217B36" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,638</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21575-wk-Fact-F970BB89E53DFCDB7ECF801F8244F550" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,051</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21594-wk-Fact-E7F460C957BC5FCAA01E801F7E03BE66" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,173</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21613-wk-Fact-3582128093A73BF0EBD0801F80323008" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21633-wk-Fact-84CFAE8D822C91DEF42D801F80EA8284" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21652-wk-Fact-8901B45EE693D1A5A42B801F7ECF7B1B" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21886-wk-Fact-9B74B38BBAC9194CDBD2801F80F44538" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21905-wk-Fact-E34AFABD364472579390801F7DF5BC3B" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21925-wk-Fact-D51127B4DF5263E26631801F80FC4240" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">187</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e21944-wk-Fact-F02B4A8F59412D2599F9801F7EBEBAF8" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e21983-wk-Fact-9963B1D022EEAF8133FA801F813667C0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22002-wk-Fact-6B515B4176DA3F1E487E801F7E934F57" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22021-wk-Fact-3C503682A37762C63BE1801F8147265C" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">208</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22041-wk-Fact-129BCA5EF7E3C4047DF8801F807EBD37" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Global equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22287-wk-Fact-378CB5AF654FAF1FC1BD801F7FB2C60E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22306-wk-Fact-A43617795041B30B05CB801F7ECAF0A6" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22325-wk-Fact-0DD70E539B87F2FB041C801F8112B0EF" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22345-wk-Fact-BA2C0B3B568CB294D55A801F7E0CA046" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22384-wk-Fact-44824C84735C2387A740801F7DE62678" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22403-wk-Fact-92F2D29881335576C0FD801F7E7CED30" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22422-wk-Fact-7658020187599961F4A5801F80F4D671" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22442-wk-Fact-1F4D93C2F9904F6D73B7801F7FFAD79C" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22486-wk-Fact-9A5E67F3D86F79B8D1B5801F80EBD774" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,922</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22505-wk-Fact-2A45E23937B1E03B0AA9801F816FD16A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22524-wk-Fact-16D5C33B23D96F298EA6801F7E18070A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,548</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22544-wk-Fact-A16FEE27FC5491A49909801F81596307" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22563-wk-Fact-B61033E055581DA45EB7801F80C6CBA8" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22583-wk-Fact-2CA9BFB53F2FCB0DF5C1801F7FB17EF9" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,876</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22602-wk-Fact-21757F62AEF00E5BF73F801F7EA5E973" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22621-wk-Fact-21863FBD06730CC6F0CE801F8133FD38" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,413</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22641-wk-Fact-EDF3B6B8EE0203C0AE3F801F80E9D531" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22660-wk-Fact-A349362A7F0F24D7725D801F8161CBEA" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">463</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22893-wk-Fact-73F6BBEE0F405305ADA4801F8143482A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22912-wk-Fact-13F5E48EBC5CD653F364801F81489ED5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22931-wk-Fact-FE7BED24ED2F7DF891B2801F80642BB5" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">796</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22951-wk-Fact-761A045667090BCC60CB801F7E75C1C9" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e22970-wk-Fact-851A65644168F7A09FFC801F80C5042F" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e22990-wk-Fact-BE2695DCCECFD887A9F8801F7E8AFD2B" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23009-wk-Fact-6343757AF4A26430D7A1801F7DD0CC07" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23028-wk-Fact-624D9122625475A0C346801F810535CB" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">727</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23048-wk-Fact-386DE871FDE603DE0A0C801F7E75C64F" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23067-wk-Fact-084E62D562F5DB1E17D2801F8025171B" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23094-wk-Fact-B027583F189DF18A6C25801F81488DCF" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23113-wk-Fact-13C4C66382AC9F3D31ED801F7E1DF337" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23132-wk-Fact-891D6E78C37A848AAD66801F8103A7FC" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23152-wk-Fact-6259E894CBE6FA9FB71A801F7E0FCAAB" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23171-wk-Fact-21E0043926A006FDE718801F80EA1DF6" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23191-wk-Fact-58CB03993CECC3B620EC801F7EDEE43C" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23210-wk-Fact-296077A478766CD8DCE5801F8128127D" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23229-wk-Fact-B1F66149E5D30EF98A05801F81603EA8" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23249-wk-Fact-4324A26D75595331CCFC801F81546900" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23268-wk-Fact-3F72EA523C34D3EBBCF1801F80C7CC92" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23293-wk-Fact-AD6D005C570E67CE5449801F7E665057" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,201</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23312-wk-Fact-91858568C939C7AE738C801F80EC0790" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23331-wk-Fact-54BB374F531662E67301801F8151A7BD" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,031</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23351-wk-Fact-99E09AD183E83160CC87801F7E8A836A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23370-wk-Fact-55065D7329FC0CE09063801F8127D52D" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,171</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23390-wk-Fact-DEEE2C690E5D9A6127B8801F7E651356" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,770</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23409-wk-Fact-43D0EA4505ACE6E465E2801F7FD72974" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23428-wk-Fact-825A924821B029DD3CBD801F7E981ACD" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,007</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23448-wk-Fact-19AE6BF04D8CC5A87EEA801F7E12AE32" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23467-wk-Fact-B6002D168EA0157D8AFF801F80E23E6D" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">762</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other investments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Partnership investments</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23701-wk-Fact-CEFD277C9DD70587E852801F80CE0B4F" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23720-wk-Fact-61637C3FAD1A1EBEC396801F7E02E832" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23739-wk-Fact-3B84715E11DB37BB7F37801F7E1EFCF3" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23759-wk-Fact-BFCA8568A70BD9B17120801F7E0B201D" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23778-wk-Fact-F8768CC4E46B6B99211A801F7EE08C5B" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23798-wk-Fact-E8F433CDF6DA732D6EF5801F7E697BF0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">57</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23817-wk-Fact-C81AF605318FDAE7E9A8801F813229BB" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23836-wk-Fact-31101E0D5A9F589C42B9801F7EDE61BF" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23856-wk-Fact-BAB81DA4890D0987B01F801F7EBE147E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23875-wk-Fact-32850438677456DE85D2801F80EF43A5" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23902-wk-Fact-32BE2AC3AB258DAE14BA801F815D5109" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,027</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23921-wk-Fact-AF3B835BA88A5AF10D40801F814757D9" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23940-wk-Fact-CEA719F9B7E460A69C70801F7ECBC889" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23960-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e23979-wk-Fact-9D87527D8A9492D75841801F7EA8D8E9" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e23999-wk-Fact-FE6953A187622C643914801F80E89DAA" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24018-wk-Fact-98EC241C0428BD0AE10C801F7E1180B1" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24037-wk-Fact-2CA6288317D80D709922801F8147D1CB" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">74</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24057-wk-Fact-EAE26AAB2C1914749716801F81E7B60A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24076-wk-Fact-3993C9034191C03D601B801F7EDE39F5" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d), (f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24103-wk-Fact-ABB7C1831B6036A1961D801F8111BCF2" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,043</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24200-wk-Fact-7D93FC3424C9D543074F801F7E17454A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,473</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,020</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24307-wk-Fact-AB8F832A31C42E104067801F82165415" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,956</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24326-wk-Fact-9560997241A91E7FCCDC801F7E780256" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24346-wk-Fact-DE1F7A8483528CB9F99C801F7DF38979" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,929</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24365-wk-Fact-70AB9AE43B82A35609DD801F7EC60B58" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,342</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24384-wk-Fact-846B26327BEE6C94A307801F8102D6F8" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,652</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24404-wk-Fact-4117EF0EF57CC9D621F0801F81EFE30E" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,215</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24423-wk-Fact-8C4DF439940F0708B5F7801F7E87B8C4" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24442-wk-Fact-EDDE1FED2572278FFC6B801F7EC0F70A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,809</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24462-wk-Fact-C5DF68B00988C4249D4D801F81707342" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,065</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24481-wk-Fact-EEDDB06313F61B23BAEB801F7EC79AC8" name="pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,300</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">U.S. postretirement plans</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24717-wk-Fact-1FD036A003F66D196001801F80EDBF09" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24736-wk-Fact-753465D7A627C0C6C864801F7E922133" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e24756-wk-Fact-81BF9447839E6277781D801F8110D158" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24814-wk-Fact-F588B19D0C5C6EC9C734801F7FE99D83" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24852-wk-Fact-83666425473B48E80163801F7E7455A0" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34661879e24872-wk-Fact-AB5ECEED024AF101A1AC801F8151B0F7" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:7pt;"></span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 1E</span><span style="font-family:Arial;font-size:7pt;">).</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span><span style="font-family:Arial;font-size:7pt;"></span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Mostly includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations are inclusive of repurchase agreements.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.</span></div></ix:footnote></td></tr></table></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-235024D196CC77C5BAC2801F83455C65-1" continuedAt="TextSelection-235024D196CC77C5BAC2801F83455C65-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-235024D196CC77C5BAC2801F83455C65-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</span></div></ix:continuation></ix:footnote></td></tr></table></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">110</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-6" continuedAt="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-7"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" id="TextSelection-4A05B63EB75FFAC8D93D801F83451851-0-wk-Fact-48DDF0F1147138EC668D801F80D056E0" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International Pension Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25527-wk-Fact-EAE26AAB2C1914749716801F81E7B60A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e25546-wk-Fact-7A6709A2CDA4ED18F63A801F81E30FBC" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2017Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">420</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e25585-wk-Fact-86177F1BC9ED7DAA2C5D801F80C8E0DE" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2017Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">468</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actual return on plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets held, ending</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25688-wk-Fact-21067B1E1FF8F6DA19E5801F81E4C327" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e25707-wk-Fact-E68EA365B2557A1A2325801F81DDF5DD" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25726-wk-Fact-68BCA950EAEC2E342DD3801F81DDFC58" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e25746-wk-Fact-53019A60C7C06A7E0755801F81E4E74E" name="us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">15</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Purchases, sales, and settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34661879e25771-wk-Fact-369FB78E5EF992B55F90801F80A1AC3A" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">40</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e25791-wk-Fact-AE8428DBA05DAA670DAA801F81E34FED" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">188</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25810-wk-Fact-AC64C6698BB91BE2DC0C801F81DF3611" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e25830-wk-Fact-8519AAABC07BA1DBCBC0801F80C7916E" name="us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements" contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Transfer into/(out&#160;of) Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25856-wk-Fact-14A7B3929125218D5E6A801F81DE053B" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">247</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e25875-wk-Fact-5E5E7E520234827504EC801F809C2217" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25894-wk-Fact-25F62796CC9F0052B3FB801F81E71502" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e25914-wk-Fact-092595F5E00F51778420801F809C634B" name="us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels" contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exchange rate changes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25940-wk-Fact-3E7990FC838DACC74110801F81E5198B" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e25959-wk-Fact-B6F7D234AB59E97AB262801F81E4B513" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">31</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e25979-wk-Fact-782627B1FCC4F297EF82801F81D8B54D" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34661879e25999-wk-Fact-2AAF53EE6C04B7D08D68801F81E51475" name="us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">20</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value, ending</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26031-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">944</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26050-wk-Fact-EAE26AAB2C1914749716801F81E7B60A" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">398</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916" name="us-gaap:DefinedBenefitPlanFairValueOfPlanAssets" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">382</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1E.</span><span style="font-family:Arial;font-size:8pt;"> For a description of the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans&#8217; assets:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">111</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-7" continuedAt="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-8"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock" id="TextSelection-EC6611ABA1A23D81DB40801F83462B8F-0-wk-Fact-CFB45404FC49C48E8AC2801F8012202A" continuedAt="TextSelection-235024D196CC77C5BAC2801F83455C65-0" escape="true"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:48%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Target</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Allocation Percentage</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Percentage of Plan Assets</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">(PERCENTAGES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-10%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26472-wk-Fact-8D92A4A4B9FA08C190A9801F7FF7DBD2" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26487-wk-Fact-884AF8AD2087D97669F4801F7F8C849D" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">35-55%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26522-wk-Fact-04945CE0460C4631AF2F801F7FFADACE" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">31.8</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26537-wk-Fact-0A5D28CF7C46374EE93B801F7FD46365" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">31.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fixed income securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">28-53%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26572-wk-Fact-264B32C84A907155F494801F7FDFA667" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">48.7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26587-wk-Fact-76D24705688E66F037EB801F7F8238FE" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">47.1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5-20%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26622-wk-Fact-EFD7F247DECDA09E6F48801F8003C2BF" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">17.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26637-wk-Fact-A94B247D4557B8E5CC4C801F7F93A1C4" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">18.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26658-wk-Fact-3CFE6BDEE6E11BA8F495801F7FE72B1D" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26673-wk-Fact-DD6160BDDCB15D9BC4E6801F7FEB72A6" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26688-wk-Fact-900A0C433DD667E1D073801F8004D440" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-10%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26775-wk-Fact-0AE2C3765352113FF0E2801F7F97CDDD" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">2.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26790-wk-Fact-E978BB4866A44C1E8279801F7F6EA381" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">3.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">20-40%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26825-wk-Fact-94B0CB413E58010326C0801F7F9BBCC0" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">21.5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26840-wk-Fact-6B860A8DA8169365CA0B801F81A6E74D" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">22.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fixed income securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">35-60%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26875-wk-Fact-8D9B79534220D7E9F8AC801F7F804C46" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">46.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26890-wk-Fact-1DD7C037665FEBD0A597801F81932B9B" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">46.3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10-35%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26925-wk-Fact-4290716CA30136DD43CE801F7FF6B17D" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">29.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26940-wk-Fact-B387961F5847F679CF37801F8195C059" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="3" scale="-2" format="ixt:numdotdecimal">27.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26961-wk-Fact-F82A6B43703A30AF1F73801F819A17F2" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e26976-wk-Fact-0B562CE7A48516C625B1801F7F7E94FE" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e26991-wk-Fact-54B4BEA5983E90FD7D6A801F81A66267" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">U.S. postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-5%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e27077-wk-Fact-49CE10C16240E92F5C9B801F81A499B3" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27091-wk-Fact-E876736E74EEB5080700801F8199E468" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">95-100%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e27125-wk-Fact-F3F3CF45DBDFDD834AE5801F7F8225F5" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27140-wk-Fact-2FE57B290588AA854309801F7F7E6C34" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e27161-wk-Fact-947B3AE3E11A5626F630801F7F770091" name="us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34661879e27176-wk-Fact-D86731FFA4669CFEBBCA801F819CC35C" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27191-wk-Fact-389AF65047725344B39F801F7F649798" name="us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations" contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">100</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans&#8217; invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of the respective plans&#8217; long-term benefit obligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset classes and our liability profile. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Each pension plan is overseen by a local committee or board that is responsible for the overall investment of the pension plan assets. In determining investment policies and associated target allocations, each committee or board considers a wide variety of factors. As such, the target asset allocation for each of our international pension plans is set on a standalone basis by the relevant board or committee. The target asset allocation ranges shown for the international pension plans seek to reflect the combined target allocations across all such plans, while also showing the range within which the target allocations for each plan typically falls.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The investment managers of certain separately managed accounts, commingled funds and private equity funds may be permitted to use repurchase agreements and derivative securities, including U.S. Treasury and equity futures contracts as described in each respective investment management, subscription, partnership or other governing agreement.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Cash Flows</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">112</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-8"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock" id="TextSelection-D5052DD7C523F01A210E801F8345B374-0-wk-Fact-6578174DC11CFDD7D968801F800AEECB" continuedAt="TextSelection-D5052DD7C523F01A210E801F8345B374-1" escape="true"><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:27%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the expected future cash flow information related to our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:center;">U.S. Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:center;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected employer contributions:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27650-wk-Fact-753DD635276562AAADD0801F7E9ACA47" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27669-wk-Fact-98BFF5893FA87300516A801F7E8D015A" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27689-wk-Fact-4A576DD84E72BF694DFE801F7E989595" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">172</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27708-wk-Fact-3DE297FCB202AC8DCCF7801F7E992601" name="us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected benefit payments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27820-wk-Fact-CD02E31A83E0B5811287801F7E930705" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27839-wk-Fact-323D92DB8BB96C4CD9AE801F7E9AEC6D" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27859-wk-Fact-F88722610C683B4F2CFE801F7E9225B3" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">355</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27878-wk-Fact-61D106EA039C7CC0E755801F7E97C96D" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27898-wk-Fact-CDB27CBFF6A5546A05E1801F7E9C36CC" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27917-wk-Fact-271EE9339F2C95C67649801F7E9E2005" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">113</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27936-wk-Fact-52C5DBBEDE4921461805801F7E8DBED8" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">358</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27956-wk-Fact-B9F816556BC38F3FB95E801F7E924955" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e27981-wk-Fact-CA35A857462FC04F8038801F7EBCAA68" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,048</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28000-wk-Fact-9D309C7357B31A429F45801F7E9CCEBE" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28019-wk-Fact-34934AB842289C268B01801F7E98CA50" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">364</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28039-wk-Fact-A28837DEBEB2FF3AF4C7801F7E933AFF" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28064-wk-Fact-47145AF1D6EF5EEC513D801F7E9D0915" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,046</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28083-wk-Fact-EAF8DAF1C21BB8753D8C801F7E97D7D4" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">110</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28102-wk-Fact-DA140C7F73332CB43365801F7E8FC48C" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">366</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28122-wk-Fact-677D184533F0A6EB4E58801F7E989189" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28147-wk-Fact-B46B3E21F38D256FBC28801F7E9D1BCD" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,028</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28166-wk-Fact-6946DF7C8ACF745C3C84801F7E92BF93" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28185-wk-Fact-80117314950A2BADE16C801F7E9389FB" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">375</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28205-wk-Fact-1312E18D2AAD95398BD4801F7E975474" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2025&#8211;2029</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28231-wk-Fact-94C48D1753008BE60A60801F7E9AFF38" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,759</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28250-wk-Fact-543C09084053AA43A926801F7EA7CF85" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">435</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28269-wk-Fact-24D2085F10B21075071E801F7E99825E" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,992</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34661879e28289-wk-Fact-B28397452B4DF28A8904801F7E9AD334" name="us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">642</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-D5052DD7C523F01A210E801F8345B374-1" continuedAt="TextSelection-D5052DD7C523F01A210E801F8345B374-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup><ix:footnote id="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-244B470B077332C11F811732546782CD-1">&#160;</ix:footnote></span></div></ix:continuation></td><td style="vertical-align:top;"><ix:continuation id="TextSelection-244B470B077332C11F811732546782CD-1"><ix:continuation id="TextSelection-D5052DD7C523F01A210E801F8345B374-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For the U.S. qualified plans, we plan to make a </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34661879e28318-wk-Fact-F1841F95F4C2B39FD6AF1B677F253E82" name="us-gaap:DefinedBenefitPlanContributionsByEmployer" contextRef="D2020Q4Jun29-Dec31_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember" unitRef="usd" decimals="-7" scale="9" format="ixt:numdotdecimal">1.25</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> voluntary contribution in the second half of 2020.</span></div></ix:continuation></ix:continuation></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation and, therefore, actual benefit payments may differ from projected benefit payments.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">F. Defined Contribution Plans</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have defined contribution plans in the U.S. and several other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. Beginning on January 1, 2011, for newly hired non-union employees, rehires and transfers to the U.S. or Puerto Rico, we no longer offer a defined benefit pension plan and, instead, offer a Retirement Savings Contribution (RSC) in the defined contribution plan. The RSC is an annual non-contributory employer contribution (that is not dependent upon the participant making a contribution) determined based on each employee&#8217;s eligible compensation, age and years of service. Beginning on January 1, 2018, all non-union employees in the U.S. and Puerto Rico defined benefit plans transitioned to the RSC in the defined contribution plans. We recorded charges related to the employer contributions to global defined contribution plans of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34661879e28342-wk-Fact-08461E8B77395876CE92172CF1864E07" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">659</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34661879e28350-wk-Fact-B1D8624AD9287C897056172DC671B95E" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">622</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34661879e28358-wk-Fact-077498470BD0CBDD688F172D429E77F7" name="us-gaap:DefinedContributionPlanCostRecognized" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">380</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div></ix:continuation><div><a id="sD9A92C6C1F7B574789CBD32067C14700"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 12</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="TextSelection-AE2295B1A6DA9AFFF160801F8347452E-0-wk-Fact-5096B386318188465FD1801F7EB68E75" continuedAt="TextSelection-AE2295B1A6DA9AFFF160801F8347452E-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Equity</span></ix:nonNumeric></div><ix:continuation id="TextSelection-AE2295B1A6DA9AFFF160801F8347452E-1" continuedAt="TextSelection-AE2295B1A6DA9AFFF160801F8347452E-2"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. Common Stock</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. On October 23, 2014, we announced that the Board of Directors had authorized an </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1315-wk-Fact-12629E0C1CB5273676EC801F7F0AC1BC" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2014Q4Oct23-2014" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">11</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> share repurchase program, which was exhausted in the first quarter of 2017. In December 2015, the Board of Directors authorized a new </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1319-wk-Fact-183C5540FDEC64E38A39801F7EBF8A21" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2015Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2015StockPurchasePlanMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">11</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> share repurchase program, which was exhausted in the third quarter of 2018. In December 2017, the Board of Directors authorized an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1323-wk-Fact-5934EBFC1F06F43AE121801F7EC2E42E" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2017Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2017StockPurchasePlanMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> share repurchase program, which was exhausted in the first quarter of 2019. In December 2018, the Board of Directors authorized a new </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1327-wk-Fact-C7D818268EA838DC2205801F7F0A9F0C" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="FI2018Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2018StockPurchasePlanMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">10</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">February&#160;2, 2017</span><span style="font-family:Arial;font-size:8pt;">, we entered into an accelerated share repurchase agreement with Citibank to repurchase </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1340-wk-Fact-280E1ED68A8E2D05D806801F7EBECE50" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">5</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1344-wk-Fact-DB7D001259ED28C74D84801F7EACE187" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" contextRef="I2017Q1Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usd" decimals="-9" scale="9" sign="-" format="ixt:numdotdecimal">5</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> to Citibank and received an initial delivery of approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1348-wk-Fact-BF0E504ED3350781CBB3801F7F00E5DD" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">126</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from Citibank at a price of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1352-wk-Fact-159B286BE0E340438567801F7EA9866E" name="us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare" contextRef="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.73</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1357-wk-Fact-190D5C6980FA8AB2916D801F7EBC1C3B" name="pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" contextRef="D2017Q1Feb02-Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1361-wk-Fact-422734FC4B97A87F2D0D801F7F0D88D4" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2017Q2May19-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">24</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1365-wk-Fact-63945409B47F55B3A2C2801F7EA858CA" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" contextRef="D2017Q2Feb06-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">33.31</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share. The common stock received is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Treasury Stock</span><span style="font-family:Arial;font-size:8pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">March&#160;12, 2018</span><span style="font-family:Arial;font-size:8pt;">, we entered into an accelerated share repurchase agreement with Citibank to repurchase </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1380-wk-Fact-177F6B663F011CCCFC30801F7EBB58D6" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2018Q1Mar12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usd" decimals="INF" scale="9" format="ixt:numdotdecimal">4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of our common stock. Pursuant to the terms of the agreement, on </span><span style="font-family:Arial;font-size:8pt;">March&#160;14, 2018</span><span style="font-family:Arial;font-size:8pt;">, we paid </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1388-wk-Fact-F58E0E33302939E7433C801F7F00C915" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" contextRef="I2018Q1Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usd" decimals="-9" scale="9" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> to Citibank and received an initial delivery of approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1392-wk-Fact-96E880A85D2229406EFE801F7EBB5CB6" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2018Q1Mar14-Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from Citibank at a price of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1397-wk-Fact-2C8F938D5134C2777154801F7EC5BA9F" name="us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare" contextRef="D2018Q1Mar14-Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">36.61</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share, which represented, based on the closing price of our common stock on the NYSE on </span><span style="font-family:Arial;font-size:8pt;">March&#160;12, 2018</span><span style="font-family:Arial;font-size:8pt;">, approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1405-wk-Fact-32C0AC373E776A37BFB9801F7ECAAC1A" name="pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" contextRef="D2018Q1Mar12-Mar12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of the notional amount of the accelerated share repurchase agreement. On September 5, 2018, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1409-wk-Fact-5F225E158EE07D9800D0801F7F0A9062" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2018Q3Sep07-Sep07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">21</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from Citibank on September 7, 2018. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1413-wk-Fact-9E848EFD2B0F3FC80F1A801F7EC616D4" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" contextRef="D2018Q3Sep07-Sep07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">36.86</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share. The common stock received is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Treasury stock</span><span style="font-family:Arial;font-size:8pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">February&#160;7, 2019</span><span style="font-family:Arial;font-size:8pt;">, we entered into an accelerated share repurchase agreement with </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> to repurchase approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1433-wk-Fact-9345AF2F1DAC0F57FDD8DEF1BFDD4C55" name="us-gaap:StockRepurchaseProgramAuthorizedAmount1" contextRef="I2019Q1Feb07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">6.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> of our common stock. Pursuant to the terms of the agreement, on </span><span style="font-family:Arial;font-size:8pt;">February&#160;12, 2019</span><span style="font-family:Arial;font-size:8pt;">, we paid approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1441-wk-Fact-9BBA9A5B8E37047536F4DEF458A9610C" name="us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt" contextRef="I2019Q1Feb12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">6.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> and received an initial delivery of approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1450-wk-Fact-7261652B81455B249BFA977918EDDC1D" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2019Q1Feb12-Feb12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">130</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;">, which represented, based on the closing price of our common stock on the NYSE on February 7, 2019, approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1458-wk-Fact-D5BD114B117A5D5D9A3B4A9B51DEB506" name="pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" contextRef="D2019Q1Feb07-Feb07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">80</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of the notional amount of the accelerated share repurchase agreement. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">113</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-AE2295B1A6DA9AFFF160801F8347452E-2"><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">August&#160;1, 2019</span><span style="font-family:Arial;font-size:8pt;">, the accelerated share repurchase agreement with </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> was completed, which, per the terms of the agreement, resulted in </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1477-wk-Fact-813974FCA52E5327989D0EE902D71DFA" name="us-gaap:TreasuryStockSharesAcquired" contextRef="D2019Q3Aug05-Aug05_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">33.5</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> on </span><span style="font-family:Arial;font-size:8pt;">August&#160;5, 2019</span><span style="font-family:Arial;font-size:8pt;">. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1490-wk-Fact-6CF37CE60FF85587A835008817260E3E" name="us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare" contextRef="D2019Q3Aug05-Aug05_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">41.42</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share. The common stock received is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Treasury stock</span><span style="font-family:Arial;font-size:8pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Open market purchases totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1501-wk-Fact-FA281C1523B933FCB347DEF7A88E4B3A" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_pfe_OpenMarketPurchasesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1509-wk-Fact-A7829A801872C65F41E4DEF7EA8F8CA0" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_pfe_OpenMarketPurchasesMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.2</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> under our publicly announced share-purchase plans.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfTreasuryStockByClassTextBlock" id="TextSelection-CEE1563EC47C01B0F9ED801F83478639-0-wk-Fact-1BE0C6DB3D4D11DEA4B3801F7EAD352E" continuedAt="TextSelection-CEE1563EC47C01B0F9ED801F83478639-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:46%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our accelerated share repurchase agreements:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(SHARES IN MILLIONS, DOLLARS IN BILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares of common stock purchased</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34524436e1696-wk-Fact-D95C333A77FF51D2367A801F8284E06B" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1715-wk-Fact-36C4BF558BFA7F0626F6801F8284052E" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1734-wk-Fact-B9B68A9EF2D595760795801F82827C2E" name="us-gaap:TreasuryStockSharesAcquired" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">150</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of purchase</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34524436e1765-wk-Fact-FB3538E362BC65E9A4AD801F8283AB6A" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.9</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1784-wk-Fact-406980FB36901507CFF4801F8284BFE7" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">12.2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1804-wk-Fact-B41D8C40DC9E96021764801F82858FF5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.0</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt">(</sup></span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-02E52614EBB7CDE55C93801F8347287F-0-wk-Footnote-02E52614EBB7CDE55C93801F8347287F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Represents shares purchased pursuant to the accelerated share repurchase agreement with</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:7pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:7pt;"> entered into on </span><span style="font-family:Arial;font-size:7pt;">February&#160;7, 2019</span><span style="font-family:Arial;font-size:7pt;">, as well as other share repurchases. See above for additional information.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-38BDAE166DE9044C0E60801F8347D176-0-wk-Footnote-38BDAE166DE9044C0E60801F8347D176_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on </span><span style="font-family:Arial;font-size:7pt;">March&#160;12, 2018</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">, as well as other share repurchases. See above for additional information.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-CEE1563EC47C01B0F9ED801F83478639-1" continuedAt="TextSelection-CEE1563EC47C01B0F9ED801F83478639-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-0-wk-Footnote-4ABFC5BADBDD92BDEF6F801F83478C48_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-1"><ix:continuation id="TextSelection-CEE1563EC47C01B0F9ED801F83478639-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"> </span><span style="font-family:Arial;font-size:7pt;">February&#160;2, 2017</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">. See above for additional information.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-1"></ix:continuation>After giving effect to the accelerated share repurchase agreement, as well as other share repurchases through </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, our remaining share-purchase authorization was approximately&#160;</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1899-wk-Fact-6E71B38CCD744BD9C9CE801F7F29B839" name="us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" contextRef="FI2019Q4" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">5.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> at </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Preferred Stock</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Series A convertible perpetual preferred stock (</span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1915-wk-Fact-46A6AEFA0D92380897DBF338873F3639" name="pfe:PreferredStockSharesHeldInEmployeeTrustShares" contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredESOPPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,500</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> shares designated) is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1919-wk-Fact-E8EAF2D8D376EE62C9E9801F7F02DA90" name="us-gaap:PreferredStockDividendRatePercentage" contextRef="FD2019Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">6.25</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">, which are accumulated and paid quarterly. The per-share stated value is </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1923-wk-Fact-72749EC9DF6A4E02395B801F7EBBF08D" name="us-gaap:PreferredStockParOrStatedValuePerShare" contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">40,300</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holder&#8217;s option, into </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1927-wk-Fact-9CC4B957607DA42366E4801F7F01A745" name="us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion" contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,574.87</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1931-wk-Fact-753C2BB94F8F9613C2BF801F7EA77A6D" name="us-gaap:PreferredStockRedemptionPricePerShare" contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">40,300</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per share.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Employee Stock Ownership Plans</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1943-wk-Fact-5040989B219D7A0AFAFD801F7EBA269B" name="pfe:NumberofEmployeeStockOwnershipPlans" contextRef="FI2019Q4" unitRef="employee_stock_ownership_plan" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP).</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, the Preferred ESOP held preferred shares convertible into approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1957-wk-Fact-1E7C47538D5B1E7C3872801F7F06DC62" name="pfe:ConvertiblePreferredStockNumberofSharesConvertible" contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock, and the Common ESOP held approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34524436e1961-wk-Fact-19AB79CFD3F59B7A0599801F7EC563E2" name="us-gaap:EmployeeStockOwnershipPlanESOPSharesInESOP" contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, all shares of preferred and common stock held by the ESOPs have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1969-wk-Fact-FD21A8A2DEE2EEA8C18B801F7EC6E228" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1978-wk-Fact-7331D1073C937D778183801F7F01523E" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">19</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34524436e1986-wk-Fact-F85EF785AEE69C51E056801F7F09CFBF" name="us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div></ix:continuation><div><a id="sB3A6DE16539E5641A4924CFD2AA5D37C"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 13. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-0-wk-Fact-A88F1F9CFDA3408C37EB801F80F59648" continuedAt="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-1" escape="true">Share-Based Payments</ix:nonNumeric></span></div><ix:continuation id="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-1" continuedAt="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our compensation programs can include share-based payments. The award value is determined by reference to the fair value of share-based awards to similar employees in competitive survey data or industry peer groups used for compensation purposes; and is allocated between different long-term incentive vehicles, in the form of TSRUs, PTSRUs, PTUs, RSUs, PPSs, PSAs and stock options, as determined by the Compensation Committee.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The 2019 Stock Plan (2019 Plan) replaced and superseded the 2014 Plan. The 2019 Plan provides for </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1310-wk-Fact-6FC2C450052B93096492801F82643506" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">400</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares to be authorized for grants, plus any shares remaining available for grant under the 2014 Plan as of April 25, 2019 (the carryforward shares). In addition, the 2019 Plan provides that the number of stock options, Stock Appreciation Rights (known as TSRUs and PTSRUs), RSUs, or other performance-based awards that may be granted to any one individual during any 36-month period is limited to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1314-wk-Fact-854C7571320A0D913933801F82901CC5" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="shares" decimals="INF" scale="6" format="ixt:numdotdecimal">20</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares, and that RSUs, PPSs and PSAs count as </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1318-wk-Fact-E522A123693B340C8D90801F7F984A2B" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> shares, while TSRUs, PTSRUs and stock options count as </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1322-wk-Fact-042E8CC246E59F30A494801F7E35C0F4" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> share, toward the maximum shares available under the 2019 plan. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1331-wk-Fact-F0BD08D907939AC63DA6801F7E2DF4CD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" contextRef="FI2019Q4" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">518</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> shares were available for award. </span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">114</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-2" continuedAt="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-3"><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. Impact on Net Income</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="TextSelection-8148B060ED7AD7AF4A1E801F834DC8D1-0-wk-Fact-C81C4E0E1895B3A8A42C801F82905353" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of share-based compensation expense and the associated tax benefit:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e1587-wk-Fact-B879D2FCD0A23F2045A2801F7ED7E9E3" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1606-wk-Fact-7891E4C59FB8C240ECF8801F7ED8C974" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1626-wk-Fact-18A55E3A510C5C5B3112801F7ED70A08" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">221</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e1646-wk-Fact-9F2D0143794D1F571F19801F7ED65330" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">275</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1665-wk-Fact-B3E12E551BC655A18FC0801F7EDC907C" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">286</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1684-wk-Fact-9750E37307390E2A75F1801F7EDCA921" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PPSs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e1710-wk-Fact-7E01A0C63FFB00E4C98A801F7ED7AF09" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1729-wk-Fact-1B624A552DD3F3058B77801F7EDC1193" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1748-wk-Fact-748EFF95AFC11AED93E6801F7EDD9652" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">209</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e1774-wk-Fact-46F717C1553CF53F7172801F7ED0930D" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">28</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1793-wk-Fact-CEE69CAB6A39F47680CC801F7ECFE9F0" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">62</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1812-wk-Fact-C387BFF2E792CFCF5605801F7EDDF8B1" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Stock options </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e1838-wk-Fact-D5E7109BD60C7188B654801F7EDD27FB" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1857-wk-Fact-57FCE1E85DD3DD4F6BD8801F7ED09BE6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1876-wk-Fact-290FC363F3F9E182FEB7801F7EDD5C6B" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Directors&#8217; compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e1902-wk-Fact-32213D56355CD79C6022801F7EDBFE08" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1921-wk-Fact-FE00D81CAAA4354BBB07801F7ED53DA6" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1940-wk-Fact-92370CDB33B5B0D0BFF9801F7EDB8EEA" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Share-based payment expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e1966-wk-Fact-406BD401F6A1617163AF801F7ED97DEF" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">718</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e1985-wk-Fact-A2235D173D1198572D6A801F7ED90D48" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">949</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2004-wk-Fact-ED3A88AD0E9EA78C1F37801F7EDD3765" name="us-gaap:AllocatedShareBasedCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">840</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax benefit for share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e2030-wk-Fact-674DC804C9A2E9F7EDF4801F7ED08970" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">137</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34594690e2050-wk-Fact-8F02E9905482BC7D9010801F7ECF51AE" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(<ix:nonFraction id="d34594690e2070-wk-Fact-BB1C8EF20AA722100577801F7EDDA77A" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">163</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Share-based payment expense, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e2103-wk-Fact-758B4D2904B68E19A0F9801F7ED9CDED" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">581</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2122-wk-Fact-F8F197A88298D7CDA4F1801F7ED69B97" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">769</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2142-wk-Fact-02AC1B14C6F316304BFA801F7ED2123F" name="us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax" contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">677</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)&#160;&#160;&#160;&#160;</sup></span><ix:footnote id="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-1"><span style="font-family:Arial;font-size:7pt;">Includes expense for PTSRUs, described in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 13C</span><span style="font-family:Arial;font-size:7pt;"> below, which is not significant for all years presented.</span></ix:footnote></div><ix:continuation id="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-1"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:nonNumeric><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The table above excludes total expense due to the modification for share-based awards in connection with our Organizing for Growth initiative. The total expense was not significant for 2019 and 2018, the year in which the Organization for Growth Initiative began and is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:8pt;">).</span><span style="font-family:Arial;font-size:7pt;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts capitalized as part of inventory cost were not significant for any period presented.</span></div><div style="line-height:120%;padding-left:4px;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Total Shareholder Return Units</span></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs are awarded to senior and other key management, and to certain other employees. TSRUs entitle the holders to receive a number of shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the </span><span style="font-family:Arial;font-size:8pt;">five</span><span style="font-family:Arial;font-size:8pt;">-year or </span><span style="font-family:Arial;font-size:8pt;">seven</span><span style="font-family:Arial;font-size:8pt;">-year term, if and to the extent the total value is positive. The settlement price is the average closing price of our common stock during the </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2249-wk-Fact-4DC9ED78933BD86361BC801F8289ACB5" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="trading_day" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant. The TSRUs are automatically settled on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Retiree eligible holders (at least age </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e2258-wk-Fact-81DCE96B00B2CC383EEF801F828E6FE8" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">55</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> with at least </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e2262-wk-Fact-163C0E18C3EB57071A63801F7E9BBD88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:durwordsen">ten years</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> of service) can elect to exercise and convert his/her TSRUs, when vested, into PTUs. The value received upon the election and conversion is calculated by taking the change in stock price (</span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2266-wk-Fact-4DC9ED78933BD86361BC801F8289ACB5" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="trading_day" decimals="INF" scale="0" format="ixt:numdotdecimal">20</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> trading day average ending on the exercise date (Election Price) less the grant price) plus accumulated dividends from the grant date, times the number of TSRUs exercised. This value is divided by the Election Price to determine the number of PTUs. The PTUs will be entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#8217; original settlement date (i.e., the fifth or seventh anniversary of grant), and will be subject to all of the terms and conditions of the original grant including forfeiture provisions. We measure the value of TSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="pfe:ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock" id="TextSelection-248891BC6096268B8EA6801F834DD3AD-0-wk-Fact-C7031F7FE33834083B74801F8283AACD" continuedAt="TextSelection-248891BC6096268B8EA6801F834DD3AD-1" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average assumptions used in the valuation of TSRUs:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected dividend yield</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e2463-wk-Fact-F35741687D18E3B4878F801F81982A44" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">3.27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2478-wk-Fact-3DAD4CB2028224ADCA3A801F819615A2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">3.73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2493-wk-Fact-3EB348FE8DB4F3058FEF801F81A6D04E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">3.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Risk-free interest rate</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e2516-wk-Fact-3BADC091FCBEA9D91D08801F819B12FC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2531-wk-Fact-5A1DD2370C1F985FBB91801F81A8925B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.60</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2546-wk-Fact-24AE793F7AF5A0FFC713801F81A5B87D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">1.98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected stock price volatility</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e2569-wk-Fact-DACC4B795F2137AD8A42801F81A81F11" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">18.34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2584-wk-Fact-09366D0018503E3621D1801F819C0D25" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">20.00</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2599-wk-Fact-A1E8D06C4BADD1A6A43D801F819A99BD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">18.39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Contractual term (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e2620-wk-Fact-D5EFC6E1EB01FD7CE6B4801F81A47D9C" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">5.13</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e2634-wk-Fact-4374254178D68E57BD72801F81A80D3E" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">5.12</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e2648-wk-Fact-225B36E2167933185C95801F819B8A2F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">5.11</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using a constant dividend yield during the expected term of the TSRU.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using the interpolated yield on U.S. Treasury zero-coupon issues.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-248891BC6096268B8EA6801F834DD3AD-1" continuedAt="TextSelection-248891BC6096268B8EA6801F834DD3AD-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-248891BC6096268B8EA6801F834DD3AD-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using implied volatility, after consideration of historical volatility.</span></div></ix:continuation></ix:footnote></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock" id="TextSelection-250C160F445EBC0BB584801F834C7D93-0-wk-Fact-09BF6DCEF2C149FF0BDC801F81CD88E3" continuedAt="TextSelection-250C160F445EBC0BB584801F834C7D93-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"></td></tr><tr><td style="width:56%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all TSRU activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant-Date</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2873-wk-Fact-2B3A7AD8D31149C70784801F82ACB4BD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">138,945</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2892-wk-Fact-29E8009CF7353E027C13801F82ADFD8D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e2911-wk-Fact-4B3368EC6957D80B4C25801F82B6ABA0" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">33.44</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e2932-wk-Fact-A53C0AC13138F9FC10A0801F82AB44D9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">39,246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e2946-wk-Fact-4188C213ECB0D342DCC5801F82AB683F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e2965-wk-Fact-47CCB4B31FABBCCE984A801F82AE4414" name="pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">43.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e2991-wk-Fact-A8E4714D3FF46F4742D9801F82B0A4CC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">47,710</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3006-wk-Fact-0BC8AC002D2D11DC55C9801F82A5B062" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.92</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3025-wk-Fact-C572B98C4A6E034CBE6C801F82AD80C0" name="pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">30.70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e3051-wk-Fact-2D766935D9716B0603B7801F82A9B1E0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,826</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3066-wk-Fact-E5EA9B34E3F68B35E39D801F82ACF0A6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.63</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3085-wk-Fact-285C0E244AD577E64B92801F82AC6621" name="pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">38.90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3111-wk-Fact-0859BCD07BA3D1199211801F82B17E9B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">122,654</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3130-wk-Fact-E0913B51212D1DBECFC6801F82B0208D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.53</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3149-wk-Fact-AE20B2F126CBCFAD2DDE801F82AF7B38" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">38.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:nonNumeric></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">115</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-3" continuedAt="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-4"><ix:continuation id="TextSelection-250C160F445EBC0BB584801F834C7D93-1"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:41%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:12%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes TSRU and PTU information as of December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PTUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant&#160;Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate Intrinsic Value (Millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3394-wk-Fact-6221149E08DD0A17F14B801F8152992D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">179,999</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3427-wk-Fact-7BB330D73286C9EA44FD801F8148FF86" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">35.33</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e3442-wk-Fact-B9A985D5E312D61B9E03801F81513582" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">2.6</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3457-wk-Fact-55A2404E40890D14A72D801F8159A9F4" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,415</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3477-wk-Fact-50F041F28B665D836084801F81547F30" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">57,345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3505-wk-Fact-DED528DDB914A2BDEF0A801F81463977" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.04</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e3525-wk-Fact-265DAD9E00B9993A01D4801F81574A5A" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">1.3</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3535-wk-Fact-654FE5FF7865D1DED1CD801F815171FE" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Expected to vest</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">118,618</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">37.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">3.2</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,096</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs exercised and converted to PTUs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3659-wk-Fact-39D10B011D5484305F0B801F814829A7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e3693-wk-Fact-268578D08E27C197EEE6801F8149CC9C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember" format="ixt-sec:duryear">0.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e3708-wk-Fact-31E5ACFB46A559DC7083801F81586817" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, we settled </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34594690e3728-wk-Fact-DF27274198C78C3FFBC6801F7E39A293" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">7,953,671</ix:nonFraction></span></span><span style="font-family:Arial;font-size:7pt;"> TSRUs with a weighted-average grant price of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34594690e3732-wk-Fact-4C1CF66DD81E59C282C3801F828B2941" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">27.33</ix:nonFraction></span></span><span style="font-family:Arial;font-size:7pt;"> per unit.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34594690e3753-wk-Fact-BA4FA60038DF8467BE65801F82642ED3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">2,173,131</ix:nonFraction></span></span><span style="font-family:Arial;font-size:7pt;"> TSRUs with a weighted-average grant price of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34594690e3757-wk-Fact-AD6AA25517BBCA4DFCA0801F82805D52" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">30.68</ix:nonFraction></span></span><span style="font-family:Arial;font-size:7pt;"> per unit were converted into </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34594690e3761-wk-Fact-603776CFA0F5467FCBEC801F7EDAAE83" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">844,871</ix:nonFraction></span></span><span style="font-family:Arial;font-size:7pt;"> PTUs.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:63%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all TSRU activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average grant-date fair value per TSRU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4024-wk-Fact-4188C213ECB0D342DCC5801F82AB683F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">8.52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4043-wk-Fact-BE507844521211CA94E6801F80A24F5C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">7.42</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4063-wk-Fact-2DD59081DEDF0560DAEF801F80CF98FE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">6.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4088-wk-Fact-E907D692F06EF7D58934801F7FF75806" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4107-wk-Fact-63D57FC7853A0D736F74801F80CB2B68" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">246</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4127-wk-Fact-794A0F522F645E6F6E8A801F80D3186F" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">232</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which TSRU cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e4147-wk-Fact-59309543825EA6AEA6E4801F80CE3AA9" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">1.6</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e4166-wk-Fact-0832C5E5BCCDDB95B157801F80DFA492" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">1.6</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e4185-wk-Fact-7434E66EC04212978FA8801F80C5A249" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember" format="ixt-sec:duryear">1.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Performance Total Shareholder Return Units</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On December 29, 2017, in connection with the Board&#8217;s succession planning,</span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4209-wk-Fact-EF3B52560A4A2544E8DA801F81BC1E84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="D2017Q4Dec29-Dec29_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">1,372,213</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> PTSRUs were awarded to the then Chairman and Chief Executive Officer, and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4213-wk-Fact-CCD4D990445B9606C1A6801F7EDC4986" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" contextRef="D2017Q4Dec29-Dec29_srt_TitleOfIndividualAxis_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" unitRef="shares" decimals="INF" scale="0" format="ixt:numdotdecimal">343,053</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President, Pfizer Innovative Health) at a grant price of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34594690e4217-wk-Fact-4C09CEF5D0AB97425644801F7E33B167" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" contextRef="D2017Q4Dec29-Dec29_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">36.22</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> and at a grant-date fair value of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34594690e4221-wk-Fact-40DB65839272DFA6B7F8801F80F3E20C" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" contextRef="D2017Q4Dec29-Dec29_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.83</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> per TSRU. In addition to having the same characteristics of TSRUs, PTSRU grants require special service and performance conditions.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of PTSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> as appropriate.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Restricted Stock Units</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of our common stock, including shares resulting from dividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e4243-wk-Fact-CA4056187AC4E787DC6E801F81E42E10" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> of continuous service from the grant date.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of RSU grants as of the grant date using the closing price of our common stock. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" id="TextSelection-01CA05E76AA7E5EF272D801F834C1B21-0-wk-Fact-6AA0AA03E616352394DE801F8285C24C" continuedAt="TextSelection-01CA05E76AA7E5EF272D801F834C1B21-1" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:66%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all RSU activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant-Date Fair Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4381-wk-Fact-7DBB7F0E572004849E2C801F80AF440E" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">27,276</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4400-wk-Fact-6E06409C1FA303566611801F80C76773" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">33.70</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4420-wk-Fact-6404D4E395D713E052ED801F80C8E5E7" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">7,478</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4434-wk-Fact-C546F354E2EE8F6C9891801F80289293" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">43.17</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e4459-wk-Fact-A92668B7862CB8ABB2D9801F80B1E88C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">10,644</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4474-wk-Fact-5C089929FC6AD8D3128E801F80230069" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Reinvested dividend equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4499-wk-Fact-45E7F2A850737653CBC2801F80BEC4E1" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4513-wk-Fact-97F88B06FF262C45C8E2801F801FA376" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">39.64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e4538-wk-Fact-DE2B73649C13DF99D4ED801F80A146EF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,614</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4553-wk-Fact-45A273B1877DCDB29980801F809E09A3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">38.82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4578-wk-Fact-86683D0AC0369864852F801F80CAF6DC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">23,407</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4597-wk-Fact-C930C1BE1CD0AD294931801F80B7C998" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">37.54</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all RSU activity:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4846-wk-Fact-137CA28F27F7A870C810801F81C79E37" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">454</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4865-wk-Fact-1D05AD6F6F2D8CB837F3801F81CB438D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4885-wk-Fact-6077434EDCF327AE1499801F81D5A9C4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">584</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e4910-wk-Fact-EE84B5518D13FA627186801F81D6A114" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">241</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4929-wk-Fact-6FDD60627A9A357C96C0801F81C90B9B" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">256</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e4949-wk-Fact-F503B707E0FD43FA4262801F81CCA124" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which RSU cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e4969-wk-Fact-9F76724182A84924F7CF801F81CAED77" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">1.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e4988-wk-Fact-0114F20D770B4848A819801F81BDDD0F" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">1.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e5007-wk-Fact-D588BD9B2B98545608FB801F81C57423" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" format="ixt-sec:duryear">1.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-01CA05E76AA7E5EF272D801F834C1B21-1" continuedAt="TextSelection-01CA05E76AA7E5EF272D801F834C1B21-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-01CA05E76AA7E5EF272D801F834C1B21-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017 includes the modification for a commitment to pay approximately </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34594690e5033-wk-Fact-BD2CAD3B252048CD7515801F8285C81F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.4</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> RSUs to approximately </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34594690e5037-wk-Fact-3436D1EFFACF27EC797F801F8283B31F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="Employee" decimals="-2" scale="0" format="ixt:numdotdecimal">9,900</ix:nonFraction></span></span><span style="font-family:Arial;font-size:7pt;"> employees, including senior and key management employees, for </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34594690e5041-wk-Fact-D9D1066F08FF5CBABD06801F7E2D4C1B" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">6.6</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> RSUs. These shares were paid in the first quarter of 2018.</span></div></ix:continuation></ix:footnote></td></tr></table></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">116</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-4" continuedAt="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-5"><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Portfolio Performance Shares</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PPSs are awards granted to select employees which, when vested, entitle the holder to receive, at the end of the performance period, a number of shares within a possible range of shares of our common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the awards vest after </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e5162-wk-Fact-9EB81BE6D030973CD761801F828D7FE8" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> of continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer&#8217;s long-term product portfolio during a </span><span style="font-family:Arial;font-size:8pt;">five</span><span style="font-family:Arial;font-size:8pt;">-year performance period from the year of the grant date. The number of shares that may be earned over the performance period ranges from </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e5170-wk-Fact-544C770E04D1784312B9801F82829192" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e5174-wk-Fact-50288B12B222EA12333D801F82859A80" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of the initial award.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of PPS grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized on a straight-line basis over the probable vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales,</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:8pt;">and/or</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Research and development expenses, </span><span style="font-family:Arial;font-size:8pt;">as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer&#8217;s common stock, changes in the number of shares that are probable of being earned and changes in management&#8217;s assessment of the probability that the specified performance criteria will be achieved and/or changes in management&#8217;s</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">assessment of the probable vesting term.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" id="TextSelection-748CD2FAD379BD0B3655801F834BE247-0-wk-Fact-7DA635DD082FF2F9F478801F7EDBF9E6" continuedAt="TextSelection-77C3FE85BF8AFD54D464801F834BC28C-0" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:65%;"></td><td style="width:1%;"></td><td style="width:14%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:16%;"></td><td style="width:1%;"></td></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all PPS activity during 2019, with the shares representing the maximum award that could be achieved:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e5322-wk-Fact-F14A9C781986E780D881801F80B6FD00" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">19,261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e5341-wk-Fact-479DD93FDE5F409502F0801F80D11F95" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">43.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e5361-wk-Fact-2F598B1406A11FE5C58D801F80AC1A27" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">6,212</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e5375-wk-Fact-339226858A639B6BCD25801F80B853D2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">43.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e5400-wk-Fact-E8F58A444C9CFF7025E4801F80E842E0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">6,882</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e5415-wk-Fact-C86C3B899E98DCD9BA3E801F80DFCCEE" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">42.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e5440-wk-Fact-47745DB83766C496A971801F80B46143" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">897</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e5455-wk-Fact-35027DE2FCE41CF272B1801F80DBC816" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">39.93</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e5482-wk-Fact-E6EDC6EB8DF84B60CE5A801F80D3642D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">17,694</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e5501-wk-Fact-3FDB29B576C0C8FDA061801F7FF11DF2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">39.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C075792364F3F1E4361D801F8348FF26-0-wk-Footnote-C075792364F3F1E4361D801F8348FF26_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vested and non-vested shares outstanding, but not paid as of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> were </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34594690e5533-wk-Fact-150F22D999AC1A6DE980801F828FE93C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">32.0</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:70%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all PPS activity:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e5791-wk-Fact-290DAB02A52F6F057DBD801F81805322" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">136</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e5810-wk-Fact-584DD122A3D879719E35801F821354D9" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">169</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e5830-wk-Fact-FCC410BA1B024EAAB0B6801F8178508D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">131</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e5855-wk-Fact-49F2DF8E8BBEEEEC5F2E801F8177102F" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">87</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e5874-wk-Fact-6F7A537347DBBAC786B0801F81883421" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">102</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e5894-wk-Fact-E377273B92CA7E29D745801F82163DAE" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">94</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which PPS cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e5914-wk-Fact-CFBF0755FFBC33523BD6801F821BAE10" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" format="ixt-sec:duryear">1.8</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e5933-wk-Fact-A77F093BE7D5AD6FCE0D801F817A333C" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" format="ixt-sec:duryear">1.8</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e5952-wk-Fact-E01B69D232C0119F3425801F8178D7A2" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember" format="ixt-sec:duryear">1.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:nonNumeric><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">F. Performance Share Awards</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PSAs are awarded to senior and other key management. PSAs vest after </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;"> years of continuous service from the grant date. The number of shares paid, if any, including shares resulting from dividend equivalents, for awards granted in 2015 and later, depends upon the achievement of predetermined goals related to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6096-wk-Fact-736458414C86A8BF1DD4801F827FDC1D" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="measure" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> measures: (i) adjusted operating income (for performance years through 2018) or adjusted net income (for 2019 and later years, except for the 2017 PSAs) over </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6100-wk-Fact-11D82C85193B213208E3801F7E94F871" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="period" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">one</span><span style="font-family:Arial;font-size:8pt;">-year periods; and (ii) TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;">-year performance period. The number of shares that are earned over the performance period ranges from </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6113-wk-Fact-5021B89D92BD42DB7A21801F7F93CFA0" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">0</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6117-wk-Fact-1E13A0191A8D061A9CA5801F81BD26A7" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">200</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of the initial award.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of PSA grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized on a straight-line basis over the probable vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer&#8217;s common stock, changes in the number of shares that are probable of being earned and changes in management&#8217;s assessment of the probability that the specified performance criteria will be achieved.</span></div><ix:continuation id="TextSelection-77C3FE85BF8AFD54D464801F834BC28C-0" continuedAt="TextSelection-77C3FE85BF8AFD54D464801F834BC28C-1"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"></td></tr><tr><td style="width:58%;"></td><td style="width:1%;"></td><td style="width:19%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:18%;"></td><td style="width:1%;"></td></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;">The following table summarizes all PSA activity during 2019, with the shares granted representing the maximum award that could be achieved:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6267-wk-Fact-1AE3F831F0AC89A46ACC801F82CC7EEA" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,282</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6286-wk-Fact-93C18C29C2F03B0FE6F3801F7EC4E280" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">43.65</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e6306-wk-Fact-772E25FB2AFDB05C0BB8801F7DC5F2DF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,716</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e6320-wk-Fact-7D7ACA0C1E68E041A0F9801F7EBC9C84" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">43.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e6345-wk-Fact-78538C632106CA60F131801F7EC91F76" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e6360-wk-Fact-43C668FD8C15F363EFB6801F7EC630C4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">42.89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e6385-wk-Fact-67E532EB9CB7EE55AF82801F7EC7C221" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">456</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e6400-wk-Fact-150485A40162B2B540F8801F80B19109" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">41.91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e6425-wk-Fact-4BB52DC78D0C6B52ACEC801F7EC89B88" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">5,061</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e6444-wk-Fact-3624CB37E827F0D87C37801F7EC12EE3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">39.18</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">117</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-5" continuedAt="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-6"><ix:continuation id="TextSelection-77C3FE85BF8AFD54D464801F834BC28C-1" continuedAt="TextSelection-77C3FE85BF8AFD54D464801F834BC28C-2"><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:61%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:10%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;">The following table provides data related to all PSA activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e6695-wk-Fact-8027040D1DF4721D6272801F7F0F7A3C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">64</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6714-wk-Fact-9179C071F6FA44A44864801F7F0CC3E4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6734-wk-Fact-3211B659D4CE729821B4801F7F0D704F" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">58</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e6759-wk-Fact-7A13E149D91E1FD0EED1801F7F0ED23C" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6778-wk-Fact-C40FD8D6B88C25BA4193801F7F1691B7" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">41</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6798-wk-Fact-425F8C7193EAD9808260801F7F2204DD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which PSA cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e6818-wk-Fact-A510C149D1946AEB622D801F7F506333" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">1.8</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e6837-wk-Fact-ABEED740F4B15AA1C834801F7F0EE6AB" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">1.8</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e6856-wk-Fact-41F3EA956045BC1117EB801F7F0E63F5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" format="ixt-sec:duryear">1.8</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-77C3FE85BF8AFD54D464801F834BC28C-2" continuedAt="TextSelection-77C3FE85BF8AFD54D464801F834BC28C-3"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-77C3FE85BF8AFD54D464801F834BC28C-3"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:Arial;font-size:7pt;">2017 </span><span style="font-family:Arial;font-size:7.5pt;">includes the modification </span><span style="font-family:Arial;font-size:7pt;">for a commitment to pay</span><span style="font-family:Arial;font-size:7.5pt;"> </span><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34594690e6890-wk-Fact-9A7F8A77EF19F15A6339801F81D63B96" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7.5pt;"> PSAs to approximately </span><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34594690e6894-wk-Fact-84A4BDBCAB54D15D1AF7801F7E59E635" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="Employee" decimals="-1" scale="0" format="ixt:numdotdecimal">90</ix:nonFraction></span></span><span style="font-family:Arial;font-size:7.5pt;"> employees, including senior and key management employees, for </span><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34594690e6898-wk-Fact-D2A25D922C72BAD1CD55801F82818882" name="pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">1.1</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7.5pt;"> PSAs. These shares were paid in the first quarter of 2018.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">G. Stock Options</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Stock options are awarded to select employees and, when vested, entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in 2016, only a limited set of overseas employees received stock option grants. </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e6947-wk-Fact-E8380CA4CC1832D7F1D6801F7E364403" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ManagementMember" unitRef="shares" decimals="INF" scale="0" format="ixt-sec:numwordsen">No</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> stock options were awarded to senior and other key management in any period presented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted vest after </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e6951-wk-Fact-1BDDB8FA0086FEFE3E84801F7E34FBF6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:durwordsen">three years</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> of continuous service from the grant date and have a contractual term of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e6955-wk-Fact-B925A635A947F49C1FB6801F7E22032D" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">10</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> years. In most cases, stock options must be held for at least </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e6959-wk-Fact-23C1B858911534788A6D801F8287D171" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:durwordsen">one year</ix:nonNumeric></span></span><span style="font-family:Arial;font-size:8pt;"> from the grant date before any vesting may occur. In the event of a sale of business or plant closing or restructuring, options held by employees are immediately vested and are exercisable for a period of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e6963-wk-Fact-30F3ED4239BD3CD5FAE0801F7E3F9C14" name="pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:durmonth">3</ix:nonNumeric> months</span></span><span style="font-family:Arial;font-size:8pt;"> following the date employment is terminated or through their remaining term, depending on various conditions.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of stock option grants as of the grant date using the Black-Scholes-Merton option-pricing model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="TextSelection-E3D77D1B0B694446EE3A801F834DABEE-0-wk-Fact-CF9993CE236C60BE28E1801F7E491E5E" continuedAt="TextSelection-E3D77D1B0B694446EE3A801F834DABEE-1" escape="true"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.40476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average assumptions used in the valuation of stock options:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected dividend yield</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7166-wk-Fact-73C56959049A2D57F4C1801F82A49C55" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">3.27</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e7181-wk-Fact-1A163CFC61DB374C9859801F82396806" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">3.73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e7196-wk-Fact-CD039103D85D7763C03A801F82921CA3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">3.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Risk-free interest rate</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7219-wk-Fact-096BFE17591BD0B2DDDC801F823E3221" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.66</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e7234-wk-Fact-DDA3C772DD5D6A9CF860801F82921818" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.85</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e7249-wk-Fact-56D7F8DD1BDAEA1F8A93801F82A07FA6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">2.23</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected stock price volatility</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7272-wk-Fact-F46555EB6318EAAE369C801F8291F711" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">18.34</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e7287-wk-Fact-2C386152CD1597FBF4FA801F82A1CFF0" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">20.02</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e7302-wk-Fact-E385705FB7C3A2995158801F82A7D035" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="number" decimals="4" scale="-2" format="ixt:numdotdecimal">18.39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected term (years)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e7325-wk-Fact-EE8C91D96F98673768FF801F82A21974" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.75</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e7339-wk-Fact-32EF9B5301DDDEC38EC0801F829FDB14" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.75</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e7353-wk-Fact-31F361F21F2837AACE1C801F82A5E94F" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">6.75</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using a constant dividend yield during the expected term of the option.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using the interpolated yield on U.S. Treasury zero-coupon issues.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using implied volatility, after consideration of historical volatility.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-E3D77D1B0B694446EE3A801F834DABEE-1" continuedAt="TextSelection-E3D77D1B0B694446EE3A801F834DABEE-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-E3D77D1B0B694446EE3A801F834DABEE-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using historical exercise and post-vesting termination patterns.</span></div></ix:continuation></ix:footnote></td></tr></table><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="TextSelection-EC14A9316BF8E3C0C206801F834CFB5F-0-wk-Fact-984F3EC33CFD7DC2074C801F7EDA5393" continuedAt="TextSelection-EC14A9316BF8E3C0C206801F834CFB5F-1" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"></td></tr><tr><td style="width:39%;"></td><td style="width:1%;"></td><td style="width:11%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:15%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td></tr><tr><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all stock option activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exercise Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Remaining Contractual Term</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e7617-wk-Fact-D4E3E637EF0690450C82801F7E2E025D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2018Q4" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">103,791</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e7636-wk-Fact-54DD743A1F7FEBC19886801F7E57C69D" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2018Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">27.69</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7687-wk-Fact-0F223FFC4C2BD7F30C2B801F7E557E89" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">1,181</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7701-wk-Fact-A69421D1832E5C73D7A3801F7E462E9A" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">43.35</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e7757-wk-Fact-F292BE49551CBC3A3875801F7E37D4DE" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">15,964</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7772-wk-Fact-475BA0477B8C782E4919801F7E44D883" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">24.84</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e7828-wk-Fact-1E235321A2F6C23760F4801F7E43B41B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">55</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7843-wk-Fact-D314A88FEE632A5D5ECF801F7E4902CB" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">37.67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(<ix:nonFraction id="d34594690e7899-wk-Fact-905B4772CC6EB5CF0191801F7E57B9B4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7914-wk-Fact-52B424F297F261DAF67F801F7E4A1996" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">31.12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7970-wk-Fact-8B357FFC428B1525E9B5801F7E45D0DC" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">88,600</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e7984-wk-Fact-F6CDEA395E802562E37E801F7E4A30B5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e8003-wk-Fact-1B2390B50A69D00EA43E801F7E64C531" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">3.6</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8019-wk-Fact-DAD0CA8E455F2B5DC7FA801F7E585E15" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested and expected to vest, December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b</sup></span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8043-wk-Fact-DD2FFFF9189C3FA5A3DB801F7E4AF4C6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" contextRef="FI2019Q4" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">88,469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8057-wk-Fact-150B8237E6AC43FC08DF801F7E45E25C" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.37</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e8076-wk-Fact-CB7E2DB668A75D5161C1801F7E45DB8D" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">3.6</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8087-wk-Fact-A41309C827BD3760EAD4801F7E667623" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">960</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercisable, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8112-wk-Fact-C944C10F71C19D743431801F7E56B988" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" contextRef="FI2019Q4" unitRef="shares" decimals="-3" scale="3" format="ixt:numdotdecimal">85,372</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8131-wk-Fact-B00F20EB6975ADFEFC60801F7E68B215" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" contextRef="FI2019Q4" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">28.04</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e8145-wk-Fact-B50C97854BE5E73FA65D801F7E67CAEB" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" contextRef="FD2019Q4YTD" format="ixt-sec:duryear">3.4</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8161-wk-Fact-6E8F52F802E68107D2ED801F7E65A2D6" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">951</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Market price of our underlying common stock less exercise price.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The number of options expected to vest takes into account an estimate of expected forfeitures.</span></div></ix:footnote></td></tr></table></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">118</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-EC14A9316BF8E3C0C206801F834CFB5F-1"><ix:continuation id="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-6"><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:73%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes data related to all stock option activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average grant-date fair value per stock option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8438-wk-Fact-92FA252097F1F382AB2C801F82504C90" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.98</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8457-wk-Fact-F7E869ED96C460CA6626801F8253E013" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">5.06</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8477-wk-Fact-849D683D90D44D0EAF9E801F8249337B" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="2" scale="0" format="ixt:numdotdecimal">4.01</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate intrinsic value on exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8502-wk-Fact-EF5C8AAC79BA024D6528801F82519503" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8521-wk-Fact-C8F488B488483C72F432801F824CF953" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8541-wk-Fact-B145092A83B74EA499B9801F824910A5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">331</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash received upon exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8566-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">394</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8585-wk-Fact-CF6EA013BF1855E39D139D5A4C827484" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,259</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8605-wk-Fact-43172D93073829A17FB6801F82AF4ECB" name="us-gaap:ProceedsFromStockOptionsExercised" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">862</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax benefits realized related to exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8630-wk-Fact-84F4790DBB7067158401801F824E0FB2" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8649-wk-Fact-6B1D8CED7A79238FF8E5801F8250F204" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">115</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8669-wk-Fact-83E956A7B5BCAE136250801F825B51AD" name="us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">95</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested stock options not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34594690e8694-wk-Fact-19BA8460C55A7E677DDD801F82522A11" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8713-wk-Fact-A1220BA84C82A0B53EC3801F825790F8" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34594690e8733-wk-Fact-3B7F4666E688C266A166801F824F031D" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which stock option compensation cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonNumeric id="d34594690e8753-wk-Fact-352195F82B7F2C9C5D40801F824B42AE" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">1.6</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e8772-wk-Fact-ED5A183817B37C3637C8801F824CFB89" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">1.7</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonNumeric id="d34594690e8791-wk-Fact-4367012342069C45EF1F801F824D50BD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember" format="ixt-sec:duryear">0.8</ix:nonNumeric></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation></ix:continuation><div><a id="sFD98A083D3175F36951524F153C2D720"></a></div><div style="line-height:120%;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 14. <ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:EarningsPerShareTextBlock" id="TextSelection-4C005DB9DFA3855AB83B801F834D6ABA-0-wk-Fact-563526BF9B4C663E8C19801F7ED71355" continuedAt="TextSelection-4C005DB9DFA3855AB83B801F834D6ABA-1" escape="true">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ix:nonNumeric></span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="TextSelection-D182ACB558010258E6A6801F834D421E-0-wk-Fact-165DA1181120ADC0E624801F7ED72DEF" continuedAt="TextSelection-D182ACB558010258E6A6801F834D421E-1" escape="true"><ix:continuation id="TextSelection-4C005DB9DFA3855AB83B801F834D6ABA-1" continuedAt="TextSelection-4C005DB9DFA3855AB83B801F834D6ABA-2"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:67%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the detailed calculation of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Earnings per common share</span><span style="font-family:Arial;font-size:8pt;">&#160;(EPS)</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e1616-wk-Fact-0035B9C9DB225A72A990E1262460243C" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1635-wk-Fact-F7E834DB2C365543A0147187D74A1E82" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,179</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1655-wk-Fact-7AB6A34649A53C89765A801F808558FA" name="us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,353</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e1675-wk-Fact-F23EAD7DE306562A925D2F7D3A1596DB" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1694-wk-Fact-C2E59E9312A2513BBF73058FCB5316FD" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1713-wk-Fact-80D79FBFC60C79D8ED0A801F7F23174B" name="us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">47</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e1739-wk-Fact-20A6B513F10556A58D86CF6794E1A92E" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1758-wk-Fact-B28BB414FBBC5123A11532CA6D6B9C9B" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1777-wk-Fact-676ED17534D4A1DDF4E5801F812EB833" name="us-gaap:IncomeLossFromContinuingOperations" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e1803-wk-Fact-73E70C0071435DCDA89552E8E50E2520" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1822-wk-Fact-0E98726E17DF5FD5994E3EDBBD540CC6" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1841-wk-Fact-687559E643972585D475801F813FF631" name="us-gaap:PreferredStockDividendsIncomeStatementImpact" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e1867-wk-Fact-6AE8267207D25ED2A3F79F71445B5011" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,268</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1886-wk-Fact-4AF655CA2FA158BDB94642F5C12FEDAB" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1905-wk-Fact-F7971B440B9DAE93D538801F8148DAA9" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e1931-wk-Fact-324E930EA3FE51309DAF874C15316ACB" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1950-wk-Fact-08237D5DF91153BBBDE19A688EC551B8" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e1969-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Discontinued operations&#8211;&#8211;net of tax, attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e1995-wk-Fact-9AC24A4B2A115C0FBCF42D71854AAB49" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2014-wk-Fact-089D98C9534857528D87686ADB3F11AD" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2033-wk-Fact-50B16320C587C88A23ED801F7F5AFA61" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2060-wk-Fact-FCE9F14CE3D15A8981141CD50168E91E" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2079-wk-Fact-EB7E7431973953F2B7E9EB2F0A78493F" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2098-wk-Fact-D27E8EDC863863FCD349801F7F4E91B2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2129-wk-Fact-012C63720C6854C98D6A6253DCA558A5" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,272</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2148-wk-Fact-D7011577FDBF586698D386953D4E65EA" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,152</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2168-wk-Fact-AA915253D7955702F6D7801F7F54B77E" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,307</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2258-wk-Fact-A00920C2431522B2968C801F7F224E5F" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2277-wk-Fact-5C85FF62621855588051D90715E8692E" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,143</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2297-wk-Fact-426E8633C226972EAFC1801F7F512F5E" name="pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2317-wk-Fact-FCE9F14CE3D15A8981141CD50168E91E" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2336-wk-Fact-EB7E7431973953F2B7E9EB2F0A78493F" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2355-wk-Fact-D27E8EDC863863FCD349801F7F4E91B2" name="us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2386-wk-Fact-EE583BC53A585E028A64E196788A920E" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">16,273</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2405-wk-Fact-B7FA3547783950158A5DFFD4B6A7F6FA" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,153</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2425-wk-Fact-13BB9B6FD324E2C231C3801F810694AE" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">21,308</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2512-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,569</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2531-wk-Fact-A641170D49AD547A8914C2CE48D6E64F" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,872</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2550-wk-Fact-09473C310A80FA565C36801F7F16DCBB" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2578-wk-Fact-31994C39581B5B71BDDB9AE8FC22964B" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">106</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2597-wk-Fact-F9C9FEE2CCBF5BBAB626316FA2913D2A" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2616-wk-Fact-027BA945C36E755C6E0D801F8147CCD2" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">89</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2642-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2019Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,675</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2661-wk-Fact-33F90922FE92534B8F84E80D9633CDA7" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2018Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">5,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2680-wk-Fact-769F1280EBF192E593C5801F7F419E21" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" contextRef="FD2017Q4YTD" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">6,058</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2708-wk-Fact-0E154CA77D6B55F38225A9B701605CD5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2727-wk-Fact-496231284B82551EA3C09B63129DD116" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">2</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2746-wk-Fact-699213AA4BB320044F47801F81563F2E" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember" unitRef="shares" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash dividends declared per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34523018e2778-wk-Fact-089AD09C4BEB171B6FF2801F7F4F7B82" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="FD2019Q4YTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">1.46</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2797-wk-Fact-2741C1D79AE51A3A6FE9D8F59BF430AA" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="FD2018Q4YTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">1.38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34523018e2817-wk-Fact-0FEBECF7E5E8F3317B88D8F59BFD549F" name="us-gaap:CommonStockDividendsPerShareDeclared" contextRef="FD2017Q4YTD" unitRef="usdPerShare" decimals="INF" scale="0" format="ixt:numdotdecimal">1.30</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017 includes the effect of the modification for a commitment to pay </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34523018e2837-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember" unitRef="shares" decimals="-5" scale="6" format="ixt:numdotdecimal">15.2</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-D182ACB558010258E6A6801F834D421E-1" continuedAt="TextSelection-D182ACB558010258E6A6801F834D421E-2"><ix:continuation id="TextSelection-4C005DB9DFA3855AB83B801F834D6ABA-2" continuedAt="TextSelection-4C005DB9DFA3855AB83B801F834D6ABA-3"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-D182ACB558010258E6A6801F834D421E-2"><ix:continuation id="TextSelection-4C005DB9DFA3855AB83B801F834D6ABA-3"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><a id="s96615865CA775D7EABC293CD1C317AAC"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 15. <ix:nonNumeric contextRef="FD2019Q4YTD" name="pfe:InsuranceCoverageDisclosureTextBlock" id="TextSelection-047EDAAD7B2238581654801F834FAD00-0-wk-Fact-ADC2FE3D389128BE8187801F81533A57" continuedAt="TextSelection-047EDAAD7B2238581654801F834FAD00-1" escape="true">Insurance</ix:nonNumeric></span></div><ix:continuation id="TextSelection-047EDAAD7B2238581654801F834FAD00-1"><div style="line-height:120%;padding-top:4px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability.</span><span style="font-family:Arial;font-size:8pt;color:#1f497d;"> </span><span style="font-family:Arial;font-size:8pt;">If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16</span><span style="font-family:Arial;font-size:8pt;">).</span></div></ix:continuation><div><a id="s4EACE3CA173E5CB785C07B8FA376C8ED"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 16</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-0-wk-Fact-BF1B990B04C3A652FB58801F828C45FC" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Contingencies and Certain Commitments</span></ix:nonNumeric></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-1" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-2"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5D.</span><span style="font-family:Arial;font-size:8pt;"> For a discussion of our legal contingencies, see below.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">119</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-2" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-3"><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Legal Proceedings</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our legal contingencies include, but are not limited to, the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A1</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. </span><span style="font-family:Arial;font-size:8pt;">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others.</span><span style="font-family:Arial;font-size:8pt;"> Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1411-wk-Fact-86074884B8895C2C906E2CE766860B2D" name="pfe:GainContingencyPatentsWithoutCourtProceedingsNumber" contextRef="D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents. In June 2018, the PTAB ruled on another patent, holding that </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1415-wk-Fact-C80F69DE66A8525F9363880D94B391A7" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2018Q2Jun01-Jun30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision. In November 2019, the U.S. Court of Appeals for the Federal Circuit vacated the PTAB&#8217;s ruling and requested that the PTAB redecide the challenge.</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:8pt;">In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We have appealed. Challenges to other patents remain pending in jurisdictions outside the U.S.</span><span style="font-family:Arial;font-size:8pt;color:#1f497d;"> </span><span style="font-family:Arial;font-size:8pt;">The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">120</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-3" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-4"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. </span><span style="font-family:Arial;font-size:8pt;">If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Actions In Which We Are The Plaintiff</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Precedex Premix</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in 2014, several generic manufacturers filed separate abbreviated new drug applications with the FDA, seeking approval to market their generic versions of our subsidiary Hospira&#8217;s premix version of Precedex prior to the expiration of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1451-wk-Fact-1BD84B766FCD5E91BA884741D04C98FC" name="pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber" contextRef="FD2014Q4YTD_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> or more patents covering the product. </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1455-wk-Fact-695196B6D3E7A1F5C2667E30227AC8FF" name="pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019" contextRef="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">One</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> of those patents expired in March 2019, while others do not expire until 2032. Beginning in 2014, Hospira brought suit against these generic manufacturers, in some cases joined by Orion Corporation (co-owner of certain of our Precedex premix patents). To date, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1459-wk-Fact-A8C7E11E02C52648F192DE89AC2F2D9C" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" contextRef="D2019Q4Dec31-31_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> of the actions have been settled or dismissed on terms not material to Pfizer: (i) the action filed against Ben Venue Laboratories, Inc., which was sued along with Hikma Pharmaceuticals PLC (together, succeeded by Eurohealth International Sarl) and West-Ward Pharmaceuticals Corp (collectively, the Ben Venue case); and (ii) the action filed against Baxter Healthcare Corporation. The remaining actions continue as described below. </span></div><div style="line-height:120%;text-align:justify;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2015, Hospira filed suit against Amneal Pharmaceuticals LLC (Amneal) in the U.S. District Court for the District of Delaware asserting the validity and infringement of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1469-wk-Fact-9A4D92389A7750658CECD5B29ED0277A" name="pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber" contextRef="D2015Q3Aug1-31_srt_LitigationCaseAxis_pfe_HospiraVersusParMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents relating to the Precedex premix formulations and their use, all of which expire in 2032. In January 2018, the District Court ruled that </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1473-wk-Fact-B33693F542A330BD344B01837126C014" name="us-gaap:GainContingencyPatentsFoundInfringedUponNumber" contextRef="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> of the </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1477-wk-Fact-87B491021A620CFDBA49017BE93B5017" name="pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber" contextRef="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusParMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents was valid and infringed, and that the other </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1481-wk-Fact-CC7A45E10285DB31D4DF01839F476D98" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" contextRef="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents were invalid. In February and March 2018, respectively, each of Amneal and Hospira appealed the District Court decision to the U.S. Court of Appeals for the Federal Circuit. In January 2019, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that certain patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois, asserting the validity and infringement of those patents. In December 2018, the District Court ruled that the asserted claims of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1490-wk-Fact-E375D51843A56BC7AA630C260D89BD0E" name="us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber" contextRef="D2018Q4Dec1-31_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents were invalid. Hospira appealed the District Court&#8217;s decision as to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1494-wk-Fact-D923CB6FB410CB214D4201900CBD5914" name="pfe:GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber" contextRef="FD2019Q4YTD_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> of the patents to the U.S. Court of Appeals for the Federal Circuit. In January 2020, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Separate actions in which Hospira sued Par Sterile Products LLC, Gland Pharma Limited, and Jiangsu Hengrui Medicine Co., Ltd., each in response to such generic manufacturer&#8217;s filing of a separate abbreviated new drug application with the FDA, seeking approval to market their generic versions of our subsidiary Hospira&#8217;s premix version of Precedex prior to the expiration of </span><span style="font-family:Arial;font-size:8pt;">one</span><span style="font-family:Arial;font-size:8pt;"> or more patents covering the product, were stayed pending the outcome of the case against Fresenius described above. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Xeljanz (tofacitinib)</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications with the FDA, seeking approval to market their generic versions of tofacitinib tablets in </span><span style="font-family:Arial;font-size:8pt;">one</span><span style="font-family:Arial;font-size:8pt;"> or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, actions against the following generic manufacturers have been settled on terms not material to Pfizer: (i) MicroLabs USA Inc. and MicroLabs Ltd.; (ii) Sun Pharmaceutical Industries Ltd.; (iii) Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC; and (iv) Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. The remaining actions continue as described below.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1522-wk-Fact-168623731935273CE8C30187B4B73E40" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusZydusMember_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2019, we brought a separate patent infringement action against Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, Ajanta) in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1537-wk-Fact-962CF888D231519CA26A5936A713ECAD" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusAjantaMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents: the patent covering the active ingredient that expires in December 2025 and the patent covering a polymorphic form of tofacitinib that expires in 2023, each of which Ajanta challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In August 2019, in response to a similar challenge by Ajanta relating the tofacitinib 10 mg tablets, we brought another patent infringement action against Ajanta in the U.S. District Court for the District of Delaware.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Inlyta (axitinib)</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">121</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-4" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-5"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Kerydin (tavaborole)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span><span style="font-family:Arial;font-size:8pt;">assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">,</span><span style="font-family:Arial;font-size:8pt;"> filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Ibrance (palbociclib)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1575-wk-Fact-D97E0D8502645F93925811BE613337A1" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusGenericCompaniesMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Chantix (varenicline) </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In January 2020, we brought a patent infringement action against Viwit Pharmaceutical Co. Ltd. (Viwit) in the U.S. District Court for the District of Delaware, asserting the validity and infringement of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1588-wk-Fact-89781F2774D8748608F17E329A160847" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2020Q1Jan1-31_srt_LitigationCaseAxis_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents challenged by Viwit in its abbreviated new drug application seeking approval to market a generic version of varenicline, 0.5 mg &#160;and 1.0 mg tablets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Eliquis</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February, March, and April 2017, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1601-wk-Fact-82F5C9F5234A5BA3A4F2084B696726A1" name="pfe:GainContingencyNumberofDefendants" contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Defendant" decimals="INF" scale="0" format="ixt-sec:numwordsen">twenty-five</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1605-wk-Fact-0EEFB150D722521B96F4D6AB8B769B9F" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents listed in the Orange Book for Eliquis. </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1609-wk-Fact-DB4D0502208C148C6BF3DE99551EF741" name="pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">One</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1613-wk-Fact-0EEFB150D722521B96F4D6AB8B769B9F" name="us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber" contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents. We and BMS have settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future. </span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Action In Which We Are The Defendant</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Inflectra (infliximab-dyyb)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1626-wk-Fact-A9297EA354685CF6AE402F34561612D9" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" contextRef="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">six</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents relating to infliximab, its manufacture and use. Claims with respect to </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1630-wk-Fact-04284ACF683C5988A8FB935618DBEEBF" name="us-gaap:LossContingencyClaimsDismissedNumber" contextRef="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">four</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> of the patents were dismissed by the plaintiffs, leaving </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1634-wk-Fact-03E4F32ED141575FA456592B789220C0" name="us-gaap:LossContingencyPatentsAllegedlyInfringedNumber" contextRef="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="Patent" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> patents at issue: the infliximab antibody patent and a patent relating to cell culture media. In January 2018, the antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, the U.S. District Court for the District of Massachusetts granted defendants&#8217; motion for summary judgment and ruled that the patent relating to cell culture media was not infringed. Janssen appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit. </span></div><div style="line-height:120%;padding-top:9px;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Asbestos</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Claims against American Optical and numerous other defendants are pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">122</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-5" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-6"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effexor</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Lipitor</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Antitrust Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re Lipitor Antitrust Litigation MDL-2332</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District</span><span style="font-family:Arial;font-size:8pt;color:#0000ff;"> </span><span style="font-family:Arial;font-size:8pt;">Court for the District of New Jersey. </span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court&#8217;s decision.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Viagra</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691</span><span style="font-family:Arial;font-size:8pt;">), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Lilly with respect to Cialis have also been consolidated in the Multi-District Litigation </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">(In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691</span><span style="font-family:Arial;font-size:8pt;">). In January 2020, the District Court granted our and Lilly&#8217;s motion to exclude all of plaintiffs&#8217; general causation opinions. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intravenous Solutions</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and certain other defendants relating to intravenous saline solution. Plaintiffs seek to represent a class consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants&#8217; allegedly unlawful conduct ceases. Plaintiffs allege that the defendants&#8217; conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. </span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">123</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-6" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-7"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. All of these actions have been consolidated in the U.S. District Court for the Northern District of Illinois. In July 2018, the District Court granted defendants&#8217; motions to dismiss the consolidated amended complaint without prejudice. Plaintiffs filed a second amended complaint in September 2018. On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, which includes intravenous saline solution, to ICU Medical. The litigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Hormone Therapy Consumer Class Action</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A certified consumer class action is pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth&#8217;s hormone-replacement products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a full refund of the purchase price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. In August 2017, a similar lawsuit brought in the U.S. District Court for the District of New Jersey on behalf of a purported class of direct purchaser plaintiffs against Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. In February 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust laws. At least </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1763-wk-Fact-2070907F0D6C56158D8777FFE08CA3A6" name="pfe:LossContingencyNumberOfLawsuits" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_EpiPenMember_srt_RangeAxis_srt_MinimumMember" unitRef="lawsuit" decimals="INF" scale="0" format="ixt-sec:numwordsen">one</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act. Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2009. In August 2017, all of these actions, except for the 2020 lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, MDL-2785</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nexium 24HR and Protonix</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re: Proton-Pump Inhibitor Products Liability Litigation</span><span style="font-family:Arial;font-size:8pt;"> (No. II)) in the U.S. District Court for the District of New Jersey. On July&#160;31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. As part of the joint venture transaction, the joint venture has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Docetaxel&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re Taxotere (Docetaxel) Products Liability Litigation, MDL-2740</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the Eastern District of Louisiana.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Mississippi Attorney General Government Investigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1812-wk-Fact-DF81DC3320DC58FC987DFBA3A82F1BC9" name="pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant" contextRef="D2018Q4Oct01-Oct31_srt_LitigationCaseAxis_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_srt_ProductOrServiceAxis_pfe_DocetaxelMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember" unitRef="manufacturer" decimals="INF" scale="0" format="ixt-sec:numwordsen">eight</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Array Securities Litigation</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In November 2017, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1822-wk-Fact-049E0E0B377C5900929BD3E0069DB2AD" name="pfe:LossContingencyClassActionsFiledNumber" contextRef="D2017Q4Nov2017" unitRef="class_action" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in July 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In March 2018, the actions were consolidated into a single proceeding. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Zantac </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A number of lawsuits have been filed against Pfizer in various federal courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and sold Zantac. Pfizer has not sold Zantac since 2006. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February 2020, these federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re Zantac/Ranitidine NDMA Litigation, MDL-2924</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the Southern District of Florida. </span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">124</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-7" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-8"><div style="line-height:120%;padding-top:9px;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A3</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Monsanto-Related Matters</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Environmental Matters</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#8217;s discontinued industrial chemical facility in North Haven, Connecticut. In September 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In September 2019, the EPA acknowledged that construction of the site remedy has been completed.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Also, in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#8217;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1870-wk-Fact-3A733DE7E05D54E4B303735F7E0AAEE4" name="pfe:FeasibilityStudyNumberOfLagoons" contextRef="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember" unitRef="lagoon" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. In September 2018, the EPA issued a final remediation plan for the </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34558932e1874-wk-Fact-DDD1CB6E0B38554486629FCE56E3CE83" name="pfe:FeasibilityStudyNumberOfLagoons" contextRef="D2018Q3Sep01-Sep30_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember" unitRef="lagoon" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and in September 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2017, a number of United States service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2018, the U.S. Department of Justice requested documents related to this matter, which are being provided.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Allergan Complaint for Indemnity</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re National Prescription Opiate Litigation MDL 2804</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In December 2018, the District Court dismissed the lawsuit. In February 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Breach of Contract</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Xalkori</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer is a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#8217;s sales of</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:8pt;">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="font-family:Arial;font-size:8pt;color:#212529;">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="font-family:Arial;font-size:8pt;"> The action was originally filed in 2013. In December 2015, the Supreme Court dismissed the action and in May 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#8217; summary judgment motions.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">125</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-8" continuedAt="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-9"><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.</span><span style="font-family:Arial;font-size:8pt;"> Among the investigations by government agencies are the matters discussed below.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Phenytoin Sodium Capsules</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In May 2013, the U.K. Competition &amp; Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market. In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust laws. In December 2016, the CMA imposed a </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;<ix:nonFraction id="d34558932e1940-wk-Fact-10E0AA7E05785EB8B65BF3D6F290EA33" name="us-gaap:LossContingencyEstimateOfPossibleLoss" contextRef="FI2016Q4_srt_ProductOrServiceAxis_pfe_PhenytoinSodiumCapsulesMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_ViolationofAntitrustLawsMember" unitRef="gbp" decimals="-5" scale="6" format="ixt:numdotdecimal">84.2</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> fine on Pfizer and Pfizer Limited. Pfizer appealed the CMA decision to The Competition Appeal Tribunal in February 2017</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:8pt;">On June 7, 2018, the Competition Appeal Tribunal overturned the CMA decision as well as the associated fine. The CMA appealed the judgment to the Court of Appeal.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Greenstone Investigations</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">U.S. Department of Justice Antitrust Division Investigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">State Attorneys General Generics Antitrust Litigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re: Generic Pharmaceuticals Pricing Antitrust Litigation MDL No. 2724)</span><span style="font-family:Arial;font-size:8pt;"> in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Subpoena relating to Manufacturing of Quillivant XR</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February 2019, we received a civil investigative demand from the U.S. Attorney&#8217;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In June 2019, we received an informal request from the U.S. Department of Justice&#8217;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA unit. We are producing records pursuant to these requests. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16A3. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Legal Proceedings&#8211;&#8211;Commercial and Other Matters&#8211;&#8211;Contracts with Iraqi Ministry of Health</span><span style="font-family:Arial;font-size:8pt;"> above for information regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Docetaxel</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Mississippi Attorney General Government Investigation</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16A2. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Legal Proceedings</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Product Litigation</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Docetaxel</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Mississippi Attorney General Government Investigation</span><span style="font-family:Arial;font-size:8pt;"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Guarantees and Indemnifications</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, the estimated fair value of these indemnification obligations was not significant. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition, in connection with our entry into certain agreements, our counterparties agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.</span></div></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">126</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-9"><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Certain Commitments</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had agreements totaling </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2070-wk-Fact-EF7451461450FE24E0FA801F7E11F8D4" name="us-gaap:LongTermPurchaseCommitmentAmount" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.5</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> to purchase goods and services that are enforceable and legally binding and include amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur, as well as obligations to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">seven</span><span style="font-family:Arial;font-size:8pt;">-year period in connection with the U.S. and EU approvals for Besponsa (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2078-wk-Fact-0B2FA3640980E2BAB54D801F8283053C" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">412</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">) and an obligation to make guaranteed fixed annual payments over an </span><span style="font-family:Arial;font-size:8pt;">eight</span><span style="font-family:Arial;font-size:8pt;">-year period for Bosulif (</span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2087-wk-Fact-A4575347EB6532721CC2801F8290C485" name="pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation" contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">217</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">), both associated with R&amp;D arrangements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, in connection with the TCJA, we have an estimated </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2103-wk-Fact-8EF9B5A847D55767BF5A5596B994B8F5" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">15</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> repatriation tax liability on accumulated post-1986 earnings of foreign subsidiaries for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. With respect to the aforementioned repatriation tax liability, it is reported in current </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:8pt;"> (approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2111-wk-Fact-7574A578AC5453EE80D42498A2BBDAA5" name="us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">600</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> due in April 2020) and the remaining liability is reported in noncurrent </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable </span><span style="font-family:Arial;font-size:8pt;">in our consolidated balance sheet as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. The first installment of </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2124-wk-Fact-71130497423450AA97DB57267DA5E202" name="pfe:PaymentForRepatriationTax" contextRef="D2019Q2Apr01-Apr30" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">750</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> was paid in April 2019. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Contingent Consideration for Acquisitions</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We may be required to make contingent consideration payments to sellers for certain prior business combinations. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1D</span><span style="font-family:Arial;font-size:8pt;">. The estimated fair value of contingent consideration as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2146-wk-Fact-498886C5C2B6716529BC0275CA691D29" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">711</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2150-wk-Fact-8DCEE1A254094A81CFDD0281A44DAD1A" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">160</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2159-wk-Fact-9ED6AEC039293C11188A028320F52725" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">551</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">. The estimated fair value of contingent consideration as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2171-wk-Fact-0F944687F28C52ABCBB60275FEF74B94" name="us-gaap:BusinessCombinationContingentConsiderationLiability" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">988</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2175-wk-Fact-3B8B41DA51CC78D751480281ED97E91C" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">280</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34558932e2184-wk-Fact-A6F57C90CD95CF105E54028498AFC178" name="us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">708</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">. The decrease in the contingent consideration balance from prior year is primarily due to payments made upon the achievement of certain milestones.</span></div></ix:continuation><div><a id="sFC8EED0BCE295111A2E9166DE65303FE"></a></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Note 17. </span><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:SegmentReportingDisclosureTextBlock" id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-0-wk-Fact-7FD6653F6AD0965AEEFB801F821F0749" continuedAt="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-1" escape="true"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Segment, Geographic and Other Revenue Information</span></ix:nonNumeric></div><ix:continuation id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-1" continuedAt="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-2"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Segment Information</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We regularly review our segments and the approach used by management to evaluate performance and allocate resources. Prior to January 1, 2019, we managed our commercial operations through </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e1317-wk-Fact-D17055AF0AB4DC9AC143801F8131E959" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2018Q4YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">two</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e1321-wk-Fact-E001667F01F95E298014FB8B5A7B8850" name="us-gaap:NumberOfOperatingSegments" contextRef="FD2019Q4YTD" unitRef="Operating_Segment" decimals="INF" scale="0" format="ixt-sec:numwordsen">three</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Pfizer&#8217;s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn and through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Consumer Healthcare, are responsible for their own R&amp;D activities while Biopharma receives its R&amp;D services from GPD and WRDM. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. As our operations were not managed under the new structure until the beginning of fiscal 2019, certain costs and expenses could not be directly attributed to one of the then new operating segments. As a result, our operating segment results for 2018 and 2017 include allocations, which management believes are reasonable. As described in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">127</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-2" continuedAt="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-3"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operating Segments</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:9%;"></td><td style="width:40%;"></td><td style="width:1%;"></td><td style="width:50%;"></td></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Some additional information about our Biopharma and Upjohn business segments follows:</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="pfizerlogo2816.jpg" alt="pfizerlogo2816.jpg" style="height:34px;width:60px;"></img></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Pfizer</span></div><div style="padding-left:72px;text-indent:-72px;font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Biopharmaceuticals</span></div><div style="padding-left:72px;text-indent:-72px;font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Group</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img src="upjohnlogo.jpg" alt="upjohnlogo.jpg" style="height:85px;width:221px;"></img></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma is a science-based medicines business that includes six business units &#8211; Oncology, Inflammation &amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer&#8217;s contract manufacturing operation, Pfizer CentreOne. At the beginning of our 2019 fiscal year, we also incorporated our biosimilar portfolio into the Oncology and Inflammation &amp; Immunology business units and certain legacy established products into the Internal Medicine business unit. Each business unit is committed to delivering breakthroughs that change patients&#8217; lives.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Prevnar 13/Prevenar 13<br/>- Ibrance<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Eliquis<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Xeljanz<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Enbrel </span><span style="font-family:Arial;font-size:8pt;">(outside the U.S. and Canada)<br/>- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Chantix/Champix<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Sutent<br/>- Xtandi<br/></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Lyrica<br/>- Lipitor<br/>- Norvasc<br/>- Celebrex<br/>- Viagra<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Certain generic medicines</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:8pt;"> for additional information.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Other Costs and Business Activities</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM&#8211;&#8211;the R&amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#8211;&#8211;including patients, healthcare providers, pharmacists, payers and health authorities&#8211;&#8211;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">GPD&#8211;&#8211;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other&#8211;&#8211;the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Corporate and Other Unallocated&#8211;&#8211;the costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investments in equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular </span></div></td></tr></table></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">128</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-3" continuedAt="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-4"><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:8pt;">basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Segment Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34586122e1584-wk-Fact-77980D14EA6E543398FA366DF6F1559F" name="us-gaap:Assets" contextRef="FI2019Q4" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">167</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$<ix:nonFraction id="d34586122e1592-wk-Fact-9A5AF0B77C295D12BF1CA751D9155BC1" name="us-gaap:Assets" contextRef="FI2018Q4" unitRef="usd" decimals="-9" scale="9" format="ixt:numdotdecimal">159</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Selected Income Statement Information</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="pfe:ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock" id="TextSelection-07EAEA8170A954930C88801F835332D1-0-wk-Fact-C6959854031DFEF3B66A801F7DE516CE" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" id="TextSelection-F8BE884DC75F74C9D8F6801F8354E5C7-0-wk-Fact-F23BEB0F90F486EFD68D801F82226D7F" continuedAt="TextSelection-F8BE884DC75F74C9D8F6801F8354E5C7-1" escape="true"><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" id="TextSelection-6E34BC7E6D74B396FAA8801F8354B510-0-wk-Fact-71B61B5F8DE4F5211BA1801F7E20CC4E" continuedAt="TextSelection-6E34BC7E6D74B396FAA8801F8354B510-1" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="37"></td></tr><tr><td style="width:28%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:5%;"></td><td style="width:1%;"></td></tr><tr><td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Earnings</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Depreciation and Amortization</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e2628-wk-Fact-21081727CA5952E381D8F466452D3002" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2647-wk-Fact-3F635FAC85E05D48B1C0CAFAFF1EADF3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2667-wk-Fact-6E9F27AE02726BB5B8FF801F8105C494" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e2686-wk-Fact-360249B3A006541E93860494E7664450" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">24,517</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2705-wk-Fact-BC7E0D00B21FF35D771B801F81A9F967" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,738</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2725-wk-Fact-111ED69E468B22889D50801F81BB10E7" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">22,194</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e2744-wk-Fact-93A83F7AF2C8708F880AD083C00A9C02" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">958</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2763-wk-Fact-F84C8C614DC11C920600801F81CCF916" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">953</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2783-wk-Fact-8D2F59DA09B7FE8B09E6801F8148C80C" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">881</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e2803-wk-Fact-5FFDD34AFE83545EA97B752E1E5B0F46" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2822-wk-Fact-EF0526EE56765857B51AB0881F18E8DA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2841-wk-Fact-58F8CEFB5E3A4154A8FB801F81203AD3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e2861-wk-Fact-084878331CAE5F50893848F4E5725E12" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,785</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2880-wk-Fact-7249016752645521B4A449214872FA3C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2900-wk-Fact-3FA833AC5BE1008431CF801F80F4EAAE" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,348</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e2919-wk-Fact-F917EC74CAF8798A2465D083C001D773" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">105</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2938-wk-Fact-048CE44A39F6A1095A80801F80E770F3" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e2958-wk-Fact-FA6F8F4B8C07145CBB9E801F8194C1D3" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">125</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e2983-wk-Fact-E6A92503D1DC56F99E0B7CD436259160" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49,653</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3002-wk-Fact-D225DC10444A544086C71ABD2D98174F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50,042</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3021-wk-Fact-967AD2D4026CFBEF4D3A801F81244E55" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48,977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3041-wk-Fact-B707042704E051E094DA0C2D5A4B4F2B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,301</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3060-wk-Fact-57F6BF74720C5F8388DA1CC92604AB69" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">32,374</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3080-wk-Fact-158D3A6B6505E95558B1801F81DBB22C" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">31,542</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3099-wk-Fact-8E4ECE37A9934A1B313CD083BFE52A99" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,063</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3118-wk-Fact-717E35B044362C67F868801F81BDF57D" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,065</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3138-wk-Fact-94EEAC12B164219871FE801F8106C475" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,006</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3163-wk-Fact-B2CA90AC8D937B13573902932E654262" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,098</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3182-wk-Fact-9862B6C2795C4DD135D202932E5D2635" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3201-wk-Fact-52A029941EC4B57D153202932E54F161" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34586122e3221-wk-Fact-F510E0B5E23456BCA1F3AB0787E1A55F" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,723</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e3241-wk-Fact-AAAC7E6A61915A9AB289BFF791014433" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,283</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e3262-wk-Fact-B844E6AF354E6B90FBC0D083BFDF0319" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,302</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3282-wk-Fact-A1E2DBD4AD5154A27F57D083C01AB381" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">108</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3301-wk-Fact-05D8B303E9C377506BB9801F81963C22" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">146</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3321-wk-Fact-BAB8B49654C57E704233801F8111DFBB" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">142</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3525-wk-Fact-472286F8FE669A33593C801F81242E10" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3544-wk-Fact-2BDDAF649C21B6CC2C10801F81391E14" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3563-wk-Fact-A80502CBDD0A15BE22F7801F812601A0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34586122e3583-wk-Fact-5EB5DEEFDF475D0D875609F4CEF1710B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">5,859</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e3603-wk-Fact-F3F4B1BA315C571D94BD569F67709BC4" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,383</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e3624-wk-Fact-2575FD938424E6650896801F80D24265" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">6,299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3644-wk-Fact-C023DBBE72C11C46F64CD083BFF55D24" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3663-wk-Fact-1B60D667972BE02E235D801F8128BBC9" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">503</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3683-wk-Fact-AA448E5E8130401937D9801F80FB6261" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3709-wk-Fact-8CFBC11982887546DF26801F811DC1B0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3728-wk-Fact-778D87A036A48FC4F187801F81BC813D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3747-wk-Fact-E79DE6E08DB25C4F55E0801F8189148C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34586122e3767-wk-Fact-F1DA5A74EBBE5412A2A5D4960C73D7D2" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,333</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e3787-wk-Fact-7CE1E0EF766B581893CBC5A1DB76D621" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,786</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e3808-wk-Fact-E19218AE39D843301427801F81BB5A43" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4,758</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3828-wk-Fact-8A13EF2DD2417F08F8E0D083BFECB190" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,347</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3847-wk-Fact-6B869F58FEDE17E7F0E5801F81D500ED" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,620</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3867-wk-Fact-74BDF519ACFF7C0C48A3801F819B32C2" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,565</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e3892-wk-Fact-6B9AEE235372BD92AE44801F81ABC925" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3911-wk-Fact-3BE3F8D57F8F66DC72BF801F8103083F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e3930-wk-Fact-42A10C575920F502EF70801F818A4284" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(<ix:nonFraction id="d34586122e3950-wk-Fact-C7C4AE8978C55E58ADD8D2CE87F7F6ED" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">185</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e3970-wk-Fact-74C1614E6C935CA08B5422036CFAC156" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e3991-wk-Fact-57987F1F001AA9CC9C56801F812C5B39" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">456</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e4011-wk-Fact-4092AEA9F2F669BF51ECD083C021CD3C" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4030-wk-Fact-241AF0F5CD243F91D7E3801F81BCFDF4" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4050-wk-Fact-5CA5DCE2265634E3F870801F81D69ABB" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Certain significant items</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e4077-wk-Fact-552B0DEF974EB94D62FC801F81213B84" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4096-wk-Fact-C8B439FC676AA180BB18801F8196982F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4115-wk-Fact-48678AE7E2417CCA04CA801F81D64B4D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e4135-wk-Fact-BC0C1F861F85562394C153BA53C5058B" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,481</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e4154-wk-Fact-6861B27FF0E359E495FAE4664EA2AD95" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3,719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(<ix:nonFraction id="d34586122e4175-wk-Fact-64B6841D8A9647CC861B801F81B47923" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">2,423</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e4195-wk-Fact-9EE24B8CE46E4AFB1CAED083C012D553" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">36</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4214-wk-Fact-60449F03FF9FEEB388F5801F81D5F45D" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">38</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4234-wk-Fact-35B362807E1AE86654F9801F811F7FF8" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e4264-wk-Fact-99447C56530B57BB99F3272D91D61246" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4283-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53,647</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4303-wk-Fact-5800B99789A546352282801F7F2D7923" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">17,682</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,885</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,305</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e4380-wk-Fact-478A747253E5F8B23E49801F81C71589" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,010</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4399-wk-Fact-535FEE135E2ABD4ECB45801F81937510" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,384</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span><ix:nonFraction id="d34586122e4419-wk-Fact-B1FE1F215AFFABD9B609801F81378823" name="us-gaap:DepreciationDepletionAndAmortization" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,269</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. Biopharma&#8217;s earnings</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> include d</span><span style="font-family:Arial;font-size:7pt;">ividend income from our investment in ViiV of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4451-wk-Fact-84CEEA0419A2A19F4094D92D338D66D4" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4459-wk-Fact-E56EBD2890F424606158801F7E221379" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4468-wk-Fact-F1179FA5256A62859C91801F7E20D9C9" name="us-gaap:InvestmentIncomeDividend" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">266</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US" continuedAt="TextSelection-AA048B95560A978BA577801F834F378C-1"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. </span></div></ix:footnote></td></tr></table><ix:continuation id="TextSelection-AA048B95560A978BA577801F834F378C-1"><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4591-wk-Fact-CC7561F7272C5ED4A5788C43F2AC96DD" name="pfe:RestructuringChargesandImplementationCosts" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">758</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4595-wk-Fact-3F312BBBF0681C2215F6801F7E16348D" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">543</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4599-wk-Fact-5BE5F702F6D43C703286801F7DE5563F" name="pfe:AssetImpairmentChargesAndOtherCharges" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">2.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4603-wk-Fact-4B94A17AAB6A549993EBA5BA9A4EABD3" name="pfe:BusinessAlignmentCosts" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">495</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4608-wk-Fact-516785FC5DC8501BA502F73998F76734" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">415</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) a pre-tax gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4612-wk-Fact-37D03FF8BE565EE899BA0F12FA922C2C" name="us-gaap:DeconsolidationGainOrLossAmount" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">8.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4616-wk-Fact-CDCCACFA72CC50AD99C347EC5E412979" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">138</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> and (viii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4620-wk-Fact-144174E08A85553D89C90841C1C869F1" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-8" scale="9" sign="-" format="ixt:numdotdecimal">1.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: an upfront license fee payment of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4624-wk-Fact-2A3A3E610C51E4ED73C5D96989B3F86C" name="pfe:PaymentForLicensingArrangement" contextRef="D2019Q4Nov1-30_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> to Akcea, which was recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses, </span><span style="font-family:Arial;font-size:7pt;">charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4633-wk-Fact-CA74717A80E9EE804D83DDD9F42AA696" name="pfe:RestructuringChargesandImplementationCosts" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">112</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4645-wk-Fact-FD16878222CF5EB2BEE79D428F8C3B48" name="us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" contextRef="FD2019Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">337</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:7pt;"> related to our acquisition of Therachon, a </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4654-wk-Fact-8A3BFD051E05520AABFD419238ADA6EB" name="pfe:Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">99</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">related to rivipansel, primarily for inventory manufactured for expected future sale and charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4662-wk-Fact-96B1BF0188FE5CF49347036DCB830182" name="pfe:DeconsolidationExternalIncrementalCostsAmount" contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">240</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, primarily in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A, Note 2A, Note 2C</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2D,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4698-wk-Fact-45B6785570C65CAC9B364B41D8371365" name="pfe:RestructuringChargesandImplementationCosts" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">977</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) net charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4702-wk-Fact-B234992E4C4F51DD9396CBB63995C735" name="us-gaap:GainLossRelatedToLitigationSettlement" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">157</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4706-wk-Fact-3A4B3F3B568F55888F5A8E1BED23726F" name="pfe:AssetImpairmentChargesAndOtherCharges" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">3.1</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4710-wk-Fact-DFD0844DF5485DD5B808561439758591" name="pfe:BusinessAlignmentCosts" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">63</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4715-wk-Fact-47F39B271F785E99BC8974BC5C6B3F22" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">586</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4719-wk-Fact-7DDB8A53183E908A30E5801F80CDA452" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">3</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4723-wk-Fact-9E4670EEC9A15C7599CFEDDC36F7401A" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">4</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4727-wk-Fact-189624AFF5015522A88BDDA2F90156A0" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">343</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4735-wk-Fact-A244813E0C615DBF81BF6373F13479D6" name="pfe:CompensationRelatedCostsNonExecutiveEmployeesBonus" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">119</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> charge, in the aggregate, in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:7pt;"> for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4744-wk-Fact-E6EB1994D63A5FC58F30FE34A48E8DE8" name="pfe:GainLossFromContributionAgreement" contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">50</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">, Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4770-wk-Fact-BDD40C60A91EA7430222801F7E1FA82D" name="pfe:RestructuringChargesandImplementationCosts" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">204</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4774-wk-Fact-931627721E7E33A6CA3A801F822CA757" name="us-gaap:LossContingencyLossInPeriod" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">237</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4778-wk-Fact-2570FFE79F2B8C13C3D6801F8223857E" name="pfe:AssetImpairmentChargesAndOtherCharges" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">379</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4782-wk-Fact-EA21A1EA07E2FA5DB466801F82C413B0" name="pfe:AlignmentCosts" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">71</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4787-wk-Fact-C2D7EA4BF46072BAE200DDE74B27C0D6" name="us-gaap:EquitySecuritiesFvNiGainLoss" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">224</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4791-wk-Fact-1647D59EDB91FA72FCA4801F7DE602AF" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">999</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4795-wk-Fact-9B86E31FA5FDE8A4024BDDE3FD81C692" name="us-gaap:OtherOperatingIncomeExpenseNet" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">756</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a charitable contribution to the Pfizer Foundation of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4799-wk-Fact-AB05C420E3B36F05C1DFDDED9568E98A" name="pfe:CharitableContributionExpense" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;">, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4807-wk-Fact-AFCFAC136365DF89060CDDF521193B0E" name="pfe:InventoryWriteDownAndOverheadCosts" contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">195</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales,</span><span style="font-family:Arial;font-size:7pt;"> an </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4816-wk-Fact-E4E691C290056D92F9C5801F80EFA503" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">81</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> loss related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34586122e4820-wk-Fact-C1577C38066176D10EAC801F80EADEC6" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">49</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;"> equity share in Hisun Pfizer, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net,</span><span style="font-family:Arial;font-size:7pt;"> charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4828-wk-Fact-FD073C40A0E2055928C6801F7E1E419D" name="us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">55</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e4837-wk-Fact-EFB9DE03407E9EBADAF5801F7E04ABC8" name="us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal" contextRef="FD2017Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="usd" decimals="-6" scale="6" sign="-" format="ixt:numdotdecimal">30</ix:nonFraction> million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34586122e4841-wk-Fact-A9A6F91B231257800749801F80B22D2E" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" contextRef="I2017Q2Jun30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">40</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34586122e4845-wk-Fact-E218FFA8B1BEC0935D45801F7EB5152A" name="us-gaap:MinorityInterestOwnershipPercentageByParent" contextRef="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">60</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership interest, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2C,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:continuation></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><ix:continuation id="TextSelection-F8BE884DC75F74C9D8F6801F8354E5C7-1"><ix:continuation id="TextSelection-6E34BC7E6D74B396FAA8801F8354B510-1"></ix:continuation></ix:continuation>Equity in the net income of investees accounted for by the equity-method is not significant for any of our operating segments.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The operating segment information does not purport to represent the revenues, costs and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">129</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-4" continuedAt="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-5"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Geographic Information</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock" id="TextSelection-FFDA9950E810EF840182801F835365F5-0-wk-Fact-B389BC08DCF48C13E73D801F7DCF9174" continuedAt="TextSelection-FFDA9950E810EF840182801F835365F5-1" escape="true"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As described in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e5186-wk-Fact-8443B983E8AC50B1A48061BEA9ACDF7D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">23,852</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5205-wk-Fact-34A880C9A5F859E8B38A36A90B002595" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">25,329</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5225-wk-Fact-67387CF71587E09BD230801F81BABBA3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">26,026</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Europe</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e5247-wk-Fact-2FA734C3E6F851F3A59F806EDB8CEAFE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,701</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5266-wk-Fact-0B2C9A8A17225E17979E8C6A9A7A0472" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5285-wk-Fact-A96A62C6E678423BC122801F80CEE810" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,508</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Rest of World</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e5313-wk-Fact-CD1DAE84A7D8575096A679F1CD7AEBB1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,465</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5332-wk-Fact-F774D66B39E3548293A7768C17FCC7C8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5351-wk-Fact-0DFBEF6B024C671D2CCB801F80B50D92" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,612</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging Markets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e5379-wk-Fact-246CB21BC49B5BF7A871DD3D4BFCC13C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5398-wk-Fact-68EA97346488548597981D4BC7C4FA17" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,651</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5417-wk-Fact-D134462A8015E9052612801F81B8005A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">11,399</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e5448-wk-Fact-99447C56530B57BB99F3272D91D61246" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5467-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53,647</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5487-wk-Fact-5800B99789A546352282801F7F2D7923" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:Arial;font-size:7pt;"> Revenues denominated in euros were </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e5522-wk-Fact-35E426F0104B5EA7891C52B921AAD3A3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">7.0</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e5531-wk-Fact-C2550351186B5BBD9A9B4697110D1389" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">7.3</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$<ix:nonFraction id="d34586122e5539-wk-Fact-D1A25E807F1B8D5B10BF801F822A676F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-8" scale="9" format="ixt:numdotdecimal">6.8</ix:nonFraction> billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span><span style="font-family:Arial;font-size:7pt;"> </span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-FFDA9950E810EF840182801F835365F5-1" continuedAt="TextSelection-FFDA9950E810EF840182801F835365F5-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-FFDA9950E810EF840182801F835365F5-2"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues exceeded </span><span style="font-family:Arial;font-size:8pt;">$500 million</span><span style="font-family:Arial;font-size:8pt;"> in each of </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5608-wk-Fact-B7406142F79CF57B0AEA801F7DED71D1" name="pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries" contextRef="FI2019Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" unitRef="Country" decimals="INF" scale="0" format="ixt:numdotdecimal">11</ix:nonFraction></span></span><span style="font-family:Arial;font-size:8pt;"> countries outside the U.S. in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. The U.S. is the only country to contribute more than </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5625-wk-Fact-5CA1E45856F54F1FEF6D801F7E1EEF84" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" unitRef="number" decimals="INF" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenue in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. As a percentage of revenues, our two largest national markets outside the U.S. were China, which contributed </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5641-wk-Fact-71770A3AFC1119613425801F821EE09E" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">9</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenue in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5650-wk-Fact-D15099678E595F4D6360801F7E20E9EE" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenue in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5658-wk-Fact-F6FF8543AA8186D5EC6A801F7DD060F6" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">7</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenues in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, and Japan, which contributed </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e5666-wk-Fact-61359DEBAFCCC4EECC28801F7DD2712B" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">8</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenue in each of </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="TextSelection-79AF505432E54A8DBF6A801F8354D617-0-wk-Fact-93FE6F40DEAA1C2E78C0801F7DF465D9" continuedAt="TextSelection-79AF505432E54A8DBF6A801F8354D617-1" escape="true"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:64%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:9%;"></td><td style="width:1%;"></td></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides long-lived assets by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e5991-wk-Fact-B2F1948685BE98B13F06801F7E8C3DA7" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,606</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6010-wk-Fact-BC8E4FB34B5192A48615801F7E9AD05E" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,089</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6030-wk-Fact-940C568E09DA38F73207801F7E8C819E" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_US" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,971</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Europe</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e6052-wk-Fact-921D990124AD87101C23801F7E92DAFD" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6071-wk-Fact-87E59A336B0A618A1F1D801F7E8AD801" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6090-wk-Fact-1D437AF9323714A08390801F7E93DC39" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Rest of World</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e6118-wk-Fact-87ADA00DA5C5D3DB1F1C801F7E7826DD" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">453</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6137-wk-Fact-2409EE5D9DDE703FA11B801F7E7C5AAF" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">490</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6156-wk-Fact-BEEC85B5E0F398A0DE71801F7E7B685A" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">632</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging Markets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e6184-wk-Fact-1F8E1E5AC854059418AF801F7E7A53FB" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,603</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6203-wk-Fact-0330CAF6E36D229B5BC3801F7E8C2429" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,602</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6222-wk-Fact-62D20C34C95D577873AD801F7E784708" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,917</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e6253-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2019Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,967</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6272-wk-Fact-7F7E046052F852439B2A0884F029C60C" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2018Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,385</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6292-wk-Fact-01CF52963FE3ADE6A712801F7E891C36" name="us-gaap:PropertyPlantAndEquipmentNet" contextRef="FI2017Q4" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,865</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;"><ix:footnote id="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;"><ix:footnote id="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span></div></ix:footnote></td></tr></table></ix:nonNumeric><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-79AF505432E54A8DBF6A801F8354D617-1" continuedAt="TextSelection-79AF505432E54A8DBF6A801F8354D617-2"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></ix:continuation></td><td style="vertical-align:top;padding-left:12px;"><ix:footnote id="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-79AF505432E54A8DBF6A801F8354D617-2"><div style="line-height:120%;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div></ix:continuation></ix:footnote></td></tr></table><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Other Revenue Information</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Significant Customers</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We sell our biopharmaceutical products primarily to customers in the wholesale sector. In all years presented, our three largest U.S. wholesaler customers are McKesson, Inc., AmerisourceBergen Corporation and Cardinal Health, Inc. In </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, sales to our </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;"> largest U.S. wholesaler customers represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6431-wk-Fact-43A376508C4FB725D03C801F7E066AC1" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6435-wk-Fact-5A5203ABF2894A85632B801F822BBEDD" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6439-wk-Fact-BE0112CFCF5AC8631260801F7DC5EA89" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenues, respectively, and, collectively, represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6444-wk-Fact-7BD550C52D2970E12B76801F822AEBC6" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">25</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total trade accounts receivable as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. In </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, sales to our </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;"> largest U.S. wholesaler customers represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6460-wk-Fact-FC503C7482C7BDBA4F51801F7E16DD89" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">15</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6464-wk-Fact-24599123E8CBDA903976801F7E211DDC" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">11</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6469-wk-Fact-7B88D563F7B5E9934D93801F7DC9C1C8" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenues, respectively, and, collectively, represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6473-wk-Fact-C8CA4706D1F7EE1EFDE7801F829F1227" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">34</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total trade accounts receivable as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">. In </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, sales to our </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;"> largest U.S. wholesaler customers represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6490-wk-Fact-18BFE9C2B0B7CBB671B8801F7DE36ECE" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">16</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6494-wk-Fact-8531894F13D09CCA0F88801F7DEF4362" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">12</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6498-wk-Fact-9A34462389F24BD2D9C8801F821E79A5" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">10</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenues, respectively, and, collectively, represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span><ix:nonFraction id="d34586122e6502-wk-Fact-DFC9511FB2C9B8A842D9801F7E216AF4" name="us-gaap:ConcentrationRiskPercentage1" contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember" unitRef="number" decimals="2" scale="-2" format="ixt:numdotdecimal">36</ix:nonFraction>%</span></span><span style="font-family:Arial;font-size:8pt;"> of total trade accounts receivable as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2017</span><span style="font-family:Arial;font-size:8pt;">. For all years presented, these sales and related trade accounts receivable were concentrated in our biopharmaceutical businesses.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Significant Product Revenues</span></div><ix:nonNumeric contextRef="FD2019Q4YTD" name="us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" id="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-0-wk-Fact-09358930CB595C743F82801F8226C526" continuedAt="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-1" escape="true"><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As described in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div></ix:nonNumeric></ix:continuation><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">130</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-1" continuedAt="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-2"><ix:continuation id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-5" continuedAt="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-6"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides detailed revenue information for several of our major products:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">TOTAL REVENUES</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e6747-wk-Fact-99447C56530B57BB99F3272D91D61246" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">51,750</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34586122e6766-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">53,647</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span><ix:nonFraction id="d34586122e6786-wk-Fact-5800B99789A546352282801F7F2D7923" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">52,546</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e6821-wk-Fact-986CD8670BD150AFB608018DDFD29424" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39,419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e6840-wk-Fact-2138A395CF995DA1A891BA3B202C9BCB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">37,558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e6860-wk-Fact-D2CE95E7B71E8C4C67B8801F7DD04AD2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">35,530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Internal Medicine</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e6897-wk-Fact-B24D04AD1CFE5421B8AAB5E1AE97DC0A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,119</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e6916-wk-Fact-3FE2875CC05E5AF0955E1F16A4747D4E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,869</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e6936-wk-Fact-8882814ACBF86601CC36801F7E885BFB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,229</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Nonvalvular Atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e6966-wk-Fact-6C731063DF07515B8278EAAAF41E82F5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e6985-wk-Fact-B3E66210D48550AA9926F625E4EBBAD4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,434</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7005-wk-Fact-2D99B1124ACE12540611801F82B4994F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,523</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7040-wk-Fact-A6B4F6B324375D53B10094F17B3C65B3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,107</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7059-wk-Fact-46F27B55B27B54EA8DB9649561CE42BB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,085</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7079-wk-Fact-62650662D7DD8D7E8080801F82C35669" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">997</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Symptoms of menopause</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7114-wk-Fact-12773FEDE0EF5957B1201377DC9142AE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">734</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7133-wk-Fact-9BBA998B2CFF5DED95D8D386714FFE6A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">832</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7153-wk-Fact-5582142AF8CAFB1642B1801F8152C802" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">977</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Development of bone and cartilage</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7188-wk-Fact-E6122F9BEB87535189F2629012724D92" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">287</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7207-wk-Fact-A83EDCFE0B465D95A739D4248C9470C0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">279</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7227-wk-Fact-1C89FA66D1ECFDF67F72801F8179DC33" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">261</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Overactive bladder</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7262-wk-Fact-1D47F48F7F3554A78127DAFE590E794E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">250</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7281-wk-Fact-999640AF0F3A5772A546D4FCE619DC98" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">271</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7301-wk-Fact-9A23FE915E5D4E701F2A801F8173E1A9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">257</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7336-wk-Fact-6A1D5D6AF4EC5CA8BE48BCBA53E3E2A8" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,521</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7355-wk-Fact-BD0B6B5222EF5CB6A5FCC1C812C3C334" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,969</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7375-wk-Fact-D025766C2E67D378C102801F81229E63" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,213</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Oncology</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7418-wk-Fact-DCCC9223184B56788CBE0DB3BD4499E3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">9,014</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7437-wk-Fact-3DB102BD4155797B5C71DE18EDD8B9B9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7457-wk-Fact-2735403E9898D9DCFDE4DE1919D0AF5E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,304</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Metastatic breast cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7487-wk-Fact-02E59B78118A5E36927E6E9D343F80C1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,961</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7506-wk-Fact-A1A886242BD55B97B9C6B7AE43B77A3F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,118</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7526-wk-Fact-1D1D9E822C1094BF0A35801F7E86E0C0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,126</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7561-wk-Fact-AE2B016013A759EB976F0B6B8F4C219E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">936</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7580-wk-Fact-34A07B3634CE5849A713202F3645E2BC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,049</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7600-wk-Fact-6C990DD2B2AD4FB4F7BA801F82BE5EDE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,081</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7635-wk-Fact-09097F7E24E55CE185B3A8241786D001" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7654-wk-Fact-DF1B3BD729A55AC0A504DFD9608FFB96" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">699</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7674-wk-Fact-26023C9A152437741F6FDE1A28B16CBA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">590</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">ALK-positive and ROS1-positive advanced NSCLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7709-wk-Fact-7DD40C3C0E31507482EEDE2CEC4E867A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">530</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7728-wk-Fact-AA23783A2EF0547FB95205FE30FF67FA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">524</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7748-wk-Fact-8806516F8B0543D58C87801F7DEE6452" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">594</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7783-wk-Fact-CBED98872E6D5AD683F5F65CF970FCE1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">477</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7802-wk-Fact-51CBEE775FF5588DB0D7DCEC07FF57B0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7822-wk-Fact-34727ACB136D8931558B801F7E88E0C5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">339</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7857-wk-Fact-5472417927D753EEBBB1072B6B105F5F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">365</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7876-wk-Fact-FD3ADF5E45AC5ABC941EDCA88225428B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">296</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7896-wk-Fact-5994144D551B14BACEFF801F7E7863C5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Retacrit</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e7933-wk-Fact-A80D878425B55E7DB0E92B5480994305" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7952-wk-Fact-A9B6D8B90E4D5AC4A32D4CCEFCEEBE96" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">82</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e7972-wk-Fact-FA8027A58E5CA9651A05801F82B7CF8D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Mektovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8007-wk-Fact-25FC84B343C1A318CA97DE1AB610DB22" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">49</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8026-wk-Fact-DF4D7D64D34A7D6D90A6DE1ABA698DA3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8046-wk-Fact-6A654FC14177C9A6479ADE1ABFE4C4D9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Braftovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8081-wk-Fact-B703DA942F77EDFDF491DE1AC4EE74EA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">48</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8100-wk-Fact-34E5BC40943A516066D70E4C8FD42F51" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8120-wk-Fact-FF2D62AF2B56AC1092D2DE1ACB8DAAEA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8155-wk-Fact-67C37AC357CC578E8A2CE9AD15A0F5DE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">585</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8174-wk-Fact-574622BD96AD5C9083C68ABC1F23BDDF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">406</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8194-wk-Fact-385EDBE1A04BC6E2A680801F829EC2AC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">274</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Hospital</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8237-wk-Fact-A8B53B0AF0215974918EFB048833F5CB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,772</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8256-wk-Fact-3D222D29334A51ED9477C50D604F7F80" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">7,955</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8276-wk-Fact-B9634D3CD51FCF12B7F1DE1F7DE2E34F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">8,369</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8306-wk-Fact-E9743691F65857D4AA21DEFCE49F0F66" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">684</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8325-wk-Fact-532A8105F0605BF7A90B026D9DC3C86C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">613</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8345-wk-Fact-1AA27963C1EA03D86E56DE208FA6FEF4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">471</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Medrol</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anti-inflammatory glucocorticoid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8382-wk-Fact-B9796D68B7845314B40EE00253EDFE48" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">469</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8401-wk-Fact-759DF68F819A59389A4AC00C6D1F61C6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">493</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8421-wk-Fact-BE0EABAA50D96FFC3507DE2093101A4D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">540</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8456-wk-Fact-937F899827ED53BF9733BC0E5A2C276B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">346</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8475-wk-Fact-356826AC764E5F1AB122D61B135DA970" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">392</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8495-wk-Fact-778F76F534866B4C274BDE209664FDB1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">421</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zithromax</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8532-wk-Fact-E97AA6E5D4FA5F64AFB7FBD507DC3DB7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8551-wk-Fact-AF503AE62454526EB03769AE56899F54" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">326</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8571-wk-Fact-1358C7993E24C71EC31CDE2099C357C1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">299</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">EpiPen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Epinephrine injection used in treatment of life-threatening allergic reactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8606-wk-Fact-D06ED7D632E3530D9D350CF38120C535" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8625-wk-Fact-F7DF3FA519E05ABBB36AF2BDC1C1D5E2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">303</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8645-wk-Fact-EA467189B34B25F5663DDE209D44E894" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">290</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Treatment/prevention of venous thromboembolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8680-wk-Fact-9F9BFF3F49E4598B845CC5FD385C80FE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">253</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8699-wk-Fact-E7318B73FA0358F7AAB3343146AFB749" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">293</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8719-wk-Fact-953503D0D518BB2D4A20DE20A0816CCB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">306</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8754-wk-Fact-5C0064D89F285BDD8A146792BE0F3384" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">251</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8773-wk-Fact-F0DD6FB9D7D65FF7A33085989120CCED" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">236</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8793-wk-Fact-93F788C458704E75C6BDDE20A3FD7BC2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zosyn/Tazocin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8828-wk-Fact-88ED49AD8223552FBECDEDC3724ABA7A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">200</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8847-wk-Fact-DD01A36819E15802AFBF1E72FE27BC50" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8867-wk-Fact-F5C4DA82D51CF805497FDE20A789D463" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">195</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Tygacil</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8902-wk-Fact-4621E7DDA21358AB9B0293A23E1E94CC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">197</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8921-wk-Fact-B344BD9ABF6754369FCF350AF52DE418" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">249</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8941-wk-Fact-813264E7C289A5D5ECB7DE20AAB91829" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">260</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Diflucan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e8976-wk-Fact-47C32F6B4940C65CF511DE20FEBC9F1E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">190</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e8995-wk-Fact-A561864E833387BD903CDE210367E099" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">189</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9015-wk-Fact-48F70FD623656D97865CDE21089CEB52" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">180</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Panzyga</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Primary humoral immunodeficiency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9051-wk-Fact-E562078593EEE80AC567801F8179DDAD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">183</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9070-wk-Fact-5955DF531022E6A702C4801F82A42A3E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">39</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9090-wk-Fact-5FF17F954895E52A550DDE22B9D0BED2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pfizer CentreOne</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9127-wk-Fact-810B1FD04766529CA8FCD18FC3883D4B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">810</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9146-wk-Fact-67635FDCF78A5B1F882CF82F5CDD09D7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">755</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9166-wk-Fact-A2F4496694D82FBCD30CDE22BCA5386D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">706</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Anti-infectives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9201-wk-Fact-801912F69D61590398C5CEEE0D4764FE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,114</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9220-wk-Fact-494DF9151E065567834DBAE4E1B562F9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,041</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9240-wk-Fact-81945090A4FFE403DEA2DE22C004E729" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,237</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Hospital</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9277-wk-Fact-710F79BB7E78505B80B3DD29D470A8D7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,436</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9296-wk-Fact-685DE43906F252099A21B0122F5E2271" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,797</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9316-wk-Fact-CAF98663333909A19E50DE22C3E7514B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,182</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9356-wk-Fact-DDB1D56C1E705432A99023025DE61FC6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,504</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9375-wk-Fact-BBDAE04D6CFA59C8AAEC3FDF42705515" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,332</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9395-wk-Fact-2252BB68D2B6CE95DE6F801F82C071DC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">6,001</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pneumococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9425-wk-Fact-96C64EFA9EB5530AB6921E0B596EB44C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,847</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9444-wk-Fact-6D96C4CA7C5659AB8ED1F8CE7B49D099" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,802</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9464-wk-Fact-D849BF316CA966119FC6801F8174CBAB" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,601</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Nimenrix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9499-wk-Fact-CCD1EAD68F3B58FEAD95E57F92CE3343" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">230</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9518-wk-Fact-657DFFC172A85133B04FF502D24434E3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">140</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9538-wk-Fact-A22D7E673C93E7C70A39DE2E93483C38" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">86</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">FSME/IMMUN-TicoVac</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Tick-borne encephalitis disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9573-wk-Fact-A0A12E1176AD5F47B4EE630D93FA9E54" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">220</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9592-wk-Fact-502A552AC2A45AA8943A75D93CF23EA3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">184</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9612-wk-Fact-0FCAEA446042111840E7801F82CE4B1B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">134</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Trumenba</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9647-wk-Fact-6CE58F4DCA21567DB73364B111AE5E4C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">135</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9666-wk-Fact-FF61F86FDE155D008B83817D0F81C403" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">116</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9686-wk-Fact-CC8278477CE6874B4A84801F8160D66D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">88</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9721-wk-Fact-6E6029DB75FA52DF9D7FAEA201A4D55F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">73</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9740-wk-Fact-77F2BBF170B358E288F7FC940DA00BD5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">90</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9760-wk-Fact-E4D515B7D6F6319CCB8C801F7E7C1315" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">91</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9802-wk-Fact-54CC08145C9B5A5BA23B67DFBAD4AE0E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,733</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9821-wk-Fact-45E0D791242D55AC81FC3EFB761F9C00" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,720</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9841-wk-Fact-92524ACC782CD4CDC985801F7E45AECD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,386</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">RA, PsA, UC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9872-wk-Fact-5771636556985C87BC8C3CB410CC66F7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,242</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9891-wk-Fact-881709D18F145B4CB609A31E6FB0D982" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,774</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9911-wk-Fact-72FA6A6777398A051E57801F7E7966A0" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,345</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e9946-wk-Fact-85E9E7AA5D595959A86313A1C0CA3A83" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,699</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9965-wk-Fact-A982B6EE13215444830BADC0E2C52ACD" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,112</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e9985-wk-Fact-56B05001ED9BC8F7B322801F8171F6EF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,452</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Inflectra/Remsima</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c), (g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Crohn&#8217;s Disease, Pediatric Crohn&#8217;s Disease, UC, Pediatric UC, RA in combination with methotrexate, Ankylosing Spondylitis, PsA and Plaque Psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10022-wk-Fact-52734113DA315C5EB0822EA6C1F6019D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">625</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10041-wk-Fact-2DA2C6E810E554E8A093A9328B417C64" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">642</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10061-wk-Fact-8479D37C35D17BB7F483DE31473AEC66" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">419</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Eucrisa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Mild-to-moderate atopic dermatitis (eczema) in adults and children 2 years of age and older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10096-wk-Fact-F6B75BABBAB55FA999FDCDEA743AF12B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">138</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10114-wk-Fact-B2445D4B47D85E9CBA4A74E1190125C3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">147</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10133-wk-Fact-5D359C48EE073DF7C9CD801F817AF13E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">67</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10168-wk-Fact-C29B3A689BD4584B967AF3ABE0A9C9D3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">29</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10187-wk-Fact-B891103106B358EFB566B38D67137E32" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">45</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10207-wk-Fact-0746CE99B3EAB2B6BC0D801F8173BC3D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">103</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div></ix:continuation></ix:continuation><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">131</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Notes to Consolidated Financial Statements</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><ix:continuation id="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-2" continuedAt="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-3"><ix:continuation id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-6" continuedAt="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-7"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"></td></tr><tr><td style="width:22%;"></td><td style="width:1%;"></td><td style="width:44%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10422-wk-Fact-2EEF4D44A62758ECA673A2C525E87810" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,278</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10441-wk-Fact-D462C85B830E5EC9A38A53665CF12AAC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,211</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10461-wk-Fact-FF3EB5CD7F2F1CB72F9F801F81478D7F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,240</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Replacement of human growth hormone</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10491-wk-Fact-6BE98570AA95526ABD53C26677B1710F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">498</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10510-wk-Fact-ECC4A2CDEC965D8FB2F629398E5BC2BC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">558</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10530-wk-Fact-0A844536B6E840560C6B801F7E79A760" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">532</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hemophilia B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10565-wk-Fact-7841FB6089E25815A6EDEE08192734A3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">488</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10584-wk-Fact-719EC870EC045A6D800C3B2FC590F735" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">554</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10604-wk-Fact-970FAB6E5C131F82582F801F82B780EF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">604</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">ATTR-Cardiomyopathy and Polyneuropathy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10639-wk-Fact-184BCA46D7B15120908057BE81C0BFBF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">473</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10658-wk-Fact-C26D40F32E8C5DF586F966DCCE25BB95" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">148</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10678-wk-Fact-7ECE376C77FD2DD56F01DE348401E779" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">124</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hemophilia A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10713-wk-Fact-B9B91A07AC415AA3A4259816262AC760" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">426</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10732-wk-Fact-8AE48012DC4B5DC984E6FAE7DC707343" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">514</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10752-wk-Fact-67C6F4B996699FB20DAB801F82C0E197" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">551</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Acromegaly</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10787-wk-Fact-DEEDFEEA02DD5254A0EF0A6659BFB537" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">264</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10806-wk-Fact-0840E546E4935A9C8A5319D9675773CF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">267</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10826-wk-Fact-887C4E6B025669711220801F82C33182" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">254</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10861-wk-Fact-42D0C86776005662879A00E1A37C431B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">129</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10880-wk-Fact-3B667D7348965CC598C1885A39DACBD1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">170</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10900-wk-Fact-4D7CC466FCEC6B66F031801F7E69E2CF" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">176</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Upjohn</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e10942-wk-Fact-76700083BB585619B1B78E77F16D4429" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">10,233</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10961-wk-Fact-414C030E79B750E3A44270BCED97927B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">12,484</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e10981-wk-Fact-1FE49E27774BBC4F7DE7801F7E5B14A7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">13,447</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Lyrica </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Epilepsy, post-herepetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11011-wk-Fact-04C938F3AC685E7389C0CF59D2959913" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,321</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11030-wk-Fact-D8245C971D9C5E578F90851085D1B795" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,970</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11050-wk-Fact-56B658880869AEACE541801F8187F9A3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,065</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Reduction of LDL cholesterol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11086-wk-Fact-D010F52EA88A56D0A3A81F17EB5D38DC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,973</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11105-wk-Fact-982E769D9AA15AF18F31878D9A3BFD37" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,062</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11125-wk-Fact-841D58224C20C05AA3AF801F82B7E834" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,915</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11160-wk-Fact-2C95573C6F895F6892E174F65C10E575" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">950</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11179-wk-Fact-CE019DDF6C655A12B3EDF80392CD6DCA" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,029</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11199-wk-Fact-6A5565AC16FAF0E46BF3801F818756A4" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">932</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Arthritis pain and inflammation, acute pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11234-wk-Fact-1869D81D977F534390770DD20D262AB7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">719</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11253-wk-Fact-3EBD6C7A46BD54608DC97B7D5BC28BC5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">686</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11273-wk-Fact-11BAC5EE7A45CC2D5AFAD082FDAA0EF1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">775</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Viagra</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11308-wk-Fact-6428270E830C52D8A83D9D78EC21F20E" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">497</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11327-wk-Fact-B57EC914CEEC57AD9AEC75DF29FD04C2" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">636</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11347-wk-Fact-8784FEB4B63967D223B8D083004C1A1D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,204</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11382-wk-Fact-A794165CEA5A51B0A3B6004B3D79A885" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">336</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11401-wk-Fact-08FCBF9B923C5EC484E72D471007E0A6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">311</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11421-wk-Fact-821C54ED7C862C84B170801F7E88C49D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">297</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11456-wk-Fact-5A942695EAC354C8809AF1522CA91E6D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">294</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11475-wk-Fact-B1C55F4CB7D652428FCC68218AAE6DD5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">298</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11495-wk-Fact-87951FBDF4C375B6753E801F81755F3D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">291</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Glaucoma and ocular hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11530-wk-Fact-2091B860985E526EACD15CD4A5669CD5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">281</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11549-wk-Fact-AD6A89B15A765F7DA13013F765D9BCCE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">318</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11569-wk-Fact-F6AEFE5F18DC80AFD6EE801F81742ECC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">335</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xanax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11604-wk-Fact-7CFB7F412548587F896D99F507DBCD19" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">198</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11623-wk-Fact-63FD058F80E55C109E636F60FC6CA539" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">223</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11643-wk-Fact-76BFF3E0ECCB06EAD23D801F82CA7536" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">225</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Revatio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pulmonary arterial hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11678-wk-Fact-75D45301C70951D3867054250941F9AE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">144</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11697-wk-Fact-D0B09E4190DD536D8D7A0B352A916E5F" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">227</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11717-wk-Fact-4D849F31F84479F6D413D0834B8AEBFC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">252</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11752-wk-Fact-FA19F775D49E5417994497ED45F8B1B7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,519</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11771-wk-Fact-2F3A89C4B2BD5133ACFBE4229DDE6CC5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">1,725</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11791-wk-Fact-F82E69C6D1AF9AB5F0E1801F7E7C93ED" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,158</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Consumer Healthcare Business</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11833-wk-Fact-CCBB2BC438EC5A9B8250ABDDBE53A9E1" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,098</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11852-wk-Fact-080B5520FFBB5986BB0E2FAA190C849C" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,605</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11872-wk-Fact-1E63E1B1645BA0E7748B801F818279BE" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,472</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11910-wk-Fact-CDC99316A1F49B8343F1DE3EC68E31D9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11929-wk-Fact-83D643576F2E4A880436DE3EC9DE5D5D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:zerodash">&#8212;</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e11949-wk-Fact-B14A778A0529F4E56FC1DE3ECD2EE7E6" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">97</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e11984-wk-Fact-81ACE807558B5C5CB92572A02959FF1A" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">4,648</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e12003-wk-Fact-0034831A3E24527FAAC34DC7E1212EFC" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">3,838</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e12023-wk-Fact-30367F2EFA82C29A0B01801F7DE3312D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">2,927</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Biosimilars</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e12058-wk-Fact-2846B8E6B6B05D109C0045899F1AADE9" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">911</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e12076-wk-Fact-D8583C2532635E7E884D51C71C684B47" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">769</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e12095-wk-Fact-C0BF06F9A6D60B722450801F82C0AE3B" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">531</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Sterile Injectable Pharmaceuticals</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span><ix:nonFraction id="d34586122e12132-wk-Fact-6E43981A243F593FB97D9CA3CEB76E6D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,035</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e12151-wk-Fact-772A4F70D4985AACB86E028464DB65E7" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,214</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span><ix:nonFraction id="d34586122e12171-wk-Fact-05EFB7BDD97ED86D525A801F8161A33D" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" unitRef="usd" decimals="-6" scale="6" format="ixt:numdotdecimal">5,673</ix:nonFraction></span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 and 2017 product revenues to the current presentation.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We performed certain reclassifications in the All other Oncology category to conform 2018 and 2017 product revenues to the current presentation.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy SIP category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 and 2017 product revenues to the current presentation. Hospital also includes Pfizer CentreOne</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span><span style="font-family:Arial;font-size:7pt;">. All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#8220;All other Anti-infectives&#8221;.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018 and 2017 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation &amp; Immunology category to conform 2018 and 2017 product revenues to the current presentation.</span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">On July 31, 2019, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C. </span></div></ix:footnote></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Represents HIS revenues through February 2, 2017, which includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. On February 3, 2017, we completed the sale of HIS to ICU Medical. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B.</span></div></ix:footnote></td></tr></table></ix:continuation></ix:continuation><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><ix:continuation id="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-3" continuedAt="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-4"><ix:continuation id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-7" continuedAt="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-8"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div></ix:continuation></ix:continuation></td><td style="vertical-align:top;"><ix:footnote id="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl" footnoteRole="http://www.xbrl.org/2003/role/footnote" xml:lang="en-US"><ix:continuation id="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-4"><ix:continuation id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-8"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</span></div></ix:continuation></ix:continuation></ix:footnote></td></tr></table><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">132</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s6DADEB5BD9D358DF8F6AE0EB83AA4873"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Selected Quarterly Financial Data (Unaudited)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">First</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Second</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Third</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Fourth</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">13,118</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">13,264</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">12,680</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">12,688</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Costs and expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">8,749</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">9,239</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">9,676</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">13,743</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c), (d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">46</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(115</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">365</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">452</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(8,087</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,323</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4,141</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10,727</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,508</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision/(benefit) for taxes on income/(loss)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">433</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(915</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,047</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(1,181</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,889</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,056</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,680</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(326</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income/(loss) before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,889</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,056</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,684</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(326</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">6</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income/(loss) attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">3,884</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5,046</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">7,680</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(337</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings/(loss) per common share&#8212;basic:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.69</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.91</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1.38</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(0.06</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.69</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.91</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1.38</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(0.06</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings/(loss) per common share&#8212;diluted:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.68</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.89</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1.36</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(0.06</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.68</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0.89</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1.36</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">(0.06</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As described in Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:7pt;">: </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation, </span><span style="font-family:Arial;font-size:7pt;">acquisitions and the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The fourth quarter historically reflects higher costs in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">and</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Research and development expenses. </span><span style="font-family:Arial;font-size:7pt;">The fourth quarter of 2019 includes </span><span style="font-family:Arial;font-size:7pt;">$2.8 billion</span><span style="font-family:Arial;font-size:7pt;"> in certain asset impairments recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4. Other (Income)/Deductions&#8212;Net</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The second quarter of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit from multiple tax years (see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5D. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Tax Matters</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Tax Contingencies</span><span style="font-family:Arial;font-size:7pt;">). The third quarter of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> includes </span><span style="font-family:Arial;font-size:7pt;">$217 million</span><span style="font-family:Arial;font-size:7pt;"> of integration costs and other, primarily including </span><span style="font-family:Arial;font-size:7pt;">$157 million</span><span style="font-family:Arial;font-size:7pt;"> in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense. The fourth quarter of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> primarily includes employee termination costs, asset impairments and other exit costs associated with cost reduction initiatives. The employee termination costs are mostly associated with (i) our improvements to operational effectiveness as part of the realignment of our organizational structure effective at the beginning of 2019 and (ii) our initiatives in connection with transforming to a more focused company. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">C. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">: </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Equity-Method Investments and Assets and Liabilities Held for Sale</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">During the second quarter of 2019, Pfizer reached settlement of disputed issues at the IRS Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2009-2010. As a result of settling these years, in the second quarter of 2019 we recorded a benefit of approximately </span><span style="font-family:Arial;font-size:7pt;">$1.4 billion</span><span style="font-family:Arial;font-size:7pt;">, representing tax and interest. The third quarter of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> reflects tax expense of approximately </span><span style="font-family:Arial;font-size:7pt;">$2.7 billion</span><span style="font-family:Arial;font-size:7pt;"> associated with the gain related to the completion of the Consumer Healthcare joint venture with GSK</span><span style="font-family:Arial;font-size:7pt;text-align:center;">.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.</span></div><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">133</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Selected Quarterly Financial Data (Unaudited)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"></td></tr><tr><td style="width:59%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:7%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:8%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Quarter</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">First</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Second</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Third</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fourth</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">12,906</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">13,466</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">13,298</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">13,976</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Costs and expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8,736</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8,895</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9,035</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">14,051</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">43</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">44</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">85</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">872</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations before provision/(benefit) for taxes on income/(loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,127</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,527</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,177</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(946</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision/(benefit) for taxes on income/(loss)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">556</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">648</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">66</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(563</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,571</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,879</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,111</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(383</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income/(loss) before allocation to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,570</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,879</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,122</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(383</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">9</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income/(loss) attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,561</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3,872</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4,114</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(394</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings/(loss) per common share&#8212;basic:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.60</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.66</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.70</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(0.07</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.60</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.66</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.70</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(0.07</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings/(loss) per common share&#8212;diluted:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income/(loss) from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.59</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.65</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.69</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(0.07</span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income/(loss) attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.59</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.65</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">0.69</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(0.07</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The fourth quarter historically reflects higher costs in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">and</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Research and development expenses.</span><span style="font-family:Arial;font-size:7pt;"> The fourth quarter of </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> included </span><span style="font-family:Arial;font-size:7pt;text-align:center;">$3.1 billion</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> in certain asset impairments </span><span style="font-family:Arial;font-size:7pt;">recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:7pt;">&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Other (Income)/Deductions&#8212;Net</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The fourth quarter of </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> included restructuring charges that were primarily related to employee termination costs and asset write downs. The employee termination costs were associated with our improvements to operational effectiveness as part of the realignment of our organizational structure effective at the beginning of 2019. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The third and fourth quarters of </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> reflect the impact of the TCJA on the </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income/(loss)</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see Notes to Consolidated Financial Statements</span><span style="font-family:Arial;font-size:8pt;">&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A. Tax Matters: Taxes on Income from Continuing Operations</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Basic and diluted EPS are computed independently for each of the periods presented. Accordingly, the sum of the quarterly EPS amounts may not agree to the total for the year.</span></div><div style="line-height:120%;padding-left:180px;text-indent:-84px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">134</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="s0FBE2FCB940A5C35AF18494661B03B99"></a></div><div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Financial Summary</span></div><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:10pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"></td></tr><tr><td style="width:55%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:1%;"></td><td style="width:6%;"></td><td style="width:1%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="19" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended/As of December 31,</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS, EXCEPT PER COMMON SHARE DATA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2016</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2015</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">51,750</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">53,647</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">52,546</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">52,824</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">48,851</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">16,298</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">11,179</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">21,353</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">7,229</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">6,975</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">167,489</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">159,422</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">171,797</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">171,615</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">167,381</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Long-term obligations</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">66,739</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">63,807</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">69,714</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">80,660</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">72,985</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings per common share&#8212;basic</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2.92</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.90</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.57</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.18</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.13</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2.92</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.90</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.57</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.18</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.13</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Earnings per common share&#8212;diluted</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2.87</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.86</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.52</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.17</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.11</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8212;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2.87</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.87</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.52</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.17</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.11</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash dividends declared per common share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">1.46</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.38</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.30</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.22</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1.14</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As described in Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:7pt;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Basis of Presentation and Significant Accounting Policies</span><span style="font-family:Arial;font-size:7pt;">: </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation, </span><span style="font-family:Arial;font-size:7pt;">acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. 2016 reflects the acquisition of Medivation on September 28, 2016 and the acquisition of Anacor on June 24, 2016, and 2015 reflects the acquisition of Hospira on September 3, 2015.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Defined as </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Long-term debt, Pension benefit obligations, net, Postretirement benefit obligations, net, Noncurrent deferred tax liabilities, Other taxes payable </span><span style="font-family:Arial;font-size:7pt;">and</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Other noncurrent liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"></td><td></td></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2019, 2018 and 2017 reflect the impact of the TCJA on the </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see Notes to Consolidated Financial Statements&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A. Tax Matters: Taxes on Income from Continuing Operations.</span></div></td></tr></table><div><br/></div><div style="text-align:center;"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.609375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:93%;"></td><td style="width:2%;"></td><td style="width:5%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report&#160;&#160;&#160;&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:right;vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-align:right;vertical-align:top;">135</span></div></td></tr></table></div></div></div><hr style="page-break-after:always"></hr><div><a id="sC88E29E8A61B5E6A830D148430B55B1B"></a></div><div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:12pt;"><span style="font-family:Arial;font-size:12pt;font-weight:bold;">Peer Group Performance Graph </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. and Subsidiary Companies</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.4375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:34%;"></td><td style="width:33%;"></td><td style="width:33%;"></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr></table></div></div></div><div><br/></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following graph assumes a $100 investment on December 31, 2014, and reinvestment of all dividends, in each of the Company&#8217;s Common Stock, the S&amp;P 500 Index, and a composite peer group of the major U.S. and European-based pharmaceutical companies, which are: AbbVie Inc., Amgen, Inc., AstraZeneca plc, Bristol-Myers Squibb Company, Eli Lilly &amp; Co., GlaxoSmithKline plc, Johnson &amp; Johnson, Merck and Co., Inc., Novartis AG, Roche Holding AG and Sanofi SA.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;"><img src="peergroupgraph2019.jpg" alt="peergroupgraph2019.jpg" style="height:480px;width:614px;"></img></div><div style="line-height:120%;padding-top:12px;text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Five Year Performance</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div><div style="line-height:120%;text-align:center;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:86.90476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"></td></tr><tr><td style="width:16%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td><td style="width:1%;"></td><td style="width:13%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2014</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2015</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2016</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PFIZER&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$100.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$107.1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$111.9</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$129.5</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$161.7</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$150.5</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PEER GROUP</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$100.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$101.6</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$102.4</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$120.0</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$129.8</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$157.7</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-left:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">S&amp;P&#160;500&#160;&#160;&#160;&#160;&#160;&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$100.0</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$101.4</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$113.5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$138.3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$132.2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$173.8</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div><div><br/></div><div><div style="line-height:120%;text-align:center;font-size:8pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.21875%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:5%;"></td><td style="width:2%;"></td><td style="width:93%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-right:1px solid #000000;"><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;vertical-align:top;">136</span></div><div style="vertical-align:top;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;vertical-align:top;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:inherit;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Financial Report</span></div></td></tr></table></div></div></div>	</div></body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21
<SEQUENCE>7
<FILENAME>pfe-exhibit21x12312019.htm
<DESCRIPTION>EXHIBIT 21
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sFD6DAE3E9585CFDE378B68FF2D39CB50"></a></div><div></div><div><br></div><div style="line-height:144%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Exhibit 21</font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:144%;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The following is a list of subsidiaries of the Company as of December 31, 2019 omitting some subsidiaries which, considered in the aggregate, would not constitute a significant subsidiary.</font><font style="font-family:inherit;font-size:10pt;">&#32;&#32;<br></font></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;background-color:#c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Company Name</font></div></td><td style="vertical-align:top;background-color:#c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">Where Incorporated or Organized</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Agouron Pharmaceuticals, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">California</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AH Robins LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AHP Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">AHP Manufacturing B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Alpharma Pharmaceuticals LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Alpharma Specialty Pharma LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">American Food Industries LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Anacor Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Array BioPharma Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Array BioPharma Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Array BioPharma Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Bamboo Therapeutics, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">BINESA 2002, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Bioren, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Blue Whale Re Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Vermont</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">C.P. Pharmaceuticals International C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">CICL Corporation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">COC I Corporation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Coley Pharmaceutical GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Coley Pharmaceutical Group, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Continental Pharma, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Covx Technologies Ireland Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cyanamid de Argentina S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Cyanamid de Colombia, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Distribuidora Mercantil Centro Americana, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Encysive Pharmaceuticals Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Excaliard Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Farminova Produtos Farmaceuticos de Inovacao, Lda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Farmogene Productos Farmaceuticos Lda</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">FoldRx Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Fort Dodge Manufatura Ltda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">G. D. Searle &amp; Co. Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">G. D. Searle International Capital LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">G. D. Searle LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Genetics Institute, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GenTrac, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wisconsin</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GI Europe, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">GI Japan, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Greenstone LLC</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 1 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Adelaide Pty Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Australia Pty Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Benelux BVBA</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Enterprises B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira France SAS</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Holdings (S.A.) Pty Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Invicta, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Ireland Holdings Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Malaysia Sdn Bhd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Malaysia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Nordic AB</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Philippines, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Philippines</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Pte. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Pty Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Puerto Rico, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Singapore Pte Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira UK Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Worldwide, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira Zagreb d.o.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Croatia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hospira, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ignite Immunotherapy, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Industrial Santa Agape, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Guatemala</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">InnoPharma, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">International Affiliated Corporation LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">IP Pharmaceuticals India Private Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">JMI-Daniels Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Florida</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">John Wyeth &amp; Brother Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Kiinteist&#246; oy Espoon Pellavaniementie 14</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Finland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">King Pharmaceuticals Holdings LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">King Pharmaceuticals LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">King Pharmaceuticals Research and Development, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Korea Pharma Holding Company Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Laboratoires Pfizer, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Morocco</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Laboratorios Parke Davis, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Laboratorios Pfizer Ltda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Laborat&#243;rios Pfizer, Lda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Laboratorios Wyeth LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pennsylvania</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Laboratorios Wyeth S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Venezuela</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mayne Pharma IP Holdings (Euro) Pty Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Medivation Field Solutions LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Medivation LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Medivation Neurology LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Medivation Prostate Therapeutics LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Medivation Services LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Medivation Technologies LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Meridian Medical Technologies Limited</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 2 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Meridian Medical Technologies, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Monarch Pharmaceuticals, LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tennessee</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">MTG Divestitures LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Neusentis Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PAH USA IN8 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Parke Davis Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Parke Davis Productos Farmaceuticos Lda</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Parke, Davis &amp; Company LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Michigan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Parkedale Pharmaceuticals, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Michigan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PBG Puerto Rico LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Puerto Rico</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PCH SpinCo B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">P-D Co., LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Peak Enterprises LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PEMB OFG Spain Holding, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Asia Manufacturing B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Consumer Healthcare Austria GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Consumer Healthcare Holdings LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Consumer Healthcare Holdings US Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Consumer Healthcare Poland sp. z.o.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Poland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Consumer Taiwan LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Czech Republic Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Finland Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG Ireland 1 B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG Ireland 2 B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG Mexico B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG Philippines B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG Philippines, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Philippines</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG Sdn. Bhd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Malaysia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG South Korea 1 B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG South Korea 2 B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF OFG Spain B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF PR Holdings C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF PRISM C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF PRISM Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF PRISM IMB B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PF Prism S.&#225;.r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PFE Holdings G.K.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PFE Pfizer Holdings 1 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PFE PHAC Holdings 1 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PFE Wyeth Holdings LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PFE Wyeth-Ayerst (Asia) LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer (China) Research and Development Co. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer (Malaysia) Sdn Bhd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Malaysia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer (Perth) Pty Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer (Thailand) Limited</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thailand</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 3 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer (Wuhan) Research and Development Co. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer AB</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Advanced Pharmaceutical Company Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Taiwan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Africa &amp; Middle East for Pharmaceuticals, Veterinarian Products &amp; Chemicals S.A.E.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Egypt</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Afrique de L'Ouest</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Senegal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer AG</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Anti-Infectives AB</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer ApS</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer AS</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Norway</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Asia Manufacturing Pte. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Asia Pacific Pte Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Australia Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Australia Holdings Pty Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Australia Investments Pty Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Australia Pty Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer BH D.o.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Bosnia and Herzegovina</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Biofarmac&#234;utica, Sociedade Unipessoal Lda</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Biologics (Hangzhou) Co. Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Biologics Ireland Holdings Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Biopharma Egypt Import LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Egypt</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Biopharmaceuticals Egypt LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Egypt</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Biotech Corporation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Taiwan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Bolivia S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Bolivia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Canada ULC / Pfizer Canada SRI</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer CentreSource Asia Pacific Pte. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Chile S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chile</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Cia. Ltda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ecuador</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Colombia Spinco I LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pennsylvania</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Commercial Holdings TRAE Kft.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Commercial TRAE Trading Kft.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Consumer Healthcare</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Corporation Austria Gesellschaft m.b.H.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Corporation Hong Kong Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Corporation S. de R.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Panama</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Croatia d.o.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Croatia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Deutschland GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Development B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Development LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Development LP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Development Services (UK) Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Dominicana, S.R.L</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Dominican Republic</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer East India B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Eastern Investments B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Egypt S.A.E.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Egypt</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 4 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Enterprise Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Enterprises LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Enterprises SARL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer ESP Pty. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Established Medicine Italy S.r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Europe Finance B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Export B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Export Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Export Holding Company B.V</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Finance Share Service (Dalian) Co., Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Financial Services</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer France International Investments</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Free Zone Panama, S. de R.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Panama</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer GEP, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Global Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Global Supply Japan Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Global Trading</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Group Luxembourg SARL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Gulf FZ-LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Arab Emirates</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer H.C.P. Corporation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">New York</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Health AB</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Health Solutions Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Healthcare India Private Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Healthcare Ireland</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Hellas, A.E.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Greece</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Himalaya Holdings Co&#246;peratief U.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Holding France</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Holding Ventures</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Holdings Corporation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Holdings Europe Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Holdings G.K.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Holdings International Corporation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Holdings International Luxembourg (PHIL) SARL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Hungary Holdings TRAE Kft.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Ilaclari Limited Sirketi</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Turkey</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Innovations AB</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Innovations LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Russia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Innovative Supply Point International BVBA</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer International LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">New York</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer International Markets B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer International Operations</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer International S. de R.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Panama</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer International Trading (Shanghai) Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Investment Capital Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Investment Co. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Investment Holdings S.a.r.l.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 5 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Ireland Investments Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Ireland PFE Holding 1 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Ireland PFE Holding 2 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Ireland Pharmaceuticals</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Ireland Ventures Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Italia S.r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Italy Group Holding S.r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Japan Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Laboratories (Pty) Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">South Africa</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Laboratories Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Kenya</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Leasing Ireland Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Leasing UK Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Taiwan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Russia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Luxco Holdings SARL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Luxembourg Global Holdings S.&#224; r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Luxembourg SARL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Manufacturing Austria G.m.b.H.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Manufacturing Belgium N.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Manufacturing Deutschland GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Manufacturing Deutschland Grundbesitz GmbH &amp; Co. KG</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Manufacturing Holdings LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Manufacturing Ireland Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Manufacturing LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Manufacturing Services</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer MAP Holding, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Medical Technology Group (Belgium) N.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Medicamentos Genericos e Participacoes Ltda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Mexico Holding 2 B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Mexico Holding B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Mexico, S.A. de C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Middle East for Pharmaceuticals, Animal Health and Chemicals S.A.E.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Egypt</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer New Zealand Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">New Zealand</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Norge AS</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Norway</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer North America Services LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer OFG Germany GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer OTC B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Overseas LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Oy</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Finland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pakistan Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pakistan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Parke Davis (Thailand) Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thailand</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Parke Davis Sdn. Bhd.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Malaysia</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 6 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE ApS</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Denmark</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE AsiaPac Holding B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Australia Holding B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Australia Pty Ltd</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Belgium SPRL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE CIA. Ltda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ecuador</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Colombia Holding LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Croatia Holding B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Eastern Investments B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Finland Oy</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Finland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE France</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Global Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE &#304;la&#231;lar&#305; Anonim &#350;irketi</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Turkey</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Ireland Pharmaceuticals Holding 1 B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Taiwan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Norway Holding S.&#224; r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Peru S.R.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Peru</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Pharmaceuticals Israel Holding LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Pharmaceuticals Israel Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Israel</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE PILSA Holdco S.&#224; r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Private Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Service Company Holding B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Singapore Holding B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Singapore Pte. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Spain B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Spain Holding, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Switzerland GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Turkey Holding 1 B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE Turkey Holding 2 B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE UK Holding 4 LP</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE US Holdings 4 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE US Holdings 5 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer PFE, spol. s r.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Czech Republic</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharm Algerie</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Algeria</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharma GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharma PFE GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Germany</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceutical (Wuxi) Co., Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceutical Trading Limited Liability Company (a/k/a Pfizer Kft. or Pfizer LLC)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceuticals Global B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceuticals Israel Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Israel</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceuticals K.K.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceuticals Korea Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Korea</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceuticals LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceuticals Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceuticals Science and Technology Co., Ltd.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 7 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pharmaceuticals Tunisie Sarl</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tunisia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Pigments Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Polska Sp. z.o.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Poland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Private Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Production LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Products Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Connecticut</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Products India Private Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer R&amp;D Holding B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer R&amp;D Japan G.K.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer R&amp;D UK Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Research (NC), Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Romania SRL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Romania</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Peru</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer S.A. (Belgium)</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer S.A.S.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Colombia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer S.G.P.S. Lda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer S.r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer S.R.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Argentina</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Saidal Manufacturing</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Algeria</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Saudi Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Saudi Arabia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Service Company BVBA</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Service Company Ireland Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Services 1</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Services LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Shared Services Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Shareholdings Intermediate SARL</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Singapore Holding Pte. Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Singapore</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Specialties Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Nigeria</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer SRB d.o.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Serbia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Strategic Investment Holdings LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Trading Polska sp.z.o.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Poland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer TRAE Holdings Kft.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Transactions Ireland Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Transactions LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Tunisie SA</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tunisia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer UPJ G.K.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Japan</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Upjohn Hong Kong Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hong Kong</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Upjohn Korea Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Korea</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Upjohn Management Co., Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Upjohn Medical Trading Co., Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">People's Republic of China</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Vaccines LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Venezuela, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Venezuela</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Venture Investments LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Ventures (US) LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Ventures LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Worldwide Services Unlimited Company</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 8 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer Zona Franca, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Costa Rica</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer, Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Philippines</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Costa Rica</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer, S.A. de C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pfizer, spol. s r.o.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Czech Republic</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia &amp; Upjohn Company LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia &amp; Upjohn LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia &amp; Upjohn, S.A. de C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia Brasil Ltda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia Hepar LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia Holding AB</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia Inter-American LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pennsylvania</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia International B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pharmacia Nostrum, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PHIVCO Corp.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PHIVCO Holdco S.&#224; r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PHIVCO Luxembourg S.&#224; r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PIMB OFG Spain Holding, S.L.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PRISM Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PT. Pfizer Indonesia</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indonesia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">PT. Pfizer Parke Davis</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Indonesia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Purepac Pharmaceutical Holdings LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Renrall LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyoming</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Rinat Neuroscience Corp.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Roerig Produtos Farmaceuticos, Lda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Roerig S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Chile</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Searle Laboratorios, Lda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Servicios P&amp;U, S. de R.L. de C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Shiley LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">California</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sinergis Farma-Produtos Farmaceuticos, Lda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Solinor LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sugen LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Tabor LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">The Pfizer Incubator LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Therachon</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">France</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Therachon Holding GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn (Thailand) Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thailand</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Australia Pty Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Australia</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Belgium B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Canada ULC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Canada</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Europe Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Export B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Global Holdings B.V.</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 9 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Group Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Hellas Pharmaceutical Limited Liability Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Greece</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Intermediate Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn International Holdings B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Laboratorios Lda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Portugal</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Manufacturing Ireland Unlimited Company</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Ireland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Middle East FZ-LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Arab Emirates</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Netherlands B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn New Zealand ULC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">New Zealand</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Pharma Mexico S. de R.L. de C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Mexico</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Pharmaceuticals Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn PR Holdings C.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn PRISM B.V.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Netherlands</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn South Africa</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">South Africa</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn UK 2 Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn UK Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn US 1 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn US 2 LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn US Employment Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn US Holdings Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Upjohn Worldwide Holdings Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Utah Acquisition Holdco Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Utah Acquisition Sub Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Vicuron Holdings LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Vinci Farma, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warner Lambert del Uruguay S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Uruguay</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warner Lambert Ilac Sanayi ve Ticaret Limited Sirketi</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Turkey</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warner-Lambert (Thailand) Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thailand</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warner-Lambert Company AG</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Switzerland</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Warner-Lambert Company LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Whitehall Laboratories Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">W-L LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth (Thailand) Ltd.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Thailand</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth AB</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Sweden</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Ayerst Inc.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Ayerst S.&#224; r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Luxembourg</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Europa Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Kingdom</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Farma, S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Spain</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Holdings LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Maine</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Industria Farmaceutica Ltda.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Brazil</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth KFT.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Hungary</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Lederle S.r.l.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Italy</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Lederle Vaccines S.A.</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Belgium</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Pakistan Limited</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Pakistan</font></div></td></tr></table></div></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 10 -</font></div></div><hr style="page-break-after:always"><div></div><div><br></div><div style="line-height:120%;padding-left:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:98.29059829059828%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:58%;"></td><td style="width:42%;"></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Pharmaceuticals FZ-LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">United Arab Emirates</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Pharmaceuticals India Private Limited</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">India</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Pharmaceuticals LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Subsidiary Illinois Corporation</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Illinois</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth Whitehall Export GmbH</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Austria</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth-Ayerst (Asia) LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth-Ayerst International LLC</font></div></td><td style="vertical-align:top;border-bottom:1px solid #c0c0c0;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Wyeth-Ayerst Promotions Limited</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Yarra Therapeutics, LLC</font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #c0c0c0;"><div style="text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">Delaware</font></div></td></tr></table></div></div><div style="line-height:138%;padding-bottom:13px;text-align:left;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:5pt;"><font style="font-family:Arial;font-size:5pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;">- 11 -</font></div></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23
<SEQUENCE>8
<FILENAME>pfe-exhibit23x12312019.htm
<DESCRIPTION>EXHIBIT 23
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s8399B765E7825BC485F94684680D22BC"></a></div><div style="line-height:120%;padding-top:4px;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 23</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:5px;text-align:left;padding-left:8px;text-indent:172px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Consent of Independent Registered Public Accounting Firm</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div style="line-height:120%;padding-top:8px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">To the Board of Directors and the Shareholders of Pfizer Inc.:</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;"><br></font></div><div style="line-height:125%;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">We consent to the incorporation by reference in this </font><font style="font-family:Arial;font-size:8pt;">2019</font><font style="font-family:Arial;font-size:8pt;">&#32;Annual Report on Form 10-K of Pfizer Inc. of our reports dated </font><font style="font-family:Arial;font-size:8pt;">February&#160;27, 2020</font><font style="font-family:Arial;font-size:8pt;">, with respect to the consolidated balance sheets of Pfizer Inc. and Subsidiary Companies as of </font><font style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</font><font style="font-family:Arial;font-size:8pt;">&#32;and </font><font style="font-family:Arial;font-size:8pt;">2018</font><font style="font-family:Arial;font-size:8pt;">, and the related consolidated statements of income, comprehensive income, equity and cash flows for each of the years in the three-year period ended </font><font style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</font><font style="font-family:Arial;font-size:8pt;">, and the effectiveness of internal control over financial reporting as of </font><font style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</font><font style="font-family:Arial;font-size:8pt;">, which reports appear in the </font><font style="font-family:Arial;font-size:8pt;">2019</font><font style="font-family:Arial;font-size:8pt;">&#32;Annual Report on Form 10-K of Pfizer Inc.</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:7.5pt;"><font style="font-family:Arial;font-size:7.5pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">We also consent to the incorporation by reference of our reports in the following Registration Statements:</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated October 27, 1983 (File No. 2-87473),</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated March 22, 1990 (File No. 33-34139),</font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated January 24, 1991 (File No. 33-38708),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated November 18, 1991 (File No. 33-44053),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated May 27, 1993 (File No. 33-49631),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated May 19, 1994 (File No. 33-53713),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated October 5, 1994 (File No. 33-55771),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated December 20, 1994 (File No. 33-56979),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated March 29, 1996 (File No. 333-02061),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated September 25, 1997 (File No. 333-36371),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated June 19, 2000 (File No. 333-39606),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated April 27, 2001 (File No. 333-59660),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated April 16, 2003 (File No. 333-104582),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated November 18, 2003 (File No. 333-110571),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated December 18, 2003 (File No. 333-111333),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated April 26, 2004 (File No. 333-114852),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated March 1, 2007 (File No. 333-140987),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-4 dated March 27, 2009 (File No. 333-158237),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated October 16, 2009 (File No. 333-162519),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated October 16, 2009 (File No. 333-162520),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated October 16, 2009 (File No. 333-162521),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated March 1, 2010 (File No. 333-165121),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated March 2, 2015 (File No. 333-202437), </font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-4 dated September 3, 2015 (File No. 333-206758),</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-3 ASR dated February 26, 2018 (File No. 333-223221), and</font></div><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">-Form S-8 dated August 8, 2019 (File No. 333-233166).</font></div><div style="line-height:120%;text-align:left;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;"><br></font></div><div style="line-height:120%;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">/s/ KPMG LLP</font></div><div style="line-height:151%;padding-top:2px;text-align:left;padding-left:6px;font-size:8pt;"><font style="font-family:Arial;font-size:8pt;">New York, New York </font><font style="font-family:Arial;font-size:8pt;">February&#160;27, 2020</font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>pfe-exh311x1231201910k.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s08410FBB3DFE5F849329F79D3F27AE56"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 31.1</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Certification by the Chief Executive Officer Pursuant to </font></div><div style="line-height:120%;padding-bottom:6px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">I, Albert Bourla, certify that:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">1.</font><font style="font-family:Arial;font-size:9pt;">I have reviewed this Annual Report on Form 10-K of Pfizer Inc.;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">2.</font><font style="font-family:Arial;font-size:9pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">3.</font><font style="font-family:Arial;font-size:9pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">4.</font><font style="font-family:Arial;font-size:9pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">5.&#160;&#160;&#160;&#160;The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Date:&#160;</font><font style="font-family:Arial;font-size:9pt;">February&#160;27, 2020</font><font style="font-family:Arial;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">/s/ ALBERT BOURLA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Albert Bourla</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Chairman and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>pfe-exh312x1231201910k.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sDF07251225205DB58EFBFF85C28CC560"></a></div><div style="line-height:120%;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 31.2</font></div><div style="line-height:120%;padding-top:10px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Certification by the Chief Financial Officer Pursuant to </font></div><div style="line-height:120%;padding-bottom:6px;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Section 302 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">I, Frank A. D'Amelio, certify that:</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">1.</font><font style="font-family:Arial;font-size:9pt;">I have reviewed this Annual Report on Form 10-K of Pfizer Inc.;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">2.</font><font style="font-family:Arial;font-size:9pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">3.</font><font style="font-family:Arial;font-size:9pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">4.</font><font style="font-family:Arial;font-size:9pt;">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(c) Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(d) Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and</font></div><div style="line-height:120%;padding-left:0px;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:24px;"><font style="padding-bottom:6px;padding-top:6px;text-align:left;font-family:Arial;font-size:9pt;padding-right:24px;">5.</font><font style="font-family:Arial;font-size:9pt;">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;padding-left:24px;text-indent:36px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Date:&#160;</font><font style="font-family:Arial;font-size:9pt;">February&#160;27, 2020</font><font style="font-family:Arial;font-size:9pt;">&#32;</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:38%;"></td><td style="width:36%;"></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">/s/ FRANK A. D'AMELIO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Frank A. D'Amelio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Chief Financial Officer, Executive Vice President,</font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Business Operations and Global Supply</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>pfe-exh321x1231201910k.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="sF48D5EB725CB57639457C7FDB0A827F6"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 32.1</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Certification by the Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Pursuant to 18 U.S.C. Section 1350, I, Albert Bourla, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended </font><font style="font-family:Arial;font-size:9pt;text-align:center;">December&#160;31, 2019</font><font style="font-family:Arial;font-size:9pt;">&#32;(the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">/s/ ALBERT BOURLA</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Albert Bourla</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Chairman and Chief Executive Officer</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February&#160;27, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="line-height:120%;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>12
<FILENAME>pfe-exh322x1231201910k.htm
<DESCRIPTION>EXHIBIT 32.2
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2020 Workiva -->
		<title>Exhibit</title>
	</head>
	<body><div style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s4EBD3FD17B9E5F31B6B86B8A201FBDEA"></a></div><div style="line-height:120%;padding-bottom:10px;text-align:right;font-size:10pt;"><font style="font-family:Arial;font-size:10pt;font-weight:bold;">EXHIBIT 32.2</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Certification by the Chief Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to</font></div><div style="line-height:120%;text-align:center;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Section 906 of the Sarbanes-Oxley Act of 2002</font></div><div style="line-height:120%;padding-bottom:6px;padding-top:12px;text-align:left;text-indent:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">Pursuant to 18 U.S.C. Section 1350, I, Frank A. D'Amelio, hereby certify that, to the best of my knowledge, the Annual Report on Form 10-K of Pfizer Inc. for the year ended </font><font style="font-family:Arial;font-size:9pt;text-align:center;">December&#160;31, 2019</font><font style="font-family:Arial;font-size:9pt;">&#32;(the &#8220;Report&#8221;) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, and that the information contained in that Report fairly presents, in all material respects, the financial condition and results of operations of Pfizer Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.80506822612085%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:26%;"></td><td style="width:37%;"></td><td style="width:37%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">/s/ FRANK A. D'AMELIO</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Frank A. D'Amelio</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Chief Financial Officer, Executive Vice President, </font></div><div style="font-size:9pt;"><font style="font-family:Arial;font-size:9pt;font-weight:bold;">Business Operations and Global Supply</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">February&#160;27, 2020</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;text-indent:48px;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;">This certification accompanies this Annual Report on Form 10-K pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except to the extent that the Company specifically incorporates it by reference.</font></div><div style="line-height:120%;text-align:left;font-size:9pt;"><font style="font-family:Arial;font-size:9pt;"><br></font></div><div><br></div>	</div></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>13
<FILENAME>pfe-20191231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<xsd:schema attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.pfizer.com/20191231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:pfe="http://www.pfizer.com/20191231" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsd="http://www.w3.org/2001/XMLSchema">
  <xsd:import namespace="http://fasb.org/srt-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-types-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2019-01-31" schemaLocation="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-roles-2019-01-31.xsd" />
  <xsd:import namespace="http://fasb.org/us-types/2019-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2019/elts/us-types-2019-01-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" schemaLocation="http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/net" schemaLocation="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2019-01-31" schemaLocation="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2019-01-31" schemaLocation="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/exch/2019-01-31" schemaLocation="https://xbrl.sec.gov/exch/2019/exch-2019-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/invest/2013-01-31" schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/naics/2017-01-31" schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/sic/2011-01-31" schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2018-01-31" schemaLocation="https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd" />
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20191231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20191231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20191231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="pfe-20191231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple" />
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests">
        <link:definition>2106100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails">
        <link:definition>2406402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails">
        <link:definition>2406403 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails">
        <link:definition>2406404 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables">
        <link:definition>2306301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements">
        <link:definition>2102100 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails">
        <link:definition>2402402 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Array BioPharma Inc (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails">
        <link:definition>2402404 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - AstraZeneca (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails">
        <link:definition>2402406 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Divestitures (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails">
        <link:definition>2402407 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Equity Method Investments and Assets and Liabilities Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails">
        <link:definition>2402410 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Licensing Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails">
        <link:definition>2402405 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Medivation, Inc. (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail">
        <link:definition>2402411 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - R &amp; D and Collaborative Arrangements (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails">
        <link:definition>2402408 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Schedule of Assets Held for Sale (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails">
        <link:definition>2402409 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables">
        <link:definition>2302301 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails">
        <link:definition>2402403 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Therachon Holding AG (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPolicies" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies">
        <link:definition>2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails">
        <link:definition>2401405 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>2401403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails">
        <link:definition>2401409 - Disclosure - Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetailsCalc2" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetailsCalc2">
        <link:definition>2401409 - Disclosure - Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails">
        <link:definition>2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Impact of Lease Standard Adoption (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails">
        <link:definition>2401408 - Disclosure - Basis of Presentation and Significant Accounting Policies - Other Supplemental Lease Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesPolicies" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies">
        <link:definition>2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails">
        <link:definition>2401406 - Disclosure - Basis of Presentation and Significant Accounting Policies - ROU Assets and Liabilities Presented in Balance Sheet (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesTables" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables">
        <link:definition>2301302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails">
        <link:definition>2401407 - Disclosure - Basis of Presentation and Significant Accounting Policies - Total Lease Cost (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheets">
        <link:definition>1003000 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlows" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows">
        <link:definition>1005000 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfCashFlowsParenthetical" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical">
        <link:definition>1005501 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncome" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome">
        <link:definition>1002000 - Statement - Consolidated Statements of Comprehensive Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfComprehensiveIncomeParenthetical" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical">
        <link:definition>1002501 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfEquity" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfEquity">
        <link:definition>1004000 - Statement - Consolidated Statements of Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfEquityParenthetical" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical">
        <link:definition>1004001 - Statement - Consolidated Statements of Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsOfIncome" roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfIncome">
        <link:definition>1001000 - Statement - Consolidated Statements of Income</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCertainCommitments" roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitments">
        <link:definition>2117100 - Disclosure - Contingencies and Certain Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails">
        <link:definition>2417402 - Disclosure - Contingencies and Certain Commitments (Action In Which We Are The Defendant) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails">
        <link:definition>2417401 - Disclosure - Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails">
        <link:definition>2417403 - Disclosure - Contingencies and Certain Commitments (Commitments and Contingent Consideration for Acquisitions) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CoverPage" roleURI="http://www.pfizer.com/role/CoverPage">
        <link:definition>0001000 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders">
        <link:definition>2114100 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails">
        <link:definition>2414402 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetailsCalc2" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetailsCalc2">
        <link:definition>2414402 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables">
        <link:definition>2314301 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.pfizer.com/role/Equity">
        <link:definition>2112100 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityNarrativeDetails" roleURI="http://www.pfizer.com/role/EquityNarrativeDetails">
        <link:definition>2412402 - Disclosure - Equity - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquitySummaryOfCommonStockPurchasesDetails" roleURI="http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails">
        <link:definition>2412403 - Disclosure - Equity - Summary of Common Stock Purchases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.pfizer.com/role/EquityTables">
        <link:definition>2312301 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstruments" roleURI="http://www.pfizer.com/role/FinancialInstruments">
        <link:definition>2107100 - Disclosure - Financial Instruments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2407404 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCreditRiskDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails">
        <link:definition>2407420 - Disclosure - Financial Instruments - Credit Risk (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails">
        <link:definition>2407418 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails">
        <link:definition>2407415 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails">
        <link:definition>2407416 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails">
        <link:definition>2407414 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails">
        <link:definition>2407402 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails">
        <link:definition>2407403 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails">
        <link:definition>2407406 - Disclosure - Financial Instruments - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails">
        <link:definition>2407407 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails">
        <link:definition>2407412 - Disclosure - Financial Instruments - Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtNarrativeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails">
        <link:definition>2407411 - Disclosure - Financial Instruments - Long-Term Debt Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsLongTermDebtNewIssuancesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails">
        <link:definition>2407410 - Disclosure - Financial Instruments - Long-Term Debt, New Issuances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsNarrativeDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails">
        <link:definition>2407419 - Disclosure - Financial Instruments - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails">
        <link:definition>2407413 - Disclosure - Financial Instruments - Other Noncurrent Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsShortTermBorrowingsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails">
        <link:definition>2407409 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTables" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables">
        <link:definition>2307301 - Disclosure - Financial Instruments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails">
        <link:definition>2407405 - Disclosure - Financial Instruments - Total Short-term and Long-term Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwill" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill">
        <link:definition>2110100 - Disclosure - Identifiable Intangible Assets and Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails">
        <link:definition>2410406 - Disclosure - Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails">
        <link:definition>2410402 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails">
        <link:definition>2410403 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails">
        <link:definition>2410407 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails">
        <link:definition>2410404 - Disclosure - Identifiable Intangible Assets and Goodwill - Intangible Assets Percentage of Total Intangibles (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails">
        <link:definition>2410405 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IdentifiableIntangibleAssetsAndGoodwillTables" roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables">
        <link:definition>2310301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Insurance" roleURI="http://www.pfizer.com/role/Insurance">
        <link:definition>2116100 - Disclosure - Insurance</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.pfizer.com/role/Inventories">
        <link:definition>2108100 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.pfizer.com/role/InventoriesDetails">
        <link:definition>2408402 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.pfizer.com/role/InventoriesTables">
        <link:definition>2308301 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNet" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet">
        <link:definition>2104100 - Disclosure - Other (Income)/Deductions - Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails">
        <link:definition>2404402 - Disclosure - Other (Income)/Deductions - Net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail">
        <link:definition>2404411 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Additional Information About Impaired Intangible Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails">
        <link:definition>2404410 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails">
        <link:definition>2404405 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Asset Disposals and Investments in Equity Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails">
        <link:definition>2404407 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Collaborative Arrangements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails">
        <link:definition>2404408 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails">
        <link:definition>2404409 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails">
        <link:definition>2404403 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesInvestmentsDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails">
        <link:definition>2404406 - Disclosure - Other (Income)/ Deductions - Net - Footnotes - Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails">
        <link:definition>2404404 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Royalty Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherIncomeDeductionsNetTables" roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables">
        <link:definition>2304301 - Disclosure - Other (Income)/Deductions - Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans">
        <link:definition>2111100 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails">
        <link:definition>2411404 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails">
        <link:definition>2411410 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails">
        <link:definition>2411413 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails">
        <link:definition>2411402 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails">
        <link:definition>2411415 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails">
        <link:definition>2411403 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails">
        <link:definition>2411409 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails">
        <link:definition>2411406 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail">
        <link:definition>2411414 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails">
        <link:definition>2411416 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails">
        <link:definition>2411408 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails">
        <link:definition>2411407 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails">
        <link:definition>2411411 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails">
        <link:definition>2411412 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables">
        <link:definition>2311301 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails">
        <link:definition>2411405 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipment" roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipment">
        <link:definition>2109100 - Disclosure - Property, Plant and Equipment</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentDetails" roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails">
        <link:definition>2409402 - Disclosure - Property, Plant and Equipment (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyPlantAndEquipmentTables" roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipmentTables">
        <link:definition>2309301 - Disclosure - Property, Plant and Equipment (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives">
        <link:definition>2103100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail">
        <link:definition>2403403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail">
        <link:definition>2403404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail">
        <link:definition>2403402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail">
        <link:definition>2403405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail">
        <link:definition>2403406 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables">
        <link:definition>2303301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformation" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation">
        <link:definition>2118100 - Disclosure - Segment, Geographic and Other Revenue Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail">
        <link:definition>2418403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationFootnotesDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail">
        <link:definition>2418404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail">
        <link:definition>2418407 - Disclosure - Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationNarrativeDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail">
        <link:definition>2418402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail">
        <link:definition>2418405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail">
        <link:definition>2418406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail">
        <link:definition>2418408 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentGeographicAndOtherRevenueInformationTables" roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables">
        <link:definition>2318301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPayments" roleURI="http://www.pfizer.com/role/ShareBasedPayments">
        <link:definition>2113100 - Disclosure - Share-Based Payments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails">
        <link:definition>2413417 - Disclosure - Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails">
        <link:definition>2413414 - Disclosure - Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail">
        <link:definition>2413411 - Disclosure - Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail">
        <link:definition>2413421 - Disclosure - Share-Based Payments - Data Related to All Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails">
        <link:definition>2413408 - Disclosure - Share-Based Payments - Data Related to All Total Shareholder Return Units (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsImpactOnNetIncomeDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail">
        <link:definition>2413403 - Disclosure - Share-Based Payments - Impact on Net Income (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsNarrativeDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail">
        <link:definition>2413402 - Disclosure - Share-Based Payments - Narrative (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails">
        <link:definition>2413407 - Disclosure - Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails">
        <link:definition>2413416 - Disclosure - Share-Based Payments - Performance Share Awards (PSAs) Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails">
        <link:definition>2413415 - Disclosure - Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails">
        <link:definition>2413409 - Disclosure - Share-Based Payments - Performance Total Shareholder Return Units Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails">
        <link:definition>2413413 - Disclosure - Share-Based Payments - Portfolio Performance Shares Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails">
        <link:definition>2413412 - Disclosure - Share-Based Payments - Portfolio Performance Shares Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsRestrictedStockUnitActivityDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail">
        <link:definition>2413410 - Disclosure - Share-Based Payments - Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsStockOptionActivityDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail">
        <link:definition>2413420 - Disclosure - Share-Based Payments - Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsStockOptionNarrativeDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails">
        <link:definition>2413418 - Disclosure - Share-Based Payments - Stock Option Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTables" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTables">
        <link:definition>2313301 - Disclosure - Share-Based Payments (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails">
        <link:definition>2413406 - Disclosure - Share-Based Payments - Total Shareholder Return Units Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails">
        <link:definition>2413404 - Disclosure - Share-Based Payments - Total Shareholder Return Units Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail">
        <link:definition>2413419 - Disclosure - Share-Based Payments - Valuation Assumptions of Stock Options (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" roleURI="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail">
        <link:definition>2413405 - Disclosure - Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMatters" roleURI="http://www.pfizer.com/role/TaxMatters">
        <link:definition>2105100 - Disclosure - Tax Matters</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersDeferredTaxesDetails" roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails">
        <link:definition>2405406 - Disclosure - Tax Matters - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersDeferredTaxesFootnotesDetails" roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails">
        <link:definition>2405407 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" roleURI="http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails">
        <link:definition>2405402 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersNarrativeDetails" roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetails">
        <link:definition>2405408 - Disclosure - Tax Matters - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersProvisionForTaxesOnIncomeDetails" roleURI="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails">
        <link:definition>2405403 - Disclosure - Tax Matters - Provision for Taxes on Income (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" roleURI="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails">
        <link:definition>2405404 - Disclosure - Tax Matters - Provision for Taxes on Income (Narrative) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" roleURI="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails">
        <link:definition>2405409 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" roleURI="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails">
        <link:definition>2405410 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTables" roleURI="http://www.pfizer.com/role/TaxMattersTables">
        <link:definition>2305301 - Disclosure - Tax Matters (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTaxRateReconciliationDetails" roleURI="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails">
        <link:definition>2405405 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" roleURI="http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails">
        <link:definition>2405411 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element abstract="true" id="pfe_A2019StockPlanMember" name="A2019StockPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AMPharmaBVMember" name="AMPharmaBVMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" name="AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AccruedRebates" name="AccruedRebates" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_AkceaAndIonisMember" name="AkceaAndIonisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AlignmentCosts" name="AlignmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherInflammationandImmunologyProductsMember" name="AllOtherInflammationandImmunologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherInternalMedicineMember" name="AllOtherInternalMedicineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherRareDiseaseProductsMember" name="AllOtherRareDiseaseProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllOtherUpjohnProductsMember" name="AllOtherUpjohnProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AllogeneMember" name="AllogeneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AmerisourceBergenCorporationMember" name="AmerisourceBergenCorporationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" name="AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AnacorMember" name="AnacorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ArrayMember" name="ArrayMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AssetAcquisitionAxis" name="AssetAcquisitionAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AssetAcquisitionConsiderationTransferred" name="AssetAcquisitionConsiderationTransferred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" name="AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" name="AssetAcquisitionConsiderationTransferredUpfrontPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AssetAcquisitionDomain" name="AssetAcquisitionDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AssetAcquisitionPercentageofSharesAcquired" name="AssetAcquisitionPercentageofSharesAcquired" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_AssetImpairmentChargesAndOtherCharges" name="AssetImpairmentChargesAndOtherCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AssetImpairmentsMember" name="AssetImpairmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AssetWriteOffsAndAssetImpairmentCharges" name="AssetWriteOffsAndAssetImpairmentCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_AssetsAndLiabilitiesLesseeTableTextBlock" name="AssetsAndLiabilitiesLesseeTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_AstraZenecaMember" name="AstraZenecaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" name="AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_BMP2Member" name="BMP2Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BainCapitalMember" name="BainCapitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BeneFIXMember" name="BeneFIXMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BesponsaMember" name="BesponsaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BionTechMember" name="BionTechMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BiopharmaSegmentMember" name="BiopharmaSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" name="BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BosulifMember" name="BosulifMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BraftoviMember" name="BraftoviMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessAlignmentCosts" name="BusinessAlignmentCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" name="BusinessCombinationAcquisitionRelatedCostsTransactionCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredAmountPayable" name="BusinessCombinationConsiderationTransferredAmountPayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredDeferredPayment" name="BusinessCombinationConsiderationTransferredDeferredPayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" name="BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" name="BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" name="BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" name="BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessCombinationsAcquisitionRelatedCostsMember" name="BusinessCombinationsAcquisitionRelatedCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" name="BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" name="BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_BusinessIntegrationCostsMember" name="BusinessIntegrationCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CardinalHealthInc.Member" name="CardinalHealthInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CelebrexMember" name="CelebrexMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CellectisMember" name="CellectisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CerevelMember" name="CerevelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CerevelTherapeuticsMember" name="CerevelTherapeuticsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CertainSignificantItemsMember" name="CertainSignificantItemsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ChantixChampixMember" name="ChantixChampixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" name="Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_CharitableContributionExpense" name="CharitableContributionExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" name="CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" name="CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" name="CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" name="CollaborativeArrangementContingentPaymentsMaximumExposure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_CollaborativeArrangementDeferredMilestonePayment" name="CollaborativeArrangementDeferredMilestonePayment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized" name="CollaborativeArrangementDeferredMilestoneRevenueRecognized" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_CollaborativeArrangementMilestonePaymentReceivable" name="CollaborativeArrangementMilestonePaymentReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_CollaborativeArrangementUpfrontAndMilestonePayments" name="CollaborativeArrangementUpfrontAndMilestonePayments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CollaborativeArrangementUpfrontCashPaymentMember" name="CollaborativeArrangementUpfrontCashPaymentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CommonESOPPlanMember" name="CommonESOPPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus" name="CompensationRelatedCostsNonExecutiveEmployeesBonus" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_ConcentrationRiskAmount" name="ConcentrationRiskAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" name="ConcentrationRiskRevenues500000000orMoreNumberofCountries" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_ConsumerHealthcareMember" name="ConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ConsumerHealthcareReportingUnitMember" name="ConsumerHealthcareReportingUnitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ConvertiblePreferredStockNumberofSharesConvertible" name="ConvertiblePreferredStockNumberofSharesConvertible" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_CopromotionMember" name="CopromotionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CortexymeInc.Member" name="CortexymeInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CreditFacilityExpiring2024Member" name="CreditFacilityExpiring2024Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_CurrentTaxAssetsMember" name="CurrentTaxAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" name="DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" name="DebtSecuritiesAccumulatedGrossUnrealizedGain" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" name="DebtSecuritiesAccumulatedGrossUnrealizedLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesAmortizedCostBasis" name="DebtSecuritiesAmortizedCostBasis" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" name="DebtSecuritiesMaturitiesAfterYearFiveFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" name="DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" name="DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" name="DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_December2015StockPurchasePlanMember" name="December2015StockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_December2017StockPurchasePlanMember" name="December2017StockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_December2018StockPurchasePlanMember" name="December2018StockPurchasePlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeconsolidationExternalIncrementalCostsAmount" name="DeconsolidationExternalIncrementalCostsAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeconsolidationGainLossAmountCashConveyed" name="DeconsolidationGainLossAmountCashConveyed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeconsolidationGainLossAmountNetOfCashConveyed" name="DeconsolidationGainLossAmountNetOfCashConveyed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeconsolidationGainLossAmountNetOfTax" name="DeconsolidationGainLossAmountNetOfTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeconsolidationNetAssetsContributed" name="DeconsolidationNetAssetsContributed" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_DeferredRevenueMember" name="DeferredRevenueMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" name="DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" name="DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" name="DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" name="DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" name="DeferredTaxAssetsStateandLocalTaxesAdjustments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" name="DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_DeferredTaxLiabilitiesNetNoncurrentMember" name="DeferredTaxLiabilitiesNetNoncurrentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" name="DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" name="DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" name="DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" name="DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" name="DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" name="DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" name="DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" name="DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" name="DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" name="DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember" name="DefinedBenefitPlanEquitySecuritiesGlobalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanExpectedAmortizationTerm" name="DefinedBenefitPlanExpectedAmortizationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" name="DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanNumberofPensionPlansFrozen" name="DefinedBenefitPlanNumberofPensionPlansFrozen" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver" name="DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge" name="DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" name="DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DevelopedEuropeMember" name="DevelopedEuropeMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DevelopedRestOfWorldMember" name="DevelopedRestOfWorldMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DiflucanMember" name="DiflucanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DirectorsCompensationMember" name="DirectorsCompensationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" name="DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" name="DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" name="DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" name="DisposalGroupIncludingDiscontinuedOperationContingentConsideration" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationMilestone" name="DisposalGroupIncludingDiscontinuedOperationMilestone" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue" name="DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" name="DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DocetaxelMember" name="DocetaxelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" name="DomesticIncomeTaxExpenseBenefitContinuedOperations" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_DomesticIncomeTaxesAbstract" name="DomesticIncomeTaxesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" name="EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent" name="EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount" name="EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount" name="EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EffectofTaxCutsandJobsActAbstract" name="EffectofTaxCutsandJobsActAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EffexorMember" name="EffexorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EliLillyCompanyMember" name="EliLillyCompanyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EliquisMember" name="EliquisMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EmergingMarketsMember" name="EmergingMarketsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EnbrelMember" name="EnbrelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EnvironmentalRemediationLitigationMember" name="EnvironmentalRemediationLitigationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EpiPenMember" name="EpiPenMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentExcessBasisAmortization" name="EquityMethodInvestmentExcessBasisAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" name="EquityMethodInvestmentExcessBasisAmortizationPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" name="EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" name="EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax" name="EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentsTaxIndemnificationLiability" name="EquityMethodInvestmentsTaxIndemnificationLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm" name="EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm" name="EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_EquitySecuritiesFVNINoncurrent" name="EquitySecuritiesFVNINoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_EquitySecuritiesFVNIRestrictedCurrent" name="EquitySecuritiesFVNIRestrictedCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_EquitySecuritiesFVNIRestrictedNoncurrent" name="EquitySecuritiesFVNIRestrictedNoncurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_EucrisaMember" name="EucrisaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FSMEIMMUNTicoVacMember" name="FSMEIMMUNTicoVacMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FacilityExpiringSeptember2020Member" name="FacilityExpiringSeptember2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_FeasibilityStudyNumberOfLagoons" name="FeasibilityStudyNumberOfLagoons" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_FeePayable" name="FeePayable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FinancialInstrumentsAbstract" name="FinancialInstrumentsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FocusedCompanyPlanMember" name="FocusedCompanyPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ForeignCurrencyLongTermDebtMember" name="ForeignCurrencyLongTermDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ForeignCurrencyShortTermBorrowingsMember" name="ForeignCurrencyShortTermBorrowingsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_FragminMember" name="FragminMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GSKConsumerHealthcareMember" name="GSKConsumerHealthcareMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GSKMember" name="GSKMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyNumberofDefendants" name="GainContingencyNumberofDefendants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" name="GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber" name="GainContingencyPatentsAllegedlyNotInfringedUponNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019" name="GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber" name="GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" name="GainContingencyPatentsWithoutCourtProceedingsNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainLossFromContributionAgreement" name="GainLossFromContributionAgreement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_GainLossOnExchangeOfDebt" name="GainLossOnExchangeOfDebt" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GeneTherapiesMember" name="GeneTherapiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GenericInjectablePainRelieverMember" name="GenericInjectablePainRelieverMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GenericSterileInjectableProductMember" name="GenericSterileInjectableProductMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GenotropinMember" name="GenotropinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" name="GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HISMember" name="HISMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HISProductsMember" name="HISProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HedgedItemAxis" name="HedgedItemAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HedgedItemDomain" name="HedgedItemDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_HeldToMaturityCashEquivalents" name="HeldToMaturityCashEquivalents" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" name="HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_HisunPfizerPharmaceuticalsCoLtdMember" name="HisunPfizerPharmaceuticalsCoLtdMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraMember" name="HospiraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraVersusAmnealPharmaceuticalsLLCMember" name="HospiraVersusAmnealPharmaceuticalsLLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraVersusFreseniusKabjUSALLCMember" name="HospiraVersusFreseniusKabjUSALLCMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospiraVersusParMember" name="HospiraVersusParMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_HospitalMember" name="HospitalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ICUMedicalMember" name="ICUMedicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IbranceMember" name="IbranceMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ImplementationCostAbstract" name="ImplementationCostAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ImplementationCosts" name="ImplementationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" name="IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" name="IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" name="IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IncomeTaxesLineItems" name="IncomeTaxesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IncomeTaxesPayableMember" name="IncomeTaxesPayableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_IncomeTaxesTable" name="IncomeTaxesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InflammationandImmunologyMember" name="InflammationandImmunologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InflectraMember" name="InflectraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InflectraRemsimaMember" name="InflectraRemsimaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InlytaMember" name="InlytaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InnoPharmaMember" name="InnoPharmaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InsuranceContractsMember" name="InsuranceContractsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InsuranceCoverageAbstract" name="InsuranceCoverageAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_InsuranceCoverageDisclosureTextBlock" name="InsuranceCoverageDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_IntangibleAssetsFairValueDisclosure" name="IntangibleAssetsFairValueDisclosure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_IntangibleAssetsLineItems" name="IntangibleAssetsLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" name="IntangibleAssetsNetPercentageofIntangibleAssetsNet" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_InterestPaidInterestRateHedges" name="InterestPaidInterestRateHedges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InternalMedicineMember" name="InternalMedicineMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_InternationalIncomeTaxesAbstract" name="InternationalIncomeTaxesAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_InventoryWriteDownAndOverheadCosts" name="InventoryWriteDownAndOverheadCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_InvestmentOwnershipPercentage" name="InvestmentOwnershipPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" name="JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LaboratorioTeutoBrasileroMember" name="LaboratorioTeutoBrasileroMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LesseeOperatingLeaseOptionToExtendTerm" name="LesseeOperatingLeaseOptionToExtendTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LicensingAgreementsAndOtherMember" name="LicensingAgreementsAndOtherMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LicensingAgreementsDevelopedTechnologyMember" name="LicensingAgreementsDevelopedTechnologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_LicensingAgreementsTechnologyInDevelopmentMember" name="LicensingAgreementsTechnologyInDevelopmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LicensingArrangementMilestoneMaximumValue" name="LicensingArrangementMilestoneMaximumValue" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_LicensingArrangementNumberOfSharesPurchased" name="LicensingArrangementNumberOfSharesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LicensingArrangementValueOfSharesPurchased" name="LicensingArrangementValueOfSharesPurchased" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" name="LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_LipitorMember" name="LipitorMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" name="LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_LongtermInvestmentsAndEquityMethodInvestments" name="LongtermInvestmentsAndEquityMethodInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" name="LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_LongtermInvestmentsMember" name="LongtermInvestmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LossContingencyClassActionsFiledNumber" name="LossContingencyClassActionsFiledNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" name="LossContingencyNumberOfDefendantsOtherThanMainDefendant" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_LossContingencyNumberOfLawsuits" name="LossContingencyNumberOfLawsuits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_LyricaMember" name="LyricaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ManufacturingOptimizationMember" name="ManufacturingOptimizationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_McKessonInc.Member" name="McKessonInc.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MedivationMember" name="MedivationMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MedrolMember" name="MedrolMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MektoviMember" name="MektoviMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MerckKGaAMember" name="MerckKGaAMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MerckMember" name="MerckMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember" name="MultiAntigenVaccineForSpinalFusionSurgeryMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MylanMember" name="MylanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_MylotargMember" name="MylotargMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NeuroscienceAssetsMember" name="NeuroscienceAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NextWaveMember" name="NextWaveMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NimenrixMember" name="NimenrixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NonUnitedStatesMember" name="NonUnitedStatesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" name="NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" name="NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" name="NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" name="NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NoncurrentDeferredTaxLiabilitiesMember" name="NoncurrentDeferredTaxLiabilitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NorvascMember" name="NorvascMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NotesDue20200.000Member" name="NotesDue20200.000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NotesDue20220.250Member" name="NotesDue20220.250Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NotesDue20271.000Member" name="NotesDue20271.000Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_NovaQuestCoInvestmentFundVL.P.Member" name="NovaQuestCoInvestmentFundVL.P.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_NumberOfAccountingStandardsAdopted" name="NumberOfAccountingStandardsAdopted" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_NumberofEmployeeStockOwnershipPlans" name="NumberofEmployeeStockOwnershipPlans" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OfficeBuildingInNewYorkCityMember" name="OfficeBuildingInNewYorkCityMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OncologyMember" name="OncologyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OncologyVaccinesStartUpMember" name="OncologyVaccinesStartUpMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OpenMarketPurchasesMember" name="OpenMarketPurchasesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherAccruals" name="OtherAccruals" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OtherActivitiesMember" name="OtherActivitiesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherAntiinfectivesMember" name="OtherAntiinfectivesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherCommingledFundsMember" name="OtherCommingledFundsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" name="OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" name="OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" name="OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" name="OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" name="OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" name="OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax" name="OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" name="OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" name="OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" name="OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherHospitalProductsMember" name="OtherHospitalProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherIncomeDeductionsAndCostOfSalesMember" name="OtherIncomeDeductionsAndCostOfSalesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherIncomeExpenseMember" name="OtherIncomeExpenseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherNonoperatingIncomeExpenseNet" name="OtherNonoperatingIncomeExpenseNet" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherNonoperatingIncomeMiscellaneous" name="OtherNonoperatingIncomeMiscellaneous" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherOncologyProductsMember" name="OtherOncologyProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherSegmentReconcilingItemsAxis" name="OtherSegmentReconcilingItemsAxis" nillable="true" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherSegmentReconcilingItemsDomain" name="OtherSegmentReconcilingItemsDomain" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_OtherTaxAssetsCurrent" name="OtherTaxAssetsCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_OtherTaxesPayableMember" name="OtherTaxesPayableMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_OtherVaccinesProductsMember" name="OtherVaccinesProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PanzygaMember" name="PanzygaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PatentInfringementMember" name="PatentInfringementMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PatentMatterMember" name="PatentMatterMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentForLicensingArrangement" name="PaymentForLicensingArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentForRepatriationTax" name="PaymentForRepatriationTax" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentsToCollaborators" name="PaymentsToCollaborators" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" name="PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" name="PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" name="PerformanceTotalShareholderReturnUnitPTSRUsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" name="PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerCentreOneMember" name="PfizerCentreOneMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusAjantaMember" name="PfizerVersusAjantaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusGenericCompaniesMember" name="PfizerVersusGenericCompaniesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member" name="PfizerVersusViwitPharmaceuticalCo.Ltd.Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerVersusZydusMember" name="PfizerVersusZydusMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" name="PfizerandBMSVersusSeveralGenericManufacturersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" name="PfizersWorldwideResearchDevelopmentAndMedicalMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" name="Phase2bReadyAMPAReceptorPotentiatorForCIASMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PhenytoinSodiumCapsulesMember" name="PhenytoinSodiumCapsulesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PortfolioPerformanceSharesMember" name="PortfolioPerformanceSharesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PrecedexPremixMember" name="PrecedexPremixMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PreferredESOPPlanMember" name="PreferredESOPPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PreferredEmployeeStockOwnershipPlanMember" name="PreferredEmployeeStockOwnershipPlanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_PreferredStockSharesHeldInEmployeeTrustShares" name="PreferredStockSharesHeldInEmployeeTrustShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_PremarinFamilyMember" name="PremarinFamilyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_PrepaymentsandPaymentstoCollaborators" name="PrepaymentsandPaymentstoCollaborators" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PrevnarPrevenarFamilyMember" name="PrevnarPrevenarFamilyMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_PrivateEquityInvestments" name="PrivateEquityInvestments" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ProceedsFromLicensingArrangement" name="ProceedsFromLicensingArrangement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ProfitUnitsMember" name="ProfitUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_PurchaseAccountingAdjustmentsMember" name="PurchaseAccountingAdjustmentsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RPIFinanceTrustMember" name="RPIFinanceTrustMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RareDiseaseMember" name="RareDiseaseMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ReFactoAfXynthaMember" name="ReFactoAfXynthaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_RebatesAndDiscountsAccrual" name="RebatesAndDiscountsAccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock" name="ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" name="ResearchandDevelopmentArrangementAggregatePaymentObligation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" name="ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure" name="ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" name="ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" name="ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount" name="ResearchandDevelopmentArrangementLiabilityBuyoutAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementMaximumFundingAmount" name="ResearchandDevelopmentArrangementMaximumFundingAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" name="ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringAssetImpairmentCharges" name="RestructuringAssetImpairmentCharges" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" name="RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringChargesAndAcquisitionRelatedCosts" name="RestructuringChargesAndAcquisitionRelatedCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" name="RestructuringChargesAndAcquisitionRelatedCostsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringChargesandImplementationCosts" name="RestructuringChargesandImplementationCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_RestructuringandRelatedCostNoncashChargesPercentage" name="RestructuringandRelatedCostNoncashChargesPercentage" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RetacritMember" name="RetacritMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_RevatioMember" name="RevatioMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfAccruedLiabilitiesLineItems" name="ScheduleOfAccruedLiabilitiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfAccruedLiabilitiesTable" name="ScheduleOfAccruedLiabilitiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" name="ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ScheduleOfIntangibleAssetsTable" name="ScheduleOfIntangibleAssetsTable" nillable="true" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" name="ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock" name="ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock" nillable="true" substitutionGroup="xbrli:item" type="nonnum:textBlockItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorNotesDue2047Member" name="SeniorNotesDue2047Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue2020Member" name="SeniorUnsecuredDebtDue2020Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue2021Member" name="SeniorUnsecuredDebtDue2021Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue2022Member" name="SeniorUnsecuredDebtDue2022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue2023Member" name="SeniorUnsecuredDebtDue2023Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue2024Member" name="SeniorUnsecuredDebtDue2024Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue20262029Member" name="SeniorUnsecuredDebtDue20262029Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue2034Member" name="SeniorUnsecuredDebtDue2034Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue20362040Member" name="SeniorUnsecuredDebtDue20362040Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue20432044Member" name="SeniorUnsecuredDebtDue20432044Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtDue20462049Member" name="SeniorUnsecuredDebtDue20462049Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtFourPercentDue2049Member" name="SeniorUnsecuredDebtFourPercentDue2049Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member" name="SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member" name="SeniorUnsecuredDebtThreePointNinePercentDue2039Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member" name="SeniorUnsecuredDebtTwoPointEightPercentDue2022Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member" name="SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" name="SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" name="SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member" name="SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SeriesAConvertiblePreferredStockMember" name="SeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ShareRepurchaseAgreementwithCitibankMember" name="ShareRepurchaseAgreementwithCitibankMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ShareRepurchaseAgreementwithGSCoMember" name="ShareRepurchaseAgreementwithGSCoMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" nillable="true" substitutionGroup="xbrli:item" type="num:percentItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="instant" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" name="SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" name="SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement" name="SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" name="SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" name="SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" nillable="true" substitutionGroup="xbrli:item" type="xbrli:integerItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" name="SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" name="SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" name="SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" nillable="true" substitutionGroup="xbrli:item" type="num:perShareItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ShireMember" name="ShireMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_ShorttermDebtGross" name="ShorttermDebtGross" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" name="ShorttermInvestmentsExcludingHeldToMaturitySecurities" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_SomavertMember" name="SomavertMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SterileInjectablePainRelieverMember" name="SterileInjectablePainRelieverMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" name="StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" name="StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SulperazonMember" name="SulperazonMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_SutentMember" name="SutentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsAndJobsActIncomeTaxBenefit" name="TaxCutsAndJobsActIncomeTaxBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit" name="TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit" name="TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" name="TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" name="TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability" name="TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" name="TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability" name="TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit" name="TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability" name="TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element abstract="true" id="pfe_TherachonAssetAcquisitionMember" name="TherachonAssetAcquisitionMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ThreeLargestUSWholesaleCustomersMember" name="ThreeLargestUSWholesaleCustomersMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TopEightProductsMember" name="TopEightProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TopNineProductsMember" name="TopNineProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TopTenProductsMember" name="TopTenProductsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TotalAllianceBiopharmaceuticalsMember" name="TotalAllianceBiopharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TotalBiosimilarsMember" name="TotalBiosimilarsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TotalShareholderReturnUnitsTSRUsMember" name="TotalShareholderReturnUnitsTSRUsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TotalSterileInjectablePharmaceuticalsMember" name="TotalSterileInjectablePharmaceuticalsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ToviazMember" name="ToviazMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TreatmentForToenailFungusMember" name="TreatmentForToenailFungusMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TreatmentOfAttentionHyperactivityDisorderMember" name="TreatmentOfAttentionHyperactivityDisorderMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TrumenbaMember" name="TrumenbaMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" name="TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_TygacilMember" name="TygacilMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_U.K.PoundDenominatedDebtMember" name="U.K.PoundDenominatedDebtMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element id="pfe_UnrecognizedTaxBenefitsExcludingInterest" name="UnrecognizedTaxBenefitsExcludingInterest" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant" />
  <xsd:element id="pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" name="UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element id="pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" name="UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_UpjohnAndMylanMember" name="UpjohnAndMylanMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_UpjohnReportingUnitMember" name="UpjohnReportingUnitMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_UpjohnSegmentMember" name="UpjohnSegmentMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_VaccinesMember" name="VaccinesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_VfendMember" name="VfendMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ViagraMember" name="ViagraMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ViivHealthcareLimitedMember" name="ViivHealthcareLimitedMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ViolationofAntitrustLawsMember" name="ViolationofAntitrustLawsMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_VyndaqelMember" name="VyndaqelMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XalatanXalacomMember" name="XalatanXalacomMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XalkoriMember" name="XalkoriMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XanaxMember" name="XanaxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XeljanzMember" name="XeljanzMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_XtandiAllianceRevenuesMember" name="XtandiAllianceRevenuesMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZithromaxZmaxMember" name="ZithromaxZmaxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZoloftMember" name="ZoloftMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZosynTazocinMember" name="ZosynTazocinMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
  <xsd:element abstract="true" id="pfe_ZyvoxMember" name="ZyvoxMember" nillable="true" substitutionGroup="xbrli:item" type="nonnum:domainItemType" xbrli:periodType="duration" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>14
<FILENAME>pfe-20191231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetailsCalc2" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:href="pfe-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfEquity" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfIncome" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:href="pfe-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetailsCalc2" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetailsCalc2" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Equity" xlink:href="pfe-20191231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:href="pfe-20191231.xsd#EquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails" xlink:href="pfe-20191231.xsd#EquitySummaryOfCommonStockPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityTables" xlink:href="pfe-20191231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Insurance" xlink:href="pfe-20191231.xsd#Insurance" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20191231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetails" xlink:href="pfe-20191231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20191231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipment" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipmentTables" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPayments" xlink:href="pfe-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsStockOptionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTables" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20191231.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:href="pfe-20191231.xsd#TaxMattersDeferredTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:href="pfe-20191231.xsd#TaxMattersDeferredTaxesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:href="pfe-20191231.xsd#TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:href="pfe-20191231.xsd#TaxMattersNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails" xlink:href="pfe-20191231.xsd#TaxMattersProvisionForTaxesOnIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:href="pfe-20191231.xsd#TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="pfe-20191231.xsd#TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:href="pfe-20191231.xsd#TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20191231.xsd#TaxMattersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:href="pfe-20191231.xsd#TaxMattersTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:href="pfe-20191231.xsd#TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_6cbcd17f-7cc9-25e5-443f-7493fc1ed69c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_6cbcd17f-7cc9-25e5-443f-7493fc1ed69c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_63f7ad53-2f46-2d31-8ea8-acc27b955109" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_63f7ad53-2f46-2d31-8ea8-acc27b955109" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_6c137664-608a-3ee7-f995-56312ea80532" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_6c137664-608a-3ee7-f995-56312ea80532" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_7ed57a7e-6f29-a005-f782-4e660d6e7f6a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_7ed57a7e-6f29-a005-f782-4e660d6e7f6a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8eebd75f-2195-0761-8bf5-e198389f5b59" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8eebd75f-2195-0761-8bf5-e198389f5b59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_ec8b70d0-b03e-7f0a-30e5-a5a4eb347150" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_ec8b70d0-b03e-7f0a-30e5-a5a4eb347150" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_b3df9d85-8c0d-2094-389e-1ea64faf716c" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_b3df9d85-8c0d-2094-389e-1ea64faf716c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_97db074b-d817-ea81-a506-6190ac41d38d" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_97db074b-d817-ea81-a506-6190ac41d38d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_ca071052-aa25-dfad-9978-9a7b935d372f" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_ca071052-aa25-dfad-9978-9a7b935d372f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49cc0415-e222-e50b-93d8-a34f07c0f8b5" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_f30b9be6-59bd-43dd-a4a4-1c4cbaaa1790" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_49cc0415-e222-e50b-93d8-a34f07c0f8b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_c8b8c71e-cc4a-f0b2-7dd7-d3b4c429a4d1" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_c8b8c71e-cc4a-f0b2-7dd7-d3b4c429a4d1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_38fcd7a5-e1dd-e864-286d-be1614b13f15" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_38fcd7a5-e1dd-e864-286d-be1614b13f15" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_2e2ea9ed-6421-481c-f77c-3d83fa5dd7c2" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_2e2ea9ed-6421-481c-f77c-3d83fa5dd7c2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_02eaf315-b21e-0220-c82a-febdbb5e12c5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_02eaf315-b21e-0220-c82a-febdbb5e12c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_77d36b17-b454-3339-eeb2-eb365a750c47" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_77d36b17-b454-3339-eeb2-eb365a750c47" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_e8667c82-6b31-2e2c-85de-773cdc22c508" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_e8667c82-6b31-2e2c-85de-773cdc22c508" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_89f2eb91-8c4d-055a-a578-234b8c2fefed" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_89f2eb91-8c4d-055a-a578-234b8c2fefed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_8c078056-e8f9-8525-d9bb-2e972b6bbf76" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_8c078056-e8f9-8525-d9bb-2e972b6bbf76" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_6290511b-930f-8891-09ad-cfeb422e30aa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_c4806eef-a524-90ca-0f29-1a54bcdcc50c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_6290511b-930f-8891-09ad-cfeb422e30aa" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_c4806eef-a524-90ca-0f29-1a54bcdcc50c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_a75c3fb2-3879-6e54-54b3-6a41b223abe3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_6290511b-930f-8891-09ad-cfeb422e30aa" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_a75c3fb2-3879-6e54-54b3-6a41b223abe3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_d3bc6e87-00e7-dcff-92d3-2e46621610f4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_4085e34c-da93-b7e0-d3ce-39a7f959f559" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_d3bc6e87-00e7-dcff-92d3-2e46621610f4" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_4085e34c-da93-b7e0-d3ce-39a7f959f559" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_2aefcbe0-3b66-18eb-ea05-71256d311934" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_d3bc6e87-00e7-dcff-92d3-2e46621610f4" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_2aefcbe0-3b66-18eb-ea05-71256d311934" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_4a6a8b9f-2587-a775-3a32-ea74c3990c93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_319b4045-cc68-f9e4-ba01-5a0515c5fbe9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_4a6a8b9f-2587-a775-3a32-ea74c3990c93" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_319b4045-cc68-f9e4-ba01-5a0515c5fbe9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_16e1702c-a83e-ec54-eba0-0553cd1fc9f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_4a6a8b9f-2587-a775-3a32-ea74c3990c93" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_16e1702c-a83e-ec54-eba0-0553cd1fc9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_bff9a3a6-6cf8-afd0-e5c9-93dd0bbe72a6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_fa34cbb7-0c80-cfcd-6ede-8aa147c28256" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_bff9a3a6-6cf8-afd0-e5c9-93dd0bbe72a6" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_fa34cbb7-0c80-cfcd-6ede-8aa147c28256" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_09e2271f-d4e2-fbba-a996-a55b7743629c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_bff9a3a6-6cf8-afd0-e5c9-93dd0bbe72a6" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_09e2271f-d4e2-fbba-a996-a55b7743629c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_27d58b06-bbf3-51a8-3496-62a350933926" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_27d58b06-bbf3-51a8-3496-62a350933926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_860833f9-954b-9e94-c46d-3d790d9ff44f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_860833f9-954b-9e94-c46d-3d790d9ff44f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_2b171e1e-ad4f-f8c0-35b1-e0c53d395c8a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_2b171e1e-ad4f-f8c0-35b1-e0c53d395c8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_3b861596-2218-d252-9702-953cfb6bbde5" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_3b861596-2218-d252-9702-953cfb6bbde5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_d646b5f0-f1b7-d843-b73d-7a0dc382293e" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_d646b5f0-f1b7-d843-b73d-7a0dc382293e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_b92955ce-1d82-f524-2f3c-6290ef54ee26" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_b92955ce-1d82-f524-2f3c-6290ef54ee26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b91d2f01-85c2-f9fb-3250-26a4b1b39c5e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingLeaseLiability_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_d18f979c-644d-9e92-9e89-21cfd1312948" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetailsCalc2" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3C1BE15243292CDC529355EEFCAE1857_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3C1BE15243292CDC529355EEFCAE1857_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3C1BE15243292CDC529355EEFCAE1857_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3C1BE15243292CDC529355EEFCAE1857_07815ffa-512a-3133-dcbb-38e09d2626b9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_3C1BE15243292CDC529355EEFCAE1857_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_3C1BE15243292CDC529355EEFCAE1857_1c2cd15f-6a97-015f-b126-1d0a0750698b" xlink:to="loc_us-gaap_OperatingLeaseLiability_3C1BE15243292CDC529355EEFCAE1857_b983c2d8-8318-0a7e-1a5c-6ab2933f7be5" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_OperatingLeaseCost_88d5ba82-39dd-36ed-37fe-92977ff632df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_VariableLeaseCost_3df88f41-850d-02ae-dd0b-ab0215935a95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_8dd289f8-9bc4-5eca-8aa4-41500fe587c8" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_ac3b1889-9651-365f-e4fc-e6474385db69" xlink:to="loc_us-gaap_SubleaseIncome_8dd289f8-9bc4-5eca-8aa4-41500fe587c8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_1417330d-29f9-c4e9-abb6-2898d623f603" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_DebtCurrent_1417330d-29f9-c4e9-abb6-2898d623f603" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_AccountsPayableCurrent_9c889623-7b4f-c89a-bbb3-2bc9fb9ad9f5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_0fa83cdd-5834-2522-0bdf-478d9b332d1d" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_DividendsPayableCurrent_0fa83cdd-5834-2522-0bdf-478d9b332d1d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_TaxesPayableCurrent_47896491-55c6-1eb9-d2fd-7a2bb89405ec" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_a2b836a7-cc87-0e4f-38a0-c91a29535622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_ebb4c1f8-b5df-aab0-ee90-1e91fd21cf92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_30dca50d-a7bd-cff0-949a-3d7ae869c50d" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_b6b21d1b-243c-e4c1-6309-f66e30ef6420" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_c6e48a52-cc78-9c88-a61e-8e078196d298" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_c6e48a52-cc78-9c88-a61e-8e078196d298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_c98aa634-a425-95e7-1d37-67e0989fceff" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_c98aa634-a425-95e7-1d37-67e0989fceff" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_64993a75-9b0c-349a-1011-cc5a81c58412" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_5f6532e8-9e6d-0a09-4d87-b823fe099192" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_5f6532e8-9e6d-0a09-4d87-b823fe099192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_44863786-cbc4-bac4-e070-0a1f19314584" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_8c850143-cd0c-0f85-9038-e19d8c4f7808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_CommitmentsAndContingencies_4d934b0d-59bc-ae5c-ffb9-b6ced82ff9f8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_d7f1ad03-6ed4-706a-15fc-eae794dee33a" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_PreferredStockValue_928e20af-e738-4a2d-05b8-cf88fed11953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_CommonStockValue_f05ab245-2bd1-7865-e7ed-1461a5a6155f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AdditionalPaidInCapital_3d5a0ca6-0f59-67e6-adb5-6aecd22b693b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_TreasuryStockValue_e6069c8d-dfec-45ff-4b3f-643d125d5b29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_62305d8f-d807-0fe8-d0ab-f2c2b3d03011" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_4b9904d8-8624-0dbb-a949-29ff2cf808a8" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_988c1346-b444-a867-fe80-f3aec1443d54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_2605fa18-bbd8-c7d7-35fc-aace43a8c019" xlink:to="loc_us-gaap_MinorityInterest_3070eb63-b0f5-1f18-a22f-cc54a94922d9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_1de780cc-9607-daa3-0bed-03c88ae94769" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_dd2cbe99-77d2-db20-3c91-750589881c79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_1c308ed5-b9e5-831c-28d9-d268508e6d83" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_pfe_OtherTaxAssetsCurrent_1c308ed5-b9e5-831c-28d9-d268508e6d83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_OtherAssetsCurrent_7832082e-fa39-48cc-a655-249c101debf9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_62bb35f3-f63d-e559-6d31-a62336122a76" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_0b3bd361-d592-2906-279e-2682647fdd27" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_62bb35f3-f63d-e559-6d31-a62336122a76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_Goodwill_37b440e2-656c-b624-0688-b7cf681bf981" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_0117f557-5521-a55e-9903-d2684d24f78a" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_0117f557-5521-a55e-9903-d2684d24f78a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_ed3f9f23-c931-eaa1-1c75-4ff1fe970e7d" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_EquityMethodInvestments_ed3f9f23-c931-eaa1-1c75-4ff1fe970e7d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_32c8bdb3-bbb3-2788-4593-d2684c6c8cf2" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_32c8bdb3-bbb3-2788-4593-d2684c6c8cf2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_4b18762d-3b2e-865d-42c0-d2684c124951" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_4b18762d-3b2e-865d-42c0-d2684c124951" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_34775225-2d8d-1841-a203-2e94d6908328" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_34775225-2d8d-1841-a203-2e94d6908328" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_D39D2BC7C6ACB2350B9413643C17BA2C" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_D39D2BC7C6ACB2350B9413643C17BA2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3421bed6-296e-da4e-f0e9-a2a8fa1f6d19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_ShareBasedCompensation_f0b9d825-b0b9-37fd-4d25-9294a8598890" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_0b001d5e-61b8-2861-23bb-d2684cd05e12" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_0b001d5e-61b8-2861-23bb-d2684cd05e12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_269710de-43ea-f1a2-1ab7-8a2fad8bcd72" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="locator" />
    <link:calculationArc order="10" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_09b7b41a-f5a1-c45e-d61b-846fff462802" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="locator" />
    <link:calculationArc order="11" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2b34f8d-2445-12ee-2c68-fa0c5409d5e0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5550ae9d-a6e2-fc35-fc50-54521e2bfb5d" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_5550ae9d-a6e2-fc35-fc50-54521e2bfb5d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ac24895d-2fd2-0db7-5c56-26fa8eb18f8f" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_ac24895d-2fd2-0db7-5c56-26fa8eb18f8f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="locator" />
    <link:calculationArc order="14" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_d7de2883-fea4-6e7c-2c8b-7fee9aa34369" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_92f23ce5-33e4-4abb-4bef-afc6704847bc" xlink:type="locator" />
    <link:calculationArc order="15" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_ce0d7b63-a366-bc9b-79e1-780981e428fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_92f23ce5-33e4-4abb-4bef-afc6704847bc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_0f8df60b-841f-6df5-83c3-e4049d366459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_64589f54-c78b-3b4d-2741-1fc26cfb953a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_64589f54-c78b-3b4d-2741-1fc26cfb953a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_99f7edad-bcea-333c-81ff-f4c7e91cfd0f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_99f7edad-bcea-333c-81ff-f4c7e91cfd0f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_b3c5a846-48bb-91c4-f1e4-895395ec9c31" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_b3c5a846-48bb-91c4-f1e4-895395ec9c31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f6cd34b6-f238-abf8-9b6c-ac9d5fcdd140" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_f6cd34b6-f238-abf8-9b6c-ac9d5fcdd140" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_cf5274cf-812b-0cd7-5862-564c4f63c703" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_cf5274cf-812b-0cd7-5862-564c4f63c703" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_6abb14d9-7978-302d-af6b-dbfc88f76bf2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="locator" />
    <link:calculationArc order="8" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_b5cf64b6-8899-5a9a-328a-4f0a312ae378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f07a806-a2da-6d18-a7a9-d734fad1f3b0" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_fabd36b2-0d2f-8f1e-b9c9-718513456b78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_f0d35d24-90f5-d279-b8ea-08a17fdbe9e3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_f0d35d24-90f5-d279-b8ea-08a17fdbe9e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_48142928-1201-6f98-3e39-a53c35d5b675" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_48142928-1201-6f98-3e39-a53c35d5b675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_4294d8d6-8977-ce88-219c-2f65a2ad3dc6" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_4294d8d6-8977-ce88-219c-2f65a2ad3dc6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_50c96d39-6558-6bd8-b3d6-7ed1c558807e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3f804297-91a1-3939-541d-a39b6288c9f9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_945d59d5-e35a-1527-d0e5-63c8ba4232c5" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_945d59d5-e35a-1527-d0e5-63c8ba4232c5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_3ddd0290-3d1a-2e62-5161-428d280d3fb6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_f73833cd-0af4-c4d5-a7c4-1151269f1da3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_1efd93c0-bb90-2a64-a997-3a70afaa3faa" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_f58bb86e-8b52-c30f-7b3a-554d3e73586f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_50231013-f048-89e7-0e20-ba139224c5f7" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6bd7c3da-2a5b-cbc6-d33a-bb097a23c2f6" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_93a02e96-cdec-754d-5e19-4ab1e0bf759a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_93a02e96-cdec-754d-5e19-4ab1e0bf759a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_10f4e187-d236-b8a3-b3b6-e65153fa455e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_93a02e96-cdec-754d-5e19-4ab1e0bf759a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_10f4e187-d236-b8a3-b3b6-e65153fa455e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_65b374a9-6ff6-b5ed-5992-2786a26be17c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_10f4e187-d236-b8a3-b3b6-e65153fa455e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_65b374a9-6ff6-b5ed-5992-2786a26be17c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_5fcfde8a-e645-4980-965d-9f9e9eb2f2f6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_10f4e187-d236-b8a3-b3b6-e65153fa455e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_5fcfde8a-e645-4980-965d-9f9e9eb2f2f6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_ddb4313e-da6d-29f2-0c3f-7461f26cd14a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_93a02e96-cdec-754d-5e19-4ab1e0bf759a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_ddb4313e-da6d-29f2-0c3f-7461f26cd14a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ba9dac0f-18cb-f0f6-4935-46f11c5e9c68" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_ddb4313e-da6d-29f2-0c3f-7461f26cd14a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_ba9dac0f-18cb-f0f6-4935-46f11c5e9c68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_dd6d12df-3608-8e4d-953c-46de57a370da" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_ddb4313e-da6d-29f2-0c3f-7461f26cd14a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_dd6d12df-3608-8e4d-953c-46de57a370da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_c4ac2521-eb1a-fa8f-6a84-e79d4c95e1da" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_93a02e96-cdec-754d-5e19-4ab1e0bf759a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_c4ac2521-eb1a-fa8f-6a84-e79d4c95e1da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_0d4250f9-c67e-da85-5b79-7bf5ce074ba3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_c4ac2521-eb1a-fa8f-6a84-e79d4c95e1da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_0d4250f9-c67e-da85-5b79-7bf5ce074ba3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_05203cd1-680d-aa15-aec2-1af403c987fb" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_c4ac2521-eb1a-fa8f-6a84-e79d4c95e1da" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_05203cd1-680d-aa15-aec2-1af403c987fb" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_36a33ea4-16e0-0f7d-e17c-d2684e0e1aef" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_c4ac2521-eb1a-fa8f-6a84-e79d4c95e1da" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_36a33ea4-16e0-0f7d-e17c-d2684e0e1aef" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_adf09d76-94f3-79db-449c-2c51cd08c316" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_93a02e96-cdec-754d-5e19-4ab1e0bf759a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_adf09d76-94f3-79db-449c-2c51cd08c316" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_edb2e7ee-0cab-645e-570b-ea86bdabd263" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_adf09d76-94f3-79db-449c-2c51cd08c316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_edb2e7ee-0cab-645e-570b-ea86bdabd263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_383f7254-a3d3-dadf-0628-aab1174b281a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_adf09d76-94f3-79db-449c-2c51cd08c316" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_383f7254-a3d3-dadf-0628-aab1174b281a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_e48ba4e7-6fc2-c85e-e59c-d26850503e7a" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_adf09d76-94f3-79db-449c-2c51cd08c316" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_e48ba4e7-6fc2-c85e-e59c-d26850503e7a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9133b20c-cd87-4b1d-0ec1-d2684e9a2ed7" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_adf09d76-94f3-79db-449c-2c51cd08c316" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_9133b20c-cd87-4b1d-0ec1-d2684e9a2ed7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_72e990d1-994f-eb9d-32ca-ee501d571e74" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_93a02e96-cdec-754d-5e19-4ab1e0bf759a" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_72e990d1-994f-eb9d-32ca-ee501d571e74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_717b328c-4a7d-76cc-1b08-9481bb101416" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_72e990d1-994f-eb9d-32ca-ee501d571e74" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_717b328c-4a7d-76cc-1b08-9481bb101416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c54e0422-131b-da76-180c-0003dbfea189" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_72e990d1-994f-eb9d-32ca-ee501d571e74" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_c54e0422-131b-da76-180c-0003dbfea189" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_8a3577d2-2d75-b75e-45a8-d2684c6062d5" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_72e990d1-994f-eb9d-32ca-ee501d571e74" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_8a3577d2-2d75-b75e-45a8-d2684c6062d5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_ab37d18a-105b-360c-bc32-d2684ea9a1ee" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_72e990d1-994f-eb9d-32ca-ee501d571e74" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_ab37d18a-105b-360c-bc32-d2684ea9a1ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_1ed26a82-dd4b-490f-d61a-b04c5d44793e" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_c4761fa8-dc2a-e270-4b5c-921deca83ad0" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_5c8b3520-1ca2-0a91-0912-70d62831826c" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_51cce957-7438-47fa-f5b3-33f2b5e56016" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_a0c542a3-925c-dbca-caae-b45f1a51036d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9296eff8-e0bf-16cc-fa86-f1b0968a0982" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_a0c542a3-925c-dbca-caae-b45f1a51036d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_9296eff8-e0bf-16cc-fa86-f1b0968a0982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_676e5c7d-beab-c0d8-be00-bb5a9211e90b" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareDiluted_a0c542a3-925c-dbca-caae-b45f1a51036d" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_676e5c7d-beab-c0d8-be00-bb5a9211e90b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f42c682-c9cf-1de0-1230-a353dc469675" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f42c682-c9cf-1de0-1230-a353dc469675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f42c682-c9cf-1de0-1230-a353dc469675" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b88c060f-09b3-b6c0-4cdb-a77cb8e75ec8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_3549c1c0-2f2a-e44b-026b-b4042153e489" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_89fcc343-1933-1e77-588e-68d1c2f1a04f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9edac52b-cd64-b6b8-351b-74213aa494c3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_44da3177-22d1-d445-53f8-d2684efa4f43" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_44da3177-22d1-d445-53f8-d2684efa4f43" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8c79b8d3-cde3-d751-64bc-d2684cb1a84a" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8c79b8d3-cde3-d751-64bc-d2684cb1a84a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_b219cf25-6261-971f-a902-1349d7e826c0" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_b219cf25-6261-971f-a902-1349d7e826c0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f42c682-c9cf-1de0-1230-a353dc469675" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9df24e1e-4f19-c5c7-c707-5fdac881a2b1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ProfitLoss_8b582348-a62e-cdfb-bc53-d5894b42e091" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9df24e1e-4f19-c5c7-c707-5fdac881a2b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_bef197d0-a606-44b8-a66d-f55118c659d3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9df24e1e-4f19-c5c7-c707-5fdac881a2b1" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_bef197d0-a606-44b8-a66d-f55118c659d3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_df7441a2-8870-448a-674e-b9ddb0cc775d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9df24e1e-4f19-c5c7-c707-5fdac881a2b1" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_df7441a2-8870-448a-674e-b9ddb0cc775d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_e170ce1e-c3a8-e8ee-88b0-37e8dd7b1d11" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_a3a6becb-cb5c-3f3c-51b9-6edd8011ed69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_43102e24-b009-a823-41c0-3a851b53c822" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b083e9ce-7a31-bc71-2302-34551814cc46" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_43102e24-b009-a823-41c0-3a851b53c822" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_b083e9ce-7a31-bc71-2302-34551814cc46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_144f1196-7804-6573-e88d-e1f54b569762" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EarningsPerShareBasic_43102e24-b009-a823-41c0-3a851b53c822" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_144f1196-7804-6573-e88d-e1f54b569762" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90e25e8e-b555-9209-062f-62d312826e2f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d9787bcc-e26a-e14e-b8ed-b82e68531cea" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90e25e8e-b555-9209-062f-62d312826e2f" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_d9787bcc-e26a-e14e-b8ed-b82e68531cea" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_1ac2c876-1d31-6fc6-edef-d2684bdb99b5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_90e25e8e-b555-9209-062f-62d312826e2f" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_1ac2c876-1d31-6fc6-edef-d2684bdb99b5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_1c82b717-d4fc-67dd-e957-d2684d157059" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_1c82b717-d4fc-67dd-e957-d2684d157059" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_b3925fb6-ca66-530c-ef66-cfcec5b7fe7d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_1c82b717-d4fc-67dd-e957-d2684d157059" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_b3925fb6-ca66-530c-ef66-cfcec5b7fe7d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f42c682-c9cf-1de0-1230-a353dc469675" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_b3925fb6-ca66-530c-ef66-cfcec5b7fe7d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_1f42c682-c9cf-1de0-1230-a353dc469675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_8b67d804-20c1-81c2-c01d-cac3dbd9c326" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_b3925fb6-ca66-530c-ef66-cfcec5b7fe7d" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_8b67d804-20c1-81c2-c01d-cac3dbd9c326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_a6a09a54-2128-96d8-30c5-702de94ed40b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_1c82b717-d4fc-67dd-e957-d2684d157059" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_a6a09a54-2128-96d8-30c5-702de94ed40b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9df24e1e-4f19-c5c7-c707-5fdac881a2b1" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_976d3954-a813-87e0-3f10-9f88f38c5886" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_9df24e1e-4f19-c5c7-c707-5fdac881a2b1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_fbdbb03d-8583-701f-d6e2-69f8229c6051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c9389ea-1fbb-7e45-ce1f-5a1d89572c0d" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_72ad9ebf-e829-cc37-8382-628e47c585ab" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetailsCalc2" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/Equity" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/EquityTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_c498d065-e002-c8b0-aba8-6aaec8302ba7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_c2051fc9-6e3c-3055-fde4-401ea0dbd57b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_c498d065-e002-c8b0-aba8-6aaec8302ba7" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_c2051fc9-6e3c-3055-fde4-401ea0dbd57b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_af83e23a-3410-1fdc-046a-00c6a71a25d6" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DerivativeLiabilities_c498d065-e002-c8b0-aba8-6aaec8302ba7" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_af83e23a-3410-1fdc-046a-00c6a71a25d6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_a71447f4-81d2-2522-8d9a-3088ad787f20" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_a71447f4-81d2-2522-8d9a-3088ad787f20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_c246b056-b56c-50f5-1400-81f56167e45a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_bd8545de-cfc2-6f31-bff6-ed0d4012c357" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_c246b056-b56c-50f5-1400-81f56167e45a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_8ca03071-424a-3e12-972c-d2684d035357" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_8ca03071-424a-3e12-972c-d2684d035357" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_8ca03071-424a-3e12-972c-d2684d035357" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_8ca03071-424a-3e12-972c-d2684d035357" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_280a1859-524b-2b72-b4d6-98ab38afc46a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_280a1859-524b-2b72-b4d6-98ab38afc46a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_af847b70-7c2f-f9cc-674f-d2684ee28dc1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_af847b70-7c2f-f9cc-674f-d2684ee28dc1" xlink:type="arc" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_af847b70-7c2f-f9cc-674f-d2684ee28dc1" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_af847b70-7c2f-f9cc-674f-d2684ee28dc1" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="arc" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_17ef3f41-42f7-52c0-cba1-93e7e0e1116a" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_a71447f4-81d2-2522-8d9a-3088ad787f20" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_9fbaf9cb-468f-3b91-9cf2-18d26152173d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_a23ab896-034e-8e96-1a84-63ffb40e496e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_27940abc-0cb4-eab4-8ef0-df4a4c0bb415" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_d870856f-841f-c3d0-a313-ca9d525216a8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_6a2a51c8-a80d-af5e-4dc1-d2eeba9d310c" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_049146be-061e-02e4-be08-d2684f0a102f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_e562c48b-3e99-2c57-8e96-c3b81056b58c" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_049146be-061e-02e4-be08-d2684f0a102f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_68681ceb-ee59-4c23-4b8e-33a166cc5b4e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_912d08f8-1726-bfae-7790-02952b46ab84" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_68681ceb-ee59-4c23-4b8e-33a166cc5b4e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_912d08f8-1726-bfae-7790-02952b46ab84" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_20c7522f-3e17-8a70-2997-1273217c0ef3" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_68681ceb-ee59-4c23-4b8e-33a166cc5b4e" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_20c7522f-3e17-8a70-2997-1273217c0ef3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_13988cfb-77d2-c4e3-c448-d2684e11992a" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_HeldToMaturitySecurities_68681ceb-ee59-4c23-4b8e-33a166cc5b4e" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_13988cfb-77d2-c4e3-c448-d2684e11992a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_9fc6d82c-8b3a-f73f-4040-d2684e22e52b" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_1a441cd4-8682-b29f-bfcb-d2684e472d25" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_9fc6d82c-8b3a-f73f-4040-d2684e22e52b" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_1a441cd4-8682-b29f-bfcb-d2684e472d25" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_44381ed2-88fe-b87e-b807-d2684e5fbe19" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_9fc6d82c-8b3a-f73f-4040-d2684e22e52b" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_44381ed2-88fe-b87e-b807-d2684e5fbe19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1f68fac9-3bca-1704-d123-07c770da2894" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_9fc6d82c-8b3a-f73f-4040-d2684e22e52b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1f68fac9-3bca-1704-d123-07c770da2894" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_f58cdd58-ff91-98c1-35e0-767a98cb995c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_49114a85-ad4d-5281-8cd5-2f6823af0c64" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_b5390da0-4b10-f083-5d88-d4657fa5b028" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_cb892318-6544-5080-d9bd-d2684b98f46e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_cb892318-6544-5080-d9bd-d2684b98f46e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b203031c-861c-8c5e-65f5-f1b72d84dfd1" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b203031c-861c-8c5e-65f5-f1b72d84dfd1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_e71f21c2-86c0-1e26-002e-d1aacd43460a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_aa2e73c1-d03e-7f76-3502-7a650f99607c" xlink:to="loc_us-gaap_OtherLongTermDebt_e71f21c2-86c0-1e26-002e-d1aacd43460a" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_1417330d-29f9-c4e9-abb6-2898d623f603" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_145c8590-6688-5fc7-5ffa-d2684f9d9c99" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_1417330d-29f9-c4e9-abb6-2898d623f603" xlink:to="loc_pfe_ShorttermDebtGross_145c8590-6688-5fc7-5ffa-d2684f9d9c99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_fbcb0c9d-15b6-cf40-b4c4-19f4d627517f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_145c8590-6688-5fc7-5ffa-d2684f9d9c99" xlink:to="loc_us-gaap_CommercialPaper_fbcb0c9d-15b6-cf40-b4c4-19f4d627517f" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_1395161c-a694-4bdd-6991-d268506923b4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_145c8590-6688-5fc7-5ffa-d2684f9d9c99" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_1395161c-a694-4bdd-6991-d268506923b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_9f9b15e1-dc80-0ddd-b9a0-9d392df98250" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_ShorttermDebtGross_145c8590-6688-5fc7-5ffa-d2684f9d9c99" xlink:to="loc_us-gaap_OtherShortTermBorrowings_9f9b15e1-dc80-0ddd-b9a0-9d392df98250" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_cb892318-6544-5080-d9bd-d2684b98f46e" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_1417330d-29f9-c4e9-abb6-2898d623f603" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_cb892318-6544-5080-d9bd-d2684b98f46e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b203031c-861c-8c5e-65f5-f1b72d84dfd1" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DebtCurrent_1417330d-29f9-c4e9-abb6-2898d623f603" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_b203031c-861c-8c5e-65f5-f1b72d84dfd1" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_c88e6350-e26e-969b-2f36-fb6881edab88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_e2b10c93-5dbd-d345-d7e4-6144b8287c24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_d00419ef-8741-763f-231b-d146540cdba8" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ShortTermInvestments_19ee0686-4389-5dfa-deaf-cddb58597060" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_d00419ef-8741-763f-231b-d146540cdba8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsAndEquityMethodInvestments" xlink:label="loc_pfe_LongtermInvestmentsAndEquityMethodInvestments_9673A68975133A61CB61F68B4C411F8E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsAndEquityMethodInvestments_9673A68975133A61CB61F68B4C411F8E" xlink:to="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNINoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent_257fa379-f250-6eff-7bfc-d2684f526f71" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:to="loc_pfe_EquitySecuritiesFVNINoncurrent_257fa379-f250-6eff-7bfc-d2684f526f71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_4f186fae-5cc1-820d-f772-86ccd7a87074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_72feffc1-ab53-750f-d84a-118c7ca54af1" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_72feffc1-ab53-750f-d84a-118c7ca54af1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrivateEquityInvestments" xlink:label="loc_pfe_PrivateEquityInvestments_c8109463-717b-3da2-5ad8-d2684ca3b95a" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermInvestments_81aff716-bdf5-d622-e5a1-514839b6b4b2" xlink:to="loc_pfe_PrivateEquityInvestments_c8109463-717b-3da2-5ad8-d2684ca3b95a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_ed3f9f23-c931-eaa1-1c75-4ff1fe970e7d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_LongtermInvestmentsAndEquityMethodInvestments_9673A68975133A61CB61F68B4C411F8E" xlink:to="loc_us-gaap_EquityMethodInvestments_ed3f9f23-c931-eaa1-1c75-4ff1fe970e7d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_e87bd6a3-2026-a858-f41a-bc281e5d594b" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_65140cb5-12a8-2030-97e2-fa6daceadf40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_8889606b-88fa-2d5e-3fb9-238bccdf9597" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_e11e8784-8f2d-ca3c-a9e8-a8115d54520c" xlink:type="arc" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_a32ca153-2a77-c1bc-f506-c7b61720c625" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_cb3c969e-ecfd-d862-86d5-39c41aa964cb" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/Insurance" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_2dee2782-8369-5635-44bf-51d0e8aa0f1e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_f4920785-d6c0-a217-e01a-0e0ef529643a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c3595f04-2335-d8d9-6a42-7d0f781ae505" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_cc720f44-4c90-5acc-2e7e-b88e80f2af28" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_c3595f04-2335-d8d9-6a42-7d0f781ae505" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_42874e20-b7e0-ab3d-628e-9e60cdbaf74b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_42874e20-b7e0-ab3d-628e-9e60cdbaf74b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_42874e20-b7e0-ab3d-628e-9e60cdbaf74b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_d1f3a8d2-a9eb-dfaa-d8d8-e9a2b8c4ce0c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_42874e20-b7e0-ab3d-628e-9e60cdbaf74b" xlink:to="loc_us-gaap_InterestExpense_16e9f6a6-5524-a7b1-7e7c-73ee97610ec6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_73284654-525c-3153-2405-f28bca71c606" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_73284654-525c-3153-2405-f28bca71c606" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_73cabc52-c416-1a4a-0557-7c2672849759" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_73cabc52-c416-1a4a-0557-7c2672849759" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_f3206833-d43a-1764-365c-1606167229ee" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_5cbc99ca-a019-a736-9b47-eaa733c2e9c2" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_5cbc99ca-a019-a736-9b47-eaa733c2e9c2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_86dd696a-0a86-c0b5-2063-d2684cd8715c" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_86dd696a-0a86-c0b5-2063-d2684cd8715c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_ed24fa2e-e2c1-1cd8-1a8f-4a232ae4aeb2" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_ed24fa2e-e2c1-1cd8-1a8f-4a232ae4aeb2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_de4daba6-07da-9e14-df22-fdf11128e44e" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_de4daba6-07da-9e14-df22-fdf11128e44e" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_b5495221-c933-5c88-514e-d2731414949c" xlink:type="locator" />
    <link:calculationArc order="9" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_AssetImpairmentCharges_b5495221-c933-5c88-514e-d2731414949c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d385978f-69ad-b055-896a-51e9bbc23743" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d385978f-69ad-b055-896a-51e9bbc23743" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_cc193170-66fd-6cd7-2c53-d2684c529306" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_cc193170-66fd-6cd7-2c53-d2684c529306" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessAlignmentCosts" xlink:label="loc_pfe_BusinessAlignmentCosts_20D7B74F2C172AE993204B66B2D9088E" xlink:type="locator" />
    <link:calculationArc order="12" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_pfe_BusinessAlignmentCosts_20D7B74F2C172AE993204B66B2D9088E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_801248B1104FE0D8007B7A78F4928AA3" xlink:type="locator" />
    <link:calculationArc order="13" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7a3a9730-2927-590e-4e76-6aeb4157256e" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_801248B1104FE0D8007B7A78F4928AA3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsFairValueDisclosure" xlink:label="loc_pfe_IntangibleAssetsFairValueDisclosure_ca244b49-b6f7-a85d-152f-d2685103cf7a" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_591f706d-3cdf-3013-5505-0c1e7db3ff71" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IntangibleAssetsFairValueDisclosure_ca244b49-b6f7-a85d-152f-d2685103cf7a" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_591f706d-3cdf-3013-5505-0c1e7db3ff71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_9c6b7029-752c-51cc-ca4f-632bec9d57bf" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_IntangibleAssetsFairValueDisclosure_ca244b49-b6f7-a85d-152f-d2685103cf7a" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_9c6b7029-752c-51cc-ca4f-632bec9d57bf" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_4dee77cc-07f5-c8ca-7639-f1dff8a9cccf" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_d1549ac3-1f52-2077-1674-9a84c40ffbb0" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_4dee77cc-07f5-c8ca-7639-f1dff8a9cccf" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_d1549ac3-1f52-2077-1674-9a84c40ffbb0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_ceaf7936-a536-0088-5fa0-9c8e7c706dec" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_4dee77cc-07f5-c8ca-7639-f1dff8a9cccf" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_ceaf7936-a536-0088-5fa0-9c8e7c706dec" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_c6c723d7-e9d1-db70-b81f-a29b45af6851" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_950e2000-4fae-d7e6-7286-3e38afff2fa4" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_c6c723d7-e9d1-db70-b81f-a29b45af6851" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_950e2000-4fae-d7e6-7286-3e38afff2fa4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_19b45600-146a-9c95-acaf-000acfa3ba0d" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_c6c723d7-e9d1-db70-b81f-a29b45af6851" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_19b45600-146a-9c95-acaf-000acfa3ba0d" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_7844f872-c1cf-e36b-b23f-b6ddec8c62e8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_7844f872-c1cf-e36b-b23f-b6ddec8c62e8" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_e14243b3-33a1-5459-a451-077ec8d3f8e3" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_e14243b3-33a1-5459-a451-077ec8d3f8e3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_08bfb8dd-9b96-b2df-e96d-3661802234df" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_08bfb8dd-9b96-b2df-e96d-3661802234df" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_65f7f8a8-89d5-6dc6-d223-452e554561e4" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_65f7f8a8-89d5-6dc6-d223-452e554561e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0d8fe3ab-8638-f17a-d512-2baaf0d8fce2" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_0d8fe3ab-8638-f17a-d512-2baaf0d8fce2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_6bc5232c-ca32-47e4-f9fd-2a89043cd46b" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_6bc5232c-ca32-47e4-f9fd-2a89043cd46b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_9909e15e-782f-ca0f-bbeb-723312cc1200" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_9909e15e-782f-ca0f-bbeb-723312cc1200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_f4ed49f6-0d68-1230-9ef2-0995b2444b8a" xlink:type="locator" />
    <link:calculationArc order="7" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_f4ed49f6-0d68-1230-9ef2-0995b2444b8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_d1ee60b8-4881-eb38-d344-87914ec338d2" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_d1ee60b8-4881-eb38-d344-87914ec338d2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_cabf789f-6ec6-1109-b829-dd6afa0261c8" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_7844f872-c1cf-e36b-b23f-b6ddec8c62e8" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_cabf789f-6ec6-1109-b829-dd6afa0261c8" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_03c8dcd1-fc7d-1caf-99fe-5edccee1c0fb" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_67fc7f3e-d62f-b42a-5539-a726e48a9426" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_03c8dcd1-fc7d-1caf-99fe-5edccee1c0fb" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_67fc7f3e-d62f-b42a-5539-a726e48a9426" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9cc42d15-a7a0-2267-301d-4a46d802a1f2" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_03c8dcd1-fc7d-1caf-99fe-5edccee1c0fb" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_9cc42d15-a7a0-2267-301d-4a46d802a1f2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_540758d9-5c85-d758-1cf1-4856b8f457a3" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_03c8dcd1-fc7d-1caf-99fe-5edccee1c0fb" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_540758d9-5c85-d758-1cf1-4856b8f457a3" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ba6fb524-25a2-9912-2ce3-daf35bbcf9c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a57e9aa7-191d-46c2-2e04-3fd2e411d7da" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ba6fb524-25a2-9912-2ce3-daf35bbcf9c3" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_a57e9aa7-191d-46c2-2e04-3fd2e411d7da" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1d5e04b8-b6a0-335a-2c79-60834f9a1f25" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_ba6fb524-25a2-9912-2ce3-daf35bbcf9c3" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_1d5e04b8-b6a0-335a-2c79-60834f9a1f25" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_94cd7971-9d17-1c6e-6642-d4d38fb682b6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_4246ec24-1a4c-19dd-57c9-32d4a8e0cbaa" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_7b7a3a8d-eb3d-0c85-68cc-b3d4d184ff23" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_1936482c-3eb0-a7c6-8d01-d2685035e0f1" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8c79b8d3-cde3-d751-64bc-d2684cb1a84a" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_1936482c-3eb0-a7c6-8d01-d2685035e0f1" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8c79b8d3-cde3-d751-64bc-d2684cb1a84a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_f555bf37-6b34-38c5-1f89-d26850ebc984" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8c79b8d3-cde3-d751-64bc-d2684cb1a84a" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_f555bf37-6b34-38c5-1f89-d26850ebc984" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_34da6843-588e-753b-e5dd-aa97b73fa286" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8c79b8d3-cde3-d751-64bc-d2684cb1a84a" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_34da6843-588e-753b-e5dd-aa97b73fa286" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_8c79b8d3-cde3-d751-64bc-d2684cb1a84a" xlink:to="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_602cce24-5ce6-992d-b143-c1204a3e69cf" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:to="loc_us-gaap_SeveranceCosts1_602cce24-5ce6-992d-b143-c1204a3e69cf" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_51b3c385-9f58-1967-5dec-d2684c2f42cd" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_51b3c385-9f58-1967-5dec-d2684c2f42cd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_7224cc1e-5bd4-30c4-2fd9-e9ae5baf7fef" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_RestructuringCharges_d445215a-3b87-2f11-ac68-3256f2f2966f" xlink:to="loc_us-gaap_BusinessExitCosts1_7224cc1e-5bd4-30c4-2fd9-e9ae5baf7fef" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_7500ebd7-cc51-e158-d410-d2684be9e472" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_1936482c-3eb0-a7c6-8d01-d2685035e0f1" xlink:to="loc_pfe_ImplementationCosts_7500ebd7-cc51-e158-d410-d2684be9e472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_a2870aec-09ac-c5a0-b074-a9e4586293f3" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_1936482c-3eb0-a7c6-8d01-d2685035e0f1" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_a2870aec-09ac-c5a0-b074-a9e4586293f3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_1936482c-3eb0-a7c6-8d01-d2685035e0f1" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_d77fe029-f23f-9e6c-6011-e5f759449bed" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_a335203f-3ccd-a617-8dc0-23ff64100eab" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_a335203f-3ccd-a617-8dc0-23ff64100eab" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9f3b1474-e7ae-6e2a-ddab-96b753d45d4b" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_120452df-d900-40f5-e99c-a8fd93010cf5" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_9f3b1474-e7ae-6e2a-ddab-96b753d45d4b" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="locator" />
    <link:calculationArc order="1" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_76823e13-ff55-7cd2-ec5d-7dac1fd75cd9" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_76823e13-ff55-7cd2-ec5d-7dac1fd75cd9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1ccc1eb-ffbd-3ad3-bc7a-09819cccad11" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_e1ccc1eb-ffbd-3ad3-bc7a-09819cccad11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_06fdd8fa-20aa-c385-b288-61c16515fae0" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_06fdd8fa-20aa-c385-b288-61c16515fae0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_9448801d-0ed4-ffaa-b87b-19d6c55aba31" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_9448801d-0ed4-ffaa-b87b-19d6c55aba31" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_3269b68e-0cd4-1561-3814-fe858340a4cd" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_3269b68e-0cd4-1561-3814-fe858340a4cd" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:label="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_fe085541-a2bb-e3d2-7926-801fc90d66b8" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_fe085541-a2bb-e3d2-7926-801fc90d66b8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:label="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_bb9eb506-9f09-19df-4ce6-801fcdb0261e" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_bb9eb506-9f09-19df-4ce6-801fcdb0261e" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:label="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_6171129a-037a-7e54-4f78-801fcc9d5c03" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_6171129a-037a-7e54-4f78-801fcc9d5c03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_a87b79d6-1ed8-a71d-1843-5c0769713f28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_040b2eac-0f1c-d62b-93e1-f93aef56dafc" xlink:type="locator" />
    <link:calculationArc order="10" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_040b2eac-0f1c-d62b-93e1-f93aef56dafc" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_3a5eb694-ff37-e546-59ac-ee71db551a0d" xlink:type="locator" />
    <link:calculationArc order="11" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_e54f6543-25d5-ceb9-ff71-ca6ba1b37623" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_3a5eb694-ff37-e546-59ac-ee71db551a0d" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_e6f5d9f5-2430-5e17-896c-5e4d69815366" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_55b78dfc-faa8-3c71-752a-e6857318d516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_f31cb66e-0de8-54fb-4788-53b3cde0ec2f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_29ebe8b5-ac00-5a10-4982-faaf28366a95" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_29ebe8b5-ac00-5a10-4982-faaf28366a95" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_3475d0a8-1430-70ae-52ae-447cd24b7e73" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_3475d0a8-1430-70ae-52ae-447cd24b7e73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5da8fd5a-89f1-3049-e781-200c2d180554" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5da8fd5a-89f1-3049-e781-200c2d180554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fee9ac69-74b7-a6ae-6ad8-e6860d7cdb9d" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:label="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_711a687d-6698-68a6-32a3-801fc6323a8a" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_711a687d-6698-68a6-32a3-801fc6323a8a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_c719ba59-db04-f478-be8c-f6e23ad15a09" xlink:type="locator" />
    <link:calculationArc order="6" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_c719ba59-db04-f478-be8c-f6e23ad15a09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_7b5330cc-8193-c814-bd66-50fd0d79ab5f" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_7b5330cc-8193-c814-bd66-50fd0d79ab5f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_4c5a1085-469a-cd6c-e26f-53287b62aa26" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_15e17ec2-d527-455f-b2cd-0be7f92a9fd5" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_4c5a1085-469a-cd6c-e26f-53287b62aa26" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3ce82195-ed3e-f261-3529-b3a868ecf6c4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_3ce82195-ed3e-f261-3529-b3a868ecf6c4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89ebd542-78ee-71d0-be95-65de1bb3ef82" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_489b61b6-7c39-240c-7f68-1c1675bca3b7" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_89ebd542-78ee-71d0-be95-65de1bb3ef82" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8feaf7d2-18e4-e500-3156-ff9a4033818b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8feaf7d2-18e4-e500-3156-ff9a4033818b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8feaf7d2-18e4-e500-3156-ff9a4033818b" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_dbb037c2-04c0-fa14-65e6-8ccd12d2a855" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8feaf7d2-18e4-e500-3156-ff9a4033818b" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_8caef893-a841-2be2-863f-e20b53026f02" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:label="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_39aece4d-45ce-0468-27ca-801fcebe3019" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_39aece4d-45ce-0468-27ca-801fcebe3019" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_39aece4d-45ce-0468-27ca-801fcebe3019" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_1007d9fe-6d83-c6c6-eef9-c29803b14ec7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_39aece4d-45ce-0468-27ca-801fcebe3019" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_7f37ab3b-992e-e1ba-f578-2c503524d7e4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_39aece4d-45ce-0468-27ca-801fcebe3019" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_db02e614-93e7-eddf-abe0-a58cca48e685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_39aece4d-45ce-0468-27ca-801fcebe3019" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_ca5c17e6-16a0-bee8-1413-d316d82a8942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_34775225-2d8d-1841-a203-2e94d6908328" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_666ca9f0-28f1-b21a-025e-36222808a6c3" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_34775225-2d8d-1841-a203-2e94d6908328" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_b83b53af-8bda-0ab2-e5b0-801fd008860d" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_34775225-2d8d-1841-a203-2e94d6908328" xlink:to="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_b83b53af-8bda-0ab2-e5b0-801fd008860d" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_6bc0b739-35b2-97b9-7fb9-801fc5ba409c" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_34775225-2d8d-1841-a203-2e94d6908328" xlink:to="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_6bc0b739-35b2-97b9-7fb9-801fc5ba409c" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended" />
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_5ef0c8c5-04c5-1c10-a59e-3eaa9cf923b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_ac4a8ca9-af9a-dc39-4649-ff7e9d7dc935" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_ac4a8ca9-af9a-dc39-4649-ff7e9d7dc935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_cb745973-9398-b1e8-0b84-89b40fb91052" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_7f1b47ec-bf33-9e4a-93c6-533c5b05a200" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_7f1b47ec-bf33-9e4a-93c6-533c5b05a200" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_a638ac53-8f6d-39c7-fdf8-801fd0a794b4" xlink:type="locator" />
    <link:calculationArc order="5" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_a638ac53-8f6d-39c7-fdf8-801fd0a794b4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="locator" />
    <link:calculationArc order="6" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_760e1cd1-b180-e0c4-17a8-eef24284a1cb" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_341c1cf5-2326-6a8c-7c27-801fd128afd4" xlink:type="locator" />
    <link:calculationArc order="7" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_341c1cf5-2326-6a8c-7c27-801fd128afd4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="locator" />
    <link:calculationArc order="8" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_c16a0eb3-02da-6ea0-91e7-3203372f71fd" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_1e672869-f645-c0d0-6967-f004dcbb1087" xlink:type="locator" />
    <link:calculationArc order="9" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_aa9fb8cf-e50d-6d5b-0236-a084fee29894" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_1e672869-f645-c0d0-6967-f004dcbb1087" xlink:type="arc" />
  </link:calculationLink>
  <link:calculationLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_d4907400-3f3d-c63c-8fd0-72082d8a40ca" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_d4907400-3f3d-c63c-8fd0-72082d8a40ca" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_76cb9588-5c04-98b6-e6d4-3ece0083561a" xlink:type="locator" />
    <link:calculationArc order="2" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_76cb9588-5c04-98b6-e6d4-3ece0083561a" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_f62e140b-5057-d4ce-e6a8-7e542303c92c" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_76cb9588-5c04-98b6-e6d4-3ece0083561a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_f62e140b-5057-d4ce-e6a8-7e542303c92c" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_591a1e0a-b08b-298c-5481-5683f215978a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_76cb9588-5c04-98b6-e6d4-3ece0083561a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_591a1e0a-b08b-298c-5481-5683f215978a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_c6e963a2-9e2d-db18-14f0-d2684bf920e1" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_76cb9588-5c04-98b6-e6d4-3ece0083561a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_c6e963a2-9e2d-db18-14f0-d2684bf920e1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_89ab4424-c682-dfd3-2dd6-f3b69eaac005" xlink:type="locator" />
    <link:calculationArc order="3" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_89ab4424-c682-dfd3-2dd6-f3b69eaac005" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b8ef4814-1b76-0342-9351-7f079381cc1f" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_89ab4424-c682-dfd3-2dd6-f3b69eaac005" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_b8ef4814-1b76-0342-9351-7f079381cc1f" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_cfbcfdf1-88f8-5111-04af-e52617367bf1" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_89ab4424-c682-dfd3-2dd6-f3b69eaac005" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_cfbcfdf1-88f8-5111-04af-e52617367bf1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_22e7198d-a521-897b-c73d-d268505fcb66" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_89ab4424-c682-dfd3-2dd6-f3b69eaac005" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_22e7198d-a521-897b-c73d-d268505fcb66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_a56cf889-084e-0bd3-009a-d2684e683428" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_a56cf889-084e-0bd3-009a-d2684e683428" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_5ac22884-77ec-29db-ccc5-e3c0407e8312" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_a56cf889-084e-0bd3-009a-d2684e683428" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_5ac22884-77ec-29db-ccc5-e3c0407e8312" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_cce75d20-ef6b-d3f2-a59e-9b5e38168b68" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_a56cf889-084e-0bd3-009a-d2684e683428" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_cce75d20-ef6b-d3f2-a59e-9b5e38168b68" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_67718c12-8803-d331-7c10-d2684eaf269b" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_a56cf889-084e-0bd3-009a-d2684e683428" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_67718c12-8803-d331-7c10-d2684eaf269b" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_da9d7b34-acd7-b59c-e349-d2684ca65c21" xlink:type="locator" />
    <link:calculationArc order="4" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_a56cf889-084e-0bd3-009a-d2684e683428" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_da9d7b34-acd7-b59c-e349-d2684ca65c21" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_f36f69da-c1a3-b52c-dca0-d2684e2d52e5" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_a56cf889-084e-0bd3-009a-d2684e683428" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_f36f69da-c1a3-b52c-dca0-d2684e2d52e5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_1eb190d0-b98b-9b34-015c-414aee95189a" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_02ee5514-cc7d-0d55-8862-28a865eecb19" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_1eb190d0-b98b-9b34-015c-414aee95189a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_24736004-5a5d-98f2-161f-d2684dc5626b" xlink:type="locator" />
    <link:calculationArc order="1" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_1eb190d0-b98b-9b34-015c-414aee95189a" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_24736004-5a5d-98f2-161f-d2684dc5626b" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_7868ce16-24c7-a9b4-28e6-bf5dff0f950a" xlink:type="locator" />
    <link:calculationArc order="2" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_1eb190d0-b98b-9b34-015c-414aee95189a" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_7868ce16-24c7-a9b4-28e6-bf5dff0f950a" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_fcd78a80-f6bb-969c-2a02-d2684e35d5df" xlink:type="locator" />
    <link:calculationArc order="3" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_1eb190d0-b98b-9b34-015c-414aee95189a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_fcd78a80-f6bb-969c-2a02-d2684e35d5df" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_0fca573c-1495-cd9d-2af6-d26850a8f3f9" xlink:type="locator" />
    <link:calculationArc order="4" weight="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_1eb190d0-b98b-9b34-015c-414aee95189a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_0fca573c-1495-cd9d-2af6-d26850a8f3f9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_5366e618-e3e6-a105-600d-d2684c4baa0b" xlink:type="locator" />
    <link:calculationArc order="5" weight="-1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_1eb190d0-b98b-9b34-015c-414aee95189a" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_5366e618-e3e6-a105-600d-d2684c4baa0b" xlink:type="arc" />
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>15
<FILENAME>pfe-20191231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:href="pfe-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfEquity" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfIncome" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:href="pfe-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Equity" xlink:href="pfe-20191231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:href="pfe-20191231.xsd#EquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails" xlink:href="pfe-20191231.xsd#EquitySummaryOfCommonStockPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityTables" xlink:href="pfe-20191231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Insurance" xlink:href="pfe-20191231.xsd#Insurance" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20191231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetails" xlink:href="pfe-20191231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20191231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipment" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipmentTables" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPayments" xlink:href="pfe-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsStockOptionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTables" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20191231.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:href="pfe-20191231.xsd#TaxMattersDeferredTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:href="pfe-20191231.xsd#TaxMattersDeferredTaxesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:href="pfe-20191231.xsd#TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:href="pfe-20191231.xsd#TaxMattersNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails" xlink:href="pfe-20191231.xsd#TaxMattersProvisionForTaxesOnIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:href="pfe-20191231.xsd#TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="pfe-20191231.xsd#TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:href="pfe-20191231.xsd#TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20191231.xsd#TaxMattersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:href="pfe-20191231.xsd#TaxMattersTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:href="pfe-20191231.xsd#TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_EC2AF5A50C05615296D7E395F3C25184" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_EC2AF5A50C05615296D7E395F3C25184" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8A712C1C70404B1D0FA0E395F3C02CA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8A712C1C70404B1D0FA0E395F3C02CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8A712C1C70404B1D0FA0E395F3C02CA8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8A712C1C70404B1D0FA0E395F3C02CA8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201802Member_D9EFE580257C051BF6DEE395F3C1EB94" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479" xlink:to="loc_us-gaap_AccountingStandardsUpdate201802Member_D9EFE580257C051BF6DEE395F3C1EB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_679C22E8120D084AC747E395F3C1A360" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_679C22E8120D084AC747E395F3C1A360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_74BF0F20683F738035D6E395F3C1A553_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_679C22E8120D084AC747E395F3C1A360" xlink:to="loc_us-gaap_EquityComponentDomain_74BF0F20683F738035D6E395F3C1A553_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_74BF0F20683F738035D6E395F3C1A553" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_679C22E8120D084AC747E395F3C1A360" xlink:to="loc_us-gaap_EquityComponentDomain_74BF0F20683F738035D6E395F3C1A553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_74BF0F20683F738035D6E395F3C1A553" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27BE007A125556AFB617E395F3C2D487" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27BE007A125556AFB617E395F3C2D487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_21B0C2BD391EE047D8BEE395F3C24F5A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_21B0C2BD391EE047D8BEE395F3C24F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_E6A0911CA0E216FFEB2AE395F3C207CA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_E6A0911CA0E216FFEB2AE395F3C207CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_EC2AF5A50C05615296D7E395F3C25184" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:to="loc_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0DC5432585F61039CD5C17195915FF03" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_22A355DB1D98979012C3171959141563" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0DC5432585F61039CD5C17195915FF03" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_22A355DB1D98979012C3171959141563" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_367C08F7B262473FE53217195B31FD54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_22A355DB1D98979012C3171959141563" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_367C08F7B262473FE53217195B31FD54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E4E192296F41D6D700A417195B32A319_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_367C08F7B262473FE53217195B31FD54" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E4E192296F41D6D700A417195B32A319_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E4E192296F41D6D700A417195B32A319" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_367C08F7B262473FE53217195B31FD54" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E4E192296F41D6D700A417195B32A319" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_E8E5FFEC04BD4CAAA26D17195B9F10FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_E4E192296F41D6D700A417195B32A319" xlink:to="loc_pfe_GSKConsumerHealthcareMember_E8E5FFEC04BD4CAAA26D17195B9F10FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0DC5432585F61039CD5C17195915FF03" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0051BE0AD6FAB5EBDE0F17195AB9C12E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0DC5432585F61039CD5C17195915FF03" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0051BE0AD6FAB5EBDE0F17195AB9C12E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_21534EF005010F10CE5216E821D79CA3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_21534EF005010F10CE5216E821D79CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_21534EF005010F10CE5216E821D79CA3" xlink:to="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_21534EF005010F10CE5216E821D79CA3" xlink:to="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0BD4D7E944AF896E15E0D803C102A9A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0BD4D7E944AF896E15E0D803C102A9A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0BD4D7E944AF896E15E0D803C102A9A5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0BD4D7E944AF896E15E0D803C102A9A5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_82C9D450E69BFD0D3F60D803C1024587" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_82C9D450E69BFD0D3F60D803C1024587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2C5013818964B2816C27D803C102BA69" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:to="loc_us-gaap_LicensingAgreementsMember_2C5013818964B2816C27D803C102BA69" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:label="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_C7DC9ECF8F874CB41DD6D803C1035E15" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:to="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_C7DC9ECF8F874CB41DD6D803C1035E15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:label="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_CF78BC9349A5E7998432D803C103DFC3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:to="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_CF78BC9349A5E7998432D803C103DFC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7EFD86A02A1D4E63881DD803C1039C59" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7EFD86A02A1D4E63881DD803C1039C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54E894D8ADC2CA3D1B8CD803C1037E69_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7EFD86A02A1D4E63881DD803C1039C59" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54E894D8ADC2CA3D1B8CD803C1037E69_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54E894D8ADC2CA3D1B8CD803C1037E69" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7EFD86A02A1D4E63881DD803C1039C59" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54E894D8ADC2CA3D1B8CD803C1037E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1557B1536D46D58857EBD803C1048F1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54E894D8ADC2CA3D1B8CD803C1037E69" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1557B1536D46D58857EBD803C1048F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F293E43AF7A75F60F71FD803C104161D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F293E43AF7A75F60F71FD803C104161D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95A6A471FF7B171D2747D803C104F4ED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F293E43AF7A75F60F71FD803C104161D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95A6A471FF7B171D2747D803C104F4ED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95A6A471FF7B171D2747D803C104F4ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F293E43AF7A75F60F71FD803C104161D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95A6A471FF7B171D2747D803C104F4ED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_74F71F9590435E6DB8D1D803C10497D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95A6A471FF7B171D2747D803C104F4ED" xlink:to="loc_pfe_ArrayMember_74F71F9590435E6DB8D1D803C10497D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0675B19F47F1CE000EE7D803C105E49F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0675B19F47F1CE000EE7D803C105E49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5A75681BACBA9A12A7AD803C105DCD6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0675B19F47F1CE000EE7D803C105E49F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5A75681BACBA9A12A7AD803C105DCD6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5A75681BACBA9A12A7AD803C105DCD6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0675B19F47F1CE000EE7D803C105E49F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5A75681BACBA9A12A7AD803C105DCD6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_0AB0DFAA557E83D45FA9D803C105238F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5A75681BACBA9A12A7AD803C105DCD6" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_0AB0DFAA557E83D45FA9D803C105238F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_12402A7A83D1451E6C66D803C105B287" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_12402A7A83D1451E6C66D803C105B287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_997AEA6201BA7AB8E43DD803C1068807" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_997AEA6201BA7AB8E43DD803C1068807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_EB6FE6EA45362631EB26D803C106A5DC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_EB6FE6EA45362631EB26D803C106A5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_0F5359AB88730BBB8FEDD803C106ED97" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_0F5359AB88730BBB8FEDD803C106ED97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9D3002EA1671779DD420D803C1060DF3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9D3002EA1671779DD420D803C1060DF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_69025665C4B27A9DB5C7D803C106D877" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_69025665C4B27A9DB5C7D803C106D877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_28E517583FE9CC3E2BE2D82F824B1C0F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_28E517583FE9CC3E2BE2D82F824B1C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_EFA8DE0AEE9F8621C131D803C106CA5E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_EFA8DE0AEE9F8621C131D803C106CA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A90B98FE2A676F2D286ED803C1072887" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_Goodwill_A90B98FE2A676F2D286ED803C1072887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A8C2593D09FDE142D061D803C1073509" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A8C2593D09FDE142D061D803C1073509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7EC82BFC62534FBA98E5CEAADE58273F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7EC82BFC62534FBA98E5CEAADE58273F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_509EF226D3B15DA2B94BCEAADE5809B9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7EC82BFC62534FBA98E5CEAADE58273F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_509EF226D3B15DA2B94BCEAADE5809B9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_509EF226D3B15DA2B94BCEAADE5809B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7EC82BFC62534FBA98E5CEAADE58273F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_509EF226D3B15DA2B94BCEAADE5809B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1F0E7E9F216E39DCF139CEAADE5823BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_509EF226D3B15DA2B94BCEAADE5809B9" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1F0E7E9F216E39DCF139CEAADE5823BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6D23BC4704340C31AADACEAADE59FD37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6D23BC4704340C31AADACEAADE59FD37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B97F8BF3F85C15BF7B3FCEAADE59F486_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6D23BC4704340C31AADACEAADE59FD37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B97F8BF3F85C15BF7B3FCEAADE59F486_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B97F8BF3F85C15BF7B3FCEAADE59F486" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6D23BC4704340C31AADACEAADE59FD37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B97F8BF3F85C15BF7B3FCEAADE59F486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0661B14EAAB61856ED17CEAADE598E68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B97F8BF3F85C15BF7B3FCEAADE59F486" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0661B14EAAB61856ED17CEAADE598E68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E782D6B91562976678D7CEAADE599F0F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_srt_RangeAxis_E782D6B91562976678D7CEAADE599F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_E782D6B91562976678D7CEAADE599F0F" xlink:to="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_E782D6B91562976678D7CEAADE599F0F" xlink:to="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_51F798075D20934C0D04CEAADE5A69A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3" xlink:to="loc_srt_MinimumMember_51F798075D20934C0D04CEAADE5A69A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7D56E7382C20A6B446C3CEAADE5A7AF8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3" xlink:to="loc_srt_MaximumMember_7D56E7382C20A6B446C3CEAADE5A7AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_103C007C91E60F0993CCCEAADE5ABC2D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_103C007C91E60F0993CCCEAADE5ABC2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1516DF3C84B0BB7CE0DACEAADE5A8AA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_103C007C91E60F0993CCCEAADE5ABC2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1516DF3C84B0BB7CE0DACEAADE5A8AA1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1516DF3C84B0BB7CE0DACEAADE5A8AA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_103C007C91E60F0993CCCEAADE5ABC2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1516DF3C84B0BB7CE0DACEAADE5A8AA1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_DD62AFDCC7B09CB8D884CEAADE5B02E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1516DF3C84B0BB7CE0DACEAADE5A8AA1" xlink:to="loc_pfe_AstraZenecaMember_DD62AFDCC7B09CB8D884CEAADE5B02E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0460163DB6B2370EA93ACEAADE5B0AEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0460163DB6B2370EA93ACEAADE5B0AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredDeferredPayment" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1419A46E4CC2527BF8D2CEAADE5C0ECB" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1419A46E4CC2527BF8D2CEAADE5C0ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A773F20177E8E61C4AA1CEAADE5D7DE7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A773F20177E8E61C4AA1CEAADE5D7DE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1C6E0F636EE408069145CEAADE5DB1ED" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_Goodwill_1C6E0F636EE408069145CEAADE5DB1ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_C53503F5F563207DAA84CEAADE5D9FD5" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_C53503F5F563207DAA84CEAADE5D9FD5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_34D7929FDE973735AAC158D7E69EBCB9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_srt_ConsolidationItemsAxis_34D7929FDE973735AAC158D7E69EBCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_E82637CE3798F9FE7ABE58D7E69E427F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_34D7929FDE973735AAC158D7E69EBCB9" xlink:to="loc_srt_ConsolidationItemsDomain_E82637CE3798F9FE7ABE58D7E69E427F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_E82637CE3798F9FE7ABE58D7E69E427F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_34D7929FDE973735AAC158D7E69EBCB9" xlink:to="loc_srt_ConsolidationItemsDomain_E82637CE3798F9FE7ABE58D7E69E427F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_047C8A9C9FB734356E8358D7E69FBAAD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_E82637CE3798F9FE7ABE58D7E69E427F" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_047C8A9C9FB734356E8358D7E69FBAAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_4E53AEFA19FBB234642B58D7E69F1BAB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_srt_OwnershipAxis_4E53AEFA19FBB234642B58D7E69F1BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_7116F8ACE061A31AEF8758D7E69F785A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4E53AEFA19FBB234642B58D7E69F1BAB" xlink:to="loc_srt_OwnershipDomain_7116F8ACE061A31AEF8758D7E69F785A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_7116F8ACE061A31AEF8758D7E69F785A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4E53AEFA19FBB234642B58D7E69F1BAB" xlink:to="loc_srt_OwnershipDomain_7116F8ACE061A31AEF8758D7E69F785A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelTherapeuticsMember" xlink:label="loc_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_7116F8ACE061A31AEF8758D7E69F785A" xlink:to="loc_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_DFD4CC5FB9222989470158D7E6A0B849" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_DFD4CC5FB9222989470158D7E6A0B849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FB653C6A73A916AC43F358D7E6A07B01_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DFD4CC5FB9222989470158D7E6A0B849" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FB653C6A73A916AC43F358D7E6A07B01_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FB653C6A73A916AC43F358D7E6A07B01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DFD4CC5FB9222989470158D7E6A0B849" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FB653C6A73A916AC43F358D7E6A07B01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_F721F5E26CCC2A22ACB358D7E6A026B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FB653C6A73A916AC43F358D7E6A07B01" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_F721F5E26CCC2A22ACB358D7E6A026B3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_A5A9053D83C59C74DB8358D7E6A01DE7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_dei_LegalEntityAxis_A5A9053D83C59C74DB8358D7E6A01DE7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AE9241C8C6CC531EEB6458D7E6A0DDC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_A5A9053D83C59C74DB8358D7E6A01DE7" xlink:to="loc_dei_EntityDomain_AE9241C8C6CC531EEB6458D7E6A0DDC8_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AE9241C8C6CC531EEB6458D7E6A0DDC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_A5A9053D83C59C74DB8358D7E6A01DE7" xlink:to="loc_dei_EntityDomain_AE9241C8C6CC531EEB6458D7E6A0DDC8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_AE9241C8C6CC531EEB6458D7E6A0DDC8" xlink:to="loc_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_CD608DC33235B328677558D7E6A11124" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_CD608DC33235B328677558D7E6A11124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CD5B07D0C08875BB2CB958D7E6A14753_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CD608DC33235B328677558D7E6A11124" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CD5B07D0C08875BB2CB958D7E6A14753_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CD5B07D0C08875BB2CB958D7E6A14753" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CD608DC33235B328677558D7E6A11124" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CD5B07D0C08875BB2CB958D7E6A14753" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_D629F48077C8963312E058D7E6A166EA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CD5B07D0C08875BB2CB958D7E6A14753" xlink:to="loc_pfe_LongtermInvestmentsMember_D629F48077C8963312E058D7E6A166EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_33ECB15FA541742C795658D7E6A2915E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_33ECB15FA541742C795658D7E6A2915E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_33ECB15FA541742C795658D7E6A2915E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_33ECB15FA541742C795658D7E6A2915E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CellectisMember" xlink:label="loc_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:to="loc_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_3D8E1D5706EF3655650958D7E6A22064" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:to="loc_pfe_AllogeneMember_3D8E1D5706EF3655650958D7E6A22064" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelMember" xlink:label="loc_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:to="loc_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_BB7A65B03A36BCA35CBB58D7E6A3975F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_srt_CounterpartyNameAxis_BB7A65B03A36BCA35CBB58D7E6A3975F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_BB7A65B03A36BCA35CBB58D7E6A3975F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_BB7A65B03A36BCA35CBB58D7E6A3975F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA" xlink:to="loc_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BainCapitalMember" xlink:label="loc_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA" xlink:to="loc_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_060A8B323A176E533AC058D7E6A4CDA3" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_060A8B323A176E533AC058D7E6A4CDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_060A8B323A176E533AC058D7E6A4CDA3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_060A8B323A176E533AC058D7E6A4CDA3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_091B4963C77751B8018F58D7E6A4AAA8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_091B4963C77751B8018F58D7E6A4AAA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_232E2D3D7AFCB4909CE058D7E6A51F6A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_232E2D3D7AFCB4909CE058D7E6A51F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_232E2D3D7AFCB4909CE058D7E6A51F6A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_232E2D3D7AFCB4909CE058D7E6A51F6A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:to="loc_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" xlink:label="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:to="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NeuroscienceAssetsMember" xlink:label="loc_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:to="loc_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InvestmentOwnershipPercentage" xlink:label="loc_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentsToCollaborators" xlink:label="loc_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossFromContributionAgreement" xlink:label="loc_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationMilestone" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:to="loc_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:to="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:to="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="loc_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="loc_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_8C6DCD8243D246E8952B55F219232E58" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_8C6DCD8243D246E8952B55F219232E58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8F6E09E0AB620BE4EF7455F219230675" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8F6E09E0AB620BE4EF7455F219230675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F97D962929DBB65D33C955F2192355EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8F6E09E0AB620BE4EF7455F219230675" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F97D962929DBB65D33C955F2192355EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F97D962929DBB65D33C955F2192355EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8F6E09E0AB620BE4EF7455F219230675" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F97D962929DBB65D33C955F2192355EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6DFD608BF335BCA766C155F219248279" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F97D962929DBB65D33C955F2192355EF" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6DFD608BF335BCA766C155F219248279" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:to="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:to="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKMember" xlink:label="loc_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:to="loc_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_81516F4B35BFDCEC907E55F21925610C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_81516F4B35BFDCEC907E55F21925610C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfTax" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTaxIndemnificationLiability" xlink:label="loc_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortization" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm" xlink:label="loc_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm" xlink:label="loc_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax" xlink:label="loc_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_321BEC1847B4BA4AB4C0CEAADE045A70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_321BEC1847B4BA4AB4C0CEAADE045A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D64465994B54554B582CCEAADE05285D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_321BEC1847B4BA4AB4C0CEAADE045A70" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D64465994B54554B582CCEAADE05285D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D64465994B54554B582CCEAADE05285D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_321BEC1847B4BA4AB4C0CEAADE045A70" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D64465994B54554B582CCEAADE05285D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_9135D3217FB0E304D471CEAADE052FB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D64465994B54554B582CCEAADE05285D" xlink:to="loc_pfe_LongtermInvestmentsMember_9135D3217FB0E304D471CEAADE052FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_7A373CF4F65F7DDF142BCEAADE068234" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:to="loc_us-gaap_LicensingAgreementsMember_7A373CF4F65F7DDF142BCEAADE068234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AkceaAndIonisMember" xlink:label="loc_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:to="loc_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShireMember" xlink:label="loc_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:to="loc_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BionTechMember" xlink:label="loc_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:to="loc_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_933346FC37A09E4A4D53CEAADE07DD4E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_933346FC37A09E4A4D53CEAADE07DD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_933346FC37A09E4A4D53CEAADE07DD4E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_933346FC37A09E4A4D53CEAADE07DD4E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9634F12BA7A963B63821CEAADE07CFA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9634F12BA7A963B63821CEAADE07CFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementMilestoneMaximumValue" xlink:label="loc_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ProceedsFromLicensingArrangement" xlink:label="loc_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementNumberOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementValueOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MedivationMember" xlink:label="loc_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:to="loc_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredAmountPayable" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" xlink:label="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4E7A9716E12481BEDFEB5B2ACAB7BEA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_srt_ProductOrServiceAxis_4E7A9716E12481BEDFEB5B2ACAB7BEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4E7A9716E12481BEDFEB5B2ACAB7BEA9" xlink:to="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4E7A9716E12481BEDFEB5B2ACAB7BEA9" xlink:to="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763" xlink:to="loc_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CopromotionMember" xlink:label="loc_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763" xlink:to="loc_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_CA289D7C436300DE6BAF5B2ACABA87AB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_CA289D7C436300DE6BAF5B2ACABA87AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6107101BC0BEA68199D45B2ACABA16A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CA289D7C436300DE6BAF5B2ACABA87AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6107101BC0BEA68199D45B2ACABA16A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6107101BC0BEA68199D45B2ACABA16A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CA289D7C436300DE6BAF5B2ACABA87AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6107101BC0BEA68199D45B2ACABA16A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6107101BC0BEA68199D45B2ACABA16A3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementUpfrontCashPaymentMember" xlink:label="loc_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:to="loc_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BDFC4EBCD2DDCD1B749B5B2ACABB511F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BDFC4EBCD2DDCD1B749B5B2ACABB511F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BDFC4EBCD2DDCD1B749B5B2ACABB511F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BDFC4EBCD2DDCD1B749B5B2ACABB511F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_CCEA1B1E2B9E4B269F425B2ACABC7CE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_CCEA1B1E2B9E4B269F425B2ACABC7CE0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredRevenueMember" xlink:label="loc_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:to="loc_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3806CDD0133245E54C365B2ACABCCD35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3806CDD0133245E54C365B2ACABCCD35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_4FF22213E4073962670E5B2ACABCDCFF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_srt_CounterpartyNameAxis_4FF22213E4073962670E5B2ACABCDCFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4FF22213E4073962670E5B2ACABCDCFF" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4FF22213E4073962670E5B2ACABCDCFF" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NovaQuestCoInvestmentFundVL.P.Member" xlink:label="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RPIFinanceTrustMember" xlink:label="loc_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EliLillyCompanyMember" xlink:label="loc_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MerckKGaAMember" xlink:label="loc_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MerckMember" xlink:label="loc_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6338F8DA497EFDA6B7005B2ACABEB6B1" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6338F8DA497EFDA6B7005B2ACABEB6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6338F8DA497EFDA6B7005B2ACABEB6B1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6338F8DA497EFDA6B7005B2ACABEB6B1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8BCE1D5068BE2196E86F5B2ACABE794B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8BCE1D5068BE2196E86F5B2ACABE794B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1DE7BDD9C618107A1A425B2ACABF3C94" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1DE7BDD9C618107A1A425B2ACABF3C94" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementMaximumFundingAmount" xlink:label="loc_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" xlink:label="loc_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" xlink:label="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure" xlink:label="loc_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12854C2E637576C61A1C5B2ACAC09F01" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12854C2E637576C61A1C5B2ACAC09F01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:label="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrepaymentsandPaymentstoCollaborators" xlink:label="loc_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementMilestonePaymentReceivable" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementDeferredMilestonePayment" xlink:label="loc_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized" xlink:label="loc_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:label="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_665D37E0AD74F1BE9EF7CEAADE175BC1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_665D37E0AD74F1BE9EF7CEAADE175BC1" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F6F9AA7AEB65C19BBEC1CEAADE1687EC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F6F9AA7AEB65C19BBEC1CEAADE1687EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_631AD5EF123CE7BED9D9CEAADE1639CD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F6F9AA7AEB65C19BBEC1CEAADE1687EC" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_631AD5EF123CE7BED9D9CEAADE1639CD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_631AD5EF123CE7BED9D9CEAADE1639CD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F6F9AA7AEB65C19BBEC1CEAADE1687EC" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_631AD5EF123CE7BED9D9CEAADE1639CD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_E387D1F46CD3CC8FD6BFCEAADE16DD06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_631AD5EF123CE7BED9D9CEAADE1639CD" xlink:to="loc_pfe_ConsumerHealthcareMember_E387D1F46CD3CC8FD6BFCEAADE16DD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9C7C089FCD6B2A34B8CDCEAADE1652AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9C7C089FCD6B2A34B8CDCEAADE1652AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8DA6F411FCA437694B45CEAADE172C52_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9C7C089FCD6B2A34B8CDCEAADE1652AD" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8DA6F411FCA437694B45CEAADE172C52_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8DA6F411FCA437694B45CEAADE172C52" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9C7C089FCD6B2A34B8CDCEAADE1652AD" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8DA6F411FCA437694B45CEAADE172C52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_558FD0AD23EA2F2BBEB4CEAADE17F5E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8DA6F411FCA437694B45CEAADE172C52" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_558FD0AD23EA2F2BBEB4CEAADE17F5E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_665D37E0AD74F1BE9EF7CEAADE175BC1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_665D37E0AD74F1BE9EF7CEAADE175BC1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_261BF74A2B318EF12ECD58D1743AD200" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_501768C6F7F4DC69254A58D174375CDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_261BF74A2B318EF12ECD58D1743AD200" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_501768C6F7F4DC69254A58D174375CDA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B77119E9A88744CD949558D17438E7C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_501768C6F7F4DC69254A58D174375CDA" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B77119E9A88744CD949558D17438E7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B77119E9A88744CD949558D17438E7C9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B77119E9A88744CD949558D17438E7C9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_A08F53B7C6BE9AA7D34E58D17439C683" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0" xlink:to="loc_pfe_GSKConsumerHealthcareMember_A08F53B7C6BE9AA7D34E58D17439C683" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_3DE2B64D71E62CAB07E558D1743A64C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0" xlink:to="loc_pfe_ViivHealthcareLimitedMember_3DE2B64D71E62CAB07E558D1743A64C4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_261BF74A2B318EF12ECD58D1743AD200" xlink:to="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_261BF74A2B318EF12ECD58D1743AD200" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_7EBF92C9F0EBED81BF2DCEC126D08737" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B2EEE25C91804D6BD59ECEC126CE6DB2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7EBF92C9F0EBED81BF2DCEC126D08737" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B2EEE25C91804D6BD59ECEC126CE6DB2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionAxis" xlink:label="loc_pfe_AssetAcquisitionAxis_CF05285F65CA56FA0518CEC126CE48DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_B2EEE25C91804D6BD59ECEC126CE6DB2" xlink:to="loc_pfe_AssetAcquisitionAxis_CF05285F65CA56FA0518CEC126CE48DD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_8EFA171CB6FB827A2EADCEC126CE765B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_AssetAcquisitionAxis_CF05285F65CA56FA0518CEC126CE48DD" xlink:to="loc_pfe_AssetAcquisitionDomain_8EFA171CB6FB827A2EADCEC126CE765B_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_8EFA171CB6FB827A2EADCEC126CE765B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_AssetAcquisitionAxis_CF05285F65CA56FA0518CEC126CE48DD" xlink:to="loc_pfe_AssetAcquisitionDomain_8EFA171CB6FB827A2EADCEC126CE765B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TherachonAssetAcquisitionMember" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_BF0E1C773CBC39DBC0F2CEC126CEA804" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_AssetAcquisitionDomain_8EFA171CB6FB827A2EADCEC126CE765B" xlink:to="loc_pfe_TherachonAssetAcquisitionMember_BF0E1C773CBC39DBC0F2CEC126CEA804" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_C32A8037359D10301E15CEC126D0D2F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7EBF92C9F0EBED81BF2DCEC126D08737" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_C32A8037359D10301E15CEC126D0D2F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_526DC71BDC8C8B64C39BCEC126D1C2E4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7EBF92C9F0EBED81BF2DCEC126D08737" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_526DC71BDC8C8B64C39BCEC126D1C2E4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionPercentageofSharesAcquired" xlink:label="loc_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7EBF92C9F0EBED81BF2DCEC126D08737" xlink:to="loc_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7EBF92C9F0EBED81BF2DCEC126D08737" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferred" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferred_9D01B9FCDE4D17EA671DCEC126D1C290" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7EBF92C9F0EBED81BF2DCEC126D08737" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferred_9D01B9FCDE4D17EA671DCEC126D1C290" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_7EBF92C9F0EBED81BF2DCEC126D08737" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_498392DBA46FF92A6FF155F1EF1FD89F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_498392DBA46FF92A6FF155F1EF1FD89F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_498392DBA46FF92A6FF155F1EF1FD89F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_498392DBA46FF92A6FF155F1EF1FD89F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:to="loc_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_D4DA0485DA87C77E117255F1EF20DE41" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_D4DA0485DA87C77E117255F1EF20DE41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AccruedRebates" xlink:label="loc_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:to="loc_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherAccruals" xlink:label="loc_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:to="loc_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_62D8A96AC9294A52B9D055F1429149CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_StatementScenarioAxis_62D8A96AC9294A52B9D055F1429149CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3B861A970FBF9837C17B55F142914DB7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_62D8A96AC9294A52B9D055F1429149CA" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3B861A970FBF9837C17B55F142914DB7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3B861A970FBF9837C17B55F142914DB7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_62D8A96AC9294A52B9D055F1429149CA" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3B861A970FBF9837C17B55F142914DB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_AC53476FDB5BBC01416455F142927A8C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3B861A970FBF9837C17B55F142914DB7" xlink:to="loc_srt_ScenarioForecastMember_AC53476FDB5BBC01416455F142927A8C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_13613626FE5B956CB06955F14292B359" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_dei_LegalEntityAxis_13613626FE5B956CB06955F14292B359" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7CB912006CE81946EF3A55F142923FDC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_13613626FE5B956CB06955F14292B359" xlink:to="loc_dei_EntityDomain_7CB912006CE81946EF3A55F142923FDC_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7CB912006CE81946EF3A55F142923FDC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_13613626FE5B956CB06955F14292B359" xlink:to="loc_dei_EntityDomain_7CB912006CE81946EF3A55F142923FDC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_6091C09AD01B751CBFEA55F14293D560" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_7CB912006CE81946EF3A55F142923FDC" xlink:to="loc_pfe_MylanMember_6091C09AD01B751CBFEA55F14293D560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_4B9DF4BD4AA8D0A667B655F14293E396" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_OwnershipAxis_4B9DF4BD4AA8D0A667B655F14293E396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_C0CCD6DABB53770B695F55F14293D2B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_4B9DF4BD4AA8D0A667B655F14293E396" xlink:to="loc_srt_OwnershipDomain_C0CCD6DABB53770B695F55F14293D2B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_C0CCD6DABB53770B695F55F14293D2B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_4B9DF4BD4AA8D0A667B655F14293E396" xlink:to="loc_srt_OwnershipDomain_C0CCD6DABB53770B695F55F14293D2B7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnAndMylanMember" xlink:label="loc_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_C0CCD6DABB53770B695F55F14293D2B7" xlink:to="loc_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8344E55A3C39577C03D955F1429439E4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_RangeAxis_8344E55A3C39577C03D955F1429439E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_8344E55A3C39577C03D955F1429439E4" xlink:to="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_8344E55A3C39577C03D955F1429439E4" xlink:to="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2C423AFFAD18429F072655F14294B8CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5" xlink:to="loc_srt_MinimumMember_2C423AFFAD18429F072655F14294B8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DDC5EFE611F8A08C7A1955F14294899F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5" xlink:to="loc_srt_MaximumMember_DDC5EFE611F8A08C7A1955F14294899F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionAxis" xlink:label="loc_pfe_AssetAcquisitionAxis_5897E9B82BA2CAC5A64E55F142956D6C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_pfe_AssetAcquisitionAxis_5897E9B82BA2CAC5A64E55F142956D6C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_172D53C81A49369B8D8955F142952E75_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_AssetAcquisitionAxis_5897E9B82BA2CAC5A64E55F142956D6C" xlink:to="loc_pfe_AssetAcquisitionDomain_172D53C81A49369B8D8955F142952E75_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_172D53C81A49369B8D8955F142952E75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_AssetAcquisitionAxis_5897E9B82BA2CAC5A64E55F142956D6C" xlink:to="loc_pfe_AssetAcquisitionDomain_172D53C81A49369B8D8955F142952E75" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TherachonAssetAcquisitionMember" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_A5B56BD6FECC308EEF7555F14295CA2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_AssetAcquisitionDomain_172D53C81A49369B8D8955F142952E75" xlink:to="loc_pfe_TherachonAssetAcquisitionMember_A5B56BD6FECC308EEF7555F14295CA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_785906BCC10BB295AEE455F14295DBE4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_785906BCC10BB295AEE455F14295DBE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E9AA2100CA967E3ED7C555F142956390_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_785906BCC10BB295AEE455F14295DBE4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E9AA2100CA967E3ED7C555F142956390_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E9AA2100CA967E3ED7C555F142956390" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_785906BCC10BB295AEE455F14295DBE4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E9AA2100CA967E3ED7C555F142956390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_3855978FB9557A62C3FC55F14296466D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E9AA2100CA967E3ED7C555F142956390" xlink:to="loc_us-gaap_LicensingAgreementsMember_3855978FB9557A62C3FC55F14296466D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FC7C4B3F441D3D20E37055F14296AF2B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FC7C4B3F441D3D20E37055F14296AF2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10AEB259A5FEBCFC266055F142964641_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FC7C4B3F441D3D20E37055F14296AF2B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10AEB259A5FEBCFC266055F142964641_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10AEB259A5FEBCFC266055F142964641" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FC7C4B3F441D3D20E37055F14296AF2B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10AEB259A5FEBCFC266055F142964641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9E14804B369A66F45D6B55F1429661B6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10AEB259A5FEBCFC266055F142964641" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9E14804B369A66F45D6B55F1429661B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_53382E72B19E4FC73D1C55F1429CBD4F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_53382E72B19E4FC73D1C55F1429CBD4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_07013B1F44993D8ECA7B55F1429C0B16_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_53382E72B19E4FC73D1C55F1429CBD4F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_07013B1F44993D8ECA7B55F1429C0B16_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_07013B1F44993D8ECA7B55F1429C0B16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_53382E72B19E4FC73D1C55F1429CBD4F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_07013B1F44993D8ECA7B55F1429C0B16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0EB67AD330A8A35ABFC355F1429D38D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_07013B1F44993D8ECA7B55F1429C0B16" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0EB67AD330A8A35ABFC355F1429D38D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C1D722AB6A8650E002EC55F1429D89B2" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C1D722AB6A8650E002EC55F1429D89B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3BDCCD474B3F389A480D55F1429D0D9D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C1D722AB6A8650E002EC55F1429D89B2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3BDCCD474B3F389A480D55F1429D0D9D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3BDCCD474B3F389A480D55F1429D0D9D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C1D722AB6A8650E002EC55F1429D89B2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3BDCCD474B3F389A480D55F1429D0D9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3BDCCD474B3F389A480D55F1429D0D9D" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A44DCCAB1C39CB6B7E4E55F1429EBF1B" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_ProductOrServiceAxis_A44DCCAB1C39CB6B7E4E55F1429EBF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_A44DCCAB1C39CB6B7E4E55F1429EBF1B" xlink:to="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_A44DCCAB1C39CB6B7E4E55F1429EBF1B" xlink:to="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopEightProductsMember" xlink:label="loc_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:to="loc_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopNineProductsMember" xlink:label="loc_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:to="loc_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopTenProductsMember" xlink:label="loc_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:to="loc_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1686806AF5466AFC65E755F1429FF788" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1686806AF5466AFC65E755F1429FF788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_EEC2F5E59AF2F71322EE55F1429F2E49_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1686806AF5466AFC65E755F1429FF788" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_EEC2F5E59AF2F71322EE55F1429F2E49_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_EEC2F5E59AF2F71322EE55F1429F2E49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1686806AF5466AFC65E755F1429FF788" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_EEC2F5E59AF2F71322EE55F1429F2E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_EEC2F5E59AF2F71322EE55F1429F2E49" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_68C62CE34EE056D0C0FF55F1429FFCBD" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_CounterpartyNameAxis_68C62CE34EE056D0C0FF55F1429FFCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_68C62CE34EE056D0C0FF55F1429FFCBD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_68C62CE34EE056D0C0FF55F1429FFCBD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AkceaAndIonisMember" xlink:label="loc_pfe_AkceaAndIonisMember_8951F4AC773432D593EA55F142A03CDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1" xlink:to="loc_pfe_AkceaAndIonisMember_8951F4AC773432D593EA55F142A03CDA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_43DD679750999CF3955655F142A0F6A4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1" xlink:to="loc_pfe_ICUMedicalMember_43DD679750999CF3955655F142A0F6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_497422472ECEB1D8103655F142A0B644" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_497422472ECEB1D8103655F142A0B644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_96FD82F4A4B08F2C634A55F142A04BE4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_497422472ECEB1D8103655F142A0B644" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_96FD82F4A4B08F2C634A55F142A04BE4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_96FD82F4A4B08F2C634A55F142A04BE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_497422472ECEB1D8103655F142A0B644" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_96FD82F4A4B08F2C634A55F142A04BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_C261D200CC3F841AB19D55F142A179A2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_96FD82F4A4B08F2C634A55F142A04BE4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_C261D200CC3F841AB19D55F142A179A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92EA77300B9487B3AE6755F142A13E57" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92EA77300B9487B3AE6755F142A13E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0A586DF5557A0681287F55F142A10B85_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92EA77300B9487B3AE6755F142A13E57" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0A586DF5557A0681287F55F142A10B85_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0A586DF5557A0681287F55F142A10B85" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92EA77300B9487B3AE6755F142A13E57" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0A586DF5557A0681287F55F142A10B85" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_D3A32199DCB0474B8AEE55F142A2D118" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0A586DF5557A0681287F55F142A10B85" xlink:to="loc_pfe_HISMember_D3A32199DCB0474B8AEE55F142A2D118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9EF87CF284B033A73A5255F142A245B5" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9EF87CF284B033A73A5255F142A245B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9EF87CF284B033A73A5255F142A245B5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9EF87CF284B033A73A5255F142A245B5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_F8338A0467F9B9B0DF6D55F142A2891A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E" xlink:to="loc_pfe_ArrayMember_F8338A0467F9B9B0DF6D55F142A2891A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_6A68AB9600593C61DF3455F142A23634" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E" xlink:to="loc_pfe_AstraZenecaMember_6A68AB9600593C61DF3455F142A23634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_82311431D13288FDD33855F142A36EB9" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_TypeOfArrangementAxis_82311431D13288FDD33855F142A36EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA7F63ECEA813C34488155F142A3E5BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_82311431D13288FDD33855F142A36EB9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA7F63ECEA813C34488155F142A3E5BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA7F63ECEA813C34488155F142A3E5BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_82311431D13288FDD33855F142A36EB9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA7F63ECEA813C34488155F142A3E5BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_7BA54C3955397E47E0FF55F142A3942B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA7F63ECEA813C34488155F142A3E5BE" xlink:to="loc_us-gaap_LicensingAgreementsMember_7BA54C3955397E47E0FF55F142A3942B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_A5552363B9E4EFBE4EEB55F142A4B10C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_A5552363B9E4EFBE4EEB55F142A4B10C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NumberOfAccountingStandardsAdopted" xlink:label="loc_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_67C3207E3E870BCAEB9955F142A9F6BD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_PaymentForLicensingArrangement_67C3207E3E870BCAEB9955F142A9F6BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_F33466F9178BF5F43CA355F142A92038" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_F33466F9178BF5F43CA355F142A92038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3C25A27DA48EAC6D422255F142AA96F2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3C25A27DA48EAC6D422255F142AA96F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_75BB982F531783427D9C55F142AA01A5" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_75BB982F531783427D9C55F142AA01A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_E558773DDA7C2863EE6B55F142AA7AED" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_E558773DDA7C2863EE6B55F142AA7AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferred" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E84A5A635C6B00BCB7B055F142AB8755" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E84A5A635C6B00BCB7B055F142AB8755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConcentrationRiskAmount" xlink:label="loc_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:label="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_2C143DA275D9F7DAAA3B55F142AC403D" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_VariableLeaseCost_2C143DA275D9F7DAAA3B55F142AC403D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OfficeBuildingInNewYorkCityMember" xlink:label="loc_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:to="loc_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A9CEA09808F94E4A2F9DCD989BB4C0A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A9CEA09808F94E4A2F9DCD989BB4C0A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8315A4025F478F868416CD989BB455D3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A9CEA09808F94E4A2F9DCD989BB4C0A0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8315A4025F478F868416CD989BB455D3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8315A4025F478F868416CD989BB455D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A9CEA09808F94E4A2F9DCD989BB4C0A0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8315A4025F478F868416CD989BB455D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8315A4025F478F868416CD989BB455D3" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_71912B4D2F5635F274392F92B61D5963" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_StatementTable_71912B4D2F5635F274392F92B61D5963" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0AA01DE5D2DC236EDEFC2F92B61DD7B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_71912B4D2F5635F274392F92B61D5963" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0AA01DE5D2DC236EDEFC2F92B61DD7B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0AA01DE5D2DC236EDEFC2F92B61DD7B9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0AA01DE5D2DC236EDEFC2F92B61DD7B9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_360FE39D6D2FA01549432F92B61EDC5B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:to="loc_pfe_GSKConsumerHealthcareMember_360FE39D6D2FA01549432F92B61EDC5B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelTherapeuticsMember" xlink:label="loc_pfe_CerevelTherapeuticsMember_F77EA2189BB97C3B93142F92B61EC345" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:to="loc_pfe_CerevelTherapeuticsMember_F77EA2189BB97C3B93142F92B61EC345" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_E37277781DB78DE964082F92B61E1F9A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:to="loc_pfe_AllogeneMember_E37277781DB78DE964082F92B61E1F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:to="loc_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:to="loc_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InterestPaidInterestRateHedges" xlink:label="loc_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:to="loc_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4670DF3D65D7F1D2785A6EE6EE71A6E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4670DF3D65D7F1D2785A6EE6EE71A6E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1CE521F6E049EAB4CABA6EE6EE710DC7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4670DF3D65D7F1D2785A6EE6EE71A6E9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1CE521F6E049EAB4CABA6EE6EE710DC7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1CE521F6E049EAB4CABA6EE6EE710DC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4670DF3D65D7F1D2785A6EE6EE71A6E9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1CE521F6E049EAB4CABA6EE6EE710DC7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_F5485CE838E548F069456EE6EE7163D4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1CE521F6E049EAB4CABA6EE6EE710DC7" xlink:to="loc_pfe_GSKConsumerHealthcareMember_F5485CE838E548F069456EE6EE7163D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A0C7DE4616046D863DE66EE6EE72F56C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A0C7DE4616046D863DE66EE6EE72F56C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_11062B4C5EA77B2BC4916EE6EE72A380_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0C7DE4616046D863DE66EE6EE72F56C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_11062B4C5EA77B2BC4916EE6EE72A380_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_11062B4C5EA77B2BC4916EE6EE72A380" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0C7DE4616046D863DE66EE6EE72F56C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_11062B4C5EA77B2BC4916EE6EE72A380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_294BCB2CAA378E73313F6EE6EE7286F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_11062B4C5EA77B2BC4916EE6EE72A380" xlink:to="loc_us-gaap_SeniorNotesMember_294BCB2CAA378E73313F6EE6EE7286F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_FB567A3B42D07902313E6EE6EE733AC6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:to="loc_us-gaap_DebtInstrumentAxis_FB567A3B42D07902313E6EE6EE733AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_FB567A3B42D07902313E6EE6EE733AC6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_FB567A3B42D07902313E6EE6EE733AC6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" xlink:label="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_42F92EAEBD1DCF3F8E3B6EE6EE732D1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:to="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_42F92EAEBD1DCF3F8E3B6EE6EE732D1E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member" xlink:label="loc_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:to="loc_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_U.K.PoundDenominatedDebtMember" xlink:label="loc_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:to="loc_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_CC68F2B3EAE7985A75BF6EE6EE743437" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_CC68F2B3EAE7985A75BF6EE6EE743437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F5B032FC710C6A9BAC766EE6EE7420A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F5B032FC710C6A9BAC766EE6EE7420A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_A20E415F16606AE1DA156EE6EE746407" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_A20E415F16606AE1DA156EE6EE746407" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossOnExchangeOfDebt" xlink:label="loc_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActIncomeTaxBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_6BD9FD5045563A15B8D96EE6EE75278A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_6BD9FD5045563A15B8D96EE6EE75278A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC4E60F2470B5B177DDF6EE6EE7516EC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC4E60F2470B5B177DDF6EE6EE7516EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationNetAssetsContributed" xlink:label="loc_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_800A157E0632C77A14D76EE6EE761378" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_800A157E0632C77A14D76EE6EE761378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_719FBDD15B2F944511F06EE6EE76D213" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_719FBDD15B2F944511F06EE6EE76D213" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:to="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EAB0C1DC4101505525227E091AF5D416" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EAB0C1DC4101505525227E091AF5D416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EAB0C1DC4101505525227E091AF5D416" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EAB0C1DC4101505525227E091AF5D416" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_99A4964DDBB37ED4D5FF7E091AF680D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:to="loc_pfe_GSKConsumerHealthcareMember_99A4964DDBB37ED4D5FF7E091AF680D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_CC7EB8761F47328FE7547E091AF6275B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_CC7EB8761F47328FE7547E091AF6275B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_80149F81486113B0DF2B7E091AF692D9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_80149F81486113B0DF2B7E091AF692D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9EC205BD67290E01A8007E091AF79888" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9EC205BD67290E01A8007E091AF79888" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EC2E18157D2D521336F46EEB80D0E94B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_09942ABF6FEAC62F1E716EEB80CEE393" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_EC2E18157D2D521336F46EEB80D0E94B" xlink:to="loc_us-gaap_StatementTable_09942ABF6FEAC62F1E716EEB80CEE393" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3C2209E238C258F439D96EEB80CE06F1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_09942ABF6FEAC62F1E716EEB80CEE393" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3C2209E238C258F439D96EEB80CE06F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3C2209E238C258F439D96EEB80CE06F1" xlink:to="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3C2209E238C258F439D96EEB80CE06F1" xlink:to="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73" xlink:to="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73" xlink:to="loc_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_EC2E18157D2D521336F46EEB80D0E94B" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsAbstract" xlink:label="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:to="loc_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:to="loc_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_16ACB2546478A1408FE016E825F55F5E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_16ACB2546478A1408FE016E825F55F5E" xlink:to="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F21D4B739432A917C31416EFC17A51B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F21D4B739432A917C31416EFC17A51B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1B914F963E0B44D2C09016EFC1935F54_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F21D4B739432A917C31416EFC17A51B7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1B914F963E0B44D2C09016EFC1935F54_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1B914F963E0B44D2C09016EFC1935F54" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F21D4B739432A917C31416EFC17A51B7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1B914F963E0B44D2C09016EFC1935F54" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OncologyVaccinesStartUpMember" xlink:label="loc_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1B914F963E0B44D2C09016EFC1935F54" xlink:to="loc_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D11C3D0A58E4F8AC8CB216E825F347EC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D11C3D0A58E4F8AC8CB216E825F347EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4E31458B0A075F01E79A16E825F44C1C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D11C3D0A58E4F8AC8CB216E825F347EC" xlink:to="loc_us-gaap_EquityComponentDomain_4E31458B0A075F01E79A16E825F44C1C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4E31458B0A075F01E79A16E825F44C1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D11C3D0A58E4F8AC8CB216E825F347EC" xlink:to="loc_us-gaap_EquityComponentDomain_4E31458B0A075F01E79A16E825F44C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9601E1A695436591CF0616E825F51EBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_4E31458B0A075F01E79A16E825F44C1C" xlink:to="loc_us-gaap_CommonStockMember_9601E1A695436591CF0616E825F51EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_79E3A0857DE7F318968616E825F68FF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16ACB2546478A1408FE016E825F55F5E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_79E3A0857DE7F318968616E825F68FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_CE7D126F11F8E337B66C16EE4C86343F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_16ACB2546478A1408FE016E825F55F5E" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_CE7D126F11F8E337B66C16EE4C86343F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_341B5BF8C0F54F5E01E178021DA8CC30" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_srt_RangeAxis_341B5BF8C0F54F5E01E178021DA8CC30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F17F26DD4C3106DE347178021ECA00EF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_341B5BF8C0F54F5E01E178021DA8CC30" xlink:to="loc_srt_RangeMember_F17F26DD4C3106DE347178021ECA00EF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F17F26DD4C3106DE347178021ECA00EF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_341B5BF8C0F54F5E01E178021DA8CC30" xlink:to="loc_srt_RangeMember_F17F26DD4C3106DE347178021ECA00EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B6DD19B6F9A6E5B0C21378023FB603E8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_F17F26DD4C3106DE347178021ECA00EF" xlink:to="loc_srt_MinimumMember_B6DD19B6F9A6E5B0C21378023FB603E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_882CA78CDBC3488CCAD777FD3DE83919" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_882CA78CDBC3488CCAD777FD3DE83919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_882CA78CDBC3488CCAD777FD3DE83919" xlink:to="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_882CA78CDBC3488CCAD777FD3DE83919" xlink:to="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViolationofAntitrustLawsMember" xlink:label="loc_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A" xlink:to="loc_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_39E3CCA44828F8CFC7C077FD3DE99F34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_srt_LitigationCaseAxis_39E3CCA44828F8CFC7C077FD3DE99F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_39E3CCA44828F8CFC7C077FD3DE99F34" xlink:to="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_39E3CCA44828F8CFC7C077FD3DE99F34" xlink:to="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" xlink:label="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E" xlink:to="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_DA810CAEDF46DCACDA3377FD3DEA722A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_srt_ProductOrServiceAxis_DA810CAEDF46DCACDA3377FD3DEA722A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_DA810CAEDF46DCACDA3377FD3DEA722A" xlink:to="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_DA810CAEDF46DCACDA3377FD3DEA722A" xlink:to="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflectraMember" xlink:label="loc_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:to="loc_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:to="loc_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DocetaxelMember" xlink:label="loc_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:to="loc_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PhenytoinSodiumCapsulesMember" xlink:label="loc_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:to="loc_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_96B7AA10D0DA6438964877FD3DEB1ADD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_us-gaap_LitigationStatusAxis_96B7AA10D0DA6438964877FD3DEB1ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_96B7AA10D0DA6438964877FD3DEB1ADD" xlink:to="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_96B7AA10D0DA6438964877FD3DEB1ADD" xlink:to="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_09E0356D15C01CCD170277FD3DEB54BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628" xlink:to="loc_us-gaap_PendingLitigationMember_09E0356D15C01CCD170277FD3DEB54BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_264808451E6BCAD916DF77FD3DEBF8AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628" xlink:to="loc_us-gaap_SettledLitigationMember_264808451E6BCAD916DF77FD3DEBF8AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyNumberOfLawsuits" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyClassActionsFiledNumber" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:to="loc_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F274F72631FB9E24E7A77E53530A55C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_srt_ProductOrServiceAxis_F274F72631FB9E24E7A77E53530A55C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_F274F72631FB9E24E7A77E53530A55C1" xlink:to="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_F274F72631FB9E24E7A77E53530A55C1" xlink:to="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrecedexPremixMember" xlink:label="loc_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:to="loc_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:to="loc_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:to="loc_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:to="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:to="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusAmnealPharmaceuticalsLLCMember" xlink:label="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusFreseniusKabjUSALLCMember" xlink:label="loc_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusParMember" xlink:label="loc_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusAjantaMember" xlink:label="loc_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusGenericCompaniesMember" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member" xlink:label="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:to="loc_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_64E37799A2F8467177AE7E53530EDBBB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_us-gaap_LitigationStatusAxis_64E37799A2F8467177AE7E53530EDBBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_64E37799A2F8467177AE7E53530EDBBB" xlink:to="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_64E37799A2F8467177AE7E53530EDBBB" xlink:to="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:to="loc_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_D72A4308E5061CB7A93D7E53530FC6B0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:to="loc_us-gaap_PendingLitigationMember_D72A4308E5061CB7A93D7E53530FC6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:to="loc_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber" xlink:label="loc_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3BC4686A7B9334266A897E0E8567EA71" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3BC4686A7B9334266A897E0E8567EA71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_AC8898B1AF487D0526177E0E85687B4D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3BC4686A7B9334266A897E0E8567EA71" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_AC8898B1AF487D0526177E0E85687B4D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_AC8898B1AF487D0526177E0E85687B4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3BC4686A7B9334266A897E0E8567EA71" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_AC8898B1AF487D0526177E0E85687B4D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_0417D08D3D7FA202E9257E0E85689D78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_AC8898B1AF487D0526177E0E85687B4D" xlink:to="loc_pfe_IncomeTaxesPayableMember_0417D08D3D7FA202E9257E0E85689D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2A98E06D5925EC07EAD87E0E85695707" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:to="loc_srt_ProductOrServiceAxis_2A98E06D5925EC07EAD87E0E85695707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_2A98E06D5925EC07EAD87E0E85695707" xlink:to="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_2A98E06D5925EC07EAD87E0E85695707" xlink:to="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_55E6786D85D2729E8C6C7E0E85695816" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A" xlink:to="loc_pfe_BesponsaMember_55E6786D85D2729E8C6C7E0E85695816" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_DAF0D5976F0F0A69C16F7E0E856A0AEC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A" xlink:to="loc_pfe_BosulifMember_DAF0D5976F0F0A69C16F7E0E856A0AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_DCCE65EFAECC4B486BD27E0E856A0F8A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_DCCE65EFAECC4B486BD27E0E856A0F8A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B37E4C330D44B808E4357E0E856BF2E4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B37E4C330D44B808E4357E0E856BF2E4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForRepatriationTax" xlink:label="loc_pfe_PaymentForRepatriationTax_AAA417EABF31A69060817E0E856B7D09" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_pfe_PaymentForRepatriationTax_AAA417EABF31A69060817E0E856B7D09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems" xlink:label="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:to="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:to="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="loc_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20200.000Member" xlink:label="loc_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="loc_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20220.250Member" xlink:label="loc_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="loc_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20271.000Member" xlink:label="loc_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="loc_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:to="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:to="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A9D3BF07CE9B87DE615555F213414E1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:to="loc_us-gaap_CommonStockMember_A9D3BF07CE9B87DE615555F213414E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:to="loc_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_41FC6478FEB90B87736155F213452007" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_41FC6478FEB90B87736155F213452007" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/Equity" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2015StockPurchasePlanMember" xlink:label="loc_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2017StockPurchasePlanMember" xlink:label="loc_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2018StockPurchasePlanMember" xlink:label="loc_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareRepurchaseAgreementwithCitibankMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OpenMarketPurchasesMember" xlink:label="loc_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_B6DC2FDF6C7DC40902ED2677F5C9941E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_B6DC2FDF6C7DC40902ED2677F5C9941E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B6DC2FDF6C7DC40902ED2677F5C9941E" xlink:to="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B6DC2FDF6C7DC40902ED2677F5C9941E" xlink:to="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_FDE274A657B5C01228902677F5C93461" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C" xlink:to="loc_us-gaap_PreferredStockMember_FDE274A657B5C01228902677F5C93461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0F748928B0C81B96BBE32677F5C94F10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C" xlink:to="loc_us-gaap_CommonStockMember_0F748928B0C81B96BBE32677F5C94F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C08BF2F9E364F092B9BF2677F5C9612C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C08BF2F9E364F092B9BF2677F5C9612C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_71FE1835C6D8B7F0D5B92677F5C9EB46_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C08BF2F9E364F092B9BF2677F5C9612C" xlink:to="loc_us-gaap_ClassOfStockDomain_71FE1835C6D8B7F0D5B92677F5C9EB46_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_71FE1835C6D8B7F0D5B92677F5C9EB46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C08BF2F9E364F092B9BF2677F5C9612C" xlink:to="loc_us-gaap_ClassOfStockDomain_71FE1835C6D8B7F0D5B92677F5C9EB46" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeriesAConvertiblePreferredStockMember" xlink:label="loc_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_71FE1835C6D8B7F0D5B92677F5C9EB46" xlink:to="loc_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredESOPPlanMember" xlink:label="loc_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:to="loc_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredEmployeeStockOwnershipPlanMember" xlink:label="loc_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:to="loc_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CommonESOPPlanMember" xlink:label="loc_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:to="loc_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_557E9E5C869C2EC800262677F5D22CAC" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_557E9E5C869C2EC800262677F5D22CAC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredStockSharesHeldInEmployeeTrustShares" xlink:label="loc_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NumberofEmployeeStockOwnershipPlans" xlink:label="loc_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConvertiblePreferredStockNumberofSharesConvertible" xlink:label="loc_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/EquityTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D098E47E012490CC274C8020722BD8F8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D098E47E012490CC274C8020722BD8F8" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_309864923D6F8273A0268020722204F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_309864923D6F8273A0268020722204F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3D1D4BC5E980CAF1DC6580207223F074_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_309864923D6F8273A0268020722204F4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3D1D4BC5E980CAF1DC6580207223F074_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3D1D4BC5E980CAF1DC6580207223F074" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_309864923D6F8273A0268020722204F4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3D1D4BC5E980CAF1DC6580207223F074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6C744DA6C78FA7D732C8802072283675" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3D1D4BC5E980CAF1DC6580207223F074" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6C744DA6C78FA7D732C8802072283675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D098E47E012490CC274C8020722BD8F8" xlink:to="loc_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:to="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialServicesSectorMember" xlink:label="loc_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:to="loc_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_14887B0F30999D5F3B6524BD7A7778D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_14887B0F30999D5F3B6524BD7A7778D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_14887B0F30999D5F3B6524BD7A7778D1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_14887B0F30999D5F3B6524BD7A7778D1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:to="loc_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:to="loc_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:to="loc_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetFairValueHedge" xlink:label="loc_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:to="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:to="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:to="loc_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:to="loc_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="loc_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_D394F6552712A8942D177A9510F35AED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_HedgingDesignationAxis_D394F6552712A8942D177A9510F35AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_861AE60ACA99F34D8E4D7A9510F4FBFC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_D394F6552712A8942D177A9510F35AED" xlink:to="loc_us-gaap_HedgingDesignationDomain_861AE60ACA99F34D8E4D7A9510F4FBFC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_861AE60ACA99F34D8E4D7A9510F4FBFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_D394F6552712A8942D177A9510F35AED" xlink:to="loc_us-gaap_HedgingDesignationDomain_861AE60ACA99F34D8E4D7A9510F4FBFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_F89572E0E9CFB0A415987A95130FFF03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_861AE60ACA99F34D8E4D7A9510F4FBFC" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_F89572E0E9CFB0A415987A95130FFF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EBE75871AA160834EC9C7A95100614C1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_EBE75871AA160834EC9C7A95100614C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EBE75871AA160834EC9C7A95100614C1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EBE75871AA160834EC9C7A95100614C1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F" xlink:to="loc_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_7493761E8C59317BD0547A9510D9269F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_7493761E8C59317BD0547A9510D9269F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DDF61AA0FA9AF60248C27A83FA591FC2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DDF61AA0FA9AF60248C27A83FA591FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_29A7F9A108939EB9B8AD7A83FA596891_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DDF61AA0FA9AF60248C27A83FA591FC2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_29A7F9A108939EB9B8AD7A83FA596891_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_29A7F9A108939EB9B8AD7A83FA596891" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DDF61AA0FA9AF60248C27A83FA591FC2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_29A7F9A108939EB9B8AD7A83FA596891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_CAC20CAA3010EA9A4EE77A83FA5AC45D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_29A7F9A108939EB9B8AD7A83FA596891" xlink:to="loc_us-gaap_UnsecuredDebtMember_CAC20CAA3010EA9A4EE77A83FA5AC45D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6B2C157D7A7FD1B7F7BB7A83FA5A5D89" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6B2C157D7A7FD1B7F7BB7A83FA5A5D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6B2C157D7A7FD1B7F7BB7A83FA5A5D89" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6B2C157D7A7FD1B7F7BB7A83FA5A5D89" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7D95FDEA226CF5F0D4337A9513299EB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7D95FDEA226CF5F0D4337A9513299EB6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_B62A8C65C20999A5529C7A83FA5A69DD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_B62A8C65C20999A5529C7A83FA5A69DD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_7C690887FF52FB1554AD7A83FA5B460A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_7C690887FF52FB1554AD7A83FA5B460A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_99D8DB75A6AAF264A3917A950FDE52B5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_99D8DB75A6AAF264A3917A950FDE52B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7D9F9BFBBD62B16C002C7A83FA5B0795" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_LongTermDebt_7D9F9BFBBD62B16C002C7A83FA5B0795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:to="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HedgedItemAxis" xlink:label="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:to="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HedgedItemDomain" xlink:label="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:to="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HedgedItemDomain" xlink:label="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:to="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:to="loc_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6E2D18684AD8314F1E01E395F32E9AC8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6E2D18684AD8314F1E01E395F32E9AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6E2D18684AD8314F1E01E395F32E9AC8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6E2D18684AD8314F1E01E395F32E9AC8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3527B0873B08F303FD0AE395F32F44C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3527B0873B08F303FD0AE395F32F44C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_CF89B0AE25DA22EACF9EE395F32FAEE9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4" xlink:to="loc_us-gaap_InterestRateContractMember_CF89B0AE25DA22EACF9EE395F32FAEE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_5FC0C3E025E8EF9FB086E395F32FEAEB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:to="loc_us-gaap_HedgingDesignationAxis_5FC0C3E025E8EF9FB086E395F32FEAEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_5FC0C3E025E8EF9FB086E395F32FEAEB" xlink:to="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_5FC0C3E025E8EF9FB086E395F32FEAEB" xlink:to="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3A5807A21B51F4419109E395F32F68A5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3A5807A21B51F4419109E395F32F68A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_729891DDAD33591AA668E395F3309448" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571" xlink:to="loc_us-gaap_NondesignatedMember_729891DDAD33591AA668E395F3309448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:to="loc_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:to="loc_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:to="loc_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_EB9D4AE78F3FF412BBE3789C863600D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_EB9D4AE78F3FF412BBE3789C863600D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EB9D4AE78F3FF412BBE3789C863600D7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EB9D4AE78F3FF412BBE3789C863600D7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_082B5EBBB213590D4C58789C86377082" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_082B5EBBB213590D4C58789C86377082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_64A9050B4E3801728101789C8638F4F8" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_64A9050B4E3801728101789C8638F4F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BD439E3B7CD73087CA8C789C86388F63" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BD439E3B7CD73087CA8C789C86388F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BD439E3B7CD73087CA8C789C86388F63" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BD439E3B7CD73087CA8C789C86388F63" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_065FA8EED186C741583E789C8638FE00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_065FA8EED186C741583E789C8638FE00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_55DA2893C0B7714E95C6789C86393541" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_55DA2893C0B7714E95C6789C86393541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_BD347C1BBFD3485B4216789C863B7C0C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_BD347C1BBFD3485B4216789C863B7C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_BD347C1BBFD3485B4216789C863B7C0C" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_BD347C1BBFD3485B4216789C863B7C0C" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_1E8160BB1EC70CF5E858789C863B36B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E" xlink:to="loc_us-gaap_InterestRateContractMember_1E8160BB1EC70CF5E858789C863B36B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_DE7FBD4C5991592C37BB789C863CCAF1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E" xlink:to="loc_us-gaap_ForeignExchangeContractMember_DE7FBD4C5991592C37BB789C863CCAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4541D4E6996F7DAD792401C9480ABDEC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F0B21CBC84969324DD9F01C94809095F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4541D4E6996F7DAD792401C9480ABDEC" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F0B21CBC84969324DD9F01C94809095F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_CBD6B3C4C32639CF7D9001C9480957A9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F0B21CBC84969324DD9F01C94809095F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_CBD6B3C4C32639CF7D9001C9480957A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_F92D2221315348CCEF7301C94809A962_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_CBD6B3C4C32639CF7D9001C9480957A9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_F92D2221315348CCEF7301C94809A962_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_F92D2221315348CCEF7301C94809A962" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_CBD6B3C4C32639CF7D9001C9480957A9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_F92D2221315348CCEF7301C94809A962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1892BE4069BA58E156F001C9480A23AB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_F92D2221315348CCEF7301C94809A962" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1892BE4069BA58E156F001C9480A23AB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNIRestrictedCurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4541D4E6996F7DAD792401C9480ABDEC" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4541D4E6996F7DAD792401C9480ABDEC" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9BEC83AEEF3B7EA4D76055F217644F98" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9BEC83AEEF3B7EA4D76055F217644F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9BEC83AEEF3B7EA4D76055F217644F98" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9BEC83AEEF3B7EA4D76055F217644F98" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_20E7297EE7EC32B848D555F21765CB6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_20E7297EE7EC32B848D555F21765CB6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8088D82AB5F77BCD1CA555F217652522" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8088D82AB5F77BCD1CA555F217652522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_DC2F6E43A4BF1F90ED5755F217651034" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_DC2F6E43A4BF1F90ED5755F217651034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="loc_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C3FD1051B23A8701F8E155F217663B4F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C3FD1051B23A8701F8E155F217663B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_BDBAA5BF06A69CE360AE55F2176606B4" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_EquitySecuritiesMember_BDBAA5BF06A69CE360AE55F2176606B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="loc_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_800751EDB3A113ACD3E3E395F343C309" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_800751EDB3A113ACD3E3E395F343C309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6F6C5A96F2C157EA5F1BE395F34353F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_800751EDB3A113ACD3E3E395F343C309" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6F6C5A96F2C157EA5F1BE395F34353F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6F6C5A96F2C157EA5F1BE395F34353F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_800751EDB3A113ACD3E3E395F343C309" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6F6C5A96F2C157EA5F1BE395F34353F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_EF6D5503F54C288E592AE395F343E558" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6F6C5A96F2C157EA5F1BE395F34353F5" xlink:to="loc_us-gaap_UnsecuredDebtMember_EF6D5503F54C288E592AE395F343E558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A3FD03CBCE5792D1AEB1E395F344FE0D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:to="loc_us-gaap_DebtInstrumentAxis_A3FD03CBCE5792D1AEB1E395F344FE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_A3FD03CBCE5792D1AEB1E395F344FE0D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_A3FD03CBCE5792D1AEB1E395F344FE0D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2020Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2021Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2023Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20262029Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2034Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20362040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20432044Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20462049Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_F2C883749F5CC57CA38DE395F347FA7E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_F2C883749F5CC57CA38DE395F347FA7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_68B6376A6FA78BD22354E395F347697F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_68B6376A6FA78BD22354E395F347697F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:to="loc_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:to="loc_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:to="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorNotesDue2047Member" xlink:label="loc_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:to="loc_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" xlink:label="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:to="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:to="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_26010E47B95FA7BA928FE798575044ED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_26010E47B95FA7BA928FE798575044ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_655476E682F8B674CA29E7985750BB39_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_26010E47B95FA7BA928FE798575044ED" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_655476E682F8B674CA29E7985750BB39_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_655476E682F8B674CA29E7985750BB39" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_26010E47B95FA7BA928FE798575044ED" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_655476E682F8B674CA29E7985750BB39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1EBCA06613BD1D149E96E798575078D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_655476E682F8B674CA29E7985750BB39" xlink:to="loc_us-gaap_SeniorNotesMember_1EBCA06613BD1D149E96E798575078D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9D5AD7AE91DBA93CF619E7985751EC76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:to="loc_us-gaap_DebtInstrumentAxis_9D5AD7AE91DBA93CF619E7985751EC76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_9D5AD7AE91DBA93CF619E7985751EC76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_9D5AD7AE91DBA93CF619E7985751EC76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtFourPercentDue2049Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CC25B1837F0B6D5A27D7E7985752ACA0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CC25B1837F0B6D5A27D7E7985752ACA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_0648999518EBE26772B3E7985753E8F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:to="loc_us-gaap_LongTermDebt_0648999518EBE26772B3E7985753E8F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_14B6D1A871C9049C7879E7985753A1FD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_14B6D1A871C9049C7879E7985753A1FD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_6C8EE0CD9798B81793910E47C55E995B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_DerivativeTable_6C8EE0CD9798B81793910E47C55E995B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1C92F3E85DB9716678B90E480443D26A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_6C8EE0CD9798B81793910E47C55E995B" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1C92F3E85DB9716678B90E480443D26A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_CB334C78825BEE5AF0B70E48068DE520_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1C92F3E85DB9716678B90E480443D26A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_CB334C78825BEE5AF0B70E48068DE520_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_CB334C78825BEE5AF0B70E48068DE520" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1C92F3E85DB9716678B90E480443D26A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_CB334C78825BEE5AF0B70E48068DE520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7DB709E70A239B90A4760E48401A9220" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_CB334C78825BEE5AF0B70E48068DE520" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7DB709E70A239B90A4760E48401A9220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BC5040E3B90F150B6DB80C10A8A885D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BC5040E3B90F150B6DB80C10A8A885D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BC5040E3B90F150B6DB80C10A8A885D6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BC5040E3B90F150B6DB80C10A8A885D6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_43F510E71A99E7C4F8C90C10A8A9D26E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_43F510E71A99E7C4F8C90C10A8A9D26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C9EF1C25BFB356267E950C10A8A93808" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C9EF1C25BFB356267E950C10A8A93808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_030A54C0F4AC24621DEB0C10A8AAA5C7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C9EF1C25BFB356267E950C10A8A93808" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_030A54C0F4AC24621DEB0C10A8AAA5C7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_030A54C0F4AC24621DEB0C10A8AAA5C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C9EF1C25BFB356267E950C10A8A93808" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_030A54C0F4AC24621DEB0C10A8AAA5C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A38F08F1C118D2735D5B0C10A8AA16C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_030A54C0F4AC24621DEB0C10A8AAA5C7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_A38F08F1C118D2735D5B0C10A8AA16C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:to="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:to="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylotargMember" xlink:label="loc_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:to="loc_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:to="loc_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:to="loc_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_8099682DEF4F4703F9B20C10A8ABCCC4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_srt_StatementGeographicalAxis_8099682DEF4F4703F9B20C10A8ABCCC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_8099682DEF4F4703F9B20C10A8ABCCC4" xlink:to="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_8099682DEF4F4703F9B20C10A8ABCCC4" xlink:to="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047" xlink:to="loc_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_A529A6B06D5F477DEF9A0C10A8AC402E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047" xlink:to="loc_country_US_A529A6B06D5F477DEF9A0C10A8AC402E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount" xlink:label="loc_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" xlink:label="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2AFE72943168C890EE4E55F2174F7C9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:to="loc_us-gaap_DebtInstrumentAxis_2AFE72943168C890EE4E55F2174F7C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AFE72943168C890EE4E55F2174F7C9A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AFE72943168C890EE4E55F2174F7C9A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CreditFacilityExpiring2024Member" xlink:label="loc_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239" xlink:to="loc_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FacilityExpiringSeptember2020Member" xlink:label="loc_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239" xlink:to="loc_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:to="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:to="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:to="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:to="loc_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:to="loc_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:label="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66081D6946264073BD97D98564302F74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66081D6946264073BD97D98564302F74" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B2ADA603A09F7D6DD55BD985643097B4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66081D6946264073BD97D98564302F74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B2ADA603A09F7D6DD55BD985643097B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B2ADA603A09F7D6DD55BD985643097B4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B2ADA603A09F7D6DD55BD985643097B4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3A3981411CF98DC7A349D9856431848C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3A3981411CF98DC7A349D9856431848C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_91841EDB161339DB1D26D98564312DBD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:to="loc_us-gaap_TradeNamesMember_91841EDB161339DB1D26D98564312DBD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_F1FA86217FE75596E2BFD9856431FA62" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_F1FA86217FE75596E2BFD9856431FA62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948F3865313A365BA969D98564323344" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948F3865313A365BA969D98564323344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948F3865313A365BA969D98564323344" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948F3865313A365BA969D98564323344" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_A4FEAD2ECA670075912CD9856433824D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:to="loc_us-gaap_TradeNamesMember_A4FEAD2ECA670075912CD9856433824D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8E7DE1D09E6D374ADDD0D985643374FF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8E7DE1D09E6D374ADDD0D985643374FF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_738A6BA9E04673556432D98564330D7C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_738A6BA9E04673556432D98564330D7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsLineItems" xlink:label="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfIntangibleAssetsTable" xlink:label="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:to="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1A3B361DAF2E76F59110D98564262161" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1A3B361DAF2E76F59110D98564262161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FAE4E98052AC0CD7C4FCD9856427D350_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1A3B361DAF2E76F59110D98564262161" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FAE4E98052AC0CD7C4FCD9856427D350_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FAE4E98052AC0CD7C4FCD9856427D350" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1A3B361DAF2E76F59110D98564262161" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FAE4E98052AC0CD7C4FCD9856427D350" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FAE4E98052AC0CD7C4FCD9856427D350" xlink:to="loc_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4E0C6324611231AA6A80D98564271CD6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4E0C6324611231AA6A80D98564271CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_FB2F6B013898613DC523D98564274832_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4E0C6324611231AA6A80D98564271CD6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_FB2F6B013898613DC523D98564274832_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_FB2F6B013898613DC523D98564274832" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4E0C6324611231AA6A80D98564271CD6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_FB2F6B013898613DC523D98564274832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F79CD38226F107BE12FBD985642841BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_FB2F6B013898613DC523D98564274832" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_F79CD38226F107BE12FBD985642841BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C2337AF1335DF17AD9F7D98564283C2D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C2337AF1335DF17AD9F7D98564283C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C2337AF1335DF17AD9F7D98564283C2D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C2337AF1335DF17AD9F7D98564283C2D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:label="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:to="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8700BAFAA24043CC904BD985642978EE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8700BAFAA24043CC904BD985642978EE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:label="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:to="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_96B67C711B9A5F88398DD98564297523" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_96B67C711B9A5F88398DD98564297523" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_BD7072350589FB7EDB79D85DCAEA8171" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:to="loc_srt_ConsolidationItemsAxis_BD7072350589FB7EDB79D85DCAEA8171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_C53609E5A5FB1FFBABEDD85DCAEC10C3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_BD7072350589FB7EDB79D85DCAEA8171" xlink:to="loc_srt_ConsolidationItemsDomain_C53609E5A5FB1FFBABEDD85DCAEC10C3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_C53609E5A5FB1FFBABEDD85DCAEC10C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_BD7072350589FB7EDB79D85DCAEA8171" xlink:to="loc_srt_ConsolidationItemsDomain_C53609E5A5FB1FFBABEDD85DCAEC10C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_7AE8BC9B385361A6E67BD85DCB07D87C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_C53609E5A5FB1FFBABEDD85DCAEC10C3" xlink:to="loc_us-gaap_OperatingSegmentsMember_7AE8BC9B385361A6E67BD85DCB07D87C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3F3CB7DEA593B6CA07D6D8111790844F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3F3CB7DEA593B6CA07D6D8111790844F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3F3CB7DEA593B6CA07D6D8111790844F" xlink:to="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3F3CB7DEA593B6CA07D6D8111790844F" xlink:to="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_43319789126211928511D85D78611FA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:to="loc_pfe_BiopharmaSegmentMember_43319789126211928511D85D78611FA6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_6693B2B323D154E20E38D85DCB16C9FA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:to="loc_pfe_UpjohnSegmentMember_6693B2B323D154E20E38D85DCB16C9FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_D115AACE5A80088701ECD85F23FF48CF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:to="loc_pfe_ConsumerHealthcareMember_D115AACE5A80088701ECD85F23FF48CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:to="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:to="loc_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90FB1BFC4F1C1B85260ED81117C58E47" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90FB1BFC4F1C1B85260ED81117C58E47" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_B29ED612989D87469F5ED81117BBA766" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_B29ED612989D87469F5ED81117BBA766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_B29ED612989D87469F5ED81117BBA766" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_B29ED612989D87469F5ED81117BBA766" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:to="loc_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_4AEB89846078AC90FBF5D81117C21FC2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_SubsegmentsAxis_4AEB89846078AC90FBF5D81117C21FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_04292D5D333ACD4D828CD81117C26BF4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_4AEB89846078AC90FBF5D81117C21FC2" xlink:to="loc_us-gaap_SubsegmentsDomain_04292D5D333ACD4D828CD81117C26BF4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_04292D5D333ACD4D828CD81117C26BF4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_4AEB89846078AC90FBF5D81117C21FC2" xlink:to="loc_us-gaap_SubsegmentsDomain_04292D5D333ACD4D828CD81117C26BF4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_8FC9306FB9A309CE0F80D83E68B645D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_04292D5D333ACD4D828CD81117C26BF4" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_8FC9306FB9A309CE0F80D83E68B645D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_A379C1FE9EF1BD791237D81117C22293" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_srt_ConsolidationItemsAxis_A379C1FE9EF1BD791237D81117C22293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_A379C1FE9EF1BD791237D81117C22293" xlink:to="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_A379C1FE9EF1BD791237D81117C22293" xlink:to="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_8FAA87EBCA62E1A81C74D81117C3BD00" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550" xlink:to="loc_us-gaap_OperatingSegmentsMember_8FAA87EBCA62E1A81C74D81117C3BD00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_3F105B6162BCC3451C97D81117C3264F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_3F105B6162BCC3451C97D81117C3264F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_10FA32B765A7CE8152ECD81117C3D0A6" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_10FA32B765A7CE8152ECD81117C3D0A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_10FA32B765A7CE8152ECD81117C3D0A6" xlink:to="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_10FA32B765A7CE8152ECD81117C3D0A6" xlink:to="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_1EAFE8DFBF0AA88EB647D83E686BA475" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F" xlink:to="loc_pfe_BiopharmaSegmentMember_1EAFE8DFBF0AA88EB647D83E686BA475" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_B46E91E3B69AF0710005D83E6890F2C5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F" xlink:to="loc_pfe_UpjohnSegmentMember_B46E91E3B69AF0710005D83E6890F2C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5BF8FC2F297C6FC56A53D81117C4D580" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5BF8FC2F297C6FC56A53D81117C4D580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5BF8FC2F297C6FC56A53D81117C4D580" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5BF8FC2F297C6FC56A53D81117C4D580" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4F7B0BB90EB67C9A6F30D81117C460D6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4F7B0BB90EB67C9A6F30D81117C460D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_E840E80460B90D471293D81117C54B15" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:to="loc_us-gaap_TradeNamesMember_E840E80460B90D471293D81117C54B15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_C0018FF5751293D7A4D0D83DF53E34C8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_C0018FF5751293D7A4D0D83DF53E34C8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90FB1BFC4F1C1B85260ED81117C58E47" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5E3ABC9C0E9D0636DD3BD81117AAA3C5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5E3ABC9C0E9D0636DD3BD81117AAA3C5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4BBAB3BB6E306FFE6606D81117AA350F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5E3ABC9C0E9D0636DD3BD81117AAA3C5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4BBAB3BB6E306FFE6606D81117AA350F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4BBAB3BB6E306FFE6606D81117AA350F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4BBAB3BB6E306FFE6606D81117AA350F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1A544FB202CB03A0C5DAD81117ABEB4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1A544FB202CB03A0C5DAD81117ABEB4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/Insurance" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/InventoriesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_BDFC7CD4ABA1DB4D2A27E395F42ABF79" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_BDFC7CD4ABA1DB4D2A27E395F42ABF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5DF7D46DD8F49A3BD529E395F42AC3E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_BDFC7CD4ABA1DB4D2A27E395F42ABF79" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5DF7D46DD8F49A3BD529E395F42AC3E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5DF7D46DD8F49A3BD529E395F42AC3E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_BDFC7CD4ABA1DB4D2A27E395F42ABF79" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5DF7D46DD8F49A3BD529E395F42AC3E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_F208B51FDE1E074D9CC6E395F42AD221" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5DF7D46DD8F49A3BD529E395F42AC3E2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_F208B51FDE1E074D9CC6E395F42AD221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0A95964F9E5FF2B617DAE395F42B907F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0A95964F9E5FF2B617DAE395F42B907F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E7F4DDE737E782AADEE4E395F42CFD76_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0A95964F9E5FF2B617DAE395F42B907F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E7F4DDE737E782AADEE4E395F42CFD76_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E7F4DDE737E782AADEE4E395F42CFD76" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0A95964F9E5FF2B617DAE395F42B907F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E7F4DDE737E782AADEE4E395F42CFD76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_36BEB86C27D4D474F6FFE395F42CFFA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E7F4DDE737E782AADEE4E395F42CFD76" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_36BEB86C27D4D474F6FFE395F42CFFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsFairValueDisclosure" xlink:label="loc_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_0F7634C19C33D4A15EA87A814AA23A80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_StatementGeographicalAxis_0F7634C19C33D4A15EA87A814AA23A80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7D11DD1E9BA9B2E7CE287A814AA3D323_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_0F7634C19C33D4A15EA87A814AA23A80" xlink:to="loc_srt_SegmentGeographicalDomain_7D11DD1E9BA9B2E7CE287A814AA3D323_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7D11DD1E9BA9B2E7CE287A814AA3D323" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_0F7634C19C33D4A15EA87A814AA23A80" xlink:to="loc_srt_SegmentGeographicalDomain_7D11DD1E9BA9B2E7CE287A814AA3D323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_7D11DD1E9BA9B2E7CE287A814AA3D323" xlink:to="loc_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7E4A5093A3168164D1A17A814AA42FAD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_ProductOrServiceAxis_7E4A5093A3168164D1A17A814AA42FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_46C0BA71EBDBE433E1097A814AA42CA6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7E4A5093A3168164D1A17A814AA42FAD" xlink:to="loc_srt_ProductsAndServicesDomain_46C0BA71EBDBE433E1097A814AA42CA6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_46C0BA71EBDBE433E1097A814AA42CA6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7E4A5093A3168164D1A17A814AA42FAD" xlink:to="loc_srt_ProductsAndServicesDomain_46C0BA71EBDBE433E1097A814AA42CA6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylotargMember" xlink:label="loc_pfe_MylotargMember_0D0FD1E38C2CDA5257BE7A814AA48D65" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_46C0BA71EBDBE433E1097A814AA42CA6" xlink:to="loc_pfe_MylotargMember_0D0FD1E38C2CDA5257BE7A814AA48D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A5B5552A27B213A254F47A814AA4A07A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A5B5552A27B213A254F47A814AA4A07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_DD318E88E2ED3940FACC7A814AA44F73_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A5B5552A27B213A254F47A814AA4A07A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_DD318E88E2ED3940FACC7A814AA44F73_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_DD318E88E2ED3940FACC7A814AA44F73" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A5B5552A27B213A254F47A814AA4A07A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_DD318E88E2ED3940FACC7A814AA44F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_96A247EB5B94B07AB16B7A814AA56DA5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_DD318E88E2ED3940FACC7A814AA44F73" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_96A247EB5B94B07AB16B7A814AA56DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_86B67C60DB16749C04677A814AA5D229" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_CounterpartyNameAxis_86B67C60DB16749C04677A814AA5D229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_276AB20E471D870D38AE7A814AA54744_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_86B67C60DB16749C04677A814AA5D229" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_276AB20E471D870D38AE7A814AA54744_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_276AB20E471D870D38AE7A814AA54744" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_86B67C60DB16749C04677A814AA5D229" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_276AB20E471D870D38AE7A814AA54744" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BainCapitalMember" xlink:label="loc_pfe_BainCapitalMember_534542882ED533B4777B7A814AA606D8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_276AB20E471D870D38AE7A814AA54744" xlink:to="loc_pfe_BainCapitalMember_534542882ED533B4777B7A814AA606D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_DDAD29CA3A30FB7327C77A814AA6C40D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_ConsolidationItemsAxis_DDAD29CA3A30FB7327C77A814AA6C40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_437132EA647540050F857A814AA6F1BE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_DDAD29CA3A30FB7327C77A814AA6C40D" xlink:to="loc_srt_ConsolidationItemsDomain_437132EA647540050F857A814AA6F1BE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_437132EA647540050F857A814AA6F1BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_DDAD29CA3A30FB7327C77A814AA6C40D" xlink:to="loc_srt_ConsolidationItemsDomain_437132EA647540050F857A814AA6F1BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_79A6EE042B21AFE9A36C7A814AA64FA2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_437132EA647540050F857A814AA6F1BE" xlink:to="loc_us-gaap_OperatingSegmentsMember_79A6EE042B21AFE9A36C7A814AA64FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D22C724D5DAFE3D54F6D7A814AA6A59C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D22C724D5DAFE3D54F6D7A814AA6A59C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D22C724D5DAFE3D54F6D7A814AA6A59C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D22C724D5DAFE3D54F6D7A814AA6A59C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelMember" xlink:label="loc_pfe_CerevelMember_466789CA484762BF9B6E7A814AA77FEF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:to="loc_pfe_CerevelMember_466789CA484762BF9B6E7A814AA77FEF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_DB1E07C3F4A6FF24838A7A814AA754AD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:to="loc_pfe_AllogeneMember_DB1E07C3F4A6FF24838A7A814AA754AD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_7CA80FB0F99C61A925127A814AA7CC62" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:to="loc_pfe_ViivHealthcareLimitedMember_7CA80FB0F99C61A925127A814AA7CC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40FF1D79D918C632ACA47A814AA860EF" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_40FF1D79D918C632ACA47A814AA860EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ED086083974553DF504B7A814AA83C8A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40FF1D79D918C632ACA47A814AA860EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ED086083974553DF504B7A814AA83C8A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ED086083974553DF504B7A814AA83C8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40FF1D79D918C632ACA47A814AA860EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ED086083974553DF504B7A814AA83C8A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_8D62645CB30C418FCE857A814AA88750" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ED086083974553DF504B7A814AA83C8A" xlink:to="loc_pfe_ViivHealthcareLimitedMember_8D62645CB30C418FCE857A814AA88750" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_61E7B26E320754F560FC7A814AA8B210" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_InvestmentIncomeDividend_61E7B26E320754F560FC7A814AA8B210" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:label="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_DD3B00798B4CE87392D67A814AA9C6B1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_DD3B00798B4CE87392D67A814AA9C6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossFromContributionAgreement" xlink:label="loc_pfe_GainLossFromContributionAgreement_FF162CB129AF6A4BAF9B7A814AA9DD01" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_pfe_GainLossFromContributionAgreement_FF162CB129AF6A4BAF9B7A814AA9DD01" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" xlink:label="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherNonoperatingIncomeMiscellaneous" xlink:label="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_165865394FB07C74F2DEE3F1DC3DEA1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_165865394FB07C74F2DEE3F1DC3DEA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6C4AFBE06633708E605DE3F1DC4CC771_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_165865394FB07C74F2DEE3F1DC3DEA1D" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6C4AFBE06633708E605DE3F1DC4CC771_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6C4AFBE06633708E605DE3F1DC4CC771" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_165865394FB07C74F2DEE3F1DC3DEA1D" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6C4AFBE06633708E605DE3F1DC4CC771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_C85C5234EF7C950DD2F5E3F1DC9FF03E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6C4AFBE06633708E605DE3F1DC4CC771" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_C85C5234EF7C950DD2F5E3F1DC9FF03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_73A68EA1F0E22B99AACEE395F470BFDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:to="loc_srt_OwnershipAxis_73A68EA1F0E22B99AACEE395F470BFDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_6D590A96E4284048B57FE395F470BD67_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_73A68EA1F0E22B99AACEE395F470BFDF" xlink:to="loc_srt_OwnershipDomain_6D590A96E4284048B57FE395F470BD67_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_6D590A96E4284048B57FE395F470BD67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_73A68EA1F0E22B99AACEE395F470BFDF" xlink:to="loc_srt_OwnershipDomain_6D590A96E4284048B57FE395F470BD67" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_4FE080165F8DC55F03E3E395F470A2D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_6D590A96E4284048B57FE395F470BD67" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_4FE080165F8DC55F03E3E395F470A2D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_38A8542A15708B41EDF5E395F471FF10" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_38A8542A15708B41EDF5E395F471FF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_38A8542A15708B41EDF5E395F471FF10" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_38A8542A15708B41EDF5E395F471FF10" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_85F5A6D32A7BCDF3B1F5E395F471422F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_85F5A6D32A7BCDF3B1F5E395F471422F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_90583F829E5ABCDD0046E395F471980D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_90583F829E5ABCDD0046E395F471980D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CortexymeInc.Member" xlink:label="loc_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:to="loc_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_F87E1F192D20C67BDA24E3F1DCCEFA45" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:to="loc_pfe_AllogeneMember_F87E1F192D20C67BDA24E3F1DCCEFA45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5B47C8F75B4EC655EB55E395F47275F3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5B47C8F75B4EC655EB55E395F47275F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_905D1F447EA5B5EE090EE395F472D568" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_905D1F447EA5B5EE090EE395F472D568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_D4AAEB290680095AEBEEE395F472D987" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_D4AAEB290680095AEBEEE395F472D987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6CB01F4D99B782F6EFE9E4011FAA783E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6CB01F4D99B782F6EFE9E4011FAA783E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43970535A76D2305B58BE4011FAC2DD9_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6CB01F4D99B782F6EFE9E4011FAA783E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43970535A76D2305B58BE4011FAC2DD9_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43970535A76D2305B58BE4011FAC2DD9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6CB01F4D99B782F6EFE9E4011FAA783E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43970535A76D2305B58BE4011FAC2DD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_02324BD4DB92B29CDC3AE401201DD763" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43970535A76D2305B58BE4011FAC2DD9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_02324BD4DB92B29CDC3AE401201DD763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A8D053F22EDFD3584420E395F45E96B7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A8D053F22EDFD3584420E395F45E96B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F41CD91D157B4D651103E395F45E512A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A8D053F22EDFD3584420E395F45E96B7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F41CD91D157B4D651103E395F45E512A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F41CD91D157B4D651103E395F45E512A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A8D053F22EDFD3584420E395F45E96B7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F41CD91D157B4D651103E395F45E512A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F41CD91D157B4D651103E395F45E512A" xlink:to="loc_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57886FA719470C0EE806E395F45FF8A8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57886FA719470C0EE806E395F45FF8A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9219E8869901C7D28AC0E395F45F7FE2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57886FA719470C0EE806E395F45FF8A8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9219E8869901C7D28AC0E395F45F7FE2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9219E8869901C7D28AC0E395F45F7FE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57886FA719470C0EE806E395F45FF8A8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9219E8869901C7D28AC0E395F45F7FE2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" xlink:label="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_A54243F01B992DBCB4B3E395F45FC3A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9219E8869901C7D28AC0E395F45F7FE2" xlink:to="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_A54243F01B992DBCB4B3E395F45FC3A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_DD664C9129C54507EF0CE395F45F774A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_DD664C9129C54507EF0CE395F45F774A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_81402B96627662AE482DE395F45F3883_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_DD664C9129C54507EF0CE395F45F774A" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_81402B96627662AE482DE395F45F3883_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_81402B96627662AE482DE395F45F3883" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_DD664C9129C54507EF0CE395F45F774A" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_81402B96627662AE482DE395F45F3883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5406049A77890636E1AFE395F4607498" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_81402B96627662AE482DE395F45F3883" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5406049A77890636E1AFE395F4607498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_D4475A9DCFA7A9DEBF93E395F4601916" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_srt_CounterpartyNameAxis_D4475A9DCFA7A9DEBF93E395F4601916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_D4475A9DCFA7A9DEBF93E395F4601916" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_D4475A9DCFA7A9DEBF93E395F4601916" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_884ABEB851E7A54D4216E400BD020D4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:to="loc_pfe_MylanMember_884ABEB851E7A54D4216E400BD020D4A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShireMember" xlink:label="loc_pfe_ShireMember_749D539E09CB1EEA448AE395F4601A6C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:to="loc_pfe_ShireMember_749D539E09CB1EEA448AE395F4601A6C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MerckMember" xlink:label="loc_pfe_MerckMember_1BD40AB01468589616DFE395F4617241" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:to="loc_pfe_MerckMember_1BD40AB01468589616DFE395F4617241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3257D7466CA211A8E810E395F461B259" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3257D7466CA211A8E810E395F461B259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3257D7466CA211A8E810E395F461B259" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3257D7466CA211A8E810E395F461B259" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_AC728A6805E3487157CBE395F4619FE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3" xlink:to="loc_us-gaap_LicensingAgreementsMember_AC728A6805E3487157CBE395F4619FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_FBB82CF08E6D21FAE895E395F4610B88" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_FBB82CF08E6D21FAE895E395F4610B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_12FE59762A687015A345E395F4626010" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_us-gaap_ProceedsFromCollaborators_12FE59762A687015A345E395F4626010" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ProceedsFromLicensingArrangement" xlink:label="loc_pfe_ProceedsFromLicensingArrangement_3807C4ACD592BC713D05E395F462553E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_pfe_ProceedsFromLicensingArrangement_3807C4ACD592BC713D05E395F462553E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_A3D75389EB11C1133D95E395F46292DF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_A3D75389EB11C1133D95E395F46292DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_502646D7CB5678EEADA6E395F4582856" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LossContingenciesLineItems_502646D7CB5678EEADA6E395F4582856" xlink:to="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:to="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:to="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:to="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:to="loc_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7C3421BDEEE9FF58CFD4E395F456B192" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:to="loc_srt_ProductOrServiceAxis_7C3421BDEEE9FF58CFD4E395F456B192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4A07DE02402B858A7A25E395F457FEBA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_7C3421BDEEE9FF58CFD4E395F456B192" xlink:to="loc_srt_ProductsAndServicesDomain_4A07DE02402B858A7A25E395F457FEBA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4A07DE02402B858A7A25E395F457FEBA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_7C3421BDEEE9FF58CFD4E395F456B192" xlink:to="loc_srt_ProductsAndServicesDomain_4A07DE02402B858A7A25E395F457FEBA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_4A07DE02402B858A7A25E395F457FEBA" xlink:to="loc_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PatentMatterMember" xlink:label="loc_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:to="loc_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LossContingenciesLineItems_502646D7CB5678EEADA6E395F4582856" xlink:to="loc_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsLineItems" xlink:label="loc_pfe_IntangibleAssetsLineItems_649E0DB2DDE8C2971A9A26D4F1F8D945" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfIntangibleAssetsTable" xlink:label="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_IntangibleAssetsLineItems_649E0DB2DDE8C2971A9A26D4F1F8D945" xlink:to="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:to="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:to="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7743E4CA858358BA162826D4F1F186DE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7743E4CA858358BA162826D4F1F186DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7743E4CA858358BA162826D4F1F186DE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7743E4CA858358BA162826D4F1F186DE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F998FCDB1001C39A7D0C26D4F1F183CB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_F998FCDB1001C39A7D0C26D4F1F183CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:to="loc_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5B9B189E0BF9270A699826D4F1F29762" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5B9B189E0BF9270A699826D4F1F29762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_099CD857F20AC3D4665526D4F1F26AE8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_099CD857F20AC3D4665526D4F1F26AE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_04F2A4F07485E88F5EAF26D4F1F25294_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_099CD857F20AC3D4665526D4F1F26AE8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_04F2A4F07485E88F5EAF26D4F1F25294_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_04F2A4F07485E88F5EAF26D4F1F25294" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_099CD857F20AC3D4665526D4F1F26AE8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_04F2A4F07485E88F5EAF26D4F1F25294" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AMPharmaBVMember" xlink:label="loc_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_04F2A4F07485E88F5EAF26D4F1F25294" xlink:to="loc_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_E174D4FB40BB9B90EE9026D4F1F369C5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_E174D4FB40BB9B90EE9026D4F1F369C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_50495FA35CD18C45A27C26D4F1F35336_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_E174D4FB40BB9B90EE9026D4F1F369C5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_50495FA35CD18C45A27C26D4F1F35336_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_50495FA35CD18C45A27C26D4F1F35336" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_E174D4FB40BB9B90EE9026D4F1F369C5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_50495FA35CD18C45A27C26D4F1F35336" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_E469394A8F09265C9DAC26D4F1F3729F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_50495FA35CD18C45A27C26D4F1F35336" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_E469394A8F09265C9DAC26D4F1F3729F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_DFD1BA372D7B7CCCDB0B26D4F1F37A1C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_srt_ConsolidationItemsAxis_DFD1BA372D7B7CCCDB0B26D4F1F37A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_6585A2B21116FDAEDD6426D4F1F41638_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_DFD1BA372D7B7CCCDB0B26D4F1F37A1C" xlink:to="loc_srt_ConsolidationItemsDomain_6585A2B21116FDAEDD6426D4F1F41638_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_6585A2B21116FDAEDD6426D4F1F41638" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_DFD1BA372D7B7CCCDB0B26D4F1F37A1C" xlink:to="loc_srt_ConsolidationItemsDomain_6585A2B21116FDAEDD6426D4F1F41638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_17FF7F97E56D431EE40E26D4F1F47B8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_6585A2B21116FDAEDD6426D4F1F41638" xlink:to="loc_us-gaap_OperatingSegmentsMember_17FF7F97E56D431EE40E26D4F1F47B8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_927B6FC641BBE990436726D4F1F447AA" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_927B6FC641BBE990436726D4F1F447AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_5E2B3E0C4DFA2D2253AA26D4F1F4EEBC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_927B6FC641BBE990436726D4F1F447AA" xlink:to="loc_us-gaap_SegmentDomain_5E2B3E0C4DFA2D2253AA26D4F1F4EEBC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_5E2B3E0C4DFA2D2253AA26D4F1F4EEBC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_927B6FC641BBE990436726D4F1F447AA" xlink:to="loc_us-gaap_SegmentDomain_5E2B3E0C4DFA2D2253AA26D4F1F4EEBC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_41EAFBA0BF30337777E626D4F1F50C48" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_5E2B3E0C4DFA2D2253AA26D4F1F4EEBC" xlink:to="loc_pfe_BiopharmaSegmentMember_41EAFBA0BF30337777E626D4F1F50C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4E8852B47E9EC2ECCCE026D4F1F57B55" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4E8852B47E9EC2ECCCE026D4F1F57B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4E8852B47E9EC2ECCCE026D4F1F57B55" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4E8852B47E9EC2ECCCE026D4F1F57B55" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InnoPharmaMember" xlink:label="loc_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_D03B0638AD9A3A6C193826D4F1F6D945" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_HospiraMember_D03B0638AD9A3A6C193826D4F1F6D945" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NextWaveMember" xlink:label="loc_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8A434232E0432B1CCBAD26D4F1F66E24" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_srt_ProductOrServiceAxis_8A434232E0432B1CCBAD26D4F1F66E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_8A434232E0432B1CCBAD26D4F1F66E24" xlink:to="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_8A434232E0432B1CCBAD26D4F1F66E24" xlink:to="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GeneTherapiesMember" xlink:label="loc_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenericSterileInjectableProductMember" xlink:label="loc_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember" xlink:label="loc_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TreatmentForToenailFungusMember" xlink:label="loc_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SterileInjectablePainRelieverMember" xlink:label="loc_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TreatmentOfAttentionHyperactivityDisorderMember" xlink:label="loc_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenericInjectablePainRelieverMember" xlink:label="loc_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IntangibleAssetsLineItems_649E0DB2DDE8C2971A9A26D4F1F8D945" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IntangibleAssetsLineItems_649E0DB2DDE8C2971A9A26D4F1F8D945" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_28498BA23FD18A9B8C2374DC3A9F9635" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:to="loc_us-gaap_HedgingDesignationAxis_28498BA23FD18A9B8C2374DC3A9F9635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1EB0A2E95661B67C8E3574DC3A9F0C1D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_HedgingDesignationAxis_28498BA23FD18A9B8C2374DC3A9F9635" xlink:to="loc_us-gaap_HedgingDesignationDomain_1EB0A2E95661B67C8E3574DC3A9F0C1D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1EB0A2E95661B67C8E3574DC3A9F0C1D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_HedgingDesignationAxis_28498BA23FD18A9B8C2374DC3A9F9635" xlink:to="loc_us-gaap_HedgingDesignationDomain_1EB0A2E95661B67C8E3574DC3A9F0C1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F568D7955970CD5463874DC3A9F694A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_HedgingDesignationDomain_1EB0A2E95661B67C8E3574DC3A9F0C1D" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F568D7955970CD5463874DC3A9F694A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_C1B073B4369C688A446074DC3AA04893" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_C1B073B4369C688A446074DC3AA04893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_CEA6DA0AE3B353D102C974DC3AA0989E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C1B073B4369C688A446074DC3AA04893" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_CEA6DA0AE3B353D102C974DC3AA0989E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_CEA6DA0AE3B353D102C974DC3AA0989E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C1B073B4369C688A446074DC3AA04893" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_CEA6DA0AE3B353D102C974DC3AA0989E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_CEA6DA0AE3B353D102C974DC3AA0989E" xlink:to="loc_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:to="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:to="loc_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_ADC764ADAB752AAB281516E81D49AC06" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_ADC764ADAB752AAB281516E81D49AC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_ADC764ADAB752AAB281516E81D49AC06" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_ADC764ADAB752AAB281516E81D49AC06" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_6EEC2EB5A2239291202416E81D4A3824" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0" xlink:to="loc_us-gaap_QualifiedPlanMember_6EEC2EB5A2239291202416E81D4A3824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_2D2110C834A0455F0DAF16E81D4A24D7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0" xlink:to="loc_us-gaap_NonqualifiedPlanMember_2D2110C834A0455F0DAF16E81D4A24D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_693A21BEA6EADB9B22B716E81D4B19D8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_693A21BEA6EADB9B22B716E81D4B19D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_693A21BEA6EADB9B22B716E81D4B19D8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_693A21BEA6EADB9B22B716E81D4B19D8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_83F488804DDBC9D0391916E81D4BF2E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1" xlink:to="loc_us-gaap_DomesticPlanMember_83F488804DDBC9D0391916E81D4BF2E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_A289FC765C823C62E2FD16E81D4C0C99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_83F488804DDBC9D0391916E81D4BF2E6" xlink:to="loc_country_US_A289FC765C823C62E2FD16E81D4C0C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_2D0859E8EEF887E4665716E81D4C7F16" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1" xlink:to="loc_us-gaap_ForeignPlanMember_2D0859E8EEF887E4665716E81D4C7F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_B47315A80149D574E7BC16E81D4CDF2E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_B47315A80149D574E7BC16E81D4CDF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_B47315A80149D574E7BC16E81D4CDF2E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_B47315A80149D574E7BC16E81D4CDF2E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_E385D86FA96BBBF6D90A16E81D4D7FD5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_E385D86FA96BBBF6D90A16E81D4D7FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_C1B72F68520EED3D02AF16E81D4DA472" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_C1B72F68520EED3D02AF16E81D4DA472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_06FBCAA23E68A931B89716E81D4D661F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_06FBCAA23E68A931B89716E81D4D661F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanExpectedAmortizationTerm" xlink:label="loc_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_05D3680510F9A8918FBAD8A794D4E3B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_05D3680510F9A8918FBAD8A794D4E3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_05D3680510F9A8918FBAD8A794D4E3B2" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_05D3680510F9A8918FBAD8A794D4E3B2" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_0E270D7DAEB9D951E3CAD8A7F51C5697" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E" xlink:to="loc_us-gaap_QualifiedPlanMember_0E270D7DAEB9D951E3CAD8A7F51C5697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_E15089F0FB246DAE927DD8A826AB6FD7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E" xlink:to="loc_us-gaap_NonqualifiedPlanMember_E15089F0FB246DAE927DD8A826AB6FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_D0C6A56A05C01FD4FFE3D81116982E50" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_D0C6A56A05C01FD4FFE3D81116982E50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_D0C6A56A05C01FD4FFE3D81116982E50" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_D0C6A56A05C01FD4FFE3D81116982E50" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_726DD82C98D8616FCA5ED8A691DE305F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727" xlink:to="loc_us-gaap_DomesticPlanMember_726DD82C98D8616FCA5ED8A691DE305F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_8A79C36562992FB81EF4D8111698546D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_726DD82C98D8616FCA5ED8A691DE305F" xlink:to="loc_country_US_8A79C36562992FB81EF4D8111698546D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_C204FDDAD6E94AB41573D8111699FFF6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727" xlink:to="loc_us-gaap_ForeignPlanMember_C204FDDAD6E94AB41573D8111699FFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_59C9961B94BF603FF382D81116991057" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_59C9961B94BF603FF382D81116991057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_59C9961B94BF603FF382D81116991057" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_59C9961B94BF603FF382D81116991057" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2A763B31EDAC47A2C2CED8111699B373" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2A763B31EDAC47A2C2CED8111699B373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_648DA7A021531C327295D811169A33ED" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_648DA7A021531C327295D811169A33ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_C18C620C24383CA2ECF9D811169AF604" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_C18C620C24383CA2ECF9D811169AF604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63C71CD0807FB0745A5326D4EFDD08E5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63C71CD0807FB0745A5326D4EFDD08E5" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_D7F359D8094B450052DC26D4EFDA1D3C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_D7F359D8094B450052DC26D4EFDA1D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_39BFB609431F31B4237226D4EFDA6149_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_D7F359D8094B450052DC26D4EFDA1D3C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_39BFB609431F31B4237226D4EFDA6149_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_39BFB609431F31B4237226D4EFDA6149" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_D7F359D8094B450052DC26D4EFDA1D3C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_39BFB609431F31B4237226D4EFDA6149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_A5E33B53D8CEF4D3A87A26D4EFDB9BBD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_39BFB609431F31B4237226D4EFDA6149" xlink:to="loc_us-gaap_ForeignPlanMember_A5E33B53D8CEF4D3A87A26D4EFDB9BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_D6AA4C6FC37FCA4BD86126D4EFDBABB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_D6AA4C6FC37FCA4BD86126D4EFDBABB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_175966872C03C54B48B026D4EFDBDB32_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_D6AA4C6FC37FCA4BD86126D4EFDBABB8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_175966872C03C54B48B026D4EFDBDB32_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_175966872C03C54B48B026D4EFDBDB32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_D6AA4C6FC37FCA4BD86126D4EFDBABB8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_175966872C03C54B48B026D4EFDBDB32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_15B75BA9C88335F810D726D4EFDBE60F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_175966872C03C54B48B026D4EFDBDB32" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_15B75BA9C88335F810D726D4EFDBE60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3FE92595E106819A3E2326D4EFDC651B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3FE92595E106819A3E2326D4EFDC651B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F52A7DC935F18F5FBCF826D4EFDC8FD8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F52A7DC935F18F5FBCF826D4EFDC8FD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F52A7DC935F18F5FBCF826D4EFDC8FD8" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F52A7DC935F18F5FBCF826D4EFDC8FD8" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceContractsMember" xlink:label="loc_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7" xlink:to="loc_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63C71CD0807FB0745A5326D4EFDD08E5" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_33B70608A4C9AE3978D126D4EFDEDC70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_33B70608A4C9AE3978D126D4EFDEDC70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:to="loc_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:to="loc_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:to="loc_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:to="loc_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:to="loc_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_DDA3F5675BAEFE62D6D15B5D784540A5" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_DDA3F5675BAEFE62D6D15B5D784540A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_DDA3F5675BAEFE62D6D15B5D784540A5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_DDA3F5675BAEFE62D6D15B5D784540A5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_20AD6D91543BC81B09355B5D78469A48" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_20AD6D91543BC81B09355B5D78469A48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:to="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:to="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:to="loc_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_67494158B76C4CB84D6F2677F5F991D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_67494158B76C4CB84D6F2677F5F991D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_67494158B76C4CB84D6F2677F5F991D2" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_67494158B76C4CB84D6F2677F5F991D2" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_459A5F8231B2384618FE2677F5FA70EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725" xlink:to="loc_us-gaap_QualifiedPlanMember_459A5F8231B2384618FE2677F5FA70EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_F10B176D54DFE271DA7D2677F5FAFA98" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725" xlink:to="loc_us-gaap_NonqualifiedPlanMember_F10B176D54DFE271DA7D2677F5FAFA98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_50CE03E9399E7530D5D62677F5FA781C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_50CE03E9399E7530D5D62677F5FA781C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_50CE03E9399E7530D5D62677F5FA781C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_50CE03E9399E7530D5D62677F5FA781C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_035A28F08AB34244B9C52677F5FB836E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33" xlink:to="loc_us-gaap_DomesticPlanMember_035A28F08AB34244B9C52677F5FB836E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D1433B03BF762441440C2677F5FBBFA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_035A28F08AB34244B9C52677F5FB836E" xlink:to="loc_country_US_D1433B03BF762441440C2677F5FBBFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_8900529224CA1100B2B22677F5FBDA00" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33" xlink:to="loc_us-gaap_ForeignPlanMember_8900529224CA1100B2B22677F5FBDA00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2DA4B5E6A7AEA809A6042677F5FB0D64" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2DA4B5E6A7AEA809A6042677F5FB0D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2DA4B5E6A7AEA809A6042677F5FB0D64" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2DA4B5E6A7AEA809A6042677F5FB0D64" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_97A304AC2E612555CF5B2677F5FCA5D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_97A304AC2E612555CF5B2677F5FCA5D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_D96323540BA5C9288A2F2677F5FC82D5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_D96323540BA5C9288A2F2677F5FC82D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_E7D307235002F1C89D7C2677F5FCB5FA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_E7D307235002F1C89D7C2677F5FCB5FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_18C8DE821CBD7409830F16E81D6EAFEB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_18C8DE821CBD7409830F16E81D6EAFEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_0799A16219699B59BEEF16E81D74A1CF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_18C8DE821CBD7409830F16E81D6EAFEB" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_0799A16219699B59BEEF16E81D74A1CF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_0799A16219699B59BEEF16E81D74A1CF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_18C8DE821CBD7409830F16E81D6EAFEB" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_0799A16219699B59BEEF16E81D74A1CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_61E13EECDC150A24506F16E81D74B9D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_0799A16219699B59BEEF16E81D74A1CF" xlink:to="loc_us-gaap_QualifiedPlanMember_61E13EECDC150A24506F16E81D74B9D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_396925BC94D775B0497116E81D75C386" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_396925BC94D775B0497116E81D75C386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7CF7F95B4825C499103916E81D75F90D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_396925BC94D775B0497116E81D75C386" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7CF7F95B4825C499103916E81D75F90D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7CF7F95B4825C499103916E81D75F90D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_396925BC94D775B0497116E81D75C386" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7CF7F95B4825C499103916E81D75F90D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_ACF5EB57B5180D05494A16E81D756A0B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7CF7F95B4825C499103916E81D75F90D" xlink:to="loc_pfe_HospiraMember_ACF5EB57B5180D05494A16E81D756A0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8D206EDAE104D1D109E016E81D766462" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8D206EDAE104D1D109E016E81D766462" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_A3550EA0A11AB52210DF16E81D761550_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8D206EDAE104D1D109E016E81D766462" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_A3550EA0A11AB52210DF16E81D761550_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_A3550EA0A11AB52210DF16E81D761550" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8D206EDAE104D1D109E016E81D766462" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_A3550EA0A11AB52210DF16E81D761550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_59954E95FA5A0EA3FFA916E81D7694E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_A3550EA0A11AB52210DF16E81D761550" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_59954E95FA5A0EA3FFA916E81D7694E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_8D78C73300428506ADF916E81D7761D2" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_8D78C73300428506ADF916E81D7761D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6D68AE92311A870CD74816E81D774CD3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8D78C73300428506ADF916E81D7761D2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6D68AE92311A870CD74816E81D774CD3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6D68AE92311A870CD74816E81D774CD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8D78C73300428506ADF916E81D7761D2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6D68AE92311A870CD74816E81D774CD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_02E3FDC36F9D1831946016E81D770329" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6D68AE92311A870CD74816E81D774CD3" xlink:to="loc_us-gaap_DomesticPlanMember_02E3FDC36F9D1831946016E81D770329" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_B6B87D2A02722DF2C19E16E81D78CF9F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_02E3FDC36F9D1831946016E81D770329" xlink:to="loc_country_US_B6B87D2A02722DF2C19E16E81D78CF9F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" xlink:label="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:to="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" xlink:label="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:to="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanNumberofPensionPlansFrozen" xlink:label="loc_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:to="loc_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_D9C717558F78B47B50F3D8A38E8DB819" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_D9C717558F78B47B50F3D8A38E8DB819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_D9C717558F78B47B50F3D8A38E8DB819" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_D9C717558F78B47B50F3D8A38E8DB819" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_9FFF5A28F7E0AE9121A8D8A3ED6B89B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980" xlink:to="loc_us-gaap_QualifiedPlanMember_9FFF5A28F7E0AE9121A8D8A3ED6B89B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_E1ED83E3E8271C7C7956D8A41C7879BF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980" xlink:to="loc_us-gaap_NonqualifiedPlanMember_E1ED83E3E8271C7C7956D8A41C7879BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_B2B03B145EE5DBCB86CCD81116ABA22C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_B2B03B145EE5DBCB86CCD81116ABA22C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_B2B03B145EE5DBCB86CCD81116ABA22C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_B2B03B145EE5DBCB86CCD81116ABA22C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_628EF5EACB08C09566FFD8A318382A74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C" xlink:to="loc_us-gaap_DomesticPlanMember_628EF5EACB08C09566FFD8A318382A74" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_121DC66E89583296252AD81116AB4589" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_628EF5EACB08C09566FFD8A318382A74" xlink:to="loc_country_US_121DC66E89583296252AD81116AB4589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_49F67057B052E09BBDBDD81116AB9A22" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C" xlink:to="loc_us-gaap_ForeignPlanMember_49F67057B052E09BBDBDD81116AB9A22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_C662CB4524F2846333B2D81116AB14EA" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_C662CB4524F2846333B2D81116AB14EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_C662CB4524F2846333B2D81116AB14EA" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_C662CB4524F2846333B2D81116AB14EA" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_DB6F071CF70CB1B9C9D4D81116AC147C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_DB6F071CF70CB1B9C9D4D81116AC147C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_7C9DA444C3AB236E4034D81116ACCE48" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_7C9DA444C3AB236E4034D81116ACCE48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_A2BFA1445B7024A78AF7D81116ACEEB0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_A2BFA1445B7024A78AF7D81116ACEEB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge" xlink:label="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:to="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver" xlink:label="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:to="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9DE34981B9B916B4CA38373A2411B93D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9DE34981B9B916B4CA38373A2411B93D" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_3C0E1C50AACC8C84FD54373A240C1FC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_3C0E1C50AACC8C84FD54373A240C1FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_A8FDED3F3BAF78A90883373A240CD743_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_3C0E1C50AACC8C84FD54373A240C1FC9" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_A8FDED3F3BAF78A90883373A240CD743_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_A8FDED3F3BAF78A90883373A240CD743" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_3C0E1C50AACC8C84FD54373A240C1FC9" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_A8FDED3F3BAF78A90883373A240CD743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_FD2C46F0D4BAE9F191B1373A240C8CD0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_A8FDED3F3BAF78A90883373A240CD743" xlink:to="loc_us-gaap_QualifiedPlanMember_FD2C46F0D4BAE9F191B1373A240C8CD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_663830AB963E4655275E373A240DDA1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_srt_RangeAxis_663830AB963E4655275E373A240DDA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_663830AB963E4655275E373A240DDA1D" xlink:to="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_663830AB963E4655275E373A240DDA1D" xlink:to="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_18B44ACC76E8E3184C2D373A240D8AC9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10" xlink:to="loc_srt_MinimumMember_18B44ACC76E8E3184C2D373A240D8AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_016AEBEE4B5D5E2C261E373A240DD323" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10" xlink:to="loc_srt_MaximumMember_016AEBEE4B5D5E2C261E373A240DD323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_0500778DFC082D0C42D7373A240D88A6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_0500778DFC082D0C42D7373A240D88A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0500778DFC082D0C42D7373A240D88A6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0500778DFC082D0C42D7373A240D88A6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_F18E3BA25FB7E35D2475373A240E44D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6" xlink:to="loc_us-gaap_DomesticPlanMember_F18E3BA25FB7E35D2475373A240E44D2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_AE4ACAEB8AD10951E05E373A240E8DF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_F18E3BA25FB7E35D2475373A240E44D2" xlink:to="loc_country_US_AE4ACAEB8AD10951E05E373A240E8DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_7E9CAF8389597A0FEBC2373A240EA073" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6" xlink:to="loc_us-gaap_ForeignPlanMember_7E9CAF8389597A0FEBC2373A240EA073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="loc_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9FCB7B4A635E388E3CCE373A24102230" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9FCB7B4A635E388E3CCE373A24102230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9FCB7B4A635E388E3CCE373A24102230" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9FCB7B4A635E388E3CCE373A24102230" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_A117B6F0BDD5B4922800373A241114D3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_A117B6F0BDD5B4922800373A241114D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F699BD3FBA4E193DAF02373A24116488" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F699BD3FBA4E193DAF02373A24116488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9DE34981B9B916B4CA38373A2411B93D" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9DE34981B9B916B4CA38373A2411B93D" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_36E625163DFE96E3B2D22F92B214A89A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_36E625163DFE96E3B2D22F92B214A89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_36E625163DFE96E3B2D22F92B214A89A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_36E625163DFE96E3B2D22F92B214A89A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_7EFC9B0A5F22CD43182C2F92B214A083" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A" xlink:to="loc_us-gaap_QualifiedPlanMember_7EFC9B0A5F22CD43182C2F92B214A083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_757528244493686C9B522F92B21588D9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A" xlink:to="loc_us-gaap_NonqualifiedPlanMember_757528244493686C9B522F92B21588D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_9B796CB79E164CC7E4CD2F92B215BA1F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_9B796CB79E164CC7E4CD2F92B215BA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9B796CB79E164CC7E4CD2F92B215BA1F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9B796CB79E164CC7E4CD2F92B215BA1F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_8C655F45E10E0D00C9E72F92B215EEC0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E" xlink:to="loc_us-gaap_DomesticPlanMember_8C655F45E10E0D00C9E72F92B215EEC0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_89886FD042B2B41CA3D72F92B2156AA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_8C655F45E10E0D00C9E72F92B215EEC0" xlink:to="loc_country_US_89886FD042B2B41CA3D72F92B2156AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_E269E0583AC43C6586812F92B216D994" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E" xlink:to="loc_us-gaap_ForeignPlanMember_E269E0583AC43C6586812F92B216D994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9D899D68F8F2020E38E12F92B216D32E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9D899D68F8F2020E38E12F92B216D32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9D899D68F8F2020E38E12F92B216D32E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9D899D68F8F2020E38E12F92B216D32E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4C85B2EB82425118BF012F92B216F30A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4C85B2EB82425118BF012F92B216F30A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_7209AF10E9B1DB462FE92F92B2177100" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_7209AF10E9B1DB462FE92F92B2177100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_54F5C01D4ABC1904B42B2F92B217E86D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_54F5C01D4ABC1904B42B2F92B217E86D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_7A800C8BFFA3D03B74A42F92B218E60B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_7A800C8BFFA3D03B74A42F92B218E60B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_936BEA389B4DE9C72DE12F92B218083E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_936BEA389B4DE9C72DE12F92B218083E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_838F431CF8CD7EF3BB2E02B665D70B4F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_838F431CF8CD7EF3BB2E02B665D70B4F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3F209C002EE5C12AA60002B665D700D9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_838F431CF8CD7EF3BB2E02B665D70B4F" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3F209C002EE5C12AA60002B665D700D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_62128E7D5211D11AF30502B665D71153_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3F209C002EE5C12AA60002B665D700D9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_62128E7D5211D11AF30502B665D71153_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_62128E7D5211D11AF30502B665D71153" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3F209C002EE5C12AA60002B665D700D9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_62128E7D5211D11AF30502B665D71153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4713BE050AE5911EA6AB02B665D86775" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_62128E7D5211D11AF30502B665D71153" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4713BE050AE5911EA6AB02B665D86775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56A3D2B8A070B9571983D8111686EEFD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56A3D2B8A070B9571983D8111686EEFD" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_B41834657FC477F7C6BED8AA673CBB77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_B41834657FC477F7C6BED8AA673CBB77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_B41834657FC477F7C6BED8AA673CBB77" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_B41834657FC477F7C6BED8AA673CBB77" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_FAE8D1F5F8FE762E6F05D8AAB97D6BEE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03" xlink:to="loc_us-gaap_QualifiedPlanMember_FAE8D1F5F8FE762E6F05D8AAB97D6BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_04F57E1B7E0E0C73D59ED8AAE895B6D1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03" xlink:to="loc_us-gaap_NonqualifiedPlanMember_04F57E1B7E0E0C73D59ED8AAE895B6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_A8F6B80311C9DEB4E05DD811167F7E0C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_A8F6B80311C9DEB4E05DD811167F7E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_A8F6B80311C9DEB4E05DD811167F7E0C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_A8F6B80311C9DEB4E05DD811167F7E0C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_126EF0E977A3C1D3AFE5D8A9E6E5B557" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB" xlink:to="loc_us-gaap_DomesticPlanMember_126EF0E977A3C1D3AFE5D8A9E6E5B557" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_C7A8780D7FD69D26A029D8111680B68B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_126EF0E977A3C1D3AFE5D8A9E6E5B557" xlink:to="loc_country_US_C7A8780D7FD69D26A029D8111680B68B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_5EF23F03DD2EABCB8D3ED81116800B9B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB" xlink:to="loc_us-gaap_ForeignPlanMember_5EF23F03DD2EABCB8D3ED81116800B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3BF1F889BFA1AA33A6A9D8111680D05A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3BF1F889BFA1AA33A6A9D8111680D05A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3BF1F889BFA1AA33A6A9D8111680D05A" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3BF1F889BFA1AA33A6A9D8111680D05A" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_315768A3DFB65731C638D8111686C6F4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_315768A3DFB65731C638D8111686C6F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_974A59F320AA2B5436CBD81116865D8B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_974A59F320AA2B5436CBD81116865D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56A3D2B8A070B9571983D8111686EEFD" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56A3D2B8A070B9571983D8111686EEFD" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6739E2E30C65E7B934612F92B1F154EC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6739E2E30C65E7B934612F92B1F154EC" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_66411F6F55F15B9FD39E2F92B1EB056A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_66411F6F55F15B9FD39E2F92B1EB056A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_A601FB9F35BF4AFE5D242F92B1EBA2B7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_66411F6F55F15B9FD39E2F92B1EB056A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_A601FB9F35BF4AFE5D242F92B1EBA2B7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_A601FB9F35BF4AFE5D242F92B1EBA2B7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_66411F6F55F15B9FD39E2F92B1EB056A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_A601FB9F35BF4AFE5D242F92B1EBA2B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_DCF4761828679351B39B2F92B1EB0089" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_A601FB9F35BF4AFE5D242F92B1EBA2B7" xlink:to="loc_us-gaap_QualifiedPlanMember_DCF4761828679351B39B2F92B1EB0089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_C442FCE6760DAD5E96772F92B1EB3B81" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_C442FCE6760DAD5E96772F92B1EB3B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_C442FCE6760DAD5E96772F92B1EB3B81" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_C442FCE6760DAD5E96772F92B1EB3B81" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_C4B6A416AF9DF457CF822F92B1ECC694" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3" xlink:to="loc_us-gaap_DomesticPlanMember_C4B6A416AF9DF457CF822F92B1ECC694" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_70D965876B4E2E8E05CC2F92B1ECAF34" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_C4B6A416AF9DF457CF822F92B1ECC694" xlink:to="loc_country_US_70D965876B4E2E8E05CC2F92B1ECAF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_A75F47361D392F32C4352F92B1EDA006" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3" xlink:to="loc_us-gaap_ForeignPlanMember_A75F47361D392F32C4352F92B1EDA006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2803480A8FED29A66EE82F92B1EDF21D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2803480A8FED29A66EE82F92B1EDF21D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2803480A8FED29A66EE82F92B1EDF21D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2803480A8FED29A66EE82F92B1EDF21D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_96B9D453A0C26D2870112F92B1EDF0C9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_96B9D453A0C26D2870112F92B1EDF0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_161FFB75087D12DCE40C2F92B1EDC424" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_161FFB75087D12DCE40C2F92B1EDC424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F32379566A3126DE22DE2F92B1EE68AC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F32379566A3126DE22DE2F92B1EE68AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F32379566A3126DE22DE2F92B1EE68AC" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F32379566A3126DE22DE2F92B1EE68AC" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_86865969C1B91C24A4762F92B1EEA300" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_86865969C1B91C24A4762F92B1EEA300" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_PartnershipInterestMember" xlink:label="loc_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceContractsMember" xlink:label="loc_pfe_InsuranceContractsMember_D191D5DE795DA778471B2F92B1EF345C" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_pfe_InsuranceContractsMember_D191D5DE795DA778471B2F92B1EF345C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherCommingledFundsMember" xlink:label="loc_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31DA11E542E3DB97FD162F92B1F02F8D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31DA11E542E3DB97FD162F92B1F02F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31DA11E542E3DB97FD162F92B1F02F8D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31DA11E542E3DB97FD162F92B1F02F8D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4BBDF47A6F54A0974BDA2F92B1F1EA3F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4BBDF47A6F54A0974BDA2F92B1F1EA3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0364B1A29B0034EB6B992F92B1F1902F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0364B1A29B0034EB6B992F92B1F1902F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02A58B266A2D909DD3042F92B1F19F5A" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_02A58B266A2D909DD3042F92B1F19F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6739E2E30C65E7B934612F92B1F154EC" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" xlink:label="loc_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6739E2E30C65E7B934612F92B1F154EC" xlink:to="loc_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_DB0BF135DF499241DDF8D811171098E9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_DB0BF135DF499241DDF8D811171098E9" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_C160216CEE36A9F8F127D880F984C1F9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_C160216CEE36A9F8F127D880F984C1F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_C160216CEE36A9F8F127D880F984C1F9" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_C160216CEE36A9F8F127D880F984C1F9" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_926D0CF2FF0997C0B102D8822C9C06FD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A" xlink:to="loc_us-gaap_QualifiedPlanMember_926D0CF2FF0997C0B102D8822C9C06FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_73098548B7C03E4FAA11D88256A016F8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A" xlink:to="loc_us-gaap_NonqualifiedPlanMember_73098548B7C03E4FAA11D88256A016F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_A37FCC1572CFFFA807D0D811170928C9" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_A37FCC1572CFFFA807D0D811170928C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_A37FCC1572CFFFA807D0D811170928C9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_A37FCC1572CFFFA807D0D811170928C9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_9FE1091B1AE573FB6142D88050EC8A37" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C" xlink:to="loc_us-gaap_DomesticPlanMember_9FE1091B1AE573FB6142D88050EC8A37" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D9D9195575A55001C269D811170FED8A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_9FE1091B1AE573FB6142D88050EC8A37" xlink:to="loc_country_US_D9D9195575A55001C269D811170FED8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_0542B401EFE39BB711B3D811170F164D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C" xlink:to="loc_us-gaap_ForeignPlanMember_0542B401EFE39BB711B3D811170F164D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_B312E75109C0B0062DFAD811170F85FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_B312E75109C0B0062DFAD811170F85FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_B312E75109C0B0062DFAD811170F85FC" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_B312E75109C0B0062DFAD811170F85FC" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_D9D86EE337B149118853D8111710656A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_D9D86EE337B149118853D8111710656A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_9FD4740A16736AC18CCFD81117102FF3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_9FD4740A16736AC18CCFD81117102FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7975EDD62F3C98FC5DABD81117101323" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7975EDD62F3C98FC5DABD81117101323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_DB0BF135DF499241DDF8D811171098E9" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_DB0BF135DF499241DDF8D811171098E9" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipment" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_99258B8E4C7B380DAD83CEAADBEBFD8B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:to="loc_srt_RangeAxis_99258B8E4C7B380DAD83CEAADBEBFD8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_99258B8E4C7B380DAD83CEAADBEBFD8B" xlink:to="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_99258B8E4C7B380DAD83CEAADBEBFD8B" xlink:to="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FF76B6408BEBB8EBF846CEAADBEB1BF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231" xlink:to="loc_srt_MinimumMember_FF76B6408BEBB8EBF846CEAADBEB1BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1D86BE19E000470E371BCEAADBEB88AB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231" xlink:to="loc_srt_MaximumMember_1D86BE19E000470E371BCEAADBEB88AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44172A8C4454B85921F4DDDC82F65D1C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44172A8C4454B85921F4DDDC82F65D1C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_66619B404AE11066CA25DDDC82F699A7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44172A8C4454B85921F4DDDC82F65D1C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_66619B404AE11066CA25DDDC82F699A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_66619B404AE11066CA25DDDC82F699A7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_66619B404AE11066CA25DDDC82F699A7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_C83365F3E821B6EB4FD7DDDC82F7B9D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_C83365F3E821B6EB4FD7DDDC82F7B9D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_5553585AC3C4674F0678DDDC82F7C762" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:to="loc_us-gaap_CostOfSalesMember_5553585AC3C4674F0678DDDC82F7C762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4079FD19ABFA5FB5E85ADDDC82F8FC04" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4079FD19ABFA5FB5E85ADDDC82F8FC04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="loc_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="loc_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="loc_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:to="loc_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_320F14144DBBEE68BE9D3CA4DFE1605A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_320F14144DBBEE68BE9D3CA4DFE1605A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8C57217C17775E65523B3CA4DFE2B326_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_320F14144DBBEE68BE9D3CA4DFE1605A" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8C57217C17775E65523B3CA4DFE2B326_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8C57217C17775E65523B3CA4DFE2B326" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_320F14144DBBEE68BE9D3CA4DFE1605A" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8C57217C17775E65523B3CA4DFE2B326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_CC50CC3D2C374699A8EF3CA4E096BF5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8C57217C17775E65523B3CA4DFE2B326" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_CC50CC3D2C374699A8EF3CA4E096BF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_9C8163EA5F6EA51DF54B3CA4DFAEF1BC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_9C8163EA5F6EA51DF54B3CA4DFAEF1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_29C777AFD018982D7DCC3CA4DFAFC2BB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_9C8163EA5F6EA51DF54B3CA4DFAEF1BC" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_29C777AFD018982D7DCC3CA4DFAFC2BB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_29C777AFD018982D7DCC3CA4DFAFC2BB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_9C8163EA5F6EA51DF54B3CA4DFAEF1BC" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_29C777AFD018982D7DCC3CA4DFAFC2BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_DA70BC783111EAC8D2393CA4E0B2CE08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_29C777AFD018982D7DCC3CA4DFAFC2BB" xlink:to="loc_us-gaap_QualifiedPlanMember_DA70BC783111EAC8D2393CA4E0B2CE08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5FED159EC9356FFA4D993CA4DF78C32D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5FED159EC9356FFA4D993CA4DF78C32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_AF696E704FEEAE51EB5C3CA4DF7C08F5_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5FED159EC9356FFA4D993CA4DF78C32D" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_AF696E704FEEAE51EB5C3CA4DF7C08F5_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_AF696E704FEEAE51EB5C3CA4DF7C08F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5FED159EC9356FFA4D993CA4DF78C32D" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_AF696E704FEEAE51EB5C3CA4DF7C08F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_E46A01F27519F56261D53CBED6569940" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_AF696E704FEEAE51EB5C3CA4DF7C08F5" xlink:to="loc_us-gaap_DomesticPlanMember_E46A01F27519F56261D53CBED6569940" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_0E1AAFC3AC19B27CFFBA3CA4E0CFAF1A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DomesticPlanMember_E46A01F27519F56261D53CBED6569940" xlink:to="loc_country_US_0E1AAFC3AC19B27CFFBA3CA4E0CFAF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2FA0B4410219BA51E7D23CA1B1837612" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2FA0B4410219BA51E7D23CA1B1837612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_86220B416E49345693283CA1B1831547_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2FA0B4410219BA51E7D23CA1B1837612" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_86220B416E49345693283CA1B1831547_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_86220B416E49345693283CA1B1831547" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2FA0B4410219BA51E7D23CA1B1837612" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_86220B416E49345693283CA1B1831547" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_86220B416E49345693283CA1B1831547" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2AFE98599C3EC9EF3AA93CA1B184125D" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2AFE98599C3EC9EF3AA93CA1B184125D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2AFE98599C3EC9EF3AA93CA1B184125D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2AFE98599C3EC9EF3AA93CA1B184125D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_46BD6D330AD72DAD86E63CA1B1849A2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D" xlink:to="loc_pfe_ArrayMember_46BD6D330AD72DAD86E63CA1B1849A2E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_1A0B8086E16DF536AD6A3CA4E07B5F90" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D" xlink:to="loc_pfe_HospiraMember_1A0B8086E16DF536AD6A3CA4E07B5F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:to="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:to="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:to="loc_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:to="loc_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:to="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:to="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:to="loc_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:to="loc_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_973CD159D7B66C5644C1DDDC83008634" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_973CD159D7B66C5644C1DDDC83008634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_973CD159D7B66C5644C1DDDC83008634" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_973CD159D7B66C5644C1DDDC83008634" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_D95CF18F6309560F6303DF3C38B80CB4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2" xlink:to="loc_pfe_ArrayMember_D95CF18F6309560F6303DF3C38B80CB4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2" xlink:to="loc_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:to="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:to="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:to="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:to="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FocusedCompanyPlanMember" xlink:label="loc_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:to="loc_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ManufacturingOptimizationMember" xlink:label="loc_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:to="loc_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherActivitiesMember" xlink:label="loc_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:to="loc_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:to="loc_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9983BD033691F1D976761A6ED04525D6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_970D637F89136920B3511A6ED044E462" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9983BD033691F1D976761A6ED04525D6" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_970D637F89136920B3511A6ED044E462" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_DADC1D3A61AA448BEB621A6ED0448CE7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_970D637F89136920B3511A6ED044E462" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_DADC1D3A61AA448BEB621A6ED0448CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_DADC1D3A61AA448BEB621A6ED0448CE7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_DADC1D3A61AA448BEB621A6ED0448CE7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:to="loc_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:to="loc_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:to="loc_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9983BD033691F1D976761A6ED04525D6" xlink:to="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:to="loc_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:to="loc_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:to="loc_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:to="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:to="loc_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:to="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:to="loc_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_CC62D3ACB2644A9D4E4C02E421E4580C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_CC62D3ACB2644A9D4E4C02E421E4580C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_CC62D3ACB2644A9D4E4C02E421E4580C" xlink:to="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_CC62D3ACB2644A9D4E4C02E421E4580C" xlink:to="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_32961C7EB6BE95B457D402E421E51F5D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288" xlink:to="loc_pfe_BiopharmaSegmentMember_32961C7EB6BE95B457D402E421E51F5D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_1FCDC8FC40B3D39DCBD902E421E5F4C4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288" xlink:to="loc_pfe_UpjohnSegmentMember_1FCDC8FC40B3D39DCBD902E421E5F4C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_451299C64EBAF6F73AF302E421E54544" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:to="loc_srt_ConsolidationItemsAxis_451299C64EBAF6F73AF302E421E54544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_451299C64EBAF6F73AF302E421E54544" xlink:to="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_451299C64EBAF6F73AF302E421E54544" xlink:to="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_D2DE3EBC788B966A162202E421E63AC7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:to="loc_us-gaap_OperatingSegmentsMember_D2DE3EBC788B966A162202E421E63AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_ADBA4194EAD5D9C28BC502E421E6CFBC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_ADBA4194EAD5D9C28BC502E421E6CFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:to="loc_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2E2E0AEB8D7488BBD32402E421E7091B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2E2E0AEB8D7488BBD32402E421E7091B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_5D8D2D4BE3C6EA1D34ABDDD5A3BF2EA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_srt_OwnershipAxis_5D8D2D4BE3C6EA1D34ABDDD5A3BF2EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_BA696117B2C615EC5A37DDD5A6B0FBA7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_OwnershipAxis_5D8D2D4BE3C6EA1D34ABDDD5A3BF2EA7" xlink:to="loc_srt_OwnershipDomain_BA696117B2C615EC5A37DDD5A6B0FBA7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_BA696117B2C615EC5A37DDD5A6B0FBA7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_OwnershipAxis_5D8D2D4BE3C6EA1D34ABDDD5A3BF2EA7" xlink:to="loc_srt_OwnershipDomain_BA696117B2C615EC5A37DDD5A6B0FBA7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_7B61BB4D8CB867EC6EB0DDD5A4ADC9BD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_OwnershipDomain_BA696117B2C615EC5A37DDD5A6B0FBA7" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_7B61BB4D8CB867EC6EB0DDD5A4ADC9BD" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9FD346BDF968A68CE42ADDD5A386DFDF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_dei_LegalEntityAxis_9FD346BDF968A68CE42ADDD5A386DFDF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AEFFFCAA9028168EEF73DDD5A68DDC25_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_9FD346BDF968A68CE42ADDD5A386DFDF" xlink:to="loc_dei_EntityDomain_AEFFFCAA9028168EEF73DDD5A68DDC25_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AEFFFCAA9028168EEF73DDD5A68DDC25" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_9FD346BDF968A68CE42ADDD5A386DFDF" xlink:to="loc_dei_EntityDomain_AEFFFCAA9028168EEF73DDD5A68DDC25" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_C96123EE7247B83F2713DDD5A48C7CCC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_AEFFFCAA9028168EEF73DDD5A68DDC25" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_C96123EE7247B83F2713DDD5A48C7CCC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionAxis" xlink:label="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:to="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D_default" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:to="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TherachonAssetAcquisitionMember" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:to="loc_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_878103D37A0DF278AB8DDDCF3D9A419C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_878103D37A0DF278AB8DDDCF3D9A419C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_878103D37A0DF278AB8DDDCF3D9A419C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_878103D37A0DF278AB8DDDCF3D9A419C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F3881EC0079081A4B699DDCF3D9AF7CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F3881EC0079081A4B699DDCF3D9AF7CC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherIncomeExpenseMember" xlink:label="loc_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:to="loc_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_BD3FDA79033EED2AC2E0DDF5B0DD3253" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:to="loc_us-gaap_CostOfSalesMember_BD3FDA79033EED2AC2E0DDF5B0DD3253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EC52F5A1A67B1C438CD0DDCF3D9BFBDA" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EC52F5A1A67B1C438CD0DDCF3D9BFBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97DBFB427805DACD2D21DDCF3D9BC30F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EC52F5A1A67B1C438CD0DDCF3D9BFBDA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97DBFB427805DACD2D21DDCF3D9BC30F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97DBFB427805DACD2D21DDCF3D9BC30F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EC52F5A1A67B1C438CD0DDCF3D9BFBDA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97DBFB427805DACD2D21DDCF3D9BC30F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_546F428202624E704F6FDDCF3D9BAE90" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97DBFB427805DACD2D21DDCF3D9BC30F" xlink:to="loc_us-gaap_LicensingAgreementsMember_546F428202624E704F6FDDCF3D9BAE90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_CD20C3BF960482ECF130DDCF3D9C5C5C" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_srt_CounterpartyNameAxis_CD20C3BF960482ECF130DDCF3D9C5C5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_CD20C3BF960482ECF130DDCF3D9C5C5C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_CD20C3BF960482ECF130DDCF3D9C5C5C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AkceaAndIonisMember" xlink:label="loc_pfe_AkceaAndIonisMember_67E99140391B6076D79FDDCF3D9D6526" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:to="loc_pfe_AkceaAndIonisMember_67E99140391B6076D79FDDCF3D9D6526" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NovaQuestCoInvestmentFundVL.P.Member" xlink:label="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_CAB0887224253A0DCD82DDD0486767C8" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:to="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_CAB0887224253A0DCD82DDD0486767C8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BainCapitalMember" xlink:label="loc_pfe_BainCapitalMember_B0B590395A458731D4E3DDCF3D9D4E27" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:to="loc_pfe_BainCapitalMember_B0B590395A458731D4E3DDCF3D9D4E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D48E70773869947D6C6ADDCF3D9D3404" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D48E70773869947D6C6ADDCF3D9D3404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D48E70773869947D6C6ADDCF3D9D3404" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D48E70773869947D6C6ADDCF3D9D3404" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_BE8DC4CF85E6AEC8E6A6DDCF3D9E4942" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_ViivHealthcareLimitedMember_BE8DC4CF85E6AEC8E6A6DDCF3D9E4942" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_5C89D6599452BA2994FADDD0463A5084" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_GSKConsumerHealthcareMember_5C89D6599452BA2994FADDD0463A5084" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelMember" xlink:label="loc_pfe_CerevelMember_F61E0370F6FFA912347DDDCF3D9EE22D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_CerevelMember_F61E0370F6FFA912347DDDCF3D9EE22D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_658B26C51A3519BE3568DDCF3D9E254C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_AllogeneMember_658B26C51A3519BE3568DDCF3D9E254C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_ABEE1367CDBD8924B8E0DDD5A3F3D7B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_ABEE1367CDBD8924B8E0DDD5A3F3D7B7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_BDA79FA5638738FA67D8DDD5A415FD7F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_BDA79FA5638738FA67D8DDD5A415FD7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1E972D5C445161B6CA33DDCF3D9F0282" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1E972D5C445161B6CA33DDCF3D9F0282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C17796D1E28FD108A47ADDCF3D9F5FDB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1E972D5C445161B6CA33DDCF3D9F0282" xlink:to="loc_us-gaap_SegmentDomain_C17796D1E28FD108A47ADDCF3D9F5FDB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C17796D1E28FD108A47ADDCF3D9F5FDB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1E972D5C445161B6CA33DDCF3D9F0282" xlink:to="loc_us-gaap_SegmentDomain_C17796D1E28FD108A47ADDCF3D9F5FDB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_DD073C9F44E824B5E468DDCF3D9FF53C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_C17796D1E28FD108A47ADDCF3D9F5FDB" xlink:to="loc_pfe_BiopharmaSegmentMember_DD073C9F44E824B5E468DDCF3D9FF53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_65DDB139139EF6703E96DDCF3DA0472C" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_65DDB139139EF6703E96DDCF3DA0472C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BEA63884DE1E94DF996ADDCF3DA1FC63_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_65DDB139139EF6703E96DDCF3DA0472C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BEA63884DE1E94DF996ADDCF3DA1FC63_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BEA63884DE1E94DF996ADDCF3DA1FC63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_65DDB139139EF6703E96DDCF3DA0472C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BEA63884DE1E94DF996ADDCF3DA1FC63" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_59893F0C894E6E7B879ADDCF3DA1035A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BEA63884DE1E94DF996ADDCF3DA1FC63" xlink:to="loc_pfe_HISMember_59893F0C894E6E7B879ADDCF3DA1035A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_3A747726E890E597FCCDDDCF3DA22111" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_srt_ConsolidationItemsAxis_3A747726E890E597FCCDDDCF3DA22111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ConsolidationItemsAxis_3A747726E890E597FCCDDDCF3DA22111" xlink:to="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ConsolidationItemsAxis_3A747726E890E597FCCDDDCF3DA22111" xlink:to="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_B4263357BDDC1C812FF7DDCF3DA38ECB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2" xlink:to="loc_us-gaap_OperatingSegmentsMember_B4263357BDDC1C812FF7DDCF3DA38ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_4578E1CC5FE22D10C830DDCF3DA3DC40" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_4578E1CC5FE22D10C830DDCF3DA3DC40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_5CBE230D96091A20DF09DDCF3DA3329C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_InvestmentIncomeDividend_5CBE230D96091A20DF09DDCF3DA3329C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetImpairmentChargesAndOtherCharges" xlink:label="loc_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessAlignmentCosts" xlink:label="loc_pfe_BusinessAlignmentCosts_B8ED089D597158E07A1DDDD03F8AB5F4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_BusinessAlignmentCosts_B8ED089D597158E07A1DDDD03F8AB5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_19CC7E07763A8FF128CCDDD040139F53" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_19CC7E07763A8FF128CCDDD040139F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_FD2179CA858CC583169CDDCF3DA52D68" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_FD2179CA858CC583169CDDCF3DA52D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_A0CCDD14B99133D95532DDCF3DA67B55" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_PaymentForLicensingArrangement_A0CCDD14B99133D95532DDCF3DA67B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" xlink:label="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_02E4A9E624B22F740ABEDDD040BCACB7" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_02E4A9E624B22F740ABEDDD040BCACB7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:label="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus" xlink:label="loc_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossFromContributionAgreement" xlink:label="loc_pfe_GainLossFromContributionAgreement_92C879F7F29853FD4EC2DDCF3DA66FA4" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_GainLossFromContributionAgreement_92C879F7F29853FD4EC2DDCF3DA66FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AlignmentCosts" xlink:label="loc_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CharitableContributionExpense" xlink:label="loc_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InventoryWriteDownAndOverheadCosts" xlink:label="loc_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8C750E6850E6E77A22BEDDD5A2991EF8" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8C750E6850E6E77A22BEDDD5A2991EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_229D192CA409075D7215DDD5A2E467BD" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_229D192CA409075D7215DDD5A2E467BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_DEACBFB9D812B95AF6ECDDD5A32A9B91" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_DEACBFB9D812B95AF6ECDDD5A32A9B91" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_F8B261A4CC8D7D0FC14280206B5C70B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F8C877CB27EB01D9749C80206B5A5BC2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_F8B261A4CC8D7D0FC14280206B5C70B7" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F8C877CB27EB01D9749C80206B5A5BC2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_CCC060C760BBBE09CA6A80206B5AC0F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F8C877CB27EB01D9749C80206B5A5BC2" xlink:to="loc_srt_StatementGeographicalAxis_CCC060C760BBBE09CA6A80206B5AC0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_CCC060C760BBBE09CA6A80206B5AC0F5" xlink:to="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_CCC060C760BBBE09CA6A80206B5AC0F5" xlink:to="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_EB4F8B4EFC829950E0FB80206B5B5CB0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:to="loc_country_US_EB4F8B4EFC829950E0FB80206B5B5CB0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_3302182D54848F56015080206B5BF610" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:to="loc_pfe_DevelopedEuropeMember_3302182D54848F56015080206B5BF610" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:to="loc_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:to="loc_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_F8B261A4CC8D7D0FC14280206B5C70B7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:to="loc_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_86FF813DC1A145071CDC732029BEED69" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_srt_StatementGeographicalAxis_86FF813DC1A145071CDC732029BEED69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_86FF813DC1A145071CDC732029BEED69" xlink:to="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_86FF813DC1A145071CDC732029BEED69" xlink:to="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NonUnitedStatesMember" xlink:label="loc_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:to="loc_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_3B9A02BEAB50AC0092E3732029BE218E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:to="loc_country_US_3B9A02BEAB50AC0092E3732029BE218E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:to="loc_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="loc_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:to="loc_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:to="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:to="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_McKessonInc.Member" xlink:label="loc_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="loc_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AmerisourceBergenCorporationMember" xlink:label="loc_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="loc_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CardinalHealthInc.Member" xlink:label="loc_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="loc_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ThreeLargestUSWholesaleCustomersMember" xlink:label="loc_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="loc_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7204487D45CF02A03760732029C0B98D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7204487D45CF02A03760732029C0B98D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:label="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7E3C96C00B05CB1E707E8020731F4D13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6677E1BE6F8E4C0515098020731AAF8E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7E3C96C00B05CB1E707E8020731F4D13" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6677E1BE6F8E4C0515098020731AAF8E" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_F20A51216F438C57842C8020731BE90B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6677E1BE6F8E4C0515098020731AAF8E" xlink:to="loc_srt_StatementGeographicalAxis_F20A51216F438C57842C8020731BE90B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_F20A51216F438C57842C8020731BE90B" xlink:to="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_F20A51216F438C57842C8020731BE90B" xlink:to="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_096CCAF2EEB244611B9E8020731D8704" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:to="loc_country_US_096CCAF2EEB244611B9E8020731D8704" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_48E2056BF52B064702888020731EB5F6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:to="loc_pfe_DevelopedEuropeMember_48E2056BF52B064702888020731EB5F6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_95EDC59415E278D517EC8020731E3586" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:to="loc_pfe_DevelopedRestOfWorldMember_95EDC59415E278D517EC8020731E3586" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_163BFA103A8812CCA9DE8020731E2E19" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:to="loc_pfe_EmergingMarketsMember_163BFA103A8812CCA9DE8020731E2E19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16D1587CAC69B627957F8020731FE368" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7E3C96C00B05CB1E707E8020731F4D13" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16D1587CAC69B627957F8020731FE368" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:to="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:to="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A_default" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:to="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:to="loc_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:to="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:to="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:to="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:to="loc_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:to="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:to="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:to="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospitalMember" xlink:label="loc_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnReportingUnitMember" xlink:label="loc_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareReportingUnitMember" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_777F0D6347E158882BD768987289BA17" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_777F0D6347E158882BD768987289BA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_777F0D6347E158882BD768987289BA17" xlink:to="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_777F0D6347E158882BD768987289BA17" xlink:to="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_B2B6B042D38B1213F49568987289BDD7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:to="loc_pfe_BiopharmaSegmentMember_B2B6B042D38B1213F49568987289BDD7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_A12ACAC8664DDAC3A1F168987289F2D3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:to="loc_pfe_UpjohnSegmentMember_A12ACAC8664DDAC3A1F168987289F2D3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_DD38FC58E249607DA41E6898728AA749" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:to="loc_pfe_ConsumerHealthcareMember_DD38FC58E249607DA41E6898728AA749" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" xlink:label="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:to="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0D0CEFF68AF73F8C08356898728AC6CC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:to="loc_srt_ProductOrServiceAxis_0D0CEFF68AF73F8C08356898728AC6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_0D0CEFF68AF73F8C08356898728AC6CC" xlink:to="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_0D0CEFF68AF73F8C08356898728AC6CC" xlink:to="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_AE2BD04475AF07EE44C76898728A2272" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EliquisMember_AE2BD04475AF07EE44C76898728A2272" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XtandiAllianceRevenuesMember" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_7D58974A16A9D6633A566898728C4497" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_BosulifMember_7D58974A16A9D6633A566898728C4497" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RetacritMember" xlink:label="loc_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MektoviMember" xlink:label="loc_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BraftoviMember" xlink:label="loc_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_1A5B2BA2D4FFC765CBD36898728E7DBA" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EpiPenMember_1A5B2BA2D4FFC765CBD36898728E7DBA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZosynTazocinMember" xlink:label="loc_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TygacilMember" xlink:label="loc_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DiflucanMember" xlink:label="loc_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:type="locator" />
    <link:definitionArc order="26" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PanzygaMember" xlink:label="loc_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:type="locator" />
    <link:definitionArc order="27" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerCentreOneMember" xlink:label="loc_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:type="locator" />
    <link:definitionArc order="28" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherAntiinfectivesMember" xlink:label="loc_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:type="locator" />
    <link:definitionArc order="29" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherHospitalProductsMember" xlink:label="loc_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:type="locator" />
    <link:definitionArc order="30" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:type="locator" />
    <link:definitionArc order="31" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NimenrixMember" xlink:label="loc_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:type="locator" />
    <link:definitionArc order="32" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FSMEIMMUNTicoVacMember" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:type="locator" />
    <link:definitionArc order="33" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TrumenbaMember" xlink:label="loc_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:type="locator" />
    <link:definitionArc order="34" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:type="locator" />
    <link:definitionArc order="35" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_A0C8BB28DB3FFDC59303689872909994" xlink:type="locator" />
    <link:definitionArc order="36" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XeljanzMember_A0C8BB28DB3FFDC59303689872909994" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:type="locator" />
    <link:definitionArc order="37" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:type="locator" />
    <link:definitionArc order="38" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_5EA784D480A34FB86391689872919D53" xlink:type="locator" />
    <link:definitionArc order="39" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EucrisaMember_5EA784D480A34FB86391689872919D53" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:type="locator" />
    <link:definitionArc order="40" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:type="locator" />
    <link:definitionArc order="41" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:type="locator" />
    <link:definitionArc order="42" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VyndaqelMember" xlink:label="loc_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:type="locator" />
    <link:definitionArc order="43" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:type="locator" />
    <link:definitionArc order="44" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:type="locator" />
    <link:definitionArc order="45" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:type="locator" />
    <link:definitionArc order="46" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:type="locator" />
    <link:definitionArc order="47" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:type="locator" />
    <link:definitionArc order="48" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:type="locator" />
    <link:definitionArc order="49" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_833443BB76F2ED16CF6E689872935EE4" xlink:type="locator" />
    <link:definitionArc order="50" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_CelebrexMember_833443BB76F2ED16CF6E689872935EE4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:type="locator" />
    <link:definitionArc order="51" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:type="locator" />
    <link:definitionArc order="52" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:type="locator" />
    <link:definitionArc order="53" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:type="locator" />
    <link:definitionArc order="54" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XanaxMember" xlink:label="loc_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:type="locator" />
    <link:definitionArc order="55" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RevatioMember" xlink:label="loc_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:type="locator" />
    <link:definitionArc order="56" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherUpjohnProductsMember" xlink:label="loc_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:type="locator" />
    <link:definitionArc order="57" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_289C9622347D66488B84689872947404" xlink:type="locator" />
    <link:definitionArc order="58" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ConsumerHealthcareMember_289C9622347D66488B84689872947404" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISProductsMember" xlink:label="loc_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:type="locator" />
    <link:definitionArc order="59" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalAllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:type="locator" />
    <link:definitionArc order="60" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalBiosimilarsMember" xlink:label="loc_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:type="locator" />
    <link:definitionArc order="61" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:type="locator" />
    <link:definitionArc order="62" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7DAB17E5C69922E83BAB6898729518AD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7DAB17E5C69922E83BAB6898729518AD" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPayments" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_EAD7BA1E197C64E571438020735B22F2" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_EAD7BA1E197C64E571438020735B22F2" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_778FC44633BE1113BBEE8020735B4D74" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_EAD7BA1E197C64E571438020735B22F2" xlink:to="loc_us-gaap_AwardTypeAxis_778FC44633BE1113BBEE8020735B4D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CD50A68C534BD88C04E8020735B3ABA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_778FC44633BE1113BBEE8020735B4D74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CD50A68C534BD88C04E8020735B3ABA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CD50A68C534BD88C04E8020735B3ABA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_778FC44633BE1113BBEE8020735B4D74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CD50A68C534BD88C04E8020735B3ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CD50A68C534BD88C04E8020735B3ABA" xlink:to="loc_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_2A228CBC1903ACA344408020735D0242" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_2A228CBC1903ACA344408020735D0242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_D7913D560A24D3ED31318020735DB5B7" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_D7913D560A24D3ED31318020735DB5B7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E6EC68D3410FE92F8DF7802074F7F748" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E6EC68D3410FE92F8DF7802074F7F748" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_657D3F3AF8BE3AB887F4802074F75022" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E6EC68D3410FE92F8DF7802074F7F748" xlink:to="loc_us-gaap_AwardTypeAxis_657D3F3AF8BE3AB887F4802074F75022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F6FFEA77606A3A1E5246802074F7108F_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_657D3F3AF8BE3AB887F4802074F75022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F6FFEA77606A3A1E5246802074F7108F_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F6FFEA77606A3A1E5246802074F7108F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_657D3F3AF8BE3AB887F4802074F75022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F6FFEA77606A3A1E5246802074F7108F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_294212D662D7444ECBC2802074F8A54D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F6FFEA77606A3A1E5246802074F7108F" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_294212D662D7444ECBC2802074F8A54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5191EAC531FA5E579667802074F82224" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5191EAC531FA5E579667802074F82224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5C030F60EC2F3EA8D8FE802074F8D9EF" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5C030F60EC2F3EA8D8FE802074F8D9EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_663E45685303169DD84C802074F92EA7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_663E45685303169DD84C802074F92EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_48150E5A318CF2CA1ABD802074F9F010" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_48150E5A318CF2CA1ABD802074F9F010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_EAF6D16BF00F07D995D5802074F9F123" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_EAF6D16BF00F07D995D5802074F9F123" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_94C183DE91D3D3ED575C80206C3A2611" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_94C183DE91D3D3ED575C80206C3A2611" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_26A52221320D3C8A630980206C3AE8C3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_94C183DE91D3D3ED575C80206C3A2611" xlink:to="loc_us-gaap_AwardTypeAxis_26A52221320D3C8A630980206C3AE8C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E972838244867613E92B80206C3BA118_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_26A52221320D3C8A630980206C3AE8C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E972838244867613E92B80206C3BA118_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E972838244867613E92B80206C3BA118" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_26A52221320D3C8A630980206C3AE8C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E972838244867613E92B80206C3BA118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7F4C21611C2934F004CA80206C3B75B8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E972838244867613E92B80206C3BA118" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7F4C21611C2934F004CA80206C3B75B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_509F7D722A08C57CBED580206C3CB468" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_509F7D722A08C57CBED580206C3CB468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C513D7AAF9B0A169ADCC80206C3CAD07" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C513D7AAF9B0A169ADCC80206C3CAD07" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B36E3863F77F89D696EB80206C3D8E95" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B36E3863F77F89D696EB80206C3D8E95" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_208643BC4F1CDEFE1B4A80206EE46225" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_208643BC4F1CDEFE1B4A80206EE46225" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D9DF35AC4084E638EBE580206EE51376" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_208643BC4F1CDEFE1B4A80206EE46225" xlink:to="loc_us-gaap_AwardTypeAxis_D9DF35AC4084E638EBE580206EE51376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C3D5934CC1A2B17DC5FB80206EE5EB61_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_D9DF35AC4084E638EBE580206EE51376" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C3D5934CC1A2B17DC5FB80206EE5EB61_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C3D5934CC1A2B17DC5FB80206EE5EB61" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_D9DF35AC4084E638EBE580206EE51376" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C3D5934CC1A2B17DC5FB80206EE5EB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88A515A070CDC992F4F380206EE590E0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C3D5934CC1A2B17DC5FB80206EE5EB61" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88A515A070CDC992F4F380206EE590E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD53A01B20DB69E2C9B880207454BACA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD53A01B20DB69E2C9B880207454BACA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E70167D239AAE757DA95802074547C2D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD53A01B20DB69E2C9B880207454BACA" xlink:to="loc_us-gaap_AwardTypeAxis_E70167D239AAE757DA95802074547C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67FA9C3546340D530F6580207455178E_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_E70167D239AAE757DA95802074547C2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67FA9C3546340D530F6580207455178E_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67FA9C3546340D530F6580207455178E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_E70167D239AAE757DA95802074547C2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67FA9C3546340D530F6580207455178E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_2C6920B5E32EB523BE0280207455DC16" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67FA9C3546340D530F6580207455178E" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_2C6920B5E32EB523BE0280207455DC16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B3910CF4DAB343C88480802074567731" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B3910CF4DAB343C88480802074567731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_A0DE82F5EC689F75984880207456E5E0" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_A0DE82F5EC689F75984880207456E5E0" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:to="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:to="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:to="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_A2019StockPlanMember" xlink:label="loc_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:to="loc_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DAEC880E34F7BEBED8B0E36C8CDCF866" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:to="loc_us-gaap_AwardTypeAxis_DAEC880E34F7BEBED8B0E36C8CDCF866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_DAEC880E34F7BEBED8B0E36C8CDCF866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_DAEC880E34F7BEBED8B0E36C8CDCF866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_4860211DABA4EAEDC39CE36C8CDC826C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_4860211DABA4EAEDC39CE36C8CDC826C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_51E0FEB25D017B1DB621E36C8CDD71C9" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_51E0FEB25D017B1DB621E36C8CDD71C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_18CD2ED0365D3488B082E36C8CDD140F" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_us-gaap_PerformanceSharesMember_18CD2ED0365D3488B082E36C8CDD140F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_50BB74A12DA51F187FF8E36C8CDD7FDC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_us-gaap_EmployeeStockOptionMember_50BB74A12DA51F187FF8E36C8CDD7FDC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DirectorsCompensationMember" xlink:label="loc_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_6CAD6389C96EA8A6C111E36C8CDD2FD6" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_6CAD6389C96EA8A6C111E36C8CDD2FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AEEA42A8B0920785C4F10CAF780285F8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:to="loc_us-gaap_AwardTypeAxis_AEEA42A8B0920785C4F10CAF780285F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_AEEA42A8B0920785C4F10CAF780285F8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_AEEA42A8B0920785C4F10CAF780285F8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_C425A65BC645BCF95D140CAF780305FE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_C425A65BC645BCF95D140CAF780305FE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_4E10E3DA5E4BB56072050CAF7803B50A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_4E10E3DA5E4BB56072050CAF7803B50A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8B594FC4FF4EB58CF0F70CAF78033354" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_us-gaap_PerformanceSharesMember_8B594FC4FF4EB58CF0F70CAF78033354" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_053DB0707BC1626615A20CAF7804FDA0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_053DB0707BC1626615A20CAF7804FDA0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_48BEE7D56C17C5B541700CAF78048DA3" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_48BEE7D56C17C5B541700CAF78048DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CDEBE1DD9786E1CCE2D90CAF7804A7A1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_us-gaap_EmployeeStockOptionMember_CDEBE1DD9786E1CCE2D90CAF7804A7A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1E3171AD1ED3869648B50CAF78048B49" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:to="loc_us-gaap_PlanNameAxis_1E3171AD1ED3869648B50CAF78048B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0B538D995B8E9429D5BE0CAF780409D7_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_1E3171AD1ED3869648B50CAF78048B49" xlink:to="loc_us-gaap_PlanNameDomain_0B538D995B8E9429D5BE0CAF780409D7_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0B538D995B8E9429D5BE0CAF780409D7" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_1E3171AD1ED3869648B50CAF78048B49" xlink:to="loc_us-gaap_PlanNameDomain_0B538D995B8E9429D5BE0CAF780409D7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_A2019StockPlanMember" xlink:label="loc_pfe_A2019StockPlanMember_2804084E7D43AA74BDEC0CAF78055776" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_0B538D995B8E9429D5BE0CAF780409D7" xlink:to="loc_pfe_A2019StockPlanMember_2804084E7D43AA74BDEC0CAF78055776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:to="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ProfitUnitsMember" xlink:label="loc_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:to="loc_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DDE032B961B6B56FA84080206F6C9972" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6293B7C8C473A8909C6380206F6BA90F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DDE032B961B6B56FA84080206F6C9972" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6293B7C8C473A8909C6380206F6BA90F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8F2D6F7F5EC0AEBB97CA80206F6BD916" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6293B7C8C473A8909C6380206F6BA90F" xlink:to="loc_us-gaap_AwardTypeAxis_8F2D6F7F5EC0AEBB97CA80206F6BD916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6296453596DAB78964E080206F6B2317_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_8F2D6F7F5EC0AEBB97CA80206F6BD916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6296453596DAB78964E080206F6B2317_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6296453596DAB78964E080206F6B2317" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_8F2D6F7F5EC0AEBB97CA80206F6BD916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6296453596DAB78964E080206F6B2317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8A7D714B893A6A3D822280206F6C1696" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6296453596DAB78964E080206F6B2317" xlink:to="loc_us-gaap_PerformanceSharesMember_8A7D714B893A6A3D822280206F6C1696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DDE032B961B6B56FA84080206F6C9972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A42E2010CD2F272338F180206F6C1108" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A42E2010CD2F272338F180206F6C1108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F384A3092108E51709B880206F6D9C06" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F384A3092108E51709B880206F6D9C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_729639DD6DD89D5F9EB980206F6D3C28" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_729639DD6DD89D5F9EB980206F6D3C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_10AEDFCFAEC3690321A180206F6DED38" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_10AEDFCFAEC3690321A180206F6DED38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DDE032B961B6B56FA84080206F6C9972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3A49938460191C1B85B180206F6DA909" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3A49938460191C1B85B180206F6DA909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_82AA15B9CF7A9EC3B94780206F6EE24F" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_82AA15B9CF7A9EC3B94780206F6EE24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_69B3824C38AEFBE9D2D080206F6E9AFD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_69B3824C38AEFBE9D2D080206F6E9AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_32FB8FE507B913A3704E80206F6EF4D9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_32FB8FE507B913A3704E80206F6EF4D9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_EAEA075A8F198C291EDE6891E7BC6BB1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:to="loc_us-gaap_AwardTypeAxis_EAEA075A8F198C291EDE6891E7BC6BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AA2B57C248C854FCB0576891E7BD52DF_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_EAEA075A8F198C291EDE6891E7BC6BB1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AA2B57C248C854FCB0576891E7BD52DF_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AA2B57C248C854FCB0576891E7BD52DF" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_EAEA075A8F198C291EDE6891E7BC6BB1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AA2B57C248C854FCB0576891E7BD52DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_7F15E120F41C591304416891E7BD6E04" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AA2B57C248C854FCB0576891E7BD52DF" xlink:to="loc_us-gaap_PerformanceSharesMember_7F15E120F41C591304416891E7BD6E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1A0366E5FBFB7D5830126891E7BDC8F5" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:to="loc_srt_RangeAxis_1A0366E5FBFB7D5830126891E7BDC8F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_1A0366E5FBFB7D5830126891E7BDC8F5" xlink:to="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_1A0366E5FBFB7D5830126891E7BDC8F5" xlink:to="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_3918E0C44115AA0BA3E96891E7BE611A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0" xlink:to="loc_srt_MinimumMember_3918E0C44115AA0BA3E96891E7BE611A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5A7050B109C1A4466DDC6891E7BEC689" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0" xlink:to="loc_srt_MaximumMember_5A7050B109C1A4466DDC6891E7BEC689" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CBEB87B59706367DCCBD6891E7BF77EB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CBEB87B59706367DCCBD6891E7BF77EB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_B4CFF39D2F5642D379CF6891E7BF7DDC" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_B4CFF39D2F5642D379CF6891E7BF7DDC" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:to="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:label="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:to="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_FF58F61D50CE2D32AA526891EE9A3197" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:to="loc_us-gaap_AwardTypeAxis_FF58F61D50CE2D32AA526891EE9A3197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34CA7FC326D36ADFEF586891EE9AAA02_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_FF58F61D50CE2D32AA526891EE9A3197" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34CA7FC326D36ADFEF586891EE9AAA02_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34CA7FC326D36ADFEF586891EE9AAA02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_FF58F61D50CE2D32AA526891EE9A3197" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34CA7FC326D36ADFEF586891EE9AAA02" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34CA7FC326D36ADFEF586891EE9AAA02" xlink:to="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306F3F07E337BD0E2C07802072D382C4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306F3F07E337BD0E2C07802072D382C4" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1A9D5F9BAAB07A95815F802072D42616" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306F3F07E337BD0E2C07802072D382C4" xlink:to="loc_us-gaap_AwardTypeAxis_1A9D5F9BAAB07A95815F802072D42616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08038D629A44EDDAFA52802072D49383_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_1A9D5F9BAAB07A95815F802072D42616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08038D629A44EDDAFA52802072D49383_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08038D629A44EDDAFA52802072D49383" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_1A9D5F9BAAB07A95815F802072D42616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08038D629A44EDDAFA52802072D49383" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_40BEF631D17FA53927C2802072D47006" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08038D629A44EDDAFA52802072D49383" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_40BEF631D17FA53927C2802072D47006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0A18F8B410CD6A0F7E96802072D56A67" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0A18F8B410CD6A0F7E96802072D56A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_91EC93AB808E62B66AAE802072D5B1BB" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_91EC93AB808E62B66AAE802072D5B1BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6F9F089CC89E352320FC802072D5828F" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6F9F089CC89E352320FC802072D5828F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB2195FBF01BB6ACBC24802072D608B7" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB2195FBF01BB6ACBC24802072D608B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_35B53DFA32575FECDEE1802072D71D68" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_35B53DFA32575FECDEE1802072D71D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1D78A1DC6520F1E21214802072D8E416" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1D78A1DC6520F1E21214802072D8E416" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7752FD0C102755D23BBA12152DEAF729" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:to="loc_us-gaap_AwardTypeAxis_7752FD0C102755D23BBA12152DEAF729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EBFD9D2C6606CDA1E28512152DEAFF57_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_7752FD0C102755D23BBA12152DEAF729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EBFD9D2C6606CDA1E28512152DEAFF57_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EBFD9D2C6606CDA1E28512152DEAFF57" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_7752FD0C102755D23BBA12152DEAF729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EBFD9D2C6606CDA1E28512152DEAFF57" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EBFD9D2C6606CDA1E28512152DEAFF57" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_EBF9A1F83089FF253D8512152DEBAD80" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:to="loc_srt_RangeAxis_EBF9A1F83089FF253D8512152DEBAD80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_EBF9A1F83089FF253D8512152DEBAD80" xlink:to="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_EBF9A1F83089FF253D8512152DEBAD80" xlink:to="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A9D6CEE4556ECBC1A14112152DEC4196" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A" xlink:to="loc_srt_MinimumMember_A9D6CEE4556ECBC1A14112152DEC4196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7ED4A438A7173C9DBE7812152DEC0E09" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A" xlink:to="loc_srt_MaximumMember_7ED4A438A7173C9DBE7812152DEC0E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_A819C2658D4F4339842612152DEC6C4A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_A819C2658D4F4339842612152DEC6C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_48CF7D3BB533C474E55312152DEDE827" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_48CF7D3BB533C474E55312152DEDE827" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D27B91AFF4E4187FB20D80206F51EEFB" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D27B91AFF4E4187FB20D80206F51EEFB" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_908EA308F2D3E3BD083C80206F519CF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D27B91AFF4E4187FB20D80206F51EEFB" xlink:to="loc_us-gaap_AwardTypeAxis_908EA308F2D3E3BD083C80206F519CF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9F3DC33A85A5CAB882C80206F5172AA_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_908EA308F2D3E3BD083C80206F519CF6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9F3DC33A85A5CAB882C80206F5172AA_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9F3DC33A85A5CAB882C80206F5172AA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_908EA308F2D3E3BD083C80206F519CF6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9F3DC33A85A5CAB882C80206F5172AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9F3DC33A85A5CAB882C80206F5172AA" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_EE685463EEABCBB7C7F480206F521623" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_EE685463EEABCBB7C7F480206F521623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F7613A87D473DF57947280206F535D80" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F7613A87D473DF57947280206F535D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7BB98AE2D172A8C80C0B80206F53CE8B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7BB98AE2D172A8C80C0B80206F53CE8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C9A8F3BF145B3B065BDB80206F53E596" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C9A8F3BF145B3B065BDB80206F53E596" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0CDA492D9328EFCD39BB80206F54893F" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0CDA492D9328EFCD39BB80206F54893F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F27A4D400AF38CA7F65380206F54EAE4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F27A4D400AF38CA7F65380206F54EAE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BD2FD9409642FC3A1E6B80206F55AF58" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BD2FD9409642FC3A1E6B80206F55AF58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E7DC5E7BE7898BDC09F980206F55CA66" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E7DC5E7BE7898BDC09F980206F55CA66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_52854D876B5A6DC009AD80206F5614C4" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_52854D876B5A6DC009AD80206F5614C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_7D620B3756A813DC176280206F58BD66" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_7D620B3756A813DC176280206F58BD66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_04C02756F3C3E293C38A80206F588B0E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_04C02756F3C3E293C38A80206F588B0E" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709EB883E692BD72710E80206A8A308C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709EB883E692BD72710E80206A8A308C" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4BDFD2E780F52595C58480206A8A3C32" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709EB883E692BD72710E80206A8A308C" xlink:to="loc_us-gaap_AwardTypeAxis_4BDFD2E780F52595C58480206A8A3C32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B964F94046B14C827D380206A8A0DDD_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_4BDFD2E780F52595C58480206A8A3C32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B964F94046B14C827D380206A8A0DDD_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B964F94046B14C827D380206A8A0DDD" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_4BDFD2E780F52595C58480206A8A3C32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B964F94046B14C827D380206A8A0DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B964F94046B14C827D380206A8A0DDD" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_EE8580B5CBF745E544CF80206A91158C" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_EE8580B5CBF745E544CF80206A91158C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_34F0F21B7C6C43322206802074D769E5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:to="loc_srt_TitleOfIndividualAxis_34F0F21B7C6C43322206802074D769E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4A3E2A8D6105C58D7432802074D74B7C_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_34F0F21B7C6C43322206802074D769E5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4A3E2A8D6105C58D7432802074D74B7C_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4A3E2A8D6105C58D7432802074D74B7C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_34F0F21B7C6C43322206802074D769E5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4A3E2A8D6105C58D7432802074D74B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ManagementMember" xlink:label="loc_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4A3E2A8D6105C58D7432802074D74B7C" xlink:to="loc_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_070B86D873F2A17F69F3802074D841F1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:to="loc_us-gaap_AwardTypeAxis_070B86D873F2A17F69F3802074D841F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9DCAF07331E06B124420802074D89EED_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_070B86D873F2A17F69F3802074D841F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9DCAF07331E06B124420802074D89EED_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9DCAF07331E06B124420802074D89EED" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_070B86D873F2A17F69F3802074D841F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9DCAF07331E06B124420802074D89EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_746D3DD7126A051989AF802074D84D9B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9DCAF07331E06B124420802074D89EED" xlink:to="loc_us-gaap_EmployeeStockOptionMember_746D3DD7126A051989AF802074D84D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_86A8860D4775EB023FCD802074D97119" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_86A8860D4775EB023FCD802074D97119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D5870E2B43CA85C1F38E802074D9CA11" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D5870E2B43CA85C1F38E802074D9CA11" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D48A81362CB5A96640658020743C05F5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D48A81362CB5A96640658020743C05F5" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_230FFEFB02E736AFE7A98020743CA236" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D48A81362CB5A96640658020743C05F5" xlink:to="loc_us-gaap_AwardTypeAxis_230FFEFB02E736AFE7A98020743CA236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC515C4969AA7870BB108020743C9F66_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_230FFEFB02E736AFE7A98020743CA236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC515C4969AA7870BB108020743C9F66_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC515C4969AA7870BB108020743C9F66" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_230FFEFB02E736AFE7A98020743CA236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC515C4969AA7870BB108020743C9F66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_CA893CAD75A845A396DD8020743D9904" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC515C4969AA7870BB108020743C9F66" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_CA893CAD75A845A396DD8020743D9904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_FCFF516250FD8A6954CA80207442921B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_FCFF516250FD8A6954CA80207442921B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_E5E6653954845DF167E88020744259F9" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_E5E6653954845DF167E88020744259F9" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6007E4EA9B538875C95F0CAF74C9EFF0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:to="loc_us-gaap_AwardTypeAxis_6007E4EA9B538875C95F0CAF74C9EFF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68C689AA9D7703FED8440CAF74C9E564_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6007E4EA9B538875C95F0CAF74C9EFF0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68C689AA9D7703FED8440CAF74C9E564_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68C689AA9D7703FED8440CAF74C9E564" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6007E4EA9B538875C95F0CAF74C9EFF0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68C689AA9D7703FED8440CAF74C9E564" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_D09295BE0B6140121C250CAF74CA1293" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68C689AA9D7703FED8440CAF74C9E564" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_D09295BE0B6140121C250CAF74CA1293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:to="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:to="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:to="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:to="loc_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:to="loc_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_3DDF7B8C4577BF5474250CAF74CC7311" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_3DDF7B8C4577BF5474250CAF74CC7311" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63DEDCFBCF03F575058D80206CC76BC8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63DEDCFBCF03F575058D80206CC76BC8" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_22A0D93FEC11AC8AFBE180206CC79E40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63DEDCFBCF03F575058D80206CC76BC8" xlink:to="loc_us-gaap_AwardTypeAxis_22A0D93FEC11AC8AFBE180206CC79E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2FEF7AEFBFD719AB9B6180206CC7B023_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_22A0D93FEC11AC8AFBE180206CC79E40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2FEF7AEFBFD719AB9B6180206CC7B023_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2FEF7AEFBFD719AB9B6180206CC7B023" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_22A0D93FEC11AC8AFBE180206CC79E40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2FEF7AEFBFD719AB9B6180206CC7B023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3BE123780AB8F17AD92680206CC757A8" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2FEF7AEFBFD719AB9B6180206CC7B023" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3BE123780AB8F17AD92680206CC757A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_991A444998EBD725BD2480206CC80E78" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_991A444998EBD725BD2480206CC80E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CD6AEA153F652E2F4A1280206CC82E78" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CD6AEA153F652E2F4A1280206CC82E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7878A306663DD66D40A980206CC9FCDB" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7878A306663DD66D40A980206CC9FCDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5697AE47247233936BFA80206E2E87B3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5697AE47247233936BFA80206E2E87B3" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C292BBDDCB920894B1A380206E2FE4B9" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5697AE47247233936BFA80206E2E87B3" xlink:to="loc_us-gaap_AwardTypeAxis_C292BBDDCB920894B1A380206E2FE4B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_142C0709AA32DC820A0880206E2FB171_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_C292BBDDCB920894B1A380206E2FE4B9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_142C0709AA32DC820A0880206E2FB171_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_142C0709AA32DC820A0880206E2FB171" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_C292BBDDCB920894B1A380206E2FE4B9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_142C0709AA32DC820A0880206E2FB171" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_C32B9432EF9E7329EEAB80206E353407" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_142C0709AA32DC820A0880206E2FB171" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_C32B9432EF9E7329EEAB80206E353407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5793F641007EAB4D6B3980206C251B4E" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5793F641007EAB4D6B3980206C251B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5793F641007EAB4D6B3980206C251B4E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5793F641007EAB4D6B3980206C251B4E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_C75689ACC71736EDB89480206C26DD59" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_C75689ACC71736EDB89480206C26DD59" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_59913AED4024573ED58380206C265333" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D" xlink:to="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_59913AED4024573ED58380206C265333" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:to="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:to="loc_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_716DE165FC60B223F95D01C31366BD08" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_716DE165FC60B223F95D01C31366BD08" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_500FDDA87890FF442DB001C313666A63" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_716DE165FC60B223F95D01C31366BD08" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_500FDDA87890FF442DB001C313666A63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_500FDDA87890FF442DB001C313666A63" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_500FDDA87890FF442DB001C313666A63" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_DC79503FD26D0D122B8A01C31367913C" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_DC79503FD26D0D122B8A01C31367913C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:label="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:to="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_2B6EAD576F94CA53877C01C31367DC3E" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:to="loc_pfe_IncomeTaxesPayableMember_2B6EAD576F94CA53877C01C31367DC3E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherTaxesPayableMember" xlink:label="loc_pfe_OtherTaxesPayableMember_B67930BB79466A953CE001C3136874CC" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:to="loc_pfe_OtherTaxesPayableMember_B67930BB79466A953CE001C3136874CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:label="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesLineItems" xlink:label="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesTable" xlink:label="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BCEB8D2CB1C49F8539072F92B3A1436A" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BCEB8D2CB1C49F8539072F92B3A1436A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3F3C1E323E14E5B5FB3C2F92B3A1444B_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BCEB8D2CB1C49F8539072F92B3A1436A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3F3C1E323E14E5B5FB3C2F92B3A1444B_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3F3C1E323E14E5B5FB3C2F92B3A1444B" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BCEB8D2CB1C49F8539072F92B3A1436A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3F3C1E323E14E5B5FB3C2F92B3A1444B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3F3C1E323E14E5B5FB3C2F92B3A1444B" xlink:to="loc_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForRepatriationTax" xlink:label="loc_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActIncomeTaxBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:type="locator" />
    <link:definitionArc order="23" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:type="locator" />
    <link:definitionArc order="24" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FeePayable" xlink:label="loc_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:type="locator" />
    <link:definitionArc order="25" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_A3ADC9A76D07B1FB99FEE395F3DCB167" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_A3ADC9A76D07B1FB99FEE395F3DCB167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A3ADC9A76D07B1FB99FEE395F3DCB167" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A3ADC9A76D07B1FB99FEE395F3DCB167" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_ECC70795F82E98E16EBDE395F3DD03BE" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_IncomeTaxesPayableMember_ECC70795F82E98E16EBDE395F3DD03BE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CurrentTaxAssetsMember" xlink:label="loc_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherTaxesPayableMember" xlink:label="loc_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:type="arc" />
  </link:definitionLink>
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:type="extended" />
  <link:definitionLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:type="arc" xbrldt:closed="true" xbrldt:contextElement="segment" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_21A7CD6A631577BFDBD30E488242A8E6" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_21A7CD6A631577BFDBD30E488242A8E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322_default" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_21A7CD6A631577BFDBD30E488242A8E6" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322_default" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_21A7CD6A631577BFDBD30E488242A8E6" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322" xlink:to="loc_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:type="locator" />
    <link:definitionArc order="1" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:type="locator" />
    <link:definitionArc order="2" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:type="locator" />
    <link:definitionArc order="3" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:type="locator" />
    <link:definitionArc order="4" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:type="locator" />
    <link:definitionArc order="5" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:type="locator" />
    <link:definitionArc order="6" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:type="locator" />
    <link:definitionArc order="7" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:type="locator" />
    <link:definitionArc order="8" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:type="locator" />
    <link:definitionArc order="9" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:type="locator" />
    <link:definitionArc order="10" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:type="locator" />
    <link:definitionArc order="11" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:type="locator" />
    <link:definitionArc order="12" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:type="locator" />
    <link:definitionArc order="13" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:type="locator" />
    <link:definitionArc order="14" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:type="locator" />
    <link:definitionArc order="15" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:type="locator" />
    <link:definitionArc order="16" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:type="locator" />
    <link:definitionArc order="17" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:type="locator" />
    <link:definitionArc order="18" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:type="locator" />
    <link:definitionArc order="19" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:type="locator" />
    <link:definitionArc order="20" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:type="locator" />
    <link:definitionArc order="21" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:type="locator" />
    <link:definitionArc order="22" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:type="arc" />
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>16
<FILENAME>pfe-20191231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_CoverAbstract_D030A2E7FA0D6D50DE9BCAF3D3CB1C8B_label_en-US" xlink:label="lab_dei_CoverAbstract_D030A2E7FA0D6D50DE9BCAF3D3CB1C8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover page.</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_D030A2E7FA0D6D50DE9BCAF3D3CB1C8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract_D030A2E7FA0D6D50DE9BCAF3D3CB1C8B" xlink:to="lab_dei_CoverAbstract_D030A2E7FA0D6D50DE9BCAF3D3CB1C8B" xlink:type="arc" />
    <link:label id="lab_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA_terseLabel_en-US" xlink:label="lab_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:label id="lab_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA_label_en-US" xlink:label="lab_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entities [Table]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:to="lab_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:to="lab_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="lab_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED_label_en-US" xlink:label="lab_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:to="lab_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:type="arc" />
    <link:label id="lab_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Due 2020, 0.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B_label_en-US" xlink:label="lab_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Due 2020, 0.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B_documentation_en-US" xlink:label="lab_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Due 2020, 0.000%  [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20200.000Member" xlink:label="loc_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:to="lab_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:type="arc" />
    <link:label id="lab_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56_label_en-US" xlink:label="lab_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56_documentation_en-US" xlink:label="lab_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Due 2022, 0.250% [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20220.250Member" xlink:label="loc_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:to="lab_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:type="arc" />
    <link:label id="lab_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822_terseLabel_en-US" xlink:label="lab_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822_label_en-US" xlink:label="lab_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:label id="lab_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822_documentation_en-US" xlink:label="lab_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Notes Due 2027, 1.000% [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20271.000Member" xlink:label="loc_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:to="lab_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:type="arc" />
    <link:label id="lab_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1_terseLabel_en-US" xlink:label="lab_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:label id="lab_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1_label_en-US" xlink:label="lab_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Information [Line Items]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems" xlink:label="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="lab_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:type="arc" />
    <link:label id="lab_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D_terseLabel_en-US" xlink:label="lab_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D_label_en-US" xlink:label="lab_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:to="lab_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:type="arc" />
    <link:label id="lab_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F_label_en-US" xlink:label="lab_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:to="lab_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:type="arc" />
    <link:label id="lab_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:to="lab_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:type="arc" />
    <link:label id="lab_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2_label_en-US" xlink:label="lab_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:to="lab_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:type="arc" />
    <link:label id="lab_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0_label_en-US" xlink:label="lab_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:to="lab_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:type="arc" />
    <link:label id="lab_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0_label_en-US" xlink:label="lab_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:to="lab_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:type="arc" />
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:to="lab_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:type="arc" />
    <link:label id="lab_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:to="lab_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:to="lab_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:to="lab_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:to="lab_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:type="arc" />
    <link:label id="lab_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:to="lab_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:type="arc" />
    <link:label id="lab_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698_label_en-US" xlink:label="lab_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:to="lab_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:type="arc" />
    <link:label id="lab_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C_label_en-US" xlink:label="lab_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:to="lab_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:type="arc" />
    <link:label id="lab_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970_label_en-US" xlink:label="lab_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:to="lab_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:type="arc" />
    <link:label id="lab_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858_label_en-US" xlink:label="lab_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:to="lab_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:type="arc" />
    <link:label id="lab_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293_label_en-US" xlink:label="lab_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:to="lab_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:type="arc" />
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:type="arc" />
    <link:label id="lab_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:to="lab_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:type="arc" />
    <link:label id="lab_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:to="lab_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:type="arc" />
    <link:label id="lab_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:to="lab_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:type="arc" />
    <link:label id="lab_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324_label_en-US" xlink:label="lab_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:to="lab_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:type="arc" />
    <link:label id="lab_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0_label_en-US" xlink:label="lab_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:to="lab_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:type="arc" />
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:to="lab_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:type="arc" />
    <link:label id="lab_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792_label_en-US" xlink:label="lab_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:to="lab_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:type="arc" />
    <link:label id="lab_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0_label_en-US" xlink:label="lab_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:to="lab_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:type="arc" />
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:to="lab_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:type="arc" />
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:type="arc" />
    <link:label id="lab_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:to="lab_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:type="arc" />
    <link:label id="lab_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:to="lab_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:to="lab_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:type="arc" />
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:to="lab_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:type="arc" />
    <link:label id="lab_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924_label_en-US" xlink:label="lab_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:to="lab_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_8A65B38961E9E8A72932802078DBA0EA_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_8A65B38961E9E8A72932802078DBA0EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8A65B38961E9E8A72932802078DBA0EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8A65B38961E9E8A72932802078DBA0EA" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_8A65B38961E9E8A72932802078DBA0EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring and Related Costs [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:to="lab_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB_terseLabel_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:label id="lab_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB_label_en-US" xlink:label="lab_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Balance Sheet Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:to="lab_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B_label_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring reserve</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:to="lab_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382B808A52B99869D47CE395F0DC354B_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382B808A52B99869D47CE395F0DC354B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382B808A52B99869D47CE395F0DC354B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382B808A52B99869D47CE395F0DC354B" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382B808A52B99869D47CE395F0DC354B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:type="arc" />
    <link:label id="lab_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:to="lab_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:type="arc" />
    <link:label id="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94_terseLabel_en-US" xlink:label="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Units (TSRUs) [Member]</link:label>
    <link:label id="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94_label_en-US" xlink:label="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Units (TSRUs) [Member]</link:label>
    <link:label id="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94_documentation_en-US" xlink:label="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Units (TSRUs) [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:to="lab_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:type="arc" />
    <link:label id="lab_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2_terseLabel_en-US" xlink:label="lab_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Profit Units [Member]</link:label>
    <link:label id="lab_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2_label_en-US" xlink:label="lab_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Profit Units [Member]</link:label>
    <link:label id="lab_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2_documentation_en-US" xlink:label="lab_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Profit Units [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ProfitUnitsMember" xlink:label="loc_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:to="lab_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted-Average Grant Price Per Share Unit (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, Share Units</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, Weighted-Average Grant Price Per Share Unit (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected to vest, Share Units</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected to vest, Weighted-Average Grant Price Per Share Unit (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected to vest, Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected to vest, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled, Share Units</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled, Weighted-Average Grant Price Per Share Per Unit (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised during period, Share Units</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised during period, Weighted-Average Grant Price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Converted awards</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares modified to accelerate vesting</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employees affected by plan modification</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:type="arc" />
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19_label_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:label id="lab_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19_documentation_en-US" xlink:label="lab_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Financial Instruments [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19" xlink:to="lab_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:to="lab_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:to="lab_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:to="lab_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:to="lab_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA_terseLabel_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:label id="lab_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA_label_en-US" xlink:label="lab_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unsecured Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:to="lab_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:to="lab_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:to="lab_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3_terseLabel_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3_label_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:label id="lab_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3_documentation_en-US" xlink:label="lab_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Notes Due 2047 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorNotesDue2047Member" xlink:label="loc_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:to="lab_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured U.K. Pound Debt, Six Point Five Percent, Due 2038 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Great Britain Pound Debt, Six Point Five Percent, Due 2038 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" xlink:label="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:to="lab_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, Five Point Seven Five Percent, Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Euro Debt, Five Point Seven Five Percent, Due 2021 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:to="lab_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="lab_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument, face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373_terseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373_label_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Weighted Average Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repurchased debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:to="lab_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, percentage</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Redemption value</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Repurchased Face Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:to="lab_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A_negatedLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on early retirement of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F_terseLabel_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of debt exchanged</link:label>
    <link:label id="lab_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F_label_en-US" xlink:label="lab_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Extinguishment of Debt, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:to="lab_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Principal amount</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E_label_en-US" xlink:label="lab_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:to="lab_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_3286AEEB6D13EA659B7780206AAAD4BC_label_en-US" xlink:label="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_3286AEEB6D13EA659B7780206AAAD4BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Benefits [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3286AEEB6D13EA659B7780206AAAD4BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3286AEEB6D13EA659B7780206AAAD4BC" xlink:to="lab_us-gaap_CompensationAndRetirementDisclosureAbstract_3286AEEB6D13EA659B7780206AAAD4BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:to="lab_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:to="lab_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement Benefits Plan [Member]</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Postretirement Benefits Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:to="lab_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan Disclosure [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:to="lab_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare cost trend rate assumed for next year (up to age 65)</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Under 65 Years of Age</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Under 65 Years of Age</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge" xlink:label="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:to="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Healthcare cost trend rate assumed for next year (age 65 and older)</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, 65 Years of Age and Over</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, 65 Years of Age and Over</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver" xlink:label="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:to="lab_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rate to which the cost trend rate is assumed to decline</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Ultimate Health Care Cost Trend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:to="lab_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_C909E5F66505B18D4BBA802077F17983_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract_C909E5F66505B18D4BBA802077F17983" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C909E5F66505B18D4BBA802077F17983" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C909E5F66505B18D4BBA802077F17983" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract_C909E5F66505B18D4BBA802077F17983" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Matters</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityAbstract_6597F9790929549DC35C8020724DAC59_label_en-US" xlink:label="lab_us-gaap_EquityAbstract_6597F9790929549DC35C8020724DAC59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6597F9790929549DC35C8020724DAC59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract_6597F9790929549DC35C8020724DAC59" xlink:to="lab_us-gaap_EquityAbstract_6597F9790929549DC35C8020724DAC59" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C" xlink:type="arc" />
    <link:label id="lab_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2_terseLabel_en-US" xlink:label="lab_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2_label_en-US" xlink:label="lab_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Income Taxes [Abstract]</link:label>
    <link:label id="lab_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2_documentation_en-US" xlink:label="lab_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Domestic Income Taxes [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DomesticIncomeTaxesAbstract" xlink:label="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:to="lab_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income taxes:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96" xlink:type="arc" />
    <link:label id="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571_totalLabel_en-US" xlink:label="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total U.S. tax benefit</link:label>
    <link:label id="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571_label_en-US" xlink:label="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Income Tax Expense (Benefit), Continued Operations</link:label>
    <link:label id="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571_documentation_en-US" xlink:label="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Domestic Income Tax Expense (Benefit), Continued Operations</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:label="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571" xlink:to="lab_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571" xlink:type="arc" />
    <link:label id="lab_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1_terseLabel_en-US" xlink:label="lab_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TCJA</link:label>
    <link:label id="lab_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1_label_en-US" xlink:label="lab_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Tax Cuts and Jobs Act [Abstract]</link:label>
    <link:label id="lab_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1_documentation_en-US" xlink:label="lab_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effect of Tax Cuts and Jobs Act [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectofTaxCutsandJobsActAbstract" xlink:label="loc_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:to="lab_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F" xlink:to="lab_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Income taxes</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E" xlink:to="lab_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46_totalLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total TCJA tax benefit</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46" xlink:type="arc" />
    <link:label id="lab_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683_terseLabel_en-US" xlink:label="lab_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683_label_en-US" xlink:label="lab_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">International Income Taxes [Abstract]</link:label>
    <link:label id="lab_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683_documentation_en-US" xlink:label="lab_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">International Income Taxes [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InternationalIncomeTaxesAbstract" xlink:label="loc_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:to="lab_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:type="arc" />
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current income taxes</link:label>
    <link:label id="lab_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A_label_en-US" xlink:label="lab_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Foreign Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A" xlink:to="lab_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:label id="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622_label_en-US" xlink:label="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Foreign Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622" xlink:to="lab_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00_totalLabel_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total international tax provision</link:label>
    <link:label id="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00_label_en-US" xlink:label="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Income Tax Expense (Benefit), Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00" xlink:to="lab_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Provision/(benefit) for taxes on income</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected stock price volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:to="lab_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB_label_en-US" xlink:label="lab_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Designation [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:to="lab_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E_terseLabel_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E_label_en-US" xlink:label="lab_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:to="lab_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:type="arc" />
    <link:label id="lab_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A_terseLabel_en-US" xlink:label="lab_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:label id="lab_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A_label_en-US" xlink:label="lab_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Not Designated as Hedging Instrument [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:to="lab_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B_terseLabel_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:label id="lab_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B_label_en-US" xlink:label="lab_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedging Relationship [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:to="lab_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:to="lab_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7_terseLabel_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:label id="lab_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7_label_en-US" xlink:label="lab_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Investment Hedging [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:to="lab_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:to="lab_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:label id="lab_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A_label_en-US" xlink:label="lab_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Contract [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="lab_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0_verboseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange contracts [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0_label_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:to="lab_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD_terseLabel_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate contracts [Member]</link:label>
    <link:label id="lab_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD_label_en-US" xlink:label="lab_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Rate Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:to="lab_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:type="arc" />
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency short-term borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5_label_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Short Term Borrowings [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign currency short - term borrowings [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:to="lab_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:type="arc" />
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E_terseLabel_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency long-term debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E_label_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Long Term Debt [Member]</link:label>
    <link:label id="lab_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E_documentation_en-US" xlink:label="lab_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Foreign currency long - term debt [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:to="lab_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:to="lab_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:to="lab_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:type="arc" />
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F_terseLabel_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F_label_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F_documentation_en-US" xlink:label="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other (Income) Deductions And Cost Of Sales [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:to="lab_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="lab_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged Item</link:label>
    <link:label id="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0_label_en-US" xlink:label="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:to="lab_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D_label_en-US" xlink:label="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:to="lab_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OID</link:label>
    <link:label id="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5_label_en-US" xlink:label="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Gain (Loss) on Derivative, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:to="lab_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Recognized in OCI</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount excluded from effectiveness testing</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gain/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:to="lab_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD" xlink:to="lab_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:to="lab_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B_label_en-US" xlink:label="lab_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Classification [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:to="lab_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7_label_en-US" xlink:label="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:to="lab_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772_label_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:type="arc" />
    <link:label id="lab_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer Healthcare [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:to="lab_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2_terseLabel_en-US" xlink:label="lab_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:label id="lab_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2_label_en-US" xlink:label="lab_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:to="lab_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:type="arc" />
    <link:label id="lab_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0_terseLabel_en-US" xlink:label="lab_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:label id="lab_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0_label_en-US" xlink:label="lab_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ownership [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:to="lab_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:type="arc" />
    <link:label id="lab_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD_terseLabel_en-US" xlink:label="lab_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratorio Teuto Brasilero [Member]</link:label>
    <link:label id="lab_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD_label_en-US" xlink:label="lab_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratorio Teuto Brasilero [Member]</link:label>
    <link:label id="lab_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD_documentation_en-US" xlink:label="lab_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratorio Teuto Brasilero [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:to="lab_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:type="arc" />
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:type="arc" />
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="lab_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:type="arc" />
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911_terseLabel_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911_label_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [Member]</link:label>
    <link:label id="lab_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911_documentation_en-US" xlink:label="lab_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK Consumer Healthcare [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:to="lab_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:type="arc" />
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1_terseLabel_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1_label_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:label id="lab_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1_documentation_en-US" xlink:label="lab_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ViiV Healthcare Limited [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:to="lab_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:type="arc" />
    <link:label id="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0_terseLabel_en-US" xlink:label="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</link:label>
    <link:label id="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0_label_en-US" xlink:label="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</link:label>
    <link:label id="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0_documentation_en-US" xlink:label="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:to="lab_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:type="arc" />
    <link:label id="lab_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74_label_en-US" xlink:label="lab_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:to="lab_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:type="arc" />
    <link:label id="lab_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D_terseLabel_en-US" xlink:label="lab_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D_label_en-US" xlink:label="lab_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:to="lab_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:type="arc" />
    <link:label id="lab_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A_terseLabel_en-US" xlink:label="lab_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A_label_en-US" xlink:label="lab_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">GSK [Member]</link:label>
    <link:label id="lab_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A_documentation_en-US" xlink:label="lab_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">GSK [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKMember" xlink:label="loc_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:to="lab_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, ownership percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155_terseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction</link:label>
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155_label_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:type="arc" />
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction, net of tax</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Tax</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfTax" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:to="lab_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax indemnification liability</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Tax Indemnification, Liability</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Tax Indemnification, Liability</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTaxIndemnificationLiability" xlink:label="loc_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:to="lab_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:to="lab_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986_verboseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments, fair value</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying equity in net assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Underlying Equity in Net Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:to="lab_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between carrying amount and underlying equity</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Difference Between Carrying Amount and Underlying Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:to="lab_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess basis amortization</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortization" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:to="lab_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Excess basis amortization period</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization, Period</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Excess Basis Amortization, Period</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:to="lab_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transitional agreement administrative services term</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Transitional Agreement, Administrative Services, Term</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Transitional Agreement, Administrative Services, Term</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm" xlink:label="loc_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:to="lab_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transitional agreement manufacture and supply term</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Transitional Agreement, Manufacture and Supply, Term</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Transitional Agreement, Manufacture and Supply, Term</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm" xlink:label="loc_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:to="lab_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividend income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Dividend</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:to="lab_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, registered capital</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment Summarized Financial Information, Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-tax income attributable to disposal group</link:label>
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E_label_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</link:label>
    <link:label id="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E_documentation_en-US" xlink:label="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:to="lab_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equity method investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:to="lab_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investment, carrying value of share sold</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Amount Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:to="lab_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of equity method investment used to cover taxes incurred on transaction</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Proceeds From Sale Used To Cover Transaction Tax</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investments, Proceeds From Sale Used To Cover Transaction Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax" xlink:label="loc_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:to="lab_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB_negatedLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of equity method investment</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Realized Gain (Loss) on Disposal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:to="lab_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by parent</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Business Acquisitions, by Acquisition [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:to="lab_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41_terseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41_label_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">In Process Research and Development [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets by Major Class [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Major Class Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F_terseLabel_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F_label_en-US" xlink:label="lab_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Technology Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:to="lab_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:to="lab_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:type="arc" />
    <link:label id="lab_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F_terseLabel_en-US" xlink:label="lab_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medivation [Member]</link:label>
    <link:label id="lab_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F_label_en-US" xlink:label="lab_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medivation [Member]</link:label>
    <link:label id="lab_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F_documentation_en-US" xlink:label="lab_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medivation [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MedivationMember" xlink:label="loc_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:to="lab_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="lab_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business acquisition, per share in cash (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:to="lab_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Payments to acquire businesses, cash portion</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash payments for acquisition, net of cash acquired</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Businesses, Net of Cash Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition consideration, amount payable</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Amount Payable</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Amount Payable</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredAmountPayable" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4_terseLabel_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquired intangible assets, useful life</link:label>
    <link:label id="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4_label_en-US" xlink:label="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Acquired Finite-lived Intangible Assets, Weighted Average Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:to="lab_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA_label_en-US" xlink:label="lab_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:to="lab_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumed contingent consideration</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740_verboseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration paid</link:label>
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740_label_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment for Contingent Consideration Liability, Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9_negatedLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reduction in identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:to="lab_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A_negatedLabel_en-US" xlink:label="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in amortization of intangible assets</link:label>
    <link:label id="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A_label_en-US" xlink:label="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets</link:label>
    <link:label id="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" xlink:label="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:to="lab_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9" xlink:type="arc" />
    <link:label id="lab_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0_label_en-US" xlink:label="lab_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Coverage [Abstract]</link:label>
    <link:label id="lab_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0_documentation_en-US" xlink:label="lab_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance Coverage [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceCoverageAbstract" xlink:label="loc_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0" xlink:to="lab_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0" xlink:type="arc" />
    <link:label id="lab_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E_terseLabel_en-US" xlink:label="lab_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance</link:label>
    <link:label id="lab_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E_label_en-US" xlink:label="lab_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Coverage Disclosure [Text Block]</link:label>
    <link:label id="lab_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E_documentation_en-US" xlink:label="lab_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance Coverage Disclosure [Text Block]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceCoverageDisclosureTextBlock" xlink:label="loc_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E" xlink:to="lab_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339_verboseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock purchased</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of purchase</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Current Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Noncurrent Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599_totalLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Current Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A_totalLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity/(deficit) attributable to shareholders</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Equity Excluding Noncontrolling Interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF_totalLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total net equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Sales</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Revenue</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Cost of Sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D_totalLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Gross Profit (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Income (Loss) from Continuing Operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Net Income (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:to="lab_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:type="arc" />
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87_terseLabel_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income attributable to shareholders</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87_label_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Net Income (Loss) Attributable To Shareholders</link:label>
    <link:label id="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87_documentation_en-US" xlink:label="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Summarized Financial Information, Net Income (Loss) Attributable To Shareholders</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:to="lab_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20_terseLabel_en-US" xlink:label="lab_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20_label_en-US" xlink:label="lab_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20_documentation_en-US" xlink:label="lab_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesTable" xlink:label="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:to="lab_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1_terseLabel_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1_label_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1_documentation_en-US" xlink:label="lab_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Taxes Payable [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:to="lab_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F_terseLabel_en-US" xlink:label="lab_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F_label_en-US" xlink:label="lab_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F_documentation_en-US" xlink:label="lab_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Income Taxes [Table]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesLineItems" xlink:label="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="lab_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repatriation tax provisional liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to measurement adjustment</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Repatriation tax liability</link:label>
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE_label_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5_terseLabel_en-US" xlink:label="lab_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for repatriation tax</link:label>
    <link:label id="lab_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5_label_en-US" xlink:label="lab_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Repatriation Tax</link:label>
    <link:label id="lab_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5_documentation_en-US" xlink:label="lab_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Repatriation Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForRepatriationTax" xlink:label="loc_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:to="lab_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provisional expense related to future taxes on global intangible low-taxed income</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Provisional Deferred Tax Liability</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Provisional Deferred Tax Liability</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:to="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liability on global intangible low-taxed income</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Measurement Period Adjustment, Global Intangible Low-Taxed Income, Deferred Tax Liability</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Measurement Period Adjustment, Global Intangible Low-Taxed Income, Deferred Tax Liability</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:to="lab_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense related to future taxes on global intangible low-taxed income</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Global Intangible Low-Taxed Income, Deferred Tax Liability</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Global Intangible Low-Taxed Income, Deferred Tax Liability</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:to="lab_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:type="arc" />
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386_terseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation gain</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits from resolution of certain tax positions</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Domestic, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:type="arc" />
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF_negatedTerseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits associated with implementation of organizational structure</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Implementation Of Organizational Structure, Gain (Loss), Amount</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Implementation Of Organizational Structure, Gain (Loss), Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefits related to certain asset impairments</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits associated with the enactment of the TCJA</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2_label_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act, Income Tax Benefit</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2_documentation_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act, Income Tax Benefit</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActIncomeTaxBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:to="lab_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits associated with certain current year tax initiatives</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76_label_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Tax Initiatives, Income Tax (Expense) Benefit</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76_documentation_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Tax Initiatives, Income Tax (Expense) Benefit</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:to="lab_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB_negatedTerseLabel_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits related to the repatriation tax on deemed repatriated accumulated earnings of foreign subsidiaries</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB_label_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Transition Tax For Accumulated Foreign Earnings, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB_documentation_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Transition Tax For Accumulated Foreign Earnings, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:to="lab_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit associated with the remeasurement of other U.S. deferred tax liabilities</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C_label_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Change In Tax Rate, Deferred Tax Liability, Income Tax (Expense) Benefit</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C_documentation_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Change In Tax Rate, Deferred Tax Liability, Income Tax (Expense) Benefit</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:to="lab_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax expense related to future taxes on global intangible low-taxed income</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932_label_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932_documentation_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:to="lab_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6_negatedLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit from Tax Cuts and Jobs Act of 2017</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change In Tax Rate, Provisional Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Change In Tax Rate, Provisional Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:to="lab_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit associated with remeasurement of U.S. deferred tax liabilities on remitted earnings of foreign subsidiaries</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC_label_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Unremitted Earnings, Provisional Income Tax (Expense) Benefit</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC_documentation_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Unremitted Earnings, Provisional Income Tax (Expense) Benefit</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:to="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit associated with remeasurement of U.S. deferred tax liabilities primarily intangibles</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91_label_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Intangible Assets, Provisional Income Tax (Expense) Benefit</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91_documentation_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Intangible Assets, Provisional Income Tax (Expense) Benefit</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:to="lab_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense related to repatriation tax on deemed repatriated accumulated pre-2017 earnings of foreign subsidiaries</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F_label_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F_documentation_en-US" xlink:label="lab_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:to="lab_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expense related to future taxes on global intangible low-taxed income</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:to="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:type="arc" />
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D_terseLabel_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit primarily associated with certain tax initiatives</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D_label_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Tax Initiatives, Income Tax (Expense) Benefit</link:label>
    <link:label id="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D_documentation_en-US" xlink:label="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Tax Initiatives, Income Tax (Expense) Benefit</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:to="lab_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income taxes on certain current-year funds earned outside of the U.S.</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:to="lab_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:type="arc" />
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73_terseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefit related to net losses on early retirement of debt</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Loss On Debt Extinguishment, Amount</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Loss On Debt Extinguishment, Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:type="arc" />
    <link:label id="lab_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D_verboseLabel_en-US" xlink:label="lab_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fee payable to Federal Government</link:label>
    <link:label id="lab_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D_label_en-US" xlink:label="lab_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fee Payable</link:label>
    <link:label id="lab_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D_documentation_en-US" xlink:label="lab_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fee Payable</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FeePayable" xlink:label="loc_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:to="lab_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Common Stock Purchases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA" xlink:to="lab_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_413650329A981E97ACA0D9856426FFE7_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_413650329A981E97ACA0D9856426FFE7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_413650329A981E97ACA0D9856426FFE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_413650329A981E97ACA0D9856426FFE7" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_413650329A981E97ACA0D9856426FFE7" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0_label_en-US" xlink:label="lab_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Intangible Assets [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0_documentation_en-US" xlink:label="lab_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets [Table]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfIntangibleAssetsTable" xlink:label="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:to="lab_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:type="arc" />
    <link:label id="lab_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA_terseLabel_en-US" xlink:label="lab_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Array [Member]</link:label>
    <link:label id="lab_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA_label_en-US" xlink:label="lab_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Array [Member]</link:label>
    <link:label id="lab_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA_documentation_en-US" xlink:label="lab_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Array [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:to="lab_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements, Developed Technology [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44_label_en-US" xlink:label="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements, Developed Technology [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreements, Developed Technology [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:label="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:to="lab_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements, Technology In Development [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40_label_en-US" xlink:label="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements, Technology In Development [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreements, Technology In Development [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:label="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:to="lab_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:type="arc" />
    <link:label id="lab_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F_terseLabel_en-US" xlink:label="lab_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Intangible Assets [Line Items]</link:label>
    <link:label id="lab_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F_label_en-US" xlink:label="lab_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets [Line Items]</link:label>
    <link:label id="lab_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F_documentation_en-US" xlink:label="lab_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Intangible Assets [Table]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsLineItems" xlink:label="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:to="lab_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A_terseLabel_en-US" xlink:label="lab_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A_label_en-US" xlink:label="lab_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:label id="lab_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A_documentation_en-US" xlink:label="lab_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:to="lab_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:to="lab_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2_label_en-US" xlink:label="lab_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:to="lab_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:type="arc" />
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15_terseLabel_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017-2019 Initiatives and Organizing for Growth Initiative [Member]</link:label>
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15_label_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]</link:label>
    <link:label id="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15_documentation_en-US" xlink:label="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:to="lab_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:type="arc" />
    <link:label id="lab_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996_terseLabel_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996_label_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:label id="lab_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996_documentation_en-US" xlink:label="lab_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Focused Company Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FocusedCompanyPlanMember" xlink:label="loc_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:to="lab_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:to="lab_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:type="arc" />
    <link:label id="lab_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F_terseLabel_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F_label_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:label id="lab_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F_documentation_en-US" xlink:label="lab_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Manufacturing Optimization [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ManufacturingOptimizationMember" xlink:label="loc_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:to="lab_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:type="arc" />
    <link:label id="lab_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D_terseLabel_en-US" xlink:label="lab_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Activities [Member]</link:label>
    <link:label id="lab_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D_label_en-US" xlink:label="lab_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Activities [Member]</link:label>
    <link:label id="lab_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D_documentation_en-US" xlink:label="lab_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Activities [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherActivitiesMember" xlink:label="loc_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:to="lab_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3_terseLabel_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3_label_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3_documentation_en-US" xlink:label="lab_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Integration Costs [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:to="lab_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring cost incurred to date</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Cost Incurred to Date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:to="lab_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected cost</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Expected Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:to="lab_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895_terseLabel_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of non-cash restructuring charges expected</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895_label_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:label id="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895_documentation_en-US" xlink:label="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Noncash Charges, Percentage</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:to="lab_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges incurred</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Incurred Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:to="lab_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:to="lab_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC_label_en-US" xlink:label="lab_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Tax Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:to="lab_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63_terseLabel_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Qualified Plan [Member]</link:label>
    <link:label id="lab_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63_label_en-US" xlink:label="lab_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Qualified Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:to="lab_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:type="arc" />
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8_terseLabel_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nonqualified Plan [Member]</link:label>
    <link:label id="lab_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8_label_en-US" xlink:label="lab_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonqualified Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:to="lab_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64_terseLabel_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:label id="lab_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64_label_en-US" xlink:label="lab_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retirement Plan Sponsor Location [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:to="lab_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:type="arc" />
    <link:label id="lab_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017_terseLabel_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:label id="lab_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017_label_en-US" xlink:label="lab_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:to="lab_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:type="arc" />
    <link:label id="lab_country_US_1C81100B7528156F9B7B5B5D784555DC_terseLabel_en-US" xlink:label="lab_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States [Member]</link:label>
    <link:label id="lab_country_US_1C81100B7528156F9B7B5B5D784555DC_label_en-US" xlink:label="lab_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:to="lab_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76_label_en-US" xlink:label="lab_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:to="lab_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C_terseLabel_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:label id="lab_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C_label_en-US" xlink:label="lab_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:to="lab_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Supplemental (Non-Qualified) Pension Plans [Member]</link:label>
    <link:label id="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3_label_en-US" xlink:label="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Employee Retirement Plan [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:to="lab_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Service cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Service Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:to="lab_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest cost</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Interest Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:to="lab_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Return (Loss) on Plan Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization of actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of prior service credits/(credits)</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amortization of Prior Service Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:to="lab_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:to="lab_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit costs/(income) reported in Income</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Income)/cost reported in Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5_totalLabel_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">(Credit)/cost recognized in Comprehensive income</link:label>
    <link:label id="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5_label_en-US" xlink:label="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:to="lab_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingAbstract_56F31490464087F5544C80206B675A17_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract_56F31490464087F5544C80206B675A17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_56F31490464087F5544C80206B675A17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract_56F31490464087F5544C80206B675A17" xlink:to="lab_us-gaap_SegmentReportingAbstract_56F31490464087F5544C80206B675A17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:type="arc" />
    <link:label id="lab_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287_terseLabel_en-US" xlink:label="lab_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:label id="lab_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287_label_en-US" xlink:label="lab_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Currency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:to="lab_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:type="arc" />
    <link:label id="lab_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A_terseLabel_en-US" xlink:label="lab_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:label id="lab_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A_label_en-US" xlink:label="lab_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Currencies [Domain]</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:to="lab_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:type="arc" />
    <link:label id="lab_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A_terseLabel_en-US" xlink:label="lab_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:label id="lab_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A_label_en-US" xlink:label="lab_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Euro Member Countries, Euro</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:to="lab_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:type="arc" />
    <link:label id="lab_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:to="lab_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:type="arc" />
    <link:label id="lab_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:to="lab_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:type="arc" />
    <link:label id="lab_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B_terseLabel_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B_label_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:label id="lab_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B_documentation_en-US" xlink:label="lab_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Europe [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:to="lab_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation, beginning</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan amendments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Changes in actuarial assumptions and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:to="lab_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:to="lab_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26_negatedLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions/divestitures/other, net</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:to="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Curtailments</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:to="lab_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Special termination benefits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:to="lab_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Benefit Obligation, Benefits Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanBenefitObligation_FE8DE4EFBDA826367B582F92B219851D_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanBenefitObligation_FE8DE4EFBDA826367B582F92B219851D" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Benefit obligation, ending</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FE8DE4EFBDA826367B582F92B219851D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FE8DE4EFBDA826367B582F92B219851D" xlink:to="lab_us-gaap_DefinedBenefitPlanBenefitObligation_FE8DE4EFBDA826367B582F92B219851D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7_periodStartLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets, beginning</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actual gain/(loss) on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Company contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Employer</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee contributions</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Contributions by Plan Participant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Foreign exchange impact</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C_verboseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions/divestitures, net</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:to="lab_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9_negatedLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Payment for Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:to="lab_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefits paid</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Benefits Paid</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9660FDA9BF7C7C7E1EB32F92B21B1AB3_periodEndLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9660FDA9BF7C7C7E1EB32F92B21B1AB3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets, ending</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9660FDA9BF7C7C7E1EB32F92B21B1AB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9660FDA9BF7C7C7E1EB32F92B21B1AB3" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9660FDA9BF7C7C7E1EB32F92B21B1AB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Funded status&#8212;Plan assets less than benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Funded (Unfunded) Status of Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:to="lab_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, accumulated benefit obligation</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:label id="lab_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB_label_en-US" xlink:label="lab_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:to="lab_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF_verboseLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:to="lab_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term borrowings, including current portion of long-term debt [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:to="lab_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt [Member]</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:to="lab_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:label id="lab_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06_label_en-US" xlink:label="lab_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="lab_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount of Actively Hedged Assets</link:label>
    <link:label id="lab_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20_label_en-US" xlink:label="lab_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Asset, Fair Value Hedge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetFairValueHedge" xlink:label="loc_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:to="lab_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Amount of Actively Hedged Liabilities</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Liability, Fair Value Hedge</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset</link:label>
    <link:label id="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D_label_en-US" xlink:label="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:to="lab_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:to="lab_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset</link:label>
    <link:label id="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2_label_en-US" xlink:label="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:to="lab_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B_terseLabel_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</link:label>
    <link:label id="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B_label_en-US" xlink:label="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:to="lab_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. statutory income tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TCJA impact</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Taxation of non-U.S. operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax settlements and resolution of certain tax positions</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Completion of Consumer Healthcare joint venture transaction(d)</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Disposition of Business, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A" xlink:type="arc" />
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5_terseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Healthcare Legislation</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Legislation, Percent</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Legislation, Percent</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">U.S. R&amp;D tax credit and manufacturing deduction</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01" xlink:type="arc" />
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445_terseLabel_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain legal settlements and charges</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445_label_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Litigation Settlement, Percent</link:label>
    <link:label id="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445_documentation_en-US" xlink:label="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Deduction, Litigation Settlement, Percent</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445" xlink:to="lab_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other, net</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Adjustments, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate for income from continuing operations</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="lab_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0_negatedLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0" xlink:to="lab_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A_label_en-US" xlink:label="lab_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A" xlink:to="lab_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net interest expense</link:label>
    <link:label id="lab_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935_label_en-US" xlink:label="lab_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Revenue (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935" xlink:to="lab_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935" xlink:type="arc" />
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A_negatedLabel_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Royalty-related income</link:label>
    <link:label id="lab_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A_label_en-US" xlink:label="lab_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Income, Nonoperating</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A" xlink:to="lab_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net (gains)/losses on asset disposals</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3" xlink:to="lab_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net gains recognized during the period on investments in equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net realized (gains)/losses on sales of investments in debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018" xlink:to="lab_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income from collaborations, out-licensing arrangements and sales of compound/product rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED_label_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:label id="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED" xlink:to="lab_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E_terseLabel_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit costs/(credits) other than service costs</link:label>
    <link:label id="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E_label_en-US" xlink:label="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E" xlink:to="lab_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Certain legal matters, net</link:label>
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009_label_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) Related to Litigation Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain asset impairments</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327" xlink:to="lab_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF_terseLabel_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business alignment costs</link:label>
    <link:label id="lab_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF_label_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Alignment Costs</link:label>
    <link:label id="lab_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF_documentation_en-US" xlink:label="lab_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Alignment Costs</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessAlignmentCosts" xlink:label="loc_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF" xlink:to="lab_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_A6E8DFE17FD10965036E7E0E8B250F5D_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_A6E8DFE17FD10965036E7E0E8B250F5D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net losses on early retirement of debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A6E8DFE17FD10965036E7E0E8B250F5D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A6E8DFE17FD10965036E7E0E8B250F5D" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_A6E8DFE17FD10965036E7E0E8B250F5D" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35_negatedTerseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35_label_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:label id="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35" xlink:to="lab_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35" xlink:type="arc" />
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC_label_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC_documentation_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense), Net</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC" xlink:to="lab_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:to="lab_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:type="arc" />
    <link:label id="lab_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56_terseLabel_en-US" xlink:label="lab_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Tax Assets [Member]</link:label>
    <link:label id="lab_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56_label_en-US" xlink:label="lab_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Tax Assets [Member]</link:label>
    <link:label id="lab_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56_documentation_en-US" xlink:label="lab_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Current Tax Assets [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CurrentTaxAssetsMember" xlink:label="loc_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:to="lab_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:type="arc" />
    <link:label id="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC_terseLabel_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</link:label>
    <link:label id="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC_label_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</link:label>
    <link:label id="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC_documentation_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:to="lab_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:type="arc" />
    <link:label id="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD_terseLabel_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent Deferred Tax Liabilities [Member]</link:label>
    <link:label id="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD_label_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent Deferred Tax Liabilities [Member]</link:label>
    <link:label id="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD_documentation_en-US" xlink:label="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncurrent Deferred Tax Liabilities [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:to="lab_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:type="arc" />
    <link:label id="lab_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5_terseLabel_en-US" xlink:label="lab_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5_label_en-US" xlink:label="lab_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Taxes Payable [Member]</link:label>
    <link:label id="lab_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5_documentation_en-US" xlink:label="lab_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Taxes Payable [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherTaxesPayableMember" xlink:label="loc_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:to="lab_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C_label_en-US" xlink:label="lab_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Contingency [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:to="lab_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5_verboseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:type="arc" />
    <link:label id="lab_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3_label_en-US" xlink:label="lab_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:label id="lab_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3_documentation_en-US" xlink:label="lab_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hedged Item [Axis]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HedgedItemAxis" xlink:label="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:to="lab_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:type="arc" />
    <link:label id="lab_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98_terseLabel_en-US" xlink:label="lab_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98_label_en-US" xlink:label="lab_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hedged Item [Domain]</link:label>
    <link:label id="lab_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98_documentation_en-US" xlink:label="lab_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Hedged Item [Axis]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HedgedItemDomain" xlink:label="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:to="lab_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98_terseLabel_en-US" xlink:label="lab_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:label id="lab_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98_label_en-US" xlink:label="lab_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:to="lab_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative, notional amount</link:label>
    <link:label id="lab_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B_label_en-US" xlink:label="lab_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Notional Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:to="lab_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative asset</link:label>
    <link:label id="lab_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D_label_en-US" xlink:label="lab_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:to="lab_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C_verboseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Derivative liability</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:to="lab_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Nonoperating Income (Expense) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191" xlink:to="lab_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Additional Information About Intangible Assets Impaired</link:label>
    <link:label id="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Impaired Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D" xlink:to="lab_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges And Acquisition-Related Costs [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF_label_en-US" xlink:label="lab_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:to="lab_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:type="arc" />
    <link:label id="lab_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB_terseLabel_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB_label_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB_documentation_en-US" xlink:label="lab_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharma Segment [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:to="lab_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:type="arc" />
    <link:label id="lab_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018_terseLabel_en-US" xlink:label="lab_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upjohn Segment [Member]</link:label>
    <link:label id="lab_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018_label_en-US" xlink:label="lab_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upjohn Segment [Member]</link:label>
    <link:label id="lab_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018_documentation_en-US" xlink:label="lab_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upjohn Segment [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:to="lab_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:label id="lab_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694_label_en-US" xlink:label="lab_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:to="lab_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:type="arc" />
    <link:label id="lab_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89_terseLabel_en-US" xlink:label="lab_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:label id="lab_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89_label_en-US" xlink:label="lab_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation Items [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:to="lab_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:label id="lab_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8_label_en-US" xlink:label="lab_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Segments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:to="lab_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C_terseLabel_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:label id="lab_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C_label_en-US" xlink:label="lab_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciling Items [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:to="lab_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charge (credit)</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:to="lab_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Post closing compensation expense for payments to Array employees for fair value of previously unvested stock options</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:to="lab_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC" xlink:to="lab_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A919E1D7B069138E707F80206AE4CDA6_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A919E1D7B069138E707F80206AE4CDA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A919E1D7B069138E707F80206AE4CDA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A919E1D7B069138E707F80206AE4CDA6" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract_A919E1D7B069138E707F80206AE4CDA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_634551C34308BC941AFA0C10A8A6017C_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract_634551C34308BC941AFA0C10A8A6017C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_634551C34308BC941AFA0C10A8A6017C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract_634551C34308BC941AFA0C10A8A6017C" xlink:to="lab_us-gaap_DebtDisclosureAbstract_634551C34308BC941AFA0C10A8A6017C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9" xlink:to="lab_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9" xlink:type="arc" />
    <link:label id="lab_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:to="lab_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:type="arc" />
    <link:label id="lab_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:to="lab_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:type="arc" />
    <link:label id="lab_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004_terseLabel_en-US" xlink:label="lab_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mylotarg [Member]</link:label>
    <link:label id="lab_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004_label_en-US" xlink:label="lab_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mylotarg [Member]</link:label>
    <link:label id="lab_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004_documentation_en-US" xlink:label="lab_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mylotarg [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylotargMember" xlink:label="loc_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:to="lab_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:type="arc" />
    <link:label id="lab_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3_terseLabel_en-US" xlink:label="lab_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3_label_en-US" xlink:label="lab_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:label id="lab_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3_documentation_en-US" xlink:label="lab_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bosulif [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:to="lab_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:type="arc" />
    <link:label id="lab_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5_terseLabel_en-US" xlink:label="lab_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5_label_en-US" xlink:label="lab_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:label id="lab_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5_documentation_en-US" xlink:label="lab_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Besponsa [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:to="lab_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE_verboseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EU [Member]</link:label>
    <link:label id="lab_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE_label_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:to="lab_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development arrangement, aggregate payment obligation, term</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Aggregate Payment Obligation, Term</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Aggregate Payment Obligation, Term</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:to="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Aggregate Payment Obligation</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Aggregate Payment Obligation</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:to="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, net</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lump sum payment for liability buyout</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Liability Buyout, Amount</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Liability Buyout, Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount" xlink:label="loc_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:to="lab_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4_verboseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Non-cash gain from buyout transaction</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Gain From Liability Extinguishment</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Gain From Liability Extinguishment</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" xlink:label="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:to="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:to="lab_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:type="arc" />
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:type="arc" />
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63_terseLabel_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:label id="lab_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63_label_en-US" xlink:label="lab_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Board of Directors Chairman [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:to="lab_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:type="arc" />
    <link:label id="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51_terseLabel_en-US" xlink:label="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]</link:label>
    <link:label id="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51_label_en-US" xlink:label="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]</link:label>
    <link:label id="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51_documentation_en-US" xlink:label="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:label="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:to="lab_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:type="arc" />
    <link:label id="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1_terseLabel_en-US" xlink:label="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Total Shareholder Return Unit (PTSRUs) [Member]</link:label>
    <link:label id="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1_label_en-US" xlink:label="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Total Shareholder Return Unit (PTSRUs) [Member]</link:label>
    <link:label id="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1_documentation_en-US" xlink:label="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Performance Total Shareholder Return Unit (PTSRUs) [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:to="lab_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred compensation arrangement, shares issued</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant price (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant-date fair value (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Exchange Contract [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0" xlink:to="lab_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:to="lab_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:label id="lab_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2_label_en-US" xlink:label="lab_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:to="lab_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:to="lab_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, gross realized loss</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on derivative instruments, net, pretax</link:label>
    <link:label id="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F_label_en-US" xlink:label="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Derivative Instruments, Net, Pretax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:to="lab_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, gross realized gain</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sale of available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:to="lab_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:to="lab_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3 [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:to="lab_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement Inputs and Valuation Techniques [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets&#8211;&#8211;Developed technology rights</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-lived Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets&#8211;&#8211;IPR&amp;D</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:type="arc" />
    <link:label id="lab_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70_totalLabel_en-US" xlink:label="lab_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70_label_en-US" xlink:label="lab_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Fair Value Disclosure</link:label>
    <link:label id="lab_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70_documentation_en-US" xlink:label="lab_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsFairValueDisclosure" xlink:label="loc_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:to="lab_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870_verboseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B27325FADFA6FA9C1E9A7E0E85670132_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B27325FADFA6FA9C1E9A7E0E85670132" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B27325FADFA6FA9C1E9A7E0E85670132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B27325FADFA6FA9C1E9A7E0E85670132" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B27325FADFA6FA9C1E9A7E0E85670132" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A_label_en-US" xlink:label="lab_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:to="lab_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6_label_en-US" xlink:label="lab_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="lab_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term purchase commitment, amount</link:label>
    <link:label id="lab_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9_label_en-US" xlink:label="lab_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Purchase Commitment, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:to="lab_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D_verboseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research arrangement, fixed payment obligation</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D" xlink:to="lab_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6_verboseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of contingent consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability, current</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent consideration liability, noncurrent</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:to="lab_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Examination [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:to="lab_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction for unrecognized tax benefit</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:to="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:to="lab_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:type="arc" />
    <link:label id="lab_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:to="lab_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total compensation cost related to nonvested awards not yet recognized, pre-tax</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9_netLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period over which nonvested award cost is expected to be recognized (years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares scheduled for near-term vesting</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Near-Term Vesting</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Near-Term Vesting</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D" xlink:to="lab_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D" xlink:type="arc" />
    <link:label id="lab_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E_terseLabel_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Variable lease cost</link:label>
    <link:label id="lab_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E_label_en-US" xlink:label="lab_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Variable Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E" xlink:to="lab_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA_negatedLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA" xlink:to="lab_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E_label_en-US" xlink:label="lab_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E" xlink:to="lab_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E" xlink:type="arc" />
    <link:label id="lab_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586_terseLabel_en-US" xlink:label="lab_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586_label_en-US" xlink:label="lab_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:to="lab_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:type="arc" />
    <link:label id="lab_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851_terseLabel_en-US" xlink:label="lab_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851_label_en-US" xlink:label="lab_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:to="lab_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:type="arc" />
    <link:label id="lab_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6_terseLabel_en-US" xlink:label="lab_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:label id="lab_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6_label_en-US" xlink:label="lab_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:to="lab_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:type="arc" />
    <link:label id="lab_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B_terseLabel_en-US" xlink:label="lab_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:label id="lab_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B_label_en-US" xlink:label="lab_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:to="lab_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading day average used to calculate the conversion</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Age of eligible unit holder which can elect to exercise and convert TSRUs when vested into PTUs</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Age Requirement</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Age Requirement</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Award requisite service period</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prior service (costs)/credits</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:to="lab_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF_label_en-US" xlink:label="lab_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:to="lab_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6_label_en-US" xlink:label="lab_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsegments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:to="lab_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:type="arc" />
    <link:label id="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9_terseLabel_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research, Development And Medical [Member]</link:label>
    <link:label id="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9_label_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research, Development And Medical [Member]</link:label>
    <link:label id="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9_documentation_en-US" xlink:label="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer's Worldwide Research, Development And Medical [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:to="lab_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC_terseLabel_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:label id="lab_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC_label_en-US" xlink:label="lab_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:to="lab_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:type="arc" />
    <link:label id="lab_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C_terseLabel_en-US" xlink:label="lab_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AM Pharma BV [Member]</link:label>
    <link:label id="lab_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C_label_en-US" xlink:label="lab_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AM Pharma BV [Member]</link:label>
    <link:label id="lab_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C_documentation_en-US" xlink:label="lab_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AM Pharma BV [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AMPharmaBVMember" xlink:label="loc_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:to="lab_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:type="arc" />
    <link:label id="lab_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897_terseLabel_en-US" xlink:label="lab_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:label id="lab_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897_label_en-US" xlink:label="lab_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:label id="lab_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897_documentation_en-US" xlink:label="lab_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Anacor [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:to="lab_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:type="arc" />
    <link:label id="lab_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D_terseLabel_en-US" xlink:label="lab_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D_label_en-US" xlink:label="lab_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:label id="lab_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D_documentation_en-US" xlink:label="lab_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AstraZeneca [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:to="lab_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:type="arc" />
    <link:label id="lab_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C_terseLabel_en-US" xlink:label="lab_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">InnoPharma [Member]</link:label>
    <link:label id="lab_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C_label_en-US" xlink:label="lab_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">InnoPharma [Member]</link:label>
    <link:label id="lab_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C_documentation_en-US" xlink:label="lab_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">InnoPharma [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InnoPharmaMember" xlink:label="loc_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:to="lab_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:type="arc" />
    <link:label id="lab_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE_terseLabel_en-US" xlink:label="lab_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NextWave [Member]</link:label>
    <link:label id="lab_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE_label_en-US" xlink:label="lab_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NextWave [Member]</link:label>
    <link:label id="lab_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE_documentation_en-US" xlink:label="lab_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NextWave [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NextWaveMember" xlink:label="loc_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:to="lab_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:type="arc" />
    <link:label id="lab_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A_terseLabel_en-US" xlink:label="lab_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:label id="lab_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A_label_en-US" xlink:label="lab_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:label id="lab_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A_documentation_en-US" xlink:label="lab_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eucrisa [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:to="lab_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:type="arc" />
    <link:label id="lab_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D_terseLabel_en-US" xlink:label="lab_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gene Therapies [Member]</link:label>
    <link:label id="lab_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D_label_en-US" xlink:label="lab_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gene Therapies [Member]</link:label>
    <link:label id="lab_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D_documentation_en-US" xlink:label="lab_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gene Therapies [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GeneTherapiesMember" xlink:label="loc_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:to="lab_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:type="arc" />
    <link:label id="lab_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1_terseLabel_en-US" xlink:label="lab_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Generic Sterile Injectable Product [Member]</link:label>
    <link:label id="lab_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1_label_en-US" xlink:label="lab_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Generic Sterile Injectable Product [Member]</link:label>
    <link:label id="lab_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1_documentation_en-US" xlink:label="lab_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Generic Sterile Injectable Product [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenericSterileInjectableProductMember" xlink:label="loc_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:to="lab_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:type="arc" />
    <link:label id="lab_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A_terseLabel_en-US" xlink:label="lab_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Multi-Antigen Vaccine For Spinal Fusion Surgery [Member]</link:label>
    <link:label id="lab_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A_label_en-US" xlink:label="lab_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Multi-Antigen Vaccine For Spinal Fusion Surgery [Member]</link:label>
    <link:label id="lab_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A_documentation_en-US" xlink:label="lab_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Multi-Antigen Vaccine For Spinal Fusion Surgery [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember" xlink:label="loc_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:to="lab_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:type="arc" />
    <link:label id="lab_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB_terseLabel_en-US" xlink:label="lab_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treatment For Toenail Fungus [Member]</link:label>
    <link:label id="lab_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB_label_en-US" xlink:label="lab_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treatment For Toenail Fungus [Member]</link:label>
    <link:label id="lab_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB_documentation_en-US" xlink:label="lab_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treatment For Toenail Fungus [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TreatmentForToenailFungusMember" xlink:label="loc_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:to="lab_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:type="arc" />
    <link:label id="lab_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180_terseLabel_en-US" xlink:label="lab_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sterile Injectable Pain Reliever [Member]</link:label>
    <link:label id="lab_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180_label_en-US" xlink:label="lab_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sterile Injectable Pain Reliever [Member]</link:label>
    <link:label id="lab_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180_documentation_en-US" xlink:label="lab_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sterile Injectable Pain Reliever [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SterileInjectablePainRelieverMember" xlink:label="loc_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:to="lab_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:type="arc" />
    <link:label id="lab_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D_terseLabel_en-US" xlink:label="lab_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treatment Of Attention Hyperactivity Disorder [Member]</link:label>
    <link:label id="lab_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D_label_en-US" xlink:label="lab_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treatment Of Attention Hyperactivity Disorder [Member]</link:label>
    <link:label id="lab_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D_documentation_en-US" xlink:label="lab_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treatment Of Attention Hyperactivity Disorder [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TreatmentOfAttentionHyperactivityDisorderMember" xlink:label="loc_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:to="lab_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:type="arc" />
    <link:label id="lab_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9_terseLabel_en-US" xlink:label="lab_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Generic Injectable Pain Reliever [Member]</link:label>
    <link:label id="lab_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9_label_en-US" xlink:label="lab_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Generic Injectable Pain Reliever [Member]</link:label>
    <link:label id="lab_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9_documentation_en-US" xlink:label="lab_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Generic Injectable Pain Reliever [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenericInjectablePainRelieverMember" xlink:label="loc_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:to="lab_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C" xlink:to="lab_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Impairment of investment</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:to="lab_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:to="lab_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49_terseLabel_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49_label_en-US" xlink:label="lab_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:to="lab_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2_terseLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Investments [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2" xlink:to="lab_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:to="lab_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:to="lab_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:type="arc" />
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450_terseLabel_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Money market funds [Member]</link:label>
    <link:label id="lab_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450_label_en-US" xlink:label="lab_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Money Market Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:to="lab_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity [Member]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:to="lab_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government and agency debt - non-U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB_label_en-US" xlink:label="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Security, Government, Non-US [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:to="lab_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government and agency - U.S. [Member]</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate and Other [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB_label_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Debt Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recurring [Member]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:to="lab_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:type="arc" />
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359_totalLabel_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total short-term investments</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359_label_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:label id="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359_documentation_en-US" xlink:label="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term Investments Excluding Held-To-Maturity Securities</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:to="lab_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:to="lab_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1_totalLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:to="lab_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent derivative assets</link:label>
    <link:label id="lab_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17_label_en-US" xlink:label="lab_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Asset, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:to="lab_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:type="arc" />
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B_terseLabel_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance contracts</link:label>
    <link:label id="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B_label_en-US" xlink:label="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Life Settlement Contracts, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:to="lab_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0_totalLabel_en-US" xlink:label="lab_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0_label_en-US" xlink:label="lab_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:to="lab_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:to="lab_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent derivative liabilities</link:label>
    <link:label id="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3_label_en-US" xlink:label="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:to="lab_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E_totalLabel_en-US" xlink:label="lab_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E" xlink:to="lab_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:to="lab_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD_negatedLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Exercised, shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAA3C56F2B8845B72B6B80206A8DA91B_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAA3C56F2B8845B72B6B80206A8DA91B" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAA3C56F2B8845B72B6B80206A8DA91B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAA3C56F2B8845B72B6B80206A8DA91B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAA3C56F2B8845B72B6B80206A8DA91B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, end of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercised, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3F94C0C0DB3CC1E9EA1080206A8F8AF3_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3F94C0C0DB3CC1E9EA1080206A8F8AF3" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3F94C0C0DB3CC1E9EA1080206A8F8AF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3F94C0C0DB3CC1E9EA1080206A8F8AF3" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3F94C0C0DB3CC1E9EA1080206A8F8AF3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, end of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, end of period, weighted-average remaining contractual term</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, end of period, aggregate intrinsic value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345_verboseLabel_en-US" xlink:label="lab_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Brands [Member]</link:label>
    <link:label id="lab_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345_label_en-US" xlink:label="lab_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trade Names [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:to="lab_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:type="arc" />
    <link:label id="lab_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15_verboseLabel_en-US" xlink:label="lab_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">IPR&amp;D [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15" xlink:to="lab_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37_terseLabel_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37_label_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:label id="lab_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37_documentation_en-US" xlink:label="lab_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Agreements And Other [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:to="lab_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:type="arc" />
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7_terseLabel_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of intangible asset amortized cost by segment</link:label>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7_label_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net, Percentage of Intangible Assets, Net</link:label>
    <link:label id="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7_documentation_en-US" xlink:label="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net, Percentage of Intangible Assets, Net</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:to="lab_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:type="arc" />
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term equity securities held in trust</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Current</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Current</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNIRestrictedCurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:to="lab_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:type="arc" />
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term equity securities held in trust</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Restricted, Noncurrent</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:to="lab_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8" xlink:to="lab_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:to="lab_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:type="arc" />
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:type="arc" />
    <link:label id="lab_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:to="lab_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:type="arc" />
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:type="arc" />
    <link:label id="lab_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054_terseLabel_en-US" xlink:label="lab_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Akcea And Ionis [Member]</link:label>
    <link:label id="lab_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054_label_en-US" xlink:label="lab_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Akcea And Ionis [Member]</link:label>
    <link:label id="lab_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054_documentation_en-US" xlink:label="lab_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Akcea And Ionis [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AkceaAndIonisMember" xlink:label="loc_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:to="lab_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:type="arc" />
    <link:label id="lab_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612_terseLabel_en-US" xlink:label="lab_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shire [Member]</link:label>
    <link:label id="lab_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612_label_en-US" xlink:label="lab_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shire [Member]</link:label>
    <link:label id="lab_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612_documentation_en-US" xlink:label="lab_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shire [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShireMember" xlink:label="loc_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:to="lab_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:type="arc" />
    <link:label id="lab_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6_terseLabel_en-US" xlink:label="lab_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BionTech [Member]</link:label>
    <link:label id="lab_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6_label_en-US" xlink:label="lab_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BionTech [Member]</link:label>
    <link:label id="lab_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6_documentation_en-US" xlink:label="lab_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BionTech [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BionTechMember" xlink:label="loc_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:to="lab_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="lab_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7_terseLabel_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payment for licensing arrangement</link:label>
    <link:label id="lab_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7_label_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payment For Licensing Arrangement</link:label>
    <link:label id="lab_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7_documentation_en-US" xlink:label="lab_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payment For Licensing Arrangement</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:to="lab_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5_terseLabel_en-US" xlink:label="lab_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Licensing arrangement, maximum potential milestones</link:label>
    <link:label id="lab_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5_label_en-US" xlink:label="lab_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Arrangement, Milestone, Maximum, Value</link:label>
    <link:label id="lab_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5_documentation_en-US" xlink:label="lab_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Arrangement, Milestone, Maximum, Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementMilestoneMaximumValue" xlink:label="loc_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:to="lab_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:type="arc" />
    <link:label id="lab_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0_terseLabel_en-US" xlink:label="lab_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from licensing arrangement</link:label>
    <link:label id="lab_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0_label_en-US" xlink:label="lab_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Licensing Arrangement</link:label>
    <link:label id="lab_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0_documentation_en-US" xlink:label="lab_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Licensing Arrangement</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ProceedsFromLicensingArrangement" xlink:label="loc_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:to="lab_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434_terseLabel_en-US" xlink:label="lab_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares purchased</link:label>
    <link:label id="lab_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434_label_en-US" xlink:label="lab_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Arrangement, Number Of Shares Purchased</link:label>
    <link:label id="lab_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434_documentation_en-US" xlink:label="lab_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Arrangement, Number Of Shares Purchased</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementNumberOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:to="lab_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:type="arc" />
    <link:label id="lab_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2_terseLabel_en-US" xlink:label="lab_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of shares purchased</link:label>
    <link:label id="lab_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2_label_en-US" xlink:label="lab_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Licensing Arrangement, Value Of Shares Purchased</link:label>
    <link:label id="lab_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2_documentation_en-US" xlink:label="lab_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Licensing Arrangement, Value Of Shares Purchased</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementValueOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:to="lab_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible asset, useful life</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Asset, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization expense for finite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162_label_en-US" xlink:label="lab_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:to="lab_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:type="arc" />
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:to="lab_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84_terseLabel_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84_label_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84_documentation_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Axis]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:to="lab_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:type="arc" />
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16_terseLabel_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Domain]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16_label_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Segment Reconciling Items [Domain]</link:label>
    <link:label id="lab_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16_documentation_en-US" xlink:label="lab_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Other Segment Reconciling Items [Axis]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:to="lab_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:type="arc" />
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129_terseLabel_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129_label_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:label id="lab_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129_documentation_en-US" xlink:label="lab_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Purchase Accounting Adjustments [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:to="lab_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisition-Related Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE_label_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Acquisition Related Costs [Member]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Acquisition Related Costs [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:to="lab_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:type="arc" />
    <link:label id="lab_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF_terseLabel_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain Significant Items [Member]</link:label>
    <link:label id="lab_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF_label_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Certain Significant Items [Member]</link:label>
    <link:label id="lab_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF_documentation_en-US" xlink:label="lab_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Certain significant items [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:to="lab_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409_verboseLabel_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Corporate [Member]</link:label>
    <link:label id="lab_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409_label_en-US" xlink:label="lab_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate, Non-Segment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:to="lab_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and Amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148_label_en-US" xlink:label="lab_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:to="lab_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">United States</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Domestic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">International</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Foreign</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BF068360DB18F66C271A8020732432FB_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BF068360DB18F66C271A8020732432FB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations before provision/(benefit) for taxes on income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BF068360DB18F66C271A8020732432FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BF068360DB18F66C271A8020732432FB" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BF068360DB18F66C271A8020732432FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_BD4D08D7CE8DC5DA929655F213406EC3_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract_BD4D08D7CE8DC5DA929655F213406EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BD4D08D7CE8DC5DA929655F213406EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BD4D08D7CE8DC5DA929655F213406EC3" xlink:to="lab_us-gaap_EarningsPerShareAbstract_BD4D08D7CE8DC5DA929655F213406EC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:to="lab_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:to="lab_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362_terseLabel_en-US" xlink:label="lab_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:label id="lab_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362_label_en-US" xlink:label="lab_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Option [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:to="lab_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">EPS Numerator-Basic</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Preferred stock dividends&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock Dividends, Income Statement Impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:to="lab_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF_totalLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders Basic</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Discontinued operations&#8211;&#8211;net of tax, attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459_terseLabel_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EPS Numerator&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459_label_en-US" xlink:label="lab_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:to="lab_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:type="arc" />
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6_terseLabel_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6_label_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Loss From Continuing Operations Available To Common Stockholders diluted</link:label>
    <link:label id="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6_documentation_en-US" xlink:label="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:to="lab_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_F8FA9D506C63B4F94C9855F21344E018_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_F8FA9D506C63B4F94C9855F21344E018" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_F8FA9D506C63B4F94C9855F21344E018" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_F8FA9D506C63B4F94C9855F21344E018" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_F8FA9D506C63B4F94C9855F21344E018" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Available to Common Stockholders, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:to="lab_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">EPS Denominator</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number Diluted Shares Outstanding Adjustment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends declared per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03_label_en-US" xlink:label="lab_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Dividends, Per Share, Declared</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:to="lab_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66_terseLabel_en-US" xlink:label="lab_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:label id="lab_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66_label_en-US" xlink:label="lab_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:to="lab_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:type="arc" />
    <link:label id="lab_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB_terseLabel_en-US" xlink:label="lab_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Buildings [Member]</link:label>
    <link:label id="lab_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB_label_en-US" xlink:label="lab_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Building [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:to="lab_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:type="arc" />
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417_terseLabel_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Machinery and equipment [Member]</link:label>
    <link:label id="lab_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417_label_en-US" xlink:label="lab_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Machinery and Equipment [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:to="lab_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:type="arc" />
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and other [Member]</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:to="lab_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D_terseLabel_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Construction in progress [Member]</link:label>
    <link:label id="lab_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D_label_en-US" xlink:label="lab_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Construction in Progress [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:to="lab_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Useful lives (years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property, plant and equipment before accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:type="arc" />
    <link:label id="lab_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E_terseLabel_en-US" xlink:label="lab_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portfolio Performance Shares [Member]</link:label>
    <link:label id="lab_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E_label_en-US" xlink:label="lab_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portfolio Performance Shares [Member]</link:label>
    <link:label id="lab_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E_documentation_en-US" xlink:label="lab_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Portfolio Performance Shares [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:to="lab_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares earned as a percentage of initial award</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning of period, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited, shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A59D4333F2EF0FCBCD348020743F1639_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A59D4333F2EF0FCBCD348020743F1639" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, end of period, shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A59D4333F2EF0FCBCD348020743F1639" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A59D4333F2EF0FCBCD348020743F1639" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A59D4333F2EF0FCBCD348020743F1639" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, weighted-average grant-date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D30B399609C0D1159F0780207440BDFE_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D30B399609C0D1159F0780207440BDFE" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D30B399609C0D1159F0780207440BDFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D30B399609C0D1159F0780207440BDFE" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D30B399609C0D1159F0780207440BDFE" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63_periodStartLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:to="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:to="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:to="lab_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_12E789AD4EF56DD800DD80207441ABFF_periodEndLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_12E789AD4EF56DD800DD80207441ABFF" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, end of period, weighted-average exercise price per share (in dollars per share)</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_12E789AD4EF56DD800DD80207441ABFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_12E789AD4EF56DD800DD80207441ABFF" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_12E789AD4EF56DD800DD80207441ABFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from legal settlements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C_label_en-US" xlink:label="lab_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Legal Settlements</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C" xlink:to="lab_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D_terseLabel_en-US" xlink:label="lab_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:label id="lab_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D_label_en-US" xlink:label="lab_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:to="lab_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:type="arc" />
    <link:label id="lab_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37_terseLabel_en-US" xlink:label="lab_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Co-promotion [Member]</link:label>
    <link:label id="lab_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37_label_en-US" xlink:label="lab_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Co-promotion [Member]</link:label>
    <link:label id="lab_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37_documentation_en-US" xlink:label="lab_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Co-promotion [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CopromotionMember" xlink:label="loc_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:to="lab_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:to="lab_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1_label_en-US" xlink:label="lab_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Adoption [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:to="lab_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2014-09 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:to="lab_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:type="arc" />
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA_terseLabel_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:label id="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA_label_en-US" xlink:label="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Initial Application Period Cumulative Effect Transition [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:to="lab_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75_terseLabel_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:label id="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75_label_en-US" xlink:label="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Difference between Revenue Guidance in Effect before and after Topic 606 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:to="lab_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:to="lab_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:to="lab_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Upfront Cash Payment [Member]</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Upfront Cash Payment [Member]</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Upfront Cash Payment [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementUpfrontCashPaymentMember" xlink:label="loc_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:to="lab_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2_terseLabel_en-US" xlink:label="lab_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:label id="lab_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2_label_en-US" xlink:label="lab_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:label id="lab_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2_documentation_en-US" xlink:label="lab_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Revenue [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredRevenueMember" xlink:label="loc_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:to="lab_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:type="arc" />
    <link:label id="lab_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79_terseLabel_en-US" xlink:label="lab_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">NovaQuest Co-Investment Fund V, L.P. [Member]</link:label>
    <link:label id="lab_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79_label_en-US" xlink:label="lab_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NovaQuest Co-Investment Fund V, L.P. [Member]</link:label>
    <link:label id="lab_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79_documentation_en-US" xlink:label="lab_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">NovaQuest Co-Investment Fund V, L.P. [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NovaQuestCoInvestmentFundVL.P.Member" xlink:label="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:to="lab_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:type="arc" />
    <link:label id="lab_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0_terseLabel_en-US" xlink:label="lab_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RPI Finance Trust [Member]</link:label>
    <link:label id="lab_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0_label_en-US" xlink:label="lab_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">RPI Finance Trust [Member]</link:label>
    <link:label id="lab_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0_documentation_en-US" xlink:label="lab_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">RPI Finance Trust [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RPIFinanceTrustMember" xlink:label="loc_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:to="lab_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:type="arc" />
    <link:label id="lab_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3_terseLabel_en-US" xlink:label="lab_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:label id="lab_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3_label_en-US" xlink:label="lab_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:label id="lab_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3_documentation_en-US" xlink:label="lab_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eli Lilly &amp; Company [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EliLillyCompanyMember" xlink:label="loc_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:to="lab_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:type="arc" />
    <link:label id="lab_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E_terseLabel_en-US" xlink:label="lab_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merck KGaA [Member]</link:label>
    <link:label id="lab_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E_label_en-US" xlink:label="lab_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck KGaA [Member]</link:label>
    <link:label id="lab_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E_documentation_en-US" xlink:label="lab_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck KGaA [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MerckKGaAMember" xlink:label="loc_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:to="lab_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:type="arc" />
    <link:label id="lab_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4_terseLabel_en-US" xlink:label="lab_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mylan [Member]</link:label>
    <link:label id="lab_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4_label_en-US" xlink:label="lab_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mylan [Member]</link:label>
    <link:label id="lab_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4_documentation_en-US" xlink:label="lab_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mylan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:to="lab_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:type="arc" />
    <link:label id="lab_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA_terseLabel_en-US" xlink:label="lab_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA_label_en-US" xlink:label="lab_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:label id="lab_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA_documentation_en-US" xlink:label="lab_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Merck [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MerckMember" xlink:label="loc_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:to="lab_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum funding amount</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Maximum Funding Amount</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Maximum Funding Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementMaximumFundingAmount" xlink:label="loc_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:to="lab_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of costs to be reimbursed</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Percentage of Costs to be Reimbursed</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Percentage of Costs to be Reimbursed</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:to="lab_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction to research and development expense</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Funding to Offset Costs Incurred</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Funding to Offset Costs Incurred</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" xlink:label="loc_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:to="lab_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:type="arc" />
    <link:label id="lab_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1_terseLabel_en-US" xlink:label="lab_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charge primarily for inventory manufactured for expected future sale</link:label>
    <link:label id="lab_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1_label_en-US" xlink:label="lab_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charge primarily for inventory manufactured for expected future sale</link:label>
    <link:label id="lab_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1_documentation_en-US" xlink:label="lab_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charge primarily for inventory manufactured for expected future sale</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" xlink:label="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:to="lab_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense (Excluding Acquired in Process Cost)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development, contingent payments, maximum exposure</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194_label_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contingent Payments, Maximum Exposure</link:label>
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194_documentation_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research and Development Arrangement, Contingent Payments, Maximum Exposure</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure" xlink:label="loc_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:to="lab_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2_negatedLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B_negatedLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income/(deductions)&#8212;net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payments and milestone payments</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Upfront And Milestone Payments</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash outflow to our partners for payments made upfront as part of a collaborative arrangement and the payments upon the achievement of milestones.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:label="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:to="lab_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds received from upfront payments and milestone payments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:to="lab_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:type="arc" />
    <link:label id="lab_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5_verboseLabel_en-US" xlink:label="lab_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Collaborative arrangement sales based milestones payments</link:label>
    <link:label id="lab_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5_label_en-US" xlink:label="lab_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepayments and Payments to Collaborators</link:label>
    <link:label id="lab_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5_documentation_en-US" xlink:label="lab_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prepayments and Payments to Collaborators</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrepaymentsandPaymentstoCollaborators" xlink:label="loc_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:to="lab_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborator's revenue and expense ownership percentage</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:to="lab_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company's revenue and expense ownership percentage</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:to="lab_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment due to be received</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Receivable</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Milestone Payment, Receivable</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementMilestonePaymentReceivable" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:to="lab_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred milestone payment</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Deferred Milestone Payment</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Deferred Milestone Payment</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementDeferredMilestonePayment" xlink:label="loc_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:to="lab_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred milestone revenue recognized</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Deferred Milestone Revenue Recognized</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Deferred Milestone Revenue Recognized</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized" xlink:label="loc_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:to="lab_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contingent Payments, Maximum Exposure</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Contingent Payments, Maximum Exposure</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:label="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:to="lab_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies and Certain Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Liabilities Not Measured at Fair Value on a Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98" xlink:to="lab_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98" xlink:type="arc" />
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Investments</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3" xlink:to="lab_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual Maturities of Available-for-sale and Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gains and Losses on Investment Securities</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569_label_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:label id="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569" xlink:to="lab_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Borrowings</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Instruments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Assets at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Assets at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25" xlink:to="lab_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Derivative Liabilities at Fair Value [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982" xlink:to="lab_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative Instruments, Gain (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC" xlink:to="lab_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374" xlink:to="lab_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4" xlink:to="lab_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impact of Adoption of Accounting Standard Updates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A" xlink:to="lab_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Information About Balance Sheet Classification of Accruals</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1" xlink:type="arc" />
    <link:label id="lab_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474_terseLabel_en-US" xlink:label="lab_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROU Assets and Liabilities Presented in Condensed Consolidated Balance Sheets</link:label>
    <link:label id="lab_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474_label_en-US" xlink:label="lab_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:label id="lab_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474_documentation_en-US" xlink:label="lab_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Assets And Liabilities, Lessee [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474" xlink:to="lab_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Lease Costs and Other Supplemental Information</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67" xlink:to="lab_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D" xlink:to="lab_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544_label_en-US" xlink:label="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Presentation and Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544" xlink:to="lab_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:to="lab_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:label id="lab_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86_label_en-US" xlink:label="lab_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:to="lab_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177_label_en-US" xlink:label="lab_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:to="lab_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD_periodStartLabel_en-US" xlink:label="lab_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD" xlink:to="lab_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98_label_en-US" xlink:label="lab_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Acquired During Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:to="lab_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537_label_en-US" xlink:label="lab_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Other Increase (Decrease)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:to="lab_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:type="arc" />
    <link:label id="lab_us-gaap_Goodwill_C6C079ED0356E45EB069D81117922E30_periodEndLabel_en-US" xlink:label="lab_us-gaap_Goodwill_C6C079ED0356E45EB069D81117922E30" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C6C079ED0356E45EB069D81117922E30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill_C6C079ED0356E45EB069D81117922E30" xlink:to="lab_us-gaap_Goodwill_C6C079ED0356E45EB069D81117922E30" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:label id="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504_label_en-US" xlink:label="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification out of Accumulated Other Comprehensive Income [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:to="lab_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification of Certain Tax Effects from AOCI [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2018-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:to="lab_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Financial Assets and Liabilities [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6_terseLabel_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:label id="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6_label_en-US" xlink:label="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:to="lab_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments of certain tax effects from AOCI to Retained earnings</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Foreign Currency Translation Adjustment, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Foreign Currency Translation Adjustment, Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:to="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), derivatives qualifying as hedges, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment For Tax On Unrealized Gains Included In Retained Earnings, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment For Tax On Unrealized Gains Included In Retained Earnings, Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:to="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), available-for-sale securities, tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to settlements, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:to="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments of certain tax effects from AOCI to Retained earnings</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Actuarial Gains, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Actuarial Gains, Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:to="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3_totalLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, amounts recognized in other comprehensive income (loss), net actuarial gain (loss), tax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:to="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339_negatedLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: prior service costs and other, net</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:to="lab_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to curtailments of prior service costs and other, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:to="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments of certain tax effects from AOCI to Retained earnings</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Prior Service (Costs) Credits, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Prior Service (Costs) Credits, Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:to="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:type="arc" />
    <link:label id="lab_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053_terseLabel_en-US" xlink:label="lab_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cerevel Therapeutics [Member]</link:label>
    <link:label id="lab_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053_label_en-US" xlink:label="lab_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cerevel Therapeutics [Member]</link:label>
    <link:label id="lab_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053_documentation_en-US" xlink:label="lab_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cerevel Therapeutics [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelTherapeuticsMember" xlink:label="loc_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:to="lab_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:type="arc" />
    <link:label id="lab_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4_terseLabel_en-US" xlink:label="lab_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Allogene [Member]</link:label>
    <link:label id="lab_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4_label_en-US" xlink:label="lab_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Allogene [Member]</link:label>
    <link:label id="lab_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4_documentation_en-US" xlink:label="lab_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Allogene [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:to="lab_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:type="arc" />
    <link:label id="lab_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78_terseLabel_en-US" xlink:label="lab_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cellectis [Member]</link:label>
    <link:label id="lab_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78_label_en-US" xlink:label="lab_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cellectis [Member]</link:label>
    <link:label id="lab_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78_documentation_en-US" xlink:label="lab_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cellectis [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CellectisMember" xlink:label="loc_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:to="lab_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:type="arc" />
    <link:label id="lab_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52_terseLabel_en-US" xlink:label="lab_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cerevel [Member]</link:label>
    <link:label id="lab_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52_label_en-US" xlink:label="lab_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cerevel [Member]</link:label>
    <link:label id="lab_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52_documentation_en-US" xlink:label="lab_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cerevel [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelMember" xlink:label="loc_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:to="lab_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:type="arc" />
    <link:label id="lab_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2_terseLabel_en-US" xlink:label="lab_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICU Medical [Member]</link:label>
    <link:label id="lab_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2_label_en-US" xlink:label="lab_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICU Medical [Member]</link:label>
    <link:label id="lab_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2_documentation_en-US" xlink:label="lab_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ICU Medical [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:to="lab_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:type="arc" />
    <link:label id="lab_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5_terseLabel_en-US" xlink:label="lab_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bain Capital [Member]</link:label>
    <link:label id="lab_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5_label_en-US" xlink:label="lab_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bain Capital [Member]</link:label>
    <link:label id="lab_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5_documentation_en-US" xlink:label="lab_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bain Capital [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BainCapitalMember" xlink:label="loc_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:to="lab_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:to="lab_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member]</link:label>
    <link:label id="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E_label_en-US" xlink:label="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:to="lab_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations, Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:to="lab_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:type="arc" />
    <link:label id="lab_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393_terseLabel_en-US" xlink:label="lab_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HIS [Member]</link:label>
    <link:label id="lab_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393_label_en-US" xlink:label="lab_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HIS [Member]</link:label>
    <link:label id="lab_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393_documentation_en-US" xlink:label="lab_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HIS [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:to="lab_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:type="arc" />
    <link:label id="lab_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74_terseLabel_en-US" xlink:label="lab_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]</link:label>
    <link:label id="lab_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74_label_en-US" xlink:label="lab_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]</link:label>
    <link:label id="lab_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74_documentation_en-US" xlink:label="lab_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" xlink:label="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:to="lab_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:type="arc" />
    <link:label id="lab_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433_terseLabel_en-US" xlink:label="lab_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Neuroscience Assets [Member]</link:label>
    <link:label id="lab_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433_label_en-US" xlink:label="lab_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Neuroscience Assets [Member]</link:label>
    <link:label id="lab_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433_documentation_en-US" xlink:label="lab_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Neuroscience Assets [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NeuroscienceAssetsMember" xlink:label="loc_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:to="lab_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and common stock to be received for disposition</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares of common stock received for disposal</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Value of common stock received for disposal</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain from sale of shares</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain representing difference between fair value of equity investment and book value of assets transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration receivable</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Consideration, Note Receivable</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash proceeds from disposal</link:label>
    <link:label id="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0_label_en-US" xlink:label="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Divestiture of Businesses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:to="lab_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum contingent consideration</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Contingent Consideration</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F_verboseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income (loss) on sale of assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F_label_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:type="arc" />
    <link:label id="lab_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422_terseLabel_en-US" xlink:label="lab_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership percentage</link:label>
    <link:label id="lab_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422_label_en-US" xlink:label="lab_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Ownership Percentage</link:label>
    <link:label id="lab_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422_documentation_en-US" xlink:label="lab_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Investment, Ownership Percentage</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InvestmentOwnershipPercentage" xlink:label="loc_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:to="lab_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E_terseLabel_en-US" xlink:label="lab_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E_label_en-US" xlink:label="lab_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments To Collaborators</link:label>
    <link:label id="lab_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E_documentation_en-US" xlink:label="lab_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments To Collaborators</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentsToCollaborators" xlink:label="loc_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:to="lab_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:type="arc" />
    <link:label id="lab_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3_terseLabel_en-US" xlink:label="lab_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain from contribution agreement</link:label>
    <link:label id="lab_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3_label_en-US" xlink:label="lab_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) From Contribution Agreement</link:label>
    <link:label id="lab_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3_documentation_en-US" xlink:label="lab_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) From Contribution Agreement</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossFromContributionAgreement" xlink:label="loc_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:to="lab_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair values(a)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1" xlink:to="lab_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6_terseLabel_en-US" xlink:label="lab_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6_label_en-US" xlink:label="lab_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Price</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:to="lab_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount of milestone payments to be received</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Milestone, Maximum, Value</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Milestone, Maximum, Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:type="arc" />
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B_terseLabel_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment recognized</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B_label_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Milestone</link:label>
    <link:label id="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B_documentation_en-US" xlink:label="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Milestone</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationMilestone" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:to="lab_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:type="arc" />
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA_terseLabel_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Committed investment from collaborator</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA_label_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Committed Investment From Collaborator, Amount</link:label>
    <link:label id="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA_documentation_en-US" xlink:label="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Committed Investment From Collaborator, Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:to="lab_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions</link:label>
    <link:label id="lab_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02_label_en-US" xlink:label="lab_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02_documentation_en-US" xlink:label="lab_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock" xlink:label="loc_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02" xlink:to="lab_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Appreciation Rights Award Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Stock Appreciation Right, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749" xlink:to="lab_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Nonvested Performance-based Units Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378" xlink:to="lab_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Valuation Assumptions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation, Stock Options, Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Table]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6_terseLabel_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Time deposits and other [Member]</link:label>
    <link:label id="lab_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6_label_en-US" xlink:label="lab_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bank Time Deposits [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="loc_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:to="lab_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4_label_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Available for sale Securities and Held to maturity Securities [Line Items]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="lab_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Amortized Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, gross unrealized gain</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities, gross unrealized loss</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:type="arc" />
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23_terseLabel_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23_label_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23_documentation_en-US" xlink:label="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:to="lab_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_CA1D25A3708066DD4E0B55F217686C05_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_CA1D25A3708066DD4E0B55F217686C05" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale securities, debt maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_CA1D25A3708066DD4E0B55F217686C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_CA1D25A3708066DD4E0B55F217686C05" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_CA1D25A3708066DD4E0B55F217686C05" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57_totalLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, amortized cost</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:to="lab_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, gross unrealized gains</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, gross unrealized losses</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, debt maturities, within 1 year, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:type="arc" />
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B_terseLabel_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity securities, debt maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B_label_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B_documentation_en-US" xlink:label="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:to="lab_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144_totalLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Debt securities, amortized cost</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Amortized Cost Basis</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:to="lab_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, gross unrealized gains</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Gain</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4_negatedTerseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Debt securities, gross unrealized losses</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4_label_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:label id="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities, Accumulated Gross Unrealized Loss</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:to="lab_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities, within 1 year, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, Next Twelve Months, Fair Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:to="lab_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities, over 1 to 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, Year Two Through Five, Fair Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:to="lab_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:type="arc" />
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309_terseLabel_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities maturities, over 5 years, fair value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309_label_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:label id="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309_documentation_en-US" xlink:label="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Securities Maturities, After Year Five, Fair Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:to="lab_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity, fair value</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale and Held-to-maturity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_02EFBDCF083C627F88A380206CB3F41F_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract_02EFBDCF083C627F88A380206CB3F41F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_02EFBDCF083C627F88A380206CB3F41F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_02EFBDCF083C627F88A380206CB3F41F" xlink:to="lab_us-gaap_InventoryDisclosureAbstract_02EFBDCF083C627F88A380206CB3F41F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Inventories, Current</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Component of Inventories, Noncurrent</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4" xlink:to="lab_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Held for Sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Inventory, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PP&amp;E</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets, less accumulated amortization</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Goodwill</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred tax assets and other noncurrent tax assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other assets held for sale</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities Held for Sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Income Tax Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related items</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension benefit obligations, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Pension Plan Benefit Obligation, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement benefit obligations, net</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Postretirement Plan Benefit Obligation, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601_label_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Consumer Healthcare liabilities held for sale</link:label>
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769_label_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:type="arc" />
    <link:label id="lab_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3_terseLabel_en-US" xlink:label="lab_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Management [Member]</link:label>
    <link:label id="lab_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3_label_en-US" xlink:label="lab_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Management [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ManagementMember" xlink:label="loc_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:to="lab_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award vesting period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C" xlink:type="arc" />
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Holding period</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Award Holding Period</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The required period of time for holding award before any vesting occurs.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:type="arc" />
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise period in the event of a divestiture or restructuring</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Award Exercise Period Special Conditions</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The exercise period for options held by employees in the event of a divestiture or restructuring.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Termination Costs [Member]</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:to="lab_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:type="arc" />
    <link:label id="lab_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B_terseLabel_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B_label_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairments [Member]</link:label>
    <link:label id="lab_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B_documentation_en-US" xlink:label="lab_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset impairments [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:to="lab_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC_terseLabel_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit Costs [Member]</link:label>
    <link:label id="lab_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC_label_en-US" xlink:label="lab_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Restructuring [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:to="lab_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:to="lab_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23_periodStartLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23" xlink:to="lab_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F_verboseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Provision</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F" xlink:to="lab_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F" xlink:type="arc" />
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760_negatedLabel_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Utilization and other</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760_label_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:label id="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760_documentation_en-US" xlink:label="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:to="lab_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserve_B009361E530AA791AC0E1A6ED04663A4_periodEndLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve_B009361E530AA791AC0E1A6ED04663A4" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_B009361E530AA791AC0E1A6ED04663A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve_B009361E530AA791AC0E1A6ED04663A4" xlink:to="lab_us-gaap_RestructuringReserve_B009361E530AA791AC0E1A6ED04663A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9_terseLabel_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9_label_en-US" xlink:label="lab_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:to="lab_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue [Member]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:to="lab_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:type="arc" />
    <link:label id="lab_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276_terseLabel_en-US" xlink:label="lab_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outside United States [Member]</link:label>
    <link:label id="lab_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276_label_en-US" xlink:label="lab_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-United States [Member]</link:label>
    <link:label id="lab_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276_documentation_en-US" xlink:label="lab_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Non-United States [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NonUnitedStatesMember" xlink:label="loc_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:to="lab_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:type="arc" />
    <link:label id="lab_country_JP_96FF3252E870FDBD95F7732029BEB7A0_terseLabel_en-US" xlink:label="lab_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:label id="lab_country_JP_96FF3252E870FDBD95F7732029BEB7A0_label_en-US" xlink:label="lab_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">JAPAN</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:to="lab_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:type="arc" />
    <link:label id="lab_country_CN_F42968A5A5C3DE529AE4732029BF5A86_terseLabel_en-US" xlink:label="lab_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:label id="lab_country_CN_F42968A5A5C3DE529AE4732029BF5A86_label_en-US" xlink:label="lab_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CHINA</link:label>
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="loc_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:to="lab_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:type="arc" />
    <link:label id="lab_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Major Customers [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916_label_en-US" xlink:label="lab_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:to="lab_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:type="arc" />
    <link:label id="lab_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name of Major Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="lab_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:type="arc" />
    <link:label id="lab_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064_terseLabel_en-US" xlink:label="lab_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">McKesson, Inc. [Member]</link:label>
    <link:label id="lab_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064_label_en-US" xlink:label="lab_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">McKesson, Inc. [Member]</link:label>
    <link:label id="lab_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064_documentation_en-US" xlink:label="lab_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">McKesson, Inc. [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_McKessonInc.Member" xlink:label="loc_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:to="lab_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:type="arc" />
    <link:label id="lab_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474_terseLabel_en-US" xlink:label="lab_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474_label_en-US" xlink:label="lab_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:label id="lab_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474_documentation_en-US" xlink:label="lab_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">AmerisourceBergen Corporation [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AmerisourceBergenCorporationMember" xlink:label="loc_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:to="lab_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:type="arc" />
    <link:label id="lab_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477_terseLabel_en-US" xlink:label="lab_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477_label_en-US" xlink:label="lab_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:label id="lab_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477_documentation_en-US" xlink:label="lab_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cardinal Health, Inc. [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CardinalHealthInc.Member" xlink:label="loc_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:to="lab_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:type="arc" />
    <link:label id="lab_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486_terseLabel_en-US" xlink:label="lab_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three Largest U.S. Wholesaler Customers [Member]</link:label>
    <link:label id="lab_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486_label_en-US" xlink:label="lab_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Largest US Wholesale Customers [Member]</link:label>
    <link:label id="lab_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486_documentation_en-US" xlink:label="lab_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three Largest US Wholesale Customers [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ThreeLargestUSWholesaleCustomersMember" xlink:label="loc_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:to="lab_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:type="arc" />
    <link:label id="lab_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594_terseLabel_en-US" xlink:label="lab_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594" xlink:to="lab_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594" xlink:type="arc" />
    <link:label id="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0_terseLabel_en-US" xlink:label="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of countries outside the U.S</link:label>
    <link:label id="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0_label_en-US" xlink:label="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Revenues, $500,000,000 or More, Number of Countries</link:label>
    <link:label id="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0_documentation_en-US" xlink:label="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Revenues, $500,000,000 or More, Number of Countries</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:label="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:to="lab_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of total revenues</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of measures used to determine share payout</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share payout measures, adjusted net income, number of periods</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share payout measures, adjusted net income, duration of period</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Duration of Period</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Duration of Period</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35_terseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F_negatedLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, accumulated amortization</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Accumulated Amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852_totalLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Finite-lived intangible assets, less accumulated amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01_terseLabel_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total indefinite-lived intangible assets</link:label>
    <link:label id="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01_label_en-US" xlink:label="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Indefinite-lived Intangible Assets (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:to="lab_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Intangible assets, gross carrying amount</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Gross (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5" xlink:to="lab_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8_totalLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets, less Accumulated Amortization</link:label>
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8_label_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible Assets, Net (Excluding Goodwill)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_1D7D05C8AEBF4A4F17D5802072D7E4D7_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_1D7D05C8AEBF4A4F17D5802072D7E4D7" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_1D7D05C8AEBF4A4F17D5802072D7E4D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_1D7D05C8AEBF4A4F17D5802072D7E4D7" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_1D7D05C8AEBF4A4F17D5802072D7E4D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Number of employees affected by accelerated vesting</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:to="lab_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:to="lab_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:type="arc" />
    <link:label id="lab_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048_terseLabel_en-US" xlink:label="lab_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2019 Stock Plan [Member]</link:label>
    <link:label id="lab_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048_label_en-US" xlink:label="lab_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2019 Stock Plan [Member]</link:label>
    <link:label id="lab_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048_documentation_en-US" xlink:label="lab_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2019 Stock Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_A2019StockPlanMember" xlink:label="loc_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:to="lab_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:type="arc" />
    <link:label id="lab_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08_terseLabel_en-US" xlink:label="lab_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Directors' compensation [Member]</link:label>
    <link:label id="lab_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08_label_en-US" xlink:label="lab_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director's Compensation [Member]</link:label>
    <link:label id="lab_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08_documentation_en-US" xlink:label="lab_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Director's Compensation [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DirectorsCompensationMember" xlink:label="loc_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:to="lab_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182_negatedLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefit for share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424_totalLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Share-based payment expense, net of tax</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense, after Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99_label_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-02 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:to="lab_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements or Change in Accounting Principle [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="lab_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:to="lab_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred tax assets and other noncurrent tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:to="lab_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4" xlink:to="lab_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained earnings</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:label id="lab_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128_label_en-US" xlink:label="lab_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Sales [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:to="lab_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of pre-tax loss to be reclassified</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:to="lab_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4_terseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying value of short-term borrowings</link:label>
    <link:label id="lab_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4_label_en-US" xlink:label="lab_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:to="lab_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A78C3CFEDE840CD154347E091AF3CC7F_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A78C3CFEDE840CD154347E091AF3CC7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A78C3CFEDE840CD154347E091AF3CC7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A78C3CFEDE840CD154347E091AF3CC7F" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A78C3CFEDE840CD154347E091AF3CC7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6_label_en-US" xlink:label="lab_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:to="lab_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066_label_en-US" xlink:label="lab_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:to="lab_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:type="arc" />
    <link:label id="lab_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD_terseLabel_en-US" xlink:label="lab_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:label id="lab_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD_label_en-US" xlink:label="lab_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:to="lab_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:type="arc" />
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3_terseLabel_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:label id="lab_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3_label_en-US" xlink:label="lab_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Scenario [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:to="lab_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:type="arc" />
    <link:label id="lab_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A_terseLabel_en-US" xlink:label="lab_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:label id="lab_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A_label_en-US" xlink:label="lab_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forecast [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:to="lab_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected contributions in 2019</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected benefit payments:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Employer Contributions [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="lab_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025-2029</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Voluntary contribution</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69" xlink:to="lab_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69" xlink:type="arc" />
    <link:label id="lab_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016_label_en-US" xlink:label="lab_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:label id="lab_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Axis]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionAxis" xlink:label="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:to="lab_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:type="arc" />
    <link:label id="lab_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D_label_en-US" xlink:label="lab_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition [Domain]</link:label>
    <link:label id="lab_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Domain] for Asset Acquisition [Axis]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:to="lab_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:type="arc" />
    <link:label id="lab_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C_terseLabel_en-US" xlink:label="lab_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Therachon Asset Acquisition [Member]</link:label>
    <link:label id="lab_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C_label_en-US" xlink:label="lab_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Therachon Asset Acquisition [Member]</link:label>
    <link:label id="lab_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C_documentation_en-US" xlink:label="lab_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Therachon Asset Acquisition [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TherachonAssetAcquisitionMember" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:to="lab_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:type="arc" />
    <link:label id="lab_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1_terseLabel_en-US" xlink:label="lab_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Income (Expense) [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1_label_en-US" xlink:label="lab_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income (Expense) [Member]</link:label>
    <link:label id="lab_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1_documentation_en-US" xlink:label="lab_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Income (Expense) [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherIncomeExpenseMember" xlink:label="loc_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:to="lab_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges and implementation costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F_label_en-US" xlink:label="lab_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges and Implementation Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges and Implementation Costs</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:to="lab_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement income (loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079" xlink:to="lab_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079" xlink:type="arc" />
    <link:label id="lab_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB_terseLabel_en-US" xlink:label="lab_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Certain asset impairments</link:label>
    <link:label id="lab_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB_label_en-US" xlink:label="lab_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges And Other Charges</link:label>
    <link:label id="lab_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB_documentation_en-US" xlink:label="lab_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of intangible assets, other than goodwill, to fair value.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetImpairmentChargesAndOtherCharges" xlink:label="loc_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:to="lab_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Gain associated with Bain Capital transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other income (charges)</link:label>
    <link:label id="lab_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A_label_en-US" xlink:label="lab_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Income (Expense), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:to="lab_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219" xlink:type="arc" />
    <link:label id="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">External incremental costs</link:label>
    <link:label id="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2_label_en-US" xlink:label="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, External Incremental Costs, Amount</link:label>
    <link:label id="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2_documentation_en-US" xlink:label="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deconsolidation, External Incremental Costs, Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:label="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:to="lab_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:type="arc" />
    <link:label id="lab_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502_terseLabel_en-US" xlink:label="lab_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One-time bonus paid to all Pfizer colleagues excluding executives</link:label>
    <link:label id="lab_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502_label_en-US" xlink:label="lab_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Non-Executive Employees, Bonus</link:label>
    <link:label id="lab_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502_documentation_en-US" xlink:label="lab_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Compensation Related Costs, Non-Executive Employees, Bonus</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus" xlink:label="loc_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:to="lab_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other legal matters, net</link:label>
    <link:label id="lab_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F_label_en-US" xlink:label="lab_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Loss in Period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:to="lab_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:type="arc" />
    <link:label id="lab_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4_verboseLabel_en-US" xlink:label="lab_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Alignment costs</link:label>
    <link:label id="lab_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4_label_en-US" xlink:label="lab_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Alignment Costs</link:label>
    <link:label id="lab_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4_documentation_en-US" xlink:label="lab_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Alignment Costs</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AlignmentCosts" xlink:label="loc_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:to="lab_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:type="arc" />
    <link:label id="lab_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707_terseLabel_en-US" xlink:label="lab_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charitable contribution expense</link:label>
    <link:label id="lab_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707_label_en-US" xlink:label="lab_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Charitable Contribution Expense</link:label>
    <link:label id="lab_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707_documentation_en-US" xlink:label="lab_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Charitable Contribution Expense</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CharitableContributionExpense" xlink:label="loc_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:to="lab_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:type="arc" />
    <link:label id="lab_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400_terseLabel_en-US" xlink:label="lab_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory losses and overhead costs</link:label>
    <link:label id="lab_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400_label_en-US" xlink:label="lab_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Write Down And Overhead Costs</link:label>
    <link:label id="lab_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400_documentation_en-US" xlink:label="lab_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inventory Write Down And Overhead Costs</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InventoryWriteDownAndOverheadCosts" xlink:label="loc_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:to="lab_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5_negatedLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposition of property</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income (Loss) on sale of HIS net assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E" xlink:to="lab_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8" xlink:to="lab_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Provision for Taxes on Income</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA_terseLabel_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA_label_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:label id="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA_documentation_en-US" xlink:label="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA" xlink:to="lab_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent [Member]</link:label>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1_label_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent [Member]</link:label>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1_documentation_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net, Noncurrent [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:label="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:to="lab_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unremitted earnings of international subsidiaries</link:label>
    <link:label id="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0_label_en-US" xlink:label="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings of Foreign Subsidiaries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:to="lab_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:type="arc" />
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A_terseLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits excluding associated interest</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Excluding Interest</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Excluding Interest</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:label="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:to="lab_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets associated with unrecognized tax benefits</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Associated With Unrecognized Tax Benefits</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets Associated With Unrecognized Tax Benefits</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:to="lab_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, interest on income taxes accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:type="arc" />
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F_negatedTerseLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized accrued interest decrease as a result of cash payments</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:to="lab_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D_verboseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted Stock Units [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinvested dividend equivalents, shares</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:type="arc" />
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1_terseLabel_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share)</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1_label_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1_documentation_en-US" xlink:label="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:to="lab_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="lab_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Costs and expenses:</link:label>
    <link:label id="lab_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE_label_en-US" xlink:label="lab_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs and Expenses [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:to="lab_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_99179A8CE52AC978EA25CAF68821A0D4_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold_99179A8CE52AC978EA25CAF68821A0D4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of sales</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_99179A8CE52AC978EA25CAF68821A0D4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold_99179A8CE52AC978EA25CAF68821A0D4" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold_99179A8CE52AC978EA25CAF68821A0D4" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_00A953CAFA1822509C21CAF688219628_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense_00A953CAFA1822509C21CAF688219628" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, informational and administrative expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A953CAFA1822509C21CAF688219628" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A953CAFA1822509C21CAF688219628" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense_00A953CAFA1822509C21CAF688219628" xlink:type="arc" />
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1_terseLabel_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of intangible assets</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1_label_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization Of Intangible Assets Not Associated With Single Function</link:label>
    <link:label id="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1_documentation_en-US" xlink:label="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1" xlink:to="lab_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30_terseLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30_label_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges And Acquisition Related Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeconsolidationGainOrLossAmount_F46C70CE7AA39CFA5901CB00E68DEC52_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeconsolidationGainOrLossAmount_F46C70CE7AA39CFA5901CB00E68DEC52" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">(Gain) on completion of Consumer Healthcare JV transaction</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_F46C70CE7AA39CFA5901CB00E68DEC52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeconsolidationGainOrLossAmount_F46C70CE7AA39CFA5901CB00E68DEC52" xlink:to="lab_us-gaap_DeconsolidationGainOrLossAmount_F46C70CE7AA39CFA5901CB00E68DEC52" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_BCA96FD8447691C8D5D2CAF68822CA88_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense_BCA96FD8447691C8D5D2CAF68822CA88" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BCA96FD8447691C8D5D2CAF68822CA88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense_BCA96FD8447691C8D5D2CAF68822CA88" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense_BCA96FD8447691C8D5D2CAF68822CA88" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_55B06756EDE11355088DCAF68822F47B_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit_55B06756EDE11355088DCAF68822F47B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Provision/(benefit) for taxes on income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_55B06756EDE11355088DCAF68822F47B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_55B06756EDE11355088DCAF68822F47B" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit_55B06756EDE11355088DCAF68822F47B" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_C381AEDA8B50F42E0157CAF688226EE1_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_C381AEDA8B50F42E0157CAF688226EE1" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_C381AEDA8B50F42E0157CAF688226EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_C381AEDA8B50F42E0157CAF688226EE1" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_C381AEDA8B50F42E0157CAF688226EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations:</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8" xlink:to="lab_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A_terseLabel_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on disposal of discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:label id="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A_label_en-US" xlink:label="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A" xlink:to="lab_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_727B8BDFC07D8F32EEE8CAF68823EFE6_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_727B8BDFC07D8F32EEE8CAF68823EFE6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_727B8BDFC07D8F32EEE8CAF68823EFE6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_727B8BDFC07D8F32EEE8CAF68823EFE6" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_727B8BDFC07D8F32EEE8CAF68823EFE6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56_totalLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56_label_en-US" xlink:label="lab_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56" xlink:to="lab_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Net income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF_label_en-US" xlink:label="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF" xlink:to="lab_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713" xlink:to="lab_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share&#8211;&#8211;basic:</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:to="lab_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Basic Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7" xlink:to="lab_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings per common share&#8211;&#8211;diluted:</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:to="lab_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations, Per Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8" xlink:to="lab_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC_totalLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC" xlink:to="lab_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9631D68B3CBE14CB297ECAF688254926_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9631D68B3CBE14CB297ECAF688254926" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares&#8211;&#8211;basic</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9631D68B3CBE14CB297ECAF688254926" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9631D68B3CBE14CB297ECAF688254926" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9631D68B3CBE14CB297ECAF688254926" xlink:type="arc" />
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7251C6C852C7E172F4E5CAF68826AA00_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7251C6C852C7E172F4E5CAF68826AA00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average shares&#8211;&#8211;diluted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7251C6C852C7E172F4E5CAF68826AA00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7251C6C852C7E172F4E5CAF68826AA00" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7251C6C852C7E172F4E5CAF68826AA00" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06" xlink:to="lab_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred payment</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Deferred Payment</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Deferred Payment</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredDeferredPayment" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Potential milestone payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Milestone Payments, Maximum</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Milestone Payments, Maximum</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum amount of sales-related payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Sales-related Payments, Maximum</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Sales-related Payments, Maximum</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE_label_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Undiscounted Royalty Payments</link:label>
    <link:label id="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred, Undiscounted Royalty Payments</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:to="lab_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consideration transferred</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Consideration Transferred</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:to="lab_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current assets</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of additional shares authorized</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:type="arc" />
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum shares available per individual during the plan period</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:type="arc" />
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117_terseLabel_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares counted toward maximum</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117_label_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee</link:label>
    <link:label id="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117_documentation_en-US" xlink:label="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:to="lab_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for award</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect on total service and interest cost components, increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:to="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect on total service and interest cost components, decrease</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:to="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect on postretirement benefit obligation, increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:to="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Effect on postretirement benefit obligation, decrease</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:to="lab_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947" xlink:to="lab_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other noncurrent liabilities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC" xlink:type="arc" />
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA_terseLabel_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA_label_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Accrued Liabilities [Line Items]</link:label>
    <link:label id="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA_documentation_en-US" xlink:label="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">[Line Items] for Schedule Of Accrued Liabilities [Table]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:to="lab_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:type="arc" />
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77_terseLabel_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued rebates and other accruals</link:label>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77_label_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rebates And Discounts Accrual</link:label>
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77_documentation_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:to="lab_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:type="arc" />
    <link:label id="lab_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2_terseLabel_en-US" xlink:label="lab_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2_label_en-US" xlink:label="lab_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Rebates</link:label>
    <link:label id="lab_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2_documentation_en-US" xlink:label="lab_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued Rebates</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AccruedRebates" xlink:label="loc_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:to="lab_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:type="arc" />
    <link:label id="lab_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924_terseLabel_en-US" xlink:label="lab_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924_label_en-US" xlink:label="lab_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Accruals</link:label>
    <link:label id="lab_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924_documentation_en-US" xlink:label="lab_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Accruals</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherAccruals" xlink:label="loc_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:to="lab_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Revenue from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405" xlink:to="lab_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4" xlink:to="lab_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4" xlink:type="arc" />
    <link:label id="lab_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A_terseLabel_en-US" xlink:label="lab_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation Of Depreciation And Amortization From Segments To Consolidated</link:label>
    <link:label id="lab_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A_label_en-US" xlink:label="lab_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation Of Depreciation And Amortization From Segments To Consolidated [Table Text Block]</link:label>
    <link:label id="lab_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A_documentation_en-US" xlink:label="lab_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reconciliation Of Depreciation And Amortization From Segments To Consolidated [Table Text Block]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock" xlink:label="loc_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A" xlink:to="lab_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518_label_en-US" xlink:label="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518" xlink:to="lab_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Significant Product Revenues</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F_label_en-US" xlink:label="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:to="lab_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Actuarial Gains/(Losses) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Service (Costs)/Credits and Other [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3_label_en-US" xlink:label="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:to="lab_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091_terseLabel_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain (loss) to be reclassified in next twelve months</link:label>
    <link:label id="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091_label_en-US" xlink:label="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:to="lab_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined contribution plan, cost recognized</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Standards Update 2016-01 [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB" xlink:to="lab_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income/(Loss) [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation Adjustments [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-For-Sale Securities [Member]</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:to="lab_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss)</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss) due to the adoption of new accounting standards</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect of New Accounting Principle in Period of Adoption</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:to="lab_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_BE31C536C04DD7535771E395F3C3BB08_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_BE31C536C04DD7535771E395F3C3BB08" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BE31C536C04DD7535771E395F3C3BB08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_BE31C536C04DD7535771E395F3C3BB08" xlink:to="lab_us-gaap_StockholdersEquity_BE31C536C04DD7535771E395F3C3BB08" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:to="lab_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:to="lab_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Industry Sector [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:to="lab_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bank sector [Member]</link:label>
    <link:label id="lab_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6_label_en-US" xlink:label="lab_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Services Sector [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialServicesSectorMember" xlink:label="loc_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:to="lab_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:to="lab_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum exposure, amount</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:to="lab_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Actuarial losses</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prior service credits and other</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Amortization, Next Fiscal Year</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:to="lab_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization period</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Amortization, Term</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Expected Amortization, Term</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanExpectedAmortizationTerm" xlink:label="loc_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:to="lab_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:to="lab_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:type="arc" />
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697_terseLabel_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697_label_en-US" xlink:label="lab_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Category [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="lab_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents [Member]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Cash and Cash Equivalents [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:to="lab_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Securities [Member]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Equity Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:to="lab_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:type="arc" />
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6_verboseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fixed Income Securities [Member]</link:label>
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6_label_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Income Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:to="lab_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643_terseLabel_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:label id="lab_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643_label_en-US" xlink:label="lab_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:to="lab_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity and debt securities, target allocation percentage</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Target Allocation, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity and debt securities, percentage of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:type="arc" />
    <link:label id="lab_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7_terseLabel_en-US" xlink:label="lab_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upjohn And Mylan [Member]</link:label>
    <link:label id="lab_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7_label_en-US" xlink:label="lab_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upjohn And Mylan [Member]</link:label>
    <link:label id="lab_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7_documentation_en-US" xlink:label="lab_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upjohn And Mylan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnAndMylanMember" xlink:label="loc_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:to="lab_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for Change in Accounting Principle [Axis]</link:label>
    <link:label id="lab_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953_label_en-US" xlink:label="lab_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Change in Accounting Principle [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:to="lab_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments for Change in Accounting Principle [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments for Change in Accounting Principle [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:to="lab_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:type="arc" />
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue [Member]</link:label>
    <link:label id="lab_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF_label_en-US" xlink:label="lab_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Product and Service Benchmark [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:to="lab_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:type="arc" />
    <link:label id="lab_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24_terseLabel_en-US" xlink:label="lab_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top Eight Products [Member]</link:label>
    <link:label id="lab_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24_label_en-US" xlink:label="lab_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top Eight Products [Member]</link:label>
    <link:label id="lab_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24_documentation_en-US" xlink:label="lab_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Top Eight Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopEightProductsMember" xlink:label="loc_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:to="lab_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:type="arc" />
    <link:label id="lab_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39_terseLabel_en-US" xlink:label="lab_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top Nine Products [Member]</link:label>
    <link:label id="lab_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39_label_en-US" xlink:label="lab_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top Nine Products [Member]</link:label>
    <link:label id="lab_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39_documentation_en-US" xlink:label="lab_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Top Nine Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopNineProductsMember" xlink:label="loc_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:to="lab_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:type="arc" />
    <link:label id="lab_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12_terseLabel_en-US" xlink:label="lab_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Top Ten Products [Member]</link:label>
    <link:label id="lab_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12_label_en-US" xlink:label="lab_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Top Ten Products [Member]</link:label>
    <link:label id="lab_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12_documentation_en-US" xlink:label="lab_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Top Ten Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopTenProductsMember" xlink:label="loc_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:to="lab_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463_terseLabel_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:label id="lab_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463_label_en-US" xlink:label="lab_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product Concentration Risk [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:to="lab_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:type="arc" />
    <link:label id="lab_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939_terseLabel_en-US" xlink:label="lab_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of accounting standards adopted</link:label>
    <link:label id="lab_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939_label_en-US" xlink:label="lab_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Accounting Standards Adopted</link:label>
    <link:label id="lab_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939_documentation_en-US" xlink:label="lab_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Accounting Standards Adopted</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NumberOfAccountingStandardsAdopted" xlink:label="loc_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:to="lab_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interest, ownership percentage by noncontrolling owners</link:label>
    <link:label id="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220_label_en-US" xlink:label="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:to="lab_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:type="arc" />
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284_verboseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Upfront payment</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284_label_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Upfront Payment</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Upfront Payment</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:to="lab_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:type="arc" />
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum potential milestone payments</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626_label_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:to="lab_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:type="arc" />
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D_verboseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of consideration transferred</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D_label_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:label id="lab_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Consideration Transferred</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferred" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:to="lab_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E_terseLabel_en-US" xlink:label="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received for disposition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E" xlink:to="lab_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROU assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities (long-term)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B_verboseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect on retained earnings, before tax</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect on Retained Earnings, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:type="arc" />
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2_terseLabel_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cumulative effect on retained earnings, net of tax</link:label>
    <link:label id="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2_label_en-US" xlink:label="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cumulative Effect on Retained Earnings, Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:to="lab_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:type="arc" />
    <link:label id="lab_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E_terseLabel_en-US" xlink:label="lab_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, amount</link:label>
    <link:label id="lab_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E_label_en-US" xlink:label="lab_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Amount</link:label>
    <link:label id="lab_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E_documentation_en-US" xlink:label="lab_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Concentration Risk, Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConcentrationRiskAmount" xlink:label="loc_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:to="lab_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133_verboseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133" xlink:type="arc" />
    <link:label id="lab_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666_verboseLabel_en-US" xlink:label="lab_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666" xlink:to="lab_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expense</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:to="lab_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease term</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:type="arc" />
    <link:label id="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D_terseLabel_en-US" xlink:label="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease term, option to extend</link:label>
    <link:label id="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D_label_en-US" xlink:label="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Term</link:label>
    <link:label id="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D_documentation_en-US" xlink:label="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Option To Extend, Term</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:label="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:to="lab_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703_terseLabel_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other (Income)/Deductions - Net</link:label>
    <link:label id="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703_label_en-US" xlink:label="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Income and Other Expense Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703" xlink:to="lab_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573_terseLabel_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, allowance for doubtful accounts</link:label>
    <link:label id="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573_label_en-US" xlink:label="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573" xlink:to="lab_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short term borrowings, current portion of long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E" xlink:to="lab_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E" xlink:to="lab_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7" xlink:to="lab_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6" xlink:to="lab_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares at cost</link:label>
    <link:label id="lab_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210_label_en-US" xlink:label="lab_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210" xlink:to="lab_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_451A1C2D5518065C37A16EEB80CECEDE_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract_451A1C2D5518065C37A16EEB80CECEDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_451A1C2D5518065C37A16EEB80CECEDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_451A1C2D5518065C37A16EEB80CECEDE" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract_451A1C2D5518065C37A16EEB80CECEDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A_terseLabel_en-US" xlink:label="lab_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; Equity</link:label>
    <link:label id="lab_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A_label_en-US" xlink:label="lab_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Parent [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="lab_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F_verboseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:to="lab_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B" xlink:to="lab_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Add&#8217;l Paid-In Capital [Member]</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:label id="lab_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038_label_en-US" xlink:label="lab_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:to="lab_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:type="arc" />
    <link:label id="lab_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:to="lab_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accum. Other Comp. Loss [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F_terseLabel_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-controlling Interests [Member]</link:label>
    <link:label id="lab_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F_label_en-US" xlink:label="lab_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:to="lab_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20_label_en-US" xlink:label="lab_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:to="lab_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F_verboseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F" xlink:to="lab_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss), net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash dividends declared:</link:label>
    <link:label id="lab_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418_label_en-US" xlink:label="lab_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsAbstract" xlink:label="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:to="lab_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Common stock</link:label>
    <link:label id="lab_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6_label_en-US" xlink:label="lab_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Common Stock, Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:to="lab_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01_negatedLabel_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Preferred stock</link:label>
    <link:label id="lab_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01_label_en-US" xlink:label="lab_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends, Preferred Stock, Cash</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:to="lab_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3_negatedLabel_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3_label_en-US" xlink:label="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:to="lab_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment transactions (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based payment transactions</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Purchases of common stock (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of common stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017" xlink:type="arc" />
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3_negatedTerseLabel_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversions and redemptions (in shares)</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3_label_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3_documentation_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:to="lab_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:type="arc" />
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A_negatedTerseLabel_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock conversions and redemptions</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A_label_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</link:label>
    <link:label id="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A_documentation_en-US" xlink:label="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:to="lab_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311_negatedLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:to="lab_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharesIssued_92A8D58AE66BE646F4286EEB80D33F13_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesIssued_92A8D58AE66BE646F4286EEB80D33F13" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_92A8D58AE66BE646F4286EEB80D33F13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssued_92A8D58AE66BE646F4286EEB80D33F13" xlink:to="lab_us-gaap_SharesIssued_92A8D58AE66BE646F4286EEB80D33F13" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6E53B072FC3A16ECEF676EEB80D39756_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6E53B072FC3A16ECEF676EEB80D39756" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6E53B072FC3A16ECEF676EEB80D39756" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6E53B072FC3A16ECEF676EEB80D39756" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6E53B072FC3A16ECEF676EEB80D39756" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine benefit obligations:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine benefit obligations, Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine net periodic benefit cost:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="lab_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine net periodic benefit cost, Discount rate</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine interest cost, Discount rate</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:to="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine service cost, Discount rate</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:to="lab_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:to="lab_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8_terseLabel_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:label id="lab_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8_label_en-US" xlink:label="lab_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Distribution Rights [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:to="lab_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain related to sale of intangible assets</link:label>
    <link:label id="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308_label_en-US" xlink:label="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:to="lab_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:type="arc" />
    <link:label id="lab_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355_terseLabel_en-US" xlink:label="lab_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oncology Vaccines Start Up [Member]</link:label>
    <link:label id="lab_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355_label_en-US" xlink:label="lab_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology Vaccines Start Up [Member]</link:label>
    <link:label id="lab_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355_documentation_en-US" xlink:label="lab_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oncology Vaccines Start Up [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OncologyVaccinesStartUpMember" xlink:label="loc_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:to="lab_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:type="arc" />
    <link:label id="lab_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33_terseLabel_en-US" xlink:label="lab_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">European Union [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33" xlink:to="lab_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33" xlink:type="arc" />
    <link:label id="lab_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF_terseLabel_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance recoveries</link:label>
    <link:label id="lab_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF_label_en-US" xlink:label="lab_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Recoveries</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:to="lab_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB_netLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Net gains recognized during the period on equity securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB" xlink:type="arc" />
    <link:label id="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259_terseLabel_en-US" xlink:label="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain from cash settlement of liability</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" xlink:label="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259" xlink:to="lab_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of fair value contingent consideration liabilities</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:to="lab_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:type="arc" />
    <link:label id="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E_terseLabel_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income from resolution of contract disagreement</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E_label_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income, Miscellaneous</link:label>
    <link:label id="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E_documentation_en-US" xlink:label="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income, Miscellaneous</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherNonoperatingIncomeMiscellaneous" xlink:label="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:to="lab_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4_label_en-US" xlink:label="lab_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:to="lab_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:label id="lab_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184_label_en-US" xlink:label="lab_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Status [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:to="lab_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:type="arc" />
    <link:label id="lab_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5_terseLabel_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5_label_en-US" xlink:label="lab_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pending Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:to="lab_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:type="arc" />
    <link:label id="lab_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A_terseLabel_en-US" xlink:label="lab_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:label id="lab_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A_label_en-US" xlink:label="lab_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:label id="lab_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A_documentation_en-US" xlink:label="lab_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Celebrex [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:to="lab_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426_label_en-US" xlink:label="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:to="lab_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A_label_en-US" xlink:label="lab_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:to="lab_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:type="arc" />
    <link:label id="lab_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C_terseLabel_en-US" xlink:label="lab_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Matter [Member]</link:label>
    <link:label id="lab_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C_label_en-US" xlink:label="lab_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Matter [Member]</link:label>
    <link:label id="lab_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C_documentation_en-US" xlink:label="lab_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patent Matter [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PatentMatterMember" xlink:label="loc_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:to="lab_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40_terseLabel_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation settlement expense</link:label>
    <link:label id="lab_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40_label_en-US" xlink:label="lab_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Settlement, Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:to="lab_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Short-term Debt [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:to="lab_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:type="arc" />
    <link:label id="lab_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328_terseLabel_en-US" xlink:label="lab_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility Expiring 2024 [Member]</link:label>
    <link:label id="lab_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328_label_en-US" xlink:label="lab_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility Expiring 2024 [Member]</link:label>
    <link:label id="lab_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328_documentation_en-US" xlink:label="lab_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Credit Facility Expiring 2024 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CreditFacilityExpiring2024Member" xlink:label="loc_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:to="lab_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:type="arc" />
    <link:label id="lab_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129_terseLabel_en-US" xlink:label="lab_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Facility Expiring September 2020 [Member]</link:label>
    <link:label id="lab_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129_label_en-US" xlink:label="lab_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Facility Expiring September 2020 [Member]</link:label>
    <link:label id="lab_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129_documentation_en-US" xlink:label="lab_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Facility Expiring September 2020 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FacilityExpiringSeptember2020Member" xlink:label="loc_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:to="lab_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448_label_en-US" xlink:label="lab_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:to="lab_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:type="arc" />
    <link:label id="lab_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A_terseLabel_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:label id="lab_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A_label_en-US" xlink:label="lab_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Credit Facility [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:to="lab_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:label id="lab_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761_label_en-US" xlink:label="lab_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:to="lab_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:to="lab_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:to="lab_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:label id="lab_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D_label_en-US" xlink:label="lab_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:to="lab_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="lab_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05_terseLabel_en-US" xlink:label="lab_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper</link:label>
    <link:label id="lab_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05_label_en-US" xlink:label="lab_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Paper</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:to="lab_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E_verboseLabel_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, principal amount</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E_label_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:label id="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E_documentation_en-US" xlink:label="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:to="lab_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F_terseLabel_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other short-term borrowings</link:label>
    <link:label id="lab_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F_label_en-US" xlink:label="lab_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Short-term Borrowings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:to="lab_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:type="arc" />
    <link:label id="lab_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62_totalLabel_en-US" xlink:label="lab_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total short-term borrowings, principal amount</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62_label_en-US" xlink:label="lab_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:label id="lab_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62_documentation_en-US" xlink:label="lab_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Short-term Debt, Gross</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:to="lab_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:type="arc" />
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD_terseLabel_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net fair value adjustments related to hedging and purchase accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD_label_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:label id="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD_documentation_en-US" xlink:label="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:to="lab_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net unamortized discounts, premiums and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:to="lab_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11_totalLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11" xlink:to="lab_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial paper, weighted average interest rate</link:label>
    <link:label id="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F_label_en-US" xlink:label="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Debt, Weighted Average Interest Rate, at Point in Time</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:to="lab_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, maximum borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:to="lab_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:type="arc" />
    <link:label id="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001_terseLabel_en-US" xlink:label="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, due to expire within one year</link:label>
    <link:label id="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001_label_en-US" xlink:label="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year</link:label>
    <link:label id="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001_documentation_en-US" xlink:label="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:label="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:to="lab_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:type="arc" />
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB_terseLabel_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Line of credit facility, remaining borrowing capacity</link:label>
    <link:label id="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB_label_en-US" xlink:label="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Line of Credit Facility, Remaining Borrowing Capacity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:to="lab_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Earning Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Assets and Liabilities Held For Sale</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28" xlink:to="lab_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summarized Financial Information of Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B" xlink:to="lab_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8" xlink:to="lab_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6_label_en-US" xlink:label="lab_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6" xlink:to="lab_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent inventories not included above</link:label>
    <link:label id="lab_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F_label_en-US" xlink:label="lab_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F" xlink:to="lab_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F" xlink:type="arc" />
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_D2B9BEC6BFA5BA631DD86EE6EE6D8E50_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract_D2B9BEC6BFA5BA631DD86EE6EE6D8E50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D2B9BEC6BFA5BA631DD86EE6EE6D8E50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2B9BEC6BFA5BA631DD86EE6EE6D8E50" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract_D2B9BEC6BFA5BA631DD86EE6EE6D8E50" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured U.K. Pound Debt, 2.735%, Due 2043 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured U.K. Pound Debt, Two Point Seven Three Five Percent, Due 2043 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured U.K. Pound Debt, Two Point Seven Three Five Percent, Due 2043  [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member" xlink:label="loc_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:to="lab_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:type="arc" />
    <link:label id="lab_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA_terseLabel_en-US" xlink:label="lab_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.K. Pound Denominated Debt [Member]</link:label>
    <link:label id="lab_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA_label_en-US" xlink:label="lab_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.K. Pound Denominated Debt [Member]</link:label>
    <link:label id="lab_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA_documentation_en-US" xlink:label="lab_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.K. Pound Denominated Debt [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_U.K.PoundDenominatedDebtMember" xlink:label="loc_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:to="lab_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:type="arc" />
    <link:label id="lab_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB_negatedTerseLabel_en-US" xlink:label="lab_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on exchange of debt</link:label>
    <link:label id="lab_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB_label_en-US" xlink:label="lab_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Exchange Of Debt</link:label>
    <link:label id="lab_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB_documentation_en-US" xlink:label="lab_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain (Loss) On Exchange Of Debt</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossOnExchangeOfDebt" xlink:label="loc_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:to="lab_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E_negatedLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Tax benefits associated with the enactment of the TCJA</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E" xlink:type="arc" />
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:to="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F" xlink:to="lab_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F" xlink:type="arc" />
    <link:label id="lab_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation net assets contributed</link:label>
    <link:label id="lab_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9_label_en-US" xlink:label="lab_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Net Assets Contributed</link:label>
    <link:label id="lab_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9_documentation_en-US" xlink:label="lab_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deconsolidation, Net Assets Contributed</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationNetAssetsContributed" xlink:label="loc_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:to="lab_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:type="arc" />
    <link:label id="lab_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB_terseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deconsolidation, cash conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB_label_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Cash Conveyed</link:label>
    <link:label id="lab_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB_documentation_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deconsolidation, Gain (Loss), Amount, Cash Conveyed</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:to="lab_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:type="arc" />
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F_terseLabel_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F_label_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:label id="lab_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F_documentation_en-US" xlink:label="lab_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Developed Rest Of World [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:to="lab_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:type="arc" />
    <link:label id="lab_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C_terseLabel_en-US" xlink:label="lab_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C_label_en-US" xlink:label="lab_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:label id="lab_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C_documentation_en-US" xlink:label="lab_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Emerging Markets [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:to="lab_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E_terseLabel_en-US" xlink:label="lab_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net income before allocation to noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E" xlink:to="lab_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:type="arc" />
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476_terseLabel_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476_label_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization</link:label>
    <link:label id="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476_documentation_en-US" xlink:label="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:to="lab_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:type="arc" />
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6_terseLabel_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset write-offs and impairments</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6_label_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6_documentation_en-US" xlink:label="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Write-Offs And Asset Impairment Charges</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:to="lab_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">TCJA impact</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595" xlink:to="lab_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595" xlink:type="arc" />
    <link:label id="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245_negatedTerseLabel_en-US" xlink:label="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245" xlink:to="lab_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred taxes from continuing operations</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:to="lab_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:type="arc" />
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314_negatedTerseLabel_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Benefit plan contributions in excess of expense/income</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314_label_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)</link:label>
    <link:label id="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314_documentation_en-US" xlink:label="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:to="lab_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C_label_en-US" xlink:label="lab_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncash Income (Expense)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:to="lab_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other changes in assets and liabilities, net of acquisitions and divestitures:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable, Trade</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Operating Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other tax accounts, net</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Taxes Payable</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, plant and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of short-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:to="lab_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from redemptions/sales of short-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:to="lab_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of long-term investments</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from redemptions/sales of long-term investments</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale, Maturity and Collection of Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:to="lab_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of businesses, net of cash acquired</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6" xlink:to="lab_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions of intangible assets</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:to="lab_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other investing activities, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D_label_en-US" xlink:label="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for (Proceeds from) Other Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:to="lab_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by/(used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financing Activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from short-term borrowings</link:label>
    <link:label id="lab_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF_label_en-US" xlink:label="lab_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:to="lab_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Principal payments on short-term borrowings</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Short-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:to="lab_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</link:label>
    <link:label id="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71_label_en-US" xlink:label="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:to="lab_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:type="arc" />
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA_negatedLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Principal payments on long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of common stock</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Cash dividends paid</link:label>
    <link:label id="lab_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F_label_en-US" xlink:label="lab_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Ordinary Dividends</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:to="lab_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6_label_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Stock Options Exercised</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other financing activities, net</link:label>
    <link:label id="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66_label_en-US" xlink:label="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from (Payments for) Other Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:to="lab_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:type="arc" />
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C_terseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5FED55984EA484B9EB9B2F92B62CAAAA_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5FED55984EA484B9EB9B2F92B62CAAAA" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5FED55984EA484B9EB9B2F92B62CAAAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5FED55984EA484B9EB9B2F92B62CAAAA" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5FED55984EA484B9EB9B2F92B62CAAAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23_label_en-US" xlink:label="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="lab_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:type="arc" />
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992_terseLabel_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity investment in exchange for Pfizer's assets</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992_label_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992_documentation_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:to="lab_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39_terseLabel_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange of $1.1 billion net book value 6.50% U.K. pound denominated bonds maturing in 2038 for $1.8 billion of new 2.735% U.K. pound denominated bonds maturing in 2043, resulting in a debt extinguishment loss of $747 million</link:label>
    <link:label id="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39_label_en-US" xlink:label="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Conversion, Converted Instrument, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:to="lab_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:type="arc" />
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B_terseLabel_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Receipt of ICU Medical common stock</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B_label_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B_documentation_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:to="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:type="arc" />
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416_terseLabel_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Promissory note from ICU Medical</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416_label_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable</link:label>
    <link:label id="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416_documentation_en-US" xlink:label="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:to="lab_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:type="arc" />
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid (received) during the period for:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:to="lab_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135_terseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:to="lab_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:type="arc" />
    <link:label id="lab_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D_terseLabel_en-US" xlink:label="lab_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate hedges</link:label>
    <link:label id="lab_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D_label_en-US" xlink:label="lab_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Interest Rate Hedges</link:label>
    <link:label id="lab_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D_documentation_en-US" xlink:label="lab_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Interest Paid, Interest Rate Hedges</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InterestPaidInterestRateHedges" xlink:label="loc_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:to="lab_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:type="arc" />
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA" xlink:to="lab_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Fair Value of Plan Assets by Measurement [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88_verboseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Plan Asset Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:type="arc" />
    <link:label id="lab_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A_terseLabel_en-US" xlink:label="lab_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insurance Contracts [Member]</link:label>
    <link:label id="lab_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A_label_en-US" xlink:label="lab_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insurance Contracts [Member]</link:label>
    <link:label id="lab_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A_documentation_en-US" xlink:label="lab_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Insurance Contracts [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceContractsMember" xlink:label="loc_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:to="lab_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Funds [Member]</link:label>
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524_label_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Security Investments [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:to="lab_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="lab_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held, ending</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:to="lab_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases, sales, and settlements, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:to="lab_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transfer into/(out of) Level 3</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:to="lab_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange rate changes</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E" xlink:to="lab_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, 2.800% Notes, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Eight Percent, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Eight Percent, Due 2022 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:to="lab_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, 2.950% Notes, Due 2024 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Nine Five Percent, Due 2024 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Two Point Nine Five Percent, Due 2024 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:to="lab_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, 3.450% Notes, Due 2029 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Three Point Four Five Percent, Due 2029 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Three Point Four Five Percent, Due 2029 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:to="lab_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, 3.900% Notes, Due 2039 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Three Point Nine Percent, Due 2039 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Three Point Nine Percent, Due 2039 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:to="lab_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, 4.000% Notes, Due 2049 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Four Percent, Due 2049 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Four Percent, Due 2049 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtFourPercentDue2049Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:to="lab_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0" xlink:to="lab_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0" xlink:type="arc" />
    <link:label id="lab_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8_terseLabel_en-US" xlink:label="lab_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of shares acquired</link:label>
    <link:label id="lab_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8_label_en-US" xlink:label="lab_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Percentage of Shares Acquired</link:label>
    <link:label id="lab_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8_documentation_en-US" xlink:label="lab_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Asset Acquisition, Percentage of Shares Acquired</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionPercentageofSharesAcquired" xlink:label="loc_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8" xlink:to="lab_pfe_AssetAcquisitionPercentageofSharesAcquired_1ACB8FC41D29FD5A48F2CEC126D1C5A8" xlink:type="arc" />
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments to asset acquisition</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Productive Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C" xlink:to="lab_us-gaap_PaymentsToAcquireProductiveAssets_621A54BB07007B2A9A34CEC126D11B8C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Charge to research and development expenses in connection with asset acquisition</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Asset Acquired Other than Through Business Combination, Written-off</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365" xlink:to="lab_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_2A3746EE2F1557CAB5A8CEC126D1C365" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets for Plan Benefits, Defined Benefit Plan</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:to="lab_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Current liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Plan, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F_negatedLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Noncurrent liabilities</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:to="lab_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Funded status</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268_label_en-US" xlink:label="lab_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="lab_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:to="lab_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A_label_en-US" xlink:label="lab_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:to="lab_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:type="arc" />
    <link:label id="lab_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6_terseLabel_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:label id="lab_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6_label_en-US" xlink:label="lab_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:to="lab_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:type="arc" />
    <link:label id="lab_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174_terseLabel_en-US" xlink:label="lab_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Precedex Premix [Member]</link:label>
    <link:label id="lab_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174_label_en-US" xlink:label="lab_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Precedex Premix [Member]</link:label>
    <link:label id="lab_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174_documentation_en-US" xlink:label="lab_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Precedex Premix [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrecedexPremixMember" xlink:label="loc_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:to="lab_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:type="arc" />
    <link:label id="lab_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108_terseLabel_en-US" xlink:label="lab_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108_label_en-US" xlink:label="lab_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:label id="lab_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108_documentation_en-US" xlink:label="lab_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xeljanz [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:to="lab_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:type="arc" />
    <link:label id="lab_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4_terseLabel_en-US" xlink:label="lab_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4_label_en-US" xlink:label="lab_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:label id="lab_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4_documentation_en-US" xlink:label="lab_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Eliquis [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:to="lab_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2_label_en-US" xlink:label="lab_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:to="lab_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:type="arc" />
    <link:label id="lab_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="lab_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0_terseLabel_en-US" xlink:label="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira Versus Amneal Pharmaceuticals LLC [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0_label_en-US" xlink:label="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira Versus Amneal Pharmaceuticals LLC [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0_documentation_en-US" xlink:label="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira Versus Amneal Pharmaceuticals LLC [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusAmnealPharmaceuticalsLLCMember" xlink:label="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:to="lab_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21_terseLabel_en-US" xlink:label="lab_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira Versus Fresenius Kabj USA LLC [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21_label_en-US" xlink:label="lab_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira Versus Fresenius Kabj USA LLC [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21_documentation_en-US" xlink:label="lab_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira Versus Fresenius Kabj USA LLC [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusFreseniusKabjUSALLCMember" xlink:label="loc_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:to="lab_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:type="arc" />
    <link:label id="lab_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4_terseLabel_en-US" xlink:label="lab_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospira Versus Par [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4_label_en-US" xlink:label="lab_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospira Versus Par [Member]</link:label>
    <link:label id="lab_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4_documentation_en-US" xlink:label="lab_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospira Versus Par [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusParMember" xlink:label="loc_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:to="lab_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7_label_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7_documentation_en-US" xlink:label="lab_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Zydus [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:to="lab_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Ajanta [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688_label_en-US" xlink:label="lab_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Ajanta [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688_documentation_en-US" xlink:label="lab_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Ajanta [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusAjantaMember" xlink:label="loc_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:to="lab_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA_label_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA_documentation_en-US" xlink:label="lab_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Generic Companies [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusGenericCompaniesMember" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:to="lab_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5_terseLabel_en-US" xlink:label="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5_label_en-US" xlink:label="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]</link:label>
    <link:label id="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5_documentation_en-US" xlink:label="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member" xlink:label="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:to="lab_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14_terseLabel_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14_label_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:label id="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14_documentation_en-US" xlink:label="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer and BMS Versus Several Generic Manufacturers [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:to="lab_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9_label_en-US" xlink:label="lab_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies, Nature [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:to="lab_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:label id="lab_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB_label_en-US" xlink:label="lab_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Nature [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:to="lab_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:type="arc" />
    <link:label id="lab_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E_terseLabel_en-US" xlink:label="lab_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E_label_en-US" xlink:label="lab_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:label id="lab_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E_documentation_en-US" xlink:label="lab_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Patent Infringement [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:to="lab_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:type="arc" />
    <link:label id="lab_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E_terseLabel_en-US" xlink:label="lab_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:label id="lab_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E_label_en-US" xlink:label="lab_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Judicial Ruling [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:to="lab_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:type="arc" />
    <link:label id="lab_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0_terseLabel_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:label id="lab_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0_label_en-US" xlink:label="lab_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Settled Litigation [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:to="lab_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:label id="lab_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD_label_en-US" xlink:label="lab_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingencies [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="lab_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents without court proceedings</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Without Court Proceedings, Number</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Without Court Proceedings, Number</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:to="lab_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Found Infringed upon, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:to="lab_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents allegedly not infringed upon</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Not Infringed Upon, Number</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of entity's patents that another entity has allegedly not infringed upon.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents not infringed upon expired March 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Not Infringed Upon, Number Due to Expire March 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Not Infringed Upon, Number Due to Expire March 2019</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents found not infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Found Not Infringed upon, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:to="lab_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents found not infringed upon subsequently appealed</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Found Not Infringed Upon, Subsequently Appealed, Number</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Found Not Infringed Upon, Subsequently Appealed, Number</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber" xlink:label="loc_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:to="lab_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3_terseLabel_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents allegedly infringed upon</link:label>
    <link:label id="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3_label_en-US" xlink:label="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed upon, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:to="lab_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9_label_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:label id="lab_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9_documentation_en-US" xlink:label="lab_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Number of Defendants</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:to="lab_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:type="arc" />
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754_terseLabel_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents allegedly infringed upon due to expire In December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754_label_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:label id="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754_documentation_en-US" xlink:label="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:to="lab_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:to="lab_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609_totalLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Short-term investments</link:label>
    <link:label id="lab_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609_label_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Short-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609" xlink:to="lab_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6_label_en-US" xlink:label="lab_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestmentsAbstract" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:to="lab_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:type="arc" />
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B_terseLabel_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity securities with readily determinable fair values</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B_label_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:label id="lab_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B_documentation_en-US" xlink:label="lab_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Noncurrent</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNINoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B" xlink:to="lab_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B" xlink:type="arc" />
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Available-for-sale debt securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445" xlink:type="arc" />
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B_terseLabel_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity debt securities</link:label>
    <link:label id="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B_label_en-US" xlink:label="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Held-to-maturity, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B" xlink:to="lab_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B" xlink:type="arc" />
    <link:label id="lab_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C_terseLabel_en-US" xlink:label="lab_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private equity securities at cost</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C_label_en-US" xlink:label="lab_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Equity Investments</link:label>
    <link:label id="lab_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C_documentation_en-US" xlink:label="lab_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Private Equity Investments</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrivateEquityInvestments" xlink:label="loc_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C" xlink:to="lab_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Long-term investments</link:label>
    <link:label id="lab_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B_label_en-US" xlink:label="lab_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B" xlink:to="lab_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B" xlink:type="arc" />
    <link:label id="lab_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC_totalLabel_en-US" xlink:label="lab_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term investments and equity-method investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC_label_en-US" xlink:label="lab_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Investments And Equity Method Investments</link:label>
    <link:label id="lab_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC_documentation_en-US" xlink:label="lab_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Long-term Investments And Equity Method Investments</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsAndEquityMethodInvestments" xlink:label="loc_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC" xlink:to="lab_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC" xlink:type="arc" />
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF_terseLabel_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Held-to-maturity cash equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF_label_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:label id="lab_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF_documentation_en-US" xlink:label="lab_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Held-To-Maturity Cash Equivalents</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HeldToMaturityCashEquivalents" xlink:label="loc_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF" xlink:to="lab_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases weighted-average remaining contractual lease term</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease weighted-average discount rate</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323" xlink:to="lab_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323" xlink:type="arc" />
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5_terseLabel_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Gains)/losses on sale and leaseback transactions, net</link:label>
    <link:label id="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5_label_en-US" xlink:label="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale and Leaseback Transaction, Gain (Loss), Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5" xlink:to="lab_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5" xlink:type="arc" />
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ROU assets obtained in exchange for new operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value per stock option (in dollars per share)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2020 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2020 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2020 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2020Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2021 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2021 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2021Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2022 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2022 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2023 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2023 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2023 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2023Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2024 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2024 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2024 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2026-2029 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2026-2029 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2026-2029 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20262029Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2034 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2034 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2034 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2034Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:to="lab_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2036-2040 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2036-2040 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2036-2040 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20362040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2043-2044 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2043-2044 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2043-2044 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20432044Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:type="arc" />
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C_terseLabel_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2046-2049 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C_label_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2046-2049 [Member]</link:label>
    <link:label id="lab_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C_documentation_en-US" xlink:label="lab_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Senior Unsecured Debt, Due 2046-2049 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20462049Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:to="lab_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest rate, percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04" xlink:to="lab_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total principal amount of long-term debt</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:to="lab_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other long-term debt</link:label>
    <link:label id="lab_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF_label_en-US" xlink:label="lab_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:to="lab_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt, carried at historical proceeds, as adjusted</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9" xlink:to="lab_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustments, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6F3D0B6DC07F4E6AEE7A6EEB810344B5_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6F3D0B6DC07F4E6AEE7A6EEB810344B5" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6F3D0B6DC07F4E6AEE7A6EEB810344B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6F3D0B6DC07F4E6AEE7A6EEB810344B5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6F3D0B6DC07F4E6AEE7A6EEB810344B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6C5E579A2E35A06BAF316EEB81032D77_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6C5E579A2E35A06BAF316EEB81032D77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains/(losses) on derivative financial instruments, net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6C5E579A2E35A06BAF316EEB81032D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6C5E579A2E35A06BAF316EEB81032D77" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6C5E579A2E35A06BAF316EEB81032D77" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_AE1EE4E62EE2A66DE7726EEB8103CFFC_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_AE1EE4E62EE2A66DE7726EEB8103CFFC" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_AE1EE4E62EE2A66DE7726EEB8103CFFC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_AE1EE4E62EE2A66DE7726EEB8103CFFC" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_AE1EE4E62EE2A66DE7726EEB8103CFFC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized holding gains/(losses) on available-for-sale securities, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for (gains)/losses included in net income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments for unrealized gains included in Retained earnings</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment For Unrealized Gains Included In Retained Earnings, Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Reclassification Adjustment For Unrealized Gains Included In Retained Earnings, Before Tax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0" xlink:to="lab_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: actuarial losses, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF_negatedTerseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to settlements, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF" xlink:to="lab_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0_totalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit Plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Benefit plans: prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3" xlink:to="lab_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to amortization of prior service costs and other, net</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346_terseLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassification adjustments related to curtailments of prior service costs and other, net</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346" xlink:to="lab_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346" xlink:type="arc" />
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90_negatedLabel_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90_label_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax</link:label>
    <link:label id="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90_documentation_en-US" xlink:label="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90" xlink:to="lab_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC" xlink:to="lab_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss), before tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), before Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossTax_3B9200347AF59E16D8896EEB8106D1B1_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossTax_3B9200347AF59E16D8896EEB8106D1B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax provision/(benefit) on other comprehensive income/(loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3B9200347AF59E16D8896EEB8106D1B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTax_3B9200347AF59E16D8896EEB8106D1B1" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossTax_3B9200347AF59E16D8896EEB8106D1B1" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D2946BA839CABB47725B6EEB8106FC81_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D2946BA839CABB47725B6EEB8106FC81" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive income/(loss) before allocation to noncontrolling interests</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D2946BA839CABB47725B6EEB8106FC81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D2946BA839CABB47725B6EEB8106FC81" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D2946BA839CABB47725B6EEB8106FC81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income before allocation to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Comprehensive income attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive income attributable to Pfizer Inc.</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation income (loss) attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative term of contract</link:label>
    <link:label id="lab_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152_label_en-US" xlink:label="lab_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Term of Contract</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:to="lab_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivatives in a net liability position</link:label>
    <link:label id="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7_label_en-US" xlink:label="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivative, Net Liability Position, Aggregate Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:to="lab_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:type="arc" />
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863_terseLabel_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collateral posted</link:label>
    <link:label id="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863_label_en-US" xlink:label="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collateral Already Posted, Aggregate Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:to="lab_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:type="arc" />
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026_terseLabel_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash collateral received</link:label>
    <link:label id="lab_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026_label_en-US" xlink:label="lab_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Securities Received as Collateral</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:to="lab_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid/deferred items - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB" xlink:to="lab_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible assets - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Goodwill and Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53" xlink:to="lab_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789" xlink:to="lab_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee benefits - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructurings and other charges - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and product liability reserves - Deferred tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:label="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF" xlink:to="lab_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss/credit carryforwards - Deferred tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:label="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8" xlink:to="lab_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD_terseLabel_en-US" xlink:label="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local tax adjustments - Deferred tax assets</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD_label_en-US" xlink:label="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, State and Local Taxes Adjustments</link:label>
    <link:label id="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD_documentation_en-US" xlink:label="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, State and Local Taxes Adjustments</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:label="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD" xlink:to="lab_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Equity Method Investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C" xlink:to="lab_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All other - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D" xlink:to="lab_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Subtotal - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A" xlink:to="lab_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred taxes - Deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F" xlink:to="lab_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA_terseLabel_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities</link:label>
    <link:label id="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA_label_en-US" xlink:label="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Components of Deferred Tax Liabilities [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="lab_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid/deferred items - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Inventories - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Inventory</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Intangible Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E" xlink:type="arc" />
    <link:label id="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3_negatedLabel_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Employee benefits - Deferred tax liabilities</link:label>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3_label_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:label id="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3_documentation_en-US" xlink:label="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:label="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3" xlink:to="lab_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Unremitted earnings - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Undistributed Foreign Earnings</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Investments - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Investment in Noncontrolled Affiliates</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">All other - Deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Other</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities, gross</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_040B52F4CE2842F8E6D02677F89F6180_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities_040B52F4CE2842F8E6D02677F89F6180" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_040B52F4CE2842F8E6D02677F89F6180" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities_040B52F4CE2842F8E6D02677F89F6180" xlink:to="lab_us-gaap_DeferredTaxLiabilities_040B52F4CE2842F8E6D02677F89F6180" xlink:type="arc" />
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04" xlink:type="arc" />
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption of New Accounting Standards in 2019</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91" xlink:type="arc" />
    <link:label id="lab_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimates and Assumptions</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F" xlink:to="lab_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C" xlink:to="lab_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34" xlink:type="arc" />
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign Currency Translation</link:label>
    <link:label id="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F_label_en-US" xlink:label="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Currency Transactions and Translations Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F" xlink:to="lab_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F" xlink:type="arc" />
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue and Collaborative Arrangements</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B_terseLabel_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade Accounts Receivable</link:label>
    <link:label id="lab_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B_label_en-US" xlink:label="lab_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Receivable [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B" xlink:to="lab_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of Sales and Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078" xlink:to="lab_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, Informational and Administrative Expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Impairment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Impairment [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333" xlink:type="arc" />
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878_terseLabel_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges and Certain Acquisition-Related Costs</link:label>
    <link:label id="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878_label_en-US" xlink:label="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878" xlink:to="lab_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows</link:label>
    <link:label id="lab_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245_label_en-US" xlink:label="lab_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Reporting of Derivative Activity [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245" xlink:to="lab_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments</link:label>
    <link:label id="lab_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907_label_en-US" xlink:label="lab_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907" xlink:to="lab_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907" xlink:type="arc" />
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC_terseLabel_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Derivative Financial Instruments</link:label>
    <link:label id="lab_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC_label_en-US" xlink:label="lab_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Derivatives, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC" xlink:to="lab_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC" xlink:type="arc" />
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Assets and Liabilities and Income Tax Contingencies</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension and Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Plans, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0" xlink:to="lab_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal and Environmental Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Payments</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements, and Research and Development and Collaborative Arrangements</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6_label_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</link:label>
    <link:label id="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6" xlink:to="lab_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Holdings [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:to="lab_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:type="arc" />
    <link:label id="lab_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8_terseLabel_en-US" xlink:label="lab_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cortexyme, Inc. [Member]</link:label>
    <link:label id="lab_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8_label_en-US" xlink:label="lab_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cortexyme, Inc. [Member]</link:label>
    <link:label id="lab_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8_documentation_en-US" xlink:label="lab_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cortexyme, Inc. [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CortexymeInc.Member" xlink:label="loc_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:to="lab_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:type="arc" />
    <link:label id="lab_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment Holdings [Line Items]</link:label>
    <link:label id="lab_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327_label_en-US" xlink:label="lab_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Holdings [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="lab_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:type="arc" />
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49_terseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gain on sale of property</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A_terseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on equity securities</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Unrealized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:type="arc" />
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1_terseLabel_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1_label_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:label id="lab_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1_documentation_en-US" xlink:label="lab_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Environmental Remediation Litigation [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:to="lab_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:type="arc" />
    <link:label id="lab_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00_terseLabel_en-US" xlink:label="lab_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Violation of Antitrust Laws [Member]</link:label>
    <link:label id="lab_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00_label_en-US" xlink:label="lab_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Violation of Antitrust Laws [Member]</link:label>
    <link:label id="lab_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00_documentation_en-US" xlink:label="lab_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Violation of Antitrust Laws [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViolationofAntitrustLawsMember" xlink:label="loc_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:to="lab_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:type="arc" />
    <link:label id="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9_terseLabel_en-US" xlink:label="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]</link:label>
    <link:label id="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9_label_en-US" xlink:label="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]</link:label>
    <link:label id="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9_documentation_en-US" xlink:label="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" xlink:label="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:to="lab_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350_terseLabel_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350_label_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:label id="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350_documentation_en-US" xlink:label="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:to="lab_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:type="arc" />
    <link:label id="lab_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C_terseLabel_en-US" xlink:label="lab_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:label id="lab_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C_label_en-US" xlink:label="lab_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:label id="lab_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C_documentation_en-US" xlink:label="lab_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inflectra [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflectraMember" xlink:label="loc_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:to="lab_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:type="arc" />
    <link:label id="lab_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109_terseLabel_en-US" xlink:label="lab_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109_label_en-US" xlink:label="lab_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Epi Pen [Member]</link:label>
    <link:label id="lab_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109_documentation_en-US" xlink:label="lab_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">EpiPen [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:to="lab_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:type="arc" />
    <link:label id="lab_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34_terseLabel_en-US" xlink:label="lab_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34_label_en-US" xlink:label="lab_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:label id="lab_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34_documentation_en-US" xlink:label="lab_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Docetaxel [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DocetaxelMember" xlink:label="loc_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:to="lab_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:type="arc" />
    <link:label id="lab_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3_terseLabel_en-US" xlink:label="lab_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Phenytoin Sodium Capsules [Member]</link:label>
    <link:label id="lab_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3_label_en-US" xlink:label="lab_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Phenytoin Sodium Capsules [Member]</link:label>
    <link:label id="lab_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3_documentation_en-US" xlink:label="lab_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Phenytoin Sodium Capsules [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PhenytoinSodiumCapsulesMember" xlink:label="loc_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:to="lab_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of patents allegedly infringed</link:label>
    <link:label id="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138_label_en-US" xlink:label="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Patents Allegedly Infringed, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:to="lab_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:type="arc" />
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of lawsuits</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB_label_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Lawsuits</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB_documentation_en-US" xlink:label="lab_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Lawsuits</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyNumberOfLawsuits" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:to="lab_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of claims dismissed</link:label>
    <link:label id="lab_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF_label_en-US" xlink:label="lab_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Claims Dismissed, Number</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:to="lab_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:type="arc" />
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of defendants other than main defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43_label_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:label id="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43_documentation_en-US" xlink:label="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Number Of Defendants Other Than Main Defendant</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:to="lab_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:type="arc" />
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D_terseLabel_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of class actions filed</link:label>
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D_label_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Class Actions Filed, Number</link:label>
    <link:label id="lab_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D_documentation_en-US" xlink:label="lab_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Loss Contingency, Class Actions Filed, Number</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyClassActionsFiledNumber" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:to="lab_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:type="arc" />
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D_terseLabel_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Feasibility study, number of lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D_label_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:label id="lab_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D_documentation_en-US" xlink:label="lab_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Feasibility Study, Number Of Lagoons</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:to="lab_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:type="arc" />
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Imposed fine</link:label>
    <link:label id="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2_label_en-US" xlink:label="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Estimate of Possible Loss</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:to="lab_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average grant-date fair value per stock option (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value on exercise</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:type="arc" />
    <link:label id="lab_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash received upon exercise</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD" xlink:to="lab_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax benefits realized related to exercise</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Exercise of Option, Tax Benefit</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total compensation cost related to nonvested stock options not yet recognized, pre-tax</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period over which stock option compensation cost is expected to be recognized (years)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment, Geographic and Other Revenue Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiGainLoss_563E611885B064BAB24616E82146E156_totalLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiGainLoss_563E611885B064BAB24616E82146E156" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net gains recognized during the period on investments in equity securities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_563E611885B064BAB24616E82146E156" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiGainLoss_563E611885B064BAB24616E82146E156" xlink:to="lab_us-gaap_EquitySecuritiesFvNiGainLoss_563E611885B064BAB24616E82146E156" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: Net gains recognized during the period on equity securities sold during the period</link:label>
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E_label_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Securities, FV-NI, Realized Gain (Loss)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E" xlink:to="lab_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F62A956FAB1CE9D02C6F16E821469FF6_verboseLabel_en-US" xlink:label="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F62A956FAB1CE9D02C6F16E821469FF6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net unrealized gains during the reporting period on equity securities still held at the reporting date</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F62A956FAB1CE9D02C6F16E821469FF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F62A956FAB1CE9D02C6F16E821469FF6" xlink:to="lab_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F62A956FAB1CE9D02C6F16E821469FF6" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Basis [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:to="lab_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:to="lab_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:type="arc" />
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97_terseLabel_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:label id="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97_label_en-US" xlink:label="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Portion at Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:to="lab_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:type="arc" />
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D_terseLabel_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Carrying Value [Member]</link:label>
    <link:label id="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D_label_en-US" xlink:label="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reported Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:to="lab_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49_terseLabel_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Estimated Fair Value [Member]</link:label>
    <link:label id="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49_label_en-US" xlink:label="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Estimate of Fair Value Measurement [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:to="lab_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt, excluding the current portion</link:label>
    <link:label id="lab_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1_label_en-US" xlink:label="lab_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-term Debt, Fair Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:to="lab_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B" xlink:type="arc" />
    <link:label id="lab_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B_terseLabel_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest costs capitalized</link:label>
    <link:label id="lab_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B_label_en-US" xlink:label="lab_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Costs Capitalized</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B" xlink:to="lab_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49" xlink:type="arc" />
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190_verboseLabel_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2024</link:label>
    <link:label id="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190_label_en-US" xlink:label="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Finite-Lived Intangible Assets, Amortization Expense, Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190" xlink:to="lab_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190" xlink:type="arc" />
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563_terseLabel_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension and Postretirement Benefit Plans and Defined Contribution Plans</link:label>
    <link:label id="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563_label_en-US" xlink:label="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension and Other Postretirement Benefits Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563" xlink:to="lab_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assumed long-term debt</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:to="lab_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="lab_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShortTermInvestments_E4F0B09F7C07D19E957201A60510C663_terseLabel_en-US" xlink:label="lab_us-gaap_ShortTermInvestments_E4F0B09F7C07D19E957201A60510C663" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Short-term investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_E4F0B09F7C07D19E957201A60510C663" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShortTermInvestments_E4F0B09F7C07D19E957201A60510C663" xlink:to="lab_us-gaap_ShortTermInvestments_E4F0B09F7C07D19E957201A60510C663" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts receivable, less allowance for doubtful accounts: 2019&#8212;$527; 2018&#8212;$541</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryNet_46852F74BA1350C33C5E01A60510EA7F_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet_46852F74BA1350C33C5E01A60510EA7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_46852F74BA1350C33C5E01A60510EA7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet_46852F74BA1350C33C5E01A60510EA7F" xlink:to="lab_us-gaap_InventoryNet_46852F74BA1350C33C5E01A60510EA7F" xlink:type="arc" />
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7_terseLabel_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current tax assets</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7_label_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:label id="lab_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7_documentation_en-US" xlink:label="lab_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Tax Assets, Current</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7" xlink:to="lab_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets held for sale</link:label>
    <link:label id="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331_label_en-US" xlink:label="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Group, Including Discontinued Operation, Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331" xlink:to="lab_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331" xlink:type="arc" />
    <link:label id="lab_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A" xlink:to="lab_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermInvestments_899B07847CB0B5357D8B01A605123302_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermInvestments_899B07847CB0B5357D8B01A605123302" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term investments</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_899B07847CB0B5357D8B01A605123302" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermInvestments_899B07847CB0B5357D8B01A605123302" xlink:to="lab_us-gaap_LongTermInvestments_899B07847CB0B5357D8B01A605123302" xlink:type="arc" />
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_E4B696C5C72A830DC7B401A605121DC2_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet_E4B696C5C72A830DC7B401A605121DC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, less accumulated depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E4B696C5C72A830DC7B401A605121DC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_E4B696C5C72A830DC7B401A605121DC2" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet_E4B696C5C72A830DC7B401A605121DC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_253638BD142C700BB05201A6051258A5_verboseLabel_en-US" xlink:label="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_253638BD142C700BB05201A6051258A5" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Identifiable intangible assets, less accumulated amortization</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_253638BD142C700BB05201A6051258A5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_253638BD142C700BB05201A6051258A5" xlink:to="lab_us-gaap_IntangibleAssetsNetExcludingGoodwill_253638BD142C700BB05201A6051258A5" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:type="arc" />
    <link:label id="lab_us-gaap_DebtCurrent_BC40D63929FD6DAB202601A605145AAA_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtCurrent_BC40D63929FD6DAB202601A605145AAA" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Short-term borrowings, including current portion of long-term debt: 2019&#8212;$1,462; 2018&#8212;$4,776</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_BC40D63929FD6DAB202601A605145AAA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtCurrent_BC40D63929FD6DAB202601A605145AAA" xlink:to="lab_us-gaap_DebtCurrent_BC40D63929FD6DAB202601A605145AAA" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trade accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53" xlink:to="lab_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53" xlink:type="arc" />
    <link:label id="lab_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4_terseLabel_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends payable</link:label>
    <link:label id="lab_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4_label_en-US" xlink:label="lab_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4" xlink:to="lab_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4" xlink:type="arc" />
    <link:label id="lab_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634_terseLabel_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes payable</link:label>
    <link:label id="lab_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634_label_en-US" xlink:label="lab_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Taxes Payable, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634" xlink:to="lab_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation and related items</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_B57CDB64BF7DD46826EB01A605153A69_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_B57CDB64BF7DD46826EB01A605153A69" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liabilities held for sale</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_B57CDB64BF7DD46826EB01A605153A69" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_B57CDB64BF7DD46826EB01A605153A69" xlink:to="lab_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_B57CDB64BF7DD46826EB01A605153A69" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C" xlink:to="lab_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_422F62FCBC2CCE38633801A60516E0DB_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent_422F62FCBC2CCE38633801A60516E0DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term debt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_422F62FCBC2CCE38633801A60516E0DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent_422F62FCBC2CCE38633801A60516E0DB" xlink:to="lab_us-gaap_LongTermDebtNoncurrent_422F62FCBC2CCE38633801A60516E0DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension benefit obligations, net</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Defined Benefit Pension Plan, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A" xlink:to="lab_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Postretirement benefit obligations, net</link:label>
    <link:label id="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4_label_en-US" xlink:label="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability, Other Postretirement Defined Benefit Plan, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4" xlink:to="lab_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Liabilities, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other taxes payable</link:label>
    <link:label id="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617_label_en-US" xlink:label="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liability for Uncertainty in Income Taxes, Noncurrent</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617" xlink:to="lab_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617" xlink:type="arc" />
    <link:label id="lab_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17_label_en-US" xlink:label="lab_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17" xlink:to="lab_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1" xlink:to="lab_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2019&#8212;431; 2018&#8212;478</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1" xlink:to="lab_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1" xlink:type="arc" />
    <link:label id="lab_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.05 par value; 12,000 shares authorized; issued: 2019&#8212;9,369; 2018&#8212;9,332</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11_label_en-US" xlink:label="lab_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11" xlink:to="lab_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11" xlink:type="arc" />
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138" xlink:to="lab_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares at cost: 2019&#8212;3,835; 2018&#8212;3,615</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E" xlink:to="lab_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquity_53EF0249BA6539701FE301A60519C80A_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity_53EF0249BA6539701FE301A60519C80A" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total Pfizer Inc. shareholders&#8217; equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_53EF0249BA6539701FE301A60519C80A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity_53EF0249BA6539701FE301A60519C80A" xlink:to="lab_us-gaap_StockholdersEquity_53EF0249BA6539701FE301A60519C80A" xlink:type="arc" />
    <link:label id="lab_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC_terseLabel_en-US" xlink:label="lab_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity attributable to noncontrolling interests</link:label>
    <link:label id="lab_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC_label_en-US" xlink:label="lab_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Attributable to Noncontrolling Interest</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC" xlink:to="lab_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4D619AF68A1C040724301A605194ABD_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4D619AF68A1C040724301A605194ABD" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4D619AF68A1C040724301A605194ABD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4D619AF68A1C040724301A605194ABD" xlink:to="lab_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4D619AF68A1C040724301A605194ABD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030" xlink:type="arc" />
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC_label_en-US" xlink:label="lab_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Treasury Stock [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="lab_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:to="lab_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450_terseLabel_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450_label_en-US" xlink:label="lab_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="lab_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:type="arc" />
    <link:label id="lab_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949_terseLabel_en-US" xlink:label="lab_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2015 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949_label_en-US" xlink:label="lab_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2015 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949_documentation_en-US" xlink:label="lab_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2015 Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2015StockPurchasePlanMember" xlink:label="loc_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:to="lab_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:type="arc" />
    <link:label id="lab_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458_terseLabel_en-US" xlink:label="lab_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2017 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458_label_en-US" xlink:label="lab_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2017 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458_documentation_en-US" xlink:label="lab_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2017 Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2017StockPurchasePlanMember" xlink:label="loc_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:to="lab_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:type="arc" />
    <link:label id="lab_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC_terseLabel_en-US" xlink:label="lab_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">December 2018 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC_label_en-US" xlink:label="lab_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">December 2018 Stock Purchase Plan [Member]</link:label>
    <link:label id="lab_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC_documentation_en-US" xlink:label="lab_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">December 2018 Stock Purchase Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2018StockPurchasePlanMember" xlink:label="loc_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:to="lab_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:type="arc" />
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A_terseLabel_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with Citibank [Member]</link:label>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A_label_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with Citibank [Member]</link:label>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A_documentation_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with Citibank [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareRepurchaseAgreementwithCitibankMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:to="lab_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:type="arc" />
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2_terseLabel_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with GS&amp;Co [Member]</link:label>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2_label_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with GS&amp;Co [Member]</link:label>
    <link:label id="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2_documentation_en-US" xlink:label="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Agreement with GS&amp;Co [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:to="lab_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:type="arc" />
    <link:label id="lab_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3_terseLabel_en-US" xlink:label="lab_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:label id="lab_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3_label_en-US" xlink:label="lab_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:label id="lab_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3_documentation_en-US" xlink:label="lab_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Open Market Purchases [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OpenMarketPurchasesMember" xlink:label="loc_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:to="lab_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:type="arc" />
    <link:label id="lab_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5_terseLabel_en-US" xlink:label="lab_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A, Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5_label_en-US" xlink:label="lab_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Series A, Convertible Preferred Stock [Member]</link:label>
    <link:label id="lab_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5_documentation_en-US" xlink:label="lab_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Series A, Convertible Preferred Stock [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeriesAConvertiblePreferredStockMember" xlink:label="loc_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:to="lab_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP) Name [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Plan [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:type="arc" />
    <link:label id="lab_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A_terseLabel_en-US" xlink:label="lab_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred ESOP Plan [Member]</link:label>
    <link:label id="lab_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A_label_en-US" xlink:label="lab_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred ESOP Plan [Member]</link:label>
    <link:label id="lab_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A_documentation_en-US" xlink:label="lab_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred ESOP Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredESOPPlanMember" xlink:label="loc_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:to="lab_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:type="arc" />
    <link:label id="lab_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247_terseLabel_en-US" xlink:label="lab_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred Employee Stock Ownership Plan [Member]</link:label>
    <link:label id="lab_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247_label_en-US" xlink:label="lab_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Employee Stock Ownership Plan [Member]</link:label>
    <link:label id="lab_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247_documentation_en-US" xlink:label="lab_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Employee Stock Ownership Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredEmployeeStockOwnershipPlanMember" xlink:label="loc_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:to="lab_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:type="arc" />
    <link:label id="lab_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5_terseLabel_en-US" xlink:label="lab_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common ESOP Plan [Member]</link:label>
    <link:label id="lab_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5_label_en-US" xlink:label="lab_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common ESOP Plan [Member]</link:label>
    <link:label id="lab_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5_documentation_en-US" xlink:label="lab_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Common ESOP Plan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CommonESOPPlanMember" xlink:label="loc_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:to="lab_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:type="arc" />
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9_terseLabel_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9_label_en-US" xlink:label="lab_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Class of Treasury Stock [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="lab_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of shares authorized in stock purchase plan, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Authorized Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:to="lab_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:type="arc" />
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E_terseLabel_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount of remaining shares authorized in stock purchase plan, value</link:label>
    <link:label id="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E_label_en-US" xlink:label="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Repurchase Program, Remaining Authorized Repurchase Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:to="lab_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated share repurchases, cash paid</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Settlement (Payment) or Receipt</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares repurchased, initial price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Initial Price Paid Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:type="arc" />
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D_terseLabel_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated share repurchase, percentage of agreement</link:label>
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D_label_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</link:label>
    <link:label id="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D_documentation_en-US" xlink:label="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:to="lab_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:type="arc" />
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated share repurchase, average price paid per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:type="arc" />
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615_terseLabel_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accelerated share repurchase, final average price paid (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615_label_en-US" xlink:label="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accelerated Share Repurchases, Final Price Paid Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:to="lab_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:type="arc" />
    <link:label id="lab_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2_terseLabel_en-US" xlink:label="lab_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares in Preferred ESOP</link:label>
    <link:label id="lab_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2_label_en-US" xlink:label="lab_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Held In Employee Trust, Shares</link:label>
    <link:label id="lab_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2_documentation_en-US" xlink:label="lab_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Held In Employee Trust, Shares</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredStockSharesHeldInEmployeeTrustShares" xlink:label="loc_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:to="lab_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares in ESOP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Shares in ESOP</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A convertible perpetual preferred stock, dividends rate</link:label>
    <link:label id="lab_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4_label_en-US" xlink:label="lab_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Dividend Rate, Percentage</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:to="lab_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A convertible perpetual preferred stock, per share stated value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:type="arc" />
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100_terseLabel_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Series A convertible perpetual preferred stock, common stock shares when converted (in shares)</link:label>
    <link:label id="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100_label_en-US" xlink:label="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Shares Issued upon Conversion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:to="lab_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:type="arc" />
    <link:label id="lab_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, redemption price per share (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F_label_en-US" xlink:label="lab_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Redemption Price Per Share</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:to="lab_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:type="arc" />
    <link:label id="lab_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013_terseLabel_en-US" xlink:label="lab_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of employee stock ownership plans</link:label>
    <link:label id="lab_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013_label_en-US" xlink:label="lab_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Employee Stock Ownership Plans</link:label>
    <link:label id="lab_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013_documentation_en-US" xlink:label="lab_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Employee Stock Ownership Plans</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NumberofEmployeeStockOwnershipPlans" xlink:label="loc_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:to="lab_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:type="arc" />
    <link:label id="lab_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1_terseLabel_en-US" xlink:label="lab_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Convertible preferred stock, number of shares convertible</link:label>
    <link:label id="lab_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1_label_en-US" xlink:label="lab_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Number of Shares Convertible</link:label>
    <link:label id="lab_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1_documentation_en-US" xlink:label="lab_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Convertible Preferred Stock, Number of Shares Convertible</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConvertiblePreferredStockNumberofSharesConvertible" xlink:label="loc_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:to="lab_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESOP compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock Ownership Plan (ESOP), Compensation Expense</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:to="lab_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension plans with an ABO in excess of plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ABO</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension plans with a PBO in excess of plan assets:</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:to="lab_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PBO</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:to="lab_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Global Equity Securities [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Global [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Global [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:to="lab_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commingled Funds Equity Securities [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:to="lab_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:type="arc" />
    <link:label id="lab_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate debt [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C" xlink:to="lab_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C" xlink:type="arc" />
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1_terseLabel_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government and Agency Obligations [Member]</link:label>
    <link:label id="lab_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1_label_en-US" xlink:label="lab_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Treasury Securities [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:to="lab_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:type="arc" />
    <link:label id="lab_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04_terseLabel_en-US" xlink:label="lab_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Income Commingled Funds [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04" xlink:to="lab_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04" xlink:type="arc" />
    <link:label id="lab_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9_terseLabel_en-US" xlink:label="lab_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:label id="lab_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9_label_en-US" xlink:label="lab_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Partnership Interest [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_PartnershipInterestMember" xlink:label="loc_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:to="lab_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:type="arc" />
    <link:label id="lab_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266_terseLabel_en-US" xlink:label="lab_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Commingled Funds [Member]</link:label>
    <link:label id="lab_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266_label_en-US" xlink:label="lab_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Commingled Funds [Member]</link:label>
    <link:label id="lab_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266_documentation_en-US" xlink:label="lab_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Commingled Funds [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherCommingledFundsMember" xlink:label="loc_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:to="lab_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:type="arc" />
    <link:label id="lab_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9" xlink:to="lab_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A_verboseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Fair value of plan assets</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A" xlink:to="lab_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets Measured at NAV</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value Of Plan Assets</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Alternative Investments, Fair Value Of Plan Assets</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" xlink:label="loc_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:to="lab_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customers by Products and Services [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:to="lab_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14_label_en-US" xlink:label="lab_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:to="lab_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F_terseLabel_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:label id="lab_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F_label_en-US" xlink:label="lab_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reporting Unit [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="lab_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:type="arc" />
    <link:label id="lab_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40_terseLabel_en-US" xlink:label="lab_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40_label_en-US" xlink:label="lab_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40_documentation_en-US" xlink:label="lab_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Internal Medicine [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:to="lab_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:type="arc" />
    <link:label id="lab_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B_terseLabel_en-US" xlink:label="lab_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B_label_en-US" xlink:label="lab_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:label id="lab_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B_documentation_en-US" xlink:label="lab_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oncology [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:to="lab_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:type="arc" />
    <link:label id="lab_pfe_HospitalMember_857A01384E293DD117D2689872885130_terseLabel_en-US" xlink:label="lab_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Hospital [Member]</link:label>
    <link:label id="lab_pfe_HospitalMember_857A01384E293DD117D2689872885130_label_en-US" xlink:label="lab_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Hospital [Member]</link:label>
    <link:label id="lab_pfe_HospitalMember_857A01384E293DD117D2689872885130_documentation_en-US" xlink:label="lab_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Hospital [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospitalMember" xlink:label="loc_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:to="lab_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:type="arc" />
    <link:label id="lab_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1_terseLabel_en-US" xlink:label="lab_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1_label_en-US" xlink:label="lab_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:label id="lab_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1_documentation_en-US" xlink:label="lab_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vaccines [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:to="lab_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:type="arc" />
    <link:label id="lab_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C_terseLabel_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C_label_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:label id="lab_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C_documentation_en-US" xlink:label="lab_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inflammation and Immunology [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:to="lab_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:type="arc" />
    <link:label id="lab_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9_terseLabel_en-US" xlink:label="lab_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9_label_en-US" xlink:label="lab_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:label id="lab_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9_documentation_en-US" xlink:label="lab_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Rare Disease [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:to="lab_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:type="arc" />
    <link:label id="lab_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E_terseLabel_en-US" xlink:label="lab_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upjohn Reporting Unit [Member]</link:label>
    <link:label id="lab_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E_label_en-US" xlink:label="lab_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upjohn Reporting Unit [Member]</link:label>
    <link:label id="lab_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E_documentation_en-US" xlink:label="lab_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upjohn Reporting Unit [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnReportingUnitMember" xlink:label="loc_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:to="lab_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:type="arc" />
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6_terseLabel_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Reporting Unit [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6_label_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Reporting Unit [Member]</link:label>
    <link:label id="lab_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6_documentation_en-US" xlink:label="lab_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Consumer Healthcare Reporting Unit [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareReportingUnitMember" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:to="lab_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:type="arc" />
    <link:label id="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795_terseLabel_en-US" xlink:label="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Biopharma, Upjohn And Consumer Healthcare Segments [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795_label_en-US" xlink:label="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Biopharma, Upjohn And Consumer Healthcare Segments [Member]</link:label>
    <link:label id="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795_documentation_en-US" xlink:label="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Biopharma, Upjohn And Consumer Healthcare Segments [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" xlink:label="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:to="lab_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:type="arc" />
    <link:label id="lab_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3_terseLabel_en-US" xlink:label="lab_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Chantix Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3_label_en-US" xlink:label="lab_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Chantix Champix [Member]</link:label>
    <link:label id="lab_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3_documentation_en-US" xlink:label="lab_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Chantix / Champix [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:to="lab_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:type="arc" />
    <link:label id="lab_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0_terseLabel_en-US" xlink:label="lab_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Premarin Family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0_label_en-US" xlink:label="lab_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Premarin Family [Member]</link:label>
    <link:label id="lab_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0_documentation_en-US" xlink:label="lab_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Premarin family [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:to="lab_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:type="arc" />
    <link:label id="lab_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5_terseLabel_en-US" xlink:label="lab_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5_label_en-US" xlink:label="lab_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:label id="lab_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5_documentation_en-US" xlink:label="lab_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">BMP2 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:to="lab_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:type="arc" />
    <link:label id="lab_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28_terseLabel_en-US" xlink:label="lab_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28_label_en-US" xlink:label="lab_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:label id="lab_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28_documentation_en-US" xlink:label="lab_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Toviaz [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:to="lab_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91_label_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91_documentation_en-US" xlink:label="lab_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Internal Medicine [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:to="lab_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:type="arc" />
    <link:label id="lab_pfe_IbranceMember_1F4C15D420E244914B016898728C5617_terseLabel_en-US" xlink:label="lab_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_1F4C15D420E244914B016898728C5617_label_en-US" xlink:label="lab_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:label id="lab_pfe_IbranceMember_1F4C15D420E244914B016898728C5617_documentation_en-US" xlink:label="lab_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Ibrance [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:to="lab_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:type="arc" />
    <link:label id="lab_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE_terseLabel_en-US" xlink:label="lab_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE_label_en-US" xlink:label="lab_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:label id="lab_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE_documentation_en-US" xlink:label="lab_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sutent [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:to="lab_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:type="arc" />
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F_terseLabel_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F_label_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:label id="lab_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F_documentation_en-US" xlink:label="lab_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xtandi Alliance Revenues [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XtandiAllianceRevenuesMember" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:to="lab_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:type="arc" />
    <link:label id="lab_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6_terseLabel_en-US" xlink:label="lab_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6_label_en-US" xlink:label="lab_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:label id="lab_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6_documentation_en-US" xlink:label="lab_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xalkori [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:to="lab_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:type="arc" />
    <link:label id="lab_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80_terseLabel_en-US" xlink:label="lab_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80_label_en-US" xlink:label="lab_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:label id="lab_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80_documentation_en-US" xlink:label="lab_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inlyta [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:to="lab_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:type="arc" />
    <link:label id="lab_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5_terseLabel_en-US" xlink:label="lab_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5_label_en-US" xlink:label="lab_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:label id="lab_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5_documentation_en-US" xlink:label="lab_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Retacrit [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RetacritMember" xlink:label="loc_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:to="lab_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:type="arc" />
    <link:label id="lab_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956_terseLabel_en-US" xlink:label="lab_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956_label_en-US" xlink:label="lab_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:label id="lab_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956_documentation_en-US" xlink:label="lab_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Mektovi [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MektoviMember" xlink:label="loc_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:to="lab_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:type="arc" />
    <link:label id="lab_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C_terseLabel_en-US" xlink:label="lab_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C_label_en-US" xlink:label="lab_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:label id="lab_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C_documentation_en-US" xlink:label="lab_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Braftovi [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BraftoviMember" xlink:label="loc_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:to="lab_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:type="arc" />
    <link:label id="lab_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897_terseLabel_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897_label_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:label id="lab_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897_documentation_en-US" xlink:label="lab_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Oncology Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:to="lab_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:type="arc" />
    <link:label id="lab_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F_terseLabel_en-US" xlink:label="lab_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F_label_en-US" xlink:label="lab_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:label id="lab_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F_documentation_en-US" xlink:label="lab_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sulperazon [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:to="lab_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:type="arc" />
    <link:label id="lab_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127_terseLabel_en-US" xlink:label="lab_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127_label_en-US" xlink:label="lab_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:label id="lab_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127_documentation_en-US" xlink:label="lab_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Medrol [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:to="lab_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:type="arc" />
    <link:label id="lab_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6_terseLabel_en-US" xlink:label="lab_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6_label_en-US" xlink:label="lab_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:label id="lab_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6_documentation_en-US" xlink:label="lab_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vfend [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:to="lab_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:type="arc" />
    <link:label id="lab_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F_terseLabel_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zithromax Zmax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F_label_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zithromax Zmax [Member]</link:label>
    <link:label id="lab_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F_documentation_en-US" xlink:label="lab_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zithromax / Zmax [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:to="lab_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:type="arc" />
    <link:label id="lab_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3_terseLabel_en-US" xlink:label="lab_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3_label_en-US" xlink:label="lab_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:label id="lab_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3_documentation_en-US" xlink:label="lab_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fragmin [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:to="lab_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:type="arc" />
    <link:label id="lab_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D_terseLabel_en-US" xlink:label="lab_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D_label_en-US" xlink:label="lab_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:label id="lab_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D_documentation_en-US" xlink:label="lab_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zyvox [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:to="lab_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:type="arc" />
    <link:label id="lab_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC_terseLabel_en-US" xlink:label="lab_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zosyn / Tazocin [Member]</link:label>
    <link:label id="lab_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC_label_en-US" xlink:label="lab_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zosyn / Tazocin [Member]</link:label>
    <link:label id="lab_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC_documentation_en-US" xlink:label="lab_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zosyn / Tazocin [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZosynTazocinMember" xlink:label="loc_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:to="lab_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:type="arc" />
    <link:label id="lab_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205_terseLabel_en-US" xlink:label="lab_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tygacil [Member]</link:label>
    <link:label id="lab_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205_label_en-US" xlink:label="lab_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tygacil [Member]</link:label>
    <link:label id="lab_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205_documentation_en-US" xlink:label="lab_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tygacil [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TygacilMember" xlink:label="loc_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:to="lab_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:type="arc" />
    <link:label id="lab_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627_terseLabel_en-US" xlink:label="lab_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Diflucan [Member]</link:label>
    <link:label id="lab_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627_label_en-US" xlink:label="lab_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Diflucan [Member]</link:label>
    <link:label id="lab_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627_documentation_en-US" xlink:label="lab_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Diflucan [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DiflucanMember" xlink:label="loc_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:to="lab_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:type="arc" />
    <link:label id="lab_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F_terseLabel_en-US" xlink:label="lab_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Panzyga [Member]</link:label>
    <link:label id="lab_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F_label_en-US" xlink:label="lab_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Panzyga [Member]</link:label>
    <link:label id="lab_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F_documentation_en-US" xlink:label="lab_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Panzyga [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PanzygaMember" xlink:label="loc_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:to="lab_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:type="arc" />
    <link:label id="lab_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7_terseLabel_en-US" xlink:label="lab_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7_label_en-US" xlink:label="lab_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:label id="lab_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7_documentation_en-US" xlink:label="lab_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer CentreOne [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerCentreOneMember" xlink:label="loc_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:to="lab_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:type="arc" />
    <link:label id="lab_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB_terseLabel_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB_label_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:label id="lab_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB_documentation_en-US" xlink:label="lab_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Anti-infectives [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherAntiinfectivesMember" xlink:label="loc_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:to="lab_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:type="arc" />
    <link:label id="lab_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439_terseLabel_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:label id="lab_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439_label_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:label id="lab_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439_documentation_en-US" xlink:label="lab_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Hospital Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherHospitalProductsMember" xlink:label="loc_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:to="lab_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:type="arc" />
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C_terseLabel_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prevenar 13/Prevnar 13 [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C_label_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prevnar Prevenar Family [Member]</link:label>
    <link:label id="lab_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C_documentation_en-US" xlink:label="lab_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Prevnar/Prevenar Family 13 [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:to="lab_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:type="arc" />
    <link:label id="lab_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C_terseLabel_en-US" xlink:label="lab_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C_label_en-US" xlink:label="lab_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:label id="lab_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C_documentation_en-US" xlink:label="lab_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Nimenrix [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NimenrixMember" xlink:label="loc_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:to="lab_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:type="arc" />
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2_terseLabel_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2_label_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:label id="lab_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2_documentation_en-US" xlink:label="lab_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">FSME/IMMUN-TicoVac [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FSMEIMMUNTicoVacMember" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:to="lab_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:type="arc" />
    <link:label id="lab_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78_terseLabel_en-US" xlink:label="lab_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trumenba [Member]</link:label>
    <link:label id="lab_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78_label_en-US" xlink:label="lab_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trumenba [Member]</link:label>
    <link:label id="lab_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78_documentation_en-US" xlink:label="lab_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Trumenba [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TrumenbaMember" xlink:label="loc_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:to="lab_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:type="arc" />
    <link:label id="lab_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9_terseLabel_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9_label_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:label id="lab_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9_documentation_en-US" xlink:label="lab_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Vaccines Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:to="lab_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:type="arc" />
    <link:label id="lab_pfe_EnbrelMember_7278A48B144320F6B03A689872900121_terseLabel_en-US" xlink:label="lab_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_7278A48B144320F6B03A689872900121_label_en-US" xlink:label="lab_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:label id="lab_pfe_EnbrelMember_7278A48B144320F6B03A689872900121_documentation_en-US" xlink:label="lab_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Enbrel [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:to="lab_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:type="arc" />
    <link:label id="lab_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715_terseLabel_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715_label_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:label id="lab_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715_documentation_en-US" xlink:label="lab_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inflectra/Remsima [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:to="lab_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510_terseLabel_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510_label_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510_documentation_en-US" xlink:label="lab_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Inflammation and Immunology Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:to="lab_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:type="arc" />
    <link:label id="lab_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19_terseLabel_en-US" xlink:label="lab_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19_label_en-US" xlink:label="lab_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:label id="lab_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19_documentation_en-US" xlink:label="lab_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genotropin [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:to="lab_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:type="arc" />
    <link:label id="lab_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D_terseLabel_en-US" xlink:label="lab_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">BeneFIX [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D_label_en-US" xlink:label="lab_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:label id="lab_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D_documentation_en-US" xlink:label="lab_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bene F I X [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:to="lab_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:type="arc" />
    <link:label id="lab_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317_terseLabel_en-US" xlink:label="lab_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vyndaqel/Vyndamax [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317_label_en-US" xlink:label="lab_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:label id="lab_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317_documentation_en-US" xlink:label="lab_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vyndaqel [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VyndaqelMember" xlink:label="loc_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:to="lab_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:type="arc" />
    <link:label id="lab_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0_terseLabel_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ReFacto AF Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0_label_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:label id="lab_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0_documentation_en-US" xlink:label="lab_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Re Facto AF Xyntha [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:to="lab_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:type="arc" />
    <link:label id="lab_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E_terseLabel_en-US" xlink:label="lab_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E_label_en-US" xlink:label="lab_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:label id="lab_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E_documentation_en-US" xlink:label="lab_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Somavert [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:to="lab_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5_terseLabel_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5_label_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5_documentation_en-US" xlink:label="lab_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Rare Disease Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:to="lab_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:type="arc" />
    <link:label id="lab_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F_terseLabel_en-US" xlink:label="lab_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:label id="lab_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F_label_en-US" xlink:label="lab_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:label id="lab_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F_documentation_en-US" xlink:label="lab_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lyrica [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:to="lab_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:type="arc" />
    <link:label id="lab_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA_terseLabel_en-US" xlink:label="lab_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:label id="lab_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA_label_en-US" xlink:label="lab_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:label id="lab_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA_documentation_en-US" xlink:label="lab_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Lipitor [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:to="lab_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:type="arc" />
    <link:label id="lab_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC_terseLabel_en-US" xlink:label="lab_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:label id="lab_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC_label_en-US" xlink:label="lab_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:label id="lab_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC_documentation_en-US" xlink:label="lab_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Norvasc [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:to="lab_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:type="arc" />
    <link:label id="lab_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861_terseLabel_en-US" xlink:label="lab_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:label id="lab_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861_label_en-US" xlink:label="lab_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:label id="lab_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861_documentation_en-US" xlink:label="lab_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Viagra [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:to="lab_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:type="arc" />
    <link:label id="lab_pfe_EffexorMember_F512674F48D8DD01778868987293A31B_terseLabel_en-US" xlink:label="lab_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:label id="lab_pfe_EffexorMember_F512674F48D8DD01778868987293A31B_label_en-US" xlink:label="lab_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:label id="lab_pfe_EffexorMember_F512674F48D8DD01778868987293A31B_documentation_en-US" xlink:label="lab_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effexor [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:to="lab_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:type="arc" />
    <link:label id="lab_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD_terseLabel_en-US" xlink:label="lab_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:label id="lab_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD_label_en-US" xlink:label="lab_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:label id="lab_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD_documentation_en-US" xlink:label="lab_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Zoloft [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:to="lab_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:type="arc" />
    <link:label id="lab_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F_terseLabel_en-US" xlink:label="lab_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xalatan Xalacom [Member]</link:label>
    <link:label id="lab_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F_label_en-US" xlink:label="lab_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xalatan Xalacom [Member]</link:label>
    <link:label id="lab_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F_documentation_en-US" xlink:label="lab_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xalatan / Xalacom [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:to="lab_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:type="arc" />
    <link:label id="lab_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1_terseLabel_en-US" xlink:label="lab_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Xanax [Member]</link:label>
    <link:label id="lab_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1_label_en-US" xlink:label="lab_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Xanax [Member]</link:label>
    <link:label id="lab_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1_documentation_en-US" xlink:label="lab_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Xanax [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XanaxMember" xlink:label="loc_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:to="lab_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:type="arc" />
    <link:label id="lab_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C_terseLabel_en-US" xlink:label="lab_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revatio [Member]</link:label>
    <link:label id="lab_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C_label_en-US" xlink:label="lab_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revatio [Member]</link:label>
    <link:label id="lab_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C_documentation_en-US" xlink:label="lab_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revatio [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RevatioMember" xlink:label="loc_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:to="lab_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:type="arc" />
    <link:label id="lab_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1_terseLabel_en-US" xlink:label="lab_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Other Upjohn Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1_label_en-US" xlink:label="lab_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Other Upjohn Products [Member]</link:label>
    <link:label id="lab_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1_documentation_en-US" xlink:label="lab_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">All Other Upjohn Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherUpjohnProductsMember" xlink:label="loc_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:to="lab_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:type="arc" />
    <link:label id="lab_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8_terseLabel_en-US" xlink:label="lab_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">HIS Products [Member]</link:label>
    <link:label id="lab_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8_label_en-US" xlink:label="lab_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">HIS Products [Member]</link:label>
    <link:label id="lab_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8_documentation_en-US" xlink:label="lab_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">HIS Products [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISProductsMember" xlink:label="loc_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:to="lab_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:type="arc" />
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F_terseLabel_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Alliance Biopharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F_label_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F_documentation_en-US" xlink:label="lab_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Alliance Biopharmaceuticals [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalAllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:to="lab_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:type="arc" />
    <link:label id="lab_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5_terseLabel_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5_label_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:label id="lab_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5_documentation_en-US" xlink:label="lab_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Biosimilars [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalBiosimilarsMember" xlink:label="loc_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:to="lab_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:type="arc" />
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33_terseLabel_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33_label_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:label id="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33_documentation_en-US" xlink:label="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Total Sterile Injectable Pharmaceuticals [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:to="lab_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:type="arc" />
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96_terseLabel_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:label id="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96_label_en-US" xlink:label="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from External Customer [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:to="lab_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642" xlink:to="lab_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amounts in Accumulated Other Comprehensive Income/(Loss) Expected to be Amortized into 2014 Net Periodic Benefit Costs</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED" xlink:to="lab_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Assumptions [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F" xlink:to="lab_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Health Care Cost Trend Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851_label_en-US" xlink:label="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851" xlink:to="lab_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA" xlink:to="lab_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330_terseLabel_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans</link:label>
    <link:label id="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330_label_en-US" xlink:label="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330" xlink:to="lab_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Amounts Recognized in Balance Sheet [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4" xlink:to="lab_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)</link:label>
    <link:label id="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789_label_en-US" xlink:label="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789" xlink:to="lab_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643_label_en-US" xlink:label="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643" xlink:to="lab_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583" xlink:to="lab_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Allocation of Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B" xlink:to="lab_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F" xlink:to="lab_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Expected Future Cash Flow Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0_label_en-US" xlink:label="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Expected Benefit Payments [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0" xlink:to="lab_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0" xlink:type="arc" />
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Identifiable Intangible Assets and Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1" xlink:type="arc" />
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Costs [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Restructuring Reserve by Type of Cost [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783" xlink:to="lab_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:label id="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97_label_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:to="lab_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net pension benefit obligation</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" xlink:label="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:to="lab_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pretax settlement gain</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" xlink:label="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:to="lab_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:type="arc" />
    <link:label id="lab_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686_terseLabel_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of pension plans frozen</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686_label_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Number of Pension Plans Frozen</link:label>
    <link:label id="lab_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686_documentation_en-US" xlink:label="lab_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Benefit Plan, Number of Pension Plans Frozen</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanNumberofPensionPlansFrozen" xlink:label="loc_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:to="lab_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:to="lab_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:type="arc" />
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24_label_en-US" xlink:label="lab_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease Arrangement, Type [Domain]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:to="lab_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:type="arc" />
    <link:label id="lab_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD_terseLabel_en-US" xlink:label="lab_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office Building In New York City [Member]</link:label>
    <link:label id="lab_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD_label_en-US" xlink:label="lab_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Building In New York City [Member]</link:label>
    <link:label id="lab_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD_documentation_en-US" xlink:label="lab_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Office Building In New York City [Member]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OfficeBuildingInNewYorkCityMember" xlink:label="loc_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:to="lab_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="lab_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Next one year</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1-2 years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2-3 years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">3-4 years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">4-5 years</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total undiscounted lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Payments, Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less: Imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Present value of minimum lease payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:to="lab_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Less: Current portion</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Noncurrent portion</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB" xlink:type="arc" />
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727_verboseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Term of corporate headquarters lease agreement</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future minimum commitment for corporate headquarters lease</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating leases, rent expense, net</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Rent Expense, Net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:to="lab_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2019</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments Due, Next Twelve Months</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2020</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Two Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2021</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Three Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2022</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Four Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due in Five Years</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">After 2023</link:label>
    <link:label id="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E_label_en-US" xlink:label="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Leases, Future Minimum Payments, Due Thereafter</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:to="lab_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA" xlink:to="lab_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4_label_en-US" xlink:label="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Indefinite-Lived Intangible Assets [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4" xlink:to="lab_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Expected Amortization Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81_label_en-US" xlink:label="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81" xlink:to="lab_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81" xlink:type="arc" />
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill</link:label>
    <link:label id="lab_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C_label_en-US" xlink:label="lab_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Goodwill [Table Text Block]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C" xlink:to="lab_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C" xlink:type="arc" />
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of shares vested</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7" xlink:type="arc" />
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average period over which RSU cost is expected to be recognized (years)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58" xlink:type="arc" />
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_1C8F35F8771F4976FD2516E82227AC52_negatedPeriodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_1C8F35F8771F4976FD2516E82227AC52" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="resource" xml:lang="en-US">Balance, beginning</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1C8F35F8771F4976FD2516E82227AC52" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_1C8F35F8771F4976FD2516E82227AC52" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_1C8F35F8771F4976FD2516E82227AC52" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Acquisitions</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Acquisition</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increases based on tax positions taken during a prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decreases based on tax positions taken during a prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decreases based on settlements for a prior period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F_negatedLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Increases based on tax positions taken during the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F" xlink:type="arc" />
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A_negatedLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Impact of foreign exchange</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" xlink:label="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A" xlink:to="lab_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A" xlink:type="arc" />
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459_negatedLabel_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other, net</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459_label_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease), Other</link:label>
    <link:label id="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459_documentation_en-US" xlink:label="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease), Other</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" xlink:label="loc_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459" xlink:to="lab_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459" xlink:type="arc" />
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_6B57701EB10A586FA86E16E822291502_negatedPeriodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits_6B57701EB10A586FA86E16E822291502" xlink:role="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="resource" xml:lang="en-US">Balance, ending</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6B57701EB10A586FA86E16E822291502" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits_6B57701EB10A586FA86E16E822291502" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits_6B57701EB10A586FA86E16E822291502" xlink:type="arc" />
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, Informational and Administrative Expenses [Member]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges:</link:label>
    <link:label id="lab_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562_label_en-US" xlink:label="lab_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges [Abstract]</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="lab_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:type="arc" />
    <link:label id="lab_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD_terseLabel_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee terminations</link:label>
    <link:label id="lab_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD_label_en-US" xlink:label="lab_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Severance Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:to="lab_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB_terseLabel_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset impairments</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB_label_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:label id="lab_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB_documentation_en-US" xlink:label="lab_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring, Asset Impairment Charges</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:to="lab_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exit costs</link:label>
    <link:label id="lab_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD_label_en-US" xlink:label="lab_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Exit Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:to="lab_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B_totalLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total restructuring charges/(credits)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B" xlink:to="lab_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B" xlink:type="arc" />
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A_terseLabel_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Transaction costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A_label_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Acquisition Related Costs, Transaction Costs</link:label>
    <link:label id="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A_documentation_en-US" xlink:label="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:to="lab_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:type="arc" />
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Integration costs</link:label>
    <link:label id="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3_label_en-US" xlink:label="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Combination, Integration Related Costs</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:to="lab_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges and certain acquisition-related costs</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7" xlink:to="lab_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7" xlink:type="arc" />
    <link:label id="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net periodic benefit costs recorded in Other (income)/deductions&#8211;&#8211;net</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05" xlink:to="lab_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05" xlink:type="arc" />
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</link:label>
    <link:label id="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D_label_en-US" xlink:label="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Accelerated Depreciation</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:to="lab_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:type="arc" />
    <link:label id="lab_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implementation costs recorded in our consolidated statements of income as follows:</link:label>
    <link:label id="lab_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820_label_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implementation Cost [Abstract]</link:label>
    <link:label id="lab_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820_documentation_en-US" xlink:label="lab_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Implementation Cost [Abstract]</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:to="lab_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:type="arc" />
    <link:label id="lab_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640_terseLabel_en-US" xlink:label="lab_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Implementation costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640_label_en-US" xlink:label="lab_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Implementation Costs</link:label>
    <link:label id="lab_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640_documentation_en-US" xlink:label="lab_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:to="lab_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:type="arc" />
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F_totalLabel_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total costs associated with acquisitions and cost-reduction/productivity initiatives</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F_label_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:label id="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F_documentation_en-US" xlink:label="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Acquisition Related Costs and Implementation Costs</link:label>
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:to="lab_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:type="arc" />
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18" xlink:type="arc" />
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_8351E2F1FC0D375A0DABCE2792B6DF6E_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent_8351E2F1FC0D375A0DABCE2792B6DF6E" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease liabilities (short-term)</link:label>
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8351E2F1FC0D375A0DABCE2792B6DF6E" xlink:type="locator" />
    <link:labelArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent_8351E2F1FC0D375A0DABCE2792B6DF6E" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent_8351E2F1FC0D375A0DABCE2792B6DF6E" xlink:type="arc" />
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>17
<FILENAME>pfe-20191231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII"?>
<!--XBRL Document Created with Wdesk from Workiva-->
<!-- -->
<link:linkbase xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:href="pfe-20191231.xsd#AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:href="pfe-20191231.xsd#AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:href="pfe-20191231.xsd#BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:href="pfe-20191231.xsd#ConsolidatedBalanceSheets" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfEquity" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfEquity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfEquityParenthetical" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ConsolidatedStatementsOfIncome" xlink:href="pfe-20191231.xsd#ConsolidatedStatementsOfIncome" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:href="pfe-20191231.xsd#ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/CoverPage" xlink:href="pfe-20191231.xsd#CoverPage" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:href="pfe-20191231.xsd#EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Equity" xlink:href="pfe-20191231.xsd#Equity" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:href="pfe-20191231.xsd#EquityNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails" xlink:href="pfe-20191231.xsd#EquitySummaryOfCommonStockPurchasesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/EquityTables" xlink:href="pfe-20191231.xsd#EquityTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstruments" xlink:href="pfe-20191231.xsd#FinancialInstruments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsCreditRiskDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:href="pfe-20191231.xsd#FinancialInstrumentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:href="pfe-20191231.xsd#FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwill" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:href="pfe-20191231.xsd#IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Insurance" xlink:href="pfe-20191231.xsd#Insurance" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/Inventories" xlink:href="pfe-20191231.xsd#Inventories" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesDetails" xlink:href="pfe-20191231.xsd#InventoriesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/InventoriesTables" xlink:href="pfe-20191231.xsd#InventoriesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNet" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:href="pfe-20191231.xsd#OtherIncomeDeductionsNetTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:href="pfe-20191231.xsd#PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipment" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipment" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipmentDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/PropertyPlantAndEquipmentTables" xlink:href="pfe-20191231.xsd#PropertyPlantAndEquipmentTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:href="pfe-20191231.xsd#RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformation" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:href="pfe-20191231.xsd#SegmentGeographicAndOtherRevenueInformationTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPayments" xlink:href="pfe-20191231.xsd#ShareBasedPayments" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsNarrativeDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsStockOptionActivityDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsStockOptionNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTables" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:href="pfe-20191231.xsd#ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMatters" xlink:href="pfe-20191231.xsd#TaxMatters" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:href="pfe-20191231.xsd#TaxMattersDeferredTaxesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:href="pfe-20191231.xsd#TaxMattersDeferredTaxesFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:href="pfe-20191231.xsd#TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:href="pfe-20191231.xsd#TaxMattersNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails" xlink:href="pfe-20191231.xsd#TaxMattersProvisionForTaxesOnIncomeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:href="pfe-20191231.xsd#TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:href="pfe-20191231.xsd#TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:href="pfe-20191231.xsd#TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTables" xlink:href="pfe-20191231.xsd#TaxMattersTables" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:href="pfe-20191231.xsd#TaxMattersTaxRateReconciliationDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:href="pfe-20191231.xsd#TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_D2DCDAF92A8FFF6BBAED8020780B4F15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_D2DCDAF92A8FFF6BBAED8020780B4F15" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_FAF86E766C45035F80588020780BF52B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_EEF548DFE9840BF81F00E395F3BF0BFB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_EEF548DFE9840BF81F00E395F3BF0BFB" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8A712C1C70404B1D0FA0E395F3C02CA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8A712C1C70404B1D0FA0E395F3C02CA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_8A712C1C70404B1D0FA0E395F3C02CA8" xlink:to="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_218FACFEF397D8600326E395F3C00DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201802Member_D9EFE580257C051BF6DEE395F3C1EB94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_B5D4B311C15EF0D04B80E395F3C0A479" xlink:to="loc_us-gaap_AccountingStandardsUpdate201802Member_D9EFE580257C051BF6DEE395F3C1EB94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_679C22E8120D084AC747E395F3C1A360" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_679C22E8120D084AC747E395F3C1A360" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_74BF0F20683F738035D6E395F3C1A553" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_679C22E8120D084AC747E395F3C1A360" xlink:to="loc_us-gaap_EquityComponentDomain_74BF0F20683F738035D6E395F3C1A553" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_74BF0F20683F738035D6E395F3C1A553" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedTranslationAdjustmentMember" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_6F1D24928350127A3177E395F3C260E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27BE007A125556AFB617E395F3C2D487" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_27BE007A125556AFB617E395F3C2D487" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_132020EC86BA7F3E8CAAE395F3C248FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_21B0C2BD391EE047D8BEE395F3C24F5A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_21B0C2BD391EE047D8BEE395F3C24F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_E6A0911CA0E216FFEB2AE395F3C207CA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_DDEDBCB1257BE152C872E395F3C13467" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_E6A0911CA0E216FFEB2AE395F3C207CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_EC2AF5A50C05615296D7E395F3C25184" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_7890F33F94FF96FA5EACE395F3BFCFE9" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_EC2AF5A50C05615296D7E395F3C25184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_EC2AF5A50C05615296D7E395F3C25184" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:to="loc_us-gaap_StockholdersEquity_094898AC110FEEAECA1AE395F3C357C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_A897102D0E780E830E57E395F3C392B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption" xlink:label="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:to="loc_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption_2A9A9F6B23B2E7EC809DE395F3C3D9A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_BE31C536C04DD7535771E395F3C3BB08" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_FCC7F6405ABE083D0321E395F3C3C37D" xlink:to="loc_us-gaap_StockholdersEquity_BE31C536C04DD7535771E395F3C3BB08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_E555B0341851AEED4C8116E821DEC982" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_22A355DB1D98979012C3171959141563" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_E555B0341851AEED4C8116E821DEC982" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_22A355DB1D98979012C3171959141563" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_367C08F7B262473FE53217195B31FD54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_22A355DB1D98979012C3171959141563" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_367C08F7B262473FE53217195B31FD54" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_E4E192296F41D6D700A417195B32A319" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_367C08F7B262473FE53217195B31FD54" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_E4E192296F41D6D700A417195B32A319" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_E8E5FFEC04BD4CAAA26D17195B9F10FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_E4E192296F41D6D700A417195B32A319" xlink:to="loc_pfe_GSKConsumerHealthcareMember_E8E5FFEC04BD4CAAA26D17195B9F10FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0DC5432585F61039CD5C17195915FF03" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_22A355DB1D98979012C3171959141563" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0DC5432585F61039CD5C17195915FF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0DC5432585F61039CD5C17195915FF03" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest_26910D18B85415FCEAF716E821DE551A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0051BE0AD6FAB5EBDE0F17195AB9C12E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_0DC5432585F61039CD5C17195915FF03" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_0051BE0AD6FAB5EBDE0F17195AB9C12E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_87BBD1E55A0B15B9904616E821D6C04C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_87BBD1E55A0B15B9904616E821D6C04C" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_21534EF005010F10CE5216E821D79CA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_21534EF005010F10CE5216E821D79CA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_21534EF005010F10CE5216E821D79CA3" xlink:to="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember" xlink:label="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:to="loc_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember_04CB93E5BDAE9108E54416E821D8087F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember_C799C811BBD73B14097F16E821D88C63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember" xlink:label="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_948586144D512940761716E821D7FD2C" xlink:to="loc_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember_498ED1171EB6525B2ABC16E821D92DC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_3F4C8F326DC6F64180E416E821D78E29" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths" xlink:label="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_F9E3900B64B92C5D691E16E821D97550" xlink:to="loc_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths_C1338B96D322E649660B16E821D97091" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_6597F9790929549DC35C8020724DAC59" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_6597F9790929549DC35C8020724DAC59" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_45863CDA441C9C3626FC8020724EB11C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_FEBA5AB192090156394ECE6EE6EF2822" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock" xlink:label="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_FEBA5AB192090156394ECE6EE6EF2822" xlink:to="loc_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock_01F1DF2CF59A9DC75D62CE6EE6EF00C6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_95D02A4D845C491019DFD803C100948C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_95D02A4D845C491019DFD803C100948C" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0BD4D7E944AF896E15E0D803C102A9A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0BD4D7E944AF896E15E0D803C102A9A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_0BD4D7E944AF896E15E0D803C102A9A5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_82C9D450E69BFD0D3F60D803C1024587" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_82C9D450E69BFD0D3F60D803C1024587" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_2C5013818964B2816C27D803C102BA69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:to="loc_us-gaap_LicensingAgreementsMember_2C5013818964B2816C27D803C102BA69" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:label="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_C7DC9ECF8F874CB41DD6D803C1035E15" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:to="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_C7DC9ECF8F874CB41DD6D803C1035E15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:label="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_CF78BC9349A5E7998432D803C103DFC3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_914B57AB5010FD1B9CF9D803C102568F" xlink:to="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_CF78BC9349A5E7998432D803C103DFC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7EFD86A02A1D4E63881DD803C1039C59" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7EFD86A02A1D4E63881DD803C1039C59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54E894D8ADC2CA3D1B8CD803C1037E69" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7EFD86A02A1D4E63881DD803C1039C59" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54E894D8ADC2CA3D1B8CD803C1037E69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1557B1536D46D58857EBD803C1048F1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_54E894D8ADC2CA3D1B8CD803C1037E69" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1557B1536D46D58857EBD803C1048F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_F293E43AF7A75F60F71FD803C104161D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_F293E43AF7A75F60F71FD803C104161D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95A6A471FF7B171D2747D803C104F4ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_F293E43AF7A75F60F71FD803C104161D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95A6A471FF7B171D2747D803C104F4ED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_74F71F9590435E6DB8D1D803C10497D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_95A6A471FF7B171D2747D803C104F4ED" xlink:to="loc_pfe_ArrayMember_74F71F9590435E6DB8D1D803C10497D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_0675B19F47F1CE000EE7D803C105E49F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_0675B19F47F1CE000EE7D803C105E49F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5A75681BACBA9A12A7AD803C105DCD6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_0675B19F47F1CE000EE7D803C105E49F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5A75681BACBA9A12A7AD803C105DCD6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_0AB0DFAA557E83D45FA9D803C105238F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5A75681BACBA9A12A7AD803C105DCD6" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_0AB0DFAA557E83D45FA9D803C105238F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_2397F496BE8F3111D6C7D803C10141FF" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_12402A7A83D1451E6C66D803C105B287" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_12402A7A83D1451E6C66D803C105B287" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_997AEA6201BA7AB8E43DD803C1068807" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_997AEA6201BA7AB8E43DD803C1068807" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_EB6FE6EA45362631EB26D803C106A5DC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_EB6FE6EA45362631EB26D803C106A5DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_0F5359AB88730BBB8FEDD803C106ED97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_0F5359AB88730BBB8FEDD803C106ED97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9D3002EA1671779DD420D803C1060DF3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_9D3002EA1671779DD420D803C1060DF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_69025665C4B27A9DB5C7D803C106D877" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_69025665C4B27A9DB5C7D803C106D877" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_28E517583FE9CC3E2BE2D82F824B1C0F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_28E517583FE9CC3E2BE2D82F824B1C0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_EFA8DE0AEE9F8621C131D803C106CA5E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_EFA8DE0AEE9F8621C131D803C106CA5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_A90B98FE2A676F2D286ED803C1072887" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_Goodwill_A90B98FE2A676F2D286ED803C1072887" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A8C2593D09FDE142D061D803C1073509" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_A8C2593D09FDE142D061D803C1073509" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_1CCE7D405F2791420598D803C105491B" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt_6FD0E7D6D9555A4CE37DD803C1074DF8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_ACC9C3EFDE0F00739C9ACEAADE576C9B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_ACC9C3EFDE0F00739C9ACEAADE576C9B" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7EC82BFC62534FBA98E5CEAADE58273F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7EC82BFC62534FBA98E5CEAADE58273F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_509EF226D3B15DA2B94BCEAADE5809B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_7EC82BFC62534FBA98E5CEAADE58273F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_509EF226D3B15DA2B94BCEAADE5809B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_1F0E7E9F216E39DCF139CEAADE5823BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_509EF226D3B15DA2B94BCEAADE5809B9" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_1F0E7E9F216E39DCF139CEAADE5823BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6D23BC4704340C31AADACEAADE59FD37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6D23BC4704340C31AADACEAADE59FD37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B97F8BF3F85C15BF7B3FCEAADE59F486" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_6D23BC4704340C31AADACEAADE59FD37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B97F8BF3F85C15BF7B3FCEAADE59F486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_0661B14EAAB61856ED17CEAADE598E68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_B97F8BF3F85C15BF7B3FCEAADE59F486" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_0661B14EAAB61856ED17CEAADE598E68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_E782D6B91562976678D7CEAADE599F0F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_srt_RangeAxis_E782D6B91562976678D7CEAADE599F0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_E782D6B91562976678D7CEAADE599F0F" xlink:to="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_51F798075D20934C0D04CEAADE5A69A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3" xlink:to="loc_srt_MinimumMember_51F798075D20934C0D04CEAADE5A69A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7D56E7382C20A6B446C3CEAADE5A7AF8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_B7EDC196295BA41029DDCEAADE5A14D3" xlink:to="loc_srt_MaximumMember_7D56E7382C20A6B446C3CEAADE5A7AF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_103C007C91E60F0993CCCEAADE5ABC2D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_103C007C91E60F0993CCCEAADE5ABC2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1516DF3C84B0BB7CE0DACEAADE5A8AA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_103C007C91E60F0993CCCEAADE5ABC2D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1516DF3C84B0BB7CE0DACEAADE5A8AA1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_DD62AFDCC7B09CB8D884CEAADE5B02E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_1516DF3C84B0BB7CE0DACEAADE5A8AA1" xlink:to="loc_pfe_AstraZenecaMember_DD62AFDCC7B09CB8D884CEAADE5B02E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_75DF7484319E8CFDAD47CEAADE57166B" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_0460163DB6B2370EA93ACEAADE5B0AEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_0460163DB6B2370EA93ACEAADE5B0AEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_5F4B7177E76FA215BF05CEAADE5BDC06" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredDeferredPayment" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredDeferredPayment_3534023A5CCB36B0B696CEAADE5C37C9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum_8FF299546EC469CEC7D0CEAADE5C4D9E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum_73F8A05BE14D0BCDA0A0CEAADE5C0F8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments_4E688997D7042A5091EACEAADE5C88BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_1238649674E1197E5C72CEAADE5C4970" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1419A46E4CC2527BF8D2CEAADE5C0ECB" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_1419A46E4CC2527BF8D2CEAADE5C0ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A773F20177E8E61C4AA1CEAADE5D7DE7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_A773F20177E8E61C4AA1CEAADE5D7DE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther_A71C76F4984439D6BBFBCEAADE5D6156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_1C6E0F636EE408069145CEAADE5DB1ED" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_Goodwill_1C6E0F636EE408069145CEAADE5DB1ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_C53503F5F563207DAA84CEAADE5D9FD5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_4CE4D385C767E73C9AAFCEAADE5B20C5" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_C53503F5F563207DAA84CEAADE5D9FD5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_6A8B8B7AA5118BA770A158D7E69C8C4C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_6A8B8B7AA5118BA770A158D7E69C8C4C" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_34D7929FDE973735AAC158D7E69EBCB9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_srt_ConsolidationItemsAxis_34D7929FDE973735AAC158D7E69EBCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_E82637CE3798F9FE7ABE58D7E69E427F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_34D7929FDE973735AAC158D7E69EBCB9" xlink:to="loc_srt_ConsolidationItemsDomain_E82637CE3798F9FE7ABE58D7E69E427F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_047C8A9C9FB734356E8358D7E69FBAAD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_E82637CE3798F9FE7ABE58D7E69E427F" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_047C8A9C9FB734356E8358D7E69FBAAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_4E53AEFA19FBB234642B58D7E69F1BAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_srt_OwnershipAxis_4E53AEFA19FBB234642B58D7E69F1BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_7116F8ACE061A31AEF8758D7E69F785A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4E53AEFA19FBB234642B58D7E69F1BAB" xlink:to="loc_srt_OwnershipDomain_7116F8ACE061A31AEF8758D7E69F785A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelTherapeuticsMember" xlink:label="loc_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_7116F8ACE061A31AEF8758D7E69F785A" xlink:to="loc_pfe_CerevelTherapeuticsMember_EF89C322B0308F3A366058D7E69F3053" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_DFD4CC5FB9222989470158D7E6A0B849" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_DFD4CC5FB9222989470158D7E6A0B849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_FB653C6A73A916AC43F358D7E6A07B01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_DFD4CC5FB9222989470158D7E6A0B849" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_FB653C6A73A916AC43F358D7E6A07B01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_F721F5E26CCC2A22ACB358D7E6A026B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_FB653C6A73A916AC43F358D7E6A07B01" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_F721F5E26CCC2A22ACB358D7E6A026B3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_A5A9053D83C59C74DB8358D7E6A01DE7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_dei_LegalEntityAxis_A5A9053D83C59C74DB8358D7E6A01DE7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AE9241C8C6CC531EEB6458D7E6A0DDC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_A5A9053D83C59C74DB8358D7E6A01DE7" xlink:to="loc_dei_EntityDomain_AE9241C8C6CC531EEB6458D7E6A0DDC8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_AE9241C8C6CC531EEB6458D7E6A0DDC8" xlink:to="loc_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_CD608DC33235B328677558D7E6A11124" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_CD608DC33235B328677558D7E6A11124" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_CD5B07D0C08875BB2CB958D7E6A14753" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_CD608DC33235B328677558D7E6A11124" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_CD5B07D0C08875BB2CB958D7E6A14753" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_D629F48077C8963312E058D7E6A166EA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_CD5B07D0C08875BB2CB958D7E6A14753" xlink:to="loc_pfe_LongtermInvestmentsMember_D629F48077C8963312E058D7E6A166EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_33ECB15FA541742C795658D7E6A2915E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_33ECB15FA541742C795658D7E6A2915E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_33ECB15FA541742C795658D7E6A2915E" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CellectisMember" xlink:label="loc_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:to="loc_pfe_CellectisMember_86DDDF1E80FF0F8D415958D7E6A24A78" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:to="loc_pfe_AllogeneMember_23B7017CBBD3889535FC58D7E6A1B2D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelMember" xlink:label="loc_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1E4E04AEEB672886F8B758D7E6A25A1D" xlink:to="loc_pfe_CerevelMember_4D5A529F4743DE49587A58D7E6A38A52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_BB7A65B03A36BCA35CBB58D7E6A3975F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_srt_CounterpartyNameAxis_BB7A65B03A36BCA35CBB58D7E6A3975F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_BB7A65B03A36BCA35CBB58D7E6A3975F" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA" xlink:to="loc_pfe_ICUMedicalMember_4BD5A3FB30CA179B13BD58D7E6A317C2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BainCapitalMember" xlink:label="loc_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_279537B363E67856D4A358D7E6A3FCFA" xlink:to="loc_pfe_BainCapitalMember_E1E935981E355E1DCEAA58D7E6A360B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_060A8B323A176E533AC058D7E6A4CDA3" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_060A8B323A176E533AC058D7E6A4CDA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_060A8B323A176E533AC058D7E6A4CDA3" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_091B4963C77751B8018F58D7E6A4AAA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_091B4963C77751B8018F58D7E6A4AAA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_093E9C9DA167B27B216158D7E6A44451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_F3F0EABBA9389C12089858D7E6A452CA" xlink:to="loc_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_AC05E6FE4ABEE777376358D7E6A45B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_232E2D3D7AFCB4909CE058D7E6A51F6A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_232E2D3D7AFCB4909CE058D7E6A51F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_232E2D3D7AFCB4909CE058D7E6A51F6A" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:to="loc_pfe_HISMember_76F15090B5EC50ACE48A58D7E6A52393" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" xlink:label="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:to="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_972967E41DADA8EF9B5E58D7E6A5BD74" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NeuroscienceAssetsMember" xlink:label="loc_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_DD2A546B3F01BD54121658D7E6A54132" xlink:to="loc_pfe_NeuroscienceAssetsMember_F15326CD8135EE5E03D758D7E6A60433" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_ADC3A2362355E7840CD758D7E69EF66E" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_6D797194FFE111A6D5D558D7E6A6B959" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares_FCF47EA8D5939749154158D7E6A68089" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests_5FFBD3ADDD3169C1B53D58D7E6A6F03A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGain" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGain_B8B3D29399B5ADEA837D58D7E6A64AE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_B3D579175FFE8C37C7EB58D7E6A7D507" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable_6E03DA1A84ADCA1E4B4058D7E6A7AD7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromDivestitureOfBusinesses" xlink:label="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_ProceedsFromDivestitureOfBusinesses_4EC2DCB14D8A7DF50B6758D7E6A7A6F0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration_E675908826E79F5A07B558D7E6A77547" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_4AFE2A165758D11F985758D7E6A72E1F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InvestmentOwnershipPercentage" xlink:label="loc_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_InvestmentOwnershipPercentage_8BA992E73BC38FA600DA58D7E6A74422" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentsToCollaborators" xlink:label="loc_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_PaymentsToCollaborators_8ACE7CED846D0725365458D7E6A7A83E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossFromContributionAgreement" xlink:label="loc_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_GainLossFromContributionAgreement_F110F51A1A48D8B0CE0558D7E6A814F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_B83796A96060352F050958D7E6A848B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharePrice" xlink:label="loc_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_SharePrice_5FBBAE23925E94E5EA2958D7E6A860B6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue_C812AFF914807DD8C77558D7E6A8D2E5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupIncludingDiscontinuedOperationMilestone" xlink:label="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone_F0652BCA4880AE05977458D7E6A8E80B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount" xlink:label="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount_FF0B270741EFB94604FE58D7E6A894CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_C385921E16772F8307F258D7E6A66CF4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_4159C037440AA8954ADB58D7E6A93CDF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_48C0A694C7D143339E5655F2191F23AD" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_40DED53D81C3F1DED98955F219206B1D" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_844DBBD85568673CA0B455F219208B5B" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_1841E43AF9B6CB483CC755F219206FF7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_E8BD30B1BE53CCE606F755F21920C55D" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0CF238D7E9E6BBCCF64855F219212772" xlink:to="loc_pfe_ConsumerHealthcareMember_4DDCB44EF95F02A9744E55F21921456A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_C78888F46D27CA4F923955F2192149E2" xlink:to="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_626F29F8E0A3A52DAD8655F219217FB0" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_15D4EB054ED33DB1EF5055F21922848B" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="loc_pfe_GSKConsumerHealthcareMember_69CDD31709014500EC8455F219223911" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="loc_pfe_ViivHealthcareLimitedMember_DB7D62B7B415E4F0D61655F21923AAE1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_E4ABAB2671E45E1D3C7155F2192383A0" xlink:type="arc" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_6949B78C9DB2B9D64D7B55F219226A52" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_8F6E09E0AB620BE4EF7455F219230675" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_8F6E09E0AB620BE4EF7455F219230675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_F97D962929DBB65D33C955F2192355EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_8F6E09E0AB620BE4EF7455F219230675" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_F97D962929DBB65D33C955F2192355EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6DFD608BF335BCA766C155F219248279" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_F97D962929DBB65D33C955F2192355EF" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_6DFD608BF335BCA766C155F219248279" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_852665761BF52EE826E355F219245A74" xlink:to="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKMember" xlink:label="loc_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:to="loc_pfe_GSKMember_AE5C372B3E6E4C76B9D855F21924736A" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_FFF9B6C3E13B3B7A264355F21924C12D" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_8A5D463E373E044E9F8F55F2192102DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_855D857DD50D85A7F1CE55F2191F9F3D" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_4F8F437C7BA2416E245355F21925FCBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_A075449C7ECC4DA0DF9755F219253155" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfTax" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfTax_5A9F41D2EB85314B91EC55F21925B70F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTaxIndemnificationLiability" xlink:label="loc_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentsTaxIndemnificationLiability_6BD1A992C661224901D455F219260A04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestments_40960BAE64F39CDCF38D55F219265DAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromEquityMethodInvestments" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_2021C539EABDBB141E1A55F219264749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_3AE3966D91822A989A3255F21926C986" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets_520D10D66C9A20C87E0655F2192630D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity_6B7A332FFA582598C49855F21926298F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortization" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortization_5B871041638E5D27EDBE55F2192713C5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod" xlink:label="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod_0134FFDE391A0830553B55F2192799B6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm" xlink:label="loc_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm_51D35BAA1331B648B96055F21927997C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm" xlink:label="loc_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm_3DE4B82A81FE13B4337C55F21927A885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_InvestmentIncomeDividend_53AD87FFBABA7DF1339155F2192726B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_7B94000DCA15718D5B4755F219271B4D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss" xlink:label="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss_D8302BEFF8E08FDD3E7A55F21927F54E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfEquityMethodInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_ProceedsFromSaleOfEquityMethodInvestments_8CFA38D7C348CDB1487A55F21928C513" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSoldCarryingAmount" xlink:label="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentSoldCarryingAmount_B6C46821AC38384C9CB255F219280E4E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax" xlink:label="loc_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax_19B1936F7A6A5F04D9BA55F21928D9B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_CF10EA89AC6C8416FF1855F219288DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_D5627C015B1A0D2DF6A955F21925D1D4" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_AC0C8FFABCA89AB992DC55F219283990" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_9B8C291B9A2BA8E0CCE0CEAADE04FC70" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_9B8C291B9A2BA8E0CCE0CEAADE04FC70" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_321BEC1847B4BA4AB4C0CEAADE045A70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_321BEC1847B4BA4AB4C0CEAADE045A70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_D64465994B54554B582CCEAADE05285D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_321BEC1847B4BA4AB4C0CEAADE045A70" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_D64465994B54554B582CCEAADE05285D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_9135D3217FB0E304D471CEAADE052FB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_D64465994B54554B582CCEAADE05285D" xlink:to="loc_pfe_LongtermInvestmentsMember_9135D3217FB0E304D471CEAADE052FB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_03D3AFDD626072617BBACEAADE054725" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_7A373CF4F65F7DDF142BCEAADE068234" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_4D93E639141FCE623F5CCEAADE05CA2D" xlink:to="loc_us-gaap_LicensingAgreementsMember_7A373CF4F65F7DDF142BCEAADE068234" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_D5267AB16BD060C942A0CEAADE06C394" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AkceaAndIonisMember" xlink:label="loc_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:to="loc_pfe_AkceaAndIonisMember_74C3C1A5809C4EFB4708CF31978BC054" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShireMember" xlink:label="loc_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:to="loc_pfe_ShireMember_599D4D30D5E28239CD53CEAADE060612" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BionTechMember" xlink:label="loc_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_88653D5CD707A4C31610CEAADE06C955" xlink:to="loc_pfe_BionTechMember_9D9036A70AFDE75828DBCEAADE0721B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_933346FC37A09E4A4D53CEAADE07DD4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_933346FC37A09E4A4D53CEAADE07DD4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_933346FC37A09E4A4D53CEAADE07DD4E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9634F12BA7A963B63821CEAADE07CFA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_9634F12BA7A963B63821CEAADE07CFA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_0B99C0A47D9DF40F22AACEAADE074A25" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_E9B06480399556A5E2ADCEAADE076868" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_650634E59A1511A6739FCEAADE04FA8F" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_PaymentForLicensingArrangement_181715AF2D983B8A5B56CEAADE08F7B7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementMilestoneMaximumValue" xlink:label="loc_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_LicensingArrangementMilestoneMaximumValue_FBEF2A49BF2C41F26D61CEAADE0811D5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ProceedsFromLicensingArrangement" xlink:label="loc_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_ProceedsFromLicensingArrangement_77E170BEA25CF5B7EA05CEAADE082FD0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementNumberOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_LicensingArrangementNumberOfSharesPurchased_6B68D03A7BDC876361B8CEAADE087434" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingArrangementValueOfSharesPurchased" xlink:label="loc_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_E4A3BCE9ED95BC80E7D9CEAADE083155" xlink:to="loc_pfe_LicensingArrangementValueOfSharesPurchased_654F3EEEF726B8502071CEAADE09F1E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_E7FDBE024EC4C964B7174AC987A6D297" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_E7FDBE024EC4C964B7174AC987A6D297" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_CCA3296555123B8056014AC987A7A1C2" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_C557AF30BA8A6C16C9CD4AC987A7B301" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_060AEC8009497C27C0114AC987A77A41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_FBA13ECD9F9F3EC073C14AC987A7BC70" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_7D766BF0E542718BF26F4AC987A80E5D" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_B0ED1835D7DE600FA9674AC987A8AE8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_8922305AF2CD24503E744AC987A89DCB" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MedivationMember" xlink:label="loc_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_91C627F2E86A78263C214AC987A867A7" xlink:to="loc_pfe_MedivationMember_F50B4D25A050F529A16F4AC987A9F39F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_4D8DB27C0C84B43E86FC4AC987A66120" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_2EEFEE26C445242467B84AC987A9CB92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_532ADE72394E64C838D14AC987A9FE44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_8AD1A38984513DAF70524AC987A9574A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationConsiderationTransferredAmountPayable" xlink:label="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_pfe_BusinessCombinationConsiderationTransferredAmountPayable_6C8A35C9E13B4F7CED074AC987AA3480" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_31CF415B5E94B955271E4AC987AAEE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife" xlink:label="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife_94DC0DD7DDD0057CB7514AC987AA7AA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_Goodwill_3CB53DD5E14C03BE4A0D4AC987AA32EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities_3451AB0240C1676EA9914AC987AA5E9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_0ED2C1678E4972AC3C714AC987AA45B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities" xlink:label="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities_6EB5B1F9C923C67276104AC987AB3740" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles" xlink:label="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles_1EF60A3715FBFE4887484AC987ABBCF9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets" xlink:label="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8A198EBC9A91A85B41AB4AC987A9B3F2" xlink:to="loc_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets_85875C6BCED20B7DB5D04AC987AB526A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_BBA2F0A633709B54E3225B2ACAB5A6D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_BBA2F0A633709B54E3225B2ACAB5A6D5" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_4E7A9716E12481BEDFEB5B2ACAB7BEA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_srt_ProductOrServiceAxis_4E7A9716E12481BEDFEB5B2ACAB7BEA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4E7A9716E12481BEDFEB5B2ACAB7BEA9" xlink:to="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductMember" xlink:label="loc_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763" xlink:to="loc_us-gaap_ProductMember_A42DB586CA9C9AB04DD35B2ACAB82A1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CopromotionMember" xlink:label="loc_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D52C999966D6D3B822765B2ACAB80763" xlink:to="loc_pfe_CopromotionMember_C5BC0994093C70C233435B2ACAB85D37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_85B196D52E7E5184A6FD5B2ACAB83BCA" xlink:to="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_27FA2D3B4DE850E98BA15B2ACAB9BBA1" xlink:to="loc_us-gaap_AccountingStandardsUpdate201409Member_E74789128C73127DB2445B2ACAB99339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain" xlink:label="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_5E6FA6B09894F99FA78A5B2ACAB99259" xlink:to="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member" xlink:label="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain_8C16B1BB8880A5CB01665B2ACAB986CA" xlink:to="loc_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_F39AFCE69948AFC28F2C5B2ACABAEE75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_CA289D7C436300DE6BAF5B2ACABA87AB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_TypeOfArrangementAxis_CA289D7C436300DE6BAF5B2ACABA87AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6107101BC0BEA68199D45B2ACABA16A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_CA289D7C436300DE6BAF5B2ACABA87AB" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6107101BC0BEA68199D45B2ACABA16A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_6107101BC0BEA68199D45B2ACABA16A3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:to="loc_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember_0458644269379F2CE8035B2ACABBB4D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementUpfrontCashPaymentMember" xlink:label="loc_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementMember_8EE53A32C8443B15A05D5B2ACABAA1A5" xlink:to="loc_pfe_CollaborativeArrangementUpfrontCashPaymentMember_080C3E0210CA816058455B2ACABB37D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BDFC4EBCD2DDCD1B749B5B2ACABB511F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BDFC4EBCD2DDCD1B749B5B2ACABB511F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BDFC4EBCD2DDCD1B749B5B2ACABB511F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_CCEA1B1E2B9E4B269F425B2ACABC7CE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_CCEA1B1E2B9E4B269F425B2ACABC7CE0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredRevenueMember" xlink:label="loc_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:to="loc_pfe_DeferredRevenueMember_EF7413D35A26D4268B0C5B2ACABCF1B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3806CDD0133245E54C365B2ACABCCD35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_BE78759B22B5C480CAF25B2ACABB6A51" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3806CDD0133245E54C365B2ACABCCD35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_4FF22213E4073962670E5B2ACABCDCFF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_srt_CounterpartyNameAxis_4FF22213E4073962670E5B2ACABCDCFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4FF22213E4073962670E5B2ACABCDCFF" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NovaQuestCoInvestmentFundVL.P.Member" xlink:label="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_B90F2D4D618BEBB765B85B2ACABD0E79" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RPIFinanceTrustMember" xlink:label="loc_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_RPIFinanceTrustMember_136F707D04373D6E93D35B2ACABD93A0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EliLillyCompanyMember" xlink:label="loc_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_EliLillyCompanyMember_1A2B14235F91C6EA023F5B2ACABD9CB3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MerckKGaAMember" xlink:label="loc_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_MerckKGaAMember_B657F0F9E88219F501AB5B2ACABDBC4E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_MylanMember_350120239F2D73F1A4125B2ACABDE1F4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MerckMember" xlink:label="loc_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_BDF19CB6310FFDE3167D5B2ACABC3CDA" xlink:to="loc_pfe_MerckMember_69B1F14DBF953BFA416F5B2ACABE6FDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6338F8DA497EFDA6B7005B2ACABEB6B1" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6338F8DA497EFDA6B7005B2ACABEB6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6338F8DA497EFDA6B7005B2ACABEB6B1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8BCE1D5068BE2196E86F5B2ACABE794B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_8BCE1D5068BE2196E86F5B2ACABE794B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1DE7BDD9C618107A1A425B2ACABF3C94" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_83B37C2E907ABEACB42F5B2ACABEDD55" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_1DE7BDD9C618107A1A425B2ACABF3C94" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_B1F4DC68236E4811BCF45B2ACAB7F0D6" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementMaximumFundingAmount" xlink:label="loc_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount_EFE91A9FE609F6CFE1535B2ACABFD717" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed" xlink:label="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed_B7FC5A974AF1243455D35B2ACABFC584" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred" xlink:label="loc_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred_0953B9E8E7A3AA84862D5B2ACABF077E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" xlink:label="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_4F828CCDEA93777182FF5B2ACABF9AA1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_8790158D8C3F46CF3E075B2ACAC02BCF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure" xlink:label="loc_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure_D88B548DFE05286078445B2ACAC0C194" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12854C2E637576C61A1C5B2ACAC09F01" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_12854C2E637576C61A1C5B2ACAC09F01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_8C71AC3F33723FD4ED4C5B2ACAC037A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_D480BAC0FCF5ED859A055B2ACAC06E8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_7A0A5D707CEC0A9F3DA25B2ACAC01770" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementUpfrontAndMilestonePayments" xlink:label="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementUpfrontAndMilestonePayments_8502C5338392DA2715F85B2ACAC13E55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_us-gaap_ProceedsFromCollaborators_78F35711029A036053FC5B2ACAC1B15E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrepaymentsandPaymentstoCollaborators" xlink:label="loc_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_PrepaymentsandPaymentstoCollaborators_F7CE5C3A8171EABE22785B2ACAC10FA5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage_8C643DB9B73F324BF89B5B2ACAC112B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage" xlink:label="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage_ADFFF33A5B83A1C951295B2ACAC16FF0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementMilestonePaymentReceivable" xlink:label="loc_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementMilestonePaymentReceivable_4CA0B6699D05C2F136505B2ACAC1B528" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementDeferredMilestonePayment" xlink:label="loc_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementDeferredMilestonePayment_3533A0ECC061796B821B5B2ACAC26DBB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized" xlink:label="loc_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized_B4D3FB4C68664F4D0A6C5B2ACAC27C35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CollaborativeArrangementContingentPaymentsMaximumExposure" xlink:label="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_8540597A2E617ACD6B755B2ACABF9519" xlink:to="loc_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure_86A1F2038865A3C4246D5B2ACAC22F83" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_748A5DF0F4FE2207EE48CEAADE135D3D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_748A5DF0F4FE2207EE48CEAADE135D3D" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F6F9AA7AEB65C19BBEC1CEAADE1687EC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F6F9AA7AEB65C19BBEC1CEAADE1687EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_631AD5EF123CE7BED9D9CEAADE1639CD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_F6F9AA7AEB65C19BBEC1CEAADE1687EC" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_631AD5EF123CE7BED9D9CEAADE1639CD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_E387D1F46CD3CC8FD6BFCEAADE16DD06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_631AD5EF123CE7BED9D9CEAADE1639CD" xlink:to="loc_pfe_ConsumerHealthcareMember_E387D1F46CD3CC8FD6BFCEAADE16DD06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_9C7C089FCD6B2A34B8CDCEAADE1652AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_9C7C089FCD6B2A34B8CDCEAADE1652AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_8DA6F411FCA437694B45CEAADE172C52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_9C7C089FCD6B2A34B8CDCEAADE1652AD" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_8DA6F411FCA437694B45CEAADE172C52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_558FD0AD23EA2F2BBEB4CEAADE17F5E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_8DA6F411FCA437694B45CEAADE172C52" xlink:to="loc_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_558FD0AD23EA2F2BBEB4CEAADE17F5E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_665D37E0AD74F1BE9EF7CEAADE175BC1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_977F5F32617A0F9C8306CEAADE135C39" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_665D37E0AD74F1BE9EF7CEAADE175BC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_665D37E0AD74F1BE9EF7CEAADE175BC1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents_37C7ECB8B44E1751FF5CCEAADE1882CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet_E548C6E55AF26CC60E2ECEAADE18B3A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent_E3706A57C3255BF2ECC9CEAADE182CF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets_B88823A1AD7637B04DC6CEAADE18F4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent_8130D33ACA809B55DFCECEAADE18199C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent_64CC40AE71D3FA7790ABCEAADE19E471" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1_3B4099E53932834B450BCEAADE1935AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets_6F510BF441CD628B0F72CEAADE199FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets_D5CAA69415FFDC3F7328CEAADE19184A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation_73AC45847B9202BD107DCEAADE19B2F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract_ADF9FD9B61146332D010CEAADE184EA4" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets_FF42A096518FDC97DCCECEAADE198C60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_665D37E0AD74F1BE9EF7CEAADE175BC1" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent_7DE006ABE9540763736FCEAADE1A8554" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable_A445C5A1B6FD0E5764F9CEAADE1A94F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent_17D97E9B9F60ED1EB18ACEAADE1A75EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities_EA4B679F4DB9D4EBC50ECEAADE1ABD81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent_A0183FFA9567C9815B46CEAADE1BCED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent_852699AB1DBC196FB180CEAADE1BC213" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities_72426D018E81FFF329BFCEAADE1BF7F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities_1E15565180EA4A15F5C0CEAADE1B8601" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract_714178FDBEAACAD0A1BDCEAADE1A661A" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_C6C63CD2AFF3AFFD27EBCEAADE1BC769" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_5E4F51086AE21D7E30C458D174342F13" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_501768C6F7F4DC69254A58D174375CDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_5E4F51086AE21D7E30C458D174342F13" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_501768C6F7F4DC69254A58D174375CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B77119E9A88744CD949558D17438E7C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_501768C6F7F4DC69254A58D174375CDA" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B77119E9A88744CD949558D17438E7C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_B77119E9A88744CD949558D17438E7C9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_A08F53B7C6BE9AA7D34E58D17439C683" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0" xlink:to="loc_pfe_GSKConsumerHealthcareMember_A08F53B7C6BE9AA7D34E58D17439C683" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_3DE2B64D71E62CAB07E558D1743A64C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_53420694772F45BB6F1C58D17439A5D0" xlink:to="loc_pfe_ViivHealthcareLimitedMember_3DE2B64D71E62CAB07E558D1743A64C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_261BF74A2B318EF12ECD58D1743AD200" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_501768C6F7F4DC69254A58D174375CDA" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_261BF74A2B318EF12ECD58D1743AD200" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_261BF74A2B318EF12ECD58D1743AD200" xlink:to="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets_7FFC1CED3A09438984D558D1743AB6BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets_51BE6E7F77518F096A8158D1743C14C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets_2F504F5F875315485F2958D1743CB599" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities_780937449282A9DE582358D1743CE681" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities_3ED13B8B777A7EDBBEBB58D1743CD3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities_4373BA65E9188FF2351E58D1743D453A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital_89AA1992146915947BAD58D1743D2B4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest_5674965DAE73EACB4EEF58D1743DA694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract_985D388E14656211F4CF58D1743A2B67" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity_08C8E294DFB238C6BF2858D1743D24DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_261BF74A2B318EF12ECD58D1743AD200" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue_E51945028872D0029D1758D1743D789F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales_BA600FC663FB8F9B4E1358D1743E493F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss_F1E06B662162DDF694EB58D1743EB70D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems_8345904FAC79E1D695AA58D1743EAA97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss" xlink:label="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss_26D295F70BEAD4FEA92858D1743EC4FD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders" xlink:label="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract_4BFC0306441658F58B4958D1743D1EAF" xlink:to="loc_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders_E9D3284AAB2077DEEC5558D1743EEB87" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_176DDC6114F7BBD144E216E8250778AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock" xlink:label="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_176DDC6114F7BBD144E216E8250778AB" xlink:to="loc_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock_249787DAC42AFE12B1B216E82507FD28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsTextBlock" xlink:label="loc_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_176DDC6114F7BBD144E216E8250778AB" xlink:to="loc_us-gaap_EquityMethodInvestmentsTextBlock_0B5FF93DE79D0C09DEBF16E82507469B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_176DDC6114F7BBD144E216E8250778AB" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_28AD6D66719F8B89F04716E82507D5F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract" xlink:label="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_F3207227D131E9AADAE9CEC126CA6719" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3058393A0872030269FCEC04C74A97D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract_F3207227D131E9AADAE9CEC126CA6719" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3058393A0872030269FCEC04C74A97D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionAxis" xlink:label="loc_pfe_AssetAcquisitionAxis_E24F769A513AA3020A0FCEC04EE291BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3058393A0872030269FCEC04C74A97D" xlink:to="loc_pfe_AssetAcquisitionAxis_E24F769A513AA3020A0FCEC04EE291BE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_073C3BCE1CC13E0630BDCEC04EE80903" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AssetAcquisitionAxis_E24F769A513AA3020A0FCEC04EE291BE" xlink:to="loc_pfe_AssetAcquisitionDomain_073C3BCE1CC13E0630BDCEC04EE80903" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TherachonAssetAcquisitionMember" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_45C6E65B69A3CB286901CEC04FB6037D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AssetAcquisitionDomain_073C3BCE1CC13E0630BDCEC04EE80903" xlink:to="loc_pfe_TherachonAssetAcquisitionMember_45C6E65B69A3CB286901CEC04FB6037D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_8B2BFE8C2CE6C442C8F2CEC04C85A9D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_F3058393A0872030269FCEC04C74A97D" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_8B2BFE8C2CE6C442C8F2CEC04C85A9D3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_A13190E3F65247E480CECEC04CE2F253" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B2BFE8C2CE6C442C8F2CEC04C85A9D3" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_A13190E3F65247E480CECEC04CE2F253" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_993931E12506D1E866FCCEC04D2F405B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B2BFE8C2CE6C442C8F2CEC04C85A9D3" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_993931E12506D1E866FCCEC04D2F405B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionPercentageofSharesAcquired" xlink:label="loc_pfe_AssetAcquisitionPercentageofSharesAcquired_EA16D06C5F97F949CDD5CEC04D7D6CB8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B2BFE8C2CE6C442C8F2CEC04C85A9D3" xlink:to="loc_pfe_AssetAcquisitionPercentageofSharesAcquired_EA16D06C5F97F949CDD5CEC04D7D6CB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireProductiveAssets" xlink:label="loc_us-gaap_PaymentsToAcquireProductiveAssets_517DC7962F1C7C4768EDCEC04DD3AAF7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B2BFE8C2CE6C442C8F2CEC04C85A9D3" xlink:to="loc_us-gaap_PaymentsToAcquireProductiveAssets_517DC7962F1C7C4768EDCEC04DD3AAF7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferred" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferred_67E703CA2FD4B43FB5E8CEC04E1F4B3A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B2BFE8C2CE6C442C8F2CEC04C85A9D3" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferred_67E703CA2FD4B43FB5E8CEC04E1F4B3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff" xlink:label="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_234EC4805E3C0D8BDFB9CEC04E865DE6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_8B2BFE8C2CE6C442C8F2CEC04C85A9D3" xlink:to="loc_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff_234EC4805E3C0D8BDFB9CEC04E865DE6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2269A2FF515E2CDDEABC80206C7DFFE5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2269A2FF515E2CDDEABC80206C7DFFE5" xlink:to="loc_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_EC9B3D754DB3291C10FB80206C7D0544" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15433EEB3D7285436F5B55F1EF1EFA7B" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAccruedLiabilitiesTable" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_15433EEB3D7285436F5B55F1EF1EFA7B" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_498392DBA46FF92A6FF155F1EF1FD89F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_498392DBA46FF92A6FF155F1EF1FD89F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_498392DBA46FF92A6FF155F1EF1FD89F" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:to="loc_us-gaap_AccountsReceivableMember_DD321DB4F6851D95777455F1EF200947" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_D4DA0485DA87C77E117255F1EF20DE41" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_D4DA0485DA87C77E117255F1EF20DE41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_192B150163B728BCB8E655F1EF208AE4" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_8725EA08D381719E5E1B55F1EF2094BC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAccruedLiabilitiesLineItems" xlink:label="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesTable_E28760D4AD67190FE20655F1EF1FA58D" xlink:to="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_AF83FE32697F5AC336D155F1EF214F77" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AccruedRebates" xlink:label="loc_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:to="loc_pfe_AccruedRebates_E6C0DA9F25C7D14BB08855F1EF21B4F2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherAccruals" xlink:label="loc_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAccruedLiabilitiesLineItems_C461C4B5703207FED13855F1EF211FFA" xlink:to="loc_pfe_OtherAccruals_7411AAFAB21C7EBF8C7955F1EF21D924" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4AC1B3D22827EB9088E455F1428E58E6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_4AC1B3D22827EB9088E455F1428E58E6" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_62D8A96AC9294A52B9D055F1429149CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_StatementScenarioAxis_62D8A96AC9294A52B9D055F1429149CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_3B861A970FBF9837C17B55F142914DB7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_62D8A96AC9294A52B9D055F1429149CA" xlink:to="loc_srt_ScenarioUnspecifiedDomain_3B861A970FBF9837C17B55F142914DB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_AC53476FDB5BBC01416455F142927A8C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_3B861A970FBF9837C17B55F142914DB7" xlink:to="loc_srt_ScenarioForecastMember_AC53476FDB5BBC01416455F142927A8C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_13613626FE5B956CB06955F14292B359" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_dei_LegalEntityAxis_13613626FE5B956CB06955F14292B359" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_7CB912006CE81946EF3A55F142923FDC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_13613626FE5B956CB06955F14292B359" xlink:to="loc_dei_EntityDomain_7CB912006CE81946EF3A55F142923FDC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_6091C09AD01B751CBFEA55F14293D560" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_7CB912006CE81946EF3A55F142923FDC" xlink:to="loc_pfe_MylanMember_6091C09AD01B751CBFEA55F14293D560" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_4B9DF4BD4AA8D0A667B655F14293E396" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_OwnershipAxis_4B9DF4BD4AA8D0A667B655F14293E396" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_C0CCD6DABB53770B695F55F14293D2B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_4B9DF4BD4AA8D0A667B655F14293E396" xlink:to="loc_srt_OwnershipDomain_C0CCD6DABB53770B695F55F14293D2B7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnAndMylanMember" xlink:label="loc_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_C0CCD6DABB53770B695F55F14293D2B7" xlink:to="loc_pfe_UpjohnAndMylanMember_084781B7F7B09979C26055F1429373B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_8344E55A3C39577C03D955F1429439E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_RangeAxis_8344E55A3C39577C03D955F1429439E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_8344E55A3C39577C03D955F1429439E4" xlink:to="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_2C423AFFAD18429F072655F14294B8CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5" xlink:to="loc_srt_MinimumMember_2C423AFFAD18429F072655F14294B8CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_DDC5EFE611F8A08C7A1955F14294899F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_DEFAC63F2C1FF284BB2255F142943BB5" xlink:to="loc_srt_MaximumMember_DDC5EFE611F8A08C7A1955F14294899F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionAxis" xlink:label="loc_pfe_AssetAcquisitionAxis_5897E9B82BA2CAC5A64E55F142956D6C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_pfe_AssetAcquisitionAxis_5897E9B82BA2CAC5A64E55F142956D6C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_172D53C81A49369B8D8955F142952E75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AssetAcquisitionAxis_5897E9B82BA2CAC5A64E55F142956D6C" xlink:to="loc_pfe_AssetAcquisitionDomain_172D53C81A49369B8D8955F142952E75" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TherachonAssetAcquisitionMember" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_A5B56BD6FECC308EEF7555F14295CA2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AssetAcquisitionDomain_172D53C81A49369B8D8955F142952E75" xlink:to="loc_pfe_TherachonAssetAcquisitionMember_A5B56BD6FECC308EEF7555F14295CA2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_785906BCC10BB295AEE455F14295DBE4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_785906BCC10BB295AEE455F14295DBE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E9AA2100CA967E3ED7C555F142956390" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_785906BCC10BB295AEE455F14295DBE4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E9AA2100CA967E3ED7C555F142956390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_3855978FB9557A62C3FC55F14296466D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E9AA2100CA967E3ED7C555F142956390" xlink:to="loc_us-gaap_LicensingAgreementsMember_3855978FB9557A62C3FC55F14296466D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_FC7C4B3F441D3D20E37055F14296AF2B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_FC7C4B3F441D3D20E37055F14296AF2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_10AEB259A5FEBCFC266055F142964641" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_FC7C4B3F441D3D20E37055F14296AF2B" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_10AEB259A5FEBCFC266055F142964641" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9E14804B369A66F45D6B55F1429661B6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_10AEB259A5FEBCFC266055F142964641" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_9E14804B369A66F45D6B55F1429661B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis" xlink:label="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInAccountingPrincipleMember" xlink:label="loc_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis_871F8DD1217BE42C9A5955F14297E953" xlink:to="loc_us-gaap_ChangeInAccountingPrincipleMember_AFE546DE5589BCE6031155F1429C3B41" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_53382E72B19E4FC73D1C55F1429CBD4F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_53382E72B19E4FC73D1C55F1429CBD4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_07013B1F44993D8ECA7B55F1429C0B16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_53382E72B19E4FC73D1C55F1429CBD4F" xlink:to="loc_us-gaap_TypeOfAdoptionMember_07013B1F44993D8ECA7B55F1429C0B16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_0EB67AD330A8A35ABFC355F1429D38D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_07013B1F44993D8ECA7B55F1429C0B16" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_0EB67AD330A8A35ABFC355F1429D38D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C1D722AB6A8650E002EC55F1429D89B2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C1D722AB6A8650E002EC55F1429D89B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3BDCCD474B3F389A480D55F1429D0D9D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_C1D722AB6A8650E002EC55F1429D89B2" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3BDCCD474B3F389A480D55F1429D0D9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesRevenueProductLineMember" xlink:label="loc_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_3BDCCD474B3F389A480D55F1429D0D9D" xlink:to="loc_us-gaap_SalesRevenueProductLineMember_3632BD83DF698C34FCE255F1429DD7EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_A44DCCAB1C39CB6B7E4E55F1429EBF1B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_ProductOrServiceAxis_A44DCCAB1C39CB6B7E4E55F1429EBF1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_A44DCCAB1C39CB6B7E4E55F1429EBF1B" xlink:to="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopEightProductsMember" xlink:label="loc_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:to="loc_pfe_TopEightProductsMember_4C95DC7D327F96D0655355F410BAEF24" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopNineProductsMember" xlink:label="loc_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:to="loc_pfe_TopNineProductsMember_818A789E70E3E049F3C555F1429ECB39" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TopTenProductsMember" xlink:label="loc_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F44BC02C65DCA7A202D55F1429E5BEE" xlink:to="loc_pfe_TopTenProductsMember_85BAE618F8BDC00A22BD55F1429FBA12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_1686806AF5466AFC65E755F1429FF788" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_1686806AF5466AFC65E755F1429FF788" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_EEC2F5E59AF2F71322EE55F1429F2E49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_1686806AF5466AFC65E755F1429FF788" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_EEC2F5E59AF2F71322EE55F1429F2E49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProductConcentrationRiskMember" xlink:label="loc_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_EEC2F5E59AF2F71322EE55F1429F2E49" xlink:to="loc_us-gaap_ProductConcentrationRiskMember_886D7AF9AAA3E8E2D73555F1429F8463" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_68C62CE34EE056D0C0FF55F1429FFCBD" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_srt_CounterpartyNameAxis_68C62CE34EE056D0C0FF55F1429FFCBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_68C62CE34EE056D0C0FF55F1429FFCBD" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AkceaAndIonisMember" xlink:label="loc_pfe_AkceaAndIonisMember_8951F4AC773432D593EA55F142A03CDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1" xlink:to="loc_pfe_AkceaAndIonisMember_8951F4AC773432D593EA55F142A03CDA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ICUMedicalMember" xlink:label="loc_pfe_ICUMedicalMember_43DD679750999CF3955655F142A0F6A4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_D197C52D8508E23537B555F142A04CA1" xlink:to="loc_pfe_ICUMedicalMember_43DD679750999CF3955655F142A0F6A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_497422472ECEB1D8103655F142A0B644" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_497422472ECEB1D8103655F142A0B644" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_96FD82F4A4B08F2C634A55F142A04BE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_497422472ECEB1D8103655F142A0B644" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_96FD82F4A4B08F2C634A55F142A04BE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_C261D200CC3F841AB19D55F142A179A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_96FD82F4A4B08F2C634A55F142A04BE4" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_C261D200CC3F841AB19D55F142A179A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92EA77300B9487B3AE6755F142A13E57" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92EA77300B9487B3AE6755F142A13E57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0A586DF5557A0681287F55F142A10B85" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_92EA77300B9487B3AE6755F142A13E57" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0A586DF5557A0681287F55F142A10B85" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_D3A32199DCB0474B8AEE55F142A2D118" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_0A586DF5557A0681287F55F142A10B85" xlink:to="loc_pfe_HISMember_D3A32199DCB0474B8AEE55F142A2D118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_9EF87CF284B033A73A5255F142A245B5" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_9EF87CF284B033A73A5255F142A245B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_9EF87CF284B033A73A5255F142A245B5" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_F8338A0467F9B9B0DF6D55F142A2891A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E" xlink:to="loc_pfe_ArrayMember_F8338A0467F9B9B0DF6D55F142A2891A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_6A68AB9600593C61DF3455F142A23634" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_AED00406F02CF5AE517A55F142A21A1E" xlink:to="loc_pfe_AstraZenecaMember_6A68AB9600593C61DF3455F142A23634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_82311431D13288FDD33855F142A36EB9" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_TypeOfArrangementAxis_82311431D13288FDD33855F142A36EB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA7F63ECEA813C34488155F142A3E5BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_82311431D13288FDD33855F142A36EB9" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA7F63ECEA813C34488155F142A3E5BE" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_CA7F63ECEA813C34488155F142A3E5BE" xlink:to="loc_us-gaap_LicensingAgreementsMember_3855978FB9557A62C3FC55F14296466D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_E473843546034E2B369D55F14290DB37" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_A5552363B9E4EFBE4EEB55F142A4B10C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_A5552363B9E4EFBE4EEB55F142A4B10C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NumberOfAccountingStandardsAdopted" xlink:label="loc_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_NumberOfAccountingStandardsAdopted_AF08F18BCB474388A34C55F142A4E939" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_67C3207E3E870BCAEB9955F142A9F6BD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_PaymentForLicensingArrangement_67C3207E3E870BCAEB9955F142A9F6BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionSharePrice" xlink:label="loc_us-gaap_BusinessAcquisitionSharePrice_F33466F9178BF5F43CA355F142A92038" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_BusinessAcquisitionSharePrice_F33466F9178BF5F43CA355F142A92038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesGross" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesGross_3C25A27DA48EAC6D422255F142AA96F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesGross_3C25A27DA48EAC6D422255F142AA96F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_75BB982F531783427D9C55F142AA01A5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_75BB982F531783427D9C55F142AA01A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_E558773DDA7C2863EE6B55F142AA7AED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_E558773DDA7C2863EE6B55F142AA7AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners_F0DE246607827644ADA455F142AAC220" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment_F451E2814AA86D53F88D55F142AA7284" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum_32160869D0A5A466976755F142AA6626" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionConsiderationTransferred" xlink:label="loc_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_AssetAcquisitionConsiderationTransferred_F76CB5BE2A2AF0D61F4755F142AA0F7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_DEF6C5372B02B47021F955F142AB7D5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E84A5A635C6B00BCB7B055F142AB8755" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_BusinessCombinationConsiderationTransferred1_E84A5A635C6B00BCB7B055F142AB8755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_E69B8B1B2AE1CC7328F955F142AB15CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_A12ED26D0F29C12F45AA55F142AB0FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1_73E435D2A4F6BC37147F55F142AB911B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1" xlink:label="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1_D50A80FBFA478B22115155F142AB88D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConcentrationRiskAmount" xlink:label="loc_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_ConcentrationRiskAmount_7DFA1C75C9EB7EB20E9F55F142AB417E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_40B74BB486885677AFB855F142ACA133" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RebatesAndDiscountsAccrual" xlink:label="loc_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_RebatesAndDiscountsAccrual_3CC9CC127DC5DCA2E3A555F142AC8666" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdvertisingExpense" xlink:label="loc_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_AdvertisingExpense_D567DEAA5003EBB8949D55F142ACC07B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_5519C20508DB31719AF055F142AC048F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LesseeOperatingLeaseOptionToExtendTerm" xlink:label="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_pfe_LesseeOperatingLeaseOptionToExtendTerm_1E646D532A59DF57B74855F142ACBD6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_2C143DA275D9F7DAAA3B55F142AC403D" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_BFF0FE57E5B2C42568E055F142A30FA8" xlink:to="loc_us-gaap_VariableLeaseCost_2C143DA275D9F7DAAA3B55F142AC403D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D6F906AF203F967A34DF55F1F2C6B5C1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionTable" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_D6F906AF203F967A34DF55F1F2C6B5C1" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:to="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeAxis_4D14C68F3EC5758CFA0255F1F2C83C13" xlink:to="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OfficeBuildingInNewYorkCityMember" xlink:label="loc_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeaseArrangementTypeDomain_143523D70CBF9820766D55F1F2C9AA24" xlink:to="loc_pfe_OfficeBuildingInNewYorkCityMember_8A7DE55142903F58A6DB55F1F2C9A2FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeaseDescriptionLineItems" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_866C522DFC90160E483555F1F2C8E62E" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract" xlink:label="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths_C6C90DFFFC04D7E74F8C55F1F2CA095A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo_11F1DD2BC4BD688A7CFE55F1F2CA0506" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree_86092AE279029CEA649655F1F2CA7497" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour_4F85FF36EFDB52BF32BF55F1F2CA65F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive_05199978EE265A1F00EB55F1F2CA09E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive_E86F0B39300ED27D4E2F55F1F2CBE35E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_AD24DDE68498D81CF12D55F1F2CB2111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_51425AE9675C934F36B655F1F2CB7997" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_OperatingLeaseLiability_841D6E6664BF696A7C3155F1F2CBA518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_14CB5E268D5307CFFB8B55F1F2CB01EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract_D942DC32D2453AFCA89055F1F2C97CA7" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_ECF05C4832C37CE0336C55F1F2CB07EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseTermOfContract" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_9D79070CE0CADF13606E55F1F2CC0727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDue_7B64E4F2DFEDF00E245355F1F2CCDB50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="loc_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_OperatingLeasesRentExpenseNet_C6126A96AB8F36E2E12655F1F2CC739D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_3BADA7003CF941F868AD55F1F2C91174" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_3C8B773C39AC7D47236755F1F2CC7707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_FC92FC1A0924F00C194155F1F2CD8BD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_F3ACCBB31AC6AC118A3E55F1F2CDB105" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_0646D7951C0F2CD2425355F1F2CDCE7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_7DA2835BE9A3A92306E755F1F2CD81C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract_03478A38DBB3CBBC726355F1F2CCE0B2" xlink:to="loc_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_D5692562ED6CBBB4265055F1F2CD940E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27FDE98B08619BB8019ACD989BB3310A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_27FDE98B08619BB8019ACD989BB3310A" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A9CEA09808F94E4A2F9DCD989BB4C0A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A9CEA09808F94E4A2F9DCD989BB4C0A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_8315A4025F478F868416CD989BB455D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_A9CEA09808F94E4A2F9DCD989BB4C0A0" xlink:to="loc_us-gaap_TypeOfAdoptionMember_8315A4025F478F868416CD989BB455D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201602Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_8315A4025F478F868416CD989BB455D3" xlink:to="loc_us-gaap_AccountingStandardsUpdate201602Member_D584873AC659673CD4A1CDF46AA82E99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems" xlink:label="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable_1D41B3D9CB57CF9B9B7ECD989BB33E39" xlink:to="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_OtherAssetsCurrent_F8BF6EA2EF051B62D890CDE666FD0CD2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B23506FE661D29E67FE0CD989BB61CE3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_FBF498961615C509C41CCD989BB648A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_E6191BB5750E8D262445CD989BB6A4CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_93470D37F9D03667BD41CD989BB6959B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems_7230EC2E6AE5AE7F666ACD989BB585C7" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_C6461A8AF673BAF7E061CD989BB728EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2AEF7F1BE18BC363F11501B535251AEA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2AEF7F1BE18BC363F11501B535251AEA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_8A09C01EE0329B64026501B53525E2B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2AEF7F1BE18BC363F11501B535251AEA" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_9BD31973C2468E7E001901B535263B7B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="loc_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2AEF7F1BE18BC363F11501B535251AEA" xlink:to="loc_us-gaap_OperatingLeasePayments_E3B42C25B150E40B74FC01B535264323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SaleAndLeasebackTransactionGainLossNet" xlink:label="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2AEF7F1BE18BC363F11501B535251AEA" xlink:to="loc_us-gaap_SaleAndLeasebackTransactionGainLossNet_DF1D3EEBC4AFB8E16B0301B535267AE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_2AEF7F1BE18BC363F11501B535251AEA" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_16B6F83B9F6951AE823A01B535260194" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_8AD1ED506C42C1D7481055F1EF4B60E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConsolidationPolicyTextBlock" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_E373D3AC5A5CAE83BA7855F1EF4BAE04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_4C7E6B864B267DEDC1EF55F1EF4BBD91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_UseOfEstimates_8CCAD30E0C66A5E81B9C55F1EF4B8A0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:label="loc_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_BusinessCombinationsPolicy_BE9FF329092666FD32E755F1EF4C6F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_F03D4C65CB5ADC57BB5F55F1EF4CEA34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock" xlink:label="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock_F453D859A56C3BCDD68455F1EF4C920F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_A4A25D472D920C4EF4D155F1EF4CCB6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReceivablesPolicyTextBlock" xlink:label="loc_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_ReceivablesPolicyTextBlock_266DE41553628D31339455F1EF4C901B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryPolicyTextBlock" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_E1461EEE594436BBBD8455F1EF4C4078" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock_539FF6B57C1C7E180C0C55F1EF4C0FDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_844AD3FBDB9FFCFFDDFF55F1EF4DF6C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_474FB454B464D75595E855F1EF4D78B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_F1E609E5A508E79EEB3755F1EF4D61A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentImpairment" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentImpairment_4BF7C97C3B15105A31FF55F1EF4DE333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock" xlink:label="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock_F71EA7845815F80BE01755F1EF4D7878" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_54B8A8A4F66809B4818E55F1EF4EFB57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesReportingOfDerivativeActivity" xlink:label="loc_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_DerivativesReportingOfDerivativeActivity_C478842FA027EE5DDD2C55F1EF4ED245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentPolicyTextBlock" xlink:label="loc_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_InvestmentPolicyTextBlock_D7BF4AD0103CED9FBF3C55F1EF4EA907" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativesPolicyTextBlock" xlink:label="loc_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_DerivativesPolicyTextBlock_4FEB2D35B3EF54BA7DCB55F1EF4E9AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_B95FE3C632DDA29DADD155F1EF4E1C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementPlansPolicy" xlink:label="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_PensionAndOtherPostretirementPlansPolicy_4DE98D1D1D7361D6BE3C55F1EF4F66D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_13A85DA4075FD09480D855F1EF4FF7BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_2DD30A536E063B06F35C55F1EF4FF830" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeLeasesPolicyTextBlock" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_5F0B8A65BDA1CE9C082155F1EF4A015D" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_79875DFC1AEAFADBB21555F1EF4FCB08" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9DFC059F77C2DE58536DCE247DF4850E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_BCDEFDF1CA1CBC55323BCE27914955D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9DFC059F77C2DE58536DCE247DF4850E" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_BCDEFDF1CA1CBC55323BCE27914955D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_8351E2F1FC0D375A0DABCE2792B6DF6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9DFC059F77C2DE58536DCE247DF4850E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_8351E2F1FC0D375A0DABCE2792B6DF6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_377C6D77AE1552DC9C7BCE27949025C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_9DFC059F77C2DE58536DCE247DF4850E" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_377C6D77AE1552DC9C7BCE27949025C3" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C217E64932417D10E211CD989BECEDC6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:label="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C217E64932417D10E211CD989BECEDC6" xlink:to="loc_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_305628E997B35C42D1DACD989BEC276A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C217E64932417D10E211CD989BECEDC6" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_BFB434FC1B3BFB8B73A4CD989BEC6CB1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetsAndLiabilitiesLesseeTableTextBlock" xlink:label="loc_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C217E64932417D10E211CD989BECEDC6" xlink:to="loc_pfe_AssetsAndLiabilitiesLesseeTableTextBlock_492DB456DC5AA50AF122CDA7F69D7474" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCostTableTextBlock" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C217E64932417D10E211CD989BECEDC6" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_314F2EF1B33B64E3F218CDA88A55AC67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C217E64932417D10E211CD989BECEDC6" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9ADB61D2CBE5DC24AC5DCDA9741FE4C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_C217E64932417D10E211CD989BECEDC6" xlink:to="loc_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_80D53A5CA306C364D4BBCDAA9852524D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingLeaseCost" xlink:label="loc_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:to="loc_us-gaap_OperatingLeaseCost_451405EFD67F410B725FCE6EE707386D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_VariableLeaseCost" xlink:label="loc_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:to="loc_us-gaap_VariableLeaseCost_F129A129367BD32E5961CE6EE708922E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubleaseIncome" xlink:label="loc_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:to="loc_us-gaap_SubleaseIncome_DB8709C24DC86AF63A70CE6EE708A7AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LeaseCost" xlink:label="loc_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_47017926569B5E7AD6FBCE6EE707BF31" xlink:to="loc_us-gaap_LeaseCost_0D6BC4B4326903A21CDCCE6EE708DD7E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_01FD425DFB269FF412D501A6050FF738" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01FD425DFB269FF412D501A6050FF738" xlink:to="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_421664969BDFE8587B9E01A605102B02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_E4F0B09F7C07D19E957201A60510C663" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_ShortTermInvestments_E4F0B09F7C07D19E957201A60510C663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_2FB9A705A1480BC516B301A60510E169" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_46852F74BA1350C33C5E01A60510EA7F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_InventoryNet_46852F74BA1350C33C5E01A60510EA7F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherTaxAssetsCurrent" xlink:label="loc_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_pfe_OtherTaxAssetsCurrent_6AD6785091A4476B2E7801A6051151C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsCurrent" xlink:label="loc_us-gaap_OtherAssetsCurrent_305096B9EE10DEC2008201A6051170D1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_OtherAssetsCurrent_305096B9EE10DEC2008201A6051170D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent" xlink:label="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent_B7AB6564C4B1A57DAA9201A605118331" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_AssetsCurrent_ED9A1FC3865AB5E85D1A01A60512848A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_E8A782748A19A0F436D101A60512AE4A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_EquityMethodInvestments_E8A782748A19A0F436D101A60512AE4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_899B07847CB0B5357D8B01A605123302" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_LongTermInvestments_899B07847CB0B5357D8B01A605123302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_E4B696C5C72A830DC7B401A605121DC2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_E4B696C5C72A830DC7B401A605121DC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_253638BD142C700BB05201A6051258A5" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_253638BD142C700BB05201A6051258A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_135A8EFE9B0F2DA1CEAB01A60513E995" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_Goodwill_135A8EFE9B0F2DA1CEAB01A60513E995" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent" xlink:label="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B6ABC0DFFF9C3A1C8D9601A60513E840" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent_B6ABC0DFFF9C3A1C8D9601A60513E840" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_64BE8BA35C900C493DB401A60513423F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_64BE8BA35C900C493DB401A60513423F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_E7AEE5092EA007618AE101A6051397C1" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_42994CE8E3160BD38D4C01A6050FF8A1" xlink:to="loc_us-gaap_Assets_E7AEE5092EA007618AE101A6051397C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_01FD425DFB269FF412D501A6050FF738" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_BC40D63929FD6DAB202601A605145AAA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_DebtCurrent_BC40D63929FD6DAB202601A605145AAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_AccountsPayableCurrent_B87167618407DAA95D0601A605144C53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPayableCurrent" xlink:label="loc_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_DividendsPayableCurrent_F82F178A81D6546FAA8401A605144FD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxesPayableCurrent" xlink:label="loc_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_TaxesPayableCurrent_2D5579B900AE8E194D7C01A605151634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_50A5B0B334ED3840568901A605157407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_9641DA49A744CD58363501A605158E9A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_9641DA49A744CD58363501A605158E9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation" xlink:label="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_B57CDB64BF7DD46826EB01A605153A69" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation_B57CDB64BF7DD46826EB01A605153A69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_LiabilitiesCurrent_02ED8F3F8631B00BB3EB01A605156B6C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_422F62FCBC2CCE38633801A60516E0DB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_422F62FCBC2CCE38633801A60516E0DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent_0CED11E1ED4674050C2B01A60516B65A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent_BA36FB50EB2DDAF915F401A6051655A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilitiesNet_1F06D3E686CB99C2F80701A60517CC75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsNoncurrent" xlink:label="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent_DE2DB6E9DFB26EE4FCEC01A605171617" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_4E207FB3283FAB830A3301A605174CFD" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_4E207FB3283FAB830A3301A605174CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_Liabilities_C6FB88598C71C865676701A60517DA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_CommitmentsAndContingencies_102CDB1608D478250BB701A60517DBB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_PreferredStockValue_30341D1E3CF3C3B484C201A605184FD1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_CommonStockValue_42DDD900D4515B52EE3601A605186C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="loc_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_AdditionalPaidInCapital_324776C6B0B0B0396A7201A605189138" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValue" xlink:label="loc_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_TreasuryStockValue_6ACA7B8DE0A693784A0A01A60518C00E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DEDE1D28738D559965C701A60519014A" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_DEDE1D28738D559965C701A60519014A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_291742CB39BCD4F9C25D01A60519B25A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaap_StockholdersEquity_53EF0249BA6539701FE301A60519C80A" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_StockholdersEquity_53EF0249BA6539701FE301A60519C80A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterest" xlink:label="loc_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_MinorityInterest_DFA4D0496C0EF933763801A605195ABC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4D619AF68A1C040724301A605194ABD" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_E4D619AF68A1C040724301A605194ABD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_6491D63C91BD05EF37DE01A60514618E" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0829AE4862578F4A78C201A6051AC030" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent" xlink:label="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="loc_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent_83EB4FD4F47057421AD2F33C9F782573" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="loc_us-gaap_LongTermDebtCurrent_4A8CA5858D1890E0D9F7F33C9F78C20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_B2944EACDB6D93899632F33C9F78CB4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="loc_us-gaap_PreferredStockSharesIssued_4B06F7DA7289730A991CF33C9F79030E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_19B34D72E87B765B4F74F33C9F7960FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_B0ED3574F32E8C24C396F33C9F7906C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="loc_us-gaap_CommonStockSharesIssued_A54774241C8D53DF7E22F33C9F7940C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockShares" xlink:label="loc_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_1992A5894504A4749296F33C9F779BF6" xlink:to="loc_us-gaap_TreasuryStockShares_AC8308F050D062110D52F33C9F79A210" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_2E9540402E5532C90DEB2F92B61DB27C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_71912B4D2F5635F274392F92B61D5963" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_2E9540402E5532C90DEB2F92B61DB27C" xlink:to="loc_us-gaap_StatementTable_71912B4D2F5635F274392F92B61D5963" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0AA01DE5D2DC236EDEFC2F92B61DD7B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71912B4D2F5635F274392F92B61D5963" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0AA01DE5D2DC236EDEFC2F92B61DD7B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_0AA01DE5D2DC236EDEFC2F92B61DD7B9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_360FE39D6D2FA01549432F92B61EDC5B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:to="loc_pfe_GSKConsumerHealthcareMember_360FE39D6D2FA01549432F92B61EDC5B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelTherapeuticsMember" xlink:label="loc_pfe_CerevelTherapeuticsMember_F77EA2189BB97C3B93142F92B61EC345" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:to="loc_pfe_CerevelTherapeuticsMember_F77EA2189BB97C3B93142F92B61EC345" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_E37277781DB78DE964082F92B61E1F9A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1B5578509C518AC23BA82F92B61D78D8" xlink:to="loc_pfe_AllogeneMember_E37277781DB78DE964082F92B61E1F9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_71912B4D2F5635F274392F92B61D5963" xlink:to="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:to="loc_us-gaap_ProfitLoss_19464F0BF17C8FB02F3B2F92B61F1D4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization" xlink:label="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization_8E56BCD1E9E7E11CC31F2F92B61F2476" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetWriteOffsAndAssetImpairmentCharges" xlink:label="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_pfe_AssetWriteOffsAndAssetImpairmentCharges_0BCDA32B9DBED081B8292F92B62052A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_947DC75F4C8E59E2214D2F92B620A595" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_2DA8BBCA01877E08848D2F92B620F245" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_3E68D4C76CDB12AE60AC2F92B6208525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_ShareBasedCompensation_38BF98CD063136434D1B2F92B6203036" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense" xlink:label="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense_F39AE63C2D7777C7CCDC2F92B6209314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="loc_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_OtherNoncashIncomeExpense_E167F1D4E5AB43F5044F2F92B621A49C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_8D59D94938184A11086A2F92B61F6388" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_2F269EBDE73C50616E352F92B621EF25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInInventories" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_AFBFD39E4A2B059096472F92B622A8A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingAssets" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingAssets_4C416D126B1D2E6CEF842F92B622ACCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableTrade" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableTrade_1A875F6883EE8D34D3612F92B62274BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInOtherOperatingLiabilities" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities_7BD5D6BF7AE5295B58792F92B622E9E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedTaxesPayable" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_42165586BF84B10EED122F92B6211A1C" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedTaxesPayable_DFFAB20697CBB70CC2FE2F92B622FD82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_A09D82777B9F965455B62F92B61E5D8D" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_C4D17F79C23B91EBDD862F92B6229735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_FF8A771326C433CA7CC42F92B62317FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireShortTermInvestments" xlink:label="loc_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquireShortTermInvestments_E2994EA28259FD6B30F12F92B6239BA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments_67502A001416DB005B0D2F92B623D41B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromShortTermInvestments" xlink:label="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsForProceedsFromShortTermInvestments_BE7B007CAEC781CC3D6C2F92B6231834" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_48E2788B51389312ACDB2F92B62321E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments" xlink:label="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments_54349F3A0D97B5F499092F92B629D12B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:label="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_0D0150EAEEEE92E06DBA2F92B6290AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsToAcquireIntangibleAssets" xlink:label="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsToAcquireIntangibleAssets_6348E60FABCBBDE85F4E2F92B629C78A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForProceedsFromOtherInvestingActivities" xlink:label="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_PaymentsForProceedsFromOtherInvestingActivities_98EA0C981C6DAC6F298B2F92B629286D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ADEBA0CFD75FBB0E7A062F92B623957E" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0A45E0F45EBAECEC87E12F92B629429B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromShortTermDebt" xlink:label="loc_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromShortTermDebt_76370F73852D85DA4F602F92B62AEBDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfShortTermDebt" xlink:label="loc_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_RepaymentsOfShortTermDebt_5A29DAA39DB1B75A376A2F92B62AF451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess" xlink:label="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess_079F7E393CF491FD5BD12F92B62A2C71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_E1851D9F11C2ED5B5EFF2F92B62BD5F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RepaymentsOfLongTermDebt" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_3E5543C85B5607B025162F92B62B5FCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_B4D822F24009E808BEAD2F92B62B930B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PaymentsOfOrdinaryDividends" xlink:label="loc_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_PaymentsOfOrdinaryDividends_1186E93DD8E72C7B850E2F92B62B594F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_5631D1B1E916B5CAD5F52F92B62B73E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromPaymentsForOtherFinancingActivities" xlink:label="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities_8254CEFA5DDB2A751E212F92B62BAC66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_D629275AEAA36F0757892F92B62A1D25" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_E2D71D49EF78174D30042F92B62BB7DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_A94EF6374BCF356BC17D2F92B62C350C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_0C041C10F2713861D7992F92B62C4741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_86E85BEFB1723E0101562F92B62C7668" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5FED55984EA484B9EB9B2F92B62CAAAA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5FED55984EA484B9EB9B2F92B62CAAAA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_887C9E2E51DD2E5E26072F92B61E9E35" xlink:to="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment_88E5B2DBB92812503B932F92B62CE992" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtConversionConvertedInstrumentAmount1" xlink:label="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_us-gaap_DebtConversionConvertedInstrumentAmount1_B0877B17DA2B8AE9E0C92F92B62DDD39" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock_52B7E1D51E8C54F9306A2F92B62DDD1B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable" xlink:label="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable_F83A37F32ABA1A3928052F92B62D2416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract_EE1DDD76369E7F6096232F92B62C9F23" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxesPaidNet" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_9891453AB8F3F1DDC8552F92B62EADC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:to="loc_us-gaap_InterestPaidNet_DA55EE46D14544491CA32F92B62E0135" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InterestPaidInterestRateHedges" xlink:label="loc_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_F2C2800720162A5352DC2F92B62E8DAC" xlink:to="loc_pfe_InterestPaidInterestRateHedges_D2D730BB2BCAB41DA90D2F92B62E258D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_D2B9BEC6BFA5BA631DD86EE6EE6D8E50" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_D2B9BEC6BFA5BA631DD86EE6EE6D8E50" xlink:to="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4670DF3D65D7F1D2785A6EE6EE71A6E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4670DF3D65D7F1D2785A6EE6EE71A6E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1CE521F6E049EAB4CABA6EE6EE710DC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_4670DF3D65D7F1D2785A6EE6EE71A6E9" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1CE521F6E049EAB4CABA6EE6EE710DC7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_F5485CE838E548F069456EE6EE7163D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1CE521F6E049EAB4CABA6EE6EE710DC7" xlink:to="loc_pfe_GSKConsumerHealthcareMember_F5485CE838E548F069456EE6EE7163D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_A0C7DE4616046D863DE66EE6EE72F56C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_A0C7DE4616046D863DE66EE6EE72F56C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_11062B4C5EA77B2BC4916EE6EE72A380" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_A0C7DE4616046D863DE66EE6EE72F56C" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_11062B4C5EA77B2BC4916EE6EE72A380" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_294BCB2CAA378E73313F6EE6EE7286F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_11062B4C5EA77B2BC4916EE6EE72A380" xlink:to="loc_us-gaap_SeniorNotesMember_294BCB2CAA378E73313F6EE6EE7286F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_FB567A3B42D07902313E6EE6EE733AC6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:to="loc_us-gaap_DebtInstrumentAxis_FB567A3B42D07902313E6EE6EE733AC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_FB567A3B42D07902313E6EE6EE733AC6" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" xlink:label="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_42F92EAEBD1DCF3F8E3B6EE6EE732D1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:to="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_42F92EAEBD1DCF3F8E3B6EE6EE732D1E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member" xlink:label="loc_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:to="loc_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_34FB178E19814824053E6EE6EE74B60A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_U.K.PoundDenominatedDebtMember" xlink:label="loc_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_D4A032FA2ED614D658DA6EE6EE733701" xlink:to="loc_pfe_U.K.PoundDenominatedDebtMember_4093DA4B91037427D1BC6EE6EE747DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_44C89D1E14B5D9F393186EE6EE704339" xlink:to="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_CC68F2B3EAE7985A75BF6EE6EE743437" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_CC68F2B3EAE7985A75BF6EE6EE743437" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F5B032FC710C6A9BAC766EE6EE7420A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_F5B032FC710C6A9BAC766EE6EE7420A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_A20E415F16606AE1DA156EE6EE746407" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_A20E415F16606AE1DA156EE6EE746407" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossOnExchangeOfDebt" xlink:label="loc_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_GainLossOnExchangeOfDebt_A53AA898FF67BA121C0D6EE6EE7513CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_41F9D870A85A9C3B82B16EE6EE75E24E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActIncomeTaxBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_6BD9FD5045563A15B8D96EE6EE75278A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_6BD9FD5045563A15B8D96EE6EE75278A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountNetOfCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_DeconsolidationGainLossAmountNetOfCashConveyed_428DFA63EFDF8883DDA06EE6EE7528BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC4E60F2470B5B177DDF6EE6EE7516EC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_BC4E60F2470B5B177DDF6EE6EE7516EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentsFairValueDisclosure" xlink:label="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_EquityMethodInvestmentsFairValueDisclosure_19D81CE4D6CFD118BF4A6EE6EE75749F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationNetAssetsContributed" xlink:label="loc_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_DeconsolidationNetAssetsContributed_C9B2BC53BE89ED28A7326EE6EE7687A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationGainLossAmountCashConveyed" xlink:label="loc_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_DeconsolidationGainLossAmountCashConveyed_E13808FDD4323A5A5B176EE6EE76C5AB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_800A157E0632C77A14D76EE6EE761378" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_800A157E0632C77A14D76EE6EE761378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_719FBDD15B2F944511F06EE6EE76D213" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_59E0A72EF17BCB68A5556EE6EE74210D" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_719FBDD15B2F944511F06EE6EE76D213" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_A1262649C8F787D1DFB66EEB8102A3C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_ProfitLoss_A1262649C8F787D1DFB66EEB8102A3C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax_03DD4F019180FB8E06BA6EEB8102018B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax_14794487126F1EE5F6206EEB810231ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6F3D0B6DC07F4E6AEE7A6EEB810344B5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6F3D0B6DC07F4E6AEE7A6EEB810344B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6C5E579A2E35A06BAF316EEB81032D77" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_6C5E579A2E35A06BAF316EEB81032D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_AE1EE4E62EE2A66DE7726EEB8103CFFC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_AE1EE4E62EE2A66DE7726EEB8103CFFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax_D480DC0B1CD44F58225E6EEB81037BCA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax_C1DC53270F01323019A06EEB810381B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax_AD1857C16D8D6E2F26B96EEB8103C1A1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax_E94E0CB7B47611DEA1AC6EEB8104ADE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax_C4875C1C1757CAE556196EEB81040DBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax_C0BEBDC2F6AC2AE9C6506EEB81045A65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax_CA8E48DE799773E32D046EEB8104B9D6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax_3C263FF569CA3C4209DA6EEB8104C5AF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax_78229A90ABEC986322346EEB8104D9A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax_9BBBDB3AD47DE3CFDCCA6EEB8104F6A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax_92944204B2B0C6047A896EEB8105D2B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax_FF5180CB946BC719E6036EEB81058039" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax_C312825C57412E657BA76EEB8105F346" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax_596BAB3A11611D9C33586EEB8105DA90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6980AF172CB8FA63F4FF6EEB81050DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossBeforeTax_6F6A9032480902709DE36EEB81065EDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_3B9200347AF59E16D8896EEB8106D1B1" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_3B9200347AF59E16D8896EEB8106D1B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D2946BA839CABB47725B6EEB8106FC81" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_D2946BA839CABB47725B6EEB8106FC81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest_320D782AD3239E67C36B6EEB8106DF99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest_DCC39D8A1E597444588D6EEB81063B5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_694557C5A8ED7BCF2D4A6EEB810253BA" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_2166982541E706ABEFEE6EEB8106A05A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A78C3CFEDE840CD154347E091AF3CC7F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_A78C3CFEDE840CD154347E091AF3CC7F" xlink:to="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EAB0C1DC4101505525227E091AF5D416" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EAB0C1DC4101505525227E091AF5D416" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_EAB0C1DC4101505525227E091AF5D416" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_99A4964DDBB37ED4D5FF7E091AF680D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:to="loc_pfe_GSKConsumerHealthcareMember_99A4964DDBB37ED4D5FF7E091AF680D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_CC7EB8761F47328FE7547E091AF6275B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_CC7EB8761F47328FE7547E091AF6275B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_80149F81486113B0DF2B7E091AF692D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_2A99359DD7F0C31D8CE47E091AF5B9BA" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_80149F81486113B0DF2B7E091AF692D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_BDA5952A057A8190CE8E7E091AF5CFC6" xlink:to="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax_6D1B79602585F5F9376C7E091AF644E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_EF262ECABB652023522A7E091AF72FA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9EC205BD67290E01A8007E091AF79888" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_11EF853575A20FD26DFA7E091AF63066" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_9EC205BD67290E01A8007E091AF79888" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfEquity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_451A1C2D5518065C37A16EEB80CECEDE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_09942ABF6FEAC62F1E716EEB80CEE393" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_451A1C2D5518065C37A16EEB80CECEDE" xlink:to="loc_us-gaap_StatementTable_09942ABF6FEAC62F1E716EEB80CEE393" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_3C2209E238C258F439D96EEB80CE06F1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09942ABF6FEAC62F1E716EEB80CEE393" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_3C2209E238C258F439D96EEB80CE06F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_3C2209E238C258F439D96EEB80CE06F1" xlink:to="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ParentMember" xlink:label="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73" xlink:to="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_PreferredStockMember_31FA96509CD97583DC2E6EEB80CFEF0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_CommonStockMember_F1E49D4C9076751C25496EEB80CF434B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_2B2A1C2998BAC77D5CBF6EEB80CF53F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockMember" xlink:label="loc_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_TreasuryStockMember_88F607DC3E89B848EAFC6EEB80D07038" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_RetainedEarningsMember_4544251A36210669AA006EEB80D0885E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ParentMember_570C13ABE16C4E5AC5C56EEB80CF089A" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51554A2FD9D2669B63026EEB80D071B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NoncontrollingInterestMember" xlink:label="loc_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_8CB1A3FEB9D42EFC5C2C6EEB80CE7E73" xlink:to="loc_us-gaap_NoncontrollingInterestMember_E4EB251B52951506F5B46EEB80D0A70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_EC2E18157D2D521336F46EEB80D0E94B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_09942ABF6FEAC62F1E716EEB80CEE393" xlink:to="loc_us-gaap_StatementLineItems_EC2E18157D2D521336F46EEB80D0E94B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_EC2E18157D2D521336F46EEB80D0E94B" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_SharesIssued_33DFEDBD68A2209431996EEB80D1AF20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_51525D149E4A6470E0A36EEB80D124B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_ProfitLoss_553106E8EDF00387B1F86EEB80D1350F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTax_5537A879AE17339FE4BF6EEB80D10BA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsAbstract" xlink:label="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsCommonStockCash" xlink:label="loc_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:to="loc_us-gaap_DividendsCommonStockCash_C2F26471916B0FD82B496EEB80D125F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DividendsPreferredStockCash" xlink:label="loc_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:to="loc_us-gaap_DividendsPreferredStockCash_86431ACDF4765789EC176EEB80D27A01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders" xlink:label="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DividendsAbstract_60300AD4A496502904D16EEB80D17418" xlink:to="loc_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders_A635EFE026C30CCA906A6EEB80D23ED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_A1786B2BD539A490928C6EEB80D21C50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_4D645D96BA1BCFEDC0326EEB80D2FD97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_2C2B08911F7FDAA769606EEB80D23A5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_EFB442724D35D4EBCCA06EEB80D36017" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock_C719AB53152E54F1F87D6EEB80D31EC3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock" xlink:label="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock_20DF2AEE91C91BFA75E96EEB80D3857A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityOther" xlink:label="loc_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockholdersEquityOther_D3A92C191BB15B316AB76EEB80D37311" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharesIssued" xlink:label="loc_us-gaap_SharesIssued_92A8D58AE66BE646F4286EEB80D33F13" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_SharesIssued_92A8D58AE66BE646F4286EEB80D33F13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6E53B072FC3A16ECEF676EEB80D39756" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_C3C24EFE37C7B3C7EC536EEB80D0293D" xlink:to="loc_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest_6E53B072FC3A16ECEF676EEB80D39756" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_9877C0935D6B8B74CB2B16E825F3C898" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_9877C0935D6B8B74CB2B16E825F3C898" xlink:to="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F21D4B739432A917C31416EFC17A51B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F21D4B739432A917C31416EFC17A51B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_1B914F963E0B44D2C09016EFC1935F54" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_F21D4B739432A917C31416EFC17A51B7" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_1B914F963E0B44D2C09016EFC1935F54" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OncologyVaccinesStartUpMember" xlink:label="loc_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_1B914F963E0B44D2C09016EFC1935F54" xlink:to="loc_pfe_OncologyVaccinesStartUpMember_75A79AE3FDC9E79AFCC016F04A397355" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_D11C3D0A58E4F8AC8CB216E825F347EC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_D11C3D0A58E4F8AC8CB216E825F347EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_4E31458B0A075F01E79A16E825F44C1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_D11C3D0A58E4F8AC8CB216E825F347EC" xlink:to="loc_us-gaap_EquityComponentDomain_4E31458B0A075F01E79A16E825F44C1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_9601E1A695436591CF0616E825F51EBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_4E31458B0A075F01E79A16E825F44C1C" xlink:to="loc_us-gaap_CommonStockMember_9601E1A695436591CF0616E825F51EBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaap_StatementLineItems_16ACB2546478A1408FE016E825F55F5E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_DF6B55B461BBC39BE1A416E825F30FE6" xlink:to="loc_us-gaap_StatementLineItems_16ACB2546478A1408FE016E825F55F5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_79E3A0857DE7F318968616E825F68FF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16ACB2546478A1408FE016E825F55F5E" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_79E3A0857DE7F318968616E825F68FF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_CE7D126F11F8E337B66C16EE4C86343F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_16ACB2546478A1408FE016E825F55F5E" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_CE7D126F11F8E337B66C16EE4C86343F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ConsolidatedStatementsOfIncome" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CDEA74D362756616149ACAF68821A29F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_CDEA74D362756616149ACAF68821A29F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostsAndExpensesAbstract" xlink:label="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfGoodsAndServicesSold" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_99179A8CE52AC978EA25CAF68821A0D4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_99179A8CE52AC978EA25CAF68821A0D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpense" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A953CAFA1822509C21CAF688219628" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_00A953CAFA1822509C21CAF688219628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_F853A8B0ADD0C4E46800CAF6882183F0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_F853A8B0ADD0C4E46800CAF6882183F0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction" xlink:label="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:to="loc_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction_98FEAE72D36E093B840DCAF68822A2A1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_7CACB6047FAE25B64C91CAF688225C30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_F46C70CE7AA39CFA5901CB00E68DEC52" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_F46C70CE7AA39CFA5901CB00E68DEC52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_BCA96FD8447691C8D5D2CAF68822CA88" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CostsAndExpensesAbstract_CFE4D60476B76A025D5ECAF688211AAE" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_BCA96FD8447691C8D5D2CAF68822CA88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B5D51F7D05F7067F040ECAF688225AC0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_B5D51F7D05F7067F040ECAF688225AC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_55B06756EDE11355088DCAF68822F47B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_55B06756EDE11355088DCAF68822F47B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_C381AEDA8B50F42E0157CAF688226EE1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_C381AEDA8B50F42E0157CAF688226EE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:to="loc_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax_0D138BC8CAAF69CE2D54CAF688239BD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax" xlink:label="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:to="loc_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax_77A1D47841598C130F45CAF68823236A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_727B8BDFC07D8F32EEE8CAF68823EFE6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract_397D6FE4FA4A67965BBCCAF68823980C" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_727B8BDFC07D8F32EEE8CAF68823EFE6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProfitLoss" xlink:label="loc_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_ProfitLoss_2FF9953E41E21F689AB7CAF688236F56" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest_0F5C0A70F7FCA8300D6ACAF6882476EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_NetIncomeLoss_28BAEA5901303268F31DCAF68824C713" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare_1DD5A04CF72AA8198021CAF68824CA0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare_F95F42B60E99E9DFEFC6CAF68824B390" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="loc_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_FF8327B175F9627A2A10CAF688241570" xlink:to="loc_us-gaap_EarningsPerShareBasic_FD386DFD53EA427ABFBFCAF68825C6D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDilutedAbstract" xlink:label="loc_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare_368B94ECA418450EC0CECAF68825566D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare_4C74DCE69E487D606B50CAF6882534D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="loc_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareDilutedAbstract_E660D5FBC12FFFDC518ACAF688256096" xlink:to="loc_us-gaap_EarningsPerShareDiluted_97F9D5B8773B910108B2CAF6882595CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9631D68B3CBE14CB297ECAF688254926" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_9631D68B3CBE14CB297ECAF688254926" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7251C6C852C7E172F4E5CAF68826AA00" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_113FAEA5DE1894D39588CAF6882082C9" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_7251C6C852C7E172F4E5CAF68826AA00" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_64F3EB76417AD0E6F5D080206DD75D9E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_64F3EB76417AD0E6F5D080206DD75D9E" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_9D7E7A38F47DB0130EA380206DD7C900" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A54C6DDA4A802B8D452877FD3DE67D93" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_A54C6DDA4A802B8D452877FD3DE67D93" xlink:to="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_341B5BF8C0F54F5E01E178021DA8CC30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_srt_RangeAxis_341B5BF8C0F54F5E01E178021DA8CC30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_F17F26DD4C3106DE347178021ECA00EF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_341B5BF8C0F54F5E01E178021DA8CC30" xlink:to="loc_srt_RangeMember_F17F26DD4C3106DE347178021ECA00EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_B6DD19B6F9A6E5B0C21378023FB603E8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_F17F26DD4C3106DE347178021ECA00EF" xlink:to="loc_srt_MinimumMember_B6DD19B6F9A6E5B0C21378023FB603E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_882CA78CDBC3488CCAD777FD3DE83919" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_882CA78CDBC3488CCAD777FD3DE83919" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_882CA78CDBC3488CCAD777FD3DE83919" xlink:to="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EnvironmentalRemediationLitigationMember" xlink:label="loc_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A" xlink:to="loc_pfe_EnvironmentalRemediationLitigationMember_B5211CF6F43850FA56E577FD3DE8A5B1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViolationofAntitrustLawsMember" xlink:label="loc_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_E3980E2DA6D7CCFF51D777FD3DE8592A" xlink:to="loc_pfe_ViolationofAntitrustLawsMember_A6A4A401D76D6B9F924077FD3DE86C00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_39E3CCA44828F8CFC7C077FD3DE99F34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_srt_LitigationCaseAxis_39E3CCA44828F8CFC7C077FD3DE99F34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_39E3CCA44828F8CFC7C077FD3DE99F34" xlink:to="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member" xlink:label="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E" xlink:to="loc_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_AAEE6A042E201629512777FD3DE94EF9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember" xlink:label="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_C3A49F5B7A819EABF3EA77FD3DE9327E" xlink:to="loc_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_C5FACD1EDDA5CD516F7277FD3DE92350" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_DA810CAEDF46DCACDA3377FD3DEA722A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_srt_ProductOrServiceAxis_DA810CAEDF46DCACDA3377FD3DEA722A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_DA810CAEDF46DCACDA3377FD3DEA722A" xlink:to="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflectraMember" xlink:label="loc_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:to="loc_pfe_InflectraMember_E1C96CF175F124F919CE77FD3DEA766C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:to="loc_pfe_EpiPenMember_9A75A38827028D84AE82780201FE8109" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DocetaxelMember" xlink:label="loc_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:to="loc_pfe_DocetaxelMember_59637A962A3D1513172377FD3DEAFF34" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PhenytoinSodiumCapsulesMember" xlink:label="loc_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_D8AB455D5D8FFA00CB0C77FD3DEAE215" xlink:to="loc_pfe_PhenytoinSodiumCapsulesMember_C9F5DDA56861984F758F77FD3DEAA2A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_96B7AA10D0DA6438964877FD3DEB1ADD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_us-gaap_LitigationStatusAxis_96B7AA10D0DA6438964877FD3DEB1ADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_96B7AA10D0DA6438964877FD3DEB1ADD" xlink:to="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_09E0356D15C01CCD170277FD3DEB54BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628" xlink:to="loc_us-gaap_PendingLitigationMember_09E0356D15C01CCD170277FD3DEB54BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_264808451E6BCAD916DF77FD3DEBF8AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_6497D27A2DE941F21AEB77FD3DEB0628" xlink:to="loc_us-gaap_SettledLitigationMember_264808451E6BCAD916DF77FD3DEBF8AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_6D7181739B0E8529E63777FD3DE7F3E9" xlink:to="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyPatentsAllegedlyInfringedNumber" xlink:label="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber_6885987742454AE4725377FD3DEC2138" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyNumberOfLawsuits" xlink:label="loc_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_pfe_LossContingencyNumberOfLawsuits_47E59616341A6024C7AC780182774EAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyClaimsDismissedNumber" xlink:label="loc_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_us-gaap_LossContingencyClaimsDismissedNumber_749AC829EB9F48EC4C9477FD3DEC18EF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant" xlink:label="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant_94187E3480DE857D46E677FD3DEC3C43" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LossContingencyClassActionsFiledNumber" xlink:label="loc_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_pfe_LossContingencyClassActionsFiledNumber_0C86CCE0E8F2CCE7654E77FD3DEC999D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FeasibilityStudyNumberOfLagoons" xlink:label="loc_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_pfe_FeasibilityStudyNumberOfLagoons_4C03828822B07045991477FD3DEC423D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyEstimateOfPossibleLoss" xlink:label="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_E636D1AD5F2D49F2CD9077FD3DECFEB3" xlink:to="loc_us-gaap_LossContingencyEstimateOfPossibleLoss_16434C49A0201B93C82E77FD3DEDA6B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9802CFB50F2969C14DD47E535309A011" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesTable" xlink:label="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9802CFB50F2969C14DD47E535309A011" xlink:to="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeAxis_C55395532802AE9765D77E53530A1626" xlink:to="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsequentEventTypeDomain_ED3A9FC9F9E2861402507E53530A102A" xlink:to="loc_us-gaap_SubsequentEventMember_35F30B3A6960BC539CE77E53530A0FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_F274F72631FB9E24E7A77E53530A55C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_srt_ProductOrServiceAxis_F274F72631FB9E24E7A77E53530A55C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_F274F72631FB9E24E7A77E53530A55C1" xlink:to="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrecedexPremixMember" xlink:label="loc_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:to="loc_pfe_PrecedexPremixMember_86C5DB931EF028F6C3B07E53530B9174" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:to="loc_pfe_XeljanzMember_26E03A068A73241041E37E53530B3108" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_61D059BA3F264EE652DC7E53530B639E" xlink:to="loc_pfe_EliquisMember_830163B8810C2FF9FCB47E53530BB9F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseAxis" xlink:label="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_LitigationCaseTypeDomain" xlink:label="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_7A698717E0903460A62C7E53530BA3A2" xlink:to="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusAmnealPharmaceuticalsLLCMember" xlink:label="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_04D263A0E6FBDDCA907D7E53530C21D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusFreseniusKabjUSALLCMember" xlink:label="loc_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_HospiraVersusFreseniusKabjUSALLCMember_15C03F006634836207677E53530C0C21" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraVersusParMember" xlink:label="loc_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_HospiraVersusParMember_525540273D241D86168B7E53530C77B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusZydusMember" xlink:label="loc_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerVersusZydusMember_FD409A0C919E7423F87A7E53530C24F7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusAjantaMember" xlink:label="loc_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerVersusAjantaMember_E421A10B1C14B65B4C477E53530DD688" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusGenericCompaniesMember" xlink:label="loc_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerVersusGenericCompaniesMember_4109ABA081D55DCDC2527E53530D0BBA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member" xlink:label="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_22A7C4D81AC3F053E7ED7E53530D6BE5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerandBMSVersusSeveralGenericManufacturersMember" xlink:label="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_739BE5854AFC103E322F7E53530C58E2" xlink:to="loc_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_0FA7D9D94BBE0AC354147E53530D5E14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesByNatureAxis" xlink:label="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyNatureDomain" xlink:label="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesByNatureAxis_F22EC5694BB301892AEA7E53530D31C9" xlink:to="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PatentInfringementMember" xlink:label="loc_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingencyNatureDomain_9D0A19F3271003029AD97E53530E1DCB" xlink:to="loc_pfe_PatentInfringementMember_9911087BF12A5FA0DD3B7E53530EAD3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_64E37799A2F8467177AE7E53530EDBBB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_us-gaap_LitigationStatusAxis_64E37799A2F8467177AE7E53530EDBBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_64E37799A2F8467177AE7E53530EDBBB" xlink:to="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_JudicialRulingMember" xlink:label="loc_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:to="loc_us-gaap_JudicialRulingMember_6ED95F6BE39BFA12373F7E53530F341E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_D72A4308E5061CB7A93D7E53530FC6B0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:to="loc_us-gaap_PendingLitigationMember_D72A4308E5061CB7A93D7E53530FC6B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SettledLitigationMember" xlink:label="loc_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_423EE618011B0CCBE4387E53530E444C" xlink:to="loc_us-gaap_SettledLitigationMember_403AC2E6CAC63EA0C65E7E53530F0AC0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingenciesLineItems" xlink:label="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesTable_49AE79DB9529AE64CDC57E535309E268" xlink:to="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsWithoutCourtProceedingsNumber" xlink:label="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber_7DEFB8A9D5A1B4577BA87E53530F6314" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsFoundInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_us-gaap_GainContingencyPatentsFoundInfringedUponNumber_944060E26A74A9F1C7757E53530F0A3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber_52A2B59769B11C15043D7E535310AF9E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019_05219344A712FEA668397E5353101BAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber_B3F37FB11475074E4EC47E5353106038" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber" xlink:label="loc_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber_E1AA670AD7BFFFD343C37E5353107516" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber" xlink:label="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber_2E51B0BEC1C0FB0026157E53531067E3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyNumberofDefendants" xlink:label="loc_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyNumberofDefendants_2C1D4DF2699AEC4D04067E535311B3E9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019" xlink:label="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GainContingenciesLineItems_A7687F85E67247E6A69B7E53530F61FD" xlink:to="loc_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019_DD7217B6E6B9BF26F6977E5353117754" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B27325FADFA6FA9C1E9A7E0E85670132" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_B27325FADFA6FA9C1E9A7E0E85670132" xlink:to="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_3BC4686A7B9334266A897E0E8567EA71" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_3BC4686A7B9334266A897E0E8567EA71" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_AC8898B1AF487D0526177E0E85687B4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_3BC4686A7B9334266A897E0E8567EA71" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_AC8898B1AF487D0526177E0E85687B4D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_0417D08D3D7FA202E9257E0E85689D78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_AC8898B1AF487D0526177E0E85687B4D" xlink:to="loc_pfe_IncomeTaxesPayableMember_0417D08D3D7FA202E9257E0E85689D78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_2A98E06D5925EC07EAD87E0E85695707" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:to="loc_srt_ProductOrServiceAxis_2A98E06D5925EC07EAD87E0E85695707" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_2A98E06D5925EC07EAD87E0E85695707" xlink:to="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_55E6786D85D2729E8C6C7E0E85695816" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A" xlink:to="loc_pfe_BesponsaMember_55E6786D85D2729E8C6C7E0E85695816" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_DAF0D5976F0F0A69C16F7E0E856A0AEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_7CC955D132235CF1B02E7E0E85693B6A" xlink:to="loc_pfe_BosulifMember_DAF0D5976F0F0A69C16F7E0E856A0AEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_7315CC1D3A83CDD507097E0E8567389A" xlink:to="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermPurchaseCommitmentAmount" xlink:label="loc_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_LongTermPurchaseCommitmentAmount_6D7D9439F29FA78F782B7E0E856AF9B9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_DCCE65EFAECC4B486BD27E0E856A0F8A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_DCCE65EFAECC4B486BD27E0E856A0F8A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_DD83DE7E261531A397C17E0E856AC50D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B37E4C330D44B808E4357E0E856BF2E4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_B37E4C330D44B808E4357E0E856BF2E4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForRepatriationTax" xlink:label="loc_pfe_PaymentForRepatriationTax_AAA417EABF31A69060817E0E856B7D09" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_pfe_PaymentForRepatriationTax_AAA417EABF31A69060817E0E856B7D09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiability_98B41DF739BC1629CB597E0E856B99F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent_53D8C6CC798649F4745E7E0E856BF0ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_F0976157621678D211427E0E856A94D6" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent_875D1D2E9D69B1780CD77E0E856B1E41" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CoverAbstract" xlink:label="loc_dei_CoverAbstract_D030A2E7FA0D6D50DE9BCAF3D3CB1C8B" xlink:type="locator" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitiesTable" xlink:label="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_D030A2E7FA0D6D50DE9BCAF3D3CB1C8B" xlink:to="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:to="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_04E09A1C6707F0F4FF31CAF3D3CE98FD" xlink:to="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="loc_us-gaap_CommonStockMember_BAA7D888B7970F5E5E14CAF3D3CEA1ED" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20200.000Member" xlink:label="loc_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="loc_pfe_NotesDue20200.000Member_0B2CDDBD616C5888C8D2CAF3D3CFEA9B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20220.250Member" xlink:label="loc_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="loc_pfe_NotesDue20220.250Member_264533B976386E2F6AB8CAF3D3CF3A56" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NotesDue20271.000Member" xlink:label="loc_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_1F1572D71AB7FF7DA48ACAF3D3CEA78E" xlink:to="loc_pfe_NotesDue20271.000Member_94F5BC9E66D36CF1FCCBCAF3D3CFD822" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInformationLineItems" xlink:label="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntitiesTable_E9570DD3062F05785728CAF3D3CDC6BA" xlink:to="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentType" xlink:label="loc_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentType_EDF6CE33CEA88477E04ACAF3D3D00B4D" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentAnnualReport" xlink:label="loc_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentAnnualReport_90764FE37B7F6444C0B5CAF9F4D86C5F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentPeriodEndDate_D9936C2E534A2EAC1363CAF3D3D0EA6B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentTransitionReport" xlink:label="loc_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentTransitionReport_C808303D63EC1A2C929FCAF3D3D0EBE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFileNumber" xlink:label="loc_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityFileNumber_C096B7C1655E49CC77B0CAF3D3D0F2B0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityRegistrantName_D5AB0E39B9D3B89FB4D3CAF3D3D142C0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityIncorporationStateCountryCode_80871C7135FAE4D6A8FBCAF3D3D1CE0B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityTaxIdentificationNumber_C0CDAE91779C23C88AB2CAF3D3D1C405" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityAddressAddressLine1_38A3AE7D4A6AE58CFE9DCAF3D3D10C17" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityAddressCityOrTown_7F1C4D625A3D0D6C93BACAF3D3D175C9" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityAddressStateOrProvince_0D08DBDA6DB2CF9F61E0CAF3D3D1B9E3" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityAddressPostalZipCode_B575F112BEED563F9705CAF3D3D27010" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CityAreaCode" xlink:label="loc_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_CityAreaCode_7B3B0CA28C00FF42954FCAF3D3D27698" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LocalPhoneNumber" xlink:label="loc_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_LocalPhoneNumber_C44722AC45A59FC913D1CAF3D3D2952C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_Security12bTitle" xlink:label="loc_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_Security12bTitle_3A4ED22C8411BCE657C2CAF3D3D29970" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_TradingSymbol" xlink:label="loc_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_TradingSymbol_7ED00353C1A8EB0E8753CAF3D3D23858" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_SecurityExchangeName" xlink:label="loc_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_SecurityExchangeName_D6E1F529F0C2B5DF97D8CAF3D3D2E293" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_AF1776680A029E83D03FCAF3D3D3A259" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityVoluntaryFilers_C9C8681E445AD219A642CAF3D3D3E158" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityCurrentReportingStatus_58C1BC36B21B78ACDF62CAF3D3D36EFB" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityInteractiveDataCurrent_F2EED1FE7FD1FFE56C23CAF3D3D32D2E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityFilerCategory_BFC80ED00EDFDB68A1B0CAF3D3D3B324" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntitySmallBusiness_A0B9FD26E8F43E5DFEFDCAF3D3D352E0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityEmergingGrowthCompany_2ED5AB05612488578F3DCAF3D3D418C7" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityShellCompany_88C7355C17452F5D1874CAF3D3D4D792" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityPublicFloat_ECEFD947B322BAD92888CAF3D3D4CDC0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_E77EE00AD75148369264CAF3D3D46EE2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_3624260077583A41F272CAF3D3D4A901" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_EntityCentralIndexKey_B5652E3005A935FA2E14CAF3D3D460B4" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_CurrentFiscalYearEndDate_FDB1F33A8F8049145A6ACAF3D3D56627" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentFiscalYearFocus_1D055A9DB4DAAFA4DE6ACAF3D3D5146C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_DocumentFiscalPeriodFocus_530468CC5025D4ED1D90CAF3D3D5847B" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityInformationLineItems_91CA4E7964977A29F3F9CAF3D3CF6AA1" xlink:to="loc_dei_AmendmentFlag_12232785CC45098BF1CBCAF3D3D53924" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_70BBDAEFCAC73F44CDD1802077FFB01D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_70BBDAEFCAC73F44CDD1802077FFB01D" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_E85077D2B9DAC843269380207800A0C0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_BD4D08D7CE8DC5DA929655F213406EC3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_BD4D08D7CE8DC5DA929655F213406EC3" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_45BDDBA130A12BC4395955F21340A01D" xlink:to="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_A9D3BF07CE9B87DE615555F213414E1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_21C4B973752A8987E2B355F213401B53" xlink:to="loc_us-gaap_CommonStockMember_A9D3BF07CE9B87DE615555F213414E1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_D98B4F6E936E1CE14ADD55F2134153C3" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_5481E92E5631948DC12E55F213416E4D" xlink:to="loc_us-gaap_StockOptionMember_EBD3D7FC5E3961B7B11555F21341F362" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_34966B214D265F53C87755F213401645" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareBasicAbstract" xlink:label="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest_0FB71D1787655C34D33955F21342316F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity_52B0A5C57B2AAE8B2CE855F21342D78B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperations" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperations_CA345524E1F76FFBE22555F213437D62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendsIncomeStatementImpact" xlink:label="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_PreferredStockDividendsIncomeStatementImpact_13C01B6C27C7A1A3703955F213435E29" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic_BF1A996F9B9FD8779A2B55F213437CCF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax_C3A18C1B3D240F97F07A55F21343B885" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest_75A0386F36712AE9E32C565EF4B0D1C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_5751B4604AA675A1195C565FAF0B19FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareBasicAbstract_4AE932F1FD850581894B55F21342E836" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic_8C2988FD43AFD1628E2855F2134329F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DilutiveSecuritiesAbstract" xlink:label="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted" xlink:label="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:to="loc_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted_17CA23BC8C5FD501C8AA55F21343BEC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity" xlink:label="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_F8FA9D506C63B4F94C9855F21344E018" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:to="loc_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity_F8FA9D506C63B4F94C9855F21344E018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted" xlink:label="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DilutiveSecuritiesAbstract_F437D81877143A27E16F55F21343A459" xlink:to="loc_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted_5A5361C020817874A47455F213443A90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_28AA2916E37D67C6CE2455F213444DF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_797695C8227E644FDCEC55F213453B7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_B7076FFC028C8550666F55F21345C5F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_D6BF06DC63F3CD1612EF55F2134512B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="loc_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_4FEC2440257B1E587B2955F21344E584" xlink:to="loc_us-gaap_CommonStockDividendsPerShareDeclared_B58F7E8A24F8FD73E53555F213459E03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_41FC6478FEB90B87736155F213452007" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_646B151BD734138C43B255F21342E0EB" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_41FC6478FEB90B87736155F213452007" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="loc_us-gaap_EarningsPerShareAbstract_412BC7479DFDAEFC34A78020711BAC61" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_412BC7479DFDAEFC34A78020711BAC61" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_56CCF0A571F48B89B9078020711B3C73" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/Equity" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_3C227292A8D9C67E57698020739D2F62" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_3C227292A8D9C67E57698020739D2F62" xlink:to="loc_us-gaap_StockholdersEquityNoteDisclosureTextBlock_B1BA6EF51CDD2876D3A18020739D2DA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquityNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_78CCBB6FECFA1619BF252677F5C6FCAE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfTreasuryStockTable" xlink:label="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_78CCBB6FECFA1619BF252677F5C6FCAE" xlink:to="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramAxis" xlink:label="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareRepurchaseProgramDomain" xlink:label="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramAxis_256CFD9D29506E359E672677F5C775AF" xlink:to="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2015StockPurchasePlanMember" xlink:label="loc_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_December2015StockPurchasePlanMember_B3D37F10FCF810501A222677F5C73949" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2017StockPurchasePlanMember" xlink:label="loc_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_December2017StockPurchasePlanMember_6FF4AADE6CBA3A3F903F2677F5C82458" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_December2018StockPurchasePlanMember" xlink:label="loc_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_December2018StockPurchasePlanMember_1BA41881D89A5B5E39C12677F5C824EC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareRepurchaseAgreementwithCitibankMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_ShareRepurchaseAgreementwithCitibankMember_F729DF862BC4AC4032032677F5C8515A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareRepurchaseAgreementwithGSCoMember" xlink:label="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_ShareRepurchaseAgreementwithGSCoMember_27884964721DE2191C0F2677F5C83DB2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OpenMarketPurchasesMember" xlink:label="loc_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareRepurchaseProgramDomain_0DF6B8D7EEBA2BB27A3E2677F5C77450" xlink:to="loc_pfe_OpenMarketPurchasesMember_EBAA676CAFAABCF212892677F5C827E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_B6DC2FDF6C7DC40902ED2677F5C9941E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_B6DC2FDF6C7DC40902ED2677F5C9941E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_B6DC2FDF6C7DC40902ED2677F5C9941E" xlink:to="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockMember" xlink:label="loc_us-gaap_PreferredStockMember_FDE274A657B5C01228902677F5C93461" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C" xlink:to="loc_us-gaap_PreferredStockMember_FDE274A657B5C01228902677F5C93461" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaap_CommonStockMember_0F748928B0C81B96BBE32677F5C94F10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_70DA9B3D68685DBCF7992677F5C9074C" xlink:to="loc_us-gaap_CommonStockMember_0F748928B0C81B96BBE32677F5C94F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="loc_us-gaap_StatementClassOfStockAxis_C08BF2F9E364F092B9BF2677F5C9612C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_StatementClassOfStockAxis_C08BF2F9E364F092B9BF2677F5C9612C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ClassOfStockDomain" xlink:label="loc_us-gaap_ClassOfStockDomain_71FE1835C6D8B7F0D5B92677F5C9EB46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_C08BF2F9E364F092B9BF2677F5C9612C" xlink:to="loc_us-gaap_ClassOfStockDomain_71FE1835C6D8B7F0D5B92677F5C9EB46" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeriesAConvertiblePreferredStockMember" xlink:label="loc_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_71FE1835C6D8B7F0D5B92677F5C9EB46" xlink:to="loc_pfe_SeriesAConvertiblePreferredStockMember_02785449A76CA29F518C2677F5CA31D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_C30819DC26951B86A3562677F5CA4AF2" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredESOPPlanMember" xlink:label="loc_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:to="loc_pfe_PreferredESOPPlanMember_B28384F7FB5745C9ABEB2677F5CB1A4A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredEmployeeStockOwnershipPlanMember" xlink:label="loc_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:to="loc_pfe_PreferredEmployeeStockOwnershipPlanMember_98BA944AED2F6BA61BE92677F5CB1247" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CommonESOPPlanMember" xlink:label="loc_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain_4A33913404F5601C55AF2677F5CAD706" xlink:to="loc_pfe_CommonESOPPlanMember_4906FBCF1FD44FD7B6BD2677F5CB9ED5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityClassOfTreasuryStockLineItems" xlink:label="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfTreasuryStockTable_13F201767F878ED848262677F5C6D2BC" xlink:to="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramAuthorizedAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_StockRepurchaseProgramAuthorizedAmount1_99C77CEF7DD3690F97362677F5CBCBA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1" xlink:label="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1_EF5F31FADD266D51DC6B2677F5CC9E6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt_D9BDC9093A0513D3061C2677F5CCF223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_C11BD8593371B59C98FD2677F5CCE751" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare_251BD5371601372585852677F5CC9B6D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount" xlink:label="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount_264B7DD138D930E8490E2677F5CCBF2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_D6DAEB52E67C493539B82677F5CC1652" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare" xlink:label="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare_21C2A2EB14D93AE98CC12677F5D21615" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_557E9E5C869C2EC800262677F5D22CAC" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_557E9E5C869C2EC800262677F5D22CAC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PreferredStockSharesHeldInEmployeeTrustShares" xlink:label="loc_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_pfe_PreferredStockSharesHeldInEmployeeTrustShares_4C864E2DA8D0FB2E2151268F0BE8EBC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP_725924908C600C74B39F2677F5D29C89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockDividendRatePercentage" xlink:label="loc_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_PreferredStockDividendRatePercentage_9B75E0BB6310FB62E31A2677F5D2DBE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_6B94A9270D2582DEF61D2677F5D31712" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion" xlink:label="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion_2720E77110A12B9E28312677F5D37100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PreferredStockRedemptionPricePerShare" xlink:label="loc_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_PreferredStockRedemptionPricePerShare_8B79B27664F4D6A2CC802677F5D30F2F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NumberofEmployeeStockOwnershipPlans" xlink:label="loc_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_pfe_NumberofEmployeeStockOwnershipPlans_DF7E897AE8459768BBBC2677F5D33013" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConvertiblePreferredStockNumberofSharesConvertible" xlink:label="loc_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_pfe_ConvertiblePreferredStockNumberofSharesConvertible_A35DA0F34FA0D616201D2677F5D36DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense" xlink:label="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityClassOfTreasuryStockLineItems_17BE322653F0E43DA1162677F5CBCBC9" xlink:to="loc_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense_1E7737859A8714F29A652677F5D32E25" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_B8E0E7E657CB5F60E847802073F1AF5F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockSharesAcquired" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B8E0E7E657CB5F60E847802073F1AF5F" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_FF22C1689AE1D6CF4ED4802073F1E339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_B8E0E7E657CB5F60E847802073F1AF5F" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_32495592BAE926105CDD802073F1FDC2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaap_EquityAbstract_68C7E9BCFF0A4D1110ED802075A07912" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfTreasuryStockByClassTextBlock" xlink:label="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_68C7E9BCFF0A4D1110ED802075A07912" xlink:to="loc_us-gaap_ScheduleOfTreasuryStockByClassTextBlock_486D0EE1109FB55377B9802075A065FA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstruments" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_1A4A235FCA0A7933ABEF80206BEBDB3F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentsDisclosureTextBlock" xlink:label="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_1A4A235FCA0A7933ABEF80206BEBDB3F" xlink:to="loc_us-gaap_FinancialInstrumentsDisclosureTextBlock_BE2E9192308244C7219380206BEB03BA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_7CD505C1AE81358272F6802072218243" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_7CD505C1AE81358272F6802072218243" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_309864923D6F8273A0268020722204F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_309864923D6F8273A0268020722204F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3D1D4BC5E980CAF1DC6580207223F074" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_309864923D6F8273A0268020722204F4" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3D1D4BC5E980CAF1DC6580207223F074" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_6C744DA6C78FA7D732C8802072283675" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3D1D4BC5E980CAF1DC6580207223F074" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_6C744DA6C78FA7D732C8802072283675" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:to="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueDisclosureItemAmountsDomain" xlink:label="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementBasisAxis_A9ACF9181D2C4B3DCDE88020722921AF" xlink:to="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:to="loc_us-gaap_PortionAtFairValueFairValueDisclosureMember_A41A5A1C05D59775D950802072293B97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CarryingReportedAmountFairValueDisclosureMember" xlink:label="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:to="loc_us-gaap_CarryingReportedAmountFairValueDisclosureMember_BBE450F4E384F961A4668020722ABD7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosureItemAmountsDomain_A7F634CC044CB800FE4E802072296F98" xlink:to="loc_us-gaap_EstimateOfFairValueFairValueDisclosureMember_827FAF0E6FEA089207E38020722AAB49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D098E47E012490CC274C8020722BD8F8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_000A4925636F30FF67E380207222708D" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D098E47E012490CC274C8020722BD8F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtFairValue" xlink:label="loc_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_D098E47E012490CC274C8020722BD8F8" xlink:to="loc_us-gaap_LongTermDebtFairValue_715CA5A76C9EB39E8A0D8020722B75A1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_DD770EA3C2979D6BC18E802072588EE3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTable" xlink:label="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_DD770EA3C2979D6BC18E802072588EE3" xlink:to="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesByIndustryAxis" xlink:label="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:to="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesIndustryMember" xlink:label="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesByIndustryAxis_C94E6742AD9573CC961680207258540D" xlink:to="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialServicesSectorMember" xlink:label="loc_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquitySecuritiesIndustryMember_1B7DD6337F1745F9DE7B802072595C97" xlink:to="loc_us-gaap_FinancialServicesSectorMember_1BDCA56C413D8490A31D802072591BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskLineItems" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_CF634006E1DDD6D58235802072588630" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure" xlink:label="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_2DA5FD93BD56E1CB770E80207259AA43" xlink:to="loc_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure_6BE80BD029AC24BACEE08020725AB809" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B56725C4EFC6191EE74324BD7A7729AB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B56725C4EFC6191EE74324BD7A7729AB" xlink:to="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_14887B0F30999D5F3B6524BD7A7778D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_14887B0F30999D5F3B6524BD7A7778D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_14887B0F30999D5F3B6524BD7A7778D1" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:to="loc_pfe_LongtermInvestmentsMember_BCC176E4023513FE36B124BD7A7806DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtMember" xlink:label="loc_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:to="loc_us-gaap_ShortTermDebtMember_11E4350CEAAE7DCC909324BD7A780ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtMember" xlink:label="loc_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_2EB8F2DA31B5CA60ED5124BD7A781E50" xlink:to="loc_us-gaap_LongTermDebtMember_95DF3E64706D200C451424BD7A78D451" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_1ABA8AD5FD82A3D0990024BD7A776FBB" xlink:to="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetFairValueHedge" xlink:label="loc_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedAssetFairValueHedge_7C46AD22D04ECA04E7A924BD7A788C20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedge" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedge_89C9E801A946D3C04F7824BD7A798C3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease_10D3FAAF0B3FF05076DA24BD7A79AA3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease_9AEC5C2E502E891CC1CC24BD7A79F98D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_E1937BEE0A51F39C82AA24BD7A795FE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease" xlink:label="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_28456B498BF29C54D9ED24BD7A78EE06" xlink:to="loc_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease_55AC45F71E713D6B2EBF24BD7A79D08B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_2C7AF6F299BA7101E63FE395F31EF78E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_2C7AF6F299BA7101E63FE395F31EF78E" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_B4D8B2745F6ECA8D1244E395F31FF5CC" xlink:to="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_245A2442F7C7AE07C6DDE395F320100E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_AB2C3329DCDF88882618E395F31FF5FB" xlink:to="loc_us-gaap_NondesignatedMember_F1A7DBF9E1BD559F466FE395F320134A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingRelationshipDomain" xlink:label="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_A389D2EF2499EC482415E395F320483D" xlink:to="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CashFlowHedgingMember" xlink:label="loc_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:to="loc_us-gaap_CashFlowHedgingMember_6720F4FF4C28E4805B2CE395F321577D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetInvestmentHedgingMember" xlink:label="loc_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingRelationshipDomain_0C8ABF6BA2BA8240B592E395F320054B" xlink:to="loc_us-gaap_NetInvestmentHedgingMember_CBC82F10F70ECEE3CE9BE395F32170A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_02ABB4F9BDC5DEE1C47BE395F321773F" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3774639183D4E9F552C7E395F32201C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="loc_us-gaap_InterestRateContractMember_D9AF645BCF8C949E898AE395F32260DD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_102DF86C67B6CD8782E9E395F32397E5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7055A678B2143E1CE0CDE395F322DA3A" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_E247D6E6ED5A113360FEE395F323620E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_30BAC35CECAC8A64E536E395F323527F" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_21AE0F188D474AD04A63E395F324F8AC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A6763F18F5EE3276DB8EE395F323E60C" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_9D9AEE5D133DE8694A04E52E4FCD6B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsGainLossLineItems" xlink:label="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable_D71AA86B99949AA2A002E395F31F6ED9" xlink:to="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1_76D4AB07AC05A60A4426E52F0BB6F8B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1" xlink:label="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1_1A441ACDF405DDA6F580E52F0F47E6C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet" xlink:label="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet_4F5E973A53285A4743A8E532235F972D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeGainLossOnDerivativeNet" xlink:label="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_DerivativeGainLossOnDerivativeNet_A94C3140B999FC9DB846E395F3262DC5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax_965208C6F62E7343F1A4E52E9A3E112B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax_94453B212948E4423DC4E52E9A6D0F9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax_4E0010244BB396C13D85E53000C1A38D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax_81CE2610E8D5C17174BEE530DEA1E0EE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax_40A0FD8CE53C78DE3C68E5322379576A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax_B10FC78FBF332F314201E53223AEB46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_4F9CFA74D41365EE5930E52E9A567500" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax_45944C2F425196C93A15E52E9A8426A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax_80EB9B8F3D75E7621F70E5300358BE2B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax_CBC7707D4BC76B4A0A87E530E2A87E5B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax_9C88FDDF0099C0725A2DE53223926074" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentsGainLossLineItems_A80CF283CA85B69C20AAE395F32550BD" xlink:to="loc_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax_A18F7D2B2C76AC68497DE53223C81D45" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_B603F5FC42BA595672AF7A83FA593521" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_B603F5FC42BA595672AF7A83FA593521" xlink:to="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_D394F6552712A8942D177A9510F35AED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_HedgingDesignationAxis_D394F6552712A8942D177A9510F35AED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_861AE60ACA99F34D8E4D7A9510F4FBFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_D394F6552712A8942D177A9510F35AED" xlink:to="loc_us-gaap_HedgingDesignationDomain_861AE60ACA99F34D8E4D7A9510F4FBFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_F89572E0E9CFB0A415987A95130FFF03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_861AE60ACA99F34D8E4D7A9510F4FBFC" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_F89572E0E9CFB0A415987A95130FFF03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_EBE75871AA160834EC9C7A95100614C1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_EBE75871AA160834EC9C7A95100614C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_EBE75871AA160834EC9C7A95100614C1" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F" xlink:to="loc_us-gaap_CostOfSalesMember_35AB983F995A5669F1AA7A960E520128" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherIncomeDeductionsAndCostOfSalesMember" xlink:label="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_7493761E8C59317BD0547A9510D9269F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_C5E1061EA360F7FCF0577A951009746F" xlink:to="loc_pfe_OtherIncomeDeductionsAndCostOfSalesMember_7493761E8C59317BD0547A9510D9269F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_DDF61AA0FA9AF60248C27A83FA591FC2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_DDF61AA0FA9AF60248C27A83FA591FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_29A7F9A108939EB9B8AD7A83FA596891" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_DDF61AA0FA9AF60248C27A83FA591FC2" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_29A7F9A108939EB9B8AD7A83FA596891" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_CAC20CAA3010EA9A4EE77A83FA5AC45D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_29A7F9A108939EB9B8AD7A83FA596891" xlink:to="loc_us-gaap_UnsecuredDebtMember_CAC20CAA3010EA9A4EE77A83FA5AC45D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6B2C157D7A7FD1B7F7BB7A83FA5A5D89" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6B2C157D7A7FD1B7F7BB7A83FA5A5D89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6B2C157D7A7FD1B7F7BB7A83FA5A5D89" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7D95FDEA226CF5F0D4337A9513299EB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7D95FDEA226CF5F0D4337A9513299EB6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyShortTermBorrowingsMember" xlink:label="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_B62A8C65C20999A5529C7A83FA5A69DD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:to="loc_pfe_ForeignCurrencyShortTermBorrowingsMember_B62A8C65C20999A5529C7A83FA5A69DD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ForeignCurrencyLongTermDebtMember" xlink:label="loc_pfe_ForeignCurrencyLongTermDebtMember_7C690887FF52FB1554AD7A83FA5B460A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_0330A271B68296E378ED7A83FA5AD4BC" xlink:to="loc_pfe_ForeignCurrencyLongTermDebtMember_7C690887FF52FB1554AD7A83FA5B460A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_F2031A909CA94C2856CE7A83FA590B29" xlink:to="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_99D8DB75A6AAF264A3917A950FDE52B5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax_99D8DB75A6AAF264A3917A950FDE52B5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months" xlink:label="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months_1C05A1DBE8C7A4AED81C7A83FA5BD7DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_7D9F9BFBBD62B16C002C7A83FA5B0795" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_LongTermDebt_7D9F9BFBBD62B16C002C7A83FA5B0795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_8C225A6CA935CB788EF37A83FA5B123B" xlink:to="loc_us-gaap_DebtCurrent_CD29D0C85A13D706083A7A83FA5C7DC4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_6DF54D4CB3B8A4C3615CE395F32D6375" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_6DF54D4CB3B8A4C3615CE395F32D6375" xlink:to="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HedgedItemAxis" xlink:label="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:to="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HedgedItemDomain" xlink:label="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemAxis_37C6FBCB0ACA54838565E395F32D52C3" xlink:to="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SalesMember" xlink:label="loc_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_HedgedItemDomain_BA270867310E572E9768E395F32E9F98" xlink:to="loc_us-gaap_SalesMember_588A1A707115682F7085E395F32E1C98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_6E2D18684AD8314F1E01E395F32E9AC8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_6E2D18684AD8314F1E01E395F32E9AC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_6E2D18684AD8314F1E01E395F32E9AC8" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_3527B0873B08F303FD0AE395F32F44C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4" xlink:to="loc_us-gaap_ForeignExchangeContractMember_3527B0873B08F303FD0AE395F32F44C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_CF89B0AE25DA22EACF9EE395F32FAEE9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_7EAC321B346317A56730E395F32EDAF4" xlink:to="loc_us-gaap_InterestRateContractMember_CF89B0AE25DA22EACF9EE395F32FAEE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_5FC0C3E025E8EF9FB086E395F32FEAEB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:to="loc_us-gaap_HedgingDesignationAxis_5FC0C3E025E8EF9FB086E395F32FEAEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_5FC0C3E025E8EF9FB086E395F32FEAEB" xlink:to="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3A5807A21B51F4419109E395F32F68A5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_3A5807A21B51F4419109E395F32F68A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NondesignatedMember" xlink:label="loc_us-gaap_NondesignatedMember_729891DDAD33591AA668E395F3309448" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_8C2D6586245056EE746EE395F32FD571" xlink:to="loc_us-gaap_NondesignatedMember_729891DDAD33591AA668E395F3309448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_E46C76F3B1BA19CB3A7DE395F32DC645" xlink:to="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNotionalAmount" xlink:label="loc_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:to="loc_us-gaap_DerivativeNotionalAmount_81A459374B8EBA0A569EE395F330C46B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssets" xlink:label="loc_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:to="loc_us-gaap_DerivativeAssets_80FAEC631F7106CFCC97E395F330A48D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_622F61AB004ED435A4ECE395F330CA5C" xlink:to="loc_us-gaap_DerivativeLiabilities_DF050F86E3F7AD4651A2E395F331379C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_E3B984AD3BFEBCDAEC24789C8632E444" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_E3B984AD3BFEBCDAEC24789C8632E444" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_EB9D4AE78F3FF412BBE3789C863600D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_EB9D4AE78F3FF412BBE3789C863600D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_EB9D4AE78F3FF412BBE3789C863600D7" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsMember" xlink:label="loc_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_ShortTermInvestmentsMember_6EE332EB67A57C9AC067789C8636255E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentAssetsMember" xlink:label="loc_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_OtherCurrentAssetsMember_860C0CF25E7D69CE558D789C8637FA49" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsMember" xlink:label="loc_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_pfe_LongtermInvestmentsMember_C406E00907D08DBF83F4789C8637FCB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentAssetsMember" xlink:label="loc_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_OtherNoncurrentAssetsMember_CCBE2CB6DB2F36539AF9789C863755CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_082B5EBBB213590D4C58789C86377082" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_082B5EBBB213590D4C58789C86377082" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_64A9050B4E3801728101789C8638F4F8" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_0D2C6A88DB3193532F8D789C86369329" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_64A9050B4E3801728101789C8638F4F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BD439E3B7CD73087CA8C789C86388F63" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BD439E3B7CD73087CA8C789C86388F63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_BD439E3B7CD73087CA8C789C86388F63" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_065FA8EED186C741583E789C8638FE00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_065FA8EED186C741583E789C8638FE00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_55DA2893C0B7714E95C6789C86393541" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_8BA252635C35D9D87860789C86389B10" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_55DA2893C0B7714E95C6789C86393541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_26E325931D111AE37E44789C86399CCD" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_MoneyMarketFundsMember_DAEE8EC18429ED97DF5B789C8639B450" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_EquitySecuritiesMember_A79DC1ABD3FB4B5D0636789C8639FB6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_1A33CB85DAFE91227156789C863ADEAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_A1DB3EBB3C0BA38588EC789C863AC1ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_0C34450A701A4F286F91789C86393F0D" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_8F61453A6EA700D5D3A4789C863AB5AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_32127AED93D615DF6B3D789C863A97E3" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_E5CFB55D9878FD999AF3789C863AF223" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_9E2D2547FFC2E2A4DFFF789C863B6D59" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_BD347C1BBFD3485B4216789C863B7C0C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_BD347C1BBFD3485B4216789C863B7C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_BD347C1BBFD3485B4216789C863B7C0C" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRateContractMember" xlink:label="loc_us-gaap_InterestRateContractMember_1E8160BB1EC70CF5E858789C863B36B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E" xlink:to="loc_us-gaap_InterestRateContractMember_1E8160BB1EC70CF5E858789C863B36B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_DE7FBD4C5991592C37BB789C863CCAF1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_F63DA693D513EA11D17E789C863B9C1E" xlink:to="loc_us-gaap_ForeignExchangeContractMember_DE7FBD4C5991592C37BB789C863CCAF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_1AC02F259798C3CD893F789C863459C5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_A2B8066A9019FF445401789C863C4AB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_76A6A59A70642753F93B789C863CE08F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities" xlink:label="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities_075B72997A5457F88F14789C863C7359" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsCurrent" xlink:label="loc_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeAssetsCurrent_C78B572B4986E6660946789C863CEBC3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments" xlink:label="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments_89C2D1B1478522508E53789C863DA0B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeAssetsNoncurrent" xlink:label="loc_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeAssetsNoncurrent_8EC3B76F64E6FC21E67F789C863D6B17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount" xlink:label="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount_8954CA0C5796A89E8AF1789C8A6BA17B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_CB3B440F150E30A8C339789C863D16D4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_Assets_DB324F4BB7814A322E1D789C8640E3E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesCurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeLiabilitiesCurrent_D1F27B04E861F9A83CCD789C8640EBE5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilitiesNoncurrent" xlink:label="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeLiabilitiesNoncurrent_0A83501BB1827F46B464789C86408BD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLiabilities" xlink:label="loc_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_3930111B6D03BF3014F6789C863CAF75" xlink:to="loc_us-gaap_DerivativeLiabilities_3AC295DA65C458F12996789C86402A9E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_EF84213EBC9FDD019A5701C948090987" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F0B21CBC84969324DD9F01C94809095F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_EF84213EBC9FDD019A5701C948090987" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F0B21CBC84969324DD9F01C94809095F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_CBD6B3C4C32639CF7D9001C9480957A9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F0B21CBC84969324DD9F01C94809095F" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_CBD6B3C4C32639CF7D9001C9480957A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_F92D2221315348CCEF7301C94809A962" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_CBD6B3C4C32639CF7D9001C9480957A9" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_F92D2221315348CCEF7301C94809A962" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_1892BE4069BA58E156F001C9480A23AB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_F92D2221315348CCEF7301C94809A962" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_1892BE4069BA58E156F001C9480A23AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4541D4E6996F7DAD792401C9480ABDEC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_F0B21CBC84969324DD9F01C94809095F" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4541D4E6996F7DAD792401C9480ABDEC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNIRestrictedCurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4541D4E6996F7DAD792401C9480ABDEC" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedCurrent_AD2501CF0048AE75513401C9480BFD0E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNIRestrictedNoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_4541D4E6996F7DAD792401C9480ABDEC" xlink:to="loc_pfe_EquitySecuritiesFVNIRestrictedNoncurrent_D0CC1430C44507B3360101C9480B07C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_2175E8E4DE0DF013C6C555F21764E7A6" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_2175E8E4DE0DF013C6C555F21764E7A6" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="loc_us-gaap_FinancialInstrumentAxis_9BEC83AEEF3B7EA4D76055F217644F98" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:to="loc_us-gaap_FinancialInstrumentAxis_9BEC83AEEF3B7EA4D76055F217644F98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_9BEC83AEEF3B7EA4D76055F217644F98" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignGovernmentDebtSecuritiesMember" xlink:label="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_20E7297EE7EC32B848D555F21765CB6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_ForeignGovernmentDebtSecuritiesMember_20E7297EE7EC32B848D555F21765CB6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8088D82AB5F77BCD1CA555F217652522" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_8088D82AB5F77BCD1CA555F217652522" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_DC2F6E43A4BF1F90ED5755F217651034" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_DC2F6E43A4BF1F90ED5755F217651034" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BankTimeDepositsMember" xlink:label="loc_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_BankTimeDepositsMember_5A531B41C14DF536711355F21765E8F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="loc_us-gaap_MoneyMarketFundsMember_C3FD1051B23A8701F8E155F217663B4F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_MoneyMarketFundsMember_C3FD1051B23A8701F8E155F217663B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesMember" xlink:label="loc_us-gaap_EquitySecuritiesMember_BDBAA5BF06A69CE360AE55F2176606B4" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_01B7EE537242DCD1924A55F217655D08" xlink:to="loc_us-gaap_EquitySecuritiesMember_BDBAA5BF06A69CE360AE55F2176606B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems" xlink:label="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable_52E5C3794FFBA811394B55F21764283F" xlink:to="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_20831A031B0685ECAF1655F21766D88C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_B33F2FFAC1AD3891031755F21767FE30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_C3094317F1EBC16BA92A55F217676C4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract_B56069D34A529976C22255F217669552" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4950C8320B969AE2C8F355F21767108F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_6B1DF7FA1A8F22D3EDFB55F21767ECB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_35ADEEDAC7635C99312655F21767E850" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:to="loc_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue_5004CBE8CFCEBFA7BA1F55F21768CC23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_CA1D25A3708066DD4E0B55F217686C05" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_910B7B9ABE47DEF788FF55F217679C02" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_CA1D25A3708066DD4E0B55F217686C05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecurities" xlink:label="loc_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="loc_us-gaap_HeldToMaturitySecurities_75077E7D96376F5A1AD055F217688C57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain_16A4BBD7F3A1A5BF6D4D55F217683F6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss_8D44570BBA20CC834B7755F21768B3DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract_9099F86AB43CA8B65EA455F21768FB82" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesFairValue_55564BD1BDCED7C40CBE55F2176962A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue_D53AAEB0D8FD5A68238F55F217691640" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_80A759F7FD851157B40E55F217698189" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract_42B0893F62A1834AC9DC55F217696D7A" xlink:to="loc_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue_F5DC1AB153F28734B0D455F217693D6B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAmortizedCostBasis" xlink:label="loc_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesAmortizedCostBasis_D4E3838542C1668082B555F2176AE144" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain_A0AA47755C66EC5CF3B455F2176A4DFF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss" xlink:label="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss_20B209378D856D0389B355F2176A87D4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue_38E59EDAA2DA7F840B4955F2176AE812" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue_11EFCC376CE414C260A355F2176AFB44" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue" xlink:label="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue_347CCBC0B4B23049A31D55F2176AE309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems_83F9E7765FA2B8C6AB4755F2176662F4" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity_1E8F5FE36346C1F6F83E55F2176B54B2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_CE50CAA95BE511E4FF3D16E821461B30" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_563E611885B064BAB24616E82146E156" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_CE50CAA95BE511E4FF3D16E821461B30" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_563E611885B064BAB24616E82146E156" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiRealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_CE50CAA95BE511E4FF3D16E821461B30" xlink:to="loc_us-gaap_EquitySecuritiesFvNiRealizedGainLoss_1F060CEFF2262F1F3BDA16E82146C99E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F62A956FAB1CE9D02C6F16E821469FF6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_CE50CAA95BE511E4FF3D16E821461B30" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_F62A956FAB1CE9D02C6F16E821469FF6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_F36AC7178FA5416BE65DE395F342C75C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F36AC7178FA5416BE65DE395F342C75C" xlink:to="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_800751EDB3A113ACD3E3E395F343C309" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_800751EDB3A113ACD3E3E395F343C309" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_6F6C5A96F2C157EA5F1BE395F34353F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_800751EDB3A113ACD3E3E395F343C309" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_6F6C5A96F2C157EA5F1BE395F34353F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_EF6D5503F54C288E592AE395F343E558" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_6F6C5A96F2C157EA5F1BE395F34353F5" xlink:to="loc_us-gaap_UnsecuredDebtMember_EF6D5503F54C288E592AE395F343E558" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_A3FD03CBCE5792D1AEB1E395F344FE0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:to="loc_us-gaap_DebtInstrumentAxis_A3FD03CBCE5792D1AEB1E395F344FE0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_A3FD03CBCE5792D1AEB1E395F344FE0D" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2020Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2020Member_443C77FF44E6CC6DE012E395F344741D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2021Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2021Member_63ED2BF68D11E64B3C2FE395F3451511" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2022Member_F26DD287692D94FA2718E395F3450605" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2023Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2023Member_A02AB7FF7D8B8F09BC1BE395F3454C1F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2024Member_84E6400E2624871E9F6EE395F345E4DF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20262029Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20262029Member_85B34B195A14777EC3A7E50A0887A57F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue2034Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue2034Member_8D3AF4E7EE921972959FE395F345C2A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20362040Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20362040Member_76786B1170EA027E67BAE50BCA810511" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20432044Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20432044Member_8A732AD90A6F6E61D922E50CA659CA8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtDue20462049Member" xlink:label="loc_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_7C5DF02C635610BBF0DBE395F344B4FA" xlink:to="loc_pfe_SeniorUnsecuredDebtDue20462049Member_76BA7948E27D9B2B170EE51698455E5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_22FF6845718645E11F86E395F342A87F" xlink:to="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_E83D0605716FD7BD9E1FE395F3467F04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentCarryingAmount" xlink:label="loc_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_DebtInstrumentCarryingAmount_19236DEA3F7E4B4F25B0E395F346EE66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_F2C883749F5CC57CA38DE395F347FA7E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_F2C883749F5CC57CA38DE395F347FA7E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_68B6376A6FA78BD22354E395F347697F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_68B6376A6FA78BD22354E395F347697F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherLongTermDebt" xlink:label="loc_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_OtherLongTermDebt_C6FCABDC39603E70D5FEE395F347DDDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtNoncurrent" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_DB7BDA929F822890B08FE395F347EBE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebtCurrent" xlink:label="loc_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_214477BF62F37B30F829E395F3469849" xlink:to="loc_us-gaap_LongTermDebtCurrent_677B4CCD45D9795A131DE395F34753C9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_2393B9275FAC54FE5FC755F2173C3E19" xlink:to="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_2557F28579603CA668A555F2173D3C6E" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:to="loc_us-gaap_SeniorNotesMember_433541533208B6F435FF55F2173D5772" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnsecuredDebtMember" xlink:label="loc_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_D8C26E4C1959D599B4D355F2173DFBD0" xlink:to="loc_us-gaap_UnsecuredDebtMember_5F8DCC675B4E443B412E55F2173E7DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:to="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2133121B971D70046DD255F2173ED73C" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorNotesDue2047Member" xlink:label="loc_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:to="loc_pfe_SeniorNotesDue2047Member_65191BE49AD9A361E87F567293258ED3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member" xlink:label="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:to="loc_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_E03A4CD5E95B8211924455F2173EF95B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member" xlink:label="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_9954E1BF4FFCF41FC29B55F2173E7939" xlink:to="loc_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_F397078C399EC81D95AC55F2173F8D86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_70A93C72454DEDA3EE0455F2173C88EE" xlink:to="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_E44E637FA2240A9ADC3B55F2173FFFB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_3DBFAEE8416DDF98E3FF55F21740B373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchaseAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentRepurchaseAmount_7E936EBE78E956AA44A255F217408A11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_69663196DD39BBCF21A055F217408810" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentRepurchasedFaceAmount" xlink:label="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_DebtInstrumentRepurchasedFaceAmount_D134079142B52A7B019C55F21740CB60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_E8321512EEAF34DA187855F21740881A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ExtinguishmentOfDebtAmount" xlink:label="loc_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_ExtinguishmentOfDebtAmount_D7D1F421BB9C09EBC44555F21740571F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_F87D6939364911AD243C55F2173FEFC3" xlink:to="loc_us-gaap_LongTermDebt_09255736249307F9C63155F21741832E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_586AB662BBDF7948D866E798574D4834" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_586AB662BBDF7948D866E798574D4834" xlink:to="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeAxis" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_26010E47B95FA7BA928FE798575044ED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_26010E47B95FA7BA928FE798575044ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongtermDebtTypeDomain" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_655476E682F8B674CA29E7985750BB39" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_26010E47B95FA7BA928FE798575044ED" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_655476E682F8B674CA29E7985750BB39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeniorNotesMember" xlink:label="loc_us-gaap_SeniorNotesMember_1EBCA06613BD1D149E96E798575078D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_655476E682F8B674CA29E7985750BB39" xlink:to="loc_us-gaap_SeniorNotesMember_1EBCA06613BD1D149E96E798575078D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_9D5AD7AE91DBA93CF619E7985751EC76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:to="loc_us-gaap_DebtInstrumentAxis_9D5AD7AE91DBA93CF619E7985751EC76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_9D5AD7AE91DBA93CF619E7985751EC76" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_D951022F0448745E1A83E79857510FE4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member" xlink:label="loc_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_C463D92040CAF07C251FE79857528EFE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_C2B5EEAA6175C89C9318E79857523FDD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member" xlink:label="loc_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_D279BBF55433928868AEE7985752C24F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SeniorUnsecuredDebtFourPercentDue2049Member" xlink:label="loc_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_A52685C192D3E5F35BD5E79857512A04" xlink:to="loc_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_80F3DB4A76C459A12439E79857527BAB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_CC8D3930E3DC3E8823A5E7985750743F" xlink:to="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CC25B1837F0B6D5A27D7E7985752ACA0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_CC25B1837F0B6D5A27D7E7985752ACA0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermDebt" xlink:label="loc_us-gaap_LongTermDebt_0648999518EBE26772B3E7985753E8F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:to="loc_us-gaap_LongTermDebt_0648999518EBE26772B3E7985753E8F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_DebtWeightedAverageInterestRate_14B6D1A871C9049C7879E7985753A1FD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_02C6B19205CB905BD474E798575297FE" xlink:to="loc_us-gaap_DebtWeightedAverageInterestRate_14B6D1A871C9049C7879E7985753A1FD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_D38F9EB59E60F121C8480E4334C195CB" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_6C8EE0CD9798B81793910E47C55E995B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_D38F9EB59E60F121C8480E4334C195CB" xlink:to="loc_us-gaap_DerivativeTable_6C8EE0CD9798B81793910E47C55E995B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_1C92F3E85DB9716678B90E480443D26A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6C8EE0CD9798B81793910E47C55E995B" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_1C92F3E85DB9716678B90E480443D26A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_CB334C78825BEE5AF0B70E48068DE520" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_1C92F3E85DB9716678B90E480443D26A" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_CB334C78825BEE5AF0B70E48068DE520" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_7DB709E70A239B90A4760E48401A9220" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_CB334C78825BEE5AF0B70E48068DE520" xlink:to="loc_us-gaap_ForeignExchangeContractMember_7DB709E70A239B90A4760E48401A9220" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_6C8EE0CD9798B81793910E47C55E995B" xlink:to="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTermOfContract" xlink:label="loc_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_DerivativeTermOfContract_6BB353DF3C8A558E4B4D0E475E057152" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeNetLiabilityPositionAggregateFairValue" xlink:label="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue_8DE3284110EF9FF299B40E4334C492A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollateralAlreadyPostedAggregateFairValue" xlink:label="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_CollateralAlreadyPostedAggregateFairValue_2EE397C498B13D19AF240E4334C50863" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SecuritiesReceivedAsCollateral" xlink:label="loc_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_BBCDA0228112046220580E47C567E62D" xlink:to="loc_us-gaap_SecuritiesReceivedAsCollateral_E3BBC464BF8B77D23CED0E4334C5C026" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaap_DebtDisclosureAbstract_634551C34308BC941AFA0C10A8A6017C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_634551C34308BC941AFA0C10A8A6017C" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BC5040E3B90F150B6DB80C10A8A885D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BC5040E3B90F150B6DB80C10A8A885D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BC5040E3B90F150B6DB80C10A8A885D6" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_43F510E71A99E7C4F8C90C10A8A9D26E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_43F510E71A99E7C4F8C90C10A8A9D26E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_935C6D3618B797F752C30C10A8A9A358" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_05C90159DF622FFDDCE60C10A8A9B1E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C9EF1C25BFB356267E950C10A8A93808" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C9EF1C25BFB356267E950C10A8A93808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_030A54C0F4AC24621DEB0C10A8AAA5C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_C9EF1C25BFB356267E950C10A8A93808" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_030A54C0F4AC24621DEB0C10A8AAA5C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_A38F08F1C118D2735D5B0C10A8AA16C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_030A54C0F4AC24621DEB0C10A8AAA5C7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_A38F08F1C118D2735D5B0C10A8AA16C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8E590C17F8844DD11BBE0C10A8AA1525" xlink:to="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylotargMember" xlink:label="loc_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:to="loc_pfe_MylotargMember_9B54196E27838DFF6DFF0C10A8AA2004" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:to="loc_pfe_BosulifMember_3D4C379431ABB62FBCEB0C10A8ABE2B3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BesponsaMember" xlink:label="loc_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_F2CA83C8E14DEB0980EF0C10A8AAE593" xlink:to="loc_pfe_BesponsaMember_33C12AE9FBA913EDFFE10C10A8ABF4D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_8099682DEF4F4703F9B20C10A8ABCCC4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_srt_StatementGeographicalAxis_8099682DEF4F4703F9B20C10A8ABCCC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_8099682DEF4F4703F9B20C10A8ABCCC4" xlink:to="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047" xlink:to="loc_us-gaap_EuropeanUnionMember_F0BB14999DF7E77FA0500C10A8ACD4AE" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_A529A6B06D5F477DEF9A0C10A8AC402E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_D1E47997D5E2B9762CDA0C10A8AB0047" xlink:to="loc_country_US_A529A6B06D5F477DEF9A0C10A8AC402E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_579EA61BEFA3F99634190C10A8A85B7D" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm_52C4D74FAFF251B8BB920C10A8ACD387" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation" xlink:label="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation_76249AE24E71CEB98E940C10A8ACFFA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_AE09923ECC64BE2F23A70C10A8ADB7B4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount" xlink:label="loc_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount_86397BD8B683C9C172D00C10A8ADF19B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" xlink:label="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_2EF1135D700CD5055F530C10A8ACF135" xlink:to="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_722612EC0A4E383CD8D90C10A8ADBCC4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_A1D57AB3EEDEA60FE53655F2174F7223" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTable" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_A1D57AB3EEDEA60FE53655F2174F7223" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaap_DebtInstrumentAxis_2AFE72943168C890EE4E55F2174F7C9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:to="loc_us-gaap_DebtInstrumentAxis_2AFE72943168C890EE4E55F2174F7C9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_2AFE72943168C890EE4E55F2174F7C9A" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CreditFacilityExpiring2024Member" xlink:label="loc_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239" xlink:to="loc_pfe_CreditFacilityExpiring2024Member_57BC3C4ECAABFC48F47055F217500328" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FacilityExpiringSeptember2020Member" xlink:label="loc_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_EFCA5729A8E2DCB393DD55F2174F6239" xlink:to="loc_pfe_FacilityExpiringSeptember2020Member_4B51DD2C5BCE050EFFD655F217502129" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityAxis" xlink:label="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:to="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CreditFacilityDomain" xlink:label="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityAxis_A5D193CE4F9888650E2755F217503448" xlink:to="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditMember" xlink:label="loc_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CreditFacilityDomain_70C33CAA81A5B340EAE955F217508D0A" xlink:to="loc_us-gaap_LineOfCreditMember_7DBCA9E6C0E3ED81784855F21751B761" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeAxis" xlink:label="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:to="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtTypeDomain" xlink:label="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeAxis_04F57040E3342EB83D5155F217511158" xlink:to="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaperMember" xlink:label="loc_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtTypeDomain_9C0D76B2D8B975534BAA55F21751D200" xlink:to="loc_us-gaap_CommercialPaperMember_DA0A5368A78FA68334CE55F21751058D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtLineItems" xlink:label="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShortTermDebtTable_10D71ABF8D6E706E1D0E55F2174F694F" xlink:to="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CommercialPaper" xlink:label="loc_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_CommercialPaper_BE3E74FC3F7642ACE1C655F217524C05" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting" xlink:label="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting_0B8393011BC7D1D05F5E55F217522A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherShortTermBorrowings" xlink:label="loc_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_OtherShortTermBorrowings_083486BCF24E2B748B9855F21752754F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShorttermDebtGross" xlink:label="loc_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_pfe_ShorttermDebtGross_E3A345046713A8EB9E8755F217520F62" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting" xlink:label="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting_59033DA825BE8A1C652B55F21753ABBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet" xlink:label="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet_1516821C1A647132131755F217530FA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtCurrent" xlink:label="loc_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_DebtCurrent_1052B7B46BB734AEA4B455F217534E11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermDebtWeightedAverageInterestRate" xlink:label="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_ShortTermDebtWeightedAverageInterestRate_D5B8D9185192713BC9D055F21753E38F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity_7396A80C77CB74E2670755F21753844D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear" xlink:label="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear_FDB8D0E0C2B23980F9AB55F21753E001" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity" xlink:label="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermDebtLineItems_21FCC8DEC7F6872ADD9955F21752090A" xlink:to="loc_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity_01DEA02181AF946103C155F21753D7BB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTables" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_F8EE7F38A22136747B48E395F3AF02CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock_8462B3FCAB99A96CCEABE395F3AFCE98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MarketableSecuritiesTextBlock" xlink:label="loc_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_MarketableSecuritiesTextBlock_4B321A71D7EEEA837095E395F3AF3BA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_F01F4CF97EAC9ED58C7FE395F3AF5584" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_7D20C45239BA6BF34F93E395F3B04EFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesTextBlock" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesTextBlock_AD37C532D5F01AA6083BE395F3B03B59" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock" xlink:label="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock_0C64110B8754541C8B77E395F3B01569" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShortTermDebtTextBlock" xlink:label="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfShortTermDebtTextBlock_4E39822DCD5DFD8F12C7E395F3B07C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_DB86E34ED964DE6B4AE8E395F3B05C0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock_16BDB2AB946D25C7FB6DE395F3B00406" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock_857597BB605B37D91054E395F3B0BB25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock_137DACAA669C4F0CB56AE395F3B13982" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock" xlink:label="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock_0D7DB4DB8023CD1A9FCEE395F3B112BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_AFCAD0BB5CA7032467C9E395F3B19374" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_F8674B705CE597852723E395F3AF6C49" xlink:to="loc_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock_C529BEEA7AD34BBDADA3E395F3B14CA4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FinancialInstrumentsAbstract" xlink:label="loc_pfe_FinancialInstrumentsAbstract_0859BA4295AEF76919AD16E8216C017E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestmentsAbstract" xlink:label="loc_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_0859BA4295AEF76919AD16E8216C017E" xlink:to="loc_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNi" xlink:label="loc_us-gaap_EquitySecuritiesFvNi_60815A92346ADD10939916E8216DA8F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:to="loc_us-gaap_EquitySecuritiesFvNi_60815A92346ADD10939916E8216DA8F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent_8A9D011A3E55B47A3A9A16E8216DFD0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesCurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesCurrent_3A1920740F44119AE93416E8216E89D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShortTermInvestments" xlink:label="loc_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShortTermInvestmentsAbstract_82E53674360A5D1B73D216E8216D4A6E" xlink:to="loc_us-gaap_ShortTermInvestments_D65863419A3B32392EAD16E8216E8609" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestmentsAbstract" xlink:label="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_0859BA4295AEF76919AD16E8216C017E" xlink:to="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EquitySecuritiesFVNINoncurrent" xlink:label="loc_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:to="loc_pfe_EquitySecuritiesFVNINoncurrent_7098ED458661860861B916E8216F083B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent_91900FDB16F25071C2B716E8216FF445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HeldToMaturitySecuritiesNoncurrent" xlink:label="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:to="loc_us-gaap_HeldToMaturitySecuritiesNoncurrent_57FC31E4097E045D381116E82170995B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrivateEquityInvestments" xlink:label="loc_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:to="loc_pfe_PrivateEquityInvestments_5DC170A6FE9527077B1A16E82170BC5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongTermInvestments" xlink:label="loc_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongTermInvestmentsAbstract_1BBD5EE0BB7DC244021616E8216F04E6" xlink:to="loc_us-gaap_LongTermInvestments_02F8AFCD01DE5C3CDE1516E821715A3B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestments" xlink:label="loc_us-gaap_EquityMethodInvestments_EE1E04E4FDAEB1FCF28E16E821710812" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_0859BA4295AEF76919AD16E8216C017E" xlink:to="loc_us-gaap_EquityMethodInvestments_EE1E04E4FDAEB1FCF28E16E821710812" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LongtermInvestmentsAndEquityMethodInvestments" xlink:label="loc_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_0859BA4295AEF76919AD16E8216C017E" xlink:to="loc_pfe_LongtermInvestmentsAndEquityMethodInvestments_4B846F8791D192F7C08B16E8217171BC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HeldToMaturityCashEquivalents" xlink:label="loc_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_FinancialInstrumentsAbstract_0859BA4295AEF76919AD16E8216C017E" xlink:to="loc_pfe_HeldToMaturityCashEquivalents_FE3D83A04FF5CA330CC316E8217289EF" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_976BA303838FD25B22BF8020744FC31A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_976BA303838FD25B22BF8020744FC31A" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_EE380BD4D3484819B128802074503EE1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EE81AD86857307E5A983D811179BC1A7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EE81AD86857307E5A983D811179BC1A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths_1D4689F797DDCCA30467D811179B71C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EE81AD86857307E5A983D811179BC1A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo_03FE8FA2F66F33DCE131D811179CB5AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EE81AD86857307E5A983D811179BC1A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree_2FA5EF2349715420040AD811179C9B0A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EE81AD86857307E5A983D811179BC1A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour_70AC320AD144DE27DF51D811179C9B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EE81AD86857307E5A983D811179BC1A7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive_04C9F97B0DB9227F752FD811179C2190" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EAC7E99B6D7FD1AEE649D985642FE6DA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66081D6946264073BD97D98564302F74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EAC7E99B6D7FD1AEE649D985642FE6DA" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66081D6946264073BD97D98564302F74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B2ADA603A09F7D6DD55BD985643097B4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66081D6946264073BD97D98564302F74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B2ADA603A09F7D6DD55BD985643097B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_B2ADA603A09F7D6DD55BD985643097B4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_3A3981411CF98DC7A349D9856431848C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_3A3981411CF98DC7A349D9856431848C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_91841EDB161339DB1D26D98564312DBD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:to="loc_us-gaap_TradeNamesMember_91841EDB161339DB1D26D98564312DBD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_F1FA86217FE75596E2BFD9856431FA62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_87E3C748B838797F51F3D98564307A3E" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_F1FA86217FE75596E2BFD9856431FA62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_66081D6946264073BD97D98564302F74" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsGross" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsGross_C5DD2409E19A135121D6D98564312A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization_AAAFC2E36D664FFE0D93D9856432E20F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsNet" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_D7A6AA3E6DF221D639C3D9856431429F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsNet_CDED06E71B15716F1053D9856432E852" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EAC7E99B6D7FD1AEE649D985642FE6DA" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948F3865313A365BA969D98564323344" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948F3865313A365BA969D98564323344" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_948F3865313A365BA969D98564323344" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:to="loc_us-gaap_TradeNamesMember_91841EDB161339DB1D26D98564312DBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8E7DE1D09E6D374ADDD0D985643374FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8E7DE1D09E6D374ADDD0D985643374FF" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_8EE5EC216DB2FE62AC44D985643284B1" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_F1FA86217FE75596E2BFD9856431FA62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable_A773057912EDB0567B8CD985643241C6" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems_9D5AC6D952323447BCEDD98564337CEF" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill_95B11AD37F13D227940ED98564346D01" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsGrossExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EAC7E99B6D7FD1AEE649D985642FE6DA" xlink:to="loc_us-gaap_IntangibleAssetsGrossExcludingGoodwill_4487139324ACBC00DC7AD985643437F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IntangibleAssetsNetExcludingGoodwill" xlink:label="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_EAC7E99B6D7FD1AEE649D985642FE6DA" xlink:to="loc_us-gaap_IntangibleAssetsNetExcludingGoodwill_CDEC73A53F96E88B47C8D9856434DDA8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_413650329A981E97ACA0D9856426FFE7" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfIntangibleAssetsTable" xlink:label="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_413650329A981E97ACA0D9856426FFE7" xlink:to="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_1A3B361DAF2E76F59110D98564262161" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_1A3B361DAF2E76F59110D98564262161" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FAE4E98052AC0CD7C4FCD9856427D350" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_1A3B361DAF2E76F59110D98564262161" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FAE4E98052AC0CD7C4FCD9856427D350" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_FAE4E98052AC0CD7C4FCD9856427D350" xlink:to="loc_pfe_ArrayMember_FCB7D1F0047B7531AC56D985642788BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4E0C6324611231AA6A80D98564271CD6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4E0C6324611231AA6A80D98564271CD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_FB2F6B013898613DC523D98564274832" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4E0C6324611231AA6A80D98564271CD6" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_FB2F6B013898613DC523D98564274832" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F79CD38226F107BE12FBD985642841BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_FB2F6B013898613DC523D98564274832" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_F79CD38226F107BE12FBD985642841BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C2337AF1335DF17AD9F7D98564283C2D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C2337AF1335DF17AD9F7D98564283C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_C2337AF1335DF17AD9F7D98564283C2D" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsDevelopedTechnologyMember" xlink:label="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:to="loc_pfe_LicensingAgreementsDevelopedTechnologyMember_8E39D85CACA42747FEA5D9856428FA44" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8700BAFAA24043CC904BD985642978EE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8700BAFAA24043CC904BD985642978EE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsTechnologyInDevelopmentMember" xlink:label="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_0CC5E17C659212916AFDD9856428E279" xlink:to="loc_pfe_LicensingAgreementsTechnologyInDevelopmentMember_23CC50D9FB95E9E5C5FED98564292A40" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsLineItems" xlink:label="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_C9A85D1EBA5A7DEF34E0D9856426D5E0" xlink:to="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles_EE6FDFF709541C8064B6D98564298C09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill" xlink:label="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_96B67C711B9A5F88398DD98564297523" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IntangibleAssetsLineItems_A7EDEF962F18BC1619EED9856429AD3F" xlink:to="loc_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill_96B67C711B9A5F88398DD98564297523" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA75DD97FA62663BCFBAD811178E379F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTable" xlink:label="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_FA75DD97FA62663BCFBAD811178E379F" xlink:to="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_BD7072350589FB7EDB79D85DCAEA8171" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:to="loc_srt_ConsolidationItemsAxis_BD7072350589FB7EDB79D85DCAEA8171" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_C53609E5A5FB1FFBABEDD85DCAEC10C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_BD7072350589FB7EDB79D85DCAEA8171" xlink:to="loc_srt_ConsolidationItemsDomain_C53609E5A5FB1FFBABEDD85DCAEC10C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_7AE8BC9B385361A6E67BD85DCB07D87C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_C53609E5A5FB1FFBABEDD85DCAEC10C3" xlink:to="loc_us-gaap_OperatingSegmentsMember_7AE8BC9B385361A6E67BD85DCB07D87C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_3F3CB7DEA593B6CA07D6D8111790844F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_3F3CB7DEA593B6CA07D6D8111790844F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_3F3CB7DEA593B6CA07D6D8111790844F" xlink:to="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_43319789126211928511D85D78611FA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:to="loc_pfe_BiopharmaSegmentMember_43319789126211928511D85D78611FA6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_6693B2B323D154E20E38D85DCB16C9FA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:to="loc_pfe_UpjohnSegmentMember_6693B2B323D154E20E38D85DCB16C9FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_D115AACE5A80088701ECD85F23FF48CF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_2079FAE629FC14E43D16D8111791C520" xlink:to="loc_pfe_ConsumerHealthcareMember_D115AACE5A80088701ECD85F23FF48CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillLineItems" xlink:label="loc_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfGoodwillTable_FD76E7567F4777E7405ED811178F745A" xlink:to="loc_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillRollForward" xlink:label="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillLineItems_F7C1D09B07DF20CC1CA8D81117914B86" xlink:to="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:to="loc_us-gaap_Goodwill_CADCD73BF973F7142A41D8111792A5DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAcquiredDuringPeriod" xlink:label="loc_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:to="loc_us-gaap_GoodwillAcquiredDuringPeriod_74B0E7C04BA919339125D8111792FF98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillOtherIncreaseDecrease" xlink:label="loc_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:to="loc_us-gaap_GoodwillOtherIncreaseDecrease_9F583AFC382405BC8D90D8111792F537" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Goodwill" xlink:label="loc_us-gaap_Goodwill_C6C079ED0356E45EB069D81117922E30" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillRollForward_B5F32D7B4255721F1084D81117914177" xlink:to="loc_us-gaap_Goodwill_C6C079ED0356E45EB069D81117922E30" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_73080E6CEFA8D3519C6ED81117BB2227" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_73080E6CEFA8D3519C6ED81117BB2227" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_B29ED612989D87469F5ED81117BBA766" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_B29ED612989D87469F5ED81117BBA766" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_B29ED612989D87469F5ED81117BBA766" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TradeNamesMember" xlink:label="loc_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:to="loc_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_8B659EB54A85A7804917D81117C12B15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LicensingAgreementsAndOtherMember" xlink:label="loc_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_13DCD6D0439221A4F610D81117BC3B57" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_4AEB89846078AC90FBF5D81117C21FC2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_SubsegmentsAxis_4AEB89846078AC90FBF5D81117C21FC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_04292D5D333ACD4D828CD81117C26BF4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_4AEB89846078AC90FBF5D81117C21FC2" xlink:to="loc_us-gaap_SubsegmentsDomain_04292D5D333ACD4D828CD81117C26BF4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_8FC9306FB9A309CE0F80D83E68B645D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_04292D5D333ACD4D828CD81117C26BF4" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_8FC9306FB9A309CE0F80D83E68B645D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_A379C1FE9EF1BD791237D81117C22293" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_srt_ConsolidationItemsAxis_A379C1FE9EF1BD791237D81117C22293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_A379C1FE9EF1BD791237D81117C22293" xlink:to="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_8FAA87EBCA62E1A81C74D81117C3BD00" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550" xlink:to="loc_us-gaap_OperatingSegmentsMember_8FAA87EBCA62E1A81C74D81117C3BD00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_3F105B6162BCC3451C97D81117C3264F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_A737FE69BB079C3E9A90D81117C26550" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_3F105B6162BCC3451C97D81117C3264F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_10FA32B765A7CE8152ECD81117C3D0A6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_10FA32B765A7CE8152ECD81117C3D0A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_10FA32B765A7CE8152ECD81117C3D0A6" xlink:to="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_1EAFE8DFBF0AA88EB647D83E686BA475" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F" xlink:to="loc_pfe_BiopharmaSegmentMember_1EAFE8DFBF0AA88EB647D83E686BA475" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_B46E91E3B69AF0710005D83E6890F2C5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_9AE37C216788F6AEB434D81117C35A2F" xlink:to="loc_pfe_UpjohnSegmentMember_B46E91E3B69AF0710005D83E6890F2C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5BF8FC2F297C6FC56A53D81117C4D580" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5BF8FC2F297C6FC56A53D81117C4D580" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_5BF8FC2F297C6FC56A53D81117C4D580" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_4F7B0BB90EB67C9A6F30D81117C460D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_4F7B0BB90EB67C9A6F30D81117C460D6" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:to="loc_us-gaap_TradeNamesMember_0D0800F5E3D3D9429AEED81117C15345" xlink:type="arc" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_3EDB4046A2218966744AD81117C46F7C" xlink:to="loc_pfe_LicensingAgreementsAndOtherMember_6F52EC899D18D60DCE7AD83D7788CD37" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90FB1BFC4F1C1B85260ED81117C58E47" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_6A64367B96B2BEDD2FC2D81117BB7272" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90FB1BFC4F1C1B85260ED81117C58E47" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet" xlink:label="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_90FB1BFC4F1C1B85260ED81117C58E47" xlink:to="loc_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet_BAD890B793DAFD96051FD81117C5D9C7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C96B4A3E38FA52F24F23D81117AA974B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5E3ABC9C0E9D0636DD3BD81117AAA3C5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_C96B4A3E38FA52F24F23D81117AA974B" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5E3ABC9C0E9D0636DD3BD81117AAA3C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4BBAB3BB6E306FFE6606D81117AA350F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5E3ABC9C0E9D0636DD3BD81117AAA3C5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4BBAB3BB6E306FFE6606D81117AA350F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_4BBAB3BB6E306FFE6606D81117AA350F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_1A544FB202CB03A0C5DAD81117ABEB4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_1A544FB202CB03A0C5DAD81117ABEB4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMember" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_6E2D744A113CD95EF8B8D81117ABB3E7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMember_F9E569D13283BBF2E894D81117AB4C11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsLineItems" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable_5E3ABC9C0E9D0636DD3BD81117AAA3C5" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetUsefulLife" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetUsefulLife_7766C1801EB85FE4FE18D81117ACD5AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmortizationOfIntangibleAssets" xlink:label="loc_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:to="loc_us-gaap_AmortizationOfIntangibleAssets_8C9E1EAF0DFBCB96A90FD81117AC7162" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsLineItems_E7770CAD824939799CB8D81117ABB6C8" xlink:to="loc_us-gaap_NumberOfOperatingSegments_C7BD2CB024483690AA30D856115E0900" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3D358F6AA2FD44311AE802075091C8E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3D358F6AA2FD44311AE802075091C8E" xlink:to="loc_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_BF07E13763CD63E9FCD98020750A95DA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3D358F6AA2FD44311AE802075091C8E" xlink:to="loc_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock_DEA1E8EA5CA48987C6BC8020750A5DC4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3D358F6AA2FD44311AE802075091C8E" xlink:to="loc_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock_EEF279D3A9C3A42A99C58020750A7D81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfGoodwillTextBlock" xlink:label="loc_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_D3D358F6AA2FD44311AE802075091C8E" xlink:to="loc_us-gaap_ScheduleOfGoodwillTextBlock_1ADB3A1B15E035BD4F1C8020750AAB6C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/Insurance" xlink:type="extended">
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceCoverageAbstract" xlink:label="loc_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceCoverageDisclosureTextBlock" xlink:label="loc_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InsuranceCoverageAbstract_8D41B2C5F12C404F26B480206ED9CAA0" xlink:to="loc_pfe_InsuranceCoverageDisclosureTextBlock_0411D1F25E3D5622D5E980206ED9619E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_F14F349E6B11F6D6D574802070550802" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureTextBlock" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_F14F349E6B11F6D6D574802070550802" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_FC6F8985FFD8195FD3CB802070557359" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_5980CF0C601D412BBDC1CEAADBF720EE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5980CF0C601D412BBDC1CEAADBF720EE" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_D8FF16CA1E2EBC14BE08CEAADBF74483" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryWorkInProcessNetOfReserves" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5980CF0C601D412BBDC1CEAADBF720EE" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_EE9EC15425F4BF12433ACEAADBF8BC19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5980CF0C601D412BBDC1CEAADBF720EE" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_416BD86F1E59E94664DDCEAADBF87B42" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNet" xlink:label="loc_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5980CF0C601D412BBDC1CEAADBF720EE" xlink:to="loc_us-gaap_InventoryNet_D888F22A6A2BDE74BE61CEAADBF80FC6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryNoncurrent" xlink:label="loc_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_5980CF0C601D412BBDC1CEAADBF720EE" xlink:to="loc_us-gaap_InventoryNoncurrent_FB209A64584BF2CE7EDBCEAADBF87D1F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InventoryDisclosureAbstract" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_02EFBDCF083C627F88A380206CB3F41F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_02EFBDCF083C627F88A380206CB3F41F" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_AFDEA557BDFB5827700080206CB3EEA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_02EFBDCF083C627F88A380206CB3F41F" xlink:to="loc_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock_8651DE716CA0B4C915A380206CB471E4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNet" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_4CD72B749F396459A83B802071757E4D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock" xlink:label="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_4CD72B749F396459A83B802071757E4D" xlink:to="loc_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock_B880526BEDBBBEEA5A09802071758703" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeInterest" xlink:label="loc_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_InvestmentIncomeInterest_E30F36F312E842B688467E0E8B23D5E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_InterestExpense_9F4DAEAED2559AD8CA807E0E8B23A56A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestRevenueExpenseNet" xlink:label="loc_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_InterestRevenueExpenseNet_FDCDA77B3DB5DB73DBA17E0E8B24C935" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RoyaltyIncomeNonoperating" xlink:label="loc_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_RoyaltyIncomeNonoperating_A9778F1C56751CA01F627E0E8B24B58A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfAssets1" xlink:label="loc_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_GainLossOnDispositionOfAssets1_3ECE9EB6E8FC4C9EF56D7E0E8B24E7B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_7F0B46E2A9F2601D39937E0E8B24A95A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesRealizedGainLoss" xlink:label="loc_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_DebtSecuritiesRealizedGainLoss_BCA1A5ED9BAD6CEB0B277E0E8B240018" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights" xlink:label="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights_A6CE8FA5B016A50853CC7E0E8B2494ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent" xlink:label="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent_BC47797C1240B9F0C0377E0E8B255E3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_98882582DAEBDA886E467E0E8B25C009" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_AssetImpairmentCharges_94A84DA665EE1C33EC6A7E0E8B259327" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessAlignmentCosts" xlink:label="loc_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_pfe_BusinessAlignmentCosts_0650C2D4A12BE6FB9C197E0E8B25DECF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A6E8DFE17FD10965036E7E0E8B250F5D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_A6E8DFE17FD10965036E7E0E8B250F5D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization" xlink:label="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization_8F1D16DCA8BD280F4A677E0E8B25DB35" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherNonoperatingIncomeExpenseNet" xlink:label="loc_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_pfe_OtherNonoperatingIncomeExpenseNet_3ACFBA225E98A73083D27E0E8B268FEC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_CC4E03853D00FEE5DA487E0E8B234325" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_9C4D35BA48DE54F6E93A7E0E8B2619CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_F380637F5555D5C9606FE395F42951FF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_F380637F5555D5C9606FE395F42951FF" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_BDFC7CD4ABA1DB4D2A27E395F42ABF79" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_BDFC7CD4ABA1DB4D2A27E395F42ABF79" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5DF7D46DD8F49A3BD529E395F42AC3E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_BDFC7CD4ABA1DB4D2A27E395F42ABF79" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5DF7D46DD8F49A3BD529E395F42AC3E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_F208B51FDE1E074D9CC6E395F42AD221" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_5DF7D46DD8F49A3BD529E395F42AC3E2" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_F208B51FDE1E074D9CC6E395F42AD221" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_00D0AF9BE98699E067C6E395F42B802E" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_359815BD936987E47E44E395F42BDE09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_14339FBE8F258A148CD9E395F42B75F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_6A1916CD76EC0342775CE395F42B4630" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_9A2763C2340A41DA5B26E395F42B00CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0A95964F9E5FF2B617DAE395F42B907F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0A95964F9E5FF2B617DAE395F42B907F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E7F4DDE737E782AADEE4E395F42CFD76" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_0A95964F9E5FF2B617DAE395F42B907F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E7F4DDE737E782AADEE4E395F42CFD76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_36BEB86C27D4D474F6FFE395F42CFFA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_E7F4DDE737E782AADEE4E395F42CFD76" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_36BEB86C27D4D474F6FFE395F42CFFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable_BAEBB0FE38E5E0A34C7EE395F429535B" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure_A2D6A2E374D7BADDE985E395F42DE295" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure_BF998294C0578B8C0F20E395F42D79DC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsFairValueDisclosure" xlink:label="loc_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_pfe_IntangibleAssetsFairValueDisclosure_CCDFAF4FB5831E70AC94E395F42DED70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems_E2D170B44DBEA9069D68E395F42CBC6F" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_248AE528CD8CE973CC44E395F42D7870" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_958D12126AB8CCE492ED7A814AA16614" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:label="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_958D12126AB8CCE492ED7A814AA16614" xlink:to="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_0F7634C19C33D4A15EA87A814AA23A80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_StatementGeographicalAxis_0F7634C19C33D4A15EA87A814AA23A80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_7D11DD1E9BA9B2E7CE287A814AA3D323" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_0F7634C19C33D4A15EA87A814AA23A80" xlink:to="loc_srt_SegmentGeographicalDomain_7D11DD1E9BA9B2E7CE287A814AA3D323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EuropeanUnionMember" xlink:label="loc_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_7D11DD1E9BA9B2E7CE287A814AA3D323" xlink:to="loc_us-gaap_EuropeanUnionMember_497C8DD242F8DB2229377A814AA3FF33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7E4A5093A3168164D1A17A814AA42FAD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_ProductOrServiceAxis_7E4A5093A3168164D1A17A814AA42FAD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_46C0BA71EBDBE433E1097A814AA42CA6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7E4A5093A3168164D1A17A814AA42FAD" xlink:to="loc_srt_ProductsAndServicesDomain_46C0BA71EBDBE433E1097A814AA42CA6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylotargMember" xlink:label="loc_pfe_MylotargMember_0D0FD1E38C2CDA5257BE7A814AA48D65" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_46C0BA71EBDBE433E1097A814AA42CA6" xlink:to="loc_pfe_MylotargMember_0D0FD1E38C2CDA5257BE7A814AA48D65" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A5B5552A27B213A254F47A814AA4A07A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A5B5552A27B213A254F47A814AA4A07A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_DD318E88E2ED3940FACC7A814AA44F73" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A5B5552A27B213A254F47A814AA4A07A" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_DD318E88E2ED3940FACC7A814AA44F73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_96A247EB5B94B07AB16B7A814AA56DA5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_DD318E88E2ED3940FACC7A814AA44F73" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_96A247EB5B94B07AB16B7A814AA56DA5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_86B67C60DB16749C04677A814AA5D229" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_CounterpartyNameAxis_86B67C60DB16749C04677A814AA5D229" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_276AB20E471D870D38AE7A814AA54744" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_86B67C60DB16749C04677A814AA5D229" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_276AB20E471D870D38AE7A814AA54744" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BainCapitalMember" xlink:label="loc_pfe_BainCapitalMember_534542882ED533B4777B7A814AA606D8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_276AB20E471D870D38AE7A814AA54744" xlink:to="loc_pfe_BainCapitalMember_534542882ED533B4777B7A814AA606D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_DDAD29CA3A30FB7327C77A814AA6C40D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_ConsolidationItemsAxis_DDAD29CA3A30FB7327C77A814AA6C40D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_437132EA647540050F857A814AA6F1BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_DDAD29CA3A30FB7327C77A814AA6C40D" xlink:to="loc_srt_ConsolidationItemsDomain_437132EA647540050F857A814AA6F1BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_79A6EE042B21AFE9A36C7A814AA64FA2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_437132EA647540050F857A814AA6F1BE" xlink:to="loc_us-gaap_OperatingSegmentsMember_79A6EE042B21AFE9A36C7A814AA64FA2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D22C724D5DAFE3D54F6D7A814AA6A59C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D22C724D5DAFE3D54F6D7A814AA6A59C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D22C724D5DAFE3D54F6D7A814AA6A59C" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelMember" xlink:label="loc_pfe_CerevelMember_466789CA484762BF9B6E7A814AA77FEF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:to="loc_pfe_CerevelMember_466789CA484762BF9B6E7A814AA77FEF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_DB1E07C3F4A6FF24838A7A814AA754AD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:to="loc_pfe_AllogeneMember_DB1E07C3F4A6FF24838A7A814AA754AD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_7CA80FB0F99C61A925127A814AA7CC62" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_A1F06EFBD097239599F97A814AA7490E" xlink:to="loc_pfe_ViivHealthcareLimitedMember_7CA80FB0F99C61A925127A814AA7CC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_40FF1D79D918C632ACA47A814AA860EF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_40FF1D79D918C632ACA47A814AA860EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ED086083974553DF504B7A814AA83C8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_40FF1D79D918C632ACA47A814AA860EF" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ED086083974553DF504B7A814AA83C8A" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_ED086083974553DF504B7A814AA83C8A" xlink:to="loc_pfe_ViivHealthcareLimitedMember_7CA80FB0F99C61A925127A814AA7CC62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:label="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_43E73E9EA9C8322ADF537A814AA2153E" xlink:to="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_61E7B26E320754F560FC7A814AA8B210" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_InvestmentIncomeDividend_61E7B26E320754F560FC7A814AA8B210" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:label="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_DD3B00798B4CE87392D67A814AA9C6B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_DD3B00798B4CE87392D67A814AA9C6B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InsuranceRecoveries" xlink:label="loc_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_InsuranceRecoveries_1F00CF3941ABC624E9A17A814AA9ADAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_BC85C5E1F0BFE6AE2BBF7A814AA9EDCB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossFromContributionAgreement" xlink:label="loc_pfe_GainLossFromContributionAgreement_FF162CB129AF6A4BAF9B7A814AA9DD01" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_pfe_GainLossFromContributionAgreement_FF162CB129AF6A4BAF9B7A814AA9DD01" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment" xlink:label="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment_496A709C90571E8FBD477A814AA9A259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:label="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_BD08537F7E464874BAF17A814AA9A1AA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherNonoperatingIncomeMiscellaneous" xlink:label="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionLineItems_0E7EC0057AE3C07D89FA7A814AA8A24B" xlink:to="loc_pfe_OtherNonoperatingIncomeMiscellaneous_2B3BAED8B607697F6B457A814AAA469E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_41094DA4BCA2B99CEA05E395F46FB5E3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsTable" xlink:label="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_41094DA4BCA2B99CEA05E395F46FB5E3" xlink:to="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_165865394FB07C74F2DEE3F1DC3DEA1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_165865394FB07C74F2DEE3F1DC3DEA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_6C4AFBE06633708E605DE3F1DC4CC771" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_165865394FB07C74F2DEE3F1DC3DEA1D" xlink:to="loc_us-gaap_TypeOfAdoptionMember_6C4AFBE06633708E605DE3F1DC4CC771" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_C85C5234EF7C950DD2F5E3F1DC9FF03E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_6C4AFBE06633708E605DE3F1DC4CC771" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_C85C5234EF7C950DD2F5E3F1DC9FF03E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_73A68EA1F0E22B99AACEE395F470BFDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:to="loc_srt_OwnershipAxis_73A68EA1F0E22B99AACEE395F470BFDF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_6D590A96E4284048B57FE395F470BD67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_73A68EA1F0E22B99AACEE395F470BFDF" xlink:to="loc_srt_OwnershipDomain_6D590A96E4284048B57FE395F470BD67" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_4FE080165F8DC55F03E3E395F470A2D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_6D590A96E4284048B57FE395F470BD67" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_4FE080165F8DC55F03E3E395F470A2D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_38A8542A15708B41EDF5E395F471FF10" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_38A8542A15708B41EDF5E395F471FF10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_38A8542A15708B41EDF5E395F471FF10" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_85F5A6D32A7BCDF3B1F5E395F471422F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_85F5A6D32A7BCDF3B1F5E395F471422F" xlink:type="arc" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_4FE080165F8DC55F03E3E395F470A2D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CortexymeInc.Member" xlink:label="loc_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:to="loc_pfe_CortexymeInc.Member_5C7B866503D9D831EAA0E3F0EE983DD8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_F87E1F192D20C67BDA24E3F1DCCEFA45" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_0F0E8D76514C4E274581E395F47110FE" xlink:to="loc_pfe_AllogeneMember_F87E1F192D20C67BDA24E3F1DCCEFA45" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentHoldingsLineItems" xlink:label="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsTable_B61913BBF0ADF6406471E395F46F1C2F" xlink:to="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_7256AB9B018B60CF6672E395F4720B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5B47C8F75B4EC655EB55E395F47275F3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_5B47C8F75B4EC655EB55E395F47275F3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_905D1F447EA5B5EE090EE395F472D568" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_905D1F447EA5B5EE090EE395F472D568" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_D4AAEB290680095AEBEEE395F472D987" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_D4AAEB290680095AEBEEE395F472D987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentHoldingsLineItems_25903BB4B1C8F544676FE395F4729327" xlink:to="loc_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss_AA22E6BAD1A6B6B153EBE3F1DBFE999A" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_E6B6CE5C01F9A4B07AF8E395F45D48D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable" xlink:label="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_E6B6CE5C01F9A4B07AF8E395F45D48D3" xlink:to="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_6CB01F4D99B782F6EFE9E4011FAA783E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_6CB01F4D99B782F6EFE9E4011FAA783E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_43970535A76D2305B58BE4011FAC2DD9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_6CB01F4D99B782F6EFE9E4011FAA783E" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_43970535A76D2305B58BE4011FAC2DD9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_02324BD4DB92B29CDC3AE401201DD763" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_43970535A76D2305B58BE4011FAC2DD9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_02324BD4DB92B29CDC3AE401201DD763" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A8D053F22EDFD3584420E395F45E96B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A8D053F22EDFD3584420E395F45E96B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F41CD91D157B4D651103E395F45E512A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_A8D053F22EDFD3584420E395F45E96B7" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F41CD91D157B4D651103E395F45E512A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DistributionRightsMember" xlink:label="loc_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_F41CD91D157B4D651103E395F45E512A" xlink:to="loc_us-gaap_DistributionRightsMember_60F71FC174B382FF52AAE395F45E15C8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57886FA719470C0EE806E395F45FF8A8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57886FA719470C0EE806E395F45FF8A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9219E8869901C7D28AC0E395F45F7FE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_57886FA719470C0EE806E395F45FF8A8" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9219E8869901C7D28AC0E395F45F7FE2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember" xlink:label="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_A54243F01B992DBCB4B3E395F45FC3A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_9219E8869901C7D28AC0E395F45F7FE2" xlink:to="loc_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_A54243F01B992DBCB4B3E395F45FC3A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationAxis" xlink:label="loc_us-gaap_DisposalGroupClassificationAxis_DD664C9129C54507EF0CE395F45F774A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_DisposalGroupClassificationAxis_DD664C9129C54507EF0CE395F45F774A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupClassificationDomain" xlink:label="loc_us-gaap_DisposalGroupClassificationDomain_81402B96627662AE482DE395F45F3883" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationAxis_DD664C9129C54507EF0CE395F45F774A" xlink:to="loc_us-gaap_DisposalGroupClassificationDomain_81402B96627662AE482DE395F45F3883" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember" xlink:label="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5406049A77890636E1AFE395F4607498" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupClassificationDomain_81402B96627662AE482DE395F45F3883" xlink:to="loc_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_5406049A77890636E1AFE395F4607498" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_D4475A9DCFA7A9DEBF93E395F4601916" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_srt_CounterpartyNameAxis_D4475A9DCFA7A9DEBF93E395F4601916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_D4475A9DCFA7A9DEBF93E395F4601916" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MylanMember" xlink:label="loc_pfe_MylanMember_884ABEB851E7A54D4216E400BD020D4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:to="loc_pfe_MylanMember_884ABEB851E7A54D4216E400BD020D4A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShireMember" xlink:label="loc_pfe_ShireMember_749D539E09CB1EEA448AE395F4601A6C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:to="loc_pfe_ShireMember_749D539E09CB1EEA448AE395F4601A6C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MerckMember" xlink:label="loc_pfe_MerckMember_1BD40AB01468589616DFE395F4617241" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_18060FCF71AB7C89495FE395F46098AA" xlink:to="loc_pfe_MerckMember_1BD40AB01468589616DFE395F4617241" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3257D7466CA211A8E810E395F461B259" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3257D7466CA211A8E810E395F461B259" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3257D7466CA211A8E810E395F461B259" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_AC728A6805E3487157CBE395F4619FE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3" xlink:to="loc_us-gaap_LicensingAgreementsMember_AC728A6805E3487157CBE395F4619FE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementMember" xlink:label="loc_us-gaap_CollaborativeArrangementMember_FBB82CF08E6D21FAE895E395F4610B88" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_8A52F467958919C7B6FCE395F46151B3" xlink:to="loc_us-gaap_CollaborativeArrangementMember_FBB82CF08E6D21FAE895E395F4610B88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems" xlink:label="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable_20CAC796FBF7E17519D3E395F45D75D7" xlink:to="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromCollaborators" xlink:label="loc_us-gaap_ProceedsFromCollaborators_12FE59762A687015A345E395F4626010" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_us-gaap_ProceedsFromCollaborators_12FE59762A687015A345E395F4626010" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ProceedsFromLicensingArrangement" xlink:label="loc_pfe_ProceedsFromLicensingArrangement_3807C4ACD592BC713D05E395F462553E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_pfe_ProceedsFromLicensingArrangement_3807C4ACD592BC713D05E395F462553E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration" xlink:label="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_A3D75389EB11C1133D95E395F46292DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration_A3D75389EB11C1133D95E395F46292DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDispositionOfIntangibleAssets" xlink:label="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems_A4CB08AE4BC9D849D0F0E395F4621961" xlink:to="loc_us-gaap_GainLossOnDispositionOfIntangibleAssets_5DD4B785B5D6D3B6CC93E395F4624308" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_178F1D31C03206533EEDE395F455DAF5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesTable" xlink:label="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_178F1D31C03206533EEDE395F455DAF5" xlink:to="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:label="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:to="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:label="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusAxis_D1F6561BB38CC63047D9E395F45515A4" xlink:to="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PendingLitigationMember" xlink:label="loc_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LitigationStatusDomain_D8E91E567BAC59DF8692E395F4566184" xlink:to="loc_us-gaap_PendingLitigationMember_E21CC7F36FCE00C293D6E395F456CCF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_7C3421BDEEE9FF58CFD4E395F456B192" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:to="loc_srt_ProductOrServiceAxis_7C3421BDEEE9FF58CFD4E395F456B192" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_4A07DE02402B858A7A25E395F457FEBA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_7C3421BDEEE9FF58CFD4E395F456B192" xlink:to="loc_srt_ProductsAndServicesDomain_4A07DE02402B858A7A25E395F457FEBA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_4A07DE02402B858A7A25E395F457FEBA" xlink:to="loc_pfe_CelebrexMember_CB98598BF6AA098BC6D0E395F457567A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesByNatureOfContingencyAxis" xlink:label="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:to="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyNatureDomain" xlink:label="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesByNatureOfContingencyAxis_7A08595A1F694CB25B85E395F457F426" xlink:to="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PatentMatterMember" xlink:label="loc_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingencyNatureDomain_7745CEEEF84A4DC12267E395F457658A" xlink:to="loc_pfe_PatentMatterMember_C76E977CECB0A38C5E46E395F458C99C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingenciesLineItems" xlink:label="loc_us-gaap_LossContingenciesLineItems_502646D7CB5678EEADA6E395F4582856" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesTable_B79EA8CF263FCD990148E395F455F739" xlink:to="loc_us-gaap_LossContingenciesLineItems_502646D7CB5678EEADA6E395F4582856" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LitigationSettlementExpense" xlink:label="loc_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LossContingenciesLineItems_502646D7CB5678EEADA6E395F4582856" xlink:to="loc_us-gaap_LitigationSettlementExpense_69910AB00D5DAF94E85DE395F4584D40" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_E178496ECEB23D0125D626D4F1F0D4A7" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleOfIntangibleAssetsTable" xlink:label="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_E178496ECEB23D0125D626D4F1F0D4A7" xlink:to="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsAxis" xlink:label="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SubsegmentsDomain" xlink:label="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsAxis_D5CC699F714117A713D326D4F1F06FFF" xlink:to="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember" xlink:label="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsegmentsDomain_280C1E817B3875D2217826D4F1F070F6" xlink:to="loc_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember_2265178DA9DB40A3B34126D4F1F1A0D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7743E4CA858358BA162826D4F1F186DE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7743E4CA858358BA162826D4F1F186DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_7743E4CA858358BA162826D4F1F186DE" xlink:to="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DevelopedTechnologyRightsMember" xlink:label="loc_us-gaap_DevelopedTechnologyRightsMember_F998FCDB1001C39A7D0C26D4F1F183CB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:to="loc_us-gaap_DevelopedTechnologyRightsMember_F998FCDB1001C39A7D0C26D4F1F183CB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:to="loc_us-gaap_LicensingAgreementsMember_0B1C477908BE9A214D2626D4F1F268CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentMember" xlink:label="loc_us-gaap_InProcessResearchAndDevelopmentMember_5B9B189E0BF9270A699826D4F1F29762" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_AB9C4C687387AB7B611E26D4F1F13FC8" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5B9B189E0BF9270A699826D4F1F29762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_099CD857F20AC3D4665526D4F1F26AE8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_099CD857F20AC3D4665526D4F1F26AE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_04F2A4F07485E88F5EAF26D4F1F25294" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_099CD857F20AC3D4665526D4F1F26AE8" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_04F2A4F07485E88F5EAF26D4F1F25294" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AMPharmaBVMember" xlink:label="loc_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_04F2A4F07485E88F5EAF26D4F1F25294" xlink:to="loc_pfe_AMPharmaBVMember_D12D96056547671BAFE126D4F1F2AF9C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_E174D4FB40BB9B90EE9026D4F1F369C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_E174D4FB40BB9B90EE9026D4F1F369C5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:label="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_50495FA35CD18C45A27C26D4F1F35336" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_E174D4FB40BB9B90EE9026D4F1F369C5" xlink:to="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_50495FA35CD18C45A27C26D4F1F35336" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain_50495FA35CD18C45A27C26D4F1F35336" xlink:to="loc_us-gaap_InProcessResearchAndDevelopmentMember_5B9B189E0BF9270A699826D4F1F29762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_DFD1BA372D7B7CCCDB0B26D4F1F37A1C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_srt_ConsolidationItemsAxis_DFD1BA372D7B7CCCDB0B26D4F1F37A1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_6585A2B21116FDAEDD6426D4F1F41638" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_DFD1BA372D7B7CCCDB0B26D4F1F37A1C" xlink:to="loc_srt_ConsolidationItemsDomain_6585A2B21116FDAEDD6426D4F1F41638" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_17FF7F97E56D431EE40E26D4F1F47B8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_6585A2B21116FDAEDD6426D4F1F41638" xlink:to="loc_us-gaap_OperatingSegmentsMember_17FF7F97E56D431EE40E26D4F1F47B8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_927B6FC641BBE990436726D4F1F447AA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_927B6FC641BBE990436726D4F1F447AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_5E2B3E0C4DFA2D2253AA26D4F1F4EEBC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_927B6FC641BBE990436726D4F1F447AA" xlink:to="loc_us-gaap_SegmentDomain_5E2B3E0C4DFA2D2253AA26D4F1F4EEBC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_41EAFBA0BF30337777E626D4F1F50C48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_5E2B3E0C4DFA2D2253AA26D4F1F4EEBC" xlink:to="loc_pfe_BiopharmaSegmentMember_41EAFBA0BF30337777E626D4F1F50C48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_4E8852B47E9EC2ECCCE026D4F1F57B55" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_4E8852B47E9EC2ECCCE026D4F1F57B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_4E8852B47E9EC2ECCCE026D4F1F57B55" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AnacorMember" xlink:label="loc_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_AnacorMember_B60B0EBE91E025068AE726D4F1F5A897" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AstraZenecaMember" xlink:label="loc_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_AstraZenecaMember_7550993D87E770CA2AC926D4F1F6A45D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InnoPharmaMember" xlink:label="loc_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_InnoPharmaMember_AA3C2A5EBDF901BBA10826D4F1F6878C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_D03B0638AD9A3A6C193826D4F1F6D945" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_HospiraMember_D03B0638AD9A3A6C193826D4F1F6D945" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NextWaveMember" xlink:label="loc_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_3ED76F8E9BB9D03EBC1026D4F1F59914" xlink:to="loc_pfe_NextWaveMember_FDD4D2AA610ADB5DB47926D4F1F6C7DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_8A434232E0432B1CCBAD26D4F1F66E24" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_srt_ProductOrServiceAxis_8A434232E0432B1CCBAD26D4F1F66E24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_8A434232E0432B1CCBAD26D4F1F66E24" xlink:to="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_EucrisaMember_B91A4E7F83AC02A7063E26D4F1F7482A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GeneTherapiesMember" xlink:label="loc_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_GeneTherapiesMember_DED29FA561DC770668CD26D4F1F7200D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenericSterileInjectableProductMember" xlink:label="loc_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_GenericSterileInjectableProductMember_37E6C70F351F3D0BF5CB26D4F1F797A1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember" xlink:label="loc_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_8BEE4A96F3BC703B2BC626D4F1F7F83A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TreatmentForToenailFungusMember" xlink:label="loc_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_TreatmentForToenailFungusMember_0C176078008E6A82E38B26D4F1F7BFBB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SterileInjectablePainRelieverMember" xlink:label="loc_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_SterileInjectablePainRelieverMember_537DF8FD834FC03DD35326D4F1F89180" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TreatmentOfAttentionHyperactivityDisorderMember" xlink:label="loc_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_TreatmentOfAttentionHyperactivityDisorderMember_F6CFEA3F42E1564E99C426D4F1F87E3D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenericInjectablePainRelieverMember" xlink:label="loc_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_794AC2A6C539577E0D7726D4F1F66223" xlink:to="loc_pfe_GenericInjectablePainRelieverMember_1FF1C54FBE18CD06918826D4F1F844D9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IntangibleAssetsLineItems" xlink:label="loc_pfe_IntangibleAssetsLineItems_649E0DB2DDE8C2971A9A26D4F1F8D945" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ScheduleOfIntangibleAssetsTable_1BF2CB64C9EE0E3A25C826D4F1F0D5F4" xlink:to="loc_pfe_IntangibleAssetsLineItems_649E0DB2DDE8C2971A9A26D4F1F8D945" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill" xlink:label="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IntangibleAssetsLineItems_649E0DB2DDE8C2971A9A26D4F1F8D945" xlink:to="loc_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill_A83041C88EF38743784426D4F1F88F1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount" xlink:label="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IntangibleAssetsLineItems_649E0DB2DDE8C2971A9A26D4F1F8D945" xlink:to="loc_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount_7B4A5BB2D5935755E8BB26D4F1F90EDD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_14F0160ED807CAE215C88020717D4E14" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InterestCostsCapitalized" xlink:label="loc_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_14F0160ED807CAE215C88020717D4E14" xlink:to="loc_us-gaap_InterestCostsCapitalized_46B174E82B2BBACF30358020717D196B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_0AAB2E8F7435EF41B26B74DC3A9E1A99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeTable" xlink:label="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_0AAB2E8F7435EF41B26B74DC3A9E1A99" xlink:to="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationAxis" xlink:label="loc_us-gaap_HedgingDesignationAxis_28498BA23FD18A9B8C2374DC3A9F9635" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:to="loc_us-gaap_HedgingDesignationAxis_28498BA23FD18A9B8C2374DC3A9F9635" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_HedgingDesignationDomain" xlink:label="loc_us-gaap_HedgingDesignationDomain_1EB0A2E95661B67C8E3574DC3A9F0C1D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationAxis_28498BA23FD18A9B8C2374DC3A9F9635" xlink:to="loc_us-gaap_HedgingDesignationDomain_1EB0A2E95661B67C8E3574DC3A9F0C1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DesignatedAsHedgingInstrumentMember" xlink:label="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F568D7955970CD5463874DC3A9F694A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_HedgingDesignationDomain_1EB0A2E95661B67C8E3574DC3A9F0C1D" xlink:to="loc_us-gaap_DesignatedAsHedgingInstrumentMember_4F568D7955970CD5463874DC3A9F694A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaap_DerivativeInstrumentRiskAxis_C1B073B4369C688A446074DC3AA04893" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:to="loc_us-gaap_DerivativeInstrumentRiskAxis_C1B073B4369C688A446074DC3AA04893" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaap_DerivativeContractTypeDomain_CEA6DA0AE3B353D102C974DC3AA0989E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeInstrumentRiskAxis_C1B073B4369C688A446074DC3AA04893" xlink:to="loc_us-gaap_DerivativeContractTypeDomain_CEA6DA0AE3B353D102C974DC3AA0989E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignExchangeContractMember" xlink:label="loc_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeContractTypeDomain_CEA6DA0AE3B353D102C974DC3AA0989E" xlink:to="loc_us-gaap_ForeignExchangeContractMember_08D5EE5909EBCF81D0D374DC3AA021D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:label="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:to="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:label="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeAxis_35E2C2241A1D4363F80A74DC3AA09051" xlink:to="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesMember" xlink:label="loc_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentTypeCategorizationMember_5D9A2425F0A55D35F4AB74DC3AA17BE2" xlink:to="loc_us-gaap_DebtSecuritiesMember_24C7493BE243A6864B5274DC3AA1480E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DerivativeLineItems" xlink:label="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeTable_CE957E818EF87C29C22974DC3A9FB9A1" xlink:to="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_956AF2E873EBAE48A37B74DC3AA1FE92" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnDerivativeInstrumentsNetPretax" xlink:label="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_GainLossOnDerivativeInstrumentsNetPretax_898CF2B4542786DE770474DC3AA2680F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_3199812A96224502411074DC3AA231FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DerivativeLineItems_7E0CC8DBA8CE7850B2F674DC3AA137ED" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_ADA4A698AC14F4058C6874DC3AA267F0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_F7FC40A8DEE86219DC4AE395F4770295" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromLegalSettlements" xlink:label="loc_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_F7FC40A8DEE86219DC4AE395F4770295" xlink:to="loc_us-gaap_ProceedsFromLegalSettlements_3071DF223856BD451C12E3E565B4017C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/OtherIncomeDeductionsNetTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherIncomeAndExpensesAbstract" xlink:label="loc_us-gaap_OtherIncomeAndExpensesAbstract_A4BC42A5864A88DE1B38802078D0A92F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_A4BC42A5864A88DE1B38802078D0A92F" xlink:to="loc_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock_EA50BF0EB7E6BA0A4EA5802078D0D191" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock" xlink:label="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherIncomeAndExpensesAbstract_A4BC42A5864A88DE1B38802078D0A92F" xlink:to="loc_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock_BFFB4C4480262E221C54802078D1571D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_BF4FE27D2E7A4418950E802075418428" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_BF4FE27D2E7A4418950E802075418428" xlink:to="loc_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_1D03177C790B0348D92480207541B563" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8DCA47ECAF949E325EAD16E81D492B88" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8DCA47ECAF949E325EAD16E81D492B88" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_ADC764ADAB752AAB281516E81D49AC06" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_ADC764ADAB752AAB281516E81D49AC06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_ADC764ADAB752AAB281516E81D49AC06" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_6EEC2EB5A2239291202416E81D4A3824" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0" xlink:to="loc_us-gaap_QualifiedPlanMember_6EEC2EB5A2239291202416E81D4A3824" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_2D2110C834A0455F0DAF16E81D4A24D7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_DC1B5D478E9B97AE446216E81D4A0EE0" xlink:to="loc_us-gaap_NonqualifiedPlanMember_2D2110C834A0455F0DAF16E81D4A24D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_693A21BEA6EADB9B22B716E81D4B19D8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_693A21BEA6EADB9B22B716E81D4B19D8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_693A21BEA6EADB9B22B716E81D4B19D8" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_83F488804DDBC9D0391916E81D4BF2E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1" xlink:to="loc_us-gaap_DomesticPlanMember_83F488804DDBC9D0391916E81D4BF2E6" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_A289FC765C823C62E2FD16E81D4C0C99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_83F488804DDBC9D0391916E81D4BF2E6" xlink:to="loc_country_US_A289FC765C823C62E2FD16E81D4C0C99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_2D0859E8EEF887E4665716E81D4C7F16" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_29D67E57DA212289DE2E16E81D4B66E1" xlink:to="loc_us-gaap_ForeignPlanMember_2D0859E8EEF887E4665716E81D4C7F16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_B47315A80149D574E7BC16E81D4CDF2E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_B47315A80149D574E7BC16E81D4CDF2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_B47315A80149D574E7BC16E81D4CDF2E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_E385D86FA96BBBF6D90A16E81D4D7FD5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_E385D86FA96BBBF6D90A16E81D4D7FD5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_C1B72F68520EED3D02AF16E81D4DA472" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_C1B72F68520EED3D02AF16E81D4DA472" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_06FBCAA23E68A931B89716E81D4D661F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_E697A1F21F6433297D9816E81D4C28AF" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_06FBCAA23E68A931B89716E81D4D661F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_C1EAB8607DFB4DA259D616E81D492BED" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear_D80F5C7FB57AFC4FC58F16E81D4EC7D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear_23898D91CD0668C5A7C216E81D4E9E9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear_10BFA40F38D0CA1D0DD916E81D53A0CE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanExpectedAmortizationTerm" xlink:label="loc_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9E482D59AA79A53B75FC16E81D4ED321" xlink:to="loc_pfe_DefinedBenefitPlanExpectedAmortizationTerm_4C75507B9FCE188CA15916E81D54E8C1" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_39788A167DE21E70A0F1D81116974F80" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_39788A167DE21E70A0F1D81116974F80" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_05D3680510F9A8918FBAD8A794D4E3B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_05D3680510F9A8918FBAD8A794D4E3B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_05D3680510F9A8918FBAD8A794D4E3B2" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_0E270D7DAEB9D951E3CAD8A7F51C5697" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E" xlink:to="loc_us-gaap_QualifiedPlanMember_0E270D7DAEB9D951E3CAD8A7F51C5697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_E15089F0FB246DAE927DD8A826AB6FD7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_64DCD4B6B95A93CD06E3D8A796F5C63E" xlink:to="loc_us-gaap_NonqualifiedPlanMember_E15089F0FB246DAE927DD8A826AB6FD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_D0C6A56A05C01FD4FFE3D81116982E50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_D0C6A56A05C01FD4FFE3D81116982E50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_D0C6A56A05C01FD4FFE3D81116982E50" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_726DD82C98D8616FCA5ED8A691DE305F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727" xlink:to="loc_us-gaap_DomesticPlanMember_726DD82C98D8616FCA5ED8A691DE305F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_8A79C36562992FB81EF4D8111698546D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_726DD82C98D8616FCA5ED8A691DE305F" xlink:to="loc_country_US_8A79C36562992FB81EF4D8111698546D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_C204FDDAD6E94AB41573D8111699FFF6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B815F499F3D30CA2AC7AD8111698F727" xlink:to="loc_us-gaap_ForeignPlanMember_C204FDDAD6E94AB41573D8111699FFF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_59C9961B94BF603FF382D81116991057" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_59C9961B94BF603FF382D81116991057" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_59C9961B94BF603FF382D81116991057" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_2A763B31EDAC47A2C2CED8111699B373" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_2A763B31EDAC47A2C2CED8111699B373" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_648DA7A021531C327295D811169A33ED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_648DA7A021531C327295D811169A33ED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_C18C620C24383CA2ECF9D811169AF604" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_6F3659414C5B90F1F173D811169919F0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_C18C620C24383CA2ECF9D811169AF604" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_90E0EA5B1DA6AD5032F6D81116976F40" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax_2F676D0C0C90CE3EC92ED811169A3C57" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax_6133F8DA3E73BEEFA6E4D811169AC14F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_3DE32A41E5F812FF1E67D811169A2808" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax_3F1831D6CD163F16C320D811169A0D66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7D45BD5D00304D37482226D4EFDA969D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_7D45BD5D00304D37482226D4EFDA969D" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_D7F359D8094B450052DC26D4EFDA1D3C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_D7F359D8094B450052DC26D4EFDA1D3C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_39BFB609431F31B4237226D4EFDA6149" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_D7F359D8094B450052DC26D4EFDA1D3C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_39BFB609431F31B4237226D4EFDA6149" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_A5E33B53D8CEF4D3A87A26D4EFDB9BBD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_39BFB609431F31B4237226D4EFDA6149" xlink:to="loc_us-gaap_ForeignPlanMember_A5E33B53D8CEF4D3A87A26D4EFDB9BBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_D6AA4C6FC37FCA4BD86126D4EFDBABB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_D6AA4C6FC37FCA4BD86126D4EFDBABB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_175966872C03C54B48B026D4EFDBDB32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_D6AA4C6FC37FCA4BD86126D4EFDBABB8" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_175966872C03C54B48B026D4EFDBDB32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_15B75BA9C88335F810D726D4EFDBE60F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_175966872C03C54B48B026D4EFDBDB32" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_15B75BA9C88335F810D726D4EFDBE60F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_599FCCCC2F205D192A7526D4EFDC1936" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_3FE92595E106819A3E2326D4EFDC651B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_902D5839BBBAFC32171C26D4EFDC4F88" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_3FE92595E106819A3E2326D4EFDC651B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F52A7DC935F18F5FBCF826D4EFDC8FD8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F52A7DC935F18F5FBCF826D4EFDC8FD8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F52A7DC935F18F5FBCF826D4EFDC8FD8" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceContractsMember" xlink:label="loc_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7" xlink:to="loc_pfe_InsuranceContractsMember_A92899F18623AC0B252F26D4EFDD2E4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_62FA3E987C6565CD0B8026D4EFDD09D7" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_8F8B1DF53502BEBF908226D4EFDDF524" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63C71CD0807FB0745A5326D4EFDD08E5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_198BDD5B3F644BBB776E26D4EFDA2121" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63C71CD0807FB0745A5326D4EFDD08E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_63C71CD0807FB0745A5326D4EFDD08E5" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_33B70608A4C9AE3978D126D4EFDEDC70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_33B70608A4C9AE3978D126D4EFDEDC70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract_AA2EBED645FA7FDC3F8F26D4EFDE59C4" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld_00C4A5C9DB15147C0F2226D4EFDE6D70" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements" xlink:label="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements_D93149BFCED19AF1283426D4EFDFB95C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels" xlink:label="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels_35A415BE6B555870CE5826D4EFDF84F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_431FB97BA10EFEDCBAC126D4EFDFD87E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_00DD1143E05FA8C1878326D4EFDFFC61" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward_B0312AFE6618BDFDB98726D4EFDE7819" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_00DD1143E05FA8C1878326D4EFDFFC61" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_EB0B43804ADEBC384C375B5D7842B3B7" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_EB0B43804ADEBC384C375B5D7842B3B7" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_EA9214CFF0D80858156B5B5D7843DDAF" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:to="loc_us-gaap_QualifiedPlanMember_BC21B78F3FA3F13A11135B5D7843CB63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_5CAC947370F5FD4EA85C5B5D78430CFC" xlink:to="loc_us-gaap_NonqualifiedPlanMember_FAE1863178EB674EB3DD5B5D7844F6E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_85842937EB039120C4BD5B5D784461BE" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:to="loc_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_64DCECC42E90AB40DA265B5D78443017" xlink:to="loc_country_US_1C81100B7528156F9B7B5B5D784555DC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_8D2BAE82793A1345C5FF5B5D7844EC64" xlink:to="loc_us-gaap_ForeignPlanMember_73755D12CA6BF7E5CA995B5D78456E76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_DDA3F5675BAEFE62D6D15B5D784540A5" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_DDA3F5675BAEFE62D6D15B5D784540A5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_DDA3F5675BAEFE62D6D15B5D784540A5" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4AB1F4B6CCFA162570BA5B5D7846178C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_E5A934897DD172A858335B5D7846E0A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_20AD6D91543BC81B09355B5D78469A48" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_462ACF963F2D1A790E5E5B5D78454263" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_20AD6D91543BC81B09355B5D78469A48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_BB2A2EDDCE1F9A740E715B5D7843031A" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_E3E979F4FBD0B3C19A2A5B5D7846A6DE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_009F8CA3DE56DD76B5D65B5D78466CDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets_7AC3752995F523FA86AB5B5D78473BDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses_6EAD969AF6E5BF1B0CF75B5D78473268" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit" xlink:label="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit_0AD1C3AF32522DB431675B5D7847BA11" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments_A62B55A8D3C174C92AD85B5D7847E663" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_554C3BE0233FFBD277FB5B5D7847746C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod" xlink:label="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod_7E1792591DB28205F3EA5B5D78477E8F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_1ECDC91D9914F50465185B5D7848CDCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax_C61655548DFAF7D2BC4E5B5D7848F533" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax" xlink:label="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_B2985D0272A499B5ACD95B5D78464F35" xlink:to="loc_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax_EF473DAA0A97105D7D0A5B5D784828D5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_072D4C560AEEC0AB913A2677F5F85C3B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_072D4C560AEEC0AB913A2677F5F85C3B" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementScenarioAxis" xlink:label="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementScenarioAxis_04B3AB12B6D9D61BB3DC2677F5F8AADD" xlink:to="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScenarioForecastMember" xlink:label="loc_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScenarioUnspecifiedDomain_DB05C40DFF4FC73C77672677F5F906A3" xlink:to="loc_srt_ScenarioForecastMember_EE9775BE3467DDB3134B2677F5F9497A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_67494158B76C4CB84D6F2677F5F991D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_67494158B76C4CB84D6F2677F5F991D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_67494158B76C4CB84D6F2677F5F991D2" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_459A5F8231B2384618FE2677F5FA70EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725" xlink:to="loc_us-gaap_QualifiedPlanMember_459A5F8231B2384618FE2677F5FA70EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_F10B176D54DFE271DA7D2677F5FAFA98" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_FF4A8EEA29C4F04AC2B72677F5FAB725" xlink:to="loc_us-gaap_NonqualifiedPlanMember_F10B176D54DFE271DA7D2677F5FAFA98" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_50CE03E9399E7530D5D62677F5FA781C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_50CE03E9399E7530D5D62677F5FA781C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_50CE03E9399E7530D5D62677F5FA781C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_035A28F08AB34244B9C52677F5FB836E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33" xlink:to="loc_us-gaap_DomesticPlanMember_035A28F08AB34244B9C52677F5FB836E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D1433B03BF762441440C2677F5FBBFA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_035A28F08AB34244B9C52677F5FB836E" xlink:to="loc_country_US_D1433B03BF762441440C2677F5FBBFA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_8900529224CA1100B2B22677F5FBDA00" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_10EF4A306D2A65FD9E0E2677F5FABC33" xlink:to="loc_us-gaap_ForeignPlanMember_8900529224CA1100B2B22677F5FBDA00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2DA4B5E6A7AEA809A6042677F5FB0D64" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2DA4B5E6A7AEA809A6042677F5FB0D64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2DA4B5E6A7AEA809A6042677F5FB0D64" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_97A304AC2E612555CF5B2677F5FCA5D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_97A304AC2E612555CF5B2677F5FCA5D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_D96323540BA5C9288A2F2677F5FC82D5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_D96323540BA5C9288A2F2677F5FC82D5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_E7D307235002F1C89D7C2677F5FCB5FA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_EEA30C24FAEA2DEEBF0C2677F5FC4C13" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_E7D307235002F1C89D7C2677F5FCB5FA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4A84A4DABF71AC7AF2332677F5F88942" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear_73ACF6A8E2F472D2B7092677F5FD7D83" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:to="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths_36349573A7019DC5CC272677F5FD2ADE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo_60FE6DE11A129EF4C93C2677F6026BF4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree_5466743DC0564BACCE342677F60337B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour_966119A6D21FD8C82DA32677F603759B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive_A4DAA2C7E51178E88E1E2677F6035B7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter" xlink:label="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract_4EBC8321DF24D5E339EC2677F5FDDE5B" xlink:to="loc_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter_67BAFA48C7729A54C9672677F603C89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_41E3E6791CD03D0730DF2677F5FDC6E0" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_B6C8E816CB4A887D102C267FB5113C69" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5CF2380A9FAA496815F116E81D6E20C2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_5CF2380A9FAA496815F116E81D6E20C2" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_18C8DE821CBD7409830F16E81D6EAFEB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_18C8DE821CBD7409830F16E81D6EAFEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_0799A16219699B59BEEF16E81D74A1CF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_18C8DE821CBD7409830F16E81D6EAFEB" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_0799A16219699B59BEEF16E81D74A1CF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_61E13EECDC150A24506F16E81D74B9D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_0799A16219699B59BEEF16E81D74A1CF" xlink:to="loc_us-gaap_QualifiedPlanMember_61E13EECDC150A24506F16E81D74B9D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_396925BC94D775B0497116E81D75C386" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_396925BC94D775B0497116E81D75C386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7CF7F95B4825C499103916E81D75F90D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_396925BC94D775B0497116E81D75C386" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7CF7F95B4825C499103916E81D75F90D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_ACF5EB57B5180D05494A16E81D756A0B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_7CF7F95B4825C499103916E81D75F90D" xlink:to="loc_pfe_HospiraMember_ACF5EB57B5180D05494A16E81D756A0B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_8D206EDAE104D1D109E016E81D766462" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_8D206EDAE104D1D109E016E81D766462" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_A3550EA0A11AB52210DF16E81D761550" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_8D206EDAE104D1D109E016E81D766462" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_A3550EA0A11AB52210DF16E81D761550" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_59954E95FA5A0EA3FFA916E81D7694E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_A3550EA0A11AB52210DF16E81D761550" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_59954E95FA5A0EA3FFA916E81D7694E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_8D78C73300428506ADF916E81D7761D2" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_8D78C73300428506ADF916E81D7761D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6D68AE92311A870CD74816E81D774CD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_8D78C73300428506ADF916E81D7761D2" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6D68AE92311A870CD74816E81D774CD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_02E3FDC36F9D1831946016E81D770329" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6D68AE92311A870CD74816E81D774CD3" xlink:to="loc_us-gaap_DomesticPlanMember_02E3FDC36F9D1831946016E81D770329" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_B6B87D2A02722DF2C19E16E81D78CF9F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_02E3FDC36F9D1831946016E81D770329" xlink:to="loc_country_US_B6B87D2A02722DF2C19E16E81D78CF9F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable_7647DA7DC8282C494EF416E81D6E1D46" xlink:to="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost" xlink:label="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:to="loc_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost_A661B4D55C50596EA85916E81D7864A7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax" xlink:label="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:to="loc_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax_C6DDA501B9F9DB9BFB8A16E81D782E5C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanNumberofPensionPlansFrozen" xlink:label="loc_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems_567E7880816A8FDDC59D16E81D78AB97" xlink:to="loc_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen_C5DC0EBD5060C4304B8E16E81D79D686" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_42ED843763A170B5EB9AD81116AAA43E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_42ED843763A170B5EB9AD81116AAA43E" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_D9C717558F78B47B50F3D8A38E8DB819" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_D9C717558F78B47B50F3D8A38E8DB819" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_D9C717558F78B47B50F3D8A38E8DB819" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_9FFF5A28F7E0AE9121A8D8A3ED6B89B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980" xlink:to="loc_us-gaap_QualifiedPlanMember_9FFF5A28F7E0AE9121A8D8A3ED6B89B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_E1ED83E3E8271C7C7956D8A41C7879BF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_FC836D1F6295BF8C4D9ED8A390AE2980" xlink:to="loc_us-gaap_NonqualifiedPlanMember_E1ED83E3E8271C7C7956D8A41C7879BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_B2B03B145EE5DBCB86CCD81116ABA22C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_B2B03B145EE5DBCB86CCD81116ABA22C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_B2B03B145EE5DBCB86CCD81116ABA22C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_628EF5EACB08C09566FFD8A318382A74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C" xlink:to="loc_us-gaap_DomesticPlanMember_628EF5EACB08C09566FFD8A318382A74" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_121DC66E89583296252AD81116AB4589" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_628EF5EACB08C09566FFD8A318382A74" xlink:to="loc_country_US_121DC66E89583296252AD81116AB4589" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_49F67057B052E09BBDBDD81116AB9A22" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_87BA4FEB2663374854EED81116AB366C" xlink:to="loc_us-gaap_ForeignPlanMember_49F67057B052E09BBDBDD81116AB9A22" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_C662CB4524F2846333B2D81116AB14EA" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_C662CB4524F2846333B2D81116AB14EA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_C662CB4524F2846333B2D81116AB14EA" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_DB6F071CF70CB1B9C9D4D81116AC147C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_DB6F071CF70CB1B9C9D4D81116AC147C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_7C9DA444C3AB236E4034D81116ACCE48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_7C9DA444C3AB236E4034D81116ACCE48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_A2BFA1445B7024A78AF7D81116ACEEB0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_1AA110958A3C299C2C22D81116AC3F9E" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_A2BFA1445B7024A78AF7D81116ACEEB0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_20461349ED7E152B5A93D81116AA9317" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent" xlink:label="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent_A7610E0434D9ACCAF9E5D81116B27E28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities_FBD30CAA7F6536742769D81116B261B4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent" xlink:label="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent_2D3E2C9B3E7A7B4D3D34D81116B2FF3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet" xlink:label="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_EF76F5BCDD774DCDA013D81116B21180" xlink:to="loc_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet_34E80511FE4558ED7B88D81116B25971" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3286AEEB6D13EA659B7780206AAAD4BC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3286AEEB6D13EA659B7780206AAAD4BC" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_56E7C636F8E383726AA380206AAB059E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_C96F19FAAFBD84D8C49980206AABDDC8" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F52E3047F107DF997C3980206AABC82E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_CBC789798C39E1C4F3D480206AAB1ADF" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge" xlink:label="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:to="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge_6772C591275CC2D226B780206AAC6527" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver" xlink:label="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:to="loc_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver_51CEC41F8E07D1BBA95980206AAE3923" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1" xlink:label="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_2F7CFD48003A1482AA9280206AACE13B" xlink:to="loc_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1_84D8C40BA035CD10E53380206AAEB9C2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8688985017D9D5FBC6CA373A240B801F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_8688985017D9D5FBC6CA373A240B801F" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_3C0E1C50AACC8C84FD54373A240C1FC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_3C0E1C50AACC8C84FD54373A240C1FC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_A8FDED3F3BAF78A90883373A240CD743" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_3C0E1C50AACC8C84FD54373A240C1FC9" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_A8FDED3F3BAF78A90883373A240CD743" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_FD2C46F0D4BAE9F191B1373A240C8CD0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_A8FDED3F3BAF78A90883373A240CD743" xlink:to="loc_us-gaap_QualifiedPlanMember_FD2C46F0D4BAE9F191B1373A240C8CD0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_663830AB963E4655275E373A240DDA1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_srt_RangeAxis_663830AB963E4655275E373A240DDA1D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_663830AB963E4655275E373A240DDA1D" xlink:to="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_18B44ACC76E8E3184C2D373A240D8AC9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10" xlink:to="loc_srt_MinimumMember_18B44ACC76E8E3184C2D373A240D8AC9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_016AEBEE4B5D5E2C261E373A240DD323" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_767D8BF5A9C7EA35AF36373A240D8F10" xlink:to="loc_srt_MaximumMember_016AEBEE4B5D5E2C261E373A240DD323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_0500778DFC082D0C42D7373A240D88A6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_0500778DFC082D0C42D7373A240D88A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_0500778DFC082D0C42D7373A240D88A6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_F18E3BA25FB7E35D2475373A240E44D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6" xlink:to="loc_us-gaap_DomesticPlanMember_F18E3BA25FB7E35D2475373A240E44D2" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_AE4ACAEB8AD10951E05E373A240E8DF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_F18E3BA25FB7E35D2475373A240E44D2" xlink:to="loc_country_US_AE4ACAEB8AD10951E05E373A240E8DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_7E9CAF8389597A0FEBC2373A240EA073" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_0A5E2B2C4975714FCAB5373A240E17C6" xlink:to="loc_us-gaap_ForeignPlanMember_7E9CAF8389597A0FEBC2373A240EA073" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_3AE3FCFA25F778EE2F47373A240F5612" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_95B1B34BAB606FB3A9D8373A240F39CA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEquitySecuritiesMember" xlink:label="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="loc_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_10C1F44394AA932D17F7373A240FD86E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_4B4A9740490388B5584C373A24108FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherInvestmentsMember" xlink:label="loc_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_CBFEB44BC4D9B6EF1825373A240FA697" xlink:to="loc_us-gaap_OtherInvestmentsMember_6048137B6DE8186C6B08373A24106643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9FCB7B4A635E388E3CCE373A24102230" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9FCB7B4A635E388E3CCE373A24102230" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9FCB7B4A635E388E3CCE373A24102230" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_A117B6F0BDD5B4922800373A241114D3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_A117B6F0BDD5B4922800373A241114D3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F699BD3FBA4E193DAF02373A24116488" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_217069F32C300868E914373A241052B0" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_F699BD3FBA4E193DAF02373A24116488" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9DE34981B9B916B4CA38373A2411B93D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_A18815E5ECF2D6892FC9373A240BD104" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9DE34981B9B916B4CA38373A2411B93D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9DE34981B9B916B4CA38373A2411B93D" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage_1F3F32D0D145CE90C847373A24114F9E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_9DE34981B9B916B4CA38373A2411B93D" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations_D42948DC0E84F9ABF8C4373A24118040" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_686DFE2A8C60F4A23E6716E81AE31458" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_686DFE2A8C60F4A23E6716E81AE31458" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_BFC2F3D7C3BD96FB277316E81AE3A8FE" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3CF33B2E2DD0976B2FED2F92B2131E92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3CF33B2E2DD0976B2FED2F92B2131E92" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_36E625163DFE96E3B2D22F92B214A89A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_36E625163DFE96E3B2D22F92B214A89A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_36E625163DFE96E3B2D22F92B214A89A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_7EFC9B0A5F22CD43182C2F92B214A083" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A" xlink:to="loc_us-gaap_QualifiedPlanMember_7EFC9B0A5F22CD43182C2F92B214A083" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_757528244493686C9B522F92B21588D9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_08A616C4365A9402CE632F92B214C33A" xlink:to="loc_us-gaap_NonqualifiedPlanMember_757528244493686C9B522F92B21588D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_9B796CB79E164CC7E4CD2F92B215BA1F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_9B796CB79E164CC7E4CD2F92B215BA1F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_9B796CB79E164CC7E4CD2F92B215BA1F" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_8C655F45E10E0D00C9E72F92B215EEC0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E" xlink:to="loc_us-gaap_DomesticPlanMember_8C655F45E10E0D00C9E72F92B215EEC0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_89886FD042B2B41CA3D72F92B2156AA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_8C655F45E10E0D00C9E72F92B215EEC0" xlink:to="loc_country_US_89886FD042B2B41CA3D72F92B2156AA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_E269E0583AC43C6586812F92B216D994" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_39F0F6BE820364218C042F92B215E20E" xlink:to="loc_us-gaap_ForeignPlanMember_E269E0583AC43C6586812F92B216D994" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_9D899D68F8F2020E38E12F92B216D32E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_9D899D68F8F2020E38E12F92B216D32E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_9D899D68F8F2020E38E12F92B216D32E" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_4C85B2EB82425118BF012F92B216F30A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_4C85B2EB82425118BF012F92B216F30A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_7209AF10E9B1DB462FE92F92B2177100" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_7209AF10E9B1DB462FE92F92B2177100" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_54F5C01D4ABC1904B42B2F92B217E86D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_3CC451F9285AE4CC10382F92B2160203" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_54F5C01D4ABC1904B42B2F92B217E86D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_6DD1186DC52B8D5A28B12F92B2149E97" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_90CBC5B2131910564C222F92B21725C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanServiceCost" xlink:label="loc_us-gaap_DefinedBenefitPlanServiceCost_7A800C8BFFA3D03B74A42F92B218E60B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanServiceCost_7A800C8BFFA3D03B74A42F92B218E60B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanInterestCost" xlink:label="loc_us-gaap_DefinedBenefitPlanInterestCost_936BEA389B4DE9C72DE12F92B218083E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanInterestCost_936BEA389B4DE9C72DE12F92B218083E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant_B54F057105CECCD415E12F92B2189A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAmendments" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAmendments_8F9ED9C515B1617D99BF2F92B2180325" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActuarialGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanActuarialGainLoss_7E0E076613C59980486B2F92B2188B39" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation_4D2990B86C37C807C41D2F92B218EA2D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation_175623F81B6CA25A1C5F2F92B2195C26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCurtailments" xlink:label="loc_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanCurtailments_46501968A3E4868E902E2F92B219F42F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation_AAAAA3AFB771BC18120D2F92B2195D26" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSpecialTerminationBenefits" xlink:label="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits_9446372408C1C7E1FC1C2F92B2190384" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid_A913F94949ADB5EDE4562F92B219022E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FE8DE4EFBDA826367B582F92B219851D" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward_CCAFC5E36FBCA26383AA2F92B2177FA9" xlink:to="loc_us-gaap_DefinedBenefitPlanBenefitObligation_FE8DE4EFBDA826367B582F92B219851D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward" xlink:label="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_F31BE61BBB539C8A6BEF2F92B21AD3A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets_5BDB0E7816EA29A2DFFE2F92B21ADAB2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanContributionsByEmployer" xlink:label="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanContributionsByEmployer_8C4F4EE320E8F1962DD72F92B21A43C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant_2EF3FD1F6FF8F88514A12F92B21A9BB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss_E6AB7346146AE7A2D8352F92B21B92A5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets" xlink:label="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets_798A0A113D374C0EE0142F92B21B2B0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanSettlementsPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanSettlementsPlanAssets_1F6D5BE0BBF91CF7C45B2F92B21B35A9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid" xlink:label="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid_C8DB8995A79C52813FE32F92B21BDDBD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9660FDA9BF7C7C7E1EB32F92B21B1AB3" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward_6D5A87EA5B9C6A4FA0382F92B21A9D10" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_9660FDA9BF7C7C7E1EB32F92B21B1AB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFundedStatusOfPlan" xlink:label="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_DefinedBenefitPlanFundedStatusOfPlan_9D5B9F26DA0053F8FD172F92B21B0A35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_8E5E679AD8779B3C08EE2F92B2170DBC" xlink:to="loc_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation_B943A6E14EACBFE639162F92B21C9FF4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3AEC976F289492D3D40302B665D6E937" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_838F431CF8CD7EF3BB2E02B665D70B4F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_3AEC976F289492D3D40302B665D6E937" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_838F431CF8CD7EF3BB2E02B665D70B4F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3F209C002EE5C12AA60002B665D700D9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_838F431CF8CD7EF3BB2E02B665D70B4F" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3F209C002EE5C12AA60002B665D700D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_62128E7D5211D11AF30502B665D71153" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3F209C002EE5C12AA60002B665D700D9" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_62128E7D5211D11AF30502B665D71153" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4713BE050AE5911EA6AB02B665D86775" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_62128E7D5211D11AF30502B665D71153" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_4713BE050AE5911EA6AB02B665D86775" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_838F431CF8CD7EF3BB2E02B665D70B4F" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents_D9C4D65817F54CB3024F02B665D8AABF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1_7EE727BFCE620EE2E38602B665D902B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation_11ECACAEA0DF5FA2D21302B665D97539" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1" xlink:label="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_A6F20673B391F27AE44502B665D81DAC" xlink:to="loc_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1_6B8FF3AE96BE27EDE21402B665D9A183" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1A6CFC3FD84224CB0F0AD811167FD5F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_1A6CFC3FD84224CB0F0AD811167FD5F3" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_B41834657FC477F7C6BED8AA673CBB77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_B41834657FC477F7C6BED8AA673CBB77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_B41834657FC477F7C6BED8AA673CBB77" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_FAE8D1F5F8FE762E6F05D8AAB97D6BEE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03" xlink:to="loc_us-gaap_QualifiedPlanMember_FAE8D1F5F8FE762E6F05D8AAB97D6BEE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_04F57E1B7E0E0C73D59ED8AAE895B6D1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_7C1885150415D0D0BB06D8AA68E98B03" xlink:to="loc_us-gaap_NonqualifiedPlanMember_04F57E1B7E0E0C73D59ED8AAE895B6D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_A8F6B80311C9DEB4E05DD811167F7E0C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_A8F6B80311C9DEB4E05DD811167F7E0C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_A8F6B80311C9DEB4E05DD811167F7E0C" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_126EF0E977A3C1D3AFE5D8A9E6E5B557" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB" xlink:to="loc_us-gaap_DomesticPlanMember_126EF0E977A3C1D3AFE5D8A9E6E5B557" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_C7A8780D7FD69D26A029D8111680B68B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_126EF0E977A3C1D3AFE5D8A9E6E5B557" xlink:to="loc_country_US_C7A8780D7FD69D26A029D8111680B68B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_5EF23F03DD2EABCB8D3ED81116800B9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_6BD257811AD61113129ED81116803ACB" xlink:to="loc_us-gaap_ForeignPlanMember_5EF23F03DD2EABCB8D3ED81116800B9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_3BF1F889BFA1AA33A6A9D8111680D05A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_3BF1F889BFA1AA33A6A9D8111680D05A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_3BF1F889BFA1AA33A6A9D8111680D05A" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_315768A3DFB65731C638D8111686C6F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_315768A3DFB65731C638D8111686C6F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_974A59F320AA2B5436CBD81116865D8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DAE79B86833929726AD2D81116807BDE" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_974A59F320AA2B5436CBD81116865D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56A3D2B8A070B9571983D8111686EEFD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_DCF6F85E32DE44C518AED811167F2999" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56A3D2B8A070B9571983D8111686EEFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56A3D2B8A070B9571983D8111686EEFD" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets_2E26AE2D1280B6E4699AD811168737F0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract_E016976618066BE9702FD81116879D77" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation_1E03BFDBA9C1493CF500D81116870143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_56A3D2B8A070B9571983D8111686EEFD" xlink:to="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets_360733674DC625132DD4D8111687EEC3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation" xlink:label="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract_5A15ED12C304156FD2A4D8111687058D" xlink:to="loc_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation_17878C2C918A6C5D6227D81116888F66" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2429798DB8E510694A302F92B1EA3769" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_2429798DB8E510694A302F92B1EA3769" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_66411F6F55F15B9FD39E2F92B1EB056A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_66411F6F55F15B9FD39E2F92B1EB056A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_A601FB9F35BF4AFE5D242F92B1EBA2B7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_66411F6F55F15B9FD39E2F92B1EB056A" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_A601FB9F35BF4AFE5D242F92B1EBA2B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_DCF4761828679351B39B2F92B1EB0089" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_A601FB9F35BF4AFE5D242F92B1EBA2B7" xlink:to="loc_us-gaap_QualifiedPlanMember_DCF4761828679351B39B2F92B1EB0089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_C442FCE6760DAD5E96772F92B1EB3B81" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_C442FCE6760DAD5E96772F92B1EB3B81" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_C442FCE6760DAD5E96772F92B1EB3B81" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_C4B6A416AF9DF457CF822F92B1ECC694" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3" xlink:to="loc_us-gaap_DomesticPlanMember_C4B6A416AF9DF457CF822F92B1ECC694" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_70D965876B4E2E8E05CC2F92B1ECAF34" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_C4B6A416AF9DF457CF822F92B1ECC694" xlink:to="loc_country_US_70D965876B4E2E8E05CC2F92B1ECAF34" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_A75F47361D392F32C4352F92B1EDA006" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_B35DB5003C5FD00528B52F92B1EC41E3" xlink:to="loc_us-gaap_ForeignPlanMember_A75F47361D392F32C4352F92B1EDA006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_2803480A8FED29A66EE82F92B1EDF21D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_2803480A8FED29A66EE82F92B1EDF21D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_2803480A8FED29A66EE82F92B1EDF21D" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_96B9D453A0C26D2870112F92B1EDF0C9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_96B9D453A0C26D2870112F92B1EDF0C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_161FFB75087D12DCE40C2F92B1EDC424" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_DC111DC75AB8AD3F67242F92B1ED3A6E" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_161FFB75087D12DCE40C2F92B1EDC424" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis" xlink:label="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F32379566A3126DE22DE2F92B1EE68AC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F32379566A3126DE22DE2F92B1EE68AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanAssetCategoriesDomain" xlink:label="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_F32379566A3126DE22DE2F92B1EE68AC" xlink:to="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember" xlink:label="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_86865969C1B91C24A4762F92B1EEA300" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_86865969C1B91C24A4762F92B1EEA300" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_C181EDF003F680EFC1CE2F92B1EE50B8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember" xlink:label="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_929B05B750227455DF032F92B1EF762E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="loc_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_CorporateDebtSecuritiesMember_A1543CB9D8FD43284A722F92B1EF161C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_USTreasurySecuritiesMember" xlink:label="loc_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_USTreasurySecuritiesMember_34295DB1AE91557797EA2F92B1EF42D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FixedIncomeSecuritiesMember" xlink:label="loc_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_FixedIncomeSecuritiesMember_751DAF83251D12534BFE2F92B1EF3E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_PartnershipInterestMember" xlink:label="loc_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_srt_PartnershipInterestMember_ED4A4CEE7DFF885CDAE62F92B1EF97A9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InsuranceContractsMember" xlink:label="loc_pfe_InsuranceContractsMember_D191D5DE795DA778471B2F92B1EF345C" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_pfe_InsuranceContractsMember_D191D5DE795DA778471B2F92B1EF345C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherCommingledFundsMember" xlink:label="loc_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_pfe_OtherCommingledFundsMember_F45537C1DD2F7CDAB01D2F92B1F00266" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherAggregatedInvestmentsMember" xlink:label="loc_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanAssetCategoriesDomain_41BE6D0B00615148BDE92F92B1EE6C4C" xlink:to="loc_us-gaap_OtherAggregatedInvestmentsMember_0B93FE5334628AAFD6EF2F92B1F087D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31DA11E542E3DB97FD162F92B1F02F8D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31DA11E542E3DB97FD162F92B1F02F8D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_31DA11E542E3DB97FD162F92B1F02F8D" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_4BBDF47A6F54A0974BDA2F92B1F1EA3F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_4BBDF47A6F54A0974BDA2F92B1F1EA3F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_0364B1A29B0034EB6B992F92B1F1902F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_0364B1A29B0034EB6B992F92B1F1902F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_02A58B266A2D909DD3042F92B1F19F5A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_9E572B29DE47296E7E942F92B1F097D0" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_02A58B266A2D909DD3042F92B1F19F5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6739E2E30C65E7B934612F92B1F154EC" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_685059D732E4012FD65B2F92B1EA87E6" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6739E2E30C65E7B934612F92B1F154EC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanFairValueOfPlanAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6739E2E30C65E7B934612F92B1F154EC" xlink:to="loc_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets_59C5ED6FB445D64EE6D42F92B1F1B42A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets" xlink:label="loc_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_6739E2E30C65E7B934612F92B1F154EC" xlink:to="loc_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets_5ABC72D621CE7758C5E32F92B1F12ED6" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock_4C692A038A471B10BB7A8020753B1642" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock_2C052AC408A977E77C3D8020753CFCED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAssumptionsUsedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock_B6A919A38233646AEC268020753C488F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock_844C24FF9A530C3DFE048020753CA851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock_AA923D677C9C056573968020753C1BBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock" xlink:label="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock_5D71E1C4C000E8A243748020753C3330" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock_B971DC93C66B93FDDE098020753C01E4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock_2A6E9910901425CCF9668020753C4789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_967AEDF9CB4F51EEF84E8020753D8643" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock_76123F8F4D567AE3BAF48020753DE583" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock_3960F80C3C4B5DE593CC8020753DA15B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock_ACBC8E0C802CDB0019C18020753DEA0F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_B48497555803E54B1B728020753B35F9" xlink:to="loc_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock_23D0BBB77BD772C6CC608020753D9EE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03FF97888F3A51FB526AD81117088D99" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable" xlink:label="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CompensationAndRetirementDisclosureAbstract_03FF97888F3A51FB526AD81117088D99" xlink:to="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_C160216CEE36A9F8F127D880F984C1F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_C160216CEE36A9F8F127D880F984C1F9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_C160216CEE36A9F8F127D880F984C1F9" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_926D0CF2FF0997C0B102D8822C9C06FD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A" xlink:to="loc_us-gaap_QualifiedPlanMember_926D0CF2FF0997C0B102D8822C9C06FD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NonqualifiedPlanMember" xlink:label="loc_us-gaap_NonqualifiedPlanMember_73098548B7C03E4FAA11D88256A016F8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_39F91F5FC8019C0331F6D880FBA4DC9A" xlink:to="loc_us-gaap_NonqualifiedPlanMember_73098548B7C03E4FAA11D88256A016F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_A37FCC1572CFFFA807D0D811170928C9" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_A37FCC1572CFFFA807D0D811170928C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_A37FCC1572CFFFA807D0D811170928C9" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_9FE1091B1AE573FB6142D88050EC8A37" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C" xlink:to="loc_us-gaap_DomesticPlanMember_9FE1091B1AE573FB6142D88050EC8A37" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_D9D9195575A55001C269D811170FED8A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_9FE1091B1AE573FB6142D88050EC8A37" xlink:to="loc_country_US_D9D9195575A55001C269D811170FED8A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignPlanMember" xlink:label="loc_us-gaap_ForeignPlanMember_0542B401EFE39BB711B3D811170F164D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_3FA6A41D0A16E308E004D811170E582C" xlink:to="loc_us-gaap_ForeignPlanMember_0542B401EFE39BB711B3D811170F164D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_B312E75109C0B0062DFAD811170F85FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_B312E75109C0B0062DFAD811170F85FC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_B312E75109C0B0062DFAD811170F85FC" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_D9D86EE337B149118853D8111710656A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_D9D86EE337B149118853D8111710656A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember" xlink:label="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_9FD4740A16736AC18CCFD81117102FF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:to="loc_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember_9FD4740A16736AC18CCFD81117102FF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember" xlink:label="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7975EDD62F3C98FC5DABD81117101323" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_2E4BC14B2B1BD2566EFAD811170F6B1A" xlink:to="loc_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember_7975EDD62F3C98FC5DABD81117101323" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanDisclosureLineItems" xlink:label="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_DB0BF135DF499241DDF8D811171098E9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable_4D650AEC6B5DE463DDB5D8111709E013" xlink:to="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_DB0BF135DF499241DDF8D811171098E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_DB0BF135DF499241DDF8D811171098E9" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate_F4D713F1E3E61FCFCBEFD8111711B035" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract_02FB2B99F380E57AFC93D8111710B9D1" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease_E5BF76A130484E78C1E3D81117111541" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract" xlink:label="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanDisclosureLineItems_DB0BF135DF499241DDF8D811171098E9" xlink:to="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate_CDFF6500934196AD1629D8111711EB32" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate_C3C58334DA680BBF836ED811171241D3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate" xlink:label="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate_722D9BE60B863E24D28DD8111712B651" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets_F1A2BB40041D18120FB7D8111712C741" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease" xlink:label="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract_E603B263F3CF560BEED2D81117116F6A" xlink:to="loc_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease_B2BE663A13FE80EF0F3FD811171220AB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipment" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A919E1D7B069138E707F80206AE4CDA6" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_A919E1D7B069138E707F80206AE4CDA6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_065297A6C102CD45F64380206AE4B187" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5D217E20E6AC31F5B07CCEAADBE99377" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5D217E20E6AC31F5B07CCEAADBE99377" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_99258B8E4C7B380DAD83CEAADBEBFD8B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:to="loc_srt_RangeAxis_99258B8E4C7B380DAD83CEAADBEBFD8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_99258B8E4C7B380DAD83CEAADBEBFD8B" xlink:to="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_FF76B6408BEBB8EBF846CEAADBEB1BF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231" xlink:to="loc_srt_MinimumMember_FF76B6408BEBB8EBF846CEAADBEB1BF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_1D86BE19E000470E371BCEAADBEB88AB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1C03D89C2D17202C3541CEAADBEBD231" xlink:to="loc_srt_MaximumMember_1D86BE19E000470E371BCEAADBEB88AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_E0D5543504D7BE0E9434CEAADBEC7CB8" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LandMember" xlink:label="loc_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_LandMember_C299E1C6426142299511CEAADBEC3F66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BuildingMember" xlink:label="loc_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_BuildingMember_11CD1AF3FE3EBFC94084CEAADBEC2DEB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MachineryAndEquipmentMember" xlink:label="loc_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_MachineryAndEquipmentMember_7FF2017FE9988C65108CCEAADBEC7417" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_99A68FAC7D28CF2C2C84CEAADBEDDA82" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_CA9EB7A8A9C2F923E0B7CEAADBEC55C0" xlink:to="loc_us-gaap_ConstructionInProgressMember_79DD3B8F9696857A99E8CEAADBED3F0D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1C34DC0C9E0191635112CEAADBE92BE9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_17183C8EEFACAB63FF8ACEAADBEDA9CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_AE82B3281E30FF4523B4CEAADBEDB542" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_051BFFB2557CC886D768CEAADBEEAC6F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_97A7658E4959F3F6561CCEAADBEDC15B" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_85E6B547DA2A28E8CFC9CEAADBEE24BC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/PropertyPlantAndEquipmentTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9E01FE21592D4714D9DE8020752FA64E" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_9E01FE21592D4714D9DE8020752FA64E" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_958BD1811C69984D039B8020752F7F67" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_AE30E7BD51456BBC0D75802074121D5A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_AE30E7BD51456BBC0D75802074121D5A" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_396F60A48A7E18FE0BB280207412D8F4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_C9B2E472156D4256A664DDDC82F64940" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44172A8C4454B85921F4DDDC82F65D1C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_C9B2E472156D4256A664DDDC82F64940" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44172A8C4454B85921F4DDDC82F65D1C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_66619B404AE11066CA25DDDC82F699A7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44172A8C4454B85921F4DDDC82F65D1C" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_66619B404AE11066CA25DDDC82F699A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_66619B404AE11066CA25DDDC82F699A7" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpenseMember" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_C83365F3E821B6EB4FD7DDDC82F7B9D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseMember_C83365F3E821B6EB4FD7DDDC82F7B9D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_5553585AC3C4674F0678DDDC82F7C762" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:to="loc_us-gaap_CostOfSalesMember_5553585AC3C4674F0678DDDC82F7C762" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_AC5337C32250CCF81A94DDDC82F7B1F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4079FD19ABFA5FB5E85ADDDC82F8FC04" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_A5C49A6D7074E179A5CBDDDC82F70BFA" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_4079FD19ABFA5FB5E85ADDDC82F8FC04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_44172A8C4454B85921F4DDDC82F65D1C" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringChargesAbstract" xlink:label="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SeveranceCosts1" xlink:label="loc_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="loc_us-gaap_SeveranceCosts1_1DC4116210DDE8F64BD0DDDC82F8C6BD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringAssetImpairmentCharges" xlink:label="loc_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="loc_pfe_RestructuringAssetImpairmentCharges_D3685C2EF7C232724680DDDC82F964DB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessExitCosts1" xlink:label="loc_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="loc_us-gaap_BusinessExitCosts1_6495D31BE5467A6C38A9DDDC82F9B6DD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringChargesAbstract_A153AA42C1DFAF2AA3E7DDDC82F89562" xlink:to="loc_us-gaap_RestructuringCharges_FF243F78AA87F82ED163DDDC82F90A9B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts" xlink:label="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts_327F9AC2D5B97EBE36C2DDDC82F9793A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationIntegrationRelatedCosts" xlink:label="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_BusinessCombinationIntegrationRelatedCosts_D4992F81389AAB0CEDE5DDDC82F983E3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCosts" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCosts_4DB97AED2FE1097B74EFDDDC82F914C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost" xlink:label="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost_73F0F752792198AEFC11DDDC82FABE05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveAcceleratedDepreciation" xlink:label="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_us-gaap_RestructuringReserveAcceleratedDepreciation_C7494415076891307B4FDDDC82FAD61D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ImplementationCostAbstract" xlink:label="loc_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ImplementationCosts" xlink:label="loc_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_ImplementationCostAbstract_8912251D5BFFE7DCF7DADDDC82FA9820" xlink:to="loc_pfe_ImplementationCosts_0C49A248B7F233ED0DD6DDDC82FAF640" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_EE9274EFB388E0FECA39DDDC82F8A42A" xlink:to="loc_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts_D5989A391C9539CBB813DDDC82FAF65F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3232F4922231B9427D4D3CA1B182CC53" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3232F4922231B9427D4D3CA1B182CC53" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeAxis" xlink:label="loc_us-gaap_RetirementPlanTypeAxis_320F14144DBBEE68BE9D3CA4DFE1605A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_RetirementPlanTypeAxis_320F14144DBBEE68BE9D3CA4DFE1605A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTypeDomain" xlink:label="loc_us-gaap_RetirementPlanTypeDomain_8C57217C17775E65523B3CA4DFE2B326" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeAxis_320F14144DBBEE68BE9D3CA4DFE1605A" xlink:to="loc_us-gaap_RetirementPlanTypeDomain_8C57217C17775E65523B3CA4DFE2B326" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PensionPlansDefinedBenefitMember" xlink:label="loc_us-gaap_PensionPlansDefinedBenefitMember_CC50CC3D2C374699A8EF3CA4E096BF5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTypeDomain_8C57217C17775E65523B3CA4DFE2B326" xlink:to="loc_us-gaap_PensionPlansDefinedBenefitMember_CC50CC3D2C374699A8EF3CA4E096BF5D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusAxis" xlink:label="loc_us-gaap_RetirementPlanTaxStatusAxis_9C8163EA5F6EA51DF54B3CA4DFAEF1BC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_RetirementPlanTaxStatusAxis_9C8163EA5F6EA51DF54B3CA4DFAEF1BC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanTaxStatusDomain" xlink:label="loc_us-gaap_RetirementPlanTaxStatusDomain_29C777AFD018982D7DCC3CA4DFAFC2BB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusAxis_9C8163EA5F6EA51DF54B3CA4DFAEF1BC" xlink:to="loc_us-gaap_RetirementPlanTaxStatusDomain_29C777AFD018982D7DCC3CA4DFAFC2BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_QualifiedPlanMember" xlink:label="loc_us-gaap_QualifiedPlanMember_DA70BC783111EAC8D2393CA4E0B2CE08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanTaxStatusDomain_29C777AFD018982D7DCC3CA4DFAFC2BB" xlink:to="loc_us-gaap_QualifiedPlanMember_DA70BC783111EAC8D2393CA4E0B2CE08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationAxis" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationAxis_5FED159EC9356FFA4D993CA4DF78C32D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationAxis_5FED159EC9356FFA4D993CA4DF78C32D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RetirementPlanSponsorLocationDomain" xlink:label="loc_us-gaap_RetirementPlanSponsorLocationDomain_AF696E704FEEAE51EB5C3CA4DF7C08F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationAxis_5FED159EC9356FFA4D993CA4DF78C32D" xlink:to="loc_us-gaap_RetirementPlanSponsorLocationDomain_AF696E704FEEAE51EB5C3CA4DF7C08F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DomesticPlanMember" xlink:label="loc_us-gaap_DomesticPlanMember_E46A01F27519F56261D53CBED6569940" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RetirementPlanSponsorLocationDomain_AF696E704FEEAE51EB5C3CA4DF7C08F5" xlink:to="loc_us-gaap_DomesticPlanMember_E46A01F27519F56261D53CBED6569940" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_0E1AAFC3AC19B27CFFBA3CA4E0CFAF1A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DomesticPlanMember_E46A01F27519F56261D53CBED6569940" xlink:to="loc_country_US_0E1AAFC3AC19B27CFFBA3CA4E0CFAF1A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_2FA0B4410219BA51E7D23CA1B1837612" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_2FA0B4410219BA51E7D23CA1B1837612" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_86220B416E49345693283CA1B1831547" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_2FA0B4410219BA51E7D23CA1B1837612" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_86220B416E49345693283CA1B1831547" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesAndAcquisitionRelatedCostsMember" xlink:label="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_86220B416E49345693283CA1B1831547" xlink:to="loc_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember_5FFA51D56452D42695CB3CA1B18359F7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_2AFE98599C3EC9EF3AA93CA1B184125D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_2AFE98599C3EC9EF3AA93CA1B184125D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_2AFE98599C3EC9EF3AA93CA1B184125D" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_46BD6D330AD72DAD86E63CA1B1849A2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D" xlink:to="loc_pfe_ArrayMember_46BD6D330AD72DAD86E63CA1B1849A2E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_1A0B8086E16DF536AD6A3CA4E07B5F90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_B17CABED78409C102B1A3CA1B184426D" xlink:to="loc_pfe_HospiraMember_1A0B8086E16DF536AD6A3CA4E07B5F90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_8C86C4B4A3248A5BBF803CA1B1843A64" xlink:to="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:to="loc_pfe_BiopharmaSegmentMember_A93317423E9B63EF6E6C3CA1B18546EB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_6A563B184A7163A083393CA1B18495FF" xlink:to="loc_pfe_UpjohnSegmentMember_ADBDE193225A3FE71E823CA1B185B018" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_B2A46C97A8CD5143CE603CA1B1851694" xlink:to="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:to="loc_us-gaap_OperatingSegmentsMember_EFB9EB69C64952140D953CA1B186EFF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_70FE89700ADE7E99B8953CA1B1855E89" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_D369ED75F7F0A958A1653CA1B186E39C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_8CC49BA8D8863A3D57D33CA1B182A1A0" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:to="loc_us-gaap_RestructuringCharges_554C6B54961890B7E22F3CA1B186E52B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized" xlink:label="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:to="loc_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized_23301F653EBA97E74AC23CA1B186AE33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1" xlink:label="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F762597391661404E433CA1B186D04D" xlink:to="loc_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1_EDD6C83EF8FA913468A73CA2BD2036AC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5367DD5DEC69DCD51021DDDC830091D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_5367DD5DEC69DCD51021DDDC830091D4" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_973CD159D7B66C5644C1DDDC83008634" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_973CD159D7B66C5644C1DDDC83008634" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_973CD159D7B66C5644C1DDDC83008634" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ArrayMember" xlink:label="loc_pfe_ArrayMember_D95CF18F6309560F6303DF3C38B80CB4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2" xlink:to="loc_pfe_ArrayMember_D95CF18F6309560F6303DF3C38B80CB4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospiraMember" xlink:label="loc_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5FD2D32157E5F645B81CDDDC830057D2" xlink:to="loc_pfe_HospiraMember_B9B62C5F18EBB4B4E003DDDC8301BE6A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanAxis" xlink:label="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:to="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringPlanDomain" xlink:label="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanAxis_98C08ED1DD590AB35188DDDC83016C90" xlink:to="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember" xlink:label="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:to="loc_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember_D95561B546903B9E0A35DDDC83019C15" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FocusedCompanyPlanMember" xlink:label="loc_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringPlanDomain_C9A0EDD424295E6ACE4FDDDC83010FC2" xlink:to="loc_pfe_FocusedCompanyPlanMember_700503A00F600719E0A7DF3783670996" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_244AA80893409B990393DDDC8302FED3" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ManufacturingOptimizationMember" xlink:label="loc_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:to="loc_pfe_ManufacturingOptimizationMember_1F35AC9D3AE1F60C0C2ADF3E6CC3D74F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherActivitiesMember" xlink:label="loc_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:to="loc_pfe_OtherActivitiesMember_C8F9DE13AD437AAE62AFDDDC8303C09D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessIntegrationCostsMember" xlink:label="loc_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_79A504109DAB35310474DDDC8302598F" xlink:to="loc_pfe_BusinessIntegrationCostsMember_FB690C35B98BEEFDDD8ADDDC830377C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_6D7A9A16042EAC1F96A0DDDC8300E755" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostCostIncurredToDate1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1_ABC5B3125AF4443AE36FDDDC8304C3B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostExpectedCost1" xlink:label="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_us-gaap_RestructuringAndRelatedCostExpectedCost1_88F2334C14D637C66C8BDDDC83046D82" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringandRelatedCostNoncashChargesPercentage" xlink:label="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_pfe_RestructuringandRelatedCostNoncashChargesPercentage_3BE49A2AF823EA2FAC71DDDC8304B895" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedCostIncurredCost" xlink:label="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_6F16C6BB01D654035B51DDDC83039089" xlink:to="loc_us-gaap_RestructuringAndRelatedCostIncurredCost_7189C838E7ACEF524A04DDDC83030049" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3D075958CF1C876F171B1A6ED04447FC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_970D637F89136920B3511A6ED044E462" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_3D075958CF1C876F171B1A6ED04447FC" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_970D637F89136920B3511A6ED044E462" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveAxis" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_DADC1D3A61AA448BEB621A6ED0448CE7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_970D637F89136920B3511A6ED044E462" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_DADC1D3A61AA448BEB621A6ED0448CE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfRestructuringDomain" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_DADC1D3A61AA448BEB621A6ED0448CE7" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeSeveranceMember" xlink:label="loc_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:to="loc_us-gaap_EmployeeSeveranceMember_CCA8C4CEB908CE2334611A6ED045CAC4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetImpairmentsMember" xlink:label="loc_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:to="loc_pfe_AssetImpairmentsMember_D33D5B2464FFC97E55EF1A6ED0450B2B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherRestructuringMember" xlink:label="loc_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_DD9AE2E29DCBB25187451A6ED045F119" xlink:to="loc_us-gaap_OtherRestructuringMember_F36A51B48E0CED257FC21A6ED045F4AC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_9983BD033691F1D976761A6ED04525D6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_970D637F89136920B3511A6ED044E462" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_9983BD033691F1D976761A6ED04525D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserveRollForward" xlink:label="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_9983BD033691F1D976761A6ED04525D6" xlink:to="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:to="loc_us-gaap_RestructuringReserve_70B676CA49EC6C8CFE621A6ED0463E23" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCharges" xlink:label="loc_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:to="loc_us-gaap_RestructuringCharges_6580BEB7FD962FD0F5A21A6ED046A18F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment" xlink:label="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:to="loc_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment_4184584BCD39075975841A6ED046C760" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_B009361E530AA791AC0E1A6ED04663A4" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringReserveRollForward_374F597151CC066A26E31A6ED0461EF6" xlink:to="loc_us-gaap_RestructuringReserve_B009361E530AA791AC0E1A6ED04663A4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8A65B38961E9E8A72932802078DBA0EA" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_8A65B38961E9E8A72932802078DBA0EA" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_E83CC4612BF6A791D617802078DD2DD3" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherCurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:to="loc_us-gaap_OtherCurrentLiabilitiesMember_3A43245765D6B245621D802078DF764B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherNoncurrentLiabilitiesMember" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_6169367046BE830B8548802078DEEDCB" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesMember_84BE5128E91668BD97EE802078DFBBFA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringCostAndReserveLineItems" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_7799B4A7A6BA4F5E2F49802078DC67C6" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringReserve" xlink:label="loc_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_49592CAEE648C24115C1802078E02CE8" xlink:to="loc_us-gaap_RestructuringReserve_07182B5FFACCEF13862A802078E086B9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_D460B64A427F5B3D1788802074306076" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_D460B64A427F5B3D1788802074306076" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock_61DEAC97E28C5627F18D802074308D48" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock" xlink:label="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_D460B64A427F5B3D1788802074306076" xlink:to="loc_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock_DA5E0575C187259A8DFE802074308783" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_B06ACF548F313DADC72280207345B720" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingDisclosureTextBlock" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_B06ACF548F313DADC72280207345B720" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_679D99501F6DE987680A802073460C31" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_0E828AB9552DC300723402E421E2FE15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_0E828AB9552DC300723402E421E2FE15" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherSegmentReconcilingItemsAxis" xlink:label="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:to="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherSegmentReconcilingItemsDomain" xlink:label="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsAxis_5BECAA9ED5748D11E0AC02E421E20C84" xlink:to="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PurchaseAccountingAdjustmentsMember" xlink:label="loc_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:to="loc_pfe_PurchaseAccountingAdjustmentsMember_08AAD6E7D26D3376092902E421E3D129" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessCombinationsAcquisitionRelatedCostsMember" xlink:label="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:to="loc_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_9155D029DCE794C8362402E421E42BEE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CertainSignificantItemsMember" xlink:label="loc_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_OtherSegmentReconcilingItemsDomain_1E69BC3F15F2B93F143D02E421E3FC16" xlink:to="loc_pfe_CertainSignificantItemsMember_5C0BDDFF8FB859E4DACF02E421E494BF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_CC62D3ACB2644A9D4E4C02E421E4580C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_CC62D3ACB2644A9D4E4C02E421E4580C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_CC62D3ACB2644A9D4E4C02E421E4580C" xlink:to="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_32961C7EB6BE95B457D402E421E51F5D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288" xlink:to="loc_pfe_BiopharmaSegmentMember_32961C7EB6BE95B457D402E421E51F5D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_1FCDC8FC40B3D39DCBD902E421E5F4C4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_53140389A7B17B96CA0102E421E44288" xlink:to="loc_pfe_UpjohnSegmentMember_1FCDC8FC40B3D39DCBD902E421E5F4C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_451299C64EBAF6F73AF302E421E54544" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:to="loc_srt_ConsolidationItemsAxis_451299C64EBAF6F73AF302E421E54544" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_451299C64EBAF6F73AF302E421E54544" xlink:to="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_D2DE3EBC788B966A162202E421E63AC7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:to="loc_us-gaap_OperatingSegmentsMember_D2DE3EBC788B966A162202E421E63AC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_ADBA4194EAD5D9C28BC502E421E6CFBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_ADBA4194EAD5D9C28BC502E421E6CFBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CorporateNonSegmentMember" xlink:label="loc_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_5AA833357E371928DD6602E421E6FB28" xlink:to="loc_us-gaap_CorporateNonSegmentMember_C855444FA6C5D3FCFE9202E421E69409" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_A7B2C3E848D5E916C01702E421E2BEB6" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2E2E0AEB8D7488BBD32402E421E7091B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_2E2E0AEB8D7488BBD32402E421E7091B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_94B766694F8D7D18062102E421E7C3E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="loc_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_9CDEB1B0734D74ECE54302E421E7670E" xlink:to="loc_us-gaap_DepreciationDepletionAndAmortization_51D7D7DBC7A12E4CE68E02E421E75148" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_7D88A9B406D066355F43DDCF3D995F9C" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7D88A9B406D066355F43DDCF3D995F9C" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipAxis" xlink:label="loc_srt_OwnershipAxis_5D8D2D4BE3C6EA1D34ABDDD5A3BF2EA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_srt_OwnershipAxis_5D8D2D4BE3C6EA1D34ABDDD5A3BF2EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_OwnershipDomain" xlink:label="loc_srt_OwnershipDomain_BA696117B2C615EC5A37DDD5A6B0FBA7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipAxis_5D8D2D4BE3C6EA1D34ABDDD5A3BF2EA7" xlink:to="loc_srt_OwnershipDomain_BA696117B2C615EC5A37DDD5A6B0FBA7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LaboratorioTeutoBrasileroMember" xlink:label="loc_pfe_LaboratorioTeutoBrasileroMember_BDA79FA5638738FA67D8DDD5A415FD7F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_OwnershipDomain_BA696117B2C615EC5A37DDD5A6B0FBA7" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_BDA79FA5638738FA67D8DDD5A415FD7F" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_dei_LegalEntityAxis_9FD346BDF968A68CE42ADDD5A386DFDF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_dei_LegalEntityAxis_9FD346BDF968A68CE42ADDD5A386DFDF" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd#dei_EntityDomain" xlink:label="loc_dei_EntityDomain_AEFFFCAA9028168EEF73DDD5A68DDC25" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_9FD346BDF968A68CE42ADDD5A386DFDF" xlink:to="loc_dei_EntityDomain_AEFFFCAA9028168EEF73DDD5A68DDC25" xlink:type="arc" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_AEFFFCAA9028168EEF73DDD5A68DDC25" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_BDA79FA5638738FA67D8DDD5A415FD7F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionAxis" xlink:label="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetAcquisitionDomain" xlink:label="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AssetAcquisitionAxis_13F2731FB3C45ED6CDCBDDD04419D016" xlink:to="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TherachonAssetAcquisitionMember" xlink:label="loc_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_AssetAcquisitionDomain_F9863AFF7EA00C659981DDD0458D1C4D" xlink:to="loc_pfe_TherachonAssetAcquisitionMember_24AAA495CD4D7DA97DA1DDD0477B878C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_878103D37A0DF278AB8DDDCF3D9A419C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_878103D37A0DF278AB8DDDCF3D9A419C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_878103D37A0DF278AB8DDDCF3D9A419C" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F3881EC0079081A4B699DDCF3D9AF7CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_F3881EC0079081A4B699DDCF3D9AF7CC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherIncomeExpenseMember" xlink:label="loc_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:to="loc_pfe_OtherIncomeExpenseMember_A59B6A5A5CA036AEF899DDDACB222BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_468872143EA9370A5968DDEECA807EAE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CostOfSalesMember" xlink:label="loc_us-gaap_CostOfSalesMember_BD3FDA79033EED2AC2E0DDF5B0DD3253" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_AE6B584118BF8F122CCFDDCF3D9ADB21" xlink:to="loc_us-gaap_CostOfSalesMember_BD3FDA79033EED2AC2E0DDF5B0DD3253" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaap_TypeOfArrangementAxis_EC52F5A1A67B1C438CD0DDCF3D9BFBDA" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_TypeOfArrangementAxis_EC52F5A1A67B1C438CD0DDCF3D9BFBDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97DBFB427805DACD2D21DDCF3D9BC30F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_EC52F5A1A67B1C438CD0DDCF3D9BFBDA" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97DBFB427805DACD2D21DDCF3D9BC30F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LicensingAgreementsMember" xlink:label="loc_us-gaap_LicensingAgreementsMember_546F428202624E704F6FDDCF3D9BAE90" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_97DBFB427805DACD2D21DDCF3D9BC30F" xlink:to="loc_us-gaap_LicensingAgreementsMember_546F428202624E704F6FDDCF3D9BAE90" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="loc_srt_CounterpartyNameAxis_CD20C3BF960482ECF130DDCF3D9C5C5C" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_srt_CounterpartyNameAxis_CD20C3BF960482ECF130DDCF3D9C5C5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_CD20C3BF960482ECF130DDCF3D9C5C5C" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AkceaAndIonisMember" xlink:label="loc_pfe_AkceaAndIonisMember_67E99140391B6076D79FDDCF3D9D6526" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:to="loc_pfe_AkceaAndIonisMember_67E99140391B6076D79FDDCF3D9D6526" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NovaQuestCoInvestmentFundVL.P.Member" xlink:label="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_CAB0887224253A0DCD82DDD0486767C8" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:to="loc_pfe_NovaQuestCoInvestmentFundVL.P.Member_CAB0887224253A0DCD82DDD0486767C8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BainCapitalMember" xlink:label="loc_pfe_BainCapitalMember_B0B590395A458731D4E3DDCF3D9D4E27" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_69442D08700A97360102DDCF3D9D5226" xlink:to="loc_pfe_BainCapitalMember_B0B590395A458731D4E3DDCF3D9D4E27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D48E70773869947D6C6ADDCF3D9D3404" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D48E70773869947D6C6ADDCF3D9D3404" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_EquityMethodInvesteeNameDomain" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_D48E70773869947D6C6ADDCF3D9D3404" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViivHealthcareLimitedMember" xlink:label="loc_pfe_ViivHealthcareLimitedMember_BE8DC4CF85E6AEC8E6A6DDCF3D9E4942" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_ViivHealthcareLimitedMember_BE8DC4CF85E6AEC8E6A6DDCF3D9E4942" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GSKConsumerHealthcareMember" xlink:label="loc_pfe_GSKConsumerHealthcareMember_5C89D6599452BA2994FADDD0463A5084" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_GSKConsumerHealthcareMember_5C89D6599452BA2994FADDD0463A5084" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CerevelMember" xlink:label="loc_pfe_CerevelMember_F61E0370F6FFA912347DDDCF3D9EE22D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_CerevelMember_F61E0370F6FFA912347DDDCF3D9EE22D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllogeneMember" xlink:label="loc_pfe_AllogeneMember_658B26C51A3519BE3568DDCF3D9E254C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_AllogeneMember_658B26C51A3519BE3568DDCF3D9E254C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HisunPfizerPharmaceuticalsCoLtdMember" xlink:label="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_ABEE1367CDBD8924B8E0DDD5A3F3D7B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_HisunPfizerPharmaceuticalsCoLtdMember_ABEE1367CDBD8924B8E0DDD5A3F3D7B7" xlink:type="arc" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_F9304D8359324E586EABDDCF3D9D965E" xlink:to="loc_pfe_LaboratorioTeutoBrasileroMember_BDA79FA5638738FA67D8DDD5A415FD7F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_1E972D5C445161B6CA33DDCF3D9F0282" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_1E972D5C445161B6CA33DDCF3D9F0282" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_C17796D1E28FD108A47ADDCF3D9F5FDB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_1E972D5C445161B6CA33DDCF3D9F0282" xlink:to="loc_us-gaap_SegmentDomain_C17796D1E28FD108A47ADDCF3D9F5FDB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_DD073C9F44E824B5E468DDCF3D9FF53C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_C17796D1E28FD108A47ADDCF3D9F5FDB" xlink:to="loc_pfe_BiopharmaSegmentMember_DD073C9F44E824B5E468DDCF3D9FF53C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_65DDB139139EF6703E96DDCF3DA0472C" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_65DDB139139EF6703E96DDCF3DA0472C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain" xlink:label="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BEA63884DE1E94DF996ADDCF3DA1FC63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_65DDB139139EF6703E96DDCF3DA0472C" xlink:to="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BEA63884DE1E94DF996ADDCF3DA1FC63" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISMember" xlink:label="loc_pfe_HISMember_59893F0C894E6E7B879ADDCF3DA1035A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain_BEA63884DE1E94DF996ADDCF3DA1FC63" xlink:to="loc_pfe_HISMember_59893F0C894E6E7B879ADDCF3DA1035A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsAxis" xlink:label="loc_srt_ConsolidationItemsAxis_3A747726E890E597FCCDDDCF3DA22111" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_srt_ConsolidationItemsAxis_3A747726E890E597FCCDDDCF3DA22111" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ConsolidationItemsDomain" xlink:label="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsAxis_3A747726E890E597FCCDDDCF3DA22111" xlink:to="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OperatingSegmentsMember" xlink:label="loc_us-gaap_OperatingSegmentsMember_B4263357BDDC1C812FF7DDCF3DA38ECB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2" xlink:to="loc_us-gaap_OperatingSegmentsMember_B4263357BDDC1C812FF7DDCF3DA38ECB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MaterialReconcilingItemsMember" xlink:label="loc_us-gaap_MaterialReconcilingItemsMember_4578E1CC5FE22D10C830DDCF3DA3DC40" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ConsolidationItemsDomain_653EC567ADAC401212E4DDCF3DA217E2" xlink:to="loc_us-gaap_MaterialReconcilingItemsMember_4578E1CC5FE22D10C830DDCF3DA3DC40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0524B45FA4F37C0DFE5BDDCF3D99BE9B" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_InvestmentIncomeDividend" xlink:label="loc_us-gaap_InvestmentIncomeDividend_5CBE230D96091A20DF09DDCF3DA3329C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_InvestmentIncomeDividend_5CBE230D96091A20DF09DDCF3DA3329C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RestructuringChargesandImplementationCosts" xlink:label="loc_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_RestructuringChargesandImplementationCosts_151D449BB60A0CE7B1F9DDCF3DA4148F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossRelatedToLitigationSettlement" xlink:label="loc_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_GainLossRelatedToLitigationSettlement_6BC8FA3AFA7E9CCD132FDDCF3DA40079" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AssetImpairmentChargesAndOtherCharges" xlink:label="loc_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_AssetImpairmentChargesAndOtherCharges_364717C0F6DF944A419CDDCF3DA59BAB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BusinessAlignmentCosts" xlink:label="loc_pfe_BusinessAlignmentCosts_B8ED089D597158E07A1DDDD03F8AB5F4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_BusinessAlignmentCosts_B8ED089D597158E07A1DDDD03F8AB5F4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquitySecuritiesFvNiGainLoss" xlink:label="loc_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_EquitySecuritiesFvNiGainLoss_49000726EB331C553B01DDCF3DA5D36B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeconsolidationGainOrLossAmount" xlink:label="loc_us-gaap_DeconsolidationGainOrLossAmount_19CC7E07763A8FF128CCDDD040139F53" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_DeconsolidationGainOrLossAmount_19CC7E07763A8FF128CCDDD040139F53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_FD2179CA858CC583169CDDCF3DA52D68" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_FD2179CA858CC583169CDDCF3DA52D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherOperatingIncomeExpenseNet" xlink:label="loc_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_OtherOperatingIncomeExpenseNet_8B46CE5D35DB94F33DCFDDCF3DA5564A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForLicensingArrangement" xlink:label="loc_pfe_PaymentForLicensingArrangement_A0CCDD14B99133D95532DDCF3DA67B55" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_PaymentForLicensingArrangement_A0CCDD14B99133D95532DDCF3DA67B55" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost_9F8A8F9D2A716E7F3807DDD0408D9219" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale" xlink:label="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_02E4A9E624B22F740ABEDDD040BCACB7" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale_02E4A9E624B22F740ABEDDD040BCACB7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeconsolidationExternalIncrementalCostsAmount" xlink:label="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_DeconsolidationExternalIncrementalCostsAmount_A5C0515FCAB4C034E2CEDDD0414428D2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus" xlink:label="loc_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus_BBC143A9C739A5B5D50BDDCF3DA56502" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GainLossFromContributionAgreement" xlink:label="loc_pfe_GainLossFromContributionAgreement_92C879F7F29853FD4EC2DDCF3DA66FA4" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_GainLossFromContributionAgreement_92C879F7F29853FD4EC2DDCF3DA66FA4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LossContingencyLossInPeriod" xlink:label="loc_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_LossContingencyLossInPeriod_0CAE12F8B1E90230C7B2DDCF3DA62B0F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AlignmentCosts" xlink:label="loc_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_AlignmentCosts_D5D89FFD03F3AE93BB02DDCF3DA68CF4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CharitableContributionExpense" xlink:label="loc_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_CharitableContributionExpense_7D8E8684BF9CFC57C3CBDDED94DF7707" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InventoryWriteDownAndOverheadCosts" xlink:label="loc_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_pfe_InventoryWriteDownAndOverheadCosts_FAE452E98FF41408C8FADDF5209AF400" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_9E7004C447D6FCB9A55BDDD5A2528EB5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8C750E6850E6E77A22BEDDD5A2991EF8" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_8C750E6850E6E77A22BEDDD5A2991EF8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal" xlink:label="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal_3606C34297AE9C946C63DDCF3DA4741E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal" xlink:label="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_229D192CA409075D7215DDD5A2E467BD" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal_229D192CA409075D7215DDD5A2E467BD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_MinorityInterestOwnershipPercentageByParent" xlink:label="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_DEACBFB9D812B95AF6ECDDD5A32A9B91" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_DC37A25F8E56C2342D19DDCF3DA30726" xlink:to="loc_us-gaap_MinorityInterestOwnershipPercentageByParent_DEACBFB9D812B95AF6ECDDD5A32A9B91" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_4B69374B0B0CABD79A8480206B5A592D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F8C877CB27EB01D9749C80206B5A5BC2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_4B69374B0B0CABD79A8480206B5A592D" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F8C877CB27EB01D9749C80206B5A5BC2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_CCC060C760BBBE09CA6A80206B5AC0F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F8C877CB27EB01D9749C80206B5A5BC2" xlink:to="loc_srt_StatementGeographicalAxis_CCC060C760BBBE09CA6A80206B5AC0F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_CCC060C760BBBE09CA6A80206B5AC0F5" xlink:to="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_EB4F8B4EFC829950E0FB80206B5B5CB0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:to="loc_country_US_EB4F8B4EFC829950E0FB80206B5B5CB0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_3302182D54848F56015080206B5BF610" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:to="loc_pfe_DevelopedEuropeMember_3302182D54848F56015080206B5BF610" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:to="loc_pfe_DevelopedRestOfWorldMember_FB896A77CD8E2469E16280206B5BD39F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_A3BD8AE51D9EFF456B4980206B5BD71C" xlink:to="loc_pfe_EmergingMarketsMember_116CFF23B3ED9AC1A13E80206B5B040C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_F8B261A4CC8D7D0FC14280206B5C70B7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_F8C877CB27EB01D9749C80206B5A5BC2" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_F8B261A4CC8D7D0FC14280206B5C70B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_F8B261A4CC8D7D0FC14280206B5C70B7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_235E40227D9897BCDFEE80206B5CA347" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_B0503C2EEC9394EEF73C732029BBEC92" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_B0503C2EEC9394EEF73C732029BBEC92" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_F00C48B6950014BB9026732029BCACE0" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_GeographicConcentrationRiskMember" xlink:label="loc_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:to="loc_us-gaap_GeographicConcentrationRiskMember_1B541E9C3AB2369F9F29732029BCA7E9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0ED0DE53B98B3E18AF7C732029BC6DCB" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_D5731DBA798F55E3F0B9732029BC277B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_41BEFD16B64E5D43D227732029BD1BD4" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerMember" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_50447DE5C4096E74CF61732029BD756D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountsReceivableMember" xlink:label="loc_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_529CEE750ECF5EBECC3F732029BD0A05" xlink:to="loc_us-gaap_AccountsReceivableMember_E538FADFE8735C028978732029BDB851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_86FF813DC1A145071CDC732029BEED69" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_srt_StatementGeographicalAxis_86FF813DC1A145071CDC732029BEED69" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_86FF813DC1A145071CDC732029BEED69" xlink:to="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NonUnitedStatesMember" xlink:label="loc_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:to="loc_pfe_NonUnitedStatesMember_FD44016B7F9676663C9F732029BEE276" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_3B9A02BEAB50AC0092E3732029BE218E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:to="loc_country_US_3B9A02BEAB50AC0092E3732029BE218E" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_JP" xlink:label="loc_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:to="loc_country_JP_96FF3252E870FDBD95F7732029BEB7A0" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_CN" xlink:label="loc_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_555187B2621576CEF0D0732029BE9E51" xlink:to="loc_country_CN_F42968A5A5C3DE529AE4732029BF5A86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MajorCustomersAxis" xlink:label="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_NameOfMajorCustomerDomain" xlink:label="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_34387EA76D03492E4242732029BFF916" xlink:to="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_McKessonInc.Member" xlink:label="loc_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="loc_pfe_McKessonInc.Member_985CCB31B7935FB80C3773229CB04064" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AmerisourceBergenCorporationMember" xlink:label="loc_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="loc_pfe_AmerisourceBergenCorporationMember_DFB58FEF2735DB72178A7323707E4474" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CardinalHealthInc.Member" xlink:label="loc_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="loc_pfe_CardinalHealthInc.Member_89273DAC05143E530D79732403D71477" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ThreeLargestUSWholesaleCustomersMember" xlink:label="loc_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_64B7373C0DAE8F27C3E5732029BFD7DC" xlink:to="loc_pfe_ThreeLargestUSWholesaleCustomersMember_E6B0B0448F182C5A9D81732029C05486" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingInformationLineItems" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_0114A0BAE7154600F044732029BB03CC" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaap_NumberOfOperatingSegments_7204487D45CF02A03760732029C0B98D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_us-gaap_NumberOfOperatingSegments_7204487D45CF02A03760732029C0B98D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_us-gaap_Assets_F7B52A038BE84BB64AC1732029C00594" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries" xlink:label="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries_11DCCAE34961B784E66C732029C0EEE0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_F25AC780496567289DA4732029C05A14" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_29BC2871D118C55E1E02732029C19196" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_5A6415A3026B46D8D3958020731AF066" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6677E1BE6F8E4C0515098020731AAF8E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_5A6415A3026B46D8D3958020731AF066" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6677E1BE6F8E4C0515098020731AAF8E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_F20A51216F438C57842C8020731BE90B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6677E1BE6F8E4C0515098020731AAF8E" xlink:to="loc_srt_StatementGeographicalAxis_F20A51216F438C57842C8020731BE90B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_F20A51216F438C57842C8020731BE90B" xlink:to="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_US" xlink:label="loc_country_US_096CCAF2EEB244611B9E8020731D8704" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:to="loc_country_US_096CCAF2EEB244611B9E8020731D8704" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_48E2056BF52B064702888020731EB5F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:to="loc_pfe_DevelopedEuropeMember_48E2056BF52B064702888020731EB5F6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedRestOfWorldMember" xlink:label="loc_pfe_DevelopedRestOfWorldMember_95EDC59415E278D517EC8020731E3586" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:to="loc_pfe_DevelopedRestOfWorldMember_95EDC59415E278D517EC8020731E3586" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EmergingMarketsMember" xlink:label="loc_pfe_EmergingMarketsMember_163BFA103A8812CCA9DE8020731E2E19" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_B4D1B713F990F295075E8020731B82C1" xlink:to="loc_pfe_EmergingMarketsMember_163BFA103A8812CCA9DE8020731E2E19" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7E3C96C00B05CB1E707E8020731F4D13" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_6677E1BE6F8E4C0515098020731AAF8E" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7E3C96C00B05CB1E707E8020731F4D13" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16D1587CAC69B627957F8020731FE368" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_7E3C96C00B05CB1E707E8020731F4D13" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_16D1587CAC69B627957F8020731FE368" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_56F31490464087F5544C80206B675A17" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_56F31490464087F5544C80206B675A17" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_CurrencyAxis" xlink:label="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:to="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_AllCurrenciesDomain" xlink:label="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CurrencyAxis_89F493F9C5F80FC12DFB80206B68B287" xlink:to="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:type="arc" />
    <link:loc xlink:href="https://xbrl.sec.gov/currency/2019/currency-2019-01-31.xsd#currency_EUR" xlink:label="loc_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_currency_AllCurrenciesDomain_50BCF0BBBFCD968C766880206B68940A" xlink:to="loc_currency_EUR_FCBA009E14AF0830250D80206B6F6C5A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:to="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_B9AAD36FB97473429C8680206B707753" xlink:to="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DevelopedEuropeMember" xlink:label="loc_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_80B92ACD4736133126E680206B71791E" xlink:to="loc_pfe_DevelopedEuropeMember_54ADB9BDC610D3BC22E880206B71F20B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_1DE8F302FA4BE57C08BD80206B677785" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_8AD7956968292E51CEAC80206B72AEAC" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_F0B1EBE518FE1CAAE74F80206B73370F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_947585E2C4E4ECD626E2689872867031" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_947585E2C4E4ECD626E2689872867031" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReportingUnitAxis" xlink:label="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:to="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReportingUnitDomain" xlink:label="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitAxis_6F9B83E25E1CFFFA2A2468987287FF14" xlink:to="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InternalMedicineMember" xlink:label="loc_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_InternalMedicineMember_E5A6CA9F497A4439CB94689872874C40" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OncologyMember" xlink:label="loc_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_OncologyMember_8F20CE3E133F5B14617168987287835B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HospitalMember" xlink:label="loc_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_HospitalMember_857A01384E293DD117D2689872885130" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VaccinesMember" xlink:label="loc_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_VaccinesMember_DF485C04E8B22FF3400D68987288F6E1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflammationandImmunologyMember" xlink:label="loc_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_InflammationandImmunologyMember_112E39E4C117931CCF4668987288B79C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RareDiseaseMember" xlink:label="loc_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_RareDiseaseMember_DD69A3EEFE4419BA546E68987288F5C9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnReportingUnitMember" xlink:label="loc_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_UpjohnReportingUnitMember_94AC3A27F2E8E747A62068987288575E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareReportingUnitMember" xlink:label="loc_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReportingUnitDomain_87A002703E57057733AE68987287437F" xlink:to="loc_pfe_ConsumerHealthcareReportingUnitMember_CE456BA7E1E2725A008C6898728981D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StatementBusinessSegmentsAxis" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_777F0D6347E158882BD768987289BA17" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_777F0D6347E158882BD768987289BA17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentDomain" xlink:label="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_777F0D6347E158882BD768987289BA17" xlink:to="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaSegmentMember" xlink:label="loc_pfe_BiopharmaSegmentMember_B2B6B042D38B1213F49568987289BDD7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:to="loc_pfe_BiopharmaSegmentMember_B2B6B042D38B1213F49568987289BDD7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UpjohnSegmentMember" xlink:label="loc_pfe_UpjohnSegmentMember_A12ACAC8664DDAC3A1F168987289F2D3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:to="loc_pfe_UpjohnSegmentMember_A12ACAC8664DDAC3A1F168987289F2D3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ConsumerHealthcareMember" xlink:label="loc_pfe_ConsumerHealthcareMember_DD38FC58E249607DA41E6898728AA749" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:to="loc_pfe_ConsumerHealthcareMember_DD38FC58E249607DA41E6898728AA749" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember" xlink:label="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_8AEF4D422DC837081EFA689872891F4C" xlink:to="loc_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember_A6CCCB1EB47457319EFC6898728A7795" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srt_ProductOrServiceAxis_0D0CEFF68AF73F8C08356898728AC6CC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:to="loc_srt_ProductOrServiceAxis_0D0CEFF68AF73F8C08356898728AC6CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_0D0CEFF68AF73F8C08356898728AC6CC" xlink:to="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EliquisMember" xlink:label="loc_pfe_EliquisMember_AE2BD04475AF07EE44C76898728A2272" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EliquisMember_AE2BD04475AF07EE44C76898728A2272" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ChantixChampixMember" xlink:label="loc_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ChantixChampixMember_F8ED58A34464D92E14466898728BAEF3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PremarinFamilyMember" xlink:label="loc_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_PremarinFamilyMember_6FD4FFF0378949BC682D6898728B4AF0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BMP2Member" xlink:label="loc_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_BMP2Member_CA167E2CB6BC20BEBB6D6898728B1CE5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ToviazMember" xlink:label="loc_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ToviazMember_6CD7F2564774348975BC6898728B4C28" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherInternalMedicineMember" xlink:label="loc_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_AllOtherInternalMedicineMember_D335F5E0092FBECFD1D46898728B3D91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IbranceMember" xlink:label="loc_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_IbranceMember_1F4C15D420E244914B016898728C5617" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SutentMember" xlink:label="loc_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_SutentMember_8C471840D4D0C7F5BA9B6898728C54AE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XtandiAllianceRevenuesMember" xlink:label="loc_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XtandiAllianceRevenuesMember_16F6D32EA2FCFDBDEF9A6898728CD52F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XalkoriMember" xlink:label="loc_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XalkoriMember_9ABC91EDD018CA1CD6306898728C6BF6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InlytaMember" xlink:label="loc_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_InlytaMember_B5B0F0B972C81989F6E66898728CEA80" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BosulifMember" xlink:label="loc_pfe_BosulifMember_7D58974A16A9D6633A566898728C4497" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_BosulifMember_7D58974A16A9D6633A566898728C4497" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RetacritMember" xlink:label="loc_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_RetacritMember_B2F99B4A4ADF10D088946898728C72F5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MektoviMember" xlink:label="loc_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_MektoviMember_0D5A4F96D21A3D9E46866898728DF956" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BraftoviMember" xlink:label="loc_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_BraftoviMember_33A5E879E8E2CDAC03286898728DFC9C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherOncologyProductsMember" xlink:label="loc_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_OtherOncologyProductsMember_ACD78168C6FF1F7862D06898728D5897" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SulperazonMember" xlink:label="loc_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_SulperazonMember_A6E7BEE00BD122C0509C6898728DBE7F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_MedrolMember" xlink:label="loc_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_MedrolMember_BE0BF2F58EADFD763BBD6898728D5127" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VfendMember" xlink:label="loc_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_VfendMember_4614260FB71C27FAC4A56898728EE1E6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZithromaxZmaxMember" xlink:label="loc_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ZithromaxZmaxMember_6DA239C71C37BDE1C0246898728EF05F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EpiPenMember" xlink:label="loc_pfe_EpiPenMember_1A5B2BA2D4FFC765CBD36898728E7DBA" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EpiPenMember_1A5B2BA2D4FFC765CBD36898728E7DBA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FragminMember" xlink:label="loc_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_FragminMember_E7A703FD52F56117392F6898728E69F3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZyvoxMember" xlink:label="loc_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ZyvoxMember_242F1A21D372FD17D0906898728EC14D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZosynTazocinMember" xlink:label="loc_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ZosynTazocinMember_C21239A6DA988CF64EF06898728EE1CC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TygacilMember" xlink:label="loc_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TygacilMember_041FD2EC4B6AD00F80E06898728F0205" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DiflucanMember" xlink:label="loc_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:type="locator" />
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_DiflucanMember_3F4F45D0510E4ED9B3B06898728FB627" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PanzygaMember" xlink:label="loc_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:type="locator" />
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_PanzygaMember_9AD949780E812573B9006898728F9F9F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PfizerCentreOneMember" xlink:label="loc_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:type="locator" />
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_PfizerCentreOneMember_F7888742D9859D4324196898728FD2C7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherAntiinfectivesMember" xlink:label="loc_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:type="locator" />
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_OtherAntiinfectivesMember_2457EFE6D5065126740E6898728F32DB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherHospitalProductsMember" xlink:label="loc_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:type="locator" />
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_OtherHospitalProductsMember_FF6E43D6E3DA40072B346898728F4439" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PrevnarPrevenarFamilyMember" xlink:label="loc_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:type="locator" />
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_PrevnarPrevenarFamilyMember_C47B735445BF1BAF33D26898728F3A2C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NimenrixMember" xlink:label="loc_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:type="locator" />
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_NimenrixMember_A98B5EA531766C51FFB868987290D96C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FSMEIMMUNTicoVacMember" xlink:label="loc_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:type="locator" />
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_FSMEIMMUNTicoVacMember_87AA838B9D9BC5F243B26898729068E2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TrumenbaMember" xlink:label="loc_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:type="locator" />
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TrumenbaMember_E12DB64A555CFCD341E268987290BC78" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherVaccinesProductsMember" xlink:label="loc_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:type="locator" />
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_OtherVaccinesProductsMember_4D3C10D96EAC66173BE268987290B8B9" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XeljanzMember" xlink:label="loc_pfe_XeljanzMember_A0C8BB28DB3FFDC59303689872909994" xlink:type="locator" />
    <link:presentationArc order="36" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XeljanzMember_A0C8BB28DB3FFDC59303689872909994" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EnbrelMember" xlink:label="loc_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:type="locator" />
    <link:presentationArc order="37" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EnbrelMember_7278A48B144320F6B03A689872900121" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InflectraRemsimaMember" xlink:label="loc_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:type="locator" />
    <link:presentationArc order="38" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_InflectraRemsimaMember_8BC9621321A7915B2DCE68987291E715" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EucrisaMember" xlink:label="loc_pfe_EucrisaMember_5EA784D480A34FB86391689872919D53" xlink:type="locator" />
    <link:presentationArc order="39" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EucrisaMember_5EA784D480A34FB86391689872919D53" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherInflammationandImmunologyProductsMember" xlink:label="loc_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:type="locator" />
    <link:presentationArc order="40" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_AllOtherInflammationandImmunologyProductsMember_CCBB5472BCE8F61933EC689872919510" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GenotropinMember" xlink:label="loc_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:type="locator" />
    <link:presentationArc order="41" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_GenotropinMember_3C3F32820C2BD23FC8C8689872919C19" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_BeneFIXMember" xlink:label="loc_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:type="locator" />
    <link:presentationArc order="42" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_BeneFIXMember_3A672E693CE7FEC8A2FB68987291BC6D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_VyndaqelMember" xlink:label="loc_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:type="locator" />
    <link:presentationArc order="43" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_VyndaqelMember_68AF9B42995BE431C2D668987291D317" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ReFactoAfXynthaMember" xlink:label="loc_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:type="locator" />
    <link:presentationArc order="44" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ReFactoAfXynthaMember_56014750167DB69FC431689872929DB0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SomavertMember" xlink:label="loc_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:type="locator" />
    <link:presentationArc order="45" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_SomavertMember_2FEA480B1CE77F96FB2F689872921F2E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherRareDiseaseProductsMember" xlink:label="loc_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:type="locator" />
    <link:presentationArc order="46" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_AllOtherRareDiseaseProductsMember_F4BA131BE6D74AFFDD60689872921AA5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LyricaMember" xlink:label="loc_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:type="locator" />
    <link:presentationArc order="47" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_LyricaMember_6DD515B5FC884472F3CD689872927C8F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_LipitorMember" xlink:label="loc_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:type="locator" />
    <link:presentationArc order="48" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_LipitorMember_D67FBFAFCD628AF3DA6968987292C1FA" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NorvascMember" xlink:label="loc_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:type="locator" />
    <link:presentationArc order="49" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_NorvascMember_C43A9013E51D0F0C1FAB689872923EAC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CelebrexMember" xlink:label="loc_pfe_CelebrexMember_833443BB76F2ED16CF6E689872935EE4" xlink:type="locator" />
    <link:presentationArc order="50" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_CelebrexMember_833443BB76F2ED16CF6E689872935EE4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ViagraMember" xlink:label="loc_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:type="locator" />
    <link:presentationArc order="51" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ViagraMember_62C3FACBEF2AC012024A689872932861" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffexorMember" xlink:label="loc_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:type="locator" />
    <link:presentationArc order="52" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_EffexorMember_F512674F48D8DD01778868987293A31B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ZoloftMember" xlink:label="loc_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:type="locator" />
    <link:presentationArc order="53" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ZoloftMember_C67A6B6BAF3AEFD61BD66898729327AD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XalatanXalacomMember" xlink:label="loc_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:type="locator" />
    <link:presentationArc order="54" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XalatanXalacomMember_0E923F4515C7307EE229689872931C1F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_XanaxMember" xlink:label="loc_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:type="locator" />
    <link:presentationArc order="55" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_XanaxMember_91740AB82F127BA4D93A68987293A6B1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_RevatioMember" xlink:label="loc_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:type="locator" />
    <link:presentationArc order="56" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_RevatioMember_25529A940AD6704E2AFE68987294E82C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_AllOtherUpjohnProductsMember" xlink:label="loc_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:type="locator" />
    <link:presentationArc order="57" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_AllOtherUpjohnProductsMember_6B61F5B67E07E58ECDB8689872942BD1" xlink:type="arc" />
    <link:presentationArc order="58" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_ConsumerHealthcareMember_DD38FC58E249607DA41E6898728AA749" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_HISProductsMember" xlink:label="loc_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:type="locator" />
    <link:presentationArc order="59" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_HISProductsMember_5B5C337DCE6AA9AD2BEC6898729428E8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalAllianceBiopharmaceuticalsMember" xlink:label="loc_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:type="locator" />
    <link:presentationArc order="60" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TotalAllianceBiopharmaceuticalsMember_BA055309DEF76E5E6E50689872942C9F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalBiosimilarsMember" xlink:label="loc_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:type="locator" />
    <link:presentationArc order="61" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TotalBiosimilarsMember_F73BF6A792790136F63F68987294F2D5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalSterileInjectablePharmaceuticalsMember" xlink:label="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:type="locator" />
    <link:presentationArc order="62" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_1F7BA700B4AAB3E338836898728A9761" xlink:to="loc_pfe_TotalSterileInjectablePharmaceuticalsMember_37E452717D140A64F501689872951C33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems" xlink:label="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable_51EDEC239D2ACCC24DFA6898728615B2" xlink:to="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7DAB17E5C69922E83BAB6898729518AD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems_F4F341B1B2DC9F981EF568987295FA96" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_7DAB17E5C69922E83BAB6898729518AD" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SegmentReportingAbstract" xlink:label="loc_us-gaap_SegmentReportingAbstract_1E22938D2DBCE54BA4407E5352EA00F3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1E22938D2DBCE54BA4407E5352EA00F3" xlink:to="loc_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock_9EDAFF0895D8151D4B9D7E5352EB3405" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock" xlink:label="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1E22938D2DBCE54BA4407E5352EA00F3" xlink:to="loc_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock_ABA87F134909AF74347A7E5352EB7BE4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock" xlink:label="loc_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1E22938D2DBCE54BA4407E5352EA00F3" xlink:to="loc_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock_8DFDF6B2E7A72C9E3D0D7E5352EB744A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1E22938D2DBCE54BA4407E5352EA00F3" xlink:to="loc_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock_13B5D98AB3511B17B4B47E5352EB4518" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1E22938D2DBCE54BA4407E5352EA00F3" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_0E8132D357D72AEB73F77E5352EB17B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock" xlink:label="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_1E22938D2DBCE54BA4407E5352EA00F3" xlink:to="loc_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock_ABEA54109511BF2243347E5352EC57E2" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPayments" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9067549E26434728CCD0802072463D15" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9067549E26434728CCD0802072463D15" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_FC376EACC975D386822B8020724693F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_126ADE5FE21E1B0665658020735B3D7B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_EAD7BA1E197C64E571438020735B22F2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_126ADE5FE21E1B0665658020735B3D7B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_EAD7BA1E197C64E571438020735B22F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_778FC44633BE1113BBEE8020735B4D74" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_EAD7BA1E197C64E571438020735B22F2" xlink:to="loc_us-gaap_AwardTypeAxis_778FC44633BE1113BBEE8020735B4D74" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CD50A68C534BD88C04E8020735B3ABA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_778FC44633BE1113BBEE8020735B4D74" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CD50A68C534BD88C04E8020735B3ABA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9CD50A68C534BD88C04E8020735B3ABA" xlink:to="loc_us-gaap_PerformanceSharesMember_0D32BB50CE82C3FB1B958020735CB5A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_EAD7BA1E197C64E571438020735B22F2" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_C5F0543440520B6991848020735C5ADA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_8C49C21FF67F1CC5EBF98020735D7CCC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_70EA7032595D14DFCF198020735D97B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_2A228CBC1903ACA344408020735D0242" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_2A228CBC1903ACA344408020735D0242" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_D7913D560A24D3ED31318020735DB5B7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_D7913D560A24D3ED31318020735DB5B7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_1B6232B307ACED4C2AFE8020735C85AF" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B0CB86552E90A4D21C288020735E0BE0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7CDF24E5004CD9360999802074F6D3C4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E6EC68D3410FE92F8DF7802074F7F748" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7CDF24E5004CD9360999802074F6D3C4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E6EC68D3410FE92F8DF7802074F7F748" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_657D3F3AF8BE3AB887F4802074F75022" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E6EC68D3410FE92F8DF7802074F7F748" xlink:to="loc_us-gaap_AwardTypeAxis_657D3F3AF8BE3AB887F4802074F75022" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F6FFEA77606A3A1E5246802074F7108F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_657D3F3AF8BE3AB887F4802074F75022" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F6FFEA77606A3A1E5246802074F7108F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_294212D662D7444ECBC2802074F8A54D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_F6FFEA77606A3A1E5246802074F7108F" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_294212D662D7444ECBC2802074F8A54D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_E6EC68D3410FE92F8DF7802074F7F748" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5191EAC531FA5E579667802074F82224" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_5191EAC531FA5E579667802074F82224" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5C030F60EC2F3EA8D8FE802074F8D9EF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_5C030F60EC2F3EA8D8FE802074F8D9EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_663E45685303169DD84C802074F92EA7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_663E45685303169DD84C802074F92EA7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_48150E5A318CF2CA1ABD802074F9F010" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_48150E5A318CF2CA1ABD802074F9F010" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_EAF6D16BF00F07D995D5802074F9F123" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B935FF378858C0525EBA802074F83D73" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_EAF6D16BF00F07D995D5802074F9F123" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71818F0B615B3809E22E80206C3A50D1" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_94C183DE91D3D3ED575C80206C3A2611" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_71818F0B615B3809E22E80206C3A50D1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_94C183DE91D3D3ED575C80206C3A2611" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_26A52221320D3C8A630980206C3AE8C3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_94C183DE91D3D3ED575C80206C3A2611" xlink:to="loc_us-gaap_AwardTypeAxis_26A52221320D3C8A630980206C3AE8C3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E972838244867613E92B80206C3BA118" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_26A52221320D3C8A630980206C3AE8C3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E972838244867613E92B80206C3BA118" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_7F4C21611C2934F004CA80206C3B75B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_E972838244867613E92B80206C3BA118" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_7F4C21611C2934F004CA80206C3B75B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_94C183DE91D3D3ED575C80206C3A2611" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_0743CC68203876F0279280206C3CD2E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_2B5DA58376D11B645C1880206C3CFFE7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_8483C87D5B579EFD705280206C3C1A58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_509F7D722A08C57CBED580206C3CB468" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_509F7D722A08C57CBED580206C3CB468" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C513D7AAF9B0A169ADCC80206C3CAD07" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_C513D7AAF9B0A169ADCC80206C3CAD07" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B36E3863F77F89D696EB80206C3D8E95" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_CAF1DBCD01FE44A603E780206C3BF7A1" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting_B36E3863F77F89D696EB80206C3D8E95" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38F415F585A26531490580206EE413D3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_208643BC4F1CDEFE1B4A80206EE46225" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_38F415F585A26531490580206EE413D3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_208643BC4F1CDEFE1B4A80206EE46225" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_D9DF35AC4084E638EBE580206EE51376" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_208643BC4F1CDEFE1B4A80206EE46225" xlink:to="loc_us-gaap_AwardTypeAxis_D9DF35AC4084E638EBE580206EE51376" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C3D5934CC1A2B17DC5FB80206EE5EB61" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_D9DF35AC4084E638EBE580206EE51376" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C3D5934CC1A2B17DC5FB80206EE5EB61" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_88A515A070CDC992F4F380206EE590E0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C3D5934CC1A2B17DC5FB80206EE5EB61" xlink:to="loc_us-gaap_EmployeeStockOptionMember_88A515A070CDC992F4F380206EE590E0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_208643BC4F1CDEFE1B4A80206EE46225" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_A38125D33F9AA8CF8C4780206EE64D17" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_16BBEEA38A29B5493F6480206EE6D987" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_ProceedsFromStockOptionsExercised_BDDFE46F9AFCBF598DE980206EE6C1AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions_B61D0F2968022886642980206EE69E62" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_84D7F462CF127CCF92B880206EE779F2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_D4096BB03E78DD0A313680206EE518CE" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_96A82FD5BB8F89A57CF280206EE7EE7F" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9EEF062B24DF8B327208802074548689" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD53A01B20DB69E2C9B880207454BACA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_9EEF062B24DF8B327208802074548689" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD53A01B20DB69E2C9B880207454BACA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_E70167D239AAE757DA95802074547C2D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD53A01B20DB69E2C9B880207454BACA" xlink:to="loc_us-gaap_AwardTypeAxis_E70167D239AAE757DA95802074547C2D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67FA9C3546340D530F6580207455178E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_E70167D239AAE757DA95802074547C2D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67FA9C3546340D530F6580207455178E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_2C6920B5E32EB523BE0280207455DC16" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_67FA9C3546340D530F6580207455178E" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_2C6920B5E32EB523BE0280207455DC16" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_CD53A01B20DB69E2C9B880207454BACA" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_214F8F97F3CA3C12C18A80207455168A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B3910CF4DAB343C88480802074567731" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions_B3910CF4DAB343C88480802074567731" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_A0DE82F5EC689F75984880207456E5E0" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/netLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_0E8EAB69247FE462EBD280207455E6D0" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_A0DE82F5EC689F75984880207456E5E0" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4248C976C6F6E4374D49E36C8CDA5813" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4248C976C6F6E4374D49E36C8CDA5813" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:to="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_7E27A1F62DDD28F62177E36C8CDB5A1E" xlink:to="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_A2019StockPlanMember" xlink:label="loc_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_45EB0A4B716103227CCEE36C8CDBAF28" xlink:to="loc_pfe_A2019StockPlanMember_0A965853EF00F130954BE392610E3048" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_DAEC880E34F7BEBED8B0E36C8CDCF866" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:to="loc_us-gaap_AwardTypeAxis_DAEC880E34F7BEBED8B0E36C8CDCF866" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_DAEC880E34F7BEBED8B0E36C8CDCF866" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_4860211DABA4EAEDC39CE36C8CDC826C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_4860211DABA4EAEDC39CE36C8CDC826C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_67C8EAD8FA07A56A9ACDE36C8CDDB008" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_51E0FEB25D017B1DB621E36C8CDD71C9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_51E0FEB25D017B1DB621E36C8CDD71C9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_18CD2ED0365D3488B082E36C8CDD140F" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_us-gaap_PerformanceSharesMember_18CD2ED0365D3488B082E36C8CDD140F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_50BB74A12DA51F187FF8E36C8CDD7FDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_us-gaap_EmployeeStockOptionMember_50BB74A12DA51F187FF8E36C8CDD7FDC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DirectorsCompensationMember" xlink:label="loc_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_pfe_DirectorsCompensationMember_B530EBE8972F29B1A540E36C8CDD6E08" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_6CAD6389C96EA8A6C111E36C8CDD2FD6" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_95D2036DA57A59E67FCCE36C8CDC3390" xlink:to="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_6CAD6389C96EA8A6C111E36C8CDD2FD6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_24F20D0D18E5F0E24537E36C8CDAD674" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_F1AA752C69BFFE2EBE4BE36C8CDE2B20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense_D3F4E6EA04729AC4E7DDE36C8CDFE182" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_583FF0EE65D1ED0DD920E36C8CDD362E" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax_FED75CE9492E259EF4CDE36C8CE09424" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43F533CF3F7B61CD96EA0CAF78021841" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43F533CF3F7B61CD96EA0CAF78021841" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_AEEA42A8B0920785C4F10CAF780285F8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:to="loc_us-gaap_AwardTypeAxis_AEEA42A8B0920785C4F10CAF780285F8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_AEEA42A8B0920785C4F10CAF780285F8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_C425A65BC645BCF95D140CAF780305FE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_C425A65BC645BCF95D140CAF780305FE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_4E10E3DA5E4BB56072050CAF7803B50A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_4E10E3DA5E4BB56072050CAF7803B50A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8B594FC4FF4EB58CF0F70CAF78033354" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_us-gaap_PerformanceSharesMember_8B594FC4FF4EB58CF0F70CAF78033354" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_053DB0707BC1626615A20CAF7804FDA0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_053DB0707BC1626615A20CAF7804FDA0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_48BEE7D56C17C5B541700CAF78048DA3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_48BEE7D56C17C5B541700CAF78048DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_CDEBE1DD9786E1CCE2D90CAF7804A7A1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_C0F180D3F65DEF83DECF0CAF7803B065" xlink:to="loc_us-gaap_EmployeeStockOptionMember_CDEBE1DD9786E1CCE2D90CAF7804A7A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaap_PlanNameAxis_1E3171AD1ED3869648B50CAF78048B49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:to="loc_us-gaap_PlanNameAxis_1E3171AD1ED3869648B50CAF78048B49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaap_PlanNameDomain_0B538D995B8E9429D5BE0CAF780409D7" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_1E3171AD1ED3869648B50CAF78048B49" xlink:to="loc_us-gaap_PlanNameDomain_0B538D995B8E9429D5BE0CAF780409D7" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_A2019StockPlanMember" xlink:label="loc_pfe_A2019StockPlanMember_2804084E7D43AA74BDEC0CAF78055776" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_0B538D995B8E9429D5BE0CAF780409D7" xlink:to="loc_pfe_A2019StockPlanMember_2804084E7D43AA74BDEC0CAF78055776" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6AC2546BF4C7D99516990CAF7802251C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized_3E5493B2BC768BC313510CAF7805CD72" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee_962F6C2B163BABA19C2D0CAF78050F1D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee_41CA5C0B0A4C42F70B460CAF78068117" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B835AD4DACBE8066C94D0CAF780532D9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_1E616FF511E5114A628F0CAF7806C3EA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382B808A52B99869D47CE395F0DC354B" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_382B808A52B99869D47CE395F0DC354B" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:to="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C9A0B13979CAAC29E8BFE395F0DD241D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_E26C828C72B9B8115F0CE395F0DDBA94" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ProfitUnitsMember" xlink:label="loc_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_8598435CDF4E9F7BCD02E395F0DDFC75" xlink:to="loc_pfe_ProfitUnitsMember_C617FD907E35FEA2E807E395F0DDE6D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_04CF196D90BAB75BBE4FE395F0DC8739" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_0B65EC5CC8101F2F4A6EE395F0DE03D0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice_6A018B64726F7CE59499E395F0DEFAE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_412CE84F5E6A2B6A54BBE395F0DE61A7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_2D310CD59E5368DA8BCDE395F0E3127A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares_9F82C53089B6345850F0E395F0E49B48" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice_B7C961902A7C10AEFAE6E395F0E4C2B1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms_7AD2BAFDE74B6DDFBC24E395F0E47D1B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_B1B717515B54794CB858E395F0E44617" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber_012BB2C69D6532BF4741E395F0E47E89" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice_998C1DD3E8FEB76074AEE395F0E510E8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm_29F3A6080BDA3FF3DB6FE395F0E51454" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest_A1AF09A35E386A40471CE395F0E50444" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares_333D473815556F796890E395F0E50A00" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice_72EA5EA783723FA56FE0E395F0E54E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_5B28BA9B8DBBF5FE9C53E395F0E6950B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice_E44C34FB4E16267DF197E395F0E67107" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion_A7FEC9FE8BAE30EA5E50E395F0E6815A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_E1B7C15FE4D4AFAC6356E395F0E63A33" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_87653145A90066D22762E395F0DE22A6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_2FE208B7AB4189FF83BAE395F0E62255" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CF56BB107145D458F26980206F6A58AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6293B7C8C473A8909C6380206F6BA90F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_CF56BB107145D458F26980206F6A58AC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6293B7C8C473A8909C6380206F6BA90F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_8F2D6F7F5EC0AEBB97CA80206F6BD916" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6293B7C8C473A8909C6380206F6BA90F" xlink:to="loc_us-gaap_AwardTypeAxis_8F2D6F7F5EC0AEBB97CA80206F6BD916" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6296453596DAB78964E080206F6B2317" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_8F2D6F7F5EC0AEBB97CA80206F6BD916" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6296453596DAB78964E080206F6B2317" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_8A7D714B893A6A3D822280206F6C1696" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6296453596DAB78964E080206F6B2317" xlink:to="loc_us-gaap_PerformanceSharesMember_8A7D714B893A6A3D822280206F6C1696" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DDE032B961B6B56FA84080206F6C9972" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6293B7C8C473A8909C6380206F6BA90F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DDE032B961B6B56FA84080206F6C9972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DDE032B961B6B56FA84080206F6C9972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A42E2010CD2F272338F180206F6C1108" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A42E2010CD2F272338F180206F6C1108" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F384A3092108E51709B880206F6D9C06" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_F384A3092108E51709B880206F6D9C06" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_729639DD6DD89D5F9EB980206F6D3C28" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_729639DD6DD89D5F9EB980206F6D3C28" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_10AEDFCFAEC3690321A180206F6DED38" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_10AEDFCFAEC3690321A180206F6DED38" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5FB1B7F3D7B8F1E52CBE80206F6D6A7D" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_6D21A82FE2E5564CE0D180206F6CE4C1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5FB1B7F3D7B8F1E52CBE80206F6D6A7D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_DDE032B961B6B56FA84080206F6C9972" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3A49938460191C1B85B180206F6DA909" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_3A49938460191C1B85B180206F6DA909" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_82AA15B9CF7A9EC3B94780206F6EE24F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_82AA15B9CF7A9EC3B94780206F6EE24F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_69B3824C38AEFBE9D2D080206F6E9AFD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_69B3824C38AEFBE9D2D080206F6E9AFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_32FB8FE507B913A3704E80206F6EF4D9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_32FB8FE507B913A3704E80206F6EF4D9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_B88F200D3F15B785364A80206F6E8CB4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_62987E6B1A8022DC028C80206F6D1917" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_B88F200D3F15B785364A80206F6E8CB4" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3A572ED0CD60B81F0AFC6891E7BB8A48" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_3A572ED0CD60B81F0AFC6891E7BB8A48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_EAEA075A8F198C291EDE6891E7BC6BB1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:to="loc_us-gaap_AwardTypeAxis_EAEA075A8F198C291EDE6891E7BC6BB1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AA2B57C248C854FCB0576891E7BD52DF" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_EAEA075A8F198C291EDE6891E7BC6BB1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AA2B57C248C854FCB0576891E7BD52DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="loc_us-gaap_PerformanceSharesMember_7F15E120F41C591304416891E7BD6E04" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AA2B57C248C854FCB0576891E7BD52DF" xlink:to="loc_us-gaap_PerformanceSharesMember_7F15E120F41C591304416891E7BD6E04" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_1A0366E5FBFB7D5830126891E7BDC8F5" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:to="loc_srt_RangeAxis_1A0366E5FBFB7D5830126891E7BDC8F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_1A0366E5FBFB7D5830126891E7BDC8F5" xlink:to="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_3918E0C44115AA0BA3E96891E7BE611A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0" xlink:to="loc_srt_MinimumMember_3918E0C44115AA0BA3E96891E7BE611A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_5A7050B109C1A4466DDC6891E7BEC689" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_55864B4D11C3EF752E4B6891E7BE8DF0" xlink:to="loc_srt_MaximumMember_5A7050B109C1A4466DDC6891E7BEC689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_270F2F5C4DE520D53AA76891E7BCBD86" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout_6A0B7DC9C4D53AD9C9786891E7BE161F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods_24561CF48F4DE0E40C96689F2BAF896A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod_59729CF537F3894DAE7068A0ABFF34C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CBEB87B59706367DCCBD6891E7BF77EB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_CBEB87B59706367DCCBD6891E7BF77EB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_B4CFF39D2F5642D379CF6891E7BF7DDC" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_175343D4B3677968BE7E6891E7BED883" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_B4CFF39D2F5642D379CF6891E7BF7DDC" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7CE0FF3BB67CFFEC9FDD6891EE973102" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7CE0FF3BB67CFFEC9FDD6891EE973102" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:to="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_2338EACDDFFAA98C59CE6891EE991258" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_BoardOfDirectorsChairmanMember" xlink:label="loc_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:to="loc_srt_BoardOfDirectorsChairmanMember_31702FC0DDE400AF68126891EE9A6E63" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember" xlink:label="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_AFE827FCA7D6F47DA89A6891EE9AFE24" xlink:to="loc_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_4B17FBE9A4DC396DFBD168981B6B3E51" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_FF58F61D50CE2D32AA526891EE9A3197" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:to="loc_us-gaap_AwardTypeAxis_FF58F61D50CE2D32AA526891EE9A3197" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34CA7FC326D36ADFEF586891EE9AAA02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_FF58F61D50CE2D32AA526891EE9A3197" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34CA7FC326D36ADFEF586891EE9AAA02" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember" xlink:label="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_34CA7FC326D36ADFEF586891EE9AAA02" xlink:to="loc_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_BDD39BA2423D570F6E076891EE9B8DE1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_2F4C294C2E67CB19F2D76891EE99E348" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_B98160DAE06411F707BB6891EE9B1720" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_B903BDAA535BAB8605806891EE9C9137" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice_15665AB5875F7DF8EE156891EE9CB6F3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_48DBB38868406D4EC8F56891EE9B4ED9" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue_372CFABABF595F202AC76891EE9C57E7" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93C0829313FCB6B3D7F0802072D3F01D" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306F3F07E337BD0E2C07802072D382C4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_93C0829313FCB6B3D7F0802072D3F01D" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306F3F07E337BD0E2C07802072D382C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_1A9D5F9BAAB07A95815F802072D42616" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306F3F07E337BD0E2C07802072D382C4" xlink:to="loc_us-gaap_AwardTypeAxis_1A9D5F9BAAB07A95815F802072D42616" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08038D629A44EDDAFA52802072D49383" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_1A9D5F9BAAB07A95815F802072D42616" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08038D629A44EDDAFA52802072D49383" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_40BEF631D17FA53927C2802072D47006" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_08038D629A44EDDAFA52802072D49383" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_40BEF631D17FA53927C2802072D47006" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_306F3F07E337BD0E2C07802072D382C4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0A18F8B410CD6A0F7E96802072D56A67" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_0A18F8B410CD6A0F7E96802072D56A67" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_91EC93AB808E62B66AAE802072D5B1BB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_91EC93AB808E62B66AAE802072D5B1BB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6F9F089CC89E352320FC802072D5828F" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_6F9F089CC89E352320FC802072D5828F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB2195FBF01BB6ACBC24802072D608B7" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_BB2195FBF01BB6ACBC24802072D608B7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D3DB51063DF7C45AD258802072D6F9AD" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_1F52AE732A54CE572353802072D5D735" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_D3DB51063DF7C45AD258802072D6F9AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_CF87D755917EF50A66BC802072D6A012" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue_FF8C6E3210D39D70566D802072D6900E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue_BE781B81C2309C1B3552802072D70027" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue_484C286A00B1271CABC8802072D7FD3D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_1D7D05C8AEBF4A4F17D5802072D7E4D7" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward_154C60526D4669B06A78802072D6CE3E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue_1D7D05C8AEBF4A4F17D5802072D7E4D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_35B53DFA32575FECDEE1802072D71D68" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_35B53DFA32575FECDEE1802072D71D68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_72C89AFA41A8FE8169B0802072D73A25" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1D78A1DC6520F1E21214802072D8E416" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6DDC34DFE60791E39A0A802072D4D3FF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_1D78A1DC6520F1E21214802072D8E416" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1C3A5A2D6ACAC02C353B12152DE77B48" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1C3A5A2D6ACAC02C353B12152DE77B48" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_7752FD0C102755D23BBA12152DEAF729" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:to="loc_us-gaap_AwardTypeAxis_7752FD0C102755D23BBA12152DEAF729" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EBFD9D2C6606CDA1E28512152DEAFF57" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_7752FD0C102755D23BBA12152DEAF729" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EBFD9D2C6606CDA1E28512152DEAFF57" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PortfolioPerformanceSharesMember" xlink:label="loc_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_EBFD9D2C6606CDA1E28512152DEAFF57" xlink:to="loc_pfe_PortfolioPerformanceSharesMember_1A08C065D89B1098449912152DEB070E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_EBF9A1F83089FF253D8512152DEBAD80" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:to="loc_srt_RangeAxis_EBF9A1F83089FF253D8512152DEBAD80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_EBF9A1F83089FF253D8512152DEBAD80" xlink:to="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_A9D6CEE4556ECBC1A14112152DEC4196" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A" xlink:to="loc_srt_MinimumMember_A9D6CEE4556ECBC1A14112152DEC4196" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_7ED4A438A7173C9DBE7812152DEC0E09" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_67BF84C03E52C915DD5E12152DEBF45A" xlink:to="loc_srt_MaximumMember_7ED4A438A7173C9DBE7812152DEC0E09" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5B86AA892C3E041EC1F112152DE98279" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_A819C2658D4F4339842612152DEC6C4A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_A819C2658D4F4339842612152DEC6C4A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_48CF7D3BB533C474E55312152DEDE827" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_48CF7D3BB533C474E55312152DEDE827" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_2FC78606DAB0C889D33912152DECA1DF" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward_5E2AE6D708035EAC328E12152DF21D04" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573CCDD65BAF4311FDC980206F502FFE" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D27B91AFF4E4187FB20D80206F51EEFB" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_573CCDD65BAF4311FDC980206F502FFE" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D27B91AFF4E4187FB20D80206F51EEFB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_908EA308F2D3E3BD083C80206F519CF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D27B91AFF4E4187FB20D80206F51EEFB" xlink:to="loc_us-gaap_AwardTypeAxis_908EA308F2D3E3BD083C80206F519CF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9F3DC33A85A5CAB882C80206F5172AA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_908EA308F2D3E3BD083C80206F519CF6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9F3DC33A85A5CAB882C80206F5172AA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_B9F3DC33A85A5CAB882C80206F5172AA" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_E482B79CE6239F2BEBE480206F524C4D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D27B91AFF4E4187FB20D80206F51EEFB" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_EE685463EEABCBB7C7F480206F521623" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_EE685463EEABCBB7C7F480206F521623" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F7613A87D473DF57947280206F535D80" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_F7613A87D473DF57947280206F535D80" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7BB98AE2D172A8C80C0B80206F53CE8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_7BB98AE2D172A8C80C0B80206F53CE8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C9A8F3BF145B3B065BDB80206F53E596" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_C9A8F3BF145B3B065BDB80206F53E596" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod_A97CA547D5A36354493480206F541F08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0CDA492D9328EFCD39BB80206F54893F" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0CDA492D9328EFCD39BB80206F54893F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_133459BF8A1ADB55391580206F54B29E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_F6AA745CEEC95B09B18280206F53E8FE" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_133459BF8A1ADB55391580206F54B29E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F27A4D400AF38CA7F65380206F54EAE4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_F27A4D400AF38CA7F65380206F54EAE4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BD2FD9409642FC3A1E6B80206F55AF58" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_BD2FD9409642FC3A1E6B80206F55AF58" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E7DC5E7BE7898BDC09F980206F55CA66" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_E7DC5E7BE7898BDC09F980206F55CA66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue_B9F527598E3DD95311B680206F5621F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_52854D876B5A6DC009AD80206F5614C4" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_52854D876B5A6DC009AD80206F5614C4" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3123E35E65C9934747B380206F576F9D" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_81E6A1FD804FA8A167C380206F541E5B" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_3123E35E65C9934747B380206F576F9D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_7D620B3756A813DC176280206F58BD66" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_7D620B3756A813DC176280206F58BD66" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_04C02756F3C3E293C38A80206F588B0E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_E599663255291E118D2780206F52890D" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_04C02756F3C3E293C38A80206F588B0E" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BD839C1514C86B03539680206A89D244" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709EB883E692BD72710E80206A8A308C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_BD839C1514C86B03539680206A89D244" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709EB883E692BD72710E80206A8A308C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_4BDFD2E780F52595C58480206A8A3C32" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709EB883E692BD72710E80206A8A308C" xlink:to="loc_us-gaap_AwardTypeAxis_4BDFD2E780F52595C58480206A8A3C32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B964F94046B14C827D380206A8A0DDD" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_4BDFD2E780F52595C58480206A8A3C32" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B964F94046B14C827D380206A8A0DDD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2B964F94046B14C827D380206A8A0DDD" xlink:to="loc_us-gaap_EmployeeStockOptionMember_F345714565DD0975312C80206A8B677D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_709EB883E692BD72710E80206A8A308C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_56ED042353F5DF5224AD80206A8C0E02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_9B1D59FC4D1D687B714D80206A8C7D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_4DEA319BA88503A9935280206A8C71CD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_4316429F8422ADE8756380206A8C0413" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_37ECE69B8BA77F60066A80206A8DE2AB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAA3C56F2B8845B72B6B80206A8DA91B" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_60D4AB42C7E4E6EFD44680206A8B022C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_FAA3C56F2B8845B72B6B80206A8DA91B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_269B0F1A2C7938E2767880206A8D98FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_8284941D4835FC22B95480206A8D77A1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_60FE67A607FEABB3CB1880206A8E1A2E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_6856975DF1CC1E8F664180206A8E351B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_0EF4EBBABF308F1ACC7480206A8E50EF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_57E9196E8D3A3D6BCF8680206A8F7FA9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_D4CE79B8B89E5FB56B9780206A8FBE5E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3F94C0C0DB3CC1E9EA1080206A8F8AF3" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_9BC752258D13B70FD0E680206A8D859E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3F94C0C0DB3CC1E9EA1080206A8F8AF3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_979F402A56AB841E778080206A8F9FF1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_E585A4ADFD1C895843A880206A8FED35" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_AE759B5792B4804CDDE980206A8F5507" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_FA06A94B1DC13F2B04A780206A909DB7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_9B24235F35C6775BF21680206A9054EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_21539C94FFE14322DCE480206A90EAC7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_B04215E9D1B477938B1680206A906DD7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_4BC7F38A2699233EAF8E80206A9172E8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_EE8580B5CBF745E544CF80206A91158C" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05ABD16696DB556851B880206A8BEA5C" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_EE8580B5CBF745E544CF80206A91158C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7AF8992437AD6D91172A802074D688B4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_7AF8992437AD6D91172A802074D688B4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="loc_srt_TitleOfIndividualAxis_34F0F21B7C6C43322206802074D769E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:to="loc_srt_TitleOfIndividualAxis_34F0F21B7C6C43322206802074D769E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4A3E2A8D6105C58D7432802074D74B7C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_34F0F21B7C6C43322206802074D769E5" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4A3E2A8D6105C58D7432802074D74B7C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_ManagementMember" xlink:label="loc_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_4A3E2A8D6105C58D7432802074D74B7C" xlink:to="loc_srt_ManagementMember_798F2F7F9D25F560B969802074D8A0E3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_070B86D873F2A17F69F3802074D841F1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:to="loc_us-gaap_AwardTypeAxis_070B86D873F2A17F69F3802074D841F1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9DCAF07331E06B124420802074D89EED" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_070B86D873F2A17F69F3802074D841F1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9DCAF07331E06B124420802074D89EED" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_746D3DD7126A051989AF802074D84D9B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_9DCAF07331E06B124420802074D89EED" xlink:to="loc_us-gaap_EmployeeStockOptionMember_746D3DD7126A051989AF802074D84D9B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_FAF85709E95F8BD1BBF4802074D78E68" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_86A8860D4775EB023FCD802074D97119" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_86A8860D4775EB023FCD802074D97119" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_826C9DDF7C901786CC03802074D9378C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D5870E2B43CA85C1F38E802074D9CA11" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_D5870E2B43CA85C1F38E802074D9CA11" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod_56095CE167C5720C83E9802074D9F3F0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions" xlink:label="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_EE140B847A512A434208802074D9E260" xlink:to="loc_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions_A8A9BF85E0DC5D27C24D802074DA685C" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91F7D65A529C514DD1F18020777690C3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91F7D65A529C514DD1F18020777690C3" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_E578D1CA524716E5A8B6802077764AA3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock" xlink:label="loc_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91F7D65A529C514DD1F18020777690C3" xlink:to="loc_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock_15BAF47FFF7FA52FFD06802077764C02" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91F7D65A529C514DD1F18020777690C3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock_46CF09FE62D656F1EBA88020777607B2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91F7D65A529C514DD1F18020777690C3" xlink:to="loc_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock_0D6576549A516FB7F54A80207778C749" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91F7D65A529C514DD1F18020777690C3" xlink:to="loc_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock_899B5AAFEC7A88AFF11F8020777A1378" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91F7D65A529C514DD1F18020777690C3" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_3C5D635A7ADB60FFA9A58020777A015E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_91F7D65A529C514DD1F18020777690C3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_C940860ADB903D20B9758020777C37F8" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26BFC88304B3A334C8558020743CF8F2" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D48A81362CB5A96640658020743C05F5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_26BFC88304B3A334C8558020743CF8F2" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D48A81362CB5A96640658020743C05F5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_230FFEFB02E736AFE7A98020743CA236" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D48A81362CB5A96640658020743C05F5" xlink:to="loc_us-gaap_AwardTypeAxis_230FFEFB02E736AFE7A98020743CA236" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC515C4969AA7870BB108020743C9F66" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_230FFEFB02E736AFE7A98020743CA236" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC515C4969AA7870BB108020743C9F66" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_CA893CAD75A845A396DD8020743D9904" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_AC515C4969AA7870BB108020743C9F66" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_CA893CAD75A845A396DD8020743D9904" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_D48A81362CB5A96640658020743C05F5" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_838B9C8F8C59F8167EC48020743EC44B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_2671BB3A5B2D2F4A2CFB8020743E0EA6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_4933706FB4A8D880C9028020743E84AD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_0F37810DC60ED0C44D508020743F5A21" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A59D4333F2EF0FCBCD348020743F1639" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_368C7FA467B9A6BE66408020743D706E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_A59D4333F2EF0FCBCD348020743F1639" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_8868F69A533FAA4BF78B8020743F0F24" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_E18C4BBE20310A7EFA97802074401339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_9FB41C1FE038AD483C8080207440D84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_E883E95C0C01A4FF98F680207440395A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D30B399609C0D1159F0780207440BDFE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_9AC58E1BD8A9039585FB8020743FB01E" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_D30B399609C0D1159F0780207440BDFE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_D0AB8A125024ACFAF78B802074419F63" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice_28212623C45A4C65EFF2802074419C48" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice_048DE9B18E13567206CC80207441F001" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice_0F6B43DBC02E9471A04F8020744178EB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_12E789AD4EF56DD800DD80207441ABFF" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract_529087754ACF7CB4E62180207440DA53" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice_12E789AD4EF56DD800DD80207441ABFF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_FCFF516250FD8A6954CA80207442921B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber_FCFF516250FD8A6954CA80207442921B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_E5E6653954845DF167E88020744259F9" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4ABCB6CD606A07554D318020743D1C91" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_E5E6653954845DF167E88020744259F9" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4DAB8E0BAE4F252F89B00CAF74C92BF3" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4DAB8E0BAE4F252F89B00CAF74C92BF3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_6007E4EA9B538875C95F0CAF74C9EFF0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:to="loc_us-gaap_AwardTypeAxis_6007E4EA9B538875C95F0CAF74C9EFF0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68C689AA9D7703FED8440CAF74C9E564" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6007E4EA9B538875C95F0CAF74C9EFF0" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68C689AA9D7703FED8440CAF74C9E564" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_D09295BE0B6140121C250CAF74CA1293" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_68C689AA9D7703FED8440CAF74C9E564" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_D09295BE0B6140121C250CAF74CA1293" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeAxis" xlink:label="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:to="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_RangeMember" xlink:label="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_7EF43AD6771C0F8E04F70CAF74CAA586" xlink:to="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MinimumMember" xlink:label="loc_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:to="loc_srt_MinimumMember_6DCA8A8A43DF977A42A40CAF74CBAEF6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/srt/2019/elts/srt-2019-01-31.xsd#srt_MaximumMember" xlink:label="loc_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_BC6B58B0E0542EB076110CAF74CA5851" xlink:to="loc_srt_MaximumMember_A0F82C243E92CB4770520CAF74CBD01B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_6CCD827FD270C7C36B2C0CAF74C9451F" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_0ED2790953B0F45C43DF0CAF74CB2D26" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage_DFEC6F6B037C8A7905DB0CAF74CBE878" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement" xlink:label="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement_CA348D171B052F2E0A760CAF74CB909C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1_FEAC1F1479859A4029BA0CAF74CC825D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_3DDF7B8C4577BF5474250CAF74CC7311" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_B610EC2088666E8ED7970CAF74CB5A27" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected_3DDF7B8C4577BF5474250CAF74CC7311" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_741042589A6904D4C43380206CC612AC" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63DEDCFBCF03F575058D80206CC76BC8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_741042589A6904D4C43380206CC612AC" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63DEDCFBCF03F575058D80206CC76BC8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_22A0D93FEC11AC8AFBE180206CC79E40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63DEDCFBCF03F575058D80206CC76BC8" xlink:to="loc_us-gaap_AwardTypeAxis_22A0D93FEC11AC8AFBE180206CC79E40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2FEF7AEFBFD719AB9B6180206CC7B023" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_22A0D93FEC11AC8AFBE180206CC79E40" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2FEF7AEFBFD719AB9B6180206CC7B023" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaap_EmployeeStockOptionMember_3BE123780AB8F17AD92680206CC757A8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2FEF7AEFBFD719AB9B6180206CC7B023" xlink:to="loc_us-gaap_EmployeeStockOptionMember_3BE123780AB8F17AD92680206CC757A8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_63DEDCFBCF03F575058D80206CC76BC8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_991A444998EBD725BD2480206CC80E78" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_991A444998EBD725BD2480206CC80E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CD6AEA153F652E2F4A1280206CC82E78" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_CD6AEA153F652E2F4A1280206CC82E78" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7878A306663DD66D40A980206CC9FCDB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_7878A306663DD66D40A980206CC9FCDB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_4760D2985280C723FE3380206CC8D685" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_77FC5060263A553525CA80206CC9FD18" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FCF5B2D7F9089FCA9B6180206E2E3F28" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5697AE47247233936BFA80206E2E87B3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_FCF5B2D7F9089FCA9B6180206E2E3F28" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5697AE47247233936BFA80206E2E87B3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaap_AwardTypeAxis_C292BBDDCB920894B1A380206E2FE4B9" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5697AE47247233936BFA80206E2E87B3" xlink:to="loc_us-gaap_AwardTypeAxis_C292BBDDCB920894B1A380206E2FE4B9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_142C0709AA32DC820A0880206E2FB171" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_C292BBDDCB920894B1A380206E2FE4B9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_142C0709AA32DC820A0880206E2FB171" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TotalShareholderReturnUnitsTSRUsMember" xlink:label="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_C32B9432EF9E7329EEAB80206E353407" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_142C0709AA32DC820A0880206E2FB171" xlink:to="loc_pfe_TotalShareholderReturnUnitsTSRUsMember_C32B9432EF9E7329EEAB80206E353407" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_5697AE47247233936BFA80206E2E87B3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_D67EE26AED40D3A30AB680206E35B70F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_B82E890B3954A68E912D80206E35A0C6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_F249654A15BF70A576AD80206E369F12" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_A811384D0F8D1645C6C380206E3502B1" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_75BE01A16102C916304980206E36567B" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMatters" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C909E5F66505B18D4BBA802077F17983" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C909E5F66505B18D4BBA802077F17983" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_356F1DCE983AC519EED1802077F19132" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_77AD1F9806DB7483AB8F2677F89B10D5" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77AD1F9806DB7483AB8F2677F89B10D5" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpense" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpense_065F902521DBD2FD34292677F89BE9E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsInventory" xlink:label="loc_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsInventory_B9AB29AC87E98F3F53792677F89B64EB" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets_59AC92ABE78FB65EB0182677F89B4D53" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment_38453F3BD0AC8C7427B72677F89C0789" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits_04F7C47312673A5F8A9A2677F89C1629" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges_A923460AE7CECC7FB91F2677F89CB6D5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves" xlink:label="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves_06B16FE1D7957972FC782677F89C5CBF" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards" xlink:label="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards_55BFC59F6BA2CDBCD5062677F89C23E8" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments" xlink:label="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments_9143DC47B428C3E48F282677F89CEECD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsEquityMethodInvestments" xlink:label="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsEquityMethodInvestments_F53340F790F291EB87642677F89C056C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_E130016146CCCDB4202B2677F89DA34D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_899A58CCC5795F92470E2677F89D848A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_1287A00AD4D4045610F72677F89D0D32" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxAssetsAbstract_17E7BBD39B1D739309A22677F89B86D6" xlink:to="loc_us-gaap_DeferredTaxAssetsNet_437916EF628A95D35B112677F89D090F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract" xlink:label="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77AD1F9806DB7483AB8F2677F89B10D5" xlink:to="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_268ACE391854B41762122677F89EDB30" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts_2413DE7B28E4F8559A502677F89E5CFD" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets_5FBEA40F78C3369AD8E22677F89E4A6D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_EF95223E379483A891DA2677F89ED57E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits" xlink:label="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits_F889737DCFE3A94DDD1B2677F89EC5A3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings_159EED08DF670FEE79752677F89E5DD2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates_D029DAC1FD68968AA7082677F89F713F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilitiesOther" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesOther_863968EA4DDA7375E6E82677F89FAA60" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract_4FE8789FB5829C2E391E2677F89D4DBA" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_D1BDD3B5FDA106D49BE02677F89FB0E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_040B52F4CE2842F8E6D02677F89F6180" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_77AD1F9806DB7483AB8F2677F89B10D5" xlink:to="loc_us-gaap_DeferredTaxLiabilities_040B52F4CE2842F8E6D02677F89F6180" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_64DF42EB5BE69C3BA7EF80206C246FCF" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationTable" xlink:label="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_64DF42EB5BE69C3BA7EF80206C246FCF" xlink:to="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_5793F641007EAB4D6B3980206C251B4E" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_5793F641007EAB4D6B3980206C251B4E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_5793F641007EAB4D6B3980206C251B4E" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_C75689ACC71736EDB89480206C26DD59" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_C75689ACC71736EDB89480206C26DD59" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_59913AED4024573ED58380206C265333" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_436FC5146F92F06F6B4080206C264A0D" xlink:to="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_59913AED4024573ED58380206C265333" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExaminationLineItems" xlink:label="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationTable_66B87DC59BAF8E87755B80206C244143" xlink:to="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:to="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward_C9A73871C36A15407D7B80206C277EB3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="loc_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExaminationLineItems_1EAA3071ED46B081664580206C26DA69" xlink:to="loc_us-gaap_DeferredTaxLiabilities_E0B7658A2D7221359F4180206C27A076" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_A76E2040CBFD31DCC0F1802073237D97" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A76E2040CBFD31DCC0F1802073237D97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic_51673BD6C55D7665502180207324FC6B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A76E2040CBFD31DCC0F1802073237D97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign_4363461C1BD91161D3C5802073241B50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BF068360DB18F66C271A8020732432FB" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_A76E2040CBFD31DCC0F1802073237D97" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_BF068360DB18F66C271A8020732432FB" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C42709755FA51CE946E501C31363BC2A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_716DE165FC60B223F95D01C31366BD08" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C42709755FA51CE946E501C31363BC2A" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_716DE165FC60B223F95D01C31366BD08" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_500FDDA87890FF442DB001C313666A63" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_716DE165FC60B223F95D01C31366BD08" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_500FDDA87890FF442DB001C313666A63" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_500FDDA87890FF442DB001C313666A63" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_DC79503FD26D0D122B8A01C31367913C" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_DC79503FD26D0D122B8A01C31367913C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxLiabilitiesNetNoncurrentMember" xlink:label="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:to="loc_pfe_DeferredTaxLiabilitiesNetNoncurrentMember_196DBB0BF78A268E696A01C313676EE1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_2B6EAD576F94CA53877C01C31367DC3E" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:to="loc_pfe_IncomeTaxesPayableMember_2B6EAD576F94CA53877C01C31367DC3E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherTaxesPayableMember" xlink:label="loc_pfe_OtherTaxesPayableMember_B67930BB79466A953CE001C3136874CC" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_4B3456CBBFA74DB92A9C01C313677ED4" xlink:to="loc_pfe_OtherTaxesPayableMember_B67930BB79466A953CE001C3136874CC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_716DE165FC60B223F95D01C31366BD08" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UndistributedEarningsOfForeignSubsidiaries" xlink:label="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_UndistributedEarningsOfForeignSubsidiaries_43A552AB73926B2F694C01C31368C3F0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsExcludingInterest" xlink:label="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_pfe_UnrecognizedTaxBenefitsExcludingInterest_7F5AA19755C7D3E3676501C31369AD2A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits" xlink:label="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits_7436FB8E3476E037448F01C31369E33C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense_95BC64515A670A760B5701C313699068" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued_16F4E70F4DC581DCA15D01C313695B11" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual" xlink:label="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual_6180E387D1D0E53DD88B01C313697F5F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlements" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlements_AABEFE97135DAA79AA9701C31369A5FE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_B2F81229216C6DB04A0201C313688A7A" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_6EB55A24E88BBC77ADE001C3136AC53D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_7B0C6C5AA1AE0C625BA255F2180831C1" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DomesticIncomeTaxesAbstract" xlink:label="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_7B0C6C5AA1AE0C625BA255F2180831C1" xlink:to="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_C0579EDE8301F254536855F21809F972" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_F56571918F589B5ECCC655F21808DE50" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_5D5A6E6731FAE440BF2A55F2180939C7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_036000EE468F70A6D47455F21809B543" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_EAFF46A369B5AB01508555F218099C96" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations" xlink:label="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_946241C2405ECF133B7A55F21809390C" xlink:to="loc_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations_CB945F7D8F4A8DCE0ACA55F2180A9571" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectofTaxCutsandJobsActAbstract" xlink:label="loc_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:to="loc_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:to="loc_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit_8B1A345712004091871255F2180AE40F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:to="loc_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit_06B79B8F9F875B7156D155F2180A2F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_EffectofTaxCutsandJobsActAbstract_3B7A221423412403EFB755F2180A27A1" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit_35C60A66B53BF320D4D555F2180AFA46" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_InternationalIncomeTaxesAbstract" xlink:label="loc_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:to="loc_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_CurrentForeignTaxExpenseBenefit" xlink:label="loc_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:to="loc_us-gaap_CurrentForeignTaxExpenseBenefit_E921E9478E30C3B8079D55F2180BA43A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_DeferredForeignIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:to="loc_us-gaap_DeferredForeignIncomeTaxExpenseBenefit_3BFC9ECF47CC58B6B35355F2180B9622" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations" xlink:label="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_InternationalIncomeTaxesAbstract_963FD518DE23DA4850BA55F2180BA683" xlink:to="loc_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations_8EBEE46338CE07CD44C755F2180B4B00" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_DomesticIncomeTaxesAbstract_CAA24C73B9F7469FB4EC55F2180872D2" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_D294C9031C6E4184108455F2180B3073" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C9FAAFEFF59CE8DE03952F92B3A12DA0" xlink:type="locator" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesTable" xlink:label="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C9FAAFEFF59CE8DE03952F92B3A12DA0" xlink:to="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_BCEB8D2CB1C49F8539072F92B3A1436A" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_BCEB8D2CB1C49F8539072F92B3A1436A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3F3C1E323E14E5B5FB3C2F92B3A1444B" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_BCEB8D2CB1C49F8539072F92B3A1436A" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3F3C1E323E14E5B5FB3C2F92B3A1444B" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3F3C1E323E14E5B5FB3C2F92B3A1444B" xlink:to="loc_pfe_IncomeTaxesPayableMember_F3D8B348645E3AB370152F92B3A220D1" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesLineItems" xlink:label="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesTable_0451FEF5C605084C9F592F92B3A1BB20" xlink:to="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability_0956392840917876567D2F92B3A27AC1" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit_3E3BE4A3AA54A11A0EAF2F92B3A2B857" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability" xlink:label="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability_7836A72285453DDD74D22F92B3A314DE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_PaymentForRepatriationTax" xlink:label="loc_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_PaymentForRepatriationTax_616A03C0A97B27DB70552F92B3A314C5" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability_18BCCDADF63586D656CC2F92B3A3FC32" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability_94CC10B8679367E5E8DC2F92B3A30B01" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability" xlink:label="loc_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability_56775450B0682D5FAD832F92B3A3319C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount_04A5FF063449AA6BA8E22F92B3A3A386" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic_90665016EA4EE32E22202F92B3A4B214" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount_427260FA16599F49B04A2F92B3A4F3DF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses_7D5ABCFAC4A426B44DEB2F92B3A44C76" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActIncomeTaxBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActIncomeTaxBenefit_4D1461D7363F5CE1DF152FCCF02A35A2" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit_15B4113DC32725FE65762F92B3A41A76" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit_CE1B997220EC11822B342F92B3A4C2EB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit_9941DBC0307DFFBB7AE12F92B3A46A3C" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_428C3E696DF490FD6D512F92B3A55932" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit_13436ABFEC2A23319E0A2F92B3A51BD6" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit_0CD7F1A8ED9E9186C7FA2F92B3A5E6AC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit_E25BC2E94FC444B1BDD92F92B3A58C91" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit_411D221FD6EE469C69F62F92B3A58D2F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit_1476A6C0544FBDF8784F2F92B3A5DFFB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit" xlink:label="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit_C4D8B39CBC30217ABDAE2F92B3A5044D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings" xlink:label="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:type="locator" />
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings_D4AD297E59E9F53EE6C22F92B3A6B552" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:type="locator" />
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount_99EC718C0D5475E2C1802F92B3A6BA73" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_FeePayable" xlink:label="loc_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:type="locator" />
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_pfe_IncomeTaxesLineItems_19BAC806DE22997EB7E42F92B3A2C48F" xlink:to="loc_pfe_FeePayable_B6F299DFBA965A4AC8C72F92B3A6E07D" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_F69FEFFA64C6B07ABED716E82227DD0F" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_F69FEFFA64C6B07ABED716E82227DD0F" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1C8F35F8771F4976FD2516E82227AC52" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1C8F35F8771F4976FD2516E82227AC52" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition_9817F58B7CF6436903F416E822280D8B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition_D234480A22C99B10079E176007F59D5B" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions_0E88F205AB8324D3FD4316E822289658" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_2A0FD1B1A79331EB91C416E82228830C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_DF637DDB22BD7AE5CE1316E82228BA76" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_D79C190036A616BDA4BC16E82228496F" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation" xlink:label="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation_B2E8E97A8B01B3149FBA16E822296C9A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther" xlink:label="loc_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther_3F3E6D02A944B01C9C4216E822295459" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_6B57701EB10A586FA86E16E822291502" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_EBB49592AB9E7B8942FD16E8222755A2" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_6B57701EB10A586FA86E16E822291502" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_1E530D62CB7D064B783FE395F3DC2328" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyTable" xlink:label="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_1E530D62CB7D064B783FE395F3DC2328" xlink:to="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationAxis" xlink:label="loc_us-gaap_BalanceSheetLocationAxis_A3ADC9A76D07B1FB99FEE395F3DCB167" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:to="loc_us-gaap_BalanceSheetLocationAxis_A3ADC9A76D07B1FB99FEE395F3DCB167" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_BalanceSheetLocationDomain" xlink:label="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationAxis_A3ADC9A76D07B1FB99FEE395F3DCB167" xlink:to="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_IncomeTaxesPayableMember" xlink:label="loc_pfe_IncomeTaxesPayableMember_ECC70795F82E98E16EBDE395F3DD03BE" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_IncomeTaxesPayableMember_ECC70795F82E98E16EBDE395F3DD03BE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_CurrentTaxAssetsMember" xlink:label="loc_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_CurrentTaxAssetsMember_D577E3EA36CE131C89DEE487D3797D56" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember" xlink:label="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember_418B2AC6DA436608956CE395F3DD89FC" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_NoncurrentDeferredTaxLiabilitiesMember" xlink:label="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_NoncurrentDeferredTaxLiabilitiesMember_B66E005D4B5DF1B3C081E395F3DD0FDD" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherTaxesPayableMember" xlink:label="loc_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BalanceSheetLocationDomain_3B82178C3EC0ED383022E395F3DD6066" xlink:to="loc_pfe_OtherTaxesPayableMember_2A51FA529E4903E3D78BE395F3DE4EF5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxContingencyLineItems" xlink:label="loc_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyTable_9FA9541B9C54815B114BE395F3DC5DDA" xlink:to="loc_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxContingencyLineItems_53CB06223C95807DE639E395F3DEB81C" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_1F8AD589C4BAB8AD55FAE395F3DEAEF5" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTables" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_C4C6123D720041BC6FDF80207369C5D4" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4C6123D720041BC6FDF80207369C5D4" xlink:to="loc_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock_4BB44301EE304C9FB75280207369FFE8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4C6123D720041BC6FDF80207369C5D4" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_754D3C65AA5D7DD4AA7880207369C8F6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4C6123D720041BC6FDF80207369C5D4" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_D137E2B02CE02B896546802073695ACF" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4C6123D720041BC6FDF80207369C5D4" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_A23EF82D089113F6E1D380207369ADBE" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4C6123D720041BC6FDF80207369C5D4" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_723A4E35FE2790C9031D8020736A23FE" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock" xlink:label="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_C4C6123D720041BC6FDF80207369C5D4" xlink:to="loc_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock_74A228C3CBF19324274F8020736A64CA" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_6538BA7FD686D534250E16E8226423B8" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent_AD994A8D61B4ED7DD3D816E822642689" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_5459C346C23181B0429D16E82265DCB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements_A0084125880EC2D28F9D16E822654DA3" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness_759D3C9DAE408E3E4CB116E82265913A" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent_9E089461AB901BB08F7A16E82265A4E5" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_0C89DD38AFE2320307A616E82265DF01" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent" xlink:label="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent_D29673A318059D17C68B16E822662445" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_0778756F71B8679E64E416E822666302" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_552303FBC7B782F8773916E82264BD7A" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_0AE27AF4F65DFD16C53C16E822667E30" xlink:type="arc" />
  </link:presentationLink>
  <link:presentationLink xlink:role="http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails" xlink:type="extended">
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_301A03C7ED85956FF7AD0E488241B168" xlink:type="locator" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable" xlink:label="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_301A03C7ED85956FF7AD0E488241B168" xlink:to="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_21A7CD6A631577BFDBD30E488242A8E6" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:to="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_21A7CD6A631577BFDBD30E488242A8E6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_21A7CD6A631577BFDBD30E488242A8E6" xlink:to="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201802Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322" xlink:to="loc_us-gaap_AccountingStandardsUpdate201802Member_C124511A8AEE030CA4CA0E4882435F40" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_AccountingStandardsUpdate201601Member" xlink:label="loc_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfAdoptionMember_1CDE8D855533E1ECBB7C0E4882437322" xlink:to="loc_us-gaap_AccountingStandardsUpdate201601Member_E5B31F4CF36E8D11D8030E4882437EBC" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems" xlink:label="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable_325D4366E95761DA17EE0E4882426504" xlink:to="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTaxAbstract" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems_E5CFF2A6952D2BE851010E48824371B6" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:type="locator" />
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax_075AAB6C5F9E0358D6E70E488244F1BA" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:type="locator" />
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax_A734C0140B6F430D0C4A0E488244CA49" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:type="locator" />
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax_AD65FC8FB3A8EB0013690E488245CA83" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:type="locator" />
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax_14AA3531B0DD07A28B250E4882452092" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:type="locator" />
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax_4547D1E1B91D6886BDDD0E4882451298" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:type="locator" />
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_916A7488BB0C268F3EBE0E48824562D0" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:type="locator" />
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax_4D3A323227FE0189970C0E4882455931" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:type="locator" />
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax_0AE7DBD71420F9DC969F0E488246B84D" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:type="locator" />
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax_2BBA463A616D2423D5F30E4882466FB9" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:type="locator" />
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax_D8851F24ECB45ABAE7010E4882468F1E" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:type="locator" />
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax_E19AC53034A31228B11A0E4882469D07" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:type="locator" />
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax_E4B943A55DE106DE9A1C0E4882474EDB" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:type="locator" />
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax_6A38423D0E3814DED3FF0E4882470213" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:type="locator" />
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax_7FA2D6EB72DB90FEBD2E0E4882473A04" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:type="locator" />
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax_C11D8A33A6C7924FCE800E4882473BE3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax" xlink:label="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:type="locator" />
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax_BE8A6B50336FA1DD958F0E4882479339" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:type="locator" />
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax_FB9B86136363FBE306FE0E488247ECB3" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:type="locator" />
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax_D571AF0CDA21D69DF77B0E4882485A8E" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:type="locator" />
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax_F3AE45BED88240E9A2F70E4882481CC0" xlink:type="arc" />
    <link:loc xlink:href="pfe-20191231.xsd#pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax" xlink:label="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:type="locator" />
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax_1DA9AD7A2E6C1FBB5A270E48824807D7" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:type="locator" />
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect_82071C02F8880A3A8EA60E488248E57A" xlink:type="arc" />
    <link:loc xlink:href="http://xbrl.fasb.org/us-gaap/2019/elts/us-gaap-2019-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossTax" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:type="locator" />
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossTaxAbstract_2A42908224D24C7CD8D60E488244CE99" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossTax_CB06F408B873C7D2620F0E488249AA95" xlink:type="arc" />
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>adjdilutedeps-nongaap2019.jpg
<TEXT>
begin 644 adjdilutedeps-nongaap2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "* 5 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#U_%'_YK*/^&H/VEO\ HXKX^?\ AZ_BC_\ -91_Q+KC_P#HJ,'_ .&RM_\
M-?K_ $M3_B9#*_\ HF,?T_YF&'\K_P#,/Z_=]_\ K<^8OH__ '[D_P#B:/,7
MT?\ []R?_$U_DC?\-0?M+?\ 1Q7Q\_\ #U_%'_YK*/\ AJ#]I;_HXKX^?^'K
M^*/_ ,UE'_$NN/\ ^BHP?_ALK?\ S7Z_TM3_ (F0RO\ Z)C']/\ F88?RO\
M\P_K]WW_ .MSYB^C_P#?N3_XFCS%]'_[]R?_ !-?Y(W_  U!^TM_T<5\?/\
MP]?Q1_\ FLH_X:@_:6_Z.*^/G_AZ_BC_ /-91_Q+KC_^BHP?_ALK?_-?K_2U
M/^)D,K_Z)C']/^9AA_*__,/Z_=]_^MSYB^C_ /?N3_XFCS%]'_[]R?\ Q-?Y
M(W_#4'[2W_1Q7Q\_\/7\4?\ YK*/^&H/VEO^CBOCY_X>OXH__-91_P 2ZX__
M **C!_\ ALK?_-?K_2U/^)D,K_Z)C']/^9AA_*__ ##^OW??_K<^8OH__?N3
M_P")H\Q?1_\ OW)_\37^2-_PU!^TM_T<5\?/_#U_%'_YK*/^&H/VEO\ HXKX
M^?\ AZ_BC_\ -91_Q+KC_P#HJ,'_ .&RM_\ -?K_ $M3_B9#*_\ HF,?T_YF
M&'\K_P#,/Z_=]_\ K<^8OH__ '[D_P#B:/,7T?\ []R?_$U_DC?\-0?M+?\
M1Q7Q\_\ #U_%'_YK*/\ AJ#]I;_HXKX^?^'K^*/_ ,UE'_$NN/\ ^BHP?_AL
MK?\ S7Z_TM3_ (F0RO\ Z)C']/\ F88?RO\ \P_K]WW_ .MSYB^C_P#?N3_X
MFCS%]'_[]R?_ !-?Y(W_  U!^TM_T<5\?/\ P]?Q1_\ FLH_X:@_:6_Z.*^/
MG_AZ_BC_ /-91_Q+KC_^BHP?_ALK?_-?K_2U/^)D,K_Z)C']/^9AA_*__,/Z
M_=]_^MSYB^C_ /?N3_XFCS%]'_[]R?\ Q-?Y(W_#4'[2W_1Q7Q\_\/7\4?\
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M^@%%?S]>%_VI?V[/$OAF3X6:'+\;?$'Q\\>?L^?#3XD>,4U?X&?#3X,:_P#
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M$0!51%4!515 554!54!5   IQ 88(!'H0"/R-+10!_)+_P %XOV*O%O[>_\
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M6?%/BSQ/KVJ74MYJWB'Q)K.J:O?2>6D]XT-O;Q0^C44 %%%% !1110 4444
M!X!/IZ=:^,/&G[75W\/OC5X:^'WBWX+>/M!^&?BWXKZ9\"O#_P :=6O_  [I
MVE:W\3-6^&VJ_%"WN-#\$75W'XNU7X8VND:%K7A_5/B3!&MM8^*M'UC&@S^#
M=&U;QI9?9YS@XQG'&>F>V>G'XU^;NJ_LI_'OQ3^V'KOQW^(?C3X(_$GX7/:7
MO@3X:>"O$_@[XC1^(_@?\)/$G@^VT'XA:?\ #J.R\;CP!_PM3XE:L=4G\9_&
M#6/#5UXFO?!=[8_#/33I/@_2KBQUD T?AU_P4-\,^+M"U/Q'XD^#?Q:\*V.L
M? C1_P!I[X,Z3H^E67Q/\9_&;X(>(M;LO#NB:KH'@WX=S:QJ^B>-I=2UWP9-
MJO@K6,V^@Z3X_P#"VI:GXIBCMO&47A#C_B'_ ,%._!7@;X(?LY_&^/X5>+M2
MTCX^?LY:A^U2VC7_ (K\!>%+_P +_"_P_P"&/AWXH\0^'=/U'Q'J]IHGQ#^,
MWV7XE:+;^%_A7X-OKF^\5S:=KL\&LZ;96VGW.J=A^S/^QAXW^$&O>%]6^(WQ
M*\+^.$^#?[+VG?L>? \>&/!.I>%+BV^%-CJNBZC>^)_B&VI^)O$<6K>.]?M/
M!/PVTS4(/#8T7PY:R^$M3U:VAE/BB'2_#7S_ ..O^"7GB/7_ (+_ +-WPMLO
MB%\,/%5S\&?V,!^QQJ<WQ?\ A3J?CGPMHTD_A_P/H[?M"_!SPU;^,=*E\!?&
M'2)?![FQN+G4KZ2^TZ?1+#_A(]$?PZUQK !^P]E=QW]G:WL*7$<5W;P7427=
MK<V-TD=Q$DT:W-E>107=G<*DBB:UNH8;FWE#PSQ1RHZBR2 ,G/X L?R )_2L
M'PKH3>%_#/A[PV^LZWXB?0-#T?1'U_Q+>_VEXBUMM)TVUTYM8U[4?+B^WZSJ
M9MC?:K>^5']JO[BXGV)YFT5/&?@?PA\1- NO"OCGPYI'BOPY>RVD]WHNN645
M_IUQ-87,=Y9RRVTP,;O;74,5Q"Q&8Y8U=>10!^)'[7VJW&D_\%Q?^"8E[:+&
M9D_8]_X**%1/&[)\@^"4RDJ&C8D20J2-P^7J,,#7ZN_\+/\ $O\ <TO_ ,!)
MO_DNOQ7_ &C?@]\/?AM_P6W_ .":UA\+_ 'A[PDNK_L@?\%#'U*U\*Z-!IYU
M![./X/+9O=1VD8:X>!K^XC@:3<R?:&C4[651^OO_  CGB'_H!:O_ ."^Y_\
MC=?:\.87+:V$J2QE/"SJ*K:+KN'-RVZ<S6E_\C\VXLQN<X?-(T\!5QT*'U6E
M*V'C4=/VCG44G>$6N:RC=-Z63.K_ .%G^)?[FE_^ DW_ ,ET?\+/\2_W-+_\
M!)O_ )+KE/\ A'/$/_0"U?\ \%]S_P#&Z/\ A'/$/_0"U?\ \%]S_P#&Z^B^
MH9#_ ,^,N^^C_P#)>7Y]V?,?VGQ-_P!!&:_^ U_+^YZ?=Y:=7_PL_P 2_P!S
M2_\ P$F_^2Z/^%G^)?[FE_\ @)-_\EURG_".>(?^@%J__@ON?_C='_".>(?^
M@%J__@ON?_C='U#(?^?&7??1_P#DO+\^[#^T^)O^@C-?_ :_E_<]/N\M.K_X
M6?XE_N:7_P" DW_R71_PL_Q+_<TO_P !)O\ Y+KE/^$<\0_] +5__!?<_P#Q
MNC_A'/$/_0"U?_P7W/\ \;H^H9#_ ,^,N^^C_P#)>7Y]V']I\3?]!&:_^ U_
M+^YZ?=Y:=7_PL_Q+_<TO_P !)O\ Y+H_X6?XE_N:7_X"3?\ R77*?\(YXA_Z
M 6K_ /@ON?\ XW1_PCGB'_H!:O\ ^"^Y_P#C='U#(?\ GQEWWT?_ )+R_/NP
M_M/B;_H(S7_P&OY?W/3[O+3J_P#A9_B7^YI?_@)-_P#)='_"S_$O]S2__ 2;
M_P"2ZY3_ (1SQ#_T M7_ /!?<_\ QNC_ (1SQ#_T M7_ /!?<_\ QNCZAD/_
M #XR[[Z/_P EY?GW8?VGQ-_T$9K_ . U_+^YZ?=Y:=7_ ,+/\2_W-+_\!)O_
M )+H_P"%G^)?[FE_^ DW_P EURG_  CGB'_H!:O_ ."^Y_\ C='_  CGB'_H
M!:O_ ."^Y_\ C='U#(?^?&7??1_^2\OS[L/[3XF_Z",U_P# :_E_<]/N\M.K
M_P"%G^)?[FE_^ DW_P ET?\ "S_$O]S2_P#P$F_^2ZY3_A'/$/\ T M7_P#!
M?<__ !NC_A'/$/\ T M7_P#!?<__ !NCZAD/_/C+OOH__)>7Y]V']I\3?]!&
M:_\ @-?R_N>GW>6G5_\ "S_$O]S2_P#P$F_^2Z/^%G^)?[FE_P#@)-_\EURG
M_".>(?\ H!:O_P""^Y_^-T?\(YXA_P"@%J__ (+[G_XW1]0R'_GQEWWT?_DO
M+\^[#^T^)O\ H(S7_P !K^7]ST^[RTZO_A9_B7^YI?\ X"3?_)='_"S_ !+_
M '-+_P# 2;_Y+KE/^$<\0_\ 0"U?_P %]S_\;H_X1SQ#_P! +5__  7W/_QN
MCZAD/_/C+OOH_P#R7E^?=A_:?$W_ $$9K_X#7\O[GI]WEIU?_"S_ !+_ '-+
M_P# 2;_Y+H_X6?XE_N:7_P" DW_R77*?\(YXA_Z 6K_^"^Y_^-T?\(YXA_Z
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M'U]\4/'_ ,?/CQ\&/%WPZ^),7PK^+_Q>UJZ\&6WPRM_$B^&OB':^+_&'PO\
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MAC_YO:/^'W_['G_0N?'7_P (?PQ_\WM'_$MGCS_T:OB__P -K_\ DP_XF9\
MO^CK<(?^''T_Z=^?]75_V)HK\=O^'W_['G_0N?'7_P (?PQ_\WM'_#[_ /8\
M_P"A<^.O_A#^&/\ YO:/^);/'G_HU?%__AM?_P F'_$S/@%_T=;A#_PX^G_3
MOS_JZO\ L317X[?\/O\ ]CS_ *%SXZ_^$/X8_P#F]H_X??\ ['G_ $+GQU_\
M(?PQ_P#-[1_Q+9X\_P#1J^+_ /PVO_Y,/^)F? +_ *.MPA_X<?3_ *=^?]75
M_P!B:*_';_A]_P#L>?\ 0N?'7_PA_#'_ ,WM'_#[_P#8\_Z%SXZ_^$/X8_\
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MY]_XIP<??]'$X0_\(,Y\O^G/F_N\S^$>BO[N/^&)OV0/^C8O@/\ ^&L\'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
3%%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>albertbourlasignatureq42019.jpg
<TEXT>
begin 644 albertbourlasignatureq42019.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!X17AI9@  34T *@    @ !@$Q  (
M   1    5@,!  4    !    : ,#  $    !     %$0  $    ! 0   %$1
M  0    !   .Q%$2  0    !   .Q     !-:6-R;W-O9G0@3V9F:6-E
M 8:@  "QC__; $, " 8&!P8%" <'!PD)" H,% T,"PL,&1(3#Q0=&A\>'1H<
M'" D+B<@(BPC'!PH-RDL,#$T-#0?)SD].#(\+C,T,O_; $,!"0D)# L,& T-
M&#(A'"$R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,O_  !$( "8 B@,!(@ "$0$#$0'_Q  ?   !!0$! 0$! 0
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/NTN4=%8!L,,CBBBD!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>biopharmrevincrease2018-2019.jpg
<TEXT>
begin 644 biopharmrevincrease2018-2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #$ JP# 2(  A$! Q$!_\0
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M/B5\&O%_@'X:_MN>$?"47BR?X9#_ (*Q?LS>,OC-X@^*&E_$'XVS^(/@7<_
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M^S_K_AU]XM%)D>H_,49'J/S% 6?9_P!?\.OO%HI,CU'YBC(]1^8H"S[/^O\
MAU]XM%)D>H_,49'J/S% K/M_7]-?>+1110 4444 %%%% !113=RCJR_F/\:
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MJ,DNH:YXC\1:W?:EK_B'6KZ1[O5M;U._U"X;S;E@/0Z "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "@C/6OP _P""AOQC^+G@K]I;6-"\
M'_%#X@^%=$B\%^"[J/1_#OB_7=&TR.ZNK?4FNKE+'3[V"V6>X,:&>41AY2B%
MV.T8^'_^&D/V@_\ HN7Q=_\ #B>*O_EG7]7\*?11X@XKX:R+B7#\6Y+A*&>9
M7@LTI8:M@L=.KAZ>-H4Z\:52<'R2G"-2TI0]UN+MHT?R-Q9]+CAWA/B;/N&<
M1PCG6+KY#FN-RJKBJ.-P,*6(J8*O*A*K3A-.<85'!RC&7O)-)ZIW_K>"J.@
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MO_D5^)K_ ,1.\0/^BLSG_P *I>7EY?B^Y]7_ /#*/AO_ **_^U%_XDS\7_\
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M*C2C)48R5-5)5)I<U23?XWXC>(^;>)F;X+.<XR3@K(<1@<LIY73PO O!?#O
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M1'9>B_(****!A1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MLO'3\6_F:6D'3\6_F:6O\+C_ 'HCLO1?D%%%% PHHHH **** "BBB@ HHHH
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MG5ZW_P!B)X#_ /2;5:_/ZO\ 8_P=_P"35^'W_9)9%_ZKZ!_BUXR_\G7\1/\
MLK\]_P#4^L%%%%?I)^:!1110 5L>'O\ D8-!_P"P]H7_ *>+&L>MCP]_R,&@
M_P#8>T+_ -/%C6&*_P!VK_\ 7J?_ *2S?"_[SA_^O]'_ -.1/[+QT_%OYFEI
M!T_%OYFEK_"X_P!Z([+T7Y!1110,**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ I#T_%?YBEI#T_%?YBG'=>J_,#^.CX
MA_\ )0?'W_8]>-/_ %*=7KCZ[#XA_P#)0?'W_8]>-/\ U*=7KCZ_W*RW_D78
M#_L"PO\ Z8IG^#N9_P#(RQ__ &&8G_T],****[3A"BBB@ K[I_X)P?\ )VW@
M'_L ?$'_ -1.\KX6K[I_X)P?\G;> ?\ L ?$'_U$[ROS_P 6/^38>(?_ &1?
M$O\ ZI\6?HOA#_R=3PY_[+?A;_U=X$_I?HHHK_&<_P!JPHHHH **** "BBB@
M HHHH *BF>%(97N&C6!8W:9IBJQ+$JDR-(SD((P@)<N0H4$L0 34M9'B#0='
M\4Z%K/AGQ#I]OJV@^(=*U'0];TN[4O:ZEI&KV4^G:GI]R@*EK>]L;F>VG4,I
M,4K@,IP0 ?E+XJN?^":6CMX#UM?B[XU\%^#_ (R6.K^,O#OASX1?'3]JCP7\
M%-9\)-XEL?"E[\0O$?@GX2>*]-^&/@3X577BC5K#3H_B!XBTSP;\--9U#4[?
MRM;U"._$DWZE^#O!OA/P!X:TKPAX'\.Z/X5\+Z);FTTK0M!T^WTS3+&$R22R
MB&TMHXT$DUQ)-<74[AKBZNII[JZEFN9I97_.+2?^"4?P*TWP-XT\"W7CCXG:
M]!X[\)?#7X1:QXBUJ#X5/XKLOV=OA:-:@T3X!:!JVF_##2XM(\+:UIOB+7M+
M\9>.TLI_C-XFM]7N;NZ^(T.JV>AZAI'Z=65G:Z=9VMA8V\-I96-O#:6=I;QI
M#;VMK;QK#;VUO"@5(H((42*&) $CC144  4 6:*** "BBB@#^;C_ (*9_P#)
MU>M_]B)X#_\ 2;5:_/ZOT!_X*9_\G5ZW_P!B)X#_ /2;5:_/ZO\ 8_P=_P"3
M5^'W_9)9%_ZKZ!_BUXR_\G7\1/\ LK\]_P#4^L%%%%?I)^:!1110 5L>'O\
MD8-!_P"P]H7_ *>+&L>MCP]_R,&@_P#8>T+_ -/%C6&*_P!VK_\ 7J?_ *2S
M?"_[SA_^O]'_ -.1/[+QT_%OYFEI!T_%OYFEK_"X_P!Z([+T7Y!1110,****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I
M#T_%?YBEI#T_%?YBG'=>J_,#^.CXA_\ )0?'W_8]>-/_ %*=7KCZ[#XA_P#)
M0?'W_8]>-/\ U*=7KCZ_W*RW_D78#_L"PO\ Z8IG^#N9_P#(RQ__ &&8G_T]
M,****[3A"BBB@ K[I_X)P?\ )VW@'_L ?$'_ -1.\KX6K[I_X)P?\G;> ?\
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M +Z'^-&]/[R_]]#_ !H =13=Z?WE_P"^A_C1O3^\O_?0_P : '44W>G]Y?\
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M]N;B]O+J?]L*WDGNKN[F>XNKF>1OA<6DFN+B62:9R<O([,>2:@_XAT/V<_\
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ME^SFP)_X;?\ ^"I0^9U_Y/ MC]UV7/\ R2T=<9]NF3UIW_$.A^SG_P!'P?\
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MXM\.Q>*_^$JT[7_ G_!,#]I'_@GWXMN?"V@76F6VF7>F3Z]\6_"?Q'T"[O\
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M\5E)?W^I>#7NK*73I;E/[%&F07,L<]O]GA^GZ "BBB@ HHHH **** "BBB@
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M8^#O#(\17/BWQ<UC(+F5[S4O'?B"+PQ/KUU+';Q)8>!O"=A:VZO9WMU?>P4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)"0H(
M.#OC'X-(BD?B"13Z0@'@C/(/X@@@_@0#0!^%O_!/?Q'^UI\6_"'@7XS>+9OV
MNO%.L>(-,^,&I:;XI^)7Q>_9HLOV4O$NO6FI^/\ 0O!D&H?#[X?I/\>-%\'7
M%W;:+;:=Y/@QM:T>2"WU/4[6ZBMIWO/4OA'_ ,%*OB)^T+X3^&VI_"[X-^!-
M%U_XV_'77?V?/AY9^-/BE=ZMI6A^*/A!\'?&7Q3^/OB?QQ?^ /#&OD^&[/4?
M ^M>&O@5:Z&S7WQH\+7/A3XSQ77AOX=>,](N8OJCP]_P3N_9"\)3WC^&?A1-
MH5E?6OBZPN-!TOXC?%RT\)_8?'=EKFG^*[*'P=%\0%\)VMIK%MXDUL36UKHL
M$%O-J$UW9):W:PSQ>@:W^QQ^S'KUEJMA=?!GP;8V^K7'PWO9CX>MK[PG<V.I
M_"'PW<^"_AMK6@WOA6_T6^\,:]X0\$7<O@?2=>\-7.DZRG@A8/!UQ?W'AJTM
M-+@ /S;^'G[<W[3VC?'?XNR?$;P7\.]6^$D?[5G[&?[/&H:#HOQ4;Q-J?PL\
M5?M&?!7X+:)K%A\+]8T3X>:?HGQ \%>%/C'XO;Q#K6M^+=3T?7=9T[Q!XCM;
M/3O#-_X3@T'4,K6/^"M_C_1+O7K6P^"7@3Q\=>^'_@3XD?!W5O"GC/XM:)X
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
$B@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>biopharmrevincrease2018v2017.jpg
<TEXT>
begin 644 biopharmrevincrease2018v2017.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #$ JP# 2(  A$! Q$!_\0
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MC_\ 6"">_ ZGCTH 6B@$$9!R#R".A'K10 4444 %%%% !1110 4444 %%%%
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M^#*^+Q56-*E!5,3BJ];$UYIU:]6I5E*;_)[_ (=T?M!?])/OVT/_  :>%/\
MY'H_X=T?M!?])/OVT/\ P:>%/_D>NL\ ?\% =;\;_M2_'/X1R_#3P7H/P=_9
M^M_&4/Q.\<ZI\8]*L_C#\/$\"/XK-U\1?'?P,U#P_87=A\(/&R^'8G\ >(/#
M_BCQ%X@U'0]:\)>-[W0HO"_BMY?#:7O_  4@TX^+OA-X*T;X6Z?+XG\?^!/@
MW\3/$'A7Q9\</A9\-?&&D>&OC]XLU?0_ACX;\"^'?'5YI#?%/XM3>'_#NO\
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M^,KC3YK.Y_H%48&/=NV.K$_C[GN><#.* '4444 %%%% '\W'_!3/_DZO6_\
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M/_LB^)?_ %3XL_1?"'_DZGAS_P!EOPM_ZN\"?TOT445_C.?[5A1110 4444
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M]<?78?$/_DH/C[_L>O&G_J4ZO7'U_N5EO_(NP'_8%A?_ $Q3/\'<S_Y&6/\
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MG]Y?^^A_C7^,Y_M6.HIN]/[R_P#?0_QI00>A!^AS_*@!:*** "BBB@ HHHH
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M 'XS'_@CDX_YRH?\%E.H_P";Y#W('_1+:^??V3?^"8OB/XX_LQ_ #XQ^+/\
M@J9_P6!B\4?%#X0?#_QUXBCT7]MQK31UUKQ-X:T_5M3&EVI^&5PUKI_VRYF-
MG;M<7#06YCB:>8H97_H;K,T71-&\-Z1IN@>'M)TS0="T:QMM,T?1=&L+32])
MTK3;*)8+/3]-TVQAM[*QLK6!$AMK2U@BMX(E6.*-$4* #\>O^'.+_P#25#_@
MLI_XG(?_ )UM'_#G%_\ I*A_P64_\3D/_P ZVOV8HH _&?\ X<XO_P!)4/\
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M=7=W,]Q=7,\C?"XM)-<7$LDTSDY>1V8\DU!_Q#H?LY_]'P?\%2O_ !+^V_\
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M= \._8O"=I_8_P#:5EHWV*7[/JVJZS>?:7^W>7%],T4 %%%% !1110 4444
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M=V,/@K0HKOQW3_\ @D7\8+KPCX9^&>O?%GX?V7A9?A/\%_!/BGQ;X=B\5_\
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M#VFFP\/Z6 ?4M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU+6_BGJ&M:M\0M2N?A_?>++OX?M<>+=6\1:YJNL;?"RQW&IZK?:@L<=Y.\U
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MT :CJ]VOAWP1X7^)/P^\'^,?"_@G0AIWA/PWK.AVTVAZ-812WD-R ?%VH?\
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M]. Y .,9 ..N,]OPI:  !@# '  Z >E% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>franksignatureq42019.jpg
<TEXT>
begin 644 franksignatureq42019.jpg
M_]C_X  02D9)1@ ! 0$ R #(  #_VP!#  (! 0(! 0(" @(" @(" P4# P,#
M P8$! ,%!P8'!P<&!P<("0L)" @*" <'"@T*"@L,# P,!PD.#PT,#@L,# S_
MVP!# 0(" @,# P8# P8," <(# P,# P,# P,# P,# P,# P,# P,# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# S_P  1" !S BD# 2(  A$! Q$!_\0
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MQ#^TS^TQX9_95^".M:Q%K5KJQG\6:AHFK):?:YH;&XN6T<RJZLHBC5+FX.0
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MM[%-!Y,WVK[,C7#2)@8D:8R,_ .YFSS7K]%%;Q22LC-L****8!1110 4444
M%%(6"CD@=J6@ HHHH ^&O^"TG_!3;5?V+O &G>"?AO=V*?%WQA&+FVNKF*.Y
MM_"^G!RK:A/"YP^]T:&)#@,WF,3MA8'Z(_8(^.^J_M-?L8_#7QUKZ64?B+Q%
MH-O-K*V43Q6HOU7R[KR5<EA%YZ2;,DG;MYK\=/A9X+UW_@KC_P % OVF_B#;
MZI'XAT+PSH>M7&AQ),9+218Q/8>&H(FW2!;:7[)=7Q,)VR2-*V-LS*WZ-_\
M!O\ ?$^V^*O_  2H^'%Y D<36<VIVLD<<:1HH_M&YDB("DKAH)(7SU^?G#9
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M9[H>)?V?/VP/AY!9EQ+=:]\'M4GMU*G'^LL!= @GHP^4^M?9E?DE_P $Z/\
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M^UJ)5< /L!49A8UZK\"_^"X=]\(OBW;?"/\ ;&^'US\ ?B(\D5G9^*(Q)<^
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M^(?%WQ3T/X?QS2QW2Z+9>/=1\*S6*,JLT)BT:UD5MO*D374QSN^8_*P^QO\
M@@9^T'J_Q]_X)N>%XM>6V.J^ KRY\(&6"82K<6UH5-DY[AOL<ELK9Y9D9@ &
M K[/K>E3]I!3E)O\#*?NMJQ^%'[8/_!#7XF_L_?LK^+OBO\ $+XJZ-\1=:T-
MX=4U6TNK74;]VB,T$<CK?75Q+,#%&TKE_+!<1$L4\QBGZ,?\$5/VEKKXS?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ ID[%('8<$*2*** 'T444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
7 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>globe.jpg
<TEXT>
begin 644 globe.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
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M:5HQ\SJ_&NEG4= D>-<RVI\U?<#[P_+G\*\LKW,C(P>0:\E\4Z(=%U=T1?\
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MF;9G_OK%<M6=;VD93AMV.^C3PWLITZ53XN_0K:8(_#?@I;@J-ZP><P(^\[=
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::M2BBO*E*4G>3U/>A"-./+%604445)9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>kpmgsignatureq42019.jpg
<TEXT>
begin 644 kpmgsignatureq42019.jpg
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L !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>lorettasignatureq42019.jpg
<TEXT>
begin 644 lorettasignatureq42019.jpg
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HIK-C'!.34%Q<Q6T,EQ-(D<$2EI)'. @')
M)/IQ0!9HKA[WXI^$++4K33UU>*\N+N0(@L%:YQG=MSY8;))4* N6RR\8YKG[
M[XD^,Q9QWUA\.]3>V;RHW2Y1EECF!+2@(H+,A3:%DVJ V<@_=H ]8HKE/ OC
M2T\;>'8M2C\B"Y)/GV27 E>W^=E7?P"-P7(R!GM75T %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 44QVV@<@>YI-_/4$9QD>M $E%-5MV>,8.*=0 4444
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MT'AWPO%:ZIKLMP+=UD=A'!+O0*AZ!R=S X<;2O/I3_#GPS.J06&I^/+>SO\
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M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%-<L!\HS]:
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MYID3+EVP"-HPISQZ($ &.:-@SF@#G--\9Z/J]W:6MH;QY+R$SVYDT^XC26,
M$L'>,*5PR\YQ\P'<5T:MN (!Z9YH" >M*%"]* %HHHH **** "BBB@ HHHH
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MGG'EF(!$4[@%CQM< ;2#C/&17LGPI\>7WCG2;A[W39(&LDAB:[+[ENI"&WD
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MJ6XRV,X;:&(Q0!U&XY )'T]*S=1U[3=)ADFU&^M[>*+RO-+MS&)'V(S?W5+
MC<>/E)SP<>)6VJ_$GXA37A?0;I-'ND1[$?:#91VDC'=#<"4 /.$QN*C()P<
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M^O0>,]3O=-T"P+S)ILM]A#+"4CVX&02P\PD1Y;D[2>M &CXH^*VN>/'MM!\
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M\*R1,D(.X2(?E<EAC\>P!R/@M=2^)&MZQK^K(Z^&)VBBMK&2W0)>)"[-'O\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;8$49! 4$<G@8Y]<TKP;I.GZM+K,L)O-:EV^;J5TB&9MJE1MV@*GRG;\BKD
M9R>: /(_AO\ #;7==)\0>+-4O7L;W[/.+5KGS?[05=KQF<'<&CQ@!6^;K]W
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH *0C-+10 W8N0>XZ4JJ%'%+10
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
B1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>marketgrowth.jpg
<TEXT>
begin 644 marketgrowth.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
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M1@R,58="#@BNE\*:!I^JVMY=:A)(L5MC[AQ@8))/Y5=_L_P+_P!!*;_OIO\
MXFN>6(BI.-F[=D=D,'.4%/F2OW=CE%OKPN/]+GZ_\]#74?$7_C^L?^N!_G4'
MB70-+T[3K*_TR65XYWP"YR&!&0>@J?XB_P#']8_]<#_.L5.,ZL)1\S=TYTJ%
M6,W_ "E/P%_R,R?]<G_E6?K5[=)K=\JW4P47#@ 2'CYC6AX"_P"1F3_KD_\
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M[2\']-M<K6-"?/2C+R-\53]G6E'S"BBNQ\*Z=I)\.7NJ:E:?:/)E(/?"A5/
M_$TZM14X\S0J%%UI\J=CCJL:?_R$K7_KLG\Q75_VSX+_ .@-)_WP/_BJ7Q+I
MFG65UHUQ86P@$\@) [C*D?SK+ZQ=\KBU<Z?JEHN<9IVMMZE+X@_\C&O_ %[K
M_,U+\.O^0Y/_ ->Y_P#0EJ+X@_\ (QK_ ->Z_P S4OPZ_P"0Y/\ ]>Y_]"6L
M7_N?R-U_R,?F6_"O_("\0?1O_06KB*[?PK_R O$'T;_T%JXBMJ'\2?R_(Y\5
M_!I>C_,[/Q!_R).A_5/_ $$TSXB_\?UC_P!<#_.G^(/^1)T/ZI_Z":9\1?\
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MZA+O9-AWI(1C(/\ =]JR<W]7]GRN]NQNJ<?K?MN>-KWW17\*_P#("\0?1O\
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C\K#YYF'S-_@/:M2BBO*E*4G>3U/>A"-./+%604445)9__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>microscope.jpg
<TEXT>
begin 644 microscope.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
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MYD,DLARQ/\OI4-?08?#1HQ\SY#&8R6)EVBMD%%%%=1Q!1110 JJSL%4%F)P
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M*\JKU,OH[U'\CP<WQ#THKU?Z!1117K'@A1110 5J>'M%DUS4TMURL2_-,_\
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M7_OS_P#94?7*'\WYA_9V*_E_%?YG$45)<P_9KF6#>K^6Y7<O0X.,BHZZT[G
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+X\L59!1114EG_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>netcashflowfromops2019.jpg
<TEXT>
begin 644 netcashflowfromops2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "* 5 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#U_%'_YK*/^&H/VEO\ HXKX^?\ AZ_BC_\ -91_Q+KC_P#HJ,'_ .&RM_\
M-?K_ $M3_B9#*_\ HF,?T_YF&'\K_P#,/Z_=]_\ K<^8OH__ '[D_P#B:/,7
MT?\ []R?_$U_DC?\-0?M+?\ 1Q7Q\_\ #U_%'_YK*/\ AJ#]I;_HXKX^?^'K
M^*/_ ,UE'_$NN/\ ^BHP?_ALK?\ S7Z_TM3_ (F0RO\ Z)C']/\ F88?RO\
M\P_K]WW_ .MSYB^C_P#?N3_XFCS%]'_[]R?_ !-?Y(W_  U!^TM_T<5\?/\
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M&'\K_P#,/Z_=]_\ K<^8OH__ '[D_P#B:/,7T?\ []R?_$U_DC?\-0?M+?\
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ME^!-(U3Q3\,[+XF0?#+7XM+\(:)I/A_3M*U7PA=:-9:?86\=MI\;JTC?3]%
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M(WXE?_%4?\0JG[3'_1TOP'_\(WXE?_%5_<=17O\ _$;?$+_H:83_ ,->7_\
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MXF_Z",U_\!K^7]ST^[RTZO\ X6?XE_N:7_X"3?\ R71_PL_Q+_<TO_P$F_\
MDNN4_P"$<\0_] +5_P#P7W/_ ,;H_P"$<\0_] +5_P#P7W/_ ,;H^H9#_P ^
M,N^^C_\ )>7Y]V']I\3?]!&:_P#@-?R_N>GW>6G5_P#"S_$O]S2__ 2;_P"2
MZ/\ A9_B7^YI?_@)-_\ )=<I_P (YXA_Z 6K_P#@ON?_ (W1_P (YXA_Z 6K
M_P#@ON?_ (W1]0R'_GQEWWT?_DO+\^[#^T^)O^@C-?\ P&OY?W/3[O+3J_\
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M9#_SXR[[Z/\ \EY?GW8?VGQ-_P!!&:_^ U_+^YZ?=Y:=7_PL_P 2_P!S2_\
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MYHKMW,%O)')NA@:1,.UQ( -P^8;3D<9%>8?\(YXA_P"@%J__ (+[G_XW78>
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M^.O_ (0_AC_YO:/^'W_['G_0N?'7_P (?PQ_\WM'_$MGCS_T:OB__P -K_\
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M^$/X8_\ F]H_XEL\>?\ HU?%_P#X;7_\F'_$S/@%_P!'6X0_\./I_P!._/\
MJZO^Q-%?CM_P^_\ V//^A<^.O_A#^&/_ )O:/^'W_P"QY_T+GQU_\(?PQ_\
M-[1_Q+9X\_\ 1J^+_P#PVO\ ^3#_ (F9\ O^CK<(?^''T_Z=^?\ 5U?]B:*_
M';_A]_\ L>?]"Y\=?_"'\,?_ #>T?\/O_P!CS_H7/CK_ .$/X8_^;VC_ (EL
M\>?^C5\7_P#AM?\ \F'_ !,SX!?]'6X0_P##CZ?]._/^KJ_[$T5^.W_#[_\
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MS,LL#36=_9R2P2>3<P3VES%N6>TO+>XL[J*&ZMYH8P#K**** "BBB@ HHHH
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M_A?XNCCNIXKK2_%/QVT'P!I/B33[)M0TS7M T+7O#>I)<:+K5R)/UI"J,D
MDY)  R?4XZGW-&!QP..!P.!TP/3CCB@ 48 '7U/ R3R2<8&2<DX &3Q7)^-]
M+\6ZQX>NK#P3XJLO!OB&6:S>UU^_\,P^+K:UABNHY+R)]#N-6T2*Y:[M5EMD
ME.H1&U>07"I,8_*;K:* /XH_^"]&@?$?0O\ @H!_P3LC^(?Q!TKQ]//\ ?VR
M#IL^E^ [?P,NGI%JGPF-VDT-OXD\1+?M=&6V*.7M5MEMF 65KAS'\!U_33^V
MC\/O OQ,_P""WG_!,3PO\1/!WACQSX;F_9&_X*$7<V@^+=$TWQ!I$EU;7/P,
M%M=-IVJ6]S:M<VQF=K:?RC+ [&2%T<;A^I__  Q-^R!_T;%\!_\ PUG@[_Y5
M5_=/T<OI8\,^"O .(X0SCA7/<YQ5;B#'YQ'&9;B<!2PZI8S"Y?AXT7#$SC4]
MI!X.4I-+E:FDM4[_ ,"_25^B#Q3XX^(M'C3)N+<@R3"4^&\LR1X/,\+F-;$N
MM@<7F6(G74\+3E2]E../C&$;\R=.5]T?PCT5_=Q_PQ-^R!_T;%\!_P#PUG@[
M_P"55'_#$W[('_1L7P'_ /#6>#O_ )55^^_\5#N!/^B XM_\+<G_ /EW]6?E
M?^??^*<''W_1Q.$/_"#.?+_ISYO[O,_A'HK^[C_AB;]D#_HV+X#_ /AK/!W_
M ,JJ/^&)OV0/^C8O@/\ ^&L\'?\ RJH_XJ'<"?\ 1 <6_P#A;D__ ,N_JS\K
MG_%.#C[_ *.)PA_X09SY?].?-_=YG\(]%?W<?\,3?L@?]&Q? ?\ \-9X._\
ME51_PQ-^R!_T;%\!_P#PUG@[_P"55'_%0[@3_H@.+?\ PMR?_P"7?U9^5S_B
MG!Q]_P!'$X0_\(,Y\O\ ISYO[O,_A'HK^[C_ (8F_9 _Z-B^ _\ X:SP=_\
M*JC_ (8F_9 _Z-B^ _\ X:SP=_\ *JC_ (J'<"?]$!Q;_P"%N3__ "[^K/RN
M?\4X./O^CB<(?^$&<^7_ $Y\W]WF?PCT5_=Q_P ,3?L@?]&Q? ?_ ,-9X._^
M55'_  Q-^R!_T;%\!_\ PUG@[_Y54?\ %0[@3_H@.+?_  MR?_Y=_5GY7/\
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MO,_A'HK^[C_AB;]D#_HV+X#_ /AK/!W_ ,JJ/^&)OV0/^C8O@/\ ^&L\'?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>peergroupgraph2019.jpg
<TEXT>
begin 644 peergroupgraph2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" '@ F8# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M7_RQH_X1O2_2^_\ !QK7_P L:WJ* ."UG1K.VU'PM##)J,<=]KMQ:W:+K.M
M3P+X<U^[6*0?VCR@N;6WG X_>0QG. 0=_P#X1O2_2^_\'&M?_+&JNO\ _(5\
M%_\ 8R77_J*>)JZB@#!_X1O2_2^_\'&M?_+&C_A&]+]+[_P<:U_\L:WJ* ,'
M_A&]+]+[_P '&M?_ "QH_P"$;TOTOO\ P<:U_P#+&MZB@#!_X1O2_2^_\'&M
M?_+&C_A&]+]+[_P<:U_\L:WJ* ,'_A&]+]+[_P '&M?_ "QH_P"$;TOTOO\
MP<:U_P#+&MZB@#!_X1O2_2^_\'&M?_+&L#1=%L[F^\41S/J,D=EK\=K:HVLZ
MT5@MSX>T"Z,4?_$QX0W%U<3$9/[R9R, @#O:YCP__P A'QE_V,\?_J+>&: +
M/_"-Z7Z7W_@XUK_Y8T?\(WI?I??^#C6O_EC6]10!@_\ "-Z7Z7W_ (.-:_\
MEC1_PC>E^E]_X.-:_P#EC6]10!F6>D65A*TUN+D.R&,^=?ZA=+M+*QQ'=W<\
M8;*CYU0.!D!@"0=.BB@ HHHH **** "BBB@ HHHH **** "BBB@#\;_^#@G_
M )0U_P#!0+_LA-U_ZF/A&OU=^'7_ "(7@O\ [%+PQ_Z8=.K\HO\ @X)_Y0U_
M\% O^R$W7_J8^$:_5WX=?\B%X+_[%+PQ_P"F'3J .SHHHH *1NA^A_E2TC=#
M]#_*@#E/"'_'KK?_ &-GBC_T\7-=97)^$/\ CUUO_L;/%'_IXN:ZR@ HHHH
M**** "BBB@ HHHH Y/QK_P @%O\ L+>&O_4FT:NLKD_&O_(!;_L+>&O_ %)M
M&KK* "BBB@ HHHH **** "BBB@ KEK?_ )';5?\ L5O#_P#Z=O$U=37+6_\
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M.1_PB7ACDZY>J<_V#IV>!X>;OT.>>N!TH ]+HK&\_P 0_P#0+T;_ ,'M]_\
M,Y1Y_B'_ *!>C?\ @]OO_F<H V:1NA^A_E6/Y_B'_H%Z-_X/;[_YG*0S^(<'
M_B5Z-T/_ #';[_YG* ,WPA_QZZW_ -C9XH_]/%S765Y[X3FUT6VL^7INDL/^
M$I\2EB^M7B$.=6N-ZJ%T"3<BMD*Y*EU 8QH3M'4^?XA_Z!>C?^#V^_\ F<H
MV:*QO/\ $/\ T"]&_P#![??_ #.4>?XA_P"@7HW_ (/;[_YG* -FBL;S_$/_
M $"]&_\ ![??_,Y1Y_B'_H%Z-_X/;[_YG* -FBL;S_$/_0+T;_P>WW_S.4>?
MXA_Z!>C?^#V^_P#F<H V:*QO/\0_] O1O_![??\ S.4>?XA_Z!>C?^#V^_\
MF<H S/&O_(!;_L+>&O\ U)M&KK*\]\93:Z=#82:;I*+_ &KX<Y36KR1MP\2:
M04&UM B&&?:K-NRBEG"N5"-U/G^(?^@7HW_@]OO_ )G* -FBL;S_ !#_ - O
M1O\ P>WW_P SE'G^(?\ H%Z-_P"#V^_^9R@#9HK&\_Q#_P! O1O_  >WW_S.
M4>?XA_Z!>C?^#V^_^9R@#9HK&\_Q#_T"]&_\'M]_\SE'G^(?^@7HW_@]OO\
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MXEC,@;6[Q0K_ /",^&QM0C0',B[ C;V$9WLR;,('< [ZBL;S_$/_ $"]&_\
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M10!R^O\ _(5\%_\ 8R77_J*>)JZBN7U__D*^"_\ L9+K_P!13Q-744 %%%%
M!1110 4444 %%%% !7,>'_\ D(^,O^QGC_\ 46\,UT]<QX?_ .0CXR_[&>/_
M -1;PS0!T]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?C?
M_P '!/\ RAK_ ."@7_9";K_U,?"-?J[\.O\ D0O!?_8I>&/_ $PZ=7Y1?\'!
M/_*&O_@H%_V0FZ_]3'PC7ZN_#K_D0O!?_8I>&/\ TPZ=0!V=%%% !2-T/T/\
MJ6D;H?H?Y4 <IX0_X]=;_P"QL\4?^GBYKK*Y/PA_QZZW_P!C9XH_]/%S764
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M5E_\?I#K^AX/_$YTKH?^8E9?_'ZT?LMM_P ^\'_?F/\ ^)I#:VV#_H\'0_\
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M6TM1)XDCDC)U&R =/^$8\-IN4^?AEWHZDC(#*RG#*P':?9;;_GW@_P"_,?\
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M]2;1JZRN3\:_\@%O^PMX:_\ 4FT:NLH **** "BBB@ HHHH **** "N6M_\
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M?1_96J?]#'??^ &B_P#ROK>HH P?[*U3_H8[[_P T7_Y7T?V5JG_ $,=]_X
M:+_\KZWJ* ,'^RM4_P"ACOO_   T7_Y7T?V5JG_0QWW_ ( :+_\ *^MZB@#S
M[P?INI/X3\-.GB"]C1M"THK&MAHY5%-E#A 6L&8A1QN9F9L;F))-='_96J?]
M#'??^ &B_P#ROJMX*_Y$_P +_P#8 TG_ -(8*Z>@#!_LK5/^ACOO_ #1?_E?
M1_96J?\ 0QWW_@!HO_ROK>HH P?[*U3_ *&.^_\  #1?_E?1_96J?]#'??\
M@!HO_P KZWJ* ,'^RM4_Z&.^_P# #1?_ )7T?V5JG_0QWW_@!HO_ ,KZWJ*
M,'^RM4_Z&.^_\ -%_P#E?1_96J?]#'??^ &B_P#ROK>HH \]US3=274_" ;Q
M!>L7\0W*HQL-'S&P\+>)&WKBQ4$E5:/#!EPY<+O1".D_LK5/^ACOO_ #1?\
MY7U5U_\ Y"O@O_L9+K_U%/$U=10!@_V5JG_0QWW_ ( :+_\ *^C^RM4_Z&.^
M_P# #1?_ )7UO44 8/\ 96J?]#'??^ &B_\ ROH_LK5/^ACOO_ #1?\ Y7UO
M44 8/]E:I_T,=]_X :+_ /*^C^RM4_Z&.^_\ -%_^5];U% &#_96J?\ 0QWW
M_@!HO_ROH_LK5/\ H8[[_P  -%_^5];U<%X^^)O@;X:0>&6\:>*?#WANZ\=>
M+M+^'G@*QU_7-,T*;QM\1-?M=1N_#G@3PU)JMQ:V^H^*-?CTG4#I>E12&XN$
MM+F4+Y4$K* 6=?G?PSH>L>(M7\3:Q'I6@Z5J.M:G+9>'K?5[N/3]*LI]0O9+
M;2]'T2_U74;A+6WE:"PTVRN[^]F"6ME:W%U-##)QWPQUJU\?Z#+XX\+^)M:F
M\.>,#H/BC0KG4?"[^'-2N]'\0>"/">KZ7<ZCX=\3>'])\0Z#?26%Y;_:M'UO
M2=*U?3I5:VU/3K2^CN(5XKP5\/O&/Q$\0^'/B[\:[9--DTR?P7\1/A%\';S3
MK"Q\5_L[>,+_ .%&L>!_B3H/B[X@_#_XA^(?!GQEU'4I?%OB"&*[BL&\*Z$L
MC1Z$VNRV^E>)(/<_#W&H>,1SQXFB'))/'A;PR!DG)/U))H L_P!E:I_T,=]_
MX :+_P#*^C^RM4_Z&.^_\ -%_P#E?6]10!@_V5JG_0QWW_@!HO\ \KZ/[*U3
M_H8[[_P T7_Y7UO44 9EG97MM*TEQJUS?(4*B&:UT^%58LI$@>TM8)"P *[6
M<H0Q)7(!&G110 4444 %%%% !1110 4444 %%%% !1110!^-_P#P<$_\H:_^
M"@7_ &0FZ_\ 4Q\(U^KOPZ_Y$+P7_P!BEX8_],.G5^47_!P3_P H:_\ @H%_
MV0FZ_P#4Q\(U^KOPZ_Y$+P7_ -BEX8_],.G4 =G1110 4C=#]#_*EI&Z'Z'^
M5 '*>$/^/76_^QL\4?\ IXN:ZRN3\(?\>NM_]C9XH_\ 3Q<UUE !1110 444
M4 %%%% !1110!R?C7_D M_V%O#7_ *DVC5UE<GXU_P"0"W_86\-?^I-HU=90
M 4444 %%%% !1110 4444 %<M;_\CMJO_8K>'_\ T[>)JZFN6M_^1VU7_L5O
M#_\ Z=O$U '4T444 %%%% !1110 4444 %%%% ',>"O^1/\ "_\ V -)_P#2
M&"NGKF/!7_(G^%_^P!I/_I#!73T %%%% !1110 4444 %%!(')X_^N< ?4G@
M#N>*_"O_ (*J?\%\/V2?^"::R?"RP:Z_:2_;%UX6NG>"/V7OA5?)J/B&WU[5
MW2#0D^*.N:=:ZS'\/;34IYK86&A_V=K/Q#U];NT;P_X-O+.=]3M0#]K=>#-J
MO@XJDCB/Q%<O(8XWD$:GPMXD0-(45A&I9T4,Y4%F5022!73!E8D!@2.H!!(]
MB.H/L:_B:^&W_!-'_@M!_P %:/'>A_M7_P#!2_\ ; ^,7_!/7POJ!U5/V<_V
M7OV8M8U;P5XR^&,NIZ%?ZK8:_P"(=$MO$L,'@\M;V,2:K%XVUCQ9\9O$ DFT
MG7+GX?V5G9V2?7<O_!/O_@Y"_9.$\O[+/_!6GX4_MC^$=.$5Q;?#_P#;9^%L
MNF^(=2CMBJQZ:/''V+XF^(;JXEARLMT_Q*\+0SNH=FMG9IE /ZJZ*_E9D_X*
MU_\ !=']EII(?VVO^"(FO?%OP_I\9;4?B?\ L+_$2;QUI[64 A>75K;P#IC_
M !GU18A;>=,\.L:[X9/FXC9+0)($]?\ A!_P=2?\$K/&VMQ>#OC5KWQV_8Z\
M>J8[>^\)_M,_!+Q1H4EC>LK%H[O6?A^WQ TS3K;S%\M;S7CH<?.^5(5#E #^
MD>BOEWX"_MM_L?\ [4=I;WG[.O[3GP)^-/VB-9#9?#CXI>#?%.LVN]=PBU#P
M]IVKR>(--N /O6VH:7:W"$%7B5@RCZ@WKQD[<\ ,"A..N P!/Y4 .HHKQ#XD
M_$?Q39:Y!\-/A5H%GK7Q8OM#T[QQ8#Q]HOQ3\/\ PA'@G3?'OAOPYXW74/C!
MX3^'OB_PGIWCVUT35=0U#PC\/;F\3Q)XDO;6">:RL?"L6L^(M+ -?Q]\7]!\
M#:KH'AZ'2/$OCGQ1K?B7X?Z)=^%/AYI]CXH\3^%=!^(?BBX\)V'Q-\8: FJV
M>IZ%\*]"U&QU.?Q/XVEMY;'3+'2=6D@BO[C3[FUCR/AM\,M:LI[7X@_%75+;
MQ!\8=;\(>#-$\<#PMKOQ'C^#-OK/@^;7[FWUGX:_"?QSXQ\6:/X"O;F7Q%?1
MZCK]@@\7:]:0:7:>(M<U.'1],2VV/AE\(](^'%FDMYKWB#XD^-FAUC3K[XK_
M !&@\*:A\4-7\-7_ (Y\5^.M#\':KXG\.>%_"ZW?A3P-=>+]0T7P5HPL(X=)
MT6WMC<-?ZU/JNLZEZO0 5S'A_P#Y"/C+_L9X_P#U%O#-=.2 "2< <DGH!ZFN
M9T!6&H>,"RNH?Q-&R%T9-Z_\(QX:7<NX#<I96 9<J2I .0: .FHHHH ****
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M::;I$GBCPQ<_$;5_"M[?Z9I6F6VKZ3I.@ZM/91ZI>:E)+]FT ?C?_P '!/\
MRAK_ ."@7_9";K_U,?"-?J[\.O\ D0O!?_8I>&/_ $PZ=7X:?\%\?C2^K?\
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M_P ?H WZ*P/[=/\ T!]=_P#!:?\ X_1_;I_Z ^N_^"T__'Z -^BL#^W3_P!
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MPK?7?B?X>6=Q;2+N@:V\'P! 2HP NWYB?_@AC_P4Z_9A1;G_ ()Y_P#!<?\
M:1T'1M-N)Y-$^$W[6^@1?&_P7! RH8[4ZI>7/B30[.(F-8Y38_")"(SOB6.7
M=O\ Z;O$_P 1/#G@GPUXA\9^,KA_"?A#PCH>K>)_%?BKQ*]CH7ASPUX;T"PN
M-5UWQ!X@US5+^UTS1M$T;2[2ZU'5=5U&ZMK#3K&VGN[N>&WADD7Y_P#$+^*?
MVAI-4\.ZCH?B'PM^SQ?Z;\1_ ?C;2;FVN[3QE\<-'\2:!\/]0^'?Q2^"'QE^
M"_QJL=7^&W@6TBOO&^EWSZKI^G?$+Q'J!L[[2(_!VG:-9ZKXI /YKG_:X_X.
M?/AIX3^(&@K\ _V2?VZM)^'_ (_NOAUXL^,/[)>KV7@[XJ^&?%O@O5].E\9>
M'E\$?%K3=!T/7M3^P@Z7>3:3\!]9TF :Q]JT34KFXMX+NV[[X2_\')?[*'[+
M%F_PO_:]_P""=O[;/_!-B?4/%WC3Q;J=GXO^#>J^)_AO)XU^(WC37?'GQ#UR
MVUSRO"?B_5;CQ%XT\2:YXEO[S3? -W#=WNJW3VR*ACB/]4EIJ$%E:6UC!HOB
M$VUK!#;PK<6EQ>2"*WB2&(/<7EY/<3.$1=TL\LDLK[I)9'D=W;F?'OB#P';>
M#O$E[\3]-TZU^'^GZ/?ZCXOO?']IHEMX*T[0+&VEN=3U#Q+=>*+I/#MAH]G9
MQS3WUYJTD-C!;H[W$BQ@F@#X3_9\_P""S_\ P2R_:B:SM_@Y^W)^S_JVKWZ!
MK/PMXO\ &47PI\:7+_NP\,'@[XKV_@KQ%<3(\@4I:Z?<!L,T;.BEA]B?'3]I
M[]G[]FCX93_&/X[?%OP5\-/AM&UG#:>)_$.L0B#7;_4N-)T3PC86 OM7\:^)
M-:<K!H7ACP?I^N^(=<N9([;2=,O)I$0_S(?M(?L5?\$__P#@JM<ZGHO["/\
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MT_\ Q^@#?HK+LM3-Y,T1T_4[7;&9/,O+3R(CAE78K^:^9#NW!<<JK'/&#J4
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M&SQ/V_ZC%S768'H/R%<IX0_X]=;_ .QL\4?^GBYKK* $P/0?D*,#T'Y"EHH
M3 ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* $P/0?D*,#T'Y"EHH Y+QJ!_83<#
M_D+>&NW_ %,VCUUF!Z#\A7*>-?\ D M_V%O#7_J3:-764 )@>@_(48'H/R%+
M10 F!Z#\A1@>@_(4M% "8'H/R%&!Z#\A2T4 )@>@_(48'H/R%+10 F!Z#\A7
M+6X'_":ZKP/^16\/]A_T%O$M=57+6_\ R.VJ_P#8K>'_ /T[>)J .HP/0?D*
M,#T'Y"EHH 3 ]!^0HP/0?D*6B@!,#T'Y"C ]!^0I:* $P/0?D*,#T'Y"EHH
M3 ]!^0HP/0?D*6B@#E_!0'_"'^%^!_R -)[#_GQ@KI\#T'Y"N9\$D'P?X7P0
M<:!I(..Q^PP<?6NGH 3 ]!^0HP/0?D*"0HR3_4GV '))[  D]A7\ZG_!4#_@
MXC_9V_8M\3R_LR_LO>&[O]N#]O+7=5_X1#PW\!/A&U_XDT3PEXOO%\BSLOB/
MX@\*V^J7=UKMM=OA_AAX'BU?QS<36\ECKC>"H9DU9 #]L_VD/VG/@!^R'\*/
M$7QP_:4^*O@_X/\ PM\+J@U3Q9XPU%;.WDO)TD>ST71;"%+C5_$OB74_*DCT
MCPQX<L-4\0:O.ODZ=IUQ)P/Y!_B+_P %-/\ @J3_ ,%Z_&'B']G?_@CY\._%
MO[)/[%UOJ5YX6^+G[>GQ-2[\*^)M:TE;GR-2M/!VN:4+N7P==75C+%);>"/A
MI<>(/B[=K/I\WB+Q3\-]&NM5@A]%_9P_X(2?MD?\%*_BIX6_;5_X+^?&77/%
MSVDRZS\-?V"/ NL2:!\/_ 6BWL@NX- \;2^%=3_LCP=:>4(H-8\'^ +R_P#&
MFN10V!^('Q7NM1@U'1&_KX^'?PX\ _"/P1X8^&OPO\&>&/A[\/O!6DV^@^$?
M!7@S0].\-^%_#6C6H/V?3-$T/2;>UT[3K.,LS>3;01B21GFE,DTDDC 'Y'?\
M$M?^"%O[&'_!+K2;;Q3X+T&3XR?M.ZC9W:>-/VI?BA86E_\ $/4KK5D']M6O
M@>P>2]T_X8^'+Z5KA9+#0)[GQ'JEI,(?%WB[Q/*@F'[2;5X&!@< 8' ]!2T4
M )@>@_(48'H/R%+10!RVO@?VKX+X'_(R778?]"IXFKJ,#T'Y"N8U_P#Y"O@O
M_L9+K_U%/$U=10 F!Z#\A7(^-O&6C^!/#NK>(=4AU'4&TW2=<U2S\/\ A[3I
MM>\7>)IM"T/4?$$^A>#O"UAOUCQ7XGO=/TJ\.D^'=%M[K5-3G006L#,2RYOQ
M!^)?AGX;0^%#XBEU*.Y\=>-=#^'/A.*P\->+_$,%YXR\3QWS:#9:O<>$O#OB
M(^%]%N'T^==0\7>(H=.\+:(@1]7U:T:>U2X\V\!?"WQ%K>LV'Q4^.KZ7K?C2
M6/P+XO\ #/PQN/\ A#?B#X!_9E^(NG?#S5_!/CF?X#_$:Z^&'@3XA7Y\5VWB
M;Q%9:QXQ\30VFLZCIE_?6.E:;X7T'6=3\/2@&-HO@_Q3\:]?L/'OQ'6_T3X9
M6L=GKWPK^'=EJ7Q&\&:GXF\(?$?X0V^B>-/"G[6/PF\1+;^%O$NI:5K>N:P=
M'\%:GI^H:?X:N+6QO-3MH/%%E>1K]-PP6UG!#;6\$-O;V\4<%O;P1)%%%##&
M$BA@@B542.*)%2.*) J(H5%"J /BS]I[]OSX"_LP:]HGPSU.;Q=\8/VC?&=E
M+??#K]E/X!>&Y?BA^T1XZM8@6?5[?P)I=S;P^"_!<(24ZC\3OBAJ_@;X9:.L
M,IU/Q;;NHB?Y<'[,O[:'[<[_ -H_MT>/+G]E_P#9VOI%DA_87_9=^(FH1^,_
M&FE"1U.E_M6_M;>&#HWB/7[34;.6:VU[X2_LXR>!? [*[Z;KGQ*^)&G&02@'
MI/Q<_P""D/AZX\?^(OV>OV)?AEJ_[</[3/AN\?1_&7A[X<Z]I_A[X"? C5%>
M$2-^TS^TQ?6NI^ ?AI=6<37-Q-\-_"\/Q#^.5^+1HM.^%YCE%[%R7AO_ ()S
M>+/V@=?T7XH?\%/_ (J:3^U9X@T?4;37_"7[+7@_1-3\%?L&?";5K1HKBQN;
M3X-ZI?ZEK7[1'BW2+G[2;;XC?M)ZIXOCAGE&H>#OAY\/76.UC_1CX1_!OX4?
M /X?^'?A5\%/ASX+^%7PW\)V@LO#G@?P!X<TKPKX8TB'DRM9Z1H]M:VBW-U*
M7N+Z^DCDOM0NI9KN_N;FZFEF?TJ@"O:VEK96\%I:6\%K:VL$5M;6UO%'#!;V
MT""."W@AC58H8(8U6.&&)4BB10D:*H $^!Z#\A2T4 )@>@_(5R_AY5&H>,@%
M4#_A)XS@  9/A?PSDX []ZZFN8\/_P#(1\9?]C/'_P"HMX9H Z; ]!^0HP/0
M?D*6B@!,#T'Y"C ]!^0I:* $P!T 'X4M%% !1110 4444 %%%% !1110 444
M4 %%%% 'XW_\'!/_ "AK_P""@7_9";K_ -3'PC7ZN_#K_D0O!?\ V*7AC_TP
MZ=7Y1?\ !P3_ ,H:_P#@H%_V0FZ_]3'PC7ZN_#K_ )$+P7_V*7AC_P!,.G4
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ML PZC_A&]+]+[_P<:U_\L: -ZBL'_A&]+]+[_P '&M?_ "QH_P"$;TOTOO\
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M\8]#^*/[5OB?0/&D>L:7J_[7/QU^,/[1>D:?K>F>']>U#3M;TSX:?$'QC?\
MP:T;5-/O;5+K3I]'^&UA'ITV9;"&V=(FB_3B**.%$CB18XXT6-$10J)&@PD:
M* %2-!\J(H"(ORJH  K@==\/Z:FI^#U"WA$OB&Y1MVK:PQ"CPOXDD&TG4"4.
MY%.Y"K$ J3L9U;I/^$;TOTOO_!QK7_RQH WJ*P?^$;TOTOO_  <:U_\ +&C_
M (1O2_2^_P#!QK7_ ,L: -ZBL'_A&]+]+[_P<:U_\L:/^$;TOTOO_!QK7_RQ
MH WJ*P?^$;TOTOO_  <:U_\ +&C_ (1O2_2^_P#!QK7_ ,L: -ZBL'_A&]+]
M+[_P<:U_\L:/^$;TOTOO_!QK7_RQH WJYCP^"-1\99&/^*GC/X?\(MX9YJS_
M ,(WI?I??^#C6O\ Y8US>A>']-?4/%P*W@$7B2.-=NK:POR_\(SX<<EB-0!=
MBSL2SEFQA00BHJ@'H5%8/_"-Z7Z7W_@XUK_Y8T?\(WI?I??^#C6O_EC0!O45
M@_\ "-Z7Z7W_ (.-:_\ EC1_PC>E^E]_X.-:_P#EC0!O45F6>D65A*TUN+D.
MR&,^=?ZA=+M+*QQ'=W<\8;*CYU0.!D!@"0=.@ HHHH **** "BBB@ HHHH ,
M#T%)@>@_*EHH **** /QO_X."?\ E#7_ ,% O^R$W7_J8^$:_5WX=?\ (A>"
M_P#L4O#'_IATZORB_P"#@G_E#7_P4"_[(3=?^ICX1K]7?AU_R(7@O_L4O#'_
M *8=.H [.BBB@ I&Z'Z'^5+2-T/T/\J .4\(?\>NM_\ 8V>*/_3Q<UUE<GX0
M_P"/76_^QL\4?^GBYKK* "BBB@ HHHH **** "BBB@#D_&O_ " 6_P"PMX:_
M]2;1JZRN3\:_\@%O^PMX:_\ 4FT:NLH **** "BBB@ HHIGF1YQYB9]-RY_+
M- #Z*874=0_X1R-_Z"IKCO&_Q'^'WPST*]\4?$?QSX/^'_AK3(6N=2\0^-_$
M^A^$]#T^V1))'N;[5O$%_IUA:0(D,KM+<3QH$BD8G:C$ ':5RT'_ ".NJ_\
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M_%?X??!WQA86OPW^&FKZAH2W-U?VOP3^ /BO0;B\N[V[?5KB\O?MK_2/@?\
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M\NO#MZ)!;R6?C[XFZ-=:=\!_A3-;WCQ6MXGQ/^+'A*>UF=UDMR8)E0 _2T
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M110 5S'A_P#Y"/C+_L9X_P#U%O#-=/7,>'_^0CXR_P"QGC_]1;PS0!T]%%%
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MNM?$"T7XP_"WQ?X$^$8\46%GXC\(_"FWU&]\+>,/#?Q1\4^%-8^(.IZ9I%W
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M$%WXFO)]?O\ 4[G5"ER@!_,9HEC_ ,'-'QG\03>';7_@HA^P#\.KR/XKZO\
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M:YJMY*S%Y+G4=8UG[?JNIWDSLTEQ>ZA>75W<2,TD\\CL6,G_  Z0_P"">_\
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M-744 8/F^)?^?/0__!AJ/_RIH\WQ+_SYZ'_X,-1_^5-;U% &#YOB7_GST/\
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M_([:K_V*WA__ -.WB:@#J:*** "BBB@ HHHH **** "BBB@#F/!7_(G^%_\
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M ./US6@Z_H*:AXO+ZWI"B3Q+&\9;4K-1(G_",^&TWH3, R[T=-RY&]&7.5(
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MX<\*>#VDT30Y;_5;C3=.M/"_@?POI:_;=5U+4M3NK"ZUS5;V?4]4NV'M5%%
M'XW?\'!"J/\ @C7_ ,% CM7/_"B;DYP,_P#(X^$>^,U^KWPZ_P"1"\%_]BEX
M8_\ 3#IU?E%_P<$_\H:_^"@7_9";K_U,?"-?J[\.O^1"\%_]BEX8_P#3#IU
M'9T444 %(W0_0_RI:1NA^A_E0!RGA#_CUUO_ +&SQ1_Z>+FNLKD_"'_'KK?_
M &-GBC_T\7-=90 4444 %%%% !1110 4444 <GXU_P"0"W_86\-?^I-HU=97
M)^-?^0"W_86\-?\ J3:-764 %%%% !1110 4444 %%%% !7+6_\ R.VJ_P#8
MK>'_ /T[>)JZFN6M_P#D=M5_[%;P_P#^G;Q-0!U-%%% !1110 4444 %%%%
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MS'@K_D3_  O_ -@#2?\ TA@KIZYCP5_R)_A?_L :3_Z0P5T] !1110 4444
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M'-=Q_P!)7O\ @L[_ .)NV'_SH: /V=WI_>7_ +Z'^-&]/[R_]]#_ !K\8O\
MAS7<?])7O^"SO_B;MA_\Z&C_ (<UW'_25[_@L[_XF[8?_.AH _9W>G]Y?^^A
M_C1O3^\O_?0_QK\8O^'-=Q_TE>_X+._^)NV'_P Z&C_AS7<?])7O^"SO_B;M
MA_\ .AH _9W>G]Y?^^A_C1O3^\O_ 'T/\:_&+_AS7<?])7O^"SO_ (F[8?\
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M_P"=#0!^SN]/[R_]]#_&C>G]Y?\ OH?XU^,7_#FNX_Z2O?\ !9W_ ,3=L/\
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M_#FNX_Z2O?\ !9W_ ,3=L/\ YT- '[.[T_O+_P!]#_&C>G]Y?^^A_C7XQ?\
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M+-;O;O4+R#3].TO0?"GA'2M=\5>)M<U.^N8+/2]"\.:+JFL:E=2I!96,SD@
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MNG>-)+'[5]N3PE?7FMPVOB1[+[%=F[31I;U[46MP9Q&()2GYT?"7Q3-\.O\
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M_P /?'3X)^+?$WC_ ,%^%/C!\+?$WC+X4;A\4?"7A[X@^$=:\3?#?8URC_\
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M6FD\R2.-7DWS,TK[V;=(S.V7)-%KIUA9"1;.RM+59@JRK;6L$ E5 P02"&-
MX4.X4-D*&8#&XYN44 8TGAW0)86MI=$TB2W8J6@DTRQ>%B@B5"T36YC)00PA
M25RHBC XC3"+X<\/K;"S70]'6S#3.+5=+L!;;KA42=O(%N(MTRQ1K*=F9%1
MY8(H&U10!D)X?T*.W2TCT;24M8VE>.V33;);>-YU"SND @$2-,H"RLJ!I% #
ME@ !H"UMA<"[%O +H0_9A<B*/SQ;E_-, FV^8(3)^\\H-Y>_Y]N[FIZ* "BB
MB@ HHHH **** "BBB@ HHHH *AN+>WNXF@NH(;B%RA:&>*.:)C&ZR(6CD5D8
MI(JNI*DJZJPPP!$U% %)M-TYK:.S:QLVM(F#Q6S6MN;>-P78-' 8S$C!G<AE
M0$%V.<LV:EOX>T&TBD@M-%TFV@FDBEEAM]-LH(I98"3#+)%% J220DGRG=6:
M/)V%<FMBB@#'M_#N@6D<L-KHFD6T4TD4LT5OIEC#'++ 6,$DB1P*DDD)=S$[
MAFC+L4*ECFXNGV"?9"ME:+_9X9;';;0#[$&C\EA:8C'V8-%^Z80>6&CPAR@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>pfizercoverlogoa01.jpg
<TEXT>
begin 644 pfizercoverlogoa01.jpg
M_]C_X  02D9)1@ ! @$ E@"6  #_[@ .061O8F4 9      !_^$5R$5X:68
M $U- "H    (  D!#@ "    #    'H!$@ #     0 !   !&@ %     0
M (8!&P %     0   (X!*  #     0 "   !,0 "    '@   )8!,@ "
M%    +2':0 $     0   ,B<FP !    &    /0   $,4&9I>F5R(&QO9V\
M !;C8   )Q  %N-@   G$$%D;V)E(%!H;W1O<VAO<"!#4S0@36%C:6YT;W-H
M #(P,#DZ,3 Z,#4@,34Z-#8Z,#<   .@ 0 #     ?__  "@ @ $     0
M @2@ P $     0   2P       !0 &8 :0!Z &4 <@ @ &P ;P!G &\
M!@$#  ,    !  8   $:  4    !   !6@$;  4    !   !8@$H  ,    !
M  (   (!  0    !   !:@("  0    !   45@        !(     0   $@
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M1I2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V)S='5V=WAY>GM\?_V@ , P$
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MX:1_IGC\[=_@O^W/^+R:<.RW.;@O$/-GI61V#?YUS?\ K;7.8NQRKF8>';<
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M%KNYKJ_0,_\ !6WJM]?OK"[IME6+@$,ZE=4X/RAJ^G'<X2RC=[6695E/T_\
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M;W @,RXP #A"24T$)0      $                      X0DE- ^T
M !  E@    $  0"6     0 !.$))300F       .             #^    X
M0DE-! T       0   !X.$))3009       $    'CA"24T#\P      "0
M         0 X0DE-)Q        H  0         !.$))30/U      !( "]F
M9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &
M       ! #4    ! "T    &       !.$))30/X      !P  #_________
M____________________ ^@     _____________________________P/H
M     /____________________________\#Z     #_________________
M____________ ^@  #A"24T$         @ !.$))300"       $     #A"
M24T$,        @$!.$))300M       &  $    #.$))300(       0
M 0   D    )      #A"24T$'@      !      X0DE-!!H      TD    &
M              $L   "!     H 50!N '0 :0!T &P 90!D "T ,0    $
M                         0             "!    2P
M         0                         0     0       &YU;&P    "
M    !F)O=6YD<T]B:F,    !        4F-T,0    0     5&]P(&QO;F<
M         $QE9G1L;VYG          !"=&]M;&]N9P   2P     4F=H=&QO
M;F<   ($    !G-L:6-E<U9L3',    !3V)J8P    $       5S;&EC90
M !(    '<VQI8V5)1&QO;F<         !V=R;W5P241L;VYG          9O
M<FEG:6YE;G5M    #$53;&EC94]R:6=I;@    UA=71O1V5N97)A=&5D
M %1Y<&5E;G5M    "D53;&EC951Y<&4     26UG(     9B;W5N9'-/8FIC
M     0       %)C=#$    $     %1O<"!L;VYG          !,969T;&]N
M9P          0G1O;6QO;F<   $L     %)G:'1L;VYG   "!     -U<FQ4
M15A4     0       &YU;&Q415A4     0       $US9V5415A4     0
M    !F%L=%1A9U1%6%0    !       .8V5L;%1E>'1)<TA434QB;V]L 0
M  AC96QL5&5X=%1%6%0    !       ):&]R>D%L:6=N96YU;0    ]%4VQI
M8V5(;W)Z06QI9VX    '9&5F875L=     EV97)T06QI9VYE;G5M    #T53
M;&EC959E<G1!;&EG;@    =D969A=6QT    "V)G0V]L;W)4>7!E96YU;0
M !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE    "71O<$]U='-E=&QO;F<
M        "FQE9G1/=71S971L;VYG          QB;W1T;VU/=71S971L;VYG
M          MR:6=H=$]U='-E=&QO;F<      #A"24T$*       #     (_
M\        #A"24T$$0       0$ .$))3004       $    !#A"24T$#
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M &( 90 @ %  : !O '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@
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M P,# P,# P,#_\  $0@!+ ($ P$1  (1 0,1 ?_$ !\    & @,!
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M9V=_/GZ:K6B7L+HOLK:H8@2OM'/;9WU'"3&MF_W+'K^21!.2#90V@:@"?1[
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MY_W@V]^Z>4?#TGJH\_[$_P#0WO?ET^OETP5)X;_7/^]\?[U[KT^/+ICF_/\
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MZ?7C_J\NF"I/_$_[T!_O8]ZZ?3XATSRG_>C_ +?CW1N)Z,81TRU!^O\ L?\
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MU:]8#[V>M(.)ZQGD_P"M[\.'7CEOLZXN;+_K\?\ %?\ >/>QUH^G6'WKK?6
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M_8^_=*$]>DS5-;5_MO\ DD7/^\^[>?3R])V=N#_OO\??CY#IY>F&I;Z_Z_\
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M'O8Z>7RZ8*EN#_OO]]Q[]Y]/+TP5+?C_ 'USR3_MO?O7IT=,%2W'^O<_[?\
MXI[]T\HR!TGJEKFW^W_V//O9P#T^HX=,52U[G^OT_P!B>/\ >![KT^.F28_7
M_$V_XK[JWETNB&>FBH:Y/^^^O'MOHP& .F.H:Y/^^X_XU[UY'I]!@],M0?K_
M *W^]\>Z'I7&.'3-.>?]O_Q3_B/=3TMC''IHG/U_UC_O/'NAX=*D'RZ:)C]?
M]C_Q0>Z^72Q!GIFJ&X/^^^OO0X]*?+I/U3?\2?\ ;\>W!U1O/I@J6^O^L?\
M>>/^(]W7IACCI@J6_P")/_$?\3[N//JGF.FJ8\'_ %_^->ZGI1&.'3;*?K_O
MO]]Q[;/2V,<.FV4_\5]T/ ]+8QTVRG_??[[_ %_;9\\]+(QT,_QM^2?:_P 2
M^Y=H=Y],[@DP6\MHUPE\,CU+X3<N%EDB.6VENO'TU32',;8SU/&(JJG,B'A9
M(WCFCBE0/\S<N;5S9L]YL>\VXDLYE^6I&_#(A(.EU.5-/4$%201;RKS-N_*&
M]V6_;)<&.]A;AG2ZGXHY "-2.,,M?0@A@"/I(_!;YI=8?._X_P"VN\.MY5H*
MJ9OX%V!LBHJHZG,=>;\H::GFS.V,FZ)%]S $J8ZFAJPB+6T$\,VF-V>*/G#S
MQR9N?(N_W.R;B-2CNBD HLL1)TN/0X(9:G2P(J10GIOR'SMM?/W+UKONVG2Y
M[98B:M#* -2-ZC(9&H-2$&@-0#C>P?T,^O>_=>Z__]??X]^Z]U[W[KW7O?NO
M=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=(CL#L;9?5NW*O=>^\_18##4H*
MB6J<M4UM05+1T.,H8@]9DJ^4 E88$=[ L0%#$'?+_+F]<T;C%M6Q6#W%X_DO
M!1YL[&BHH\V8@<!Q('04YRYWY6]O]CN.8N;MYBL]KC\W-6=O*.*,5>60^2(K
M-2IH%!(I;^1'SOWQV@:[;'7)R&P-BR:Z>:HAJ/#N[<-.P97&1KZ21AB*&=#9
MJ6E<LRW66:1&*#-#V\]B=CY8$&Y\QB/<-]%" 16WA/\ 01A^HP_C<4!H512-
M1Y9^]?WO.;>?S=[#R09MFY1:JLRMIO+E>!\21#^C&PP8HF)(J))75B@(+[GW
MK#GKWOW7NO>_=>Z][]U[KWOW7NO>_=>Z][]U[K$S7X'T]V ZW6F!UP)M[V>M
MJ*Y/#K"3?WX#KQ)8]8V/NP'5B=(H./6$G\>]GTZT@_$>CR_"'XS#N[>LF[=V
M4+2]9[(K*>3(PSQWIMTY\!:FCVV"WIFHH8],]>!?]EDB('G#+!WO9[E'DK95
MVG:9Z<RWJ$(0<P1<&F^3$U6+^D&8?!0Y8?=8]C![J<T/S#S%:%N1=JE4R*P[
M;JXPR6V<%%%'N./84C-/%!&P,B)&B1QHL<<:JB(BA41% 5415 55518 < >\
M V8L2S$EB:DGSZ[$*JHJHB@(!0 8  X #R ZY>]=6ZJK_F3]^5&W<'B^C-M5
MC09'==%'G=\5$# /#MD5,D.*P8E1BT;9JNI)):E?2WV\"*=4=0P.4GW<>0X]
MPO;KG?<H0UO:N8K8'@9J O+3S\-6"H<C6S'#1CK /[[?NY-LVU6'M5L=R4O-
MPB$]\RG(MM1$4%0<&9T9Y!@^'&@-4F(ZI08V%O>9W7,(>OEU')_/NPZ;'<W5
MO7\K_IFAK)MU]YY>G$U1BJR?9.S1*@M25<N/IJO<V6B#>KS-09*"CBD6P"2U
M*&Y)TXE_>9YPGA3:N2+233'*@N;BGXE#,L,9^6I&D8'S$9QY]&?N+>VMK<R;
M_P"Z>XPAIK>1K*SJ/@<QJ]S**^9CDCA1AC2TZYKBY'WA_P!=).O>_=>Z][]U
M[K6<^?IIQ\M>W?M?#X_-LL-X-&C[C_1UM'[O5X_3YON]?D_M>35JYO[Z/^Q
MD/M5RGXNK52XXUX?5SZ>/EII3RI2F.N)'WM#"/O!^X9@TZ-5G\-*:OW?::^'
MXM>K5YZJUS7HFGN7^L;P*D#K"QY_UO?AUMC5NH[G_>?;@ZJW *./355R6O\
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M^=48U+-3D-][7V+@]M>8[;FSEBTT<F;K(P\-0 EI=9=H5 PL4J@R0+^'3+&
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M^JL?+K"QL/>SZ=>7%6/6!CP?=AU7B>H[M;_8>[\!7K1RP'D.F6KD^O\ MO\
M??ZP]^'3@%<=)ZJD^OOW3ZBIZ3=5)>_Y_/\ L!]/]N?>^GE'2=J)+DW/]?\
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MO,'KF?0^AZ[][ZUU[W[KW7O>NO4/IU<?_+%V/]IM;L?L6HA.O-9G';2QDC@
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M[]MPY@W.2>:ITJ32.,'\,<8HJ#[!4\6)-3UT%Y5Y,Y:Y*V]=MY;VJ.W@H-3
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MC_V^=7']X)7_ ,%'_P!U3_OG=-\O\Z$1W_YQNU6_[_#;_6_YI:?>_P#@4/\
MP_O^S'_M\ZN/[P&O_@I/^ZI_WSNF^7^=>(S;_9:=7_E9;?\ S*C^??O^!/\
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M]^Z]T1[^8?O_ /N+\8=W4D-1X,COS(8?8M 0?4\>3J&R6:CTCDI/MS$5D1/
M'D'^ ,T^P.Q?OOW*VF5X]5O8QR7+?:@T1G\I9(V_+K&#[X'-G]5_8_F&WBET
M7NZS0V,?J1(WB3"GHUO%,I]-0^0.M*S?[?\ WKWT8 ZXKL:8''J!43:00/\
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MK&T: 'NBMVJLLQIE:BL<1P2Y9E)\)J:*]1)]?]]_K_[<^^@0'7,ICQZV6?\
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MH,-0&IHMD[)HZF27![-P<LJL*2D#+$*W+5WB1Z^O=%EJY5'$<,<,,71[V_Y
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M\^NB?]A[W3JVE1Q/7 M[W3K1<#@.N!?_ !O_ *WO>!U7N;CUC+'_ %O?NMT
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M%[-%IO-WN9KUZ\=+$00Y_A:&!)%' >(3Q)Z/%[A/K*;KWOW7NB+_ ,Q#?O\
M<WXWYO$P2^/(=@9S#;/I])_=6D:63/9:0*"#X9<=A'IW)! ^X ^I!]S?]WW8
MOWQ[BV5TZU@L()+@^FJ@BC'VAY X_P!(?0]8K??'YK_JW[*[IMT4FF[WBZAL
MUIQ"5,\IIZ&.!HV/#]0#B1UKMW_UO?0:G7&[2HXGKCJ_Q]^IUJJ#KK5_A[W3
MKQ?T'7 O_C_MO>\=5JQZXEOZ#_;^_5Z]I]>N!)_)]^ZW@=<2P]^IU77Z"O7
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M$KWF]U]X]WN<;K?[W5'M46J.SMZU$$%<5' RR4#S/YM11V(@4GM1-]?]]?\
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M;?\ .:Z_ZW]8F_EG_!IOU?'W;Q_\F+??_$;J]^_U[O=/_IKYO^<<'_6KK?\
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M_D[OG",NV-K9.G5Y>B=H9>%EGQK(TTL*]C;FH'092?0LV,IG;'H5+UOGP?\
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MN8J,D_[O2KSGW$8'-Z<GZ ^X,^\/O?[I]N;JS5Z3[A<10#UT@^*Y^S3'H/\
MIZ>?667W,.5?ZP^]>W[G)'JM=GLY[IOX=;+]/$/],'G\1:><9/EUL7^^?/79
M'KWOW7NO>_=>ZU./DIOT]F=\]K;U$_W-+E=Y96GQ,UPWDP.$D7 [>-QQQ@\7
M3CBX'TN?K[ZE^W6Q#ESD?E?9M&F6*S0N/260>++_ -5'?K@/[T<UMSO[K<^\
MRB77!/N4JQ-ZP0GP+?\ ZH11] :6_P!@/8U ZC'"Y/6%G ')M[MP^WJN6^2]
M7:?RE-A^+ ]K=HU,#7R64Q.QL1.RZ=,.)IOXYG1&2+ND\V5H 2#8- 1R;VPS
M^]/OOB7W+'+4;XCC>YD'S<^''7Y@))^3==-ON!\I>#M7/?.\T7=-/%91,1Y1
M+X\]/4,98/E5*<>%Q?O$GKHEU[W[KW1?_E5V..I?CKV_OQ9Q3UN(V5E:3#3&
M01F/<.?1-N[<8'ZDKG,K3G2+%@+ @\^QK[<;%_67GKE?9BFJ*6[1I!QK%'^K
M+_U31NHQ]Y^:QR3[5\]<R+)HN(-OD6(UI2>8>!!_U6D0TXGK33GJ+7YY^G^
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MY>@Y6Y1WJWM]GCD>0*;6WD8O(VIF+O&S,3P%2:  # '2ZE_F=_+U+VW]@_\
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MW9^VQ_Y3+8''^WP'U]Z_X'SVM_Z,LW_91/\ ]!].?\%9[V?]-';_ /9);?\
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MYY+ /O&TA/,B2X)_9],*_M'2U_O<^W81C'L6]%Z8!BM@/S(NV(_8>BQ=F_\
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M;[,^W^S/'INFL$N90>(ENR;EU;YH9?#^00 $@#HQ_N/.IFZ][]U[JKS^:MV
MFWNDMI[$AG\=;V!O)*B>&Y'W& V?2_Q"O&GB_BS>1Q;7/ _I>ULE/NQ;&;[G
M+=-\=*PV%F0#Z2SMI7]L:3#K!_[]W-0VOVSV'E6*2ESN^Y!F'\4%HOB/^R:2
MV/\ JQKY2U0%^?\ ?<_[$^\[NN30'E3IKEJ2?S_Q7_C7OWV=7"^O3;+4_P"/
MOW3@7IIFJOKS_P 4'O?3H6G33-4_7G\?[$_ZW^I'O?V=7"]-,U23< _\4_XV
M?\?>^G .FR6:U^?^)_Y&?>JUP.K@=-<U1]>>/Z_\4_J??N&//IP+TU33\?7C
M_B?\?ZGW[_#TX!TURS_6_P#MO^)/]3[]TX!3[>FF>?Z\_P"^_P"*^]].JM/M
MZ:)I[W-^/]]]/ZD^_$_MZ<"\.FJ:?^O^P _'_%3_ (^Z].@4Z:I922?]];WX
MFG2B./UX]-\DGY_'^]_XG_#W0G]O2Z./IMFFO?GW3I2!3 Z:)Y2;\^]?/IY%
M\SPZ:Y9?KS_OO^*>ZD]/JM>FN66]_P"G)_US_7_6'NIZ5HM/MZ;)9+^ZD]*4
M6G3;+)]?]]?W4G]O2A%Z;)9+WY_J?^-^]=*E7ILED^O].;>ZD]*56G3143?7
MGCWL#K9Z9*B6]_\ ?6'_ !4^[CIMCY=,L\OU/^V_WW]![< Z:8^0Z99Y?J+\
MG_??[S[M\^F^..FR1_K_ +[G_C7O1Z>1>F^5_P#;GW0GI6B]0)'_ -L/=.E:
M+TWR/]?]]Q[H3TK1>'4"5_K[;Z5HO4"1O=2>E:+U!D;_ 'W^^_K[KTJ1>E[U
M'T]V?W_V+MKJ?IS96<[ ["W=6BAP6VMOTIJ:NH8 O4UE5*QCI,9B<=3JTU76
MU,D-)1TZ-+-(D:LP*]WWC;-AV^YW3=[Q(-OA6K.QH!Z >98G"J 68D  G'1[
MLNR[GOVX6VU;/9/<;A*U%1!4GU)\E4#+,Q"J*EB!GK?1_E1?R7.M?@IC\5W#
MVY_!^SOE;74#%L]$IK-G=10U]-+!6X/KB&JIX):O-U%+4-!7YZ>-:B:.\-)'
M30//]U@O[I>\6X\[R2[3M6NVY75OAX23D&H:6A-%!%5B!H#EBS!=.>?M7[-[
M;R-'%N^[:+GFEE^+C'!44*PU JQ!HTI%2.U JEM5Z/N$NIOZ][]U[KWOW7NO
M>_=>Z][]U[KWOW7NO>_=>Z__TMY#Y"]3TO=O3N^.NIEA6NS6(DFV_4S:52AW
M/C&7([?JFE*LT4 R=-&DY6S-3O(M_5[&/('-,O)G-VR\PH3X,,H$H'XH7[)5
MIYG025K@.%/EU&GO!R!![G>W/-')L@475S;DV[-P2YC_ %+=B:&B^*JJY&3&
MSKY]:HV1QU=B,C7XG)TLU#DL76U6.R-%4H8ZBCKJ*=Z:KI9XSS'-3U$3(ZGD
M,"/?4>WN(+NW@NK:57MI45T89#*P!5@?,$$$?+K@9>V5WMUY=;??6[17L$K1
MR(PHR.C%75AY%6!!'D1U#N?ZG_;^WJ#I-J8>9Z[U-_4^]4'IUO4WKUWK;^OO
MVD=;UGY==^1O\/\ ;>_:1UK4?0=>\C?X?[;W[2.O:CZ=>\C?X?[;W[2.MZSZ
M#KK6W]??J#TZUJ/76HG\GWN@].O:F]>NO?NJUKQZZN/?J];TGTZ]<>]5ZMH/
M7$N/]]S[]4^G7M*CBW7$O[]0^O7M2C@O7$L?];WNG6BS'K@6'^O[W3K5#T)'
M3FR9>R^U^N]@I&\D>Z]X8'#UOCU%HL74Y"#^+U1T^H)1XM9IF(Y"H?8>YNWE
M>7.5^8-]9@&M;261:^;A#X:_:SZ5'S/0U]N.5FYTY]Y/Y45"RW^XP1/3RB:1
M?%;&:)$'<_)3UMV1QQPQQPPQI%#$B1Q11HL<<<<:A4CC10%1$4     #WRB9
MF=F=V)<FI)R23Q)/7T((B1HD<:!8U   %  ,  #  ' =<_>NK=>]^Z]UKH?S
M5.QO[Q_(7';)IIKT?6VS,505,.O6$SVYBVY*^4 65/+AJO&H5Y(,5R>0!GS]
MVC8OW=R'<;NZ?K;A=NP/#].'])1\Z2+*?S_;R*^_%S4=[]VK/ER*3_%MGVZ)
M&%:TGN/\8<_*L+6XIQ[:^=!5]+4_X_['\_C_ &WO(G[>L-0OH.FR:J^O/^^_
MWQ]^Z<"^O35-57_/^V/^]G\>]TZ< Z:YJD?UO_3_  _UA[WU<#IKEG)O<_[S
M_O9][) ZN%Z;I:BU^?=>/'AU<#IKFG^MS_L/]]]![W\ATX%Z;)I_\?\ 6 _X
MC^@_Q]^Z< Z:Y9[?G_B@_P!;_BOOW5P/3IJFG^O/^^_P][Z=5<=-,TU_J>/P
M!^?\![T3Z<>G%7IKFG^I_/X_XU_Q7WKIX#@*=-<LI-^?^*#WXFG3\:'B>/3?
M)+P?Z?[W_P :]MD]+HH^FV::_P#OO]Y/^'NO2H"F!TU33?7_ 'U_>NG53]G3
M7++]>?\ ??X>]$]/*M>FR66]_P#>?^*#_B?=3TJ1:4QTV2R?7_??[X>Z$]*D
M7S/3;+)_C_K^]=*%6O3;+)_OO^(]UX\>E*K2F,]-LLG^/^O_ +[^GNI/2E%Z
M:9YOJ >??@.G#TRU$WU'^^)_XI[<'39/3+/+]>?]?_??[U[N!TTQITS3R_4_
M[8>[_+IL]-,CW)/]?]]?WXGJRKU D?\ VP]T)Z5(O3?(_P#MS[;/2Q%Z@2O^
M/]O[J3^WI4B]0)'_ !_OO]\/;9/2M%Z@2/\ [QQ_L?=3TK1>H,C?7_??Z_\
MM_=#TJ1>CW_!'^7#\C?Y@F^_[O=3X$X38.'K8(=_=Q[EI:N'8FS('"2R4WW*
M*C[BW1)3,&I\31LU3)J5Y6IZ?5.@"YZ]Q.7N0K'ZC=9]=^ZGPK="/%D^=/P)
M7B[8&0-344R1R![;\Q<_WW@;5;Z-O1@);AP?"C'I7\;TX1KDX)TK5AOX_ O^
M7)\=_P"7UU^VV>I<)_&=]9RCIXNP>X=QTM))OK>]1&8I6I9*J)67 [5@JHP]
M+B*1A2PD!Y#/4%ZB3 [GGW#Y@Y^O_J=UFT6*$^%;H3X48]:?B<CXI&[CP&E:
M*,_N0_;KE[V_V_Z7:8-=\X'BW#@>+*?2OX4!^&->T<3J:K$_/L"=#WKWOW7N
MO>_=>Z][]U[KWOW7NO>_=>Z][]U[KWOW7NO_T]_CW[KW5"_\R_X\2;,WO3]X
M;9H=.UM_U*4>[4@3]O%;X6*205T@#?MT^Z** R7"V^\@F9VU3(#G']W+G]=X
MV63DO<I_]V=@NJ GB]M4#2/4PL:<?[-D %$8]<I?OK^T$G+7,\/NALEK38MV
M<)=A1B*]H3K/HMRBZJTIXR2%C611U5IK/^^/O)JGSZP4UCS7KO7[]GUZ]5?X
M>O:_?L]>JGIUWK]^SU[LZ]K'^^O_ ,5]^SU[L^?7M?OV>O=GIUUK_P!]Q[]G
MUZ]5/X>O:_\ ?7]^H?7KVI?X>NM1]^IU[6?(==:C_7WNG6M3'SZXZA_7_B?>
MZ=:R>NM7^'OU.MTZXEO\0/>Z=>[1Q/7 M_OC[M3K6L?A'7!I /J;>_8ZUW'C
M@=6-_P KW8W]Z?D15;MF@UT/7&S\OE4G8!D3-;@"[:QT)!^CRXVOKY%/X,']
M;>\>?O*;[^[N0(]J1Z3;A=QH1ZQQ?K.?L#K$#_INLRON/<I?OKW?FYAEBK;;
M-M\LH8\!-/\ XM&/M,<D[ ^6CUIUL2>\ ^NOW7O?NO=<6945G=E1$4L[L0JJ
MJB[,S&P55 N2?I[V 6( %2>M,P4%F("@5)/EUIK]\]D/VCW'V;V"TQE@W5O3
M/Y/',QYCPK5\L."I@3R5I,-#!$/R0G/OJWR9L@Y;Y4Y=V(+1[:TC1OG)I!D/
M^VD+'\^OG]]RN9GYV]P><N:V?5'?;C/)'\H=9$*_[6$(H^0Z!::J_P ?^*_[
M;V)Z= H#IMEJ?K<_["_/^Q/X][ZN!\^FR6I)^GT_WC_8#\GWOJX'3=)/:]S[
MU7TZN%Z;I:CZB_\ Q3_C7OU ./'JX'3;+/\ XW/]?^*>_?;TX!TV2S_7G_7/
M^^_4??NK@?LZ;9I_KS_L?R??NG M?D.FJ:H^O/\ L/\ BOO?3@'RZ:Y9OZ_7
M^G_$G^@]Z)].G0OGTUS3_7FY_P"(_P"('O73@'IQZ;)9;WY_US[T33[>E,<?
M[>H,DG]3Q_3^O^)]T)Z61Q<.FV::_P#OO][]UZ5 4P.FJ:;Z\_\ &_>NG56N
M3PZ;)9?KS[T3T^JU^SILEE^O/^O_ (?X#_$^ZUZ4(GGTVRR_7_??[ >ZD]*D
M2N3TW2R?X^Z]*%6O3;-)_C_OOZ_ZY]UX]*46G3;+)]?]];_??GWHGI0B^O37
M/-;WH"O3W3-43?7G_C7_ !L^[@=5)Z99Y?K_ +P/=P.FB>F>>7Z\\?D^[TI]
MO3)->F>:2Y/]/Q_OOZGWOAUY17/3?*_X_P!O_A[J3TI1>H$K_P"V'MLGI6B_
MMZ@2/]3^?Q[J?Y=*T7J!(_NA/[>E:+U D?\ 'Y/^\>Z=*D7SZP0T]3755/0T
M-//65E9/#2TE)2PR5%555-1(L5/34U/$KRSU%1*X5$4%F8@ $GVV[JBL[L @
M%23@ #B2?(>O2R*-Y&5$4L[$  "I).  /,];,O\ +>_X3T=A=MO@NW_G##FN
MJNLY/M<GA^D:663%]J[TIR$J(AO6H4";K/ U*,J24O\ Q\$J^1&3&N(YGQG]
MQOO ;?M0GVCDEDNMRRK7)[H(SP_3'^C,/)O[(8-9!51E/[:?=WW'=OI]XYY5
M[3;#1EMAVSR#C^J>,*GS7^U.01$:,=R[K7K+KWIS9&W^MNJ]F[=V!L/:M$N/
MV_M7:V,IL3A\;3AFDD:.EI402U574.TU142%YZF=WEE=Y'9CAYN6Y;AO%[<;
MCNEY)<7TK5=W8LQ/VGR P ,*     .LT-LVS;MFL;?;=JLH[>PB6B1HH50/L
M'F3DDY8DDDDD]+KVAZ7=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U
M[W[KW7__U-_CW[KW2,[#V#MKM'96X]@;OH5R&WMSXV7'5\/I$T18K+2UU'(R
MN(,AC:R*.HIY;$QSQ*P^GLXV#?=QY9WG;]]VF;P[^VD#J?(^3*P\T=25<>:D
MCSZ#?.'*>R\\\L[SRGS%:B;:+Z$QR#S'FKH2#IDC<+)&U.UU5O+K5A[^Z2W3
M\?NRLUU_N=&F2F<UNW<VD;)2;CVY4RR#&Y>EU JKR(ACJ(@6\%3')'=M(8].
M.1.<MLY\Y=L]^VTT9AIECKW12@#7&WR%:JV-2%6H*T'";W9]LM[]I>=-RY1W
MQ=2H==O, 0EQ;L3X<J_,@:9%J=$BNE3IJ07U_P"(]C#3U&O;Z]>U?ZWOU.MT
M'KUWJ/\ A[]3KU!U[4?\/?J=>H.NM7^M[]3KU!Z]>U_ZWOU.M=OKUUK_ ,?>
M]/RZ]5?7KK7_ (GW[3U[4O7'5[W3Y]:UGR7KHO;\@>_8Z]5_LZQF91^?]]_O
M7OU?EUZA/%NL#5*CZ?[[_8#WZIZV%'IU&>K_ ,;?[&W^]<^_4ZM3RZAO5'GG
M_B/^-^_8ZL%/6P/_ "F=A'"]+;T[#J8@E7V!O/\ A]&^C_/8'9E&:2DE$AY-
M\YE\E&5 L/$#<DD+@K]Y_??K>;MHV*-JQ6-IJ;/"2X;4P_YQI$:_/]O5_P"X
MCRG^ZO;KF/FR9*7&Z[CH4TXP6B:5-?\ FM+<+3AV@US06K^\9^LY.O>_=>Z+
M/\Q^QO\ 17\8^Y=WQU/VE>FS:_ 8:97T3QYS=S1;5Q,], 0SST=;F$G %["(
ML?2#[D#VLV+^L7N#RKMC1ZH#=K)(/(QPUF<'Y,J%?SIQ(ZB+WYYJ_J;[0<_;
MXDVBZ&WO#$0:$37-+:-E]2CRA_L4DX!ZT\Y:KZ\\_P"O<_[$_0>^HE.N$P'3
M=+5?6Q_WG_>S]3[W3JX'4"2?^I_V'_&O>JCJX7]O4"6HM?GWJE<GJX'3=+4?
MU)'^'Y_XU[W]G5PO3=+4<?6P_P /]]S[]U<#INEG^MS_ +#\_P"Q]^ZN!3[>
MFV6H_P ?]A_OOI[WTX%]>/37+4?T-S_OOI[]PZ< ].FR6?Z\W/\ 7\#_ %OZ
MGWKCTZJ]-DT_UL?]C?\ WG_$^]=.*I)H.FZ26_-_^*G_ (GWHFG#CTICC\NH
M,DMKW/\ L/\ BO\ 4^Z$_MZ6QQ4ITVRS?4D_[[_'W7I0!Z=-DTWO73BKYGAT
MV2R_7GWHGI]5KTVRR_6Q_P!<_P!/\!_C[J37[.E*)Y]-LLOX'T]U)Z4HGF>F
MZ67\#W7Y]*%6O^K_ %8Z;99?^1_\3[K6O2E%Q7INED_V_P#ON?\ 7]Z)Z4*M
M>/39-+8$W]U&3T_@"G3//-^?R?I_OOZ>W .JD],T\WUY_P!]_7W8#IHG]G3/
M/-]>>?\ >O;@'GTT3TSSRWN ?^1_\:][^WCU4"O3=(]O^(_XK[T3T^B]0)'_
M .-_[[_#VV3TK1>H$C_[8>Z]*T7]O4"1_K[H3^SI4B\.H,C_ )]MGI6B]'>^
M%W\N?Y2?/#<ZXOI78TT.RZ*OBI-U]N;L^XPG6NU$9T$Z5.<>"67.Y>".0/\
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MW7IT"G39+/>_X_XG_#_6]^Z<5">/#J!)+_R+_BONI/ITKCCK04ZA2S6_Q/\
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MP*LI(((/N\<DD,D<L4C+*K JP)!!!J"",@@Y!&0>FYH8;B&6WN(ED@D4JRL
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M^Z]TBM_=<;#[3V[5;3[%VC@=Y[=J[M+B\_CJ>O@CFTLB5=&\J&:@KX0Q,51
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MW[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]T&G<W^CK_1)V7_I?_P"95?W&W/\
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:U[KWOW7NO>_=>Z][]U[KWOW7NO>_=>Z__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>pfizerlogo2816.jpg
<TEXT>
begin 644 pfizerlogo2816.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_X1$T17AI9@  34T *@    @ " $.  (
M   ,   (>@$2  ,    !  $   $Q  (    >   (A@$R  (    4   (I(=I
M  0    !   (N)R;  $    8   0_)R?  $    8   1%.H<  <   @,
M;@     <Z@    @
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                                                     %!F:7IE
M<B!L;V=O $%D;V)E(%!H;W1O<VAO<"!#4S0@36%C:6YT;W-H #(P,#DZ,3 Z
M,#4@,34Z-#8Z,#<   2@ 0 #     ?__  "@ @ $     0   @2@ P $
M 0   2SJ'  '   (#   ".X     '.H    (
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M                 %  9@!I 'H 90!R "  ; !O &< ;P   %  9@!I 'H
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M" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(" @(_\  $0@
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MC<+Y-PG6_=Y;3HS:[<LG^-V?B?'?$W'U%*IGE;$0C/;F<HQ?Y(M>(_B)X_\
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( !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>pfizerlogo.jpg
<TEXT>
begin 644 pfizerlogo.jpg
M_]C_X  02D9)1@ ! @$ 8 !@  #_[0]\4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  8     $  0!@     0 !.$))300-       $    'CA"24T$&0
M    !    !XX0DE- _,       D           $ .$))300*       !   X
M0DE-)Q        H  0         ".$))30/U      !( "]F9@ ! &QF9@ &
M       ! "]F9@ ! *&9F@ &       ! #(    ! %H    &       ! #4
M   ! "T    &       !.$))30/X      !P  #_____________________
M________ ^@     _____________________________P/H     /______
M______________________\#Z     #_____________________________
M ^@  #A"24T$"       $     $   )    "0      X0DE-!!X       0
M    .$))300:      !M    !@              <    ,     & &< -  W
M 'D -P S     0                         !              #
M<                                              X0DE-!!$
M  $! #A"24T$%       !     (X0DE-! P     #.     !    <    $$
M  %0  !54   #,0 &  !_]C_X  02D9)1@ ! @$ 2 !(  #_[@ .061O8F4
M9(     !_]L A  ," @("0@,"0D,$0L*"Q$5#PP,#Q48$Q,5$Q,8$0P,# P,
M#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0T+"PT.#1 .#A 4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" !! ' # 2(  A$! Q$!_]T !  '_\0!/P   04! 0$! 0$
M         P ! @0%!@<("0H+ 0 !!0$! 0$! 0         !  (#! 4&!P@)
M"@L0  $$ 0,"! (%!P8(!0,,,P$  A$#!"$2,05!46$3(G&!,@84D:&Q0B,D
M%5+!8C,T<H+10P<EDE/PX?%C<S46HK*#)D235&1%PJ-T-A?25>)E\K.$P]-U
MX_-&)Y2DA;25Q-3D]*6UQ=7E]59F=H:6IK;&UN;V-T=79W>'EZ>WQ]?G]Q$
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MK;6?GM_MK.YGD_;!G W$;C]*+L\E\2&8C'D CD/RD?+/_P!"?__0]4) !),
M:DE<YU/K%N8[[+A$MJ>0S>-'6%QV^W]VO_SXB?6/J1#OV?48$!V01X'Z%7_?
M[%1Z)5]HZG2#JVJ;7?V=&_\ @CV*UAQ",/=D.G%$-+/G,IC# [GAD1^3M]0^
MR]-P&NKHK<YNVNL.:(/Q_L-<JO3KL+JKK,?(PZV/:T.#V")$[?I#;8QW]I1^
MLIR+;:,>FFRP-#K'%C'.$GV,]S1M_P!(C="Z>_!IMR\R*GV :.(]E;9/Z1WT
M6[OI.0  P\1/KD?3KZDDRES' !^KB*EIZ-G,/2MO7*^GDE])(MD]Z@-^U_\
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M &\ <    !, 00!D &\ 8@!E "  4 !H &\ = !O ', : !O '  (  V "X
M,     $ .$))300&       '  @  0 ! 0#_[@ .061O8F4 9$     !_]L
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M,T-3)9;6%T>72/%B@I(T1,3&AU@9$0 " 0,"! 0"!@0'"0T)   ! @,1! 4
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M+(5H 2:J"PZ5-.O0]7.]-S=U\EDMM[#NUQ^(AA+27$G4LDHZ@H4% S1!JD@
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M.8UJ9:'CRCTH#@J:J5.OP"JP&[@<.(J+:LW+G?8H"+EPD8_0 #XN@ '34?\
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MQ]]P6Z73)T1&V=_3CCC2-%ZO74'@E310"Q)I4DF.KOV8+6Y VW(&!)O]^/9
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M2R/\/\8:*<P_JZ"$7?ZVNT\>:I_M,S=C*E&2^8:R]KCU91 >OE@X<3SD^3H
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M%N1(7J#.[VI]O\.SLC!N3=%]'>9R+C#'&#Z$+4^W5P&DD'W"514/S ,W2R2
MY(<KL8\<:Z]<3LJSF;RJT,:O8^CWB9YR2=*$ 6JTD1(%S0,)N;O.[<%*4R93
M B5979,>/V/V[S^][V)+.W:+$AOQ+AE/IJ!S"UIZC^ 12:$CJ*K5AWW<_O!M
M3MCC)Y<A=QSY\I^#9HP]5V(^4N!7THO$R. " 0@=Z*12>WP6?SCR\M^9K:?Y
M^0@(>RV^0>@4?ETK%;%0KT:P;I&,?P-D(B0>@V('PHI-2E#T#1#]YC9;3[;8
MW:^-'1#-+%"H\3'"/49B?$EU3J/WBY)YG0@^V\Y+?_>?,[WS#>I<6T$]R[>
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M$T@.<YSF.JJ=5=154\F^T=HX+8^#M=O[>M/2L8N))H7D<TZI)6H.N1J<30
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M;EP>"$1+1Y.N.X>BBBV12;MTDT&Z"::*""*94D444B@1)))(@%(FFF0H 4H
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MC52SQM&&)7C5>KJ'ZP&FY[M>^'>7=?M_G]@7.S[&PM,@(EDFAEF:0)'-',5
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M';9#I'^"NHD"03-3DD\"K%6E%DA 9JS(- N!<0_NS?K'1>="^0U&764<G/\
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E(U51P ' <@-??UX];+2TM+2TM+2TM+2TM+2TM+2TM+2TM+7_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>pfizerpipeline2020a02.jpg
<TEXT>
begin 644 pfizerpipeline2020a02.jpg
M_]C_X  02D9)1@ ! 0$ ?0!]  #_X0 B17AI9@  34T *@    @  0$2  ,
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MU]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$! 0$! 0
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MV/H[_A=7@[_H:O#O_@PB_P#BJ/\ A=7@[_H:O#O_ (,(O_BJ^ F.325^'?\
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M_H;/#7_@S@_^*K\_**/^(Q8O_GPOO8?ZP3_E1^@?_"Y_!_\ T-GAK_P9P?\
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M$/\ B87'_P#0+'[V?N-_PUQ\*?\ HIGP_P#_  H;3_XY1_PUQ\*?^BF?#_\
M\*&T_P#CE?AS11_Q"'#?\_W]W_!#_B87'_\ 0+'[V?N-_P -<?"G_HIGP_\
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M_";6Y-,\5?$KP#X9U*$A7M-5\0VEG.A*A@"DDBL/E93TZ,#WK"_X;_\ @/\
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M#3O_ (]1_P / O@+_P!%L^$G_A8:=_\ 'J_EWHH_U-I?SO[@_LR/\S/ZB/\
MAX%\!?\ HMGPD_\ "PT[_P"/4?\ #P+X"_\ 1;/A)_X6&G?_ !ZOY=Z*/]3:
M7\[^X/[,C_,S^HC_ (>!? 7_ *+9\)/_  L-._\ CU'_  \"^ O_ $6SX2?^
M%AIW_P >K^7>BC_4VE_._N#^S(_S,_J(_P"'@7P%_P"BV?"3_P +#3O_ (]1
M_P / O@+_P!%L^$G_A8:=_\ 'J_EWHH_U-I?SO[@_LR/\S/ZB/\ AX%\!?\
MHMGPD_\ "PT[_P"/4?\ #P+X"_\ 1;/A)_X6&G?_ !ZOY=Z*/]3:7\[^X/[,
MC_,S^HC_ (>!? 7_ *+9\)/_  L-._\ CU'_  \"^ O_ $6SX2?^%AIW_P >
MK^7>BC_4VE_._N#^S(_S,_J(_P"'@7P%_P"BV?"3_P +#3O_ (]1_P / O@+
M_P!%L^$G_A8:=_\ 'J_EWHH_U-I?SO[@_LR/\S/ZB/\ AX%\!?\ HMGPD_\
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MH^IV_C?P?:^.O"5WI-XOF0W493W4]C7P7\0_ %]\./$]UIM]&RM;RLBL5P)
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M Y>BBB@ HHHH **** +_ (9_Y#D'_ O_ $$UUM<EX9_Y#D'_  +_ -!-=;0
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M[0/Q>U[P]HNM:7'H/AEIYM3\23';86]I$Y7[1ZD.JEE4D9'4@ D>A^%_V"?
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MM(R_%SX)MX=U2\AFU;PN5AC#.?.D@(.TG(^;&#R">O..*_*>O2/V4_V@+_\
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M"I-3T2Y;*SO>2NDU;>VJM?3</;17Q;W:25WLDWTZ7U/D2BOI[XK_ +''P0\
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M8'T(K?\ B+\5_$'Q9U*WNO$&H'4+BUB\J)S#'%M3).,1JH/)/6MX\4J>28C
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MF67U<#B9X6LK2BVG_GZ/='PM:E*G-PEN@HHHK@,0KI/@]_R5SPK_ -ABT_\
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M6?[/L?,:7ROLD,GSMC)RZ,>P[UI:O^V#\1M=TFZL;KQ%YUK=QM#,GV"V7>C
MAAD1 C()Y!S73+&Y8LO6%H3G!M)R]Q/FDM4F^=-13Z6\PHU*,:/+=J3W:2>G
M9:K3OW/-****^2//"BBB@ HHHH [;X"?%6?X4?$"UO@Q^QS'R;I,X#(3U_ X
M-?:VC>/K+7/ L>O6[--:-;&X(B&YN!RH'<@@BOSSKW[]B?XR_P!B:RWA>^F_
MT6^;?:ECG9)C&W\<# ]37ZOX:\62P>(678A_NYO3R;M;Y/8]S*,=[.?L9[/\
M&>U> /']G\??#>K6%YI;16^TP3Q2C='(K9&/TK\I?VV/V0M2_9>^(EXBQR2>
M';J\DCT^XZ_)M5U5C_>VMCZJ:_92QTVWTN-H[>&&!'8NPC4*"3U/'>O.OVLO
MV=]/_:8^#&J>';Q5^U>69K&; W0SJ,I@]LD;3[$U_8? _%$\IQEIO]W.REY>
M:]#Y[Q.X'I\09<Y4U^^IIN+[]T_)V/Q#'+<TG2M3QIX2O_ GBK4-(U*&2WOM
M-F:"5&&""#C\B.?H:RR<U_45.HIP4X:IG\-5J,Z<W3FK-:-=F@HHHK0Q.T_9
MP&/VB/ /_8Q:?_Z4QU]??MR?MU:Q\!?VS?&%CH/@;X7G4M+>V2'7;G03)JS%
MK6%]S3^8-S#.!E< *HQQ7PWX=\0WGA#Q'I^JZ?-]GU#2[F.[MI=BOY4L;!T;
M# @X8 X((/<5J?%'XHZ]\:?'NH>)_$U]_:FN:H4:ZNO)CB\TJBQK\D:J@PJ*
M. .GK7S.9</PQN80Q&(2E3C%JSO>[<6MM+6O>[Z['V.4\45<MRJKA,-)QJ3G
M"2DDK62DFKO5.[5K+YG<Z9\?/&'[0G[2O@G5O&.O7FNWL&M6<<33[52!6NE<
MJB* JC<3PH'8= ,=G_P5CO);G]OGQTLDC.+<6,<8/\"_8;=L#\23^-?/NA:W
M=>&=;L]2L9?(O=/G2YMY-H;RY$8,K88$'! .""*UOBI\5M>^-WCV_P#%'BC4
M/[4UW5/+^U71ACA\TI&L:_)&JH,(BCA1TSUR:VCDZIX^E7HJ,:<(2C9*UG)Q
M:LDK6LG?\C"7$,ZN6U\-B9RE4J5*<G)N]U&,TTVW>]Y*VEM/(^G?V]=$;Q1\
M,?V7=-$T-NVH>#;2V$LS;8XBZVZ[F/91G)/I5WX[_#7X0_LD_%6R^&@^#_B#
MXH^)/L\$CZE=>(+O3VOI9ER%@AMEPR\X!QG(*_,1D_+_ ,1OCAXH^+6B>&]-
M\0:LVH67A&Q73=)C-O%%]DMU"@)F-%+8"K\SEFXZUZ9I_P#P4S^.>E>&(]'B
M^(6H?8X8?(1I+.TDN-N,?Z]HC+NQ_$7W>]?/_P"K^94\-2H4Y)J+J<T5.4+\
MTKQ=XJ^BO=:)WW/JEQ7E%7%U\36A)2E&DHR<(S:Y(J,URRER^\TK/5I+8]@_
MX*>P^)/#/[8W@&'P39:Q9^(+/P3:Q65KIQDO+R$"2]5U4C<[[8]X+')(!)/4
MU#X)^//AC]M7XHZ;X%^,_P +Y!XXU.9-,'B;04>QU.";A%>X@QAMO5F;*H 2
M(P!Q\TZ_^TWX]\3>.-%\37OB;4)?$'AW3TTK3]078EQ!;H) %+JH+G$L@+OE
MVW')->BWO_!4CX\:CICV<GC^X6*2,QEHM+LHI,$8XD6 ,#[A@?>LO]6<=#!T
ML/&,'.$6E/GE&46VW=-1;:V;3LF][E1XPR^>8U\5.<XTYR3</9PG&:22LTY)
M1>Z32;2>A]#_ +$?@32?A._[3?PS;25\?7FEQB"/2H[QK&?7[6$SJ\:R1Y=6
M^8*0N?F<#O7E_P '?VN/AG\+/BYI^H>#_P!FC4+7QAIL\B6J1>--1N+B.4JT
M;KY+1,&.&8%2I^F:^9_"'Q0\1> O'4?B;1]:U+3_ !!',T_V^*=O.=V.6+-_
M%NR=P;(;)SG->RW/_!5/X]7=HT+>/Y DB[25T>P1\>S+ "#[@YIXCA7&2KSJ
MRM5]I&*E>I4IJ\8J+NH)J2=KV=NJV-,'QO@(X:G0C>C[*4W"U*G5=I2<DDYM
M.+C>UTWLCQSXM>+F^('Q4\3Z\UBVEMK>K76H&R+ES:&69Y/*+$*3MW;<X&<=
M!TJUH%OXX^%%I;^*=)C\6>&K>\C*P:O:K/9),C$@A)UVAE)4CAL$J?2N8NKJ
M2^NY)II&DFF<N[L<EV)R2?J:]?\ A5^W]\7O@GX0M?#_ (:\97&GZ/9;A!:O
M8VMRL09BQ"F6)R!DDXSQDU]=BJ&(AAHT<)",K63C)M+EM:U[2?;=/S/@\+B,
M+5QTZ^-J3BG>2E"*<N9M--IN*[O1Z/8]_P#V4/''B[X[?L??&*'XI76H>(_
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M%3/ XBMSRJ<L6X."LV]6MV[*R\K&>)PLZL);7E*+\DHN^_5NYV'[&-Y+?_\
M!13X63SR2333?$32I))'8LSL=1B)))Y))YS7:?\ !:(Y_P""H?QB_P"PQ'_Z
M30U\\^"?B%K'P[^(>D^*M%O/L>O:'J$6JV-UY22>1<Q2"6.38X*-AU!VLI4X
MP01Q5[XT_&?Q-^T-\4=8\9^,-2_MCQ-X@F$]_>?9XK?[0X54!\N)51?E4#"J
M!Q75]3FL12JJUHP<7ZMQ:MY:'H5GS8B=5;.UOO;.7HHHKT@"GQS-#(&5F5E(
M*D=013** /W._P""('_!3NU^._PW\/\ PN\57B_\)AH]O/;6LTDG-[! $,0
M/<1L1UY\L^M?HM7\H?P8^+>L_ GXHZ'XN\/W+6NL:#=QWENX/RLR,&VL.ZG&
M"#P0:_ID_8H_:FTG]L3]G7P_XVTF2/=?0^7>P#[UK<*!O1AZ\@_1A7YKQ+E*
MH5/;TE[LM_)_Y,\+'8?DESQV9Z]97CV4P=&QZ^]=A8WBWULLB_Q#GVKB:U/#
M6J_8[KRW/[N3CZ&OE3@.HHHHH **** &]%KR']OI<?L4_%+_ +%N\_\ 135Z
M]TS6+X_\ Z3\4?!6J>'=<M?MVCZU;/9WMOYKQ>=$XPR[D(9<@]5(/O65:+E!
MQ756*IRY9J79G*_LC''[*WPY_P"Q8T[_ -)8Z\9_X);W]OX>\*?$;P;?2+#X
MM\/>--2DU2UD;$SK*ZF.XP>61U'#=#MKZ6\(^$M/\">%]-T72X/LNEZ/:QV=
MI#O:3R8HU"(NYB6.% &223W)KSWXW_L3_"[]I#6X-4\9>$++5-4MT\M;V*>>
MSN'3LKR0.C.H[!B0.<8S6LG>ISKK=?>T_P!#."M34'NK/[E_P3ROXT7\/C7_
M (*A_![3]%DCNM0\&Z3J]_KIA;=]BMYX!%")2.A:0C"GGY@>XJ;]EZ=+/_@H
MQ^T=:R2)'<7":!<11,</)&+-P7 ZE064$]BP]:]G^!W[,_@7]FO2+BQ\$^&K
M#08;Q@]P\9>6XN2,X\R:1FD?&3@,Q R<8R:Q?CA^Q+\+OVC_ !/;:UXQ\)V^
MJZM:1"!+M+JXLYFC!R%=H)$+@<X#YQDXQDTHMPLEM9I_-W_#8<O>O?2]K?*V
M_J<9^T1\>O&EW^T]X7^#_@>_T?PK?:_H\^M77B#4;(WS0QQNR"*V@+HCRY0D
M[R0%.<<5XY\2=)\2>#_^"AWP%T7Q1\5&^(6I1SZI=&TDTBRT]])1K,A6(MU#
M$2X; <G_ %7'<U]3?&[]D_X>?M&:-I]CXR\,6>M0Z3_QY.9);>XM1@ JDT3+
M(%.!E0V#@9!P*S/AY^Q+\*_A9<:)/X?\&V.EW7AV[>^LKB.:9IUF>-HF:21G
M+S?(S "4L!G@ T4U9IO5IZ^>]O2R?X#E=IVZJWH[?B>!:Q_RFGT__L!VX_\
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MO+$#DDD*.,D9&<'X0_M@Z%\5?'S^%;W0?&7@?Q,UNUW:Z7XGTP6,VHPKC?)
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MFEZ#92W]TR %S'&A8A02 6., 9&217,_M4?!P?'[]G?Q?X0W;9M;TZ2*V;.
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M=-O);>XC>&:%S'(CC#(P.""/4&H\YKW#_@HA=>$[S]JOQ(WA%56S\T+=;/\
M5FY  E*_\#W9]\XXKP_J*_KW+\4\3A:=>47'F2=GNKJ]F?YZ9Q@5@\;5PD9*
M7))JZV=G:Z.N^"/P-\3?M#_$.S\,^%--;4=6NLN1N"1P1@@-+(QX5%R,GW
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M8^@L1A)J47U7Y/LUU04445Y9Z 4444 %%%%  >17M7[*O[/C^/\ 48?$%_\
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MDJ%"&&A\_P"O-D%%%%?B)\V%%%% !1110 4444  4N0%^\>!Q7UM^R1^S_\
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M^Q9X DV_.OC6)0?0&PO,_P A7X/UGPO-RR^-^C:_$G RO104445]"=@4444
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MD_C7%5_/7'7$TLVQ[]F_W<-(K\W\_P C\LS+&.M5T^%;?YA1117Q!YH4444
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M.(HJK'E9_4!_P4@_X)9^ ?\ @I)X+M+?7I+C0?%&C*XTGQ!9QJ\]J&Y,<B'
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MRK=G:/KE0WY"O9/V</V&(?AIKEOKWB*ZAU+5+8[K>VA!^SV[_P!_) +L.V0
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MBJ\56IN$+ZN6EEULMV_D:X?*<1.24HV7=GK/A'2%\+>#=-L688L;2.)CV^5
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M22V3MHV]K>2NSZG@_P (,[Q>,A5Q]-T:46FW+1M)JZ2WNUU9ZA\3O$]K\/\
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MG=M_F_T1Y]:L\1)4X;'YV?\ !3K]JW_AL[]MGQQXWMYI)M%N+O[#HP<#Y+*
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M'EB?FTIRD^:6X4444$A1UHHSF@!2?E'ZU^FO_!(W]DY? '@-_'^L6W_$VUY
ME@'7F"WZ[A_O\?3;7QS^P5^R_+^TW\<K'3[JWD;P_I[+=:G)C :('[@/JV"*
M_9#3-,AT;38;2UC6&WMT$<:*,!5' K\=\4.)O94EE>'?O2UEY+HOGU/Z,\#^
M"?;UWGF+C[D7:"?5]7\NGF<?\8O@I!\6/L+27<UK):$K\O*LAZC'K[U\G_\
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M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK8\
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M/X)XTXHK9]FE3&U=MHKM%;+]6%%%%?0'R84444 %%%% !1110 4444 %%%%
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MZ6=[B5GD9I'8[F9CDD^I--K]7P6$AAJ,:4-E_5S[*C35.*B@HHHKK- HHHH
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MPE/#T(4*2M&*27H@HHHKC.H**** "BBB@ HHHH **** "BBB@ HHHH ****
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M O\ T K?_P &%W_\77N.*,4?ZL91_P! U/\ \ 7^0?4Z'\B^X\._X81\"_\
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M?_@"_P @^IT/Y%]QX=_PPCX%_P"@%;_^#"[_ /BZ/^&$? O_ $ K?_P87?\
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M*_BIXOO->\1>%QJFK7S;Y[B36M04N>W"RA0 .    *Q3_P $A/@B1_R),/\
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M8?\ P=ZC_P#'J/\ AT#\$?\ H28?_!WJ/_QZOJCRZ-GO1_K-FW_034_\#?\
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MC_T),/\ X.]1_P#CU?4U%/\ UDS?_H)J?^!O_,7^I>0?] 5+_P  C_D?+/\
MPZ%^!_\ T),/_@\U+_X]6IX._P""6WPA^'_B6SUC2?!]K;ZEITJS6\KZK?3"
M-U.0VUY64X//(-?20CR?K2[-HK*7$6:2BXSQ$VG_ 'G_ )ET^#\BA)3A@Z2:
MU34(II^6AS8\&W2KPT 7TR?\*BOO <NIV,UM*T9AN(VB?9*Z-M(P<,N"#@]0
M01VKJ]@I:\F[W/I%IL?%&N?\$$/V:?$>L76H7WPW6ZO+Z9YYYI/%&LEI9&)9
MF/\ I/4DDU6_XA]?V7O^B70_^%/K/_R37V_FCBNW^U,8MJDOO?\ F;?6*O\
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MO?\ 1+H?_"GUG_Y)H_XA]?V7O^B70_\ A3ZS_P#)-?;^:,T?VIC/^?LOO?\
MF'UBK_,_O/B#_B'U_9>_Z)=#_P"%/K/_ ,DT?\0^?[+O_1+X?_"FUG_Y*K[>
MHH_M3&?\_)?>P^L5?YG]Y\0G_@WV_9='_-+X/_"GUG_Y*H'_  ;[?LNG_FE\
M'_A3ZS_\E5]O  T[I1_:F,O_ !)?>_\ ,/K%3^9_>?#_ /Q#Z_LO?]$NA_\
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M'_"C_A#KG_GI;_\ ?1_PKIJ* .9_X0ZY_P">EO\ ]]'_  H_X0ZY_P">EO\
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M-?V8?BAXZT_X4)X(_:%O=)T:[T#1;&_75/#T^HV+S6MXM_)<M'<1O)&"]O\
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M"T^*]0T.WGM]>L+^YL'CFN[2$QH)3;WRQS"W,&7C8Q^1N"H4;U7&,-Y.R_\
M!L:5_E.27>VJ3%4]SFYOL[_^"W52^<%Z7T;1^DE%?*?[/GCWXB?"G_@HGXF^
M#'BSXBZQ\4/#M]X!M?&^D:AKFEZ;9ZGI<XOY;.YMBVGVUM#) W[ETW1&13O!
M<C%8O[1GQ*^*GCC_ (*I>$/@OX3^)M]\._!>L?##4/%>JS:;H>G7VJ&YM]4M
MK>-K6:\AFBA<B8*QEAGC,?F 1K(R31D7S.FHZ\_/;_MQ3<K_ /@N2\W;H[A+
M3GO]CEO_ -O<G+;UYXORUZH^QJ*_+;3_ -K3]H[PM^P?XN^->M?%JUU;5/@W
M\0[GPB=#M_#6GVNG>,].L]>CTR>;4W,+S+>2QF1U:Q>TA1@@,+C=GL_VF?VX
MO'7CK]JGXV>#/#/CWXN?#F'X0VMGIFA0>"?A!>>-H?$&KW%BE\TNISQZ5?)'
M;*);>)+>&2UF(,SM)AHRN?M(\BGW7-Y\O+&2=MW=3BDE>5WJE9LI1;G*'6+L
M_7F<6K[:--MNRMLV]#]%J\@E_;S^$\&DV]\WBK%K=>.V^&<3_P!F7GS>(5F:
M!K+'E9&)$9?-(\GC._&#7SKX'_:8^+W[:WQK^'?P]76?%'[.^H-\);#XD>+H
M[#0[.76DU&]G>U33 NJVMQ'#!"\-P\@,'G,?*4/'M<-X1^SI\<_B1^S=^SSI
MT=KXFL!XB\4?MB:AX4\47UCI4<=MJUM<ZM.MVL<,YF,"RE 1M<N@X$G<[PIM
MXA49;-V7F_;PHO76RO*6N^TDI+1YU)*.'E56ZU?DG1G56G5V4=+VW3:=FOU@
MKC?A!^T!X1^/,WBJ/PGJW]K/X)U^Y\,:T/LLT'V+4;<(9H/WB+OVB1/G3<AS
MPQP<?-G[,7C;XJ?MO>-OB!X\T[XLZOX#\-^#?B#?^$=%\(V6AZ3>Z;?VNE7(
MM[F747F@>]::YD6?'V>ZMA%'Y.%8AFD\8\9_MX_&S_A3/Q/NM!\8Z7:^)-)_
M:@L_AEH=UJ.AV]U9V.CSW]A;BVEAC$33(%N),MYBS$'B53AA%']Y.$%]N,6O
M^WYTHQ;_ /!JNM]W=./+*JON1DW]F4HO_MV-24DO_!;UVV5G>\?TLHKX1\9?
MM9_$']@GXX?&K0/%WC?6OC'X;\(_!V7XJ:/+K6FZ;8ZI:W%K/<07%D9-/MK6
M%X)-L+(6B,BDN"[#&>:_9'_:Z^+NL?'7X+K=>)?C1\4--^)%O<Q>.K'6O@MJ
M/A?P_P""YGLGO(+O3;^32;4_94FC^R!+JYNGD6XC</N4EBC^]?N?U[TX^OQ4
MY*]K+1MI.XJO[N_-TO\ A&$G_P"2SB[;O5)-JQ]S_!#XY>%OVC_AO9^+O!>J
M?VSX=OYKFW@N_LTUOYCV\\EO,-DJ(XVRQ2+DJ =N1D$$]97Q#^TSX8\7_L&_
M#WX3>"?AI)\5-(^#[:SK$WC+Q/X(\-67B7Q1H+7,LEW;;;)K.Y5K-KBXG\V2
M*QFD1(HA\NYG/T?^QC\7-)^.W[,/@_Q5H?Q#LOBMI6K66^V\56]DEBVKH'90
M\T"!5AN5"[)D"1!9DD'DP?ZI"G[\')?9:3];?@GTO:_2^HY7BTI=;M??MZ^G
MX:'I]%%% #3U_&OG]_\ @JU^R[$[+)^TC\ XV4D,K?$'205(]1]HKWXG=7QK
M\=?^4X?[/A_ZIUXR_P#2C1ZF+O-1[W_!-_C8)646_3\TCZV\)>+-+^(/A?3=
M<T'5-/UK1-8MH[VPU"PN$N;6^@D4/'+%*A*O&RD,K*2""""16LAQ7YS?M+?M
MP>.O'/[4GQI\&^&?'GQ<^'</PCMK/3-#@\%?"*\\:0Z_JUQ8I?-+J<\>E7R1
MVRB6WB2WADM9F!F=I,-&53XY?ML?%ZU\/?"_QA\0&^+_ .SW\,=<^&R>(O$6
MN^#O \/B"Z\-^(=OF75GJ]O=6%]/9V4,*Y1Q;1Y9G$DR;,4HRYDI+1.V_GL'
M*T[/?_AC]&#\K8H)XK\Z_B+X%UKXT?\ !6?X"Z]HOQT\21V?B+X3ZYJ5KJ?A
M2RT-]-GB2?0O,-F+FSNS]ENRXE;S)9G7:@BE1=V[V?\ X*[_ !Z^(G[/7[-G
MAS5/A;KNF^'_ !9K'COP[H$-WJ&GI?6ACO-2@MY4EB;DQLKD-L9) ,['1L,*
ME&RCWD[)>=[?H2I)M]DKW^5SZO84U#@U\)_M?_M!^-OV7/&OP=^#K?%3XL:E
M>>/CJ^MZ[XYTSP%;>)/$UM96"V_^BV>GZ9I,MNGF37,2F::QE6.)9 6,C(Z\
MC:_M;?M%WG[)'B*73M(^+NN-X4^)<6BW'B]?AT=*\9:IX0DB2X;5+/1KZSAC
MFOH7E6T8)9,CB&65+<G"A<VEUT_*Z16UK]3]&L C-8GQ \?:3\*_ VM>)M<N
MOL.B^';&;4M0N?*>3[/;PQM)(^Q 6;:BL<*"3C !/%?!WQ"_;PU?2/V7OAMK
M'PU^-FH?$634/CKH?@/6=7U?PO:Z7KMM;3:DD%[I6IV36L @NE!9=PL[601-
M"0N[]])T7[<'QU\57WQQ_:)^&LFJ;O!-C^SI<>)(-.^S0_)J$L^J023>;L\T
MYCAC787*#;D*"23E6FXPNM]4NUTE+\F."]ZWI?YNQ]F?#?XDZ+\7?A[H/BSP
M_>?VAH'B;3X-5TVZ\IX?M-M/&LD4FR0*Z[D93M90PS@@'BMY>F37Y/\ [./P
M=\1>,/VHOV,)=/\ BMX^\*QWG[.\]Q##I5GHLBV,<*>'ED@C-UI\[&.<L'D,
MA>0,B^4\2[E;VC0OVL_''A7]MR_T#XO_ !#\=_".:^\>G0O!.@WO@VSG\ >-
M=+>-C:1Q:PMJTJZG/%'(WER:C"RW!1%MI5!BDZ94[22[WM\G;]#*$_=YGT2O
M;S2;^X^]PVZE/7_/%?-__!17]H?Q5\'O#GPW\*^!]0MM!\4?&#QG:>#+77KB
MTCNU\/QRP7%Q/>)#(1'+.L-M((ED#)YKH71U!1O-[KQ=\2?A=^UEJ'P'UCXQ
M>,O$^G^/OA]?^*]"\5W.FZ%;^(O#-W87-M#<1#[/81V4L$J7,3(9;-G1DE&]
MP5\OGY[[;K3U:5_R--FK]4G\F[7^\^C?@#^UAX'_ &I!K$G@:\US5]/T6X:V
M?4YO#NI6.EWS+++$QLKRX@CM[Y%DAD4O:R2H,#) 92?2^IKXC_X-]/!FJ>&?
M^"5/PFU#4/&7B+Q);ZUH<<]I8:C#8);Z&HDF!BMFM[:&5D8G<3<23/D<,!D5
MX?\ $?\ X*/?%KQR/B]XT\#Z[\8O[<^'?BZ^T+PI\.?#OP>O]>\.^*8=*NO(
MGBO]5BTJ=A<WCQW"A[>^@2V4P;D++)OWFK5/9]=?P:N"NX\_2]OOV^^Q^IAI
M<X/X5\"_\%'/VP=8^&MGX\O/"/QH^(GAWQIX)\)KK]EX.\*?#)O$FGV,YMY)
MX4\0W2Z;?-;+.T1 Q/8%(=S?-CS:C\1_M+?&#]I/]KG]G?P?X3^($OPQ\+?%
M'X2W?CCQ(-,TJPO[^WF5].:/[%+>6\R)(&N/+)ECDC,3R_N_,\N2.(W;Y4M?
M^ W?[D3*2C:_57_+_,^F?B1^WW\)?A"_Q(7Q%XL_L]OA'%ILWBT?V7>3?V2F
MH8^QG]W"WG>9D?ZG?M_BVU[''(LJ*RG*L,YK\H?VEOC;XP_92^*'_!0'QEX+
M\0W%IXP\,Z3\.5M-7GM+:XE9VB\F21XFB,!9T=\@1A06^55P,>C_ +1O[<7C
MSQW^T[\9O!_AOQ[\6OAW'\);2STW1(?!7PAO/&L.OZO<6$=\TNI3QZ5?)';*
M)K>-+>&2UF(,SM)AHRJO=VWTO\M-?Q*Y7MZ?DC]&@VXT#[]?GFW[2_QX_:2_
M:F_9S\$VOB35O@7:_$CX37GC'QII2:!:3:SH]_#+IX,5M_:%O*(9DDG:(BXB
MD7RGES'YOER1_?VD6LFFZ9:V\UY<7TT,2Q/=3JBRW+  &1Q&JH&8\G8JKD\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV:/V<?#?[*'P<TSP3X6&H2:=I\D]S-=ZA<&YO=3N[B9Y[F[N),#?--/))(Y
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MV[>=V>*F5F^5]=$OEK^"#9-^GYJWXG WW_!.#P]:6WP?F\->-OB!X*U[X+:
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M(L+.?5)8Y;R:,,S9D:-(T+98_=11[5Y\W_!/33M&^(?B/5?"?Q*^*GP_\/\
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M/!_C+P'I/A_Q#X8FWO')=:46TV.VNM/:1)H6<KJ"@/ 1<1N?WOTWX"_8XO\
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M+XR\'PWGQ<L[!8-(@TN2.WG.G:BZWR_:[.<FX10T:JY:':[$Q%MKCVGX:_\
M!.+2O!_[07@_XI>(_B=\6OB3XX\#:=?:1I=]XFU&Q\E+*[CB1X6MK.TM[?<#
M%O\ .$8G=FQ++*J1+'Z#^T%^RQX?_:1\3_#75M<O-9M;CX6^*HO%VE+8RQQI
M<7<=O/ J3AXW+1;;AR0A1LA?F R#F[<U&_V)J3MII[5S>W51?_@6ST3-(O\
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M]/DOM5TB! ([2]AO;.YLYU#CS5?[.'C<OY;(KNK>S?#+P OPS\"6.AC6-?\
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MXTE&F>*_%5YXDEBN(K?30]Q%<7KRW*&8;%:(2>0#$#'%&S2%_N_XF?#3P_\
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M6MLDKJZ2:3:2L[&>#_=RINIKRR@Y?WE%2NW?=MM;MWY4V[H_-_P#X2\=VWP
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M*J0X6B_+7\6VK?>KF*A*WGIKZ))W^X\1^,_]J?M-?\%.E^#NN>)O&GAWX?\
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MB3X@Z;H^FZ_?V6G6^F+;:?8WAD4RRW4][% /(>,+(@<R.9%,*SA9"EKXY_\
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MK]#]VX4?9\[_ *+];E=7VNTO1/0DHHHH **** "BBB@ HHHH **** "BBB@
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M0^ _^&E_$WCWX3^$A=SZGX'\90Z#X=^'M\UC)=VQN;9]2L%U)R%2XECDAO\
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M"T444#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MIFE06D<\%O"(((F6-0&CBA41HIX1 %  &*Q_@G^R?\+/V:K/5+?X<_#7X?\
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M/VH/AU\9?%NL>&?#'Q \#^)/%GAD;==T;2-<MKR_T:0-L9;F".1I(2) 4(D
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MCX+^%^FW%GX9\(^%_#MG>6UO97$&F:5!:1SP6\(@@B98U :.*%1&BGA$ 4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?$'B3PMJ&JQZ_K5W:1W?DV=G#J%J;2WCB=&:22XN&)G5 O[LN^5H7_!*O5?
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MZ9:+IKV%ZT-O/N):8V4@58HE#1"16))M*W6ZMZ=2N7W^7I;[[I/\#WC]K/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% #-O\JXC3OV>?".E?'C5/B=#I/_%=:UI$'A^YU22YFD86$$LDL=O'
M&SF.)/,E=V\M5+L06+%5P45,?B_KL*6QW5%%%4,**** "BBB@ KA_"'[/GA'
MX=_%WQIX^TO2?)\7?$!+)->U%[J:9KU+*)HK5 CNR1)&KO\ +$J*6=F(+,22
MB@#N*,444 %%%% !BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
0@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>pharmapack.jpg
<TEXT>
begin 644 pharmapack.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
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M;[;_ *'+T5WFNW.A:*]LI\/P3>?").H&,]NE4X8-$\4VES%9:?\ V??01F1
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M1?,]3*,0[NB_5?J<Q\0KXSZS%:!OEMH^1_M-R?TVUR=:/B&X^T^(+^7.09V
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MT8_C/.!^E6CXQLU)6+P[8A!]T,H)Q^5.55\SC&-[$QH1Y%.I*U]MV<M17?\
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M7_A.K[_H':;_ -^&_P#BJ/\ A.K[_H':;_WX;_XJN:HH^KTOY0^N5_YCI?\
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+CRQ5D%%%%26?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>pharmapill.jpg
<TEXT>
begin 644 pharmapill.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MK.UC7++1+;S;J3YR/DB7EG^@_K51BY.RW)G.,(\TG9&C6#JGC+2-,)C\XW,H
M_@@^;'U/2N%UOQ9J.LEHRWV>V[0QGK_O'O\ RK#KU*.7]:C^1X6(S?6U%?-_
MY'67WQ#U*8D6<,-LG8D;V_,\?I6)<>(M9N<^;J5S@]0LA4?D,5G45Z$*%*'P
MQ/(J8JO4^*3)6NKASEIY6/NY-"W5PARL\JGU#D5%16MD8<S[FC;^(=9ML>5J
M5R .@:0L/R-;=E\0M3@(%W##=+W.-C'\1Q^E<G164Z%*?Q11O3Q5>G\,F>JZ
M7XSTC4BL9E-K,?X)N ?H>E;U>&5MZ)XKU'12L:OY]MWAD/ _W3V_E7GULOZT
MW\CUL/F[O:LOFO\ (]9HK-T;7;'7+?S+63#J/GB;[R?_ %O>M*O+E%Q=I;GO
M0G&<>:+N@HHHJ2@HHK.US6(=$TU[J7#/]V*//WV["JC%R?*MR9SC"+E+9%7Q
M)XD@T&V  $MW(/W<6?\ QX^W\Z\LO+VXU"Z>YNI6EE<Y+'^7L*+V\N-0NY+J
MYD,DLARQ/\OI4-?08?#1HQ\SY#&8R6)EVBMD%%%%=1Q!1110 4444 %%%% !
M1110!-:7EQ87*7-K*T4J'*L*]1\,^)H=>MRC@17<8_>1YX(_O+[?RKRBIK2[
MGL;J.ZMI#'+&<JPKFQ&'C6CYG;@\9/#3_N]4>W45FZ#K4.N::EU'A9!\LL?]
MQO\ #TK2KYZ47%\KW/KX3C.*E'9B5Y/XLULZUJS&-LVT&4A'8^K?C_+%=UXR
MU0Z9H$HC;$MR?*3VSU/Y9_,5Y57J9?1WJ/Y'@YOB'I17J_T"BBBO6/!"BBB@
M HHHH **** "BBB@ HHHH **** -KPKK9T75E=V/V:;"3#T'9OP_QKUD'(R.
M0:\,KU/P3JAU'0421LRVI\IO4C^$_EQ^%>5F%'15%\SWLHQ#NZ+]5^IS'Q"O
MC/K,5H&^6VCY'^TW)_3;7)UH^(;C[3X@OY<Y!G8 ^P.!^@K.KOH0Y*48GDXJ
MI[2O*7F2VUK/>7"6]M$TLKG"JHZUUD?A?2-$@6?Q%? R,,BWB/\ AR?T%36P
MB\&>'5O'16U2]7Y P^X/_K<9]ZS=)\/W7B R:MJMVT-KDEYI#R_TSP!7/.JY
MW=[17WOT.NG05-J/+S3>MGLEYEL>(_"UJ3';^'EE3LTJ*2?SS2_\)9X=_P"A
M9M_^_4?^%(]_X*L#Y4.G2WA7@R')S[\D?RK U*[TVXU99[.R:&TRNZ$GDXZ_
M3-*%*$WK&7S?_!+J5ZE-:3B_)+_@'0?\)9X=_P"A9M_^_4?^%'_"6>'?^A9M
M_P#OU'_A4,NM^$W@=4T%PQ4A3P,'ZYKE*=.A"6\6OG_P2*N*J0M:47Z)?Y'H
MF@ZCH.O7S6L?A^UA*QE]S0H>A ]/>L^7Q1X>BE>,^&;<E&*Y\J/M^%5?AW_R
M'Y?^O=O_ $):YJ[_ ./R?_KHW\ZF-"#JRCK96ZLN>*J*A":M=M]%Y'6?\)9X
M=_Z%FW_[]1_X4?\ "6>'?^A9M_\ OU'_ (5QU%;_ %6GY_>SF^O5O+[E_D=C
M_P )9X=_Z%FW_P"_4?\ A0NI>#=38K=::]BS' >,8 _[Y_PKCJ*/JL%LVOFP
M^O5'\237HCI=8\'R6UM]OTJ<7UF1G*\LH_#K7-5K>'_$%SH5X&1B]NY_>PD\
M$>H]#6AXOT>"!H=7T_!L[T9PHX5CS^O^-$)SA/DJ:WV85*=.K3=6DK6W7ZKR
M.9KJOA]?&WUQ[4M\ES&0!_M+R/TW5RM7]"N/LNO6,V<!9TR?8G!_0UI7ASTY
M1,<-4]G6C+S*EPV^YE?^\Y/ZU<T"T^W:]96Y7<K2@L/8<G] :I7"[+B5/[KD
M?K6KX1F6#Q38NW0N4_%E*C^=%1M4VUV%12=:*EW7YFCXE9]:\:K8!B$5T@7/
M;U/ZFG^.-2V7,>B6O[NUM47<BG@MCC/T&*SO$C3V/BV[EC9HY5F\Q&'49 (-
M9%Q<37=P]Q<2&260Y9CW-8TJ5U"71+\3IKUVG4CU;U]%T(Z***ZS@"BBB@#J
MOAW_ ,A^7_KW;_T):YJ[_P"/R?\ ZZ-_.NE^'?\ R'Y?^O=O_0EKFKO_ (_)
M_P#KHW\ZYH?QY^B_4[*G^ZT_5_H14445TG&%%%% !78:.W]I^ M3LY#DV>9(
MR>P W?T/YUQ]==X63RO"NO7#'"M"8QGUVG_$5S8GX$_-?F=F"_B-=&G?[CD:
M=&VR5'_NL#3:=&N^14_O$"NDXUN7M?M_LVOW\6, 3L0/8G(_0U2@F>WGCFC.
M'C8,I]P<UT_Q"LC!K<=V%^2YC&3_ +2\']-M<K6-&2G2B_(Z,3!TJ\H]F=EX
MMM$UG3+;Q%9+N4H%G4=5]S]#Q^5<;6YX;\2/HDKPS)YUE-_K8CSCW'^'>M6]
M\(VNK1F^\.74<D;<F!FQM/H/3Z&L83]A[D]NC_1G34I_6OWM/XNJ_5''45IS
M>&]:MSB339^O55W#]*B_L/5O^@;=?]^FKI52#ZHXG1J+>+^XHT5>_L/5O^@;
M=?\ ?IJ/[#U;_H&W7_?IJ.>'<7LJG\K^XW/AW_R'Y?\ KW;_ -"6N:N_^/R?
M_KHW\ZZ[P)IM]::W+)<VDT*& @,Z$#.17/W6BZJUW,RZ=<D&1B"(CZUSPG'V
M\G?HCLJ4Y_5H*SW?Z&915[^P]6_Z!MU_WZ:C^P]6_P"@;=?]^FKHYX=SC]E4
M_E?W%&BKW]AZM_T#;K_OTU7;/P?KEVX'V)H5/5ICM _K2=6FE=M%1H59.RB_
MN,:**2>5(HD+R.=JJ!R378^(-GA[PK;Z$C W-P?,GP>G.3^H _"I8X]'\$Q-
M+)(M]JI7"J.B?X?SKCKZ^N-2O)+NZD+RR')/I[#VK!-UYIKX5^+_ ,CJ:6%I
MN+?ORT]%_FR"KVAV_P!JUVQAQD-.F?H#D_I5&NH^']D;C7FN2/DMHR<_[3<#
M],_E6U:?)3E(Y\-3]I6C'S.K\:Z6=1T"1XUS+:GS5]P/O#\N?PKRRO<R,C!Y
M!KR7Q3HAT75W1%_T>;+PGT'=?P_PKS\OK:.F_D>OF^'=U67H_P!#&J2WNKBT
MD$EO-)"X_B1B#4=%>JU<\%-IW1MIXR\01J%746(']Z-"?S(IW_":^(O^@A_Y
M!C_^)K"HK+V%+^5?<;_6J_\ ._O9N_\ ":^(O^@A_P"08_\ XFC_ (37Q%_T
M$/\ R#'_ /$UA44>PI?RK[D'UJO_ #O[V;O_  FOB+_H(?\ D&/_ .)H_P"$
MU\1?]!#_ ,@Q_P#Q-85%'L*7\J^Y!]:K_P [^]F[_P )KXB_Z"'_ )!C_P#B
M:/\ A-?$7_00_P#(,?\ \36%11["E_*ON0?6J_\ ._O9N_\ ":^(O^@A_P"0
M8_\ XFJ]UXIUR\39-J,NWN$ 3/\ WR!6510J-):J*^X3Q-9JSF_O8$DDDG)/
M4FBBBM3$*]1\#Z6VGZ$LLBXENCYA]0O\(_+G\:X;PQHK:WJR1,#]GB^>8^WI
M^/3\Z]; "@   #H!7E9A6T5-?,]W*,.[NL_1"UF:_HL.N::]M)A9!\T4G]UO
M\/6M.BO*C)Q:DMSWIPC.+C+9GB%W:SV-U);7,9CEC.&4U%7JWB?PQ#KT DC*
MQ7D8^20]&']T^W\J\NNK6>RN7MKF)HI8SAE;M7T.'Q$:T?,^1QF#GAI_W>C(
MJ***Z3B"BBB@ HHHH **** "BBB@ J6VMIKRYCM[>,R2R'"J.]%M;3WEPEO;
MQM++(<*JCDUZ?X7\+Q:%#YTVV2\D&'<=$']T?XUS8C$1HQ\SLPF$GB9Z;=67
M/#^B1:%IJVZ8:5OFFD_O-_@.U:E%%?/2DY2<GN?7PA&G%1CL@HHHJ2PK,UK0
M+'7+?9<IME4?),H^9?\ $>U:=%5&3B[Q>I$X1G'EDKH\CUOPOJ.B,6D3SK?/
M$\8X_'TK'KW,@,"" 0>H-<]JG@C2=19I(D:TE/>'[I^J]/RQ7JT<P6U1?,\'
M$90[WHOY/_,\MHKJ;[X?ZM;DFV:*[0=-K;&_(\?K6)<:)JMKGSM.N4 [^42/
MSZ5Z$*U.?PR/)J8:M3^*+*-%*R,APRE3[C%"HSG"J6/H!FM3 2BKMOHFJW6/
M)TZY<'OY1Q^?2MNR^'^KW!!N6BM4[[FW-^0X_6LIUJ</BD;T\-6J?#%G+UKZ
M+X8U'6V#11^5;YYGD&%_#U-=UI?@?2=/823*UY*.\V-H^B_XYKH@ H"J  !@
M =J\^MF"VIKYGK8?*'>]9_)&9HGA^QT*#;;IOE8?/,P^9O\  >U:E%%>5*4I
2.\GJ>]"$:<>6*L@HHHJ2S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>prescription.jpg
<TEXT>
begin 644 prescription.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#V:BBB@ HH
MK.UC7++1+;S;J3YR/DB7EG^@_K51BY.RW)G.,(\TG9&C6#JGC+2-,)C\XW,H
M_@@^;'U/2N%UOQ9J.LEHRWV>V[0QGK_O'O\ RK#KU*.7]:C^1X6(S?6U%?-_
MY'67WQ#U*8D6<,-LG8D;V_,\?I6)<>(M9N<^;J5S@]0LA4?D,5G45Z$*%*'P
MQ/(J8JO4^*3)6NKASEIY6/NY-"W5PARL\JGU#D5%16MD8<S[FC;^(=9ML>5J
M5R .@:0L/R-;=E\0M3@(%W##=+W.-C'\1Q^E<G164Z%*?Q11O3Q5>G\,F>JZ
M7XSTC4BL9E-K,?X)N ?H>E;U>&5MZ)XKU'12L:OY]MWAD/ _W3V_E7GULOZT
MW\CUL/F[O:LOFO\ (]9HK-T;7;'7+?S+63#J/GB;[R?_ %O>M*O+E%Q=I;GO
M0G&<>:+N@HHHJ2@HHK.US6(=$TU[J7#/]V*//WV["JC%R?*MR9SC"+E+9%7Q
M)XD@T&V  $MW(/W<6?\ QX^W\Z\LO+VXU"Z>YNI6EE<Y+'^7L*+V\N-0NY+J
MYD,DLARQ/\OI4-?08?#1HQ\SY#&8R6)EVBMD%:OAW11KFHM \WDQ1H9)' R=
MH]/SK*KJ/ ?_ "$+[_KS;^8K2O)QIMK<RPL(SK1C+84V'@C/_(5O_P#OG_["
MC[#X(_Z"E_\ ]\__ &%<M14^Q?\ ._Z^1?UE?\^X_<_\SJ?L/@C_ *"E_P#]
M\_\ V%'V'P1_T%+_ /[Y_P#L*Y:BCV+_ )W_ %\@^LK_ )]Q^Y_YG4_8?!'_
M $%+_P#[Y_\ L*='IO@N618TU2^W.0JY ZG_ (!7*5/8_P#(0M_^NJ_S%)T6
ME\;_ *^0XXB+:7LX_<_\RSKFE'1=5EL3)YH3!5\8R",UGUT7CO\ Y&B;_KFG
M\JYVM*,G*G&3WL8XB"A6E&.R;)K2\N+"Y2YM96BE0Y5A7J/AGQ-#KUN4<"*[
MC'[R//!']Y?;^5>45-:7<]C=1W5M(8Y8SE6%9XC#QK1\S?!XR>&G_=ZH]NHK
M-T'6H=<TU+J/"R#Y98_[C?X>E:5?/2BXOE>Y]?"<9Q4H[,2O)_%FMG6M68QM
MFV@RD(['U;\?Y8KNO&6J'3- E$;8EN3Y2>V>I_+/YBO*J]3+Z.]1_(\'-\0]
M**]7^@4445ZQX(5U7P_8+JEXS+N M&)'K\PKE:OZ-K%QHE\+JW"ME2KHW1E/
M:LJ\'.FXHWPU14ZT9RV1M?\ "4Z)_P!"O;?]]C_XFC_A*=$_Z%>V_P"^Q_\
M$UK6FLVMSX;O-6.B6(>WD"!/+&#G'?'O61_PF<'_ $+^G_\ ? _PKBC'FO:#
MT_O?\$]*4W!)NHM=?@7^0O\ PE.B?]"O;?\ ?8_^)H_X2G1/^A7MO^^Q_P#$
MTG_"9P?]"_I__? _PH_X3.#_ *%_3_\ O@?X5?LG_(__  +_ ()'MU_S]7_@
M'_ %_P"$IT3_ *%>V_[['_Q-2VWB;1I+J)%\,VZ,SJ P8<'/7[M0_P#"9P?]
M"_I__? _PK8U/6[;3-*TS4(]&LF>[7>1Y8&PC!X./>HE"S2Y'K_>_P""7"IS
M)R5166_NK_(P?'?_ "-$W_7-/Y5SM6]4U*?5M0EO;C >0]%'  X %5*[J47"
MFHOHCS,1-5*LIK9MA1116AB;7A76SHNK*[L?LTV$F'H.S?A_C7K(.1D<@UX9
M7J?@G5#J.@HDC9EM3Y3>I'\)_+C\*\K,*.BJ+YGO91B'=T7ZK]3F/B%?&?68
MK0-\MM'R/]IN3^FVN3K1\0W'VGQ!?RYR#.P!]@<#]!6=7?0AR4HQ/)Q53VE>
M4O,****V.<L:?I]SJ=XEK:1EY'_(#U/H*Z5]%\-:+^ZU;4);FZ'WHK<<*?\
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M_P#$U5Z_9?>_\B;87O+[E_F9G]E:C_T#[K_ORW^%']E:C_T#[K_ORW^%:?\
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=_P ![5J445Y4I2D[R>I[T(1IQY8JR"BBBI+/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>reporteddilutedeps2019.jpg
<TEXT>
begin 644 reporteddilutedeps2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "* 5 # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#U_%'_YK*/^&H/VEO\ HXKX^?\ AZ_BC_\ -91_Q+KC_P#HJ,'_ .&RM_\
M-?K_ $M3_B9#*_\ HF,?T_YF&'\K_P#,/Z_=]_\ K<^8OH__ '[D_P#B:/,7
MT?\ []R?_$U_DC?\-0?M+?\ 1Q7Q\_\ #U_%'_YK*/\ AJ#]I;_HXKX^?^'K
M^*/_ ,UE'_$NN/\ ^BHP?_ALK?\ S7Z_TM3_ (F0RO\ Z)C']/\ F88?RO\
M\P_K]WW_ .MSYB^C_P#?N3_XFCS%]'_[]R?_ !-?Y(W_  U!^TM_T<5\?/\
MP]?Q1_\ FLH_X:@_:6_Z.*^/G_AZ_BC_ /-91_Q+KC_^BHP?_ALK?_-?K_2U
M/^)D,K_Z)C']/^9AA_*__,/Z_=]_^MSYB^C_ /?N3_XFCS%]'_[]R?\ Q-?Y
M(W_#4'[2W_1Q7Q\_\/7\4?\ YK*/^&H/VEO^CBOCY_X>OXH__-91_P 2ZX__
M **C!_\ ALK?_-?K_2U/^)D,K_Z)C']/^9AA_*__ ##^OW??_K<^8OH__?N3
M_P")H\Q?1_\ OW)_\37^2-_PU!^TM_T<5\?/_#U_%'_YK*/^&H/VEO\ HXKX
M^?\ AZ_BC_\ -91_Q+KC_P#HJ,'_ .&RM_\ -?K_ $M3_B9#*_\ HF,?T_YF
M&'\K_P#,/Z_=]_\ K<^8OH__ '[D_P#B:/,7T?\ []R?_$U_DC?\-0?M+?\
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MT[4OBM807VF74?ASP/K_ ('T"V:/4[3Q!=:B ??%%%% !1110 4444 %%%%
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MO+__ )G]?Z6I_P 01\//^A3B.G_,PQGE_P!/?)_>S^''_B%4_:8_Z.E^ _\
MX1OQ*_\ BJ/^(53]IC_HZ7X#_P#A&_$K_P"*K^XZBC_B-OB%_P!#3"?^&O+_
M /YG]?Z6I_Q!'P\_Z%.(Z?\ ,PQGE_T]\G][/X<?^(53]IC_ *.E^ __ (1O
MQ*_^*K^C?_@D+_P3^\<_\$Y/V</&GP4^('C[PE\1=8\3_&7Q#\3+;6?!NF:W
MI6F6NG:SX1\$>'(=,GM]>/VQ[V&?PM<W$DT?^CM#=0(N9$E-?JO17A\0^)?%
MO%&6SRG.,;0KX*=6E7E3IX'"4).I1?-3:J4:4)I)MW7-9IV:T/=X=\-.$>%L
MQCFN38"KA\;"C5H*I/%XBLO9UHQC47)5J2CJEO:ZZ/>_R)XO_88_9K\<?'6V
M_:*\0>"M3D^(T96]U$:=XT\::+X2\1>*['3_  IH_AKXB^)?!&D:_9>%M:^)
MG@C2/!?AS3O!7CR[TMO$6@)HOAN^@O9-6\$^ M1\*S?"/]B#]GGX%>#K/X>_
M"W2OBEX;\"Z7I'@K0=#\(S?M'?M'^(?#OAC1?A[XAT_Q1X5TSPCI/B?XL:S9
M^$+.TU?3+8ZE#X9BTI?$FFM>Z'XG_MG0]3U+3KOZUHKX$^^/FOP]^R'^SYX6
M^(&I_$W1? 3V_BK4;OXC:E#Y_BWQQJ/AKPYJ_P 7[J*^^*FO>!/ VI>)KSP1
M\._$7Q&O8WO/&OB'P)X=\.ZUXCN[W5;G4KZ:;6M8:^]K\#>"?"_PU\$^#_AU
MX(TJ/0?!G@'PMX>\%>$=#AN+R[BT;PQX5TBST+0-*BNM1N;S4+F/3M)L+2S2
MXOKNZO)EA$MU<SSM)*_4T4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M > 3Z>G6OC#QI^UU=_#[XU>&OA]XM^"WC[0?AGXM^*^F? KP_P#&G5K_ ,.Z
M=I6M_$S5OAMJOQ0M[C0_!%U=Q^+M5^&-KI&A:UX?U3XDP1K;6/BK1]8QH,_@
MW1M6\:67V><X.,9QQGIGMGIQ^-?F[JO[*?Q[\4_MAZ[\=_B'XT^"/Q)^%SVE
M[X$^&G@KQ/X.^(T?B/X'_"3Q)X/MM!^(6G_#J.R\;CP!_P +4^)6K'5)_&?Q
M@UCPU=>)KWP7>V/PSTTZ3X/TJXL=9 -'X=?\%#?#/B[0M3\1^)/@W\6O"MCK
M'P(T?]I[X,Z3H^E67Q/\9_&;X(>(M;LO#NB:KH'@WX=S:QJ^B>-I=2UWP9-J
MO@K6,V^@Z3X_\+:EJ?BF*.V\91>$./\ B'_P4[\%>!O@A^SG\;X_A5XNU+2/
MCY^SEJ'[5+:-?^*_ 7A2_P#"_P +_#_ACX=^*/$/AW3]1\1ZO::)\0_C-]E^
M)6BV_A?X5^#;ZYOO%<VG:[/!K.FV5MI]SJG8?LS_ +&'C?X0:]X7U;XC?$KP
MOXX3X-_LO:=^QY\#QX8\$ZEX4N+;X4V.JZ+J-[XG^(;:GXF\1Q:MX[U^T\$_
M#;3-0@\-C1?#EK+X2U/5K:&4^*(=+\-?/_CK_@EYXCU_X+_LW?"VR^(7PP\5
M7/P9_8P'['&IS?%_X4ZGXY\+:-)/X?\  ^CM^T+\'/#5OXQTJ7P%\8=(E\'N
M;&XN=2OI+[3I]$L/^$CT1_#K7&L '[#V5W'?V=K>PI<1Q7=O!=1)=VMS8W21
MW$231K<V5Y%!=V=PJ2*)K6ZAAN;>4/#/%'*CJ+)( R<_@"Q_( G]*P?"NA-X
M7\,^'O#;ZSK?B)] T/1]$?7_ !+>_P!I>(M;;2=-M=.;6->U'RXOM^LZF;8W
MVJWOE1_:K^XN)]B>9M%3QGX'\(?$30+KPKXY\.:1XK\.7LMI/=Z+KEE%?Z=<
M36%S'>6<LMM,#&[VUU#%<0L1F.6-77D4 ?B1^U]JMQI/_!<7_@F)>VBQF9/V
M/?\ @HH5$\;LGR#X)3*2H:-B1)"I(W#Y>HPP-?J[_P +/\2_W-+_ / 2;_Y+
MK\5_VC?@]\/?AM_P6W_X)K6'PO\  'A[PDNK_L@?\%#'U*U\*Z-!IYU![./X
M/+9O=1VD8:X>!K^XC@:3<R?:&C4[651^OO\ PCGB'_H!:O\ ^"^Y_P#C=?:\
M.87+:V$J2QE/"SJ*K:+KN'-RVZ<S6E_\C\VXLQN<X?-(T\!5QT*'U6E*V'C4
M=/VCG44G>$6N:RC=-Z63.K_X6?XE_N:7_P" DW_R71_PL_Q+_<TO_P !)O\
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MGI]WEIU?_"S_ !+_ '-+_P# 2;_Y+H_X6?XE_N:7_P" DW_R77*?\(YXA_Z
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M ,3,^ 7_ $=;A#_PX^G_ $[\_P"KJ_[$T5^.W_#[_P#8\_Z%SXZ_^$/X8_\
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MV4XX^,81OS)TY7W1_"/17]W'_#$W[('_ $;%\!__  UG@[_Y54?\,3?L@?\
M1L7P'_\ #6>#O_E57[[_ ,5#N!/^B XM_P#"W)__ )=_5GY7_GW_ (IP<??]
M'$X0_P#"#.?+_ISYO[O,_A'HK^[C_AB;]D#_ *-B^ __ (:SP=_\JJ/^&)OV
M0/\ HV+X#_\ AK/!W_RJH_XJ'<"?]$!Q;_X6Y/\ _+OZL_*Y_P 4X./O^CB<
M(?\ A!G/E_TY\W]WF?PCT5_=Q_PQ-^R!_P!&Q? ?_P -9X._^55'_#$W[('_
M $;%\!__  UG@[_Y54?\5#N!/^B XM_\+<G_ /EW]6?E<_XIP<??]'$X0_\
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4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>revbynatlmarket2017-2019.jpg
<TEXT>
begin 644 revbynatlmarket2017-2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #% J # 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_@H;^Q;\>$^%[_"/]HGX=^-S\9?''CGX9?#F#2KW4H[O7_B-\-_!\?Q"\:>
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M:UV>X\.S7,6M7FDZ7=:]I=C?Z$J:D_YJ?%/_ (),?M)^+OB=^T-\-/#7Q?\
M@;;?L6_M:?MW?!_]OGXLZSX@\)^/KC]KCP1XQ^&GB#X->+M:^%/PRURPU#_A
M75_X9\3:]\#/#5MX7\<^))K35OAGX8\1>)/#]KX2\511:;,O6?##_@E'\6O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "
M 9QGGU))_,DG'/ Z#L*6BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH ***3<N[;N7<1D+D;L>N.N* %HI RMG#*<'!P0<'
MT..A^M)O3Y?F7YON_,/F_P!WGG\,T .HHK\RO^"D/[6GQ0_96U[_ ()W:?\
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M /@TL/\ Y(HY9?RR^Y_UU7WASP_FC]_]=_S[,VJ*Q?\ A)/#_P#T'-'XY/\
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MU+PP-$UJ+PYKOB/1WU.2Q\2Z_#J7@0_X-5?AV  /VEOVBP   !\$/@^  .
M!\5,  < #@#@5VY=QED.$C5I5\S56DG2]A+ZMC)5DE3A&<:LG1C!J,HJ-/V<
M()QASN,93<5Y6=^''$V8SH5\+DT</7:K?6X_6\###R<JTITY480J2FI2C*4Z
MKJ3FU*7)&4E!2E_&%YDO_/67_O[)_P#%4>9+_P ]9?\ O[)_\57]GO\ Q"J_
M#O\ Z.6_:,_\,C\(/_GJ4?\ $*K\._\ HY;]HS_PR/P@_P#GJ5Z7^OG#'_0=
M+I_S"XGR_P"G/3_VWT/"_P"(5<:_]"VC_P"%N%_^6?U9^5_XPO,E_P">LO\
MW]D_^*H\R7_GK+_W]D_^*K^SW_B%5^'?_1RW[1G_ (9'X0?_ #U*/^(57X=_
M]'+?M&?^&1^$'_SU*/\ 7SAC_H.ET_YA<3Y?].>G_MOH'_$*N-?^A;1_\+<+
M_P#+/ZL_*_\ &%YDO_/67_O[)_\ %4>9+_SUE_[^R?\ Q5?V>_\ $*K\._\
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MCG^\W_?3?XU^G/\ P[ZT;_H>_'/_ (2OA;_Y>T?\.^M&_P"A[\<_^$KX6_\
ME[1_K1DG_06__!%?R_Z=^?\ 5U<_U5SS_H$[?\OZ']W_ *>^?X+NC\QN?[S?
M]]-_C1S_ 'F_[Z;_ !K].?\ AWUHW_0]^.?_  E?"W_R]H_X=]:-_P!#WXY_
M\)7PM_\ +VC_ %HR3_H+?_@BOY?]._/^KJY_JKGG_0)V_P"7]#^[_P!/?/\
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M2^&/#$DLTTSM+--+(^O%Y)99':221R7=V9V)9B2S_AWUHW_0]^.?_"5\+?\
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M*'_H]OX0_EXR_P#F3K_+?WR_WI/^^F_QHWR_WI/^^F_QH_XA=DO_ $,,S_\
M L)_\S>:^\/^(X9]_P!"?*/OQGE_T_\ +^K*W^I!_P /Q?\ @E#_ -'M_"'\
MO&7_ ,R='_#\7_@E#_T>W\(?R\9?_,G7^6_OE_O2?]]-_C1OE_O2?]]-_C1_
MQ"[)?^AAF?\ X%A/_F;S7WA_Q'#/O^A/E'WXSR_Z?^7]65O]2#_A^+_P2A_Z
M/;^$/Y>,O_F3H_X?B_\ !*'_ */;^$/Y>,O_ )DZ_P M_?+_ 'I/^^F_QHWR
M_P!Z3_OIO\:/^(79+_T,,S_\"PG_ ,S>:^\/^(X9]_T)\H^_&>7_ $_\OZLK
M?ZD'_#\7_@E#_P!'M_"'\O&7_P R='_#\7_@E#_T>W\(?R\9?_,G7^6_OE_O
M2?\ ?3?XT;Y?[TG_ 'TW^-'_ !"[)?\ H89G_P"!83_YF\U]X?\ $<,^_P"A
M/E'WXSR_Z?\ E_5E;_4@_P"'XO\ P2A_Z/;^$/Y>,O\ YDZ]M^ G_!3?]@_]
MJ#QK?_#OX!_M+?#_ .)WC73/"NM^-[_P]X>'B/[=;>%?#DEA%K>M2'4= L+?
M[)ITFJ6"3A9VF)N8_+AD <K_ ).6^7^])_WTW^-?T#_\&V;2']OKXC;F<C_A
MC;]H#J6(S_:?PUQU[UP9GX<93@<!BL73QV83G0I\\8SEAN63YHJTN7#IVM+H
MUT/7R'Q@SK-LWP&75<KRNE3Q=;V4ZE/ZTYP7)*5XJ5=QO>"W5ON5O[9A_P %
M8?\ @G<P##]JKX;X8!@=GB@9!&0<'PZ",@]QFE_X>O\ _!.__HZKX;_]\^)_
M_F=K_/\ 8C)Y46"_^JB[M_SS6G@R9^\X]\MQ[U_9?_$E7AW_ -%/QE\\1DG]
MW_J2^OWH_DM_3>\0E)K_ %3X-T=OX6=='%?]#;R_%>5O] +_ (>M_P#!/3RF
MG'[4OP\-NLBQ/<"#Q6;9)F4NL#W \-^2D[HK2)"[B5HU:14**6$TO_!5/_@G
M[;R2PW'[3G@6WG@B2>>"XL/&,%Q;V\JQ217%Q!-X826"WECG@DBN)42&2.XM
MY$=DGB9_YF/A?XD_X1W]C#PVZ6NI:MX5TC]G?XE>)]4\2WWBG2/^&>8?B;I?
M[1UMXVT;X3_$'X3NRZEK_P"T1KUOX<TS0/"WQ ;5['6K7P_XK\,OIO@C7/#'
MAZ\\1IMZ[HLG[;EEJ4]GJ/B?X:^)_%/PWT/Q)K%SXHO1\6O' ^$E_P#&3X@>
M)/!4WC_Q$B^"/['^&$?CSQ%JGB#Q!XB%A>-X#^"/PY^!T1L-835&=/RFI]';
MP^PV*QKQN,XQPN3Y?GF89-C,V_MK(\0J$<'BJ5"CBJF"P_#,\3&>)@L14E@N
M5UL+*.'AB)0AC,-5G^NT_I%>(.(PF"^I8'@W%YQF&0Y=G6$RB.3YU0=>6,PT
MJ]7"T\=6XGAAI4\-/ZM36-;C1Q*JXB6'A*>!Q%*']4'@?]N;]DWXD^ _B'\3
MO _QO\(>(O ?PH.C#XA^)K$:TNG>%CXAD:+1AJ)N=)M[@_VA(C) ;6"Y&Y2)
M-E<I_P /'OV(1_S<9X!_[ZUW_P"4M?S'_P#!.MW?_@G'_P %-Y/F!<_ 1P"3
MD;]3O6(S[ X)XSCI7Q^QDR>7ZGNWK5X/Z,O!M?B#C3*9YYQ-[#AO/\)E.#J1
MKY6JM>AB.&>'\[G4Q+>5N#K+$9MB*,72A2@J-.DG!U%.I/#&_2?XSPW#_!.;
M4\BX9]OQ+P[BLWQM*='-)4J&(H<3<09)&EAN7-(25%X?**%62J2JS]M5K-35
M-PA#^S-?^"C7[$L@E:/]HCP-(L$1GG:-?$$@@@5@K7$Y30V$%NKLJ-/+LB5F
M52X9@#)_P\4_8LQ;'_AH#P;B^5VL3]F\2XOUCE:"1K _V!B]6.X5K>1K7SA'
M<*T#E959!_/Q^P[J$FG>$':U@\2:J+W]H+PC_P )@/"?BK2/"EKX*\$V7@#6
M+27QA\;K?59U/CWX$RW.N7[:IX,E?0M':]\-ZX+[Q78ZCK6E6-Q=\%^,Q\:O
M!/@3P=%9ZWX?U7P[!XB\"_#S6]+N&\7RZCK'@CX#Q:#XSO\ X$^ 6@\/3:-)
MJGP^\*V\^F^&)M<N)-9^.'Q9T744O[>31I _S.-\">#\'F6:X7V_%$\#E$Z*
MQ>8_VQDJE3IUL+BJWMJF7QR&>,C3I5,+.554X5:LL$JF.HTJM",)3^FP7CWQ
MEB\MRG%.APM#'9Q"L\)E_P#8V=N-2I1Q>#H>QIX^6?PP<YU:>*C&FYSHTHXV
M5/ 5JM+$2E&G^^8_X*/_ +$)&1^T;X!(/((;7<$>O_(%KV#3?VH?@%J_@;0/
MB5IOQ/\ #EWX%\4:EJVD:!XDB.HG3]4U+0YY[;5K2VW6"W'FV,]M<1S>9!&F
MZ)MC.,$_Q2?$KP9+\-_B%XV^'[:K;:T?!?B;5O#7]K6"-#::A_95RUN+B* S
M3_9FVJ([FT\^?[%=QW%GY\WD>:_[)_"DM_P[R_9NY;/_  M3XSYZY_Y&+Q'U
MKB\1/ SA+A3A[)\[R?.,^QJS7-\%@H_7:F!]D\'C,KS''QK0A3R[#U8U6\'1
MY54=HPJ3C*GS\KCV^''COQ?Q;Q%G&1YSDV08%Y5D^-QLOJ5/'^U6,PF:Y7ET
MJ,YU<RQ%*5)+&5VW32<IPA*-3DNI?M[_ ,-8?L[_ /15O#7_ )4__E?1_P -
M8?L[_P#15O#7_E3_ /E?7X'Y/J?S-&3ZG\S7Y)_J3EO_ $%8[_P*A_\ */7^
MEK^O?Z\YE_T"X+_P"OY?]/\ U_K;]\/^&L/V=_\ HJWAK_RI_P#ROH_X:P_9
MW_Z*MX:_\J?_ ,KZ_ _)]3^9HR?4_F:/]2<M_P"@K'?^!4/_ )1Z_P!+4_UY
MS+_H%P7_ (!7\O\ I_Z_UM^^'_#6'[.__15O#7_E3_\ E?1_PUA^SO\ ]%6\
M-?\ E3_^5]?@?D^I_,T9/J?S-'^I.6_]!6._\"H?_*/7^EJ?Z\YE_P! N"_\
M K^7_3_U_K;]\/\ AK#]G?\ Z*MX:_\ *G_\KZ/^&L/V=_\ HJWAK_RI_P#R
MOK\#\GU/YFC)]3^9H_U)RW_H*QW_ (%0_P#E'K_2U/\ 7G,O^@7!?^ 5_+_I
M_P"O];?OA_PUA^SO_P!%6\-?^5/_ .5].3]JW]GJ5UCB^*?AV61L[8XTU621
MMH+-M1--+-M4%FV@X4%C@ D?@;D^I_,UZG\)W\7)K.J2>$EU>[ECTZT?6M(\
M*Z[9^&_'&MZ$NKV,ES8>#]8GL[V[L[M;N.RGU>72XVN4T=+AKN&XTT72IE6X
M,RZE3G4^M8N\4K<]7#TX7;2UF\.U'5Z<UHW:3E%7DM:'&N95:L*;PV%7,[7A
M1Q%26U](+$*4MG=1O*UW&,G:)^TB?M2_ *2+SX_B7HLEO\Q^T1VVM26^%R&/
MGII;184@ACO^4C!Q36_:I_9^4HK?$_0%:6$7$2M#JZM+;%6<7,8.F R6[(CN
MLZ!HBB.X<JC$?ECXW\6:IX:@^-=WH?BV[EM_%?C[6/ >@V&D:M/'H&E:3K%E
M)XF\>ZA8:-9ZE<:2MW.MUI_A)M4M1-#<2W/B*^LKEGNXY5ZNWOF^-L&FVRV^
MJ^&=5UC1O$UOIHC<>+-73PU)K'A:P\46WA73E&AFR\*+J@L])T32C<2/I'A?
M3_B/=>?< )&W ^&<!",*LYXQ8>3M*K[>BW37L85;NF\&IRMS3C)1]Y.E4;C9
M1YO17$^/E*=&$<'+$15XT?85DJG[Z5*RJ?7'"'-RQE!S:C)5J:4KM\OZ/?\
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MQW_@5#_Y1Z_TM3_7G,O^@7!?^ 5_+_I_Z_UM^^'_  UA^SO_ -%6\-?^5/\
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ME3C54UR4*E1<KE6E'64+.\7HWUM;]5****^#/OPHHHH **** "BBB@ HHHH
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M_4#Y/[V?9O\ PX'_ .";?_1FOP=_\.=^TS_\]"C_ (<#_P#!-O\ Z,U^#O\
MX<[]IG_YZ%?&7_$6#^P[_P!$ _:Q_P#!'\'?_GM4?\18/[#O_1 /VL?_  1_
M!W_Y[5']G^(?\N>?^%];_P":_)?<']K^$G_/SACI_P RK#>7_4#Y/[V?9O\
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MJG%W_4T_\*ZG_P T>?Y]F'UOA#^;*^G_ #!T^G+_ -./[OXGIO\ PQY\#?\
MHF'AC_P>^.?_ )?T?\,>? W_ *)AX8_\'OCG_P"7]>9?\/#/A5_T)WQ$_P#
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M_#'GP-_Z)AX8_P#![XY_^7]'_#'GP-_Z)AX8_P#![XY_^7]>9?\ #PSX5?\
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M3]0\0WLUVEA)/+9(5UC4;Z*-89+JX8F)8W;S,,6"J%^9?^'AGPJ_Z$[XB?\
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MK\H/^"I_[*/Q;_:JU#_@G'#\+O#%EXETKX#?\%,?V?OVA_C$U[J_A'3E\/\
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M?#__ )]]._\ #;_!#_YU5'_#.'P__P"??3O_  V_P0_^=51_Q%.C_P!"E_\
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MA_Q VM_T/9?^&ZEY?]3'S?W>9_C\?:;7_G[L_P#P+MO_ ([1]IM?^?NS_P#
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MX?\ _/OIW_AM_@A_\ZJC_AG#X?\ _/OIW_AM_@A_\ZJC_B*='_H4O_PME_\
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M*2HQS"NJ:A''*C9UJCDZ3J7BI^SC_-EY\'_/>#_O]%_\71Y\'_/>#_O]%_\
M%U_2;_PA.C_W(?\ P2>%?_F?H_X0G1_[D/\ X)/"O_S/UX7^O%+_ *%[_P#"
MM^7_ %">OX>9[G^HE;_H8Q_\)%_\U^O]+7^;+SX/^>\'_?Z+_P"+H\^#_GO!
M_P!_HO\ XNOZ3?\ A"='_N0_^"3PK_\ ,_1_PA.C_P!R'_P2>%?_ )GZ/]>*
M7_0O?_A6_+_J$]?P\P_U$K?]#&/_ (2+_P":_7^EK_-EY\'_ #W@_P"_T7_Q
M='GP?\]X/^_T7_Q=?TF_\(3H_P#<A_\ !)X5_P#F?H_X0G1_[D/_ ()/"O\
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M\^#_ )[P?]_HO_BZ_I-_X0G1_P"[#_X)/"O_ ,S]'_"$Z/\ W(?_  2>%?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !117XB_P#!8S_@KGK_ /P2S/[/@T/X%Z/\:/\ A=S?$\7/]K?$._\  ?\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %?R<_\'/?[*O[2O[3
M!_8M_P"&>?@/\5OC9_PAC_'\^+/^%9>#=6\6_P#".?V^GPC&B?VS_9D4OV#^
MU3I&J?8//V_:?[/NQ'DPM7]8U! /4 _6O4R7-:N2YEALSHTH5JF&]KRTZCDH
M2]K1J4)<SC:6D:C:L]TNAX?$>1T.),FQF2XFM4H4<9]7YZM%1=2'U?%4<5'E
M4TXOFE147?HWU/\ -1_X)L_\$XOV_/AQ_P % ?V-/'OC[]C3]I'P;X)\'_M&
M?#+Q#XK\5^(_A5XETO0/#FA:;K:7&H:QK.I7%LMO8:=90J9+J[G98H4^9FZ
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21110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>revbynatlmrkt2017-2019.jpg
<TEXT>
begin 644 revbynatlmrkt2017-2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #Z @H# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKX-_M/>'==N-.T2ZA:W^+OP2_:*\4>&/#UMID]U;WTZR67B631K*5;Y=U?\
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M% !1110 4444 %%%% !1110 4444 %%%% "$9&#G\"0?S!!I>G2BB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#^S/^UMK7PC^$/Q?^.WPR;X0_&SQU\'-;^$_PP^*O@J?XK>"G\"?#&6/Q;I
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M_P#S2T?\1:/[,7_1J/[1/_A1?"7_ .:6OX2J*/\ B'G"_P#T"8C_ ,+,3_\
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M5G*2C"%.$^:2E*$9?KC_ ,19W[,F=O\ PR?^T7N_N_\ "0?";/Y?\))FF_\
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M^%%\)?\ YI:/^(M']F+_ *-1_:)_\*+X2_\ S2U_"511_P 0\X7_ .@3$?\
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M\66?A?P;<^"KO4_$;?%SQ;8PZEXV^'NF^(?$WAJTLO"5G%87/B:.;1/#FO\
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M@>K_ .%%;_Y/^KORL?ZWYY_T$T^G_,/0\O\ IWY/[V?K-_P\4\"_]$Y\;?\
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M\S_'S^U6G_/W:?\ @5;_ /QRC[5:?\_=I_X%6_\ \<K_ &#/^&=_ W]RR_\
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M[;1=+TK3K1;BZO+LP6=E;Q(9[NZN+F:0O-<3/(YQ^H?_  B6F>D?_@I\.?\
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MO^H3U_#S''@2LFG_ &C'1I_[HNC7_47Z_AVUZZBF1J4C1&D>5D55:60())"
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M45^:O_#QK1?^B3ZY_P"%7I/_ ,JZ/^'C6B_]$GUS_P *O2?_ )5T?ZL9[_T
M2_\ "C"__+_/\^S#_6G(?^AA'_PGQ7_R@_2JBOS5_P"'C6B_]$GUS_PJ])_^
M5=2P?\%%M%FGMX!\*=;4SW$$ 8^*M*(4SS)"&(&EY(4ON(XR!C(S2_U8SW_H
M E_X487_ .7_ -:]F"XIR%NRS"-WHO\ 9\5_\H/TEHHHKP3Z **** "BBB@
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MW:,K7TNG>W2_GJOO*E%6_L%__P ^%_\ ^ %Y_P#&*/L%_P#\^%__ . %Y_\
M&*+KNOO0N67\LON?]=5]Y4HJW]@O_P#GPO\ _P  +S_XQ1]@O_\ GPO_ /P
MO/\ XQ1==U]Z#EE_++[G_75?>5**M_8+_P#Y\+__ , +S_XQ1]@O_P#GPO\
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M4C&HVVG!U)/W8*G[.$(\KDY.,N&HI_E3?\\9_P#OQ+_\11Y4W_/&?_OQ+_\
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MWG?_  K]_P#H=/&G_@9H7_S.4?\ "OW_ .AT\:?^!FA?_,Y7HE%'MJG\R_\
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M90B765LS;G6-1+M:M<^>HG%O!]\_\1=6I?\ 1A-I_P")*R?_ #DJ_B$^#_\
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M_P")*R?_ #DJ_C.HH_U"X3_Z%2_\+<P_^:_ZN_*Q_P 14X\_Z'K_ /#;E/\
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M%9V%K;VT;2RR2E(E,DCN68M\3?\ (O:Y_P!@?5?_ $W75;E8WB+_ ) 6L?\
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M#>O];8?\0,H_]#ZOT_Y@:?\ =_ZB?-_=Y,_Q_?\ A5/Q2_Z)C\2O_#>>-?\
MY14?\*I^*7_1,?B5_P"&\\:__**O]@+_ (5UIW_0Q_$#_P +[Q5_\LZ/^%=:
M=_T,?Q _\+[Q5_\ +.C_ (BI/_H40_\ "N7E_P!0WK_6Q_Q RC_T/J_3_F!I
M_P!W_J)\W]WDS_']_P"%4_%+_HF/Q*_\-YXU_P#E%1_PJGXI?]$Q^)7_ (;S
MQK_\HJ_V O\ A76G?]#'\0/_  OO%7_RSH_X5UIW_0Q_$#_POO%7_P LZ/\
MB*D_^A1#_P *Y>7_ %#>O];'_$#*/_0^K]/^8&G_ '?^HGS?W>3/\?W_ (53
M\4O^B8_$K_PWGC7_ .45?7__  3X^&?Q(L?V\_V*KV^^'7Q!LK.T_:O_ &?;
MJ[O+WP+XNL[.TMK?XI>&)9[FZN[G18K>VMX8T:2:>>6.&%%9Y71%9A_JA_\
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M]4NOCOXHGM=,U.XA;2_"P2>VTZ^N(69-#MPP6:"WDC8JW#!6)5@0P!K]5/\
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M*+K4CYL;1$MJ5XS*&*G=&6F)CD&T!9$PZ@L <,08/[$@_P"?[6?_  <ZC_\
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M1_KS_P!2Y?\ A2__ )1_5GY7/]0_^IB__"9>7_3_ -?ZW_FU_L'7O^@!K_\
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MI_ Z?IZ7Q? EW=YE)MN[;PR;;=KMOV^^_P#P>O\ -K_8.O?] #7_ /P1:O\
M_(5']@Z]_P! #7__  1:O_\ (5?TE?V)!_S_ &L_^#G4?_DBC^Q(/^?[6?\
MP<ZC_P#)%/\ UY_ZER_\*7_\H_JS\KG^H?\ U,7_ .$R\O\ I_Z_UO\ S:_V
M#KW_ $ -?_\ !%J__P A59L=!U[[?I__ !(=> &H6!).AZL  +R DDFR   Y
M)[ $G@5_2#_8D'_/]K/_ (.=1_\ DBC^Q(/^?[6?_!SJ/_R12_UX_P"I>E_W
M,O3_ ,H?U9^5VN!+-/\ M%Z-/_=ETM_T_P#7^M]FBF1QB*-(PSN(T5 TKM)(
MP4  O(Y+.YQEF8EF.222:?7Y^?H84444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5%/!%<PRV\Z"2&>.2&6-LX>.5&CD0D$'#(S*<$'!."#4
MM% 'DGP)^!/PF_9G^$W@OX&? SP5I?PZ^%'P[TZXTCP9X+T:;4I],T#3KO4[
M_6;BUM)M7OM2U*1)=3U._O':[OKB3S;F0!P@1%];HHH **** "BBB@ HHHH
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M36&@:IJUIJ7A+5]=2TM;2YU&&[T*^OA.K64@_-N7Q-\0_AK\7K3]H#XJ:?\
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M/G_9K:6^>WL8;6RBM[6'KZ "BBB@#\\O^"KM]?:9_P $]?VH+[3;V\TZ^M_
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M_!5&A4R[!<.4<NQ3JYS0RV7UR&:9CB915*K5IRFE0Q-%^T2:=W&]XM+]2/\
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MEDO]MY!C/:/,,/3D\-@*650Q4OJ\JJJ74L+6M#EO/E32?,?7R]!]!_*EH'
M]**_FL_IE;*^]E<Q/$GB7PYX.T+5O%/B[7]%\+>&=!L9]3USQ%XBU2QT30]&
MTVU7?<ZAJNK:G/:V&GV5NGS375W<0P1+S)(HYK\9?%'[2/Q3^$G[4/[=UGHO
MBW3GDU/XT_L4?#'X8Z/\0M'^-_Q6TS0Y_%/[->L>./'-I\)_@;\&=(USQQ\1
M_&LNF>']3\57_@#PE=>!;2XL+36O'GC+QEH>A>&=2N[C]D/&7@[PK\0_"7B?
MP%XZ\/:/XM\%^-/#^L>%?%OA;Q#I]OJN@^(_#?B#3[C2M;T+6M,O$EM=0TO5
M=-NKFRO[*YC>"YMII(I%*L:^8X?V"?V3H/AP?A9#\)+*/PQ_PL/3_BTMZOBO
MX@#QW'\3-)\/IX0TKQW#\5?^$N_X6I!XJTSP7&G@73]:A\:)>V7@,'P1;2Q>
M$V;1V!GYQ?"W_@HC^V+\=M7\+_#WX=^"?V>O"_CNQ^%W[='C;Q]K'Q4T+XQ^
M'-*O=<_8R_:KTW]G+3=+T;P'_P )%;>,/ MI\6(M1AU?7(/%^KZ[K'P9NGF6
MZM/B1)91Z1J)\4/^"L?Q!TWP)X ^.GPV\*> =1^'M[\-/V*OB9XV^%;>"/CU
M\1/B!I-I^UCJ7@*YU'PYXZ^-?A'0O#OP&_9W\1>$?"/Q%T/7?".D^-IOB'XB
M^(UJ$UBY\,^#/#^L:#>7_P!.:S_P2<_98UCXO^#?%G_"!>%-,^#W@_X-_&CX
M;6_P.T/3/$'A_2+GQ'\=?B]X%^*WQ"\6OX@T#Q;I=V=)\9R^$M3TCX@^!;BR
MNO#_ ,0E\3:E<>*DO[::_P!.U'Z!^('[ O['_P 4/$EYXJ\;_ CP9K.HZCI?
M@K2M2M(SKFC^&]37X:K;Q_#;5-3\&Z#K.E>#M1\3?#F&SL;7X?\ B^]T&?Q9
MX)L]/TZR\+ZUI5IIUC!;@'R#\/?VZ?VC-=^+'@&X\5>#/@S:_ _XB_\ !0W]
MJ/\ 8&T?2]!;QT_Q4LYO@C'^T-=^$?B]?Z[J&K-X0-MK<GP"U'0/$?P_A\,B
M6'^V+3Q9I7C=07\'P?K\#D ^H!_,9KQ2R_9R^"6G_P#"/?8OAUH%O_PBGQL\
M9_M&^'O+%]_Q*OC;\0O^$[_X3/XBVVZ]/_$_\0_\+-\>?;S)YEB?^$FU'R;*
M'-OY'M@&!@=!P* "D/\ 4?S%+0>?T_0YH _G>^+>MZW'\5OB;''KFN11Q_$+
MQHD<<6M:K%'&B>(]25$CCCO%2-$4!51%554 *  !7WO_ ,$Z[^_OK/XNF^O[
M^^,5[X*$1OKZ[O3$&M?$NX1&ZFF,8?:I<)MWE5+9*C'>>*/V"_ ?BGQ-XB\3
MW7CCQK:W/B/7=7UVXMK:+PZ;>WGU?4+C4)H+<S:5),88I+AHXC*[R%%7>S-D
MGVSX#?L]>'O@'#XHAT'7]=UP>*9M(FNCK::8AM6T>/4(X1;?V=:6H(F&H2&7
MSO,(,<?E[1N!^]S;/<KQ>23P5"I)XF5/"Q470G%<U*K1E4]]Q4=(PEK?6UEN
M?G^3Y!FV$SR&-Q,(K#1J8N3DJ\)NU6E5A#W%)O5SBGIIUT1]!4445\$?H!^>
M/[74VJ>//VBOV/OV:M9\8^+O!7P?^,<?[0?BKX@-X&\5>(_A_P"(/B5XA^#W
M@_P;JW@;X*'QSX/U;0O%^DZ-XCLO%7C?XG>(=*\)ZQI&K^*=&^#UUHE_?OX2
MD\4Z3JWYZ?M&^,?CS^S-\7/%7[//[)?QIU+2_ ]O\8O^"4'B2.S^+.M>,OC8
MGPJO_P!I/]L;Q)\$?B)\(['7M>\;)\1HO WQ2\*>$?#'CBY\#ZSXRNET#0!\
M0;/PE/X8TWQ_X?ET/]R/B]\%?A;\>?"2^"/BWX+TCQKX=@U?3?$>FV^I+=6]
M]H'B;19))-&\4^%]=TNYT_Q!X3\5:,\TYTCQ/X9U72=?TS[1<+8ZC EQ.LGE
M%K^Q1^R_9?"GQ-\%[?X2:(G@3QGXLT3Q_P"+8CJ?BB3Q5XF^('AG5]!UWPU\
M0-=^(\NOO\2M5\>^'-4\+>&;CP_XUO?&$WB?1%\.Z);:7JMI::596\ !^3'[
M-/[:O[1GP+\!?#37OC/%X2^)?P6^*'[2'_!5CP?I<UG>>/\ 5_CQHT/[-WQ"
M_;,^.&A:S>>(/$&M7_AG5] U'PQ\#_$7PQ\.?#2ST&RN/!6E)X$EL/'&N64-
M]X>TVQ/_ ,%4/VL=*^"_BGXH7'[/>@ZE+KOP6^$/Q;^&EYXE^&OQ[^!_@;P]
MXF^)OQU^"/PK/P<\2>(OB0EU>_%M?[ ^-MEXBT7XR_#'2_#VC7%QX0\1QZO\
M.=,M;OPT=:_9?1?V;/@;X=M_AW::/\-_#UE;_"?QQ\2OB3\/8@M].GACQS\8
M8OB#!\3?$EB+J]G\W4?&<7Q4^(2:T;[[7!,/%>JF*"$O"8?'O#7_  3P_8O\
M(V7B33M!_9^\$VECXHT_PKH=Y:3/X@U&#2O"_@?QUIWQ,\)>"/!T>J:Y?+\/
M_A]H'C[1])\6Z;\// 7_  C/@B#6],L+P^'W:SMQ& ?4'@"+QY!X/T&'XG:C
MX2U;QY%9F/Q/J/@31M:\/^$;S4TN)U:;0=&\1:]XHUK3K%H! %MM1U_5;A91
M*QNV1D5.QI  . ,<D_B223^))-+0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
F1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>revbyopsegment-geography2017.jpg
<TEXT>
begin 644 revbyopsegment-geography2017.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #% 7$# 2(  A$! Q$!_\0
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M4N[-7TO5;$6[S7=PEK0![/13=Z\<]<8X/?\ #C'\6?NY&[&1E0<^O?J".GU
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M"/PD_:H^,>IIK<'CN^/CNQ_9^_;]^,/[*&@>"M'U71?&%M;^%IO%O@#X8_\
M"1ZMX[ET_P 6P:%XS,J67@G5=$U);'1_5O''_!0']H[P?\0M<_9]7PAX6\2_
M%'1_VC?BS\*E^)'P\^!GQ0^(WA>7P?\ #W]FK]GS]H;3)Y/@IHWQ<T_Q7'XI
MU-?VB-)\+ZA=)\6I-+M-,\#>)?&-KI5P^HV?AS30#]J**_-/]AW]J_X]_M6>
M,?B9JWC/PC\-?AK\-/A_X;^ ]DG@[3EUCQ/\2+KX@_%S]G3X+_';6IKKQW9>
M,)O Z^$?"MW\0=9\/:5;Z;X5U&_\6Z=/HFLS:SX<GTJ_TS7/@#P%^TU^V;J'
M[/'[*VH:SHEY%X/\3_\ !1WP1\.=9^/7_#0=UJ'CSQ1X O/V_?'G@0>%M;\
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MGQ#JQL;*.&RM'U+5+JYO)+>SA@M8I)G6W@AB"1+VO[</_)F'[6__ &;'\?\
M_P!5'XQKY_\ ^".?_**'_@F]_P!F0_LR_P#JI/"] 'Z24444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8)[KX/?%RUMHGGN;GX5?$J"W@B&Z6:>;P/KT<44:_P 3R2,J(.[,!7\"=O\
M\>ME_P!>%A_Z1P5_H$>/_P#D0O'G_8C>-/\ U%M7K_/WM_\ CULO^O"P_P#2
M."OVWZ.C_P!HXL714<G?WSS+_)'YC])";? W#%.RM'BK,9I]6ZF4X6+3Z62I
MJWJ_(EHHHK^HC^+PHSC]1]01@@CH002"#P02#Q110!^Y7_!+S_@K]XX_92U3
MP]\%?CKJ6I^./V:[V]LM+T_4+R6\U/Q1\$H9Y8K<:CX<D_TF[U?X?V:,T^K>
M!Q'-<:9"K7_@YK9XKG0M7_M>\*^*_#7CGPWH?C#P=KVD>*/"OB;2[+6_#WB+
M0=0MM5T;6M(U&!+FQU+3-1LY);6]LKN!TE@N()'1U/4$$#_+7!(.0<$<@CJ#
MZU_0'_P15_X*8WWP!\<:-^RM\9=:FN/@?\1_$$-A\/M:U&XC\GX3?$#Q!?1Q
M102W=W-&++X?>,;^98M3@WFS\-^);B'78(K>SU;Q#,/XW^D3X X3.L%C^/."
M\###Y]A(5,9GV482G&%+.\/!.>(S#"T8)1CFU&*E6KTZ:2S*FJDU&68)+%_V
MM]&_Z0F+R?&X#@#C?'RQ&1XN=/!\/YQBYN57)L3-QIX?+L77E>4\JK2M2P]2
MHV\NJ2A!SC@6WA?[1:* <_Y'![CC(R#P?>BO\[S_ $:"BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "J=[J-AIJV[ZA>VEBEW>6FG6K7EU!
M:K<7]],MO964#3R1B:[NYV6&UMHRT]Q*PCAC=R%-ROA#_@H/H.K7OPH^%?C&
MQTO5]7TCX._M7_LI_&?QS#H&A:SXGUFP^'7PZ^-GA;5O'7B&R\/>'M/U77=7
MC\*^'9+WQ/J=IH^FWVHKHND:G<VMK/);B-@#[BCU+3YKV[TZ*^LY+^PAM+B^
MLH[JW>[LX+_[3]AFNK59#/;0WGV.[^RRS1QQW/V6X\EI/(EV,75=+;49M'74
M;!M5MK"UU2XTQ;RV.H0:;>W%W:6>H360E-U%8W=U87UM;7<D2V]Q/9W4,,KR
MV\RI_/%\;OC!?Q_M0:C\</!WQ/\ B?\ "W]G3X\_M&_L6?LR>)?B]\/_  AJ
M\%]XWT#X:?L_?MT^/OB7I?AS4-6\+7>K6W@6T\2^)_AOI6O_ !7\*Z<]OX8N
MM,\27.E^)--NO"^LWVE<YX?^._[3DWBK1[+QSXU^)^A>%KOX7_LR-\4?BM;?
M#O3=#^/6D_LLZ[^V7^W]X6\)?%[6H=/^'D'BS0-;^(/PU\#_ +.\7Q,OW\.V
M"_#/0_&_CKXAZ?HG@36DUCQ#HP!_2$-3TTWYTH7]D=3%FFHG3Q=V_P!N%A)<
M-:1WIL_,^TBT>Z1K=+KRO(:=6A60R*5%W<N<;ES@G&1G X)QUP#P?2OY=]=;
M]JG6]8^/_P"T)X3\=_M%6_B7X/?L!?M)ZQ^SGX[3P0-.\6?&K2_A;^UQ\2_$
MO[-<WQ#TK4?AS:R^++WQ'X-T"SM7\(C0M'O?B?X)UVP\9:WI%[?Z_I>KQ_:W
MA+Q3^U%%\=;#Q;XJ^*/QT/@CQ+^W_P#MC_ ;Q!X4?P_:Q>"?"?[+WAC]G7XP
M>/OAWXDT2P@\%27EM?\ A_XA_#_P[>>$/B5)>7M[K,VOR>"C<ZYI^H:1HT(!
M^T&L:UI'A_2[W6]=U33M%T;3;=[O4-6U:^M=-TRPM8QF2YO=0O98+2TMT!!>
M>XFCB7(W.,BN7\0?%'X;>$Y/#\7BCX@>"?#DGBSR_P#A%X]>\6^'M&D\1^=)
M:Q1?V"FIZE:MK/FR7UE'%_9HNA(]Y:JFXW$(?X1_;-^)GP5^'?[*/PA\<>//
M FO?M+V@\5?"$_!G1?'5OXIATKQ?\3;_ ,.7Q\!^/?CO>:?X0N[7PSX+T+3Y
M=2^('Q!\3^,_AWJECX6O]/BU;0O 6I_$VT\#>')?RL?X?>'OA7X8^#_CKX7>
M._\ A<7Q7\,?L]V4GP#^'MS^Q?<>)O@-\;_B+XF_:Q^*/Q%\??"?X0ZUXITC
M5/$_P@\.Z1XOUO2/ MEX1TRZ\!^)/@S\*/"OPD^)6I>*/$O@KPWK<%F ?TRZ
MUK^A^'+(:CX@UG2M#T]KJTLA?:QJ-GI=D;R_N8[.QM!=WT]O;_:KV[EBM;2W
M\SSKFYD2"!))75#%_P )/X<_MF^\.?V]HW_"0:9I,&O:CH?]J6']L6&B74UQ
M;VVL7NE_:/M]II=Q/:74$&HW%O'9S36UQ%'.TD$JI^+/_!1XZ?\ %+XE?!/5
MM4UN"R^ /@OP9^VK\//&FK^(OV;/$GQX\/Z;^TA'IGPHL?AQH-]\/M8T:YT:
M\?Q7X3L?C'X+T;Q.NA:C+XFM-9\0?#WX:^*M"\8_$30]6KQ7QE\ /%'PSM](
M_:>U'PMK*?$?X@?LB^)/BE\5_P!EWP9X7OK?QMX*\.>%/V5?V=_"?QW^#UM\
M4M0\1>)/$&M^%=4'P,^'OP<^$O@?4/#\^N^%/B)\4_B)\1UU_P 8WFG6VD::
M ?T40S0W,,5Q;RQSP3QQS0S0R)+%-%*@DCEBDC+))'(C*Z.C,KJP9200:DKY
MG_9%^.$O[0_P,\/?$R7PYH_AQ+G7_'_A6T/A34KC6_ 7B73?A_X]\1^!=+\=
M_#37;S2M!O-:^&OCO3_#UOXJ\#:G<Z)IKW/A[5+/RXKBW2"^N_%/VI;G_@J=
M#\1--7]BKP[^P#JWPH/A+3FU>Y_:B\<?M'>&_B$OCDZIK(U6'3;#X2> _$WA
MJ3PFNC#P^^GW5UJ$>LR:F^L17-I':16,LH!^@=>-_';XI0?"7X>:KXCC:WDU
MRXVZ5X9LIV7%UK=XK+!(\9R9+;3HA+J5X ,&"U,193,A/YW67[6O_!2KX 6D
M;?M=_P#!/G2OC3X>@AEN]4^*G_!-3XKGXTOI*7$VVVMM5_9R^/6E_!7XSWG]
MGPX^UW'PTU+XJ7^H;6FM/#UL[I95YU\;?VE?#/[3$G@[Q9X#MO&-AX'M-#G_
M +,L/B!X#\;_  O\96^MW=ZUOXDM_$?P^^(NA>&?&7A;4M*O-+319+#7="L;
MEVLI[RV-SIEY974_Z%X8\*PXNXMP.!Q,.?+<'&69YG'I4PF%E!1PSUB[8O$U
M*&&GROGC1JU:D?X;M^=>*7%D^#^$,=C\-/DS+&2CEF5RO9T\7BHS<L1&RE[V
M$PU/$8JGS)PE5I4Z<]*FOB%S<W%Y<W%Y=SRW5W=SS75U=3N9)[FYN)&FN+F>
M1B6>:>9WEE<DEG=CFH***_O5)1244HI))))))+1))6226B25DM$?Y^MN3<I-
MN3;;;;;;;NVV]6V]6WJV%%%%,0?B1[C@CW![$=CV/-?</P[\2#Q/X5TZ]DD#
MW]HO]FZF,C=]LLU1/.('07<!AN03U:5\=*^'J]E^"WB3^RO$;Z+<2;;/Q!&(
M8P2=J:I;*\EFW7 -Q%Y]H3W=H >@KY/C'+/[0RBI6A'FQ&7\V*IV5Y.DDEBH
M+R=)>U:2O*5"$5N?7\%9I_9V<4Z,Y6P^8J.%J7?NJJY?[-4MM=57[*[TC"M.
M3T3/I/Q99G4?"GBK3A((3J'A;Q-8><5+B$WN@ZC:B4H&4N(C,'*!E+A2H92<
MC_/M1/*BMXL[O*M;6+=C&[RK>)-V.<;MN<9.,XR>M?Z$&L_\@;6/^P/JW_IM
MNJ_SXV_A_P"N<7_HM*^H^CG_ +UQ;_V#Y+_Z<S0X/I'2?^J'#L+^ZN(\5)*R
MWEEL4W??516E[::=1M%%%?U(?QN%%%% !1P<@@,""&!Z%2""..1D$C(((Z@@
MT44!ML?W?_\ !%_]MM_VK_V8[/P9XUU>*[^,WP$CTGP+XM-Q="35?%'A**P2
M'P+X^N$D9KBXN-4L+2?0M?O&:8S>)-"O;R=XSJD$9_8FO\][_@DU^TRW[+_[
M;?PJ\1ZA<)!X,^)%['\&/'S37)M;:V\/_$'5-+L].UJXE9U@2+PUXMMO#NMW
M#W"NBZ=;:DB^7)*LJ?Z$ .1V]#CID<']:_RE^D=X>T> O$+$U,NH>QR/B>E/
M/,MIQBHT<+7J5I0S/ 4DM%##8O\ ?TJ<8QC1PN,PU&*:A=_ZW?1L\1:OB!X=
M86.8U_;9[PS5CD>9SE)RJXFC1HPEEN/JMJ[GB<):E5G*4I5L5A<35DUSV2T4
M45^ G]!!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %(0",'_#\B
M.01V(Y!Y%+10!Q7BSX=>"O'-_P"!=4\6>'[/7-0^&?C.'XA^!;J\>Z\WPYXS
M@\-^)O"$.OV)AN(@]Y'X;\9>)M(5;L7-M]FU>Y)MS,()8JNC_"[P+H7Q!\:?
M%/3-"6+Q_P#$'1?!_AOQ5XFGU'5[Z]OO#O@+^W'\):#:1:AJ%U9:'HNCW/B;
MQ%J,6EZ!:Z78W.L:YJ^M7T%WJVH75[+W]% #0H P,],?>;/USG.[_:SN]Z7
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MFDNKEFDE\BVCN;_4KNTTFQ^R:-87NK:Q>V&G6UWJ^IS7?K=% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
64444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>revbyopsegment-geography2018.jpg
<TEXT>
begin 644 revbyopsegment-geography2018.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #% 7$# 2(  A$! Q$!_\0
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M?]H'XBZWXQ\+>$M+\(3_ ! T;X6^$]"LM?OVAU?Q_P#$;Q[JFE>)K[PY\/\
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M"T'0=/\ T@H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX"UGX?7'C;]DV?X4_ NQ\#^$-<\:WJV/P.N_C_>^-_@EHM]\2_#WA7QMXO\
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M)]3]OP6+I8["8?&4'>EB:-.M#O%3BFX2MM.#O":Z2BUT)[7_ (^[3_K[M?\
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MM UVT216:UNE:"\MVCU'2;K4=+N+:^F^@J_S1_V7_P!J_P"-W[(/Q+L/B?\
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M68')LOPF5Y;AX87 X*C&AAZ$-5"$;MN4G[TZE23E4JU9MSJU9SJ5)2G.3?\
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M&_@?X$Z!\%]5\%:99V=GK'A>3Q%\--8\6>#_ !%9V^H^&O%&FP?:;"Z^WJ*
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M9QZ4]S)IB>+/#&A>)4TZ2\6)+M[%=;T^_6S>Y2"!+AK81-.L,2REQ&@7LZ*
M/SX_:8_X)[_L/?%'PW_PF_CSX)^&_!/B[X8:;JNO^"OC3\$)+OX"?'CX<7%I
M:7-U]J\ ?&+X07/@OQYH3M<[;@Z+_;5UX;U:^6W&M:'J<0,+?FA;#4DL["'5
M_$?BCQ?J5II^GV-YXI\;:LFO>,?$,NGV-M8+JWBK6XK/3XM6\07D-K%)JVHP
MZ?8PW=[YT\-E:QNL$?Z\?MJ>*GT+X1+H<$RI<>,?$&GZ1+'R)'TNQ6;6M0V$
M,"%9["RMY<AE,=RR,/G%?D:3DDGJ>37];?1_R"GA<BS+B*K!?6<TQ<L#AYM:
MQP&!47/D>EE7QDZBJ)74GA*3O>-C^0/I#<05,5GV6\.4JC^K95@UCL3!-6EC
ML>VJ:FNKH8.G3E2;LTL962TD%%%%?T$?SL%%%% !7O'P.\2"TU2]\,W,F(-6
M0WM@&( 74;2/]_$N>]U9#<%'+/:#NW/@]7=-O[K2M0LM2LG,=W874-W;MDC]
M[ X=5.,?+)@QN.Z.P/!->;F^7PS3+L5@9V3K4W[*3VA7@U.C-O=*-6,7*V\.
M:.S9Z>39C/*LSPF.A>U&JE5C'5SH3]RO!)Z-RI2DHWVGRRW2/T2M?^/NT_Z^
M[7_THCK^!KXX_P#):OC!_P!E6^)7_J<:_7]ZGA[5+;6[71-7LSFVU+[!=Q#N
MGF31^9"W</!*'A<'G?&W%?P5_''_ )+5\8/^RK?$K_U.-?KJ^CQ"=/-N+:=2
M+A4IX3+*<X25I0G#$X^,HR71QDFFNC31S_2-G"KDO"=2G)3IU,;F-2$UJI0G
MA<#*$D^JE%II]4SRVBBBOZH/Y,"BBB@ HHHH T-(U74M"U73-;T6_N-+UC1M
M0L=6TC4[21HKK3=5TRZAO],U"VE3#QW%C?6]O=PNI#++"I'2O](K]B#]I"R_
M:S_9:^#_ ,=(1##JWB[PQ%!XQL(!$B:7X]\/7$WA[QO81PQLWD6J^)--O[G3
MD?$C:5=6$Q4>:!7^;+7];'_!MU\9KG4_ /[1'P"U&^5X_"/B;PM\4_"UG(Q:
M=;+QO97OAOQ8L.Z0[;.VU7PIH5T8XXE5+O69Y7=FN1C^5_I:\(4LZ\/*/$U.
MDGC^$<QH5752O.65YO6H9=C*"2U:^N3RW$W=U3AAZK22G)G]:?1 XQK9+XB8
MCA6K5?\ 9_%V75X1I-VA'-LII5<?A*]V[)O!PS##623J3KTE=N$(O^G"BBBO
M\SS_ $\"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH _,S]O369I?$GP^\/;E$%EH>M:V4!.XS:EJ%KIT
M;.,8 $.FSK&02QWR@A0/F^ J^SOVYG=OBWHB%V*)X#TK8I8E4WZWXB+[5)PN
MXJ"V -Q )R0*^,:_OGPLP\,-X?\ #%."24L!/$2MUGBL7B,3-OSYJS3]--+(
M_P ^?%?$3Q/B'Q14FVW''TZ$;N]H87!X7#07;X*,7Z[ZZA1117WY^>A1110
M4444 ?3WP!\1B7SO"]Q(-]I>V^J::&(RUM-=0IJ$"C&3Y-PT5R%'"K<RGH#7
M\3?QQ_Y+5\8/^RK?$K_U.-?K^M+3_B#H?PKU71_&OB?7]'\,:+I6H6T]_J/B
M#5;+1=/?3VE1+^(W6H7%M#)YEH92D:-([2(A5"5%?R/?%W4].UOXK_$_6=(O
M(=0TG5_B/X\U32[^W8O!?:;J7B[6;ZPO(&(4M#=V=Q#<1,0"8Y%) .0/J_"S
M*IX/B3BC,*=.2PN9X#*YJ:B_9_6Z5?&+$P4K<O-)2I5Y*_,YU:CM9'RGBMG$
M,;POPQEU2K&6+RS,,QC[-R7M'@ZM#"O#3<?BY8N-6@G:RA2IJ]V>>4445^ZG
MX$%%%% !1110 5^WG_! #Q[>^%?V^+7PM#*@L_B?\'_B-X8O()&8>;-X?&C>
M/+"2%55@]Q ?#=ZJ^8446UQ=D-OVH_XAU^G_ /P1GU&33?\ @I/^S,\;7JB[
MU3XB:;*+))W=XK_X2>/(2EPD'S&Q#B.2\>0&WABC$T^$CW#\]\6L%3S#PP\0
M,-5BIQ_U0S_$14E=>VP66XC&T)6TUA7P].<7NG%-:H_2/!['5,N\5/#W$TI.
M,GQ?D&&DXNS=''9EA\%B(M]I4,14C*^G*VC_ $":*1>0/H/Y4M?XTG^TZ=TG
MW5PHHHH&%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% 'Y3_MU6;Q?%'PU>DDQWO@:V1<@ !['7=8650=Q)(%W$
MS950-X"EN=OQ/7Z2?MZ^'E?3_A]XLCA8-;7VL^'+R<#(\N_MH=5L$<XXQ-IM
MZ$R>3*P').?S;_KP/KZ5_>7A+C(8WP^X=E&5Y8?#XG!U5I>,\)C<31C%I=Z4
M:<UU<91;W/X!\7L%/ ^(G$D)*T<17PN,I.[:E#%X#"UI--V=E5E4AV4H2BFT
M@HKC_&?Q"\!_#FP;4_'WC+PSX-LE3>)?$>LV6ER2CD@6UG<2B^O';!"1V=K<
M2.>$5CQ7P9\2?^"G'P2\+F>S\ :+XG^)VH('5+V*(>$?#.]<@$:CK,$VLW4>
MX#FV\/HCIEHYC\N?U; Y3F69-+ X+$8E-I>TA#EHIO\ FKS<*$=-;2J)VVN?
MDF.S;+,MBY8[&X?#M*_).HG6:TUC0AS5I+5*\:;6JN?I'D#J<5S7BSQGX0\!
M::^L^-_%/A[PAI2*6^W^)-7L='@< 9Q!]MFBDNG/18K2.>5SPJ,2!7X _$K_
M (*,?M%>.6GM?#NJ:3\+](E+!+;P59!]9\INBS>*-:^WZF)   7TV+203DJB
MCBOB37_$?B#Q7J4VL^*-=UCQ)J\[,TVJ:]J=[K&H2%B6.;S49[B<#).%1U1>
MBJ!Q7V> \/,=5Y9YCBZ.$@[-TJ">(K6ZQ<WR482M?WHNO%/HT?%YAXBY?1YH
M9?A*V,FKI5:S6'H76TE%>TJU(MZ6:HRW=UL_WR^)7_!2KX!>#A/:^"XO$7Q3
MU6,.L;Z):-X>\->:HX$FO^((8KJ:(MU?3M#OE8 [).AK\_OB1_P4I_:!\8BX
MM/"'_"._"W3)2RHWARQ.K^(A"V1M?Q%X@6[$4H7_ );:9I6FR!CN1E(%?GH2
M3R3D^IHK[7 <'9#@>67U3ZY56]7'2]O=_P#7BT<,K/5-4>9?S,^(S#C3/L?S
M1CBOJ5*7_+O!)T6M+->VO+$--;IU;=DCH_$_B_Q7XVU*36/&/B77?%6JRLS/
MJ/B+5K[6;O+$GY)M0GG:%1G"I!Y<:#A%4<5SE%%?30A"G&,(1C"$5:,8148Q
M2V48I))+LE8^5G.=23G4G*<Y.\I3DY2;>[<I-MM]VPHHHJB0HHHH **** "O
MUB_X(C:#-K?_  4E^ T\;.D7A[3?BOXBNG1%<""U^%OBK3%60-)&522ZUBUC
MWH)'5W0>64+NGY.U_0]_P;F?"Y?$?[3WQB^*MW9&>T^&/P@A\/V%TRKLL_$/
MQ+\36D<4B,06$Q\/>#M>@^3&(;N3<P#X;\Q\:,SIY1X4\?8NK+EC4X9S'+HO
M3^-G%+^R*"]YI7=?'4TK]6K)O1_JO@=E=3./%SP_PE.+FZ7$N79G**;3]EDU
M59O6>FMHTL#.3\HN]MU_94!@ >@Q1117^.I_LV%%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!\C?MUVN
MMK^RM\8/$OA?PVOB_P 4_#WPIJ'Q'\/>'&O)K$:O>^#+>75[RP6>VMKNX\Z[
MT2+5H((H('EN)WB@3:T@9?X4/B1_P4)_:1^("W%KIGB>P^'>BW.\)9?#_3QI
ME\UM*H\M)/$NH2:CX@8E#DR6EYI^[<2$484?Z,DT,<\4D$T<<T4J-'+%*JO%
M+&ZE7BE1@RO'(A*2(RE71F4@@D5_G9?\%+?V59OV0?VO?B=\,K&R>U\":U?'
MXB?"J3K#)\//&5U>WFF:?"WE1;CX6U6'6?"$X*+\VA1RC='/$[_W!]$#/\HQ
M53B#@W-,/AZV/IRCQ!DL\3%55*CRT<)FF'I0JWIQG1FL%B::A%U)1K8NH[1I
M-G\+_3&X>SC"T>'^-<JQ&(HX&2?#^=QPS]FXU'*KBLKQ%6=-*HX55+&8:I*4
ME"+IX6F[NK%+X8U35M4UR_GU76M2U#6-4N7,ESJ>JWMUJ6HW#DY+S7U]+/=2
M,3R2\IK/HHK^]TDDDDDDDDDK)):))+1)+1);'^?$I2FW*<I2DVVY2;DVV[MM
MN[;;;;\V%%%%,04444 %%%% !1110 4444 %%%%   20!R2< >I-?V[_ /!
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MLKK-*?*WRR2ZFBBBO\\C_1D**** "BBB@ HHHH **** "BBB@ HHHH ****
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M>_NOC?XHU7XMZKX&TJXT7P''\6+GQWI/@;X5:EKLVG^(IOAUIJZZ-9U_[O\
MVE_ ?B/XR_%7]F7X17_AS5-2^!G_  E?BGXV_&F\6RO+CPYKK_!"#PO>_"/X
M7>*K@(^G?8_$WQ6\7>'_ (CC1-2^3Q-:_!C4-+FCNM+;5[68 ^CM&^+/PN\1
M>.O$?PPT#XC>!=:^)/@ZSM]1\6_#_2?%N@:CXV\+V%V+-K6]\0^%;/4)M=T:
MUN%U"P,4^HV%M$POK+YA]LMO-+CXL?"ZT^(>G_"*Z^(_@2V^*NJZ1)K^E_#2
M?Q=X?A\?:CH44=U++K-CX/DU%?$-WI<<=C>R/?P:=);".RO)?,\NTN'B_'CX
M4>!OB+X*^*OP6L]7^$_Q6A\2_LS_ !Y_X*8?&[XZ?$:S^$^NOI/Q$^&_QJUO
MXL^(/AW9^ O%.F:?-;?%SQ)\6&\>?";Q!8^!_ MYXB\66.H_"FXT3Q?HV@:K
MX=T&TO+OC/X8_$/Q#\<O''@I?A=\2+WQ3\2_^"CG[-W[4OAKXL2?#C5[/P9I
M?[-GA'X#?"7PWXW@UCXH?9HM)\+:_HN@^!/BK\#I/ .JZOIOQ#FN_B#9S:'X
M;O/#WB?4M9MP#];?!?QJ^$'Q'TBV\0?#_P"*/P^\<:%>>*KWP+::QX1\8^'_
M !'IESXSTZWFO+_PI!?:/J%Y;2^(;.S@FO+G1TD:_BLHVO&@%KB8^FU_.YJ/
M@/XH?\$]["XUOX!^"?B+^T/IO@?QYI'PN\/3>._ ^NZ]<ZIXK\(_LFV'@CP#
M8:-X;^$&@^'W@AN? 7PF^!W['/@?XP7EA<>'M(^(WQ$^+7Q \?R:GI\UGHA_
MH@C9G16=&B9E!:-BI9"0"48HS(2ARI9&9&(W(Q4@T /HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH :RJX*L P/!! ((/!!!X((R"#
MP02"""17\MG_  4Z_P""'K:E/XH_: _8JT,"^G>YUWQK^SQ8H E_<S2-<:KK
M7PA9Y%6WO9Y'EU"[^'5RPM;J1KD>"[FTG-EX6NOZE:" >",CT-?=>'_B+Q/X
M;9W#.N&\9[)S]G3S#+ZZE5R[-<+"?-]6QV'4H<Z5Y^QKTY4\5AG.<L/6I.<^
M;X3Q!\.>%_$O(YY'Q-@E6C'GJ9?F%&U/,<JQ4XJ/UG XBS<).T?:T*BJ8;$Q
MA".(HU%"'+_EA7]A?:7>WFFZE9W>GZCIUW<6&H:??VT]E?6%_9RM!=V-]974
M<5U97MI.CP75I=117-M,CQ31)(K**E?Z"7[;?_!*3]F']M6+4_$NM:(?AE\:
M+FW5+3XQ^!;.VM]9O)X55;8>.- 9[?1?'UFB)' SZNMOXAALXDMM+\2:9&H%
M?RG_ +5W_!&G]LW]F(ZEKNG^#O\ A>GPVLE:?_A.?A#:7^M7UC9JKNTOB3X?
M.DGC+13;PHTU[=Z?:>(M!M(_GEUU1E5_TD\.?I$\ <>TL/A<1CZ7#'$-10A5
MR?.J].A2K5VHIK+,SG[/"8Z$YRY*-*<L-CYR3_V)1Y9R_P SO$KZ-WB#P!6Q
M.*PF!J\5<.TW.=/-\FH5*U>C03;OF660]IBL'.G!*5:K36(P,$U;&-\T8_D[
M13VC='DB92)869)HB")874D,DT9Q)$ZD$,DBJRGA@#Q3*_>M]C^?&FG9IIK=
M-6:^3"BBB@0444I&T!F(13P&=E12?0,Y52?;.30-)MV2;?9*[$H[$G "C+,2
M%51ZLQ( 'N2.>*_0S]E;_@EW^V-^UN^GZIX#^&5WX3^']Z\9/Q2^)XN_!?@D
MVKR*C76C_:K.;Q'XM106*_\ "*Z%JEL[(4EOK;[X_J?_ &(/^"*7[-O[*\VD
M>.?B.MO^T%\9M-NH-2T_Q/XKT6.R\%>$+^W82VTO@SP#-=ZG9+J%G,%DB\2>
M)KK7-82Y@AO-)70&'D#\6\0_'KP_\/:6(H8G,Z>=Y]24HPR#):M/%8J-9:<F
M88B+EA<LC&3BZL<34^MJFW.A@\0UR/\ </#CZ/OB'XBU</B*&65,AX?JN,ZG
M$&=4JF%PTJ+LW++\--1Q>93E'F]E+#4OJKJ1Y*^+PZ?,?CG_ ,$R_P#@B9XH
M^.!\._'+]K32]7\$_!QY(-4\-_":ZCU#1/'/Q2L=J36U[XB;-IJ/@GP%J =&
MB1#!XN\3V:R-:+X>TJ>UU74O[%-#T/1O#.C:5X>\/:78:)H6AZ?9Z3HVCZ5:
M06.FZ5I>GVZ6MAIVGV5LD=O:65G;11P6UO#&D4,2*B* *U  !@?Y]R>I/N:6
MO\V/$OQ2XH\4<X699]75+!89U(Y3DN%E)9?E5"HUS*E%V=?%55&'UK'5DZ]=
MQC%>RP].AAZ/^FOAEX5\+>%F2_V7D&&=3&8F-.6;9UB8Q>8YK7IIVE6FE:CA
MJ3E-87!4FJ.'C*3?M*]2M7JE%%%?FY^E"$ ]0#R#R.XZ'ZCL:,#K@9]<#L<C
M]>?KSUI:* .>\-^$O"_@ZPNM+\)>'=$\,Z;>ZYXD\37EAH.EV6DV=UXC\8Z_
MJ/BKQ;KMQ;6,,,4VK^)O$NKZIX@U[49$:[U;6=1OM2OI9KNZFE?H, ]0/R]B
M/Y$CZ$BEHH 3 QC Q@#&.,#H,>@[4$ Y! (/7(Z\8Y_#CZ4M% "8'H.QZ#J!
M@'\!P/:EHHH 3 ]!W[#OC/YX&?7 STHP,YP,]<X&<X(SGZ$CZ$BEHH 0@'\\
M]3U_/IV(Z$<$8I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH *0@'K^?0CZ$<C\*6B@#Y2^.?[#?[)'[21FG^-'P"^'7
MC/5IW5Y/$[:*N@>,V,<30QJ?&OA>31/%311H<+!)J\EO\J%H6V+C\O/B=_P;
MQ_L:>+&GNOA[XP^,_P )[N6;?'9V/B72?''A^WB,@9X8[#QGHUYK>-F8XG/B
M8F/Y6<2X*M^^%%?=</>)WB#PK"G1R#C#/\OPU*WL\%',*]?+X6M\.78J5? K
M16?^SZK1Z6/A.(?##P\XKG4K<0<'9!F.)JMNIC)Y?1H8^;;O[V886-#&O776
MOI+WEJ[G\M.K_P#!M+IKW);0OVO]1M[0HY6'6?@C8WMRKF20Q*UQIWQ)TZ%E
M6(Q)(XM59Y%DD58T9(DHZ3_P;2?-:OKG[8+!3"3>PZ/\#D!6X,1PMK<:C\3I
M0T"3;<M<6JRR1 C$4A!7^J2BONE])3QJ5/V:XSE:UE)Y#PRYVLU\3R:]];W>
MMTG<^!?T9/!!U?:_ZDP3OS<BS[B:-*Z:?\..<J*6GPI*+N[IZ6_GP^'/_!NC
M^RAX=N?M7Q%^*GQJ^).QD:/3K6^\,> =)D "ETNAH>BW^MRJ[!\?9]=LRB,J
MY9U,C?I?\#_^";O[$?[/%W;ZM\,/V=O -CXBMHX5A\5^)K2\\?\ BJ":!MZW
M5EKWCJ[\0WVEW3/\TDVD/I[-PO" */N"BOC<^\5_$CB:G4HYUQIG^*PU6/+5
MP=/'5,%@:L;)<M7 8#ZK@ZBTVG0:U?=GVV0>$WAKPO.G6R/@KA_!XBE)2I8N
M> I8W&TI*UI4L;C_ *SBZ;T6M.M'9=AJHJ !5"A0%4   *.B@#@*.RC"CH !
M3J**_/3]#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
***** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>revbyopsegment-geography2019.jpg
<TEXT>
begin 644 revbyopsegment-geography2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #% 7$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHKQ/XN?M%?!SX&S:-9_$OQE#HNJ^(;+6]4T7P_IVC>)?%OBC4=%\
M,PV\_B7Q!;^%?!>B^(_$A\->'$O+$>(/$KZ4F@Z)+J&G0:GJ-K/J%E'. >V4
M5S?A+QAX5\>^&/#OC;P1XBT;Q=X/\7:+IOB/PMXI\-ZC:ZWX>\0Z!K-I%?Z3
MK6C:SITMQI^HZ7J5E-#=65[:W$MO<P2I+%(RL#71;QDC#<#)RC@?@2N&/H!D
MGL* '44T,",X;N>58'CKP0#]!U/49%(7 .,/TSQ&Y[9ZA2,^W7/&,\4 /HIN
M]1C[W/3Y6('^\0,+_P "QC!]#7,^-?&GA?X=>#?%WQ!\;:S:>&_!G@/PSKWC
M+Q=XAU+SH]/T+PQX8TJ[US7]9O7CBEE%GI>DV-W?730Q32+#!(4C=P%(!U%%
M<#-\4? %OXJ\#^"9O%.EQ^*OB3X=\3^+/ VB%YC>^)?#O@R/PO-XHU?30L)B
M>TT6+QIX6>\::6%PNMV1C23?)Y?=[UQG#8SC&Q]W_?.W=CWQCWH ?17E.I_'
M+X1:+XYG^&FL_$/PMI'CR"7X>6Y\+ZIJ<>GZM-=?%B;QU;_#FQLX+L0I?ZAX
MOD^&7C_^QM/L9+B]GC\):U,\$4-HTC=)\/OB#X-^*O@?PI\2?A[X@L/%?@;Q
MQH&F>*?"?B72C,^FZ[X?UFV2[TS5+!YH8)7MKVV=)H=\,<A1U+1J2!0!V5%,
MWK@'YL'_ &'R/]X;<KU_B XYZ4I=1G.[CT1SGG'&%.[WVYP.3P<T .HI 0>F
M>0#T(X/U'7U'4=P*\\M_BU\-KOXJ:I\$+7QIH%Q\6M#\":-\3M9\ 07R2^)M
M*\ ^(]?U?POH'BO4=/C5FLM'UKQ!H&N:5I5S</&;^ZTC4EM4E2RN'0 ]$HKS
MC5_C!\+=!\=M\,=;^(/A#2?B!'\.=>^+]QX1U#7M.M-=LOA;X9UC3- UWX@Z
MA8S3I)IO@_3=:U>QTN?7]0^RZ:;V2:"&>5K.^^S<G\+_ -I7X&_&?1/#OB'X
M9_$?0?%>F^*]?UCPOH9LQJ-I?W6NZ#H)\5:IIT^C:K8:?K6G2P>%VM/$L<FJ
M:?96]YX?U;0M:LIKG3/$&AW6H@'N=>!_M'?$GXO?##P!9:O\#?@5/^T#\1=;
M\8^%O"6E^$)_B!HWPM\)Z%9:_?M#J_C_ .(WCW5-*\37WASX?^#--AN-4\07
M/A;P3X[\6W.;2QT+PEJ<]U)+:>^5\._\%#?V3?'W[;O[,WB;]G'P'^T5KW[-
M,/CO6-#B\>>,?#?@G3?'=]XK^'=C)<W/B+X7WNEZAXB\+?9_#?CN8:;IWC%K
M;5E;6O"D.L>$+ZVN=%\2ZK$P!^7^I?\ !??2$^$7PX^+NA?LN:KK>F6W[/7Q
M$_:O_:<T\?&GPU;#X/? #X9_M0ZA^REJ_C7X2ZK!X-U"P_:(?Q3XP\/>+_'_
M ,,T4?"S0O&OPD\-_P#"21^(M.U[7=$\,W7T?\7_ /@L+X-^#?QW_;2^%OB3
M]G[XOP^"OV,?V(/$G[9.K_$/5-/E\.7OQDL?#/C36?!]]H?P=\(ZQIT3Z[X&
MN+S1Y[+2_C#JFLZ5X;UK6+/6GT?3;_PAI<7C#4?+OB+_ ,$5M?\ C%X+^'OA
MWXG_ +7VH:CKK?LZ:K^QE^T7KO@?]FWX0_##1/C7^R*WQJTWXP>$/A+X-^'W
MA&\M?!WP"U7P';::_P ./#_B[P?8Z_9#P/K.N";P>/$4NCZYHOW9\0OV%M-\
M<?M3_%7]J&R^)^K>$]9^)?[!K?L-V_AW3_!'@O7[+PIIB_$KQO\ $>T^)-E'
MXTM/$?A7Q#J%E=>,VTQ? WBWP1K7@W4+;3(TURVU;3[Z\TI@"+]AK]MR]_:R
MN?CQX$\=_#70_A#\;_V;O&O@3PI\4/ WA/XJZ;\;/!BV/Q6^$OA#XU?#;Q)X
M4^)6G>%O!#:Y8:WX,\806>JVNH>$-#O-%\4Z)K^EQ+JNEP:=K>I??M?G;_P3
MT_X)[>#OV"_#/Q3BTS6O!OB7QW\9_%OA?Q/X[UCX;_!/P%^SE\-[:V\!^ -!
M^&W@KPYX$^"OPT>X\*>"M&TW0M#FUK5Q!?ZE>:]XV\3>+/$,MQ9VFI6.B:5^
MB5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !7P)\1['XA?!O]K;Q)^T+IWP:\?\ QP\$?$K]G3X?_");;X6'P5J/
MC7X>>+OA-\1/BQXXCMI="\8>)O! ?PW\6;'XJ6MJNNZ9K=Y::)XF\ :>OB^/
M2-&U#3M9M/OND(!X(!'7! //KS0!^#6M_ 3]IO6/'\'B#4_V==7\$_%KQ-XA
M_8T\3_L_>)?A7X]\-W?P7_8Y\(^#?%/A_5?VC/A?JEQ;>)?!B+YEM#\0M3\?
MP^&/A[K.A?'^V\>Z/X(@;Q-I/AZ/^P>!_P"&+?VC])^'=C-I?@[XWZ1XN^)7
MP<_X*9^%?CQJ'@/XK^'+?XGZTOC?]ICPQX\_94T&PUGQGXOO/"4^LZ;\/XO$
M-C\+;/49HO#7AWPI?:[\.-6U7P=HWBS42/Z(\#(.!D=#CD9ZX/O1@>@[]AWZ
M_GW]: /YW]&^%/[9_@WP;<7VF_L^>+KW3]4^!G_!0_X'^"/#7PI;3OA+$_B[
MXWI^SIXP^"/Q%\0_!CQG^T1\0-'^ 6AZIXF\"_%CPQ'I7@SQYJ'A?P'*--\5
MZ3X-^'%C\2+_ ,.Z9M>%/V&/C3K?BOX<^)_B7X \::QJ/_#8'[.L'CN75?B/
M<76G7'[*NA?\$P/AA\-/BKX8U#2H/&9L=0^&.N_M/>']2C\=^ GLKF'QUXTT
M^+Q7KN@Z[I\=GJX_H&VK@#:,#D# P#Z@=NIZ>M&!Z#KGIWQC/UQQ].* /YFM
M._96_;VCTOX Z3XKTCXB37/AOX.?!#X?_#O6;?1=#^)7CCX$>-?AY^TA\4=1
M\8>([7XB:M^U1\.=)^&^I:E\)KKX-ZAJ'C74_ WQD7Q_\/O!^H?#;6+#5;JT
M'@7QI]N>"OV3/B1H'_!,W]LOX>3>!M=F_:8_:#^'G[<=IJ&GZOXJ76_$?C'7
MO'.N_'S2_@AI$>LZMXCO]$TK3(_ OB+P/H/A#2TU'3-(\,^'FTK2[J/3AI\\
M=M^Q.U>/E''(X'!]1Z?A1@8Q@8YXQQSUX]^] 'X2_&O]AC]J72-9\#:U\#/B
MW\>?&OCFV_81_;2^%>B>+/BO\2/"NJ6'PG^,?Q#\)_LZVOPR30)=,L_ NIZ1
MJWB*_P#!_BS3H/$-E?W-MHLVE0:G/J>BR):7DGFOA_X"_M+Z7X)U/36^ /B'
M5_A3XK_:*^%6H7_PIU;X4:=H7A?P-X?\+?!#QUIWB/QMX?\ V9K?]N'Q99>/
MH?&/C^[\#>#/&X^(?QD/@@>-]+7X_6OPF\83Z=-XYU#^B7 XX''3V^E-VKC&
MU<9SC QGUQC&?>@#^8CX5_L,_M47]U^QSXO^/GP6\1^*O$'P7UC_ ()A7_BV
MY\0>)/"'BCQ+H^I? CXC_P#!0WPUXWU,W=IXPOAX@E^&'A7XR_ S7-=NK/4M
M874O"TOVG0'\67NBWEF.A^&G["G[3WPA^ GP,\%^#/AI\1-(2^_8:^#7A[]J
MOP=X=^*EKI6N?$KX@_#W]JKX#^-/B-\-AK7_  L#3K9_B+XN_9YN?VAOASX6
M\26FMZ;H2>'=9@\!MXJT708_#T6E_P!*^U?[H_(=CD?D23]3FC ]!TQT'3T^
MGM0!_-7^UK\ _P!IOQQ\,?%OA/\ 9L_8\^(OPWTS_A5WQTU7]FP:AXRM_&7C
M7P1\6-9\?VWB/P_)X;T[7?VB/"'P]_8W$EYH&F>-O!.HZ)X>^)^OZ5X;U.?P
M'H,OP^N(]0^'6J>C_$']CS]I*V/Q ^)%AX0U+7Y/&G_!07XX>-/BSX3\4:-<
M?'%_B)^R\^D_$"W_ &>["V^%LGQZ^#UCK_PU\%^/O$.C>/#\+[7QSH<MKJ%S
M=>+;KP7XBU329=(NOZ#=J\?*O (' X!&"!Z C@XZB@@$$$ @]00,'ZCO0!\+
M_L0?#WQA\/OAI\/=#^*OA7XE#XM:9\$?!FC^)/B#X]N_#]U+-X?@\?\ Q3U7
MP?\ ":[ET+XH_$I7\4_"S1M82VU:9M8\59TC6_#R7/Q1^(&L1ZK=6'QI\!OV
M<_VQ/@#^VY\4/V@OBM8^"_C;X:\1?LK>*'\6^,?A%X0U'0O'_P 3OBI)\<]2
M\5>%_ >DZ;\0OB]<65G<>&/ <>E^&_"NF:A>V/A'1O".F:!H.G:K8WB:MJ-[
M^VF!Z>WX#H/PI" >H!R,'([>GTH _/WQW^R_I/BO]N:R^)=W\*M#N_AK\1_V
M*/VD?@Q\<O%MK:Z/IMYXSUSQK\0_V9+7PCX4\67UC<6?BO6Y+GX<^#O&]CHU
MXYN+;0M)TRZL+>^TR6ZM(+KX8U;X2_M,_LF>(=+UO]E+X9_$'XE07_Q8UOX>
M1:S\4M.@\<>+_$D.F^%/A5X;C\0^,+C3KOP?:>"/ GQ.3P!X=^%<GQ:71HK+
MP/\ "_\ 9W^'/B&Y@OM6^)FN:MJ/[U<9SQGIGOSVS]:\O^(/QB^&_P ,H&?Q
M?XDL;.]V&6WT2VSJ&O71V;T\C2;02W:B4<)<7*V]KG&^X0<CKP. QV9XFG@\
MNP>)QV+JNU/#82A4Q%>>UW&G2C*;2O[TK<L5K)I:G'CLPP&5X:IC,RQF%P&$
MI*]3$XNO3P]&">W-4JRC%-[15[R>B39Z>I)'S#!W,,>P8A3^*@'\>U?SN?MN
M_!W_ (*8_L>?LO?M _M:^&O^"N'QV^*$W[/7@37?C8WPG\6?LO?L6:7X1\7^
M'/ %[:^*?$O@_6M9\-_"#3?%UGI6H>#[+6=-EU+1-6M==ME*WMC)/?1QVMQ^
MC>I_MSQ7^O:9I?A/P9]FTNZU.VM+C6/$]\#<BUN9!!YL.DZ4S10.DCQR;KC5
M9@$#*T()!%KXFZW=?&#P1XS^&?Q&L](\2?#[XA>&/$'@GQOX,OM+MWT+Q/X1
M\5:7=Z'XC\.:Q"VZ[N-+UC2+Z\TZ^A6\CD>VN) DL<FV1?N*WA?Q9@UAWF>%
MP^6/$TY5:4,3B:=2HX1=FG#"?6%":;C>G4E"<5*/.HMV/A*/BIPCC'B5E>*Q
M&:+"U(TJL\+AITZ:G*/,N6>+^K>T@_>2J4E4A)Q?)*23:^]+"]MM1LK74+.;
M[1:7UO!>6L^QXO-M;N)+BWD$<BI(@:"6,[9$209PZJ^0+61_^L$#\^E? .A:
MSK.CVF@Z'I6L:KI^CZ/;:/HNEZ=:ZE>Q6ECI6FQVUA86$$?GDF"ULH(K9/-:
M21HT'FR2.68_Q3_%7]MK]L?PW\9OBA#H?[5?[16F0:5\3?B)9Z9:VWQD\?"R
ML+.W\7:[96UI:V$NN2V,5K;6BK;6UNMOY-M"D:0)&(H]OZ#P%]'O.>/:V9X?
M"<0Y7E]3+:&&K3>)PV+JPJ_69UH1C&5*TH\KHOFDX/22:BVK'Y[Q_P#2)R7@
M'#Y9B<9P[FF/I9EB,10C]6Q6%I3I?5X49RG*-1-3YHUO=BI+6-G*SNO]%8$'
MH0<=<$'%+7^?5\._^"PO_!13X<7 DM/VC]?\7VK-$9M-^)7A_P )>.[2988U
MC5/M6JZ+'KENK(H\UK+6;629RTLCM,[2G],/@C_P<@?$[2[JWL?VAO@)X0\7
M:6P@BE\0?"/5]2\&Z[:JI/VB[E\-^+;SQ+HFKS.NTI;0:_X;C5@V)"&4)[&?
M?1-\4\IISK9:LBXCIQ7,J669E+#XMI)<W[G-L/EU)R6K4*6(JRDE:*E-J#\?
MA_Z7'A1G%2G0S&>><-U)R4'5S3+57P:;LHOV^55\?54&VDY5<-24'=RM3BYG
M]<M%? 7[*_\ P4U_8\_:\%CI?PS^*-EHOCV\51_PJSXBI#X+^(0F=RBP:=I5
M_=2Z;XI?"EV?P;J_B&..,JTQA8E%^_ 0>G_UQ[$'D'V-?SSG60YUPYCJF69]
ME689/F%+X\)F.%K82ORW:52,*T(.I2G:].M3YJ52-I4YRBTW_1>2Y]DG$F!I
MYGD&:Y?G&7U?@Q>78JCBZ/-9-TY3HSE[.K"Z52C4Y:M.5XU(1DFDM%%%>2>L
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
MF1SR/EZ\CCC//IQSSVYI:_)'XK?&WXH>'/!G_!:B]M_'VO:9?_ KP5>^(O@M
M*+Z.*;X>V<_[ 7@;QIINJ^%]T1-E!<?%:'Q3K-I/()HYO$\6I"(M+&\"@'ZW
M4 @C(.0>01T(]:_%U?VXOC]I%SXGT_Q/X7\ 7/P[\,_'[Q!^QK<2:5X@\7?\
M+QF\=Z=^QW9_'FW^)FL7-I(FA>'UL_%2:EX<\2>%8],.KV/A:1/BO9^);:/3
MAX4U//\ A)^WM\9O$7PQ^'OCX>%_!MM\)K'QI^R%^S/XJL=8\1>-O$/QXU;Q
MY^T=\ _@?XV/Q0T/7[]K;1M5TOPGXE^//@N'^P=:T>^U_P ?^%M%\9?$5O&6
M@3_V5X>OP#]L@01D'(/((Z$>M%?SX? K_@H1^UEX3_9U_9IT;XA>'OA9\2/B
MM\5?V6_^";_Q+\)>*+W6_&EJMU/^U)^T!\,?V8?&;_%75V:YG\0>)]+?Q_HW
MQ47Q#X6TCP_I^L:A+KWA)_#]O'9:?XFU7]/?V5OCE\7/C<GBV'Q?IOPZTV;X
M,_&;]H+X"_%"Z\.6_BF&/Q9XG^&WB7PS;^ /&'@.QU35M5/AO0=<\+ZI?W?B
M[PWXDU3Q)J6EZZ]G8Z)X@U#3[2XOKP ^TLC(&1DYP.YQUP/;(S]:0,K9VL&P
M<'!!P?0XZ'VK\TOCWXQ_:0\*_MO_  O\/>$/BSX:M?A_XZ_9!_;)U_P;\+]7
M\.0:+X2L?BK\*YOV<#X5\>_%#QG+JE_J_B"TMM2^(.J65OI^EP>%]$\.>&)=
M4FN[/7]:O4U73_,/^"?'Q;^-VJ?$Z[^&/Q$D^..M:9>?LK?!CXO^+]<^/>M>
M M<UV#XYZ_XX\=^#?']W\/Y_ &H7^E+\(_'7]@_VMX*FT60?#*^@\.3WWPEB
MA\/R:H9P#]>]RY8;EROWAD97_>YX_&E!!P0001D$$'(]1ZCD<^]?S@^"?C/^
MV;\5O%7CZP\ ?$_Q[9)^TK\.OVV+[]GCQ3XC\6^'$\+_ !;N?@_^T=X*L/!R
M?"+P7;Z)<:M^R?KW@;X"3>+? ]OJ'C6YGM_&'B7Q#H7C7Q-,?%OAUM0/US^S
M+^U3J_@#QK\/O@_^TKX^\8_\)7<S^(_AAX3TZ\>7QTD.K>)?CKXFT3P@GQ=^
M(VB6<VD:UXE\*JOP_P#V5M,\9F_O[;QA\;O _P :[L:GJUI=P^);L _8:BN6
M\;>([OPCX*\7>+M.\+^(_'-]X8\+Z_XCL?!7@^'39_%OC"[T72;O4[7POX6@
MUK4M&TB;Q'X@FMDTG1(=6U?2M-DU.\M4O]2L;4RW47Y">)/^"PWB/X;Z+=^.
M?C1_P2S_ ."H/PA^$_AT6VH?$+XJZ]\)/@=XP\._#;PF;B&+6/'/B?P[\*OV
M@O'GQ$O/"_A6UE?6?$\WA7P;XAU33-#L]0U,:9/#9RK0!^TE8/B;Q1X?\&Z+
M>^(?$^JVFC:-I\8DNKZ\DV1IN.V.*-%#2W%S.Y$5M:V\<MS<RLL4$4DC!3Y-
MI_[2WP3\0_!?P]^T#X+^(7AKQ[\*/&>BVNN>!?%_@K5K'Q!I/CBUOTD-A'X7
MO+*=[?4KFXEBFMY81)&^F3V][%JZV#V%\EO^4GQ=^,_B_P",&NOJ.N74EKHU
MK/(V@^&;:=SI>C0$%$;: BW^J21G_2]5N$,TC,\5JMK9".V7].\._#3,N.,2
M\14G/ 9#A:JAB\P<+U*\U:4L)E\9+DJ8AQ:]I5E>CA8R4ZBJ3E2H5?RWQ'\3
M\LX$PRPU.$,PX@Q5-SPF7*=J="#NHXS,)1:G2P_-=4J4;5L5.,H4W3A&K7H^
M\?&']L?Q7XK>]T/X<K/X0\.,SP?VT?E\5ZG""/WL4JL8_#T,N/EBM3/J?ED>
M9?6DC/;I\7W%S<7=Q/=74\]U=7,C2W-U<S2W%S<RL<M+<7$[R3SR,>3)-([D
M]6J&BO[,X?X8R/A?!QP.29?1P5*T?:U8KGQ6*G%)>UQ>)G>M7FVK^_+DA?EI
M0IP2@OXIXBXISWBK&RQV>9C7QM6[]C2E+DPN%@_^7>%PL+4:$$M&X04ZEN:K
M.I-N;52RD,A*N#E"."''*-_P%@#]17W_ .'=476]!T;5U(/]H:;:W#X[3M$J
MW*^Q6X65<'GBOS_KZU^".J_;?"<^G.V9=&U*:)5)R5M+]?MEN!DYVB9KM1Q@
M;< D<#PN/L'[;+,/C(J\L'B5&3MM1Q24)-O_ *_0P\5?^9]SW_#W&>QS3$X.
M3M'&89RBOYJV%ESQ2]*,\0WZ7Z'M5K_Q]VG_ %]VO_I1'7\#7QQ_Y+5\8/\
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MW"LFKZ7976FI=K-8M<BZAEB7\._A7^WA^U9X2_9N^%OQI^*7BG]INZ@^*?[
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MQIXP\+/\6OBS>^'O%OB6PU#7=,U3XF^-=6CO&U+6/M5N ?6'7I10   !P ,
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
&%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>revenuedecreasein2019.jpg
<TEXT>
begin 644 revenuedecreasein2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #. JP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M">./#&F>$?AYX:^'.F>+L;X@>$]8NOV\U'PO/AOQ'XY\>?MA_LS?'=?B%?\
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M*MD6.^L86E6PM/ZM5KPQ=#\S/^'R'_!/+_HN=Y_X:[XL?_,71_P^0_X)Y?\
M1<[S_P -=\6/_F+K])/^$<\.9Q_86C9X_P"8388R>@)^S8!/H3GD>HR?\(WX
M=_Z 6C=<?\@JPY/H/]&Y_P#U^E?,_4>/_P#HH^$NG_-(9OY?]5IY/[V?KO\
MK!]&3_HU/C;T_P";Z<$^7_6/WEK\^Z/S;_X?(?\ !/+_ *+G>?\ AKOBQ_\
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MN<_9\$#N1P.]2Q>']"ADCFAT728I8G62*6/3;&.2.1"&1T=(%9'5@"K*0RD
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M28/V7(-&^/&C^%1^Q+\6O@QH&F>#/V=];^&,E\WA#]F;QUJGPF\)^&?B38?
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M@: \+&;2K/7]>T?4-*TA+_1_RU^&OQ7\2^(?$7[.O[5'CKXA:3\;M(M/ _\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAILEY;VS7VE7;P/-IFJVJRZ9JUBT&HZ3=WNFW-M=S?DG\0_VYOV/=8OOA_\
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MNJ?[M</_ /(AR3_L49;_ .H5$****\@]<**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N*^)/_)._'G_8
MF>*?_3#J%=K7%?$G_DG?CS_L3/%/_IAU"N_*O^1IEO\ V'X/_P!2*9Y^;?\
M(KS'_L!Q?_IB9_'/!_Q[VW_7M;_^B(ZEJ*#_ (][;_KVM_\ T1'4M?[E2W?J
M_P S_!V'P1_PQ_)!1112*"BBB@#^CS_@F)_R:SIG_8^>/?\ T[I7Z&5^>?\
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M"^+'[.WBKP5X _:3O_$/B?4-9\&W5GI5O\ OVG+>6>#2_%&FZC?2"6\^"]O
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M _9BBOQG_P"(@C_@D=_T==<?^(^?M3?_ #CZ/^(@C_@D=_T==<?^(^?M3?\
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M_HZZX_\ $?/VIO\ YQ] '[,45^,;_P#!P;_P2(C>&.7]K4Q27#M';12_ /\
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M/G[4W_SCZ^_OV5?VQ/V=/VV/A_J_Q2_9F^(3_$CP+H7BZ_\  NJZW)X.\?\
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M!'J""/S%+0 SRU]7_P"_DG_Q5'EKZO\ ]_)/_BJ?0"#T(..N.W /\B#]"#0
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M-+T'X6W^J:UI]GXJ\=6OB+3/^$4U+PF/KCQ'XO\ V$=?G\/Z9K^H?#BUTWX
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M\.Z3IFA:)ID"VNFZ1HVGVFE:7I]LI9EM['3K"&WL[2!69BL-O!'&"S$+EB2
M:E%%% !1110 5YO\8M;M_#7PE^)OB*[^(VE?!ZTT+P!XPUB[^+.NVNDWVC?#
M&UTWP_J%Y<_$#5;/7IH-"N;#P=!#)XANH-:E7298M/9-1$EFTT3^D5G:OI&E
M:_I>H:)KNF:?K.C:K:3V&IZ5JME:ZEINHV-U&8KFSOK"]BGM+RUN(F:.>VN8
M98948I(C*2* /PMU#X^_&"W\!V-]JO[0OQ!^%_P>\63?M3?$OX-?$CQWJ?PM
MC^+]UH7PE^"OPIU[X1^#/BA>W?A8Z)I%W\0?%.I?&#XZZ9\/=<T6T\>Q?"W0
M_"?@[QY:Z7+;>*/!^G^C?%/X]?M8V6LZOJ!^)WA;X9'Q'_P30L_CA:^#-8\.
MZ!X1TSX3_%6P\:_#>R^(6OZMXQ\9R>)+:7Q''8>*?$.C^%[GQ?8Z7\.O!5Q8
MZ')XNT'5+6'Q+K=Y^K>F?"7X6Z+HO_"-Z1\./ 6E>'O[=M_$YT+3?!OAJPT8
M^([1[>2UU\Z7::7#8'6[9[2U>WU;[/\ VC ]M;M%<HT,13L+C1])N[F2\NM,
MT^XNY=.N-(ENI[*VFN9-*NY$FNM,>XDB:9]/N98TEN+)G-M-(BO+$[*I !\>
M_L0_$?QI\0_!OQ:C\57GB/5-'\"?'/Q3X ^'NL^,M=\%^*_&.I^#='\'_#_5
M+F+Q7XK^'$]_X$\1:]X:\=Z[XW\&7M_X;UC78K?_ (1N/2=6UO5/$6F:S=-]
MJ5F:-HNC^'-+L=#T#2M-T31M,MTM--TG2+&UTS3-/M8\^7;66GV,-O9VENF3
ML@MH8HDR=J#-:= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5X-^T3\,K[XG^!='M-#NM+L_%?@OXF?"CXI
M^#GUN::#1[SQ+\,OB#H'B^ST+4IH$EF@L_%%IIU_X7ENX8+FXT\ZTNI6UM<7
M%G%#)[S7Q]^VYI6O:C\(_!M_H'AGQ1XMD\(_M,?LC?$#6=(\&^'=6\6>(QX3
M\ ?M,_"WQ=XOU33_  YH-K?:UJXT/PWI&IZQ=VFE65Y?&RLKB2"VF9-A / ;
M3_@FG\&_#/A[XE>"?^$O&D> /BQH.M_";4M(@\$?#'0_$FH_"#XF_%%?B)\5
M_A1K'Q.M- M/B!XJ3XF6+7?PR?5+K7HM8TOP'<B6PAOOB'8:?X_M;1_8M\*>
M%-+UGX:P?M0>*_#NC_$'X9:?\*_'GAF\C^&*:UX\T+0/!OC/X6?"^2ZN=2TT
M:M:76B_#[Q+H'A77QH\5N?'\_P //"FK2OHFK7_C27Q5#\3;3PQX]^+K?%?X
MK?LV?%#XZ?!WQ1\"-,\&?"_PQJOP7UGQ!K'@#Q_I/CKX@O\ %+2=9^$?CBWT
M[5?!.L_&'0K_ .&\/A_XEZGHFD:%_9/@>?3M?\6>&=-DT>YUSXY_9\^#'Q6^
M%OQLNKWX]^ 9]:\1OX9_8IM[WQ1KG['?CC]IK6-=U7P'\(=(\/>*(M$_:%\,
MZ[<Z1X7OO"NM6\7AW5O$>JV^L7EMXATN[^(DDE_;ZY<.0#]8O$G[.EKXX^ G
MBSX :[\0-:OO#&L:?HOAC2-5M-*T&UU;POX=\,V?A*TLM%B:"$VVJ7$5YX7N
M+RZU#54>^:76;JV;9;V=DD?A$O\ P3J^'DT&E6[_ ! \8^7IVD:OHBE+;0%:
M:VUO]L#P]^U]=2EC:2(MQ'XJ\/P^$XBL;QGP_/+<2H^J*DH])\5?"6?]G#]G
M_P#:,N?V>-(^*/B;QUXTU7XA_%>UTVR\:?\ "2>,I/'OC-X9=4?P3=?$'3_&
M.F:/9Z>XFU;1?"MGX;URPMFAN+7P_P"%M4U*\M-+NOS7M+G_ (*-:E:>.M2T
MO5_VB=.TWX=V/QNUOX16$WA>UAN?'IL/CQ\"-1^$-CXIMO'7AI_%_B>WN/AE
M??%?2K'2O%L.A^)=5\+SWQ\9:?IGB;0],&B 'T3\'_\ @G/XET3X7^#M*^)?
MQMU;_A;/AO0=!T'1/^$>M- U#P5H?A#0/C9JGQHUGX>:CI7]D>%[_P")?@7Q
M;K%]X;TCQ9;^(Y-/N[OP_P"&/#6F_:$NCXBU'Q7Z?\%?^"?GASX-Z#IOA+P/
M\<OB ?A[J7AT>'/B5X=M])^'%NOQ-BTFY^(]OI3W>J:9X9B3PG NE>/I=!\1
M:5X,LM*T[4[?P9X4.E0>%I8O$R>(_,_@YX9^/NL_MX^$?&_Q.TSXX75KX2\"
M_MW^&O$VH>*= \/6OP,\-1^+?CU^S[/\ -/^$FNZ9IUEJ%_%XG^"_@N._G0W
M6J)--H^JS>-&TOXB0ZK8GQ[P5X'_ &X$MM$2+6?C7\.-+T;Q!^S+I2>$_!OA
MWP'X>\.7FC?$?]NO]J/1/VF==O\ 3/\ A#;O=J6G_LU:M\-/$5UJ=I-92>%H
M!X>\>:;L\43W&IS@'WR_[(]U9_#C]G/PSX7^,7BCPO\ $3]FKPB? _@KXJV7
MAOPAJ.H:MX;O/ =M\.=8A\1>$-:L]0\+W-WJ.@:9H6KQ7EA#8"Q\6^'],U.*
M&;09M9\*ZMVW[/'[+_@O]FQ_%,?@O7/$&I:3K_A[X,>%+2Q\0S:?<RZ/H_P0
M^$OAWX0>&XEU"SM+)[^[U#0_#EIJ.KW5Q!%YFJ3W#6T%O;&.!/R@^%/Q._;D
MOOC%)X(O=9^/GBGXA?"_2OV85O/!-WI7@*Q^'NJ^#M1\9?M*67Q;U7XI:Y>Z
M);6FE_$+QK\&O!/@36?#=W?WVBV%W\1;KP+J?AK3A::K\0;&/=\ ^*/VY=4T
MW6X?'T?[6FC?">?QE\(-6U[4?#?A&UO?CMIUIKG[.OQ$F\=Z3X-E\0> -#UW
M5M'T[]I+2O EAXO;P_X"T72-*DO-W@K2+/X(ZIJNK$ _=P$$D @D=1W'U'OV
M]:KSWMG;&W%Q=6\!N[A+2U$T\41N;J19'CMH/,=?.G=(I62&+?*ZQR,J$(Y7
M\MOAMX1_:4\%>!?^"BVM>$K/XM'XW_$#Q+H7Q&^#EO\ $^;PYJ,$][??LB?
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !7@G[1OQ5USX2^ --U/PII&F:QXP\9?$;X6_"?P>GB!K
M^+PMIOB7XK^/=!\"Z;K_ (JFTP?;VT'P\=9EUF[T^REL[[7YK*U\-V&I:7?:
MS;:C:^]UX9^T=JWP6TKX2:\GQ_@CO/AIKFJ^#O"E]I_]A>*?$E]J7B3Q7XST
M#0? 5AH&D>"-.U3QC-XIN/'=]X<'A2Z\+VG]OZ5XC73-6TJZL+VQAO[8 \-U
MS]HSXD?!R_F\"?$CPAI7QT^(VI7OC#Q#X,TO]GBQM/#&J:A\*O O@[PGXF\8
M>*?&GA'XI>/9-*\#ZSHFK>)[3PIH^AV/Q*\63^.[G5?"^JZ;#H4&I:[:^&?/
M=._X*9_";6;SQ)<:-\+_ (S:]X4TZU^)9\(^+O#_ (<\.ZX/BAJ_PP^!W@G]
MH74= \">$;#Q/+X]N]2USX<^-[9_#G]K>&=*@NO$6BZ[X>O9+"ZATZ34^I\"
M? K]B;XY^&/%5MX8T#6->GTSX@ZW+\0=5\1>)OCMX5^-D?CCQ3\/-"\,:QIO
MQ'\3^-=<\/?'&>+Q5\*;KPMH#^'O%^I2:!XB^'8\-:;::=>>'+31XX/:+K]D
M?]FVZANX7^&.C6UO=ZMXYU=[;3M4\1Z5:6^I_$+X<6'PE\82:=::7K=G;Z3%
M>_#K2--\-6ECI<=E9^'K33K:[\/VVD:E;)?( >#Z=_P4;^$VHZ$=:3POXEOX
M4\'^$?%\LGACQ%\,?'.CS6?C']HV7]FBQMM/\2^#O&^M>']0G@\7Q?V_=Q"^
M@N[+PS(L6JV.F^*H;SPU:\OI_P#P4W^'MQK%A97OP4^,VC:%J&JWJ1>++]/A
MF='3PEI/[30_9-UKQQ-9V?Q!N=>32+#XJ7>@W<6EC1V\1ZIX(UN'Q+IVE3W&
MGZCHT'OLW[$'[+5T-$>\^'#7]QINJ7&N-J=[XZ^(U[K/B[6+SQUX;^)_]J?$
M/6[CQA+JWQ4OX/'O@SPQXNTRZ^(UYXJDTO5]"L;S239I RG>F_8__9KEM;>V
ME^&>G_9K/2]1TF #Q!XM0P:9J7QDT[X_W\*S)XA64";XOZ3I_C5K@N9H;RU7
M3XY8M$:72W /F:R_X*??"CQ!87=]X$^&?Q3\?7%_XT^&/@[P):^&X/!:IX[?
MXK_$S4?A1X<OXM:U7Q;IOA_P@]OXATY==U3P]XZU;P]XIA\!:EI?C&RT:_M#
MJ=II7L'Q%_:LN_AI^TQX/^#NL>"O%&L^%/%'[/OB7XKR3> OAI\0OB;XQL/$
MV@_$SP-X.CTN\@^']CX@M=/T,Z9XJO;DW%[IB"\U*Q_T'5&2*2TG[O3OV4?V
M==!O9-4MO!8AQXM\,?$+3K:]\9^.KS0_#6N>!?%FL>/_  [-X+T'4O%-SH'@
M;PYH_BS7]4\1R>$_!VG:'X.N+ZZ2?4M$N8+>QCM^:TWXW?L;>(_'/@;XN:)\
M4/AMX@\>>+OAW\3_  K\/M;T3Q9)K&I^)O /P[UVQ\4?$_2?#FAZ;>7,>M'P
MYKGA^TU'5%M-)N=;C?3WBLWDMA<0N ?*W[/_ /P4X^&WQ"T'X6W'B3P+JA^)
M7CGX2_#KQ-\2;SP'HNE1:1H'CWQ%\ (_V@(/"%QINO\ B2+Q=IVA:=X.U*&P
M/B_Q/*O@OPIXD\1:)X6\1>*M.N=0OKRSX;XK_P#!5/4],\'^(O%OP<^$MAXJ
ME\#:'\=U\4^$]>\4>$[U]4\6?#?X<?LZ?%#P9%X3\?\ @7QEKO@2_P##VL>$
M_P!H'3+O6[^*]OF34M/N]!M)[6:Q?4+[[>T+]C/]DO5O#&A+X>^']AJ7@"]^
M'&D>$=+T*P\;^/+WX=>(O!#_  QF^&.@ZCJ?A1/%TGA#Q=K2?"G5/^$0TCQ_
MKFEZKXRA\*M965GXC2"ST]K:Z/V&OV8I+#Q18:C\/-0\0?\ ":P>,X/%>I^+
M/B+\4?%_B+7V^('@#P+\+?%=YJ?BCQ/XVU;Q)<ZKJ'@/X9?#_P /VNKMJHU/
M18O".AWV@W>EZG9)>D ^<_"'_!1NVL1XYM/BY\)O&FB7]A\5/VG_ (?_  PO
M/"UIX6N].^*MW\!OVB].^!>C^#- L[GQ[=:M:>.M:G\8>"+)]5\3P^&/ ^JZ
MZOBJ\LM4TC0M/L#>>J>(_P!N?PYX!\8?"OP+\2/A-\0? 'B7XD>,/!7@6?1]
M:UWX27&L>'=>^(_Q*U+X4>#;Q/#^C_$;4?$?BOPCJOBBQLKNZ\9^$](U#0-)
M\/\ B#1+[4+B/5/[9T'1?6=1_9!_9SU?28]$U7X:6.J:?'-\7KM4U+7/%=].
M=0^//B"V\6?%;59+VYU^2^EUGQ5XILK/Q+_;+W+:IH6OVEKK'AF\T74+>&X3
MG;?]AK]F*VUW1O$L?P]U!M<T;Q+X/\:R:A/\1OBE=2^)O&WP_P#'>I?$OP5X
MV^(<=SXVFM_B=XS\,^-M7U+6M(\5_$6'Q1KUJ;VYT]+_ /LITL(P#YZ\&?\
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M%T=-2U[6=0NX-&T;2=)MY8M.TVRMH/1Z "BBB@ HHHH **** "BBB@ HHHH
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M..!HXU^C*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>structure.jpg
<TEXT>
begin 644 structure.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
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MHOF>]E&(=W1?JOU.8^(5\9]9BM WRVT?(_VFY/Z;:Y.M'Q#<?:?$%_+G(,[
M'V!P/T%9U=]"')2C$\G%5/:5Y2\PJUINF7>K7:VUG$7<]3V4>I/855KH]#\7
MMHFGBTCTZ&0[B6DW$%_K_*JJN:C[BNR:$:<I_O79%Y[C3/!D316A2]U=EP\I
MY6'V'^'7UKE+N[N+ZY>XNI6EE<\LQKJM/\00:IJ$5G!X;TWS9B<%P .F3D[?
M:K$NHB&PN;Y_#>E^5;7!MWQC)8=<?+TKDA*5-^]&\GYH[ZD(U8^[.T5T2=O^
M'.'HKI_^$NL?^A:T_P#[Y'_Q-'_"76/_ $+6G_\ ?(_^)KH]I5_D_%')[&C_
M ,_/P9S%%=K9ZO'?6-W>0^&],\JS4-)N !.?3Y?:DU+6(]*^S_:?#>F'[1$)
M4V ' /K\O6H]O*_+RZ^J-/JL.7FY]/1G%T5T_P#PEUC_ -"UI_\ WR/_ (FC
M_A+K'_H6M/\ ^^1_\35^TJ_R?BC/V-'_ )^?@S!T_4;K2[I;FSE,<B]?1AZ$
M=Q74M'IGC2(R0[+'6%&60\+-_G\_K3X-62XTF;4T\-:9Y$,@C8$#<2<=!M]Q
M1J>MKH5^L$_AW35G51(&BQQGISMZUS3E*<O=C:7JCLIPA3A:<[P?D_O78Y&\
MLKC3[I[:ZB:*5#RI_F/45!6]X@\4-K\$<<EC%"\;9$@;+8]/I6#7;3<W'WU9
MGG5HTXS:INZ"NJ^'U\;?7'M2WR7,9 '^TO(_3=7*U?T*X^RZ]8S9P%G3)]B<
M']#4UX<].42L-4]G6C+S*EPV^YE?^\Y/ZU'3[A=EQ*G]UR/UIE:+8Q>X4444
MQ&UX/_Y&JQ_WF_\ 036SJ'_(I:S_ -A9_P#T(5C>#_\ D:K'_>;_ -!-;.H?
M\BEK/_86?_T(5P5OXR^7YL]7#?[M+_M[\D<91117>>4=1X;_ .15\0?]<E_D
MU'C;KI7_ %Y+1X;_ .15\0?]<E_DU'C;KI7_ %Y+7 O]Y^?Z(]67^Y_)?^E,
MY>BBBN\\HZO2_P#DGU]_U^)_-*B^('_(R?\ ;!/ZU+I?_)/K[_K\3^:5%\0/
M^1D_[8)_6N"G_'?J_P!#UJO^Z+TC^<CF:***[SR0IT;;)4?^ZP--IT:[Y%3^
M\0* 6Y>U^W^S:_?Q8P!.Q ]B<C]#6?75?$*R,&MQW87Y+F,9/^TO!_3;7*UC
M0GSTHR\C?%4_9UI1\PHHHK8P-KP?_P C58_[S?\ H)K9U#_D4M9_["S_ /H0
MK&\'_P#(U6/^\W_H)K9U#_D4M9_["S_^A"N"M_&7R_-GJX;_ ':7_;WY(XRB
MBBN\\HZCPW_R*OB#_KDO\FH\;==*_P"O):/#?_(J^(/^N2_R:CQMUTK_ *\E
MK@7^\_/]$>K+_<_DO_2F<O1117>>4=7I?_)/K[_K\3^:5%\0/^1D_P"V"?UJ
M72_^2?7W_7XG\TJ+X@?\C)_VP3^M<%/^._5_H>M5_P!T7I'\Y',T445WGDA5
M[0[?[5KMC#C(:=,_0')_2J-=1\/[(W&O-<D?);1DY_VFX'Z9_*LJT^2G*1OA
MJ?M*T8^9U?C72SJ.@2/&N9;4^:ON!]X?ES^%>65[F1D8/(->2^*=$.BZNZ(O
M^CS9>$^@[K^'^%>?E];1TW\CU\WP[NJR]'^AC445MZ9XJNM*LEM(;.RD523N
MEB)8Y]2"*].;DE[JN>)3C!NTW9>ERUH=OH=O';WSZ]):7JY)419V'D>ASQ5]
MTT"2TFM7\43-#/+YTBF'[S^OW:H_\)W?_P#0/TW_ +\M_P#%4?\ "=W_ /T#
M]-_[\M_\57#*G6D[V_%?Y'IPK8>,>6Z^Z7_R1AZE#9V]])'87+7-N,;9&7:3
MQS5>((TJ+(Q1"P#,!G [G%=)_P )W?\ _0/TW_ORW_Q5'_"=W_\ T#]-_P"_
M+?\ Q5="E62MR_C_ , Y7##N5^?\/^"6[>#P[:6MQ;0>)IDAN0!*OD_> _X#
MQ27\/AZ_2,W/B::4P1[(_P!ST Z#@<U5_P"$[O\ _H'Z;_WY;_XJC_A.[_\
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AP^>9A\S?X#VK4HHKRI2E)WD]3WH0C3CRQ5D%%%%26?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>syringe.jpg
<TEXT>
begin 644 syringe.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
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MDT^>>LG^'DC2O74E[.GI!?CYL,YHHHKH.0**** "BBB@ HHHH **** "O4?
M^EMI^A++(N);H^8?4+_"/RY_&N&\,:*VMZLD3 _9XOGF/MZ?CT_.O6P H
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)8JR"BBBI+/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>tagline_1.jpg
<TEXT>
begin 644 tagline_1.jpg
M_]C_X  02D9)1@ ! 0$!+ $L  #_X0!:17AI9@  34T *@    @ !0,!  4
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /W\HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **H^)
M/$VG^#M$N-2U:^M=-T^T7?-<W,HCCB'NQX]OK7Q?^TK_ ,%6"&N-)^&MN.Z-
MK=Y%^L,+?^A2#U^3H:]K)N'\=FE3DPD+KJWI%>K_ $5WY'S/$O%^5Y%1]KF%
M2S>T5K*7HOU=EW9]9?%?XX^%/@AHOV[Q1K5GI<; F.-VW33X[1QKEV_ <=\5
M\<_'3_@K3JFJF:Q^'^DKI</*_P!I:BBRW!]"D7*+_P #+YST%?(_BWQCJWCS
M79M3UK4KW5=0N#^\N+J9I9&]!DGH.P' [5FU^S9'X<X#")5,9^]GYZ17RZ_/
M3R1_-7%'C1F^8-T<M_V>GW6LWZRZ?]NI-=V;GCSXD^(/BAK3:AXBUC4-8O&S
MB2ZF,FP'LH/"CV4 5AT4V1L"OT&G3A3BH0226R6B/Q^K6J5INI5DY2>[;NWZ
MMD<C9J.1L"G$U[=^QG^Q/JO[5&NR7ES+)I?A+3I0EY>J/WD[\'R80>"V",L>
M%!'4X!YLPS##X*A+$XF7+&/7]%W;Z(]/)\GQ>98J&"P4'*<ME^K?1+JV>'Z9
MH]YX@U&.TL+6YOKJ4X2&WB:21S[*H)->@:=^QA\5]:MO.@\ >)E0]/.LV@;\
MGP?TK].++PM\.OV)/A)J&IVNGV>@Z1IL(:ZN%3?=7C=%5G/S2.S$  G&3Q@=
M/B7XI?\ !7'X@>(?$<C>%[72_#NDQO\ N8Y+<75Q*N?^6C-\O/HJC'J>M?#X
M'BS,\VG)Y3ATJ<=.:HVE?M9=?)7MUW/U7,N ,ER"E!9_C).K)7Y*44VEWO+I
M?JU&^MD[,\"\9_LX^/\ X?VCSZSX,\3:?;1Y+3RZ=+Y*@=<OMV_K7",:_:#]
ME?XLZC\<OV?_  UXJU:QCT_4=6@=IX8E98\I*\>]0V2%<(' )/##D]:\3_X*
M$?L*^'?B3\-=9\8>'M.MM)\6:+;O?2FUC$<>J11J6=)%''F;02K@9) 4Y!&W
MCRWQ$OC?J.94E"7,X\T7=)IVU7:_5-_<>IF_A#;+EFF3UW4BXJ:C*-I.+5]&
MNMNC2];Z'YB2FH7/RT^0Y-12G%?J!^-1(935:=JGD-5)VH-XE:5N:JSFK$C<
M54G:@WB5Y356X-6)35.<TT:Q*\IYJK.:L2FJDYIQ-(E:8U4G-69C568\U2-H
MGI7[,/[9'CS]D#Q?_:G@_5GAMY7#7FEW&9+#4!C&)(\CG'1U(8=B.:_9#]AG
M_@H;X-_;>\*-_9K?V+XLL(U;4M"N) TL7K)$W'FQ9XW  CC<JY&?P;F/%7_A
M[\2=<^$/CG3?$GAO4KK2-;TB83VEW V'C8<?1E(R"I!# D$$$BOCN*.#<)FU
M-S24*RVEW\I=UY[KIV?WO"/&^,R:HJ;;G1;UB^GG'L_+9]>Z_I3HKYY_X)S?
MMXZ7^W'\'?MLBV]AXPT,);Z[IR'"JY'RSQ DGR9,-C/*D,IS@,WT-7\Y8[ U
ML'7EAL1'EG%V:_KH]T^J/Z>R_'T,;AX8K#2YH25T_P"NJV:Z,****Y3L"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYQBO6]-U*'6-.M[RUD6:VNHUFBD7HZ, 5(^H(-?@3^V3_P G>_%;_L<-7_\
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M,GRO,:.58VKRU:MN56;6KLKM:*[5E^-EJ?H11117SY]8%%%% !1110 4444
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MM7_$4,I_DJ?^ Q_^2/YP7@EGW\]+_P "E_\ ('Y12O4#')K]3/'O_!-WX&^
M/!&L:]>^'M0^R:+937TW_$WN%RD:%R,[_05\#_L8?!2U_:(_:6\/^&[Z!FT>
MXDEN=02-V7;!&C.5W [AN(5,@Y!85[F5\7X+'8:MBZ2DH4E=MI+HWI9N[T\M
MT?.9QX?YEEF,P^!KRA*I7=HJ+;MJE=WBK*[\]F>32O5>5^*_6T_\$IO@HW_,
MNZA_X-KG_P"+IC?\$H?@FW7PYJ'_ (-[G_XNO#_XBAE/\E3_ ,!C_P#)'U:\
M%\]7VZ7_ (%+_P"0/R*G>JLC<5^OC?\ !)CX(-_S+>H?^#>Y_P#BZY_XI?\
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M>J1:Y<6OBCXD76J/%IUQ/8QV\%C9^5&?,E6%45V#EPB@ GDL< !O%=2_:?\
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M_".-HT5S2E*:275N$#\O\3,91POB#EN)Q$E&$(4VV]DE5J-L_<VBOQ]^,/\
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M+#_MA?$#]E2R^'L7@/6HM#D\0/J#WLQL8+IW$ M@B@3(ZJ/WS$X&3A>0,@^
M_#O_ (+7^,O"?[->J1:Y<6OBCXD76J/%IUQ/8QV\%C9^5&?,E6%45V#EPB@
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M.4;>^G%7<6KVO;;6SNK,^2/^"_'_ "1GP#_V&IO_ $0:YC_@WQ_YJY_W!O\
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MHHKSSUPHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_DNOA,+X;\18>M&O1Y8SB[IJ6J9^IXWQEX.Q>'GA,3SRIS5FG!V:9XK^PO\
M%[4OV6?VS?#=U*[6T8U,:%K,0/RM;RRB*4'UV-AQ_M1K7[E:WK-OX=T:\U"\
MD$-G8PO<3R'I&B*68_@ 37\\>M^)]4^(OQ.O-:C@!UK7-3DOEAM(R1Y\LI?;
M&I+'&YL $D].M?M]_P %$O%$GA#]B'XF7D996DT26SRHYQ.1 >X[2'_Z_2OH
M/$W+%7S# WTG5]QV]8V_]*9\GX(YW+"Y3FEKRI4/WD;^<9M_>H*Z\S\<?V@_
MB]KW[9/[3&I:YY4USJ'B;45L]*L@<M#$7$=M;KVR 5!QU8D]Z_9']BS]C+PU
M^QW\+;/2]-M;:X\17$"G6-8,8\^^E/+ -U6)3PJ#@  G+$L?R<_X)>^%8?&/
M[>OPXL[@*8X;Z:^&1GYK>VFN%_\ 'HA7[D5S^*F82PWL,GPWNTU%2:757<8I
M^2Y7\]>B.KP)RF&->+XCQGOUI3<5)ZM.RE-KLY<RU[*RT;([JUCOK:2&:..:
M&92DD;J&5U(P00>"".,&ORA_X+*?L5>&?V?O$.B>-/"-O#I.G^*KB2VO-*B7
M;!!<*H820J!A589RO0$<<' _6*O@3_@OQ_R1GP#_ -AJ;_T0:^5\.L=7HYY1
MI4Y-1G=271JS>J\GL?>>,66X7$\+XBO6@G.FDXOK%\T4[/S3::V9S'_!OC_S
M5S_N#?\ M_7Z15^;O_!OC_S5S_N#?^W]?I%4>(W_ "46(_[<_P#3<33P;_Y(
M_!_]Q/\ T[,_GB^"?_)9O"/_ &&K/_T>E?K#_P %2/\ @H=%^RUX-;PGX5NH
MY/B!KD!Q(A#?V) PQY[#_GJW_+-2/5CP &_(3PYKUQX6\0V&J6NS[5IMS'=0
M[QN7>C!ER.XR!6KX]\5:UXK^)-YKGC#[?J&L:E<+?7_VLM%-<B3#CME59"-N
M!@*5P,8K]XSSA>CF>88?$XG6%)2?+_,VU:_DK:]]%M<_E7ACCC$Y'E&+P6"O
M&K7<5S_R12E>W]YWT[*[6MCZ>_X)D?\ !/B]_:V\<GQIXPCN?^$&TRZ,DK3,
M?,UZY!W&($CYHP?]8^<G.T'))7]?K"P@TJQAM;6&&VM;:-8H88D"1Q(HPJJH
MX     X %>?_ +)/Q#\(?$_]G;PKJO@6VMM/\-M9)#;V$./^)<R#:]NW^VC
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M8;0<D@G;CL?^#@[_ )I'_P!QG_VPKI_^" __ "1GQ]_V&H?_ $0*VIXNMA^
M(5*$G%ZJZT=G5DG]ZT.>KE^&QGBS4I8J"G%*,K/575"+3MUL]?4^^D18D554
M*JC  & !7RQ_P5W_ &FKK]GO]EN:PTBX>UU[QM,=)MY8SB2W@VEKB13V.S"
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M"[1?ASI-P]O=>,-UWJC1G#"RB8!8\]<22=<=1$P/#$'Z'_X)S_\ )COPS_[
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MVU% 498DG Y))[U\6_LT_P#!;[P/\2KRUTOQ[IDW@C4IB(Q?)(;G378\?,V
M\0)/\090.KBOMK3M1M]7L(;JTGANK6X02130N'CE0C(96'!!'((K\5S;)<PR
MR?L,;3<+[=G;JFM'^ES^EL@XDRC.Z?UK+*L:EM'TE&_1IVDKVZJSMUL34445
MXY]$%%%% !1110!^ ?[9/_)WOQ6_['#5_P#TMFK]VOA%_P DG\+_ /8)M/\
MT2E?A+^V3_R=[\5O^QPU?_TMFK]VOA%_R2?PO_V";3_T2E?LWB=_R+<!Z/\
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MW_87^+VI?LL_MF^&[J5VMHQJ8T+68@?E:WEE$4H/KL;#C_:C6O:O^'\WQ?\
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M5XW3]?P=GT/R'P=X;PN>Y)F678I:2=.SZQDE/EDO-/[U=;-GXX_\$G_VX/\
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M0'_Y(SX^_P"PU#_Z(%<Q_P '!W_-(_\ N,_^V%=/_P $!_\ DC/C[_L-0_\
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M/H?&K%4<3PBZV'FIP<X6<6FGJ]FM&?7'_!%?_DQ?3/\ L+7W_HP5]95\F_\
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MH*^3_P#@@S_R=[XD_P"Q/N?_ $ML:\O_ &S?VJ?&7_!03QEJFO6^DW5KX/\
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M_P"23^%_^P3:?^B4K]F\3O\ D6X#T?\ Z3$_FWP/_P"1SFW^)?\ I<S\W?\
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MW_!4VU_9Z^#6B>$+7X>_;DTB-P]U_;GE&YD=VD=]OV=L99CQN.!@9K=^(/\
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M\:_MSDUZ-Z+Y*R/O30O^"V-KX7T*RTVS^%?E6>GVZ6T"#Q)]R-%"J/\ CU[
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MR55.W5Q3?WVU]7<_+<5X,\*5\0Z[H.-W=QC*2C]U]%Y)I=CY;^ '_!)?X;_
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M[*O_  34\?:3X-T*UTC[<VFQRW!S+=WSC4;9_P!Y*V6; #$ D*.< =*^4?\
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MW KYL94@PK@Y/4\="-/]@;]AZ/\ 8;\":YHZ^)9/$\VMWZWCW!L!9K$%C"!
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M#!8VMA*\<3AWRSB[IZ.S]'=?>>MF66X;,,+/!8R/-3FK25VKKU337R9\P_L
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M_8%LOY/7Z9X4_P#(Z?\ @E^<3\5\>O\ DF5_U]A^4CW3]EW_ ()M>!_VS/\
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MSC)QFN(_:Q_9&\)_MB?#D>'_ !1#-'):N9]/U"V(6ZT^4C!9"00588#(00P
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MP.'PE%8?#048+9+^M^[W84445RG4%%%% !1110 4444 %%%% !1110 4444
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MG4E*32V3DV_U/>RC+H9?@:. IMM4H1@F]VHQ44WYNP4445QGH!1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGS25E>_1I'YF7O\ P0>\5*@^S_$#P_(V>1)83( /P)JHW_!![QJ?^9Z\+_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
IBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>team.jpg
<TEXT>
begin 644 team.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "1 )$# 2(  A$! Q$!_\0
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M%%_?W&IWDEW=2%Y)#SZ >@]JKU]#AL-&C'S/D<9C)8B7:/1!11174<(4444
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M(SQKF6T;S!Z[?XO\?PKR^O<V4.I5@"I&"#WKR'Q'HSZ)JTEO@F%OGA8]U/\
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>?.5OXC/L</\ PHA11161N%%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>testtubes.jpg
<TEXT>
begin 644 testtubes.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  H'!P@'!@H(" @+"@H+#A@0#@T-
M#AT5%A$8(Q\E)"(?(B$F*S<O)BDT*2$B,$$Q-#D[/CX^)2Y$24,\2#<]/CO_
MVP!# 0H+"PX-#AP0$!P[*"(H.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SL[
M.SL[.SL[.SL[.SL[.SL[.SL[.SL[.SO_P  1" "0 ) # 2(  A$! Q$!_\0
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M<@?>-;'@>:6?Q1&TTKR$1/@NQ/:L+5/^0M>?]=W_ /0C6UX"_P"1F3_KD_\
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MFZZ,/_!CZ''C/]XGZL*ZKX?7QM]<>U+?)<QD ?[2\C]-U<K5_0KC[+KUC-G
M6=,GV)P?T-57ASTY1)PU3V=:,O,J7#;[F5_[SD_K4=/N%V7$J?W7(_6EMY?L
M]S%-Y:R>6X;8XR&P<X/M6G30Q>^I'@^E=A\./^0K=_\ 7#_V85+_ ,+#C_Z
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:M6I117E2E*3O)ZGO0A&G'EBK(****DL__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>totalrev2019.jpg
<TEXT>
begin 644 totalrev2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" "* 5 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#^_BBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_#U_%'_YK*/^&H/VEO\ HXKX^?\ AZ_BC_\ -91_Q+KC_P#HJ,'_ .&RM_\
M-?K_ $M3_B9#*_\ HF,?T_YF&'\K_P#,/Z_=]_\ K<^8OH__ '[D_P#B:/,7
MT?\ []R?_$U_DC?\-0?M+?\ 1Q7Q\_\ #U_%'_YK*/\ AJ#]I;_HXKX^?^'K
M^*/_ ,UE'_$NN/\ ^BHP?_ALK?\ S7Z_TM3_ (F0RO\ Z)C']/\ F88?RO\
M\P_K]WW_ .MSYB^C_P#?N3_XFCS%]'_[]R?_ !-?Y(W_  U!^TM_T<5\?/\
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M&'\K_P#,/Z_=]_\ K<^8OH__ '[D_P#B:/,7T?\ []R?_$U_DC?\-0?M+?\
M1Q7Q\_\ #U_%'_YK*/\ AJ#]I;_HXKX^?^'K^*/_ ,UE'_$NN/\ ^BHP?_AL
MK?\ S7Z_TM3_ (F0RO\ Z)C']/\ F88?RO\ \P_K]WW_ .MSYB^C_P#?N3_X
MFCS%]'_[]R?_ !-?Y(W_  U!^TM_T<5\?/\ P]?Q1_\ FLH_X:@_:6_Z.*^/
MG_AZ_BC_ /-91_Q+KC_^BHP?_ALK?_-?K_2U/^)D,K_Z)C']/^9AA_*__,/Z
M_=]_^MSYB^C_ /?N3_XFCS%]'_[]R?\ Q-?Y(W_#4'[2W_1Q7Q\_\/7\4?\
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M?U_I:G_$$?#S_H4XCI_S,,9Y?]/?)_>S^''_ (A5/VF/^CI?@/\ ^$;\2O\
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M,_ _ASXLV=SXVDM/C5HWA3Q3=7VNZ#8?%V'QM!I^H:GJ\D*^7K&J17?U710
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M_'7_  2\\1Z_\%_V;OA;9?$+X8>*KGX,_L8#]CC4YOB_\*=3\<^%M&DG\/\
M@?1V_:%^#GAJW\8Z5+X"^,.D2^#W-C<7.I7TE]IT^B6'_"1Z(_AUKC6 #]A[
M*[CO[.UO84N(XKNW@NHDN[6YL;I([B))HUN;*\B@N[.X5)%$UK=0PW-O*'AG
MBCE1U%DD 9.?P!8_D 3^E8/A70F\+^&?#WAM]9UOQ$^@:'H^B/K_ (EO?[2\
M1:VVDZ;:Z<VL:]J/EQ?;]9U,VQOM5O?*C^U7]Q<3[$\S:*GC/P/X0^(F@77A
M7QSX<TCQ7X<O9;2>[T77+**_TZXFL+F.\LY9;:8&-WMKJ&*XA8C,<L:NO(H
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M_P# 2;_Y+H_X6?XE_N:7_P" DW_R77*?\(YXA_Z 6K_^"^Y_^-T?\(YXA_Z
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M_P# 2;_Y+H_X6?XE_N:7_P" DW_R77*?\(YXA_Z 6K_^"^Y_^-T?\(YXA_Z
M6K_^"^Y_^-T?4,A_Y\9=]]'_ .2\OS[L/[3XF_Z",U_\!K^7]ST^[RTZO_A9
M_B7^YI?_ ("3?_)='_"S_$O]S2__  $F_P#DNN4_X1SQ#_T M7_\%]S_ /&Z
M/^$<\0_] +5__!?<_P#QNCZAD/\ SXR[[Z/_ ,EY?GW8?VGQ-_T$9K_X#7\O
M[GI]WEIU?_"S_$O]S2__  $F_P#DNC_A9_B7^YI?_@)-_P#)=<I_PCGB'_H!
M:O\ ^"^Y_P#C='_".>(?^@%J_P#X+[G_ .-T?4,A_P"?&7??1_\ DO+\^[#^
MT^)O^@C-?_ :_E_<]/N\M.K_ .%G^)?[FE_^ DW_ ,ET?\+/\2_W-+_\!)O_
M )+KE/\ A'/$/_0"U?\ \%]S_P#&Z/\ A'/$/_0"U?\ \%]S_P#&Z/J&0_\
M/C+OOH__ "7E^?=A_:?$W_01FO\ X#7\O[GI]WEIU?\ PL_Q+_<TO_P$F_\
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MS[L/[3XF_P"@C-?_  &OY?W/3[O+3J_^%G^)?[FE_P#@)-_\ET?\+/\ $O\
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M]U+2H#"&MW$TC7:E,J0C G;]7_\ #[_]CS_H7/CK_P"$/X8_^;VOTGA/P?\
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M_P 2V>//_1J^+_\ PVO_ .3#_B9GP"_Z.MPA_P"''T_Z=^?]75_V)HK\=O\
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M_#CZ?]._/^KJ_P"Q-%?CM_P^_P#V//\ H7/CK_X0_AC_ .;VC_A]_P#L>?\
M0N?'7_PA_#'_ ,WM'_$MGCS_ -&KXO\ _#:__DP_XF9\ O\ HZW"'_AQ]/\
MIWY_U=7_ &)HK\=O^'W_ .QY_P!"Y\=?_"'\,?\ S>T?\/O_ -CS_H7/CK_X
M0_AC_P";VC_B6SQY_P"C5\7_ /AM?_R8?\3,^ 7_ $=;A#_PX^G_ $[\_P"K
MJ_[$T5^.W_#[_P#8\_Z%SXZ_^$/X8_\ F]H_X??_ +'G_0N?'7_PA_#'_P W
MM'_$MGCS_P!&KXO_ /#:_P#Y,/\ B9GP"_Z.MPA_X<?3_IWY_P!75_V)HK\=
MO^'W_P"QY_T+GQU_\(?PQ_\ -[1_P^__ &//^A<^.O\ X0_AC_YO:/\ B6SQ
MY_Z-7Q?_ .&U_P#R8?\ $S/@%_T=;A#_ ,./I_T[\_ZNK_L317X[?\/O_P!C
MS_H7/CK_ .$/X8_^;VC_ (??_L>?]"Y\=?\ PA_#'_S>T?\ $MGCS_T:OB__
M ,-K_P#DP_XF9\ O^CK<(?\ AQ]/^G?G_5U?]B:*_';_ (??_L>?]"Y\=?\
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M@MKIM.U2WN;5KFV,SM;3^498'8R0NCC</U/_ .&)OV0/^C8O@/\ ^&L\'?\
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MK/!W_P JJ/\ BH=P)_T0'%O_ (6Y/_\ +OZL_*Y_Q3@X^_Z.)PA_X09SY?\
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M:GIEQ=VM_P".[?P>;(7]Q<WM]XC_ +,;1X?&]]=^.8O$EQ)]:4@      X
MP /0 =*6@ HHHH **** "BBB@ HHHH **** ,FXT'1+K5[#7[G2-+N-<TJUO
MK'3-9GTZSFU73K+4S VHVECJ4D#7MG;7[6ML;VWMIXH;LV\!N$D,,>W6HHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
/ "BBB@ HHHH **** /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>totalrevbycustomer.jpg
<TEXT>
begin 644 totalrevbycustomer.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #8 3(# 2(  A$! Q$!_\0
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M^+,WQ6_97_:&G_;?^$>LM\7/BI>_!WP7\(VU7X>_"+P;XRL_V@O%'C5-*M/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MM+EANOA_=>.;;7?"\UQXJ\,2ZWH^GZE/: 'Z.T4BL&&1ZL/Q4E2/P((_E2T
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M^N4445_,9_484444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M5A^)8-?NM U>V\+:IIFB>([FPN+?1-8UK1[CQ!I6EZG.ABL]0U#0K35] N=8
MM;.9TN)=,AUS2&OEC^S?VC9B0SIN4?Y_+I0!^''@S]H/XW^._A%^PC)I'[3.
MKZW^TK\6?AE\+O%E]X!TSP[\*]'\,:WI%O\ $31[7XT_M!_'NYN=/<:3\,9?
M"DUUX'\)>"?!I\+7VL?$#6X-$\ 3ZMXC,6L> ?0/#?[1OQJ_9Q\2:GIG[8/Q
M#OM1T/2_B-XS\87>I>#+#0/&,UMX.LOA]'>W]CJTGA[PWX8C\/?##PXL7C#X
MY7.@O!K/Q,\$>!9OA-X7U'4?&-WX@O(Y?TYU3X)_!W6[W0=2UGX4_#75M0\+
M6ME9>&K[4_ 7A._O/#]GIM[-J.G6NAW5WH\T^D6UA?W$][9P:=);16MY/-=6
MZ1SR/(;WB7X3_"_QG'!%XO\ ASX&\4QVWBRP\>VR>(_"FA:VMMXXTNVM[+3/
M&$ U.QNA#XGT^QM+:QLM<CVZE;65O#9Q7*VT21  [\$,,CIEA^*L5/Z@TM
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M<X[B'-L=G.95/:8S'UY5JK7-R4XV4:5"DI.3C0P]*,*-&#E)QI4XQ;;3;_T
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M>Z:-?T;P3'H^E>)=4M) #ZT(R,<]NY!X]P<_7UZ'BDVCC[W'^TW?GGGGVSG
MX''%.HH 3:/?GG[S>N?7CGL."/E/'% 4#U_%F/\ ,G\OH>H%+10 A4'U]/O,
M#Q[@Y^OKQG.!1@8QSV/WFSQCOG/;D=#SG.32T4  &!CTXY))_$GD_4\T444
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M]3K4_P"T<!%OI1YZU#%T(MW;Y\1B8QO:G3C%**_GAVL>0"1Z@$C\QP:78_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
? **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>totandusrevbiowhlslrs2019.jpg
<TEXT>
begin 644 totandusrevbiowhlslrs2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #8 3(# 2(  A$! Q$!_\0
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M>^--WJFE_'OPM\-?&O@7Q!;_  L^,3>%]+\+?&?QWJ/PO^#VM?%/Q7_P@/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M\::AX1NO!VD6/A*YU/Q?X6\367PY\>7.A^.O#5IJO@;4X_".O_9?$;G3;G8
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MC.&]/N/GUZ;<_CC&>.M.H **** "BBB@ HHHH **** "D(!X(!'H1FEHH 3
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MQW=?'>SA\(Z )M=^(WC73_#VIP^)].AU/2=2M]7TS1]!@\23>#/'?CUK/D?
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MUGX[\(?#WP]XH^.'A#XCIH]OX+T+X'_#[2)[C3_!_A_4[+PU=_!:_P#@]?>
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ME]!XJ^+OC5M&GE$J,OA?0]7G\,>$K98YV>6&.T\,:'I-ND+',8C*X'0?U/\
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M LJO!)-&_O=>6>(_&FJ7^JW/@OX?16U_XDA"IK>N7*F;0/!<,RMB74F0XO\
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M?ASX-NK#P=;:A/#=7]OX5LY]%DM_#L%[<6\$]W#H\=E'<S0Q33J\L:.OK=%
M'F>O?!;X/>*M#TWPSXG^%/PV\1>&]&N]5O\ 2/#^N^!/"NL:)I=_KK7K:W>Z
M=I.HZ3<V%C=ZPVI:BVJW-K;PS:B=0O3>/,;J<OJ1?#+X;V[WLL'P_P#!,$FI
M7VF:GJ$D/A/0(I+[4M%\8ZA\0]'U"\=-/5KJ^TKQ]JVJ^.--NYS)<6'B_4M0
M\36LD.MWMS?2]Q10!Y;HGP/^"_AK59M>\._"+X8:#KESK \0W&LZ+X \):5J
ML^OB?4[D:Y-J-AH]O>2ZQ]IUK6+C^TY)FO1/JNI2B<27]VTW47W@;P3J=OXJ
MM-1\'^%K^U\<Q0P^-;:]\/:1=V_B^&WTV#1H(O%,-Q9R1^((X-(M;;2H8]76
M\2/3;>"Q15M8HXEZJB@#RZ\^!_P8U"X\:W5_\(_AC?7/Q*AM[?XBW%YX \)7
M4_CZWM+A+JU@\:S3Z/)+XJAMKF-)X(]=>_2&9%FC"RJKAL7P-^"L.CR>'XOA
M#\+X]!EAL;>71$^'_A%-(EM],\2W7C/3H)--31ULGAL/&%]>^*[*(P;+3Q)>
M76NVZQZK<37;^IT4 >&_$3PQ\*_ GA;_ (6%<?")/$ES\+-,T#5?"VB?#OX?
MVNN>-V;P%I_B32? OA[P7H^CVUK<3SZ+;^-?$^D^$M*%S9:+H,?BC6W$ND:7
M?:Q=CYPO/VJ?V<TL[3QIXN^#OBK2O'MW^TOX1_9?\0:%<?"S0/%OC#PM\8O%
MD_A/X8:=<^+/&7@^Z\4>"-/\(6?A?XO:+;7OCZ;QTVD1>$?$]SX.@EF\47MS
MX'E^N/C!X4\<^.?AAXY\'_#7XD3?"#QUXE\.:CHOAKXG6OAJR\7WG@;4M0B^
MSIXDL/#FI:AI>GZIJ6FPO-+IL-]>1VD-_P#9KJ>.YCMVM9_GG0OV1(-,_9[\
M(? .;Q/X<TVR\'_&#X2?%BVUOP5X*U[21K-S\+?CMX(^/-V/$\/C;XE_$CQ)
MXG\8_$+Q/X2U"7Q[\1]?\9ZEK^OZUXGU/Q7?6]SK'FB\ //_  9\9_V2/B-\
M3?'?PVT3X&:5<^-?!^HZ?^S4ZW?PO^'#_P#"3_#^[USXM?#K6M#T>XM[N\O(
M?A-X7NO@1\7;'Q#X1\3P: 5\.>$(-3T_PEJ7A_QAX)G\0_H<N   ,# P   !
MC@ #@8'&!QZ5\'_M'?L=:I\7V\5ZM\/?&'AOX5>)-=O-(NTO-*\+ZQIL>M74
MNFZAIOBW6?'.K> /%'@/QAXAU^_EB^'FLZ)J4/B2SFTZ^^#G@C2M0?4_"^I>
M*M%U3[3\+:1>^'_#7A[0M2UW4?$^H:-H>DZ5?>)-7$"ZKK]YINGVUE=:WJ:V
ML<5L-1U:>"34;X6\4< NKF80HD>U0 <G>_#87MU=W1\>_$JV%W<3W!M;/Q4;
M>TMQ/(\GV>UB6Q9H+>+?Y<$8<F*)54,2N:ZWPYX;T;PII-OHNA64=E8V^Y]J
MEI)KBXDP9[R\N9"T]Y>W+C?<W=P[SS.<NY  &[10 5\L_M9_L7_LY?MM_#>7
MX8_M$_#K3/&FCPFZN?#FMQEM*\9^!]7NHEB;7/ _BVR5=7\.:G^[A:Y6VE?3
M=52".TUS3M4L=]J_U-171A,7BL!B:.,P6(K83%8>:J4,1AZLZ-:E..TJ=2FX
MSB^ETU=-IZ-HY\5A,+CL/6PF-P]'%86O!TZV'Q%.-6C5@]XU*<TXR76S3U2>
MZ/X*_P!MS_@VL_:<^#5[K'B[]DG68?VEOALCW5W;^#KZ;2O"WQOT&Q0>:MI)
MI]U+8>$?B"UO%^Z6]\.WV@ZSJ$JXA\'*[9/X+7O[.GQ?\*?%OP;\&?BG\-/'
MWPL\8^+_ !CX:\'PZ!\1/!_B#P9JQE\1:Y8Z-OM[/Q#8:<]XJI>/*DEF;B*1
M%W)(5^:O];T@$8(!!Z@\@_A7/>(?"/A7Q;#:6WBKPWH/B:VT^_M]4L;;Q#H^
MG:W;V6I6K;[6_LX=3MKJ.UO;=P'@N[=8KB%@&CD4\U^Z\/>/N?9?2IX?/LNP
MV=TX)1^MTJG]GX^44K7JN%*MA:TDEO'#X>4M7.<I-R/P?B+Z/W#V85:F)R#'
MXC(ZLVYK"5(/'8!3NFE3C*K2Q5&#UO\ [164;KDA%*Q_/39:=;:59VFEZ?$$
MT_2[6VTNP1% 1+'38(["R1 HVA5M;>%5"\8 QQ5G8_\ =;_OD_X5^XFI?LY_
M _5I7FO/AGX7621R[M8V<NEY8L[DXTN>S4 L[%@% ;@,"%4+1M_V8_@/;/YD
M?PUT%FQC%P^IW:?>#9$=UJ$T8;*CY@H;&5SM9@?OH?2$X6]G'GR?/XU%%)QC
M3RZ5-.RT51X^$FO/V2\HGYU+Z.G%:J-0SKAZ5*^DY5,RA4M?=TUEU2*=NGM6
MK]=-?Q+@AEN9X[:VCDN+F5@D5M;QO<7,CG@+';0K)/(Q) "I&Q)( !R*]S\-
M_LW_ !;U_3+W79_"M_H&AZ;92:C<WFO0M87L]I AFG&E:)*4U;4+H6RRS0Q/
M!9P3%!$+M9)$#?LCX?\ !'@[PHJKX9\+>'M VQ^3OTC1]/T^5H\D[7FMK>.:
M098G]Y(W))ZG-=.0"", Y&"#R#['U'8YZBODL\^D)F%>G4H\/9)1P$I1<8XW
M,:WUVM&_VZ>$I0HT*=2.\?;5<73O\5.2T/L,A^CIEU"I3K<1YY6S!1E&4L#E
MM#ZE1G:S=.KBZM2M7J4Y.\9.C2PE6U^6I%M-?.WP4_9]^&WPULK'Q#H@/BG7
MK^P@N(?&&JQPR2_9KR!)5?0K5 UOHUK<Q.'S;F6^DB?RKF_N$RM?15>7> S_
M ,(WJOB#X>S$I!I,IU[PF&/$GA'6;B1ELX2<LP\/:Q]LTME+?N+*72A@+(E>
MGEN..3D#CGEB "<=AG)]@:_ \VSC-,]QM3,<WQV(S#&U;*=?$3<Y**ORTZ<5
M:G1HPNU3HT80I4T[0A%:']!91DV59#@:66Y/@</E^"H_!0P\%%.324JE23O4
MK5IV3J5JLIU:C5YSD]1U%?FC:_M*?'=_">@?M%_;/A[=?"[Q/^T;9? BT^!S
M>$-9T_QQ::+KO[1\O[,VBZS_ ,+)?Q9=))\2M-\6-:>,_&7AFX\"1:!I/AJ'
M7_!L,(UO0AXRU#YZ_9Q_X*@_$[7]$LO&W[2/P>TKPKX%UO2?V;KB[\5_#?7[
M#6=)\%:W\;?V3]$^/K6+:/J-V/%WBO2IM2.H*+ZTL+6;PQ9^(O#6CL?%ATOQ
M+X@L/-/3/VSHK\S? O\ P44N_B+J'PJT#P[^SE\38?$/Q;^)>A>#M C\27<7
M@[P]#X3U[X/>.OC:/'+>)/%>A:/%K']@>%_A[K>B^*?#7AFPUJ\TSQ=>>'[&
MPU+6- UNV\3+Z-XW^+7QN\3?$[X]>'_AGXU^#WPL\.?LU:%X$U76)OB[X<U;
M5].\=7WBKPC>^/\ 5M3\4^);'Q=X;_X5E\+M,\.+!H-MXPT_3/$>HP^)]/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>52
<FILENAME>upjohnlogo.jpg
<TEXT>
begin 644 upjohnlogo.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"_P?0 P$1  (1 0,1 ?_$ 18  0 !! (# 0
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MM%71PF.#HY34A487\-+#1%2DQ"5%I<56=C@9X?%FA.3E9)6U)K;_V@ , P$
M A$#$0 _ )_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]8
M
M
M
M
M
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MZ5K1I^)D;%R[&;863C2ZK,N3HU7[*3.8SX#Z
M
M
M
M
M
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MB5S4D?'$Z-LLC6=>YS(W3,1RHG1%>G7Z4,8T=*^!ZL]R@
M
M
M
M
M
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M=EW\.75:4G&M&N*H^3X\FN:,I3IC[@
M
M
M
M
M
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MIP=>F2]E:--/DTUQI5Y@TS4K&JXD<O'JHO@T^<9+FG]GGXIIF8!T1V
M
M
M
M
M
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MIT7-I-\B5:87/<@
M
M
M
M
M
M        $5;]9(]RN7B'CJ#P1X>S[JW(W+^!CR_.F8Q5OMMZEQ+?>^/'Z,LT
M"J^KE^37P/==C5[)(\#$K)(W0Y.-Z9H[3;16=E/<F?&N)8E2RFN$KJYS^2WX
M?HW5.L&>&WCK+Q[/XKQW]^N*LVO"'W/RR\?T/Z8@NDCC&0
M!V.?ZNGP/K7$?MH<;;SCH:LFU>0>T[URCN62CC<L[W4-HRO'VL8CYJ5$F?2Q
M>M:;!*D*(V&&Y<M*Q'+(Z62*/=74KV=NZ]C3KY.+"%N"^6*G)T]KE-JO-I+V
M467]HXL,?1H75^R792DW\[BE\R7V6S>P8W/3@
M
M
M
M
M
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M=LJS'2,EM75)^6Z-IIMOI=.33KQ?"G#A0E]&"S(
M
M
M
M
M
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MG[28 8*,@
M
M
M
M
M
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M+FGZ3;LWE2]*LI+V.7)/WI43]YM</%'>@
M
M
M
M
M
M                      ]))(X8Y)II&111,=)++(YK(XXV-5SY)'N5&L8Q
MJ*JJJHB(A5)MT7,'6->\OY[S^?'F9M^UZWE9K?"'%/S?%_!U5K^E&[K.'ORK
MF][CA9(L3[/(NP-EOQS.8RQ]U)0KRIUK(B2^V#ME;9T"W8O1IJ-^ER\_%2:X
M0_41^&G+JZFN9A;<6JO5=1E<@_WM;^&'R+G+]4^/R47@:G#VYT0
M       ) OL-^V%O_EWSOA/([:GYC2_';@G9ZF1GV>M7^5RW(>_T6+9H:7HF
M3M4IV8^7"]\=K*9FF^/(X7OKK0FKY"6"W4QAW*WABZ'ILM)L]-S5<F%.GFH0
M?.<TGQKRC!_#/CU)Q3C+U>U]%NZAE+,G6.):E6OC*7LB_=S;7%<*-.C78@P0
MQ5H8:\#&Q0P11PPQM_@QQ1,1D;&]>J]K&-1$(LMMNKYLRVN'!<BJ4
M
M
M
M
M
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M27!)<$DDN",SXV/9Q+$<;'BHV8*B7_AS;YM\V^+.3SXSG
M
M
M
M
M
M                                  !8Y3)X["8S(YG,7JF+Q&(HV\GE
M,G?L15*..QU"O):O7KMJ=S(:U2I6B=))(]4:QC5551$+H0G<FK=M-SDTDEQ;
M;X)+WLI*2C%RDZ12JV=6A[I/FQEO/7S*Y/YL2[=DX\H77:%PKB;7J1MPW$^J
MW+L.NO;4E1'TKFT6K%G.78G*Y8[V3F8BJQC$296S=O0VUH%G3Z+ZTUUW6O&Y
M)+JX^*BJ07NBF80UO4I:KJ,\FK\E/I@O9%<OL\9/WMFO$]4=2
M    <_>,'C1RQY>\X:+P!PM@OOS>M[R:5*\ECYB'"Z]B:[?7S6U[1D*]>V_%
M:SKN/8^Q;G].1Z,:C(V23/CC?UFL:OA:%IUS4]0ETXUI5]\GX1BN%92?!+[-
M%5GU86%?U#)CB8RK=D_F2\6_8ES9V@'@;X1<3^ 7COJ? O%E=EV6DQN9Y!WN
MS0KTL[R7R!=KP,SNX9IL+YG0LF="VOCZ:S3ICL;!!6223TUE?#O<NXLW<^JS
MU/-=$^$(5JK<%]&*_/DZ+JDVZ*M%FO2]-L:5B1Q;'&G&4O&4O%O^XO!41F:=
M =B
M
M
M
M
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MZ,>'!N5<Q;=T..D8W7=2>=<7Q/V+[A/V+QIS?N2-T)C\]&
M
M
M
M
M
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MWO[7W<?%4ESF#CWP
M
M
M
M
M
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M!7K5X&-BA@@AB:V.&&&-J-:UJ(UK41$3H15;<FY2=9,RZDDJ+D5BA4
M
M
M
M
M
M                                              '7!?K!WE^[R?\
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M8F.J6X*GO;\6_>WQ9D =8?6
M
M
M
M
M
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M>Q
M
M
M
M
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M6HB(G0B VY-RDZR9FA))47(K%"H
M
M
M
M
M
M                    !U9_NS^3C_+3W ?(SE.CG'Y[3,?NUSCCC.RUR+CT
MX]XX>[5,#9P[&OD2/&;#+CY\NWJJ.DER,DCFL<]S4F7LC1_Q)MC$PI1Z<AVU
M<N>WKN?$Z^^-5']2D80U[-^OZK>OIUMJ73']+'@J>Y\_G-<AZLZ@
M     '9?>Q[X(S>#OA/JU3<L)]U<W\X35N5^78[,369/#39*DV/2M"MO^,D?
MYEZO(Q+%=RJD&7NW^U>CR(O<7<BW'N&<L>75IV-][M>QT?QS7Z>7)^,5$S+M
MK2_Q9IL5<5,F[\4_:O9'YE^:V;C3P9Z$
M
M
M
M
M
M                          UX>Z[Y(S^*7M]^3/+V+N/I;7%H%C1M$L03
M^A=K;OR=<J<?:[EJ"HJ.?9UJWL?WJK4^/I47K]"*>IV5I*UK=&'@S5;'F]<_
M9T6TYR3_ $RCT_.=1KN8\#2;V1%TN='3']-+X4_FK7YCJPR9IA
M    &YSV*/"23S)\Z](N;)A69/A[Q\?0YEY/6[7=/BLE8PE]B\?:9::O]SV7
M[3N$,,DU67JRSBJ%Y%:Y&JU? =R-PK0-MW(V94S\JMJW3FJKXY_J8UHURE*)
MZ+;&F_C'5(N:KCVOCE[.'T5\[\/%)G97D2#,@
M
M
M
M
M
M                                (@OZUEY'_=^E^-/B9A[_ &V-ESF;
MYYWJE%+Z4S,5K=:[HW';)T8OJ6,?ELGFMAE=&_I'Z^+B?T<]C5CSIV6TGKR,
MO6[BX0BK,'[Y4G/YTE#YI/Y\?[ZS*6[.!%\9-SE\B^&/V6Y?8(5Q((QR
M         #LBO8%\+8_$OP0U/;=DP[:'+7DT['<R[Q+8KO@RE#6,A05O%6I6
MO69#8CBPVI6UR#X)6-DK9'-7(UZ]$(F]S=P/6]R3L6I5P<.MJ'L<D_ODE\LE
MTU\8PBS,.U=-^H:7&Y-4R+WQR]M/M5\RX^YMF\$QV>E
M
M
M
M
M
M                                      !UDOOE^0[O(OW+_(?*5+K;
MNL\49BGP+J79*LT5>CQ7'+AME;#*DLD,E>YR--F[<:Q]K%993X*O5SI>]N=*
M_%6T<6$E2]?B[TOEN<8_8M]"^8PON;+^N:S>DG\%M]"_4\'_ (74S4<>Y.A
M           -@OM;^(T_FSYQ<'<(6Z$US1G[''O'+,L<?=#5XLT9T>>VRO9E
M^*5/SEC@BPE>96O;'=RD"JUR=4/+[RUQ;>V[DZC%I9/1T6O?<GPC\O3QFU[(
ML[71-/>I:G:QFOO5>J7Z6/%_9Y?*T=J!6K5Z=>"I4@AJU*L,5:K5K1,@KUJ\
M#&Q0P00Q-;'###&U&M:U$:UJ(B)T(9-N3<I.LF9P225%R*Q0J
M
M
M
M
M
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M:A-?'<?3']+'G3Y9</U)*[,*GN@
M
M
M
M
M
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M:YOYW5_.<\G6GU
M
M
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M_#J==>Q<G'2=^W<@GRZHM5^RD=MCYN%E-QQ;UJY)+BH3C*GRT;H?I' ?4
M
M
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M[& BH9>
M
M
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M_*6>61,YR5O^921(VR)EMQV+(H](E1T2/^<R,W<D;DZMZ_0OT'H<;;FWL/\
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MFN:J*CD5.J*BI\%14/$--.CYF0TTU5<CR"H
M
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MX[\V_P!3&L5^;U/YR2,8F/8@
M
M
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ML5',]GP62QC;;E5.J]5ZJN&-?],/;O55*YI+R]-OODK=SS;=7[87NN=/=&Y
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M#>5CZQM;4L/.@EQ5J[&4X_I[=?,@_=.,7Q1R^>=/4@
M
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M8?1MP4?EHJ5^?F<T'7GT@
M
M
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M<)S@
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M-KXOUO6K2:K"W6;_ %/+_"Z3LQ2(IF8
M
M
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M\*[%2A<MRC.$XOBI1G%N,HOP:;3/UC@/I
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MF(F!S(0
M
M
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MBJEE9/5CXJ?A*%KADWE[8S6*_%29J4YB\N?('G-UFOO7(66^X+*O3\T-??\
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M?PTC=23;MJ/Q/9>89,[
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MF/5W<&5Q3<K=?AO8\W&#O6Z45Q="G:GPFNF5N<]B!A@DF
M      1 ?ULGD!]73/"_BR"S*L>;V?F/D#*4VND2%K]6Q6AZ[@K,S/A%)*]N
MX9%L2IW.8C9.O:CD[LZ]DL52R-0S6N,86H)_IG.3_61_,,?[\NTMXUA>,IR?
MS**7Y[(61($QR            =FC[$_!GZ"O;!\;:=NG\KGN4\-E^<\_)Z?I
M?/?I3R]G/:A<[%3N_P 6WW'%W*KN_P!+N3HUR-;$/N1J7XRWAERBZVK,E9C[
MO+73)?NG6_G,S;8Q?JNB64U\<TYO]4ZK_!Z3;T>%/0
M
M
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MB\M7_05.1%H]?I_9^(K["^):/7X@O1:/^HJO%G)XEJ]?@[\G^H%R+UR+5_\
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MX-2C*,E52C)-J46N*:;37%%^<1S
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M=F,?R]NY&2^=S,:^:%N%/'VREX+Y^!BW?%SJU.U:\(V4_G<I?W$B,49@/%@
M         ^LT+3<QR+O6E\?:]%Z^?WO;-<TW!P].[ULQL^8IX3&1=J*BKZEV
M\Q.G5/I.#)R+>)C7,J[^Q6H2F_DBFW^8B^U;E>NQM0^G*22^5NB.WQT#2\+Q
MOH>D\=ZW VMKNA:CK>EX&LUJ,;7PNK8:E@\7 UC>K6-BHT8VHB?!.A!?*R+F
M7DW,J[QNW;DIR^63;?YK,_VK<;-J-F'T(127R)41]<<!R
M
M
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MX#L0
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MVXG2=RVK2]_FR4)+^\<G\B.]VUC_ %G6[$7]&,NM_J$Y+\U([.LA^9I
M
M
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MQ',
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M*Y=6DY5ZL;F;@6VW:M7>KC];L65%R3;=RW&3;<K4YSW9D6R=8
M   !U;'O![0_;_<Y\U,M(]\CJG-VP:NCI&5V.1FD5<?I<3$;51(U9%'@$:U5
M_C'-1%D_C%<3)V)95C9^GP7CCQE_?MS_ -]_N<#".X)^9K63+_A6O[WA_<-;
M9ZTZ<          $J3]5.XG9L'E!Y*<SSP^M%QCPI@M%JJZ)71U<KRUN,64@
MMLE_@Q6DQ7%=V%J?2Z.>3I]"F&.].;Y6CXFGKG>R'-^]6HTI]FXG\R/<;&L=
M>;>R7RA;4?GFZ_G19.G(X&3@
M
M
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M+UZ=?@C24OI2U&]:WCJ.E)OZM?TUW6N-.NS>M1BZ<OHWI\?F\2#/KPT?&O\
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MI&Y%]5N3_3+DWX1DHR:XT/3Z;K.GZK']Z3K<2XQ?"2^;Q7O55[S/0\T=H
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M\N]:DE.W.G)2BE)?%!RBU)\UGESW0                          !KO\
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M/A"TKLWP4+=^%R[8<I.BA"=RW<N-J,(.3H;+C!I*,
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MQEQ7"E^"59I<*1O1<;L:<(]3A5N#,]#&!E<
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M]NUIUK/N^5J.E)K]X9[C*YUXZHNK"RXPN7++BJ6IPN6FK?PVXX5&4#!@
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M_>ED;BT"]#'E<F^JY<QKD92Q9W'S<TH7;/4ZN:LJ<I2G*3-MQ'4F,
M                                                        <7<O
M<R\><&:=<WCDC/U\'AJRK#5A^$^5S>05CGPXG!8UKFSY/)3HU51C/LL8CI)'
M,C:][?2;5VEKV]-6AHVWK$KV7+C)\H6X^,[D^4(+VOBW2,4Y-)^([@=Q=H]L
M-NW-S[RRX8VG0X17TKMZY2JM6+=>JY<E3Z*X12<YN,(RDHVGEAYP\C^3&0L8
M.NZQI?%%:TC\9I%&TYTV6^7D1]?)[C>A]-,Q?61B21UD1*514:C&OE:ZQ)L*
M[7]F=O\ ;JQ'-N=.9N>4?CR)1X0JN,+$77RXTX.?[)/C5J+5N.FSOSZF]X]Z
M,N>F6G/3=APG6WA0EQN]+K&YES5/.G5*4;?[#::CTQE.+NSM_;XXWBY*\J>/
M*UVI%=P^GNR._P"8BFB;/$D6M55?AWOB>UT;V_G3:Q[5[O@B.Z_3T1>3OON&
M6WNV>?<LS<,O+Z,:VTZ.MYTN<>?[#&[R.+TE;-AO/OII%G)MQN:?I[N9UU-=
M2IC1K9;333_?,K"X^WVT1*(_-C6O_M>P?_UIH?\ TN:VOQCJ'^7O?W\O]TW>
M?B71O_1,7]RA_P"*/S8UK_[7L'_]::'_ -+C\8ZA_E[W]_+_ '1^)=&_]$Q?
MW*'_ (H_-C6O_M>P?_UIH?\ TN/QCJ'^7O?W\O\ ='XET;_T3%_<H?\ BC\V
M-:_^U[!__6FA_P#2X_&.H?Y>]_?R_P!T?B71O_1,7]RA_P"*4Y=3U:>.2&;6
MM?FAF8^*6*7#8Z2.6.1JLDCDC?65KV/:JHJ*BHJ*5CJFI0DIPR+ZFG5-7)II
MKDTZ\RV>@Z'=@[=S"Q)6Y)IIV;;33X--.-&FN#3/CLKP?PMG6]N<X@XNS+>U
MC.W*Z!J>1;V1O=+&SI;Q,R=L<CE<B?0CE54^)V^+O/>&$ZX6JZE9=:_!E7X<
M6J/Z,US7#Y#SN?VR[;ZHJ:GM[0\E42^^X&+<X)U2^.T^"?%>Q\3@K;/ +Q)V
M^.5+7#^'PME[42.YJ>1SFKR5W)\$?%4PV3JXJ1W;U14EKR-7KUZ=414]KI??
M+NEI4EY6K7KUM<XWX6[R?N<KD)37S23]]#%VO>E+L%N"$O/V]CXUYKA/%N7L
M9Q]ZA9N1M/\ 56Y+QI6C,+.3?:!U.[%8M\1<I9O!VT9+)!A-^H5,]C9YE3K%
M7;G<'#A[V+JM=_LW4[\G;T^"K\5R]MWU6:I:E&UNK3;-ZU5)W,:4K<TO%^7<
M=R,W[E<M*OL(X[S_ +/O0,B$\CM_KF3BY%&XV<Z$;]N3\(^?95J=N*]KLWY4
M]KXFJ?G+Q-YV\>YI).0M+M)KR3+#6W3 .=G-0MJLBQPJN7K1M=BY++D_BH+\
M52R]/BD9)K9G=#96^X):%F1^OTJ\>[][OQX5?P-_&EXRM.<%]T0:[E]ANY_:
M:XY[MTZ?XJZJ1S+#\[$EQHOOL5][<OM87XVKC7VAC0YQD'G\AAY*O%E)5Z?M
ME2Y*I35?K4IS.1+P125?K#]B+TC;E[3?C\FZ\D9OG;8*22Z]QBKL/JJ3,1T-
MS?<K21TUEG<CHY%UG 6_45JHCF6+U:1B]8R+GJ;WS^*-OV=EX,Z9VH_?+U'Q
MCC0EP7M7G7(T]\;=R+X2)Y^AKM6MP[NR.Y>J6^K2M&^]8U5PGFW8<9+P?U>Q
M+JH^*G>LSBZQ)$A \VP  X>\@N3H>&>$^3>3I'1MGU#4<KD,4V5(UBGV":+Y
M#6JDB2_86.YL%RM$O5'?!_P:Y?@OJMC[=ENS=VG;=C7HRLJ$9TK56D^J[)4\
M8VHSE\W-<SP?=#>$-@=O-8WA)KS,'!N3MUI1WVNBQ%UX4G?E;B^?/D^3A;6[
M5BY8L6[<TMFU:FELV;$SW233V)WNEFFED>JNDEED>KG.55557J;9[=N%N$;=
MI*-J*227!)+@DEX)+@C\_-V[=OW99%^3G>G)RE)NKE)NK;?BVW5OVEBY?J.3
MDCC7'B4G+]01R(SY]N;R4P_CISU&_<;K<?Q]R-BDT_:,C,]S:F!M+=@N:]LU
MM&_#Y;&WF/@G>Y>V&I<FE5%[$0PIWWV%E;[V8UI4.O6\"YY]F*^E<72XW;4?
M?.-)17.4X0CXDF_2KW7P>UG<A2UVXK6V-5L_5<B;?PV9=:E9OR_0VYIPFWPC
M;NW)_:DKZO8@MP06JL\-FK9ACL5K->1DT%B"9C9(9X)HW.CEAEC<CFN:JM<U
M45%Z&M><)VINW<3C<BVFFJ--<&FGQ33X-,W26KMN];C>LRC.S.*E&46FI)JJ
M::X--<4UP:*Q:7GR.][[I_&6IYK>=]V#':QJNOU'W<KF,I.D->"-J=&0Q,1'
M37+MJ14C@KPMDGL3.;'&QSW-:O9Z/HVJ;@U*UI&C6+F1J-^73"$%5M^U^$8I
M<92DU&,4Y2:2;.EW%N/0]IZ-?W!N/)M8FCXT'*Y=N.B27))<Y3D_AA"*<YR:
MC"+DTB'_ .9ODMD/*;F[-\@^C9Q^J8^M%K&@8:UZ:6,;J6,L69JTUUL76-,I
MF;UN>[93ND])\Z0H]\<3%-G?:S8-CMWM*SHE8SU*<G=R;BY2O3234:\>B$5&
MW'@JJ/6TI29I([Y]U<GN_O\ R-S.,K6CVHK'P[4J5ACVW)Q<J</,NRE.[/B^
MES\M2E&$68FN4R0O:8@7M*#E"*KVE%R_4/$OB6[U_>!R>'O9:N4KXE\2U>OT
MK^0JB]<2T>OU?NA>TO+5Z_!?Q_#\O]HJ<A:O7]X>!?%%H]?WRON+ESJ6SU^*
M_B!R>XM'J57%U+UP52T<OTK^$%\46KU^*_B*^!>N):R+^^O4'(6KU^G]GXBO
ML1>N1:.7]XKXE\2T>OT_C*HO\2UD4HN1?X4+1ZE3D7M+5R_3^S]GP*OV%\46
MCU^/[14O1:/4+FV7EJ]?X2_L_ $<BY%J\KX%\2S>O[ZE?<7KF6LB_257,O\
M8BU>H7.IR+D6CU^"_C4%\46CU^DKX%ZXLM9/J0J7FXSV1?*B7@/R\Q?&N=RO
MRG'GD;'2X\RD%B3MIUM^BEL3<999&][4^=L9FW-AF?2U6YE5<B]K5;'SU(;)
MCNC8<]8QH=6K:16_%KF[#261'Y%!*Z_VKAS=9)^F'?<MI]P;>BY5SIT?65''
MDGR5]-O&G^F<V[*_;N/)-3@S6X;/P
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M3/N'9^KX=JQ]Q;C'^]BE_<.:3KSZ0             =27YI?TQ?++^LOSO\
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MK!W_ #1O\O?_ !+$V_1Q_P!H_P#J_P#]M-8O]HY_V-_ZV_\ IA&Z)MFL8
MD"^P'<LLY3\A\>R9S:=GC_3KD]=.G9+9H[%D8:DSOAW=T$60F:G1>G21>OU=
M(>>L"W;>@:->:^^QS+R3]BE;BVOG<8_8-B_]G9>NQW;N3'4GY$].QI->#E"]
M-1?S*<E\[)0A PVN
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MOG-S^R-R6MW[1T[<UFB69B6[DDN4;CC2[#]1<4H?J3G4\R>I
M                                              !J,]XKQ9L<\^-R
M\CZMCTM\@<!OR>X5XH8FON9?0+-6/\^\3"K6>K)-0K4:^5C;W+U;CY8V-=),
MA(STU;_AM'>_XDU"?3H^KJ-EMOX89";\B;\*2<I6G^V1DVE%D-_6KVEN=P>V
M/Y3:3;Z]Q[><\E)+XKF)**^MVUXMPC"&1%5Y69QBG*:(=)LJ-*@
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MG_S&SO\ B?\ 6+1Z':G\?X_ZO\',[+DB.9E
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M!?\ &_Y ?S;:S_*>0B!ZO_YMZ/\ PZ[^"-B7]G=_/3<7\EV/P[)1I @VP@
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M*_27KLM2[:W=(NNL].U"["*]EJ\HWX_9NSO?8KXF](C22B
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M_P"ET\2O\O/_ +LO,YX'N?\ S&SO^)_UBT>AVI_'^/\ J_P<SLN2(YF4
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M=#VYB8^#H]B-+=FS"-NW%>-(Q256^,I.LI2;E)MML^K.O.W
M              (W?ZP=_P T;_+W_P 2Q-OT<?\ :/\ ZO\ _;36+_:.?]C?
M^MO_ *81NB;9K&   -_GL"_XW_(#^;;6?Y3R$0/5_P#S;T?^'7?P1L2_L[OY
MZ;B_DNQ^'9*-($&V$
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MV=2OA0N1:/7Z@7^):O7X+^,KXG)[BU<OQ_:!>N1:/7]]2I?'F6LB_3^+X%?
MO\:%H]?J!R>!:N7X+^,J^9?$M7K\5_$5+D6CU^A O:<GB6CU^"_C^'[/W <A
M:O4KX%\2T>O[ZE?$O1)N_5MMMFAVKRNT5ZO?7R6 XIVRNBMZLKS8/([OA[JM
M=WHC76V;#!U16N[D@3HK>BHZ&OJ\P8RPM#U-?2A=R;3]ZG&S-?8Z)?9^Q-WT
M:9\HYVO:6_H3LXMU>YPE>@_L^9'^]\/&5H0B)W@
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MW=O^3M!VZ_LN3:C]CJG_ +SP_.J>KV9;Z]:4ON+4G^='_?'8AD63+8
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M7JR2)[F.3XHJGB;ENY9F[5V,HW8NC3333]C3XIG>QE&<5.#3B^37%,_4+"X
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MJ2(QLG&S,>&7AW(7<6Y%2A.$E*$HOBI1E%M237%--IEZ<1S@
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MRXU3V?BK_P!HLDQ$@(;#P
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M3O?P_I'<.?S)1_R[VXV">D3^9.I_RJ_P%DU%_P!H9_2;HG\A+_6\@T3DLB
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M-/ZK%8.[\6">5A2FI22X+S[$N#NX[D^GJHIVY-0N175;E<SX,0DA@
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MP
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M;M5K/9S?N7LW5JW+$'YF-?I19&+-ORKJ7A+@X7(IOHNPG%-I*3QB/=F*P
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M7=VKU;(YSU3[36HUBNCYWMO]67I^-]S;NR_OG!?[PR/L.W2SDW?;*"^PI/\
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M+)M\3>AV%VG^1?:'0M#G'HROJ,;]U-4:O93>1<C+WPE=\OY()+@D95&.C+P
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M.UH^MZW)?#>R<>Q%\/\ $PN7))/GQ\^#EX.D?829"'A-$
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M=_W%]DREL:--+NS]M]_F0A_NDF\Q >T               .I]]Q?_2#^=O\
M7)\GO\]N\$U]J?S7TW^ 8_X&!@G5_P"-LK^$7/U\C#8[\Z\   [%/]6K_P!&
M#JW\\O+O]]L>16[M_P \9_P>U^<S+FS?XEC^V3_/1OX,9'J@       1</UK
M#^AUXZ_UEX?\UO(!F3LM_'V5_ __ "D#Q.^?XNL_MW^]D00R21B\   W)?J_
M?^ET\2O\O/\ [LO,YX'N?_,;._XG_6+1Z':G\?X_ZO\ !S.RY(CF90 =27YI
M?TQ?++^LOSO_ )TMJ)O[?_B'!_@=G\'$P+J7\8W_ -NG^N9C0=N?&
M        ?J8/.9K6,WA]EUS+9' [#KV4Q^<P.<P]VQCLOA<UB;<-_%Y;%Y"I
M)%;H9''7J\<T$T3VR12L:YJHJ(I9<MV[UN5F[%2M3BU)-5335&FGP::X-%8R
ME"2G!M33JFN#37)H[//VB//FI[@WA[J7).;GK1\R:),SC;G/&0-K5VNWO"T*
MDT>W4J5=L+:^&W[#V(,G$UD4<%>W+:IQJ]*BO6'N^=LRVOKT\2VG]0N??++_
M $#;^%OVP=8OQ:2D_I&:M U5:MI\;TO](C\,U^B7C\DEQ^6J\#:(>..[ !#A
M]ZW^G+GOYM^//[WVS9=Z7?Z*;/\ #LC]<C2AZY_Z?,C^3,/]9(U*$B"'8  !
M*Q]@_P#HX\Q_SVR?R$U$U]^KO^>VF?R4OP]XVZ?V>?\ 1EK?\NO_ %3'-[!$
MTG^ #AGR!YUT3QMXDV_F'D2[\MK^J8]TT5*&2)N2V',V%]'#:UA8I7-2QE\U
M><V&)/X$:*Z616Q1R/;Z?9VT]6WON+&VUHL.K,R)T<G7IMP7&=V;7*$(U;\7
MPC&LFD_$=QM_[?[8;.S=Z;EN=.G8=NJBFNN]<?"W8M)\[EV=(Q\%QG)J$924
M%GR6\CN1_*?EG8.6>2LBZ?(Y25U7!X.":5^%T[68)YY<3JNOP2+_ !&-QK)W
M*YW1)+-A\EB5732O<NV#8VR=$V!MVSMW0X4LVU6Y<:77>NM)3NW&N<I4Y<HQ
M481I&*2T#=T>YNYN[6\,G>&Z+KEDW7TVK2;\K&L)MV\>RGRA"KJ_I3FY7)UG
M.3? 1Z\QX               ;U?:%]P2UQ1M>*\7^7<XY_%FZY1:_'&P9:VJ
MP\=[EDI/XK!2V+#^E73]NNN1C6HJ14<I*DO:V.S:E9$[U']G;>X=/N;\VY:_
M]_XMNN3;@N.19BN-Q)<[UF/&O.=I.-7*%N+G[Z,_4;>VAJ]GM3O/(;VEG7:8
M5ZY+AAY,WPM-M_#C9$N"7T;5^2G11NW9J5H:^C;L "-W^L'?\T;_ "]_\2Q-
MOT<?]H_^K_\ VTUB_P!HY_V-_P"MO_IA&Z)MFL8                &Y'V2
M^=;'&_E58XJOWI8M8YUUF]A$JND<VHS==2K7-EUC(2HKD8DKL9!E*,?P57RW
MF)U(T>J7:<-;[?QW!9@GGZ3?C.OCY%YQM78KW=3M7'[%;;)L^A3?]S;'=R6T
M<BXUI6X,6=KIK\/UG'C*_8F_"O0K]I>V5V*)?!K@-S0 (IWOX?TCN'/YDH_Y
M=[<;!/2)_,G4_P"57^ LFHO^T,_I-T3^0E_K>0:)R61
M $@_V&>>+.*WOE7QRRUY?NG;,*SD[3Z\TG2*OLNNR4L+M%2FSZ7VL[@+M2P]
M/H2/#JJ=%5>L./5QM*&1I.G[UQX?OC'N_5;S2XNU<ZIVG+W6[D9Q7OO?8V._
MV?'<&[B;@U?MGF7/WGF6%G8T6^"OV7&U?C%?=7;,K<W^AQG\\GH@@;5@
M            :WO<F\GG\'<2)HFJ9%*_)'*U>]B*4M>;LNZ[IZ1K7V+86+&O
MJUKEM)DHT7_8=ZLLLT;N^JJ&?_3[VY6\MT?CK4[?5M_3)1G)-?#=OUK:M<>#
MC&GF7%Q5%&$E2Y4B'ZO^\TNVVP_R9T.[T;OUR$[4'%TGCXM.F_?5.,9RKY-E
M_"^J4[D)=5EHC'=R&Q2C-,U&>>J?A0<2E&>>J_A!0=5_"HJ*(=5_"HJ*(Y^\
M6..7\L^1'$6B.A6Q2RVZ8NYF8>WO237M?<_8]C8J*J-3OP>)L(BKU1%5/@OT
M+X?N5K_Y,;#U76E+IO6L2<;;]EV[]ZM?\I.)E/LCM![Z[LZ!MAQZ\>_J-N=U
M4K6Q8KD9"^>S:FOE\'R)B1JD/T"   &A+WB^1OFMJXCXHJV&^GA<)E][S$#'
M=W=9SUS[CP:3HBJV.6K6P=US6KT=V647Z%;UFQZ4=!5K3=4W-=C\5Z]#&MOW
M6X^9<I[5)W+:]E84YIFK_P#M =V>?K>@['LR73CXUW-NI/[:]/R;-?8XQLWF
MESI<KR:-*RK^%27=7X&NQ(]%<*-\RZGM/57%:"J7(V1^ _A#FO(#:L=R)R!B
M;5#A+7KB6Y)+<4D"<B9.C95B:[B%<K'RX6*S"YN2MLZM1&+7C7U7O=#'_O9W
MBP]CZ;<T'0[L9[POPZ5TM/ZK"2_99\Z7&FO*@^/%7)?"DIR\],'IPU+NEK=G
M=>Z;$[7;G$N=3<DX_7[D)4\BUR;LJ2:R+JX))VHOKE*5N3G###6ABKUXHH*\
M$4<,$$,;8H888FHR***)B-9'%&QJ(UJ(B(B=$-=LYSN3=RXW*<FVVW5MOFV_
M%OQ9N2MV[=FW&U:BHVHI))))))4227!)+@DN"15+2\ &'WF]Y(T/&S@[/[!6
MOQ0[_M,%O5^-Z".C=;DV"Y6<R;.MKJO>ZAJM67YN5ZM6+UDAA<J.G9URGV@V
M#?W_ +QL8-R#>B8THWLJ7VJM1?"W7[J\UT17/IZYKA!TP/ZB>[6+VD[<Y6J6
M;L8[GS8RQ\"%5U._*-'>Z>?1C1?FR=.GJ\NVVG<C6(K--)-+)//+)-/-(^6:
M:5[I)999'*^2221ZJ]\CWJJJY5555>JFS^*C"*A!)12HDN"27))>"7L-&4Y3
MNS=RXW*Y)MMMU;;XMMOBVWS9(5]F[CK[KXPY2Y1M5NRSN.W8_5,9-+']MV)T
M['+=L3U7JGPK6\KLTD3^U?M24^BI]A"#7JKU[ZSN+3MNVY5ABXLKTTN77?ET
MI/WQA:37L5SAS9M+]!&T_J.S]9WE>A2[GYT,:VVN/E8MOKDXO[F5S(<73G*U
MQ^BC<L12)]  MKMRKCJ=O(7IXZM*A6GN7+,J]L5>K5B?/8GD=\>D<4+%<J_@
M0Y+5JY?NQL64Y7IR48I<VVZ)+WM\#AR+]G%L3RLB2ACVX.4I/E&,4W)OW))M
MD:#,>[_Y-/RV4?A,3Q=7PS\C==B(+NJ9B>Y#C'695H16YF;5&R:S'55C9'(U
MJ.<BJB)]!/[%]+W;Y8UM9=W499:MQZW&]!1<Z+J<5Y+HFZT5>"-2^=ZX^[DL
MV]+ L:/' =V?EJ>/=<E;ZGT*360DY*-%)I*KJZ'Y;O=^\KD_^IW$G_F?FO\
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M15%<$EC7?^D%-?>3\MT_^IO$'_F;F_\ "\/TO]MO\IJ=?V^W_F2Y>MCO(_\
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MJ-JGIPV^] [2Z<[D>G)SG<RY^_S94M/Y[$+3^?V&U4PF9T
M                                                  !&4]ZGP@9@
M,G_RON,\,V+#YVW4QG-N+Q\*,BQ^?MR,J87D)((F(QD&P3/92R;T[?[N6"94
M=)9GD2=7I?[J/,L?]V^NW:Y-J+E@SD^,K:59X]7XVU6=I?Y/KCP5N"-6/KE[
M#1T[*_[Y]K6$L+(G&&J6X*BA>DU&UF47!*\VK5]\/OOES:<KMR2CPDS#6T
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MG9;^/LK^!_\ E('B=\_Q=9_;O][(@ADDC%X  !N2_5^_]+IXE?Y>?_=EYG/
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M[^']([AS^9*/^7>W&P3TB?S)U/\ E5_@+)J+_M#/Z3=$_D)?ZWD&B<ED0
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M:&=_3)N">VN_6V,^#:5[4X8C\:K-C+#HUQ\;Z?N:4N%*J=::G#?X
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M)MLW+]MNVVV>UNV;6VMM6J6U25Z])+S<B[2DKMV2YM\HQ7PPC2$$DCGL\>9
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MNSN3E]U.<G*3^>3;-T&GX.+I>!8TS"CT8>/9A:MQ^YA;BH17S121]$?(?6
M
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MDOS2_IB^67]9?G?_ #I;43?V_P#Q#@_P.S^#B8%U+^,;_P"W3_7,QH.W/C
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M<QM"1TF<^TN[[L,C\E\^;E9FF[#;^C)*LK?'[623E%>$DTOI*G@-XZ+"5O\
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MA-5FW??;M6637],Q,SGKZUI[71-O9B['#(VC0C>V:U(U558X6331> [A=Q=
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MRX/ZGIL'9L-\GD7HM3:]OE6&U)<&G>@UXDPH@.;"@
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M8VY2?-RN8TK%R3?%RFZM\WL),-DCP    =?K^M$:4FN>X;I.T0QN^7Y!\9M
MS-B?[2-=EL'NW)6J6:Z(^U.JN@Q6%HO5S60QKZR(C7/1[W2>[.9'F[6N67SM
M9DU\SA;E^>W[>1BG>UOHU>,URG9B_G3DOSDB-\98/'@        '9#?JZ?\
MHIN#_P#RRYK_ ,[&V$3NZO\ /7)_:[7X*)F#:/\ $5K]-/\ 7LWBF.CTP
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M;@_S),Q3WUQK>5V5W;:NUZ5MS49_/;Q+MR/^%%5]WL("IMZ/SQ   ')'#?\
MC?XJ_G(T;^4^+.DW-_-O4/X#?_!3/3[)_GGI'\IXOX>V=B":9#])@
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M:^&QR-D7.?VK%3TQL;V)VJOJ.7(9>A$K.J=/LN5W5?HZ=5,F6O3-W-N2:G'
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M?P0?/RX07@9=GA#(
M                         !%2]Z3PM_1IOT/E)Q]B?2T7E#*-H\DTJ476
M'7.2K$<TS,\Z**-J5L7O->NZ21Z]6MRT4RO>CK<+#8'Z8.Y_X\T=[!UFY75L
M"WU8TI/C<QE1>75\YV&Z)?Y%QHJ6Y,U&^N/L=^2^XH]V=N6::!JU[HS8Q7"S
MFM-J[1+X;>5%-R?%+(C-RE6]")HC)9FOX                &^WV'.:I->Y
MBY2X)R-I4QG(^IU]TU^*6;^+CVG19U@OUJ<"JG]T9?6LW+-,Y/BK,4SK]!$7
MU;[76;MK W99C]_PLAV+C2XNU?58MOV0NP45[[K-A7]GUOF6F[UU;M_DS_>N
MIX:R;*;X*_BNDXQ7MN6+LI2?LQX^PE.$ S;2    "&'^ME: L6=\*^4J\'<V
M_B>:= RUE&O3T5Q%SCS8M=@<Y;#HW_,IF\HYJ-B8YOI+W/>CFHS/W9+*K;U#
M";Y2M37SJ<9?G1^R8ZWY:^+&OKQ4XOYNEK\]D/ SP8^         .R&_5T_]
M%-P?_P"67-?^=C;")W=7^>N3^UVOP43,&T?XBM?II_KV;Q3'1Z8
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MK5N^$M5O1K^*]'R;\'[+ER5K$5/8W;R+OS)DP UNFY\      ZW8W;'YC
M  =B!PU_B@XJ_FVT;^3&+-,FYOYR:A_#K_X69^DS9'\R](_DO%_ 6SDDZ0].
M13O?P_I'<.?S)1_R[VXV">D3^9.I_P JO\!9-1?]H9_2;HG\A+_6\@T3DLB
M   !( ]@?CVKE.5>?>4IXN^SIFB:KI./?(Q'1L=R#G,AF+TT*N^#;,4/'D<:
MN:G<V.=S55$>J.A]ZOM9N6-OZ/H$'2&5EW;\O_W>W&$4_<WD-T?!N*?-<-BO
M]G?MNUE[NW%NRXJW<'3\?%A5<%]<NSN2:_1)8:55Q2FU5*7&420*-KP    ,
M;O,G^B#Y5_U;N<O\V&T'M^V?])&W_P"6\'_6K1C'O;_0SN[_ /#&J_ZC?( Y
MM_/SM   ')'#?^-_BK^<C1OY3XLZ3<W\V]0_@-_\%,]/LG^>>D?RGB_A[9V(
M)ID/TF              ^$Y1W>MQKQKO_(5QL<E?2--V3:GPR]W987!8BWDH
MZO1CFO<ZU+7;&U&JCG.<B)\5.YV[I%S<&OX6AVJJ>9EVK-5X>9.,&_F3KQX<
M#S>\MQ6=H[2U/=-])VM.P+^2T^4O)M2N*/"C^)Q44EQ;=$0F,CDKF8R-_+9*
MR^YD<I=M9'(6Y>WU;5V[.^S:L2=J-;ZD\\KG+T1$ZJ;=<>S9Q;$,;'BH6+<%
M&,5R48I))>Y)4/SR9>3DYV5=SLN3N9=ZY*Y.3YRG-N4I.GBVVV6G5?PG-P9\
MU#SW**(I1'GN_$*"@[OQ"A3I'<GXRE!1F9_M^<<)R;Y9\3XZ>ND^,U;+R\@Y
M;N171QP:5 _,XU96IU1\<^Q0TH5:[[*I+T7JGP7$_?#7GM[MEJ=^$J9&3:6-
M#VMY#\N=/>K3N2]O#@2!]+NT?RO[WZ'BW8J6'A7WFW?8EB1=VW5>*=]6H-/@
M^KCPX$MPUB&\D   C<>[[R1^<G/NI\=UK#I*7&>D0RVX%?\ 9K['NUAN7R"-
M8CE1OJZ]1Q+E5>CG?@Z(BK/KTMZ"M/V5E:[<BE>U#,:B_;:QUT1^Q=E>7_ZV
M:E?79NS\;]S<':MJ5<?1].3DON;^7)79\/?8AC.O-_(D:F.J?A)-51"*AZ]R
M"K*]+/57E.(HES/57?L4K05]AZ*_]TK2@HWS/17*HK["M$>JJB%.++DCT554
MKP1<D>BN1"E6RY(DF^SMQQ^;G NZ<CV8?3N\E[RZK4D[.GKZ[HU5^-H2>HO1
M7]F?RN59T^AO;]/551(#^J77OK^\\30;;K:T_#K)>R[D/KE_R<++^<VP^A7:
MGXI[;9^ZKL:9&K:CTQ=/I6,2+MP=?=>N9*]U/>S;J1C)O  _(V#.8[6,#F]E
MS$WR^)U[$9+.92QT1?0QV)IS7[LW1SFM7TJU=SOBJ)\/I/IPL2_J&99P,5=6
M3?NQMP7ME.2C%?.VCXM2U#%TG3LC5<Z73A8UB=VX_9"W%SF_FBFR#3O.W9/?
M=TV[>,R[OS&Y;-G=IRCNY7I]X;!E+65N='*UO<U+%MR)\$^'U)]!M[TC3+&C
MZ5BZ1B\,7%Q[=F'Z6W!0C^9%'Y[-?UG+W)KV;N'/=<W/R[V1<\?CO7)7)?X4
MF?**OUJ=ER.J2\$4U7J4+TJ&ZGV6^-?O?E#E;E>U7:^MI>HX[4,5+*SJU,QN
M>16]:L5'*G_?%+$ZP^*145.V.]TZ+W?"*'JLU[ZMM[3=MVY4N9>3*]-+[BQ'
MI2?NE.ZFO?;]Q/3T([4^N;MUC>5Z*=K!PH8UMO\ RF5/KE*/OC;L.+]BN^\D
M9D&39\   0DO+?D_],/DIS1R''8;;H9O>\Q6P=EC_4;/K6O/9K.K2([JY%[M
M<P]7Z%5J?5\.AM@[;:!^3.P]*T-QZ;MG#@[BY4NW/OMU?NLY^_V\31%WCW5^
M6G='7=R0DIV,C4+D;4N=;%FEC'?[C;M^[V<#&]SCV_N7(QLD6[W?4G[J@O\
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MPN9#5)W>/.-B+I%T_99)IJ5IHEZ$#38(
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M5$7N:Y>US,M]F\OR=S7<9_1O8DJ?IHSA)?X/4>-WO9Z]*A=7.%Y?8:DOSZ$
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M^*OYR-&_E/BSI-S?S;U#^ W_ ,%,]/LG^>>D?RGB_A[9V()ID/TF
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M]H&F;7T3&V]HUORM,Q+2MVX^-%SE)_;3G)N<Y<Y3DY/BSDDZ@[D
M
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M?\4'D!_.1K/\F)"!/J__ )R:/_ ;OX5&V#^SN_F9N/\ E.Q^ 9O\(?FQ,
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MR<8QV7&'S-
M                         !"M]U+Q#3Q;\B[^5U;&?)\1\PNR6YZ&VO V
M+'X+)+9C=N&D0)&R.&*/7LG=CGJ1,:C8L9>JQ]7/CD4V@^G_ +C_ )?;+ACZ
MA<ZMQZ;TV<BKK*Y&C\F^ZU;=R,7&;;J[L+DN":1HT]6_9E=INY=S+TFUT;.U
MISR<2BI"U/J7UG%5$DE9G)2MQ2I&Q=M1JW&3-9!G4BN               2D
MO8/Y/^]^(>;.(K5KOL:1O>&W;&5Y7?;;B]\PSL7:BJ]5ZNK5<GI;I'HB=&26
M^J_[8A ?U=Z#]6W'I>X[<:0RL2=B37W>//K3?O<;]%[5#W&V/^SSW5]<V9KN
MS;LZW,#4+>5!/GY>7:\N2C^AC/&;:7*5RK^D;]R()L0   /@.5]!QW*W%O)7
M%V7[/NGDG0-QT'*>JSOC^[MQUW(Z[=]1G1>]GRV1=U3ZT/JPLF6%FV<R'T[-
MV$U\L9*2_..*_:5^Q.Q+Z,X.+^=4.H'SF%R>MYO,:[FJDM#,X#*9#"Y:C,U6
MS4LGB[<U&_4E:O16RU[4#V.3ZE0G3;N0O6XW;;K;E%-/VIJJ?V"/\HRA)PEP
MDG1_*C\LO*        GC_JJ6P)9\*_('5?4J*N&\HLGL"Q,5WSS$V7B?C#')
M)91958E25=35(>C&KWLEZN=\$;&OO3:IN#%O<?BPU'W?#<N/[/Q<?F,H;&G7
M3;MOV7V_LQC_ +A*$,.GM@              "$#^M6^/4^"YH\<O)_&47_=7
M(>AYGB#:K<+?[GK[+Q[E9MEUJ6ZYS_\ OS/8#<K447:G18L,[KT5$ZR([+:H
MKFGY>CS?QVKJNQ7Z&:Z94]RE%-^^9C3?.)TY-G-BOAG%P?RQ=5]E-_8(F1FX
M\(   <G<+<Q<@^/O*^@<U\59V;6N0N--FQVU:MF(4[V0Y#'2]SJUVNKFLOXG
M)U725;M63K%:J320R(K'N1?CU# Q=4PKNGYL>O%O0<9+W/V>QKFGX-)HYL;(
MNXE^&38=+L))I_\ AX/DUXH[-KVV/<OX0]QOA['[7I63QVN<PZ[A\>O,7"]F
M]W[!HV:D7Y6QD,:RPV&?/Z+E+L:OQV4A:YBQR,AL)#;;) R(.[=HZCM3/=C(
M3G@3D_*NT^&:YT?W,TOI1?RJL:,S1HVLXVL8ZG;:60E\</&+]WMB_!_9H^!L
MC/)G<     TD^\-[NO'GM^<6YWC[C[/8;9_+S=<&ZKHFDUY8;Z\;T\U5LQ0<
MI;W7]&U4IT\0U/7QF-LHDV7M>FB1_*)8FCR'L38V5N?-CE9490T*W*LY\O,:
M_P 7#DVWRE)<(JO'JHGYK<.OV=)L.U9:EJ$E\,?N:_;2^3P3YOW59UO>8S&5
MV'+Y3/Y[)7LSG,YD;V8S.8REJ:]DLKE<G9ENY')9&[9?)8N7KUR=\LTLCG/D
MD<KG*JJJDL+=N%J$;5I*-N*227!)+@DEX)+D8?E*4Y.4FW)NK;YMGYQ>4
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M?SD:-_*?%G2;F_FWJ'\!O_@IGI]D_P \](_E/%_#VSL033(?I,
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M6_;KCV9+CBVIKZ<EX7[D71KG:@^ETG.<8R"2+!+0
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M4*_5H\>7G=4LAM<)0N6:JL#<81J)K$;O]8._YHW^7O\ XEB;?HX_[1_]7_\
MMIK%_M'/^QO_ %M_],(W1-LUC   &_SV!?\ &_Y ?S;:S_*>0B!ZO_YMZ/\
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MHE;Z-=HK<G>G&U.]#JP]'Q+V7*OT>MQ5BRG[U<O*[&G&MJO)-$J URFY
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MAD7E]URE9MOZ/"Y+XNE1D^D,R;P
M                                              (87NY^,K?'[RIS
M.S8'',I<>\YLN<B:RRNQ&5:&Q23Q1\@X*-J(QD:UMAM)?9'&UL4%3*01-_@+
MTV<^G/?3WCV_M8.9-SUG27'&NUYRMI/ZO<?RVUY;;=93M3D^9H_]9/:Q=N>[
M=_5=/M*WMO7U+,L45(PO-I9EI>"Z;TO.44E&-N_;@OHLU9F?2)@
M    ,E?#?D).*O*OQ]WR2RM2C@^5]-9F;".<Q8M=R^8KX/9%ZM^*HN R5E%3
MZ'(O1?@IX?N7HWY0=O\ 6=(C'JNW=/O="]MR$'<M?\I&)E#LGN3\D>[FW-PR
MET6,?6,;S)>RS<N1M7_^1G/Y>1/T-0)^B,    $"G]:8X5_,SS,X>YKI5O0Q
MG-O"D6(OR^ET^<W+B?8+6+R]CUVM:R3LU':-?B[%[GL]+JJ]KV-;);LUJ'UC
M0+^GR=9X^15>Z%R*:_PHS9BW>^-Y>HV\E?1NVZ?/%T?YCB1BC,!XL
M$K_]5!VYM+R&\L-#61J/V3AG3-N;%T3N>W2=W?AG2([UFJC8EY 1%3TW=>]/
MM-Z='X3[UV.K2\+)^XR)Q_OX5_WA[K8ERF7?M?=6T_[V5/\ ?$XPCJ9,
M            ! V_6*_; R/!?+&3\XN'-??)PMS1L'K<PXW$T^L'&?,&9L(M
MC8;<5>)J5-6Y4ORK82P[N9#L#[$4CV?.T8G24[5;QAJ6$MNY\_\ WACQ^]-O
M]DM+[5>V5M<*>,*-?1DS%V[M$>+?>IXZ_>UQ_'3[6;\?DE^NK[41?3,1XH
M              $TO]6V]L#(ZO7@]PSF_7WT<IG,3?Q'C'K>7I^G<J:]F:DN
M/V+F26O8B]:M^<N,L2XS OZL=+C9KEKM?!:I3+'[NSO&%Y_DMITZPC)/(DGP
M<DZQM?J7\4_T2BN<9(R-L[1'!?C;)5)-4MI^Q\Y_.N$?=5\FF3 #!1D    Z
MDOS2_IB^67]9?G?_ #I;43?V_P#Q#@_P.S^#B8%U+^,;_P"W3_7,QH.W/C
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M%3DKF^Q_<\DV*SERBV'7N/8K-=TK9*/'N$D2M)TEFBDRT]^>)R13M:V(>_\
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M7V3L:K>U[ S\O5M1G9C&5A6>F%FRIOI;N78/JE.XW*BI2,>/@MBW_70<$?\
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MNX]NY=\A0MN]!VY3;A>E*L8RDXTB_B2\"/,Y_P#K$T>7+F:ZDJE!SNGQ7]Q
M7)4)*6M^]?X]:]KFOX"/B/E]L>$PF*Q$;86::Z)&8VC!2:D2R[5ZBQHV#[*N
M^TJ?3\2#&=Z6=YYN;>S):EIM;MV<^/GU^*3EQI:I7CX&S32_6SV\T_3<?3XZ
M1K'38L6[:HL:GP14>%;]:<.%>/M/V%]\GQ\3_>DYD_W/2?\ "H^1>E#>3_\
MB.F?9O\ ^:/O_KR=O?\ 9&L_8QO\^>B^^9X]I_O1\R_[GI'^%8_JH;R_VCIG
MV;_^:*_UX^WS_P#A&L_8QO\ /GHOOH>/2?[T?,O^YZ1_A65_JH;R_P!I:9_R
M_P#FBO\ 7C[??[(UG[&-_GST7WT_'E/]Z+F;_<](_P *Q_50WE_M+3/LW_\
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MQMV9+X/I7%UTC"3L0T)O
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M*<DN/M/P7-<URM<BM<U5:YKD5'-<B]%147XHJ*?6FFJKD? TTZ/F> 4
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MM1-_;_\ $.#_  .S^#B8%U+^,;_[=/\ 7,QH.W/C               )GOL
M^S3EM:R.I^>GE9J<N-RL$5+8/&CB[/UT9=Q[[$3Y:G,FXX:W6]2E>9#)'+J]
M:56RPN5<D^-KTH2)@#N=OZ%Z$]M:+.L'6.1<CR?MM1:YKPN/D_H5^DC(NU=N
MR@XZIG1I+G;B_P!>U^M7ZKV$PXP09!   (</O6_TY<]_-OQY_>^V;+O2[_13
M9_AV1^N1I0]<_P#3YD?R9A_K)&I0D00[   )6/L'_P!''F/^>V3^0FHFOOU=
M_P ]M,_DI?A[QMT_L\_Z,M;_ )=?^J8YO8(FD_P  #63[B'MT:CYEZNFT:L[
M$Z?S]K-#T-:VZS&^#%[3CH5=(S4=W?3@GLRX[N<Y:=UL<MC'RN7M;)"^2)V=
M>S'>G4NV>?\ 4,_S,G9]^=;ME<96I/\ QUBK24ONX-J-Q+BU)1DHL>I/TT:-
MWMTG\:Z3Y.%W$Q;=+&1)-0OP7%8^4XIR<.?EW4I3LR?!2@Y0<.CDSC#?^'-T
MS?'G)NK9;3MRU^Q\OE,)F(/1GC[D[H+5:5CI*V0QUR+I)7M0/DKV(E1\;W-5
M%-E>A:]H^Y=+M:SH61;R=,O1K&<'5>]-<XRB^$HR2E%\)),TI[IVIN+96N7]
MM[JQ+V%K>-*ERU<5&O9*+58SA)<83@Y0G%J49-.I\&=L>?            -A
MW@E[>'*'F=L\62='D-(X1PUWTMMY.L44>RW- K7S:QI->TZ*/.[).W[,LC>^
MIC&.26RJO=!6LX:[M=YM![8X#L)PRMU785LXJER3Y7;[57;M+P7"=UKIAP4Y
MPDEZ?_3;NSO?JJRFKF!L.Q<ID9TH_2:XNQBQE17;[Y2DJV["?7=JW;M79FO$
MG$^A\'<>:QQ;QI@H-=TS4<>W'XG'1/?-*Y7/?/;OY"W*KI[^4R=R5\]FQ(JR
M332.<OTFLG<6X=7W7K-_7]<NN]J>3/JG)\%[%&*7",(Q2C&*X**2-W>SMG[>
MV%MO$VGM;'CC:)AV^BW!5;YMRG.3XSN3DW.<Y<92;;.1CI#TP (W?ZP=_P T
M;_+W_P 2Q-OT<?\ :/\ ZO\ _;36+_:.?]C?^MO_ *81NB;9K&   -_GL"_X
MW_(#^;;6?Y3R$0/5_P#S;T?^'7?P1L2_L[OYZ;B_DNQ^'9*-($&V$      Z
MW8W;'YC     =B!PU_B@XJ_FVT;^3&+-,FYOYR:A_#K_ .%F?I,V1_,O2/Y+
MQ?P%LY).D/3D4[W\/Z1W#G\R4?\ +O;C8)Z1/YDZG_*K_ 6347_:&?TFZ)_(
M2_UO(-$Y+(@    2C?8%_P 4'D!_.1K/\F)"!/J__G)H_P# ;OX5&V#^SN_F
M9N/^4['X!F_PA^;$P    8W>9/\ 1!\J_P"K=SE_FPV@]OVS_I(V_P#RW@_Z
MU:,8][?Z&=W?_AC5?]1OD <V_GYV@  #DCAO_&_Q5_.1HW\I\6=)N;^;>H?P
M&_\ @IGI]D_SSTC^4\7\/;.Q!-,A^DP             'QW(>F8[D;0=UT#+
M]/NO=M4V#5+[E9WK'5S^*M8N69C>YJ^K VUWL5%:Y'-145%1%.TT/5;^A:SB
M:UB_Z1B9-N]'WNW-32^1TH_<='N?0<7=&V\_;6=_H>H8=['GPK2-ZW*VVN7%
M*55Q332::9!SV+!9;5-@SNK9VLZEF];S.4P&8IO^+ZF5P]V?'9"JY?AU=!;K
M/8OXT-N^#F8VI85G4<.77B7[4+D)?=0G%2B_GBTS\^>J:9EZ-J>1I&H0=O/Q
M;]RS=C]S<M3<)Q^:46OF/Q^[\1]5#X.D=R?C'$=)Y[D_"*LI1CN3\)6K%&>>
MJ?A0I5B@ZI^%!5B@ZI^%!5BAX[D_"*L48[D'$KTGCN_$*,=)X[E%"M$>.J_A
M*T0HCUZHGUBI6C/"N3ZBE2[I/57+^T"M$>JK^$%3U5R%:>TK3VF5G@]QN[EC
MRNX2U.2!+&/@W2EM>:C>U5KR871XYMPR-:TO1>V#(PX3Y7ZE<Z=&HJ.5%,<=
MW-?6V^W&K:C%]-]XDK-M^*GD-6(M>^+N=?R1;Y(S'V VM^6/>+0-&E'JQHYT
M<BZGR=K$3R9QE[IJUY?O<TDTVB9H:L#>:   1W?>SY,2[NG#7$-2=>W7M=S7
M(&:A8Y'1R6=GR"8#!-GZ*J,LT:VLW7(U>CDCN(Y?@YI-STH: [6E:IN:Y'C?
MOV\:V_&EJ/F7*>Z3NVU7VPIX,UI^N_=*R-=T/9=F7#&QKN9=2Y.5^?DVJ^R4
M(V+KISI<3Y-&BY7?@)=$ Z>TI.>5I[2O%_(47._=4?)R+E$HN?\ NK_8!=\A
M1<[\/Q4J52*#G_E_ .?R%_(H.=^4>Y%4JE%SNGXU*EY0<[]U1\I5*I0<_P#*
M.?/D7TH6[G?ZY4N2]I0<[ZD*E_+Y2@YWY/[(Y?*52^R6[G#D7^Y%NYWY?[!4
MN2^P6[G?5^4>]EW/Y"W<[\B#WG(E0MW.Z_'\B%2J52W>[\O]@<_D.1<"V<[^
MV5YER1;O=^1!S+_<6[G#GP7(N2+5[NO^J5+EQXEN]P]QR<OE+9SBO/AX%R1;
M/=U^'Y2I<N);O=]?Y![CD2I\I:N7^V5_.+HKQ+9[OJ^I/[(+RV>[Z_R#FZ>!
M>E0MG+]7Y2I<EXEJ]W]H<SD]Q;N7]G[/PE>;]Q>O:6KG?7^#Z"I<E]DMGN^K
M\/TA>TO]Q:N=]?U("]*B+W!X'.[7F\5K6L8;*;%L>>OU<5A,%A*%K*9C+Y.[
M*V"GC\;C:44]N[=M3/1D<4;'/>Y41$53ARLK%P<:YF9MR%K$M1<ISG)1C&*5
M7*4FTDDN+;=$?7AX>5GY5O"P;=R]F79J,(0BY3G*3HHQC%-R;?!))MDOCVOO
M9PPW K\%SYY1XO%[-S5%Z62TWCB5:>8U;BN94[Z^6R[FI8H;'R!7^#H7L5]'
M$R?;A6:RV.Q! ?O/Z@<C<ZN[7V5.=G;KK&[D*L+F2O&,.4K=A^*=)W5PETP;
MA+8CV-].6-M1VMV;ZMV[^YE25G'=)VL5^$Y\XW,A>#586GQCU349QD#$6"6X
M
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M[:KMQWDSUA6^C0-7_?\ C47PI7Y2\^VO!>7D*YTQ7T;4K7!)HUQ&:R,H
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M5Q7;4G&[%IIIM--<FFN*:\&BV48SBX32<&J-/BFO8T1/?<2_5F].WVYGN5O
M?.XOC78[+;.1R'CYN%JRG'V5NK_&R,X[VZ1UF]H\MES7=F-R#+>,6:5&QV,?
M78D:9LVKW=R,:,<+<T97K2X*_'Z:7Z./*?Z:-)4YJ3XGA-7V9;NMW]*:A/\
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M+IBU!;23"AG4
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MC;&%G2=;KLJ,W^CM_!)OY91;^<P=KF)]2U:_CI4@IMK]++XE]A.A@(>G.J
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MT?\ 5%^WG_T?/^%?F_\ ]I0_K&=Y?]L_^J8/_1A_4V]-W_VY_P#,-4_Z:/\
MJB_;S_Z/G_"OS?\ ^TH?UC.\O^V?_5,'_HP_J;>F[_[<_P#F&J?]-.?^ ?"[
MQH\7<QL&>X*XV_,;+;3C:V(SMO\ /'?MF^>QU.TMVM7]#<-JV"M5].RO=WPL
MC>OT*Y4^!X_>'<_?._<:SA[LSOK>/CS<[:\G'M=,I+I;K9M6VZKA23:]QD7M
MWV.[6]I\W)U'8&E_4,S+M1MW9?6<N_UPC+JBJ9.1>C&DN-8I-\FZ&49X$RP
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M]D8KX81C!**R$/*'KP
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M(0HW5A_4-R9V(E2,,JY3]*Y-Q_P6C.ND7OK&EX][Q=F-?E22?YJ9F2= =B
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MCTO4]1R\I<$FTIQQ4WPKQ^J\&ZMQHT^GI-L9'DF
M
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M!)+@DN"1<EA>
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M%D6;5S_!\M_9=M_.9>V??\[1(0\;<Y1_-ZOSI&^$QL>H
M                        !U)?FE_3%\LOZR_._P#G2VHF_M_^(<'^!V?P
M<3 NI?QC?_;I_KF8T';GQ@  ':G^U9_HW?"#^K1Q/_)3'D+]Y_SLU'^&7?US
M,XZ'_$^-^TP_.,_#S)VH          (-6H>Y[YYZ/CVXW"^1^WW:[4Z))M^(
MTWD+(*GV?X66W[6=ERCU^S]*S*OT_A4VM:EV'[1ZK>\_*T3&C/V69WL>/]YC
MW;4/\$T(:+ZJ_4'H.-]5P=SYMRTO')MXV9/]TR[%^Y_A%KNGN8^=F^TY*&=\
MD=VIUY8O1>NG5-8X[LJSX]>V]Q]@-8NL<O7XN;(CE3X*IR:7V,[3:1=5[$T3
M%E-.OWYW<E?WN1<NQ_,.'7/5+Z@-PV'CZAN?/A;:H_JT;&'*GZ;#LV)+Y4ZF
M$F4RF3S>1N9?-9&_E\MD;$EO(9/*7+%_(W[4SNZ6S<NVY);-JQ*Y>KGO<YSE
M^E3*=C'L8MF.-BPA;QX)*,8I1C%+DHQ2227@DJ&"<O+RL_)GFYUVY>S+LG*=
MRY)SG.3YRE*3<I-^+;;98'*?.   ?LZYK^8VW8<%JNNT)\KL&S9G%Z_@L96;
MW6<CF,S=@QV,H5V]4[I[EVRR-B?6YR'S9N9C:=AWM0S9JWAV+4KER3Y1A"+E
M*3]RBFW\A]NF:=FZQJ6/I&FVY7M1RK]NS:MQ^E.Y=DH0@O?*4DE[V=@KP+Q7
M1X/X5XMXBQ\D5B#CS1M=U::Y"BHS)9'&8V"++Y;HL<*H[+Y7UK+OL,^U*OV4
M^@TZ;NW!=W5NC/W'>34LW+N75%_:QE)N$.;^A#ICS?+F?HU[>[2Q]A[&TG9N
M,U*WIN!9L.2Y3G""5RYR7[)<ZIO@N,N2.6SSI[$
M
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M452W%M]$(IT,E3QQ[<
M                                                   CT>_KQ/\
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MPN?3PBI;M_E'V%N27QYVV-PQ?+C'#UBQTTKXPMY> N''IGE/BNM)X>&23"P
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M^S6?V#WVQ,E=.1B/G6,U^ME_O28J8',A
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M-D>M3U!W=:O:5I<\"]>5^Y"W;A@J<Y*,I<%&+<I-1571<DV?O_\ 6D>Z)_\
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MZ^\M2T;N!&RM-QM,\ZWT8OD/S?/M0XR\5T3E\/S^!O$(J$]
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MNQ.W*MYT;7XQW'"C^M9$4W"7ML6OBA9]TDY75Q7FM.ALX,,&=
M
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M5NXTX7E^I?3+[$)R?S';;3ROJVM6XOA&[&4'\ZJO\)([),B:9B
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MIF],:SYKM*YYEG(M)J,IV)-1FI0<H]=F2;49*49W$I]&T<P(2P
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M2&6_/41OC>'7AZ;/\5:+*J\NQ)^;*/LN9%(S?#@U;5J+7"49<R=7;OTR]O\
M9/EYVJP_'&NQH_,R(KR82]MK&K*"XT:=UW9IJL91Y&W1C&1,9'&QL<<;6LCC
M8U&,8QB(UC&,:B-:UK4Z(B?!$,"-N3ZI<6R1B2BE&*I%'L4*@
M
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MJGQ(-Y>-=P\J[AWU2]:N2A)>R46XO\U&?;-V%^U&];XVYQ4E\C54?9'SG(
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M&&3.@
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M3G%_8=/U)OQ,9GJ@
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MD5J*K6)+KE+#.3X(Y?K^':3_ /2UH/XOV/DZY-4O:AF.C]MK'7EQ^Q=E>_\
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MOS<KLUXTE-I/DD9"GDCV@
M
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M-A]-/M>F[7XDO"496J3]T[7B=KL>]&$KMCA6XJU\:P\'[FIUC\DR9Z8!,B@
M
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MU+D2:VEZ+]2O.%_>VK6K%OF[.'%W)M>QWKJA"$EXTLW57DVN)N1X+]L?PKX
M6E=U;A?!;5LU/T7MW'D__P#Z#L'S5?HL5^I%GF3:_@KS7)U]3&4*/Q^/0CKN
MCO5W(W9U6\[4KMC"E7[SC?>+='SB^BER<?=<G,E#M'L'VJV9T7=.TJSD9\:?
M?\K]\W*KE)*Y6W;E[[5NV9\-:UK4:U$:UJ(UK6HB-:U$Z(B(GP1$0Q4VVZOF
M9C225%R/(
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MD_EVG";S%=M/Z-R/4O=)-*5/=\4'['<B_ [#$BV9:
M
M
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M<NKYII&4YX8R(
M
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M*$B49C
M
M
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M=S_",FFM:UJ-:B-:U$:UK41&M:B=$1$3X(B(>);;=7S,@I)*BY'D
M
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M,E**]R1ZK;NH?C'2K=V3K>A\$OECX_.J/YS:H>+.\
M
M
M                                               . >:/%O@'R'GP
M]OF?C/"[Y;P%:>GA;62LYBG9QM6U,RQ9@JV,1DL=-''8FB:YZ=WV^U.O5$0]
M=MG?N[]FPN6]LYUW$MWI)S45!J32HFU.,DVDW3V5/";Q[9;$W_<M7=X:;9SK
MMB+C;E-W(RA&33:B[<X-)M)OCQHJF(>;]G[P2RR_W#QILNM?&->F$Y*WN=/L
M(Y')_P",>=SZ])5<BN^OJB=O1.J+D;%]1W=C'_9<ZQ?_ $^-87X.W;Y?_KJ8
MGS?27V0ROV'3<C'Y?L>9DO\ "W;O/Q_,H<2Y3V./$*]T6EMW/&%<ULJ(VCN&
MEV(7O?T6-TS,KQUD)7-A5/@C)(U5%7JO7HJ>AL>JCN-:X7<?2;JX?2LWD_FZ
M,B*X^],\MD^BOM/?XV<O7++H_HW\=KW5Z\23X>YHX[R'L.<&2I%]U\V\LTG(
MK_66_0T_)-D:J-[$B;6Q.)6)6JB]557]>J?!.GQ[BSZL=U1;\_2]/E[.F5Z/
MV:SG7\PZ&_Z']DR2^JZSJD'X]4;$Z^RE(0I^:?)7?8.T62=SL?Y(;;5JJC>R
M&YQYA[]AJHU$>KK,.SXZ-Z.=U5$2)O1/AU7Z3L;7JVU50I>T7'E<]L<B<5]A
MVI/\TZN]Z&M$E-NQN'*C:]DL6W)_95Z"_P %?.67_4$ZBOT^3.R?^K#&?X:G
M)_6WU#_8=G_G4O\ ,''_ %&=*_\ N/(_YG#_ *0>%]@?45_YS.R?^K#&?X:C
M^MQJ/AH=G_G4O\P%Z&M*7_:/(_YG#_I![1>P/I:31+/Y+;1)721BSQP\:XF"
M:2%'(LK(IW[?89#(]G5&O6.1&K\5:[Z%MEZM]3<7TZ)84Z<&\F;5?"J\E57N
MJJ^U%\/0YI"FG<W%DN%55+$@FUXI-WVD_>TZ>QGU%'V$.$HYU=D^=>5+=?L<
MB14<1J6.G]55;VO6Q8I92-6(G7JWTNJJJ?:3I\?@N^K/=#A2QI6!&=><IW9*
MGR*4?LU^8[2SZ(=G1G7)UK4YVZ<HPL1=?E<9\/=3YS[G%>Q%XEU/EY,KR%S_
M )>>-9%L1ILV@8_'V4<LB1M^7@XUDO0I&QS>O;:ZN>WK\&KVG59'JL[@W.I6
M,/2+<7R?E9$I+V\7D]+_ +WE[^)W>+Z*^U]KI>3GZY=FJU7G8T8OG3@L1R5%
M3[?BU7EP.3<-[+/@SC&M2]K7(>QJV%\2NS/(F7@5[W2-D2P[\WHL"U)F-3L1
M$1(^U5ZM5W1R=%D^I?NG??WJ_AV56OP8\'X<OOCN</'VU\:<#TF)Z1>S6,J7
ML?/O\*??,J:KQK7[TK?%<O93PKQ.9\#[7'@1KB]<?XY:U87J]?\ P]L>_;4G
MVUC5WV=GVW,-Z)Z:=$Z=&]5Z=.YW7S67WU[L9G[-K-^/[7;L6OP5J'M_\*(]
M;A>F_LEI[K8T#'E^V7<F][/\M>G[/FXTYLYYUKQ,\6].]-VL>.?!^%GB7JVY
M2XLTEF154DED:LF3=A79"98W3.[.^5W8U>UO1$1#RF;W WUJ55G:SJEV+\)9
M5[I\.4>OI7+C1<>;XGMM/[8]N-*H].T#1[,U]M'#QU+FWQGY?4Z5=*O@N"X'
M.N.QF-Q%6.CB<?1Q=*+_ &JGCJD%*K'\$3^+KUHXH6?!$^A$^@\K>OWLBX[N
M1.4[KYN3<F_G=6>SL8^/BVU9QH0MV5RC&*BE\B22+XXCF
M
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M\4%<@O\ )R<N!YK:.0\?4[N%;3>+>AYD?&B7%5^:73)_=)(FJD?3(X
M
M
M
M
M
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M
M
M
M
M
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MA<BW]+JEXQ:7%HOF8UJ6F7GU.S^QR^[M2^@U^E^BTN5%[4;3#QAW@
M
M
M
M
M
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M?7QJ;5/0[H/XG[!8>:X],M3U#,RGPHW2XL1/V\8XJHWS5&N%#01[P.59DO<
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MJ+W+V?F+[!^B6%0
M
M
M
M
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MD?%)\)*O'I:9D"=6?4
M
M
M
M
M                                                       #0W[K
M^VTLQY3^ G%-IRNQ."WJ?EO=JWVI?5UFEM&KHZPE=E>RO?4P>GYSM5S'L>K^
MBHC6N59;^GK3KN-L#=^X;?\ I%W$6)8?*EV5J[PK5<[EZQXIJGBVC7SZOM8L
M9O=KMWM&\ZX>/J#U#*CSK8C?L<:*,N,;6-E4JFG7C1)LU%:KO-K%>VGY.9C(
M2P2YGG[ROXWTW(R)ZWS5I=:PUGER_8=W.5'5H<C5BZ*KGJU\_P!KXN:I(W4-
M)MY'?'0<:RFL;1]O9-Z/*B\V:PXKY7%OV<(\.3(;:3K]W$]+NZLW)<7F[BW?
MA8TWQZI>1:EJ,W^E4XQ\71RX\TS[?F;C69W!'M4^-D'6#,\K/V/D7,PM:CK%
MM_D'R-J>.TB\Z!K&6FI#KK/2B5KD29.O3JK45.JVSKD5NWN!OB?'%T]6\:#\
M%^+\:]*_&O+C<XOV?.SOM[[7F^WW:/M?;^'.U=WLRXO&3UC-QX8LZ4ZN%GX8
MT?Q>^B)B-B?&X#$SV9W0X_$87'23S.1BI!1QN-K.DD<D<;7.2&M5A7X-15[6
M]$0UK0A?S,A6X5GDW9I+VRE)^_Q;9NHN7,73L.5VYTV\*Q:;?#A&$(U?!>$8
MKDO!'79[[M-C>=ZW3=K;59:W#;-CVFRUR-:YMC8,Q<RTS5:Q7,:J26U^"*J)
M]1N@TC3X:3I.+I=O]CQL>W:7R6X1@OS$?FMW#JUS7]?SM=O<+N;F7K\OEO7)
M7'R]\B8G[9^+EXS]M#0,\V:EA<G/J?+/(=G)W(7/I5I9]IW+(8?*WHTK-FGK
MU\#2I.E16R*YD:HU7,[36MWSOQUWOGF8C4KMA9&)CJ*?Q-*U9C.$76B;N2FE
MQ7%\:.INI]+>)+:WI;T[4%*%C*EAZAF2G)5C%N_DSMW)+IJTK4;3EPE5*B;5
M"+CPC8?JW!OEGR9*Z7YW)Z;HO!6#MRJKF_?G+F\U=JS<G>YJNFLS<>\39VNO
MVT5K;:N5%^!/?=4%G[KV[H4:>5;R;^?-+[C#L.U#Y$LC+L2Y<X45#4]L.Y+2
M=@[PW3-OS[N%B:5:D_\ *ZCE1OW7[Y/#T_*ASX*XVZ\#$XR$8?)K/M&\3OXK
M\'>,YK=;Y7+\GWL_RQEH^Q6^HS:+4=#6;/<YK'2?-Z-@\5)W*G1.[HBN:B.7
M5YZC-PK<'=;.C;EU8V!"WB0]WE)RNKW4OW+J^:KH^!O/]&^SY;2["Z5.]#HS
M=5N7M0N*G-7Y*%B7OZL6UCRK[Z*J2;V8&#"4@              !UV?NN\$W
M/;)]U=O,&KZK4RW#7+F;O<UZ_J4Z^G@=ITWD%^2UOR%X5R3NQ[*F'SS,SF\7
M+7B;TKX'-UD9T54Z2HV5J4=W[+^H7IN.?8BK4I>,9PI*Q=7M:I"5?&<&8CUW
M%>BZ[]8MQKCW'UI>#4JJY!^YUDOTLD:;_(_BK'\,<T;OHFOY:78M)AMX_9N,
MMIF:UDNW<2[WA\=O'%.VSQL9&R"WLG'NPXVY8A1$6M8EDA=T=&Y$][I.;+4-
M/MY-V/1D4<;D?N;L&X7(_)&<9)/Q23\3SV986-DRM0=;?!Q?MA)=47\\6F;?
M?U>7S8=XM><&)XKVK-.H<3>546+XMST-AZICL?R3';G?Q%L4B>HQ(K#\]D)\
M'WKUC9#G7R2)TC:YGA>Z6WOQSMV6;9C7.PJW(^UVZ??8_P!ZE/Y847,]!M+4
MOJ.IJQ-TL7Z1?Z;[1_9^']43F=WL/X-\F].Y'=+\MQEY+LP7#'(B.<D=#7N;
M<(R]+P;NL_\ !AK?I$Q4U[2K]A_66WDX]6J,^@CECI:CH]S$YYF)6[#VRLNG
MG0_4.EV*Y*/G29DVZ_JV;&]_B+U(2]TU]!_JE6#]K\M&8QT)V
M
M
M
M
M
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M"OSO6G"]_I-N71/],OME[IIJ:]TDC)$ZD^P
M
M
M
M
M
M         'R6_P"ZX3C?1=RY"V6?Y;7M&U;/[=G)^J=T>*UW%VLO?<Q%_A2_
M+5'(UOTN=T1/BIV.CZ7E:WJV-HV"NK-R\BW9@O;.Y-0C\U6J^XZ?<6N8&V-
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M*$5<7L=II*LW7WUZ/U?+AEQ_8YTMW/L_>Y?-)N/R3J^$3,,Z$[
M
M
M
M
M
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M]
M
M
M
M
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M::;!=5V\Z1O2E2Y"GT;B7Q.+Y],UTS2]_5SDS/\ /,':@
M
M
M
M
M
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MS?[/[MJ]2W)J7=+/M_O33K;P\1M<'DWXIWYQ?-.SCN-M^#64^;3I*'(%FUX
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M:TM7??TOX9/QB^I\$B3X8>/:@
M
M
M
M
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M7C8ZEDSCQ5S*NOS,B:?-Q\R3C;KRMQA'DC)D\*93
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MHRK7JASBW[^FB;\6F_$Y\.L/J
M
M
M
M
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MY+;M.LL>3\8<W"OMCQ^:O)=)OC,:GJ
M
M
M
M
M
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M21VND:C^,<:MQ=&9;?1=AXQFN?#V/FOL5JF9]'F3M0
M
M
M
M
M
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M&(I+X;N<XI]:3YK%MR4T_"]<M2BZVY)2M#7T;=@
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MUS3X,Y(/D.8
M
M
M
M
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MEI.$OI<9J3E6/3Z#'PH8EYO%I'&G5RAX*;=>J/LK5J2Y<(TI1URM.E/N
M
M
M
M
M
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MKZ9>YHV:GD#N@
M
M
M
M
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M&J\&T^3]JXI.M&UQ?UVY3E;4KD>F;7%5K1_*N:]C_,7(^F.$O
M
M
M
M
M
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M?[:;0PMF;9M^7I6':Z4W3KNS?Q7+UUI+JN79MSFZ))OIBHP48KEX\V>S
M
M
M
M
M
M
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M&HJ4(0SC,4F>@
M
M
M
M
M
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MQMVZAB?5H8.']3T7!FOXLP'QG<G%K^,]0E6]GW:>9'J6,Y2Z+D[F>1B0D$
M
M
M
M
M
M
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MBVMNPA9RM=ORMW\[)<4_.R8-3AT=2JK6-))8ZHG%Q\ZBNSFWFR8M,Z@
M
M
M
M
M
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M5N,I)7+M_8F87)*@
M
M
M
M
M
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MLQ5Z,6P_I0QNJ+^LY$4Z0C<C:K*,Y6Y GAYXP_HGJY7SA\MJF,FYLVG#X?\
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M3LZ39N<)7+C3<+VI7X]/UB["MNT_O5J5Q6[=Q9P&*C/(
M
M
M
M
M
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M3H_%)\T2\E;MSE&4XQ<H2K%M)N+HXU7L?3*4:KC1M<FRL6EX
M
M
M
M
M
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MB22X))<$EP2*Q:7@
M
M
M
M
M
M                        '!>X<!:?R/RIIW)W(B?G>SC*M-)QEIN1JQKJ
MNK;/D',^]=[MT7R3LV'<'00104)[")!BX6.=7A2R]UA?6:;N_4M$V_DZ%HO[
MV>=)+*O1;\V[:C]"PI</+LU;E<C'XKLFE.3@E \#K7;O1=S;MPMU;E_?L=*B
MW@XTXKZO8OSIYF7*#;\[)HHPM3G\-B*;MP5V3N'.AY,]\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
9                              ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>53
<FILENAME>upjohnlogoa02.jpg
<TEXT>
begin 644 upjohnlogoa02.jpg
M_]C_X  02D9)1@ ! @  9 !D  #_[  11'5C:WD  0 $    9   _^X #D%D
M;V)E &3      ?_; (0  0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0(" @(" @(" @(" P,# P,# P,# P$! 0$! 0$" 0$"
M @(! @(# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,# P,#
M P,# P,# P,#_\  $0@"_P?0 P$1  (1 0,1 ?_$ 18  0 !! (# 0
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MM%71PF.#HY34A487\-+#1%2DQ"5%I<56=C@9X?%FA.3E9)6U)K;_V@ , P$
M A$#$0 _ )_
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
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M]8
M
M
M
M
M
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MZ5K1I^)D;%R[&;863C2ZK,N3HU7[*3.8SX#Z
M
M
M
M
M
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MB5S4D?'$Z-LLC6=>YS(W3,1RHG1%>G7Z4,8T=*^!ZL]R@
M
M
M
M
M
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M=EW\.75:4G&M&N*H^3X\FN:,I3IC[@
M
M
M
M
M
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MIP=>F2]E:--/DTUQI5Y@TS4K&JXD<O'JHO@T^<9+FG]GGXIIF8!T1V
M
M
M
M
M
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MIT7-I-\B5:87/<@
M
M
M
M
M
M        $5;]9(]RN7B'CJ#P1X>S[JW(W+^!CR_.F8Q5OMMZEQ+?>^/'Z,LT
M"J^KE^37P/==C5[)(\#$K)(W0Y.-Z9H[3;16=E/<F?&N)8E2RFN$KJYS^2WX
M?HW5.L&>&WCK+Q[/XKQW]^N*LVO"'W/RR\?T/Z8@NDCC&0
M!V.?ZNGP/K7$?MH<;;SCH:LFU>0>T[URCN62CC<L[W4-HRO'VL8CYJ5$F?2Q
M>M:;!*D*(V&&Y<M*Q'+(Z62*/=74KV=NZ]C3KY.+"%N"^6*G)T]KE-JO-I+V
M467]HXL,?1H75^R792DW\[BE\R7V6S>P8W/3@
M
M
M
M
M
M                             Q=\SO*OC_PJ\;.4?(WD::)^)T+ RRX3
M ?,MK7]TW3(JE#3]*Q*JV61;VQYV>&%TC8Y$J5O5M2HD,$KF]SH&BY6X-6LZ
M3B?3NRXR\(07&4W[HJK][HEQ:/AU'.M:;ASS+WT8+@O:_!+Y7]A<>2.JLYSY
MIY \B^8.1N<N4\S+G]_Y0VK*;;LN1>KDA2WD9NL&.QT#G/;1PF%HLBI4*K%2
M*I2KQ0QHC(VHDS]-T_%TK M:=A1Z<6S!1BO<O%^UMU<GXMMOF8.RLF[F9$\F
M^ZW9R;?_ (>Q<DO!<#BD^XX               ":C^KK>ZUQO4XTTCV\.:+V
M3PF_8G:<S0\=,Y#A<OFL7N>'V_,93;;NB9:YBJF0GPN<U_.Y&_8JV[J18Y^+
MD9"LL*U6-FC[W4V5ERR[FZ=/2EC2@G?54G!Q2BII-JJDE%-*LNKC1]7#(VT=
M=LJS'2,EM75)^6Z-IIMOI=.33KQ?"G#A0E]&"S(
M
M
M
M
M
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MG[28 8*,@
M
M
M
M
M
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M+FGZ3;LWE2]*LI+V.7)/WI43]YM</%'>@
M
M
M
M
M
M                      ]))(X8Y)II&111,=)++(YK(XXV-5SY)'N5&L8Q
MJ*JJJHB(A5)MT7,'6->\OY[S^?'F9M^UZWE9K?"'%/S?%_!U5K^E&[K.'ORK
MF][CA9(L3[/(NP-EOQS.8RQ]U)0KRIUK(B2^V#ME;9T"W8O1IJ-^ER\_%2:X
M0_41^&G+JZFN9A;<6JO5=1E<@_WM;^&'R+G+]4^/R47@:G#VYT0
M       ) OL-^V%O_EWSOA/([:GYC2_';@G9ZF1GV>M7^5RW(>_T6+9H:7HF
M3M4IV8^7"]\=K*9FF^/(X7OKK0FKY"6"W4QAW*WABZ'ILM)L]-S5<F%.GFH0
M?.<TGQKRC!_#/CU)Q3C+U>U]%NZAE+,G6.):E6OC*7LB_=S;7%<*-.C78@P0
MQ5H8:\#&Q0P11PPQM_@QQ1,1D;&]>J]K&-1$(LMMNKYLRVN'!<BJ4
M
M
M
M
M
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M27!)<$DDN",SXV/9Q+$<;'BHV8*B7_AS;YM\V^+.3SXSG
M
M
M
M
M
M                                  !8Y3)X["8S(YG,7JF+Q&(HV\GE
M,G?L15*..QU"O):O7KMJ=S(:U2I6B=))(]4:QC5551$+H0G<FK=M-SDTDEQ;
M;X)+WLI*2C%RDZ12JV=6A[I/FQEO/7S*Y/YL2[=DX\H77:%PKB;7J1MPW$^J
MW+L.NO;4E1'TKFT6K%G.78G*Y8[V3F8BJQC$296S=O0VUH%G3Z+ZTUUW6O&Y
M)+JX^*BJ07NBF80UO4I:KJ,\FK\E/I@O9%<OL\9/WMFO$]4=2
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M =B
M
M
M
M
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MZ,>'!N5<Q;=T..D8W7=2>=<7Q/V+[A/V+QIS?N2-T)C\]&
M
M
M
M
M
M                                     4;-FO3KSV[<\-6I5AELVK5F
M5D%>M7@8Z6:>>:5S8X888VJYSG*C6M155>A5)R:C%5DRC:2J^1U</NT>:-CS
MI\WN5^7,;E9LAQGK]U.,^%87=[*U?C#3+5RMBLE5@D<Z2#\\LO8NYZ5KU[V2
MY1S.C6L:QLR-D;?6V]NV,&<:9DEYEW]LFE5/](J07NB82U[47J>IW,A.ME/I
MA^E7+[+K+YS6P>M.G               )LGZNO[3GYEX; >X)Y":YV[;LV,=
M:\9M-R]7H_6]5RU66O-S!E*=F+O;F=KQ\[H]?141(,5*Z\GJ.N57UX]=U-[?
M6+DMKZ7/[Q!_OB:?TI+_ !2:\(OZ?ME\/#I=<D;1T'RXK5LM??)+[VGX)_;O
MWO[7W<?%4ESF#CWP
M
M
M
M
M
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M!7K5X&-BA@@AB:V.&&&-J-:UJ(UK41$3H15;<FY2=9,RZDDJ+D5BA4
M
M
M
M
M
M                                              '7!?K!WE^[R?\
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M8F.J6X*GO;\6_>WQ9D =8?6
M
M
M
M
M
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M>Q
M
M
M
M
M                                                        (C7Z
MU5Y-_<G''CSXC8++NBO[UGLGS;R'C:SY8IOS7U)EG5N/ZU]6N;'9Q>=V7)9>
MPV)4<B6L%'(O:K&=<X]E]'\S+RM<NQ^&W%68/]%+XIT]ZBHJOLFT>!WSF]-F
MSI\7QDW.7R+A'YFV_GB0F20IC<             &V#V:O B3SY\S-1T_9L9-
M:X1XM97Y0YPL_:CJW=6PU^!F'T99^U&NL\A;"L./DB8^.PF+^>L0JCJRJGB=
M_;F6V= G?LNFHWOO=GW2:XS_ %$:R]G5TI\SO=NZ5^-=1C;FOWM#XI_(N4?U
M3X?)5^!V<M:M7IUX*E2"&K4JPQ5JM6M$R"O6KP,;%#!!#$UL<,,,;4:UK41K
M6HB(G0B VY-RDZR9FA))47(K%"H
M
M
M
M
M
M                    !U9_NS^3C_+3W ?(SE.CG'Y[3,?NUSCCC.RUR+CT
MX]XX>[5,#9P[&OD2/&;#+CY\NWJJ.DER,DCFL<]S4F7LC1_Q)MC$PI1Z<AVU
M<N>WKN?$Z^^-5']2D80U[-^OZK>OIUMJ73']+'@J>Y\_G-<AZLZ@
M     '9?>Q[X(S>#OA/JU3<L)]U<W\X35N5^78[,369/#39*DV/2M"MO^,D?
MYEZO(Q+%=RJD&7NW^U>CR(O<7<BW'N&<L>75IV-][M>QT?QS7Z>7)^,5$S+M
MK2_Q9IL5<5,F[\4_:O9'YE^:V;C3P9Z$
M
M
M
M
M
M                          UX>Z[Y(S^*7M]^3/+V+N/I;7%H%C1M$L03
M^A=K;OR=<J<?:[EJ"HJ.?9UJWL?WJK4^/I47K]"*>IV5I*UK=&'@S5;'F]<_
M9T6TYR3_ $RCT_.=1KN8\#2;V1%TN='3']-+X4_FK7YCJPR9IA
M    &YSV*/"23S)\Z](N;)A69/A[Q\?0YEY/6[7=/BLE8PE]B\?:9::O]SV7
M[3N$,,DU67JRSBJ%Y%:Y&JU? =R-PK0-MW(V94S\JMJW3FJKXY_J8UHURE*)
MZ+;&F_C'5(N:KCVOCE[.'T5\[\/%)G97D2#,@
M
M
M
M
M
M                                (@OZUEY'_=^E^-/B9A[_ &V-ESF;
MYYWJE%+Z4S,5K=:[HW';)T8OJ6,?ELGFMAE=&_I'Z^+B?T<]C5CSIV6TGKR,
MO6[BX0BK,'[Y4G/YTE#YI/Y\?[ZS*6[.!%\9-SE\B^&/V6Y?8(5Q((QR
M         #LBO8%\+8_$OP0U/;=DP[:'+7DT['<R[Q+8KO@RE#6,A05O%6I6
MO69#8CBPVI6UR#X)6-DK9'-7(UZ]$(F]S=P/6]R3L6I5P<.MJ'L<D_ODE\LE
MTU\8PBS,.U=-^H:7&Y-4R+WQR]M/M5\RX^YMF\$QV>E
M
M
M
M
M
M                                      !UDOOE^0[O(OW+_(?*5+K;
MNL\49BGP+J79*LT5>CQ7'+AME;#*DLD,E>YR--F[<:Q]K%993X*O5SI>]N=*
M_%6T<6$E2]?B[TOEN<8_8M]"^8PON;+^N:S>DG\%M]"_4\'_ (74S4<>Y.A
M           -@OM;^(T_FSYQ<'<(6Z$US1G[''O'+,L<?=#5XLT9T>>VRO9E
M^*5/SEC@BPE>96O;'=RD"JUR=4/+[RUQ;>V[DZC%I9/1T6O?<GPC\O3QFU[(
ML[71-/>I:G:QFOO5>J7Z6/%_9Y?*T=J!6K5Z=>"I4@AJU*L,5:K5K1,@KUJ\
M#&Q0P00Q-;'###&U&M:U$:UJ(B)T(9-N3<I.LF9P225%R*Q0J
M
M
M
M
M
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M:A-?'<?3']+'G3Y9</U)*[,*GN@
M
M
M
M
M
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M:YOYW5_.<\G6GU
M
M
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M_#J==>Q<G'2=^W<@GRZHM5^RD=MCYN%E-QQ;UJY)+BH3C*GRT;H?I' ?4
M
M
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M[& BH9>
M
M
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M_*6>61,YR5O^921(VR)EMQV+(H](E1T2/^<R,W<D;DZMZ_0OT'H<;;FWL/\
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MFN:J*CD5.J*BI\%14/$--.CYF0TTU5<CR"H
M
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MX[\V_P!3&L5^;U/YR2,8F/8@
M
M
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ML5',]GP62QC;;E5.J]5ZJN&-?],/;O55*YI+R]-OODK=SS;=7[87NN=/=&Y
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M#>5CZQM;4L/.@EQ5J[&4X_I[=?,@_=.,7Q1R^>=/4@
M
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M8?1MP4?EHJ5^?F<T'7GT@
M
M
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M<)S@
M                                                   &OWW5^4%X
M=]N/S+WB.RRG;;P1NFH8VV]KW+6S/)=-O&N%GB1G_P!$Q9;;870JY%8DJ-5Z
M*WJB^GV7A_7]UX&,U6/UF$FO=;?F/\R+K[CJ==O_ %?1\B[X^4TOEE\*_-9U
M6Q,\P>            ;AO8=X!9S_ .YOX_U\A19>UOB"SFN>MD1\:R)63C.D
MES3;?9VJQ?3Y/OX%J]RHB(Y5^*]&KX/N3J;TS:&4X.EV^E9C_P 8Z37[FIGH
M-KXOUO6K2:K"W6;_ %/+_"Z3LQ2(IF8
M
M
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M\*[%2A<MRC.$XOBI1G%N,HOP:;3/UC@/I
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MF(F!S(0
M
M
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MBJEE9/5CXJ?A*%KADWE[8S6*_%29J4YB\N?('G-UFOO7(66^X+*O3\T-??\
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M?PTC=23;MJ/Q/9>89,[
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MF/5W<&5Q3<K=?AO8\W&#O6Z45Q="G:GPFNF5N<]B!A@DF
M      1 ?ULGD!]73/"_BR"S*L>;V?F/D#*4VND2%K]6Q6AZ[@K,S/A%)*]N
MX9%L2IW.8C9.O:CD[LZ]DL52R-0S6N,86H)_IG.3_61_,,?[\NTMXUA>,IR?
MS**7Y[(61($QR            =FC[$_!GZ"O;!\;:=NG\KGN4\-E^<\_)Z?I
M?/?I3R]G/:A<[%3N_P 6WW'%W*KN_P!+N3HUR-;$/N1J7XRWAERBZVK,E9C[
MO+73)?NG6_G,S;8Q?JNB64U\<TYO]4ZK_!Z3;T>%/0
M
M
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MB\M7_05.1%H]?I_9^(K["^):/7X@O1:/^HJO%G)XEJ]?@[\G^H%R+UR+5_\
MJ%? OB6;U_L]2I>N9:O7XK^3_4"YG)["T>H7BR_P+1_T%? Y(EH]?I_9^(J_
M NB6K_I!>BS?]7[9<N9R%J]?@[\G^H47(Y%R+5WU%7R+XGI6N6\?;JWZ%JS1
MOT;,%RE=ISRUK=.W5E;-6M5;,+F35[->9C7L>QR.8Y$5%14+;ENW=MNU=BI6
MI1:E%I--/@TT^#37!I\&CFM7+EFZKUF4H7823C*+:<6G5--<4TU5-<4R1W[>
MOO;9'!283AWS-REK,85SZ^,UWGE[)K>:Q2.<V&O6Y/@B;)/FJ#>J(N9A:MR/
MIW6V3HY]B.'O=GTVV<E7=P=NH1MY-'*Y@\%"7BWC-\(2_P"!;Z'RMN-%!SB[
M,^J>_B.SMGN=<E=QG2-O/XN</!+*2JYQ_P"&2ZUSN*=7.,HC%Y3&9S&X_,X7
M(T,QA\M3K9'%Y7%W*^0QN2Q]R%EBG>Q]ZI)-5N4[4$C7QRQO<R1CD5JJB]2$
MU^Q>QKT\?)A*WD6Y.,HR3C*,DZ.,HNC33X--53YD]\?(L9=B&5BSA<QKD5*$
MX-2C*,E52C)-J46N*:;37%%^<1S
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M=F,?R]NY&2^=S,:^:%N%/'VREX+Y^!BW?%SJU.U:\(V4_G<I?W$B,49@/%@
M         ^LT+3<QR+O6E\?:]%Z^?WO;-<TW!P].[ULQL^8IX3&1=J*BKZEV
M\Q.G5/I.#)R+>)C7,J[^Q6H2F_DBFW^8B^U;E>NQM0^G*22^5NB.WQT#2\+Q
MOH>D\=ZW VMKNA:CK>EX&LUJ,;7PNK8:E@\7 UC>K6-BHT8VHB?!.A!?*R+F
M7DW,J[QNW;DIR^63;?YK,_VK<;-J-F'T(127R)41]<<!R
M
M
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MX#L0
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MVXG2=RVK2]_FR4)+^\<G\B.]VUC_ %G6[$7]&,NM_J$Y+\U([.LA^9I
M
M
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MQ',
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M*Y=6DY5ZL;F;@6VW:M7>KC];L65%R3;=RW&3;<K4YSW9D6R=8
M   !U;'O![0_;_<Y\U,M(]\CJG-VP:NCI&5V.1FD5<?I<3$;51(U9%'@$:U5
M_C'-1%D_C%<3)V)95C9^GP7CCQE_?MS_ -]_N<#".X)^9K63+_A6O[WA_<-;
M9ZTZ<          $J3]5.XG9L'E!Y*<SSP^M%QCPI@M%JJZ)71U<KRUN,64@
MMLE_@Q6DQ7%=V%J?2Z.>3I]"F&.].;Y6CXFGKG>R'-^]6HTI]FXG\R/<;&L=
M>;>R7RA;4?GFZ_G19.G(X&3@
M
M
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M+UZ=?@C24OI2U&]:WCJ.E)OZM?TUW6N-.NS>M1BZ<OHWI\?F\2#/KPT?&O\
M;O2-><5]=QM95B+X55O(QK\YJO/C+&M<%[*^!&T<OQ_:)X&K*/(HO4KX'(N"
M+=WTE5R"Y%%R_']HHCD7(MGK^^57.IR>-"U>OTA%ZY%JY?J*^!?$M'K]/XU_
M9^\/<7KF6KU^/[2%2\M'K\/VU"YG(N1:O7Z2J+XHM'J/ O7.I:2+^^I4O\2U
M>OT_B0J<BY%JX>)?$M'K]*_L_9T*HO7,M'K^\@7(O+5Z_#]LJ<B+1Z_3^3_4
M'L+XEH]?B5+T6CU*KVG)XEK(OT_D_9^Z%R+O M7E? Y(EF]?WU*^)?$MI%^*
M_B3^W_J@O+1Z_0%XLY/ M'K\%_&O]LJ<D2T<OT_B*OD71+1X+US+61?WU*KF
M<A)=]C?W#)<7E,?X5<P9U[\5EI;$G .P96QU;C<J_P!:[?XOL6YY.C*>67OL
M81KE3MM^I38KEGJQ-AMZE>U$;]F?<;;]K[_!+Z]"*^E'@HY*2\8\(WO;&EQT
MZ9R<X?2SWAE8O0[9;CNMX]QOZA<F_HSXREBMO[6?&5FO*=;:KUVXJ5&0C)Z@
M                                                           $
M?OWZ=MY;U[1.#,/K.?SF&XIVW([]B^0*>%MVJ-+/9^M6U:WJV)VB2"2-+U!^
M.;DY:E1RK#(^&=\K7.CA5DP_2-IVW<W5M6R<^S:N[AQH8\\=S2E*W;;NJ[.T
MG]&75Y2G/FDXJ+2E*NNC^T(UG>.F[?T#"TK(R+&T,R[EV\N-J4H1NWHQL2L6
M[[377#H\^5NV_A;C<E--Q@XQ>B>9JC   ,X_#CSZYM\.-@8FJY!VV\89&WZV
MU<2[%=LNUG)LF5K;E_!OZ3OU39)(4Z)=K,<R5S6):ALQL;&F*NY?:':W<O#;
MU"'U;7H1I:R[<5YL:<HW.7FVJ_:2=5Q\N4&VS/?9/U#[[[)ZDEI%QYFU+DZW
M]/O2EY$Z_2G:?%X]]KE=@FI-1\V%V,5$R$\H?&KB_P @]/V+S,\&:Z7=%C8W
M+<\<!05H*FY<&YR>%T]_,T-=JOD^9T?(.AGLR)3]6M3[)9:RK39+%C_&["WQ
MKVS=2L]LNZ\NG5F^C U!MNSG6TZ1A*XZ4OQK&*ZZ2G6,9KS7&5[(_=?M?M3N
M/HN3WN[!QZ] 2\S5M(45')TJZU6=V%F+?5BSI*;\OJA;I.=INQ&<,;4P2'(>
M@    RQY*\JL]S)X]\9<-<FX6#9-JX6REJKQORC+9G39ZV@9*I7AGT7/S2R2
MQY7$8F2A#\GW1^NC&P-;-"RM)'>Q[H?;_$VSO+/W-H5UV-/U2VGDXJ2\IY$6
MVK]M*CA.:E+KX]->IN,G<C*UE_='=S4-[=N-*V3NFQ'*U;0[THX6>Y/SXXDX
MI/$NMMJY;MN$?+JNNBMI3A&U*.1B<9",0  _;UK9,]IVPX3;-6RU[ [)K>4H
MYO!9K&SNKW\7E<;8CMT;U29OQCGK6(FN:OQ3JGQ14^!\N=@XFIX=W3M0MPO8
M-^W*%R$E6,X25)1:]C3H??I>J:AHFI6-8TF]<Q]4Q;T+MJ[!],[=R$E*$XOP
M<6DT39O;M\X<%YF\0LN962ABN9M%AI8OD_6:_;#'8GDC6.ANN#K+\4U[9E@>
M[TTZK1MLEKNZL;#+-JW[T=JLOMEN-V\=3N;9RW*>+=?&BK\5BX_\I:JN/V\'
M&:XN48[U?37WZT_O?LQ7LMV[.]]/C&WG6%P3;5(95J/^1OT;Z>=JXIVW6*A.
M>P@PV2/             !U*WG#L";9YJ>7^U))4E39?*+G_8$EH*Y:,J9GEC
M;<BDE)7RS/6H]+/6/J]Z]BIU<OTDW=NVO(V_@6>/P8=F/'GPMQ7'WF!M3GYF
MI9%S[J_<?V9,Q=.Y/B          !/2_58.+OS;\+N:^5+,#X;W*'D#<PM1S
MJ_8VUK?'.E:S!C[<=E41T[/SAVK+P]J=61NA7HO<YR-C3WFS/.W!CX2?PV<5
M-^Z5R<JK^]C%_.91V/8Z-.NWWSG=I\T4O[K9)Y,/GM0             14N8
MOUHG0^(N7>4^)[/AWMV<L<8<C[QQY/FX.9L-0AS$VE;-E-;ERD-&3CJT^G%D
M'XQ96Q.ED6-']JN=TZKFC [.9.=@V<U9\(J]:A.GE-TZXJ5*^8JTK2IX;(WM
M:Q\BY8>/)N$Y1KUKC1M5^C[CCG_XLSCW_H3;E_Z\,)_[,SZ_^Y+*_P!HV_W%
M_P"<.'\O+7_HTO[]?^*?6:E^M@<"7,A%'O?B3R]KF+69C9KFI;YIFZY".NK)
M%DEBQN8H:#7EF9(C$;&MMC7-<JJ]JM1'<%_LIJ<8UQLZQ.?LE"<%]E.?YQR6
M]]XK?WW'N1C[I*7YCZ?SS>GX7>Y;X>^>^,M2>/?*%?(;=BJ,.0V'BW;:<FI\
MFZ_6E1J26+.LY"1S<UCJDCVQSW\1/DL;%*]K'6$>YJ+CC<&T=>VS-+5++5B3
MI&Y%]5N3_3+DWX1DHR:XT/3Z;K.GZK']Z3K<2XQ?"2^;Q7O55[S/0\T=H
M       #6#YM^[]X/^!>3L:AR]R'D-HY5@I17G\/<4XN'<M^JP68VS5?OY)<
MAB=5U":W!(R6*',9.A8FKR-EBC?&Y'+[';VQ=Q;E@K^#:4,)NGFW'T0?MZ>#
ME*G)N,9)/@VF=)J6X-,TN7EY$W*_]Q%5E\_)+YVF:9M@_6Q.&*U]\>J^'G)^
M9Q:=_9<V#D_5-9ONZ2.2/OQN.UO;*[.Z)&N7I;=VN56_%$[E]]:[)Z@XUOY]
MF,_9&W*2^RY1_./.SWWCI_>\>;C[Y)?F4?YY^'_\69Q[_P!";<O_ %X83_V9
MG)_W)97^T;?[B_\ .%OY>6O_ $:7]^O_ !3+SP-_6&=.\Y?*[BKQ:Q7BYLW'
M5_E'\^?0W+(<J8O9*>'_ #)XWW#D27UL+6T;#S7?O"'4756]MF/TW3I(O<C5
M:[H]R]K;^W-$O:S/,A=C9Z/@5MQ;Z[D8<^MTIU5Y>%#L-+W;;U//MX,;$H.?
M5QZDZ4BY<NE>RG,D;F*#UX                          !K)\G/=@\6/&
MO.Y'27Y+.<K<@XI\M;*:UQQ!0O4,#?B=VNH[%M62O4,)3M,>CF2P5'7[=:1O
M;-#&JH9UV)Z>M_[XQ(:HH6M/T:XDX7<ERC*Y%_;6[48RG)<FI35N$DZQDR+'
M=3U?=I>U^?=T)W<C5]QV6XW+&$H2A:FOM+V1.<+49+BI0MN[<@U2<(F'FK>_
MOP]>RS*^Y\"<BZYAGR,8[*:_LNN;;=B:YRM663$WJ^I1JR-.BJC++W=.O1%5
M$1<E:AZ0=R6L=STS5\*_DI?1N6KEF+]RG%WOS8I?W,+:1_:(;+R,Q6];V]J>
M+A-_LEF_9R)+WNW)8ZHO=-OG1/QW'<$>1'#ODKI<>^<,[KC=PP;98ZN2B@2:
MGF=?R3X6S+BMBP=Z.OD\-D&L7JC9HVMF8G?$Z2-6O6-&[=F;EV/J;TC<^+/&
MRZ5BW1PN1K3KMSBW&<?>G5/A)*5436[?]R=E=T-#6X-D9UK-P*J,TJQN69M5
M\N]:DE.W.G)2BE)?%!RBU)\UGESW0                          !KO\
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M/A"TKLWP4+=^%R[8<I.BA"=RW<N-J,(.3H;+C!I*,
M                                               M+^0H8JC<R>4N
MU,;C<=6GNY#(7[,-.C1IU8W36;=RW8?'7K5J\+%>^1[FL8U%551$.6Q8OY5Z
M&-C0G<R+DE&,(IRE*3=%&,55MM\$DJM\$?/EY>+@8MS-SKMNSA682G<N7)*$
M(0BJRG.<FHQC%)N4FTDE5NAI0\L_=!1OWGH'C5.CG(LM+*\L6:W5B?!8YXM'
MQMR'[2HY>U,E99T^#EKQ*BQV28?:[TW-^7KO<2/#A*&$G\Z>1.+^?R8/V*Y)
M?%;-;'?OUN*/G;4[,2J^,+NJ2CP]DEA6YKC[/K%Q4YNU;?P7C2AE<ME,[D[^
M9S>1O9?+Y2U/>R64R=J>]D,A=LR.EL6[MRR^6Q9LSR.5SWO<KG*O55)AXN+C
M86/##P[<+6):BHPA"*C&,4J*,8I)))<$DJ(UKY^?G:IFW=1U*]=R-0OW)3N7
M;DI3N7)R=93G.3<I2D^+;;;?,_/.<^0       !5Z%2I25>I1OP1>E0IN=^3
M^R52IQ+N7RE!R_VQSXA+Q93<O3X?65+TJE)5Z%%Q+TJE_A<-EMDS.)U[ T+.
M6SF=R5'#X?&4XUEMY'*9*S'3HTJT:?&2>U:F:QJ?6YR'S9F9C8&)=SLV<;6%
M8MRG.<G2,803E*3?@DDV_<=CINFYVL:A8TG3+4[^HY-Z%JU;@JRN7+DE"$(K
MQE*322]K)=WB?X\87QIX<U_0:3:]G8K#&YS>\W"WJ[-[=?@B^\)&2*B.=CL8
MR-E.FWHW^YH&N<GJ/D<[5MW-WWE]PMUW];O=4<"+\O&MO_%V(M]*I]W.KG<Y
M_')I/I44M\W8[M3IW9_M_B[7QU">K27G9MY?X[*FEUM/_)VTE:M+A][@I-=<
MI-Y*F/C+X (I_N2<Z3<R>2FRXNA>^9T_BETV@:W'%*CZLE_'3?\ C=E6(WK$
M^6]L398$E:JI+5IP+U^"&R?L%LZ.T^W^/DWH=.JZG3)NMKBHR7WB'MI&U25'
MRG.9I5]6G<>YO_NYEX6+<Z]!T5O"L).L7.#_ 'U<7A6=_JAU*O5;M6N/ U]N
M4S:B,;]A05?K*OV%R1O']E+%XZ;-^1.;ECC7+X_%<8XNC,O9ZL>-S%O>K>4B
M9U3U/3ELX.FKNBHG5C>OQZ=(?>K7(OPP]"PXM_59W,N<EX.4(X\8/V52N3I\
MK]YL7_L_<+$GJ&Z=0FE]>M6=/MP?"JA=EF2N)>-'*S:;\."KX&_0A6;+0  #
M2G[U6ZTZG%?#O'?JQ.R&?Y R6Z^BCVK-%3U'7+V"]62-$5\<5B?=^C%541ZQ
MN1.O:O;+#TH:3=N;CU37:/R+.%&Q7P<KUV-RGO:5CC[*JM*JL"O7IKUBSL_0
M]KU3R<G4YY5*\5'&L3M5:YI-Y7!\*]+I6CI'-5?I4G*:PT47*5YLN?L*"K\.
MH?L+D4'+T0'(BV>O[Q7P+EQ+21?J_=4'(6KU^G\B%?&AR+D6KE^/[14OCR+1
MZ_2OX?[ +ES+5Z_O!<B_W%H]?AT*G(N52U>OT_D*^XOBBU>OQ_:*EZXEH]?W
MU"YG(6KU^E?P("]<BT=^ KX%\2T>OT_C7]G[Q7W%ZYEJ]?C^T@+_  +5Z_ K
MXG(N1:/7Z0B^*+1Z_$>!>BUD7]\J7^):2+]/Y/\ 4*^*.1<BU=])7Q+XEH]?
MI_&O]L%ZYEI(OT_B0JN1>6K_ *@<G@6CE^G\97Q+XEH]?BOXD_ME2Z):/4+V
MG)XE;%Y?)X#*8W.X3(6\3FL-D:66Q&4Q\\E6_C<GCK,=RAD*5J%S9:UNG:A9
M)'(U4<Q[45%ZH<5^Q9RK$\7)A&YCW(.,XR58RC)4E%I\&FFTT^:/JQ\B_B7[
M>5BSE;R;4XSA*+I*,HM2C*+7%--)IKDSL"?;@\P:'FCXPZAR/;GJLY'UWMT?
MEW%5T;%\IO>$J55LY>"JUD20XO;L=/!E*S6(Z*'YE]9'O?6D5-5W=W8%WMWO
M/(TBVI?BB]]^Q9/C6S-ND&_&5J2=N5>+Z5.B4T;=>S'<6UW+V-CZU<<5K-G[
MQEQ7"E^"59I<*1O1<;L:<(]3A5N#,]#&!E<
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M]NUIUK/N^5J.E)K]X9[C*YUXZHNK"RXPN7++BJ6IPN6FK?PVXX5&4#!@
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M_>ED;BT"]#'E<F^JY<QKD92Q9W'S<TH7;/4ZN:LJ<I2G*3-MQ'4F,
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MCU^/[14O1:/4+FV7EJ]?X2_L_ $<BY%J\KX%\2S>O[ZE?<7KF6LB_257,O\
M8BU>H7.IR+D6CU^"_C4%\46CU^DKX%ZXLM9/J0J7FXSV1?*B7@/R\Q?&N=RO
MRG'GD;'2X\RD%B3MIUM^BEL3<999&][4^=L9FW-AF?2U6YE5<B]K5;'SU(;)
MCNC8<]8QH=6K:16_%KF[#261'Y%!*Z_VKAS=9)^F'?<MI]P;>BY5SIT?65''
MDGR5]-O&G^F<V[*_;N/)-3@S6X;/P
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M3/N'9^KX=JQ]Q;C'^]BE_<.:3KSZ0             =27YI?TQ?++^LOSO\
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MK!W_ #1O\O?_ !+$V_1Q_P!H_P#J_P#]M-8O]HY_V-_ZV_\ IA&Z)MFL8
MD"^P'<LLY3\A\>R9S:=GC_3KD]=.G9+9H[%D8:DSOAW=T$60F:G1>G21>OU=
M(>>L"W;>@:->:^^QS+R3]BE;BVOG<8_8-B_]G9>NQW;N3'4GY$].QI->#E"]
M-1?S*<E\[)0A PVN
M                  Q<\H?*_COQ@U3[RV.9N:W+*UIEU'0Z%F%N6S4Z))''
M=NJJN7$ZY!89VSW7M=]"LB9++TC7)7;;MAK_ '(U3ZOIZ\G2+4EY^3)/HMK@
MW&/W=UKZ-M->#DXQ^(P?WN[\;0[):#]=UB2R=Q7X/ZI@PDE=O2XI3GS\K'C)
M4G>:?)QMQN7*0<8_G+GKD?R%W2SNG(N9?=G1TT6$PE99(<!J^-D>US<7@<<Z
M1[*L';&SU9%5T]E[4?,][_M&QK9>R-O[#TB.CZ!94(<'<N.CNWIK[>[.E9/B
MZ+A&"=(1BN!I3[G=U-X]V]R3W)N_)=R[5JS9C56,:VW^Q6+=6HQX+JDZSN-=
M5R4I<3AD]<8Y-Y7L^\=>GC>7>6;4/5;=S#\>X2?MZ*QM&%NQ[-&KE:JO;,Z]
MB53HJ(BQKUZ]4Z0P]5^O]61I6U[;^C"YE7%^F?E67\W3>^ROGV=_V>^T.C#W
M!OV_'C<N6L"S+V*"^L9*]]>O%I3ETNM:JFZ\AX;)P 4Y98H(I)II(X888WRR
MRRO;'%%%&U7R222/5&,C8Q%55541$3JI=&,IR4()N;=$EQ;;Y)+VELYPM0=R
MXU&W%-MMT22XMMO@DEQ;9K5D]USQ=8][&U.4)6M>YK98]2Q:,D1JJB2,279H
MY$8]$ZIW-:[HOQ1%^!(>/IA[DN*;GIJ;7)WYU7NX66OL-HAC+UW]D(R<5;UR
M23YK%M4?O5<E.C]Z3]J1^OB/=)\4,E(UEW+;QK[72.8LN7TRW-&QJ-:Y)G)@
M;6;E6-RN5J(UJOZHO5J)T5?DR_35W/QXMV;6%?=*TMY$4W[OOJMJOCSI[SL=
M/]<78?-FHY-_4\1-TK=PYM)4YOR)7G1\N";JN5*-Y/\ &WD_X_<NSP4N/>6-
M0SN4M=GRN"EONPFQV>].J?+:WL$.*SL_;U1'=E=>Q51'=%5$,;[A[;[ZVK!W
MM>TO+L8T>=Q1\RTOENVG.VO=67'P,V[-[V=I]_W8XVTM>T_*SITZ;+F[.1*O
MW./?5J_*GC2VZ.B=&SG@\292 !:7\?0RM&WC,I2J9+&WZ\M2]C[]:&Y1NU9V
M+'/6MU+#)(+->:-RM>Q[5:Y%Z*G0Y;%^_BWHY&-.=O(A)2C*+<91DN*<9*C3
M3XIIU1\^5B8N=C7,+.MV[V'=@XSMSBIPG&2I*,HR3C*+7!IIIK@S0_YX>W92
MT_&9GFK@+%R1Z[1;9RF\\<UNLC,#28WU;6P:C&[NE7#5NCGVZ'5RU&?;@_B&
MK'#-7LKWZO:KD6=H;XN)Y\Z0Q\I\/-ER5J^^7F/@H7.'6^$_C:E/6#ZG_21C
M:!AY'<;M98<=(MJ5S-P(\58@N,K^*N?E1XN[8J_*7Q6OO2<+>EE5^M27)KN2
M\$4U7J*TX>)>D>B(Z1S61M<][W(QC&HKG/>Y>C6M:B*KG.5>B(GQ*<(JLN"1
MR1BVU&*;FW1)<V_83"/$GAR+@GQ]XXX_DK)7S=?"Q9O;55B,FEVW8?\ PMG6
M3N[6ND7'6;/R42N1')7K1M7Z#59W0W7+>F^<_7(RZL.5YV['L5BU\%NGLZDO
M,=.'5.3\3?IV*[?P[9]K-(VM*'3J,<=7LKA1O*O_ 'V\I<J^7*7E1;X]%N"\
M#) \ 9< !J7]W_D9VM< ZEQ[5L>E<Y*WF"2Y#W)_=6NZ75^][S.WZ5]/8+N)
M?U^A.WI]:$F?2YH*U#>V5KER-;6GX;47[+M]]$?LVHWE\Y"'UV;J>E=LL':U
MF73?U?4DYK[JQB1\V:^:_/&?S>\C9.4GXC4N^+H457ZRG-ER7@4E7ZRK]AR)
M%)5^E07KV&7O!_GCY+>/V+@US2]X;E-1J-5M+4-RH1;+A,>Q>G;%BG6'PY?$
M5FKU5(*EN"OW.5RL5R]3%N[^S>P=[9,L_5L/R]3E]*]8D[5R7OG2L)O]%.$I
M<*5H9U[>^HWNQVSPX:3H&H*]HD%\.-E05^U#W6ZM7;4?T%NY"'%OIKQ,E\C[
MQ_E/=J35ZVK<)8B:1JHR_CM4W&6W756JB/B9EN0<G1<YJKU3O@>G5/BG3JBX
M_L^EKMU9NJ<\G5[L5]K*]847\O1C0E]B2,NY/KH[PY%EVK6'M^Q<?*<,?)<E
M\BN9MR'V8LP'YH\C^:_(+)Q9/EOD#-;6VI*Z;&XAZU\;K>)>K'Q^IB];Q,%'
M"4[/H/['3M@^8E;_ +9(]?B9EVIL3:6R<=V-M85K&<E24^,KL_&D[LW*Y)5X
MJ+ETI_12(Z[[[I;^[EY<<K>FI7\Q0=86GTV[%M\JV[%M0M1E1T<U#KDOI2D<
M%JOTJ>M/!I>!1<I5^PN?L*"K]*E>2*I>!1<OTJ41RI>!;/7ZBJ]I=XEJ]WT_
MD0%]/ M7+]17P.2/M+1Z_OCW%RYEM(OQ_:0J7EH]?A^V%Q9R+@BU<OTK^ J7
MQ1:O4>\N7%U+21?I*KD<GN+5Z_O Y%RJ6KE_?*OF711:O7XK^+X?L_=*HO1:
M/7Z$_="]IR%H]?@JE3D1:O4>!=$M'K^^5+_$M9%^G\G[/W2OB<G@6KU'C4O7
M*I:.7Z?QE47Q1:O7XK^)!X%ZXLM'K\$3\/\ J%2\M7K]/Y/]0>-#DB6CE^/[
M17Q+HEH]2J]IR>):R+]/Y/V?NA<B_P!B+5ZCP.1<JEF]?WU+O$OB6SU^*_B0
M%Z*N+R^3P&6Q>=PMZSC,SA<C2R^)R5.5T-S'Y/&V8KE"]5F9T=%9J6H6R1N3
MXM<U%.*_8LY5BYCY$5/'N0<91?%2C)-2BUXIIT:]A]./D7\2_;RL:4H9-J<9
MPDG1QE%IQDGX--)I^T[)?QBYGQ_D1X]\.\VX[T6-Y(T#7MCR%6NY'18W8)Z4
M<&SX=KD^#EPNQU[51R__ "H5-0F\MO7=I[JU#;EVM</*N6XM\Y03K;G^KMN,
MOG-S^R-R6MW[1T[<UFB69B6[DDN4;CC2[#]1<4H?J3G4\R>I
M                                              !J,]XKQ9L<\^-R
M\CZMCTM\@<!OR>X5XH8FON9?0+-6/\^\3"K6>K)-0K4:^5C;W+U;CY8V-=),
MA(STU;_AM'>_XDU"?3H^KJ-EMOX89";\B;\*2<I6G^V1DVE%D-_6KVEN=P>V
M/Y3:3;Z]Q[><\E)+XKF)**^MVUXMPC"&1%5Y69QBG*:(=)LJ-*@
M          )<'LX^:GZ;N*E\?=^RRS\I<-X>NS7[EZPQ]S<.,()8J.+L-[E;
M+8R.E/EAQUI>U5=5?3D<Y\CYG)KJ]2W:_P#)7<'Y8Z/;IH&IW'YD8KX;.4TY
M27L4;])7(_HU<BDHJ*-QOHH[Y_EYM'_NXW%>ZMV:)97DRG)=63@IJ%M^USQ:
MQLSX<;;LR;E)S:W4D7B<P        !\;R-_B]WO_ ,C=H_O)>/HQ?]*M_MD?
MST<=[]BE^E?YQT\Q.XCZ          #GSQ3X_;RQY0^-_%KXFS1\D<\\0Z'+
M$]J/8^';N0->P$R2-6:LU8O2OKW=9(T[>O5S4^*=9K65]1T;+S5SLXUV?]["
M4O[A]6#:\_-LV/N[L(_9DD=N>0<,^               '4G^;$,U;S,\MZ]B
M&6O8K^3G/4,\$T;XIH9HN5-KCEAFBD1KXY8WM5'-5$5%3HI-[;S3T#!:XIX=
MG\'$P-J2:U'(3Y^?/]<S&0[@^(   [%/]6K_ -&#JW\\O+O]]L>16[M_SQG_
M  >U^<S+FS?XEC^V3_/1OX,9'J@       1</UK#^AUXZ_UEX?\ -;R 9D[+
M?Q]E?P/_ ,I \3OG^+K/[=_O9$$,DD8O   -R7ZOW_I=/$K_ "\_^[+S.>![
MG_S&SO\ B?\ 6+1Z':G\?X_ZO\',[+DB.9E
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M!?\ &_Y ?S;:S_*>0B!ZO_YMZ/\ PZ[^"-B7]G=_/3<7\EV/P[)1I @VP@
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M*_27KLM2[:W=(NNL].U"["*]EJ\HWX_9NSO?8KXF](C22B
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M_P"ET\2O\O/_ +LO,YX'N?\ S&SO^)_UBT>AVI_'^/\ J_P<SLN2(YF4
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M=#VYB8^#H]B-+=FS"-NW%>-(Q256^,I.LI2;E)MML^K.O.W
M              (W?ZP=_P T;_+W_P 2Q-OT<?\ :/\ ZO\ _;36+_:.?]C?
M^MO_ *81NB;9K&   -_GL"_XW_(#^;;6?Y3R$0/5_P#S;T?^'7?P1L2_L[OY
MZ;B_DNQ^'9*-($&V$
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MV=2OA0N1:/7Z@7^):O7X+^,KXG)[BU<OQ_:!>N1:/7]]2I?'F6LB_3^+X%?
MO\:%H]?J!R>!:N7X+^,J^9?$M7K\5_$5+D6CU^A O:<GB6CU^"_C^'[/W <A
M:O4KX%\2T>O[ZE?$O1)N_5MMMFAVKRNT5ZO?7R6 XIVRNBMZLKS8/([OA[JM
M=WHC76V;#!U16N[D@3HK>BHZ&OJ\P8RPM#U-?2A=R;3]ZG&S-?8Z)?9^Q-WT
M:9\HYVO:6_H3LXMU>YPE>@_L^9'^]\/&5H0B)W@
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MW=O^3M!VZ_LN3:C]CJG_ +SP_.J>KV9;Z]:4ON+4G^='_?'8AD63+8
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M7JR2)[F.3XHJGB;ENY9F[5V,HW8NC3333]C3XIG>QE&<5.#3B^37%,_4+"X
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MJ2(QLG&S,>&7AW(7<6Y%2A.$E*$HOBI1E%M237%--IEZ<1S@
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MRXU3V?BK_P!HLDQ$@(;#P
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M3O?P_I'<.?S)1_R[VXV">D3^9.I_RJ_P%DU%_P!H9_2;HG\A+_6\@T3DLB
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M-/ZK%8.[\6">5A2FI22X+S[$N#NX[D^GJHIVY-0N175;E<SX,0DA@
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MP
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M;M5K/9S?N7LW5JW+$'YF-?I19&+-ORKJ7A+@X7(IOHNPG%-I*3QB/=F*P
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M7=VKU;(YSU3[36HUBNCYWMO]67I^-]S;NR_OG!?[PR/L.W2SDW?;*"^PI/\
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M+)M\3>AV%VG^1?:'0M#G'HROJ,;]U-4:O93>1<C+WPE=\OY()+@D95&.C+P
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M.UH^MZW)?#>R<>Q%\/\ $PN7))/GQ\^#EX.D?829"'A-$
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M=_W%]DREL:--+NS]M]_F0A_NDF\Q >T               .I]]Q?_2#^=O\
M7)\GO\]N\$U]J?S7TW^ 8_X&!@G5_P"-LK^$7/U\C#8[\Z\   [%/]6K_P!&
M#JW\\O+O]]L>16[M_P \9_P>U^<S+FS?XEC^V3_/1OX,9'J@       1</UK
M#^AUXZ_UEX?\UO(!F3LM_'V5_ __ "D#Q.^?XNL_MW^]D00R21B\   W)?J_
M?^ET\2O\O/\ [LO,YX'N?_,;._XG_6+1Z':G\?X_ZO\ !S.RY(CF90 =27YI
M?TQ?++^LOSO_ )TMJ)O[?_B'!_@=G\'$P+J7\8W_ -NG^N9C0=N?&
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M=[<;!/2)_,G4_P"57^ LFHO^T,_I-T3^0E_K>0:)R61
M $@_V&>>+.*WOE7QRRUY?NG;,*SD[3Z\TG2*OLNNR4L+M%2FSZ7VL[@+M2P]
M/H2/#JJ=%5>L./5QM*&1I.G[UQX?OC'N_5;S2XNU<ZIVG+W6[D9Q7OO?8V._
MV?'<&[B;@U?MGF7/WGF6%G8T6^"OV7&U?C%?=7;,K<W^AQG\\GH@@;5@
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MV]+ L:/' =V?EJ>/=<E;ZGT*360DY*-%)I*KJZ'Y;O=^\KD_^IW$G_F?FO\
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M15%<$EC7?^D%-?>3\MT_^IO$'_F;F_\ "\/TO]MO\IJ=?V^W_F2Y>MCO(_\
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MJ-JGIPV^] [2Z<[D>G)SG<RY^_S94M/Y[$+3^?V&U4PF9T
M                                                  !&4]ZGP@9@
M,G_RON,\,V+#YVW4QG-N+Q\*,BQ^?MR,J87D)((F(QD&P3/92R;T[?[N6"94
M=)9GD2=7I?[J/,L?]V^NW:Y-J+E@SD^,K:59X]7XVU6=I?Y/KCP5N"-6/KE[
M#1T[*_[Y]K6$L+(G&&J6X*BA>DU&UF47!*\VK5]\/OOES:<KMR2CPDS#6T
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MG9;^/LK^!_\ E('B=\_Q=9_;O][(@ADDC%X  !N2_5^_]+IXE?Y>?_=EYG/
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M[^']([AS^9*/^7>W&P3TB?S)U/\ E5_@+)J+_M#/Z3=$_D)?ZWD&B<ED0
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M:&=_3)N">VN_6V,^#:5[4X8C\:K-C+#HUQ\;Z?N:4N%*J=::G#?X
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M)MLW+]MNVVV>UNV;6VMM6J6U25Z])+S<B[2DKMV2YM\HQ7PPC2$$DCGL\>9
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MNSN3E]U.<G*3^>3;-T&GX.+I>!8TS"CT8>/9A:MQ^YA;BH17S121]$?(?6
M
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MDOS2_IB^67]9?G?_ #I;43?V_P#Q#@_P.S^#B8%U+^,;_P"W3_7,QH.W/C
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M<QM"1TF<^TN[[L,C\E\^;E9FF[#;^C)*LK?'[623E%>$DTOI*G@-XZ+"5O\
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MA-5FW??;M6637],Q,SGKZUI[71-O9B['#(VC0C>V:U(U558X6331> [A=Q=
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MRX/ZGIL'9L-\GD7HM3:]OE6&U)<&G>@UXDPH@.;"@
M                                                :[?<K\-JWE[P
M'?J:_3@_2_QNW(;7QA=5L;9\G:951V:T66=ZL:VIN-2JR.)7.8R+(PU97N2)
MDB.S1V.[F3[<;OA<S)/\F\[IM94?"*K\%]+VV6VW1-NW*Y%+J<:1K]479*UW
MF[>7+.G0C^6FEJ>1@RX5G+I^^XK;I\.3&*C&K2C>C:G)J,9)PD+=2U0M6:-Z
MM8I7J5B:I<IVX9*UJI:K2.AL5K->9K)H+$$S%8]CT1S7(J*B*AM+MW+=ZW&[
M:DI6I).,DTTTU5--<&FN*:X-&B2]9O8]Z>/D0E;OVY.,HR3C*,HNCC).C333
M3354^#+<O.,                $X#VNN=G<]>&?%V5R%SYO:./:TO$NV/?,
MEB=<CHT-2IAK-J54;+);R>G6<9;F<].]TT[U57_PW:K>_>TUM'N;GX]F/3@9
MDEEV>%%TWVW-)<DHWE=@DN%(K@N2WR>E#N ^X79'2<O)GUZKIL7I^1QJ^O%4
M8VY2?-RN8TK%R3?%RFZM\WL),-DCP    =?K^M$:4FN>X;I.T0QN^7Y!\9M
MS-B?[2-=EL'NW)6J6:Z(^U.JN@Q6%HO5S60QKZR(C7/1[W2>[.9'F[6N67SM
M9DU\SA;E^>W[>1BG>UOHU>,URG9B_G3DOSDB-\98/'@        '9#?JZ?\
MHIN#_P#RRYK_ ,[&V$3NZO\ /7)_:[7X*)F#:/\ $5K]-/\ 7LWBF.CTP
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M;@_S),Q3WUQK>5V5W;:NUZ5MS49_/;Q+MR/^%%5]WL("IMZ/SQ   ')'#?\
MC?XJ_G(T;^4^+.DW-_-O4/X#?_!3/3[)_GGI'\IXOX>V=B":9#])@
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M:^&QR-D7.?VK%3TQL;V)VJOJ.7(9>A$K.J=/LN5W5?HZ=5,F6O3-W-N2:G'
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M?P0?/RX07@9=GA#(
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M%-P?_P"67-?^=C;")W=7^>N3^UVOP43,&T?XBM?II_KV;Q3'1Z8
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MK5N^$M5O1K^*]'R;\'[+ER5K$5/8W;R+OS)DP UNFY\      ZW8W;'YC
M  =B!PU_B@XJ_FVT;^3&+-,FYOYR:A_#K_X69^DS9'\R](_DO%_ 6SDDZ0].
M13O?P_I'<.?S)1_R[VXV">D3^9.I_P JO\!9-1?]H9_2;HG\A+_6\@T3DLB
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M6G='7=R0DIV,C4+D;4N=;%FEC'?[C;M^[V<#&]SCV_N7(QLD6[W?4G[J@O\
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MPN9#5)W>/.-B+I%T_99)IJ5IHEZ$#38(
M                                          #CSEGB[3^:N-MSXIW[
M')E=1WG!V\%F:J*C)F13HV2M?I3*UWRV3Q5Z**U4F1%=#9ACD3XM0[G;NO:E
MM?6\7<&CS\O4L2ZKD'X57!QDO&,XMPG'[:,FO$\WO#:FB[YVQG;1W%:\[1L_
M'E:NQY.CXQG%_:SMS4;EN7.,XQDN*(&'DMX_[CXQ<T;KPUNS%ER&KY%WW7F6
M5WUZ6T:U<ZV-?V;',>Z1$JY?'.:]T:/>M>=)('N]2)Z)MPV-O#3-][8Q=S:6
MZ6<B'QPK65J['A<M2Y<82JJT75'IFE22/SX=T>W6M=JM\9VR-=5<G$N_>[B3
M4;]B7Q6;\%Q^&Y"C:J^B75;;ZH,X(/6F/P              #('Q3Y@EX#\C
MN&N76RR14]+WO#7<[Z+_ $Y9M5ORNPVX5(W]'=KKVK9*Y#U5%3^,^**GP/']
MP=MQW?LG4]N-)W,K$G&W7DKL5UV7^INQA+YC(W:+>D^WG<W1-YIM6<'4+4KM
M.#>/-^5DQ3_16)W(_/R9V L4L<\<<T,C)H9F,EBEB>V2.6.1J/9)&]BJU['M
M5%14545%-/4HRC)QDFI)T:?-/V,_17"<;D5.#4H254UQ33Y-/Q3/<H7   $:
MK]:/XY_.?P(XXWZO"K[W&/D9J<]J;MB5L.N[AIV\:]D&JKF>LUTN?7$].UZ-
M5$7N:Y>US,M]F\OR=S7<9_1O8DJ?IHSA)?X/4>-WO9Z]*A=7.%Y?8:DOSZ$
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M^*OYR-&_E/BSI-S?S;U#^ W_ ,%,]/LG^>>D?RGB_A[9V()ID/TF
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M]H&F;7T3&V]HUORM,Q+2MVX^-%SE)_;3G)N<Y<Y3DY/BSDDZ@[D
M
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M?\4'D!_.1K/\F)"!/J__ )R:/_ ;OX5&V#^SN_F9N/\ E.Q^ 9O\(?FQ,
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MR<8QV7&'S-
M                         !"M]U+Q#3Q;\B[^5U;&?)\1\PNR6YZ&VO V
M+'X+)+9C=N&D0)&R.&*/7LG=CGJ1,:C8L9>JQ]7/CD4V@^G_ +C_ )?;+ACZ
MA<ZMQZ;TV<BKK*Y&C\F^ZU;=R,7&;;J[L+DN":1HT]6_9E=INY=S+TFUT;.U
MISR<2BI"U/J7UG%5$DE9G)2MQ2I&Q=M1JW&3-9!G4BN               2D
MO8/Y/^]^(>;.(K5KOL:1O>&W;&5Y7?;;B]\PSL7:BJ]5ZNK5<GI;I'HB=&26
M^J_[8A ?U=Z#]6W'I>X[<:0RL2=B37W>//K3?O<;]%[5#W&V/^SSW5]<V9KN
MS;LZW,#4+>5!/GY>7:\N2C^AC/&;:7*5RK^D;]R()L0   /@.5]!QW*W%O)7
M%V7[/NGDG0-QT'*>JSOC^[MQUW(Z[=]1G1>]GRV1=U3ZT/JPLF6%FV<R'T[-
MV$U\L9*2_..*_:5^Q.Q+Z,X.+^=4.H'SF%R>MYO,:[FJDM#,X#*9#"Y:C,U6
MS4LGB[<U&_4E:O16RU[4#V.3ZE0G3;N0O6XW;;K;E%-/VIJJ?V"/\HRA)PEP
MDG1_*C\LO*        GC_JJ6P)9\*_('5?4J*N&\HLGL"Q,5WSS$V7B?C#')
M)91958E25=35(>C&KWLEZN=\$;&OO3:IN#%O<?BPU'W?#<N/[/Q<?F,H;&G7
M3;MOV7V_LQC_ +A*$,.GM@              "$#^M6^/4^"YH\<O)_&47_=7
M(>AYGB#:K<+?[GK[+Q[E9MEUJ6ZYS_\ OS/8#<K447:G18L,[KT5$ZR([+:H
MKFGY>CS?QVKJNQ7Z&:Z94]RE%-^^9C3?.)TY-G-BOAG%P?RQ=5]E-_8(F1FX
M\(   <G<+<Q<@^/O*^@<U\59V;6N0N--FQVU:MF(4[V0Y#'2]SJUVNKFLOXG
M)U725;M63K%:J320R(K'N1?CU# Q=4PKNGYL>O%O0<9+W/V>QKFGX-)HYL;(
MNXE^&38=+L))I_\ AX/DUXH[-KVV/<OX0]QOA['[7I63QVN<PZ[A\>O,7"]F
M]W[!HV:D7Y6QD,:RPV&?/Z+E+L:OQV4A:YBQR,AL)#;;) R(.[=HZCM3/=C(
M3G@3D_*NT^&:YT?W,TOI1?RJL:,S1HVLXVL8ZG;:60E\</&+]WMB_!_9H^!L
MC/)G<     TD^\-[NO'GM^<6YWC[C[/8;9_+S=<&ZKHFDUY8;Z\;T\U5LQ0<
MI;W7]&U4IT\0U/7QF-LHDV7M>FB1_*)8FCR'L38V5N?-CE9490T*W*LY\O,:
M_P 7#DVWRE)<(JO'JHGYK<.OV=)L.U9:EJ$E\,?N:_;2^3P3YOW59UO>8S&5
MV'+Y3/Y[)7LSG,YD;V8S.8REJ:]DLKE<G9ENY')9&[9?)8N7KUR=\LTLCG/D
MD<KG*JJJDL+=N%J$;5I*-N*227!)+@DEX)+D8?E*4Y.4FW)NK;YMGYQ>4
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M?SD:-_*?%G2;F_FWJ'\!O_@IGI]D_P \](_E/%_#VSL033(?I,
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M6_;KCV9+CBVIKZ<EX7[D71KG:@^ETG.<8R"2+!+0
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M4*_5H\>7G=4LAM<)0N6:JL#<81J)K$;O]8._YHW^7O\ XEB;?HX_[1_]7_\
MMIK%_M'/^QO_ %M_],(W1-LUC   &_SV!?\ &_Y ?S;:S_*>0B!ZO_YMZ/\
MPZ[^"-B7]G=_/3<7\EV/P[)1I @VP@     '6[&[8_,8    #L0.&O\ %!Q5
M_-MHW\F,6:9-S?SDU#^'7_PLS])FR/YEZ1_)>+^ MG))TAZ<BG>_A_2.X<_F
M2C_EWMQL$](G\R=3_E5_@+)J+_M#/Z3=$_D)?ZWD&B<ED0    )1OL"_XH/(
M#^<C6?Y,2$"?5_\ SDT?^ W?PJ-L']G=_,S<?\IV/P#-_A#\V)@    QN\R?
MZ(/E7_5NYR_S8;0>W[9_TD;?_EO!_P!:M&,>]O\ 0SN[_P##&J_ZC?( YM_/
MSM   ')'#?\ C?XJ_G(T;^4^+.DW-_-O4/X#?_!3/3[)_GGI'\IXOX>V=B":
M9#])@             -/'O.89T_ W%^P-8KDQ/+46*>Y'.^PS.:ALMGN<Q&J
MWL63!-3N54[55$3KW?"4?I3RU;WEJ.$_\;ICG^YW[2_\H^'S^!!GUYX#N]N-
M(U.G[#K:MOW*]C7Y<O96RE5\G1>)&^[T)XFJJGL//<@%&>>J?A3\I4I1GGJO
MX04'5?PJ!1&R7VJ^-?S]\L,%G[5?U\5Q=K>?W>SZC6K7=D7UV:S@HWJJ=?7@
MR6?;<A1JHO?3Z_0U47 GJ/U_\2]M;V%;ETY.HY%O'5.?37S;C^1QM]$O=.G-
MHE;Z-=HK<G>G&U.]#JP]'Q+V7*OT>MQ5BRG[U<O*[&G&MJO)-$J URFY
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MAD7E]URE9MOZ/"Y+XNE1D^D,R;P
M                                              (87NY^,K?'[RIS
M.S8'',I<>\YLN<B:RRNQ&5:&Q23Q1\@X*-J(QD:UMAM)?9'&UL4%3*01-_@+
MTV<^G/?3WCV_M8.9-SUG27'&NUYRMI/ZO<?RVUY;;=93M3D^9H_]9/:Q=N>[
M=_5=/M*WMO7U+,L45(PO-I9EI>"Z;TO.44E&-N_;@OHLU9F?2)@
M    ,E?#?D).*O*OQ]WR2RM2C@^5]-9F;".<Q8M=R^8KX/9%ZM^*HN R5E%3
MZ'(O1?@IX?N7HWY0=O\ 6=(C'JNW=/O="]MR$'<M?\I&)E#LGN3\D>[FW-PR
MET6,?6,;S)>RS<N1M7_^1G/Y>1/T-0)^B,    $"G]:8X5_,SS,X>YKI5O0Q
MG-O"D6(OR^ET^<W+B?8+6+R]CUVM:R3LU':-?B[%[GL]+JJ]KV-;);LUJ'UC
M0+^GR=9X^15>Z%R*:_PHS9BW>^-Y>HV\E?1NVZ?/%T?YCB1BC,!XL
M$K_]5!VYM+R&\L-#61J/V3AG3-N;%T3N>W2=W?AG2([UFJC8EY 1%3TW=>]/
MM-Z='X3[UV.K2\+)^XR)Q_OX5_WA[K8ERF7?M?=6T_[V5/\ ?$XPCJ9,
M            ! V_6*_; R/!?+&3\XN'-??)PMS1L'K<PXW$T^L'&?,&9L(M
MC8;<5>)J5-6Y4ORK82P[N9#L#[$4CV?.T8G24[5;QAJ6$MNY\_\ WACQ^]-O
M]DM+[5>V5M<*>,*-?1DS%V[M$>+?>IXZ_>UQ_'3[6;\?DE^NK[41?3,1XH
M              $TO]6V]L#(ZO7@]PSF_7WT<IG,3?Q'C'K>7I^G<J:]F:DN
M/V+F26O8B]:M^<N,L2XS OZL=+C9KEKM?!:I3+'[NSO&%Y_DMITZPC)/(DGP
M<DZQM?J7\4_T2BN<9(R-L[1'!?C;)5)-4MI^Q\Y_.N$?=5\FF3 #!1D    Z
MDOS2_IB^67]9?G?_ #I;43?V_P#Q#@_P.S^#B8%U+^,;_P"W3_7,QH.W/C
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M%3DKF^Q_<\DV*SERBV'7N/8K-=TK9*/'N$D2M)TEFBDRT]^>)R13M:V(>_\
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M7V3L:K>U[ S\O5M1G9C&5A6>F%FRIOI;N78/JE.XW*BI2,>/@MBW_70<$?\
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MNX]NY=\A0MN]!VY3;A>E*L8RDXTB_B2\"/,Y_P#K$T>7+F:ZDJE!SNGQ7]Q
M7)4)*6M^]?X]:]KFOX"/B/E]L>$PF*Q$;86::Z)&8VC!2:D2R[5ZBQHV#[*N
M^TJ?3\2#&=Z6=YYN;>S):EIM;MV<^/GU^*3EQI:I7CX&S32_6SV\T_3<?3XZ
M1K'38L6[:HL:GP14>%;]:<.%>/M/V%]\GQ\3_>DYD_W/2?\ "H^1>E#>3_\
MB.F?9O\ ^:/O_KR=O?\ 9&L_8QO\^>B^^9X]I_O1\R_[GI'^%8_JH;R_VCIG
MV;_^:*_UX^WS_P#A&L_8QO\ /GHOOH>/2?[T?,O^YZ1_A65_JH;R_P!I:9_R
M_P#FBO\ 7C[??[(UG[&-_GST7WT_'E/]Z+F;_<](_P *Q_50WE_M+3/LW_\
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MQMV9+X/I7%UTC"3L0T)O
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M*<DN/M/P7-<URM<BM<U5:YKD5'-<B]%147XHJ*?6FFJKD? TTZ/F> 4
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MM1-_;_\ $.#_  .S^#B8%U+^,;_[=/\ 7,QH.W/C               )GOL
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M
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M[:KMQWDSUA6^C0-7_?\ C47PI7Y2\^VO!>7D*YTQ7T;4K7!)HUQ&:R,H
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M5Q7;4G&[%IIIM--<FFN*:\&BV48SBX32<&J-/BFO8T1/?<2_5F].WVYGN5O
M?.XOC78[+;.1R'CYN%JRG'V5NK_&R,X[VZ1UF]H\MES7=F-R#+>,6:5&QV,?
M78D:9LVKW=R,:,<+<T97K2X*_'Z:7Z./*?Z:-)4YJ3XGA-7V9;NMW]*:A/\
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M+IBU!;23"AG4
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MC;&%G2=;KLJ,W^CM_!)OY91;^<P=KF)]2U:_CI4@IMK]++XE]A.A@(>G.J
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MT?\ 5%^WG_T?/^%?F_\ ]I0_K&=Y?]L_^J8/_1A_4V]-W_VY_P#,-4_Z:/\
MJB_;S_Z/G_"OS?\ ^TH?UC.\O^V?_5,'_HP_J;>F[_[<_P#F&J?]-.?^ ?"[
MQH\7<QL&>X*XV_,;+;3C:V(SMO\ /'?MF^>QU.TMVM7]#<-JV"M5].RO=WPL
MC>OT*Y4^!X_>'<_?._<:SA[LSOK>/CS<[:\G'M=,I+I;K9M6VZKA23:]QD7M
MWV.[6]I\W)U'8&E_4,S+M1MW9?6<N_UPC+JBJ9.1>C&DN-8I-\FZ&49X$RP
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M]D8KX81C!**R$/*'KP
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M(0HW5A_4-R9V(E2,,JY3]*Y-Q_P6C.ND7OK&EX][Q=F-?E22?YJ9F2= =B
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MCTO4]1R\I<$FTIQQ4WPKQ^J\&ZMQHT^GI-L9'DF
M
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M!)+@DN"1<EA>
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M%D6;5S_!\M_9=M_.9>V??\[1(0\;<Y1_-ZOSI&^$QL>H
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M,U*WIN!9L.2Y3G""5RYR7[)<ZIO@N,N2.6SSI[$
M
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M452W%M]$(IT,E3QQ[<
M                                                   CT>_KQ/\
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MPN?3PBI;M_E'V%N27QYVV-PQ?+C'#UBQTTKXPMY> N''IGE/BNM)X>&23"P
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M^S6?V#WVQ,E=.1B/G6,U^ME_O28J8',A
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M-D>M3U!W=:O:5I<\"]>5^Y"W;A@J<Y*,I<%&+<I-1571<DV?O_\ 6D>Z)_\
M:1_P!Y?_ .ECX_\ N#["_P#I7_S"'^Z=C_6Q]5__ *!_\IN?^*<J<$>^KROA
M=MQ^!\F>.-6S6IR6Z]#,;%HF-RNL[IKK>K8;>4M8+(Y3)X?8/EU;WOIQ,QDG
MQ<K9%Z-B7S^[?2=M[*TZ>7L7-R+6HJ+E"W?E"[8N>*BKD8QG;KR4V[JY57.1
MZWM_Z_=WX.L6]/[I:9B7]'<XPN7L2%RQDV?"4Y6ISN6[U.;MQ5A\Z2=% DR:
MOL^O[KK6 W'5,M4SNL;3AL;L.O9J@]9*65PN8IPW\;D*KU:URP6Z<['MZHCD
M1WQ1%ZH08S\#,TO.O:;J%N5G/Q[LK=R$N$H3@W&47[TTT;2])U73M=TO'UK2
M+T,C2LNQ"]9NP=8W+5R*G"<7[)1::KQX\41W/,7W?^<\#Y![5P5XLZGK5JKI
MNT6M!DS.0UK*;IMVX[MB,A)C,U6US$5+L-&+&19:&2E7B;5N6+:Q+.R5K961
MLF?VT]-^U,O9V/NS?^1?C<R<=9'1&[&Q9LV)QZH.Y-Q<G)P:G)N<(PKT.+<7
M)ZU^]?K/W]I_<;+V!VEP\6=G!RY8CNSL7,G(R<JW-PNQLVXR4%;5Q.U"*MW)
MW.GS%-*:C'9W[=?,_E%S1Q?NF5\K=!R?'V\X#>EPF%Q^8XZV#C6_DM<?K^'R
M462EPVP,AEM([(79XFSPQQPJD?;T5S7*N".]&V-A;8U[%Q^WV9;S-*O8G7.4
M,FWDQC<\R<7%3MU2^&,7TR;?&O)HE5Z:M[]V-\;3SLSN]IUW3M?Q]0\JU"YA
MWL*<[/DVYJ;M7DG+XY2BIQ2CPI2J;-?/MS>X)Y?>1GDMB^-.9JV&BTFUJ&V9
MB=U+CUVN3_>.)J02X]$R:KT:U9)%ZL_V9F/O5V=[;[*V-<US;$KKU6.39@NK
M(\Q=,VU+X?[O@1R],_J,[S]R^Z-K:^]XV%H,\+(N/IP_)?7;BG#X_E?+Q)!A
M#DV-@              $2#<_=_\ .BGR?N.D:I<TG)?=N[;-KV"QE/C6OE,I
M9KXO-7Z5.".&O/)9N64K5DZ]K5<Y45>AL6TSTW=I[N@XVJZA'*AUXMJY<D\E
MP@G.$92;;2455^TTY:YZS^_UC=>;H6D3P+OE9]^S:A'"C<N2C;NSC%))N4I=
M,?!5?,\7?=6]S;&U9;V1U2K0I5T:Z>Y=X+R-6K"U[VQM66Q/#'%&CI'HU.JI
MU543Z5%KT_=BK]Q6K.1*=U\E'/BV_D2=64O^KGU48MIW\G$A;L1YREI4XQ7&
MG%M)+CPX^)S'P+[\?(E'/4,9Y'<9ZML&J6)XH+>T\8U\A@=HQ$+W(DF0FP&9
MS.6PVQ^E_P#@(9<6O;\4<YR=KO-;N]).BW<2=_9.=D6=0BFU:RG&Y:F_"*N0
MA"=NOW35WCX)<5[;M[_:"[EQ]0MXO<W2L3)TB4DI7\%3M7[:?.;M7;ERU>I]
MS&5CAQJVJ.29Q]R!IW*FEZWR)Q]GZ&T:9MN,AR^ SN->Y]6]2F5S%ZLD;'/6
MM5IXWPV()6,GK6(WQ2L9(QS4A!K&CZGM_5+^BZQ9GCZGC7'"Y;ESC)?)P::I
M*,DW&46I1;BTS9]MS<6B;MT/%W)MS(MY>B9EI7+-V#^&<7P\:.,HM.,X22E"
M:E":4HM+1Y[EGGQY:^-7D32X[X2KX>739^.-9V.5U[0';--]]9/*;'5O(F11
M>C6)!C8>D?\ L5ZK]9*OL=VA[=;XV7+6MTRN+4UFW;:Z<CRET1A;<?A^64N/
MC\Q OU1>H;O%VO[E6]M;$C9>B2TRQ>?7B>>_-G<O1E\?LI"/P^'SF\3CW,9'
M8=!T?/YA&IE\YI^LYC*(R'Y=B9')X6E=O(RO_P!P:EF=W1G^Q3X?414UG&L8
M>L9>'C?Z-:R;L(<:_#&<HQX^/!+CXD]-MYN3J6W<#4<VGUS(PK%RY1=*ZYVH
MREP\/B;X>'(^P.M.Z   (^>C^X)Y?9SW$[OCOE*V&3AN'R/Y"XXBE9QZZ"[^
M9>O;3LN+P[EV/KT=.M#&0=UG_NB]7?[(F-JO9WMOB]EX[SQY7?RF>B8^2U]8
MK'S[EJU.?WOV=4I?#X<O UR:#ZC.\^?ZE+G;7+C8_(F.Y\S"3^ITE]6LW[]N
MW]^]O1"-9^//Q)!A#DV-@  ''',>QYK3N(N5-NUM&.V+5>.-XV/ I+6^<C7-
M8/6,ID\6DE/_ .BV+>JQ]8_^Z)]GZSN]M86+J>X]/T[.K]2R,VQ;N4?2^BY=
MC&?'P^%OCX<SS.]=3SM%V;J^LZ93\98FF95ZU6/4O-M6+D[=8_;+KBOA\>1J
M"]KKSA\I/*+EWD'4>=H,5%KNO\</V/#K0T9VK2+FDV? XQ$?<5?[H9\C?E_B
M_P /VOJ)(=^^U6P=A;<P]1VD[CS;V;Y<^J_YJZ/*N2Y>'Q17'YB&/I/[\]V>
MZ^\M2T;N!&RM-QM,\ZWT8OD/S?/M0XR\5T3E\/S^!O$(J$]
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MNQ.W*MYT;7XQW'"C^M9$4W"7ML6OBA9]TDY75Q7FM.ALX,,&=
M
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M5NXTX7E^I?3+[$)R?S';;3ROJVM6XOA&[&4'\ZJO\)([),B:9B
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MIF],:SYKM*YYEG(M)J,IV)-1FI0<H]=F2;49*49W$I]&T<P(2P
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M2&6_/41OC>'7AZ;/\5:+*J\NQ)^;*/LN9%(S?#@U;5J+7"49<R=7;OTR]O\
M9/EYVJP_'&NQH_,R(KR82]MK&K*"XT:=UW9IJL91Y&W1C&1,9'&QL<<;6LCC
M8U&,8QB(UC&,:B-:UK4Z(B?!$,"-N3ZI<6R1B2BE&*I%'L4*@
M
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MJGQ(-Y>-=P\J[AWU2]:N2A)>R46XO\U&?;-V%^U&];XVYQ4E\C54?9'SG(
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M&&3.@
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M3G%_8=/U)OQ,9GJ@
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MD5J*K6)+KE+#.3X(Y?K^':3_ /2UH/XOV/DZY-4O:AF.C]MK'7EQ^Q=E>_\
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MOS<KLUXTE-I/DD9"GDCV@
M
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M-A]-/M>F[7XDO"496J3]T[7B=KL>]&$KMCA6XJU\:P\'[FIUC\DR9Z8!,B@
M
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MU+D2:VEZ+]2O.%_>VK6K%OF[.'%W)M>QWKJA"$EXTLW57DVN)N1X+]L?PKX
M6E=U;A?!;5LU/T7MW'D__P#Z#L'S5?HL5^I%GF3:_@KS7)U]3&4*/Q^/0CKN
MCO5W(W9U6\[4KMC"E7[SC?>+='SB^BER<?=<G,E#M'L'VJV9T7=.TJSD9\:?
M?\K]\W*KE)*Y6W;E[[5NV9\-:UK4:U$:UJ(UK6HB-:U$Z(B(GP1$0Q4VVZOF
M9C225%R/(
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MD_EVG";S%=M/Z-R/4O=)-*5/=\4'['<B_ [#$BV9:
M
M
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M<NKYII&4YX8R(
M
M        #A?R1PC-E\=^>]<>V)[,_P +\I81[9I)H87,RNCYVBYLLM=%L11*
MD_1SF?;:GQ;\>AZ?9&4\'>>D9JK6SJF+/@DW\%^W+@GP;X<GP]IX?N=@K5.V
MNX=,DDXY&AY]IU;2^^8MV'%KBEQXM<5X<2.?[!&=?7YNYWUE'=(\OQ7ALZ]G
M?&G<_7-MIX^-WIJU97=C=I<G<CD:WNZ*BJK>DU/5]B*>UM)SOMK>H3M_NEER
MY\O\4O[G)FM#^SOU"5O?>X-*K\-[2+=VE5SLY$8+ASX>>^*=%7C6JIKPR5"+
M7Z'N%Z.[Y5L>"SF(M5H(+%A49:U3R1PFJ1RU6R21NLTH:6T3L5TL:N19(UZM
M5>CLS6+TLR]LW55U5O6IIMI<KNFSNM.E:2<K47P=.#Y^$;<G'AIV/W(T%]"C
MCY%N44F_I8^M6L=.-6NJ*C?FJRBW\47P?/<U[-/'6@\Z>$?.G#O*FKXS;]&R
M?.61M7\1D%G;(LM[0^/?0M5;5:>&YB[F/LX5DU6S6?%/%-W.:_J1D]3.M:OM
M/NGI.Y=OY%S&U6WI,5&<:<HY&15---2C)3<9QDG%JB:)N^B3;6WM_P#8C7]E
M;MQ+6;H%W7YRG;G6M98F'2491:E;E"5I2MS@XSC*K4C19YM<"8GQC\HN6>%-
M?OW\GKFI9;#V=<NY-S9<@_ ;3K&$V_$U;MB.O4BN7,73SS:DTS(F,EF@<Y&I
MUZ)+'M;N_(WWL+3MT9D(6\W)MS5R,>$?,M79V9N*JVHRE;<XQ;;49)5(!]]N
MWF'VK[KZQL73KER[IF'>MRLRGQGY5^Q:R;<9248J4K<;JMRDHI2E!M)<C%8]
M^8D    !)-_5^,"C:OE)M$D:*LUCB+ TY>LZ+&E>/D3(9.-4^%9Z2K:J*B_:
M>SL_V*.^U"'UB9=;F@8$7RCF7)+AXO&C'W\*3]SKXTX;/O[.?3TK.[-5DN+E
MIUJ+X\*+,G-?<NO5;]K5/!/C(\(3FS4         ZS[WYO'QOC[[FO/4-"@V
MAK?,LN&Y^UI&QI$VRWDJ">;<K;6M56]LG*&+SS45.G7L^A%^!+KMKJGXTVAC
M.3K>QZV9?\7]!?N;@8:W3B?5-:NT5(7*7%^JY_X2D:=3WAYX   EH?J]&$UC
MR!\>O,WPHW>>%NE>1''6TT5@2*.>77MKUBK0Q-_<6(Z5K?OS-8KE?"S8N%R,
M?W:-/-$Z1(YO0PCW1N7M+U33]PXZ?UC%NQ?Z:,JM0^1.W-2?_#).E57WFTHP
MR\3)TV[^QWH/YFN%?E:DJ?I&_;36S[8_*W(WM9>Z%J.#YRH2Z)A[FR6?'7GN
MO?F[\=B]<WNQC%HYNU<KO=%'1UO9ZF)S4CW,65*E*>)8V2I(UGK=X86)O/9T
M[FG/S;B@K]FG-RA6JI[91<H?*TZTI7IM%OWM#UN,<I=,:^7/W*5./S.C^1,[
M*$B49C
M
M
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M=S_",FFM:UJ-:B-:U$:UK41&M:B=$1$3X(B(>);;=7S,@I)*BY'D
M
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M,E**]R1ZK;NH?C'2K=V3K>A\$OECX_.J/YS:H>+.\
M
M
M                                               . >:/%O@'R'GP
M]OF?C/"[Y;P%:>GA;62LYBG9QM6U,RQ9@JV,1DL=-''8FB:YZ=WV^U.O5$0]
M=MG?N[]FPN6]LYUW$MWI)S45!J32HFU.,DVDW3V5/";Q[9;$W_<M7=X:;9SK
MMB+C;E-W(RA&33:B[<X-)M)OCQHJF(>;]G[P2RR_W#QILNM?&->F$Y*WN=/L
M(Y')_P",>=SZ])5<BN^OJB=O1.J+D;%]1W=C'_9<ZQ?_ $^-87X.W;Y?_KJ8
MGS?27V0ROV'3<C'Y?L>9DO\ "W;O/Q_,H<2Y3V./$*]T6EMW/&%<ULJ(VCN&
MEV(7O?T6-TS,KQUD)7-A5/@C)(U5%7JO7HJ>AL>JCN-:X7<?2;JX?2LWD_FZ
M,B*X^],\MD^BOM/?XV<O7++H_HW\=KW5Z\23X>YHX[R'L.<&2I%]U\V\LTG(
MK_66_0T_)-D:J-[$B;6Q.)6)6JB]557]>J?!.GQ[BSZL=U1;\_2]/E[.F5Z/
MV:SG7\PZ&_Z']DR2^JZSJD'X]4;$Z^RE(0I^:?)7?8.T62=SL?Y(;;5JJC>R
M&YQYA[]AJHU$>KK,.SXZ-Z.=U5$2)O1/AU7Z3L;7JVU50I>T7'E<]L<B<5]A
MVI/\TZN]Z&M$E-NQN'*C:]DL6W)_95Z"_P %?.67_4$ZBOT^3.R?^K#&?X:G
M)_6WU#_8=G_G4O\ ,''_ %&=*_\ N/(_YG#_ *0>%]@?45_YS.R?^K#&?X:C
M^MQJ/AH=G_G4O\P%Z&M*7_:/(_YG#_I![1>P/I:31+/Y+;1)721BSQP\:XF"
M:2%'(LK(IW[?89#(]G5&O6.1&K\5:[Z%MEZM]3<7TZ)84Z<&\F;5?"J\E57N
MJJ^U%\/0YI"FG<W%DN%55+$@FUXI-WVD_>TZ>QGU%'V$.$HYU=D^=>5+=?L<
MB14<1J6.G]55;VO6Q8I92-6(G7JWTNJJJ?:3I\?@N^K/=#A2QI6!&=><IW9*
MGR*4?LU^8[2SZ(=G1G7)UK4YVZ<HPL1=?E<9\/=3YS[G%>Q%XEU/EY,KR%S_
M )>>-9%L1ILV@8_'V4<LB1M^7@XUDO0I&QS>O;:ZN>WK\&KVG59'JL[@W.I6
M,/2+<7R?E9$I+V\7D]+_ +WE[^)W>+Z*^U]KI>3GZY=FJU7G8T8OG3@L1R5%
M3[?BU7EP.3<-[+/@SC&M2]K7(>QJV%\2NS/(F7@5[W2-D2P[\WHL"U)F-3L1
M$1(^U5ZM5W1R=%D^I?NG??WJ_AV56OP8\'X<OOCN</'VU\:<#TF)Z1>S6,J7
ML?/O\*??,J:KQK7[TK?%<O93PKQ.9\#[7'@1KB]<?XY:U87J]?\ P]L>_;4G
MVUC5WV=GVW,-Z)Z:=$Z=&]5Z=.YW7S67WU[L9G[-K-^/[7;L6OP5J'M_\*(]
M;A>F_LEI[K8T#'E^V7<F][/\M>G[/FXTYLYYUKQ,\6].]-VL>.?!^%GB7JVY
M2XLTEF154DED:LF3=A79"98W3.[.^5W8U>UO1$1#RF;W WUJ55G:SJEV+\)9
M5[I\.4>OI7+C1<>;XGMM/[8]N-*H].T#1[,U]M'#QU+FWQGY?4Z5=*O@N"X'
M.N.QF-Q%6.CB<?1Q=*+_ &JGCJD%*K'\$3^+KUHXH6?!$^A$^@\K>OWLBX[N
M1.4[KYN3<F_G=6>SL8^/BVU9QH0MV5RC&*BE\B22+XXCF
M
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M\4%<@O\ )R<N!YK:.0\?4[N%;3>+>AYD?&B7%5^:73)_=)(FJD?3(X
M
M
M
M
M
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M
M
M
M
M
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MA<BW]+JEXQ:7%HOF8UJ6F7GU.S^QR^[M2^@U^E^BTN5%[4;3#QAW@
M
M
M
M
M
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M?7QJ;5/0[H/XG[!8>:X],M3U#,RGPHW2XL1/V\8XJHWS5&N%#01[P.59DO<
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MJ+W+V?F+[!^B6%0
M
M
M
M
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MD?%)\)*O'I:9D"=6?4
M
M
M
M
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MG0_4.EV*Y*/G29DVZ_JV;&]_B+U(2]TU]!_JE6#]K\M&8QT)V
M
M
M
M
M
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M"OSO6G"]_I-N71/],OME[IIJ:]TDC)$ZD^P
M
M
M
M
M
M         'R6_P"ZX3C?1=RY"V6?Y;7M&U;/[=G)^J=T>*UW%VLO?<Q%_A2_
M+5'(UOTN=T1/BIV.CZ7E:WJV-HV"NK-R\BW9@O;.Y-0C\U6J^XZ?<6N8&V-
MSMR:I+ITW Q+V1=?LMV;<KDZ>_IBZ+Q? B6<<<,<K\N^'GG!Y>2ZKL.U<B>2
M&^:KH.G8K5\9F,MG+E'*\[Z7O')&0Q=#&PV[5[#Y+8:=+$PL8U.WY&S&[[/1
MJ[$=;W/M[;G<K:O;B.19Q]%T3$NY%Z=V4(6XRA@7[&-&4I-*,XVY3O-M\>N#
M7'BM/&V=D;OWEV6W[WFGB9.7N7<^H8^)C6[$+ER[*-S5<;*S9VX04I3MSO1M
M8\4EP\J[%\*)\E^W=P99RWN'8+5M@2&3$^%W&=NMG8/F(K.,QO(F*JR8O:\/
M\^R18IDQG-6_9_(5Y(U:UWR'5?LHY'='WGW7#'[,W=0PZK)W/G)VW1J4L:;Z
M[4^FE5U86/CVY)U:\SVTIZGTU[!NYGJ2Q])U&CP]CZ7*-U54H0S+<7;R+?6G
M1]&IY>7>@U1/RJOA6N1'M.V'<[^<_FOY0N1;&-G?E\=@Y9D5?EZ/)N_V\Q@(
M8%5J(K\?K''[:_=_"2-_1?X9XOU#06TNU&UMA+X;Z4)7$O&6+CJ%QO\ 37<A
MR]E5[C)/H_NON!W]WUW7?Q8LG<A:;^UAG9<KEE+WPL8:A7FHOC](^_\ ?HY?
M;@>&^).$Z-EK;_(6Z7=TS44;U69-=T.@E2I6LQI\&ULEGMFAFC5?BZ3'+T_@
MN.H](^VWE[FU'=-V/WG"Q8V8-\O,R)5;7OC;M-/W7./-'HO[0C>:T_9.C[%L
M22R-2SI9-U)\?)Q(=,8R7W,[M^,E[79=.3(Y/CMQU)RYSUPUQDV!+$6\\F:7
MK=YCDZQLQ.2V"A!F;,R=%5:]/$NFFDZ(KNQB]$5>B+-7>FM+;FT=3UUOIEB8
M-^['V]<;<G!+WRGTI>]FLWMKMJ6\NX6B;54>J&?JF-9FO!6YWH*[)^Z-OJE+
MQHG1-\"0?[^'*4D&F\#<&8R>66WL^S9SD;-4*W>LRU]<HLUG6(Y8V)W6(\E>
MV;(+'&G<BRTT54[D8I#CTB: IZGJ^Z[Z2MV+$,:$GRK<EYMVC\'&-JW5^R?L
MJ;'?[0S=DK>B;>V#BR;O9>5=S;L(UK2S'R+":7-3E?O47'XK=:5431#Y83MQ
M_+*\;5YFRT.#-/TWA*)L:JL3,WQ_A*]+D.:+[3F)'D^4[&=NHC/LI\S]+OB]
MTM>WL'>V[^.YJE[5LF]G/V]&1-RQT_?'%5B''C\/AR6OWN_<6-O#\F+<D\?0
M,+&TM4Y>;B6E',:\*3SWE7>'#X^;^D\Z?93X4?R5Y=1\A7JSI=?X.U3*;9)*
MZ-7U9-JV&&?5-6H2N3X,G2'(7\A"J_[/&F)_5%NE:'VY>C6I4S-5R(64J\?*
MMM7;LE[JQMVY>ZZ9^]#&Q9;H[RK<F1!O3M P[F0W2L7D7D\>Q!^QTG=O1]]@
MF%&MDW2                  $!'WQ_$6Y[?GG!CO*CB[5HK7 ?E-%N;MJU*
M.M\GK$>S[1B+F!YTXJMV(*]J'#X[DC6L]/E<;.UL=BG9NVGT&1NQ<4C),]NM
M<CNC;KT7,G34\+HZ9<Y=,6I6;BY5=N45&2Y-)*5>MHQ7N;3WI.IK.L1_>M^M
M5X5:I./NZDZKV-NGT2.#M&-QF)SV1J8/)/S.!];YC!96:&&M:O8:VUMG&RY"
MI7L7(*.695E:R[69-,VK<9+#WO\ 3[ERQ9G.=I2N+INT^)>QKG1\*JO)T551
MTXGCYJ,9-1=8^#]WA\_M]C)17ZM)S/D^&>1-DQ61VVI8XAY^VW'\1;9K]CYB
M";CCG*MBY-@X%V:U.Z*Q1;@>:,7^<FLU7-?7DFSV/K5YNJNI)-ASNYI\-0Q8
M3A!K.Q8.[&7^4LUZ;T?;6T_+N/G2$FU]M3VVS<F6-><927U>[+H:^YG2L'\D
M_BBOT22]A+?Y/P\G#_D/H'D)AH/1U3E.'7O'KR BB>YE=BV\M>D\>>2[-='>
MG)=UGD+8;6IV9&,]66CN,,UA_P MB8O3P?AW%GZ5=TNX_O\ 9ZK]CYDO/M_)
M*$5<7L=II*LW7WUZ/U?+AEQ_8YTMW/L_>Y?-)N/R3J^$3,,Z$[
M
M
M
M
M
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M]
M
M
M
M
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M::;!=5V\Z1O2E2Y"GT;B7Q.+Y],UTS2]_5SDS/\ /,':@
M
M
M
M
M
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MS?[/[MJ]2W)J7=+/M_O33K;P\1M<'DWXIWYQ?-.SCN-M^#64^;3I*'(%FUX
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M:TM7??TOX9/QB^I\$B3X8>/:@
M
M
M
M
M                                                           X
M9\A^9,+X^<(<F\S9_P!-]'0-4R&9@J2N5C<IFGHRAK6#1Z.8K9,]L=RK28O<
MU$?.G54^D]/LS;.5O'=6!MC#JKN9D1@VOM(?2NW/DMVXSF_=$\1W)WM@]N-A
MZKO?4:/'T[#G=47P\R[PA8M>'&]>E;M+BN,UQ1B;[9?CMG.$N I=VY&BL2\W
M^0V<L<P<K9#)1]N89;V&2S?U_!9%RHR1MC&X_(R6[,4C4?!D\E<8OP1#(??3
M>F)NG=ZTO1'%;5T:TL/$C'Z%+=(W+D?"DI14(M.DK5NVS#_I9[:Y^Q.WCUW<
MRD]^;DR'J.H3FOOG5><IV;4^3K"$W<G%JL+]Z]'V&PC+97'8+%9/-YBY!CL3
MAL?<RN4R%E_IUJ..Q]:2W>N6'_'L@K5H7/>OU-:IAO'Q[V7D6\7&BYY%V<80
MBN<I2:48KWMM)$CLS+QM/Q+N?FSC:P[%N5RY.7",(0BY2DWX*,4V_<B EY:<
M\9+R6\B.4N9+TEA*6U;+:;J]*PZ178K2\2C<1J&,]-ZHV*6M@*4"S]C6-DM.
MED[45ZFWSMWM*QL?9FG[9M*/FX]A>;)?;WY_'>E[T[DI=-:M048UHD?G@[P]
MP<GNCW)U;>U]R\C+RI>1%U^]XUO[WCPH^3C9C#KHDG<<Y43DS*;VEN!'<X^9
M&BWLA1^:U/AZ.7EG8W2Q(^LZWKEBM#IU-SWN;$L\^Y7*4_I*CUEKU9OLJUKG
M-\!ZB-WK:G;3+M69].HZDUB6Z/C2XF[TO;168SC7A24H\:M)Y:]'G;Q[][V8
M&1DV^O1]%3U"]5?#U67%8T>/"KR96I=/%RA;GPHFURUYC\V8[R"]P7D3D"_+
M7S'$?B=A\A)4ISR/FPV6J\29!L%7%3]CH&2T.3N=<U5PWS$2]75,G"K7/2-B
MKYWMIM:]L[L[A:/93M[CW#=C5I4G!Y<:N:YTEBX$)WNE\IVI)I59['O7OK&[
MC>HW4MQY#C>V;L^S-QBVW:N1T^=(VW2B<,[5;MO&ZX\7;OVVG)1BS4G_ .,6
M];3_ /1NP[;N.P?_ +?)9S8MAR/[GK7<GD[GXNZ1Y(G]Y:3I_P!I9T[&L_)&
MW;MQ_,C&*^9(AU_[SW!JW^,R=8S<GY9W;UZ?YLISE\[9/0\//'W'^,'CGQEP
MY6;7?E=?P<=W<+U9WJ1Y7>,X]V6VR\R=WVYZJ9BU)#55WQ;3AA9]#40U']RM
MXWM^;USMRW*K'O7>FS%_:6+?P68T\'T)2G3G-R?B?H/[+=N<;M3VSTK95I1>
M7C8ZEDSCQ5S*NOS,B:?-Q\R3C;KRMQA'DC)D\*93
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MHRK7JASBW[^FB;\6F_$Y\.L/J
M
M
M
M
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MY+;M.LL>3\8<W"OMCQ^:O)=)OC,:GJ
M
M
M
M
M
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M21VND:C^,<:MQ=&9;?1=AXQFN?#V/FOL5JF9]'F3M0
M
M
M
M
M
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M&(I+X;N<XI]:3YK%MR4T_"]<M2BZVY)2M#7T;=@
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MUS3X,Y(/D.8
M
M
M
M
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MEI.$OI<9J3E6/3Z#'PH8EYO%I'&G5RAX*;=>J/LK5J2Y<(TI1URM.E/N
M
M
M
M
M
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MKZ9>YHV:GD#N@
M
M
M
M
M                                         4;%B"I!/:M3PUJM:&2Q
M9LV)&0P5X(6.DFGGFD<V.*&*-JN<YRHUK4557H70A.Y-6[:<KDFDDE5MO@DD
MN+;?)%ERY;LVY7KTHPM0BW*3:222JVV^"27%M\$B$G[F7F+)Y<^0-ZUKEZ67
MB'C/[PU'C&!KGI6RL"6F_?\ O/I2,C>R?<;M2-\2.:U[,=7JL>U)&O5=I?8O
MMJNW.SH6\V"6X\[IO93\8.GWNQ7CPLQ;3I5.Y*XT^EJFB;U2]ZI=Y.XUR[IE
MQO9FE=>/@KCTW%U??LJC2:>3*,7&J35F%F+2DI5S3]D_PX_/[?;OE3OF(]34
M.,\A)B.,*UZ#K7SG(JUT6]L<,4OV;%31Z-EOH2=CF?>EACXWI-2>C<8>J/N7
M^)](AV_TBY34LZ"GE.+XV\:OPVVUR=^2?4JU\J+4ETW57./H6[*?E%N&YW;W
M!9KHVE7';P8S7"[F4^.\D^<<6,ET.C7GSC*,E.Q)+Y7SPYUC\]O+>'B; ;2F
M$\:?'FOLF3V_=ZTC;&,KX/5W,EY7Y1B:UCH,G-Z=>/#:Y"BRMR-MU9M=W=D>
MT^_M)M.7:+MT]PYF/YN^=9=J-FPU23G=X8F*_&*JW>R9<';AUN:I8J=3Z@M_
MQ]0O>..S].R_([7;;C?GDY47U05JQ1ZAGKA2XZ16-A1^)7KCM*VZY-"AX*^-
M,_N!>4&6YNW35$P'C/P_:U_$8#3'];.(EQ.H4JF/XPX:J2646/*4,/KV/KV-
MAL(U5M]7.F1LN221+^[&^8]GMAV]JZ7D>=OG4HW)W+W*:G>DY96:TOH2G<E*
M./'[3@HUC8H<?8'M=/U&=U[V_-<P_J_:W19V;=G&?Q6W;QXQA@Z;%RX7(6[,
M(3S)TK<XN:4\KJ4L]K6M:C6HC6M1&M:U$1K6HG1$1$^"(B&N]MMU?,W"))*B
MY'D%0                                #%[R3\<H^:&Z)ONEYRMQ[Y"
M\)9F[M/"'*BXUN1;A<AD:2X_9-'W"C%)5N[#Q/R3B43'[%BHYX'S0I%9KR0W
M:E6>+N-)U5Z?YF-D1=W2\B*C>MUI5)UC.+Y1N6W\4)4='5-.,I)_#F8?UGIN
MVWT9=IUA*G+VQ?MA)<)+YUQ29SWIN3V/,ZK@,GM^L?F9M5S&5I-BU=N8H;!!
MA<RC.S(4Z.=QJMJYC&-LL<ZK9].O+-6<Q\L%>57P1];D0M6[TH6)^993^&5'
M&J\&T^3]JXI.M&UQ?UVY3E;4KD>F;7%5K1_*N:]C_,7(^F.$O
M
M
M
M
M
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M?[:;0PMF;9M^7I6':Z4W3KNS?Q7+UUI+JN79MSFZ))OIBHP48KEX\V>S
M
M
M
M
M
M
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M&HJ4(0SC,4F>@
M
M
M
M
M
M                 :^?,;W'> _$C"9W&6M@QF^\S5JO;AN)->R*6,HS(SM:
MM9VY9*G#=IZ9CHF2LFD2VK;LL"HM>O-U^&8^VG9/=_<7*M7[=FYA[9E+X\NY
M&D>E<_)BW%WI.CBNCX%+A.<2./>OU-=O.SF#D8EW)M:CO>$/O>GV9UN*;^C]
M9G%2CC055*7F4NRAQMVYU(FW,_,W.ON!>1>,R63J2YO==XR^,TWCO0L&^T[!
MZSC[-EL&-P.$BMS3)3HQR2/M7[DKFM?*Z:S,K&=>S8;MC;.T^SVR[EBQ)6M+
MQ+<KV3D3IYEV2597)M)=4G11MP5:+IMQ3?/3]OC>^_\ U%]R[65E0=_7<^];
MQL/$M.7E6(2E2%JTI-],4V[EVY)I.3G=FXJM-R_ GC9IW*.7B\(N%7I-X]\5
M7]=V#SLY\PLTD,OD1ROB)$M4N&]3S,/;;_,7$9:O)VLBE8RM!%)+]FPD4^2C
M-N_>^I:!C/NGNA4WEJ$+EO0=/FJK3L2:I+-NP?#SYP:JVFY2<8\8.4+$W.WO
M;#1=V9D>Q&Q7U=N-(N6;VZM6M-IZSJ%M]4=-Q[J^+ZK;N)T49)0C&4^%Q0N9
M7Q_F)OF5\^O)'!^&/!M^GJ?B_P".B+D>4MSQ$,46G8>GI<"XS9=FA@HM92GP
M>BXM78;7Z434CMY%\CV.6M)'+#V7;72,?M#LB[W.W7"61OS6OAQ;,VW>G*^^
MJU:;E\2N7YTO9$VZPMJ*:ZU*,NE[U;AS/4/W/Q^R&P;D,/M3MGX\_)MI+&MQ
MQET7[Z4/A=K%MUQL.U%=-R\Y.+\J49PV[>,'BY@=2RNO<IYW54UV+3=37C_Q
MQXROPJJ\*<63]LM_+9.K8C9V<T\KVU?DMIOJU+4*3MQRR/\ 2L2V(X[\W]EZ
MCCWM Q,CSI961]8U+*B_].REPC"+3_T+$5+6+;KT2Z7>HNJ$83+[4]I]/T?+
MQMVZAB?5H8.']3T7!FOXLP'QG<G%K^,]0E6]GW:>9'J6,Y2Z+D[F>1B0D$
M
M
M
M
M
M
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MBVMNPA9RM=ORMW\[)<4_.R8-3AT=2JK6-))8ZHG%Q\ZBNSFWFR8M,Z@
M
M
M
M
M
M                                                           P
MT\V?,WC[PRXIM[AL4U+,[WFX;5'C3C[YM8<AMN<C:Q'3SI"V6>CK6&6=DN0N
M*U&,8K8F*L\T+'Y-[6]L=8[F[@CIN$I6M)M-2R<BE8V;;\%6BE=G1JW#FW63
M71&36$>^O>_;G9#:,]:U*4+^X+\91P</JI/(NJG%TJXV+55*]<I1*D(MW)PB
MX07*O*.[\U<A[7RER/F[&P[GN>6FR^:R4Z]K5D>UD-:C2KHJQT<3BJ44=6G6
MCZ15JL,<3$1C$1-J.W] TK:^C8^@:):5G3,6VH0BO9S<I/G*<Y-RG)\93;D^
M+9H=W=NS7M\[DS-V;FORR=<SKSN79OVNBC&*Y0MVXJ-NW!?#"W&,(I))&1/#
MG'ECC+$:9S-LVJMVWD#>LHW%^+O#=S&SY&YO&TK?BQ=+E38-?6N]<IQ[K.<D
M]'$TW(L>R[!"D"I)1IWXY?%[EUF&NY.5MC!R/J^CXEOKU3-4E&-BUTN<L2W<
MK\&1=A\5Z:XXV.^NL;MRRXY*V5MNYM;"P=[ZIB+,W'J%[R]"TV4'.65?ZU;C
MGWK-'YF'8NOIQ[;X9N9'RVI6+.1&<DOB#5-/]K[Q9SW*G+\MO?\ R1YBS-;*
M[BVI._+[IRIS#LSKEK6.+-:M)%;R.2BQ]R[.L]AK;#GS/O7NUS7QP-A%N34-
M2[\[_L[?VVHX>R-,M.%FJZ+&)AVNE7<JZJJ,7*,8],:QI%6K54TYO9[LS1]%
M]*7:;(W=O-SU'N?K=]7,GI;N9.?J-_JE8P+$J2G-0E*77-*;<G?R*-2C;7,/
MAGXK;AJVR;7Y6>3,M78O*WF)BS9.NU8;6%X8T^57-Q7&FF.:^Q'"^IBVP0W[
M$<DB+Z+:\<DC6SV;OFNYO<#3=0P<?M]L52L]OM-=(OBIYMY?3R;W*M9=4K<6
MES<Y*+<+=KVG9'M)K6DZGE]W>Z;AD]W=:59KA*UIF,_V/"QN+2<;?1&[--_1
M5N,I)7+M_8F87)*@
M
M
M
M
M
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MLQ5Z,6P_I0QNJ+^LY$4Z0C<C:K*,Y6Y GAYXP_HGJY7SA\MJF,FYLVG#X?\
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M3LZ39N<)7+C3<+VI7X]/UB["MNT_O5J5Q6[=Q9P&*C/(
M
M
M
M
M
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M3H_%)\T2\E;MSE&4XQ<H2K%M)N+HXU7L?3*4:KC1M<FRL6EX
M
M
M
M
M
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MB22X))<$EP2*Q:7@
M
M
M
M
M
M                        '!>X<!:?R/RIIW)W(B?G>SC*M-)QEIN1JQKJ
MNK;/D',^]=[MT7R3LV'<'00104)[")!BX6.=7A2R]UA?6:;N_4M$V_DZ%HO[
MV>=)+*O1;\V[:C]"PI</+LU;E<C'XKLFE.3@E \#K7;O1=S;MPMU;E_?L=*B
MW@XTXKZO8OSIYF7*#;\[)HHPM3G\-B*;MP5V3N'.AY,]\
M
M
M
M
M
M
M
M
M
M
M
M
M
M
M
9                              ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>54
<FILENAME>upjohnrevdecrease2018-2019.jpg
<TEXT>
begin 644 upjohnrevdecrease2018-2019.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #$ JP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK@QKL C1 3GXU_X;J_:T_P"BU^(O_!-X*_\ F6KTW_@IG_R=7K?_ &(G@/\
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M_7CC@@X(."1D'(."1FC_ (AWPUWXC_\ $TXR_P#G]_5WY6/^)I?%O^3PK_\
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M #!95Y6_YE_DOZ8?\2)?1&_Z,KD/_A]XS_\ HE/W_P#^(@CXV_\ 1N_PI_\
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M !1110 4444 %%%% !00""#R",$>H-%% 'QYXZ_X)_\ [&OQ+\8>(?'WCO\
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ML13E1KX?$4*N:RI5J%>E*5*K2J1E3J4Y2A.,HMH.E%%%?0'Y@%%%% !1110
M5^57Q#_X)R?%CQOX]\:^,]._X*'?M@>"]/\ %GBO7_$ECX/\->+5MO#GA2TU
MK4[C4+?PYH%O_:41@T;1HIUL--A*+Y=I!$FU<8K]5:*\;.<@RK/Z5&CFM"M7
MIX>I*K25''8_ N,Y1Y9-SP&)PTYIQTY:DI16Z2>I][P'XF<9>&>+Q^.X-S#
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MDDKMO1'ZI?\ #V;XU_\ 1-OA7_W\\8__ "XH_P"'LWQK_P"B;?"O_OYXQ_\
MEQ7Y6T5U_P#$ _![_H@\H_\ !V9?_-WDON./_B8+QF_Z+_./_!.6?_,'DON/
MU2_X>S?&O_HFWPK_ ._GC'_Y<4?\/9OC7_T3;X5_]_/&/_RXK\K:*/\ B ?@
M]_T0>4?^#LR_^;O)?<'_ !,%XS?]%_G'_@G+/_F#R7W'ZI?\/9OC7_T3;X5_
M]_/&/_RXKZ+_ &4_^"@?Q.^/7QN\-?#'Q+X*\!:-H^M:9XGOKC4="?Q&VI12
MZ'HMQJ=ND(U'4;BUV32Q+'/YD3-Y1;RRKX-?A%7W3_P3@_Y.V\ _]@#X@_\
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MWIET;W0M?T74[K3=<TK4+5DCC^B** /E[X9?LN>#/@E\2-+\4_",1^$?!?\
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M6&WMK>% J1000HD4,2 )'&BHH  H LT444 %%%% '\W'_!3/_DZO6_\ L1/
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MP'_8%A?_ $Q3/\'<S_Y&6/\ ^PS$_P#IZ84445VG"%%%% !7W3_P3@_Y.V\
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M /25#_@LI_XG(?\ YUM?LQ17SQ],?C/_ ,.<7_Z2H?\ !93_ ,3D/_SK:/\
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M?^)R'_YUM'_#G%_^DJ'_  64_P#$Y#_\ZVOV8HH _&?_ (<XO_TE0_X+*?\
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M!^2/P$3_ (-TOV<V!/\ PV__ ,%2A\SK_P G@6Q^Z[+G_DEHZXS[=,GK3O\
MB'0_9S_Z/@_X*E?^)?VW_P ZZOZ#L =!CJ?Q)R3^)Y/O11_K=Q9_T5/$G_A]
MS7R_ZB_)!_J5P9_T2'"W_B/91Y?]0?DC^?'_ (AT/V<_^CX/^"I7_B7]M_\
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M4=%@\"? ;X?_  EU5/$ N+>*RDO[_4O!KW5E+ITMRG]BC3(+F6.>W^SP_3]
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M:N=)UE/!"P>#KB_N/#5I::7  ?FW\//VYOVGM&^._P 79/B-X+^'>K?"2/\
M:L_8S_9XU#0=%^*C>)M3^%GBK]HSX*_!;1-8L/A?K&B?#S3]$^('@KPI\8_%
M[>(=:UOQ;J>CZ[K.G>(/$=K9Z=X9O_"<&@ZAE:Q_P5O\?Z)=Z]:V'P2\">/C
MKWP_\"?$CX.ZMX4\9_%K1/ 'B;2O%?[7/P2_9=O-+_X6?X^^!_AKPYX^T^W@
M^.WA+QS9_$GX*V?CCP#>#3]6TBUN;_3[GPUXDU_]1?#_ .R+^S3X4T=/#WAG
MX+> ] T*+QE\)OB##H^D:.-/TV#QG\"K#PIIGPC\0P65K-';P:AX#L? _A2#
M07BC2.(:):27,5S,9Y)N%T/_ ()^?L;>')S<Z3^S]X"@G32M'\/6<DT&KWS:
M1X5\.?$?P;\7/#7@W0!J.KW:^'?!'A?XD_#[P?XQ\+^"="&G>$_#>LZ';3:'
MHUA%+>0W(!\7:A_P4?\ CS#JGQS^&>D_ WX3ZA\8/V7/#7[0_C_XN?VE\5_%
MWA_X;>*/"7P4T+X:>(?#=A\.-?N/AS>ZQ;>(/'UG\4M-AURY\5Z='HGPRNO#
MMZ=1G\267B3P_>)N^"O^"FGB[QQ\9/"W@G1/@-KVJ>#Y/'7P$^%/CG4=#\+_
M !VUS4]"\4_'#X0?"KXK7'C*R\9Z?\&)O@)!X"^'Q^,7A'1_$.G>*?BUH'C6
M]T:T\3^,K/3;>&S\+:#XS]:_:J_X)S> ?VBX?$]MH-Q\._ $/Q&M/BNGQ-N-
M9^#>G?$+6-=UOXO>#_ 7P^\2^.?#^N'QAX.U/1?&!\%_#[0-"ETGQ+/XZ^#_
M (D32/#.H>-_A+XGU/P?X>N[3Z$T?]C?]F_1_%7@?QS'\+]"O?&'P^T_P3:^
M']?U&34;J5M1^'/A1O _@?Q;K&DB]B\,Z[X\\+^%&.AZ#XYU;0KOQ5HNFI!9
MZ1JUC:VEE!; 'TX#D XQD XZXSV_"EH  & , < #H!Z44 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
44 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>55
<FILENAME>upjohnrevdecrease2018v2017.jpg
<TEXT>
begin 644 upjohnrevdecrease2018v2017.jpg
M_]C_X  02D9)1@ ! 0   0 !  #_VP!#  $! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_
MVP!# 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0$!
M 0$! 0$! 0$! 0$! 0$! 0$! 0$! 0'_P  1" #$ JP# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG_@J#=ZO^U)^S1XWTGPU\0OV,OVKO!FJZ;XR\3_!KXC? O1/@=X5^/'P'N?
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M?F*,CU'YB@!:*3(]1^8HR/4?F* %HI,CU'YBC(]1^8H 6BBB@ HHHH ****
M"BBB@ KQWXX?M!?!7]FSP6?B'\=OB7X3^%_@[^TK31H=;\6:FEC%?:M?"62W
MTS2[5$GU#5M0-K;W>H36>F6=W/:Z58:CJUTD&F:=?7=O[%7Y/_\ !5SPXES\
M//AEXTM-!^/NE^(?!?B?7U\/_&O]G[PG9_%'6/A3/XGT>RT74K#QS\'7T?Q/
MJ?C_ .'_ ,2=)^U^&[Y=*\,WLFC>)++PN]WK'A:TU)M=M@#]++3XD?#S4(_
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MM]?_ ,1A\2?^BJQW_@G!?_,OE^?=G<?\,7:;_P!')_ME_P#B2_C;_P"-4?\
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M#;GX#?%J]\3:C>:;XRN-/FL[G^@51@8]V[8ZL3^/N>YYP,XH =1110 4444
M?S<?\%,_^3J];_[$3P'_ .DVJU^?U?H#_P %,_\ DZO6_P#L1/ ?_I-JM?G]
M7^Q_@[_R:OP^_P"R2R+_ -5] _Q:\9?^3K^(G_97Y[_ZGU@HHHK])/S0****
M "MCP]_R,&@_]A[0O_3Q8UCUL>'O^1@T'_L/:%_Z>+&L,5_NU?\ Z]3_ /26
M;X7_ 'G#_P#7^C_Z<B?V7CI^+?S-+2#I^+?S-+7^%Q_O1'9>B_(****!A111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M(>GXK_,4M(>GXK_,4X[KU7Y@?QT?$/\ Y*#X^_['KQI_ZE.KUQ]=A\0_^2@^
M/O\ L>O&G_J4ZO7'U_N5EO\ R+L!_P!@6%_],4S_  =S/_D98_\ [#,3_P"G
MIA1117:<(4444 %?=/\ P3@_Y.V\ _\ 8 ^(/_J)WE?"U?=/_!.#_D[;P#_V
M /B#_P"HG>5^?^+'_)L/$/\ [(OB7_U3XL_1?"'_ ).IX<_]EOPM_P"KO G]
M+]%%%?XSG^U84444 %%%% !1110 4444 %076/LT^0"/)FX;RMI_=OP?/_<X
M(X/F_N\?ZSY-U3U%.RI#*[H9$2.1GC 5BZJC%D"N54E@"H#$*<X8@9- '\HE
MU\.O@MHGC70(-+T_]E'Q%'</X1U5=3L?!?\ P0]T22'4-4@TK4M1TB*VNH(O
M$D]YX:U2YN= FU32U;^UK[3)-4\/226]U82-_5^/ZG^9_P _SK^:K1[0:SJE
MI)\!?V OCG_P3T\/R^);&\FTR/\ 8XNOC-<:Y8+K4,][#=? SP]I]]^S!\-C
MK$8N#<^)?#'C;Q%K=@EX^JQ8O8E"?TGP7$%RCO;S13JDT\#M$Z.$F@E>*>!]
MC,$F@E1HIHVQ)'(C)(JN&4 $]%%% !1110!_-Q_P4S_Y.KUO_L1/ ?\ Z3:K
M7Y_5^@/_  4S_P"3J];_ .Q$\!_^DVJU^?U?['^#O_)J_#[_ +)+(O\ U7T#
M_%KQE_Y.OXB?]E?GO_J?6"BBBOTD_- HHHH *V/#W_(P:#_V'M"_]/%C6/6Q
MX>_Y&#0?^P]H7_IXL:PQ7^[5_P#KU/\ ])9OA?\ ></_ -?Z/_IR)_9>.GXM
M_,TM(.GXM_,TM?X7'^]$=EZ+\@HHHH&%%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4AZ?BO\Q2TAZ?BO\Q3CNO5?F!_
M'1\0_P#DH/C[_L>O&G_J4ZO7'UV'Q#_Y*#X^_P"QZ\:?^I3J]<?7^Y66_P#(
MNP'_ &!87_TQ3/\ !W,_^1EC_P#L,Q/_ *>F%%%%=IPA1110 5]T_P#!.#_D
M[;P#_P!@#X@_^HG>5\+5]T_\$X/^3MO /_8 ^(/_ *B=Y7Y_XL?\FP\0_P#L
MB^)?_5/BS]%\(?\ DZGAS_V6_"W_ *N\"?TOT445_C.?[5A1110 4444 %%%
M% !1110 5%,\*0RO<-&L"QNTS3%5B6)5)D:1G(01A 2Y<A0H)8@ FI:R/$&@
MZ/XIT+6?#/B'3[?5M!\0Z5J.AZWI=VI>UU+2-7LI].U/3[E 5+6][8W,]M.H
M928I7 93@@ _*7Q5<_\ !-+1V\!ZVOQ=\:^"_!_QDL=7\9>'?#GPB^.G[5'@
MOX*:SX2;Q+8^%+WXA>(_!/PD\5Z;\,? GPJNO%&K6&G1_$#Q%IG@WX::SJ&I
MV_E:WJ$=^))OU+\'>#?"?@#PUI7A#P/X=T?PKX7T2W-II6A:#I]OIFF6,)DD
MEE$-I;1QH))KB2:XNIW#7%U=33W5U+-<S2RO^<6D_P#!*/X%:;X&\:>!;KQQ
M\3M>@\=^$OAK\(M8\1:U!\*G\5V7[.WPM&M0:)\ M U;3?AAI<6D>%M:TWQ%
MKVE^,O':64_QF\36^KW-W=?$:'5;/0]0TC].K*SM=.L[6PL;>&TLK&WAM+.T
MMXTAM[6UMXUAM[:WA0*D4$$*)%#$@"1QHJ*  * +-%%% !1110!_-Q_P4S_Y
M.KUO_L1/ ?\ Z3:K7Y_5^@/_  4S_P"3J];_ .Q$\!_^DVJU^?U?['^#O_)J
M_#[_ +)+(O\ U7T#_%KQE_Y.OXB?]E?GO_J?6"BBBOTD_- HHHH *V/#W_(P
M:#_V'M"_]/%C6/6QX>_Y&#0?^P]H7_IXL:PQ7^[5_P#KU/\ ])9OA?\ ></_
M -?Z/_IR)_9>.GXM_,TM(.GXM_,TM?X7'^]$=EZ+\@HHHH&%%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4AZ?BO\Q2T
MAZ?BO\Q3CNO5?F!_'1\0_P#DH/C[_L>O&G_J4ZO7'UV'Q#_Y*#X^_P"QZ\:?
M^I3J]<?7^Y66_P#(NP'_ &!87_TQ3/\ !W,_^1EC_P#L,Q/_ *>F%%%%=IPA
M1110 5]T_P#!.#_D[;P#_P!@#X@_^HG>5\+5]T_\$X/^3MO /_8 ^(/_ *B=
MY7Y_XL?\FP\0_P#LB^)?_5/BS]%\(?\ DZGAS_V6_"W_ *N\"?TOT445_C.?
M[5A1110 4444 %%%% !1110 4444 %%%% !12$@=2!]3C^=)O3^\O_?0_P :
M '44W>G]Y?\ OH?XT;T_O+_WT/\ &@#^;K_@IG_R=7K?_8B> _\ TFU6OS^K
M[_\ ^"F;*?VJ];PRG_BA/ ?<?\^VJ^]?G_D>H_,5_L?X._\ )J_#[_LDLB_]
M5] _Q:\94_\ B*_B)H_^2OSW_P!3ZPM%)D>H_,49'J/S%?I)^:6?9_U_PZ^\
M6BDR/4?F*,CU'YB@+/L_Z_X=?>+6QX>_Y&#0?^P]H7_IXL:QLCU'YBMCP\R_
M\)!H'S#_ )#VA=Q_T&+&L,5_NU?_ *]3_P#26;X5/ZSA]'_'I?\ IR)_9@.G
MXM_,TM,#IC[R]6_B'J?>EWI_>7_OH?XU_A<?[T1V7HOR'44W>G]Y?^^A_C1O
M3^\O_?0_QH&.HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7
M_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?
MXT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .
MHIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]
M/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_
M]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_
M !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HW
MI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7
M_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?
MXT .HIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .
MHIN]/[R_]]#_ !HWI_>7_OH?XT .HIN]/[R_]]#_ !HWI_>7_OH?XT .I#T_
M%?YBDWI_>7_OH?XTA=,?>7JO\0]1[TX[KU7Y@?QU?$/_ )*#X^_['KQI_P"I
M3J]<?77_ !"93\0/'V&!_P"*Z\:=Q_T-.K5Q^1ZC\Q7^Y66_\B[ ?]@6%_\
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M /25#_@LI_XG(?\ YUM'_#G%_P#I*A_P64_\3D/_ ,ZVOV8HH _&?_ASB_\
MTE0_X+*?^)R'_P"=;1_PYQ?_ *2H?\%E/_$Y#_\ .MK]F** /QG_ .'.+_\
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M /25#_@LI_XG(?\ YUM'_#G%_P#I*A_P64_\3D/_ ,ZVOV8HH _&?_ASB_\
MTE0_X+*?^)R'_P"=;1_PYQ?_ *2H?\%E/_$Y#_\ .MK]F** /QG_ .'.+_\
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M=?L_VL'[36K:3\3_ !)-X[U?XCWMS\$?C5J7PR\ _"SQUJ7A2UTCPJ8/C=X
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M;"T2[=#J[>&HC97;VVG7NDZLT5YIOV3X=_8?_92\*Z;XPT;1?@CX-@TCQO\
M#OQ)\(M:TRZCU;5=/M?A1XOBF@\3_#'PO::OJM_!X%^'FNPRI%J7@OP,GAOP
MY<QV6EH^G;=(TH66S\&OV1_@/\ -=G\1_"KPIK/AW4Y] ?PPQO/B/\4O%>GQ
M:(]SI]U]BM=&\:>-_$>BV?ERZ79"&YL].@O+>&$VT%S';37$,H!P/@GQK\5_
M!7[2WPZ^!WQ&\7P>/?\ A8?[)VK?$C4=5M](M-(M-,^)WP.\<?#;P5\1]5T>
MUT_3K-+70OB-#\</#-[9Z/<D)H\_@B22SCB?6M04_:->/V?P@TU/CEK'QUU/
M4[C5=?E^&VE_"SPIIKVX@L?!WAD>(KGQ;XN:QD%S*]YJ7COQ!%X8GUZZECMX
MDL/ WA.PM;=7L[VZOO8* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ IDA(4$'!WQC\&D12/Q!(I](0#P1GD'\000?P(!H _"W_@
MGOXC_:T^+?A#P+\9O%LW[77BG6/$&F?&#4M-\4_$KXO?LT67[*7B77K34_'^
MA>#(-0^'WP_2?X\:+X.N+NVT6VT[R?!C:UH\D%OJ>IVMU%;3O>>I?"/_ (*5
M?$3]H7PG\-M3^%WP;\":+K_QM^.NN_L^?#RS\:?%*[U;2M#\4?"#X.^,OBG\
M??$_CB_\ >&-?)\-V>H^!]:\-? JUT-FOOC1X6N?"GQGBNO#?PZ\9Z1<Q?5'
MA[_@G=^R%X2GO'\,_"B;0K*^M?%UA<:#I?Q&^+EIX3^P^.[+7-/\5V4/@Z+X
M@+X3M;36+;Q)K8FMK718(+>;4)KNR2UNUAGB] UO]CC]F/7K+5;"Z^#/@VQM
M]6N/AO>S'P];7WA.YL=3^$/ANY\%_#;6M!O?"M_HM]X8U[PAX(NY? ^DZ]X:
MN=)UE/!"P>#KB_N/#5I::7  ?FW\//VYOVGM&^._Q=D^(W@OX=ZM\)(_VK/V
M,_V>-0T'1?BHWB;4_A9XJ_:,^"OP6T36+#X7ZQHGP\T_1/B!X*\*?&/Q>WB'
M6M;\6ZGH^NZSIWB#Q':V>G>&;_PG!H.H96L?\%;_ !_HEWKUK8?!+P)X^.O?
M#_P)\2/@[JWA3QG\6M$\ >)M*\5_M<_!+]EV\TO_ (6?X^^!_AKPYX^T^W@^
M.WA+QS9_$GX*V?CCP#>#3]6TBUN;_3[GPUXDU_\ 47P_^R+^S3X4T=/#WAGX
M+> ] T*+QE\)OB##H^D:.-/TV#QG\"K#PIIGPC\0P65K-';P:AX#L? _A2#0
M7BC2.(:):27,5S,9Y)N%T/\ X)^?L;>')S<Z3^S]X"@G32M'\/6<DT&KWS:1
MX5\.?$?P;\7/#7@W0!J.KW:^'?!'A?XD_#[P?XQ\+^"="&G>$_#>LZ';3:'H
MUA%+>0W(!\7:A_P4?^/,.J?'/X9Z3\#?A/J'Q@_9<\-?M#^/_BY_:7Q7\7>'
M_AMXH\)?!30OAIXA\-V'PXU^X^'-[K%MX@\?6?Q2TV'7+GQ7IT>B?#*Z\.WI
MU&?Q)9>)/#]XF[X*_P""FGB[QQ\9/"W@G1/@-KVJ>#Y/'7P$^%/CG4=#\+_'
M;7-3T+Q3\</A!\*OBM<>,K+QGI_P8F^ D'@+X?'XQ>$='\0Z=XI^+6@>-;W1
MK3Q/XRL]-MX;/PMH/C/UK]JK_@G-X!_:+A\3VV@W'P[\ 0_$:T^*Z?$VXUGX
M-Z=\0M8UW6_B]X/\!?#[Q+XY\/ZX?&'@[4]%\8'P7\/M T*72?$L_CKX/^)$
MTCPSJ'C?X2^)]3\'^'KNT^A-'_8W_9OT?Q5X'\<Q_"_0KWQA\/M/\$VOA_7]
M1DU&ZE;4?ASX4;P/X'\6ZQI(O8O#.N^//"_A1CH>@^.=6T*[\5:+IJ06>D:M
M8VMI906P!]. Y .,9 ..N,]OPI:  !@# '  Z >E% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952954512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment, Geographic and Other Revenue Information</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Segment, Geographic and Other Revenue Information</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Segment Information</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We regularly review our segments and the approach used by management to evaluate performance and allocate resources. Prior to January 1, 2019, we managed our commercial operations through </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Pfizer&#8217;s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn and through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Consumer Healthcare, are responsible for their own R&amp;D activities while Biopharma receives its R&amp;D services from GPD and WRDM. These services include IPR&amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. As our operations were not managed under the new structure until the beginning of fiscal 2019, certain costs and expenses could not be directly attributed to one of the then new operating segments. As a result, our operating segment results for 2018 and 2017 include allocations, which management believes are reasonable. As described in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Operating Segments</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:14pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"/></tr><tr><td style="width:9%;"/><td style="width:40%;"/><td style="width:1%;"/><td style="width:50%;"/></tr><tr><td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Some additional information about our Biopharma and Upjohn business segments follows:</span></div></td></tr><tr><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img alt="pfizerlogo2816.jpg" src="pfizerlogo2816.jpg" style="height:34px;width:60px;"/></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Pfizer</span></div><div style="padding-left:72px;text-indent:-72px;font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Biopharmaceuticals</span></div><div style="padding-left:72px;text-indent:-72px;font-size:14pt;"><span style="font-family:Arial;font-size:14pt;font-weight:bold;">Group</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;"><img alt="upjohnlogo.jpg" src="upjohnlogo.jpg" style="height:85px;width:221px;"/></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma is a science-based medicines business that includes six business units &#8211; Oncology, Inflammation &amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer&#8217;s contract manufacturing operation, Pfizer CentreOne. At the beginning of our 2019 fiscal year, we also incorporated our biosimilar portfolio into the Oncology and Inflammation &amp; Immunology business units and certain legacy established products into the Internal Medicine business unit. Each business unit is committed to delivering breakthroughs that change patients&#8217; lives.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone.</span></div></td></tr><tr><td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:10pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Prevnar 13/Prevenar 13<br/>- Ibrance<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Eliquis<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Xeljanz<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Enbrel </span><span style="font-family:Arial;font-size:8pt;">(outside the U.S. and Canada)<br/>- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Chantix/Champix<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Sutent<br/>- Xtandi<br/></span><span style="font-family:inherit;font-size:10pt;font-style:italic;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Select products include:<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Lyrica<br/>- Lipitor<br/>- Norvasc<br/>- Celebrex<br/>- Viagra<br/></span><span style="font-family:Arial;font-size:8pt;">- </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Certain generic medicines</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:8pt;"> for additional information.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Other Costs and Business Activities</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM&#8211;&#8211;the R&amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#8211;&#8211;including patients, healthcare providers, pharmacists, payers and health authorities&#8211;&#8211;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#8217;s medicines.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">GPD&#8211;&#8211;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other&#8211;&#8211;the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Corporate and Other Unallocated&#8211;&#8211;the costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investments in equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:8pt;">basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Segment Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$167 billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$159 billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Selected Income Statement Information</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="37"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Earnings</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Depreciation and Amortization</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>39,419</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>37,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>35,530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>24,517</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>23,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>22,194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>958</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>10,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12,484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>13,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>6,785</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>8,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>9,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>105</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>49,653</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>50,042</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>48,977</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>31,301</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>32,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>31,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>1,063</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>2,098</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>3,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>3,472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,723</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,283</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,302</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,859</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,383</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,299</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(4,333</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(4,786</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(4,758</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>4,347</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>4,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>4,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(185</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(318</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(456</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Certain significant items</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>2,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(3,719</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(2,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>51,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>53,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>52,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>17,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>11,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>6,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>6,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>6,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. Biopharma&#8217;s earnings</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> include d</span><span style="font-family:Arial;font-size:7pt;">ividend income from our investment in ViiV of </span><span style="font-family:Arial;font-size:7pt;"><span>$220 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$253 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$266 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. </span></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$758 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$543 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$495 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$415 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) a pre-tax gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$8.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$138 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (viii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: an upfront license fee payment of </span><span style="font-family:Arial;font-size:7pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:7pt;"> to Akcea, which was recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses, </span><span style="font-family:Arial;font-size:7pt;">charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$112 million</span></span><span style="font-family:Arial;font-size:7pt;"> recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a </span><span style="font-family:Arial;font-size:7pt;"><span>$337 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:7pt;"> related to our acquisition of Therachon, a </span><span style="font-family:Arial;font-size:7pt;"><span>$99 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">related to rivipansel, primarily for inventory manufactured for expected future sale and charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$240 million</span></span><span style="font-family:Arial;font-size:7pt;">, primarily in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A, Note 2A, Note 2C</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2D,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$977 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) net charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$157 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$3.1 billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$63 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$586 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$4 million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$343 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a </span><span style="font-family:Arial;font-size:7pt;"><span>$119 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge, in the aggregate, in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:7pt;"> for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">, Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$204 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$237 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$379 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$71 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$224 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$999 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$756 million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a charitable contribution to the Pfizer Foundation of </span><span style="font-family:Arial;font-size:7pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:7pt;">, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$195 million</span></span><span style="font-family:Arial;font-size:7pt;"> in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales,</span><span style="font-family:Arial;font-size:7pt;"> an </span><span style="font-family:Arial;font-size:7pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:7pt;"> loss related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>49%</span></span><span style="font-family:Arial;font-size:7pt;"> equity share in Hisun Pfizer, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net,</span><span style="font-family:Arial;font-size:7pt;"> charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$55 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>40%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:Arial;font-size:7pt;"><span>60%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership interest, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2C,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity in the net income of investees accounted for by the equity-method is not significant for any of our operating segments.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The operating segment information does not purport to represent the revenues, costs and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Geographic Information</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As described in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>23,852</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>25,329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>26,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Europe</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,701</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Rest of World</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,465</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,612</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging Markets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,399</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>51,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>53,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>52,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:Arial;font-size:7pt;"> Revenues denominated in euros were </span><span style="font-family:Arial;font-size:7pt;"><span>$7.0 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$7.3 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$6.8 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Revenues exceeded </span><span style="font-family:Arial;font-size:8pt;">$500 million</span><span style="font-family:Arial;font-size:8pt;"> in each of </span><span style="font-family:Arial;font-size:8pt;"><span>11</span></span><span style="font-family:Arial;font-size:8pt;"> countries outside the U.S. in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. The U.S. is the only country to contribute more than </span><span style="font-family:Arial;font-size:8pt;"><span>10%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenue in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. As a percentage of revenues, our two largest national markets outside the U.S. were China, which contributed </span><span style="font-family:Arial;font-size:8pt;"><span>9%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenue in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>8%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenue in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>7%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenues in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, and Japan, which contributed </span><span style="font-family:Arial;font-size:8pt;"><span>8%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenue in each of </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides long-lived assets by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,606</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,089</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,971</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Europe</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,304</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Rest of World</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging Markets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>13,967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div></td></tr></table><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Other Revenue Information</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Significant Customers</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We sell our biopharmaceutical products primarily to customers in the wholesale sector. In all years presented, our three largest U.S. wholesaler customers are McKesson, Inc., AmerisourceBergen Corporation and Cardinal Health, Inc. In </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, sales to our </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;"> largest U.S. wholesaler customers represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span>16%</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>12%</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>10%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenues, respectively, and, collectively, represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span>25%</span></span><span style="font-family:Arial;font-size:8pt;"> of total trade accounts receivable as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. In </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;">, sales to our </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;"> largest U.S. wholesaler customers represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span>15%</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>11%</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>10%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenues, respectively, and, collectively, represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span>34%</span></span><span style="font-family:Arial;font-size:8pt;"> of total trade accounts receivable as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">. In </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, sales to our </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;"> largest U.S. wholesaler customers represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span>16%</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>12%</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>10%</span></span><span style="font-family:Arial;font-size:8pt;"> of total revenues, respectively, and, collectively, represented approximately </span><span style="font-family:Arial;font-size:8pt;"><span>36%</span></span><span style="font-family:Arial;font-size:8pt;"> of total trade accounts receivable as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2017</span><span style="font-family:Arial;font-size:8pt;">. For all years presented, these sales and related trade accounts receivable were concentrated in our biopharmaceutical businesses.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Significant Product Revenues</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As described in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides detailed revenue information for several of our major products:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">TOTAL REVENUES</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>51,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>53,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>52,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>39,419</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>37,558</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>35,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Internal Medicine</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>9,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Nonvalvular Atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,220</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,523</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,107</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>997</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Symptoms of menopause</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>734</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>832</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Development of bone and cartilage</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>287</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>279</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Overactive bladder</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>250</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Oncology</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>9,014</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>7,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>6,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Metastatic breast cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,961</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>4,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>936</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>838</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>590</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">ALK-positive and ROS1-positive advanced NSCLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>530</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>477</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>365</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Retacrit</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>225</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Mektovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>49</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Braftovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>585</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Hospital</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>7,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8,369</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>684</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>613</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Medrol</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anti-inflammatory glucocorticoid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>469</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>493</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>346</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zithromax</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>336</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">EpiPen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Epinephrine injection used in treatment of life-threatening allergic reactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Treatment/prevention of venous thromboembolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>253</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>251</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zosyn/Tazocin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>200</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Tygacil</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>197</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Diflucan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Panzyga</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Primary humoral immunodeficiency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>183</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pfizer CentreOne</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>810</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>755</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>706</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Anti-infectives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Hospital</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,436</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6,504</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>6,332</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>6,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pneumococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>5,847</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,802</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Nimenrix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>230</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">FSME/IMMUN-TicoVac</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Tick-borne encephalitis disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Trumenba</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>135</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>4,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>4,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">RA, PsA, UC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,242</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,699</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Inflectra/Remsima</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c), (g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Crohn&#8217;s Disease, Pediatric Crohn&#8217;s Disease, UC, Pediatric UC, RA in combination with methotrexate, Ankylosing Spondylitis, PsA and Plaque Psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>625</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>642</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Eucrisa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Mild-to-moderate atopic dermatitis (eczema) in adults and children 2 years of age and older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,240</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Replacement of human growth hormone</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>498</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hemophilia B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>488</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>554</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">ATTR-Cardiomyopathy and Polyneuropathy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hemophilia A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>426</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Acromegaly</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>264</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>129</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Upjohn</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>10,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>12,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>13,447</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Lyrica </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Epilepsy, post-herepetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>3,321</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>4,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Reduction of LDL cholesterol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,062</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>950</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,029</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>932</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Arthritis pain and inflammation, acute pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>719</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Viagra</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>497</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>336</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Glaucoma and ocular hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>281</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xanax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>198</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Revatio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pulmonary arterial hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,519</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Consumer Healthcare Business</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,098</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,605</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,472</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,927</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Biosimilars</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>911</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>769</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Sterile Injectable Pharmaceuticals</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>5,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 and 2017 product revenues to the current presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We performed certain reclassifications in the All other Oncology category to conform 2018 and 2017 product revenues to the current presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy SIP category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 and 2017 product revenues to the current presentation. Hospital also includes Pfizer CentreOne</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span><span style="font-family:Arial;font-size:7pt;">. All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#8220;All other Anti-infectives&#8221;.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018 and 2017 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation &amp; Immunology category to conform 2018 and 2017 product revenues to the current presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">On July 31, 2019, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Represents HIS revenues through February 2, 2017, which includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. On February 3, 2017, we completed the sale of HIS to ICU Medical. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -URI http://asc.fasb.org/topic&amp;trid=2134510<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R130.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7045184656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Summary of Common Stock Purchases (Details) - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares of common stock purchased</a></td>
<td class="nump">213<span></span>
</td>
<td class="nump">307<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of purchase</a></td>
<td class="nump">$ 8,865<span></span>
</td>
<td class="nump">$ 12,198<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R134.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7033524544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail) - Total Shareholder Return Units (TSRUs) [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.27%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">3.69%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.55%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
<td class="nump">1.98%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">18.34%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="nump">18.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Contractual term (years)</a></td>
<td class="text">5 years 1 month 17 days<span></span>
</td>
<td class="text">5 years 1 month 13 days<span></span>
</td>
<td class="text">5 years 1 month 9 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7035241280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our compensation programs can include share-based payments. The award value is determined by reference to the fair value of share-based awards to similar employees in competitive survey data or industry peer groups used for compensation purposes; and is allocated between different long-term incentive vehicles, in the form of TSRUs, PTSRUs, PTUs, RSUs, PPSs, PSAs and stock options, as determined by the Compensation Committee.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The 2019 Stock Plan (2019 Plan) replaced and superseded the 2014 Plan. The 2019 Plan provides for </span><span style="font-family:Arial;font-size:8pt;"><span>400 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares to be authorized for grants, plus any shares remaining available for grant under the 2014 Plan as of April 25, 2019 (the carryforward shares). In addition, the 2019 Plan provides that the number of stock options, Stock Appreciation Rights (known as TSRUs and PTSRUs), RSUs, or other performance-based awards that may be granted to any one individual during any 36-month period is limited to </span><span style="font-family:Arial;font-size:8pt;"><span>20 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares, and that RSUs, PPSs and PSAs count as </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> shares, while TSRUs, PTSRUs and stock options count as </span><span style="font-family:Arial;font-size:8pt;"><span>one</span></span><span style="font-family:Arial;font-size:8pt;"> share, toward the maximum shares available under the 2019 plan. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>518 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares were available for award. </span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. Impact on Net Income</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of share-based compensation expense and the associated tax benefit:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>275</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PPSs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Stock options </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Directors&#8217; compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Share-based payment expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>949</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>840</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax benefit for share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(163</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Share-based payment expense, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>769</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>677</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)&#160;&#160;&#160;&#160;</sup></span><span style="font-family:Arial;font-size:7pt;">Includes expense for PTSRUs, described in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 13C</span><span style="font-family:Arial;font-size:7pt;"> below, which is not significant for all years presented.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The table above excludes total expense due to the modification for share-based awards in connection with our Organizing for Growth initiative. The total expense was not significant for 2019 and 2018, the year in which the Organization for Growth Initiative began and is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:8pt;">).</span><span style="font-family:Arial;font-size:7pt;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts capitalized as part of inventory cost were not significant for any period presented.</span></div><div style="line-height:120%;padding-left:4px;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Total Shareholder Return Units</span></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs are awarded to senior and other key management, and to certain other employees. TSRUs entitle the holders to receive a number of shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the </span><span style="font-family:Arial;font-size:8pt;">five</span><span style="font-family:Arial;font-size:8pt;">-year or </span><span style="font-family:Arial;font-size:8pt;">seven</span><span style="font-family:Arial;font-size:8pt;">-year term, if and to the extent the total value is positive. The settlement price is the average closing price of our common stock during the </span><span style="font-family:Arial;font-size:8pt;"><span>20</span></span><span style="font-family:Arial;font-size:8pt;"> trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant. The TSRUs are automatically settled on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Retiree eligible holders (at least age </span><span style="font-family:Arial;font-size:8pt;"><span>55</span></span><span style="font-family:Arial;font-size:8pt;"> with at least </span><span style="font-family:Arial;font-size:8pt;"><span>ten years</span></span><span style="font-family:Arial;font-size:8pt;"> of service) can elect to exercise and convert his/her TSRUs, when vested, into PTUs. The value received upon the election and conversion is calculated by taking the change in stock price (</span><span style="font-family:Arial;font-size:8pt;"><span>20</span></span><span style="font-family:Arial;font-size:8pt;"> trading day average ending on the exercise date (Election Price) less the grant price) plus accumulated dividends from the grant date, times the number of TSRUs exercised. This value is divided by the Election Price to determine the number of PTUs. The PTUs will be entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#8217; original settlement date (i.e., the fifth or seventh anniversary of grant), and will be subject to all of the terms and conditions of the original grant including forfeiture provisions. We measure the value of TSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average assumptions used in the valuation of TSRUs:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected dividend yield</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.27</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.69</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Risk-free interest rate</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.60</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.98</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected stock price volatility</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>18.34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>20.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>18.39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Contractual term (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using a constant dividend yield during the expected term of the TSRU.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using the interpolated yield on U.S. Treasury zero-coupon issues.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using implied volatility, after consideration of historical volatility.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all TSRU activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant-Date</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>138,945</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39,246</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8.52</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.35</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(47,710</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.92</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>30.70</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(7,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.63</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38.90</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>122,654</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.53</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes TSRU and PTU information as of December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PTUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant&#160;Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate Intrinsic Value (Millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>179,999</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35.33</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>57,345</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>31.04</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>775</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Expected to vest</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>118,618</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37.23</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,096</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs exercised and converted to PTUs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, we settled </span><span style="font-family:Arial;font-size:7pt;"><span>7,953,671</span></span><span style="font-family:Arial;font-size:7pt;"> TSRUs with a weighted-average grant price of </span><span style="font-family:Arial;font-size:7pt;"><span>$27.33</span></span><span style="font-family:Arial;font-size:7pt;"> per unit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>2,173,131</span></span><span style="font-family:Arial;font-size:7pt;"> TSRUs with a weighted-average grant price of </span><span style="font-family:Arial;font-size:7pt;"><span>$30.68</span></span><span style="font-family:Arial;font-size:7pt;"> per unit were converted into </span><span style="font-family:Arial;font-size:7pt;"><span>844,871</span></span><span style="font-family:Arial;font-size:7pt;"> PTUs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all TSRU activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average grant-date fair value per TSRU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8.52</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>229</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which TSRU cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Performance Total Shareholder Return Units</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On December 29, 2017, in connection with the Board&#8217;s succession planning,</span><span style="font-family:Arial;font-size:8pt;"><span>1,372,213</span></span><span style="font-family:Arial;font-size:8pt;"> PTSRUs were awarded to the then Chairman and Chief Executive Officer, and </span><span style="font-family:Arial;font-size:8pt;"><span>343,053</span></span><span style="font-family:Arial;font-size:8pt;"> PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President, Pfizer Innovative Health) at a grant price of </span><span style="font-family:Arial;font-size:8pt;"><span>$36.22</span></span><span style="font-family:Arial;font-size:8pt;"> and at a grant-date fair value of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.83</span></span><span style="font-family:Arial;font-size:8pt;"> per TSRU. In addition to having the same characteristics of TSRUs, PTSRU grants require special service and performance conditions.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of PTSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> as appropriate.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Restricted Stock Units</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of our common stock, including shares resulting from dividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after </span><span style="font-family:Arial;font-size:8pt;"><span>three years</span></span><span style="font-family:Arial;font-size:8pt;"> of continuous service from the grant date.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of RSU grants as of the grant date using the closing price of our common stock. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all RSU activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant-Date Fair Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>27,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33.70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,478</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.17</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(10,644</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>31.66</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Reinvested dividend equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>911</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39.64</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38.82</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>23,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37.54</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all RSU activity:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>454</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which RSU cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017 includes the modification for a commitment to pay approximately </span><span style="font-family:Arial;font-size:7pt;"><span>6.4 million</span></span><span style="font-family:Arial;font-size:7pt;"> RSUs to approximately </span><span style="font-family:Arial;font-size:7pt;"><span>9,900</span></span><span style="font-family:Arial;font-size:7pt;"> employees, including senior and key management employees, for </span><span style="font-family:Arial;font-size:7pt;"><span>6.6 million</span></span><span style="font-family:Arial;font-size:7pt;"> RSUs. These shares were paid in the first quarter of 2018.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Portfolio Performance Shares</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PPSs are awards granted to select employees which, when vested, entitle the holder to receive, at the end of the performance period, a number of shares within a possible range of shares of our common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the awards vest after </span><span style="font-family:Arial;font-size:8pt;"><span>three years</span></span><span style="font-family:Arial;font-size:8pt;"> of continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer&#8217;s long-term product portfolio during a </span><span style="font-family:Arial;font-size:8pt;">five</span><span style="font-family:Arial;font-size:8pt;">-year performance period from the year of the grant date. The number of shares that may be earned over the performance period ranges from </span><span style="font-family:Arial;font-size:8pt;"><span>0%</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span>200%</span></span><span style="font-family:Arial;font-size:8pt;"> of the initial award.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of PPS grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized on a straight-line basis over the probable vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales,</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:8pt;">and/or</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Research and development expenses, </span><span style="font-family:Arial;font-size:8pt;">as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer&#8217;s common stock, changes in the number of shares that are probable of being earned and changes in management&#8217;s assessment of the probability that the specified performance criteria will be achieved and/or changes in management&#8217;s</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">assessment of the probable vesting term.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all PPS activity during 2019, with the shares representing the maximum award that could be achieved:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>19,261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>43.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,212</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.35</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(6,882</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>42.89</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(897</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39.93</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17,694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vested and non-vested shares outstanding, but not paid as of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> were </span><span style="font-family:Arial;font-size:7pt;"><span>32.0 million</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all PPS activity:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>136</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which PPS cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">F. Performance Share Awards</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PSAs are awarded to senior and other key management. PSAs vest after </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;"> years of continuous service from the grant date. The number of shares paid, if any, including shares resulting from dividend equivalents, for awards granted in 2015 and later, depends upon the achievement of predetermined goals related to </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> measures: (i) adjusted operating income (for performance years through 2018) or adjusted net income (for 2019 and later years, except for the 2017 PSAs) over </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">one</span><span style="font-family:Arial;font-size:8pt;">-year periods; and (ii) TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the </span><span style="font-family:Arial;font-size:8pt;">three</span><span style="font-family:Arial;font-size:8pt;">-year performance period. The number of shares that are earned over the performance period ranges from </span><span style="font-family:Arial;font-size:8pt;"><span>0%</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span>200%</span></span><span style="font-family:Arial;font-size:8pt;"> of the initial award.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of PSA grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized on a straight-line basis over the probable vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer&#8217;s common stock, changes in the number of shares that are probable of being earned and changes in management&#8217;s assessment of the probability that the specified performance criteria will be achieved.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;">The following table summarizes all PSA activity during 2019, with the shares granted representing the maximum award that could be achieved:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>43.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,716</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.35</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,481</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>42.89</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>41.91</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,061</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;">The following table provides data related to all PSA activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which PSA cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:Arial;font-size:7pt;">2017 </span><span style="font-family:Arial;font-size:7.5pt;">includes the modification </span><span style="font-family:Arial;font-size:7pt;">for a commitment to pay</span><span style="font-family:Arial;font-size:7.5pt;"> </span><span style="font-family:Arial;font-size:7.5pt;"><span>1.1 million</span></span><span style="font-family:Arial;font-size:7.5pt;"> PSAs to approximately </span><span style="font-family:Arial;font-size:7.5pt;"><span>90</span></span><span style="font-family:Arial;font-size:7.5pt;"> employees, including senior and key management employees, for </span><span style="font-family:Arial;font-size:7.5pt;"><span>1.1 million</span></span><span style="font-family:Arial;font-size:7.5pt;"> PSAs. These shares were paid in the first quarter of 2018.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">G. Stock Options</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Stock options are awarded to select employees and, when vested, entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in 2016, only a limited set of overseas employees received stock option grants. </span><span style="font-family:Arial;font-size:8pt;"><span>No</span></span><span style="font-family:Arial;font-size:8pt;"> stock options were awarded to senior and other key management in any period presented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted vest after </span><span style="font-family:Arial;font-size:8pt;"><span>three years</span></span><span style="font-family:Arial;font-size:8pt;"> of continuous service from the grant date and have a contractual term of </span><span style="font-family:Arial;font-size:8pt;"><span>10</span></span><span style="font-family:Arial;font-size:8pt;"> years. In most cases, stock options must be held for at least </span><span style="font-family:Arial;font-size:8pt;"><span>one year</span></span><span style="font-family:Arial;font-size:8pt;"> from the grant date before any vesting may occur. In the event of a sale of business or plant closing or restructuring, options held by employees are immediately vested and are exercisable for a period of </span><span style="font-family:Arial;font-size:8pt;"><span>3 months</span></span><span style="font-family:Arial;font-size:8pt;"> following the date employment is terminated or through their remaining term, depending on various conditions.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We measure the value of stock option grants as of the grant date using the Black-Scholes-Merton option-pricing model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;">, and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.40476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average assumptions used in the valuation of stock options:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected dividend yield</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.27</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.69</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Risk-free interest rate</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.66</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.85</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected stock price volatility</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>18.34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>20.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>18.39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected term (years)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using a constant dividend yield during the expected term of the option.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using the interpolated yield on U.S. Treasury zero-coupon issues.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using implied volatility, after consideration of historical volatility.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using historical exercise and post-vesting termination patterns.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all stock option activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exercise Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Remaining Contractual Term</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>103,791</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>27.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,181</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.35</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(15,964</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>24.84</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37.67</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(353</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>31.12</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>88,600</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>28.39</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>960</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested and expected to vest, December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b</sup></span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>88,469</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>28.37</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>960</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercisable, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>85,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>28.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>951</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Market price of our underlying common stock less exercise price.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The number of options expected to vest takes into account an estimate of expected forfeitures.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes data related to all stock option activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average grant-date fair value per stock option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.98</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.01</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate intrinsic value on exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>331</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash received upon exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>394</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax benefits realized related to exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested stock options not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which stock option compensation cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R138.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952860032">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Share-Based Payments - Performance Total Shareholder Return Units Narrative (Details) - Performance Total Shareholder Return Unit (PTSRUs) [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 29, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice', window );">Grant price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 36.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue', window );">Grant-date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 5.83<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember', window );">Board of Directors Chairman [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Deferred compensation arrangement, shares issued | shares</a></td>
<td class="nump">1,372,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember', window );">Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted', window );">Deferred compensation arrangement, shares issued | shares</a></td>
<td class="nump">343,053<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net number of non-option equity instruments granted to participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_BoardOfDirectorsChairmanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R117.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7035922784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Weighted-average assumptions used to determine benefit obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Weighted-average assumptions used to determine benefit obligations, Discount rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Weighted-average assumptions used to determine net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Weighted-average assumptions used to determine net periodic benefit cost, Discount rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets</a></td>
<td class="nump">7.30%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Weighted-average assumptions used to determine benefit obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Weighted-average assumptions used to determine benefit obligations, Discount rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Weighted-average assumptions used to determine net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate', window );">Weighted-average assumptions used to determine interest cost, Discount rate</a></td>
<td class="nump">2.20%<span></span>
</td>
<td class="nump">2.00%<span></span>
</td>
<td class="nump">2.10%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate', window );">Weighted-average assumptions used to determine service cost, Discount rate</a></td>
<td class="nump">2.40%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
<td class="nump">2.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets</a></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase</a></td>
<td class="nump">1.40%<span></span>
</td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Weighted-average assumptions used to determine benefit obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Weighted-average assumptions used to determine benefit obligations, Discount rate</a></td>
<td class="nump">3.30%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Weighted-average assumptions used to determine net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Weighted-average assumptions used to determine net periodic benefit cost, Discount rate</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets', window );">Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets</a></td>
<td class="nump">7.20%<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan [Member] | United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract', window );"><strong>Weighted-average assumptions used to determine benefit obligations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate', window );">Weighted-average assumptions used to determine benefit obligations, Discount rate</a></td>
<td class="nump">3.20%<span></span>
</td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease', window );">Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract', window );"><strong>Weighted-average assumptions used to determine net periodic benefit cost:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate', window );">Weighted-average assumptions used to determine net periodic benefit cost, Discount rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease', window );">Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
<td class="nump">2.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R113.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036018000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Goodwill (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">$ 53,411<span></span>
</td>
<td class="nump">$ 55,952<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">5,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(2,541)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">58,653<span></span>
</td>
<td class="nump">53,411<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">5,411<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(432)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember', window );">Upjohn Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_ConsumerHealthcareMember', window );">Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAcquiredDuringPeriod', window );">Additions</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,993)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">42,927<span></span>
</td>
<td class="nump">43,359<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">48,202<span></span>
</td>
<td class="nump">42,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Upjohn Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">10,484<span></span>
</td>
<td class="nump">10,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="num">(33)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">10,451<span></span>
</td>
<td class="nump">10,484<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillRollForward', window );"><strong>Goodwill [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillOtherIncreaseDecrease', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Ending balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAcquiredDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAcquiredDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillOtherIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillOtherIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036779232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes - Asset Disposals and Investments in Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 02, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 10, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 60<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember', window );">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Gain on sale of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (81)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeInc.Member', window );">Cortexyme, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 295<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember', window );">Allogene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentHoldingsLineItems', window );"><strong>Investment Holdings [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Unrealized gain on equity securities</a></td>
<td class="nump">$ 477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentHoldingsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentHoldingsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CortexymeInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R99.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040559840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Other Noncurrent Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="4">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Aug. 31, 2018</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,387<span></span>
</td>
<td class="nump">$ 31,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_MylotargMember', window );">Mylotarg [Member] | EU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Research and development arrangement, aggregate payment obligation, term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BosulifMember', window );">Bosulif [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Research and development arrangement, aggregate payment obligation, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BosulifMember', window );">Bosulif [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Research and development arrangement, aggregate payment obligation, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BesponsaMember', window );">Besponsa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Research and development arrangement, aggregate payment obligation, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BesponsaMember', window );">Besponsa [Member] | EU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Research and development arrangement, aggregate payment obligation, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BesponsaMember', window );">Besponsa [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Research and development arrangement, aggregate payment obligation, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,625<span></span>
</td>
<td class="nump">30,535<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Mylotarg [Member] | EU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="nump">$ 240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount', window );">Lump sum payment for liability buyout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment', window );">Non-cash gain from buyout transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Bosulif [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">191<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount', window );">Lump sum payment for liability buyout</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment', window );">Non-cash gain from buyout transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Besponsa [Member] | EU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Besponsa [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Developed Technology Rights [Member] | Bosulif [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Developed Technology Rights [Member] | Besponsa [Member] | EU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Developed Technology Rights [Member] | Besponsa [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">235<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member] | Developed Technology Rights [Member] | Bosulif [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member] | Developed Technology Rights [Member] | Besponsa [Member] | EU [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member] | Developed Technology Rights [Member] | Besponsa [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Aggregate Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Aggregate Payment Obligation, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Gain From Liability Extinguishment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Liability Buyout, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MylotargMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MylotargMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BesponsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BesponsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7010567968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Shareholders&#8217; Equity</div></th>
<th class="th"><div>Preferred Stock [Member]</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Add&#8217;l Paid-In Capital [Member]</div></th>
<th class="th"><div>Treasury Stock [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Accum. Other Comp. Loss [Member]</div></th>
<th class="th"><div>Non-controlling Interests [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Beginning balance (in shares) at Dec. 31, 2016</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">597<span></span>
</td>
<td class="nump">9,230,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,160,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Beginning balance at Dec. 31, 2016</a></td>
<td class="nump">$ 59,840<span></span>
</td>
<td class="nump">$ 59,544<span></span>
</td>
<td class="nump">$ 24<span></span>
</td>
<td class="nump">$ 461<span></span>
</td>
<td class="nump">$ 82,685<span></span>
</td>
<td class="num">$ (84,364)<span></span>
</td>
<td class="nump">$ 71,774<span></span>
</td>
<td class="num">$ (11,036)<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">21,355<span></span>
</td>
<td class="nump">21,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,308<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="nump">1,730<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,715<span></span>
</td>
<td class="nump">14<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(7,789)<span></span>
</td>
<td class="num">(7,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(7,789)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="num">(9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="nump">$ 1,536<span></span>
</td>
<td class="nump">1,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,597<span></span>
</td>
<td class="num">$ (63)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="num">(150,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(150,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="num">$ (5,000)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(73)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="num">(5)<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="num">$ (3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">9,275,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,296,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2017</a></td>
<td class="nump">71,656<span></span>
</td>
<td class="nump">71,308<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">$ 464<span></span>
</td>
<td class="nump">84,278<span></span>
</td>
<td class="num">$ (89,425)<span></span>
</td>
<td class="nump">85,291<span></span>
</td>
<td class="num">(9,321)<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">11,188<span></span>
</td>
<td class="nump">11,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">36<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="num">(1,975)<span></span>
</td>
<td class="num">(1,955)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,955)<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(8,060)<span></span>
</td>
<td class="num">(8,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,060)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="num">(12)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(12,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="nump">$ 1,993<span></span>
</td>
<td class="nump">1,993<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">1,977<span></span>
</td>
<td class="nump">$ 13<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="num">(307,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(307,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="num">$ (12,198)<span></span>
</td>
<td class="num">(12,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (12,198)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(46)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="nump">1,172<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2018</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">478<span></span>
</td>
<td class="nump">9,332,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,615,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2018</a></td>
<td class="nump">63,758<span></span>
</td>
<td class="nump">63,407<span></span>
</td>
<td class="nump">$ 19<span></span>
</td>
<td class="nump">$ 467<span></span>
</td>
<td class="nump">86,253<span></span>
</td>
<td class="num">$ (101,610)<span></span>
</td>
<td class="nump">89,554<span></span>
</td>
<td class="num">(11,275)<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income</a></td>
<td class="nump">16,302<span></span>
</td>
<td class="nump">16,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,273<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss), net of tax</a></td>
<td class="num">(376)<span></span>
</td>
<td class="num">(365)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(365)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsAbstract', window );"><strong>Cash dividends declared:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsCommonStockCash', window );">Common stock</a></td>
<td class="num">(8,174)<span></span>
</td>
<td class="num">(8,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,174)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPreferredStockCash', window );">Preferred stock</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders', window );">Noncontrolling interests</a></td>
<td class="num">(6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Share-based payment transactions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(8,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Share-based payment transactions</a></td>
<td class="nump">$ 894<span></span>
</td>
<td class="nump">894<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">1,219<span></span>
</td>
<td class="num">$ (326)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Purchases of common stock (in shares)</a></td>
<td class="num">(213,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(213,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Purchases of common stock</a></td>
<td class="num">$ (8,865)<span></span>
</td>
<td class="num">(8,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (8,865)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(47)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock', window );">Preferred stock conversions and redemptions</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityOther', window );">Other</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(21)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssued', window );">Ending balance (in shares) at Dec. 31, 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">9,369,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,835,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Ending balance at Dec. 31, 2019</a></td>
<td class="nump">$ 63,447<span></span>
</td>
<td class="nump">$ 63,143<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="nump">$ 468<span></span>
</td>
<td class="nump">$ 87,428<span></span>
</td>
<td class="num">$ (110,801)<span></span>
</td>
<td class="nump">$ 97,670<span></span>
</td>
<td class="num">$ (11,640)<span></span>
</td>
<td class="nump">$ 303<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsCommonStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsCommonStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPreferredStockCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 405<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6957935&amp;loc=d3e64057-112817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPreferredStockCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7008778560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="nump">$ 16,302<span></span>
</td>
<td class="nump">$ 11,188<span></span>
</td>
<td class="nump">$ 21,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">654<span></span>
</td>
<td class="num">(799)<span></span>
</td>
<td class="nump">1,116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax', window );">Reclassification adjustments</a></td>
<td class="num">(288)<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="nump">162<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total</a></td>
<td class="nump">366<span></span>
</td>
<td class="num">(821)<span></span>
</td>
<td class="nump">1,278<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="nump">476<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="num">(664)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(520)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax', window );">Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total</a></td>
<td class="num">(188)<span></span>
</td>
<td class="nump">247<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="nump">818<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="nump">39<span></span>
</td>
<td class="nump">124<span></span>
</td>
<td class="num">(244)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax', window );">Reclassification adjustments for unrealized gains included in Retained earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(462)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax', window );">Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total</a></td>
<td class="nump">38<span></span>
</td>
<td class="num">(522)<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax', window );">Benefit plans: actuarial losses, net</a></td>
<td class="num">(826)<span></span>
</td>
<td class="num">(649)<span></span>
</td>
<td class="num">(212)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="nump">241<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="nump">588<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="nump">274<span></span>
</td>
<td class="nump">142<span></span>
</td>
<td class="nump">117<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="nump">22<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="num">(145)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax', window );">Defined benefit Plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total</a></td>
<td class="num">(289)<span></span>
</td>
<td class="num">(153)<span></span>
</td>
<td class="nump">348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax', window );">Benefit plans: prior service costs and other, net</a></td>
<td class="num">(7)<span></span>
</td>
<td class="num">(9)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="num">(181)<span></span>
</td>
<td class="num">(181)<span></span>
</td>
<td class="num">(184)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax', window );">Reclassification adjustments related to curtailments of prior service costs and other, net</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
<td class="num">(18)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax', window );">Other</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(207)<span></span>
</td>
<td class="num">(203)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax', window );">Other comprehensive income/(loss), before tax</a></td>
<td class="num">(262)<span></span>
</td>
<td class="num">(1,457)<span></span>
</td>
<td class="nump">1,468<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax', window );">Other comprehensive income/(loss) before allocation to noncontrolling interests</a></td>
<td class="num">(376)<span></span>
</td>
<td class="num">(1,975)<span></span>
</td>
<td class="nump">1,730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest', window );">Comprehensive income before allocation to noncontrolling interests</a></td>
<td class="nump">15,926<span></span>
</td>
<td class="nump">9,214<span></span>
</td>
<td class="nump">23,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Comprehensive income attributable to noncontrolling interests</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive income attributable to Pfizer Inc.</a></td>
<td class="nump">$ 15,908<span></span>
</td>
<td class="nump">$ 9,198<span></span>
</td>
<td class="nump">$ 23,023<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Reclassification Adjustment For Unrealized Gains Included In Retained Earnings, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e557-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613674-111683<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118948100&amp;loc=d3e30304-110892<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32022-110900<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33775-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118948100&amp;loc=d3e30304-110892<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e709-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118951672&amp;loc=d3e1436-108581<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL34724391-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R95.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952699968">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Short-Term Borrowings (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommercialPaper', window );">Commercial paper</a></td>
<td class="nump">$ 13,915<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting', window );">Current portion of long-term debt, principal amount</a></td>
<td class="nump">1,458<span></span>
</td>
<td class="nump">4,781<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherShortTermBorrowings', window );">Other short-term borrowings</a></td>
<td class="nump">860<span></span>
</td>
<td class="nump">966<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermDebtGross', window );">Total short-term borrowings, principal amount</a></td>
<td class="nump">16,233<span></span>
</td>
<td class="nump">8,847<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="nump">$ 16,195<span></span>
</td>
<td class="nump">$ 8,831<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtWeightedAverageInterestRate', window );">Commercial paper, weighted average interest rate</a></td>
<td class="nump">1.92%<span></span>
</td>
<td class="nump">2.42%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 537<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear', window );">Line of credit facility, due to expire within one year</a></td>
<td class="nump">508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember', window );">Line of Credit [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity', window );">Line of credit facility, remaining borrowing capacity</a></td>
<td class="nump">15,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pfe_CreditFacilityExpiring2024Member', window );">Credit Facility Expiring 2024 [Member] | Line of Credit [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">7,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pfe_FacilityExpiringSeptember2020Member', window );">Facility Expiring September 2020 [Member] | Line of Credit [Member] | Commercial Paper [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermDebtLineItems', window );"><strong>Short-term Debt [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity', window );">Line of credit facility, maximum borrowing capacity</a></td>
<td class="nump">$ 8,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermDebtGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Debt, Gross</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermDebtGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommercialPaper">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(13)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommercialPaper</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b),22(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherShortTermBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherShortTermBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of short-term debt outstanding calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermDebtTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CreditFacilityAxis=us-gaap_LineOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_CreditFacilityExpiring2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_CreditFacilityExpiring2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_FacilityExpiringSeptember2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_FacilityExpiringSeptember2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7185694800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 933<span></span>
</td>
<td class="nump">$ 1,252<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">714<span></span>
</td>
<td class="nump">823<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring reserve</a></td>
<td class="nump">$ 219<span></span>
</td>
<td class="nump">$ 428<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7020537952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">$ 967<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember', window );">Business Integration Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="num">(197)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember', window );">2017-2019 Initiatives and Organizing for Growth Initiative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">695<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember', window );">2017-2019 Initiatives and Organizing for Growth Initiative [Member] | Manufacturing Optimization [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost incurred to date</a></td>
<td class="nump">921<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember', window );">2017-2019 Initiatives and Organizing for Growth Initiative [Member] | Other Activities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1', window );">Restructuring cost incurred to date</a></td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember', window );">Focused Company Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostExpectedCost1', window );">Expected cost</a></td>
<td class="nump">$ 1,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage', window );">Percentage of non-cash restructuring charges expected</a></td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">$ 87<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member] | Business Integration Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member] | Business Integration Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostIncurredCost', window );">Restructuring charges incurred</a></td>
<td class="nump">$ 94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringandRelatedCostNoncashChargesPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring and Related Cost, Noncash Charges, Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringandRelatedCostNoncashChargesPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostCostIncurredToDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of costs incurred to date for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostCostIncurredToDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostExpectedCost1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount expected to be recognized in earnings for the specified restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostExpectedCost1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostIncurredCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostIncurredCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_BusinessIntegrationCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_ManufacturingOptimizationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_OtherActivitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_OtherActivitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringPlanAxis=pfe_FocusedCompanyPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R91.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7038916784">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember', window );">Carrying Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion</a></td>
<td class="nump">$ 35,955<span></span>
</td>
<td class="nump">$ 32,909<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Estimated Fair Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion</a></td>
<td class="nump">40,842<span></span>
</td>
<td class="nump">35,260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Estimated Fair Value [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtFairValue', window );">Long-term debt, excluding the current portion</a></td>
<td class="nump">$ 40,842<span></span>
</td>
<td class="nump">$ 35,260<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_CarryingReportedAmountFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R159.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7021275120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 51,750<span></span>
</td>
<td class="nump">$ 53,647<span></span>
</td>
<td class="nump">$ 52,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8,701<span></span>
</td>
<td class="nump">9,116<span></span>
</td>
<td class="nump">8,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CurrencyAxis=currency_EUR', window );">Euro Member Countries, Euro | Developed Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 7,000<span></span>
</td>
<td class="nump">$ 7,300<span></span>
</td>
<td class="nump">$ 6,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CurrencyAxis=currency_EUR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CurrencyAxis=currency_EUR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R155.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039801360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Narrative (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Operating_Segment </div>
<div>Country</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Operating_Segment </div>
<div>Country</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>Country</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Operating_Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets | $</a></td>
<td class="nump">$ 167,489<span></span>
</td>
<td class="nump">$ 159,422<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenue [Member] | Outside United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries', window );">Number of countries outside the U.S | Country</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenue [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenue [Member] | JAPAN</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember', window );">Geographic Concentration Risk [Member] | Revenue [Member] | CHINA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">9.00%<span></span>
</td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue [Member] | McKesson, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">16.00%<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">16.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue [Member] | AmerisourceBergen Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">12.00%<span></span>
</td>
<td class="nump">11.00%<span></span>
</td>
<td class="nump">12.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Revenue [Member] | Cardinal Health, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk [Member] | Accounts Receivable [Member] | Three Largest U.S. Wholesaler Customers [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of total revenues</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">36.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Revenues, $500,000,000 or More, Number of Countries</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_GeographicConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_NonUnitedStatesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_NonUnitedStatesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_JP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_JP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_CN">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_CN</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_McKessonInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_McKessonInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_AmerisourceBergenCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_AmerisourceBergenCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_CardinalHealthInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_CardinalHealthInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=pfe_ThreeLargestUSWholesaleCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=pfe_ThreeLargestUSWholesaleCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7035241280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Earning Per Share</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the detailed calculation of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Earnings per common share</span><span style="font-family:Arial;font-size:8pt;">&#160;(EPS)</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,298</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,179</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,269</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,268</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,142</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,305</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Discontinued operations&#8211;&#8211;net of tax, attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,269</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,569</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,872</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash dividends declared per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.46</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017 includes the effect of the modification for a commitment to pay </span><span style="font-family:Arial;font-size:7pt;"><span>15.2 million</span></span><span style="font-family:Arial;font-size:7pt;"> common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040769536">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Accrued rebates and other accruals</a></td>
<td class="nump">$ 5,689<span></span>
</td>
<td class="nump">$ 5,426<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember', window );">Trade accounts receivable, less allowance for doubtful accounts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Accrued rebates and other accruals</a></td>
<td class="nump">1,257<span></span>
</td>
<td class="nump">1,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other current liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AccruedRebates', window );">Accrued rebates</a></td>
<td class="nump">3,285<span></span>
</td>
<td class="nump">3,208<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherAccruals', window );">Other accruals</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other noncurrent liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleOfAccruedLiabilitiesLineItems', window );"><strong>Schedule Of Accrued Liabilities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Accrued rebates and other accruals</a></td>
<td class="nump">$ 565<span></span>
</td>
<td class="nump">$ 399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AccruedRebates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued Rebates</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AccruedRebates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Accruals</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RebatesAndDiscountsAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RebatesAndDiscountsAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleOfAccruedLiabilitiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Schedule Of Accrued Liabilities [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleOfAccruedLiabilitiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R151.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7038968048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>EPS Numerator-Basic</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">$ 16,298<span></span>
</td>
<td class="nump">$ 11,179<span></span>
</td>
<td class="nump">$ 21,353<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperations', window );">Income from continuing operations attributable to Pfizer Inc.</a></td>
<td class="nump">16,269<span></span>
</td>
<td class="nump">11,143<span></span>
</td>
<td class="nump">21,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendsIncomeStatementImpact', window );">Less: Preferred stock dividends&#8211;&#8211;net of tax</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders</a></td>
<td class="nump">16,268<span></span>
</td>
<td class="nump">11,142<span></span>
</td>
<td class="nump">21,305<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest', window );">Less: Discontinued operations&#8211;&#8211;net of tax, attributable to noncontrolling interests</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net income attributable to Pfizer Inc. common shareholders</a></td>
<td class="nump">16,272<span></span>
</td>
<td class="nump">11,152<span></span>
</td>
<td class="nump">21,307<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DilutiveSecuritiesAbstract', window );"><strong>EPS Numerator&#8211;&#8211;Diluted</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="nump">16,269<span></span>
</td>
<td class="nump">11,143<span></span>
</td>
<td class="nump">21,306<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity', window );">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted', window );">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</a></td>
<td class="nump">$ 16,273<span></span>
</td>
<td class="nump">$ 11,153<span></span>
</td>
<td class="nump">$ 21,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</a></td>
<td class="nump">5,569.0<span></span>
</td>
<td class="nump">5,872.0<span></span>
</td>
<td class="nump">5,970.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</a></td>
<td class="nump">106.0<span></span>
</td>
<td class="nump">105.0<span></span>
</td>
<td class="nump">89.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</a></td>
<td class="nump">5,675.0<span></span>
</td>
<td class="nump">5,977.0<span></span>
</td>
<td class="nump">6,058.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Cash dividends declared per share (in dollars per share)</a></td>
<td class="nump">$ 1.46<span></span>
</td>
<td class="nump">$ 1.38<span></span>
</td>
<td class="nump">$ 1.30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans</a></td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">36.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>EPS Denominator</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of shares modified to accelerate vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DilutiveSecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DilutiveSecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4613673-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1377-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendsIncomeStatementImpact">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendsIncomeStatementImpact</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>77
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M/_QNPKZW[N#^L?%5L*GAUUTT7U!+ P04    " #@<5M0F5R<(Q &  "<)P
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M*Y>\ 4EJ0!8;T,CH^PYC%!;,8  :OY8PF"^RF'@QD;P'2?HY8J<2Y^U 4CO
M/7,U,N96Z@P_VFN&@AGNJPRD9GI*,N\&DKJ!Q6X@:?_&?>9K)'N(W$OE'4#2
MCQ\0^.MGA-(ORDLIIKP4>E!>WG.D(6L*Q-2'.N\$DG$"LJA2)FO\ K5F*)CA
M5\.,H7S:4VV6MP3)6 )95;27DU7U)9(]1.ZW('A'4-01Z*H:(?.XO@P%A,H8
M:KJ^BO<#1?T L$&M%&WD6B?8$C@J-1*+9BAKIBK-VX*BM@ "OR@H^C&A$[SQ
MM.8H:TBE*94(\K4:W6S*E:[9#QN>;;"IWZNNW]RZN7K=5'T9]E31]14\9Y>M
MT9_#7'9J_\B;_;%J@[>ZZ^IRV-C;U77GO$@Q\VWQX/+M]:1PNZX_-/ZXN>R0
M7DZZ^C3N_D;7+>CE_U!+ P04    " #@<5M0(W[#D8H$  #Q%@  &    'AL
M+W=O<FMS:&5E=',O<VAE970S+GAM;(V86V_C-A"%_XKA=Z\THWM@&X@D%"W0
M L$6;9\5FXF-E2Q74N+MOZ]N\=HSA\&^Q)+RS?"0&O)07%_JYEM[,*9;?*_*
M4[M9'KKN_. X[>Y@JJ+]4I_-J?_/2]U41=??-J].>VY,L1^#JM)AUPV=JCB>
MEMOU^.RIV:[KMZX\GLQ3LVC?JJIH_DM-65\V2UI^//AZ?#UTPP-GNSX7K^9/
MT_UU?FKZ.^>:97^LS*D]UJ=%8UXVRT=ZR#UW"!B)OX_FTMY<+X:N/-?UM^'F
MM_UFZ0Z*3&EVW9"BZ'_>36;*<LC4Z_AW3KJ\MCD$WEY_9/]E['S?F>>B-5E=
M_G/<=X?-,EXN]N:E>"N[K_7E5S-W*%@NYM[_;MY-V>.#DKZ-75VVX]_%[JWM
MZFK.TDNIBN_3[_$T_E[F_!]A.(#G +X&4/AI@#<'>#\"_$\#_#G %P'.U)5Q
M;/*B*[;KIKXLFNGUGHNABNC![T=_-SP<!WO\7S\\;?_T?4NNOW;>AT0SDTX,
MWS)7PNFS7YM@U$3**ISO&\@T$07W2 Z0$(OP8#^],=Z[ZV> $_@P@3\F\&\2
M)'*<)B08D=/41NBYLK. (HICT5]-,7F!17$ %0=*,;FAD#PQX4TS82"ZE6EF
M%26)T*NAOE>6-Q1"N2&0&PFYH9;"<N@R!(F7D&N&0L9J(Z@V FJ%D#12C7BA
M> &99E8QDU"K(>(HQG)C*#<&<L4K3&/5BA])N9IA=H5:S:S(Q6(3*#;18DDT
MDB:ZD3"4E:LA%A65@SP!6]22BY=0%^@EN8:Z8%14Z0**?2D9I0H\FV;+LD]
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M.:#8<V.+_S'V/P;^QVK9T)XEWWR&F% JUHRM-CQL?1ZR/FG7,Q3<C[(\)<@
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M>B_<Q72!XN/RYN#UX2M_ U!+ P04    " #@<5M0S@GA4R@%   $&P  &
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ML3!5"5#5<:J2Q*7VNN"I"9#EN4G$(&&H$H"JXU E2<LX='S2D<JG%F)*I*
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MS&6JKT57J'0-Q=N^"$-#);CY!U!+ P04    " #@<5M0NGVE"#0'  !T*@
M&    'AL+W=O<FMS:&5E=',O<VAE970W+GAM;(V:VV[B2!"&7P5QST!W=;OM
M41)I,00'[4JC6>WNM2=Q$C2 L^!,9M]^;>,AZ:J_C7,13E^5JX]_5=M7;^7A
M^_&Y**K1S]UV?[P>/U?5R^?I]'C_7.SRXZ?RI=C7OSR6AUU>U1\/3]/CRZ'(
M'UJCW7:J9[-HNLLW^_'-5?O=E\/-5?E:;3?[XLMA='S=[?+#?_-B6[Y=C]7X
MUQ=?-T_/5?/%].;J)7\J_BRJOUZ^'.I/T[.7A\VNV!\WY7YT*!ZOQ[^ISVO;
M&K3$WYOB[?CA_:AIRK>R_-Y\N'NX'L^:B(IM<5\U+O+ZY4>1%MMMXZF.X]_.
MZ?A\S<;PX_M?WF_;QM>-^98?B[3<_K-YJ)ZOQ_%X]% \YJ_;ZFOYEA5=@^QX
MU+7^]^)'L:WQ)I+Z&O?E]MC^']V_'JMRUWFI0]GE/T^OFWW[^G;ZQ2:=&3;0
MG8$^&ZA9KP%U!G0VT*K7P'0&YMW ]AK8SL"^&^A>@Z@SB,X&U!^2ZPS<^Q5,
MKT'<&<3O!J[7(.D,DO>0J->@[O5NY&;O)FT_34]#WLZA15[E-U>'\FUT."V#
ME[Q9;>JS:J;I??-M.RO;'^MY=*R__7&C$GLU_=%XZICYB=$>$_E,BACG,PO$
MQ#ZSE(QER"URD_C,2C+UGN$S&6*4S]PA1OO,&C%T9J9U_Y\'0>-!T*T'XWDP
MK/-.3-0R^U/'\ Y>2B;1-#O]L0Z2**F(HU[LA&,G$#N?0"?&>K''AH64(LH:
MW@^2T@Q92L1$;&!O)1/K*&:!KR0UB0U%[(*9Q)QRCE%WP)E2,V(K:0T:^&&U
M>4-B\)"8U@-Y0Q+P8+$'"P:53;:Y%3-(*[*L!U-(S=B2S@91:TD9AYL5X69%
MH%GL(O-(7$0YXE,508HU_6X(M :0P6URN$T.#':"/<380RQ[1;$&SV,1YL2Y
MF.VZZ2 JNT1Y,2<XY@3$S);X/)'784AZ&<EZ$2_41HNAQ,Y L$Q$YAWD78=U
MW+J?\6,)R;T"L1#;/SO(6V@6J@@@%2?]N (*J( $*L/[2(NM45F^?Z9*2IND
MEL 7&Y);Z(AK[@HXFD0!^5<!#55 1/E.,>\@?R9:K.[#6#^V@)@H V*+>&Q&
M=H(58:4=%O5CJXO>_, #&J: B"F1DDI-F;C0Z 5410%945Q6E-SH)UPK!S"+
MCO'ZAOC$!7Z(]['T$]K6 L*CG&BVDLUV(A0Q*2XB62_B!QO0.(5$+N%]*Y7)
MBN020(EV@>U1LE0G<[W+,"!X"BB>YBJMI%@Y%5FQ0R),I%N+#O.V2,5[0S*&
MI\>WX'JQT2[FO25]3>+$:,MG W!G=2)*-Z#<"?$6K %&)L:#HP,*KV?#,VX=
M4&8-E%GDW!KH;;WH6$^F&+-L#\B&86N 4:AQH0(75;A\K]!2;R<J<7R7Q!@O
M/.Z&86N$Z<#:U 'YUC0\!]<!F=5(9OGZUD _XUG$=]1A6'81\P,/R*Q&,LM3
M<0UDEN?B YBLG_'C#:BU1FK-LW$-%)1#ZPN0'TU 1+4449F/:RE_UN%3'4G6
M(?7IC0X(ID:"R1/R#O*2B"0A/K!2!26U!+YX7@,=.9Z0HZ!"QW$!L=6HO.3Y
MN ;Z0K/ N QB_>.V@-80JB9Y/MY!_EF3%J>M*8&*$G"KR_[\V ,:1ZCZY"DY
M2;F9F(#>4$!O")637&\(;/V&=]!E9D&@ N2U)/+#4W+@)S0W0F>QLHZ4*3G)
MVE IIWG#AU#9)<J/.B!]!*2/IVD+DF)E> :Y!%!"Q/>_KK<E2U'_X04%))"
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M0/M-6V@0 Y#>XH(NLJ5G/@<&FA#=:_+=>-EC$+"?WK&8?Z;R/U!+ P04
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M1P=-M=>X$PT=%;.A]^,E'+I$Y4QS=WZ!VBJBG$L:( G8A(?C]+OV_FR<)>Z
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ML1)4$6F4(9%^?=<@$>7>N G&@H!73SZ#0\%!6J)=HKES&()#IJ"C CKE$E
M))?+HP5'5BG_?W ..-H%%.TT20-X,2&F7*^!3,>0-R7G?G&\"RC>959)P%$H
MH"B4<X&C4$!1R,R:C1SFJ T(0;K":=[LY]PM#C\!A)^4ZP('@P".)V7G##^<
M >1L=L[V(GEKSJRDU.]EWNQF;W9V<N9NU6X>=N<9MY/;[GG=CT?73GX]GIG\
MZ,8S>^KWBBZ;_<G'G]WL#V+^,=\\+-;;R=>N[[O5[MS>?=?U[>"P^#!X>VSG
M=\<OR_:^'S_&X?-F?P!R_Z7OG@Z'.V?'$Z8W_P%02P,$%     @ X'%;4)$S
MXR?< @  = L  !D   !X;"]W;W)K<VAE971S+W-H965T,3 N>&ULC5;MCMHP
M$'R5* ]PB>U\^01(!U752JUTNJKM;Q\8B"Z)4]O ]>WK."$']@;*#Q*;V9E9
MFUWM["3DF]ISKH/WNFK4/-QKW3Y&D5KO><W4@VAY8W[9"EDS;99R%ZE6<K:Q
M0745X3C.HIJ53;B8V;UGN9B)@Z[*AC_+0!WJFLF_2UZ)TSQ$X7GCI=SM=;<1
M+68MV_$?7/]LGZ5912/+IJQYHTK1!))OY^$3>EQA&V 1OTI^4A?O09?*JQ!O
MW>+K9A[&G2->\;7N*)AY'/F*5U7'9'S\&4C#4;,+O'P_LW^VR9MD7IGB*U']
M+C=Z/P^+,-CP+3M4^D6<OO AH30,ANR_\2.O#+QS8C36HE+V.U@?E!;UP&*L
MU.R]?Y:-?9X&_G,8'("' #P&](<S&4"& .($1+TSF^HGIMEB)L4ID/UMM:S[
M4Z!'8@YSW6W:L[._F6R5V3TN<(%FT;$C&C#+'H,O,!^(R+"/$AB26&(_G#@2
M*Q^#"PR+$# /8@F2*P+BY-%C4HMI+(9@$MN/8\='HCC+8@=[92L!;27_8:O'
M9%>VTEM2*2B5^E(D<:123ZK !#X"'SKA)@/=9$#BKIO,D\!Y?/.0<U K![12
M1ROWM! IP,1])*7TEJD"-%4 IC*8@(($%"#(':_4\YHG^2VO*(:[0 R(%1,4
M$XT$ 134\3N K@H+W;YR!#:5)X1].>I>)0B:Z%T([BL(:"QTHC,AN <@H GX
M5B$0F="!&P ".@!-7)W4OX'BS@W %8[\$D=DRC%<N BH7*]G#:#TJFG=<0R7
M)/)K$A&W48"@B<)%<.4BH'2IIT/]BTCOM#\,5R\&JI=FCMX NNH5V1TYN-(Q
M4.DT=^6 2D\R4"VZF%5J+G=VK%/!6AP:W<T$%[OCZ/B$NUG'V5^:D;*?@3YH
M^GGT.Y.[LE'!J]!FDK+SSE8(S8W3^,%XW)L1>%Q4?*N[U]R\RWX.[!=:M,.,
M&XV#]N(?4$L#!!0    ( .!Q6U 'XI22LP$  -(#   9    >&PO=V]R:W-H
M965T<R]S:&5E=#$Q+GAM;'U386^<, S]*U%^0,/E;EU[ J1>IVJ3-NG4:>WG
M'!B(FA"6A*/[]W,"1UF+]H78QN_YV7'2P=@7UP!X\JI5ZS+:>-_M&7-% UJX
M*]-!BW\J8[7PZ-J:N<Z"*"-(*\:3Y)II(5N:IS%VM'EJ>J]D"T=+7*^UL'\.
MH,R0T0V]!!YEW?@08'G:B1I^@O_5'2UZ;&8II8;62=,2"U5&[S;[PR[DQX0G
M"8-;V"1T<C+F)3C?RHPF01 H*'Q@$'B<X1Z4"D0HX_?$2>>2 ;BT+^P/L7?L
MY20<W!OU+$O?9/2&DA(JT2O_:(:O,/7SB9*I^>]P!H7I00G6*(QR\4N*WGFC
M)Q:4HL7K>,HVGL/$?X&M _@$X.\ ;"P4E7\17N2I-0.QX^P[$:YXL^<XFR($
MXRCB/Q3O,'K.^>U-RLZ!:,HYC#E\D;.9,QBRSR7X6HD#_P#GZ_#MJL)MA&__
M47B[3K!;)=A%@MU_6_R8LTV2=T788J8:;!VWR9'"]&W<Y$5T7M@['N_D+7W<
M]A_"UK)UY&0\WFR<?V6,!Y227.$*-?C 9D=!Y8/Y&6T[KMGH>---+XC-SSC_
M"U!+ P04    " #@<5M0N ,!1K(!  #2 P  &0   'AL+W=O<FMS:&5E=',O
M<VAE970Q,BYX;6QU4]MNG# 0_17+'Q"SAJ;5"I"RJ:I6:J55JC;/7AC BB_$
M-DOZ][4-2\B&O."98<Z9,^-Q/FKS9#L AUZD4+; G7/]GA!;=2"9O=$]*/^G
MT48RYUW3$ML;8'4$24%HDMP2R;C"91YC1U/F>G""*S@:9 <IF?EW *'' N_P
M)?# V\Z% "GSGK7P&]R?_FB\1Q:6FDM0EFN%##0%OMOM#UG(CPE_.8QV9:/0
MR4GKI^#\J N<!$$@H'*!@?GC#/<@1"#R,IYG3KR4#,"U?6'_%GOWO9R8A7LM
M'GGMN@)_P:B&A@W"/>CQ.\S]?,)H;OXGG$'X]*#$UZBTL/&+JL$Z+6<6+T6R
ME^GD*I[CS'^!;0/H#*!7 #(5BLJ_,L?*W.@1F6GV/0M7O-M3/YLJ!.,HXC\O
MWOKHN4R374[.@6C..4PY=)7SFD$\^U*";I4XT'=PN@U/-Q6F$9Z^4?@!0;9)
MD$6"[ U!>M7B5DYV582L9BK!M'&;+*KTH.(FKZ++PM[1>">OZ=.V_V*FY<JB
MDW;^9N/\&ZT=>"G)C5^ASC^PQ1'0N&!^]K:9UFQRG.[G%T269US^!U!+ P04
M    " #@<5M0^^Y/T;$!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE970Q
M,RYX;6Q]4VUOG# ,_BM1?D##<=<7G0"IUZEJI4TZ==KV.0<&HB8Q3<+1_OLE
M@6.L0_M";./G\6/'R08TK[8%<.1=26USVCK7[1FS90N*VROL0/L_-1K%G7=-
MPVQG@%<1I"1+D^2&*2XT+;(8.YHBP]Y)H>%HB.V5XN;C !*'G&[H)? BFM:%
M "NRCC?P'=R/[FB\QV:62BC05J F!NJ<WF_VAUW(CPD_!0QV89/0R0GQ-3C/
M54Z3( @DE"XP<'^<X0&D#$1>QMO$2>>2 ;BT+^R/L7??RXE;>$#Y2U2NS>D=
M)174O)?N!8<GF/JYIF1J_BN<0?KTH,37*%':^"5E;QVJB<5+4?Q]/(6.YS#Q
M7V#K@'0"I)\ ;"P4E7_ACA>9P8&8<?8=#U>\V:=^-F4(QE'$?UZ\]=%SL4VN
M,W8.1%/.8<Q)%SF;.8-Y]KE$NE;BD/X#3]?AVU6%VPC?_J7P9IU@MTJPBP2[
M_[:XEG/[J0A;S%2!:>(V65)BK^,F+Z+SPMZG\4[^I(_;_HV;1FA+3NC\S<;Y
MUX@.O)3DRJ]0ZQ_8[$BH73!OO6W&-1L=A]WT@MC\C(O?4$L#!!0    ( .!Q
M6U!1#2?CM@$  -(#   9    >&PO=V]R:W-H965T<R]S:&5E=#$T+GAM;'U3
MVV[<(!#]%<0'!!MOD^W*MI1-%;52*ZU2-7EF[;&-PL4%O$[_OH =QVVLO  S
MS#ES9ACR49MGVP$X]"*%L@7NG.L/A-BJ \GLE>Y!^9M&&\F<-TU+;&^ U1$D
M!:%)<DTDXPJ7>?2=3)GKP0FNX&20':1DYL\1A!X+G.)7QP-O.Q<<I,Q[UL)/
M<+_ZD_$665AJ+D%9KA4RT!3X-CT<=R$^!CQR&.WJC$(E9ZV?@_&M+G 2!(&
MR@4&YK<+W($0@<C+^#USXB5E *[/K^SWL79?RYE9N-/BB=>N*_ >HQH:-@CW
MH,>O,-?S":.Y^.]P >'#@Q*?H]+"QA55@W5:SBQ>BF0OT\Y5W,?I)KN98=L
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M;#4DM"X<[_W9S&,V&PZ'Y0>Q]1M7OP!02P,$%     @ X'%;4-9@DR>U 0
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M$AH?CK=XMM.8388W_?R#V/*-RS]02P,$%     @ X'%;4(#]7M>T 0  T@,
M !D   !X;"]W;W)K<VAE971S+W-H965T,3@N>&UL?5/;;IPP$/T5RQ\0LX:T
MT0J0LJFB5FJE5:JVSUX8P(J-J6V6].\[-H2@!O7%]HS/.7/Q.)^,?78=@"<O
M6O6NH)WWPY$Q5W6@A;LQ _1XTQBKA4?3MLP-%D0=25HQGB0?F!:RIV4>?6=;
MYF;T2O9PML2-6@O[YP3*3 4]T%?'DVP['QRLS ?1PG?P/X:S18NM*K74T#MI
M>F*A*>C]X7C* CX"?DJ8W.9,0B478YZ#\:4N:!(2 @65#PH"MRL\@%)!"-/X
MO6C2-60@;L^OZH^Q=JSE(AP\&/5+UKXKZ!TE-31B5/[)3)]AJ>>6DJ7XKW %
MA?"0"<:HC')Q)=7HO-&+"J:BQ<N\RS[NTWR3\H6V3^ +@:^$NQB'S8%BYI^$
M%V5NS43LW/M!A"<^'#GVI@K.V(IXA\D[]%[+0\9S=@U""^8T8_@6LR(8JJ\A
M^%Z($W]'Y_OT=#?#--+3#3WER;Y MBN018'LOR6^QZ3\WR+9IJ<:;!NGR9'*
MC'V<Y(UW'=C[^(CL#3Y/^S=A6]D[<C$>7S;VOS'& Z:2W. (=?C!5D-!X\/Q
M(Y[M/&:SX<VP_""V?N/R+U!+ P04    " #@<5M0."\U![0!  #2 P  &0
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M+QO[WQKC :4D=SA"/7ZPU9#0^G!\AV<[C]EL>#,L/XBMW[CZ#5!+ P04
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M%4O H-)V>VOV<AJ8*="BG]\"LCQ(^1]02P,$%     @ X'%;4*L : ?# 0
M-P0  !D   !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL;51A;YLP$/TKEG]
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M%^.V&[M7PWP9 B/;<722:7X7?P%02P,$%     @ X'%;4,?,Q/BT 0  T@,
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MO;?-O&:SX_2PO""R/N/J#U!+ P04    " #@<5M0IMWT"FT"  !T"0  &0
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M,Y;=/:";:-'V=YSH?M%:_@-02P,$%     @ X'%;4/29.\;& 0  -P0  !D
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M@;F>:TKFXK_!!23"0R88HS32Q964@_-&S2J8BA)OT][IN(_3S?7-3-LF\)G
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M\QXM 8-:VVEJYG*ZE5.@Q3 _.&1Y]8J_4$L#!!0    ( .!Q6U XUI_?6P(
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MA[_@E90&;"[1@_T.:]O"IP6'RKCIUL[5T,>&A9'=V*/)]*/(_P%02P,$%
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M4(+($<17!-',QH!)'*9UF"3-BYD3!!2'*2XE1J7$B)08)TA0@N3Q8J0H0?I
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M^D=WD";",\NIX="J1K1(PGD7/$7;?6[Q#O"S@4$M]L@Z.0KQ:H,OIUT0VH:
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M;8[RC%4K@1Y=$F>8K%8)YK1N@B)SL;TL,M%I5C>PETAUG%/Y9P=,]'D0!M?
M:WVNM W@(FOI&7Z _MGNI3GAB>58<VA4+1HDX90'3^%VEUJ\ _RJH5>S/;).
M#D*\V</78QZL;$' H-26@9KE L_ F"4R9;R/G,$D:1/G^RO[B_-NO!RH@F?!
M?M='7>5!&J CG&C']*OHO\#H)P[0:/X;7( 9N*W$:)2"*?=$9:>TX".+*873
MCV&M&[?V(_\US9] Q@0R)9#8>1F$7.6?J:9%)D6/Y'#W+;6?.-P2<S>E#;JK
M<.],\<I$+T42QAF^6*(1LQLP9(8))P0V[),$\4GLR&UZ=(<@\M88.8)H1D >
M'_T$:R_!VA&L_S.9+$SZ,!N_2.P5B3T$Z4+$A[GC)/&*)+<$9+40&3"QPS0.
M$ZT3O\C&*[+QB(0+D0&3S$0^D3M.4J](ZA$A"Y'TU@E9.L&S/YV#/+L>5Z@4
M7>/FRRPZC9$GXCKE'WR80=^I/->-0@>A3;^YKC@)H<&4LGHP551F[$T'!B=M
MMQNSET/S#P<MVG&NX6FX%G\!4$L#!!0    ( .!Q6U )5_P&. ,  ((-   9
M    >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;(V7T6Z;,!2&7P7Q  4?VT"J
M)%*3=MJD3:HZ;;NFB9.@ L[ 2;JWGS&4!ONXZDW!SG_.YV/LO_;\(IN7]B"$
M"EZKLFX7X4&IXVT4M9N#J/+V1AY%K7_9R:;*E6XV^Z@]-B+?FJ"JC"".DZC*
MBSI<SDW?8[.<RY,JBUH\-D%[JJJ\^;<2I;PL0A*^=3P5^X/J.J+E_)COQ4^A
M?AT?&]V*QBS;HA)U6\@Z:,1N$=Z1VP=(N@"C^%V(2WOU'G2E/$OYTC6^;1=A
MW(U(E&*CNA2Y?IS%6I1EETF/X^^0-!R97>#U^UOV+Z9X7<QSWHJU+/\46W58
MA%D8;,4N/Y7J25Z^BJ$@'@9#]=_%691:WHU$,S:R;,W?8'-JE:R&+'HH5?[:
M/XO:/"]#_K<P/ "& !@#2/)A !T"Z'L ^S" #0'LLP%\".!60-37;B;S/E?Y
M<M[(2]#TZ^&8=\N.W'+]N39=I_DZYC<]GZWN/2\3H//HW"4:-*M> U<:,BHB
MG7U$ (98@1.>\BEAC4B2J>3>E<!4\> J$F#X0"DZ%]0DH),$'$_ T 3,)&"3
M!'8=O88;36TT]&K")Q".0C@"22U(KTFN() E."1!(0D"R2Q(XD(@QB$I"DD1
MR,R"I Z$9!Y(AD(R%T)C"Y(YD%F*,V8H8X8PB,68.0SF6YTDQK=JC&"L37 _
MB"83QJEGQHC'$P@"HC:(N)\_]JPQ@AK#'0&$PVP.N 51[\SA&YM0!,1M$'4+
M2GT%X?N?( 9 ;0,@K@.0F&4>$.X!!#$!FMJVS5VKB:UEN<9$Q#>[N%>0Q/5-
MZJL'=P+B6@%G=CFN%=#8M[!Q+R"8&<QLCNL&P,'#P?V ((; 8IOC.@(03SV
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M+ R\S<3$6*FBZ7Z#U:'1JAR\F%3*[*U_YE7W/ W^W\UP Q@,X&Q V'\-Z&!
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MO-?]E;0?:+4?KMO1^<X__P=02P,$%     @ X'%;4(,!>]\, @  '@8  !D
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M[YOA_#$L!*_5V<J['?!6?P%02P,$%     @ X'%;4!+"&F!E!0  OAX  !D
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MS X,FQZLCGMDR/S@=Z/,"):9"[-4U( E:&8#<&8$S\P%VJG[P8B:=4^^*)O
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M>^4$C'H<.M@ QQ>50)W;2PI@U!>KVZT,33H0I L;#<"D9PXP@"8=,.E,V&
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MWDS1PX=*>HY-7;3C9[ YMUU=VBQ]*67^<_H^5N/WQ>9_#Z,#P ; -:#G_BQ
MV #Q$: ^#8AM0/P1$'\:(&V _&J L@'*"8BFR1IG?YUW^6K1U)>@F1;0*1_6
M*;]7_?O=# _'USG^UK^ MG_ZMM(I7T1O0R*+>9PP<(.!6TR&,1]9HKZ":QE
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M"K/KADO=7S?3T=ATT]4G>^P77<\>5_\!4$L#!!0    ( .!Q6U T,SX:,P,
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M5W\ONE>+NA]5OO>O32T.[VZ=_P]02P,$%     @ X'%;4/#?RAFR @  '0L
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M6@5KH4V/Y#J9G1":FU3B!Y/$P?2J_:#D.VU?I^9=M@U;.]"BZ9K1J.^(%_\
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MH'\W9VDL/*KD-0.N:L&1A"+QGE;[4V3Q#O"GADY-]LA6<A'BU1K?\\3S;4)
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M:'/YW!4IA-!@,O0?3'*5>65&@T*A[79K]K*?M=[0HAF>$3R^9>E_4$L#!!0
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M^YJ:][9O_?N!5L?A6A.-=ZO%?U!+ P04    " #@<5M0"LNC_YH#  "6$
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M)& GVO+4H<;M8;^\7<S$)A.X4PG8J5/IP$U(R#4E@9N0A/]5DM 1IRBQ)1L
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ML1CZIV&B>#_VAM'4H*[^ 5!+ P04    " #@<5M00]-(=(L"   D"@  &0
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M$Q@CK1L"NB%.(+QS@Q)8(0050J<0W>>1]O*H0=2!2@>B88I[D0Q!,:&S7B@
MB-+><FM@N93$L*L(=!4-7:$(PPH45* /)!N#"O&49&M0W+&*40^S C C5A*P
MD 0J9 8KI*!"^D 8,U!A-B6,V<!HO^V&B)$D,(*['P%UH&A$8V0'P0^D@>&^
MQ61*'@VJ:Y?VNP[ 1&.UP#L AK8 1$<TX'[#T2.9P!V'Z:1,Z/ E21'JIS)$
MA:2#NJ\'[E\,-3 >\P2W'DX>R05N/IQ.RB4=;)HD&N8R1(5HD$O0^9C:\]-W
M)H]9J;RMT.:[[+Z>!R$T-XKHR6B=S)&M'>3\H.UM8NYE?6ZI!UI4S9DL: ^&
MRW]02P,$%     @ X'%;4 S\TPL-!   2Q0  !D   !X;"]W;W)K<VAE971S
M+W-H965T.#4N>&ULE9A;C^)&$(7_BN5WUN[R?01( ]8JD1)IM-$FSQYH+EK;
M36PS;/Y]?!L6JHZ9W9?!]IRJ_KHIZK1[?C'5M_J@=6-]+_*R7MB'ICD].4Z]
M.>@BJS^9DR[;_^Q,561->UOMG?I4Z6S;!Q6Y0ZX;.D5V+.WEO'_V4BWGYMSD
MQU*_5%9]+HJL^F^E<W-9V,I^?_#EN#\TW0-G.3]E>_V7;KZ>7JKVSKEFV1X+
M7=9'4UJ5WBWL9_644M(%](J_C_I2WUQ;W51>C?G6W?R^7=AN1Z1SO6FZ%%G[
M\:;7.L^[3"W'OV-2^SIF%WA[_9[]<S_Y=C*O6:W7)O_GN&T."SNVK:W>9>>\
M^6(NO^EQ0H%MC;/_0[_IO)5W).T8&Y/7_5]K<ZX;4XQ96I0B^SY\'LO^\S+F
M?P_# 30&T#5 A0\#O#' ^Q'@/PSPQP"?!3C#5/JU2;,F6\XK<[&JX>L]95T5
MJ2>_7?U-][!?[/Y_[?+4[=.WI5*>.W?>NDRC:#6(Z%9T53AM^NL8A,98D0BG
M^P'64A$%]Y(42$(,X<&)>GV\=S_1B6GX,(/?9_!O,[@A6ZE!$_2:<IAJX+/)
M2DW")*F4S$@%&#: L & 31CLH EO1HD]QBHEI!BKE$2$24-(&DI2Q0LP%&/,
M%+$*64L118P5Y"'R,6T$:2- Z[%R7D5R&)^7O-0$;-8I2*."B;6-(6T,:#EL
M+$9A'&NIF!$KE%1JE#N!FD#4Y"?*()%KQE"E0K&?:"HEL]#%I,K%/=-%1>#Q
MINE^2 LDLX"O+!#Y$RNK)GJ\ KP!QU6@VL*$$R.5SUL"4@7)!#/TC&=%@)EW
MVU%TM\1BC3_6I$"CDJDUQO:B/, ;<5Y/C!,*7JGAI94"S61)8"]3P,Q4S'%]
M\&7SY@!$E'!>D,B;J@?L9PH8FO)\3BS-:!;$G%B*0MX54R!27C2!C(U- 6<C
ML;5"UL:!@;-Q7"F9ZFG8UQ0P-F[U*X6,C6\9D,@3%0%$X=3R8F]3P-R(FYL"
MWB66%VCXA@QIIG"QORED<.(7)\U)_-X^E*0/)??[=6QP! V..P8!]_)Y.T,B
M%8O-/5!%$_LRPB9'P.3X%G%%TIB$$ZZ!*.#?5 I$,PHGFC!ACR/D<=[$6PUA
MWZ%?>:\A; :$S,#CYD6RB?/:!!*^-7B8Y1X6&P%!(Q"PLGT+6& #/$_Z,,\]
M+C8!0J\W$O=1^QYQD5'XO$\]3'3/BWV X M./)$#=V:*?Z4F<;LDU"ZYC:Q&
M5?!HW:1$=*GT89X!U[DY42ETM>]/JVIK8\YETYU+W#R]GH@]4W<BPYZOU%,Z
MG&O]2#,<L_V95?MC65NOIFE,T9_*[(QI=$OH?FK9#CK;7F]RO6NZRZB]KH;C
MK>&F,:?QZ,ZYGA\N_P=02P,$%     @ X'%;4)3KCQO-!   >1H  !D   !X
M;"]W;W)K<VAE971S+W-H965T.#8N>&ULE9EO;Z,X$,:_2I3W7?",#:1*(C5)
M3W?2G53MZ>Y>T\1MHH60 ]+L??OC7[-@/U[!FP;H,^.9L?TS-LM;EG\KCEJ7
ML^]I<BY6\V-97AX]K]@?=1H77[*+/E?_><OR-"ZKV_S=*RZYC@^-49IXY/N!
ME\:G\WR];)Z]Y.ME=BV3TUF_Y+/BFJ9Q_M]&)]EM-1?SSP=?3^_'LG[@K9>7
M^%W_J<N_+B]Y=>?=O1Q.J3X7I^P\R_7;:OXD'I]58] H_C[I6]&[GM6IO&;9
MM_KFM\-J[M<1Z43OR]I%7/U\Z*U.DMI3%<>_G=/YO<W:L'_]Z?V7)ODJF=>X
MT-LL^>=T*(^K>32?'?1;?$W*K]GM5]TEI.:S+OO?]8=.*GD=2=7&/DN*YN]L
M?RW*+.V\5*&D\??V]W1N?F^=_T\S;$"= =T-1/!3 ^X,^(>!_*F![ SD6 /5
M&2C#P&MS;XJYB\MXO<RSVRQOQ\,EKH>=>%15=^WKATWO-/^KZEE43S_60DA_
MZ7W4GCK1IA517W17>)7[>QN$VMB094[#!K:V(E1#R0Y(@J'DV994N3@B95@-
M;CSPT -A#Q)ZD(T'V?,0+8Q4-JU&-9ISHPE8^B%N1L%FE-5,%2@;[;2BH-?.
M P=&,%ME!?,@_%[5VNK;*A$*A2,.8,0!*$QD!!Q8 0=LI;5%*F?Y0AA,B,HG
ML8<(>H@FC)0%]+ 8,5(6=@\*0>;<V +9@LGL0^C,YP '+7S,"Q^5S@CHN5,-
M1M5"L*,E!YG$B!'3B8RD I-@6ZRS*KE#ND$IAY%#WCT)0C5RU1F32$Q!D< L
M$F-@U(D&&0>^-<203(G(-^N'O 5JX8@;PTV,HINP\2;(9 40/40+-J,&KF3H
M"AKS38P!G+#9]: 6REP.D<SNDQWTUN^38=P8A0*RT$%3@6$HIM!08!R*,3P4
M-L-$$)K5 Z!C:Z#:(I81CI@P"@FBT!RFG6I('FF\NFR!2IBC9X=<<>@*&E.5
MQE"5; J2252@L;IB!T3]KA@&C&%*$*:NI#%,:0I,"<.4QL"4$/XBLW*V2/KF
M8HT\"7:]=F..TBB.D@T_-C$*- _*I"@0*785&4.4QD"4 /;87*^0R.R)'1#U
M>V(8,<8G07PZE@["^*0I^"2,3QJ#3P)D#'PR 8IDB@(RJX=D,G2\Y3&&*(^"
M* /R$1MS9HM4@LQ.!RH2KETBABB/@2@#]@6DS&)#F=4G.R0;],DP;LQ21BQ5
M#AZS8XL\A:6,6<IC6,HV 4.S,[=(I,RU'H@BU]L=8Y3R*)0RP&1_7]G%C%1!
M8 :-5.2*&N.4Q^"T$_7W:BJR8K9%5F?LD,@YNC!.&>%4N68GQBE/P2ECG+*-
M4[#-94! UVD1QI]$^%,N'YA&4DS(5V(R2/B69>;;J0;Y2N'8V$K,#\DH8\>B
M(1V';')*QGA&2SBCK8S1+'2T@^>@M.=@E:_CK$GB62'#*?GB62&C4?E&8#5B
MQVY0XKDCT=Q1CL-"A>>%\B=DK/"\4/8J#3+N5(.C3>LHT.L=IZ<Z?V^^;12S
M?78]E_6)<^_I_?O)$]7'\<;SC7C<M5]!?KAI/\K\$>?OIW,Q>\W*,DN;(_FW
M+"MU%:/_I8KNJ./#_2;1;V5]&5;7>?LQI+TILTOWH<>[?VU:_P]02P,$%
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M_7E__.OQJ<_V<1_^QV_VF_O+Q_]DX.+E?SIX_W]02P,$%     @ X'%;4$K
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MNN^&^7I82-&.WP[1] &S^@=02P,$%     @ X'%;4-BT;SOJ @  U0P  !D
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M?N?-M6OS4/*#O%*VVGOMZ1]02P,$%     @ X'%;4+&_.1;=!   )!L  !D
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MQB+4< 5D2>&GX(:MG10.<BW'VG$YA]3L.FYKK$$]YJBLL08U/"K;&TG-;[/
M#0] \1L>_^I>.C/EKKOSK[QU<<KK]G;WJO3R7>%)MO?:5OE2/*[ZKP._PO0?
M*_Y,RMTAK[S7HJZ+K+O;WA9%;1J.P9>&W=XDF\M+:K9U^Q@USV7_D:!_J8OC
M\ '$OWR%6?P/4$L#!!0    ( .%Q6U!Z."I9Q (  ,<*   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$P,BYX;6R55EUOFS 4_2N(]Q9LS$>J)%*3:MJD3:HZ
M;7MV$R=!!<QL)^G^_6SC4F(N5?H2L'/NN?=<..;.SUR\R -C*GBMJT8NPH-2
M[5T4R<V!U53>\I8U^I\=%S55>BGVD6P%HUL;5%<1CN,LJFG9A,NYW7L4RSD_
MJJILV*,(Y+&NJ?BW8A4_+T(4OFT\E?N#,AO1<M[2/?O)U*_V4>A5U+-LRYHU
MLN1-(-AN$=ZCNP=L RSB=\G.<G ?&"G/G+^8Q;?M(HQ-1:QB&V4HJ+Z<V)I5
ME6'2=?QUI&&?TP0.[]_8OUCQ6LPSE6S-JS_E5AT681$&6[:CQTH]\?-7Y@2E
M8>#4?V<G5FFXJ43GV/!*VM]@<Y2*UXY%EU+3U^Y:-O9Z=OQO87  =@&X#T#9
MAP&)"TC> \B' <0%$"\@ZJ38WCQ019=SP<^!Z!YO2\U;A.Z([O[&;-IFV_]T
M>Z3>/2T1(7@>G0R3 ZTZ$!Z">D2DZ?L<&,JQPJ-P+\%ZC,C32\@# ,G@(A)0
M:&+CDT'\+"$P 0$)B"4@%YW"B=>I#I1:4&-!648\L6/,#<X]M6-,BF.XVA2L
M-@6J)7ZU'2@;9$$DA;-D8)8,RN+I767C+!F:><]W/48513+QFN5@,3E4S(2<
M F0HKG]'9B#![)I^S,;]0/'$PT4Q[-H82C3A!S3A?'2]6@0:^Q[A<1D)\O4Z
MU%"P_BY-"8;=BQ(@4SK% 1L8D4\(AEV% %L!@@%?%9."86<AT%KY! =L")1_
M0C#L"%1<<^HYU,43)MZ1M@9 -RB9J :V%P+]54Q\BV#KX/CZIF#8.1A=TQ2'
MNCS#_5,/ -V@ GOE1(.O><W$WDY*,MCP8Z/,-W&PVT]C]]A, ][^2D]IW4SU
M3M.->#^HV)>-#)ZYTK.&G0AVG"NFBXQO=7D'/57VBXKME+G-];WH1JMNH7CK
MQL:HGUV7_P%02P,$%     @ X7%;4($7//Y\ @  = D  !H   !X;"]W;W)K
M<VAE971S+W-H965T,3 S+GAM;)667Z^:,!C&OPKA_APH?\4@R719MF1+3LZR
M[;IJ%7(*96W5LV^_MB"!\JK;C;3U>1]^+>6A^87Q-U$2(IWWFC9BY992MDO/
M$[N2U%@\LY8TZI\#XS66JLN/GF@YP7M35%,O\/W$JW'5N$5NQEYXD;.3I%5#
M7K@C3G6-^9\UH>RR<I%['7BMCJ74 UZ1M_A(OA/YHWWAJN<-+ONJ)HVH6.-P
M<EBY']!R@Q)=8!0_*W(1H[:CI[)E[$UWONQ7KJ^)""4[J2VPNIS)AE"JG13'
M[][4'>ZI"\?MJ_LG,WDUF2T69,/HKVHORY6[<)T].> 3E:_L\IGT$XI=IY_]
M5W(F5,DUB;K'CE%A?IW=24A6]RX*I<;OW;5JS/72^U_+X(*@+PB& A3=+0C[
M@M J\#HR,]6/6.(BY^SB\.YIM5AO"K0,U6+N]*!9._.?FJU0H^<"15&6>V?M
MU(O6G2@8B8*I8C-7I/$@\13!@!& &(&ICR88L0\[A*!#:!S"D4,61K!!!!I$
M$ *R5J(3Q4;4&%$46TMQ5S+AB$&.&.*PUGO=B9+137P+8ZYX0C!& F(D$$9H
M820/,>XI)A0I2)%"%#<>ZP)T6/S[OLA @PQ"L![Z.GNX$',%BK(,!D$^_*[Z
M$$IBOZS^0Q9 \G1CCZ(;L8$@E-1&08]1[DFF)'!R(# Z%C<\X.Q _Q$>"$X/
M!,:'O4UZU7BVJ9_-PG2NRK)1!$QYX!1!8(S,]LH\)8(DL7& *+D5:0@.$P2F
MR6R[)+/H3++9AIF+4&"_1][H\Z?/(]\P/U:-<+9,JB^I^=X=&)-$&?K/RJI4
M1Z"A0\E!ZF:JVKP[!W0=R=K^C.,-!ZWB+U!+ P04    " #A<5M0@XA9?/T!
M  ",!0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,#0N>&ULC53;;IPP$/T5
MQ ?$W'=9 5(V4=5*K;1*U?39RPX7Q<;4]B[IW]<70BEQI;Q@S_C,.7.,/,7$
M^(OH *3W2LD@2K^3<CP@).H.*!9W;(1!G32,4RQ5R%LD1@[X8HHH05$09(CB
M?O"KPN1.O"K859)^@!/WQ)52S'\?@;"I]$/_+?'4MYW4"505(V[A.\@?XXFK
M""TLEY["('HV>!R:TK\/#\=<XPW@N8=)K/:>=G)F[$4'7RZE'^B&@$ M-0-6
MRPT>@!!-I-KX-7/ZBZ0N7._?V#\9[\K+&0MX8.1G?Y%=Z>]][P(-OA+YQ*;/
M,/M)?6\V_Q5N0!1<=Z(T:D:$^7KU54A&9Q;5"L6O=NT'LT[V)-W/9>Z":"Z(
MEH+(>K%"IO-'+'%5<#9YW-[]B/4O#@^1NIM:)\U5F#/5O%#96Q4F:5Z@FV::
M04<+BM:@!8$4_:(1N32.T?OR^#\$L;/)V!#$*X(\3MP$B9,@,03)/RZS8./2
M@E(#&@PH27*W2NI425TJX4;%@K*URBYPJV1.E<RE$FU4LG=>]G'J5MDY578N
ME=C-L'<R[#_^TW(G0>YJ(=D8=8*V3M'J-5#@K9D#PJO9=3 S:)5=1LU]9%[3
M7[B=4]\P;_M!>&<FU9LT+Z=A3(+J);A3]]VIT;@$!!JIMSNUYW9 V$"R<9Y]
M:!G U1]02P,$%     @ X7%;4/!67/;& 0  &@0  !H   !X;"]W;W)K<VAE
M971S+W-H965T,3 U+GAM;'54VXZ;,!#]%<L?$ ="LML(D#9;5:W42M%6W3X[
M,("UOE#;A.W?UQ="V2U]P3/C,V?.>&SR4>D7TP%8]"JX- 7NK.V/A)BJ T'-
M1O4@W4ZCM*#6N;HEIM= ZY D.$FWVP,1E$E<YB%VUF6N!LN9A+-&9A""ZM\G
MX&HL<()O@2?6=M8'2)GWM(7O8'_T9^T\,K/43( T3$FDH2GP0W(\[3T^ )X9
MC&9A(]_)1:D7[WRI"[SU@H!#93T#=<L5'H%S3^1D_)HX\5S2)R[M&_NGT+OK
MY4(-/"K^D]6V*_ ]1C4T=.#V28V?8>IGC]'4_%>X G=PK\35J!0WX8NJP5@E
M)A8G1=#7N#(9UC'N'&YIZPGIE)#."6GL)18*RC]22\M<JQ'I>/8]]2-.CJD[
MF\H'PU&$/2?>N.BU3++#(2=7SS2!3A&4+D$S@CCZN4:Z5N.4_IN^^P_!;E7D
M+A!D;T7>K3-DJPQ98-B]9;A?9]BO,NS7-'QX=U 1E,0Z,J(VV;LR9#$; ;H-
MM]*@2@TRO(A%=+[X#VF8[5]X?#7?J&Z9-.BBK+LA88Z-4A:<ENW&B>G<0YT=
M#HWUYIVS=;RNT;&JGUXBF7\'Y1]02P,$%     @ X7%;4 &GQ2$. @  _P4
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MEY#,A,0AH,F9C?J)*EH5@H^!F#[60,T_$>\3W<RSV;2]L^]T6JEW'U6<DJA
M#Z,T@PX3"*] ^#VBWB)(MD"0=K#8P%X;V/*3%3_!D5\@\0HD5B!]GR-V<DR@
MS(+Z*0?)G+"U!X1S[/>2>KVD/B].QPX3*%^524F:.%Y\H"CV>\F\7C*?%Z?,
M(=N4(1_<MFPQ69K[G>1>)[G'B=N4?%-DAW=N4[8@_1%W?BO$:X7XFI(Z7LCF
M/R"Q@ZFWF#QVG:#54317XW<J;FTO@Q-7^E3;LW?E7('6BYZT5*-OXV7!X*K,
ME.BYF.ZD::'X,%^W:+GSJW]02P,$%     @ X7%;4$[@EI2! P  !!$  !H
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MEM^WYL,8LTHBW<W552NUTJI5VV=O0C96;9/:WDW[[XL_-DK@T)N\Q(:<&<X
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M!C M?M(+194[+4! J Q-"Y8&FB$^@7RD6!RHO&5><%)3F-7>O*"TEJ[$ %1
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MQL'2?N+ ?;P#UXYF"QP+)8+7F\7NXX_#%<?7@N9^,5[TZRX3[*J3A4K%[AK
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M6&UOFS 0_BN([RW8QVN51&HR39NT256G;9]IXB2H@#-PFN[?SS:4 CYWY$O
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M%#V<$XL.G*\TNJ8D<+Y2[,0T2L(\#(D?),$T,1@L\BVLI#CY*4)^LR1,[M^
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MA^QT,O3^=_?NL@9OE31M;(JLZOY.-F]57>1#+8V4//W1?^X/W>=IJ/^C&"Y
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MTUD=:B6+(4LCI4A?^^^L[+Y/0_ZW,!Q AP Z!A#^80 ; MA[0/!A0# $!%J
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MM+D,[LA60F@PI82/IHK:O$GS@D&E[30U<SG>S'&A13<].GA^^?*_4$L#!!0
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MI>2I5?/U ,IOKIDGL27%Q91E"BO)026YJZ2T\EWGSB5%EEI" $SI*4D!"BF
M?R?WI#('&>8?Z) 29"BG=$CI9#K#);8^J0V$2@J/&A3#WVX\I4T,ZOXJ6PX
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M6QS1*IP)[[>PJ8XS'5-E0P0-A^#.])J(?^%Z'@")(P:&,ST">@L[O>JAL2=
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MH)26+<?P4\ON)+/][:60!]T])NUS/=Q/#2]:G<>[M^!V ;C^#U!+ P04
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MFYP18W"X37GN@2J>!CX0W7J#(>2 '6T480/#PWU&5 2F1["4YP"HR $+C)B
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M2:X+O^ZD\+C6X>KP$.G7O/SJ%]_3^K>R^B%/=N9W0.?P8^3\?U!+ P04
M" #A<5M0YY_761 "  ".!0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,S N
M>&UL?53;CILP$/T5Q >LN2>- &D35+52*T5;=?OLD F@M3&UG;#]^_I"6 )H
M7[ ]G'/FS& F[1E_$S6 =-XI:47FUE)V.X1$60/%XHEUT*HW%\8IENK(*R0Z
M#OAL2)2@P/,21''3NGEJ8D>>I^PJ2=/"D3OB2BGF__9 6)^YOGL/O#15+74
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M!T&,&*D;/TMM[""RE)\5K1LX"$^>&2/BSQXH[[9^Z%\#+W59*1- 6=J2$GZ
M^MD>A%ZAD>54,VADS1M/0+'U=^%F'V*38!&O-71R,O>,E2/G;V;Q];3U U,1
M4,B5H2!ZN, S4&J8=!V_!U)_U#2)T_F5_;,UK\T<B81G3G_5)U5M_<3W3E"0
M,U4OO/L"@Z'(]P;WW^ "5,--)5HCYU3:IY>?I>)L8-&E,/+>CW5CQV[@OZ:Y
M$_"0@,<$'%DOO9"M_!-1)$L%[SS1;WY+S!F'&ZSW)C=!NQ7VG2Y>ZN@E"Y,$
MI^ABF ;0O@?A*6A$($T_:F"7QA[?IR?)PLVP<%:YL R+&X8X<#,LG0Q+R["\
MK6$Y\]F#8@MJ+ @_$(F<(I%+))J).$&Q6R9VRL0NAM5,YAX4K1^<VLJILKHG
MF&S8#4'B)$@^<&AK)\/:9329&;T'11/,C4H8N.] X*!8/Z!X<(W"#Y@-G==D
M%^+_L>M"+=;S[P=-[C\#4=K.)[V<GQO;=B?1L;ON;'-%_^!]:_Y.1%DWTCMR
MI;N0[14%YPIT,<&3_I@K_3<8%Q0*9:8K/1=]2^P7BK=#NT?C/R?["U!+ P04
M    " #A<5M0B*WN-C,"  #S!@  &@   'AL+W=O<FMS:&5E=',O<VAE970Q
M,S0N>&ULC55A;YLP$/TKB!]0"!!((H+4$$V;M$E1IW6?'7()J#9FMA.Z?S_;
M$)JXMZI?L'V\]_SN,.>\Y^)%U@#*>V6TE6N_5JI;!8&L:F!$/O .6OWFR 4C
M2B_%*9"= '*P)$:#* S3@)&F]8O<QG:BR/E9T::%G?#DF3$B_FZ \G[MS_QK
MX*DYU<H$@B+OR E^@OK5[81>!9/*H6'0RH:WGH#CVG^<K;:9P5O <P.]O)E[
M)I,]YR]F\>VP]D-C""A4RB@0/5R@!$J-D+;Q9]3TIRT-\79^5?]B<]>Y[(F$
MDM/?S4'5:W_A>P<XDC-53[S_"F,^<]\;D_\.%Z :;ISH/2I.I7UZU5DJSD85
M;861UV%L6COVH_Z5AA.BD1!-A"CYD!"/A/BSA&0D)&^$V%9K2,769DL4*7+!
M>T\,7[<CYA#-5HFN?F6"MMCVG2Z/U-%+,5LLEGEP,4HC:#. HEO0A BT_+1'
MA.VQB=[1H_L-RO>(;'X/V2*0%#<1HXG&EA_?)9J&N$*"*B16(;E36(9.J5#0
MS$D7!3DUV:*@&#<\1PW/,87$,8R"G.*7""@-%XYA5.D_WRA%#:>80N881D&.
MEQ(!9:EK&%5:XH8SU'"&*"R<;38(:!DZYZ9$0<ZYV:*@R#$<W/SZ#,3)ME7I
M5?S<*O,#W42GSOT8F=;AQ#>ZHP\-^$UFN Y^$'%J6NGMN=*-R;:/(^<*M,?P
M01^#6M] TX+"49EIIN=BZ,/#0O%NO&*"Z9XK_@%02P,$%     @ X7%;4,/%
M<G4' P  J L  !H   !X;"]W;W)K<VAE971S+W-H965T,3,U+GAM;'V676^;
M,!2&_PKB?H _^*J22$VB:9,VJ>K4[=I-G 05,,-.TOW[V>!28@ZY*>"\YSSG
M&//V+*ZB?9,GSI7W7I6U7/HGI9J',)2[$Z^8#$3#:_W+0;054_JQ/8:R:3G;
M=T%5&>(H2L**%;6_6G1K3^UJ(<ZJ+&K^U'KR7%6L_;?FI;@N?>1_+#P7QY,R
M"^%JT; C_\752_/4ZJ=PR+(O*E[+0M1>RP]+_Q$];'%D CK%[X)?Y>C>,ZV\
M"O%F'K[OEWYD*N(EWRF3@NG+A6]X69I,NHZ_-JD_,$W@^/XC^]>N>=W,*Y-\
M(\H_Q5Z=EG[F>WM^8.=2/8OK-VX;BGW/=O^#7WBIY:82S=B)4G9_O=U9*E'9
M++J4BKWWUZ+NKE>;_R,,#L V  \!*+D;0&P ^0R@=P.H#:!.0-BWTNW-EBFV
M6K3BZK7]ZVV8.47H@>K=WYG%;K.[W_3V2+UZ6:$\(HOP8C)9T;H7X;%H4(0Z
M_<# $&.-)^'X%K"9*M+X5K(%) E<! $;)5T\N6V4PADHF(%V&>AM!J?,=2]*
M.E'=BTB6TQ@&Q2 HAD") XHG())C.K,E"<A)($[J<)()YPM-4Q3!H!0$I1 H
M<T#I%)1F>*:A#.1D$"=W.-GT#6&<Q-0YDH#LSHO,P7IRX,S-[1R*X.\S GI"
MR/U >U4ZJC8):#9#FG$"!)&P2^I5V8B4!;'[/5O5N)XTH(YJ"ZB2 ).9JD%O
M>408JGIB8'A2=1SD>(8$&P@B$(FZ)#(AI4$RUQ-L- AR&N0ZC57=DF+BOHFI
MZL[)@/T(Q= YGODR$>PU"#(;Y)J-58VK)22@,S:-8+=!D-T@UVZL:HRB)" S
MWS>"#0=!CH-<Q[&JFZZB()TAP5:"<H"$(Y>43TE9D,,D##L.AAP'NXZ#IXZC
M29$CVT RX(6&HW&EXNVQ&P6EMQ/G6IE_^J/58=Q\Q&;<<=;7>@SMA\;/-/T,
M^Y.UQZ*6WJM0>ICJ1IZ#$(KK*J- '_"3'IN'AY(?E+E-]7W;SX[]@Q*-G8O#
M83A?_0=02P,$%     @ X7%;4 AQ&H$> P  D0P  !H   !X;"]W;W)K<VAE
M971S+W-H965T,3,V+GAM;)57VXZ;,!3\%<0'!'QL,*R22)NMJE9JI=56;9^]
MB9.@!9R"DVS_OL802LQQI>8A@#.>\24S/BROJGEKCU+JX+TJZW85'K4^/411
MNSW*2K0+=9*U^66OFDIH\]@<HO;42+&SG:HR@CA.HTH4=;A>VK;G9KU49UT6
MM7QN@O9<5:+YO9&ENJY"$MX:7HK#47<-T7IY$@?Y3>KOI^?&/$4CRZZH9-T6
MJ@X:N5^%C^1A VG7P2)^%/+:3NZ#;BJO2KUU#Y]WJS#N1B1+N=4=A3"7BWR2
M9=DQF7'\&DC#4;/K.+V_L7^TDS>3>16M?%+ESV*GCZLP"X.=W(MSJ5_4]9,<
M)I2$P3#[+_(B2P/O1F(TMJIL[7>P/;=:50.+&4HEWOMK4=OK=>"_=<,[P- !
MQ@Z4V[GT0G;D'X06ZV6CKD'3+_Y)='M,'L"LS;9KM$MA?S.#;TWK94UR@&5T
MZ9@&T*8'P10T(B)#/VH IK&!>?<<*,Y T5%2R\"F#!E/<0:&,C#+0.\8TAAG
M2%"&9#Z&')BS4CTHM:"Z!_'<?.+8HY6B6BFFE3A:/8A/M&BRH)YUY:@.QW12
M1P<%<5PF0V4RC"%S9'I0,ETZ1A)<)D=E<DPF=V3RV0XEG++$NT$DQGT3(V(T
M=HT3S_>(+&+FD?)8E&!2Q)5"4>!10HWZ2 #CH*X2S':*<\]&$=S/!#%T3ETS
M#:@[-QG7DLR_6;CY"</D7#\-J+O-X@M?4!$\)0@6$]2U%([R>(K@&4&PD*"N
MJP;4G:WBW!.=!$\)@B4 =8TUH*:[Q?.$IMQS5A \*P@6%FQFK&RV5\"]X4?P
MO"!88+"9L>:) 8130GUG(!X8@ 4&<T]:0 (C7J291PH/#,"B@'G6!O H /B/
M Q-PEP/F\MF1"8C+X1\G)N >!\SCL[,,13%/'@-N<4 K ==X VIJO,3WC\$-
M#IC!F9M: VJZ?!ECV<QUT:0BK&1SL+5P&VS5N;:%^*1UK+<?P5:4?^%]L?Y5
M-(>B;H-7I4U=:JO'O5):FN'$"S/AHWD_&!]*N=?=+3?W35\D]P]:G887@&A\
M"UG_ 5!+ P04    " #A<5M0C>2W>"8"   _!@  &@   'AL+W=O<FMS:&5E
M=',O<VAE970Q,S<N>&ULC57MCILP$'P5Q /$Q'PD%Q&D2U#52JT47=7K;P<V
M 9V-J>V$Z]O7-H0CQ*KN3["7F=G9C;VD'1=OL@)0WCNCC=SZE5+M!B%95,"(
M7/ 6&OWFQ 4C2F_%&<E6 "DMB5&$@R!!C-2-GZ4V=A!9RB^*U@T<A"<OC!'Q
M=P>4=UM_Z=\"+_6Y4B: LK0E9_@)ZE=[$'J'1I6R9M#(FC>>@-/6?UYN\L3@
M+>"UADY.UIZIY,CYF]E\*[=^8 P!A4(9!:(?5]@#I49(V_@S:/IC2D.<KF_J
M7VSMNI8CD;#G]'==JFKKKWVOA!.Y4/7"NZ\PU!/[WE#\=[@"U7#C1.<H.)7V
MURLN4G$VJ&@KC+SWS[JQSV[0O]'<!#P0\$C X7\)X4 (/TN(!D+T08ALM_I2
M;&]RHDB6"MYYHO]W6V(.T7(3Z>X7)FB;;=_I]D@=O6;+IRA)T=4H#:!=#\)3
MT(A 6G[,@5TY=OB!CN\3[!\1J_@>DCL@B=M$Z"PTM/QP6L,Z"=P*D5,AL@K1
M?:M6LU;UH)4%-1:T7L3S<A]!JT4T ^6/H&2!0[?AV&DX=AE>SPSWH'B2!N.G
MF5\'9GY&<@<FQ&ZWB=-MXG([<[)S@>)@9O<SH-P)FA]K-+E&#,39CBCI%?S2
M*',8)]%Q"CYC<PUG\9V>COTP^Y#I1^L/(LYU([TC5_J2VZMXXER!]A@L=#LK
M/<W'#863,LN57HM^IO4;Q=MA7*/QFY'] U!+ P04    " #A<5M0OC4DT_@!
M  "F!0  &@   'AL+W=O<FMS:&5E=',O<VAE970Q,S@N>&ULE53MCILP$'P5
MQ /$8#X3$:3FJJJ56BFZJM??#BP!G8VI[83KV]<V!'$YG]3[@[W+[,R.P5N,
M7#S+%D!Y+XSV<N^W2@T[A&35 B-RPP?H]9N&"T:4#L49R4$ J6T1HP@'08H8
MZ7J_+&SN*,J"7Q3M>C@*3UX8(^+O 2@?]W[HWQ*/W;E5)H'*8B!G^ GJUW 4
M.D(+2]TQZ&7'>T] L_<_A;M#&)@"BWCJ8)2KO6>LG#A_-L&W>N\'IB.@4"E#
M0?1RA0>@U##I/O[,I/ZB:0K7^QO[%VM>FSD1"0^<_NYJU>[]W/=J:,B%JD<^
M?H794.)[L_OO< 6JX:83K5%Q*NW3JRY2<3:SZ%88>9G6KK?K.//?RMP%>"[
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MQTG-C]H.F1G+OE7J)UIT0QL8C[WHYB]02P,$%     @ X7%;4$,45DM3 @
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M20@-IIC@P1RRQC3I><'@I.UT8^9R[%3C0HM^ZL)D_A64?P!02P,$%     @
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M($"NZ4RN!:A0 +FFRTFN19 K8IC,["L%.13BD F'!AR"$88Q#,0P"%-,,"S
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M>Y[M3&?.%>A(@@==6I5^>\8%A;,RT[6>B[X!]PO%V^%Q0>,+5_P%4$L#!!0
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M+._RU:)1%Z<9'N\I-U7$'D.M_M8,]F+WOVEY6CWZNN)^&"^\5Y-I!*T'$)^
MV!7AZ?37.3B:8\VM<'X[P<9&Q-$M) ,0@4D$<*%!'Q_<+C3!&4*8(>PSA),,
M24J$&B!1#ZD'H01/$[):@&(L)KDR&\59$ 68<0091Q;CE,BZ'B!B.@LALK$A
M@2!<;<BDAFZ("DA46$3UPZ'B"FL2+:Z@; &*L3 @A&V4%M>?*:@8<HX!Y\@G
MG&.;#>'[+B*[A[CAF4">">))YE@G4%M:N "EM25_YLQ&&6TCS#F%G%.[<,D3
M7*=VR1&V-H*1QY/9$(YI,A]W3Q^)RVG[]*UI")'-^Y#L+N26[$RK9X@LU75$
MW1,60"QE 69.6F@:3XPCMB%ERU'AQM1?$(PQ^J R #.E.]/*&#8:AIPFFBE_
MAJV&V5ZC<PBZ^/"/.B*"@98(8'=Z(L..PVS+034&_(*2MB%VC0'SFF&+;8<A
MWXFLW8] KAX'E#& Z1JS9+9A1N:9G0C#WL-B5&-S.; O,&@,U'29W<VCR"XQ
M@$KHOS!#J#2>:V+8&9AM#=P7U'89ZOV"DD8@NNT$H,FN[W;SBSV"(X\0U("Y
MW=TC03?!&X1*8U*P&4")V>K@V"PX,@M!G6U$Q5,)'T(J-$0%"64-43.DL6=P
MY!EB+@=NWQRV[SGQ</OFJ'T+ZET<-%RJW+N0#$""F9[-<<_F=L^>72_NHUS\
MC6:XI7%[/\W2F.Z%1U0Z+9+H@79];_+V6\GFT)\LM,Y6G>O.O$-.1J^G%T_<
MO#V3\35[S(8SB-]IAB.1?_/F4-2M\Z(Z_6[>OT'OE>JD)ND_:$&/,M]=;TJY
M[\QEK*^;X2ABN.G4:3QF\:YG/:M?4$L#!!0    ( .%Q6U#\H;5UD@,  !43
M   :    >&PO=V]R:W-H965T<R]S:&5E=#$U,BYX;6R56-MRFS 0_16&#RA(
M,K>,[9G&:>Z9R:33]IG8LLT$D NRG?Y]!<B.D7<]XL5<?,Y9K59'"XSWHOJH
MUYQ+Y[/(RWKBKJ7<7'E>/5_S(JV_B0TOU3]+416I5)?5RJLW%4\7+:G(/>K[
MH5>D6>E.Q^V]UVHZ%EN99R5_K9QZ6Q1I]>^:YV(_<8E[N/&6K=:RN>%-QYMT
MQ7]R^6OS6JDK[ZBRR I>UIDHG8HO)^YW<O7"DH;0(GYG?%^?G#M-*N]"?#07
M#XN)ZS<CXCF?RT8B58<=G_$\;Y34./YJ4?<8LR&>GA_4;]OD53+O:<UG(O^3
M+>1ZXL:NL^#+=)O+-[&_YSJAP'5T]L]\QW,%;T:B8LQ%7K>_SGQ;2U%H%364
M(OWLCEG9'O=:_T"#"503Z)% R44"TP1F2QAIPLB6$&A"8$L(-2&T)42:$-D2
M8DV(;0F))B2V!.(?*N=;4X[%_JHVNUQM<B@WL:XW.12<F!7WNK78+NZ;5*;3
M<27V3M7Y<Y,VVP"Y4BPEWMQM[=+^J19XK>[NIM0/@[&W:Z0TZ+H#T3XH[(-F
M("CJ@VY 4-P'_0!!21]T"X$BOP^Z T&D#[H'0;0/>@!!K ]Z!$&C/N@)!!DS
M_FPSXR^@TA?(4Y4_EI_"Y:>MQ*@O$<$2#)9@K03K2\2PQ B6&$&C, I^WX'"
M%E1V(#A(  <)@""Q#TN$L$0X(-4(EHB@41@K\C8Z2Y7 06(X2 P%068K@262
M :DVNR.XM_C0.)BY)?BVA278'D:@."-$!'$"H4,R1KQ F%7&S#ICQ# $<DP<
M("*((4@P)&/$$B2$1G*V4X6V*YH@OB&@<9"=BB"^(/&0C!%GD,3"PG<:99$Q
M1=Q#0?<8O?*&GKL'BX.XAX+N,7;?.XTZC<.0.%BK@7I-@FS %#$8'=)M*.(>
M"KK'R/B:7FHXW8/*14A_*(@'*=25$F,Q/6N439$1FU+(I@DV6,2#-!HR^8@'
M*=B<0G.YQ6<9&\]1CQ<A_:$@3J:0DQ-D63/$ILP?,"D,\2 #/6CTC0=F[4&&
M>)"!'D2FC6$/?$,\R! /,M"#1L9/[-Q@6,:(P1AHL,",<VXPBG13ACB,@0X+
MS4#6C9 A)F10(TRP1W;$A&Q((V2(?1C8"(T2SMAY(S1+Z)V\K38?C%[2:I65
MM?,NI'KU;=].ET)(KN3\;ZI2:YXNCA<Y7\KF-%+G5?>AIKN08J,_0GG'+V'3
M_U!+ P04    " #A<5M0-V<KJ_4"  "2#   &@   'AL+W=O<FMS:&5E=',O
M<VAE970Q-3,N>&ULE5?M;ILP%'T5Q ,4;+ZC)%+3STF;5'7:]MM-G 05,+.=
MI'O[V<:A0"\1^1.P<^XY]]H^MIF?&'\7>TJE\U$6E5BX>RGKF>>)]9Z61-RP
MFE;JGRWC)9&JR7>>J#DE&Q-4%A[V_=@K25ZYR[GI>^'+.3O((J_H"W?$H2P)
M_[>B!3LM7.2>.U[SW5[J#F\YK\F._J3R5_W"5<MK639Y22N1L\KA=+MP;]'L
M&4<ZP"!^Y_0D.N^.+N6-L7?=^+99N+[.B!9T+34%48\CO:-%H9E4'G\MJ=MJ
MZL#N^YG]T12OBGDC@MZQXD^^D?N%F[K.AF[)H9"O[/1,;4&1Z]CJO],C+11<
M9Z(TUJP0YM=9'X1DI651J93DHWGFE7F>+/\Y# [ -@"W 3B^&!#8@. SX+)"
M: /"J0J1#8@^ ]#%@-@&Q%-32FQ ,E4AM0'I(,!KIL/,[SV19#GG[.3P9HG6
M1#L!S5*U@M:ZTRP8\Y^:8J%ZCTOL9^G<.VHF"UHU(-P!)7[88CPET*I@2&6%
MOQ HE:RO<@> D._W0?<@"/5!#R (]T&/("CH@YY 4-@'/8.@"!Z? )R%P# $
M'88L&AG@$"0(#4'83R$>C%T#B@VH:D"P1@1J1)!& C/$($,\O<P$)$B@% :K
M]2'Y4F8,:Z2@1@II9#!#!C)DT\M$/NQ*?TJA%C5A0M&(^1$@@_P1#M#:MPA?
M42V\^E$ I3$TM45UJQV3@3V"().@L1&#/8"B*ZJ%38!B*(U@N.7&7ZI-1V1@
MJR#(*V@L5=@**+VB6M@+*(/2B 9;OT7!*[G9KB]"^D<0["D,>0J-; T8-@Q&
MTP<$PW[!&$HC&1XI#0J%W?D/;\8JAGV%05^-+",,FP:'5U0,>P9#!P<:G/Y/
M%M6=7S20\3J7FI+RG;GT"F?-#I74YV^GM[U8WV)]*1KTK]#LL;DL?=(TM_4?
MA._R2CAO3*HKE[D8;1F35&7HWZ@,]^H#H6T4="OU:Z+>>7-+;AJ2U?8+P&L_
M0Y;_ 5!+ P04    " #A<5M0@5 R ,X"  "S"@  &@   'AL+W=O<FMS:&5E
M=',O<VAE970Q-30N>&ULE5;;CILP$/T5Q <LMKFODDBYJ&JE5HJVZO;9FS@)
M6L#4=I+MW]<VA"5X6&U? CAGYIPYR0PSNW+Q*D^,*>^M*FLY]T]*-8]!('<G
M5E'YP!M6ZV\.7%14Z4=Q#&0C&-W;H*H,"$))4-&B]A<S>[85BQD_J[*HV59X
M\EQ55/Q=L9)?YS[V;P=/Q?&DS$&PF#7TR'XR]:O9"OT4]%GV1<5J6?#:$^PP
M]Y?X<4.0";"(YX)=Y>#>,Z6\</YJ'K[MYSXRBEC)=LJDH/IR86M6EB:3UO&G
M2^KWG"9P>'_+_L46KXMYH9*M>?F[V*O3W,]\;\\.]%RJ)W[]RKJ"8M_KJO_.
M+JS4<*-$<^QX*>VGMSM+Q:LNBY92T;?V6M3V>NWRW\+@ -(%D#Y <W\4$'8!
MX7M \F% U 5$[P&1=:LMQ7JSH8HN9H)?/='^O TU_R+\&&GW=^;0FFV_T_9(
M?7I9$$S0++B83!UHU8+( )2BZ!ZS=C&X1P1:0J^#0#I6Q U'.!UQN"!RC]BX
MB#2&982@':&-#P?Q>1S!"2(P06031/=^XE$=+2BVH+H%Q0C!-#%($SLT&#DT
M+2@9T&!-,\&3@#P)Q#,R?94XY:3Q!$L*LJ0.2Y*-BTF=8E(\PFQ21TB>9;"0
M#!220;_>J-QUYMJ:C#IFXV)(-F%)#BK)(27A2$GNU!O'8T]<3(HF/,$('A'(
M_1.$^41;X8DQ@S_?6!B<$$M,(!EH/(9 5#+!! \!'$+F.P,O=)R-,)D@@H<%
M=J>%%CN5 YX$./X/9^$FQT"7 \Z"J'"""6YT['8ZY*S;QV3P+K@G@AL9NYV,
M433Q1L)P"^+\\\X2N'4(T#KNG.Y0PWH39TP'@S=ZQ<31;DO2V_%S;5>UP6F_
MD2V)W0C>X>TZ]X.*8U%+[X4KO5?8M_^!<\6T%O2@59ST!MD_E.R@S&VJ[T6[
M1K4/BC?=BACT>^KB'U!+ P04    " #A<5M0.L^''3,#   C#P  &@   'AL
M+W=O<FMS:&5E=',O<VAE970Q-34N>&ULE5?MCILP$'P5Q ,4O)B/G))(EZ"J
ME5KI=%7;WUSB).@ 4W"2Z]O7!HZ"O5S"GX"=V?%X8-?L\LJKU_K$F+#>\JRH
M5_9)B/+!<>K=B>5)_8F7K)#_''B5)T(.JZ-3EQ5+]DU0GCG@NH&3)VEAKY?-
MW%.U7O*SR-*"/556?<[SI/J[81F_KFQBOT\\I\>34!/.>EDF1_:#B9_E4R5'
M3L^R3W-6U"DOK(H=5O8C>8AAH0(:Q*^47>O!O:6V\L+YJQI\W:]L5REB&=L)
M19'(RX5M698I)JGC3T=J]VNJP.']._OG9O-R,R])S;8\^YWNQ6EE1[:U9X?D
MG(EG?OW"N@WYMM7M_AN[L$S"E1*YQHYG=?-K[<ZUX'G'(J7DR5M[38OF>NWX
MW\/P .@"H ^@_H<!7A?@W1M NP#:!T#K5KN5QILX$<EZ6?&K5;6/MTS46T0>
MJ'1_IR8;LYO_I#VUG+VL@8"_="Z*J0-M6A ,0*1'.)*^7P.P-39@A,LU@O$:
M6Q04CD$Q"HIP+1ZZ7Z]A\,8,"YR!H@RT8: #!M\'S; 6$S28HL%XVG9-!. B
M?%2$;X@ XKF:BA;D#]8@04BCA28%@?D+"A-Z E1/@.F9>$E"E"&<\6 BE"'"
M-.A/)C)\)T3SXS8D_A RDKI I2XPJ1[.0%P\<=T9AI&)Y">8#JIGOXF* @VT
MO0<4WP"-):.UY)$ )MF?X,!K )E3! A>!8A9!C#K3)3*+=V[>U#Q+=18-5XV
M"%HW@@D./-5),,<]/-E)>)=[*"K4W3-1F'LF*AP<+V/1>'TA:(&9.'T(GOAD
M,<,\P#,?W'O,PU%Z[4=15#M(XEM<8]5XK0&LUM"I[P@\^0'FN(<G/WAWN8>A
M*.CNH2A/=^\&UU@U7FX *S=T(OD!3W[PY[B')S^@![WAGHDR3XQ[0/$-T%@R
M7FL JR)TXL0 //4AFF,=GOJ 'OJ&=28J!"-K,2H:Z-ZA*+WF.8-.(6?5L>G"
M:FO'SX50G]J#V;[3>P35:6CS&]D!MAW(?YJV??R>5,>TJ*T7+F0?TW0;!\X%
MDR+=3_*E/,F.M1]D["#4;2COJ[9M:P>"EUU+ZO1]\?H?4$L#!!0    ( .%Q
M6U EOC9 %P4  )<<   :    >&PO=V]R:W-H965T<R]S:&5E=#$U-BYX;6R5
MF5%OHS@4A?]*E/<.V-> J=)(;:+1KK0K5;/:G6>:N$TT$+) F]E_OX;0#/$]
M3LA+ _3X<GQ]^6SP[%!6/^J-,<WD9Y'OZH?IIFGV]T%0KS:FR.HOY=[L[']>
MRZK(&GM:O07UOC+9NFM4Y($,PS@HLNUN.I]UUYZK^:Q\;_+MSCQ7D_J]*++J
MOR>3EX>'J9A^7OBV?=LT[85@/MMG;^8OT_R]?Z[L67"*LMX69E=OR]VD,J\/
MTT=QOU1IVZ!3_+,UAWIP/&F[\E*6/]J3W]</T[!U9'*S:MH0F?WY, N3YVTD
MZ^/?/NCT=,^VX?#X,_K7KO.V,R]9;19E_GV[;C8/4SV=K,UK]IXWW\K#;Z;O
M4#2=]+W_PWR8W,I;)_8>JS*ON[^3U7O=E$4?Q5HILI_'W^VN^SWT\3^;X0:R
M;R!/#41\L0'U#>A7 W6Q@>H;**=!<.Q*EYMEUF3S654>)M5Q>/=96T7B7MGL
MK]J+7;*[_]GTU/;JQUP*I6?!1QNI%ST=17(@$B=%8,.?[B'1/9XD:R[/;[#@
MBB0ZERR!),8F"':4NO9TUE&9X@@*1E!=!#5TX";J*(DZR:Z31"*)0J>W0$6Q
M2IP. Y6,E*?/$70<,<=V<%/'\U$4#^XCDEB[(P140FMWD(!*4AAASS'T' //
M;@:?8G:?.!1NFH&(M'(< Y&,/6610,,),ZRU9Y0T#*!OJ,P41DBO5V;*^JG2
M."(G95P5A:%R:F$)8NDT2;!C$6+NA&-JLU<-;T6"0N'81C))B3O6,%HTZ-ZY
M<0\PQ9@"[55G3T(8N^G&*O>A@JK04V("(OA12%XBY*DQ@0$J;B&HP @5(QC:
M:X;=E6&JW=1Q%<4A2QU0J<0WX!BB8A1%!4??791(-N)()C6YOI&,0I]Q3%(Q
M"J6"$U"$+-M -)B*>M-(Y+.,62HX3*UESV)#8)R*6W@J,%#%"*(*CD%W!KHN
M60))ZB&IQ"25HT@J.?ON(ATYL@62V5G3K4\HDZDGR1*35(XBJ>3T4VS> J(H
M9*9!I-BS-I$8HY)CU$X@RA,#<U3>PE&).2I'<%0"]J5*L!$'LB2*M)L\((LL
MDCRV,4HE1ZG6OFK'4)/Q+=G#E)&<,CQ[R;CL 1G*'I!=R!X&F]2C'G3-IT]E
MWT)<XT!&"3'C0"9%ZJMX3%/):8H>=$!"-Y$+*&(/.A=I[9E$"$.5.%2UUIX0
M&&\D;JA4PKPAL&QS*[77G$_@DEQ$(IE4['T(R4@IST-*GG=M&E.IO>KLW2MQ
M7RD70*5C<M<>0)62\@T8ABIQJ((R)0Y"X:X[%T@DW-<H))*>^8@P4 FM32//
MFHLP4>D6HA(F*HT@*G$&NNNEZY+E1<FY54Q1&D51XMR[4\0?*B1+-*M.*(M\
MY8DI2J,H2N#EG-QO2PNDBB7+-5!%OA63PB!5:'4Z(/9Y#$Q2=0M)%2:I&D%2
MQ=G'/MU=E2PO2LZM8GJJ4?14G'AW@M$3J4BXLSQ2V9'VN/9\'1U%3P66D:YE
MA$77,%K;>NQB<BI(3L^Z1F%RJEO(J3 YU0ARJNODO"Y97I2<6\7D5*/(J=#Z
M4[M?[(#JCA)W>;U$,JFD#Q\8G&H4.'O5\'N[N\I8( U[EKB&3<C!8'>F,-5;
MM_-53U;E^ZYI]S@&5T^[:X^RW=UQKC^)^^5QC^Q7F..6W9]9];;=U9.7LFG*
MHMOA>2W+QEB+X1=K;F.R]>DD-Z]->YC8X^JX578\:<I]OPT8G/8BY_\#4$L#
M!!0    ( .%Q6U#VA.XD/P<  .LL   :    >&PO=V]R:W-H965T<R]S:&5E
M=#$U-RYX;6R56MMRVD@0_16*=P?F/G+9KHHOB8.52V5K=Y\56[:I /*";"=_
MOQ((@KK[&.G%@'QZIGMFSNF>T9R\%LN?J\<\+P>_YK/%ZG3X6)9/QZ/1ZO8Q
MGV>K=\53OJC^<U\LYUE9_5P^C%9/RSR[6QO-9R,]'OO1/)LNAF<GZV??EF<G
MQ7,YFR[R;\O!ZGD^SY:_S_-9\7HZ5,/M@^_3A\>R?C Z.WG*'O*_\O+OIV_+
MZM=HU\K==)XO5M-B,5CF]Z?#]^KX:S*N#=:(?Z;YZVKO^Z .Y4=1_*Q_?+H[
M'8YKC_)9?EO63635QTM^D<]F=4N5'_\UC0YW?=:&^]^WK7]8!U\%\R-;Y1?%
M[-_I7?EX.HS#P5U^GSW/RN_%ZW7>!.2&@R;Z-'_)9Q6\]J3JX[:8K=9_![?/
MJ[*8-ZU4KLRS7YO/Z6+]^=JTOS63#71CH'<&5=]O&9C&P/PQL&\:V,; =C5P
MC8'KZI)O#'S7'D)C$+H:Q,8@=C5(&H.DJX$:;V=N_,?$OVVRFVS5N9?M="O=
MV60[X:KSC*OME*O.<ZZVDZX<,1EM5OR:0I=9F9V=+(O7P7*C D]9+3;JN+*J
M&J^?KDFY_F=%HU7U].5,*^=.1B]U4PWH? /2>Z PMFW,E80A[4PX1NT0H\K/
MG;-:=/9<,_M(^[C@F# .;<RE@/$D' [1;<0'CO AMC$?)6<(YOJP,Y^$KN*8
MC.U!AV^$CLC@I8=]^2Q +&GFBX0A[7R5,%%>#49>NF;=@FDM79W(35BY";MN
MPK97/_%TL@&Y-6BQ!ATY1Y;_C0!2CJR[5 !I.Y8]=K+'CGF<*+*B)AN,W^O&
M&(*YX1AOB+<<$@!=O>RKET:7C,G$LUXL&UR.<9',4LHQ6EO9W2"[&YB[P2GB
M;6"]Q#%UY8:#"%G3MQ M5Z/L:N0C&PD)+R-;;$F2D' B\T.QE<(Q=*%PQ'Y/
MK7@2.9Z$Q1.)>DT2/O+>D7&]$4!5I4S<Y:#@HY']K<L+,6V..0\#'=T&U!I>
M1U59 BD-O$%)7$E,HQ/9H/9[.O)T94H@A]R1T_1[I3F3#%@0"HB[ZJ/N"LB[
M$O6=39/E"X(/'@<E@>J[ -)C($(*"+SB"B_D),7%^<A90YT64/L*W'8(J+CB
M,IXHJN)*D-^*>M0?CC**HE()%=#, RU77,QYGE1<AFWBJ,\<Y)%8 +56@ESS
M1*BXC%K%O.$@G@H%$,R%"BBRXI+,4LQ$<2EE^2,50# ]:""WFLNM5E2[)EJ0
M4L,6H8 B]48J0,(>!=LN TW6DB9[19WA<JL4&AP@MYK+;=63IC%IOB@,D (-
M1%D;J2=:#C2H+H6C!L*M)>'V8 EKH*3:]4@A&JB?EHI83VFIN60I.BH<<K2W
MT6X[ U1-"R6J1P$!,=*QSZ@ ==!<'4*@M7(#<BT98FSDZJ =6U$"R ,^&B A
MADN(,F0>KP10"%1F#H#:W@!U,*(ZH)  \8WN,94&[:(YI_E4-J"WI])PWO.I
ME$ P;J .AJN#,B G&R .IH\X&" .AHL#VS)^:$#[8Q?WBYYV3X#YAC-?6+T2
MB%:.74"?#X#:+@.A,5+5XT'&,4!H3-)CFBR@OA4(RW;V#:C;-%E :\MIS;>%
MEN=\> ID ?6MD/,C:@,PW_8Z0$,G:)R+P1!E^&CYP1?;NEN^=W(H(,!I*VV=
M/#A4M(#3UO<9%4!7*R1J.BHWEN\L8,2 8Y9S+ 2P6[> 8K8/Q1R@F),*=+J)
M3IW$,= 18)CC#&-">"F '$WCUUU :1?0EP.@=ER T$XX,Z%G[]<-J-/X =([
M*=T#47: \\[V63'H()N359A(#@KT)<MU%U#:!?3U *@=%] /)]0$[(6.XS4!
ME8?T;4S;%R!#CLM0U*!0<D!B7)_]@@,:XSH<\#KA, 'LCSQ0(<]5*&IZZN/Y
MYAX=1W@@0EZLWE$C@/&^3_7N 9T]I[,0,:^Y8<2 \IZG^22"_;@'C/=]2FZ/
MWBEU>:ETX07NL--1+YPS6L .#QCF.<.T0MKO <5\'XIY0#$O'-BQ@;GQ?$\.
M8PZ 94'*]>B$)P *!=4CY@ H%'C2=+3</@\\:6I:?5X= +6] 5P,TND8JL8"
M(%KHDUL#8%H0WR'0?4C@;P?@FZ< Z!@D.@:TH-"+U] G9D"B(&TW SW9#<+1
M.-KD!<"T("0S5(9%P*$X[A%R!!R*4AIB=SH:U/[25@E(K!$0+4I'S $<"$3
MC]AGOQD!/R)/1*R2B'R[:=!1=P04BE(IB-H Y(A]MI(1D"/R#.,2DLHN!5"@
M0GC=!90> +5=1K<3A%TI.IR(@&2QSZXT 2Q+>*;B8R> ^-AU :4'0!N71WM7
M\^;Y\F%].W8UN"V>%V5MN_=T=P/WO:ZO]I'GY^KX4@G/K]3Q)^GY1!VGFWNW
M?[K=7 /^G"T?IHO5X$=1EL5\?1OPOBC*O(II_*[BP6.>W>U^S/+[LOY:9X_E
MYOKMYD=9/)UNKA:/=O>;S_X'4$L#!!0    ( .%Q6U 4]XSMJ@(  ,L)   :
M    >&PO=V]R:W-H965T<R]S:&5E=#$U."YX;6R55M%NFS 4_17$!Q1LL"%5
M$JEI-&W2)E6=UCV[B9.@ F:VDW1_/]L02LUE;5Z";<XYOO<$7]_Y6<@7=>!<
M!Z]56:M%>-"ZN8TBM3GPBJD;T?#:O-D)63%MIG(?J49RMG6DJHQP'-.H8D4=
M+N=N[4$NY^*HRZ+F#S)0QZIB\N^*E^*\"%%X67@L]@=M%Z+EO&%[_I/K7\V#
M-+.H5]D6%:]5(>I \MTBO$.W:T0MP2&>"GY6@W%@4WD6XL5.OFT786PCXB7?
M:"O!S./$[WE96B43QY].-.SWM,3A^*+^Q25ODGEFBM^+\G>QU8=%F(?!EN_8
ML=2/XOR5=PF1,.BR_\Y/O#1P&XG98R-*Y7Z#S5%I474J)I2*O;;/HG;/<Z=_
MH<$$W!%P3VC-F20D'2%Y(Z3_):0=(?4(49N*\V;--%O.I3@'LOU[&V:_(G2;
M&O<W=M&9[=X9>Y19/2TQRK)Y=+)*'6C5@O  A'I$9.3[/3"TQPJ/Z/C]!O=C
M1$;>0]8 A,)!)&"BB>,G[Q/-88445$B=0CJ,(/>,:B'$06H'(2@CL9<M@$IH
MZIF^!E"8I!,Y$S!B,HK8Y#R#%2BH0*]P+0,5LH]=:R%TD"E.<N)_(P"*)'CF
MN0:@:(PG7,O!B'/ M3R&%6:@PNP*UU ,G\OX8]\ZS##9/(N1YQN FB%$/=\@
M+1)/Q3Q12Q#DW$2I0&"MN$/X&N_@HXZ23WB7C/*E*26^=P"*$.1[!Z HPA,Q
MP\4%C:N+\6Y* S[NB%SC'7S@$?V$=W14FA#.DL0W#X+1L7L #"4SOTQ%@QNM
MXG+ON@45;,2QUO9>&*SV'<D=MC>BM[ZRG8J[*=]DVC;G!Y/[HE;!L]#FOG6W
MXDX(S4V4\8V)[V ZJWY2\IVVP\R,9=M>M!,MFJYUBOK^;?D/4$L#!!0    (
M .%Q6U!^*_.<4 (  $T'   :    >&PO=V]R:W-H965T<R]S:&5E=#$U.2YX
M;6R55>UNFS 4?17$ ]3FFT0$J4DT;=(F19VV_7;(34 UF-E.Z-Y^MB&4$+=5
M_V#[<L[Q/1=SG76,/XL20#HO-6W$RBVE;)<(B:*$FH@'UD*CWAP9KXE42WY"
MHN5 #H944^1C'*.:5(V;9R:VXWG&SI)6#>RX(\YU3?B_-5#6K5S/O0:>JE,I
M=0#E64M.\!/DKW;'U0J-*H>JAD94K'$X'%?NH[?<>E@3#.)W!9V8S!UM9<_8
MLUY\.ZQ<K#,""H74$D0-%]@ I5I)Y?%W$'7'/35Q.K^J?S'FE9D]$;!A]$]U
MD.7*35WG $=RIO*)=5]A,!2YSN#^.UR *KC.1.U1,"K,TRG.0K)Z4%&IU.2E
M'ZO&C-V@?Z79"?Y \$>"%[]+" 9"\$H(WR6$ R&<$5!OQ=1F2R3),\XZA_>?
MMR7Z%'G+4%6_T$%3;/-.E4>HZ"7WO33(T$4K#:!U#_(G(&]$("4_[N';]EC[
M=W3_=H/-/2*);B%;"R2V)Q%8C0:&']P835*[0FA5"(U".,T@G16JAT0&TAA(
MY"41GKFUH((X3&:&+2@_"M_P'%DSCNXR5A\7VQ5BJT+\B:HE5H7DXZKUD'CB
M-$VP-RO:/6CA>?&L9A:E"+^1;FI--[65++0K+*P*BT^43'5,ZT^)/R[:@)F>
MCP3C^5&SH8(Y:FM!Q2F>'Q0TZ2DU\)/IU\(IV+F1^L^<1,<[X='7/6D67^N[
MPO2J5YG^HOE!^*EJA+-G4G4\TY>.C$E02>('E5ZI[K9Q0>$H]311<]XW^'XA
M63M<7FB\0?/_4$L#!!0    ( .%Q6U!8!+P7;@(  #4)   :    >&PO=V]R
M:W-H965T<R]S:&5E=#$V,"YX;6R55FVOFC 8_2N$'W!I><<@R:YFV9(M,7?9
M]KEJ%7*!LK;*W;]?6Y!H>5STB[3EG,-YCO"T><_XNR@IE<Y'4[=BZ992=@O/
M$[N2-D2\L(ZVZLZ!\89(->5'3W2<DKTA-;7G(Q1[#:E:M\C-VH87.3O)NFKI
MACOBU#2$_WVE->N7+G8O"V_5L91ZP2ORCASI#RI_=ANN9MZDLJ\:VHJ*M0ZG
MAZ7["2_6.-($@_A5T5Y<C1U=RI:Q=SWYNE^Z2#NB-=U)+4'4Y4Q7M*ZUDO+Q
M9Q1UIV=JXO7XHO[9%*^*V1)!5ZS^7>UEN713U]G3 SG5\HWU7^A84.0Z8_7?
MZ)G6"JZ=J&?L6"W,K[,["<F:4459:<C'<*U:<^U'_0L-)O@CP9\(./PO(1@)
MP:.$<"2$%L$;2C'9K(DD1<Y9[_#A[^V(?HOP(E3I[_2B"=O<4_$(M7HN?)Q&
MN7?62B/H=0#YUZ!;Q&J.2"R1-0"))XBG3$Y.?="I;_C!C=,DA14"4"$P"N%M
MK;%5ZP"*#*@U(!QD<6+5"Z$".[<UA$KC"/8<@IY#P'.2P0H1J! ]D5L,*L2/
MY#: XJM:DQA9H!4 0FEFI38'Q5F"8<,):#B!#"-8(045TB="RT"%[)'0LEFI
M88!"*S0 Y-N@-:04WGG3,(); 8(LWPD>WVDG^(G@,/RA8_^1Z$;43<518+<E
M )0ANS'-07'@W[$,=Q8,MI9[&O"7CL-GHH._=1P]%%TT[TLQFF4'HGP[/ "5
MX<1R[5UM1_I \9WP8]4*9\NDVMG,_G-@3%*EB%Z45JG.,-.DI@>IAXD:\V$C
M'R:2=>,AQ9M.2L4_4$L#!!0    ( .%Q6U!6'N'LM P  /E;   :    >&PO
M=V]R:W-H965T<R]S:&5E=#$V,2YX;6R5G.]N6[D1Q5_%\ .L.</_01P@D5"T
M0 LLMFC[64EN$F-MRY649/OVO9(EK\0Y)R&_Q+9R+GTYY@SYXSV7K[^O-[]O
MOTS3[NJ/A_O'[>WUE]WNZ=7-S?;#E^EAM?UE_30]SO_S:;UY6.WF'S>?;[9/
MFVGU\7#1P_V-.I=N'E9WC]=O7A\^^W7SYO7ZZ^[^[G'Z=7.U_?KPL-K\[]UT
MO_Y^>RW7IP]^N_O\9;?_X.;-ZZ?5Y^F?T^Y?3[]NYI]N7EKY>/<P/6[OUH]7
MF^G3[?5;>;54"?LK#I)_WTW?MV??7^W[\GZ]_GW_P]\^WEZ[_2U-]].'W;Z-
MU?SEV[28[N_W3<TW\M]CJ]<OOW1_X?GWI];_<NC]W)OWJ^VT6-__Y^[C[LOM
M=;F^^CA]6GV]W_VV_O[7Z=BC>'UU[/[?IV_3_2S?W\G\.SZL[[>'?Z\^?-WN
MU@_'5N9;>5C]\?SU[O'P]?NQ_=-E^ (]7J O%TCZX07^>('_\X+PPPO"\8+0
M7'#SW)5#;):KW>K-Z\WZ^]7F^>_[M-H/(WD5YNA_V']X"/;A_^;P;.=/O[U1
M*?GUS;=]2T?1NV>1GHGD17$S-__R.Q3]CG=J+M?+7["PBAPO)4L@2?@F/.RH
M/USO+SM:< L!MA .+83S.RA-H)XE\2!Y/$BBY.B:W@*53Z$)^A*H- ;2YPCO
M.)H[EA@";B'!%M) U#)L(?\\:L^2=-937X/4)FI E6-LVEH"58S>X3LN\(Z+
MN>.YSQ6W4&$+=2!JXG!>NI_'[:@Y[VP[U'XN60))S>1>20T1$+%*8BZP1KP5
M'8D93G'Q'3'SIK<AA=*&S:I\\>U8 RJMRF*'BXK8JC+'CI17P6DN<21V.-$E
M=<0NV9$BTH;.BG*J;>2L*'K6:5Q7Q!:6.7!*VL"9+F4D<#C7I78$KMKN.A_;
MR '5O*9J0P=4*7LR'^/BHK:XS+%C;>"D5QF(G>*D5_UY[(Z:9M"UDP-0E6*&
M'5*IDM*NN,BH+3)S[,BDJCCI-8S$#B>]VLG=QB[:8J?:SA% Y8-OQQU0:50V
M9G"145MDYMA%T@;.>\TCL<-YKW:*M[$KIK\B+K>Q RI7S-K5JBJ;8Q67&;5E
M9@X=6P'CM/=N('0>I[VW<[T)W5%S,06TXVD!1,4W7+ $HII)X#RN,=[6F#EP
MK W"#B/PX''.^PY\.&HN<JR%L042Y;;2(5$B$ZS'!<;; C,'CG4:)[P?X0>/
M$]YW$(2WRWXUV(5$6=K H9;8:,'5Q2. J&26\3C=_0A"!)SNH0,A@EW\SU6]
M7=,A536S*U!Y%3)#!%Q> D )=00E L[X,((2 6=\Z$")8)?_U;7KM050Y6"&
M'5 E[\BJ(I#]"8 2ZDC2!YST800E D[ZT($2P0) J,F,.Z 2:3$,J+PHF1H#
M+C(!T(0Z0A,!YWT8H8F \SYTT$2P!%!]:D-G1>*"25FD*F3(1%QF(H )=23M
M(T[[. (3$:=][(")" "@Q?H%$*7:1@Z((MORB+C&1$ 2RG(^XIR/(R01R2YA
M!TE$N_H_WU4[!@Z(M.4()&+X%'&!B0 CU!&,B#CAXPA&1)SPL0,CHEWZA]PN
MZ8!(:UOF@,A[LJJ(N+I$ !'J2*5,.-W3"$0DG.ZI R*27?K[U&Z9 )'6IA0N
MD<B3^I1P;4D (M2196'"Z9Y&("+A=$\=$)' TE]-X*RHM/ %-(EU&5>6!!!"
M'>LR>0(Q@A ))WOJ0(AD%_[M=+D FG8W_8>2RWO%124!>E!'\CSA/$\C])!Q
MGN<.>LAVQ6^VTH&FC=D/)9?WBNM)1M0@K V<XGF$&C).\=Q!#=FN]&.[8;0
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M3*N/+S_<3Y]V^V_W6R6;Y[.HGW_8K9]NGP_:OGDY[?O-_P%02P,$%     @
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MI<A36F+\8U:#/(,='PP/9T? .>:;$C9UVUAQ=-#K3Z(UK/,^6;;%-8C7!7&
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M3CT:?HS/)?RWM[#>;"E*(WR=SV<+U<^*LBP>4&F-1:<E7YM,8,T1#F0)2WN
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M6_E%&F5C% ][<3GWQOE% @-9&]!\U8Z)"0UWV7K-B?:+= EZ@HDIP)U>8D$
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M(=VOA"_@S\A6+B[/KW&W7V8XSZ *8AKGX>KLV*4;NS1CK[>.;2PGOC+:DM?
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MOQ![J &2@0S'?+BBGEB-[F05T &</"G6ZAT'LH9#DNO_A9"U1/^#(YL$-4[
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MQUVV3&T PKH]R!. Z:C(__?4_[;*+[)4E)-/]:+:QTO3:?**Q\[E"!GVK/$
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M!3UD[(1D#]FK[2[(Q1/V;CH8/W'OALKF.>HU<\A%\%V*X'OELEF/,8@3?MS
MGL#77QNG>W>:>N<GA 0Q5K25[_@\YPFB^BNC?Y>NCI@[_R8,>C,\8?2;T6@D
M/]#%LX];Y3K!2S^9(NX+XN3 ?9_V!5"F\2@\@$&DTU%T.CV+/G#ID(JG\O=G
M>,GA.02_82XT/D,D'ASRD$"QCYZ)1&=A#+]?9!68 7@/\-8<CHA?3/'_CR?T
M(KWG04^Y5'%35IY;^(D4J$Q(:X'?GXR)_YP2(L]P.);9D%L4!VM/BV-!%#1R
MD!N4YC"KO?%!AS9,:C >X+=HDS6$SW+)I>D99?:Y\C42/;KTU14;%C>VQL7(
M00.2@*K$X>"$]_>4_C/$E-8MT4P7"[;H*V .^$H4"OZ3,8Q%0P[Z ^SW2"R*
M6QY)TR1&OSR\.XHFB!0$1N-PW+>/-J,H,&P&!!N?CD%2Q(/!)!H!1;S4W?5X
M=$J3>E2IHS*IWXY UIUB3&[*X5IW0MR@53D%,;,%3^?P$\P?7AI%9T!W76E[
M?_JU >AE[RJ5F1]BKW7:UF8TDVZV;,.*D)WX*.CAP]$0__6$VX\07)/I*>,0
M#ECHC^&_>"WIIM_W^++[KS9OO6FHOM"9%YC512@3B";RD'H0!H)IW&LS!)<O
M)$94PY:@W$'SB,I 7R?8)]U@):NTCY"?R.^QS=:).DB:[C'8(RCQZ%2M/Z6J
M-HDTI$&KA?XHJ!MW<$-0*!4B*!/I](Z/P+4CJ\;DYA@U,9$0+AL6E%;&ETBV
MG;=_^J_8?AWE\$Y UEG=@<%D@(%D%&KS&8N%%;,GIX0?9GA5!-_.^3<?V2=3
MS"4Q:BN^3,]@[D@59V/>E&6']80JUTE!]&%H/ C1AP'S)D0?JVH= L9MD!N^
ME6[$C;$09D2I2##?8KF1>'0W_,09*U#,F5 R(>X,T@SHA J&B_4[XWQR,U!V
ML!4P[.-AL<+.,G3+2\LZ5=6KXU^A$7,/#L@.3RRKZ3.23W&J9HGL#Q&:!%)@
M&XZ%C[.5>PO1.!P:>6./C_=UB^H@<H9?= 1V)OP(G.-.=2S?U 8'PY9^8NBI
M 6^B/L-4VN%]V/. )MZQ+S@]@C420X*AK$_,%<UOX39N<N\[ F6I,@P]Y[.G
M;UP@"MCG1T3+(1 ,/([K-:H^?R[*3U4()Z,YN5-'/^V)A'0FG-UXJK/YI+FF
MK1'\:M^1P%)XH5S'+X/[-590G@UCR2>F<U#0,42YIW]F^)(F0S]/7T:=;E$;
M [\M^;:IN]?0&2WF\S%\\)A(JJDWTHKZCJ[XFGFW2P4/29%<I%1"3%:? BI%
M1P:3RT9PGN[2Q6UJBAC('+8MG*V18AQDL!V$]+1[RN$KU-@,2U5/W8OAJ6:"
M5Q@921>J1:*YEWL,1V1UH!OMR3U0[N'=Q_K%*QE/!CH/=O>>?3D!#94L"!&0
M LO]KT!!W^A<!XUSG;)[U;I:,F5\&80*JB5M0V+0,YPUJ(PT.C24("95P0[W
ME;:;CN&);FW(+RPX#J:>+N56H"=%U40M3%82!0VI_.;5N85%L*@R9(0EFWQ.
MT8<_9Y_A'7C[;C,#G7<P';^(J))3"C11?U_<8^#O559]VE3FF<.;)7VY*AAG
M;XTL5^K;8%M66 5;(+'=)8(NM2X>@![9.Z0E;.<ZK?=*P%]<K#JH?W5L*1JD
MK8:8>^QR^^LX%@P&K_?#KULR"P!B*+Q7G0<BT=%4^NAM$:#?"%!C3U@1/J51
MQT05SL<VY)%_Z)P[H';@B/# VU@UA(]FM5OK5G*GY]K/GKIEFT];M@7JQKNK
M<]J*=5V4%F"G9F=T='%Y?HW?>IFA3H+SN0>2.?'(W?BV[.;L] 'AM ]AH 25
M"#M4&XF%^0/8YY\B1JSX38JX7.!+HTN!PKNY768WR^+WS)I(KW_96Y&*Y8=7
M3J,:OHZVBMT.OH?^IZ?<J?;MY*/-O=.[Y69>>^^SA,-,/DQ :5!.=Q'CJL\J
M>>#%C+K0:>FF$<T5,FX]'ZRQHL0A'9WRLF\1"#,A5-2<U/;9YA$3W4P9LP/G
M*J/E9K6.JLW*&ON]Z+6-&S1"4/$3)HQ7'S;]]S3G_E14<&C\C3:>H;)(3SF9
MD]OVRMXTVA*P?R0<8.? HG,G8?S1 E<0">O L3B#S45M!I&EI;44JE?H*+BE
MQAGB%+7EE\8@I,P)B9]:WX(X8-S?N'B5_4E\EJR8/"%"?'>DM0-.5[%TQKX(
M#,"6IHS=8JY*O;'GIMTN&9\\W'Y9W\9E(C2 2:&8,L<**?<)A9]!8RI!MTM7
MY.'B#-'MFGGB5<)Q1IP4O&(X&P$V,4U"@MB@S#Q4&XQX9>B.@GE*M>UZ4\Y1
MH)3":R4G^2)=IK,R_:QQ#IDIIK:/Y1P=8F1;PO26JCT#3&W:3-;CJ9'!'"V2
M54+520\)Y<F2T^&W3?G( DZ0,'B7>Z2;7 9\6IE3;?U^8Z&"!3(,>J=62;:J
MIJIO?$Z?@L=.U&.*$;W>S,NL(N0/E]#J]?A5^)<.ZIBXIDN9ZP!):KJ#*;W/
MP #1MF%*QT)2 JQ[&2T1T"]K5>I@G1*4-59GXLA-*ZQ*KUZ(?G86]%+]^<.K
M=]'EE:U.%H3B,CVVVD95P]G)1EM+H3'[E\EJ5A#V!*G(5.6=K$W>*$6G+.2>
MIZ^$T4++A#(D&154$21?->N!MZ@R@FQ34,XYEO>:@61>=H'>J1CL/_4Q7:/T
M0K0FK5NHG=,TT4T&\5/IX"=*5:6-1'QU#@,AAB ZERVPM*:2#F?;-M)Q'D8?
MEX*JE>"D0612G.:%*&JCP:X=4#M<D<O]J>2/\>B_ NG,$V>; ;T<2U^%>U5,
M[Z!]]K@F+TA#/!CL/,,][_735R87NZVNTV^*- >3'V$%;C>5 VS7NI.T[RC@
MMC?XP]./_H4HS9F_)^BCYFP!_QRKIZ[V,L]E0W?(WGUY^$@Y.D(\O,W"U?GN
M<T-1SQZ.@SFG[O4 >K(8@Z=!P@I<C-A@]AOBW9)#;K,A#4-%GP.V3LFHVR;"
MWYNL"^$'C5R^>]AM;$6"Q0B,F&#EP& P#5\%1I3 2P=?A!'F"&&A",(HUYP>
M P]+XVV&L$V7HE+#S',"5B7=%$00*#J/EI=V<)+\'\-,O^#N[;R"<H.(+ZJM
M_$?>H-BDT.^\,:&<SGWH1SC*T_F)%Q1IAL2M,I+F]UE9"!J6"WB+_="60=A
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MH\:^I-UFO0P].T@Y/6<TE8H?G80W]8Y;L[T]'5AKFEXJ"%OHXS^UM3F\F+>
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M@#@*):D>GGKNZ3FA$4E\*54<FD<4L'>#D5>(AG+Q.DW/&,49Q)A79S.LJ_Y
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MTR%_C=Y^N#BC$'>6#4R0<"V$.L!:+/;OI]WAV!7J'PDJYJX+_"JZKVM[<FU
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M$/4R3J=1,9U$XRR/\I+0NG(*2(06,5D^*HNH3*/I*'IC-')8B-V&8G#H9)B
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M<4N*IK9Z":+"L>6.5=%>$9=XKUY7*97%UB?H87:'L^6(:2[$JZ!2&9]OMM[
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M\R+#9P7K/O?=SH,T#7B&<8T14GI,3FX5XQ&69!T#@#49H><Z3LD]G2#0-/Y
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M]>UZ*WJ%JY+82&WU]0,5J"0-VK3*P%^+S6QWC[+]S*'UX\='*F(+<M>E+7Q
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M>N[NOT G AU(?8V^XS@8ES5FDN$D0J17@KV\.E(P6%BKA[[7^7P*R@4%F+Q
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M2F!SEWB@<%]KV59U)I'#B:[%LM[&G:0K1;^4ZIEB\(Q]$181I&;RKIL+MFG
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M1CS'&U:<6D%[E[MJ4=7X"\[;UW:A.G&Z@?\U;0;8N.!(+"_6S)$W 7&KRD5
MR.&)_2M9IK5345?P);N"5?,_=\Y5+WK@Y:S,!F//?*_KY-&R-PVMXXZ-H](M
M\1)251:K.6A-< VSVQRU=5LR9L/$\+CLAKA'Y/)(@XEB8B37#'ZJDDC6?%DR
MU)\H"#&L0&"/MAK9-[)T/*PTA7:\_.F7/>3.V5[V[)S#?Q\SW#_8VHML.BZ6
M,VVU3>&%&X)DNL)F-!;J"A7$UCS'O^/'"E9YN<LR[.C@*V383;4$AGN1U;#:
M,MM/;LB5PH7NJH%PZ%$&7K]BVLC /JK882<TT_8PG/3*+%5W"4]K?10[]6*D
MZ>L$L8B2L7@A+N"P<4%KIKI.;/P^ 6_\X*&5)! A*+[D^1=6N/]<8-:?D(!E
MBQVG&^G<4M1:V_IBY .X$@5\ 5DPW9WK_+7.:.>FF ([SH!)P=(66!NVN_EJ
MI'PECL\&R6X:*O6[9F?(7 S\:@:F:%G-,K5I.!Z2 3G?FMEIWWD),^/E>)Q;
M(<F8^[XOD(+;CMX+S.Y310OC:FO=F!N8$O&DS?M*V4?\KIU/V22;XL<OV.XU
MT P;;CA5'N.:C2:#ND6Y_9-<[W/75<IP8:[?5E+-X;837O(EMO9ZS$L48C<5
M-O#<Z"([7N\BB]UA7T7?BNS1S0;37*U?JGHZ8?>3%39O%<4KW#J;C I4&EEN
M5W"^,/XF00QV:?FU][NW-LW%HLJ;HF9".(.4K:C?)6X6I]2T;G[/>/HPMB*H
MJ>$42,GY4G+).!V:Q<Q=\07-\3HK*#T(!0T>E_<_X67YA_3VE?[$I*$]LTV+
M!TI+K*2I#FWY=KZOGB/O"?W H+,FIZ9VG%:ZT9N2-\P8J(,;@X&Z)']_B,]Z
M73:MW-.7!'5B>OC=PSH;KVI?DMX:/K8N^ZYI1V*B"9*AB,S&C$3D^GCF9@)'
MIRER AL;5F7?XT6[U SSUX,6/$H#"(,V5&+E0%.DD!_?3ZM;2C6YXY;(S:J!
M$9L$6[AS<T?@69<WEC&@W:LWG"REJ%Y>_,30-MF4O<!Q$SB:AN#8HNNPKIIF
M3VPI)AQ.Q=)2!& DE"_M[$/W!I?MVFU:CA!&]0Q3J6$:=39?43\N\@NS0T_2
MD<]=>QOS'$===$+WFE;:QA:T1[KW!C4H"O_II0J-+F=J.FA*SH.L:2%K"@F%
MN-F$=8/)5U5=W!>EL*]IIXSA8"3?]X*A:4U--X.C'('[T]I-C,N$]D#>(-2R
MM@1C/>)6,@SMAI^=<45[T!T.V(M&DH;1)(F=M9.AE*\MJ&T;2!&_ /8!/&LM
M^G!DEB#^+ &>EY/ #X6(B*OM*[QHI$QX:_-D6V5B36R-6C]WPZ"5 =BV?<<B
M<2@1+43&_J*Y#Q_R&C.:2ONBOM>$NSTEGL(/JZE\G7],+A[0??'N2S[F5NC<
M+0!>_4.>D7KR!@3F^&%]"&Y]Z(VN28B_N2C;;"Z=D->%V*B'-(F=<D4HX2Y6
MA0'C)06ZH],C':<TA%@A1*"WL]\K\-7UW 6H O&^6-W!5WN=8Z&==>@-_K@A
MUZ!#0(R!K'3BSIU@'H&1@VI38VNYV*/<DE:QTP6U_^[*"9Q^6V7:K_TO&=SA
MK69.=A#-WHAE[6[U$M]SNQ?S/2$ES5(VO5AZ*$=Z[@X'$8<'NA]@,IUW?)W=
MNYQNO%-B!['KP_1;'B^ 0O>-J]3LDC6JNYX(96A5:JN=$L":U#[FV,0E2C#C
MKVT?L36>U K;BEI[OD 7>\-XI$I+G&)*2V[\FG6M3 0\ =%U= +7V1CK9:CD
M\FZZS!GD',W?JJZ7\T7RL;[/RN(?4JYXCM<ZLB/@S4S&74^I!9S5^=4?=EZ"
M!,-RX!+VZ\%EQ[C4"G)'NY(,L4VR!=R*VR5C<(.:A4G/V,.*U]LO#-HG^*RE
MX+7Y3M86GVXC#L.#LQZ>UZ.KI]0^;![NM[\)DB#;B?Z-JPKGO<$;NUTD\+7.
M>N>= Q"_)(AQTE)_NKEZUB?;%T44!\C)Z='+7;#"U%RU'$]RK]T%4=G>IB-N
M)2&D706 XA>H2TG+AWV0*%^*Y2P9'OYPK4[GQ7]\L_C/__BF*?[S/_!_B_^\
MR<7C^GU>46DPW&_\[D>:\#7WC,=[I/T#UPP 7R49#9/Z_\YO&VJ]_O__YI<E
MYXC/R2_P?_Y%.WUCRJ=TQB%DREQ3U4144 DRIB,LI03-]<=#+Q3VN2=$JKRF
MT;4G.W8>P4XO5"8 TH!<#0I@&=NN#!+ XTXZ?3!"/V8Q_*G8;4(^&2"36VR<
ME9,ZRS-_K6SNLBRK1[;4N98PV;G\8=?GCKS#XBQ*U-,OO/MAE[@IKMSE@6A/
MR@;-IU6>U6':=5XQ+]PX=7PIC)>57!&/*]UBH1F5AXO1"12QY%+"V"7%-:U;
M[,>;HIJWP'6^A_?,DQW[9!?N^?S7ZD%ZH.H\R- ?R6$E:5MVFH7H2C9M&CL]
MG^X*A,24*0K5H/)^JB1@^2^\(1C $ )&C[J 7!7B:95<7;^1OF%*6,W:Q?3,
M+R5.8&^:YLJ=BAKK(I+K_RN;S;]]Z]XD /^VD=@ .2_0A823T^^#HL1:$"D_
MWU^]I8G]<OWV@^9]V#?$=9!<7NG#< V1&;.(0;HHRD=TH-\K)GTH=,'K%QSI
M:"PIL !["_;( Q&,8-IN.S%J  6JBC&8NZI:8)=-+/E%UT.KUAYX04VQ3DF@
MXK;:8S*)PAE:M&>6?<X)?%J3U(EGB3LUJTL26F)8=$B@E0 EO4%33H1Q'$C8
MDBH3RH.4*Y'[-QP6?D4I1;K$455Z31R9]0AY?V@$Q7WK)XS*NV?]W0.+W;GV
M2WLG2TL9"?1.NS$$=KHK2@PA*&G G,$1/-,U/D =5*EJ.' .4A*X'IVY:?#U
M(,D$'A*LN8C-"8MC[F91SJH1JL*VP25;GU@0C2^ZS8-.KYJ7E'26#EX"- N<
M0/= HSZPJ5^/N_C\*9,O^NXTA>C$[DDXV";=T,B5[[7V::=WAW0""GJ Q!J<
M)RD7XC%D3B,M?(7#ZV2J.[_S5*4G0!<TLU2=FKPGHN)7!%RR@5_*P7]_\Y?>
M[Q'<18(=A? 47SBO24$< Q]]P9I.$KC1=B0WJB 0K$/$9@+IAQ[+O9>L(Z,$
MP7@+617&HU+(9DQ-K/?8(3@3=/#&;2>C H@?%@OW[2/T<S6)U$8G'\MQ-:WN
M*;'Z;IK-9"7$?)/+V6Q9RL?7> R@I6+X1")4BVR:)C]S.S.^*-(M9&J Y>SZ
MT6_3NV-LDL8[F$-+-SB01C#376<A#CB 1@^;+F7 8>T,^2(K;HEJ(D?L1ATJ
M9^CFZYFK;$\NT&;-/^+$UZE#1%9.)^)"<33]X.U2YRSDY=N$V=*LYYQNO>S<
MAMUO'YZ/ V*3A/$JR3&P-"V:!X]E8J_JG$L\8EL4TC$5K%T4"^%K8-P7@HIU
M"[SDLR@6VIR!^X]KGKJZ$/"1H(\0[?)98X?C8L;N(_1@BW>!<"A$P!JH=X>\
M.X&&+"8=L!_Y+23,QM4]ZZED0B85VN,3K"^AE\7MCC,RTN1>R00H,7"!MQSL
M#U Z"<8[1_MBFH\7?K=I-J^3/<2N?RSAU >C;ZY(TM//\('B^.P9@CS\K83]
MG"8[G>:(Y'D ;C[)=A6-ZQOX=S:'Z[R7W"QIQ_:2GU?E)/M[/OV&?IAE7S;-
M[/T*"\GAAPNAG^XN?]00UYDS4S*P*I;D#]&.;EKT(W5L)-O9@QY2X;DKX"T2
MG)" =R2/@8P6[%]W"G\O(,.*FP#V\UT"M3<9MF\+^#K5G?IGHF]C#PYB3_K<
M]A-AUNCRQ$,.XLOS''['0[^X(WV'5][WU4CB(;&%%7*:+_P\O&"'3.^N[(MU
M?&%JS!M]^WE0X)4,R(D"I"-*CZA3:LT:5L5:'25T,981FJ8:N]@!N=D4K_^U
MY2ZB$1"C=> 7S= @+P5'[TP'4Q5/>D?B"$GE_'*N;CFX0-M&#489J+@E,B]B
MR1U8"FN-\-7J;@_^'XZ+'%8$+_" &I:E='):&B4/TI&$8C9[D6HZ8 ;Y:;,N
M#V8&S1&+]@SHP1EY8H)PR-+L*PTXSJA@AC7#Y1RL+<E%!A&4$]/"QJ&J>:QK
MTZQMK%%P=S:7!=T:@]32^R+MQ.&9"!O=,W//#QT*]^KJ$?D@QFH6U1YE3N?C
MA]+(H%X4@A[*X]IPLK7J?&V;D!&GQR]:?HU1&0YZPR B")@RMRZ%94/:H_<G
MRSP;+FQ<@'V'[8KSN@4_XT  1#BF_I[+*-1<G3D?1E>UTSI-2%JQ94N@I)JN
M;?P&QNV2Z#U[D>>X<^@NC?13B1S71?-9?3,EL.V>ZQJ6R!*DJ5QB' *1H#G+
M3C*0X_B>D#2..8#5DP1J<W+](+1FBP4;0PV)S' ENKR@GYW@36W?H*TNOEVL
M!>-:D$N"R%R<M#WWWX>"T0&+AWWO&W/3!=QGSP;>#Z.,0+?-<H[?7T.ULMUM
M@N4ABZ:S"H&P$.E)H6ET:E(PNUG>4@:L^M^H1;A%FCF'T+X,ZRC'A3\$$AK=
M8PB,W]M,SUAU:UQIJ7"UWH.EO>EU:T4&?M:0NQIG$4X,=H;5C"AX3[<3E7(T
M8TP".TZ:NJ-TUC/'G]2?,L[F#M1'.95!GB#,)>4;L?,DCN3C3(-SQY%LV'9%
M2,J=7_NGTN3OMO="66QR)RE93;*C@OG)N!V1I=AUHG75V#TOE_)6,X53,B^F
M*55T TL'SK6$'0K.[=2-.E^" 3+&V$-6(#LCCE3P8\0,PC=#F>!NJFP1U)A'
M6"S8,N[(O:5C*1OJWE):T9VC+0F*"!$^5G*@73;3/D.D1?"$[C4QC["N."#,
MWD7UN05Q@0HA\&'G"^IC2;%YN1-9*:T/D39P;WK.D)DNK'*W+?XC9[E4GN"M
M"*XH7$?#^AJJL6UUC=84VWD[\M&NI_U)%=TWB=C1!CN:E8,A=<=B4KC+CZ1C
MZ$%@G6Q(N1J32DTW<X*Q3MGK)\('>D*!!;2Q?ILI.#/#B-$_0@ 9"(ZN:N['
MY$18G$J%"+B8B%G>$POEG#4.B5P1SWTG_9R<^\NB;4)6K0GR_4-FG'/^B[:5
M")M![\SOZ]!SPF"N6C$2RBM=*FGP]1:[0NP?:Y<*DS0]R_7Z+C A+PT)-%$!
MQ&.NP<%EN6R6>*%9,OA.N4!!R[JF("<-%A@'WQ-1'D3/D)V/_7*>$-+6HB12
M+!Q%?Z7VB@@'OODJ$HH0;-T""Z=AFL0<=L,=T' <)<=12JJ5.X$26C2M !XK
MZQG<AKP@'M+-TP>"*C-:%";M@G16-$QQ_B)]CM4P&B-!.(F$K*!$K6L:[AI.
M3&.//"EIKLZ;/:99$Z-@X Z]V@%.,"6<\SX*;>TTTZMC7DRK1+=:S\2G$#(\
M!$Q\0?Y1+!'18.BD -6C054)DV3XXL#SNJXH48Y>*HC.<,]2RL!R%SC815&T
M2@.UYSSZ+[D/%>HK<?L6U2)X!'@34SZ0U1I6-Y/,\MAVU?N/=7L/!-I9L<Y!
M\;A)H'QA5HW$M611\;!CX#<593XRD'/]*!$.S#V83_NB.;L"AP8'D;/O_YFP
MD;'C3O!:=CA?1(I^WWYP;!-71!D?V.X(F)FD4;+6LN5(V)8/#T*VD8(O9 H@
MWNH"\TY>#8Y/$M"6I@7W^2249TDH-:\,>7-;CQV=/?/8::*.MQR=IB38J6ZS
M$^K_Y#T.B;6F9\6\T2%$-VALB-;BN[&PUXD%N#2XE>QDNS!38+U(Z*J>G'LI
MM7.[F_P71M#?D7\S6M9+_[[SX?+]^\N//]XD'[]+WGY\__[\^F:7]Y1VB((7
MFW^]#LNZL8!Y4*1?):.S]!">@!].TJ.C4_SA*#T:'< /P\/T"(: 'T;IR0@_
M&@[3P=DA_'!&WSP[&L%_3T\'ZO0;'*3#T2@9#-/#T\-D,$H/#T^2XQ238T[3
MX]%Q<I:.#D_A:T?)8#"$[QT)A?5$(I/#L_087G!TD!X<#I/#T_3LY 2W970P
M2$;#='1RB+\=P6>#].!X1/\]PO\>'(M>;3S9*9K#].#L-!FEQS 'F-_),-DY
M2D^&HV07?QB>R@\C*JD<',!D#X_A?T/8270'<5?52V3EKUNZ/&NIRZ#+<^QE
M^*W]>W:"0Y\"[<,[CM,1O^PX'9[A7PYIL:/D$%9QM5F+ZHRL_^X<IJ,1C7H(
MNWXL/\!AP?"P]2?PW^/A ?SW"%YRODX'6C_\@-*<=D:#4QKZ"-^ YPUD9%IB
M1UM)=L:[:X=$4AG B.G)@+8%?J?# &(!DCL: H$=#6 )2)!'<&R'2)!'0SCW
M8_AA<)(>G^)W!H/T%.;V"FEO=( _'*<(9X/_CDX/Z=_A\1E=8.$FY!$0)- H
M2(09ZG>5NFR0.W^S(PZ47>E9\T4U%QK)Q=K-[6&A?K4*@ 4A2RJ-%='[428$
M_0?5GY^+XF=DB*^&<% SX9$:Y4SAST F\9\Y7/QJ>'S<^@ CFUMYTP_WB6\%
M'[$:)AY#,TC1_9@'%HWS'UOI D9B9XK1-']8->0>"4/O(]\DF?O Y</L<=%\
M1LF=;;':R"!H6PR]9[E/U+>>-J.:_J_4GQD86POV=_];J)QX[N\"#2KYK#4I
M+,;&O7%[=7K>##0+D%C%7;+6;8>? %]12J*@$:6KM6S:]K,$$F&<B:X"<C E
M[90-.)^0ZD.D4^G^0V3WZNAP%#_HK*JV&AQ,%;Q\^Z>FH*3<6M>_,4@6M&3H
MM91MCCG8L+.:2OWJ\.S(OQ]&"480?3X(G[L IH,9DL2;JL<NP@'1E+68SKV@
M!KTZW1\X]:IK5\>VW?;Y&)'-"R\O>#W!E,M%95T4M>633_);WHS!*)PB&;F/
M=![BW7&;/]@?N<V/0\!]"%&OD68T#J+P6'>Y14'X1(\".X6+=?YYG&<Z^!/%
M.5!A9G_>M4:-R# *#D3S5J3Q?$$ ^E/485@+V6%^O_O-1.]"R,J0?W$3(XN>
MX.+K*@$FEC'3)2YJD?3X>I*'7RF2'0K"(8/VH/.U^4G;@JT.'DLY7HU&)[9*
M'FVKK6JCX+?N-I7AC1^0H. =H AU7W$A.($-I62[X6J0J& A@H[OLPPXXB7N
MH!AKGKTXPEVY 0G7/Y+[S5__PP-W;\/85&6)-:+(_(,HE8!2-@'#LB ?-(J2
MX-HR3V\/+<0>7Z2$5.8IJ1SP"%\F,HDCSZ>[CRZ+C7\B>#AII_ML5I;$]NV!
MF*7UAG@MUO0"!K)U<#^5N+?]<)'H3V_EAU$(CQ\FO?+N]-]6WJ&ETY)W2!C;
MR;S!T<G7R;R1DQJ_0>8=CS:*O*/3X]\L\EX@=$8=D=,G<0[=E+>2-^2B WWP
M =[@=(Q($F^2 -U;WT=2_G[3']]D!"'$27:8=(.9-;EDE]RVDPK5@X9MAS [
M:9I*"BXW/_#<F@OC?&Y5E)F Z[(_<%2TS)=U)1D ZB$*C'*!>\L>KJ(1Y#?A
M%&-,O8-ARKQ^I)(O*C(G]C\8M/E_JN':[/X>BY@6_)>O8,*40(,17 RPI)B]
MNT? $K=529&[@D3*8U%CEH3@"$FXEGJ'9_?+G&N8)-Z8:SELX]4(R0K6UIL:
M+<&L ?(S(>CA'28::0JW$+V))6YD^9@3D7,2J^Z<;SEW I<//O)='S]=_/F<
M#19/GD[M^4W4V0&XZ4O]13L08_+%.+DXOTX^<1\A+4OW! ?:S7V=S91RBF[_
M%N:I[ATAW2Q*2:,OG\N+MY0PPS=)CQCIE2(G_[929'AP^'56TW#TM1+DY"QZ
M\"LER,E@HP09#@__F1+DS"FEFV3(R='QBZ4(/E^PWS,B=?%_"/_Y#CLZ9>Y<
M#[HO,E*<?!U_3('[.F.U*)T.S1N5AM@XDZ_3Q-VF&^064O/5$LBF2JZ+<84I
M"];T#2G8?#3!S=)1=*6.E =D]H.:.WK.'M ) S>1P8G\B_3>,F9/'FU,9$M0
M!NBKTT!MN-#VLCP^"G>/20[/_F2$]<!O2'XHFF5IM9>]A[(]NXW-RZ/H6%[
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MUFDP)6EJG),>9K6;)N\),EB:0J9@F<1'='['?R?(FV(R@0N#7TFYN@UDCU
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MGB3#$SCYXT'R"8@S^T?R\9$+.!'2?)I-<#J8M30$?7AX=,( Z*2G=(_L9ZE
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MPAQFS=X6.#UR1,<0N[[HB2N8;5YT(ETUBKP28O3ODU)O&CX!PL9P1(PF^X=
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M:#T<S-M6*I99(ET!<%_C^SM:>(NR,]K6G!VSP>92KN7J7.O<IPA(VI$:;^9
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M@VE="*4AH^HW9M#JN];HK)7(VUTFA.=J=G,>0TZ9J_,B\')B%+-VR' _(K?
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MNL2?<9[VQ'JDLR:&^Q<8 VM$;%&978"\^\XR:JJXLPJ J.9?%K,O7;:,L2Z
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M@!7@'5CBE"X?QD^(-*>5%_!,$G VK&4ABYYTFY(C6[_>+Y"5STA!'([EXQ&
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M.OP-$UQ'V(,M-+(74%4#+-6\;7!E7PB2Z@[H69[F=R2C<[&"N\6"@0A"CF;
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M)W$5%B+ZPMI\#X_^;N1DVOH?/9;DCIC>O9-\OW-$KUF14B+>EO6(M]>J9K'
ML?IAQN9>1MY QNX1PXR8-LR<QD]*W..WI;AQ9MZ,5(W)2'#9 O9@PQL>)3E'
MX#%2&Z2NG#%&(M+]U9\C_C- 3DA5AGH5I8+F%G!\+SS=48:PW1A_3IC2@A^Y
M-''L0P",8==E[-HT#DUE][[47XX-XI-#N_8P_@-U=8Z"86AC2KXL9G2-(YRH
M!KQ5U7!&-'P'5J/%-I7VTHL>M7EX0/.">?Q ;5^O%Y,_["$]F%SG&^99<%Y
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MS'W4 [).FB%I?("&(?6N2-6KY;=R.:FT:C+!_BY52[R6CE^D<"W;1"QL%]=
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M#YF=@KVX72X>.%JKFF\X$LG6.F1DR9"/1"#98:@ZY8/E2G%S5!%1^1+CQBX
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MD?<OC3QNC_F,<PI1__*AQ,-TAC<*/4K8;;5T(^O=6&D@NG 9ZX].K;S(M_Q
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M4]MOC7)3[G.F)7:G:52F_6!VC73?,P2Z=0'E0_Z6FN10 <7&E$#FO(>:3P#
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M5DU0:*W-A+^$O07QQ3K6*\-I5XIZ5'+[SVB!C(;O/#9-! &R1EBUCU5S1I*
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M@N/%VRI6P&7@_O&1HMF/=*QJCX-"IR=Q- ]2!0\R@I#Q_2F</=&F!#7(82:
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M%@7YB?(;"_.0O].:+5MD7>;0NS3-RB'O" O,ZF9:!TW^&=!"6%!'?!9(N#J
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M52)5["Z42QH6J8T4J5);10H/?8O,KA<L^;+U>BGDL;^2UWY%/Z5?4E_V B1
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M&>)!MUHUJB!"6,N?<4QR9E\\7OU2'OX!4$L#!!0    ( .%Q6U"JX6=[8PD
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M=ZP";%'ZX D&*TCN9(4+H!_V/C"U*P(*M<0=LW !]%9Y)>YU34"AEKB#%BZ
M+K4;/HZ 0BUQ1RU< !UV)YB*/+:'60N2.VP!GGK:F6#Z@APE?B&<>NO\VM9D
M?@$F,$CN" 8(>M*BT$SL(0SPU)-Q"$QAD-PQ#+#7G[0HCB =QTQ'4-JBT$S<
M40SXU).1'<QBD-QA#!= ^Z+YB_BP(Z#03-QQ#+!Z.KE&H9FX QE@BYZ 0C-Q
M1S+@:Y0,ZF$F@^0.9<"9.Z37PU0&R1W+ #,FZ:F'N0R2.Y@!@](6A6;BCF;
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M97-=+GAM;,W;RT[;0!B&X5M!V5;$_GQV1=BTW;9([0VX]H18^*29@8:[[R1
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M<F5L<R\N<F5L<U!+ 0(4 Q0    ( .!Q6U GZ(<.@@   +$    0
M      "  >D   !D;V-0<F]P<R]A<' N>&UL4$L! A0#%     @ X'%;4. R
M-G_N    *P(  !$              ( !F0$  &1O8U!R;W!S+V-O<F4N>&UL
M4$L! A0#%     @ X'%;4)E<G",0!@  G"<  !,              ( !M@(
M 'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4    " #@<5M00%D><@T$  #+
M%@  &               @ 'W"   >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
M4$L! A0#%     @ X'%;4$LT@8*+!   CA8  !@              ( !.@T
M 'AL+W=O<FMS:&5E=',O<VAE970R+GAM;%!+ 0(4 Q0    ( .!Q6U C?L.1
MB@0  /$6   8              "  ?L1  !X;"]W;W)K<VAE971S+W-H965T
M,RYX;6Q02P$"% ,4    " #@<5M0B$P/J.@!   $!0  &
M@ &[%@  >&PO=V]R:W-H965T<R]S:&5E=#0N>&UL4$L! A0#%     @ X'%;
M4,X)X5,H!0  !!L  !@              ( !V1@  'AL+W=O<FMS:&5E=',O
M<VAE970U+GAM;%!+ 0(4 Q0    ( .!Q6U!%?6[7L@(  !4*   8
M      "  3<>  !X;"]W;W)K<VAE971S+W-H965T-BYX;6Q02P$"% ,4
M" #@<5M0NGVE"#0'  !T*@  &               @ $?(0  >&PO=V]R:W-H
M965T<R]S:&5E=#<N>&UL4$L! A0#%     @ X'%;4+2^'+"6 0  6 ,  !@
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M970Q,BYX;6Q02P$"% ,4    " #@<5M0^^Y/T;$!  #2 P  &0
M    @ '".   >&PO=V]R:W-H965T<R]S:&5E=#$S+GAM;%!+ 0(4 Q0    (
M .!Q6U!1#2?CM@$  -(#   9              "  :HZ  !X;"]W;W)K<VAE
M971S+W-H965T,30N>&UL4$L! A0#%     @ X'%;4$+GI].S 0  T@,  !D
M             ( !ESP  'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6Q02P$"
M% ,4    " #@<5M0^T.]T+4!  #2 P  &0              @ &!/@  >&PO
M=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4 Q0    ( .!Q6U#68),GM0$
M -(#   9              "  6U   !X;"]W;W)K<VAE971S+W-H965T,3<N
M>&UL4$L! A0#%     @ X'%;4(#]7M>T 0  T@,  !D              ( !
M64(  'AL+W=O<FMS:&5E=',O<VAE970Q."YX;6Q02P$"% ,4    " #@<5M0
M."\U![0!  #2 P  &0              @ %$1   >&PO=V]R:W-H965T<R]S
M:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .!Q6U 8,YCSM0$  -(#   9
M      "  2]&  !X;"]W;W)K<VAE971S+W-H965T,C N>&UL4$L! A0#%
M  @ X'%;4(D;!X&V 0  T@,  !D              ( !&T@  'AL+W=O<FMS
M:&5E=',O<VAE970R,2YX;6Q02P$"% ,4    " #@<5M015ML%K,!  #2 P
M&0              @ $(2@  >&PO=V]R:W-H965T<R]S:&5E=#(R+GAM;%!+
M 0(4 Q0    ( .!Q6U MYMUFM0$  -(#   9              "  ?)+  !X
M;"]W;W)K<VAE971S+W-H965T,C,N>&UL4$L! A0#%     @ X'%;4&4R10&U
M 0  T@,  !D              ( !WDT  'AL+W=O<FMS:&5E=',O<VAE970R
M-"YX;6Q02P$"% ,4    " #@<5M0GQ4T*+0!  #2 P  &0
M@ '*3P  >&PO=V]R:W-H965T<R]S:&5E=#(U+GAM;%!+ 0(4 Q0    ( .!Q
M6U +U]"XM $  -(#   9              "  ;51  !X;"]W;W)K<VAE971S
M+W-H965T,C8N>&UL4$L! A0#%     @ X'%;4!]8HE*T 0  T@,  !D
M         ( !H%,  'AL+W=O<FMS:&5E=',O<VAE970R-RYX;6Q02P$"% ,4
M    " #@<5M0%4\J2_("  "$#0  &0              @ &+50  >&PO=V]R
M:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0    ( .!Q6U"RS<,X]@$  ,L%
M   9              "  ;18  !X;"]W;W)K<VAE971S+W-H965T,CDN>&UL
M4$L! A0#%     @ X'%;4*GDBCS/ 0  G 0  !D              ( !X5H
M 'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q02P$"% ,4    " #@<5M0JP!H
M!\,!   W!   &0              @ 'G7   >&PO=V]R:W-H965T<R]S:&5E
M=#,Q+GAM;%!+ 0(4 Q0    ( .!Q6U G?VJ^Q@$  #<$   9
M  "  >%>  !X;"]W;W)K<VAE971S+W-H965T,S(N>&UL4$L! A0#%     @
MX'%;4%@Z\D+V 0  RP4  !D              ( !WF   'AL+W=O<FMS:&5E
M=',O<VAE970S,RYX;6Q02P$"% ,4    " #@<5M0Q\S$^+0!  #2 P  &0
M            @ $+8P  >&PO=V]R:W-H965T<R]S:&5E=#,T+GAM;%!+ 0(4
M Q0    ( .!Q6U"FW?0*;0(  '0)   9              "  ?9D  !X;"]W
M;W)K<VAE971S+W-H965T,S4N>&UL4$L! A0#%     @ X'%;4/29.\;& 0
M-P0  !D              ( !FF<  'AL+W=O<FMS:&5E=',O<VAE970S-BYX
M;6Q02P$"% ,4    " #@<5M0@B@M%[8!  #2 P  &0              @ &7
M:0  >&PO=V]R:W-H965T<R]S:&5E=#,W+GAM;%!+ 0(4 Q0    ( .!Q6U .
MCLY"X $   $%   9              "  81K  !X;"]W;W)K<VAE971S+W-H
M965T,S@N>&UL4$L! A0#%     @ X'%;4#C6G]]; @  I @  !D
M     ( !FVT  'AL+W=O<FMS:&5E=',O<VAE970S.2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .!Q6U#2Z1O<& 4  % =   9              "
M 7)X  !X;"]W;W)K<VAE971S+W-H965T-#0N>&UL4$L! A0#%     @ X'%;
M4%)S?B[2 @  MPH  !D              ( !P7T  'AL+W=O<FMS:&5E=',O
M<VAE970T-2YX;6Q02P$"% ,4    " #@<5M08(%HF#8"  "-!P  &0
M        @ '*@   >&PO=V]R:W-H965T<R]S:&5E=#0V+GAM;%!+ 0(4 Q0
M   ( .!Q6U#[,4FGP@$  "8$   9              "  3>#  !X;"]W;W)K
M<VAE971S+W-H965T-#<N>&UL4$L! A0#%     @ X'%;4#6SUL+Q 0   P4
M !D              ( !,(4  'AL+W=O<FMS:&5E=',O<VAE970T."YX;6Q0
M2P$"% ,4    " #@<5M05RQ4_OD!  !H!0  &0              @ %8AP
M>&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+ 0(4 Q0    ( .!Q6U )5_P&
M. ,  ((-   9              "  8B)  !X;"]W;W)K<VAE971S+W-H965T
M-3 N>&UL4$L! A0#%     @ X'%;4,;]7 MA P  _P\  !D
M ( !]XP  'AL+W=O<FMS:&5E=',O<VAE970U,2YX;6Q02P$"% ,4    " #@
M<5M0@P%[WPP"   >!@  &0              @ &/D   >&PO=V]R:W-H965T
M<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( .!Q6U!-?,#?:@,  /(/   9
M          "  =*2  !X;"]W;W)K<VAE971S+W-H965T-3,N>&UL4$L! A0#
M%     @ X'%;4+Y&Q1XV P  [ T  !D              ( !<Y8  'AL+W=O
M<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4    " #@<5M0$L(:8&4%  "^
M'@  &0              @ '@F0  >&PO=V]R:W-H965T<R]S:&5E=#4U+GAM
M;%!+ 0(4 Q0    ( .!Q6U"646TX+ 4  .(=   9              "  7R?
M  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL4$L! A0#%     @ X'%;4'2(
M0;,8 P  E T  !D              ( !WZ0  'AL+W=O<FMS:&5E=',O<VAE
M970U-RYX;6Q02P$"% ,4    " #@<5M05/&$^5$$  "'%   &0
M    @ $NJ   >&PO=V]R:W-H965T<R]S:&5E=#4X+GAM;%!+ 0(4 Q0    (
M .!Q6U T,SX:,P,   4.   9              "  ;:L  !X;"]W;W)K<VAE
M971S+W-H965T-3DN>&UL4$L! A0#%     @ X'%;4/I.E<5@!@  QR4  !D
M             ( !(+   'AL+W=O<FMS:&5E=',O<VAE970V,"YX;6Q02P$"
M% ,4    " #@<5M0\-_*&;("   ="P  &0              @ &WM@  >&PO
M=V]R:W-H965T<R]S:&5E=#8Q+GAM;%!+ 0(4 Q0    ( .!Q6U C6FMXV ,
M .,2   9              "  :"Y  !X;"]W;W)K<VAE971S+W-H965T-C(N
M>&UL4$L! A0#%     @ X'%;4*T_ZLSJ @  "0P  !D              ( !
MK[T  'AL+W=O<FMS:&5E=',O<VAE970V,RYX;6Q02P$"% ,4    " #@<5M0
M307ZS%L#   M#P  &0              @ '0P   >&PO=V]R:W-H965T<R]S
M:&5E=#8T+GAM;%!+ 0(4 Q0    ( .!Q6U#$>KC=#0(  & &   9
M      "  6+$  !X;"]W;W)K<VAE971S+W-H965T-C4N>&UL4$L! A0#%
M  @ X'%;4$SXPQJ7 P  V0\  !D              ( !IL8  'AL+W=O<FMS
M:&5E=',O<VAE970V-BYX;6Q02P$"% ,4    " #@<5M0BAH=[>L!  #7!
M&0              @ %TR@  >&PO=V]R:W-H965T<R]S:&5E=#8W+GAM;%!+
M 0(4 Q0    ( .!Q6U =]"*9OP$  -4#   9              "  9;,  !X
M;"]W;W)K<VAE971S+W-H965T-C@N>&UL4$L! A0#%     @ X'%;4+L>+?=+
M P  O0X  !D              ( !C,X  'AL+W=O<FMS:&5E=',O<VAE970V
M.2YX;6Q02P$"% ,4    " #@<5M0HG5"S# "  "#!@  &0
M@ $.T@  >&PO=V]R:W-H965T<R]S:&5E=#<P+GAM;%!+ 0(4 Q0    ( .!Q
M6U"0R,7OEP,  )\0   9              "  774  !X;"]W;W)K<VAE971S
M+W-H965T-S$N>&UL4$L! A0#%     @ X'%;4#FW[Q[C 0  ^@0  !D
M         ( !0]@  'AL+W=O<FMS:&5E=',O<VAE970W,BYX;6Q02P$"% ,4
M    " #@<5M0:'GNM00$  #/%0  &0              @ %=V@  >&PO=V]R
M:W-H965T<R]S:&5E=#<S+GAM;%!+ 0(4 Q0    ( .!Q6U!8ZHG8^P(  ,H+
M   9              "  9C>  !X;"]W;W)K<VAE971S+W-H965T-S0N>&UL
M4$L! A0#%     @ X'%;4#6=]1%? P  71   !D              ( !RN$
M 'AL+W=O<FMS:&5E=',O<VAE970W-2YX;6Q02P$"% ,4    " #@<5M0/PPH
M)S0"  !&!@  &0              @ %@Y0  >&PO=V]R:W-H965T<R]S:&5E
M=#<V+GAM;%!+ 0(4 Q0    ( .!Q6U"%]OV40P,  &<-   9
M  "  <OG  !X;"]W;W)K<VAE971S+W-H965T-S<N>&UL4$L! A0#%     @
MX'%;4 K+H_^: P  EA   !D              ( !1>L  'AL+W=O<FMS:&5E
M=',O<VAE970W."YX;6Q02P$"% ,4    " #@<5M0:5B?(;X"   T"P  &0
M            @ $6[P  >&PO=V]R:W-H965T<R]S:&5E=#<Y+GAM;%!+ 0(4
M Q0    ( .!Q6U"K]  AJ0,  .40   9              "  0OR  !X;"]W
M;W)K<VAE971S+W-H965T.# N>&UL4$L! A0#%     @ X'%;4)$?_K]  @
M& <  !D              ( !Z_4  'AL+W=O<FMS:&5E=',O<VAE970X,2YX
M;6Q02P$"% ,4    " #@<5M07+PODAX#   6#0  &0              @ %B
M^   >&PO=V]R:W-H965T<R]S:&5E=#@R+GAM;%!+ 0(4 Q0    ( .!Q6U!W
MC +2UP(  *P*   9              "  ;?[  !X;"]W;W)K<VAE971S+W-H
M965T.#,N>&UL4$L! A0#%     @ X'%;4$/32'2+ @  ) H  !D
M     ( !Q?X  'AL+W=O<FMS:&5E=',O<VAE970X-"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .!Q6U"7W1 ,>0P  /5@   9              "
M 5 / 0!X;"]W;W)K<VAE971S+W-H965T.#DN>&UL4$L! A0#%     @ X'%;
M4$K J2"_ 0  . 0  !D              ( ! !P! 'AL+W=O<FMS:&5E=',O
M<VAE970Y,"YX;6Q02P$"% ,4    " #@<5M0>PG-UPH"  !"!@  &0
M        @ 'V'0$ >&PO=V]R:W-H965T<R]S:&5E=#DQ+GAM;%!+ 0(4 Q0
M   ( .!Q6U"F<7I,K0(  "@*   9              "  3<@ 0!X;"]W;W)K
M<VAE971S+W-H965T.3(N>&UL4$L! A0#%     @ X'%;4%X01?L(!0  +!T
M !D              ( !&R,! 'AL+W=O<FMS:&5E=',O<VAE970Y,RYX;6Q0
M2P$"% ,4    " #@<5M0(B#"G2("  #P!0  &0              @ %:* $
M>&PO=V]R:W-H965T<R]S:&5E=#DT+GAM;%!+ 0(4 Q0    ( .!Q6U"ED*,6
M^ (  ,P,   9              "  ;,J 0!X;"]W;W)K<VAE971S+W-H965T
M.34N>&UL4$L! A0#%     @ X'%;4-BT;SOJ @  U0P  !D
M ( !XBT! 'AL+W=O<FMS:&5E=',O<VAE970Y-BYX;6Q02P$"% ,4    " #@
M<5M0FG%!EV0$  #C%@  &0              @ $#,0$ >&PO=V]R:W-H965T
M<R]S:&5E=#DW+GAM;%!+ 0(4 Q0    ( .!Q6U"QOSD6W00  "0;   9
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M:&5E=#$P,BYX;6Q02P$"% ,4    " #A<5M0@1<\_GP"  !T"0  &@
M        @ ':2@$ >&PO=V]R:W-H965T<R]S:&5E=#$P,RYX;6Q02P$"% ,4
M    " #A<5M0@XA9?/T!  ",!0  &@              @ &.30$ >&PO=V]R
M:W-H965T<R]S:&5E=#$P-"YX;6Q02P$"% ,4    " #A<5M0\%9<]L8!   :
M!   &@              @ '#3P$ >&PO=V]R:W-H965T<R]S:&5E=#$P-2YX
M;6Q02P$"% ,4    " #A<5M0 :?%(0X"  #_!0  &@              @ '!
M40$ >&PO=V]R:W-H965T<R]S:&5E=#$P-BYX;6Q02P$"% ,4    " #A<5M0
M3N"6E($#   $$0  &@              @ $'5 $ >&PO=V]R:W-H965T<R]S
M:&5E=#$P-RYX;6Q02P$"% ,4    " #A<5M0IZ9NXY8#  #0$   &@
M        @ ' 5P$ >&PO=V]R:W-H965T<R]S:&5E=#$P."YX;6Q02P$"% ,4
M    " #A<5M0Q.7:12$"   -!P  &@              @ &.6P$ >&PO=V]R
M:W-H965T<R]S:&5E=#$P.2YX;6Q02P$"% ,4    " #A<5M0Q0I;WUL#  "D
M$P  &@              @ 'G70$ >&PO=V]R:W-H965T<R]S:&5E=#$Q,"YX
M;6Q02P$"% ,4    " #A<5M0*YB',3H"  #8!@  &@              @ %Z
M80$ >&PO=V]R:W-H965T<R]S:&5E=#$Q,2YX;6Q02P$"% ,4    " #A<5M0
M97D9*.$!  #U!   &@              @ 'L8P$ >&PO=V]R:W-H965T<R]S
M:&5E=#$Q,BYX;6Q02P$"% ,4    " #A<5M0W)UGS'<#   9$   &@
M        @ $%9@$ >&PO=V]R:W-H965T<R]S:&5E=#$Q,RYX;6Q02P$"% ,4
M    " #A<5M04^ 7S L&  !F)   &@              @ &T:0$ >&PO=V]R
M:W-H965T<R]S:&5E=#$Q-"YX;6Q02P$"% ,4    " #A<5M0>%M?=B "  !L
M!@  &@              @ 'W;P$ >&PO=V]R:W-H965T<R]S:&5E=#$Q-2YX
M;6Q02P$"% ,4    " #A<5M0#:[PK<0"  #*"P  &@              @ %/
M<@$ >&PO=V]R:W-H965T<R]S:&5E=#$Q-BYX;6Q02P$"% ,4    " #A<5M0
MV0[*#KH#  #3$P  &@              @ %+=0$ >&PO=V]R:W-H965T<R]S
M:&5E=#$Q-RYX;6Q02P$"% ,4    " #A<5M0<28L5/\!  !^!0  &@
M        @ $]>0$ >&PO=V]R:W-H965T<R]S:&5E=#$Q."YX;6Q02P$"% ,4
M    " #A<5M0X%L%;NT!   %!0  &@              @ %T>P$ >&PO=V]R
M:W-H965T<R]S:&5E=#$Q.2YX;6Q02P$"% ,4    " #A<5M07BB1BN (  "0
M.P  &@              @ &9?0$ >&PO=V]R:W-H965T<R]S:&5E=#$R,"YX
M;6Q02P$"% ,4    " #A<5M01NK2IQT#  #W#0  &@              @ &Q
MA@$ >&PO=V]R:W-H965T<R]S:&5E=#$R,2YX;6Q02P$"% ,4    " #A<5M0
M.JU51L8"  # "P  &@              @ $&B@$ >&PO=V]R:W-H965T<R]S
M:&5E=#$R,BYX;6Q02P$"% ,4    " #A<5M0LS5K:;<"  #\"@  &@
M        @ $$C0$ >&PO=V]R:W-H965T<R]S:&5E=#$R,RYX;6Q02P$"% ,4
M    " #A<5M0<1\/S/,,   A:   &@              @ 'SCP$ >&PO=V]R
M:W-H965T<R]S:&5E=#$R-"YX;6Q02P$"% ,4    " #A<5M0/-J'"O #   ,
M%   &@              @ $>G0$ >&PO=V]R:W-H965T<R]S:&5E=#$R-2YX
M;6Q02P$"% ,4    " #A<5M0##'@HY$%   \)P  &@              @ %&
MH0$ >&PO=V]R:W-H965T<R]S:&5E=#$R-BYX;6Q02P$"% ,4    " #A<5M0
M.YRFDT,$  #0%0  &@              @ $/IP$ >&PO=V]R:W-H965T<R]S
M:&5E=#$R-RYX;6Q02P$"% ,4    " #A<5M0>8QX1^\!  #<!   &@
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M:&5E=#$S,BYX;6Q02P$"% ,4    " #A<5M0^K'T[1T"  !_!@  &@
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M:&5E=#$S-RYX;6Q02P$"% ,4    " #A<5M0OC4DT_@!  "F!0  &@
M        @ $AR0$ >&PO=V]R:W-H965T<R]S:&5E=#$S."YX;6Q02P$"% ,4
M    " #A<5M0=VKR(-P"  "7"@  &@              @ %1RP$ >&PO=V]R
M:W-H965T<R]S:&5E=#$S.2YX;6Q02P$"% ,4    " #A<5M00Q162U,"  !U
M!P  &@              @ %ES@$ >&PO=V]R:W-H965T<R]S:&5E=#$T,"YX
M;6Q02P$"% ,4    " #A<5M0ELF5C@@"   6!@  &@              @ 'P
MT $ >&PO=V]R:W-H965T<R]S:&5E=#$T,2YX;6Q02P$"% ,4    " #A<5M0
M^=/'\IX"   Q"0  &@              @ $PTP$ >&PO=V]R:W-H965T<R]S
M:&5E=#$T,BYX;6Q02P$"% ,4    " #A<5M0:>9,82 "   Z!@  &@
M        @ $&U@$ >&PO=V]R:W-H965T<R]S:&5E=#$T,RYX;6Q02P$"% ,4
M    " #A<5M0[ZL#HB@"  #F!@  &@              @ %>V $ >&PO=V]R
M:W-H965T<R]S:&5E=#$T-"YX;6Q02P$"% ,4    " #A<5M0-+\>CV4"  #0
M!P  &@              @ &^V@$ >&PO=V]R:W-H965T<R]S:&5E=#$T-2YX
M;6Q02P$"% ,4    " #A<5M01W98M%,"  !L!P  &@              @ %;
MW0$ >&PO=V]R:W-H965T<R]S:&5E=#$T-BYX;6Q02P$"% ,4    " #A<5M0
M#!;7G30"  #M!@  &@              @ 'FWP$ >&PO=V]R:W-H965T<R]S
M:&5E=#$T-RYX;6Q02P$"% ,4    " #A<5M0Y NQ33 "  #S!@  &@
M        @ %2X@$ >&PO=V]R:W-H965T<R]S:&5E=#$T."YX;6Q02P$"% ,4
M    " #A<5M0F90P@R(#  #,#   &@              @ &ZY $ >&PO=V]R
M:W-H965T<R]S:&5E=#$T.2YX;6Q02P$"% ,4    " #A<5M0\F129I$"  #2
M"   &@              @ $4Z $ >&PO=V]R:W-H965T<R]S:&5E=#$U,"YX
M;6Q02P$"% ,4    " #A<5M0>:6AD=,#  #W$0  &@              @ '=
MZ@$ >&PO=V]R:W-H965T<R]S:&5E=#$U,2YX;6Q02P$"% ,4    " #A<5M0
M_*&U=9(#   5$P  &@              @ 'H[@$ >&PO=V]R:W-H965T<R]S
M:&5E=#$U,BYX;6Q02P$"% ,4    " #A<5M0-V<KJ_4"  "2#   &@
M        @ &R\@$ >&PO=V]R:W-H965T<R]S:&5E=#$U,RYX;6Q02P$"% ,4
M    " #A<5M0@5 R ,X"  "S"@  &@              @ '?]0$ >&PO=V]R
M:W-H965T<R]S:&5E=#$U-"YX;6Q02P$"% ,4    " #A<5M0.L^''3,#   C
M#P  &@              @ 'E^ $ >&PO=V]R:W-H965T<R]S:&5E=#$U-2YX
M;6Q02P$"% ,4    " #A<5M0);XV0!<%  "7'   &@              @ %0
M_ $ >&PO=V]R:W-H965T<R]S:&5E=#$U-BYX;6Q02P$"% ,4    " #A<5M0
M]H3N)#\'  #K+   &@              @ &? 0( >&PO=V]R:W-H965T<R]S
M:&5E=#$U-RYX;6Q02P$"% ,4    " #A<5M0%/>,[:H"  #+"0  &@
M        @ $6"0( >&PO=V]R:W-H965T<R]S:&5E=#$U."YX;6Q02P$"% ,4
M    " #A<5M0?BOSG% "  !-!P  &@              @ 'X"P( >&PO=V]R
M:W-H965T<R]S:&5E=#$U.2YX;6Q02P$"% ,4    " #A<5M06 2\%VX"   U
M"0  &@              @ & #@( >&PO=V]R:W-H965T<R]S:&5E=#$V,"YX
M;6Q02P$"% ,4    " #A<5M05A[A[+0,  #Y6P  &@              @ $F
M$0( >&PO=V]R:W-H965T<R]S:&5E=#$V,2YX;6Q02P$"% ,4    " #A<5M0
M=N]=T,07 @ C_@@ %               @ $2'@( >&PO<VAA<F5D4W1R:6YG
M<RYX;6Q02P$"% ,4    " #A<5M0Y*Q_79D"   V#P  #0
M@ $(-@0 >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .%Q6U"JX6=[8PD  $MJ
M   /              "  <PX! !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M" #A<5M0[!/>K6 $  #77@  &@              @ %<0@0 >&PO7W)E;',O
M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #A<5M0$YSS02$#   M6@
M$P              @ 'T1@0 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
..J@"J !8O  !&2@0    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7041058080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Tax Matters - Deferred Taxes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract', window );"><strong>Deferred Tax Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense', window );">Prepaid/deferred items - Deferred tax assets</a></td>
<td class="nump">$ 2,195<span></span>
</td>
<td class="nump">$ 1,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInventory', window );">Inventories - Deferred tax assets</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets', window );">Intangible assets - Deferred tax assets</a></td>
<td class="nump">743<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment', window );">Property, plant and equipment - Deferred tax assets</a></td>
<td class="nump">179<span></span>
</td>
<td class="nump">160<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits', window );">Employee benefits - Deferred tax assets</a></td>
<td class="nump">2,217<span></span>
</td>
<td class="nump">2,292<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges', window );">Restructurings and other charges - Deferred tax assets</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">266<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves', window );">Legal and product liability reserves - Deferred tax assets</a></td>
<td class="nump">496<span></span>
</td>
<td class="nump">415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards', window );">Net operating loss/credit carryforwards - Deferred tax assets</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">2,512<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments', window );">State and local tax adjustments - Deferred tax assets</a></td>
<td class="nump">152<span></span>
</td>
<td class="nump">264<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments', window );">Investments - Deferred tax assets</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">All other - Deferred tax assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">182<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal - Deferred tax assets</a></td>
<td class="nump">9,215<span></span>
</td>
<td class="nump">8,576<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(1,927)<span></span>
</td>
<td class="num">(2,068)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred taxes - Deferred tax assets</a></td>
<td class="nump">7,288<span></span>
</td>
<td class="nump">6,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract', window );"><strong>Deferred Tax Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid/deferred items - Deferred tax liabilities</a></td>
<td class="num">(204)<span></span>
</td>
<td class="num">(325)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts', window );">Inventories - Deferred tax liabilities</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets - Deferred tax liabilities</a></td>
<td class="num">(7,099)<span></span>
</td>
<td class="num">(7,620)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, plant and equipment - Deferred tax liabilities</a></td>
<td class="num">(1,226)<span></span>
</td>
<td class="num">(1,011)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits', window );">Employee benefits - Deferred tax liabilities</a></td>
<td class="num">(39)<span></span>
</td>
<td class="num">(134)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings', window );">Unremitted earnings - Deferred tax liabilities</a></td>
<td class="num">(79)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates', window );">Investments - Deferred tax liabilities</a></td>
<td class="num">(3,318)<span></span>
</td>
<td class="num">(162)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesOther', window );">All other - Deferred tax liabilities</a></td>
<td class="num">(9)<span></span>
</td>
<td class="num">(112)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities, gross</a></td>
<td class="num">(11,988)<span></span>
</td>
<td class="num">(9,456)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="num">$ (4,700)<span></span>
</td>
<td class="num">$ (2,948)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, State and Local Taxes Adjustments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInventory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInventory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7014249984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/ Deductions - Net - Footnotes - Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Available-for-sale debt securities, gross realized loss</a></td>
<td class="num">$ (402)<span></span>
</td>
<td class="num">$ (281)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Available-for-sale debt securities, gross realized gain</a></td>
<td class="nump">280<span></span>
</td>
<td class="nump">451<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sale of available-for-sale debt securities</a></td>
<td class="nump">5,700<span></span>
</td>
<td class="nump">5,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign Exchange Contract [Member] | Debt Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax', window );">Loss on derivative instruments, net, pretax</a></td>
<td class="nump">$ 18<span></span>
</td>
<td class="nump">$ 120<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDerivativeInstrumentsNetPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDerivativeInstrumentsNetPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3151-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_DebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7037512464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Jul. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationExternalIncrementalCostsAmount', window );">External incremental costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 152<span></span>
</td>
<td class="nump">$ 112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InsuranceRecoveries', window );">Insurance recoveries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains recognized during the period on equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of fair value contingent consideration liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeMiscellaneous', window );">Income from resolution of contract disagreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember', window );">Allogene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainLossFromContributionAgreement', window );">Gain from contribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV Healthcare Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">$ 266<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BainCapitalMember', window );">Bain Capital [Member] | Cerevel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains recognized during the period on equity securities</a></td>
<td class="nump">$ 343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember', window );">European Union [Member] | Mylotarg [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment', window );">Gain from cash settlement of liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationExternalIncrementalCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, External Incremental Costs, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationExternalIncrementalCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainLossFromContributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Contribution Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainLossFromContributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeMiscellaneous">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income, Miscellaneous</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeMiscellaneous</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Gain From Liability Extinguishment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InsuranceRecoveries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InsuranceRecoveries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BainCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BainCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=us-gaap_EuropeanUnionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MylotargMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MylotargMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7037982272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 5,381<span></span>
</td>
<td class="nump">$ 6,259<span></span>
</td>
<td class="nump">$ 6,558<span></span>
</td>
<td class="nump">$ 5,826<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember', window );">Income Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_CurrentTaxAssetsMember', window );">Current Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember', window );">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember', window );">Noncurrent Deferred Tax Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">3,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember', window );">Other Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized tax benefits</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_CurrentTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_CurrentTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R88.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7045499520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Gain (loss) to be reclassified in next twelve months</a></td>
<td class="nump">$ 179<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Actuarial Gains/(Losses) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Gain (loss) to be reclassified in next twelve months</a></td>
<td class="num">(265)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember', window );">Prior Service (Costs)/Credits and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths', window );">Gain (loss) to be reclassified in next twelve months</a></td>
<td class="nump">$ 178<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7021128720">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Provision for Taxes on Income (Narrative) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability', window );">Repatriation tax provisional liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,200<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit', window );">Tax benefit related to measurement adjustment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForRepatriationTax', window );">Payment for repatriation tax</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability', window );">Provisional expense related to future taxes on global intangible low-taxed income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability', window );">Deferred tax liability on global intangible low-taxed income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability', window );">Expense related to future taxes on global intangible low-taxed income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount', window );">Deconsolidation gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="nump">2,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic', window );">Tax benefits from resolution of certain tax positions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,600)<span></span>
</td>
<td class="nump">700<span></span>
</td>
<td class="nump">150<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount', window );">Tax benefits associated with implementation of organizational structure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses', window );">Tax benefits related to certain asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(620)<span></span>
</td>
<td class="num">(740)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActIncomeTaxBenefit', window );">Tax benefits associated with the enactment of the TCJA</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">325<span></span>
</td>
<td class="nump">600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit', window );">Tax benefits associated with certain current year tax initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit', window );">Tax benefits related to the repatriation tax on deemed repatriated accumulated earnings of foreign subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit', window );">Tax benefit associated with the remeasurement of other U.S. deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit', window );">Tax expense related to future taxes on global intangible low-taxed income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit', window );">Tax benefit from Tax Cuts and Jobs Act of 2017</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit', window );">Tax benefit associated with remeasurement of U.S. deferred tax liabilities on remitted earnings of foreign subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">22,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit', window );">Tax benefit associated with remeasurement of U.S. deferred tax liabilities primarily intangibles</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit', window );">Expense related to repatriation tax on deemed repatriated accumulated pre-2017 earnings of foreign subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,900<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit', window );">Expense related to future taxes on global intangible low-taxed income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit', window );">Tax benefit primarily associated with certain tax initiatives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings', window );">Deferred income taxes on certain current-year funds earned outside of the U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount', window );">Tax benefit related to net losses on early retirement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FeePayable', window );">Fee payable to Federal Government</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 307<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember', window );">Income Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Implementation Of Organizational Structure, Gain (Loss), Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Loss On Debt Extinguishment, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FeePayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fee Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FeePayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Income Taxes [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForRepatriationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Repatriation Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForRepatriationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act, Income Tax Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Change In Tax Rate, Deferred Tax Liability, Income Tax (Expense) Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act Of 2017, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Intangible Assets, Provisional Income Tax (Expense) Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Unremitted Earnings, Provisional Income Tax (Expense) Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Tax Initiatives, Income Tax (Expense) Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act of 2017, Transition Tax For Accumulated Foreign Earnings, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Change In Tax Rate, Provisional Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Global Intangible Low-Taxed Income, Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Provisional Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Tax Initiatives, Income Tax (Expense) Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Measurement Period Adjustment, Global Intangible Low-Taxed Income, Deferred Tax Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to domestic income tax settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of reasonable estimate for tax liability for which accounting for tax effect from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated is incomplete pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2A<br> -Subparagraph (SAB Topic 5.EE.Q2(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=SL116722634-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2A<br> -Subparagraph (SAB Topic 5.EE.Q2(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=SL116722634-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R140.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7019735424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Employee </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested | $</a></td>
<td class="nump">$ 454<span></span>
</td>
<td class="nump">$ 146<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax | $</a></td>
<td class="nump">$ 241<span></span>
</td>
<td class="nump">$ 256<span></span>
</td>
<td class="nump">$ 254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which RSU cost is expected to be recognized (years)</a></td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of shares modified to accelerate vesting | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Number of employees affected by accelerated vesting | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting', window );">Number of shares scheduled for near-term vesting | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Near-Term Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of grantees affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7032477904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Schedule of Assets Held for Sale (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total Consumer Healthcare liabilities held for sale</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,725<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets', window );">Other assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember', window );">Consumer Healthcare [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Assets Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet', window );">Trade accounts receivable, less allowance for doubtful accounts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent', window );">Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">538<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent', window );">PP&amp;E</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent', window );">Identifiable intangible assets, less accumulated amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,763<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,678<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract', window );"><strong>Liabilities Held for Sale</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">406<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable', window );">Income taxes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent', window );">Accrued compensation and related items</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent', window );">Pension benefit obligations, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent', window );">Postretirement benefit obligations, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities', window );">Noncurrent deferred tax liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">56<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Total Consumer Healthcare liabilities held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,890<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as income tax obligations attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as goodwill attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as defined benefit plan benefit obligations attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as defined benefit non-pension postretirement plan obligations attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2510-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7033758176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - AstraZeneca (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2016</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Apr. 01, 2018</div></th>
<th class="th"><div>Jul. 02, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 711,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 988,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,653,000,000<span></span>
</td>
<td class="nump">$ 55,952,000,000<span></span>
</td>
<td class="nump">$ 53,411,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember', window );">AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, cash portion</a></td>
<td class="nump">$ 555,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 605,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 125,000,000<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredDeferredPayment', window );">Deferred payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum', window );">Maximum amount of sales-related payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="nump">1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="nump">485,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">894,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther', window );">Other current assets</a></td>
<td class="nump">92,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">73,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">19,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">315,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments', window );">Royalty payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 542,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">728,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 166,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredDeferredPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Deferred Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredDeferredPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Sales-related Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Undiscounted Royalty Payments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R144.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7189760528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details) - Performance Shares [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>measure </div>
<div>period</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout', window );">Number of measures used to determine share payout | measure</a></td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods', window );">Share payout measures, adjusted net income, number of periods | period</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod', window );">Share payout measures, adjusted net income, duration of period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Duration of Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R148.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7026685248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Valuation Assumptions of Stock Options (Detail) - Share-based Payment Arrangement, Option [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">3.27%<span></span>
</td>
<td class="nump">3.73%<span></span>
</td>
<td class="nump">3.69%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.66%<span></span>
</td>
<td class="nump">2.85%<span></span>
</td>
<td class="nump">2.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected stock price volatility</a></td>
<td class="nump">18.34%<span></span>
</td>
<td class="nump">20.02%<span></span>
</td>
<td class="nump">18.39%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
<td class="text">6 years 9 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R129.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7023618048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 05, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 12, 2019 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 07, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Sep. 07, 2018 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 14, 2018 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 12, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 19, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 06, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 02, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 19, 2017 </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>employee_stock_ownership_plan </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Oct. 23, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1', window );">Amount of remaining shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">213,000,000<span></span>
</td>
<td class="nump">307,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,865,000,000<span></span>
</td>
<td class="nump">$ 12,198,000,000<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NumberofEmployeeStockOwnershipPlans', window );">Number of employee stock ownership plans | employee_stock_ownership_plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_PreferredESOPPlanMember', window );">Preferred ESOP Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PreferredStockSharesHeldInEmployeeTrustShares', window );">Number of shares in Preferred ESOP | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_CommonESOPPlanMember', window );">Common ESOP Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense', window );">ESOP compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="nump">19,000,000<span></span>
</td>
<td class="nump">11,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_SeriesAConvertiblePreferredStockMember', window );">Series A, Convertible Preferred Stock [Member] | Preferred Employee Stock Ownership Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockDividendRatePercentage', window );">Series A convertible perpetual preferred stock, dividends rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Series A convertible perpetual preferred stock, per share stated value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockRedemptionPricePerShare', window );">Preferred stock, redemption price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Preferred Employee Stock Ownership Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion', window );">Series A convertible perpetual preferred stock, common stock shares when converted (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,574.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConvertiblePreferredStockNumberofSharesConvertible', window );">Convertible preferred stock, number of shares convertible | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | Common ESOP Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP', window );">Number of shares in ESOP | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2015StockPurchasePlanMember', window );">December 2015 Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2017StockPurchasePlanMember', window );">December 2017 Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2018StockPurchasePlanMember', window );">December 2018 Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithCitibankMember', window );">Share Repurchase Agreement with Citibank [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchases, cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (4,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (5,000,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21,000,000<span></span>
</td>
<td class="nump">87,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">126,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare', window );">Shares repurchased, initial price per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.61<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31.73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount', window );">Accelerated share repurchase, percentage of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Accelerated share repurchase, average price paid per share (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 33.31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Accelerated share repurchase, final average price paid (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36.86<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithGSCoMember', window );">Share Repurchase Agreement with GS&amp;Co [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1', window );">Amount of shares authorized in stock purchase plan, value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt', window );">Accelerated share repurchases, cash paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6,800,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Shares repurchased | shares</a></td>
<td class="nump">33,500,000<span></span>
</td>
<td class="nump">130,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount', window );">Accelerated share repurchase, percentage of agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare', window );">Accelerated share repurchase, final average price paid (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 41.42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareRepurchaseProgramAxis=pfe_OpenMarketPurchasesMember', window );">Open Market Purchases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityClassOfTreasuryStockLineItems', window );"><strong>Equity, Class of Treasury Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Cost of purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,100,000,000<span></span>
</td>
<td class="nump">$ 8,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConvertiblePreferredStockNumberofSharesConvertible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Convertible Preferred Stock, Number of Shares Convertible</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConvertiblePreferredStockNumberofSharesConvertible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NumberofEmployeeStockOwnershipPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of Employee Stock Ownership Plans</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NumberofEmployeeStockOwnershipPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PreferredStockSharesHeldInEmployeeTrustShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Preferred Stock, Shares Held In Employee Trust, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PreferredStockSharesHeldInEmployeeTrustShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 25<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=6405686&amp;loc=d3e22802-112653<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for each share of convertible preferred stock that is converted.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of plan compensation cost recognized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the allocated, committed-to-be-released and suspense shares of the entity held by the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109244661&amp;loc=d3e17540-113929<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityClassOfTreasuryStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityClassOfTreasuryStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockDividendRatePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage rate used to calculate dividend payments on preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockDividendRatePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockRedemptionPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21488-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21564-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockRedemptionPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount remaining of a stock repurchase plan authorized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_PreferredESOPPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_PreferredESOPPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_CommonESOPPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_CommonESOPPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_SeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_SeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_PreferredEmployeeStockOwnershipPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis=pfe_PreferredEmployeeStockOwnershipPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2015StockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_December2015StockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2017StockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_December2017StockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_December2018StockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_December2018StockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithCitibankMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithCitibankMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithGSCoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_ShareRepurchaseAgreementwithGSCoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareRepurchaseProgramAxis=pfe_OpenMarketPurchasesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareRepurchaseProgramAxis=pfe_OpenMarketPurchasesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953317264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock', window );">Schedule of Other Nonoperating Income (Expense)</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(226</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(333</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest expense</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,348</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Royalty-related income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(648</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(495</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(499</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net (gains)/losses on asset disposals</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(31</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net gains recognized during the period on equity securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(454</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(586</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net realized (gains)/losses on sales of investments in debt securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(168</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(488</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit costs/(credits) other than service costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(288</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain legal matters, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>554</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain asset impairments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,843</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Business and legal entity alignment costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>338</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net losses on early retirement of debt</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">GSK Consumer Healthcare JV equity method (income)/loss</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(m)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(388</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(417</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(328</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,116</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,416</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;Interest income decreased primarily driven by a lower investment balance. Interest expense increased mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year period. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;Interest income decreased primarily driven by a lower investment balance. Interest expense increased primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017. Capitalized interest expense totaled </span><span style="font-family:Arial;font-size:7pt;"><span>$88 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, $</span><span style="font-family:Arial;font-size:7pt;"><span>73 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and $</span><span style="font-family:Arial;font-size:7pt;"><span>72 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Royalty-related income </span><span style="font-family:Arial;font-size:7pt;">increased</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, primarily due to a one-time favorable resolution in the second quarter of </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> of a legal dispute for </span><span style="font-family:Arial;font-size:7pt;"><span>$82 million</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily included a realized gain on sale of property of </span><span style="font-family:Arial;font-size:7pt;"><span>$60 million</span></span><span style="font-family:Arial;font-size:7pt;">. In </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, primarily included an </span><span style="font-family:Arial;font-size:7pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:7pt;"> realized loss related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>49%</span></span><span style="font-family:Arial;font-size:7pt;">-owned equity-method investment in Hisun Pfizer and a realized net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>40%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the then remaining </span><span style="font-family:Arial;font-size:7pt;"><span>60%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership interest, partially offset by a realized gain on sale of property of </span><span style="font-family:Arial;font-size:7pt;"><span>$52 million</span></span><span style="font-family:Arial;font-size:7pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The gains in 2019 include, among other things, unrealized gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$295 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to investments in Cortexyme, Inc. and SpringWorks Therapeutics, Inc. The gains in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> included unrealized gains on equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$477 million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting the adoption of a new accounting standard in the first quarter of 2018 and were primarily driven by unrealized gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$466 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to our investment in Allogene. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7B</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2018, primarily includes gross realized losses on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$402 million</span></span><span style="font-family:Arial;font-size:7pt;"> and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$18 million</span></span><span style="font-family:Arial;font-size:7pt;"> from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities, partially offset by gross realized gains on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$280 million</span></span><span style="font-family:Arial;font-size:7pt;">. Proceeds from the sale of available-for-sale debt securities were </span><span style="font-family:Arial;font-size:7pt;"><span>$5.7 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in 2018. In 2017, primarily includes gross realized gains on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$451 million</span></span><span style="font-family:Arial;font-size:7pt;">, partially offset by gross realized losses on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$281 million</span></span><span style="font-family:Arial;font-size:7pt;"> and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$120 million</span></span><span style="font-family:Arial;font-size:7pt;"> from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debt securities were </span><span style="font-family:Arial;font-size:7pt;"><span>$5.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in 2017.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, mainly includes, among other things, </span><span style="font-family:Arial;font-size:7pt;"><span>$78 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">, a generic of Advair Diskus</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">(fluticasone propionate and salmeterol inhalation powder) and </span><span style="font-family:Arial;font-size:7pt;"><span>$52 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from multiple licensees. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes, among other things, (i) approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$118 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from multiple licensees, (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$110 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone payments received from Shire, of which </span><span style="font-family:Arial;font-size:7pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:7pt;"> was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of ulcerative colitis and </span><span style="font-family:Arial;font-size:7pt;"><span>$35 million</span></span><span style="font-family:Arial;font-size:7pt;"> was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn&#8217;s disease, (iii) an upfront payment to us and a recognized milestone totaling </span><span style="font-family:Arial;font-size:7pt;"><span>$85 million</span></span><span style="font-family:Arial;font-size:7pt;"> for the sale of an AMPA receptor potentiator for CIAS to Biogen, (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$62 million</span></span><span style="font-family:Arial;font-size:7pt;"> in gains related to sales of compound/product rights and (v) a </span><span style="font-family:Arial;font-size:7pt;"><span>$40 million</span></span><span style="font-family:Arial;font-size:7pt;"> milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2D </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</span><span style="font-family:Arial;font-size:7pt;">. In 2017, primarily includes, among other things, </span><span style="font-family:Arial;font-size:7pt;"><span>$101 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone payments received from multiple licensees and an </span><span style="font-family:Arial;font-size:7pt;"><span>$85 million</span></span><span style="font-family:Arial;font-size:7pt;"> gain related to sales of compound/product rights. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019, primarily includes settlement losses within the U.S. Pfizer Consolidated Pension Plan related to special restructuring initiatives, a small annuity buyout program and regular lump sum activity. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to 2017. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, mostly includes legal reserves for certain pending legal matters. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes legal reserves for certain pending legal matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In 2017, primarily includes a </span><span style="font-family:Arial;font-size:7pt;"><span>$94 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which was approved by the court in April 2018, and a </span><span style="font-family:Arial;font-size:7pt;"><span>$79 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge to reflect damages awarded by a jury in a patent matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">, mainly composed of: (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$2.6 billion</span></span><span style="font-family:Arial;font-size:7pt;">, related to Eucrisa, a Biopharma finite-lived developed technology right acquired in connection with our acquisition of Anacor, and reflects updated commercial forecasts mainly reflecting competitive pressures; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$90 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$40 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions; (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$31 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma IPR&amp;D asset, acquired in connection with our acquisition of AstraZeneca&#8217;s anti-infectives business, which reflects updated commercial forecasts; (v) </span><span style="font-family:Arial;font-size:7pt;"><span>$10 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">U.S. market only, </span><span style="font-family:Arial;font-size:7pt;text-align:center;">and reflects</span><span style="font-family:Arial;font-size:7pt;">, among other things, updated commercial forecasts; and (vi) </span><span style="font-family:Arial;font-size:7pt;"><span>$10 million</span></span><span style="font-family:Arial;font-size:7pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of Innopharma.</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:1px;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$3.1 billion</span></span><span style="font-family:Arial;font-size:7pt;">, mainly composed of (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$2.6 billion</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma developed technology rights, </span><span style="font-family:Arial;font-size:7pt;"><span>$242 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma licensing agreements and </span><span style="font-family:Arial;font-size:7pt;"><span>$80 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma IPR&amp;D, all of which relate to our acquisition of Hospira, for generic sterile injectable products associated with various indications; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$117 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a multi-antigen vaccine IPR&amp;D program for adults undergoing elective spinal fusion surgery; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$31 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to an Biopharma developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus market marketed in the U.S. market only; and (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$17 million</span></span><span style="font-family:Arial;font-size:7pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of Innopharma. In 2018, the intangible asset impairment charges associated with the generic sterile injectable products reflect, among other things, updated commercial forecasts, reflecting an increased competitive environment as well as higher manufacturing costs, largely stemming from manufacturing and supply issues. The intangible asset impairment charge for the multi-antigen vaccine IPR&amp;D program was the result of the Phase 2b trial reaching futility at a pre-planned interim analysis. </span><span style="font-family:Arial;font-size:7pt;text-align:center;">The intangible asset impairment charge related to the </span><span style="font-family:Arial;font-size:7pt;">Biopharma developed technology right</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> reflects</span><span style="font-family:Arial;font-size:7pt;">, among other things, updated commercial forecasts. .</span></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2017, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$337 million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$127 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$124 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$39 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$26 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) </span><span style="font-family:Arial;font-size:7pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with Biopharma and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$43 million</span></span><span style="font-family:Arial;font-size:7pt;"> for an impairment of our AM-Pharma B.V. long-term investment.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019 and 2018, mainly represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In 2017, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019 and 2017, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(m)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, includes, among other things, (i) dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$220 million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, (ii) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$152 million</span></span><span style="font-family:Arial;font-size:7pt;"> for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> of income from insurance recoveries related to Hurricane Maria. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, includes, among other things, (i) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$343 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">), (ii) dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$253 million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, (iii) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain on the contribution of Pfizer&#8217;s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained an ownership stake in Allogene (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">), (iv) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$17 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7E</span><span style="font-family:Arial;font-size:7pt;">), (v) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$207 million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting the change in the fair value of contingent consideration. and (vi) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$112 million</span></span><span style="font-family:Arial;font-size:7pt;"> for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. In 2017, includes, among other things, dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$266 million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, and income of </span><span style="font-family:Arial;font-size:7pt;"><span>$62 million</span></span><span style="font-family:Arial;font-size:7pt;"> from resolution of a contract disagreement. </span></div></td></tr></table><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock', window );">Schedule of Additional Information About Intangible Assets Impaired</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides additional information about the intangible assets that were impaired during 2019 in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impairment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets&#8211;&#8211;Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,213</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,213</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,639</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>131</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,770</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1E.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Reflects intangible assets written down to fair value in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R125.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040138928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details) - Pension Plan [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Level 3 [Member] | Other Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfer into/(out of) Level 3</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (51)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">8,215<span></span>
</td>
<td class="nump">8,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Exchange rate changes</a></td>
<td class="nump">42<span></span>
</td>
<td class="num">(380)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">8,215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Insurance Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Other Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">1,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Level 3 [Member] | Insurance Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Assets held, ending</a></td>
<td class="nump">50<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases, sales, and settlements, net</a></td>
<td class="num">(40)<span></span>
</td>
<td class="nump">188<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels', window );">Transfer into/(out of) Level 3</a></td>
<td class="nump">247<span></span>
</td>
<td class="nump">107<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Exchange rate changes</a></td>
<td class="nump">2<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">684<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Level 3 [Member] | Other Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward', window );"><strong>Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">382<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract', window );"><strong>Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld', window );">Assets held, ending</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">15<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements', window );">Purchases, sales, and settlements, net</a></td>
<td class="nump">6<span></span>
</td>
<td class="num">(31)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Exchange rate changes</a></td>
<td class="nump">4<span></span>
</td>
<td class="num">(20)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">$ 398<span></span>
</td>
<td class="nump">$ 382<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(A)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(B)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)(C)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAggregatedInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAggregatedInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_InsuranceContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_InsuranceContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R121.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039921696">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(24)<span></span>
</td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="num">(1,124)<span></span>
</td>
<td class="num">(1,371)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Funded status</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">401<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(30)<span></span>
</td>
<td class="num">(28)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="num">(2,526)<span></span>
</td>
<td class="num">(2,111)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Funded status</a></td>
<td class="num">(2,103)<span></span>
</td>
<td class="num">(1,738)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="num">(1,949)<span></span>
</td>
<td class="num">(2,088)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Funded status</a></td>
<td class="num">(1,949)<span></span>
</td>
<td class="num">(2,089)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan [Member] | United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent', window );">Noncurrent assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities', window );">Current liabilities</a></td>
<td class="num">(189)<span></span>
</td>
<td class="num">(167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent', window );">Noncurrent liabilities</a></td>
<td class="num">(1,162)<span></span>
</td>
<td class="num">(1,113)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet', window );">Funded status</a></td>
<td class="num">$ (1,351)<span></span>
</td>
<td class="num">$ (1,280)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952766416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Components of Inventories, Current</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Inventories</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,743</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>790</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Inventories</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,508</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent inventories not included above</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>618</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The change from </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;"> reflects increases for certain products, including inventory build for new product launches, supply recovery and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:Arial;font-size:7pt;">. There are no recoverability issues associated with these amounts.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock', window );">Schedule of Component of Inventories, Noncurrent</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Inventories</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,743</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>790</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Inventories</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,508</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent inventories not included above</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>618</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The change from </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;"> reflects increases for certain products, including inventory build for new product launches, supply recovery and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:Arial;font-size:7pt;">. There are no recoverability issues associated with these amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953001808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Property, Plant and Equipment</span><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of Property, plant and equipment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Useful Lives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Years)&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>516</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Buildings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">33-50</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>10,068</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,920</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8-20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>12,281</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Furniture, fixtures and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3-12 1/2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,930</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,693</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>30,756</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>29,977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Accumulated depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,789</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16,591</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>13,967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><span style="font-family:Arial;font-size:7pt;">The increase in total property, plant and equipment is mainly due to capital additions, partially offset by depreciation, reductions due to asset impairments largely associated with cost reduction initiatives not associated with acquisitions (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span>), and the impact of foreign exchange.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952733968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Tax Matters</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Tax Matters</span><div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. Taxes on Income from Continuing Operations</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,931</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4,403</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6,879</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>9,751</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>19,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(</sup></span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">a), (b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;">The domestic income in 2019 versus domestic loss in 2018 was mainly related to the completion of the Consumer Healthcare joint venture transaction with GSK as well as lower certain asset impairments, partially offset by reduced Lyrica revenues in the U.S., higher business and legal entity </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">alignment costs as well as increased costs related to certain legal matters. The decrease in the international income was primarily related to higher certain asset impairments as well as the write off of assets contributed to the Consumer Healthcare joint venture with GSK.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;">The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on equity securities and increased revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the legacy SIP portfolio. The decrease in international income was primarily related to lower interest income received primarily from intercompany borrowings from Pfizer Inc. and higher charges related to certain cost reduction initiatives, partially offset by increased revenue related to Ibrance and Eliquis.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;">&#160;based on the location of the taxing authorities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,641</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(166</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred income taxes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,258</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,663</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,064</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>275</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(304</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total U.S. tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(274</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">TCJA</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(135</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(3,035</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(187</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(23,795</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total TCJA tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(323</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(10,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,900</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,831</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,709</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(919</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(558</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total international tax provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(9,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The 2018 current tax benefit and deferred tax expense primarily relate to the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See discussion below and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including (i) the impact on deferred tax assets and liabilities from the reduction in the U.S. Federal corporate tax rate from 35% to </span><span style="font-family:Arial;font-size:8pt;">21%</span><span style="font-family:Arial;font-size:8pt;">, (ii) the impact on valuation allowances and other state income tax considerations, (iii) the </span><span style="font-family:Arial;font-size:8pt;"><span>$15.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 and (iv) deferred taxes on basis differences expected to give rise to future taxes on global intangible low-taxed income. In addition, we had provided deferred tax liabilities in the past on foreign earnings that were not indefinitely reinvested. As a result of the TCJA, in the fourth quarter of 2017, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to the territorial tax system. </span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2018, we finalized our provisional accounting for the tax effects of the TCJA, based on our best estimates of available information and data, and reported and disclosed the impacts within the applicable measurement period, in accordance with guidance issued by the SEC, and recorded a favorable adjustment of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$100 million</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;">. We believe that there may be additional interpretations, clarifications and guidance from the U.S. Department of Treasury. Any change to our calculations resulting from such additional interpretations, clarifications and guidance would be reflected in the period of issuance. In addition, our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.</span></div><div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">With respect to the aforementioned repatriation tax liability, our revised estimate is approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$15 billion</span></span><span style="font-family:Arial;font-size:8pt;">, which is reported in current </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:8pt;"> (approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$600 million</span></span><span style="font-family:Arial;font-size:8pt;">) and the remaining liability is reported in noncurrent </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable </span><span style="font-family:Arial;font-size:8pt;">in our consolidated balance sheet as of December 31, 2019. The first installment of </span><span style="font-family:Arial;font-size:8pt;"><span>$750 million</span></span><span style="font-family:Arial;font-size:8pt;"> was paid in April 2019. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;A, Topic 740, No. 5, </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accounting for Global Intangible Low-Taxed Income</span><span style="font-family:Arial;font-size:8pt;">, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years. In 2017, we provided a provisional deferred tax liability of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> based on the evaluation of certain temporary differences inside each of our foreign subsidiaries that are expected to reverse as global intangible low-taxed income. In 2018, this estimate was finalized and we provided for an additional deferred tax liability of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:8pt;">, resulting in a deferred tax liability of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.2 billion</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2019, the</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> was impacted by the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax expense of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$2.7 billion</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.6 billion</span></span><span style="font-family:Arial;font-size:8pt;">, representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years, primarily resulting from a favorable settlement with the IRS (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5D</span><span style="font-family:Arial;font-size:8pt;"> below);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$400 million</span></span><span style="font-family:Arial;font-size:8pt;"> related to certain tax initiatives associated with the implementation of our new organizational structure; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$325 million</span></span><span style="font-family:Arial;font-size:8pt;"> recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the enactment of the TCJA; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$620 million</span></span><span style="font-family:Arial;font-size:8pt;"> related to certain asset impairments.</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2018, the</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> was impacted by the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">estimated U.S. net tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$600 million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the enactment of the TCJA (see discussion above), primarily reflecting:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$500 million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated primarily with certain 2018 tax initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$100 million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated with adjustments to our provisional accounting for the tax effects of the TCJA, reported and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC, mainly consisting of:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$160 million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits related to the repatriation tax on deemed repatriated accumulated earnings of foreign subsidiaries; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$140 million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated with the remeasurement of other U.S. deferred tax liabilities,</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;padding-left:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">partially offset by:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:36px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:24px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax expense related to future taxes on global intangible low-taxed income;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$700 million</span></span><span style="font-family:Arial;font-size:8pt;"> representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years mostly with various foreign tax authorities, and the expiration of certain statutes of limitations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$740 million</span></span><span style="font-family:Arial;font-size:8pt;"> related to certain asset impairments.</span></div></td></tr></table><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2017, the</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> was impacted by the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">estimated U.S. net tax benefits of </span><span style="font-family:Arial;font-size:8pt;"><span>$10.7 billion</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the enactment of the TCJA (see discussion above), primarily reflecting:</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$22.8 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated with the remeasurement of U.S. deferred tax liabilities on unremitted earnings of foreign subsidiaries (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:8pt;">);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$1.6 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits associated with the remeasurement of other U.S. deferred tax liabilities, mainly associated with intangibles (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:8pt;">);</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$12.9 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of tax expense related to the repatriation tax on deemed repatriated accumulated pre-2017 post-1986 earnings of foreign subsidiaries; </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of tax expense related to future taxes on global intangible low-taxed income (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:8pt;">); and </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;">&#9702;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$100 million</span></span><span style="font-family:Arial;font-size:8pt;"> of tax benefits mostly associated with certain tax initiatives;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. tax expense of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:8pt;"> related to the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$370 million</span></span><span style="font-family:Arial;font-size:8pt;"> related to net losses on early retirement of debt;</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">tax benefits of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$150 million</span></span><span style="font-family:Arial;font-size:8pt;"> representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations; and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">the non-deductibility of a </span><span style="font-family:Arial;font-size:8pt;"><span>$307 million</span></span><span style="font-family:Arial;font-size:8pt;"> fee payable to the federal government as a result of the U.S. Healthcare Legislation. </span></div></td></tr></table><div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Tax Rate Reconciliation</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The reconciliation of the U.S. statutory income tax rate to our effective tax rate for </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations</span><span style="font-family:Arial;font-size:8pt;">&#160;follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. statutory income tax rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TCJA impact</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(86.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Taxation of non-U.S. operations</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(17.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax settlements and resolution of certain tax positions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Completion of Consumer Healthcare joint venture transaction</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Healthcare Legislation</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. R&amp;D tax credit and manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain legal settlements and charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effective tax rate for income from continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(73.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)%</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For a discussion about the enactment of the TCJA, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which, for 2017, includes the repatriation tax on deemed repatriated 2017 earnings of foreign subsidiaries discussed in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:7pt;">, changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions,&#8221; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A </span><span style="font-family:Arial;font-size:7pt;">for the components of pre-tax income and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income, </span><span style="font-family:Arial;font-size:7pt;">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2045 on income from manufacturing and other operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For a discussion about tax settlements and resolution of certain tax positions, the impact of the gain on the completion of the Consumer Healthcare joint venture transaction and the impact of U.S. Healthcare Legislation, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The favorable rate impact in 2018 is a result of the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods, as well as certain tax initiatives.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">All other, net in 2019 is primarily due to routine business operations. 2018 is primarily due to routine business operations and the non-recurrence of tax benefits associated with certain tax initiatives. 2017 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Deferred Taxes</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Deferred Tax*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018 Deferred Tax*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Liabilities)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Liabilities)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prepaid/deferred items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,195</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(204</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(325</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>743</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(7,099</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(7,620</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>179</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,226</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,011</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,217</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(39</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructurings and other charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>225</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Legal and product liability reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>496</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net operating loss/tax credit carryforwards</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,427</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unremitted earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(79</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local tax adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Investments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(3,318</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>9,215</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(11,988</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(9,456</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Valuation allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,927</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,068</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total deferred taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(11,988</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,508</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(9,456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net deferred tax liability</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories above. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:7pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The increase in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> is primarily related to the capitalization of certain R&amp;D-related expenses.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The decrease in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> is primarily the result of amortization of intangible assets and certain impairment charges, mainly offset by deferred tax liabilities established on intangible assets from the acquisition of Array.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The amounts in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> are reduced for unrecognized tax benefits of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.9 billion</span></span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$3.3 billion</span></span><span style="font-family:Arial;font-size:7pt;">, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The increase in 2019 is primarily related to the Consumer Healthcare joint venture with GSK. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$0.9 billion</span></span><span style="font-family:Arial;font-size:7pt;">), and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$5.6 billion</span></span><span style="font-family:Arial;font-size:7pt;">). In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$0.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">), and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$3.7 billion</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have carryforwards, primarily related to net operating and capital losses, general business credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2020 to 2039. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section&#160;382.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax assets.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we have not made a U.S. tax provision on approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$29.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is not practicable.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Tax Contingencies</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For a description of our accounting policies associated with accounting for income tax contingencies, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1P. </span><span style="font-family:Arial;font-size:8pt;">For a description of the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Uncertain Tax Positions</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$4.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in net unrecognized tax benefits, excluding associated interest and as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">, we had approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$5.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in net unrecognized tax benefits, excluding associated interest.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in </span><span style="font-family:Arial;font-size:8pt;">one</span><span style="font-family:Arial;font-size:8pt;"> tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in assets associated with uncertain tax positions. These amounts were included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:8pt;">) and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax liabilities (</span><span style="font-family:Arial;font-size:8pt;"><span>$109 million</span></span><span style="font-family:Arial;font-size:8pt;">). As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">, we had approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in assets associated with uncertain tax positions. These amounts were included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:8pt;">) and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax liabilities (</span><span style="font-family:Arial;font-size:8pt;"><span>$128 million</span></span><span style="font-family:Arial;font-size:8pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(6,259</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6,558</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5,826</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(44</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increases based on tax positions taken during a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(36</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decreases based on tax positions taken during a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,109</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decreases based on settlements for a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increases based on tax positions taken during the current period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(383</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(370</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(753</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(121</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, ending</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(5,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6,259</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6,558</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For 2019, primarily related to the acquisition of Array. For 2017, primarily related to the acquisitions of Medivation and Anacor. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to cash payments and reductions of tax attributes.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$108 million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Current tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$2 million</span></span><span style="font-family:Arial;font-size:7pt;">),</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$51 million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$2.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$2.4 billion</span></span><span style="font-family:Arial;font-size:7pt;">). In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$11 million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Current tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$1 million</span></span><span style="font-family:Arial;font-size:7pt;">) </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$47 million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$3.2 billion</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$3.0 billion</span></span><span style="font-family:Arial;font-size:7pt;">). </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> in our consolidated statements of income. In </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, we recorded a net decrease in interest of </span><span style="font-family:Arial;font-size:8pt;"><span>$564 million</span></span><span style="font-family:Arial;font-size:8pt;">, resulting primarily from a settlement with the IRS. In </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, we recorded a net increase in interest of </span><span style="font-family:Arial;font-size:8pt;"><span>$103 million</span></span><span style="font-family:Arial;font-size:8pt;">; and in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, we recorded a net increase in interest of </span><span style="font-family:Arial;font-size:8pt;"><span>$208 million</span></span><span style="font-family:Arial;font-size:8pt;">. Gross accrued interest totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$485 million</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> (reflecting a decrease of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$13 million</span></span><span style="font-family:Arial;font-size:8pt;"> as a result of cash payments) and gross accrued interest totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;"> (reflecting a decrease of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$16 million</span></span><span style="font-family:Arial;font-size:8pt;"> as a result of cash payments). In </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, this amount was included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable </span><span style="font-family:Arial;font-size:8pt;">(</span><span style="font-family:Arial;font-size:8pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:8pt;">) and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$465 million</span></span><span style="font-family:Arial;font-size:8pt;">). In </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, this amount was included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable </span><span style="font-family:Arial;font-size:8pt;">(</span><span style="font-family:Arial;font-size:8pt;"><span>$6 million</span></span><span style="font-family:Arial;font-size:8pt;">)</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:8pt;">). Accrued penalties are not significant. See also </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">During the second quarter of 2019, Pfizer reached settlement of disputed issues at the IRS Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2009-2010. As a result of settling these years, in the second quarter of 2019 we recorded a benefit of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:Arial;font-size:8pt;">, representing tax and interest. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">With respect to Pfizer, tax years 2011-2015 are currently under audit. Tax years 2016-2019 are open, but not under audit. All other tax years are closed.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2019), Japan (2017-2019), Europe (2011-2019, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2019, primarily reflecting Brazil) and Puerto Rico (2015-2019).</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as </span><span style="font-family:Arial;font-size:8pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:8pt;">, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.</span></div><div style="line-height:120%;padding-top:1px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of the </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency translation adjustments, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(215</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unrealized holding gains/(losses) on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>83</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for (gains)/losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(125</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unrealized holding gains/(losses) on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for (gains)/losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(60</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for tax on unrealized gains from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit plans: actuarial losses, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(169</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(141</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>612</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit plans: prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to curtailments of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(144</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income/(loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B</span><span style="font-family:Arial;font-size:7pt;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R102.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7021233408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">$ 664<span></span>
</td>
<td class="num">$ (27)<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months', window );">Amount of pre-tax loss to be reclassified</a></td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Carrying value of short-term borrowings</a></td>
<td class="nump">16,195<span></span>
</td>
<td class="nump">8,831<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember', window );">Foreign currency short-term borrowings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Carrying value of short-term borrowings</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember', window );">Foreign currency long-term debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="nump">2,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="nump">1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cost of Sales [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">247<span></span>
</td>
<td class="num">(13)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Other (Income) Deductions And Cost Of Sales [Member] | Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">$ 525<span></span>
</td>
<td class="num">$ (182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=112277219&amp;loc=d3e80748-113994<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R106.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952614928">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">$ 2,750<span></span>
</td>
<td class="nump">$ 2,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">4,743<span></span>
</td>
<td class="nump">4,701<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">790<span></span>
</td>
<td class="nump">546<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">8,283<span></span>
</td>
<td class="nump">7,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNoncurrent', window );">Noncurrent inventories not included above</a></td>
<td class="nump">$ 714<span></span>
</td>
<td class="nump">$ 618<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011343&amp;loc=d3e100047-122729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952955376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock', window );">Basis of Presentation and Significant Accounting Policies</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Basis of Presentation and Significant Accounting Policies</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A.</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> Basis of Presentation</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See the Glossary of Defined Terms at the beginning of this </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report for terms used throughout the consolidated financial statements and related notes in this </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> Financial Report.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Beginning on January 1, 2018, only taxes paid on intercompany inventory sales transactions are deferred until recognized upon the sale of the inventory to a third party, reflecting the adoption of a new accounting standard in the first quarter of 2018. Prior to the adoption of this new accounting standard in the first quarter of 2018, taxes paid on intercompany sales transactions were deferred until recognized upon sale of the asset to a third party.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> business segments&#8211;&#8211;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. We have revised prior-period segment information to reflect the reorganization. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17</span><span style="font-family:Arial;font-size:8pt;">. In addition, certain amounts within </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span><span style="font-family:Arial;font-size:8pt;"> in the December 31, 2018 consolidated balance sheet have been reclassified to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Equity-method investments</span><span style="font-family:Arial;font-size:8pt;"> to conform to the current presentation. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2C.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the first quarter of 2019, as of January 1, 2019, we adopted </span><span style="font-family:Arial;font-size:8pt;"><span>four</span></span><span style="font-family:Arial;font-size:8pt;"> new accounting standards. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1B</span><span style="font-family:Arial;font-size:8pt;"> for further information.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our recent significant business development activities include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">License Agreement with Akcea Therapeutics, Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">In October 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. The transaction closed in November 2019 and we made an upfront payment of</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">to Akcea and Ionis, which was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:8pt;">in our fiscal fourth quarter of 2019. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Formation of a New Consumer Healthcare Joint Venture</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">In accordance with our domestic and international reporting periods, our financial results, and our Consumer Healthcare segment&#8217;s operating results, for 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of Array BioPharma Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On </span><span style="font-family:Arial;font-size:8pt;">July&#160;30, 2019</span><span style="font-family:Arial;font-size:8pt;">, we acquired Array for </span><span style="font-family:Arial;font-size:8pt;"><span>$48</span></span><span style="font-family:Arial;font-size:8pt;"> per share in cash. The total fair value of the consideration transferred for Array was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$11.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$10.9 billion</span></span><span style="font-family:Arial;font-size:8pt;">, net of cash acquired). </span><span style="font-family:Arial;font-size:8pt;">Our financial statements for 2019 reflect the assets, liabilities, operating results and cash flows of Array, commencing from the acquisition date</span><span style="font-family:Arial;font-size:8pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Agreement to Combine Upjohn with Mylan N.V.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun off or split off to Pfizer&#8217;s shareholders and, immediately thereafter, combined with Mylan.</span><span style="font-family:Arial;font-size:8pt;"> Pfizer shareholders would own </span><span style="font-family:Arial;font-size:8pt;"><span>57%</span></span><span style="font-family:Arial;font-size:8pt;"> of the combined new company, and former Mylan shareholders would own </span><span style="font-family:Arial;font-size:8pt;"><span>43%</span></span><span style="font-family:Arial;font-size:8pt;">.  Closing of the transaction is subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of Therachon Holding AG</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On July 1, 2019, we acquired all the remaining shares of Therachon for </span><span style="font-family:Arial;font-size:8pt;"><span>$340 million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront, plus potential milestone payments of up to </span><span style="font-family:Arial;font-size:8pt;"><span>$470 million</span></span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;">contingent on the achievement of key milestones in the development and commercialization of the lead asset. The total fair value of the consideration transferred for Therachon was approximately</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$322 million</span></span><span style="font-family:Arial;font-size:8pt;">. </span><span style="font-family:Arial;font-size:8pt;">Our financial statements for 2019 reflect the assets, liabilities, operating results and cash flows of Therachon, commencing from the acquisition date and, in accordance with our international reporting period, reflect five months of Therachon operations and cash flows.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc.</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical for up to approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$900 million</span></span><span style="font-family:Arial;font-size:8pt;">, composed of cash and contingent cash consideration, ICU Medical common stock (all of which we sold during 2018) and seller financing. HIS includes IV pumps, solutions and devices. The operating results of HIS are included in our consolidated statement of income through February 2, 2017 and, therefore, our financial results for 2017 reflect one month of HIS domestic operations and two months of HIS international operations. Our financial results for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> do not reflect any contribution from HIS global operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:8pt;text-indent:-12px;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Acquisition of AstraZeneca&#8217;s Small Molecule Anti-Infectives Business</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S. for approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:8pt;">, composed of cash and contingent consideration. </span><span style="font-family:Arial;font-size:8pt;">Our financial statements reflect the assets, liabilities, operating results and cash flows of this business, commencing from the acquisition date and, in accordance with our international reporting period, for 2017 reflect approximately 11 months of the small molecule anti-infectives business operations and cash flows acquired from AstraZeneca.</span><span style="font-family:Arial;font-size:8pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B.</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Adoption of New Accounting Standards in 2019</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On January 1, 2019, we adopted </span><span style="font-family:Arial;font-size:8pt;"><span>four</span></span><span style="font-family:Arial;font-size:8pt;"> new accounting standards.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Leases</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of </span><span style="font-family:Arial;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> and current and noncurrent operating lease liabilities of </span><span style="font-family:Arial;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"> by </span><span style="font-family:Arial;font-size:8pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:8pt;"> on a pre-tax basis (</span><span style="font-family:Arial;font-size:8pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:8pt;"> after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adopting the standard related to leases impacted our prior period consolidated balance sheet as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As Previously Reported Balance at</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect of Change</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher/(Lower)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance at</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,461</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,460</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,913</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,149</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>258</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11,011</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,060</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,910</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>89,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>89,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adoption of the standard related to leases did not have a material impact on our consolidated statements of income or consolidated statements of cash flows in</span><span style="font-family:Arial;font-size:8pt;text-align:center;"> 2019</span><span style="font-family:Arial;font-size:8pt;">. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1T</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Amortization Period for Certain Callable Debt Securities Held at a Premium</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Accounting for Share-Based Payments to Nonemployees</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Estimates and Assumptions</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&amp;D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For information on estimates and assumptions in connection with the TCJA, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Tax Matters: Taxes on Income from Continuing Operations.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Acquisitions</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16D</span><span style="font-family:Arial;font-size:8pt;">. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Fair Value</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income approach, which is based on the present value of a future stream of net cash flows. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our fair value methodologies depend on the following types of inputs:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">F. Foreign Currency Translation</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">, and we translate non-monetary items at historical rates.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">G</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenues and Trade Accounts Receivable</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We recorded direct product sales and/or alliance revenues of more than </span><span style="font-family:Arial;font-size:8pt;"><span>$1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> for each of </span><span style="font-family:Arial;font-size:8pt;">eight</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, for each of </span><span style="font-family:Arial;font-size:8pt;">ten</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and for each of </span><span style="font-family:Arial;font-size:8pt;">nine</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. In the aggregate, these direct products sales and/or alliance product revenues represent </span><span style="font-family:Arial;font-size:8pt;"><span>49%</span></span><span style="font-family:Arial;font-size:8pt;"> of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>51%</span></span><span style="font-family:Arial;font-size:8pt;"> of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>46%</span></span><span style="font-family:Arial;font-size:8pt;color:#ffffff;"> </span><span style="font-family:Arial;font-size:8pt;">of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17C </span><span style="font-family:Arial;font-size:8pt;">for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business, which was combined with GSK&#8217;s Consumer Healthcare business into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name on July 31, 2019, included OTC brands with a focus on dietary supplements, pain management, gastrointestinal and respiratory and personal care. We sell biopharmaceutical products after patent expiration, and under patent, and, to a much lesser extent, through July 31, 2019, we sold consumer healthcare products worldwide to developed and emerging market countries.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenue Recognition</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Customers</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Customers for our consumer healthcare business, which were part of the business that was combined with GSK&#8217;s Consumer Healthcare business into a new consumer healthcare joint venture on July 31, 2019, included retailers and, to a lesser extent, wholesalers and distributors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Our Sales Contracts</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales</span><span style="font-family:Arial;font-size:8pt;color:#ff0000;"> </span><span style="font-family:Arial;font-size:8pt;">are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of exclusivity, product recalls or a changing competitive environment. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Deductions from Revenues</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Specifically:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managers and legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period&#8217;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#8220;coverage gap,&#8221; also known as the &#8220;doughnut hole,&#8221; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#8217;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$5.7 billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$5.4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information about the balance sheet classification of these accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reserve against </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,257</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrued rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,285</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,208</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>581</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>565</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total accrued rebates and other accruals</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Trade Accounts Receivable</span><span style="font-family:Arial;font-size:8pt;">&#8212;Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">H. Collaborative Arrangements</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues,</span><span style="font-family:Arial;font-size:8pt;"> when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable period. The related expenses for selling and marketing these products are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses.</span><span style="font-family:Arial;font-size:8pt;"> In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;">. Royalty payments received from collaboration partners are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reimbursements to or from our collaboration partners for development costs are recorded net in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets&#8212;Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;"> over the development period for the collaboration products, when our performance obligations include providing R&amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;"> immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">I. Cost of Sales and Inventories</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">J. Selling, Informational and Administrative Expenses</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$2.6 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$3.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$3.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs. </span></div><div style="line-height:120%;padding-top:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">K. Research and Development Expenses</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">R&amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:8pt;"> and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">L. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Long-lived assets include:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Property, plant and equipment, less accumulated depreciation</span><span style="font-family:Arial;font-size:8pt;">&#8212;These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:8pt;">&#8212;These acquired assets are recorded at fair value. Intangible assets with finite lives</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;">&#8212;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:8pt;"> as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses,</span><span style="font-family:Arial;font-size:8pt;"> as appropriate.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Specifically:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For indefinite-lived intangible assets, such as Brands and IPR&amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">M. Restructuring Charges and Certain Acquisition-Related Costs</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:8pt;"> are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">N. Cash Equivalents and Statement of Cash Flows</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term investments</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.</span></div><div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">O. Investments and Derivative Financial Instruments</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our investments are comprised of the following: public equity securities with readily determinable fair values, available-for-sale debt securities, held-to-maturity debt securities (when we have both the positive intent and ability to hold the investment to maturity), private equity securities </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">without readily determinable fair values and equity-method investments. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Public equity securities with readily determinable fair values are carried at fair value, with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities are carried at fair value, with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss) </span><span style="font-family:Arial;font-size:8pt;">until realized.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities are carried at amortized cost.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#8217;s income and expenses in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;">. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Realized gains or losses on sales of investments are determined by using the specific identification cost method.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative financial instruments are carried at fair value in various balance sheet categories (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7A</span><span style="font-family:Arial;font-size:8pt;">), with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Net income</span><span style="font-family:Arial;font-size:8pt;"> or, for derivative financial instruments in certain qualifying hedging relationships, in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss) </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7F</span><span style="font-family:Arial;font-size:8pt;">). </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A single estimate of fair value and impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">P. Tax Assets and Liabilities and Income Tax Contingencies</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Tax Assets and Liabilities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current tax assets primarily includes (i) tax effects associated with intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party, as well as (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws, including the impact of the TCJA enacted in December 2017. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet. Amounts recorded for valuation allowances can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other non-current tax assets </span><span style="font-family:Arial;font-size:8pt;">primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:8pt;"> in our consolidated balance sheet as of December 31, 2019 includes liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability on the deemed repatriated accumulated post-1986 foreign earnings recorded in connection with the TCJA for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5D</span><span style="font-family:Arial;font-size:8pt;"> for uncertain tax positions and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;"> for the repatriation tax liability.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Income Tax Contingencies</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#8220;more likely than not&#8221;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and local and foreign income tax filings, statute of limitations expirations, changes and clarification in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> and are classified on our consolidated balance sheet with the related tax liability.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Q. Pension and Postretirement Benefit Plans</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">R. Legal and Environmental Contingencies</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">S. Share-Based Payments</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">T. Leases</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On January&#160;1, 2019, we adopted a new accounting standard for leases. For further information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1B</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of </span><span style="font-family:Arial;font-size:8pt;"><span>1</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span>30</span></span><span style="font-family:Arial;font-size:8pt;"> years, some of which include options to terminate or extend leases for up to </span><span style="font-family:Arial;font-size:8pt;"><span>5</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span>10</span></span><span style="font-family:Arial;font-size:8pt;"> years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to </span><span style="font-family:Arial;font-size:8pt;"><span>$328 million</span></span><span style="font-family:Arial;font-size:8pt;"> for the year ended </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For operating leases, the ROU assets and liabilities are presented in our consolidated balance sheet as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance at</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance Sheet Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease liabilities (short-term)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease liabilities (long-term)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our total lease costs are as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>416</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Variable lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>328</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other supplemental information includes the following:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average Remaining Contractual Lease Term (Years) as of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average Discount Rate as of</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>346</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gains)/losses on sale and leaseback transactions, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(29</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ROU assets obtained in exchange for new operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating Lease Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Next one year</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>323</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1-2 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>286</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2-3 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3-4 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4-5 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>424</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total undiscounted lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,530</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Present value of minimum lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,324</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Reflects lease payments due within 12 months subsequent to the balance sheet date.</span><span style="font-family:Arial;font-size:8pt;"> </span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, we entered an agreement to lease space in an office building in New York City. We expect to take control of the property in 2021 and relocate our global headquarters to this new office building in 2022. Our future minimum rental commitment under this </span><span style="font-family:Arial;font-size:8pt;"><span>20</span></span><span style="font-family:Arial;font-size:8pt;">-year lease is approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.7 billion</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior to our adoption of the new lease standard, rental expense, net of sublease income, was </span><span style="font-family:Arial;font-size:8pt;"><span>$301 million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2018 and </span><span style="font-family:Arial;font-size:8pt;"><span>$314 million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2017.</span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">After 2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease commitments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,040</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>100
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "pfe-12312019x10kshell.htm pfe-exhibit13x12312019.htm": {
   "axisCustom": 3,
   "axisStandard": 60,
   "contextCount": 1359,
   "dts": {
    "calculationLink": {
     "local": [
      "pfe-20191231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "us-gaap-eedm-def-2019-01-31.xml",
      "srt-eedm1-def-2019-01-31.xml",
      "pfe-20191231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "pfe-12312019x10kshell.htm",
      "pfe-exhibit13x12312019.htm"
     ]
    },
    "labelLink": {
     "local": [
      "pfe-20191231_lab.xml",
      "us-gaap-doc-2019-01-31.xml",
      "dei-doc-2019-01-31.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "pfe-20191231_pre.xml"
     ]
    },
    "referenceLink": {
     "local": [
      "us-gaap-ref-2019-01-31.xml",
      "dei-ref-2019-01-31.xml"
     ]
    },
    "schema": {
     "local": [
      "pfe-20191231.xsd",
      "srt-types-2019-01-31.xsd",
      "xbrl-instance-2003-12-31.xsd",
      "xbrl-linkbase-2003-12-31.xsd",
      "xl-2003-12-31.xsd",
      "xlink-2003-12-31.xsd",
      "numeric-2009-12-16.xsd",
      "nonNumeric-2009-12-16.xsd",
      "ref-2006-02-27.xsd",
      "srt-2019-01-31.xsd",
      "xbrldt-2005.xsd",
      "us-gaap-2019-01-31.xsd",
      "us-roles-2019-01-31.xsd",
      "srt-roles-2019-01-31.xsd",
      "country-2017-01-31.xsd",
      "us-types-2019-01-31.xsd",
      "factExplanatory-2009-12-16.xsd",
      "negated-2009-12-16.xsd",
      "net-2009-12-16.xsd",
      "currency-2019-01-31.xsd",
      "dei-2019-01-31.xsd",
      "exch-2019-01-31.xsd",
      "invest-2013-01-31.xsd",
      "naics-2017-01-31.xsd",
      "sic-2011-01-31.xsd",
      "stpr-2018-01-31.xsd",
      "reference-2009-12-16.xsd",
      "us-parts-codification-2019-01-31.xsd",
      "deprecated-2009-12-16.xsd"
     ]
    }
   },
   "elementCount": 1585,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2019-01-31": 77,
    "http://www.pfizer.com/20191231": 15,
    "http://xbrl.sec.gov/dei/2019-01-31": 5,
    "total": 97
   },
   "keyCustom": 235,
   "keyStandard": 788,
   "memberCustom": 221,
   "memberStandard": 113,
   "nsprefix": "pfe",
   "nsuri": "http://www.pfizer.com/20191231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-12312019x10kshell.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "0001000 - Document - Cover Page",
     "role": "http://www.pfizer.com/role/CoverPage",
     "shortName": "Cover Page",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-12312019x10kshell.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005501 - Statement - Consolidated Statements of Cash Flows (Parenthetical)",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
     "shortName": "Consolidated Statements of Cash Flows (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_U.K.PoundDenominatedDebtMember",
      "decimals": "-6",
      "lang": "en-US",
      "name": "pfe:GainLossOnExchangeOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R100": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407414 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
     "shortName": "Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
       "us-gaap:ScheduleOfDerivativeInstrumentsTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R101": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407415 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R102": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407416 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
     "shortName": "Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R103": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:HedgedAssetFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407418 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
     "shortName": "Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:HedgedAssetFairValueHedge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R104": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407419 - Disclosure - Financial Instruments - Narrative (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails",
     "shortName": "Financial Instruments - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DerivativeNetLiabilityPositionAggregateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R105": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407420 - Disclosure - Financial Instruments - Credit Risk (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails",
     "shortName": "Financial Instruments - Credit Risk (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R106": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2408402 - Disclosure - Inventories (Details)",
     "role": "http://www.pfizer.com/role/InventoriesDetails",
     "shortName": "Inventories (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InventoryFinishedGoodsNetOfReserves",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R107": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2409402 - Disclosure - Property, Plant and Equipment (Details)",
     "role": "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails",
     "shortName": "Property, Plant and Equipment (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R108": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410402 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R109": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410403 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R110": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410404 - Disclosure - Identifiable Intangible Assets and Goodwill - Intangible Assets Percentage of Total Intangibles (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Intangible Assets Percentage of Total Intangibles (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R111": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "Operating_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410405 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:AmortizationOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R112": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410406 - Disclosure - Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R113": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2410407 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Details)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
     "shortName": "Identifiable Intangible Assets and Goodwill - Goodwill (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfGoodwillTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:GoodwillAcquiredDuringPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R114": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanServiceCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411402 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R115": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2018Q1Jan01",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DefinedBenefitPlanNumberofPensionPlansFrozen",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pension_plan",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411403 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2018Q1Jan01",
      "decimals": "INF",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DefinedBenefitPlanNumberofPensionPlansFrozen",
      "reportCount": 1,
      "unique": true,
      "unitRef": "pension_plan",
      "xsiNil": "false"
     }
    },
    "R116": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411404 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R117": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411405 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAssumptionsUsedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R118": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411406 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R119": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411407 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock",
       "us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2102100 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R120": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanBenefitObligation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411408 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R121": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411409 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R122": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411410 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R123": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411411 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R124": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411412 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanFairValueOfPlanAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R125": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411413 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R126": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411414 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R127": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411415 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R128": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2411416 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanCostRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R129": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2014Q4Oct23-2014",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412402 - Disclosure - Equity - Narrative (Details)",
     "role": "http://www.pfizer.com/role/EquityNarrativeDetails",
     "shortName": "Equity - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2014Q4Oct23-2014",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockRepurchaseProgramAuthorizedAmount1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2103100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R130": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:TreasuryStockSharesAcquired",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2412403 - Disclosure - Equity - Summary of Common Stock Purchases (Details)",
     "role": "http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails",
     "shortName": "Equity - Summary of Common Stock Purchases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R131": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413402 - Disclosure - Share-Based Payments - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
     "shortName": "Share-Based Payments - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R132": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413403 - Disclosure - Share-Based Payments - Impact on Net Income (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
     "shortName": "Share-Based Payments - Impact on Net Income (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R133": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "trading_day",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413404 - Disclosure - Share-Based Payments - Total Shareholder Return Units Narrative (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails",
     "shortName": "Share-Based Payments - Total Shareholder Return Units Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "trading_day",
      "xsiNil": "false"
     }
    },
    "R134": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413405 - Disclosure - Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail",
     "shortName": "Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R135": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413406 - Disclosure - Share-Based Payments - Total Shareholder Return Units Activity (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails",
     "shortName": "Share-Based Payments - Total Shareholder Return Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R136": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413407 - Disclosure - Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails",
     "shortName": "Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R137": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413408 - Disclosure - Share-Based Payments - Data Related to All Total Shareholder Return Units (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails",
     "shortName": "Share-Based Payments - Data Related to All Total Shareholder Return Units (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R138": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2017Q4Dec29-Dec29_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413409 - Disclosure - Share-Based Payments - Performance Total Shareholder Return Units Narrative (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails",
     "shortName": "Share-Based Payments - Performance Total Shareholder Return Units Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2017Q4Dec29-Dec29_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R139": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413410 - Disclosure - Share-Based Payments - Restricted Stock Unit Activity (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
     "shortName": "Share-Based Payments - Restricted Stock Unit Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2104100 - Disclosure - Other (Income)/Deductions - Net",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNet",
     "shortName": "Other (Income)/Deductions - Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R140": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413411 - Disclosure - Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
     "shortName": "Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R141": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413412 - Disclosure - Share-Based Payments - Portfolio Performance Shares Narrative (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
     "shortName": "Share-Based Payments - Portfolio Performance Shares Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R142": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413413 - Disclosure - Share-Based Payments - Portfolio Performance Shares Activity (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
     "shortName": "Share-Based Payments - Portfolio Performance Shares Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R143": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413414 - Disclosure - Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
     "shortName": "Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R144": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout",
      "reportCount": 1,
      "unique": true,
      "unitRef": "measure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413415 - Disclosure - Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
     "shortName": "Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout",
      "reportCount": 1,
      "unique": true,
      "unitRef": "measure",
      "xsiNil": "false"
     }
    },
    "R145": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413416 - Disclosure - Share-Based Payments - Performance Share Awards (PSAs) Activity (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
     "shortName": "Share-Based Payments - Performance Share Awards (PSAs) Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R146": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413417 - Disclosure - Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
     "shortName": "Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R147": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "reportCount": 1,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413418 - Disclosure - Share-Based Payments - Stock Option Narrative (Details)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails",
     "shortName": "Share-Based Payments - Stock Option Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R148": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413419 - Disclosure - Share-Based Payments - Valuation Assumptions of Stock Options (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
     "shortName": "Share-Based Payments - Valuation Assumptions of Stock Options (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember",
      "decimals": "4",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R149": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413420 - Disclosure - Share-Based Payments - Stock Option Activity (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail",
     "shortName": "Share-Based Payments - Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2105100 - Disclosure - Tax Matters",
     "role": "http://www.pfizer.com/role/TaxMatters",
     "shortName": "Tax Matters",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R150": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2413421 - Disclosure - Share-Based Payments - Data Related to All Stock Option Activity (Detail)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail",
     "shortName": "Share-Based Payments - Data Related to All Stock Option Activity (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R151": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2414402 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted (Details)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R152": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:GainContingencyPatentsWithoutCourtProceedingsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Patent",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417401 - Disclosure - Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails",
     "shortName": "Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:GainContingencyPatentsWithoutCourtProceedingsNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Patent",
      "xsiNil": "false"
     }
    },
    "R153": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2017Q4Nov2017",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:LossContingencyClassActionsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_action",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417402 - Disclosure - Contingencies and Certain Commitments (Action In Which We Are The Defendant) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
     "shortName": "Contingencies and Certain Commitments (Action In Which We Are The Defendant) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2017Q4Nov2017",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "pfe:LossContingencyClassActionsFiledNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "class_action",
      "xsiNil": "false"
     }
    },
    "R154": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2417403 - Disclosure - Contingencies and Certain Commitments (Commitments and Contingent Consideration for Acquisitions) (Details)",
     "role": "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
     "shortName": "Contingencies and Certain Commitments (Commitments and Contingent Consideration for Acquisitions) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermPurchaseCommitmentAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R155": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "Operating_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember",
      "decimals": "INF",
      "lang": null,
      "name": "pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Country",
      "xsiNil": "false"
     }
    },
    "R156": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
     "shortName": "Segment, Geographic and Other Revenue Information (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "pfe:ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R157": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainLossRelatedToLitigationSettlement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "pfe:ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:RestructuringChargesandImplementationCosts",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R158": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_srt_StatementGeographicalAxis_country_US",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R159": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2106100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R160": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418407 - Disclosure - Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_srt_StatementGeographicalAxis_country_US",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentNet",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R161": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2418408 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail",
     "shortName": "Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2107100 - Disclosure - Financial Instruments",
     "role": "http://www.pfizer.com/role/FinancialInstruments",
     "shortName": "Financial Instruments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FinancialInstrumentsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2108100 - Disclosure - Inventories",
     "role": "http://www.pfizer.com/role/Inventories",
     "shortName": "Inventories",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2109100 - Disclosure - Property, Plant and Equipment",
     "role": "http://www.pfizer.com/role/PropertyPlantAndEquipment",
     "shortName": "Property, Plant and Equipment",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1001000 - Statement - Consolidated Statements of Income",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
     "shortName": "Consolidated Statements of Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2110100 - Disclosure - Identifiable Intangible Assets and Goodwill",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill",
     "shortName": "Identifiable Intangible Assets and Goodwill",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2111100 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2112100 - Disclosure - Equity",
     "role": "http://www.pfizer.com/role/Equity",
     "shortName": "Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2113100 - Disclosure - Share-Based Payments",
     "role": "http://www.pfizer.com/role/ShareBasedPayments",
     "shortName": "Share-Based Payments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2114100 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:InsuranceCoverageDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2116100 - Disclosure - Insurance",
     "role": "http://www.pfizer.com/role/Insurance",
     "shortName": "Insurance",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "pfe:InsuranceCoverageDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2117100 - Disclosure - Contingencies and Certain Commitments",
     "role": "http://www.pfizer.com/role/ContingenciesAndCertainCommitments",
     "shortName": "Contingencies and Certain Commitments",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2118100 - Disclosure - Segment, Geographic and Other Revenue Information",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation",
     "shortName": "Segment, Geographic and Other Revenue Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2301302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables",
     "shortName": "Basis of Presentation and Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002000 - Statement - Consolidated Statements of Comprehensive Income",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome",
     "shortName": "Consolidated Statements of Comprehensive Income",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2302301 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements (Tables)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2303301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2304301 - Disclosure - Other (Income)/Deductions - Net (Tables)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables",
     "shortName": "Other (Income)/Deductions - Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2305301 - Disclosure - Tax Matters (Tables)",
     "role": "http://www.pfizer.com/role/TaxMattersTables",
     "shortName": "Tax Matters (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2306301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2307301 - Disclosure - Financial Instruments (Tables)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTables",
     "shortName": "Financial Instruments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2308301 - Disclosure - Inventories (Tables)",
     "role": "http://www.pfizer.com/role/InventoriesTables",
     "shortName": "Inventories (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2309301 - Disclosure - Property, Plant and Equipment (Tables)",
     "role": "http://www.pfizer.com/role/PropertyPlantAndEquipmentTables",
     "shortName": "Property, Plant and Equipment (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2310301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)",
     "role": "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables",
     "shortName": "Identifiable Intangible Assets and Goodwill (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2311301 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)",
     "role": "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables",
     "shortName": "Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1002501 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
     "shortName": "Consolidated Statements of Comprehensive Income (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember",
      "decimals": "-8",
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2312301 - Disclosure - Equity (Tables)",
     "role": "http://www.pfizer.com/role/EquityTables",
     "shortName": "Equity (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfTreasuryStockByClassTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2313301 - Disclosure - Share-Based Payments (Tables)",
     "role": "http://www.pfizer.com/role/ShareBasedPaymentsTables",
     "shortName": "Share-Based Payments (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2314301 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)",
     "role": "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables",
     "shortName": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "pfe:ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2318301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)",
     "role": "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables",
     "shortName": "Segment, Geographic and Other Revenue Information (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
       "pfe:ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unitRef": "Operating_Segment",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2019Q1Jan01",
      "decimals": "INF",
      "lang": null,
      "name": "pfe:NumberOfAccountingStandardsAdopted",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Accounting_standard",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Impact of Lease Standard Adoption (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Impact of Lease Standard Adoption (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2019Q1Jan01",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherAssetsCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:RebatesAndDiscountsAccrual",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401405 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:RebatesAndDiscountsAccrual",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:AssetsAndLiabilitiesLesseeTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseRightOfUseAsset",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401406 - Disclosure - Basis of Presentation and Significant Accounting Policies - ROU Assets and Liabilities Presented in Balance Sheet (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - ROU Assets and Liabilities Presented in Balance Sheet (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401407 - Disclosure - Basis of Presentation and Significant Accounting Policies - Total Lease Cost (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Total Lease Cost (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeaseCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401408 - Disclosure - Basis of Presentation and Significant Accounting Policies - Other Supplemental Lease Information (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Other Supplemental Lease Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003000 - Statement - Consolidated Balance Sheets",
     "role": "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2401409 - Disclosure - Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details)",
     "role": "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails",
     "shortName": "Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402402 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Array BioPharma Inc (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Array BioPharma Inc (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember",
      "decimals": "-8",
      "lang": null,
      "name": "us-gaap:Goodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402403 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Therachon Holding AG (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Therachon Holding AG (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember",
      "decimals": "2",
      "lang": null,
      "name": "pfe:AssetAcquisitionPercentageofSharesAcquired",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:BusinessCombinationContingentConsiderationLiability",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402404 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - AstraZeneca (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - AstraZeneca (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R54": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402405 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Medivation, Inc. (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Medivation, Inc. (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:BusinessAcquisitionSharePrice",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usdPerShare",
      "xsiNil": "false"
     }
    },
    "R55": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402406 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Divestitures (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Divestitures (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2018Q2Apr01-Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R56": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeconsolidationGainOrLossAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402407 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Equity Method Investments and Assets and Liabilities Held for Sale (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Equity Method Investments and Assets and Liabilities Held for Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember",
      "decimals": "-8",
      "lang": null,
      "name": "pfe:DeconsolidationGainLossAmountNetOfTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R57": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402408 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Schedule of Assets Held for Sale (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Schedule of Assets Held for Sale (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R58": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402409 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R59": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:ProceedsFromLicensingArrangement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402410 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Licensing Arrangements (Details)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Licensing Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2019Q4Nov1-30_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-8",
      "lang": null,
      "name": "pfe:LicensingArrangementMilestoneMaximumValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1003501 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "role": "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R60": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2402411 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - R & D and Collaborative Arrangements (Detail)",
     "role": "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
     "shortName": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - R & D and Collaborative Arrangements (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2016Q2Apr01-Apr30_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member",
      "decimals": "INF",
      "lang": null,
      "name": "pfe:ResearchandDevelopmentArrangementMaximumFundingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R61": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringAndRelatedCostIncurredCost",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R62": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:SeveranceCosts1",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R63": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:RestructuringCharges",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R64": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R65": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2403406 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)",
     "role": "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
     "shortName": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:RestructuringReserve",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R66": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404402 - Disclosure - Other (Income)/Deductions - Net (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails",
     "shortName": "Other (Income)/Deductions - Net (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:InvestmentIncomeInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R67": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404403 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails",
     "shortName": "Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InterestCostsCapitalized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R68": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404404 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Royalty Income (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails",
     "shortName": "Other (Income)/Deductions - Net - Footnotes - Royalty Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q2QTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ProceedsFromLegalSettlements",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R69": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2018Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:GainLossOnSaleOfPropertyPlantEquipment",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404405 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Asset Disposals and Investments in Equity Securities (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
     "shortName": "Other (Income)/Deductions - Net - Footnotes - Asset Disposals and Investments in Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004000 - Statement - Consolidated Statements of Equity",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
     "shortName": "Consolidated Statements of Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesIssued",
      "reportCount": 1,
      "unique": true,
      "unitRef": "shares",
      "xsiNil": "false"
     }
    },
    "R70": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2018Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404406 - Disclosure - Other (Income)/ Deductions - Net - Footnotes - Investments (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails",
     "shortName": "Other (Income)/ Deductions - Net - Footnotes - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2018Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R71": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:ProceedsFromLicensingArrangement",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404407 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Collaborative Arrangements (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
     "shortName": "Other (Income)/Deductions - Net - Footnotes - Collaborative Arrangements (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainLossOnDispositionOfIntangibleAssets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R72": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2017Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404408 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails",
     "shortName": "Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2017Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LitigationSettlementExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R73": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404409 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
     "shortName": "Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R74": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DeconsolidationExternalIncrementalCostsAmount",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404410 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Additional Information (Details)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
     "shortName": "Other (Income)/Deductions - Net - Footnotes - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:InsuranceRecoveries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R75": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2404411 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Additional Information About Impaired Intangible Assets (Detail)",
     "role": "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
     "shortName": "Other (Income)/Deductions - Net - Footnotes - Additional Information About Impaired Intangible Assets (Detail)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:IntangibleAssetsFairValueDisclosure",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R76": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405402 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails",
     "shortName": "Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R77": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405403 - Disclosure - Tax Matters - Provision for Taxes on Income (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails",
     "shortName": "Tax Matters - Provision for Taxes on Income (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R78": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405404 - Disclosure - Tax Matters - Provision for Taxes on Income (Narrative) (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails",
     "shortName": "Tax Matters - Provision for Taxes on Income (Narrative) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2017Q4",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R79": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405405 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails",
     "shortName": "Tax Matters - Tax Rate Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_OncologyVaccinesStartUpMember",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1004001 - Statement - Consolidated Statements of Equity (Parenthetical)",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical",
     "shortName": "Consolidated Statements of Equity (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_OncologyVaccinesStartUpMember",
      "decimals": "2",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EquityMethodInvestmentOwnershipPercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "number",
      "xsiNil": "false"
     }
    },
    "R80": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405406 - Disclosure - Tax Matters - Deferred Taxes (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails",
     "shortName": "Tax Matters - Deferred Taxes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsTaxDeferredExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R81": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405407 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
     "shortName": "Tax Matters - Deferred Taxes - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-8",
      "first": true,
      "lang": "en-US",
      "name": "pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R82": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405408 - Disclosure - Tax Matters - Narrative (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
     "shortName": "Tax Matters - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-8",
      "first": true,
      "lang": null,
      "name": "us-gaap:UndistributedEarningsOfForeignSubsidiaries",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R83": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405409 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails",
     "shortName": "Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R84": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405410 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails",
     "shortName": "Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "link:footnote",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R85": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2405411 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)",
     "role": "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails",
     "shortName": "Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R86": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R87": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406403 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R88": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2406404 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Narrative (Details)",
     "role": "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails",
     "shortName": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R89": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407402 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:Assets",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "1005000 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R90": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:EquitySecuritiesFVNIRestrictedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407403 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails",
     "shortName": "Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:EquitySecuritiesFVNIRestrictedCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R91": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407404 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails",
     "shortName": "Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebtFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R92": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNi",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407405 - Disclosure - Financial Instruments - Total Short-term and Long-term Investments (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails",
     "shortName": "Financial Instruments - Total Short-term and Long-term Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:MarketableSecuritiesTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R93": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407406 - Disclosure - Financial Instruments - Investments (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails",
     "shortName": "Financial Instruments - Investments (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:HeldToMaturitySecuritiesTextBlock",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:DebtSecuritiesAmortizedCostBasis",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R94": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
       "us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiGainLoss",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407407 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails",
     "shortName": "Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FD2019Q4YTD",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:EquitySecuritiesFvNiRealizedGainLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R95": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407409 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails",
     "shortName": "Financial Instruments - Short-Term Borrowings (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommercialPaper",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R96": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407410 - Disclosure - Financial Instruments - Long-Term Debt, New Issuances (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
     "shortName": "Financial Instruments - Long-Term Debt, New Issuances (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R97": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2017Q4Dec01-Dec31",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407411 - Disclosure - Financial Instruments - Long-Term Debt Narrative (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
     "shortName": "Financial Instruments - Long-Term Debt Narrative (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "link:footnote",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member",
      "decimals": "-6",
      "lang": "en-US",
      "name": "us-gaap:GainsLossesOnExtinguishmentOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R98": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "us-gaap:ScheduleOfShortTermDebtTextBlock",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407412 - Disclosure - Financial Instruments - Long-Term Debt (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
     "shortName": "Financial Instruments - Long-Term Debt (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember",
      "decimals": "-6",
      "lang": null,
      "name": "us-gaap:DebtInstrumentCarryingAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    },
    "R99": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "FI2019Q4",
      "decimals": "-6",
      "first": true,
      "lang": null,
      "name": "us-gaap:FiniteLivedIntangibleAssetsNet",
      "reportCount": 1,
      "unitRef": "usd",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "2407413 - Disclosure - Financial Instruments - Other Noncurrent Liabilities (Details)",
     "role": "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
     "shortName": "Financial Instruments - Other Noncurrent Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "span",
       "div",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "baseRef": "pfe-exhibit13x12312019.htm",
      "contextRef": "I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember",
      "decimals": "-6",
      "lang": null,
      "name": "pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation",
      "reportCount": 1,
      "unique": true,
      "unitRef": "usd",
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 349,
   "tag": {
    "country_CN": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "CHINA",
        "terseLabel": "CHINA"
       }
      }
     },
     "localname": "CN",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_JP": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "JAPAN",
        "terseLabel": "JAPAN"
       }
      }
     },
     "localname": "JP",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "country_US": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "UNITED STATES",
        "terseLabel": "United States [Member]"
       }
      }
     },
     "localname": "US",
     "nsuri": "http://xbrl.sec.gov/country/2017-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_AllCurrenciesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "All Currencies [Domain]",
        "terseLabel": "All Currencies [Domain]"
       }
      }
     },
     "localname": "AllCurrenciesDomain",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "currency_EUR": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Euro Member Countries, Euro",
        "terseLabel": "Euro Member Countries, Euro"
       }
      }
     },
     "localname": "EUR",
     "nsuri": "http://xbrl.sec.gov/currency/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag",
        "terseLabel": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code",
        "terseLabel": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover page."
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date",
        "terseLabel": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r808"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report",
        "terseLabel": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus",
        "terseLabel": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus",
        "terseLabel": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.",
        "label": "Document Period End Date",
        "terseLabel": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r807"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report",
        "terseLabel": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type",
        "terseLabel": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r805"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]",
        "terseLabel": "Documents Incorporated by Reference"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Container to assemble all relevant information about each entity associated with the document instance",
        "label": "Entities [Table]",
        "terseLabel": "Entities [Table]"
       }
      }
     },
     "localname": "EntitiesTable",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One",
        "terseLabel": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town",
        "terseLabel": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code",
        "terseLabel": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province",
        "terseLabel": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key",
        "terseLabel": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding",
        "terseLabel": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status",
        "terseLabel": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]",
        "terseLabel": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company",
        "terseLabel": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number",
        "terseLabel": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category",
        "terseLabel": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code",
        "terseLabel": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Entity Information [Line Items]",
        "terseLabel": "Entity Information [Line Items]"
       }
      }
     },
     "localname": "EntityInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r810"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current",
        "terseLabel": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float",
        "terseLabel": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name",
        "terseLabel": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company",
        "terseLabel": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business",
        "terseLabel": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r809"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number",
        "terseLabel": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers",
        "terseLabel": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer",
        "terseLabel": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]",
        "terseLabel": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number",
        "terseLabel": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r804"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security",
        "terseLabel": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r806"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name",
        "terseLabel": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol",
        "terseLabel": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "pfe_A2019StockPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "2019 Stock Plan [Member]",
        "label": "2019 Stock Plan [Member]",
        "terseLabel": "2019 Stock Plan [Member]"
       }
      }
     },
     "localname": "A2019StockPlanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AMPharmaBVMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AM Pharma BV [Member]",
        "label": "AM Pharma BV [Member]",
        "terseLabel": "AM Pharma BV [Member]"
       }
      }
     },
     "localname": "AMPharmaBVMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount",
        "label": "Accelerated Share Repurchases, Shares Repurchased During Period, Percentage of Agreement Amount",
        "terseLabel": "Accelerated share repurchase, percentage of agreement"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_AccruedRebates": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accrued Rebates",
        "label": "Accrued Rebates",
        "terseLabel": "Accrued rebates"
       }
      }
     },
     "localname": "AccruedRebates",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AkceaAndIonisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Akcea And Ionis [Member]",
        "label": "Akcea And Ionis [Member]",
        "terseLabel": "Akcea And Ionis [Member]"
       }
      }
     },
     "localname": "AkceaAndIonisMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AlignmentCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Alignment Costs",
        "label": "Alignment Costs",
        "verboseLabel": "Alignment costs"
       }
      }
     },
     "localname": "AlignmentCosts",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AllOtherInflammationandImmunologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Inflammation and Immunology Products [Member]",
        "label": "All Other Inflammation and Immunology Products [Member]",
        "terseLabel": "All Other Inflammation and Immunology Products [Member]"
       }
      }
     },
     "localname": "AllOtherInflammationandImmunologyProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherInternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Internal Medicine [Member]",
        "label": "All Other Internal Medicine [Member]",
        "terseLabel": "All Other Internal Medicine [Member]"
       }
      }
     },
     "localname": "AllOtherInternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherRareDiseaseProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Rare Disease Products [Member]",
        "label": "All Other Rare Disease Products [Member]",
        "terseLabel": "All Other Rare Disease Products [Member]"
       }
      }
     },
     "localname": "AllOtherRareDiseaseProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllOtherUpjohnProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "All Other Upjohn Products [Member]",
        "label": "All Other Upjohn Products [Member]",
        "terseLabel": "All Other Upjohn Products [Member]"
       }
      }
     },
     "localname": "AllOtherUpjohnProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AllogeneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Allogene [Member]",
        "label": "Allogene [Member]",
        "terseLabel": "Allogene [Member]"
       }
      }
     },
     "localname": "AllogeneMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AmerisourceBergenCorporationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AmerisourceBergen Corporation [Member]",
        "label": "AmerisourceBergen Corporation [Member]",
        "terseLabel": "AmerisourceBergen Corporation [Member]"
       }
      }
     },
     "localname": "AmerisourceBergenCorporationMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.",
        "label": "Amortization Of Intangible Assets Not Associated With Single Function",
        "terseLabel": "Amortization of intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AnacorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Anacor [Member]",
        "label": "Anacor [Member]",
        "terseLabel": "Anacor [Member]"
       }
      }
     },
     "localname": "AnacorMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ArrayMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Array [Member]",
        "label": "Array [Member]",
        "terseLabel": "Array [Member]"
       }
      }
     },
     "localname": "ArrayMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetAcquisitionAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Axis]",
        "terseLabel": "Asset Acquisition [Axis]"
       }
      }
     },
     "localname": "AssetAcquisitionAxis",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_AssetAcquisitionConsiderationTransferred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred",
        "label": "Asset Acquisition, Consideration Transferred",
        "verboseLabel": "Fair value of consideration transferred"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferred",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum",
        "label": "Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum",
        "terseLabel": "Maximum potential milestone payments"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Consideration Transferred, Upfront Payment",
        "label": "Asset Acquisition, Consideration Transferred, Upfront Payment",
        "verboseLabel": "Upfront payment"
       }
      }
     },
     "localname": "AssetAcquisitionConsiderationTransferredUpfrontPayment",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetAcquisitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Asset Acquisition [Axis]",
        "label": "Asset Acquisition [Domain]",
        "terseLabel": "Asset Acquisition [Domain]"
       }
      }
     },
     "localname": "AssetAcquisitionDomain",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetAcquisitionPercentageofSharesAcquired": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Acquisition, Percentage of Shares Acquired",
        "label": "Asset Acquisition, Percentage of Shares Acquired",
        "terseLabel": "Percentage of shares acquired"
       }
      }
     },
     "localname": "AssetAcquisitionPercentageofSharesAcquired",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_AssetImpairmentChargesAndOtherCharges": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of intangible assets, other than goodwill, to fair value.",
        "label": "Asset Impairment Charges And Other Charges",
        "terseLabel": "Certain asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentChargesAndOtherCharges",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetImpairmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset impairments [Member]",
        "label": "Asset Impairments [Member]",
        "terseLabel": "Asset Impairment Charges [Member]"
       }
      }
     },
     "localname": "AssetImpairmentsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AssetWriteOffsAndAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset Write-Offs And Asset Impairment Charges",
        "label": "Asset Write-Offs And Asset Impairment Charges",
        "terseLabel": "Asset write-offs and impairments"
       }
      }
     },
     "localname": "AssetWriteOffsAndAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_AssetsAndLiabilitiesLesseeTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets And Liabilities, Lessee [Table Text Block]",
        "label": "Assets And Liabilities, Lessee [Table Text Block]",
        "terseLabel": "ROU Assets and Liabilities Presented in Condensed Consolidated Balance Sheets"
       }
      }
     },
     "localname": "AssetsAndLiabilitiesLesseeTableTextBlock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_AstraZenecaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "AstraZeneca [Member]",
        "label": "AstraZeneca [Member]",
        "terseLabel": "AstraZeneca [Member]"
       }
      }
     },
     "localname": "AstraZenecaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Available-for-sale securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BMP2Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BMP2 [Member]",
        "label": "BMP2 [Member]",
        "terseLabel": "BMP2 [Member]"
       }
      }
     },
     "localname": "BMP2Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BainCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bain Capital [Member]",
        "label": "Bain Capital [Member]",
        "terseLabel": "Bain Capital [Member]"
       }
      }
     },
     "localname": "BainCapitalMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BeneFIXMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bene F I X [Member]",
        "label": "Bene F I X [Member]",
        "terseLabel": "BeneFIX [Member]"
       }
      }
     },
     "localname": "BeneFIXMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BesponsaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Besponsa [Member]",
        "label": "Besponsa [Member]",
        "terseLabel": "Besponsa [Member]"
       }
      }
     },
     "localname": "BesponsaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BionTechMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "BionTech [Member]",
        "label": "BionTech [Member]",
        "terseLabel": "BionTech [Member]"
       }
      }
     },
     "localname": "BionTechMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BiopharmaSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharma Segment [Member]",
        "label": "Biopharma Segment [Member]",
        "terseLabel": "Biopharma Segment [Member]"
       }
      }
     },
     "localname": "BiopharmaSegmentMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Biopharma, Upjohn And Consumer Healthcare Segments [Member]",
        "label": "Biopharma, Upjohn And Consumer Healthcare Segments [Member]",
        "terseLabel": "Biopharma, Upjohn And Consumer Healthcare Segments [Member]"
       }
      }
     },
     "localname": "BiopharmaUpjohnAndConsumerHealthcareSegmentsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BosulifMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bosulif [Member]",
        "label": "Bosulif [Member]",
        "terseLabel": "Bosulif [Member]"
       }
      }
     },
     "localname": "BosulifMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BraftoviMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Braftovi [Member]",
        "label": "Braftovi [Member]",
        "terseLabel": "Braftovi [Member]"
       }
      }
     },
     "localname": "BraftoviMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessAlignmentCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 12.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Alignment Costs",
        "label": "Business Alignment Costs",
        "terseLabel": "Business alignment costs"
       }
      }
     },
     "localname": "BusinessAlignmentCosts",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.",
        "label": "Business Combination, Acquisition Related Costs, Transaction Costs",
        "terseLabel": "Transaction costs"
       }
      }
     },
     "localname": "BusinessCombinationAcquisitionRelatedCostsTransactionCosts",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredAmountPayable": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Amount Payable",
        "label": "Business Combination, Consideration Transferred, Amount Payable",
        "terseLabel": "Acquisition consideration, amount payable"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredAmountPayable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredDeferredPayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Deferred Payment",
        "label": "Business Combination, Consideration Transferred, Deferred Payment",
        "terseLabel": "Deferred payment"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredDeferredPayment",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Milestone Payments, Maximum",
        "label": "Business Combination, Consideration Transferred, Milestone Payments, Maximum",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Sales-related Payments, Maximum",
        "label": "Business Combination, Consideration Transferred, Sales-related Payments, Maximum",
        "terseLabel": "Maximum amount of sales-related payments"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Consideration Transferred, Undiscounted Royalty Payments",
        "label": "Business Combination, Consideration Transferred, Undiscounted Royalty Payments",
        "terseLabel": "Royalty payments"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets",
        "negatedLabel": "Decrease in amortization of intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_BusinessCombinationsAcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Acquisition Related Costs [Member]",
        "label": "Business Combinations, Acquisition Related Costs [Member]",
        "terseLabel": "Acquisition-Related Costs [Member]"
       }
      }
     },
     "localname": "BusinessCombinationsAcquisitionRelatedCostsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]",
        "label": "Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]"
       }
      }
     },
     "localname": "BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "xbrltype": "stringItemType"
    },
    "pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]",
        "label": "Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]",
        "terseLabel": "Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements, and Research and Development and Collaborative Arrangements"
       }
      }
     },
     "localname": "BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_BusinessIntegrationCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Business Integration Costs [Member]",
        "label": "Business Integration Costs [Member]",
        "terseLabel": "Business Integration Costs [Member]"
       }
      }
     },
     "localname": "BusinessIntegrationCostsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CardinalHealthInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cardinal Health, Inc. [Member]",
        "label": "Cardinal Health, Inc. [Member]",
        "terseLabel": "Cardinal Health, Inc. [Member]"
       }
      }
     },
     "localname": "CardinalHealthInc.Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CelebrexMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Celebrex [Member]",
        "label": "Celebrex [Member]",
        "terseLabel": "Celebrex [Member]"
       }
      }
     },
     "localname": "CelebrexMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CellectisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cellectis [Member]",
        "label": "Cellectis [Member]",
        "terseLabel": "Cellectis [Member]"
       }
      }
     },
     "localname": "CellectisMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CerevelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cerevel [Member]",
        "label": "Cerevel [Member]",
        "terseLabel": "Cerevel [Member]"
       }
      }
     },
     "localname": "CerevelMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CerevelTherapeuticsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cerevel Therapeutics [Member]",
        "label": "Cerevel Therapeutics [Member]",
        "terseLabel": "Cerevel Therapeutics [Member]"
       }
      }
     },
     "localname": "CerevelTherapeuticsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CertainSignificantItemsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Certain significant items [Member]",
        "label": "Certain Significant Items [Member]",
        "terseLabel": "Certain Significant Items [Member]"
       }
      }
     },
     "localname": "CertainSignificantItemsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ChantixChampixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Chantix / Champix [Member]",
        "label": "Chantix Champix [Member]",
        "terseLabel": "Chantix Champix [Member]"
       }
      }
     },
     "localname": "ChantixChampixMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Charge primarily for inventory manufactured for expected future sale",
        "label": "Charge primarily for inventory manufactured for expected future sale",
        "terseLabel": "Charge primarily for inventory manufactured for expected future sale"
       }
      }
     },
     "localname": "Chargeprimarilyforinventorymanufacturedforexpectedfuturesale",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CharitableContributionExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Charitable Contribution Expense",
        "label": "Charitable Contribution Expense",
        "terseLabel": "Charitable contribution expense"
       }
      }
     },
     "localname": "CharitableContributionExpense",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage",
        "label": "Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage",
        "terseLabel": "Collaborator's revenue and expense ownership percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Committed Investment From Collaborator, Amount",
        "label": "Collaborative Arrangement, Committed Investment From Collaborator, Amount",
        "terseLabel": "Committed investment from collaborator"
       }
      }
     },
     "localname": "CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage",
        "label": "Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage",
        "terseLabel": "Company's revenue and expense ownership percentage"
       }
      }
     },
     "localname": "CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_CollaborativeArrangementContingentPaymentsMaximumExposure": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Contingent Payments, Maximum Exposure",
        "label": "Collaborative Arrangement, Contingent Payments, Maximum Exposure",
        "terseLabel": "Potential milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementContingentPaymentsMaximumExposure",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementDeferredMilestonePayment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Deferred Milestone Payment",
        "label": "Collaborative Arrangement, Deferred Milestone Payment",
        "terseLabel": "Deferred milestone payment"
       }
      }
     },
     "localname": "CollaborativeArrangementDeferredMilestonePayment",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Deferred Milestone Revenue Recognized",
        "label": "Collaborative Arrangement, Deferred Milestone Revenue Recognized",
        "terseLabel": "Deferred milestone revenue recognized"
       }
      }
     },
     "localname": "CollaborativeArrangementDeferredMilestoneRevenueRecognized",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementMilestonePaymentReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Milestone Payment, Receivable",
        "label": "Collaborative Arrangement, Milestone Payment, Receivable",
        "terseLabel": "Milestone payment due to be received"
       }
      }
     },
     "localname": "CollaborativeArrangementMilestonePaymentReceivable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementUpfrontAndMilestonePayments": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to our partners for payments made upfront as part of a collaborative arrangement and the payments upon the achievement of milestones.",
        "label": "Collaborative Arrangement Upfront And Milestone Payments",
        "terseLabel": "Upfront payments and milestone payments"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontAndMilestonePayments",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_CollaborativeArrangementUpfrontCashPaymentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative Arrangement, Upfront Cash Payment [Member]",
        "label": "Collaborative Arrangement, Upfront Cash Payment [Member]",
        "terseLabel": "Collaborative Arrangement, Upfront Cash Payment [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementUpfrontCashPaymentMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CommonESOPPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Common ESOP Plan [Member]",
        "label": "Common ESOP Plan [Member]",
        "terseLabel": "Common ESOP Plan [Member]"
       }
      }
     },
     "localname": "CommonESOPPlanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Compensation Related Costs, Non-Executive Employees, Bonus",
        "label": "Compensation Related Costs, Non-Executive Employees, Bonus",
        "terseLabel": "One-time bonus paid to all Pfizer colleagues excluding executives"
       }
      }
     },
     "localname": "CompensationRelatedCostsNonExecutiveEmployeesBonus",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ConcentrationRiskAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Concentration Risk, Amount",
        "label": "Concentration Risk, Amount",
        "terseLabel": "Concentration risk, amount"
       }
      }
     },
     "localname": "ConcentrationRiskAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ConcentrationRiskRevenues500000000orMoreNumberofCountries": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Concentration Risk, Revenues, $500,000,000 or More, Number of Countries",
        "label": "Concentration Risk, Revenues, $500,000,000 or More, Number of Countries",
        "terseLabel": "Number of countries outside the U.S"
       }
      }
     },
     "localname": "ConcentrationRiskRevenues500000000orMoreNumberofCountries",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_ConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consumer Healthcare [Member]",
        "label": "Consumer Healthcare [Member]",
        "terseLabel": "Consumer Healthcare [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConsumerHealthcareReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Consumer Healthcare Reporting Unit [Member]",
        "label": "Consumer Healthcare Reporting Unit [Member]",
        "terseLabel": "Consumer Healthcare Reporting Unit [Member]"
       }
      }
     },
     "localname": "ConsumerHealthcareReportingUnitMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ConvertiblePreferredStockNumberofSharesConvertible": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Convertible Preferred Stock, Number of Shares Convertible",
        "label": "Convertible Preferred Stock, Number of Shares Convertible",
        "terseLabel": "Convertible preferred stock, number of shares convertible"
       }
      }
     },
     "localname": "ConvertiblePreferredStockNumberofSharesConvertible",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_CopromotionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Co-promotion [Member]",
        "label": "Co-promotion [Member]",
        "terseLabel": "Co-promotion [Member]"
       }
      }
     },
     "localname": "CopromotionMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CortexymeInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cortexyme, Inc. [Member]",
        "label": "Cortexyme, Inc. [Member]",
        "terseLabel": "Cortexyme, Inc. [Member]"
       }
      }
     },
     "localname": "CortexymeInc.Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CreditFacilityExpiring2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Credit Facility Expiring 2024 [Member]",
        "label": "Credit Facility Expiring 2024 [Member]",
        "terseLabel": "Credit Facility Expiring 2024 [Member]"
       }
      }
     },
     "localname": "CreditFacilityExpiring2024Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_CurrentTaxAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Current Tax Assets [Member]",
        "label": "Current Tax Assets [Member]",
        "terseLabel": "Current Tax Assets [Member]"
       }
      }
     },
     "localname": "CurrentTaxAssetsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "label": "Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting",
        "terseLabel": "Net fair value adjustments related to hedging and purchase accounting"
       }
      }
     },
     "localname": "DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Gain",
        "label": "Debt Securities, Accumulated Gross Unrealized Gain",
        "terseLabel": "Debt securities, gross unrealized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedGain",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Accumulated Gross Unrealized Loss",
        "label": "Debt Securities, Accumulated Gross Unrealized Loss",
        "negatedTerseLabel": "Debt securities, gross unrealized losses"
       }
      }
     },
     "localname": "DebtSecuritiesAccumulatedGrossUnrealizedLoss",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Amortized Cost Basis",
        "label": "Debt Securities, Amortized Cost Basis",
        "totalLabel": "Debt securities, amortized cost"
       }
      }
     },
     "localname": "DebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities Maturities, After Year Five, Fair Value",
        "label": "Debt Securities Maturities, After Year Five, Fair Value",
        "terseLabel": "Debt securities maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "label": "Debt Securities Maturities, Next Twelve Months, Fair Value",
        "terseLabel": "Debt securities maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesNextTwelveMonthsFairValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "label": "Debt Securities Maturities, Year Two Through Five, Fair Value",
        "terseLabel": "Debt securities maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "label": "Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]",
        "terseLabel": "Schedule of Gains and Losses on Investment Securities"
       }
      }
     },
     "localname": "DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_December2015StockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2015 Stock Purchase Plan [Member]",
        "label": "December 2015 Stock Purchase Plan [Member]",
        "terseLabel": "December 2015 Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "December2015StockPurchasePlanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_December2017StockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2017 Stock Purchase Plan [Member]",
        "label": "December 2017 Stock Purchase Plan [Member]",
        "terseLabel": "December 2017 Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "December2017StockPurchasePlanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_December2018StockPurchasePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "December 2018 Stock Purchase Plan [Member]",
        "label": "December 2018 Stock Purchase Plan [Member]",
        "terseLabel": "December 2018 Stock Purchase Plan [Member]"
       }
      }
     },
     "localname": "December2018StockPurchasePlanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DeconsolidationExternalIncrementalCostsAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deconsolidation, External Incremental Costs, Amount",
        "label": "Deconsolidation, External Incremental Costs, Amount",
        "terseLabel": "External incremental costs"
       }
      }
     },
     "localname": "DeconsolidationExternalIncrementalCostsAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationGainLossAmountCashConveyed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Cash Conveyed",
        "label": "Deconsolidation, Gain (Loss), Amount, Cash Conveyed",
        "terseLabel": "Deconsolidation, cash conveyed"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountCashConveyed",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationGainLossAmountNetOfCashConveyed": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed",
        "label": "Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed",
        "negatedTerseLabel": "Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed",
        "terseLabel": "Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountNetOfCashConveyed",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationGainLossAmountNetOfTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deconsolidation, Gain (Loss), Amount, Net Of Tax",
        "label": "Deconsolidation, Gain (Loss), Amount, Net Of Tax",
        "terseLabel": "Gain on completion of Consumer Healthcare JV transaction, net of tax"
       }
      }
     },
     "localname": "DeconsolidationGainLossAmountNetOfTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeconsolidationNetAssetsContributed": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deconsolidation, Net Assets Contributed",
        "label": "Deconsolidation, Net Assets Contributed",
        "terseLabel": "Deconsolidation net assets contributed"
       }
      }
     },
     "localname": "DeconsolidationNetAssetsContributed",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredRevenueMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Revenue [Member]",
        "label": "Deferred Revenue [Member]",
        "terseLabel": "Deferred Revenue [Member]"
       }
      }
     },
     "localname": "DeferredRevenueMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets Associated With Unrecognized Tax Benefits",
        "label": "Deferred Tax Assets Associated With Unrecognized Tax Benefits",
        "terseLabel": "Deferred tax assets associated with unrecognized tax benefits"
       }
      }
     },
     "localname": "DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward",
        "label": "Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward",
        "terseLabel": "Reduction for unrecognized tax benefit"
       }
      }
     },
     "localname": "DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "label": "Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent",
        "terseLabel": "Noncurrent deferred tax assets and other noncurrent tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards And Tax Credit Carryforwards",
        "terseLabel": "Net operating loss/credit carryforwards - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsStateandLocalTaxesAdjustments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, State and Local Taxes Adjustments",
        "label": "Deferred Tax Assets, State and Local Taxes Adjustments",
        "terseLabel": "State and local tax adjustments - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsStateandLocalTaxesAdjustments",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Legal and Product Liability Reserves",
        "terseLabel": "Legal and product liability reserves - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DeferredTaxLiabilitiesNetNoncurrentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Net, Noncurrent [Member]",
        "label": "Deferred Tax Liabilities, Net, Noncurrent [Member]",
        "terseLabel": "Deferred Tax Liabilities, Net, Noncurrent [Member]"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetNoncurrentMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "label": "Deferred Tax Liabilities, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "negatedLabel": "Employee benefits - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost",
        "label": "Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost",
        "terseLabel": "Net pension benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Alternative Investments, Fair Value Of Plan Assets",
        "label": "Defined Benefit Plan, Alternative Investments, Fair Value Of Plan Assets",
        "terseLabel": "Assets Measured at NAV"
       }
      }
     },
     "localname": "DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax",
        "totalLabel": "Defined benefit plan, amounts recognized in other comprehensive income (loss), net actuarial gain (loss), tax"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax",
        "label": "Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax",
        "negatedLabel": "Benefit plans: prior service costs and other, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Interest Cost, Discount Rate",
        "terseLabel": "Weighted-average assumptions used to determine interest cost, Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Service Cost, Discount Rate",
        "terseLabel": "Weighted-average assumptions used to determine service cost, Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation",
        "label": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation",
        "negatedLabel": "Acquisitions/divestitures/other, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets",
        "label": "Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets",
        "verboseLabel": "Acquisitions/divestitures, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]",
        "label": "Defined Benefit Plan, Equity Securities, Equity Commingled Funds [Member]",
        "terseLabel": "Commingled Funds Equity Securities [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Equity Securities, Global [Member]",
        "label": "Defined Benefit Plan, Equity Securities, Global [Member]",
        "terseLabel": "Global Equity Securities [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesGlobalMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DefinedBenefitPlanExpectedAmortizationTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Expected Amortization, Term",
        "label": "Defined Benefit Plan, Expected Amortization, Term",
        "terseLabel": "Amortization period"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedAmortizationTerm",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax",
        "terseLabel": "Pretax settlement gain"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DefinedBenefitPlanNumberofPensionPlansFrozen": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Number of Pension Plans Frozen",
        "label": "Defined Benefit Plan, Number of Pension Plans Frozen",
        "terseLabel": "Number of pension plans frozen"
       }
      }
     },
     "localname": "DefinedBenefitPlanNumberofPensionPlansFrozen",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, 65 Years of Age and Over",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, 65 Years of Age and Over",
        "terseLabel": "Healthcare cost trend rate assumed for next year (age 65 and older)"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Under 65 Years of Age",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Under 65 Years of Age",
        "terseLabel": "Healthcare cost trend rate assumed for next year (up to age 65)"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.",
        "label": "Depreciation, Depletion And Amortization, Including Discontinued Operation, Depreciation and Amortization",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DevelopedEuropeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developed Europe [Member]",
        "label": "Developed Europe [Member]",
        "terseLabel": "Developed Europe [Member]"
       }
      }
     },
     "localname": "DevelopedEuropeMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DevelopedRestOfWorldMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Developed Rest Of World [Member]",
        "label": "Developed Rest Of World [Member]",
        "terseLabel": "Developed Rest Of World [Member]"
       }
      }
     },
     "localname": "DevelopedRestOfWorldMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DiflucanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Diflucan [Member]",
        "label": "Diflucan [Member]",
        "terseLabel": "Diflucan [Member]"
       }
      }
     },
     "localname": "DiflucanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DirectorsCompensationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Director's Compensation [Member]",
        "label": "Director's Compensation [Member]",
        "terseLabel": "Directors' compensation [Member]"
       }
      }
     },
     "localname": "DirectorsCompensationMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable",
        "label": "Disposal Group, Including Discontinued Operation, Consideration, Note Receivable",
        "terseLabel": "Consideration receivable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests",
        "label": "Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests",
        "terseLabel": "Value of common stock received for disposal"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares",
        "label": "Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares",
        "terseLabel": "Shares of common stock received for disposal"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "label": "Disposal Group, Including Discontinued Operation, Contingent Consideration",
        "terseLabel": "Maximum contingent consideration"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationContingentConsideration",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationMilestone": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Milestone",
        "label": "Disposal Group, Including Discontinued Operation, Milestone",
        "terseLabel": "Milestone payment recognized"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationMilestone",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Including Discontinued Operation, Milestone, Maximum, Value",
        "label": "Disposal Group, Including Discontinued Operation, Milestone, Maximum, Value",
        "terseLabel": "Maximum amount of milestone payments to be received"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)",
        "label": "Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)",
        "terseLabel": "Pre-tax income attributable to disposal group"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DocetaxelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Docetaxel [Member]",
        "label": "Docetaxel [Member]",
        "terseLabel": "Docetaxel [Member]"
       }
      }
     },
     "localname": "DocetaxelMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Income Tax Expense (Benefit), Continued Operations",
        "label": "Domestic Income Tax Expense (Benefit), Continued Operations",
        "totalLabel": "Total U.S. tax benefit"
       }
      }
     },
     "localname": "DomesticIncomeTaxExpenseBenefitContinuedOperations",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_DomesticIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Domestic Income Taxes [Abstract]",
        "label": "Domestic Income Taxes [Abstract]",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "DomesticIncomeTaxesAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount",
        "label": "Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount",
        "terseLabel": "Deconsolidation gain"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Deduction, Litigation Settlement, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Deduction, Litigation Settlement, Percent",
        "terseLabel": "Certain legal settlements and charges"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Implementation Of Organizational Structure, Gain (Loss), Amount",
        "label": "Effective Income Tax Rate Reconciliation, Implementation Of Organizational Structure, Gain (Loss), Amount",
        "negatedTerseLabel": "Tax benefits associated with implementation of organizational structure"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Loss On Debt Extinguishment, Amount",
        "label": "Effective Income Tax Rate Reconciliation, Loss On Debt Extinguishment, Amount",
        "terseLabel": "Tax benefit related to net losses on early retirement of debt"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Legislation, Percent",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Legislation, Percent",
        "terseLabel": "U.S. Healthcare Legislation"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_EffectofTaxCutsandJobsActAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of Tax Cuts and Jobs Act [Abstract]",
        "label": "Effect of Tax Cuts and Jobs Act [Abstract]",
        "terseLabel": "TCJA"
       }
      }
     },
     "localname": "EffectofTaxCutsandJobsActAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_EffexorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effexor [Member]",
        "label": "Effexor [Member]",
        "terseLabel": "Effexor [Member]"
       }
      }
     },
     "localname": "EffexorMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EliLillyCompanyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eli Lilly &amp; Company [Member]",
        "label": "Eli Lilly &amp; Company [Member]",
        "terseLabel": "Eli Lilly &amp; Company [Member]"
       }
      }
     },
     "localname": "EliLillyCompanyMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EliquisMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eliquis [Member]",
        "label": "Eliquis [Member]",
        "terseLabel": "Eliquis [Member]"
       }
      }
     },
     "localname": "EliquisMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EmergingMarketsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Emerging Markets [Member]",
        "label": "Emerging Markets [Member]",
        "terseLabel": "Emerging Markets [Member]"
       }
      }
     },
     "localname": "EmergingMarketsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnbrelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Enbrel [Member]",
        "label": "Enbrel [Member]",
        "terseLabel": "Enbrel [Member]"
       }
      }
     },
     "localname": "EnbrelMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EnvironmentalRemediationLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Environmental Remediation Litigation [Member]",
        "label": "Environmental Remediation Litigation [Member]",
        "terseLabel": "Environmental Remediation Litigation [Member]"
       }
      }
     },
     "localname": "EnvironmentalRemediationLitigationMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EpiPenMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "EpiPen [Member]",
        "label": "Epi Pen [Member]",
        "terseLabel": "Epi Pen [Member]"
       }
      }
     },
     "localname": "EpiPenMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_EquityMethodInvestmentExcessBasisAmortization": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Excess Basis Amortization",
        "label": "Equity Method Investment, Excess Basis Amortization",
        "terseLabel": "Excess basis amortization"
       }
      }
     },
     "localname": "EquityMethodInvestmentExcessBasisAmortization",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Excess Basis Amortization, Period",
        "label": "Equity Method Investment, Excess Basis Amortization, Period",
        "terseLabel": "Excess basis amortization period"
       }
      }
     },
     "localname": "EquityMethodInvestmentExcessBasisAmortizationPeriod",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]",
        "label": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]",
        "terseLabel": "Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investment, Summarized Financial Information, Net Income (Loss) Attributable To Shareholders",
        "label": "Equity Method Investment, Summarized Financial Information, Net Income (Loss) Attributable To Shareholders",
        "terseLabel": "Income attributable to shareholders"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Proceeds From Sale Used To Cover Transaction Tax",
        "label": "Equity Method Investments, Proceeds From Sale Used To Cover Transaction Tax",
        "terseLabel": "Proceeds from sale of equity method investment used to cover taxes incurred on transaction"
       }
      }
     },
     "localname": "EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquityMethodInvestmentsTaxIndemnificationLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Tax Indemnification, Liability",
        "label": "Equity Method Investments, Tax Indemnification, Liability",
        "terseLabel": "Tax indemnification liability"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTaxIndemnificationLiability",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Transitional Agreement, Administrative Services, Term",
        "label": "Equity Method Investments, Transitional Agreement, Administrative Services, Term",
        "terseLabel": "Transitional agreement administrative services term"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Method Investments, Transitional Agreement, Manufacture and Supply, Term",
        "label": "Equity Method Investments, Transitional Agreement, Manufacture and Supply, Term",
        "terseLabel": "Transitional agreement manufacture and supply term"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_EquitySecuritiesFVNINoncurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Noncurrent",
        "label": "Equity Securities, FV-NI, Noncurrent",
        "terseLabel": "Equity securities with readily determinable fair values"
       }
      }
     },
     "localname": "EquitySecuritiesFVNINoncurrent",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesFVNIRestrictedCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restricted, Current",
        "label": "Equity Securities, FV-NI, Restricted, Current",
        "terseLabel": "Short-term equity securities held in trust"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictedCurrent",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EquitySecuritiesFVNIRestrictedNoncurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "label": "Equity Securities, FV-NI, Restricted, Noncurrent",
        "terseLabel": "Long-term equity securities held in trust"
       }
      }
     },
     "localname": "EquitySecuritiesFVNIRestrictedNoncurrent",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_EucrisaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Eucrisa [Member]",
        "label": "Eucrisa [Member]",
        "terseLabel": "Eucrisa [Member]"
       }
      }
     },
     "localname": "EucrisaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FSMEIMMUNTicoVacMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "FSME/IMMUN-TicoVac [Member]",
        "label": "FSME/IMMUN-TicoVac [Member]",
        "terseLabel": "FSME/IMMUN-TicoVac [Member]"
       }
      }
     },
     "localname": "FSMEIMMUNTicoVacMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FacilityExpiringSeptember2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility Expiring September 2020 [Member]",
        "label": "Facility Expiring September 2020 [Member]",
        "terseLabel": "Facility Expiring September 2020 [Member]"
       }
      }
     },
     "localname": "FacilityExpiringSeptember2020Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FeasibilityStudyNumberOfLagoons": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Feasibility Study, Number Of Lagoons",
        "label": "Feasibility Study, Number Of Lagoons",
        "terseLabel": "Feasibility study, number of lagoons"
       }
      }
     },
     "localname": "FeasibilityStudyNumberOfLagoons",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_FeePayable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fee Payable",
        "label": "Fee Payable",
        "verboseLabel": "Fee payable to Federal Government"
       }
      }
     },
     "localname": "FeePayable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_FinancialInstrumentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial Instruments [Abstract]",
        "label": "Financial Instruments [Abstract]"
       }
      }
     },
     "localname": "FinancialInstrumentsAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "xbrltype": "stringItemType"
    },
    "pfe_FocusedCompanyPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Focused Company Plan [Member]",
        "label": "Focused Company Plan [Member]",
        "terseLabel": "Focused Company Plan [Member]"
       }
      }
     },
     "localname": "FocusedCompanyPlanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyLongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign currency long - term debt [Member]",
        "label": "Foreign Currency Long Term Debt [Member]",
        "terseLabel": "Foreign currency long-term debt [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyLongTermDebtMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ForeignCurrencyShortTermBorrowingsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Foreign currency short - term borrowings [Member]",
        "label": "Foreign Currency Short Term Borrowings [Member]",
        "terseLabel": "Foreign currency short-term borrowings [Member]"
       }
      }
     },
     "localname": "ForeignCurrencyShortTermBorrowingsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_FragminMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fragmin [Member]",
        "label": "Fragmin [Member]",
        "terseLabel": "Fragmin [Member]"
       }
      }
     },
     "localname": "FragminMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GSKConsumerHealthcareMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "GSK Consumer Healthcare [Member]",
        "label": "GSK Consumer Healthcare [Member]",
        "terseLabel": "GSK Consumer Healthcare [Member]"
       }
      }
     },
     "localname": "GSKConsumerHealthcareMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GSKMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "GSK [Member]",
        "label": "GSK [Member]",
        "terseLabel": "GSK [Member]"
       }
      }
     },
     "localname": "GSKMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GainContingencyNumberofDefendants": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Number of Defendants",
        "label": "Gain Contingency, Number of Defendants",
        "terseLabel": "Number of defendants"
       }
      }
     },
     "localname": "GainContingencyNumberofDefendants",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "label": "Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019",
        "terseLabel": "Number of patents allegedly infringed upon due to expire In December 2019"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly not infringed upon.",
        "label": "Gain Contingency, Patents Allegedly Not Infringed Upon, Number",
        "terseLabel": "Number of patents allegedly not infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyNotInfringedUponNumber",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Patents Allegedly Not Infringed Upon, Number Due to Expire March 2019",
        "label": "Gain Contingency, Patents Allegedly Not Infringed Upon, Number Due to Expire March 2019",
        "terseLabel": "Number of patents not infringed upon expired March 2019"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Patents Found Not Infringed Upon, Subsequently Appealed, Number",
        "label": "Gain Contingency, Patents Found Not Infringed Upon, Subsequently Appealed, Number",
        "terseLabel": "Number of patents found not infringed upon subsequently appealed"
       }
      }
     },
     "localname": "GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainContingencyPatentsWithoutCourtProceedingsNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain Contingency, Patents Without Court Proceedings, Number",
        "label": "Gain Contingency, Patents Without Court Proceedings, Number",
        "terseLabel": "Number of patents without court proceedings"
       }
      }
     },
     "localname": "GainContingencyPatentsWithoutCourtProceedingsNumber",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_GainLossFromContributionAgreement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) From Contribution Agreement",
        "label": "Gain (Loss) From Contribution Agreement",
        "terseLabel": "Gain from contribution agreement"
       }
      }
     },
     "localname": "GainLossFromContributionAgreement",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_GainLossOnExchangeOfDebt": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gain (Loss) On Exchange Of Debt",
        "label": "Gain (Loss) On Exchange Of Debt",
        "negatedTerseLabel": "Loss on exchange of debt"
       }
      }
     },
     "localname": "GainLossOnExchangeOfDebt",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_GeneTherapiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gene Therapies [Member]",
        "label": "Gene Therapies [Member]",
        "terseLabel": "Gene Therapies [Member]"
       }
      }
     },
     "localname": "GeneTherapiesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GenericInjectablePainRelieverMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generic Injectable Pain Reliever [Member]",
        "label": "Generic Injectable Pain Reliever [Member]",
        "terseLabel": "Generic Injectable Pain Reliever [Member]"
       }
      }
     },
     "localname": "GenericInjectablePainRelieverMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GenericSterileInjectableProductMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Generic Sterile Injectable Product [Member]",
        "label": "Generic Sterile Injectable Product [Member]",
        "terseLabel": "Generic Sterile Injectable Product [Member]"
       }
      }
     },
     "localname": "GenericSterileInjectableProductMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GenotropinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Genotropin [Member]",
        "label": "Genotropin [Member]",
        "terseLabel": "Genotropin [Member]"
       }
      }
     },
     "localname": "GenotropinMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]",
        "label": "Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]",
        "terseLabel": "Group President, Chief Business Officer or Former Group President, Pfizer Innovative Health [Member]"
       }
      }
     },
     "localname": "GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HISMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HIS [Member]",
        "label": "HIS [Member]",
        "terseLabel": "HIS [Member]"
       }
      }
     },
     "localname": "HISMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HISProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "HIS Products [Member]",
        "label": "HIS Products [Member]",
        "terseLabel": "HIS Products [Member]"
       }
      }
     },
     "localname": "HISProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HedgedItemAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedged Item [Axis]",
        "label": "Hedged Item [Axis]",
        "terseLabel": "Hedged Item [Axis]"
       }
      }
     },
     "localname": "HedgedItemAxis",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_HedgedItemDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Hedged Item [Axis]",
        "label": "Hedged Item [Domain]",
        "terseLabel": "Hedged Item [Domain]"
       }
      }
     },
     "localname": "HedgedItemDomain",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HeldToMaturityCashEquivalents": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Held-To-Maturity Cash Equivalents",
        "label": "Held-To-Maturity Cash Equivalents",
        "terseLabel": "Held-to-maturity cash equivalents"
       }
      }
     },
     "localname": "HeldToMaturityCashEquivalents",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "label": "Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 5 years, fair value"
       }
      }
     },
     "localname": "HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_HisunPfizerPharmaceuticalsCoLtdMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hisun Pfizer Pharmaceuticals Co. Ltd [Member]",
        "label": "Hisun Pfizer Pharmaceuticals Co. Ltd [Member]",
        "terseLabel": "Hisun Pfizer Pharmaceuticals Co. Ltd [Member]"
       }
      }
     },
     "localname": "HisunPfizerPharmaceuticalsCoLtdMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira [Member]",
        "label": "Hospira [Member]",
        "terseLabel": "Hospira [Member]"
       }
      }
     },
     "localname": "HospiraMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraVersusAmnealPharmaceuticalsLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira Versus Amneal Pharmaceuticals LLC [Member]",
        "label": "Hospira Versus Amneal Pharmaceuticals LLC [Member]",
        "terseLabel": "Hospira Versus Amneal Pharmaceuticals LLC [Member]"
       }
      }
     },
     "localname": "HospiraVersusAmnealPharmaceuticalsLLCMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraVersusFreseniusKabjUSALLCMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira Versus Fresenius Kabj USA LLC [Member]",
        "label": "Hospira Versus Fresenius Kabj USA LLC [Member]",
        "terseLabel": "Hospira Versus Fresenius Kabj USA LLC [Member]"
       }
      }
     },
     "localname": "HospiraVersusFreseniusKabjUSALLCMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospiraVersusParMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospira Versus Par [Member]",
        "label": "Hospira Versus Par [Member]",
        "terseLabel": "Hospira Versus Par [Member]"
       }
      }
     },
     "localname": "HospiraVersusParMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_HospitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hospital [Member]",
        "label": "Hospital [Member]",
        "terseLabel": "Hospital [Member]"
       }
      }
     },
     "localname": "HospitalMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ICUMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ICU Medical [Member]",
        "label": "ICU Medical [Member]",
        "terseLabel": "ICU Medical [Member]"
       }
      }
     },
     "localname": "ICUMedicalMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IbranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ibrance [Member]",
        "label": "Ibrance [Member]",
        "terseLabel": "Ibrance [Member]"
       }
      }
     },
     "localname": "IbranceMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ImplementationCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Implementation Cost [Abstract]",
        "label": "Implementation Cost [Abstract]",
        "terseLabel": "Implementation costs recorded in our consolidated statements of income as follows:"
       }
      }
     },
     "localname": "ImplementationCostAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.",
        "label": "Implementation Costs",
        "terseLabel": "Implementation costs"
       }
      }
     },
     "localname": "ImplementationCosts",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "label": "Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights",
        "negatedTerseLabel": "Income from collaborations, out-licensing arrangements and sales of compound/product rights"
       }
      }
     },
     "localname": "IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders Basic",
        "totalLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the income or loss from continuing operations available to common stockholders which may also be defined as revenue less expenses and taxes from ongoing operations before extraordinary items and cumulative effects of changes in accounting principles, but after deduction of those portions of income or loss from continuing operations that are allocable to noncontrolling interests and preferred stock dividends declared or paid in the period, if any.",
        "label": "Income Loss From Continuing Operations Available To Common Stockholders diluted",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 13.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "label": "Income (Loss) From Equity Method Investments, Net Excess Basis Amortization",
        "negatedTerseLabel": "Income (Loss) from Equity Method Investments"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IncomeTaxesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Income Taxes [Table]",
        "label": "Income Taxes [Line Items]",
        "terseLabel": "Income Taxes [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxesLineItems",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_IncomeTaxesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Taxes Payable [Member]",
        "label": "Income Taxes Payable [Member]",
        "terseLabel": "Income Taxes Payable [Member]"
       }
      }
     },
     "localname": "IncomeTaxesPayableMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_IncomeTaxesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Income Taxes [Table]",
        "label": "Income Taxes [Table]",
        "terseLabel": "Income Taxes [Table]"
       }
      }
     },
     "localname": "IncomeTaxesTable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_InflammationandImmunologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inflammation and Immunology [Member]",
        "label": "Inflammation and Immunology [Member]",
        "terseLabel": "Inflammation and Immunology [Member]"
       }
      }
     },
     "localname": "InflammationandImmunologyMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InflectraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inflectra [Member]",
        "label": "Inflectra [Member]",
        "terseLabel": "Inflectra [Member]"
       }
      }
     },
     "localname": "InflectraMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InflectraRemsimaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inflectra/Remsima [Member]",
        "label": "Inflectra/Remsima [Member]",
        "terseLabel": "Inflectra/Remsima [Member]"
       }
      }
     },
     "localname": "InflectraRemsimaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InlytaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inlyta [Member]",
        "label": "Inlyta [Member]",
        "terseLabel": "Inlyta [Member]"
       }
      }
     },
     "localname": "InlytaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InnoPharmaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "InnoPharma [Member]",
        "label": "InnoPharma [Member]",
        "terseLabel": "InnoPharma [Member]"
       }
      }
     },
     "localname": "InnoPharmaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InsuranceContractsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Insurance Contracts [Member]",
        "label": "Insurance Contracts [Member]",
        "terseLabel": "Insurance Contracts [Member]"
       }
      }
     },
     "localname": "InsuranceContractsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InsuranceCoverageAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Insurance Coverage [Abstract]",
        "label": "Insurance Coverage [Abstract]"
       }
      }
     },
     "localname": "InsuranceCoverageAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "xbrltype": "stringItemType"
    },
    "pfe_InsuranceCoverageDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Insurance Coverage Disclosure [Text Block]",
        "label": "Insurance Coverage Disclosure [Text Block]",
        "terseLabel": "Insurance"
       }
      }
     },
     "localname": "InsuranceCoverageDisclosureTextBlock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/Insurance"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_IntangibleAssetsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Assets, Fair Value Disclosure",
        "label": "Intangible Assets, Fair Value Disclosure",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "IntangibleAssetsFairValueDisclosure",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_IntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Intangible Assets [Table]",
        "label": "Intangible Assets [Line Items]",
        "terseLabel": "Schedule of Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IntangibleAssetsLineItems",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intangible Assets, Net, Percentage of Intangible Assets, Net",
        "label": "Intangible Assets, Net, Percentage of Intangible Assets, Net",
        "terseLabel": "Percentage of intangible asset amortized cost by segment"
       }
      }
     },
     "localname": "IntangibleAssetsNetPercentageofIntangibleAssetsNet",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_InterestPaidInterestRateHedges": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Interest Paid, Interest Rate Hedges",
        "label": "Interest Paid, Interest Rate Hedges",
        "terseLabel": "Interest rate hedges"
       }
      }
     },
     "localname": "InterestPaidInterestRateHedges",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InternalMedicineMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Internal Medicine [Member]",
        "label": "Internal Medicine [Member]",
        "terseLabel": "Internal Medicine [Member]"
       }
      }
     },
     "localname": "InternalMedicineMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_InternationalIncomeTaxesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "International Income Taxes [Abstract]",
        "label": "International Income Taxes [Abstract]",
        "terseLabel": "International"
       }
      }
     },
     "localname": "InternationalIncomeTaxesAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_InventoryWriteDownAndOverheadCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventory Write Down And Overhead Costs",
        "label": "Inventory Write Down And Overhead Costs",
        "terseLabel": "Inventory losses and overhead costs"
       }
      }
     },
     "localname": "InventoryWriteDownAndOverheadCosts",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_InvestmentOwnershipPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment, Ownership Percentage",
        "label": "Investment, Ownership Percentage",
        "terseLabel": "Ownership percentage"
       }
      }
     },
     "localname": "InvestmentOwnershipPercentage",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]",
        "label": "Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]",
        "terseLabel": "Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member]"
       }
      }
     },
     "localname": "JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LaboratorioTeutoBrasileroMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Laboratorio Teuto Brasilero [Member]",
        "label": "Laboratorio Teuto Brasilero [Member]",
        "terseLabel": "Laboratorio Teuto Brasilero [Member]"
       }
      }
     },
     "localname": "LaboratorioTeutoBrasileroMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LesseeOperatingLeaseOptionToExtendTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lessee, Operating Lease, Option To Extend, Term",
        "label": "Lessee, Operating Lease, Option To Extend, Term",
        "terseLabel": "Operating lease term, option to extend"
       }
      }
     },
     "localname": "LesseeOperatingLeaseOptionToExtendTerm",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_LicensingAgreementsAndOtherMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Agreements And Other [Member]",
        "label": "Licensing Agreements And Other [Member]",
        "terseLabel": "Licensing Agreements And Other [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsAndOtherMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingAgreementsDevelopedTechnologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Agreements, Developed Technology [Member]",
        "label": "Licensing Agreements, Developed Technology [Member]",
        "terseLabel": "Licensing Agreements, Developed Technology [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsDevelopedTechnologyMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingAgreementsTechnologyInDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Agreements, Technology In Development [Member]",
        "label": "Licensing Agreements, Technology In Development [Member]",
        "terseLabel": "Licensing Agreements, Technology In Development [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsTechnologyInDevelopmentMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LicensingArrangementMilestoneMaximumValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Arrangement, Milestone, Maximum, Value",
        "label": "Licensing Arrangement, Milestone, Maximum, Value",
        "terseLabel": "Licensing arrangement, maximum potential milestones"
       }
      }
     },
     "localname": "LicensingArrangementMilestoneMaximumValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LicensingArrangementNumberOfSharesPurchased": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Arrangement, Number Of Shares Purchased",
        "label": "Licensing Arrangement, Number Of Shares Purchased",
        "terseLabel": "Number of shares purchased"
       }
      }
     },
     "localname": "LicensingArrangementNumberOfSharesPurchased",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_LicensingArrangementValueOfSharesPurchased": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Licensing Arrangement, Value Of Shares Purchased",
        "label": "Licensing Arrangement, Value Of Shares Purchased",
        "terseLabel": "Value of shares purchased"
       }
      }
     },
     "localname": "LicensingArrangementValueOfSharesPurchased",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity, Due To Expire Within One Year",
        "terseLabel": "Line of credit facility, due to expire within one year"
       }
      }
     },
     "localname": "LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LipitorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lipitor [Member]",
        "label": "Lipitor [Member]",
        "terseLabel": "Lipitor [Member]"
       }
      }
     },
     "localname": "LipitorMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "label": "Long-term Debt, Current Maturities, Excluding Net Fair Value Adjustments Related To Hedging And Purchase Accounting",
        "verboseLabel": "Current portion of long-term debt, principal amount"
       }
      }
     },
     "localname": "LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsAndEquityMethodInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Investments And Equity Method Investments",
        "label": "Long-term Investments And Equity Method Investments",
        "totalLabel": "Total long-term investments and equity-method investments"
       }
      }
     },
     "localname": "LongtermInvestmentsAndEquityMethodInvestments",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "label": "Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments",
        "totalLabel": "Total long-term investments"
       }
      }
     },
     "localname": "LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_LongtermInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Long-term Investments [Member]",
        "label": "Long-term Investments [Member]",
        "terseLabel": "Long-term Investments [Member]",
        "verboseLabel": "Long-term investments [Member]"
       }
      }
     },
     "localname": "LongtermInvestmentsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_LossContingencyClassActionsFiledNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Class Actions Filed, Number",
        "label": "Loss Contingency, Class Actions Filed, Number",
        "terseLabel": "Number of class actions filed"
       }
      }
     },
     "localname": "LossContingencyClassActionsFiledNumber",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "label": "Loss Contingency, Number Of Defendants Other Than Main Defendant",
        "terseLabel": "Number of defendants other than main defendant"
       }
      }
     },
     "localname": "LossContingencyNumberOfDefendantsOtherThanMainDefendant",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_LossContingencyNumberOfLawsuits": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Loss Contingency, Number Of Lawsuits",
        "label": "Loss Contingency, Number Of Lawsuits",
        "terseLabel": "Number of lawsuits"
       }
      }
     },
     "localname": "LossContingencyNumberOfLawsuits",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_LyricaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Lyrica [Member]",
        "label": "Lyrica [Member]",
        "terseLabel": "Lyrica [Member]"
       }
      }
     },
     "localname": "LyricaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ManufacturingOptimizationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Manufacturing Optimization [Member]",
        "label": "Manufacturing Optimization [Member]",
        "terseLabel": "Manufacturing Optimization [Member]"
       }
      }
     },
     "localname": "ManufacturingOptimizationMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_McKessonInc.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "McKesson, Inc. [Member]",
        "label": "McKesson, Inc. [Member]",
        "terseLabel": "McKesson, Inc. [Member]"
       }
      }
     },
     "localname": "McKessonInc.Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MedivationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medivation [Member]",
        "label": "Medivation [Member]",
        "terseLabel": "Medivation [Member]"
       }
      }
     },
     "localname": "MedivationMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MedrolMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medrol [Member]",
        "label": "Medrol [Member]",
        "terseLabel": "Medrol [Member]"
       }
      }
     },
     "localname": "MedrolMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MektoviMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mektovi [Member]",
        "label": "Mektovi [Member]",
        "terseLabel": "Mektovi [Member]"
       }
      }
     },
     "localname": "MektoviMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MerckKGaAMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Merck KGaA [Member]",
        "label": "Merck KGaA [Member]",
        "terseLabel": "Merck KGaA [Member]"
       }
      }
     },
     "localname": "MerckKGaAMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MerckMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Merck [Member]",
        "label": "Merck [Member]",
        "terseLabel": "Merck [Member]"
       }
      }
     },
     "localname": "MerckMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Multi-Antigen Vaccine For Spinal Fusion Surgery [Member]",
        "label": "Multi-Antigen Vaccine For Spinal Fusion Surgery [Member]",
        "terseLabel": "Multi-Antigen Vaccine For Spinal Fusion Surgery [Member]"
       }
      }
     },
     "localname": "MultiAntigenVaccineForSpinalFusionSurgeryMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MylanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mylan [Member]",
        "label": "Mylan [Member]",
        "terseLabel": "Mylan [Member]"
       }
      }
     },
     "localname": "MylanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_MylotargMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Mylotarg [Member]",
        "label": "Mylotarg [Member]",
        "terseLabel": "Mylotarg [Member]"
       }
      }
     },
     "localname": "MylotargMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NeuroscienceAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Neuroscience Assets [Member]",
        "label": "Neuroscience Assets [Member]",
        "terseLabel": "Neuroscience Assets [Member]"
       }
      }
     },
     "localname": "NeuroscienceAssetsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NextWaveMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NextWave [Member]",
        "label": "NextWave [Member]",
        "terseLabel": "NextWave [Member]"
       }
      }
     },
     "localname": "NextWaveMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NimenrixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nimenrix [Member]",
        "label": "Nimenrix [Member]",
        "terseLabel": "Nimenrix [Member]"
       }
      }
     },
     "localname": "NimenrixMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NonUnitedStatesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Non-United States [Member]",
        "label": "Non-United States [Member]",
        "terseLabel": "Outside United States [Member]"
       }
      }
     },
     "localname": "NonUnitedStatesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock",
        "terseLabel": "Receipt of ICU Medical common stock"
       }
      }
     },
     "localname": "NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable",
        "label": "Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable",
        "terseLabel": "Promissory note from ICU Medical"
       }
      }
     },
     "localname": "NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment",
        "label": "Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment",
        "terseLabel": "Equity investment in exchange for Pfizer's assets"
       }
      }
     },
     "localname": "NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]",
        "label": "Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]",
        "terseLabel": "Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]"
       }
      }
     },
     "localname": "NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NoncurrentDeferredTaxLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Noncurrent Deferred Tax Liabilities [Member]",
        "label": "Noncurrent Deferred Tax Liabilities [Member]",
        "terseLabel": "Noncurrent Deferred Tax Liabilities [Member]"
       }
      }
     },
     "localname": "NoncurrentDeferredTaxLiabilitiesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NorvascMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Norvasc [Member]",
        "label": "Norvasc [Member]",
        "terseLabel": "Norvasc [Member]"
       }
      }
     },
     "localname": "NorvascMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20200.000Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Due 2020, 0.000%  [Member]",
        "label": "Notes Due 2020, 0.000% [Member]",
        "terseLabel": "Notes Due 2020, 0.000% [Member]"
       }
      }
     },
     "localname": "NotesDue20200.000Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20220.250Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Due 2022, 0.250% [Member]",
        "label": "Notes Due 2022, 0.250% [Member]",
        "terseLabel": "Notes Due 2022, 0.250% [Member]"
       }
      }
     },
     "localname": "NotesDue20220.250Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NotesDue20271.000Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Notes Due 2027, 1.000% [Member]",
        "label": "Notes Due 2027, 1.000% [Member]",
        "terseLabel": "Notes Due 2027, 1.000% [Member]"
       }
      }
     },
     "localname": "NotesDue20271.000Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NovaQuestCoInvestmentFundVL.P.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "NovaQuest Co-Investment Fund V, L.P. [Member]",
        "label": "NovaQuest Co-Investment Fund V, L.P. [Member]",
        "terseLabel": "NovaQuest Co-Investment Fund V, L.P. [Member]"
       }
      }
     },
     "localname": "NovaQuestCoInvestmentFundVL.P.Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_NumberOfAccountingStandardsAdopted": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number Of Accounting Standards Adopted",
        "label": "Number Of Accounting Standards Adopted",
        "terseLabel": "Number of accounting standards adopted"
       }
      }
     },
     "localname": "NumberOfAccountingStandardsAdopted",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_NumberofEmployeeStockOwnershipPlans": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of Employee Stock Ownership Plans",
        "label": "Number of Employee Stock Ownership Plans",
        "terseLabel": "Number of employee stock ownership plans"
       }
      }
     },
     "localname": "NumberofEmployeeStockOwnershipPlans",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_OfficeBuildingInNewYorkCityMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Office Building In New York City [Member]",
        "label": "Office Building In New York City [Member]",
        "terseLabel": "Office Building In New York City [Member]"
       }
      }
     },
     "localname": "OfficeBuildingInNewYorkCityMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OncologyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Oncology [Member]",
        "label": "Oncology [Member]",
        "terseLabel": "Oncology [Member]"
       }
      }
     },
     "localname": "OncologyMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OncologyVaccinesStartUpMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Oncology Vaccines Start Up [Member]",
        "label": "Oncology Vaccines Start Up [Member]",
        "terseLabel": "Oncology Vaccines Start Up [Member]"
       }
      }
     },
     "localname": "OncologyVaccinesStartUpMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OpenMarketPurchasesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Open Market Purchases [Member]",
        "label": "Open Market Purchases [Member]",
        "terseLabel": "Open Market Purchases [Member]"
       }
      }
     },
     "localname": "OpenMarketPurchasesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherAccruals": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Accruals",
        "label": "Other Accruals",
        "terseLabel": "Other accruals"
       }
      }
     },
     "localname": "OtherAccruals",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherActivitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Activities [Member]",
        "label": "Other Activities [Member]",
        "terseLabel": "Other Activities [Member]"
       }
      }
     },
     "localname": "OtherActivitiesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherAntiinfectivesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Anti-infectives [Member]",
        "label": "Other Anti-infectives [Member]",
        "terseLabel": "Other Anti-infectives [Member]"
       }
      }
     },
     "localname": "OtherAntiinfectivesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherCommingledFundsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Commingled Funds [Member]",
        "label": "Other Commingled Funds [Member]",
        "terseLabel": "Other Commingled Funds [Member]"
       }
      }
     },
     "localname": "OtherCommingledFundsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax",
        "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax",
        "terseLabel": "Reclassification adjustments related to curtailments of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), before Tax",
        "terseLabel": "Reclassification adjustments related to curtailments of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gain/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "label": "Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans prior service (costs)/credits.",
        "label": "Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, before Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 5.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax",
        "negatedTerseLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pre tax adjustment to other comprehensive income for other adjustments related to defined benefit plans actuarial gains /losses.",
        "label": "Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, before Tax",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment For Tax On Unrealized Gains Included In Retained Earnings, Tax",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment For Tax On Unrealized Gains Included In Retained Earnings, Tax",
        "negatedTerseLabel": "Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment For Unrealized Gains Included In Retained Earnings, Before Tax",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment For Unrealized Gains Included In Retained Earnings, Before Tax",
        "negatedTerseLabel": "Reclassification adjustments for unrealized gains included in Retained earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 4.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Actuarial Gains, Tax",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Actuarial Gains, Tax",
        "negatedTerseLabel": "Reclassification adjustments of certain tax effects from AOCI to Retained earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Prior Service (Costs) Credits, Tax",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Prior Service (Costs) Credits, Tax",
        "terseLabel": "Reclassification adjustments of certain tax effects from AOCI to Retained earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Foreign Currency Translation Adjustment, Tax",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Foreign Currency Translation Adjustment, Tax",
        "negatedTerseLabel": "Reclassification adjustments of certain tax effects from AOCI to Retained earnings"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of pre tax adjustment to other comprehensive income for curtailments and settlements, net, related to defined benefit plans.",
        "label": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Before Tax",
        "negatedTerseLabel": "Reclassification adjustments related to settlements, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax",
        "label": "Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax",
        "negatedTerseLabel": "Reclassification adjustments related to settlements, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherHospitalProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Hospital Products [Member]",
        "label": "Other Hospital Products [Member]",
        "terseLabel": "Other Hospital Products [Member]"
       }
      }
     },
     "localname": "OtherHospitalProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherIncomeDeductionsAndCostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other (Income) Deductions And Cost Of Sales [Member]",
        "label": "Other (Income) Deductions And Cost Of Sales [Member]",
        "terseLabel": "Other (Income) Deductions And Cost Of Sales [Member]"
       }
      }
     },
     "localname": "OtherIncomeDeductionsAndCostOfSalesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Income (Expense) [Member]",
        "label": "Other Income (Expense) [Member]",
        "terseLabel": "Other Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherIncomeExpenseMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherNonoperatingIncomeExpenseNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Nonoperating Income (Expense), Net",
        "label": "Other Nonoperating Income (Expense), Net",
        "negatedTerseLabel": "Other, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseNet",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherNonoperatingIncomeMiscellaneous": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Nonoperating Income, Miscellaneous",
        "label": "Other Nonoperating Income, Miscellaneous",
        "terseLabel": "Income from resolution of contract disagreement"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeMiscellaneous",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherOncologyProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Oncology Products [Member]",
        "label": "Other Oncology Products [Member]",
        "terseLabel": "Other Oncology Products [Member]"
       }
      }
     },
     "localname": "OtherOncologyProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherSegmentReconcilingItemsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Segment Reconciling Items [Axis]",
        "label": "Other Segment Reconciling Items [Axis]",
        "terseLabel": "Other Segment Reconciling Items [Axis]"
       }
      }
     },
     "localname": "OtherSegmentReconcilingItemsAxis",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_OtherSegmentReconcilingItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Domain] for Other Segment Reconciling Items [Axis]",
        "label": "Other Segment Reconciling Items [Domain]",
        "terseLabel": "Other Segment Reconciling Items [Domain]"
       }
      }
     },
     "localname": "OtherSegmentReconcilingItemsDomain",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherTaxAssetsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Tax Assets, Current",
        "label": "Other Tax Assets, Current",
        "terseLabel": "Current tax assets"
       }
      }
     },
     "localname": "OtherTaxAssetsCurrent",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_OtherTaxesPayableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Taxes Payable [Member]",
        "label": "Other Taxes Payable [Member]",
        "terseLabel": "Other Taxes Payable [Member]"
       }
      }
     },
     "localname": "OtherTaxesPayableMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_OtherVaccinesProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other Vaccines Products [Member]",
        "label": "Other Vaccines Products [Member]",
        "terseLabel": "Other Vaccines Products [Member]"
       }
      }
     },
     "localname": "OtherVaccinesProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PanzygaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Panzyga [Member]",
        "label": "Panzyga [Member]",
        "terseLabel": "Panzyga [Member]"
       }
      }
     },
     "localname": "PanzygaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PatentInfringementMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patent Infringement [Member]",
        "label": "Patent Infringement [Member]",
        "terseLabel": "Patent Infringement [Member]"
       }
      }
     },
     "localname": "PatentInfringementMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PatentMatterMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Patent Matter [Member]",
        "label": "Patent Matter [Member]",
        "terseLabel": "Patent Matter [Member]"
       }
      }
     },
     "localname": "PatentMatterMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PaymentForLicensingArrangement": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment For Licensing Arrangement",
        "label": "Payment For Licensing Arrangement",
        "terseLabel": "Payment for licensing arrangement"
       }
      }
     },
     "localname": "PaymentForLicensingArrangement",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentForRepatriationTax": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payment For Repatriation Tax",
        "label": "Payment For Repatriation Tax",
        "terseLabel": "Payment for repatriation tax"
       }
      }
     },
     "localname": "PaymentForRepatriationTax",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsToCollaborators": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments To Collaborators",
        "label": "Payments To Collaborators",
        "terseLabel": "Upfront payment"
       }
      }
     },
     "localname": "PaymentsToCollaborators",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "label": "Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment",
        "negatedLabel": "Utilization and other"
       }
      }
     },
     "localname": "PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).",
        "label": "Pension And Other Postretirement Benefit Contributions, Net Of Pension And Other Postretirement Benefit (Expense)",
        "negatedTerseLabel": "Benefit plan contributions in excess of expense/income"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Performance Total Shareholder Return Unit (PTSRUs) [Member]",
        "label": "Performance Total Shareholder Return Unit (PTSRUs) [Member]",
        "terseLabel": "Performance Total Shareholder Return Unit (PTSRUs) [Member]"
       }
      }
     },
     "localname": "PerformanceTotalShareholderReturnUnitPTSRUsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "label": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]",
        "terseLabel": "Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member]"
       }
      }
     },
     "localname": "PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerCentreOneMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer CentreOne [Member]",
        "label": "Pfizer CentreOne [Member]",
        "terseLabel": "Pfizer CentreOne [Member]"
       }
      }
     },
     "localname": "PfizerCentreOneMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusAjantaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Ajanta [Member]",
        "label": "Pfizer Versus Ajanta [Member]",
        "terseLabel": "Pfizer Versus Ajanta [Member]"
       }
      }
     },
     "localname": "PfizerVersusAjantaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusGenericCompaniesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Generic Companies [Member]",
        "label": "Pfizer Versus Generic Companies [Member]",
        "terseLabel": "Pfizer Versus Generic Companies [Member]"
       }
      }
     },
     "localname": "PfizerVersusGenericCompaniesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]",
        "label": "Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]",
        "terseLabel": "Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member]"
       }
      }
     },
     "localname": "PfizerVersusViwitPharmaceuticalCo.Ltd.Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerVersusZydusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer Versus Zydus [Member]",
        "label": "Pfizer Versus Zydus [Member]",
        "terseLabel": "Pfizer Versus Zydus [Member]"
       }
      }
     },
     "localname": "PfizerVersusZydusMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizerandBMSVersusSeveralGenericManufacturersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "label": "Pfizer and BMS Versus Several Generic Manufacturers [Member]",
        "terseLabel": "Pfizer and BMS Versus Several Generic Manufacturers [Member]"
       }
      }
     },
     "localname": "PfizerandBMSVersusSeveralGenericManufacturersMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Pfizer's Worldwide Research, Development And Medical [Member]",
        "label": "Pfizer's Worldwide Research, Development And Medical [Member]",
        "terseLabel": "Pfizer's Worldwide Research, Development And Medical [Member]"
       }
      }
     },
     "localname": "PfizersWorldwideResearchDevelopmentAndMedicalMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]",
        "label": "Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]",
        "terseLabel": "Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]"
       }
      }
     },
     "localname": "Phase2bReadyAMPAReceptorPotentiatorForCIASMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PhenytoinSodiumCapsulesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Phenytoin Sodium Capsules [Member]",
        "label": "Phenytoin Sodium Capsules [Member]",
        "terseLabel": "Phenytoin Sodium Capsules [Member]"
       }
      }
     },
     "localname": "PhenytoinSodiumCapsulesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PortfolioPerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portfolio Performance Shares [Member]",
        "label": "Portfolio Performance Shares [Member]",
        "terseLabel": "Portfolio Performance Shares [Member]"
       }
      }
     },
     "localname": "PortfolioPerformanceSharesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrecedexPremixMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Precedex Premix [Member]",
        "label": "Precedex Premix [Member]",
        "terseLabel": "Precedex Premix [Member]"
       }
      }
     },
     "localname": "PrecedexPremixMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PreferredESOPPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred ESOP Plan [Member]",
        "label": "Preferred ESOP Plan [Member]",
        "terseLabel": "Preferred ESOP Plan [Member]"
       }
      }
     },
     "localname": "PreferredESOPPlanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PreferredEmployeeStockOwnershipPlanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred Employee Stock Ownership Plan [Member]",
        "label": "Preferred Employee Stock Ownership Plan [Member]",
        "terseLabel": "Preferred Employee Stock Ownership Plan [Member]"
       }
      }
     },
     "localname": "PreferredEmployeeStockOwnershipPlanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PreferredStockSharesHeldInEmployeeTrustShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred Stock, Shares Held In Employee Trust, Shares",
        "label": "Preferred Stock, Shares Held In Employee Trust, Shares",
        "terseLabel": "Number of shares in Preferred ESOP"
       }
      }
     },
     "localname": "PreferredStockSharesHeldInEmployeeTrustShares",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_PremarinFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Premarin family [Member]",
        "label": "Premarin Family [Member]",
        "terseLabel": "Premarin Family [Member]"
       }
      }
     },
     "localname": "PremarinFamilyMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrepaymentsandPaymentstoCollaborators": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prepayments and Payments to Collaborators",
        "label": "Prepayments and Payments to Collaborators",
        "verboseLabel": "Collaborative arrangement sales based milestones payments"
       }
      }
     },
     "localname": "PrepaymentsandPaymentstoCollaborators",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_PrevnarPrevenarFamilyMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Prevnar/Prevenar Family 13 [Member]",
        "label": "Prevnar Prevenar Family [Member]",
        "terseLabel": "Prevenar 13/Prevnar 13 [Member]"
       }
      }
     },
     "localname": "PrevnarPrevenarFamilyMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PrivateEquityInvestments": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Private Equity Investments",
        "label": "Private Equity Investments",
        "terseLabel": "Private equity securities at cost"
       }
      }
     },
     "localname": "PrivateEquityInvestments",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ProceedsFromLicensingArrangement": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Proceeds From Licensing Arrangement",
        "label": "Proceeds From Licensing Arrangement",
        "terseLabel": "Proceeds from licensing arrangement"
       }
      }
     },
     "localname": "ProceedsFromLicensingArrangement",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ProfitUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Profit Units [Member]",
        "label": "Profit Units [Member]",
        "terseLabel": "Profit Units [Member]"
       }
      }
     },
     "localname": "ProfitUnitsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_PurchaseAccountingAdjustmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Purchase Accounting Adjustments [Member]",
        "label": "Purchase Accounting Adjustments [Member]",
        "terseLabel": "Purchase Accounting Adjustments [Member]"
       }
      }
     },
     "localname": "PurchaseAccountingAdjustmentsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RPIFinanceTrustMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "RPI Finance Trust [Member]",
        "label": "RPI Finance Trust [Member]",
        "terseLabel": "RPI Finance Trust [Member]"
       }
      }
     },
     "localname": "RPIFinanceTrustMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RareDiseaseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rare Disease [Member]",
        "label": "Rare Disease [Member]",
        "terseLabel": "Rare Disease [Member]"
       }
      }
     },
     "localname": "RareDiseaseMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ReFactoAfXynthaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Re Facto AF Xyntha [Member]",
        "label": "Re Facto AF Xyntha [Member]",
        "terseLabel": "ReFacto AF Xyntha [Member]"
       }
      }
     },
     "localname": "ReFactoAfXynthaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RebatesAndDiscountsAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts",
        "label": "Rebates And Discounts Accrual",
        "terseLabel": "Accrued rebates and other accruals",
        "verboseLabel": "Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns"
       }
      }
     },
     "localname": "RebatesAndDiscountsAccrual",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reconciliation Of Depreciation And Amortization From Segments To Consolidated [Table Text Block]",
        "label": "Reconciliation Of Depreciation And Amortization From Segments To Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation Of Depreciation And Amortization From Segments To Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Aggregate Payment Obligation",
        "label": "Research and Development Arrangement, Aggregate Payment Obligation",
        "terseLabel": "Aggregate amount of guaranteed fixed annual payments to be made in connection with research and development arrangement",
        "verboseLabel": "Research arrangement, fixed payment obligation"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementAggregatePaymentObligation",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Aggregate Payment Obligation, Term",
        "label": "Research and Development Arrangement, Aggregate Payment Obligation, Term",
        "terseLabel": "Research and development arrangement, aggregate payment obligation, term"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementAggregatePaymentObligationTerm",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Contingent Payments, Maximum Exposure",
        "label": "Research and Development Arrangement, Contingent Payments, Maximum Exposure",
        "terseLabel": "Research and development, contingent payments, maximum exposure"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Funding to Offset Costs Incurred",
        "label": "Research and Development Arrangement, Funding to Offset Costs Incurred",
        "terseLabel": "Reduction to research and development expense"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Gain From Liability Extinguishment",
        "label": "Research and Development Arrangement, Gain From Liability Extinguishment",
        "terseLabel": "Gain from cash settlement of liability",
        "verboseLabel": "Non-cash gain from buyout transaction"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementLiabilityBuyoutAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Liability Buyout, Amount",
        "label": "Research and Development Arrangement, Liability Buyout, Amount",
        "terseLabel": "Lump sum payment for liability buyout"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementLiabilityBuyoutAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementMaximumFundingAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Maximum Funding Amount",
        "label": "Research and Development Arrangement, Maximum Funding Amount",
        "terseLabel": "Maximum funding amount"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementMaximumFundingAmount",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Research and Development Arrangement, Percentage of Costs to be Reimbursed",
        "label": "Research and Development Arrangement, Percentage of Costs to be Reimbursed",
        "terseLabel": "Percentage of costs to be reimbursed"
       }
      }
     },
     "localname": "ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_RestructuringAssetImpairmentCharges": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring, Asset Impairment Charges",
        "label": "Restructuring, Asset Impairment Charges",
        "terseLabel": "Asset impairments"
       }
      }
     },
     "localname": "RestructuringAssetImpairmentCharges",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "label": "Restructuring Charges, Acquisition Related Costs and Implementation Costs",
        "totalLabel": "Total costs associated with acquisitions and cost-reduction/productivity initiatives"
       }
      }
     },
     "localname": "RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 6.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 1.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.",
        "label": "Restructuring Charges And Acquisition Related Costs",
        "terseLabel": "Restructuring charges and certain acquisition-related costs",
        "totalLabel": "Restructuring charges and certain acquisition-related costs"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCosts",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringChargesAndAcquisitionRelatedCostsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring Charges And Acquisition-Related Costs [Member]",
        "label": "Restructuring Charges And Acquisition-Related Costs [Member]",
        "terseLabel": "Restructuring Charges And Acquisition-Related Costs [Member]"
       }
      }
     },
     "localname": "RestructuringChargesAndAcquisitionRelatedCostsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RestructuringChargesandImplementationCosts": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring Charges and Implementation Costs",
        "label": "Restructuring Charges and Implementation Costs",
        "terseLabel": "Restructuring charges and implementation costs"
       }
      }
     },
     "localname": "RestructuringChargesandImplementationCosts",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_RestructuringandRelatedCostNoncashChargesPercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "label": "Restructuring and Related Cost, Noncash Charges, Percentage",
        "terseLabel": "Percentage of non-cash restructuring charges expected"
       }
      }
     },
     "localname": "RestructuringandRelatedCostNoncashChargesPercentage",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_RetacritMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Retacrit [Member]",
        "label": "Retacrit [Member]",
        "terseLabel": "Retacrit [Member]"
       }
      }
     },
     "localname": "RetacritMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_RevatioMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revatio [Member]",
        "label": "Revatio [Member]",
        "terseLabel": "Revatio [Member]"
       }
      }
     },
     "localname": "RevatioMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "[Line Items] for Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Line Items]",
        "terseLabel": "Schedule Of Accrued Liabilities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesLineItems",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAccruedLiabilitiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule Of Accrued Liabilities [Table]",
        "label": "Schedule Of Accrued Liabilities [Table]",
        "terseLabel": "Schedule Of Accrued Liabilities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Line Items]",
        "terseLabel": "Schedule of Available for sale Securities and Held to maturity Securities [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesLineItems",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Available for sale Securities and Held to maturity Securities [Table]",
        "label": "Schedule Of Available For Sale Securities And Held To Maturity Securities [Table]",
        "terseLabel": "Schedule of Available for sale Securities and Held to maturity Securities [Table]"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesAndHeldToMaturitySecuritiesTable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleOfIntangibleAssetsTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Intangible Assets [Table]",
        "label": "Schedule Of Intangible Assets [Table]",
        "terseLabel": "Schedule of Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIntangibleAssetsTable",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "label": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)"
       }
      }
     },
     "localname": "ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions [Table Text Block]",
        "label": "Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "pfe_SeniorNotesDue2047Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Notes Due 2047 [Member]",
        "label": "Senior Notes Due 2047 [Member]",
        "terseLabel": "Senior Notes Due 2047 [Member]"
       }
      }
     },
     "localname": "SeniorNotesDue2047Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2020Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2020 [Member]",
        "label": "Senior Unsecured Debt, Due 2020 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2020 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2020Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2021 [Member]",
        "label": "Senior Unsecured Debt, Due 2021 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2021 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2021Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2022 [Member]",
        "label": "Senior Unsecured Debt, Due 2022 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2022 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2022Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2023Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2023 [Member]",
        "label": "Senior Unsecured Debt, Due 2023 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2023 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2023Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2024 [Member]",
        "label": "Senior Unsecured Debt, Due 2024 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2024 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2024Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20262029Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2026-2029 [Member]",
        "label": "Senior Unsecured Debt, Due 2026-2029 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2026-2029 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20262029Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue2034Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2034 [Member]",
        "label": "Senior Unsecured Debt, Due 2034 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2034 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue2034Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20362040Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2036-2040 [Member]",
        "label": "Senior Unsecured Debt, Due 2036-2040 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2036-2040 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20362040Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20432044Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2043-2044 [Member]",
        "label": "Senior Unsecured Debt, Due 2043-2044 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2043-2044 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20432044Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtDue20462049Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Due 2046-2049 [Member]",
        "label": "Senior Unsecured Debt, Due 2046-2049 [Member]",
        "terseLabel": "Senior Unsecured Debt, Due 2046-2049 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtDue20462049Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtFourPercentDue2049Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Four Percent, Due 2049 [Member]",
        "label": "Senior Unsecured Debt, Four Percent, Due 2049 [Member]",
        "terseLabel": "Senior Unsecured Debt, 4.000% Notes, Due 2049 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtFourPercentDue2049Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Three Point Four Five Percent, Due 2029 [Member]",
        "label": "Senior Unsecured Debt, Three Point Four Five Percent, Due 2029 [Member]",
        "terseLabel": "Senior Unsecured Debt, 3.450% Notes, Due 2029 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Three Point Nine Percent, Due 2039 [Member]",
        "label": "Senior Unsecured Debt, Three Point Nine Percent, Due 2039 [Member]",
        "terseLabel": "Senior Unsecured Debt, 3.900% Notes, Due 2039 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtThreePointNinePercentDue2039Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Two Point Eight Percent, Due 2022 [Member]",
        "label": "Senior Unsecured Debt, Two Point Eight Percent, Due 2022 [Member]",
        "terseLabel": "Senior Unsecured Debt, 2.800% Notes, Due 2022 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtTwoPointEightPercentDue2022Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Debt, Two Point Nine Five Percent, Due 2024 [Member]",
        "label": "Senior Unsecured Debt, Two Point Nine Five Percent, Due 2024 [Member]",
        "terseLabel": "Senior Unsecured Debt, 2.950% Notes, Due 2024 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Euro Debt, Five Point Seven Five Percent, Due 2021 [Member]",
        "label": "Senior Unsecured Euro Debt, Five Point Seven Five Percent, Due 2021 [Member]",
        "terseLabel": "Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured Great Britain Pound Debt, Six Point Five Percent, Due 2038 [Member]",
        "label": "Senior Unsecured U.K. Pound Debt, Six Point Five Percent, Due 2038 [Member]",
        "terseLabel": "Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Senior Unsecured U.K. Pound Debt, Two Point Seven Three Five Percent, Due 2043  [Member]",
        "label": "Senior Unsecured U.K. Pound Debt, Two Point Seven Three Five Percent, Due 2043 [Member]",
        "terseLabel": "Senior Unsecured U.K. Pound Debt, 2.735%, Due 2043 [Member]"
       }
      }
     },
     "localname": "SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Series A, Convertible Preferred Stock [Member]",
        "label": "Series A, Convertible Preferred Stock [Member]",
        "terseLabel": "Series A, Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "SeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The exercise period for options held by employees in the event of a divestiture or restructuring.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Award Exercise Period Special Conditions",
        "terseLabel": "Exercise period in the event of a divestiture or restructuring"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The required period of time for holding award before any vesting occurs.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Award Holding Period",
        "terseLabel": "Holding period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee",
        "terseLabel": "Maximum shares available per individual during the plan period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee",
        "terseLabel": "Number of shares counted toward maximum"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_ShareRepurchaseAgreementwithCitibankMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase Agreement with Citibank [Member]",
        "label": "Share Repurchase Agreement with Citibank [Member]",
        "terseLabel": "Share Repurchase Agreement with Citibank [Member]"
       }
      }
     },
     "localname": "ShareRepurchaseAgreementwithCitibankMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShareRepurchaseAgreementwithGSCoMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share Repurchase Agreement with GS&amp;Co [Member]",
        "label": "Share Repurchase Agreement with GS&amp;Co [Member]",
        "terseLabel": "Share Repurchase Agreement with GS&amp;Co [Member]"
       }
      }
     },
     "localname": "ShareRepurchaseAgreementwithGSCoMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price",
        "terseLabel": "Settled, Weighted-Average Grant Price Per Share Per Unit (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price",
        "terseLabel": "Vested, Weighted-Average Grant Price Per Share Unit (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest",
        "terseLabel": "Expected to vest, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price",
        "terseLabel": "Exercised during period, Weighted-Average Grant Price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number",
        "terseLabel": "Expected to vest, Share Units"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price",
        "terseLabel": "Expected to vest, Weighted-Average Grant Price Per Share Unit (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term",
        "terseLabel": "Expected to vest, Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Near-Term Vesting",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Near-Term Vesting",
        "terseLabel": "Number of shares scheduled for near-term vesting"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price",
        "periodEndLabel": "Outstanding, end of period, weighted-average exercise price per share (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award",
        "terseLabel": "Number of shares earned as a percentage of initial award"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price",
        "terseLabel": "Outstanding, Weighted-Average Grant Price Per Share Unit (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period",
        "terseLabel": "Reinvested dividend equivalents, shares"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares",
        "terseLabel": "Settled, Share Units"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares",
        "terseLabel": "Vested, Share Units"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Vested, Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion",
        "terseLabel": "Converted awards"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Grant Date Fair Value",
        "terseLabel": "Grant-date fair value (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Grants in Period, Price",
        "terseLabel": "Grant price (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Measures Used to Determine Share Payout",
        "terseLabel": "Number of measures used to determine share payout"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Age Requirement",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Age Requirement",
        "terseLabel": "Age of eligible unit holder which can elect to exercise and convert TSRUs when vested into PTUs"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average",
        "terseLabel": "Trading day average used to calculate the conversion"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Duration of Period",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Duration of Period",
        "terseLabel": "Share payout measures, adjusted net income, duration of period"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Share Payout Measures, Adjusted Net Income, Number of Periods",
        "terseLabel": "Share payout measures, adjusted net income, number of periods"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price",
        "terseLabel": "Expired, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price",
        "terseLabel": "Granted, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price",
        "terseLabel": "Forfeited, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "pfe_ShireMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shire [Member]",
        "label": "Shire [Member]",
        "terseLabel": "Shire [Member]"
       }
      }
     },
     "localname": "ShireMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ShorttermDebtGross": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term Debt, Gross",
        "label": "Short-term Debt, Gross",
        "totalLabel": "Total short-term borrowings, principal amount"
       }
      }
     },
     "localname": "ShorttermDebtGross",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Short-term Investments Excluding Held-To-Maturity Securities",
        "label": "Short-term Investments Excluding Held-To-Maturity Securities",
        "totalLabel": "Total short-term investments"
       }
      }
     },
     "localname": "ShorttermInvestmentsExcludingHeldToMaturitySecurities",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SomavertMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Somavert [Member]",
        "label": "Somavert [Member]",
        "terseLabel": "Somavert [Member]"
       }
      }
     },
     "localname": "SomavertMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SterileInjectablePainRelieverMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sterile Injectable Pain Reliever [Member]",
        "label": "Sterile Injectable Pain Reliever [Member]",
        "terseLabel": "Sterile Injectable Pain Reliever [Member]"
       }
      }
     },
     "localname": "SterileInjectablePainRelieverMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock",
        "label": "Stock Issued And Redeemed During Period, Shares, Conversion And Redemption of Stock",
        "negatedTerseLabel": "Preferred stock conversions and redemptions (in shares)"
       }
      }
     },
     "localname": "StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "pfe_StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock",
        "label": "Stock Issued And Redeemed During Period, Value, Conversion And Redemption of Stock",
        "negatedTerseLabel": "Preferred stock conversions and redemptions"
       }
      }
     },
     "localname": "StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_SulperazonMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sulperazon [Member]",
        "label": "Sulperazon [Member]",
        "terseLabel": "Sulperazon [Member]"
       }
      }
     },
     "localname": "SulperazonMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_SutentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sutent [Member]",
        "label": "Sutent [Member]",
        "terseLabel": "Sutent [Member]"
       }
      }
     },
     "localname": "SutentMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TaxCutsAndJobsActIncomeTaxBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act, Income Tax Benefit",
        "label": "Tax Cuts And Jobs Act, Income Tax Benefit",
        "terseLabel": "Tax benefits associated with the enactment of the TCJA"
       }
      }
     },
     "localname": "TaxCutsAndJobsActIncomeTaxBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Change In Tax Rate, Deferred Tax Liability, Income Tax (Expense) Benefit",
        "label": "Tax Cuts And Jobs Act Of 2017, Change In Tax Rate, Deferred Tax Liability, Income Tax (Expense) Benefit",
        "terseLabel": "Tax benefit associated with the remeasurement of other U.S. deferred tax liabilities"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act Of 2017, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)",
        "label": "Tax Cuts And Jobs Act Of 2017, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)",
        "terseLabel": "Tax expense related to future taxes on global intangible low-taxed income"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)",
        "label": "Tax Cuts And Jobs Act Of 2017, Incomplete Accounting, Transition Tax For Accumulated Foreign Earnings, Provisional Income Tax Expense (Benefit)",
        "terseLabel": "Expense related to repatriation tax on deemed repatriated accumulated pre-2017 earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Intangible Assets, Provisional Income Tax (Expense) Benefit",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Intangible Assets, Provisional Income Tax (Expense) Benefit",
        "terseLabel": "Tax benefit associated with remeasurement of U.S. deferred tax liabilities primarily intangibles"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Unremitted Earnings, Provisional Income Tax (Expense) Benefit",
        "label": "Tax Cuts And Jobs Act of 2017, Incomplete Accounting, Change In Tax Rate, Deferred Tax Liability, Unremitted Earnings, Provisional Income Tax (Expense) Benefit",
        "terseLabel": "Tax benefit associated with remeasurement of U.S. deferred tax liabilities on remitted earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Tax Initiatives, Income Tax (Expense) Benefit",
        "label": "Tax Cuts And Jobs Act of 2017, Tax Initiatives, Income Tax (Expense) Benefit",
        "terseLabel": "Tax benefits associated with certain current year tax initiatives"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts And Jobs Act of 2017, Transition Tax For Accumulated Foreign Earnings, Income Tax Expense (Benefit)",
        "label": "Tax Cuts And Jobs Act of 2017, Transition Tax For Accumulated Foreign Earnings, Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Tax benefits related to the repatriation tax on deemed repatriated accumulated earnings of foreign subsidiaries"
       }
      }
     },
     "localname": "TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Change In Tax Rate, Provisional Income Tax Expense (Benefit)",
        "label": "Tax Cuts and Jobs Act of 2017, Change In Tax Rate, Provisional Income Tax Expense (Benefit)",
        "negatedLabel": "Tax benefit from Tax Cuts and Jobs Act of 2017"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)",
        "label": "Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)",
        "terseLabel": "Current income taxes"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)",
        "label": "Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred Income taxes"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Global Intangible Low-Taxed Income, Deferred Tax Liability",
        "label": "Tax Cuts and Jobs Act of 2017, Global Intangible Low-Taxed Income, Deferred Tax Liability",
        "terseLabel": "Expense related to future taxes on global intangible low-taxed income"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)",
        "label": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Income Tax Expense (Benefit)",
        "terseLabel": "Expense related to future taxes on global intangible low-taxed income"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Provisional Deferred Tax Liability",
        "label": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Global Intangible Low-Taxed Income, Provisional Deferred Tax Liability",
        "terseLabel": "Provisional expense related to future taxes on global intangible low-taxed income"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Tax Initiatives, Income Tax (Expense) Benefit",
        "label": "Tax Cuts and Jobs Act of 2017, Incomplete Accounting, Tax Initiatives, Income Tax (Expense) Benefit",
        "terseLabel": "Tax benefit primarily associated with certain tax initiatives"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax Cuts and Jobs Act of 2017, Measurement Period Adjustment, Global Intangible Low-Taxed Income, Deferred Tax Liability",
        "label": "Tax Cuts and Jobs Act of 2017, Measurement Period Adjustment, Global Intangible Low-Taxed Income, Deferred Tax Liability",
        "terseLabel": "Deferred tax liability on global intangible low-taxed income"
       }
      }
     },
     "localname": "TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_TherachonAssetAcquisitionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Therachon Asset Acquisition [Member]",
        "label": "Therachon Asset Acquisition [Member]",
        "terseLabel": "Therachon Asset Acquisition [Member]"
       }
      }
     },
     "localname": "TherachonAssetAcquisitionMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ThreeLargestUSWholesaleCustomersMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Three Largest US Wholesale Customers [Member]",
        "label": "Three Largest US Wholesale Customers [Member]",
        "terseLabel": "Three Largest U.S. Wholesaler Customers [Member]"
       }
      }
     },
     "localname": "ThreeLargestUSWholesaleCustomersMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TopEightProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Top Eight Products [Member]",
        "label": "Top Eight Products [Member]",
        "terseLabel": "Top Eight Products [Member]"
       }
      }
     },
     "localname": "TopEightProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TopNineProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Top Nine Products [Member]",
        "label": "Top Nine Products [Member]",
        "terseLabel": "Top Nine Products [Member]"
       }
      }
     },
     "localname": "TopNineProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TopTenProductsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Top Ten Products [Member]",
        "label": "Top Ten Products [Member]",
        "terseLabel": "Top Ten Products [Member]"
       }
      }
     },
     "localname": "TopTenProductsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalAllianceBiopharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Alliance Biopharmaceuticals [Member]",
        "label": "Total Alliance Biopharmaceuticals [Member]",
        "terseLabel": "Alliance Biopharmaceuticals [Member]"
       }
      }
     },
     "localname": "TotalAllianceBiopharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalBiosimilarsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Biosimilars [Member]",
        "label": "Total Biosimilars [Member]",
        "terseLabel": "Total Biosimilars [Member]"
       }
      }
     },
     "localname": "TotalBiosimilarsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalShareholderReturnUnitsTSRUsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Shareholder Return Units (TSRUs) [Member]",
        "label": "Total Shareholder Return Units (TSRUs) [Member]",
        "terseLabel": "Total Shareholder Return Units (TSRUs) [Member]"
       }
      }
     },
     "localname": "TotalShareholderReturnUnitsTSRUsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TotalSterileInjectablePharmaceuticalsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total Sterile Injectable Pharmaceuticals [Member]",
        "label": "Total Sterile Injectable Pharmaceuticals [Member]",
        "terseLabel": "Total Sterile Injectable Pharmaceuticals [Member]"
       }
      }
     },
     "localname": "TotalSterileInjectablePharmaceuticalsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ToviazMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Toviaz [Member]",
        "label": "Toviaz [Member]",
        "terseLabel": "Toviaz [Member]"
       }
      }
     },
     "localname": "ToviazMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TreatmentForToenailFungusMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Treatment For Toenail Fungus [Member]",
        "label": "Treatment For Toenail Fungus [Member]",
        "terseLabel": "Treatment For Toenail Fungus [Member]"
       }
      }
     },
     "localname": "TreatmentForToenailFungusMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TreatmentOfAttentionHyperactivityDisorderMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Treatment Of Attention Hyperactivity Disorder [Member]",
        "label": "Treatment Of Attention Hyperactivity Disorder [Member]",
        "terseLabel": "Treatment Of Attention Hyperactivity Disorder [Member]"
       }
      }
     },
     "localname": "TreatmentOfAttentionHyperactivityDisorderMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TrumenbaMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Trumenba [Member]",
        "label": "Trumenba [Member]",
        "terseLabel": "Trumenba [Member]"
       }
      }
     },
     "localname": "TrumenbaMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]",
        "label": "Twenty-Seventeen Through Twenty-Nineteen Initiatives And Organizing For Growth [Member]",
        "terseLabel": "2017-2019 Initiatives and Organizing for Growth Initiative [Member]"
       }
      }
     },
     "localname": "TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_TygacilMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tygacil [Member]",
        "label": "Tygacil [Member]",
        "terseLabel": "Tygacil [Member]"
       }
      }
     },
     "localname": "TygacilMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_U.K.PoundDenominatedDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "U.K. Pound Denominated Debt [Member]",
        "label": "U.K. Pound Denominated Debt [Member]",
        "terseLabel": "U.K. Pound Denominated Debt [Member]"
       }
      }
     },
     "localname": "U.K.PoundDenominatedDebtMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UnrecognizedTaxBenefitsExcludingInterest": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Excluding Interest",
        "label": "Unrecognized Tax Benefits, Excluding Interest",
        "terseLabel": "Unrecognized tax benefits excluding associated interest"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsExcludingInterest",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation",
        "label": "Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation",
        "negatedLabel": "Impact of foreign exchange"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual",
        "negatedTerseLabel": "Unrecognized accrued interest decrease as a result of cash payments"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unrecognized Tax Benefits, Period Increase (Decrease), Other",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease), Other",
        "negatedLabel": "Other, net"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "pfe_UpjohnAndMylanMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upjohn And Mylan [Member]",
        "label": "Upjohn And Mylan [Member]",
        "terseLabel": "Upjohn And Mylan [Member]"
       }
      }
     },
     "localname": "UpjohnAndMylanMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnReportingUnitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upjohn Reporting Unit [Member]",
        "label": "Upjohn Reporting Unit [Member]",
        "terseLabel": "Upjohn Reporting Unit [Member]"
       }
      }
     },
     "localname": "UpjohnReportingUnitMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_UpjohnSegmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Upjohn Segment [Member]",
        "label": "Upjohn Segment [Member]",
        "terseLabel": "Upjohn Segment [Member]"
       }
      }
     },
     "localname": "UpjohnSegmentMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VaccinesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vaccines [Member]",
        "label": "Vaccines [Member]",
        "terseLabel": "Vaccines [Member]"
       }
      }
     },
     "localname": "VaccinesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VfendMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vfend [Member]",
        "label": "Vfend [Member]",
        "terseLabel": "Vfend [Member]"
       }
      }
     },
     "localname": "VfendMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViagraMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Viagra [Member]",
        "label": "Viagra [Member]",
        "terseLabel": "Viagra [Member]"
       }
      }
     },
     "localname": "ViagraMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViivHealthcareLimitedMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "ViiV Healthcare Limited [Member]",
        "label": "ViiV Healthcare Limited [Member]",
        "terseLabel": "ViiV Healthcare Limited [Member]"
       }
      }
     },
     "localname": "ViivHealthcareLimitedMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ViolationofAntitrustLawsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Violation of Antitrust Laws [Member]",
        "label": "Violation of Antitrust Laws [Member]",
        "terseLabel": "Violation of Antitrust Laws [Member]"
       }
      }
     },
     "localname": "ViolationofAntitrustLawsMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_VyndaqelMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Vyndaqel [Member]",
        "label": "Vyndaqel [Member]",
        "terseLabel": "Vyndaqel/Vyndamax [Member]"
       }
      }
     },
     "localname": "VyndaqelMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalatanXalacomMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xalatan / Xalacom [Member]",
        "label": "Xalatan Xalacom [Member]",
        "terseLabel": "Xalatan Xalacom [Member]"
       }
      }
     },
     "localname": "XalatanXalacomMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XalkoriMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xalkori [Member]",
        "label": "Xalkori [Member]",
        "terseLabel": "Xalkori [Member]"
       }
      }
     },
     "localname": "XalkoriMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XanaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xanax [Member]",
        "label": "Xanax [Member]",
        "terseLabel": "Xanax [Member]"
       }
      }
     },
     "localname": "XanaxMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XeljanzMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xeljanz [Member]",
        "label": "Xeljanz [Member]",
        "terseLabel": "Xeljanz [Member]"
       }
      }
     },
     "localname": "XeljanzMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_XtandiAllianceRevenuesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Xtandi Alliance Revenues [Member]",
        "label": "Xtandi Alliance Revenues [Member]",
        "terseLabel": "Xtandi Alliance Revenues [Member]"
       }
      }
     },
     "localname": "XtandiAllianceRevenuesMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZithromaxZmaxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zithromax / Zmax [Member]",
        "label": "Zithromax Zmax [Member]",
        "terseLabel": "Zithromax Zmax [Member]"
       }
      }
     },
     "localname": "ZithromaxZmaxMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZoloftMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zoloft [Member]",
        "label": "Zoloft [Member]",
        "terseLabel": "Zoloft [Member]"
       }
      }
     },
     "localname": "ZoloftMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZosynTazocinMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zosyn / Tazocin [Member]",
        "label": "Zosyn / Tazocin [Member]",
        "terseLabel": "Zosyn / Tazocin [Member]"
       }
      }
     },
     "localname": "ZosynTazocinMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "pfe_ZyvoxMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Zyvox [Member]",
        "label": "Zyvox [Member]",
        "terseLabel": "Zyvox [Member]"
       }
      }
     },
     "localname": "ZyvoxMember",
     "nsuri": "http://www.pfizer.com/20191231",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_BoardOfDirectorsChairmanMember": {
     "auth_ref": [
      "r248"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Board of Directors Chairman [Member]",
        "terseLabel": "Board of Directors Chairman [Member]"
       }
      }
     },
     "localname": "BoardOfDirectorsChairmanMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ConsolidationItemsAxis": {
     "auth_ref": [
      "r226",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Axis]",
        "terseLabel": "Consolidation Items [Axis]"
       }
      }
     },
     "localname": "ConsolidationItemsAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ConsolidationItemsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Consolidation Items [Domain]",
        "terseLabel": "Consolidation Items [Domain]"
       }
      }
     },
     "localname": "ConsolidationItemsDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r91",
      "r178"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Axis]",
        "terseLabel": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_CurrencyAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Currency [Axis]",
        "terseLabel": "Currency [Axis]"
       }
      }
     },
     "localname": "CurrencyAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Domain]",
        "terseLabel": "Investment, Name [Domain]"
       }
      }
     },
     "localname": "EquityMethodInvesteeNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_LitigationCaseAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Axis]",
        "terseLabel": "Litigation Case [Axis]"
       }
      }
     },
     "localname": "LitigationCaseAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_LitigationCaseTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Litigation Case [Domain]",
        "terseLabel": "Litigation Case [Domain]"
       }
      }
     },
     "localname": "LitigationCaseTypeDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MajorCustomersAxis": {
     "auth_ref": [
      "r246",
      "r406",
      "r410",
      "r785"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Axis]",
        "terseLabel": "Major Customers [Axis]"
       }
      }
     },
     "localname": "MajorCustomersAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ManagementMember": {
     "auth_ref": [
      "r248",
      "r725"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Management [Member]",
        "terseLabel": "Management [Member]"
       }
      }
     },
     "localname": "ManagementMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Maximum [Member]",
        "terseLabel": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Minimum [Member]",
        "terseLabel": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_NameOfMajorCustomerDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Customer [Domain]",
        "terseLabel": "Name of Major Customer [Domain]"
       }
      }
     },
     "localname": "NameOfMajorCustomerDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_OwnershipAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Axis]",
        "terseLabel": "Ownership [Axis]"
       }
      }
     },
     "localname": "OwnershipAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_OwnershipDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Ownership [Domain]",
        "terseLabel": "Ownership [Domain]"
       }
      }
     },
     "localname": "OwnershipDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_PartnershipInterestMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Partnership Interest [Member]",
        "terseLabel": "Partnership Interest [Member]"
       }
      }
     },
     "localname": "PartnershipInterestMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ProductOrServiceAxis": {
     "auth_ref": [
      "r242",
      "r406",
      "r408",
      "r782",
      "r783"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Axis]",
        "terseLabel": "Product and Service [Axis]"
       }
      }
     },
     "localname": "ProductOrServiceAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_ProductsAndServicesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Product and Service [Domain]",
        "terseLabel": "Product and Service [Domain]"
       }
      }
     },
     "localname": "ProductsAndServicesDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Axis]",
        "terseLabel": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statistical Measurement [Domain]",
        "terseLabel": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Counterparty Name [Domain]",
        "terseLabel": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioForecastMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Forecast [Member]",
        "terseLabel": "Forecast [Member]"
       }
      }
     },
     "localname": "ScenarioForecastMember",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScenarioUnspecifiedDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Domain]",
        "terseLabel": "Scenario [Domain]"
       }
      }
     },
     "localname": "ScenarioUnspecifiedDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Investment, Name [Axis]",
        "terseLabel": "Investment, Name [Axis]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_SegmentGeographicalDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Domain]",
        "terseLabel": "Geographical [Domain]"
       }
      }
     },
     "localname": "SegmentGeographicalDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_StatementGeographicalAxis": {
     "auth_ref": [
      "r245",
      "r406",
      "r409",
      "r784",
      "r799",
      "r803"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Geographical [Axis]",
        "terseLabel": "Geographical [Axis]"
       }
      }
     },
     "localname": "StatementGeographicalAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_StatementScenarioAxis": {
     "auth_ref": [
      "r370",
      "r727"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Scenario [Axis]",
        "terseLabel": "Scenario [Axis]"
       }
      }
     },
     "localname": "StatementScenarioAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r248",
      "r725"
     ],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Axis]",
        "terseLabel": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Title of Individual [Domain]",
        "terseLabel": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Roll Forward]"
       }
      }
     },
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesFinalPricePaidPerShare": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Final price paid per share for the purchase of the targeted number of shares, determined by an average market price over a fixed period of time.",
        "label": "Accelerated Share Repurchases, Final Price Paid Per Share",
        "terseLabel": "Accelerated share repurchase, final average price paid (in dollars per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesFinalPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesInitialPricePaidPerShare": {
     "auth_ref": [
      "r399"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price paid per share to immediately purchase the targeted number of shares on the date of executing the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Initial Price Paid Per Share",
        "terseLabel": "Shares repurchased, initial price per share (in dollars per share)"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesInitialPricePaidPerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_AcceleratedShareRepurchasesSettlementPaymentOrReceipt": {
     "auth_ref": [
      "r399"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash receipt from (payment to) bank; or stock received from (issuance to) bank in the settlement of the accelerated share repurchase agreement.",
        "label": "Accelerated Share Repurchases, Settlement (Payment) or Receipt",
        "terseLabel": "Accelerated share repurchases, cash paid"
       }
      }
     },
     "localname": "AcceleratedShareRepurchasesSettlementPaymentOrReceipt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountingStandardsUpdate201409Member": {
     "auth_ref": [
      "r412"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2014-09 Revenue from Contracts with Customers (Topic 606).",
        "label": "Accounting Standards Update 2014-09 [Member]",
        "terseLabel": "Revenues [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201409Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201601Member": {
     "auth_ref": [
      "r686"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-01 Financial Instruments-Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities.",
        "label": "Accounting Standards Update 2016-01 [Member]",
        "terseLabel": "Accounting Standards Update 2016-01 [Member]",
        "verboseLabel": "Financial Assets and Liabilities [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201601Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201602Member": {
     "auth_ref": [
      "r706"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2016-02 Leases (Topic 842).",
        "label": "Accounting Standards Update 2016-02 [Member]",
        "terseLabel": "Accounting Standards Update 2016-02 [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201602Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingStandardsUpdate201802Member": {
     "auth_ref": [
      "r119"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accounting Standards Update 2018-02 Income Statement-Reporting Comprehensive Income (Topic 220): Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income.",
        "label": "Accounting Standards Update 2018-02 [Member]",
        "terseLabel": "Reclassification of Certain Tax Effects from AOCI [Member]"
       }
      }
     },
     "localname": "AccountingStandardsUpdate201802Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r69"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccountsReceivableMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold.",
        "label": "Accounts Receivable [Member]",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts [Member]",
        "verboseLabel": "Accounts Receivable [Member]"
       }
      }
     },
     "localname": "AccountsReceivableMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "auth_ref": [
      "r24",
      "r47",
      "r249",
      "r250",
      "r407"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts: 2019\u2014$527; 2018\u2014$541"
       }
      }
     },
     "localname": "AccountsReceivableNetCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember": {
     "auth_ref": [
      "r101",
      "r106",
      "r110",
      "r457",
      "r613"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive (income) loss related to prior service cost (credit) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Prior Service Attributable to Parent [Member]",
        "terseLabel": "Prior Service (Costs)/Credits and Other [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember": {
     "auth_ref": [
      "r99",
      "r106",
      "r110",
      "r457",
      "r613"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) related to gain (loss) component of defined benefit plans attributable to the parent.",
        "label": "Accumulated Defined Benefit Plans Adjustment, Net Gain (Loss) Attributable to Parent [Member]",
        "terseLabel": "Actuarial Gains/(Losses) [Member]"
       }
      }
     },
     "localname": "AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r66",
      "r342"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "terseLabel": "Less: Accumulated depreciation"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember": {
     "auth_ref": [
      "r106",
      "r118",
      "r612"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) from gain (loss) of derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness, attributable to parent.",
        "label": "Accumulated Gain (Loss), Net, Cash Flow Hedge, Parent [Member]",
        "terseLabel": "Derivative Financial Instruments [Member]"
       }
      }
     },
     "localname": "AccumulatedGainLossNetCashFlowHedgeParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "auth_ref": [
      "r96",
      "r97",
      "r98",
      "r106",
      "r110"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-sale, Parent [Member]",
        "terseLabel": "Available-For-Sale Securities [Member]"
       }
      }
     },
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r103",
      "r105",
      "r106"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss).",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r102",
      "r106",
      "r110",
      "r613"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "AOCI Attributable to Parent [Member]",
        "terseLabel": "Accum. Other Comp. Loss [Member]",
        "verboseLabel": "Accumulated Other Comprehensive Income/(Loss) [Member]"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "auth_ref": [
      "r93",
      "r106",
      "r110",
      "r613"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent.",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "terseLabel": "Foreign Currency Translation Adjustments [Member]"
       }
      }
     },
     "localname": "AccumulatedTranslationAdjustmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Acquired Finite-lived Intangible Assets, Weighted Average Useful Life",
        "terseLabel": "Acquired intangible assets, useful life"
       }
      }
     },
     "localname": "AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Additional Cash Flow Elements and Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental Cash Flow Information"
       }
      }
     },
     "localname": "AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]",
        "terseLabel": "Add\u2019l Paid-In Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsForChangeInAccountingPrincipleAxis": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of change in accounting principle. Does not include error corrections.",
        "label": "Adjustments for Change in Accounting Principle [Axis]",
        "terseLabel": "Adjustments for Change in Accounting Principle [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForChangeInAccountingPrincipleAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsForNewAccountingPronouncementsAxis": {
     "auth_ref": [
      "r191"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by new accounting pronouncement.",
        "label": "Adjustments for New Accounting Pronouncements [Axis]",
        "terseLabel": "Adjustments for New Accounting Pronouncements [Axis]"
       }
      }
     },
     "localname": "AdjustmentsForNewAccountingPronouncementsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AdvertisingExpense": {
     "auth_ref": [
      "r536"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.",
        "label": "Advertising Expense",
        "terseLabel": "Advertising expense"
       }
      }
     },
     "localname": "AdvertisingExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r490",
      "r523",
      "r529"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Share-based Payment Arrangement, Expense",
        "terseLabel": "Share-based payment expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after tax, of expense for award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, after Tax",
        "totalLabel": "Share-based payment expense, net of tax"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpenseNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent": {
     "auth_ref": [
      "r53",
      "r252",
      "r290"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of allowance for credit loss on accounts receivable, classified as current.",
        "label": "Accounts Receivable, Allowance for Credit Loss, Current",
        "terseLabel": "Accounts receivable, allowance for doubtful accounts"
       }
      }
     },
     "localname": "AllowanceForDoubtfulAccountsReceivableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmortizationOfIntangibleAssets": {
     "auth_ref": [
      "r164",
      "r317",
      "r327"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Amortization of Intangible Assets",
        "terseLabel": "Amortization expense for finite-lived intangible assets"
       }
      }
     },
     "localname": "AmortizationOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.",
        "label": "Defined Benefit Plan, Amount Recognized in Net Periodic Benefit Cost (Credit) and Other Comprehensive (Income) Loss, before Tax",
        "totalLabel": "(Credit)/cost recognized in Comprehensive income"
       }
      }
     },
     "localname": "AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]",
        "terseLabel": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]",
        "terseLabel": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]"
       }
      }
     },
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentCharges": {
     "auth_ref": [
      "r164",
      "r338"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.",
        "label": "Asset Impairment Charges",
        "terseLabel": "Certain asset impairments"
       }
      }
     },
     "localname": "AssetImpairmentCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r232",
      "r739",
      "r769"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "terseLabel": "Total assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r25",
      "r26",
      "r88"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Assets",
        "terseLabel": "Assets held for sale",
        "totalLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Assets [Abstract]",
        "terseLabel": "Assets Held for Sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r340",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Assets, Current",
        "terseLabel": "Assets held for sale"
       }
      }
     },
     "localname": "AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r262"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Available-for-sale debt securities, gross unrealized gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r263"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedTerseLabel": "Available-for-sale debt securities, gross unrealized loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "auth_ref": [
      "r260",
      "r297"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Amortized Cost",
        "totalLabel": "Available-for-sale debt securities, amortized cost"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "terseLabel": "Available-for-sale Securities, Debt Maturities [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r264",
      "r266",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "Available-for-sale securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r264",
      "r265",
      "r759"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Available-for-sale securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "auth_ref": [
      "r257",
      "r261",
      "r297"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale",
        "terseLabel": "Available-for-sale securities, debt securities",
        "totalLabel": "Available-for-sale securities, debt maturities",
        "verboseLabel": "Available-for-sale securities, debt maturities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent": {
     "auth_ref": [
      "r259",
      "r297"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-sale, Current",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent": {
     "auth_ref": [
      "r259",
      "r297"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.",
        "label": "Debt Securities, Available-for-sale, Noncurrent",
        "terseLabel": "Available-for-sale debt securities"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtSecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]",
        "terseLabel": "Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r492",
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]",
        "terseLabel": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location on balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Axis]",
        "terseLabel": "Balance Sheet Location [Axis]"
       }
      }
     },
     "localname": "BalanceSheetLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BalanceSheetLocationDomain": {
     "auth_ref": [
      "r629",
      "r634"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the balance sheet (statement of financial position).",
        "label": "Balance Sheet Location [Domain]",
        "terseLabel": "Balance Sheet Location [Domain]"
       }
      }
     },
     "localname": "BalanceSheetLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail",
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails",
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BankTimeDepositsMember": {
     "auth_ref": [
      "r758"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Certificates of deposit (CD) or savings accounts with a fixed term or understanding the customer can only withdraw by giving advanced notice with a bank or other financial institution. A CD is a short to medium-term investment available at banks and savings and loan institutions where a customer agrees to lend money to the institution for a certain amount of time and is paid a predetermined rate of interest.",
        "label": "Bank Time Deposits [Member]",
        "terseLabel": "Time deposits and other [Member]"
       }
      }
     },
     "localname": "BankTimeDepositsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "terseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BasisOfPresentationAndSignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for the basis of presentation and significant accounting policies concepts. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).  Accounting policies describe all significant accounting policies of the reporting entity.",
        "label": "Basis of Presentation and Significant Accounting Policies [Text Block]",
        "terseLabel": "Basis of Presentation and Significant Accounting Policies"
       }
      }
     },
     "localname": "BasisOfPresentationAndSignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BuildingMember": {
     "auth_ref": [
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Facility held for productive use including, but not limited to, office, production, storage and distribution facilities.",
        "label": "Building [Member]",
        "terseLabel": "Buildings [Member]"
       }
      }
     },
     "localname": "BuildingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree.",
        "label": "Business Acquisition, Acquiree [Domain]",
        "terseLabel": "Business Acquisition, Acquiree [Domain]"
       }
      }
     },
     "localname": "BusinessAcquisitionAcquireeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "auth_ref": [
      "r584",
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business combination or series of individually immaterial business combinations.",
        "label": "Business Acquisition [Axis]",
        "terseLabel": "Business Acquisition [Axis]"
       }
      }
     },
     "localname": "BusinessAcquisitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Business Acquisition [Line Items]",
        "terseLabel": "Business Acquisition [Line Items]"
       }
      }
     },
     "localname": "BusinessAcquisitionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BusinessAcquisitionSharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.",
        "label": "Business Acquisition, Share Price",
        "terseLabel": "Business acquisition, per share in cash (in dollars per share)"
       }
      }
     },
     "localname": "BusinessAcquisitionSharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_BusinessCombinationConsiderationTransferred1": {
     "auth_ref": [
      "r593",
      "r594",
      "r597"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.",
        "label": "Business Combination, Consideration Transferred",
        "terseLabel": "Consideration transferred"
       }
      }
     },
     "localname": "BusinessCombinationConsiderationTransferred1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1": {
     "auth_ref": [
      "r163",
      "r600"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.",
        "label": "Business Combination, Contingent Consideration Arrangements, Change in Amount of Contingent Consideration, Liability",
        "terseLabel": "Change in fair value of fair value contingent consideration liabilities"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiability": {
     "auth_ref": [
      "r592",
      "r595",
      "r599"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination.",
        "label": "Business Combination, Contingent Consideration, Liability",
        "terseLabel": "Assumed contingent consideration",
        "verboseLabel": "Fair value of contingent consideration"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent": {
     "auth_ref": [
      "r592",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Current",
        "terseLabel": "Contingent consideration liability, current"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent": {
     "auth_ref": [
      "r592",
      "r596"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.",
        "label": "Business Combination, Contingent Consideration, Liability, Noncurrent",
        "terseLabel": "Contingent consideration liability, noncurrent"
       }
      }
     },
     "localname": "BusinessCombinationContingentConsiderationLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationIntegrationRelatedCosts": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 2.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.",
        "label": "Business Combination, Integration Related Costs",
        "terseLabel": "Integration costs"
       }
      }
     },
     "localname": "BusinessCombinationIntegrationRelatedCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles": {
     "auth_ref": [
      "r588"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.",
        "label": "Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Intangibles",
        "negatedLabel": "Reduction in identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of other assets expected to be realized or consumed before one year or the normal operating cycle, if longer, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Current Assets, Other",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities": {
     "auth_ref": [
      "r546",
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Deferred Tax Liabilities",
        "terseLabel": "Net deferred tax liabilities"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of intangible assets, excluding goodwill, acquired at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Intangible Assets, Other than Goodwill",
        "terseLabel": "Intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles": {
     "auth_ref": [
      "r586",
      "r587"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of identifiable intangible assets recognized as of the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Finite-Lived Intangibles",
        "verboseLabel": "Identifiable intangible assets"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt": {
     "auth_ref": [
      "r587"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.",
        "label": "Business Combination, Recognized Identifiable Assets Acquired and Liabilities Assumed, Noncurrent Liabilities, Long-term Debt",
        "terseLabel": "Assumed long-term debt"
       }
      }
     },
     "localname": "BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized": {
     "auth_ref": [
      "r583"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.",
        "label": "Business Combination, Separately Recognized Transactions, Expenses and Losses Recognized",
        "terseLabel": "Post closing compensation expense for payments to Array employees for fair value of previously unvested stock options"
       }
      }
     },
     "localname": "BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BusinessCombinationsPolicy": {
     "auth_ref": [
      "r174",
      "r582"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.",
        "label": "Business Combinations Policy [Policy Text Block]",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "BusinessCombinationsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_BusinessExitCosts1": {
     "auth_ref": [
      "r164",
      "r352",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 3.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Business Exit Costs",
        "terseLabel": "Exit costs"
       }
      }
     },
     "localname": "BusinessExitCosts1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CarryingReportedAmountFairValueDisclosureMember": {
     "auth_ref": [
      "r678",
      "r679"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as reported on the statement of financial position (balance sheet).",
        "label": "Reported Value Measurement [Member]",
        "terseLabel": "Carrying Value [Member]"
       }
      }
     },
     "localname": "CarryingReportedAmountFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r22",
      "r62",
      "r166"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r31",
      "r169",
      "r174"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r158",
      "r166",
      "r173"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at end of period",
        "periodStartLabel": "Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r158",
      "r689"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated net amount of existing gains or losses on cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Cash Flow Hedge Gain (Loss) to be Reclassified within Twelve Months",
        "terseLabel": "Gain (loss) to be reclassified in next twelve months"
       }
      }
     },
     "localname": "CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowHedgingMember": {
     "auth_ref": [
      "r625"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedge of the exposure to variability in the cash flows of a recognized asset or liability, or of a forecasted transaction, that is attributable to a particular risk.",
        "label": "Cash Flow Hedging [Member]",
        "terseLabel": "Cash Flow Hedging [Member]"
       }
      }
     },
     "localname": "CashFlowHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInAccountingPrincipleMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A change from one generally accepted accounting principle to another generally accepted accounting principle when there are two or more generally accepted accounting principles that apply or when the accounting principle formerly used is no longer generally accepted. A change in the method of applying an accounting principle that is not treated as a change in accounting estimate also is considered a change in accounting principle.",
        "label": "Adjustments for Change in Accounting Principle [Domain]",
        "terseLabel": "Adjustments for Change in Accounting Principle [Domain]"
       }
      }
     },
     "localname": "ChangeInAccountingPrincipleMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1": {
     "auth_ref": [
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Fair Value Hedging Instruments",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1": {
     "auth_ref": [
      "r662"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.",
        "label": "Change in Unrealized Gain (Loss) on Hedged Item in Fair Value Hedge",
        "terseLabel": "Hedged Item"
       }
      }
     },
     "localname": "ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock": {
     "auth_ref": [
      "r429"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.",
        "label": "Changes in Projected Benefit Obligations, Fair Value of Plan Assets, and Funded Status of Plan [Table Text Block]",
        "terseLabel": "Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans"
       }
      }
     },
     "localname": "ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ClassOfStockDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock.",
        "label": "Class of Stock [Domain]",
        "terseLabel": "Class of Stock [Domain]"
       }
      }
     },
     "localname": "ClassOfStockDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfTreasuryStockTable": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table]",
        "terseLabel": "Class of Treasury Stock [Table]"
       }
      }
     },
     "localname": "ClassOfTreasuryStockTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollaborativeArrangementMember": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual arrangement that involves two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity.",
        "label": "Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement [Member]"
       }
      }
     },
     "localname": "CollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Collaborative arrangement transaction between parties to collaborative arrangement.",
        "label": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement [Member]",
        "terseLabel": "Collaborative Arrangement, Transaction with Party to Collaborative Arrangement"
       }
      }
     },
     "localname": "CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]"
       }
      }
     },
     "localname": "CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CollateralAlreadyPostedAggregateFairValue": {
     "auth_ref": [
      "r656"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.",
        "label": "Collateral Already Posted, Aggregate Fair Value",
        "terseLabel": "Collateral posted"
       }
      }
     },
     "localname": "CollateralAlreadyPostedAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaper": {
     "auth_ref": [
      "r36",
      "r740",
      "r770"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 1.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of short-term borrowings using unsecured obligations issued by banks, corporations and other borrowers to investors. The maturities of these money market securities generally do not exceed 270 days.",
        "label": "Commercial Paper",
        "terseLabel": "Commercial paper"
       }
      }
     },
     "localname": "CommercialPaper",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommercialPaperMember": {
     "auth_ref": [
      "r383"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unsecured promissory note (generally negotiable) that provides institutions with short-term funds.",
        "label": "Commercial Paper [Member]",
        "terseLabel": "Commercial Paper [Member]"
       }
      }
     },
     "localname": "CommercialPaperMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r80",
      "r369",
      "r750",
      "r775"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r368",
      "r379"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Contingencies and Certain Commitments"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r382",
      "r800",
      "r801"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "terseLabel": "Legal and Environmental Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Cash dividends declared per share (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]",
        "terseLabel": "Common Stock [Member]",
        "verboseLabel": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical",
      "http://www.pfizer.com/role/CoverPage",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r46"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, $0.05 par value; 12,000 shares authorized; issued: 2019\u20149,369; 2018\u20149,332"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Retirement Benefits [Abstract]"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Assets [Abstract]",
        "terseLabel": "Deferred Tax Assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Components of Deferred Tax Liabilities [Abstract]",
        "terseLabel": "Deferred Tax Liabilities"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r113",
      "r115",
      "r116"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Comprehensive income attributable to Pfizer Inc."
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r113",
      "r115",
      "r606",
      "r607",
      "r617"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income (loss) and other comprehensive income (loss), attributable to noncontrolling interests. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Comprehensive income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r113",
      "r115",
      "r605",
      "r617"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "totalLabel": "Comprehensive income before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "auth_ref": [
      "r140"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "terseLabel": "Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests"
       }
      }
     },
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r680",
      "r681"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage.",
        "label": "Concentration Risk Benchmark [Domain]",
        "terseLabel": "Concentration Risk Benchmark [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskBenchmarkDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r680",
      "r681",
      "r788"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by benchmark of concentration risk.",
        "label": "Concentration Risk Benchmark [Axis]",
        "terseLabel": "Concentration Risk Benchmark [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "auth_ref": [
      "r219",
      "r220",
      "r680",
      "r681",
      "r788"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender.",
        "label": "Concentration Risk Type [Axis]",
        "terseLabel": "Concentration Risk Type [Axis]"
       }
      }
     },
     "localname": "ConcentrationRiskByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure": {
     "auth_ref": [
      "r682"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.",
        "label": "Concentration Risk, Credit Risk, Financial Instrument, Maximum Exposure",
        "terseLabel": "Maximum exposure, amount"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Concentration Risk [Line Items]",
        "terseLabel": "Concentration Risk [Line Items]"
       }
      }
     },
     "localname": "ConcentrationRiskLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "auth_ref": [
      "r219",
      "r220",
      "r680",
      "r681"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.",
        "label": "Concentration Risk, Percentage",
        "terseLabel": "Percentage of total revenues",
        "verboseLabel": "Concentration risk, percentage"
       }
      }
     },
     "localname": "ConcentrationRiskPercentage1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ConcentrationRiskTable": {
     "auth_ref": [
      "r215",
      "r219",
      "r220",
      "r221",
      "r680",
      "r683"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes the nature of a concentration, a benchmark to which it is compared, and the percentage that the risk is to the benchmark.",
        "label": "Concentration Risk [Table]",
        "terseLabel": "Concentration Risk [Table]"
       }
      }
     },
     "localname": "ConcentrationRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "auth_ref": [
      "r219",
      "r220",
      "r680",
      "r681"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration.",
        "label": "Concentration Risk Type [Domain]",
        "terseLabel": "Concentration Risk Type [Domain]"
       }
      }
     },
     "localname": "ConcentrationRiskTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r608",
      "r618",
      "r619"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.",
        "label": "Consolidation, Policy [Policy Text Block]",
        "terseLabel": "Consolidation"
       }
      }
     },
     "localname": "ConsolidationPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in Progress [Member]",
        "terseLabel": "Construction in progress [Member]"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConvertiblePreferredStockSharesIssuedUponConversion": {
     "auth_ref": [
      "r44",
      "r45",
      "r392",
      "r394"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares issued for each share of convertible preferred stock that is converted.",
        "label": "Convertible Preferred Stock, Shares Issued upon Conversion",
        "terseLabel": "Series A convertible perpetual preferred stock, common stock shares when converted (in shares)"
       }
      }
     },
     "localname": "ConvertiblePreferredStockSharesIssuedUponConversion",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r440",
      "r482",
      "r787"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate Debt Securities [Member]",
        "terseLabel": "Corporate debt [Member]",
        "verboseLabel": "Corporate and Other [Member]"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateNonSegmentMember": {
     "auth_ref": [
      "r241"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Corporate headquarters or functional department that may not earn revenues or may earn revenues that are only incidental to the activities of the entity and is not considered an operating segment.",
        "label": "Corporate, Non-Segment [Member]",
        "verboseLabel": "Corporate [Member]"
       }
      }
     },
     "localname": "CorporateNonSegmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "auth_ref": [
      "r132"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.",
        "label": "Cost of Goods and Services Sold",
        "negatedLabel": "Cost of sales",
        "terseLabel": "Cost of sales"
       }
      }
     },
     "localname": "CostOfGoodsAndServicesSold",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CostOfSalesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing cost of sales.",
        "label": "Cost of Sales [Member]",
        "terseLabel": "Cost of Sales [Member]"
       }
      }
     },
     "localname": "CostOfSalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CostsAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Costs and Expenses [Abstract]",
        "terseLabel": "Costs and expenses:"
       }
      }
     },
     "localname": "CostsAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r358",
      "r359",
      "r366"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.",
        "label": "Costs Associated with Exit or Disposal Activities or Restructurings, Policy [Policy Text Block]",
        "terseLabel": "Restructuring Charges and Certain Acquisition-Related Costs"
       }
      }
     },
     "localname": "CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CreditFacilityAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Axis]",
        "terseLabel": "Credit Facility [Axis]"
       }
      }
     },
     "localname": "CreditFacilityAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CreditFacilityDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of credit facility. Credit facilities provide capital to borrowers without the need to structure a loan for each borrowing.",
        "label": "Credit Facility [Domain]",
        "terseLabel": "Credit Facility [Domain]"
       }
      }
     },
     "localname": "CreditFacilityDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.",
        "label": "Cumulative Effect of New Accounting Principle in Period of Adoption",
        "terseLabel": "Other comprehensive income/(loss) due to the adoption of new accounting standards"
       }
      }
     },
     "localname": "CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1": {
     "auth_ref": [
      "r194",
      "r735"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cumulative effect on retained earnings before related income tax effect.",
        "label": "Cumulative Effect on Retained Earnings, before Tax",
        "verboseLabel": "Cumulative effect on retained earnings, before tax"
       }
      }
     },
     "localname": "CumulativeEffectOnRetainedEarningsBeforeTax1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1": {
     "auth_ref": [
      "r194"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cumulative effect on retained earnings net of related income tax effect.",
        "label": "Cumulative Effect on Retained Earnings, Net of Tax",
        "terseLabel": "Cumulative effect on retained earnings, net of tax"
       }
      }
     },
     "localname": "CumulativeEffectOnRetainedEarningsNetOfTax1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "auth_ref": [
      "r177",
      "r568",
      "r573"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 1.0,
       "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Federal Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "CurrentFederalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentForeignTaxExpenseBenefit": {
     "auth_ref": [
      "r184",
      "r570"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current Foreign Tax Expense (Benefit)",
        "verboseLabel": "Current income taxes"
       }
      }
     },
     "localname": "CurrentForeignTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Current income taxes:"
       }
      }
     },
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "auth_ref": [
      "r177",
      "r568",
      "r573"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 2.0,
       "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Current State and Local Tax Expense (Benefit)",
        "verboseLabel": "State and local"
       }
      }
     },
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "auth_ref": [
      "r216"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer.",
        "label": "Customer Concentration Risk [Member]",
        "terseLabel": "Customer Concentration Risk [Member]"
       }
      }
     },
     "localname": "CustomerConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtConversionConvertedInstrumentAmount1": {
     "auth_ref": [
      "r171",
      "r172"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. \"Part noncash\" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.",
        "label": "Debt Conversion, Converted Instrument, Amount",
        "terseLabel": "Exchange of $1.1 billion net book value 6.50% U.K. pound denominated bonds maturing in 2038 for $1.8 billion of new 2.735% U.K. pound denominated bonds maturing in 2043, resulting in a debt extinguishment loss of $747 million"
       }
      }
     },
     "localname": "DebtConversionConvertedInstrumentAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtCurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.",
        "label": "Debt, Current",
        "terseLabel": "Carrying value of short-term borrowings",
        "totalLabel": "Total Short-term borrowings, including current portion of long-term debt, carried at historical proceeds, as adjusted",
        "verboseLabel": "Short-term borrowings, including current portion of long-term debt: 2019\u2014$1,462; 2018\u2014$4,776"
       }
      }
     },
     "localname": "DebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentAxis": {
     "auth_ref": [
      "r37",
      "r39",
      "r40",
      "r741",
      "r743",
      "r765"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities.",
        "label": "Debt Instrument [Axis]",
        "terseLabel": "Debt Instrument [Axis]"
       }
      }
     },
     "localname": "DebtInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentCarryingAmount": {
     "auth_ref": [
      "r40",
      "r385",
      "r743",
      "r765"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.",
        "label": "Long-term Debt, Gross",
        "verboseLabel": "Total principal amount of long-term debt"
       }
      }
     },
     "localname": "DebtInstrumentCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r699",
      "r701"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Debt instrument, face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "auth_ref": [
      "r77"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement.",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "terseLabel": "Interest rate, percentage"
       }
      }
     },
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DebtInstrumentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Instrument [Line Items]",
        "terseLabel": "Debt Instrument [Line Items]"
       }
      }
     },
     "localname": "DebtInstrumentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities.",
        "label": "Debt Instrument, Name [Domain]",
        "terseLabel": "Debt Instrument, Name [Domain]"
       }
      }
     },
     "localname": "DebtInstrumentNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtInstrumentRepurchaseAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value amount of debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchase Amount",
        "terseLabel": "Repurchased debt"
       }
      }
     },
     "localname": "DebtInstrumentRepurchaseAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentRepurchasedFaceAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face (par) amount of the original debt instrument that was repurchased.",
        "label": "Debt Instrument, Repurchased Face Amount",
        "terseLabel": "Redemption value"
       }
      }
     },
     "localname": "DebtInstrumentRepurchasedFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtInstrumentTable": {
     "auth_ref": [
      "r78",
      "r179",
      "r392",
      "r395",
      "r396",
      "r397",
      "r698",
      "r699",
      "r701",
      "r762"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to long-term debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table]",
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]"
       }
      }
     },
     "localname": "DebtInstrumentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet": {
     "auth_ref": [
      "r386",
      "r700"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtCurrent",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unamortized debt discount (premium) and debt issuance costs.",
        "label": "Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net",
        "negatedTerseLabel": "Net unamortized discounts, premiums and debt issuance costs"
       }
      }
     },
     "localname": "DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "pfe_DebtSecuritiesAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale and Held-to-maturity",
        "terseLabel": "Debt Securities, Available-for-sale and Held-to-maturity, fair value"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAndHeldToMaturity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Available-for-sale debt securities, gross realized gain"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "auth_ref": [
      "r274"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Loss",
        "negatedTerseLabel": "Available-for-sale debt securities, gross realized loss"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesMember": {
     "auth_ref": [
      "r276"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt instrument issued by corporations, governments and governmental agencies, municipalities, and other institutions.",
        "label": "Debt Securities [Member]",
        "terseLabel": "Debt Securities [Member]"
       }
      }
     },
     "localname": "DebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtSecuritiesRealizedGainLoss": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).",
        "label": "Debt Securities, Realized Gain (Loss)",
        "negatedTerseLabel": "Net realized (gains)/losses on sales of investments in debt securities"
       }
      }
     },
     "localname": "DebtSecuritiesRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtWeightedAverageInterestRate": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average interest rate of debt outstanding.",
        "label": "Debt, Weighted Average Interest Rate",
        "terseLabel": "Weighted average interest rate",
        "verboseLabel": "Interest rate, percentage"
       }
      }
     },
     "localname": "DebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DeconsolidationGainOrLossAmount": {
     "auth_ref": [
      "r614"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 7.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.",
        "label": "Deconsolidation, Gain (Loss), Amount",
        "negatedTerseLabel": "(Gain) on completion of Consumer Healthcare JV transaction",
        "terseLabel": "Gain on completion of Consumer Healthcare JV transaction"
       }
      }
     },
     "localname": "DeconsolidationGainOrLossAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "auth_ref": [
      "r551"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "verboseLabel": "Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit"
       }
      }
     },
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r177",
      "r569",
      "r573"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 3.0,
       "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "verboseLabel": "Federal"
       }
      }
     },
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredForeignIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r177",
      "r569",
      "r573"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Foreign Income Tax Expense (Benefit)",
        "verboseLabel": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredForeignIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r164",
      "r177",
      "r569",
      "r573"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred Income Tax Expense (Benefit)",
        "terseLabel": "Deferred taxes from continuing operations"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]",
        "terseLabel": "Deferred income taxes:"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r42",
      "r43",
      "r560",
      "r742",
      "r764"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Deferred tax liabilities, gross"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r547",
      "r564"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred Income Tax Liabilities, Net",
        "terseLabel": "Noncurrent deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r177",
      "r569",
      "r573"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 4.0,
       "parentTag": "pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "verboseLabel": "State and local"
       }
      }
     },
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsEquityMethodInvestments": {
     "auth_ref": [
      "r541",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 11.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from equity method investments.",
        "label": "Deferred Tax Assets, Equity Method Investments",
        "terseLabel": "Investments - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGoodwillAndIntangibleAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from intangible assets including goodwill.",
        "label": "Deferred Tax Assets, Goodwill and Intangible Assets",
        "terseLabel": "Intangible assets - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGoodwillAndIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r561"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Subtotal - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsInventory": {
     "auth_ref": [
      "r541",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from inventory.",
        "label": "Deferred Tax Assets, Inventory",
        "terseLabel": "Inventories - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsInventory",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r562"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred taxes - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "auth_ref": [
      "r541",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets, Other",
        "terseLabel": "All other - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsPropertyPlantAndEquipment": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Assets, Property, Plant and Equipment",
        "terseLabel": "Property, plant and equipment - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpense": {
     "auth_ref": [
      "r541",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowances, of deferred tax asset attributable to deductible differences from reserves and accruals, compensation and benefit costs, and other provisions, reserves, and allowances.",
        "label": "Deferred Tax Assets, Tax Deferred Expense",
        "terseLabel": "Prepaid/deferred items - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits": {
     "auth_ref": [
      "r539",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences from employee benefits, classified as other.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Employee Benefits",
        "terseLabel": "Employee benefits - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges": {
     "auth_ref": [
      "r539",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from restructuring reserve.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Restructuring Charges",
        "terseLabel": "Restructurings and other charges - Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r563"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r547",
      "r564"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "Deferred Tax Liabilities, Net",
        "negatedTotalLabel": "Net deferred tax liability",
        "terseLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails",
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts": {
     "auth_ref": [
      "r540",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from inventory.",
        "label": "Deferred Tax Liabilities, Inventory",
        "negatedLabel": "Inventories - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r541",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "Deferred Tax Liabilities, Intangible Assets",
        "negatedLabel": "Intangible assets - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates": {
     "auth_ref": [
      "r541",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from investments in unconsolidated subsidiaries and investments in other affiliates which are not controlled nor consolidated.",
        "label": "Deferred Tax Liabilities, Investment in Noncontrolled Affiliates",
        "negatedTerseLabel": "Investments - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesOther": {
     "auth_ref": [
      "r541",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences classified as other.",
        "label": "Deferred Tax Liabilities, Other",
        "negatedLabel": "All other - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "negatedLabel": "Prepaid/deferred items - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "auth_ref": [
      "r541",
      "r566",
      "r567"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "negatedLabel": "Property, plant and equipment - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesUndistributedForeignEarnings": {
     "auth_ref": [
      "r566"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from undistributed earnings of subsidiary and other recognized entity not within country of domicile. Includes, but is not limited to, other basis differences.",
        "label": "Deferred Tax Liabilities, Undistributed Foreign Earnings",
        "negatedLabel": "Unremitted earnings - Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesUndistributedForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41",
      "r417",
      "r418",
      "r437"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.",
        "label": "Liability, Defined Benefit Pension Plan, Noncurrent",
        "terseLabel": "Pension benefit obligations, net"
       }
      }
     },
     "localname": "DefinedBenefitPensionPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation": {
     "auth_ref": [
      "r446"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.",
        "label": "Defined Benefit Plan, Accumulated Benefit Obligation",
        "terseLabel": "Defined benefit plan, accumulated benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax": {
     "auth_ref": [
      "r100",
      "r106"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, before Tax",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax": {
     "auth_ref": [
      "r106",
      "r458"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive Income (Loss), Gain (Loss), before Tax",
        "terseLabel": "Actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r106",
      "r458"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Defined Benefit Plan, Accumulated Other Comprehensive (Income) Loss, Prior Service Cost (Credit), before Tax",
        "negatedTerseLabel": "Prior service (costs)/credits"
       }
      }
     },
     "localname": "DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets": {
     "auth_ref": [
      "r431",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.",
        "label": "Defined Benefit Plan, Plan Assets, Increase (Decrease) for Actual Return (Loss)",
        "terseLabel": "Actual gain/(loss) on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]",
        "terseLabel": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement [Abstract]"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld": {
     "auth_ref": [
      "r443",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan from actual return (loss) on assets still held.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Actual Return (Loss) on Plan Assets Still Held",
        "terseLabel": "Assets held, ending"
       }
      }
     },
     "localname": "DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanActuarialGainLoss": {
     "auth_ref": [
      "r425"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Actuarial Gain (Loss)",
        "negatedTerseLabel": "Changes in actuarial assumptions and other"
       }
      }
     },
     "localname": "DefinedBenefitPlanActuarialGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses": {
     "auth_ref": [
      "r453",
      "r478",
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Gain (Loss)",
        "negatedLabel": "Amortization of actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfGainsLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit": {
     "auth_ref": [
      "r454",
      "r479",
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.",
        "label": "Defined Benefit Plan, Amortization of Prior Service Cost (Credit)",
        "terseLabel": "Amortization of prior service credits/(credits)"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmortizationOfPriorServiceCostCredit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet": {
     "auth_ref": [
      "r417",
      "r437"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset (liability), recognized in statement of financial position, for defined benefit pension and other postretirement plans.",
        "label": "Defined Benefit Plan, Amounts for Asset (Liability) Recognized in Statement of Financial Position",
        "totalLabel": "Funded status"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax": {
     "auth_ref": [
      "r99",
      "r103",
      "r456"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of increase (decrease) in accumulated other comprehensive income from gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), after Reclassification Adjustment, before Tax",
        "totalLabel": "Defined benefit Plan, amounts recognized in other comprehensive income (loss), net gain (loss), before tax, total"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r101",
      "r103",
      "r456"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income from prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), after Reclassification Adjustment, before Tax",
        "negatedTotalLabel": "Defined benefit plan, amounts recognized in other comprehensive income (loss), net prior service cost, before tax"
       }
      }
     },
     "localname": "DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent": {
     "auth_ref": [
      "r35",
      "r417",
      "r418",
      "r437",
      "r738",
      "r768"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset, recognized in statement of financial position, for overfunded defined benefit pension and other postretirement plans.",
        "label": "Assets for Plan Benefits, Defined Benefit Plan",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Discount Rate",
        "terseLabel": "Weighted-average assumptions used to determine benefit obligations, Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average rate increase of compensation, used to determine benefit obligation of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Benefit Obligation, Rate of Compensation Increase",
        "terseLabel": "Weighted-average assumptions used to determine benefit obligations, Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average rate for present value of future retirement benefits cash flows, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Discount Rate",
        "terseLabel": "Weighted-average assumptions used to determine net periodic benefit cost, Discount rate"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets": {
     "auth_ref": [
      "r462"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average rate of return on plan assets, reflecting average rate of earnings expected on existing plan assets and expected contributions, used to determine net periodic benefit cost of defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Expected Long-term Rate of Return on Plan Assets",
        "terseLabel": "Weighted-average assumptions used to determine net periodic benefit cost, Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average rate of compensation increase used to determine net periodic benefit cost of defined benefit plan. Plan includes, but is not limited to, pay-related defined benefit plan.",
        "label": "Defined Benefit Plan, Assumptions Used Calculating Net Periodic Benefit Cost, Rate of Compensation Increase",
        "terseLabel": "Weighted-average assumptions used to determine net periodic benefit cost, Rate of compensation increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligation": {
     "auth_ref": [
      "r420"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation",
        "periodEndLabel": "Benefit obligation, ending",
        "periodStartLabel": "Benefit obligation, beginning"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid": {
     "auth_ref": [
      "r427",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Benefit Obligation, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant": {
     "auth_ref": [
      "r424"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increase benefit obligation.",
        "label": "Defined Benefit Plan, Benefit Obligation, Contributions by Plan Participant",
        "terseLabel": "Employee contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis": {
     "auth_ref": [
      "r440",
      "r441",
      "r465",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Axis]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Axis]"
       }
      }
     },
     "localname": "DefinedBenefitPlanByPlanAssetCategoriesAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash and cash equivalent in which defined benefit plan asset is invested.",
        "label": "Defined Benefit Plan, Cash and Cash Equivalents [Member]",
        "terseLabel": "Cash and Cash Equivalents [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Benefit Obligation [Roll Forward]",
        "terseLabel": "Change in benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInBenefitObligationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]",
        "terseLabel": "Defined Benefit Plan, Change in Fair Value of Plan Assets, Level 3 Reconciliation [Roll Forward]"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsLevel3ReconciliationRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Defined Benefit Plan, Change in Fair Value of Plan Assets [Roll Forward]",
        "terseLabel": "Change in plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanContributionsByEmployer": {
     "auth_ref": [
      "r433",
      "r440",
      "r441",
      "r481",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contribution received by defined benefit plan from employer which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Employer",
        "terseLabel": "Voluntary contribution",
        "verboseLabel": "Company contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanContributionsByEmployer",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.",
        "label": "Defined Benefit Plan, Cost of Providing Special and Contractual Termination Benefits",
        "terseLabel": "Special termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanCurtailments": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Curtailment",
        "negatedTerseLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanDisclosureLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plan Disclosure [Line Items]",
        "terseLabel": "Defined Benefit Plan Disclosure [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlanDisclosureLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in accumulated postretirement benefit obligation from one-percentage-point decrease in assumed health care cost trend rate.",
        "label": "Defined Benefit Plan, Effect of One Percentage Point Decrease on Accumulated Postretirement Benefit Obligation",
        "negatedTerseLabel": "Effect on postretirement benefit obligation, decrease"
       }
      }
     },
     "localname": "DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in service and interest cost components of net periodic postretirement benefit cost from one-percentage-point decrease in assumed health care cost trend rate.",
        "label": "Defined Benefit Plan, Effect of One Percentage Point Decrease on Service and Interest Cost Components",
        "negatedTerseLabel": "Effect on total service and interest cost components, decrease"
       }
      }
     },
     "localname": "DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in accumulated postretirement benefit obligation from one-percentage-point increase in assumed health care cost trend rate.",
        "label": "Defined Benefit Plan, Effect of One Percentage Point Increase on Accumulated Postretirement Benefit Obligation",
        "terseLabel": "Effect on postretirement benefit obligation, increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents": {
     "auth_ref": [
      "r464"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in service and interest cost components of net periodic postretirement benefit cost from one-percentage-point increase in assumed health care cost trend rate.",
        "label": "Defined Benefit Plan, Effect of One Percentage Point Increase on Service and Interest Cost Components",
        "terseLabel": "Effect on total service and interest cost components, increase"
       }
      }
     },
     "localname": "DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanEquitySecuritiesMember": {
     "auth_ref": [
      "r440",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Security representing ownership in corporation or other legal entity for which ownership is represented by share of stock, in which defined benefit plan asset is invested. Includes, but is not limited to, common stock, preferred stock, convertible security, stock right and stock warrant.",
        "label": "Defined Benefit Plan, Equity Securities [Member]",
        "terseLabel": "Equity Securities [Member]"
       }
      }
     },
     "localname": "DefinedBenefitPlanEquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Defined Benefit Plan, Expected Future Employer Contributions [Abstract]",
        "terseLabel": "Expected benefit payments:"
       }
      }
     },
     "localname": "DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost (credit) included in accumulated other comprehensive (income) loss expected to be recognized in net periodic benefit cost (credit) for fiscal year following most recent annual statement of financial position.",
        "label": "Defined Benefit Plan, Expected Amortization, Next Fiscal Year",
        "negatedTotalLabel": "Total"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedAmortizationNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount included in accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan expected to be recognized in net periodic benefit (cost) credit for fiscal year following most recent annual statement of financial position.",
        "label": "Defined Benefit Plan, Expected Amortization of Gain (Loss), Next Fiscal Year",
        "verboseLabel": "Actuarial losses"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear": {
     "auth_ref": [
      "r467"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount included in accumulated other comprehensive (income) loss for prior service cost (credit) expected to be recognized in net periodic benefit cost (credit) for fiscal year following most recent annual statement of financial position.",
        "label": "Defined Benefit Plan, Expected Amortization of Prior Service Cost (Credit), Next Fiscal Year",
        "negatedTerseLabel": "Prior service credits and other"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Five Fiscal Years Thereafter",
        "terseLabel": "2025-2029"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in next fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Next Twelve Months",
        "verboseLabel": "2020"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in fifth fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Five",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in fourth fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Four",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in third fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Three",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo": {
     "auth_ref": [
      "r447"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of benefits for defined benefit plan expected to be paid in second fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Benefit Payment, Year Two",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear": {
     "auth_ref": [
      "r448"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contributions expected to be received by defined benefit plan from employer in next fiscal year following latest fiscal year.",
        "label": "Defined Benefit Plan, Expected Future Employer Contributions, Next Fiscal Year",
        "terseLabel": "Expected contributions in 2019"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets": {
     "auth_ref": [
      "r452",
      "r477",
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Expected Return (Loss) on Plan Assets",
        "negatedLabel": "Expected return on plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanExpectedReturnOnPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFairValueOfPlanAssets": {
     "auth_ref": [
      "r430",
      "r440",
      "r441",
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanFundedStatusOfPlan",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.",
        "label": "Defined Benefit Plan, Plan Assets, Amount",
        "periodEndLabel": "Fair value of plan assets, ending",
        "periodStartLabel": "Fair value of plan assets, beginning",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation": {
     "auth_ref": [
      "r426"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Foreign Currency Translation Gain (Loss)",
        "negatedTerseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanFundedStatusOfPlan": {
     "auth_ref": [
      "r417",
      "r437"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.",
        "label": "Defined Benefit Plan, Funded (Unfunded) Status of Plan",
        "totalLabel": "Funded status\u2014Plan assets less than benefit obligation"
       }
      }
     },
     "localname": "DefinedBenefitPlanFundedStatusOfPlan",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanInterestCost": {
     "auth_ref": [
      "r423",
      "r451",
      "r476",
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost recognized for passage of time related to defined benefit plan.",
        "label": "Defined Benefit Plan, Interest Cost",
        "terseLabel": "Interest cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanInterestCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost": {
     "auth_ref": [
      "r449",
      "r474",
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 4.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of net periodic benefit cost (credit) for defined benefit plan.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit)",
        "terseLabel": "Net periodic benefit costs recorded in Other (income)/deductions\u2013\u2013net",
        "totalLabel": "Net periodic benefit costs/(income) reported in Income"
       }
      }
     },
     "localname": "DefinedBenefitPlanNetPeriodicBenefitCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation": {
     "auth_ref": [
      "r470"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Pension Plan with Projected Benefit Obligation in Excess of Plan Assets, Projected Benefit Obligation",
        "terseLabel": "PBO"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Pension plans with an ABO in excess of plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation": {
     "auth_ref": [
      "r470",
      "r471",
      "r482"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Accumulated Benefit Obligation",
        "terseLabel": "ABO"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets": {
     "auth_ref": [
      "r470",
      "r471",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets, Plan Assets",
        "verboseLabel": "Fair value of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAmendments": {
     "auth_ref": [
      "r428"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.",
        "label": "Defined Benefit Plan, Benefit Obligation, Increase (Decrease) for Plan Amendment",
        "terseLabel": "Plan amendments"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAmendments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid": {
     "auth_ref": [
      "r435",
      "r485"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.",
        "label": "Defined Benefit Plan, Plan Assets, Benefits Paid",
        "negatedTerseLabel": "Benefits paid"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsBenefitsPaid",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant": {
     "auth_ref": [
      "r434"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of contributions received by defined benefit plan from participant which increases plan assets.",
        "label": "Defined Benefit Plan, Plan Assets, Contributions by Plan Participant",
        "terseLabel": "Employee contributions"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss": {
     "auth_ref": [
      "r432"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.",
        "label": "Defined Benefit Plan, Plan Assets, Foreign Currency Translation Gain (Loss)",
        "terseLabel": "Exchange rate changes",
        "verboseLabel": "Foreign exchange impact"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage": {
     "auth_ref": [
      "r439",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Target Allocation, Percentage",
        "terseLabel": "Equity and debt securities, target allocation percentage"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlanAssetsTargetAllocationPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Defined Benefit Plan, Pension Plan with Project Benefit Obligation in Excess of Plan Assets [Abstract]",
        "terseLabel": "Pension plans with a PBO in excess of plan assets:"
       }
      }
     },
     "localname": "DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanPurchasesSalesAndSettlements": {
     "auth_ref": [
      "r444",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, measured using unobservable input, of increase (decrease) in plan asset of defined benefit plan from purchase, sale and settlement of trade associated with underlying investment.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Purchase, Sale, and Settlement",
        "terseLabel": "Purchases, sales, and settlements, net"
       }
      }
     },
     "localname": "DefinedBenefitPlanPurchasesSalesAndSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments": {
     "auth_ref": [
      "r455",
      "r480"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Curtailment",
        "negatedLabel": "Curtailments"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1": {
     "auth_ref": [
      "r455",
      "r480"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.",
        "label": "Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement",
        "negatedTerseLabel": "Settlements",
        "terseLabel": "Gain on settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanServiceCost": {
     "auth_ref": [
      "r421",
      "r450",
      "r475",
      "r482"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.",
        "label": "Defined Benefit Plan, Service Cost",
        "terseLabel": "Service cost"
       }
      }
     },
     "localname": "DefinedBenefitPlanServiceCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsBenefitObligation": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.",
        "label": "Defined Benefit Plan, Benefit Obligation, (Increase) Decrease for Settlement",
        "negatedTerseLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsBenefitObligation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSettlementsPlanAssets": {
     "auth_ref": [
      "r436"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.",
        "label": "Defined Benefit Plan, Plan Assets, Payment for Settlement",
        "negatedLabel": "Settlements"
       }
      }
     },
     "localname": "DefinedBenefitPlanSettlementsPlanAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanSpecialTerminationBenefits": {
     "auth_ref": [
      "r422"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.",
        "label": "Defined Benefit Plan, Benefit Obligation, Special and Contractual Termination Benefits",
        "terseLabel": "Special termination benefits"
       }
      }
     },
     "localname": "DefinedBenefitPlanSpecialTerminationBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanTransfersBetweenMeasurementLevels": {
     "auth_ref": [
      "r445",
      "r482"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, measured using unobservable inputs, of increase (decrease) in plan assets of defined benefit plan, for assets transferred into (out of) Level 3 of fair value hierarchy. Includes, but is not limited to, transfer due to change in observability of significant inputs.",
        "label": "Defined Benefit Plan, Plan Assets Level 3 Reconciliation, Increase (Decrease) for Assets Transferred into (out of) Level 3",
        "terseLabel": "Transfer into/(out of) Level 3"
       }
      }
     },
     "localname": "DefinedBenefitPlanTransfersBetweenMeasurementLevels",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ultimate trend rate for health care cost for defined benefit postretirement plan.",
        "label": "Defined Benefit Plan, Ultimate Health Care Cost Trend Rate",
        "terseLabel": "Rate to which the cost trend rate is assumed to decline"
       }
      }
     },
     "localname": "DefinedBenefitPlanUltimateHealthCareCostTrendRate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations": {
     "auth_ref": [
      "r439"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.",
        "label": "Defined Benefit Plan, Plan Assets, Actual Allocation, Percentage",
        "terseLabel": "Equity and debt securities, percentage of plan assets"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssetAllocations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Benefit Obligation [Abstract]",
        "terseLabel": "Weighted-average assumptions used to determine benefit obligations:"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingBenefitObligationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Defined Benefit Plan, Weighted Average Assumptions Used in Calculating Net Periodic Benefit Cost [Abstract]",
        "terseLabel": "Weighted-average assumptions used to determine net periodic benefit cost:"
       }
      }
     },
     "localname": "DefinedBenefitPlanWeightedAverageAssumptionsUsedInCalculatingNetPeriodicBenefitCostAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r468",
      "r469",
      "r472",
      "r473",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures and provisions pertaining to defined benefit pension plans or other postretirement defined benefit plans. The arrangements are generally based on terms and conditions stipulated by the entity, and which contain a promise by the employer to pay certain amounts or awards at designated future dates, including a period after retirement, upon compliance with stipulated requirements. Excludes disclosures pertaining to defined contribution plans.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]",
        "terseLabel": "Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]"
       }
      }
     },
     "localname": "DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "auth_ref": [
      "r486"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost for defined contribution plan.",
        "label": "Defined Contribution Plan, Cost",
        "terseLabel": "Defined contribution plan, cost recognized"
       }
      }
     },
     "localname": "DefinedContributionPlanCostRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r164",
      "r229"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and Amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssets": {
     "auth_ref": [
      "r89",
      "r90",
      "r677"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset",
        "verboseLabel": "Derivative asset"
       }
      }
     },
     "localname": "DerivativeAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsCurrent": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Current",
        "terseLabel": "Current derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeAssetsNoncurrent": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Asset, Noncurrent",
        "terseLabel": "Noncurrent derivative assets"
       }
      }
     },
     "localname": "DerivativeAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeContractTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Financial instrument or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset.",
        "label": "Derivative Contract [Domain]",
        "terseLabel": "Derivative Contract [Domain]"
       }
      }
     },
     "localname": "DerivativeContractTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DerivativeGainLossOnDerivativeNet": {
     "auth_ref": [
      "r631"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.",
        "label": "Derivative, Gain (Loss) on Derivative, Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeGainLossOnDerivativeNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeInstrumentRiskAxis": {
     "auth_ref": [
      "r630",
      "r633",
      "r642",
      "r650"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of derivative contract.",
        "label": "Derivative Instrument [Axis]",
        "terseLabel": "Derivative Instrument [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentRiskAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis": {
     "auth_ref": [
      "r627",
      "r630",
      "r642"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of hedging relationship.",
        "label": "Hedging Relationship [Axis]",
        "terseLabel": "Hedging Relationship [Axis]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable": {
     "auth_ref": [
      "r627",
      "r630",
      "r642",
      "r650",
      "r651",
      "r660",
      "r663"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table]",
        "terseLabel": "Derivative Instruments, Gain (Loss) by Hedging Relationship, by Income Statement Location, by Derivative Instrument Risk [Table]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossByHedgingRelationshipByIncomeStatementLocationByDerivativeInstrumentRiskTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsGainLossLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative Instruments, Gain (Loss) [Line Items]",
        "terseLabel": "Derivative Instruments, Gain (Loss) [Line Items]"
       }
      }
     },
     "localname": "DerivativeInstrumentsGainLossLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet": {
     "auth_ref": [
      "r641",
      "r643"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.",
        "label": "Derivative Instruments Not Designated as Hedging Instruments, Gain (Loss), Net",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OID"
       }
      }
     },
     "localname": "DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilities": {
     "auth_ref": [
      "r89",
      "r90",
      "r677"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability",
        "totalLabel": "Total liabilities",
        "verboseLabel": "Derivative liability"
       }
      }
     },
     "localname": "DerivativeLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesCurrent": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Current",
        "terseLabel": "Current derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLiabilitiesNoncurrent": {
     "auth_ref": [
      "r89"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DerivativeLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.",
        "label": "Derivative Liability, Noncurrent",
        "terseLabel": "Noncurrent derivative liabilities"
       }
      }
     },
     "localname": "DerivativeLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Derivative [Line Items]",
        "terseLabel": "Derivative [Line Items]"
       }
      }
     },
     "localname": "DerivativeLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeNetLiabilityPositionAggregateFairValue": {
     "auth_ref": [
      "r655"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.",
        "label": "Derivative, Net Liability Position, Aggregate Fair Value",
        "terseLabel": "Derivatives in a net liability position"
       }
      }
     },
     "localname": "DerivativeNetLiabilityPositionAggregateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeNotionalAmount": {
     "auth_ref": [
      "r622",
      "r624"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nominal or face amount used to calculate payment on derivative.",
        "label": "Derivative, Notional Amount",
        "terseLabel": "Derivative, notional amount"
       }
      }
     },
     "localname": "DerivativeNotionalAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DerivativeTable": {
     "auth_ref": [
      "r185",
      "r621",
      "r623",
      "r624",
      "r627",
      "r628",
      "r635",
      "r642",
      "r657",
      "r659",
      "r663"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule that describes and identifies a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Derivative [Table]",
        "terseLabel": "Derivative [Table]"
       }
      }
     },
     "localname": "DerivativeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DerivativeTermOfContract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Derivative, Term of Contract",
        "terseLabel": "Derivative term of contract"
       }
      }
     },
     "localname": "DerivativeTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_DerivativesPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r187",
      "r621",
      "r623",
      "r627",
      "r628",
      "r658"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities.",
        "label": "Derivatives, Policy [Policy Text Block]",
        "terseLabel": "Derivative Financial Instruments"
       }
      }
     },
     "localname": "DerivativesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DerivativesReportingOfDerivativeActivity": {
     "auth_ref": [
      "r174",
      "r186",
      "r621"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.",
        "label": "Derivatives, Reporting of Derivative Activity [Policy Text Block]",
        "terseLabel": "Statement of Cash Flows"
       }
      }
     },
     "localname": "DerivativesReportingOfDerivativeActivity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DesignatedAsHedgingInstrumentMember": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Designated as Hedging Instrument [Member]",
        "terseLabel": "Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "DesignatedAsHedgingInstrumentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DevelopedTechnologyRightsMember": {
     "auth_ref": [
      "r591"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights to developed technology, which can include the right to develop, use, market, sell, or offer for sale products, compounds, or intellectual property.",
        "label": "Developed Technology Rights [Member]",
        "terseLabel": "Developed Technology Rights [Member]"
       }
      }
     },
     "localname": "DevelopedTechnologyRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect in current period from application of guidance for revenue from contract with customer compared with guidance for revenue recognition applicable prior to change when using transition method for cumulative effect in period including initial date of application.",
        "label": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]",
        "terseLabel": "Difference between Revenue Guidance in Effect before and after Topic 606 [Member]"
       }
      }
     },
     "localname": "DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DilutiveSecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dilutive Securities, Effect on Basic Earnings Per Share [Abstract]",
        "terseLabel": "EPS Numerator\u2013\u2013Diluted"
       }
      }
     },
     "localname": "DilutiveSecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r534"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]",
        "verboseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPayments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Payment Arrangement [Abstract]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax": {
     "auth_ref": [
      "r2",
      "r4",
      "r6",
      "r18"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.",
        "label": "Discontinued Operation, Gain (Loss) on Disposal of Discontinued Operation, Net of Tax",
        "terseLabel": "Gain on disposal of discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r18"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.",
        "label": "Discontinued Operation, Income (Loss) from Discontinued Operation During Phase-out Period, Net of Tax",
        "terseLabel": "Income from discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupClassificationAxis": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by disposal group classification.",
        "label": "Disposal Group Classification [Axis]",
        "terseLabel": "Disposal Group Classification [Axis]"
       }
      }
     },
     "localname": "DisposalGroupClassificationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DisposalGroupClassificationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Component or group of components disposed of, including but not limited to, disposal group held-for-sale or disposed of by sale, disposed of by means other than sale, and discontinued operations.",
        "label": "Disposal Group Classification [Domain]",
        "terseLabel": "Disposal Group Classification [Domain]"
       }
      }
     },
     "localname": "DisposalGroupClassificationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r337",
      "r339"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group that is disposed of other than by sale. For example, but not limited to, abandonment, in an exchange measured based on the recorded amount of the nonmonetary asset relinquished, or in a distribution to owners in a spinoff. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member]"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r339",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group that has been sold. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Disposed of by Sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposed of by Sale, Not Discontinued Operations [Member]"
       }
      }
     },
     "localname": "DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember": {
     "auth_ref": [
      "r17",
      "r336",
      "r349"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disposal group that is classified as held-for-sale. Excludes disposals classified as discontinued operations.",
        "label": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]",
        "terseLabel": "Disposal Group, Held-for-sale, Not Discontinued Operations [Member]"
       }
      }
     },
     "localname": "DisposalGroupHeldforsaleNotDiscontinuedOperationsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accounts, notes and loans receivable attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts, Notes and Loans Receivable, Net",
        "terseLabel": "Trade accounts receivable, less allowance for doubtful accounts"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r340",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accounts payable attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accounts Payable, Current",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r340",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as income tax obligations attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Income Tax Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r340",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as accrued liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Accrued Liabilities, Current",
        "terseLabel": "Accrued compensation and related items"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as cash and cash equivalents attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Cash and Cash Equivalents",
        "terseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.",
        "label": "Disposal Group, Including Discontinued Operation, Consideration",
        "terseLabel": "Cash received for disposition",
        "verboseLabel": "Cash and common stock to be received for disposition"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationConsideration",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as deferred tax assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Assets",
        "terseLabel": "Noncurrent deferred tax assets and other noncurrent tax assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as deferred tax liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Deferred Tax Liabilities",
        "terseLabel": "Noncurrent deferred tax liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationGoodwill1": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as goodwill attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Goodwill",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationGoodwill1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r335",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as intangible assets, excluding goodwill, attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Intangible Assets, Noncurrent",
        "terseLabel": "Identifiable intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationInventoryCurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r340",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as inventory attributable to disposal group, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Inventory, Current",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationInventoryCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets",
        "terseLabel": "Other assets held for sale"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r340",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r340",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r335",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other assets attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Assets, Noncurrent",
        "terseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r335",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as other liabilities attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent": {
     "auth_ref": [
      "r1",
      "r15",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as defined benefit plan benefit obligations attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Pension Plan Benefit Obligation, Noncurrent",
        "terseLabel": "Pension benefit obligations, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent": {
     "auth_ref": [
      "r1",
      "r15",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as defined benefit non-pension postretirement plan obligations attributable to disposal group held for sale or disposed of, expected to be disposed of beyond one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Postretirement Plan Benefit Obligation, Noncurrent",
        "terseLabel": "Postretirement benefit obligations, net"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r335",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as property, plant and equipment attributable to disposal group held for sale or disposed of, expected to be disposed of after one year or the normal operating cycle, if longer.",
        "label": "Disposal Group, Including Discontinued Operation, Property, Plant and Equipment, Noncurrent",
        "terseLabel": "PP&amp;E"
       }
      }
     },
     "localname": "DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal": {
     "auth_ref": [
      "r164",
      "r339",
      "r345"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.",
        "label": "Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal",
        "terseLabel": "Income (Loss) on sale of HIS net assets",
        "verboseLabel": "Income (loss) on sale of assets"
       }
      }
     },
     "localname": "DisposalGroupNotDiscontinuedOperationGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisposalGroupsIncludingDiscontinuedOperationsNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of disposal group.",
        "label": "Disposal Group Name [Domain]",
        "terseLabel": "Disposal Group Name [Domain]",
        "verboseLabel": "Disposal Groups, Including Discontinued Operations, Name [Domain]"
       }
      }
     },
     "localname": "DisposalGroupsIncludingDiscontinuedOperationsNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DistributionRightsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Legal rights, generally of a limited duration, to distribute a product or products, often within specific geographic areas or supply channels.",
        "label": "Distribution Rights [Member]",
        "terseLabel": "Distribution Rights [Member]"
       }
      }
     },
     "localname": "DistributionRightsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DividendsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Dividends [Abstract]",
        "terseLabel": "Cash dividends declared:"
       }
      }
     },
     "localname": "DividendsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DividendsCommonStockCash": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid common stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Common Stock, Cash",
        "negatedLabel": "Common stock"
       }
      }
     },
     "localname": "DividendsCommonStockCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPayableCurrent": {
     "auth_ref": [
      "r29",
      "r75"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Dividends Payable, Current",
        "terseLabel": "Dividends payable"
       }
      }
     },
     "localname": "DividendsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DividendsPreferredStockCash": {
     "auth_ref": [
      "r398",
      "r761"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of paid and unpaid preferred stock dividends declared with the form of settlement in cash.",
        "label": "Dividends, Preferred Stock, Cash",
        "negatedLabel": "Preferred stock"
       }
      }
     },
     "localname": "DividendsPreferredStockCash",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DomesticPlanMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Domestic Plan [Member]",
        "terseLabel": "Domestic Plan [Member]"
       }
      }
     },
     "localname": "DomesticPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r128",
      "r192",
      "r198",
      "r200",
      "r201",
      "r202",
      "r205",
      "r756",
      "r780"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareBasicAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Basic [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013basic:",
        "verboseLabel": "EPS Numerator-Basic"
       }
      }
     },
     "localname": "EarningsPerShareBasicAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r128",
      "r192",
      "r198",
      "r200",
      "r201",
      "r202",
      "r205",
      "r756",
      "r780"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Earnings Per Share, Diluted [Abstract]",
        "terseLabel": "Earnings per common share\u2013\u2013diluted:"
       }
      }
     },
     "localname": "EarningsPerShareDilutedAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r689"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "terseLabel": "Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents"
       }
      }
     },
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r183",
      "r548",
      "r549"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Effective tax rate for income from continuing operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r548",
      "r549",
      "r572"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "terseLabel": "U.S. statutory income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness": {
     "auth_ref": [
      "r548",
      "r549",
      "r572"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 9.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.",
        "label": "Effective Income Tax Rate Reconciliation, Disposition of Business, Percent",
        "terseLabel": "Completion of Consumer Healthcare joint venture transaction(d)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationDispositionOfBusiness",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential": {
     "auth_ref": [
      "r548",
      "r549",
      "r572"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Percent",
        "terseLabel": "Taxation of non-U.S. operations"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments": {
     "auth_ref": [
      "r548",
      "r549",
      "r572"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.",
        "label": "Effective Income Tax Rate Reconciliation, Other Adjustments, Percent",
        "terseLabel": "All other, net"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOtherAdjustments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits": {
     "auth_ref": [
      "r548",
      "r549",
      "r572"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Percent",
        "negatedTerseLabel": "U.S. R&amp;D tax credit and manufacturing deduction"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCredits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent": {
     "auth_ref": [
      "r548"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Cuts and Jobs Act, Percent",
        "terseLabel": "TCJA impact"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements": {
     "auth_ref": [
      "r548",
      "r549",
      "r572"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Percent",
        "terseLabel": "Tax settlements and resolution of certain tax positions"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r75"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Accrued compensation and related items"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost related to nonvested stock options not yet recognized, pre-tax"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r525"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "netLabel": "Weighted-average period over which nonvested award cost is expected to be recognized (years)",
        "terseLabel": "Weighted-average period over which stock option compensation cost is expected to be recognized (years)",
        "verboseLabel": "Weighted-average period over which RSU cost is expected to be recognized (years)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions": {
     "auth_ref": [
      "r525"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount",
        "terseLabel": "Total compensation cost related to nonvested awards not yet recognized, pre-tax",
        "verboseLabel": "Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense": {
     "auth_ref": [
      "r523"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail": {
       "order": 2.0,
       "parentTag": "us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit for recognition of expense of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Expense, Tax Benefit",
        "negatedLabel": "Tax benefit for share-based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions": {
     "auth_ref": [
      "r527"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax benefit from exercise of option under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Exercise of Option, Tax Benefit",
        "terseLabel": "Tax benefits realized related to exercise"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeSeveranceMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan.",
        "label": "Employee Severance [Member]",
        "terseLabel": "Employee Termination Costs [Member]"
       }
      }
     },
     "localname": "EmployeeSeveranceMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r521"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]",
        "terseLabel": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPCompensationExpense": {
     "auth_ref": [
      "r531"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of plan compensation cost recognized during the period.",
        "label": "Employee Stock Ownership Plan (ESOP), Compensation Expense",
        "terseLabel": "ESOP compensation expense"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis": {
     "auth_ref": [
      "r533"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of employee stock ownership plan.",
        "label": "Employee Stock Ownership Plan (ESOP) Name [Axis]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP) Name [Axis]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPPlanDomain": {
     "auth_ref": [
      "r530"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Entities identify multiple employee stock ownership plans by unique name.",
        "label": "Employee Stock Ownership Plan (ESOP), Plan [Domain]",
        "terseLabel": "Employee Stock Ownership Plan (ESOP), Plan [Domain]"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EmployeeStockOwnershipPlanESOPSharesInESOP": {
     "auth_ref": [
      "r532"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the allocated, committed-to-be-released and suspense shares of the entity held by the plan.",
        "label": "Employee Stock Ownership Plan (ESOP), Shares in ESOP",
        "terseLabel": "Number of shares in ESOP"
       }
      }
     },
     "localname": "EmployeeStockOwnershipPlanESOPSharesInESOP",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenue from External Customer [Line Items]",
        "terseLabel": "Revenue from External Customer [Line Items]"
       }
      }
     },
     "localname": "EntityWideInformationRevenueFromExternalCustomerLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityClassOfTreasuryStockLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Equity, Class of Treasury Stock [Line Items]",
        "terseLabel": "Equity, Class of Treasury Stock [Line Items]"
       }
      }
     },
     "localname": "EquityClassOfTreasuryStockLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]",
        "terseLabel": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.",
        "label": "Equity Method Investment, Difference Between Carrying Amount and Underlying Equity",
        "terseLabel": "Difference between carrying amount and underlying equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.",
        "label": "Equity Method Investment, Ownership Percentage",
        "terseLabel": "Equity method investment, ownership percentage"
       }
      }
     },
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal": {
     "auth_ref": [
      "r129",
      "r130",
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of an equity method investment.",
        "label": "Equity Method Investment, Realized Gain (Loss) on Disposal",
        "negatedLabel": "Loss on disposal of equity method investment"
       }
      }
     },
     "localname": "EquityMethodInvestmentRealizedGainLossOnDisposal",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSoldCarryingAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the entity's equity method investment which has been sold.",
        "label": "Equity Method Investment, Amount Sold",
        "terseLabel": "Equity method investment, carrying value of share sold"
       }
      }
     },
     "localname": "EquityMethodInvestmentSoldCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of assets reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales": {
     "auth_ref": [
      "r21",
      "r287"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the cost of sales reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Cost of Sales",
        "negatedTerseLabel": "Cost of sales"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationCostOfSales",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of current assets reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Current Assets",
        "terseLabel": "Current assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of current liabilities reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Current Liabilities",
        "terseLabel": "Current liabilities"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity": {
     "auth_ref": [
      "r21",
      "r188",
      "r287",
      "r684",
      "r685"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity.",
        "label": "Equity Method Investment Summarized Financial Information, Equity",
        "terseLabel": "Equity method investment, registered capital",
        "totalLabel": "Total net equity"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital": {
     "auth_ref": [
      "r21",
      "r180",
      "r282",
      "r287",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity, excluding noncontrolling interest, attributable to the equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Equity Excluding Noncontrolling Interests",
        "terseLabel": "Equity/(deficit) attributable to shareholders"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of gross profit (loss) reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Gross Profit (Loss)",
        "totalLabel": "Gross profit"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations reported by an equity method investee.",
        "label": "Equity Method Investment, Summarized Financial Information, Income (Loss) from Continuing Operations",
        "terseLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]",
        "terseLabel": "Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of liabilities reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of equity attributable to noncontrolling interests of an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Noncontrolling Interest",
        "terseLabel": "Equity attributable to noncontrolling interests"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287",
      "r684"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Net Income (Loss)",
        "terseLabel": "Net income"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of noncurrent assets reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Noncurrent Assets",
        "terseLabel": "Noncurrent assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities": {
     "auth_ref": [
      "r21",
      "r176",
      "r282",
      "r287",
      "r684"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of noncurrent liabilities reported by an equity method investment of the entity.",
        "label": "Equity Method Investment, Summarized Financial Information, Noncurrent Liabilities",
        "terseLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue": {
     "auth_ref": [
      "r21",
      "r287"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of revenue from sale of product and rendering of service reported by equity method investee.",
        "label": "Equity Method Investment, Summarized Financial Information, Revenue",
        "terseLabel": "Net Sales"
       }
      }
     },
     "localname": "EquityMethodInvestmentSummarizedFinancialInformationRevenue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets": {
     "auth_ref": [
      "r285"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.",
        "label": "Equity Method Investment, Underlying Equity in Net Assets",
        "terseLabel": "Underlying equity in net assets"
       }
      }
     },
     "localname": "EquityMethodInvestmentUnderlyingEquityInNetAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestments": {
     "auth_ref": [
      "r63",
      "r233",
      "r280"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 8.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "pfe_LongtermInvestmentsAndEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.",
        "label": "Equity Method Investments",
        "terseLabel": "Equity-method investments"
       }
      }
     },
     "localname": "EquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsFairValueDisclosure": {
     "auth_ref": [
      "r279"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of investments accounted under the equity method.",
        "label": "Equity Method Investments, Fair Value Disclosure",
        "terseLabel": "Equity method investments",
        "verboseLabel": "Equity method investments, fair value"
       }
      }
     },
     "localname": "EquityMethodInvestmentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquityMethodInvestmentsTextBlock": {
     "auth_ref": [
      "r288"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.",
        "label": "Equity Method Investments [Table Text Block]",
        "terseLabel": "Summarized Financial Information of Equity Method Investments"
       }
      }
     },
     "localname": "EquityMethodInvestmentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EquitySecuritiesByIndustryAxis": {
     "auth_ref": [
      "r296"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by industry sector, examples include but are not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Axis]",
        "terseLabel": "Industry Sector [Axis]"
       }
      }
     },
     "localname": "EquitySecuritiesByIndustryAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquitySecuritiesFvNi": {
     "auth_ref": [
      "r675"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI",
        "terseLabel": "Equity securities with readily determinable fair values(a)",
        "verboseLabel": "Equity securities"
       }
      }
     },
     "localname": "EquitySecuritiesFvNi",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiGainLoss": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Gain (Loss)",
        "negatedTerseLabel": "Net gains recognized during the period on investments in equity securities",
        "netLabel": "Net gains recognized during the period on equity securities",
        "terseLabel": "Gain representing difference between fair value of equity investment and book value of assets transferred",
        "totalLabel": "Net gains recognized during the period on investments in equity securities",
        "verboseLabel": "Gain associated with Bain Capital transaction"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGain": {
     "auth_ref": [
      "r278"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain",
        "terseLabel": "Gain from sale of shares"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiRealizedGainLoss": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Realized Gain (Loss)",
        "negatedTerseLabel": "Less: Net gains recognized during the period on equity securities sold during the period"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiRealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss": {
     "auth_ref": [
      "r278"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EquitySecuritiesFvNiGainLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).",
        "label": "Equity Securities, FV-NI, Unrealized Gain (Loss)",
        "terseLabel": "Unrealized gain on equity securities",
        "verboseLabel": "Net unrealized gains during the reporting period on equity securities still held at the reporting date"
       }
      }
     },
     "localname": "EquitySecuritiesFvNiUnrealizedGainLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EquitySecuritiesIndustryMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Industry sector consisting of government, private and corporate entities engaged in business activities, including but not limited to, commercial, industrial, agricultural, financial services, technology, healthcare and real estate.",
        "label": "Industry Sector [Domain]",
        "terseLabel": "Industry Sector [Domain]"
       }
      }
     },
     "localname": "EquitySecuritiesIndustryMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesMember": {
     "auth_ref": [
      "r32",
      "r38",
      "r276",
      "r749",
      "r766",
      "r798"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ownership interest or right to acquire or dispose of ownership interest in corporations and other legal entities for which ownership interest is represented by shares of common or preferred stock, convertible securities, stock rights, or stock warrants.",
        "label": "Equity Securities [Member]",
        "verboseLabel": "Equity [Member]"
       }
      }
     },
     "localname": "EquitySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount": {
     "auth_ref": [
      "r277"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.",
        "label": "Equity Securities without Readily Determinable Fair Value, Impairment Loss, Cumulative Amount",
        "verboseLabel": "Impairment of investment"
       }
      }
     },
     "localname": "EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r677"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Estimate of Fair Value Measurement [Member]",
        "terseLabel": "Estimated Fair Value [Member]"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EuropeanUnionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Economic and political union of member states, located primarily in Europe.",
        "label": "European Union [Member]",
        "terseLabel": "European Union [Member]",
        "verboseLabel": "EU [Member]"
       }
      }
     },
     "localname": "EuropeanUnionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ExtinguishmentOfDebtAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross amount of debt extinguished.",
        "label": "Extinguishment of Debt, Amount",
        "terseLabel": "Amount of debt exchanged"
       }
      }
     },
     "localname": "ExtinguishmentOfDebtAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "auth_ref": [
      "r665",
      "r666",
      "r667",
      "r672"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis.",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": {
     "auth_ref": [
      "r668"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.",
        "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]",
        "terseLabel": "Fair Value Measurement Inputs and Valuation Techniques [Table]"
       }
      }
     },
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r440",
      "r441",
      "r482",
      "r666",
      "r729"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "verboseLabel": "Defined Benefit Plan, Fair Value of Plan Assets by Measurement [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r665",
      "r673"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]",
        "terseLabel": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "auth_ref": [
      "r665",
      "r666",
      "r669",
      "r670",
      "r674"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by measurement frequency.",
        "label": "Measurement Frequency [Axis]",
        "terseLabel": "Measurement Frequency [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementFrequencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosureItemAmountsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement basis, for example, but not limited to, reported value, fair value, portion at fair value, portion at other than fair value.",
        "label": "Fair Value Measurement [Domain]",
        "terseLabel": "Fair Value Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueDisclosureItemAmountsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r440",
      "r441",
      "r482",
      "r666",
      "r730"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "terseLabel": "Level 1 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r440",
      "r441",
      "r482",
      "r666",
      "r731"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "terseLabel": "Level 2 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "auth_ref": [
      "r440",
      "r441",
      "r482",
      "r666",
      "r732"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "terseLabel": "Level 3 [Member]"
       }
      }
     },
     "localname": "FairValueInputsLevel3Member",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measurement frequency.",
        "label": "Measurement Frequency [Domain]",
        "terseLabel": "Measurement Frequency [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementFrequencyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "terseLabel": "Fair Value"
       }
      }
     },
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "verboseLabel": "Fair Value Plan Asset Measurement [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "auth_ref": [
      "r671",
      "r674"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.",
        "label": "Fair Value, Recurring [Member]",
        "terseLabel": "Recurring [Member]"
       }
      }
     },
     "localname": "FairValueMeasurementsRecurringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]",
        "terseLabel": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.",
        "label": "Financial Instruments Disclosure [Text Block]",
        "terseLabel": "Financial Instruments"
       }
      }
     },
     "localname": "FinancialInstrumentsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstruments"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialServicesSectorMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sector of the economy consisting of companies engaged in financial services.",
        "label": "Financial Services Sector [Member]",
        "terseLabel": "Bank sector [Member]"
       }
      }
     },
     "localname": "FinancialServicesSectorMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Finite-Lived Intangible Asset, Useful Life",
        "terseLabel": "Finite-lived intangible asset, useful life"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Accumulated Amortization",
        "negatedLabel": "Finite-lived intangible assets, accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAccumulatedAmortization",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Next Twelve Months",
        "verboseLabel": "2020"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Five",
        "verboseLabel": "2024"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Four",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Three",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo": {
     "auth_ref": [
      "r328"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Finite-Lived Intangible Assets, Amortization Expense, Year Two",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r318",
      "r322",
      "r326",
      "r330",
      "r736"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by major type or class of finite-lived intangible assets.",
        "label": "Finite-Lived Intangible Assets by Major Class [Axis]",
        "terseLabel": "Finite-Lived Intangible Assets by Major Class [Axis]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure": {
     "auth_ref": [
      "r665"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail": {
       "order": 1.0,
       "parentTag": "pfe_IntangibleAssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-lived Intangible Assets, Fair Value Disclosure",
        "terseLabel": "Intangible assets\u2013\u2013Developed technology rights"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsGross": {
     "auth_ref": [
      "r326",
      "r736"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_FiniteLivedIntangibleAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Gross",
        "terseLabel": "Finite-lived intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Finite-Lived Intangible Assets [Line Items]",
        "terseLabel": "Finite-Lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r318",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of finite-lived intangible asset (for example, patents, trademarks, copyrights, etc.) A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of a company.",
        "label": "Finite-Lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Finite-Lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Assets, excluding financial assets, that lack physical substance, having a limited useful life.",
        "label": "Finite-Lived Intangible Assets [Member]",
        "terseLabel": "Finite-Lived Intangible Assets [Member]"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FiniteLivedIntangibleAssetsNet": {
     "auth_ref": [
      "r326"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IntangibleAssetsNetExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Finite-Lived Intangible Assets, Net",
        "terseLabel": "Finite-lived intangible assets, net",
        "totalLabel": "Finite-lived intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "FiniteLivedIntangibleAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FixedIncomeSecuritiesMember": {
     "auth_ref": [
      "r440",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investment that provides a return in the form of fixed periodic payments and eventual return of principal at maturity.",
        "label": "Fixed Income Securities [Member]",
        "terseLabel": "Fixed Income Commingled Funds [Member]",
        "verboseLabel": "Fixed Income Securities [Member]"
       }
      }
     },
     "localname": "FixedIncomeSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months": {
     "auth_ref": [
      "r664"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated net amount of unrealized gains or losses on foreign currency cash flow hedges at the reporting date expected to be reclassified to earnings within the next 12 months.",
        "label": "Foreign Currency Cash Flow Hedge Gain (Loss) to be Reclassified During Next 12 Months",
        "terseLabel": "Amount of pre-tax loss to be reclassified"
       }
      }
     },
     "localname": "ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r688",
      "r695"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.",
        "label": "Foreign Currency Transactions and Translations Policy [Policy Text Block]",
        "terseLabel": "Foreign Currency Translation"
       }
      }
     },
     "localname": "ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ForeignExchangeContractMember": {
     "auth_ref": [
      "r440",
      "r648"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to foreign exchange rates.",
        "label": "Foreign Exchange Contract [Member]",
        "terseLabel": "Foreign Exchange Contract [Member]",
        "verboseLabel": "Foreign exchange contracts [Member]"
       }
      }
     },
     "localname": "ForeignExchangeContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignGovernmentDebtSecuritiesMember": {
     "auth_ref": [
      "r440",
      "r787"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt security issued by government not domiciled in United States of America (US).",
        "label": "Debt Security, Government, Non-US [Member]",
        "terseLabel": "Government and agency debt - non-U.S. [Member]"
       }
      }
     },
     "localname": "ForeignGovernmentDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations": {
     "auth_ref": [
      "r182"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.",
        "label": "Foreign Income Tax Expense (Benefit), Continuing Operations",
        "totalLabel": "Total international tax provision"
       }
      }
     },
     "localname": "ForeignIncomeTaxExpenseBenefitContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ForeignPlanMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan, designed to provide retirement benefits, not determined as principal place of business. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Foreign Plan [Member]",
        "terseLabel": "Foreign Plan [Member]"
       }
      }
     },
     "localname": "ForeignPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and Fixtures [Member]",
        "terseLabel": "Furniture, fixtures and other [Member]"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingenciesByNatureAxis": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by nature of gain contingency.",
        "label": "Gain Contingencies, Nature [Axis]",
        "terseLabel": "Gain Contingencies, Nature [Axis]"
       }
      }
     },
     "localname": "GainContingenciesByNatureAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Gain Contingencies [Line Items]",
        "terseLabel": "Gain Contingencies [Line Items]"
       }
      }
     },
     "localname": "GainContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingenciesTable": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sets forth the existing conditions, situations, or sets of circumstances involving uncertainties as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization, and previously disclosed contingent gains that were recognized as income in the period.",
        "label": "Gain Contingencies [Table]",
        "terseLabel": "Gain Contingencies [Table]"
       }
      }
     },
     "localname": "GainContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GainContingencyNatureDomain": {
     "auth_ref": [
      "r378"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Describes any existing condition, situation, or set of circumstances involving uncertainty as of the balance sheet date (or before issuance of the financial statements) that might result in a gain, typically reflecting care to avoid misleading implications as to the likelihood of realization.",
        "label": "Gain Contingency, Nature [Domain]",
        "terseLabel": "Gain Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "GainContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity has allegedly infringed.",
        "label": "Gain Contingency, Patents Allegedly Infringed upon, Number",
        "terseLabel": "Number of patents allegedly infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsAllegedlyInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainContingencyPatentsFoundInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity was found to have infringed.",
        "label": "Gain Contingency, Patents Found Infringed upon, Number",
        "terseLabel": "Number of patents infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsFoundInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of entity's patents that another entity was found not to have infringed.",
        "label": "Gain Contingency, Patents Found Not Infringed upon, Number",
        "terseLabel": "Number of patents found not infringed upon"
       }
      }
     },
     "localname": "GainContingencyPatentsFoundNotInfringedUponNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_GainLossOnDerivativeInstrumentsNetPretax": {
     "auth_ref": [
      "r630"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate net gain (loss) on all derivative instruments recognized in earnings during the period, before tax effects.",
        "label": "Gain (Loss) on Derivative Instruments, Net, Pretax",
        "negatedLabel": "Loss on derivative instruments, net, pretax"
       }
      }
     },
     "localname": "GainLossOnDerivativeInstrumentsNetPretax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfAssets1": {
     "auth_ref": [
      "r164"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.",
        "label": "Gain (Loss) on Disposition of Assets",
        "negatedTerseLabel": "Net (gains)/losses on asset disposals"
       }
      }
     },
     "localname": "GainLossOnDispositionOfAssets1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnDispositionOfIntangibleAssets": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of intangible assets.",
        "label": "Gain (Loss) on Disposition of Intangible Assets",
        "terseLabel": "Gain related to sale of intangible assets"
       }
      }
     },
     "localname": "GainLossOnDispositionOfIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r164"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposition of property",
        "terseLabel": "Gain on sale of property"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainLossRelatedToLitigationSettlement": {
     "auth_ref": [
      "r369"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 8.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.",
        "label": "Gain (Loss) Related to Litigation Settlement",
        "negatedTerseLabel": "Certain legal matters, net",
        "terseLabel": "Litigation settlement income (loss)"
       }
      }
     },
     "localname": "GainLossRelatedToLitigationSettlement",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "auth_ref": [
      "r164",
      "r388",
      "r389"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 10.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "negatedLabel": "Loss on early retirement of debt",
        "negatedTerseLabel": "Net losses on early retirement of debt"
       }
      }
     },
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeographicConcentrationRiskMember": {
     "auth_ref": [
      "r218"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that a specified dollar value on the balance sheet or income statement in the period from one or more specified geographic areas is to a corresponding consolidated, segment, or product line amount. Risk is the materially adverse effects of economic decline or antagonistic political actions resulting in loss of assets, sales volume, labor supply, or source of materials and supplies in a US state or a specified country, continent, or region such as EMEA (Europe, Middle East, Africa).",
        "label": "Geographic Concentration Risk [Member]",
        "terseLabel": "Geographic Concentration Risk [Member]"
       }
      }
     },
     "localname": "GeographicConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Goodwill": {
     "auth_ref": [
      "r308",
      "r309"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Goodwill"
       }
      }
     },
     "localname": "Goodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAcquiredDuringPeriod": {
     "auth_ref": [
      "r310"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized resulting from a business combination.",
        "label": "Goodwill, Acquired During Period",
        "terseLabel": "Additions"
       }
      }
     },
     "localname": "GoodwillAcquiredDuringPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r334"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "terseLabel": "Identifiable Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r312",
      "r323"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Intangible Assets and Goodwill"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GoodwillLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Goodwill [Line Items]",
        "terseLabel": "Goodwill [Line Items]"
       }
      }
     },
     "localname": "GoodwillLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_GoodwillOtherIncreaseDecrease": {
     "auth_ref": [
      "r311"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease), classified as other, of an asset representing the future economic benefits from other assets acquired in a business combination that are not individually identified and separately recognized.",
        "label": "Goodwill, Other Increase (Decrease)",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "GoodwillOtherIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GoodwillRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Goodwill [Roll Forward]",
        "terseLabel": "Goodwill [Roll Forward]"
       }
      }
     },
     "localname": "GoodwillRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r654"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged asset in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Asset, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset"
       }
      }
     },
     "localname": "HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedAssetFairValueHedge": {
     "auth_ref": [
      "r652"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of asset hedged in fair value hedging relationship.",
        "label": "Hedged Asset, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Actively Hedged Assets"
       }
      }
     },
     "localname": "HedgedAssetFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r653"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged asset in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Asset, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset"
       }
      }
     },
     "localname": "HedgedAssetFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r654"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.",
        "label": "Hedged Liability, Discontinued Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedge": {
     "auth_ref": [
      "r652"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability hedged in fair value hedging relationship.",
        "label": "Hedged Liability, Fair Value Hedge",
        "terseLabel": "Carrying Amount of Actively Hedged Liabilities"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedge",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease": {
     "auth_ref": [
      "r653"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.",
        "label": "Hedged Liability, Fair Value Hedge, Cumulative Increase (Decrease)",
        "terseLabel": "Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability"
       }
      }
     },
     "localname": "HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HedgingDesignationAxis": {
     "auth_ref": [
      "r627",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Axis]",
        "terseLabel": "Hedging Designation [Axis]"
       }
      }
     },
     "localname": "HedgingDesignationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HedgingDesignationDomain": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Designation of purpose of derivative instrument.",
        "label": "Hedging Designation [Domain]",
        "terseLabel": "Hedging Designation [Domain]"
       }
      }
     },
     "localname": "HedgingDesignationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HedgingRelationshipDomain": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Nature or intent of a hedge.",
        "label": "Hedging Relationship [Domain]",
        "terseLabel": "Hedging Relationship [Domain]"
       }
      }
     },
     "localname": "HedgingRelationshipDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_HeldToMaturitySecurities": {
     "auth_ref": [
      "r257",
      "r267"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity",
        "totalLabel": "Held-to-maturity securities, amortized cost"
       }
      }
     },
     "localname": "HeldToMaturitySecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain": {
     "auth_ref": [
      "r269"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Gain",
        "terseLabel": "Held-to-maturity securities, gross unrealized gains"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss": {
     "auth_ref": [
      "r270"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Accumulated Unrecognized Loss",
        "negatedTerseLabel": "Held-to-maturity securities, gross unrealized losses"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesCurrent": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_ShortTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.",
        "label": "Debt Securities, Held-to-maturity, Current",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Maturity [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "auth_ref": [
      "r272",
      "r760"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, after One Through Five Years, Fair Value",
        "terseLabel": "Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]",
        "terseLabel": "Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r271",
      "r759"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_HeldToMaturitySecurities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.",
        "label": "Debt Securities, Held-to-maturity, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Held-to-maturity securities, debt maturities, within 1 year, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesFairValue": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity, Fair Value",
        "terseLabel": "Held-to-maturity securities, fair value"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesNoncurrent": {
     "auth_ref": [
      "r259"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LongTermInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.",
        "label": "Debt Securities, Held-to-maturity, Noncurrent",
        "terseLabel": "Held-to-maturity debt securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_HeldToMaturitySecuritiesTextBlock": {
     "auth_ref": [
      "r273"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).",
        "label": "Debt Securities, Held-to-maturity [Table Text Block]",
        "terseLabel": "Held-to-maturity Securities"
       }
      }
     },
     "localname": "HeldToMaturitySecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r164",
      "r331"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.",
        "label": "Impairment of Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Intangible asset impairments",
        "verboseLabel": "Impairment"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InProcessResearchAndDevelopmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "In process investigation of new knowledge useful in developing new product or service or new process or technique or improvement to existing product or process, and translation of knowledge into plan or design for new product or process or for improvement to existing product or process.",
        "label": "In Process Research and Development [Member]",
        "terseLabel": "In Process Research and Development [Member]",
        "verboseLabel": "IPR&amp;D [Member]"
       }
      }
     },
     "localname": "InProcessResearchAndDevelopmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperations": {
     "auth_ref": [
      "r131",
      "r165",
      "r202",
      "r604"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 1.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the parent.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent",
        "totalLabel": "Income from continuing operations attributable to Pfizer Inc."
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity": {
     "auth_ref": [
      "r602",
      "r605"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Domestic",
        "terseLabel": "United States"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r124",
      "r192",
      "r737",
      "r753",
      "r781"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "terseLabel": "Earnings",
        "totalLabel": "Income from continuing operations before provision/(benefit) for taxes on income"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign": {
     "auth_ref": [
      "r181"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Foreign",
        "terseLabel": "International"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r605"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperations",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.",
        "label": "Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Income from continuing operations",
        "totalLabel": "Income from continuing operations"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerBasicShare": {
     "auth_ref": [
      "r121",
      "r128",
      "r198",
      "r200",
      "r201",
      "r751",
      "r754",
      "r756",
      "r777"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Basic Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare": {
     "auth_ref": [
      "r121",
      "r128",
      "r198",
      "r200",
      "r201",
      "r202",
      "r756",
      "r777",
      "r780"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Income (Loss) from Continuing Operations, Per Diluted Share",
        "terseLabel": "Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r18",
      "r128",
      "r778"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ProfitLoss",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax",
        "totalLabel": "Discontinued operations\u2013\u2013net of tax"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest [Abstract]",
        "terseLabel": "Discontinued operations:"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r14",
      "r18",
      "r602",
      "r605"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Discontinued operations\u2013\u2013net of tax, attributable to noncontrolling interests"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity": {
     "auth_ref": [
      "r2",
      "r3",
      "r4",
      "r5",
      "r6",
      "r14",
      "r18",
      "r605"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of income (loss) from a discontinued operation attributable to the parent. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.",
        "label": "Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax, attributable to Pfizer Inc. common shareholders",
        "verboseLabel": "Discontinued operations\u2013\u2013net of tax, attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare": {
     "auth_ref": [
      "r126",
      "r128",
      "r199",
      "r200",
      "r201",
      "r756",
      "r778",
      "r780"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareBasic",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Basic Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare": {
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r620"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_EarningsPerShareDiluted",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.",
        "label": "Income (Loss) from Discontinued Operations and Disposal of Discontinued Operations, Net of Tax, Per Diluted Share",
        "terseLabel": "Discontinued operations\u2013\u2013net of tax (in dollars per share)"
       }
      }
     },
     "localname": "IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "auth_ref": [
      "r125",
      "r164",
      "r230",
      "r280",
      "r752",
      "r776"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss).",
        "label": "Income (Loss) from Equity Method Investments",
        "verboseLabel": "Equity method investment earnings"
       }
      }
     },
     "localname": "IncomeLossFromEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by name of disposal group.",
        "label": "Disposal Group Name [Axis]",
        "terseLabel": "Disposal Group Name [Axis]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "auth_ref": [
      "r1",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r16",
      "r19",
      "r20",
      "r21",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]"
       }
      }
     },
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r346"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]",
        "terseLabel": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]",
        "terseLabel": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxContingencyLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Contingency [Line Items]",
        "terseLabel": "Income Tax Contingency [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxContingencyLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxContingencyTable": {
     "auth_ref": [
      "r552",
      "r557",
      "r559",
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about tax positions taken in the tax returns filed or to be filed for which it is more likely than not that the tax position will not be sustained upon examination by taxing authorities and other income tax contingencies. Includes, but is not limited to, interest and penalties, reconciliation of unrecognized tax benefits, unrecognized tax benefits that would affect the effective tax rate, tax years that remain subject to examination by tax jurisdictions, and information about positions for which it is reasonably possible that amounts unrecognized will significantly change within 12 months.",
        "label": "Income Tax Contingency [Table]",
        "terseLabel": "Income Tax Contingency [Table]"
       }
      }
     },
     "localname": "IncomeTaxContingencyTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r581"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Tax Matters"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMatters"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExaminationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Income Tax Examination [Line Items]",
        "terseLabel": "Income Tax Examination [Line Items]"
       }
      }
     },
     "localname": "IncomeTaxExaminationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExaminationTable": {
     "auth_ref": [
      "r552",
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A summary of income tax examinations that an enterprise is currently subject to or that have been completed in the current period typically including a description of the examination, the jurisdiction conducting the examination, the tax year(s) under examination, the likelihood of an unfavorable settlement, the range of possible losses, the liability recorded, the Increase or Decrease in the liability from the prior period, and any penalties and interest that have been incurred or accrued.",
        "label": "Income Tax Examination [Table]",
        "verboseLabel": "Income Tax Examination [Table]"
       }
      }
     },
     "localname": "IncomeTaxExaminationTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r177",
      "r231",
      "r577"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Income Tax Expense (Benefit)",
        "terseLabel": "Provision/(benefit) for taxes on income",
        "totalLabel": "Provision/(benefit) for taxes on income"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r117",
      "r174",
      "r544",
      "r545",
      "r558",
      "r559",
      "r565",
      "r579",
      "r802"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Tax Assets and Liabilities and Income Tax Contingencies"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible impairment loss.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Amount",
        "negatedLabel": "Tax benefits related to certain asset impairments"
       }
      }
     },
     "localname": "IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationRepatriationOfForeignEarnings": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to repatriation of foreign earnings.",
        "label": "Effective Income Tax Rate Reconciliation, Repatriation of Foreign Earnings, Amount",
        "terseLabel": "Deferred income taxes on certain current-year funds earned outside of the U.S."
       }
      }
     },
     "localname": "IncomeTaxReconciliationRepatriationOfForeignEarnings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlements": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount",
        "terseLabel": "Effective Income Tax Rate Reconciliation, Tax Settlement, Amount"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxReconciliationTaxSettlementsDomestic": {
     "auth_ref": [
      "r548",
      "r549"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to domestic income tax settlement.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Settlement, Domestic, Amount",
        "negatedTerseLabel": "Tax benefits from resolution of certain tax positions"
       }
      }
     },
     "localname": "IncomeTaxReconciliationTaxSettlementsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "auth_ref": [
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.",
        "label": "Income Taxes Paid, Net",
        "terseLabel": "Income taxes"
       }
      }
     },
     "localname": "IncomeTaxesPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableTrade": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 13.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Payable, Trade",
        "terseLabel": "Trade accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableTrade",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.",
        "label": "Increase (Decrease) in Accounts Receivable",
        "negatedLabel": "Trade accounts receivable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInAccruedTaxesPayable": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 15.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.",
        "label": "Increase (Decrease) in Accrued Taxes Payable",
        "terseLabel": "Other tax accounts, net"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedTaxesPayable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 11.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.",
        "label": "Increase (Decrease) in Inventories",
        "negatedTerseLabel": "Inventories"
       }
      }
     },
     "localname": "IncreaseDecreaseInInventories",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Other changes in assets and liabilities, net of acquisitions and divestitures:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingAssets": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 12.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating assets classified as other.",
        "label": "Increase (Decrease) in Other Operating Assets",
        "negatedTerseLabel": "Other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherOperatingLiabilities": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 14.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase (decrease) in operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Operating Liabilities",
        "terseLabel": "Other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherOperatingLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis": {
     "auth_ref": [
      "r320",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type or class of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets [Axis]",
        "terseLabel": "Indefinite-lived Intangible Assets [Axis]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Indefinite-lived Intangible Assets [Line Items]",
        "terseLabel": "Indefinite-lived Intangible Assets [Line Items]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsByMajorClassLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r329"
     ],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_IntangibleAssetsGrossExcludingGoodwill",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill)",
        "terseLabel": "Total indefinite-lived intangible assets"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure": {
     "auth_ref": [
      "r665"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail": {
       "order": 2.0,
       "parentTag": "pfe_IntangibleAssetsFairValueDisclosure",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.",
        "label": "Indefinite-lived Intangible Assets (Excluding Goodwill), Fair Value Disclosure",
        "terseLabel": "Intangible assets\u2013\u2013IPR&amp;D"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsMajorClassNameDomain": {
     "auth_ref": [
      "r320",
      "r329"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The major class of indefinite-lived intangible asset (for example, trade names, etc. but not all-inclusive), excluding goodwill. A major class is composed of intangible assets that can be grouped together because they are similar, either by their nature or by their use in the operations of the company.",
        "label": "Indefinite-lived Intangible Assets, Major Class Name [Domain]",
        "terseLabel": "Indefinite-lived Intangible Assets, Major Class Name [Domain]"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsMajorClassNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis": {
     "auth_ref": [
      "r411"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information about effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Axis]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Axis]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InitialApplicationPeriodCumulativeEffectTransitionDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Effect of transition method for cumulative effect in initial period of application.",
        "label": "Initial Application Period Cumulative Effect Transition [Domain]",
        "terseLabel": "Initial Application Period Cumulative Effect Transition [Domain]"
       }
      }
     },
     "localname": "InitialApplicationPeriodCumulativeEffectTransitionDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InsuranceRecoveries": {
     "auth_ref": [
      "r133"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount recovered from insurance. These recoveries reduce costs and losses that are reported as a separate line item under operating expenses.",
        "label": "Insurance Recoveries",
        "terseLabel": "Insurance recoveries"
       }
      }
     },
     "localname": "InsuranceRecoveries",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsGrossExcludingGoodwill": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated amortization of intangible assets, excluding goodwill.",
        "label": "Intangible Assets, Gross (Excluding Goodwill)",
        "totalLabel": "Intangible assets, gross carrying amount"
       }
      }
     },
     "localname": "IntangibleAssetsGrossExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IntangibleAssetsNetExcludingGoodwill": {
     "auth_ref": [
      "r316",
      "r324"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.",
        "label": "Intangible Assets, Net (Excluding Goodwill)",
        "totalLabel": "Identifiable Intangible Assets, less Accumulated Amortization",
        "verboseLabel": "Identifiable intangible assets, less accumulated amortization"
       }
      }
     },
     "localname": "IntangibleAssetsNetExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestCostsCapitalized": {
     "auth_ref": [
      "r697"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest capitalized during the period.",
        "label": "Interest Costs Capitalized",
        "terseLabel": "Interest costs capitalized"
       }
      }
     },
     "localname": "InterestCostsCapitalized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestExpense": {
     "auth_ref": [
      "r122",
      "r228",
      "r696",
      "r700",
      "r757"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense.",
        "label": "Interest Expense",
        "terseLabel": "Interest expense"
       }
      }
     },
     "localname": "InterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r156",
      "r161",
      "r170"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestRateContractMember": {
     "auth_ref": [
      "r440",
      "r647"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument whose primary underlying risk is tied to the right to receive or pay a sum of money at a given interest rate.",
        "label": "Interest Rate Contract [Member]",
        "terseLabel": "Interest rate contracts [Member]"
       }
      }
     },
     "localname": "InterestRateContractMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InterestRevenueExpenseNet": {
     "auth_ref": [
      "r232"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).",
        "label": "Interest Revenue (Expense), Net",
        "negatedTotalLabel": "Net interest expense"
       }
      }
     },
     "localname": "InterestRevenueExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "localname": "InventoryDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "auth_ref": [
      "r307"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.",
        "label": "Inventory Disclosure [Text Block]",
        "terseLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/Inventories"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "auth_ref": [
      "r54",
      "r306"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "terseLabel": "Finished goods"
       }
      }
     },
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNet": {
     "auth_ref": [
      "r23",
      "r84",
      "r303"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/InventoriesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.",
        "label": "Inventory, Net",
        "terseLabel": "Inventories",
        "totalLabel": "Inventories"
       }
      }
     },
     "localname": "InventoryNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryNoncurrent": {
     "auth_ref": [
      "r86"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle.",
        "label": "Inventory, Noncurrent",
        "terseLabel": "Noncurrent inventories not included above"
       }
      }
     },
     "localname": "InventoryNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "auth_ref": [
      "r30",
      "r85",
      "r174",
      "r209",
      "r304",
      "r305"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.",
        "label": "Inventory, Policy [Policy Text Block]",
        "terseLabel": "Cost of Sales and Inventories"
       }
      }
     },
     "localname": "InventoryPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "auth_ref": [
      "r56",
      "r57",
      "r306"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "terseLabel": "Raw materials and supplies"
       }
      }
     },
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "auth_ref": [
      "r55",
      "r306"
     ],
     "calculation": {
      "http://www.pfizer.com/role/InventoriesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.",
        "label": "Inventory, Work in Process, Net of Reserves",
        "terseLabel": "Work in process"
       }
      }
     },
     "localname": "InventoryWorkInProcessNetOfReserves",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentHoldingsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Investment Holdings [Line Items]",
        "terseLabel": "Investment Holdings [Line Items]"
       }
      }
     },
     "localname": "InvestmentHoldingsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentHoldingsTable": {
     "auth_ref": [
      "r790",
      "r792",
      "r795",
      "r796"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The investment holdings table is used for any listing of investments. The \"Investment [Axis]\" identifies the investment for which the line items apply. The other axes are used for categorizing the investments and creating useful subtotals. These axes cover different categorizations. The appropriate axes are expected to be used. Additional axes can be added for alternative categorizations.",
        "label": "Investment Holdings [Table]",
        "terseLabel": "Investment Holdings [Table]"
       }
      }
     },
     "localname": "InvestmentHoldingsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentIncomeDividend": {
     "auth_ref": [
      "r135"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of dividend income on nonoperating securities.",
        "label": "Investment Income, Dividend",
        "terseLabel": "Dividend income"
       }
      }
     },
     "localname": "InvestmentIncomeDividend",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentIncomeInterest": {
     "auth_ref": [
      "r136",
      "r227"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_InterestRevenueExpenseNet",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.",
        "label": "Investment Income, Interest",
        "negatedLabel": "Interest income"
       }
      }
     },
     "localname": "InvestmentIncomeInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentPolicyTextBlock": {
     "auth_ref": [
      "r284"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment in financial asset.",
        "label": "Investment, Policy [Policy Text Block]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "InvestmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_InvestmentTypeAxis": {
     "auth_ref": [
      "r789",
      "r791",
      "r794",
      "r797"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of investments.",
        "label": "Investment Type [Axis]",
        "terseLabel": "Investment Type [Axis]"
       }
      }
     },
     "localname": "InvestmentTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentTypeCategorizationMember": {
     "auth_ref": [
      "r789",
      "r791",
      "r794",
      "r797"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Asset obtained to generate income or appreciate in value.",
        "label": "Investments [Domain]",
        "terseLabel": "Investments [Domain]"
       }
      }
     },
     "localname": "InvestmentTypeCategorizationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "terseLabel": "Contractual Maturities of Available-for-sale and Held-to-maturity Securities"
       }
      }
     },
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_JudicialRulingMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Litigation outcome that occurs as a result of judicial intervention, supervision, or approval.",
        "label": "Judicial Ruling [Member]",
        "terseLabel": "Judicial Ruling [Member]"
       }
      }
     },
     "localname": "JudicialRulingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LandMember": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Part of earth's surface not covered by water.",
        "label": "Land [Member]",
        "terseLabel": "Land [Member]"
       }
      }
     },
     "localname": "LandMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseArrangementTypeAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Axis]",
        "terseLabel": "Lease Arrangement, Type [Axis]"
       }
      }
     },
     "localname": "LeaseArrangementTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LeaseArrangementTypeDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Group of related lease arrangements. For example, but not limited to, leases grouped by facility or contractual terms.",
        "label": "Lease Arrangement, Type [Domain]",
        "terseLabel": "Lease Arrangement, Type [Domain]"
       }
      }
     },
     "localname": "LeaseArrangementTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeaseCost": {
     "auth_ref": [
      "r721",
      "r723"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lease cost recognized by lessee for lease contract.",
        "label": "Lease, Cost",
        "totalLabel": "Total lease cost"
       }
      }
     },
     "localname": "LeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "auth_ref": [
      "r721"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.",
        "label": "Lease, Cost [Table Text Block]",
        "terseLabel": "Total Lease Costs and Other Supplemental Information"
       }
      }
     },
     "localname": "LeaseCostTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Lessee, Lease, Description [Line Items]",
        "terseLabel": "Lessee, Lease, Description [Line Items]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "auth_ref": [
      "r712"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about lessee's leases.",
        "label": "Lessee, Lease, Description [Table]",
        "terseLabel": "Lessee, Lease, Description [Table]"
       }
      }
     },
     "localname": "LesseeLeaseDescriptionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "auth_ref": [
      "r710"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee.",
        "label": "Lessee, Leases [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeLeasesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r722"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetailsCalc2": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due",
        "totalLabel": "Total undiscounted lease payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due after Rolling Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Five",
        "terseLabel": "4-5 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Four",
        "terseLabel": "3-4 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Three",
        "terseLabel": "2-3 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due in Rolling Year Two",
        "terseLabel": "1-2 years"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.",
        "label": "Lessee, Operating Lease, Liability, Payments, Due Next Rolling Twelve Months",
        "terseLabel": "Next one year"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r722"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetailsCalc2": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "terseLabel": "Less: Imputed interest"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "auth_ref": [
      "r711"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Term of Contract",
        "terseLabel": "Operating lease term",
        "verboseLabel": "Term of corporate headquarters lease agreement"
       }
      }
     },
     "localname": "LesseeOperatingLeaseTermOfContract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r74"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r52",
      "r745",
      "r773"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r76"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation": {
     "auth_ref": [
      "r0",
      "r1",
      "r15",
      "r17",
      "r347"
     ],
     "calculation": {
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount classified as liabilities attributable to disposal group held for sale or disposed of.",
        "label": "Disposal Group, Including Discontinued Operation, Liabilities",
        "terseLabel": "Liabilities held for sale",
        "totalLabel": "Total Consumer Healthcare liabilities held for sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Disposal Group, Including Discontinued Operation, Liabilities [Abstract]",
        "terseLabel": "Liabilities Held for Sale"
       }
      }
     },
     "localname": "LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilityForUncertainTaxPositionsNoncurrent": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount recognized for uncertainty in income taxes classified as noncurrent.",
        "label": "Liability for Uncertainty in Income Taxes, Noncurrent",
        "terseLabel": "Other taxes payable"
       }
      }
     },
     "localname": "LiabilityForUncertainTaxPositionsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LicensingAgreementsMember": {
     "auth_ref": [
      "r590"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights, generally of limited duration, under a license arrangement (for example, to sell or otherwise utilize specified products or processes in a specified territory).",
        "label": "Licensing Agreements [Member]",
        "terseLabel": "Licensing Agreements [Member]"
       }
      }
     },
     "localname": "LicensingAgreementsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount": {
     "auth_ref": [
      "r289"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value amount of life settlement contracts accounted for under the fair value method.",
        "label": "Life Settlement Contracts, Fair Value",
        "terseLabel": "Insurance contracts"
       }
      }
     },
     "localname": "LifeSettlementContractsFairValueMethodCarryingAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityMaximumBorrowingCapacity": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Maximum borrowing capacity under the credit facility without consideration of any current restrictions on the amount that could be borrowed or the amounts currently outstanding under the facility.",
        "label": "Line of Credit Facility, Maximum Borrowing Capacity",
        "terseLabel": "Line of credit facility, maximum borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityMaximumBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditFacilityRemainingBorrowingCapacity": {
     "auth_ref": [
      "r71"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowing capacity currently available under the credit facility (current borrowing capacity less the amount of borrowings outstanding).",
        "label": "Line of Credit Facility, Remaining Borrowing Capacity",
        "terseLabel": "Line of credit facility, remaining borrowing capacity"
       }
      }
     },
     "localname": "LineOfCreditFacilityRemainingBorrowingCapacity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LineOfCreditMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A contractual arrangement with a lender under which borrowings can be made up to a specific amount at any point in time, and under which borrowings outstanding may be either short-term or long-term, depending upon the particulars.",
        "label": "Line of Credit [Member]",
        "terseLabel": "Line of Credit [Member]"
       }
      }
     },
     "localname": "LineOfCreditMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LitigationSettlementExpense": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.",
        "label": "Litigation Settlement, Expense",
        "terseLabel": "Litigation settlement expense"
       }
      }
     },
     "localname": "LitigationSettlementExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LitigationStatusAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Axis]",
        "terseLabel": "Litigation Status [Axis]"
       }
      }
     },
     "localname": "LitigationStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LitigationStatusDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Status of pending, threatened, or settled litigation.",
        "label": "Litigation Status [Domain]",
        "terseLabel": "Litigation Status [Domain]"
       }
      }
     },
     "localname": "LitigationStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r244"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.",
        "label": "Long-lived Assets by Geographic Areas [Table Text Block]",
        "terseLabel": "Long-lived Assets by Geographic Areas"
       }
      }
     },
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r40",
      "r387",
      "r743",
      "r770"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt",
        "terseLabel": "Principal amount"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtCurrent": {
     "auth_ref": [
      "r73"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Current Maturities",
        "terseLabel": "Short term borrowings, current portion of long term debt",
        "verboseLabel": "Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))"
       }
      }
     },
     "localname": "LongTermDebtCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtFairValue": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The fair value amount of long-term debt whether such amount is presented as a separate caption or as a parenthetical disclosure. Additionally, this element may be used in connection with the fair value disclosures required in the footnote disclosures to the financial statements. The element may be used in both the balance sheet and disclosure in the same submission.",
        "label": "Long-term Debt, Fair Value",
        "verboseLabel": "Long-term debt, excluding the current portion"
       }
      }
     },
     "localname": "LongTermDebtFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer.",
        "label": "Long-term Debt [Member]",
        "terseLabel": "Long-term debt [Member]"
       }
      }
     },
     "localname": "LongTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "auth_ref": [
      "r78"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.",
        "label": "Long-term Debt, Excluding Current Maturities",
        "terseLabel": "Long-term debt",
        "totalLabel": "Total long-term debt, carried at historical proceeds, as adjusted"
       }
      }
     },
     "localname": "LongTermDebtNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestments": {
     "auth_ref": [
      "r63"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": 1.0,
       "parentTag": "pfe_LongtermInvestmentsAndEquityMethodInvestments",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).",
        "label": "Long-term Investments",
        "terseLabel": "Long-term investments",
        "totalLabel": "Total Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Long-term Investments [Abstract]",
        "terseLabel": "Long-term investments"
       }
      }
     },
     "localname": "LongTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermPurchaseCommitmentAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The minimum amount the entity agreed to spend under the long-term purchase commitment.",
        "label": "Long-term Purchase Commitment, Amount",
        "terseLabel": "Long-term purchase commitment, amount"
       }
      }
     },
     "localname": "LongTermPurchaseCommitmentAmount",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "auth_ref": [
      "r78"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-term debt.",
        "label": "Long-term Debt, Type [Axis]",
        "terseLabel": "Long-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "LongtermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "auth_ref": [
      "r78",
      "r384"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer.",
        "label": "Long-term Debt, Type [Domain]",
        "terseLabel": "Long-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "LongtermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingenciesByNatureOfContingencyAxis": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur.",
        "label": "Loss Contingency Nature [Axis]",
        "terseLabel": "Loss Contingency Nature [Axis]"
       }
      }
     },
     "localname": "LossContingenciesByNatureOfContingencyAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Loss Contingencies [Line Items]",
        "terseLabel": "Loss Contingencies [Line Items]"
       }
      }
     },
     "localname": "LossContingenciesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingenciesTable": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the specific components (such as the nature, name, and date) of the loss contingency and gives an estimate of the possible loss or range of loss, or states that a reasonable estimate cannot be made. Excludes environmental contingencies, warranties and unconditional purchase obligations.",
        "label": "Loss Contingencies [Table]",
        "terseLabel": "Loss Contingencies [Table]"
       }
      }
     },
     "localname": "LossContingenciesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LossContingencyClaimsDismissedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of claims dismissed.",
        "label": "Loss Contingency, Claims Dismissed, Number",
        "terseLabel": "Number of claims dismissed"
       }
      }
     },
     "localname": "LossContingencyClaimsDismissedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_LossContingencyEstimateOfPossibleLoss": {
     "auth_ref": [
      "r372",
      "r376",
      "r380"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.",
        "label": "Loss Contingency, Estimate of Possible Loss",
        "terseLabel": "Imposed fine"
       }
      }
     },
     "localname": "LossContingencyEstimateOfPossibleLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyLossInPeriod": {
     "auth_ref": [
      "r369"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.",
        "label": "Loss Contingency, Loss in Period",
        "terseLabel": "Other legal matters, net"
       }
      }
     },
     "localname": "LossContingencyLossInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LossContingencyNatureDomain": {
     "auth_ref": [
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r377",
      "r380",
      "r381"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "An existing condition, situation, or set of circumstances involving uncertainty as to possible loss to an enterprise that will ultimately be resolved when one or more future events occur or fail to occur. Resolution of the uncertainty may confirm the incurrence of a loss or impairment of an asset or the incurrence of a liability.",
        "label": "Loss Contingency, Nature [Domain]",
        "terseLabel": "Loss Contingency, Nature [Domain]"
       }
      }
     },
     "localname": "LossContingencyNatureDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LossContingencyPatentsAllegedlyInfringedNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of another entity's patents that the entity has allegedly infringed.",
        "label": "Loss Contingency, Patents Allegedly Infringed, Number",
        "terseLabel": "Number of patents allegedly infringed"
       }
      }
     },
     "localname": "LossContingencyPatentsAllegedlyInfringedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_MachineryAndEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services, including, but is not limited to, tools, dies and molds, computer and office equipment.",
        "label": "Machinery and Equipment [Member]",
        "terseLabel": "Machinery and equipment [Member]"
       }
      }
     },
     "localname": "MachineryAndEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MarketableSecuritiesTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.",
        "label": "Marketable Securities [Table Text Block]",
        "terseLabel": "Summary of Investments"
       }
      }
     },
     "localname": "MarketableSecuritiesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MaterialReconcilingItemsMember": {
     "auth_ref": [
      "r237",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Items used in reconciling reportable segments' amounts to consolidated amount. Excludes corporate-level activity.",
        "label": "Segment Reconciling Items [Member]",
        "terseLabel": "Segment Reconciling Items [Member]"
       }
      }
     },
     "localname": "MaterialReconcilingItemsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_MinorityInterest": {
     "auth_ref": [
      "r83",
      "r744",
      "r772"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).",
        "label": "Stockholders' Equity Attributable to Noncontrolling Interest",
        "terseLabel": "Equity attributable to noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders": {
     "auth_ref": [
      "r398"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Decrease in noncontrolling interest balance from payment of dividends or other distributions by the non-wholly owned subsidiary or partially owned entity, included in the consolidation of the parent entity, to the noncontrolling interest holders.",
        "label": "Noncontrolling Interest, Decrease from Distributions to Noncontrolling Interest Holders",
        "negatedLabel": "Noncontrolling interests"
       }
      }
     },
     "localname": "MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.",
        "label": "Noncontrolling Interest, Ownership Percentage by Noncontrolling Owners",
        "terseLabel": "Noncontrolling interest, ownership percentage by noncontrolling owners"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByNoncontrollingOwners",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MinorityInterestOwnershipPercentageByParent": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The parent entity's interest in net assets of the subsidiary, expressed as a percentage.",
        "label": "Noncontrolling Interest, Ownership Percentage by Parent",
        "terseLabel": "Noncontrolling interest, ownership percentage by parent"
       }
      }
     },
     "localname": "MinorityInterestOwnershipPercentageByParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r440"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money Market Funds [Member]",
        "terseLabel": "Money market funds [Member]"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash used in financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Financing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r158"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by/(used in) investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Investing Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r158",
      "r162",
      "r165"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash provided by operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Operating Activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r111",
      "r114",
      "r127",
      "r165",
      "r204",
      "r755",
      "r779"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "totalLabel": "Net income attributable to Pfizer Inc."
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r111",
      "r114",
      "r610",
      "r616"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of Net Income (Loss) attributable to noncontrolling interest.",
        "label": "Net Income (Loss) Attributable to Noncontrolling Interest",
        "terseLabel": "Less: Net income attributable to noncontrolling interests"
       }
      }
     },
     "localname": "NetIncomeLossAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r192",
      "r196"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Basic",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": {
     "auth_ref": [
      "r196",
      "r197"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders.",
        "label": "Net Income (Loss) Available to Common Stockholders, Diluted",
        "totalLabel": "Net income attributable to Pfizer Inc. common shareholders and assumed conversions"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetInvestmentHedgingMember": {
     "auth_ref": [
      "r626"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Hedges of a net investment in a foreign operation.",
        "label": "Net Investment Hedging [Member]",
        "terseLabel": "Net Investment Hedging [Member]"
       }
      }
     },
     "localname": "NetInvestmentHedgingMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent": {
     "auth_ref": [
      "r419"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 7.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.",
        "label": "Net Periodic Defined Benefits Expense (Reversal of Expense), Excluding Service Cost Component",
        "terseLabel": "Net periodic benefit costs/(credits) other than service costs"
       }
      }
     },
     "localname": "NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Line Items]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleTable": {
     "auth_ref": [
      "r191",
      "r193"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of the changes in an accounting principle or a new accounting pronouncement, including the line items affected by the change and the financial effects of the change on those particular line items.",
        "label": "New Accounting Pronouncements or Change in Accounting Principle [Table]",
        "terseLabel": "New Accounting Pronouncements or Change in Accounting Principle [Table]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsOrChangeInAccountingPrincipleTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Adoption of New Accounting Standards in 2019"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncontrollingInterestMember": {
     "auth_ref": [
      "r602"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents that portion of equity (net assets) in a subsidiary not attributable, directly or indirectly, to the parent. A noncontrolling interest is sometimes called a minority interest.",
        "label": "Noncontrolling Interest [Member]",
        "terseLabel": "Non-controlling Interests [Member]"
       }
      }
     },
     "localname": "NoncontrollingInterestMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NondesignatedMember": {
     "auth_ref": [
      "r627"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Derivative instrument not designated as hedging instrument under Generally Accepted Accounting Principles (GAAP).",
        "label": "Not Designated as Hedging Instrument [Member]",
        "terseLabel": "Not Designated as Hedging Instrument [Member]"
       }
      }
     },
     "localname": "NondesignatedMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NonqualifiedPlanMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan without tax-exempt status in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Nonqualified Plan [Member]",
        "terseLabel": "Nonqualified Plan [Member]"
       }
      }
     },
     "localname": "NonqualifiedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segments"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingLeaseCost": {
     "auth_ref": [
      "r713",
      "r723"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.",
        "label": "Operating Lease, Cost",
        "terseLabel": "Operating lease cost"
       }
      }
     },
     "localname": "OperatingLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]",
        "terseLabel": "Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r708"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetailsCalc2": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r708"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "terseLabel": "Lease liabilities (short-term)",
        "verboseLabel": "Less: Current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r708"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingLeaseLiability",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "terseLabel": "Lease liabilities (long-term)",
        "verboseLabel": "Noncurrent portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r709",
      "r717"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "terseLabel": "Operating cash flows from operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r707"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "ROU assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r720",
      "r723"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Operating lease weighted-average discount rate"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r719",
      "r723"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Operating leases weighted-average remaining contractual lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDue": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.",
        "label": "Operating Leases, Future Minimum Payments Due",
        "terseLabel": "Future minimum commitment for corporate headquarters lease"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]",
        "terseLabel": "Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments Due, Next Twelve Months",
        "verboseLabel": "2019"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Five Years",
        "verboseLabel": "2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFiveYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Four Years",
        "verboseLabel": "2022"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInFourYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Three Years",
        "verboseLabel": "2021"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInThreeYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due in Two Years",
        "verboseLabel": "2020"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueInTwoYears",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter": {
     "auth_ref": [
      "r702",
      "r704"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.",
        "label": "Operating Leases, Future Minimum Payments, Due Thereafter",
        "terseLabel": "After 2023"
       }
      }
     },
     "localname": "OperatingLeasesFutureMinimumPaymentsDueThereafter",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r703"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Operating leases, rent expense, net"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingSegmentsMember": {
     "auth_ref": [
      "r226",
      "r239"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Operating Segments [Member]",
        "terseLabel": "Operating Segments [Member]"
       }
      }
     },
     "localname": "OperatingSegmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherAggregatedInvestmentsMember": {
     "auth_ref": [
      "r793"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Other investments in debt and equity securities and other forms of securities that provide ownership interests.",
        "label": "Other Security Investments [Member]",
        "terseLabel": "Other [Member]",
        "verboseLabel": "Other Funds [Member]"
       }
      }
     },
     "localname": "OtherAggregatedInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherAssetsCurrent": {
     "auth_ref": [
      "r87"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of current assets classified as other.",
        "label": "Other Assets, Current",
        "terseLabel": "Other current assets"
       }
      }
     },
     "localname": "OtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r67"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "totalLabel": "Total other noncurrent assets",
        "verboseLabel": "Other noncurrent assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r101",
      "r103",
      "r456"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), before Tax",
        "negatedLabel": "Benefit plans: prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Benefit plans: actuarial losses, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r605",
      "r606",
      "r612"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Foreign currency translation income (loss) attributable to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r92",
      "r103",
      "r687",
      "r690",
      "r691"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax": {
     "auth_ref": [
      "r103",
      "r107",
      "r109",
      "r456"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, before Tax",
        "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Reclassification Adjustment from AOCI, Tax",
        "terseLabel": "Reclassification adjustments related to amortization of prior service costs and other, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax": {
     "auth_ref": [
      "r96",
      "r97",
      "r103"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Adjustment, before Tax",
        "totalLabel": "Other comprehensive income (loss), available-for-sale securities adjustment, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax": {
     "auth_ref": [
      "r96",
      "r97",
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-sale, Tax",
        "totalLabel": "Other comprehensive income (loss), available-for-sale securities, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossBeforeTax": {
     "auth_ref": [
      "r281"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), before Tax",
        "totalLabel": "Other comprehensive income/(loss), before tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax": {
     "auth_ref": [
      "r94",
      "r103"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and after reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, before Tax",
        "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), after Reclassification, Tax",
        "totalLabel": "Other comprehensive income (loss), derivatives qualifying as hedges, tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r94",
      "r103",
      "r632",
      "r637",
      "r661"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net",
        "verboseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), before Reclassification, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on derivative financial instruments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r103",
      "r107",
      "r639"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, before Tax",
        "negatedLabel": "Reclassification adjustments for (gains)/losses included in net income",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.",
        "label": "Other Comprehensive Income (Loss), Cash Flow Hedge, Gain (Loss), Reclassification, Tax",
        "negatedLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax": {
     "auth_ref": [
      "r95",
      "r103",
      "r107",
      "r640"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), Adjustments, before Tax",
        "terseLabel": "Amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax": {
     "auth_ref": [
      "r95",
      "r103",
      "r638",
      "r646",
      "r661"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.",
        "label": "Other Comprehensive Income (Loss), Derivative, Excluded Component, Increase (Decrease), before Adjustments and Tax",
        "terseLabel": "Amount excluded from effectiveness testing"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax": {
     "auth_ref": [
      "r92",
      "r103",
      "r687",
      "r693"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, before Tax",
        "terseLabel": "Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax",
        "totalLabel": "Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax, total"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax": {
     "auth_ref": [
      "r92",
      "r692"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax",
        "terseLabel": "Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax": {
     "auth_ref": [
      "r103",
      "r107",
      "r108",
      "r109",
      "r694"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for translation gain (loss) realized upon the sale or liquidation of an investment in a foreign entity and foreign currency hedges that are designated and qualified as hedging instruments for hedges of the foreign currency exposure of a net investment in a foreign operation.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Reclassification Adjustment from AOCI, Realized upon Sale or Liquidation, before Tax",
        "negatedTerseLabel": "Reclassification adjustments"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax": {
     "auth_ref": [
      "r92",
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Tax",
        "terseLabel": "Foreign currency translation adjustments, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax": {
     "auth_ref": [
      "r644"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), before Reclassification and Tax",
        "terseLabel": "Amount of Gains/(Losses) Recognized in OCI"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax": {
     "auth_ref": [
      "r645"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.",
        "label": "Other Comprehensive Income (Loss), Net Investment Hedge, Gain (Loss), Reclassification, before Tax",
        "terseLabel": "Amount of Gains/(Losses) Reclassified from OCI into OID and COS"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r112",
      "r115",
      "r118",
      "r391"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax and reclassification adjustments of other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Net of Tax",
        "terseLabel": "Other comprehensive income/(loss), net of tax",
        "totalLabel": "Other comprehensive income/(loss) before allocation to noncontrolling interests"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "auth_ref": [
      "r112",
      "r115",
      "r605",
      "r606",
      "r612"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity.",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "verboseLabel": "Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax": {
     "auth_ref": [
      "r100",
      "r103"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, before Tax",
        "terseLabel": "(Income)/cost reported in Other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect": {
     "auth_ref": [
      "r104",
      "r605"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).",
        "label": "Other Comprehensive (Income) Loss, Defined Benefit Plan, Prior Service Cost (Credit), Tax",
        "negatedTotalLabel": "Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r99",
      "r103",
      "r456"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of gain (loss) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Benefit plans: actuarial losses, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax": {
     "auth_ref": [
      "r103",
      "r107",
      "r109",
      "r275"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, before Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax": {
     "auth_ref": [
      "r104",
      "r275"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI for Sale of Securities, Tax",
        "negatedTerseLabel": "Reclassification adjustments for (gains)/losses included in net income"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax": {
     "auth_ref": [
      "r103",
      "r107",
      "r109",
      "r456"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, before tax, of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, before Tax",
        "negatedLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax": {
     "auth_ref": [
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 2.0,
       "parentTag": "pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.",
        "label": "Other Comprehensive Income (Loss), Defined Benefit Plan, Gain (Loss), Reclassification Adjustment from AOCI, Tax",
        "negatedTerseLabel": "Reclassification adjustments related to amortization"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTax": {
     "auth_ref": [
      "r104",
      "r576",
      "r578"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTax",
       "weight": -1.0
      },
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) allocated to other comprehensive income (loss).",
        "label": "Other Comprehensive Income (Loss), Tax",
        "terseLabel": "Tax provision/(benefit) on other comprehensive income/(loss)",
        "totalLabel": "Tax provision/(benefit) on other comprehensive income/(loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossTaxAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Tax [Abstract]",
        "terseLabel": "Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossTaxAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax": {
     "auth_ref": [
      "r96",
      "r103",
      "r275"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before tax and reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, before Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r97",
      "r104"
     ],
     "calculation": {
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Unrealized holding gains/(losses) on available-for-sale securities, net"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentAssetsMember": {
     "auth_ref": [
      "r629",
      "r660"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current assets.",
        "label": "Other Current Assets [Member]",
        "terseLabel": "Other Current Assets [Member]"
       }
      }
     },
     "localname": "OtherCurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other current liabilities.",
        "label": "Other Current Liabilities [Member]",
        "terseLabel": "Other current liabilities [Member]",
        "verboseLabel": "Other Current Liabilities [Member]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherIncomeAndExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Other Income and Expenses [Abstract]"
       }
      }
     },
     "localname": "OtherIncomeAndExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock": {
     "auth_ref": [
      "r414",
      "r537"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.",
        "label": "Other Income and Other Expense Disclosure [Text Block]",
        "terseLabel": "Other (Income)/Deductions - Net"
       }
      }
     },
     "localname": "OtherIncomeAndOtherExpenseDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherInvestmentsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other investments.",
        "label": "Other Investments [Member]",
        "terseLabel": "Other Investments [Member]"
       }
      }
     },
     "localname": "OtherInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r28",
      "r75"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 6.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "terseLabel": "Other current liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r79"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 7.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other noncurrent liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLongTermDebt": {
     "auth_ref": [
      "r40",
      "r743",
      "r770"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LongTermDebtNoncurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of long-term debt classified as other.",
        "label": "Other Long-term Debt",
        "terseLabel": "Other long-term debt"
       }
      }
     },
     "localname": "OtherLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncashIncomeExpense": {
     "auth_ref": [
      "r165"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.",
        "label": "Other Noncash Income (Expense)",
        "negatedTerseLabel": "Other adjustments, net"
       }
      }
     },
     "localname": "OtherNoncashIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNoncurrentAssetsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent assets.",
        "label": "Other Noncurrent Assets [Member]",
        "terseLabel": "Other Noncurrent Assets [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentAssetsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNoncurrentLiabilitiesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other noncurrent liabilities.",
        "label": "Other Noncurrent Liabilities [Member]",
        "terseLabel": "Other Noncurrent Liabilities [Member]",
        "verboseLabel": "Other noncurrent liabilities [Member]"
       }
      }
     },
     "localname": "OtherNoncurrentLiabilitiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r138"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 8.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "negatedLabel": "Other (income)/deductions\u2013\u2013net",
        "negatedTotalLabel": "Other (income)/deductions\u2013\u2013net",
        "terseLabel": "Other income/(deductions)\u2014net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing other nonoperating income (expense).",
        "label": "Other Nonoperating Income (Expense) [Member]",
        "terseLabel": "Other Nonoperating Income (Expense) [Member]"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherOperatingIncomeExpenseNet": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.",
        "label": "Other Operating Income (Expense), Net",
        "negatedTerseLabel": "Other income (charges)"
       }
      }
     },
     "localname": "OtherOperatingIncomeExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember": {
     "auth_ref": [
      "r416",
      "r468",
      "r469",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide other postretirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes pension benefits.",
        "label": "Other Postretirement Benefits Plan [Member]",
        "terseLabel": "Postretirement Benefits Plan [Member]"
       }
      }
     },
     "localname": "OtherPostretirementBenefitPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41",
      "r417",
      "r418",
      "r437"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.",
        "label": "Liability, Other Postretirement Defined Benefit Plan, Noncurrent",
        "terseLabel": "Postretirement benefit obligations, net"
       }
      }
     },
     "localname": "OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherRestructuringMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Restructuring and related activities classified as other.",
        "label": "Other Restructuring [Member]",
        "terseLabel": "Exit Costs [Member]"
       }
      }
     },
     "localname": "OtherRestructuringMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_OtherShortTermBorrowings": {
     "auth_ref": [
      "r68"
     ],
     "calculation": {
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails": {
       "order": 3.0,
       "parentTag": "pfe_ShorttermDebtGross",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of borrowings classified as other, maturing within one year or the normal operating cycle, if longer.",
        "label": "Other Short-term Borrowings",
        "terseLabel": "Other short-term borrowings"
       }
      }
     },
     "localname": "OtherShortTermBorrowings",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ParentMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Portion of equity, or net assets, in the consolidated entity attributable, directly or indirectly, to the parent. Excludes noncontrolling interests.",
        "label": "Parent [Member]",
        "terseLabel": "Shareholders\u2019 Equity"
       }
      }
     },
     "localname": "ParentMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities": {
     "auth_ref": [
      "r148"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.",
        "label": "Payment for Contingent Consideration Liability, Investing Activities",
        "terseLabel": "Milestone payment",
        "verboseLabel": "Contingent consideration paid"
       }
      }
     },
     "localname": "PaymentForContingentConsiderationLiabilityInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromOtherInvestingActivities": {
     "auth_ref": [
      "r144",
      "r149",
      "r189"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash (inflow) outflow from investing activities classified as other.",
        "label": "Payments for (Proceeds from) Other Investing Activities",
        "negatedLabel": "Other investing activities, net"
       }
      }
     },
     "localname": "PaymentsForProceedsFromOtherInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForProceedsFromShortTermInvestments": {
     "auth_ref": [
      "r142",
      "r145",
      "r167"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments for (Proceeds from) Short-term Investments",
        "negatedLabel": "Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less"
       }
      }
     },
     "localname": "PaymentsForProceedsFromShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to reacquire common stock during the period.",
        "label": "Payments for Repurchase of Common Stock",
        "negatedLabel": "Purchases of common stock"
       }
      }
     },
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfOrdinaryDividends": {
     "auth_ref": [
      "r153"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.",
        "label": "Payments of Ordinary Dividends",
        "negatedLabel": "Cash dividends paid"
       }
      }
     },
     "localname": "PaymentsOfOrdinaryDividends",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesGross": {
     "auth_ref": [
      "r146",
      "r598"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.",
        "label": "Payments to Acquire Businesses, Gross",
        "verboseLabel": "Payments to acquire businesses, cash portion"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired": {
     "auth_ref": [
      "r146"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.",
        "label": "Payments to Acquire Businesses, Net of Cash Acquired",
        "negatedLabel": "Acquisitions of businesses, net of cash acquired",
        "terseLabel": "Cash payments for acquisition, net of cash acquired"
       }
      }
     },
     "localname": "PaymentsToAcquireBusinessesNetOfCashAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireIntangibleAssets": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.",
        "label": "Payments to Acquire Intangible Assets",
        "negatedTerseLabel": "Acquisitions of intangible assets"
       }
      }
     },
     "localname": "PaymentsToAcquireIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r258"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of long-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireProductiveAssets": {
     "auth_ref": [
      "r147"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.",
        "label": "Payments to Acquire Productive Assets",
        "terseLabel": "Payments to asset acquisition"
       }
      }
     },
     "localname": "PaymentsToAcquireProductiveAssets",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r147"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property, plant and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireShortTermInvestments": {
     "auth_ref": [
      "r149"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Payments to Acquire Short-term Investments",
        "negatedLabel": "Purchases of short-term investments"
       }
      }
     },
     "localname": "PaymentsToAcquireShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PendingLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Risk of loss associated with the outcome of pending litigation against the entity, for example, but not limited to, litigation in arbitration or within the trial process.",
        "label": "Pending Litigation [Member]",
        "terseLabel": "Pending Litigation [Member]"
       }
      }
     },
     "localname": "PendingLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r488"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for pension and other postretirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Pension and Postretirement Benefit Plans and Defined Contribution Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities": {
     "auth_ref": [
      "r39",
      "r417",
      "r418",
      "r437"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as current.",
        "label": "Liability, Defined Benefit Plan, Current",
        "negatedLabel": "Current liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent": {
     "auth_ref": [
      "r41",
      "r417",
      "r418",
      "r437"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DefinedBenefitPlanAmountsRecognizedInBalanceSheet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of liability, recognized in statement of financial position, for defined benefit pension and other postretirement plans, classified as noncurrent.",
        "label": "Liability, Defined Benefit Plan, Noncurrent",
        "negatedLabel": "Noncurrent liabilities"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementPlansPolicy": {
     "auth_ref": [
      "r174",
      "r468",
      "r483",
      "r484",
      "r486",
      "r487"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.",
        "label": "Pension and Other Postretirement Plans, Policy [Policy Text Block]",
        "terseLabel": "Pension and Postretirement Benefit Plans"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementPlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PensionPlansDefinedBenefitMember": {
     "auth_ref": [
      "r415",
      "r468",
      "r469",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide participant with pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans. Excludes other postretirement benefits.",
        "label": "Pension Plan [Member]",
        "terseLabel": "Pension Plan [Member]"
       }
      }
     },
     "localname": "PensionPlansDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]",
        "terseLabel": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanAssetCategoriesDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Defined benefit plan asset investment.",
        "label": "Defined Benefit Plan, Plan Assets, Category [Domain]",
        "terseLabel": "Defined Benefit Plan, Plan Assets, Category [Domain]"
       }
      }
     },
     "localname": "PlanAssetCategoriesDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r492",
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]",
        "terseLabel": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]",
        "terseLabel": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r676"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]",
        "terseLabel": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockDividendRatePercentage": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The percentage rate used to calculate dividend payments on preferred stock.",
        "label": "Preferred Stock, Dividend Rate, Percentage",
        "terseLabel": "Series A convertible perpetual preferred stock, dividends rate"
       }
      }
     },
     "localname": "PreferredStockDividendRatePercentage",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_PreferredStockDividendsIncomeStatementImpact": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 2.0,
       "parentTag": "pfe_IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of preferred stock dividends that is an adjustment to net income apportioned to common stockholders.",
        "label": "Preferred Stock Dividends, Income Statement Impact",
        "terseLabel": "Less: Preferred stock dividends\u2013\u2013net of tax"
       }
      }
     },
     "localname": "PreferredStockDividendsIncomeStatementImpact",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company.",
        "label": "Preferred Stock [Member]",
        "verboseLabel": "Preferred Stock [Member]"
       }
      }
     },
     "localname": "PreferredStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Series A convertible perpetual preferred stock, per share stated value (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockRedemptionPricePerShare": {
     "auth_ref": [
      "r390",
      "r392",
      "r393"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The price per share at which the preferred stock of an entity that has priority over common stock in the distribution of dividends and in the event of liquidation of the entity is redeemed or may be called at. The redemption features of this preferred stock are solely within the control of the issuer.",
        "label": "Preferred Stock, Redemption Price Per Share",
        "terseLabel": "Preferred stock, redemption price per share (in dollars per share)"
       }
      }
     },
     "localname": "PreferredStockRedemptionPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r45"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "terseLabel": "Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2019\u2014431; 2018\u2014478"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromCollaborators": {
     "auth_ref": [
      "r159"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received from collaborators during the current period.",
        "label": "Proceeds from Collaborators",
        "terseLabel": "Proceeds received from upfront payments and milestone payments"
       }
      }
     },
     "localname": "ProceedsFromCollaborators",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromDivestitureOfBusinesses": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.",
        "label": "Proceeds from Divestiture of Businesses",
        "terseLabel": "Cash proceeds from disposal"
       }
      }
     },
     "localname": "ProceedsFromDivestitureOfBusinesses",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.",
        "label": "Proceeds from Issuance of Long-term Debt",
        "terseLabel": "Proceeds from issuance of long-term debt"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromLegalSettlements": {
     "auth_ref": [
      "r160"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Cash received for the settlement of litigation during the current period.",
        "label": "Proceeds from Legal Settlements",
        "terseLabel": "Proceeds from legal settlements"
       }
      }
     },
     "localname": "ProceedsFromLegalSettlements",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromPaymentsForOtherFinancingActivities": {
     "auth_ref": [
      "r152",
      "r155",
      "r189"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities classified as other.",
        "label": "Proceeds from (Payments for) Other Financing Activities",
        "terseLabel": "Other financing activities, net"
       }
      }
     },
     "localname": "ProceedsFromPaymentsForOtherFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess": {
     "auth_ref": [
      "r151",
      "r154",
      "r168"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.",
        "label": "Proceeds from (Repayments of) Short-term Debt, Maturing in Three Months or Less",
        "terseLabel": "Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.",
        "label": "Proceeds from Sale, Maturity and Collection of Long-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of long-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments": {
     "auth_ref": [
      "r144"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.",
        "label": "Proceeds from Sale, Maturity and Collection of Short-term Investments",
        "terseLabel": "Proceeds from redemptions/sales of short-term investments"
       }
      }
     },
     "localname": "ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "auth_ref": [
      "r141",
      "r142",
      "r258"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Proceeds from Sale of Debt Securities, Available-for-sale",
        "terseLabel": "Proceeds from sale of available-for-sale debt securities"
       }
      }
     },
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfEquityMethodInvestments": {
     "auth_ref": [
      "r143"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.",
        "label": "Proceeds from Sale of Equity Method Investments",
        "terseLabel": "Proceeds from sale of equity method investments"
       }
      }
     },
     "localname": "ProceedsFromSaleOfEquityMethodInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromShortTermDebt": {
     "auth_ref": [
      "r151"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Proceeds from Short-term Debt",
        "terseLabel": "Proceeds from short-term borrowings"
       }
      }
     },
     "localname": "ProceedsFromShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r150",
      "r527"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Cash received upon exercise",
        "verboseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProductConcentrationRiskMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Reflects the percentage that revenues during the period from a specified product are to a specified benchmark, such as total net revenues, segment revenues or product line revenues. May also reflect the percentage contribution the product made to operating results. Risk is materially adverse effects of a loss of sales of a significant product or line of products, which could occur upon loss of rights to sell, distribute or license others; loss of patent or copyright protection; or technological obsolescence.",
        "label": "Product Concentration Risk [Member]",
        "terseLabel": "Product Concentration Risk [Member]"
       }
      }
     },
     "localname": "ProductConcentrationRiskMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProductMember": {
     "auth_ref": [
      "r408"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Article or substance produced by nature, labor or machinery.",
        "label": "Product [Member]",
        "terseLabel": "Product [Member]"
       }
      }
     },
     "localname": "ProductMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r111",
      "r114",
      "r157",
      "r232",
      "r240",
      "r605",
      "r609",
      "r611",
      "r616",
      "r617"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net income before allocation to noncontrolling interests",
        "totalLabel": "Net income before allocation to noncontrolling interests",
        "verboseLabel": "Net income"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r66",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]",
        "terseLabel": "Property, Plant and Equipment by Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r351"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "verboseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipment"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r65",
      "r341"
     ],
     "calculation": {
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Total property, plant and equipment before accumulated depreciation"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentImpairment": {
     "auth_ref": [
      "r174",
      "r344"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.",
        "label": "Property, Plant and Equipment, Impairment [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment, Impairment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentImpairment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, Plant and Equipment [Line Items]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r33",
      "r34",
      "r343",
      "r774"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property, plant and equipment, less accumulated depreciation",
        "totalLabel": "Property, plant and equipment",
        "verboseLabel": "Property, plant and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r64",
      "r174",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r33",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Schedule of Components of Property, Plant and Equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r33",
      "r341"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]",
        "terseLabel": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "Property, Plant and Equipment, Useful Life",
        "terseLabel": "Useful lives (years)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_QualifiedPlanMember": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan with tax-exempt status designed and operated in accordance with applicable tax provision of designated taxing authority. Taxing authority includes, but is not limited to, U.S. Internal Revenue Service (IRS). Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Qualified Plan [Member]",
        "terseLabel": "Qualified Plan [Member]"
       }
      }
     },
     "localname": "QualifiedPlanMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ReceivablesPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r251",
      "r254",
      "r255",
      "r256"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.",
        "label": "Receivable [Policy Text Block]",
        "terseLabel": "Trade Accounts Receivable"
       }
      }
     },
     "localname": "ReceivablesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]",
        "terseLabel": "Reclassification Adjustment out of Accumulated Other Comprehensive Income on Derivatives [Line Items]"
       }
      }
     },
     "localname": "ReclassificationAdjustmentOutOfAccumulatedOtherComprehensiveIncomeOnDerivativesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about items reclassified out of accumulated other comprehensive income (loss).",
        "label": "Reclassification out of Accumulated Other Comprehensive Income [Table]",
        "terseLabel": "Reclassification out of Accumulated Other Comprehensive Income [Table]"
       }
      }
     },
     "localname": "ReclassificationOutOfAccumulatedOtherComprehensiveIncomeTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r236",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.",
        "label": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Operating Profit (Loss) from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock": {
     "auth_ref": [
      "r235",
      "r238"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.",
        "label": "Reconciliation of Revenue from Segments to Consolidated [Table Text Block]",
        "terseLabel": "Reconciliation of Revenue from Segments to Consolidated"
       }
      }
     },
     "localname": "ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]",
        "terseLabel": "Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]"
       }
      }
     },
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.",
        "label": "Repayments of Long-term Debt",
        "negatedLabel": "Principal payments on long-term debt"
       }
      }
     },
     "localname": "RepaymentsOfLongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RepaymentsOfShortTermDebt": {
     "auth_ref": [
      "r154"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.",
        "label": "Repayments of Short-term Debt",
        "negatedTerseLabel": "Principal payments on short-term borrowings"
       }
      }
     },
     "localname": "RepaymentsOfShortTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ReportingUnitAxis": {
     "auth_ref": [
      "r313",
      "r314"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by reporting unit.",
        "label": "Reporting Unit [Axis]",
        "terseLabel": "Reporting Unit [Axis]"
       }
      }
     },
     "localname": "ReportingUnitAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ReportingUnitDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Level of reporting at which goodwill is tested for impairment.",
        "label": "Reporting Unit [Domain]",
        "terseLabel": "Reporting Unit [Domain]"
       }
      }
     },
     "localname": "ReportingUnitDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff": {
     "auth_ref": [
      "r321"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.",
        "label": "Research and Development Asset Acquired Other than Through Business Combination, Written-off",
        "terseLabel": "Charge to research and development expenses in connection with asset acquisition"
       }
      }
     },
     "localname": "ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost": {
     "auth_ref": [
      "r538"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 4.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.",
        "label": "Research and Development Expense (Excluding Acquired in Process Cost)",
        "terseLabel": "Research and development expenses",
        "verboseLabel": "Research and development expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]",
        "terseLabel": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r174",
      "r538"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Expenses"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "terseLabel": "Restricted Stock Units (RSUs) [Member]",
        "verboseLabel": "Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "auth_ref": [
      "r367"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "terseLabel": "Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestructuringAndRelatedCostCostIncurredToDate1": {
     "auth_ref": [
      "r353",
      "r355",
      "r362",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of costs incurred to date for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Cost Incurred to Date",
        "terseLabel": "Restructuring cost incurred to date"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostCostIncurredToDate1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostExpectedCost1": {
     "auth_ref": [
      "r353",
      "r355",
      "r362",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount expected to be recognized in earnings for the specified restructuring cost.",
        "label": "Restructuring and Related Cost, Expected Cost",
        "terseLabel": "Expected cost"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostExpectedCost1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringAndRelatedCostIncurredCost": {
     "auth_ref": [
      "r353",
      "r355",
      "r362",
      "r365"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Discloses the amount charged against the accrued restructuring reserves, or earnings if not previously accrued, during the period for the specified type of restructuring cost.",
        "label": "Restructuring and Related Cost, Incurred Cost",
        "terseLabel": "Restructuring charges incurred"
       }
      }
     },
     "localname": "RestructuringAndRelatedCostIncurredCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringCharges": {
     "auth_ref": [
      "r164",
      "r352",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAndAcquisitionRelatedCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.",
        "label": "Restructuring Charges",
        "terseLabel": "Restructuring charge (credit)",
        "totalLabel": "Total restructuring charges/(credits)",
        "verboseLabel": "Provision"
       }
      }
     },
     "localname": "RestructuringCharges",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Restructuring Charges [Abstract]",
        "terseLabel": "Restructuring charges:"
       }
      }
     },
     "localname": "RestructuringChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of restructuring cost.",
        "label": "Restructuring Type [Axis]",
        "terseLabel": "Restructuring Type [Axis]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "terseLabel": "Restructuring Cost and Reserve [Line Items]"
       }
      }
     },
     "localname": "RestructuringCostAndReserveLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by individual restructuring plan.",
        "label": "Restructuring Plan [Axis]",
        "terseLabel": "Restructuring Plan [Axis]"
       }
      }
     },
     "localname": "RestructuringPlanAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestructuringPlanDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the individual restructuring plans.",
        "label": "Restructuring Plan [Domain]",
        "terseLabel": "Restructuring Plan [Domain]"
       }
      }
     },
     "localname": "RestructuringPlanDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RestructuringReserve": {
     "auth_ref": [
      "r354",
      "r360"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.",
        "label": "Restructuring Reserve",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "terseLabel": "Restructuring reserve"
       }
      }
     },
     "localname": "RestructuringReserve",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveAcceleratedDepreciation": {
     "auth_ref": [],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 3.0,
       "parentTag": "pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.",
        "label": "Restructuring and Related Cost, Accelerated Depreciation",
        "terseLabel": "Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales"
       }
      }
     },
     "localname": "RestructuringReserveAcceleratedDepreciation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestructuringReserveRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Restructuring Reserve [Roll Forward]",
        "terseLabel": "Restructuring Reserve [Roll Forward]"
       }
      }
     },
     "localname": "RestructuringReserveRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r49",
      "r398",
      "r771"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Retained earnings"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]",
        "terseLabel": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationAxis": {
     "auth_ref": [
      "r469",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Axis]",
        "terseLabel": "Retirement Plan Sponsor Location [Axis]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanSponsorLocationDomain": {
     "auth_ref": [
      "r469",
      "r473"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Location of employer sponsoring plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Sponsor Location [Domain]",
        "terseLabel": "Retirement Plan Sponsor Location [Domain]"
       }
      }
     },
     "localname": "RetirementPlanSponsorLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTaxStatusAxis": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Tax Status [Axis]",
        "terseLabel": "Retirement Plan Tax Status [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTaxStatusAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTaxStatusDomain": {
     "auth_ref": [
      "r469"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tax status of plan designed to provide retirement benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Retirement Plan Tax Status [Domain]",
        "terseLabel": "Retirement Plan Tax Status [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTaxStatusDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetirementPlanTypeAxis": {
     "auth_ref": [
      "r415",
      "r416",
      "r468",
      "r469",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of retirement benefit plan. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Axis]",
        "terseLabel": "Retirement Plan Type [Axis]"
       }
      }
     },
     "localname": "RetirementPlanTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RetirementPlanTypeDomain": {
     "auth_ref": [
      "r415",
      "r416",
      "r468",
      "r469",
      "r486"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of plan designed to provide participants with retirement benefits. Includes, but is not limited to, retirement benefit arrangement for defined benefit pension and other postretirement plans, retirement benefit arrangement for defined contribution pension and other postretirement plans, and special and contractual termination benefits payable upon retirement.",
        "label": "Retirement Plan Type [Domain]",
        "terseLabel": "Retirement Plan Type [Domain]"
       }
      }
     },
     "localname": "RetirementPlanTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "auth_ref": [
      "r405",
      "r406"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "terseLabel": "Revenues"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "auth_ref": [
      "r219"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation.",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "terseLabel": "Revenue [Member]"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r175",
      "r413"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue and Collaborative Arrangements"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock": {
     "auth_ref": [
      "r243"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.",
        "label": "Revenue from External Customers by Geographic Areas [Table Text Block]",
        "terseLabel": "Revenue from External Customers by Geographic Areas"
       }
      }
     },
     "localname": "RevenueFromExternalCustomersByGeographicAreasTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]"
       }
      }
     },
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r718",
      "r723"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "ROU assets obtained in exchange for new operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RoyaltyIncomeNonoperating": {
     "auth_ref": [
      "r137"
     ],
     "calculation": {
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherNonoperatingIncomeExpense",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.",
        "label": "Royalty Income, Nonoperating",
        "negatedLabel": "Royalty-related income"
       }
      }
     },
     "localname": "RoyaltyIncomeNonoperating",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleAndLeasebackTransactionGainLossNet": {
     "auth_ref": [
      "r716",
      "r723",
      "r724"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.",
        "label": "Sale and Leaseback Transaction, Gain (Loss), Net",
        "terseLabel": "(Gains)/losses on sale and leaseback transactions, net"
       }
      }
     },
     "localname": "SaleAndLeasebackTransactionGainLossNet",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SalesMember": {
     "auth_ref": [
      "r649"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing revenue from sale of goods and services rendered in the normal course of business.",
        "label": "Sales [Member]",
        "terseLabel": "Sales [Member]"
       }
      }
     },
     "localname": "SalesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SalesRevenueProductLineMember": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Revenue from specified product or service, when it serves as benchmark in concentration of risk calculation. Includes, but is not limited to, revenue from contract with customer and other sources.",
        "label": "Revenue, Product and Service Benchmark [Member]",
        "terseLabel": "Revenue [Member]"
       }
      }
     },
     "localname": "SalesRevenueProductLineMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Information About Balance Sheet Classification of Accruals"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r470",
      "r471",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Accumulated Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [
      "r106"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss).",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax"
       }
      }
     },
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r438"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.",
        "label": "Schedule of Allocation of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Allocation of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfAllocationOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock": {
     "auth_ref": [
      "r467"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year, including the net gain (loss), net prior service cost or credit, and net transition asset or obligation.",
        "label": "Schedule of Amounts in Accumulated Other Comprehensive Income (Loss) to be Recognized over Next Fiscal Year [Table Text Block]",
        "terseLabel": "Schedule of Amounts in Accumulated Other Comprehensive Income/(Loss) Expected to be Amortized into 2014 Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock": {
     "auth_ref": [
      "r437"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.",
        "label": "Schedule of Amounts Recognized in Balance Sheet [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Balance Sheet"
       }
      }
     },
     "localname": "ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r203"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]",
        "terseLabel": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAssumptionsUsedTableTextBlock": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.",
        "label": "Defined Benefit Plan, Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Assumptions Used"
       }
      }
     },
     "localname": "ScheduleOfAssumptionsUsedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Available-for-sale Securities Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r470",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.",
        "label": "Defined Benefit Plan, Plan with Projected Benefit Obligation in Excess of Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable": {
     "auth_ref": [
      "r584",
      "r585"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting each material business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities.",
        "label": "Schedule of Business Acquisitions, by Acquisition [Table]",
        "terseLabel": "Schedule of Business Acquisitions, by Acquisition [Table]"
       }
      }
     },
     "localname": "ScheduleOfBusinessAcquisitionsByAcquisitionTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.",
        "label": "Schedule of Carrying Values and Estimated Fair Values of Debt Instruments [Table Text Block]",
        "terseLabel": "Financial Liabilities Not Measured at Fair Value on a Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r637"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Cash Flow Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges"
       }
      }
     },
     "localname": "ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Table]"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Table Text Block]",
        "terseLabel": "Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions"
       }
      }
     },
     "localname": "ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "auth_ref": [
      "r570"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "terseLabel": "Schedule of Provision for Taxes on Income"
       }
      }
     },
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "auth_ref": [
      "r78",
      "r179",
      "r392",
      "r395",
      "r396",
      "r397",
      "r698",
      "r699",
      "r701",
      "r762"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.",
        "label": "Schedule of Long-term Debt Instruments [Table Text Block]",
        "terseLabel": "Schedule of Long-term Debt Instruments"
       }
      }
     },
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r564"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Schedule of Deferred Tax Assets and Liabilities"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.",
        "label": "Schedule of Defined Benefit Plan Amounts Recognized in Other Comprehensive Income (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Net Periodic Benefit Costs"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDefinedBenefitPlansDisclosuresTable": {
     "auth_ref": [
      "r468",
      "r469",
      "r472",
      "r473",
      "r482"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosures about an individual defined benefit pension plan or an other postretirement defined benefit plan. It may be appropriate to group certain similar plans.  Also includes schedule for fair value of plan assets by major categories of plan assets by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets or liabilities (Level 1), Significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Defined Benefit Plans Disclosures [Table]",
        "terseLabel": "Schedule of Defined Benefit Plans Disclosures [Table]"
       }
      }
     },
     "localname": "ScheduleOfDefinedBenefitPlansDisclosuresTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of derivative assets at fair value.",
        "label": "Schedule of Derivative Assets at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Assets at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeAssetsAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock": {
     "auth_ref": [
      "r630",
      "r642",
      "r651"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.",
        "label": "Derivative Instruments, Gain (Loss) [Table Text Block]",
        "terseLabel": "Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeInstrumentsTextBlock": {
     "auth_ref": [
      "r185",
      "r621",
      "r623",
      "r624",
      "r627",
      "r628",
      "r635",
      "r642",
      "r657",
      "r659"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.",
        "label": "Schedule of Derivative Instruments [Table Text Block]",
        "terseLabel": "Schedule of Derivative Financial Instruments"
       }
      }
     },
     "localname": "ScheduleOfDerivativeInstrumentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of derivative liabilities at fair value.",
        "label": "Schedule of Derivative Liabilities at Fair Value [Table Text Block]",
        "terseLabel": "Schedule of Derivative Liabilities at Fair Value"
       }
      }
     },
     "localname": "ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock": {
     "auth_ref": [
      "r1",
      "r8",
      "r9",
      "r10",
      "r11",
      "r12",
      "r13",
      "r16",
      "r19",
      "r20",
      "r21",
      "r349",
      "r350"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.",
        "label": "Disposal Groups, Including Discontinued Operations [Table Text Block]",
        "terseLabel": "Summary of Assets and Liabilities Held For Sale"
       }
      }
     },
     "localname": "ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "auth_ref": [
      "r204"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "terseLabel": "Schedule of Basic and Diluted Earning Per Share"
       }
      }
     },
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r464"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effect of a one-percentage-point increase and the effect of a one-percentage-point decrease in the assumed health care cost trend rates on the aggregate of the service and interest cost components of net periodic postretirement health care benefit costs and the accumulated postretirement benefit obligation for health care benefits.",
        "label": "Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates"
       }
      }
     },
     "localname": "ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock": {
     "auth_ref": [
      "r442"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.",
        "label": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets [Table Text Block]",
        "terseLabel": "Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets"
       }
      }
     },
     "localname": "ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r548"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of Effective Income Tax Rate Reconciliation"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r490",
      "r522",
      "r529"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "terseLabel": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular presentation of the description and amount of revenues from a product or service, or a group of similar products or similar services, reported from external customers during the period, if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table]",
        "terseLabel": "Revenue from External Customers by Products and Services [Table]"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock": {
     "auth_ref": [
      "r242"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.",
        "label": "Revenue from External Customers by Products and Services [Table Text Block]",
        "terseLabel": "Schedule of Significant Product Revenues"
       }
      }
     },
     "localname": "ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "terseLabel": "Schedule of Equity Method Investments [Line Items]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "auth_ref": [
      "r286"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Summarization of information required and determined to be disclosed concerning equity method investments in common stock. The summarized information includes: (a) the name of each investee or group of investees for which combined disclosure is appropriate, (2) the percentage ownership of common stock, (3) the difference, if any, between the carrying amount of an investment and the value of the underlying equity in the net assets and the accounting treatment of difference, if any, and (4) the aggregate value of each identified investment based on its quoted market price, if available.",
        "label": "Schedule of Equity Method Investments [Table]",
        "terseLabel": "Schedule of Equity Method Investments [Table]"
       }
      }
     },
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock": {
     "auth_ref": [
      "r447"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.",
        "label": "Schedule of Expected Benefit Payments [Table Text Block]",
        "terseLabel": "Schedule of Expected Future Cash Flow Information"
       }
      }
     },
     "localname": "ScheduleOfExpectedBenefitPaymentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "auth_ref": [
      "r665",
      "r666"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis"
       }
      }
     },
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock": {
     "auth_ref": [
      "r636"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.",
        "label": "Schedule of Fair Value Hedging Instruments, Statements of Financial Performance and Financial Position, Location [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges"
       }
      }
     },
     "localname": "ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r318",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r318",
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.",
        "label": "Schedule of Finite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Finite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock": {
     "auth_ref": [
      "r705"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.",
        "label": "Schedule of Future Minimum Rental Payments for Operating Leases [Table Text Block]",
        "terseLabel": "Schedule of Future Minimum Rental Payments for Operating Leases"
       }
      }
     },
     "localname": "ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfGoodwillTable": {
     "auth_ref": [
      "r312",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of goodwill and the changes during the year due to acquisition, sale, impairment or for other reasons.",
        "label": "Schedule of Goodwill [Table]",
        "terseLabel": "Schedule of Goodwill [Table]"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfGoodwillTextBlock": {
     "auth_ref": [
      "r312",
      "r315"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.",
        "label": "Schedule of Goodwill [Table Text Block]",
        "terseLabel": "Schedule of Goodwill"
       }
      }
     },
     "localname": "ScheduleOfGoodwillTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock": {
     "auth_ref": [
      "r463"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.",
        "label": "Schedule of Health Care Cost Trend Rates [Table Text Block]",
        "terseLabel": "Schedule of Health Care Cost Trend Rates"
       }
      }
     },
     "localname": "ScheduleOfHealthCareCostTrendRatesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfImpairedIntangibleAssetsTextBlock": {
     "auth_ref": [
      "r333"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of impaired intangible assets excluding goodwill. This may include a description of the facts and circumstances leading to the recording of impairment charges of intangible assets in the period, the amount of the impairment charges, the methods of determining fair value of the associated assets, the caption in the income statement in which the impairment losses are aggregated, and the segment in which the impaired intangible assets are reported.",
        "label": "Schedule of Impaired Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Additional Information About Intangible Assets Impaired"
       }
      }
     },
     "localname": "ScheduleOfImpairedIntangibleAssetsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of income before income tax between domestic and foreign jurisdictions.",
        "label": "Schedule of Income before Income Tax, Domestic and Foreign [Table Text Block]",
        "terseLabel": "Schedule of Income before Income Tax, Domestic and Foreign"
       }
      }
     },
     "localname": "ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTable": {
     "auth_ref": [
      "r329",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock": {
     "auth_ref": [
      "r329",
      "r332"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.",
        "label": "Schedule of Indefinite-Lived Intangible Assets [Table Text Block]",
        "terseLabel": "Schedule of Indefinite-Lived Intangible Assets"
       }
      }
     },
     "localname": "ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "auth_ref": [
      "r30",
      "r58",
      "r59",
      "r60"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "terseLabel": "Schedule of Components of Inventories, Current"
       }
      }
     },
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfInventoryNoncurrentTableTextBlock": {
     "auth_ref": [
      "r30",
      "r58",
      "r59",
      "r60",
      "r61"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of inventories not expected to be converted to cash, sold or exchanged within the normal operating cycle including inventoried costs relating to long-term contracts or programs.",
        "label": "Schedule of Inventory, Noncurrent [Table Text Block]",
        "terseLabel": "Schedule of Component of Inventories, Noncurrent"
       }
      }
     },
     "localname": "ScheduleOfInventoryNoncurrentTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/InventoriesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation.",
        "label": "Schedule of Net Periodic Benefit Cost Not yet Recognized [Table Text Block]",
        "terseLabel": "Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "auth_ref": [
      "r191",
      "r193",
      "r207",
      "r208",
      "r210"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.",
        "label": "Schedule of New Accounting Pronouncements and Changes in Accounting Principles [Table Text Block]",
        "terseLabel": "Impact of Adoption of Accounting Standard Updates"
       }
      }
     },
     "localname": "ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested performance-based units.",
        "label": "Schedule of Nonvested Performance-based Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Performance-based Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock": {
     "auth_ref": [
      "r505"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock units.",
        "label": "Schedule of Nonvested Restricted Stock Units Activity [Table Text Block]",
        "terseLabel": "Schedule of Nonvested Restricted Stock Units Activity"
       }
      }
     },
     "localname": "ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the components of non-operating income or non-operating expense that may include amounts earned from dividends, interest on securities, gains (losses) on securities sold, equity earnings of unconsolidated affiliates, net gain (loss) on sales of business, interest expense and other miscellaneous income or expense items.",
        "label": "Schedule of Other Nonoperating Income (Expense) [Table Text Block]",
        "terseLabel": "Schedule of Other Nonoperating Income (Expense)"
       }
      }
     },
     "localname": "ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r66",
      "r343"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]",
        "terseLabel": "Schedule of Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "auth_ref": [
      "r356",
      "r357",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Table presenting the description of the restructuring costs, such as the expected cost; the costs incurred during the period; the cumulative costs incurred as of the balance sheet date; the income statement caption within which the restructuring charges recognized for the period are included; and the amount of and periodic changes to an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost by type of restructuring.",
        "label": "Schedule of Restructuring and Related Costs [Table]",
        "terseLabel": "Schedule of Restructuring and Related Costs [Table]"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock": {
     "auth_ref": [
      "r356",
      "r357",
      "r361"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.",
        "label": "Restructuring and Related Costs [Table Text Block]",
        "terseLabel": "Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives"
       }
      }
     },
     "localname": "ScheduleOfRestructuringAndRelatedCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock": {
     "auth_ref": [
      "r354",
      "r363"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.",
        "label": "Schedule of Restructuring Reserve by Type of Cost [Table Text Block]",
        "terseLabel": "Schedule of Restructuring Reserve by Type of Cost"
       }
      }
     },
     "localname": "ScheduleOfRestructuringReserveByTypeOfCostTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "auth_ref": [
      "r120",
      "r123",
      "r245"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule of material long-lived assets (excluding financial instruments, customer relationships with financial institutions, mortgage and other servicing rights, deferred policy acquisition costs, and deferred taxes assets) located in identified geographic areas and/or the amount of revenue from external customers attributed to that country from which revenue is material.  An entity may also provide subtotals of geographic information about groups of countries.",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]"
       }
      }
     },
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "auth_ref": [
      "r225",
      "r232",
      "r234",
      "r237",
      "r312"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table disclosing the profit or loss and total assets for each reportable segment of the entity. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]"
       }
      }
     },
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r492",
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r497"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock appreciation rights awards that were outstanding at the beginning and end of the year, and the number of stock appreciation rights awards that were granted, exercised or converted, forfeited, and expired during the year.",
        "label": "Share-based Payment Arrangement, Stock Appreciation Right, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Appreciation Rights Award Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r497",
      "r510",
      "r513"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]",
        "terseLabel": "Schedule of Share-based Compensation, Stock Options, Activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r516"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Schedule of Valuation Assumptions"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTable": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A table or schedule providing information pertaining to borrowings under which repayment was required in less than twelve months (or normal operating cycle, if longer) after its issuance. It may include: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date and measures of the maximum and average amount outstanding during the period; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table]",
        "terseLabel": "Schedule of Short-term Debt [Table]"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShortTermDebtTextBlock": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.",
        "label": "Schedule of Short-term Debt [Table Text Block]",
        "terseLabel": "Schedule of Short-term Borrowings"
       }
      }
     },
     "localname": "ScheduleOfShortTermDebtTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfTreasuryStockByClassTextBlock": {
     "auth_ref": [
      "r400",
      "r401",
      "r402",
      "r403"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.",
        "label": "Class of Treasury Stock [Table Text Block]",
        "terseLabel": "Summary of Common Stock Purchases"
       }
      }
     },
     "localname": "ScheduleOfTreasuryStockByClassTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "auth_ref": [
      "r557",
      "r571"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits.",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "terseLabel": "Schedule of Unrecognized Tax Benefits Roll Forward"
       }
      }
     },
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.",
        "label": "Schedule of Finite-Lived Intangible Assets, Future Amortization Expense [Table Text Block]",
        "terseLabel": "Schedule of Expected Amortization Expense"
       }
      }
     },
     "localname": "ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SecuritiesReceivedAsCollateral": {
     "auth_ref": [
      "r728",
      "r733"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.",
        "label": "Securities Received as Collateral",
        "terseLabel": "Cash collateral received"
       }
      }
     },
     "localname": "SecuritiesReceivedAsCollateral",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SegmentDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Segments [Domain]",
        "terseLabel": "Segments [Domain]"
       }
      }
     },
     "localname": "SegmentDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SegmentReportingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "localname": "SegmentReportingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "auth_ref": [
      "r247"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.",
        "label": "Segment Reporting Disclosure [Text Block]",
        "terseLabel": "Segment, Geographic and Other Revenue Information"
       }
      }
     },
     "localname": "SegmentReportingDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Segment Reporting Information [Line Items]",
        "terseLabel": "Segment Reporting Information [Line Items]"
       }
      }
     },
     "localname": "SegmentReportingInformationLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r134",
      "r302"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.",
        "label": "Selling, General and Administrative Expense",
        "negatedLabel": "Selling, informational and administrative expenses",
        "terseLabel": "Selling, informational and administrative expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "auth_ref": [
      "r139"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense.",
        "label": "Selling, General and Administrative Expenses [Member]",
        "terseLabel": "Selling, General and Administrative Expenses [Member]",
        "verboseLabel": "Selling, Informational and Administrative Expenses [Member]"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock": {
     "auth_ref": [
      "r174",
      "r535"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.",
        "label": "Selling, General and Administrative Expenses, Policy [Policy Text Block]",
        "terseLabel": "Selling, Informational and Administrative Expenses"
       }
      }
     },
     "localname": "SellingGeneralAndAdministrativeExpensesPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeniorNotesMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors.",
        "label": "Senior Notes [Member]",
        "terseLabel": "Senior Notes [Member]"
       }
      }
     },
     "localname": "SeniorNotesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SettledLitigationMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Agreement reached between parties in a litigation that occurs without judicial intervention, supervision or approval.",
        "label": "Settled Litigation [Member]",
        "terseLabel": "Settled Litigation [Member]"
       }
      }
     },
     "localname": "SettledLitigationMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails",
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SeveranceCosts1": {
     "auth_ref": [
      "r164",
      "r352",
      "r358",
      "r364"
     ],
     "calculation": {
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail": {
       "order": 1.0,
       "parentTag": "us-gaap_RestructuringCharges",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.",
        "label": "Severance Costs",
        "terseLabel": "Employee terminations"
       }
      }
     },
     "localname": "SeveranceCosts1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r163"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Noncash Expense",
        "terseLabel": "Share-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Requisite Service Period",
        "terseLabel": "Award vesting period",
        "verboseLabel": "Award requisite service period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r493"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Award vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "negatedLabel": "Forfeited, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Intrinsic Value, Amount Per Share",
        "terseLabel": "Forfeited, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r509"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "terseLabel": "Forfeited, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "verboseLabel": "Granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Granted, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r507"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Granted, weighted-average grant-date fair value per share (in dollars per share)",
        "verboseLabel": "Weighted-average grant-date fair value per stock option (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other than Option, Nonvested, Intrinsic Value",
        "periodEndLabel": "Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)",
        "periodStartLabel": "Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Intrinsic Value, Amount Per Share [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "periodEndLabel": "Nonvested, end of period, shares",
        "periodStartLabel": "Nonvested, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r506"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "periodEndLabel": "Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)",
        "periodStartLabel": "Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Remaining Contractual Terms",
        "terseLabel": "Outstanding, Weighted-Average Remaining Contractual Term (Years)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "negatedLabel": "Vested, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Intrinsic Value, Amount Per Share",
        "terseLabel": "Vested, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "terseLabel": "Total fair value of shares vested",
        "verboseLabel": "Total fair value of shares vested"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r508"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Vested, weighted-average grant date fair value per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "terseLabel": "Expected dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "terseLabel": "Expected stock price volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r520"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised": {
     "auth_ref": [
      "r502"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of non-option equity instruments exercised by participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised",
        "terseLabel": "Exercised during period, Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted": {
     "auth_ref": [
      "r501"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Net number of non-option equity instruments granted to participants.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted",
        "terseLabel": "Deferred compensation arrangement, shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber": {
     "auth_ref": [
      "r498",
      "r500"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of equity instruments other than options outstanding, including both vested and non-vested instruments.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Outstanding, Number",
        "terseLabel": "Outstanding, Share Units"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized",
        "terseLabel": "Number of additional shares authorized"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant",
        "terseLabel": "Shares available for award"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r512"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value on exercise"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r504"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period",
        "negatedLabel": "Expired, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r503"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeited, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "verboseLabel": "Granted, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r511"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted-average grant-date fair value per stock option (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r526"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "terseLabel": "Outstanding, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r499",
      "r526"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding, end of period, shares",
        "periodStartLabel": "Outstanding, beginning of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r498"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding, end of period, weighted-average exercise price per share (in dollars per share)",
        "periodStartLabel": "Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r515"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "terseLabel": "Exercisable, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "terseLabel": "Exercisable, end of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "terseLabel": "Exercisable, end of period, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "auth_ref": [
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "terseLabel": "Vested and expected to vest, end of period, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "terseLabel": "Vested and expected to vest, end of period, shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "terseLabel": "Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected": {
     "auth_ref": [
      "r524"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of grantees affected by modification of award under share-based payment arrangement.",
        "label": "Share-based Payment Arrangement, Plan Modification, Number of Grantees Affected",
        "terseLabel": "Number of employees affected by plan modification",
        "verboseLabel": "Number of employees affected by accelerated vesting"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r489",
      "r495"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]",
        "terseLabel": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "terseLabel": "Expired, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted, weighted-average exercise price per share (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r174",
      "r492",
      "r496"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]",
        "terseLabel": "Share-Based Payments"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "terseLabel": "Share price (in dollars per share)"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareRepurchaseProgramAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by share repurchase program.",
        "label": "Share Repurchase Program [Axis]",
        "terseLabel": "Share Repurchase Program [Axis]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareRepurchaseProgramDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Name of the share repurchase program.",
        "label": "Share Repurchase Program [Domain]",
        "terseLabel": "Share Repurchase Program [Domain]"
       }
      }
     },
     "localname": "ShareRepurchaseProgramDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Accelerated Vesting, Number",
        "terseLabel": "Number of shares modified to accelerate vesting"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Outstanding",
        "terseLabel": "Outstanding, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Vested",
        "terseLabel": "Vested, Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r494"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period",
        "terseLabel": "Contractual term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails",
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r517",
      "r528"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Contractual term (years)",
        "verboseLabel": "Expected term (years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail",
      "http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r515"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r514"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Vested and expected to vest, end of period, weighted-average remaining contractual term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharesIssued": {
     "auth_ref": [
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury.",
        "label": "Shares, Issued",
        "periodEndLabel": "Ending balance (in shares)",
        "periodStartLabel": "Beginning balance (in shares)"
       }
      }
     },
     "localname": "SharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShortTermDebtLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Short-term Debt [Line Items]",
        "terseLabel": "Short-term Debt [Line Items]"
       }
      }
     },
     "localname": "ShortTermDebtLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt arrangement having an initial term within one year or the normal operating cycle, if longer.",
        "label": "Short-term Debt [Member]",
        "terseLabel": "Short-term borrowings, including current portion of long-term debt [Member]"
       }
      }
     },
     "localname": "ShortTermDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtTypeAxis": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by type of short-term debt arrangement.",
        "label": "Short-term Debt, Type [Axis]",
        "terseLabel": "Short-term Debt, Type [Axis]"
       }
      }
     },
     "localname": "ShortTermDebtTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermDebtTypeDomain": {
     "auth_ref": [
      "r69"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Type of short-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing.",
        "label": "Short-term Debt, Type [Domain]",
        "terseLabel": "Short-term Debt, Type [Domain]"
       }
      }
     },
     "localname": "ShortTermDebtTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShortTermDebtWeightedAverageInterestRate": {
     "auth_ref": [
      "r70"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Weighted average interest rate of short-term debt outstanding calculated at point in time.",
        "label": "Short-term Debt, Weighted Average Interest Rate, at Point in Time",
        "terseLabel": "Commercial paper, weighted average interest rate"
       }
      }
     },
     "localname": "ShortTermDebtWeightedAverageInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShortTermInvestments": {
     "auth_ref": [
      "r38",
      "r746",
      "r747",
      "r749",
      "r767"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.",
        "label": "Short-term Investments",
        "terseLabel": "Short-term investments",
        "totalLabel": "Total Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestments",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShortTermInvestmentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Short-term Investments [Abstract]",
        "terseLabel": "Short-term investments"
       }
      }
     },
     "localname": "ShortTermInvestmentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShortTermInvestmentsMember": {
     "auth_ref": [
      "r797"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Investments which are not otherwise included in another category or item that the entity has the intent to sell or dispose of within one year from the date of the balance sheet.",
        "label": "Short-term Investments [Member]",
        "terseLabel": "Short-term Investments [Member]"
       }
      }
     },
     "localname": "ShortTermInvestmentsMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "auth_ref": [
      "r7",
      "r232",
      "r312",
      "r348",
      "r355",
      "r365",
      "r782"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business segments.",
        "label": "Segments [Axis]",
        "terseLabel": "Segments [Axis]"
       }
      }
     },
     "localname": "StatementBusinessSegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementClassOfStockAxis": {
     "auth_ref": [
      "r44",
      "r45",
      "r46",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by the different classes of stock of the entity.",
        "label": "Class of Stock [Axis]",
        "terseLabel": "Class of Stock [Axis]"
       }
      }
     },
     "localname": "StatementClassOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/CoverPage",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r82",
      "r391"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]",
        "terseLabel": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails",
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]",
        "terseLabel": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]",
        "terseLabel": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "auth_ref": [
      "r45",
      "r46",
      "r391",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Shares, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r45",
      "r46",
      "r391",
      "r398",
      "r502"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised, shares"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "auth_ref": [
      "r45",
      "r46",
      "r398",
      "r491",
      "r511"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).",
        "label": "Shares Issued, Value, Share-based Payment Arrangement, after Forfeiture",
        "terseLabel": "Share-based payment transactions"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Contracts conveying rights, but not obligations, to buy or sell a specific quantity of stock at a specified price during a specified period (an American option) or at a specified date (a European option).",
        "label": "Equity Option [Member]",
        "terseLabel": "Equity Option [Member]"
       }
      }
     },
     "localname": "StockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StockRepurchaseProgramAuthorizedAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Authorized Amount",
        "terseLabel": "Amount of shares authorized in stock purchase plan, value"
       }
      }
     },
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount remaining of a stock repurchase plan authorized.",
        "label": "Stock Repurchase Program, Remaining Authorized Repurchase Amount",
        "terseLabel": "Amount of remaining shares authorized in stock purchase plan, value"
       }
      }
     },
     "localname": "StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r46",
      "r50",
      "r51",
      "r253"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total Pfizer Inc. shareholders\u2019 equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r602",
      "r603",
      "r615"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest",
        "periodEndLabel": "Ending balance",
        "periodStartLabel": "Beginning balance",
        "totalLabel": "Total equity"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r404"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]",
        "terseLabel": "Equity"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/Equity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityOther": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This element represents movements included in the statement of changes in stockholders' equity which are not separately disclosed or provided for elsewhere in the taxonomy.",
        "label": "Stockholders' Equity, Other",
        "negatedLabel": "Other"
       }
      }
     },
     "localname": "StockholdersEquityOther",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubleaseIncome": {
     "auth_ref": [
      "r715",
      "r723"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of sublease income excluding finance and operating lease expense.",
        "label": "Sublease Income",
        "negatedLabel": "Sublease income"
       }
      }
     },
     "localname": "SubleaseIncome",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SubsegmentsAxis": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by business subsegments.",
        "label": "Subsegments [Axis]",
        "terseLabel": "Subsegments [Axis]"
       }
      }
     },
     "localname": "SubsegmentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsegmentsDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Divisions of a component of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity.",
        "label": "Subsegments [Domain]",
        "terseLabel": "Subsegments [Domain]"
       }
      }
     },
     "localname": "SubsegmentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]",
        "terseLabel": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]",
        "terseLabel": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r726"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]",
        "terseLabel": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Cash paid (received) during the period for:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Plan designed to provide limited group of employees with supplemental retirement benefits, in addition to other pension benefits. Includes, but is not limited to, defined benefit and defined contribution plans.",
        "label": "Supplemental Employee Retirement Plan [Member]",
        "terseLabel": "U.S. Supplemental (Non-Qualified) Pension Plans [Member]"
       }
      }
     },
     "localname": "SupplementalEmployeeRetirementPlanDefinedBenefitMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails",
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r570"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Income Tax Expense (Benefit)",
        "negatedLabel": "Tax benefits associated with the enactment of the TCJA",
        "terseLabel": "TCJA impact",
        "totalLabel": "Total TCJA tax benefit"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows",
      "http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability": {
     "auth_ref": [
      "r574"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of reasonable estimate for tax liability for which accounting for tax effect from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated is incomplete pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Incomplete Accounting, Transition Tax for Accumulated Foreign Earnings, Provisional Liability",
        "terseLabel": "Repatriation tax provisional liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r575"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of income tax expense (benefit) for measurement period adjustment from accounting for tax effect pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Measurement Period Adjustment, Income Tax Expense (Benefit)",
        "negatedTerseLabel": "Tax benefit related to measurement adjustment"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability": {
     "auth_ref": [
      "r581"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.",
        "label": "Tax Cuts and Jobs Act, Transition Tax for Accumulated Foreign Earnings, Liability",
        "terseLabel": "Repatriation tax liability"
       }
      }
     },
     "localname": "TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails",
      "http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TaxesPayableCurrent": {
     "auth_ref": [
      "r73"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Taxes Payable, Current",
        "terseLabel": "Income taxes payable"
       }
      }
     },
     "localname": "TaxesPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TradeNamesMember": {
     "auth_ref": [
      "r589"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Rights acquired through registration of a business name to gain or protect exclusive use thereof.",
        "label": "Trade Names [Member]",
        "verboseLabel": "Brands [Member]"
       }
      }
     },
     "localname": "TradeNamesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails",
      "http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r734"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]",
        "terseLabel": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "auth_ref": [
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased.",
        "label": "Treasury Stock Acquired, Average Cost Per Share",
        "terseLabel": "Accelerated share repurchase, average price paid per share (in dollars per share)"
       }
      }
     },
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EquityNarrativeDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_TreasuryStockMember": {
     "auth_ref": [
      "r81",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Shares of an entity that have been repurchased by the entity. This stock has no voting rights and receives no dividends. Note that treasury stock may be recorded at its total cost or separately as par (or stated) value and additional paid in capital. Classified within stockholders' equity if nonredeemable or redeemable solely at the option of the issuer. Classified within temporary equity if redemption is outside the control of the issuer.",
        "label": "Treasury Stock [Member]",
        "terseLabel": "Treasury Stock [Member]"
       }
      }
     },
     "localname": "TreasuryStockMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TreasuryStockShares": {
     "auth_ref": [
      "r81",
      "r400"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.",
        "label": "Treasury Stock, Shares",
        "terseLabel": "Treasury stock, shares at cost"
       }
      }
     },
     "localname": "TreasuryStockShares",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "auth_ref": [
      "r46",
      "r391",
      "r398"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury.",
        "label": "Treasury Stock, Shares, Acquired",
        "negatedTerseLabel": "Purchases of common stock (in shares)",
        "terseLabel": "Shares repurchased",
        "verboseLabel": "Shares of common stock purchased"
       }
      }
     },
     "localname": "TreasuryStockSharesAcquired",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/EquityNarrativeDetails",
      "http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_TreasuryStockValue": {
     "auth_ref": [
      "r81",
      "r400",
      "r403"
     ],
     "calculation": {
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.",
        "label": "Treasury Stock, Value",
        "negatedLabel": "Treasury stock, shares at cost: 2019\u20143,835; 2018\u20143,615"
       }
      }
     },
     "localname": "TreasuryStockValue",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "auth_ref": [
      "r391",
      "r398",
      "r400"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "negatedLabel": "Purchases of common stock",
        "terseLabel": "Cost of purchase"
       }
      }
     },
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfEquity",
      "http://www.pfizer.com/role/EquityNarrativeDetails",
      "http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_TypeOfAdoptionMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Adoption and early adoption of sources of change to generally accepted accounting principles (GAAP) in the United States. The FASB released the FASB Accounting Standards Codification as the authoritative source of literature effective for interim and annual periods ending after September 15, 2009. As part of the Codification process, the FASB issues Accounting Standards Updates to amend the Codification but otherwise the Accounting Standards Updates are not authoritative in their own right. All previous accounting standards (such as FASB Statements of Financial Accounting Standards, FASB Interpretations, FASB Staff Positions, Emerging Issues Task Force Consensuses, other pronouncements of the FASB or other designated bodies, or other forms of GAAP are considered accounting pronouncements) were superseded upon the adoption of the Codification. For an interim period, references to the superseded standards are included to help users transition from the previous accounting hierarchy and will be removed from future versions of this taxonomy.",
        "label": "Type of Adoption [Domain]",
        "terseLabel": "Type of Adoption [Domain]"
       }
      }
     },
     "localname": "TypeOfAdoptionMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails",
      "http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_TypeOfArrangementAxis": {
     "auth_ref": [
      "r601"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]"
       }
      }
     },
     "localname": "TypeOfArrangementAxis",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails",
      "http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails",
      "http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Identification of the types of restructuring costs.",
        "label": "Type of Restructuring [Domain]",
        "terseLabel": "Type of Restructuring [Domain]"
       }
      }
     },
     "localname": "TypeOfRestructuringDomain",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail",
      "http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r440",
      "r748"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "US Government Agencies Debt Securities [Member]",
        "terseLabel": "Government and agency - U.S. [Member]"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USTreasurySecuritiesMember": {
     "auth_ref": [
      "r440",
      "r482",
      "r748"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "This category includes information about debt securities issued by the United States Department of the Treasury and backed by the United States government. Such securities primarily consist of treasury bills (short-term maturities - one year or less), treasury notes (intermediate term maturities - two to ten years), and treasury bonds (long-term maturities - ten to thirty years).",
        "label": "US Treasury Securities [Member]",
        "terseLabel": "Government and Agency Obligations [Member]"
       }
      }
     },
     "localname": "USTreasurySecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UndistributedEarningsOfForeignSubsidiaries": {
     "auth_ref": [
      "r542",
      "r580",
      "r763",
      "r786"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.",
        "label": "Undistributed Earnings of Foreign Subsidiaries",
        "terseLabel": "Unremitted earnings of international subsidiaries"
       }
      }
     },
     "localname": "UndistributedEarningsOfForeignSubsidiaries",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r543",
      "r553"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "negatedPeriodEndLabel": "Balance, ending",
        "negatedPeriodStartLabel": "Balance, beginning",
        "verboseLabel": "Unrecognized tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails",
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Acquisition",
        "terseLabel": "Acquisitions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Prior Period Tax Positions",
        "terseLabel": "Decreases based on tax positions taken during a prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "auth_ref": [
      "r556"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "terseLabel": "Decreases based on settlements for a prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from acquisitions.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Acquisition",
        "negatedTerseLabel": "Acquisitions"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "auth_ref": [
      "r555"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "negatedLabel": "Increases based on tax positions taken during the current period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions": {
     "auth_ref": [
      "r554"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Prior Period Tax Positions",
        "negatedLabel": "Increases based on tax positions taken during a prior period"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "credit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense accrued for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Accrued",
        "terseLabel": "Unrecognized tax benefits, interest on income taxes accrued"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense": {
     "auth_ref": [
      "r550"
     ],
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of interest expense for an underpayment of income taxes.",
        "label": "Unrecognized Tax Benefits, Interest on Income Taxes Expense",
        "negatedTerseLabel": "Unrecognized tax benefits, interest on income taxes expense"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/TaxMattersNarrativeDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnsecuredDebtMember": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Debt obligation not collateralized by pledge of, mortgage of or other lien on the entity's assets.",
        "label": "Unsecured Debt [Member]",
        "terseLabel": "Unsecured Debt [Member]"
       }
      }
     },
     "localname": "UnsecuredDebtMember",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails",
      "http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r211",
      "r212",
      "r213",
      "r214",
      "r222",
      "r223",
      "r224"
     ],
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Estimates and Assumptions"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_VariableLeaseCost": {
     "auth_ref": [
      "r714",
      "r723"
     ],
     "calculation": {
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.",
        "label": "Variable Lease, Cost",
        "terseLabel": "Variable lease cost"
       }
      }
     },
     "localname": "VariableLeaseCost",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "auth_ref": [
      "r202"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.",
        "label": "Weighted Average Number Diluted Shares Outstanding Adjustment",
        "terseLabel": "Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements"
       }
      }
     },
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r197",
      "r202"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "terseLabel": "Weighted-average shares\u2013\u2013diluted",
        "totalLabel": "Weighted-average number of common shares outstanding\u2013\u2013Diluted"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "auth_ref": [],
     "lang": {
      "en-US": {
       "role": {
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]",
        "terseLabel": "EPS Denominator"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r195",
      "r202"
     ],
     "calculation": {
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0
      }
     },
     "lang": {
      "en-US": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "terseLabel": "Weighted-average number of common shares outstanding\u2013\u2013Basic",
        "verboseLabel": "Weighted-average shares\u2013\u2013basic"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2019-01-31",
     "presentation": [
      "http://www.pfizer.com/role/ConsolidatedStatementsOfIncome",
      "http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 21
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1107-107759"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721533-107759"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721659-107760"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i-k)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e637-108580"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e640-108580"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e681-108580"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669686-108580"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e689-108580"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e709-108580"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724391-108580"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721663-107760"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL34724394-108580"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=d3e557-108580"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657188&loc=SL116659661-227067"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118951672&loc=d3e1436-108581"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116657190&loc=SL116659633-172590"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721665-107760"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-03(e))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(13))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868656-224227"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(210.5-03(11))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(1))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(12))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(14))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(21))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(7)(c))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721671-107760"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(b)(9)(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.13)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.2(a),(d))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.3)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(a))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7(b))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.7)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "220",
   "URI": "http://asc.fasb.org/topic&trid=2134417"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3151-108585"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3179-108585"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3291-108585"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3367-108585"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3000-108585"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3521-108585"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721673-107760"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3536-108585"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3044-108585"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3098-108585"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=118932676&loc=d3e3098-108585"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4273-108586"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4297-108586"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4304-108586"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=d3e4332-108586"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=98513485&loc=SL98516268-108586"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18780-107790"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=84158767&loc=d3e18823-107790"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(e),(f))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(g))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1)(i))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n)(7))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.(n))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08.g)",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.12-04(a))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=26873400&loc=d3e24072-122690"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721675-107760"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22499-107794"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22583-107794"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=109234566&loc=d3e22663-107794"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1278-109256"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e957-107759"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721677-107760"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "http://asc.fasb.org/topic&trid=2144383"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e725-108305"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e765-108305"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=116846552&loc=d3e543-108305"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.10-01.(b)(6))",
   "Topic": "270",
   "URI": "http://asc.fasb.org/extlink&oid=27015980&loc=d3e46468-122699"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6327-108592"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6351-108592"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6404-108592"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6442-108592"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8721-108599"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8813-108599"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8906-108599"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8924-108599"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8933-108599"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e8475-108599"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9031-108599"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "a",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "b",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "41",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9038-108599"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "42",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=115929826&loc=d3e9054-108599"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "280",
   "URI": "http://asc.fasb.org/topic&trid=2134510"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4647-111522"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4428-111522"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6676-107765"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118952595&loc=d3e4531-111522"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5033-111524"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=118936363&loc=d3e5074-111524"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10133-111534"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10149-111534"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=84159169&loc=d3e10178-111534"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26610-111562"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26853-111562"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118954083&loc=d3e26626-111562"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6801-107765"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27161-111563"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27198-111563"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(aa)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6904-107765"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27232-111563"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "http://asc.fasb.org/extlink&oid=118939692&loc=d3e27357-111563"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "http://asc.fasb.org/topic&trid=2196928"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117539-209714"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "321",
   "URI": "http://asc.fasb.org/extlink&oid=116654751&loc=SL75117546-209714"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=117311354&loc=d3e32014-111567"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6911-107765"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33749-111570"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=109237563&loc=d3e33775-111570"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33912-111571"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(b)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "325",
   "URI": "http://asc.fasb.org/extlink&oid=73718008&loc=d3e42732-111610"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=118951113&loc=d3e6935-107765"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955202&loc=SL82895884-210446"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919244-210447"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919249-210447"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919253-210447"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919258-210447"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=119407570&loc=SL82919230-210447"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955255&loc=SL82921835-210448"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942338&loc=SL82898722-210454"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922888-210455"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922895-210455"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721523-107759"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6361739&loc=d3e7789-107766"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118955579&loc=SL82922900-210455"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=118942371&loc=SL82922954-210456"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=68048583&loc=d3e3636-108311"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116846819&loc=d3e3927-108312"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4492-108314"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=116847112&loc=d3e4556-108314"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Topic": "330",
   "URI": "http://asc.fasb.org/extlink&oid=27011343&loc=d3e100047-122729"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "330",
   "URI": "http://asc.fasb.org/topic&trid=2126998"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=99380562&loc=d3e13770-109266"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=77989000&loc=SL49117168-202975"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13816-109267"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=SL108378252-109267"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=108376223&loc=d3e13854-109267"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16212-109274"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=6388964&loc=d3e16225-109274"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(12))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "((a)(1),(b))",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(2)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(3)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b),(d)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "350",
   "URI": "http://asc.fasb.org/topic&trid=2144416"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2510-110228"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2599-110228"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2611-110228"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2420-110228"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2443-110228"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226348&loc=d3e2473-110228"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2921-110230"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=SL51724579-110230"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "http://asc.fasb.org/topic&trid=2155823"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140864-122747"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(1))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b)(2))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(b))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4(d))",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.P.4)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=115931487&loc=d3e140904-122747"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "420",
   "URI": "http://asc.fasb.org/topic&trid=2175745"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14326-108349"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(19))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14615-108349"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14394-108349"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14435-108349"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14453-108349"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14472-108349"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=118942415&loc=d3e14557-108349"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=6397426&loc=d3e17499-108355"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(2))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12021-110248"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=118943654&loc=d3e12053-110248"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "460",
   "URI": "http://asc.fasb.org/extlink&oid=68068213&loc=d3e12565-110249"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=SL5988623-112600"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=6802200&loc=SL6230698-112601"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=109500613&loc=SL6031897-161870"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12317-112629"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "40",
   "SubTopic": "50",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=117329964&loc=d3e12355-112629"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(20))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21564-112644"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21488-112644"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21506-112644"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21521-112644"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=109259400&loc=d3e21538-112644"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405686&loc=d3e22802-112653"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=SL51721525-107759"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405813&loc=d3e23239-112655"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23309-112656"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6405834&loc=d3e23315-112656"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118956577&loc=SL49130549-203045"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(24))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "91",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=118944142&loc=SL49130690-203046-203046"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(i)(1)",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "http://asc.fasb.org/extlink&oid=113356391&loc=SL49131195-203048"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "http://asc.fasb.org/topic&trid=49130388"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "610",
   "URI": "http://asc.fasb.org/topic&trid=49130413"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "15",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "712",
   "URI": "http://asc.fasb.org/extlink&oid=6410066&loc=d3e79218-111664"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1703-114919"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=d3e1731-114919"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=109237824&loc=SL108413299-114919"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(10)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(6)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(b)(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r431": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(8)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r452": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r453": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r454": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r455": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r456": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r457": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i),(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r458": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(j)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r459": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r460": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r461": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(k)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(m)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(n)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(s)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e1928-114920"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2410-114920"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2417-114920"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2439-114920"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(1)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(2)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(4)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(5)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(7)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118255775&loc=d3e2709-114920"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=118257860&loc=d3e4179-114921"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6412939&loc=d3e15145-114933"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=66047640&loc=d3e39622-114963"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=6414203&loc=d3e39716-114964"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=d3e29149-114947"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "http://asc.fasb.org/topic&trid=2235017"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222160&loc=d3e1012-107759"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=116856206&loc=SL79508275-113901"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=115993241&loc=d3e301413-122809"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(4)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r533": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=109244661&loc=d3e17540-113929"
  },
  "r534": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r535": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(a)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r536": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "35",
   "Subparagraph": "(b)",
   "Topic": "720",
   "URI": "http://asc.fasb.org/extlink&oid=6420018&loc=d3e36677-107848"
  },
  "r537": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "720",
   "URI": "http://asc.fasb.org/topic&trid=2122503"
  },
  "r538": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r539": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r540": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r541": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28680-109314"
  },
  "r542": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117330534&loc=d3e28200-109314"
  },
  "r543": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=SL37586934-109318"
  },
  "r544": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32247-109318"
  },
  "r545": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e32280-109318"
  },
  "r546": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31917-109318"
  },
  "r547": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116821951&loc=d3e31931-109318"
  },
  "r548": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32687-109319"
  },
  "r549": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32698-109319"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r550": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r551": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r552": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32718-109319"
  },
  "r553": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r554": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r555": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r556": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r557": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=SL6600010-109319"
  },
  "r558": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32809-109319"
  },
  "r559": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32840-109319"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(4))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r560": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r561": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r562": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r563": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r564": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32537-109319"
  },
  "r565": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32847-109319"
  },
  "r566": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32621-109319"
  },
  "r567": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32632-109319"
  },
  "r568": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r569": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a)(5))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r570": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=84230637&loc=d3e32639-109319"
  },
  "r571": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "217",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=117331294&loc=d3e36027-109320"
  },
  "r572": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r573": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=d3e330036-122817"
  },
  "r574": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.EE.Q2(b))",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817"
  },
  "r575": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.EE.Q2(f))",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=116825942&loc=SL116722634-122817"
  },
  "r576": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e39076-109324"
  },
  "r577": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r578": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324"
  },
  "r579": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "30",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=65884525&loc=d3e40913-109327"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r580": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r581": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r582": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Subparagraph": "(a)-(d)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6909625&loc=d3e227-128457"
  },
  "r583": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(3)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r584": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1392-128463"
  },
  "r585": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=79982066&loc=d3e1486-128463"
  },
  "r586": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "37",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116868840&loc=d3e2207-128464"
  },
  "r587": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=d3e4845-128472"
  },
  "r588": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116869197&loc=SL65897772-128472"
  },
  "r589": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5263-128473"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r590": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5419-128473"
  },
  "r591": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "38",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=77890550&loc=d3e5504-128473"
  },
  "r592": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=6911189&loc=d3e6408-128476"
  },
  "r593": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6578-128477"
  },
  "r594": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "30",
   "SubTopic": "30",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859721&loc=d3e6613-128477"
  },
  "r595": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r596": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "30",
   "Subparagraph": "b",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=116859824&loc=d3e6819-128478"
  },
  "r597": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r598": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r599": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e6927-128479"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r600": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)(1)",
   "Topic": "805",
   "URI": "http://asc.fasb.org/extlink&oid=35744584&loc=d3e7008-128479"
  },
  "r601": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "808",
   "URI": "http://asc.fasb.org/extlink&oid=6931272&loc=SL5834143-161434"
  },
  "r602": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568447-111683"
  },
  "r603": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4568740-111683"
  },
  "r604": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613673-111683"
  },
  "r605": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569616-111683"
  },
  "r606": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4569643-111683"
  },
  "r607": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=108774443&loc=SL4613674-111683"
  },
  "r608": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=d3e5614-111684"
  },
  "r609": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(6)(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r610": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r611": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r612": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r613": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684"
  },
  "r614": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=109239629&loc=SL4582445-111684"
  },
  "r615": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4590271-111686"
  },
  "r616": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591551-111686"
  },
  "r617": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116874947&loc=SL4591552-111686"
  },
  "r618": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-02)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355033-122828"
  },
  "r619": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3A-03)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355100-122828"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r620": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 5.E)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116822174&loc=d3e355146-122828"
  },
  "r621": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579240-113959"
  },
  "r622": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r623": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5579245-113959"
  },
  "r624": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5580258-113959"
  },
  "r625": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(ii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r626": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)(iii)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r627": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41620-113959"
  },
  "r628": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41638-113959"
  },
  "r629": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.12)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r630": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r631": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r632": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5618551-113959"
  },
  "r633": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r634": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r635": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624163-113959"
  },
  "r636": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r637": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r638": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r639": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r640": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r641": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r642": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624171-113959"
  },
  "r643": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998890-113959"
  },
  "r644": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r645": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r646": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4CCC",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109998896-113959"
  },
  "r647": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r648": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r649": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r650": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624177-113959"
  },
  "r651": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624181-113959"
  },
  "r652": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959"
  },
  "r653": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959"
  },
  "r654": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4EE",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL109999712-113959"
  },
  "r655": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624258-113959"
  },
  "r656": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=SL5624258-113959"
  },
  "r657": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41641-113959"
  },
  "r658": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41675-113959"
  },
  "r659": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109980867&loc=d3e41678-113959"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.14)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r660": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "182",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=116861445&loc=SL5629052-113961"
  },
  "r661": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109974929&loc=SL110061190-113977"
  },
  "r662": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Subparagraph": "(a)(1)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r663": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "25",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=109977999&loc=d3e76258-113986"
  },
  "r664": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=112277219&loc=d3e80748-113994"
  },
  "r665": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r666": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r667": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r668": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r669": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(1)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r670": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r671": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258"
  },
  "r672": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=d3e19279-110258"
  },
  "r673": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r674": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=117815213&loc=SL6742756-110258"
  },
  "r675": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=99377092&loc=SL75136599-209740"
  },
  "r676": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=116690757&loc=d3e13220-108610"
  },
  "r677": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13433-108611"
  },
  "r678": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13467-108611"
  },
  "r679": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13476-108611"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a)(7))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r680": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13531-108611"
  },
  "r681": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r682": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r683": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=118260190&loc=d3e13537-108611"
  },
  "r684": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r685": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=75031198&loc=d3e14064-108612"
  },
  "r686": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=117336053&loc=SL75039408-165497"
  },
  "r687": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118948100&loc=d3e30304-110892"
  },
  "r688": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450222&loc=d3e30840-110895"
  },
  "r689": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=98513438&loc=d3e33268-110906"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r690": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32022-110900"
  },
  "r691": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r692": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r693": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b,d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r694": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r695": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r696": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r697": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391"
  },
  "r698": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28541-108399"
  },
  "r699": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28551-108399"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r700": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399"
  },
  "r701": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "http://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400"
  },
  "r702": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "40",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Subparagraph": "(Note 3)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=82846649&loc=d3e38371-112697"
  },
  "r703": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41499-112717"
  },
  "r704": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r705": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "http://asc.fasb.org/extlink&oid=77902758&loc=d3e41502-112717"
  },
  "r706": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=119364159&loc=SL77916155-209984"
  },
  "r707": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r708": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977"
  },
  "r709": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888419&loc=SL77918643-209977"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(b),22(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r710": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918666-209980"
  },
  "r711": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r712": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918673-209980"
  },
  "r713": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r714": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r715": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r716": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r717": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r718": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r719": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r720": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r721": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980"
  },
  "r722": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888426&loc=SL77918701-209980"
  },
  "r723": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971"
  },
  "r724": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=77888430&loc=SL77919786-209982"
  },
  "r725": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r726": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r727": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314020-165662"
  },
  "r728": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109246787&loc=d3e93645-111703"
  },
  "r729": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19,20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r730": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r731": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r732": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=118948506&loc=d3e107207-111719"
  },
  "r733": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=109249958&loc=SL6224234-111729"
  },
  "r734": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122625-111746"
  },
  "r735": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=116651436&loc=d3e122869-111746"
  },
  "r736": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "340",
   "Topic": "928",
   "URI": "http://asc.fasb.org/extlink&oid=6473545&loc=d3e61844-108004"
  },
  "r737": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953"
  },
  "r738": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(10))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r739": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r740": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r741": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(13))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r742": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r743": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r744": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r745": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r746": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(4))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r747": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(5))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r748": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6)(a)(1))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r749": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(6))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r750": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878"
  },
  "r751": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r752": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r753": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r754": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(20))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r755": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r756": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r757": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04.9)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260"
  },
  "r758": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Subparagraph": "b.",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6477933&loc=d3e60009-112784"
  },
  "r759": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r760": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75019621&loc=d3e62586-112803"
  },
  "r761": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "405",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6957935&loc=d3e64057-112817"
  },
  "r762": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "470",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=75038535&loc=d3e64711-112823"
  },
  "r763": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=6479915&loc=d3e66715-112838"
  },
  "r764": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r765": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r766": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(b))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r767": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(1)(g))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r768": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r769": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r770": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r771": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r772": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(24))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r773": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r774": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r775": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910"
  },
  "r776": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(10))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r777": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(11))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r778": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r779": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.22)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r780": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(19))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r781": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263"
  },
  "r782": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4H",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=116884468&loc=SL65671331-158438"
  },
  "r783": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(a)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r784": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r785": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13H",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Subparagraph": "(c)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117419784&loc=SL117783719-158441"
  },
  "r786": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Subparagraph": "(b)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=6487024&loc=d3e29054-158556"
  },
  "r787": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=117420044&loc=d3e19393-158473"
  },
  "r788": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=99380617&loc=SL75241803-196195"
  },
  "r789": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12(2)(i))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r790": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611133-123010"
  },
  "r791": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C(1)(a))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r792": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r793": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-12C.4,6)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611225-123010"
  },
  "r794": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13(1))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r795": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-13)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611282-123010"
  },
  "r796": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-14)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611322-123010"
  },
  "r797": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15(Column A))",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r798": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "320",
   "Subparagraph": "(SX 210.12-15)",
   "Topic": "946",
   "URI": "http://asc.fasb.org/extlink&oid=50485924&loc=d3e611379-123010"
  },
  "r799": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "310",
   "Subparagraph": "(SX 210.12-29(Footnote 4))",
   "Topic": "948",
   "URI": "http://asc.fasb.org/extlink&oid=6589523&loc=d3e617274-123014"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1361-107760"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r800": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6049-115624"
  },
  "r801": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "450",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491354&loc=d3e6052-115624"
  },
  "r802": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "740",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491622&loc=d3e9504-115650"
  },
  "r803": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "360",
   "Subparagraph": "(SX 210.12-28(Footnote 2))",
   "Topic": "970",
   "URI": "http://asc.fasb.org/extlink&oid=6590653&loc=d3e638233-123024"
  },
  "r804": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r805": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r806": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r807": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1-"
  },
  "r808": {
   "Name": "Forms 10-K, 20-F, 40-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d-1"
  },
  "r809": {
   "Name": "Regulation 12B",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29,30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r810": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.6(d))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.8)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=51824906&loc=SL20225862-175312"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=d3e1474-107760"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226008-175313"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a),(b),(c)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(dd)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=118930883&loc=SL7669646-108580"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R89.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7018256272">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="nump">4,450<span></span>
</td>
<td class="nump">$ 4,149<span></span>
</td>
<td class="nump">2,799<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">167,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">159,422<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="nump">718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">11,176<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,110<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="nump">718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency debt - non-U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">4,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,703<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">1,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,260<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">9,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,850<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Total liabilities</a></td>
<td class="nump">718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">6,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,091<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="nump">7,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,691<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Money market funds [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Equity [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">29<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">4,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Money market funds [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Equity [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 1 [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,583<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">6,687<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,091<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities', window );">Total short-term investments</a></td>
<td class="nump">7,392<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16,674<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Money market funds [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Equity [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">4,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,609<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember', window );">Short-term Investments [Member] | Level 2 [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">1,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,045<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">465<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">574<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember', window );">Other Current Assets [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsCurrent', window );">Current derivative assets</a></td>
<td class="nump">413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="nump">2,216<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,764<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">1,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="nump">1,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,243<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 1 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 1 [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 1 [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities</a></td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments', window );">Total long-term investments</a></td>
<td class="nump">354<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">521<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 2 [Member] | Government and agency debt - non-U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">94<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 2 [Member] | Government and agency - U.S. [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Level 2 [Member] | Corporate and Other [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt securities</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="nump">575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">526<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">566<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount', window );">Insurance contracts</a></td>
<td class="nump">575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">515<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total other noncurrent assets</a></td>
<td class="nump">1,102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,082<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember', window );">Other Noncurrent Assets [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssetsNoncurrent', window );">Noncurrent derivative assets</a></td>
<td class="nump">261<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">232<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">82<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember', window );">Other Current Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesCurrent', window );">Current derivative liabilities</a></td>
<td class="nump">114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">78<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 1 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 1 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 2 [Member] | Recurring [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">942<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Interest rate contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">378<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember', window );">Other Noncurrent Liabilities [Member] | Level 2 [Member] | Recurring [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilitiesNoncurrent', window );">Noncurrent derivative liabilities</a></td>
<td class="nump">$ 604<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 564<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Investments Excluding Held-To-Maturity Securities And Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Short-term Investments Excluding Held-To-Maturity Securities</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShorttermInvestmentsExcludingHeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled within one year or normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of life settlement contracts accounted for under the fair value method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 325<br> -SubTopic 30<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=73718008&amp;loc=d3e42732-111610<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LifeSettlementContractsFairValueMethodCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_EquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherCurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6917853184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. statutory income tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent', window );">TCJA impact</a></td>
<td class="num">(0.018)<span></span>
</td>
<td class="num">(0.050)<span></span>
</td>
<td class="num">(0.866)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Taxation of non-U.S. operations</a></td>
<td class="num">(5.70%)<span></span>
</td>
<td class="num">(6.10%)<span></span>
</td>
<td class="num">(17.00%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements', window );">Tax settlements and resolution of certain tax positions</a></td>
<td class="num">(9.00%)<span></span>
</td>
<td class="num">(5.80%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness', window );">Completion of Consumer Healthcare joint venture transaction(d)</a></td>
<td class="nump">5.30%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent', window );">U.S. Healthcare Legislation</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="nump">0.90%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">U.S. R&amp;D tax credit and manufacturing deduction</a></td>
<td class="num">(0.50%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
<td class="num">(0.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent', window );">Certain legal settlements and charges</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="num">(0.10%)<span></span>
</td>
<td class="nump">0.10%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">All other, net</a></td>
<td class="num">(1.50%)<span></span>
</td>
<td class="nump">3.10%<span></span>
</td>
<td class="num">(3.90%)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate for income from continuing operations</a></td>
<td class="nump">7.80%<span></span>
</td>
<td class="nump">5.90%<span></span>
</td>
<td class="num">(73.50%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deduction, Litigation Settlement, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Change In Legislation, Percent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to disposition of a business not qualifying as a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationDispositionOfBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operations, attributable to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6837571904">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Deferred Taxes - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward', window );">Reduction for unrecognized tax benefit</a></td>
<td class="nump">$ 2,900<span></span>
</td>
<td class="nump">$ 3,300<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">4,700<span></span>
</td>
<td class="nump">2,948<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember', window );">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">900<span></span>
</td>
<td class="nump">800<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember', window );">Noncurrent Deferred Tax Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationLineItems', window );"><strong>Income Tax Examination [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">$ 5,600<span></span>
</td>
<td class="nump">$ 3,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Associated With Unrecognized Tax Benefits, Operating Loss Carryforward And Credit Carryforward</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7042085440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes - Collaborative Arrangements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Apr. 01, 2018</div></th>
<th class="th"><div>Apr. 02, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Jul. 01, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ProceedsFromLicensingArrangement', window );">Proceeds from licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_MylanMember', window );">Mylan [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ShireMember', window );">Shire [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ProceedsFromLicensingArrangement', window );">Proceeds from licensing arrangement</a></td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_MerckMember', window );">Merck [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="nump">150<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember', window );">Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member] | Disposed of by Sale, Not Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash received for disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember', window );">Distribution Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfIntangibleAssets', window );">Gain related to sale of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">$ 85<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Shire [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ProceedsFromLicensingArrangement', window );">Proceeds from licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Merck [Member] | Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member] | Disposed of by Sale, Not Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash received for disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ProceedsFromLicensingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Licensing Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ProceedsFromLicensingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_MylanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_MylanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ShireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ShireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DistributionRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6834607840">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes - Additional Information About Impaired Intangible Assets (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">$ 1,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">2,770<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Intangible assets&#8211;&#8211;Developed technology rights</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">2,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member', window );">Level 1 [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Intangible assets&#8211;&#8211;Developed technology rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Level 2 [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Intangible assets&#8211;&#8211;Developed technology rights</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsFairValueDisclosure', window );">Total</a></td>
<td class="nump">1,229<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member', window );">Level 3 [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure', window );">Intangible assets&#8211;&#8211;Developed technology rights</a></td>
<td class="nump">1,213<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Intangible assets&#8211;&#8211;IPR&amp;D</a></td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Impairment</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Intangible assets&#8211;&#8211;IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Intangible assets&#8211;&#8211;IPR&amp;D</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems', window );"><strong>Fair Value Measurement Inputs and Valuation Techniques [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure', window );">Intangible assets&#8211;&#8211;IPR&amp;D</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Fair Value Disclosure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets, that lack physical substance, having a limited useful life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of assets, excluding financial assets and goodwill, that lack physical substance, having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039650656">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax', window );">Foreign currency translation adjustments, net</a></td>
<td class="nump">$ 254<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
<td class="num">$ (215)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax', window );">Unrealized holding gains/(losses) on derivative financial instruments, net</a></td>
<td class="nump">83<span></span>
</td>
<td class="nump">21<span></span>
</td>
<td class="nump">72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="num">(125)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax', window );">Other comprehensive income (loss), derivatives qualifying as hedges, tax, total</a></td>
<td class="num">(42)<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="num">(152)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized holding gains/(losses) on available-for-sale securities, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(23)<span></span>
</td>
<td class="nump">102<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax', window );">Reclassification adjustments for (gains)/losses included in net income</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(60)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax', window );">Other comprehensive income (loss), available-for-sale securities, tax, total</a></td>
<td class="nump">5<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax', window );">Benefit plans: actuarial losses, net</a></td>
<td class="num">(169)<span></span>
</td>
<td class="num">(141)<span></span>
</td>
<td class="num">(59)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax', window );">Reclassification adjustments related to amortization</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax', window );">Reclassification adjustments related to settlements, net</a></td>
<td class="nump">65<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax', window );">Other</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="num">(39)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax', window );">Defined benefit plan, amounts recognized in other comprehensive income (loss), net actuarial gain (loss), tax</a></td>
<td class="num">(58)<span></span>
</td>
<td class="nump">612<span></span>
</td>
<td class="nump">137<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax', window );">Benefit plans: prior service costs and other, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to amortization of prior service costs and other, net</a></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(39)<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax', window );">Reclassification adjustments related to curtailments of prior service costs and other, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax', window );">Other</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect', window );">Other comprehensive income (loss), pension and other postretirement benefit plans, net prior service cost (credit), tax</a></td>
<td class="num">(45)<span></span>
</td>
<td class="num">(185)<span></span>
</td>
<td class="num">(74)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTax', window );">Tax provision/(benefit) on other comprehensive income/(loss)</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">518<span></span>
</td>
<td class="num">(262)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member', window );">Reclassification of Certain Tax Effects from AOCI [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax', window );">Reclassification adjustments of certain tax effects from AOCI to Retained earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax', window );">Reclassification adjustments of certain tax effects from AOCI to Retained earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">637<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax', window );">Reclassification adjustments of certain tax effects from AOCI to Retained earnings</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(144)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Financial Assets and Liabilities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract', window );"><strong>Tax Expense/(Benefit) on Other Comprehensive Income/(Loss)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax', window );">Reclassification adjustments for tax on unrealized gains from AOCI to Retained earnings</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (45)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Actuarial Gain (Loss), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Amounts Recognized in Other Comprehensive Income (Loss), Net Prior Service Cost (Credit) And Other, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Curtailment Adjustment from AOCI, Pension and Other Postretirement Benefit Plans, for Net Prior Service Cost (Credit), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive (Income) Loss, Pension and Other Postretirement Benefit Plans, Other Net Prior Service Cost (Credit) Arising During Period, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Pension and Other Postretirement Benefit Plans, Other Net Unamortized Gain (Loss) Arising During Period, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Reclassification Adjustment For Tax On Unrealized Gains Included In Retained Earnings, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Actuarial Gains, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Defined Benefit Plans, Prior Service (Costs) Credits, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Reclassification Adjustment from AOCI to Retained Earnings, Foreign Currency Translation Adjustment, Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Settlement Adjustment From AOCI, Pension And Other Postretirement Benefit Plans, for Net Gain (Loss), Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for (increase) decrease in value of benefit obligation for change in actuarial assumptions and increase (decrease) in value of plan assets from experience different from that assumed of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit of reclassification adjustment from accumulated other comprehensive (income) loss for prior service cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments, of appreciation (loss) in value of unsold available-for-sale securities. Excludes amounts related to other than temporary impairment (OTTI) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before reclassification, of tax expense (benefit) for gain (loss) from derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) for reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit), after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax (expense) benefit for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income for unrealized gain (loss) realized upon the sale of available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) of reclassification adjustment from accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) allocated to other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e39076-109324<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax expense (benefit) before reclassification adjustments of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R149.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6951281808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Stock Option Activity (Detail)<br> $ / shares in Units, shares in Thousands, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, beginning of period, shares | shares</a></td>
<td class="nump">103,791<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares | shares</a></td>
<td class="nump">1,181<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised, shares | shares</a></td>
<td class="num">(15,964)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited, shares | shares</a></td>
<td class="num">(55)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired, shares | shares</a></td>
<td class="num">(353)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding, end of period, shares | shares</a></td>
<td class="nump">88,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of period, shares | shares</a></td>
<td class="nump">88,469<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable, end of period, shares | shares</a></td>
<td class="nump">85,372<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.69<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">43.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">24.84<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">37.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">31.12<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">28.39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">28.37<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable, end of period, weighted-average exercise price per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 28.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding, end of period, weighted-average remaining contractual term</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, end of period, weighted-average remaining contractual term</a></td>
<td class="text">3 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, end of period, weighted-average remaining contractual term</a></td>
<td class="text">3 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding, end of period, aggregate intrinsic value | $</a></td>
<td class="nump">$ 960<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest, end of period, aggregate intrinsic value | $</a></td>
<td class="nump">960<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable, end of period, aggregate intrinsic value | $</a></td>
<td class="nump">$ 951<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.3.a.u2</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1359</ContextCount>
  <ElementCount>1023</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>true</FootnotesReported>
  <SegmentCount>349</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>21</UnitCount>
  <MyReports>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0001000 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>1001000 - Statement - Consolidated Statements of Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsOfIncome</Role>
      <ShortName>Consolidated Statements of Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>1002000 - Statement - Consolidated Statements of Comprehensive Income</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncome</Role>
      <ShortName>Consolidated Statements of Comprehensive Income</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>1002501 - Statement - Consolidated Statements of Comprehensive Income (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsOfComprehensiveIncomeParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Income (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>1003000 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>1003501 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>1004000 - Statement - Consolidated Statements of Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsOfEquity</Role>
      <ShortName>Consolidated Statements of Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>1004001 - Statement - Consolidated Statements of Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsOfEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>1005000 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>1005501 - Statement - Consolidated Statements of Cash Flows (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ConsolidatedStatementsOfCashFlowsParenthetical</Role>
      <ShortName>Consolidated Statements of Cash Flows (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>2101100 - Disclosure - Basis of Presentation and Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>2102100 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>2103100 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>2104100 - Disclosure - Other (Income)/Deductions - Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNet</Role>
      <ShortName>Other (Income)/Deductions - Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>2105100 - Disclosure - Tax Matters</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMatters</Role>
      <ShortName>Tax Matters</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>2106100 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>2107100 - Disclosure - Financial Instruments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstruments</Role>
      <ShortName>Financial Instruments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>2108100 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>2109100 - Disclosure - Property, Plant and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PropertyPlantAndEquipment</Role>
      <ShortName>Property, Plant and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>2110100 - Disclosure - Identifiable Intangible Assets and Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>2111100 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>2112100 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>2113100 - Disclosure - Share-Based Payments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPayments</Role>
      <ShortName>Share-Based Payments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>2114100 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>2116100 - Disclosure - Insurance</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/Insurance</Role>
      <ShortName>Insurance</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>2117100 - Disclosure - Contingencies and Certain Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesAndCertainCommitments</Role>
      <ShortName>Contingencies and Certain Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>2118100 - Disclosure - Segment, Geographic and Other Revenue Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation</Role>
      <ShortName>Segment, Geographic and Other Revenue Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>2201201 - Disclosure - Basis of Presentation and Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>2301302 - Disclosure - Basis of Presentation and Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTables</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPolicies</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>2302301 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>2303301 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiatives</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>2304301 - Disclosure - Other (Income)/Deductions - Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</Role>
      <ShortName>Other (Income)/Deductions - Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNet</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>2305301 - Disclosure - Tax Matters (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTables</Role>
      <ShortName>Tax Matters (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/TaxMatters</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>2306301 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterests</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>2307301 - Disclosure - Financial Instruments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTables</Role>
      <ShortName>Financial Instruments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/FinancialInstruments</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>2308301 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/Inventories</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>2309301 - Disclosure - Property, Plant and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PropertyPlantAndEquipmentTables</Role>
      <ShortName>Property, Plant and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PropertyPlantAndEquipment</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>2310301 - Disclosure - Identifiable Intangible Assets and Goodwill (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillTables</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwill</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>2311301 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlans</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>2312301 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/Equity</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>2313301 - Disclosure - Share-Based Payments (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsTables</Role>
      <ShortName>Share-Based Payments (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ShareBasedPayments</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>2314301 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersTables</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholders</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>2318301 - Disclosure - Segment, Geographic and Other Revenue Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</Role>
      <ShortName>Segment, Geographic and Other Revenue Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformation</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>2401403 - Disclosure - Basis of Presentation and Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>2401404 - Disclosure - Basis of Presentation and Significant Accounting Policies - Impact of Lease Standard Adoption (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesImpactOfLeaseStandardAdoptionDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Impact of Lease Standard Adoption (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>2401405 - Disclosure - Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesAccruedRebatesAndOtherAccrualsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Accrued Rebates and Other Accruals (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>2401406 - Disclosure - Basis of Presentation and Significant Accounting Policies - ROU Assets and Liabilities Presented in Balance Sheet (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesRouAssetsAndLiabilitiesPresentedInBalanceSheetDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - ROU Assets and Liabilities Presented in Balance Sheet (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>2401407 - Disclosure - Basis of Presentation and Significant Accounting Policies - Total Lease Cost (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesTotalLeaseCostDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Total Lease Cost (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>2401408 - Disclosure - Basis of Presentation and Significant Accounting Policies - Other Supplemental Lease Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesOtherSupplementalLeaseInformationDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Other Supplemental Lease Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>2401409 - Disclosure - Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/BasisOfPresentationAndSignificantAccountingPoliciesFutureMinimumRentalCommitmentsDetails</Role>
      <ShortName>Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>2402402 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Array BioPharma Inc (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsArrayBiopharmaIncDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Array BioPharma Inc (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>2402403 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Therachon Holding AG (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTherachonHoldingAgDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Therachon Holding AG (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>2402404 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - AstraZeneca (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsAstrazenecaDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - AstraZeneca (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</ParentRole>
      <Position>53</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>2402405 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Medivation, Inc. (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsMedivationIncDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Medivation, Inc. (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</ParentRole>
      <Position>54</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>2402406 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Divestitures (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsDivestituresDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Divestitures (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>2402407 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Equity Method Investments and Assets and Liabilities Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Equity Method Investments and Assets and Liabilities Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>2402408 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Schedule of Assets Held for Sale (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsScheduleOfAssetsHeldForSaleDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Schedule of Assets Held for Sale (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>2402409 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsSummarizedFinancialInformationOfEquityMethodInvesteeDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>2402410 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Licensing Arrangements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsLicensingArrangementsDetails</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Licensing Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</ParentRole>
      <Position>59</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>2402411 - Disclosure - Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - R &amp; D and Collaborative Arrangements (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsRDAndCollaborativeArrangementsDetail</Role>
      <ShortName>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - R &amp; D and Collaborative Arrangements (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AcquisitionsDivestituresEquityMethodInvestmentsAndAssetsAndLiabilitiesHeldForSaleLicensingArrangementsAndResearchAndDevelopmentAndCollaborativeArrangementsTables</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>2403402 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesNarrativeDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>61</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>2403403 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>62</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>2403404 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesCostsFootnotesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>63</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>2403405 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>2403406 - Disclosure - Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/RestructuringChargesAndOtherCostsAssociatedWithAcquisitionsAndCostReductionProductivityInitiativesRestructuringAccrualsFootnotesDetail</Role>
      <ShortName>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>2404402 - Disclosure - Other (Income)/Deductions - Net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetDetails</Role>
      <ShortName>Other (Income)/Deductions - Net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>66</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>2404403 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInterestIncomeExpenseDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>2404404 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Royalty Income (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesRoyaltyIncomeDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes - Royalty Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>68</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>2404405 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Asset Disposals and Investments in Equity Securities (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAssetDisposalsAndInvestmentsInEquitySecuritiesDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes - Asset Disposals and Investments in Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>69</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>2404406 - Disclosure - Other (Income)/ Deductions - Net - Footnotes - Investments (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesInvestmentsDetails</Role>
      <ShortName>Other (Income)/ Deductions - Net - Footnotes - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>70</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>2404407 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Collaborative Arrangements (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCollaborativeArrangementsDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes - Collaborative Arrangements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>2404408 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesCommitmentsAndContingenciesDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>72</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>2404409 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesIntangibleAssetsDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>73</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>2404410 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Additional Information (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationDetails</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>2404411 - Disclosure - Other (Income)/Deductions - Net - Footnotes - Additional Information About Impaired Intangible Assets (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/OtherIncomeDeductionsNetFootnotesAdditionalInformationAboutImpairedIntangibleAssetsDetail</Role>
      <ShortName>Other (Income)/Deductions - Net - Footnotes - Additional Information About Impaired Intangible Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/OtherIncomeDeductionsNetTables</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>2405402 - Disclosure - Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersIncomeFromContinuingOperationsBeforeProvisionForTaxesOnIncomeDetails</Role>
      <ShortName>Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>2405403 - Disclosure - Tax Matters - Provision for Taxes on Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeDetails</Role>
      <ShortName>Tax Matters - Provision for Taxes on Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>2405404 - Disclosure - Tax Matters - Provision for Taxes on Income (Narrative) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersProvisionForTaxesOnIncomeNarrativeDetails</Role>
      <ShortName>Tax Matters - Provision for Taxes on Income (Narrative) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>2405405 - Disclosure - Tax Matters - Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTaxRateReconciliationDetails</Role>
      <ShortName>Tax Matters - Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>2405406 - Disclosure - Tax Matters - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersDeferredTaxesDetails</Role>
      <ShortName>Tax Matters - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>2405407 - Disclosure - Tax Matters - Deferred Taxes - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersDeferredTaxesFootnotesDetails</Role>
      <ShortName>Tax Matters - Deferred Taxes - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>2405408 - Disclosure - Tax Matters - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersNarrativeDetails</Role>
      <ShortName>Tax Matters - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>2405409 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>83</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>2405410 - Disclosure - Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersReconciliationOfGrossUnrecognizedTaxBenefitsFootnotesDetails</Role>
      <ShortName>Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>2405411 - Disclosure - Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/TaxMattersTaxesOnItemsOfOtherComprehensiveIncomeLossDetails</Role>
      <ShortName>Tax Matters - Taxes on Items of Other Comprehensive Income/(Loss) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>2406402 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</ParentRole>
      <Position>86</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>2406403 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsFootnotesDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</ParentRole>
      <Position>87</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R88.htm</HtmlFileName>
      <LongName>2406404 - Disclosure - Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsNarrativeDetails</Role>
      <ShortName>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/AccumulatedOtherComprehensiveLossExcludingNoncontrollingInterestsTables</ParentRole>
      <Position>88</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R89.htm</HtmlFileName>
      <LongName>2407402 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>89</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R90.htm</HtmlFileName>
      <LongName>2407403 - Disclosure - Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFinancialAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasisFootnotesDetails</Role>
      <ShortName>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>90</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R91.htm</HtmlFileName>
      <LongName>2407404 - Disclosure - Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsAssetsAndLiabilitiesNotMeasuredAtFairValueOnRecurringBasisDetails</Role>
      <ShortName>Financial Instruments - Assets and Liabilities Not Measured at Fair Value on a Recurring Basis (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>91</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R92.htm</HtmlFileName>
      <LongName>2407405 - Disclosure - Financial Instruments - Total Short-term and Long-term Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsTotalShortTermAndLongTermInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Total Short-term and Long-term Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>92</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R93.htm</HtmlFileName>
      <LongName>2407406 - Disclosure - Financial Instruments - Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsDetails</Role>
      <ShortName>Financial Instruments - Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>93</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R94.htm</HtmlFileName>
      <LongName>2407407 - Disclosure - Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsInvestmentsUnrealizedGainsAndLossesRelatedToEquitySecuritiesDetails</Role>
      <ShortName>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>94</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R95.htm</HtmlFileName>
      <LongName>2407409 - Disclosure - Financial Instruments - Short-Term Borrowings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsShortTermBorrowingsDetails</Role>
      <ShortName>Financial Instruments - Short-Term Borrowings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>95</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R96.htm</HtmlFileName>
      <LongName>2407410 - Disclosure - Financial Instruments - Long-Term Debt, New Issuances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNewIssuancesDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt, New Issuances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>96</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R97.htm</HtmlFileName>
      <LongName>2407411 - Disclosure - Financial Instruments - Long-Term Debt Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtNarrativeDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>97</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R98.htm</HtmlFileName>
      <LongName>2407412 - Disclosure - Financial Instruments - Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsLongTermDebtDetails</Role>
      <ShortName>Financial Instruments - Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>98</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R99.htm</HtmlFileName>
      <LongName>2407413 - Disclosure - Financial Instruments - Other Noncurrent Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsOtherNoncurrentLiabilitiesDetails</Role>
      <ShortName>Financial Instruments - Other Noncurrent Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>99</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R100.htm</HtmlFileName>
      <LongName>2407414 - Disclosure - Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsFairValueOfDerivativeFinancialInstrumentsAndRelatedNotionalAmountsDetails</Role>
      <ShortName>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>100</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R101.htm</HtmlFileName>
      <LongName>2407415 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>101</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R102.htm</HtmlFileName>
      <LongName>2407416 - Disclosure - Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsDerivativeFinancialInstrumentsAndHedgingActivitiesFootnotesDetails</Role>
      <ShortName>Financial Instruments - Derivative Financial Instruments and Hedging Activities - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>102</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R103.htm</HtmlFileName>
      <LongName>2407418 - Disclosure - Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCumulativeBasisAdjustmentsForFairValueHedgesDetails</Role>
      <ShortName>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>103</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R104.htm</HtmlFileName>
      <LongName>2407419 - Disclosure - Financial Instruments - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsNarrativeDetails</Role>
      <ShortName>Financial Instruments - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>104</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R105.htm</HtmlFileName>
      <LongName>2407420 - Disclosure - Financial Instruments - Credit Risk (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/FinancialInstrumentsCreditRiskDetails</Role>
      <ShortName>Financial Instruments - Credit Risk (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>105</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R106.htm</HtmlFileName>
      <LongName>2408402 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/InventoriesTables</ParentRole>
      <Position>106</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R107.htm</HtmlFileName>
      <LongName>2409402 - Disclosure - Property, Plant and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PropertyPlantAndEquipmentDetails</Role>
      <ShortName>Property, Plant and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PropertyPlantAndEquipmentTables</ParentRole>
      <Position>107</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R108.htm</HtmlFileName>
      <LongName>2410402 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>108</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R109.htm</HtmlFileName>
      <LongName>2410403 - Disclosure - Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillFiniteLivedAndIndefiniteLivedIntangibleAssetsFootnotesDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>109</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R110.htm</HtmlFileName>
      <LongName>2410404 - Disclosure - Identifiable Intangible Assets and Goodwill - Intangible Assets Percentage of Total Intangibles (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillIntangibleAssetsPercentageOfTotalIntangiblesDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Intangible Assets Percentage of Total Intangibles (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>110</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R111.htm</HtmlFileName>
      <LongName>2410405 - Disclosure - Identifiable Intangible Assets and Goodwill - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillNarrativeDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>111</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R112.htm</HtmlFileName>
      <LongName>2410406 - Disclosure - Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillExpectedAnnualAmortizationExpenseDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>112</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R113.htm</HtmlFileName>
      <LongName>2410407 - Disclosure - Identifiable Intangible Assets and Goodwill - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/IdentifiableIntangibleAssetsAndGoodwillGoodwillDetails</Role>
      <ShortName>Identifiable Intangible Assets and Goodwill - Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>113</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R114.htm</HtmlFileName>
      <LongName>2411402 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables</ParentRole>
      <Position>114</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R115.htm</HtmlFileName>
      <LongName>2411403 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Footnotes (Details)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFootnotesDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Footnotes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables</ParentRole>
      <Position>115</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R116.htm</HtmlFileName>
      <LongName>2411404 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsExpectedToBeAmortizedIntoNetPeriodicBenefitCostsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>116</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R117.htm</HtmlFileName>
      <LongName>2411405 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansWeightedAverageActuarialAssumptionsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Weighted-Average Actuarial Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>117</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R118.htm</HtmlFileName>
      <LongName>2411406 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansHealthcareCostTrendRateAssumptionsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>118</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R119.htm</HtmlFileName>
      <LongName>2411407 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansOnePercentagePointIncreaseOrDecreaseInHealthcareCostTrendRateDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>119</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R120.htm</HtmlFileName>
      <LongName>2411408 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansObligationsAndFundedStatusDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>120</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R121.htm</HtmlFileName>
      <LongName>2411409 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansFundedStatusRecognizedInConsolidatedBalanceSheetsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Funded Status Recognized in Consolidated Balance Sheets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>121</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R122.htm</HtmlFileName>
      <LongName>2411410 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAmountsRecognizedInAccumulatedOtherComprehensiveLossIncomeDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>122</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R123.htm</HtmlFileName>
      <LongName>2411411 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPensionPlansInExcessOfPlanAssetsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>123</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R124.htm</HtmlFileName>
      <LongName>2411412 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansPlanAssetsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables</ParentRole>
      <Position>124</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R125.htm</HtmlFileName>
      <LongName>2411413 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansAnalysisOfChangesInSignificantInvestmentsValuedUsingSignificantUnobservableInputsDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Analysis of Changes in Significant Investments Valued Using Significant Unobservable Inputs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>125</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R126.htm</HtmlFileName>
      <LongName>2411414 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansLongTermTargetAssetAllocationsRangesAndPercentageOfFairValueOfPlanAssetsDetail</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>126</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R127.htm</HtmlFileName>
      <LongName>2411415 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansExpectedFutureCashFlowInformationDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>127</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R128.htm</HtmlFileName>
      <LongName>2411416 - Disclosure - Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansNarrativeDetails</Role>
      <ShortName>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/PensionAndPostretirementBenefitPlansAndDefinedContributionPlansTables</ParentRole>
      <Position>128</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R129.htm</HtmlFileName>
      <LongName>2412402 - Disclosure - Equity - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquityNarrativeDetails</Role>
      <ShortName>Equity - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>129</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R130.htm</HtmlFileName>
      <LongName>2412403 - Disclosure - Equity - Summary of Common Stock Purchases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EquitySummaryOfCommonStockPurchasesDetails</Role>
      <ShortName>Equity - Summary of Common Stock Purchases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>130</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R131.htm</HtmlFileName>
      <LongName>2413402 - Disclosure - Share-Based Payments - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsNarrativeDetail</Role>
      <ShortName>Share-Based Payments - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>131</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R132.htm</HtmlFileName>
      <LongName>2413403 - Disclosure - Share-Based Payments - Impact on Net Income (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsImpactOnNetIncomeDetail</Role>
      <ShortName>Share-Based Payments - Impact on Net Income (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>132</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R133.htm</HtmlFileName>
      <LongName>2413404 - Disclosure - Share-Based Payments - Total Shareholder Return Units Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsNarrativeDetails</Role>
      <ShortName>Share-Based Payments - Total Shareholder Return Units Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>133</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R134.htm</HtmlFileName>
      <LongName>2413405 - Disclosure - Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfTotalShareholderReturnUnitsDetail</Role>
      <ShortName>Share-Based Payments - Valuation Assumptions of Total Shareholder Return Units (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>134</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R135.htm</HtmlFileName>
      <LongName>2413406 - Disclosure - Share-Based Payments - Total Shareholder Return Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsTotalShareholderReturnUnitsActivityDetails</Role>
      <ShortName>Share-Based Payments - Total Shareholder Return Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>135</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R136.htm</HtmlFileName>
      <LongName>2413407 - Disclosure - Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsOutstandingTotalShareholderReturnUnitsActivityDetails</Role>
      <ShortName>Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>136</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R137.htm</HtmlFileName>
      <LongName>2413408 - Disclosure - Share-Based Payments - Data Related to All Total Shareholder Return Units (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllTotalShareholderReturnUnitsDetails</Role>
      <ShortName>Share-Based Payments - Data Related to All Total Shareholder Return Units (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>137</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R138.htm</HtmlFileName>
      <LongName>2413409 - Disclosure - Share-Based Payments - Performance Total Shareholder Return Units Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsPerformanceTotalShareholderReturnUnitsNarrativeDetails</Role>
      <ShortName>Share-Based Payments - Performance Total Shareholder Return Units Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>138</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R139.htm</HtmlFileName>
      <LongName>2413410 - Disclosure - Share-Based Payments - Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsRestrictedStockUnitActivityDetail</Role>
      <ShortName>Share-Based Payments - Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>139</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R140.htm</HtmlFileName>
      <LongName>2413411 - Disclosure - Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllRestrictedStockUnitActivityDetail</Role>
      <ShortName>Share-Based Payments - Data Related to All Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>140</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R141.htm</HtmlFileName>
      <LongName>2413412 - Disclosure - Share-Based Payments - Portfolio Performance Shares Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesNarrativeDetails</Role>
      <ShortName>Share-Based Payments - Portfolio Performance Shares Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>141</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R142.htm</HtmlFileName>
      <LongName>2413413 - Disclosure - Share-Based Payments - Portfolio Performance Shares Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsPortfolioPerformanceSharesActivityDetails</Role>
      <ShortName>Share-Based Payments - Portfolio Performance Shares Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>142</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R143.htm</HtmlFileName>
      <LongName>2413414 - Disclosure - Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPortfolioPerformanceSharesActivityDetails</Role>
      <ShortName>Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>143</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R144.htm</HtmlFileName>
      <LongName>2413415 - Disclosure - Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasNarrativeDetails</Role>
      <ShortName>Share-Based Payments - Performance Share Awards (PSAs) Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>144</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R145.htm</HtmlFileName>
      <LongName>2413416 - Disclosure - Share-Based Payments - Performance Share Awards (PSAs) Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsPerformanceShareAwardsPsasActivityDetails</Role>
      <ShortName>Share-Based Payments - Performance Share Awards (PSAs) Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>145</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R146.htm</HtmlFileName>
      <LongName>2413417 - Disclosure - Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllPerformanceShareAwardsPsasDetails</Role>
      <ShortName>Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>146</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R147.htm</HtmlFileName>
      <LongName>2413418 - Disclosure - Share-Based Payments - Stock Option Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsStockOptionNarrativeDetails</Role>
      <ShortName>Share-Based Payments - Stock Option Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>147</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R148.htm</HtmlFileName>
      <LongName>2413419 - Disclosure - Share-Based Payments - Valuation Assumptions of Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsValuationAssumptionsOfStockOptionsDetail</Role>
      <ShortName>Share-Based Payments - Valuation Assumptions of Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>148</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R149.htm</HtmlFileName>
      <LongName>2413420 - Disclosure - Share-Based Payments - Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsStockOptionActivityDetail</Role>
      <ShortName>Share-Based Payments - Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>149</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R150.htm</HtmlFileName>
      <LongName>2413421 - Disclosure - Share-Based Payments - Data Related to All Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ShareBasedPaymentsDataRelatedToAllStockOptionActivityDetail</Role>
      <ShortName>Share-Based Payments - Data Related to All Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>150</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R151.htm</HtmlFileName>
      <LongName>2414402 - Disclosure - Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/EarningsPerCommonShareAttributableToPfizerIncCommonShareholdersBasicAndDilutedDetails</Role>
      <ShortName>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders - Basic and Diluted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>151</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R152.htm</HtmlFileName>
      <LongName>2417401 - Disclosure - Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeArePlaintiffDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesAndCertainCommitments</ParentRole>
      <Position>152</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R153.htm</HtmlFileName>
      <LongName>2417402 - Disclosure - Contingencies and Certain Commitments (Action In Which We Are The Defendant) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsActionInWhichWeAreDefendantDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Action In Which We Are The Defendant) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesAndCertainCommitments</ParentRole>
      <Position>153</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R154.htm</HtmlFileName>
      <LongName>2417403 - Disclosure - Contingencies and Certain Commitments (Commitments and Contingent Consideration for Acquisitions) (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/ContingenciesAndCertainCommitmentsCommitmentsAndContingentConsiderationForAcquisitionsDetails</Role>
      <ShortName>Contingencies and Certain Commitments (Commitments and Contingent Consideration for Acquisitions) (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/ContingenciesAndCertainCommitments</ParentRole>
      <Position>154</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R155.htm</HtmlFileName>
      <LongName>2418402 - Disclosure - Segment, Geographic and Other Revenue Information - Narrative (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationNarrativeDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Narrative (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>155</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R156.htm</HtmlFileName>
      <LongName>2418403 - Disclosure - Segment, Geographic and Other Revenue Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>156</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R157.htm</HtmlFileName>
      <LongName>2418404 - Disclosure - Segment, Geographic and Other Revenue Information - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationFootnotesDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationTables</ParentRole>
      <Position>157</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R158.htm</HtmlFileName>
      <LongName>2418405 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>158</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R159.htm</HtmlFileName>
      <LongName>2418406 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByGeographicAreaFootnotesDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area - Footnotes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>159</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R160.htm</HtmlFileName>
      <LongName>2418407 - Disclosure - Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationLongLivedAssetsByGeographicRegionDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>160</Position>
    </Report>
    <Report instance="pfe-12312019x10kshell.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R161.htm</HtmlFileName>
      <LongName>2418408 - Disclosure - Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.pfizer.com/role/SegmentGeographicAndOtherRevenueInformationRevenuesByProductsDetail</Role>
      <ShortName>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>161</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="pfe-12312019x10kshell.htm">pfe-12312019x10kshell.htm</File>
    <File doctype="10-K" original="pfe-exhibit13x12312019.htm">pfe-exhibit13x12312019.htm</File>
    <File>pfe-20191231.xsd</File>
    <File>pfe-20191231_cal.xml</File>
    <File>pfe-20191231_def.xml</File>
    <File>pfe-20191231_lab.xml</File>
    <File>pfe-20191231_pre.xml</File>
    <File>pfe-ex1015x12312019xk.htm</File>
    <File>pfe-exh1029x12312019x1.htm</File>
    <File>pfe-exh311x1231201910k.htm</File>
    <File>pfe-exh312x1231201910k.htm</File>
    <File>pfe-exh321x1231201910k.htm</File>
    <File>pfe-exh322x1231201910k.htm</File>
    <File>pfe-exhibit21x12312019.htm</File>
    <File>pfe-exhibit23x12312019.htm</File>
    <File>pfe-exhibit24x12312019.htm</File>
    <File>pfe-exhibit421x123119x.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>adjdilutedeps-nongaap2019.jpg</File>
    <File>albertbourlasignatureq42019.jpg</File>
    <File>biopharmrevincrease2018-2019.jpg</File>
    <File>biopharmrevincrease2018v2017.jpg</File>
    <File>franksignatureq42019.jpg</File>
    <File>globe.jpg</File>
    <File>kpmgsignatureq42019.jpg</File>
    <File>lorettasignatureq42019.jpg</File>
    <File>marketgrowth.jpg</File>
    <File>microscope.jpg</File>
    <File>netcashflowfromops2019.jpg</File>
    <File>peergroupgraph2019.jpg</File>
    <File>pfizercoverlogoa01.jpg</File>
    <File>pfizerlogo.jpg</File>
    <File>pfizerlogo2816.jpg</File>
    <File>pfizerpipeline2020a02.jpg</File>
    <File>pharmapack.jpg</File>
    <File>pharmapill.jpg</File>
    <File>prescription.jpg</File>
    <File>reporteddilutedeps2019.jpg</File>
    <File>revbynatlmarket2017-2019.jpg</File>
    <File>revbynatlmrkt2017-2019.jpg</File>
    <File>revbyopsegment-geography2017.jpg</File>
    <File>revbyopsegment-geography2018.jpg</File>
    <File>revbyopsegment-geography2019.jpg</File>
    <File>revenuedecreasein2019.jpg</File>
    <File>structure.jpg</File>
    <File>syringe.jpg</File>
    <File>tagline_1.jpg</File>
    <File>team.jpg</File>
    <File>testtubes.jpg</File>
    <File>totalrev2019.jpg</File>
    <File>totalrevbycustomer.jpg</File>
    <File>totandusrevbiowhlslrs2019.jpg</File>
    <File>upjohnlogo.jpg</File>
    <File>upjohnlogoa02.jpg</File>
    <File>upjohnrevdecrease2018-2019.jpg</File>
    <File>upjohnrevdecrease2018v2017.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/currency/2019-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R141.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7190555968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Portfolio Performance Shares Narrative (Details) - Portfolio Performance Shares [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward', window );">Number of shares earned as a percentage of initial award</a></td>
<td class="nump">200.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Number of Shares Earned, Percentage of Initial Award</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7019149808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Equity Method Investments and Assets and Liabilities Held for Sale (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="4">3 Months Ended</th>
<th class="th" colspan="1">7 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Nov. 10, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 02, 2017</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2012</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of Consumer Healthcare JV transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,086,000,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,133,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,133,000,000<span></span>
</td>
<td class="nump">181,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of Consumer Healthcare JV transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfTax', window );">Gain on completion of Consumer Healthcare JV transaction, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,400,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentsTaxIndemnificationLiability', window );">Tax indemnification liability</a></td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 45,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Equity method investment earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity method investments, fair value</a></td>
<td class="nump">15,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,700,000,000<span></span>
</td>
<td class="nump">$ 15,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets', window );">Underlying equity in net assets</a></td>
<td class="nump">11,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity', window );">Difference between carrying amount and underlying equity</a></td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod', window );">Excess basis amortization period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">17 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm', window );">Transitional agreement administrative services term</a></td>
<td class="text">24 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm', window );">Transitional agreement manufacture and supply term</a></td>
<td class="text">6 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity', window );">Equity method investment, registered capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,304,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member] | GSK [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentExcessBasisAmortization', window );">Excess basis amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV Healthcare Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220,000,000<span></span>
</td>
<td class="nump">253,000,000<span></span>
</td>
<td class="nump">$ 266,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember', window );">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 122,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity', window );">Equity method investment, registered capital</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments', window );">Proceeds from sale of equity method investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 286,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount', window );">Equity method investment, carrying value of share sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">270,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax', window );">Proceeds from sale of equity method investment used to cover taxes incurred on transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss', window );">Pre-tax income attributable to disposal group</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 654,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 977,000,000<span></span>
</td>
<td class="nump">$ 863,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Not Discontinued Operation, Pre-tax Income (Loss)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentExcessBasisAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Excess Basis Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentExcessBasisAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Excess Basis Amortization, Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentExcessBasisAmortizationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Proceeds From Sale Used To Cover Transaction Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentsTaxIndemnificationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Tax Indemnification, Liability</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentsTaxIndemnificationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Transitional Agreement, Administrative Services, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investments, Transitional Agreement, Manufacture and Supply, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between amount at which an investment accounted for under the equity method of accounting is carried (reported) on the balance sheet and amount of underlying equity in net assets the reporting Entity has in the investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSoldCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the entity's equity method investment which has been sold.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSoldCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.g)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the entity's ownership percentage in the investee multiplied by the investee's total equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentUnderlyingEquityInNetAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117311354&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the sale of equity method investments, which are investments in joint ventures and entities in which the entity has an equity ownership interest normally of 20 to 50 percent and exercises significant influence.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_GSKMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_GSKMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7010613104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Therachon Holding AG (Details) - Therachon Asset Acquisition [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 02, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment', window );">Upfront payment</a></td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum', window );">Maximum potential milestone payments</a></td>
<td class="nump">470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionPercentageofSharesAcquired', window );">Percentage of shares acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireProductiveAssets', window );">Payments to asset acquisition</a></td>
<td class="nump">317<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionConsiderationTransferred', window );">Fair value of consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff', window );">Charge to research and development expenses in connection with asset acquisition</a></td>
<td class="nump">$ 337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionPercentageofSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Percentage of Shares Acquired</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionPercentageofSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireProductiveAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireProductiveAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the write-off for research and development assets that were acquired in a transaction other than a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R145.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952599472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Performance Share Awards (PSAs) Activity (Details) - Performance Shares [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares | shares</a></td>
<td class="nump">5,282<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares | shares</a></td>
<td class="nump">1,716<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares | shares</a></td>
<td class="num">(1,481)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares | shares</a></td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares | shares</a></td>
<td class="nump">5,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 43.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">43.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">42.89<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">41.91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 39.18<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6849445472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock', window );">Schedule of Income before Income Tax, Domestic and Foreign</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,931</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4,403</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6,879</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>9,751</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>19,184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(</sup></span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">a), (b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;">The domestic income in 2019 versus domestic loss in 2018 was mainly related to the completion of the Consumer Healthcare joint venture transaction with GSK as well as lower certain asset impairments, partially offset by reduced Lyrica revenues in the U.S., higher business and legal entity </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">alignment costs as well as increased costs related to certain legal matters. The decrease in the international income was primarily related to higher certain asset impairments as well as the write off of assets contributed to the Consumer Healthcare joint venture with GSK.</span></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;">The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on equity securities and increased revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the legacy SIP portfolio. The decrease in international income was primarily related to lower interest income received primarily from intercompany borrowings from Pfizer Inc. and higher charges related to certain cost reduction initiatives, partially offset by increased revenue related to Ibrance and Eliquis.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Provision for Taxes on Income</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;">&#160;based on the location of the taxing authorities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,641</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(166</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred income taxes:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Federal</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,258</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,663</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,064</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>275</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(304</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total U.S. tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(274</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(970</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,055</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">TCJA</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(135</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(3,035</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,135</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred Income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(187</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,439</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(23,795</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total TCJA tax benefit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(323</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(596</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(10,660</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,900</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,831</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,709</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred income taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(919</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(558</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(42</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total international tax provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,981</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>706</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(9,049</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The 2018 current tax benefit and deferred tax expense primarily relate to the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See discussion below and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5C</span><span style="font-family:Arial;font-size:7pt;">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The reconciliation of the U.S. statutory income tax rate to our effective tax rate for </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income from continuing operations</span><span style="font-family:Arial;font-size:8pt;">&#160;follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. statutory income tax rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>35.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TCJA impact</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(86.6</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Taxation of non-U.S. operations</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(5.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(17.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax settlements and resolution of certain tax positions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(9.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Completion of Consumer Healthcare joint venture transaction</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Healthcare Legislation</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(0.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>0.9</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. R&amp;D tax credit and manufacturing deduction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(0.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(0.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain legal settlements and charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(0.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>0.1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(3.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effective tax rate for income from continuing operations</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(73.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)%</span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For a discussion about the enactment of the TCJA, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which, for 2017, includes the repatriation tax on deemed repatriated 2017 earnings of foreign subsidiaries discussed in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:7pt;">, changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions,&#8221; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#8220;Tax settlements and resolution of certain tax positions&#8221; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A </span><span style="font-family:Arial;font-size:7pt;">for the components of pre-tax income and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income, </span><span style="font-family:Arial;font-size:7pt;">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. </span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2045 on income from manufacturing and other operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For a discussion about tax settlements and resolution of certain tax positions, the impact of the gain on the completion of the Consumer Healthcare joint venture transaction and the impact of U.S. Healthcare Legislation, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The favorable rate impact in 2018 is a result of the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods, as well as certain tax initiatives.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">All other, net in 2019 is primarily due to routine business operations. 2018 is primarily due to routine business operations and the non-recurrence of tax benefits associated with certain tax initiatives. 2017 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business. </span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:1px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019 Deferred Tax*</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018 Deferred Tax*</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Liabilities)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Liabilities)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prepaid/deferred items</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,195</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(204</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,655</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(325</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(14</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(10</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>743</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(7,099</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(7,620</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>179</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,226</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>160</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,011</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,217</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(39</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,292</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(134</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructurings and other charges</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>225</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>266</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Legal and product liability reserves</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>496</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>415</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net operating loss/tax credit carryforwards</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,427</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,512</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unremitted earnings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(79</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">State and local tax adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>264</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Investments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(3,318</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>18</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(162</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>196</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>182</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>9,215</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(11,988</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,576</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(9,456</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Valuation allowances</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,927</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,068</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total deferred taxes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,288</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(11,988</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,508</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(9,456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net deferred tax liability</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4,700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,948</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;">*</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories above. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:7pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The increase in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> is primarily related to the capitalization of certain R&amp;D-related expenses.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The decrease in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> is primarily the result of amortization of intangible assets and certain impairment charges, mainly offset by deferred tax liabilities established on intangible assets from the acquisition of Array.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The amounts in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> are reduced for unrecognized tax benefits of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.9 billion</span></span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$3.3 billion</span></span><span style="font-family:Arial;font-size:7pt;">, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The increase in 2019 is primarily related to the Consumer Healthcare joint venture with GSK. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$0.9 billion</span></span><span style="font-family:Arial;font-size:7pt;">), and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$5.6 billion</span></span><span style="font-family:Arial;font-size:7pt;">). In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$0.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">), and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$3.7 billion</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits Roll Forward</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;text-indent:0px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(6,259</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6,558</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5,826</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(44</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increases based on tax positions taken during a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(36</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(192</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(49</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decreases based on tax positions taken during a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b), (c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,109</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>561</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>28</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decreases based on settlements for a prior period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>35</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increases based on tax positions taken during the current period</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(383</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(370</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(753</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impact of foreign exchange</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>25</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(121</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b), (e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>107</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>121</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, ending</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(5,381</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6,259</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6,558</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For 2019, primarily related to the acquisition of Array. For 2017, primarily related to the acquisitions of Medivation and Anacor. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to cash payments and reductions of tax attributes.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:24px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:12px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$108 million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Current tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$2 million</span></span><span style="font-family:Arial;font-size:7pt;">),</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$51 million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$2.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$2.4 billion</span></span><span style="font-family:Arial;font-size:7pt;">). In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$11 million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Current tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$1 million</span></span><span style="font-family:Arial;font-size:7pt;">) </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$47 million</span></span><span style="font-family:Arial;font-size:7pt;">), </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$3.2 billion</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$3.0 billion</span></span><span style="font-family:Arial;font-size:7pt;">). </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit)</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:69%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of the </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency translation adjustments, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>254</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(215</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unrealized holding gains/(losses) on derivative financial instruments, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>83</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for (gains)/losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(125</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>27</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unrealized holding gains/(losses) on available-for-sale securities, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for (gains)/losses included in net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(60</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments for tax on unrealized gains from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit plans: actuarial losses, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(169</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(141</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(59</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>65</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>637</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>612</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit plans: prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to amortization of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(67</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments related to curtailments of prior service costs and other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reclassification adjustments of certain tax effects from AOCI to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(144</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(185</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Tax provision/(benefit) on other comprehensive income/(loss)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>518</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(262</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B</span><span style="font-family:Arial;font-size:7pt;">. </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Other Comprehensive Income (Loss), Components of Income Tax Expense (Benefit) [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of income before income tax between domestic and foreign jurisdictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 55<br> -Paragraph 217<br> -URI http://asc.fasb.org/extlink&amp;oid=117331294&amp;loc=d3e36027-109320<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R124.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7009518672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Plan Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 519<span></span>
</td>
<td class="nump">$ 469<span></span>
</td>
<td class="nump">$ 494<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member] | Insurance Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">8,215<span></span>
</td>
<td class="nump">8,863<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">2,652<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">4,929<span></span>
</td>
<td class="nump">4,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,342<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">221<span></span>
</td>
<td class="nump">246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">33<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">187<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Global Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Commingled Funds Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,922<span></span>
</td>
<td class="nump">1,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">374<span></span>
</td>
<td class="nump">463<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Commingled Funds Equity Securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Commingled Funds Equity Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,548<span></span>
</td>
<td class="nump">1,413<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Commingled Funds Equity Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Corporate debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">796<span></span>
</td>
<td class="nump">727<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Government and Agency Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,305<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">2,201<span></span>
</td>
<td class="nump">1,770<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">1,171<span></span>
</td>
<td class="nump">762<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,031<span></span>
</td>
<td class="nump">1,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Partnership Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">57<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Insurance Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">74<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">944<span></span>
</td>
<td class="nump">684<span></span>
</td>
<td class="nump">420<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,524<span></span>
</td>
<td class="nump">1,473<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">1,043<span></span>
</td>
<td class="nump">1,020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Other [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Other [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member] | Other [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">398<span></span>
</td>
<td class="nump">382<span></span>
</td>
<td class="nump">468<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">14,586<span></span>
</td>
<td class="nump">13,051<span></span>
</td>
<td class="nump">$ 14,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">2,638<span></span>
</td>
<td class="nump">2,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,496<span></span>
</td>
<td class="nump">3,173<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">8,451<span></span>
</td>
<td class="nump">7,294<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">363<span></span>
</td>
<td class="nump">443<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">53<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">284<span></span>
</td>
<td class="nump">390<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Cash and Cash Equivalents [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Global Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,464<span></span>
</td>
<td class="nump">3,156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">3,406<span></span>
</td>
<td class="nump">3,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">57<span></span>
</td>
<td class="nump">37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Global Equity Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Commingled Funds Equity Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,179<span></span>
</td>
<td class="nump">933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">360<span></span>
</td>
<td class="nump">299<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Commingled Funds Equity Securities [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Commingled Funds Equity Securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">819<span></span>
</td>
<td class="nump">634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Commingled Funds Equity Securities [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Corporate debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5,292<span></span>
</td>
<td class="nump">4,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5,281<span></span>
</td>
<td class="nump">4,650<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Corporate debt [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Government and Agency Obligations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,799<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,799<span></span>
</td>
<td class="nump">1,391<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Government and Agency Obligations [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">96<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Fixed Income Commingled Funds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Partnership Interest [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">1,212<span></span>
</td>
<td class="nump">1,165<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Partnership Interest [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Insurance Contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">196<span></span>
</td>
<td class="nump">192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Insurance Contracts [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Other Commingled Funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">1,075<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets', window );">Assets Measured at NAV</a></td>
<td class="nump">1,066<span></span>
</td>
<td class="nump">1,021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member] | Other Commingled Funds [Member] | Level 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Alternative Investments, Fair Value Of Plan Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_InsuranceContractsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_InsuranceContractsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasurySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_USTreasurySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=srt_PartnershipInterestMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=srt_PartnershipInterestMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAggregatedInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherAggregatedInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_OtherCommingledFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=pfe_OtherCommingledFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R120.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7024796096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Obligations and Funded Status (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, beginning</a></td>
<td class="nump">$ 1,870<span></span>
</td>
<td class="nump">$ 2,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">37<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="num">(56)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Changes in actuarial assumptions and other</a></td>
<td class="num">(87)<span></span>
</td>
<td class="num">(122)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign exchange impact</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation', window );">Acquisitions/divestitures/other, net</a></td>
<td class="num">(36)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, ending</a></td>
<td class="nump">1,667<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
<td class="nump">2,028<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">494<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual gain/(loss) on plan assets</a></td>
<td class="nump">50<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">137<span></span>
</td>
<td class="nump">145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">84<span></span>
</td>
<td class="nump">102<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets', window );">Acquisitions/divestitures, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(221)<span></span>
</td>
<td class="num">(249)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">519<span></span>
</td>
<td class="nump">469<span></span>
</td>
<td class="nump">494<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status&#8212;Plan assets less than benefit obligation</a></td>
<td class="num">(1,148)<span></span>
</td>
<td class="num">(1,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, beginning</a></td>
<td class="nump">9,952<span></span>
</td>
<td class="nump">10,607<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">18<span></span>
</td>
<td class="nump">29<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Changes in actuarial assumptions and other</a></td>
<td class="nump">1,224<span></span>
</td>
<td class="num">(169)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign exchange impact</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(457)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation', window );">Acquisitions/divestitures/other, net</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, ending</a></td>
<td class="nump">11,059<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
<td class="nump">10,607<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">8,215<span></span>
</td>
<td class="nump">8,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual gain/(loss) on plan assets</a></td>
<td class="nump">873<span></span>
</td>
<td class="num">(77)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">209<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign exchange impact</a></td>
<td class="nump">42<span></span>
</td>
<td class="num">(380)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets', window );">Acquisitions/divestitures, net</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(34)<span></span>
</td>
<td class="num">(34)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(360)<span></span>
</td>
<td class="num">(373)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">8,956<span></span>
</td>
<td class="nump">8,215<span></span>
</td>
<td class="nump">8,863<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status&#8212;Plan assets less than benefit obligation</a></td>
<td class="num">(2,103)<span></span>
</td>
<td class="num">(1,738)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation', window );">Defined benefit plan, accumulated benefit obligation</a></td>
<td class="nump">10,600<span></span>
</td>
<td class="nump">9,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, beginning</a></td>
<td class="nump">15,141<span></span>
</td>
<td class="nump">16,702<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(22)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Changes in actuarial assumptions and other</a></td>
<td class="nump">2,001<span></span>
</td>
<td class="num">(1,219)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation', window );">Acquisitions/divestitures/other, net</a></td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(692)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(544)<span></span>
</td>
<td class="num">(546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, ending</a></td>
<td class="nump">16,535<span></span>
</td>
<td class="nump">15,141<span></span>
</td>
<td class="nump">16,702<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">13,051<span></span>
</td>
<td class="nump">14,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets', window );">Actual gain/(loss) on plan assets</a></td>
<td class="nump">2,760<span></span>
</td>
<td class="num">(796)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets', window );">Acquisitions/divestitures, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(692)<span></span>
</td>
<td class="num">(391)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(544)<span></span>
</td>
<td class="num">(546)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">14,586<span></span>
</td>
<td class="nump">13,051<span></span>
</td>
<td class="nump">14,284<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status&#8212;Plan assets less than benefit obligation</a></td>
<td class="num">(1,949)<span></span>
</td>
<td class="num">(2,089)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan [Member] | United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward', window );"><strong>Change in benefit obligation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, beginning</a></td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAmendments', window );">Plan amendments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanActuarialGainLoss', window );">Changes in actuarial assumptions and other</a></td>
<td class="nump">152<span></span>
</td>
<td class="num">(152)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation', window );">Foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation', window );">Acquisitions/divestitures/other, net</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation', window );">Settlements</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits', window );">Special termination benefits</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanBenefitObligation', window );">Benefit obligation, ending</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
<td class="nump">1,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward', window );"><strong>Change in plan assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, beginning</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Company contributions</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">129<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant', window );">Employee contributions</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss', window );">Foreign exchange impact</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets', window );">Settlements</a></td>
<td class="num">(70)<span></span>
</td>
<td class="num">(72)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid', window );">Benefits paid</a></td>
<td class="num">(74)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets', window );">Fair value of plan assets, ending</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan', window );">Funded status&#8212;Plan assets less than benefit obligation</a></td>
<td class="num">$ (1,351)<span></span>
</td>
<td class="num">$ (1,280)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Benefit Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Business Combinations, Acquisitions and Divestitures, Plan Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to employee service rendered, excluding assumptions about future compensation level.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in plan assets of defined benefit plan from actual return (loss) determined by change in fair value of plan assets adjusted for contributions, benefit payments, and other expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActualReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanActuarialGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from change in actuarial assumptions which (increases) decreases benefit obligation of defined benefit plan. Assumptions include, but are not limited to, interest, mortality, employee turnover, salary, and temporary deviation from substantive plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanActuarialGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant of defined benefit plan which decreases benefit obligation. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(6)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increase benefit obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInBenefitObligationRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanChangeInFairValueOfPlanAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease in benefit obligation of defined benefit plan from event reducing expected years of future service of present employees or eliminating accrual of benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset segregated and restricted to provide benefit under defined benefit plan. Asset includes, but is not limited to, stock, bond, other investment, earning from investment, and contribution by employer and employee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which (increases) decreases benefit obligation of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanFundedStatusOfPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of funded (unfunded) status of defined benefit plan, measured as difference between fair value of plan assets and benefit obligation. Includes, but is not limited to, overfunded (underfunded) status.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanFundedStatusOfPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAmendments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in benefit obligation of defined benefit plan from change in terms of existing plan or initiation of new plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAmendments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment to participant under defined benefit plan which decreases plan assets. For pension plan, payment includes, but is not limited to, pension benefits and death benefits. For other postretirement plan, payment includes, but is not limited to, prescription drug benefits, health care benefits, life insurance benefits, and legal, educational and advisory services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39716-114964<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsBenefitsPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions received by defined benefit plan from participant which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of foreign currency translation gain (loss) which increases (decreases) plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of (increase) decrease to benefit obligation of defined benefit plan from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Includes, but is not limited to, lump-sum cash payment to participant in exchange for right to receive specified benefits, purchase of nonparticipating annuity contract and change from remeasurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSettlementsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of payment, which decreases plan assets of defined benefit plan, for irrevocable action relieving primary responsibility for benefit obligation and eliminating risk for obligation and assets used to effect settlement. Transaction constituting settlement includes, but is not limited to, making lump-sum cash payment to participant in exchange for their rights to receive specified benefits and purchasing nonparticipating annuity contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(8)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSettlementsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanSpecialTerminationBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in benefit obligation for benefits provided to employees payable from defined benefit plan or payable upon retirement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(10)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanSpecialTerminationBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953017632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Components of Property, Plant and Equipment</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="11"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of Property, plant and equipment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Useful Lives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Years)&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Land</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>516</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Buildings</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">33-50</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>10,068</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,920</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Machinery and equipment</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">8-20</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>12,281</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,871</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Furniture, fixtures and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3-12 1/2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,930</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,693</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Construction in progress</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">-</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,960</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>30,756</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>29,977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Accumulated depreciation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,789</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16,591</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>13,967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><span style="font-family:Arial;font-size:7pt;">The increase in total property, plant and equipment is mainly due to capital additions, partially offset by depreciation, reductions due to asset impairments largely associated with cost reduction initiatives not associated with acquisitions (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span>), and the impact of foreign exchange.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R128.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7041205376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Defined contribution plan, cost recognized</a></td>
<td class="nump">$ 659<span></span>
</td>
<td class="nump">$ 622<span></span>
</td>
<td class="nump">$ 380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6951152000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock', window );">Other (Income)/Deductions - Net</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Other (Income)/Deductions&#8212;Net</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(226</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(333</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest expense</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,270</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net interest expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,348</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>983</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Royalty-related income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(648</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(495</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(499</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net (gains)/losses on asset disposals</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(31</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(71</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net gains recognized during the period on equity securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(454</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(586</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(224</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net realized (gains)/losses on sales of investments in debt securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from collaborations, out-licensing arrangements and sales of compound/product rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(168</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(488</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(217</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit costs/(credits) other than service costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(288</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain legal matters, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>554</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>157</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>240</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain asset impairments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,843</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>395</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Business and legal entity alignment costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>338</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>63</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net losses on early retirement of debt</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>999</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">GSK Consumer Healthcare JV equity method (income)/loss</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(17</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other, net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(m)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(388</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(417</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(328</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,578</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,116</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,416</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;Interest income decreased primarily driven by a lower investment balance. Interest expense increased mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year period. </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> v. </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;Interest income decreased primarily driven by a lower investment balance. Interest expense increased primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017. Capitalized interest expense totaled </span><span style="font-family:Arial;font-size:7pt;"><span>$88 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, $</span><span style="font-family:Arial;font-size:7pt;"><span>73 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and $</span><span style="font-family:Arial;font-size:7pt;"><span>72 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Royalty-related income </span><span style="font-family:Arial;font-size:7pt;">increased</span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, primarily due to a one-time favorable resolution in the second quarter of </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> of a legal dispute for </span><span style="font-family:Arial;font-size:7pt;"><span>$82 million</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily included a realized gain on sale of property of </span><span style="font-family:Arial;font-size:7pt;"><span>$60 million</span></span><span style="font-family:Arial;font-size:7pt;">. In </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, primarily included an </span><span style="font-family:Arial;font-size:7pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:7pt;"> realized loss related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>49%</span></span><span style="font-family:Arial;font-size:7pt;">-owned equity-method investment in Hisun Pfizer and a realized net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>40%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the then remaining </span><span style="font-family:Arial;font-size:7pt;"><span>60%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership interest, partially offset by a realized gain on sale of property of </span><span style="font-family:Arial;font-size:7pt;"><span>$52 million</span></span><span style="font-family:Arial;font-size:7pt;">. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The gains in 2019 include, among other things, unrealized gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$295 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to investments in Cortexyme, Inc. and SpringWorks Therapeutics, Inc. The gains in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> included unrealized gains on equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$477 million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting the adoption of a new accounting standard in the first quarter of 2018 and were primarily driven by unrealized gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$466 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to our investment in Allogene. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7B</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2018, primarily includes gross realized losses on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$402 million</span></span><span style="font-family:Arial;font-size:7pt;"> and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$18 million</span></span><span style="font-family:Arial;font-size:7pt;"> from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities, partially offset by gross realized gains on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$280 million</span></span><span style="font-family:Arial;font-size:7pt;">. Proceeds from the sale of available-for-sale debt securities were </span><span style="font-family:Arial;font-size:7pt;"><span>$5.7 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in 2018. In 2017, primarily includes gross realized gains on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$451 million</span></span><span style="font-family:Arial;font-size:7pt;">, partially offset by gross realized losses on sales of available-for-sale debt securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$281 million</span></span><span style="font-family:Arial;font-size:7pt;"> and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$120 million</span></span><span style="font-family:Arial;font-size:7pt;"> from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debt securities were </span><span style="font-family:Arial;font-size:7pt;"><span>$5.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in 2017.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, mainly includes, among other things, </span><span style="font-family:Arial;font-size:7pt;"><span>$78 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">, a generic of Advair Diskus</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#174;</sup></span><span style="font-family:Arial;font-size:7pt;">(fluticasone propionate and salmeterol inhalation powder) and </span><span style="font-family:Arial;font-size:7pt;"><span>$52 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from multiple licensees. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes, among other things, (i) approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$118 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone income from multiple licensees, (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$110 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone payments received from Shire, of which </span><span style="font-family:Arial;font-size:7pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:7pt;"> was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of ulcerative colitis and </span><span style="font-family:Arial;font-size:7pt;"><span>$35 million</span></span><span style="font-family:Arial;font-size:7pt;"> was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn&#8217;s disease, (iii) an upfront payment to us and a recognized milestone totaling </span><span style="font-family:Arial;font-size:7pt;"><span>$85 million</span></span><span style="font-family:Arial;font-size:7pt;"> for the sale of an AMPA receptor potentiator for CIAS to Biogen, (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$62 million</span></span><span style="font-family:Arial;font-size:7pt;"> in gains related to sales of compound/product rights and (v) a </span><span style="font-family:Arial;font-size:7pt;"><span>$40 million</span></span><span style="font-family:Arial;font-size:7pt;"> milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2D </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</span><span style="font-family:Arial;font-size:7pt;">. In 2017, primarily includes, among other things, </span><span style="font-family:Arial;font-size:7pt;"><span>$101 million</span></span><span style="font-family:Arial;font-size:7pt;"> in milestone payments received from multiple licensees and an </span><span style="font-family:Arial;font-size:7pt;"><span>$85 million</span></span><span style="font-family:Arial;font-size:7pt;"> gain related to sales of compound/product rights. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019, primarily includes settlement losses within the U.S. Pfizer Consolidated Pension Plan related to special restructuring initiatives, a small annuity buyout program and regular lump sum activity. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to 2017. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, mostly includes legal reserves for certain pending legal matters. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes legal reserves for certain pending legal matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In 2017, primarily includes a </span><span style="font-family:Arial;font-size:7pt;"><span>$94 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which was approved by the court in April 2018, and a </span><span style="font-family:Arial;font-size:7pt;"><span>$79 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge to reflect damages awarded by a jury in a patent matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">, mainly composed of: (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$2.6 billion</span></span><span style="font-family:Arial;font-size:7pt;">, related to Eucrisa, a Biopharma finite-lived developed technology right acquired in connection with our acquisition of Anacor, and reflects updated commercial forecasts mainly reflecting competitive pressures; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$90 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$40 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions; (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$31 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma IPR&amp;D asset, acquired in connection with our acquisition of AstraZeneca&#8217;s anti-infectives business, which reflects updated commercial forecasts; (v) </span><span style="font-family:Arial;font-size:7pt;"><span>$10 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a Biopharma finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the </span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-align:left;"><span style="font-family:Arial;font-size:7pt;">U.S. market only, </span><span style="font-family:Arial;font-size:7pt;text-align:center;">and reflects</span><span style="font-family:Arial;font-size:7pt;">, among other things, updated commercial forecasts; and (vi) </span><span style="font-family:Arial;font-size:7pt;"><span>$10 million</span></span><span style="font-family:Arial;font-size:7pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of Innopharma.</span></div><div style="line-height:120%;padding-left:4px;padding-bottom:1px;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$3.1 billion</span></span><span style="font-family:Arial;font-size:7pt;">, mainly composed of (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$2.6 billion</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma developed technology rights, </span><span style="font-family:Arial;font-size:7pt;"><span>$242 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma licensing agreements and </span><span style="font-family:Arial;font-size:7pt;"><span>$80 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to Biopharma IPR&amp;D, all of which relate to our acquisition of Hospira, for generic sterile injectable products associated with various indications; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$117 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to a multi-antigen vaccine IPR&amp;D program for adults undergoing elective spinal fusion surgery; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$31 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to an Biopharma developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus market marketed in the U.S. market only; and (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$17 million</span></span><span style="font-family:Arial;font-size:7pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of Innopharma. In 2018, the intangible asset impairment charges associated with the generic sterile injectable products reflect, among other things, updated commercial forecasts, reflecting an increased competitive environment as well as higher manufacturing costs, largely stemming from manufacturing and supply issues. The intangible asset impairment charge for the multi-antigen vaccine IPR&amp;D program was the result of the Phase 2b trial reaching futility at a pre-planned interim analysis. </span><span style="font-family:Arial;font-size:7pt;text-align:center;">The intangible asset impairment charge related to the </span><span style="font-family:Arial;font-size:7pt;">Biopharma developed technology right</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> reflects</span><span style="font-family:Arial;font-size:7pt;">, among other things, updated commercial forecasts. .</span></div><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2017, primarily includes intangible asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$337 million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting (i) </span><span style="font-family:Arial;font-size:7pt;"><span>$127 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) </span><span style="font-family:Arial;font-size:7pt;"><span>$124 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$39 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) </span><span style="font-family:Arial;font-size:7pt;"><span>$26 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) </span><span style="font-family:Arial;font-size:7pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with Biopharma and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$43 million</span></span><span style="font-family:Arial;font-size:7pt;"> for an impairment of our AM-Pharma B.V. long-term investment.</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019 and 2018, mainly represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In 2017, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(k)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019 and 2017, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(l)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(m)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, includes, among other things, (i) dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$220 million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, (ii) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$152 million</span></span><span style="font-family:Arial;font-size:7pt;"> for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> of income from insurance recoveries related to Hurricane Maria. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, includes, among other things, (i) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$343 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">), (ii) dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$253 million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, (iii) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain on the contribution of Pfizer&#8217;s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained an ownership stake in Allogene (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">), (iv) a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$17 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7E</span><span style="font-family:Arial;font-size:7pt;">), (v) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$207 million</span></span><span style="font-family:Arial;font-size:7pt;">, reflecting the change in the fair value of contingent consideration. and (vi) charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$112 million</span></span><span style="font-family:Arial;font-size:7pt;"> for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. In 2017, includes, among other things, dividend income of </span><span style="font-family:Arial;font-size:7pt;"><span>$266 million</span></span><span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, and income of </span><span style="font-family:Arial;font-size:7pt;"><span>$62 million</span></span><span style="font-family:Arial;font-size:7pt;"> from resolution of a contract disagreement. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The asset impairment charges included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> are based on estimates of fair value.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides additional information about the intangible assets that were impaired during 2019 in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Level 3</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impairment</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets&#8211;&#8211;Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,213</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,213</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,639</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible assets</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>131</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,770</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1E.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Reflects intangible assets written down to fair value in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other income or other expense items (both operating and nonoperating). Sources of nonoperating income or nonoperating expense that may be disclosed, include amounts earned from dividends, interest on securities, profits (losses) on securities, net and miscellaneous other income or income deductions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -URI http://asc.fasb.org/topic&amp;trid=2122503<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 610<br> -URI http://asc.fasb.org/topic&amp;trid=49130413<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndOtherExpenseDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R103.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7187323776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Cumulative Basis Adjustments for Fair Value Hedges (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term investments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetFairValueHedge', window );">Carrying Amount of Actively Hedged Assets</a></td>
<td class="nump">$ 45<span></span>
</td>
<td class="nump">$ 45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermDebtMember', window );">Short-term borrowings, including current portion of long-term debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Actively Hedged Liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,499<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember', window );">Long-term debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedge', window );">Carrying Amount of Actively Hedged Liabilities</a></td>
<td class="nump">7,092<span></span>
</td>
<td class="nump">9,952<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Active Hedging Relationships, Liability</a></td>
<td class="nump">266<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease', window );">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to Carrying Amount, Discontinued Hedging Relationships, Liability</a></td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged asset in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedAssetFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedAssetFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged asset in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedAssetFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk, remaining after discontinued hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability hedged in fair value hedging relationship.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative increase (decrease) in fair value of hedged liability in fair value hedge, attributable to hedged risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4EE<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109999712-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_ShortTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_LongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>pfe-12312019x10kshell_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:country="http://xbrl.sec.gov/country/2017-01-31"
  xmlns:currency="http://xbrl.sec.gov/currency/2019-01-31"
  xmlns:dei="http://xbrl.sec.gov/dei/2019-01-31"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:pfe="http://www.pfizer.com/20191231"
  xmlns:srt="http://fasb.org/srt/2019-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2019-01-31"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xhtml="http://www.w3.org/1999/xhtml"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="pfe-20191231.xsd" xlink:type="simple"/>
    <context id="FD2019Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="I2020Q1Feb25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2020-02-25</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20220.250Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20200.000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20200.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:NotesDue20271.000Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_OncologyVaccinesStartUpMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:OncologyVaccinesStartUpMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:NoncontrollingInterestMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:ParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelTherapeuticsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_U.K.PoundDenominatedDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:U.K.PoundDenominatedDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="I2019Q1Jan01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2019-01-01</instant>
        </period>
    </context>
    <context id="D2019Q1Jan01-Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201602Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-01</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TopTenProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopTenProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-12-22</startDate>
            <endDate>2016-12-22</endDate>
        </period>
    </context>
    <context id="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-07-01</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:AkceaAndIonisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TopEightProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopEightProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q2Apr30_us-gaap_LeaseArrangementTypeAxis_pfe_OfficeBuildingInNewYorkCityMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">pfe:OfficeBuildingInNewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="FI2020Q2_srt_OwnershipAxis_pfe_UpjohnAndMylanMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:UpjohnAndMylanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q3Jan01-Jul02_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2019-07-02</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TopNineProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TopNineProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueProductLineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:ProductConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-03</instant>
        </period>
    </context>
    <context id="FI2020Q2_dei_LegalEntityAxis_pfe_MylanMember_srt_OwnershipAxis_pfe_UpjohnAndMylanMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:UpjohnAndMylanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:MylanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-06-28</instant>
        </period>
    </context>
    <context id="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-09-30</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-01</startDate>
            <endDate>2019-09-29</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="D2019Q3Jul31-Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-31</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="I2017Q4Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-11-10</instant>
        </period>
    </context>
    <context id="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-07-01</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2014Q4QTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-29</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q1_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-01</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="FI2018Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-01</instant>
        </period>
    </context>
    <context id="FD2018Q4QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BionTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FI2018Q1_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-01</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:RPIFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BainCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-04-01</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-03</startDate>
            <endDate>2017-07-02</endDate>
        </period>
    </context>
    <context id="D2016Q1Jan2016_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:RPIFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-01-31</endDate>
        </period>
    </context>
    <context id="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct01-Oct31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-04-01</endDate>
        </period>
    </context>
    <context id="FD2013Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_BalanceSheetLocationAxis_pfe_DeferredRevenueMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-01-01</startDate>
            <endDate>2013-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q4Oct31_dei_LegalEntityAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-10-31</instant>
        </period>
    </context>
    <context id="FD2014Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CellectisMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CellectisMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2016Q4Oct06_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-10-06</instant>
        </period>
    </context>
    <context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-22</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-28</startDate>
            <endDate>2016-09-28</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BionTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-02</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsDevelopedTechnologyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Nov10-Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-10</startDate>
            <endDate>2017-11-10</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BionTechMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:RPIFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q1Jan01-Jan31_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-01-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2014Q4QTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_pfe_CollaborativeArrangementUpfrontCashPaymentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">pfe:CollaborativeArrangementUpfrontCashPaymentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-09-29</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="FI2012Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2012-09-30</instant>
        </period>
    </context>
    <context id="FD2017Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-02</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-29</endDate>
        </period>
    </context>
    <context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-22</instant>
        </period>
    </context>
    <context id="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-01-01</startDate>
            <endDate>2016-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2018Q2Apr01-Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_NeuroscienceAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BainCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:NeuroscienceAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-04-01</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_srt_OwnershipAxis_pfe_CerevelTherapeuticsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:CerevelTherapeuticsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-09-28</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MylanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-22</instant>
        </period>
    </context>
    <context id="I2017Q2Jun30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul31_dei_LegalEntityAxis_pfe_GSKMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">pfe:GSKMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckKGaAMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_BalanceSheetLocationAxis_pfe_DeferredRevenueMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredRevenueMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InitialApplicationPeriodCumulativeEffectTransitionAxis">us-gaap:DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-04-01</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2016Q2Apr01-Apr30_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-04-01</startDate>
            <endDate>2016-04-30</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q3Jan1-Jul31_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-07-31</endDate>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-02</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsTechnologyInDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsTechnologyInDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q2_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-07-01</instant>
        </period>
    </context>
    <context id="D2018Q2Apr01-Apr30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-30</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-03</startDate>
            <endDate>2017-07-02</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:EliLillyCompanyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-09-30</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IncomeStatementLocationAxis_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:RestructuringChargesAndAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q4Nov1-30_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:AkceaAndIonisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-11-01</startDate>
            <endDate>2019-11-30</endDate>
        </period>
    </context>
    <context id="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-30</startDate>
            <endDate>2019-07-30</endDate>
        </period>
    </context>
    <context id="FD2017Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-04-02</endDate>
        </period>
    </context>
    <context id="I2018Q2Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-07-01</startDate>
            <endDate>2019-09-29</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-04-01</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ICUMedicalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:HISMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Sept-Dec2017_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:MedivationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2016-09-29</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:RPIFinanceTrustMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CopromotionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:ProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:ManufacturingOptimizationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:FocusedCompanyPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_OtherActivitiesMember_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:OtherActivitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:ArrayMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringPlanAxis">pfe:TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:BusinessIntegrationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:OtherRestructuringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">pfe:AssetImpairmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:MerckMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:CollaborativeArrangementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q2QTD">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-06-30</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-04-01</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DistributionRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_GeneTherapiesMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GeneTherapiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SterileInjectablePainRelieverMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SterileInjectablePainRelieverMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:InnoPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TreatmentForToenailFungusMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TreatmentForToenailFungusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:PatentMatterMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MultiAntigenVaccineForSpinalFusionSurgeryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:OwnershipAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AstraZenecaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:HisunPfizerPharmaceuticalsCoLtdMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-04-01</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AMPharmaBVMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AMPharmaBVMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TreatmentOfAttentionHyperactivityDisorderMember_us-gaap_BusinessAcquisitionAxis_pfe_NextWaveMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TreatmentOfAttentionHyperactivityDisorderMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:NextWaveMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DisposalGroupClassificationAxis">us-gaap:DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis">pfe:Phase2bReadyAMPAReceptorPotentiatorForCIASMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:InnoPharmaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BainCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericSterileInjectableProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:ShireMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenericInjectablePainRelieverMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenericInjectablePainRelieverMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CortexymeInc.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:AnacorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">us-gaap:LicensingAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:LaboratorioTeutoBrasileroMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:DebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:IncomeTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_DeferredTaxLiabilitiesNetNoncurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredTaxLiabilitiesNetNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_DeferredTaxLiabilitiesNetNoncurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:DeferredTaxLiabilitiesNetNoncurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:NoncurrentDeferredTaxLiabilitiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_CurrentTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:CurrentTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="D2019Q2Apr01-Apr30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2019-04-01</startDate>
            <endDate>2019-04-30</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:OtherTaxesPayableMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_CurrentTaxAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:CurrentTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201802Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201601Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:EquitySecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentAssetsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:CarryingReportedAmountFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:ForeignGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:BankTimeDepositsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_pfe_CreditFacilityExpiring2024Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:CreditFacilityExpiring2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_pfe_FacilityExpiringSeptember2020Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">us-gaap:LineOfCreditMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:FacilityExpiringSeptember2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShortTermDebtTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20262029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20462049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2020Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20362040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20362040Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20432044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2034Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20432044Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20262029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue20462049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtDue2023Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointEightPercentDue2022Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtThreePointNinePercentDue2039Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredDebtFourPercentDue2049Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="I2017Q1Mar31_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorNotesDue2047Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="I2017Q1Mar31_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:UnsecuredDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-03-31</instant>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q1QTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">pfe:SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="I2018Q3Aug31_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-08-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2017Q3Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2017Q2Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="FD2018Q3QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-07-02</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-04-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherCurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2018Q2Jun30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-06-30</instant>
        </period>
    </context>
    <context id="I2017Q2Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-06-30</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:OtherNoncurrentLiabilitiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2017Q3Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-08-31</instant>
        </period>
    </context>
    <context id="D2017Q2Jun01-Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-06-01</startDate>
            <endDate>2017-06-30</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec01-Dec31_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q2Apr01-Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MylotargMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">us-gaap:EuropeanUnionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-04-02</startDate>
            <endDate>2018-04-30</endDate>
        </period>
    </context>
    <context id="D2017Q3Aug01-Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-08-01</startDate>
            <endDate>2017-08-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:CostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:HedgedItemAxis">us-gaap:SalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:ShortTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">pfe:LongtermInvestmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">us-gaap:LongTermDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:NondesignatedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyLongTermDebtMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:InterestRateContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:OtherNonoperatingIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:NetInvestmentHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">pfe:ForeignCurrencyShortTermBorrowingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:ForeignExchangeContractMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentsGainLossByHedgingRelationshipAxis">us-gaap:CashFlowHedgingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:HedgingDesignationAxis">us-gaap:DesignatedAsHedgingInstrumentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeDeductionsAndCostOfSalesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EquitySecuritiesByIndustryAxis">us-gaap:FinancialServicesSectorMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LandMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:MachineryAndEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:TradeNamesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">pfe:LicensingAgreementsAndOtherMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:DevelopedTechnologyRightsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsegmentsAxis">pfe:PfizersWorldwideResearchDevelopmentAndMedicalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IndefiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:InProcessResearchAndDevelopmentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:FiniteLivedIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:NonqualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:SupplementalEmployeeRetirementPlanDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherAggregatedInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">srt:PartnershipInterestMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:USTreasurySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:DefinedBenefitPlanEquitySecuritiesGlobalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:InsuranceContractsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">pfe:OtherCommingledFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-03</startDate>
            <endDate>2017-07-02</endDate>
        </period>
    </context>
    <context id="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">pfe:HospiraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-04-03</startDate>
            <endDate>2017-07-02</endDate>
        </period>
    </context>
    <context id="I2018Q1Jan01">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2018-01-01</instant>
        </period>
    </context>
    <context id="D2020Q4Jun29-Dec31_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementScenarioAxis">srt:ScenarioForecastMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-06-29</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:OtherPostretirementBenefitPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:OtherInvestmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanEquitySecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">us-gaap:ForeignPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:DefinedBenefitPlanCashAndCashEquivalentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DefinedBenefitPlanByPlanAssetCategoriesAxis">us-gaap:FixedIncomeSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanSponsorLocationAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTaxStatusAxis">us-gaap:QualifiedPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:RetirementPlanTypeAxis">us-gaap:PensionPlansDefinedBenefitMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_pfe_OpenMarketPurchasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:PreferredEmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-06</startDate>
            <endDate>2017-02-06</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2019Q1Feb12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-12</instant>
        </period>
    </context>
    <context id="D2018Q1Mar12-Mar12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-12</startDate>
            <endDate>2018-03-12</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep07-Sep07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-07</startDate>
            <endDate>2018-09-07</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:PreferredEmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2017Q1Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-06</instant>
        </period>
    </context>
    <context id="D2019Q3Aug05-Aug05_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-08-05</startDate>
            <endDate>2019-08-05</endDate>
        </period>
    </context>
    <context id="FI2015Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2015StockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2015StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1Mar12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-12</instant>
        </period>
    </context>
    <context id="D2019Q1Feb07-Feb07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-07</startDate>
            <endDate>2019-02-07</endDate>
        </period>
    </context>
    <context id="D2017Q1Feb02-Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-02</startDate>
            <endDate>2017-02-02</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:PreferredEmployeeStockOwnershipPlanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">pfe:SeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2017StockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2017StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="D2019Q1Feb12-Feb12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-02-12</startDate>
            <endDate>2019-02-12</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2018Q1Mar14-Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-03-14</startDate>
            <endDate>2018-03-14</endDate>
        </period>
    </context>
    <context id="D2017Q2May19-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-05-19</startDate>
            <endDate>2017-05-19</endDate>
        </period>
    </context>
    <context id="D2017Q2Feb06-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-06</startDate>
            <endDate>2017-05-19</endDate>
        </period>
    </context>
    <context id="I2019Q1Feb07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithGSCoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-02-07</instant>
        </period>
    </context>
    <context id="I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-02-02</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredESOPPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:PreferredESOPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="I2018Q1Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:ShareRepurchaseAgreementwithCitibankMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-03-14</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_pfe_OpenMarketPurchasesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:OpenMarketPurchasesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="I2014Q4Oct23-2014">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <instant>2014-10-23</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2018StockPurchasePlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareRepurchaseProgramAxis">pfe:December2018StockPurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis">pfe:CommonESOPPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:ProfitUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec29-Dec29_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:BoardOfDirectorsChairmanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec29-Dec29_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ManagementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:ManagementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Dec29-Dec29_srt_TitleOfIndividualAxis_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">pfe:GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-12-29</startDate>
            <endDate>2017-12-29</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:DirectorsCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:DirectorsCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:DirectorsCompensationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PortfolioPerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:TotalShareholderReturnUnitsTSRUsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">pfe:PerformanceTotalShareholderReturnUnitPTSRUsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">pfe:A2019StockPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="D2019Q4Dec31-31_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusFreseniusKabjUSALLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-31</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerandBMSVersusSeveralGenericManufacturersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-02-01</startDate>
            <endDate>2017-04-30</endDate>
        </period>
    </context>
    <context id="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusAmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Nov2017">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusAmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Oct01-Oct31_srt_LitigationCaseAxis_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_srt_ProductOrServiceAxis_pfe_DocetaxelMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DocetaxelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-10-01</startDate>
            <endDate>2018-10-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_EpiPenMember_srt_RangeAxis_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusAjantaMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusAjantaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2020Q1Jan1-31_srt_LitigationCaseAxis_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusViwitPharmaceuticalCo.Ltd.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="FI2016Q4_srt_ProductOrServiceAxis_pfe_PhenytoinSodiumCapsulesMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_ViolationofAntitrustLawsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PhenytoinSodiumCapsulesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:ViolationofAntitrustLawsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2016-12-31</instant>
        </period>
    </context>
    <context id="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-03-01</startDate>
            <endDate>2013-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusFreseniusKabjUSALLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2014Q4YTD_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusAmnealPharmaceuticalsLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2014-01-01</startDate>
            <endDate>2014-12-31</endDate>
        </period>
    </context>
    <context id="D2017Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusZydusMember_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusZydusMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-03-01</startDate>
            <endDate>2017-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q3Sep01-Sep30_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LossContingenciesByNatureOfContingencyAxis">pfe:EnvironmentalRemediationLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="D2015Q3Aug1-31_srt_LitigationCaseAxis_pfe_HospiraVersusParMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusParMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-08-01</startDate>
            <endDate>2015-08-31</endDate>
        </period>
    </context>
    <context id="D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-10-01</startDate>
            <endDate>2017-10-31</endDate>
        </period>
    </context>
    <context id="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusGenericCompaniesMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:PfizerVersusGenericCompaniesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-03-01</startDate>
            <endDate>2019-03-31</endDate>
        </period>
    </context>
    <context id="D2018Q4Dec1-31_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusFreseniusKabjUSALLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:SettledLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-12-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="D2018Q2Jun01-Jun30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:GainContingenciesByNatureAxis">pfe:PatentInfringementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:JudicialRulingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-06-01</startDate>
            <endDate>2018-06-30</endDate>
        </period>
    </context>
    <context id="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusParMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:HospiraVersusParMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrecedexPremixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">us-gaap:PendingLitigationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-01-31</endDate>
        </period>
    </context>
    <context id="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">pfe:JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-03-01</startDate>
            <endDate>2015-03-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BesponsaMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BesponsaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedRestOfWorldMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:EmergingMarketsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XanaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DiflucanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZosynTazocinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalkoriMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InflectraRemsimaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EnbrelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZosynTazocinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ToviazMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FragminMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XalatanXalacomMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ReFactoAfXynthaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XanaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PrevnarPrevenarFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PfizerCentreOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:ConsumerHealthcareReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:ConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DiflucanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EffexorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XeljanzMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MektoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:CelebrexMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherHospitalProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NorvascMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherOncologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SomavertMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RevatioMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BeneFIXMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherRareDiseaseProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherVaccinesProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:GenotropinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EucrisaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ChantixChampixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:RetacritMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:IbranceMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:NimenrixMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TygacilMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BMP2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:OtherAntiinfectivesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LipitorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalSterileInjectablePharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BosulifMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:FSMEIMMUNTicoVacMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ViagraMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XtandiAllianceRevenuesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:DiflucanMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EliquisMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SulperazonMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherUpjohnProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:BraftoviMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TrumenbaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:VaccinesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZoloftMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:HISProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalAllianceBiopharmaceuticalsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:InlytaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VfendMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:HISProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:XanaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PremarinFamilyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InternalMedicineMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:LyricaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:UpjohnReportingUnitMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZyvoxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:HISProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:MedrolMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:PanzygaMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:AllOtherInflammationandImmunologyProductsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:InflammationandImmunologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:TotalBiosimilarsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:SutentMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:OncologyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:EpiPenMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZosynTazocinMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:VyndaqelMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:RareDiseaseMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">pfe:ZithromaxZmaxMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ReportingUnitAxis">pfe:HospitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:BusinessCombinationsAcquisitionRelatedCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:PurchaseAccountingAdjustmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:OtherSegmentReconcilingItemsAxis">pfe:CertainSignificantItemsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:UpjohnSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:CorporateNonSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="pfe:AssetAcquisitionAxis">pfe:TherachonAssetAcquisitionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FI2019Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CurrencyAxis">currency:EUR</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:DevelopedEuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:NovaQuestCoInvestmentFundVL.P.Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:AllogeneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">pfe:BainCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:CerevelMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:McKessonInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:CardinalHealthInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:CN</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:AmerisourceBergenCorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:OperatingSegmentsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:ViivHealthcareLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">pfe:BiopharmaSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ConsolidationItemsAxis">us-gaap:MaterialReconcilingItemsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">pfe:GSKConsumerHealthcareMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">pfe:OtherIncomeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">pfe:ThreeLargestUSWholesaleCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="FI2017Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:JP</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="FI2018Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">pfe:NonUnitedStatesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-12-31</instant>
        </period>
    </context>
    <context id="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0000078003</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:GeographicConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <unit id="Accounting_standard">
        <measure>pfe:Accounting_standard</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="Operating_Segment">
        <measure>pfe:Operating_Segment</measure>
    </unit>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="iso4217_EUR">
        <measure>iso4217:EUR</measure>
    </unit>
    <unit id="gbp">
        <measure>iso4217:GBP</measure>
    </unit>
    <unit id="pension_plan">
        <measure>pfe:pension_plan</measure>
    </unit>
    <unit id="employee_stock_ownership_plan">
        <measure>pfe:employee_stock_ownership_plan</measure>
    </unit>
    <unit id="Country">
        <measure>pfe:Country</measure>
    </unit>
    <unit id="Defendant">
        <measure>pfe:Defendant</measure>
    </unit>
    <unit id="Employee">
        <measure>pfe:Employee</measure>
    </unit>
    <unit id="measure">
        <measure>pfe:measure</measure>
    </unit>
    <unit id="class_action">
        <measure>pfe:class_action</measure>
    </unit>
    <unit id="lawsuit">
        <measure>pfe:lawsuit</measure>
    </unit>
    <unit id="trading_day">
        <measure>pfe:trading_day</measure>
    </unit>
    <unit id="lagoon">
        <measure>pfe:lagoon</measure>
    </unit>
    <unit id="Patent">
        <measure>pfe:Patents</measure>
    </unit>
    <unit id="period">
        <measure>pfe:period</measure>
    </unit>
    <unit id="manufacturer">
        <measure>pfe:manufacturer</measure>
    </unit>
    <dei:AmendmentFlag
      contextRef="FD2019Q4YTD"
      id="Fact-2B657D43D8938771F232801F7F5CD86D-wk-Fact-2B657D43D8938771F232801F7F5CD86D">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate
      contextRef="FD2019Q4YTD"
      id="Fact-FDAD72B0C6D4E294BFE4801F7F5E799B-wk-Fact-FDAD72B0C6D4E294BFE4801F7F5E799B">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus
      contextRef="FD2019Q4YTD"
      id="Fact-0AF5AB95C5E316F58D8A801F7F4CEA86-wk-Fact-0AF5AB95C5E316F58D8A801F7F4CEA86">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus
      contextRef="FD2019Q4YTD"
      id="Fact-3EDCF98D3543816108FA801F7F5D9A85-wk-Fact-3EDCF98D3543816108FA801F7F5D9A85">2019</dei:DocumentFiscalYearFocus>
    <dei:EntityCentralIndexKey
      contextRef="FD2019Q4YTD"
      id="Fact-A9C087689D4F948E379E801F7F5D9FC6-wk-Fact-A9C087689D4F948E379E801F7F5D9FC6">0000078003</dei:EntityCentralIndexKey>
    <pfe:ConcentrationRiskAmount
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TopNineProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="-8"
      id="Fact-08663DB808564A9164DF801F7EFCD207-wk-Fact-08663DB808564A9164DF801F7EFCD207"
      unitRef="usd">1000000000</pfe:ConcentrationRiskAmount>
    <pfe:ConcentrationRiskAmount
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TopTenProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="-8"
      id="Fact-33192B704B3D1FC9AC37801F7EFDC507-wk-Fact-33192B704B3D1FC9AC37801F7EFDC507"
      unitRef="usd">1000000000</pfe:ConcentrationRiskAmount>
    <pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="INF"
      id="Fact-07B7861ECCCF49CF9868D91F8AA0B6BC-wk-Fact-07B7861ECCCF49CF9868D91F8AA0B6BC"
      unitRef="Country">11</pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries>
    <pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="INF"
      id="Fact-2FD12D144CF5F0BCA9F0801F7EA63D72-wk-Fact-2FD12D144CF5F0BCA9F0801F7EA63D72"
      unitRef="Country">11</pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="D2017Q2Jun01-Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      id="Fact-CE9D7C462BF5775EE0E60172459C0EFD-wk-Fact-CE9D7C462BF5775EE0E60172459C0EFD">P9Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="D2017Q3Aug01-Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US"
      id="Fact-B34FA96F5D29BF16F8E90171DB2837FD-wk-Fact-B34FA96F5D29BF16F8E90171DB2837FD">P9Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="D2017Q4Dec01-Dec31_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US"
      id="Fact-5B2E909BB7EB119FE74D01700E6A1601-wk-Fact-5B2E909BB7EB119FE74D01700E6A1601">P10Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="D2018Q2Apr01-Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      id="Fact-25869237F7D2F57A1A0C0C106D287EAC-wk-Fact-25869237F7D2F57A1A0C0C106D287EAC">P10Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BesponsaMember"
      id="Fact-18AC9D0320158F920D920CBB1E7659E2-wk-Fact-18AC9D0320158F920D920CBB1E7659E2">P7Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember"
      id="Fact-865416170C3E90E5A5220CBB38A610BB-wk-Fact-865416170C3E90E5A5220CBB38A610BB">P8Y</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligationTerm>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="INF"
      id="Fact-F05521051C8C3FD2AFED801F7EE47945-wk-Fact-F05521051C8C3FD2AFED801F7EE47945"
      unitRef="shares">1</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="INF"
      id="Fact-23D45D4F9652521A040F801F7EE0019B-wk-Fact-23D45D4F9652521A040F801F7EE0019B"
      unitRef="shares">3</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="INF"
      id="Fact-63DC8ECD22B4D3148FFF801F7EE1EF8F-wk-Fact-63DC8ECD22B4D3148FFF801F7EE1EF8F"
      unitRef="shares">1</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="INF"
      id="Fact-360680CD5A0D33FD8939801F7EE0D449-wk-Fact-360680CD5A0D33FD8939801F7EE0D449"
      unitRef="shares">3</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="Fact-0B400448D25558A313A71217CF67418B-wk-Fact-0B400448D25558A313A71217CF67418B">P1Y</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeDurationofPeriod>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="Fact-DBA38F5FA084593399643607C04AC75E-wk-Fact-DBA38F5FA084593399643607C04AC75E"
      unitRef="usd">541000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="Fact-07091715647256CDB4AD8057DCE577E8-wk-Fact-07091715647256CDB4AD8057DCE577E8"
      unitRef="usd">527000000</us-gaap:AllowanceForDoubtfulAccountsReceivableCurrent>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-B0ADFA04558E26682149801F804BAD07-wk-Fact-B0ADFA04558E26682149801F804BAD07"
      unitRef="usdPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-37E466B377E093574704801F823ADEB7-wk-Fact-37E466B377E093574704801F823ADEB7"
      unitRef="usdPerShare">0.05</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-516E2DBFF137FF395442801F824C52D5-wk-Fact-516E2DBFF137FF395442801F824C52D5"
      unitRef="shares">12000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-00B42AB6C63D4D47D995801F8250336C-wk-Fact-00B42AB6C63D4D47D995801F8250336C"
      unitRef="shares">12000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2018Q4"
      decimals="-6"
      id="Fact-9426C78F4864E19099BE801F824ECFDE-wk-Fact-9426C78F4864E19099BE801F824ECFDE"
      unitRef="shares">9332000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued
      contextRef="FI2019Q4"
      decimals="-6"
      id="Fact-43A568A1B2F110213B88801F806FD23A-wk-Fact-43A568A1B2F110213B88801F806FD23A"
      unitRef="shares">9369000000</us-gaap:CommonStockSharesIssued>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="2"
      id="Fact-2D6BDB639B30D9971A39801F7EC66802-wk-Fact-2D6BDB639B30D9971A39801F7EC66802"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="INF"
      id="Fact-A8F6BC46C9DE51BCA5D7801F7EEA5272-wk-Fact-A8F6BC46C9DE51BCA5D7801F7EEA5272"
      unitRef="number">0.1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="2"
      id="Fact-FA8C73E73D60150B05E2801F7EC90777-wk-Fact-FA8C73E73D60150B05E2801F7EC90777"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="INF"
      id="Fact-2B0B9AC8F3B089659683801F7EEB5D61-wk-Fact-2B0B9AC8F3B089659683801F7EEB5D61"
      unitRef="number">0.1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-502EBE080DE28256D76B801F7E07D4E4-wk-Fact-502EBE080DE28256D76B801F7E07D4E4"
      unitRef="usd">1800000000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-63A97B54CDA8AA2AC3A8801F7E06374A-wk-Fact-63A97B54CDA8AA2AC3A8801F7E06374A"
      unitRef="number">0.02735</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-7501CCEC7B4D0192DEEF801F81E84FD3-wk-Fact-7501CCEC7B4D0192DEEF801F81E84FD3"
      unitRef="number">0.04</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-2CBB41D064359126314C801F82CC8933-wk-Fact-2CBB41D064359126314C801F82CC8933"
      unitRef="number">0.0345</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-DF805AE36913A86A1B9C801F81E89568-wk-Fact-DF805AE36913A86A1B9C801F81E89568"
      unitRef="number">0.039</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-38352E73A1AC3A38585F801F81E7E0C5-wk-Fact-38352E73A1AC3A38585F801F81E7E0C5"
      unitRef="number">0.028</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="Fact-666BF4CEF70690419B91801F81E7FF4C-wk-Fact-666BF4CEF70690419B91801F81E7FF4C"
      unitRef="number">0.0295</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-EF7AF87778B8BF220999801F81CDFFA1-wk-Fact-EF7AF87778B8BF220999801F81CDFFA1"
      unitRef="number">0.034</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-871845D615D6741D412B801F81BA2DA1-wk-Fact-871845D615D6741D412B801F81BA2DA1"
      unitRef="number">0.003</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-71B06D495A3D578308EE801F81CC9DA9-wk-Fact-71B06D495A3D578308EE801F81CC9DA9"
      unitRef="number">0.038</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-642D5A87658829931DEB801F81C28AD1-wk-Fact-642D5A87658829931DEB801F81C28AD1"
      unitRef="number">0.044</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-38C5A1566BA31025F756801F81C7A7E0-wk-Fact-38C5A1566BA31025F756801F81C7A7E0"
      unitRef="number">0.060</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-F1A4832E4D5F6041A612801F81C06ABC-wk-Fact-F1A4832E4D5F6041A612801F81C06ABC"
      unitRef="number">0.042</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-BE07C1C52CE5A7D41240801F81C8FBE9-wk-Fact-BE07C1C52CE5A7D41240801F81C8FBE9"
      unitRef="number">0.013</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-27232A0FA21D95C62103801F81CD890F-wk-Fact-27232A0FA21D95C62103801F81CD890F"
      unitRef="number">0.007</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-E3F9F325914858818975801F81CDD56D-wk-Fact-E3F9F325914858818975801F81CDD56D"
      unitRef="number">0.010</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-E253864A1112EAD0DDE2801F824B2E5D-wk-Fact-E253864A1112EAD0DDE2801F824B2E5D"
      unitRef="number">0.037</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-56003317C811A762BCE6801F81C691E0-wk-Fact-56003317C811A762BCE6801F81C691E0"
      unitRef="number">0.039</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-B29CF7EA6EBA8F9EB379801F81BD2934-wk-Fact-B29CF7EA6EBA8F9EB379801F81BD2934"
      unitRef="number">0.033</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-81623C201F9DA92074C8801F81CA98F9-wk-Fact-81623C201F9DA92074C8801F81CA98F9"
      unitRef="number">0.065</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-DA12961832EB1C963A31801F81CCCBD2-wk-Fact-DA12961832EB1C963A31801F81CCCBD2"
      unitRef="number">0.058</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-7D484FBD1E68D916F0AF801F81BCEB31-wk-Fact-7D484FBD1E68D916F0AF801F81BCEB31"
      unitRef="number">0.035</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-9297627A69595560275B801F81CC162E-wk-Fact-9297627A69595560275B801F81CC162E"
      unitRef="number">0.041</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="3"
      id="Fact-27D7795FCD321467BE07801F81BCD4A5-wk-Fact-27D7795FCD321467BE07801F81BCD4A5"
      unitRef="number">0.012</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-53CB1A49574D5CE257FC801F818882B4-wk-Fact-53CB1A49574D5CE257FC801F818882B4"
      unitRef="number">0.1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-17913D5BA00FFB4127B5801F80F3DC70-wk-Fact-17913D5BA00FFB4127B5801F80F3DC70"
      unitRef="number">0.10</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-36CFDFF82E0CB7B2841F801F81A7DA64-wk-Fact-36CFDFF82E0CB7B2841F801F81A7DA64"
      unitRef="number">0.05</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-7FCB72B2BDFEFCCC5B37801F81048B8C-wk-Fact-7FCB72B2BDFEFCCC5B37801F81048B8C"
      unitRef="number">0.5500</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-11DD842422E9A0F2A3DE801F8102E0D1-wk-Fact-11DD842422E9A0F2A3DE801F8102E0D1"
      unitRef="number">0.40</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-3C3F9BCACFE22DCF06DA801F810484FE-wk-Fact-3C3F9BCACFE22DCF06DA801F810484FE"
      unitRef="number">0.53</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-0B960140FF9DAC00DD8E801F81887BC6-wk-Fact-0B960140FF9DAC00DD8E801F81887BC6"
      unitRef="number">0.60</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-8F3483B4DE3FA66058B3801F81BA4C9C-wk-Fact-8F3483B4DE3FA66058B3801F81BA4C9C"
      unitRef="number">0.20</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-4C4FEF80804DE4BD33B3801F8194D45A-wk-Fact-4C4FEF80804DE4BD33B3801F8194D45A"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-C84FC8BF46E630041A72801F81174C9F-wk-Fact-C84FC8BF46E630041A72801F81174C9F"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-87C0C6806493E29D6238801F80EE5176-wk-Fact-87C0C6806493E29D6238801F80EE5176"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-D8A598710B92EDB2594A801F80F4F418-wk-Fact-D8A598710B92EDB2594A801F80F4F418"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-93C88483D18B83B0BEE5801F81968492-wk-Fact-93C88483D18B83B0BEE5801F81968492"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-876A47F0039172E0C563801F81B8D5E8-wk-Fact-876A47F0039172E0C563801F81B8D5E8"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-1D33269243E8BFFC198B801F8110C571-wk-Fact-1D33269243E8BFFC198B801F8110C571"
      unitRef="number">0.20</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-9957215E4BDF713E4784801F80EC4A69-wk-Fact-9957215E4BDF713E4784801F80EC4A69"
      unitRef="number">0.28</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-08DEA385BD5A96B817D2801F80F34999-wk-Fact-08DEA385BD5A96B817D2801F80F34999"
      unitRef="number">0.35</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-149F3B0F304C8FC2DD56801F818A1A56-wk-Fact-149F3B0F304C8FC2DD56801F818A1A56"
      unitRef="number">0.05</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-F9D716E92CB45B192770801F8101D592-wk-Fact-F9D716E92CB45B192770801F8101D592"
      unitRef="number">0.10</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-040F1EC048A6CC10E966801F810641F6-wk-Fact-040F1EC048A6CC10E966801F810641F6"
      unitRef="number">0.95</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-860B3E24E16561D80A9C801F8102C4C5-wk-Fact-860B3E24E16561D80A9C801F8102C4C5"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="Fact-65A04078CF26655074A5801F8104D5D8-wk-Fact-65A04078CF26655074A5801F8104D5D8"
      unitRef="number">0</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-8"
      id="Fact-3130505587C151D09D4B801F7E062A88-wk-Fact-3130505587C151D09D4B801F7E062A88"
      unitRef="usd">1100000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="Fact-C13CFC3CB21F52099D562C221C465A73-wk-Fact-C13CFC3CB21F52099D562C221C465A73"
      unitRef="usd">4776000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="Fact-7414237C2DE558C2A570279D3852E356-wk-Fact-7414237C2DE558C2A570279D3852E356"
      unitRef="usd">1462000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2018Q4"
      decimals="INF"
      id="Fact-B1B9FBB3E65B02DB442A801F8086325E-wk-Fact-B1B9FBB3E65B02DB442A801F8086325E"
      unitRef="shares">27000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="FI2019Q4"
      decimals="INF"
      id="Fact-61D00E77EE76E65E4F9F801F823CCE99-wk-Fact-61D00E77EE76E65E4F9F801F823CCE99"
      unitRef="shares">27000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2018Q4"
      decimals="0"
      id="Fact-B3981B3D44CB5A0D36C3801F8253C52A-wk-Fact-B3981B3D44CB5A0D36C3801F8253C52A"
      unitRef="shares">478</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="FI2019Q4"
      decimals="0"
      id="Fact-9D817CFBE8E27DFE8D7A801F80886593-wk-Fact-9D817CFBE8E27DFE8D7A801F80886593"
      unitRef="shares">431</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      id="Fact-F0FEE16982B3DD9280F3801F7E7BB2D3-wk-Fact-F0FEE16982B3DD9280F3801F7E7BB2D3">P50Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="Fact-F998F6CFFEA92A32DD15801F7E7A91D9-wk-Fact-F998F6CFFEA92A32DD15801F7E7A91D9">P12Y6M</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      id="Fact-557A5D82EB3A050CC7AE801F7E7BC830-wk-Fact-557A5D82EB3A050CC7AE801F7E7BC830">P20Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      id="Fact-90776A5E9858FF074F59801F7E7A1869-wk-Fact-90776A5E9858FF074F59801F7E7A1869">P33Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      id="Fact-9F29060FFD5AC29F8FC6801F7E78605F-wk-Fact-9F29060FFD5AC29F8FC6801F7E78605F">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      id="Fact-21E6539C99EA15E24D5B801F7E7A74D8-wk-Fact-21E6539C99EA15E24D5B801F7E7A74D8">P8Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      id="Fact-42A6B4CC4728DCFCF8D71214EEA5550F-wk-Fact-42A6B4CC4728DCFCF8D71214EEA5550F">P5Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="Fact-ED5E433E1E4A6F191CB912189D887EDC-wk-Fact-ED5E433E1E4A6F191CB912189D887EDC">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="Fact-4BB44F61DD66844E4DB20CAE9E2A3888-wk-Fact-4BB44F61DD66844E4DB20CAE9E2A3888">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="Fact-EAF0B2177CC3A35A89CC0CAE49EA87B5-wk-Fact-EAF0B2177CC3A35A89CC0CAE49EA87B5">P5Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:TreasuryStockShares
      contextRef="FI2018Q4"
      decimals="-6"
      id="Fact-B2C06C2292CD5F05AEAF801F825BDEAA-wk-Fact-B2C06C2292CD5F05AEAF801F825BDEAA"
      unitRef="shares">3615000000</us-gaap:TreasuryStockShares>
    <us-gaap:TreasuryStockShares
      contextRef="FI2019Q4"
      decimals="-6"
      id="Fact-BFE1E325EAE23FB57CC7801F82423AA9-wk-Fact-BFE1E325EAE23FB57CC7801F82423AA9"
      unitRef="shares">3835000000</us-gaap:TreasuryStockShares>
    <dei:DocumentType
      contextRef="FD2019Q4YTD"
      id="d34666028e513-wk-Fact-0DE47614AD1F7C218E5B1A605CB4DB2B">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="FD2019Q4YTD"
      id="d34666028e555-wk-Fact-E92CA8A0CBDB1D49653BD7555A2B223B">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="FD2019Q4YTD"
      id="d34666028e565-wk-Fact-AE3A07A803AAEE6BBA631A6117870CEE">2019-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="FD2019Q4YTD"
      id="d34666028e582-wk-Fact-DC1C87A0E7539A399A28D757139C85E3">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="FD2019Q4YTD"
      id="d34666028e599-wk-Fact-9576174C12745AD7B04072F87B5CE0F2">1-3619</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="FD2019Q4YTD"
      id="d34666028e606-wk-Fact-924554071C555A81B9AD8B8963A6EFF6">PFIZER INC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="FD2019Q4YTD"
      id="d34666028e627-wk-Fact-E7762A4376DC5B6CBED86E223B486A55">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="FD2019Q4YTD"
      id="d34666028e632-wk-Fact-ADC05CA6FA1B5C05B7CB5D0163D37541">13-5315170</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="FD2019Q4YTD"
      id="d34666028e648-wk-Fact-824BC2808993F1D647251A64A58D58B5">235 East 42nd Street</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="FD2019Q4YTD"
      id="d34666028e652-wk-Fact-A286BFAA6693510082A67B33B9DEEA7F">New York</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="FD2019Q4YTD"
      id="d34666028e656-wk-Fact-4508AA3B089055F9BABF1E5C4CCC91CD">NY</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="FD2019Q4YTD"
      id="d34666028e660-wk-Fact-6D9F28CF77D25E7DB1ED323F5AB0729B">10017</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="FD2019Q4YTD"
      id="d34666028e670-wk-Fact-A8F59C52B0D25235B53B9CC43A7E7B30">212</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="FD2019Q4YTD"
      id="d34666028e674-wk-Fact-2FC696AFEDA15E708F1E6C13D033F657">733-2323</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      id="d34666028e727-wk-Fact-C0663720DFCC5BBF8748AF7E30ADB7B4">Common Stock, $.05 par value</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      id="d34666028e732-wk-Fact-4DCF02DE9FCD5311A11F6F1DBBB5411E">PFE</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_us-gaap_CommonStockMember"
      id="d34666028e737-wk-Fact-BD3D554CEF44594D9687B580217D371E">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20200.000Member"
      id="d34666028e743-wk-Fact-A7C96037DE0858978100C564955F8913">0.000% Notes due 2020</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20200.000Member"
      id="d34666028e748-wk-Fact-16123E0663B45490B33BE7F7EDFBF57D">PFE20A</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20200.000Member"
      id="d34666028e753-wk-Fact-38EA800BC5C15FF39221569997E29414">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member"
      id="d34666028e759-wk-Fact-CC4EC4DF8CD157A18C4E86288502B7D3">0.250% Notes due 2022</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member"
      id="d34666028e764-wk-Fact-F1BEFEBBCA255DC1AA1056BEA6513E6C">PFE22</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20220.250Member"
      id="d34666028e769-wk-Fact-CB148444D4C655A59A016B49B0F911AC">NYSE</dei:SecurityExchangeName>
    <dei:Security12bTitle
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member"
      id="d34666028e775-wk-Fact-769591A72C41593FB46221C0CEB26D96">1.000% Notes due 2027</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member"
      id="d34666028e780-wk-Fact-BAA8AAFC057A5693865364DF4522B448">PFE27</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="FD2019Q4YTD_us-gaap_StatementClassOfStockAxis_pfe_NotesDue20271.000Member"
      id="d34666028e785-wk-Fact-7C0690AFE7B65DBCAEB584CF885946C5">NYSE</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="FD2019Q4YTD"
      id="d34666028e806-wk-Fact-4D4E1222DF067BD0609AD7584777B4A7">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="FD2019Q4YTD"
      id="d34666028e826-wk-Fact-75518DC909E5C9437CBCD758D0272473">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="FD2019Q4YTD"
      id="d34666028e836-wk-Fact-C5DD8A1E7155F9C4A5ABD7592DE303DC">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="FD2019Q4YTD"
      id="d34666028e853-wk-Fact-5A64DFA7C18879E7BB21D75990CBAB64">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="FD2019Q4YTD"
      id="d34666028e870-wk-Fact-DC94FCCB6B808F6B10A9D784C460A8B2">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="FD2019Q4YTD"
      id="d34666028e900-wk-Fact-26E48308B17947822A14D7850FA0B506">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="FD2019Q4YTD"
      id="d34666028e909-wk-Fact-C311D3C4CFCACD97C6BCD785681FDAF4">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany
      contextRef="FD2019Q4YTD"
      id="d34666028e922-wk-Fact-AFEDBD89AE868CF5238AD75A0CDEB96B">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="FI2019Q2"
      decimals="-9"
      id="d34666028e934-wk-Fact-39CD82BC0F711C8BD8051A64D31AE13E"
      unitRef="usd">241000000000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="I2020Q1Feb25"
      decimals="INF"
      id="d34666028e949-wk-Fact-4F66DC7318685148819BD0F1BEC68760"
      unitRef="shares">5547639005</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-AE0128151DF5C78FF5FAD77E81B27A7D-0-wk-Fact-E13451DE98FB5847FE6FD77E8E654B2E">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:653px;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="2"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:532px;"/&gt;&lt;td style="width:121px;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;DOCUMENTS INCORPORATED BY REFERENCE&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Portions of the 2019 Annual Report to Shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Parts&#160;I,&#160;II&#160;and&#160;IV&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Portions of the Proxy Statement for the 2020 Annual Meeting of Shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Part III&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e1459-wk-Fact-99447C56530B57BB99F3272D91D61246"
      unitRef="usd">51750000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e1478-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
      unitRef="usd">53647000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e1498-wk-Fact-5800B99789A546352282801F7F2D7923"
      unitRef="usd">52546000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e1585-wk-Fact-28DD1757DF955D578E13DE8351B692BB"
      unitRef="usd">10219000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e1604-wk-Fact-0489780C77A658BF8868E1551D1C625D"
      unitRef="usd">11248000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e1623-wk-Fact-2F12F18AD8251A365397801F7F1D63C2"
      unitRef="usd">11228000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e1651-wk-Fact-AB74A10364F359F29349BB0B21ECB2F3"
      unitRef="usd">14350000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e1670-wk-Fact-29CC16548E2E546280762B10A285EBB3"
      unitRef="usd">14455000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e1689-wk-Fact-83E1143E04F5A91F1232801F80AB7507"
      unitRef="usd">14804000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e1717-wk-Fact-3482AAEFC33858968E580ACA1EF44907"
      unitRef="usd">8650000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e1736-wk-Fact-6EED17ECA25F58D092D7F74CB80AA63D"
      unitRef="usd">8006000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e1755-wk-Fact-B6E23DD26A27DC66F8C3CAFFFD2CBF22"
      unitRef="usd">7683000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e1781-wk-Fact-5ABF4791BE6951B3BD213F08FF302F41"
      unitRef="usd">4610000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e1800-wk-Fact-60979D16D8DE563EA2F73F6D211A9A3F"
      unitRef="usd">4893000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e1819-wk-Fact-27CD0201DE5939C1D6C9801F7F2B2695"
      unitRef="usd">4758000000</pfe:AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e1845-wk-Fact-61EEF037EA245BC58651F6491A13B057"
      unitRef="usd">747000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e1864-wk-Fact-20A55537F0675518894025A232665AAA"
      unitRef="usd">1044000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e1883-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409"
      unitRef="usd">351000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e1909-wk-Fact-0612C9171BB1563BAA0D97F47098AC20"
      unitRef="usd">8086000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e1929-wk-Fact-C36972272EBF57F09D3E0A0B47D781D3"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e1948-wk-Fact-51D5CD0734BBD4CF6AB0CB00E2C1C110"
      unitRef="usd">0</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e1974-wk-Fact-58A10D106477541896C64514721528B2"
      unitRef="usd">-3578000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e1993-wk-Fact-F590D4C627155C828C90476F227A1511"
      unitRef="usd">-2116000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2012-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927"
      unitRef="usd">-1416000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
      unitRef="usd">17682000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
      unitRef="usd">11885000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
      unitRef="usd">12305000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2103-wk-Fact-FC65E982593353C58EDD19521634B9BF"
      unitRef="usd">1384000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2122-wk-Fact-316CD294736155A2BF815F488E7DB6E0"
      unitRef="usd">706000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2141-wk-Fact-C55A09F5044EA944EC43801F7F3390E1"
      unitRef="usd">-9049000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2168-wk-Fact-0035B9C9DB225A72A990E1262460243C"
      unitRef="usd">16298000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2187-wk-Fact-F7E834DB2C365543A0147187D74A1E82"
      unitRef="usd">11179000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2206-wk-Fact-7AB6A34649A53C89765A801F808558FA"
      unitRef="usd">21353000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2299-wk-Fact-70A89F04606E5C478C49B14416D6CE2D"
      unitRef="usd">4000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2318-wk-Fact-92574249FA1B5792A5D2D0D169042981"
      unitRef="usd">10000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2337-wk-Fact-3C80ECF87216CAD55440801F7F4B62D4"
      unitRef="usd">-1000000</us-gaap:DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2364-wk-Fact-C602001194365B76BEA91037F0F0DB98"
      unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2383-wk-Fact-96EE1FC21874513CAC2C4A3E7FCA2B60"
      unitRef="usd">0</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2402-wk-Fact-C2C7E920844E64417EE0801F7F43A1D0"
      unitRef="usd">3000000</us-gaap:DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2428-wk-Fact-324E930EA3FE51309DAF874C15316ACB"
      unitRef="usd">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2447-wk-Fact-08237D5DF91153BBBDE19A688EC551B8"
      unitRef="usd">10000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2466-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F"
      unitRef="usd">2000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
      unitRef="usd">16302000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F"
      unitRef="usd">11188000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
      unitRef="usd">21355000000</us-gaap:ProfitLoss>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2556-wk-Fact-0E9DF21E8B8D568689FB453465570C12"
      unitRef="usd">29000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2575-wk-Fact-BAD8CA6C4B6A5AE88554A9B88D8A8209"
      unitRef="usd">36000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLossAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2594-wk-Fact-D83DE49486164AB0AD35801F7F32BB1B"
      unitRef="usd">47000000</us-gaap:NetIncomeLossAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e2625-wk-Fact-9F4115E6A91F5D5A8F7DBFD6C8FE97D2"
      unitRef="usd">16273000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e2644-wk-Fact-07EEAB5D75BE5733BBE5DDB62C46DAC9"
      unitRef="usd">11153000000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e2664-wk-Fact-B84B5B2E9880B8DB72EA801F7F15BA80"
      unitRef="usd">21308000000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34430544e2823-wk-Fact-68C3B0FD2C4751708C56BFF9C8FF5735"
      unitRef="usdPerShare">2.92</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d34430544e2842-wk-Fact-5947CFACA921556B9FFF58244C1A10F0"
      unitRef="usdPerShare">1.90</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerBasicShare
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d34430544e2862-wk-Fact-5A1858B72D840CA48B81801F8088EC92"
      unitRef="usdPerShare">3.57</us-gaap:IncomeLossFromContinuingOperationsPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34430544e2882-wk-Fact-C0A19D1D9DC45DD6801580B6A3ACBEA6"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d34430544e2901-wk-Fact-2CB4512C4635516E90761E4D85A4869E"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d34430544e2920-wk-Fact-E3D918CD118292C5AA27801F802986E2"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34430544e2951-wk-Fact-A8B9CC29B1BD5DCCB10156807AFD46CF"
      unitRef="usdPerShare">2.92</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d34430544e2970-wk-Fact-2F3CA3A3FAD45C6BBFFA9AF52B012B5D"
      unitRef="usdPerShare">1.90</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d34430544e2990-wk-Fact-80382989DBE2B2A99A05801F7F3B9C46"
      unitRef="usdPerShare">3.57</us-gaap:EarningsPerShareBasic>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34430544e3080-wk-Fact-33025D2CE7995F16A707BC65C2D0FAA0"
      unitRef="usdPerShare">2.87</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d34430544e3099-wk-Fact-9CA9F5D6598257E8B08FB6226CA68B1F"
      unitRef="usdPerShare">1.86</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d34430544e3119-wk-Fact-C2867733F38A06F7227D801F7F30AEAD"
      unitRef="usdPerShare">3.52</us-gaap:IncomeLossFromContinuingOperationsPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34430544e3139-wk-Fact-1607AE44D7025E1EB5295964DC39F488"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d34430544e3158-wk-Fact-166D37DCD0615EB59DA9AF177DA4F7E9"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d34430544e3177-wk-Fact-B281E1948A327D1F074D801F7F417F9A"
      unitRef="usdPerShare">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34430544e3208-wk-Fact-ADE382A1D3945AC3B461E0B1B11CBDE7"
      unitRef="usdPerShare">2.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d34430544e3227-wk-Fact-098C50B89DAF5EB9A094993C8FEEA183"
      unitRef="usdPerShare">1.87</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d34430544e3247-wk-Fact-388802394B995CDECA90801F7F4A337B"
      unitRef="usdPerShare">3.52</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e3334-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
      unitRef="shares">5569000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e3353-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
      unitRef="shares">5872000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e3372-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
      unitRef="shares">5970000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34430544e3398-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027"
      unitRef="shares">5675000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34430544e3417-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
      unitRef="shares">5977000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34430544e3436-wk-Fact-769F1280EBF192E593C5801F7F419E21"
      unitRef="shares">6058000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
      unitRef="usd">16302000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F"
      unitRef="usd">11188000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
      unitRef="usd">21355000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e1590-wk-Fact-3328F0DAC738681A6D21801F7ECF7D37"
      unitRef="usd">654000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e1609-wk-Fact-00FA4D10D2645A50AEDEE8302484A6D5"
      unitRef="usd">-799000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e1630-wk-Fact-1C949239FD4407E55222801F7FD72F26"
      unitRef="usd">1116000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e1652-wk-Fact-C13328F655305F8CB43D006E17681322"
      unitRef="usd">288000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e1672-wk-Fact-15E210D3DD0D5FB08B54D80504EBC060"
      unitRef="usd">22000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e1692-wk-Fact-563BB6FEBF5717E60D97CB0A84CDFE98"
      unitRef="usd">-162000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationReclassificationAdjustmentFromAOCIRealizedUponSaleOrLiquidationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e1718-wk-Fact-01A8C48E01D25B3EAFDAC449EB4857D2"
      unitRef="usd">366000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e1737-wk-Fact-860CFBCF363653FC86BC0095D64D864D"
      unitRef="usd">-821000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e1757-wk-Fact-D92D96928692FE5AFF2B801F7F150711"
      unitRef="usd">1278000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e1783-wk-Fact-A8ECAB64FC345D158EED4CF5EB8D3C49"
      unitRef="usd">476000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e1802-wk-Fact-6325E2F134D45571A3E0DD3C60FB9C6F"
      unitRef="usd">220000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e1821-wk-Fact-BAE279F5EB71087D83F2801F7EE05475"
      unitRef="usd">-10000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e1850-wk-Fact-4D8CEC7EA9FB5F60A15FD79906165FE2"
      unitRef="usd">664000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e1870-wk-Fact-4752641D09C957ACBC4D5CB0E30EFE1F"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e1889-wk-Fact-0861F3F4D28BB35D854E801F80ADCAA4"
      unitRef="usd">520000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e1916-wk-Fact-F2276591896D5AF8B95530B8937AAC4D"
      unitRef="usd">-188000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e1936-wk-Fact-A0580F12FEFB5184AF83F23E7628F9E3"
      unitRef="usd">247000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e1955-wk-Fact-B3FD5671955A957CB3C8801F7ECD2BE6"
      unitRef="usd">-530000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e1982-wk-Fact-DDD211C8993350B79EF8D3FEBE1A053B"
      unitRef="usd">-1000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2002-wk-Fact-EFFB4E372D675AF89AAD0163ED875CE2"
      unitRef="usd">-185000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2022-wk-Fact-8C7EA7D7F43807E0390D801F7ECD3AD1"
      unitRef="usd">818000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2051-wk-Fact-93625872A9D656368D7E152DE8C08019"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2070-wk-Fact-7952617F186F5E01B2B1132FE8B404CC"
      unitRef="usd">-124000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2089-wk-Fact-CF0794E1A8A3CA0BB480801F7F0C5847"
      unitRef="usd">244000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesBeforeTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2120-wk-Fact-D5F5556E181E5148B38700A64385FDDC"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2139-wk-Fact-0E93D2D6EF205317999004B109639A0A"
      unitRef="usd">462000000</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2159-wk-Fact-4E0F3852D83E28ABDBED801F7ECDFF6C"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForUnrealizedGainsIncludedInRetainedEarningsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2185-wk-Fact-09EB80731D7155BD844BFECD417399D3"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2204-wk-Fact-BAF546B82D94528D8306C20351599D86"
      unitRef="usd">-522000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2224-wk-Fact-50686A372E736C0F5647801F82939361"
      unitRef="usd">574000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2250-wk-Fact-CAA3EF8F2067516F9B2E0F85B4BF5AD0"
      unitRef="usd">-826000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2270-wk-Fact-28E378BA49F05856958E09125890B46D"
      unitRef="usd">-649000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2290-wk-Fact-31991F01AC86E4619B23801F800998F2"
      unitRef="usd">-212000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansNetUnamortizedGainLossArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2317-wk-Fact-C51C12B9003E560B915ACD09B3E99840"
      unitRef="usd">-241000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2336-wk-Fact-5326AFF91A2251119CB3EA737ED72B03"
      unitRef="usd">-242000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2355-wk-Fact-8A1F93452E32511246DC801F7F0CF497"
      unitRef="usd">-588000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2381-wk-Fact-44EF20E31F87512BB82C3578F60D84E2"
      unitRef="usd">-274000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2400-wk-Fact-CA434D2888FB588EB4655963352B2A4D"
      unitRef="usd">-142000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2419-wk-Fact-752CABA8E508F4880C7C801F81391188"
      unitRef="usd">-117000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossBeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2445-wk-Fact-D72EAE58B45655088BE6DF720737CDA8"
      unitRef="usd">-22000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2464-wk-Fact-54104279652F5BA598DF82A20E111838"
      unitRef="usd">-112000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2483-wk-Fact-CBF9C7A23687212604C8801F829129F8"
      unitRef="usd">145000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2510-wk-Fact-D5EB172CCBCC5F4D8D27B6F5728E0EBD"
      unitRef="usd">-289000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2530-wk-Fact-532861FAECEE50D0A6F6D5AEF071E5B9"
      unitRef="usd">-153000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2550-wk-Fact-8A35E5331DDD75689E2C801F829E69B4"
      unitRef="usd">348000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossNetGainLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2576-wk-Fact-DE50E7770F245761B8991D27CD7FA8EE"
      unitRef="usd">7000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2596-wk-Fact-C815B28EFCEB57A091D4DD245EBDE146"
      unitRef="usd">9000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2616-wk-Fact-923B7EF4CCA59EE61341801F7F2C1401"
      unitRef="usd">2000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlanNetPriorServiceCostCreditArisingDuringPeriodBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2643-wk-Fact-B56F71AB068951F5B6B9C531420B33FC"
      unitRef="usd">-181000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2663-wk-Fact-4D09902765CD56939721BF43E88C545F"
      unitRef="usd">-181000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2683-wk-Fact-7A0B0B97234568FCF5ED801F8263730F"
      unitRef="usd">-184000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditBeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2710-wk-Fact-E6FC35E4FFF354B58F58E4CFFF29DCB8"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2730-wk-Fact-0ABC054ABD705474B81B86310757E0CC"
      unitRef="usd">-19000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2750-wk-Fact-FB5AEC684D9BF5EB4428801F8178F643"
      unitRef="usd">-18000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2778-wk-Fact-DD92E4AF9BD15F60838130DCE8A678BE"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2797-wk-Fact-AF85C0A522725220A32AC451BBAD97DA"
      unitRef="usd">-2000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2816-wk-Fact-1579B10788C733E8AAC8801F828B55EB"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodbeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2842-wk-Fact-43B675EB3B86596CAC5E7949E794E330"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2862-wk-Fact-4F41970AB5AF5A55B4EA05E37BD7A829"
      unitRef="usd">207000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2882-wk-Fact-9AFB6DAE6BF5A7027999801F7ED8C9BD"
      unitRef="usd">203000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2909-wk-Fact-FFE4B8C9C5A45A3BB02F23579673DDAA"
      unitRef="usd">-262000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2929-wk-Fact-30AD1982C6115A29A36BF68B59AEDB47"
      unitRef="usd">-1457000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e2949-wk-Fact-C691D683EBCB98306D23801F7F16756B"
      unitRef="usd">1468000000</us-gaap:OtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e2977-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
      unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e2996-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
      unitRef="usd">518000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e3015-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
      unitRef="usd">-262000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e3047-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
      unitRef="usd">-376000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e3067-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
      unitRef="usd">-1975000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e3088-wk-Fact-5F457A9009553F04B717801F7FB266B9"
      unitRef="usd">1730000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e3177-wk-Fact-211494DFE1B65B998EAAA38B4550E8C1"
      unitRef="usd">15926000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e3196-wk-Fact-C1EB256C91145D3BB9F80464D5790C53"
      unitRef="usd">9214000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e3216-wk-Fact-C8753C9584514B8878AE801F81306F2E"
      unitRef="usd">23085000000</us-gaap:ComprehensiveIncomeNetOfTaxIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e3236-wk-Fact-D8D3C4F5774A56769436D861E4EEF751"
      unitRef="usd">18000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e3255-wk-Fact-E3F086AF3830512484E4717330E2CA08"
      unitRef="usd">16000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e3274-wk-Fact-D358FB74D462C490D295801F7FC14EB5"
      unitRef="usd">62000000</us-gaap:ComprehensiveIncomeNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34428379e3305-wk-Fact-60CD4D80F7AE528A9A1801629A9AD807"
      unitRef="usd">15908000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34428379e3324-wk-Fact-EDB5A19EC991587EA94D6F34F8FC39F7"
      unitRef="usd">9198000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34428379e3344-wk-Fact-AD91E61606B3F9D31977801F7FE885E5"
      unitRef="usd">23023000000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34428379e3358-wk-Fact-BD803F6CBE8619C04B2F16E6F1410DC8"
      unitRef="usd">1300000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34428379e3362-wk-Fact-7585EA770858DD8F140716EB02CF3463"
      unitRef="usd">978000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34428379e3409-wk-Fact-CACD50923894EDD99872801F80B0B6C2"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="2"
      id="d34428379e3414-wk-Fact-C1577C38066176D10EAC801F80EADEC6"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1488-wk-Fact-A3B4914B172C5BC59639B98C6FB3F588"
      unitRef="usd">1305000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1507-wk-Fact-92028286814C58C496DAD3D9CE00EA8A"
      unitRef="usd">1139000000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:ShortTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1527-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6"
      unitRef="usd">8525000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1546-wk-Fact-E3E97336ACA652838D81F531EE99F43B"
      unitRef="usd">17694000000</us-gaap:ShortTermInvestments>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1571-wk-Fact-3C889F3A20C0530CB57A37DDC3BC5CFD"
      unitRef="usd">8724000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1590-wk-Fact-58A9D592472E54ACB181BBAE9BC91E05"
      unitRef="usd">8025000000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1615-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
      unitRef="usd">8283000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1634-wk-Fact-C16D2F781E815917AC4E583A6245970B"
      unitRef="usd">7508000000</us-gaap:InventoryNet>
    <pfe:OtherTaxAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1659-wk-Fact-47C637A51CEE5EF080D18BCE1B38E7DA"
      unitRef="usd">3344000000</pfe:OtherTaxAssetsCurrent>
    <pfe:OtherTaxAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1678-wk-Fact-7C95FE45B026572C9C6575056E409438"
      unitRef="usd">3374000000</pfe:OtherTaxAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1703-wk-Fact-A68C33E581015A07BF02867B616768F9"
      unitRef="usd">2600000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1722-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD"
      unitRef="usd">2461000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1747-wk-Fact-22FC256F29955A5AAC465714927146A3"
      unitRef="usd">21000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1766-wk-Fact-41F671B8835D59FE8632B22D5D005E66"
      unitRef="usd">9725000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1792-wk-Fact-B2196219F55E53698D0DA829DF1E2B27"
      unitRef="usd">32803000000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1811-wk-Fact-88F8256AB81452CCA864D49A834C7EC7"
      unitRef="usd">49926000000</us-gaap:AssetsCurrent>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1836-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F"
      unitRef="usd">17133000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1855-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE"
      unitRef="usd">181000000</us-gaap:EquityMethodInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1880-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC"
      unitRef="usd">3014000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1899-wk-Fact-38B878301DB957B297D2601592AD511A"
      unitRef="usd">2586000000</us-gaap:LongTermInvestments>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1924-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
      unitRef="usd">13967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1943-wk-Fact-7F7E046052F852439B2A0884F029C60C"
      unitRef="usd">13385000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
      unitRef="usd">35370000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
      unitRef="usd">35211000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2012-wk-Fact-6EE57D419E98505BB872CDF37DAACD72"
      unitRef="usd">58653000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2031-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04"
      unitRef="usd">53411000000</us-gaap:Goodwill>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2056-wk-Fact-AB13686A614A540891E5DB6A56F3428E"
      unitRef="usd">2099000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2075-wk-Fact-E658F74A5A8852C19F682FC523E87C64"
      unitRef="usd">1924000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2100-wk-Fact-B8D6B5CC80C55A49A1EE3141CCBD5ACE"
      unitRef="usd">4450000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2119-wk-Fact-4A424945B16E50C896282B201E79955C"
      unitRef="usd">2799000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2149-wk-Fact-7613A3BE7B3C52548720187D3E9B29CB"
      unitRef="usd">167489000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2168-wk-Fact-BF946A4349E2545BA4A121AADE5B3A9D"
      unitRef="usd">159422000000</us-gaap:Assets>
    <us-gaap:DebtCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2284-wk-Fact-D592F35F847457ABB1C2D0D22ED64864"
      unitRef="usd">16195000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2303-wk-Fact-A51B51A828275272A7C573C440BF63F4"
      unitRef="usd">8831000000</us-gaap:DebtCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2323-wk-Fact-DCCF1CBB1A0259B4B4B8B56A33FFAE88"
      unitRef="usd">4220000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2342-wk-Fact-C0D03D29D7BD5A5094E94025EADCF408"
      unitRef="usd">4674000000</us-gaap:AccountsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2367-wk-Fact-0AA2D540FDE353DF84FFCE6640225D60"
      unitRef="usd">2104000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:DividendsPayableCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2386-wk-Fact-52056BFD52B55AD7B0B223B4DB2C6129"
      unitRef="usd">2047000000</us-gaap:DividendsPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2411-wk-Fact-31D197A179335FA6BF6A7BC5D0D64EA2"
      unitRef="usd">980000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:TaxesPayableCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2430-wk-Fact-DFC5C4232A535405BE8E98D62FCA6018"
      unitRef="usd">1265000000</us-gaap:TaxesPayableCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2455-wk-Fact-729C012AD2435DBEB3A6986C8E3F0F60"
      unitRef="usd">2720000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2474-wk-Fact-77801D3C57905C8C93FABB42EA4BACE1"
      unitRef="usd">2397000000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2499-wk-Fact-DC09811A83505392B3800EEDE627AFCD"
      unitRef="usd">11083000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2518-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31"
      unitRef="usd">10753000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2543-wk-Fact-6C6D242FEDF05A7CADA10BE9ECFC67DD"
      unitRef="usd">0</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2562-wk-Fact-D213F8E63BD05CEBBE34196677D85307"
      unitRef="usd">1890000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2587-wk-Fact-4B1590ADE87B568D8CC8C86F0B307CF0"
      unitRef="usd">37304000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2606-wk-Fact-0CE5B6DDA0365CB096E454B209F9983E"
      unitRef="usd">31858000000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2677-wk-Fact-92CFAEDA1D275CCFA954DF7DFEDFAB50"
      unitRef="usd">35955000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2696-wk-Fact-05108BE54FE052919D68B32B6466B9DF"
      unitRef="usd">32909000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2721-wk-Fact-EAC2A8EBA0265A18879BA13F53119C66"
      unitRef="usd">5638000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2740-wk-Fact-D2AF16FAEA7B5A13BDB49C7D1827AC2B"
      unitRef="usd">5272000000</us-gaap:DefinedBenefitPensionPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2766-wk-Fact-DB90E025117E5EE7A0F72EE7BD31627B"
      unitRef="usd">1124000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2785-wk-Fact-E3FD9DF1F7065B2BAFE310C3379623D1"
      unitRef="usd">1338000000</us-gaap:OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2810-wk-Fact-0DCDEA0AFFF95ED982FB39EAA2FBC94A"
      unitRef="usd">5578000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2829-wk-Fact-96A8E9E0E31B5853A1D087253B1B6301"
      unitRef="usd">3700000000</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2854-wk-Fact-13191F129DFB57EB8DE4693D33017900"
      unitRef="usd">12126000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:LiabilityForUncertainTaxPositionsNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2873-wk-Fact-897222CA063B5438BA0EAAE6C107C7B6"
      unitRef="usd">14737000000</us-gaap:LiabilityForUncertainTaxPositionsNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2898-wk-Fact-75F7E84A031750E0A49F77B3AEF45671"
      unitRef="usd">6317000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2917-wk-Fact-6DF270940FC65894A5CA91BBF63EB321"
      unitRef="usd">5850000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e2942-wk-Fact-54259B5ADCDB523D95E357958F32EAA5"
      unitRef="usd">104042000000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e2961-wk-Fact-1C6A9F20611E5E39AE756F72080F3817"
      unitRef="usd">95664000000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2019Q4"
      id="d34423000e3032-wk-Fact-789D85DCBD5CAAFAC780801F7E9C6FBB"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="FI2018Q4"
      id="d34423000e3050-wk-Fact-DCF7E4E72A2BD2587C67801F7EA7706F"
      unitRef="usd"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3120-wk-Fact-65AD28ADEA625EEBBB3613A384127FAA"
      unitRef="usd">17000000</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3139-wk-Fact-29D31CFA7A6550EBAA66F5ACE1A10761"
      unitRef="usd">19000000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3164-wk-Fact-F60C602F8EF1574C98B984D666B6FDE3"
      unitRef="usd">468000000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3183-wk-Fact-C48222126B9050F9BFAC0CB6B70D58A1"
      unitRef="usd">467000000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3208-wk-Fact-1B23844B5232538ABD87C7C1814A1CF1"
      unitRef="usd">87428000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3227-wk-Fact-7B3EE432FBB3579996CA5926DC51D999"
      unitRef="usd">86253000000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:TreasuryStockValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3253-wk-Fact-562D6F8F14805BDBA1EEB5EC76E5A656"
      unitRef="usd">110801000000</us-gaap:TreasuryStockValue>
    <us-gaap:TreasuryStockValue
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3273-wk-Fact-7747152390E65C85B0029AEB713C8F55"
      unitRef="usd">101610000000</us-gaap:TreasuryStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3299-wk-Fact-856AC81ACCEC5011ACDEA26123CED5EE"
      unitRef="usd">97670000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3318-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F"
      unitRef="usd">89554000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3343-wk-Fact-66EE9ACDD29C54A495F8D48FB257E0D9"
      unitRef="usd">-11640000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3363-wk-Fact-1C1A48D8D8FB59F484CD69BF32113D2E"
      unitRef="usd">-11275000000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3389-wk-Fact-CF4BCD6471CF5A67AD13EFC0CB141620"
      unitRef="usd">63143000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3408-wk-Fact-DA95F5D557CD51E498E32E8F9370AC31"
      unitRef="usd">63407000000</us-gaap:StockholdersEquity>
    <us-gaap:MinorityInterest
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3433-wk-Fact-DF4C7D7A1BC15C8FB52ACDC98F4B191B"
      unitRef="usd">303000000</us-gaap:MinorityInterest>
    <us-gaap:MinorityInterest
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3452-wk-Fact-3AE7E9A85D765783A134E8B901625365"
      unitRef="usd">351000000</us-gaap:MinorityInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3477-wk-Fact-48600923F2B454478E9D06C9836F179C"
      unitRef="usd">63447000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3496-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
      unitRef="usd">63758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34423000e3526-wk-Fact-1967B402D8BE56648C1FED785998B3C6"
      unitRef="usd">167489000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34423000e3545-wk-Fact-86C1962CA09E5E038A8356A346B1940A"
      unitRef="usd">159422000000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesIssued
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d34458032e2069-wk-Fact-270C12BCCD80680CE432CB2DE5F8DC92"
      unitRef="shares">597</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d34458032e2088-wk-Fact-59C2713351C3718503CECB2DE492EDAD"
      unitRef="usd">24000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e2102-wk-Fact-86FCF4A9AC35C93C9512CB2DE640F043"
      unitRef="shares">9230000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e2122-wk-Fact-81C7586111FF1F4FF011CB2DE6212D3A"
      unitRef="usd">461000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e2141-wk-Fact-5244EF9D70AB4BF20E72CB2DE505A72E"
      unitRef="usd">82685000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e2155-wk-Fact-CEBB6ABAEC10A6B4CDAFCB2DE5909958"
      unitRef="shares">3160000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e2176-wk-Fact-AEFB6F4B2F0FF7051095CB2DE528EDFE"
      unitRef="usd">-84364000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e2196-wk-Fact-E54EE12FB1C1E89110A9CB2DE5B4B413"
      unitRef="usd">71774000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34458032e2215-wk-Fact-1526F7310FFB6F8E8B4BCB2DE56B079F"
      unitRef="usd">-11036000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e2236-wk-Fact-4BF8867A9673AACA0E31CB2DE4C160C4"
      unitRef="usd">59544000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e2255-wk-Fact-DFD2BE3FC86FDFD923FDCB2DE4E53FC7"
      unitRef="usd">296000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2016Q4"
      decimals="-6"
      id="d34458032e2275-wk-Fact-51AF8A24F6320B3DD4D9CB2DE5470BE9"
      unitRef="usd">59840000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e2422-wk-Fact-43F9860B2E4FABD39FD0801F824B7F7B"
      unitRef="usd">21308000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e2462-wk-Fact-14F1C2A6A168BD044F0E801F802AA8F2"
      unitRef="usd">21308000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e2481-wk-Fact-FF2092BE1BF7CB316625801F7E1E3368"
      unitRef="usd">47000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
      unitRef="usd">21355000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34458032e2673-wk-Fact-218AEF14B977A83E4A06801F7EFF265B"
      unitRef="usd">1715000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e2693-wk-Fact-538AD0D1FEAC9B9942E5801F80805FA6"
      unitRef="usd">1715000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e2712-wk-Fact-F98321594AC5D5415DB0801F825F0776"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e2731-wk-Fact-5F457A9009553F04B717801F7FB266B9"
      unitRef="usd">1730000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e3119-wk-Fact-681CAA08E088E04EA79E801F7ECB79CF"
      unitRef="usd">7789000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e3160-wk-Fact-84A9A3C57D9468DD47C4801F80615D38"
      unitRef="usd">7789000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e3200-wk-Fact-9EC5142FF1350AFCC36A801F7FDF5605"
      unitRef="usd">7789000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e3354-wk-Fact-EA60695FBD38F2408E8C801F7EC802D2"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e3395-wk-Fact-64527C0F87BA22A2495F801F7FFC6A1A"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e3435-wk-Fact-8EAE4EB5674D9D1095E0801F7FEA5B11"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e3649-wk-Fact-C481ECF3EFBB0708C01D801F7EFDD582"
      unitRef="usd">9000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e3669-wk-Fact-9C15C23B033F2F07DF6B801F823D2E2E"
      unitRef="usd">9000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e3733-wk-Fact-CC66745CDAB046F9CA50801F7EC633DE"
      unitRef="shares">45000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e3748-wk-Fact-DF31EFE36B91F582343D801F80809133"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e3767-wk-Fact-1561A8609FA608E10A98801F80706999"
      unitRef="usd">1597000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e3786-wk-Fact-99C23B4E5EC579EA4F26801F7DF197AB"
      unitRef="shares">15000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e3801-wk-Fact-1A7E3821C23A4DED79AC801F7E1FD112"
      unitRef="usd">-63000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e3862-wk-Fact-FA5370553D0E753807A4801F800C2D97"
      unitRef="usd">1536000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e3901-wk-Fact-760E7E634C39F63FC233801F7E0F6B98"
      unitRef="usd">1536000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e4019-wk-Fact-F3866D134A97F71188EB801F7E1851F4"
      unitRef="shares">150000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e4035-wk-Fact-B5FF23DD831E759A71FF801F7DE6500E"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e4096-wk-Fact-7918FE9F0C5FFB8CDA07801F8037553C"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e4136-wk-Fact-72DE426063852BE9262D801F7E146126"
      unitRef="usd">5000000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d34458032e4163-wk-Fact-7CA1E8DB0EEA61585658801F8257D851"
      unitRef="shares">73</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d34458032e4178-wk-Fact-89A0361AA02CC1515879801F8245AD29"
      unitRef="usd">3000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e4234-wk-Fact-0F427D37984EF6A14C01801F80833398"
      unitRef="usd">3000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e4269-wk-Fact-E826CDDD3780AEBA80B0CB2DE5D9E519"
      unitRef="usd">-1000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e4329-wk-Fact-EE63D6A60A1762912BF4801F8259FD6E"
      unitRef="usd">5000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e4369-wk-Fact-33AFDD4662101709F692801F7E18C5FF"
      unitRef="usd">5000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e4513-wk-Fact-0584C0E58CA0A6B96247801F7EC7A79A"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e4551-wk-Fact-97A49B0ECEA9517FFBB7801F7E06BC9B"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458032e4589-wk-Fact-46AB28E4CC157C45741A801F823EEFDA"
      unitRef="usd">0</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d34458032e4615-wk-Fact-192DA984185DD0ED8BF0801F803D17EF"
      unitRef="shares">524</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d34458032e4629-wk-Fact-6586B6AD1EA296008717801F7EBC80FD"
      unitRef="usd">21000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e4648-wk-Fact-CB5E098B3EA566270808801F7E0EF978"
      unitRef="shares">9275000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e4663-wk-Fact-89C1C2FF8BAE35AB2220801F7FC7C2B0"
      unitRef="usd">464000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e4682-wk-Fact-2BBF90C0E0ACDECC1704801F80243029"
      unitRef="usd">84278000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e4701-wk-Fact-35E0049DFF2E76A140E3801F8089CAA6"
      unitRef="shares">3296000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e4717-wk-Fact-D132FA43C9BCB6877BE6801F802DED15"
      unitRef="usd">-89425000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e4737-wk-Fact-1A7FFDC660ABEFAC6697801F7ECAA2B8"
      unitRef="usd">85291000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34458032e4756-wk-Fact-8F27495BD68561A9487C801F7DC77927"
      unitRef="usd">-9321000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e4777-wk-Fact-27E943B33C7E2180DED5801F807FD2B1"
      unitRef="usd">71308000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e4796-wk-Fact-1381E356C11529474B50801F7FE67AD8"
      unitRef="usd">348000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2017Q4"
      decimals="-6"
      id="d34458032e4815-wk-Fact-53A4C5E0F7DCF0473DB8801F8250BB73"
      unitRef="usd">71656000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e4968-wk-Fact-87DF5DD60C52EBFDCA12801F7F002312"
      unitRef="usd">11153000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e5008-wk-Fact-EC11057FA838BD75D525801F824F6767"
      unitRef="usd">11153000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e5027-wk-Fact-2CA67D7D788BA11D095F801F7FD36422"
      unitRef="usd">36000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F"
      unitRef="usd">11188000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34458032e5219-wk-Fact-5F191F9F323C685F3993801F7DCDF586"
      unitRef="usd">-1955000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e5240-wk-Fact-B7BD42B10C099A6A26D1801F7FD5AF39"
      unitRef="usd">-1955000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e5260-wk-Fact-AAADFB48294C3599DB10801F82605B2C"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e5280-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
      unitRef="usd">-1975000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e5669-wk-Fact-324D6E1724EEC6BE2FE9801F7DF40048"
      unitRef="usd">8060000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e5710-wk-Fact-ED209CAAD0144B632B7B801F7DF7158B"
      unitRef="usd">8060000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e5748-wk-Fact-12B293ED1A777402AC1F801F7ECA154F"
      unitRef="usd">8060000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e5902-wk-Fact-ADB247F63E15672E1A7D801F7DC78C20"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e5943-wk-Fact-EFC8C046FEC7E568BE67801F803C6F71"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e5981-wk-Fact-B6F40B75323EE6EF4FC4801F7DF547A2"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e6195-wk-Fact-9A4592A1FACA84D5869A801F8024E489"
      unitRef="usd">12000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e6215-wk-Fact-14FD69433DA24328385A801F7DF3375A"
      unitRef="usd">12000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e6277-wk-Fact-24A404127FF2306D6A2E801F7FC76C30"
      unitRef="shares">57000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e6292-wk-Fact-EE6CC8909F1494988B7A801F7DF1C8F7"
      unitRef="usd">3000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e6311-wk-Fact-CC0C0ECD3677090B8283801F80884BB4"
      unitRef="usd">1977000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e6330-wk-Fact-B657D1ACB72B0C617B94801F7ECE5765"
      unitRef="shares">-12000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e6346-wk-Fact-95C3D7179E1C7455799D801F7EC9AC19"
      unitRef="usd">13000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e6406-wk-Fact-BC35357C49C864E19515801F7EFFF359"
      unitRef="usd">1993000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e6445-wk-Fact-46A676894226F74F6BFC801F7EFC1911"
      unitRef="usd">1993000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e6561-wk-Fact-30D9418081FBA848CBA2801F7ECCAB71"
      unitRef="shares">307000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e6577-wk-Fact-3699E726612D593C213A801F7E0FB736"
      unitRef="usd">12198000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e6638-wk-Fact-C12C1FBA8458EC3FD4D1801F7E041A29"
      unitRef="usd">12198000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e6678-wk-Fact-3AD0784E9548664647E8801F7EFA79D4"
      unitRef="usd">12198000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d34458032e6705-wk-Fact-7D359D4DCFEB1E002351801F7DEFB4FE"
      unitRef="shares">46</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d34458032e6720-wk-Fact-89DB22A158608FA629D2801F8240115D"
      unitRef="usd">2000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e6774-wk-Fact-CAB1BA2F9C800F5BD664801F825C70B5"
      unitRef="usd">3000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e6809-wk-Fact-BB8EECA4B442C1A654CD801F7DF0331C"
      unitRef="usd">0</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e6869-wk-Fact-62C88B2989C62E56687F801F7DE4D234"
      unitRef="usd">4000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e6909-wk-Fact-6F45B7B7D9041F4DACD1801F7DC65341"
      unitRef="usd">4000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e7059-wk-Fact-13FB97E7671458A9E0F4801F7EBCE117"
      unitRef="usd">-1172000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e7097-wk-Fact-694C315E46A521BE92D5801F7DD0578A"
      unitRef="usd">-1172000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458032e7135-wk-Fact-5F2D4ADDF8FF1844A040801F7E00C1DC"
      unitRef="usd">-1172000000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d34458032e7161-wk-Fact-72F12325846A255A2934801F823A73B8"
      unitRef="shares">478</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d34458032e7175-wk-Fact-1CA134AD576458FCA79E9C753A5EF8FD"
      unitRef="usd">19000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e7194-wk-Fact-C0D2C058A53A516D89F67516151CA125"
      unitRef="shares">9332000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e7209-wk-Fact-07FAC1C1243E5138A0C37BBBC348368F"
      unitRef="usd">467000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e7228-wk-Fact-075B080714B45D30944D97942F14A858"
      unitRef="usd">86253000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e7247-wk-Fact-D7F3F8AF036E5D0FB8EF97E397FAB8AF"
      unitRef="shares">3615000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e7263-wk-Fact-CCCD894D3B3A5080B54BA18BB185ECA4"
      unitRef="usd">-101610000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e7283-wk-Fact-5000F0EEE05D5658998A06FB2C356390"
      unitRef="usd">89554000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34458032e7302-wk-Fact-479F4E8A21C856B284E67E3F6C120C46"
      unitRef="usd">-11275000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e7323-wk-Fact-FD92DBC7FD8183249D6D801F80213CFC"
      unitRef="usd">63407000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e7342-wk-Fact-C3D92DAFDA945B9CB8FF4887D799EB18"
      unitRef="usd">351000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34458032e7361-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
      unitRef="usd">63758000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e7514-wk-Fact-C787510F91375F8DA60A77279DBC12D7"
      unitRef="usd">16273000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e7554-wk-Fact-6B459265E6775C47B37741B8BA18E170"
      unitRef="usd">16273000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e7573-wk-Fact-CA6EF8716A5E5BD1809B42697B1223C5"
      unitRef="usd">29000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
      unitRef="usd">16302000000</us-gaap:ProfitLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34458032e7765-wk-Fact-B5FF4C264E8259AB8C76122637225C36"
      unitRef="usd">-365000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e7786-wk-Fact-91841B5580A65F1AB688FCF8F5511CF9"
      unitRef="usd">-365000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e7806-wk-Fact-28116B03F1F1501FA19804A781E93B54"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e7826-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
      unitRef="usd">-376000000</us-gaap:OtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e8215-wk-Fact-B8848B5AC5765E01A8796908F66409AA"
      unitRef="usd">8174000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e8256-wk-Fact-89FA221AF605553CA7321BB43DD73142"
      unitRef="usd">8174000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsCommonStockCash
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e8296-wk-Fact-0D6DA45C2A7C59239CB62D356266BA2F"
      unitRef="usd">8174000000</us-gaap:DividendsCommonStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e8450-wk-Fact-1618790FEEDB5D8FA14CCFA4F0B219DF"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e8491-wk-Fact-E04CC84099F25E25851523F603002A2A"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:DividendsPreferredStockCash
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e8531-wk-Fact-3A992D3D837957AFBC4539641549FE54"
      unitRef="usd">1000000</us-gaap:DividendsPreferredStockCash>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e8745-wk-Fact-FFA1CCE628C152E085CCD1B102488E00"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e8765-wk-Fact-B337B62ABBFB5C5696C49995587C6B7B"
      unitRef="usd">6000000</us-gaap:MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e8827-wk-Fact-5AE29E30628550D4AAC86546A2DDB7C3"
      unitRef="shares">37000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e8842-wk-Fact-9B1DCEF966A955A2B00217967C88ACDA"
      unitRef="usd">2000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e8861-wk-Fact-DD18335422DB5858902DCD3895050F71"
      unitRef="usd">1219000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e8880-wk-Fact-9EED0554CF1857D8B1887EDCD838B377"
      unitRef="shares">-8000000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e8896-wk-Fact-C5A4FB3948D259AA97E130C3BE069EA0"
      unitRef="usd">-326000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e8957-wk-Fact-7DFD68914530594697567F87F6C1044E"
      unitRef="usd">894000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e8996-wk-Fact-5971AF67CC945F6EA0252DF12812F82F"
      unitRef="usd">894000000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e9114-wk-Fact-F3755FEC2162588F811E0BE706D54E9C"
      unitRef="shares">213000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e9130-wk-Fact-798874FBBD7A57AD8D423B83A189AC62"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e9191-wk-Fact-AB82307C2179145E356A801F824B4798"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e9231-wk-Fact-31D3680708335B049E798A2ECB5508B4"
      unitRef="usd">8865000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d34458032e9258-wk-Fact-B0C3BCD9194159029B0449658B7BCFBA"
      unitRef="shares">47</pfe:StockIssuedAndRedeemedDuringPeriodSharesConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d34458032e9273-wk-Fact-9672E748D5A35A1AB1475BEE8450A06D"
      unitRef="usd">2000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e9329-wk-Fact-1975D34B81EE58A99F75AD822E7EA8D7"
      unitRef="usd">3000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e9424-wk-Fact-F7BF280E6470537B8D74D0E1C2349E3E"
      unitRef="usd">4000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e9464-wk-Fact-871389EB45915ACC83623B1FF4BA7915"
      unitRef="usd">4000000</pfe:StockIssuedAndRedeemedDuringPeriodValueConversionAndRedemptionofStock>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e9562-wk-Fact-455D7F50A78999F57E0BE7AEB28EE379"
      unitRef="usd">40000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e9617-wk-Fact-D5FAE833F4155DD697072C1983D12DD3"
      unitRef="usd">-19000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e9657-wk-Fact-364B4EF7858D52F1B60FF23BA7D7CA9F"
      unitRef="usd">21000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e9677-wk-Fact-8B4254960B2E50548FD24AC21D991E6A"
      unitRef="usd">60000000</us-gaap:StockholdersEquityOther>
    <us-gaap:StockholdersEquityOther
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458032e9697-wk-Fact-40E0EB9593AE56E6ABE3328268CD2D11"
      unitRef="usd">81000000</us-gaap:StockholdersEquityOther>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="0"
      id="d34458032e9724-wk-Fact-4DE63B25DF8F54C98BE8801F7DD138D7"
      unitRef="shares">431</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_PreferredStockMember"
      decimals="-6"
      id="d34458032e9743-wk-Fact-C3DE40879A16565EBD6E29F02FEBF113"
      unitRef="usd">17000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e9757-wk-Fact-8D841CA3F88A9E41A873801F823E6F2C"
      unitRef="shares">9369000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34458032e9777-wk-Fact-4638B594C90A5D0FB3648867A34E71BB"
      unitRef="usd">468000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember"
      decimals="-6"
      id="d34458032e9796-wk-Fact-6B8B35F0C5A25612B8D5FB3898261F5D"
      unitRef="usd">87428000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharesIssued
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e9810-wk-Fact-CA576382E824210D03C9801F7EFD8AAC"
      unitRef="shares">3835000000</us-gaap:SharesIssued>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_TreasuryStockMember"
      decimals="-6"
      id="d34458032e9831-wk-Fact-0396A14A962557AD9B92CF1A5FBBC4F5"
      unitRef="usd">-110801000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember"
      decimals="-6"
      id="d34458032e9851-wk-Fact-35D3A5D66469542E865E5AA0C2D06B43"
      unitRef="usd">97670000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34458032e9870-wk-Fact-14994130FABC5D73BECDDC06FF0B8749"
      unitRef="usd">-11640000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_ParentMember"
      decimals="-6"
      id="d34458032e9891-wk-Fact-DF536431A96ABD94CF42801F825CE145"
      unitRef="usd">63143000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_NoncontrollingInterestMember"
      decimals="-6"
      id="d34458032e9910-wk-Fact-80FEC9DEE7D7156F2215801F8243459B"
      unitRef="usd">303000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34458032e9930-wk-Fact-48600923F2B454478E9D06C9836F179C"
      unitRef="usd">63447000000</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d34458032e9953-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639"
      unitRef="shares">15200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_OncologyVaccinesStartUpMember"
      decimals="2"
      id="d34458032e10027-wk-Fact-8948518703BA8CF15EC216EE4CBB53B8"
      unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProfitLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
      unitRef="usd">16302000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F"
      unitRef="usd">11188000000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
      unitRef="usd">21355000000</us-gaap:ProfitLoss>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e1718-wk-Fact-F7E8D2F6BA545C88B2145BBF4BB71213"
      unitRef="usd">6010000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e1737-wk-Fact-1879B130A48A521A91B25AA7A433481D"
      unitRef="usd">6384000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e1756-wk-Fact-E70CA54923CC1FAD4F80801F7E7CC351"
      unitRef="usd">6269000000</pfe:DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e1782-wk-Fact-8812B04713F051B0AF0A1F76A2EBAA85"
      unitRef="usd">2953000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e1801-wk-Fact-59B0AF76AAAA5B66B8EF1D2F0CE5B1EC"
      unitRef="usd">3398000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <pfe:AssetWriteOffsAndAssetImpairmentCharges
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e1820-wk-Fact-3608CBE3F82FCEC11A98801F7EB42466"
      unitRef="usd">634000000</pfe:AssetWriteOffsAndAssetImpairmentCharges>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
      unitRef="usd">-323000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0"
      unitRef="usd">-596000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
      unitRef="usd">-10660000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e1917-wk-Fact-EB399C3D7F4B5217B1ECA17E1450C7CB"
      unitRef="usd">8233000000</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e1937-wk-Fact-9D26812D16985C8A83C043FBACDEB01A"
      unitRef="usd">0</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e1956-wk-Fact-19AEA7C81E205D2B0C4DCB55FB59380E"
      unitRef="usd">0</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e1984-wk-Fact-6DBE94D819C45C32A44ABAD8E234B1BA"
      unitRef="usd">614000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2003-wk-Fact-393C1336661B5502A717C267B3C8D41C"
      unitRef="usd">-2205000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2023-wk-Fact-7E730D2AED1D0795DF3D801F82A5E242"
      unitRef="usd">-2410000000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2051-wk-Fact-49C7F7BFD94F58259E8F91521C863A5D"
      unitRef="usd">718000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2070-wk-Fact-416C8D02D1AC53CF8E7B9B0BE22D3ECD"
      unitRef="usd">949000000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2089-wk-Fact-EC38E965C828B3438D45801F82AD8435"
      unitRef="usd">840000000</us-gaap:ShareBasedCompensation>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2115-wk-Fact-142A53BD92AA56EB8F30C720D04947B1"
      unitRef="usd">336000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2135-wk-Fact-13109FFF8177575B8F1774DB9B952255"
      unitRef="usd">1095000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2155-wk-Fact-17A18791930ECAD2DCEB801F82A24FA8"
      unitRef="usd">961000000</pfe:PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2182-wk-Fact-599EFC3C5A9B585D8082B26EDB29D9AA"
      unitRef="usd">1086000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2202-wk-Fact-D7F3CECA708D58BE9F756B50300BDB3F"
      unitRef="usd">1269000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:OtherNoncashIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2222-wk-Fact-B1E7467675494F8418B3801F82B05100"
      unitRef="usd">-399000000</us-gaap:OtherNoncashIncomeExpense>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2315-wk-Fact-E8B4FB59DE0025523471801F82937FF6"
      unitRef="usd">742000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2335-wk-Fact-2AA90167164D2E1A59FA801F7E8DBF9F"
      unitRef="usd">644000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2355-wk-Fact-78EA4E1EB168C708F8A0801F7E99078A"
      unitRef="usd">-259000000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2381-wk-Fact-5978204D04A9412FC943801F82AB9CA2"
      unitRef="usd">1050000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2401-wk-Fact-3428A9878F8D11970A11801F7E90E64E"
      unitRef="usd">717000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2421-wk-Fact-F8A9B839E0BCBA875A7D801F82AD2263"
      unitRef="usd">357000000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2448-wk-Fact-1A17F756201A26636A56801F825B0538"
      unitRef="usd">-795000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2467-wk-Fact-74710073FCDBB8BA38A9AB460A554FBE"
      unitRef="usd">16000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInOtherOperatingAssets
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2487-wk-Fact-8641DEB0F388E97194C5801F8260F41E"
      unitRef="usd">-7000000</us-gaap:IncreaseDecreaseInOtherOperatingAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2513-wk-Fact-28FF4AB5B22B53EA235C801F82B2C028"
      unitRef="usd">-564000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2533-wk-Fact-879A192382A7330D4759801F7E97C8E7"
      unitRef="usd">431000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInAccountsPayableTrade
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2552-wk-Fact-F8064D62E55D3D14B6F5801F82AA72CC"
      unitRef="usd">46000000</us-gaap:IncreaseDecreaseInAccountsPayableTrade>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2578-wk-Fact-70AE538A79495076EEEF801F82A94AED"
      unitRef="usd">267000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2597-wk-Fact-05A1EA23D34141CA08B0801F825F2A0B"
      unitRef="usd">98000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOtherOperatingLiabilities
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2616-wk-Fact-1D9D8C11D13199ACE522801F82C58824"
      unitRef="usd">-67000000</us-gaap:IncreaseDecreaseInOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2643-wk-Fact-3A431FAAB1251C8B2F11801F7EAD8859"
      unitRef="usd">-2737000000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2663-wk-Fact-13DF08A1DA2702456A68801F7E99FA8D"
      unitRef="usd">-78000000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:IncreaseDecreaseInAccruedTaxesPayable
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2683-wk-Fact-A7D8A59FD536FC537EA7801F82CDAF6E"
      unitRef="usd">1446000000</us-gaap:IncreaseDecreaseInAccruedTaxesPayable>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2709-wk-Fact-3FAC1D7D150D5D3693952644AB014570"
      unitRef="usd">12588000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2728-wk-Fact-44E9A00560B253F9B13272B4DADC5EE7"
      unitRef="usd">15827000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2747-wk-Fact-1878ED88AD3662670B3D801F82BFC1A3"
      unitRef="usd">16802000000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2906-wk-Fact-276AE48F003C5B94964313479CA47CC4"
      unitRef="usd">2176000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2926-wk-Fact-68A35B6201B05F6791E934C35C4FF3BB"
      unitRef="usd">2042000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e2946-wk-Fact-BC27D7DE57C7FCDFEA06801F82A12BD1"
      unitRef="usd">1956000000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e2973-wk-Fact-BA711E164C3C5AA1A6F841BD16FF39C7"
      unitRef="usd">6835000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e2993-wk-Fact-F7A1A47C403158F4A0050A07FD1FD932"
      unitRef="usd">11677000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:PaymentsToAcquireShortTermInvestments
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3013-wk-Fact-8413E641C55A4976D254801F7EBA5C58"
      unitRef="usd">14596000000</us-gaap:PaymentsToAcquireShortTermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3040-wk-Fact-BD795F9219995817AC05CE7BBCBF719E"
      unitRef="usd">9183000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3059-wk-Fact-DC14423F4FD126343D5EAB460A5E402A"
      unitRef="usd">17581000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3078-wk-Fact-D6D3D533E39ABD216739AB460AAB7F32"
      unitRef="usd">10302000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3104-wk-Fact-E83DC31A66C95716944B69D6571C0712"
      unitRef="usd">-6925000000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3123-wk-Fact-4E6373F9AE145393977B4D50CD0C3C97"
      unitRef="usd">3917000000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsForProceedsFromShortTermInvestments
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3143-wk-Fact-0B0BC391D4C7298B505D801F82CD3D11"
      unitRef="usd">-2058000000</us-gaap:PaymentsForProceedsFromShortTermInvestments>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3169-wk-Fact-43647EACB2365019AF739809E6A7AA33"
      unitRef="usd">201000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3189-wk-Fact-07104F174ED656CF8AABB4441FC28486"
      unitRef="usd">1797000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3209-wk-Fact-ED884752BC3FCC09AA86801F82ADF8F8"
      unitRef="usd">3537000000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3236-wk-Fact-48F3227EB91F519693B62AAB048CF3C2"
      unitRef="usd">232000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3255-wk-Fact-3A0EED0F100854319344F954D1578C77"
      unitRef="usd">6244000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3274-wk-Fact-82DF9C203377249F2601AB460A6EF1A6"
      unitRef="usd">3579000000</us-gaap:ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3300-wk-Fact-AE4BE372D7E0566CA33FCE7A63C55830"
      unitRef="usd">10861000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3320-wk-Fact-A866155102FA518DAD8A3AC3849A29ED"
      unitRef="usd">0</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3339-wk-Fact-E926E550228AFBDF79A3801F7EAA2096"
      unitRef="usd">1000000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3366-wk-Fact-10B388DAE9985C6E9C8A0D8BD38AD150"
      unitRef="usd">418000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3386-wk-Fact-C6871A6C06945BFABCFCA1C5346E9560"
      unitRef="usd">154000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3406-wk-Fact-E8C1F0E054CC0BFAC98F801F7EA87952"
      unitRef="usd">261000000</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003"
      unitRef="usd">-205000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4"
      unitRef="usd">-288000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:PaymentsForProceedsFromOtherInvestingActivities
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E"
      unitRef="usd">-671000000</us-gaap:PaymentsForProceedsFromOtherInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3500-wk-Fact-987B313113ED573B8A810513702726B3"
      unitRef="usd">-3945000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3520-wk-Fact-A08B5E2989AB58B0A8139571535F4EFB"
      unitRef="usd">4525000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3539-wk-Fact-BC04211B3B4E671AA2DC801F82A46721"
      unitRef="usd">-4740000000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3698-wk-Fact-8322EE49CD6D5BD6A6C9E81023F930D3"
      unitRef="usd">16455000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3717-wk-Fact-855EC1B85F5A5E84B3ACFB91DAA41FBE"
      unitRef="usd">3711000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:ProceedsFromShortTermDebt
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3736-wk-Fact-DF223CDEB60EF38BA68C801F829307E6"
      unitRef="usd">8464000000</us-gaap:ProceedsFromShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3762-wk-Fact-51E697B313F65177AA951CD8E64EC1C9"
      unitRef="usd">8378000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3782-wk-Fact-80E620F0079F9C476673AB460A2BDC83"
      unitRef="usd">4437000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:RepaymentsOfShortTermDebt
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3802-wk-Fact-5D06811EF4C34003FE7FAB460A240C38"
      unitRef="usd">9947000000</us-gaap:RepaymentsOfShortTermDebt>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3829-wk-Fact-A591E3AF789D5180A58CDB8F61EA51D0"
      unitRef="usd">2551000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3848-wk-Fact-BAD831174C94566A924C53EC67145618"
      unitRef="usd">-1617000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3868-wk-Fact-643BD36B0A7BD2A450F4801F8291FACD"
      unitRef="usd">1422000000</us-gaap:ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3894-wk-Fact-3706D36BE0715C4B909C295C63B57B4F"
      unitRef="usd">4942000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3913-wk-Fact-60E259DD84E55069AE8582467CCBEEF4"
      unitRef="usd">4974000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3932-wk-Fact-82F8E32880CAD288D376801F7EB6D6B3"
      unitRef="usd">5274000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e3958-wk-Fact-7A6C38FEB7545F758C160BD056416478"
      unitRef="usd">6806000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e3978-wk-Fact-89458B2935BE5CA5AF20EE141CB4DDAE"
      unitRef="usd">3566000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e3998-wk-Fact-536D379D583EEC0E6BB0801F7E8674D3"
      unitRef="usd">6154000000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e4025-wk-Fact-606A9D26C4D35A40A035883CAA24CCE7"
      unitRef="usd">8865000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e4045-wk-Fact-09761C58BD65590B9D0A94898AC11853"
      unitRef="usd">12198000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e4065-wk-Fact-333989DFC77B15A1F172801F7E787CBF"
      unitRef="usd">5000000000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e4092-wk-Fact-BD8A72C249F655DE8F2BC9B4F95D1DCA"
      unitRef="usd">8043000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e4111-wk-Fact-D017797EF627548D8B995B4200D51DEC"
      unitRef="usd">7978000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:PaymentsOfOrdinaryDividends
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e4130-wk-Fact-638270EA30AE2FE9D14C801F7E7BF6D8"
      unitRef="usd">7659000000</us-gaap:PaymentsOfOrdinaryDividends>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e4157-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0"
      unitRef="usd">394000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e4176-wk-Fact-CF6EA013BF1855E39D139D5A4C827484"
      unitRef="usd">1259000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e4195-wk-Fact-43172D93073829A17FB6801F82AF4ECB"
      unitRef="usd">862000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e4222-wk-Fact-C99D0BA3F6095B8AB635F01DBE0D4EF8"
      unitRef="usd">-736000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e4242-wk-Fact-C8B9E3934BFD630207B2AB460A1A7731"
      unitRef="usd">-588000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:ProceedsFromPaymentsForOtherFinancingActivities
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e4262-wk-Fact-6556B2C27E285E515E05801F82C1264D"
      unitRef="usd">-611000000</us-gaap:ProceedsFromPaymentsForOtherFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e4289-wk-Fact-105EFED9824651F6ABA05E9CA04F453B"
      unitRef="usd">-8485000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e4309-wk-Fact-9967D5B336225ACF8C7C4F042D7A1102"
      unitRef="usd">-20441000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e4329-wk-Fact-1374505693265BF17B2B801F82AB7A82"
      unitRef="usd">-13350000000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e4356-wk-Fact-0CDEC0D247EB505292D3E60E677BC871"
      unitRef="usd">-32000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e4376-wk-Fact-197F4485B7325617ACD30B3E17928D84"
      unitRef="usd">-116000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e4396-wk-Fact-6675DE4C808280B705BC801F825EB10F"
      unitRef="usd">53000000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e4422-wk-Fact-E9440844908157FB84B59804D5572F92"
      unitRef="usd">125000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e4441-wk-Fact-E71BAB60F8F54CE72E1EAB460A620A61"
      unitRef="usd">-205000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e4461-wk-Fact-721F3FC462E1384F6A25801F7EB6DE98"
      unitRef="usd">-1235000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34458036e4488-wk-Fact-DBDD38161F5354477BEEAB460A4A0822"
      unitRef="usd">1225000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-6"
      id="d34458036e4507-wk-Fact-753BABE650466031F517AB460A3BD22C"
      unitRef="usd">1431000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2016Q4"
      decimals="-6"
      id="d34458036e4526-wk-Fact-8A5BA32EB90D3260C033801F82C4798C"
      unitRef="usd">2666000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34458036e4557-wk-Fact-F9953003974753B0A6C247B19A717620"
      unitRef="usd">1350000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34458036e4576-wk-Fact-DBDD38161F5354477BEEAB460A4A0822"
      unitRef="usd">1225000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="FI2017Q4"
      decimals="-6"
      id="d34458036e4596-wk-Fact-753BABE650466031F517AB460A3BD22C"
      unitRef="usd">1431000000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34458036e5115-wk-Fact-D632D615CB115AE398552F0296C267F2"
      unitRef="usd">15711000000</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34458036e5134-wk-Fact-C6E28D0783BF5F14B7C1F693DE2205FC"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34458036e5154-wk-Fact-CF81983A611C3D14907CCB572FBC8D5D"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember"
      decimals="-6"
      id="d34458036e5176-wk-Fact-276A8A35EE68509F999B815A3BCBFE8E"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember"
      decimals="-6"
      id="d34458036e5195-wk-Fact-14ADBD55BE745ADEBD77EA9D5312ED22"
      unitRef="usd">343000000</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelTherapeuticsMember"
      decimals="-6"
      id="d34458036e5214-wk-Fact-40C3E909042539E5B10F801F7E98C05E"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d34458036e5242-wk-Fact-F99E6C3DC2CC5F62AF63CD1ED043A574"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d34458036e5261-wk-Fact-B7FAC3FC55D55C4A8390CDA9B27086EE"
      unitRef="usd">92000000</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d34458036e5280-wk-Fact-5763263A0462B65542D3801F82B1A33F"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e5308-wk-Fact-46C48E9C21AF899B9CBE801F824C920A"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e5327-wk-Fact-1EA1B7699985D7A7899C801F7E93B603"
      unitRef="usd">0</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <us-gaap:DebtConversionConvertedInstrumentAmount1
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e5346-wk-Fact-EF43F96DEFFEE9BA1C18801F82C1C357"
      unitRef="usd">1848000000</us-gaap:DebtConversionConvertedInstrumentAmount1>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e5374-wk-Fact-539977E9F571B801F8F2801F82CC3FC2"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e5393-wk-Fact-9C12B5D1FDF6DC56A5B8801F7E7A2727"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e5412-wk-Fact-9281B6AE49D7C2B2BA97801F825215AE"
      unitRef="usd">428000000</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e5440-wk-Fact-AF2E68BBA8025433B3103D89BFF2ABC1"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e5459-wk-Fact-6CFCA119539F5C0D846D537B1FB079D6"
      unitRef="usd">0</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable>
    <pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e5478-wk-Fact-F803761CFD33D77A1C43801F82624A72"
      unitRef="usd">75000000</pfe:NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e5575-wk-Fact-34AD8E413C695FBD8469975721FFB0F6"
      unitRef="usd">3664000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e5594-wk-Fact-64DE649A1DC85272824F592AAE2FEBD3"
      unitRef="usd">3655000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e5614-wk-Fact-B655A10CD6EE090891E7801F82B1C3E5"
      unitRef="usd">2489000000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e5634-wk-Fact-0688D8F87F0B5FFEBC9B4EB51F7A9A52"
      unitRef="usd">1587000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e5653-wk-Fact-6C6813303FAB516E9EF5ED555B6EFC07"
      unitRef="usd">1311000000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e5672-wk-Fact-9A5FE66D958474E62B0B801F7E97F314"
      unitRef="usd">1518000000</us-gaap:InterestPaidNet>
    <pfe:InterestPaidInterestRateHedges
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e5698-wk-Fact-570F688A036C517B8DC6519B9EEC35DC"
      unitRef="usd">-42000000</pfe:InterestPaidInterestRateHedges>
    <pfe:InterestPaidInterestRateHedges
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e5718-wk-Fact-13A50261D17557B8A175FB539D8C549E"
      unitRef="usd">-38000000</pfe:InterestPaidInterestRateHedges>
    <pfe:InterestPaidInterestRateHedges
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34458036e5738-wk-Fact-0951D465F2EAA589DB57801F7EA951E3"
      unitRef="usd">-199000000</pfe:InterestPaidInterestRateHedges>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34458036e5773-wk-Fact-4AB2319F04C6B9C93D3ACB57A40C195C"
      unitRef="usd">-10700000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <pfe:TaxCutsAndJobsActIncomeTaxBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34458036e5777-wk-Fact-07D7749619A14DC9F0CF801F7F3C1F9A"
      unitRef="usd">600000000</pfe:TaxCutsAndJobsActIncomeTaxBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
      unitRef="usd">-323000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <pfe:DeconsolidationGainLossAmountNetOfCashConveyed
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34458036e5803-wk-Fact-A057140022E852CCB9A6C67AE43A9EB2"
      unitRef="usd">8200000000</pfe:DeconsolidationGainLossAmountNetOfCashConveyed>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d34458036e5811-wk-Fact-57A1AFBB73FE59E08A57E18D20754A66"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34458036e5815-wk-Fact-864ED6D8892F5C49A719105F87AE47B5"
      unitRef="usd">15700000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <pfe:DeconsolidationNetAssetsContributed
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34458036e5819-wk-Fact-F5CA5E5BAD9355008E552A9D050A0743"
      unitRef="usd">7600000000</pfe:DeconsolidationNetAssetsContributed>
    <pfe:DeconsolidationGainLossAmountCashConveyed
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34458036e5824-wk-Fact-40C813D724515B76A8F32C0048A56ABC"
      unitRef="usd">146000000</pfe:DeconsolidationGainLossAmountCashConveyed>
    <pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount
      contextRef="FD2018Q4YTD"
      decimals="-8"
      id="d34458036e5853-wk-Fact-44A0BFD4912753E3ABE6A533D3956A57"
      unitRef="usd">2700000000</pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount>
    <pfe:GainLossOnExchangeOfDebt
      contextRef="FD2017Q4YTD_us-gaap_DebtInstrumentAxis_pfe_U.K.PoundDenominatedDebtMember"
      decimals="-6"
      id="d34458036e5891-wk-Fact-191A3FC341F9978F83CF801F81E890B0"
      unitRef="usd">-747000000</pfe:GainLossOnExchangeOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member"
      decimals="-6"
      id="d34458036e5895-wk-Fact-046237D900496E5BF3D0801F81E93368"
      unitRef="usd">-846000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8F1609EDD8E991CF1022801F82FF407A-0-wk-Fact-279D5DA1C29A0403BF5C801F7FEB22AD">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Basis of Presentation and Significant Accounting Policies&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt; Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;See the Glossary of Defined Terms at the beginning of this &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; Financial Report for terms used throughout the consolidated financial statements and related notes in this &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. Beginning on January 1, 2018, only taxes paid on intercompany inventory sales transactions are deferred until recognized upon the sale of the inventory to a third party, reflecting the adoption of a new accounting standard in the first quarter of 2018. Prior to the adoption of this new accounting standard in the first quarter of 2018, taxes paid on intercompany sales transactions were deferred until recognized upon sale of the asset to a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;From the second quarter of our 2016 fiscal year until the end of 2018, we managed our commercial operations through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our 2019 fiscal year, we began to manage our commercial operations through a new global structure consisting of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; business segments&#x2013;&#x2013;Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, Consumer Healthcare. Biopharma and Upjohn are the only reportable segments. We have revised prior-period segment information to reflect the reorganization. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 17&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In addition, certain amounts within &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the December 31, 2018 consolidated balance sheet have been reclassified to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Equity-method investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to conform to the current presentation. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 2C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain amounts in the consolidated financial statements and associated notes may not add due to rounding. All percentages have been calculated using unrounded amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the first quarter of 2019, as of January 1, 2019, we adopted &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; new accounting standards. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for further information.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our recent significant business development activities include:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;License Agreement with Akcea Therapeutics, Inc.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In October 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. The transaction closed in November 2019 and we made an upfront payment of&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;to Akcea and Ionis, which was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in our fiscal fourth quarter of 2019. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Formation of a New Consumer Healthcare Joint Venture&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In accordance with our domestic and international reporting periods, our financial results, and our Consumer Healthcare segment&#x2019;s operating results, for 2019 reflect seven months of Consumer Healthcare segment domestic operations and eight months of Consumer Healthcare segment international operations. Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Acquisition of Array BioPharma Inc.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we acquired Array for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$48&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share in cash. The total fair value of the consideration transferred for Array was approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$11.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$10.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, net of cash acquired). &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our financial statements for 2019 reflect the assets, liabilities, operating results and cash flows of Array, commencing from the acquisition date&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Agreement to Combine Upjohn with Mylan N.V.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company, Viatris. Under the terms of the agreement, which is structured as an all-stock, Reverse Morris Trust transaction, Upjohn is expected to be spun off or split off to Pfizer&#x2019;s shareholders and, immediately thereafter, combined with Mylan.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; Pfizer shareholders would own &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;57%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the combined new company, and former Mylan shareholders would own &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;43%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.  Closing of the transaction is subject to Mylan shareholder approval and satisfaction of other customary closing conditions, including receipt of regulatory approvals.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Acquisition of Therachon Holding AG&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;On July 1, 2019, we acquired all the remaining shares of Therachon for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$340 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upfront, plus potential milestone payments of up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$470 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;contingent on the achievement of key milestones in the development and commercialization of the lead asset. The total fair value of the consideration transferred for Therachon was approximately&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$322 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our financial statements for 2019 reflect the assets, liabilities, operating results and cash flows of Therachon, commencing from the acquisition date and, in accordance with our international reporting period, reflect five months of Therachon operations and cash flows.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, to ICU Medical for up to approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$900 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, composed of cash and contingent cash consideration, ICU Medical common stock (all of which we sold during 2018) and seller financing. HIS includes IV pumps, solutions and devices. The operating results of HIS are included in our consolidated statement of income through February 2, 2017 and, therefore, our financial results for 2017 reflect one month of HIS domestic operations and two months of HIS international operations. Our financial results for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; do not reflect any contribution from HIS global operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;text-indent:-12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Acquisition of AstraZeneca&#x2019;s Small Molecule Anti-Infectives Business&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca&#x2019;s small molecule anti-infectives business, primarily outside the U.S. for approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, composed of cash and contingent consideration. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our financial statements reflect the assets, liabilities, operating results and cash flows of this business, commencing from the acquisition date and, in accordance with our international reporting period, for 2017 reflect approximately 11 months of the small molecule anti-infectives business operations and cash flows acquired from AstraZeneca.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 2&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Adoption of New Accounting Standards in 2019&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On January 1, 2019, we adopted &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; new accounting standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and current and noncurrent operating lease liabilities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; by &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; on a pre-tax basis (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Adopting the standard related to leases impacted our prior period consolidated balance sheet as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As Previously Reported Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect of Change&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Higher/(Lower)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,461&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,924&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;89,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;89,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Adoption of the standard related to leases did not have a material impact on our consolidated statements of income or consolidated statements of cash flows in&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt; 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1T&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Amortization Period for Certain Callable Debt Securities Held at a Premium&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Accounting for Share-Based Payments to Nonemployees&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. Estimates and Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&amp;amp;D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For information on estimates and assumptions in connection with the TCJA, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; Tax Matters: Taxes on Income from Continuing Operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;D. Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;amp;D is expensed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 16D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;E. Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income approach, which is based on the present value of a future stream of net cash flows. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;F. Foreign Currency Translation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and we translate non-monetary items at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;G&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Revenues and Trade Accounts Receivable&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We recorded direct product sales and/or alliance revenues of more than &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for each of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;eight&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; products in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, for each of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ten&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; products in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and for each of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; products in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In the aggregate, these direct products sales and/or alliance product revenues represent &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of our revenues in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;51%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of our revenues in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;46%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;of our revenues in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 17C &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business, which was combined with GSK&#x2019;s Consumer Healthcare business into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name on July 31, 2019, included OTC brands with a focus on dietary supplements, pain management, gastrointestinal and respiratory and personal care. We sell biopharmaceutical products after patent expiration, and under patent, and, to a much lesser extent, through July 31, 2019, we sold consumer healthcare products worldwide to developed and emerging market countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We determine transfer of control based on when the product is shipped or delivered and title passes to the customer.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Customers&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Customers for our consumer healthcare business, which were part of the business that was combined with GSK&#x2019;s Consumer Healthcare business into a new consumer healthcare joint venture on July 31, 2019, included retailers and, to a lesser extent, wholesalers and distributors.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Our Sales Contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#ff0000;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of exclusivity, product recalls or a changing competitive environment. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Deductions from Revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Specifically:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managers and legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period&#x2019;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#x201c;coverage gap,&#x201d; also known as the &#x201c;doughnut hole,&#x201d; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#x2019;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts totaled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information about the balance sheet classification of these accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reserve against &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Accrued rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total accrued rebates and other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Trade Accounts Receivable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;H. Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenues,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable period. The related expenses for selling and marketing these products are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Royalty payments received from collaboration partners are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reimbursements to or from our collaboration partners for development costs are recorded net in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&#x2014;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; over the development period for the collaboration products, when our performance obligations include providing R&amp;amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;I. Cost of Sales and Inventories&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;J. Selling, Informational and Administrative Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense. Advertising expenses totaled approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$2.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$3.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$3.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Production costs are expensed as incurred and the costs of radio time, television time and space in publications are expensed when the related advertising occurs. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;K. Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;R&amp;amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;L. Amortization of Intangible Assets, Depreciation and Certain Long-Lived Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Long-lived assets include:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Property, plant and equipment, less accumulated depreciation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;These acquired assets are recorded at fair value. Intangible assets with finite lives&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Specifically:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For indefinite-lived intangible assets, such as Brands and IPR&amp;amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;M. Restructuring Charges and Certain Acquisition-Related Costs&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;N. Cash Equivalents and Statement of Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;padding-top:9px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;O. Investments and Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our investments are comprised of the following: public equity securities with readily determinable fair values, available-for-sale debt securities, held-to-maturity debt securities (when we have both the positive intent and ability to hold the investment to maturity), private equity securities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;without readily determinable fair values and equity-method investments. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Public equity securities with readily determinable fair values are carried at fair value, with changes in fair value reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Available-for-sale debt securities are carried at fair value, with changes in fair value reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;until realized.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Held-to-maturity debt securities are carried at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#x2019;s income and expenses in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Realized gains or losses on sales of investments are determined by using the specific identification cost method.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative financial instruments are carried at fair value in various balance sheet categories (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 7A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;), with changes in fair value reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Net income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; or, for derivative financial instruments in certain qualifying hedging relationships, in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 7F&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A single estimate of fair value and impairment reviews can involve a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;P. Tax Assets and Liabilities and Income Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current tax assets primarily includes (i) tax effects associated with intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party, as well as (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws, including the impact of the TCJA enacted in December 2017. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet. Amounts recorded for valuation allowances can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other non-current tax assets &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in our consolidated balance sheet as of December 31, 2019 includes liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability on the deemed repatriated accumulated post-1986 foreign earnings recorded in connection with the TCJA for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for uncertain tax positions and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for the repatriation tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Income Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#x201c;more likely than not&#x201d;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and local and foreign income tax filings, statute of limitations expirations, changes and clarification in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and are classified on our consolidated balance sheet with the related tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Q. Pension and Postretirement Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;R. Legal and Environmental Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;S. Share-Based Payments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;T. Leases&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On January&#160;1, 2019, we adopted a new accounting standard for leases. For further information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; years, some of which include options to terminate or extend leases for up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$328 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for the year ended &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For operating leases, the ROU assets and liabilities are presented in our consolidated balance sheet as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Lease liabilities (short-term)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Lease liabilities (long-term)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,048&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our total lease costs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other supplemental information includes the following:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average Remaining Contractual Lease Term (Years) as of&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average Discount Rate as of&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Gains)/losses on sale and leaseback transactions, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Operating Lease Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Next one year&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;1-2 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;3-4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;4-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,048&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects lease payments due within 12 months subsequent to the balance sheet date.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In April 2018, we entered an agreement to lease space in an office building in New York City. We expect to take control of the property in 2021 and relocate our global headquarters to this new office building in 2022. Our future minimum rental commitment under this &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year lease is approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prior to our adoption of the new lease standard, rental expense, net of sublease income, was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$301 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in 2018 and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$314 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;After 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Lease commitments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-AE5BFF9C0E5225E61570801F82FAB796-0-wk-Fact-737A33A41F26B0EF78C8801F811185F3">The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). </us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-DF28F64A56F53AD329E6801F82F9C5D2-0-wk-Fact-3756AF0F79AAE11D26C5801F809AC715">The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. </us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d34519344e1369-wk-Fact-D17055AF0AB4DC9AC143801F8131E959"
      unitRef="Operating_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d34519344e1373-wk-Fact-E001667F01F95E298014FB8B5A7B8850"
      unitRef="Operating_Segment">3</us-gaap:NumberOfOperatingSegments>
    <pfe:NumberOfAccountingStandardsAdopted
      contextRef="I2019Q1Jan01"
      decimals="INF"
      id="d34519344e1407-wk-Fact-EF0C3233F7CA5E6898CC271647FD9CD6"
      unitRef="Accounting_standard">4</pfe:NumberOfAccountingStandardsAdopted>
    <pfe:PaymentForLicensingArrangement
      contextRef="FD2019Q4QTD_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34519344e1433-wk-Fact-820E4481EA1BBFE4406DCDC046424C7F"
      unitRef="usd">250000000</pfe:PaymentForLicensingArrangement>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="INF"
      id="d34519344e1476-wk-Fact-87A73243BF595DD18C64026B1A594F00"
      unitRef="usdPerShare">48</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d34519344e1480-wk-Fact-661D03E21572543CB5AFEBAECACF8E2B"
      unitRef="usd">11200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d34519344e1484-wk-Fact-AA9C766FC51A56248B8278DB552969BB"
      unitRef="usd">10900000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="FI2020Q2_srt_OwnershipAxis_pfe_UpjohnAndMylanMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember"
      decimals="2"
      id="d34519344e1506-wk-Fact-77A45F205D1B51C0BEAB73201E304C18"
      unitRef="number">0.57</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners
      contextRef="FI2020Q2_dei_LegalEntityAxis_pfe_MylanMember_srt_OwnershipAxis_pfe_UpjohnAndMylanMember_srt_StatementScenarioAxis_srt_ScenarioForecastMember"
      decimals="2"
      id="d34519344e1510-wk-Fact-853CDBE591765273B550231BC64EAA86"
      unitRef="number">0.43</us-gaap:MinorityInterestOwnershipPercentageByNoncontrollingOwners>
    <pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment
      contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34519344e1523-wk-Fact-D4613DCD361C587C8CEC0BB4595ED1E7"
      unitRef="usd">340000000</pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment>
    <pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum
      contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34519344e1527-wk-Fact-F4590EEA4BAF5B65B61201FB5AB77321"
      unitRef="usd">470000000</pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum>
    <pfe:AssetAcquisitionConsiderationTransferred
      contextRef="D2019Q3Jan01-Jul02_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34519344e1535-wk-Fact-E471A84C0B3850C393C12C737086419C"
      unitRef="usd">322000000</pfe:AssetAcquisitionConsiderationTransferred>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34519344e1551-wk-Fact-1322BD020F41F6AA79BF801F7F42DBE6"
      unitRef="usd">900000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-8"
      id="d34519344e1572-wk-Fact-AE69E3A5F2E6833E0DD1801F7F120629"
      unitRef="usd">1000000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-26D19012E03173D569AB801F8302F7ED-0-wk-Fact-D4D50358F1EC83E9AF72801F7F300322">&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Adoption of New Accounting Standards in 2019&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On January 1, 2019, we adopted &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; new accounting standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Leases&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and current and noncurrent operating lease liabilities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; by &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; on a pre-tax basis (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Adopting the standard related to leases impacted our prior period consolidated balance sheet as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As Previously Reported Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect of Change&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Higher/(Lower)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,461&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,924&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;89,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;89,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Adoption of the standard related to leases did not have a material impact on our consolidated statements of income or consolidated statements of cash flows in&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt; 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1T&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Amortization Period for Certain Callable Debt Securities Held at a Premium&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Accounting for Share-Based Payments to Nonemployees&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <pfe:NumberOfAccountingStandardsAdopted
      contextRef="I2019Q1Jan01"
      decimals="INF"
      id="d34519344e1612-wk-Fact-EF0C3233F7CA5E6898CC271647FD9CD6"
      unitRef="Accounting_standard">4</pfe:NumberOfAccountingStandardsAdopted>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-8"
      id="d34519344e1621-wk-Fact-7D219E92EFD05A6EA6E0DA4E2FA5E1BA"
      unitRef="usd">1400000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-8"
      id="d34519344e1625-wk-Fact-4E411801636956FF8E2A3D3670608235"
      unitRef="usd">1400000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:CumulativeEffectOnRetainedEarningsBeforeTax1
      contextRef="D2019Q1Jan01-Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d34519344e1633-wk-Fact-8219CF42872D5F67860A4641102A46CD"
      unitRef="usd">30000000</us-gaap:CumulativeEffectOnRetainedEarningsBeforeTax1>
    <us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1
      contextRef="D2019Q1Jan01-Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d34519344e1637-wk-Fact-E63442DE4A725840B73A5D18F5D4D595"
      unitRef="usd">20000000</us-gaap:CumulativeEffectOnRetainedEarningsNetOfTax1>
    <us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EBAA92A02A869580AA71801F82F924CB-0-wk-Fact-B66E6EAE1AD3F4007BBA801F7F289AFE">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Adopting the standard related to leases impacted our prior period consolidated balance sheet as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As Previously Reported Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect of Change&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Higher/(Lower)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;January 1, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,461&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,460&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,924&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,910&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;89,554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;89,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:OtherAssetsCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e1823-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD"
      unitRef="usd">2461000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d34519344e1842-wk-Fact-B0F1DF2EE48E52F0A94EDC5C8D8C5EB2"
      unitRef="usd">-1000000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent
      contextRef="I2019Q1Jan01"
      decimals="-6"
      id="d34519344e1863-wk-Fact-D1DF428DA372513ABF9E3876EB4AB068"
      unitRef="usd">2460000000</us-gaap:OtherAssetsCurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e1883-wk-Fact-E658F74A5A8852C19F682FC523E87C64"
      unitRef="usd">1924000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d34519344e1902-wk-Fact-F4AD0B3FF2885637B1AD0ACDBAFDB9B0"
      unitRef="usd">-11000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent
      contextRef="I2019Q1Jan01"
      decimals="-6"
      id="d34519344e1922-wk-Fact-DEAB1874587E5D5BB8EFCBEF3E0BF9FC"
      unitRef="usd">1913000000</pfe:DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e1948-wk-Fact-4A424945B16E50C896282B201E79955C"
      unitRef="usd">2799000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d34519344e1967-wk-Fact-4E0465F4DDB65B9BB78223A77CFE6EE2"
      unitRef="usd">1351000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="I2019Q1Jan01"
      decimals="-6"
      id="d34519344e1986-wk-Fact-4EFDDF01BAAE55DF88C3947BA6EB0E02"
      unitRef="usd">4149000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e2012-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31"
      unitRef="usd">10753000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d34519344e2031-wk-Fact-5200EE176D305D8AA059957DCF18B445"
      unitRef="usd">258000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="I2019Q1Jan01"
      decimals="-6"
      id="d34519344e2050-wk-Fact-8377E7FB3B4B5E8F8147DEC7AF66B25D"
      unitRef="usd">11011000000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e2076-wk-Fact-6DF270940FC65894A5CA91BBF63EB321"
      unitRef="usd">5850000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d34519344e2095-wk-Fact-4D0778A972C45D2A9B5ACE0D983EDC3D"
      unitRef="usd">1060000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="I2019Q1Jan01"
      decimals="-6"
      id="d34519344e2114-wk-Fact-DB9E42CC42D95101905E3312C16BF1B0"
      unitRef="usd">6910000000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e2140-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F"
      unitRef="usd">89554000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2019Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201602Member"
      decimals="-6"
      id="d34519344e2159-wk-Fact-3EDA657D41A55B7D929ACD659463C508"
      unitRef="usd">20000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="I2019Q1Jan01"
      decimals="-6"
      id="d34519344e2178-wk-Fact-C08349F2EE27559983B1A81217A728C6"
      unitRef="usd">89574000000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:UseOfEstimates
      contextRef="FD2019Q4YTD"
      id="TextSelection-2CC1CBFF9C364F35586C801F82FF42BD-0-wk-Fact-ACFAD16F72DE559FC03C801F81050652">Estimates and Assumptions&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&amp;amp;D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:BusinessCombinationsPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-AEFF5DF203FBB50D92E9801F830237EB-0-wk-Fact-2F28DC64542A7F10C645801F7FC156F1">Acquisitions&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;amp;D is expensed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 16D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</us-gaap:BusinessCombinationsPolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-46B2DA26826D57DD1BED801F8300C51B-0-wk-Fact-00279C1CF2B0246859DD801F812713CE">Fair Value&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income approach, which is based on the present value of a future stream of net cash flows. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our fair value methodologies depend on the following types of inputs:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-118A7D836807EFE5E5FC801F82FC0212-0-wk-Fact-C36556CB1BF7E1E78909801F7F4BD286">Foreign Currency Translation&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and we translate non-monetary items at historical rates.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-31400FAA85C073F417AD801F8301991B-0-wk-Fact-DA61EB0AF0042B352FFB801F802AD447">&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Revenues and Trade Accounts Receivable&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We recorded direct product sales and/or alliance revenues of more than &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for each of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;eight&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; products in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, for each of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ten&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; products in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and for each of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; products in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In the aggregate, these direct products sales and/or alliance product revenues represent &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of our revenues in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;51%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of our revenues in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;46%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;of our revenues in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 17C &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business, which was combined with GSK&#x2019;s Consumer Healthcare business into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name on July 31, 2019, included OTC brands with a focus on dietary supplements, pain management, gastrointestinal and respiratory and personal care. We sell biopharmaceutical products after patent expiration, and under patent, and, to a much lesser extent, through July 31, 2019, we sold consumer healthcare products worldwide to developed and emerging market countries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenue Recognition&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We determine transfer of control based on when the product is shipped or delivered and title passes to the customer.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Customers&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Customers for our consumer healthcare business, which were part of the business that was combined with GSK&#x2019;s Consumer Healthcare business into a new consumer healthcare joint venture on July 31, 2019, included retailers and, to a lesser extent, wholesalers and distributors.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Our Sales Contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#ff0000;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of exclusivity, product recalls or a changing competitive environment. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Deductions from Revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Specifically:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managers and legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period&#x2019;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#x201c;coverage gap,&#x201d; also known as the &#x201c;doughnut hole,&#x201d; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#x2019;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;Collaborative Arrangements&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenues,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable period. The related expenses for selling and marketing these products are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Royalty payments received from collaboration partners are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reimbursements to or from our collaboration partners for development costs are recorded net in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&#x2014;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; over the development period for the collaboration products, when our performance obligations include providing R&amp;amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <pfe:ConcentrationRiskAmount
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TopEightProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="-9"
      id="d34519344e2461-wk-Fact-BBCDC3C9165F5704C6C1801F7F32A97B"
      unitRef="usd">1000000000</pfe:ConcentrationRiskAmount>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TopEightProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d34519344e2490-wk-Fact-F85FDF185EF539090E35801F7F3B68D3"
      unitRef="number">0.49</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TopTenProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d34519344e2498-wk-Fact-0B4BF375084A125303CA801F7FB014D7"
      unitRef="number">0.51</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TopNineProductsMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_SalesRevenueProductLineMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_ProductConcentrationRiskMember"
      decimals="2"
      id="d34519344e2507-wk-Fact-CD8C03F1D7453B6FE934801F7FFBE54C"
      unitRef="number">0.46</us-gaap:ConcentrationRiskPercentage1>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2019Q4"
      decimals="-8"
      id="d34519344e2610-wk-Fact-C66567CD14E95F92AFFC0E08F8683BC1"
      unitRef="usd">5700000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2018Q4"
      decimals="-8"
      id="d34519344e2620-wk-Fact-C5B82205C7F5510AAB55F9B3C6A1D874"
      unitRef="usd">5400000000</pfe:RebatesAndDiscountsAccrual>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-412809AC9762DE565764801F82FB9290-0-wk-Fact-1912928CAD6A19BFE86F801F805FBEE4">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:71%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information about the balance sheet classification of these accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reserve against &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Accrued rebates&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,285&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total accrued rebates and other accruals&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,689&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-6"
      id="d34519344e2804-wk-Fact-8402D23656C955A385898AA9E62ECD6F"
      unitRef="usd">1257000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_AccountsReceivableMember"
      decimals="-6"
      id="d34519344e2823-wk-Fact-AE11515EF3ED597F8A84C997EBC1D5F1"
      unitRef="usd">1288000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:AccruedRebates
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d34519344e2937-wk-Fact-3468E93B75C15267A94589A1BC13D5C9"
      unitRef="usd">3285000000</pfe:AccruedRebates>
    <pfe:AccruedRebates
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d34519344e2956-wk-Fact-276A53E02F1354F58F2FD3DB009E15BE"
      unitRef="usd">3208000000</pfe:AccruedRebates>
    <pfe:OtherAccruals
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d34519344e2981-wk-Fact-163F9FFCF1335A1996EA5783150DB776"
      unitRef="usd">581000000</pfe:OtherAccruals>
    <pfe:OtherAccruals
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d34519344e3000-wk-Fact-67DADA72665A53ED8493A3A1CEDCB3CE"
      unitRef="usd">531000000</pfe:OtherAccruals>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d34519344e3071-wk-Fact-8A436208B4215FD58BBA2A089EC34291"
      unitRef="usd">565000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d34519344e3090-wk-Fact-72B28649003C52259374DD039402E60C"
      unitRef="usd">399000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e3120-wk-Fact-A3FC32B0BB005D76B9DEF4997F522592"
      unitRef="usd">5689000000</pfe:RebatesAndDiscountsAccrual>
    <pfe:RebatesAndDiscountsAccrual
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e3139-wk-Fact-FBFA31360AAD5FA3BF289C2EA275A636"
      unitRef="usd">5426000000</pfe:RebatesAndDiscountsAccrual>
    <us-gaap:ReceivablesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-678FAF2F794D349E85FF801F82FD3981-0-wk-Fact-82A8DEBB2A29B34926F2801F7F4DF6E1">&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Trade Accounts Receivable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ReceivablesPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3B93404216BFEF1732C7801F82FB11A5-0-wk-Fact-3D4608BC7ECCAC649140801F8099C769">Cost of Sales and Inventories&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6B3EE57EBD1E8B931B55801F83029006-0-wk-Fact-86FFA8D514F02E2DB623801F7F2FC1CE">Selling, Informational and Administrative Expenses&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.</us-gaap:SellingGeneralAndAdministrativeExpensesPolicyTextBlock>
    <us-gaap:AdvertisingExpense
      contextRef="FD2019Q4YTD"
      decimals="-8"
      id="d34519344e3307-wk-Fact-744D1DB29E3F183A7ECA801F812FC803"
      unitRef="usd">2600000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="FD2018Q4YTD"
      decimals="-8"
      id="d34519344e3315-wk-Fact-01D9995CCBE49C7109F9801F8027E29F"
      unitRef="usd">3100000000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34519344e3323-wk-Fact-0327569D3B2AE41DA377801F7F3CFC98"
      unitRef="usd">3100000000</us-gaap:AdvertisingExpense>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-61EBAEF1CDEC87697540801F8300F291-0-wk-Fact-0EB1CE205D8FAD93BA52801F802932F7">Research and Development Expenses&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;R&amp;amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-AF5E92C24ADD2F082EC2801F83021985-0-wk-Fact-7D4471CA5742D2F44F36801F7F15740E">&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Property, plant and equipment, less accumulated depreciation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentImpairment
      contextRef="FD2019Q4YTD"
      id="TextSelection-D02927152D57FEAE4A89801F83001914-0-wk-Fact-8F15A110E2E2C6609E55801F8049E1A7">&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentImpairment>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-295BE658210B6EABCB29801F82FAC2DD-0-wk-Fact-17FEC3AA2A6816D304BD801F80890C06">&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Specifically:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For indefinite-lived intangible assets, such as Brands and IPR&amp;amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;These acquired assets are recorded at fair value. Intangible assets with finite lives&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as appropriate.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-398CA238E0C1691AAF8C801F8301E8E1-0-wk-Fact-5B6E8434952A8A2EF8CD801F7FB385EC">Restructuring Charges and Certain Acquisition-Related Costs&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. </us-gaap:CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3E2DC8C373CD8F4401C5801F8300AEA3-0-wk-Fact-6D79ECC490DD2580B06D801F7F1B0B95">&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:DerivativesReportingOfDerivativeActivity
      contextRef="FD2019Q4YTD"
      id="TextSelection-17ECBA1B31B86AF0582A801F82F9FCD5-0-wk-Fact-37AEAB810E8BA3AFA8A1801F8060E3FF">&lt;div style="line-height:120%;padding-top:9px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesReportingOfDerivativeActivity>
    <us-gaap:InvestmentPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6649E9B4FFE282BCBC15801F8302F923-0-wk-Fact-B09123B438D6667F41A0801F80470BB5">Investments and Derivative Financial Instruments&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our investments are comprised of the following: public equity securities with readily determinable fair values, available-for-sale debt securities, held-to-maturity debt securities (when we have both the positive intent and ability to hold the investment to maturity), private equity securities &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;without readily determinable fair values and equity-method investments. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Public equity securities with readily determinable fair values are carried at fair value, with changes in fair value reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Available-for-sale debt securities are carried at fair value, with changes in fair value reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;until realized.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Held-to-maturity debt securities are carried at amortized cost.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#x2019;s income and expenses in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Realized gains or losses on sales of investments are determined by using the specific identification cost method.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentPolicyTextBlock>
    <us-gaap:DerivativesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8CE12F84BDA7436996D7801F82FFE3B4-0-wk-Fact-D5DA0AF32329F55E54F6801F807BA2F5">&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative financial instruments are carried at fair value in various balance sheet categories (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 7A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;), with changes in fair value reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Net income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; or, for derivative financial instruments in certain qualifying hedging relationships, in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 7F&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DerivativesPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-77172E47F9FF78C04BD1801F830066FF-0-wk-Fact-28FD4D961CF125D368E1801F7F1ED4FA">Tax Assets and Liabilities and Income Tax Contingencies&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Tax Assets and Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current tax assets primarily includes (i) tax effects associated with intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party, as well as (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws, including the impact of the TCJA enacted in December 2017. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet. Amounts recorded for valuation allowances can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other non-current tax assets &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in our consolidated balance sheet as of December 31, 2019 includes liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability on the deemed repatriated accumulated post-1986 foreign earnings recorded in connection with the TCJA for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for uncertain tax positions and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for the repatriation tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Income Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#x201c;more likely than not&#x201d;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and local and foreign income tax filings, statute of limitations expirations, changes and clarification in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and are classified on our consolidated balance sheet with the related tax liability.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. </us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:PensionAndOtherPostretirementPlansPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-0017DA01FC2F0718B450801F8301824C-0-wk-Fact-3B0FF820F4F887E41EF1801F800C84F3">Pension and Postretirement Benefit Plans&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</us-gaap:PensionAndOtherPostretirementPlansPolicy>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EBFF4AA6E70C2B18AD01801F82FF5586-0-wk-Fact-D379C09B7F692F87AFD8801F8021B0E3">Legal and Environmental Contingencies&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="FD2019Q4YTD"
      id="TextSelection-DCE60D5A78F2CCB333F7801F82FC332A-0-wk-Fact-868690B64604F59F72CB801F800303F3">Share-Based Payments&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:LesseeLeasesPolicyTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-032647AC333E2273918BCDA467C2A1A0-0-wk-Fact-6BE4C2427D8EA8B28867CDA4ED371538">Leases&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On January&#160;1, 2019, we adopted a new accounting standard for leases. For further information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; years, some of which include options to terminate or extend leases for up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$328 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for the year ended &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q4_srt_RangeAxis_srt_MinimumMember"
      id="d34519344e3955-wk-Fact-02F2C3D3C7D05BF68C223C1E9808C491">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="FI2019Q4_srt_RangeAxis_srt_MaximumMember"
      id="d34519344e3959-wk-Fact-3DF3199445B252908034E40D3085935A">P30Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <pfe:LesseeOperatingLeaseOptionToExtendTerm
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember"
      id="d34519344e3963-wk-Fact-F1552967F9435D9D96ED1CA07DE28384">P5Y</pfe:LesseeOperatingLeaseOptionToExtendTerm>
    <pfe:LesseeOperatingLeaseOptionToExtendTerm
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember"
      id="d34519344e3967-wk-Fact-C3765EA1D4B354B1B1C0C07B639C33A8">P10Y</pfe:LesseeOperatingLeaseOptionToExtendTerm>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34519344e3971-wk-Fact-4A75EB86316D58CE867E4A4BEED4F2E7"
      unitRef="usd">328000000</us-gaap:VariableLeaseCost>
    <pfe:AssetsAndLiabilitiesLesseeTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EF204A16865E7FE4BB3CCDA79F2399BD-0-wk-Fact-71941A4FF67E8B5FA06DCDA7F6B73516">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:54%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For operating leases, the ROU assets and liabilities are presented in our consolidated balance sheet as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Balance at&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance Sheet Classification&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ROU assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Lease liabilities (short-term)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Lease liabilities (long-term)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,048&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</pfe:AssetsAndLiabilitiesLesseeTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e4134-wk-Fact-93FC417D6E65516CB36353AAC42EF2F6"
      unitRef="usd">1313000000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e4164-wk-Fact-CA151A9102D05D7088F2EE43B5CF948D"
      unitRef="usd">276000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e4199-wk-Fact-6F319B62FDF25CFA8D0A320A329799AA"
      unitRef="usd">1048000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LeaseCostTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-53858455EAEA03F0BAF9CDA8516728A8-0-wk-Fact-BCBD4F30354D30A9CD53CDA88A6240FE">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:80%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our total lease costs are as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Operating lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Variable lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Sublease income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total lease cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:17%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other supplemental information includes the following:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average Remaining Contractual Lease Term (Years) as of&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average Discount Rate as of&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Gains)/losses on sale and leaseback transactions, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ROU assets obtained in exchange for new operating lease liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34519344e4321-wk-Fact-102A92581701552CB40498078D34E5C3"
      unitRef="usd">416000000</us-gaap:OperatingLeaseCost>
    <us-gaap:VariableLeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34519344e4341-wk-Fact-4A75EB86316D58CE867E4A4BEED4F2E7"
      unitRef="usd">328000000</us-gaap:VariableLeaseCost>
    <us-gaap:SubleaseIncome
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34519344e4366-wk-Fact-39C55B542D345ECFBDCE70F6B2EB86DE"
      unitRef="usd">45000000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34519344e4397-wk-Fact-71624EFD7D5450439FF0ADE33112C760"
      unitRef="usd">700000000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="FI2019Q4"
      id="d34519344e4583-wk-Fact-7ABEE86154625A10920AD28E665C31B3">P6Y9M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="FI2019Q4"
      decimals="3"
      id="d34519344e4593-wk-Fact-BDCDBC9DCEFF5EF1BBF2AABC81D7EE35"
      unitRef="number">0.035</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasePayments
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34519344e4715-wk-Fact-9D79BFB44E8E5BC78A4220F4C01916F2"
      unitRef="usd">346000000</us-gaap:OperatingLeasePayments>
    <us-gaap:SaleAndLeasebackTransactionGainLossNet
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34519344e4760-wk-Fact-9955BF04D4B95FF29504B4DD502F74AE"
      unitRef="usd">-29000000</us-gaap:SaleAndLeasebackTransactionGainLossNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34519344e4811-wk-Fact-903437B5E0BE5C3BB05954945635C81D"
      unitRef="usd">326000000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-AA9B51D843078125692DCDA91F50CFB5-0-wk-Fact-51C20EAD59E06446F1A6CDA97440FBB9">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Operating Lease Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Next one year&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;1-2 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2-3 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;3-4 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;4-5 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Thereafter&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;424&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total undiscounted lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Imputed interest&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;206&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Present value of minimum lease payments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,324&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,048&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects lease payments due within 12 months subsequent to the balance sheet date.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e4935-wk-Fact-D4A071180EDE5CEF82B5ECC8A1B682B0"
      unitRef="usd">323000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e4955-wk-Fact-78AA6EF829B550D78A2B4D19A3F5F6AA"
      unitRef="usd">286000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e4980-wk-Fact-150C91F824A554F1893E496F70051414"
      unitRef="usd">220000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e5005-wk-Fact-5C807D5E2A165038BF0483B7D22FE73F"
      unitRef="usd">180000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e5030-wk-Fact-C1CA5A551CAC5F658E17FB58880C4600"
      unitRef="usd">97000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e5055-wk-Fact-1927129FE3AC5361A96E8A5B591FCF9E"
      unitRef="usd">424000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e5080-wk-Fact-87F0A32A2D1C51398079AE5E55E45F50"
      unitRef="usd">1530000000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e5105-wk-Fact-3D92602F15F05AA49F55A2FBE80F83F0"
      unitRef="usd">206000000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e5131-wk-Fact-AAD4F64B7D4A5E6287C77330CB4E4C2F"
      unitRef="usd">1324000000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e5156-wk-Fact-CA151A9102D05D7088F2EE43B5CF948D"
      unitRef="usd">276000000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34519344e5186-wk-Fact-6F319B62FDF25CFA8D0A320A329799AA"
      unitRef="usd">1048000000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:LesseeOperatingLeaseTermOfContract
      contextRef="I2018Q2Apr30_us-gaap_LeaseArrangementTypeAxis_pfe_OfficeBuildingInNewYorkCityMember"
      id="d34519344e5207-wk-Fact-5B4FDBBFA36454E0B7045E3ED44E0122">P20Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue
      contextRef="I2018Q2Apr30_us-gaap_LeaseArrangementTypeAxis_pfe_OfficeBuildingInNewYorkCityMember"
      decimals="-8"
      id="d34519344e5211-wk-Fact-496AB503F40803FDFA8BCE1515E7651E"
      unitRef="usd">1700000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34519344e5219-wk-Fact-A8104E75C62D567E9ADC847E6F6A1E2C"
      unitRef="usd">301000000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34519344e5223-wk-Fact-E8E07C6373FF5F32AAE2C17FE497989E"
      unitRef="usd">314000000</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-25B3763D59BF3E461447CDAA1521FE4E-0-wk-Fact-05262257643BCD37850ECDAA6D143F69">&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;After 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Lease commitments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;210&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;248&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e5531-wk-Fact-175B6519BF8F5665A96150F7C1277CD3"
      unitRef="usd">300000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e5550-wk-Fact-11F23E7E46ED59299C14AA0CEF0CD735"
      unitRef="usd">252000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e5570-wk-Fact-FAD9C7B04BC757218CDAF1BED4984288"
      unitRef="usd">210000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e5589-wk-Fact-E7AB6DA1C7925147A4F53D065D1E45C7"
      unitRef="usd">267000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e5608-wk-Fact-BD11FEDCA0075B93AA4F69282B0BD690"
      unitRef="usd">248000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34519344e5628-wk-Fact-2978B8F81ACC5F4B9C547D637D7643F7"
      unitRef="usd">2040000000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8C88EA3EF0FDFD43555C801F8303C9CF-0-wk-Fact-55709442E36C72041BEF801F803DBC16">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Array BioPharma Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;30, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$48&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share in cash. The total fair value of the consideration transferred for Array was approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$11.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$10.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, net of cash acquired). In addition, approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$157 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in the consolidated statement of income in the third quarter of 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). We financed the majority of the transaction with debt and the balance with existing cash. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Array&#x2019;s portfolio includes the approved combined use of Braftovi (encorafenib) and Mektovi (binimetinib) for the treatment of BRAF&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;V600E&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;- or BRAF&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;V600K&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-mutant unresectable or metastatic melanoma. The combination therapy has significant potential for long-term growth via expansion into additional areas of unmet need and is currently being investigated in over 30 clinical trials across several solid tumor indications, including in BRAF-mutant mCRC, through collaborations with third parties. In December 2019, the FDA accepted and granted priority review to our supplemental new drug application for Braftovi in combination with Erbitux (cetuximab) (Braftovi Doublet) in BRAF-mutant mCRC. Pfizer has exclusive rights to commercialize Braftovi and Mektovi in the U.S. and Canada. In addition to the combination therapy for BRAF-mutant metastatic melanoma, Array brings a broad pipeline of targeted cancer medicines in different stages of R&amp;amp;D, as well as a portfolio of out-licensed medicines, which may generate milestones and royalties over time.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In connection with this acquisition, we provisionally recorded: (i) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$7.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, consisting of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; with a useful life of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#0000ff;"&gt;,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Licensing agreements &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for technology in development&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;indefinite-lived licensing agreements and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$340 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for developed technology&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;finite-lived licensing agreements with a useful life of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;), (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of net deferred tax liabilities and (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$451 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of assumed long-term debt, which was paid in full in the third quarter of 2019. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Therachon Holding AG&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$340 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upfront, plus potential milestone payments of up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$470 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; contingent on the achievement of key milestones in the development and commercialization of the lead asset. In 2018, we acquired approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of Therachon&#x2019;s outstanding shares for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$322 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, which consisted of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$317 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of cash and our previous &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; investment in Therachon. Therachon is a wholly-owned subsidiary of Pfizer. In connection with this asset acquisition, we recorded a charge of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$337 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;AstraZeneca&#x2019;s Small Molecule Anti-Infectives Business&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca&#x2019;s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the marketed products Zavicefta&#x2122; (ceftazidime-avibactam), Merrem&#x2122;/Meronem&#x2122; (meropenem) and Zinforo&#x2122;&#160;(ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). In 2017, under the terms of the agreement, we made payments of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$605 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to AstraZeneca related to the transaction. We made an additional milestone payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$125 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in our first fiscal quarter of 2018, we made a deferred payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$175 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to AstraZeneca in January 2019, and we made an additional milestone payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in our third fiscal quarter of 2019. We may make payments of up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$600 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to AstraZeneca if sales of Zavicefta&#x2122; exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta&#x2122; and ATM-AVI in certain markets for a period ending on the later of 10 years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$315 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$542 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The total fair value of consideration transferred for AstraZeneca&#x2019;s small molecule anti-infectives business was approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; inclusive of cash paid of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$555 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and the fair value of contingent consideration of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$485 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (which is composed of the fair values of the deferred payment, the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; milestone payment made in the second quarter of 2017, the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$125 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; milestone payment made in our first fiscal quarter of 2018, the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; milestone payment made in the third quarter of 2019, and the future expected milestone and royalty payments). In connection with this acquisition, we recorded &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$894 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, consisting of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$728 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$166 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. We also recorded &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$92 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$73 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$19 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Medivation, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On September 28, 2016, we acquired Medivation for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$81.50&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share. The total fair value of consideration transferred for Medivation was approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$14.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in cash (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$13.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, net of cash acquired). Of this consideration, approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$365 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; was not paid as of December 31, 2016, and was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; The remaining consideration was paid as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Medivation is a wholly-owned subsidiary of Pfizer. Medivation is focused on developing and commercializing small molecules for oncology. Medivation&#x2019;s portfolio includes Xtandi (enzalutamide). Xtandi is FDA-approved for the treatment of non-metastatic and metastatic castration-resistant &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;prostate cancer as well as metastatic castration sensitive prostate cancer. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. The Medivation portfolio also includes talazoparib, which was approved by the FDA in October 2018, under the trade name Talzenna, for the treatment of adults with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer and is currently in development for other types of cancer. In connection with this acquisition, we recorded &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$12.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, primarily consisting of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$8.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; with an average useful life of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; years and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;IPR&amp;amp;D, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;and recorded &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$6.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; Goodwill,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of net income tax liabilities, and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$259 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of assumed contingent consideration of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$51 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; has been paid through December 31, 2019. In 2017 and 2016, we recorded measurement period adjustments to the estimated fair values initially recorded in 2016, which resulted in a reduction in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; with a corresponding change to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The 2017 results included a decrease of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$38 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; which reflected the cumulative pre-tax impact of the measurement period adjustments to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Divestitures&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical, a global device manufacturer, agreed to acquire all of our global infusion systems net assets, HIS, for approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in cash and ICU Medical common stock. HIS includes IV pumps, solutions, and devices. As a result of the performance of HIS relative to ICU Medical&#x2019;s expectations, on January 5, 2017 we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$900 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The revised transaction closed on February 3, 2017. At closing, we received &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$428 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which were reported as equity securities at fair value in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; on the consolidated balance sheet as of December 31, 2017. Upon the sale of these shares in 2018, we realized a full gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$302 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; on these securities, although our income statement only reflects a gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$47 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as the balance of the previously unrealized gain was recorded as a cumulative effect adjustment upon the adoption of a new accounting standard. We also received a promissory note in the amount of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, which was repaid in full as of December 31, 2017, and net cash of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; before customary adjustments for net working capital, which was reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other investing activities, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; on the consolidated statement of cash flows for the year-ended December 31, 2017. In addition, we are entitled to receive a contingent amount of up to an additional &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$225 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in cash based on ICU Medical&#x2019;s achievement of certain cumulative performance targets for the combined company through December 31, 2019. The amount of contingent payment we will receive, if any, will be determined during the first half of 2020. We recognized a pre-tax gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and a pre-tax loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$55 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;representing adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The sale of the HIS net assets was fully completed in all jurisdictions as of year-end 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily related to administrative services, and were provided for a period of 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Contribution Agreement Between Pfizer and Allogene Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In April 2018, Pfizer and Allogene announced that the two companies entered into a contribution agreement for Pfizer&#x2019;s portfolio of assets related to allogeneic CAR T therapy, an investigational immune cell therapy approach to treating cancer. Under this agreement, Allogene received from Pfizer rights to pre-clinical and clinical CAR T assets, all of which were previously licensed to Pfizer from French cell therapy company, Cellectis, beginning in 2014 and French pharmaceutical company, Servier, beginning in 2015. Allogene assumed responsibility for all potential financial obligations to both Cellectis and Servier. Pfizer continues to participate financially in the development of the CAR T portfolio through an ownership stake in Allogene. Separately, Pfizer continues to maintain its approximate &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; ownership stake in Cellectis that was obtained in 2014 as part of the licensing agreement in which Pfizer obtained exclusive rights to pursue the development and commercialization of certain Cellectis CAR T therapies in exchange for an upfront payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as well as potential future development, regulatory and commercial milestone payments and royalties. In connection with the Allogene transaction, Pfizer recognized a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in the second quarter of 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; representing the difference between the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; fair value of the equity investment received and the book value of assets transferred (including an allocation of goodwill) (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In October 2018, Allogene consummated an initial public offering of new shares of its common stock, which resulted in Pfizer&#x2019;s preferred stock converting into common stock and a decrease in our ownership percentage from approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of December 31, 2018. The closing price on the day of the initial public offering was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$25&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share. Beginning as of the date of the initial public offering, our investment in Allogene is being measured at fair value with changes in fair value recognized in net income (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In April 2018, we sold our Phase 2b ready AMPA receptor potentiator for CIAS to Biogen. We received &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upfront and have the opportunity to receive up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$515 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in total development and commercialization milestones, as well as tiered royalties in the low-to-mid-teen percentages. We recognized the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upfront payment in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the second quarter of 2018 (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). In the fourth quarter of 2018, we recognized an additional &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; milestone in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We will record the other milestones and royalties to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; when due, or earlier if we have sufficient experience to determine such amounts are not probable of significant reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Divestiture of Neuroscience Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In September 2018, we and Bain Capital entered into a transaction to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system including Parkinson&#x2019;s disease, epilepsy, Alzheimer&#x2019;s disease, schizophrenia and addiction. These assets were part of the neuroscience discovery and early development efforts, which we announced we were ending in January 2018. In connection with this transaction, we out-licensed the portfolio to Cerevel in exchange for a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; ownership stake in Cerevel&#x2019;s parent company, Cerevel Therapeutics, Inc., and potential future regulatory and commercial milestone payments and royalties. Bain Capital has committed to invest &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$350 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to develop the portfolio, with the potential for additional funding as the assets advance. In connection with the transaction, we recognized a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$343 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in the third quarter of 2018, representing the fair value of the equity investment received as the assets transferred&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;had a book value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$0&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). Our investment in Cerevel Therapeutics, Inc. is reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;on the consolidated balance sheets as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. Equity-Method Investments and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Assets and Liabilities Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Formation of a New Consumer Healthcare Joint Venture&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; equity stake in the new company and GSK owns the remaining &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;68%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$8.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, net of tax) in our fiscal third quarter of 2019 in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;(Gain) on completion of Consumer Healthcare JV transaction&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for the difference in the fair value of our &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In valuing our investment in GSK Consumer Healthcare, we used discounted cash flow techniques. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long term; the discount rate, which seeks to reflect our best estimate of the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows. As part of the joint venture transaction, we agreed to indemnify GSK with respect to certain tax matters related to periods prior to closing of the transaction as well as certain potential environmental or other legal liabilities associated with the previous operation of our Consumer Healthcare business. We recognized a liability of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$45 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; with respect to the tax matters indemnification. The value of the environmental and legal indemnifications was not considered to be material.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our investment in GSK Consumer Healthcare is approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$17.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and it is reported as a private equity investment in the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Equity-method investments &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;line in our consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Our consolidated statement of income for 2019 includes revenues and expenses associated with Pfizer&#x2019;s Consumer Healthcare business through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. We record our share of earnings from the Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; commencing from August 1, 2019. Therefore, we recorded our share of two months of the joint venture&#x2019;s earnings generated in the third quarter of 2019 totaling &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$47 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in our operating results in the fourth quarter of 2019. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$15.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$11.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; resulting in an initial basis difference of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; commencing August 1, 2019. The amortization of these basis differences for two months of the third quarter of 2019 totaling approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$31 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is included in our operating results in the fourth quarter of 2019. Amortization of basis differences on inventory and related deferred tax liabilities will be completely recognized by the first quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;17 years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The increase in the value of our investment from the closing date to December 31, 2019 is primarily due to foreign currency translation adjustments (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 6&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;While we have received our full &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; interest in GSK Consumer Healthcare as of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; closing and transferred control of our Consumer Healthcare business to GSK Consumer Healthcare, the contribution of the business was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, we have continued to operate the business for the net economic benefit of GSK Consumer Healthcare, and we are indemnified by GSK Consumer Healthcare against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. We expect the contribution of our &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Consumer Healthcare business in these jurisdictions to be fully completed by the first half of 2021. As such, and as we and GSK Consumer Healthcare are contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In connection with the contribution of our Consumer Healthcare business, we entered into certain transitional agreements designed to facilitate the orderly transition of the business to GSK Consumer Healthcare. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;24 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; after the closing date. We will also manufacture and supply certain consumer products for GSK Consumer Healthcare and GSK Consumer Healthcare will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;six years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. These agreements are not material to Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. The Consumer Healthcare business assets held for sale are reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Assets held for sale&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and Consumer Healthcare business liabilities held for sale are reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Liabilities held for sale &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in the consolidated balance sheet as of December 31, 2018. This includes the Consumer Healthcare business tax assets and liabilities related to fully dedicated consumer healthcare subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;538&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PP&amp;amp;E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,972&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total Consumer Healthcare assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,678&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other assets held for sale&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Liabilities Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Trade accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income taxes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Accrued compensation and related items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension benefit obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement benefit obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total Consumer Healthcare liabilities held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other assets held for sale consist of PP&amp;amp;E.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$654 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$977 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in 2018 and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$863 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the two months ending September 30, 2019, the most recent period available, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,505&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;46,081&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,536&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;10,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total net equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For the Two Months Ending&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;September 30,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Gross profit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Investment in ViiV Healthcare Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11.7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of ViiV, and we have historically accounted for our investment in ViiV under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;zero&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; due to the recognition of cumulative equity method losses and dividends. Since 2016, we have recognized dividends from ViiV as income in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; when earned, including dividends of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$220 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$266 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Summarized financial information for our equity method investee, ViiV, as of December 31, 2019 and 2018 and for the years ending December 31, 2019, 2018, and 2017 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,765&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total net equity/(deficit) attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,489&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Gross profit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,757&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Investment in Hisun Pfizer Pharmaceuticals Company Limited&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In September 2012, we and Hisun, a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, of which our portion was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$122.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious disease, oncology, mental health and other therapeutic areas.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We accounted for our interest in Hisun Pfizer as an equity-method investment, due to the significant influence we had over the operations of Hisun Pfizer through our board representation, minority veto rights and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; voting interest. Our investment in Hisun Pfizer was reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and our share of Hisun Pfizer&#x2019;s net income was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On November 10, 2017, we sold our &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; equity share in Hisun Pfizer to Sapphire I (HK) Holdings Limited, an investment fund managed by Hillhouse Capital, for a total of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$286 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in cash which included our carrying value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$270 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in cash plus &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$16 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to cover certain taxes incurred on the transaction.&#160;As a result of the sale transaction, we recognized a loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the fourth quarter of 2017 for the recognition in earnings of the currency translation adjustment associated with our investment. After the sale transaction, Hisun Pfizer changed its name but retained its current rights to manufacture, sell and distribute all of Hisun Pfizer&#x2019;s currently marketed and pipeline products in China. We are providing technical, manufacturing and regulatory services in connection with a technology transfer process being run by Hisun Pfizer to support Hisun Pfizer&#x2019;s objective that the products that we had previously licensed to Hisun Pfizer, will in the future, be manufactured locally in China.&#160;We continue to supply certain products to Hisun Pfizer for a period of time, after the sale transaction, to facilitate a smooth transition.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Investment in Laborat&#xf3;rio Teuto Brasileiro S.A.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We entered into an agreement on June 30, 2017 to exit our investment in Teuto, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-owned generics company in Brazil, and sell our &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; interest in Teuto to the majority shareholders. As part of the agreement, we waived our option to acquire the remaining &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of Teuto, and Teuto&#x2019;s other shareholders have waived their option to sell their &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; stake in the company to us. As a result, in the second quarter of 2017, we recognized a net loss of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;), which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders&#x2019; option to sell their &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; stake in the company to us, and the recognition in earnings of the currency translation adjustment associated with the Teuto investment. The transaction closed on August 16, 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;D. Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Akcea Therapeutics, Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In October 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. The transaction closed in November 2019 and we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to Akcea and Ionis, which was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in our fiscal fourth quarter of 2019. Under the terms of the agreement, Akcea and Ionis will split equally the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upfront license fee. We may be required to make development, regulatory and sales milestone payments of up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and tiered, double-digit royalties on annual worldwide net sales upon marketing approval of AKCEA-ANGPTL3-LRx and these payments will also be split equally between Akcea and Ionis. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with the ongoing Phase 2 study.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Shire International GmbH&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2016, we out-licensed PF-00547659, an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease, including ulcerative colitis and Crohn&#x2019;s disease, to Shire for an upfront payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, up to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$460 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in development and sales-based milestone payments and potential future royalty payments on commercialized products. The &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upfront payment was initially deferred and recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; ratably through December 2017. In the first quarter of 2018, we recognized &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of ulcerative colitis, and in the third quarter of 2018, we recognized &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$35 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of Crohn&#x2019;s disease (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;BionTech AG&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In August 2018, a multi-year R&amp;amp;D arrangement went into effect between BionTech AG (BionTech), a privately held company, and Pfizer to develop mRNA-based vaccines for prevention of influenza (flu). In September 2018, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to BionTech, which was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;and BionTech became eligible to receive up to an additional &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$325 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in future development and sales based milestones and future royalty payments associated with worldwide sales. As part of the transaction, we also purchased &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;169,670&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; newly-issued ordinary shares of BionTech for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the third quarter of 2018, which are reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in the consolidated balance sheets as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;E. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Research and Development and Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest would fund up to&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in development costs related to certain Phase 3 clinical trials of Pfizer&#x2019;s rivipansel compound and Pfizer would use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest&#x2019;s development funding was expected to cover up to&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;of the development &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;costs and was received over approximately 13 quarters from 2016 through the second quarter of 2019 after which Pfizer would be responsible for the remaining development costs. As there was a substantive and genuine transfer of risk to NovaQuest, the development funding was recognized by us as an obligation to perform contractual services and therefore a reduction of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as incurred. The funding cap was reached in 2019.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; The reduction to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and Development expenses &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;totaled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$24 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for 2019, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$58 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for 2018 and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$72 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In August 2019, we announced that the Phase 3 RESET (Rivipansel Evaluating Safety, Efficacy and Time to Discharge)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:11pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease who were hospitalized for a vaso-occlusive crisis and required treatment with IV opioids. As a result, in 2019, we recorded a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$99 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;related to rivipansel&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; primarily for inventory manufactured for expected future sale&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;as well as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$15 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of anticipated clinical development program close-out costs, which were recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development costs &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in the consolidated statement of income. In January 2020, we discontinued development of rivipansel resulting in the termination of the R&amp;amp;D arrangement with NovaQuest. No payments have been or are expected to be received from or paid to NovaQuest as part of the termination of the arrangement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Research and Development Arrangement with RPI Finance Trust&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI would fund up to&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$300 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in development costs related to certain Phase 3 clinical trials of Pfizer&#x2019;s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI&#x2019;s development funding is expected to cover up to&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;of the costs primarily for the applicable clinical trials until the first quarter of 2020 after which Pfizer will be responsible for the remaining cost of the trials. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as incurred. The reduction to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; totaled&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$99 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$76 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Amortization of intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; when incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Collaborative Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;Revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenue&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;s&#x2014;Alliance revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total revenues from collaborative arrangements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,533&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other income/(deductions)&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Represents sales to our partners of products manufactured by us.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in each of the periods presented reflect increases in alliance revenues from Eliquis and Xtandi.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$15 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. There were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;no&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; upfront and milestone payments in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Our collaboration with Lilly (see below) also includes reimbursements of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$67 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$98 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$147 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily relates to royalties from our collaboration partners. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The amounts disclosed in the above table do not include transactions with third parties other than our collaboration partners, or other costs associated with the products under the collaborative arrangements.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In addition, in connection with our collaborative arrangements, we paid post-approval milestones of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to our collaboration with Merck KGaA (see below). These payments were recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We did not pay post-approval milestones to collaboration partners in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. We also recorded milestones earned related to (i) our collaboration with Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub&#xae;, a generic of Advair Diskus&#xae; (fluticasone propionate and salmeterol inhalation powder) of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$78 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) and (ii) our &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:8px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;collaboration with Merck (see below) of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in 2018 in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$150 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, substantially all of which was included in the adjustment to increase the opening balance of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upon the adoption of a new accounting standard for revenue recognition, effective January 1, 2018.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Collaboration with Merck &amp;amp; Co., Inc.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Under a worldwide collaboration agreement, except for Japan, we collaborated with Merck on the clinical development of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets, which were approved by the FDA in December 2017 and the EC in March 2018 as Steglatro, Segluromet and Steglujan. Merck exclusively promotes Steglatro and the two fixed-dose combination products and we share revenues and certain costs with Merck on a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;/&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; basis, with Pfizer having the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; share. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the first quarter of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we received a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; milestone payment from Merck upon the FDA&#x2019;s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which, as of December 31, 2017, was deferred and primarily reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;and through December 31, 2017, was being recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; over a multi-year period. As of December 31, 2017, we were due a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$60 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; milestone payment from Merck, which we received in the first quarter of 2018, in conjunction with the approval of ertugliflozin by the FDA. As of December 31, 2017, the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$60 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; due from Merck was deferred and primarily reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In the first quarter of 2018, in connection with the approval of ertugliflozin in the EU, we recognized a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; milestone payment from Merck in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). We are eligible for additional payments associated with the achievement of future commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard for revenue recognition, as of January 1, 2018, the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$60 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of deferred income and approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$85 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of deferred income associated with the above-mentioned milestone payments were recorded as a cumulative effect adjustment to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Collaboration with Eli Lilly &amp;amp; Company&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer&#x2019;s tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. We received a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which was deferred and primarily reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;and through December 31, 2017, was being recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard for revenue recognition, as of January 1, 2018, approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$107 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of deferred income associated with the above-mentioned upfront payment was recorded as a cumulative effect adjustment to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the upfront payment continues to be deferred, and is reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. This amount is being recognized in&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; over the remaining development period for the product in 2020.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Collaboration with Merck KGaA&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In November 2014, we entered into a collaborative arrangement with Merck KGaA, to jointly develop and commercialize avelumab, currently approved as Bavencio for metastatic MCC in the U.S., the EU, Japan and select other markets, in combination with Inlyta for the first-line treatment of patients with advanced RCC in the U.S., the EU, Japan and select other markets, as well as for the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma in the U.S. and select other markets. Avelumab is also in development as a potential treatment for multiple other types of cancer. We and Merck KGaA are exploring the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with our and Merck KGaA&#x2019;s broad portfolio of approved and investigational oncology therapies. Also, as part of the agreement, we gave Merck KGaA certain co-promotion rights for Xalkori in the U.S. and several other key markets. Under the terms of the agreement, in the fourth quarter of 2014, we made an upfront payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$850 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to Merck KGaA and Merck KGaA is eligible to receive regulatory and commercial milestone payments of up to approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. During 2017, we made &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in milestone payments to Merck KGaA, which were recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;for approvals of avelumab received in 2017 for the MCC indication in the U.S., the EU and Japan, and for the metastatic urothelial carcinoma indication in the U.S. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Both companies jointly fund the majority of development and commercialization costs, and split equally any profits related to net sales generated from selling any products containing avelumab from this collaboration.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; In December 2018, both companies amended the collaborative agreement such that Pfizer will be solely responsible for the development and commercialization of its anti PD-1 antibody. Under the terms of the amended agreement, we paid Merck KGaA an up-front payment and we will make a potential milestone and tiered royalty payments should the Pfizer anti PD-1 antibody achieve regulatory and commercial success. We made &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in milestone payments to Merck KGaA, which were recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for the U.S. and the EU approvals received in 2019 related to the use of Bavencio in combination with Inlyta for the first-line treatment of patients with advanced RCC.&lt;/span&gt;&lt;/div&gt;</pfe:BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="INF"
      id="d34506804e1330-wk-Fact-87A73243BF595DD18C64026B1A594F00"
      unitRef="usdPerShare">48</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d34506804e1334-wk-Fact-661D03E21572543CB5AFEBAECACF8E2B"
      unitRef="usd">11200000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d34506804e1338-wk-Fact-AA9C766FC51A56248B8278DB552969BB"
      unitRef="usd">10900000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IncomeStatementLocationAxis_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"
      decimals="-6"
      id="d34506804e1342-wk-Fact-5162BD37F8C9541ABBF3ACA81FB246B3"
      unitRef="usd">157000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d34506804e1373-wk-Fact-ECD43E8C3A0558F781B405A81919ABC0"
      unitRef="usd">7200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-8"
      id="d34506804e1381-wk-Fact-48D871521FAD5D3CB39F25B3CDCABD0C"
      unitRef="usd">1800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="d34506804e1389-wk-Fact-C774FEDE0545501F9BB639A8CF466F64">P16Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-8"
      id="d34506804e1396-wk-Fact-BAFC3442AE0D55949C2C6B7CE309CF0F"
      unitRef="usd">4000000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember"
      decimals="-8"
      id="d34506804e1404-wk-Fact-BEE0EA2666355F388C62D01084A3CB20"
      unitRef="usd">1400000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsTechnologyInDevelopmentMember"
      decimals="-8"
      id="d34506804e1412-wk-Fact-D6F35499769551BEA123C478BC1A6C46"
      unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember"
      decimals="-6"
      id="d34506804e1421-wk-Fact-72B7FF5E1A7E524A93960464DEEF1FB5"
      unitRef="usd">340000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="D2019Q3Jul30-Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember"
      id="d34506804e1429-wk-Fact-E87FB5E6A8AF50FBA3ECDA73F9A15DA5">P10Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:Goodwill
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d34506804e1433-wk-Fact-12359B4DCB395C95B28A9B9EB3E7A049"
      unitRef="usd">5400000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-8"
      id="d34506804e1442-wk-Fact-CD8FF14A7B1C59B991937BD3707EA01D"
      unitRef="usd">1300000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember"
      decimals="-6"
      id="d34506804e1446-wk-Fact-865E3F37E167521D80077626A70B91B9"
      unitRef="usd">451000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt>
    <pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment
      contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34506804e1456-wk-Fact-D4613DCD361C587C8CEC0BB4595ED1E7"
      unitRef="usd">340000000</pfe:AssetAcquisitionConsiderationTransferredUpfrontPayment>
    <pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum
      contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34506804e1460-wk-Fact-F4590EEA4BAF5B65B61201FB5AB77321"
      unitRef="usd">470000000</pfe:AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum>
    <pfe:AssetAcquisitionPercentageofSharesAcquired
      contextRef="FI2018Q4_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="2"
      id="d34506804e1464-wk-Fact-E6FF67223EDB578184BDA6503B4EBD20"
      unitRef="number">0.03</pfe:AssetAcquisitionPercentageofSharesAcquired>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="FD2018Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34506804e1468-wk-Fact-01AD44704E345567B79909ABB7D672A0"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <pfe:AssetAcquisitionConsiderationTransferred
      contextRef="D2019Q3Jan01-Jul02_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34506804e1472-wk-Fact-E471A84C0B3850C393C12C737086419C"
      unitRef="usd">322000000</pfe:AssetAcquisitionConsiderationTransferred>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34506804e1477-wk-Fact-3F87DE71178655C298052D90DCCA243B"
      unitRef="usd">317000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:PaymentsToAcquireProductiveAssets
      contextRef="FD2018Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34506804e1481-wk-Fact-01AD44704E345567B79909ABB7D672A0"
      unitRef="usd">5000000</us-gaap:PaymentsToAcquireProductiveAssets>
    <us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff
      contextRef="D2019Q3Jul01-Jul01_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember"
      decimals="-6"
      id="d34506804e1485-wk-Fact-B8FF75B1EBFC518A84B141992E2D3739"
      unitRef="usd">337000000</us-gaap:ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationWrittenOff>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1497-wk-Fact-664BC8C9F3B14EC1DB76801F7E12B000"
      unitRef="usd">605000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1501-wk-Fact-3EF90B540EEF9FA9EE5B801F7E68742B"
      unitRef="usd">125000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <pfe:BusinessCombinationConsiderationTransferredDeferredPayment
      contextRef="D2019Q1Jan01-Jan31_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1505-wk-Fact-ACA67D96ACE081C2E2BA801F7DF2A1D2"
      unitRef="usd">175000000</pfe:BusinessCombinationConsiderationTransferredDeferredPayment>
    <pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1509-wk-Fact-616ABF59A568AB9DC1DC801F7E740972"
      unitRef="usd">75000000</pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum>
    <pfe:BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="INF"
      id="d34506804e1513-wk-Fact-400ACAF3BCCDE458A25E801F80898CC4"
      unitRef="usd">600000000</pfe:BusinessCombinationConsiderationTransferredSalesrelatedPaymentsMaximum>
    <pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1518-wk-Fact-A8DCA49065364D6AA9B4801F80094C56"
      unitRef="usd">315000000</pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments>
    <pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1522-wk-Fact-D5239ED646294574B776801F7DE2C909"
      unitRef="usd">542000000</pfe:BusinessCombinationConsiderationTransferredUndiscountedRoyaltyPayments>
    <us-gaap:BusinessCombinationConsiderationTransferred1
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-8"
      id="d34506804e1526-wk-Fact-AE69E3A5F2E6833E0DD1801F7F120629"
      unitRef="usd">1000000000.0</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2016Q4Dec22-Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1530-wk-Fact-48BF4859B0A32BA23E7E801F7FD413C0"
      unitRef="usd">555000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1534-wk-Fact-66B2EA2967DFB66FBE1B801F7DF246E1"
      unitRef="usd">485000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1538-wk-Fact-873A2FCE13E3F7A54D7C801F7DCFDE8B"
      unitRef="usd">50000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="FD2018Q1QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1543-wk-Fact-3EF90B540EEF9FA9EE5B801F7E68742B"
      unitRef="usd">125000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum
      contextRef="FD2019Q3QTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1547-wk-Fact-616ABF59A568AB9DC1DC801F7E740972"
      unitRef="usd">75000000</pfe:BusinessCombinationConsiderationTransferredMilestonePaymentsMaximum>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1551-wk-Fact-9ABE5A7329F9817A9547801F8039E9C8"
      unitRef="usd">894000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34506804e1559-wk-Fact-B7E02A378830B1F7BE49801F824C00E6"
      unitRef="usd">728000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34506804e1568-wk-Fact-22EF0C4475B2A4AD777C801F7E3C7ED6"
      unitRef="usd">166000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1576-wk-Fact-087AFE02EC26F193B1BC801F807D250A"
      unitRef="usd">92000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsOther>
    <us-gaap:Goodwill
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1584-wk-Fact-B6FE64416F37E28459E5801F7E1E4151"
      unitRef="usd">73000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2016Q4Dec22_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember"
      decimals="-6"
      id="d34506804e1593-wk-Fact-640C87204CEB4736BE4A801F7E1F3BF2"
      unitRef="usd">19000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessAcquisitionSharePrice
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="INF"
      id="d34506804e1604-wk-Fact-FFA5B333BCCD36025568801F812EB76E"
      unitRef="usdPerShare">81.50</us-gaap:BusinessAcquisitionSharePrice>
    <us-gaap:PaymentsToAcquireBusinessesGross
      contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d34506804e1608-wk-Fact-00602B0CD59829308488801F7F23C922"
      unitRef="usd">14300000000</us-gaap:PaymentsToAcquireBusinessesGross>
    <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired
      contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d34506804e1612-wk-Fact-B394D27B91D0ACE67F00801F7FF7C501"
      unitRef="usd">13900000000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
    <pfe:BusinessCombinationConsiderationTransferredAmountPayable
      contextRef="FI2016Q4_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-6"
      id="d34506804e1616-wk-Fact-DE3E474FC158525238FC801F7E11B4BC"
      unitRef="usd">365000000</pfe:BusinessCombinationConsiderationTransferredAmountPayable>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d34506804e1632-wk-Fact-1F746802082F744ED275801F7E119565"
      unitRef="usd">12200000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-8"
      id="d34506804e1640-wk-Fact-DFAD2DD567A64747F364801F8013EB7A"
      unitRef="usd">8100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife
      contextRef="D2016Q3Sep28-Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="d34506804e1648-wk-Fact-3B9263C0723F412B07FB801F7DF75E50">P12Y</us-gaap:AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-8"
      id="d34506804e1653-wk-Fact-946A9DD73966AD8AF05E801F7EA7FC7B"
      unitRef="usd">4100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <us-gaap:Goodwill
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d34506804e1661-wk-Fact-CC812ED22CC64D569887801F7E063673"
      unitRef="usd">6100000000</us-gaap:Goodwill>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d34506804e1669-wk-Fact-7C35F09640F10B40702C801F801983DE"
      unitRef="usd">4000000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="I2016Q3Sep28_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-6"
      id="d34506804e1673-wk-Fact-085A909DD62E24B7BC59801F7DF30D52"
      unitRef="usd">259000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-6"
      id="d34506804e1678-wk-Fact-05F1F7D310362DFE91C5801F7DCA3DF0"
      unitRef="usd">51000000</us-gaap:PaymentForContingentConsiderationLiabilityInvestingActivities>
    <us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles
      contextRef="D2017Q4Sept-Dec2017_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-8"
      id="d34506804e1686-wk-Fact-FDDF47CA1670EC5067F6801F7E102CF5"
      unitRef="usd">-1000000000.0</us-gaap:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles>
    <pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets
      contextRef="FD2017Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_MedivationMember"
      decimals="-6"
      id="d34506804e1694-wk-Fact-BDCB3FDB89F9F323D8CB801F7E165A14"
      unitRef="usd">-38000000</pfe:BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2016Q4Oct06_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-9"
      id="d34506804e1806-wk-Fact-ED1041F6C5DE51F1929F801F7E0DB7A1"
      unitRef="usd">1000000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1810-wk-Fact-1322BD020F41F6AA79BF801F7F42DBE6"
      unitRef="usd">900000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares
      contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-5"
      id="d34506804e1817-wk-Fact-448F0E07DB88579118FA801F806FAF0C"
      unitRef="shares">3200000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests
      contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1821-wk-Fact-1575B0E58607CCACD1D7801F80322FE0"
      unitRef="usd">428000000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests>
    <us-gaap:EquitySecuritiesFvNiRealizedGain
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1829-wk-Fact-859D36A3E54BEC0F9084801F7E6E2F0B"
      unitRef="usd">302000000</us-gaap:EquitySecuritiesFvNiRealizedGain>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1833-wk-Fact-0DE148F4345D12970895801F800B323E"
      unitRef="usd">47000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable
      contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1838-wk-Fact-33FAD1E8644FB8E7555A801F7E285732"
      unitRef="usd">75000000</pfe:DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable>
    <us-gaap:ProceedsFromDivestitureOfBusinesses
      contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1842-wk-Fact-FC643562DEFCD98D4323801F8014EC76"
      unitRef="usd">200000000</us-gaap:ProceedsFromDivestitureOfBusinesses>
    <pfe:DisposalGroupIncludingDiscontinuedOperationContingentConsideration
      contextRef="I2017Q1Feb03_srt_CounterpartyNameAxis_pfe_ICUMedicalMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1850-wk-Fact-E673F86D3B6DCD055732801F7E198E89"
      unitRef="usd">225000000</pfe:DisposalGroupIncludingDiscontinuedOperationContingentConsideration>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1854-wk-Fact-32377B62BE4A55EC2219801F7E248AA4"
      unitRef="usd">1000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34506804e1863-wk-Fact-FD073C40A0E2055928C6801F7E1E419D"
      unitRef="usd">-55000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <pfe:InvestmentOwnershipPercentage
      contextRef="FD2014Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CellectisMember"
      decimals="2"
      id="d34506804e1908-wk-Fact-F3DD7017E52B31896A59801F8022A2B8"
      unitRef="number">0.07</pfe:InvestmentOwnershipPercentage>
    <pfe:PaymentsToCollaborators
      contextRef="FD2014Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CellectisMember"
      decimals="-6"
      id="d34506804e1912-wk-Fact-A33AE9DFFC0C74A11C01801F7E02E26C"
      unitRef="usd">80000000</pfe:PaymentsToCollaborators>
    <pfe:GainLossFromContributionAgreement
      contextRef="FD2018Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d34506804e1916-wk-Fact-A5E7D7BC9D54165BB084801F7E2758E6"
      unitRef="usd">50000000</pfe:GainLossFromContributionAgreement>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q2_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d34506804e1929-wk-Fact-075EFE0D84976CB138EE801F7E08FB58"
      unitRef="usd">127000000</us-gaap:EquitySecuritiesFvNi>
    <pfe:InvestmentOwnershipPercentage
      contextRef="D2018Q2Apr01-Apr30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="2"
      id="d34506804e1940-wk-Fact-1176056932330F446070801F8033D073"
      unitRef="number">0.25</pfe:InvestmentOwnershipPercentage>
    <pfe:InvestmentOwnershipPercentage
      contextRef="D2018Q4Oct01-Oct31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="2"
      id="d34506804e1944-wk-Fact-D787171481B12E3FC3E7801F7E6C1F8C"
      unitRef="number">0.18</pfe:InvestmentOwnershipPercentage>
    <us-gaap:SharePrice
      contextRef="I2018Q4Oct31_dei_LegalEntityAxis_pfe_AllogeneMember"
      decimals="INF"
      id="d34506804e1948-wk-Fact-131227EE45E7CC40CFAD801F7DFFF38B"
      unitRef="usdPerShare">25</us-gaap:SharePrice>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="I2018Q2Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember"
      decimals="-6"
      id="d34506804e1962-wk-Fact-A4F674735729A9F8CD8D801F7E113FE3"
      unitRef="usd">75000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <pfe:DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue
      contextRef="D2018Q2Apr01-Apr30_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember"
      decimals="-6"
      id="d34506804e1966-wk-Fact-E306FE4D7394A9BB8A65801F7E0861F3"
      unitRef="usd">515000000</pfe:DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="FI2018Q2_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34506804e1970-wk-Fact-DF8338F8650651A27C5B801F7E226BB4"
      unitRef="usd">75000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <pfe:DisposalGroupIncludingDiscontinuedOperationMilestone
      contextRef="FD2018Q4QTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34506804e1983-wk-Fact-DE918A1FC21AD25686BB801F7DFB978A"
      unitRef="usd">10000000</pfe:DisposalGroupIncludingDiscontinuedOperationMilestone>
    <pfe:InvestmentOwnershipPercentage
      contextRef="D2018Q3Sep01-Sep30_srt_OwnershipAxis_pfe_CerevelTherapeuticsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember"
      decimals="2"
      id="d34506804e2014-wk-Fact-9780104E0674E74703FA801F7E8A9CDA"
      unitRef="number">0.25</pfe:InvestmentOwnershipPercentage>
    <pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount
      contextRef="FI2019Q4_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_NeuroscienceAssetsMember"
      decimals="-6"
      id="d34506804e2018-wk-Fact-BBAB3B97A23EB6C69499801F7E757F14"
      unitRef="usd">350000000</pfe:CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember"
      decimals="-6"
      id="d34506804e2022-wk-Fact-EC27A4D700FE4C13F119801F7DEEEE80"
      unitRef="usd">343000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="FI2019Q4_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_NeuroscienceAssetsMember"
      decimals="0"
      id="d34506804e2035-wk-Fact-1E7359DCA4D652684527801F824E86BA"
      unitRef="usd">0</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d34506804e2072-wk-Fact-78CADF80D88F5D26B975A32DFECE8696"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_dei_LegalEntityAxis_pfe_GSKMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d34506804e2076-wk-Fact-3C52A8025F775FF2941B2078743A61DB"
      unitRef="number">0.68</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34506804e2080-wk-Fact-6FB83529DF93F0640B1ECEEC0219391B"
      unitRef="usd">8100000000</us-gaap:DeconsolidationGainOrLossAmount>
    <pfe:DeconsolidationGainLossAmountNetOfTax
      contextRef="FD2019Q3QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34506804e2084-wk-Fact-C548F63688345C97AFB500E3F9AE108E"
      unitRef="usd">5400000000</pfe:DeconsolidationGainLossAmountNetOfTax>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d34506804e2093-wk-Fact-78CADF80D88F5D26B975A32DFECE8696"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <pfe:EquityMethodInvestmentsTaxIndemnificationLiability
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2100-wk-Fact-8F92B12236CC501DBD513A872742A01E"
      unitRef="usd">45000000</pfe:EquityMethodInvestmentsTaxIndemnificationLiability>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34506804e2108-wk-Fact-8C19A93F0FA83CD0C952DED514D5992B"
      unitRef="usd">17000000000.0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments
      contextRef="FD2019Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2129-wk-Fact-6964A67E8C8EEAF8CAC7DED7C4577E23"
      unitRef="usd">47000000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentsFairValueDisclosure
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34506804e2133-wk-Fact-1BCE009B4C84501F9E6F999405CD2256"
      unitRef="usd">15700000000</us-gaap:EquityMethodInvestmentsFairValueDisclosure>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d34506804e2137-wk-Fact-78CADF80D88F5D26B975A32DFECE8696"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34506804e2141-wk-Fact-8AD421AE1F909925EB9FDED2FE82D234"
      unitRef="usd">11200000000</us-gaap:EquityMethodInvestmentUnderlyingEquityInNetAssets>
    <us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34506804e2145-wk-Fact-D05BE98D05DD16B17813DED36595C9FF"
      unitRef="usd">4500000000</us-gaap:EquityMethodInvestmentDifferenceBetweenCarryingAmountAndUnderlyingEquity>
    <pfe:EquityMethodInvestmentExcessBasisAmortization
      contextRef="FD2019Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34506804e2154-wk-Fact-57E21065191F2530367EDEDE0DF1A6DD"
      unitRef="usd">31000000</pfe:EquityMethodInvestmentExcessBasisAmortization>
    <pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      id="d34506804e2158-wk-Fact-1C54400B4B1EC34C1F20DEE22A08B149">P17Y</pfe:EquityMethodInvestmentExcessBasisAmortizationPeriod>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2019Q3Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="2"
      id="d34506804e2169-wk-Fact-78CADF80D88F5D26B975A32DFECE8696"
      unitRef="number">0.32</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <pfe:EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm
      contextRef="D2019Q3Jul31-Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      id="d34506804e2185-wk-Fact-0A6EA1E5982E52838384E83BEDB387B3">P24M</pfe:EquityMethodInvestmentsTransitionalAgreementAdministrativeServicesTerm>
    <pfe:EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm
      contextRef="D2019Q3Jul31-Jul31_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      id="d34506804e2189-wk-Fact-1E66E90486245B569877E206170888A1">P6Y</pfe:EquityMethodInvestmentsTransitionalAgreementManufactureandSupplyTerm>
    <us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CFF910E2FF62DCB0AC97801F83031BD3-0-wk-Fact-9CD41D024D01F6EA1B85801F7E8C51C5">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:84%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Assets Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Trade accounts receivable, less allowance for doubtful accounts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;538&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PP&amp;amp;E&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Identifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Goodwill&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,972&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total Consumer Healthcare assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,678&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other assets held for sale&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Assets held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Liabilities Held for Sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Trade accounts payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income taxes payable&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Accrued compensation and related items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension benefit obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement benefit obligations, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total Consumer Healthcare liabilities held for sale&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other assets held for sale consist of PP&amp;amp;E.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2317-wk-Fact-45112D3279E857839DEC7A6FBF8A4B78"
      unitRef="usd">32000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationCashAndCashEquivalents>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2337-wk-Fact-0FEB8933B5BF5F038DDD2C4EE723E66F"
      unitRef="usd">532000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsNotesAndLoansReceivableNet>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2362-wk-Fact-173058331C9451B68EE04F3C60505868"
      unitRef="usd">538000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationInventoryCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2387-wk-Fact-FB04B98A18A05FB98DF48C6E99CA5C09"
      unitRef="usd">56000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2412-wk-Fact-AAD1939A887656679721C6629EC48F41"
      unitRef="usd">675000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPropertyPlantAndEquipmentNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2437-wk-Fact-94487BCDA5AF5703A087551E0D441E3E"
      unitRef="usd">5763000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationIntangibleAssetsNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2462-wk-Fact-9941E434A8F95432B56195B857FA97F5"
      unitRef="usd">1972000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationGoodwill1>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2487-wk-Fact-63D8CE1AFEFE56B4B678B86104AABD73"
      unitRef="usd">54000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxAssets>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2513-wk-Fact-11FA7057DB795D3DA296405EBB97C4FB"
      unitRef="usd">57000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2538-wk-Fact-2C2C66055C2174B78ED9CEAD4E815BF7"
      unitRef="usd">9678000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"
      decimals="-6"
      id="d34506804e2565-wk-Fact-9148FA2E247D578D82EBB7DE0DEF4259"
      unitRef="usd">46000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherAssets>
    <us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember"
      decimals="-6"
      id="d34506804e2595-wk-Fact-7F0F129B1B105287B103012D369F6DD3"
      unitRef="usd">9725000000</us-gaap:AssetsOfDisposalGroupIncludingDiscontinuedOperation>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2698-wk-Fact-6B62E8B0F9115522987359E688076CAE"
      unitRef="usd">406000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccountsPayableCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2718-wk-Fact-B895AF3FE19B55038A7E4C5E91E7EF8D"
      unitRef="usd">39000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedIncomeTaxesPayable>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2743-wk-Fact-80F1C64966CE5CBAB434F7BBED0C0160"
      unitRef="usd">93000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationAccruedLiabilitiesCurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2768-wk-Fact-F4FFE05A62A25EF8A58AD8835551D87A"
      unitRef="usd">353000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherCurrentLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2794-wk-Fact-48035F8355055AC093FF574AFC27018B"
      unitRef="usd">39000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPensionPlanBenefitObligationNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2819-wk-Fact-0FA16478D17F5FA58D1B86939B9FD680"
      unitRef="usd">33000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationPostretirementPlanBenefitObligationNoncurrent>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2844-wk-Fact-5011C87A900F507FB10ED767D3DE03FD"
      unitRef="usd">870000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationDeferredTaxLiabilities>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2869-wk-Fact-0AF07267B277A8D732FC801F820FE6DA"
      unitRef="usd">56000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationOtherNoncurrentLiabilities>
    <us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2899-wk-Fact-4C3A29DAD8215858A7BE8022585EBBDD"
      unitRef="usd">1890000000</us-gaap:LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation>
    <pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss
      contextRef="D2019Q3Jan1-Jul31_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2924-wk-Fact-65723A0397095AF7B007D658D8B043F9"
      unitRef="usd">654000000</pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss>
    <pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss
      contextRef="FD2018Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2932-wk-Fact-2D6A9470E011FF868CCACF28171D66E1"
      unitRef="usd">977000000</pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss>
    <pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss
      contextRef="FD2017Q4YTD_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e2936-wk-Fact-7FE1760824C493E1DA90CF287A95D063"
      unitRef="usd">863000000</pfe:DisposalGroupNotDiscontinuedOperationPretaxIncomeLoss>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3023-wk-Fact-7CC19C48EE82EF102ECFD80D7DFCC80F"
      unitRef="usd">7505000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3043-wk-Fact-FF1986FCBEF78493C07ED80D980A3DFE"
      unitRef="usd">38575000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3073-wk-Fact-14D2C87FE29379F24D27D80DAF1B2820"
      unitRef="usd">46081000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3124-wk-Fact-5471ABE4F754CAED1DBCD80DE237C53C"
      unitRef="usd">5241000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3144-wk-Fact-4589C988E38A86D5D306D80DFE377500"
      unitRef="usd">5536000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3174-wk-Fact-8E7C13B0B160B2DCD949D80E247CB8D8"
      unitRef="usd">10776000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3225-wk-Fact-A9EADF74E4566B7583BFD80E6E636780"
      unitRef="usd">35199000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3246-wk-Fact-45D5C27D308DA4ADE116D80E8409C05D"
      unitRef="usd">105000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity
      contextRef="I2019Q4Sep30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3276-wk-Fact-296C4C8626AE7E2AAAABD80EA14B01CF"
      unitRef="usd">35304000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue
      contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3345-wk-Fact-EC0687894B328D5FDE1ED81F5AE06EB0"
      unitRef="usd">2161000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales
      contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3365-wk-Fact-2C2A9C5544FC02D16741D81F91A04579"
      unitRef="usd">803000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss
      contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3396-wk-Fact-40021FBA838260F57A3DD8226C21BD73"
      unitRef="usd">1358000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
      contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3416-wk-Fact-176941966F2340DD8BA0D822EDE82CB0"
      unitRef="usd">152000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
      contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3441-wk-Fact-ED961F99F0225534B213D8234BF734E1"
      unitRef="usd">152000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>
    <pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders
      contextRef="D2019Q3Aug1-Sep29_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34506804e3466-wk-Fact-5DB361186A428AEBE921D824E9777C48"
      unitRef="usd">148000000</pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="3"
      id="d34506804e3489-wk-Fact-3607A4CEBF721D5C1C601702F5A24ED3"
      unitRef="number">0.117</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2016Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="INF"
      id="d34506804e3493-wk-Fact-01F30C5C613FDA5BECF317075137F7FB"
      unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3501-wk-Fact-293451C69DA75DC8A70D7BAEFB4F73E3"
      unitRef="usd">220000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3510-wk-Fact-99E3F4A21F825B05BD4E31F27E393D8A"
      unitRef="usd">253000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3518-wk-Fact-D2DD3479116FE8BE100C801F82405EAA"
      unitRef="usd">266000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:EquityMethodInvestmentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-AA13452F640F2A4402C116FD0A41F93E-0-wk-Fact-FE58EF29FF0F2323205716FD25000C0C">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Summarized financial information for our equity method investee, ViiV, as of December 31, 2019 and 2018 and for the years ending December 31, 2019, 2018, and 2017 is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,839&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,904&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,765&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total net equity/(deficit) attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,489&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,139&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Gross profit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,757&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,867&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the two months ending September 30, 2019, the most recent period available, is as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;September 30, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,505&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38,575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;46,081&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,536&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;10,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35,199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total net equity&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="5"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:77%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For the Two Months Ending&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;September 30,&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net Sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,161&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Gross profit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income attributable to shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:EquityMethodInvestmentsTextBlock>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3700-wk-Fact-756E779A50B370D76DDB17048C17AF4D"
      unitRef="usd">3839000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3719-wk-Fact-9E1F570561A13A098D9F17019FFED5C9"
      unitRef="usd">3381000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3739-wk-Fact-AC975EB9AFA734FABE4A170491C627A3"
      unitRef="usd">3437000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3758-wk-Fact-ED221A0040813B89CAD31701A3FCDB29"
      unitRef="usd">3664000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3783-wk-Fact-2674DC1C3C6EAE76FD6E17049763BF13"
      unitRef="usd">7276000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3802-wk-Fact-3BA48703B0F912F98C671701A7FE6627"
      unitRef="usd">7045000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationAssets>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3873-wk-Fact-9C99815A057E3FD3227F17049EDF92AF"
      unitRef="usd">2904000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3892-wk-Fact-FA264AF25D5B00E43CFD1701AEB132B6"
      unitRef="usd">2725000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3917-wk-Fact-93A2DF9C04EC633F956A1704A2FB5768"
      unitRef="usd">5860000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3936-wk-Fact-34A2A0583B59667107A01701B294ADC6"
      unitRef="usd">6636000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3961-wk-Fact-4C0B5B4AB6CF615CA4AD1704A777122F"
      unitRef="usd">8765000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e3980-wk-Fact-BBC3C1448ACF2E0C87C71701B84357DA"
      unitRef="usd">9361000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationLiabilities>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital
      contextRef="FI2019Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4057-wk-Fact-5FC46DA6CCE6729429741704AD797643"
      unitRef="usd">-1489000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital
      contextRef="FI2018Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4077-wk-Fact-A80EDE2381E30C74A3291703F2382BEC"
      unitRef="usd">-2316000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4254-wk-Fact-534B074DAAB21D5BBD311700E6A35248"
      unitRef="usd">6139000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4273-wk-Fact-65EB10A98B6EF978CBA417009361701B"
      unitRef="usd">6219000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4293-wk-Fact-51E80473A79DC3AEFF3916FFA4767128"
      unitRef="usd">5504000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationRevenue>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4313-wk-Fact-B3C718AB997933CABE3E1700EA8821BA"
      unitRef="usd">516000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4333-wk-Fact-E529F0FAE9E040BCD11B170097D4BBC5"
      unitRef="usd">462000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4353-wk-Fact-12078C1B08741A95310116FFA8556F82"
      unitRef="usd">381000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationCostOfSales>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4385-wk-Fact-060A22E35788DEEAED791700F090CB0B"
      unitRef="usd">5623000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4404-wk-Fact-2B2F44F13A84524A863C17009E7A26C6"
      unitRef="usd">5757000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4424-wk-Fact-7ED1E954F2F455B2E4A616FFAE39BAF4"
      unitRef="usd">5123000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4444-wk-Fact-F7CC2FD80B2F9B0AB9721700F623B56B"
      unitRef="usd">3398000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4463-wk-Fact-BF97D05D87738B5EAB081700A4AC907B"
      unitRef="usd">2154000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4482-wk-Fact-163253688A67DD27138116FFB21E50F9"
      unitRef="usd">1867000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4508-wk-Fact-675520A1617915B3943F1700FAC4B07D"
      unitRef="usd">3398000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4527-wk-Fact-23040D64DF6C7026C0B21700A923E996"
      unitRef="usd">2154000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4546-wk-Fact-4FF53142A8833EEDCA3016FFB68822E1"
      unitRef="usd">1867000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss>
    <pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4572-wk-Fact-3A5C5B9B69F71A5515501700FFD9F945"
      unitRef="usd">3398000000</pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders>
    <pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4591-wk-Fact-1E62924188C9559A3A2C1700AF9B134F"
      unitRef="usd">2154000000</pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders>
    <pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34506804e4610-wk-Fact-CB5AB588B9E6BE19EBBC16FFBA195258"
      unitRef="usd">1867000000</pfe:EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders>
    <us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity
      contextRef="FI2012Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d34506804e4632-wk-Fact-A69AB67901B1693A06EE801F824F24D4"
      unitRef="usd">250000000</us-gaap:EquityMethodInvestmentSummarizedFinancialInformationEquity>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2012Q3_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-5"
      id="d34506804e4636-wk-Fact-F33B79E8146797F6C84C801F7DF69ED7"
      unitRef="usd">122500000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q4Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="2"
      id="d34506804e4645-wk-Fact-D463C701915DC8589776801F7E38E976"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q4Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="2"
      id="d34506804e4661-wk-Fact-D463C701915DC8589776801F7E38E976"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:ProceedsFromSaleOfEquityMethodInvestments
      contextRef="D2017Q4Nov10-Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d34506804e4665-wk-Fact-FAF0A0AA15AB0F567459801F7FAE3EA9"
      unitRef="usd">286000000</us-gaap:ProceedsFromSaleOfEquityMethodInvestments>
    <us-gaap:EquityMethodInvestmentSoldCarryingAmount
      contextRef="D2017Q4Nov10-Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d34506804e4669-wk-Fact-38BA9FA67C5A095962A7801F7E23083D"
      unitRef="usd">270000000</us-gaap:EquityMethodInvestmentSoldCarryingAmount>
    <pfe:EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax
      contextRef="D2017Q4Nov10-Nov10_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d34506804e4673-wk-Fact-689DB61425FC2EB1D2B2801F824B9C9E"
      unitRef="usd">16000000</pfe:EquityMethodInvestmentsProceedsFromSaleUsedToCoverTransactionTax>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="FD2017Q4QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d34506804e4677-wk-Fact-CB0BFC52281CFB30A9D4801F7DF61F42"
      unitRef="usd">-81000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q2Jun30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34506804e4689-wk-Fact-A9A6F91B231257800749801F80B22D2E"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q2Jun30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34506804e4693-wk-Fact-A9A6F91B231257800749801F80B22D2E"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34506804e4697-wk-Fact-E218FFA8B1BEC0935D45801F7EB5152A"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34506804e4701-wk-Fact-E218FFA8B1BEC0935D45801F7EB5152A"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="FD2017Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="-6"
      id="d34506804e4705-wk-Fact-EFB9DE03407E9EBADAF5801F7E04ABC8"
      unitRef="usd">-30000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34506804e4718-wk-Fact-E218FFA8B1BEC0935D45801F7EB5152A"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <pfe:PaymentForLicensingArrangement
      contextRef="FD2019Q4QTD_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4731-wk-Fact-820E4481EA1BBFE4406DCDC046424C7F"
      unitRef="usd">250000000</pfe:PaymentForLicensingArrangement>
    <pfe:PaymentForLicensingArrangement
      contextRef="FD2019Q4QTD_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4739-wk-Fact-820E4481EA1BBFE4406DCDC046424C7F"
      unitRef="usd">250000000</pfe:PaymentForLicensingArrangement>
    <pfe:LicensingArrangementMilestoneMaximumValue
      contextRef="D2019Q4Nov1-30_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-8"
      id="d34506804e4743-wk-Fact-1AA439CC811F2AA27273CF41187095B1"
      unitRef="usd">1300000000</pfe:LicensingArrangementMilestoneMaximumValue>
    <pfe:ProceedsFromLicensingArrangement
      contextRef="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4753-wk-Fact-5C2CDA321DC50E528ED2801F7EB34AB0"
      unitRef="usd">90000000</pfe:ProceedsFromLicensingArrangement>
    <pfe:LicensingArrangementMilestoneMaximumValue
      contextRef="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4757-wk-Fact-C79D4C2F20F407BD31DE801F8251BB2B"
      unitRef="usd">460000000</pfe:LicensingArrangementMilestoneMaximumValue>
    <pfe:ProceedsFromLicensingArrangement
      contextRef="FD2016Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4761-wk-Fact-5C2CDA321DC50E528ED2801F7EB34AB0"
      unitRef="usd">90000000</pfe:ProceedsFromLicensingArrangement>
    <pfe:ProceedsFromLicensingArrangement
      contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4769-wk-Fact-9B02DFA06D6C407B8EBA801F7DF39CFD"
      unitRef="usd">75000000</pfe:ProceedsFromLicensingArrangement>
    <pfe:ProceedsFromLicensingArrangement
      contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4778-wk-Fact-6B9F402AA8B68FB924E1801F7DF7B11B"
      unitRef="usd">35000000</pfe:ProceedsFromLicensingArrangement>
    <pfe:PaymentForLicensingArrangement
      contextRef="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4797-wk-Fact-8C08BEB8EA9DA92FF080801F7E02D8C3"
      unitRef="usd">50000000</pfe:PaymentForLicensingArrangement>
    <pfe:LicensingArrangementMilestoneMaximumValue
      contextRef="D2018Q3Sep01-Sep30_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4805-wk-Fact-075CF4B1A5E59C280D9C801F7DFC6B78"
      unitRef="usd">325000000</pfe:LicensingArrangementMilestoneMaximumValue>
    <pfe:LicensingArrangementNumberOfSharesPurchased
      contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="INF"
      id="d34506804e4809-wk-Fact-D3DF515F4556BD3C6160801F7E05E6FB"
      unitRef="shares">169670</pfe:LicensingArrangementNumberOfSharesPurchased>
    <pfe:LicensingArrangementValueOfSharesPurchased
      contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_BionTechMember_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34506804e4813-wk-Fact-2F12672D61E0D4EA57ED801F7DE6DA39"
      unitRef="usd">50000000</pfe:LicensingArrangementValueOfSharesPurchased>
    <pfe:ResearchandDevelopmentArrangementMaximumFundingAmount
      contextRef="D2016Q2Apr01-Apr30_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member"
      decimals="INF"
      id="d34506804e4842-wk-Fact-95D2F3BC71A15123ABC280C6AB1F298C"
      unitRef="usd">200000000</pfe:ResearchandDevelopmentArrangementMaximumFundingAmount>
    <pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed
      contextRef="D2016Q2Apr01-Apr30_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member"
      decimals="INF"
      id="d34506804e4850-wk-Fact-D0A58E872FDE52CE99EF49E0F224B3E7"
      unitRef="number">1</pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed>
    <pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member"
      decimals="-6"
      id="d34506804e4869-wk-Fact-50241778B655BF8E4796CF4DD205C66A"
      unitRef="usd">24000000</pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred>
    <pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member"
      decimals="-6"
      id="d34506804e4873-wk-Fact-DCDCB6F3FC9A522970E8801F7E0063AC"
      unitRef="usd">58000000</pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred>
    <pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred
      contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member"
      decimals="-6"
      id="d34506804e4877-wk-Fact-BE6EF9680988B352E583801F8024A94F"
      unitRef="usd">72000000</pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred>
    <pfe:Chargeprimarilyforinventorymanufacturedforexpectedfuturesale
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member"
      decimals="-6"
      id="d34506804e4889-wk-Fact-19106036A66C5E329303022952750D15"
      unitRef="usd">99000000</pfe:Chargeprimarilyforinventorymanufacturedforexpectedfuturesale>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member"
      decimals="-6"
      id="d34506804e4906-wk-Fact-B21500386AC65000A800D0268E9F0B2F"
      unitRef="usd">15000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <pfe:ResearchandDevelopmentArrangementMaximumFundingAmount
      contextRef="D2016Q1Jan2016_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember"
      decimals="INF"
      id="d34506804e4922-wk-Fact-2755488F3B1EC974F719801F7E077AE7"
      unitRef="usd">300000000</pfe:ResearchandDevelopmentArrangementMaximumFundingAmount>
    <pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed
      contextRef="D2016Q1Jan2016_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember"
      decimals="INF"
      id="d34506804e4930-wk-Fact-4F996FA8CF4E161995BD801F824D0ECB"
      unitRef="number">1</pfe:ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed>
    <pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember"
      decimals="-6"
      id="d34506804e4947-wk-Fact-448FF7439D9960ADF98BCF5125A3910B"
      unitRef="usd">63000000</pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred>
    <pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember"
      decimals="-6"
      id="d34506804e4956-wk-Fact-60CF78C302DFD56BDE20801F7E67965D"
      unitRef="usd">99000000</pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred>
    <pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred
      contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember"
      decimals="-6"
      id="d34506804e4964-wk-Fact-42F43048CF5DCD2BFACA801F7E94A1D2"
      unitRef="usd">76000000</pfe:ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred>
    <pfe:ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure
      contextRef="D2016Q1Jan2016_srt_CounterpartyNameAxis_pfe_RPIFinanceTrustMember"
      decimals="-6"
      id="d34506804e4977-wk-Fact-F01BFC5AF4E17BD39321801F7E1C31D1"
      unitRef="usd">250000000</pfe:ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure>
    <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0CD3AB4C217E2BDA80FB801F8303CE8E-0-wk-Fact-41677BE726F33E38899D801F7E148CA9">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;Revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;664&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenue&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;s&#x2014;Alliance revenues&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total revenues from collaborative arrangements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,409&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,533&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;222&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other income/(deductions)&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;362&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Represents sales to our partners of products manufactured by us.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in each of the periods presented reflect increases in alliance revenues from Eliquis and Xtandi.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$15 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. There were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;no&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; upfront and milestone payments in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Our collaboration with Lilly (see below) also includes reimbursements of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$67 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$98 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$147 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily relates to royalties from our collaboration partners. &lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5247-wk-Fact-B43EBF08C38CF8025BE1801F81E33B35"
      unitRef="usd">664000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5266-wk-Fact-A63F83E6394508389223801F8216DDFD"
      unitRef="usd">571000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_us-gaap_ProductMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5286-wk-Fact-44258E2A7EC67FA448C2801F81E421B4"
      unitRef="usd">606000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5310-wk-Fact-A6CC259B83A6C2A0E036801F81DB019C"
      unitRef="usd">4648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5329-wk-Fact-F887DA1F92BAA8B8385A801F81DC8EFC"
      unitRef="usd">3838000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CopromotionMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5348-wk-Fact-ECECA9DC935CC99E3524801F82146F62"
      unitRef="usd">2927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5379-wk-Fact-1AD4FC7E6C5F6201A8F9801F81DE0A32"
      unitRef="usd">5313000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5398-wk-Fact-11F06651487134351FBA801F81E22087"
      unitRef="usd">4409000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5418-wk-Fact-1839921A9C96AE08AAC2801F8213BA92"
      unitRef="usd">3533000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5445-wk-Fact-16DA44395D73061538E3801F81E5A68D"
      unitRef="usd">351000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5465-wk-Fact-A161DD024D9F78FE3297801F82161F7E"
      unitRef="usd">296000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5486-wk-Fact-E188FF1B79A2458CF37A801F81E69759"
      unitRef="usd">329000000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5509-wk-Fact-81475F9812C2036C8F54801F821721D4"
      unitRef="usd">173000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5529-wk-Fact-3E8F06EF234D88E987EF801F821B72E3"
      unitRef="usd">90000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5549-wk-Fact-55FAF1E14383FE9A5716801F81DC7AAF"
      unitRef="usd">54000000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5578-wk-Fact-FA33375103F0D9AB7DC6801F81DED8EA"
      unitRef="usd">99000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5597-wk-Fact-868049DF95AAA71CE427801F81DEE776"
      unitRef="usd">162000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5616-wk-Fact-52CE05D4D58AA63DFD75801F8215C3D3"
      unitRef="usd">222000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5644-wk-Fact-725EA7A18943A5F5A993801F8216D9F7"
      unitRef="usd">362000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5663-wk-Fact-C89921B0CDF57E82D509801F81DD2CD9"
      unitRef="usd">281000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5682-wk-Fact-95B614941C4A9D8BE504801F81DF6C76"
      unitRef="usd">249000000</us-gaap:OtherNonoperatingIncomeExpense>
    <pfe:CollaborativeArrangementUpfrontAndMilestonePayments
      contextRef="FD2018Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5796-wk-Fact-F931C5FC13CE7B1730D4801F7E158B86"
      unitRef="usd">50000000</pfe:CollaborativeArrangementUpfrontAndMilestonePayments>
    <pfe:CollaborativeArrangementUpfrontAndMilestonePayments
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5804-wk-Fact-C208ABE0944AC41B18BE801F7E926471"
      unitRef="usd">15000000</pfe:CollaborativeArrangementUpfrontAndMilestonePayments>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5824-wk-Fact-4459DCA7DE631BFB2D7D801F803878A3"
      unitRef="usd">67000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5832-wk-Fact-3EF8A54A3B4DC8EBB7BE801F7EAA0046"
      unitRef="usd">98000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5841-wk-Fact-13D2E85B97ABBA3D8A1C801F7E310712"
      unitRef="usd">147000000</us-gaap:ProceedsFromCollaborators>
    <pfe:PrepaymentsandPaymentstoCollaborators
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5891-wk-Fact-E6464EADDEED74D5E50D801F7E79FC67"
      unitRef="usd">80000000</pfe:PrepaymentsandPaymentstoCollaborators>
    <pfe:PrepaymentsandPaymentstoCollaborators
      contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5899-wk-Fact-C6F667B7E72C2EE962DACF542D0F85F7"
      unitRef="usd">140000000</pfe:PrepaymentsandPaymentstoCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5920-wk-Fact-5835DC1A6A915225A9600FFCFE38DEB7"
      unitRef="usd">78000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5940-wk-Fact-6F4495CFCE1DF91F84C7801F7E10B364"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5948-wk-Fact-B163B6E925A72E83E353801F7E1248A8"
      unitRef="usd">150000000</us-gaap:ProceedsFromCollaborators>
    <pfe:CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="2"
      id="d34506804e5969-wk-Fact-A038863CC52D0D3FE3E9801F7E453EE9"
      unitRef="number">0.60</pfe:CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage>
    <pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="2"
      id="d34506804e5973-wk-Fact-B2D96210B463227E337F801F824F3A11"
      unitRef="number">0.40</pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage>
    <pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="2"
      id="d34506804e5977-wk-Fact-B2D96210B463227E337F801F824F3A11"
      unitRef="number">0.40</pfe:CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2017Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e5988-wk-Fact-E8A8A1B02F5E6446CF60801F7E175019"
      unitRef="usd">90000000</us-gaap:ProceedsFromCollaborators>
    <pfe:CollaborativeArrangementMilestonePaymentReceivable
      contextRef="FI2017Q4_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6000-wk-Fact-93A9FCCAB5CDC404537D801F7E7AA5B9"
      unitRef="usd">60000000</pfe:CollaborativeArrangementMilestonePaymentReceivable>
    <pfe:CollaborativeArrangementDeferredMilestonePayment
      contextRef="FI2017Q4_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6005-wk-Fact-EC4A9E54B7BAF8048F75801F7E4A07C4"
      unitRef="usd">60000000</pfe:CollaborativeArrangementDeferredMilestonePayment>
    <pfe:CollaborativeArrangementMilestonePaymentReceivable
      contextRef="FI2018Q1_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6013-wk-Fact-CEECCA4D7D7866D636BF801F7E3379BD"
      unitRef="usd">40000000</pfe:CollaborativeArrangementMilestonePaymentReceivable>
    <pfe:CollaborativeArrangementDeferredMilestonePayment
      contextRef="FI2018Q1_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6025-wk-Fact-3BDA3AA292AFCFEA0BF1801F7FFA828D"
      unitRef="usd">60000000</pfe:CollaborativeArrangementDeferredMilestonePayment>
    <pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized
      contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6030-wk-Fact-FC8128034C8C3B9D8145801F7E41D02C"
      unitRef="usd">85000000</pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized>
    <pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized
      contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6034-wk-Fact-D1271CABBF13B1912B13801F80802437"
      unitRef="usd">90000000</pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2013Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_BalanceSheetLocationAxis_pfe_DeferredRevenueMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6050-wk-Fact-A7DF59A2823657DD7E8D801F807E6427"
      unitRef="usd">200000000</us-gaap:ProceedsFromCollaborators>
    <pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized
      contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201409Member_us-gaap_BalanceSheetLocationAxis_pfe_DeferredRevenueMember_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis_us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6062-wk-Fact-462950995AE174C0887E801F7DF66066"
      unitRef="usd">107000000</pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized>
    <pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_EliLillyCompanyMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6071-wk-Fact-90197255FB5636C73542801F7EAAAF7A"
      unitRef="usd">9000000</pfe:CollaborativeArrangementDeferredMilestoneRevenueRecognized>
    <pfe:CollaborativeArrangementUpfrontAndMilestonePayments
      contextRef="FD2014Q4QTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_pfe_CollaborativeArrangementUpfrontCashPaymentMember"
      decimals="-6"
      id="d34506804e6095-wk-Fact-1309562FA35D882361EB801F824C9DD7"
      unitRef="usd">850000000</pfe:CollaborativeArrangementUpfrontAndMilestonePayments>
    <pfe:CollaborativeArrangementContingentPaymentsMaximumExposure
      contextRef="FD2014Q4QTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-8"
      id="d34506804e6099-wk-Fact-7006CB4ABF913028435E801F824D60AB"
      unitRef="usd">2000000000.0</pfe:CollaborativeArrangementContingentPaymentsMaximumExposure>
    <pfe:PrepaymentsandPaymentstoCollaborators
      contextRef="FD2017Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6103-wk-Fact-C6F667B7E72C2EE962DACF542D0F85F7"
      unitRef="usd">140000000</pfe:PrepaymentsandPaymentstoCollaborators>
    <pfe:PrepaymentsandPaymentstoCollaborators
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MerckKGaAMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34506804e6216-wk-Fact-E6464EADDEED74D5E50D801F7E79FC67"
      unitRef="usd">80000000</pfe:PrepaymentsandPaymentstoCollaborators>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D3FF2B4C31C8C79644D6801F8305867E-0-wk-Fact-56C11D9BB3DA16C398EA801F815764AF">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives&lt;/span&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;amp;D, as well as groups such as information technology, shared services and corporate operations. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;2017-2019 Initiatives and Organizing for Growth&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;During 2018, we determined that at the start of our 2019 fiscal year, we would begin operating under our new commercial structure, which reorganized our operations into three businesses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharma,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;a science-based innovative medicines business; Upjohn, a global, primarily off-patent branded and generic established medicines business; and through July 31, 2019, a Consumer Healthcare business (See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 17&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). To operate effectively in this structure and position ourselves for future growth, we focused on creating a simpler, more efficient operating structure within each business as well as the functions that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new structure and combined the 2017-2019 initiatives with our Organizing for Growth initiatives to form one cohesive plan. Initiatives for the combined program included activities related to the optimization of our manufacturing plant network, the centralization of our corporate and platform functions, and the simplification and optimization of our operating business structure and functions that support them. From 2017 through December 31, 2019, we incurred approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$921 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with manufacturing optimization, approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with other activities, and have substantially completed this program.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Transforming to a More Focused Company&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;With the formation of the GSK Consumer Healthcare venture and the pending combination of Upjohn with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base as a result of both the completed Consumer Healthcare and expected Upjohn transactions.&#160;While certain direct costs have transferred or will transfer to the Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;amp;D, Manufacturing and Commercial.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We expect the costs associated with this multi-year effort to continue through 2022 and to total approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; on a pre-tax basis and approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of this to be non-cash. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs are currently in development but will include severance and benefit plan impacts, exit costs as well as associated implementation costs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Current-Period Key Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we incurred costs of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$967 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; composed of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$695 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with 2017-2019 Initiatives and Organizing for Growth, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$288 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with the integration of Array, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with the integration of Hospira, and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$87 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with the Transforming to a More Focused Company initiative, partially offset by income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$197 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, primarily due to the reversal of certain accruals upon the effective favorable settlement of a U.S. IRS audit for multiple tax years and other acquisition-related initiatives.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee terminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset impairments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Exit costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Restructuring charges&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Transaction costs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Integration costs and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:18px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;747&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,044&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net periodic benefit costs recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;recorded in our consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Implementation costs recorded in our consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;967&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The asset impairment charges for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are largely associated with cost reduction initiatives not associated with acquisitions. The asset impairment charges for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are primarily associated with abandoned assets. See (b) below for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;). In 2018, restructuring charges were primarily related to employee termination costs and asset write downs. The employee termination costs for 2019 and 2018 were primarily associated with our improvements to operational effectiveness as part of the realignment of our organizational structure, and for 2019, also includes employee termination costs associated with the Transforming to a More Focused Company initiative. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, restructuring charges were primarily associated with our acquisitions of Hospira and Medivation, partially offset by credits associated with cost-reduction and productivity initiatives not associated with acquisitions that mostly related to the reversal of previously recorded accruals for employee termination costs resulting from revisions of our severance benefit estimates. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The restructuring activities in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Biopharma (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$118 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge); Upjohn (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge); and Other (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$180 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:18px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate 2018 and 2017 restructuring charges with the new individual segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total reportable segments (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$207 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge); and Other (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$575 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge). &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:24px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total reportable segments (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$89 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; credit); and Other (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Transaction costs represent external costs for banking, legal, accounting and other similar services. In 2019, transaction costs relate to our acquisition of Array. In 2017, transaction costs were directly related to our acquisitions of Hospira, Anacor and Medivation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, integration costs and other mainly related to our acquisitions of Array (including &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$157 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;)) and Hospira. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, integration costs and other mostly related to our acquisition of Hospira. In 2017, integration costs primarily related to our acquisitions of Hospira and Medivation, as well as a net gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 11&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2018, primarily represents the net pension curtailments and settlements included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;upon the adoption of a new accounting standard in the first quarter of 2018. In 2017, mainly represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 11&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of and changes in our restructuring accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Exit Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Accrual&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, January 1, 2018 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,039&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Utilization and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Provision&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Utilization and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(555&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$823 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$428 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other current liabilities &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$714 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$219 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_ManufacturingOptimizationMember_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember"
      decimals="-6"
      id="d34468079e1345-wk-Fact-24F95B4A48115E7D9824550A385C7315"
      unitRef="usd">921000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostCostIncurredToDate1
      contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_OtherActivitiesMember_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember"
      decimals="-8"
      id="d34468079e1349-wk-Fact-7F89C5B8FBA256B399D166B53D1171C4"
      unitRef="usd">1200000000</us-gaap:RestructuringAndRelatedCostCostIncurredToDate1>
    <us-gaap:RestructuringAndRelatedCostExpectedCost1
      contextRef="FI2019Q4_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember"
      decimals="-8"
      id="d34468079e1362-wk-Fact-D7AE96CB42E95D9285D30E8FF3BF0F06"
      unitRef="usd">1400000000</us-gaap:RestructuringAndRelatedCostExpectedCost1>
    <pfe:RestructuringandRelatedCostNoncashChargesPercentage
      contextRef="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember"
      decimals="2"
      id="d34468079e1366-wk-Fact-EF31A94230125A87BF09B55A8734C3FA"
      unitRef="number">0.10</pfe:RestructuringandRelatedCostNoncashChargesPercentage>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e1381-wk-Fact-F0744E01A0FB5DFEA7D16C346630F69E"
      unitRef="usd">967000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_TwentySeventeenThroughTwentyNineteenInitiativesAndOrganizingForGrowthMember"
      decimals="-6"
      id="d34468079e1385-wk-Fact-EAF9566A792158DBB4D8F5DB6EAC565F"
      unitRef="usd">695000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember"
      decimals="-6"
      id="d34468079e1389-wk-Fact-D366DE5A260059998E345C38D8B662E8"
      unitRef="usd">288000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember"
      decimals="-6"
      id="d34468079e1393-wk-Fact-1AEBA4704C0C536D87CF3B46F4055CD6"
      unitRef="usd">94000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q4YTD_us-gaap_RestructuringPlanAxis_pfe_FocusedCompanyPlanMember"
      decimals="-6"
      id="d34468079e1398-wk-Fact-C827156933C6D7E41FB1DF3BC04EEF1B"
      unitRef="usd">87000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:RestructuringAndRelatedCostIncurredCost
      contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_BusinessIntegrationCostsMember"
      decimals="-6"
      id="d34468079e1402-wk-Fact-885B1F7F683852998AAB24877643C16E"
      unitRef="usd">-197000000</us-gaap:RestructuringAndRelatedCostIncurredCost>
    <us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C4E60A7004F00BD70FBB801F8306C89A-0-wk-Fact-A5D8D9B6A624D074088B801F7F501A00">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Restructuring charges/(credits):&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee terminations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset impairments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Exit costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Restructuring charges&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Transaction costs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Integration costs and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:18px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;747&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,044&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net periodic benefit costs recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;recorded in our consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total additional depreciation&#x2013;&#x2013;asset restructuring&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Implementation costs recorded in our consolidated statements of income as follows&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:24px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total implementation costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total costs associated with acquisitions and cost-reduction/productivity initiatives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;967&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;805&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The asset impairment charges for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are largely associated with cost reduction initiatives not associated with acquisitions. The asset impairment charges for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are primarily associated with abandoned assets. See (b) below for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;). In 2018, restructuring charges were primarily related to employee termination costs and asset write downs. The employee termination costs for 2019 and 2018 were primarily associated with our improvements to operational effectiveness as part of the realignment of our organizational structure, and for 2019, also includes employee termination costs associated with the Transforming to a More Focused Company initiative. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, restructuring charges were primarily associated with our acquisitions of Hospira and Medivation, partially offset by credits associated with cost-reduction and productivity initiatives not associated with acquisitions that mostly related to the reversal of previously recorded accruals for employee termination costs resulting from revisions of our severance benefit estimates. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The restructuring activities in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Biopharma (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$118 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge); Upjohn (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge); and Other (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$180 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:18px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate 2018 and 2017 restructuring charges with the new individual segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total reportable segments (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$207 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge); and Other (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$575 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge). &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:24px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The restructuring activities for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:18px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total reportable segments (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$89 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; credit); and Other (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Transaction costs represent external costs for banking, legal, accounting and other similar services. In 2019, transaction costs relate to our acquisition of Array. In 2017, transaction costs were directly related to our acquisitions of Hospira, Anacor and Medivation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, integration costs and other mainly related to our acquisitions of Array (including &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$157 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;)) and Hospira. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, integration costs and other mostly related to our acquisition of Hospira. In 2017, integration costs primarily related to our acquisitions of Hospira and Medivation, as well as a net gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$12 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 11&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2018, primarily represents the net pension curtailments and settlements included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;upon the adoption of a new accounting standard in the first quarter of 2018. In 2017, mainly represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 11&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringAndRelatedCostsTextBlock>
    <us-gaap:SeveranceCosts1
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e1718-wk-Fact-BE908F2453EA50FA8150D8F2D27D26EA"
      unitRef="usd">239000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e1737-wk-Fact-2B433FF03CAB56B5838157F4075CF704"
      unitRef="usd">459000000</us-gaap:SeveranceCosts1>
    <us-gaap:SeveranceCosts1
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e1757-wk-Fact-C9D679DF86868316C76A801F7EAE0194"
      unitRef="usd">-181000000</us-gaap:SeveranceCosts1>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e1780-wk-Fact-1E3FF9437BEA5C5E903FC608EF1570C3"
      unitRef="usd">81000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e1799-wk-Fact-5C1105B34A8A5168A29CDA6A58BEDCE8"
      unitRef="usd">290000000</pfe:RestructuringAssetImpairmentCharges>
    <pfe:RestructuringAssetImpairmentCharges
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e1818-wk-Fact-8847B6BEC2EEE8F6B106801F81DD12BF"
      unitRef="usd">190000000</pfe:RestructuringAssetImpairmentCharges>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e1844-wk-Fact-8096B46077615DE7AF9036BAB775555D"
      unitRef="usd">53000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e1863-wk-Fact-4B798D68157055D3B944663B4AE87FE6"
      unitRef="usd">33000000</us-gaap:BusinessExitCosts1>
    <us-gaap:BusinessExitCosts1
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e1882-wk-Fact-4528BBA3F3476E752AC6801F7F2FFC8F"
      unitRef="usd">21000000</us-gaap:BusinessExitCosts1>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e1910-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
      unitRef="usd">373000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e1929-wk-Fact-0FFA20352D33594482BE61F2516C104D"
      unitRef="usd">782000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e1948-wk-Fact-7FFA047BAF9ADE9DA824801F81229B16"
      unitRef="usd">30000000</us-gaap:RestructuringCharges>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e1976-wk-Fact-1720732DC86856B0BBAA3408390B34EC"
      unitRef="usd">63000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e1995-wk-Fact-5C6CEA6ACFCD5D859F39208DA973ACEC"
      unitRef="usd">1000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e2014-wk-Fact-09785B23D3307BE69A79801F8181F4E8"
      unitRef="usd">4000000</pfe:BusinessCombinationAcquisitionRelatedCostsTransactionCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e2042-wk-Fact-559668800F8D5F39871CB0D8FAB473CD"
      unitRef="usd">311000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e2061-wk-Fact-D8F202BB5B6A5B28A9A31C0EB79F405E"
      unitRef="usd">260000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <us-gaap:BusinessCombinationIntegrationRelatedCosts
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e2080-wk-Fact-CBD997DC56489F4D822B801F818B8507"
      unitRef="usd">317000000</us-gaap:BusinessCombinationIntegrationRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e2106-wk-Fact-61EEF037EA245BC58651F6491A13B057"
      unitRef="usd">747000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e2125-wk-Fact-20A55537F0675518894025A232665AAA"
      unitRef="usd">1044000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <pfe:RestructuringChargesAndAcquisitionRelatedCosts
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e2144-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409"
      unitRef="usd">351000000</pfe:RestructuringChargesAndAcquisitionRelatedCosts>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34468079e2175-wk-Fact-F6552983FEE057A7B0758F714B47B201"
      unitRef="usd">23000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34468079e2194-wk-Fact-6828C32532055C2D9F9FCA7D73FE1813"
      unitRef="usd">146000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34468079e2213-wk-Fact-726DD7EC40B27F8510DA801F81EF7AF4"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34468079e2314-wk-Fact-B984EC8BD3C15978AA373038C05C04C3"
      unitRef="usd">27000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34468079e2333-wk-Fact-A80DE1A520AD557392F9597D3D60F83A"
      unitRef="usd">48000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34468079e2352-wk-Fact-48FBE878E867A2126357801F828892B1"
      unitRef="usd">91000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d34468079e2378-wk-Fact-3F54F0E033DA5F4EB9E1DB8292AC5F35"
      unitRef="usd">3000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d34468079e2397-wk-Fact-2955D81BA66657739DD6267CF9D38630"
      unitRef="usd">2000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d34468079e2416-wk-Fact-9EBE45B86EF3A4ED4BB6801F7E8624C1"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d34468079e2442-wk-Fact-00B28A85A0415720B146A31F5401E641"
      unitRef="usd">8000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d34468079e2461-wk-Fact-F2F4F04B9714562C8431CD66A86B0259"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d34468079e2480-wk-Fact-C61A53394E697A7EF8C6801F7E98760D"
      unitRef="usd">0</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e2506-wk-Fact-E1D5C5643E20593EBC9062EA4C0879C4"
      unitRef="usd">38000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e2525-wk-Fact-D3FD2148011D5F65AD0C27F9F1F55576"
      unitRef="usd">50000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <us-gaap:RestructuringReserveAcceleratedDepreciation
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e2544-wk-Fact-D1EEE24D840C1A7260A5801F823B70E3"
      unitRef="usd">91000000</us-gaap:RestructuringReserveAcceleratedDepreciation>
    <pfe:ImplementationCosts
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34468079e2641-wk-Fact-A42CFC7A5BC659D7A3189F4AF6F5EC83"
      unitRef="usd">63000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34468079e2660-wk-Fact-3B3FED2A33115ED2B476EFD5B5811F3E"
      unitRef="usd">83000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34468079e2679-wk-Fact-7A1567D519C2CFE241FC801F7EDF7AAB"
      unitRef="usd">118000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d34468079e2705-wk-Fact-56CA584C4B365E4B845856D506783484"
      unitRef="usd">73000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d34468079e2724-wk-Fact-901416E0C584524B87DD0ACFD655A517"
      unitRef="usd">72000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d34468079e2743-wk-Fact-37BB967598E60C472CDF801F80B12AD6"
      unitRef="usd">71000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d34468079e2769-wk-Fact-8E28EFA6EB215BD0993C634ED8262AFF"
      unitRef="usd">22000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d34468079e2788-wk-Fact-648F7B6A7F165EE0A40B6056F82B93C7"
      unitRef="usd">39000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember"
      decimals="-6"
      id="d34468079e2807-wk-Fact-0B920E93F75F59F63ECE801F80F39A24"
      unitRef="usd">38000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e2833-wk-Fact-7C5CEEA458045143ABEBEAB70E5E4CE1"
      unitRef="usd">158000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e2852-wk-Fact-C6ADF4DB93D254E5BD23EA5C35CC303C"
      unitRef="usd">194000000</pfe:ImplementationCosts>
    <pfe:ImplementationCosts
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e2871-wk-Fact-1F2788F8C7EAC31BDBAF801F7E00C985"
      unitRef="usd">227000000</pfe:ImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e2903-wk-Fact-A1E43A2C3B855213AF3B8554389B681D"
      unitRef="usd">967000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e2922-wk-Fact-45894ADF56F25DBEADA95E5BD8039DA0"
      unitRef="usd">1434000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34468079e2942-wk-Fact-A2D16AA3017966681D6D801F81781BDA"
      unitRef="usd">805000000</pfe:RestructuringChargesAcquisitionRelatedCostsandImplementationCosts>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34468079e2999-wk-Fact-64CF7C8E2712CFF754E8DF537C7026EE"
      unitRef="usd">118000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34468079e3003-wk-Fact-14E4EFD0594C358063DEDF53E92DE6CD"
      unitRef="usd">75000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34468079e3007-wk-Fact-83DEF9E24F2573FC1B5BDF53FCF75417"
      unitRef="usd">180000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34468079e3028-wk-Fact-364749052680DD985FE8DF57BFD46E59"
      unitRef="usd">207000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34468079e3032-wk-Fact-02CBB78F6D9F27211F2EDF584015F818"
      unitRef="usd">575000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34468079e3051-wk-Fact-AE30A8C819EF462FD6DCDF58B3545147"
      unitRef="usd">-89000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34468079e3055-wk-Fact-A71CF8F00EF366C0B730DF58EDFF80B7"
      unitRef="usd">119000000</us-gaap:RestructuringCharges>
    <us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IncomeStatementLocationAxis_pfe_RestructuringChargesAndAcquisitionRelatedCostsMember"
      decimals="-6"
      id="d34468079e3123-wk-Fact-5162BD37F8C9541ABBF3ACA81FB246B3"
      unitRef="usd">157000000</us-gaap:BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34468079e3135-wk-Fact-DABEA993F2C7DDD92BE0801F7F1190FF"
      unitRef="usd">12000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-41160BB593BAEABA27A3801F83054962-0-wk-Fact-30C4BC67732AC5FAAC2A801F8179FE0B">&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of and changes in our restructuring accruals:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Termination&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Exit Costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Accrual&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, January 1, 2018 &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,039&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Utilization and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(295&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,203&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Provision&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;239&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Utilization and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(555&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(81&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;887&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Includes adjustments for foreign currency translation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$823 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$428 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other current liabilities &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$714 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent liabilities &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$219 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestructuringReserveByTypeOfCostTextBlock>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d34468079e3461-wk-Fact-1AD523662FC594F56AF7801F7F6374E9"
      unitRef="usd">1039000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d34468079e3480-wk-Fact-A5BB74C41800892C284F801F7F6D5279"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d34468079e3500-wk-Fact-B363698564CC60A8F987801F7F83CEF8"
      unitRef="usd">66000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2017Q4"
      decimals="-6"
      id="d34468079e3519-wk-Fact-FB9F815761D4E6FE8EF6801F7F625307"
      unitRef="usd">1105000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d34468079e3539-wk-Fact-07DA85B128480ADDAA18801F7FA181C3"
      unitRef="usd">459000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d34468079e3558-wk-Fact-17DE2955CFE34577B72B801F7F7E553C"
      unitRef="usd">290000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d34468079e3577-wk-Fact-85674BF73C1723FE154B801F7F6023E6"
      unitRef="usd">33000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e3597-wk-Fact-0FFA20352D33594482BE61F2516C104D"
      unitRef="usd">782000000</us-gaap:RestructuringCharges>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d34468079e3624-wk-Fact-DDF2C025AF9CF365CD89801F7F653ACA"
      unitRef="usd">295000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d34468079e3644-wk-Fact-464A486895AEEBF8EC5F801F7FA5F9F7"
      unitRef="usd">290000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2018Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d34468079e3664-wk-Fact-0DABBE66E4D8805F212A801F7F93FAD2"
      unitRef="usd">51000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34468079e3685-wk-Fact-4EC473580DFC97201347801F7F618775"
      unitRef="usd">636000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <us-gaap:RestructuringReserve
      contextRef="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d34468079e3713-wk-Fact-8B63FA0079F150DF8891946F5AC894DF"
      unitRef="usd">1203000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d34468079e3732-wk-Fact-B9F8D9C900D35DCE8A6D80AA6FAD17C8"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2018Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d34468079e3751-wk-Fact-F2E147AA2E8654AB8038D339B5F38F4E"
      unitRef="usd">49000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34468079e3771-wk-Fact-CB5261FF2DCF567B98B84D4EEBACC61C"
      unitRef="usd">1252000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d34468079e3798-wk-Fact-5F0D40017013586D8F17BC834125A378"
      unitRef="usd">239000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d34468079e3817-wk-Fact-5D65BE3231925A3690D7162CD4FAA218"
      unitRef="usd">81000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d34468079e3836-wk-Fact-13B8F46793BB5B219C40DD3378500D40"
      unitRef="usd">53000000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e3856-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
      unitRef="usd">373000000</us-gaap:RestructuringCharges>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d34468079e3883-wk-Fact-204C8AF80ED25BDE9A77B2C926C838B9"
      unitRef="usd">555000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d34468079e3903-wk-Fact-ECAA0C7EF7645E87A5DF7782CF068255"
      unitRef="usd">81000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2019Q4YTD_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d34468079e3923-wk-Fact-942BEE47CDD75096A0AEFEFF55769ACA"
      unitRef="usd">55000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34468079e3944-wk-Fact-190D7B7514575574AE1769D904D6CA82"
      unitRef="usd">691000000</pfe:PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_EmployeeSeveranceMember"
      decimals="-6"
      id="d34468079e3977-wk-Fact-8A3D3D8306295DD7A9624AA8071C2632"
      unitRef="usd">887000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_pfe_AssetImpairmentsMember"
      decimals="-6"
      id="d34468079e3996-wk-Fact-5438260A5AB3500C8619EA7A64AD5E8B"
      unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_RestructuringCostAndReserveAxis_us-gaap_OtherRestructuringMember"
      decimals="-6"
      id="d34468079e4016-wk-Fact-34056A88C0D75E6C9FEE2D3BDD894FE8"
      unitRef="usd">46000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34468079e4035-wk-Fact-0DC222C12EB155DBBE6BAFA5807A4EE1"
      unitRef="usd">933000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d34468079e4064-wk-Fact-7AB2F2EE679D5ADC924CD773BACAE5BB"
      unitRef="usd">823000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d34468079e4072-wk-Fact-69A2DA9CA81853E1BF49E1F300B9A667"
      unitRef="usd">428000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember"
      decimals="-6"
      id="d34468079e4144-wk-Fact-6515848AB69B5943967B3AD5A80D285F"
      unitRef="usd">714000000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember"
      decimals="-6"
      id="d34468079e4152-wk-Fact-8CE5D6955AF7510A8AC5F2E039DBAF62"
      unitRef="usd">219000000</us-gaap:RestructuringReserve>
    <us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-826105A02755431DA39A801F830ED4AF-0-wk-Fact-2DFC020800236EB46466801F823B863D">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Other (Income)/Deductions&#x2014;Net&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest expense&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Royalty-related income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(499&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net gains recognized during the period on equity securities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net realized (gains)/losses on sales of investments in debt securities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(488&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net periodic benefit costs/(credits) other than service costs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain legal matters, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;395&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Business and legal entity alignment costs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;338&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net losses on early retirement of debt&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(k)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GSK Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(l)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(m)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(388&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; v. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&#x2013;Interest income decreased primarily driven by a lower investment balance. Interest expense increased mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year period. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; v. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&#x2013;Interest income decreased primarily driven by a lower investment balance. Interest expense increased primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017. Capitalized interest expense totaled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$88 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, $&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;73 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;72 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Royalty-related income &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;increased&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily due to a one-time favorable resolution in the second quarter of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of a legal dispute for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$82 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily included a realized gain on sale of property of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$60 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily included an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; realized loss related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;-owned equity-method investment in Hisun Pfizer and a realized net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership investment in Teuto, including the extinguishment of a put option for the then remaining &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership interest, partially offset by a realized gain on sale of property of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The gains in 2019 include, among other things, unrealized gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$295 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to investments in Cortexyme, Inc. and SpringWorks Therapeutics, Inc. The gains in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; included unrealized gains on equity securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$477 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, reflecting the adoption of a new accounting standard in the first quarter of 2018 and were primarily driven by unrealized gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$466 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to our investment in Allogene. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 7B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2018, primarily includes gross realized losses on sales of available-for-sale debt securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$402 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and a net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$18 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities, partially offset by gross realized gains on sales of available-for-sale debt securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$280 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Proceeds from the sale of available-for-sale debt securities were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in 2018. In 2017, primarily includes gross realized gains on sales of available-for-sale debt securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$451 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, partially offset by gross realized losses on sales of available-for-sale debt securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$281 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and a net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$120 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debt securities were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in 2017.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, mainly includes, among other things, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$78 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, a generic of Advair Diskus&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(fluticasone propionate and salmeterol inhalation powder) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone income from multiple licensees. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily includes, among other things, (i) approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$118 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone income from multiple licensees, (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$110 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone payments received from Shire, of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of ulcerative colitis and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$35 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn&#x2019;s disease, (iii) an upfront payment to us and a recognized milestone totaling &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$85 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for the sale of an AMPA receptor potentiator for CIAS to Biogen, (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$62 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in gains related to sales of compound/product rights and (v) a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B, Note 2D &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. In 2017, primarily includes, among other things, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$101 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone payments received from multiple licensees and an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$85 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; gain related to sales of compound/product rights. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2019, primarily includes settlement losses within the U.S. Pfizer Consolidated Pension Plan related to special restructuring initiatives, a small annuity buyout program and regular lump sum activity. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to 2017. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 11&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, mostly includes legal reserves for certain pending legal matters. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily includes legal reserves for certain pending legal matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In 2017, primarily includes a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which was approved by the court in April 2018, and a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$79 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge to reflect damages awarded by a jury in a patent matter.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, mainly composed of: (i) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, related to Eucrisa, a Biopharma finite-lived developed technology right acquired in connection with our acquisition of Anacor, and reflects updated commercial forecasts mainly reflecting competitive pressures; (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to WRDM IPR&amp;amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases which was the result of a determination to not use certain Bamboo IPR&amp;amp;D acquired in future rare disease development; (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions; (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$31 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to a Biopharma IPR&amp;amp;D asset, acquired in connection with our acquisition of AstraZeneca&#x2019;s anti-infectives business, which reflects updated commercial forecasts; (v) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to a Biopharma finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;U.S. market only, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;and reflects&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, among other things, updated commercial forecasts; and (vi) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of other IPR&amp;amp;D assets acquired in connection with our acquisition of Innopharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-bottom:1px;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, mainly composed of (i) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to Biopharma developed technology rights, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$242 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to Biopharma licensing agreements and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to Biopharma IPR&amp;amp;D, all of which relate to our acquisition of Hospira, for generic sterile injectable products associated with various indications; (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$117 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to a multi-antigen vaccine IPR&amp;amp;D program for adults undergoing elective spinal fusion surgery; (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$31 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to an Biopharma developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus market marketed in the U.S. market only; and (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$17 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of other IPR&amp;amp;D assets acquired in connection with our acquisition of Innopharma. In 2018, the intangible asset impairment charges associated with the generic sterile injectable products reflect, among other things, updated commercial forecasts, reflecting an increased competitive environment as well as higher manufacturing costs, largely stemming from manufacturing and supply issues. The intangible asset impairment charge for the multi-antigen vaccine IPR&amp;amp;D program was the result of the Phase 2b trial reaching futility at a pre-planned interim analysis. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;The intangible asset impairment charge related to the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Biopharma developed technology right&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt; reflects&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, among other things, updated commercial forecasts. .&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2017, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$337 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, reflecting (i) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$124 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$39 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$26 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with Biopharma and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$43 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for an impairment of our AM-Pharma B.V. long-term investment.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2019 and 2018, mainly represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In 2017, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(k)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2019 and 2017, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(l)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(m)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, includes, among other things, (i) dividend income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$220 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from our investment in ViiV, (ii) charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$152 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of income from insurance recoveries related to Hurricane Maria. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, includes, among other things, (i) a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$343 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), (ii) dividend income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from our investment in ViiV, (iii) a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain on the contribution of Pfizer&#x2019;s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained an ownership stake in Allogene (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), (iv) a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$17 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), (v) charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$207 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, reflecting the change in the fair value of contingent consideration. and (vi) charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$112 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. In 2017, includes, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$266 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from our investment in ViiV, and income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$62 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from resolution of a contract disagreement. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The asset impairment charges included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; are based on estimates of fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides additional information about the intangible assets that were impaired during 2019 in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intangible assets&#x2013;&#x2013;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1E.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects intangible assets written down to fair value in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:OtherIncomeAndOtherExpenseDisclosureTextBlock>
    <us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5DB921DE076476C9D7E1801F830E43C0-0-wk-Fact-3A7CE1EDDD2BAED269E6801F80B71CAD">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest expense&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,316&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,270&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net interest expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Royalty-related income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(499&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net (gains)/losses on asset disposals&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net gains recognized during the period on equity securities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net realized (gains)/losses on sales of investments in debt securities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from collaborations, out-licensing arrangements and sales of compound/product rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(488&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net periodic benefit costs/(credits) other than service costs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain legal matters, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;157&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain asset impairments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;395&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Business and legal entity alignment costs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;338&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net losses on early retirement of debt&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(k)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GSK Consumer Healthcare JV equity method (income)/loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(l)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(m)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(388&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(417&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(328&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,578&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; v. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&#x2013;Interest income decreased primarily driven by a lower investment balance. Interest expense increased mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year period. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; v. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&#x2013;Interest income decreased primarily driven by a lower investment balance. Interest expense increased primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017. Capitalized interest expense totaled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$88 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, $&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;73 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and $&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;72 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Royalty-related income &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;increased&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily due to a one-time favorable resolution in the second quarter of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of a legal dispute for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$82 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily included a realized gain on sale of property of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$60 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily included an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; realized loss related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;-owned equity-method investment in Hisun Pfizer and a realized net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership investment in Teuto, including the extinguishment of a put option for the then remaining &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership interest, partially offset by a realized gain on sale of property of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The gains in 2019 include, among other things, unrealized gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$295 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to investments in Cortexyme, Inc. and SpringWorks Therapeutics, Inc. The gains in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; included unrealized gains on equity securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$477 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, reflecting the adoption of a new accounting standard in the first quarter of 2018 and were primarily driven by unrealized gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$466 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to our investment in Allogene. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 7B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2018, primarily includes gross realized losses on sales of available-for-sale debt securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$402 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and a net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$18 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities, partially offset by gross realized gains on sales of available-for-sale debt securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$280 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Proceeds from the sale of available-for-sale debt securities were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in 2018. In 2017, primarily includes gross realized gains on sales of available-for-sale debt securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$451 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, partially offset by gross realized losses on sales of available-for-sale debt securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$281 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and a net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$120 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debt securities were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in 2017.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, mainly includes, among other things, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$78 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, a generic of Advair Diskus&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#xae;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(fluticasone propionate and salmeterol inhalation powder) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$52 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone income from multiple licensees. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily includes, among other things, (i) approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$118 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone income from multiple licensees, (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$110 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone payments received from Shire, of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$75 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of ulcerative colitis and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$35 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn&#x2019;s disease, (iii) an upfront payment to us and a recognized milestone totaling &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$85 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for the sale of an AMPA receptor potentiator for CIAS to Biogen, (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$62 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in gains related to sales of compound/product rights and (v) a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B, Note 2D &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. In 2017, primarily includes, among other things, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$101 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in milestone payments received from multiple licensees and an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$85 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; gain related to sales of compound/product rights. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2019, primarily includes settlement losses within the U.S. Pfizer Consolidated Pension Plan related to special restructuring initiatives, a small annuity buyout program and regular lump sum activity. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to 2017. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 11&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, mostly includes legal reserves for certain pending legal matters. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily includes legal reserves for certain pending legal matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In 2017, primarily includes a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$94 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which was approved by the court in April 2018, and a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$79 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge to reflect damages awarded by a jury in a patent matter.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, mainly composed of: (i) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, related to Eucrisa, a Biopharma finite-lived developed technology right acquired in connection with our acquisition of Anacor, and reflects updated commercial forecasts mainly reflecting competitive pressures; (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$90 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to WRDM IPR&amp;amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases which was the result of a determination to not use certain Bamboo IPR&amp;amp;D acquired in future rare disease development; (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$40 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions; (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$31 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to a Biopharma IPR&amp;amp;D asset, acquired in connection with our acquisition of AstraZeneca&#x2019;s anti-infectives business, which reflects updated commercial forecasts; (v) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to a Biopharma finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;U.S. market only, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;and reflects&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, among other things, updated commercial forecasts; and (vi) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$10 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of other IPR&amp;amp;D assets acquired in connection with our acquisition of Innopharma.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-bottom:1px;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, mainly composed of (i) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to Biopharma developed technology rights, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$242 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to Biopharma licensing agreements and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$80 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to Biopharma IPR&amp;amp;D, all of which relate to our acquisition of Hospira, for generic sterile injectable products associated with various indications; (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$117 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to a multi-antigen vaccine IPR&amp;amp;D program for adults undergoing elective spinal fusion surgery; (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$31 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to an Biopharma developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus market marketed in the U.S. market only; and (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$17 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of other IPR&amp;amp;D assets acquired in connection with our acquisition of Innopharma. In 2018, the intangible asset impairment charges associated with the generic sterile injectable products reflect, among other things, updated commercial forecasts, reflecting an increased competitive environment as well as higher manufacturing costs, largely stemming from manufacturing and supply issues. The intangible asset impairment charge for the multi-antigen vaccine IPR&amp;amp;D program was the result of the Phase 2b trial reaching futility at a pre-planned interim analysis. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;The intangible asset impairment charge related to the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Biopharma developed technology right&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt; reflects&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, among other things, updated commercial forecasts. .&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2017, primarily includes intangible asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$337 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, reflecting (i) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$127 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$124 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$39 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$26 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with Biopharma and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$43 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for an impairment of our AM-Pharma B.V. long-term investment.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2019 and 2018, mainly represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In 2017, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(k)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In 2019 and 2017, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(l)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(m)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, includes, among other things, (i) dividend income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$220 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from our investment in ViiV, (ii) charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$152 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of income from insurance recoveries related to Hurricane Maria. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, includes, among other things, (i) a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$343 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), (ii) dividend income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from our investment in ViiV, (iii) a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain on the contribution of Pfizer&#x2019;s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained an ownership stake in Allogene (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), (iv) a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$17 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 7E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), (v) charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$207 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, reflecting the change in the fair value of contingent consideration. and (vi) charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$112 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. In 2017, includes, among other things, dividend income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$266 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from our investment in ViiV, and income of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$62 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; from resolution of a contract disagreement. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfOtherNonoperatingIncomeExpenseTableTextBlock>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e1554-wk-Fact-2B2A9C8657C8CAF5F992801F80CD8F28"
      unitRef="usd">226000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e1574-wk-Fact-3C5E1456EFEB580EB0B057546407A424"
      unitRef="usd">333000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e1595-wk-Fact-3C9472B7B150D7664833801F80B066CF"
      unitRef="usd">391000000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InterestExpense
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e1618-wk-Fact-C811C044F93768A92542801F80F5DB92"
      unitRef="usd">1574000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e1637-wk-Fact-D1493B6B95195AACB13FF4316F418040"
      unitRef="usd">1316000000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e1656-wk-Fact-813E0BD933FADF623E45801F80DB191F"
      unitRef="usd">1270000000</us-gaap:InterestExpense>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e1682-wk-Fact-FA8FA8545A905408BEAE292045650881"
      unitRef="usd">-1348000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e1701-wk-Fact-9D91736F368753D8933FDDCC4EBA4F82"
      unitRef="usd">-983000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:InterestRevenueExpenseNet
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e1720-wk-Fact-2BCA4DCC54ACAAB37390801F80D172EF"
      unitRef="usd">-879000000</us-gaap:InterestRevenueExpenseNet>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e1748-wk-Fact-D46423C593ED51E19EFC3DB182C18357"
      unitRef="usd">648000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e1768-wk-Fact-6B8F488463125E46B584902709E619F5"
      unitRef="usd">495000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:RoyaltyIncomeNonoperating
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e1788-wk-Fact-E0737BFD19C0100A5FE8801F80CB7FAE"
      unitRef="usd">499000000</us-gaap:RoyaltyIncomeNonoperating>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e1817-wk-Fact-528109C6117952069FCC0A02E9E0964C"
      unitRef="usd">31000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e1837-wk-Fact-FB53920211195F4191C78C4B2EA1ECDE"
      unitRef="usd">71000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:GainLossOnDispositionOfAssets1
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e1857-wk-Fact-B712982E5A7317455650801F80ECC2E5"
      unitRef="usd">-45000000</us-gaap:GainLossOnDispositionOfAssets1>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e1885-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
      unitRef="usd">454000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e1905-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
      unitRef="usd">586000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e1925-wk-Fact-0F5337E2D08EAAB68D68801F80EB1026"
      unitRef="usd">224000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e1954-wk-Fact-BB9B4543336C561697FD0F59A7D23B67"
      unitRef="usd">0</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e1973-wk-Fact-50D8069E0C6A50D989482D5B5834E63D"
      unitRef="usd">-141000000</us-gaap:DebtSecuritiesRealizedGainLoss>
    <us-gaap:DebtSecuritiesRealizedGainLoss
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e1992-wk-Fact-0D4501C3F382F4D74FB6801F80B5B5B4"
      unitRef="usd">45000000</us-gaap:DebtSecuritiesRealizedGainLoss>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2021-wk-Fact-58D64728C9445B32B7001C141E840546"
      unitRef="usd">168000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2041-wk-Fact-D580F9F59A215E69A2F8C8CF9897A050"
      unitRef="usd">488000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2061-wk-Fact-BC2A634BA20E3AB6E549801F823C4316"
      unitRef="usd">217000000</pfe:IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2091-wk-Fact-DCBD066B5B3F57A98C5A6477D74A4C3D"
      unitRef="usd">64000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2110-wk-Fact-7A7351669AE1529E97E70E745B581A4A"
      unitRef="usd">-288000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2130-wk-Fact-11293434603BE982F98F801F80B2BCE9"
      unitRef="usd">101000000</us-gaap:NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2158-wk-Fact-19792256C9155CD4A4B30F1FFD71D2BF"
      unitRef="usd">-554000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2177-wk-Fact-8376203D932F5639A955E3156349142D"
      unitRef="usd">-157000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2196-wk-Fact-3CE8EBCFF7A37827A78B801F80EE18A9"
      unitRef="usd">-240000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2224-wk-Fact-B70F6FAB9C4E502489A9A03753771E32"
      unitRef="usd">2843000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2243-wk-Fact-31EE472AE3C7503BA361B44F0445BA6E"
      unitRef="usd">3115000000</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2262-wk-Fact-F2F93F5F2FC3C51352FB801F80F4AFFE"
      unitRef="usd">395000000</us-gaap:AssetImpairmentCharges>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2290-wk-Fact-372575356B8E57CCAFE65ACA01B572B8"
      unitRef="usd">338000000</pfe:BusinessAlignmentCosts>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2309-wk-Fact-274A4E3678CE5C1E9A3DE2C7A5DF6A4D"
      unitRef="usd">63000000</pfe:BusinessAlignmentCosts>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2328-wk-Fact-6D614FEC811C0CB49DA6801F823ECDD2"
      unitRef="usd">71000000</pfe:BusinessAlignmentCosts>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2356-wk-Fact-644EBFAF34BD5FBA9B1CF394FD689FBB"
      unitRef="usd">-138000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2375-wk-Fact-7DDB8A53183E908A30E5801F80CDA452"
      unitRef="usd">-3000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2394-wk-Fact-13FBCE16090D77486260801F80AF4E2A"
      unitRef="usd">-999000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2422-wk-Fact-B86C473D53F433E01138E3D722277F0D"
      unitRef="usd">17000000</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2442-wk-Fact-7993C88B8674482BA763E3D78533039D"
      unitRef="usd">0</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2461-wk-Fact-D3148F133483360760CAE3D7A356B4E2"
      unitRef="usd">0</pfe:IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2489-wk-Fact-0B4B7D09A234587DBD0FEB3766ED94BB"
      unitRef="usd">388000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2509-wk-Fact-1A6E3FA2203C5CDDA2BD99ED3CEEEA51"
      unitRef="usd">417000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <pfe:OtherNonoperatingIncomeExpenseNet
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2529-wk-Fact-BCF75818718DFBE05AB3801F80FDBB16"
      unitRef="usd">328000000</pfe:OtherNonoperatingIncomeExpenseNet>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2561-wk-Fact-58A10D106477541896C64514721528B2"
      unitRef="usd">-3578000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2580-wk-Fact-F590D4C627155C828C90476F227A1511"
      unitRef="usd">-2116000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2600-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927"
      unitRef="usd">-1416000000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InterestCostsCapitalized
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e2636-wk-Fact-5235225ADE188E03402A801F824771B5"
      unitRef="usd">88000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2644-wk-Fact-F890E2D2FC370D2706C3801F80B6F568"
      unitRef="usd">73000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:InterestCostsCapitalized
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2653-wk-Fact-7FE0123B867DECE583EF801F80ED4EA5"
      unitRef="usd">72000000</us-gaap:InterestCostsCapitalized>
    <us-gaap:ProceedsFromLegalSettlements
      contextRef="FD2019Q2QTD"
      decimals="-6"
      id="d34471435e2689-wk-Fact-B43F7B053D7E59F6B88D8574E3EC4B5C"
      unitRef="usd">82000000</us-gaap:ProceedsFromLegalSettlements>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2711-wk-Fact-B57C908DD253153CF24A801F8247C249"
      unitRef="usd">60000000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d34471435e2719-wk-Fact-E4E691C290056D92F9C5801F80EFA503"
      unitRef="usd">-81000000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="2"
      id="d34471435e2723-wk-Fact-C1577C38066176D10EAC801F80EADEC6"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="-6"
      id="d34471435e2728-wk-Fact-334BEB1ABA3E2F123F0F801F7EFEBE74"
      unitRef="usd">-30000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34471435e2732-wk-Fact-CACD50923894EDD99872801F80B0B6C2"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="FI2017Q4_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34471435e2736-wk-Fact-18D02467A559416641BC801F82423683"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2740-wk-Fact-69AEF90E3186D6721976801F80E7F6F4"
      unitRef="usd">52000000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CortexymeInc.Member"
      decimals="-6"
      id="d34471435e2755-wk-Fact-04F60A3E414CD2F241ABE3EFFA0096F9"
      unitRef="usd">295000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2018Q1QTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member"
      decimals="-6"
      id="d34471435e2766-wk-Fact-A970E59AE1F26ACBAD36801F7F1604B0"
      unitRef="usd">477000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d34471435e2770-wk-Fact-84F9F87ED8E49B6F0322801F7EFABC9F"
      unitRef="usd">466000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2796-wk-Fact-004D224EE01D2948B0B7E3F2CE7152F9"
      unitRef="usd">402000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-6"
      id="d34471435e2800-wk-Fact-87A4F3641AAEC2B2D8F5E3F322880714"
      unitRef="usd">-18000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e2804-wk-Fact-7F49C9F6FD160EA29BA8E3FC2949637C"
      unitRef="usd">280000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2018Q4YTD"
      decimals="-8"
      id="d34471435e2808-wk-Fact-46B1D276FC9164CE6226E3FC6462E9EE"
      unitRef="usd">5700000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2812-wk-Fact-651B86B3A1644EE8E8DFE3FCA782953B"
      unitRef="usd">451000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e2817-wk-Fact-E3B65CD44F857A7FB9C1E3FD0826888C"
      unitRef="usd">281000000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:GainLossOnDerivativeInstrumentsNetPretax
      contextRef="FD2017Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_InvestmentTypeAxis_us-gaap_DebtSecuritiesMember"
      decimals="-6"
      id="d34471435e2821-wk-Fact-DEB72249336B456167F3E3FF2E934DF7"
      unitRef="usd">-120000000</us-gaap:GainLossOnDerivativeInstrumentsNetPretax>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34471435e2825-wk-Fact-B889D85343AC5CDC9870E3FF809FDFF6"
      unitRef="usd">5100000000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2019Q4YTD_srt_CounterpartyNameAxis_pfe_MylanMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34471435e2846-wk-Fact-5835DC1A6A915225A9600FFCFE38DEB7"
      unitRef="usd">78000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34471435e2858-wk-Fact-485AEAE0E42D5A18A290481FA47A4259"
      unitRef="usd">52000000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34471435e2867-wk-Fact-4F9D6F155F741267B53FE4034C447D72"
      unitRef="usd">118000000</us-gaap:ProceedsFromCollaborators>
    <pfe:ProceedsFromLicensingArrangement
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34471435e2871-wk-Fact-761A93B33CF65581E410801F823D8C66"
      unitRef="usd">110000000</pfe:ProceedsFromLicensingArrangement>
    <pfe:ProceedsFromLicensingArrangement
      contextRef="FD2018Q1QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34471435e2875-wk-Fact-F4371ABC579CB963235C801F80CF3AE8"
      unitRef="usd">75000000</pfe:ProceedsFromLicensingArrangement>
    <pfe:ProceedsFromLicensingArrangement
      contextRef="FD2018Q3QTD_srt_CounterpartyNameAxis_pfe_ShireMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34471435e2879-wk-Fact-6B9F402AA8B68FB924E1801F7DF7B11B"
      unitRef="usd">35000000</pfe:ProceedsFromLicensingArrangement>
    <us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration
      contextRef="FI2018Q4_us-gaap_DisposalGroupClassificationAxis_us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember"
      decimals="-6"
      id="d34471435e2884-wk-Fact-FEB456A1917AB5E671F6801F7EFFEAEE"
      unitRef="usd">85000000</us-gaap:DisposalGroupIncludingDiscontinuedOperationConsideration>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"
      decimals="-6"
      id="d34471435e2888-wk-Fact-3EB7ADBE9CCB7DB05414801F80C9FF93"
      unitRef="usd">62000000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:ProceedsFromCollaborators
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_MerckMember_us-gaap_TypeOfArrangementAxis_us-gaap_CollaborativeArrangementMember"
      decimals="-6"
      id="d34471435e2892-wk-Fact-5CA1811E9BDCF0302608801F8247A337"
      unitRef="usd">40000000</us-gaap:ProceedsFromCollaborators>
    <pfe:ProceedsFromLicensingArrangement
      contextRef="FD2017Q4YTD_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34471435e2904-wk-Fact-F3E183ABF14138D68140801F80890CE2"
      unitRef="usd">101000000</pfe:ProceedsFromLicensingArrangement>
    <us-gaap:GainLossOnDispositionOfIntangibleAssets
      contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DistributionRightsMember"
      decimals="-6"
      id="d34471435e2909-wk-Fact-C2429C6DAA41C84D4FA5801F824887B6"
      unitRef="usd">85000000</us-gaap:GainLossOnDispositionOfIntangibleAssets>
    <us-gaap:LitigationSettlementExpense
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="-6"
      id="d34471435e2980-wk-Fact-9B54FC0F1D02D181288F801F7EFD355D"
      unitRef="usd">94000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:LitigationSettlementExpense
      contextRef="FD2017Q4YTD_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_PatentMatterMember"
      decimals="-6"
      id="d34471435e2984-wk-Fact-666D4B08682B43C36845801F823F65F5"
      unitRef="usd">79000000</us-gaap:LitigationSettlementExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD"
      decimals="-8"
      id="d34471435e3012-wk-Fact-410824BC55BD5125B692CC025A3ADB69"
      unitRef="usd">2800000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-8"
      id="d34471435e3016-wk-Fact-7D859E3866CB3AF41EF9E41D2013CCFE"
      unitRef="usd">2600000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_GeneTherapiesMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="-6"
      id="d34471435e3020-wk-Fact-120DFFCBD8C55A598D93A678B4F009DE"
      unitRef="usd">90000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34471435e3024-wk-Fact-66781254418F59FCB02D385D42D0F9E4"
      unitRef="usd">40000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_AstraZenecaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34471435e3029-wk-Fact-9883A55836FE9D7DB1C1E420C6801BDB"
      unitRef="usd">31000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TreatmentForToenailFungusMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34471435e3033-wk-Fact-4D4CA291BAE458C090F10D6D4CD134FE"
      unitRef="usd">10000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34471435e3054-wk-Fact-EEAF3F751228C1976BDFE423B8E78A86"
      unitRef="usd">10000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2018Q4YTD"
      decimals="-8"
      id="d34471435e3066-wk-Fact-46D0EBEAC481F3E003A8E42584F9BFDE"
      unitRef="usd">3100000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-8"
      id="d34471435e3070-wk-Fact-E3AC35F114D6E5793435E42743531ACB"
      unitRef="usd">2600000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_LicensingAgreementsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34471435e3074-wk-Fact-DFB4CBF42A1D29C6CD53E427CF66D45C"
      unitRef="usd">242000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34471435e3078-wk-Fact-C9C72BE5E041C8B13BCFE4282FC48AD1"
      unitRef="usd">80000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34471435e3083-wk-Fact-BB65CA4C86C88A8ED1ECE42A25FEE224"
      unitRef="usd">117000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_BusinessAcquisitionAxis_pfe_AnacorMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34471435e3087-wk-Fact-EEA91F40C06A2F62FC74E4291EF6DA0E"
      unitRef="usd">31000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2018Q4YTD_us-gaap_BusinessAcquisitionAxis_pfe_InnoPharmaMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34471435e3091-wk-Fact-63CAACB19640CEF34F5EE42998C91F1D"
      unitRef="usd">17000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e3108-wk-Fact-0DB96D89C59B54A8C3EB801F80DC200F"
      unitRef="usd">337000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenericSterileInjectableProductMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3112-wk-Fact-7411695F32DBAB6BEF4E801F80DB6913"
      unitRef="usd">127000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SterileInjectablePainRelieverMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3116-wk-Fact-529F87DF004170B964DB801F82422BF8"
      unitRef="usd">124000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TreatmentOfAttentionHyperactivityDisorderMember_us-gaap_BusinessAcquisitionAxis_pfe_NextWaveMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3120-wk-Fact-60431E4C7A2BDF64B46C801F80B15BEB"
      unitRef="usd">39000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenericInjectablePainRelieverMember_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3124-wk-Fact-459AC32F88910EB0AE27801F7EFFC506"
      unitRef="usd">26000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3129-wk-Fact-AFA012CED968899433A6801F8240AD80"
      unitRef="usd">20000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount
      contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AMPharmaBVMember"
      decimals="-6"
      id="d34471435e3133-wk-Fact-53AD1925EC34AC46119B801F80DEDB85"
      unitRef="usd">43000000</us-gaap:EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34471435e3209-wk-Fact-293451C69DA75DC8A70D7BAEFB4F73E3"
      unitRef="usd">220000000</us-gaap:InvestmentIncomeDividend>
    <pfe:DeconsolidationExternalIncrementalCostsAmount
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e3213-wk-Fact-97A07A88B994572FA52511223AB8DBC2"
      unitRef="usd">152000000</pfe:DeconsolidationExternalIncrementalCostsAmount>
    <us-gaap:InsuranceRecoveries
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e3217-wk-Fact-B06F61437C8457F4804C65B8FE9BFC57"
      unitRef="usd">50000000</us-gaap:InsuranceRecoveries>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q4YTD_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember"
      decimals="-6"
      id="d34471435e3226-wk-Fact-B92017FC9E90D38A36B6801F7EF53786"
      unitRef="usd">343000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34471435e3234-wk-Fact-99E3F4A21F825B05BD4E31F27E393D8A"
      unitRef="usd">253000000</us-gaap:InvestmentIncomeDividend>
    <pfe:GainLossFromContributionAgreement
      contextRef="FD2018Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d34471435e3238-wk-Fact-AFBF7664142F02703EC6801F80F1B3ED"
      unitRef="usd">50000000</pfe:GainLossFromContributionAgreement>
    <pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3247-wk-Fact-8ECBDE405C33A1FF9D79801F80B2C01E"
      unitRef="usd">17000000</pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment>
    <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e3255-wk-Fact-950F9736F5FA5CA8B49089B7C8C362F1"
      unitRef="usd">207000000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
    <pfe:DeconsolidationExternalIncrementalCostsAmount
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34471435e3259-wk-Fact-2E0E562A8A0E8D216B00E43D608AD298"
      unitRef="usd">112000000</pfe:DeconsolidationExternalIncrementalCostsAmount>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember"
      decimals="-6"
      id="d34471435e3263-wk-Fact-D2DD3479116FE8BE100C801F82405EAA"
      unitRef="usd">266000000</us-gaap:InvestmentIncomeDividend>
    <pfe:OtherNonoperatingIncomeMiscellaneous
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34471435e3267-wk-Fact-6C3CC82B8C5AD303C0DF801F80DE21E1"
      unitRef="usd">62000000</pfe:OtherNonoperatingIncomeMiscellaneous>
    <us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-19978966E7FCBD7EB6CD801F830E3FA9-0-wk-Fact-4ADB6E87730BC8EADB47801F80ADC3BF">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides additional information about the intangible assets that were impaired during 2019 in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Impairment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intangible assets&#x2013;&#x2013;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,639&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1E.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects intangible assets written down to fair value in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfImpairedIntangibleAssetsTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3818-wk-Fact-CDFA015BEFBB5917ADD08A5A17C5EE6F"
      unitRef="usd">1213000000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3837-wk-Fact-D197856ADE315AF9B1BD0141D8126013"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3857-wk-Fact-18E37EACB23652878A34A31EF09685A7"
      unitRef="usd">0</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3876-wk-Fact-6D7C9A2836915BA9A1C8765EC5343BEF"
      unitRef="usd">1213000000</us-gaap:FiniteLivedIntangibleAssetsFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34471435e3895-wk-Fact-5344A287AEC4338D220DE3C58F9727B5"
      unitRef="usd">2639000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34471435e3921-wk-Fact-213E32B8B2FE51C690B80D561FAEFE40"
      unitRef="usd">16000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34471435e3939-wk-Fact-341D9ED90C94596BB9FAE98E1294E451"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34471435e3957-wk-Fact-86415D4CAB5E59DBBD55EC735E24E7F2"
      unitRef="usd">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34471435e3976-wk-Fact-D3A3B59227395C7B84054756B56717E7"
      unitRef="usd">16000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwillFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34471435e3994-wk-Fact-0F2EB7A6D4B3040B6027E3C58F8C7591"
      unitRef="usd">131000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <pfe:IntangibleAssetsFairValueDisclosure
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34471435e4024-wk-Fact-6218C747DBEE55A9AF76EE26E178A31C"
      unitRef="usd">1229000000</pfe:IntangibleAssetsFairValueDisclosure>
    <pfe:IntangibleAssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member"
      decimals="-6"
      id="d34471435e4043-wk-Fact-62C2FD859415581FBF973FCE94B77BC7"
      unitRef="usd">0</pfe:IntangibleAssetsFairValueDisclosure>
    <pfe:IntangibleAssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member"
      decimals="-6"
      id="d34471435e4063-wk-Fact-F16E0A41BA8953F7AFA1ACB2D90C1AB8"
      unitRef="usd">0</pfe:IntangibleAssetsFairValueDisclosure>
    <pfe:IntangibleAssetsFairValueDisclosure
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member"
      decimals="-6"
      id="d34471435e4082-wk-Fact-FF50DEB8A335501E80F11891D08A50FF"
      unitRef="usd">1229000000</pfe:IntangibleAssetsFairValueDisclosure>
    <us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34471435e4101-wk-Fact-0ED887E0106DA5C62DCAE3C58F9CB840"
      unitRef="usd">2770000000</us-gaap:ImpairmentOfIntangibleAssetsExcludingGoodwill>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D37C7FB2A397C20BFB88801F8314877E-0-wk-Fact-B6BEDCBFC51301EE7B3B801F7F5796C4">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Tax Matters&lt;/span&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A. Taxes on Income from Continuing Operations&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;9,751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16,288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;19,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; v. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The domestic income in 2019 versus domestic loss in 2018 was mainly related to the completion of the Consumer Healthcare joint venture transaction with GSK as well as lower certain asset impairments, partially offset by reduced Lyrica revenues in the U.S., higher business and legal entity &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;alignment costs as well as increased costs related to certain legal matters. The decrease in the international income was primarily related to higher certain asset impairments as well as the write off of assets contributed to the Consumer Healthcare joint venture with GSK.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; v. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on equity securities and increased revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the legacy SIP portfolio. The decrease in international income was primarily related to lower interest income received primarily from intercompany borrowings from Pfizer Inc. and higher charges related to certain cost reduction initiatives, partially offset by increased revenue related to Ibrance and Eliquis.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;based on the location of the taxing authorities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current income taxes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred income taxes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,663&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total U.S. tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;TCJA&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(3,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred Income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(23,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total TCJA tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(10,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total international tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(9,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:justify;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The 2018 current tax benefit and deferred tax expense primarily relate to the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See discussion below and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the fourth quarter of 2017, we recorded an estimate of certain tax effects of the TCJA, including (i) the impact on deferred tax assets and liabilities from the reduction in the U.S. Federal corporate tax rate from 35% to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;21%&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, (ii) the impact on valuation allowances and other state income tax considerations, (iii) the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$15.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; repatriation tax liability on accumulated post-1986 foreign earnings for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026 and (iv) deferred taxes on basis differences expected to give rise to future taxes on global intangible low-taxed income. In addition, we had provided deferred tax liabilities in the past on foreign earnings that were not indefinitely reinvested. As a result of the TCJA, in the fourth quarter of 2017, we reversed an estimate of the deferred taxes that are no longer expected to be needed due to the change to the territorial tax system. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2018, we finalized our provisional accounting for the tax effects of the TCJA, based on our best estimates of available information and data, and reported and disclosed the impacts within the applicable measurement period, in accordance with guidance issued by the SEC, and recorded a favorable adjustment of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$100 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. We believe that there may be additional interpretations, clarifications and guidance from the U.S. Department of Treasury. Any change to our calculations resulting from such additional interpretations, clarifications and guidance would be reflected in the period of issuance. In addition, our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;With respect to the aforementioned repatriation tax liability, our revised estimate is approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$15 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, which is reported in current &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$600 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) and the remaining liability is reported in noncurrent &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other taxes payable &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in our consolidated balance sheet as of December 31, 2019. The first installment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$750 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; was paid in April 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The TCJA subjects a U.S. shareholder to current tax on global intangible low-taxed income earned by certain foreign subsidiaries. The FASB Staff Q&amp;amp;A, Topic 740, No. 5, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Accounting for Global Intangible Low-Taxed Income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, states that we are permitted to make an accounting policy election to either recognize deferred taxes for temporary basis differences expected to reverse as global intangible low-taxed income in future years or provide for the tax expense related to such income in the year the tax is incurred. We elected to recognize deferred taxes for temporary differences expected to reverse as global intangible low-taxed income in future years. In 2017, we provided a provisional deferred tax liability of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; based on the evaluation of certain temporary differences inside each of our foreign subsidiaries that are expected to reverse as global intangible low-taxed income. In 2018, this estimate was finalized and we provided for an additional deferred tax liability of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, resulting in a deferred tax liability of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2019, the&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; was impacted by the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax expense of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$2.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years, primarily resulting from a favorable settlement with the IRS (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; below);&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$400 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to certain tax initiatives associated with the implementation of our new organizational structure; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$325 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; recorded as a result of additional guidance issued by the U.S. Department of Treasury related to the enactment of the TCJA; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$620 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to certain asset impairments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2018, the&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; was impacted by the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;estimated U.S. net tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$600 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with the enactment of the TCJA (see discussion above), primarily reflecting:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$500 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax benefits associated primarily with certain 2018 tax initiatives;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$100 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax benefits associated with adjustments to our provisional accounting for the tax effects of the TCJA, reported and disclosed within the applicable measurement period, in accordance with guidance issued by the SEC, mainly consisting of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:36px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:24px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$160 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax benefits related to the repatriation tax on deemed repatriated accumulated earnings of foreign subsidiaries; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:36px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:24px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$140 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax benefits associated with the remeasurement of other U.S. deferred tax liabilities,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-left:24px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;partially offset by:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:36px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:24px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax expense related to future taxes on global intangible low-taxed income;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$700 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years mostly with various foreign tax authorities, and the expiration of certain statutes of limitations; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$740 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to certain asset impairments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2017, the&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; was impacted by the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;estimated U.S. net tax benefits of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$10.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; associated with the enactment of the TCJA (see discussion above), primarily reflecting:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$22.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax benefits associated with the remeasurement of U.S. deferred tax liabilities on unremitted earnings of foreign subsidiaries (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;);&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax benefits associated with the remeasurement of other U.S. deferred tax liabilities, mainly associated with intangibles (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;);&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$12.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax expense related to the repatriation tax on deemed repatriated accumulated pre-2017 post-1986 earnings of foreign subsidiaries; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax expense related to future taxes on global intangible low-taxed income (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;); and &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x25e6;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$100 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of tax benefits mostly associated with certain tax initiatives;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. tax expense of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to the repatriation tax on deemed repatriated current year earnings of foreign subsidiaries;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$370 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to net losses on early retirement of debt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;tax benefits of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$150 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; representing tax and interest resulting from the resolution of certain tax positions pertaining to prior years primarily with various foreign tax authorities, and the expiration of certain statutes of limitations; and&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;the non-deductibility of a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$307 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; fee payable to the federal government as a result of the U.S. Healthcare Legislation. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In all years, federal, state and international net tax liabilities assumed or established as part of a business acquisition are not included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B. Tax Rate Reconciliation&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The reconciliation of the U.S. statutory income tax rate to our effective tax rate for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income from continuing operations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. statutory income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TCJA impact&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(86.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Taxation of non-U.S. operations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(5.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(17.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Tax settlements and resolution of certain tax positions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Completion of Consumer Healthcare joint venture transaction&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Healthcare Legislation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d), (e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. R&amp;amp;D tax credit and manufacturing deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain legal settlements and charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All other, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effective tax rate for income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(73.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For a discussion about the enactment of the TCJA, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which, for 2017, includes the repatriation tax on deemed repatriated 2017 earnings of foreign subsidiaries discussed in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions,&#x201d; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for the components of pre-tax income and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;which is based on the location of the taxing authorities, and for information about settlements and other items impacting &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2045 on income from manufacturing and other operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For a discussion about tax settlements and resolution of certain tax positions, the impact of the gain on the completion of the Consumer Healthcare joint venture transaction and the impact of U.S. Healthcare Legislation, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The favorable rate impact in 2018 is a result of the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods, as well as certain tax initiatives.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;All other, net in 2019 is primarily due to routine business operations. 2018 is primarily due to routine business operations and the non-recurrence of tax benefits associated with certain tax initiatives. 2017 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. Deferred Taxes&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred taxes arise as a result of basis differentials between financial statement accounting and tax amounts.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:1px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019 Deferred Tax*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018 Deferred Tax*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Liabilities)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Liabilities)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prepaid/deferred items&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(7,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(7,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Restructurings and other charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Legal and product liability reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net operating loss/tax credit carryforwards&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,512&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Unremitted earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;State and local tax adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(3,318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;9,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(11,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(9,456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total deferred taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(11,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(9,456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net deferred tax liability&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories above. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; is primarily related to the capitalization of certain R&amp;amp;D-related expenses.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The decrease in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; is primarily the result of amortization of intangible assets and certain impairment charges, mainly offset by deferred tax liabilities established on intangible assets from the acquisition of Array.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The amounts in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are reduced for unrecognized tax benefits of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in 2019 is primarily related to the Consumer Healthcare joint venture with GSK. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$0.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;). In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$0.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We have carryforwards, primarily related to net operating and capital losses, general business credits and charitable contributions, which are available to reduce future U.S. federal and/or state, as well as international, income taxes payable with either an indefinite life or expiring at various times from 2020 to 2039. Certain of our U.S. net operating losses and general business credits are subject to limitations under IRC Section&#160;382.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Valuation allowances are provided when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax planning strategies, that would be implemented, if necessary, to realize the deferred tax assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we have not made a U.S. tax provision on approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$29.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of unremitted earnings of our international subsidiaries. As these earnings are intended to be indefinitely reinvested overseas, the determination of a hypothetical unrecognized deferred tax liability as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is not practicable.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;D. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Tax Contingencies&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We are subject to income tax in many jurisdictions, and a certain degree of estimation is required in recording the assets and liabilities related to income taxes. All of our tax positions are subject to audit by the local taxing authorities in each tax jurisdiction. These tax audits can involve complex issues, interpretations and judgments and the resolution of matters may span multiple years, particularly if subject to negotiation or litigation. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For a description of our accounting policies associated with accounting for income tax contingencies, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1P. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For a description of the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As tax law is complex and often subject to varied interpretations, it is uncertain whether some of our tax positions will be sustained upon audit. As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in net unrecognized tax benefits, excluding associated interest and as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in net unrecognized tax benefits, excluding associated interest.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Tax assets associated with uncertain tax positions primarily represent our estimate of the potential tax benefits in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction. As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in assets associated with uncertain tax positions. These amounts were included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$109 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we had approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in assets associated with uncertain tax positions. These amounts were included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$128 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Tax liabilities associated with uncertain tax positions represent unrecognized tax benefits, which arise when the estimated benefit recorded in our financial statements differs from the amounts taken or expected to be taken in a tax return because of the uncertainties described above. These unrecognized tax benefits relate primarily to issues common among multinational corporations. Substantially all of these unrecognized tax benefits, if recognized, would impact our effective income tax rate. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:0px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(6,259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increases based on tax positions taken during a prior period&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Decreases based on tax positions taken during a prior period&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;561&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Decreases based on settlements for a prior period&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increases based on tax positions taken during the current period&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Impact of foreign exchange&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b), (e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, ending&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(5,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6,259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For 2019, primarily related to the acquisition of Array. For 2017, primarily related to the acquisitions of Medivation and Anacor. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily related to cash payments and reductions of tax attributes.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily related to decreases as a result of a lapse of applicable statutes of limitations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Income taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$108 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Current tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;),&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$51 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;). In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Income taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$11 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Current tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$47 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;). &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest related to our unrecognized tax benefits is recorded in accordance with the laws of each jurisdiction and is recorded primarily in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in our consolidated statements of income. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we recorded a net decrease in interest of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$564 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, resulting primarily from a settlement with the IRS. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we recorded a net increase in interest of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$103 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;; and in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we recorded a net increase in interest of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$208 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Gross accrued interest totaled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$485 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (reflecting a decrease of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$13 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as a result of cash payments) and gross accrued interest totaled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (reflecting a decrease of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$16 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as a result of cash payments). In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, this amount was included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income taxes payable &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$465 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, this amount was included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income taxes payable &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). Accrued penalties are not significant. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Status of Tax Audits and Potential Impact on Accruals for Uncertain Tax Positions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The U.S. is one of our major tax jurisdictions, and we are regularly audited by the IRS:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;During the second quarter of 2019, Pfizer reached settlement of disputed issues at the IRS Office of Appeals, thereby settling all issues related to U.S. tax returns of Pfizer for the years 2009-2010. As a result of settling these years, in the second quarter of 2019 we recorded a benefit of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, representing tax and interest. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;With respect to Pfizer, tax years 2011-2015 are currently under audit. Tax years 2016-2019 are open, but not under audit. All other tax years are closed.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In addition to the open audit years in the U.S., we have open audit years in other major tax jurisdictions, such as Canada (2013-2019), Japan (2017-2019), Europe (2011-2019, primarily reflecting Ireland, the U.K., France, Italy, Spain and Germany), Latin America (1998-2019, primarily reflecting Brazil) and Puerto Rico (2015-2019).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Any settlements or statutes of limitations expirations could result in a significant decrease in our uncertain tax positions. We estimate that it is reasonably possible that within the next 12 months, our gross unrecognized tax benefits, exclusive of interest, could decrease by as much as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as a result of settlements with taxing authorities or the expiration of the statutes of limitations. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;E. Tax Provision/(Benefit) on Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments of certain tax effects from AOCI to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments for tax on unrealized gains from AOCI to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefit plans: actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments of certain tax effects from AOCI to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefit plans: prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments related to curtailments of prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments of certain tax effects from AOCI to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;in our 2018 Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;in our 2018 Financial Report.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-924CA535A7A2F4010C49801F8313A81F-0-wk-Fact-773A1C92A027F5AE9077801F7F0946EC">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,931&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4,403&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6,879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;9,751&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16,288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;19,184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; v. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The domestic income in 2019 versus domestic loss in 2018 was mainly related to the completion of the Consumer Healthcare joint venture transaction with GSK as well as lower certain asset impairments, partially offset by reduced Lyrica revenues in the U.S., higher business and legal entity &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;alignment costs as well as increased costs related to certain legal matters. The decrease in the international income was primarily related to higher certain asset impairments as well as the write off of assets contributed to the Consumer Healthcare joint venture with GSK.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; v. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on equity securities and increased revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the legacy SIP portfolio. The decrease in international income was primarily related to lower interest income received primarily from intercompany borrowings from Pfizer Inc. and higher charges related to certain cost reduction initiatives, partially offset by increased revenue related to Ibrance and Eliquis.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIncomeBeforeIncomeTaxDomesticAndForeignTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e1556-wk-Fact-1BC519E69BB49056C007801F82245363"
      unitRef="usd">7931000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e1575-wk-Fact-FF3DBEC39977C9767D1A801F8228542C"
      unitRef="usd">-4403000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e1596-wk-Fact-C82BF6B0380BE44B2200801F82262EBF"
      unitRef="usd">-6879000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e1617-wk-Fact-D2824C5EC1C4EDDB4263801F822A6B70"
      unitRef="usd">9751000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e1636-wk-Fact-9E2A666D208853B9E414801F822BB433"
      unitRef="usd">16288000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e1655-wk-Fact-B8B8CF251AA5B84F90B4801F82328842"
      unitRef="usd">19184000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
      unitRef="usd">17682000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
      unitRef="usd">11885000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
      unitRef="usd">12305000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-376560E0FBF696AFABDE801F83141D13-0-wk-Fact-D02FFAEFE2515CCAD0A8801F7ECDE705">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;based on the location of the taxing authorities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current income taxes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,641&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred income taxes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Federal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,258&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,663&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,064&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;State and local&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total U.S. tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,055&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;TCJA&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(3,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred Income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,439&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(23,795&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total TCJA tax benefit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(323&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(596&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(10,660&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,709&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:0px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Deferred income taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total international tax provision&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,981&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(9,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The 2018 current tax benefit and deferred tax expense primarily relate to the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See discussion below and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2188-wk-Fact-3F7EC138A0DC0ABC3933801F81ED0CBB"
      unitRef="usd">-1641000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2208-wk-Fact-B89F4B544CBB0490F3B8801F7F6AFF52"
      unitRef="usd">668000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2228-wk-Fact-6D7B0BA6A2EC7869C725801F8272AB50"
      unitRef="usd">1267000000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2248-wk-Fact-056CFAFF734D8F7BCDA0801F7F81D397"
      unitRef="usd">-166000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2268-wk-Fact-330AC293DD571A8A50E2801F7F60612E"
      unitRef="usd">9000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2287-wk-Fact-B73E8A4817ACDB834A0A801F82518698"
      unitRef="usd">45000000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2380-wk-Fact-2057D665282AC77BBAE1801F7ED735BA"
      unitRef="usd">1258000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2399-wk-Fact-C11FE48D970CBE734C6E801F7F9B5371"
      unitRef="usd">-1663000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2419-wk-Fact-8FF6BDE678C111BEDBFD801F7FA28AC1"
      unitRef="usd">-2064000000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2446-wk-Fact-F163C7558F8F1B24207F801F818A4A97"
      unitRef="usd">275000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2465-wk-Fact-29AB13F630E825842305801F818B62FE"
      unitRef="usd">16000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2484-wk-Fact-647101E5C54496C433B1801F81A62C65"
      unitRef="usd">-304000000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2511-wk-Fact-3000EF77327890BBB78C801F7F7F63CF"
      unitRef="usd">-274000000</pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations>
    <pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2531-wk-Fact-DF173E4CA56C50A2CFC7801F7F6EBCC8"
      unitRef="usd">-970000000</pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations>
    <pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2551-wk-Fact-36DDCC8E8EF16316AAE0801F8248EA9E"
      unitRef="usd">-1055000000</pfe:DomesticIncomeTaxExpenseBenefitContinuedOperations>
    <pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2648-wk-Fact-A3F4A2E507D5855FCA57801F7FA5036E"
      unitRef="usd">-135000000</pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2668-wk-Fact-47EFFB693B37262CF809801F82673E4B"
      unitRef="usd">-3035000000</pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2688-wk-Fact-54AA553FEEBE8772CC50801F7F6E0504"
      unitRef="usd">13135000000</pfe:TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2714-wk-Fact-2EFB3D5BD681B11EF065801F7F7EB754"
      unitRef="usd">-187000000</pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2734-wk-Fact-48209B5C749FB96707F8801F82806943"
      unitRef="usd">2439000000</pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2753-wk-Fact-40815EB793804FE4A834801F7EBFA646"
      unitRef="usd">-23795000000</pfe:TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
      unitRef="usd">-323000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0"
      unitRef="usd">-596000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
      unitRef="usd">-10660000000</us-gaap:TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2914-wk-Fact-9590EF045DCC52CAD89B801F820F27E5"
      unitRef="usd">2900000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2933-wk-Fact-D228C3B1EAB94AF6BA3F801F7F629AC6"
      unitRef="usd">2831000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:CurrentForeignTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e2952-wk-Fact-B81A9D59D04BF20FD6F6801F7F9F288D"
      unitRef="usd">2709000000</us-gaap:CurrentForeignTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e2978-wk-Fact-35CDF23725BF18F025AB801F81D852B4"
      unitRef="usd">-919000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e2998-wk-Fact-779B14E06CE1E12EE07A801F81C6F3F6"
      unitRef="usd">-558000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:DeferredForeignIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e3018-wk-Fact-D8F4169E7E3389CFF4A5801F8199261A"
      unitRef="usd">-42000000</us-gaap:DeferredForeignIncomeTaxExpenseBenefit>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e3045-wk-Fact-66C6B89DC7211DDC88F9801F828BA851"
      unitRef="usd">1981000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3064-wk-Fact-7C37580A0C7C455B1B63801F7EDE8688"
      unitRef="usd">2273000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e3083-wk-Fact-D7B843C0B89966AD917F801F8284A242"
      unitRef="usd">2667000000</us-gaap:ForeignIncomeTaxExpenseBenefitContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e3114-wk-Fact-FC65E982593353C58EDD19521634B9BF"
      unitRef="usd">1384000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3133-wk-Fact-316CD294736155A2BF815F488E7DB6E0"
      unitRef="usd">706000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e3153-wk-Fact-C55A09F5044EA944EC43801F7F3390E1"
      unitRef="usd">-9049000000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability
      contextRef="FI2017Q4"
      decimals="-8"
      id="d34545404e3201-wk-Fact-4C248E3EED82997E3F30801F818A95A5"
      unitRef="usd">15200000000</us-gaap:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalLiability>
    <us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3208-wk-Fact-8FC80FE596B3F9A11181801F7F60C048"
      unitRef="usd">-100000000</us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="FI2019Q4"
      decimals="-9"
      id="d34545404e3219-wk-Fact-8EF9B5A847D55767BF5A5596B994B8F5"
      unitRef="usd">15000000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember"
      decimals="-6"
      id="d34545404e3227-wk-Fact-7574A578AC5453EE80D42498A2BBDAA5"
      unitRef="usd">600000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <pfe:PaymentForRepatriationTax
      contextRef="D2019Q2Apr01-Apr30"
      decimals="-6"
      id="d34545404e3235-wk-Fact-71130497423450AA97DB57267DA5E202"
      unitRef="usd">750000000</pfe:PaymentForRepatriationTax>
    <pfe:TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability
      contextRef="FI2017Q4"
      decimals="-8"
      id="d34545404e3246-wk-Fact-A465ABA143208C4BD9BB801F7F7FB74D"
      unitRef="usd">1000000000.0</pfe:TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeProvisionalDeferredTaxLiability>
    <pfe:TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e3250-wk-Fact-2FD831C8D0DBA5F87C24801F7FA06750"
      unitRef="usd">200000000</pfe:TaxCutsandJobsActof2017MeasurementPeriodAdjustmentGlobalIntangibleLowTaxedIncomeDeferredTaxLiability>
    <pfe:TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability
      contextRef="FI2018Q4"
      decimals="-8"
      id="d34545404e3254-wk-Fact-C8453589A84C97B68431801F7E16D271"
      unitRef="usd">1200000000</pfe:TaxCutsandJobsActof2017GlobalIntangibleLowTaxedIncomeDeferredTaxLiability>
    <pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount
      contextRef="FD2019Q4YTD"
      decimals="-8"
      id="d34545404e3275-wk-Fact-3FA3D32052ED5CAE8FF3C5026CEA3C3D"
      unitRef="usd">2700000000</pfe:EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount>
    <us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic
      contextRef="FD2019Q4YTD"
      decimals="-8"
      id="d34545404e3286-wk-Fact-2481F3648C7E706F2FDA26BB2077F715"
      unitRef="usd">1600000000</us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic>
    <pfe:EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e3301-wk-Fact-BD80A7223EB34D352BA926D8AA6958A4"
      unitRef="usd">-400000000</pfe:EffectiveIncomeTaxRateReconciliationImplementationOfOrganizationalStructureGainLossAmount>
    <pfe:TaxCutsAndJobsActIncomeTaxBenefit
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e3312-wk-Fact-AF0F55D57BA4C56267FD26B6D5B4AD11"
      unitRef="usd">325000000</pfe:TaxCutsAndJobsActIncomeTaxBenefit>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e3323-wk-Fact-F6269740018EEB425B0426D916F90DF0"
      unitRef="usd">620000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <pfe:TaxCutsAndJobsActIncomeTaxBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3343-wk-Fact-07D7749619A14DC9F0CF801F7F3C1F9A"
      unitRef="usd">600000000</pfe:TaxCutsAndJobsActIncomeTaxBenefit>
    <pfe:TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3354-wk-Fact-F2FB1653C705DD800EBA801F7F58CDD1"
      unitRef="usd">500000000</pfe:TaxCutsAndJobsActof2017TaxInitiativesIncomeTaxExpenseBenefit>
    <us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3366-wk-Fact-8FC80FE596B3F9A11181801F7F60C048"
      unitRef="usd">-100000000</us-gaap:TaxCutsAndJobsActOf2017MeasurementPeriodAdjustmentIncomeTaxExpenseBenefit>
    <pfe:TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3375-wk-Fact-585427480B760D39EED4801F7F8CD629"
      unitRef="usd">-160000000</pfe:TaxCutsAndJobsActof2017TransitionTaxForAccumulatedForeignEarningsIncomeTaxExpenseBenefit>
    <pfe:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3384-wk-Fact-138C0E1B6ECE90FC029E801F81988E02"
      unitRef="usd">140000000</pfe:TaxCutsAndJobsActOf2017ChangeInTaxRateDeferredTaxLiabilityIncomeTaxExpenseBenefit>
    <pfe:TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3396-wk-Fact-78FA610E519E881EBF18801F81E147FA"
      unitRef="usd">200000000</pfe:TaxCutsAndJobsActOf2017GlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3407-wk-Fact-150DF36522EA02E6063D801F8175182D"
      unitRef="usd">-700000000</us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e3418-wk-Fact-29920DBB462D8E0B8DF2801F82261BFE"
      unitRef="usd">740000000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseImpairmentLosses>
    <pfe:TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34545404e3442-wk-Fact-6EF023A8A9E99AB130BB801F7FA7E5E9"
      unitRef="usd">-10700000000</pfe:TaxCutsandJobsActof2017ChangeInTaxRateProvisionalIncomeTaxExpenseBenefit>
    <pfe:TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34545404e3451-wk-Fact-A00621752ABDDD277B07801F7F5E3ED3"
      unitRef="usd">22800000000</pfe:TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityUnremittedEarningsProvisionalIncomeTaxExpenseBenefit>
    <pfe:TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34545404e3465-wk-Fact-308CA9CFDD807F36DB5E801F821DAAB2"
      unitRef="usd">1600000000</pfe:TaxCutsAndJobsActof2017IncompleteAccountingChangeInTaxRateDeferredTaxLiabilityIntangibleAssetsProvisionalIncomeTaxExpenseBenefit>
    <pfe:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34545404e3478-wk-Fact-F12986874994AC3A9E4B801F7EC7895A"
      unitRef="usd">12900000000</pfe:TaxCutsAndJobsActOf2017IncompleteAccountingTransitionTaxForAccumulatedForeignEarningsProvisionalIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34545404e3487-wk-Fact-B71E12DEDD43B2443728801F8241317A"
      unitRef="usd">1000000000.0</pfe:TaxCutsandJobsActof2017IncompleteAccountingGlobalIntangibleLowTaxedIncomeIncomeTaxExpenseBenefit>
    <pfe:TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e3502-wk-Fact-030584978E6092910AAA801F8187E52B"
      unitRef="usd">100000000</pfe:TaxCutsandJobsActof2017IncompleteAccountingTaxInitiativesIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34545404e3513-wk-Fact-1479E3C7DC19C0A18E23801F822EC363"
      unitRef="usd">1300000000</us-gaap:IncomeTaxReconciliationRepatriationOfForeignEarnings>
    <pfe:EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e3524-wk-Fact-2CFB549FFCFF1EEF806E801F7F5F2C76"
      unitRef="usd">370000000</pfe:EffectiveIncomeTaxRateReconciliationLossOnDebtExtinguishmentAmount>
    <us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e3535-wk-Fact-3EB7CE245B545F236D8E801F7F544692"
      unitRef="usd">-150000000</us-gaap:IncomeTaxReconciliationTaxSettlementsDomestic>
    <pfe:FeePayable
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e3546-wk-Fact-161FDD6910BA2F5EE807E475101CD09F"
      unitRef="usd">307000000</pfe:FeePayable>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-2F42A64E1F51B8C5C776801F8314DB98-0-wk-Fact-BEC115F614B83A4E5831801F7F93BCF8">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The reconciliation of the U.S. statutory income tax rate to our effective tax rate for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income from continuing operations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. statutory income tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;35.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TCJA impact&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(86.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Taxation of non-U.S. operations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;&#160;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(5.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(17.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Tax settlements and resolution of certain tax positions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(9.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Completion of Consumer Healthcare joint venture transaction&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Healthcare Legislation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d), (e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(0.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. R&amp;amp;D tax credit and manufacturing deduction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(0.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain legal settlements and charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All other, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effective tax rate for income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(73.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For a discussion about the enactment of the TCJA, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which, for 2017, includes the repatriation tax on deemed repatriated 2017 earnings of foreign subsidiaries discussed in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions,&#x201d; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for the components of pre-tax income and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;which is based on the location of the taxing authorities, and for information about settlements and other items impacting &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2045 on income from manufacturing and other operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For a discussion about tax settlements and resolution of certain tax positions, the impact of the gain on the completion of the Consumer Healthcare joint venture transaction and the impact of U.S. Healthcare Legislation, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The favorable rate impact in 2018 is a result of the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods, as well as certain tax initiatives.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;All other, net in 2019 is primarily due to routine business operations. 2018 is primarily due to routine business operations and the non-recurrence of tax benefits associated with certain tax initiatives. 2017 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d34545404e3761-wk-Fact-90AEB5A2B77DDDF5B25A801F828FE42C"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d34545404e3776-wk-Fact-325C040A07204AD82DA7801F828F2519"
      unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d34545404e3791-wk-Fact-F5EA8A7C5E11031C2FF8801F826DB301"
      unitRef="number">0.350</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e3814-wk-Fact-264673D948622D0AA0A4801F7F4D3D67"
      unitRef="number">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e3829-wk-Fact-4E680D94DBBF677FF299801F7EAAEC74"
      unitRef="number">-0.050</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e3844-wk-Fact-39A51FF36D53F8FAFD27801F828948C3"
      unitRef="number">-0.866</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCutsAndJobsActOf2017Percent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e3867-wk-Fact-42EBCBC4C248331A0BFD801F82753FD6"
      unitRef="number">-0.057</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e3882-wk-Fact-27063B77FAD0699D0962801F7E91ACE2"
      unitRef="number">-0.061</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e3897-wk-Fact-540F98E963893D555BBC801F8251C495"
      unitRef="number">-0.170</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e3920-wk-Fact-A684767625371E2C2BE9801F82707B93"
      unitRef="number">-0.090</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e3935-wk-Fact-BB9E538422B53CC7D9FE801F82463C58"
      unitRef="number">-0.058</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e3950-wk-Fact-E6A475BF77FF3BDAAABB801F825FD297"
      unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationTaxSettlements>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e3973-wk-Fact-BE07CE4FFFBA7AA6551D01C7EE81842C"
      unitRef="number">0.053</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e3987-wk-Fact-565E3B0013E83A6400DF01C7EED4523E"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e4001-wk-Fact-556CBCAD88F04EADEC0B01C7EFA1BB3D"
      unitRef="number">0</us-gaap:EffectiveIncomeTaxRateReconciliationDispositionOfBusiness>
    <pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e4023-wk-Fact-F48375E1B07289C166E7801F7E895D8F"
      unitRef="number">0</pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent>
    <pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e4037-wk-Fact-7F97E24FF7E81A914961801F825D5D9B"
      unitRef="number">-0.004</pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent>
    <pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e4052-wk-Fact-1FB0890125B2E2F568A0801F82580255"
      unitRef="number">0.009</pfe:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseChangeInLegislationPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e4072-wk-Fact-BEF6BECFD4BD3C366DF7801F82740289"
      unitRef="number">0.005</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e4087-wk-Fact-82FF14169890F771EBF0801F824C9659"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e4102-wk-Fact-0FA556A52E26309BA17F801F8287A576"
      unitRef="number">0.007</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e4123-wk-Fact-73F70D43DC2CCFC9DBDD801F7F08261D"
      unitRef="number">0</pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent>
    <pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e4137-wk-Fact-5D5A6E4E5C5269ADAE16801F7F1D9556"
      unitRef="number">-0.001</pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent>
    <pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e4152-wk-Fact-9250C6C0BF97305C67CB801F82816E88"
      unitRef="number">0.001</pfe:EffectiveIncomeTaxRateReconciliationDeductionLitigationSettlementPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e4175-wk-Fact-2D81E359A3F32671B09D801F7F331769"
      unitRef="number">-0.015</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e4190-wk-Fact-154E2A860FA2D40C9895801F828D41CB"
      unitRef="number">0.031</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e4204-wk-Fact-636FAEFED881C9A536B7801F7EB61207"
      unitRef="number">-0.039</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2019Q4YTD"
      decimals="3"
      id="d34545404e4225-wk-Fact-1795C85B49296663CC88801F82632A48"
      unitRef="number">0.078</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2018Q4YTD"
      decimals="3"
      id="d34545404e4240-wk-Fact-53054E0275D8FD11662B801F7F0C1F97"
      unitRef="number">0.059</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="FD2017Q4YTD"
      decimals="3"
      id="d34545404e4255-wk-Fact-BC1C58E1C5F3B7C2FE82801F7E9969CF"
      unitRef="number">-0.735</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C475332A5330C86813C8801F831448E3-0-wk-Fact-3296DCFE64606FE2860D801F821A0EC9">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:52%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:1px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The components of our deferred tax assets and liabilities, shown before jurisdictional netting, follow:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019 Deferred Tax*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018 Deferred Tax*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Liabilities)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Liabilities)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prepaid/deferred items&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,655&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(325&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Inventories&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(7,099&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(7,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Property, plant and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,226&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;160&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,011&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,217&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Restructurings and other charges&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Legal and product liability reserves&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net operating loss/tax credit carryforwards&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,427&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,512&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Unremitted earnings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(79&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;State and local tax adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(3,318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;9,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(11,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,576&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(9,456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Valuation allowances&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total deferred taxes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,288&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(11,988&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(9,456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net deferred tax liability&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4,700&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,948&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories above. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; is primarily related to the capitalization of certain R&amp;amp;D-related expenses.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The decrease in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; is primarily the result of amortization of intangible assets and certain impairment charges, mainly offset by deferred tax liabilities established on intangible assets from the acquisition of Array.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The amounts in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are reduced for unrecognized tax benefits of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in 2019 is primarily related to the Consumer Healthcare joint venture with GSK. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$0.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;). In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$0.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e4760-wk-Fact-48A2AF59E0EAFF0A6B26801F81171029"
      unitRef="usd">2195000000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e4779-wk-Fact-BEE8E31AD112200FA011801F7F3392D2"
      unitRef="usd">204000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpense
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e4800-wk-Fact-D15932B9102F00678306801F7F4183A3"
      unitRef="usd">1655000000</us-gaap:DeferredTaxAssetsTaxDeferredExpense>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e4819-wk-Fact-563A84C808D48A91680F801F7F11733F"
      unitRef="usd">325000000</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e4840-wk-Fact-B6A199DD0727BCEC4725801F7F2F06A4"
      unitRef="usd">373000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e4859-wk-Fact-BE134C05DCF6ADAF9FBF801F7F4DDC1B"
      unitRef="usd">14000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsInventory
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e4879-wk-Fact-8927DC5325C709371727801F81339286"
      unitRef="usd">280000000</us-gaap:DeferredTaxAssetsInventory>
    <us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e4899-wk-Fact-A6D28E13D65A157B5F67801F81407A21"
      unitRef="usd">10000000</us-gaap:DeferredTaxLiabilitiesDeferredExpenseCapitalizedInventoryCosts>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e4927-wk-Fact-91D4D1D5754CB771E91B801F7F1DC0E3"
      unitRef="usd">743000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e4946-wk-Fact-BBB1AC598EA163A20CDE801F7F453119"
      unitRef="usd">7099000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e4966-wk-Fact-5A2A15D93FBF9DBC472E801F7F42D616"
      unitRef="usd">532000000</us-gaap:DeferredTaxAssetsGoodwillAndIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e4986-wk-Fact-E33B08E22E8C41C41495801F7F33C2F5"
      unitRef="usd">7620000000</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5012-wk-Fact-D379165107988FEE1AB7801F7F399F8C"
      unitRef="usd">179000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5031-wk-Fact-29D9AEE0EF874B7D2804801F810F970F"
      unitRef="usd">1226000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5051-wk-Fact-347BAF696A1993925737801F8131C37D"
      unitRef="usd">160000000</us-gaap:DeferredTaxAssetsPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5071-wk-Fact-E89AA763E81D428EDA17801F811E14C7"
      unitRef="usd">1011000000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5097-wk-Fact-B17BA65FC5E9803F8ED2801F8133E381"
      unitRef="usd">2217000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5116-wk-Fact-1F4672D432636FBAB1D9801F811E4A03"
      unitRef="usd">39000000</pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5136-wk-Fact-A26746429C1908FDD4E5801F7F1B893B"
      unitRef="usd">2292000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsEmployeeBenefits>
    <pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5156-wk-Fact-0A18106D10AC563B54F9801F7F18F45F"
      unitRef="usd">134000000</pfe:DeferredTaxLiabilitiesTaxDeferredExpenseCompensationandBenefitsEmployeeBenefits>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5182-wk-Fact-EDC9BC9984C3F470119D801F8127899E"
      unitRef="usd">225000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5220-wk-Fact-BA7D87048EFE8B8832B0801F812594B2"
      unitRef="usd">266000000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsRestructuringCharges>
    <pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5265-wk-Fact-4A34A51B3998F315A6C3801F81061EB9"
      unitRef="usd">496000000</pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves>
    <pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5303-wk-Fact-CDADF0B40C985D2FD733801F814361A2"
      unitRef="usd">415000000</pfe:DeferredTaxAssetsTaxDeferredExpenseReservesandAccrualsLegalandProductLiabilityReserves>
    <pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5350-wk-Fact-783053BF5BCEAF088BA3801F7F1B9FD6"
      unitRef="usd">2427000000</pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5388-wk-Fact-AC840D295965D51F3AEB801F7F1296E1"
      unitRef="usd">2512000000</pfe:DeferredTaxAssetsOperatingLossCarryforwardsAndTaxCreditCarryforwards>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5453-wk-Fact-3886E93F27E98EE28D2C801F7F4E0594"
      unitRef="usd">79000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5493-wk-Fact-6955E2160BED229E172F801F7F0EBB71"
      unitRef="usd">83000000</us-gaap:DeferredTaxLiabilitiesUndistributedForeignEarnings>
    <pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5519-wk-Fact-F9D55A1BA8C4FB2C64FC801F7F4A5D64"
      unitRef="usd">152000000</pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments>
    <pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5557-wk-Fact-365F3C6454AE5427308D801F8123E06B"
      unitRef="usd">264000000</pfe:DeferredTaxAssetsStateandLocalTaxesAdjustments>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5604-wk-Fact-EC03DB407E47C12F595C02108AD6FC21"
      unitRef="usd">11000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5623-wk-Fact-24C3D095E2CC3CF22E410211B6D446C8"
      unitRef="usd">3318000000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxAssetsEquityMethodInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5643-wk-Fact-47070BCAA8F0873AE2800210CE266E9B"
      unitRef="usd">18000000</us-gaap:DeferredTaxAssetsEquityMethodInvestments>
    <us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5663-wk-Fact-CF3BF8A51EB1AF804C9D0215472652F8"
      unitRef="usd">162000000</us-gaap:DeferredTaxLiabilitiesInvestmentInNoncontrolledAffiliates>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5689-wk-Fact-65066DE8900A50DCDF11801F7F0E6375"
      unitRef="usd">196000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5708-wk-Fact-7FCA3EEAD1E583C6014B801F7F1DA91D"
      unitRef="usd">9000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsOther
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5728-wk-Fact-8837BD3A347667C998B0801F7F1627AE"
      unitRef="usd">182000000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxLiabilitiesOther
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5748-wk-Fact-FBAE50428F678875E52F801F7F51C451"
      unitRef="usd">112000000</us-gaap:DeferredTaxLiabilitiesOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5774-wk-Fact-678AA5395AAB27D2692D801F7F41983A"
      unitRef="usd">9215000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5793-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7"
      unitRef="usd">11988000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5813-wk-Fact-55BA3A8CA443922DFC21801F812BB48D"
      unitRef="usd">8576000000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5833-wk-Fact-3156136D7E33FEA3D6A7801F7F106890"
      unitRef="usd">9456000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5859-wk-Fact-40EBEAFCE6C7703C624E801F7F333340"
      unitRef="usd">1927000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5898-wk-Fact-87316DD24D8C6C196E84801F813793DC"
      unitRef="usd">2068000000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5949-wk-Fact-CB369BD69160A09C5DFC801F7F340DDE"
      unitRef="usd">7288000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e5968-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7"
      unitRef="usd">11988000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e5989-wk-Fact-D9F7707EF4A74E9CF2A9801F812F89DC"
      unitRef="usd">6508000000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e6008-wk-Fact-3156136D7E33FEA3D6A7801F7F106890"
      unitRef="usd">9456000000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e6056-wk-Fact-540977569490C9755BD3801F7F1FE236"
      unitRef="usd">4700000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e6097-wk-Fact-2169B9839E1C354CF47B801F7F1FEF95"
      unitRef="usd">2948000000</us-gaap:DeferredTaxLiabilities>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward
      contextRef="FD2019Q4YTD"
      decimals="-8"
      id="d34545404e6195-wk-Fact-B729B37153358FD18E1B801F822A8F9F"
      unitRef="usd">2900000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward
      contextRef="FD2018Q4YTD"
      decimals="-8"
      id="d34545404e6199-wk-Fact-43B0827F2B463BF3D801801F7F58ADAC"
      unitRef="usd">3300000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefitsOperatingLossCarryforwardAndCreditCarryforward>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"
      decimals="-8"
      id="d34545404e6242-wk-Fact-763A330A97E93835FC39801F7FB32AB4"
      unitRef="usd">900000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember"
      decimals="-8"
      id="d34545404e6250-wk-Fact-086B819F1F2ED9F70CA3801F7F5113A9"
      unitRef="usd">5600000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"
      decimals="-8"
      id="d34545404e6263-wk-Fact-AF8EA33F5B1812B0D5C3801F7FA2FF9E"
      unitRef="usd">800000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember"
      decimals="-8"
      id="d34545404e6278-wk-Fact-EEFA2D0875440957E9DB801F82340482"
      unitRef="usd">3700000000</us-gaap:DeferredTaxLiabilities>
    <us-gaap:UndistributedEarningsOfForeignSubsidiaries
      contextRef="FI2019Q4"
      decimals="-8"
      id="d34545404e6312-wk-Fact-552EB646EB24B4826935801F822C3FB4"
      unitRef="usd">29000000000.0</us-gaap:UndistributedEarningsOfForeignSubsidiaries>
    <pfe:UnrecognizedTaxBenefitsExcludingInterest
      contextRef="FI2019Q4"
      decimals="-8"
      id="d34545404e6359-wk-Fact-4EDA2F7467F304BE96E9801F7F648CE0"
      unitRef="usd">4200000000</pfe:UnrecognizedTaxBenefitsExcludingInterest>
    <pfe:UnrecognizedTaxBenefitsExcludingInterest
      contextRef="FI2018Q4"
      decimals="-8"
      id="d34545404e6367-wk-Fact-1A17855576752B62383D801F81A43863"
      unitRef="usd">5100000000</pfe:UnrecognizedTaxBenefitsExcludingInterest>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-8"
      id="d34545404e6386-wk-Fact-F0C58AB0D30FAC60222A801F8127AEF3"
      unitRef="usd">1200000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"
      decimals="-8"
      id="d34545404e6394-wk-Fact-B3BAB779A524D76D2E91801F7F5896CF"
      unitRef="usd">1000000000.0</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_DeferredTaxLiabilitiesNetNoncurrentMember"
      decimals="-6"
      id="d34545404e6401-wk-Fact-B5A08DDC42BCDF95F48A801F8220BDA2"
      unitRef="usd">109000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-8"
      id="d34545404e6409-wk-Fact-D85749D1C3DF3A5BD572801F7F0012EF"
      unitRef="usd">1100000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"
      decimals="-8"
      id="d34545404e6417-wk-Fact-9B6B15AF95D01C886271801F7EE08116"
      unitRef="usd">1000000000.0</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_DeferredTaxLiabilitiesNetNoncurrentMember"
      decimals="-6"
      id="d34545404e6424-wk-Fact-9313CA75922B84E732FB801F81D5AEBF"
      unitRef="usd">128000000</pfe:DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-671A0589A742B88B1FBB801F83146612-0-wk-Fact-87160A3660C682440996801F7DC71A21">&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:97.22222222222221%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The reconciliation of the beginning and ending amounts of gross unrecognized tax benefits follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:0px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(6,259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Acquisitions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increases based on tax positions taken during a prior period&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Decreases based on tax positions taken during a prior period&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;561&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Decreases based on settlements for a prior period&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increases based on tax positions taken during the current period&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(753&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Impact of foreign exchange&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b), (e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, ending&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(5,381&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6,259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For 2019, primarily related to the acquisition of Array. For 2017, primarily related to the acquisitions of Medivation and Anacor. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Provision/(benefit) for taxes on income.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See also &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 5A.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily related to cash payments and reductions of tax attributes.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:24px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily related to decreases as a result of a lapse of applicable statutes of limitations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:12px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Income taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$108 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Current tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;),&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$51 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;). In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Income taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$11 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Current tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax assets and other noncurrent tax assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$47 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Noncurrent deferred tax liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;) and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;). &lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e6616-wk-Fact-5131EE518687D3BFD19B801F7E64723A"
      unitRef="usd">6259000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-6"
      id="d34545404e6636-wk-Fact-597816EBBEA9C653591F801F7EEC46E1"
      unitRef="usd">6558000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2016Q4"
      decimals="-6"
      id="d34545404e6657-wk-Fact-F5108EFBE23CA2D3B82E801F7E3D99DB"
      unitRef="usd">5826000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e6680-wk-Fact-D8BAB29A7AEA2D495984801F80E9FBD5"
      unitRef="usd">44000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e6700-wk-Fact-EF6483D67C1CC41F73AB801F8280AE16"
      unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e6719-wk-Fact-608268E446BF53A67800801F7ECCEFB9"
      unitRef="usd">10000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e6747-wk-Fact-936D6A2CF388244CD289801F80ED7BAA"
      unitRef="usd">36000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e6767-wk-Fact-2D59B5E05ED9F368C224801F80B95B6D"
      unitRef="usd">192000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e6787-wk-Fact-22F8C804B14DB17BB996801F7E35F6F2"
      unitRef="usd">49000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e6816-wk-Fact-06AF0A8C537DC59A1463801F827D4A6F"
      unitRef="usd">1109000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e6835-wk-Fact-14B110795751DD5A5119801F7E469842"
      unitRef="usd">561000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e6854-wk-Fact-4F592E77B2B5EA96F0FA801F7EF1FA0F"
      unitRef="usd">28000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e6882-wk-Fact-F23CE49E146AE8ABD01E801F80CDC5E3"
      unitRef="usd">100000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e6901-wk-Fact-D3921F90DA63770751B7801F7F0233BF"
      unitRef="usd">123000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e6920-wk-Fact-13974E7B4E179154410C801F7E5B86C1"
      unitRef="usd">35000000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e6948-wk-Fact-540CAB81FBF19E5166CE801F82251FFC"
      unitRef="usd">383000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e6968-wk-Fact-E1A13D9EA58071BA48AC801F8231AA2E"
      unitRef="usd">370000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e6988-wk-Fact-DA36ACA13488CC4953E0801F822DA219"
      unitRef="usd">753000000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e7015-wk-Fact-41F52651DBC455660A50801F7E765F09"
      unitRef="usd">-25000000</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e7034-wk-Fact-4ED079FF22AE813B13E1801F80A2650D"
      unitRef="usd">-56000000</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation>
    <pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e7053-wk-Fact-841C7DCDECCC2487454D801F80F3097C"
      unitRef="usd">121000000</pfe:UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation>
    <pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e7082-wk-Fact-1431F69E27412BDBF397801F7E6A58E6"
      unitRef="usd">-107000000</pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther>
    <pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e7101-wk-Fact-C66ABB169512D5FA96F6801F7EE94810"
      unitRef="usd">-121000000</pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther>
    <pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e7120-wk-Fact-85827D800B7F9E2973DA801F80DC2984"
      unitRef="usd">-118000000</pfe:UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e7153-wk-Fact-583AA105D95E04AFAC9B801F7E2BE5D7"
      unitRef="usd">5381000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34545404e7173-wk-Fact-5131EE518687D3BFD19B801F7E64723A"
      unitRef="usd">6259000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2017Q4"
      decimals="-6"
      id="d34545404e7194-wk-Fact-597816EBBEA9C653591F801F7EEC46E1"
      unitRef="usd">6558000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember"
      decimals="-6"
      id="d34545404e7350-wk-Fact-1816CFFF9458B56DB440801F8248D281"
      unitRef="usd">108000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_CurrentTaxAssetsMember"
      decimals="-6"
      id="d34545404e7358-wk-Fact-A96C3597D5A3B4CE10D7E487434AA3D2"
      unitRef="usd">2000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"
      decimals="-6"
      id="d34545404e7367-wk-Fact-FE11DF7FFD9F85DD6032801F82317883"
      unitRef="usd">51000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember"
      decimals="-8"
      id="d34545404e7375-wk-Fact-090D2A341B752BA7D0E2801F8194027D"
      unitRef="usd">2800000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember"
      decimals="-8"
      id="d34545404e7384-wk-Fact-2F7BCEFE3C8437463BAF801F80471155"
      unitRef="usd">2400000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember"
      decimals="-6"
      id="d34545404e7396-wk-Fact-FC5189E17EB5AB41ABAB801F8215B782"
      unitRef="usd">11000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_CurrentTaxAssetsMember"
      decimals="-6"
      id="d34545404e7404-wk-Fact-16CC8D6DB77E99136D81E4884308E0CE"
      unitRef="usd">1000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember"
      decimals="-6"
      id="d34545404e7413-wk-Fact-5F35EAFC34C3D70F3A83801F8253CBA8"
      unitRef="usd">47000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_NoncurrentDeferredTaxLiabilitiesMember"
      decimals="-8"
      id="d34545404e7421-wk-Fact-ECF2C4E26D92FFDF3562801F7F94E038"
      unitRef="usd">3200000000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember"
      decimals="-8"
      id="d34545404e7435-wk-Fact-E61FC398BDF688206289801F7F631802"
      unitRef="usd">3000000000.0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e7466-wk-Fact-97B34122802EC1B4822F801F824E822A"
      unitRef="usd">-564000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e7474-wk-Fact-F1EE088065A52DCFDC3E801F81CC100F"
      unitRef="usd">103000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e7483-wk-Fact-C7D6C99CFE1CF4603C64801F7F59BD31"
      unitRef="usd">208000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e7487-wk-Fact-A38512BECF9994FC35CB801F8222DA73"
      unitRef="usd">485000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e7495-wk-Fact-B5484FFEAFBF4B71E7DF801F81BBD194"
      unitRef="usd">-13000000</pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="FI2018Q4"
      decimals="-8"
      id="d34545404e7500-wk-Fact-CCF68568819E21598906801F7F4FB19A"
      unitRef="usd">1100000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e7508-wk-Fact-C2874A4CBCCB26F05DC1801F7F4A5AF7"
      unitRef="usd">-16000000</pfe:UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember"
      decimals="-6"
      id="d34545404e7520-wk-Fact-BA818087B713C8380E8F801F7EDC0395"
      unitRef="usd">20000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember"
      decimals="-6"
      id="d34545404e7529-wk-Fact-AB1361AF52AA3FAECE5D801F7E029EAA"
      unitRef="usd">465000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember"
      decimals="-6"
      id="d34545404e7541-wk-Fact-4C6587999EDA433052AEE4833875C94C"
      unitRef="usd">6000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_OtherTaxesPayableMember"
      decimals="-8"
      id="d34545404e7554-wk-Fact-5F3BAA22D7842F1B0210801F7F6FE4A4"
      unitRef="usd">1100000000</us-gaap:UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued>
    <us-gaap:IncomeTaxReconciliationTaxSettlements
      contextRef="FD2019Q2QTD"
      decimals="-8"
      id="d34545404e7576-wk-Fact-820F0AB2E3455B89B1C5D508B0396F53"
      unitRef="usd">-1400000000</us-gaap:IncomeTaxReconciliationTaxSettlements>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34545404e7595-wk-Fact-063690F1028046438F4E801F7F0C4E62"
      unitRef="usd">200000000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B457160A54EABE938283801F8315935B-0-wk-Fact-AB670A82CCB5F5E7001B801F7F5EA5A0">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:69%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign currency translation adjustments, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments of certain tax effects from AOCI to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Unrealized holding gains/(losses) on available-for-sale securities, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments for (gains)/losses included in net income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments for tax on unrealized gains from AOCI to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefit plans: actuarial losses, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments related to amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments related to settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments of certain tax effects from AOCI to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefit plans: prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments related to amortization of prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments related to curtailments of prior service costs and other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Reclassification adjustments of certain tax effects from AOCI to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Retained earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Tax provision/(benefit) on other comprehensive income/(loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;518&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;in our 2018 Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;in our 2018 Financial Report.&lt;/span&gt;&lt;/div&gt;</pfe:ScheduleofOtherComprehensiveIncomeLossComponentsofIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e7858-wk-Fact-D363B0E0565C5479A3956F6F31D775C9"
      unitRef="usd">254000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e7877-wk-Fact-7A6A6BE7AC6954D4AA27EA74C266AF79"
      unitRef="usd">94000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e7897-wk-Fact-E60F964DE99E4B40AE50801F7ECFCAC9"
      unitRef="usd">-215000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e7985-wk-Fact-14EE8427216251379FB2DB35DA22921F"
      unitRef="usd">83000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8004-wk-Fact-1630FC0671C050EF8D9447A8118D6A12"
      unitRef="usd">21000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8023-wk-Fact-9B2D44BD7D665244E7D4801F80F7EF91"
      unitRef="usd">72000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8049-wk-Fact-0E98AA3D93CF556C8B16CFFEA1407271"
      unitRef="usd">125000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8069-wk-Fact-0093ACEC508452AF9A2F82E421DD10DE"
      unitRef="usd">-27000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8088-wk-Fact-BF8E217572DBED3A3A5A801F7EE0757F"
      unitRef="usd">224000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e8119-wk-Fact-FF8055EC7C995980A43AA0986DC6DBB3"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e8138-wk-Fact-9CF783F2B69B5D93A482F2C929ED1566"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax
      contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e8157-wk-Fact-13DACBE475EF4ADD4FF8801F828BECB3"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsForeignCurrencyTranslationAdjustmentTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8183-wk-Fact-4ABE41A898CF5A888CADB00DB029A36D"
      unitRef="usd">-42000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8203-wk-Fact-3B7B9F399E625C0EBF51C027705482E0"
      unitRef="usd">50000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8222-wk-Fact-CD9CD6315AF805EE110C801F82314B93"
      unitRef="usd">-152000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossAfterReclassificationTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8249-wk-Fact-5D743E25975C55F698680794C6AAFEF7"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8268-wk-Fact-D910B98A2A495A7F8D104D295E58A27F"
      unitRef="usd">-23000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8288-wk-Fact-AB2A09EB63C492976F0D801F7EEB7CDE"
      unitRef="usd">102000000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8314-wk-Fact-17B1980D02D45F8CBB7A7EE19E813B6C"
      unitRef="usd">-5000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8333-wk-Fact-56219AC4AD4A515C98D6A194CC02DB93"
      unitRef="usd">-16000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8352-wk-Fact-F721A594086A30EF7197801F81E88F06"
      unitRef="usd">60000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax
      contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member"
      decimals="-6"
      id="d34545404e8384-wk-Fact-EE402418A54D574CB441079C7682C003"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax
      contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member"
      decimals="-6"
      id="d34545404e8403-wk-Fact-40C546EC33A35AFE9BEEFE176817495B"
      unitRef="usd">45000000</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax
      contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member"
      decimals="-6"
      id="d34545404e8423-wk-Fact-B8C0D0C18DFF193C78E9801F81F22825"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentForTaxOnUnrealizedGainsIncludedInRetainedEarningsTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8449-wk-Fact-7D2C105FB948503BAF6CC2609691190E"
      unitRef="usd">5000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8468-wk-Fact-2308D4804BC15820A1BF5683286AA0FE"
      unitRef="usd">-53000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8488-wk-Fact-5D53591A115642D67AE0801F7EC62B8C"
      unitRef="usd">42000000</us-gaap:OtherComprehensiveIncomeLossAvailableForSaleSecuritiesTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8514-wk-Fact-7551743EA0D951E684816768D46FC02B"
      unitRef="usd">-169000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8534-wk-Fact-DA7AAA48051D5116A888E1C05B7AF9B0"
      unitRef="usd">-141000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8554-wk-Fact-CA440F669FCEB236B7D8801F7E232594"
      unitRef="usd">-59000000</us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansNetUnamortizedGainLossArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8581-wk-Fact-B996875DBCC5546FAAB96F580C28152A"
      unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8600-wk-Fact-F3FEF704731B57E083E1DC74B4FC2A72"
      unitRef="usd">-55000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8619-wk-Fact-905810C790D95874B61F801F7FF91C19"
      unitRef="usd">-192000000</us-gaap:OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8645-wk-Fact-3FC35AF0A0035C01A2C52C65991A37D0"
      unitRef="usd">-65000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8664-wk-Fact-7DF52F6B60C351408D7D1B4E6372978E"
      unitRef="usd">-33000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8683-wk-Fact-A4B4A3A0512F365E0A32801F7E66E4D9"
      unitRef="usd">-42000000</pfe:OtherComprehensiveIncomeLossSettlementAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansforNetGainLossTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax
      contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e8713-wk-Fact-7F748C891A4E562C8DD5B4D163881419"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax
      contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e8732-wk-Fact-2A00978854A95D9F943FA975DD0E0D7C"
      unitRef="usd">-637000000</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax
      contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e8751-wk-Fact-5E2F8A36DD7104849060801F7E8B4BB0"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansActuarialGainsTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8777-wk-Fact-1150CC9401495F9D800257EC24C62047"
      unitRef="usd">10000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8797-wk-Fact-C56097F7E7AB54E8AE9F4369097D3551"
      unitRef="usd">-29000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8816-wk-Fact-B6A7C6683A702A90E4D1801F8200ACEA"
      unitRef="usd">39000000</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetUnamortizedGainLossArisingDuringPeriodTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8843-wk-Fact-81134306EC6D54A09C274118E4D1C067"
      unitRef="usd">-58000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8863-wk-Fact-9F55F08803BF5F45847FA3A824860C15"
      unitRef="usd">612000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8882-wk-Fact-F3FDA88D35E923A114BB801F80DF4B90"
      unitRef="usd">137000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetActuarialGainLossTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8908-wk-Fact-DF810DD1097A5410A0DF2B9B68489689"
      unitRef="usd">1000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8928-wk-Fact-DF2E50CD4CA35A2BAD120EF77A9E40B7"
      unitRef="usd">-2000000</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e8947-wk-Fact-78686DD7C3CF2BED3AAC801F80261C1C"
      unitRef="usd">0</pfe:DefinedBenefitPlanAmountsRecognizedinOtherComprehensiveIncomeLossNetPriorServiceCostCreditAndOtherTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e8973-wk-Fact-417D7502C1BF56A4B101A79DA9D93249"
      unitRef="usd">-43000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e8993-wk-Fact-A9FA63273C945D2EBB3A7A4D635ACA5A"
      unitRef="usd">-39000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e9013-wk-Fact-2490D79719E94549B951801F825DEFD6"
      unitRef="usd">-67000000</us-gaap:OtherComprehensiveIncomeLossAmortizationAdjustmentFromAOCIPensionAndOtherPostretirementBenefitPlansForNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e9040-wk-Fact-87C57E77ED2851889371E52CAC0A5B81"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e9060-wk-Fact-40C9BC3950405881AB74766C2652C4E3"
      unitRef="usd">-4000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e9080-wk-Fact-80E77E93974A4CCAEF7A801F82C19FF3"
      unitRef="usd">-7000000</pfe:OtherComprehensiveIncomeLossCurtailmentAdjustmentfromAOCIPensionandOtherPostretirementBenefitPlansforNetPriorServiceCostCreditTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax
      contextRef="FD2019Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e9112-wk-Fact-0A2EFD43015A58319E9B6A5301E68F22"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax
      contextRef="FD2018Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e9131-wk-Fact-04675E47A2C7545A8AB05010E81694A0"
      unitRef="usd">-144000000</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax>
    <pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax
      contextRef="FD2017Q4YTD_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member"
      decimals="-6"
      id="d34545404e9151-wk-Fact-8EA5960B76BF5C90C28C801F7E3E9349"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossReclassificationAdjustmentfromAOCItoRetainedEarningsDefinedBenefitPlansPriorServiceCostsCreditsTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e9177-wk-Fact-36227FCE11595F1F9D306583FDE3D074"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e9196-wk-Fact-755F73D7231255828A1000E65ADC951D"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e9215-wk-Fact-125154CCF8A90975CB54801F7EDF647C"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossPensionandOtherPostretirementBenefitPlansOtherNetPriorServiceCostCreditArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e9241-wk-Fact-D9381AAF79DA5454BE10EDA3EB3EB5B6"
      unitRef="usd">45000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e9261-wk-Fact-BCD4F0E137B953A7A2950B6827C5DBB1"
      unitRef="usd">185000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e9281-wk-Fact-C55F5FB0BDA5A6D6BFB9801F7E9B9974"
      unitRef="usd">74000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansBenefitPlanImprovementTaxEffect>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34545404e9313-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
      unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34545404e9332-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
      unitRef="usd">518000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:OtherComprehensiveIncomeLossTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34545404e9352-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
      unitRef="usd">-262000000</us-gaap:OtherComprehensiveIncomeLossTax>
    <us-gaap:ComprehensiveIncomeNoteTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C6360B662F97512739DF801F83155286-0-wk-Fact-E3F3B121856F1F639616801F8270F361">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests&lt;div style="line-height:100%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the changes, net of tax, in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Net Unrealized Gain/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Actuarial Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Prior Service (Costs)/ Credits and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Balance, January 1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(11,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(9,321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other comprehensive income/(loss) due to the adoption of new accounting standards&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(893&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(1,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,075&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(11,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(6,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(11,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:100%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:100%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$11 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; loss in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; loss in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$14 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; income in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Amounts in 2019 include after-tax gains of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$978 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), partially offset by the strengthening of the U.S. dollar against the euro and the Australian dollar, and the results of our net investment hedging program.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:100%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:100%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;in our 2018 Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we estimate that we will reclassify into 2020 income the following pre-tax amounts currently held in&lt;/span&gt;&lt;span style="font-family:Arial;font-size:11pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Accumulated other comprehensive loss:&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$179 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of unrealized pre-tax net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;gains&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; on derivative financial instruments (which are expected to be offset primarily by net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;losses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; from foreign currency exchange-denominated forecasted intercompany inventory sales upon the sale of the inventory to a third party); &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$265 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$178 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of prior service credits, primarily related to benefit plan amendments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-7E7D74B57003153923E9801F8315CC5F-0-wk-Fact-C534EFF51308BA9974D0801F827478B4">&lt;div style="line-height:100%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:31%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the changes, net of tax, in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Net Unrealized Gain/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Benefit Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Foreign Currency Translation Adjustments &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Derivative Financial Instruments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Available-For-Sale Securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Actuarial Gains/(Losses)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Prior Service (Costs)/ Credits and Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Accumulated Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Balance, January 1, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,659&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;879&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(11,036&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,715&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Balance, December 31, 2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(9,321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other comprehensive income/(loss) due to the adoption of new accounting standards&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(416&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(637&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(913&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(893&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(128&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(1,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,075&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;728&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(11,275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;123&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(231&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(6,257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(11,640&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:100%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:100%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$11 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; loss in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; loss in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$14 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; income in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Amounts in 2019 include after-tax gains of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$978 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), partially offset by the strengthening of the U.S. dollar against the euro and the Australian dollar, and the results of our net investment hedging program.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:100%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:100%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;in our 2018 Financial Report.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d34460716e1741-wk-Fact-45B677F0CAC7B2BB8E94801F828E270A"
      unitRef="usd">-6659000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e1761-wk-Fact-0E1AD8AA858515F533CF801F82A8444C"
      unitRef="usd">348000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d34460716e1781-wk-Fact-B35E76F70D28C4AEDAAC801F7F632F3A"
      unitRef="usd">-131000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e1801-wk-Fact-A9AB3B70952527329597801F82A8F5C5"
      unitRef="usd">-5473000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e1821-wk-Fact-9F0D8940B8C31C6C01B7801F7F946036"
      unitRef="usd">879000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2016Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34460716e1841-wk-Fact-67FB49FA8269AAD714CF801F827EF758"
      unitRef="usd">-11036000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d34460716e1864-wk-Fact-925E28131BC6D032A9E6801F827FCD84"
      unitRef="usd">1479000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e1883-wk-Fact-D71CC752F8554F4A326D801F7F9F4E99"
      unitRef="usd">-378000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d34460716e1903-wk-Fact-798B7A350A5E13556B82801F82A90157"
      unitRef="usd">532000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e1923-wk-Fact-F0E9225B40E6D9F21243801F7E9BDD39"
      unitRef="usd">211000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e1942-wk-Fact-EC3C848AE6A9CBDEC522801F7E7CD417"
      unitRef="usd">-129000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34460716e1963-wk-Fact-73675557E3290275CFB2801F8179DBF8"
      unitRef="usd">1715000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d34460716e1988-wk-Fact-C2B9A885BD41E748D726801F7F95A6F9"
      unitRef="usd">-5180000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e2008-wk-Fact-AF4DC105F488A9B76F07801F82809612"
      unitRef="usd">-30000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d34460716e2028-wk-Fact-12458EC442838137DFE2801F7F5E1492"
      unitRef="usd">401000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e2048-wk-Fact-98F0E97021A68E61CFF6801F82888A95"
      unitRef="usd">-5262000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e2068-wk-Fact-5C11A243F019E5C8E2A9801F7F5E83A9"
      unitRef="usd">750000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2017Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34460716e2088-wk-Fact-62FC79EF34B6077783F9801F828D4F15"
      unitRef="usd">-9321000000</us-gaap:StockholdersEquity>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d34460716e2116-wk-Fact-7B2716E1C24FE2422E5FCF6EF0CCB67A"
      unitRef="usd">-2000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e2136-wk-Fact-07A3726E8AD3C897B843CF6EF6032DBA"
      unitRef="usd">-1000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201601Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d34460716e2156-wk-Fact-B51D44885CA609BBF357CF6EFC35BB67"
      unitRef="usd">-416000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e2177-wk-Fact-38838F053717CF5598FFCF6EFFF59BAF"
      unitRef="usd">-637000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Jan01_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_us-gaap_AccountingStandardsUpdate201802Member_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e2197-wk-Fact-95156657E2A6B44ABF2BCF6F034F6554"
      unitRef="usd">144000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption
      contextRef="I2018Q1Jan01_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34460716e2217-wk-Fact-8B8742C522CFC603BD73CF6F077A96B2"
      unitRef="usd">-913000000</us-gaap:CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d34460716e2245-wk-Fact-AAFD78C12C113C0D686D801F8281F391"
      unitRef="usd">-893000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e2265-wk-Fact-7BBA68F22C4A3BB9286A801F7F95841D"
      unitRef="usd">198000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d34460716e2284-wk-Fact-74D8FB512BB0C16FBCA9801F7F9F040A"
      unitRef="usd">-53000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e2305-wk-Fact-AA09423469405CACDD8C801F7F53FDB0"
      unitRef="usd">-128000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e2325-wk-Fact-2101798BE4EDF6E78C8F801F803DE4E4"
      unitRef="usd">-166000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34460716e2346-wk-Fact-FFFCC0F0F24614B44437801F828D0336"
      unitRef="usd">-1041000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d34460716e2372-wk-Fact-0689B897DFBC5343838A8A7EB0A52E72"
      unitRef="usd">-6075000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e2392-wk-Fact-DA332392557D5698BA6257EDB819B3ED"
      unitRef="usd">167000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d34460716e2411-wk-Fact-895D5C0C88E55E1B96A4FA1F22547BAB"
      unitRef="usd">-68000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e2432-wk-Fact-BBA2A405B9915134881653F29E094498"
      unitRef="usd">-6027000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e2452-wk-Fact-2CB61C1AD5CE5D859A08D0BA215C1D89"
      unitRef="usd">728000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2018Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34460716e2472-wk-Fact-447ADAC3DD0B55E9A6CBCBA1E1BC0F65"
      unitRef="usd">-11275000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d34460716e2500-wk-Fact-80135A3F2616CE4B3FFE801F7E2617E5"
      unitRef="usd">123000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e2519-wk-Fact-56CDBBCBD4E37D7B159C801F7FF5592A"
      unitRef="usd">-146000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d34460716e2539-wk-Fact-6D3E645E9EBC03EFCF4B801F82A9D31C"
      unitRef="usd">33000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e2559-wk-Fact-4158106AA31D76C528FD801F7F58702B"
      unitRef="usd">-231000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e2579-wk-Fact-C3564D2578C699EB2759801F8289A914"
      unitRef="usd">-144000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34460716e2600-wk-Fact-50C71B602D558F20976C801F828D6F53"
      unitRef="usd">-365000000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedTranslationAdjustmentMember"
      decimals="-6"
      id="d34460716e2631-wk-Fact-06D7A8BC9046570A84EF75C326DEC822"
      unitRef="usd">-5952000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e2651-wk-Fact-073F8F502DCA5A9A95A692421AEC503D"
      unitRef="usd">20000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"
      decimals="-6"
      id="d34460716e2671-wk-Fact-E3C97EAFCD455D8082781F59E563A366"
      unitRef="usd">-35000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e2691-wk-Fact-060AC96DC6AD5934B52935ADA8EC68E5"
      unitRef="usd">-6257000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e2711-wk-Fact-4666F139A7605E0CA364A6577C1CB991"
      unitRef="usd">584000000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="FI2019Q4_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember"
      decimals="-6"
      id="d34460716e2731-wk-Fact-3C8FFBEEEB0F5A01AE02EF005CAE3929"
      unitRef="usd">-11640000000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34460716e2752-wk-Fact-BF952FA65727E3F2FF24801F827DA355"
      unitRef="usd">-11000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34460716e2760-wk-Fact-1A7F82C1579D03FCE652801F827D8FD8"
      unitRef="usd">-20000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34460716e2768-wk-Fact-03AC7888089D910F5F60801F826DDC85"
      unitRef="usd">14000000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest>
    <us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
      contextRef="FD2019Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34460716e2784-wk-Fact-7585EA770858DD8F140716EB02CF3463"
      unitRef="usd">978000000</us-gaap:OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember"
      decimals="-6"
      id="d34460716e2830-wk-Fact-13A3ADFFD070509FB934DDECF30C0647"
      unitRef="usd">179000000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember"
      decimals="-6"
      id="d34460716e2851-wk-Fact-D723C9396BE2C89E7E25171D9AE5E56B"
      unitRef="usd">-265000000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths
      contextRef="FD2019Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember"
      decimals="-6"
      id="d34460716e2855-wk-Fact-1F46739006A073AA9C40171D53707AD7"
      unitRef="usd">178000000</us-gaap:CashFlowHedgeGainLossToBeReclassifiedWithinTwelveMonths>
    <us-gaap:FinancialInstrumentsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C6E571358FCD4C6B8359801F8316BFE3-0-wk-Fact-EE1A927A3B971A7EEA4B801F7E3F853A">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Financial Instruments&lt;/span&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Fair Value Measurements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-style:italic;"&gt;Note 1E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Classified as equity securities with readily determinable fair values:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;9,609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;9,609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;15,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;15,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;7,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;7,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;16,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;16,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Derivative assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Classified as equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;2,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,764&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Derivative assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total derivative assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Insurance contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;11,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;9,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;20,110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;18,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Financial liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, long-term equity securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$176 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, short-term equity securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$11 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and long-term equity securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$132 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in the consolidated statements of income (see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:bold;"&gt;Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Long-term debt, excluding the current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;35,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;40,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;40,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;32,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;35,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;35,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In addition, as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we had long-term receivables whose fair value is based on Level 3 inputs. As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the differences between the estimated fair values and carrying values of these receivables were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Total Short-Term and Long-Term Investments and Equity-Method Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table represents our investments by classification type:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Total Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;17,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Private equity securities at cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Total Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;20,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,767&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Fair Value Methodology&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following inputs and valuation techniques were used to estimate the fair value of our financial assets and liabilities:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Available-for-sale debt securities&#x2014;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities with readily determinable fair values&#x2014;quoted market prices and observable net asset value prices.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative assets and liabilities&#x2014;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Money market funds&#x2014;observable net asset value prices.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B. Investments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Debt Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="45"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Maturities (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;9,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;9,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Corporate and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;798&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;8,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;8,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;16,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;16,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily issued by a diverse group of corporations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Equity Securities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table presents the net unrealized (gains) and losses for the period that relate to equity securities, excluding equity method investments, still held at the reporting date, calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net gains recognized during the period on equity securities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Net gains recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net unrealized gains during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(429&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The net gains on equity securities are reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. Short-Term Borrowings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Commercial paper &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,915&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,458&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,847&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other short-term borrowings primarily include cash collateral. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 7F&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The weighted-average effective interest rate on commercial paper outstanding was approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.92%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.42%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we had access to a total of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$15 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in U.S. revolving credit facilities consisting of a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; facility expiring in 2024 and an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; facility expiring in September 2020, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$537 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in lines of credit, of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$508 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; expire within one year. Of these total lines of credit, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$15.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; were unused as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;D. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Long-Term Debt&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;New Issuances&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the first quarter of 2019, we issued the following senior unsecured notes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2.800% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;11, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2.950% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;15, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;3.450% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;15, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;3.900% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;15, 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;4.000% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;15, 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total long-term debt issued in the first quarter of 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The weighted-average effective interest rate for the notes at issuance was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3.57%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In September 2018, we completed a public offering of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.56%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In March 2017, we completed a public offering of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.065 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; principal amount of senior unsecured notes due 2047 with an interest rate of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.20%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and also in March 2017, we completed a public offering of &#x20ac;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; principal amount of senior unsecured notes with a weighted-average effective interest rate of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0.23%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Retirements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In January 2019, we repurchased all &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x20ac;1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, at exchange rates on settlement) principal amount outstanding of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; euro-denominated debt that was due June 2021 before the maturity date at a redemption value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x20ac;1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, at exchange rates on settlement). As a result, in the first quarter of 2019, we recorded a net loss of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$138 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, which included the related termination of cross-currency swaps, and is reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in the consolidated statements of income (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In December 2017, we exchanged approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#xa3;833 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and repurchased &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#xa3;197 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; principal amount of the outstanding &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; debt before the maturity date at a redemption value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#xa3;1.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, leaving &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#xa3;470 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; principal amount of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.50%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; debt due 2038 outstanding. Also, in December 2017, we repurchased approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x20ac;834 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; principal amount of the outstanding &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; debt before the maturity date at a redemption value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x20ac;1.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, leaving approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x20ac;1.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.75%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; euro-denominated debt due 2021 outstanding as of December 31, 2017. As a result, we recorded a net loss of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$846 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$153 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; upon the exchange and early retirement of the U.K. pound-denominated debt and the early retirement of the euro-denominated debt, respectively, for a net loss on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$999 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, which included the related termination of cross-currency swaps, and that were recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the consolidated statement of income (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2019 and 2018 by maturity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2020 (1.2%)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,474&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2021 (0.7% and 3.4%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2022 (1.0% and 0.3%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,624&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2023 (3.7% and 3.8%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2024 (3.9% and 4.4%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2026-2029 (3.3%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2034 (6.5%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2036-2040 (5.8% and 6.0%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2043-2044 (3.5%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2046-2049 (4.1% and 4.2%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;34,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;At December 31, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the debt issuances have been reclassified to the current portion of long-term debt.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our long-term debt, provided in the above table, is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;E. Other Noncurrent Liabilities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Mylotarg (gemtuzumab ozogamicin)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In April 2018, the EU approved Mylotarg for the treatment of acute myeloid leukemia. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ten&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year period aggregating &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$301 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to an R&amp;amp;D arrangement. We recorded the estimated net present value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$240 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as a liability and an intangible asset in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of the approval date. In June 2018, we entered into a transaction with the obligee to buyout the remaining liability for the fixed annual payments for a lump sum payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$224 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. As a result of the buyout transaction, the liability was extinguished and we recognized a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$17&#160;million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the second quarter of 2018 (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Bosulif (bosutinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In December 2017, the FDA approved Bosulif for the treatment of patients with newly-diagnosed chronic-phase Ph+ CML. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ten&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year period aggregating &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$416 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to an R&amp;amp;D arrangement. We recorded the estimated net present value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$364 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of the approval date as an intangible asset in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In August 2018, we entered into a transaction with the obligee to buyout a portion of the remaining liability for the fixed annual payments for a lump sum payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. As a result of the buyout transaction, the liability was reduced and we recognized a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$9 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the third quarter of 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; The present value of the remaining future payments as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$191 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$22 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$169 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Besponsa (inotuzumab ozogamicin)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In August 2017, the FDA approved Besponsa and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year period aggregating &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$296 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to an R&amp;amp;D arrangement. We recorded the estimated net present value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$248 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of the approval date as an intangible asset in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The present value of the remaining future payments as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$242 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$7 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$235 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;nine&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year period aggregating &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$148 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; related to an R&amp;amp;D arrangement. We recorded the estimated net present value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$123 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of the approval date as an intangible asset in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The present value of the remaining future payments as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$122 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the differences between&#160;the estimated fair values, using a market approach in the Level 2 fair value hierarchy, and carrying values of these obligations were not significant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;F&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Derivative Financial Instruments and Hedging Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Foreign Exchange Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet. The derivative financial instruments primarily hedge or offset exposures in the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;euro, U.K. pound, Japanese yen, Chinese renminbi and Swedish krona&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. Changes in fair value are reported in earnings or in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, depending on the nature and purpose of the financial instrument (hedge or offset relationship) and the effectiveness of the hedge relationships, as follows: &lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Generally, we record in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings. For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We record in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. For foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For certain foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses on foreign currency exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-denominated intercompany inventory sales expected to occur no more than &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; from the date of each hedge. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For 2017, any ineffectiveness was recognized immediately into earnings. There was no significant ineffectiveness for 2017.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Interest Rate Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings, as follows:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We recognize the gains and losses on interest rate contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We also recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk in earnings.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For 2017, any ineffectiveness was recognized immediately into earnings. There was no significant ineffectiveness for 2017.&lt;/span&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;25,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;22,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;19,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of December 31, 2018.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount of&lt;br/&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount excluded from effectiveness testing recognized in earnings based on an amortization approach&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All other net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;808&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;OID = Other (income)/deductions&#x2014;net,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in the consolidated statements of income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other comprehensive income/(loss)&#x2013;&#x2013;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other comprehensive income/(loss)&#x2013;&#x2013;Foreign currency translation adjustments, net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The amounts reclassified from OCI into COS were a net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$247 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in 2019 and a net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$13 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in 2018. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$145 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; within the next 12 months into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The maximum length of time over which we are hedging future foreign exchange cash flow relates to our &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; U.K. pound debt maturing in 2043. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;These amounts were reclassified from OCI into OID. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Short-term borrowings include foreign currency short-term borrowings with carrying values of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which are used as hedging instruments in net investment hedges.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cumulative Amount of Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Value Hedging Adjustment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,499&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain of our derivative financial instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties&#x2019; exposure to risk of defaulting on amounts owed by the other party. As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the aggregate fair value of these derivative financial instruments that are in a net liability position was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$449 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, for which we have posted collateral of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$470 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the normal course of business. If there had been a downgrade to below an A rating by S&amp;amp;P or the equivalent rating by Moody&#x2019;s, we would not have been required to post any additional collateral to our counterparties. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we received cash collateral of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$835 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;G. Credit Risk&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. For additional information about concentrations of credit risk related to certain significant customers, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 17C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we had amounts due from a well-diversified, high quality group of banks (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$1.4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) from around the world. For details about our investments, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 7B &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;above&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 7F&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; above.&lt;/span&gt;&lt;/div&gt;</us-gaap:FinancialInstrumentsDisclosureTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-97951772D086F2E7D669801F831564D4-0-wk-Fact-49BE2C853E6AF7073601801F7E409B90">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:42%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-style:italic;"&gt;Note 1E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Financial assets measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Classified as equity securities with readily determinable fair values:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Money market funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,583&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;9,609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;9,609&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,437&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,013&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;15,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;15,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;7,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;7,392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;16,691&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;16,674&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Derivative assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total other current assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;574&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Classified as equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Classified as available-for-sale debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency&#x2014;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency&#x2014;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Corporate and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;2,216&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;354&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,764&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,243&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Derivative assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total derivative assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Insurance contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;575&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;515&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total other noncurrent assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,082&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;11,176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;9,313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;20,110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;18,850&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Financial liabilities measured at fair value on a recurring basis:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;78&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total other current liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Derivative liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;378&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;564&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total other noncurrent liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, long-term equity securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$176 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, short-term equity securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$11 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and long-term equity securities of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$132 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in the consolidated statements of income (see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d34496162e2136-wk-Fact-18A31C1027BB58C7AEE2D01F4BAFE1A4"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d34496162e2155-wk-Fact-EA8F59D151265C778A8BF582D77C5F0F"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d34496162e2175-wk-Fact-2FAA3D8195A85949B1B7904C1AF5FAEE"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d34496162e2194-wk-Fact-68FE043C11DF54BC9F0FFE645351BD48"
      unitRef="usd">1571000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d34496162e2213-wk-Fact-F4E96D2D7D3F55B8B9ADE3F7599880D8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_MoneyMarketFundsMember"
      decimals="-6"
      id="d34496162e2233-wk-Fact-E79DA86BB814502983E0AD71C67E2D07"
      unitRef="usd">1571000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-6"
      id="d34496162e2255-wk-Fact-82A2245601F85681A011C5CF5DC22574"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-6"
      id="d34496162e2274-wk-Fact-CC4D6529B853515DB76F971BB80BD1F7"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-6"
      id="d34496162e2293-wk-Fact-96F4F464AA385AAC8472ED5CE5876AE8"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-6"
      id="d34496162e2313-wk-Fact-F565F733B4BA5FB3ADE3708106F7C196"
      unitRef="usd">29000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-6"
      id="d34496162e2332-wk-Fact-9854A94284F15962BD709C1580BF94CD"
      unitRef="usd">17000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_EquitySecuritiesMember"
      decimals="-6"
      id="d34496162e2352-wk-Fact-EF9132C281325EE9AE260DB5D59CEC4A"
      unitRef="usd">11000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e2377-wk-Fact-CCB52DE5DD65542F8C2130217B569DED"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e2396-wk-Fact-FF683B87604B5AA0BDFF0C60E4A26196"
      unitRef="usd">0</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e2415-wk-Fact-1E44D0DF9C955A63A29BB0B87F7FCBF9"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e2435-wk-Fact-CEB8B772487B5B06A33B1C9CAF5BD42B"
      unitRef="usd">1600000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e2454-wk-Fact-26187F0F4DCC5BB49F82A4FF2EFEB8D1"
      unitRef="usd">17000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e2474-wk-Fact-BC134874FE23539EB55130C0C5C3883B"
      unitRef="usd">1583000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2627-wk-Fact-C4D233838522D85F276FE492C1893CCB"
      unitRef="usd">4863000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2646-wk-Fact-FB348C48D67827AA929FE492C1FC405B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2665-wk-Fact-C288FFF8E55A42068BBBE492C1785EA8"
      unitRef="usd">4863000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2685-wk-Fact-0F43A348432352809466BA6165ACC781"
      unitRef="usd">9609000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2704-wk-Fact-3A138C1AA4265C5A8C51D5EF397A96D7"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2724-wk-Fact-E01927E7540E55609E2F028A9E13CEBA"
      unitRef="usd">9609000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2750-wk-Fact-BEB6FA8944B221D5D3ACE4969D2B28CF"
      unitRef="usd">811000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2769-wk-Fact-32AC1CE3A82326390403E496A5FA0032"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2788-wk-Fact-33E26AFC9B29497D5F28E496B2295334"
      unitRef="usd">811000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2808-wk-Fact-0A888C6EA71281096E7EE496BE5BE562"
      unitRef="usd">3437000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2827-wk-Fact-A01EB7CCDF98B20D0963E496C8212B0F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2847-wk-Fact-54C311CFC9AB409967BEE496D546A1BA"
      unitRef="usd">3437000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2872-wk-Fact-5077E4384E7A561BF943E492C19F9D79"
      unitRef="usd">1013000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2891-wk-Fact-84F716536FFD7461E32FE492C1AF5AD8"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2910-wk-Fact-9D175383CC37B74A3499E492C1D64386"
      unitRef="usd">1013000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2930-wk-Fact-325CA3D29BCC5DFAB11F3EEAD5E9BC5F"
      unitRef="usd">2045000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2949-wk-Fact-315360939EAA54B1B683FA1723D1E241"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e2969-wk-Fact-704A8BE5CDEA5D89A5BB1DCAEFBA04C5"
      unitRef="usd">2045000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e2994-wk-Fact-1DC111F71152E373E9A3E492C1ECC35C"
      unitRef="usd">6687000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3013-wk-Fact-978B9851E588046AB935E492C15A77A9"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3032-wk-Fact-587EC5D4D115CF7E6E53E492C1C5CB21"
      unitRef="usd">6687000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3052-wk-Fact-1340C63DB9D65E649AA906709DE68608"
      unitRef="usd">15091000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3071-wk-Fact-1EAD0055E74C5D478C6750898FAB8A74"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3091-wk-Fact-E7EE26479BEC513FBF2ACA13187EB86F"
      unitRef="usd">15091000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3116-wk-Fact-935E22FFBF5AAFEE4AF1E492C23879F8"
      unitRef="usd">7392000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3135-wk-Fact-86B2386B118EB38735FBE492C2285E2C"
      unitRef="usd">0</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3154-wk-Fact-5B22A20F564EA38D7879E492C212632F"
      unitRef="usd">7392000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3174-wk-Fact-8749D47064FB54E9933321CE575E44EC"
      unitRef="usd">16691000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3193-wk-Fact-3A9E58C8B4A85F76B7F283490AD3C962"
      unitRef="usd">17000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3213-wk-Fact-8358C43DF139515D9C21DE64E451060A"
      unitRef="usd">16674000000</pfe:ShorttermInvestmentsExcludingHeldToMaturitySecurities>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3494-wk-Fact-D7DF3A09858B55868ECE129A95EFE4FC"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3513-wk-Fact-BA94DEFAE4E6538F965D0700DFFBE9B5"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3532-wk-Fact-DEC9C8E8C4AD5EB79A3AE4083CEF7E09"
      unitRef="usd">53000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3552-wk-Fact-0E03A97C9221553EB38057AA4DD0D52F"
      unitRef="usd">97000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3571-wk-Fact-6DA6B830F80755E9889BD443B66DA5B4"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3591-wk-Fact-0F56928953AD53F2AD1F6EAB148221B9"
      unitRef="usd">97000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3616-wk-Fact-EE086EFDC8FA52CCB471FE8C94E16435"
      unitRef="usd">413000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3635-wk-Fact-CF5518D0FB265AAA939627B794ECEFC5"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3654-wk-Fact-35A8FB07BE6D5A63A2013D50650B7DEA"
      unitRef="usd">413000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3674-wk-Fact-42C381B09D9B518A9A7191BDF380D611"
      unitRef="usd">477000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3693-wk-Fact-DBDBE6E5915C5182B38AF6FDB20D4289"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3713-wk-Fact-5307CF33306B5D62862738025E01DF12"
      unitRef="usd">477000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3738-wk-Fact-8AE409969906556DA1D53C980AC310B0"
      unitRef="usd">465000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3757-wk-Fact-01ACA4F20AB650619B7440B93917DE4C"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3776-wk-Fact-CCECB9974AF95B5F9EE035BF23A75955"
      unitRef="usd">465000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3796-wk-Fact-21DF23FF6C4C59DD9E2D3E728846EBA2"
      unitRef="usd">574000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3815-wk-Fact-D028FF2C08935CD9AE09E6D0E70533FE"
      unitRef="usd">0</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:DerivativeAssetsCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3835-wk-Fact-CD39609331BC5197B01763529602916E"
      unitRef="usd">574000000</us-gaap:DerivativeAssetsCurrent>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e3990-wk-Fact-5179B25EF13E5D03A1D07028891DCE31"
      unitRef="usd">1902000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4009-wk-Fact-600150099E535A6B80046F755F61C891"
      unitRef="usd">1863000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4028-wk-Fact-C57C6FA8EFB95CF381E0002884269AA9"
      unitRef="usd">39000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4048-wk-Fact-8B5032647C685E9F9D6182CF0CECC704"
      unitRef="usd">1273000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4067-wk-Fact-6E4007B2C88C5199890DA9C2769B5FEA"
      unitRef="usd">1243000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4087-wk-Fact-7458E0BF72155C08BCB5FE5F3AECA0AF"
      unitRef="usd">30000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4241-wk-Fact-A717235A24F9529BA4CAE4A93E01F11F"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4260-wk-Fact-6D1C11320F745232A6B45B64ECDF855C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4279-wk-Fact-903BDDA5C92A5EFE9DACA3579B11388C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4299-wk-Fact-03F8CAA92E315BBE84140B697EA81F5B"
      unitRef="usd">94000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4318-wk-Fact-9E4A63A2CDDA5380B4E12D11690D3288"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4338-wk-Fact-2D0CE7B602F850499115214B23691F30"
      unitRef="usd">94000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4363-wk-Fact-6FBE889C698B9862CC16E495A2997897"
      unitRef="usd">303000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4382-wk-Fact-B00DE80EAD8FD1FEB4F3E495AE6566B4"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4401-wk-Fact-7B4D458BF2AD62C9C279E495BDE1A56F"
      unitRef="usd">303000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4421-wk-Fact-6B43A18CDC36B0745648E495C8579E94"
      unitRef="usd">345000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4440-wk-Fact-C90053C9FF3B013F818FE495D20C0A20"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4460-wk-Fact-CABF50D72BF9D0D7717CE495DCF152EC"
      unitRef="usd">345000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4485-wk-Fact-DB7E035B52545F9684840ED31FAA73EA"
      unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4504-wk-Fact-305270CD550F5BE4A26F0069121DCBB1"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4523-wk-Fact-BE807AB737D65A628603813AF86048D6"
      unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4543-wk-Fact-A941D61E67FC510A89C7BFCD14430154"
      unitRef="usd">52000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4562-wk-Fact-0D65DD0C4BE65C79BB91BA309F46864A"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34496162e4582-wk-Fact-6387209973DC50E6B4E4A436C2EED446"
      unitRef="usd">52000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4607-wk-Fact-70C7D977F3BF5855A2CFCAA6F80FA1E7"
      unitRef="usd">315000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4626-wk-Fact-AAEA41CCB0205B50938F2E5C8461493B"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4645-wk-Fact-AC369E91E45457C18B876B8FF7A1A832"
      unitRef="usd">315000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4665-wk-Fact-7AA2BA053AA95E74ACA2FC251B8DEB0B"
      unitRef="usd">491000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4684-wk-Fact-22A737D942F75227B2ADDDF3B788A91C"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4704-wk-Fact-5CC6477F813F52EDA085A9676B88A165"
      unitRef="usd">491000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4729-wk-Fact-9AB951C740D95C2B856C33A24A2DD8A9"
      unitRef="usd">2216000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4748-wk-Fact-750AEC70E0C0589CBE6F8EB2DF3B4686"
      unitRef="usd">1863000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4767-wk-Fact-E004DB8AC02057C89199EC46EF3C60C7"
      unitRef="usd">354000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4787-wk-Fact-18DEE7C8F0565278872947FD1E794B3D"
      unitRef="usd">1764000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4806-wk-Fact-9479348F703C5D70905D4147AAAAC37F"
      unitRef="usd">1243000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e4826-wk-Fact-637AA01CC45C5CF3A8A73104013714D4"
      unitRef="usd">521000000</pfe:LongtermInvestmentsExcludingHeldToMaturitySecuritiesAndPrivateEquityInvestments>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5107-wk-Fact-CF6FF91EA0C656829B0FE9BCD0F437F1"
      unitRef="usd">266000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5126-wk-Fact-330BA14691C35D85BF0A08554B551678"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5145-wk-Fact-AFCC550826335673871863EA1BF058E3"
      unitRef="usd">266000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5165-wk-Fact-B0FDBB60323852A69746D3D88D52EA2E"
      unitRef="usd">335000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5184-wk-Fact-3CF1EBDAE05A5B9687F1241ECDEA475D"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5204-wk-Fact-FB292FBDF9955A15B2B0826F09654CF6"
      unitRef="usd">335000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5229-wk-Fact-5AEA46F5548F51A9BC889C00FCD90958"
      unitRef="usd">261000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5248-wk-Fact-1F69C9931CB35D6EB11DD36D79F8E4E2"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5267-wk-Fact-28ACC47374E85BE499E3952D62C96425"
      unitRef="usd">261000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5287-wk-Fact-E174AC0DB1515C5F94C362F71A12F7DD"
      unitRef="usd">232000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5306-wk-Fact-3572C66DD48C50C5A5E64A0AB46068D6"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5326-wk-Fact-625FA27659285EF48A9E7E763EFB8313"
      unitRef="usd">232000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5351-wk-Fact-B0DA2F41368A5038BCD9C7AC01BAA2EC"
      unitRef="usd">526000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5370-wk-Fact-E64826395A6151B2931C102DE0198C19"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5389-wk-Fact-1BE30E22F1CA5A9F869BD4C2DFE5DA2B"
      unitRef="usd">526000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5409-wk-Fact-C7F7003A3AD95E89BC3924C47864116F"
      unitRef="usd">566000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5428-wk-Fact-A15C45D042075C208067A211014F6CF0"
      unitRef="usd">0</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:DerivativeAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5448-wk-Fact-8BE904F401E05C03AD2D4FAE21091311"
      unitRef="usd">566000000</us-gaap:DerivativeAssetsNoncurrent>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5476-wk-Fact-1260CCD84F5EAA993014023A45379D65"
      unitRef="usd">575000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5495-wk-Fact-FE5FA64237140370947E0C1E584B0DA8"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5514-wk-Fact-9120BAFF50D1AEC6196F023AB29B9891"
      unitRef="usd">575000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5534-wk-Fact-09A4B51093258130F5FD023AB0BF7398"
      unitRef="usd">515000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5553-wk-Fact-8A8CC7E111309130A3F9023AB1C2B87A"
      unitRef="usd">0</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5573-wk-Fact-CC98EE15F05729F82BC1023AB01871BC"
      unitRef="usd">515000000</us-gaap:LifeSettlementContractsFairValueMethodCarryingAmount>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5598-wk-Fact-664194EED949E86811A20230BABF845E"
      unitRef="usd">1102000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5617-wk-Fact-3C60B4A7CB4612E88D3C0230BBDA0271"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5636-wk-Fact-896D109D3632C3DC21120230BC07B0C1"
      unitRef="usd">1102000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5656-wk-Fact-CEA4DCE70A52E69024AE0230B99E6DCC"
      unitRef="usd">1082000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5675-wk-Fact-3575C07F4462677F03940230BA2F6E24"
      unitRef="usd">0</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentAssetsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5695-wk-Fact-69D773C2A27F49B7099C0230BB4E3AAB"
      unitRef="usd">1082000000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5725-wk-Fact-89CE6A1289DA40501E4D801F82A04C25"
      unitRef="usd">11176000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5744-wk-Fact-697894D665ED502CB19B801F82A8684A"
      unitRef="usd">1863000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5763-wk-Fact-3FBD613AFFFEA2C8FB63801F82B5E5DC"
      unitRef="usd">9313000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5782-wk-Fact-0E52443F5C76774FA75C801F82B5973B"
      unitRef="usd">20110000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5801-wk-Fact-775862C803513248303E801F7F4E0495"
      unitRef="usd">1260000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e5821-wk-Fact-F56E374FB2E1D63FF319801F82A6F4DA"
      unitRef="usd">18850000000</us-gaap:Assets>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6358-wk-Fact-2D068435DD4A5F5295FA0CCC82EE051D"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6377-wk-Fact-6A9EA96081CA5C8E9BAD5DB1CAFD477F"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6397-wk-Fact-D0A3E10B0A4B5A64B5A6B8443F163774"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6416-wk-Fact-EB5CE6232D575639B91CB12849C35E50"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6435-wk-Fact-8F8D54ADCDC959E695062DDC7BE6B922"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6455-wk-Fact-CD0EF8C046065C3A9EC9B8862112C530"
      unitRef="usd">5000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6475-wk-Fact-AD9607E44D0E5BE38E7237F5FFD41AC2"
      unitRef="usd">114000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6494-wk-Fact-CED4F45B846256F098E3A02AF01EBF08"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6513-wk-Fact-03E72CB89EAB50FA894324460D74A640"
      unitRef="usd">114000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6533-wk-Fact-0148A0906CE35EC4A8412EB93331A984"
      unitRef="usd">78000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6552-wk-Fact-8BF17EB8E8705AE79684AF8AD8B57842"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6572-wk-Fact-CE86BCC2D3505DD09A39C0422DD25E0F"
      unitRef="usd">78000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6597-wk-Fact-5C099920B8B55A4CAFAF9D7169C6D890"
      unitRef="usd">114000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6616-wk-Fact-FE757A0E7E9E57E9B8BA9E594BA25DCC"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6635-wk-Fact-025EF0801C8E5AED84E50FDB8C0A446C"
      unitRef="usd">114000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6655-wk-Fact-279994B1608C5BBF86C5E2B4E0BAED6D"
      unitRef="usd">82000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6674-wk-Fact-0BE5F4B5A42B5CE580832FE51C9E437B"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesCurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6694-wk-Fact-13EC5BB83BC650FF89A60A6223B8AEB5"
      unitRef="usd">82000000</us-gaap:DerivativeLiabilitiesCurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6976-wk-Fact-000D7A7EF4CF591AB16A9C594E15D42C"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e6995-wk-Fact-D77B1AC41096549BB413220935C7618C"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7014-wk-Fact-6A6B94B545F757568AB45A75C118CA9B"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7034-wk-Fact-F8C1B53CA9E45C8490DD20893F3B6ECE"
      unitRef="usd">378000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7053-wk-Fact-1DF13C3541FB5E39AFDF3B3B26D6E8A2"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7073-wk-Fact-75F99BC9FE0557F09AD81513398AE1C9"
      unitRef="usd">378000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7098-wk-Fact-C4D87CCD51D05F1792598B2E4B0ECC76"
      unitRef="usd">604000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7117-wk-Fact-B7C1638E0DF05D0E8B6219C5B4D6D0F9"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7136-wk-Fact-4C05222BCA8D5C1F975FF29251154B32"
      unitRef="usd">604000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7156-wk-Fact-ED9EBDFE36E15B32AAE1DAE3CE253FBD"
      unitRef="usd">564000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7175-wk-Fact-25F9EDE8D1D25D7CB1F21FADE82504EA"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7195-wk-Fact-79876789308457AF901FB8884DCAF40E"
      unitRef="usd">564000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7220-wk-Fact-8336B6DD8E085B03B2E3B66852F632AD"
      unitRef="usd">604000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7239-wk-Fact-A4491DE6736452438C71F500E4E3E53E"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7258-wk-Fact-B61D859E15E75D4EA3481D593DEC8612"
      unitRef="usd">604000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7278-wk-Fact-0AA852D7EA865FE28E7DD9FC9ECA6A8D"
      unitRef="usd">942000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7297-wk-Fact-71F9B9B38D7E533981480976FC4071BD"
      unitRef="usd">0</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7317-wk-Fact-36D5848BB3695543A5468FB8D316B7D5"
      unitRef="usd">942000000</us-gaap:DerivativeLiabilitiesNoncurrent>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7347-wk-Fact-B1DCB7979801D0C2E1A2801F82C7DB23"
      unitRef="usd">718000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7366-wk-Fact-8D2AC5EEA5E88C141E4C801F829FB355"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7386-wk-Fact-77EE121F057E517A91C5801F82ABF006"
      unitRef="usd">718000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7405-wk-Fact-3118F0B7D408D547FCA5801F82A1CA5A"
      unitRef="usd">1024000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7424-wk-Fact-5FE26F1BA5B2869602AC801F80F25EC2"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7444-wk-Fact-406C8008BEAD002ABC34801F82A1EDFE"
      unitRef="usd">1024000000</us-gaap:DerivativeLiabilities>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7462-wk-Fact-9A98CA2603B6ADF2A73F023785E272F4"
      unitRef="usd">176000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <pfe:EquitySecuritiesFVNIRestrictedCurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7472-wk-Fact-FD047506F5725CCDBC6185E76C2B8E82"
      unitRef="usd">11000000</pfe:EquitySecuritiesFVNIRestrictedCurrent>
    <pfe:EquitySecuritiesFVNIRestrictedNoncurrent
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementFrequencyAxis_us-gaap_FairValueMeasurementsRecurringMember"
      decimals="-6"
      id="d34496162e7477-wk-Fact-34920CE8F316DAC9DDA1E4C6BFD9B105"
      unitRef="usd">132000000</pfe:EquitySecuritiesFVNIRestrictedNoncurrent>
    <us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-24E6EA3C2C152DC08565801F83151E7C-0-wk-Fact-98E29AD4000D6F8F6756801F7E3DFFE3">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:36%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Carrying Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Estimated Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:bold;"&gt;Financial Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Long-term debt, excluding the current portion&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;35,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;40,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;40,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;32,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;35,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;35,260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d34496162e8296-wk-Fact-C18B2B1FFA4D5577BE1E15FA7DB4215D"
      unitRef="usd">35955000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-6"
      id="d34496162e8315-wk-Fact-2F306B9ABED5537F91E4E56214919A3B"
      unitRef="usd">40842000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-6"
      id="d34496162e8335-wk-Fact-A548C68EC6AF5D8895F5938FC53151B5"
      unitRef="usd">40842000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember"
      decimals="-6"
      id="d34496162e8354-wk-Fact-7D3EA5FDAECD5B7DA616312E9C0CCE69"
      unitRef="usd">32909000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2018Q4_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-6"
      id="d34496162e8373-wk-Fact-67B03B54AF825D7F962A5FCE5EF3925B"
      unitRef="usd">35260000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:LongTermDebtFairValue
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember"
      decimals="-6"
      id="d34496162e8393-wk-Fact-3571C13CA37A50F0B6DC64608D67AF4F"
      unitRef="usd">35260000000</us-gaap:LongTermDebtFairValue>
    <us-gaap:MarketableSecuritiesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-387995A8D4D18DA6834E801F83164548-0-wk-Fact-2AB2C968200FC7012E86801F7E327739">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table represents our investments by classification type:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;705&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,687&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,091&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,003&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Total Short-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;17,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities with readily determinable fair values&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,902&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;491&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;59&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Private equity securities at cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;763&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Total Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;"&gt;Equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17,133&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total long-term investments and equity-method investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;20,147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,767&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Held-to-maturity cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;199&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesTextBlock>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e8665-wk-Fact-A2C8D5C7533E515EB203A3E9F7008E7C"
      unitRef="usd">705000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:EquitySecuritiesFvNi
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e8684-wk-Fact-F57AC8E1967F55269DC8AFBFE79580C5"
      unitRef="usd">1600000000</us-gaap:EquitySecuritiesFvNi>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e8704-wk-Fact-481D19D52F17581AA778E6FEED4C0D68"
      unitRef="usd">6687000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e8723-wk-Fact-9A66FB2163DA5DAE918ECBCC09D77765"
      unitRef="usd">15091000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e8748-wk-Fact-7FCABA1279235052A9F940D43842EFE9"
      unitRef="usd">1133000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:HeldToMaturitySecuritiesCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e8767-wk-Fact-A1BC31C07767581A93AF73531CEB5E54"
      unitRef="usd">1003000000</us-gaap:HeldToMaturitySecuritiesCurrent>
    <us-gaap:ShortTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e8797-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6"
      unitRef="usd">8525000000</us-gaap:ShortTermInvestments>
    <us-gaap:ShortTermInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e8816-wk-Fact-E3E97336ACA652838D81F531EE99F43B"
      unitRef="usd">17694000000</us-gaap:ShortTermInvestments>
    <pfe:EquitySecuritiesFVNINoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e8933-wk-Fact-B825E1F8270E5073B6C19C6710864302"
      unitRef="usd">1902000000</pfe:EquitySecuritiesFVNINoncurrent>
    <pfe:EquitySecuritiesFVNINoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e8952-wk-Fact-1B305BDAC1905A55BF6F156149BF8268"
      unitRef="usd">1273000000</pfe:EquitySecuritiesFVNINoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e8973-wk-Fact-466FA462BC555C57AE0A89AFA6C53AB5"
      unitRef="usd">315000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e8992-wk-Fact-0461922369945B39A341ADD2D54221CE"
      unitRef="usd">491000000</us-gaap:AvailableForSaleSecuritiesDebtSecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e9017-wk-Fact-12C700ACAEA5526091725A9A1BD61E05"
      unitRef="usd">42000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <us-gaap:HeldToMaturitySecuritiesNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e9036-wk-Fact-D986B7B4ED2A5457A00D615881506333"
      unitRef="usd">59000000</us-gaap:HeldToMaturitySecuritiesNoncurrent>
    <pfe:PrivateEquityInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e9061-wk-Fact-491578780A2C5C66A70F92CC76ABE497"
      unitRef="usd">756000000</pfe:PrivateEquityInvestments>
    <pfe:PrivateEquityInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e9080-wk-Fact-EE96DEF0DD8B5A6B94DF2AB4D8D613D4"
      unitRef="usd">763000000</pfe:PrivateEquityInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e9110-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC"
      unitRef="usd">3014000000</us-gaap:LongTermInvestments>
    <us-gaap:LongTermInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e9129-wk-Fact-38B878301DB957B297D2601592AD511A"
      unitRef="usd">2586000000</us-gaap:LongTermInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e9149-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F"
      unitRef="usd">17133000000</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e9168-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE"
      unitRef="usd">181000000</us-gaap:EquityMethodInvestments>
    <pfe:LongtermInvestmentsAndEquityMethodInvestments
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e9198-wk-Fact-473FC4853D285A2D884D0B7E2D4AB721"
      unitRef="usd">20147000000</pfe:LongtermInvestmentsAndEquityMethodInvestments>
    <pfe:LongtermInvestmentsAndEquityMethodInvestments
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e9217-wk-Fact-D9709CC6314D535485F61A85A5508983"
      unitRef="usd">2767000000</pfe:LongtermInvestmentsAndEquityMethodInvestments>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34496162e9242-wk-Fact-B73BEBEF348353D2842BA6BE71FDAC31"
      unitRef="usd">163000000</pfe:HeldToMaturityCashEquivalents>
    <pfe:HeldToMaturityCashEquivalents
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34496162e9261-wk-Fact-C36BF92CAF1E56628AE6498286970DCB"
      unitRef="usd">199000000</pfe:HeldToMaturityCashEquivalents>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0EC9F2BC7D65E3B08DFC801F8316E68A-0-wk-Fact-0E7BB5B4C26A9B11F078801F7DE53458">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="45"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Maturities (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;9,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;9,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Corporate and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;798&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;8,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;8,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;16,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;16,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily issued by a diverse group of corporations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4E3D455FFC94E05929FC801F8316FA33-0-wk-Fact-B371FA0F786D34DAEE73801F8111B988">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="45"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Maturities (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;9,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;9,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Corporate and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;798&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;8,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;8,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;16,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;16,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily issued by a diverse group of corporations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:HeldToMaturitySecuritiesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B05D83F00BEFD41C6AEE801F83178EDF-0-wk-Fact-29437B32360C22211954801F7DD3953C">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="45"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Maturities (in Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gross Unrealized&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:justify;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Within 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Over 1&lt;br/&gt;to 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Over 5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Amortized Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;"&gt;Available-for-sale debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;9,754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;9,703&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;811&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,804&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,782&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Corporate and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,025&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,097&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;"&gt;Held-to-maturity debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Time deposits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;668&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Government and agency&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-style:italic;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;non-U.S.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;803&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;798&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;592&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Total debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;8,380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;8,340&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;322&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;16,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;(85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;16,842&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily issued by a diverse group of corporations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:HeldToMaturitySecuritiesTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2526-wk-Fact-060DC2337D305CB589C3930B2AD02F4F"
      unitRef="usd">4895000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2545-wk-Fact-9CA917534AE450CEAADED4A4F94030D1"
      unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2565-wk-Fact-A75D5E0D1AE05935941EB4DCE9A667D4"
      unitRef="usd">38000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2585-wk-Fact-9938D6F7107B5482967DACD21E8DAA38"
      unitRef="usd">4863000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2604-wk-Fact-030163DFAA6D5539933A8B3F30DAA159"
      unitRef="usd">4863000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2624-wk-Fact-DB135AE5378150EFB07A732967B7ED02"
      unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2643-wk-Fact-2590F356B7AE53EB895073F1E2DE7FF6"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2662-wk-Fact-01D12574EFCE5397BFCE09A29051D331"
      unitRef="usd">9754000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2682-wk-Fact-A3B04B9190C5524FABA474FDBEC0A1D6"
      unitRef="usd">7000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2701-wk-Fact-0593789538C254FB9B922CC6ED28C5BB"
      unitRef="usd">58000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2721-wk-Fact-18AB1FBD36BF5912B8D2D6ACB0182D0B"
      unitRef="usd">9703000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2746-wk-Fact-76AB23BB530F07D6CB16E4D1534480CF"
      unitRef="usd">1120000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2765-wk-Fact-5C34C702ED52A020D19BE4D158B1218F"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2784-wk-Fact-D7650322FA82EA4D1827267B2561DEEA"
      unitRef="usd">6000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2805-wk-Fact-B00D1C2A51063472DDB3267B2554715C"
      unitRef="usd">1114000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2824-wk-Fact-21487183205063A0D95FE4D168620FFE"
      unitRef="usd">811000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2844-wk-Fact-D3D3F7A5FE587D9647C8E4D16D912ED9"
      unitRef="usd">303000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2863-wk-Fact-37BAC7540AA10942CD9DE4D172DEDF5E"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2882-wk-Fact-AFF7D1034A7949C4C9F1E4CFF755B236"
      unitRef="usd">3804000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2902-wk-Fact-532754C7D7DC08C12B1FE4CFFC0446F9"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2921-wk-Fact-DA816034E43A7DA06928E4D000CB53F0"
      unitRef="usd">23000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2941-wk-Fact-A5F57A1DF8373D93DDC8E4D0052E96C6"
      unitRef="usd">3782000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2969-wk-Fact-D4B1E0BBE3F058D3B98806E9C6B99CAF"
      unitRef="usd">1027000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e2988-wk-Fact-7BA94F9ED2EC5F1A966CB3304B53AF56"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3007-wk-Fact-1F6DDFC5F407544BA48EE7A820F1CB06"
      unitRef="usd">2000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3028-wk-Fact-FB08398EDEE850A395E7D7BAD4CE39AD"
      unitRef="usd">1025000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3047-wk-Fact-B708802DEAF9567DBA106E1C0C84390C"
      unitRef="usd">1014000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3067-wk-Fact-F1667F5FCAC154B8954BDD808EA7CF01"
      unitRef="usd">11000000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3086-wk-Fact-AF6AA38DDBAD57078BE06AFBF6047957"
      unitRef="usd">0</pfe:AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3105-wk-Fact-D993A80C463256F1AA201062DD098CB4"
      unitRef="usd">2101000000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3125-wk-Fact-E756524CD9B052E3BC12448706C676DB"
      unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3144-wk-Fact-A0AE51B2124A549B9B82AE9C29097AF0"
      unitRef="usd">4000000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3164-wk-Fact-CD12D99291BD50F3BBC6B2BCAA5E89C9"
      unitRef="usd">2097000000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3420-wk-Fact-6BC5A5E262B2505AAFEB907075209997"
      unitRef="usd">535000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3439-wk-Fact-4734762739535CD587A0902B5A3B1488"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3458-wk-Fact-04585002970655668AECF04C9BB7B467"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3478-wk-Fact-B62369EB738157BA93A99FB83E03BDCA"
      unitRef="usd">535000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3497-wk-Fact-3EE2CE7C4A3A5E5897773D88C7FC8785"
      unitRef="usd">498000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3517-wk-Fact-570F53C118FE5E3097E443D45CBF8904"
      unitRef="usd">7000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3536-wk-Fact-0CDB8052D62B5FF0A88AD6BA33BADAEA"
      unitRef="usd">30000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3555-wk-Fact-9814239CCA795853A5E0998F66E96EDE"
      unitRef="usd">668000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3575-wk-Fact-379D8C1E85AB5E9896437DCD5EF28643"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3594-wk-Fact-3426C0EC192658D9A253878122888165"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_BankTimeDepositsMember"
      decimals="-6"
      id="d34501946e3613-wk-Fact-4330F174398C5BBE83E439423EE4F668"
      unitRef="usd">668000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3643-wk-Fact-E33D3AF2318A516B9D5A5C9CA441D6B1"
      unitRef="usd">803000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3662-wk-Fact-4DD1E9425CBF5FCAB26591893C3A6513"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3681-wk-Fact-D545407F7F8D570D89503AD709A9B7AF"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3701-wk-Fact-90286A5BFB335674BA830B962989A1F0"
      unitRef="usd">803000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3720-wk-Fact-C0D6DB9F21A15096B97726601B96FAD3"
      unitRef="usd">798000000</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3740-wk-Fact-3B5526BFEC3151138F0F054A13698657"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue
      contextRef="FI2019Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3759-wk-Fact-8D61E28CEF0C5E9DB11B9F7A1B506BF8"
      unitRef="usd">4000000</pfe:HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue>
    <us-gaap:HeldToMaturitySecurities
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3778-wk-Fact-111714A65B915059991385B8F9897C0F"
      unitRef="usd">592000000</us-gaap:HeldToMaturitySecurities>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3798-wk-Fact-B59C18D8450655D8874D7478DDE7BE96"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain>
    <us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3817-wk-Fact-B7C16C235F81570C9E1ADA7A5B0B50C4"
      unitRef="usd">0</us-gaap:HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss>
    <us-gaap:HeldToMaturitySecuritiesFairValue
      contextRef="FI2018Q4_us-gaap_FinancialInstrumentAxis_us-gaap_ForeignGovernmentDebtSecuritiesMember"
      decimals="-6"
      id="d34501946e3836-wk-Fact-FFD4B813A0D25F0884657117E53BA608"
      unitRef="usd">592000000</us-gaap:HeldToMaturitySecuritiesFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34501946e3868-wk-Fact-C7CB820F9ED75968AD8E30E7D40DD61B"
      unitRef="usd">8380000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34501946e3887-wk-Fact-3B1D9B6888B05CC98299BAD0C52665B6"
      unitRef="usd">6000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34501946e3907-wk-Fact-B2E46496D8EF56EABBD814F260C33030"
      unitRef="usd">47000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34501946e3927-wk-Fact-AC0BFF2EA6D959F59969F893CF59CD09"
      unitRef="usd">8340000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34501946e3946-wk-Fact-C470477049895AF99CC6FC97EA0B27E4"
      unitRef="usd">7984000000</pfe:DebtSecuritiesMaturitiesNextTwelveMonthsFairValue>
    <pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34501946e3966-wk-Fact-875C26BCE94D541C9463C55E244301C6"
      unitRef="usd">322000000</pfe:DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue>
    <pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34501946e3985-wk-Fact-17832A2FC52E599589ECDAD934E52823"
      unitRef="usd">35000000</pfe:DebtSecuritiesMaturitiesAfterYearFiveFairValue>
    <pfe:DebtSecuritiesAmortizedCostBasis
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34501946e4004-wk-Fact-0AEF4901D7965A55A4C1D45A592D3711"
      unitRef="usd">16920000000</pfe:DebtSecuritiesAmortizedCostBasis>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34501946e4024-wk-Fact-46FFB6099D71532FA46A93F0B309D4FC"
      unitRef="usd">8000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedGain>
    <pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34501946e4043-wk-Fact-688574457BB35963ABE4860299A7CAFC"
      unitRef="usd">85000000</pfe:DebtSecuritiesAccumulatedGrossUnrealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34501946e4063-wk-Fact-B6299971D97B5083B4F8EAFD4F149957"
      unitRef="usd">16842000000</us-gaap:DebtSecuritiesAvailableForSaleAndHeldToMaturity>
    <pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-84945A5AB6E23ACFCFFE801F83162822-0-wk-Fact-0A67D073155EE41A8B90801F7DD3F3D7">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:68%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table presents the net unrealized (gains) and losses for the period that relate to equity securities, excluding equity method investments, still held at the reporting date, calculated as follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net gains recognized during the period on equity securities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Net gains recognized during the period on equity securities sold during the period&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(25&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(109&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net unrealized gains during the reporting period on equity securities still held at the reporting date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(429&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The net gains on equity securities are reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</pfe:DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34501946e4245-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
      unitRef="usd">454000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34501946e4265-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
      unitRef="usd">586000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34501946e4286-wk-Fact-EF7F75F88BB456C49FDEB414EDA4D808"
      unitRef="usd">25000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiRealizedGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34501946e4306-wk-Fact-8DFAE7CF1D355F33865A28A45027185B"
      unitRef="usd">109000000</us-gaap:EquitySecuritiesFvNiRealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34501946e4337-wk-Fact-2F8853D15C6E51BAB72642AB190884C3"
      unitRef="usd">429000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34501946e4357-wk-Fact-E53E9E5C1A0D55788064DA6EAE2FA60D"
      unitRef="usd">477000000</us-gaap:EquitySecuritiesFvNiUnrealizedGainLoss>
    <us-gaap:ScheduleOfShortTermDebtTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5BE56D549088AB135614801F8317E547-0-wk-Fact-31EFB2431FA0FC2A48E8801F7FA14F9D">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Short-term borrowings include:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Commercial paper &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,915&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current portion of long-term debt, principal amount&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,458&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,781&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other short-term borrowings, principal amount&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;860&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;966&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total short-term borrowings, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,847&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(43&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,831&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 7D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other short-term borrowings primarily include cash collateral. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 7F&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShortTermDebtTextBlock>
    <us-gaap:CommercialPaper
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34498941e1472-wk-Fact-F5F921B1937655B28A2E8CB3ACD2E6F6"
      unitRef="usd">13915000000</us-gaap:CommercialPaper>
    <us-gaap:CommercialPaper
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34498941e1491-wk-Fact-F4A852513E8B58CDA9569CE187B368C3"
      unitRef="usd">3100000000</us-gaap:CommercialPaper>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34498941e1513-wk-Fact-A98C87D2BA285EA58206340681E8AC55"
      unitRef="usd">1458000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34498941e1532-wk-Fact-BA94151A8C0D50BF9AA027BBFC277D06"
      unitRef="usd">4781000000</pfe:LongtermDebtCurrentMaturitiesExcludingNetFairValueAdjustmentsRelatedToHedgingAndPurchaseAccounting>
    <us-gaap:OtherShortTermBorrowings
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34498941e1559-wk-Fact-7BD53D154D3451E59F8DCFF457C25E21"
      unitRef="usd">860000000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34498941e1578-wk-Fact-C822D3E8545E59F38E6D05A0A14FFE9D"
      unitRef="usd">966000000</us-gaap:OtherShortTermBorrowings>
    <pfe:ShorttermDebtGross
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34498941e1603-wk-Fact-C8AE244F49C55C63878B4951E1449455"
      unitRef="usd">16233000000</pfe:ShorttermDebtGross>
    <pfe:ShorttermDebtGross
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34498941e1622-wk-Fact-CB930CFE3CB15C809A3960EE663060A2"
      unitRef="usd">8847000000</pfe:ShorttermDebtGross>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34498941e1647-wk-Fact-91CC3EC5DF5C5B229D9F46662E336761"
      unitRef="usd">5000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34498941e1666-wk-Fact-747327EC3AF258B9B09B9F73900E3D87"
      unitRef="usd">-5000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34498941e1692-wk-Fact-95A8D8EAFF2057A79B308FFF9869400B"
      unitRef="usd">43000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34498941e1712-wk-Fact-07E994299E79573F8142DD38A281D53E"
      unitRef="usd">11000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34498941e1747-wk-Fact-D592F35F847457ABB1C2D0D22ED64864"
      unitRef="usd">16195000000</us-gaap:DebtCurrent>
    <us-gaap:DebtCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34498941e1766-wk-Fact-A51B51A828275272A7C573C440BF63F4"
      unitRef="usd">8831000000</us-gaap:DebtCurrent>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember"
      decimals="4"
      id="d34498941e1817-wk-Fact-5FE40B9980006BD32E48801F7F9C39B0"
      unitRef="number">0.0192</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:ShortTermDebtWeightedAverageInterestRate
      contextRef="FI2018Q4_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember"
      decimals="4"
      id="d34498941e1825-wk-Fact-A2150506C09AEDD8981F801F7FA2F90A"
      unitRef="number">0.0242</us-gaap:ShortTermDebtWeightedAverageInterestRate>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-9"
      id="d34498941e1840-wk-Fact-3AECDDFC3B75BEE92C95E4DBE4F88D41"
      unitRef="usd">15000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_pfe_CreditFacilityExpiring2024Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-9"
      id="d34498941e1844-wk-Fact-94285FDA5DF62BB0436BE4DC06A0DA59"
      unitRef="usd">7000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_DebtInstrumentAxis_pfe_FacilityExpiringSeptember2020Member_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-9"
      id="d34498941e1848-wk-Fact-21EEE5902AB5540FA72BE4DB2DA9AEA2"
      unitRef="usd">8000000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember"
      decimals="-6"
      id="d34498941e1852-wk-Fact-EE5EB8BE1F59F6BEB5DDE4E451D17EAA"
      unitRef="usd">537000000</us-gaap:LineOfCreditFacilityMaximumBorrowingCapacity>
    <pfe:LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember"
      decimals="-6"
      id="d34498941e1857-wk-Fact-4E985C0FD5B521765F09E4DF24FAC57F"
      unitRef="usd">508000000</pfe:LineofCreditFacilityMaximumBorrowingCapacityDueToExpireWithinOneYear>
    <us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity
      contextRef="FI2019Q4_us-gaap_CreditFacilityAxis_us-gaap_LineOfCreditMember_us-gaap_ShortTermDebtTypeAxis_us-gaap_CommercialPaperMember"
      decimals="-8"
      id="d34498941e1861-wk-Fact-B69774305BABA06FB0B7E4DB78354020"
      unitRef="usd">15500000000</us-gaap:LineOfCreditFacilityRemainingBorrowingCapacity>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-1218F39AFD6723DC3AF4801F8318625F-0-wk-Fact-F93E14F1B9F34BC106A0801F7E4414C9">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:62%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the first quarter of 2019, we issued the following senior unsecured notes:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Principal&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest Rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Maturity Date&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;As of December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2.800% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;11, 2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2.950% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;15, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;3.450% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;15, 2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;3.900% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;15, 2039&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;4.000% notes&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;15, 2049&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total long-term debt issued in the first quarter of 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,000&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The weighted-average effective interest rate for the notes at issuance was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3.57%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:74%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2019 and 2018 by maturity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2020 (1.2%)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,474&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2021 (0.7% and 3.4%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,459&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2022 (1.0% and 0.3%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,624&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2023 (3.7% and 3.8%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,892&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2024 (3.9% and 4.4%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2026-2029 (3.3%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2034 (6.5%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2036-2040 (5.8% and 6.0%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,566&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2043-2044 (3.5%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3,568&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,509&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notes due 2046-2049 (4.1% and 4.2%)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,315&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total long-term debt, principal amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;34,820&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net fair value adjustments related to hedging and purchase accounting&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;479&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net unamortized discounts, premiums and debt issuance costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total long-term debt, carried at historical proceeds, as adjusted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;32,909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,462&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,776&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;At December 31, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the debt issuances have been reclassified to the current portion of long-term debt.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1462-wk-Fact-D5263DBF4F0653D689363EDF0100721F"
      unitRef="usd">500000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1494-wk-Fact-6BB7FEB12FCA5295BF226B2D59D4A270"
      unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1531-wk-Fact-56A324A412FD5174AE9EB2CCB959DCC2"
      unitRef="usd">1750000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1568-wk-Fact-4489672EEE795DBDBE301A22943A4351"
      unitRef="usd">750000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtFourPercentDue2049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1605-wk-Fact-E938067A39DA5B6A9EF9220D29E6E1FC"
      unitRef="usd">1250000000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1646-wk-Fact-9A07B781512B6DC74011801F80FC2C4F"
      unitRef="usd">5000000000</us-gaap:LongTermDebt>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="4"
      id="d34509238e1673-wk-Fact-F386309A598956EE993526A09B54CDE1"
      unitRef="number">0.0357</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="d34509238e1712-wk-Fact-E2B34CF4ABAE85C9D525E501A4A07820"
      unitRef="usd">5000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="FI2018Q3_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="4"
      id="d34509238e1716-wk-Fact-C4823693F75884F3BC7C801F7E574D18"
      unitRef="number">0.0356</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2017Q1Mar31_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="d34509238e1723-wk-Fact-574FF2D5FB890E80F40A801F7E24A90C"
      unitRef="usd">1065000000.000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="I2017Q1Mar31_us-gaap_DebtInstrumentAxis_pfe_SeniorNotesDue2047Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="4"
      id="d34509238e1727-wk-Fact-B567A1791E477D503600801F82375E38"
      unitRef="number">0.0420</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="I2017Q1Mar31_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="INF"
      id="d34509238e1731-wk-Fact-1E6510C1833D190811AE801F7E779E3D"
      unitRef="iso4217_EUR">4000000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtWeightedAverageInterestRate
      contextRef="I2017Q1Mar31_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="4"
      id="d34509238e1735-wk-Fact-E40D0BE76E944AA41AA0801F7E2CACF7"
      unitRef="number">0.0023</us-gaap:DebtWeightedAverageInterestRate>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-8"
      id="d34509238e1745-wk-Fact-FD1441877E4D577081ECD81348D608A5"
      unitRef="iso4217_EUR">1100000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-8"
      id="d34509238e1749-wk-Fact-16BEC6A7C12856B28778212B2F5A701C"
      unitRef="usd">1300000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d34509238e1753-wk-Fact-F14B894984A456E3A081F63F8B4AA566"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-8"
      id="d34509238e1757-wk-Fact-76ACE1D3EB0D50B29FB6B4B0728CE8AD"
      unitRef="iso4217_EUR">1300000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="I2019Q1Jan31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-8"
      id="d34509238e1761-wk-Fact-42166BFE3C1C5620871B1D3BE4813114"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q1QTD_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member"
      decimals="-6"
      id="d34509238e1766-wk-Fact-526566BDFD6457DF82D7214A82842C7E"
      unitRef="usd">-138000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:ExtinguishmentOfDebtAmount
      contextRef="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1784-wk-Fact-DA69EC3C235DC4AD5934801F7E2D3172"
      unitRef="gbp">833000000</us-gaap:ExtinguishmentOfDebtAmount>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1788-wk-Fact-2AE12B62DF94665F3663801F7E6A2AD6"
      unitRef="gbp">197000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d34509238e1792-wk-Fact-DC7954590A15CD344806801F7E10C87C"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-8"
      id="d34509238e1796-wk-Fact-C949C6CEDD3921D0B5F1801F7E37BE01"
      unitRef="gbp">1700000000</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1800-wk-Fact-4C6C066F59D043EB915D801F7E585968"
      unitRef="gbp">470000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d34509238e1805-wk-Fact-DC7954590A15CD344806801F7E10C87C"
      unitRef="number">0.0650</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchaseAmount
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-6"
      id="d34509238e1809-wk-Fact-056670FCDF4076E094FD801F7E37CBC7"
      unitRef="iso4217_EUR">834000000</us-gaap:DebtInstrumentRepurchaseAmount>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d34509238e1813-wk-Fact-C93C3EAA2AA3B5EE6C61801F82399DF7"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentRepurchasedFaceAmount
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-8"
      id="d34509238e1817-wk-Fact-A8560D27AAEBCAB664AC801F7E419A48"
      unitRef="iso4217_EUR">1000000000.0</us-gaap:DebtInstrumentRepurchasedFaceAmount>
    <us-gaap:LongTermDebt
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="-8"
      id="d34509238e1821-wk-Fact-6E30A7AD0F844EF8739D801F8232845C"
      unitRef="iso4217_EUR">1200000000</us-gaap:LongTermDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="FI2017Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_SeniorNotesMember"
      decimals="INF"
      id="d34509238e1825-wk-Fact-C93C3EAA2AA3B5EE6C61801F82399DF7"
      unitRef="number">0.0575</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member"
      decimals="-6"
      id="d34509238e1830-wk-Fact-046237D900496E5BF3D0801F81E93368"
      unitRef="usd">-846000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="D2017Q4Dec01-Dec31_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member"
      decimals="-6"
      id="d34509238e1834-wk-Fact-5DF392EBA37AB264B17D801F7E26D604"
      unitRef="usd">-153000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="D2017Q4Dec01-Dec31"
      decimals="-6"
      id="d34509238e1838-wk-Fact-9C352E3DD4A785F70BF4801F8231A7DB"
      unitRef="usd">-999000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2027-wk-Fact-67276C3C3805655E626C801F80B6FF7C"
      unitRef="usd">0</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2020Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2046-wk-Fact-F86E93B23C3F1D21812D801F7FA074B1"
      unitRef="usd">1474000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2066-wk-Fact-B03CD7C3B7455EC05821801F7F9FFF54"
      unitRef="usd">3153000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2021Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2085-wk-Fact-972D3A38CB237CF20087801F809FB547"
      unitRef="usd">4459000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2110-wk-Fact-A424E690D91C218393CB801F7FA7AF24"
      unitRef="usd">1624000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2022Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2129-wk-Fact-615A33CB3760FBC7EDBD801F7FA05F61"
      unitRef="usd">1145000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2154-wk-Fact-D03913D170D5C40EA459801F7FA292DB"
      unitRef="usd">2892000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2023Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2173-wk-Fact-ED38E0D5C570B27F5801801F80A250BC"
      unitRef="usd">2892000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2198-wk-Fact-D9C1046CC79564D4CCCD801F80B35532"
      unitRef="usd">2250000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2024Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2217-wk-Fact-9730CD26A5E9CF8ABB4E801F80ADD397"
      unitRef="usd">1500000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2242-wk-Fact-3498CA6D4701B2985288801F809B48C0"
      unitRef="usd">7453000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20262029Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2261-wk-Fact-1890D02F21CDB814AF05801F809CB7CD"
      unitRef="usd">5718000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2286-wk-Fact-098DA8FBD6308DE75972801F7F9EA5A9"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue2034Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2305-wk-Fact-84CCFD6D52B2CE636E5A801F7F9ED404"
      unitRef="usd">750000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2330-wk-Fact-9FDEB71FF42D94FCDD19801F809F3477"
      unitRef="usd">8566000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20362040Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2349-wk-Fact-1E8E3C18B4297EC24D84801F7FA4FE02"
      unitRef="usd">7796000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2375-wk-Fact-DA10C7FC03F893411721801F80998712"
      unitRef="usd">3568000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20432044Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2394-wk-Fact-96EB7418C24EB73658CC801F80AD96C4"
      unitRef="usd">3509000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2419-wk-Fact-A32CC770EFA1E649CDA4E4E8F88BFF20"
      unitRef="usd">4565000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_DebtInstrumentAxis_pfe_SeniorUnsecuredDebtDue20462049Member_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2438-wk-Fact-357778E4FFB2BFF68161E4E8F884955A"
      unitRef="usd">3315000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2463-wk-Fact-D0B826C952035A20B1FFC436D83EA983"
      unitRef="usd">34820000000</us-gaap:DebtInstrumentCarryingAmount>
    <us-gaap:DebtInstrumentCarryingAmount
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2482-wk-Fact-5F3EB27291CC30BEC668801F7FA9458E"
      unitRef="usd">32558000000</us-gaap:DebtInstrumentCarryingAmount>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2507-wk-Fact-BEFE7AE513FF556C97743777B6248C49"
      unitRef="usd">1305000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2526-wk-Fact-C7FAB96EE775813977FD801F7FA522FA"
      unitRef="usd">479000000</pfe:DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2551-wk-Fact-6D5E88C5179C563ABFFAE70C4B2A72C8"
      unitRef="usd">176000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2571-wk-Fact-F1C73F1DEB6D9381494D801F7FA86824"
      unitRef="usd">136000000</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:OtherLongTermDebt
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2597-wk-Fact-9BBE2B0BC12F5A3DBB215842E824C5E9"
      unitRef="usd">5000000</us-gaap:OtherLongTermDebt>
    <us-gaap:OtherLongTermDebt
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2616-wk-Fact-99FFB0A353AA4D10E92F801F7FA46C94"
      unitRef="usd">7000000</us-gaap:OtherLongTermDebt>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2646-wk-Fact-0D2E3798CA9654F998CE592D24D1A644"
      unitRef="usd">35955000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2665-wk-Fact-A5909D837FBA536A99C7801F80B4572B"
      unitRef="usd">32909000000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2690-wk-Fact-9A71EE683E7D5DBF8DD77514DFAAF238"
      unitRef="usd">1462000000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent
      contextRef="FI2018Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-6"
      id="d34509238e2709-wk-Fact-8BB6F735B7DE1C3C3269801F80B24346"
      unitRef="usd">4776000000</us-gaap:LongTermDebtCurrent>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      decimals="-6"
      id="d34510350e1309-wk-Fact-163B919565D8A70146E1801F7F00AA31"
      unitRef="usd">301000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="I2018Q2Apr30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1313-wk-Fact-00C07AAC561D097B0950801F7E99AA40"
      unitRef="usd">240000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pfe:ResearchandDevelopmentArrangementLiabilityBuyoutAmount
      contextRef="I2018Q2Jun30_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1321-wk-Fact-DDCB2EFD60013E67F003801F7F01E0F0"
      unitRef="usd">224000000</pfe:ResearchandDevelopmentArrangementLiabilityBuyoutAmount>
    <pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MylotargMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1326-wk-Fact-8ECBDE405C33A1FF9D79801F80B2C01E"
      unitRef="usd">17000000</pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="FI2017Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d34510350e1348-wk-Fact-C1F815EBAE353BC7AC20801F7E9DB48C"
      unitRef="usd">416000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2017Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1352-wk-Fact-E66436555A85696DBF1D801F7EB9218D"
      unitRef="usd">364000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pfe:ResearchandDevelopmentArrangementLiabilityBuyoutAmount
      contextRef="I2018Q3Aug31_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1360-wk-Fact-D617339AAB02E972F970801F7EABC4C2"
      unitRef="usd">71000000</pfe:ResearchandDevelopmentArrangementLiabilityBuyoutAmount>
    <pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment
      contextRef="FD2018Q3QTD_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1365-wk-Fact-DF87F9BAC5571D656F5D801F7E9D0E33"
      unitRef="usd">9000000</pfe:ResearchandDevelopmentArrangementGainFromLiabilityExtinguishment>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1381-wk-Fact-F2B49F2C13D3BACB39F9801F7EAA213A"
      unitRef="usd">191000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1385-wk-Fact-21995516ED50C011ADAB801F7F0ABDC0"
      unitRef="usd">22000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1394-wk-Fact-1DD27AE6CAF3A7303888801F7F01F6BF"
      unitRef="usd">169000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="I2017Q3Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d34510350e1412-wk-Fact-8E9E6C510B365E9FB6C0801F7E998EB8"
      unitRef="usd">296000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="I2017Q3Aug31_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1416-wk-Fact-CCE7DE2A116A121D3D71801F7EACD200"
      unitRef="usd">248000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1429-wk-Fact-034930D7B011E36B4E09801F7E9C4E21"
      unitRef="usd">242000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1433-wk-Fact-B4F4E77C842393826437801F7EAD406D"
      unitRef="usd">7000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_country_US_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1441-wk-Fact-E925D753331636286CA1801F7F00E1DE"
      unitRef="usd">235000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="I2017Q2Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember"
      decimals="-6"
      id="d34510350e1454-wk-Fact-AC00F9C78BF29D9105A9801F7F090C2F"
      unitRef="usd">148000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="I2017Q2Jun30_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1458-wk-Fact-A559A68BD922DC8D726C801F7EAEABDC"
      unitRef="usd">123000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1470-wk-Fact-8473DFBA86E608ED81F0801F7EB9F8E7"
      unitRef="usd">122000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherCurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1475-wk-Fact-B63C3E37FDF3FE997E9B801F7EB94BBF"
      unitRef="usd">3000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember_srt_StatementGeographicalAxis_us-gaap_EuropeanUnionMember_us-gaap_BalanceSheetLocationAxis_us-gaap_OtherNoncurrentLiabilitiesMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34510350e1483-wk-Fact-586A388A57E0DE309C59801F7F0178AD"
      unitRef="usd">119000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:DerivativeTermOfContract
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember"
      id="d34538474e1371-wk-Fact-5B9755264B5E6ED7A26F0E475E856CDD">P2Y</us-gaap:DerivativeTermOfContract>
    <us-gaap:ScheduleOfDerivativeInstrumentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F7B56E23462F1BE25538801F831A5DA8-0-wk-Fact-EE2E5F1DBCE1A40D4CB9801F7EED2316">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;25,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;22,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;19,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.8 billion&lt;/span&gt;&lt;/span&gt; as of December 31, 2018</us-gaap:ScheduleOfDerivativeInstrumentsTextBlock>
    <us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-644F6BDED09D6467178C801F831A1D80-0-wk-Fact-B6D1CC995678F82567B2801F7EEC9AEA">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;25,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;22,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;19,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.8 billion&lt;/span&gt;&lt;/span&gt; as of December 31, 2018</us-gaap:ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock>
    <us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EDE44C023F3E5F409CF5801F831AA267-0-wk-Fact-C9F10EBB47C17C0C20CB801F7EEF21B1">&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Notional&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Asset&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Liability&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Derivatives designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;25,193&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;22,984&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,645&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;909&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;662&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;968&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Derivatives not designated as hedging instruments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;19,623&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,024&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.9 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$5.8 billion&lt;/span&gt;&lt;/span&gt; as of December 31, 2018</us-gaap:ScheduleOfDerivativeAssetsAtFairValueTableTextBlock>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2109-wk-Fact-18D776DBF49C5BD0821AEAF95ADFD3B6"
      unitRef="usd">25193000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2128-wk-Fact-53FADFD5082D5F7483E92BF38D157660"
      unitRef="usd">591000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2148-wk-Fact-523DC6B2EC505EFFBFCB4D7A7C5179A9"
      unitRef="usd">662000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2167-wk-Fact-626CCC40E7795A0A83CE3935A24DFAFC"
      unitRef="usd">22984000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2186-wk-Fact-61E9846E1AC95B2E9188CB7391BD7711"
      unitRef="usd">654000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2206-wk-Fact-34FF2F3BFE615D19B8D425D5797E438A"
      unitRef="usd">586000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2226-wk-Fact-FAB97B3154565FF7ACCDE5926A30648B"
      unitRef="usd">6645000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2245-wk-Fact-10E78B9FC2CB567FA39F57B7F46A3527"
      unitRef="usd">318000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2264-wk-Fact-1D2EE74A6CFE5572B3888D1EB149327B"
      unitRef="usd">0</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2284-wk-Fact-CF35E2A094F2575F8AA3613567A8087C"
      unitRef="usd">11145000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2303-wk-Fact-5FA9776EA82D59F491FACA0BC9F26789"
      unitRef="usd">432000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2323-wk-Fact-08B759B927FB5CCF8401B6D7A0012D3C"
      unitRef="usd">383000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2368-wk-Fact-1E8193513ADF509FB28268AD60667A35"
      unitRef="usd">909000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2387-wk-Fact-6FD3222CDBF95A90B3B10D57B96416B5"
      unitRef="usd">662000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2427-wk-Fact-B8D69335CB0953BFBDD5D1DCFA2937C8"
      unitRef="usd">1085000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2018Q4_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e2447-wk-Fact-FEA472EE6FBE5B139E815023CB1EF451"
      unitRef="usd">968000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d34538474e2733-wk-Fact-A6D7EF46287050348AD6FE8061437BB9"
      unitRef="usd">19623000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d34538474e2747-wk-Fact-241ACB57C79A574A94DA7D7DBDA87F6A"
      unitRef="usd">82000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d34538474e2766-wk-Fact-15150F20255B56FCA245DF8F8F9516F6"
      unitRef="usd">55000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d34538474e2791-wk-Fact-35CA45EADD6754889DF3AA5DC2254E4A"
      unitRef="usd">15154000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeAssets
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d34538474e2805-wk-Fact-4C94D50EF315552AA69DBA71A7B15845"
      unitRef="usd">55000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2018Q4_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember"
      decimals="-6"
      id="d34538474e2825-wk-Fact-C097E998B9A95CD985D87DA5B76EB616"
      unitRef="usd">55000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34538474e3004-wk-Fact-2EA512967C8E54CBBF9C424D590E48B5"
      unitRef="usd">992000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34538474e3024-wk-Fact-8F4ABD1ACB045BD49AD9EC7BC62A82E8"
      unitRef="usd">718000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeAssets
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34538474e3063-wk-Fact-D78D2820B7EA526D95346F88EB4D9FC6"
      unitRef="usd">1140000000</us-gaap:DerivativeAssets>
    <us-gaap:DerivativeLiabilities
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34538474e3083-wk-Fact-9208AEA66AC559878BBF9748FF1C6BB1"
      unitRef="usd">1024000000</us-gaap:DerivativeLiabilities>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2019Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-8"
      id="d34538474e3099-wk-Fact-6D2B160F53805A7DAAE8238BDE54594A"
      unitRef="usd">5900000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:DerivativeNotionalAmount
      contextRef="FI2018Q4_pfe_HedgedItemAxis_us-gaap_SalesMember_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-8"
      id="d34538474e3107-wk-Fact-0ADB280C3A6E575B8FE863989BFF8858"
      unitRef="usd">5800000000</us-gaap:DerivativeNotionalAmount>
    <us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D14AF9D6BD4B90C78D73801F831A4FBB-0-wk-Fact-8F5D88659A92A76AA675801F7EEE2B36">&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:34%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount of&lt;br/&gt;Gains/(Losses)&lt;br/&gt;Recognized in OID&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Recognized in OCI&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount of Gains/(Losses)&lt;br/&gt;Reclassified from&lt;br/&gt;OCI into OID and COS&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative Financial Instruments in Cash Flow Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;525&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount excluded from effectiveness testing recognized in earnings based on an amortization approach&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative Financial Instruments in Fair Value Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest rate contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(900&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Hedged item &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(313&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;175&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:18px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Non-Derivative Financial Instruments in Net Investment Hedge Relationships:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign currency short-term borrowings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;68&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign currency long-term debt&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;149&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Derivative Financial Instruments Not Designated as Hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All other net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;688&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;808&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;OID = Other (income)/deductions&#x2014;net,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2014;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in the consolidated statements of income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; COS = Cost of Sales, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other comprehensive income/(loss)&#x2013;&#x2013;Unrealized holding gains/(losses) on derivative financial instruments, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other comprehensive income/(loss)&#x2013;&#x2013;Foreign currency translation adjustments, net.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The amounts reclassified from OCI into COS were a net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$247 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in 2019 and a net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$13 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in 2018. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;gain&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$145 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; within the next 12 months into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The maximum length of time over which we are hedging future foreign exchange cash flow relates to our &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; U.K. pound debt maturing in 2043. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;These amounts were reclassified from OCI into OID. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Short-term borrowings include foreign currency short-term borrowings with carrying values of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which are used as hedging instruments in net investment hedges.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cumulative Amount of Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Value Hedging Adjustment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,499&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63"
      unitRef="usd">339000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E"
      unitRef="usd">80000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81"
      unitRef="usd">525000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D"
      unitRef="usd">-182000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427"
      unitRef="usd">136000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5"
      unitRef="usd">140000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6"
      unitRef="usd">140000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_CashFlowHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638"
      unitRef="usd">153000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e4318-wk-Fact-19D10F7FBBB55166B828C57515F0E5DC"
      unitRef="usd">900000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e4337-wk-Fact-722AC42D560351C29546696AF2E1458D"
      unitRef="usd">-348000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e4441-wk-Fact-99F422E9BA7958F2846EA6E7D03791DC"
      unitRef="usd">-900000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_InterestRateContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e4461-wk-Fact-0F12AD78F79C5102A8E62FEDCC592E95"
      unitRef="usd">348000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e4565-wk-Fact-98F2A54AC46334361761E5206F313F68"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e4584-wk-Fact-BE88CEC570F652B19EAF84B100B1E47E"
      unitRef="usd">5000000</us-gaap:ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e4687-wk-Fact-A0164F459FB4FEDAE7F5E5206F2A0E3C"
      unitRef="usd">0</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e4706-wk-Fact-1317FDFBDCC45E05A5F89D304C128317"
      unitRef="usd">-5000000</us-gaap:ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e5104-wk-Fact-D82E84CD29B95374845A78E05E6E431A"
      unitRef="usd">-313000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e5125-wk-Fact-1AAB635BCEF5567C8400CCFFA9F211E9"
      unitRef="usd">175000000</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e5144-wk-Fact-90C896B3582A49B87DFDE5206F18DC24"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e5164-wk-Fact-9703446C4160595B906FE4A04D8E2262"
      unitRef="usd">0</us-gaap:OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217"
      unitRef="usd">188000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7"
      unitRef="usd">77000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26"
      unitRef="usd">144000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis_us-gaap_NetInvestmentHedgingMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D"
      unitRef="usd">68000000</us-gaap:OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D"
      unitRef="usd">34000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961"
      unitRef="usd">68000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09"
      unitRef="usd">36000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember"
      decimals="-6"
      id="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2"
      unitRef="usd">149000000</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e6074-wk-Fact-380993016EC856A5A43F951D0C773A80"
      unitRef="usd">-172000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_NondesignatedMember_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e6094-wk-Fact-AF8B407E154F54148E312BE4E9BB335A"
      unitRef="usd">136000000</us-gaap:DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985"
      unitRef="usd">0</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB"
      unitRef="usd">-1000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219"
      unitRef="usd">2000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e6328-wk-Fact-2A9ACB09597856F4AD1723B635334EC2"
      unitRef="usd">-172000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <us-gaap:DerivativeGainLossOnDerivativeNet
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_OtherNonoperatingIncomeExpenseMember"
      decimals="-6"
      id="d34538474e6348-wk-Fact-BFDC8661881B55B6A476783E59E9740E"
      unitRef="usd">136000000</us-gaap:DerivativeGainLossOnDerivativeNet>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34538474e6368-wk-Fact-2022231E382951F7A5219EA645136F0E"
      unitRef="usd">421000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34538474e6387-wk-Fact-50286E7377FA596E859503D29B20ABBF"
      unitRef="usd">688000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e6406-wk-Fact-1C0A16C44A2B5C6AAE89B204324775E1"
      unitRef="usd">808000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeDeductionsAndCostOfSalesMember"
      decimals="-6"
      id="d34538474e6426-wk-Fact-516913B914BB588F94ACCEBA9291FDAD"
      unitRef="usd">41000000</pfe:OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66"
      unitRef="usd">247000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_DerivativeInstrumentRiskAxis_us-gaap_ForeignExchangeContractMember_us-gaap_HedgingDesignationAxis_us-gaap_DesignatedAsHedgingInstrumentMember_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD"
      unitRef="usd">-13000000</us-gaap:OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax>
    <us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34538474e6515-wk-Fact-EB69CCFC7CC65A8982AD547836C2F1E3"
      unitRef="usd">145000000</us-gaap:ForeignCurrencyCashFlowHedgeGainLossToBeReclassifiedDuringNext12Months>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_LongtermDebtTypeAxis_us-gaap_UnsecuredDebtMember"
      decimals="-8"
      id="d34538474e6523-wk-Fact-D369DD04BB2C55228C07E30F70F86B77"
      unitRef="usd">1800000000</us-gaap:LongTermDebt>
    <us-gaap:DebtCurrent
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyShortTermBorrowingsMember"
      decimals="-8"
      id="d34538474e6551-wk-Fact-021E1E6E160854329B4D39B736D664D5"
      unitRef="usd">1100000000</us-gaap:DebtCurrent>
    <us-gaap:LongTermDebt
      contextRef="FI2019Q4_us-gaap_DerivativeInstrumentRiskAxis_pfe_ForeignCurrencyLongTermDebtMember"
      decimals="-8"
      id="d34538474e6559-wk-Fact-A7EED1EE212B5BB4B30051042FFAB771"
      unitRef="usd">2000000000.0</us-gaap:LongTermDebt>
    <us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-83CBBCE91EBE7CE359F0801F8319F56E-0-wk-Fact-65FE9949F00B2F692555801F7EEDC54A">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cumulative Amount of Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Value Hedging Adjustment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,499&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-03A9A6352EB6D362933C801F831AA954-0-wk-Fact-847F8D04641F39FF4FEC801F7EEE8165">&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:24%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cumulative Amount of Fair&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Value Hedging Adjustment&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to &lt;br/&gt;Carrying Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Active&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Hedging&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying Amount of Hedged Assets/Liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Active Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued Hedging Relationships&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Short-term borrowings, including current portion of long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,499&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Long-term debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,092&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;266&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;690&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Carrying amounts exclude the cumulative amount of fair value hedging adjustments.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock>
    <us-gaap:HedgedAssetFairValueHedge
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d34538474e7152-wk-Fact-60FB429DDE645C968BD3DD43109F92F8"
      unitRef="usd">45000000</us-gaap:HedgedAssetFairValueHedge>
    <us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d34538474e7171-wk-Fact-08B6A3D22C1A50089C120A749928C2BD"
      unitRef="usd">0</us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d34538474e7191-wk-Fact-A44BF54E1F40576DB69A53789CAD540E"
      unitRef="usd">0</us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetFairValueHedge
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d34538474e7210-wk-Fact-D7A2B5A28D785F81AA97C51023C56D44"
      unitRef="usd">45000000</us-gaap:HedgedAssetFairValueHedge>
    <us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d34538474e7229-wk-Fact-432AB64A13FE55C8A7D98DBD67233F30"
      unitRef="usd">-1000000</us-gaap:HedgedAssetFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_pfe_LongtermInvestmentsMember"
      decimals="-6"
      id="d34538474e7250-wk-Fact-3AC24C0C17AC5CEEB4628BA45D979F98"
      unitRef="usd">0</us-gaap:HedgedAssetDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d34538474e7270-wk-Fact-6081521688175CC5A7553A80707D9EAC"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d34538474e7289-wk-Fact-B5DD5D7C7E2859FCA19283FF4DD6F377"
      unitRef="usd">0</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d34538474e7308-wk-Fact-EE56520C829954B3B37BD3262F4F7122"
      unitRef="usd">0</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d34538474e7328-wk-Fact-43DA714AD1B2538FB19B58AC471FCC10"
      unitRef="usd">1499000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d34538474e7347-wk-Fact-F9C02E38A7885C6DA0C47A9C8CCAFEF4"
      unitRef="usd">-5000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_ShortTermDebtMember"
      decimals="-6"
      id="d34538474e7368-wk-Fact-EF408127DA3553578EB7BE6AF018F5E8"
      unitRef="usd">0</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d34538474e7393-wk-Fact-5AE5207BC2F85C839F3BD7D293D59B4E"
      unitRef="usd">7092000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d34538474e7412-wk-Fact-FC3625E26DF05F378B439729C453FCA2"
      unitRef="usd">266000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d34538474e7431-wk-Fact-75CD43D1A6B55A7AA81A0BC872B73E3E"
      unitRef="usd">690000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityFairValueHedge
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d34538474e7451-wk-Fact-1D12DA44A07559DC9FEEB6C80CC2BAAA"
      unitRef="usd">9952000000</us-gaap:HedgedLiabilityFairValueHedge>
    <us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d34538474e7470-wk-Fact-EBDA3F55BD2454A2A6CE5D2BD1F8A8B5"
      unitRef="usd">-45000000</us-gaap:HedgedLiabilityFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease
      contextRef="FI2018Q4_us-gaap_BalanceSheetLocationAxis_us-gaap_LongTermDebtMember"
      decimals="-6"
      id="d34538474e7491-wk-Fact-DE35A00897A457A09B77F3C527455709"
      unitRef="usd">129000000</us-gaap:HedgedLiabilityDiscontinuedFairValueHedgeCumulativeIncreaseDecrease>
    <us-gaap:DerivativeNetLiabilityPositionAggregateFairValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34538474e7537-wk-Fact-21ADEB1537B054B39B8E1324C8A46177"
      unitRef="usd">449000000</us-gaap:DerivativeNetLiabilityPositionAggregateFairValue>
    <us-gaap:CollateralAlreadyPostedAggregateFairValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34538474e7541-wk-Fact-75AE77D361305A62A4114AC5EEE9B19E"
      unitRef="usd">470000000</us-gaap:CollateralAlreadyPostedAggregateFairValue>
    <us-gaap:SecuritiesReceivedAsCollateral
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34538474e7553-wk-Fact-B8AF1FCEAC105FF98FB132BD1C7544F8"
      unitRef="usd">835000000</us-gaap:SecuritiesReceivedAsCollateral>
    <us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure
      contextRef="FD2019Q4YTD_us-gaap_EquitySecuritiesByIndustryAxis_us-gaap_FinancialServicesSectorMember"
      decimals="-8"
      id="d34511230e1310-wk-Fact-AC1B73048EA85B86B06D2C3DA8DC9707"
      unitRef="usd">1400000000</us-gaap:ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure>
    <us-gaap:InventoryDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-04E8C12735852B56AD5C801F831C6AEC-0-wk-Fact-1BF268384744A67B7CB3801F8281A143">Inventories&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;790&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; reflects increases for certain products, including inventory build for new product launches, supply recovery and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. There are no recoverability issues associated with these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EEACAA4F6498C625F665801F831BDC68-0-wk-Fact-7870D0A1C712F6576AA7801F828182AF">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;790&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; reflects increases for certain products, including inventory build for new product launches, supply recovery and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. There are no recoverability issues associated with these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-B09CE6DB897A1AB29ABF801F831CC68A-0-wk-Fact-2AE72965378337BBF53F801F8283C102">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Finished goods&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,262&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Work in process&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Raw materials and supplies&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;790&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Inventories&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent inventories not included above&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;714&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The change from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; reflects increases for certain products, including inventory build for new product launches, supply recovery and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. There are no recoverability issues associated with these amounts.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryNoncurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34512803e1495-wk-Fact-BD6370B452D35ABB91099D08BEF75B41"
      unitRef="usd">2750000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34512803e1514-wk-Fact-419A5831FB265852854144F3E0A65D0B"
      unitRef="usd">2262000000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34512803e1534-wk-Fact-F9BD92BFAD3E54C78BAB5EE118A99C9A"
      unitRef="usd">4743000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34512803e1553-wk-Fact-C3A88391A2C858AE96AFCA01DAB816E8"
      unitRef="usd">4701000000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34512803e1578-wk-Fact-D58C1FEECC34507AB139DF2853E0618F"
      unitRef="usd">790000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34512803e1597-wk-Fact-45EB0661720F55BFAFC6A474125D98EA"
      unitRef="usd">546000000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34512803e1629-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
      unitRef="usd">8283000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34512803e1648-wk-Fact-C16D2F781E815917AC4E583A6245970B"
      unitRef="usd">7508000000</us-gaap:InventoryNet>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34512803e1675-wk-Fact-1F6DFBB307AD56A78E5BB87151D63936"
      unitRef="usd">714000000</us-gaap:InventoryNoncurrent>
    <us-gaap:InventoryNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34512803e1694-wk-Fact-B3F7F06F30815B7EB3DF94113CFBD851"
      unitRef="usd">618000000</us-gaap:InventoryNoncurrent>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EF693C715660F196895C801F833558EF-0-wk-Fact-4F4968FD6524A8A2BD4C801F827F9433">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Property, Plant and Equipment&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of Property, plant and equipment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Years)&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;33-50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;10,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;8-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;12,281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;3-12 1/2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,693&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;30,756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;29,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16,591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,967&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,385&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in total property, plant and equipment is mainly due to capital additions, partially offset by depreciation, reductions due to asset impairments largely associated with cost reduction initiatives not associated with acquisitions (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;), and the impact of foreign exchange.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-3EE67E4834D35F8A7589801F8335D02C-0-wk-Fact-389FEC8CAF30481CBC74801F827E5368">&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="11"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of Property, plant and equipment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Useful Lives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Years)&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Land&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;516&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Buildings&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;33-50&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;10,068&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,920&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Machinery and equipment&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;8-20&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;12,281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,871&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Furniture, fixtures and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;3-12 1/2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,930&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,693&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Construction in progress&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;30,756&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;29,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Accumulated depreciation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,789&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16,591&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Property, plant and equipment&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,967&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,385&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in total property, plant and equipment is mainly due to capital additions, partially offset by depreciation, reductions due to asset impairments largely associated with cost reduction initiatives not associated with acquisitions (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;), and the impact of foreign exchange.</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-6"
      id="d34514486e1528-wk-Fact-487FEE7950F882D5EFFF801F7EE999FF"
      unitRef="usd">516000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LandMember"
      decimals="-6"
      id="d34514486e1547-wk-Fact-1B3713B8B96882C8BB79801F7EE74AB8"
      unitRef="usd">500000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-6"
      id="d34514486e1577-wk-Fact-165BE26211760ABF4668801F7E70F367"
      unitRef="usd">10068000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_BuildingMember"
      decimals="-6"
      id="d34514486e1596-wk-Fact-17D2A084B9127B4205BC801F7E72470A"
      unitRef="usd">9920000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      decimals="-6"
      id="d34514486e1631-wk-Fact-D349C4ABE3A60240D999801F7EE8C9B3"
      unitRef="usd">12281000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_MachineryAndEquipmentMember"
      decimals="-6"
      id="d34514486e1650-wk-Fact-89AFFA89857503D34C30801F7E774504"
      unitRef="usd">11871000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-6"
      id="d34514486e1685-wk-Fact-5FD95F1BF2BD85AA0C38801F7E6A97B5"
      unitRef="usd">4930000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember"
      decimals="-6"
      id="d34514486e1704-wk-Fact-8AC34551898939EE4337801F7E773DB2"
      unitRef="usd">4693000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-6"
      id="d34514486e1739-wk-Fact-8B292287F89F655C383B801F7EE4F681"
      unitRef="usd">2960000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember"
      decimals="-6"
      id="d34514486e1758-wk-Fact-BAB82E487E2040734D6A801F7EE54E34"
      unitRef="usd">2992000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34514486e1793-wk-Fact-5A4A1109352F7996D99B801F7E71508D"
      unitRef="usd">30756000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34514486e1812-wk-Fact-E77A61A440EA6B42BFC0801F7EE6FC71"
      unitRef="usd">29977000000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34514486e1847-wk-Fact-66F574BF6D6B4D7B9CA3801F7E76E8E4"
      unitRef="usd">16789000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34514486e1866-wk-Fact-818B506C032C30CFD6A8801F7EE99D49"
      unitRef="usd">16591000000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34514486e1908-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
      unitRef="usd">13967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34514486e1927-wk-Fact-7F7E046052F852439B2A0884F029C60C"
      unitRef="usd">13385000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-838FF2C77F703A0AD01D801F833686D0-0-wk-Fact-159C7D87F8C9D28A908D801F81A8491B">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Identifiable Intangible Assets and Goodwill&lt;/span&gt;&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Identifiable Intangible Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;text-decoration:underline;"&gt;Balance Sheet Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:30%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Carrying&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Identifiable&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Intangible&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Assets, less&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Accumulated&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:right;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Finite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;88,730&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(63,106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;25,625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;89,430&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(58,895&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;30,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(741&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;923&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(708&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,191&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;582&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;91,425&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(65,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;26,387&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;91,788&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(60,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;31,045&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Indefinite-lived intangible assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,991&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,919&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements and other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,073&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,983&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Identifiable intangible assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100,408&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(65,037&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35,370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;95,954&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(60,743&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;35,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt;mainly reflects the impact of the acquisition of Array, including the addition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$340 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;finite-lived &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Licensing agreements, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$4.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of indefinite-lived &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Licensing agreement&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;s&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), partially offset by intangible asset impairment charges, primarily for Eucrisa in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. See&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 4 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for additional information on intangible asset impairments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects acquired licensing agreements for technology in development.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;is mostly due to the additions noted in (a) above, partially offset by amortization and intangible asset impairment charges, primarily for Eucrisa in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. See&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 4 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for additional information on intangible asset impairments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;WRDM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed technology rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements and other, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements and other, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;text-decoration:underline;"&gt;Developed Technology Rights&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Xtandi, Prevnar 13/Prevenar 13 Infant, Braftovi/Mektovi, Eucrisa, Premarin, Prevnar 13/Prevenar 13 Adult, and, to a lesser extent Tygacil, Zavicefta, Pristiq, Refacto AF and Bosulif. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;text-decoration:underline;"&gt;Brands&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protection. The more significant components of indefinite-lived brands are the following (in order of significance): Xanax, Medrol and Depo-Medrol. The more significant components of finite-lived brands are the following (in order of significance): Depo-Provera and Zavedos.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;text-decoration:underline;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;IPR&amp;amp;D assets represent R&amp;amp;D assets that have not yet received regulatory approval in a major market. The significant components of IPR&amp;amp;D at December 31, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; include IPR&amp;amp;D assets acquired in connection with the Array acquisition and the program for the oral PARP inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer acquired as part of the Medivation acquisition. IPR&amp;amp;D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&amp;amp;D effort. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&amp;amp;D and begin amortization. If the associated R&amp;amp;D effort is abandoned, the related IPR&amp;amp;D assets will likely be written-off, and we will record an impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;For IPR&amp;amp;D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and, as such, we expect that many of these IPR&amp;amp;D assets will become impaired and be written off at some time in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;text-decoration:underline;"&gt;Licensing Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements for developed technology and licensing agreements for technology in development primarily relate to out-licensing arrangements acquired from third parties, including the Array acquisition. These intangible assets represent the amortized or unamortized cost associated with the license, where Pfizer has acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partner. A significant component of the licensing arrangements at &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; are for out-licensing arrangements with a number of partners for oncology technology in varying stages of development that have not yet received regulatory approval in a major market. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will likely be written-off, and we will record an impairment charge.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;text-decoration:underline;"&gt;Amortization&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The weighted-average life for each of our total finite-lived intangible assets and the largest component, developed technology rights, is approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;background-color:#ffffff;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;background-color:#ffffff;"&gt;years.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total amortization expense for finite-lived intangible assets was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4.7 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#000000;text-decoration:none;"&gt;&lt;span&gt;$5.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the annual amortization expense expected for the years 2020 through 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amortization expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B. Goodwill&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prior to 2019, we managed our commercial operations through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our 2019 fiscal year, we reorganized our commercial operations and our businesses have been managed through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; different operating segments&#x2013;&#x2013;Biopharma, Upjohn and through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, Pfizer&#x2019;s Consumer Healthcare business (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 17&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for further information). Our Consumer Healthcare business was classified as held for sale as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for further information). Additionally, upon closing of the transaction during the third quarter of 2019, we deconsolidated our Consumer Healthcare business and derecognized Consumer Healthcare goodwill.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As a result of the reorganization of our commercial operations, our remaining goodwill was required to be reallocated amongst the then new Biopharma and Upjohn operating segments by determining the fair value of each reporting unit under our old and new management structure and the portions being transferred. We completed this re-allocation based on relative fair value in the second quarter of 2019 and have retrospectively presented goodwill according to the new operating structure.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of and changes in the carrying amount of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Consumer Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;43,359&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;42,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;53,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Additions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;48,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;10,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;58,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily reflects the reclassification of our Consumer Healthcare business as&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;held for sale (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), the impact of foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Biopharma additions relate to our acquisition of Array (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily reflects the impact of foreign exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34529301e1929-wk-Fact-A089F24D480155BE84E9E384AAB61EDF"
      unitRef="usd">88730000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34529301e1948-wk-Fact-D40799FE54FE50768D7FC07B9F31BF58"
      unitRef="usd">63106000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34529301e1969-wk-Fact-AA8CABF2F570588CA468DCE619BE951F"
      unitRef="usd">25625000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34529301e1988-wk-Fact-0CDCE653A5E45D5BA0F60BE9927B384C"
      unitRef="usd">89430000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34529301e2007-wk-Fact-9727ED04B3395B12A9B3B5A9C5599258"
      unitRef="usd">58895000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-6"
      id="d34529301e2028-wk-Fact-9C0330EE00BC595DB7D0BE5577BD9383"
      unitRef="usd">30535000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2048-wk-Fact-B57EC916EB03577B91F7FAFE4CBFD72C"
      unitRef="usd">922000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2067-wk-Fact-C9B6349A00AF54CF9FD25791C74053D6"
      unitRef="usd">741000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2087-wk-Fact-DD7AC3C2C7A55E84A0C7863FF827A99F"
      unitRef="usd">181000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2107-wk-Fact-B7E1675F707854F0B9ACB50C0CA3FFDD"
      unitRef="usd">923000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2126-wk-Fact-4E4551ADFB795B0DA95CA235A2FEBD3B"
      unitRef="usd">708000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2147-wk-Fact-EB804E5AFF285115BCBB6276A7DB4B48"
      unitRef="usd">215000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2174-wk-Fact-FF4615007CC653C7B1758F53F75C3121"
      unitRef="usd">1772000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2193-wk-Fact-E9E2C2D229FB5FD08F618AA417F7A246"
      unitRef="usd">1191000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2213-wk-Fact-19548AB61F0E5995A6CDA20B4FE892D2"
      unitRef="usd">582000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2233-wk-Fact-8266B3DB731A5825ABEED6BC4888318C"
      unitRef="usd">1436000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2252-wk-Fact-B9EEDF4C478F5FE399BD8F88FA3C4292"
      unitRef="usd">1140000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2273-wk-Fact-6353F406AD7D5730BA1BF2FBE27EFAE9"
      unitRef="usd">296000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e2298-wk-Fact-FBA220C2143D5E3A8C4CA612D459EA25"
      unitRef="usd">91425000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e2317-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
      unitRef="usd">65037000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e2337-wk-Fact-7793C4E0CE4652AE81162C77F4E13B72"
      unitRef="usd">26387000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e2357-wk-Fact-4FE2437D504C55B3B558E838499BAEC5"
      unitRef="usd">91788000000</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e2376-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
      unitRef="usd">60743000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e2397-wk-Fact-C970DDB03A565589B9F58C3B89469AE1"
      unitRef="usd">31045000000</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2550-wk-Fact-D0D03595E4C355EA8B97FD0E2AB14588"
      unitRef="usd">1991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2587-wk-Fact-D0D03595E4C355EA8B97FD0E2AB14588"
      unitRef="usd">1991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2607-wk-Fact-E20757D4B07A542F8E595AF676431E1A"
      unitRef="usd">1991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember"
      decimals="-6"
      id="d34529301e2645-wk-Fact-E20757D4B07A542F8E595AF676431E1A"
      unitRef="usd">1991000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34529301e2672-wk-Fact-B2B1CAAC615F5CB290A86932BBE5F716"
      unitRef="usd">5919000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34529301e2709-wk-Fact-B2B1CAAC615F5CB290A86932BBE5F716"
      unitRef="usd">5919000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34529301e2729-wk-Fact-EA2A0D133C2F552A835AAE5BE5CEA71E"
      unitRef="usd">2171000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-6"
      id="d34529301e2767-wk-Fact-EA2A0D133C2F552A835AAE5BE5CEA71E"
      unitRef="usd">2171000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2795-wk-Fact-643D9E90F2225078A9387D3F21E73814"
      unitRef="usd">1073000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2832-wk-Fact-643D9E90F2225078A9387D3F21E73814"
      unitRef="usd">1073000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2852-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
      unitRef="usd">3000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember"
      decimals="-6"
      id="d34529301e2892-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
      unitRef="usd">3000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e2917-wk-Fact-C75772DD1349525E977292533AAEBDD9"
      unitRef="usd">8983000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e2954-wk-Fact-C75772DD1349525E977292533AAEBDD9"
      unitRef="usd">8983000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e2974-wk-Fact-78A6E01615AC5CA5AA78BEDF0E5647D2"
      unitRef="usd">4165000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e3012-wk-Fact-78A6E01615AC5CA5AA78BEDF0E5647D2"
      unitRef="usd">4165000000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e3044-wk-Fact-BB4D97BFDF50513BAE0BF29E98F95690"
      unitRef="usd">100408000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e3063-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
      unitRef="usd">65037000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
      unitRef="usd">35370000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:IntangibleAssetsGrossExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e3103-wk-Fact-E4D712528036514CA1CCFB0C4C138D8D"
      unitRef="usd">95954000000</us-gaap:IntangibleAssetsGrossExcludingGoodwill>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e3122-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
      unitRef="usd">60743000000</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:IntangibleAssetsNetExcludingGoodwill
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
      unitRef="usd">35211000000</us-gaap:IntangibleAssetsNetExcludingGoodwill>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-29EE02E10588E0192531801F8336F241-0-wk-Fact-85AC8C1CFEA3C8C75837801F81B7665B">&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt;mainly reflects the impact of the acquisition of Array, including the addition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$340 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;finite-lived &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Licensing agreements, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$4.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of indefinite-lived &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Licensing agreement&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;s&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), partially offset by intangible asset impairment charges, primarily for Eucrisa in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. See&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 4 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for additional information on intangible asset impairments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects acquired licensing agreements for technology in development.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;is mostly due to the additions noted in (a) above, partially offset by amortization and intangible asset impairment charges, primarily for Eucrisa in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. See&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 4 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for additional information on intangible asset impairments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;WRDM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed technology rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements and other, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements and other, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EF6F5828EFAB414A3B3A801F83369516-0-wk-Fact-53E42CCE5976B2998E41801F81BAF02F">&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in the gross carrying amount of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt;mainly reflects the impact of the acquisition of Array, including the addition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$340 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;finite-lived &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Licensing agreements, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$4.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; of indefinite-lived &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Licensing agreement&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;s&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), partially offset by intangible asset impairment charges, primarily for Eucrisa in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. See&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 4 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for additional information on intangible asset impairments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects acquired licensing agreements for technology in development.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The increase in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;I&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;"&gt;dentifiable intangible assets, less accumulated amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:right;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;is mostly due to the additions noted in (a) above, partially offset by amortization and intangible asset impairment charges, primarily for Eucrisa in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Developed technology rights&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. See&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 4 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for additional information on intangible asset impairments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;WRDM&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed technology rights&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;99&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Brands, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;IPR&amp;amp;D&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements and other, finite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Licensing agreements and other, indefinite-lived&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      decimals="-8"
      id="d34529301e3179-wk-Fact-48D871521FAD5D3CB39F25B3CDCABD0C"
      unitRef="usd">1800000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsDevelopedTechnologyMember"
      decimals="-6"
      id="d34529301e3187-wk-Fact-72B7FF5E1A7E524A93960464DEEF1FB5"
      unitRef="usd">340000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember"
      decimals="-8"
      id="d34529301e3198-wk-Fact-BAFC3442AE0D55949C2C6B7CE309CF0F"
      unitRef="usd">4000000000.0</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles>
    <us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill
      contextRef="I2019Q3Jul30_us-gaap_BusinessAcquisitionAxis_pfe_ArrayMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsTechnologyInDevelopmentMember"
      decimals="-8"
      id="d34529301e3206-wk-Fact-D6F35499769551BEA123C478BC1A6C46"
      unitRef="usd">1100000000</us-gaap:BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d34529301e3466-wk-Fact-29E9C2979F21521B9EC402EC880FB20B"
      unitRef="number">0.99</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d34529301e3481-wk-Fact-CDAC44F40E515B25B7264AE3B5C51C8C"
      unitRef="number">0.01</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d34529301e3496-wk-Fact-7F417EF288B15C9F87FD23B676E50412"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d34529301e3516-wk-Fact-5612C284C4185608AD176585068C6961"
      unitRef="number">1</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d34529301e3531-wk-Fact-844C37786CAF534396F9FDF10C810FC8"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d34529301e3545-wk-Fact-6DE44FEB16EA57E58CD89ED2117B86F1"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d34529301e3565-wk-Fact-903ABB244B4C5D57B66CFE5FEC304D42"
      unitRef="number">0.42</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d34529301e3580-wk-Fact-9B1C3CCD6E1E5C8DA8E36F17D44E57B5"
      unitRef="number">0.58</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_TradeNamesMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d34529301e3595-wk-Fact-D4117B92D54A554FA5A3733B037B745B"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d34529301e3615-wk-Fact-D790102B2F3F57EFA369326A27D47D8E"
      unitRef="number">0.95</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d34529301e3630-wk-Fact-D689D021180F559A892AC702882DBE27"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_InProcessResearchAndDevelopmentMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d34529301e3644-wk-Fact-65ABED6A74FF545CBFFD4E8030920025"
      unitRef="number">0.05</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d34529301e3665-wk-Fact-63A31C70A4EB5D59B08B35B2AA4B6BD4"
      unitRef="number">0.98</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d34529301e3680-wk-Fact-4ECE9221166E5692953AFD721C1B6459"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d34529301e3694-wk-Fact-601110CBEAC158A8938D91FB12927A84"
      unitRef="number">0.01</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="2"
      id="d34529301e3715-wk-Fact-9284C38811555BD4A1839CE964530C2E"
      unitRef="number">1</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="2"
      id="d34529301e3730-wk-Fact-2CFDD7F50551528883630C303C4B6D92"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis_pfe_LicensingAgreementsAndOtherMember_us-gaap_SubsegmentsAxis_pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember"
      decimals="2"
      id="d34529301e3744-wk-Fact-B85D149E46075BA8A28D5AE51B33D2EA"
      unitRef="number">0</pfe:IntangibleAssetsNetPercentageofIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetUsefulLife
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_DevelopedTechnologyRightsMember"
      id="d34529301e3833-wk-Fact-727D7A8D27B17F862B66801F81A8419A">P9Y</us-gaap:FiniteLivedIntangibleAssetUsefulLife>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2019Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d34529301e3843-wk-Fact-0AC50A34D7CC5E289579E8C791E6DF78"
      unitRef="usd">4700000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2018Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d34529301e3851-wk-Fact-2D211E0C2F355AE4A0A872BB8501DD69"
      unitRef="usd">5000000000.0</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="FD2017Q4YTD_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_us-gaap_FiniteLivedIntangibleAssetsMember"
      decimals="-8"
      id="d34529301e3860-wk-Fact-678050803F2269F67D6E801F81B6A225"
      unitRef="usd">4800000000</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-39120F38C52C37E24B2B801F83363E4D-0-wk-Fact-D8BE298EB7C2ECAAD7BB801F81A92318">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="21"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the annual amortization expense expected for the years 2020 through 2024:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amortization expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3,151&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,851&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e4126-wk-Fact-97B7669EBAA1A8397234801F81D529FD"
      unitRef="usd">3477000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e4145-wk-Fact-522358F6C59BAB94111A801F81CD6DF7"
      unitRef="usd">3391000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e4165-wk-Fact-4647C2C66537B5556274801F81CE125D"
      unitRef="usd">3151000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearThree>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e4184-wk-Fact-84AD40105039733D4972801F81CEDE1A"
      unitRef="usd">2851000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFour>
    <us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e4203-wk-Fact-0D600E3EFF5EBE564FD6801F81CE55F2"
      unitRef="usd">2602000000</us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseYearFive>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d34529301e4234-wk-Fact-D17055AF0AB4DC9AC143801F8131E959"
      unitRef="Operating_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d34529301e4238-wk-Fact-E001667F01F95E298014FB8B5A7B8850"
      unitRef="Operating_Segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfGoodwillTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-A96462E6E9EB7A3A8B7F801F83363325-0-wk-Fact-BAA6B1F0437AD4E92B18801F81AC215E">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of and changes in the carrying amount of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Goodwill&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Consumer Healthcare&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, January 1, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;43,359&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,993&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,541&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Balance, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;42,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;53,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Additions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,411&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Balance, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;48,202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;10,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;58,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily reflects the reclassification of our Consumer Healthcare business as&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;held for sale (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;), the impact of foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Biopharma additions relate to our acquisition of Array (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Primarily reflects the impact of foreign exchange.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfGoodwillTextBlock>
    <us-gaap:Goodwill
      contextRef="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34529301e4481-wk-Fact-78B0E3B991B3A3C123F8D85DDC02ABB7"
      unitRef="usd">43359000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34529301e4500-wk-Fact-E0D2F908D32839362EFAD85DDBA5311D"
      unitRef="usd">10600000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2017Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34529301e4520-wk-Fact-A6A7CAA05C1DF579FB00D85E8610EE29"
      unitRef="usd">1993000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2017Q4"
      decimals="-6"
      id="d34529301e4539-wk-Fact-28BA1C6C5DA1C76DC680D85DDBC04825"
      unitRef="usd">55952000000</us-gaap:Goodwill>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34529301e4561-wk-Fact-E2D26B3B9514260520BAD85DDAA659BB"
      unitRef="usd">-432000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34529301e4581-wk-Fact-BD96EFDCEF39E408FD37D85DDBD98655"
      unitRef="usd">-116000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34529301e4601-wk-Fact-7F9C57983A364C82C7B8D85DDABE68FA"
      unitRef="usd">-1993000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34529301e4621-wk-Fact-DC29F3E24AC4E1D31CB3D85DDB384CCC"
      unitRef="usd">-2541000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34529301e4647-wk-Fact-76674072D9805C48BC3A510964694B90"
      unitRef="usd">42927000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34529301e4666-wk-Fact-77B10850E22057F2BD7241BFDBA92E2A"
      unitRef="usd">10484000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34529301e4685-wk-Fact-4F877B49DAAE56C1C475D85E8A984C1B"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34529301e4705-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04"
      unitRef="usd">53411000000</us-gaap:Goodwill>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34529301e4732-wk-Fact-267B1096BA37527F9F57BD86C5CF0ACF"
      unitRef="usd">5411000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34529301e4751-wk-Fact-C45B07370E9D1070339E801F7FB12D9A"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34529301e4770-wk-Fact-BE4C23E3208BEB55E46ED85E8DBE2AC5"
      unitRef="usd">0</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillAcquiredDuringPeriod
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34529301e4790-wk-Fact-CC09067F9E93539BA598F5986D30A0D2"
      unitRef="usd">5411000000</us-gaap:GoodwillAcquiredDuringPeriod>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34529301e4817-wk-Fact-7331B3996B7156028ABA17B0B6F034DA"
      unitRef="usd">-136000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34529301e4837-wk-Fact-F3A34AC6947D589C87DC5D125305250F"
      unitRef="usd">-33000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34529301e4857-wk-Fact-D9E19CB4E10F040A89ABD85E8FD4E4A8"
      unitRef="usd">0</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:GoodwillOtherIncreaseDecrease
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34529301e4877-wk-Fact-36EFF26A70BF5280BEBB3D0AA77CBFFB"
      unitRef="usd">-169000000</us-gaap:GoodwillOtherIncreaseDecrease>
    <us-gaap:Goodwill
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34529301e4908-wk-Fact-76552E517DE250B9A465A80EEC1B1FED"
      unitRef="usd">48202000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34529301e4927-wk-Fact-A43F18A2464E5CFCB172C24E0F20C54E"
      unitRef="usd">10451000000</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34529301e4947-wk-Fact-9467D88470844F708747D85DDAAFF235"
      unitRef="usd">0</us-gaap:Goodwill>
    <us-gaap:Goodwill
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34529301e4965-wk-Fact-6EE57D419E98505BB872CDF37DAACD72"
      unitRef="usd">58653000000</us-gaap:Goodwill>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E9A2E5CA5A49BA1EC469801F83461F2E-0-wk-Fact-9C67C68015CFEABC39A9801F8080D7B5">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Pension and Postretirement Benefit Plans and Defined Contribution Plans&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="49"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="49" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the annual (credit)/cost and changes in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;for our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="47" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Qualified&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Service cost&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actuarial losses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;393&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prior service cost/(credit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Curtailments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Credit)/cost reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;570&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Credit)/cost recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$156 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; net pension benefit obligation and recorded a pretax settlement gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$41 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Effective January 1, 2018, we froze &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;We adopted an accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; on the consolidated statements of income. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the amounts in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;expected to be amortized into 2020 net periodic benefit costs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&lt;br/&gt;Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Supplemental&lt;br/&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actuarial (losses)/gains&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prior service credits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;24.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; years for our U.S. qualified plans, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;24.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; years for our U.S. supplemental (non-qualified) plans, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;19.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; years for our international plans, and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; years for our postretirement plans.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B. Actuarial Assumptions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the weighted-average actuarial assumptions of our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6pt;"&gt;&lt;span style="font-family:Arial;font-size:6pt;"&gt;(PERCENTAGES)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Weighted-average assumptions used to determine benefit obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discount rate:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. non-qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Rate of compensation increase:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. non-qualified pension plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Weighted-average assumptions used to determine net periodic benefit cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discount rate:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. non-qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected return on plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Rate of compensation increase:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. non-qualified pension plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#x2019; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the net periodic benefit cost for the subsequent fiscal year. Therefore, the assumptions used to determine net periodic benefit cost for each year are established at the end of each previous fiscal year, while the assumptions used to determine benefit obligations are established at each fiscal year-end.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing retirement benefits.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; resulted in lower discount rates as compared to the prior year.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Healthcare cost trend rate assumed for next year (up to age 65)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Healthcare cost trend rate assumed for next year (age 65 and older)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year that the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the effects as of December 31, 2019 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Decrease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect on total service and interest cost components&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect on postretirement benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Obligations and Funded Status&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&#160;Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Change in benefit obligation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefit obligation, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16,702&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;9,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,607&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee contributions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Plan amendments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Changes in actuarial assumptions and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(122&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange impact&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Acquisitions/divestitures/other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Curtailments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefits paid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefit obligation, ending&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11,059&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Change in plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;14,284&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actual gain/(loss) on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Company contributions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee contributions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange impact&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Acquisitions/divestitures, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefits paid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets, ending&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,956&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Funded status&#x2014;Plan assets less than benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The PBO represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases. The ABO is similar to the PBO but does not factor in future compensation increases. For the U.S. qualified and supplemental (non-qualified) pension plans, the benefit obligation is the PBO, which is also equal to the ABO. Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#x2019; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$10.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$9.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For the postretirement plans, the benefit obligation is the ABO.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information as to how the funded status is recognized in our consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&#160;Supplemental&lt;br/&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Funded status&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Accrued compensation and related items&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;As of December 31, 2019, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Pension benefit obligations, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Postretirement benefit obligations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;as appropriate. In 2018, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Pension benefit obligations, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Postretirement benefit obligations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, as well as in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Liabilities held for sale&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;, as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;appropriate.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&#160;Supplemental&lt;br/&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actuarial losses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4,812&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5,061&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prior service (costs)/credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;830&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our PBO, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the average life expectancy of plan participants for frozen plans, primarily using the corridor approach.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information related to the funded status of selected benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Supplemental (Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension plans with an ABO in excess of plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ABO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension plans with a PBO in excess of plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,947&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PBO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;All of our U.S. plans and many of our international plans were underfunded as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;D. Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="41"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="41" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:10px;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;The following table provides the components of plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fair Value&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fair Value&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;As of&lt;br/&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Assets Measured at NAV&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;As of&lt;br/&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Assets Measured at NAV&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;text-decoration:underline;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;443&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Global equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;3,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;3,406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity commingled funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed income securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;5,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;5,281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;4,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;4,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed income commingled funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other investments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Partnership investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Insurance contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other commingled funds&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,075&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;3,496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;8,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;2,638&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;7,294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;text-decoration:underline;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Global equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity commingled funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,548&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,876&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed income securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency obligations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed income commingled funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;2,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,007&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other investments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Partnership investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Insurance contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d), (f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;8,956&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;4,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;2,652&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;8,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;4,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;text-decoration:underline;"&gt;U.S. postretirement plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Insurance contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"/&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 1E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"/&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Mostly includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency obligations are inclusive of repurchase agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Insurance contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Assets held, ending&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Purchases, sales, and settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Transfer into/(out&#160;of) Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;247&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Exchange rate changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value, ending&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1E.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; For a description of the risks associated with estimates and assumptions, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1C.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans&#x2019; assets:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:8px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Target&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Allocation Percentage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Percentage of Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6pt;"&gt;&lt;span style="font-family:Arial;font-size:6pt;"&gt;(PERCENTAGES)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;0-10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;35-55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fixed income securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;28-53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;48.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;47.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;5-20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;0-10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;20-40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;21.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;22.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fixed income securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;35-60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;46.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;46.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;10-35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;27.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;U.S. postretirement plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;0-5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;95-100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans&#x2019; invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of the respective plans&#x2019; long-term benefit obligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset classes and our liability profile. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Each pension plan is overseen by a local committee or board that is responsible for the overall investment of the pension plan assets. In determining investment policies and associated target allocations, each committee or board considers a wide variety of factors. As such, the target asset allocation for each of our international pension plans is set on a standalone basis by the relevant board or committee. The target asset allocation ranges shown for the international pension plans seek to reflect the combined target allocations across all such plans, while also showing the range within which the target allocations for each plan typically falls.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The investment managers of certain separately managed accounts, commingled funds and private equity funds may be permitted to use repurchase agreements and derivative securities, including U.S. Treasury and equity futures contracts as described in each respective investment management, subscription, partnership or other governing agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;E. Cash Flows&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the expected future cash flow information related to our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;U.S. Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected employer contributions:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected benefit payments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,048&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2025&#x2013;2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;642&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For the U.S. qualified plans, we plan to make a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.25 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; voluntary contribution in the second half of 2020.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation and, therefore, actual benefit payments may differ from projected benefit payments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;F. Defined Contribution Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We have defined contribution plans in the U.S. and several other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. Beginning on January 1, 2011, for newly hired non-union employees, rehires and transfers to the U.S. or Puerto Rico, we no longer offer a defined benefit pension plan and, instead, offer a Retirement Savings Contribution (RSC) in the defined contribution plan. The RSC is an annual non-contributory employer contribution (that is not dependent upon the participant making a contribution) determined based on each employee&#x2019;s eligible compensation, age and years of service. Beginning on January 1, 2018, all non-union employees in the U.S. and Puerto Rico defined benefit plans transitioned to the RSC in the defined contribution plans. We recorded charges related to the employer contributions to global defined contribution plans of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$659 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$622 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$380 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D3D653DC07673AEE8478801F8345DAE5-0-wk-Fact-58FDE3F84B838840532E801F80CA871A">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="49"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="49" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the annual (credit)/cost and changes in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;for our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="47" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Qualified&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Service cost&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected return on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(890&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,040&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,005&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(317&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amortization of:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actuarial losses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;120&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;393&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;101&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prior service cost/(credit)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(178&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Curtailments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(19&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;26&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net periodic benefit cost/(credit) reported in income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;166&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Credit)/cost reported in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other comprehensive income/(loss)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;361&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;570&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Credit)/cost recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Comprehensive income&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;685&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;168&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(154&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(83&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$156 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; net pension benefit obligation and recorded a pretax settlement gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$41 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2014;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Effective January 1, 2018, we froze &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;We adopted an accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; on the consolidated statements of income. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2692-wk-Fact-6933FD29A03F60C5C1DB801F8037A1E9"
      unitRef="usd">269000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2711-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2730-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2750-wk-Fact-E2FFF18A87ED82A265A1801F8065BD9A"
      unitRef="usd">24000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2769-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
      unitRef="usd">125000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2788-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2808-wk-Fact-B8932CAFC2CF99FDC067801F7FD54D8F"
      unitRef="usd">171000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2827-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2846-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2866-wk-Fact-AFB9A55388F572AD8D2E801F7FC2597A"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2886-wk-Fact-823CFC536B2415CC760F801F821963E0"
      unitRef="usd">629000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2905-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
      unitRef="usd">598000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2924-wk-Fact-A1514905E048F0FFA68C801F800B7A4F"
      unitRef="usd">634000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2944-wk-Fact-1645F7BA211F13D895DB801F821CDBB9"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2963-wk-Fact-B14453A638517C4D7C51801F82449662"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e2983-wk-Fact-4D7E696D36452A8FBABE801F80035C76"
      unitRef="usd">54000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3002-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2"
      unitRef="usd">215000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3021-wk-Fact-56AC0425594EB6B614D8801F82235863"
      unitRef="usd">212000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3041-wk-Fact-E9C0E588D60EFF449BEC801F802BF05A"
      unitRef="usd">204000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3060-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3079-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3099-wk-Fact-9ED0AE1AAFE89D27C637801F7F9951A8"
      unitRef="usd">90000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3124-wk-Fact-E90985269B2154239A430851FD659027"
      unitRef="usd">890000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3144-wk-Fact-0065C22DDD425D5EB99735A6E835EC0F"
      unitRef="usd">1040000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3164-wk-Fact-6178D606D0576009E7D8801F800B47C5"
      unitRef="usd">1005000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3185-wk-Fact-2DBF4D472C975F0AA14D950D65306807"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3204-wk-Fact-76BACCA131EA51D1B5D320A3CF59AF39"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3224-wk-Fact-850543A2F7B16A871226801F7FC88CC3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3243-wk-Fact-AB60FFA4D6735ECEAE192A4A707DAC2B"
      unitRef="usd">317000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3263-wk-Fact-9106EFBD5E1A5015B50F669BF7823045"
      unitRef="usd">360000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3284-wk-Fact-BBD005126C8B7BF17012801F7F829DC1"
      unitRef="usd">345000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3304-wk-Fact-BACCC5530F605EA1BB11F5908E9CB895"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3324-wk-Fact-8F2397DD8AFC5996996D132715997194"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3345-wk-Fact-38C16925125E7F347AD0801F80703D12"
      unitRef="usd">36000000</us-gaap:DefinedBenefitPlanExpectedReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3615-wk-Fact-3F59543875025E468AEF3F683189F304"
      unitRef="usd">-147000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3634-wk-Fact-C3D0942856A1581EAF48531154A4786E"
      unitRef="usd">-120000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3653-wk-Fact-378E7CFB0C3366BE1636801F7F982A6D"
      unitRef="usd">-393000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3673-wk-Fact-931C9AE7EA695C8789803ED34BF3218D"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3692-wk-Fact-D3F2DE5872EC5230B439CD011DA01871"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3712-wk-Fact-F538ACACF4943B2112FE801F7FAADCE2"
      unitRef="usd">-50000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3731-wk-Fact-6DB8EEE5D9865BED9C6C65D55477AD7B"
      unitRef="usd">-80000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3750-wk-Fact-0AFCCC455878510D879042E7F8FF809D"
      unitRef="usd">-101000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3770-wk-Fact-5FCA9B06E5F243C62A7E801F7F95C2A9"
      unitRef="usd">-116000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3789-wk-Fact-4B742D12220955FCB8512E0C28478091"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3808-wk-Fact-D8C77E7DECB85CFDA69FCED349A74F3B"
      unitRef="usd">-7000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3828-wk-Fact-945DBFC591102C8BB117801F803ED887"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanAmortizationOfGainsLosses>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3853-wk-Fact-C8FEE220A6AD511B90AEDFED4C8522CE"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3873-wk-Fact-AB1A5D7154D55524B1896C7D13EEE1BE"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3892-wk-Fact-3503C852F9E4ADA0D97B801F7FA9C9D8"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3912-wk-Fact-FB5534AC2119581C97F07FAA8E748328"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3932-wk-Fact-613E0B05B7865D04A43CD9F51978D9DE"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3953-wk-Fact-686319F7B5604E2276BE801F7FE6F206"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3973-wk-Fact-034EF17B9785562AAB08D4DFF03B6380"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e3993-wk-Fact-D723E7932AD45B5CBA0CD8286F87796C"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4014-wk-Fact-FA93D99FAC7F7CCD240D801F7F9D9735"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4034-wk-Fact-6E21A5F3FA86557DA2ADBE81D11BF014"
      unitRef="usd">-173000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4054-wk-Fact-299F68F3E4305B7396AD49A92B1DBD31"
      unitRef="usd">-178000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4075-wk-Fact-8D966B14A8E40A9AFA58801F80294ADF"
      unitRef="usd">-182000000</us-gaap:DefinedBenefitPlanAmortizationOfPriorServiceCostCredit>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4102-wk-Fact-2648C18B67135722AC996F7545880D80"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4121-wk-Fact-4BC04F50F859575786CDEB42846504B3"
      unitRef="usd">-12000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4140-wk-Fact-EB4AB9F6D4F4A8E5149B801F8025CB18"
      unitRef="usd">-13000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4160-wk-Fact-ADD074ED2993574E8FE7A245F23A9D4B"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4179-wk-Fact-6BAF9C5EBA26505A8C43CBAC57E0BE83"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4199-wk-Fact-AE778EF034BB21B505CE801F8013E5BF"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4218-wk-Fact-18079E34B32C53C996423C831A0FD2B8"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4238-wk-Fact-BDFDACC2489653DB8B1E70291B40AAAF"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4259-wk-Fact-A9E0EFC1F162C6867416801F7FA92E48"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4278-wk-Fact-250C34725FF05BB883239FC420341A54"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4298-wk-Fact-A16A027B92E3524680E14BE5F7592565"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4319-wk-Fact-41C48699245DA0B3860D801F7FFA7301"
      unitRef="usd">19000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4345-wk-Fact-07AD3C926A5E57D3A3F93B11BDBF155E"
      unitRef="usd">-230000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4364-wk-Fact-36071102556E5A8BB41605B5E0E61960"
      unitRef="usd">-113000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4383-wk-Fact-4F6A9D76BC23A664699C801F8033D7FF"
      unitRef="usd">-75000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4403-wk-Fact-C0B43F53E7035856B1B1655A6BCF5C25"
      unitRef="usd">-27000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4422-wk-Fact-0B9C9F05CB1359C9B15B904FBBE01B56"
      unitRef="usd">-26000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4442-wk-Fact-F4700D93FA2B1270B85C801F7FEB6678"
      unitRef="usd">-39000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4461-wk-Fact-900B4862554A52598347DDC7EF675D33"
      unitRef="usd">-16000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4480-wk-Fact-AEB2DA29464457BA8DD64A5602FF3160"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4500-wk-Fact-EDC2B33055CD699CD5D1801F7FD79DE8"
      unitRef="usd">-4000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4519-wk-Fact-421F0B17A1105BA186D024847A9EBECA"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4539-wk-Fact-6A30FA2A36BB576592292682CE57A8D6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4559-wk-Fact-6E00A7BE0DEEA1145279801F7F63CF6A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4584-wk-Fact-691D5136507A5CF6B58B87FA8C2DFF67"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4603-wk-Fact-2CA2DA51FA5858A080A8149D1EF99AE3"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4622-wk-Fact-C8A8BF249D3C3080DE9D801F803E1DD7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4642-wk-Fact-4CD2842806B75D2987F3D6D6054096C4"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4661-wk-Fact-5BCE1C36478B5183BA92A14694D138F2"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4681-wk-Fact-87F7B018BE7018B441C1801F804B0D50"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4700-wk-Fact-D9CF230D68F550D2B21951B73C9C2B82"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4719-wk-Fact-F3515DDE6FCB5C6F827698B135BF72F5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4739-wk-Fact-EA99DFE18AC2A9E31A59801F7F7FCB2A"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4758-wk-Fact-8401190048BF54B4B1327C5B7A8B73E7"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4777-wk-Fact-5010E3E80A16592EA0A75F6671DD8D80"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4797-wk-Fact-2D245F010E417F9A342B801F7FB3C282"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4824-wk-Fact-B85C9CC9D293576C909EA9314FC824EE"
      unitRef="usd">116000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4843-wk-Fact-1D9607EC2BA2B2BE84B8801F807C0925"
      unitRef="usd">-189000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4863-wk-Fact-9D37210D257EF686844E801F800CB2CA"
      unitRef="usd">382000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4883-wk-Fact-F926238DB44A5C97B1224C96A9C8141E"
      unitRef="usd">100000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4902-wk-Fact-E197FC2A851A0D8F91E2801F7FC6EAB4"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4922-wk-Fact-1CD88F40E9218841E1F5801F7F82CECD"
      unitRef="usd">166000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4941-wk-Fact-59FCEED3F6055C9A869BCCC59046D785"
      unitRef="usd">115000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4960-wk-Fact-7FAB76E95E2266217B40801F7FD40652"
      unitRef="usd">84000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4980-wk-Fact-0D7980FB1A19BDA52E10801F8004B06B"
      unitRef="usd">147000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e4999-wk-Fact-EADEAA54DF8A5541A925A32BD98FDB78"
      unitRef="usd">-146000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5019-wk-Fact-D61DE1C8D5314D9446A3801F7FA8246B"
      unitRef="usd">-111000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5040-wk-Fact-831DB9576209A9ACB46A801F7FE98854"
      unitRef="usd">-75000000</us-gaap:DefinedBenefitPlanNetPeriodicBenefitCost>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5068-wk-Fact-E12E0298D04CBB2C3A47801F7F8D79BA"
      unitRef="usd">-246000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5088-wk-Fact-3EF2B8E9997739EA3A5F801F7FF78369"
      unitRef="usd">361000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5107-wk-Fact-6490FB80A4F21290128A801F7FC0275E"
      unitRef="usd">141000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5127-wk-Fact-F859D941124BCB940900801F7F8154F3"
      unitRef="usd">115000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5146-wk-Fact-A87F10406B18404F9B51801F7FABCCF6"
      unitRef="usd">-189000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5167-wk-Fact-82E209022CD1F47E9F9D801F7F8D9AAD"
      unitRef="usd">23000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5186-wk-Fact-0A67FC94C1A335307661801F7FD76CCD"
      unitRef="usd">570000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5205-wk-Fact-60D31D33F54AF44431A9801F7F6208AA"
      unitRef="usd">84000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5225-wk-Fact-AEEF2220D35942CB0DD3801F7F6F13D1"
      unitRef="usd">-301000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5245-wk-Fact-E599ED1AA40A2469EC61801F804BAEDF"
      unitRef="usd">38000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5264-wk-Fact-D0DD8A60AF26952B3CEA801F7FF27C88"
      unitRef="usd">105000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5284-wk-Fact-494803F49419B09647DE801F7F92F83D"
      unitRef="usd">-8000000</us-gaap:OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5317-wk-Fact-C2A34D3ABFB1A91EA818801F7FB1393F"
      unitRef="usd">-129000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5337-wk-Fact-C09AF6E13F933AFF10EF801F7FC152C9"
      unitRef="usd">171000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5357-wk-Fact-E19185551DC6EBA76F10801F8027D89E"
      unitRef="usd">523000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5376-wk-Fact-4CD2A5D18BF6FA6ED4E1801F7F629857"
      unitRef="usd">215000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5395-wk-Fact-87360E241875CDAFD283801F802DFA3B"
      unitRef="usd">-86000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5416-wk-Fact-BCD330DBBD645293232E801F806462D8"
      unitRef="usd">189000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5435-wk-Fact-1F93183F5D4875A34B19801F7F8D1D5D"
      unitRef="usd">685000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5454-wk-Fact-CB20215A2101BBDA321C801F7F803B72"
      unitRef="usd">168000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5474-wk-Fact-8E19A652CCE7A84C8EF2801F7FB2DD1C"
      unitRef="usd">-154000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5494-wk-Fact-03BF3C273A7FF17CCC1D801F7FD6B64C"
      unitRef="usd">-107000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5514-wk-Fact-F0C23B9E8CA41E5682F8801F80498C05"
      unitRef="usd">-6000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5535-wk-Fact-EAFC8BF958C2209A7EF6801F7F845105"
      unitRef="usd">-83000000</us-gaap:AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax>
    <pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost
      contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5553-wk-Fact-0BDDE461852B17B8365E17245E828279"
      unitRef="usd">156000000</pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost>
    <pfe:DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax
      contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5557-wk-Fact-2F609D849A8B71F42EE4801F8027C25F"
      unitRef="usd">41000000</pfe:DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax>
    <pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost
      contextRef="FD2017Q2QTD_us-gaap_BusinessAcquisitionAxis_pfe_HospiraMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e5561-wk-Fact-BE24BBF0713388350C6D801F80284F3C"
      unitRef="usd">30000000</pfe:DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost>
    <pfe:DefinedBenefitPlanNumberofPensionPlansFrozen
      contextRef="I2018Q1Jan01"
      decimals="INF"
      id="d34661879e5592-wk-Fact-909C95070CBD74A122F2801F80651727"
      unitRef="pension_plan">2</pfe:DefinedBenefitPlanNumberofPensionPlansFrozen>
    <us-gaap:ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-5EF5C87432873DAB49E1801F83442F97-0-wk-Fact-CBCBABC1710CE6B31FEB801F8021D542">&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:23%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:20%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the amounts in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;expected to be amortized into 2020 net periodic benefit costs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&lt;br/&gt;Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Supplemental&lt;br/&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actuarial (losses)/gains&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(127&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prior service credits and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(14&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(121&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; are &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;24.9&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; years for our U.S. qualified plans, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;24.5&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; years for our U.S. supplemental (non-qualified) plans, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;19.4&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; years for our international plans, and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;9.2&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; years for our postretirement plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6000-wk-Fact-3AD6F4B4A41632FD0B68801F817F1B4F"
      unitRef="usd">-127000000</us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6020-wk-Fact-35607E33C1EA7F8BC8EF801F7E4B3C15"
      unitRef="usd">-14000000</us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6041-wk-Fact-C92D70667288365FCFEA801F82243A1E"
      unitRef="usd">-124000000</us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6061-wk-Fact-9050CF9D6C997910CB96801F7E3C9CE2"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6081-wk-Fact-38C75D351712D4A2B7C1801F7E2E26E8"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6100-wk-Fact-8FEDD9FF84373B0F979D801F814907AD"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6119-wk-Fact-6420F2B3E2E088D80671801F82280E75"
      unitRef="usd">-3000000</us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6139-wk-Fact-F96B4A04826575457FC4801F7E338884"
      unitRef="usd">-172000000</us-gaap:DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6169-wk-Fact-01331CF69D5828BD374E801F81872799"
      unitRef="usd">124000000</us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6189-wk-Fact-D80694D39D46BE0892B8801F7E5AED89"
      unitRef="usd">14000000</us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6210-wk-Fact-B4CE2A5E54FB9489E5A3801F7E4277D0"
      unitRef="usd">121000000</us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e6230-wk-Fact-52B636E2E0FAAEE98365801F7E5698DB"
      unitRef="usd">-172000000</us-gaap:DefinedBenefitPlanExpectedAmortizationNextFiscalYear>
    <pfe:DefinedBenefitPlanExpectedAmortizationTerm
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      id="d34661879e6257-wk-Fact-B15C404893F9FF56B1871727A086D353">P24Y10M24D</pfe:DefinedBenefitPlanExpectedAmortizationTerm>
    <pfe:DefinedBenefitPlanExpectedAmortizationTerm
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      id="d34661879e6261-wk-Fact-1E8C536F0B87B6FE6D4D172800706240">P24Y6M</pfe:DefinedBenefitPlanExpectedAmortizationTerm>
    <pfe:DefinedBenefitPlanExpectedAmortizationTerm
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      id="d34661879e6265-wk-Fact-582F6F0142957E8B541F172887E36FD9">P19Y4M24D</pfe:DefinedBenefitPlanExpectedAmortizationTerm>
    <pfe:DefinedBenefitPlanExpectedAmortizationTerm
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      id="d34661879e6269-wk-Fact-9E79A99D16317B9F000C1729038FD591">P9Y2M12D</pfe:DefinedBenefitPlanExpectedAmortizationTerm>
    <us-gaap:ScheduleOfAssumptionsUsedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-812178B86602E889B935801F834620AF-0-wk-Fact-66E5D3D1B44E13F6FB7F801F802E8B99">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the weighted-average actuarial assumptions of our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6pt;"&gt;&lt;span style="font-family:Arial;font-size:6pt;"&gt;(PERCENTAGES)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Weighted-average assumptions used to determine benefit obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discount rate:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. non-qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Rate of compensation increase:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. non-qualified pension plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Weighted-average assumptions used to determine net periodic benefit cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discount rate:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. non-qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected return on plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Rate of compensation increase:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. non-qualified pension plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#x2019; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAssumptionsUsedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6524-wk-Fact-A10088B30BB98D823A5E801F81FE7834"
      unitRef="number">0.033</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6539-wk-Fact-F4E28D1CA67A086FF726801F80DA0F0D"
      unitRef="number">0.044</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6554-wk-Fact-FAAD98FCE0138D8F7D42801F81EED701"
      unitRef="number">0.038</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e6575-wk-Fact-5AD94F1A4E64A9050C68801F7F5276F1"
      unitRef="number">0.032</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e6590-wk-Fact-A62E67DC97322F95F554801F81FF775D"
      unitRef="number">0.043</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e6605-wk-Fact-04C24B36955CEEC5ADDF801F7EEFFC7C"
      unitRef="number">0.037</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6626-wk-Fact-36BA9E860097EF857906801F81FCAC2C"
      unitRef="number">0.017</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6641-wk-Fact-A4199A292961EE91C57F801F81EAD662"
      unitRef="number">0.025</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6656-wk-Fact-60DF5AEA2E2098724171801F7FC13C14"
      unitRef="number">0.023</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6677-wk-Fact-C5EA9DE67D02F29142D1801F7EFC2CC7"
      unitRef="number">0.032</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6692-wk-Fact-640BF9D80D8F5B2A4A9C801F7F6FC900"
      unitRef="number">0.043</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate
      contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6707-wk-Fact-D104EA94EE16D1F1F072801F82031DB4"
      unitRef="number">0.037</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6781-wk-Fact-D2DF1C2AD15035E416EB801F7FC07A27"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6795-wk-Fact-C4A0AC65971AD463ED33801F81E8AD2D"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6809-wk-Fact-A97915E9582AC1C02322801F80D9D022"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e6832-wk-Fact-8AF87FC965702ACF9270801F80DB9038"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e6846-wk-Fact-D7952502BA2F1E69FE54801F820C8790"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e6860-wk-Fact-0451479DAEAC08A2B0C5801F820E384C"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6882-wk-Fact-7540B045D1F4D34D894E801F7F605756"
      unitRef="number">0.014</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6897-wk-Fact-6509BC0AB3F6034C0A1E801F81EFF1E5"
      unitRef="number">0.014</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e6912-wk-Fact-F89D862758DBEC9A52D6801F7EFB563E"
      unitRef="number">0.025</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingBenefitObligationRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7035-wk-Fact-324C5DE15600B0537AF6801F821142E3"
      unitRef="number">0.044</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7050-wk-Fact-170E5CC230F6DF73ADDD801F7FC98598"
      unitRef="number">0.038</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7065-wk-Fact-59266DC078E867B8154A801F81FD879E"
      unitRef="number">0.043</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e7086-wk-Fact-B7E89B80435FBA9D2015801F80D27F55"
      unitRef="number">0.043</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e7101-wk-Fact-890110D94E74323B227F801F7EBE5C6A"
      unitRef="number">0.037</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e7116-wk-Fact-45240A2F103D85093A6F801F8202535A"
      unitRef="number">0.042</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7137-wk-Fact-52B29039EB69049E6496801F82067B03"
      unitRef="number">0.022</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7152-wk-Fact-9727EBBE51C4177AF65D801F80EDBB10"
      unitRef="number">0.020</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7167-wk-Fact-915581A3FD69CD808C17801F80F020E0"
      unitRef="number">0.021</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingInterestCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7188-wk-Fact-DD965C2897CAF9EC9175801F820FA09E"
      unitRef="number">0.024</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7203-wk-Fact-AB35FA0FC4A6932A38D9801F820E7C5A"
      unitRef="number">0.023</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate>
    <pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7218-wk-Fact-E0C719691900484E40C2801F820C6B56"
      unitRef="number">0.023</pfe:DefinedBenefitPlanAssumptionsUsedCalculatingServiceCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7239-wk-Fact-7705F0E112C1AEE7C1E2801F7EAC8BF2"
      unitRef="number">0.043</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7254-wk-Fact-A0602E1C2A395B026AC5801F81EC9E3A"
      unitRef="number">0.037</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7269-wk-Fact-5A7DF338890207B47CEB801F8210C59D"
      unitRef="number">0.042</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostDiscountRate>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7341-wk-Fact-6E5C77D7B3E8F282445E801F7EF190C6"
      unitRef="number">0.072</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7356-wk-Fact-2684EE8C5D7ED2DBEBCB801F7EFE7FE4"
      unitRef="number">0.075</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7371-wk-Fact-AB3D3D96B4CA7C55B31B801F7F9A4C20"
      unitRef="number">0.080</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7392-wk-Fact-6F25380B960D59999C03801F7F585A6D"
      unitRef="number">0.039</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7407-wk-Fact-10C102482859A51971D8801F7EB6C89A"
      unitRef="number">0.044</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7422-wk-Fact-BEA766E72B254A056073801F81E921D2"
      unitRef="number">0.047</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7444-wk-Fact-54D0EDA1C744571877FE801F81E94F9E"
      unitRef="number">0.073</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7459-wk-Fact-A9E4C34ED0AA40BD1775801F81FF128A"
      unitRef="number">0.075</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7474-wk-Fact-0238E055F26CEAEA5813801F7EEA6867"
      unitRef="number">0.080</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostExpectedLongTermReturnOnAssets>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7548-wk-Fact-8060BA9EC76EA962A052801F7EFC1E79"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7562-wk-Fact-58349156F701DBD2FAE9801F7F55CCA1"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7577-wk-Fact-E02ED63B97645048DC3D801F80ED740C"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e7600-wk-Fact-4E0DBFBB79A3239D00CC801F7F5FBA6F"
      unitRef="number">0</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e7614-wk-Fact-E880D275F9E61ED56A76801F7EE80BBC"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="3"
      id="d34661879e7629-wk-Fact-A6FC51038FA814464645801F81FD9227"
      unitRef="number">0.028</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7650-wk-Fact-082F937FD346A54D75CA801F82093B2A"
      unitRef="number">0.014</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7665-wk-Fact-1E5F4F807ADB025DD4BD801F7EBAA5CD"
      unitRef="number">0.025</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease
      contextRef="FD2017Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7680-wk-Fact-42064D442E67BDEAE3EA801F80D3D1D2"
      unitRef="number">0.026</us-gaap:DefinedBenefitPlanAssumptionsUsedCalculatingNetPeriodicBenefitCostRateOfCompensationIncrease>
    <us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EBC9083D6D823E93B03B801F83451725-0-wk-Fact-7CD2CAE5FF3A9FD24828801F803C7458">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="7"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Healthcare cost trend rate assumed for next year (up to age 65)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Healthcare cost trend rate assumed for next year (age 65 and older)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Rate to which the cost trend rate is assumed to decline&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year that the rate reaches the ultimate trend rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2037&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the effects as of December 31, 2019 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Decrease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect on total service and interest cost components&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect on postretirement benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfHealthCareCostTrendRatesTableTextBlock>
    <pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7843-wk-Fact-BF66DABEAA11A0AB30A0801F821A0996"
      unitRef="number">0.056</pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge>
    <pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7858-wk-Fact-96E9DA0DB9E8401FC29B801F8218381F"
      unitRef="number">0.058</pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge>
    <pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7879-wk-Fact-4674D59AF05EFCB9EABE801F821B62F7"
      unitRef="number">0.060</pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver>
    <pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7894-wk-Fact-2FE334E874B9704130BF801F8219736C"
      unitRef="number">0.065</pfe:DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7915-wk-Fact-EC5CDE3A9F793BE8E2B4801F821AEC2B"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e7930-wk-Fact-4568EFAA5E7994817813801F821A53A4"
      unitRef="number">0.045</us-gaap:DefinedBenefitPlanUltimateHealthCareCostTrendRate1>
    <us-gaap:ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-BF361D661E112EC4042B801F83468E60-0-wk-Fact-ACF158D06E311091FDE7801F8023CC61">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="9"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:76%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the effects as of December 31, 2019 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Increase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Decrease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect on total service and interest cost components&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Effect on postretirement benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock>
    <us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e8107-wk-Fact-9A5007514C1F38D9F209801F7EB931AB"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents>
    <us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e8126-wk-Fact-04F871BD21ADFD1AACB0801F7EB71A37"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1>
    <us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e8147-wk-Fact-67710200F4F38C97A16B801F7EB8B6B2"
      unitRef="usd">38000000</us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation>
    <us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e8166-wk-Fact-511281176A9BC5953B9B801F7EC9B7E6"
      unitRef="usd">27000000</us-gaap:DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1>
    <us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-41A0A9F2277C231DD1F6801F8345B719-0-wk-Fact-7FA2337AE374D988BED1801F80245DE7">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&#160;Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Change in benefit obligation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefit obligation, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16,702&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,495&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;9,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10,607&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Service cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Interest cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;629&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;598&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee contributions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Plan amendments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(56&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Changes in actuarial assumptions and other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,219&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,224&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(122&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange impact&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(457&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Acquisitions/divestitures/other, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Curtailments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Special termination benefits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefits paid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefit obligation, ending&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11,059&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,952&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,667&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,870&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;height:5px;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Change in plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;14,284&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,863&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;494&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actual gain/(loss) on plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2,760&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;873&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(77&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(22&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Company contributions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;500&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;145&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Employee contributions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Foreign exchange impact&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(380&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Acquisitions/divestitures, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(16&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Settlements&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(692&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(72&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Benefits paid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(544&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(373&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets, ending&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,956&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Funded status&#x2014;Plan assets less than benefit obligation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The PBO represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases. The ABO is similar to the PBO but does not factor in future compensation increases. For the U.S. qualified and supplemental (non-qualified) pension plans, the benefit obligation is the PBO, which is also equal to the ABO. Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#x2019; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$10.6 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$9.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For the postretirement plans, the benefit obligation is the ABO.&lt;/span&gt;&lt;/div&gt;</us-gaap:ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9456-wk-Fact-B46984BEC265F2CB3433801F822E334D"
      unitRef="usd">15141000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9475-wk-Fact-2227E15F117DFBBA6CDF801F823CAC01"
      unitRef="usd">16702000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9495-wk-Fact-73596D19D7B15B05E6A9801F820D7E85"
      unitRef="usd">1280000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9514-wk-Fact-1BB3443744FA4A3A8997801F822C8818"
      unitRef="usd">1495000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9533-wk-Fact-9C92BDF888590B6AA55E801F82481AA2"
      unitRef="usd">9952000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9553-wk-Fact-28AB86F70D2CD4381B5F801F81FA1B6D"
      unitRef="usd">10607000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9572-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB"
      unitRef="usd">1870000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9591-wk-Fact-22F449DB433F0BD91E88801F8227AC5A"
      unitRef="usd">2028000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9649-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9669-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9688-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
      unitRef="usd">125000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9708-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9727-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanServiceCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9746-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanServiceCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9771-wk-Fact-823CFC536B2415CC760F801F821963E0"
      unitRef="usd">629000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9790-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
      unitRef="usd">598000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9809-wk-Fact-1645F7BA211F13D895DB801F821CDBB9"
      unitRef="usd">47000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9829-wk-Fact-B14453A638517C4D7C51801F82449662"
      unitRef="usd">55000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9848-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2"
      unitRef="usd">215000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9868-wk-Fact-56AC0425594EB6B614D8801F82235863"
      unitRef="usd">212000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9887-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C"
      unitRef="usd">75000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanInterestCost
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9906-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanInterestCost>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9931-wk-Fact-3550225B14CDA4F396FD801F81FC93AD"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9950-wk-Fact-1BCCBE0EAF7ECB6D503C801F821CEE76"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9969-wk-Fact-19B551E7615E5B2D61BB801F81EC6B71"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e9989-wk-Fact-A339E48382383D402CC3801F81FAD97A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10008-wk-Fact-8FB2D62A8EBEF9B34218801F8228C56A"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10028-wk-Fact-1CFEC5FF204858E76294801F8228D349"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10047-wk-Fact-F507F3DBBA00388E5CD9801F820B8A6C"
      unitRef="usd">84000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10066-wk-Fact-DFBA5F50241AD6477837801F820D9779"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanBenefitObligationContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10092-wk-Fact-225081F555A03A27E808801F8232C488"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10111-wk-Fact-E31F7F0602F984C69606801F822B89AD"
      unitRef="usd">-22000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10131-wk-Fact-DEDF8AC547B275C98BB2801F81FE5559"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10151-wk-Fact-6734B0CCF706755370DC801F82248099"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10170-wk-Fact-88DB7F79687BCA54F881801F82414571"
      unitRef="usd">18000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10190-wk-Fact-378CC18954DCD2BE6AD2801F8208C07A"
      unitRef="usd">29000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10209-wk-Fact-E5C179E74FC2148A9039801F81F8B818"
      unitRef="usd">-56000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanPlanAmendments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10229-wk-Fact-C92813FC360B292546D9801F821F48E6"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAmendments>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10254-wk-Fact-587F4F874523BF22E7AF801F823BD65E"
      unitRef="usd">-2001000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10273-wk-Fact-3332CC39DDDB775F98DD801F82319453"
      unitRef="usd">1219000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10293-wk-Fact-45B18C9F6F2875D22AB6801F81F7973B"
      unitRef="usd">-152000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10313-wk-Fact-EBE912A2B8B787111E58801F81ECF50B"
      unitRef="usd">152000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10333-wk-Fact-B8EF963B8EAAA02A9097801F82143358"
      unitRef="usd">-1224000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10353-wk-Fact-EF1120B81FCABC3479FE801F81EE2ED4"
      unitRef="usd">169000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10373-wk-Fact-E89A524C2D8E94D7B82F801F820D0235"
      unitRef="usd">87000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanActuarialGainLoss
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10393-wk-Fact-1855B6419A7F5D4AE722801F81FE1A9A"
      unitRef="usd">122000000</us-gaap:DefinedBenefitPlanActuarialGainLoss>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10419-wk-Fact-6D9D6801D8F49E72AC9F801F8247BF37"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10438-wk-Fact-0239ED48FEE8F23ED2EC801F81FB9BC5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10457-wk-Fact-85CA80585D2874D45B54801F82219616"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10477-wk-Fact-34CCCF8B6B98C5A6827D801F8243C77E"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10496-wk-Fact-D1066964CCBB2F06D211801F8229BFCC"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10517-wk-Fact-791EAF9C41A719B8AE07801F821A4C3E"
      unitRef="usd">457000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10537-wk-Fact-5265E1D654B7823D4E63801F82280344"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10557-wk-Fact-CB5E2C6E53AA4E02F333801F82392BCB"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanForeignCurrencyExchangeRateChangesBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10583-wk-Fact-51C0100384A147990743801F81EB9934"
      unitRef="usd">4000000</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10603-wk-Fact-9C416A8427655856201B801F81FBE3C5"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10622-wk-Fact-707FF8E8FE2A2798AEDA801F8220322D"
      unitRef="usd">1000000</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10643-wk-Fact-15BADC559EFA5E2148B7801F8234494C"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10662-wk-Fact-101EC636E37E5D65C52C801F81EB2366"
      unitRef="usd">55000000</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10683-wk-Fact-5B79851311CC6FFAB3EF801F820E9581"
      unitRef="usd">2000000</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10703-wk-Fact-893F257BDBDAF32100A5801F81FC6EC8"
      unitRef="usd">36000000</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10723-wk-Fact-FB2A542C8BE81796CCFD801F824281CD"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresBenefitObligation>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10748-wk-Fact-EEAFCF15A92A73FE4BC1801F820BA9BC"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10767-wk-Fact-F3A9A889D5F803CEA915801F81FC88F0"
      unitRef="usd">-11000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10786-wk-Fact-23DB84919E70B73B1647801F8249C9E2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10806-wk-Fact-BD46B1A4E13BB0CD2D7F801F81EA9171"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10825-wk-Fact-A4C2A6D0663F5845176B801F81F80E32"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10846-wk-Fact-5F786390C2E8481D63AB801F820FDD80"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10866-wk-Fact-2FA5505B9C078F2C7287801F821DF04C"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanCurtailments
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10885-wk-Fact-578D671C8F705BCD1B24801F82058BDF"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanCurtailments>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10911-wk-Fact-DEAEDE0078E36DBB07CB801F82112993"
      unitRef="usd">692000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10931-wk-Fact-D327E219A54033D54A8F801F82396897"
      unitRef="usd">391000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10951-wk-Fact-2B8A551F74454F44A11F801F8230140D"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10972-wk-Fact-C356BA78C171B344C1E7801F823FA26C"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e10992-wk-Fact-420050CC9AF1183EA21D801F82478087"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11013-wk-Fact-D02BC6C959B70F0C42F4801F81EA9247"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11033-wk-Fact-B37B6F505700BFB86614801F8217AF5C"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSettlementsBenefitObligation
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11052-wk-Fact-18D66D9FD2EF5E4071F3801F820F2C81"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsBenefitObligation>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11077-wk-Fact-FAED8312CB6DE3371555801F822F66EF"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11096-wk-Fact-B06D18314819524CDB53801F8224ECF4"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11115-wk-Fact-FFA2D2947052B95B9E66801F822852A2"
      unitRef="usd">17000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11135-wk-Fact-3FAA9033222E4A62E69F801F822B103B"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11154-wk-Fact-3436CB2133E67A0CED9C801F8220C53D"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11174-wk-Fact-8EA2843D9C6DF208E5AC801F820B737B"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11193-wk-Fact-61950C831388E08B6286801F81EDD259"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanSpecialTerminationBenefits
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11212-wk-Fact-A2924772A01FADBA0AFC801F8209EC9B"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanSpecialTerminationBenefits>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11237-wk-Fact-AB51FFA5E25BF090B8E4801F821615F8"
      unitRef="usd">544000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11257-wk-Fact-32E1EBDBF1BACBF6E103801F8241B168"
      unitRef="usd">546000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11277-wk-Fact-E3F7F347B26B1F422343801F81F13EF8"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11298-wk-Fact-0F4B80AB484F70EADA00801F822053F3"
      unitRef="usd">58000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11318-wk-Fact-BA7C888E080F79CDEA22801F8225858E"
      unitRef="usd">360000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11339-wk-Fact-CD4577912E966CBCE234801F821708AE"
      unitRef="usd">373000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11359-wk-Fact-3A17F7C7D9A8C3BFB338801F82230016"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11379-wk-Fact-236A48C44D219DB1205A801F8231D63E"
      unitRef="usd">249000000</us-gaap:DefinedBenefitPlanBenefitObligationBenefitsPaid>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11407-wk-Fact-390B954ED7FDBB67E7CD801F8201DB61"
      unitRef="usd">16535000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11426-wk-Fact-B46984BEC265F2CB3433801F822E334D"
      unitRef="usd">15141000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11445-wk-Fact-00777F633E4D23DFB02C801F81EE6F40"
      unitRef="usd">1351000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11465-wk-Fact-73596D19D7B15B05E6A9801F820D7E85"
      unitRef="usd">1280000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11484-wk-Fact-DCDE7C80F284CDA4BB90801F823D07A2"
      unitRef="usd">11059000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11504-wk-Fact-9C92BDF888590B6AA55E801F82481AA2"
      unitRef="usd">9952000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11523-wk-Fact-3172D79ECC315BEBFB19801F822ED289"
      unitRef="usd">1667000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11542-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB"
      unitRef="usd">1870000000</us-gaap:DefinedBenefitPlanBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11904-wk-Fact-F970BB89E53DFCDB7ECF801F8244F550"
      unitRef="usd">13051000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11923-wk-Fact-19ED68D32560E34AAE3A801F8209EABD"
      unitRef="usd">14284000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11942-wk-Fact-9CF470D6794F6C0CCEC7801F81F8A544"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11962-wk-Fact-10FF72843765F8BB3027801F82271E5C"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e11981-wk-Fact-4117EF0EF57CC9D621F0801F81EFE30E"
      unitRef="usd">8215000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2017Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12001-wk-Fact-7016255C04AF4B9A9ACA801F822C27CF"
      unitRef="usd">8863000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12020-wk-Fact-3A8C22ABE707DD992DEC801F81EB2BCC"
      unitRef="usd">469000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2017Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12039-wk-Fact-311D92B89F4214E789BE801F822A0850"
      unitRef="usd">494000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12064-wk-Fact-E5A9EC3B299F57294718801F81ED9CB6"
      unitRef="usd">2760000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12083-wk-Fact-7E988DB3F16BD0DA91DD801F82219CEC"
      unitRef="usd">-796000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12142-wk-Fact-FAEB11DD8DF99633BE69801F821EA34A"
      unitRef="usd">873000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12162-wk-Fact-E7F44177B21B50981524801F81FBDA91"
      unitRef="usd">-77000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12182-wk-Fact-CFDB540F996DE5B99D46801F81F03D49"
      unitRef="usd">50000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12201-wk-Fact-B9AC8307A779D6F09949801F821995B5"
      unitRef="usd">-22000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssets>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12227-wk-Fact-00164FB29E93F021AA7C801F81EF5943"
      unitRef="usd">11000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12246-wk-Fact-06198EDFD387D35B92AE801F82464881"
      unitRef="usd">500000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12265-wk-Fact-2F4EF0691232172CBE50801F823725C4"
      unitRef="usd">144000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12285-wk-Fact-895FBC55A2C014AE60DB801F822EA4D6"
      unitRef="usd">129000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12304-wk-Fact-5F9A7586AB2C91889EEF801F81FA1407"
      unitRef="usd">230000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12324-wk-Fact-1AEDB7ED4A8DCF189D67801F823C442D"
      unitRef="usd">209000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12343-wk-Fact-4CF49C83803A70FBB008801F820EACE2"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12362-wk-Fact-C14FE55B8A46DB34463B801F82457CA0"
      unitRef="usd">145000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12387-wk-Fact-0CF957CDB8DB1B8E8BF5801F82103803"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12406-wk-Fact-9DCABAFB274FAF64432B801F82199D36"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12425-wk-Fact-66AB59873DDB47AB89F7801F820EAC51"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12445-wk-Fact-F80314ACBE555E3E9E3B801F82492D5E"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12464-wk-Fact-8F98F1D658D9E120463D801F81EB97FB"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12484-wk-Fact-4E1FE6F7B598C8807AD3801F81EC5BDA"
      unitRef="usd">7000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12503-wk-Fact-90C6D26954260814C1B0801F821DB384"
      unitRef="usd">84000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12522-wk-Fact-677D1FC6A611834BD89C801F821B9488"
      unitRef="usd">102000000</us-gaap:DefinedBenefitPlanPlanAssetsContributionsByPlanParticipant>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12547-wk-Fact-C7D9E0717066F0D4B259801F81FC0FA0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12566-wk-Fact-2405E4B9D661A0DF12B8801F8223FB9F"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12585-wk-Fact-CC7370FF7EA5E47BA51C801F82497BFE"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12605-wk-Fact-6CC25BEC0E1A84069BE2801F8232DF80"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12624-wk-Fact-A032E560DF4882B29B08801F821F0585"
      unitRef="usd">42000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12644-wk-Fact-C83D9C05172B44F8773E801F822B264A"
      unitRef="usd">-380000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12664-wk-Fact-168A9585B7249F9C82D6801F8230053A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12683-wk-Fact-001F470AF34EA1EB4561801F8243CC17"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12708-wk-Fact-BE53F1DBA31B16AE1779801F82410B8F"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12785-wk-Fact-ADB4BDBE18F10B2C4ADA801F81F79BF7"
      unitRef="usd">-16000000</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12806-wk-Fact-22EAF7C9B4B7E34A06D1801F8249E751"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12825-wk-Fact-216A99E53878AF5DAB01801F82482689"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets>
    <pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12844-wk-Fact-B441AEA30237DE1B4AA7801F82269A65"
      unitRef="usd">0</pfe:DefinedBenefitPlanBusinessCombinationsAcquisitionsandDivestituresPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12869-wk-Fact-89722D85FCA1B5DF7C7C801F81EF8ED7"
      unitRef="usd">692000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12889-wk-Fact-A64428C832FF96F45A86801F822511CE"
      unitRef="usd">391000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12909-wk-Fact-B5CDD0A07D672D455A6A801F822590FF"
      unitRef="usd">70000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12930-wk-Fact-E5FCA4E5F636714478C5801F820C7680"
      unitRef="usd">72000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12950-wk-Fact-7954C90D77268CFDD706801F81FEE484"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12971-wk-Fact-96A54F4085DA003D93DD801F821A8215"
      unitRef="usd">34000000</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e12991-wk-Fact-4ECAFCF00E51EE589F24801F81FD193A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanSettlementsPlanAssets
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13010-wk-Fact-9DD8F0FD0B6AE7A88D34801F81FB074D"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanSettlementsPlanAssets>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13035-wk-Fact-9AC099DABD33C274FD2E801F821F3862"
      unitRef="usd">544000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13055-wk-Fact-E7EFDBF2583292D4FFAB801F8229244B"
      unitRef="usd">546000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13075-wk-Fact-264D65694E907003263E801F82200311"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13096-wk-Fact-52A30F4A2E33A0CF3492801F8211EF86"
      unitRef="usd">58000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13116-wk-Fact-14C3A3D1B63D331729AB801F81EBA652"
      unitRef="usd">360000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13137-wk-Fact-79CBA17C3000A01BA7EF801F82007698"
      unitRef="usd">373000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="FD2019Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13157-wk-Fact-CB7DB76C64C38F31AE27801F823D303F"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid
      contextRef="FD2018Q4YTD_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13177-wk-Fact-0067A36D794EDE2178A3801F8218C6D2"
      unitRef="usd">249000000</us-gaap:DefinedBenefitPlanPlanAssetsBenefitsPaid>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13203-wk-Fact-17659B69964921976360801F821EE135"
      unitRef="usd">14586000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13222-wk-Fact-F970BB89E53DFCDB7ECF801F8244F550"
      unitRef="usd">13051000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13241-wk-Fact-E9371F5D7FA12FFF576E801F820909B8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13261-wk-Fact-9CF470D6794F6C0CCEC7801F81F8A544"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13280-wk-Fact-AB8F832A31C42E104067801F82165415"
      unitRef="usd">8956000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13300-wk-Fact-4117EF0EF57CC9D621F0801F81EFE30E"
      unitRef="usd">8215000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13319-wk-Fact-839D55BF4D8629637604801F822D8BC9"
      unitRef="usd">519000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13338-wk-Fact-3A8C22ABE707DD992DEC801F81EB2BCC"
      unitRef="usd">469000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13368-wk-Fact-B1BB4B65E728C0E688B6801F81EE8DEE"
      unitRef="usd">-1949000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13388-wk-Fact-310C89B3053C8C2C8E70801F82279E3C"
      unitRef="usd">-2089000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13409-wk-Fact-56675EE303722890B7D7801F823F0231"
      unitRef="usd">-1351000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13429-wk-Fact-E427FCA54636A4F6EDAF801F823E20D3"
      unitRef="usd">-1280000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13449-wk-Fact-DE9C7F290C3856B78A7C801F8218A88B"
      unitRef="usd">-2103000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13470-wk-Fact-B622EA29E741BF176CC3801F81EDCC43"
      unitRef="usd">-1738000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13490-wk-Fact-9EE216D56140FCED146C801F81EF7937"
      unitRef="usd">-1148000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanFundedStatusOfPlan
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e13510-wk-Fact-486A293311150B87248C801F824470AE"
      unitRef="usd">-1401000000</us-gaap:DefinedBenefitPlanFundedStatusOfPlan>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-8"
      id="d34661879e13578-wk-Fact-0BB54A71AC3D332E19E3801F804F31BC"
      unitRef="usd">10600000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-8"
      id="d34661879e13586-wk-Fact-C8077BC3D5B73FFE8069801F807CF447"
      unitRef="usd">9500000000</us-gaap:DefinedBenefitPlanAccumulatedBenefitObligation>
    <us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C6E91E8FCB72BB10FAEE801F8344DBF8-0-wk-Fact-D3BC0E7A467A5994F5E4801F8037F47C">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information as to how the funded status is recognized in our consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&#160;Supplemental&lt;br/&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(167&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(24&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,088&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,162&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,526&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,111&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,371&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Funded status&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(1,401&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other noncurrent assets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Accrued compensation and related items&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;As of December 31, 2019, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Pension benefit obligations, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Postretirement benefit obligations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;as appropriate. In 2018, included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Pension benefit obligations, net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Postretirement benefit obligations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, as well as in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Liabilities held for sale&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;, as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;appropriate.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14504-wk-Fact-1FABDAEE54CD68890F1E801F7F0BED57"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14523-wk-Fact-759056D49537AAD9E899801F7F0EAFC2"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14543-wk-Fact-B51A8E65B32A1B7A347F801F7F099B83"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14562-wk-Fact-5BFD4CE5B0EB344F1A4A801F7F0AA68E"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14581-wk-Fact-248A8F8CD6CA4B37A1DD801F7F0C957E"
      unitRef="usd">453000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14601-wk-Fact-88C4C82D6AD7A0143C97801F7F066B14"
      unitRef="usd">401000000</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14620-wk-Fact-3C628A0CB0E19BD342B2801F7F090262"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14639-wk-Fact-1BDD07D787E81176926F801F7F11CAEA"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAssetsForPlanBenefitsNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14661-wk-Fact-42DC91E16F73927C464F801F7F0DDD4E"
      unitRef="usd">0</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14680-wk-Fact-6D8465E75F36770F95BA801F7F0AFDCF"
      unitRef="usd">1000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14700-wk-Fact-FC73D9D20F903DB9A545801F7F1031E7"
      unitRef="usd">189000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14721-wk-Fact-9D6C46A96E8CE95D147B801F7F0D5028"
      unitRef="usd">167000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14741-wk-Fact-63A8380FD8882B8BF33C801F7F0B001F"
      unitRef="usd">30000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14762-wk-Fact-A2A4CC4306DEA373350A801F7F0B3827"
      unitRef="usd">28000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14782-wk-Fact-1F63287DE71910139202801F7F087DC5"
      unitRef="usd">24000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14802-wk-Fact-A816C66465B359E5274A801F7F026BDF"
      unitRef="usd">29000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansCurrentLiabilities>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14830-wk-Fact-7D0DED212B5AD84E6737801F7F10668E"
      unitRef="usd">1949000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14850-wk-Fact-2062BC7C0DF48822A1BA801F7F02D514"
      unitRef="usd">2088000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14870-wk-Fact-346579D6E7C0E2843401801F7F121ACE"
      unitRef="usd">1162000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14891-wk-Fact-324241AD63CEF2D77B12801F7F01BBA9"
      unitRef="usd">1113000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14911-wk-Fact-C5F159D4AD69FB122084801F7F082E6A"
      unitRef="usd">2526000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14932-wk-Fact-E0B910DD31466DB4F6A3801F7F105131"
      unitRef="usd">2111000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14952-wk-Fact-F6F791A5DBF42B041441801F7F0A62EE"
      unitRef="usd">1124000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e14972-wk-Fact-BCFF3D61A9114065510B801F7F0C89BE"
      unitRef="usd">1371000000</us-gaap:PensionAndOtherPostretirementDefinedBenefitPlansLiabilitiesNoncurrent>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e15003-wk-Fact-8223FA410497BC998CCE801F7F1282DD"
      unitRef="usd">-1949000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e15023-wk-Fact-34A9429009D83D55259D801F7F10FE12"
      unitRef="usd">-2089000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e15044-wk-Fact-45798B521425290247CE801F7F09A82E"
      unitRef="usd">-1351000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e15064-wk-Fact-D330AA4C3284CC10FAE3801F7F138479"
      unitRef="usd">-1280000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e15084-wk-Fact-45CDA847129743A56995801F7F0713E6"
      unitRef="usd">-2103000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e15105-wk-Fact-E4467A3E3845B64C6B37801F7F04FDBE"
      unitRef="usd">-1738000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e15125-wk-Fact-B34B7ED0357C3D7009E4801F7F0DE644"
      unitRef="usd">-1148000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e15145-wk-Fact-D463454916E58C050165801F7F098A0E"
      unitRef="usd">-1401000000</us-gaap:DefinedBenefitPlanAmountsRecognizedInBalanceSheet>
    <us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-2CF961F86D484EEB0DC5801F83467D02-0-wk-Fact-4FCD1F496712736AB0C3801F8021F4B6">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="33"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:25%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the pre-tax components of cumulative amounts recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S.&#160;Supplemental&lt;br/&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement&lt;br/&gt;Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actuarial losses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4,812&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5,061&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,921&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(76&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(202&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Prior service (costs)/credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(21&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;830&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;994&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(4,814&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(5,060&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(485&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(370&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(2,942&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(2,372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;754&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;792&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our PBO, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Accumulated other comprehensive loss&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the average life expectancy of plan participants for frozen plans, primarily using the corridor approach.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16176-wk-Fact-AF3CA0CEC8AD61474DDB801F82306D75"
      unitRef="usd">-4812000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16196-wk-Fact-3575E2B197DFFB710849801F822BF3AD"
      unitRef="usd">-5061000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16217-wk-Fact-0A0820F3891084F2D3BC801F822ACC1A"
      unitRef="usd">-484000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16237-wk-Fact-31E13FD9B07B11996B5E801F8233F654"
      unitRef="usd">-370000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16257-wk-Fact-C971B93D19C9DBDCC70B801F827FFB9E"
      unitRef="usd">-2921000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16278-wk-Fact-99AD0A449205CDDA0508801F827E53C0"
      unitRef="usd">-2372000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16298-wk-Fact-20C1F8EC97D87AA8FE1C801F822F40EA"
      unitRef="usd">-76000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16318-wk-Fact-0DEFE5C159BAEC795B00801F82386F80"
      unitRef="usd">-202000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16339-wk-Fact-F30596A8A3FB54FFA87F801F826FA947"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16359-wk-Fact-D52C68581C63DD1029F1801F82712F9C"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16378-wk-Fact-267B9D4315F3CD2AC3C3801F822D7560"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16398-wk-Fact-5E9D557ED38FF39C1E62801F8268CE91"
      unitRef="usd">-1000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16417-wk-Fact-EAC2389D8A0B2017163F801F822DF567"
      unitRef="usd">21000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16438-wk-Fact-144F8F48827BD80FA36B801F8275991E"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16457-wk-Fact-4712309073C4B9708668801F823192E9"
      unitRef="usd">-830000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16476-wk-Fact-7912AF6308BF77884C6A801F8262DF0A"
      unitRef="usd">-994000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16506-wk-Fact-DAAA3AF9D54C2B5C1782801F8272DE9E"
      unitRef="usd">4814000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16526-wk-Fact-6A5C67E264C343591301801F826473DD"
      unitRef="usd">5060000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16547-wk-Fact-F46779058B1DFD0DF4B7801F82397B67"
      unitRef="usd">485000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16567-wk-Fact-6EC7FC598AC8D15B3ACB801F8233BAFF"
      unitRef="usd">370000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16587-wk-Fact-8EA2B9AA06147DC86AAD801F827E82CE"
      unitRef="usd">2942000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16608-wk-Fact-4AB6619926524113671B801F827DAAED"
      unitRef="usd">2372000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16628-wk-Fact-5C68B2AB9351FC4AA68B801F823052FD"
      unitRef="usd">-754000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e16647-wk-Fact-67732A5B9D27859B3231801F822F6C7F"
      unitRef="usd">-792000000</us-gaap:DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax>
    <us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-0A841C966B9019B38DC7801F8344640F-0-wk-Fact-4C9BB48140B666042170801F8027F40C">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information related to the funded status of selected benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Supplemental (Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension plans with an ABO in excess of plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ABO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension plans with a PBO in excess of plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,947&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PBO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D33965E5C3EB09A0ABE8801F8346AE30-0-wk-Fact-BD9FB87B81F01CB58FE9801F803CA726">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="25"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides information related to the funded status of selected benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Supplemental (Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension plans with an ABO in excess of plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,843&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;ABO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension plans with a PBO in excess of plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value of plan assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,947&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,432&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PBO&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,535&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15,141&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,351&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,280&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,571&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17515-wk-Fact-3FCA20C4F2B691E985DA801F7EEC213D"
      unitRef="usd">14586000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17534-wk-Fact-A2A83C6B6FC78D2018CE801F7EF3B0A0"
      unitRef="usd">13051000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17592-wk-Fact-ED1A82E0BD316C6A233B801F7EF4EB6E"
      unitRef="usd">5843000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17612-wk-Fact-0EEB63BC554165DECA44801F7EE70289"
      unitRef="usd">4514000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17632-wk-Fact-EABF1AF3646DE7888489801F7EEBC7DD"
      unitRef="usd">16535000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17651-wk-Fact-2E5E18582EAC2644A3EB801F7EEE1F4A"
      unitRef="usd">15141000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17670-wk-Fact-05C77FED557C785B920F801F7EEB544B"
      unitRef="usd">1351000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17690-wk-Fact-40F08CA7A1EB5A21E509801F7EED05BA"
      unitRef="usd">1280000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17709-wk-Fact-3917675B93724860214B801F7EF24F57"
      unitRef="usd">7960000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17729-wk-Fact-CDE677BC1925643ACFC0801F7EEA30A9"
      unitRef="usd">6286000000</us-gaap:DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17882-wk-Fact-929612D77F162F4D628C801F7EEBEE0F"
      unitRef="usd">14586000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17901-wk-Fact-2648CEC07EC5A4DF1ED5801F7EEA138B"
      unitRef="usd">13051000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17959-wk-Fact-0D60EBCAACAFC3567EF4801F7EE8F50C"
      unitRef="usd">5947000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e17979-wk-Fact-3B8EE448C569BD634FBF801F7EEC4C1E"
      unitRef="usd">5432000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e18004-wk-Fact-31EA2DC95E21A6C03AF3801F7EEA0948"
      unitRef="usd">16535000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e18023-wk-Fact-9697CE7A634D261B05EC801F7EE78E0F"
      unitRef="usd">15141000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e18042-wk-Fact-8357A30CF4B85743C57D801F7EEA3193"
      unitRef="usd">1351000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e18062-wk-Fact-91AAB974411866DE09AD801F7EC4E40D"
      unitRef="usd">1280000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e18081-wk-Fact-43A73C31C22675F5778B801F7EEB83CF"
      unitRef="usd">8503000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e18101-wk-Fact-286AC20570D3AE7BACA2801F7EEED97C"
      unitRef="usd">7571000000</us-gaap:DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19061-wk-Fact-7F93F5882C266AF7AC03801F7EDE88E2"
      unitRef="usd">363000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19080-wk-Fact-FFA28E99A41E4CCC026F801F803FFF5D"
      unitRef="usd">80000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19100-wk-Fact-27B7F1F490681634429E801F80F1F370"
      unitRef="usd">284000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19119-wk-Fact-86DEF6460514D6862E92801F80F116B8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19158-wk-Fact-275CC2A0A7045D3DF218801F80FED32D"
      unitRef="usd">443000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19177-wk-Fact-FF00362B6AD5984309B1801F80812477"
      unitRef="usd">53000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19196-wk-Fact-2C64274CCAA479E1D7CD801F7E6C51E8"
      unitRef="usd">390000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19216-wk-Fact-8E57072868D5458BD30A801F7EA6C7E3"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19462-wk-Fact-BA8E84FCF063363DC8CB801F7EB43BDE"
      unitRef="usd">3464000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19481-wk-Fact-EC53E968779C6028ED9C801F7EC737F6"
      unitRef="usd">3406000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19500-wk-Fact-885642E3FF5078D7E180801F8136338F"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19520-wk-Fact-B8D531637E8DF54F3F7E801F80AB0923"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19559-wk-Fact-9CDB5B0698B41567BC37801F7E7B816B"
      unitRef="usd">3156000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19578-wk-Fact-65B741C45407AAE78B32801F815BCE12"
      unitRef="usd">3119000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19597-wk-Fact-A730E8A1EA686A58B9A9801F812B26B3"
      unitRef="usd">37000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19617-wk-Fact-E73373912ABEFE585146801F81629B0E"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19661-wk-Fact-F658713FC86B180E500C801F7EC720B0"
      unitRef="usd">1179000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19680-wk-Fact-F1A609A7255A0AC15A90801F8171F6C4"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19699-wk-Fact-5A20A9FE6AC6B79177A4801F8146DDEB"
      unitRef="usd">819000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19719-wk-Fact-4ED0DD3E047FEF605271801F7E880A91"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19738-wk-Fact-516E83BACCC191ED5F55801F7E89AB76"
      unitRef="usd">360000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19758-wk-Fact-E5CDD80B41C6B8D81144801F80FD49C0"
      unitRef="usd">933000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19777-wk-Fact-C8943A121EEDA141FD9B801F7DF3C7FA"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19796-wk-Fact-1A8B2C6C459DCC13D002801F7FD5858E"
      unitRef="usd">634000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19816-wk-Fact-ADFD09EFBAAE17E76B8C801F812CED5A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e19835-wk-Fact-B782F5C9086BF99E0D5C801F80CEC6DC"
      unitRef="usd">299000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20067-wk-Fact-739A3CBCA31942929991801F80709576"
      unitRef="usd">5292000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20086-wk-Fact-0F1DB5BD6CE9D70B16BE801F812DE5BC"
      unitRef="usd">10000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20105-wk-Fact-A320D830DB302CFA5F67801F7E9BA879"
      unitRef="usd">5281000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20125-wk-Fact-67EBD4339740E27DDD1E801F7FFC6246"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20164-wk-Fact-90597CDC08F5FDEBD38A801F7E8F8D74"
      unitRef="usd">4654000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20183-wk-Fact-CB978D333D218C3AA504801F81620995"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20202-wk-Fact-A2751CB79E5C657710FC801F7E6BAF40"
      unitRef="usd">4650000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20222-wk-Fact-050ACDA8F1A6426D3F26801F7FFAD77E"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20266-wk-Fact-4380540F36E2ACCC4664801F8126079D"
      unitRef="usd">1799000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20285-wk-Fact-9667992F4720EEBE8507801F7E9223CD"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20304-wk-Fact-8ADF784CF3544B521652801F7DE5428D"
      unitRef="usd">1799000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20324-wk-Fact-6C6A4F5106ED00592CB9801F80B9D6FC"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20363-wk-Fact-2F3F139C5086316CC068801F7EBA7D64"
      unitRef="usd">1391000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20382-wk-Fact-99C3C972AE8486FA89F4801F7E139ECD"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20401-wk-Fact-278022090600AF2B386D801F811D7324"
      unitRef="usd">1391000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20421-wk-Fact-00B706497805EC20E4D4801F80E92761"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20466-wk-Fact-B11EE53E100C9A594AFF801F7E6AAEE9"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20504-wk-Fact-93B234B3231C3F13BFA0801F813200A4"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20524-wk-Fact-37C2E96F0C06B8BE58DC801F81379E3A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20543-wk-Fact-162134FF808D683214CB801F80F133F9"
      unitRef="usd">0</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20563-wk-Fact-31948D8451621942863C801F7DE7EB90"
      unitRef="usd">96000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20582-wk-Fact-F412DE60776769E48B4D801F8102E063"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20601-wk-Fact-EDE6AA3E50AC798E1DBE801F7DF2E87B"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20621-wk-Fact-131B4259055DC4154011801F7E6A5E45"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20640-wk-Fact-4B8271E7A0E5A3CF5E04801F7EC8BD2A"
      unitRef="usd">96000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20874-wk-Fact-D487984B48B22F1A5D80801F7E671411"
      unitRef="usd">1212000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20893-wk-Fact-01207FB539212ED3CB3B801F810048DB"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20932-wk-Fact-F7341069EEF19CA78430801F7ECE7A09"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20951-wk-Fact-A543C6B15A6318DF95B8801F7E694554"
      unitRef="usd">1212000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20971-wk-Fact-732BFC75898DC67D4551801F7E2006BB"
      unitRef="usd">1165000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e20990-wk-Fact-32F10B48A55F1AE6E300801F813AC7A0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21009-wk-Fact-6F6B7321CCFF4B9C9028801F7EBC6553"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21029-wk-Fact-A1CED4074FA1FDF7A5FC801F8022EF72"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21048-wk-Fact-1A3B6926FC4FE6AFF9C8801F807EB040"
      unitRef="usd">1165000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21073-wk-Fact-C3645AC626FE234DB1B2801F7E1F35E3"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21092-wk-Fact-9D5C193DFCEF155D2BA5801F8158E97D"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21111-wk-Fact-13CB94F03E493E18A76F801F8065B591"
      unitRef="usd">196000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21131-wk-Fact-1784E446F9B0340EF1E7801F80F5F65A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21170-wk-Fact-F6026AF8147DEDB6DEB0801F7EAD9085"
      unitRef="usd">192000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21189-wk-Fact-C987C1B42EE95EB272F6801F7DFFD049"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21208-wk-Fact-59B1E65891137B9A016D801F7ED92BBC"
      unitRef="usd">192000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21228-wk-Fact-341E870038AF69B1EEA5801F813FD1D5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21274-wk-Fact-A66838ACCE990B7D1974801F80F24A8B"
      unitRef="usd">1075000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21293-wk-Fact-12704F96F376D4121D69801F80E15138"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21312-wk-Fact-5051258CEF279EAE4904801F8082EB61"
      unitRef="usd">9000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21332-wk-Fact-4924E685A3ACAA7EBD6E801F7FD67A92"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21351-wk-Fact-A621438BD8C8D4F1F9D1801F7E16B826"
      unitRef="usd">1066000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21371-wk-Fact-7901A59E0B6D8AB6EE3A801F81370C3C"
      unitRef="usd">1021000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21390-wk-Fact-57959C448E7CB9BAE6F1801F81494C11"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21429-wk-Fact-BDDDC33CB2AC40243C72801F7E12971A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_OtherCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21448-wk-Fact-72790138A19EAC31CA09801F807E33DE"
      unitRef="usd">1021000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21478-wk-Fact-17659B69964921976360801F821EE135"
      unitRef="usd">14586000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21497-wk-Fact-71ACBA717F716B8607A4801F80F2069A"
      unitRef="usd">3496000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21517-wk-Fact-F6CAFC8B9758DAA23D9B801F80F1603E"
      unitRef="usd">8451000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21536-wk-Fact-D2A4F992E497F4962F79801F7ECCF7C9"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21555-wk-Fact-B0690B2915B8FC4A125C801F80217B36"
      unitRef="usd">2638000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21575-wk-Fact-F970BB89E53DFCDB7ECF801F8244F550"
      unitRef="usd">13051000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21594-wk-Fact-E7F460C957BC5FCAA01E801F7E03BE66"
      unitRef="usd">3173000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21613-wk-Fact-3582128093A73BF0EBD0801F80323008"
      unitRef="usd">7294000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21633-wk-Fact-84CFAE8D822C91DEF42D801F80EA8284"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21652-wk-Fact-8901B45EE693D1A5A42B801F7ECF7B1B"
      unitRef="usd">2581000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21886-wk-Fact-9B74B38BBAC9194CDBD2801F80F44538"
      unitRef="usd">221000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21905-wk-Fact-E34AFABD364472579390801F7DF5BC3B"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21925-wk-Fact-D51127B4DF5263E26631801F80FC4240"
      unitRef="usd">187000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21944-wk-Fact-F02B4A8F59412D2599F9801F7EBEBAF8"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e21983-wk-Fact-9963B1D022EEAF8133FA801F813667C0"
      unitRef="usd">246000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22002-wk-Fact-6B515B4176DA3F1E487E801F7E934F57"
      unitRef="usd">39000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22021-wk-Fact-3C503682A37762C63BE1801F8147265C"
      unitRef="usd">208000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22041-wk-Fact-129BCA5EF7E3C4047DF8801F807EBD37"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22287-wk-Fact-378CB5AF654FAF1FC1BD801F7FB2C60E"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22306-wk-Fact-A43617795041B30B05CB801F7ECAF0A6"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22325-wk-Fact-0DD70E539B87F2FB041C801F8112B0EF"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22345-wk-Fact-BA2C0B3B568CB294D55A801F7E0CA046"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22384-wk-Fact-44824C84735C2387A740801F7DE62678"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22403-wk-Fact-92F2D29881335576C0FD801F7E7CED30"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22422-wk-Fact-7658020187599961F4A5801F80F4D671"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesGlobalMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22442-wk-Fact-1F4D93C2F9904F6D73B7801F7FFAD79C"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22486-wk-Fact-9A5E67F3D86F79B8D1B5801F80EBD774"
      unitRef="usd">1922000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22505-wk-Fact-2A45E23937B1E03B0AA9801F816FD16A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22524-wk-Fact-16D5C33B23D96F298EA6801F7E18070A"
      unitRef="usd">1548000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22544-wk-Fact-A16FEE27FC5491A49909801F81596307"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22563-wk-Fact-B61033E055581DA45EB7801F80C6CBA8"
      unitRef="usd">374000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22583-wk-Fact-2CA9BFB53F2FCB0DF5C1801F7FB17EF9"
      unitRef="usd">1876000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22602-wk-Fact-21757F62AEF00E5BF73F801F7EA5E973"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22621-wk-Fact-21863FBD06730CC6F0CE801F8133FD38"
      unitRef="usd">1413000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22641-wk-Fact-EDF3B6B8EE0203C0AE3F801F80E9D531"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_DefinedBenefitPlanEquitySecuritiesEquityCommingledFundsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22660-wk-Fact-A349362A7F0F24D7725D801F8161CBEA"
      unitRef="usd">463000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22893-wk-Fact-73F6BBEE0F405305ADA4801F8143482A"
      unitRef="usd">796000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22912-wk-Fact-13F5E48EBC5CD653F364801F81489ED5"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22931-wk-Fact-FE7BED24ED2F7DF891B2801F80642BB5"
      unitRef="usd">796000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22951-wk-Fact-761A045667090BCC60CB801F7E75C1C9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22970-wk-Fact-851A65644168F7A09FFC801F80C5042F"
      unitRef="usd">0</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e22990-wk-Fact-BE2695DCCECFD887A9F8801F7E8AFD2B"
      unitRef="usd">727000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23009-wk-Fact-6343757AF4A26430D7A1801F7DD0CC07"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23028-wk-Fact-624D9122625475A0C346801F810535CB"
      unitRef="usd">727000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23048-wk-Fact-386DE871FDE603DE0A0C801F7E75C64F"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23067-wk-Fact-084E62D562F5DB1E17D2801F8025171B"
      unitRef="usd">0</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23094-wk-Fact-B027583F189DF18A6C25801F81488DCF"
      unitRef="usd">1200000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23113-wk-Fact-13C4C66382AC9F3D31ED801F7E1DF337"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23132-wk-Fact-891D6E78C37A848AAD66801F8103A7FC"
      unitRef="usd">1200000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23152-wk-Fact-6259E894CBE6FA9FB71A801F7E0FCAAB"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23171-wk-Fact-21E0043926A006FDE718801F80EA1DF6"
      unitRef="usd">0</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23191-wk-Fact-58CB03993CECC3B620EC801F7EDEE43C"
      unitRef="usd">1305000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23210-wk-Fact-296077A478766CD8DCE5801F8128127D"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23229-wk-Fact-B1F66149E5D30EF98A05801F81603EA8"
      unitRef="usd">1305000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23249-wk-Fact-4324A26D75595331CCFC801F81546900"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_USTreasurySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23268-wk-Fact-3F72EA523C34D3EBBCF1801F80C7CC92"
      unitRef="usd">0</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23293-wk-Fact-AD6D005C570E67CE5449801F7E665057"
      unitRef="usd">2201000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23312-wk-Fact-91858568C939C7AE738C801F80EC0790"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23331-wk-Fact-54BB374F531662E67301801F8151A7BD"
      unitRef="usd">1031000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23351-wk-Fact-99E09AD183E83160CC87801F7E8A836A"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23370-wk-Fact-55065D7329FC0CE09063801F8127D52D"
      unitRef="usd">1171000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23390-wk-Fact-DEEE2C690E5D9A6127B8801F7E651356"
      unitRef="usd">1770000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23409-wk-Fact-43D0EA4505ACE6E465E2801F7FD72974"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23428-wk-Fact-825A924821B029DD3CBD801F7E981ACD"
      unitRef="usd">1007000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23448-wk-Fact-19AE6BF04D8CC5A87EEA801F7E12AE32"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23467-wk-Fact-B6002D168EA0157D8AFF801F80E23E6D"
      unitRef="usd">762000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23701-wk-Fact-CEFD277C9DD70587E852801F80CE0B4F"
      unitRef="usd">66000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23720-wk-Fact-61637C3FAD1A1EBEC396801F7E02E832"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23739-wk-Fact-3B84715E11DB37BB7F37801F7E1EFCF3"
      unitRef="usd">3000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23759-wk-Fact-BFCA8568A70BD9B17120801F7E0B201D"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23778-wk-Fact-F8768CC4E46B6B99211A801F7EE08C5B"
      unitRef="usd">63000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23798-wk-Fact-E8F433CDF6DA732D6EF5801F7E697BF0"
      unitRef="usd">57000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23817-wk-Fact-C81AF605318FDAE7E9A8801F813229BB"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23836-wk-Fact-31101E0D5A9F589C42B9801F7EDE61BF"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23856-wk-Fact-BAB81DA4890D0987B01F801F7EBE147E"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_srt_PartnershipInterestMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23875-wk-Fact-32850438677456DE85D2801F80EF43A5"
      unitRef="usd">53000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23902-wk-Fact-32BE2AC3AB258DAE14BA801F815D5109"
      unitRef="usd">1027000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23921-wk-Fact-AF3B835BA88A5AF10D40801F814757D9"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23940-wk-Fact-CEA719F9B7E460A69C70801F7ECBC889"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23960-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
      unitRef="usd">944000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23979-wk-Fact-9D87527D8A9492D75841801F7EA8D8E9"
      unitRef="usd">1000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e23999-wk-Fact-FE6953A187622C643914801F80E89DAA"
      unitRef="usd">759000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24018-wk-Fact-98EC241C0428BD0AE10C801F7E1180B1"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24037-wk-Fact-2CA6288317D80D709922801F8147D1CB"
      unitRef="usd">74000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24057-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
      unitRef="usd">684000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24076-wk-Fact-3993C9034191C03D601B801F7EDE39F5"
      unitRef="usd">1000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24103-wk-Fact-ABB7C1831B6036A1961D801F8111BCF2"
      unitRef="usd">1524000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32"
      unitRef="usd">82000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
      unitRef="usd">398000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724"
      unitRef="usd">1043000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24200-wk-Fact-7D93FC3424C9D543074F801F7E17454A"
      unitRef="usd">1473000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0"
      unitRef="usd">71000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
      unitRef="usd">382000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB"
      unitRef="usd">1020000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24307-wk-Fact-AB8F832A31C42E104067801F82165415"
      unitRef="usd">8956000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24326-wk-Fact-9560997241A91E7FCCDC801F7E780256"
      unitRef="usd">33000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24346-wk-Fact-DE1F7A8483528CB9F99C801F7DF38979"
      unitRef="usd">4929000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24365-wk-Fact-70AB9AE43B82A35609DD801F7EC60B58"
      unitRef="usd">1342000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24384-wk-Fact-846B26327BEE6C94A307801F8102D6F8"
      unitRef="usd">2652000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24404-wk-Fact-4117EF0EF57CC9D621F0801F81EFE30E"
      unitRef="usd">8215000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24423-wk-Fact-8C4DF439940F0708B5F7801F7E87B8C4"
      unitRef="usd">40000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24442-wk-Fact-EDDE1FED2572278FFC6B801F7EC0F70A"
      unitRef="usd">4809000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24462-wk-Fact-C5DF68B00988C4249D4D801F81707342"
      unitRef="usd">1065000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24481-wk-Fact-EEDDB06313F61B23BAEB801F7EC79AC8"
      unitRef="usd">2300000000</pfe:DefinedBenefitPlanAlternativeInvestmentsFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24717-wk-Fact-1FD036A003F66D196001801F80EDBF09"
      unitRef="usd">519000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24736-wk-Fact-753465D7A627C0C6C864801F7E922133"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24756-wk-Fact-81BF9447839E6277781D801F8110D158"
      unitRef="usd">519000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24814-wk-Fact-F588B19D0C5C6EC9C734801F7FE99D83"
      unitRef="usd">469000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24852-wk-Fact-83666425473B48E80163801F7E7455A0"
      unitRef="usd">469000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e24872-wk-Fact-AB5ECEED024AF101A1AC801F8151B0F7"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4A05B63EB75FFAC8D93D801F83451851-0-wk-Fact-48DDF0F1147138EC668D801F80D056E0">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Insurance contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value, beginning&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;420&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;468&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Actual return on plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Assets held, ending&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;50&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Purchases, sales, and settlements, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;188&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Transfer into/(out&#160;of) Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;247&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Exchange rate changes&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(31&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(20&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair value, ending&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25527-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
      unitRef="usd">684000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2017Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25546-wk-Fact-7A6709A2CDA4ED18F63A801F81E30FBC"
      unitRef="usd">420000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
      unitRef="usd">382000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2017Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25585-wk-Fact-86177F1BC9ED7DAA2C5D801F80C8E0DE"
      unitRef="usd">468000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25688-wk-Fact-21067B1E1FF8F6DA19E5801F81E4C327"
      unitRef="usd">50000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25707-wk-Fact-E68EA365B2557A1A2325801F81DDF5DD"
      unitRef="usd">1000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25726-wk-Fact-68BCA950EAEC2E342DD3801F81DDFC58"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld
      contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25746-wk-Fact-53019A60C7C06A7E0755801F81E4E74E"
      unitRef="usd">15000000</us-gaap:DefinedBenefitPlanActualReturnOnPlanAssetsStillHeld>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25771-wk-Fact-369FB78E5EF992B55F90801F80A1AC3A"
      unitRef="usd">-40000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25791-wk-Fact-AE8428DBA05DAA670DAA801F81E34FED"
      unitRef="usd">188000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25810-wk-Fact-AC64C6698BB91BE2DC0C801F81DF3611"
      unitRef="usd">6000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements
      contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25830-wk-Fact-8519AAABC07BA1DBCBC0801F80C7916E"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanPurchasesSalesAndSettlements>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25856-wk-Fact-14A7B3929125218D5E6A801F81DE053B"
      unitRef="usd">247000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25875-wk-Fact-5E5E7E520234827504EC801F809C2217"
      unitRef="usd">107000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25894-wk-Fact-25F62796CC9F0052B3FB801F81E71502"
      unitRef="usd">0</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels
      contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25914-wk-Fact-092595F5E00F51778420801F809C634B"
      unitRef="usd">-51000000</us-gaap:DefinedBenefitPlanTransfersBetweenMeasurementLevels>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25940-wk-Fact-3E7990FC838DACC74110801F81E5198B"
      unitRef="usd">2000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25959-wk-Fact-B6F7D234AB59E97AB262801F81E4B513"
      unitRef="usd">-31000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2019Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25979-wk-Fact-782627B1FCC4F297EF82801F81D8B54D"
      unitRef="usd">4000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss
      contextRef="FD2018Q4YTD_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e25999-wk-Fact-2AAF53EE6C04B7D08D68801F81E51475"
      unitRef="usd">-20000000</us-gaap:DefinedBenefitPlanPlanAssetsForeignCurrencyTranslationGainLoss>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e26031-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
      unitRef="usd">944000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_pfe_InsuranceContractsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e26050-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
      unitRef="usd">684000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
      unitRef="usd">398000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:DefinedBenefitPlanFairValueOfPlanAssets
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherAggregatedInvestmentsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel3Member_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
      unitRef="usd">382000000</us-gaap:DefinedBenefitPlanFairValueOfPlanAssets>
    <us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EC6611ABA1A23D81DB40801F83462B8F-0-wk-Fact-CFB45404FC49C48E8AC2801F8012202A">&lt;div style="line-height:120%;padding-top:6px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:48%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:8px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Target&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Allocation Percentage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Percentage of Plan Assets&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6pt;"&gt;&lt;span style="font-family:Arial;font-size:6pt;"&gt;(PERCENTAGES)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;0-10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;35-55%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;31.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;31.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fixed income securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;28-53%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;48.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;47.1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;5-20%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;0-10%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;20-40%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;21.5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;22.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fixed income securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;35-60%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;46.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;46.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;10-35%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;29.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;27.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;"&gt;U.S. postretirement plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;0-5%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other investments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;95-100%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;100&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="41"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:3%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:4%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="41" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:10px;text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;The following table provides the components of plan assets:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fair Value&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fair Value&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;As of&lt;br/&gt;December&#160;31, &lt;br/&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Assets Measured at NAV&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;As of&lt;br/&gt;December&#160;31, &lt;br/&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 1&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Level 3&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Assets Measured at NAV&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;text-decoration:underline;"&gt;U.S. qualified pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;363&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;80&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;284&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;443&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;390&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Global equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;3,464&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;3,406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,156&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity commingled funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;819&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;360&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;933&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;634&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed income securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;5,292&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;5,281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;4,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;4,650&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,799&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,391&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed income commingled funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;96&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other investments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Partnership investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,165&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Insurance contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;196&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;192&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other commingled funds&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,075&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,066&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,021&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;14,586&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;3,496&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;8,451&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;2,638&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;13,051&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3,173&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;7,294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;text-decoration:underline;"&gt;International pension plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;187&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;208&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Global equity securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Equity commingled funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,922&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,548&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,876&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,413&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;463&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed income securities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Corporate debt securities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;796&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;727&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency obligations&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fixed income commingled funds&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;2,201&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,031&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,171&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,770&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,007&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;762&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other investments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Partnership investments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;57&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Insurance contracts&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,027&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;944&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;74&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d), (f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;398&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,043&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;71&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;382&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,020&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Total&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;8,956&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;4,929&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;1,342&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;2,652&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;8,215&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;40&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;4,809&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;1,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,300&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;text-decoration:underline;"&gt;U.S. postretirement plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Insurance contracts&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"/&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; Note 1E&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;).&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"/&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Mostly includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Government and agency obligations are inclusive of repurchase agreements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfAllocationOfPlanAssetsTableTextBlock>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26472-wk-Fact-8D92A4A4B9FA08C190A9801F7FF7DBD2"
      unitRef="number">0.025</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26487-wk-Fact-884AF8AD2087D97669F4801F7F8C849D"
      unitRef="number">0.034</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26522-wk-Fact-04945CE0460C4631AF2F801F7FFADACE"
      unitRef="number">0.318</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26537-wk-Fact-0A5D28CF7C46374EE93B801F7FD46365"
      unitRef="number">0.313</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26572-wk-Fact-264B32C84A907155F494801F7FDFA667"
      unitRef="number">0.487</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26587-wk-Fact-76D24705688E66F037EB801F7F8238FE"
      unitRef="number">0.471</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26622-wk-Fact-EFD7F247DECDA09E6F48801F8003C2BF"
      unitRef="number">0.170</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26637-wk-Fact-A94B247D4557B8E5CC4C801F7F93A1C4"
      unitRef="number">0.182</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e26658-wk-Fact-3CFE6BDEE6E11BA8F495801F7FE72B1D"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e26673-wk-Fact-DD6160BDDCB15D9BC4E6801F7FEB72A6"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e26688-wk-Fact-900A0C433DD667E1D073801F8004D440"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26775-wk-Fact-0AE2C3765352113FF0E2801F7F97CDDD"
      unitRef="number">0.025</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26790-wk-Fact-E978BB4866A44C1E8279801F7F6EA381"
      unitRef="number">0.030</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26825-wk-Fact-94B0CB413E58010326C0801F7F9BBCC0"
      unitRef="number">0.215</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanEquitySecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26840-wk-Fact-6B860A8DA8169365CA0B801F81A6E74D"
      unitRef="number">0.229</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26875-wk-Fact-8D9B79534220D7E9F8AC801F7F804C46"
      unitRef="number">0.469</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_FixedIncomeSecuritiesMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26890-wk-Fact-1DD7C037665FEBD0A597801F81932B9B"
      unitRef="number">0.463</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26925-wk-Fact-4290716CA30136DD43CE801F7FF6B17D"
      unitRef="number">0.292</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="3"
      id="d34661879e26940-wk-Fact-B387961F5847F679CF37801F8195C059"
      unitRef="number">0.279</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e26961-wk-Fact-F82A6B43703A30AF1F73801F819A17F2"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e26976-wk-Fact-0B562CE7A48516C625B1801F7F7E94FE"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e26991-wk-Fact-54B4BEA5983E90FD7D6A801F81A66267"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e27077-wk-Fact-49CE10C16240E92F5C9B801F81A499B3"
      unitRef="number">0</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e27091-wk-Fact-E876736E74EEB5080700801F8199E468"
      unitRef="number">0</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e27125-wk-Fact-F3F3CF45DBDFDD834AE5801F7F8225F5"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis_us-gaap_OtherInvestmentsMember_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e27140-wk-Fact-2FE57B290588AA854309801F7F7E6C34"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e27161-wk-Fact-947B3AE3E11A5626F630801F7F770091"
      unitRef="number">1</us-gaap:DefinedBenefitPlanPlanAssetsTargetAllocationPercentage>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e27176-wk-Fact-D86731FFA4669CFEBBCA801F819CC35C"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations
      contextRef="FI2018Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="INF"
      id="d34661879e27191-wk-Fact-389AF65047725344B39F801F7F649798"
      unitRef="number">1</us-gaap:DefinedBenefitPlanWeightedAverageAssetAllocations>
    <us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D5052DD7C523F01A210E801F8345B374-0-wk-Fact-6578174DC11CFDD7D968801F800AEECB">&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:27%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the expected future cash flow information related to our benefit plans:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pension Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;U.S. Qualified&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;U.S. Supplemental&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;(Non-Qualified)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;International&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Postretirement Plans&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected employer contributions:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;172&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected benefit payments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2020&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;355&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2021&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;113&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;358&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2022&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,048&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;364&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,046&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;110&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;366&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,028&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;375&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2025&#x2013;2029&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,759&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;435&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,992&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;642&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For the U.S. qualified plans, we plan to make a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.25 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; voluntary contribution in the second half of 2020.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfExpectedBenefitPaymentsTableTextBlock>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27650-wk-Fact-753DD635276562AAADD0801F7E9ACA47"
      unitRef="usd">1276000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27669-wk-Fact-98BFF5893FA87300516A801F7E8D015A"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27689-wk-Fact-4A576DD84E72BF694DFE801F7E989595"
      unitRef="usd">172000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27708-wk-Fact-3DE297FCB202AC8DCCF7801F7E992601"
      unitRef="usd">147000000</us-gaap:DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27820-wk-Fact-CD02E31A83E0B5811287801F7E930705"
      unitRef="usd">1477000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27839-wk-Fact-323D92DB8BB96C4CD9AE801F7E9AEC6D"
      unitRef="usd">189000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27859-wk-Fact-F88722610C683B4F2CFE801F7E9225B3"
      unitRef="usd">355000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27878-wk-Fact-61D106EA039C7CC0E755801F7E97C96D"
      unitRef="usd">153000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27898-wk-Fact-CDB27CBFF6A5546A05E1801F7E9C36CC"
      unitRef="usd">1089000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27917-wk-Fact-271EE9339F2C95C67649801F7E9E2005"
      unitRef="usd">113000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27936-wk-Fact-52C5DBBEDE4921461805801F7E8DBED8"
      unitRef="usd">358000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27956-wk-Fact-B9F816556BC38F3FB95E801F7E924955"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e27981-wk-Fact-CA35A857462FC04F8038801F7EBCAA68"
      unitRef="usd">1048000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28000-wk-Fact-9D309C7357B31A429F45801F7E9CCEBE"
      unitRef="usd">115000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28019-wk-Fact-34934AB842289C268B01801F7E98CA50"
      unitRef="usd">364000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28039-wk-Fact-A28837DEBEB2FF3AF4C7801F7E933AFF"
      unitRef="usd">137000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28064-wk-Fact-47145AF1D6EF5EEC513D801F7E9D0915"
      unitRef="usd">1046000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28083-wk-Fact-EAF8DAF1C21BB8753D8C801F7E97D7D4"
      unitRef="usd">110000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28102-wk-Fact-DA140C7F73332CB43365801F7E8FC48C"
      unitRef="usd">366000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28122-wk-Fact-677D184533F0A6EB4E58801F7E989189"
      unitRef="usd">136000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28147-wk-Fact-B46B3E21F38D256FBC28801F7E9D1BCD"
      unitRef="usd">1028000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28166-wk-Fact-6946DF7C8ACF745C3C84801F7E92BF93"
      unitRef="usd">103000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28185-wk-Fact-80117314950A2BADE16C801F7E9389FB"
      unitRef="usd">375000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28205-wk-Fact-1312E18D2AAD95398BD4801F7E975474"
      unitRef="usd">134000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28231-wk-Fact-94C48D1753008BE60A60801F7E9AFF38"
      unitRef="usd">4759000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_NonqualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28250-wk-Fact-543C09084053AA43A926801F7EA7CF85"
      unitRef="usd">435000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="FI2019Q4_us-gaap_RetirementPlanSponsorLocationAxis_us-gaap_ForeignPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28269-wk-Fact-24D2085F10B21075071E801F7E99825E"
      unitRef="usd">1992000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter
      contextRef="FI2019Q4_us-gaap_RetirementPlanTypeAxis_us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember"
      decimals="-6"
      id="d34661879e28289-wk-Fact-B28397452B4DF28A8904801F7E9AD334"
      unitRef="usd">642000000</us-gaap:DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter>
    <us-gaap:DefinedBenefitPlanContributionsByEmployer
      contextRef="D2020Q4Jun29-Dec31_srt_StatementScenarioAxis_srt_ScenarioForecastMember_us-gaap_RetirementPlanSponsorLocationAxis_country_US_us-gaap_RetirementPlanTaxStatusAxis_us-gaap_QualifiedPlanMember_us-gaap_RetirementPlanTypeAxis_us-gaap_PensionPlansDefinedBenefitMember"
      decimals="-7"
      id="d34661879e28318-wk-Fact-F1841F95F4C2B39FD6AF1B677F253E82"
      unitRef="usd">1250000000</us-gaap:DefinedBenefitPlanContributionsByEmployer>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34661879e28342-wk-Fact-08461E8B77395876CE92172CF1864E07"
      unitRef="usd">659000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34661879e28350-wk-Fact-B1D8624AD9287C897056172DC671B95E"
      unitRef="usd">622000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34661879e28358-wk-Fact-077498470BD0CBDD688F172D429E77F7"
      unitRef="usd">380000000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-AE2295B1A6DA9AFFF160801F8347452E-0-wk-Fact-5096B386318188465FD1801F7EB68E75">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Equity&lt;/span&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A. Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. On October 23, 2014, we announced that the Board of Directors had authorized an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$11 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; share repurchase program, which was exhausted in the first quarter of 2017. In December 2015, the Board of Directors authorized a new &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$11 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; share repurchase program, which was exhausted in the third quarter of 2018. In December 2017, the Board of Directors authorized an additional &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$10 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; share repurchase program, which was exhausted in the first quarter of 2019. In December 2018, the Board of Directors authorized a new &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$10 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;February&#160;2, 2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we entered into an accelerated share repurchase agreement with Citibank to repurchase &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to Citibank and received an initial delivery of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;126 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock from Citibank at a price of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$31.73&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;80%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#x2019;s settlement terms, we received an additional &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;24 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$33.31&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share. The common stock received is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Treasury Stock&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. This agreement was entered into pursuant to our previously announced share repurchase authorization.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;12, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we entered into an accelerated share repurchase agreement with Citibank to repurchase &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of our common stock. Pursuant to the terms of the agreement, on &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;14, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we paid &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$4 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to Citibank and received an initial delivery of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;87 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock from Citibank at a price of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$36.61&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share, which represented, based on the closing price of our common stock on the NYSE on &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;March&#160;12, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;80%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the notional amount of the accelerated share repurchase agreement. On September 5, 2018, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#x2019;s settlement terms, we received an additional &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock from Citibank on September 7, 2018. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$36.86&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share. The common stock received is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Treasury stock&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. This agreement was entered into pursuant to our previously announced share repurchase authorization.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;February&#160;7, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we entered into an accelerated share repurchase agreement with &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GS&amp;amp;Co.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to repurchase approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$6.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of our common stock. Pursuant to the terms of the agreement, on &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;February&#160;12, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we paid approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$6.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GS&amp;amp;Co.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and received an initial delivery of approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;130 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GS&amp;amp;Co.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, which represented, based on the closing price of our common stock on the NYSE on February 7, 2019, approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;80%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the notional amount of the accelerated share repurchase agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;August&#160;1, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the accelerated share repurchase agreement with &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GS&amp;amp;Co.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; was completed, which, per the terms of the agreement, resulted in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GS&amp;amp;Co.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#x2019;s settlement terms, we received an additional &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33.5 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GS&amp;amp;Co.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; on &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;August&#160;5, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$41.42&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share. The common stock received is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Treasury stock&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. This agreement was entered into pursuant to our previously announced share repurchase authorization.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Open market purchases totaled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$2.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$8.2 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; under our publicly announced share-purchase plans.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our accelerated share repurchase agreements:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(SHARES IN MILLIONS, DOLLARS IN BILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares of common stock purchased&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cost of purchase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt"&gt;(&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Represents shares purchased pursuant to the accelerated share repurchase agreement with&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;GS&amp;amp;Co.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; entered into on &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;February&#160;7, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, as well as other share repurchases. See above for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;March&#160;12, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;, as well as other share repurchases. See above for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;February&#160;2, 2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;. See above for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;After giving effect to the accelerated share repurchase agreement, as well as other share repurchases through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, our remaining share-purchase authorization was approximately&#160;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; at &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B. Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The Series A convertible perpetual preferred stock (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,500&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares designated) is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, which are accumulated and paid quarterly. The per-share stated value is &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$40,300&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holder&#x2019;s option, into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2,574.87&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$40,300&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per share.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. Employee Stock Ownership Plans&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We have &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP).&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the Preferred ESOP held preferred shares convertible into approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock, and the Common ESOP held approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;47 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares of our common stock. As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, all shares of preferred and common stock held by the ESOPs have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$19 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$11 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2014Q4Oct23-2014"
      decimals="INF"
      id="d34524436e1315-wk-Fact-12629E0C1CB5273676EC801F7F0AC1BC"
      unitRef="usd">11000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2015Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2015StockPurchasePlanMember"
      decimals="INF"
      id="d34524436e1319-wk-Fact-183C5540FDEC64E38A39801F7EBF8A21"
      unitRef="usd">11000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2017Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2017StockPurchasePlanMember"
      decimals="INF"
      id="d34524436e1323-wk-Fact-5934EBFC1F06F43AE121801F7EC2E42E"
      unitRef="usd">10000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="FI2018Q4_us-gaap_ShareRepurchaseProgramAxis_pfe_December2018StockPurchasePlanMember"
      decimals="INF"
      id="d34524436e1327-wk-Fact-C7D818268EA838DC2205801F7F0A9F0C"
      unitRef="usd">10000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2017Q1Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="INF"
      id="d34524436e1340-wk-Fact-280E1ED68A8E2D05D806801F7EBECE50"
      unitRef="usd">5000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="I2017Q1Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-9"
      id="d34524436e1344-wk-Fact-DB7D001259ED28C74D84801F7EACE187"
      unitRef="usd">-5000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-6"
      id="d34524436e1348-wk-Fact-BF0E504ED3350781CBB3801F7F00E5DD"
      unitRef="shares">126000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare
      contextRef="D2017Q1Feb06-Feb06_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="2"
      id="d34524436e1352-wk-Fact-159B286BE0E340438567801F7EA9866E"
      unitRef="usdPerShare">31.73</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare>
    <pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount
      contextRef="D2017Q1Feb02-Feb02_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="2"
      id="d34524436e1357-wk-Fact-190D5C6980FA8AB2916D801F7EBC1C3B"
      unitRef="number">0.80</pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2017Q2May19-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-6"
      id="d34524436e1361-wk-Fact-422734FC4B97A87F2D0D801F7F0D88D4"
      unitRef="shares">24000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="D2017Q2Feb06-May19_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="2"
      id="d34524436e1365-wk-Fact-63945409B47F55B3A2C2801F7EA858CA"
      unitRef="usdPerShare">33.31</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2018Q1Mar12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="INF"
      id="d34524436e1380-wk-Fact-177F6B663F011CCCFC30801F7EBB58D6"
      unitRef="usd">4000000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="I2018Q1Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-9"
      id="d34524436e1388-wk-Fact-F58E0E33302939E7433C801F7F00C915"
      unitRef="usd">-4000000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2018Q1Mar14-Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-6"
      id="d34524436e1392-wk-Fact-96E880A85D2229406EFE801F7EBB5CB6"
      unitRef="shares">87000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare
      contextRef="D2018Q1Mar14-Mar14_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="2"
      id="d34524436e1397-wk-Fact-2C8F938D5134C2777154801F7EC5BA9F"
      unitRef="usdPerShare">36.61</us-gaap:AcceleratedShareRepurchasesInitialPricePaidPerShare>
    <pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount
      contextRef="D2018Q1Mar12-Mar12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="2"
      id="d34524436e1405-wk-Fact-32C0AC373E776A37BFB9801F7ECAAC1A"
      unitRef="number">0.80</pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2018Q3Sep07-Sep07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="-6"
      id="d34524436e1409-wk-Fact-5F225E158EE07D9800D0801F7F0A9062"
      unitRef="shares">21000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="D2018Q3Sep07-Sep07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithCitibankMember"
      decimals="2"
      id="d34524436e1413-wk-Fact-9E848EFD2B0F3FC80F1A801F7EC616D4"
      unitRef="usdPerShare">36.86</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:StockRepurchaseProgramAuthorizedAmount1
      contextRef="I2019Q1Feb07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember"
      decimals="-8"
      id="d34524436e1433-wk-Fact-9345AF2F1DAC0F57FDD8DEF1BFDD4C55"
      unitRef="usd">6800000000</us-gaap:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt
      contextRef="I2019Q1Feb12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember"
      decimals="-8"
      id="d34524436e1441-wk-Fact-9BBA9A5B8E37047536F4DEF458A9610C"
      unitRef="usd">-6800000000</us-gaap:AcceleratedShareRepurchasesSettlementPaymentOrReceipt>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2019Q1Feb12-Feb12_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember"
      decimals="-6"
      id="d34524436e1450-wk-Fact-7261652B81455B249BFA977918EDDC1D"
      unitRef="shares">130000000</us-gaap:TreasuryStockSharesAcquired>
    <pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount
      contextRef="D2019Q1Feb07-Feb07_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember"
      decimals="2"
      id="d34524436e1458-wk-Fact-D5BD114B117A5D5D9A3B4A9B51DEB506"
      unitRef="number">0.80</pfe:AcceleratedShareRepurchasesSharesRepurchasedDuringPeriodPercentageofAgreementAmount>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="D2019Q3Aug05-Aug05_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember"
      decimals="-5"
      id="d34524436e1477-wk-Fact-813974FCA52E5327989D0EE902D71DFA"
      unitRef="shares">33500000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare
      contextRef="D2019Q3Aug05-Aug05_us-gaap_ShareRepurchaseProgramAxis_pfe_ShareRepurchaseAgreementwithGSCoMember"
      decimals="2"
      id="d34524436e1490-wk-Fact-6CF37CE60FF85587A835008817260E3E"
      unitRef="usdPerShare">41.42</us-gaap:AcceleratedShareRepurchasesFinalPricePaidPerShare>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD_us-gaap_ShareRepurchaseProgramAxis_pfe_OpenMarketPurchasesMember"
      decimals="-8"
      id="d34524436e1501-wk-Fact-FA281C1523B933FCB347DEF7A88E4B3A"
      unitRef="usd">2100000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD_us-gaap_ShareRepurchaseProgramAxis_pfe_OpenMarketPurchasesMember"
      decimals="-8"
      id="d34524436e1509-wk-Fact-A7829A801872C65F41E4DEF7EA8F8CA0"
      unitRef="usd">8200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:ScheduleOfTreasuryStockByClassTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-CEE1563EC47C01B0F9ED801F83478639-0-wk-Fact-1BE0C6DB3D4D11DEA4B3801F7EAD352E">&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:46%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our accelerated share repurchase agreements:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(SHARES IN MILLIONS, DOLLARS IN BILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares of common stock purchased&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;150&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cost of purchase&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8.9&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.0&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt"&gt;(&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Represents shares purchased pursuant to the accelerated share repurchase agreement with&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;GS&amp;amp;Co.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; entered into on &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;February&#160;7, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, as well as other share repurchases. See above for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;&lt;sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;March&#160;12, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;, as well as other share repurchases. See above for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;February&#160;2, 2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"&gt;. See above for additional information.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfTreasuryStockByClassTextBlock>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34524436e1696-wk-Fact-D95C333A77FF51D2367A801F8284E06B"
      unitRef="shares">213000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34524436e1715-wk-Fact-36C4BF558BFA7F0626F6801F8284052E"
      unitRef="shares">307000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockSharesAcquired
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34524436e1734-wk-Fact-B9B68A9EF2D595760795801F82827C2E"
      unitRef="shares">150000000</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2019Q4YTD"
      decimals="-8"
      id="d34524436e1765-wk-Fact-FB3538E362BC65E9A4AD801F8283AB6A"
      unitRef="usd">8900000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2018Q4YTD"
      decimals="-8"
      id="d34524436e1784-wk-Fact-406980FB36901507CFF4801F8284BFE7"
      unitRef="usd">12200000000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod
      contextRef="FD2017Q4YTD"
      decimals="-8"
      id="d34524436e1804-wk-Fact-B41D8C40DC9E96021764801F82858FF5"
      unitRef="usd">5000000000.0</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1
      contextRef="FI2019Q4"
      decimals="-8"
      id="d34524436e1899-wk-Fact-6E71B38CCD744BD9C9CE801F7F29B839"
      unitRef="usd">5300000000</us-gaap:StockRepurchaseProgramRemainingAuthorizedRepurchaseAmount1>
    <pfe:PreferredStockSharesHeldInEmployeeTrustShares
      contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredESOPPlanMember"
      decimals="INF"
      id="d34524436e1915-wk-Fact-46A6AEFA0D92380897DBF338873F3639"
      unitRef="shares">7500</pfe:PreferredStockSharesHeldInEmployeeTrustShares>
    <us-gaap:PreferredStockDividendRatePercentage
      contextRef="FD2019Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="d34524436e1919-wk-Fact-E8EAF2D8D376EE62C9E9801F7F02DA90"
      unitRef="number">0.0625</us-gaap:PreferredStockDividendRatePercentage>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="d34524436e1923-wk-Fact-72749EC9DF6A4E02395B801F7EBBF08D"
      unitRef="usdPerShare">40300</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion
      contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="INF"
      id="d34524436e1927-wk-Fact-9CC4B957607DA42366E4801F7F01A745"
      unitRef="shares">2574.87</us-gaap:ConvertiblePreferredStockSharesIssuedUponConversion>
    <us-gaap:PreferredStockRedemptionPricePerShare
      contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementClassOfStockAxis_pfe_SeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="d34524436e1931-wk-Fact-753C2BB94F8F9613C2BF801F7EA77A6D"
      unitRef="usdPerShare">40300</us-gaap:PreferredStockRedemptionPricePerShare>
    <pfe:NumberofEmployeeStockOwnershipPlans
      contextRef="FI2019Q4"
      decimals="INF"
      id="d34524436e1943-wk-Fact-5040989B219D7A0AFAFD801F7EBA269B"
      unitRef="employee_stock_ownership_plan">2</pfe:NumberofEmployeeStockOwnershipPlans>
    <pfe:ConvertiblePreferredStockNumberofSharesConvertible
      contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_PreferredEmployeeStockOwnershipPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34524436e1957-wk-Fact-1E7C47538D5B1E7C3872801F7F06DC62"
      unitRef="shares">1000000</pfe:ConvertiblePreferredStockNumberofSharesConvertible>
    <us-gaap:EmployeeStockOwnershipPlanESOPSharesInESOP
      contextRef="FI2019Q4_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-6"
      id="d34524436e1961-wk-Fact-19AB79CFD3F59B7A0599801F7EC563E2"
      unitRef="shares">47000000</us-gaap:EmployeeStockOwnershipPlanESOPSharesInESOP>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember"
      decimals="-6"
      id="d34524436e1969-wk-Fact-FD21A8A2DEE2EEA8C18B801F7EC6E228"
      unitRef="usd">20000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember"
      decimals="-6"
      id="d34524436e1978-wk-Fact-7331D1073C937D778183801F7F01523E"
      unitRef="usd">19000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_EmployeeStockOwnershipPlanESOPDisclosuresByPlanAxis_pfe_CommonESOPPlanMember"
      decimals="-6"
      id="d34524436e1986-wk-Fact-F85EF785AEE69C51E056801F7F09CFBF"
      unitRef="usd">11000000</us-gaap:EmployeeStockOwnershipPlanESOPCompensationExpense>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EDBCFEEE2E7395F06A90801F834C8280-0-wk-Fact-A88F1F9CFDA3408C37EB801F80F59648">Share-Based Payments&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our compensation programs can include share-based payments. The award value is determined by reference to the fair value of share-based awards to similar employees in competitive survey data or industry peer groups used for compensation purposes; and is allocated between different long-term incentive vehicles, in the form of TSRUs, PTSRUs, PTUs, RSUs, PPSs, PSAs and stock options, as determined by the Compensation Committee.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The 2019 Stock Plan (2019 Plan) replaced and superseded the 2014 Plan. The 2019 Plan provides for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;400 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares to be authorized for grants, plus any shares remaining available for grant under the 2014 Plan as of April 25, 2019 (the carryforward shares). In addition, the 2019 Plan provides that the number of stock options, Stock Appreciation Rights (known as TSRUs and PTSRUs), RSUs, or other performance-based awards that may be granted to any one individual during any 36-month period is limited to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;20 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares, and that RSUs, PPSs and PSAs count as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares, while TSRUs, PTSRUs and stock options count as &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; share, toward the maximum shares available under the 2019 plan. As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;518 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; shares were available for award. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Although not required to do so, we have used authorized and unissued shares and, to a lesser extent, treasury stock to satisfy our obligations under these programs.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A. Impact on Net Income&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of share-based compensation expense and the associated tax benefit:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TSRUs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PPSs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PSAs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Stock options &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Directors&#x2019; compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Share-based payment expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Tax benefit for share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Share-based payment expense, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;769&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;677&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Includes expense for PTSRUs, described in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 13C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; below, which is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The table above excludes total expense due to the modification for share-based awards in connection with our Organizing for Growth initiative. The total expense was not significant for 2019 and 2018, the year in which the Organization for Growth Initiative began and is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Restructuring charges and certain acquisition-related costs &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts capitalized as part of inventory cost were not significant for any period presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B. Total Shareholder Return Units&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TSRUs are awarded to senior and other key management, and to certain other employees. TSRUs entitle the holders to receive a number of shares of our common stock with a value equal to the difference between the defined settlement price and the grant price, plus the dividends accumulated during the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;seven&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year term, if and to the extent the total value is positive. The settlement price is the average closing price of our common stock during the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; trading days ending on the fifth or seventh anniversary of the grant, as applicable; the grant price is the closing price of our common stock on the date of the grant. The TSRUs are automatically settled on the fifth or seventh anniversary of the grant but vest on the third anniversary of the grant, after which time there is no longer a substantial risk of forfeiture.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Retiree eligible holders (at least age &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; with at least &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;ten years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of service) can elect to exercise and convert his/her TSRUs, when vested, into PTUs. The value received upon the election and conversion is calculated by taking the change in stock price (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;20&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; trading day average ending on the exercise date (Election Price) less the grant price) plus accumulated dividends from the grant date, times the number of TSRUs exercised. This value is divided by the Election Price to determine the number of PTUs. The PTUs will be entitled to earn Dividend Equivalent Units (DEUs), and the PTUs and DEUs will be settled in our common stock on the TSRUs&#x2019; original settlement date (i.e., the fifth or seventh anniversary of grant), and will be subject to all of the terms and conditions of the original grant including forfeiture provisions. We measure the value of TSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the weighted-average assumptions used in the valuation of TSRUs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected stock price volatility&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;18.34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Contractual term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using a constant dividend yield during the expected term of the TSRU.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using the interpolated yield on U.S. Treasury zero-coupon issues.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using implied volatility, after consideration of historical volatility.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes all TSRU activity during 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TSRUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Grant-Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per TSRU&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Grant Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per TSRU&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Nonvested, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;138,945&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33.44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39,246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(47,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;30.70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(7,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nonvested, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;122,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes TSRU and PTU information as of December 31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TSRUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PTUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Grant&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per TSRU&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Remaining Contractual Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Aggregate Intrinsic Value (Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;TSRUs Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;179,999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;TSRUs Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;57,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;31.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;TSRUs Expected to vest&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;118,618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;TSRUs exercised and converted to PTUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, we settled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;7,953,671&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; TSRUs with a weighted-average grant price of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$27.33&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; per unit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,173,131&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; TSRUs with a weighted-average grant price of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30.68&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; per unit were converted into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;844,871&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; PTUs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides data related to all TSRU activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average grant-date fair value per TSRU&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which TSRU cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. Performance Total Shareholder Return Units&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On December 29, 2017, in connection with the Board&#x2019;s succession planning,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,372,213&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; PTSRUs were awarded to the then Chairman and Chief Executive Officer, and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;343,053&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; PTSRUs were awarded to the Group President, Chief Business Officer (former role Group President, Pfizer Innovative Health) at a grant price of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$36.22&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and at a grant-date fair value of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$5.83&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; per TSRU. In addition to having the same characteristics of TSRUs, PTSRU grants require special service and performance conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We measure the value of PTSRU grants as of the grant date using a Monte Carlo simulation model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;D. Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;RSUs are awarded to select employees and, when vested, entitle the holder to receive a specified number of shares of our common stock, including shares resulting from dividend equivalents paid on such RSUs. For RSUs granted during the periods presented, in virtually all instances, the units vest after &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of continuous service from the grant date.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We measure the value of RSU grants as of the grant date using the closing price of our common stock. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes all RSU activity during 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Grant-Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Nonvested, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;27,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33.70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(10,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;31.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Reinvested dividend equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39.64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nonvested, December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;23,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides data related to all RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total fair value of shares vested&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which RSU cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017 includes the modification for a commitment to pay approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;6.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; RSUs to approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;9,900&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; employees, including senior and key management employees, for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;6.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; RSUs. These shares were paid in the first quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;E. Portfolio Performance Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PPSs are awards granted to select employees which, when vested, entitle the holder to receive, at the end of the performance period, a number of shares within a possible range of shares of our common stock, including shares resulting from dividend equivalents paid on such shares. For PPSs granted during the period presented, the awards vest after &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of continuous service from the grant date and the number of shares paid, if any, depends on the achievement of predetermined goals related to Pfizer&#x2019;s long-term product portfolio during a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;five&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year performance period from the year of the grant date. The number of shares that may be earned over the performance period ranges from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the initial award.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We measure the value of PPS grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized on a straight-line basis over the probable vesting term into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;and/or&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; Research and development expenses, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer&#x2019;s common stock, changes in the number of shares that are probable of being earned and changes in management&#x2019;s assessment of the probability that the specified performance criteria will be achieved and/or changes in management&#x2019;s&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;assessment of the probable vesting term.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes all PPS activity during 2019, with the shares representing the maximum award that could be achieved:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Nonvested, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;19,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;43.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(6,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;42.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nonvested, December 31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Vested and non-vested shares outstanding, but not paid as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;32.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides data related to all PPS activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which PPS cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;F. Performance Share Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PSAs are awarded to senior and other key management. PSAs vest after &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; years of continuous service from the grant date. The number of shares paid, if any, including shares resulting from dividend equivalents, for awards granted in 2015 and later, depends upon the achievement of predetermined goals related to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; measures: (i) adjusted operating income (for performance years through 2018) or adjusted net income (for 2019 and later years, except for the 2017 PSAs) over &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year periods; and (ii) TSR as compared to the NYSE ARCA Pharmaceutical Index (DRG Index) over the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year performance period. The number of shares that are earned over the performance period ranges from &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;200%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the initial award.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We measure the value of PSA grants as of the grant date using the intrinsic value method, for which we use the closing price of our common stock. The values are amortized on a straight-line basis over the probable vesting term into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as appropriate, and adjusted each reporting period, as necessary, to reflect changes in the price of Pfizer&#x2019;s common stock, changes in the number of shares that are probable of being earned and changes in management&#x2019;s assessment of the probability that the specified performance criteria will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;background-color:#ffffff;"&gt;The following table summarizes all PSA activity during 2019, with the shares granted representing the maximum award that could be achieved:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Nonvested, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;43.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,716&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;42.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;41.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nonvested, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,061&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;background-color:#ffffff;"&gt;The following table provides data related to all PSA activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total fair value of shares vested&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which PSA cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;includes the modification &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for a commitment to pay&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt; PSAs to approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt; employees, including senior and key management employees, for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt; PSAs. These shares were paid in the first quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;G. Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Stock options are awarded to select employees and, when vested, entitle the holder to purchase a specified number of shares of our common stock at a price per share equal to the closing market price of our common stock on the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Beginning in 2016, only a limited set of overseas employees received stock option grants. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;No&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; stock options were awarded to senior and other key management in any period presented; however, stock options were awarded to certain other employees. In virtually all instances, stock options granted vest after &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three years&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of continuous service from the grant date and have a contractual term of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; years. In most cases, stock options must be held for at least &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;one year&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; from the grant date before any vesting may occur. In the event of a sale of business or plant closing or restructuring, options held by employees are immediately vested and are exercisable for a period of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3 months&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; following the date employment is terminated or through their remaining term, depending on various conditions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We measure the value of stock option grants as of the grant date using the Black-Scholes-Merton option-pricing model. The values determined through this fair value methodology generally are amortized on a straight-line basis over the vesting term into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Cost of sales, Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and/or &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, as appropriate.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.40476190476191%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the weighted-average assumptions used in the valuation of stock options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected stock price volatility&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;18.34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;20.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected term (years)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using a constant dividend yield during the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using the interpolated yield on U.S. Treasury zero-coupon issues.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using implied volatility, after consideration of historical volatility.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using historical exercise and post-vesting termination patterns.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes all stock option activity during 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Remaining Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intrinsic Value&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Outstanding, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;103,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;27.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(15,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;24.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;31.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;88,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;28.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested and expected to vest, December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;88,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;28.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercisable, December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;85,372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;28.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;951&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Market price of our underlying common stock less exercise price.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The number of options expected to vest takes into account an estimate of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:8px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes data related to all stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year&#160;Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average grant-date fair value per stock option&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Aggregate intrinsic value on exercise&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash received upon exercise&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Tax benefits realized related to exercise&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested stock options not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which stock option compensation cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="INF"
      id="d34594690e1310-wk-Fact-6FC2C450052B93096492801F82643506"
      unitRef="shares">400000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="INF"
      id="d34594690e1314-wk-Fact-854C7571320A0D913933801F82901CC5"
      unitRef="shares">20000000</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="INF"
      id="d34594690e1318-wk-Fact-E522A123693B340C8D90801F7F984A2B"
      unitRef="shares">3</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="INF"
      id="d34594690e1322-wk-Fact-042E8CC246E59F30A494801F7E35C0F4"
      unitRef="shares">1</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34594690e1331-wk-Fact-F0BD08D907939AC63DA6801F7E2DF4CD"
      unitRef="shares">518000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-8148B060ED7AD7AF4A1E801F834DC8D1-0-wk-Fact-C81C4E0E1895B3A8A42C801F82905353">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the components of share-based compensation expense and the associated tax benefit:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TSRUs&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;221&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;RSUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;275&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;286&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PPSs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;209&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PSAs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;28&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;62&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Stock options &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Directors&#x2019; compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Share-based payment expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;718&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;949&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;840&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Tax benefit for share-based compensation expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(137&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;(163&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Share-based payment expense, net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;581&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;769&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;677&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&#160;&#160;&#160;&#160;&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Includes expense for PTSRUs, described in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 13C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; below, which is not significant for all years presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1587-wk-Fact-B879D2FCD0A23F2045A2801F7ED7E9E3"
      unitRef="usd">294000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1606-wk-Fact-7891E4C59FB8C240ECF8801F7ED8C974"
      unitRef="usd">302000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1626-wk-Fact-18A55E3A510C5C5B3112801F7ED70A08"
      unitRef="usd">221000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1646-wk-Fact-9F2D0143794D1F571F19801F7ED65330"
      unitRef="usd">275000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1665-wk-Fact-B3E12E551BC655A18FC0801F7EDC907C"
      unitRef="usd">286000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1684-wk-Fact-9750E37307390E2A75F1801F7EDCA921"
      unitRef="usd">301000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1710-wk-Fact-7E01A0C63FFB00E4C98A801F7ED7AF09"
      unitRef="usd">114000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1729-wk-Fact-1B624A552DD3F3058B77801F7EDC1193"
      unitRef="usd">276000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1748-wk-Fact-748EFF95AFC11AED93E6801F7EDD9652"
      unitRef="usd">209000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1774-wk-Fact-46F717C1553CF53F7172801F7ED0930D"
      unitRef="usd">28000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1793-wk-Fact-CEE69CAB6A39F47680CC801F7ECFE9F0"
      unitRef="usd">62000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1812-wk-Fact-C387BFF2E792CFCF5605801F7EDDF8B1"
      unitRef="usd">47000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1838-wk-Fact-D5E7109BD60C7188B654801F7EDD27FB"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1857-wk-Fact-57FCE1E85DD3DD4F6BD8801F7ED09BE6"
      unitRef="usd">12000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1876-wk-Fact-290FC363F3F9E182FEB7801F7EDD5C6B"
      unitRef="usd">55000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1902-wk-Fact-32213D56355CD79C6022801F7EDBFE08"
      unitRef="usd">0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1921-wk-Fact-FE00D81CAAA4354BBB07801F7ED53DA6"
      unitRef="usd">10000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_DirectorsCompensationMember_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1940-wk-Fact-92370CDB33B5B0D0BFF9801F7EDB8EEA"
      unitRef="usd">7000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1966-wk-Fact-406BD401F6A1617163AF801F7ED97DEF"
      unitRef="usd">718000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e1985-wk-Fact-A2235D173D1198572D6A801F7ED90D48"
      unitRef="usd">949000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e2004-wk-Fact-ED3A88AD0E9EA78C1F37801F7EDD3765"
      unitRef="usd">840000000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e2030-wk-Fact-674DC804C9A2E9F7EDF4801F7ED08970"
      unitRef="usd">137000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e2050-wk-Fact-8F02E9905482BC7D9010801F7ECF51AE"
      unitRef="usd">180000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e2070-wk-Fact-BB1C8EF20AA722100577801F7EDDA77A"
      unitRef="usd">163000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2019Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e2103-wk-Fact-758B4D2904B68E19A0F9801F7ED9CDED"
      unitRef="usd">581000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2018Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e2122-wk-Fact-F8F197A88298D7CDA4F1801F7ED69B97"
      unitRef="usd">769000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax
      contextRef="FD2017Q4YTD_us-gaap_PlanNameAxis_pfe_A2019StockPlanMember"
      decimals="-6"
      id="d34594690e2142-wk-Fact-02AC1B14C6F316304BFA801F7ED2123F"
      unitRef="usd">677000000</us-gaap:AllocatedShareBasedCompensationExpenseNetOfTax>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="INF"
      id="d34594690e2249-wk-Fact-4DC9ED78933BD86361BC801F8289ACB5"
      unitRef="trading_day">20</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e2258-wk-Fact-81DCE96B00B2CC383EEF801F828E6FE8">P55Y</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e2262-wk-Fact-163C0E18C3EB57071A63801F7E9BBD88">P10Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="INF"
      id="d34594690e2266-wk-Fact-4DC9ED78933BD86361BC801F8289ACB5"
      unitRef="trading_day">20</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage>
    <pfe:ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-248891BC6096268B8EA6801F834DD3AD-0-wk-Fact-C7031F7FE33834083B74801F8283AACD">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the weighted-average assumptions used in the valuation of TSRUs:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.60&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected stock price volatility&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;18.34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;20.00&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Contractual term (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.13&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.11&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using a constant dividend yield during the expected term of the TSRU.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using the interpolated yield on U.S. Treasury zero-coupon issues.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using implied volatility, after consideration of historical volatility.&lt;/span&gt;&lt;/div&gt;</pfe:ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2463-wk-Fact-F35741687D18E3B4878F801F81982A44"
      unitRef="number">0.0327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2478-wk-Fact-3DAD4CB2028224ADCA3A801F819615A2"
      unitRef="number">0.0373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2493-wk-Fact-3EB348FE8DB4F3058FEF801F81A6D04E"
      unitRef="number">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2516-wk-Fact-3BADC091FCBEA9D91D08801F819B12FC"
      unitRef="number">0.0255</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2531-wk-Fact-5A1DD2370C1F985FBB91801F81A8925B"
      unitRef="number">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2546-wk-Fact-24AE793F7AF5A0FFC713801F81A5B87D"
      unitRef="number">0.0198</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2569-wk-Fact-DACC4B795F2137AD8A42801F81A81F11"
      unitRef="number">0.1834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2584-wk-Fact-09366D0018503E3621D1801F819C0D25"
      unitRef="number">0.2000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="4"
      id="d34594690e2599-wk-Fact-A1E8D06C4BADD1A6A43D801F819A99BD"
      unitRef="number">0.1839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e2620-wk-Fact-D5EFC6E1EB01FD7CE6B4801F81A47D9C">P5Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e2634-wk-Fact-4374254178D68E57BD72801F81A80D3E">P5Y1M13D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e2648-wk-Fact-225B36E2167933185C95801F819B8A2F">P5Y1M9D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-250C160F445EBC0BB584801F834C7D93-0-wk-Fact-09BF6DCEF2C149FF0BDC801F81CD88E3">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="12"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:56%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes all TSRU activity during 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TSRUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Grant-Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per TSRU&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Grant Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per TSRU&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Nonvested, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;138,945&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33.44&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39,246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(47,710&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.92&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;30.70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(7,826&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.63&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38.90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nonvested, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;122,654&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7.53&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="17"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:41%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:12%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes TSRU and PTU information as of December 31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a), (b)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;TSRUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;PTUs&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Grant&#160;Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per TSRU&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Remaining Contractual Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Aggregate Intrinsic Value (Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;TSRUs Outstanding&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;179,999&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;35.33&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,415&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;TSRUs Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;57,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;31.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;TSRUs Expected to vest&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;118,618&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,096&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;TSRUs exercised and converted to PTUs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#x2014;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;0.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;51&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, we settled &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;7,953,671&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; TSRUs with a weighted-average grant price of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$27.33&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; per unit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;2,173,131&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; TSRUs with a weighted-average grant price of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30.68&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; per unit were converted into &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;844,871&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; PTUs.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:center;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:63%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides data related to all TSRU activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average grant-date fair value per TSRU&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8.52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7.42&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;246&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;232&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which TSRU cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-3"
      id="d34594690e2873-wk-Fact-2B3A7AD8D31149C70784801F82ACB4BD"
      unitRef="shares">138945000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e2892-wk-Fact-29E8009CF7353E027C13801F82ADFD8D"
      unitRef="usdPerShare">6.48</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e2911-wk-Fact-4B3368EC6957D80B4C25801F82B6ABA0"
      unitRef="usdPerShare">33.44</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-3"
      id="d34594690e2932-wk-Fact-A53C0AC13138F9FC10A0801F82AB44D9"
      unitRef="shares">39246000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e2946-wk-Fact-4188C213ECB0D342DCC5801F82AB683F"
      unitRef="usdPerShare">8.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e2965-wk-Fact-47CCB4B31FABBCCE984A801F82AE4414"
      unitRef="usdPerShare">43.35</pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-3"
      id="d34594690e2991-wk-Fact-A8E4714D3FF46F4742D9801F82B0A4CC"
      unitRef="shares">47710000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3006-wk-Fact-0BC8AC002D2D11DC55C9801F82A5B062"
      unitRef="usdPerShare">5.92</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3025-wk-Fact-C572B98C4A6E034CBE6C801F82AD80C0"
      unitRef="usdPerShare">30.70</pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-3"
      id="d34594690e3051-wk-Fact-2D766935D9716B0603B7801F82A9B1E0"
      unitRef="shares">7826000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3066-wk-Fact-E5EA9B34E3F68B35E39D801F82ACF0A6"
      unitRef="usdPerShare">7.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3085-wk-Fact-285C0E244AD577E64B92801F82AC6621"
      unitRef="usdPerShare">38.90</pfe:SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-3"
      id="d34594690e3111-wk-Fact-0859BCD07BA3D1199211801F82B17E9B"
      unitRef="shares">122654000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3130-wk-Fact-E0913B51212D1DBECFC6801F82B0208D"
      unitRef="usdPerShare">7.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3149-wk-Fact-AE20B2F126CBCFAD2DDE801F82AF7B38"
      unitRef="usdPerShare">38.01</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-3"
      id="d34594690e3394-wk-Fact-6221149E08DD0A17F14B801F8152992D"
      unitRef="shares">179999000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3427-wk-Fact-7BB330D73286C9EA44FD801F8148FF86"
      unitRef="usdPerShare">35.33</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e3442-wk-Fact-B9A985D5E312D61B9E03801F81513582">P2Y7M6D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-6"
      id="d34594690e3457-wk-Fact-55A2404E40890D14A72D801F8159A9F4"
      unitRef="usd">1415000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-3"
      id="d34594690e3477-wk-Fact-50F041F28B665D836084801F81547F30"
      unitRef="shares">57345000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3505-wk-Fact-DED528DDB914A2BDEF0A801F81463977"
      unitRef="usdPerShare">31.04</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e3525-wk-Fact-265DAD9E00B9993A01D4801F81574A5A">P1Y3M18D</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-6"
      id="d34594690e3535-wk-Fact-654FE5FF7865D1DED1CD801F815171FE"
      unitRef="usd">775000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-3"
      id="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E"
      unitRef="shares">118618000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105"
      unitRef="usdPerShare">37.23</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD">P3Y2M12D</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-6"
      id="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4"
      unitRef="usd">1096000000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember"
      decimals="-3"
      id="d34594690e3659-wk-Fact-39D10B011D5484305F0B801F814829A7"
      unitRef="shares">1299000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember"
      id="d34594690e3693-wk-Fact-268578D08E27C197EEE6801F8149CC9C">P0Y8M12D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember"
      decimals="-6"
      id="d34594690e3708-wk-Fact-31E5ACFB46A559DC7083801F81586817"
      unitRef="usd">51000000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="INF"
      id="d34594690e3728-wk-Fact-DF27274198C78C3FFBC6801F7E39A293"
      unitRef="shares">7953671</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3732-wk-Fact-4C1CF66DD81E59C282C3801F828B2941"
      unitRef="usdPerShare">27.33</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="INF"
      id="d34594690e3753-wk-Fact-BA4FA60038DF8467BE65801F82642ED3"
      unitRef="shares">2173131</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e3757-wk-Fact-AD6AA25517BBCA4DFCA0801F82805D52"
      unitRef="usdPerShare">30.68</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_ProfitUnitsMember"
      decimals="INF"
      id="d34594690e3761-wk-Fact-603776CFA0F5467FCBEC801F7EDAAE83"
      unitRef="shares">844871</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e4024-wk-Fact-4188C213ECB0D342DCC5801F82AB683F"
      unitRef="usdPerShare">8.52</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e4043-wk-Fact-BE507844521211CA94E6801F80A24F5C"
      unitRef="usdPerShare">7.42</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="2"
      id="d34594690e4063-wk-Fact-2DD59081DEDF0560DAEF801F80CF98FE"
      unitRef="usdPerShare">6.23</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-6"
      id="d34594690e4088-wk-Fact-E907D692F06EF7D58934801F7FF75806"
      unitRef="usd">229000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-6"
      id="d34594690e4107-wk-Fact-63D57FC7853A0D736F74801F80CB2B68"
      unitRef="usd">246000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      decimals="-6"
      id="d34594690e4127-wk-Fact-794A0F522F645E6F6E8A801F80D3186F"
      unitRef="usd">232000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e4147-wk-Fact-59309543825EA6AEA6E4801F80CE3AA9">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e4166-wk-Fact-0832C5E5BCCDDB95B157801F80DFA492">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_TotalShareholderReturnUnitsTSRUsMember"
      id="d34594690e4185-wk-Fact-7434E66EC04212978FA8801F80C5A249">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="D2017Q4Dec29-Dec29_srt_TitleOfIndividualAxis_srt_BoardOfDirectorsChairmanMember_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember"
      decimals="INF"
      id="d34594690e4209-wk-Fact-EF3B52560A4A2544E8DA801F81BC1E84"
      unitRef="shares">1372213</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted
      contextRef="D2017Q4Dec29-Dec29_srt_TitleOfIndividualAxis_pfe_GroupPresidentChiefBusinessOfficerorFormerGroupPresidentPfizerInnovativeHealthMember_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember"
      decimals="INF"
      id="d34594690e4213-wk-Fact-CCD4D990445B9606C1A6801F7EDC4986"
      unitRef="shares">343053</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice
      contextRef="D2017Q4Dec29-Dec29_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember"
      decimals="2"
      id="d34594690e4217-wk-Fact-4C09CEF5D0AB97425644801F7E33B167"
      unitRef="usdPerShare">36.22</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodPrice>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue
      contextRef="D2017Q4Dec29-Dec29_us-gaap_AwardTypeAxis_pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember"
      decimals="2"
      id="d34594690e4221-wk-Fact-40DB65839272DFA6B7F8801F80F3E20C"
      unitRef="usdPerShare">5.83</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantsinPeriodGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d34594690e4243-wk-Fact-CA4056187AC4E787DC6E801F81E42E10">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-01CA05E76AA7E5EF272D801F834C1B21-0-wk-Fact-6AA0AA03E616352394DE801F8285C24C">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:66%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes all RSU activity during 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Grant-Date Fair Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Nonvested, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;27,276&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;33.70&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,478&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.17&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(10,644&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;31.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Reinvested dividend equivalents&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39.64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,614&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;38.82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nonvested, December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;23,407&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37.54&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides data related to all RSU activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total fair value of shares vested&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;454&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;584&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;241&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;256&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which RSU cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017 includes the modification for a commitment to pay approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;6.4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; RSUs to approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;9,900&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; employees, including senior and key management employees, for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;6.6 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; RSUs. These shares were paid in the first quarter of 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d34594690e4381-wk-Fact-7DBB7F0E572004849E2C801F80AF440E"
      unitRef="shares">27276000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d34594690e4400-wk-Fact-6E06409C1FA303566611801F80C76773"
      unitRef="usdPerShare">33.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d34594690e4420-wk-Fact-6404D4E395D713E052ED801F80C8E5E7"
      unitRef="shares">7478000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d34594690e4434-wk-Fact-C546F354E2EE8F6C9891801F80289293"
      unitRef="usdPerShare">43.17</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d34594690e4459-wk-Fact-A92668B7862CB8ABB2D9801F80B1E88C"
      unitRef="shares">10644000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d34594690e4474-wk-Fact-5C089929FC6AD8D3128E801F80230069"
      unitRef="usdPerShare">31.66</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d34594690e4499-wk-Fact-45E7F2A850737653CBC2801F80BEC4E1"
      unitRef="shares">911000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d34594690e4513-wk-Fact-97F88B06FF262C45C8E2801F801FA376"
      unitRef="usdPerShare">39.64</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d34594690e4538-wk-Fact-DE2B73649C13DF99D4ED801F80A146EF"
      unitRef="shares">1614000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d34594690e4553-wk-Fact-45A273B1877DCDB29980801F809E09A3"
      unitRef="usdPerShare">38.82</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-3"
      id="d34594690e4578-wk-Fact-86683D0AC0369864852F801F80CAF6DC"
      unitRef="shares">23407000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="2"
      id="d34594690e4597-wk-Fact-C930C1BE1CD0AD294931801F80B7C998"
      unitRef="usdPerShare">37.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-6"
      id="d34594690e4846-wk-Fact-137CA28F27F7A870C810801F81C79E37"
      unitRef="usd">454000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-6"
      id="d34594690e4865-wk-Fact-1D05AD6F6F2D8CB837F3801F81CB438D"
      unitRef="usd">146000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-6"
      id="d34594690e4885-wk-Fact-6077434EDCF327AE1499801F81D5A9C4"
      unitRef="usd">584000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-6"
      id="d34594690e4910-wk-Fact-EE84B5518D13FA627186801F81D6A114"
      unitRef="usd">241000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-6"
      id="d34594690e4929-wk-Fact-6FDD60627A9A357C96C0801F81C90B9B"
      unitRef="usd">256000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-6"
      id="d34594690e4949-wk-Fact-F503B707E0FD43FA4262801F81CCA124"
      unitRef="usd">254000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d34594690e4969-wk-Fact-9F76724182A84924F7CF801F81CAED77">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d34594690e4988-wk-Fact-0114F20D770B4848A819801F81BDDD0F">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      id="d34594690e5007-wk-Fact-D588BD9B2B98545608FB801F81C57423">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d34594690e5033-wk-Fact-BD2CAD3B252048CD7515801F8285C81F"
      unitRef="shares">6400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-2"
      id="d34594690e5037-wk-Fact-3436D1EFFACF27EC797F801F8283B31F"
      unitRef="Employee">9900</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_RestrictedStockUnitsRSUMember"
      decimals="-5"
      id="d34594690e5041-wk-Fact-D9D1066F08FF5CBABD06801F7E2D4C1B"
      unitRef="shares">6600000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      id="d34594690e5162-wk-Fact-9EB81BE6D030973CD761801F828D7FE8">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="INF"
      id="d34594690e5170-wk-Fact-544C770E04D1784312B9801F82829192"
      unitRef="number">0</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="INF"
      id="d34594690e5174-wk-Fact-50288B12B222EA12333D801F82859A80"
      unitRef="number">2</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-748CD2FAD379BD0B3655801F834BE247-0-wk-Fact-7DA635DD082FF2F9F478801F7EDBF9E6">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:65%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:14%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:16%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes all PPS activity during 2019, with the shares representing the maximum award that could be achieved:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Nonvested, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;19,261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;43.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,212&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(6,882&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;42.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(897&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39.93&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nonvested, December 31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;17,694&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Vested and non-vested shares outstanding, but not paid as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;32.0 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:70%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:7%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides data related to all PPS activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total fair value of shares vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;136&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;169&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;131&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;87&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;102&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;94&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which PPS cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="8"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:58%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:19%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:18%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;background-color:#ffffff;"&gt;The following table summarizes all PSA activity during 2019, with the shares granted representing the maximum award that could be achieved:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intrinsic Value&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Nonvested, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,282&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;43.65&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,716&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(1,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;42.89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;41.91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nonvested, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,061&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;39.18&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:61%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:10%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;background-color:#ffffff;"&gt;The following table provides data related to all PSA activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total fair value of shares vested&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;64&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;58&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;41&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which PSA cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7.5pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017 &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;includes the modification &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;for a commitment to pay&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt; PSAs to approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt; employees, including senior and key management employees, for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1.1 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt; PSAs. These shares were paid in the first quarter of 2018.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-3"
      id="d34594690e5322-wk-Fact-F14A9C781986E780D881801F80B6FD00"
      unitRef="shares">19261000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="2"
      id="d34594690e5341-wk-Fact-479DD93FDE5F409502F0801F80D11F95"
      unitRef="usdPerShare">43.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-3"
      id="d34594690e5361-wk-Fact-2F598B1406A11FE5C58D801F80AC1A27"
      unitRef="shares">6212000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="2"
      id="d34594690e5375-wk-Fact-339226858A639B6BCD25801F80B853D2"
      unitRef="usdPerShare">43.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-3"
      id="d34594690e5400-wk-Fact-E8F58A444C9CFF7025E4801F80E842E0"
      unitRef="shares">6882000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="2"
      id="d34594690e5415-wk-Fact-C86C3B899E98DCD9BA3E801F80DFCCEE"
      unitRef="usdPerShare">42.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-3"
      id="d34594690e5440-wk-Fact-47745DB83766C496A971801F80B46143"
      unitRef="shares">897000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="2"
      id="d34594690e5455-wk-Fact-35027DE2FCE41CF272B1801F80DBC816"
      unitRef="usdPerShare">39.93</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-3"
      id="d34594690e5482-wk-Fact-E6EDC6EB8DF84B60CE5A801F80D3642D"
      unitRef="shares">17694000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="2"
      id="d34594690e5501-wk-Fact-3FDB29B576C0C8FDA061801F7FF11DF2"
      unitRef="usdPerShare">39.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-5"
      id="d34594690e5533-wk-Fact-150F22D999AC1A6DE980801F828FE93C"
      unitRef="shares">32000000.0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-6"
      id="d34594690e5791-wk-Fact-290DAB02A52F6F057DBD801F81805322"
      unitRef="usd">136000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-6"
      id="d34594690e5810-wk-Fact-584DD122A3D879719E35801F821354D9"
      unitRef="usd">169000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-6"
      id="d34594690e5830-wk-Fact-FCC410BA1B024EAAB0B6801F8178508D"
      unitRef="usd">131000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-6"
      id="d34594690e5855-wk-Fact-49F2DF8E8BBEEEEC5F2E801F8177102F"
      unitRef="usd">87000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-6"
      id="d34594690e5874-wk-Fact-6F7A537347DBBAC786B0801F81883421"
      unitRef="usd">102000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      decimals="-6"
      id="d34594690e5894-wk-Fact-E377273B92CA7E29D745801F82163DAE"
      unitRef="usd">94000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      id="d34594690e5914-wk-Fact-CFBF0755FFBC33523BD6801F821BAE10">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      id="d34594690e5933-wk-Fact-A77F093BE7D5AD6FCE0D801F817A333C">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_pfe_PortfolioPerformanceSharesMember"
      id="d34594690e5952-wk-Fact-E01B69D232C0119F3425801F8178D7A2">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d34594690e6096-wk-Fact-736458414C86A8BF1DD4801F827FDC1D"
      unitRef="measure">2</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardNumberofMeasuresUsedtoDetermineSharePayout>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d34594690e6100-wk-Fact-11D82C85193B213208E3801F7E94F871"
      unitRef="period">3</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardSharePayoutMeasuresAdjustedNetIncomeNumberofPeriods>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MinimumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d34594690e6113-wk-Fact-5021B89D92BD42DB7A21801F7F93CFA0"
      unitRef="number">0</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward
      contextRef="FD2019Q4YTD_srt_RangeAxis_srt_MaximumMember_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="INF"
      id="d34594690e6117-wk-Fact-1E13A0191A8D061A9CA5801F81BD26A7"
      unitRef="number">2</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNumberofSharesEarnedPercentageofInitialAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-3"
      id="d34594690e6267-wk-Fact-1AE3F831F0AC89A46ACC801F82CC7EEA"
      unitRef="shares">5282000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="d34594690e6286-wk-Fact-93C18C29C2F03B0FE6F3801F7EC4E280"
      unitRef="usdPerShare">43.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-3"
      id="d34594690e6306-wk-Fact-772E25FB2AFDB05C0BB8801F7DC5F2DF"
      unitRef="shares">1716000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="d34594690e6320-wk-Fact-7D7ACA0C1E68E041A0F9801F7EBC9C84"
      unitRef="usdPerShare">43.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-3"
      id="d34594690e6345-wk-Fact-78538C632106CA60F131801F7EC91F76"
      unitRef="shares">1481000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="d34594690e6360-wk-Fact-43C668FD8C15F363EFB6801F7EC630C4"
      unitRef="usdPerShare">42.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-3"
      id="d34594690e6385-wk-Fact-67E532EB9CB7EE55AF82801F7EC7C221"
      unitRef="shares">456000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="d34594690e6400-wk-Fact-150485A40162B2B540F8801F80B19109"
      unitRef="usdPerShare">41.91</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-3"
      id="d34594690e6425-wk-Fact-4BB52DC78D0C6B52ACEC801F7EC89B88"
      unitRef="shares">5061000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="2"
      id="d34594690e6444-wk-Fact-3624CB37E827F0D87C37801F7EC12EE3"
      unitRef="usdPerShare">39.18</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-6"
      id="d34594690e6695-wk-Fact-8027040D1DF4721D6272801F7F0F7A3C"
      unitRef="usd">64000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-6"
      id="d34594690e6714-wk-Fact-9179C071F6FA44A44864801F7F0CC3E4"
      unitRef="usd">4000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-6"
      id="d34594690e6734-wk-Fact-3211B659D4CE729821B4801F7F0D704F"
      unitRef="usd">58000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-6"
      id="d34594690e6759-wk-Fact-7A13E149D91E1FD0EED1801F7F0ED23C"
      unitRef="usd">34000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-6"
      id="d34594690e6778-wk-Fact-C40FD8D6B88C25BA4193801F7F1691B7"
      unitRef="usd">41000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-6"
      id="d34594690e6798-wk-Fact-425F8C7193EAD9808260801F7F2204DD"
      unitRef="usd">34000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="d34594690e6818-wk-Fact-A510C149D1946AEB622D801F7F506333">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="d34594690e6837-wk-Fact-ABEED740F4B15AA1C834801F7F0EE6AB">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      id="d34594690e6856-wk-Fact-41F3EA956045BC1117EB801F7F0E63F5">P1Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d34594690e6890-wk-Fact-9A7F8A77EF19F15A6339801F81D63B96"
      unitRef="shares">1100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-1"
      id="d34594690e6894-wk-Fact-84A4BDBCAB54D15D1AF7801F7E59E635"
      unitRef="Employee">90</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected>
    <pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_PerformanceSharesMember"
      decimals="-5"
      id="d34594690e6898-wk-Fact-D2A25D922C72BAD1CD55801F82818882"
      unitRef="shares">1100000</pfe:SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD_srt_TitleOfIndividualAxis_srt_ManagementMember"
      decimals="INF"
      id="d34594690e6947-wk-Fact-E8380CA4CC1832D7F1D6801F7E364403"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e6951-wk-Fact-1BDDB8FA0086FEFE3E84801F7E34FBF6">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e6955-wk-Fact-B925A635A947F49C1FB6801F7E22032D">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e6959-wk-Fact-23C1B858911534788A6D801F8287D171">P1Y</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod>
    <pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e6963-wk-Fact-30F3ED4239BD3CD5FAE0801F7E3F9C14">P3M</pfe:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-E3D77D1B0B694446EE3A801F834DABEE-0-wk-Fact-CF9993CE236C60BE28E1801F7E491E5E">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.40476190476191%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="10"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:55%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the weighted-average assumptions used in the valuation of stock options:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.27&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;3.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2.66&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.85&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2.23&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected stock price volatility&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;18.34&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;20.02&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;18.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Expected term (years)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6.75&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using a constant dividend yield during the expected term of the option.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using the interpolated yield on U.S. Treasury zero-coupon issues.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using implied volatility, after consideration of historical volatility.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Determined using historical exercise and post-vesting termination patterns.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7166-wk-Fact-73C56959049A2D57F4C1801F82A49C55"
      unitRef="number">0.0327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7181-wk-Fact-1A163CFC61DB374C9859801F82396806"
      unitRef="number">0.0373</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7196-wk-Fact-CD039103D85D7763C03A801F82921CA3"
      unitRef="number">0.0369</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7219-wk-Fact-096BFE17591BD0B2DDDC801F823E3221"
      unitRef="number">0.0266</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7234-wk-Fact-DDA3C772DD5D6A9CF860801F82921818"
      unitRef="number">0.0285</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7249-wk-Fact-56D7F8DD1BDAEA1F8A93801F82A07FA6"
      unitRef="number">0.0223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7272-wk-Fact-F46555EB6318EAAE369C801F8291F711"
      unitRef="number">0.1834</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7287-wk-Fact-2C386152CD1597FBF4FA801F82A1CFF0"
      unitRef="number">0.2002</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="4"
      id="d34594690e7302-wk-Fact-E385705FB7C3A2995158801F82A7D035"
      unitRef="number">0.1839</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e7325-wk-Fact-EE8C91D96F98673768FF801F82A21974">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e7339-wk-Fact-32EF9B5301DDDEC38EC0801F829FDB14">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e7353-wk-Fact-31F361F21F2837AACE1C801F82A5E94F">P6Y9M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-EC14A9316BF8E3C0C206801F834CFB5F-0-wk-Fact-984F3EC33CFD7DC2074C801F7EDA5393">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="14"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:39%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:11%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:15%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:13%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes all stock option activity during 2019:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Thousands)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Per Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Remaining Contractual Term&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Aggregate&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Intrinsic Value&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(Millions)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Outstanding, December 31, 2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;103,791&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;27.69&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Granted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,181&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;43.35&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercised&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(15,964&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;24.84&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Forfeited&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(55&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;37.67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Expired&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;(353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;31.12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Outstanding, December 31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;88,600&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;28.39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Vested and expected to vest, December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;88,469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;28.37&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;960&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Exercisable, December&#160;31, 2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;85,372&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;28.04&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;3.4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;951&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Market price of our underlying common stock less exercise price.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;The number of options expected to vest takes into account an estimate of expected forfeitures.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:73%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:6%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-top:8px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table summarizes data related to all stock option activity:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year&#160;Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average grant-date fair value per stock option&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5.98&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5.06&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4.01&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Aggregate intrinsic value on exercise&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;331&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash received upon exercise&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;394&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,259&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;862&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Tax benefits realized related to exercise&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;115&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;95&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Total compensation cost related to nonvested stock options not yet recognized, pre-tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average period over which stock option compensation cost is expected to be recognized (years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.6&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.7&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;0.8&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2018Q4"
      decimals="-3"
      id="d34594690e7617-wk-Fact-D4E3E637EF0690450C82801F7E2E025D"
      unitRef="shares">103791000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2018Q4"
      decimals="2"
      id="d34594690e7636-wk-Fact-54DD743A1F7FEBC19886801F7E57C69D"
      unitRef="usdPerShare">27.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d34594690e7687-wk-Fact-0F223FFC4C2BD7F30C2B801F7E557E89"
      unitRef="shares">1181000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34594690e7701-wk-Fact-A69421D1832E5C73D7A3801F7E462E9A"
      unitRef="usdPerShare">43.35</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d34594690e7757-wk-Fact-F292BE49551CBC3A3875801F7E37D4DE"
      unitRef="shares">15964000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34594690e7772-wk-Fact-475BA0477B8C782E4919801F7E44D883"
      unitRef="usdPerShare">24.84</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d34594690e7828-wk-Fact-1E235321A2F6C23760F4801F7E43B41B"
      unitRef="shares">55000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34594690e7843-wk-Fact-D314A88FEE632A5D5ECF801F7E4902CB"
      unitRef="usdPerShare">37.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="FD2019Q4YTD"
      decimals="-3"
      id="d34594690e7899-wk-Fact-905B4772CC6EB5CF0191801F7E57B9B4"
      unitRef="shares">353000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34594690e7914-wk-Fact-52B424F297F261DAF67F801F7E4A1996"
      unitRef="usdPerShare">31.12</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="FI2019Q4"
      decimals="-3"
      id="d34594690e7970-wk-Fact-8B357FFC428B1525E9B5801F7E45D0DC"
      unitRef="shares">88600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d34594690e7984-wk-Fact-F6CDEA395E802562E37E801F7E4A30B5"
      unitRef="usdPerShare">28.39</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="FD2019Q4YTD"
      id="d34594690e8003-wk-Fact-1B2390B50A69D00EA43E801F7E64C531">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34594690e8019-wk-Fact-DAD0CA8E455F2B5DC7FA801F7E585E15"
      unitRef="usd">960000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="FI2019Q4"
      decimals="-3"
      id="d34594690e8043-wk-Fact-DD2FFFF9189C3FA5A3DB801F7E4AF4C6"
      unitRef="shares">88469000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d34594690e8057-wk-Fact-150B8237E6AC43FC08DF801F7E45E25C"
      unitRef="usdPerShare">28.37</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q4YTD"
      id="d34594690e8076-wk-Fact-CB7E2DB668A75D5161C1801F7E45DB8D">P3Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34594690e8087-wk-Fact-A41309C827BD3760EAD4801F7E667623"
      unitRef="usd">960000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="FI2019Q4"
      decimals="-3"
      id="d34594690e8112-wk-Fact-C944C10F71C19D743431801F7E56B988"
      unitRef="shares">85372000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="FI2019Q4"
      decimals="2"
      id="d34594690e8131-wk-Fact-B00F20EB6975ADFEFC60801F7E68B215"
      unitRef="usdPerShare">28.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="FD2019Q4YTD"
      id="d34594690e8145-wk-Fact-B50C97854BE5E73FA65D801F7E67CAEB">P3Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34594690e8161-wk-Fact-6E8F52F802E68107D2ED801F7E65A2D6"
      unitRef="usd">951000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2019Q4YTD"
      decimals="2"
      id="d34594690e8438-wk-Fact-92FA252097F1F382AB2C801F82504C90"
      unitRef="usdPerShare">5.98</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2018Q4YTD"
      decimals="2"
      id="d34594690e8457-wk-Fact-F7E869ED96C460CA6626801F8253E013"
      unitRef="usdPerShare">5.06</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="FD2017Q4YTD"
      decimals="2"
      id="d34594690e8477-wk-Fact-849D683D90D44D0EAF9E801F8249337B"
      unitRef="usdPerShare">4.01</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34594690e8502-wk-Fact-EF5C8AAC79BA024D6528801F82519503"
      unitRef="usd">261000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34594690e8521-wk-Fact-C8F488B488483C72F432801F824CF953"
      unitRef="usd">625000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34594690e8541-wk-Fact-B145092A83B74EA499B9801F824910A5"
      unitRef="usd">331000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34594690e8566-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0"
      unitRef="usd">394000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34594690e8585-wk-Fact-CF6EA013BF1855E39D139D5A4C827484"
      unitRef="usd">1259000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34594690e8605-wk-Fact-43172D93073829A17FB6801F82AF4ECB"
      unitRef="usd">862000000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34594690e8630-wk-Fact-84F4790DBB7067158401801F824E0FB2"
      unitRef="usd">47000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34594690e8649-wk-Fact-6B1D8CED7A79238FF8E5801F8250F204"
      unitRef="usd">115000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34594690e8669-wk-Fact-83E956A7B5BCAE136250801F825B51AD"
      unitRef="usd">95000000</us-gaap:EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2019Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-6"
      id="d34594690e8694-wk-Fact-19BA8460C55A7E677DDD801F82522A11"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2018Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-6"
      id="d34594690e8713-wk-Fact-A1220BA84C82A0B53EC3801F825790F8"
      unitRef="usd">5000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="FI2017Q4_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      decimals="-6"
      id="d34594690e8733-wk-Fact-3B7F4666E688C266A166801F824F031D"
      unitRef="usd">10000000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2019Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e8753-wk-Fact-352195F82B7F2C9C5D40801F824B42AE">P1Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2018Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e8772-wk-Fact-ED5A183817B37C3637C8801F824CFB89">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="FD2017Q4YTD_us-gaap_AwardTypeAxis_us-gaap_EmployeeStockOptionMember"
      id="d34594690e8791-wk-Fact-4367012342069C45EF1F801F824D50BD">P0Y9M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-4C005DB9DFA3855AB83B801F834D6ABA-0-wk-Fact-563526BF9B4C663E8C19801F7ED71355">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the detailed calculation of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Earnings per common share&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;(EPS)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(IN MILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Discontinued operations&#x2013;&#x2013;net of tax, attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;EPS Denominator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash dividends declared per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017 includes the effect of the modification for a commitment to pay &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;15.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-D182ACB558010258E6A6801F834D421E-0-wk-Fact-165DA1181120ADC0E624801F7ED72DEF">&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:67%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides the detailed calculation of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Earnings per common share&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;(EPS)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31, &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(IN MILLIONS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Basic&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,179&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,353&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Net income attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;47&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations attributable to Pfizer Inc.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Preferred stock dividends&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,268&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Less: Discontinued operations&#x2013;&#x2013;net of tax, attributable to noncontrolling interests&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net income attributable to Pfizer Inc. common shareholders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,272&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,152&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,307&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;EPS Numerator&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,143&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Discontinued operations&#x2013;&#x2013;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Net income attributable to Pfizer Inc. common shareholders and assumed conversions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;16,273&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,153&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;21,308&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;EPS Denominator&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Basic&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,569&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,872&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;106&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;89&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Weighted-average number of common shares outstanding&#x2013;&#x2013;Diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;5,675&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;5,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,058&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;2&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Cash dividends declared per share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1.46&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1.30&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017 includes the effect of the modification for a commitment to pay &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;15.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e1616-wk-Fact-0035B9C9DB225A72A990E1262460243C"
      unitRef="usd">16298000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e1635-wk-Fact-F7E834DB2C365543A0147187D74A1E82"
      unitRef="usd">11179000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e1655-wk-Fact-7AB6A34649A53C89765A801F808558FA"
      unitRef="usd">21353000000</us-gaap:IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e1675-wk-Fact-F23EAD7DE306562A925D2F7D3A1596DB"
      unitRef="usd">29000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e1694-wk-Fact-C2E59E9312A2513BBF73058FCB5316FD"
      unitRef="usd">36000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e1713-wk-Fact-80D79FBFC60C79D8ED0A801F7F23174B"
      unitRef="usd">47000000</us-gaap:IncomeLossFromContinuingOperationsAttributableToNoncontrollingEntity>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e1739-wk-Fact-20A6B513F10556A58D86CF6794E1A92E"
      unitRef="usd">16269000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e1758-wk-Fact-B28BB414FBBC5123A11532CA6D6B9C9B"
      unitRef="usd">11143000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:IncomeLossFromContinuingOperations
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e1777-wk-Fact-676ED17534D4A1DDF4E5801F812EB833"
      unitRef="usd">21306000000</us-gaap:IncomeLossFromContinuingOperations>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e1803-wk-Fact-73E70C0071435DCDA89552E8E50E2520"
      unitRef="usd">1000000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e1822-wk-Fact-0E98726E17DF5FD5994E3EDBBD540CC6"
      unitRef="usd">1000000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <us-gaap:PreferredStockDividendsIncomeStatementImpact
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e1841-wk-Fact-687559E643972585D475801F813FF631"
      unitRef="usd">1000000</us-gaap:PreferredStockDividendsIncomeStatementImpact>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e1867-wk-Fact-6AE8267207D25ED2A3F79F71445B5011"
      unitRef="usd">16268000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e1886-wk-Fact-4AF655CA2FA158BDB94642F5C12FEDAB"
      unitRef="usd">11142000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e1905-wk-Fact-F7971B440B9DAE93D538801F8148DAA9"
      unitRef="usd">21305000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersBasic>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e1931-wk-Fact-324E930EA3FE51309DAF874C15316ACB"
      unitRef="usd">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e1950-wk-Fact-08237D5DF91153BBBDE19A688EC551B8"
      unitRef="usd">10000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e1969-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F"
      unitRef="usd">2000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTax>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e1995-wk-Fact-9AC24A4B2A115C0FBCF42D71854AAB49"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2014-wk-Fact-089D98C9534857528D87686ADB3F11AD"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2033-wk-Fact-50B16320C587C88A23ED801F7F5AFA61"
      unitRef="usd">0</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToNoncontrollingInterest>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e2060-wk-Fact-FCE9F14CE3D15A8981141CD50168E91E"
      unitRef="usd">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2079-wk-Fact-EB7E7431973953F2B7E9EB2F0A78493F"
      unitRef="usd">10000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2098-wk-Fact-D27E8EDC863863FCD349801F7F4E91B2"
      unitRef="usd">2000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e2129-wk-Fact-012C63720C6854C98D6A6253DCA558A5"
      unitRef="usd">16272000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2148-wk-Fact-D7011577FDBF586698D386953D4E65EA"
      unitRef="usd">11152000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2168-wk-Fact-AA915253D7955702F6D7801F7F54B77E"
      unitRef="usd">21307000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e2258-wk-Fact-A00920C2431522B2968C801F7F224E5F"
      unitRef="usd">16269000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2277-wk-Fact-5C85FF62621855588051D90715E8692E"
      unitRef="usd">11143000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2297-wk-Fact-426E8633C226972EAFC1801F7F512F5E"
      unitRef="usd">21306000000</pfe:IncomeLossFromContinuingOperationsAvailableToCommonStockholdersdiluted>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e2317-wk-Fact-FCE9F14CE3D15A8981141CD50168E91E"
      unitRef="usd">4000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2336-wk-Fact-EB7E7431973953F2B7E9EB2F0A78493F"
      unitRef="usd">10000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2355-wk-Fact-D27E8EDC863863FCD349801F7F4E91B2"
      unitRef="usd">2000000</us-gaap:IncomeLossFromDiscontinuedOperationsNetOfTaxAttributableToReportingEntity>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e2386-wk-Fact-EE583BC53A585E028A64E196788A920E"
      unitRef="usd">16273000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2405-wk-Fact-B7FA3547783950158A5DFFD4B6A7F6FA"
      unitRef="usd">11153000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2425-wk-Fact-13BB9B6FD324E2C231C3801F810694AE"
      unitRef="usd">21308000000</us-gaap:NetIncomeLossAvailableToCommonStockholdersDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e2512-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
      unitRef="shares">5569000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2531-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
      unitRef="shares">5872000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2550-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
      unitRef="shares">5970000000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e2578-wk-Fact-31994C39581B5B71BDDB9AE8FC22964B"
      unitRef="shares">106000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2597-wk-Fact-F9C9FEE2CCBF5BBAB626316FA2913D2A"
      unitRef="shares">105000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2616-wk-Fact-027BA945C36E755C6E0D801F8147CCD2"
      unitRef="shares">89000000</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34523018e2642-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027"
      unitRef="shares">5675000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34523018e2661-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
      unitRef="shares">5977000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34523018e2680-wk-Fact-769F1280EBF192E593C5801F7F419E21"
      unitRef="shares">6058000000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2019Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember"
      decimals="-6"
      id="d34523018e2708-wk-Fact-0E154CA77D6B55F38225A9B701605CD5"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2018Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember"
      decimals="-6"
      id="d34523018e2727-wk-Fact-496231284B82551EA3C09B63129DD116"
      unitRef="shares">2000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="FD2017Q4YTD_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_StockOptionMember"
      decimals="-6"
      id="d34523018e2746-wk-Fact-699213AA4BB320044F47801F81563F2E"
      unitRef="shares">36000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d34523018e2778-wk-Fact-089AD09C4BEB171B6FF2801F7F4F7B82"
      unitRef="usdPerShare">1.46</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d34523018e2797-wk-Fact-2741C1D79AE51A3A6FE9D8F59BF430AA"
      unitRef="usdPerShare">1.38</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="FD2017Q4YTD"
      decimals="INF"
      id="d34523018e2817-wk-Fact-0FEBECF7E5E8F3317B88D8F59BFD549F"
      unitRef="usdPerShare">1.30</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber
      contextRef="FD2017Q4YTD_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember"
      decimals="-5"
      id="d34523018e2837-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639"
      unitRef="shares">15200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber>
    <pfe:InsuranceCoverageDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-047EDAAD7B2238581654801F834FAD00-0-wk-Fact-ADC2FE3D389128BE8187801F81533A57">Insurance&lt;div style="line-height:120%;padding-top:4px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#1f497d;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued (see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 16&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;).&lt;/span&gt;&lt;/div&gt;</pfe:InsuranceCoverageDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-71FDA1D27EDA67EBAA6A801F834F2A06-0-wk-Fact-BF1B990B04C3A652FB58801F828C45FC">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Contingencies and Certain Commitments&lt;/span&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5D.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; For a discussion of our legal contingencies, see below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Legal Proceedings&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Our legal contingencies include, but are not limited to, the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#x2019;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A1&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Legal Proceedings&#x2013;&#x2013;Patent Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents. In June 2018, the PTAB ruled on another patent, holding that &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision. In November 2019, the U.S. Court of Appeals for the Federal Circuit vacated the PTAB&#x2019;s ruling and requested that the PTAB redecide the challenge.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We have appealed. Challenges to other patents remain pending in jurisdictions outside the U.S.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#1f497d;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Actions In Which We Are The Plaintiff&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#x2019;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Precedex Premix&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Beginning in 2014, several generic manufacturers filed separate abbreviated new drug applications with the FDA, seeking approval to market their generic versions of our subsidiary Hospira&#x2019;s premix version of Precedex prior to the expiration of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; or more patents covering the product. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;One&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of those patents expired in March 2019, while others do not expire until 2032. Beginning in 2014, Hospira brought suit against these generic manufacturers, in some cases joined by Orion Corporation (co-owner of certain of our Precedex premix patents). To date, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the actions have been settled or dismissed on terms not material to Pfizer: (i) the action filed against Ben Venue Laboratories, Inc., which was sued along with Hikma Pharmaceuticals PLC (together, succeeded by Eurohealth International Sarl) and West-Ward Pharmaceuticals Corp (collectively, the Ben Venue case); and (ii) the action filed against Baxter Healthcare Corporation. The remaining actions continue as described below. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In August 2015, Hospira filed suit against Amneal Pharmaceuticals LLC (Amneal) in the U.S. District Court for the District of Delaware asserting the validity and infringement of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents relating to the Precedex premix formulations and their use, all of which expire in 2032. In January 2018, the District Court ruled that &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents was valid and infringed, and that the other &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents were invalid. In February and March 2018, respectively, each of Amneal and Hospira appealed the District Court decision to the U.S. Court of Appeals for the Federal Circuit. In January 2019, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#x2019;s decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#x2019;s premix version of Precedex and containing allegations that certain patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois, asserting the validity and infringement of those patents. In December 2018, the District Court ruled that the asserted claims of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents were invalid. Hospira appealed the District Court&#x2019;s decision as to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the patents to the U.S. Court of Appeals for the Federal Circuit. In January 2020, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#x2019;s decision. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Separate actions in which Hospira sued Par Sterile Products LLC, Gland Pharma Limited, and Jiangsu Hengrui Medicine Co., Ltd., each in response to such generic manufacturer&#x2019;s filing of a separate abbreviated new drug application with the FDA, seeking approval to market their generic versions of our subsidiary Hospira&#x2019;s premix version of Precedex prior to the expiration of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; or more patents covering the product, were stayed pending the outcome of the case against Fresenius described above. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Xeljanz (tofacitinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications with the FDA, seeking approval to market their generic versions of tofacitinib tablets in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;one&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, actions against the following generic manufacturers have been settled on terms not material to Pfizer: (i) MicroLabs USA Inc. and MicroLabs Ltd.; (ii) Sun Pharmaceutical Industries Ltd.; (iii) Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC; and (iv) Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. The remaining actions continue as described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In March 2019, we brought a separate patent infringement action against Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, Ajanta) in the U.S. District Court for the District of Delaware asserting the infringement and validity of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents: the patent covering the active ingredient that expires in December 2025 and the patent covering a polymorphic form of tofacitinib that expires in 2023, each of which Ajanta challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In August 2019, in response to a similar challenge by Ajanta relating the tofacitinib 10 mg tablets, we brought another patent infringement action against Ajanta in the U.S. District Court for the District of Delaware.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Inlyta (axitinib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Kerydin (tavaborole)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Ibrance (palbociclib)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Chantix (varenicline) &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In January 2020, we brought a patent infringement action against Viwit Pharmaceutical Co. Ltd. (Viwit) in the U.S. District Court for the District of Delaware, asserting the validity and infringement of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents challenged by Viwit in its abbreviated new drug application seeking approval to market a generic version of varenicline, 0.5 mg &#160;and 1.0 mg tablets.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Matter Involving Our Collaboration/Licensing Partners&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Eliquis&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In February, March, and April 2017, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;twenty-five&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents listed in the Orange Book for Eliquis. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;One&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#x2019; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents. We and BMS have settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;Action In Which We Are The Defendant&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Inflectra (infliximab-dyyb)&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;six&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents relating to infliximab, its manufacture and use. Claims with respect to &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;four&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of the patents were dismissed by the plaintiffs, leaving &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; patents at issue: the infliximab antibody patent and a patent relating to cell culture media. In January 2018, the antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, the U.S. District Court for the District of Massachusetts granted defendants&#x2019; motion for summary judgment and ruled that the patent relating to cell culture media was not infringed. Janssen appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Federal Circuit. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A2. Legal Proceedings&#x2013;&#x2013;Product Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Asbestos&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Claims against American Optical and numerous other defendants are pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#x2019; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In October 2014, the District Court dismissed the direct purchaser plaintiffs&#x2019; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Antitrust Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#x2019; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In re Lipitor Antitrust Litigation MDL-2332&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) in the U.S. District&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#0000ff;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Court for the District of New Jersey. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#x2019;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#x2019;s decisions and remanded the claims to the District Court.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#x2019;s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court&#x2019;s decision.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Viagra&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Lilly with respect to Cialis have also been consolidated in the Multi-District Litigation &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;(In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;). In January 2020, the District Court granted our and Lilly&#x2019;s motion to exclude all of plaintiffs&#x2019; general causation opinions. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Intravenous Solutions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and certain other defendants relating to intravenous saline solution. Plaintiffs seek to represent a class consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants&#x2019; allegedly unlawful conduct ceases. Plaintiffs allege that the defendants&#x2019; conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. All of these actions have been consolidated in the U.S. District Court for the Northern District of Illinois. In July 2018, the District Court granted defendants&#x2019; motions to dismiss the consolidated amended complaint without prejudice. Plaintiffs filed a second amended complaint in September 2018. On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, which includes intravenous saline solution, to ICU Medical. The litigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Hormone Therapy Consumer Class Action&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A certified consumer class action is pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth&#x2019;s hormone-replacement products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a full refund of the purchase price.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#x2019; allegedly unlawful conduct. In August 2017, a similar lawsuit brought in the U.S. District Court for the District of New Jersey on behalf of a purported class of direct purchaser plaintiffs against Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. In February 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#x2019;s and/or its affiliates&#x2019; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust laws. At least &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;one&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act. Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2009. In August 2017, all of these actions, except for the 2020 lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, MDL-2785&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Nexium 24HR and Protonix&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In re: Proton-Pump Inhibitor Products Liability Litigation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (No. II)) in the U.S. District Court for the District of New Jersey. On July&#160;31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. As part of the joint venture transaction, the joint venture has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Docetaxel&#160;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Personal Injury Actions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In re Taxotere (Docetaxel) Products Liability Litigation, MDL-2740&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) in the U.S. District Court for the Eastern District of Louisiana.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;eight&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Array Securities Litigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In November 2017, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in July 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In March 2018, the actions were consolidated into a single proceeding. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Zantac &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;A number of lawsuits have been filed against Pfizer in various federal courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and sold Zantac. Pfizer has not sold Zantac since 2006. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In February 2020, these federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In re Zantac/Ranitidine NDMA Litigation, MDL-2924&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) in the U.S. District Court for the Southern District of Florida. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Legal Proceedings&#x2013;&#x2013;Commercial and Other Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Monsanto-Related Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp;amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#x2019;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#x2019;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#x2019;s indemnification obligations relating to Former Monsanto&#x2019;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#x2019;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#x2019;s and New Monsanto&#x2019;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#x2019;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#x2019;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Environmental Matters&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#x2019;s discontinued industrial chemical facility in North Haven, Connecticut. In September 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In September 2019, the EPA acknowledged that construction of the site remedy has been completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Also, in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#x2019;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#x2019;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. In September 2018, the EPA issued a final remediation plan for the &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and in September 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In October 2017, a number of United States service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2018, the U.S. Department of Justice requested documents related to this matter, which are being provided.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Allergan Complaint for Indemnity&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In August 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In re National Prescription Opiate Litigation MDL 2804&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In December 2018, the District Court dismissed the lawsuit. In February 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:5pt;"&gt;&lt;span style="font-family:Arial;font-size:5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Breach of Contract&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pfizer is a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#x2019;s sales of&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;color:#212529;"&gt;Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; The action was originally filed in 2013. In December 2015, the Supreme Court dismissed the action and in May 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#x2019; summary judgment motions.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A4. Legal Proceedings&#x2013;&#x2013;Government Investigations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; Among the investigations by government agencies are the matters discussed below.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Phenytoin Sodium Capsules&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In May 2013, the U.K. Competition &amp;amp; Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market. In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust laws. In December 2016, the CMA imposed a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;&#xa3;84.2 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; fine on Pfizer and Pfizer Limited. Pfizer appealed the CMA decision to The Competition Appeal Tribunal in February 2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On June 7, 2018, the Competition Appeal Tribunal overturned the CMA decision as well as the associated fine. The CMA appealed the judgment to the Court of Appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Greenstone Investigations&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;U.S. Department of Justice Antitrust Division Investigation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;State Attorneys General Generics Antitrust Litigation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;In re: Generic Pharmaceuticals Pricing Antitrust Litigation MDL No. 2724)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Subpoena relating to Manufacturing of Quillivant XR&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In October 2018, we received a subpoena from the U.S. Attorney&#x2019;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Government Inquiries relating to Meridian Medical Technologies &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In February 2019, we received a civil investigative demand from the U.S. Attorney&#x2019;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#x2019;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;U.S. Department of Justice/SEC Inquiry relating to Russian Operations&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In June 2019, we received an informal request from the U.S. Department of Justice&#x2019;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#x2019;s FCPA unit. We are producing records pursuant to these requests. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 16A3. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Contingencies and Certain Commitments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;: Legal Proceedings&#x2013;&#x2013;Commercial and Other Matters&#x2013;&#x2013;Contracts with Iraqi Ministry of Health&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; above for information regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Docetaxel&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 16A2. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;"&gt;Contingencies and Certain Commitments&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;: Legal Proceedings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Product Litigation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Docetaxel&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2013;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Mississippi Attorney General Government Investigation&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; above for information regarding a government investigation related to Docetaxel marketing practices.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B. Guarantees and Indemnifications&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the estimated fair value of these indemnification obligations was not significant. &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;In addition, in connection with our entry into certain agreements, our counterparties agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. Certain Commitments&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, we had agreements totaling &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$2.5 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; to purchase goods and services that are enforceable and legally binding and include amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur, as well as obligations to make guaranteed fixed annual payments over a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;seven&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year period in connection with the U.S. and EU approvals for Besponsa (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$412 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;) and an obligation to make guaranteed fixed annual payments over an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;eight&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;-year period for Bosulif (&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$217 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;), both associated with R&amp;amp;D arrangements.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, in connection with the TCJA, we have an estimated &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$15 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; repatriation tax liability on accumulated post-1986 earnings of foreign subsidiaries for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. With respect to the aforementioned repatriation tax liability, it is reported in current &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income taxes payable&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; (approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$600 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; due in April 2020) and the remaining liability is reported in noncurrent &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other taxes payable &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;in our consolidated balance sheet as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The first installment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$750 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; was paid in April 2019. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 5A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;D. Contingent Consideration for Acquisitions&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We may be required to make contingent consideration payments to sellers for certain prior business combinations. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1D&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The estimated fair value of contingent consideration as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$711 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$160 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$551 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The estimated fair value of contingent consideration as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$988 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, of which &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$280 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other current liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$708 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; is recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Other noncurrent liabilities&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The decrease in the contingent consideration balance from prior year is primarily due to payments made upon the achievement of certain milestones.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <pfe:GainContingencyPatentsWithoutCourtProceedingsNumber
      contextRef="D2017Q4Oct01-Oct31_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember"
      decimals="INF"
      id="d34558932e1411-wk-Fact-86074884B8895C2C906E2CE766860B2D"
      unitRef="Patent">2</pfe:GainContingencyPatentsWithoutCourtProceedingsNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2018Q2Jun01-Jun30_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_JudicialRulingMember"
      decimals="INF"
      id="d34558932e1415-wk-Fact-C80F69DE66A8525F9363880D94B391A7"
      unitRef="Patent">1</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber
      contextRef="FD2014Q4YTD_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1451-wk-Fact-1BD84B766FCD5E91BA884741D04C98FC"
      unitRef="Patent">1</pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019
      contextRef="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember"
      decimals="INF"
      id="d34558932e1455-wk-Fact-695196B6D3E7A1F5C2667E30227AC8FF"
      unitRef="Patent">1</pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="D2019Q4Dec31-31_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember"
      decimals="INF"
      id="d34558932e1459-wk-Fact-A8C7E11E02C52648F192DE89AC2F2D9C"
      unitRef="Patent">2</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber
      contextRef="D2015Q3Aug1-31_srt_LitigationCaseAxis_pfe_HospiraVersusParMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1469-wk-Fact-9A4D92389A7750658CECD5B29ED0277A"
      unitRef="Patent">4</pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundInfringedUponNumber
      contextRef="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember"
      decimals="INF"
      id="d34558932e1473-wk-Fact-B33693F542A330BD344B01837126C014"
      unitRef="Patent">1</us-gaap:GainContingencyPatentsFoundInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber
      contextRef="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusParMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1477-wk-Fact-87B491021A620CFDBA49017BE93B5017"
      unitRef="Patent">4</pfe:GainContingencyPatentsAllegedlyNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="D2018Q1Jan2018_srt_LitigationCaseAxis_pfe_HospiraVersusAmnealPharmaceuticalsLLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember"
      decimals="INF"
      id="d34558932e1481-wk-Fact-CC7A45E10285DB31D4DF01839F476D98"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber
      contextRef="D2018Q4Dec1-31_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember"
      decimals="INF"
      id="d34558932e1490-wk-Fact-E375D51843A56BC7AA630C260D89BD0E"
      unitRef="Patent">2</us-gaap:GainContingencyPatentsFoundNotInfringedUponNumber>
    <pfe:GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber
      contextRef="FD2019Q4YTD_srt_LitigationCaseAxis_pfe_HospiraVersusFreseniusKabjUSALLCMember_srt_ProductOrServiceAxis_pfe_PrecedexPremixMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember"
      decimals="INF"
      id="d34558932e1494-wk-Fact-D923CB6FB410CB214D4201900CBD5914"
      unitRef="Patent">1</pfe:GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusZydusMember_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1522-wk-Fact-168623731935273CE8C30187B4B73E40"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusAjantaMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1537-wk-Fact-962CF888D231519CA26A5936A713ECAD"
      unitRef="Patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2019Q1Mar01-Mar31_srt_LitigationCaseAxis_pfe_PfizerVersusGenericCompaniesMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1575-wk-Fact-D97E0D8502645F93925811BE613337A1"
      unitRef="Patent">2</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2020Q1Jan1-31_srt_LitigationCaseAxis_pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember"
      decimals="INF"
      id="d34558932e1588-wk-Fact-89781F2774D8748608F17E329A160847"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyNumberofDefendants
      contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1601-wk-Fact-82F5C9F5234A5BA3A4F2084B696726A1"
      unitRef="Defendant">25</pfe:GainContingencyNumberofDefendants>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1605-wk-Fact-0EEFB150D722521B96F4D6AB8B769B9F"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019
      contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1609-wk-Fact-DB4D0502208C148C6BF3DE99551EF741"
      unitRef="Patent">1</pfe:GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019>
    <us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber
      contextRef="D2017Q2Feb01-Apr30_srt_LitigationCaseAxis_pfe_PfizerandBMSVersusSeveralGenericManufacturersMember_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_GainContingenciesByNatureAxis_pfe_PatentInfringementMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1613-wk-Fact-0EEFB150D722521B96F4D6AB8B769B9F"
      unitRef="Patent">3</us-gaap:GainContingencyPatentsAllegedlyInfringedUponNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember"
      decimals="INF"
      id="d34558932e1626-wk-Fact-A9297EA354685CF6AE402F34561612D9"
      unitRef="Patent">6</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <us-gaap:LossContingencyClaimsDismissedNumber
      contextRef="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember_us-gaap_LitigationStatusAxis_us-gaap_SettledLitigationMember"
      decimals="INF"
      id="d34558932e1630-wk-Fact-04284ACF683C5988A8FB935618DBEEBF"
      unitRef="Patent">4</us-gaap:LossContingencyClaimsDismissedNumber>
    <us-gaap:LossContingencyPatentsAllegedlyInfringedNumber
      contextRef="D2015Q1March2015_srt_LitigationCaseAxis_pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member_srt_ProductOrServiceAxis_pfe_InflectraMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1634-wk-Fact-03E4F32ED141575FA456592B789220C0"
      unitRef="Patent">2</us-gaap:LossContingencyPatentsAllegedlyInfringedNumber>
    <pfe:LossContingencyNumberOfLawsuits
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_EpiPenMember_srt_RangeAxis_srt_MinimumMember"
      decimals="INF"
      id="d34558932e1763-wk-Fact-2070907F0D6C56158D8777FFE08CA3A6"
      unitRef="lawsuit">1</pfe:LossContingencyNumberOfLawsuits>
    <pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant
      contextRef="D2018Q4Oct01-Oct31_srt_LitigationCaseAxis_pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember_srt_ProductOrServiceAxis_pfe_DocetaxelMember_us-gaap_LitigationStatusAxis_us-gaap_PendingLitigationMember"
      decimals="INF"
      id="d34558932e1812-wk-Fact-DF81DC3320DC58FC987DFBA3A82F1BC9"
      unitRef="manufacturer">8</pfe:LossContingencyNumberOfDefendantsOtherThanMainDefendant>
    <pfe:LossContingencyClassActionsFiledNumber
      contextRef="D2017Q4Nov2017"
      decimals="INF"
      id="d34558932e1822-wk-Fact-049E0E0B377C5900929BD3E0069DB2AD"
      unitRef="class_action">2</pfe:LossContingencyClassActionsFiledNumber>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="D2013Q1MonthOfMarch_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember"
      decimals="INF"
      id="d34558932e1870-wk-Fact-3A733DE7E05D54E4B303735F7E0AAEE4"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <pfe:FeasibilityStudyNumberOfLagoons
      contextRef="D2018Q3Sep01-Sep30_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_EnvironmentalRemediationLitigationMember"
      decimals="INF"
      id="d34558932e1874-wk-Fact-DDD1CB6E0B38554486629FCE56E3CE83"
      unitRef="lagoon">2</pfe:FeasibilityStudyNumberOfLagoons>
    <us-gaap:LossContingencyEstimateOfPossibleLoss
      contextRef="FI2016Q4_srt_ProductOrServiceAxis_pfe_PhenytoinSodiumCapsulesMember_us-gaap_LossContingenciesByNatureOfContingencyAxis_pfe_ViolationofAntitrustLawsMember"
      decimals="-5"
      id="d34558932e1940-wk-Fact-10E0AA7E05785EB8B65BF3D6F290EA33"
      unitRef="gbp">84200000</us-gaap:LossContingencyEstimateOfPossibleLoss>
    <us-gaap:LongTermPurchaseCommitmentAmount
      contextRef="FD2019Q4YTD"
      decimals="-8"
      id="d34558932e2070-wk-Fact-EF7451461450FE24E0FA801F7E11F8D4"
      unitRef="usd">2500000000</us-gaap:LongTermPurchaseCommitmentAmount>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BesponsaMember"
      decimals="-6"
      id="d34558932e2078-wk-Fact-0B2FA3640980E2BAB54D801F8283053C"
      unitRef="usd">412000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation
      contextRef="FI2019Q4_srt_ProductOrServiceAxis_pfe_BosulifMember"
      decimals="-6"
      id="d34558932e2087-wk-Fact-A4575347EB6532721CC2801F8290C485"
      unitRef="usd">217000000</pfe:ResearchandDevelopmentArrangementAggregatePaymentObligation>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="FI2019Q4"
      decimals="-9"
      id="d34558932e2103-wk-Fact-8EF9B5A847D55767BF5A5596B994B8F5"
      unitRef="usd">15000000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability
      contextRef="FI2019Q4_us-gaap_BalanceSheetLocationAxis_pfe_IncomeTaxesPayableMember"
      decimals="-6"
      id="d34558932e2111-wk-Fact-7574A578AC5453EE80D42498A2BBDAA5"
      unitRef="usd">600000000</us-gaap:TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability>
    <pfe:PaymentForRepatriationTax
      contextRef="D2019Q2Apr01-Apr30"
      decimals="-6"
      id="d34558932e2124-wk-Fact-71130497423450AA97DB57267DA5E202"
      unitRef="usd">750000000</pfe:PaymentForRepatriationTax>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34558932e2146-wk-Fact-498886C5C2B6716529BC0275CA691D29"
      unitRef="usd">711000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34558932e2150-wk-Fact-8DCEE1A254094A81CFDD0281A44DAD1A"
      unitRef="usd">160000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34558932e2159-wk-Fact-9ED6AEC039293C11188A028320F52725"
      unitRef="usd">551000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiability
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34558932e2171-wk-Fact-0F944687F28C52ABCBB60275FEF74B94"
      unitRef="usd">988000000</us-gaap:BusinessCombinationContingentConsiderationLiability>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34558932e2175-wk-Fact-3B8B41DA51CC78D751480281ED97E91C"
      unitRef="usd">280000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityCurrent>
    <us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34558932e2184-wk-Fact-A6F57C90CD95CF105E54028498AFC178"
      unitRef="usd">708000000</us-gaap:BusinessCombinationContingentConsiderationLiabilityNoncurrent>
    <us-gaap:SegmentReportingDisclosureTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-95E0041F8DF21F63C4E7801F8353EDD5-0-wk-Fact-7FD6653F6AD0965AEEFB801F821F0749">&lt;span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"&gt;Segment, Geographic and Other Revenue Information&lt;/span&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;A. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Segment Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We regularly review our segments and the approach used by management to evaluate performance and allocate resources. Prior to January 1, 2019, we managed our commercial operations through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;two&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our fiscal year 2019, we reorganized our commercial operations and began to manage our commercial operations through a new global structure consisting of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;three&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; distinct business segments: Pfizer Biopharmaceuticals Group (Biopharma), Upjohn and, through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, Pfizer&#x2019;s Consumer Healthcare business (Consumer Healthcare), each led by a single manager. Each operating segment has responsibility for its commercial activities. Upjohn and through &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, Consumer Healthcare, are responsible for their own R&amp;amp;D activities while Biopharma receives its R&amp;amp;D services from GPD and WRDM. These services include IPR&amp;amp;D projects for new investigational products and additional indications for in-line products. Each business has a geographic footprint across developed and emerging markets. Our chief operating decision maker uses the revenues and earnings of the operating segments, among other factors, for performance evaluation and resource allocation. Biopharma and Upjohn are the only reportable segments. We have revised prior-period information (Revenues and Earnings, as defined by management) to conform to the current management structure. As our operations were not managed under the new structure until the beginning of fiscal 2019, certain costs and expenses could not be directly attributed to one of the then new operating segments. As a result, our operating segment results for 2018 and 2017 include allocations, which management believes are reasonable. As described in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, acquisitions impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and divestitures impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Operating Segments&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:14pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="4"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:40%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:50%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="4" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Some additional information about our Biopharma and Upjohn business segments follows:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;"&gt;&lt;img alt="pfizerlogo2816.jpg" src="pfizerlogo2816.jpg" style="height:34px;width:60px;"/&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:14pt;"&gt;&lt;span style="font-family:Arial;font-size:14pt;font-weight:bold;"&gt;Pfizer&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72px;text-indent:-72px;font-size:14pt;"&gt;&lt;span style="font-family:Arial;font-size:14pt;font-weight:bold;"&gt;Biopharmaceuticals&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:72px;text-indent:-72px;font-size:14pt;"&gt;&lt;span style="font-family:Arial;font-size:14pt;font-weight:bold;"&gt;Group&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:center;"&gt;&lt;img alt="upjohnlogo.jpg" src="upjohnlogo.jpg" style="height:85px;width:221px;"/&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Biopharma is a science-based medicines business that includes six business units &#x2013; Oncology, Inflammation &amp;amp; Immunology, Rare Disease, Hospital, Vaccines and Internal Medicine. The Hospital unit commercializes our global portfolio of sterile injectable and anti-infective medicines and includes Pfizer&#x2019;s contract manufacturing operation, Pfizer CentreOne. At the beginning of our 2019 fiscal year, we also incorporated our biosimilar portfolio into the Oncology and Inflammation &amp;amp; Immunology business units and certain legacy established products into the Internal Medicine business unit. Each business unit is committed to delivering breakthroughs that change patients&#x2019; lives.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:1px dotted #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Upjohn is a global, primarily off-patent branded and generic medicines business, which includes a portfolio of 20 globally recognized solid oral dose brands, as well as a U.S.-based generics platform, Greenstone.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="2" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"&gt;&lt;div style="font-size:10pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Select products include:&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Prevnar 13/Prevenar 13&lt;br/&gt;- Ibrance&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Eliquis&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Xeljanz&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Enbrel &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;(outside the U.S. and Canada)&lt;br/&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Chantix/Champix&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Sutent&lt;br/&gt;- Xtandi&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:inherit;font-size:10pt;font-style:italic;"&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px dotted #000000;"&gt;&lt;div style="font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;Select products include:&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Lyrica&lt;br/&gt;- Lipitor&lt;br/&gt;- Norvasc&lt;br/&gt;- Celebrex&lt;br/&gt;- Viagra&lt;br/&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;- &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Certain generic medicines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On July 29, 2019, we announced that we entered into a definitive agreement to combine Upjohn with Mylan, creating a new global pharmaceutical company. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;On &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;July&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, Pfizer&#x2019;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare joint venture. See &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; for additional information.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Other Costs and Business Activities&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:justify;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain pre-tax costs are not allocated to our operating segment results, such as costs associated with the following:&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;WRDM&#x2013;&#x2013;the R&amp;amp;D and Medical expenses managed by our WRDM organization, which is generally responsible for research projects for our Biopharma portfolio until proof-of-concept is achieved and then for transitioning those projects to the GPD organization for possible clinical and commercial development. R&amp;amp;D spending may include upfront and milestone payments for intellectual property rights. The WRDM organization also has responsibility for certain science-based and other platform-services organizations, which provide end-to-end technical expertise and other services to the various R&amp;amp;D projects, as well as the Worldwide Medical and Safety group, which ensures that Pfizer provides all stakeholders&#x2013;&#x2013;including patients, healthcare providers, pharmacists, payers and health authorities&#x2013;&#x2013;with complete and up-to-date information on the risks and benefits associated with Pfizer products so that they can make appropriate decisions on how and when to use Pfizer&#x2019;s medicines.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;GPD&#x2013;&#x2013;the costs associated with our GPD organization, which is generally responsible for clinical trials from WRDM in the Biopharma portfolio, including late stage portfolio spend. GPD also provides technical support and other services to Pfizer R&amp;amp;D projects. GPD is responsible for facilitating all regulatory submissions and interactions with regulatory agencies.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Other&#x2013;&#x2013;the operating results of our Consumer Healthcare business, through July 31, 2019, and costs associated with other commercial activities not managed as part of Biopharma or Upjohn, including all strategy, business development, portfolio management and valuation capabilities, which previously had been reported in various parts of the organization.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Corporate and Other Unallocated&#x2013;&#x2013;the costs associated with platform functions (such as worldwide technology, global real estate operations, legal, finance, human resources, worldwide public affairs, compliance, and worldwide procurement), patient advocacy activities and certain compensation and other corporate costs, such as interest income and expense, and gains and losses on investments, as well as overhead expenses associated with our manufacturing (which include manufacturing variances associated with production) and commercial operations that are not directly assessed to an operating segment, as business unit (segment) management does not manage these costs. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:8pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#x2022;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Certain transactions and events such as (i) purchase accounting adjustments, where we incur expenses associated with the amortization of fair value adjustments to inventory, intangible assets and PP&amp;amp;E; (ii) acquisition-related costs, where we incur costs for executing the transaction, integrating the acquired operations and restructuring the combined company; and (iii) certain significant items, representing substantive and/or unusual, and in some cases recurring, items (such as gains on the completion of joint venture transactions, restructuring charges, legal charges or net gains and losses on investments in equity securities) that are evaluated on an individual basis by management and that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-left:12px;text-align:left;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;basis. Such items can include, but are not limited to, non-acquisition-related restructuring costs, as well as costs incurred for legal settlements, asset impairments and disposals of assets or businesses, including, as applicable, any associated transition activities.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Segment Assets&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We manage our assets on a total company basis, not by operating segment, as many of our operating assets are shared or commingled (such as accounts receivable, as many of our customers are served by multiple operating segments). Therefore, our chief operating decision maker does not regularly review any asset information by operating segment and, accordingly, we do not report asset information by operating segment. Total assets were approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$167 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;$159 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Selected Income Statement Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="37"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Depreciation and Amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;39,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;37,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;35,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;24,517&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;23,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;22,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;881&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;10,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;13,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,785&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;8,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;9,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;49,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;50,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;48,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;31,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;32,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;31,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,098&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;3,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;3,472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,859&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(4,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(4,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(4,758&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;4,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;4,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(3,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(2,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;51,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;53,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;52,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;17,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;11,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,010&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;6,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;6,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Biopharma&#x2019;s earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt; include d&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;ividend income from our investment in ViiV of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$220 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$266 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$758 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$543 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$495 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$415 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) a pre-tax gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$8.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$138 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (viii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: an upfront license fee payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; to Akcea, which was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Research and development expenses, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$112 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$337 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to our acquisition of Therachon, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$99 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;related to rivipansel, primarily for inventory manufactured for expected future sale and charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$240 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1A, Note 2A, Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2D,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$977 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) net charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$157 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$586 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (vii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$343 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge, in the aggregate, in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;, Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$204 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$237 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$379 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$224 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$999 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (vii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$756 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: a charitable contribution to the Pfizer Foundation of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$195 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; loss related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; equity share in Hisun Pfizer, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$55 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership investment in Teuto, including the extinguishment of a put option for the remaining &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership interest, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B, Note 2C,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:4px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Equity in the net income of investees accounted for by the equity-method is not significant for any of our operating segments.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The operating segment information does not purport to represent the revenues, costs and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; that each of our operating segments would have recorded had each segment operated as a standalone company during the periods presented.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;B. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Geographic Information&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As described in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, acquisitions impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and divestitures impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides revenues by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;23,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;25,329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;26,026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed Europe&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed Rest of World&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Emerging Markets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;12,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;51,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;53,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;52,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; Revenues denominated in euros were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$7.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$7.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$6.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Revenues exceeded &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$500 million&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; in each of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; countries outside the U.S. in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. The U.S. is the only country to contribute more than &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total revenue in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. As a percentage of revenues, our two largest national markets outside the U.S. were China, which contributed &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total revenue in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total revenue in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total revenues in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, and Japan, which contributed &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total revenue in each of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides long-lived assets by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed Europe&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed Rest of World&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Emerging Markets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,967&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,385&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,865&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;font-size:7pt;text-indent:-12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;C. &lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt;Other Revenue Information&lt;/span&gt;&lt;span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Significant Customers&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;We sell our biopharmaceutical products primarily to customers in the wholesale sector. In all years presented, our three largest U.S. wholesaler customers are McKesson, Inc., AmerisourceBergen Corporation and Cardinal Health, Inc. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, sales to our &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; largest U.S. wholesaler customers represented approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total revenues, respectively, and, collectively, represented approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;25%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total trade accounts receivable as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, sales to our &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; largest U.S. wholesaler customers represented approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;15%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total revenues, respectively, and, collectively, represented approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;34%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total trade accounts receivable as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. In &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, sales to our &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;three&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; largest U.S. wholesaler customers represented approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;16%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;10%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total revenues, respectively, and, collectively, represented approximately &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;36%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; of total trade accounts receivable as of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;text-align:center;"&gt;December&#160;31, 2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;. For all years presented, these sales and related trade accounts receivable were concentrated in our biopharmaceutical businesses.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;text-decoration:underline;"&gt;Significant Product Revenues&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As described in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, acquisitions impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and divestitures impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PRODUCT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;TOTAL REVENUES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;51,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;53,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;52,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;39,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;37,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;35,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Internal Medicine&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;9,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8,869&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Nonvalvular Atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Premarin family&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Symptoms of menopause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;832&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;BMP2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Development of bone and cartilage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Toviaz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Overactive bladder&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;271&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Oncology&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;9,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;7,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;6,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Ibrance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Metastatic breast cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,961&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;4,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;936&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,081&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;590&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Inlyta&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Advanced RCC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bosulif&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Retacrit&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Anemia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Mektovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Braftovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Hospital&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7,772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;7,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8,369&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Sulperazon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;613&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Medrol&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;493&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Vfend&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fungal infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Zithromax&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;336&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Epinephrine injection used in treatment of life-threatening allergic reactions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fragmin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Zyvox&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Zosyn/Tazocin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Tygacil&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Diflucan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fungal infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Panzyga&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Primary humoral immunodeficiency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;755&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Anti-infectives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Hospital&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6,504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;6,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;6,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Pneumococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;5,847&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Nimenrix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Meningococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;FSME/IMMUN-TicoVac&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Tick-borne encephalitis disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Trumenba&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Meningococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;4,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;4,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xeljanz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;RA, PsA, UC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,242&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Inflectra/Remsima&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c), (g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Crohn&#x2019;s Disease, Pediatric Crohn&#x2019;s Disease, UC, Pediatric UC, RA in combination with methotrexate, Ankylosing Spondylitis, PsA and Plaque Psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;642&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Eucrisa&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Mild-to-moderate atopic dermatitis (eczema) in adults and children 2 years of age and older&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PRODUCT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Genotropin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;BeneFIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Hemophilia B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;488&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;ATTR-Cardiomyopathy and Polyneuropathy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Hemophilia A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Somavert&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Acromegaly&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Upjohn&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;10,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;12,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;13,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Lyrica &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Epilepsy, post-herepetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;3,321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;4,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Reduction of LDL cholesterol&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,062&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,915&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Norvasc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;950&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;932&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Celebrex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Arthritis pain and inflammation, acute pain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;686&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Viagra&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Erectile dysfunction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Depression and certain anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;336&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Zoloft&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Depression and certain anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xalatan/Xalacom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Glaucoma and ocular hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xanax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Revatio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Pulmonary arterial hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Consumer Healthcare Business&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,098&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Total Alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Total Biosimilars&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;769&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Total Sterile Injectable Pharmaceuticals&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;5,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,673&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 and 2017 product revenues to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;We performed certain reclassifications in the All other Oncology category to conform 2018 and 2017 product revenues to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy SIP category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 and 2017 product revenues to the current presentation. Hospital also includes Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#x201c;All other Anti-infectives&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018 and 2017 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation &amp;amp; Immunology category to conform 2018 and 2017 product revenues to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;On July 31, 2019, Pfizer&#x2019;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Represents HIS revenues through February 2, 2017, which includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. On February 3, 2017, we completed the sale of HIS to ICU Medical. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1A &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2018Q4YTD"
      decimals="INF"
      id="d34586122e1317-wk-Fact-D17055AF0AB4DC9AC143801F8131E959"
      unitRef="Operating_Segment">2</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="FD2019Q4YTD"
      decimals="INF"
      id="d34586122e1321-wk-Fact-E001667F01F95E298014FB8B5A7B8850"
      unitRef="Operating_Segment">3</us-gaap:NumberOfOperatingSegments>
    <us-gaap:Assets
      contextRef="FI2019Q4"
      decimals="-9"
      id="d34586122e1584-wk-Fact-77980D14EA6E543398FA366DF6F1559F"
      unitRef="usd">167000000000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="FI2018Q4"
      decimals="-9"
      id="d34586122e1592-wk-Fact-9A5AF0B77C295D12BF1CA751D9155BC1"
      unitRef="usd">159000000000</us-gaap:Assets>
    <pfe:ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-07EAEA8170A954930C88801F835332D1-0-wk-Fact-C6959854031DFEF3B66A801F7DE516CE">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="37"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Depreciation and Amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;39,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;37,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;35,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;24,517&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;23,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;22,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;881&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;10,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;13,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,785&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;8,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;9,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;49,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;50,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;48,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;31,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;32,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;31,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,098&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;3,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;3,472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,859&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(4,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(4,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(4,758&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;4,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;4,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(3,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(2,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;51,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;53,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;52,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;17,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;11,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,010&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;6,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;6,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Biopharma&#x2019;s earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt; include d&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;ividend income from our investment in ViiV of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$220 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$266 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$758 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$543 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$495 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$415 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) a pre-tax gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$8.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$138 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (viii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: an upfront license fee payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; to Akcea, which was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Research and development expenses, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$112 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$337 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to our acquisition of Therachon, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$99 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;related to rivipansel, primarily for inventory manufactured for expected future sale and charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$240 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1A, Note 2A, Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2D,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$977 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) net charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$157 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$586 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (vii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$343 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge, in the aggregate, in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;, Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$204 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$237 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$379 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$224 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$999 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (vii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$756 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: a charitable contribution to the Pfizer Foundation of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$195 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; loss related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; equity share in Hisun Pfizer, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$55 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership investment in Teuto, including the extinguishment of a put option for the remaining &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership interest, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B, Note 2C,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</pfe:ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock>
    <us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-F8BE884DC75F74C9D8F6801F8354E5C7-0-wk-Fact-F23BEB0F90F486EFD68D801F82226D7F">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="37"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Depreciation and Amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;39,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;37,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;35,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;24,517&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;23,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;22,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;881&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;10,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;13,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,785&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;8,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;9,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;49,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;50,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;48,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;31,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;32,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;31,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,098&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;3,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;3,472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,859&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(4,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(4,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(4,758&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;4,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;4,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(3,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(2,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;51,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;53,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;52,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;17,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;11,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,010&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;6,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;6,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Biopharma&#x2019;s earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt; include d&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;ividend income from our investment in ViiV of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$220 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$266 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$758 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$543 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$495 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$415 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) a pre-tax gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$8.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$138 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (viii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: an upfront license fee payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; to Akcea, which was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Research and development expenses, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$112 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$337 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to our acquisition of Therachon, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$99 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;related to rivipansel, primarily for inventory manufactured for expected future sale and charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$240 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1A, Note 2A, Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2D,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$977 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) net charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$157 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$586 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (vii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$343 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge, in the aggregate, in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;, Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$204 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$237 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$379 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$224 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$999 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (vii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$756 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: a charitable contribution to the Pfizer Foundation of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$195 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; loss related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; equity share in Hisun Pfizer, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$55 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership investment in Teuto, including the extinguishment of a put option for the remaining &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership interest, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B, Note 2C,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock>
    <us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-6E34BC7E6D74B396FAA8801F8354B510-0-wk-Fact-71B61B5F8DE4F5211BA1801F7E20CC4E">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="37"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:28%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:5%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides selected income statement information by reportable segment:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Depreciation and Amortization&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Reportable Segments:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Biopharma&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;39,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;37,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;35,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;24,517&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;23,738&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;22,194&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;958&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;953&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;881&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;10,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;13,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,785&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;8,636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;9,348&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;105&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;125&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Total reportable segments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;49,653&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;50,042&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;48,977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;31,301&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;32,374&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;31,542&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;1,063&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;1,006&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Other business activities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,098&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;3,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;3,472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,723&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,283&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(5,302&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;108&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;146&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;142&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Reconciling Items:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Corporate and other unallocated&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(5,859&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,383&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(6,299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;503&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Purchase accounting adjustments&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(4,333&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(4,786&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(4,758&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;4,347&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;4,620&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;4,565&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Acquisition-related costs&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;(185&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(456&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;3&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;Certain significant items&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;2,481&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(3,719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;(2,423&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;36&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;38&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;52&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;51,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;53,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;52,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;17,682&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;11,885&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;12,305&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;6,010&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;6,384&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;"&gt;&lt;span&gt;6,269&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Income from continuing operations before provision/(benefit) for taxes on income&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. Biopharma&#x2019;s earnings&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt; include d&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;ividend income from our investment in ViiV of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$220 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$253 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$266 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$758 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$543 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$2.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$495 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$415 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) a pre-tax gain of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$8.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$138 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (viii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$1.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: an upfront license fee payment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$250 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; to Akcea, which was recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Research and development expenses, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$112 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recorded in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&#x2013;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$337 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Research and development expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to our acquisition of Therachon, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$99 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;related to rivipansel, primarily for inventory manufactured for expected future sale and charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$240 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, primarily in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1A, Note 2A, Note 2C&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2D,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;text-align:center;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$977 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) net charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$157 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3.1 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$63 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$586 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$3 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (vii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$4 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$343 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$119 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charge, in the aggregate, in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$50 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; pre-tax gain in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;, Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;For Earnings in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$204 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (ii) charges for certain legal matters of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$237 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iii) certain asset impairment charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$379 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (iv) charges for business and legal entity alignment of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$71 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, (v) net gains of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$224 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; recognized during the period on equity securities, (vi) net losses on early retirement of debt of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$999 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and (vii) other charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$756 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which includes, among other things: a charitable contribution to the Pfizer Foundation of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$200 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Selling, informational and administrative expenses,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$195 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Cost of sales,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; an &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$81 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; loss related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;49%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; equity share in Hisun Pfizer, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; charges of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$55 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$30 million&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; related to the sale of our former &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;40%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership investment in Teuto, including the extinguishment of a put option for the remaining &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;60%&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; ownership interest, which is included in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Other (income)/deductions&#x2013;&#x2013;net&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B, Note 2C,&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 3&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 4&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2628-wk-Fact-21081727CA5952E381D8F466452D3002"
      unitRef="usd">39419000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2647-wk-Fact-3F635FAC85E05D48B1C0CAFAFF1EADF3"
      unitRef="usd">37558000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2667-wk-Fact-6E9F27AE02726BB5B8FF801F8105C494"
      unitRef="usd">35530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2686-wk-Fact-360249B3A006541E93860494E7664450"
      unitRef="usd">24517000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2705-wk-Fact-BC7E0D00B21FF35D771B801F81A9F967"
      unitRef="usd">23738000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2725-wk-Fact-111ED69E468B22889D50801F81BB10E7"
      unitRef="usd">22194000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2744-wk-Fact-93A83F7AF2C8708F880AD083C00A9C02"
      unitRef="usd">958000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2763-wk-Fact-F84C8C614DC11C920600801F81CCF916"
      unitRef="usd">953000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e2783-wk-Fact-8D2F59DA09B7FE8B09E6801F8148C80C"
      unitRef="usd">881000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2803-wk-Fact-5FFDD34AFE83545EA97B752E1E5B0F46"
      unitRef="usd">10233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2822-wk-Fact-EF0526EE56765857B51AB0881F18E8DA"
      unitRef="usd">12484000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2841-wk-Fact-58F8CEFB5E3A4154A8FB801F81203AD3"
      unitRef="usd">13447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2861-wk-Fact-084878331CAE5F50893848F4E5725E12"
      unitRef="usd">6785000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2880-wk-Fact-7249016752645521B4A449214872FA3C"
      unitRef="usd">8636000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2900-wk-Fact-3FA833AC5BE1008431CF801F80F4EAAE"
      unitRef="usd">9348000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2919-wk-Fact-F917EC74CAF8798A2465D083C001D773"
      unitRef="usd">105000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2938-wk-Fact-048CE44A39F6A1095A80801F80E770F3"
      unitRef="usd">112000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e2958-wk-Fact-FA6F8F4B8C07145CBB9E801F8194C1D3"
      unitRef="usd">125000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e2983-wk-Fact-E6A92503D1DC56F99E0B7CD436259160"
      unitRef="usd">49653000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e3002-wk-Fact-D225DC10444A544086C71ABD2D98174F"
      unitRef="usd">50042000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e3021-wk-Fact-967AD2D4026CFBEF4D3A801F81244E55"
      unitRef="usd">48977000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e3041-wk-Fact-B707042704E051E094DA0C2D5A4B4F2B"
      unitRef="usd">31301000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e3060-wk-Fact-57F6BF74720C5F8388DA1CC92604AB69"
      unitRef="usd">32374000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e3080-wk-Fact-158D3A6B6505E95558B1801F81DBB22C"
      unitRef="usd">31542000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e3099-wk-Fact-8E4ECE37A9934A1B313CD083BFE52A99"
      unitRef="usd">1063000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e3118-wk-Fact-717E35B044362C67F868801F81BDF57D"
      unitRef="usd">1065000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember"
      decimals="-6"
      id="d34586122e3138-wk-Fact-94EEAC12B164219871FE801F8106C475"
      unitRef="usd">1006000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3163-wk-Fact-B2CA90AC8D937B13573902932E654262"
      unitRef="usd">2098000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3182-wk-Fact-9862B6C2795C4DD135D202932E5D2635"
      unitRef="usd">3605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3201-wk-Fact-52A029941EC4B57D153202932E54F161"
      unitRef="usd">3472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3221-wk-Fact-F510E0B5E23456BCA1F3AB0787E1A55F"
      unitRef="usd">-5723000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3241-wk-Fact-AAAC7E6A61915A9AB289BFF791014433"
      unitRef="usd">-5283000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3262-wk-Fact-B844E6AF354E6B90FBC0D083BFDF0319"
      unitRef="usd">-5302000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3282-wk-Fact-A1E2DBD4AD5154A27F57D083C01AB381"
      unitRef="usd">108000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3301-wk-Fact-05D8B303E9C377506BB9801F81963C22"
      unitRef="usd">146000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3321-wk-Fact-BAB8B49654C57E704233801F8111DFBB"
      unitRef="usd">142000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3525-wk-Fact-472286F8FE669A33593C801F81242E10"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3544-wk-Fact-2BDDAF649C21B6CC2C10801F81391E14"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3563-wk-Fact-A80502CBDD0A15BE22F7801F812601A0"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3583-wk-Fact-5EB5DEEFDF475D0D875609F4CEF1710B"
      unitRef="usd">-5859000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3603-wk-Fact-F3F4B1BA315C571D94BD569F67709BC4"
      unitRef="usd">-6383000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3624-wk-Fact-2575FD938424E6650896801F80D24265"
      unitRef="usd">-6299000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3644-wk-Fact-C023DBBE72C11C46F64CD083BFF55D24"
      unitRef="usd">453000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3663-wk-Fact-1B60D667972BE02E235D801F8128BBC9"
      unitRef="usd">503000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_CorporateNonSegmentMember"
      decimals="-6"
      id="d34586122e3683-wk-Fact-AA448E5E8130401937D9801F80FB6261"
      unitRef="usd">465000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3709-wk-Fact-8CFBC11982887546DF26801F811DC1B0"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3728-wk-Fact-778D87A036A48FC4F187801F81BC813D"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3747-wk-Fact-E79DE6E08DB25C4F55E0801F8189148C"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3767-wk-Fact-F1DA5A74EBBE5412A2A5D4960C73D7D2"
      unitRef="usd">-4333000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3787-wk-Fact-7CE1E0EF766B581893CBC5A1DB76D621"
      unitRef="usd">-4786000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3808-wk-Fact-E19218AE39D843301427801F81BB5A43"
      unitRef="usd">-4758000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3828-wk-Fact-8A13EF2DD2417F08F8E0D083BFECB190"
      unitRef="usd">4347000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3847-wk-Fact-6B869F58FEDE17E7F0E5801F81D500ED"
      unitRef="usd">4620000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_PurchaseAccountingAdjustmentsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3867-wk-Fact-74BDF519ACFF7C0C48A3801F819B32C2"
      unitRef="usd">4565000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3892-wk-Fact-6B9AEE235372BD92AE44801F81ABC925"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3911-wk-Fact-3BE3F8D57F8F66DC72BF801F8103083F"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3930-wk-Fact-42A10C575920F502EF70801F818A4284"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3950-wk-Fact-C7C4AE8978C55E58ADD8D2CE87F7F6ED"
      unitRef="usd">-185000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3970-wk-Fact-74C1614E6C935CA08B5422036CFAC156"
      unitRef="usd">-318000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e3991-wk-Fact-57987F1F001AA9CC9C56801F812C5B39"
      unitRef="usd">-456000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4011-wk-Fact-4092AEA9F2F669BF51ECD083C021CD3C"
      unitRef="usd">3000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4030-wk-Fact-241AF0F5CD243F91D7E3801F81BCFDF4"
      unitRef="usd">12000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_BusinessCombinationsAcquisitionRelatedCostsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4050-wk-Fact-5CA5DCE2265634E3F870801F81D69ABB"
      unitRef="usd">39000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4077-wk-Fact-552B0DEF974EB94D62FC801F81213B84"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4096-wk-Fact-C8B439FC676AA180BB18801F8196982F"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4115-wk-Fact-48678AE7E2417CCA04CA801F81D64B4D"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4135-wk-Fact-BC0C1F861F85562394C153BA53C5058B"
      unitRef="usd">2481000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4154-wk-Fact-6861B27FF0E359E495FAE4664EA2AD95"
      unitRef="usd">-3719000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4175-wk-Fact-64B6841D8A9647CC861B801F81B47923"
      unitRef="usd">-2423000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4195-wk-Fact-9EE24B8CE46E4AFB1CAED083C012D553"
      unitRef="usd">36000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4214-wk-Fact-60449F03FF9FEEB388F5801F81D5F45D"
      unitRef="usd">38000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD_pfe_OtherSegmentReconcilingItemsAxis_pfe_CertainSignificantItemsMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4234-wk-Fact-35B362807E1AE86654F9801F811F7FF8"
      unitRef="usd">52000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34586122e4264-wk-Fact-99447C56530B57BB99F3272D91D61246"
      unitRef="usd">51750000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34586122e4283-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
      unitRef="usd">53647000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34586122e4303-wk-Fact-5800B99789A546352282801F7F2D7923"
      unitRef="usd">52546000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
      unitRef="usd">17682000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
      unitRef="usd">11885000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
      unitRef="usd">12305000000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34586122e4380-wk-Fact-478A747253E5F8B23E49801F81C71589"
      unitRef="usd">6010000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34586122e4399-wk-Fact-535FEE135E2ABD4ECB45801F81937510"
      unitRef="usd">6384000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34586122e4419-wk-Fact-B1FE1F215AFFABD9B609801F81378823"
      unitRef="usd">6269000000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e4451-wk-Fact-84CEEA0419A2A19F4094D92D338D66D4"
      unitRef="usd">220000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e4459-wk-Fact-E56EBD2890F424606158801F7E221379"
      unitRef="usd">253000000</us-gaap:InvestmentIncomeDividend>
    <us-gaap:InvestmentIncomeDividend
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_OperatingSegmentsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_ViivHealthcareLimitedMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e4468-wk-Fact-F1179FA5256A62859C91801F7E20D9C9"
      unitRef="usd">266000000</us-gaap:InvestmentIncomeDividend>
    <pfe:RestructuringChargesandImplementationCosts
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4591-wk-Fact-CC7561F7272C5ED4A5788C43F2AC96DD"
      unitRef="usd">758000000</pfe:RestructuringChargesandImplementationCosts>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4595-wk-Fact-3F312BBBF0681C2215F6801F7E16348D"
      unitRef="usd">-543000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <pfe:AssetImpairmentChargesAndOtherCharges
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-8"
      id="d34586122e4599-wk-Fact-5BE5F702F6D43C703286801F7DE5563F"
      unitRef="usd">2800000000</pfe:AssetImpairmentChargesAndOtherCharges>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4603-wk-Fact-4B94A17AAB6A549993EBA5BA9A4EABD3"
      unitRef="usd">495000000</pfe:BusinessAlignmentCosts>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4608-wk-Fact-516785FC5DC8501BA502F73998F76734"
      unitRef="usd">415000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:DeconsolidationGainOrLossAmount
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-8"
      id="d34586122e4612-wk-Fact-37D03FF8BE565EE899BA0F12FA922C2C"
      unitRef="usd">8100000000</us-gaap:DeconsolidationGainOrLossAmount>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4616-wk-Fact-CDCCACFA72CC50AD99C347EC5E412979"
      unitRef="usd">-138000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-8"
      id="d34586122e4620-wk-Fact-144174E08A85553D89C90841C1C869F1"
      unitRef="usd">-1300000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <pfe:PaymentForLicensingArrangement
      contextRef="D2019Q4Nov1-30_srt_CounterpartyNameAxis_pfe_AkceaAndIonisMember_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_us-gaap_TypeOfArrangementAxis_us-gaap_LicensingAgreementsMember"
      decimals="-6"
      id="d34586122e4624-wk-Fact-2A3A3E610C51E4ED73C5D96989B3F86C"
      unitRef="usd">250000000</pfe:PaymentForLicensingArrangement>
    <pfe:RestructuringChargesandImplementationCosts
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember_us-gaap_IncomeStatementLocationAxis_pfe_OtherIncomeExpenseMember"
      decimals="-6"
      id="d34586122e4633-wk-Fact-CA74717A80E9EE804D83DDD9F42AA696"
      unitRef="usd">112000000</pfe:RestructuringChargesandImplementationCosts>
    <us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
      contextRef="FD2019Q4YTD_pfe_AssetAcquisitionAxis_pfe_TherachonAssetAcquisitionMember_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4645-wk-Fact-FD16878222CF5EB2BEE79D428F8C3B48"
      unitRef="usd">337000000</us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost>
    <pfe:Chargeprimarilyforinventorymanufacturedforexpectedfuturesale
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_CounterpartyNameAxis_pfe_NovaQuestCoInvestmentFundVL.P.Member"
      decimals="-6"
      id="d34586122e4654-wk-Fact-8A3BFD051E05520AABFD419238ADA6EB"
      unitRef="usd">99000000</pfe:Chargeprimarilyforinventorymanufacturedforexpectedfuturesale>
    <pfe:DeconsolidationExternalIncrementalCostsAmount
      contextRef="FD2019Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_GSKConsumerHealthcareMember"
      decimals="-6"
      id="d34586122e4662-wk-Fact-96B1BF0188FE5CF49347036DCB830182"
      unitRef="usd">240000000</pfe:DeconsolidationExternalIncrementalCostsAmount>
    <pfe:RestructuringChargesandImplementationCosts
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4698-wk-Fact-45B6785570C65CAC9B364B41D8371365"
      unitRef="usd">977000000</pfe:RestructuringChargesandImplementationCosts>
    <us-gaap:GainLossRelatedToLitigationSettlement
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4702-wk-Fact-B234992E4C4F51DD9396CBB63995C735"
      unitRef="usd">-157000000</us-gaap:GainLossRelatedToLitigationSettlement>
    <pfe:AssetImpairmentChargesAndOtherCharges
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-8"
      id="d34586122e4706-wk-Fact-3A4B3F3B568F55888F5A8E1BED23726F"
      unitRef="usd">3100000000</pfe:AssetImpairmentChargesAndOtherCharges>
    <pfe:BusinessAlignmentCosts
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4710-wk-Fact-DFD0844DF5485DD5B808561439758591"
      unitRef="usd">63000000</pfe:BusinessAlignmentCosts>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4715-wk-Fact-47F39B271F785E99BC8974BC5C6B3F22"
      unitRef="usd">586000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34586122e4719-wk-Fact-7DDB8A53183E908A30E5801F80CDA452"
      unitRef="usd">-3000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4723-wk-Fact-9E4670EEC9A15C7599CFEDDC36F7401A"
      unitRef="usd">-4000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_CounterpartyNameAxis_pfe_BainCapitalMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_CerevelMember"
      decimals="-6"
      id="d34586122e4727-wk-Fact-189624AFF5015522A88BDDA2F90156A0"
      unitRef="usd">343000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <pfe:CompensationRelatedCostsNonExecutiveEmployeesBonus
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4735-wk-Fact-A244813E0C615DBF81BF6373F13479D6"
      unitRef="usd">119000000</pfe:CompensationRelatedCostsNonExecutiveEmployeesBonus>
    <pfe:GainLossFromContributionAgreement
      contextRef="FD2018Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_AllogeneMember"
      decimals="-6"
      id="d34586122e4744-wk-Fact-E6EB1994D63A5FC58F30FE34A48E8DE8"
      unitRef="usd">50000000</pfe:GainLossFromContributionAgreement>
    <pfe:RestructuringChargesandImplementationCosts
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4770-wk-Fact-BDD40C60A91EA7430222801F7E1FA82D"
      unitRef="usd">204000000</pfe:RestructuringChargesandImplementationCosts>
    <us-gaap:LossContingencyLossInPeriod
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4774-wk-Fact-931627721E7E33A6CA3A801F822CA757"
      unitRef="usd">237000000</us-gaap:LossContingencyLossInPeriod>
    <pfe:AssetImpairmentChargesAndOtherCharges
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4778-wk-Fact-2570FFE79F2B8C13C3D6801F8223857E"
      unitRef="usd">379000000</pfe:AssetImpairmentChargesAndOtherCharges>
    <pfe:AlignmentCosts
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4782-wk-Fact-EA21A1EA07E2FA5DB466801F82C413B0"
      unitRef="usd">71000000</pfe:AlignmentCosts>
    <us-gaap:EquitySecuritiesFvNiGainLoss
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4787-wk-Fact-C2D7EA4BF46072BAE200DDE74B27C0D6"
      unitRef="usd">224000000</us-gaap:EquitySecuritiesFvNiGainLoss>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4791-wk-Fact-1647D59EDB91FA72FCA4801F7DE602AF"
      unitRef="usd">-999000000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingIncomeExpenseNet
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember"
      decimals="-6"
      id="d34586122e4795-wk-Fact-9B86E31FA5FDE8A4024BDDE3FD81C692"
      unitRef="usd">-756000000</us-gaap:OtherOperatingIncomeExpenseNet>
    <pfe:CharitableContributionExpense
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_SellingGeneralAndAdministrativeExpensesMember"
      decimals="-6"
      id="d34586122e4799-wk-Fact-AB05C420E3B36F05C1DFDDED9568E98A"
      unitRef="usd">200000000</pfe:CharitableContributionExpense>
    <pfe:InventoryWriteDownAndOverheadCosts
      contextRef="FD2017Q4YTD_us-gaap_IncomeStatementLocationAxis_us-gaap_CostOfSalesMember"
      decimals="-6"
      id="d34586122e4807-wk-Fact-AFCFAC136365DF89060CDDF521193B0E"
      unitRef="usd">195000000</pfe:InventoryWriteDownAndOverheadCosts>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="FD2017Q4YTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="-6"
      id="d34586122e4816-wk-Fact-E4E691C290056D92F9C5801F80EFA503"
      unitRef="usd">-81000000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="FI2017Q4_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_HisunPfizerPharmaceuticalsCoLtdMember"
      decimals="2"
      id="d34586122e4820-wk-Fact-C1577C38066176D10EAC801F80EADEC6"
      unitRef="number">0.49</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal
      contextRef="FD2017Q4YTD_srt_ConsolidationItemsAxis_us-gaap_MaterialReconcilingItemsMember_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis_pfe_HISMember"
      decimals="-6"
      id="d34586122e4828-wk-Fact-FD073C40A0E2055928C6801F7E1E419D"
      unitRef="usd">-55000000</us-gaap:DisposalGroupNotDiscontinuedOperationGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal
      contextRef="FD2017Q2QTD_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="-6"
      id="d34586122e4837-wk-Fact-EFB9DE03407E9EBADAF5801F7E04ABC8"
      unitRef="usd">-30000000</us-gaap:EquityMethodInvestmentRealizedGainLossOnDisposal>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage
      contextRef="I2017Q2Jun30_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34586122e4841-wk-Fact-A9A6F91B231257800749801F80B22D2E"
      unitRef="number">0.40</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:MinorityInterestOwnershipPercentageByParent
      contextRef="FI2017Q4_dei_LegalEntityAxis_pfe_LaboratorioTeutoBrasileroMember_srt_OwnershipAxis_pfe_LaboratorioTeutoBrasileroMember"
      decimals="2"
      id="d34586122e4845-wk-Fact-E218FFA8B1BEC0935D45801F7EB5152A"
      unitRef="number">0.60</us-gaap:MinorityInterestOwnershipPercentageByParent>
    <us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-FFDA9950E810EF840182801F835365F5-0-wk-Fact-B389BC08DCF48C13E73D801F7DCF9174">&lt;div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As described in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, acquisitions impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and divestitures impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides revenues by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7.5pt;"&gt;&lt;span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"&gt;&lt;span&gt;23,852&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;25,329&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;26,026&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed Europe&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;8,701&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;9,116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;8,508&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed Rest of World&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;6,465&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,612&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Emerging Markets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;12,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;12,651&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;11,399&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;text-indent:6px;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;51,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;53,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;52,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; Revenues denominated in euros were &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$7.0 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;, &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$7.3 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;$6.8 billion&lt;/span&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromExternalCustomersByGeographicAreasTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d34586122e5186-wk-Fact-8443B983E8AC50B1A48061BEA9ACDF7D"
      unitRef="usd">23852000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d34586122e5205-wk-Fact-34A880C9A5F859E8B38A36A90B002595"
      unitRef="usd">25329000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d34586122e5225-wk-Fact-67387CF71587E09BD230801F81BABBA3"
      unitRef="usd">26026000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d34586122e5247-wk-Fact-2FA734C3E6F851F3A59F806EDB8CEAFE"
      unitRef="usd">8701000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d34586122e5266-wk-Fact-0B2C9A8A17225E17979E8C6A9A7A0472"
      unitRef="usd">9116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d34586122e5285-wk-Fact-A96A62C6E678423BC122801F80CEE810"
      unitRef="usd">8508000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d34586122e5313-wk-Fact-CD1DAE84A7D8575096A679F1CD7AEBB1"
      unitRef="usd">6465000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d34586122e5332-wk-Fact-F774D66B39E3548293A7768C17FCC7C8"
      unitRef="usd">6551000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d34586122e5351-wk-Fact-0DFBEF6B024C671D2CCB801F80B50D92"
      unitRef="usd">6612000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d34586122e5379-wk-Fact-246CB21BC49B5BF7A871DD3D4BFCC13C"
      unitRef="usd">12733000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d34586122e5398-wk-Fact-68EA97346488548597981D4BC7C4FA17"
      unitRef="usd">12651000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d34586122e5417-wk-Fact-D134462A8015E9052612801F81B8005A"
      unitRef="usd">11399000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34586122e5448-wk-Fact-99447C56530B57BB99F3272D91D61246"
      unitRef="usd">51750000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34586122e5467-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
      unitRef="usd">53647000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34586122e5487-wk-Fact-5800B99789A546352282801F7F2D7923"
      unitRef="usd">52546000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d34586122e5522-wk-Fact-35E426F0104B5EA7891C52B921AAD3A3"
      unitRef="usd">7000000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d34586122e5531-wk-Fact-C2550351186B5BBD9A9B4697110D1389"
      unitRef="usd">7300000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_CurrencyAxis_currency_EUR_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-8"
      id="d34586122e5539-wk-Fact-D1A25E807F1B8D5B10BF801F822A676F"
      unitRef="usd">6800000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_pfe_NonUnitedStatesMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="INF"
      id="d34586122e5608-wk-Fact-B7406142F79CF57B0AEA801F7DED71D1"
      unitRef="Country">11</pfe:ConcentrationRiskRevenues500000000orMoreNumberofCountries>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_US_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="INF"
      id="d34586122e5625-wk-Fact-5CA1E45856F54F1FEF6D801F7E1EEF84"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="2"
      id="d34586122e5641-wk-Fact-71770A3AFC1119613425801F821EE09E"
      unitRef="number">0.09</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="2"
      id="d34586122e5650-wk-Fact-D15099678E595F4D6360801F7E20E9EE"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_StatementGeographicalAxis_country_CN_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="2"
      id="d34586122e5658-wk-Fact-F6FF8543AA8186D5EC6A801F7DD060F6"
      unitRef="number">0.07</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_StatementGeographicalAxis_country_JP_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_GeographicConcentrationRiskMember"
      decimals="2"
      id="d34586122e5666-wk-Fact-61359DEBAFCCC4EECC28801F7DD2712B"
      unitRef="number">0.08</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-79AF505432E54A8DBF6A801F8354D617-0-wk-Fact-93FE6F40DEAA1C2E78C0801F7DF465D9">&lt;div style="line-height:120%;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="13"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:64%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:9%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides long-lived assets by geographic area:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As of December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;United States&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;7,606&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;7,089&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;6,971&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed Europe&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;4,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;4,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Developed Rest of World&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;453&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;490&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;632&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;Emerging Markets&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;1,603&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,602&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;1,917&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Property, plant and equipment, net&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;font-weight:bold;"&gt;&lt;span&gt;13,967&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,385&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;span&gt;13,865&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:12px;"&gt;&lt;div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;text-indent:-12px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.&lt;/span&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d34586122e5991-wk-Fact-B2F1948685BE98B13F06801F7E8C3DA7"
      unitRef="usd">7606000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d34586122e6010-wk-Fact-BC8E4FB34B5192A48615801F7E9AD05E"
      unitRef="usd">7089000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_country_US"
      decimals="-6"
      id="d34586122e6030-wk-Fact-940C568E09DA38F73207801F7E8C819E"
      unitRef="usd">6971000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d34586122e6052-wk-Fact-921D990124AD87101C23801F7E92DAFD"
      unitRef="usd">4304000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d34586122e6071-wk-Fact-87E59A336B0A618A1F1D801F7E8AD801"
      unitRef="usd">4204000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_pfe_DevelopedEuropeMember"
      decimals="-6"
      id="d34586122e6090-wk-Fact-1D437AF9323714A08390801F7E93DC39"
      unitRef="usd">4345000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d34586122e6118-wk-Fact-87ADA00DA5C5D3DB1F1C801F7E7826DD"
      unitRef="usd">453000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d34586122e6137-wk-Fact-2409EE5D9DDE703FA11B801F7E7C5AAF"
      unitRef="usd">490000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_pfe_DevelopedRestOfWorldMember"
      decimals="-6"
      id="d34586122e6156-wk-Fact-BEEC85B5E0F398A0DE71801F7E7B685A"
      unitRef="usd">632000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d34586122e6184-wk-Fact-1F8E1E5AC854059418AF801F7E7A53FB"
      unitRef="usd">1603000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d34586122e6203-wk-Fact-0330CAF6E36D229B5BC3801F7E8C2429"
      unitRef="usd">1602000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4_srt_StatementGeographicalAxis_pfe_EmergingMarketsMember"
      decimals="-6"
      id="d34586122e6222-wk-Fact-62D20C34C95D577873AD801F7E784708"
      unitRef="usd">1917000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2019Q4"
      decimals="-6"
      id="d34586122e6253-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
      unitRef="usd">13967000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2018Q4"
      decimals="-6"
      id="d34586122e6272-wk-Fact-7F7E046052F852439B2A0884F029C60C"
      unitRef="usd">13385000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="FI2017Q4"
      decimals="-6"
      id="d34586122e6292-wk-Fact-01CF52963FE3ADE6A712801F7E891C36"
      unitRef="usd">13865000000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6431-wk-Fact-43A376508C4FB725D03C801F7E066AC1"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6435-wk-Fact-5A5203ABF2894A85632B801F822BBEDD"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6439-wk-Fact-BE0112CFCF5AC8631260801F7DC5EA89"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2019Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6444-wk-Fact-7BD550C52D2970E12B76801F822AEBC6"
      unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6460-wk-Fact-FC503C7482C7BDBA4F51801F7E16DD89"
      unitRef="number">0.15</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6464-wk-Fact-24599123E8CBDA903976801F7E211DDC"
      unitRef="number">0.11</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6469-wk-Fact-7B88D563F7B5E9934D93801F7DC9C1C8"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2018Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6473-wk-Fact-C8CA4706D1F7EE1EFDE7801F829F1227"
      unitRef="number">0.34</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_McKessonInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6490-wk-Fact-18BFE9C2B0B7CBB671B8801F7DE36ECE"
      unitRef="number">0.16</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_AmerisourceBergenCorporationMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6494-wk-Fact-8531894F13D09CCA0F88801F7DEF4362"
      unitRef="number">0.12</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_CardinalHealthInc.Member_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_RevenueFromContractWithCustomerMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6498-wk-Fact-9A34462389F24BD2D9C8801F821E79A5"
      unitRef="number">0.10</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="FD2017Q4YTD_srt_MajorCustomersAxis_pfe_ThreeLargestUSWholesaleCustomersMember_us-gaap_ConcentrationRiskByBenchmarkAxis_us-gaap_AccountsReceivableMember_us-gaap_ConcentrationRiskByTypeAxis_us-gaap_CustomerConcentrationRiskMember"
      decimals="2"
      id="d34586122e6502-wk-Fact-DFC9511FB2C9B8A842D9801F7E216AF4"
      unitRef="number">0.36</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock
      contextRef="FD2019Q4YTD"
      id="TextSelection-C8CC0E46AA9E07AFADE6801F8354B844-0-wk-Fact-09358930CB595C743F82801F8226C526">&lt;div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;As described in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, acquisitions impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2019&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt; and divestitures impacted our results of operations in &lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;2017&lt;/span&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:8pt;"&gt;&lt;span style="font-family:Arial;font-size:8pt;"&gt;The following table provides detailed revenue information for several of our major products:&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PRODUCT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;TOTAL REVENUES&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;&lt;span&gt;51,750&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;53,647&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;span&gt;52,546&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;39,419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;37,558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;35,530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Internal Medicine&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;9,119&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8,869&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8,229&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Eliquis alliance revenues and direct sales&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Nonvalvular Atrial fibrillation, deep vein thrombosis, pulmonary embolism&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,434&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,523&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Chantix/Champix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;An aid to smoking cessation treatment in adults 18 years of age or older&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,107&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,085&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;997&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Premarin family&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Symptoms of menopause&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;734&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;832&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;977&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;BMP2&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Development of bone and cartilage&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;287&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;279&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;261&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Toviaz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Overactive bladder&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;250&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;271&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;257&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Internal Medicine&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,521&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,969&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,213&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Oncology&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;9,014&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;7,471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;6,304&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Ibrance&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Metastatic breast cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,961&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;4,118&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,126&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Sutent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;936&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,049&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,081&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xtandi alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;590&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xalkori&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;ALK-positive and ROS1-positive advanced NSCLC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;530&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;524&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;594&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Inlyta&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Advanced RCC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;477&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;339&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bosulif&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Philadelphia&#160;chromosome&#x2013;positive&#160;chronic myelogenous leukemia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;365&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;296&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Retacrit&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Anemia&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;82&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Mektovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;49&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Braftovi&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;48&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Oncology&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;585&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;406&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;274&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Hospital&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;7,772&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;7,955&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;8,369&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Sulperazon&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;684&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;613&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;471&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Medrol&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Anti-inflammatory glucocorticoid&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;469&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;493&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;540&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Vfend&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fungal infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;346&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;392&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;421&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Zithromax&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(e)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;336&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;326&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;299&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;EpiPen&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Epinephrine injection used in treatment of life-threatening allergic reactions&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;303&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;290&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fragmin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Treatment/prevention of venous thromboembolism&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;253&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;293&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;306&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Zyvox&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;251&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;236&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Zosyn/Tazocin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;200&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;195&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Tygacil&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Bacterial infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;197&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;249&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;260&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Diflucan&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Fungal infections&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;190&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;189&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;180&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Panzyga&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Primary humoral immunodeficiency&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;183&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;39&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;810&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;755&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;706&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Anti-infectives&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,114&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,041&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,237&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Hospital&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(d)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,436&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,797&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,182&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;6,504&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;6,332&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;6,001&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Prevnar 13/Prevenar 13&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Pneumococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;5,847&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,802&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,601&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Nimenrix&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Meningococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;230&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;140&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;86&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;FSME/IMMUN-TicoVac&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Tick-borne encephalitis disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;220&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;184&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;134&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Trumenba&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Meningococcal disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;135&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;116&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;88&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Vaccines&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;73&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;90&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;91&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Inflammation &amp;amp; Immunology (I&amp;amp;I)&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,733&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;4,720&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;4,386&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xeljanz&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;RA, PsA, UC&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,242&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,774&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,345&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Enbrel (Outside the U.S. and Canada)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,699&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,112&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,452&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Inflectra/Remsima&lt;/span&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(c), (g)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Crohn&#x2019;s Disease, Pediatric Crohn&#x2019;s Disease, UC, Pediatric UC, RA in combination with methotrexate, Ankylosing Spondylitis, PsA and Plaque Psoriasis&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;625&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;642&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;419&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Eucrisa&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Mild-to-moderate atopic dermatitis (eczema) in adults and children 2 years of age and older&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;138&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;147&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;67&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other I&amp;amp;I&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;29&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;45&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;103&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;div style="line-height:120%;text-align:left;font-size:10pt;"&gt;&lt;div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"&gt;&lt;tr&gt;&lt;td colspan="15"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="width:22%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:44%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;td style="width:8%;"/&gt;&lt;td style="width:1%;"/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;(MILLIONS OF DOLLARS)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:center;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Year Ended December 31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PRODUCT&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:6px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;PRIMARY INDICATION OR CLASS&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;2019&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2017&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,278&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,211&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,240&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Genotropin&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Replacement of human growth hormone&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;498&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;558&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;532&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;BeneFIX&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Hemophilia B&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;488&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;554&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;604&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Vyndaqel/Vyndamax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;ATTR-Cardiomyopathy and Polyneuropathy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;473&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;148&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;124&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Refacto AF/Xyntha&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Hemophilia A&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;426&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;514&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;551&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Somavert&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Acromegaly&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;264&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;267&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;254&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Rare Disease&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;129&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;170&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;176&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;padding-left:12px;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Upjohn&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;10,233&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;12,484&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;13,447&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Lyrica &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Epilepsy, post-herepetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;3,321&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;4,970&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,065&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Lipitor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Reduction of LDL cholesterol&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,973&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,062&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,915&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Norvasc&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;950&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,029&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;932&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Celebrex&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Arthritis pain and inflammation, acute pain&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;719&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;686&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;775&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Viagra&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Erectile dysfunction&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;497&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;636&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,204&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Effexor&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Depression and certain anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;336&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;311&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;297&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Zoloft&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Depression and certain anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;294&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;298&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;291&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xalatan/Xalacom&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Glaucoma and ocular hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;281&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;318&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;335&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Xanax&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Anxiety disorders&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;198&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;223&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;225&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Revatio&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Pulmonary arterial hypertension&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;144&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;227&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;252&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;padding-left:18px;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;All other Upjohn&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;1,519&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;1,725&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,158&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Consumer Healthcare Business&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;2,098&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,605&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,472&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Other&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;&#x2014;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;97&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Total Alliance revenues&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;4,648&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;3,838&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;2,927&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Total Biosimilars&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;Various&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;911&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;769&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;531&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;font-weight:bold;"&gt;Total Sterile Injectable Pharmaceuticals&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"&gt;&lt;span&gt;5,035&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,214&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"&gt;&lt;div style="overflow:hidden;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;$&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"&gt;&lt;div style="text-align:right;font-size:6.5pt;"&gt;&lt;span style="font-family:Arial;font-size:6.5pt;"&gt;&lt;span&gt;5,673&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"&gt;&lt;div style="text-align:left;font-size:10pt;"&gt;&lt;span style="font-family:inherit;font-size:10pt;"&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;/div&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(a)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 and 2017 product revenues to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(b)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;We performed certain reclassifications in the All other Oncology category to conform 2018 and 2017 product revenues to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(c)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(d)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy SIP category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 and 2017 product revenues to the current presentation. Hospital also includes Pfizer CentreOne&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;. All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#x201c;All other Anti-infectives&#x201d;.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(e)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;2018 and 2017 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(f)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(g)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation &amp;amp; Immunology category to conform 2018 and 2017 product revenues to the current presentation.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(h)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;On July 31, 2019, Pfizer&#x2019;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1A&lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt; and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2C. &lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"&gt;&lt;tr&gt;&lt;td style="width:12px;"/&gt;&lt;td/&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top"&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(i)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:top;"&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Represents HIS revenues through February 2, 2017, which includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. On February 3, 2017, we completed the sale of HIS to ICU Medical. For additional information, see &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 1A &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;and &lt;/span&gt;&lt;span style="font-family:Arial;font-size:7pt;font-style:italic;"&gt;Note 2B.&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="line-height:120%;font-size:7pt;padding-left:0px;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:5pt"&gt;(j)&lt;/sup&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="line-height:120%;font-size:7pt;"&gt;&lt;span style="font-family:Arial;font-size:7pt;"&gt;Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD"
      decimals="-6"
      id="d34586122e6747-wk-Fact-99447C56530B57BB99F3272D91D61246"
      unitRef="usd">51750000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD"
      decimals="-6"
      id="d34586122e6766-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
      unitRef="usd">53647000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD"
      decimals="-6"
      id="d34586122e6786-wk-Fact-5800B99789A546352282801F7F2D7923"
      unitRef="usd">52546000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e6821-wk-Fact-986CD8670BD150AFB608018DDFD29424"
      unitRef="usd">39419000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e6840-wk-Fact-2138A395CF995DA1A891BA3B202C9BCB"
      unitRef="usd">37558000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e6860-wk-Fact-D2CE95E7B71E8C4C67B8801F7DD04AD2"
      unitRef="usd">35530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e6897-wk-Fact-B24D04AD1CFE5421B8AAB5E1AE97DC0A"
      unitRef="usd">9119000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e6916-wk-Fact-3FE2875CC05E5AF0955E1F16A4747D4E"
      unitRef="usd">8869000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e6936-wk-Fact-8882814ACBF86601CC36801F7E885BFB"
      unitRef="usd">8229000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e6966-wk-Fact-6C731063DF07515B8278EAAAF41E82F5"
      unitRef="usd">4220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e6985-wk-Fact-B3E66210D48550AA9926F625E4EBBAD4"
      unitRef="usd">3434000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EliquisMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7005-wk-Fact-2D99B1124ACE12540611801F82B4994F"
      unitRef="usd">2523000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7040-wk-Fact-A6B4F6B324375D53B10094F17B3C65B3"
      unitRef="usd">1107000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7059-wk-Fact-46F27B55B27B54EA8DB9649561CE42BB"
      unitRef="usd">1085000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ChantixChampixMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7079-wk-Fact-62650662D7DD8D7E8080801F82C35669"
      unitRef="usd">997000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7114-wk-Fact-12773FEDE0EF5957B1201377DC9142AE"
      unitRef="usd">734000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7133-wk-Fact-9BBA998B2CFF5DED95D8D386714FFE6A"
      unitRef="usd">832000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PremarinFamilyMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7153-wk-Fact-5582142AF8CAFB1642B1801F8152C802"
      unitRef="usd">977000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7188-wk-Fact-E6122F9BEB87535189F2629012724D92"
      unitRef="usd">287000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7207-wk-Fact-A83EDCFE0B465D95A739D4248C9470C0"
      unitRef="usd">279000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BMP2Member_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7227-wk-Fact-1C89FA66D1ECFDF67F72801F8179DC33"
      unitRef="usd">261000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7262-wk-Fact-1D47F48F7F3554A78127DAFE590E794E"
      unitRef="usd">250000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7281-wk-Fact-999640AF0F3A5772A546D4FCE619DC98"
      unitRef="usd">271000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ToviazMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7301-wk-Fact-9A23FE915E5D4E701F2A801F8173E1A9"
      unitRef="usd">257000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7336-wk-Fact-6A1D5D6AF4EC5CA8BE48BCBA53E3E2A8"
      unitRef="usd">2521000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7355-wk-Fact-BD0B6B5222EF5CB6A5FCC1C812C3C334"
      unitRef="usd">2969000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInternalMedicineMember_us-gaap_ReportingUnitAxis_pfe_InternalMedicineMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7375-wk-Fact-D025766C2E67D378C102801F81229E63"
      unitRef="usd">3213000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7418-wk-Fact-DCCC9223184B56788CBE0DB3BD4499E3"
      unitRef="usd">9014000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7437-wk-Fact-3DB102BD4155797B5C71DE18EDD8B9B9"
      unitRef="usd">7471000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7457-wk-Fact-2735403E9898D9DCFDE4DE1919D0AF5E"
      unitRef="usd">6304000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7487-wk-Fact-02E59B78118A5E36927E6E9D343F80C1"
      unitRef="usd">4961000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7506-wk-Fact-A1A886242BD55B97B9C6B7AE43B77A3F"
      unitRef="usd">4118000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_IbranceMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7526-wk-Fact-1D1D9E822C1094BF0A35801F7E86E0C0"
      unitRef="usd">3126000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7561-wk-Fact-AE2B016013A759EB976F0B6B8F4C219E"
      unitRef="usd">936000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7580-wk-Fact-34A07B3634CE5849A713202F3645E2BC"
      unitRef="usd">1049000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SutentMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7600-wk-Fact-6C990DD2B2AD4FB4F7BA801F82BE5EDE"
      unitRef="usd">1081000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7635-wk-Fact-09097F7E24E55CE185B3A8241786D001"
      unitRef="usd">838000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7654-wk-Fact-DF1B3BD729A55AC0A504DFD9608FFB96"
      unitRef="usd">699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XtandiAllianceRevenuesMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7674-wk-Fact-26023C9A152437741F6FDE1A28B16CBA"
      unitRef="usd">590000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7709-wk-Fact-7DD40C3C0E31507482EEDE2CEC4E867A"
      unitRef="usd">530000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7728-wk-Fact-AA23783A2EF0547FB95205FE30FF67FA"
      unitRef="usd">524000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XalkoriMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7748-wk-Fact-8806516F8B0543D58C87801F7DEE6452"
      unitRef="usd">594000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7783-wk-Fact-CBED98872E6D5AD683F5F65CF970FCE1"
      unitRef="usd">477000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7802-wk-Fact-51CBEE775FF5588DB0D7DCEC07FF57B0"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_InlytaMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7822-wk-Fact-34727ACB136D8931558B801F7E88E0C5"
      unitRef="usd">339000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7857-wk-Fact-5472417927D753EEBBB1072B6B105F5F"
      unitRef="usd">365000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7876-wk-Fact-FD3ADF5E45AC5ABC941EDCA88225428B"
      unitRef="usd">296000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BosulifMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7896-wk-Fact-5994144D551B14BACEFF801F7E7863C5"
      unitRef="usd">233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7933-wk-Fact-A80D878425B55E7DB0E92B5480994305"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7952-wk-Fact-A9B6D8B90E4D5AC4A32D4CCEFCEEBE96"
      unitRef="usd">82000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_RetacritMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e7972-wk-Fact-FA8027A58E5CA9651A05801F82B7CF8D"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8007-wk-Fact-25FC84B343C1A318CA97DE1AB610DB22"
      unitRef="usd">49000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8026-wk-Fact-DF4D7D64D34A7D6D90A6DE1ABA698DA3"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_MektoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8046-wk-Fact-6A654FC14177C9A6479ADE1ABFE4C4D9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8081-wk-Fact-B703DA942F77EDFDF491DE1AC4EE74EA"
      unitRef="usd">48000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8100-wk-Fact-34E5BC40943A516066D70E4C8FD42F51"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BraftoviMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8120-wk-Fact-FF2D62AF2B56AC1092D2DE1ACB8DAAEA"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8155-wk-Fact-67C37AC357CC578E8A2CE9AD15A0F5DE"
      unitRef="usd">585000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8174-wk-Fact-574622BD96AD5C9083C68ABC1F23BDDF"
      unitRef="usd">406000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherOncologyProductsMember_us-gaap_ReportingUnitAxis_pfe_OncologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8194-wk-Fact-385EDBE1A04BC6E2A680801F829EC2AC"
      unitRef="usd">274000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8237-wk-Fact-A8B53B0AF0215974918EFB048833F5CB"
      unitRef="usd">7772000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8256-wk-Fact-3D222D29334A51ED9477C50D604F7F80"
      unitRef="usd">7955000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8276-wk-Fact-B9634D3CD51FCF12B7F1DE1F7DE2E34F"
      unitRef="usd">8369000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8306-wk-Fact-E9743691F65857D4AA21DEFCE49F0F66"
      unitRef="usd">684000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8325-wk-Fact-532A8105F0605BF7A90B026D9DC3C86C"
      unitRef="usd">613000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SulperazonMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8345-wk-Fact-1AA27963C1EA03D86E56DE208FA6FEF4"
      unitRef="usd">471000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8382-wk-Fact-B9796D68B7845314B40EE00253EDFE48"
      unitRef="usd">469000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8401-wk-Fact-759DF68F819A59389A4AC00C6D1F61C6"
      unitRef="usd">493000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_MedrolMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8421-wk-Fact-BE0EABAA50D96FFC3507DE2093101A4D"
      unitRef="usd">540000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8456-wk-Fact-937F899827ED53BF9733BC0E5A2C276B"
      unitRef="usd">346000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8475-wk-Fact-356826AC764E5F1AB122D61B135DA970"
      unitRef="usd">392000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_VfendMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8495-wk-Fact-778F76F534866B4C274BDE209664FDB1"
      unitRef="usd">421000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8532-wk-Fact-E97AA6E5D4FA5F64AFB7FBD507DC3DB7"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8551-wk-Fact-AF503AE62454526EB03769AE56899F54"
      unitRef="usd">326000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZithromaxZmaxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8571-wk-Fact-1358C7993E24C71EC31CDE2099C357C1"
      unitRef="usd">299000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8606-wk-Fact-D06ED7D632E3530D9D350CF38120C535"
      unitRef="usd">303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8625-wk-Fact-F7DF3FA519E05ABBB36AF2BDC1C1D5E2"
      unitRef="usd">303000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EpiPenMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8645-wk-Fact-EA467189B34B25F5663DDE209D44E894"
      unitRef="usd">290000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8680-wk-Fact-9F9BFF3F49E4598B845CC5FD385C80FE"
      unitRef="usd">253000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8699-wk-Fact-E7318B73FA0358F7AAB3343146AFB749"
      unitRef="usd">293000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_FragminMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8719-wk-Fact-953503D0D518BB2D4A20DE20A0816CCB"
      unitRef="usd">306000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8754-wk-Fact-5C0064D89F285BDD8A146792BE0F3384"
      unitRef="usd">251000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8773-wk-Fact-F0DD6FB9D7D65FF7A33085989120CCED"
      unitRef="usd">236000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZyvoxMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8793-wk-Fact-93F788C458704E75C6BDDE20A3FD7BC2"
      unitRef="usd">281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8828-wk-Fact-88ED49AD8223552FBECDEDC3724ABA7A"
      unitRef="usd">200000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8847-wk-Fact-DD01A36819E15802AFBF1E72FE27BC50"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZosynTazocinMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8867-wk-Fact-F5C4DA82D51CF805497FDE20A789D463"
      unitRef="usd">195000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8902-wk-Fact-4621E7DDA21358AB9B0293A23E1E94CC"
      unitRef="usd">197000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8921-wk-Fact-B344BD9ABF6754369FCF350AF52DE418"
      unitRef="usd">249000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TygacilMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8941-wk-Fact-813264E7C289A5D5ECB7DE20AAB91829"
      unitRef="usd">260000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8976-wk-Fact-47C32F6B4940C65CF511DE20FEBC9F1E"
      unitRef="usd">190000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e8995-wk-Fact-A561864E833387BD903CDE210367E099"
      unitRef="usd">189000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_DiflucanMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9015-wk-Fact-48F70FD623656D97865CDE21089CEB52"
      unitRef="usd">180000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9051-wk-Fact-E562078593EEE80AC567801F8179DDAD"
      unitRef="usd">183000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9070-wk-Fact-5955DF531022E6A702C4801F82A42A3E"
      unitRef="usd">39000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PanzygaMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9090-wk-Fact-5FF17F954895E52A550DDE22B9D0BED2"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9127-wk-Fact-810B1FD04766529CA8FCD18FC3883D4B"
      unitRef="usd">810000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9146-wk-Fact-67635FDCF78A5B1F882CF82F5CDD09D7"
      unitRef="usd">755000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PfizerCentreOneMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9166-wk-Fact-A2F4496694D82FBCD30CDE22BCA5386D"
      unitRef="usd">706000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9201-wk-Fact-801912F69D61590398C5CEEE0D4764FE"
      unitRef="usd">1114000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9220-wk-Fact-494DF9151E065567834DBAE4E1B562F9"
      unitRef="usd">1041000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherAntiinfectivesMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9240-wk-Fact-81945090A4FFE403DEA2DE22C004E729"
      unitRef="usd">1237000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9277-wk-Fact-710F79BB7E78505B80B3DD29D470A8D7"
      unitRef="usd">2436000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9296-wk-Fact-685DE43906F252099A21B0122F5E2271"
      unitRef="usd">2797000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherHospitalProductsMember_us-gaap_ReportingUnitAxis_pfe_HospitalMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9316-wk-Fact-CAF98663333909A19E50DE22C3E7514B"
      unitRef="usd">3182000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9356-wk-Fact-DDB1D56C1E705432A99023025DE61FC6"
      unitRef="usd">6504000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9375-wk-Fact-BBDAE04D6CFA59C8AAEC3FDF42705515"
      unitRef="usd">6332000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9395-wk-Fact-2252BB68D2B6CE95DE6F801F82C071DC"
      unitRef="usd">6001000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9425-wk-Fact-96C64EFA9EB5530AB6921E0B596EB44C"
      unitRef="usd">5847000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9444-wk-Fact-6D96C4CA7C5659AB8ED1F8CE7B49D099"
      unitRef="usd">5802000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_PrevnarPrevenarFamilyMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9464-wk-Fact-D849BF316CA966119FC6801F8174CBAB"
      unitRef="usd">5601000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9499-wk-Fact-CCD1EAD68F3B58FEAD95E57F92CE3343"
      unitRef="usd">230000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9518-wk-Fact-657DFFC172A85133B04FF502D24434E3"
      unitRef="usd">140000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_NimenrixMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9538-wk-Fact-A22D7E673C93E7C70A39DE2E93483C38"
      unitRef="usd">86000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9573-wk-Fact-A0A12E1176AD5F47B4EE630D93FA9E54"
      unitRef="usd">220000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9592-wk-Fact-502A552AC2A45AA8943A75D93CF23EA3"
      unitRef="usd">184000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_FSMEIMMUNTicoVacMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9612-wk-Fact-0FCAEA446042111840E7801F82CE4B1B"
      unitRef="usd">134000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9647-wk-Fact-6CE58F4DCA21567DB73364B111AE5E4C"
      unitRef="usd">135000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9666-wk-Fact-FF61F86FDE155D008B83817D0F81C403"
      unitRef="usd">116000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TrumenbaMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9686-wk-Fact-CC8278477CE6874B4A84801F8160D66D"
      unitRef="usd">88000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9721-wk-Fact-6E6029DB75FA52DF9D7FAEA201A4D55F"
      unitRef="usd">73000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9740-wk-Fact-77F2BBF170B358E288F7FC940DA00BD5"
      unitRef="usd">90000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_OtherVaccinesProductsMember_us-gaap_ReportingUnitAxis_pfe_VaccinesMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9760-wk-Fact-E4D515B7D6F6319CCB8C801F7E7C1315"
      unitRef="usd">91000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9802-wk-Fact-54CC08145C9B5A5BA23B67DFBAD4AE0E"
      unitRef="usd">4733000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9821-wk-Fact-45E0D791242D55AC81FC3EFB761F9C00"
      unitRef="usd">4720000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9841-wk-Fact-92524ACC782CD4CDC985801F7E45AECD"
      unitRef="usd">4386000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9872-wk-Fact-5771636556985C87BC8C3CB410CC66F7"
      unitRef="usd">2242000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9891-wk-Fact-881709D18F145B4CB609A31E6FB0D982"
      unitRef="usd">1774000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XeljanzMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9911-wk-Fact-72FA6A6777398A051E57801F7E7966A0"
      unitRef="usd">1345000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9946-wk-Fact-85E9E7AA5D595959A86313A1C0CA3A83"
      unitRef="usd">1699000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9965-wk-Fact-A982B6EE13215444830BADC0E2C52ACD"
      unitRef="usd">2112000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EnbrelMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e9985-wk-Fact-56B05001ED9BC8F7B322801F8171F6EF"
      unitRef="usd">2452000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10022-wk-Fact-52734113DA315C5EB0822EA6C1F6019D"
      unitRef="usd">625000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10041-wk-Fact-2DA2C6E810E554E8A093A9328B417C64"
      unitRef="usd">642000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_InflectraRemsimaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10061-wk-Fact-8479D37C35D17BB7F483DE31473AEC66"
      unitRef="usd">419000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10096-wk-Fact-F6B75BABBAB55FA999FDCDEA743AF12B"
      unitRef="usd">138000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10114-wk-Fact-B2445D4B47D85E9CBA4A74E1190125C3"
      unitRef="usd">147000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EucrisaMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10133-wk-Fact-5D359C48EE073DF7C9CD801F817AF13E"
      unitRef="usd">67000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10168-wk-Fact-C29B3A689BD4584B967AF3ABE0A9C9D3"
      unitRef="usd">29000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10187-wk-Fact-B891103106B358EFB566B38D67137E32"
      unitRef="usd">45000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherInflammationandImmunologyProductsMember_us-gaap_ReportingUnitAxis_pfe_InflammationandImmunologyMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10207-wk-Fact-0746CE99B3EAB2B6BC0D801F8173BC3D"
      unitRef="usd">103000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10422-wk-Fact-2EEF4D44A62758ECA673A2C525E87810"
      unitRef="usd">2278000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10441-wk-Fact-D462C85B830E5EC9A38A53665CF12AAC"
      unitRef="usd">2211000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10461-wk-Fact-FF3EB5CD7F2F1CB72F9F801F81478D7F"
      unitRef="usd">2240000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10491-wk-Fact-6BE98570AA95526ABD53C26677B1710F"
      unitRef="usd">498000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10510-wk-Fact-ECC4A2CDEC965D8FB2F629398E5BC2BC"
      unitRef="usd">558000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_GenotropinMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10530-wk-Fact-0A844536B6E840560C6B801F7E79A760"
      unitRef="usd">532000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10565-wk-Fact-7841FB6089E25815A6EDEE08192734A3"
      unitRef="usd">488000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10584-wk-Fact-719EC870EC045A6D800C3B2FC590F735"
      unitRef="usd">554000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_BeneFIXMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10604-wk-Fact-970FAB6E5C131F82582F801F82B780EF"
      unitRef="usd">604000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10639-wk-Fact-184BCA46D7B15120908057BE81C0BFBF"
      unitRef="usd">473000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10658-wk-Fact-C26D40F32E8C5DF586F966DCCE25BB95"
      unitRef="usd">148000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_VyndaqelMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10678-wk-Fact-7ECE376C77FD2DD56F01DE348401E779"
      unitRef="usd">124000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10713-wk-Fact-B9B91A07AC415AA3A4259816262AC760"
      unitRef="usd">426000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10732-wk-Fact-8AE48012DC4B5DC984E6FAE7DC707343"
      unitRef="usd">514000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ReFactoAfXynthaMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10752-wk-Fact-67C6F4B996699FB20DAB801F82C0E197"
      unitRef="usd">551000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10787-wk-Fact-DEEDFEEA02DD5254A0EF0A6659BFB537"
      unitRef="usd">264000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10806-wk-Fact-0840E546E4935A9C8A5319D9675773CF"
      unitRef="usd">267000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_SomavertMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10826-wk-Fact-887C4E6B025669711220801F82C33182"
      unitRef="usd">254000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10861-wk-Fact-42D0C86776005662879A00E1A37C431B"
      unitRef="usd">129000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10880-wk-Fact-3B667D7348965CC598C1885A39DACBD1"
      unitRef="usd">170000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherRareDiseaseProductsMember_us-gaap_ReportingUnitAxis_pfe_RareDiseaseMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaSegmentMember"
      decimals="-6"
      id="d34586122e10900-wk-Fact-4D7CC466FCEC6B66F031801F7E69E2CF"
      unitRef="usd">176000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e10942-wk-Fact-76700083BB585619B1B78E77F16D4429"
      unitRef="usd">10233000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e10961-wk-Fact-414C030E79B750E3A44270BCED97927B"
      unitRef="usd">12484000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e10981-wk-Fact-1FE49E27774BBC4F7DE7801F7E5B14A7"
      unitRef="usd">13447000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11011-wk-Fact-04C938F3AC685E7389C0CF59D2959913"
      unitRef="usd">3321000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11030-wk-Fact-D8245C971D9C5E578F90851085D1B795"
      unitRef="usd">4970000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_LyricaMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11050-wk-Fact-56B658880869AEACE541801F8187F9A3"
      unitRef="usd">5065000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11086-wk-Fact-D010F52EA88A56D0A3A81F17EB5D38DC"
      unitRef="usd">1973000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11105-wk-Fact-982E769D9AA15AF18F31878D9A3BFD37"
      unitRef="usd">2062000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_LipitorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11125-wk-Fact-841D58224C20C05AA3AF801F82B7E834"
      unitRef="usd">1915000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11160-wk-Fact-2C95573C6F895F6892E174F65C10E575"
      unitRef="usd">950000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11179-wk-Fact-CE019DDF6C655A12B3EDF80392CD6DCA"
      unitRef="usd">1029000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_NorvascMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11199-wk-Fact-6A5565AC16FAF0E46BF3801F818756A4"
      unitRef="usd">932000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11234-wk-Fact-1869D81D977F534390770DD20D262AB7"
      unitRef="usd">719000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11253-wk-Fact-3EBD6C7A46BD54608DC97B7D5BC28BC5"
      unitRef="usd">686000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_CelebrexMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11273-wk-Fact-11BAC5EE7A45CC2D5AFAD082FDAA0EF1"
      unitRef="usd">775000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11308-wk-Fact-6428270E830C52D8A83D9D78EC21F20E"
      unitRef="usd">497000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11327-wk-Fact-B57EC914CEEC57AD9AEC75DF29FD04C2"
      unitRef="usd">636000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ViagraMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11347-wk-Fact-8784FEB4B63967D223B8D083004C1A1D"
      unitRef="usd">1204000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11382-wk-Fact-A794165CEA5A51B0A3B6004B3D79A885"
      unitRef="usd">336000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11401-wk-Fact-08FCBF9B923C5EC484E72D471007E0A6"
      unitRef="usd">311000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_EffexorMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11421-wk-Fact-821C54ED7C862C84B170801F7E88C49D"
      unitRef="usd">297000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11456-wk-Fact-5A942695EAC354C8809AF1522CA91E6D"
      unitRef="usd">294000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11475-wk-Fact-B1C55F4CB7D652428FCC68218AAE6DD5"
      unitRef="usd">298000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_ZoloftMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11495-wk-Fact-87951FBDF4C375B6753E801F81755F3D"
      unitRef="usd">291000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11530-wk-Fact-2091B860985E526EACD15CD4A5669CD5"
      unitRef="usd">281000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11549-wk-Fact-AD6A89B15A765F7DA13013F765D9BCCE"
      unitRef="usd">318000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XalatanXalacomMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11569-wk-Fact-F6AEFE5F18DC80AFD6EE801F81742ECC"
      unitRef="usd">335000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11604-wk-Fact-7CFB7F412548587F896D99F507DBCD19"
      unitRef="usd">198000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11623-wk-Fact-63FD058F80E55C109E636F60FC6CA539"
      unitRef="usd">223000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_XanaxMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11643-wk-Fact-76BFF3E0ECCB06EAD23D801F82CA7536"
      unitRef="usd">225000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11678-wk-Fact-75D45301C70951D3867054250941F9AE"
      unitRef="usd">144000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11697-wk-Fact-D0B09E4190DD536D8D7A0B352A916E5F"
      unitRef="usd">227000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_RevatioMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11717-wk-Fact-4D849F31F84479F6D413D0834B8AEBFC"
      unitRef="usd">252000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11752-wk-Fact-FA19F775D49E5417994497ED45F8B1B7"
      unitRef="usd">1519000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11771-wk-Fact-2F3A89C4B2BD5133ACFBE4229DDE6CC5"
      unitRef="usd">1725000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_AllOtherUpjohnProductsMember_us-gaap_ReportingUnitAxis_pfe_UpjohnReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_UpjohnSegmentMember"
      decimals="-6"
      id="d34586122e11791-wk-Fact-F82E69C6D1AF9AB5F0E1801F7E7C93ED"
      unitRef="usd">2158000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34586122e11833-wk-Fact-CCBB2BC438EC5A9B8250ABDDBE53A9E1"
      unitRef="usd">2098000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34586122e11852-wk-Fact-080B5520FFBB5986BB0E2FAA190C849C"
      unitRef="usd">3605000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_us-gaap_ReportingUnitAxis_pfe_ConsumerHealthcareReportingUnitMember_us-gaap_StatementBusinessSegmentsAxis_pfe_ConsumerHealthcareMember"
      decimals="-6"
      id="d34586122e11872-wk-Fact-1E63E1B1645BA0E7748B801F818279BE"
      unitRef="usd">3472000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e11910-wk-Fact-CDC99316A1F49B8343F1DE3EC68E31D9"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e11929-wk-Fact-83D643576F2E4A880436DE3EC9DE5D5D"
      unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_HISProductsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e11949-wk-Fact-B14A778A0529F4E56FC1DE3ECD2EE7E6"
      unitRef="usd">97000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e11984-wk-Fact-81ACE807558B5C5CB92572A02959FF1A"
      unitRef="usd">4648000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e12003-wk-Fact-0034831A3E24527FAAC34DC7E1212EFC"
      unitRef="usd">3838000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalAllianceBiopharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e12023-wk-Fact-30367F2EFA82C29A0B01801F7DE3312D"
      unitRef="usd">2927000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e12058-wk-Fact-2846B8E6B6B05D109C0045899F1AADE9"
      unitRef="usd">911000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e12076-wk-Fact-D8583C2532635E7E884D51C71C684B47"
      unitRef="usd">769000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalBiosimilarsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e12095-wk-Fact-C0BF06F9A6D60B722450801F82C0AE3B"
      unitRef="usd">531000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2019Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e12132-wk-Fact-6E43981A243F593FB97D9CA3CEB76E6D"
      unitRef="usd">5035000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2018Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e12151-wk-Fact-772A4F70D4985AACB86E028464DB65E7"
      unitRef="usd">5214000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="FD2017Q4YTD_srt_ProductOrServiceAxis_pfe_TotalSterileInjectablePharmaceuticalsMember_us-gaap_StatementBusinessSegmentsAxis_pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember"
      decimals="-6"
      id="d34586122e12171-wk-Fact-05EFB7BDD97ED86D525A801F8161A33D"
      unitRef="usd">5673000000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#d34523018e1616-wk-Fact-0035B9C9DB225A72A990E1262460243C"
          xlink:label="d34523018e1616-wk-Fact-0035B9C9DB225A72A990E1262460243C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2168-wk-Fact-0035B9C9DB225A72A990E1262460243C"
          xlink:label="d34430544e2168-wk-Fact-0035B9C9DB225A72A990E1262460243C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl" xlink:label="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-top:1px;padding-left:12px;text-indent:-12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e1616-wk-Fact-0035B9C9DB225A72A990E1262460243C"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2168-wk-Fact-0035B9C9DB225A72A990E1262460243C"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3144-wk-Fact-0065C22DDD425D5EB99735A6E835EC0F"
          xlink:label="d34661879e3144-wk-Fact-0065C22DDD425D5EB99735A6E835EC0F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl" xlink:label="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$156 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> net pension benefit obligation and recorded a pretax settlement gain of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$41 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$30 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</xhtml:span><xhtml:span style="font-family:Arial;font-size:8pt;font-style:italic;">&#x2014;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">net </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">(see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3144-wk-Fact-0065C22DDD425D5EB99735A6E835EC0F"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11445-wk-Fact-00777F633E4D23DFB02C801F81EE6F40"
          xlink:label="d34661879e11445-wk-Fact-00777F633E4D23DFB02C801F81EE6F40"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl" xlink:label="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#160;<xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The PBO represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases. The ABO is similar to the PBO but does not factor in future compensation increases. For the U.S. qualified and supplemental (non-qualified) pension plans, the benefit obligation is the PBO, which is also equal to the ABO. Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#x2019; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$10.6 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$9.5 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. For the postretirement plans, the benefit obligation is the ABO.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11445-wk-Fact-00777F633E4D23DFB02C801F81EE6F40"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2442-wk-Fact-00B28A85A0415720B146A31F5401E641"
          xlink:label="d34468079e2442-wk-Fact-00B28A85A0415720B146A31F5401E641"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl" xlink:label="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Additional depreciation&#x2013;&#x2013;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2442-wk-Fact-00B28A85A0415720B146A31F5401E641"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-00B42AB6C63D4D47D995801F8250336C-wk-Fact-00B42AB6C63D4D47D995801F8250336C"
          xlink:label="Fact-00B42AB6C63D4D47D995801F8250336C-wk-Fact-00B42AB6C63D4D47D995801F8250336C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl" xlink:label="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-00B42AB6C63D4D47D995801F8250336C-wk-Fact-00B42AB6C63D4D47D995801F8250336C"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20421-wk-Fact-00B706497805EC20E4D4801F80E92761"
          xlink:label="d34661879e20421-wk-Fact-00B706497805EC20E4D4801F80E92761"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl" xlink:label="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 1E</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20421-wk-Fact-00B706497805EC20E4D4801F80E92761"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1609-wk-Fact-00FA4D10D2645A50AEDEE8302484A6D5"
          xlink:label="d34428379e1609-wk-Fact-00FA4D10D2645A50AEDEE8302484A6D5"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl" xlink:label="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Amounts in 2019 include a gain of approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$1.3 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> pre-tax (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$978 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> after-tax) related to foreign currency translation adjustments attributable to our equity method investment in the GSK Consumer Healthcare joint venture (see</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), partially offset by the strengthening of the U.S. dollar against the euro and the Australian dollar, and the results of our net investment hedging program. In 2018, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Foreign currency translation adjustments, net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily reflects the strengthening of the U.S. dollar against the euro, U.K. pound and Chinese renminbi, In 2017, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Foreign currency translation adjustments, net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily reflects the weakening of the U.S. dollar against the euro, U.K. pound and the Canadian dollar.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1609-wk-Fact-00FA4D10D2645A50AEDEE8302484A6D5"
          xlink:to="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl" xlink:label="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-top:2px;padding-left:12px;text-indent:-12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1609-wk-Fact-00FA4D10D2645A50AEDEE8302484A6D5"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20893-wk-Fact-01207FB539212ED3CB3B801F810048DB"
          xlink:label="d34661879e20893-wk-Fact-01207FB539212ED3CB3B801F810048DB"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl" xlink:label="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20893-wk-Fact-01207FB539212ED3CB3B801F810048DB"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20893-wk-Fact-01207FB539212ED3CB3B801F810048DB"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1718-wk-Fact-01A8C48E01D25B3EAFDAC449EB4857D2"
          xlink:label="d34428379e1718-wk-Fact-01A8C48E01D25B3EAFDAC449EB4857D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1718-wk-Fact-01A8C48E01D25B3EAFDAC449EB4857D2"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10438-wk-Fact-0239ED48FEE8F23ED2EC801F81FB9BC5"
          xlink:label="d34661879e10438-wk-Fact-0239ED48FEE8F23ED2EC801F81FB9BC5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10438-wk-Fact-0239ED48FEE8F23ED2EC801F81FB9BC5"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9572-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB"
          xlink:label="d34661879e9572-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e11542-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB"
          xlink:label="d34661879e11542-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9572-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11542-wk-Fact-02534E0A6009BF8A9CB7801F8227BBBB"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2616-wk-Fact-027BA945C36E755C6E0D801F8147CCD2"
          xlink:label="d34523018e2616-wk-Fact-027BA945C36E755C6E0D801F8147CCD2"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl" xlink:label="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">2017 includes the effect of the modification for a commitment to pay </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>15.2 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2616-wk-Fact-027BA945C36E755C6E0D801F8147CCD2"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7487-wk-Fact-02E59B78118A5E36927E6E9D343F80C1"
          xlink:label="d34586122e7487-wk-Fact-02E59B78118A5E36927E6E9D343F80C1"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl" xlink:label="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">We performed certain reclassifications in the All other Oncology category to conform 2018 and 2017 product revenues to the current presentation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7487-wk-Fact-02E59B78118A5E36927E6E9D343F80C1"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6203-wk-Fact-0330CAF6E36D229B5BC3801F7E8C2429"
          xlink:label="d34586122e6203-wk-Fact-0330CAF6E36D229B5BC3801F7E8C2429"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl" xlink:label="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;text-indent:-12px;"><xhtml:span style="font-family:Arial;font-size:7pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6203-wk-Fact-0330CAF6E36D229B5BC3801F7E8C2429"
          xlink:to="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9831-wk-Fact-0396A14A962557AD9B92CF1A5FBBC4F5"
          xlink:label="d34458032e9831-wk-Fact-0396A14A962557AD9B92CF1A5FBBC4F5"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl" xlink:label="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-top:2px;padding-left:12px;text-indent:-12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9831-wk-Fact-0396A14A962557AD9B92CF1A5FBBC4F5"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6860-wk-Fact-0451479DAEAC08A2B0C5801F820E384C"
          xlink:label="d34661879e6860-wk-Fact-0451479DAEAC08A2B0C5801F820E384C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl" xlink:label="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#x2019; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6860-wk-Fact-0451479DAEAC08A2B0C5801F820E384C"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e9131-wk-Fact-04675E47A2C7545A8AB05010E81694A0"
          xlink:label="d34545404e9131-wk-Fact-04675E47A2C7545A8AB05010E81694A0"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl" xlink:label="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For additional information on the adoption of a new accounting standard related to reclassification of certain tax effects from AOCI, see Notes to Consolidated Financial Statements&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9131-wk-Fact-04675E47A2C7545A8AB05010E81694A0"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63"
          xlink:label="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl" xlink:label="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other comprehensive income/(loss)&#x2013;&#x2013;Unrealized holding gains/(losses) on derivative financial instruments, net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other comprehensive income/(loss)&#x2013;&#x2013;Foreign currency translation adjustments, net.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl" xlink:label="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The amounts reclassified from OCI into COS were a net </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">gain</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$247 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in 2019 and a net </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">loss</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$13 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in 2018. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">gain</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$145 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> within the next 12 months into </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$1.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> U.K. pound debt maturing in 2043. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63"
          xlink:to="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl" xlink:label="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">OID = Other (income)/deductions&#x2014;net,</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">&#160;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2014;net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> COS = Cost of Sales, included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3859-wk-Fact-0475F06CF4E95DD7877E5F79DC80AC63"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1604-wk-Fact-0489780C77A658BF8868E1551D1C625D"
          xlink:label="d34430544e1604-wk-Fact-0489780C77A658BF8868E1551D1C625D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl" xlink:label="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Exclusive of amortization of intangible assets, except as disclosed in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1L.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1604-wk-Fact-0489780C77A658BF8868E1551D1C625D"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1604-wk-Fact-0489780C77A658BF8868E1551D1C625D"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2938-wk-Fact-048CE44A39F6A1095A80801F80E770F3"
          xlink:label="d34586122e2938-wk-Fact-048CE44A39F6A1095A80801F80E770F3"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl" xlink:label="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2938-wk-Fact-048CE44A39F6A1095A80801F80E770F3"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11011-wk-Fact-04C938F3AC685E7389C0CF59D2959913"
          xlink:label="d34586122e11011-wk-Fact-04C938F3AC685E7389C0CF59D2959913"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl" xlink:label="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 and 2017 product revenues to the current presentation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11011-wk-Fact-04C938F3AC685E7389C0CF59D2959913"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20222-wk-Fact-050ACDA8F1A6426D3F26801F7FFAD77E"
          xlink:label="d34661879e20222-wk-Fact-050ACDA8F1A6426D3F26801F7FFAD77E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20222-wk-Fact-050ACDA8F1A6426D3F26801F7FFAD77E"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2696-wk-Fact-05108BE54FE052919D68B32B6466B9DF"
          xlink:label="d34423000e2696-wk-Fact-05108BE54FE052919D68B32B6466B9DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2696-wk-Fact-05108BE54FE052919D68B32B6466B9DF"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4513-wk-Fact-0584C0E58CA0A6B96247801F7EC7A79A"
          xlink:label="d34458032e4513-wk-Fact-0584C0E58CA0A6B96247801F7EC7A79A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4513-wk-Fact-0584C0E58CA0A6B96247801F7EC7A79A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl" xlink:label="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">2017 treasury shares include the effect of the modification for a commitment to pay </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>15.2 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4513-wk-Fact-0584C0E58CA0A6B96247801F7EC7A79A"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2597-wk-Fact-05A1EA23D34141CA08B0801F825F2A0B"
          xlink:label="d34458036e2597-wk-Fact-05A1EA23D34141CA08B0801F825F2A0B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl" xlink:label="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;padding-top:2px;padding-left:12px;text-indent:-12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2597-wk-Fact-05A1EA23D34141CA08B0801F825F2A0B"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3301-wk-Fact-05D8B303E9C377506BB9801F81963C22"
          xlink:label="d34586122e3301-wk-Fact-05D8B303E9C377506BB9801F81963C22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3301-wk-Fact-05D8B303E9C377506BB9801F81963C22"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e12171-wk-Fact-05EFB7BDD97ED86D525A801F8161A33D"
          xlink:label="d34586122e12171-wk-Fact-05EFB7BDD97ED86D525A801F8161A33D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl" xlink:label="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e12171-wk-Fact-05EFB7BDD97ED86D525A801F8161A33D"
          xlink:to="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1909-wk-Fact-0612C9171BB1563BAA0D97F47098AC20"
          xlink:label="d34430544e1909-wk-Fact-0612C9171BB1563BAA0D97F47098AC20"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1909-wk-Fact-0612C9171BB1563BAA0D97F47098AC20"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5634-wk-Fact-0688D8F87F0B5FFEBC9B4EB51F7A9A52"
          xlink:label="d34458036e5634-wk-Fact-0688D8F87F0B5FFEBC9B4EB51F7A9A52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5634-wk-Fact-0688D8F87F0B5FFEBC9B4EB51F7A9A52"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6816-wk-Fact-06AF0A8C537DC59A1463801F827D4A6F"
          xlink:label="d34545404e6816-wk-Fact-06AF0A8C537DC59A1463801F827D4A6F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl" xlink:label="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6816-wk-Fact-06AF0A8C537DC59A1463801F827D4A6F"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl" xlink:label="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily related to effectively settling certain issues with the U.S. and foreign tax authorities. See also </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6816-wk-Fact-06AF0A8C537DC59A1463801F827D4A6F"
          xlink:to="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-07091715647256CDB4AD8057DCE577E8-wk-Fact-07091715647256CDB4AD8057DCE577E8"
          xlink:label="Fact-07091715647256CDB4AD8057DCE577E8-wk-Fact-07091715647256CDB4AD8057DCE577E8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-07091715647256CDB4AD8057DCE577E8-wk-Fact-07091715647256CDB4AD8057DCE577E8"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3189-wk-Fact-07104F174ED656CF8AABB4441FC28486"
          xlink:label="d34458036e3189-wk-Fact-07104F174ED656CF8AABB4441FC28486"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3189-wk-Fact-07104F174ED656CF8AABB4441FC28486"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10207-wk-Fact-0746CE99B3EAB2B6BC0D801F8173BC3D"
          xlink:label="d34586122e10207-wk-Fact-0746CE99B3EAB2B6BC0D801F8173BC3D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl" xlink:label="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation &amp; Immunology category to conform 2018 and 2017 product revenues to the current presentation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10207-wk-Fact-0746CE99B3EAB2B6BC0D801F8173BC3D"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7228-wk-Fact-075B080714B45D30944D97942F14A858"
          xlink:label="d34458032e7228-wk-Fact-075B080714B45D30944D97942F14A858"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7228-wk-Fact-075B080714B45D30944D97942F14A858"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2136-wk-Fact-07A3726E8AD3C897B843CF6EF6032DBA"
          xlink:label="d34460716e2136-wk-Fact-07A3726E8AD3C897B843CF6EF6032DBA"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl" xlink:label="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:100%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2136-wk-Fact-07A3726E8AD3C897B843CF6EF6032DBA"
          xlink:to="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4345-wk-Fact-07AD3C926A5E57D3A3F93B11BDBF155E"
          xlink:label="d34661879e4345-wk-Fact-07AD3C926A5E57D3A3F93B11BDBF155E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4345-wk-Fact-07AD3C926A5E57D3A3F93B11BDBF155E"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2644-wk-Fact-07EEAB5D75BE5733BBE5DDB62C46DAC9"
          xlink:label="d34430544e2644-wk-Fact-07EEAB5D75BE5733BBE5DDB62C46DAC9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2644-wk-Fact-07EEAB5D75BE5733BBE5DDB62C46DAC9"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7209-wk-Fact-07FAC1C1243E5138A0C37BBBC348368F"
          xlink:label="d34458032e7209-wk-Fact-07FAC1C1243E5138A0C37BBBC348368F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7209-wk-Fact-07FAC1C1243E5138A0C37BBBC348368F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11852-wk-Fact-080B5520FFBB5986BB0E2FAA190C849C"
          xlink:label="d34586122e11852-wk-Fact-080B5520FFBB5986BB0E2FAA190C849C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl" xlink:label="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">On July 31, 2019, Pfizer&#x2019;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#x2019;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11852-wk-Fact-080B5520FFBB5986BB0E2FAA190C849C"
          xlink:to="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e1950-wk-Fact-08237D5DF91153BBBDE19A688EC551B8"
          xlink:label="d34523018e1950-wk-Fact-08237D5DF91153BBBDE19A688EC551B8"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2447-wk-Fact-08237D5DF91153BBBDE19A688EC551B8"
          xlink:label="d34430544e2447-wk-Fact-08237D5DF91153BBBDE19A688EC551B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e1950-wk-Fact-08237D5DF91153BBBDE19A688EC551B8"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2447-wk-Fact-08237D5DF91153BBBDE19A688EC551B8"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2861-wk-Fact-084878331CAE5F50893848F4E5725E12"
          xlink:label="d34586122e2861-wk-Fact-084878331CAE5F50893848F4E5725E12"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl" xlink:label="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. Biopharma&#x2019;s earnings</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;"> include d</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">ividend income from our investment in ViiV of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$220 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$253 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$266 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2861-wk-Fact-084878331CAE5F50893848F4E5725E12"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23067-wk-Fact-084E62D562F5DB1E17D2801F8025171B"
          xlink:label="d34661879e23067-wk-Fact-084E62D562F5DB1E17D2801F8025171B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl" xlink:label="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23067-wk-Fact-084E62D562F5DB1E17D2801F8025171B"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1889-wk-Fact-0861F3F4D28BB35D854E801F80ADCAA4"
          xlink:label="d34428379e1889-wk-Fact-0861F3F4D28BB35D854E801F80ADCAA4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1889-wk-Fact-0861F3F4D28BB35D854E801F80ADCAA4"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl" xlink:label="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Reclassified into </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income. For additional information on amounts reclassified into </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales,</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7F.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1889-wk-Fact-0861F3F4D28BB35D854E801F80ADCAA4"
          xlink:to="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11401-wk-Fact-08FCBF9B923C5EC484E72D471007E0A6"
          xlink:label="d34586122e11401-wk-Fact-08FCBF9B923C5EC484E72D471007E0A6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11401-wk-Fact-08FCBF9B923C5EC484E72D471007E0A6"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7635-wk-Fact-09097F7E24E55CE185B3A8241786D001"
          xlink:label="d34586122e7635-wk-Fact-09097F7E24E55CE185B3A8241786D001"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7635-wk-Fact-09097F7E24E55CE185B3A8241786D001"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2584-wk-Fact-09366D0018503E3621D1801F819C0D25"
          xlink:label="d34594690e2584-wk-Fact-09366D0018503E3621D1801F819C0D25"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl" xlink:label="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Determined using implied volatility, after consideration of historical volatility.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2584-wk-Fact-09366D0018503E3621D1801F819C0D25"
          xlink:to="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2550-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
          xlink:label="d34523018e2550-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e3372-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
          xlink:label="d34430544e3372-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2550-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3372-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2550-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3372-wk-Fact-09473C310A80FA565C36801F7F16DCBB"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5738-wk-Fact-0951D465F2EAA589DB57801F7EA951E3"
          xlink:label="d34458036e5738-wk-Fact-0951D465F2EAA589DB57801F7EA951E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5738-wk-Fact-0951D465F2EAA589DB57801F7EA951E3"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7219-wk-Fact-096BFE17591BD0B2DDDC801F823E3221"
          xlink:label="d34594690e7219-wk-Fact-096BFE17591BD0B2DDDC801F823E3221"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl" xlink:label="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Determined using the interpolated yield on U.S. Treasury zero-coupon issues.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7219-wk-Fact-096BFE17591BD0B2DDDC801F823E3221"
          xlink:to="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4045-wk-Fact-09761C58BD65590B9D0A94898AC11853"
          xlink:label="d34458036e4045-wk-Fact-09761C58BD65590B9D0A94898AC11853"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4045-wk-Fact-09761C58BD65590B9D0A94898AC11853"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2014-wk-Fact-09785B23D3307BE69A79801F8181F4E8"
          xlink:label="d34468079e2014-wk-Fact-09785B23D3307BE69A79801F8181F4E8"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl" xlink:label="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services. In 2019, transaction costs relate to our acquisition of Array. In 2017, transaction costs were directly related to our acquisitions of Hospira, Anacor and Medivation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2014-wk-Fact-09785B23D3307BE69A79801F8181F4E8"
          xlink:to="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3227-wk-Fact-098C50B89DAF5EB9A094993C8FEEA183"
          xlink:label="d34430544e3227-wk-Fact-098C50B89DAF5EB9A094993C8FEEA183"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3227-wk-Fact-098C50B89DAF5EB9A094993C8FEEA183"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e5534-wk-Fact-09A4B51093258130F5FD023AB0BF7398"
          xlink:label="d34496162e5534-wk-Fact-09A4B51093258130F5FD023AB0BF7398"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl" xlink:label="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income (see</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e5534-wk-Fact-09A4B51093258130F5FD023AB0BF7398"
          xlink:to="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:label="d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:label="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl" xlink:label="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The increase in the gross carrying amount of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">I</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:right;">mainly reflects the impact of the acquisition of Array, including the addition of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$1.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:right;"> of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights,</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$340 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">finite-lived </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreements, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$4.0 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">IPR&amp;D</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$1.1 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of indefinite-lived </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreement</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">s</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">(see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), partially offset by intangible asset impairment charges, primarily for Eucrisa in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. See</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl" xlink:label="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The increase in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">I</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:right;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">is mostly due to the additions noted in (a) above, partially offset by amortization and intangible asset impairment charges, primarily for Eucrisa in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. See</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3143-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1987-wk-Fact-09BF7B2E862E5B3B896E2F70C7FC9A1D"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2185-wk-Fact-09EB80731D7155BD844BFECD417399D3"
          xlink:label="d34428379e2185-wk-Fact-09EB80731D7155BD844BFECD417399D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2185-wk-Fact-09EB80731D7155BD844BFECD417399D3"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e16217-wk-Fact-0A0820F3891084F2D3BC801F822ACC1A"
          xlink:label="d34661879e16217-wk-Fact-0A0820F3891084F2D3BC801F822ACC1A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl" xlink:label="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our PBO, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Accumulated other comprehensive loss</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the average life expectancy of plan participants for frozen plans, primarily using the corridor approach.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e16217-wk-Fact-0A0820F3891084F2D3BC801F822ACC1A"
          xlink:to="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5156-wk-Fact-0A18106D10AC563B54F9801F7F18F45F"
          xlink:label="d34545404e5156-wk-Fact-0A18106D10AC563B54F9801F7F18F45F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl" xlink:label="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The deferred tax assets and liabilities associated with global intangible low-taxed income are included in the relevant categories above. See </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5156-wk-Fact-0A18106D10AC563B54F9801F7F18F45F"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e9112-wk-Fact-0A2EFD43015A58319E9B6A5301E68F22"
          xlink:label="d34545404e9112-wk-Fact-0A2EFD43015A58319E9B6A5301E68F22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9112-wk-Fact-0A2EFD43015A58319E9B6A5301E68F22"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2367-wk-Fact-0AA2D540FDE353DF84FFCE6640225D60"
          xlink:label="d34423000e2367-wk-Fact-0AA2D540FDE353DF84FFCE6640225D60"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2367-wk-Fact-0AA2D540FDE353DF84FFCE6640225D60"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2730-wk-Fact-0ABC054ABD705474B81B86310757E0CC"
          xlink:label="d34428379e2730-wk-Fact-0ABC054ABD705474B81B86310757E0CC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2730-wk-Fact-0ABC054ABD705474B81B86310757E0CC"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3750-wk-Fact-0AFCCC455878510D879042E7F8FF809D"
          xlink:label="d34661879e3750-wk-Fact-0AFCCC455878510D879042E7F8FF809D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl" xlink:label="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Effective January 1, 2018, we froze </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>two</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3750-wk-Fact-0AFCCC455878510D879042E7F8FF809D"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3143-wk-Fact-0B0BC391D4C7298B505D801F82CD3D11"
          xlink:label="d34458036e3143-wk-Fact-0B0BC391D4C7298B505D801F82CD3D11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3143-wk-Fact-0B0BC391D4C7298B505D801F82CD3D11"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5266-wk-Fact-0B2C9A8A17225E17979E8C6A9A7A0472"
          xlink:label="d34586122e5266-wk-Fact-0B2C9A8A17225E17979E8C6A9A7A0472"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl" xlink:label="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> Revenues denominated in euros were </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$7.0 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$7.3 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$6.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5266-wk-Fact-0B2C9A8A17225E17979E8C6A9A7A0472"
          xlink:to="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2489-wk-Fact-0B4B7D09A234587DBD0FEB3766ED94BB"
          xlink:label="d34471435e2489-wk-Fact-0B4B7D09A234587DBD0FEB3766ED94BB"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl" xlink:label="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, includes, among other things, (i) dividend income of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$220 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, (ii) charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$152 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture and (iii) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$50 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of income from insurance recoveries related to Hurricane Maria. In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, includes, among other things, (i) a non-cash </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$343 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> pre-tax gain associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), (ii) dividend income of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$253 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, (iii) a non-cash </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$50 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> pre-tax gain on the contribution of Pfizer&#x2019;s allogeneic CAR T therapy development program assets obtained from Cellectis and Servier in connection with our contribution agreement entered into with Allogene in which Pfizer obtained an ownership stake in Allogene (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), (iv) a non-cash </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$17 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> pre-tax gain on the cash settlement of a liability that we incurred in April 2018 upon the EU approval of Mylotarg (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7E</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), (v) charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$207 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, reflecting the change in the fair value of contingent consideration. and (vi) charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$112 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity, associated with the formation of the GSK Consumer Healthcare joint venture. In 2017, includes, among other things, dividend income of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$266 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> from our investment in ViiV, and income of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$62 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> from resolution of a contract disagreement. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2489-wk-Fact-0B4B7D09A234587DBD0FEB3766ED94BB"
          xlink:to="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2807-wk-Fact-0B920E93F75F59F63ECE801F80F39A24"
          xlink:label="d34468079e2807-wk-Fact-0B920E93F75F59F63ECE801F80F39A24"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl" xlink:label="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">mplementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2807-wk-Fact-0B920E93F75F59F63ECE801F80F39A24"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e1988-wk-Fact-0CDCE653A5E45D5BA0F60BE9927B384C"
          xlink:label="d34529301e1988-wk-Fact-0CDCE653A5E45D5BA0F60BE9927B384C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e1988-wk-Fact-0CDCE653A5E45D5BA0F60BE9927B384C"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4356-wk-Fact-0CDEC0D247EB505292D3E60E677BC871"
          xlink:label="d34458036e4356-wk-Fact-0CDEC0D247EB505292D3E60E677BC871"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4356-wk-Fact-0CDEC0D247EB505292D3E60E677BC871"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D"
          xlink:label="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D"
          xlink:to="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3917-wk-Fact-0CE1A0CC697651DA8F55126601EE6E2D"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2606-wk-Fact-0CE5B6DDA0365CB096E454B209F9983E"
          xlink:label="d34423000e2606-wk-Fact-0CE5B6DDA0365CB096E454B209F9983E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2606-wk-Fact-0CE5B6DDA0365CB096E454B209F9983E"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1992-wk-Fact-0D4501C3F382F4D74FB6801F80B5B5B4"
          xlink:label="d34471435e1992-wk-Fact-0D4501C3F382F4D74FB6801F80B5B5B4"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl" xlink:label="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In 2018, primarily includes gross realized losses on sales of available-for-sale debt securities of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$402 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and a net loss of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$18 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities, partially offset by gross realized gains on sales of available-for-sale debt securities of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$280 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. Proceeds from the sale of available-for-sale debt securities were </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$5.7 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in 2018. In 2017, primarily includes gross realized gains on sales of available-for-sale debt securities of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$451 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, partially offset by gross realized losses on sales of available-for-sale debt securities of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$281 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and a net loss of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$120 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> from derivative financial instruments used to hedge the foreign exchange component of the matured available-for-sale debt securities. Proceeds from the sale of available-for-sale debt securities were </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$5.1 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in 2017.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1992-wk-Fact-0D4501C3F382F4D74FB6801F80B5B5B4"
          xlink:to="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8296-wk-Fact-0D6DA45C2A7C59239CB62D356266BA2F"
          xlink:label="d34458032e8296-wk-Fact-0D6DA45C2A7C59239CB62D356266BA2F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8296-wk-Fact-0D6DA45C2A7C59239CB62D356266BA2F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4980-wk-Fact-0D7980FB1A19BDA52E10801F8004B06B"
          xlink:label="d34661879e4980-wk-Fact-0D7980FB1A19BDA52E10801F8004B06B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl" xlink:label="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">We adopted an accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> on the consolidated statements of income. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4980-wk-Fact-0D7980FB1A19BDA52E10801F8004B06B"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3664-wk-Fact-0DABBE66E4D8805F212A801F7F93FAD2"
          xlink:label="d34468079e3664-wk-Fact-0DABBE66E4D8805F212A801F7F93FAD2"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl" xlink:label="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Includes adjustments for foreign currency translation.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3664-wk-Fact-0DABBE66E4D8805F212A801F7F93FAD2"
          xlink:to="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e4035-wk-Fact-0DC222C12EB155DBBE6BAFA5807A4EE1"
          xlink:label="d34468079e4035-wk-Fact-0DC222C12EB155DBBE6BAFA5807A4EE1"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl" xlink:label="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other current liabilities </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">(</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$714 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">) and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent liabilities </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">(</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$219 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e4035-wk-Fact-0DC222C12EB155DBBE6BAFA5807A4EE1"
          xlink:to="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2810-wk-Fact-0DCDEA0AFFF95ED982FB39EAA2FBC94A"
          xlink:label="d34423000e2810-wk-Fact-0DCDEA0AFFF95ED982FB39EAA2FBC94A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2810-wk-Fact-0DCDEA0AFFF95ED982FB39EAA2FBC94A"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22325-wk-Fact-0DD70E539B87F2FB041C801F8112B0EF"
          xlink:label="d34661879e22325-wk-Fact-0DD70E539B87F2FB041C801F8112B0EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22325-wk-Fact-0DD70E539B87F2FB041C801F8112B0EF"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e16318-wk-Fact-0DEFE5C159BAEC795B00801F82386F80"
          xlink:label="d34661879e16318-wk-Fact-0DEFE5C159BAEC795B00801F82386F80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e16318-wk-Fact-0DEFE5C159BAEC795B00801F82386F80"
          xlink:to="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5351-wk-Fact-0DFBEF6B024C671D2CCB801F80B50D92"
          xlink:label="d34586122e5351-wk-Fact-0DFBEF6B024C671D2CCB801F80B50D92"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl" xlink:label="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5351-wk-Fact-0DFBEF6B024C671D2CCB801F80B50D92"
          xlink:to="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2708-wk-Fact-0E154CA77D6B55F38225A9B701605CD5"
          xlink:label="d34523018e2708-wk-Fact-0E154CA77D6B55F38225A9B701605CD5"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl" xlink:label="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2708-wk-Fact-0E154CA77D6B55F38225A9B701605CD5"
          xlink:to="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2139-wk-Fact-0E93D2D6EF205317999004B109639A0A"
          xlink:label="d34428379e2139-wk-Fact-0E93D2D6EF205317999004B109639A0A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl" xlink:label="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For additional information, see Notes to Consolidated Financial Statements</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">&#x2014;Note 1B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2139-wk-Fact-0E93D2D6EF205317999004B109639A0A"
          xlink:to="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2139-wk-Fact-0E93D2D6EF205317999004B109639A0A"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB"
          xlink:label="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl" xlink:label="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">These amounts were reclassified from OCI into OID. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6277-wk-Fact-0E9B8E41A9575E8688065AFD24D41DAB"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2556-wk-Fact-0E9DF21E8B8D568689FB453465570C12"
          xlink:label="d34430544e2556-wk-Fact-0E9DF21E8B8D568689FB453465570C12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2556-wk-Fact-0E9DF21E8B8D568689FB453465570C12"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4461-wk-Fact-0F12AD78F79C5102A8E62FEDCC592E95"
          xlink:label="d34538474e4461-wk-Fact-0F12AD78F79C5102A8E62FEDCC592E95"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4461-wk-Fact-0F12AD78F79C5102A8E62FEDCC592E95"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20086-wk-Fact-0F1DB5BD6CE9D70B16BE801F812DE5BC"
          xlink:label="d34661879e20086-wk-Fact-0F1DB5BD6CE9D70B16BE801F812DE5BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20086-wk-Fact-0F1DB5BD6CE9D70B16BE801F812DE5BC"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3994-wk-Fact-0F2EB7A6D4B3040B6027E3C58F8C7591"
          xlink:label="d34471435e3994-wk-Fact-0F2EB7A6D4B3040B6027E3C58F8C7591"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl" xlink:label="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Reflects intangible assets written down to fair value in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. Fair value was determined using the income approach, specifically the multi-period excess earnings method, also known as the discounted cash flow method. We started with a forecast of all the expected net cash flows associated with the asset and then applied an asset-specific discount rate to arrive at a net present value amount. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which includes the expected impact of competitive, legal and/or regulatory forces on the product; the discount rate, which seeks to reflect the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3994-wk-Fact-0F2EB7A6D4B3040B6027E3C58F8C7591"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4234-wk-Fact-0F427D37984EF6A14C01801F80833398"
          xlink:label="d34458032e4234-wk-Fact-0F427D37984EF6A14C01801F80833398"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4234-wk-Fact-0F427D37984EF6A14C01801F80833398"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11298-wk-Fact-0F4B80AB484F70EADA00801F822053F3"
          xlink:label="d34661879e11298-wk-Fact-0F4B80AB484F70EADA00801F822053F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11298-wk-Fact-0F4B80AB484F70EADA00801F822053F3"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1925-wk-Fact-0F5337E2D08EAAB68D68801F80EB1026"
          xlink:label="d34471435e1925-wk-Fact-0F5337E2D08EAAB68D68801F80EB1026"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl" xlink:label="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The gains in 2019 include, among other things, unrealized gains of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$295 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to investments in Cortexyme, Inc. and SpringWorks Therapeutics, Inc. The gains in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> included unrealized gains on equity securities of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$477 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, reflecting the adoption of a new accounting standard in the first quarter of 2018 and were primarily driven by unrealized gains of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$466 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to our investment in Allogene. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1925-wk-Fact-0F5337E2D08EAAB68D68801F80EB1026"
          xlink:to="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e9168-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE"
          xlink:label="d34496162e9168-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e1855-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE"
          xlink:label="d34423000e1855-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e9168-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1855-wk-Fact-0FC728040E7159B0B437E8FFC6FD10AE"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3597-wk-Fact-0FFA20352D33594482BE61F2516C104D"
          xlink:label="d34468079e3597-wk-Fact-0FFA20352D33594482BE61F2516C104D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34468079e1929-wk-Fact-0FFA20352D33594482BE61F2516C104D"
          xlink:label="d34468079e1929-wk-Fact-0FFA20352D33594482BE61F2516C104D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl" xlink:label="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">). In 2018, restructuring charges were primarily related to employee termination costs and asset write downs. The employee termination costs for 2019 and 2018 were primarily associated with our improvements to operational effectiveness as part of the realignment of our organizational structure, and for 2019, also includes employee termination costs associated with the Transforming to a More Focused Company initiative. In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, restructuring charges were primarily associated with our acquisitions of Hospira and Medivation, partially offset by credits associated with cost-reduction and productivity initiatives not associated with acquisitions that mostly related to the reversal of previously recorded accruals for employee termination costs resulting from revisions of our severance benefit estimates. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The restructuring activities in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> are associated with the following:</xhtml:span></xhtml:div><xhtml:table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:18px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:7pt;padding-left:12px;"><xhtml:span style="font-family:Arial;font-size:7pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Biopharma (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$118 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge); Upjohn (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$75 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge); and Other (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$180 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge).</xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:18px;text-indent:-6px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate 2018 and 2017 restructuring charges with the new individual segments.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The restructuring activities for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> are associated with the following:</xhtml:span></xhtml:div><xhtml:table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><xhtml:tr><xhtml:td style="width:18px;"/><xhtml:td/></xhtml:tr><xhtml:tr><xhtml:td style="vertical-align:top"><xhtml:div style="line-height:120%;font-size:7pt;padding-left:12px;"><xhtml:span style="font-family:Arial;font-size:7pt;">&#x2022;</xhtml:span></xhtml:div></xhtml:td><xhtml:td style="vertical-align:top;"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Total reportable segments (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$207 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge); and Other (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$575 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge). </xhtml:span></xhtml:div></xhtml:td></xhtml:tr></xhtml:table><xhtml:div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:24px;text-indent:-12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The restructuring activities for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> are associated with the following:</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;font-size:7pt;padding-left:12px;"><xhtml:span style="font-family:Arial;font-size:7pt;">&#x2022;</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Total reportable segments (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$89 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> credit); and Other (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$119 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3597-wk-Fact-0FFA20352D33594482BE61F2516C104D"
          xlink:to="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1929-wk-Fact-0FFA20352D33594482BE61F2516C104D"
          xlink:to="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10662-wk-Fact-101EC636E37E5D65C52C801F81EB2366"
          xlink:label="d34661879e10662-wk-Fact-101EC636E37E5D65C52C801F81EB2366"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10662-wk-Fact-101EC636E37E5D65C52C801F81EB2366"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4289-wk-Fact-105EFED9824651F6ABA05E9CA04F453B"
          xlink:label="d34458036e4289-wk-Fact-105EFED9824651F6ABA05E9CA04F453B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4289-wk-Fact-105EFED9824651F6ABA05E9CA04F453B"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3366-wk-Fact-10B388DAE9985C6E9C8A0D8BD38AD150"
          xlink:label="d34458036e3366-wk-Fact-10B388DAE9985C6E9C8A0D8BD38AD150"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3366-wk-Fact-10B388DAE9985C6E9C8A0D8BD38AD150"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2725-wk-Fact-111ED69E468B22889D50801F81BB10E7"
          xlink:label="d34586122e2725-wk-Fact-111ED69E468B22889D50801F81BB10E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2725-wk-Fact-111ED69E468B22889D50801F81BB10E7"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2130-wk-Fact-11293434603BE982F98F801F80B2BCE9"
          xlink:label="d34471435e2130-wk-Fact-11293434603BE982F98F801F80B2BCE9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl" xlink:label="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">n 2019, primarily includes settlement losses within the U.S. Pfizer Consolidated Pension Plan related to special restructuring initiatives, a small annuity buyout program and regular lump sum activity. Effective January 1, 2018, the U.S. Pfizer Consolidated Pension Plan was frozen to future benefit accruals and for <xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, resulted in the recognition of lower net periodic benefit costs due to the extension of the amortization period for the actuarial losses. There was also a greater than expected gain on plan assets due to a higher plan asset base compared to 2017. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2130-wk-Fact-11293434603BE982F98F801F80B2BCE9"
          xlink:to="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961"
          xlink:label="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl" xlink:label="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Short-term borrowings include foreign currency short-term borrowings with carrying values of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$1.1 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> as of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.0 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> as of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, which are used as hedging instruments in net investment hedges.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961"
          xlink:to="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5629-wk-Fact-1129A57B16895F78BBBC16AD10A95961"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11273-wk-Fact-11BAC5EE7A45CC2D5AFAD082FDAA0EF1"
          xlink:label="d34586122e11273-wk-Fact-11BAC5EE7A45CC2D5AFAD082FDAA0EF1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11273-wk-Fact-11BAC5EE7A45CC2D5AFAD082FDAA0EF1"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e5476-wk-Fact-1260CCD84F5EAA993014023A45379D65"
          xlink:label="d34496162e5476-wk-Fact-1260CCD84F5EAA993014023A45379D65"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e5476-wk-Fact-1260CCD84F5EAA993014023A45379D65"
          xlink:to="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21293-wk-Fact-12704F96F376D4121D69801F80E15138"
          xlink:label="d34661879e21293-wk-Fact-12704F96F376D4121D69801F80E15138"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl" xlink:label="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Mostly includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21293-wk-Fact-12704F96F376D4121D69801F80E15138"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21293-wk-Fact-12704F96F376D4121D69801F80E15138"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7114-wk-Fact-12773FEDE0EF5957B1201377DC9142AE"
          xlink:label="d34586122e7114-wk-Fact-12773FEDE0EF5957B1201377DC9142AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7114-wk-Fact-12773FEDE0EF5957B1201377DC9142AE"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22041-wk-Fact-129BCA5EF7E3C4047DF8801F807EBD37"
          xlink:label="d34661879e22041-wk-Fact-129BCA5EF7E3C4047DF8801F807EBD37"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22041-wk-Fact-129BCA5EF7E3C4047DF8801F807EBD37"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5748-wk-Fact-12B293ED1A777402AC1F801F7ECA154F"
          xlink:label="d34458032e5748-wk-Fact-12B293ED1A777402AC1F801F7ECA154F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5748-wk-Fact-12B293ED1A777402AC1F801F7ECA154F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2135-wk-Fact-13109FFF8177575B8F1774DB9B952255"
          xlink:label="d34458036e2135-wk-Fact-13109FFF8177575B8F1774DB9B952255"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2135-wk-Fact-13109FFF8177575B8F1774DB9B952255"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4706-wk-Fact-1317FDFBDCC45E05A5F89D304C128317"
          xlink:label="d34538474e4706-wk-Fact-1317FDFBDCC45E05A5F89D304C128317"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4706-wk-Fact-1317FDFBDCC45E05A5F89D304C128317"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2854-wk-Fact-13191F129DFB57EB8DE4693D33017900"
          xlink:label="d34423000e2854-wk-Fact-13191F129DFB57EB8DE4693D33017900"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2854-wk-Fact-13191F129DFB57EB8DE4693D33017900"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20621-wk-Fact-131B4259055DC4154011801F7E6A5E45"
          xlink:label="d34661879e20621-wk-Fact-131B4259055DC4154011801F7E6A5E45"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20621-wk-Fact-131B4259055DC4154011801F7E6A5E45"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8571-wk-Fact-1358C7993E24C71EC31CDE2099C357C1"
          xlink:label="d34586122e8571-wk-Fact-1358C7993E24C71EC31CDE2099C357C1"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl" xlink:label="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy SIP category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 and 2017 product revenues to the current presentation. Hospital also includes Pfizer CentreOne</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</xhtml:sup></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#x201c;All other Anti-infectives&#x201d;.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8571-wk-Fact-1358C7993E24C71EC31CDE2099C357C1"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl" xlink:label="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">2018 and 2017 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8571-wk-Fact-1358C7993E24C71EC31CDE2099C357C1"
          xlink:to="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4329-wk-Fact-1374505693265BF17B2B801F82AB7A82"
          xlink:label="d34458036e4329-wk-Fact-1374505693265BF17B2B801F82AB7A82"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4329-wk-Fact-1374505693265BF17B2B801F82AB7A82"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e4846-wk-Fact-137CA28F27F7A870C810801F81C79E37"
          xlink:label="d34594690e4846-wk-Fact-137CA28F27F7A870C810801F81C79E37"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl" xlink:label="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">2017 includes the modification for a commitment to pay approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>6.4 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> RSUs to approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>9,900</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> employees, including senior and key management employees, for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>6.6 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> RSUs. These shares were paid in the first quarter of 2018.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e4846-wk-Fact-137CA28F27F7A870C810801F81C79E37"
          xlink:to="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4796-wk-Fact-1381E356C11529474B50801F7FE67AD8"
          xlink:label="d34458032e4796-wk-Fact-1381E356C11529474B50801F7FE67AD8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4796-wk-Fact-1381E356C11529474B50801F7FE67AD8"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6920-wk-Fact-13974E7B4E179154410C801F7E5B86C1"
          xlink:label="d34545404e6920-wk-Fact-13974E7B4E179154410C801F7E5B86C1"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl" xlink:label="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily related to cash payments and reductions of tax attributes.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6920-wk-Fact-13974E7B4E179154410C801F7E5B86C1"
          xlink:to="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5718-wk-Fact-13A50261D17557B8A175FB539D8C549E"
          xlink:label="d34458036e5718-wk-Fact-13A50261D17557B8A175FB539D8C549E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5718-wk-Fact-13A50261D17557B8A175FB539D8C549E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3836-wk-Fact-13B8F46793BB5B219C40DD3378500D40"
          xlink:label="d34468079e3836-wk-Fact-13B8F46793BB5B219C40DD3378500D40"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl" xlink:label="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5D</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3836-wk-Fact-13B8F46793BB5B219C40DD3378500D40"
          xlink:to="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23113-wk-Fact-13C4C66382AC9F3D31ED801F7E1DF337"
          xlink:label="d34661879e23113-wk-Fact-13C4C66382AC9F3D31ED801F7E1DF337"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23113-wk-Fact-13C4C66382AC9F3D31ED801F7E1DF337"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl" xlink:label="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Government and agency obligations are inclusive of repurchase agreements.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23113-wk-Fact-13C4C66382AC9F3D31ED801F7E1DF337"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21111-wk-Fact-13CB94F03E493E18A76F801F8065B591"
          xlink:label="d34661879e21111-wk-Fact-13CB94F03E493E18A76F801F8065B591"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21111-wk-Fact-13CB94F03E493E18A76F801F8065B591"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8157-wk-Fact-13DACBE475EF4ADD4FF8801F828BECB3"
          xlink:label="d34545404e8157-wk-Fact-13DACBE475EF4ADD4FF8801F828BECB3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8157-wk-Fact-13DACBE475EF4ADD4FF8801F828BECB3"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2663-wk-Fact-13DF08A1DA2702456A68801F7E99FA8D"
          xlink:label="d34458036e2663-wk-Fact-13DF08A1DA2702456A68801F7E99FA8D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2663-wk-Fact-13DF08A1DA2702456A68801F7E99FA8D"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22912-wk-Fact-13F5E48EBC5CD653F364801F81489ED5"
          xlink:label="d34661879e22912-wk-Fact-13F5E48EBC5CD653F364801F81489ED5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22912-wk-Fact-13F5E48EBC5CD653F364801F81489ED5"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7059-wk-Fact-13FB97E7671458A9E0F4801F7EBCE117"
          xlink:label="d34458032e7059-wk-Fact-13FB97E7671458A9E0F4801F7EBCE117"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7059-wk-Fact-13FB97E7671458A9E0F4801F7EBCE117"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl" xlink:label="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily represents the cumulative effect of the adoption of new accounting standards in the first quarter of 2018 for revenues, financial assets and liabilities, income tax accounting, and the reclassification of certain tax effects from </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Accumulated other comprehensive income</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. For additional information, see Notes to Consolidated Financial Statements&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in our 2018 Financial Report.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7059-wk-Fact-13FB97E7671458A9E0F4801F7EBCE117"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2394-wk-Fact-13FBCE16090D77486260801F80AF4E2A"
          xlink:label="d34471435e2394-wk-Fact-13FBCE16090D77486260801F80AF4E2A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl" xlink:label="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In 2019 and 2017, represents net losses due to the early retirement of debt, inclusive of the related termination of cross currency swaps.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2394-wk-Fact-13FBCE16090D77486260801F80AF4E2A"
          xlink:to="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2115-wk-Fact-142A53BD92AA56EB8F30C720D04947B1"
          xlink:label="d34458036e2115-wk-Fact-142A53BD92AA56EB8F30C720D04947B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2115-wk-Fact-142A53BD92AA56EB8F30C720D04947B1"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e7082-wk-Fact-1431F69E27412BDBF397801F7E6A58E6"
          xlink:label="d34545404e7082-wk-Fact-1431F69E27412BDBF397801F7E6A58E6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7082-wk-Fact-1431F69E27412BDBF397801F7E6A58E6"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl" xlink:label="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily related to decreases as a result of a lapse of applicable statutes of limitations.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7082-wk-Fact-1431F69E27412BDBF397801F7E6A58E6"
          xlink:to="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9870-wk-Fact-14994130FABC5D73BECDDC06FF0B8749"
          xlink:label="d34458032e9870-wk-Fact-14994130FABC5D73BECDDC06FF0B8749"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9870-wk-Fact-14994130FABC5D73BECDDC06FF0B8749"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5195-wk-Fact-14ADBD55BE745ADEBD77EA9D5312ED22"
          xlink:label="d34458036e5195-wk-Fact-14ADBD55BE745ADEBD77EA9D5312ED22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5195-wk-Fact-14ADBD55BE745ADEBD77EA9D5312ED22"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl" xlink:label="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For additional information, see</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2B.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5195-wk-Fact-14ADBD55BE745ADEBD77EA9D5312ED22"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6835-wk-Fact-14B110795751DD5A5119801F7E469842"
          xlink:label="d34545404e6835-wk-Fact-14B110795751DD5A5119801F7E469842"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6835-wk-Fact-14B110795751DD5A5119801F7E469842"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6835-wk-Fact-14B110795751DD5A5119801F7E469842"
          xlink:to="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2462-wk-Fact-14F1C2A6A168BD044F0E801F802AA8F2"
          xlink:label="d34458032e2462-wk-Fact-14F1C2A6A168BD044F0E801F802AA8F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2462-wk-Fact-14F1C2A6A168BD044F0E801F802AA8F2"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6215-wk-Fact-14FD69433DA24328385A801F7DF3375A"
          xlink:label="d34458032e6215-wk-Fact-14FD69433DA24328385A801F7DF3375A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6215-wk-Fact-14FD69433DA24328385A801F7DF3375A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e8057-wk-Fact-150B8237E6AC43FC08DF801F7E45E25C"
          xlink:label="d34594690e8057-wk-Fact-150B8237E6AC43FC08DF801F7E45E25C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl" xlink:label="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The number of options expected to vest takes into account an estimate of expected forfeitures.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8057-wk-Fact-150B8237E6AC43FC08DF801F7E45E25C"
          xlink:to="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2215-wk-Fact-1526F7310FFB6F8E8B4BCB2DE56B079F"
          xlink:label="d34458032e2215-wk-Fact-1526F7310FFB6F8E8B4BCB2DE56B079F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2215-wk-Fact-1526F7310FFB6F8E8B4BCB2DE56B079F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4190-wk-Fact-154E2A860FA2D40C9895801F828D41CB"
          xlink:label="d34545404e4190-wk-Fact-154E2A860FA2D40C9895801F828D41CB"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl" xlink:label="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">All other, net in 2019 is primarily due to routine business operations. 2018 is primarily due to routine business operations and the non-recurrence of tax benefits associated with certain tax initiatives. 2017 primarily relates to tax benefits associated with certain tax initiatives in the normal course of business. </xhtml:span></xhtml:div><xhtml:div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:5pt;"><xhtml:span style="font-family:Arial;font-size:5pt;"><xhtml:br/></xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4190-wk-Fact-154E2A860FA2D40C9895801F828D41CB"
          xlink:to="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3767-wk-Fact-1561A8609FA608E10A98801F80706999"
          xlink:label="d34458032e3767-wk-Fact-1561A8609FA608E10A98801F80706999"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3767-wk-Fact-1561A8609FA608E10A98801F80706999"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3767-wk-Fact-1561A8609FA608E10A98801F80706999"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2816-wk-Fact-1579B10788C733E8AAC8801F828B55EB"
          xlink:label="d34428379e2816-wk-Fact-1579B10788C733E8AAC8801F828B55EB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2816-wk-Fact-1579B10788C733E8AAC8801F828B55EB"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3080-wk-Fact-158D3A6B6505E95558B1801F81DBB22C"
          xlink:label="d34586122e3080-wk-Fact-158D3A6B6505E95558B1801F81DBB22C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3080-wk-Fact-158D3A6B6505E95558B1801F81DBB22C"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5968-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7"
          xlink:label="d34545404e5968-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e5793-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7"
          xlink:label="d34545404e5793-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5968-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5793-wk-Fact-1593E8A858EC890CF6B8801F7F1EE3C7"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10643-wk-Fact-15BADC559EFA5E2148B7801F8234494C"
          xlink:label="d34661879e10643-wk-Fact-15BADC559EFA5E2148B7801F8234494C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10643-wk-Fact-15BADC559EFA5E2148B7801F8234494C"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1672-wk-Fact-15E210D3DD0D5FB08B54D80504EBC060"
          xlink:label="d34428379e1672-wk-Fact-15E210D3DD0D5FB08B54D80504EBC060"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl" xlink:label="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For the year ended December 31, 2019, the foreign currency translation adjustments are primarily reclassified into </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">(Gain) on completion of Consumer Healthcare JV transaction </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">in the consolidated statement of income as a result of the contribution of our Consumer Healthcare business to the Consumer Healthcare joint venture with GSK.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">See </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> For the year ended December 31, 2017, the foreign currency translation adjustments reclassified into </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2014;net </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">in the consolidated statement of income primarily result from the sale of our former </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>40%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto and the sale of our former </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>49%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">-owned equity method investment in Hisun Pfizer. See </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1672-wk-Fact-15E210D3DD0D5FB08B54D80504EBC060"
          xlink:to="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1672-wk-Fact-15E210D3DD0D5FB08B54D80504EBC060"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3139-wk-Fact-1607AE44D7025E1EB5295964DC39F488"
          xlink:label="d34430544e3139-wk-Fact-1607AE44D7025E1EB5295964DC39F488"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3139-wk-Fact-1607AE44D7025E1EB5295964DC39F488"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8450-wk-Fact-1618790FEEDB5D8FA14CCFA4F0B219DF"
          xlink:label="d34458032e8450-wk-Fact-1618790FEEDB5D8FA14CCFA4F0B219DF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8450-wk-Fact-1618790FEEDB5D8FA14CCFA4F0B219DF"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20543-wk-Fact-162134FF808D683214CB801F80F133F9"
          xlink:label="d34661879e20543-wk-Fact-162134FF808D683214CB801F80F133F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20543-wk-Fact-162134FF808D683214CB801F80F133F9"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2944-wk-Fact-1645F7BA211F13D895DB801F821CDBB9"
          xlink:label="d34661879e2944-wk-Fact-1645F7BA211F13D895DB801F821CDBB9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9809-wk-Fact-1645F7BA211F13D895DB801F821CDBB9"
          xlink:label="d34661879e9809-wk-Fact-1645F7BA211F13D895DB801F821CDBB9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2944-wk-Fact-1645F7BA211F13D895DB801F821CDBB9"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9809-wk-Fact-1645F7BA211F13D895DB801F821CDBB9"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3158-wk-Fact-166D37DCD0615EB59DA9AF177DA4F7E9"
          xlink:label="d34430544e3158-wk-Fact-166D37DCD0615EB59DA9AF177DA4F7E9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3158-wk-Fact-166D37DCD0615EB59DA9AF177DA4F7E9"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22524-wk-Fact-16D5C33B23D96F298EA6801F7E18070A"
          xlink:label="d34661879e22524-wk-Fact-16D5C33B23D96F298EA6801F7E18070A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22524-wk-Fact-16D5C33B23D96F298EA6801F7E18070A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5445-wk-Fact-16DA44395D73061538E3801F81E5A68D"
          xlink:label="d34506804e5445-wk-Fact-16DA44395D73061538E3801F81E5A68D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl" xlink:label="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5445-wk-Fact-16DA44395D73061538E3801F81E5A68D"
          xlink:to="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e1976-wk-Fact-1720732DC86856B0BBAA3408390B34EC"
          xlink:label="d34468079e1976-wk-Fact-1720732DC86856B0BBAA3408390B34EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1976-wk-Fact-1720732DC86856B0BBAA3408390B34EC"
          xlink:to="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21131-wk-Fact-1784E446F9B0340EF1E7801F80F5F65A"
          xlink:label="d34661879e21131-wk-Fact-1784E446F9B0340EF1E7801F80F5F65A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21131-wk-Fact-1784E446F9B0340EF1E7801F80F5F65A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1905-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
          xlink:label="d34471435e1905-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34501946e4265-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
          xlink:label="d34501946e4265-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1905-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
          xlink:to="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e4265-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
          xlink:to="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl" xlink:label="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The net gains on equity securities are reported in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">net.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1905-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
          xlink:to="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e4265-wk-Fact-179DB1010A3B5AE99E1D0E90CD9BB962"
          xlink:to="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2155-wk-Fact-17A18791930ECAD2DCEB801F82A24FA8"
          xlink:label="d34458036e2155-wk-Fact-17A18791930ECAD2DCEB801F82A24FA8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2155-wk-Fact-17A18791930ECAD2DCEB801F82A24FA8"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10393-wk-Fact-1855B6419A7F5D4AE722801F81FE1A9A"
          xlink:label="d34661879e10393-wk-Fact-1855B6419A7F5D4AE722801F81FE1A9A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10393-wk-Fact-1855B6419A7F5D4AE722801F81FE1A9A"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11234-wk-Fact-1869D81D977F534390770DD20D262AB7"
          xlink:label="d34586122e11234-wk-Fact-1869D81D977F534390770DD20D262AB7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11234-wk-Fact-1869D81D977F534390770DD20D262AB7"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2747-wk-Fact-1878ED88AD3662670B3D801F82BFC1A3"
          xlink:label="d34458036e2747-wk-Fact-1878ED88AD3662670B3D801F82BFC1A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2747-wk-Fact-1878ED88AD3662670B3D801F82BFC1A3"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1737-wk-Fact-1879B130A48A521A91B25AA7A433481D"
          xlink:label="d34458036e1737-wk-Fact-1879B130A48A521A91B25AA7A433481D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1737-wk-Fact-1879B130A48A521A91B25AA7A433481D"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e1626-wk-Fact-18A55E3A510C5C5B3112801F7ED70A08"
          xlink:label="d34594690e1626-wk-Fact-18A55E3A510C5C5B3112801F7ED70A08"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl" xlink:label="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family:Arial;font-size:7pt;">Includes expense for PTSRUs, described in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 13C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> below, which is not significant for all years presented.</xhtml:span><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:8pt;"><xhtml:br/></xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e1626-wk-Fact-18A55E3A510C5C5B3112801F7ED70A08"
          xlink:to="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11052-wk-Fact-18D66D9FD2EF5E4071F3801F820F2C81"
          xlink:label="d34661879e11052-wk-Fact-18D66D9FD2EF5E4071F3801F820F2C81"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11052-wk-Fact-18D66D9FD2EF5E4071F3801F820F2C81"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e2109-wk-Fact-18D776DBF49C5BD0821AEAF95ADFD3B6"
          xlink:label="d34538474e2109-wk-Fact-18D776DBF49C5BD0821AEAF95ADFD3B6"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl" xlink:label="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$5.9 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> as of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$5.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> as of December 31, 2018.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e2109-wk-Fact-18D776DBF49C5BD0821AEAF95ADFD3B6"
          xlink:to="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3857-wk-Fact-18E37EACB23652878A34A31EF09685A7"
          xlink:label="d34471435e3857-wk-Fact-18E37EACB23652878A34A31EF09685A7"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl" xlink:label="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The fair value amount is presented as of the date of impairment, as these assets are not measured at fair value on a recurring basis. See also </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1E.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3857-wk-Fact-18E37EACB23652878A34A31EF09685A7"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3857-wk-Fact-18E37EACB23652878A34A31EF09685A7"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3944-wk-Fact-190D7B7514575574AE1769D904D6CA82"
          xlink:label="d34468079e3944-wk-Fact-190D7B7514575574AE1769D904D6CA82"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3944-wk-Fact-190D7B7514575574AE1769D904D6CA82"
          xlink:to="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4615-wk-Fact-192DA984185DD0ED8BF0801F803D17EF"
          xlink:label="d34458032e4615-wk-Fact-192DA984185DD0ED8BF0801F803D17EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4615-wk-Fact-192DA984185DD0ED8BF0801F803D17EF"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2213-wk-Fact-19548AB61F0E5995A6CDA20B4FE892D2"
          xlink:label="d34529301e2213-wk-Fact-19548AB61F0E5995A6CDA20B4FE892D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2213-wk-Fact-19548AB61F0E5995A6CDA20B4FE892D2"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3526-wk-Fact-1967B402D8BE56648C1FED785998B3C6"
          xlink:label="d34423000e3526-wk-Fact-1967B402D8BE56648C1FED785998B3C6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3526-wk-Fact-1967B402D8BE56648C1FED785998B3C6"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9329-wk-Fact-1975D34B81EE58A99F75AD822E7EA8D7"
          xlink:label="d34458032e9329-wk-Fact-1975D34B81EE58A99F75AD822E7EA8D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9329-wk-Fact-1975D34B81EE58A99F75AD822E7EA8D7"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2158-wk-Fact-19792256C9155CD4A4B30F1FFD71D2BF"
          xlink:label="d34471435e2158-wk-Fact-19792256C9155CD4A4B30F1FFD71D2BF"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl" xlink:label="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, mostly includes legal reserves for certain pending legal matters. In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily includes legal reserves for certain pending legal matters, partially offset by the reversal of a legal accrual where a loss was no longer deemed probable. In 2017, primarily includes a </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$94 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge to resolve a class action lawsuit filed by direct purchasers relating to Celebrex, which was approved by the court in April 2018, and a </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$79 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge to reflect damages awarded by a jury in a patent matter.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2158-wk-Fact-19792256C9155CD4A4B30F1FFD71D2BF"
          xlink:to="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4376-wk-Fact-197F4485B7325617ACD30B3E17928D84"
          xlink:label="d34458036e4376-wk-Fact-197F4485B7325617ACD30B3E17928D84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4376-wk-Fact-197F4485B7325617ACD30B3E17928D84"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23448-wk-Fact-19AE6BF04D8CC5A87EEA801F7E12AE32"
          xlink:label="d34661879e23448-wk-Fact-19AE6BF04D8CC5A87EEA801F7E12AE32"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23448-wk-Fact-19AE6BF04D8CC5A87EEA801F7E12AE32"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1956-wk-Fact-19AEA7C81E205D2B0C4DCB55FB59380E"
          xlink:label="d34458036e1956-wk-Fact-19AEA7C81E205D2B0C4DCB55FB59380E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1956-wk-Fact-19AEA7C81E205D2B0C4DCB55FB59380E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl" xlink:label="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$8.2 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> reflects the receipt of a </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>32%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> equity-method investment in the new company initially valued at </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$15.7 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in exchange for net assets contributed of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$7.6 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and is presented in operating activities net of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$146 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> cash conveyed that is reflected in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other investing activities, net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. For additional information, see</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2C.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1956-wk-Fact-19AEA7C81E205D2B0C4DCB55FB59380E"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9969-wk-Fact-19B551E7615E5B2D61BB801F81EC6B71"
          xlink:label="d34661879e9969-wk-Fact-19B551E7615E5B2D61BB801F81EC6B71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9969-wk-Fact-19B551E7615E5B2D61BB801F81EC6B71"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4318-wk-Fact-19D10F7FBBB55166B828C57515F0E5DC"
          xlink:label="d34538474e4318-wk-Fact-19D10F7FBBB55166B828C57515F0E5DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4318-wk-Fact-19D10F7FBBB55166B828C57515F0E5DC"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7181-wk-Fact-1A163CFC61DB374C9859801F82396806"
          xlink:label="d34594690e7181-wk-Fact-1A163CFC61DB374C9859801F82396806"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl" xlink:label="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Determined using a constant dividend yield during the expected term of the option.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7181-wk-Fact-1A163CFC61DB374C9859801F82396806"
          xlink:to="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2448-wk-Fact-1A17F756201A26636A56801F825B0538"
          xlink:label="d34458036e2448-wk-Fact-1A17F756201A26636A56801F825B0538"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2448-wk-Fact-1A17F756201A26636A56801F825B0538"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21048-wk-Fact-1A3B6926FC4FE6AFF9C8801F807EB040"
          xlink:label="d34661879e21048-wk-Fact-1A3B6926FC4FE6AFF9C8801F807EB040"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21048-wk-Fact-1A3B6926FC4FE6AFF9C8801F807EB040"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21048-wk-Fact-1A3B6926FC4FE6AFF9C8801F807EB040"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2509-wk-Fact-1A6E3FA2203C5CDDA2BD99ED3CEEEA51"
          xlink:label="d34471435e2509-wk-Fact-1A6E3FA2203C5CDDA2BD99ED3CEEEA51"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2509-wk-Fact-1A6E3FA2203C5CDDA2BD99ED3CEEEA51"
          xlink:to="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3801-wk-Fact-1A7E3821C23A4DED79AC801F7E1FD112"
          xlink:label="d34458032e3801-wk-Fact-1A7E3821C23A4DED79AC801F7E1FD112"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3801-wk-Fact-1A7E3821C23A4DED79AC801F7E1FD112"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3801-wk-Fact-1A7E3821C23A4DED79AC801F7E1FD112"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4737-wk-Fact-1A7FFDC660ABEFAC6697801F7ECAA2B8"
          xlink:label="d34458032e4737-wk-Fact-1A7FFDC660ABEFAC6697801F7ECAA2B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4737-wk-Fact-1A7FFDC660ABEFAC6697801F7ECAA2B8"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19796-wk-Fact-1A8B2C6C459DCC13D002801F7FD5858E"
          xlink:label="d34661879e19796-wk-Fact-1A8B2C6C459DCC13D002801F7FD5858E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19796-wk-Fact-1A8B2C6C459DCC13D002801F7FD5858E"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8345-wk-Fact-1AA27963C1EA03D86E56DE208FA6FEF4"
          xlink:label="d34586122e8345-wk-Fact-1AA27963C1EA03D86E56DE208FA6FEF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8345-wk-Fact-1AA27963C1EA03D86E56DE208FA6FEF4"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5125-wk-Fact-1AAB635BCEF5567C8400CCFFA9F211E9"
          xlink:label="d34538474e5125-wk-Fact-1AAB635BCEF5567C8400CCFFA9F211E9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5125-wk-Fact-1AAB635BCEF5567C8400CCFFA9F211E9"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5125-wk-Fact-1AAB635BCEF5567C8400CCFFA9F211E9"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3208-wk-Fact-1B23844B5232538ABD87C7C1814A1CF1"
          xlink:label="d34423000e3208-wk-Fact-1B23844B5232538ABD87C7C1814A1CF1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3208-wk-Fact-1B23844B5232538ABD87C7C1814A1CF1"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3663-wk-Fact-1B60D667972BE02E235D801F8128BBC9"
          xlink:label="d34586122e3663-wk-Fact-1B60D667972BE02E235D801F8128BBC9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3663-wk-Fact-1B60D667972BE02E235D801F8128BBC9"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9514-wk-Fact-1BB3443744FA4A3A8997801F822C8818"
          xlink:label="d34661879e9514-wk-Fact-1BB3443744FA4A3A8997801F822C8818"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9514-wk-Fact-1BB3443744FA4A3A8997801F822C8818"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9950-wk-Fact-1BCCBE0EAF7ECB6D503C801F821CEE76"
          xlink:label="d34661879e9950-wk-Fact-1BCCBE0EAF7ECB6D503C801F821CEE76"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9950-wk-Fact-1BCCBE0EAF7ECB6D503C801F821CEE76"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14639-wk-Fact-1BDD07D787E81176926F801F7F11CAEA"
          xlink:label="d34661879e14639-wk-Fact-1BDD07D787E81176926F801F7F11CAEA"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl" xlink:label="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14639-wk-Fact-1BDD07D787E81176926F801F7F11CAEA"
          xlink:to="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6406-wk-Fact-1C0A16C44A2B5C6AAE89B204324775E1"
          xlink:label="d34538474e6406-wk-Fact-1C0A16C44A2B5C6AAE89B204324775E1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6406-wk-Fact-1C0A16C44A2B5C6AAE89B204324775E1"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6406-wk-Fact-1C0A16C44A2B5C6AAE89B204324775E1"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3363-wk-Fact-1C1A48D8D8FB59F484CD69BF32113D2E"
          xlink:label="d34423000e3363-wk-Fact-1C1A48D8D8FB59F484CD69BF32113D2E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3363-wk-Fact-1C1A48D8D8FB59F484CD69BF32113D2E"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2961-wk-Fact-1C6A9F20611E5E39AE756F72080F3817"
          xlink:label="d34423000e2961-wk-Fact-1C6A9F20611E5E39AE756F72080F3817"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2961-wk-Fact-1C6A9F20611E5E39AE756F72080F3817"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7227-wk-Fact-1C89FA66D1ECFDF67F72801F8179DC33"
          xlink:label="d34586122e7227-wk-Fact-1C89FA66D1ECFDF67F72801F8179DC33"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7227-wk-Fact-1C89FA66D1ECFDF67F72801F8179DC33"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1630-wk-Fact-1C949239FD4407E55222801F7FD72F26"
          xlink:label="d34428379e1630-wk-Fact-1C949239FD4407E55222801F7FD72F26"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1630-wk-Fact-1C949239FD4407E55222801F7FD72F26"
          xlink:to="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1630-wk-Fact-1C949239FD4407E55222801F7FD72F26"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:label="d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:label="d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:label="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl" xlink:label="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> v. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">The decrease in the domestic loss was primarily due to lower interest expense paid to certain foreign subsidiaries, lower net losses on the retirement of debt, higher net gains on equity securities and increased revenue related to Eliquis, partially offset by higher certain asset impairments and lower revenue for Viagra and the legacy SIP portfolio. The decrease in international income was primarily related to lower interest income received primarily from intercompany borrowings from Pfizer Inc. and higher charges related to certain cost reduction initiatives, partially offset by increased revenue related to Ibrance and Eliquis.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1729-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4361-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2077-wk-Fact-1C9D1BB3B510D7CEA6E6801F809C9997"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7175-wk-Fact-1CA134AD576458FCA79E9C753A5EF8FD"
          xlink:label="d34458032e7175-wk-Fact-1CA134AD576458FCA79E9C753A5EF8FD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7175-wk-Fact-1CA134AD576458FCA79E9C753A5EF8FD"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4922-wk-Fact-1CD88F40E9218841E1F5801F7F82CECD"
          xlink:label="d34661879e4922-wk-Fact-1CD88F40E9218841E1F5801F7F82CECD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4922-wk-Fact-1CD88F40E9218841E1F5801F7F82CECD"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10028-wk-Fact-1CFEC5FF204858E76294801F8228D349"
          xlink:label="d34661879e10028-wk-Fact-1CFEC5FF204858E76294801F8228D349"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10028-wk-Fact-1CFEC5FF204858E76294801F8228D349"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e4865-wk-Fact-1D05AD6F6F2D8CB837F3801F81CB438D"
          xlink:label="d34594690e4865-wk-Fact-1D05AD6F6F2D8CB837F3801F81CB438D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e4865-wk-Fact-1D05AD6F6F2D8CB837F3801F81CB438D"
          xlink:to="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7526-wk-Fact-1D1D9E822C1094BF0A35801F7E86E0C0"
          xlink:label="d34586122e7526-wk-Fact-1D1D9E822C1094BF0A35801F7E86E0C0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7526-wk-Fact-1D1D9E822C1094BF0A35801F7E86E0C0"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6090-wk-Fact-1D437AF9323714A08390801F7E93DC39"
          xlink:label="d34586122e6090-wk-Fact-1D437AF9323714A08390801F7E93DC39"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl" xlink:label="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"><xhtml:span style="font-family:Arial;font-size:7pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6090-wk-Fact-1D437AF9323714A08390801F7E93DC39"
          xlink:to="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7262-wk-Fact-1D47F48F7F3554A78127DAFE590E794E"
          xlink:label="d34586122e7262-wk-Fact-1D47F48F7F3554A78127DAFE590E794E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7262-wk-Fact-1D47F48F7F3554A78127DAFE590E794E"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4843-wk-Fact-1D9607EC2BA2B2BE84B8801F807C0925"
          xlink:label="d34661879e4843-wk-Fact-1D9607EC2BA2B2BE84B8801F807C0925"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4843-wk-Fact-1D9607EC2BA2B2BE84B8801F807C0925"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4843-wk-Fact-1D9607EC2BA2B2BE84B8801F807C0925"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2616-wk-Fact-1D9D8C11D13199ACE522801F82C58824"
          xlink:label="d34458036e2616-wk-Fact-1D9D8C11D13199ACE522801F82C58824"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2616-wk-Fact-1D9D8C11D13199ACE522801F82C58824"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e1780-wk-Fact-1E3FF9437BEA5C5E903FC608EF1570C3"
          xlink:label="d34468079e1780-wk-Fact-1E3FF9437BEA5C5E903FC608EF1570C3"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl" xlink:label="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The asset impairment charges for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> are largely associated with cost reduction initiatives not associated with acquisitions. The asset impairment charges for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> are primarily associated with abandoned assets. See (b) below for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1780-wk-Fact-1E3FF9437BEA5C5E903FC608EF1570C3"
          xlink:to="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11872-wk-Fact-1E63E1B1645BA0E7748B801F818279BE"
          xlink:label="d34586122e11872-wk-Fact-1E63E1B1645BA0E7748B801F818279BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11872-wk-Fact-1E63E1B1645BA0E7748B801F818279BE"
          xlink:to="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5327-wk-Fact-1EA1B7699985D7A7899C801F7E93B603"
          xlink:label="d34458036e5327-wk-Fact-1EA1B7699985D7A7899C801F7E93B603"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5327-wk-Fact-1EA1B7699985D7A7899C801F7E93B603"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl" xlink:label="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$747 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> is included in the net loss of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$846 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> upon the exchange and early retirement of the U.K. pound-denominated debt. See</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 7D.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5327-wk-Fact-1EA1B7699985D7A7899C801F7E93B603"
          xlink:to="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E"
          xlink:label="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E"
          xlink:to="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3878-wk-Fact-1EFEA91138DB5A9889C028FFE6AE503E"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2871-wk-Fact-1F2788F8C7EAC31BDBAF801F7E00C985"
          xlink:label="d34468079e2871-wk-Fact-1F2788F8C7EAC31BDBAF801F7E00C985"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2871-wk-Fact-1F2788F8C7EAC31BDBAF801F7E00C985"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5116-wk-Fact-1F4672D432636FBAB1D9801F811E4A03"
          xlink:label="d34545404e5116-wk-Fact-1F4672D432636FBAB1D9801F811E4A03"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5116-wk-Fact-1F4672D432636FBAB1D9801F811E4A03"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22442-wk-Fact-1F4D93C2F9904F6D73B7801F7FFAD79C"
          xlink:label="d34661879e22442-wk-Fact-1F4D93C2F9904F6D73B7801F7FFAD79C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22442-wk-Fact-1F4D93C2F9904F6D73B7801F7FFAD79C"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14782-wk-Fact-1F63287DE71910139202801F7F087DC5"
          xlink:label="d34661879e14782-wk-Fact-1F63287DE71910139202801F7F087DC5"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl" xlink:label="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Accrued compensation and related items</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14782-wk-Fact-1F63287DE71910139202801F7F087DC5"
          xlink:to="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3007-wk-Fact-1F6DDFC5F407544BA48EE7A820F1CB06"
          xlink:label="d34501946e3007-wk-Fact-1F6DDFC5F407544BA48EE7A820F1CB06"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl" xlink:label="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily issued by a diverse group of corporations.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3007-wk-Fact-1F6DDFC5F407544BA48EE7A820F1CB06"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34512803e1675-wk-Fact-1F6DFBB307AD56A78E5BB87151D63936"
          xlink:label="d34512803e1675-wk-Fact-1F6DFBB307AD56A78E5BB87151D63936"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-99ECE6937087FF439970801F831B2740-0-wk-Footnote-99ECE6937087FF439970801F831B2740_lbl" xlink:label="TextSelection-99ECE6937087FF439970801F831B2740-0-wk-Footnote-99ECE6937087FF439970801F831B2740_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. There are no recoverability issues associated with these amounts.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34512803e1675-wk-Fact-1F6DFBB307AD56A78E5BB87151D63936"
          xlink:to="TextSelection-99ECE6937087FF439970801F831B2740-0-wk-Footnote-99ECE6937087FF439970801F831B2740_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6184-wk-Fact-1F8E1E5AC854059418AF801F7E7A53FB"
          xlink:label="d34586122e6184-wk-Fact-1F8E1E5AC854059418AF801F7E7A53FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6184-wk-Fact-1F8E1E5AC854059418AF801F7E7A53FB"
          xlink:to="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14504-wk-Fact-1FABDAEE54CD68890F1E801F7F0BED57"
          xlink:label="d34661879e14504-wk-Fact-1FABDAEE54CD68890F1E801F7F0BED57"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14504-wk-Fact-1FABDAEE54CD68890F1E801F7F0BED57"
          xlink:to="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4052-wk-Fact-1FB0890125B2E2F568A0801F82580255"
          xlink:label="d34545404e4052-wk-Fact-1FB0890125B2E2F568A0801F82580255"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl" xlink:label="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The favorable rate impact in 2018 is a result of the updated 2017 invoice received from the federal government, which reflected a lower expense than what was previously estimated for invoiced periods, as well as certain tax initiatives.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4052-wk-Fact-1FB0890125B2E2F568A0801F82580255"
          xlink:to="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl" xlink:label="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:span style="font-family:Arial;font-size:7pt;">For a discussion about tax settlements and resolution of certain tax positions, the impact of the gain on the completion of the Consumer Healthcare joint venture transaction and the impact of U.S. Healthcare Legislation, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</xhtml:span></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4052-wk-Fact-1FB0890125B2E2F568A0801F82580255"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24717-wk-Fact-1FD036A003F66D196001801F80EDBF09"
          xlink:label="d34661879e24717-wk-Fact-1FD036A003F66D196001801F80EDBF09"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl" xlink:label="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24717-wk-Fact-1FD036A003F66D196001801F80EDBF09"
          xlink:to="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10981-wk-Fact-1FE49E27774BBC4F7DE7801F7E5B14A7"
          xlink:label="d34586122e10981-wk-Fact-1FE49E27774BBC4F7DE7801F7E5B14A7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10981-wk-Fact-1FE49E27774BBC4F7DE7801F7E5B14A7"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6368-wk-Fact-2022231E382951F7A5219EA645136F0E"
          xlink:label="d34538474e6368-wk-Fact-2022231E382951F7A5219EA645136F0E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6368-wk-Fact-2022231E382951F7A5219EA645136F0E"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6368-wk-Fact-2022231E382951F7A5219EA645136F0E"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3883-wk-Fact-204C8AF80ED25BDE9A77B2C926C838B9"
          xlink:label="d34468079e3883-wk-Fact-204C8AF80ED25BDE9A77B2C926C838B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3883-wk-Fact-204C8AF80ED25BDE9A77B2C926C838B9"
          xlink:to="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14850-wk-Fact-2062BC7C0DF48822A1BA801F7F02D514"
          xlink:label="d34661879e14850-wk-Fact-2062BC7C0DF48822A1BA801F7F02D514"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl" xlink:label="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">As of December 31, 2019, included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Pension benefit obligations, net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Postretirement benefit obligations</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">net, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">as appropriate. In 2018, included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Pension benefit obligations, net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Postretirement benefit obligations</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, as well as in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Liabilities held for sale</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">)</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">, as </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">appropriate.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14850-wk-Fact-2062BC7C0DF48822A1BA801F7F02D514"
          xlink:to="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11530-wk-Fact-2091B860985E526EACD15CD4A5669CD5"
          xlink:label="d34586122e11530-wk-Fact-2091B860985E526EACD15CD4A5669CD5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11530-wk-Fact-2091B860985E526EACD15CD4A5669CD5"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2125-wk-Fact-20A55537F0675518894025A232665AAA"
          xlink:label="d34468079e2125-wk-Fact-20A55537F0675518894025A232665AAA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e1864-wk-Fact-20A55537F0675518894025A232665AAA"
          xlink:label="d34430544e1864-wk-Fact-20A55537F0675518894025A232665AAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2125-wk-Fact-20A55537F0675518894025A232665AAA"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1864-wk-Fact-20A55537F0675518894025A232665AAA"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e16298-wk-Fact-20C1F8EC97D87AA8FE1C801F822F40EA"
          xlink:label="d34661879e16298-wk-Fact-20C1F8EC97D87AA8FE1C801F822F40EA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e16298-wk-Fact-20C1F8EC97D87AA8FE1C801F822F40EA"
          xlink:to="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2325-wk-Fact-2101798BE4EDF6E78C8F801F803DE4E4"
          xlink:label="d34460716e2325-wk-Fact-2101798BE4EDF6E78C8F801F803DE4E4"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl" xlink:label="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:100%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$11 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> loss in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$20 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> loss in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$14 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> income in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. Amounts in 2019 include after-tax gains of approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$978 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), partially offset by the strengthening of the U.S. dollar against the euro and the Australian dollar, and the results of our net investment hedging program.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2325-wk-Fact-2101798BE4EDF6E78C8F801F803DE4E4"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3177-wk-Fact-211494DFE1B65B998EAAA38B4550E8C1"
          xlink:label="d34428379e3177-wk-Fact-211494DFE1B65B998EAAA38B4550E8C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3177-wk-Fact-211494DFE1B65B998EAAA38B4550E8C1"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3921-wk-Fact-213E32B8B2FE51C690B80D561FAEFE40"
          xlink:label="d34471435e3921-wk-Fact-213E32B8B2FE51C690B80D561FAEFE40"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3921-wk-Fact-213E32B8B2FE51C690B80D561FAEFE40"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3921-wk-Fact-213E32B8B2FE51C690B80D561FAEFE40"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6097-wk-Fact-2169B9839E1C354CF47B801F7F1FEF95"
          xlink:label="d34545404e6097-wk-Fact-2169B9839E1C354CF47B801F7F1FEF95"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6097-wk-Fact-2169B9839E1C354CF47B801F7F1FEF95"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-B6A3FF5187C02063A75F801F8312B48A-0-wk-Footnote-B6A3FF5187C02063A75F801F8312B48A_lbl" xlink:label="TextSelection-B6A3FF5187C02063A75F801F8312B48A-0-wk-Footnote-B6A3FF5187C02063A75F801F8312B48A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$0.9 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$5.6 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">). In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$0.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$3.7 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6097-wk-Fact-2169B9839E1C354CF47B801F7F1FEF95"
          xlink:to="TextSelection-B6A3FF5187C02063A75F801F8312B48A-0-wk-Footnote-B6A3FF5187C02063A75F801F8312B48A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22602-wk-Fact-21757F62AEF00E5BF73F801F7EA5E973"
          xlink:label="d34661879e22602-wk-Fact-21757F62AEF00E5BF73F801F7EA5E973"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22602-wk-Fact-21757F62AEF00E5BF73F801F7EA5E973"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22621-wk-Fact-21863FBD06730CC6F0CE801F8133FD38"
          xlink:label="d34661879e22621-wk-Fact-21863FBD06730CC6F0CE801F8133FD38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22621-wk-Fact-21863FBD06730CC6F0CE801F8133FD38"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2673-wk-Fact-218AEF14B977A83E4A06801F7EFF265B"
          xlink:label="d34458032e2673-wk-Fact-218AEF14B977A83E4A06801F7EFF265B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2673-wk-Fact-218AEF14B977A83E4A06801F7EFF265B"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23171-wk-Fact-21E0043926A006FDE718801F80EA1DF6"
          xlink:label="d34661879e23171-wk-Fact-21E0043926A006FDE718801F80EA1DF6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23171-wk-Fact-21E0043926A006FDE718801F80EA1DF6"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23171-wk-Fact-21E0043926A006FDE718801F80EA1DF6"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9475-wk-Fact-2227E15F117DFBBA6CDF801F823CAC01"
          xlink:label="d34661879e9475-wk-Fact-2227E15F117DFBBA6CDF801F823CAC01"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9475-wk-Fact-2227E15F117DFBBA6CDF801F823CAC01"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10092-wk-Fact-225081F555A03A27E808801F8232C488"
          xlink:label="d34661879e10092-wk-Fact-225081F555A03A27E808801F8232C488"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10092-wk-Fact-225081F555A03A27E808801F8232C488"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9591-wk-Fact-22F449DB433F0BD91E88801F8227AC5A"
          xlink:label="d34661879e9591-wk-Fact-22F449DB433F0BD91E88801F8227AC5A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9591-wk-Fact-22F449DB433F0BD91E88801F8227AC5A"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6787-wk-Fact-22F8C804B14DB17BB996801F7E35F6F2"
          xlink:label="d34545404e6787-wk-Fact-22F8C804B14DB17BB996801F7E35F6F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6787-wk-Fact-22F8C804B14DB17BB996801F7E35F6F2"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1747-wk-Fact-22FC256F29955A5AAC465714927146A3"
          xlink:label="d34423000e1747-wk-Fact-22FC256F29955A5AAC465714927146A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1747-wk-Fact-22FC256F29955A5AAC465714927146A3"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11379-wk-Fact-236A48C44D219DB1205A801F8231D63E"
          xlink:label="d34661879e11379-wk-Fact-236A48C44D219DB1205A801F8231D63E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11379-wk-Fact-236A48C44D219DB1205A801F8231D63E"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10786-wk-Fact-23DB84919E70B73B1647801F8249C9E2"
          xlink:label="d34661879e10786-wk-Fact-23DB84919E70B73B1647801F8249C9E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10786-wk-Fact-23DB84919E70B73B1647801F8249C9E2"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6137-wk-Fact-2409EE5D9DDE703FA11B801F7E7C5AAF"
          xlink:label="d34586122e6137-wk-Fact-2409EE5D9DDE703FA11B801F7E7C5AAF"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl" xlink:label="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"><xhtml:span style="font-family:Arial;font-size:7pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6137-wk-Fact-2409EE5D9DDE703FA11B801F7E7C5AAF"
          xlink:to="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4030-wk-Fact-241AF0F5CD243F91D7E3801F81BCFDF4"
          xlink:label="d34586122e4030-wk-Fact-241AF0F5CD243F91D7E3801F81BCFDF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4030-wk-Fact-241AF0F5CD243F91D7E3801F81BCFDF4"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5379-wk-Fact-246CB21BC49B5BF7A871DD3D4BFCC13C"
          xlink:label="d34586122e5379-wk-Fact-246CB21BC49B5BF7A871DD3D4BFCC13C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl" xlink:label="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5379-wk-Fact-246CB21BC49B5BF7A871DD3D4BFCC13C"
          xlink:to="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81"
          xlink:label="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81"
          xlink:to="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3897-wk-Fact-2471EA04578D559B862F15CF77806D81"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14581-wk-Fact-248A8F8CD6CA4B37A1DD801F7F0C957E"
          xlink:label="d34661879e14581-wk-Fact-248A8F8CD6CA4B37A1DD801F7F0C957E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14581-wk-Fact-248A8F8CD6CA4B37A1DD801F7F0C957E"
          xlink:to="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6277-wk-Fact-24A404127FF2306D6A2E801F7FC76C30"
          xlink:label="d34458032e6277-wk-Fact-24A404127FF2306D6A2E801F7FC76C30"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6277-wk-Fact-24A404127FF2306D6A2E801F7FC76C30"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6277-wk-Fact-24A404127FF2306D6A2E801F7FC76C30"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2546-wk-Fact-24AE793F7AF5A0FFC713801F81A5B87D"
          xlink:label="d34594690e2546-wk-Fact-24AE793F7AF5A0FFC713801F81A5B87D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl" xlink:label="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Determined using the interpolated yield on U.S. Treasury zero-coupon issues.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2546-wk-Fact-24AE793F7AF5A0FFC713801F81A5B87D"
          xlink:to="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5623-wk-Fact-24C3D095E2CC3CF22E410211B6D446C8"
          xlink:label="d34545404e5623-wk-Fact-24C3D095E2CC3CF22E410211B6D446C8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5623-wk-Fact-24C3D095E2CC3CF22E410211B6D446C8"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl" xlink:label="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The increase in 2019 is primarily related to the Consumer Healthcare joint venture with GSK. See </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5623-wk-Fact-24C3D095E2CC3CF22E410211B6D446C8"
          xlink:to="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3624-wk-Fact-2575FD938424E6650896801F80D24265"
          xlink:label="d34586122e3624-wk-Fact-2575FD938424E6650896801F80D24265"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3624-wk-Fact-2575FD938424E6650896801F80D24265"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8007-wk-Fact-25FC84B343C1A318CA97DE1AB610DB22"
          xlink:label="d34586122e8007-wk-Fact-25FC84B343C1A318CA97DE1AB610DB22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8007-wk-Fact-25FC84B343C1A318CA97DE1AB610DB22"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7674-wk-Fact-26023C9A152437741F6FDE1A28B16CBA"
          xlink:label="d34586122e7674-wk-Fact-26023C9A152437741F6FDE1A28B16CBA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7674-wk-Fact-26023C9A152437741F6FDE1A28B16CBA"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3814-wk-Fact-264673D948622D0AA0A4801F7F4D3D67"
          xlink:label="d34545404e3814-wk-Fact-264673D948622D0AA0A4801F7F4D3D67"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl" xlink:label="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For a discussion about the enactment of the TCJA, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3814-wk-Fact-264673D948622D0AA0A4801F7F4D3D67"
          xlink:to="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4102-wk-Fact-2648C18B67135722AC996F7545880D80"
          xlink:label="d34661879e4102-wk-Fact-2648C18B67135722AC996F7545880D80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4102-wk-Fact-2648C18B67135722AC996F7545880D80"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3525-wk-Fact-265DAD9E00B9993A01D4801F81574A5A"
          xlink:label="d34594690e3525-wk-Fact-265DAD9E00B9993A01D4801F81574A5A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl" xlink:label="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>2,173,131</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> TSRUs with a weighted-average grant price of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$30.68</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> per unit were converted into </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>844,871</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> PTUs.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3525-wk-Fact-265DAD9E00B9993A01D4801F81574A5A"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl" xlink:label="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, we settled </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>7,953,671</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> TSRUs with a weighted-average grant price of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$27.33</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> per unit.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3525-wk-Fact-265DAD9E00B9993A01D4801F81574A5A"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4732-wk-Fact-267B1096BA37527F9F57BD86C5CF0ACF"
          xlink:label="d34529301e4732-wk-Fact-267B1096BA37527F9F57BD86C5CF0ACF"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl" xlink:label="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Reflects acquired licensing agreements for technology in development.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4732-wk-Fact-267B1096BA37527F9F57BD86C5CF0ACF"
          xlink:to="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3693-wk-Fact-268578D08E27C197EEE6801F8149CC9C"
          xlink:label="d34594690e3693-wk-Fact-268578D08E27C197EEE6801F8149CC9C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3693-wk-Fact-268578D08E27C197EEE6801F8149CC9C"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3693-wk-Fact-268578D08E27C197EEE6801F8149CC9C"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3882-wk-Fact-27063B77FAD0699D0962801F7E91ACE2"
          xlink:label="d34545404e3882-wk-Fact-27063B77FAD0699D0962801F7E91ACE2"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl" xlink:label="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For taxation of non-U.S. operations, this rate impact reflects the income tax rates and relative earnings in the locations where we do business outside the U.S., together with the cost of repatriation decisions, which, for 2017, includes the repatriation tax on deemed repatriated 2017 earnings of foreign subsidiaries discussed in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions,&#x201d; as well as changes in valuation allowances. Specifically: (i) the jurisdictional location of earnings is a significant component of our effective tax rate each year, and the rate impact of this component is influenced by the specific location of non-U.S. earnings and the level of such earnings as compared to our total earnings; (ii) the cost of repatriation decisions, and other U.S. tax implications of our foreign operations, is a significant component of our effective tax rate each year and generally offsets some of the reduction to our effective tax rate each year resulting from the jurisdictional location of earnings; (iii) </xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-left:12px;text-align:left;"><xhtml:span style="font-family:Arial;font-size:7pt;">certain tax initiatives; and (iv) the impact of changes in uncertain tax positions not included in the reconciling item called &#x201c;Tax settlements and resolution of certain tax positions&#x201d; is a component of our effective tax rate each year that can result in either an increase or decrease to our effective tax rate. The jurisdictional mix of earnings, which includes the impact of the location of earnings as well as repatriation costs, can vary as a result of the repatriation decisions, as a result of operating fluctuations in the normal course of business and as a result of the extent and location of other income and expense items, such as restructuring charges, asset impairments and gains and losses on strategic business decisions. See also </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5A </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">for the components of pre-tax income and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">which is based on the location of the taxing authorities, and for information about settlements and other items impacting </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3882-wk-Fact-27063B77FAD0699D0962801F7E91ACE2"
          xlink:to="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl" xlink:label="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In all periods presented, the reduction in our effective tax rate resulting from the jurisdictional location of earnings is largely due to lower tax rates in certain jurisdictions, as well as manufacturing and other incentives associated with our subsidiaries in Puerto Rico and Singapore. We benefit from a Puerto Rican incentive grant that expires in 2029. Under the grant, we are partially exempt from income, property and municipal taxes. In Singapore, we benefit from incentive tax rates effective through 2045 on income from manufacturing and other operations.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3882-wk-Fact-27063B77FAD0699D0962801F7E91ACE2"
          xlink:to="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2069-wk-Fact-270C12BCCD80680CE432CB2DE5F8DC92"
          xlink:label="d34458032e2069-wk-Fact-270C12BCCD80680CE432CB2DE5F8DC92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2069-wk-Fact-270C12BCCD80680CE432CB2DE5F8DC92"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7457-wk-Fact-2735403E9898D9DCFDE4DE1919D0AF5E"
          xlink:label="d34586122e7457-wk-Fact-2735403E9898D9DCFDE4DE1919D0AF5E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7457-wk-Fact-2735403E9898D9DCFDE4DE1919D0AF5E"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2309-wk-Fact-274A4E3678CE5C1E9A3DE2C7A5DF6A4D"
          xlink:label="d34471435e2309-wk-Fact-274A4E3678CE5C1E9A3DE2C7A5DF6A4D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl" xlink:label="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In 2019 and 2018, mainly represents incremental costs associated with the design, planning and implementation of our new organizational structure, effective in the beginning of 2019, and primarily includes consulting, legal, tax and advisory services. In 2017, represents expenses for changes to our infrastructure to align our commercial operations that existed through December 31, 2018, including costs to internally separate our businesses into distinct legal entities, as well as to streamline our intercompany supply operations to better support each business.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2309-wk-Fact-274A4E3678CE5C1E9A3DE2C7A5DF6A4D"
          xlink:to="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5176-wk-Fact-276A8A35EE68509F999B815A3BCBFE8E"
          xlink:label="d34458036e5176-wk-Fact-276A8A35EE68509F999B815A3BCBFE8E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5176-wk-Fact-276A8A35EE68509F999B815A3BCBFE8E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5176-wk-Fact-276A8A35EE68509F999B815A3BCBFE8E"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2906-wk-Fact-276AE48F003C5B94964313479CA47CC4"
          xlink:label="d34458036e2906-wk-Fact-276AE48F003C5B94964313479CA47CC4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2906-wk-Fact-276AE48F003C5B94964313479CA47CC4"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20401-wk-Fact-278022090600AF2B386D801F811D7324"
          xlink:label="d34661879e20401-wk-Fact-278022090600AF2B386D801F811D7324"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20401-wk-Fact-278022090600AF2B386D801F811D7324"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19100-wk-Fact-27B7F1F490681634429E801F80F1F370"
          xlink:label="d34661879e19100-wk-Fact-27B7F1F490681634429E801F80F1F370"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19100-wk-Fact-27B7F1F490681634429E801F80F1F370"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1819-wk-Fact-27CD0201DE5939C1D6C9801F7F2B2695"
          xlink:label="d34430544e1819-wk-Fact-27CD0201DE5939C1D6C9801F7F2B2695"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1819-wk-Fact-27CD0201DE5939C1D6C9801F7F2B2695"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4777-wk-Fact-27E943B33C7E2180DED5801F807FD2B1"
          xlink:label="d34458032e4777-wk-Fact-27E943B33C7E2180DED5801F807FD2B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4777-wk-Fact-27E943B33C7E2180DED5801F807FD2B1"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7806-wk-Fact-28116B03F1F1501FA19804A781E93B54"
          xlink:label="d34458032e7806-wk-Fact-28116B03F1F1501FA19804A781E93B54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7806-wk-Fact-28116B03F1F1501FA19804A781E93B54"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228"
          xlink:label="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228"
          xlink:to="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5792-wk-Fact-2820B2D1FBF85FA7A76FFC4DE8061228"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e12058-wk-Fact-2846B8E6B6B05D109C0045899F1AADE9"
          xlink:label="d34586122e12058-wk-Fact-2846B8E6B6B05D109C0045899F1AADE9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl" xlink:label="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e12058-wk-Fact-2846B8E6B6B05D109C0045899F1AADE9"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9553-wk-Fact-28AB86F70D2CD4381B5F801F81FA1B6D"
          xlink:label="d34661879e9553-wk-Fact-28AB86F70D2CD4381B5F801F81FA1B6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9553-wk-Fact-28AB86F70D2CD4381B5F801F81FA1B6D"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1585-wk-Fact-28DD1757DF955D578E13DE8351B692BB"
          xlink:label="d34430544e1585-wk-Fact-28DD1757DF955D578E13DE8351B692BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1585-wk-Fact-28DD1757DF955D578E13DE8351B692BB"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1585-wk-Fact-28DD1757DF955D578E13DE8351B692BB"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2270-wk-Fact-28E378BA49F05856958E09125890B46D"
          xlink:label="d34428379e2270-wk-Fact-28E378BA49F05856958E09125890B46D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2270-wk-Fact-28E378BA49F05856958E09125890B46D"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2513-wk-Fact-28FF4AB5B22B53EA235C801F82B2C028"
          xlink:label="d34458036e2513-wk-Fact-28FF4AB5B22B53EA235C801F82B2C028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2513-wk-Fact-28FF4AB5B22B53EA235C801F82B2C028"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638"
          xlink:label="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4037-wk-Fact-293B43D0694A5E4FB900E2955F7C5638"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2397-wk-Fact-2955D81BA66657739DD6267CF9D38630"
          xlink:label="d34468079e2397-wk-Fact-2955D81BA66657739DD6267CF9D38630"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2397-wk-Fact-2955D81BA66657739DD6267CF9D38630"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23210-wk-Fact-296077A478766CD8DCE5801F8128127D"
          xlink:label="d34661879e23210-wk-Fact-296077A478766CD8DCE5801F8128127D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23210-wk-Fact-296077A478766CD8DCE5801F8128127D"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23210-wk-Fact-296077A478766CD8DCE5801F8128127D"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219"
          xlink:label="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6298-wk-Fact-297502689FA45CA4B2574BF9DC211219"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1670-wk-Fact-29CC16548E2E546280762B10A285EBB3"
          xlink:label="d34430544e1670-wk-Fact-29CC16548E2E546280762B10A285EBB3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1670-wk-Fact-29CC16548E2E546280762B10A285EBB3"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1670-wk-Fact-29CC16548E2E546280762B10A285EBB3"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3139-wk-Fact-29D31CFA7A6550EBAA66F5ACE1A10761"
          xlink:label="d34423000e3139-wk-Fact-29D31CFA7A6550EBAA66F5ACE1A10761"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3139-wk-Fact-29D31CFA7A6550EBAA66F5ACE1A10761"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5031-wk-Fact-29D9AEE0EF874B7D2804801F810F970F"
          xlink:label="d34545404e5031-wk-Fact-29D9AEE0EF874B7D2804801F810F970F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5031-wk-Fact-29D9AEE0EF874B7D2804801F810F970F"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8732-wk-Fact-2A00978854A95D9F943FA975DD0E0D7C"
          xlink:label="d34545404e8732-wk-Fact-2A00978854A95D9F943FA975DD0E0D7C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8732-wk-Fact-2A00978854A95D9F943FA975DD0E0D7C"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22505-wk-Fact-2A45E23937B1E03B0AA9801F816FD16A"
          xlink:label="d34661879e22505-wk-Fact-2A45E23937B1E03B0AA9801F816FD16A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22505-wk-Fact-2A45E23937B1E03B0AA9801F816FD16A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6328-wk-Fact-2A9ACB09597856F4AD1723B635334EC2"
          xlink:label="d34538474e6328-wk-Fact-2A9ACB09597856F4AD1723B635334EC2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6328-wk-Fact-2A9ACB09597856F4AD1723B635334EC2"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2335-wk-Fact-2AA90167164D2E1A59FA801F7E8DBF9F"
          xlink:label="d34458036e2335-wk-Fact-2AA90167164D2E1A59FA801F7E8DBF9F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2335-wk-Fact-2AA90167164D2E1A59FA801F7E8DBF9F"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3079-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495"
          xlink:label="d34661879e3079-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9906-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495"
          xlink:label="d34661879e9906-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3079-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9906-wk-Fact-2ADA45F22BD4CC0B7A53801F8200F495"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1554-wk-Fact-2B2A9C8657C8CAF5F992801F80CD8F28"
          xlink:label="d34471435e1554-wk-Fact-2B2A9C8657C8CAF5F992801F80CD8F28"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl" xlink:label="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> v. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">&#x2013;&#x2013;Interest income decreased primarily driven by a lower investment balance. Interest expense increased mainly as a result of an increased commercial paper balance due to the acquisition of Array, as well as the retirement of lower-coupon debt and the issuance of new debt with a higher coupon than the debt outstanding for the comparative prior year period. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> v. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">&#x2013;&#x2013;Interest income decreased primarily driven by a lower investment balance. Interest expense increased primarily as a result of higher short-term interest rates, offset, in part, by refinancing activity that occurred in the fourth quarter of 2017. Capitalized interest expense totaled </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$88 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, $</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>73 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and $</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>72 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1554-wk-Fact-2B2A9C8657C8CAF5F992801F80CD8F28"
          xlink:to="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10951-wk-Fact-2B8A551F74454F44A11F801F8230140D"
          xlink:label="d34661879e10951-wk-Fact-2B8A551F74454F44A11F801F8230140D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10951-wk-Fact-2B8A551F74454F44A11F801F8230140D"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34519344e2140-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F"
          xlink:label="d34519344e2140-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e3318-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F"
          xlink:label="d34423000e3318-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34519344e2140-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3318-wk-Fact-2BB5E1CDCD3E5C778EB98DBAD031065F"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4682-wk-Fact-2BBF90C0E0ACDECC1704801F80243029"
          xlink:label="d34458032e4682-wk-Fact-2BBF90C0E0ACDECC1704801F80243029"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4682-wk-Fact-2BBF90C0E0ACDECC1704801F80243029"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7287-wk-Fact-2C386152CD1597FBF4FA801F82A1CFF0"
          xlink:label="d34594690e7287-wk-Fact-2C386152CD1597FBF4FA801F82A1CFF0"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl" xlink:label="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Determined using implied volatility, after consideration of historical volatility.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7287-wk-Fact-2C386152CD1597FBF4FA801F82A1CFF0"
          xlink:to="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19196-wk-Fact-2C64274CCAA479E1D7CD801F7E6C51E8"
          xlink:label="d34661879e19196-wk-Fact-2C64274CCAA479E1D7CD801F7E6C51E8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19196-wk-Fact-2C64274CCAA479E1D7CD801F7E6C51E8"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11160-wk-Fact-2C95573C6F895F6892E174F65C10E575"
          xlink:label="d34586122e11160-wk-Fact-2C95573C6F895F6892E174F65C10E575"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11160-wk-Fact-2C95573C6F895F6892E174F65C10E575"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4603-wk-Fact-2CA2DA51FA5858A080A8149D1EF99AE3"
          xlink:label="d34661879e4603-wk-Fact-2CA2DA51FA5858A080A8149D1EF99AE3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4603-wk-Fact-2CA2DA51FA5858A080A8149D1EF99AE3"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24037-wk-Fact-2CA6288317D80D709922801F8147D1CB"
          xlink:label="d34661879e24037-wk-Fact-2CA6288317D80D709922801F8147D1CB"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl" xlink:label="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24037-wk-Fact-2CA6288317D80D709922801F8147D1CB"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24037-wk-Fact-2CA6288317D80D709922801F8147D1CB"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5027-wk-Fact-2CA67D7D788BA11D095F801F7FD36422"
          xlink:label="d34458032e5027-wk-Fact-2CA67D7D788BA11D095F801F7FD36422"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5027-wk-Fact-2CA67D7D788BA11D095F801F7FD36422"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2901-wk-Fact-2CB4512C4635516E90761E4D85A4869E"
          xlink:label="d34430544e2901-wk-Fact-2CB4512C4635516E90761E4D85A4869E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2901-wk-Fact-2CB4512C4635516E90761E4D85A4869E"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-2CBB41D064359126314C801F82CC8933-wk-Fact-2CBB41D064359126314C801F82CC8933"
          xlink:label="Fact-2CBB41D064359126314C801F82CC8933-wk-Fact-2CBB41D064359126314C801F82CC8933"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl" xlink:label="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-2CBB41D064359126314C801F82CC8933-wk-Fact-2CBB41D064359126314C801F82CC8933"
          xlink:to="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6767-wk-Fact-2D59B5E05ED9F368C224801F80B95B6D"
          xlink:label="d34545404e6767-wk-Fact-2D59B5E05ED9F368C224801F80B95B6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6767-wk-Fact-2D59B5E05ED9F368C224801F80B95B6D"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4175-wk-Fact-2D81E359A3F32671B09D801F7F331769"
          xlink:label="d34545404e4175-wk-Fact-2D81E359A3F32671B09D801F7F331769"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4175-wk-Fact-2D81E359A3F32671B09D801F7F331769"
          xlink:to="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7005-wk-Fact-2D99B1124ACE12540611801F82B4994F"
          xlink:label="d34586122e7005-wk-Fact-2D99B1124ACE12540611801F82B4994F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7005-wk-Fact-2D99B1124ACE12540611801F82B4994F"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10041-wk-Fact-2DA2C6E810E554E8A093A9328B417C64"
          xlink:label="d34586122e10041-wk-Fact-2DA2C6E810E554E8A093A9328B417C64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10041-wk-Fact-2DA2C6E810E554E8A093A9328B417C64"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10041-wk-Fact-2DA2C6E810E554E8A093A9328B417C64"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e2714-wk-Fact-2EFB3D5BD681B11EF065801F7F7EB754"
          xlink:label="d34545404e2714-wk-Fact-2EFB3D5BD681B11EF065801F7F7EB754"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl" xlink:label="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:justify;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The 2018 current tax benefit and deferred tax expense primarily relate to the utilization of tax credit carryforwards against the repatriation tax liability associated with the enactment of the TCJA. See discussion below and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2714-wk-Fact-2EFB3D5BD681B11EF065801F7F7EB754"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1623-wk-Fact-2F12F18AD8251A365397801F7F1D63C2"
          xlink:label="d34430544e1623-wk-Fact-2F12F18AD8251A365397801F7F1D63C2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1623-wk-Fact-2F12F18AD8251A365397801F7F1D63C2"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1623-wk-Fact-2F12F18AD8251A365397801F7F1D63C2"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11771-wk-Fact-2F3A89C4B2BD5133ACFBE4229DDE6CC5"
          xlink:label="d34586122e11771-wk-Fact-2F3A89C4B2BD5133ACFBE4229DDE6CC5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11771-wk-Fact-2F3A89C4B2BD5133ACFBE4229DDE6CC5"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2970-wk-Fact-2F3CA3A3FAD45C6BBFFA9AF52B012B5D"
          xlink:label="d34430544e2970-wk-Fact-2F3CA3A3FAD45C6BBFFA9AF52B012B5D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2970-wk-Fact-2F3CA3A3FAD45C6BBFFA9AF52B012B5D"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10866-wk-Fact-2FA5505B9C078F2C7287801F821DF04C"
          xlink:label="d34661879e10866-wk-Fact-2FA5505B9C078F2C7287801F821DF04C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10866-wk-Fact-2FA5505B9C078F2C7287801F821DF04C"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5247-wk-Fact-2FA734C3E6F851F3A59F806EDB8CEAFE"
          xlink:label="d34586122e5247-wk-Fact-2FA734C3E6F851F3A59F806EDB8CEAFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5247-wk-Fact-2FA734C3E6F851F3A59F806EDB8CEAFE"
          xlink:to="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2929-wk-Fact-30AD1982C6115A29A36BF68B59AEDB47"
          xlink:label="d34428379e2929-wk-Fact-30AD1982C6115A29A36BF68B59AEDB47"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2929-wk-Fact-30AD1982C6115A29A36BF68B59AEDB47"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6561-wk-Fact-30D9418081FBA848CBA2801F7ECCAB71"
          xlink:label="d34458032e6561-wk-Fact-30D9418081FBA848CBA2801F7ECCAB71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6561-wk-Fact-30D9418081FBA848CBA2801F7ECCAB71"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23836-wk-Fact-31101E0D5A9F589C42B9801F7EDE61BF"
          xlink:label="d34661879e23836-wk-Fact-31101E0D5A9F589C42B9801F7EDE61BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23836-wk-Fact-31101E0D5A9F589C42B9801F7EDE61BF"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23836-wk-Fact-31101E0D5A9F589C42B9801F7EDE61BF"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6008-wk-Fact-3156136D7E33FEA3D6A7801F7F106890"
          xlink:label="d34545404e6008-wk-Fact-3156136D7E33FEA3D6A7801F7F106890"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e5833-wk-Fact-3156136D7E33FEA3D6A7801F7F106890"
          xlink:label="d34545404e5833-wk-Fact-3156136D7E33FEA3D6A7801F7F106890"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6008-wk-Fact-3156136D7E33FEA3D6A7801F7F106890"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5833-wk-Fact-3156136D7E33FEA3D6A7801F7F106890"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2122-wk-Fact-316CD294736155A2BF815F488E7DB6E0"
          xlink:label="d34430544e2122-wk-Fact-316CD294736155A2BF815F488E7DB6E0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e3133-wk-Fact-316CD294736155A2BF815F488E7DB6E0"
          xlink:label="d34545404e3133-wk-Fact-316CD294736155A2BF815F488E7DB6E0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2122-wk-Fact-316CD294736155A2BF815F488E7DB6E0"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3133-wk-Fact-316CD294736155A2BF815F488E7DB6E0"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11523-wk-Fact-3172D79ECC315BEBFB19801F822ED289"
          xlink:label="d34661879e11523-wk-Fact-3172D79ECC315BEBFB19801F822ED289"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11523-wk-Fact-3172D79ECC315BEBFB19801F822ED289"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2290-wk-Fact-31991F01AC86E4619B23801F800998F2"
          xlink:label="d34428379e2290-wk-Fact-31991F01AC86E4619B23801F800998F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2290-wk-Fact-31991F01AC86E4619B23801F800998F2"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2578-wk-Fact-31994C39581B5B71BDDB9AE8FC22964B"
          xlink:label="d34523018e2578-wk-Fact-31994C39581B5B71BDDB9AE8FC22964B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2578-wk-Fact-31994C39581B5B71BDDB9AE8FC22964B"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2411-wk-Fact-31D197A179335FA6BF6A7BC5D0D64EA2"
          xlink:label="d34423000e2411-wk-Fact-31D197A179335FA6BF6A7BC5D0D64EA2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2411-wk-Fact-31D197A179335FA6BF6A7BC5D0D64EA2"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9231-wk-Fact-31D3680708335B049E798A2ECB5508B4"
          xlink:label="d34458032e9231-wk-Fact-31D3680708335B049E798A2ECB5508B4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9231-wk-Fact-31D3680708335B049E798A2ECB5508B4"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e16237-wk-Fact-31E13FD9B07B11996B5E801F8233F654"
          xlink:label="d34661879e16237-wk-Fact-31E13FD9B07B11996B5E801F8233F654"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e16237-wk-Fact-31E13FD9B07B11996B5E801F8233F654"
          xlink:to="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3708-wk-Fact-31E5ACFB46A559DC7083801F81586817"
          xlink:label="d34594690e3708-wk-Fact-31E5ACFB46A559DC7083801F81586817"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3708-wk-Fact-31E5ACFB46A559DC7083801F81586817"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3708-wk-Fact-31E5ACFB46A559DC7083801F81586817"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2243-wk-Fact-31EE472AE3C7503BA361B44F0445BA6E"
          xlink:label="d34471435e2243-wk-Fact-31EE472AE3C7503BA361B44F0445BA6E"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl" xlink:label="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily includes intangible asset impairment charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, mainly composed of: (i) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.6 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, related to Eucrisa, a Biopharma finite-lived developed technology right acquired in connection with our acquisition of Anacor, and reflects updated commercial forecasts mainly reflecting competitive pressures; (ii) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$90 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to WRDM IPR&amp;D, for a pre-clinical stage asset from our acquisition of Bamboo for gene therapies for the potential treatment of patients with certain rare diseases which was the result of a determination to not use certain Bamboo IPR&amp;D acquired in future rare disease development; (iii) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$40 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to a Biopharma developed technology right, acquired in connection with our acquisition of King, for government defense products and reflects, among other things, updated commercial forecasts including manufacturing cost assumptions; (iv) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$31 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to a Biopharma IPR&amp;D asset, acquired in connection with our acquisition of AstraZeneca&#x2019;s anti-infectives business, which reflects updated commercial forecasts; (v) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$10 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to a Biopharma finite-lived developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus marketed in the </xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-left:12px;text-align:left;"><xhtml:span style="font-family:Arial;font-size:7pt;">U.S. market only, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">and reflects</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, among other things, updated commercial forecasts; and (vi) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$10 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of Innopharma.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-left:4px;padding-bottom:1px;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily includes intangible asset impairment charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$3.1 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, mainly composed of (i) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.6 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to Biopharma developed technology rights, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$242 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to Biopharma licensing agreements and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$80 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to Biopharma IPR&amp;D, all of which relate to our acquisition of Hospira, for generic sterile injectable products associated with various indications; (ii) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$117 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to a multi-antigen vaccine IPR&amp;D program for adults undergoing elective spinal fusion surgery; (iii) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$31 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to an Biopharma developed technology right, acquired in connection with our acquisition of Anacor, for the treatment for toenail fungus market marketed in the U.S. market only; and (iv) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$17 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of other IPR&amp;D assets acquired in connection with our acquisition of Innopharma. In 2018, the intangible asset impairment charges associated with the generic sterile injectable products reflect, among other things, updated commercial forecasts, reflecting an increased competitive environment as well as higher manufacturing costs, largely stemming from manufacturing and supply issues. The intangible asset impairment charge for the multi-antigen vaccine IPR&amp;D program was the result of the Phase 2b trial reaching futility at a pre-planned interim analysis. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">The intangible asset impairment charge related to the </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">Biopharma developed technology right</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;"> reflects</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, among other things, updated commercial forecasts. .</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In 2017, primarily includes intangible asset impairment charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$337 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, reflecting (i) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$127 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic sterile injectable product for the treatment of edema associated with certain conditions; (ii) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$124 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a sterile injectable pain reliever; (iii) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$39 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of NextWave, for the treatment of attention deficit hyperactivity disorder; (iv) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$26 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to developed technology rights, acquired in connection with our acquisition of Hospira, for a generic injectable antibiotic product for the treatment of bacterial infections; and (v) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$20 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to other developed technology rights. The intangible asset impairment charges for 2017 are associated with Biopharma and reflect, among other things, updated commercial forecasts and an increased competitive environment. In addition, 2017 includes a loss of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$43 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> for an impairment of our AM-Pharma B.V. long-term investment.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2243-wk-Fact-31EE472AE3C7503BA361B44F0445BA6E"
          xlink:to="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7353-wk-Fact-31F361F21F2837AACE1C801F82A5E94F"
          xlink:label="d34594690e7353-wk-Fact-31F361F21F2837AACE1C801F82A5E94F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl" xlink:label="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Determined using historical exercise and post-vesting termination patterns.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7353-wk-Fact-31F361F21F2837AACE1C801F82A5E94F"
          xlink:to="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e6734-wk-Fact-3211B659D4CE729821B4801F7F0D704F"
          xlink:label="d34594690e6734-wk-Fact-3211B659D4CE729821B4801F7F0D704F"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl" xlink:label="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7.5pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">2017 </xhtml:span><xhtml:span style="font-family:Arial;font-size:7.5pt;">includes the modification </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">for a commitment to pay</xhtml:span><xhtml:span style="font-family:Arial;font-size:7.5pt;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7.5pt;"><xhtml:span>1.1 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7.5pt;"> PSAs to approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7.5pt;"><xhtml:span>90</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7.5pt;"> employees, including senior and key management employees, for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7.5pt;"><xhtml:span>1.1 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7.5pt;"> PSAs. These shares were paid in the first quarter of 2018.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e6734-wk-Fact-3211B659D4CE729821B4801F7F0D704F"
          xlink:to="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4"
          xlink:label="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3454-wk-Fact-3219AB4ECEBC69524913AB460AA61DE4"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14891-wk-Fact-324241AD63CEF2D77B12801F7F01BBA9"
          xlink:label="d34661879e14891-wk-Fact-324241AD63CEF2D77B12801F7F01BBA9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14891-wk-Fact-324241AD63CEF2D77B12801F7F01BBA9"
          xlink:to="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5669-wk-Fact-324D6E1724EEC6BE2FE9801F7DF40048"
          xlink:label="d34458032e5669-wk-Fact-324D6E1724EEC6BE2FE9801F7DF40048"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5669-wk-Fact-324D6E1724EEC6BE2FE9801F7DF40048"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e1931-wk-Fact-324E930EA3FE51309DAF874C15316ACB"
          xlink:label="d34523018e1931-wk-Fact-324E930EA3FE51309DAF874C15316ACB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2428-wk-Fact-324E930EA3FE51309DAF874C15316ACB"
          xlink:label="d34430544e2428-wk-Fact-324E930EA3FE51309DAF874C15316ACB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e1931-wk-Fact-324E930EA3FE51309DAF874C15316ACB"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2428-wk-Fact-324E930EA3FE51309DAF874C15316ACB"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23875-wk-Fact-32850438677456DE85D2801F80EF43A5"
          xlink:label="d34661879e23875-wk-Fact-32850438677456DE85D2801F80EF43A5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23875-wk-Fact-32850438677456DE85D2801F80EF43A5"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23875-wk-Fact-32850438677456DE85D2801F80EF43A5"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23902-wk-Fact-32BE2AC3AB258DAE14BA801F815D5109"
          xlink:label="d34661879e23902-wk-Fact-32BE2AC3AB258DAE14BA801F815D5109"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23902-wk-Fact-32BE2AC3AB258DAE14BA801F815D5109"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11257-wk-Fact-32E1EBDBF1BACBF6E103801F8241B168"
          xlink:label="d34661879e11257-wk-Fact-32E1EBDBF1BACBF6E103801F8241B168"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11257-wk-Fact-32E1EBDBF1BACBF6E103801F8241B168"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7339-wk-Fact-32EF9B5301DDDEC38EC0801F829FDB14"
          xlink:label="d34594690e7339-wk-Fact-32EF9B5301DDDEC38EC0801F829FDB14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7339-wk-Fact-32EF9B5301DDDEC38EC0801F829FDB14"
          xlink:to="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20990-wk-Fact-32F10B48A55F1AE6E300801F813AC7A0"
          xlink:label="d34661879e20990-wk-Fact-32F10B48A55F1AE6E300801F813AC7A0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20990-wk-Fact-32F10B48A55F1AE6E300801F813AC7A0"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20990-wk-Fact-32F10B48A55F1AE6E300801F813AC7A0"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3080-wk-Fact-33025D2CE7995F16A707BC65C2D0FAA0"
          xlink:label="d34430544e3080-wk-Fact-33025D2CE7995F16A707BC65C2D0FAA0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3080-wk-Fact-33025D2CE7995F16A707BC65C2D0FAA0"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1590-wk-Fact-3328F0DAC738681A6D21801F7ECF7D37"
          xlink:label="d34428379e1590-wk-Fact-3328F0DAC738681A6D21801F7ECF7D37"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1590-wk-Fact-3328F0DAC738681A6D21801F7ECF7D37"
          xlink:to="TextSelection-60B4D1BC59F2495B2D8E16DF8C3F6651-0-wk-Footnote-60B4D1BC59F2495B2D8E16DF8C3F6651_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1590-wk-Fact-3328F0DAC738681A6D21801F7ECF7D37"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10273-wk-Fact-3332CC39DDDB775F98DD801F82319453"
          xlink:label="d34661879e10273-wk-Fact-3332CC39DDDB775F98DD801F82319453"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10273-wk-Fact-3332CC39DDDB775F98DD801F82319453"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4065-wk-Fact-333989DFC77B15A1F172801F7E787CBF"
          xlink:label="d34458036e4065-wk-Fact-333989DFC77B15A1F172801F7E787CBF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4065-wk-Fact-333989DFC77B15A1F172801F7E787CBF"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4369-wk-Fact-33AFDD4662101709F692801F7E18C5FF"
          xlink:label="d34458032e4369-wk-Fact-33AFDD4662101709F692801F7E18C5FF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4369-wk-Fact-33AFDD4662101709F692801F7E18C5FF"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2661-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
          xlink:label="d34523018e2661-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e3417-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
          xlink:label="d34430544e3417-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2661-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3417-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2661-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3417-wk-Fact-33F90922FE92534B8F84E80D9633CDA7"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e4016-wk-Fact-34056A88C0D75E6C9FEE2D3BDD894FE8"
          xlink:label="d34468079e4016-wk-Fact-34056A88C0D75E6C9FEE2D3BDD894FE8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e4016-wk-Fact-34056A88C0D75E6C9FEE2D3BDD894FE8"
          xlink:to="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3939-wk-Fact-341D9ED90C94596BB9FAE98E1294E451"
          xlink:label="d34471435e3939-wk-Fact-341D9ED90C94596BB9FAE98E1294E451"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3939-wk-Fact-341D9ED90C94596BB9FAE98E1294E451"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3939-wk-Fact-341D9ED90C94596BB9FAE98E1294E451"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21228-wk-Fact-341E870038AF69B1EEA5801F813FD1D5"
          xlink:label="d34661879e21228-wk-Fact-341E870038AF69B1EEA5801F813FD1D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21228-wk-Fact-341E870038AF69B1EEA5801F813FD1D5"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2401-wk-Fact-3428A9878F8D11970A11801F7E90E64E"
          xlink:label="d34458036e2401-wk-Fact-3428A9878F8D11970A11801F7E90E64E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2401-wk-Fact-3428A9878F8D11970A11801F7E90E64E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724"
          xlink:label="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24180-wk-Fact-342C1D529758AE2897FA801F7EBF4724"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11154-wk-Fact-3436CB2133E67A0CED9C801F8220C53D"
          xlink:label="d34661879e11154-wk-Fact-3436CB2133E67A0CED9C801F8220C53D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11154-wk-Fact-3436CB2133E67A0CED9C801F8220C53D"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14870-wk-Fact-346579D6E7C0E2843401801F7F121ACE"
          xlink:label="d34661879e14870-wk-Fact-346579D6E7C0E2843401801F7F121ACE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14870-wk-Fact-346579D6E7C0E2843401801F7F121ACE"
          xlink:to="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7822-wk-Fact-34727ACB136D8931558B801F7E88E0C5"
          xlink:label="d34586122e7822-wk-Fact-34727ACB136D8931558B801F7E88E0C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7822-wk-Fact-34727ACB136D8931558B801F7E88E0C5"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5051-wk-Fact-347BAF696A1993925737801F8131C37D"
          xlink:label="d34545404e5051-wk-Fact-347BAF696A1993925737801F8131C37D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5051-wk-Fact-347BAF696A1993925737801F8131C37D"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1717-wk-Fact-3482AAEFC33858968E580ACA1EF44907"
          xlink:label="d34430544e1717-wk-Fact-3482AAEFC33858968E580ACA1EF44907"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1717-wk-Fact-3482AAEFC33858968E580ACA1EF44907"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1717-wk-Fact-3482AAEFC33858968E580ACA1EF44907"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7580-wk-Fact-34A07B3634CE5849A713202F3645E2BC"
          xlink:label="d34586122e7580-wk-Fact-34A07B3634CE5849A713202F3645E2BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7580-wk-Fact-34A07B3634CE5849A713202F3645E2BC"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5575-wk-Fact-34AD8E413C695FBD8469975721FFB0F6"
          xlink:label="d34458036e5575-wk-Fact-34AD8E413C695FBD8469975721FFB0F6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5575-wk-Fact-34AD8E413C695FBD8469975721FFB0F6"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10477-wk-Fact-34CCCF8B6B98C5A6827D801F8243C77E"
          xlink:label="d34661879e10477-wk-Fact-34CCCF8B6B98C5A6827D801F8243C77E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10477-wk-Fact-34CCCF8B6B98C5A6827D801F8243C77E"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e2206-wk-Fact-34FF2F3BFE615D19B8D425D5797E438A"
          xlink:label="d34538474e2206-wk-Fact-34FF2F3BFE615D19B8D425D5797E438A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e2206-wk-Fact-34FF2F3BFE615D19B8D425D5797E438A"
          xlink:to="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3892-wk-Fact-3503C852F9E4ADA0D97B801F7FA9C9D8"
          xlink:label="d34661879e3892-wk-Fact-3503C852F9E4ADA0D97B801F7FA9C9D8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3892-wk-Fact-3503C852F9E4ADA0D97B801F7FA9C9D8"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9931-wk-Fact-3550225B14CDA4F396FD801F81FC93AD"
          xlink:label="d34661879e9931-wk-Fact-3550225B14CDA4F396FD801F81FC93AD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9931-wk-Fact-3550225B14CDA4F396FD801F81FC93AD"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6020-wk-Fact-35607E33C1EA7F8BC8EF801F7E4B3C15"
          xlink:label="d34661879e6020-wk-Fact-35607E33C1EA7F8BC8EF801F7E4B3C15"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl" xlink:label="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2020</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> are </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>24.9</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> years for our U.S. qualified plans, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>24.5</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> years for our U.S. supplemental (non-qualified) plans, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>19.4</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> years for our international plans, and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>9.2</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> years for our postretirement plans.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6020-wk-Fact-35607E33C1EA7F8BC8EF801F7E4B3C15"
          xlink:to="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8475-wk-Fact-356826AC764E5F1AB122D61B135DA970"
          xlink:label="d34586122e8475-wk-Fact-356826AC764E5F1AB122D61B135DA970"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8475-wk-Fact-356826AC764E5F1AB122D61B135DA970"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e16196-wk-Fact-3575E2B197DFFB710849801F822BF3AD"
          xlink:label="d34661879e16196-wk-Fact-3575E2B197DFFB710849801F822BF3AD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e16196-wk-Fact-3575E2B197DFFB710849801F822BF3AD"
          xlink:to="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21613-wk-Fact-3582128093A73BF0EBD0801F80323008"
          xlink:label="d34661879e21613-wk-Fact-3582128093A73BF0EBD0801F80323008"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21613-wk-Fact-3582128093A73BF0EBD0801F80323008"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4234-wk-Fact-35B362807E1AE86654F9801F811F7FF8"
          xlink:label="d34586122e4234-wk-Fact-35B362807E1AE86654F9801F811F7FF8"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl" xlink:label="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. </xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For Earnings in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$758 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$543 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$495 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (v) net gains of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$415 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) a pre-tax gain of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$8.1 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$138 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and (viii) other charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$1.3 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, which includes, among other things: an upfront license fee payment of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$250 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> to Akcea, which was recorded in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$112 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> recorded in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">&#x2013;net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$337 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to our acquisition of Therachon, a </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$99 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">related to rivipansel, primarily for inventory manufactured for expected future sale and charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$240 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A, Note 2A, Note 2C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2D,</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For Earnings in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$977 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (ii) net charges for certain legal matters of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$157 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$3.1 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$63 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (v) net gains of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$586 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$3 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$4 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a non-cash </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$343 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$119 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charge, in the aggregate, in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$50 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">, Note 3</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For Earnings in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$204 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$237 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$379 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$71 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, (v) net gains of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$224 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$999 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$756 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a charitable contribution to the Pfizer Foundation of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$200 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, which is included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses,</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$195 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales,</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> an </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$81 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> loss related to the sale of our former </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>49%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> equity share in Hisun Pfizer, which is included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net,</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> charges of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$55 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$30 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>40%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>60%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> ownership interest, which is included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2C,</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4234-wk-Fact-35B362807E1AE86654F9801F811F7FF8"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4234-wk-Fact-35B362807E1AE86654F9801F811F7FF8"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9851-wk-Fact-35D3A5D66469542E865E5AA0C2D06B43"
          xlink:label="d34458032e9851-wk-Fact-35D3A5D66469542E865E5AA0C2D06B43"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9851-wk-Fact-35D3A5D66469542E865E5AA0C2D06B43"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4701-wk-Fact-35E0049DFF2E76A140E3801F8089CAA6"
          xlink:label="d34458032e4701-wk-Fact-35E0049DFF2E76A140E3801F8089CAA6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4701-wk-Fact-35E0049DFF2E76A140E3801F8089CAA6"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2686-wk-Fact-360249B3A006541E93860494E7664450"
          xlink:label="d34586122e2686-wk-Fact-360249B3A006541E93860494E7664450"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2686-wk-Fact-360249B3A006541E93860494E7664450"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4364-wk-Fact-36071102556E5A8BB41605B5E0E61960"
          xlink:label="d34661879e4364-wk-Fact-36071102556E5A8BB41605B5E0E61960"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4364-wk-Fact-36071102556E5A8BB41605B5E0E61960"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1820-wk-Fact-3608CBE3F82FCEC11A98801F7EB42466"
          xlink:label="d34458036e1820-wk-Fact-3608CBE3F82FCEC11A98801F7EB42466"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1820-wk-Fact-3608CBE3F82FCEC11A98801F7EB42466"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0"
          xlink:label="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24219-wk-Fact-3633344E6ACA0DAF45C1801F7DEEE7D0"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9657-wk-Fact-364B4EF7858D52F1B60FF23BA7D7CA9F"
          xlink:label="d34458032e9657-wk-Fact-364B4EF7858D52F1B60FF23BA7D7CA9F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9657-wk-Fact-364B4EF7858D52F1B60FF23BA7D7CA9F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl" xlink:label="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The increase to </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Retained earnings</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in 2019 includes the cumulative effect of the adoption of a new accounting standard for leases in the first quarter of 2019. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> The decrease in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Equity attributable to noncontrolling interests </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">resulted from the deconsolidation of our Consumer Healthcare business in connection with the formation of the GSK Consumer Healthcare joint venture. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:5pt"> </xhtml:sup></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">The decrease in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Additional paid in capital</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> relates to our buyout of the remaining </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>50%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of noncontrolling interests in an oncology vaccines start up, which has historically been consolidated by us.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9657-wk-Fact-364B4EF7858D52F1B60FF23BA7D7CA9F"
          xlink:to="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e4245-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
          xlink:label="d34501946e4245-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34471435e1885-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
          xlink:label="d34471435e1885-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e4245-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
          xlink:to="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1885-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
          xlink:to="TextSelection-5F8A582ABBC805FB2DBB801F830A48CF-0-wk-Footnote-5F8A582ABBC805FB2DBB801F830A48CF_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e4245-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
          xlink:to="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1885-wk-Fact-364D49347A25577A9FDDC9569F869ED0"
          xlink:to="TextSelection-E41196B9AFBC55040560801F83162759-0-wk-Footnote-E41196B9AFBC55040560801F83162759_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5557-wk-Fact-365F3C6454AE5427308D801F8123E06B"
          xlink:label="d34545404e5557-wk-Fact-365F3C6454AE5427308D801F8123E06B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5557-wk-Fact-365F3C6454AE5427308D801F8123E06B"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6577-wk-Fact-3699E726612D593C213A801F7E0FB736"
          xlink:label="d34458032e6577-wk-Fact-3699E726612D593C213A801F7E0FB736"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6577-wk-Fact-3699E726612D593C213A801F7E0FB736"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34524436e1715-wk-Fact-36C4BF558BFA7F0626F6801F8284052E"
          xlink:label="d34524436e1715-wk-Fact-36C4BF558BFA7F0626F6801F8284052E"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-38BDAE166DE9044C0E60801F8347D176-0-wk-Footnote-38BDAE166DE9044C0E60801F8347D176_lbl" xlink:label="TextSelection-38BDAE166DE9044C0E60801F8347D176-0-wk-Footnote-38BDAE166DE9044C0E60801F8347D176_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">March&#160;12, 2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">, as well as other share repurchases. See above for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34524436e1715-wk-Fact-36C4BF558BFA7F0626F6801F8284052E"
          xlink:to="TextSelection-38BDAE166DE9044C0E60801F8347D176-0-wk-Footnote-38BDAE166DE9044C0E60801F8347D176_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4877-wk-Fact-36EFF26A70BF5280BEBB3D0AA77CBFFB"
          xlink:label="d34529301e4877-wk-Fact-36EFF26A70BF5280BEBB3D0AA77CBFFB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4877-wk-Fact-36EFF26A70BF5280BEBB3D0AA77CBFFB"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3894-wk-Fact-3706D36BE0715C4B909C295C63B57B4F"
          xlink:label="d34458036e3894-wk-Fact-3706D36BE0715C4B909C295C63B57B4F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3894-wk-Fact-3706D36BE0715C4B909C295C63B57B4F"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2290-wk-Fact-372575356B8E57CCAFE65ACA01B572B8"
          xlink:label="d34471435e2290-wk-Fact-372575356B8E57CCAFE65ACA01B572B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2290-wk-Fact-372575356B8E57CCAFE65ACA01B572B8"
          xlink:to="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10190-wk-Fact-378CC18954DCD2BE6AD2801F8208C07A"
          xlink:label="d34661879e10190-wk-Fact-378CC18954DCD2BE6AD2801F8208C07A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10190-wk-Fact-378CC18954DCD2BE6AD2801F8208C07A"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3653-wk-Fact-378E7CFB0C3366BE1636801F7F982A6D"
          xlink:label="d34661879e3653-wk-Fact-378E7CFB0C3366BE1636801F7F982A6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3653-wk-Fact-378E7CFB0C3366BE1636801F7F982A6D"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3653-wk-Fact-378E7CFB0C3366BE1636801F7F982A6D"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2743-wk-Fact-37BB967598E60C472CDF801F80B12AD6"
          xlink:label="d34468079e2743-wk-Fact-37BB967598E60C472CDF801F80B12AD6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2743-wk-Fact-37BB967598E60C472CDF801F80B12AD6"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20524-wk-Fact-37C2E96F0C06B8BE58DC801F81379E3A"
          xlink:label="d34661879e20524-wk-Fact-37C2E96F0C06B8BE58DC801F81379E3A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20524-wk-Fact-37C2E96F0C06B8BE58DC801F81379E3A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-37E466B377E093574704801F823ADEB7-wk-Fact-37E466B377E093574704801F823ADEB7"
          xlink:label="Fact-37E466B377E093574704801F823ADEB7-wk-Fact-37E466B377E093574704801F823ADEB7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-37E466B377E093574704801F823ADEB7-wk-Fact-37E466B377E093574704801F823ADEB7"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6074-wk-Fact-380993016EC856A5A43F951D0C773A80"
          xlink:label="d34538474e6074-wk-Fact-380993016EC856A5A43F951D0C773A80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6074-wk-Fact-380993016EC856A5A43F951D0C773A80"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-38352E73A1AC3A38585F801F81E7E0C5-wk-Fact-38352E73A1AC3A38585F801F81E7E0C5"
          xlink:label="Fact-38352E73A1AC3A38585F801F81E7E0C5-wk-Fact-38352E73A1AC3A38585F801F81E7E0C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-38352E73A1AC3A38585F801F81E7E0C5-wk-Fact-38352E73A1AC3A38585F801F81E7E0C5"
          xlink:to="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8194-wk-Fact-385EDBE1A04BC6E2A680801F829EC2AC"
          xlink:label="d34586122e8194-wk-Fact-385EDBE1A04BC6E2A680801F829EC2AC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8194-wk-Fact-385EDBE1A04BC6E2A680801F829EC2AC"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23048-wk-Fact-386DE871FDE603DE0A0C801F7E75C64F"
          xlink:label="d34661879e23048-wk-Fact-386DE871FDE603DE0A0C801F7E75C64F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23048-wk-Fact-386DE871FDE603DE0A0C801F7E75C64F"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2177-wk-Fact-38838F053717CF5598FFCF6EFFF59BAF"
          xlink:label="d34460716e2177-wk-Fact-38838F053717CF5598FFCF6EFFF59BAF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2177-wk-Fact-38838F053717CF5598FFCF6EFFF59BAF"
          xlink:to="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5453-wk-Fact-3886E93F27E98EE28D2C801F7F4E0594"
          xlink:label="d34545404e5453-wk-Fact-3886E93F27E98EE28D2C801F7F4E0594"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5453-wk-Fact-3886E93F27E98EE28D2C801F7F4E0594"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3247-wk-Fact-388802394B995CDECA90801F7F4A337B"
          xlink:label="d34430544e3247-wk-Fact-388802394B995CDECA90801F7F4A337B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3247-wk-Fact-388802394B995CDECA90801F7F4A337B"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1899-wk-Fact-38B878301DB957B297D2601592AD511A"
          xlink:label="d34423000e1899-wk-Fact-38B878301DB957B297D2601592AD511A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34496162e9129-wk-Fact-38B878301DB957B297D2601592AD511A"
          xlink:label="d34496162e9129-wk-Fact-38B878301DB957B297D2601592AD511A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1899-wk-Fact-38B878301DB957B297D2601592AD511A"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e9129-wk-Fact-38B878301DB957B297D2601592AD511A"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11407-wk-Fact-390B954ED7FDBB67E7CD801F8201DB61"
          xlink:label="d34661879e11407-wk-Fact-390B954ED7FDBB67E7CD801F8201DB61"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11407-wk-Fact-390B954ED7FDBB67E7CD801F8201DB61"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2003-wk-Fact-393C1336661B5502A717C267B3C8D41C"
          xlink:label="d34458036e2003-wk-Fact-393C1336661B5502A717C267B3C8D41C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2003-wk-Fact-393C1336661B5502A717C267B3C8D41C"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl" xlink:label="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Includes tax expense of approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.7 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> associated with the gain related to the completion of the Consumer Healthcare joint venture transaction with GSK. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">and</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 5</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">A.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2003-wk-Fact-393C1336661B5502A717C267B3C8D41C"
          xlink:to="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24076-wk-Fact-3993C9034191C03D601B801F7EDE39F5"
          xlink:label="d34661879e24076-wk-Fact-3993C9034191C03D601B801F7EDE39F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24076-wk-Fact-3993C9034191C03D601B801F7EDE39F5"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24076-wk-Fact-3993C9034191C03D601B801F7EDE39F5"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3844-wk-Fact-39A51FF36D53F8FAFD27801F828948C3"
          xlink:label="d34545404e3844-wk-Fact-39A51FF36D53F8FAFD27801F828948C3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3844-wk-Fact-39A51FF36D53F8FAFD27801F828948C3"
          xlink:to="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3659-wk-Fact-39D10B011D5484305F0B801F814829A7"
          xlink:label="d34594690e3659-wk-Fact-39D10B011D5484305F0B801F814829A7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3659-wk-Fact-39D10B011D5484305F0B801F814829A7"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3659-wk-Fact-39D10B011D5484305F0B801F814829A7"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3255-wk-Fact-3A0EED0F100854319344F954D1578C77"
          xlink:label="d34458036e3255-wk-Fact-3A0EED0F100854319344F954D1578C77"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3255-wk-Fact-3A0EED0F100854319344F954D1578C77"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11359-wk-Fact-3A17F7C7D9A8C3BFB338801F82230016"
          xlink:label="d34661879e11359-wk-Fact-3A17F7C7D9A8C3BFB338801F82230016"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11359-wk-Fact-3A17F7C7D9A8C3BFB338801F82230016"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2643-wk-Fact-3A431FAAB1251C8B2F11801F7EAD8859"
          xlink:label="d34458036e2643-wk-Fact-3A431FAAB1251C8B2F11801F7EAD8859"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2643-wk-Fact-3A431FAAB1251C8B2F11801F7EAD8859"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8531-wk-Fact-3A992D3D837957AFBC4539641549FE54"
          xlink:label="d34458032e8531-wk-Fact-3A992D3D837957AFBC4539641549FE54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8531-wk-Fact-3A992D3D837957AFBC4539641549FE54"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6678-wk-Fact-3AD0784E9548664647E8801F7EFA79D4"
          xlink:label="d34458032e6678-wk-Fact-3AD0784E9548664647E8801F7EFA79D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6678-wk-Fact-3AD0784E9548664647E8801F7EFA79D4"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6000-wk-Fact-3AD6F4B4A41632FD0B68801F817F1B4F"
          xlink:label="d34661879e6000-wk-Fact-3AD6F4B4A41632FD0B68801F817F1B4F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6000-wk-Fact-3AD6F4B4A41632FD0B68801F817F1B4F"
          xlink:to="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3452-wk-Fact-3AE7E9A85D765783A134E8B901625365"
          xlink:label="d34423000e3452-wk-Fact-3AE7E9A85D765783A134E8B901625365"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3452-wk-Fact-3AE7E9A85D765783A134E8B901625365"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2660-wk-Fact-3B3FED2A33115ED2B476EFD5B5811F3E"
          xlink:label="d34468079e2660-wk-Fact-3B3FED2A33115ED2B476EFD5B5811F3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2660-wk-Fact-3B3FED2A33115ED2B476EFD5B5811F3E"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23739-wk-Fact-3B84715E11DB37BB7F37801F7E1EFCF3"
          xlink:label="d34661879e23739-wk-Fact-3B84715E11DB37BB7F37801F7E1EFCF3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23739-wk-Fact-3B84715E11DB37BB7F37801F7E1EFCF3"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23739-wk-Fact-3B84715E11DB37BB7F37801F7E1EFCF3"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2516-wk-Fact-3BADC091FCBEA9D91D08801F819B12FC"
          xlink:label="d34594690e2516-wk-Fact-3BADC091FCBEA9D91D08801F819B12FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2516-wk-Fact-3BADC091FCBEA9D91D08801F819B12FC"
          xlink:to="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22021-wk-Fact-3C503682A37762C63BE1801F8147265C"
          xlink:label="d34661879e22021-wk-Fact-3C503682A37762C63BE1801F8147265C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22021-wk-Fact-3C503682A37762C63BE1801F8147265C"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1574-wk-Fact-3C5E1456EFEB580EB0B057546407A424"
          xlink:label="d34471435e1574-wk-Fact-3C5E1456EFEB580EB0B057546407A424"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1574-wk-Fact-3C5E1456EFEB580EB0B057546407A424"
          xlink:to="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14620-wk-Fact-3C628A0CB0E19BD342B2801F7F090262"
          xlink:label="d34661879e14620-wk-Fact-3C628A0CB0E19BD342B2801F7F090262"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14620-wk-Fact-3C628A0CB0E19BD342B2801F7F090262"
          xlink:to="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2337-wk-Fact-3C80ECF87216CAD55440801F7F4B62D4"
          xlink:label="d34430544e2337-wk-Fact-3C80ECF87216CAD55440801F7F4B62D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2337-wk-Fact-3C80ECF87216CAD55440801F7F4B62D4"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1571-wk-Fact-3C889F3A20C0530CB57A37DDC3BC5CFD"
          xlink:label="d34423000e1571-wk-Fact-3C889F3A20C0530CB57A37DDC3BC5CFD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1571-wk-Fact-3C889F3A20C0530CB57A37DDC3BC5CFD"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1595-wk-Fact-3C9472B7B150D7664833801F80B066CF"
          xlink:label="d34471435e1595-wk-Fact-3C9472B7B150D7664833801F80B066CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1595-wk-Fact-3C9472B7B150D7664833801F80B066CF"
          xlink:to="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2196-wk-Fact-3CE8EBCFF7A37827A78B801F80EE18A9"
          xlink:label="d34471435e2196-wk-Fact-3CE8EBCFF7A37827A78B801F80EE18A9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2196-wk-Fact-3CE8EBCFF7A37827A78B801F80EE18A9"
          xlink:to="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8256-wk-Fact-3D222D29334A51ED9477C50D604F7F80"
          xlink:label="d34586122e8256-wk-Fact-3D222D29334A51ED9477C50D604F7F80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8256-wk-Fact-3D222D29334A51ED9477C50D604F7F80"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2478-wk-Fact-3DAD4CB2028224ADCA3A801F819615A2"
          xlink:label="d34594690e2478-wk-Fact-3DAD4CB2028224ADCA3A801F819615A2"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl" xlink:label="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Determined using a constant dividend yield during the expected term of the TSRU.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2478-wk-Fact-3DAD4CB2028224ADCA3A801F819615A2"
          xlink:to="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7437-wk-Fact-3DB102BD4155797B5C71DE18EDD8B9B9"
          xlink:label="d34586122e7437-wk-Fact-3DB102BD4155797B5C71DE18EDD8B9B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7437-wk-Fact-3DB102BD4155797B5C71DE18EDD8B9B9"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e27708-wk-Fact-3DE297FCB202AC8DCCF7801F7E992601"
          xlink:label="d34661879e27708-wk-Fact-3DE297FCB202AC8DCCF7801F7E992601"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl" xlink:label="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#160;<xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For the U.S. qualified plans, we plan to make a </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$1.25 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> voluntary contribution in the second half of 2020.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e27708-wk-Fact-3DE297FCB202AC8DCCF7801F7E992601"
          xlink:to="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5529-wk-Fact-3E8F06EF234D88E987EF801F821B72E3"
          xlink:label="d34506804e5529-wk-Fact-3E8F06EF234D88E987EF801F821B72E3"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl" xlink:label="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:justify;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5529-wk-Fact-3E8F06EF234D88E987EF801F821B72E3"
          xlink:to="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2493-wk-Fact-3EB348FE8DB4F3058FEF801F81A6D04E"
          xlink:label="d34594690e2493-wk-Fact-3EB348FE8DB4F3058FEF801F81A6D04E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2493-wk-Fact-3EB348FE8DB4F3058FEF801F81A6D04E"
          xlink:to="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11253-wk-Fact-3EBD6C7A46BD54608DC97B7D5BC28BC5"
          xlink:label="d34586122e11253-wk-Fact-3EBD6C7A46BD54608DC97B7D5BC28BC5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11253-wk-Fact-3EBD6C7A46BD54608DC97B7D5BC28BC5"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e5088-wk-Fact-3EF2B8E9997739EA3A5F801F7FF78369"
          xlink:label="d34661879e5088-wk-Fact-3EF2B8E9997739EA3A5F801F7FF78369"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e5088-wk-Fact-3EF2B8E9997739EA3A5F801F7FF78369"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2378-wk-Fact-3F54F0E033DA5F4EB9E1DB8292AC5F35"
          xlink:label="d34468079e2378-wk-Fact-3F54F0E033DA5F4EB9E1DB8292AC5F35"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2378-wk-Fact-3F54F0E033DA5F4EB9E1DB8292AC5F35"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3615-wk-Fact-3F59543875025E468AEF3F683189F304"
          xlink:label="d34661879e3615-wk-Fact-3F59543875025E468AEF3F683189F304"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3615-wk-Fact-3F59543875025E468AEF3F683189F304"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3615-wk-Fact-3F59543875025E468AEF3F683189F304"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23268-wk-Fact-3F72EA523C34D3EBBCF1801F80C7CC92"
          xlink:label="d34661879e23268-wk-Fact-3F72EA523C34D3EBBCF1801F80C7CC92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23268-wk-Fact-3F72EA523C34D3EBBCF1801F80C7CC92"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23268-wk-Fact-3F72EA523C34D3EBBCF1801F80C7CC92"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2900-wk-Fact-3FA833AC5BE1008431CF801F80F4EAAE"
          xlink:label="d34586122e2900-wk-Fact-3FA833AC5BE1008431CF801F80F4EAAE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2900-wk-Fact-3FA833AC5BE1008431CF801F80F4EAAE"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11135-wk-Fact-3FAA9033222E4A62E69F801F822B103B"
          xlink:label="d34661879e11135-wk-Fact-3FAA9033222E4A62E69F801F822B103B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11135-wk-Fact-3FAA9033222E4A62E69F801F822B103B"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2709-wk-Fact-3FAC1D7D150D5D3693952644AB014570"
          xlink:label="d34458036e2709-wk-Fact-3FAC1D7D150D5D3693952644AB014570"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2709-wk-Fact-3FAC1D7D150D5D3693952644AB014570"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2977-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
          xlink:label="d34428379e2977-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e9313-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
          xlink:label="d34545404e9313-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl" xlink:label="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For additional information. see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5E. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2977-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
          xlink:to="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9313-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
          xlink:to="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2977-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9313-wk-Fact-3FC035A6DA275AF19D7E26F6CFB4BFFC"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e5501-wk-Fact-3FDB29B576C0C8FDA061801F7FF11DF2"
          xlink:label="d34594690e5501-wk-Fact-3FDB29B576C0C8FDA061801F7FF11DF2"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C075792364F3F1E4361D801F8348FF26-0-wk-Footnote-C075792364F3F1E4361D801F8348FF26_lbl" xlink:label="TextSelection-C075792364F3F1E4361D801F8348FF26-0-wk-Footnote-C075792364F3F1E4361D801F8348FF26_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Vested and non-vested shares outstanding, but not paid as of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> were </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>32.0 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e5501-wk-Fact-3FDB29B576C0C8FDA061801F7FF11DF2"
          xlink:to="TextSelection-C075792364F3F1E4361D801F8348FF26-0-wk-Footnote-C075792364F3F1E4361D801F8348FF26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6916-wk-Fact-3FE2875CC05E5AF0955E1F16A4747D4E"
          xlink:label="d34586122e6916-wk-Fact-3FE2875CC05E5AF0955E1F16A4747D4E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6916-wk-Fact-3FE2875CC05E5AF0955E1F16A4747D4E"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34524436e1784-wk-Fact-406980FB36901507CFF4801F8284BFE7"
          xlink:label="d34524436e1784-wk-Fact-406980FB36901507CFF4801F8284BFE7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34524436e1784-wk-Fact-406980FB36901507CFF4801F8284BFE7"
          xlink:to="TextSelection-38BDAE166DE9044C0E60801F8347D176-0-wk-Footnote-38BDAE166DE9044C0E60801F8347D176_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e2753-wk-Fact-40815EB793804FE4A834801F7EBFA646"
          xlink:label="d34545404e2753-wk-Fact-40815EB793804FE4A834801F7EBFA646"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2753-wk-Fact-40815EB793804FE4A834801F7EBFA646"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4011-wk-Fact-4092AEA9F2F669BF51ECD083C021CD3C"
          xlink:label="d34586122e4011-wk-Fact-4092AEA9F2F669BF51ECD083C021CD3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4011-wk-Fact-4092AEA9F2F669BF51ECD083C021CD3C"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5214-wk-Fact-40C3E909042539E5B10F801F7E98C05E"
          xlink:label="d34458036e5214-wk-Fact-40C3E909042539E5B10F801F7E98C05E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5214-wk-Fact-40C3E909042539E5B10F801F7E98C05E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5214-wk-Fact-40C3E909042539E5B10F801F7E98C05E"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8403-wk-Fact-40C546EC33A35AFE9BEEFE176817495B"
          xlink:label="d34545404e8403-wk-Fact-40C546EC33A35AFE9BEEFE176817495B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl" xlink:label="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For additional information on the adoption of a new accounting standard related to financial assets and liabilities, see Notes to Consolidated Financial Statements&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8403-wk-Fact-40C546EC33A35AFE9BEEFE176817495B"
          xlink:to="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9697-wk-Fact-40E0EB9593AE56E6ABE3328268CD2D11"
          xlink:label="d34458032e9697-wk-Fact-40E0EB9593AE56E6ABE3328268CD2D11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9697-wk-Fact-40E0EB9593AE56E6ABE3328268CD2D11"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9697-wk-Fact-40E0EB9593AE56E6ABE3328268CD2D11"
          xlink:to="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5859-wk-Fact-40EBEAFCE6C7703C624E801F7F333340"
          xlink:label="d34545404e5859-wk-Fact-40EBEAFCE6C7703C624E801F7F333340"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5859-wk-Fact-40EBEAFCE6C7703C624E801F7F333340"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10961-wk-Fact-414C030E79B750E3A44270BCED97927B"
          xlink:label="d34586122e10961-wk-Fact-414C030E79B750E3A44270BCED97927B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10961-wk-Fact-414C030E79B750E3A44270BCED97927B"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2559-wk-Fact-4158106AA31D76C528FD801F7F58702B"
          xlink:label="d34460716e2559-wk-Fact-4158106AA31D76C528FD801F7F58702B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2559-wk-Fact-4158106AA31D76C528FD801F7F58702B"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2070-wk-Fact-416C8D02D1AC53CF8E7B9B0BE22D3ECD"
          xlink:label="d34458036e2070-wk-Fact-416C8D02D1AC53CF8E7B9B0BE22D3ECD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2070-wk-Fact-416C8D02D1AC53CF8E7B9B0BE22D3ECD"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1766-wk-Fact-41F671B8835D59FE8632B22D5D005E66"
          xlink:label="d34423000e1766-wk-Fact-41F671B8835D59FE8632B22D5D005E66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1766-wk-Fact-41F671B8835D59FE8632B22D5D005E66"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10992-wk-Fact-420050CC9AF1183EA21D801F82478087"
          xlink:label="d34661879e10992-wk-Fact-420050CC9AF1183EA21D801F82478087"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10992-wk-Fact-420050CC9AF1183EA21D801F82478087"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9746-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
          xlink:label="d34661879e9746-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e2846-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
          xlink:label="d34661879e2846-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9746-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2846-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9746-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2846-wk-Fact-421D8FAFB46FBD2A14FD801F81FD1B0A"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:label="d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:label="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3084-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1968-wk-Fact-42C763E1DFE25FFE8918A11795208B81"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14661-wk-Fact-42DC91E16F73927C464F801F7F0DDD4E"
          xlink:label="d34661879e14661-wk-Fact-42DC91E16F73927C464F801F7F0DDD4E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14661-wk-Fact-42DC91E16F73927C464F801F7F0DDD4E"
          xlink:to="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3867-wk-Fact-42EBCBC4C248331A0BFD801F82753FD6"
          xlink:label="d34545404e3867-wk-Fact-42EBCBC4C248331A0BFD801F82753FD6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3867-wk-Fact-42EBCBC4C248331A0BFD801F82753FD6"
          xlink:to="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3867-wk-Fact-42EBCBC4C248331A0BFD801F82753FD6"
          xlink:to="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4195-wk-Fact-43172D93073829A17FB6801F82AF4ECB"
          xlink:label="d34458036e4195-wk-Fact-43172D93073829A17FB6801F82AF4ECB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34594690e8605-wk-Fact-43172D93073829A17FB6801F82AF4ECB"
          xlink:label="d34594690e8605-wk-Fact-43172D93073829A17FB6801F82AF4ECB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4195-wk-Fact-43172D93073829A17FB6801F82AF4ECB"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8605-wk-Fact-43172D93073829A17FB6801F82AF4ECB"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23249-wk-Fact-4324A26D75595331CCFC801F81546900"
          xlink:label="d34661879e23249-wk-Fact-4324A26D75595331CCFC801F81546900"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23249-wk-Fact-4324A26D75595331CCFC801F81546900"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23249-wk-Fact-4324A26D75595331CCFC801F81546900"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3334-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
          xlink:label="d34430544e3334-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34523018e2512-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
          xlink:label="d34523018e2512-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3334-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2512-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3334-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2512-wk-Fact-4341D3EBACB35B32A9AD2068D645CA6B"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3169-wk-Fact-43647EACB2365019AF739809E6A7AA33"
          xlink:label="d34458036e3169-wk-Fact-43647EACB2365019AF739809E6A7AA33"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3169-wk-Fact-43647EACB2365019AF739809E6A7AA33"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-43A568A1B2F110213B88801F806FD23A-wk-Fact-43A568A1B2F110213B88801F806FD23A"
          xlink:label="Fact-43A568A1B2F110213B88801F806FD23A-wk-Fact-43A568A1B2F110213B88801F806FD23A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-43A568A1B2F110213B88801F806FD23A-wk-Fact-43A568A1B2F110213B88801F806FD23A"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2842-wk-Fact-43B675EB3B86596CAC5E7949E794E330"
          xlink:label="d34428379e2842-wk-Fact-43B675EB3B86596CAC5E7949E794E330"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2842-wk-Fact-43B675EB3B86596CAC5E7949E794E330"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23409-wk-Fact-43D0EA4505ACE6E465E2801F7FD72974"
          xlink:label="d34661879e23409-wk-Fact-43D0EA4505ACE6E465E2801F7FD72974"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23409-wk-Fact-43D0EA4505ACE6E465E2801F7FD72974"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2422-wk-Fact-43F9860B2E4FABD39FD0801F824B7F7B"
          xlink:label="d34458032e2422-wk-Fact-43F9860B2E4FABD39FD0801F824B7F7B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2422-wk-Fact-43F9860B2E4FABD39FD0801F824B7F7B"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5286-wk-Fact-44258E2A7EC67FA448C2801F81E421B4"
          xlink:label="d34506804e5286-wk-Fact-44258E2A7EC67FA448C2801F81E421B4"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl" xlink:label="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:justify;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Represents sales to our partners of products manufactured by us.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5286-wk-Fact-44258E2A7EC67FA448C2801F81E421B4"
          xlink:to="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2728-wk-Fact-44E9A00560B253F9B13272B4DADC5EE7"
          xlink:label="d34458036e2728-wk-Fact-44E9A00560B253F9B13272B4DADC5EE7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2728-wk-Fact-44E9A00560B253F9B13272B4DADC5EE7"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2381-wk-Fact-44EF20E31F87512BB82C3578F60D84E2"
          xlink:label="d34428379e2381-wk-Fact-44EF20E31F87512BB82C3578F60D84E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2381-wk-Fact-44EF20E31F87512BB82C3578F60D84E2"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9562-wk-Fact-455D7F50A78999F57E0BE7AEB28EE379"
          xlink:label="d34458032e9562-wk-Fact-455D7F50A78999F57E0BE7AEB28EE379"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9562-wk-Fact-455D7F50A78999F57E0BE7AEB28EE379"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9562-wk-Fact-455D7F50A78999F57E0BE7AEB28EE379"
          xlink:to="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10293-wk-Fact-45B18C9F6F2875D22AB6801F81F7973B"
          xlink:label="d34661879e10293-wk-Fact-45B18C9F6F2875D22AB6801F81F7973B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10293-wk-Fact-45B18C9F6F2875D22AB6801F81F7973B"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9821-wk-Fact-45E0D791242D55AC81FC3EFB761F9C00"
          xlink:label="d34586122e9821-wk-Fact-45E0D791242D55AC81FC3EFB761F9C00"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9821-wk-Fact-45E0D791242D55AC81FC3EFB761F9C00"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8902-wk-Fact-4621E7DDA21358AB9B0293A23E1E94CC"
          xlink:label="d34586122e8902-wk-Fact-4621E7DDA21358AB9B0293A23E1E94CC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8902-wk-Fact-4621E7DDA21358AB9B0293A23E1E94CC"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9777-wk-Fact-4638B594C90A5D0FB3648867A34E71BB"
          xlink:label="d34458032e9777-wk-Fact-4638B594C90A5D0FB3648867A34E71BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9777-wk-Fact-4638B594C90A5D0FB3648867A34E71BB"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3644-wk-Fact-464A486895AEEBF8EC5F801F7FA5F9F7"
          xlink:label="d34468079e3644-wk-Fact-464A486895AEEBF8EC5F801F7FA5F9F7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3644-wk-Fact-464A486895AEEBF8EC5F801F7FA5F9F7"
          xlink:to="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6445-wk-Fact-46A676894226F74F6BFC801F7EFC1911"
          xlink:label="d34458032e6445-wk-Fact-46A676894226F74F6BFC801F7EFC1911"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6445-wk-Fact-46A676894226F74F6BFC801F7EFC1911"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6445-wk-Fact-46A676894226F74F6BFC801F7EFC1911"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4589-wk-Fact-46AB28E4CC157C45741A801F823EEFDA"
          xlink:label="d34458032e4589-wk-Fact-46AB28E4CC157C45741A801F823EEFDA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4589-wk-Fact-46AB28E4CC157C45741A801F823EEFDA"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4589-wk-Fact-46AB28E4CC157C45741A801F823EEFDA"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5308-wk-Fact-46C48E9C21AF899B9CBE801F824C920A"
          xlink:label="d34458036e5308-wk-Fact-46C48E9C21AF899B9CBE801F824C920A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5308-wk-Fact-46C48E9C21AF899B9CBE801F824C920A"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5308-wk-Fact-46C48E9C21AF899B9CBE801F824C920A"
          xlink:to="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7059-wk-Fact-46F27B55B27B54EA8DB9649561CE42BB"
          xlink:label="d34586122e7059-wk-Fact-46F27B55B27B54EA8DB9649561CE42BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7059-wk-Fact-46F27B55B27B54EA8DB9649561CE42BB"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5643-wk-Fact-47070BCAA8F0873AE2800210CE266E9B"
          xlink:label="d34545404e5643-wk-Fact-47070BCAA8F0873AE2800210CE266E9B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5643-wk-Fact-47070BCAA8F0873AE2800210CE266E9B"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5643-wk-Fact-47070BCAA8F0873AE2800210CE266E9B"
          xlink:to="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1870-wk-Fact-4752641D09C957ACBC4D5CB0E30EFE1F"
          xlink:label="d34428379e1870-wk-Fact-4752641D09C957ACBC4D5CB0E30EFE1F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1870-wk-Fact-4752641D09C957ACBC4D5CB0E30EFE1F"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1870-wk-Fact-4752641D09C957ACBC4D5CB0E30EFE1F"
          xlink:to="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4380-wk-Fact-478A747253E5F8B23E49801F81C71589"
          xlink:label="d34586122e4380-wk-Fact-478A747253E5F8B23E49801F81C71589"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4380-wk-Fact-478A747253E5F8B23E49801F81C71589"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7302-wk-Fact-479F4E8A21C856B284E67E3F6C120C46"
          xlink:label="d34458032e7302-wk-Fact-479F4E8A21C856B284E67E3F6C120C46"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7302-wk-Fact-479F4E8A21C856B284E67E3F6C120C46"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8976-wk-Fact-47C32F6B4940C65CF511DE20FEBC9F1E"
          xlink:label="d34586122e8976-wk-Fact-47C32F6B4940C65CF511DE20FEBC9F1E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8976-wk-Fact-47C32F6B4940C65CF511DE20FEBC9F1E"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1659-wk-Fact-47C637A51CEE5EF080D18BCE1B38E7DA"
          xlink:label="d34423000e1659-wk-Fact-47C637A51CEE5EF080D18BCE1B38E7DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1659-wk-Fact-47C637A51CEE5EF080D18BCE1B38E7DA"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e2668-wk-Fact-47EFFB693B37262CF809801F82673E4B"
          xlink:label="d34545404e2668-wk-Fact-47EFFB693B37262CF809801F82673E4B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2668-wk-Fact-47EFFB693B37262CF809801F82673E4B"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e2734-wk-Fact-48209B5C749FB96707F8801F82806943"
          xlink:label="d34545404e2734-wk-Fact-48209B5C749FB96707F8801F82806943"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2734-wk-Fact-48209B5C749FB96707F8801F82806943"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:label="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:label="d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:label="d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:label="d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2492-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7592-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1594-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1460-wk-Fact-48486E15B713539CBD57CE17552FEB9D"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9930-wk-Fact-48600923F2B454478E9D06C9836F179C"
          xlink:label="d34458032e9930-wk-Fact-48600923F2B454478E9D06C9836F179C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e3477-wk-Fact-48600923F2B454478E9D06C9836F179C"
          xlink:label="d34423000e3477-wk-Fact-48600923F2B454478E9D06C9836F179C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9930-wk-Fact-48600923F2B454478E9D06C9836F179C"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3477-wk-Fact-48600923F2B454478E9D06C9836F179C"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9930-wk-Fact-48600923F2B454478E9D06C9836F179C"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3477-wk-Fact-48600923F2B454478E9D06C9836F179C"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4760-wk-Fact-48A2AF59E0EAFF0A6B26801F81171029"
          xlink:label="d34545404e4760-wk-Fact-48A2AF59E0EAFF0A6B26801F81171029"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4760-wk-Fact-48A2AF59E0EAFF0A6B26801F81171029"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl" xlink:label="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The increase in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> is primarily related to the capitalization of certain R&amp;D-related expenses.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4760-wk-Fact-48A2AF59E0EAFF0A6B26801F81171029"
          xlink:to="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3236-wk-Fact-48F3227EB91F519693B62AAB048CF3C2"
          xlink:label="d34458036e3236-wk-Fact-48F3227EB91F519693B62AAB048CF3C2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3236-wk-Fact-48F3227EB91F519693B62AAB048CF3C2"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9015-wk-Fact-48F70FD623656D97865CDE21089CEB52"
          xlink:label="d34586122e9015-wk-Fact-48F70FD623656D97865CDE21089CEB52"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9015-wk-Fact-48F70FD623656D97865CDE21089CEB52"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2352-wk-Fact-48FBE878E867A2126357801F828892B1"
          xlink:label="d34468079e2352-wk-Fact-48FBE878E867A2126357801F828892B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2352-wk-Fact-48FBE878E867A2126357801F828892B1"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21332-wk-Fact-4924E685A3ACAA7EBD6E801F7FD67A92"
          xlink:label="d34661879e21332-wk-Fact-4924E685A3ACAA7EBD6E801F7FD67A92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21332-wk-Fact-4924E685A3ACAA7EBD6E801F7FD67A92"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21332-wk-Fact-4924E685A3ACAA7EBD6E801F7FD67A92"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9220-wk-Fact-494DF9151E065567834DBAE4E1B562F9"
          xlink:label="d34586122e9220-wk-Fact-494DF9151E065567834DBAE4E1B562F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9220-wk-Fact-494DF9151E065567834DBAE4E1B562F9"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2727-wk-Fact-496231284B82551EA3C09B63129DD116"
          xlink:label="d34523018e2727-wk-Fact-496231284B82551EA3C09B63129DD116"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2727-wk-Fact-496231284B82551EA3C09B63129DD116"
          xlink:to="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2051-wk-Fact-49C7F7BFD94F58259E8F91521C863A5D"
          xlink:label="d34458036e2051-wk-Fact-49C7F7BFD94F58259E8F91521C863A5D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2051-wk-Fact-49C7F7BFD94F58259E8F91521C863A5D"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5265-wk-Fact-4A34A51B3998F315A6C3801F81061EB9"
          xlink:label="d34545404e5265-wk-Fact-4A34A51B3998F315A6C3801F81061EB9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5265-wk-Fact-4A34A51B3998F315A6C3801F81061EB9"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2119-wk-Fact-4A424945B16E50C896282B201E79955C"
          xlink:label="d34423000e2119-wk-Fact-4A424945B16E50C896282B201E79955C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34519344e1948-wk-Fact-4A424945B16E50C896282B201E79955C"
          xlink:label="d34519344e1948-wk-Fact-4A424945B16E50C896282B201E79955C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2119-wk-Fact-4A424945B16E50C896282B201E79955C"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34519344e1948-wk-Fact-4A424945B16E50C896282B201E79955C"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e27689-wk-Fact-4A576DD84E72BF694DFE801F7E989595"
          xlink:label="d34661879e27689-wk-Fact-4A576DD84E72BF694DFE801F7E989595"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e27689-wk-Fact-4A576DD84E72BF694DFE801F7E989595"
          xlink:to="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2587-wk-Fact-4B1590ADE87B568D8CC8C86F0B307CF0"
          xlink:label="d34423000e2587-wk-Fact-4B1590ADE87B568D8CC8C86F0B307CF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2587-wk-Fact-4B1590ADE87B568D8CC8C86F0B307CF0"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820"
          xlink:label="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24122-wk-Fact-4B4D076EC780A3936C2E801F80493820"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3789-wk-Fact-4B742D12220955FCB8512E0C28478091"
          xlink:label="d34661879e3789-wk-Fact-4B742D12220955FCB8512E0C28478091"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3789-wk-Fact-4B742D12220955FCB8512E0C28478091"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20640-wk-Fact-4B8271E7A0E5A3CF5E04801F7EC8BD2A"
          xlink:label="d34661879e20640-wk-Fact-4B8271E7A0E5A3CF5E04801F7EC8BD2A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20640-wk-Fact-4B8271E7A0E5A3CF5E04801F7EC8BD2A"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4121-wk-Fact-4BC04F50F859575786CDEB42846504B3"
          xlink:label="d34661879e4121-wk-Fact-4BC04F50F859575786CDEB42846504B3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4121-wk-Fact-4BC04F50F859575786CDEB42846504B3"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2236-wk-Fact-4BF8867A9673AACA0E31CB2DE4C160C4"
          xlink:label="d34458032e2236-wk-Fact-4BF8867A9673AACA0E31CB2DE4C160C4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2236-wk-Fact-4BF8867A9673AACA0E31CB2DE4C160C4"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2663-wk-Fact-4D09902765CD56939721BF43E88C545F"
          xlink:label="d34428379e2663-wk-Fact-4D09902765CD56939721BF43E88C545F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2663-wk-Fact-4D09902765CD56939721BF43E88C545F"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11717-wk-Fact-4D849F31F84479F6D413D0834B8AEBFC"
          xlink:label="d34586122e11717-wk-Fact-4D849F31F84479F6D413D0834B8AEBFC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11717-wk-Fact-4D849F31F84479F6D413D0834B8AEBFC"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1850-wk-Fact-4D8CEC7EA9FB5F60A15FD79906165FE2"
          xlink:label="d34428379e1850-wk-Fact-4D8CEC7EA9FB5F60A15FD79906165FE2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1850-wk-Fact-4D8CEC7EA9FB5F60A15FD79906165FE2"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1850-wk-Fact-4D8CEC7EA9FB5F60A15FD79906165FE2"
          xlink:to="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9724-wk-Fact-4DE63B25DF8F54C98BE8801F7DD138D7"
          xlink:label="d34458032e9724-wk-Fact-4DE63B25DF8F54C98BE8801F7DD138D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9724-wk-Fact-4DE63B25DF8F54C98BE8801F7DD138D7"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e7600-wk-Fact-4E0DBFBB79A3239D00CC801F7F5FBA6F"
          xlink:label="d34661879e7600-wk-Fact-4E0DBFBB79A3239D00CC801F7F5FBA6F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e7600-wk-Fact-4E0DBFBB79A3239D00CC801F7F5FBA6F"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2159-wk-Fact-4E0F3852D83E28ABDBED801F7ECDFF6C"
          xlink:label="d34428379e2159-wk-Fact-4E0F3852D83E28ABDBED801F7ECDFF6C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2159-wk-Fact-4E0F3852D83E28ABDBED801F7ECDFF6C"
          xlink:to="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2159-wk-Fact-4E0F3852D83E28ABDBED801F7ECDFF6C"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3123-wk-Fact-4E6373F9AE145393977B4D50CD0C3C97"
          xlink:label="d34458036e3123-wk-Fact-4E6373F9AE145393977B4D50CD0C3C97"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3123-wk-Fact-4E6373F9AE145393977B4D50CD0C3C97"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3829-wk-Fact-4E680D94DBBF677FF299801F7EAAEC74"
          xlink:label="d34545404e3829-wk-Fact-4E680D94DBBF677FF299801F7EAAEC74"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3829-wk-Fact-4E680D94DBBF677FF299801F7EAAEC74"
          xlink:to="TextSelection-18C491CEE8E2BC3B4824801F83104A30-0-wk-Footnote-18C491CEE8E2BC3B4824801F83104A30_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3685-wk-Fact-4EC473580DFC97201347801F7F618775"
          xlink:label="d34468079e3685-wk-Fact-4EC473580DFC97201347801F7F618775"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3685-wk-Fact-4EC473580DFC97201347801F7F618775"
          xlink:to="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19719-wk-Fact-4ED0DD3E047FEF605271801F7E880A91"
          xlink:label="d34661879e19719-wk-Fact-4ED0DD3E047FEF605271801F7E880A91"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19719-wk-Fact-4ED0DD3E047FEF605271801F7E880A91"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2862-wk-Fact-4F41970AB5AF5A55B4EA05E37BD7A829"
          xlink:label="d34428379e2862-wk-Fact-4F41970AB5AF5A55B4EA05E37BD7A829"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2862-wk-Fact-4F41970AB5AF5A55B4EA05E37BD7A829"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6854-wk-Fact-4F592E77B2B5EA96F0FA801F7EF1FA0F"
          xlink:label="d34545404e6854-wk-Fact-4F592E77B2B5EA96F0FA801F7EF1FA0F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6854-wk-Fact-4F592E77B2B5EA96F0FA801F7EF1FA0F"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6854-wk-Fact-4F592E77B2B5EA96F0FA801F7EF1FA0F"
          xlink:to="TextSelection-F21FCE7985528313C7DD801F831167F5-0-wk-Footnote-F21FCE7985528313C7DD801F831167F5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4383-wk-Fact-4F6A9D76BC23A664699C801F8033D7FF"
          xlink:label="d34661879e4383-wk-Fact-4F6A9D76BC23A664699C801F8033D7FF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4383-wk-Fact-4F6A9D76BC23A664699C801F8033D7FF"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7283-wk-Fact-5000F0EEE05D5658998A06FB2C356390"
          xlink:label="d34458032e7283-wk-Fact-5000F0EEE05D5658998A06FB2C356390"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7283-wk-Fact-5000F0EEE05D5658998A06FB2C356390"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6387-wk-Fact-50286E7377FA596E859503D29B20ABBF"
          xlink:label="d34538474e6387-wk-Fact-50286E7377FA596E859503D29B20ABBF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6387-wk-Fact-50286E7377FA596E859503D29B20ABBF"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6387-wk-Fact-50286E7377FA596E859503D29B20ABBF"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21312-wk-Fact-5051258CEF279EAE4904801F8082EB61"
          xlink:label="d34661879e21312-wk-Fact-5051258CEF279EAE4904801F8082EB61"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21312-wk-Fact-5051258CEF279EAE4904801F8082EB61"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21312-wk-Fact-5051258CEF279EAE4904801F8082EB61"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2224-wk-Fact-50686A372E736C0F5647801F82939361"
          xlink:label="d34428379e2224-wk-Fact-50686A372E736C0F5647801F82939361"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2224-wk-Fact-50686A372E736C0F5647801F82939361"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2600-wk-Fact-50C71B602D558F20976C801F828D6F53"
          xlink:label="d34460716e2600-wk-Fact-50C71B602D558F20976C801F828D6F53"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2600-wk-Fact-50C71B602D558F20976C801F828D6F53"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1973-wk-Fact-50D8069E0C6A50D989482D5B5834E63D"
          xlink:label="d34471435e1973-wk-Fact-50D8069E0C6A50D989482D5B5834E63D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1973-wk-Fact-50D8069E0C6A50D989482D5B5834E63D"
          xlink:to="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3477-wk-Fact-50F041F28B665D836084801F81547F30"
          xlink:label="d34594690e3477-wk-Fact-50F041F28B665D836084801F81547F30"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3477-wk-Fact-50F041F28B665D836084801F81547F30"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3477-wk-Fact-50F041F28B665D836084801F81547F30"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6616-wk-Fact-5131EE518687D3BFD19B801F7E64723A"
          xlink:label="d34545404e6616-wk-Fact-5131EE518687D3BFD19B801F7E64723A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e7173-wk-Fact-5131EE518687D3BFD19B801F7E64723A"
          xlink:label="d34545404e7173-wk-Fact-5131EE518687D3BFD19B801F7E64723A"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl" xlink:label="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Income taxes payable</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$108 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Current tax assets</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">),</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> Noncurrent deferred tax assets and other noncurrent tax assets</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$51 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.8 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">) and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other taxes payable</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.4 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">). In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Income taxes payable</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$11 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Current tax assets</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$1 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$47 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Noncurrent deferred tax liabilities</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$3.2 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">) and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other taxes payable</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$3.0 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">). </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6616-wk-Fact-5131EE518687D3BFD19B801F7E64723A"
          xlink:to="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7173-wk-Fact-5131EE518687D3BFD19B801F7E64723A"
          xlink:to="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6426-wk-Fact-516913B914BB588F94ACCEBA9291FDAD"
          xlink:label="d34538474e6426-wk-Fact-516913B914BB588F94ACCEBA9291FDAD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6426-wk-Fact-516913B914BB588F94ACCEBA9291FDAD"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6426-wk-Fact-516913B914BB588F94ACCEBA9291FDAD"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-516E2DBFF137FF395442801F824C52D5-wk-Fact-516E2DBFF137FF395442801F824C52D5"
          xlink:label="Fact-516E2DBFF137FF395442801F824C52D5-wk-Fact-516E2DBFF137FF395442801F824C52D5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-516E2DBFF137FF395442801F824C52D5-wk-Fact-516E2DBFF137FF395442801F824C52D5"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19738-wk-Fact-516E83BACCC191ED5F55801F7E89AB76"
          xlink:label="d34661879e19738-wk-Fact-516E83BACCC191ED5F55801F7E89AB76"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19738-wk-Fact-516E83BACCC191ED5F55801F7E89AB76"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2012-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927"
          xlink:label="d34430544e2012-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34471435e2600-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927"
          xlink:label="d34471435e2600-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2012-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2600-wk-Fact-51979ABA5C43A91A59F4801F7F4A4927"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2275-wk-Fact-51AF8A24F6320B3DD4D9CB2DE5470BE9"
          xlink:label="d34458032e2275-wk-Fact-51AF8A24F6320B3DD4D9CB2DE5470BE9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2275-wk-Fact-51AF8A24F6320B3DD4D9CB2DE5470BE9"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10583-wk-Fact-51C0100384A147990743801F81EB9934"
          xlink:label="d34661879e10583-wk-Fact-51C0100384A147990743801F81EB9934"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10583-wk-Fact-51C0100384A147990743801F81EB9934"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7802-wk-Fact-51CBEE775FF5588DB0D7DCEC07FF57B0"
          xlink:label="d34586122e7802-wk-Fact-51CBEE775FF5588DB0D7DCEC07FF57B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7802-wk-Fact-51CBEE775FF5588DB0D7DCEC07FF57B0"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1948-wk-Fact-51D5CD0734BBD4CF6AB0CB00E2C1C110"
          xlink:label="d34430544e1948-wk-Fact-51D5CD0734BBD4CF6AB0CB00E2C1C110"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1948-wk-Fact-51D5CD0734BBD4CF6AB0CB00E2C1C110"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3762-wk-Fact-51E697B313F65177AA951CD8E64EC1C9"
          xlink:label="d34458036e3762-wk-Fact-51E697B313F65177AA951CD8E64EC1C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3762-wk-Fact-51E697B313F65177AA951CD8E64EC1C9"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2386-wk-Fact-52056BFD52B55AD7B0B223B4DB2C6129"
          xlink:label="d34423000e2386-wk-Fact-52056BFD52B55AD7B0B223B4DB2C6129"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2386-wk-Fact-52056BFD52B55AD7B0B223B4DB2C6129"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e2148-wk-Fact-523DC6B2EC505EFFBFCB4D7A7C5179A9"
          xlink:label="d34538474e2148-wk-Fact-523DC6B2EC505EFFBFCB4D7A7C5179A9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e2148-wk-Fact-523DC6B2EC505EFFBFCB4D7A7C5179A9"
          xlink:to="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2141-wk-Fact-5244EF9D70AB4BF20E72CB2DE505A72E"
          xlink:label="d34458032e2141-wk-Fact-5244EF9D70AB4BF20E72CB2DE505A72E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2141-wk-Fact-5244EF9D70AB4BF20E72CB2DE505A72E"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10537-wk-Fact-5265E1D654B7823D4E63801F82280344"
          xlink:label="d34661879e10537-wk-Fact-5265E1D654B7823D4E63801F82280344"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10537-wk-Fact-5265E1D654B7823D4E63801F82280344"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10022-wk-Fact-52734113DA315C5EB0822EA6C1F6019D"
          xlink:label="d34586122e10022-wk-Fact-52734113DA315C5EB0822EA6C1F6019D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10022-wk-Fact-52734113DA315C5EB0822EA6C1F6019D"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10022-wk-Fact-52734113DA315C5EB0822EA6C1F6019D"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1817-wk-Fact-528109C6117952069FCC0A02E9E0964C"
          xlink:label="d34471435e1817-wk-Fact-528109C6117952069FCC0A02E9E0964C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl" xlink:label="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily included a realized gain on sale of property of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$60 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily included an </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$81 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> realized loss related to the sale of our former </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>49%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">-owned equity-method investment in Hisun Pfizer and a realized net loss of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$30 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>40%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the then remaining </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>60%</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> ownership interest, partially offset by a realized gain on sale of property of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$52 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1817-wk-Fact-528109C6117952069FCC0A02E9E0964C"
          xlink:to="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5616-wk-Fact-52CE05D4D58AA63DFD75801F8215C3D3"
          xlink:label="d34506804e5616-wk-Fact-52CE05D4D58AA63DFD75801F8215C3D3"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl" xlink:label="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:justify;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$50 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$15 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. There were </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">no</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> upfront and milestone payments in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. Our collaboration with Lilly (see below) also includes reimbursements of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$67 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$98 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$147 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5616-wk-Fact-52CE05D4D58AA63DFD75801F8215C3D3"
          xlink:to="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2336-wk-Fact-5326AFF91A2251119CB3EA737ED72B03"
          xlink:label="d34428379e2336-wk-Fact-5326AFF91A2251119CB3EA737ED72B03"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2336-wk-Fact-5326AFF91A2251119CB3EA737ED72B03"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2530-wk-Fact-532861FAECEE50D0A6F6D5AEF071E5B9"
          xlink:label="d34428379e2530-wk-Fact-532861FAECEE50D0A6F6D5AEF071E5B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2530-wk-Fact-532861FAECEE50D0A6F6D5AEF071E5B9"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8325-wk-Fact-532A8105F0605BF7A90B026D9DC3C86C"
          xlink:label="d34586122e8325-wk-Fact-532A8105F0605BF7A90B026D9DC3C86C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8325-wk-Fact-532A8105F0605BF7A90B026D9DC3C86C"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3895-wk-Fact-5344A287AEC4338D220DE3C58F9727B5"
          xlink:label="d34471435e3895-wk-Fact-5344A287AEC4338D220DE3C58F9727B5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3895-wk-Fact-5344A287AEC4338D220DE3C58F9727B5"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4399-wk-Fact-535FEE135E2ABD4ECB45801F81937510"
          xlink:label="d34586122e4399-wk-Fact-535FEE135E2ABD4ECB45801F81937510"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4399-wk-Fact-535FEE135E2ABD4ECB45801F81937510"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3998-wk-Fact-536D379D583EEC0E6BB0801F7E8674D3"
          xlink:label="d34458036e3998-wk-Fact-536D379D583EEC0E6BB0801F7E8674D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3998-wk-Fact-536D379D583EEC0E6BB0801F7E8674D3"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2693-wk-Fact-538AD0D1FEAC9B9942E5801F80805FA6"
          xlink:label="d34458032e2693-wk-Fact-538AD0D1FEAC9B9942E5801F80805FA6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2693-wk-Fact-538AD0D1FEAC9B9942E5801F80805FA6"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5374-wk-Fact-539977E9F571B801F8F2801F82CC3FC2"
          xlink:label="d34458036e5374-wk-Fact-539977E9F571B801F8F2801F82CC3FC2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5374-wk-Fact-539977E9F571B801F8F2801F82CC3FC2"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5374-wk-Fact-539977E9F571B801F8F2801F82CC3FC2"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4815-wk-Fact-53A4C5E0F7DCF0473DB8801F8250BB73"
          xlink:label="d34458032e4815-wk-Fact-53A4C5E0F7DCF0473DB8801F8250BB73"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4815-wk-Fact-53A4C5E0F7DCF0473DB8801F8250BB73"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e3063-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
          xlink:label="d34529301e3063-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34529301e2317-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
          xlink:label="d34529301e2317-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3063-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2317-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3063-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2317-wk-Fact-53B0ABD165CB5128A16A15B7A3884D41"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e2128-wk-Fact-53FADFD5082D5F7483E92BF38D157660"
          xlink:label="d34538474e2128-wk-Fact-53FADFD5082D5F7483E92BF38D157660"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e2128-wk-Fact-53FADFD5082D5F7483E92BF38D157660"
          xlink:to="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6056-wk-Fact-540977569490C9755BD3801F7F1FE236"
          xlink:label="d34545404e6056-wk-Fact-540977569490C9755BD3801F7F1FE236"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6056-wk-Fact-540977569490C9755BD3801F7F1FE236"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6056-wk-Fact-540977569490C9755BD3801F7F1FE236"
          xlink:to="TextSelection-B6A3FF5187C02063A75F801F8312B48A-0-wk-Footnote-B6A3FF5187C02063A75F801F8312B48A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6948-wk-Fact-540CAB81FBF19E5166CE801F82251FFC"
          xlink:label="d34545404e6948-wk-Fact-540CAB81FBF19E5166CE801F82251FFC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6948-wk-Fact-540CAB81FBF19E5166CE801F82251FFC"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3897-wk-Fact-540F98E963893D555BBC801F8251C495"
          xlink:label="d34545404e3897-wk-Fact-540F98E963893D555BBC801F8251C495"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3897-wk-Fact-540F98E963893D555BBC801F8251C495"
          xlink:to="TextSelection-5A6821546E16E8AD2DA6801F83101D80-0-wk-Footnote-5A6821546E16E8AD2DA6801F83101D80_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3897-wk-Fact-540F98E963893D555BBC801F8251C495"
          xlink:to="TextSelection-BB025DA6AC46BC46BD12801F83107B07-0-wk-Footnote-BB025DA6AC46BC46BD12801F83107B07_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2464-wk-Fact-54104279652F5BA598DF82A20E111838"
          xlink:label="d34428379e2464-wk-Fact-54104279652F5BA598DF82A20E111838"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2464-wk-Fact-54104279652F5BA598DF82A20E111838"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2942-wk-Fact-54259B5ADCDB523D95E357958F32EAA5"
          xlink:label="d34423000e2942-wk-Fact-54259B5ADCDB523D95E357958F32EAA5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2942-wk-Fact-54259B5ADCDB523D95E357958F32EAA5"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3996-wk-Fact-5438260A5AB3500C8619EA7A64AD5E8B"
          xlink:label="d34468079e3996-wk-Fact-5438260A5AB3500C8619EA7A64AD5E8B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3996-wk-Fact-5438260A5AB3500C8619EA7A64AD5E8B"
          xlink:to="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7857-wk-Fact-5472417927D753EEBBB1072B6B105F5F"
          xlink:label="d34586122e7857-wk-Fact-5472417927D753EEBBB1072B6B105F5F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7857-wk-Fact-5472417927D753EEBBB1072B6B105F5F"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2788-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
          xlink:label="d34661879e2788-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9708-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
          xlink:label="d34661879e9708-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2788-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9708-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2788-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9708-wk-Fact-547A9426B8FEDD3D980A801F821CD025"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e2688-wk-Fact-54AA553FEEBE8772CC50801F7F6E0504"
          xlink:label="d34545404e2688-wk-Fact-54AA553FEEBE8772CC50801F7F6E0504"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2688-wk-Fact-54AA553FEEBE8772CC50801F7F6E0504"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23331-wk-Fact-54BB374F531662E67301801F8151A7BD"
          xlink:label="d34661879e23331-wk-Fact-54BB374F531662E67301801F8151A7BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23331-wk-Fact-54BB374F531662E67301801F8151A7BD"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9802-wk-Fact-54CC08145C9B5A5BA23B67DFBAD4AE0E"
          xlink:label="d34586122e9802-wk-Fact-54CC08145C9B5A5BA23B67DFBAD4AE0E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9802-wk-Fact-54CC08145C9B5A5BA23B67DFBAD4AE0E"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23370-wk-Fact-55065D7329FC0CE09063801F8127D52D"
          xlink:label="d34661879e23370-wk-Fact-55065D7329FC0CE09063801F8127D52D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23370-wk-Fact-55065D7329FC0CE09063801F8127D52D"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4077-wk-Fact-552B0DEF974EB94D62FC801F81213B84"
          xlink:label="d34586122e4077-wk-Fact-552B0DEF974EB94D62FC801F81213B84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4077-wk-Fact-552B0DEF974EB94D62FC801F81213B84"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4001-wk-Fact-556CBCAD88F04EADEC0B01C7EFA1BB3D"
          xlink:label="d34545404e4001-wk-Fact-556CBCAD88F04EADEC0B01C7EFA1BB3D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4001-wk-Fact-556CBCAD88F04EADEC0B01C7EFA1BB3D"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7153-wk-Fact-5582142AF8CAFB1642B1801F8152C802"
          xlink:label="d34586122e7153-wk-Fact-5582142AF8CAFB1642B1801F8152C802"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7153-wk-Fact-5582142AF8CAFB1642B1801F8152C802"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2042-wk-Fact-559668800F8D5F39871CB0D8FAB473CD"
          xlink:label="d34468079e2042-wk-Fact-559668800F8D5F39871CB0D8FAB473CD"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl" xlink:label="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, integration costs and other mainly related to our acquisitions of Array (including </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$157 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">)) and Hospira. In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, integration costs and other mostly related to our acquisition of Hospira. In 2017, integration costs primarily related to our acquisitions of Hospira and Medivation, as well as a net gain of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$12 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2042-wk-Fact-559668800F8D5F39871CB0D8FAB473CD"
          xlink:to="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3457-wk-Fact-55A2404E40890D14A72D801F8159A9F4"
          xlink:label="d34594690e3457-wk-Fact-55A2404E40890D14A72D801F8159A9F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3457-wk-Fact-55A2404E40890D14A72D801F8159A9F4"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3457-wk-Fact-55A2404E40890D14A72D801F8159A9F4"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5813-wk-Fact-55BA3A8CA443922DFC21801F812BB48D"
          xlink:label="d34545404e5813-wk-Fact-55BA3A8CA443922DFC21801F812BB48D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5813-wk-Fact-55BA3A8CA443922DFC21801F812BB48D"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5549-wk-Fact-55FAF1E14383FE9A5716801F81DC7AAF"
          xlink:label="d34506804e5549-wk-Fact-55FAF1E14383FE9A5716801F81DC7AAF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5549-wk-Fact-55FAF1E14383FE9A5716801F81DC7AAF"
          xlink:to="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2892-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
          xlink:label="d34529301e2892-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34529301e2852-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
          xlink:label="d34529301e2852-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2892-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2852-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2892-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
          xlink:to="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2852-wk-Fact-561E433B6B30525EBA77DD0C09816B40"
          xlink:to="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3253-wk-Fact-562D6F8F14805BDBA1EEB5EC76E5A656"
          xlink:label="d34423000e3253-wk-Fact-562D6F8F14805BDBA1EEB5EC76E5A656"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3253-wk-Fact-562D6F8F14805BDBA1EEB5EC76E5A656"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4819-wk-Fact-563A84C808D48A91680F801F7F11733F"
          xlink:label="d34545404e4819-wk-Fact-563A84C808D48A91680F801F7F11733F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4819-wk-Fact-563A84C808D48A91680F801F7F11733F"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4819-wk-Fact-563A84C808D48A91680F801F7F11733F"
          xlink:to="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1692-wk-Fact-563BB6FEBF5717E60D97CB0A84CDFE98"
          xlink:label="d34428379e1692-wk-Fact-563BB6FEBF5717E60D97CB0A84CDFE98"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1692-wk-Fact-563BB6FEBF5717E60D97CB0A84CDFE98"
          xlink:to="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1692-wk-Fact-563BB6FEBF5717E60D97CB0A84CDFE98"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3987-wk-Fact-565E3B0013E83A6400DF01C7EED4523E"
          xlink:label="d34545404e3987-wk-Fact-565E3B0013E83A6400DF01C7EED4523E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3987-wk-Fact-565E3B0013E83A6400DF01C7EED4523E"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3021-wk-Fact-56AC0425594EB6B614D8801F82235863"
          xlink:label="d34661879e3021-wk-Fact-56AC0425594EB6B614D8801F82235863"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9868-wk-Fact-56AC0425594EB6B614D8801F82235863"
          xlink:label="d34661879e9868-wk-Fact-56AC0425594EB6B614D8801F82235863"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3021-wk-Fact-56AC0425594EB6B614D8801F82235863"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9868-wk-Fact-56AC0425594EB6B614D8801F82235863"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9985-wk-Fact-56B05001ED9BC8F7B322801F8171F6EF"
          xlink:label="d34586122e9985-wk-Fact-56B05001ED9BC8F7B322801F8171F6EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9985-wk-Fact-56B05001ED9BC8F7B322801F8171F6EF"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11050-wk-Fact-56B658880869AEACE541801F8187F9A3"
          xlink:label="d34586122e11050-wk-Fact-56B658880869AEACE541801F8187F9A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11050-wk-Fact-56B658880869AEACE541801F8187F9A3"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2705-wk-Fact-56CA584C4B365E4B845856D506783484"
          xlink:label="d34468079e2705-wk-Fact-56CA584C4B365E4B845856D506783484"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2705-wk-Fact-56CA584C4B365E4B845856D506783484"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2519-wk-Fact-56CDBBCBD4E37D7B159C801F7FF5592A"
          xlink:label="d34460716e2519-wk-Fact-56CDBBCBD4E37D7B159C801F7FF5592A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2519-wk-Fact-56CDBBCBD4E37D7B159C801F7FF5592A"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7249-wk-Fact-56D7F8DD1BDAEA1F8A93801F82A07FA6"
          xlink:label="d34594690e7249-wk-Fact-56D7F8DD1BDAEA1F8A93801F82A07FA6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7249-wk-Fact-56D7F8DD1BDAEA1F8A93801F82A07FA6"
          xlink:to="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5698-wk-Fact-570F688A036C517B8DC6519B9EEC35DC"
          xlink:label="d34458036e5698-wk-Fact-570F688A036C517B8DC6519B9EEC35DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5698-wk-Fact-570F688A036C517B8DC6519B9EEC35DC"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8174-wk-Fact-574622BD96AD5C9083C68ABC1F23BDDF"
          xlink:label="d34586122e8174-wk-Fact-574622BD96AD5C9083C68ABC1F23BDDF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8174-wk-Fact-574622BD96AD5C9083C68ABC1F23BDDF"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5280-wk-Fact-5763263A0462B65542D3801F82B1A33F"
          xlink:label="d34458036e5280-wk-Fact-5763263A0462B65542D3801F82B1A33F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5280-wk-Fact-5763263A0462B65542D3801F82B1A33F"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5280-wk-Fact-5763263A0462B65542D3801F82B1A33F"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9872-wk-Fact-5771636556985C87BC8C3CB410CC66F7"
          xlink:label="d34586122e9872-wk-Fact-5771636556985C87BC8C3CB410CC66F7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9872-wk-Fact-5771636556985C87BC8C3CB410CC66F7"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10885-wk-Fact-578D671C8F705BCD1B24801F82058BDF"
          xlink:label="d34661879e10885-wk-Fact-578D671C8F705BCD1B24801F82058BDF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10885-wk-Fact-578D671C8F705BCD1B24801F82058BDF"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21390-wk-Fact-57959C448E7CB9BAE6F1801F81494C11"
          xlink:label="d34661879e21390-wk-Fact-57959C448E7CB9BAE6F1801F81494C11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21390-wk-Fact-57959C448E7CB9BAE6F1801F81494C11"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21390-wk-Fact-57959C448E7CB9BAE6F1801F81494C11"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3991-wk-Fact-57987F1F001AA9CC9C56801F812C5B39"
          xlink:label="d34586122e3991-wk-Fact-57987F1F001AA9CC9C56801F812C5B39"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3991-wk-Fact-57987F1F001AA9CC9C56801F812C5B39"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3060-wk-Fact-57F6BF74720C5F8388DA1CC92604AB69"
          xlink:label="d34586122e3060-wk-Fact-57F6BF74720C5F8388DA1CC92604AB69"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3060-wk-Fact-57F6BF74720C5F8388DA1CC92604AB69"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6786-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:label="d34586122e6786-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e4303-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:label="d34586122e4303-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e5487-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:label="d34586122e5487-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e1498-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:label="d34430544e1498-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6786-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4303-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5487-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1498-wk-Fact-5800B99789A546352282801F7F2D7923"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e7562-wk-Fact-58349156F701DBD2FAE9801F7F55CCA1"
          xlink:label="d34661879e7562-wk-Fact-58349156F701DBD2FAE9801F7F55CCA1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e7562-wk-Fact-58349156F701DBD2FAE9801F7F55CCA1"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e7153-wk-Fact-583AA105D95E04AFAC9B801F7E2BE5D7"
          xlink:label="d34545404e7153-wk-Fact-583AA105D95E04AFAC9B801F7E2BE5D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7153-wk-Fact-583AA105D95E04AFAC9B801F7E2BE5D7"
          xlink:to="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10254-wk-Fact-587F4F874523BF22E7AF801F823BD65E"
          xlink:label="d34661879e10254-wk-Fact-587F4F874523BF22E7AF801F823BD65E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10254-wk-Fact-587F4F874523BF22E7AF801F823BD65E"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1974-wk-Fact-58A10D106477541896C64514721528B2"
          xlink:label="d34430544e1974-wk-Fact-58A10D106477541896C64514721528B2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34471435e2561-wk-Fact-58A10D106477541896C64514721528B2"
          xlink:label="d34471435e2561-wk-Fact-58A10D106477541896C64514721528B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1974-wk-Fact-58A10D106477541896C64514721528B2"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2561-wk-Fact-58A10D106477541896C64514721528B2"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1590-wk-Fact-58A9D592472E54ACB181BBAE9BC91E05"
          xlink:label="d34423000e1590-wk-Fact-58A9D592472E54ACB181BBAE9BC91E05"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1590-wk-Fact-58A9D592472E54ACB181BBAE9BC91E05"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23191-wk-Fact-58CB03993CECC3B620EC801F7EDEE43C"
          xlink:label="d34661879e23191-wk-Fact-58CB03993CECC3B620EC801F7EDEE43C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23191-wk-Fact-58CB03993CECC3B620EC801F7EDEE43C"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2021-wk-Fact-58D64728C9445B32B7001C141E840546"
          xlink:label="d34471435e2021-wk-Fact-58D64728C9445B32B7001C141E840546"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl" xlink:label="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Includes income from upfront and milestone payments from our collaboration partners and income from out-licensing arrangements and sales of compound/product rights. In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, mainly includes, among other things, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$78 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in milestone income from Mylan Pharmaceuticals Inc. related to the FDA&#x2019;s approval and launch of Wixela Inhub</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:5pt">&#xae;</xhtml:sup></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, a generic of Advair Diskus</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:sup style="vertical-align:top;line-height:120%;font-size:5pt">&#xae;</xhtml:sup></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">(fluticasone propionate and salmeterol inhalation powder) and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$52 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in milestone income from multiple licensees. In </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily includes, among other things, (i) approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$118 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in milestone income from multiple licensees, (ii) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$110 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in milestone payments received from Shire, of which </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$75 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> was received in the first quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of ulcerative colitis and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$35 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> was received from Shire in the third quarter of 2018 related to their first dosing of a patient in a Phase 3 clinical trial for the treatment of Crohn&#x2019;s disease, (iii) an upfront payment to us and a recognized milestone totaling </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$85 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> for the sale of an AMPA receptor potentiator for CIAS to Biogen, (iv) </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$62 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in gains related to sales of compound/product rights and (v) a </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$40 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> milestone payment from Merck in conjunction with the approval of ertugliflozin in the EU. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2D </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">. In 2017, primarily includes, among other things, </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$101 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in milestone payments received from multiple licensees and an </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$85 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> gain related to sales of compound/product rights. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2021-wk-Fact-58D64728C9445B32B7001C141E840546"
          xlink:to="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34512803e1629-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
          xlink:label="d34512803e1629-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e1615-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
          xlink:label="d34423000e1615-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34512803e1629-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1615-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl" xlink:label="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The change from </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> reflects increases for certain products, including inventory build for new product launches, supply recovery and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34512803e1629-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
          xlink:to="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1615-wk-Fact-5903E441EBEC586A82C0C493CE40C7F9"
          xlink:to="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2842-wk-Fact-5947CFACA921556B9FFF58244C1A10F0"
          xlink:label="d34430544e2842-wk-Fact-5947CFACA921556B9FFF58244C1A10F0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2842-wk-Fact-5947CFACA921556B9FFF58244C1A10F0"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9070-wk-Fact-5955DF531022E6A702C4801F82A42A3E"
          xlink:label="d34586122e9070-wk-Fact-5955DF531022E6A702C4801F82A42A3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9070-wk-Fact-5955DF531022E6A702C4801F82A42A3E"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8996-wk-Fact-5971AF67CC945F6EA0252DF12812F82F"
          xlink:label="d34458032e8996-wk-Fact-5971AF67CC945F6EA0252DF12812F82F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8996-wk-Fact-5971AF67CC945F6EA0252DF12812F82F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6636-wk-Fact-597816EBBEA9C653591F801F7EEC46E1"
          xlink:label="d34545404e6636-wk-Fact-597816EBBEA9C653591F801F7EEC46E1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e7194-wk-Fact-597816EBBEA9C653591F801F7EEC46E1"
          xlink:label="d34545404e7194-wk-Fact-597816EBBEA9C653591F801F7EEC46E1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6636-wk-Fact-597816EBBEA9C653591F801F7EEC46E1"
          xlink:to="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7194-wk-Fact-597816EBBEA9C653591F801F7EEC46E1"
          xlink:to="TextSelection-7A2B1C1756585F2A404B801F8312719C-0-wk-Footnote-7A2B1C1756585F2A404B801F8312719C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2381-wk-Fact-5978204D04A9412FC943801F82AB9CA2"
          xlink:label="d34458036e2381-wk-Fact-5978204D04A9412FC943801F82AB9CA2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2381-wk-Fact-5978204D04A9412FC943801F82AB9CA2"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7896-wk-Fact-5994144D551B14BACEFF801F7E7863C5"
          xlink:label="d34586122e7896-wk-Fact-5994144D551B14BACEFF801F7E7863C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7896-wk-Fact-5994144D551B14BACEFF801F7E7863C5"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2182-wk-Fact-599EFC3C5A9B585D8082B26EDB29D9AA"
          xlink:label="d34458036e2182-wk-Fact-599EFC3C5A9B585D8082B26EDB29D9AA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2182-wk-Fact-599EFC3C5A9B585D8082B26EDB29D9AA"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1801-wk-Fact-59B0AF76AAAA5B66B8EF1D2F0CE5B1EC"
          xlink:label="d34458036e1801-wk-Fact-59B0AF76AAAA5B66B8EF1D2F0CE5B1EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1801-wk-Fact-59B0AF76AAAA5B66B8EF1D2F0CE5B1EC"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21208-wk-Fact-59B1E65891137B9A016D801F7ED92BBC"
          xlink:label="d34661879e21208-wk-Fact-59B1E65891137B9A016D801F7ED92BBC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21208-wk-Fact-59B1E65891137B9A016D801F7ED92BBC"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2088-wk-Fact-59C2713351C3718503CECB2DE492EDAD"
          xlink:label="d34458032e2088-wk-Fact-59C2713351C3718503CECB2DE492EDAD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2088-wk-Fact-59C2713351C3718503CECB2DE492EDAD"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4941-wk-Fact-59FCEED3F6055C9A869BCCC59046D785"
          xlink:label="d34661879e4941-wk-Fact-59FCEED3F6055C9A869BCCC59046D785"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4941-wk-Fact-59FCEED3F6055C9A869BCCC59046D785"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2862-wk-Fact-5A1858B72D840CA48B81801F8088EC92"
          xlink:label="d34430544e2862-wk-Fact-5A1858B72D840CA48B81801F8088EC92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2862-wk-Fact-5A1858B72D840CA48B81801F8088EC92"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2531-wk-Fact-5A1DD2370C1F985FBB91801F81A8925B"
          xlink:label="d34594690e2531-wk-Fact-5A1DD2370C1F985FBB91801F81A8925B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2531-wk-Fact-5A1DD2370C1F985FBB91801F81A8925B"
          xlink:to="TextSelection-2BB3A03E685299A6C109801F83490A93-0-wk-Footnote-2BB3A03E685299A6C109801F83490A93_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19699-wk-Fact-5A20A9FE6AC6B79177A4801F8146DDEB"
          xlink:label="d34661879e19699-wk-Fact-5A20A9FE6AC6B79177A4801F8146DDEB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19699-wk-Fact-5A20A9FE6AC6B79177A4801F8146DDEB"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4966-wk-Fact-5A2A15D93FBF9DBC472E801F7F42D616"
          xlink:label="d34545404e4966-wk-Fact-5A2A15D93FBF9DBC472E801F7F42D616"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4966-wk-Fact-5A2A15D93FBF9DBC472E801F7F42D616"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl" xlink:label="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The decrease in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> is primarily the result of amortization of intangible assets and certain impairment charges, mainly offset by deferred tax liabilities established on intangible assets from the acquisition of Array.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4966-wk-Fact-5A2A15D93FBF9DBC472E801F7F42D616"
          xlink:to="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11456-wk-Fact-5A942695EAC354C8809AF1522CA91E6D"
          xlink:label="d34586122e11456-wk-Fact-5A942695EAC354C8809AF1522CA91E6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11456-wk-Fact-5A942695EAC354C8809AF1522CA91E6D"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1781-wk-Fact-5ABF4791BE6951B3BD213F08FF302F41"
          xlink:label="d34430544e1781-wk-Fact-5ABF4791BE6951B3BD213F08FF302F41"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1781-wk-Fact-5ABF4791BE6951B3BD213F08FF302F41"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8827-wk-Fact-5AE29E30628550D4AAC86546A2DDB7C3"
          xlink:label="d34458032e8827-wk-Fact-5AE29E30628550D4AAC86546A2DDB7C3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8827-wk-Fact-5AE29E30628550D4AAC86546A2DDB7C3"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e7393-wk-Fact-5AE5207BC2F85C839F3BD7D293D59B4E"
          xlink:label="d34538474e7393-wk-Fact-5AE5207BC2F85C839F3BD7D293D59B4E"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl" xlink:label="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7.5pt;"><xhtml:span style="font-family:Arial;font-size:7.5pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e7393-wk-Fact-5AE5207BC2F85C839F3BD7D293D59B4E"
          xlink:to="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10683-wk-Fact-5B79851311CC6FFAB3EF801F820E9581"
          xlink:label="d34661879e10683-wk-Fact-5B79851311CC6FFAB3EF801F820E9581"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10683-wk-Fact-5B79851311CC6FFAB3EF801F820E9581"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14562-wk-Fact-5BFD4CE5B0EB344F1A4A801F7F0AA68E"
          xlink:label="d34661879e14562-wk-Fact-5BFD4CE5B0EB344F1A4A801F7F0AA68E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14562-wk-Fact-5BFD4CE5B0EB344F1A4A801F7F0AA68E"
          xlink:to="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8754-wk-Fact-5C0064D89F285BDD8A146792BE0F3384"
          xlink:label="d34586122e8754-wk-Fact-5C0064D89F285BDD8A146792BE0F3384"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8754-wk-Fact-5C0064D89F285BDD8A146792BE0F3384"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e1799-wk-Fact-5C1105B34A8A5168A29CDA6A58BEDCE8"
          xlink:label="d34468079e1799-wk-Fact-5C1105B34A8A5168A29CDA6A58BEDCE8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1799-wk-Fact-5C1105B34A8A5168A29CDA6A58BEDCE8"
          xlink:to="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e1995-wk-Fact-5C6CEA6ACFCD5D859F39208DA973ACEC"
          xlink:label="d34468079e1995-wk-Fact-5C6CEA6ACFCD5D859F39208DA973ACEC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1995-wk-Fact-5C6CEA6ACFCD5D859F39208DA973ACEC"
          xlink:to="TextSelection-247A3B89234CB67B20FD801F8304EDFE-0-wk-Footnote-247A3B89234CB67B20FD801F8304EDFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4050-wk-Fact-5CA5DCE2265634E3F870801F81D69ABB"
          xlink:label="d34586122e4050-wk-Fact-5CA5DCE2265634E3F870801F81D69ABB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4050-wk-Fact-5CA5DCE2265634E3F870801F81D69ABB"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3802-wk-Fact-5D06811EF4C34003FE7FAB460A240C38"
          xlink:label="d34458036e3802-wk-Fact-5D06811EF4C34003FE7FAB460A240C38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3802-wk-Fact-5D06811EF4C34003FE7FAB460A240C38"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10133-wk-Fact-5D359C48EE073DF7C9CD801F817AF13E"
          xlink:label="d34586122e10133-wk-Fact-5D359C48EE073DF7C9CD801F817AF13E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10133-wk-Fact-5D359C48EE073DF7C9CD801F817AF13E"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3817-wk-Fact-5D65BE3231925A3690D7162CD4FAA218"
          xlink:label="d34468079e3817-wk-Fact-5D65BE3231925A3690D7162CD4FAA218"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3817-wk-Fact-5D65BE3231925A3690D7162CD4FAA218"
          xlink:to="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8751-wk-Fact-5E2F8A36DD7104849060801F7E8B4BB0"
          xlink:label="d34545404e8751-wk-Fact-5E2F8A36DD7104849060801F7E8B4BB0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8751-wk-Fact-5E2F8A36DD7104849060801F7E8B4BB0"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34519344e1823-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD"
          xlink:label="d34519344e1823-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e1722-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD"
          xlink:label="d34423000e1722-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34519344e1823-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1722-wk-Fact-5EA34295E0AA5DD7AA563B5234C1D9BD"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3583-wk-Fact-5EB5DEEFDF475D0D875609F4CEF1710B"
          xlink:label="d34586122e3583-wk-Fact-5EB5DEEFDF475D0D875609F4CEF1710B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3583-wk-Fact-5EB5DEEFDF475D0D875609F4CEF1710B"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3798-wk-Fact-5F0D40017013586D8F17BC834125A378"
          xlink:label="d34468079e3798-wk-Fact-5F0D40017013586D8F17BC834125A378"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3798-wk-Fact-5F0D40017013586D8F17BC834125A378"
          xlink:to="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5219-wk-Fact-5F191F9F323C685F3993801F7DCDF586"
          xlink:label="d34458032e5219-wk-Fact-5F191F9F323C685F3993801F7DCDF586"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5219-wk-Fact-5F191F9F323C685F3993801F7DCDF586"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7135-wk-Fact-5F2D4ADDF8FF1844A040801F7E00C1DC"
          xlink:label="d34458032e7135-wk-Fact-5F2D4ADDF8FF1844A040801F7E00C1DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7135-wk-Fact-5F2D4ADDF8FF1844A040801F7E00C1DC"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7135-wk-Fact-5F2D4ADDF8FF1844A040801F7E00C1DC"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2731-wk-Fact-5F457A9009553F04B717801F7FB266B9"
          xlink:label="d34458032e2731-wk-Fact-5F457A9009553F04B717801F7FB266B9"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34428379e3088-wk-Fact-5F457A9009553F04B717801F7FB266B9"
          xlink:label="d34428379e3088-wk-Fact-5F457A9009553F04B717801F7FB266B9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2731-wk-Fact-5F457A9009553F04B717801F7FB266B9"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3088-wk-Fact-5F457A9009553F04B717801F7FB266B9"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2731-wk-Fact-5F457A9009553F04B717801F7FB266B9"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3088-wk-Fact-5F457A9009553F04B717801F7FB266B9"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10846-wk-Fact-5F786390C2E8481D63AB801F820FDD80"
          xlink:label="d34661879e10846-wk-Fact-5F786390C2E8481D63AB801F820FDD80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10846-wk-Fact-5F786390C2E8481D63AB801F820FDD80"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3770-wk-Fact-5FCA9B06E5F243C62A7E801F7F95C2A9"
          xlink:label="d34661879e3770-wk-Fact-5FCA9B06E5F243C62A7E801F7F95C2A9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3770-wk-Fact-5FCA9B06E5F243C62A7E801F7F95C2A9"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9090-wk-Fact-5FF17F954895E52A550DDE22B9D0BED2"
          xlink:label="d34586122e9090-wk-Fact-5FF17F954895E52A550DDE22B9D0BED2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9090-wk-Fact-5FF17F954895E52A550DDE22B9D0BED2"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4214-wk-Fact-60449F03FF9FEEB388F5801F81D5F45D"
          xlink:label="d34586122e4214-wk-Fact-60449F03FF9FEEB388F5801F81D5F45D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4214-wk-Fact-60449F03FF9FEEB388F5801F81D5F45D"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4214-wk-Fact-60449F03FF9FEEB388F5801F81D5F45D"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4025-wk-Fact-606A9D26C4D35A40A035883CAA24CCE7"
          xlink:label="d34458036e4025-wk-Fact-606A9D26C4D35A40A035883CAA24CCE7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4025-wk-Fact-606A9D26C4D35A40A035883CAA24CCE7"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e4885-wk-Fact-6077434EDCF327AE1499801F81D5A9C4"
          xlink:label="d34594690e4885-wk-Fact-6077434EDCF327AE1499801F81D5A9C4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e4885-wk-Fact-6077434EDCF327AE1499801F81D5A9C4"
          xlink:to="TextSelection-B2F6F28597C47AAA5CDF801F834AA713-0-wk-Footnote-B2F6F28597C47AAA5CDF801F834AA713_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e7270-wk-Fact-6081521688175CC5A7553A80707D9EAC"
          xlink:label="d34538474e7270-wk-Fact-6081521688175CC5A7553A80707D9EAC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e7270-wk-Fact-6081521688175CC5A7553A80707D9EAC"
          xlink:to="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6719-wk-Fact-608268E446BF53A67800801F7ECCEFB9"
          xlink:label="d34545404e6719-wk-Fact-608268E446BF53A67800801F7ECCEFB9"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl" xlink:label="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For 2019, primarily related to the acquisition of Array. For 2017, primarily related to the acquisitions of Medivation and Anacor. See also </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6719-wk-Fact-608268E446BF53A67800801F7ECCEFB9"
          xlink:to="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1800-wk-Fact-60979D16D8DE563EA2F73F6D211A9A3F"
          xlink:label="d34430544e1800-wk-Fact-60979D16D8DE563EA2F73F6D211A9A3F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1800-wk-Fact-60979D16D8DE563EA2F73F6D211A9A3F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3305-wk-Fact-60CD4D80F7AE528A9A1801629A9AD807"
          xlink:label="d34428379e3305-wk-Fact-60CD4D80F7AE528A9A1801629A9AD807"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3305-wk-Fact-60CD4D80F7AE528A9A1801629A9AD807"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3913-wk-Fact-60E259DD84E55069AE8582467CCBEEF4"
          xlink:label="d34458036e3913-wk-Fact-60E259DD84E55069AE8582467CCBEEF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3913-wk-Fact-60E259DD84E55069AE8582467CCBEEF4"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e7152-wk-Fact-60FB429DDE645C968BD3DD43109F92F8"
          xlink:label="d34538474e7152-wk-Fact-60FB429DDE645C968BD3DD43109F92F8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e7152-wk-Fact-60FB429DDE645C968BD3DD43109F92F8"
          xlink:to="TextSelection-B79C1ADE452DDF32E1E3E523EFEE9FBA-0-wk-Footnote-B79C1ADE452DDF32E1E3E523EFEE9FBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23720-wk-Fact-61637C3FAD1A1EBEC396801F7E02E832"
          xlink:label="d34661879e23720-wk-Fact-61637C3FAD1A1EBEC396801F7E02E832"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23720-wk-Fact-61637C3FAD1A1EBEC396801F7E02E832"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23720-wk-Fact-61637C3FAD1A1EBEC396801F7E02E832"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3164-wk-Fact-6178D606D0576009E7D8801F800B47C5"
          xlink:label="d34661879e3164-wk-Fact-6178D606D0576009E7D8801F800B47C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3164-wk-Fact-6178D606D0576009E7D8801F800B47C5"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11193-wk-Fact-61950C831388E08B6286801F81EDD259"
          xlink:label="d34661879e11193-wk-Fact-61950C831388E08B6286801F81EDD259"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11193-wk-Fact-61950C831388E08B6286801F81EDD259"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-61D00E77EE76E65E4F9F801F823CCE99-wk-Fact-61D00E77EE76E65E4F9F801F823CCE99"
          xlink:label="Fact-61D00E77EE76E65E4F9F801F823CCE99-wk-Fact-61D00E77EE76E65E4F9F801F823CCE99"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-61D00E77EE76E65E4F9F801F823CCE99-wk-Fact-61D00E77EE76E65E4F9F801F823CCE99"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e2186-wk-Fact-61E9846E1AC95B2E9188CB7391BD7711"
          xlink:label="d34538474e2186-wk-Fact-61E9846E1AC95B2E9188CB7391BD7711"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e2186-wk-Fact-61E9846E1AC95B2E9188CB7391BD7711"
          xlink:to="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1845-wk-Fact-61EEF037EA245BC58651F6491A13B057"
          xlink:label="d34430544e1845-wk-Fact-61EEF037EA245BC58651F6491A13B057"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34468079e2106-wk-Fact-61EEF037EA245BC58651F6491A13B057"
          xlink:label="d34468079e2106-wk-Fact-61EEF037EA245BC58651F6491A13B057"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1845-wk-Fact-61EEF037EA245BC58651F6491A13B057"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2106-wk-Fact-61EEF037EA245BC58651F6491A13B057"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e4024-wk-Fact-6218C747DBEE55A9AF76EE26E178A31C"
          xlink:label="d34471435e4024-wk-Fact-6218C747DBEE55A9AF76EE26E178A31C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e4024-wk-Fact-6218C747DBEE55A9AF76EE26E178A31C"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3394-wk-Fact-6221149E08DD0A17F14B801F8152992D"
          xlink:label="d34594690e3394-wk-Fact-6221149E08DD0A17F14B801F8152992D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3394-wk-Fact-6221149E08DD0A17F14B801F8152992D"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3394-wk-Fact-6221149E08DD0A17F14B801F8152992D"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23028-wk-Fact-624D9122625475A0C346801F810535CB"
          xlink:label="d34661879e23028-wk-Fact-624D9122625475A0C346801F810535CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23028-wk-Fact-624D9122625475A0C346801F810535CB"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23152-wk-Fact-6259E894CBE6FA9FB71A801F7E0FCAAB"
          xlink:label="d34661879e23152-wk-Fact-6259E894CBE6FA9FB71A801F7E0FCAAB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23152-wk-Fact-6259E894CBE6FA9FB71A801F7E0FCAAB"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23152-wk-Fact-6259E894CBE6FA9FB71A801F7E0FCAAB"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7079-wk-Fact-62650662D7DD8D7E8080801F82C35669"
          xlink:label="d34586122e7079-wk-Fact-62650662D7DD8D7E8080801F82C35669"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7079-wk-Fact-62650662D7DD8D7E8080801F82C35669"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e2167-wk-Fact-626CCC40E7795A0A83CE3935A24DFAFC"
          xlink:label="d34538474e2167-wk-Fact-626CCC40E7795A0A83CE3935A24DFAFC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e2167-wk-Fact-626CCC40E7795A0A83CE3935A24DFAFC"
          xlink:to="TextSelection-8EADFC2F387551800A48801F8318C4AA-0-wk-Footnote-8EADFC2F387551800A48801F8318C4AA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e4043-wk-Fact-62C2FD859415581FBF973FCE94B77BC7"
          xlink:label="d34471435e4043-wk-Fact-62C2FD859415581FBF973FCE94B77BC7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e4043-wk-Fact-62C2FD859415581FBF973FCE94B77BC7"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6869-wk-Fact-62C88B2989C62E56687F801F7DE4D234"
          xlink:label="d34458032e6869-wk-Fact-62C88B2989C62E56687F801F7DE4D234"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6869-wk-Fact-62C88B2989C62E56687F801F7DE4D234"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6222-wk-Fact-62D20C34C95D577873AD801F7E784708"
          xlink:label="d34586122e6222-wk-Fact-62D20C34C95D577873AD801F7E784708"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6222-wk-Fact-62D20C34C95D577873AD801F7E784708"
          xlink:to="TextSelection-CCA751B81A19C6E85024801F83517B73-0-wk-Footnote-CCA751B81A19C6E85024801F83517B73_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1802-wk-Fact-6325E2F134D45571A3E0DD3C60FB9C6F"
          xlink:label="d34428379e1802-wk-Fact-6325E2F134D45571A3E0DD3C60FB9C6F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1802-wk-Fact-6325E2F134D45571A3E0DD3C60FB9C6F"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23009-wk-Fact-6343757AF4A26430D7A1801F7DD0CC07"
          xlink:label="d34661879e23009-wk-Fact-6343757AF4A26430D7A1801F7DD0CC07"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23009-wk-Fact-6343757AF4A26430D7A1801F7DD0CC07"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2273-wk-Fact-6353F406AD7D5730BA1BF2FBE27EFAE9"
          xlink:label="d34529301e2273-wk-Fact-6353F406AD7D5730BA1BF2FBE27EFAE9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2273-wk-Fact-6353F406AD7D5730BA1BF2FBE27EFAE9"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4204-wk-Fact-636FAEFED881C9A536B7801F7EB61207"
          xlink:label="d34545404e4204-wk-Fact-636FAEFED881C9A536B7801F7EB61207"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4204-wk-Fact-636FAEFED881C9A536B7801F7EB61207"
          xlink:to="TextSelection-109807EBE4EECBA09C38801F831279A4-0-wk-Footnote-109807EBE4EECBA09C38801F831279A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4130-wk-Fact-638270EA30AE2FE9D14C801F7E7BF6D8"
          xlink:label="d34458036e4130-wk-Fact-638270EA30AE2FE9D14C801F7E7BF6D8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4130-wk-Fact-638270EA30AE2FE9D14C801F7E7BF6D8"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14741-wk-Fact-63A8380FD8882B8BF33C801F7F0B001F"
          xlink:label="d34661879e14741-wk-Fact-63A8380FD8882B8BF33C801F7F0B001F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14741-wk-Fact-63A8380FD8882B8BF33C801F7F0B001F"
          xlink:to="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11623-wk-Fact-63FD058F80E55C109E636F60FC6CA539"
          xlink:label="d34586122e11623-wk-Fact-63FD058F80E55C109E636F60FC6CA539"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11623-wk-Fact-63FD058F80E55C109E636F60FC6CA539"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11308-wk-Fact-6428270E830C52D8A83D9D78EC21F20E"
          xlink:label="d34586122e11308-wk-Fact-6428270E830C52D8A83D9D78EC21F20E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11308-wk-Fact-6428270E830C52D8A83D9D78EC21F20E"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3868-wk-Fact-643BD36B0A7BD2A450F4801F8291FACD"
          xlink:label="d34458036e3868-wk-Fact-643BD36B0A7BD2A450F4801F8291FACD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3868-wk-Fact-643BD36B0A7BD2A450F4801F8291FACD"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2832-wk-Fact-643D9E90F2225078A9387D3F21E73814"
          xlink:label="d34529301e2832-wk-Fact-643D9E90F2225078A9387D3F21E73814"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34529301e2795-wk-Fact-643D9E90F2225078A9387D3F21E73814"
          xlink:label="d34529301e2795-wk-Fact-643D9E90F2225078A9387D3F21E73814"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2832-wk-Fact-643D9E90F2225078A9387D3F21E73814"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2795-wk-Fact-643D9E90F2225078A9387D3F21E73814"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2832-wk-Fact-643D9E90F2225078A9387D3F21E73814"
          xlink:to="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2795-wk-Fact-643D9E90F2225078A9387D3F21E73814"
          xlink:to="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2356-wk-Fact-644EBFAF34BD5FBA9B1CF394FD689FBB"
          xlink:label="d34471435e2356-wk-Fact-644EBFAF34BD5FBA9B1CF394FD689FBB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2356-wk-Fact-644EBFAF34BD5FBA9B1CF394FD689FBB"
          xlink:to="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3395-wk-Fact-64527C0F87BA22A2495F801F7FFC6A1A"
          xlink:label="d34458032e3395-wk-Fact-64527C0F87BA22A2495F801F7FFC6A1A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3395-wk-Fact-64527C0F87BA22A2495F801F7FFC6A1A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2788-wk-Fact-648F7B6A7F165EE0A40B6056F82B93C7"
          xlink:label="d34468079e2788-wk-Fact-648F7B6A7F165EE0A40B6056F82B93C7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2788-wk-Fact-648F7B6A7F165EE0A40B6056F82B93C7"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e5107-wk-Fact-6490FB80A4F21290128A801F7FC0275E"
          xlink:label="d34661879e5107-wk-Fact-6490FB80A4F21290128A801F7FC0275E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e5107-wk-Fact-6490FB80A4F21290128A801F7FC0275E"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4175-wk-Fact-64B6841D8A9647CC861B801F81B47923"
          xlink:label="d34586122e4175-wk-Fact-64B6841D8A9647CC861B801F81B47923"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4175-wk-Fact-64B6841D8A9647CC861B801F81B47923"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4175-wk-Fact-64B6841D8A9647CC861B801F81B47923"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5594-wk-Fact-64DE649A1DC85272824F592AAE2FEBD3"
          xlink:label="d34458036e5594-wk-Fact-64DE649A1DC85272824F592AAE2FEBD3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5594-wk-Fact-64DE649A1DC85272824F592AAE2FEBD3"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5689-wk-Fact-65066DE8900A50DCDF11801F7F0E6375"
          xlink:label="d34545404e5689-wk-Fact-65066DE8900A50DCDF11801F7F0E6375"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5689-wk-Fact-65066DE8900A50DCDF11801F7F0E6375"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:label="d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:label="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9630-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2672-wk-Fact-654A196AF43D03B9980A801F82387787"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3535-wk-Fact-654FE5FF7865D1DED1CD801F815171FE"
          xlink:label="d34594690e3535-wk-Fact-654FE5FF7865D1DED1CD801F815171FE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3535-wk-Fact-654FE5FF7865D1DED1CD801F815171FE"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3535-wk-Fact-654FE5FF7865D1DED1CD801F815171FE"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4262-wk-Fact-6556B2C27E285E515E05801F82C1264D"
          xlink:label="d34458036e4262-wk-Fact-6556B2C27E285E515E05801F82C1264D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4262-wk-Fact-6556B2C27E285E515E05801F82C1264D"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4629-wk-Fact-6586B6AD1EA296008717801F7EBC80FD"
          xlink:label="d34458032e4629-wk-Fact-6586B6AD1EA296008717801F7EBC80FD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4629-wk-Fact-6586B6AD1EA296008717801F7EBC80FD"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3120-wk-Fact-65AD28ADEA625EEBBB3613A384127FAA"
          xlink:label="d34423000e3120-wk-Fact-65AD28ADEA625EEBBB3613A384127FAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3120-wk-Fact-65AD28ADEA625EEBBB3613A384127FAA"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19578-wk-Fact-65B741C45407AAE78B32801F815BCE12"
          xlink:label="d34661879e19578-wk-Fact-65B741C45407AAE78B32801F815BCE12"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19578-wk-Fact-65B741C45407AAE78B32801F815BCE12"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-666BF4CEF70690419B91801F81E7FF4C-wk-Fact-666BF4CEF70690419B91801F81E7FF4C"
          xlink:label="Fact-666BF4CEF70690419B91801F81E7FF4C-wk-Fact-666BF4CEF70690419B91801F81E7FF4C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-666BF4CEF70690419B91801F81E7FF4C-wk-Fact-666BF4CEF70690419B91801F81E7FF4C"
          xlink:to="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4396-wk-Fact-6675DE4C808280B705BC801F825EB10F"
          xlink:label="d34458036e4396-wk-Fact-6675DE4C808280B705BC801F825EB10F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4396-wk-Fact-6675DE4C808280B705BC801F825EB10F"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3343-wk-Fact-66EE9ACDD29C54A495F8D48FB257E0D9"
          xlink:label="d34423000e3343-wk-Fact-66EE9ACDD29C54A495F8D48FB257E0D9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3343-wk-Fact-66EE9ACDD29C54A495F8D48FB257E0D9"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34509238e2027-wk-Fact-67276C3C3805655E626C801F80B6FF7C"
          xlink:label="d34509238e2027-wk-Fact-67276C3C3805655E626C801F80B6FF7C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-1B6D1520B957E6708C32801F8318DAAD-0-wk-Footnote-1B6D1520B957E6708C32801F8318DAAD_lbl" xlink:label="TextSelection-1B6D1520B957E6708C32801F8318DAAD-0-wk-Footnote-1B6D1520B957E6708C32801F8318DAAD_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:8pt;">At December 31, </xhtml:span><xhtml:span style="font-family:Arial;font-size:8pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:8pt;">, the debt issuances have been reclassified to the current portion of long-term debt.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34509238e2027-wk-Fact-67276C3C3805655E626C801F80B6FF7C"
          xlink:to="TextSelection-1B6D1520B957E6708C32801F8318DAAD-0-wk-Footnote-1B6D1520B957E6708C32801F8318DAAD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10151-wk-Fact-6734B0CCF706755370DC801F82248099"
          xlink:label="d34661879e10151-wk-Fact-6734B0CCF706755370DC801F82248099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10151-wk-Fact-6734B0CCF706755370DC801F82248099"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9146-wk-Fact-67635FDCF78A5B1F882CF82F5CDD09D7"
          xlink:label="d34586122e9146-wk-Fact-67635FDCF78A5B1F882CF82F5CDD09D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9146-wk-Fact-67635FDCF78A5B1F882CF82F5CDD09D7"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl" xlink:label="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9146-wk-Fact-67635FDCF78A5B1F882CF82F5CDD09D7"
          xlink:to="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5774-wk-Fact-678AA5395AAB27D2692D801F7F41983A"
          xlink:label="d34545404e5774-wk-Fact-678AA5395AAB27D2692D801F7F41983A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5774-wk-Fact-678AA5395AAB27D2692D801F7F41983A"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8155-wk-Fact-67C37AC357CC578E8A2CE9AD15A0F5DE"
          xlink:label="d34586122e8155-wk-Fact-67C37AC357CC578E8A2CE9AD15A0F5DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8155-wk-Fact-67C37AC357CC578E8A2CE9AD15A0F5DE"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20125-wk-Fact-67EBD4339740E27DDD1E801F7FFC6246"
          xlink:label="d34661879e20125-wk-Fact-67EBD4339740E27DDD1E801F7FFC6246"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20125-wk-Fact-67EBD4339740E27DDD1E801F7FFC6246"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3119-wk-Fact-681CAA08E088E04EA79E801F7ECB79CF"
          xlink:label="d34458032e3119-wk-Fact-681CAA08E088E04EA79E801F7ECB79CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3119-wk-Fact-681CAA08E088E04EA79E801F7ECB79CF"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2194-wk-Fact-6828C32532055C2D9F9FCA7D73FE1813"
          xlink:label="d34468079e2194-wk-Fact-6828C32532055C2D9F9FCA7D73FE1813"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl" xlink:label="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">In 2018, primarily represents the net pension curtailments and settlements included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">upon the adoption of a new accounting standard in the first quarter of 2018. In 2017, mainly represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#x2013;&#x2013;net</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2194-wk-Fact-6828C32532055C2D9F9FCA7D73FE1813"
          xlink:to="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9296-wk-Fact-685DE43906F252099A21B0122F5E2271"
          xlink:label="d34586122e9296-wk-Fact-685DE43906F252099A21B0122F5E2271"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9296-wk-Fact-685DE43906F252099A21B0122F5E2271"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4154-wk-Fact-6861B27FF0E359E495FAE4664EA2AD95"
          xlink:label="d34586122e4154-wk-Fact-6861B27FF0E359E495FAE4664EA2AD95"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4154-wk-Fact-6861B27FF0E359E495FAE4664EA2AD95"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4154-wk-Fact-6861B27FF0E359E495FAE4664EA2AD95"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2926-wk-Fact-68A35B6201B05F6791E934C35C4FF3BB"
          xlink:label="d34458036e2926-wk-Fact-68A35B6201B05F6791E934C35C4FF3BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2926-wk-Fact-68A35B6201B05F6791E934C35C4FF3BB"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2823-wk-Fact-68C3B0FD2C4751708C56BFF9C8FF5735"
          xlink:label="d34430544e2823-wk-Fact-68C3B0FD2C4751708C56BFF9C8FF5735"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2823-wk-Fact-68C3B0FD2C4751708C56BFF9C8FF5735"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5398-wk-Fact-68EA97346488548597981D4BC7C4FA17"
          xlink:label="d34586122e5398-wk-Fact-68EA97346488548597981D4BC7C4FA17"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5398-wk-Fact-68EA97346488548597981D4BC7C4FA17"
          xlink:to="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4584-wk-Fact-691D5136507A5CF6B58B87FA8C2DFF67"
          xlink:label="d34661879e4584-wk-Fact-691D5136507A5CF6B58B87FA8C2DFF67"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4584-wk-Fact-691D5136507A5CF6B58B87FA8C2DFF67"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2692-wk-Fact-6933FD29A03F60C5C1DB801F8037A1E9"
          xlink:label="d34661879e2692-wk-Fact-6933FD29A03F60C5C1DB801F8037A1E9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2692-wk-Fact-6933FD29A03F60C5C1DB801F8037A1E9"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2692-wk-Fact-6933FD29A03F60C5C1DB801F8037A1E9"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7097-wk-Fact-694C315E46A521BE92D5801F7DD0578A"
          xlink:label="d34458032e7097-wk-Fact-694C315E46A521BE92D5801F7DD0578A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7097-wk-Fact-694C315E46A521BE92D5801F7DD0578A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7097-wk-Fact-694C315E46A521BE92D5801F7DD0578A"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5493-wk-Fact-6955E2160BED229E172F801F7F0EBB71"
          xlink:label="d34545404e5493-wk-Fact-6955E2160BED229E172F801F7F0EBB71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5493-wk-Fact-6955E2160BED229E172F801F7F0EBB71"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2746-wk-Fact-699213AA4BB320044F47801F81563F2E"
          xlink:label="d34523018e2746-wk-Fact-699213AA4BB320044F47801F81563F2E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2746-wk-Fact-699213AA4BB320044F47801F81563F2E"
          xlink:to="TextSelection-5B011D6787F1E1CE5BB6801F834DE58E-0-wk-Footnote-5B011D6787F1E1CE5BB6801F834DE58E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7336-wk-Fact-6A1D5D6AF4EC5CA8BE48BCBA53E3E2A8"
          xlink:label="d34586122e7336-wk-Fact-6A1D5D6AF4EC5CA8BE48BCBA53E3E2A8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7336-wk-Fact-6A1D5D6AF4EC5CA8BE48BCBA53E3E2A8"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11199-wk-Fact-6A5565AC16FAF0E46BF3801F818756A4"
          xlink:label="d34586122e11199-wk-Fact-6A5565AC16FAF0E46BF3801F818756A4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11199-wk-Fact-6A5565AC16FAF0E46BF3801F818756A4"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8046-wk-Fact-6A654FC14177C9A6479ADE1ABFE4C4D9"
          xlink:label="d34586122e8046-wk-Fact-6A654FC14177C9A6479ADE1ABFE4C4D9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8046-wk-Fact-6A654FC14177C9A6479ADE1ABFE4C4D9"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7554-wk-Fact-6B459265E6775C47B37741B8BA18E170"
          xlink:label="d34458032e7554-wk-Fact-6B459265E6775C47B37741B8BA18E170"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7554-wk-Fact-6B459265E6775C47B37741B8BA18E170"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22002-wk-Fact-6B515B4176DA3F1E487E801F7E934F57"
          xlink:label="d34661879e22002-wk-Fact-6B515B4176DA3F1E487E801F7E934F57"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22002-wk-Fact-6B515B4176DA3F1E487E801F7E934F57"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3847-wk-Fact-6B869F58FEDE17E7F0E5801F81D500ED"
          xlink:label="d34586122e3847-wk-Fact-6B869F58FEDE17E7F0E5801F81D500ED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3847-wk-Fact-6B869F58FEDE17E7F0E5801F81D500ED"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9796-wk-Fact-6B8B35F0C5A25612B8D5FB3898261F5D"
          xlink:label="d34458032e9796-wk-Fact-6B8B35F0C5A25612B8D5FB3898261F5D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9796-wk-Fact-6B8B35F0C5A25612B8D5FB3898261F5D"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1768-wk-Fact-6B8F488463125E46B584902709E619F5"
          xlink:label="d34471435e1768-wk-Fact-6B8F488463125E46B584902709E619F5"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl" xlink:label="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Royalty-related income </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">increased</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily due to a one-time favorable resolution in the second quarter of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> of a legal dispute for </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$82 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1768-wk-Fact-6B8F488463125E46B584902709E619F5"
          xlink:to="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5653-wk-Fact-6C6813303FAB516E9EF5ED555B6EFC07"
          xlink:label="d34458036e5653-wk-Fact-6C6813303FAB516E9EF5ED555B6EFC07"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5653-wk-Fact-6C6813303FAB516E9EF5ED555B6EFC07"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20324-wk-Fact-6C6A4F5106ED00592CB9801F80B9D6FC"
          xlink:label="d34661879e20324-wk-Fact-6C6A4F5106ED00592CB9801F80B9D6FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20324-wk-Fact-6C6A4F5106ED00592CB9801F80B9D6FC"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2543-wk-Fact-6C6D242FEDF05A7CADA10BE9ECFC67DD"
          xlink:label="d34423000e2543-wk-Fact-6C6D242FEDF05A7CADA10BE9ECFC67DD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2543-wk-Fact-6C6D242FEDF05A7CADA10BE9ECFC67DD"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6966-wk-Fact-6C731063DF07515B8278EAAAF41E82F5"
          xlink:label="d34586122e6966-wk-Fact-6C731063DF07515B8278EAAAF41E82F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6966-wk-Fact-6C731063DF07515B8278EAAAF41E82F5"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32"
          xlink:label="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24141-wk-Fact-6C7A0487DAD2EC075F99801F80D38A32"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7600-wk-Fact-6C990DD2B2AD4FB4F7BA801F82BE5EDE"
          xlink:label="d34586122e7600-wk-Fact-6C990DD2B2AD4FB4F7BA801F82BE5EDE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7600-wk-Fact-6C990DD2B2AD4FB4F7BA801F82BE5EDE"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5459-wk-Fact-6CFCA119539F5C0D846D537B1FB079D6"
          xlink:label="d34458036e5459-wk-Fact-6CFCA119539F5C0D846D537B1FB079D6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5459-wk-Fact-6CFCA119539F5C0D846D537B1FB079D6"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5459-wk-Fact-6CFCA119539F5C0D846D537B1FB079D6"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2539-wk-Fact-6D3E645E9EBC03EFCF4B801F82A9D31C"
          xlink:label="d34460716e2539-wk-Fact-6D3E645E9EBC03EFCF4B801F82A9D31C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2539-wk-Fact-6D3E645E9EBC03EFCF4B801F82A9D31C"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2328-wk-Fact-6D614FEC811C0CB49DA6801F823ECDD2"
          xlink:label="d34471435e2328-wk-Fact-6D614FEC811C0CB49DA6801F823ECDD2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2328-wk-Fact-6D614FEC811C0CB49DA6801F823ECDD2"
          xlink:to="TextSelection-581C6D9E3DF784EC6F32801F830D4927-0-wk-Footnote-581C6D9E3DF784EC6F32801F830D4927_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3876-wk-Fact-6D7C9A2836915BA9A1C8765EC5343BEF"
          xlink:label="d34471435e3876-wk-Fact-6D7C9A2836915BA9A1C8765EC5343BEF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3876-wk-Fact-6D7C9A2836915BA9A1C8765EC5343BEF"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3876-wk-Fact-6D7C9A2836915BA9A1C8765EC5343BEF"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14680-wk-Fact-6D8465E75F36770F95BA801F7F0AFDCF"
          xlink:label="d34661879e14680-wk-Fact-6D8465E75F36770F95BA801F7F0AFDCF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14680-wk-Fact-6D8465E75F36770F95BA801F7F0AFDCF"
          xlink:to="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10419-wk-Fact-6D9D6801D8F49E72AC9F801F8247BF37"
          xlink:label="d34661879e10419-wk-Fact-6D9D6801D8F49E72AC9F801F8247BF37"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10419-wk-Fact-6D9D6801D8F49E72AC9F801F8247BF37"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3731-wk-Fact-6DB8EEE5D9865BED9C6C65D55477AD7B"
          xlink:label="d34661879e3731-wk-Fact-6DB8EEE5D9865BED9C6C65D55477AD7B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3731-wk-Fact-6DB8EEE5D9865BED9C6C65D55477AD7B"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1984-wk-Fact-6DBE94D819C45C32A44ABAD8E234B1BA"
          xlink:label="d34458036e1984-wk-Fact-6DBE94D819C45C32A44ABAD8E234B1BA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1984-wk-Fact-6DBE94D819C45C32A44ABAD8E234B1BA"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1984-wk-Fact-6DBE94D819C45C32A44ABAD8E234B1BA"
          xlink:to="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2917-wk-Fact-6DF270940FC65894A5CA91BBF63EB321"
          xlink:label="d34423000e2917-wk-Fact-6DF270940FC65894A5CA91BBF63EB321"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34519344e2076-wk-Fact-6DF270940FC65894A5CA91BBF63EB321"
          xlink:label="d34519344e2076-wk-Fact-6DF270940FC65894A5CA91BBF63EB321"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2917-wk-Fact-6DF270940FC65894A5CA91BBF63EB321"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34519344e2076-wk-Fact-6DF270940FC65894A5CA91BBF63EB321"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e12132-wk-Fact-6E43981A243F593FB97D9CA3CEB76E6D"
          xlink:label="d34586122e12132-wk-Fact-6E43981A243F593FB97D9CA3CEB76E6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e12132-wk-Fact-6E43981A243F593FB97D9CA3CEB76E6D"
          xlink:to="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66"
          xlink:label="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66"
          xlink:to="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6498-wk-Fact-6E4E6240FE387C53B46265484D6E4F66"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e8161-wk-Fact-6E8F52F802E68107D2ED801F7E65A2D6"
          xlink:label="d34594690e8161-wk-Fact-6E8F52F802E68107D2ED801F7E65A2D6"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl" xlink:label="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Market price of our underlying common stock less exercise price.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8161-wk-Fact-6E8F52F802E68107D2ED801F7E65A2D6"
          xlink:to="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E"
          xlink:label="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl" xlink:label="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E"
          xlink:to="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3562-wk-Fact-6ED08D25CF69C2157415801F8157C81E"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4965-wk-Fact-6EE57D419E98505BB872CDF37DAACD72"
          xlink:label="d34529301e4965-wk-Fact-6EE57D419E98505BB872CDF37DAACD72"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e2012-wk-Fact-6EE57D419E98505BB872CDF37DAACD72"
          xlink:label="d34423000e2012-wk-Fact-6EE57D419E98505BB872CDF37DAACD72"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4965-wk-Fact-6EE57D419E98505BB872CDF37DAACD72"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2012-wk-Fact-6EE57D419E98505BB872CDF37DAACD72"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1736-wk-Fact-6EED17ECA25F58D092D7F74CB80AA63D"
          xlink:label="d34430544e1736-wk-Fact-6EED17ECA25F58D092D7F74CB80AA63D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1736-wk-Fact-6EED17ECA25F58D092D7F74CB80AA63D"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1736-wk-Fact-6EED17ECA25F58D092D7F74CB80AA63D"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6909-wk-Fact-6F45B7B7D9041F4DACD1801F7DC65341"
          xlink:label="d34458032e6909-wk-Fact-6F45B7B7D9041F4DACD1801F7DC65341"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6909-wk-Fact-6F45B7B7D9041F4DACD1801F7DC65341"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21009-wk-Fact-6F6B7321CCFF4B9C9028801F7EBC6553"
          xlink:label="d34661879e21009-wk-Fact-6F6B7321CCFF4B9C9028801F7EBC6553"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21009-wk-Fact-6F6B7321CCFF4B9C9028801F7EBC6553"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21009-wk-Fact-6F6B7321CCFF4B9C9028801F7EBC6553"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7826-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
          xlink:label="d34458032e7826-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34428379e3047-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
          xlink:label="d34428379e3047-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7826-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3047-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7826-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3047-wk-Fact-6FF5FE27BFE5595DB0718AE8A3361ED5"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10622-wk-Fact-707FF8E8FE2A2798AEDA801F8220322D"
          xlink:label="d34661879e10622-wk-Fact-707FF8E8FE2A2798AEDA801F8220322D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10622-wk-Fact-707FF8E8FE2A2798AEDA801F8220322D"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:label="d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:label="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:label="d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e25566-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24258-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26089-wk-Fact-70871FBF27C378E47CDA801F81DC2916"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2299-wk-Fact-70A89F04606E5C478C49B14416D6CE2D"
          xlink:label="d34430544e2299-wk-Fact-70A89F04606E5C478C49B14416D6CE2D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2299-wk-Fact-70A89F04606E5C478C49B14416D6CE2D"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24365-wk-Fact-70AB9AE43B82A35609DD801F7EC60B58"
          xlink:label="d34661879e24365-wk-Fact-70AB9AE43B82A35609DD801F7EC60B58"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24365-wk-Fact-70AB9AE43B82A35609DD801F7EC60B58"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2578-wk-Fact-70AE538A79495076EEEF801F82A94AED"
          xlink:label="d34458036e2578-wk-Fact-70AE538A79495076EEEF801F82A94AED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2578-wk-Fact-70AE538A79495076EEEF801F82A94AED"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9277-wk-Fact-710F79BB7E78505B80B3DD29D470A8D7"
          xlink:label="d34586122e9277-wk-Fact-710F79BB7E78505B80B3DD29D470A8D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9277-wk-Fact-710F79BB7E78505B80B3DD29D470A8D7"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3118-wk-Fact-717E35B044362C67F868801F81BDF57D"
          xlink:label="d34586122e3118-wk-Fact-717E35B044362C67F868801F81BDF57D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3118-wk-Fact-717E35B044362C67F868801F81BDF57D"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21497-wk-Fact-71ACBA717F716B8607A4801F80F2069A"
          xlink:label="d34661879e21497-wk-Fact-71ACBA717F716B8607A4801F80F2069A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21497-wk-Fact-71ACBA717F716B8607A4801F80F2069A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4461-wk-Fact-721F3FC462E1384F6A25801F7EB6DE98"
          xlink:label="d34458036e4461-wk-Fact-721F3FC462E1384F6A25801F7EB6DE98"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4461-wk-Fact-721F3FC462E1384F6A25801F7EB6DE98"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4337-wk-Fact-722AC42D560351C29546696AF2E1458D"
          xlink:label="d34538474e4337-wk-Fact-722AC42D560351C29546696AF2E1458D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4337-wk-Fact-722AC42D560351C29546696AF2E1458D"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1"
          xlink:label="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1"
          xlink:to="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5648-wk-Fact-7246C3D01254B6131560E5206F400BD1"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2880-wk-Fact-7249016752645521B4A449214872FA3C"
          xlink:label="d34586122e2880-wk-Fact-7249016752645521B4A449214872FA3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2880-wk-Fact-7249016752645521B4A449214872FA3C"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5644-wk-Fact-725EA7A18943A5F5A993801F8216D9F7"
          xlink:label="d34506804e5644-wk-Fact-725EA7A18943A5F5A993801F8216D9F7"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl" xlink:label="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:justify;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily relates to royalties from our collaboration partners. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5644-wk-Fact-725EA7A18943A5F5A993801F8216D9F7"
          xlink:to="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2213-wk-Fact-726DD7EC40B27F8510DA801F81EF7AF4"
          xlink:label="d34468079e2213-wk-Fact-726DD7EC40B27F8510DA801F81EF7AF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2213-wk-Fact-726DD7EC40B27F8510DA801F81EF7AF4"
          xlink:to="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21448-wk-Fact-72790138A19EAC31CA09801F807E33DE"
          xlink:label="d34661879e21448-wk-Fact-72790138A19EAC31CA09801F807E33DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21448-wk-Fact-72790138A19EAC31CA09801F807E33DE"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21448-wk-Fact-72790138A19EAC31CA09801F807E33DE"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2455-wk-Fact-729C012AD2435DBEB3A6986C8E3F0F60"
          xlink:label="d34423000e2455-wk-Fact-729C012AD2435DBEB3A6986C8E3F0F60"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2455-wk-Fact-729C012AD2435DBEB3A6986C8E3F0F60"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4136-wk-Fact-72DE426063852BE9262D801F7E146126"
          xlink:label="d34458032e4136-wk-Fact-72DE426063852BE9262D801F7E146126"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4136-wk-Fact-72DE426063852BE9262D801F7E146126"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7161-wk-Fact-72F12325846A255A2934801F823A73B8"
          xlink:label="d34458032e7161-wk-Fact-72F12325846A255A2934801F823A73B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7161-wk-Fact-72F12325846A255A2934801F823A73B8"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9911-wk-Fact-72FA6A6777398A051E57801F7E7966A0"
          xlink:label="d34586122e9911-wk-Fact-72FA6A6777398A051E57801F7E7966A0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9911-wk-Fact-72FA6A6777398A051E57801F7E7966A0"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20971-wk-Fact-732BFC75898DC67D4551801F7E2006BB"
          xlink:label="d34661879e20971-wk-Fact-732BFC75898DC67D4551801F7E2006BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20971-wk-Fact-732BFC75898DC67D4551801F7E2006BB"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4817-wk-Fact-7331B3996B7156028ABA17B0B6F034DA"
          xlink:label="d34529301e4817-wk-Fact-7331B3996B7156028ABA17B0B6F034DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4817-wk-Fact-7331B3996B7156028ABA17B0B6F034DA"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9495-wk-Fact-73596D19D7B15B05E6A9801F820D7E85"
          xlink:label="d34661879e9495-wk-Fact-73596D19D7B15B05E6A9801F820D7E85"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e11465-wk-Fact-73596D19D7B15B05E6A9801F820D7E85"
          xlink:label="d34661879e11465-wk-Fact-73596D19D7B15B05E6A9801F820D7E85"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9495-wk-Fact-73596D19D7B15B05E6A9801F820D7E85"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11465-wk-Fact-73596D19D7B15B05E6A9801F820D7E85"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e1963-wk-Fact-73675557E3290275CFB2801F8179DBF8"
          xlink:label="d34460716e1963-wk-Fact-73675557E3290275CFB2801F8179DBF8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e1963-wk-Fact-73675557E3290275CFB2801F8179DBF8"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7166-wk-Fact-73C56959049A2D57F4C1801F82A49C55"
          xlink:label="d34594690e7166-wk-Fact-73C56959049A2D57F4C1801F82A49C55"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7166-wk-Fact-73C56959049A2D57F4C1801F82A49C55"
          xlink:to="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-7414237C2DE558C2A570279D3852E356-wk-Fact-7414237C2DE558C2A570279D3852E356"
          xlink:label="Fact-7414237C2DE558C2A570279D3852E356-wk-Fact-7414237C2DE558C2A570279D3852E356"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-7414237C2DE558C2A570279D3852E356-wk-Fact-7414237C2DE558C2A570279D3852E356"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2467-wk-Fact-74710073FCDBB8BA38A9AB460A554FBE"
          xlink:label="d34458036e2467-wk-Fact-74710073FCDBB8BA38A9AB460A554FBE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2467-wk-Fact-74710073FCDBB8BA38A9AB460A554FBE"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3867-wk-Fact-74BDF519ACFF7C0C48A3801F819B32C2"
          xlink:label="d34586122e3867-wk-Fact-74BDF519ACFF7C0C48A3801F819B32C2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3867-wk-Fact-74BDF519ACFF7C0C48A3801F819B32C2"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3970-wk-Fact-74C1614E6C935CA08B5422036CFAC156"
          xlink:label="d34586122e3970-wk-Fact-74C1614E6C935CA08B5422036CFAC156"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3970-wk-Fact-74C1614E6C935CA08B5422036CFAC156"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2284-wk-Fact-74D8FB512BB0C16FBCA9801F7F9F040A"
          xlink:label="d34460716e2284-wk-Fact-74D8FB512BB0C16FBCA9801F7F9F040A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2284-wk-Fact-74D8FB512BB0C16FBCA9801F7F9F040A"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-7501CCEC7B4D0192DEEF801F81E84FD3-wk-Fact-7501CCEC7B4D0192DEEF801F81E84FD3"
          xlink:label="Fact-7501CCEC7B4D0192DEEF801F81E84FD3-wk-Fact-7501CCEC7B4D0192DEEF801F81E84FD3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-7501CCEC7B4D0192DEEF801F81E84FD3-wk-Fact-7501CCEC7B4D0192DEEF801F81E84FD3"
          xlink:to="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2419-wk-Fact-752CABA8E508F4880C7C801F81391188"
          xlink:label="d34428379e2419-wk-Fact-752CABA8E508F4880C7C801F81391188"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2419-wk-Fact-752CABA8E508F4880C7C801F81391188"
          xlink:to="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2419-wk-Fact-752CABA8E508F4880C7C801F81391188"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24736-wk-Fact-753465D7A627C0C6C864801F7E922133"
          xlink:label="d34661879e24736-wk-Fact-753465D7A627C0C6C864801F7E922133"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24736-wk-Fact-753465D7A627C0C6C864801F7E922133"
          xlink:to="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24736-wk-Fact-753465D7A627C0C6C864801F7E922133"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4507-wk-Fact-753BABE650466031F517AB460A3BD22C"
          xlink:label="d34458036e4507-wk-Fact-753BABE650466031F517AB460A3BD22C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e4596-wk-Fact-753BABE650466031F517AB460A3BD22C"
          xlink:label="d34458036e4596-wk-Fact-753BABE650466031F517AB460A3BD22C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4507-wk-Fact-753BABE650466031F517AB460A3BD22C"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4596-wk-Fact-753BABE650466031F517AB460A3BD22C"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e27650-wk-Fact-753DD635276562AAADD0801F7E9ACA47"
          xlink:label="d34661879e27650-wk-Fact-753DD635276562AAADD0801F7E9ACA47"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e27650-wk-Fact-753DD635276562AAADD0801F7E9ACA47"
          xlink:to="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14523-wk-Fact-759056D49537AAD9E899801F7F0EAFC2"
          xlink:label="d34661879e14523-wk-Fact-759056D49537AAD9E899801F7F0EAFC2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14523-wk-Fact-759056D49537AAD9E899801F7F0EAFC2"
          xlink:to="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8401-wk-Fact-759DF68F819A59389A4AC00C6D1F61C6"
          xlink:label="d34586122e8401-wk-Fact-759DF68F819A59389A4AC00C6D1F61C6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8401-wk-Fact-759DF68F819A59389A4AC00C6D1F61C6"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8401-wk-Fact-759DF68F819A59389A4AC00C6D1F61C6"
          xlink:to="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11678-wk-Fact-75D45301C70951D3867054250941F9AE"
          xlink:label="d34586122e11678-wk-Fact-75D45301C70951D3867054250941F9AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11678-wk-Fact-75D45301C70951D3867054250941F9AE"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2898-wk-Fact-75F7E84A031750E0A49F77B3AEF45671"
          xlink:label="d34423000e2898-wk-Fact-75F7E84A031750E0A49F77B3AEF45671"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2898-wk-Fact-75F7E84A031750E0A49F77B3AEF45671"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3901-wk-Fact-760E7E634C39F63FC233801F7E0F6B98"
          xlink:label="d34458032e3901-wk-Fact-760E7E634C39F63FC233801F7E0F6B98"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3901-wk-Fact-760E7E634C39F63FC233801F7E0F6B98"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3901-wk-Fact-760E7E634C39F63FC233801F7E0F6B98"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2149-wk-Fact-7613A3BE7B3C52548720187D3E9B29CB"
          xlink:label="d34423000e2149-wk-Fact-7613A3BE7B3C52548720187D3E9B29CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2149-wk-Fact-7613A3BE7B3C52548720187D3E9B29CB"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22951-wk-Fact-761A045667090BCC60CB801F7E75C1C9"
          xlink:label="d34661879e22951-wk-Fact-761A045667090BCC60CB801F7E75C1C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22951-wk-Fact-761A045667090BCC60CB801F7E75C1C9"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22422-wk-Fact-7658020187599961F4A5801F80F4D671"
          xlink:label="d34661879e22422-wk-Fact-7658020187599961F4A5801F80F4D671"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22422-wk-Fact-7658020187599961F4A5801F80F4D671"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10942-wk-Fact-76700083BB585619B1B78E77F16D4429"
          xlink:label="d34586122e10942-wk-Fact-76700083BB585619B1B78E77F16D4429"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10942-wk-Fact-76700083BB585619B1B78E77F16D4429"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3436-wk-Fact-769F1280EBF192E593C5801F7F419E21"
          xlink:label="d34430544e3436-wk-Fact-769F1280EBF192E593C5801F7F419E21"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34523018e2680-wk-Fact-769F1280EBF192E593C5801F7F419E21"
          xlink:label="d34523018e2680-wk-Fact-769F1280EBF192E593C5801F7F419E21"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3436-wk-Fact-769F1280EBF192E593C5801F7F419E21"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2680-wk-Fact-769F1280EBF192E593C5801F7F419E21"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3436-wk-Fact-769F1280EBF192E593C5801F7F419E21"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2680-wk-Fact-769F1280EBF192E593C5801F7F419E21"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11643-wk-Fact-76BFF3E0ECCB06EAD23D801F82CA7536"
          xlink:label="d34586122e11643-wk-Fact-76BFF3E0ECCB06EAD23D801F82CA7536"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11643-wk-Fact-76BFF3E0ECCB06EAD23D801F82CA7536"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e12151-wk-Fact-772A4F70D4985AACB86E028464DB65E7"
          xlink:label="d34586122e12151-wk-Fact-772A4F70D4985AACB86E028464DB65E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e12151-wk-Fact-772A4F70D4985AACB86E028464DB65E7"
          xlink:to="TextSelection-28B7FD6277F0F57BFCCE801F8352A34C-0-wk-Footnote-28B7FD6277F0F57BFCCE801F8352A34C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3273-wk-Fact-7747152390E65C85B0029AEB713C8F55"
          xlink:label="d34423000e3273-wk-Fact-7747152390E65C85B0029AEB713C8F55"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3273-wk-Fact-7747152390E65C85B0029AEB713C8F55"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2474-wk-Fact-77801D3C57905C8C93FABB42EA4BACE1"
          xlink:label="d34423000e2474-wk-Fact-77801D3C57905C8C93FABB42EA4BACE1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2474-wk-Fact-77801D3C57905C8C93FABB42EA4BACE1"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8495-wk-Fact-778F76F534866B4C274BDE209664FDB1"
          xlink:label="d34586122e8495-wk-Fact-778F76F534866B4C274BDE209664FDB1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8495-wk-Fact-778F76F534866B4C274BDE209664FDB1"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5350-wk-Fact-783053BF5BCEAF088BA3801F7F1B9FD6"
          xlink:label="d34545404e5350-wk-Fact-783053BF5BCEAF088BA3801F7F1B9FD6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5350-wk-Fact-783053BF5BCEAF088BA3801F7F1B9FD6"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-90990489192C50447F2C801F831133E5-0-wk-Footnote-90990489192C50447F2C801F831133E5_lbl" xlink:label="TextSelection-90990489192C50447F2C801F831133E5-0-wk-Footnote-90990489192C50447F2C801F831133E5_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">The amounts in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;text-align:center;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> are reduced for unrecognized tax benefits of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$2.9 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$3.3 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, respectively, where we have net operating loss carryforwards, similar tax losses, and/or tax credit carryforwards that are available, under the tax law of the applicable jurisdiction, to settle any additional income taxes that would result from the disallowance of a tax position. </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5350-wk-Fact-783053BF5BCEAF088BA3801F7F1B9FD6"
          xlink:to="TextSelection-90990489192C50447F2C801F831133E5-0-wk-Footnote-90990489192C50447F2C801F831133E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e1606-wk-Fact-7891E4C59FB8C240ECF8801F7ED8C974"
          xlink:label="d34594690e1606-wk-Fact-7891E4C59FB8C240ECF8801F7ED8C974"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e1606-wk-Fact-7891E4C59FB8C240ECF8801F7ED8C974"
          xlink:to="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3032-wk-Fact-789D85DCBD5CAAFAC780801F7E9C6FBB"
          xlink:label="d34423000e3032-wk-Fact-789D85DCBD5CAAFAC780801F7E9C6FBB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3032-wk-Fact-789D85DCBD5CAAFAC780801F7E9C6FBB"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2144-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409"
          xlink:label="d34468079e2144-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e1883-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409"
          xlink:label="d34430544e1883-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2144-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1883-wk-Fact-78C729D57DE6667BF6E4801F7F4CA409"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2355-wk-Fact-78EA4E1EB168C708F8A0801F7E99078A"
          xlink:label="d34458036e2355-wk-Fact-78EA4E1EB168C708F8A0801F7E99078A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2355-wk-Fact-78EA4E1EB168C708F8A0801F7E99078A"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21371-wk-Fact-7901A59E0B6D8AB6EE3A801F81370C3C"
          xlink:label="d34661879e21371-wk-Fact-7901A59E0B6D8AB6EE3A801F81370C3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21371-wk-Fact-7901A59E0B6D8AB6EE3A801F81370C3C"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4096-wk-Fact-7918FE9F0C5FFB8CDA07801F8037553C"
          xlink:label="d34458032e4096-wk-Fact-7918FE9F0C5FFB8CDA07801F8037553C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4096-wk-Fact-7918FE9F0C5FFB8CDA07801F8037553C"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10517-wk-Fact-791EAF9C41A719B8AE07801F821A4C3E"
          xlink:label="d34661879e10517-wk-Fact-791EAF9C41A719B8AE07801F821A4C3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10517-wk-Fact-791EAF9C41A719B8AE07801F821A4C3E"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2070-wk-Fact-7952617F186F5E01B2B1132FE8B404CC"
          xlink:label="d34428379e2070-wk-Fact-7952617F186F5E01B2B1132FE8B404CC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2070-wk-Fact-7952617F186F5E01B2B1132FE8B404CC"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2070-wk-Fact-7952617F186F5E01B2B1132FE8B404CC"
          xlink:to="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9130-wk-Fact-798874FBBD7A57AD8D423B83A189AC62"
          xlink:label="d34458032e9130-wk-Fact-798874FBBD7A57AD8D423B83A189AC62"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9130-wk-Fact-798874FBBD7A57AD8D423B83A189AC62"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e1903-wk-Fact-798B7A350A5E13556B82801F82A90157"
          xlink:label="d34460716e1903-wk-Fact-798B7A350A5E13556B82801F82A90157"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e1903-wk-Fact-798B7A350A5E13556B82801F82A90157"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2442-wk-Fact-7993C88B8674482BA763E3D78533039D"
          xlink:label="d34471435e2442-wk-Fact-7993C88B8674482BA763E3D78533039D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl" xlink:label="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">See </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2442-wk-Fact-7993C88B8674482BA763E3D78533039D"
          xlink:to="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4705-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04"
          xlink:label="d34529301e4705-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e2031-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04"
          xlink:label="d34423000e2031-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4705-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2031-wk-Fact-799C06C37CC65B608ECD5EF0A1F11C04"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D"
          xlink:label="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D"
          xlink:to="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5609-wk-Fact-79E8EC5CB80652D28BC54F6EEDE9EE7D"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2683-wk-Fact-7A0B0B97234568FCF5ED801F8263730F"
          xlink:label="d34428379e2683-wk-Fact-7A0B0B97234568FCF5ED801F8263730F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2683-wk-Fact-7A0B0B97234568FCF5ED801F8263730F"
          xlink:to="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2683-wk-Fact-7A0B0B97234568FCF5ED801F8263730F"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2679-wk-Fact-7A1567D519C2CFE241FC801F7EDF7AAB"
          xlink:label="d34468079e2679-wk-Fact-7A1567D519C2CFE241FC801F7EDF7AAB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2679-wk-Fact-7A1567D519C2CFE241FC801F7EDF7AAB"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e7877-wk-Fact-7A6A6BE7AC6954D4AA27EA74C266AF79"
          xlink:label="d34545404e7877-wk-Fact-7A6A6BE7AC6954D4AA27EA74C266AF79"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl" xlink:label="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Taxes are not provided for foreign currency translation adjustments relating to investments in international subsidiaries that will be held indefinitely.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7877-wk-Fact-7A6A6BE7AC6954D4AA27EA74C266AF79"
          xlink:to="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3958-wk-Fact-7A6C38FEB7545F758C160BD056416478"
          xlink:label="d34458036e3958-wk-Fact-7A6C38FEB7545F758C160BD056416478"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3958-wk-Fact-7A6C38FEB7545F758C160BD056416478"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2110-wk-Fact-7A7351669AE1529E97E70E745B581A4A"
          xlink:label="d34471435e2110-wk-Fact-7A7351669AE1529E97E70E745B581A4A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2110-wk-Fact-7A7351669AE1529E97E70E745B581A4A"
          xlink:to="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2206-wk-Fact-7AB6A34649A53C89765A801F808558FA"
          xlink:label="d34430544e2206-wk-Fact-7AB6A34649A53C89765A801F808558FA"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34523018e1655-wk-Fact-7AB6A34649A53C89765A801F808558FA"
          xlink:label="d34523018e1655-wk-Fact-7AB6A34649A53C89765A801F808558FA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2206-wk-Fact-7AB6A34649A53C89765A801F808558FA"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e1655-wk-Fact-7AB6A34649A53C89765A801F808558FA"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2116-wk-Fact-7B2716E1C24FE2422E5FCF6EF0CCB67A"
          xlink:label="d34460716e2116-wk-Fact-7B2716E1C24FE2422E5FCF6EF0CCB67A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2116-wk-Fact-7B2716E1C24FE2422E5FCF6EF0CCB67A"
          xlink:to="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3227-wk-Fact-7B3EE432FBB3579996CA5926DC51D999"
          xlink:label="d34423000e3227-wk-Fact-7B3EE432FBB3579996CA5926DC51D999"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3227-wk-Fact-7B3EE432FBB3579996CA5926DC51D999"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e2988-wk-Fact-7BA94F9ED2EC5F1A966CB3304B53AF56"
          xlink:label="d34501946e2988-wk-Fact-7BA94F9ED2EC5F1A966CB3304B53AF56"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e2988-wk-Fact-7BA94F9ED2EC5F1A966CB3304B53AF56"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3427-wk-Fact-7BB330D73286C9EA44FD801F8148FF86"
          xlink:label="d34594690e3427-wk-Fact-7BB330D73286C9EA44FD801F8148FF86"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3427-wk-Fact-7BB330D73286C9EA44FD801F8148FF86"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3427-wk-Fact-7BB330D73286C9EA44FD801F8148FF86"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2265-wk-Fact-7BBA68F22C4A3BB9286A801F7F95841D"
          xlink:label="d34460716e2265-wk-Fact-7BBA68F22C4A3BB9286A801F7F95841D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2265-wk-Fact-7BBA68F22C4A3BB9286A801F7F95841D"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34498941e1559-wk-Fact-7BD53D154D3451E59F8DCFF457C25E21"
          xlink:label="d34498941e1559-wk-Fact-7BD53D154D3451E59F8DCFF457C25E21"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-80773A0CFA5531791DCE801F8317B622-0-wk-Footnote-80773A0CFA5531791DCE801F8317B622_lbl" xlink:label="TextSelection-80773A0CFA5531791DCE801F8317B622-0-wk-Footnote-80773A0CFA5531791DCE801F8317B622_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7F</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34498941e1559-wk-Fact-7BD53D154D3451E59F8DCFF457C25E21"
          xlink:to="TextSelection-80773A0CFA5531791DCE801F8317B622-0-wk-Footnote-80773A0CFA5531791DCE801F8317B622_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2833-wk-Fact-7C5CEEA458045143ABEBEAB70E5E4CE1"
          xlink:label="d34468079e2833-wk-Fact-7C5CEEA458045143ABEBEAB70E5E4CE1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2833-wk-Fact-7C5CEEA458045143ABEBEAB70E5E4CE1"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1678-wk-Fact-7C95FE45B026572C9C6575056E409438"
          xlink:label="d34423000e1678-wk-Fact-7C95FE45B026572C9C6575056E409438"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1678-wk-Fact-7C95FE45B026572C9C6575056E409438"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4163-wk-Fact-7CA1E8DB0EEA61585658801F8257D851"
          xlink:label="d34458032e4163-wk-Fact-7CA1E8DB0EEA61585658801F8257D851"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4163-wk-Fact-7CA1E8DB0EEA61585658801F8257D851"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3787-wk-Fact-7CE1E0EF766B581893CBC5A1DB76D621"
          xlink:label="d34586122e3787-wk-Fact-7CE1E0EF766B581893CBC5A1DB76D621"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3787-wk-Fact-7CE1E0EF766B581893CBC5A1DB76D621"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11604-wk-Fact-7CFB7F412548587F896D99F507DBCD19"
          xlink:label="d34586122e11604-wk-Fact-7CFB7F412548587F896D99F507DBCD19"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11604-wk-Fact-7CFB7F412548587F896D99F507DBCD19"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14830-wk-Fact-7D0DED212B5AD84E6737801F7F10668E"
          xlink:label="d34661879e14830-wk-Fact-7D0DED212B5AD84E6737801F7F10668E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14830-wk-Fact-7D0DED212B5AD84E6737801F7F10668E"
          xlink:to="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6705-wk-Fact-7D359D4DCFEB1E002351801F7DEFB4FE"
          xlink:label="d34458032e6705-wk-Fact-7D359D4DCFEB1E002351801F7DEFB4FE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6705-wk-Fact-7D359D4DCFEB1E002351801F7DEFB4FE"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24200-wk-Fact-7D93FC3424C9D543074F801F7E17454A"
          xlink:label="d34661879e24200-wk-Fact-7D93FC3424C9D543074F801F7E17454A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24200-wk-Fact-7D93FC3424C9D543074F801F7E17454A"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24200-wk-Fact-7D93FC3424C9D543074F801F7E17454A"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427"
          xlink:label="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3978-wk-Fact-7DA502580CA05DFDBF5C1B80E7D1A427"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7709-wk-Fact-7DD40C3C0E31507482EEDE2CEC4E867A"
          xlink:label="d34586122e7709-wk-Fact-7DD40C3C0E31507482EEDE2CEC4E867A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7709-wk-Fact-7DD40C3C0E31507482EEDE2CEC4E867A"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4719-wk-Fact-7DDB8A53183E908A30E5801F80CDA452"
          xlink:label="d34586122e4719-wk-Fact-7DDB8A53183E908A30E5801F80CDA452"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34471435e2375-wk-Fact-7DDB8A53183E908A30E5801F80CDA452"
          xlink:label="d34471435e2375-wk-Fact-7DDB8A53183E908A30E5801F80CDA452"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4719-wk-Fact-7DDB8A53183E908A30E5801F80CDA452"
          xlink:to="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2375-wk-Fact-7DDB8A53183E908A30E5801F80CDA452"
          xlink:to="TextSelection-8C5A30D25594BFE918E2801F830D83A7-0-wk-Footnote-8C5A30D25594BFE918E2801F830D83A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8957-wk-Fact-7DFD68914530594697567F87F6C1044E"
          xlink:label="d34458032e8957-wk-Fact-7DFD68914530594697567F87F6C1044E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8957-wk-Fact-7DFD68914530594697567F87F6C1044E"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2023-wk-Fact-7E730D2AED1D0795DF3D801F82A5E242"
          xlink:label="d34458036e2023-wk-Fact-7E730D2AED1D0795DF3D801F82A5E242"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2023-wk-Fact-7E730D2AED1D0795DF3D801F82A5E242"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2023-wk-Fact-7E730D2AED1D0795DF3D801F82A5E242"
          xlink:to="TextSelection-B5C9C58A773D6453CA3C801F82F96540-0-wk-Footnote-B5C9C58A773D6453CA3C801F82F96540_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26"
          xlink:label="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5268-wk-Fact-7ED237CC746A5E8BAAAD13E73CCAED26"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8713-wk-Fact-7F748C891A4E562C8DD5B4D163881419"
          xlink:label="d34545404e8713-wk-Fact-7F748C891A4E562C8DD5B4D163881419"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8713-wk-Fact-7F748C891A4E562C8DD5B4D163881419"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1943-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:label="d34423000e1943-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e6272-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:label="d34586122e6272-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34514486e1927-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:label="d34514486e1927-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1943-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6272-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34514486e1927-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl" xlink:label="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"> </link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1943-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:to="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6272-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:to="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34514486e1927-wk-Fact-7F7E046052F852439B2A0884F029C60C"
          xlink:to="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4037-wk-Fact-7F97E24FF7E81A914961801F825D5D9B"
          xlink:label="d34545404e4037-wk-Fact-7F97E24FF7E81A914961801F825D5D9B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4037-wk-Fact-7F97E24FF7E81A914961801F825D5D9B"
          xlink:to="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4037-wk-Fact-7F97E24FF7E81A914961801F825D5D9B"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4601-wk-Fact-7F9C57983A364C82C7B8D85DDABE68FA"
          xlink:label="d34529301e4601-wk-Fact-7F9C57983A364C82C7B8D85DDABE68FA"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl" xlink:label="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Primarily reflects the reclassification of our Consumer Healthcare business as</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">held for sale (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">), the impact of foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4601-wk-Fact-7F9C57983A364C82C7B8D85DDABE68FA"
          xlink:to="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4960-wk-Fact-7FAB76E95E2266217B40801F7FD40652"
          xlink:label="d34661879e4960-wk-Fact-7FAB76E95E2266217B40801F7FD40652"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4960-wk-Fact-7FAB76E95E2266217B40801F7FD40652"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5708-wk-Fact-7FCA3EEAD1E583C6014B801F7F1DA91D"
          xlink:label="d34545404e5708-wk-Fact-7FCA3EEAD1E583C6014B801F7F1DA91D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5708-wk-Fact-7FCA3EEAD1E583C6014B801F7F1DA91D"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e1948-wk-Fact-7FFA047BAF9ADE9DA824801F81229B16"
          xlink:label="d34468079e1948-wk-Fact-7FFA047BAF9ADE9DA824801F81229B16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1948-wk-Fact-7FFA047BAF9ADE9DA824801F81229B16"
          xlink:to="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2500-wk-Fact-80135A3F2616CE4B3FFE801F7E2617E5"
          xlink:label="d34460716e2500-wk-Fact-80135A3F2616CE4B3FFE801F7E2617E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2500-wk-Fact-80135A3F2616CE4B3FFE801F7E2617E5"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9201-wk-Fact-801912F69D61590398C5CEEE0D4764FE"
          xlink:label="d34586122e9201-wk-Fact-801912F69D61590398C5CEEE0D4764FE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9201-wk-Fact-801912F69D61590398C5CEEE0D4764FE"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e6695-wk-Fact-8027040D1DF4721D6272801F7F0F7A3C"
          xlink:label="d34594690e6695-wk-Fact-8027040D1DF4721D6272801F7F0F7A3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e6695-wk-Fact-8027040D1DF4721D6272801F7F0F7A3C"
          xlink:to="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2990-wk-Fact-80382989DBE2B2A99A05801F7F3B9C46"
          xlink:label="d34430544e2990-wk-Fact-80382989DBE2B2A99A05801F7F3B9C46"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2990-wk-Fact-80382989DBE2B2A99A05801F7F3B9C46"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e7548-wk-Fact-8060BA9EC76EA962A052801F7EFC1E79"
          xlink:label="d34661879e7548-wk-Fact-8060BA9EC76EA962A052801F7EFC1E79"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e7548-wk-Fact-8060BA9EC76EA962A052801F7EFC1E79"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843"
          xlink:label="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843"
          xlink:to="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5772-wk-Fact-80CEAE93649A00F15E35E5206F8C2843"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB"
          xlink:label="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24277-wk-Fact-80D9719F15C10923EB77801F7EBC12FB"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3782-wk-Fact-80E620F0079F9C476673AB460A2BDC83"
          xlink:label="d34458036e3782-wk-Fact-80E620F0079F9C476673AB460A2BDC83"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3782-wk-Fact-80E620F0079F9C476673AB460A2BDC83"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9910-wk-Fact-80FEC9DEE7D7156F2215801F8243459B"
          xlink:label="d34458032e9910-wk-Fact-80FEC9DEE7D7156F2215801F8243459B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9910-wk-Fact-80FEC9DEE7D7156F2215801F8243459B"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9127-wk-Fact-810B1FD04766529CA8FCD18FC3883D4B"
          xlink:label="d34586122e9127-wk-Fact-810B1FD04766529CA8FCD18FC3883D4B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9127-wk-Fact-810B1FD04766529CA8FCD18FC3883D4B"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9127-wk-Fact-810B1FD04766529CA8FCD18FC3883D4B"
          xlink:to="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8941-wk-Fact-813264E7C289A5D5ECB7DE20AAB91829"
          xlink:label="d34586122e8941-wk-Fact-813264E7C289A5D5ECB7DE20AAB91829"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8941-wk-Fact-813264E7C289A5D5ECB7DE20AAB91829"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1656-wk-Fact-813E0BD933FADF623E45801F80DB191F"
          xlink:label="d34471435e1656-wk-Fact-813E0BD933FADF623E45801F80DB191F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1656-wk-Fact-813E0BD933FADF623E45801F80DB191F"
          xlink:to="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5509-wk-Fact-81475F9812C2036C8F54801F821721D4"
          xlink:label="d34506804e5509-wk-Fact-81475F9812C2036C8F54801F821721D4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5509-wk-Fact-81475F9812C2036C8F54801F821721D4"
          xlink:to="TextSelection-A31525DEB3F7F319ACBB801F83036AB0-0-wk-Footnote-A31525DEB3F7F319ACBB801F83036AB0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9240-wk-Fact-81945090A4FFE403DEA2DE22C004E729"
          xlink:label="d34586122e9240-wk-Fact-81945090A4FFE403DEA2DE22C004E729"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9240-wk-Fact-81945090A4FFE403DEA2DE22C004E729"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24756-wk-Fact-81BF9447839E6277781D801F8110D158"
          xlink:label="d34661879e24756-wk-Fact-81BF9447839E6277781D801F8110D158"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24756-wk-Fact-81BF9447839E6277781D801F8110D158"
          xlink:to="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24756-wk-Fact-81BF9447839E6277781D801F8110D158"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2122-wk-Fact-81C7586111FF1F4FF011CB2DE6212D3A"
          xlink:label="d34458032e2122-wk-Fact-81C7586111FF1F4FF011CB2DE6212D3A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2122-wk-Fact-81C7586111FF1F4FF011CB2DE6212D3A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11421-wk-Fact-821C54ED7C862C84B170801F7E88C49D"
          xlink:label="d34586122e11421-wk-Fact-821C54ED7C862C84B170801F7E88C49D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11421-wk-Fact-821C54ED7C862C84B170801F7E88C49D"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2886-wk-Fact-823CFC536B2415CC760F801F821963E0"
          xlink:label="d34661879e2886-wk-Fact-823CFC536B2415CC760F801F821963E0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9771-wk-Fact-823CFC536B2415CC760F801F821963E0"
          xlink:label="d34661879e9771-wk-Fact-823CFC536B2415CC760F801F821963E0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2886-wk-Fact-823CFC536B2415CC760F801F821963E0"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9771-wk-Fact-823CFC536B2415CC760F801F821963E0"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2886-wk-Fact-823CFC536B2415CC760F801F821963E0"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9771-wk-Fact-823CFC536B2415CC760F801F821963E0"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23428-wk-Fact-825A924821B029DD3CBD801F7E981ACD"
          xlink:label="d34661879e23428-wk-Fact-825A924821B029DD3CBD801F7E981ACD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23428-wk-Fact-825A924821B029DD3CBD801F7E981ACD"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2233-wk-Fact-8266B3DB731A5825ABEED6BC4888318C"
          xlink:label="d34529301e2233-wk-Fact-8266B3DB731A5825ABEED6BC4888318C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2233-wk-Fact-8266B3DB731A5825ABEED6BC4888318C"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3274-wk-Fact-82DF9C203377249F2601AB460A6EF1A6"
          xlink:label="d34458036e3274-wk-Fact-82DF9C203377249F2601AB460A6EF1A6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3274-wk-Fact-82DF9C203377249F2601AB460A6EF1A6"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3932-wk-Fact-82F8E32880CAD288D376801F7EB6D6B3"
          xlink:label="d34458036e3932-wk-Fact-82F8E32880CAD288D376801F7EB6D6B3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3932-wk-Fact-82F8E32880CAD288D376801F7EB6D6B3"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e5040-wk-Fact-831DB9576209A9ACB46A801F7FE98854"
          xlink:label="d34661879e5040-wk-Fact-831DB9576209A9ACB46A801F7FE98854"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e5040-wk-Fact-831DB9576209A9ACB46A801F7FE98854"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3698-wk-Fact-8322EE49CD6D5BD6A6C9E81023F930D3"
          xlink:label="d34458036e3698-wk-Fact-8322EE49CD6D5BD6A6C9E81023F930D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3698-wk-Fact-8322EE49CD6D5BD6A6C9E81023F930D3"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24852-wk-Fact-83666425473B48E80163801F7E7455A0"
          xlink:label="d34661879e24852-wk-Fact-83666425473B48E80163801F7E7455A0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24852-wk-Fact-83666425473B48E80163801F7E7455A0"
          xlink:to="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24852-wk-Fact-83666425473B48E80163801F7E7455A0"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2177-wk-Fact-8376203D932F5639A955E3156349142D"
          xlink:label="d34471435e2177-wk-Fact-8376203D932F5639A955E3156349142D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2177-wk-Fact-8376203D932F5639A955E3156349142D"
          xlink:to="TextSelection-7697A0CA92ECD57A95D4801F830CEDD7-0-wk-Footnote-7697A0CA92ECD57A95D4801F830CEDD7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11929-wk-Fact-83D643576F2E4A880436DE3EC9DE5D5D"
          xlink:label="d34586122e11929-wk-Fact-83D643576F2E4A880436DE3EC9DE5D5D"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl" xlink:label="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Represents HIS revenues through February 2, 2017, which includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. On February 3, 2017, we completed the sale of HIS to ICU Medical. For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11929-wk-Fact-83D643576F2E4A880436DE3EC9DE5D5D"
          xlink:to="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1689-wk-Fact-83E1143E04F5A91F1232801F80AB7507"
          xlink:label="d34430544e1689-wk-Fact-83E1143E04F5A91F1232801F80AB7507"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1689-wk-Fact-83E1143E04F5A91F1232801F80AB7507"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1689-wk-Fact-83E1143E04F5A91F1232801F80AB7507"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3013-wk-Fact-8413E641C55A4976D254801F7EBA5C58"
          xlink:label="d34458036e3013-wk-Fact-8413E641C55A4976D254801F7EBA5C58"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3013-wk-Fact-8413E641C55A4976D254801F7EBA5C58"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11125-wk-Fact-841D58224C20C05AA3AF801F82B7E834"
          xlink:label="d34586122e11125-wk-Fact-841D58224C20C05AA3AF801F82B7E834"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11125-wk-Fact-841D58224C20C05AA3AF801F82B7E834"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24384-wk-Fact-846B26327BEE6C94A307801F8102D6F8"
          xlink:label="d34661879e24384-wk-Fact-846B26327BEE6C94A307801F8102D6F8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24384-wk-Fact-846B26327BEE6C94A307801F8102D6F8"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10061-wk-Fact-8479D37C35D17BB7F483DE31473AEC66"
          xlink:label="d34586122e10061-wk-Fact-8479D37C35D17BB7F483DE31473AEC66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10061-wk-Fact-8479D37C35D17BB7F483DE31473AEC66"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10061-wk-Fact-8479D37C35D17BB7F483DE31473AEC66"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3160-wk-Fact-84A9A3C57D9468DD47C4801F80615D38"
          xlink:label="d34458032e3160-wk-Fact-84A9A3C57D9468DD47C4801F80615D38"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3160-wk-Fact-84A9A3C57D9468DD47C4801F80615D38"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21633-wk-Fact-84CFAE8D822C91DEF42D801F80EA8284"
          xlink:label="d34661879e21633-wk-Fact-84CFAE8D822C91DEF42D801F80EA8284"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21633-wk-Fact-84CFAE8D822C91DEF42D801F80EA8284"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22970-wk-Fact-851A65644168F7A09FFC801F80C5042F"
          xlink:label="d34661879e22970-wk-Fact-851A65644168F7A09FFC801F80C5042F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22970-wk-Fact-851A65644168F7A09FFC801F80C5042F"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3717-wk-Fact-855EC1B85F5A5E84B3ACFB91DAA41FBE"
          xlink:label="d34458036e3717-wk-Fact-855EC1B85F5A5E84B3ACFB91DAA41FBE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3717-wk-Fact-855EC1B85F5A5E84B3ACFB91DAA41FBE"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3299-wk-Fact-856AC81ACCEC5011ACDEA26123CED5EE"
          xlink:label="d34423000e3299-wk-Fact-856AC81ACCEC5011ACDEA26123CED5EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3299-wk-Fact-856AC81ACCEC5011ACDEA26123CED5EE"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e7120-wk-Fact-85827D800B7F9E2973DA801F80DC2984"
          xlink:label="d34545404e7120-wk-Fact-85827D800B7F9E2973DA801F80DC2984"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7120-wk-Fact-85827D800B7F9E2973DA801F80DC2984"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7120-wk-Fact-85827D800B7F9E2973DA801F80DC2984"
          xlink:to="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5467-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:label="d34586122e5467-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e6766-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:label="d34586122e6766-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e1478-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:label="d34430544e1478-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e4283-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:label="d34586122e4283-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5467-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6766-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1478-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4283-wk-Fact-85AE677FB4BE5835853FEF3A42BFC03E"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD"
          xlink:label="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD"
          xlink:to="TextSelection-7C71A3E3A519BAC893B6801F8319FB37-0-wk-Footnote-7C71A3E3A519BAC893B6801F8319FB37_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6506-wk-Fact-85C6357352EBB588EA3A654B1EBD0EAD"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10457-wk-Fact-85CA80585D2874D45B54801F82219616"
          xlink:label="d34661879e10457-wk-Fact-85CA80585D2874D45B54801F82219616"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10457-wk-Fact-85CA80585D2874D45B54801F82219616"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9946-wk-Fact-85E9E7AA5D595959A86313A1C0CA3A83"
          xlink:label="d34586122e9946-wk-Fact-85E9E7AA5D595959A86313A1C0CA3A83"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9946-wk-Fact-85E9E7AA5D595959A86313A1C0CA3A83"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1737-wk-Fact-860CFBCF363653FC86BC0095D64D864D"
          xlink:label="d34428379e1737-wk-Fact-860CFBCF363653FC86BC0095D64D864D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1737-wk-Fact-860CFBCF363653FC86BC0095D64D864D"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2"
          xlink:label="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6257-wk-Fact-862BFB202BCE5796ADEF2A6B6F9B22C2"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3957-wk-Fact-86415D4CAB5E59DBBD55EC735E24E7F2"
          xlink:label="d34471435e3957-wk-Fact-86415D4CAB5E59DBBD55EC735E24E7F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3957-wk-Fact-86415D4CAB5E59DBBD55EC735E24E7F2"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3957-wk-Fact-86415D4CAB5E59DBBD55EC735E24E7F2"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2487-wk-Fact-8641DEB0F388E97194C5801F8260F41E"
          xlink:label="d34458036e2487-wk-Fact-8641DEB0F388E97194C5801F8260F41E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2487-wk-Fact-8641DEB0F388E97194C5801F8260F41E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5597-wk-Fact-868049DF95AAA71CE427801F81DEE776"
          xlink:label="d34506804e5597-wk-Fact-868049DF95AAA71CE427801F81DEE776"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5597-wk-Fact-868049DF95AAA71CE427801F81DEE776"
          xlink:to="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3545-wk-Fact-86C1962CA09E5E038A8356A346B1940A"
          xlink:label="d34423000e3545-wk-Fact-86C1962CA09E5E038A8356A346B1940A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3545-wk-Fact-86C1962CA09E5E038A8356A346B1940A"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19119-wk-Fact-86DEF6460514D6862E92801F80F116B8"
          xlink:label="d34661879e19119-wk-Fact-86DEF6460514D6862E92801F80F116B8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19119-wk-Fact-86DEF6460514D6862E92801F80F116B8"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2102-wk-Fact-86FCF4A9AC35C93C9512CB2DE640F043"
          xlink:label="d34458032e2102-wk-Fact-86FCF4A9AC35C93C9512CB2DE640F043"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2102-wk-Fact-86FCF4A9AC35C93C9512CB2DE640F043"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9464-wk-Fact-871389EB45915ACC83623B1FF4BA7915"
          xlink:label="d34458032e9464-wk-Fact-871389EB45915ACC83623B1FF4BA7915"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9464-wk-Fact-871389EB45915ACC83623B1FF4BA7915"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5898-wk-Fact-87316DD24D8C6C196E84801F813793DC"
          xlink:label="d34545404e5898-wk-Fact-87316DD24D8C6C196E84801F813793DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5898-wk-Fact-87316DD24D8C6C196E84801F813793DC"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11347-wk-Fact-8784FEB4B63967D223B8D083004C1A1D"
          xlink:label="d34586122e11347-wk-Fact-8784FEB4B63967D223B8D083004C1A1D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11347-wk-Fact-8784FEB4B63967D223B8D083004C1A1D"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11495-wk-Fact-87951FBDF4C375B6753E801F81755F3D"
          xlink:label="d34586122e11495-wk-Fact-87951FBDF4C375B6753E801F81755F3D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11495-wk-Fact-87951FBDF4C375B6753E801F81755F3D"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2533-wk-Fact-879A192382A7330D4759801F7E97C8E7"
          xlink:label="d34458036e2533-wk-Fact-879A192382A7330D4759801F7E97C8E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2533-wk-Fact-879A192382A7330D4759801F7E97C8E7"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6118-wk-Fact-87ADA00DA5C5D3DB1F1C801F7E7826DD"
          xlink:label="d34586122e6118-wk-Fact-87ADA00DA5C5D3DB1F1C801F7E7826DD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6118-wk-Fact-87ADA00DA5C5D3DB1F1C801F7E7826DD"
          xlink:to="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4968-wk-Fact-87DF5DD60C52EBFDCA12801F7F002312"
          xlink:label="d34458032e4968-wk-Fact-87DF5DD60C52EBFDCA12801F7F002312"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4968-wk-Fact-87DF5DD60C52EBFDCA12801F7F002312"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6071-wk-Fact-87E59A336B0A618A1F1D801F7E8AD801"
          xlink:label="d34586122e6071-wk-Fact-87E59A336B0A618A1F1D801F7E8AD801"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6071-wk-Fact-87E59A336B0A618A1F1D801F7E8AD801"
          xlink:to="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7748-wk-Fact-8806516F8B0543D58C87801F7DEE6452"
          xlink:label="d34586122e7748-wk-Fact-8806516F8B0543D58C87801F7DEE6452"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7748-wk-Fact-8806516F8B0543D58C87801F7DEE6452"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1782-wk-Fact-8812B04713F051B0AF0A1F76A2EBAA85"
          xlink:label="d34458036e1782-wk-Fact-8812B04713F051B0AF0A1F76A2EBAA85"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1782-wk-Fact-8812B04713F051B0AF0A1F76A2EBAA85"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9891-wk-Fact-881709D18F145B4CB609A31E6FB0D982"
          xlink:label="d34586122e9891-wk-Fact-881709D18F145B4CB609A31E6FB0D982"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9891-wk-Fact-881709D18F145B4CB609A31E6FB0D982"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5728-wk-Fact-8837BD3A347667C998B0801F7F1627AE"
          xlink:label="d34545404e5728-wk-Fact-8837BD3A347667C998B0801F7F1627AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5728-wk-Fact-8837BD3A347667C998B0801F7F1627AE"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e1818-wk-Fact-8847B6BEC2EEE8F6B106801F81DD12BF"
          xlink:label="d34468079e1818-wk-Fact-8847B6BEC2EEE8F6B106801F81DD12BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1818-wk-Fact-8847B6BEC2EEE8F6B106801F81DD12BF"
          xlink:to="TextSelection-44382EF51988B6CC47FB801F8303F83A-0-wk-Footnote-44382EF51988B6CC47FB801F8303F83A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19500-wk-Fact-885642E3FF5078D7E180801F8136338F"
          xlink:label="d34661879e19500-wk-Fact-885642E3FF5078D7E180801F8136338F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19500-wk-Fact-885642E3FF5078D7E180801F8136338F"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6936-wk-Fact-8882814ACBF86601CC36801F7E885BFB"
          xlink:label="d34586122e6936-wk-Fact-8882814ACBF86601CC36801F7E885BFB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6936-wk-Fact-8882814ACBF86601CC36801F7E885BFB"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14601-wk-Fact-88C4C82D6AD7A0143C97801F7F066B14"
          xlink:label="d34661879e14601-wk-Fact-88C4C82D6AD7A0143C97801F7F066B14"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14601-wk-Fact-88C4C82D6AD7A0143C97801F7F066B14"
          xlink:to="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10170-wk-Fact-88DB7F79687BCA54F881801F82414571"
          xlink:label="d34661879e10170-wk-Fact-88DB7F79687BCA54F881801F82414571"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10170-wk-Fact-88DB7F79687BCA54F881801F82414571"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8828-wk-Fact-88ED49AD8223552FBECDEDC3724ABA7A"
          xlink:label="d34586122e8828-wk-Fact-88ED49AD8223552FBECDEDC3724ABA7A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8828-wk-Fact-88ED49AD8223552FBECDEDC3724ABA7A"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1811-wk-Fact-88F8256AB81452CCA864D49A834C7EC7"
          xlink:label="d34423000e1811-wk-Fact-88F8256AB81452CCA864D49A834C7EC7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1811-wk-Fact-88F8256AB81452CCA864D49A834C7EC7"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21652-wk-Fact-8901B45EE693D1A5A42B801F7ECF7B1B"
          xlink:label="d34661879e21652-wk-Fact-8901B45EE693D1A5A42B801F7ECF7B1B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21652-wk-Fact-8901B45EE693D1A5A42B801F7ECF7B1B"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23132-wk-Fact-891D6E78C37A848AAD66801F8103A7FC"
          xlink:label="d34661879e23132-wk-Fact-891D6E78C37A848AAD66801F8103A7FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23132-wk-Fact-891D6E78C37A848AAD66801F8103A7FC"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23132-wk-Fact-891D6E78C37A848AAD66801F8103A7FC"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4879-wk-Fact-8927DC5325C709371727801F81339286"
          xlink:label="d34545404e4879-wk-Fact-8927DC5325C709371727801F81339286"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4879-wk-Fact-8927DC5325C709371727801F81339286"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10703-wk-Fact-893F257BDBDAF32100A5801F81FC6EC8"
          xlink:label="d34661879e10703-wk-Fact-893F257BDBDAF32100A5801F81FC6EC8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10703-wk-Fact-893F257BDBDAF32100A5801F81FC6EC8"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3978-wk-Fact-89458B2935BE5CA5AF20EE141CB4DDAE"
          xlink:label="d34458036e3978-wk-Fact-89458B2935BE5CA5AF20EE141CB4DDAE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3978-wk-Fact-89458B2935BE5CA5AF20EE141CB4DDAE"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2873-wk-Fact-897222CA063B5438BA0EAAE6C107C7B6"
          xlink:label="d34423000e2873-wk-Fact-897222CA063B5438BA0EAAE6C107C7B6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2873-wk-Fact-897222CA063B5438BA0EAAE6C107C7B6"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4178-wk-Fact-89A0361AA02CC1515879801F8245AD29"
          xlink:label="d34458032e4178-wk-Fact-89A0361AA02CC1515879801F8245AD29"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4178-wk-Fact-89A0361AA02CC1515879801F8245AD29"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4663-wk-Fact-89C1C2FF8BAE35AB2220801F7FC7C2B0"
          xlink:label="d34458032e4663-wk-Fact-89C1C2FF8BAE35AB2220801F7FC7C2B0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4663-wk-Fact-89C1C2FF8BAE35AB2220801F7FC7C2B0"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6720-wk-Fact-89DB22A158608FA629D2801F8240115D"
          xlink:label="d34458032e6720-wk-Fact-89DB22A158608FA629D2801F8240115D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6720-wk-Fact-89DB22A158608FA629D2801F8240115D"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8256-wk-Fact-89FA221AF605553CA7321BB43DD73142"
          xlink:label="d34458032e8256-wk-Fact-89FA221AF605553CA7321BB43DD73142"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8256-wk-Fact-89FA221AF605553CA7321BB43DD73142"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3828-wk-Fact-8A13EF2DD2417F08F8E0D083BFECB190"
          xlink:label="d34586122e3828-wk-Fact-8A13EF2DD2417F08F8E0D083BFECB190"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3828-wk-Fact-8A13EF2DD2417F08F8E0D083BFECB190"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2355-wk-Fact-8A1F93452E32511246DC801F7F0CF497"
          xlink:label="d34428379e2355-wk-Fact-8A1F93452E32511246DC801F7F0CF497"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2355-wk-Fact-8A1F93452E32511246DC801F7F0CF497"
          xlink:to="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2355-wk-Fact-8A1F93452E32511246DC801F7F0CF497"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2550-wk-Fact-8A35E5331DDD75689E2C801F829E69B4"
          xlink:label="d34428379e2550-wk-Fact-8A35E5331DDD75689E2C801F829E69B4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2550-wk-Fact-8A35E5331DDD75689E2C801F829E69B4"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3977-wk-Fact-8A3D3D8306295DD7A9624AA8071C2632"
          xlink:label="d34468079e3977-wk-Fact-8A3D3D8306295DD7A9624AA8071C2632"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3977-wk-Fact-8A3D3D8306295DD7A9624AA8071C2632"
          xlink:to="TextSelection-B696B296F7A2B6FEDE80DF32A09A7CEF-0-wk-Footnote-B696B296F7A2B6FEDE80DF32A09A7CEF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4526-wk-Fact-8A5BA32EB90D3260C033801F82C4798C"
          xlink:label="d34458036e4526-wk-Fact-8A5BA32EB90D3260C033801F82C4798C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4526-wk-Fact-8A5BA32EB90D3260C033801F82C4798C"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e5553-wk-Fact-8A8CC7E111309130A3F9023AB1C2B87A"
          xlink:label="d34496162e5553-wk-Fact-8A8CC7E111309130A3F9023AB1C2B87A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e5553-wk-Fact-8A8CC7E111309130A3F9023AB1C2B87A"
          xlink:to="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9669-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
          xlink:label="d34661879e9669-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e2730-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
          xlink:label="d34661879e2730-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9669-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2730-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9669-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2730-wk-Fact-8ACD50A587CEC7867541801F81EBAED4"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20304-wk-Fact-8ADF784CF3544B521652801F7DE5428D"
          xlink:label="d34661879e20304-wk-Fact-8ADF784CF3544B521652801F7DE5428D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20304-wk-Fact-8ADF784CF3544B521652801F7DE5428D"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6832-wk-Fact-8AF87FC965702ACF9270801F80DB9038"
          xlink:label="d34661879e6832-wk-Fact-8AF87FC965702ACF9270801F80DB9038"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6832-wk-Fact-8AF87FC965702ACF9270801F80DB9038"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9677-wk-Fact-8B4254960B2E50548FD24AC21D991E6A"
          xlink:label="d34458032e9677-wk-Fact-8B4254960B2E50548FD24AC21D991E6A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9677-wk-Fact-8B4254960B2E50548FD24AC21D991E6A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9677-wk-Fact-8B4254960B2E50548FD24AC21D991E6A"
          xlink:to="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3713-wk-Fact-8B63FA0079F150DF8891946F5AC894DF"
          xlink:label="d34468079e3713-wk-Fact-8B63FA0079F150DF8891946F5AC894DF"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl" xlink:label="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Included in </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other current liabilities</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$823 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">) and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent liabilities</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$428 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">).</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3713-wk-Fact-8B63FA0079F150DF8891946F5AC894DF"
          xlink:to="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2217-wk-Fact-8B8742C522CFC603BD73CF6F077A96B2"
          xlink:label="d34460716e2217-wk-Fact-8B8742C522CFC603BD73CF6F077A96B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2217-wk-Fact-8B8742C522CFC603BD73CF6F077A96B2"
          xlink:to="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24423-wk-Fact-8C4DF439940F0708B5F7801F7E87B8C4"
          xlink:label="d34661879e24423-wk-Fact-8C4DF439940F0708B5F7801F7E87B8C4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24423-wk-Fact-8C4DF439940F0708B5F7801F7E87B8C4"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2022-wk-Fact-8C7EA7D7F43807E0390D801F7ECD3AD1"
          xlink:label="d34428379e2022-wk-Fact-8C7EA7D7F43807E0390D801F7ECD3AD1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2022-wk-Fact-8C7EA7D7F43807E0390D801F7ECD3AD1"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2783-wk-Fact-8D2F59DA09B7FE8B09E6801F8148C80C"
          xlink:label="d34586122e2783-wk-Fact-8D2F59DA09B7FE8B09E6801F8148C80C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2783-wk-Fact-8D2F59DA09B7FE8B09E6801F8148C80C"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9757-wk-Fact-8D841CA3F88A9E41A873801F823E6F2C"
          xlink:label="d34458032e9757-wk-Fact-8D841CA3F88A9E41A873801F823E6F2C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9757-wk-Fact-8D841CA3F88A9E41A873801F823E6F2C"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2769-wk-Fact-8E28EFA6EB215BD0993C634ED8262AFF"
          xlink:label="d34468079e2769-wk-Fact-8E28EFA6EB215BD0993C634ED8262AFF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2769-wk-Fact-8E28EFA6EB215BD0993C634ED8262AFF"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3099-wk-Fact-8E4ECE37A9934A1B313CD083BFE52A99"
          xlink:label="d34586122e3099-wk-Fact-8E4ECE37A9934A1B313CD083BFE52A99"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3099-wk-Fact-8E4ECE37A9934A1B313CD083BFE52A99"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19216-wk-Fact-8E57072868D5458BD30A801F7EA6C7E3"
          xlink:label="d34661879e19216-wk-Fact-8E57072868D5458BD30A801F7EA6C7E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19216-wk-Fact-8E57072868D5458BD30A801F7EA6C7E3"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11174-wk-Fact-8EA2843D9C6DF208E5AC801F820B737B"
          xlink:label="d34661879e11174-wk-Fact-8EA2843D9C6DF208E5AC801F820B737B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11174-wk-Fact-8EA2843D9C6DF208E5AC801F820B737B"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e9151-wk-Fact-8EA5960B76BF5C90C28C801F7E3E9349"
          xlink:label="d34545404e9151-wk-Fact-8EA5960B76BF5C90C28C801F7E3E9349"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9151-wk-Fact-8EA5960B76BF5C90C28C801F7E3E9349"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3435-wk-Fact-8EAE4EB5674D9D1095E0801F7FEA5B11"
          xlink:label="d34458032e3435-wk-Fact-8EAE4EB5674D9D1095E0801F7FEA5B11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3435-wk-Fact-8EAE4EB5674D9D1095E0801F7FEA5B11"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4756-wk-Fact-8F27495BD68561A9487C801F7DC77927"
          xlink:label="d34458032e4756-wk-Fact-8F27495BD68561A9487C801F7DC77927"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4756-wk-Fact-8F27495BD68561A9487C801F7DC77927"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD"
          xlink:label="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD"
          xlink:to="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3610-wk-Fact-8F572F253EE0EF2FB92F801F813805AD"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10008-wk-Fact-8FB2D62A8EBEF9B34218801F8228C56A"
          xlink:label="d34661879e10008-wk-Fact-8FB2D62A8EBEF9B34218801F8228C56A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10008-wk-Fact-8FB2D62A8EBEF9B34218801F8228C56A"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2724-wk-Fact-901416E0C584524B87DD0ACFD655A517"
          xlink:label="d34468079e2724-wk-Fact-901416E0C584524B87DD0ACFD655A517"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2724-wk-Fact-901416E0C584524B87DD0ACFD655A517"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6061-wk-Fact-9050CF9D6C997910CB96801F7E3C9CE2"
          xlink:label="d34661879e6061-wk-Fact-9050CF9D6C997910CB96801F7E3C9CE2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6061-wk-Fact-9050CF9D6C997910CB96801F7E3C9CE2"
          xlink:to="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5144-wk-Fact-90C896B3582A49B87DFDE5206F18DC24"
          xlink:label="d34538474e5144-wk-Fact-90C896B3582A49B87DFDE5206F18DC24"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5144-wk-Fact-90C896B3582A49B87DFDE5206F18DC24"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5144-wk-Fact-90C896B3582A49B87DFDE5206F18DC24"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e5514-wk-Fact-9120BAFF50D1AEC6196F023AB29B9891"
          xlink:label="d34496162e5514-wk-Fact-9120BAFF50D1AEC6196F023AB29B9891"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e5514-wk-Fact-9120BAFF50D1AEC6196F023AB29B9891"
          xlink:to="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e2565-wk-Fact-9148FA2E247D578D82EBB7DE0DEF4259"
          xlink:label="d34506804e2565-wk-Fact-9148FA2E247D578D82EBB7DE0DEF4259"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-CE8D3299C54E02D979FA801F8303D076-0-wk-Footnote-CE8D3299C54E02D979FA801F8303D076_lbl" xlink:label="TextSelection-CE8D3299C54E02D979FA801F8303D076-0-wk-Footnote-CE8D3299C54E02D979FA801F8303D076_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Other assets held for sale consist of PP&amp;E.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e2565-wk-Fact-9148FA2E247D578D82EBB7DE0DEF4259"
          xlink:to="TextSelection-CE8D3299C54E02D979FA801F8303D076-0-wk-Footnote-CE8D3299C54E02D979FA801F8303D076_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e6714-wk-Fact-9179C071F6FA44A44864801F7F0CC3E4"
          xlink:label="d34594690e6714-wk-Fact-9179C071F6FA44A44864801F7F0CC3E4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e6714-wk-Fact-9179C071F6FA44A44864801F7F0CC3E4"
          xlink:to="TextSelection-C40FA46C2E0E93657B12801F83470010-0-wk-Footnote-C40FA46C2E0E93657B12801F83470010_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7786-wk-Fact-91841B5580A65F1AB688FCF8F5511CF9"
          xlink:label="d34458032e7786-wk-Fact-91841B5580A65F1AB688FCF8F5511CF9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7786-wk-Fact-91841B5580A65F1AB688FCF8F5511CF9"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23312-wk-Fact-91858568C939C7AE738C801F80EC0790"
          xlink:label="d34661879e23312-wk-Fact-91858568C939C7AE738C801F80EC0790"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23312-wk-Fact-91858568C939C7AE738C801F80EC0790"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4927-wk-Fact-91D4D1D5754CB771E91B801F7F1DC0E3"
          xlink:label="d34545404e4927-wk-Fact-91D4D1D5754CB771E91B801F7F1DC0E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4927-wk-Fact-91D4D1D5754CB771E91B801F7F1DC0E3"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4927-wk-Fact-91D4D1D5754CB771E91B801F7F1DC0E3"
          xlink:to="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1507-wk-Fact-92028286814C58C496DAD3D9CE00EA8A"
          xlink:label="d34423000e1507-wk-Fact-92028286814C58C496DAD3D9CE00EA8A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1507-wk-Fact-92028286814C58C496DAD3D9CE00EA8A"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6052-wk-Fact-921D990124AD87101C23801F7E92DAFD"
          xlink:label="d34586122e6052-wk-Fact-921D990124AD87101C23801F7E92DAFD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6052-wk-Fact-921D990124AD87101C23801F7E92DAFD"
          xlink:to="TextSelection-9130AEB24B4680381496801F8351B097-0-wk-Footnote-9130AEB24B4680381496801F8351B097_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2616-wk-Fact-923B7EF4CCA59EE61341801F7F2C1401"
          xlink:label="d34428379e2616-wk-Fact-923B7EF4CCA59EE61341801F7F2C1401"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2616-wk-Fact-923B7EF4CCA59EE61341801F7F2C1401"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9841-wk-Fact-92524ACC782CD4CDC985801F7E45AECD"
          xlink:label="d34586122e9841-wk-Fact-92524ACC782CD4CDC985801F7E45AECD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9841-wk-Fact-92524ACC782CD4CDC985801F7E45AECD"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2318-wk-Fact-92574249FA1B5792A5D2D0D169042981"
          xlink:label="d34430544e2318-wk-Fact-92574249FA1B5792A5D2D0D169042981"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2318-wk-Fact-92574249FA1B5792A5D2D0D169042981"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e1864-wk-Fact-925E28131BC6D032A9E6801F827FCD84"
          xlink:label="d34460716e1864-wk-Fact-925E28131BC6D032A9E6801F827FCD84"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e1864-wk-Fact-925E28131BC6D032A9E6801F827FCD84"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5412-wk-Fact-9281B6AE49D7C2B2BA97801F825215AE"
          xlink:label="d34458036e5412-wk-Fact-9281B6AE49D7C2B2BA97801F825215AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5412-wk-Fact-9281B6AE49D7C2B2BA97801F825215AE"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5412-wk-Fact-9281B6AE49D7C2B2BA97801F825215AE"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2677-wk-Fact-92CFAEDA1D275CCFA954DF7DFEDFAB50"
          xlink:label="d34423000e2677-wk-Fact-92CFAEDA1D275CCFA954DF7DFEDFAB50"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2677-wk-Fact-92CFAEDA1D275CCFA954DF7DFEDFAB50"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22403-wk-Fact-92F2D29881335576C0FD801F7E7CED30"
          xlink:label="d34661879e22403-wk-Fact-92F2D29881335576C0FD801F7E7CED30"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22403-wk-Fact-92F2D29881335576C0FD801F7E7CED30"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3673-wk-Fact-931C9AE7EA695C8789803ED34BF3218D"
          xlink:label="d34661879e3673-wk-Fact-931C9AE7EA695C8789803ED34BF3218D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3673-wk-Fact-931C9AE7EA695C8789803ED34BF3218D"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217"
          xlink:label="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5229-wk-Fact-9320CAD5A942580CA150A74240F23217"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2051-wk-Fact-93625872A9D656368D7E152DE8C08019"
          xlink:label="d34428379e2051-wk-Fact-93625872A9D656368D7E152DE8C08019"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2051-wk-Fact-93625872A9D656368D7E152DE8C08019"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2051-wk-Fact-93625872A9D656368D7E152DE8C08019"
          xlink:to="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6747-wk-Fact-936D6A2CF388244CD289801F80ED7BAA"
          xlink:label="d34545404e6747-wk-Fact-936D6A2CF388244CD289801F80ED7BAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6747-wk-Fact-936D6A2CF388244CD289801F80ED7BAA"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8456-wk-Fact-937F899827ED53BF9733BC0E5A2C276B"
          xlink:label="d34586122e8456-wk-Fact-937F899827ED53BF9733BC0E5A2C276B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8456-wk-Fact-937F899827ED53BF9733BC0E5A2C276B"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2744-wk-Fact-93A83F7AF2C8708F880AD083C00A9C02"
          xlink:label="d34586122e2744-wk-Fact-93A83F7AF2C8708F880AD083C00A9C02"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2744-wk-Fact-93A83F7AF2C8708F880AD083C00A9C02"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20504-wk-Fact-93B234B3231C3F13BFA0801F813200A4"
          xlink:label="d34661879e20504-wk-Fact-93B234B3231C3F13BFA0801F813200A4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20504-wk-Fact-93B234B3231C3F13BFA0801F813200A4"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3015-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
          xlink:label="d34428379e3015-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e9352-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
          xlink:label="d34545404e9352-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3015-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
          xlink:to="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9352-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
          xlink:to="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3015-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9352-wk-Fact-93DDC1938188F9E00A7E801F808A913C"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8793-wk-Fact-93F788C458704E75C6BDDE20A3FD7BC2"
          xlink:label="d34586122e8793-wk-Fact-93F788C458704E75C6BDDE20A3FD7BC2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8793-wk-Fact-93F788C458704E75C6BDDE20A3FD7BC2"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e3122-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
          xlink:label="d34529301e3122-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34529301e2376-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
          xlink:label="d34529301e2376-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3122-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2376-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3122-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2376-wk-Fact-940CD216AF3B5681959A8635C41B9FA0"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-9426C78F4864E19099BE801F824ECFDE-wk-Fact-9426C78F4864E19099BE801F824ECFDE"
          xlink:label="Fact-9426C78F4864E19099BE801F824ECFDE-wk-Fact-9426C78F4864E19099BE801F824ECFDE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-9426C78F4864E19099BE801F824ECFDE-wk-Fact-9426C78F4864E19099BE801F824ECFDE"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3923-wk-Fact-942BEE47CDD75096A0AEFEFF55769ACA"
          xlink:label="d34468079e3923-wk-Fact-942BEE47CDD75096A0AEFEFF55769ACA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3923-wk-Fact-942BEE47CDD75096A0AEFEFF55769ACA"
          xlink:to="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3828-wk-Fact-945DBFC591102C8BB117801F803ED887"
          xlink:label="d34661879e3828-wk-Fact-945DBFC591102C8BB117801F803ED887"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3828-wk-Fact-945DBFC591102C8BB117801F803ED887"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3138-wk-Fact-94EEAC12B164219871FE801F8106C475"
          xlink:label="d34586122e3138-wk-Fact-94EEAC12B164219871FE801F8106C475"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3138-wk-Fact-94EEAC12B164219871FE801F8106C475"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2197-wk-Fact-95156657E2A6B44ABF2BCF6F034F6554"
          xlink:label="d34460716e2197-wk-Fact-95156657E2A6B44ABF2BCF6F034F6554"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2197-wk-Fact-95156657E2A6B44ABF2BCF6F034F6554"
          xlink:to="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8719-wk-Fact-953503D0D518BB2D4A20DE20A0816CCB"
          xlink:label="d34586122e8719-wk-Fact-953503D0D518BB2D4A20DE20A0816CCB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8719-wk-Fact-953503D0D518BB2D4A20DE20A0816CCB"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24326-wk-Fact-9560997241A91E7FCCDC801F7E780256"
          xlink:label="d34661879e24326-wk-Fact-9560997241A91E7FCCDC801F7E780256"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24326-wk-Fact-9560997241A91E7FCCDC801F7E780256"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5682-wk-Fact-95B614941C4A9D8BE504801F81DF6C76"
          xlink:label="d34506804e5682-wk-Fact-95B614941C4A9D8BE504801F81DF6C76"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5682-wk-Fact-95B614941C4A9D8BE504801F81DF6C76"
          xlink:to="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6346-wk-Fact-95C3D7179E1C7455799D801F7EC9AC19"
          xlink:label="d34458032e6346-wk-Fact-95C3D7179E1C7455799D801F7EC9AC19"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6346-wk-Fact-95C3D7179E1C7455799D801F7EC9AC19"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6346-wk-Fact-95C3D7179E1C7455799D801F7EC9AC19"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20285-wk-Fact-9667992F4720EEBE8507801F7E9223CD"
          xlink:label="d34661879e20285-wk-Fact-9667992F4720EEBE8507801F7E9223CD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20285-wk-Fact-9667992F4720EEBE8507801F7E9223CD"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9273-wk-Fact-9672E748D5A35A1AB1475BEE8450A06D"
          xlink:label="d34458032e9273-wk-Fact-9672E748D5A35A1AB1475BEE8450A06D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9273-wk-Fact-9672E748D5A35A1AB1475BEE8450A06D"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2829-wk-Fact-96A8E9E0E31B5853A1D087253B1B6301"
          xlink:label="d34423000e2829-wk-Fact-96A8E9E0E31B5853A1D087253B1B6301"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2829-wk-Fact-96A8E9E0E31B5853A1D087253B1B6301"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2383-wk-Fact-96EE1FC21874513CAC2C4A3E7FCA2B60"
          xlink:label="d34430544e2383-wk-Fact-96EE1FC21874513CAC2C4A3E7FCA2B60"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2383-wk-Fact-96EE1FC21874513CAC2C4A3E7FCA2B60"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5164-wk-Fact-9703446C4160595B906FE4A04D8E2262"
          xlink:label="d34538474e5164-wk-Fact-9703446C4160595B906FE4A04D8E2262"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5164-wk-Fact-9703446C4160595B906FE4A04D8E2262"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5164-wk-Fact-9703446C4160595B906FE4A04D8E2262"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2007-wk-Fact-9727ED04B3395B12A9B3B5A9C5599258"
          xlink:label="d34529301e2007-wk-Fact-9727ED04B3395B12A9B3B5A9C5599258"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2007-wk-Fact-9727ED04B3395B12A9B3B5A9C5599258"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4"
          xlink:label="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4"
          xlink:to="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3620-wk-Fact-973D8F5135D53A4B0286801F81525EB4"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4551-wk-Fact-97A49B0ECEA9517FFBB7801F7E06BC9B"
          xlink:label="d34458032e4551-wk-Fact-97A49B0ECEA9517FFBB7801F7E06BC9B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4551-wk-Fact-97A49B0ECEA9517FFBB7801F7E06BC9B"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4551-wk-Fact-97A49B0ECEA9517FFBB7801F7E06BC9B"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5"
          xlink:label="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e3998-wk-Fact-97B6059E91E25669AECD79B3E8AC87C5"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11105-wk-Fact-982E769D9AA15AF18F31878D9A3BFD37"
          xlink:label="d34586122e11105-wk-Fact-982E769D9AA15AF18F31878D9A3BFD37"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11105-wk-Fact-982E769D9AA15AF18F31878D9A3BFD37"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3500-wk-Fact-987B313113ED573B8A810513702726B3"
          xlink:label="d34458036e3500-wk-Fact-987B313113ED573B8A810513702726B3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3500-wk-Fact-987B313113ED573B8A810513702726B3"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e27669-wk-Fact-98BFF5893FA87300516A801F7E8D015A"
          xlink:label="d34661879e27669-wk-Fact-98BFF5893FA87300516A801F7E8D015A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e27669-wk-Fact-98BFF5893FA87300516A801F7E8D015A"
          xlink:to="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24018-wk-Fact-98EC241C0428BD0AE10C801F7E1180B1"
          xlink:label="d34661879e24018-wk-Fact-98EC241C0428BD0AE10C801F7E1180B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24018-wk-Fact-98EC241C0428BD0AE10C801F7E1180B1"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24018-wk-Fact-98EC241C0428BD0AE10C801F7E1180B1"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4565-wk-Fact-98F2A54AC46334361761E5206F313F68"
          xlink:label="d34538474e4565-wk-Fact-98F2A54AC46334361761E5206F313F68"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4565-wk-Fact-98F2A54AC46334361761E5206F313F68"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5448-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:label="d34586122e5448-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e4264-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:label="d34586122e4264-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e6747-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:label="d34586122e6747-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e1459-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:label="d34430544e1459-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5448-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4264-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6747-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1459-wk-Fact-99447C56530B57BB99F3272D91D61246"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4309-wk-Fact-9967D5B336225ACF8C7C4F042D7A1102"
          xlink:label="d34458036e4309-wk-Fact-9967D5B336225ACF8C7C4F042D7A1102"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4309-wk-Fact-9967D5B336225ACF8C7C4F042D7A1102"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7281-wk-Fact-999640AF0F3A5772A546D4FCE619DC98"
          xlink:label="d34586122e7281-wk-Fact-999640AF0F3A5772A546D4FCE619DC98"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7281-wk-Fact-999640AF0F3A5772A546D4FCE619DC98"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e16278-wk-Fact-99AD0A449205CDDA0508801F827E53C0"
          xlink:label="d34661879e16278-wk-Fact-99AD0A449205CDDA0508801F827E53C0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e16278-wk-Fact-99AD0A449205CDDA0508801F827E53C0"
          xlink:to="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3786-wk-Fact-99C23B4E5EC579EA4F26801F7DF197AB"
          xlink:label="d34458032e3786-wk-Fact-99C23B4E5EC579EA4F26801F7DF197AB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3786-wk-Fact-99C23B4E5EC579EA4F26801F7DF197AB"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3786-wk-Fact-99C23B4E5EC579EA4F26801F7DF197AB"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20382-wk-Fact-99C3C972AE8486FA89F4801F7E139ECD"
          xlink:label="d34661879e20382-wk-Fact-99C3C972AE8486FA89F4801F7E139ECD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20382-wk-Fact-99C3C972AE8486FA89F4801F7E139ECD"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23351-wk-Fact-99E09AD183E83160CC87801F7E8A836A"
          xlink:label="d34661879e23351-wk-Fact-99E09AD183E83160CC87801F7E8A836A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23351-wk-Fact-99E09AD183E83160CC87801F7E8A836A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4441-wk-Fact-99F422E9BA7958F2846EA6E7D03791DC"
          xlink:label="d34538474e4441-wk-Fact-99F422E9BA7958F2846EA6E7D03791DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4441-wk-Fact-99F422E9BA7958F2846EA6E7D03791DC"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7301-wk-Fact-9A23FE915E5D4E701F2A801F8173E1A9"
          xlink:label="d34586122e7301-wk-Fact-9A23FE915E5D4E701F2A801F8173E1A9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7301-wk-Fact-9A23FE915E5D4E701F2A801F8173E1A9"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6195-wk-Fact-9A4592A1FACA84D5869A801F8024E489"
          xlink:label="d34458032e6195-wk-Fact-9A4592A1FACA84D5869A801F8024E489"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6195-wk-Fact-9A4592A1FACA84D5869A801F8024E489"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:label="d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:label="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26070-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24161-wk-Fact-9A5D6BABC942D9AA1A8F801F81E3D3FE"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5672-wk-Fact-9A5FE66D958474E62B0B801F7E97F314"
          xlink:label="d34458036e5672-wk-Fact-9A5FE66D958474E62B0B801F7E97F314"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5672-wk-Fact-9A5FE66D958474E62B0B801F7E97F314"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2882-wk-Fact-9AFB6DAE6BF5A7027999801F7ED8C9BD"
          xlink:label="d34428379e2882-wk-Fact-9AFB6DAE6BF5A7027999801F7ED8C9BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2882-wk-Fact-9AFB6DAE6BF5A7027999801F7ED8C9BD"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8842-wk-Fact-9B1DCEF966A955A2B00217967C88ACDA"
          xlink:label="d34458032e8842-wk-Fact-9B1DCEF966A955A2B00217967C88ACDA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8842-wk-Fact-9B1DCEF966A955A2B00217967C88ACDA"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7133-wk-Fact-9BBA998B2CFF5DED95D8D386714FFE6A"
          xlink:label="d34586122e7133-wk-Fact-9BBA998B2CFF5DED95D8D386714FFE6A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7133-wk-Fact-9BBA998B2CFF5DED95D8D386714FFE6A"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2028-wk-Fact-9C0330EE00BC595DB7D0BE5577BD9383"
          xlink:label="d34529301e2028-wk-Fact-9C0330EE00BC595DB7D0BE5577BD9383"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2028-wk-Fact-9C0330EE00BC595DB7D0BE5577BD9383"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5393-wk-Fact-9C12B5D1FDF6DC56A5B8801F7E7A2727"
          xlink:label="d34458036e5393-wk-Fact-9C12B5D1FDF6DC56A5B8801F7E7A2727"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5393-wk-Fact-9C12B5D1FDF6DC56A5B8801F7E7A2727"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5393-wk-Fact-9C12B5D1FDF6DC56A5B8801F7E7A2727"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3669-wk-Fact-9C15C23B033F2F07DF6B801F823D2E2E"
          xlink:label="d34458032e3669-wk-Fact-9C15C23B033F2F07DF6B801F823D2E2E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3669-wk-Fact-9C15C23B033F2F07DF6B801F823D2E2E"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10603-wk-Fact-9C416A8427655856201B801F81FBE3C5"
          xlink:label="d34661879e10603-wk-Fact-9C416A8427655856201B801F81FBE3C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10603-wk-Fact-9C416A8427655856201B801F81FBE3C5"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11504-wk-Fact-9C92BDF888590B6AA55E801F82481AA2"
          xlink:label="d34661879e11504-wk-Fact-9C92BDF888590B6AA55E801F82481AA2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9533-wk-Fact-9C92BDF888590B6AA55E801F82481AA2"
          xlink:label="d34661879e9533-wk-Fact-9C92BDF888590B6AA55E801F82481AA2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11504-wk-Fact-9C92BDF888590B6AA55E801F82481AA2"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9533-wk-Fact-9C92BDF888590B6AA55E801F82481AA2"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3099-wk-Fact-9CA9F5D6598257E8B08FB6226CA68B1F"
          xlink:label="d34430544e3099-wk-Fact-9CA9F5D6598257E8B08FB6226CA68B1F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3099-wk-Fact-9CA9F5D6598257E8B08FB6226CA68B1F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1836-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F"
          xlink:label="d34423000e1836-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34496162e9149-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F"
          xlink:label="d34496162e9149-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1836-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e9149-wk-Fact-9CB5F0CEA5D15AE4A4370372D6D0713F"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8138-wk-Fact-9CF783F2B69B5D93A482F2C929ED1566"
          xlink:label="d34545404e8138-wk-Fact-9CF783F2B69B5D93A482F2C929ED1566"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8138-wk-Fact-9CF783F2B69B5D93A482F2C929ED1566"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1937-wk-Fact-9D26812D16985C8A83C043FBACDEB01A"
          xlink:label="d34458036e1937-wk-Fact-9D26812D16985C8A83C043FBACDEB01A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1937-wk-Fact-9D26812D16985C8A83C043FBACDEB01A"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1937-wk-Fact-9D26812D16985C8A83C043FBACDEB01A"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4863-wk-Fact-9D37210D257EF686844E801F800CB2CA"
          xlink:label="d34661879e4863-wk-Fact-9D37210D257EF686844E801F800CB2CA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4863-wk-Fact-9D37210D257EF686844E801F800CB2CA"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4863-wk-Fact-9D37210D257EF686844E801F800CB2CA"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21092-wk-Fact-9D5C193DFCEF155D2BA5801F8158E97D"
          xlink:label="d34661879e21092-wk-Fact-9D5C193DFCEF155D2BA5801F8158E97D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21092-wk-Fact-9D5C193DFCEF155D2BA5801F8158E97D"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14721-wk-Fact-9D6C46A96E8CE95D147B801F7F0D5028"
          xlink:label="d34661879e14721-wk-Fact-9D6C46A96E8CE95D147B801F7F0D5028"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14721-wk-Fact-9D6C46A96E8CE95D147B801F7F0D5028"
          xlink:to="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-9D817CFBE8E27DFE8D7A801F80886593-wk-Fact-9D817CFBE8E27DFE8D7A801F80886593"
          xlink:label="Fact-9D817CFBE8E27DFE8D7A801F80886593-wk-Fact-9D817CFBE8E27DFE8D7A801F80886593"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-9D817CFBE8E27DFE8D7A801F80886593-wk-Fact-9D817CFBE8E27DFE8D7A801F80886593"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23979-wk-Fact-9D87527D8A9492D75841801F7EA8D8E9"
          xlink:label="d34661879e23979-wk-Fact-9D87527D8A9492D75841801F7EA8D8E9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23979-wk-Fact-9D87527D8A9492D75841801F7EA8D8E9"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23979-wk-Fact-9D87527D8A9492D75841801F7EA8D8E9"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2416-wk-Fact-9EBE45B86EF3A4ED4BB6801F7E8624C1"
          xlink:label="d34468079e2416-wk-Fact-9EBE45B86EF3A4ED4BB6801F7E8624C1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2416-wk-Fact-9EBE45B86EF3A4ED4BB6801F7E8624C1"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3200-wk-Fact-9EC5142FF1350AFCC36A801F7FDF5605"
          xlink:label="d34458032e3200-wk-Fact-9EC5142FF1350AFCC36A801F7FDF5605"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3200-wk-Fact-9EC5142FF1350AFCC36A801F7FDF5605"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4195-wk-Fact-9EE24B8CE46E4AFB1CAED083C012D553"
          xlink:label="d34586122e4195-wk-Fact-9EE24B8CE46E4AFB1CAED083C012D553"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4195-wk-Fact-9EE24B8CE46E4AFB1CAED083C012D553"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4195-wk-Fact-9EE24B8CE46E4AFB1CAED083C012D553"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8880-wk-Fact-9EED0554CF1857D8B1887EDCD838B377"
          xlink:label="d34458032e8880-wk-Fact-9EED0554CF1857D8B1887EDCD838B377"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8880-wk-Fact-9EED0554CF1857D8B1887EDCD838B377"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2625-wk-Fact-9F4115E6A91F5D5A8F7DBFD6C8FE97D2"
          xlink:label="d34430544e2625-wk-Fact-9F4115E6A91F5D5A8F7DBFD6C8FE97D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2625-wk-Fact-9F4115E6A91F5D5A8F7DBFD6C8FE97D2"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8680-wk-Fact-9F9BFF3F49E4598B845CC5FD385C80FE"
          xlink:label="d34586122e8680-wk-Fact-9F9BFF3F49E4598B845CC5FD385C80FE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8680-wk-Fact-9F9BFF3F49E4598B845CC5FD385C80FE"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4687-wk-Fact-A0164F459FB4FEDAE7F5E5206F2A0E3C"
          xlink:label="d34538474e4687-wk-Fact-A0164F459FB4FEDAE7F5E5206F2A0E3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4687-wk-Fact-A0164F459FB4FEDAE7F5E5206F2A0E3C"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1936-wk-Fact-A0580F12FEFB5184AF83F23E7628F9E3"
          xlink:label="d34428379e1936-wk-Fact-A0580F12FEFB5184AF83F23E7628F9E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1936-wk-Fact-A0580F12FEFB5184AF83F23E7628F9E3"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e1929-wk-Fact-A089F24D480155BE84E9E384AAB61EDF"
          xlink:label="d34529301e1929-wk-Fact-A089F24D480155BE84E9E384AAB61EDF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e1929-wk-Fact-A089F24D480155BE84E9E384AAB61EDF"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3520-wk-Fact-A08B5E2989AB58B0A8139571535F4EFB"
          xlink:label="d34458036e3520-wk-Fact-A08B5E2989AB58B0A8139571535F4EFB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3520-wk-Fact-A08B5E2989AB58B0A8139571535F4EFB"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3144-wk-Fact-A0AE51B2124A549B9B82AE9C29097AF0"
          xlink:label="d34501946e3144-wk-Fact-A0AE51B2124A549B9B82AE9C29097AF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3144-wk-Fact-A0AE51B2124A549B9B82AE9C29097AF0"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2924-wk-Fact-A1514905E048F0FFA68C801F800B7A4F"
          xlink:label="d34661879e2924-wk-Fact-A1514905E048F0FFA68C801F800B7A4F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2924-wk-Fact-A1514905E048F0FFA68C801F800B7A4F"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5465-wk-Fact-A161DD024D9F78FE3297801F82161F7E"
          xlink:label="d34506804e5465-wk-Fact-A161DD024D9F78FE3297801F82161F7E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5465-wk-Fact-A161DD024D9F78FE3297801F82161F7E"
          xlink:to="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22544-wk-Fact-A16FEE27FC5491A49909801F81596307"
          xlink:label="d34661879e22544-wk-Fact-A16FEE27FC5491A49909801F81596307"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22544-wk-Fact-A16FEE27FC5491A49909801F81596307"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7506-wk-Fact-A1A886242BD55B97B9C6B7AE43B77A3F"
          xlink:label="d34586122e7506-wk-Fact-A1A886242BD55B97B9C6B7AE43B77A3F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7506-wk-Fact-A1A886242BD55B97B9C6B7AE43B77A3F"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21029-wk-Fact-A1CED4074FA1FDF7A5FC801F8022EF72"
          xlink:label="d34661879e21029-wk-Fact-A1CED4074FA1FDF7A5FC801F8022EF72"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21029-wk-Fact-A1CED4074FA1FDF7A5FC801F8022EF72"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21029-wk-Fact-A1CED4074FA1FDF7A5FC801F8022EF72"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3282-wk-Fact-A1E2DBD4AD5154A27F57D083C01AB381"
          xlink:label="d34586122e3282-wk-Fact-A1E2DBD4AD5154A27F57D083C01AB381"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3282-wk-Fact-A1E2DBD4AD5154A27F57D083C01AB381"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2599-wk-Fact-A1E8D06C4BADD1A6A43D801F819A99BD"
          xlink:label="d34594690e2599-wk-Fact-A1E8D06C4BADD1A6A43D801F819A99BD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2599-wk-Fact-A1E8D06C4BADD1A6A43D801F819A99BD"
          xlink:to="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5136-wk-Fact-A26746429C1908FDD4E5801F7F1B893B"
          xlink:label="d34545404e5136-wk-Fact-A26746429C1908FDD4E5801F7F1B893B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5136-wk-Fact-A26746429C1908FDD4E5801F7F1B893B"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20202-wk-Fact-A2751CB79E5C657710FC801F7E6BAF40"
          xlink:label="d34661879e20202-wk-Fact-A2751CB79E5C657710FC801F7E6BAF40"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20202-wk-Fact-A2751CB79E5C657710FC801F7E6BAF40"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11212-wk-Fact-A2924772A01FADBA0AFC801F8209EC9B"
          xlink:label="d34661879e11212-wk-Fact-A2924772A01FADBA0AFC801F8209EC9B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11212-wk-Fact-A2924772A01FADBA0AFC801F8209EC9B"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14762-wk-Fact-A2A4CC4306DEA373350A801F7F0B3827"
          xlink:label="d34661879e14762-wk-Fact-A2A4CC4306DEA373350A801F7F0B3827"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14762-wk-Fact-A2A4CC4306DEA373350A801F7F0B3827"
          xlink:to="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e8665-wk-Fact-A2C8D5C7533E515EB203A3E9F7008E7C"
          xlink:label="d34496162e8665-wk-Fact-A2C8D5C7533E515EB203A3E9F7008E7C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-00B1F244805F23E229ECE4C97135F977-0-wk-Footnote-00B1F244805F23E229ECE4C97135F977_lbl" xlink:label="TextSelection-00B1F244805F23E229ECE4C97135F977-0-wk-Footnote-00B1F244805F23E229ECE4C97135F977_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">&#160;<xhtml:div style="line-height:120%;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">As of </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> and </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.</xhtml:span></xhtml:div><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:8pt;"><xhtml:br/></xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e8665-wk-Fact-A2C8D5C7533E515EB203A3E9F7008E7C"
          xlink:to="TextSelection-00B1F244805F23E229ECE4C97135F977-0-wk-Footnote-00B1F244805F23E229ECE4C97135F977_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9166-wk-Fact-A2F4496694D82FBCD30CDE22BCA5386D"
          xlink:label="d34586122e9166-wk-Fact-A2F4496694D82FBCD30CDE22BCA5386D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9166-wk-Fact-A2F4496694D82FBCD30CDE22BCA5386D"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9166-wk-Fact-A2F4496694D82FBCD30CDE22BCA5386D"
          xlink:to="TextSelection-FAB3E51A25ED7909F51D801F83524BD0-0-wk-Footnote-FAB3E51A25ED7909F51D801F83524BD0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20105-wk-Fact-A320D830DB302CFA5F67801F7E9BA879"
          xlink:label="d34661879e20105-wk-Fact-A320D830DB302CFA5F67801F7E9BA879"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20105-wk-Fact-A320D830DB302CFA5F67801F7E9BA879"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9989-wk-Fact-A339E48382383D402CC3801F81FAD97A"
          xlink:label="d34661879e9989-wk-Fact-A339E48382383D402CC3801F81FAD97A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9989-wk-Fact-A339E48382383D402CC3801F81FAD97A"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22660-wk-Fact-A349362A7F0F24D7725D801F8161CBEA"
          xlink:label="d34661879e22660-wk-Fact-A349362A7F0F24D7725D801F8161CBEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22660-wk-Fact-A349362A7F0F24D7725D801F8161CBEA"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1488-wk-Fact-A3B4914B172C5BC59639B98C6FB3F588"
          xlink:label="d34423000e1488-wk-Fact-A3B4914B172C5BC59639B98C6FB3F588"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1488-wk-Fact-A3B4914B172C5BC59639B98C6FB3F588"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e2648-wk-Fact-A3F4A2E507D5855FCA57801F7FA5036E"
          xlink:label="d34545404e2648-wk-Fact-A3F4A2E507D5855FCA57801F7FA5036E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2648-wk-Fact-A3F4A2E507D5855FCA57801F7FA5036E"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:label="d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:label="d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:label="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-3923C06B7BCB649C5D4E801F8313BABC-0-wk-Footnote-3923C06B7BCB649C5D4E801F8313BABC_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl" xlink:label="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> v. </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">2018</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">&#x2013;&#x2013;</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">The domestic income in 2019 versus domestic loss in 2018 was mainly related to the completion of the Consumer Healthcare joint venture transaction with GSK as well as lower certain asset impairments, partially offset by reduced Lyrica revenues in the U.S., higher business and legal entity </xhtml:span></xhtml:div><xhtml:div style="line-height:120%;padding-left:12px;text-align:left;"><xhtml:span style="font-family:Arial;font-size:7pt;">alignment costs as well as increased costs related to certain legal matters. The decrease in the international income was primarily related to higher certain asset impairments as well as the write off of assets contributed to the Consumer Healthcare joint venture with GSK.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1709-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4341-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2058-wk-Fact-A412826B4CFF56B085E2D90775F16ECB"
          xlink:to="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e8087-wk-Fact-A41309C827BD3760EAD4801F7E667623"
          xlink:label="d34594690e8087-wk-Fact-A41309C827BD3760EAD4801F7E667623"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8087-wk-Fact-A41309C827BD3760EAD4801F7E667623"
          xlink:to="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8087-wk-Fact-A41309C827BD3760EAD4801F7E667623"
          xlink:to="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2641-wk-Fact-A42CFC7A5BC659D7A3189F4AF6F5EC83"
          xlink:label="d34468079e2641-wk-Fact-A42CFC7A5BC659D7A3189F4AF6F5EC83"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2641-wk-Fact-A42CFC7A5BC659D7A3189F4AF6F5EC83"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22306-wk-Fact-A43617795041B30B05CB801F7ECAF0A6"
          xlink:label="d34661879e22306-wk-Fact-A43617795041B30B05CB801F7ECAF0A6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22306-wk-Fact-A43617795041B30B05CB801F7ECAF0A6"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10825-wk-Fact-A4C2A6D0663F5845176B801F81F80E32"
          xlink:label="d34661879e10825-wk-Fact-A4C2A6D0663F5845176B801F81F80E32"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10825-wk-Fact-A4C2A6D0663F5845176B801F81F80E32"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2303-wk-Fact-A51B51A828275272A7C573C440BF63F4"
          xlink:label="d34423000e2303-wk-Fact-A51B51A828275272A7C573C440BF63F4"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34498941e1766-wk-Fact-A51B51A828275272A7C573C440BF63F4"
          xlink:label="d34498941e1766-wk-Fact-A51B51A828275272A7C573C440BF63F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2303-wk-Fact-A51B51A828275272A7C573C440BF63F4"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34498941e1766-wk-Fact-A51B51A828275272A7C573C440BF63F4"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20951-wk-Fact-A543C6B15A6318DF95B8801F7E694554"
          xlink:label="d34661879e20951-wk-Fact-A543C6B15A6318DF95B8801F7E694554"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20951-wk-Fact-A543C6B15A6318DF95B8801F7E694554"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20951-wk-Fact-A543C6B15A6318DF95B8801F7E694554"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8995-wk-Fact-A561864E833387BD903CDE210367E099"
          xlink:label="d34586122e8995-wk-Fact-A561864E833387BD903CDE210367E099"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8995-wk-Fact-A561864E833387BD903CDE210367E099"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3829-wk-Fact-A591E3AF789D5180A58CDB8F61EA51D0"
          xlink:label="d34458036e3829-wk-Fact-A591E3AF789D5180A58CDB8F61EA51D0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3829-wk-Fact-A591E3AF789D5180A58CDB8F61EA51D0"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2837-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639"
          xlink:label="d34523018e2837-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458032e9953-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639"
          xlink:label="d34458032e9953-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2837-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9953-wk-Fact-A5E7BADCDC9D374AE198801F7EAD9639"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21351-wk-Fact-A621438BD8C8D4F1F9D1801F7E16B826"
          xlink:label="d34661879e21351-wk-Fact-A621438BD8C8D4F1F9D1801F7E16B826"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21351-wk-Fact-A621438BD8C8D4F1F9D1801F7E16B826"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21351-wk-Fact-A621438BD8C8D4F1F9D1801F7E16B826"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5266-wk-Fact-A63F83E6394508389223801F8216DDFD"
          xlink:label="d34506804e5266-wk-Fact-A63F83E6394508389223801F8216DDFD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5266-wk-Fact-A63F83E6394508389223801F8216DDFD"
          xlink:to="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3353-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
          xlink:label="d34430544e3353-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34523018e2531-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
          xlink:label="d34523018e2531-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3353-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2531-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3353-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2531-wk-Fact-A641170D49AD547A8914C2CE48D6E64F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21274-wk-Fact-A66838ACCE990B7D1974801F80F24A8B"
          xlink:label="d34661879e21274-wk-Fact-A66838ACCE990B7D1974801F80F24A8B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21274-wk-Fact-A66838ACCE990B7D1974801F80F24A8B"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3920-wk-Fact-A684767625371E2C2BE9801F82707B93"
          xlink:label="d34545404e3920-wk-Fact-A684767625371E2C2BE9801F82707B93"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3920-wk-Fact-A684767625371E2C2BE9801F82707B93"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1703-wk-Fact-A68C33E581015A07BF02867B616768F9"
          xlink:label="d34423000e1703-wk-Fact-A68C33E581015A07BF02867B616768F9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1703-wk-Fact-A68C33E581015A07BF02867B616768F9"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7040-wk-Fact-A6B4F6B324375D53B10094F17B3C65B3"
          xlink:label="d34586122e7040-wk-Fact-A6B4F6B324375D53B10094F17B3C65B3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7040-wk-Fact-A6B4F6B324375D53B10094F17B3C65B3"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5310-wk-Fact-A6CC259B83A6C2A0E036801F81DB019C"
          xlink:label="d34506804e5310-wk-Fact-A6CC259B83A6C2A0E036801F81DB019C"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl" xlink:label="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in each of the periods presented reflect increases in alliance revenues from Eliquis and Xtandi.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5310-wk-Fact-A6CC259B83A6C2A0E036801F81DB019C"
          xlink:to="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4899-wk-Fact-A6D28E13D65A157B5F67801F81407A21"
          xlink:label="d34545404e4899-wk-Fact-A6D28E13D65A157B5F67801F81407A21"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4899-wk-Fact-A6D28E13D65A157B5F67801F81407A21"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e7629-wk-Fact-A6FC51038FA814464645801F81FD9227"
          xlink:label="d34661879e7629-wk-Fact-A6FC51038FA814464645801F81FD9227"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e7629-wk-Fact-A6FC51038FA814464645801F81FD9227"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19597-wk-Fact-A730E8A1EA686A58B9A9801F812B26B3"
          xlink:label="d34661879e19597-wk-Fact-A730E8A1EA686A58B9A9801F812B26B3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19597-wk-Fact-A730E8A1EA686A58B9A9801F812B26B3"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11382-wk-Fact-A794165CEA5A51B0A3B6004B3D79A885"
          xlink:label="d34586122e11382-wk-Fact-A794165CEA5A51B0A3B6004B3D79A885"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11382-wk-Fact-A794165CEA5A51B0A3B6004B3D79A885"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2683-wk-Fact-A7D8A59FD536FC537EA7801F82CDAF6E"
          xlink:label="d34458036e2683-wk-Fact-A7D8A59FD536FC537EA7801F82CDAF6E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2683-wk-Fact-A7D8A59FD536FC537EA7801F82CDAF6E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3563-wk-Fact-A80502CBDD0A15BE22F7801F812601A0"
          xlink:label="d34586122e3563-wk-Fact-A80502CBDD0A15BE22F7801F812601A0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3563-wk-Fact-A80502CBDD0A15BE22F7801F812601A0"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7933-wk-Fact-A80D878425B55E7DB0E92B5480994305"
          xlink:label="d34586122e7933-wk-Fact-A80D878425B55E7DB0E92B5480994305"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7933-wk-Fact-A80D878425B55E7DB0E92B5480994305"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7933-wk-Fact-A80D878425B55E7DB0E92B5480994305"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2333-wk-Fact-A80DE1A520AD557392F9597D3D60F83A"
          xlink:label="d34468079e2333-wk-Fact-A80DE1A520AD557392F9597D3D60F83A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2333-wk-Fact-A80DE1A520AD557392F9597D3D60F83A"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14802-wk-Fact-A816C66465B359E5274A801F7F026BDF"
          xlink:label="d34661879e14802-wk-Fact-A816C66465B359E5274A801F7F026BDF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14802-wk-Fact-A816C66465B359E5274A801F7F026BDF"
          xlink:to="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e26031-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
          xlink:label="d34661879e26031-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e23960-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
          xlink:label="d34661879e23960-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26031-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23960-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26031-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23960-wk-Fact-A8286C3D6BAFB2ACA154801F80D0E961"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7207-wk-Fact-A83EDCFE0B465D95A739D4248C9470C0"
          xlink:label="d34586122e7207-wk-Fact-A83EDCFE0B465D95A739D4248C9470C0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7207-wk-Fact-A83EDCFE0B465D95A739D4248C9470C0"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7361-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
          xlink:label="d34458032e7361-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e3496-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
          xlink:label="d34423000e3496-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7361-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3496-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7361-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3496-wk-Fact-A856A5C9461154769813BC75D3DBEF25"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3320-wk-Fact-A866155102FA518DAD8A3AC3849A29ED"
          xlink:label="d34458036e3320-wk-Fact-A866155102FA518DAD8A3AC3849A29ED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3320-wk-Fact-A866155102FA518DAD8A3AC3849A29ED"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8237-wk-Fact-A8B53B0AF0215974918EFB048833F5CB"
          xlink:label="d34586122e8237-wk-Fact-A8B53B0AF0215974918EFB048833F5CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8237-wk-Fact-A8B53B0AF0215974918EFB048833F5CB"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2951-wk-Fact-A8B9CC29B1BD5DCCB10156807AFD46CF"
          xlink:label="d34430544e2951-wk-Fact-A8B9CC29B1BD5DCCB10156807AFD46CF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2951-wk-Fact-A8B9CC29B1BD5DCCB10156807AFD46CF"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1783-wk-Fact-A8ECAB64FC345D158EED4CF5EB8D3C49"
          xlink:label="d34428379e1783-wk-Fact-A8ECAB64FC345D158EED4CF5EB8D3C49"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1783-wk-Fact-A8ECAB64FC345D158EED4CF5EB8D3C49"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5285-wk-Fact-A96A62C6E678423BC122801F80CEE810"
          xlink:label="d34586122e5285-wk-Fact-A96A62C6E678423BC122801F80CEE810"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5285-wk-Fact-A96A62C6E678423BC122801F80CEE810"
          xlink:to="TextSelection-858EF4BBFB37BC08DFC3801F834F6BE7-0-wk-Footnote-858EF4BBFB37BC08DFC3801F834F6BE7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6809-wk-Fact-A97915E9582AC1C02322801F80D9D022"
          xlink:label="d34661879e6809-wk-Fact-A97915E9582AC1C02322801F80D9D022"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6809-wk-Fact-A97915E9582AC1C02322801F80D9D022"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9965-wk-Fact-A982B6EE13215444830BADC0E2C52ACD"
          xlink:label="d34586122e9965-wk-Fact-A982B6EE13215444830BADC0E2C52ACD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9965-wk-Fact-A982B6EE13215444830BADC0E2C52ACD"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34498941e1513-wk-Fact-A98C87D2BA285EA58206340681E8AC55"
          xlink:label="d34498941e1513-wk-Fact-A98C87D2BA285EA58206340681E8AC55"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-A750B31D2CDA1870AFBA801F8317F8FF-0-wk-Footnote-A750B31D2CDA1870AFBA801F8317F8FF_lbl" xlink:label="TextSelection-A750B31D2CDA1870AFBA801F8317F8FF-0-wk-Footnote-A750B31D2CDA1870AFBA801F8317F8FF_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">For additional information, see </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7D</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34498941e1513-wk-Fact-A98C87D2BA285EA58206340681E8AC55"
          xlink:to="TextSelection-A750B31D2CDA1870AFBA801F8317F8FF-0-wk-Footnote-A750B31D2CDA1870AFBA801F8317F8FF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7952-wk-Fact-A9B6D8B90E4D5AC4A32D4CCEFCEEBE96"
          xlink:label="d34586122e7952-wk-Fact-A9B6D8B90E4D5AC4A32D4CCEFCEEBE96"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7952-wk-Fact-A9B6D8B90E4D5AC4A32D4CCEFCEEBE96"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7952-wk-Fact-A9B6D8B90E4D5AC4A32D4CCEFCEEBE96"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2305-wk-Fact-AA09423469405CACDD8C801F7F53FDB0"
          xlink:label="d34460716e2305-wk-Fact-AA09423469405CACDD8C801F7F53FDB0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2305-wk-Fact-AA09423469405CACDD8C801F7F53FDB0"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7728-wk-Fact-AA23783A2EF0547FB95205FE30FF67FA"
          xlink:label="d34586122e7728-wk-Fact-AA23783A2EF0547FB95205FE30FF67FA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7728-wk-Fact-AA23783A2EF0547FB95205FE30FF67FA"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3683-wk-Fact-AA448E5E8130401937D9801F80FB6261"
          xlink:label="d34586122e3683-wk-Fact-AA448E5E8130401937D9801F80FB6261"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3683-wk-Fact-AA448E5E8130401937D9801F80FB6261"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e1969-wk-Fact-AA8CABF2F570588CA468DCE619BE951F"
          xlink:label="d34529301e1969-wk-Fact-AA8CABF2F570588CA468DCE619BE951F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e1969-wk-Fact-AA8CABF2F570588CA468DCE619BE951F"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3241-wk-Fact-AAAC7E6A61915A9AB289BFF791014433"
          xlink:label="d34586122e3241-wk-Fact-AAAC7E6A61915A9AB289BFF791014433"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3241-wk-Fact-AAAC7E6A61915A9AB289BFF791014433"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5260-wk-Fact-AAADFB48294C3599DB10801F82605B2C"
          xlink:label="d34458032e5260-wk-Fact-AAADFB48294C3599DB10801F82605B2C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5260-wk-Fact-AAADFB48294C3599DB10801F82605B2C"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2245-wk-Fact-AAFD78C12C113C0D686D801F8281F391"
          xlink:label="d34460716e2245-wk-Fact-AAFD78C12C113C0D686D801F8281F391"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2245-wk-Fact-AAFD78C12C113C0D686D801F8281F391"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2056-wk-Fact-AB13686A614A540891E5DB6A56F3428E"
          xlink:label="d34423000e2056-wk-Fact-AB13686A614A540891E5DB6A56F3428E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2056-wk-Fact-AB13686A614A540891E5DB6A56F3428E"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3873-wk-Fact-AB1A5D7154D55524B1896C7D13EEE1BE"
          xlink:label="d34661879e3873-wk-Fact-AB1A5D7154D55524B1896C7D13EEE1BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3873-wk-Fact-AB1A5D7154D55524B1896C7D13EEE1BE"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11237-wk-Fact-AB51FFA5E25BF090B8E4801F821615F8"
          xlink:label="d34661879e11237-wk-Fact-AB51FFA5E25BF090B8E4801F821615F8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11237-wk-Fact-AB51FFA5E25BF090B8E4801F821615F8"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24872-wk-Fact-AB5ECEED024AF101A1AC801F8151B0F7"
          xlink:label="d34661879e24872-wk-Fact-AB5ECEED024AF101A1AC801F8151B0F7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24872-wk-Fact-AB5ECEED024AF101A1AC801F8151B0F7"
          xlink:to="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24872-wk-Fact-AB5ECEED024AF101A1AC801F8151B0F7"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1651-wk-Fact-AB74A10364F359F29349BB0B21ECB2F3"
          xlink:label="d34430544e1651-wk-Fact-AB74A10364F359F29349BB0B21ECB2F3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1651-wk-Fact-AB74A10364F359F29349BB0B21ECB2F3"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1651-wk-Fact-AB74A10364F359F29349BB0B21ECB2F3"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9191-wk-Fact-AB82307C2179145E356A801F824B4798"
          xlink:label="d34458032e9191-wk-Fact-AB82307C2179145E356A801F824B4798"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9191-wk-Fact-AB82307C2179145E356A801F824B4798"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24103-wk-Fact-ABB7C1831B6036A1961D801F8111BCF2"
          xlink:label="d34661879e24103-wk-Fact-ABB7C1831B6036A1961D801F8111BCF2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24103-wk-Fact-ABB7C1831B6036A1961D801F8111BCF2"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24103-wk-Fact-ABB7C1831B6036A1961D801F8111BCF2"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5388-wk-Fact-AC840D295965D51F3AEB801F7F1296E1"
          xlink:label="d34545404e5388-wk-Fact-AC840D295965D51F3AEB801F7F1296E1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5388-wk-Fact-AC840D295965D51F3AEB801F7F1296E1"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5388-wk-Fact-AC840D295965D51F3AEB801F7F1296E1"
          xlink:to="TextSelection-90990489192C50447F2C801F831133E5-0-wk-Footnote-90990489192C50447F2C801F831133E5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34514486e1908-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:label="d34514486e1908-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e6253-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:label="d34586122e6253-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e1924-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:label="d34423000e1924-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34514486e1908-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6253-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1924-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34514486e1908-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:to="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6253-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:to="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1924-wk-Fact-ACBC6F3483A35F8889C4437E4C294FFD"
          xlink:to="TextSelection-64EC3BBC07F5F3F34FBC801F8334E70E-0-wk-Footnote-64EC3BBC07F5F3F34FBC801F8334E70E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11549-wk-Fact-AD6A89B15A765F7DA13013F765D9BCCE"
          xlink:label="d34586122e11549-wk-Fact-AD6A89B15A765F7DA13013F765D9BCCE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11549-wk-Fact-AD6A89B15A765F7DA13013F765D9BCCE"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3344-wk-Fact-AD91E61606B3F9D31977801F7FE885E5"
          xlink:label="d34428379e3344-wk-Fact-AD91E61606B3F9D31977801F7FE885E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3344-wk-Fact-AD91E61606B3F9D31977801F7FE885E5"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5902-wk-Fact-ADB247F63E15672E1A7D801F7DC78C20"
          xlink:label="d34458032e5902-wk-Fact-ADB247F63E15672E1A7D801F7DC78C20"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5902-wk-Fact-ADB247F63E15672E1A7D801F7DC78C20"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3208-wk-Fact-ADE382A1D3945AC3B461E0B1B11CBDE7"
          xlink:label="d34430544e3208-wk-Fact-ADE382A1D3945AC3B461E0B1B11CBDE7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3208-wk-Fact-ADE382A1D3945AC3B461E0B1B11CBDE7"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19816-wk-Fact-ADFD09EFBAAE17E76B8C801F812CED5A"
          xlink:label="d34661879e19816-wk-Fact-ADFD09EFBAAE17E76B8C801F812CED5A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19816-wk-Fact-ADFD09EFBAAE17E76B8C801F812CED5A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7561-wk-Fact-AE2B016013A759EB976F0B6B8F4C219E"
          xlink:label="d34586122e7561-wk-Fact-AE2B016013A759EB976F0B6B8F4C219E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7561-wk-Fact-AE2B016013A759EB976F0B6B8F4C219E"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3300-wk-Fact-AE4BE372D7E0566CA33FCE7A63C55830"
          xlink:label="d34458036e3300-wk-Fact-AE4BE372D7E0566CA33FCE7A63C55830"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3300-wk-Fact-AE4BE372D7E0566CA33FCE7A63C55830"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2176-wk-Fact-AEFB6F4B2F0FF7051095CB2DE528EDFE"
          xlink:label="d34458032e2176-wk-Fact-AEFB6F4B2F0FF7051095CB2DE528EDFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2176-wk-Fact-AEFB6F4B2F0FF7051095CB2DE528EDFE"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5440-wk-Fact-AF2E68BBA8025433B3103D89BFF2ABC1"
          xlink:label="d34458036e5440-wk-Fact-AF2E68BBA8025433B3103D89BFF2ABC1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5440-wk-Fact-AF2E68BBA8025433B3103D89BFF2ABC1"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5440-wk-Fact-AF2E68BBA8025433B3103D89BFF2ABC1"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23921-wk-Fact-AF3B835BA88A5AF10D40801F814757D9"
          xlink:label="d34661879e23921-wk-Fact-AF3B835BA88A5AF10D40801F814757D9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23921-wk-Fact-AF3B835BA88A5AF10D40801F814757D9"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23921-wk-Fact-AF3B835BA88A5AF10D40801F814757D9"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e16176-wk-Fact-AF3CA0CEC8AD61474DDB801F82306D75"
          xlink:label="d34661879e16176-wk-Fact-AF3CA0CEC8AD61474DDB801F82306D75"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e16176-wk-Fact-AF3CA0CEC8AD61474DDB801F82306D75"
          xlink:to="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8551-wk-Fact-AF503AE62454526EB03769AE56899F54"
          xlink:label="d34586122e8551-wk-Fact-AF503AE62454526EB03769AE56899F54"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8551-wk-Fact-AF503AE62454526EB03769AE56899F54"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8551-wk-Fact-AF503AE62454526EB03769AE56899F54"
          xlink:to="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3086-wk-Fact-AF6AA38DDBAD57078BE06AFBF6047957"
          xlink:label="d34501946e3086-wk-Fact-AF6AA38DDBAD57078BE06AFBF6047957"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3086-wk-Fact-AF6AA38DDBAD57078BE06AFBF6047957"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2797-wk-Fact-AF85C0A522725220A32AC451BBAD97DA"
          xlink:label="d34428379e2797-wk-Fact-AF85C0A522725220A32AC451BBAD97DA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2797-wk-Fact-AF85C0A522725220A32AC451BBAD97DA"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6094-wk-Fact-AF8B407E154F54148E312BE4E9BB335A"
          xlink:label="d34538474e6094-wk-Fact-AF8B407E154F54148E312BE4E9BB335A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6094-wk-Fact-AF8B407E154F54148E312BE4E9BB335A"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2866-wk-Fact-AFB9A55388F572AD8D2E801F7FC2597A"
          xlink:label="d34661879e2866-wk-Fact-AFB9A55388F572AD8D2E801F7FC2597A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2866-wk-Fact-AFB9A55388F572AD8D2E801F7FC2597A"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23094-wk-Fact-B027583F189DF18A6C25801F81488DCF"
          xlink:label="d34661879e23094-wk-Fact-B027583F189DF18A6C25801F81488DCF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23094-wk-Fact-B027583F189DF18A6C25801F81488DCF"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21555-wk-Fact-B0690B2915B8FC4A125C801F80217B36"
          xlink:label="d34661879e21555-wk-Fact-B0690B2915B8FC4A125C801F80217B36"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21555-wk-Fact-B0690B2915B8FC4A125C801F80217B36"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11096-wk-Fact-B06D18314819524CDB53801F8224ECF4"
          xlink:label="d34661879e11096-wk-Fact-B06D18314819524CDB53801F8224ECF4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11096-wk-Fact-B06D18314819524CDB53801F8224ECF4"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-B0ADFA04558E26682149801F804BAD07-wk-Fact-B0ADFA04558E26682149801F804BAD07"
          xlink:label="Fact-B0ADFA04558E26682149801F804BAD07-wk-Fact-B0ADFA04558E26682149801F804BAD07"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-B0ADFA04558E26682149801F804BAD07-wk-Fact-B0ADFA04558E26682149801F804BAD07"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9258-wk-Fact-B0C3BCD9194159029B0449658B7BCFBA"
          xlink:label="d34458032e9258-wk-Fact-B0C3BCD9194159029B0449658B7BCFBA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9258-wk-Fact-B0C3BCD9194159029B0449658B7BCFBA"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2963-wk-Fact-B14453A638517C4D7C51801F82449662"
          xlink:label="d34661879e2963-wk-Fact-B14453A638517C4D7C51801F82449662"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9829-wk-Fact-B14453A638517C4D7C51801F82449662"
          xlink:label="d34661879e9829-wk-Fact-B14453A638517C4D7C51801F82449662"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2963-wk-Fact-B14453A638517C4D7C51801F82449662"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9829-wk-Fact-B14453A638517C4D7C51801F82449662"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11949-wk-Fact-B14A778A0529F4E56FC1DE3ECD2EE7E6"
          xlink:label="d34586122e11949-wk-Fact-B14A778A0529F4E56FC1DE3ECD2EE7E6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11949-wk-Fact-B14A778A0529F4E56FC1DE3ECD2EE7E6"
          xlink:to="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5097-wk-Fact-B17BA65FC5E9803F8ED2801F8133E381"
          xlink:label="d34545404e5097-wk-Fact-B17BA65FC5E9803F8ED2801F8133E381"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5097-wk-Fact-B17BA65FC5E9803F8ED2801F8133E381"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-B1B9FBB3E65B02DB442A801F8086325E-wk-Fact-B1B9FBB3E65B02DB442A801F8086325E"
          xlink:label="Fact-B1B9FBB3E65B02DB442A801F8086325E-wk-Fact-B1B9FBB3E65B02DB442A801F8086325E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-B1B9FBB3E65B02DB442A801F8086325E-wk-Fact-B1B9FBB3E65B02DB442A801F8086325E"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11475-wk-Fact-B1C55F4CB7D652428FCC68218AAE6DD5"
          xlink:label="d34586122e11475-wk-Fact-B1C55F4CB7D652428FCC68218AAE6DD5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11475-wk-Fact-B1C55F4CB7D652428FCC68218AAE6DD5"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2222-wk-Fact-B1E7467675494F8418B3801F82B05100"
          xlink:label="d34458036e2222-wk-Fact-B1E7467675494F8418B3801F82B05100"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2222-wk-Fact-B1E7467675494F8418B3801F82B05100"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23229-wk-Fact-B1F66149E5D30EF98A05801F81603EA8"
          xlink:label="d34661879e23229-wk-Fact-B1F66149E5D30EF98A05801F81603EA8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23229-wk-Fact-B1F66149E5D30EF98A05801F81603EA8"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23229-wk-Fact-B1F66149E5D30EF98A05801F81603EA8"
          xlink:to="TextSelection-C47F5D99BBE34FB735B5801F8339CB61-0-wk-Footnote-C47F5D99BBE34FB735B5801F8339CB61_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4419-wk-Fact-B1FE1F215AFFABD9B609801F81378823"
          xlink:label="d34586122e4419-wk-Fact-B1FE1F215AFFABD9B609801F81378823"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4419-wk-Fact-B1FE1F215AFFABD9B609801F81378823"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1792-wk-Fact-B2196219F55E53698D0DA829DF1E2B27"
          xlink:label="d34423000e1792-wk-Fact-B2196219F55E53698D0DA829DF1E2B27"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1792-wk-Fact-B2196219F55E53698D0DA829DF1E2B27"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10114-wk-Fact-B2445D4B47D85E9CBA4A74E1190125C3"
          xlink:label="d34586122e10114-wk-Fact-B2445D4B47D85E9CBA4A74E1190125C3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10114-wk-Fact-B2445D4B47D85E9CBA4A74E1190125C3"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6897-wk-Fact-B24D04AD1CFE5421B8AAB5E1AE97DC0A"
          xlink:label="d34586122e6897-wk-Fact-B24D04AD1CFE5421B8AAB5E1AE97DC0A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6897-wk-Fact-B24D04AD1CFE5421B8AAB5E1AE97DC0A"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3177-wk-Fact-B281E1948A327D1F074D801F7F417F9A"
          xlink:label="d34430544e3177-wk-Fact-B281E1948A327D1F074D801F7F417F9A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3177-wk-Fact-B281E1948A327D1F074D801F7F417F9A"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-B2C06C2292CD5F05AEAF801F825BDEAA-wk-Fact-B2C06C2292CD5F05AEAF801F825BDEAA"
          xlink:label="Fact-B2C06C2292CD5F05AEAF801F825BDEAA-wk-Fact-B2C06C2292CD5F05AEAF801F825BDEAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-B2C06C2292CD5F05AEAF801F825BDEAA-wk-Fact-B2C06C2292CD5F05AEAF801F825BDEAA"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8765-wk-Fact-B337B62ABBFB5C5696C49995587C6B7B"
          xlink:label="d34458032e8765-wk-Fact-B337B62ABBFB5C5696C49995587C6B7B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8765-wk-Fact-B337B62ABBFB5C5696C49995587C6B7B"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8921-wk-Fact-B344BD9ABF6754369FCF350AF52DE418"
          xlink:label="d34586122e8921-wk-Fact-B344BD9ABF6754369FCF350AF52DE418"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8921-wk-Fact-B344BD9ABF6754369FCF350AF52DE418"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3067-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
          xlink:label="d34428379e3067-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458032e5280-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
          xlink:label="d34458032e5280-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3067-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5280-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3067-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5280-wk-Fact-B36327A0C18B5E19A4C35DF771B8B10A"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11033-wk-Fact-B37B6F505700BFB86614801F8217AF5C"
          xlink:label="d34661879e11033-wk-Fact-B37B6F505700BFB86614801F8217AF5C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11033-wk-Fact-B37B6F505700BFB86614801F8217AF5C"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-B3981B3D44CB5A0D36C3801F8253C52A-wk-Fact-B3981B3D44CB5A0D36C3801F8253C52A"
          xlink:label="Fact-B3981B3D44CB5A0D36C3801F8253C52A-wk-Fact-B3981B3D44CB5A0D36C3801F8253C52A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-B3981B3D44CB5A0D36C3801F8253C52A-wk-Fact-B3981B3D44CB5A0D36C3801F8253C52A"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6985-wk-Fact-B3E66210D48550AA9926F625E4EBBAD4"
          xlink:label="d34586122e6985-wk-Fact-B3E66210D48550AA9926F625E4EBBAD4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6985-wk-Fact-B3E66210D48550AA9926F625E4EBBAD4"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34512803e1694-wk-Fact-B3F7F06F30815B7EB3DF94113CFBD851"
          xlink:label="d34512803e1694-wk-Fact-B3F7F06F30815B7EB3DF94113CFBD851"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34512803e1694-wk-Fact-B3F7F06F30815B7EB3DF94113CFBD851"
          xlink:to="TextSelection-99ECE6937087FF439970801F831B2740-0-wk-Footnote-99ECE6937087FF439970801F831B2740_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1955-wk-Fact-B3FD5671955A957CB3C8801F7ECD2BE6"
          xlink:label="d34428379e1955-wk-Fact-B3FD5671955A957CB3C8801F7ECD2BE6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1955-wk-Fact-B3FD5671955A957CB3C8801F7ECD2BE6"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34524436e1804-wk-Fact-B41D8C40DC9E96021764801F82858FF5"
          xlink:label="d34524436e1804-wk-Fact-B41D8C40DC9E96021764801F82858FF5"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-0-wk-Footnote-4ABFC5BADBDD92BDEF6F801F83478C48_lbl" xlink:label="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-0-wk-Footnote-4ABFC5BADBDD92BDEF6F801F83478C48_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">February&#160;2, 2017</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">. See above for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34524436e1804-wk-Fact-B41D8C40DC9E96021764801F82858FF5"
          xlink:to="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-0-wk-Footnote-4ABFC5BADBDD92BDEF6F801F83478C48_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5247-wk-Fact-B43EBF08C38CF8025BE1801F81E33B35"
          xlink:label="d34506804e5247-wk-Fact-B43EBF08C38CF8025BE1801F81E33B35"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5247-wk-Fact-B43EBF08C38CF8025BE1801F81E33B35"
          xlink:to="TextSelection-1BC6AAD29A2FA764B230801F83025F6D-0-wk-Footnote-1BC6AAD29A2FA764B230801F83025F6D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9456-wk-Fact-B46984BEC265F2CB3433801F822E334D"
          xlink:label="d34661879e9456-wk-Fact-B46984BEC265F2CB3433801F822E334D"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e11426-wk-Fact-B46984BEC265F2CB3433801F822E334D"
          xlink:label="d34661879e11426-wk-Fact-B46984BEC265F2CB3433801F822E334D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9456-wk-Fact-B46984BEC265F2CB3433801F822E334D"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11426-wk-Fact-B46984BEC265F2CB3433801F822E334D"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:label="d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:label="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnote id="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl" xlink:label="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">As a result of the enactment of the TCJA in December 2017, Pfizer&#x2019;s </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">Provision/(benefit) for taxes on income</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> (i) for the year ended December 31, 2017 was favorably impacted by approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$10.7 billion</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily reflecting the remeasurement of U.S. deferred tax liabilities, which includes the repatriation tax on deemed repatriated accumulated post-1986 earnings of foreign subsidiaries, (ii) for the year ended December 31, 2018 was favorably impacted by approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$600 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily related to certain tax initiatives associated with the TCJA, as well as favorable adjustments to the provisional estimates of the legislation and (iii) for the year ended December 31, 2019 was favorably impacted by approximately </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"><xhtml:span>$323 million</xhtml:span></xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, primarily as a result of additional guidance issued by the U.S. Department of Treasury. See </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:normal;text-decoration:none;">Note 5</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;font-style:italic;">A.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:to="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:to="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2800-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1868-wk-Fact-B517F5E954855927AD811C36500A2AF0"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14543-wk-Fact-B51A8E65B32A1B7A347F801F7F099B83"
          xlink:label="d34661879e14543-wk-Fact-B51A8E65B32A1B7A347F801F7F099B83"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14543-wk-Fact-B51A8E65B32A1B7A347F801F7F099B83"
          xlink:to="TextSelection-94D30F114C827583A69B801F83385815-0-wk-Footnote-94D30F114C827583A69B801F83385815_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2156-wk-Fact-B51D44885CA609BBF357CF6EFC35BB67"
          xlink:label="d34460716e2156-wk-Fact-B51D44885CA609BBF357CF6EFC35BB67"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2156-wk-Fact-B51D44885CA609BBF357CF6EFC35BB67"
          xlink:to="TextSelection-4D3D893575D79794178C801F83159EA5-0-wk-Footnote-4D3D893575D79794178C801F83159EA5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:label="d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:label="d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:label="d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:label="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5046-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1479-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1613-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2511-wk-Fact-B543D8BD726058AABA86B88A419A081F"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2643-wk-Fact-B56F71AB068951F5B6B9C531420B33FC"
          xlink:label="d34428379e2643-wk-Fact-B56F71AB068951F5B6B9C531420B33FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2643-wk-Fact-B56F71AB068951F5B6B9C531420B33FC"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11327-wk-Fact-B57EC914CEEC57AD9AEC75DF29FD04C2"
          xlink:label="d34586122e11327-wk-Fact-B57EC914CEEC57AD9AEC75DF29FD04C2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11327-wk-Fact-B57EC914CEEC57AD9AEC75DF29FD04C2"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4035-wk-Fact-B5FF23DD831E759A71FF801F7DE6500E"
          xlink:label="d34458032e4035-wk-Fact-B5FF23DD831E759A71FF801F7DE6500E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4035-wk-Fact-B5FF23DD831E759A71FF801F7DE6500E"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7765-wk-Fact-B5FF4C264E8259AB8C76122637225C36"
          xlink:label="d34458032e7765-wk-Fact-B5FF4C264E8259AB8C76122637225C36"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7765-wk-Fact-B5FF4C264E8259AB8C76122637225C36"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23467-wk-Fact-B6002D168EA0157D8AFF801F80E23E6D"
          xlink:label="d34661879e23467-wk-Fact-B6002D168EA0157D8AFF801F80E23E6D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23467-wk-Fact-B6002D168EA0157D8AFF801F80E23E6D"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22563-wk-Fact-B61033E055581DA45EB7801F80C6CBA8"
          xlink:label="d34661879e22563-wk-Fact-B61033E055581DA45EB7801F80C6CBA8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22563-wk-Fact-B61033E055581DA45EB7801F80C6CBA8"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5614-wk-Fact-B655A10CD6EE090891E7801F82B1C3E5"
          xlink:label="d34458036e5614-wk-Fact-B655A10CD6EE090891E7801F82B1C3E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5614-wk-Fact-B655A10CD6EE090891E7801F82B1C3E5"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6330-wk-Fact-B657D1ACB72B0C617B94801F7ECE5765"
          xlink:label="d34458032e6330-wk-Fact-B657D1ACB72B0C617B94801F7ECE5765"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6330-wk-Fact-B657D1ACB72B0C617B94801F7ECE5765"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6330-wk-Fact-B657D1ACB72B0C617B94801F7ECE5765"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4840-wk-Fact-B6A199DD0727BCEC4725801F7F2F06A4"
          xlink:label="d34545404e4840-wk-Fact-B6A199DD0727BCEC4725801F7F2F06A4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4840-wk-Fact-B6A199DD0727BCEC4725801F7F2F06A4"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1755-wk-Fact-B6E23DD26A27DC66F8C3CAFFFD2CBF22"
          xlink:label="d34430544e1755-wk-Fact-B6E23DD26A27DC66F8C3CAFFFD2CBF22"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1755-wk-Fact-B6E23DD26A27DC66F8C3CAFFFD2CBF22"
          xlink:to="TextSelection-740582342279F0C70BD9801F82F76E00-0-wk-Footnote-740582342279F0C70BD9801F82F76E00_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1755-wk-Fact-B6E23DD26A27DC66F8C3CAFFFD2CBF22"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5981-wk-Fact-B6F40B75323EE6EF4FC4801F7DF547A2"
          xlink:label="d34458032e5981-wk-Fact-B6F40B75323EE6EF4FC4801F7DF547A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5981-wk-Fact-B6F40B75323EE6EF4FC4801F7DF547A2"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8081-wk-Fact-B703DA942F77EDFDF491DE1AC4EE74EA"
          xlink:label="d34586122e8081-wk-Fact-B703DA942F77EDFDF491DE1AC4EE74EA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8081-wk-Fact-B703DA942F77EDFDF491DE1AC4EE74EA"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3041-wk-Fact-B707042704E051E094DA0C2D5A4B4F2B"
          xlink:label="d34586122e3041-wk-Fact-B707042704E051E094DA0C2D5A4B4F2B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3041-wk-Fact-B707042704E051E094DA0C2D5A4B4F2B"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3047-wk-Fact-B708802DEAF9567DBA106E1C0C84390C"
          xlink:label="d34501946e3047-wk-Fact-B708802DEAF9567DBA106E1C0C84390C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3047-wk-Fact-B708802DEAF9567DBA106E1C0C84390C"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2224-wk-Fact-B70F6FAB9C4E502489A9A03753771E32"
          xlink:label="d34471435e2224-wk-Fact-B70F6FAB9C4E502489A9A03753771E32"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2224-wk-Fact-B70F6FAB9C4E502489A9A03753771E32"
          xlink:to="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1857-wk-Fact-B712982E5A7317455650801F80ECC2E5"
          xlink:label="d34471435e1857-wk-Fact-B712982E5A7317455650801F80ECC2E5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1857-wk-Fact-B712982E5A7317455650801F80ECC2E5"
          xlink:to="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19835-wk-Fact-B782F5C9086BF99E0D5C801F80CEC6DC"
          xlink:label="d34661879e19835-wk-Fact-B782F5C9086BF99E0D5C801F80CEC6DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19835-wk-Fact-B782F5C9086BF99E0D5C801F80CEC6DC"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5240-wk-Fact-B7BD42B10C099A6A26D1801F7FD5AF39"
          xlink:label="d34458032e5240-wk-Fact-B7BD42B10C099A6A26D1801F7FD5AF39"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5240-wk-Fact-B7BD42B10C099A6A26D1801F7FD5AF39"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5261-wk-Fact-B7FAC3FC55D55C4A8390CDA9B27086EE"
          xlink:label="d34458036e5261-wk-Fact-B7FAC3FC55D55C4A8390CDA9B27086EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5261-wk-Fact-B7FAC3FC55D55C4A8390CDA9B27086EE"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5261-wk-Fact-B7FAC3FC55D55C4A8390CDA9B27086EE"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:label="d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:label="d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:label="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:label="d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1633-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1499-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2530-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2500-wk-Fact-B803A92A99B7B178AB36801F7F30E096"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3262-wk-Fact-B844E6AF354E6B90FBC0D083BFDF0319"
          xlink:label="d34586122e3262-wk-Fact-B844E6AF354E6B90FBC0D083BFDF0319"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3262-wk-Fact-B844E6AF354E6B90FBC0D083BFDF0319"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2664-wk-Fact-B84B5B2E9880B8DB72EA801F7F15BA80"
          xlink:label="d34430544e2664-wk-Fact-B84B5B2E9880B8DB72EA801F7F15BA80"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2664-wk-Fact-B84B5B2E9880B8DB72EA801F7F15BA80"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4824-wk-Fact-B85C9CC9D293576C909EA9314FC824EE"
          xlink:label="d34661879e4824-wk-Fact-B85C9CC9D293576C909EA9314FC824EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4824-wk-Fact-B85C9CC9D293576C909EA9314FC824EE"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4824-wk-Fact-B85C9CC9D293576C909EA9314FC824EE"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2422-wk-Fact-B86C473D53F433E01138E3D722277F0D"
          xlink:label="d34471435e2422-wk-Fact-B86C473D53F433E01138E3D722277F0D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2422-wk-Fact-B86C473D53F433E01138E3D722277F0D"
          xlink:to="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e1587-wk-Fact-B879D2FCD0A23F2045A2801F7ED7E9E3"
          xlink:label="d34594690e1587-wk-Fact-B879D2FCD0A23F2045A2801F7ED7E9E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e1587-wk-Fact-B879D2FCD0A23F2045A2801F7ED7E9E3"
          xlink:to="TextSelection-F09E6DBFD0F1C24008D40C2EE7BC9B26-0-wk-Footnote-F09E6DBFD0F1C24008D40C2EE7BC9B26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8215-wk-Fact-B8848B5AC5765E01A8796908F66409AA"
          xlink:label="d34458032e8215-wk-Fact-B8848B5AC5765E01A8796908F66409AA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8215-wk-Fact-B8848B5AC5765E01A8796908F66409AA"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10187-wk-Fact-B891103106B358EFB566B38D67137E32"
          xlink:label="d34586122e10187-wk-Fact-B891103106B358EFB566B38D67137E32"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10187-wk-Fact-B891103106B358EFB566B38D67137E32"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2808-wk-Fact-B8932CAFC2CF99FDC067801F7FD54D8F"
          xlink:label="d34661879e2808-wk-Fact-B8932CAFC2CF99FDC067801F7FD54D8F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2808-wk-Fact-B8932CAFC2CF99FDC067801F7FD54D8F"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7"
          xlink:label="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5249-wk-Fact-B89914355BA75F4EB79DB0937B28FAC7"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8423-wk-Fact-B8C0D0C18DFF193C78E9801F81F22825"
          xlink:label="d34545404e8423-wk-Fact-B8C0D0C18DFF193C78E9801F81F22825"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8423-wk-Fact-B8C0D0C18DFF193C78E9801F81F22825"
          xlink:to="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19520-wk-Fact-B8D531637E8DF54F3F7E801F80AB0923"
          xlink:label="d34661879e19520-wk-Fact-B8D531637E8DF54F3F7E801F80AB0923"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19520-wk-Fact-B8D531637E8DF54F3F7E801F80AB0923"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2100-wk-Fact-B8D6B5CC80C55A49A1EE3141CCBD5ACE"
          xlink:label="d34423000e2100-wk-Fact-B8D6B5CC80C55A49A1EE3141CCBD5ACE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2100-wk-Fact-B8D6B5CC80C55A49A1EE3141CCBD5ACE"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10333-wk-Fact-B8EF963B8EAAA02A9097801F82143358"
          xlink:label="d34661879e10333-wk-Fact-B8EF963B8EAAA02A9097801F82143358"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10333-wk-Fact-B8EF963B8EAAA02A9097801F82143358"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2"
          xlink:label="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2"
          xlink:to="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5753-wk-Fact-B92C01A1BBAB52D5880211444BD320E2"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8276-wk-Fact-B9634D3CD51FCF12B7F1DE1F7DE2E34F"
          xlink:label="d34586122e8276-wk-Fact-B9634D3CD51FCF12B7F1DE1F7DE2E34F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8276-wk-Fact-B9634D3CD51FCF12B7F1DE1F7DE2E34F"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8382-wk-Fact-B9796D68B7845314B40EE00253EDFE48"
          xlink:label="d34586122e8382-wk-Fact-B9796D68B7845314B40EE00253EDFE48"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8382-wk-Fact-B9796D68B7845314B40EE00253EDFE48"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8382-wk-Fact-B9796D68B7845314B40EE00253EDFE48"
          xlink:to="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2314-wk-Fact-B984EC8BD3C15978AA373038C05C04C3"
          xlink:label="d34468079e2314-wk-Fact-B984EC8BD3C15978AA373038C05C04C3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2314-wk-Fact-B984EC8BD3C15978AA373038C05C04C3"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3442-wk-Fact-B9A985D5E312D61B9E03801F81513582"
          xlink:label="d34594690e3442-wk-Fact-B9A985D5E312D61B9E03801F81513582"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3442-wk-Fact-B9A985D5E312D61B9E03801F81513582"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3442-wk-Fact-B9A985D5E312D61B9E03801F81513582"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34524436e1734-wk-Fact-B9B68A9EF2D595760795801F82827C2E"
          xlink:label="d34524436e1734-wk-Fact-B9B68A9EF2D595760795801F82827C2E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34524436e1734-wk-Fact-B9B68A9EF2D595760795801F82827C2E"
          xlink:to="TextSelection-4ABFC5BADBDD92BDEF6F801F83478C48-0-wk-Footnote-4ABFC5BADBDD92BDEF6F801F83478C48_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2252-wk-Fact-B9EEDF4C478F5FE399BD8F88FA3C4292"
          xlink:label="d34529301e2252-wk-Fact-B9EEDF4C478F5FE399BD8F88FA3C4292"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2252-wk-Fact-B9EEDF4C478F5FE399BD8F88FA3C4292"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3732-wk-Fact-B9F8D9C900D35DCE8A6D80AA6FAD17C8"
          xlink:label="d34468079e3732-wk-Fact-B9F8D9C900D35DCE8A6D80AA6FAD17C8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3732-wk-Fact-B9F8D9C900D35DCE8A6D80AA6FAD17C8"
          xlink:to="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22345-wk-Fact-BA2C0B3B568CB294D55A801F7E0CA046"
          xlink:label="d34661879e22345-wk-Fact-BA2C0B3B568CB294D55A801F7E0CA046"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22345-wk-Fact-BA2C0B3B568CB294D55A801F7E0CA046"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2973-wk-Fact-BA711E164C3C5AA1A6F841BD16FF39C7"
          xlink:label="d34458036e2973-wk-Fact-BA711E164C3C5AA1A6F841BD16FF39C7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2973-wk-Fact-BA711E164C3C5AA1A6F841BD16FF39C7"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11318-wk-Fact-BA7C888E080F79CDEA22801F8225858E"
          xlink:label="d34661879e11318-wk-Fact-BA7C888E080F79CDEA22801F8225858E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11318-wk-Fact-BA7C888E080F79CDEA22801F8225858E"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5220-wk-Fact-BA7D87048EFE8B8832B0801F812594B2"
          xlink:label="d34545404e5220-wk-Fact-BA7D87048EFE8B8832B0801F812594B2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5220-wk-Fact-BA7D87048EFE8B8832B0801F812594B2"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34498941e1532-wk-Fact-BA94151A8C0D50BF9AA027BBFC277D06"
          xlink:label="d34498941e1532-wk-Fact-BA94151A8C0D50BF9AA027BBFC277D06"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34498941e1532-wk-Fact-BA94151A8C0D50BF9AA027BBFC277D06"
          xlink:to="TextSelection-A750B31D2CDA1870AFBA801F8317F8FF-0-wk-Footnote-A750B31D2CDA1870AFBA801F8317F8FF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23856-wk-Fact-BAB81DA4890D0987B01F801F7EBE147E"
          xlink:label="d34661879e23856-wk-Fact-BAB81DA4890D0987B01F801F7EBE147E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23856-wk-Fact-BAB81DA4890D0987B01F801F7EBE147E"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23856-wk-Fact-BAB81DA4890D0987B01F801F7EBE147E"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3321-wk-Fact-BAB8B49654C57E704233801F8111DFBB"
          xlink:label="d34586122e3321-wk-Fact-BAB8B49654C57E704233801F8111DFBB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3321-wk-Fact-BAB8B49654C57E704233801F8111DFBB"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3848-wk-Fact-BAD831174C94566A924C53EC67145618"
          xlink:label="d34458036e3848-wk-Fact-BAD831174C94566A924C53EC67145618"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3848-wk-Fact-BAD831174C94566A924C53EC67145618"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2575-wk-Fact-BAD8CA6C4B6A5AE88554A9B88D8A8209"
          xlink:label="d34430544e2575-wk-Fact-BAD8CA6C4B6A5AE88554A9B88D8A8209"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2575-wk-Fact-BAD8CA6C4B6A5AE88554A9B88D8A8209"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1821-wk-Fact-BAE279F5EB71087D83F2801F7EE05475"
          xlink:label="d34428379e1821-wk-Fact-BAE279F5EB71087D83F2801F7EE05475"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1821-wk-Fact-BAE279F5EB71087D83F2801F7EE05475"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2204-wk-Fact-BAF546B82D94528D8306C20351599D86"
          xlink:label="d34428379e2204-wk-Fact-BAF546B82D94528D8306C20351599D86"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2204-wk-Fact-BAF546B82D94528D8306C20351599D86"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e3044-wk-Fact-BB4D97BFDF50513BAE0BF29E98F95690"
          xlink:label="d34529301e3044-wk-Fact-BB4D97BFDF50513BAE0BF29E98F95690"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3044-wk-Fact-BB4D97BFDF50513BAE0BF29E98F95690"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3044-wk-Fact-BB4D97BFDF50513BAE0BF29E98F95690"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6809-wk-Fact-BB8EECA4B442C1A654CD801F7DF0331C"
          xlink:label="d34458032e6809-wk-Fact-BB8EECA4B442C1A654CD801F7DF0331C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6809-wk-Fact-BB8EECA4B442C1A654CD801F7DF0331C"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1954-wk-Fact-BB9B4543336C561697FD0F59A7D23B67"
          xlink:label="d34471435e1954-wk-Fact-BB9B4543336C561697FD0F59A7D23B67"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1954-wk-Fact-BB9B4543336C561697FD0F59A7D23B67"
          xlink:to="TextSelection-9004B65C4C0D4DF3F861801F830C1043-0-wk-Footnote-9004B65C4C0D4DF3F861801F830C1043_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3935-wk-Fact-BB9E538422B53CC7D9FE801F82463C58"
          xlink:label="d34545404e3935-wk-Fact-BB9E538422B53CC7D9FE801F82463C58"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3935-wk-Fact-BB9E538422B53CC7D9FE801F82463C58"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4946-wk-Fact-BBB1AC598EA163A20CDE801F7F453119"
          xlink:label="d34545404e4946-wk-Fact-BBB1AC598EA163A20CDE801F7F453119"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4946-wk-Fact-BBB1AC598EA163A20CDE801F7F453119"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4946-wk-Fact-BBB1AC598EA163A20CDE801F7F453119"
          xlink:to="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3539-wk-Fact-BC04211B3B4E671AA2DC801F82A46721"
          xlink:label="d34458036e3539-wk-Fact-BC04211B3B4E671AA2DC801F82A46721"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3539-wk-Fact-BC04211B3B4E671AA2DC801F82A46721"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4135-wk-Fact-BC0C1F861F85562394C153BA53C5058B"
          xlink:label="d34586122e4135-wk-Fact-BC0C1F861F85562394C153BA53C5058B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4135-wk-Fact-BC0C1F861F85562394C153BA53C5058B"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4135-wk-Fact-BC0C1F861F85562394C153BA53C5058B"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2946-wk-Fact-BC27D7DE57C7FCDFEA06801F82A12BD1"
          xlink:label="d34458036e2946-wk-Fact-BC27D7DE57C7FCDFEA06801F82A12BD1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2946-wk-Fact-BC27D7DE57C7FCDFEA06801F82A12BD1"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2061-wk-Fact-BC2A634BA20E3AB6E549801F823C4316"
          xlink:label="d34471435e2061-wk-Fact-BC2A634BA20E3AB6E549801F823C4316"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2061-wk-Fact-BC2A634BA20E3AB6E549801F823C4316"
          xlink:to="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6406-wk-Fact-BC35357C49C864E19515801F7EFFF359"
          xlink:label="d34458032e6406-wk-Fact-BC35357C49C864E19515801F7EFFF359"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6406-wk-Fact-BC35357C49C864E19515801F7EFFF359"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6406-wk-Fact-BC35357C49C864E19515801F7EFFF359"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2705-wk-Fact-BC7E0D00B21FF35D771B801F81A9F967"
          xlink:label="d34586122e2705-wk-Fact-BC7E0D00B21FF35D771B801F81A9F967"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2705-wk-Fact-BC7E0D00B21FF35D771B801F81A9F967"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2529-wk-Fact-BCF75818718DFBE05AB3801F80FDBB16"
          xlink:label="d34471435e2529-wk-Fact-BCF75818718DFBE05AB3801F80FDBB16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2529-wk-Fact-BCF75818718DFBE05AB3801F80FDBB16"
          xlink:to="TextSelection-47E9F3EA3B1C2E9378F3801F830D0F2C-0-wk-Footnote-47E9F3EA3B1C2E9378F3801F830D0F2C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14972-wk-Fact-BCFF3D61A9114065510B801F7F0C89BE"
          xlink:label="d34661879e14972-wk-Fact-BCFF3D61A9114065510B801F7F0C89BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14972-wk-Fact-BCFF3D61A9114065510B801F7F0C89BE"
          xlink:to="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7355-wk-Fact-BD0B6B5222EF5CB6A5FCC1C812C3C334"
          xlink:label="d34586122e7355-wk-Fact-BD0B6B5222EF5CB6A5FCC1C812C3C334"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7355-wk-Fact-BD0B6B5222EF5CB6A5FCC1C812C3C334"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10806-wk-Fact-BD46B1A4E13BB0CD2D7F801F81EA9171"
          xlink:label="d34661879e10806-wk-Fact-BD46B1A4E13BB0CD2D7F801F81EA9171"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10806-wk-Fact-BD46B1A4E13BB0CD2D7F801F81EA9171"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3040-wk-Fact-BD795F9219995817AC05CE7BBCBF719E"
          xlink:label="d34458036e3040-wk-Fact-BD795F9219995817AC05CE7BBCBF719E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3040-wk-Fact-BD795F9219995817AC05CE7BBCBF719E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4092-wk-Fact-BD8A72C249F655DE8F2BC9B4F95D1DCA"
          xlink:label="d34458036e4092-wk-Fact-BD8A72C249F655DE8F2BC9B4F95D1DCA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4092-wk-Fact-BD8A72C249F655DE8F2BC9B4F95D1DCA"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4581-wk-Fact-BD96EFDCEF39E408FD37D85DDBD98655"
          xlink:label="d34529301e4581-wk-Fact-BD96EFDCEF39E408FD37D85DDBD98655"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4581-wk-Fact-BD96EFDCEF39E408FD37D85DDBD98655"
          xlink:to="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21429-wk-Fact-BDDDC33CB2AC40243C72801F7E12971A"
          xlink:label="d34661879e21429-wk-Fact-BDDDC33CB2AC40243C72801F7E12971A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21429-wk-Fact-BDDDC33CB2AC40243C72801F7E12971A"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21429-wk-Fact-BDDDC33CB2AC40243C72801F7E12971A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3973-wk-Fact-BE07CE4FFFBA7AA6551D01C7EE81842C"
          xlink:label="d34545404e3973-wk-Fact-BE07CE4FFFBA7AA6551D01C7EE81842C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3973-wk-Fact-BE07CE4FFFBA7AA6551D01C7EE81842C"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8421-wk-Fact-BE0EABAA50D96FFC3507DE2093101A4D"
          xlink:label="d34586122e8421-wk-Fact-BE0EABAA50D96FFC3507DE2093101A4D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8421-wk-Fact-BE0EABAA50D96FFC3507DE2093101A4D"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8421-wk-Fact-BE0EABAA50D96FFC3507DE2093101A4D"
          xlink:to="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4859-wk-Fact-BE134C05DCF6ADAF9FBF801F7F4DDC1B"
          xlink:label="d34545404e4859-wk-Fact-BE134C05DCF6ADAF9FBF801F7F4DDC1B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4859-wk-Fact-BE134C05DCF6ADAF9FBF801F7F4DDC1B"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4770-wk-Fact-BE4C23E3208BEB55E46ED85E8DBE2AC5"
          xlink:label="d34529301e4770-wk-Fact-BE4C23E3208BEB55E46ED85E8DBE2AC5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4770-wk-Fact-BE4C23E3208BEB55E46ED85E8DBE2AC5"
          xlink:to="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4584-wk-Fact-BE88CEC570F652B19EAF84B100B1E47E"
          xlink:label="d34538474e4584-wk-Fact-BE88CEC570F652B19EAF84B100B1E47E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4584-wk-Fact-BE88CEC570F652B19EAF84B100B1E47E"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9790-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
          xlink:label="d34661879e9790-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e2905-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
          xlink:label="d34661879e2905-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9790-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2905-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9790-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2905-wk-Fact-BEC38FABB5D7D9815D6F801F81FE9000"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4779-wk-Fact-BEE8E31AD112200FA011801F7F3392D2"
          xlink:label="d34545404e4779-wk-Fact-BEE8E31AD112200FA011801F7F3392D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4779-wk-Fact-BEE8E31AD112200FA011801F7F3392D2"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4779-wk-Fact-BEE8E31AD112200FA011801F7F3392D2"
          xlink:to="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e6156-wk-Fact-BEEC85B5E0F398A0DE71801F7E7B685A"
          xlink:label="d34586122e6156-wk-Fact-BEEC85B5E0F398A0DE71801F7E7B685A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e6156-wk-Fact-BEEC85B5E0F398A0DE71801F7E7B685A"
          xlink:to="TextSelection-C48216615E4B68E82EBD801F8351B517-0-wk-Footnote-C48216615E4B68E82EBD801F8351B517_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003"
          xlink:label="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3435-wk-Fact-BF4BB69D4CA45BFCBBFC8F23D9115003"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2168-wk-Fact-BF946A4349E2545BA4A121AADE5B3A9D"
          xlink:label="d34423000e2168-wk-Fact-BF946A4349E2545BA4A121AADE5B3A9D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2168-wk-Fact-BF946A4349E2545BA4A121AADE5B3A9D"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23759-wk-Fact-BFCA8568A70BD9B17120801F7E0B201D"
          xlink:label="d34661879e23759-wk-Fact-BFCA8568A70BD9B17120801F7E0B201D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23759-wk-Fact-BFCA8568A70BD9B17120801F7E0B201D"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23759-wk-Fact-BFCA8568A70BD9B17120801F7E0B201D"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6348-wk-Fact-BFDC8661881B55B6A476783E59E9740E"
          xlink:label="d34538474e6348-wk-Fact-BFDC8661881B55B6A476783E59E9740E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6348-wk-Fact-BFDC8661881B55B6A476783E59E9740E"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-BFE1E325EAE23FB57CC7801F82423AA9-wk-Fact-BFE1E325EAE23FB57CC7801F82423AA9"
          xlink:label="Fact-BFE1E325EAE23FB57CC7801F82423AA9-wk-Fact-BFE1E325EAE23FB57CC7801F82423AA9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-BFE1E325EAE23FB57CC7801F82423AA9-wk-Fact-BFE1E325EAE23FB57CC7801F82423AA9"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3644-wk-Fact-C023DBBE72C11C46F64CD083BFF55D24"
          xlink:label="d34586122e3644-wk-Fact-C023DBBE72C11C46F64CD083BFF55D24"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3644-wk-Fact-C023DBBE72C11C46F64CD083BFF55D24"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e5337-wk-Fact-C09AF6E13F933AFF10EF801F7FC152C9"
          xlink:label="d34661879e5337-wk-Fact-C09AF6E13F933AFF10EF801F7FC152C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e5337-wk-Fact-C09AF6E13F933AFF10EF801F7FC152C9"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2882-wk-Fact-C0A19D1D9DC45DD6801580B6A3ACBEA6"
          xlink:label="d34430544e2882-wk-Fact-C0A19D1D9DC45DD6801580B6A3ACBEA6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2882-wk-Fact-C0A19D1D9DC45DD6801580B6A3ACBEA6"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e12095-wk-Fact-C0BF06F9A6D60B722450801F82C0AE3B"
          xlink:label="d34586122e12095-wk-Fact-C0BF06F9A6D60B722450801F82C0AE3B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e12095-wk-Fact-C0BF06F9A6D60B722450801F82C0AE3B"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2342-wk-Fact-C0D03D29D7BD5A5094E94025EADCF408"
          xlink:label="d34423000e2342-wk-Fact-C0D03D29D7BD5A5094E94025EADCF408"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2342-wk-Fact-C0D03D29D7BD5A5094E94025EADCF408"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7194-wk-Fact-C0D2C058A53A516D89F67516151CA125"
          xlink:label="d34458032e7194-wk-Fact-C0D2C058A53A516D89F67516151CA125"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7194-wk-Fact-C0D2C058A53A516D89F67516151CA125"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6638-wk-Fact-C12C1FBA8458EC3FD4D1801F7E041A29"
          xlink:label="d34458032e6638-wk-Fact-C12C1FBA8458EC3FD4D1801F7E041A29"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6638-wk-Fact-C12C1FBA8458EC3FD4D1801F7E041A29"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1652-wk-Fact-C13328F655305F8CB43D006E17681322"
          xlink:label="d34428379e1652-wk-Fact-C13328F655305F8CB43D006E17681322"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1652-wk-Fact-C13328F655305F8CB43D006E17681322"
          xlink:to="TextSelection-8E46612132BB401EAD8E801F82F7F7DF-0-wk-Footnote-8E46612132BB401EAD8E801F82F7F7DF_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1652-wk-Fact-C13328F655305F8CB43D006E17681322"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-C13CFC3CB21F52099D562C221C465A73-wk-Fact-C13CFC3CB21F52099D562C221C465A73"
          xlink:label="Fact-C13CFC3CB21F52099D562C221C465A73-wk-Fact-C13CFC3CB21F52099D562C221C465A73"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-C13CFC3CB21F52099D562C221C465A73-wk-Fact-C13CFC3CB21F52099D562C221C465A73"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1634-wk-Fact-C16D2F781E815917AC4E583A6245970B"
          xlink:label="d34423000e1634-wk-Fact-C16D2F781E815917AC4E583A6245970B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34512803e1648-wk-Fact-C16D2F781E815917AC4E583A6245970B"
          xlink:label="d34512803e1648-wk-Fact-C16D2F781E815917AC4E583A6245970B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1634-wk-Fact-C16D2F781E815917AC4E583A6245970B"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34512803e1648-wk-Fact-C16D2F781E815917AC4E583A6245970B"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1634-wk-Fact-C16D2F781E815917AC4E583A6245970B"
          xlink:to="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34512803e1648-wk-Fact-C16D2F781E815917AC4E583A6245970B"
          xlink:to="TextSelection-F21054ED24F2C9B7501A801F831BCAFF-0-wk-Footnote-F21054ED24F2C9B7501A801F831BCAFF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3196-wk-Fact-C1EB256C91145D3BB9F80464D5790C53"
          xlink:label="d34428379e3196-wk-Fact-C1EB256C91145D3BB9F80464D5790C53"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3196-wk-Fact-C1EB256C91145D3BB9F80464D5790C53"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3119-wk-Fact-C2867733F38A06F7227D801F7F30AEAD"
          xlink:label="d34430544e3119-wk-Fact-C2867733F38A06F7227D801F7F30AEAD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3119-wk-Fact-C2867733F38A06F7227D801F7F30AEAD"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10168-wk-Fact-C29B3A689BD4584B967AF3ABE0A9C9D3"
          xlink:label="d34586122e10168-wk-Fact-C29B3A689BD4584B967AF3ABE0A9C9D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10168-wk-Fact-C29B3A689BD4584B967AF3ABE0A9C9D3"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e5317-wk-Fact-C2A34D3ABFB1A91EA818801F7FB1393F"
          xlink:label="d34661879e5317-wk-Fact-C2A34D3ABFB1A91EA818801F7FB1393F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e5317-wk-Fact-C2A34D3ABFB1A91EA818801F7FB1393F"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2402-wk-Fact-C2C7E920844E64417EE0801F7F43A1D0"
          xlink:label="d34430544e2402-wk-Fact-C2C7E920844E64417EE0801F7F43A1D0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2402-wk-Fact-C2C7E920844E64417EE0801F7F43A1D0"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:label="d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:label="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:to="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:to="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2820-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1888-wk-Fact-C31FF0260B8088C2BC0DAB460A9A6857"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2579-wk-Fact-C3564D2578C699EB2759801F8289A914"
          xlink:label="d34460716e2579-wk-Fact-C3564D2578C699EB2759801F8289A914"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2579-wk-Fact-C3564D2578C699EB2759801F8289A914"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10972-wk-Fact-C356BA78C171B344C1E7801F823FA26C"
          xlink:label="d34661879e10972-wk-Fact-C356BA78C171B344C1E7801F823FA26C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10972-wk-Fact-C356BA78C171B344C1E7801F823FA26C"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1929-wk-Fact-C36972272EBF57F09D3E0A0B47D781D3"
          xlink:label="d34430544e1929-wk-Fact-C36972272EBF57F09D3E0A0B47D781D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1929-wk-Fact-C36972272EBF57F09D3E0A0B47D781D3"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3634-wk-Fact-C3D0942856A1581EAF48531154A4786E"
          xlink:label="d34661879e3634-wk-Fact-C3D0942856A1581EAF48531154A4786E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3634-wk-Fact-C3D0942856A1581EAF48531154A4786E"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3634-wk-Fact-C3D0942856A1581EAF48531154A4786E"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7342-wk-Fact-C3D92DAFDA945B9CB8FF4887D799EB18"
          xlink:label="d34458032e7342-wk-Fact-C3D92DAFDA945B9CB8FF4887D799EB18"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7342-wk-Fact-C3D92DAFDA945B9CB8FF4887D799EB18"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9743-wk-Fact-C3DE40879A16565EBD6E29F02FEBF113"
          xlink:label="d34458032e9743-wk-Fact-C3DE40879A16565EBD6E29F02FEBF113"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9743-wk-Fact-C3DE40879A16565EBD6E29F02FEBF113"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4751-wk-Fact-C45B07370E9D1070339E801F7FB12D9A"
          xlink:label="d34529301e4751-wk-Fact-C45B07370E9D1070339E801F7FB12D9A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4751-wk-Fact-C45B07370E9D1070339E801F7FB12D9A"
          xlink:to="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3649-wk-Fact-C481ECF3EFBB0708C01D801F7EFDD582"
          xlink:label="d34458032e3649-wk-Fact-C481ECF3EFBB0708C01D801F7EFDD582"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3649-wk-Fact-C481ECF3EFBB0708C01D801F7EFDD582"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3183-wk-Fact-C48222126B9050F9BFAC0CB6B70D58A1"
          xlink:label="d34423000e3183-wk-Fact-C48222126B9050F9BFAC0CB6B70D58A1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3183-wk-Fact-C48222126B9050F9BFAC0CB6B70D58A1"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6795-wk-Fact-C4A0AC65971AD463ED33801F81E8AD2D"
          xlink:label="d34661879e6795-wk-Fact-C4A0AC65971AD463ED33801F81E8AD2D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6795-wk-Fact-C4A0AC65971AD463ED33801F81E8AD2D"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2317-wk-Fact-C51C12B9003E560B915ACD09B3E99840"
          xlink:label="d34428379e2317-wk-Fact-C51C12B9003E560B915ACD09B3E99840"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2317-wk-Fact-C51C12B9003E560B915ACD09B3E99840"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3153-wk-Fact-C55A09F5044EA944EC43801F7F3390E1"
          xlink:label="d34545404e3153-wk-Fact-C55A09F5044EA944EC43801F7F3390E1"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2141-wk-Fact-C55A09F5044EA944EC43801F7F3390E1"
          xlink:label="d34430544e2141-wk-Fact-C55A09F5044EA944EC43801F7F3390E1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3153-wk-Fact-C55A09F5044EA944EC43801F7F3390E1"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2141-wk-Fact-C55A09F5044EA944EC43801F7F3390E1"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8896-wk-Fact-C5A4FB3948D259AA97E130C3BE069EA0"
          xlink:label="d34458032e8896-wk-Fact-C5A4FB3948D259AA97E130C3BE069EA0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8896-wk-Fact-C5A4FB3948D259AA97E130C3BE069EA0"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24462-wk-Fact-C5DF68B00988C4249D4D801F81707342"
          xlink:label="d34661879e24462-wk-Fact-C5DF68B00988C4249D4D801F81707342"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24462-wk-Fact-C5DF68B00988C4249D4D801F81707342"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14911-wk-Fact-C5F159D4AD69FB122084801F7F082E6A"
          xlink:label="d34661879e14911-wk-Fact-C5F159D4AD69FB122084801F7F082E6A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14911-wk-Fact-C5F159D4AD69FB122084801F7F082E6A"
          xlink:to="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2364-wk-Fact-C602001194365B76BEA91037F0F0DB98"
          xlink:label="d34430544e2364-wk-Fact-C602001194365B76BEA91037F0F0DB98"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2364-wk-Fact-C602001194365B76BEA91037F0F0DB98"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2480-wk-Fact-C61A53394E697A7EF8C6801F7E98760D"
          xlink:label="d34468079e2480-wk-Fact-C61A53394E697A7EF8C6801F7E98760D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2480-wk-Fact-C61A53394E697A7EF8C6801F7E98760D"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e7101-wk-Fact-C66ABB169512D5FA96F6801F7EE94810"
          xlink:label="d34545404e7101-wk-Fact-C66ABB169512D5FA96F6801F7EE94810"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7101-wk-Fact-C66ABB169512D5FA96F6801F7EE94810"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7101-wk-Fact-C66ABB169512D5FA96F6801F7EE94810"
          xlink:to="TextSelection-D18F4ABD009D1B329ACA801F8312407D-0-wk-Footnote-D18F4ABD009D1B329ACA801F8312407D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3386-wk-Fact-C6871A6C06945BFABCFCA1C5346E9560"
          xlink:label="d34458036e3386-wk-Fact-C6871A6C06945BFABCFCA1C5346E9560"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3386-wk-Fact-C6871A6C06945BFABCFCA1C5346E9560"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2949-wk-Fact-C691D683EBCB98306D23801F7F16756B"
          xlink:label="d34428379e2949-wk-Fact-C691D683EBCB98306D23801F7F16756B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2949-wk-Fact-C691D683EBCB98306D23801F7F16756B"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2852-wk-Fact-C6ADF4DB93D254E5BD23EA5C35CC303C"
          xlink:label="d34468079e2852-wk-Fact-C6ADF4DB93D254E5BD23EA5C35CC303C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2852-wk-Fact-C6ADF4DB93D254E5BD23EA5C35CC303C"
          xlink:to="TextSelection-6EB19A358FB435AA6254801F8305544A-0-wk-Footnote-6EB19A358FB435AA6254801F8305544A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5134-wk-Fact-C6E28D0783BF5F14B7C1F693DE2205FC"
          xlink:label="d34458036e5134-wk-Fact-C6E28D0783BF5F14B7C1F693DE2205FC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5134-wk-Fact-C6E28D0783BF5F14B7C1F693DE2205FC"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5134-wk-Fact-C6E28D0783BF5F14B7C1F693DE2205FC"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7514-wk-Fact-C787510F91375F8DA60A77279DBC12D7"
          xlink:label="d34458032e7514-wk-Fact-C787510F91375F8DA60A77279DBC12D7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7514-wk-Fact-C787510F91375F8DA60A77279DBC12D7"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3950-wk-Fact-C7C4AE8978C55E58ADD8D2CE87F7F6ED"
          xlink:label="d34586122e3950-wk-Fact-C7C4AE8978C55E58ADD8D2CE87F7F6ED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3950-wk-Fact-C7C4AE8978C55E58ADD8D2CE87F7F6ED"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1618-wk-Fact-C811C044F93768A92542801F80F5DB92"
          xlink:label="d34471435e1618-wk-Fact-C811C044F93768A92542801F80F5DB92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1618-wk-Fact-C811C044F93768A92542801F80F5DB92"
          xlink:to="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2596-wk-Fact-C815B28EFCEB57A091D4DD245EBDE146"
          xlink:label="d34428379e2596-wk-Fact-C815B28EFCEB57A091D4DD245EBDE146"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2596-wk-Fact-C815B28EFCEB57A091D4DD245EBDE146"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23817-wk-Fact-C81AF605318FDAE7E9A8801F813229BB"
          xlink:label="d34661879e23817-wk-Fact-C81AF605318FDAE7E9A8801F813229BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23817-wk-Fact-C81AF605318FDAE7E9A8801F813229BB"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23817-wk-Fact-C81AF605318FDAE7E9A8801F813229BB"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34498941e1578-wk-Fact-C822D3E8545E59F38E6D05A0A14FFE9D"
          xlink:label="d34498941e1578-wk-Fact-C822D3E8545E59F38E6D05A0A14FFE9D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34498941e1578-wk-Fact-C822D3E8545E59F38E6D05A0A14FFE9D"
          xlink:to="TextSelection-80773A0CFA5531791DCE801F8317B622-0-wk-Footnote-80773A0CFA5531791DCE801F8317B622_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3216-wk-Fact-C8753C9584514B8878AE801F81306F2E"
          xlink:label="d34428379e3216-wk-Fact-C8753C9584514B8878AE801F81306F2E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3216-wk-Fact-C8753C9584514B8878AE801F81306F2E"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19777-wk-Fact-C8943A121EEDA141FD9B801F7DF3C7FA"
          xlink:label="d34661879e19777-wk-Fact-C8943A121EEDA141FD9B801F7DF3C7FA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19777-wk-Fact-C8943A121EEDA141FD9B801F7DF3C7FA"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5663-wk-Fact-C89921B0CDF57E82D509801F81DD2CD9"
          xlink:label="d34506804e5663-wk-Fact-C89921B0CDF57E82D509801F81DD2CD9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5663-wk-Fact-C89921B0CDF57E82D509801F81DD2CD9"
          xlink:to="TextSelection-6F64B92D6ED017F5DCCE801F8303D4C2-0-wk-Footnote-6F64B92D6ED017F5DCCE801F8303D4C2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4622-wk-Fact-C8A8BF249D3C3080DE9D801F803E1DD7"
          xlink:label="d34661879e4622-wk-Fact-C8A8BF249D3C3080DE9D801F803E1DD7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4622-wk-Fact-C8A8BF249D3C3080DE9D801F803E1DD7"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e4096-wk-Fact-C8B439FC676AA180BB18801F8196982F"
          xlink:label="d34586122e4096-wk-Fact-C8B439FC676AA180BB18801F8196982F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4096-wk-Fact-C8B439FC676AA180BB18801F8196982F"
          xlink:to="TextSelection-AA048B95560A978BA577801F834F378C-0-wk-Footnote-AA048B95560A978BA577801F834F378C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4242-wk-Fact-C8B9E3934BFD630207B2AB460A1A7731"
          xlink:label="d34458036e4242-wk-Fact-C8B9E3934BFD630207B2AB460A1A7731"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4242-wk-Fact-C8B9E3934BFD630207B2AB460A1A7731"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3853-wk-Fact-C8FEE220A6AD511B90AEDFED4C8522CE"
          xlink:label="d34661879e3853-wk-Fact-C8FEE220A6AD511B90AEDFED4C8522CE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3853-wk-Fact-C8FEE220A6AD511B90AEDFED4C8522CE"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10229-wk-Fact-C92813FC360B292546D9801F821F48E6"
          xlink:label="d34661879e10229-wk-Fact-C92813FC360B292546D9801F821F48E6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10229-wk-Fact-C92813FC360B292546D9801F821F48E6"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6041-wk-Fact-C92D70667288365FCFEA801F82243A1E"
          xlink:label="d34661879e6041-wk-Fact-C92D70667288365FCFEA801F82243A1E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6041-wk-Fact-C92D70667288365FCFEA801F82243A1E"
          xlink:to="TextSelection-012CB0D1CBECC8892491801F83396F31-0-wk-Footnote-012CB0D1CBECC8892491801F83396F31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e16257-wk-Fact-C971B93D19C9DBDCC70B801F827FFB9E"
          xlink:label="d34661879e16257-wk-Fact-C971B93D19C9DBDCC70B801F827FFB9E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e16257-wk-Fact-C971B93D19C9DBDCC70B801F827FFB9E"
          xlink:to="TextSelection-EC039A2EA27496CBA7B4801F833815DA-0-wk-Footnote-EC039A2EA27496CBA7B4801F833815DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21189-wk-Fact-C987C1B42EE95EB272F6801F7DFFD049"
          xlink:label="d34661879e21189-wk-Fact-C987C1B42EE95EB272F6801F7DFFD049"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21189-wk-Fact-C987C1B42EE95EB272F6801F7DFFD049"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4222-wk-Fact-C99D0BA3F6095B8AB635F01DBE0D4EF8"
          xlink:label="d34458036e4222-wk-Fact-C99D0BA3F6095B8AB635F01DBE0D4EF8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4222-wk-Fact-C99D0BA3F6095B8AB635F01DBE0D4EF8"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2400-wk-Fact-CA434D2888FB588EB4655963352B2A4D"
          xlink:label="d34428379e2400-wk-Fact-CA434D2888FB588EB4655963352B2A4D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2400-wk-Fact-CA434D2888FB588EB4655963352B2A4D"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9810-wk-Fact-CA576382E824210D03C9801F7EFD8AAC"
          xlink:label="d34458032e9810-wk-Fact-CA576382E824210D03C9801F7EFD8AAC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9810-wk-Fact-CA576382E824210D03C9801F7EFD8AAC"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7573-wk-Fact-CA6EF8716A5E5BD1809B42697B1223C5"
          xlink:label="d34458032e7573-wk-Fact-CA6EF8716A5E5BD1809B42697B1223C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7573-wk-Fact-CA6EF8716A5E5BD1809B42697B1223C5"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2250-wk-Fact-CAA3EF8F2067516F9B2E0F85B4BF5AD0"
          xlink:label="d34428379e2250-wk-Fact-CAA3EF8F2067516F9B2E0F85B4BF5AD0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2250-wk-Fact-CAA3EF8F2067516F9B2E0F85B4BF5AD0"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6774-wk-Fact-CAB1BA2F9C800F5BD664801F825C70B5"
          xlink:label="d34458032e6774-wk-Fact-CAB1BA2F9C800F5BD664801F825C70B5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6774-wk-Fact-CAB1BA2F9C800F5BD664801F825C70B5"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9316-wk-Fact-CAF98663333909A19E50DE22C3E7514B"
          xlink:label="d34586122e9316-wk-Fact-CAF98663333909A19E50DE22C3E7514B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9316-wk-Fact-CAF98663333909A19E50DE22C3E7514B"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5949-wk-Fact-CB369BD69160A09C5DFC801F7F340DDE"
          xlink:label="d34545404e5949-wk-Fact-CB369BD69160A09C5DFC801F7F340DDE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5949-wk-Fact-CB369BD69160A09C5DFC801F7F340DDE"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3771-wk-Fact-CB5261FF2DCF567B98B84D4EEBACC61C"
          xlink:label="d34468079e3771-wk-Fact-CB5261FF2DCF567B98B84D4EEBACC61C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3771-wk-Fact-CB5261FF2DCF567B98B84D4EEBACC61C"
          xlink:to="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4648-wk-Fact-CB5E098B3EA566270808801F7E0EF978"
          xlink:label="d34458032e4648-wk-Fact-CB5E098B3EA566270808801F7E0EF978"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4648-wk-Fact-CB5E098B3EA566270808801F7E0EF978"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10557-wk-Fact-CB5E2C6E53AA4E02F333801F82392BCB"
          xlink:label="d34661879e10557-wk-Fact-CB5E2C6E53AA4E02F333801F82392BCB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10557-wk-Fact-CB5E2C6E53AA4E02F333801F82392BCB"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e8076-wk-Fact-CB7E2DB668A75D5161C1801F7E45DB8D"
          xlink:label="d34594690e8076-wk-Fact-CB7E2DB668A75D5161C1801F7E45DB8D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8076-wk-Fact-CB7E2DB668A75D5161C1801F7E45DB8D"
          xlink:to="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20183-wk-Fact-CB978D333D218C3AA504801F81620995"
          xlink:label="d34661879e20183-wk-Fact-CB978D333D218C3AA504801F81620995"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20183-wk-Fact-CB978D333D218C3AA504801F81620995"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2080-wk-Fact-CBD997DC56489F4D822B801F818B8507"
          xlink:label="d34468079e2080-wk-Fact-CBD997DC56489F4D822B801F818B8507"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2080-wk-Fact-CBD997DC56489F4D822B801F818B8507"
          xlink:to="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7783-wk-Fact-CBED98872E6D5AD683F5F65CF970FCE1"
          xlink:label="d34586122e7783-wk-Fact-CBED98872E6D5AD683F5F65CF970FCE1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7783-wk-Fact-CBED98872E6D5AD683F5F65CF970FCE1"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2483-wk-Fact-CBF9C7A23687212604C8801F829129F8"
          xlink:label="d34428379e2483-wk-Fact-CBF9C7A23687212604C8801F829129F8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2483-wk-Fact-CBF9C7A23687212604C8801F829129F8"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4790-wk-Fact-CC09067F9E93539BA598F5986D30A0D2"
          xlink:label="d34529301e4790-wk-Fact-CC09067F9E93539BA598F5986D30A0D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4790-wk-Fact-CC09067F9E93539BA598F5986D30A0D2"
          xlink:to="TextSelection-9DDE6A6A437378EE62C0801F8336D31B-0-wk-Footnote-9DDE6A6A437378EE62C0801F8336D31B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6311-wk-Fact-CC0C0ECD3677090B8283801F80884BB4"
          xlink:label="d34458032e6311-wk-Fact-CC0C0ECD3677090B8283801F80884BB4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6311-wk-Fact-CC0C0ECD3677090B8283801F80884BB4"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6311-wk-Fact-CC0C0ECD3677090B8283801F80884BB4"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6"
          xlink:label="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e4017-wk-Fact-CC37105F2F015FFCB75E36B8084C29C6"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3733-wk-Fact-CC66745CDAB046F9CA50801F7EC633DE"
          xlink:label="d34458032e3733-wk-Fact-CC66745CDAB046F9CA50801F7EC633DE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3733-wk-Fact-CC66745CDAB046F9CA50801F7EC633DE"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3733-wk-Fact-CC66745CDAB046F9CA50801F7EC633DE"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e5573-wk-Fact-CC98EE15F05729F82BC1023AB01871BC"
          xlink:label="d34496162e5573-wk-Fact-CC98EE15F05729F82BC1023AB01871BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e5573-wk-Fact-CC98EE15F05729F82BC1023AB01871BC"
          xlink:to="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11833-wk-Fact-CCBB2BC438EC5A9B8250ABDDBE53A9E1"
          xlink:label="d34586122e11833-wk-Fact-CCBB2BC438EC5A9B8250ABDDBE53A9E1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11833-wk-Fact-CCBB2BC438EC5A9B8250ABDDBE53A9E1"
          xlink:to="TextSelection-2AC27314DEA12FC5202C801F835214B5-0-wk-Footnote-2AC27314DEA12FC5202C801F835214B5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7263-wk-Fact-CCCD894D3B3A5080B54BA18BB185ECA4"
          xlink:label="d34458032e7263-wk-Fact-CCCD894D3B3A5080B54BA18BB185ECA4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7263-wk-Fact-CCCD894D3B3A5080B54BA18BB185ECA4"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7196-wk-Fact-CD039103D85D7763C03A801F82921CA3"
          xlink:label="d34594690e7196-wk-Fact-CD039103D85D7763C03A801F82921CA3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7196-wk-Fact-CD039103D85D7763C03A801F82921CA3"
          xlink:to="TextSelection-C5C1805C7675447604E9801F834AE7A4-0-wk-Footnote-C5C1805C7675447604E9801F834AE7A4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3164-wk-Fact-CD12D99291BD50F3BBC6B2BCAA5E89C9"
          xlink:label="d34501946e3164-wk-Fact-CD12D99291BD50F3BBC6B2BCAA5E89C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3164-wk-Fact-CD12D99291BD50F3BBC6B2BCAA5E89C9"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5313-wk-Fact-CD1DAE84A7D8575096A679F1CD7AEBB1"
          xlink:label="d34586122e5313-wk-Fact-CD1DAE84A7D8575096A679F1CD7AEBB1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5313-wk-Fact-CD1DAE84A7D8575096A679F1CD7AEBB1"
          xlink:to="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11339-wk-Fact-CD4577912E966CBCE234801F821708AE"
          xlink:label="d34661879e11339-wk-Fact-CD4577912E966CBCE234801F821708AE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11339-wk-Fact-CD4577912E966CBCE234801F821708AE"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5303-wk-Fact-CDADF0B40C985D2FD733801F814361A2"
          xlink:label="d34545404e5303-wk-Fact-CDADF0B40C985D2FD733801F814361A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5303-wk-Fact-CDADF0B40C985D2FD733801F814361A2"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11910-wk-Fact-CDC99316A1F49B8343F1DE3EC68E31D9"
          xlink:label="d34586122e11910-wk-Fact-CDC99316A1F49B8343F1DE3EC68E31D9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11910-wk-Fact-CDC99316A1F49B8343F1DE3EC68E31D9"
          xlink:to="TextSelection-D46F07DC34049E3F798C801F83529028-0-wk-Footnote-D46F07DC34049E3F798C801F83529028_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3818-wk-Fact-CDFA015BEFBB5917ADD08A5A17C5EE6F"
          xlink:label="d34471435e3818-wk-Fact-CDFA015BEFBB5917ADD08A5A17C5EE6F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3818-wk-Fact-CDFA015BEFBB5917ADD08A5A17C5EE6F"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3818-wk-Fact-CDFA015BEFBB5917ADD08A5A17C5EE6F"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11179-wk-Fact-CE019DDF6C655A12B3EDF80392CD6DCA"
          xlink:label="d34586122e11179-wk-Fact-CE019DDF6C655A12B3EDF80392CD6DCA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11179-wk-Fact-CE019DDF6C655A12B3EDF80392CD6DCA"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3060-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C"
          xlink:label="d34661879e3060-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9887-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C"
          xlink:label="d34661879e9887-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3060-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9887-wk-Fact-CE49C9090CB1F5DA400C801F821A7D3C"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23940-wk-Fact-CEA719F9B7E460A69C70801F7ECBC889"
          xlink:label="d34661879e23940-wk-Fact-CEA719F9B7E460A69C70801F7ECBC889"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23940-wk-Fact-CEA719F9B7E460A69C70801F7ECBC889"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23940-wk-Fact-CEA719F9B7E460A69C70801F7ECBC889"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2155-wk-Fact-CEBB6ABAEC10A6B4CDAFCB2DE5909958"
          xlink:label="d34458032e2155-wk-Fact-CEBB6ABAEC10A6B4CDAFCB2DE5909958"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2155-wk-Fact-CEBB6ABAEC10A6B4CDAFCB2DE5909958"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23701-wk-Fact-CEFD277C9DD70587E852801F80CE0B4F"
          xlink:label="d34661879e23701-wk-Fact-CEFD277C9DD70587E852801F80CE0B4F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23701-wk-Fact-CEFD277C9DD70587E852801F80CE0B4F"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2089-wk-Fact-CF0794E1A8A3CA0BB480801F7F0C5847"
          xlink:label="d34428379e2089-wk-Fact-CF0794E1A8A3CA0BB480801F7F0C5847"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2089-wk-Fact-CF0794E1A8A3CA0BB480801F7F0C5847"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2089-wk-Fact-CF0794E1A8A3CA0BB480801F7F0C5847"
          xlink:to="TextSelection-D85562EF2A7E951F7F53801F82F7A33B-0-wk-Footnote-D85562EF2A7E951F7F53801F82F7A33B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5663-wk-Fact-CF3BF8A51EB1AF804C9D0215472652F8"
          xlink:label="d34545404e5663-wk-Fact-CF3BF8A51EB1AF804C9D0215472652F8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5663-wk-Fact-CF3BF8A51EB1AF804C9D0215472652F8"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5663-wk-Fact-CF3BF8A51EB1AF804C9D0215472652F8"
          xlink:to="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3389-wk-Fact-CF4BCD6471CF5A67AD13EFC0CB141620"
          xlink:label="d34423000e3389-wk-Fact-CF4BCD6471CF5A67AD13EFC0CB141620"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3389-wk-Fact-CF4BCD6471CF5A67AD13EFC0CB141620"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e8585-wk-Fact-CF6EA013BF1855E39D139D5A4C827484"
          xlink:label="d34594690e8585-wk-Fact-CF6EA013BF1855E39D139D5A4C827484"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e4176-wk-Fact-CF6EA013BF1855E39D139D5A4C827484"
          xlink:label="d34458036e4176-wk-Fact-CF6EA013BF1855E39D139D5A4C827484"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8585-wk-Fact-CF6EA013BF1855E39D139D5A4C827484"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4176-wk-Fact-CF6EA013BF1855E39D139D5A4C827484"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5154-wk-Fact-CF81983A611C3D14907CCB572FBC8D5D"
          xlink:label="d34458036e5154-wk-Fact-CF81983A611C3D14907CCB572FBC8D5D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5154-wk-Fact-CF81983A611C3D14907CCB572FBC8D5D"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5154-wk-Fact-CF81983A611C3D14907CCB572FBC8D5D"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11086-wk-Fact-D010F52EA88A56D0A3A81F17EB5D38DC"
          xlink:label="d34586122e11086-wk-Fact-D010F52EA88A56D0A3A81F17EB5D38DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11086-wk-Fact-D010F52EA88A56D0A3A81F17EB5D38DC"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4111-wk-Fact-D017797EF627548D8B995B4200D51DEC"
          xlink:label="d34458036e4111-wk-Fact-D017797EF627548D8B995B4200D51DEC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4111-wk-Fact-D017797EF627548D8B995B4200D51DEC"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7375-wk-Fact-D025766C2E67D378C102801F81229E63"
          xlink:label="d34586122e7375-wk-Fact-D025766C2E67D378C102801F81229E63"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7375-wk-Fact-D025766C2E67D378C102801F81229E63"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11013-wk-Fact-D02BC6C959B70F0C42F4801F81EA9247"
          xlink:label="d34661879e11013-wk-Fact-D02BC6C959B70F0C42F4801F81EA9247"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11013-wk-Fact-D02BC6C959B70F0C42F4801F81EA9247"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8606-wk-Fact-D06ED7D632E3530D9D350CF38120C535"
          xlink:label="d34586122e8606-wk-Fact-D06ED7D632E3530D9D350CF38120C535"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8606-wk-Fact-D06ED7D632E3530D9D350CF38120C535"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11697-wk-Fact-D0B09E4190DD536D8D7A0B352A916E5F"
          xlink:label="d34586122e11697-wk-Fact-D0B09E4190DD536D8D7A0B352A916E5F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11697-wk-Fact-D0B09E4190DD536D8D7A0B352A916E5F"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10496-wk-Fact-D1066964CCBB2F06D211801F8229BFCC"
          xlink:label="d34661879e10496-wk-Fact-D1066964CCBB2F06D211801F8229BFCC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10496-wk-Fact-D1066964CCBB2F06D211801F8229BFCC"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D"
          xlink:label="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5288-wk-Fact-D10C154FFD53538889B9440700D77E4D"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4717-wk-Fact-D132FA43C9BCB6877BE6801F802DED15"
          xlink:label="d34458032e4717-wk-Fact-D132FA43C9BCB6877BE6801F802DED15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4717-wk-Fact-D132FA43C9BCB6877BE6801F802DED15"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5417-wk-Fact-D134462A8015E9052612801F81B8005A"
          xlink:label="d34586122e5417-wk-Fact-D134462A8015E9052612801F81B8005A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5417-wk-Fact-D134462A8015E9052612801F81B8005A"
          xlink:to="TextSelection-5C7002083B7A31477BEF801F8350BAAC-0-wk-Footnote-5C7002083B7A31477BEF801F8350BAAC_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1637-wk-Fact-D1493B6B95195AACB13FF4316F418040"
          xlink:label="d34471435e1637-wk-Fact-D1493B6B95195AACB13FF4316F418040"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1637-wk-Fact-D1493B6B95195AACB13FF4316F418040"
          xlink:to="TextSelection-2BBB93907F3938C3FCC6801F8309EC57-0-wk-Footnote-2BBB93907F3938C3FCC6801F8309EC57_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4800-wk-Fact-D15932B9102F00678306801F7F4183A3"
          xlink:label="d34545404e4800-wk-Fact-D15932B9102F00678306801F7F4183A3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4800-wk-Fact-D15932B9102F00678306801F7F4183A3"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4800-wk-Fact-D15932B9102F00678306801F7F4183A3"
          xlink:to="TextSelection-21E6EF69D7253F5B84CD801F83110DF3-0-wk-Footnote-21E6EF69D7253F5B84CD801F83110DF3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3837-wk-Fact-D197856ADE315AF9B1BD0141D8126013"
          xlink:label="d34471435e3837-wk-Fact-D197856ADE315AF9B1BD0141D8126013"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3837-wk-Fact-D197856ADE315AF9B1BD0141D8126013"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3837-wk-Fact-D197856ADE315AF9B1BD0141D8126013"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e3398-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027"
          xlink:label="d34430544e3398-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34523018e2642-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027"
          xlink:label="d34523018e2642-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e3398-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2642-wk-Fact-D1B896AD5AF55CAFA326548F58CC6027"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2544-wk-Fact-D1EEE24D840C1A7260A5801F823B70E3"
          xlink:label="d34468079e2544-wk-Fact-D1EEE24D840C1A7260A5801F823B70E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2544-wk-Fact-D1EEE24D840C1A7260A5801F823B70E3"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2562-wk-Fact-D213F8E63BD05CEBBE34196677D85307"
          xlink:label="d34423000e2562-wk-Fact-D213F8E63BD05CEBBE34196677D85307"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2562-wk-Fact-D213F8E63BD05CEBBE34196677D85307"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985"
          xlink:label="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985"
          xlink:to="TextSelection-3F32803ED8FCC97ED5F9801F831909FD-0-wk-Footnote-3F32803ED8FCC97ED5F9801F831909FD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e6237-wk-Fact-D215EE5893325488A1AABBC2C0D59985"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21536-wk-Fact-D2A4F992E497F4962F79801F7ECCF7C9"
          xlink:label="d34661879e21536-wk-Fact-D2A4F992E497F4962F79801F7ECCF7C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21536-wk-Fact-D2A4F992E497F4962F79801F7ECCF7C9"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2740-wk-Fact-D2AF16FAEA7B5A13BDB49C7D1827AC2B"
          xlink:label="d34423000e2740-wk-Fact-D2AF16FAEA7B5A13BDB49C7D1827AC2B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2740-wk-Fact-D2AF16FAEA7B5A13BDB49C7D1827AC2B"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6781-wk-Fact-D2DF1C2AD15035E416EB801F7FC07A27"
          xlink:label="d34661879e6781-wk-Fact-D2DF1C2AD15035E416EB801F7FC07A27"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6781-wk-Fact-D2DF1C2AD15035E416EB801F7FC07A27"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2461-wk-Fact-D3148F133483360760CAE3D7A356B4E2"
          xlink:label="d34471435e2461-wk-Fact-D3148F133483360760CAE3D7A356B4E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2461-wk-Fact-D3148F133483360760CAE3D7A356B4E2"
          xlink:to="TextSelection-07981DCBB70CEC605E0C801F830DD25C-0-wk-Footnote-07981DCBB70CEC605E0C801F830DD25C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10931-wk-Fact-D327E219A54033D54A8F801F82396897"
          xlink:label="d34661879e10931-wk-Fact-D327E219A54033D54A8F801F82396897"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10931-wk-Fact-D327E219A54033D54A8F801F82396897"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3274-wk-Fact-D358FB74D462C490D295801F7FC14EB5"
          xlink:label="d34428379e3274-wk-Fact-D358FB74D462C490D295801F7FC14EB5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3274-wk-Fact-D358FB74D462C490D295801F7FC14EB5"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e7858-wk-Fact-D363B0E0565C5479A3956F6F31D775C9"
          xlink:label="d34545404e7858-wk-Fact-D363B0E0565C5479A3956F6F31D775C9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7858-wk-Fact-D363B0E0565C5479A3956F6F31D775C9"
          xlink:to="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5012-wk-Fact-D379165107988FEE1AB7801F7F399F8C"
          xlink:label="d34545404e5012-wk-Fact-D379165107988FEE1AB7801F7F399F8C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5012-wk-Fact-D379165107988FEE1AB7801F7F399F8C"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6901-wk-Fact-D3921F90DA63770751B7801F7F0233BF"
          xlink:label="d34545404e6901-wk-Fact-D3921F90DA63770751B7801F7F0233BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6901-wk-Fact-D3921F90DA63770751B7801F7F0233BF"
          xlink:to="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e3976-wk-Fact-D3A3B59227395C7B84054756B56717E7"
          xlink:label="d34471435e3976-wk-Fact-D3A3B59227395C7B84054756B56717E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3976-wk-Fact-D3A3B59227395C7B84054756B56717E7"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e3976-wk-Fact-D3A3B59227395C7B84054756B56717E7"
          xlink:to="TextSelection-E76F87F43019142429B8801F830D4D15-0-wk-Footnote-E76F87F43019142429B8801F830D4D15_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3692-wk-Fact-D3F2DE5872EC5230B439CD011DA01871"
          xlink:label="d34661879e3692-wk-Fact-D3F2DE5872EC5230B439CD011DA01871"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3692-wk-Fact-D3F2DE5872EC5230B439CD011DA01871"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2525-wk-Fact-D3FD2148011D5F65AD0C27F9F1F55576"
          xlink:label="d34468079e2525-wk-Fact-D3FD2148011D5F65AD0C27F9F1F55576"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2525-wk-Fact-D3FD2148011D5F65AD0C27F9F1F55576"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e1948-wk-Fact-D40799FE54FE50768D7FC07B9F31BF58"
          xlink:label="d34529301e1948-wk-Fact-D40799FE54FE50768D7FC07B9F31BF58"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e1948-wk-Fact-D40799FE54FE50768D7FC07B9F31BF58"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1748-wk-Fact-D46423C593ED51E19EFC3DB182C18357"
          xlink:label="d34471435e1748-wk-Fact-D46423C593ED51E19EFC3DB182C18357"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1748-wk-Fact-D46423C593ED51E19EFC3DB182C18357"
          xlink:to="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20874-wk-Fact-D487984B48B22F1A5D80801F7E671411"
          xlink:label="d34661879e20874-wk-Fact-D487984B48B22F1A5D80801F7E671411"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20874-wk-Fact-D487984B48B22F1A5D80801F7E671411"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34519344e4935-wk-Fact-D4A071180EDE5CEF82B5ECC8A1B682B0"
          xlink:label="d34519344e4935-wk-Fact-D4A071180EDE5CEF82B5ECC8A1B682B0"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-13B98780E3A32428D56ECDA99D9FF8D0-0-wk-Footnote-13B98780E3A32428D56ECDA99D9FF8D0_lbl" xlink:label="TextSelection-13B98780E3A32428D56ECDA99D9FF8D0-0-wk-Footnote-13B98780E3A32428D56ECDA99D9FF8D0_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:8pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Reflects lease payments due within 12 months subsequent to the balance sheet date.</xhtml:span><xhtml:span style="font-family:Arial;font-size:8pt;"> </xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34519344e4935-wk-Fact-D4A071180EDE5CEF82B5ECC8A1B682B0"
          xlink:to="TextSelection-13B98780E3A32428D56ECDA99D9FF8D0-0-wk-Footnote-13B98780E3A32428D56ECDA99D9FF8D0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e2969-wk-Fact-D4B1E0BBE3F058D3B98806E9C6B99CAF"
          xlink:label="d34501946e2969-wk-Fact-D4B1E0BBE3F058D3B98806E9C6B99CAF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e2969-wk-Fact-D4B1E0BBE3F058D3B98806E9C6B99CAF"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21925-wk-Fact-D51127B4DF5263E26631801F80FC4240"
          xlink:label="d34661879e21925-wk-Fact-D51127B4DF5263E26631801F80FC4240"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21925-wk-Fact-D51127B4DF5263E26631801F80FC4240"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2041-wk-Fact-D580F9F59A215E69A2F8C8CF9897A050"
          xlink:label="d34471435e2041-wk-Fact-D580F9F59A215E69A2F8C8CF9897A050"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2041-wk-Fact-D580F9F59A215E69A2F8C8CF9897A050"
          xlink:to="TextSelection-C5F743ABC777B912E8EF801F830C483E-0-wk-Footnote-C5F743ABC777B912E8EF801F830C483E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34498941e1747-wk-Fact-D592F35F847457ABB1C2D0D22ED64864"
          xlink:label="d34498941e1747-wk-Fact-D592F35F847457ABB1C2D0D22ED64864"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e2284-wk-Fact-D592F35F847457ABB1C2D0D22ED64864"
          xlink:label="d34423000e2284-wk-Fact-D592F35F847457ABB1C2D0D22ED64864"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34498941e1747-wk-Fact-D592F35F847457ABB1C2D0D22ED64864"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2284-wk-Fact-D592F35F847457ABB1C2D0D22ED64864"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2510-wk-Fact-D5EB172CCBCC5F4D8D27B6F5728E0EBD"
          xlink:label="d34428379e2510-wk-Fact-D5EB172CCBCC5F4D8D27B6F5728E0EBD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2510-wk-Fact-D5EB172CCBCC5F4D8D27B6F5728E0EBD"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2120-wk-Fact-D5F5556E181E5148B38700A64385FDDC"
          xlink:label="d34428379e2120-wk-Fact-D5F5556E181E5148B38700A64385FDDC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2120-wk-Fact-D5F5556E181E5148B38700A64385FDDC"
          xlink:to="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2120-wk-Fact-D5F5556E181E5148B38700A64385FDDC"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9617-wk-Fact-D5FAE833F4155DD697072C1983D12DD3"
          xlink:label="d34458032e9617-wk-Fact-D5FAE833F4155DD697072C1983D12DD3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9617-wk-Fact-D5FAE833F4155DD697072C1983D12DD3"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9617-wk-Fact-D5FAE833F4155DD697072C1983D12DD3"
          xlink:to="TextSelection-70E315F0A0EF81C63CC8801F82F80B92-0-wk-Footnote-70E315F0A0EF81C63CC8801F82F80B92_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e5019-wk-Fact-D61DE1C8D5314D9446A3801F7FA8246B"
          xlink:label="d34661879e5019-wk-Fact-D61DE1C8D5314D9446A3801F7FA8246B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e5019-wk-Fact-D61DE1C8D5314D9446A3801F7FA8246B"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5115-wk-Fact-D632D615CB115AE398552F0296C267F2"
          xlink:label="d34458036e5115-wk-Fact-D632D615CB115AE398552F0296C267F2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5115-wk-Fact-D632D615CB115AE398552F0296C267F2"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5115-wk-Fact-D632D615CB115AE398552F0296C267F2"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3078-wk-Fact-D6D3D533E39ABD216739AB460AAB7F32"
          xlink:label="d34458036e3078-wk-Fact-D6D3D533E39ABD216739AB460AAB7F32"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3078-wk-Fact-D6D3D533E39ABD216739AB460AAB7F32"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e1883-wk-Fact-D71CC752F8554F4A326D801F7F9F4E99"
          xlink:label="d34460716e1883-wk-Fact-D71CC752F8554F4A326D801F7F9F4E99"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e1883-wk-Fact-D71CC752F8554F4A326D801F7F9F4E99"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2445-wk-Fact-D72EAE58B45655088BE6DF720737CDA8"
          xlink:label="d34428379e2445-wk-Fact-D72EAE58B45655088BE6DF720737CDA8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2445-wk-Fact-D72EAE58B45655088BE6DF720737CDA8"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e6846-wk-Fact-D7952502BA2F1E69FE54801F820C8790"
          xlink:label="d34661879e6846-wk-Fact-D7952502BA2F1E69FE54801F820C8790"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e6846-wk-Fact-D7952502BA2F1E69FE54801F820C8790"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2202-wk-Fact-D7F3CECA708D58BE9F756B50300BDB3F"
          xlink:label="d34458036e2202-wk-Fact-D7F3CECA708D58BE9F756B50300BDB3F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2202-wk-Fact-D7F3CECA708D58BE9F756B50300BDB3F"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7247-wk-Fact-D7F3F8AF036E5D0FB8EF97E397FAB8AF"
          xlink:label="d34458032e7247-wk-Fact-D7F3F8AF036E5D0FB8EF97E397FAB8AF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7247-wk-Fact-D7F3F8AF036E5D0FB8EF97E397FAB8AF"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11030-wk-Fact-D8245C971D9C5E578F90851085D1B795"
          xlink:label="d34586122e11030-wk-Fact-D8245C971D9C5E578F90851085D1B795"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11030-wk-Fact-D8245C971D9C5E578F90851085D1B795"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5104-wk-Fact-D82E84CD29B95374845A78E05E6E431A"
          xlink:label="d34538474e5104-wk-Fact-D82E84CD29B95374845A78E05E6E431A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5104-wk-Fact-D82E84CD29B95374845A78E05E6E431A"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5104-wk-Fact-D82E84CD29B95374845A78E05E6E431A"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2594-wk-Fact-D83DE49486164AB0AD35801F7F32BB1B"
          xlink:label="d34430544e2594-wk-Fact-D83DE49486164AB0AD35801F7F32BB1B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2594-wk-Fact-D83DE49486164AB0AD35801F7F32BB1B"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e12076-wk-Fact-D8583C2532635E7E884D51C71C684B47"
          xlink:label="d34586122e12076-wk-Fact-D8583C2532635E7E884D51C71C684B47"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e12076-wk-Fact-D8583C2532635E7E884D51C71C684B47"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6680-wk-Fact-D8BAB29A7AEA2D495984801F80E9FBD5"
          xlink:label="d34545404e6680-wk-Fact-D8BAB29A7AEA2D495984801F80E9FBD5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6680-wk-Fact-D8BAB29A7AEA2D495984801F80E9FBD5"
          xlink:to="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2769-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
          xlink:label="d34661879e2769-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9688-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
          xlink:label="d34661879e9688-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2769-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9688-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2769-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9688-wk-Fact-D8C072D06B49773A72EE801F81FC0B93"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3808-wk-Fact-D8C77E7DECB85CFDA69FCED349A74F3B"
          xlink:label="d34661879e3808-wk-Fact-D8C77E7DECB85CFDA69FCED349A74F3B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3808-wk-Fact-D8C77E7DECB85CFDA69FCED349A74F3B"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3236-wk-Fact-D8D3C4F5774A56769436D861E4EEF751"
          xlink:label="d34428379e3236-wk-Fact-D8D3C4F5774A56769436D861E4EEF751"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3236-wk-Fact-D8D3C4F5774A56769436D861E4EEF751"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2061-wk-Fact-D8F202BB5B6A5B28A9A31C0EB79F405E"
          xlink:label="d34468079e2061-wk-Fact-D8F202BB5B6A5B28A9A31C0EB79F405E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2061-wk-Fact-D8F202BB5B6A5B28A9A31C0EB79F405E"
          xlink:to="TextSelection-1D4C65BD347685B92550801F8304BE9A-0-wk-Footnote-1D4C65BD347685B92550801F8304BE9A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1757-wk-Fact-D92D96928692FE5AFF2B801F7F150711"
          xlink:label="d34428379e1757-wk-Fact-D92D96928692FE5AFF2B801F7F150711"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1757-wk-Fact-D92D96928692FE5AFF2B801F7F150711"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34524436e1696-wk-Fact-D95C333A77FF51D2367A801F8284E06B"
          xlink:label="d34524436e1696-wk-Fact-D95C333A77FF51D2367A801F8284E06B"
          xlink:type="locator"/>
        <link:footnote id="TextSelection-02E52614EBB7CDE55C93801F8347287F-0-wk-Footnote-02E52614EBB7CDE55C93801F8347287F_lbl" xlink:label="TextSelection-02E52614EBB7CDE55C93801F8347287F-0-wk-Footnote-02E52614EBB7CDE55C93801F8347287F_lbl" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US"><xhtml:div style="line-height:120%;text-align:left;font-size:7pt;"><xhtml:span style="font-family:Arial;font-size:7pt;">Represents shares purchased pursuant to the accelerated share repurchase agreement with</xhtml:span><xhtml:span style="font-family:Arial;font-size:8pt;"> </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">GS&amp;Co.</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;"> entered into on </xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">February&#160;7, 2019</xhtml:span><xhtml:span style="font-family:Arial;font-size:7pt;">, as well as other share repurchases. See above for additional information.</xhtml:span></xhtml:div></link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34524436e1696-wk-Fact-D95C333A77FF51D2367A801F8284E06B"
          xlink:to="TextSelection-02E52614EBB7CDE55C93801F8347287F-0-wk-Footnote-02E52614EBB7CDE55C93801F8347287F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3105-wk-Fact-D993A80C463256F1AA201062DD098CB4"
          xlink:label="d34501946e3105-wk-Fact-D993A80C463256F1AA201062DD098CB4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3105-wk-Fact-D993A80C463256F1AA201062DD098CB4"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4857-wk-Fact-D9E19CB4E10F040A89ABD85E8FD4E4A8"
          xlink:label="d34529301e4857-wk-Fact-D9E19CB4E10F040A89ABD85E8FD4E4A8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4857-wk-Fact-D9E19CB4E10F040A89ABD85E8FD4E4A8"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5989-wk-Fact-D9F7707EF4A74E9CF2A9801F812F89DC"
          xlink:label="d34545404e5989-wk-Fact-D9F7707EF4A74E9CF2A9801F812F89DC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5989-wk-Fact-D9F7707EF4A74E9CF2A9801F812F89DC"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6988-wk-Fact-DA36ACA13488CC4953E0801F822DA219"
          xlink:label="d34545404e6988-wk-Fact-DA36ACA13488CC4953E0801F822DA219"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6988-wk-Fact-DA36ACA13488CC4953E0801F822DA219"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3408-wk-Fact-DA95F5D557CD51E498E32E8F9370AC31"
          xlink:label="d34423000e3408-wk-Fact-DA95F5D557CD51E498E32E8F9370AC31"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3408-wk-Fact-DA95F5D557CD51E498E32E8F9370AC31"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2569-wk-Fact-DACC4B795F2137AD8A42801F81A81F11"
          xlink:label="d34594690e2569-wk-Fact-DACC4B795F2137AD8A42801F81A81F11"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2569-wk-Fact-DACC4B795F2137AD8A42801F81A81F11"
          xlink:to="TextSelection-1AFFADC5948A275D088D801F834922CD-0-wk-Footnote-1AFFADC5948A275D088D801F834922CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e8019-wk-Fact-DAD0CA8E455F2B5DC7FA801F7E585E15"
          xlink:label="d34594690e8019-wk-Fact-DAD0CA8E455F2B5DC7FA801F7E585E15"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8019-wk-Fact-DAD0CA8E455F2B5DC7FA801F7E585E15"
          xlink:to="TextSelection-55CFE1F2A4A16CB78B2E801F834B4FD1-0-wk-Footnote-55CFE1F2A4A16CB78B2E801F834B4FD1_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2766-wk-Fact-DB90E025117E5EE7A0F72EE7BD31627B"
          xlink:label="d34423000e2766-wk-Fact-DB90E025117E5EE7A0F72EE7BD31627B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2766-wk-Fact-DB90E025117E5EE7A0F72EE7BD31627B"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2827-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
          xlink:label="d34661879e2827-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9727-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
          xlink:label="d34661879e9727-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2827-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9727-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2827-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9727-wk-Fact-DB9558D1E67DB9DBC296801F821D4332"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-DBA38F5FA084593399643607C04AC75E-wk-Fact-DBA38F5FA084593399643607C04AC75E"
          xlink:label="Fact-DBA38F5FA084593399643607C04AC75E-wk-Fact-DBA38F5FA084593399643607C04AC75E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-DBA38F5FA084593399643607C04AC75E-wk-Fact-DBA38F5FA084593399643607C04AC75E"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4576-wk-Fact-DBDD38161F5354477BEEAB460A4A0822"
          xlink:label="d34458036e4576-wk-Fact-DBDD38161F5354477BEEAB460A4A0822"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e4488-wk-Fact-DBDD38161F5354477BEEAB460A4A0822"
          xlink:label="d34458036e4488-wk-Fact-DBDD38161F5354477BEEAB460A4A0822"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4576-wk-Fact-DBDD38161F5354477BEEAB460A4A0822"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4488-wk-Fact-DBDD38161F5354477BEEAB460A4A0822"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2499-wk-Fact-DC09811A83505392B3800EEDE627AFCD"
          xlink:label="d34423000e2499-wk-Fact-DC09811A83505392B3800EEDE627AFCD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2499-wk-Fact-DC09811A83505392B3800EEDE627AFCD"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3059-wk-Fact-DC14423F4FD126343D5EAB460A5E402A"
          xlink:label="d34458036e3059-wk-Fact-DC14423F4FD126343D5EAB460A5E402A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3059-wk-Fact-DC14423F4FD126343D5EAB460A5E402A"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4621-wk-Fact-DC29F3E24AC4E1D31CB3D85DDB384CCC"
          xlink:label="d34529301e4621-wk-Fact-DC29F3E24AC4E1D31CB3D85DDB384CCC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4621-wk-Fact-DC29F3E24AC4E1D31CB3D85DDB384CCC"
          xlink:to="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2091-wk-Fact-DCBD066B5B3F57A98C5A6477D74A4C3D"
          xlink:label="d34471435e2091-wk-Fact-DCBD066B5B3F57A98C5A6477D74A4C3D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2091-wk-Fact-DCBD066B5B3F57A98C5A6477D74A4C3D"
          xlink:to="TextSelection-CD7793FEBBD4E26A18A1801F830CE93C-0-wk-Footnote-CD7793FEBBD4E26A18A1801F830CE93C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7418-wk-Fact-DCCC9223184B56788CBE0DB3BD4499E3"
          xlink:label="d34586122e7418-wk-Fact-DCCC9223184B56788CBE0DB3BD4499E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7418-wk-Fact-DCCC9223184B56788CBE0DB3BD4499E3"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2323-wk-Fact-DCCF1CBB1A0259B4B4B8B56A33FFAE88"
          xlink:label="d34423000e2323-wk-Fact-DCCF1CBB1A0259B4B4B8B56A33FFAE88"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2323-wk-Fact-DCCF1CBB1A0259B4B4B8B56A33FFAE88"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11484-wk-Fact-DCDE7C80F284CDA4BB90801F823D07A2"
          xlink:label="d34661879e11484-wk-Fact-DCDE7C80F284CDA4BB90801F823D07A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11484-wk-Fact-DCDE7C80F284CDA4BB90801F823D07A2"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3050-wk-Fact-DCF7E4E72A2BD2587C67801F7EA7706F"
          xlink:label="d34423000e3050-wk-Fact-DCF7E4E72A2BD2587C67801F7EA7706F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3050-wk-Fact-DCF7E4E72A2BD2587C67801F7EA7706F"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8847-wk-Fact-DD01A36819E15802AFBF1E72FE27BC50"
          xlink:label="d34586122e8847-wk-Fact-DD01A36819E15802AFBF1E72FE27BC50"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8847-wk-Fact-DD01A36819E15802AFBF1E72FE27BC50"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8861-wk-Fact-DD18335422DB5858902DCD3895050F71"
          xlink:label="d34458032e8861-wk-Fact-DD18335422DB5858902DCD3895050F71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8861-wk-Fact-DD18335422DB5858902DCD3895050F71"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e8043-wk-Fact-DD2FFFF9189C3FA5A3DB801F7E4AF4C6"
          xlink:label="d34594690e8043-wk-Fact-DD2FFFF9189C3FA5A3DB801F7E4AF4C6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8043-wk-Fact-DD2FFFF9189C3FA5A3DB801F7E4AF4C6"
          xlink:to="TextSelection-992969861456FAA45C31801F834AEA1D-0-wk-Footnote-992969861456FAA45C31801F834AEA1D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2778-wk-Fact-DD92E4AF9BD15F60838130DCE8A678BE"
          xlink:label="d34428379e2778-wk-Fact-DD92E4AF9BD15F60838130DCE8A678BE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2778-wk-Fact-DD92E4AF9BD15F60838130DCE8A678BE"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7234-wk-Fact-DDA3C772DD5D6A9CF860801F82921818"
          xlink:label="d34594690e7234-wk-Fact-DDA3C772DD5D6A9CF860801F82921818"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7234-wk-Fact-DDA3C772DD5D6A9CF860801F82921818"
          xlink:to="TextSelection-459789DC41B7EB0ACDC0801F834A6091-0-wk-Footnote-459789DC41B7EB0ACDC0801F834A6091_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1982-wk-Fact-DDD211C8993350B79EF8D3FEBE1A053B"
          xlink:label="d34428379e1982-wk-Fact-DDD211C8993350B79EF8D3FEBE1A053B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1982-wk-Fact-DDD211C8993350B79EF8D3FEBE1A053B"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3624-wk-Fact-DDF2C025AF9CF365CD89801F7F653ACA"
          xlink:label="d34468079e3624-wk-Fact-DDF2C025AF9CF365CD89801F7F653ACA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3624-wk-Fact-DDF2C025AF9CF365CD89801F7F653ACA"
          xlink:to="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24346-wk-Fact-DE1F7A8483528CB9F99C801F7DF38979"
          xlink:label="d34661879e24346-wk-Fact-DE1F7A8483528CB9F99C801F7DF38979"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24346-wk-Fact-DE1F7A8483528CB9F99C801F7DF38979"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2576-wk-Fact-DE50E7770F245761B8991D27CD7FA8EE"
          xlink:label="d34428379e2576-wk-Fact-DE50E7770F245761B8991D27CD7FA8EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2576-wk-Fact-DE50E7770F245761B8991D27CD7FA8EE"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10911-wk-Fact-DEAEDE0078E36DBB07CB801F82112993"
          xlink:label="d34661879e10911-wk-Fact-DEAEDE0078E36DBB07CB801F82112993"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10911-wk-Fact-DEAEDE0078E36DBB07CB801F82112993"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3505-wk-Fact-DED528DDB914A2BDEF0A801F81463977"
          xlink:label="d34594690e3505-wk-Fact-DED528DDB914A2BDEF0A801F81463977"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3505-wk-Fact-DED528DDB914A2BDEF0A801F81463977"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3505-wk-Fact-DED528DDB914A2BDEF0A801F81463977"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10131-wk-Fact-DEDF8AC547B275C98BB2801F81FE5559"
          xlink:label="d34661879e10131-wk-Fact-DEDF8AC547B275C98BB2801F81FE5559"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10131-wk-Fact-DEDF8AC547B275C98BB2801F81FE5559"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7654-wk-Fact-DF1B3BD729A55AC0A504DFD9608FFB96"
          xlink:label="d34586122e7654-wk-Fact-DF1B3BD729A55AC0A504DFD9608FFB96"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7654-wk-Fact-DF1B3BD729A55AC0A504DFD9608FFB96"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3736-wk-Fact-DF223CDEB60EF38BA68C801F829307E6"
          xlink:label="d34458036e3736-wk-Fact-DF223CDEB60EF38BA68C801F829307E6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3736-wk-Fact-DF223CDEB60EF38BA68C801F829307E6"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3748-wk-Fact-DF31EFE36B91F582343D801F80809133"
          xlink:label="d34458032e3748-wk-Fact-DF31EFE36B91F582343D801F80809133"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3748-wk-Fact-DF31EFE36B91F582343D801F80809133"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3748-wk-Fact-DF31EFE36B91F582343D801F80809133"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3433-wk-Fact-DF4C7D7A1BC15C8FB52ACDC98F4B191B"
          xlink:label="d34423000e3433-wk-Fact-DF4C7D7A1BC15C8FB52ACDC98F4B191B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3433-wk-Fact-DF4C7D7A1BC15C8FB52ACDC98F4B191B"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8026-wk-Fact-DF4D7D64D34A7D6D90A6DE1ABA698DA3"
          xlink:label="d34586122e8026-wk-Fact-DF4D7D64D34A7D6D90A6DE1ABA698DA3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8026-wk-Fact-DF4D7D64D34A7D6D90A6DE1ABA698DA3"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9891-wk-Fact-DF536431A96ABD94CF42801F825CE145"
          xlink:label="d34458032e9891-wk-Fact-DF536431A96ABD94CF42801F825CE145"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9891-wk-Fact-DF536431A96ABD94CF42801F825CE145"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact-DF805AE36913A86A1B9C801F81E89568-wk-Fact-DF805AE36913A86A1B9C801F81E89568"
          xlink:label="Fact-DF805AE36913A86A1B9C801F81E89568-wk-Fact-DF805AE36913A86A1B9C801F81E89568"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact-DF805AE36913A86A1B9C801F81E89568-wk-Fact-DF805AE36913A86A1B9C801F81E89568"
          xlink:to="TextSelection-DC98FDB5728C52A02456801F8317EA26-0-wk-Footnote-DC98FDB5728C52A02456801F8317EA26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2466-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F"
          xlink:label="d34430544e2466-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34523018e1969-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F"
          xlink:label="d34523018e1969-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2466-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e1969-wk-Fact-DFAEC99B2CEAA9E6BA7B801F7F154A2F"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10066-wk-Fact-DFBA5F50241AD6477837801F820D9779"
          xlink:label="d34661879e10066-wk-Fact-DFBA5F50241AD6477837801F820D9779"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10066-wk-Fact-DFBA5F50241AD6477837801F820D9779"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66"
          xlink:label="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66"
          xlink:to="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5668-wk-Fact-DFC4295A20055F3888D81501EBA99D66"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2430-wk-Fact-DFC5C4232A535405BE8E98D62FCA6018"
          xlink:label="d34423000e2430-wk-Fact-DFC5C4232A535405BE8E98D62FCA6018"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2430-wk-Fact-DFC5C4232A535405BE8E98D62FCA6018"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2255-wk-Fact-DFD2BE3FC86FDFD923FDCB2DE4E53FC7"
          xlink:label="d34458032e2255-wk-Fact-DFD2BE3FC86FDFD923FDCB2DE4E53FC7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2255-wk-Fact-DFD2BE3FC86FDFD923FDCB2DE4E53FC7"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e7577-wk-Fact-E02ED63B97645048DC3D801F80ED740C"
          xlink:label="d34661879e7577-wk-Fact-E02ED63B97645048DC3D801F80ED740C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e7577-wk-Fact-E02ED63B97645048DC3D801F80ED740C"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8491-wk-Fact-E04CC84099F25E25851523F603002A2A"
          xlink:label="d34458032e8491-wk-Fact-E04CC84099F25E25851523F603002A2A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8491-wk-Fact-E04CC84099F25E25851523F603002A2A"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1788-wk-Fact-E0737BFD19C0100A5FE8801F80CB7FAE"
          xlink:label="d34471435e1788-wk-Fact-E0737BFD19C0100A5FE8801F80CB7FAE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1788-wk-Fact-E0737BFD19C0100A5FE8801F80CB7FAE"
          xlink:to="TextSelection-A099B3EA6D215F69153A801F830A9C72-0-wk-Footnote-A099B3EA6D215F69153A801F830A9C72_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14932-wk-Fact-E0B910DD31466DB4F6A3801F7F105131"
          xlink:label="d34661879e14932-wk-Fact-E0B910DD31466DB4F6A3801F7F105131"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14932-wk-Fact-E0B910DD31466DB4F6A3801F7F105131"
          xlink:to="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e5068-wk-Fact-E12E0298D04CBB2C3A47801F7F8D79BA"
          xlink:label="d34661879e5068-wk-Fact-E12E0298D04CBB2C3A47801F7F8D79BA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e5068-wk-Fact-E12E0298D04CBB2C3A47801F7F8D79BA"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5486-wk-Fact-E188FF1B79A2458CF37A801F81E69759"
          xlink:label="d34506804e5486-wk-Fact-E188FF1B79A2458CF37A801F81E69759"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5486-wk-Fact-E188FF1B79A2458CF37A801F81E69759"
          xlink:to="TextSelection-D5B28291A6E2DE939ECD801F8302134D-0-wk-Footnote-D5B28291A6E2DE939ECD801F8302134D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e5357-wk-Fact-E19185551DC6EBA76F10801F8027D89E"
          xlink:label="d34661879e5357-wk-Fact-E19185551DC6EBA76F10801F8027D89E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e5357-wk-Fact-E19185551DC6EBA76F10801F8027D89E"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3808-wk-Fact-E19218AE39D843301427801F81BB5A43"
          xlink:label="d34586122e3808-wk-Fact-E19218AE39D843301427801F81BB5A43"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3808-wk-Fact-E19218AE39D843301427801F81BB5A43"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4902-wk-Fact-E197FC2A851A0D8F91E2801F7FC6EAB4"
          xlink:label="d34661879e4902-wk-Fact-E197FC2A851A0D8F91E2801F7FC6EAB4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4902-wk-Fact-E197FC2A851A0D8F91E2801F7FC6EAB4"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6968-wk-Fact-E1A13D9EA58071BA48AC801F8231AA2E"
          xlink:label="d34545404e6968-wk-Fact-E1A13D9EA58071BA48AC801F8231AA2E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6968-wk-Fact-E1A13D9EA58071BA48AC801F8231AA2E"
          xlink:to="TextSelection-6A020DC0451471254AA0801F83116145-0-wk-Footnote-6A020DC0451471254AA0801F83116145_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2506-wk-Fact-E1D5C5643E20593EBC9062EA4C0879C4"
          xlink:label="d34468079e2506-wk-Fact-E1D5C5643E20593EBC9062EA4C0879C4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2506-wk-Fact-E1D5C5643E20593EBC9062EA4C0879C4"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09"
          xlink:label="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09"
          xlink:to="TextSelection-1B4C5830EF635DC12BD97A94230376AD-0-wk-Footnote-1B4C5830EF635DC12BD97A94230376AD_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09"
          xlink:to="TextSelection-74B8B8E30D87649A0146801F83190686-0-wk-Footnote-74B8B8E30D87649A0146801F83190686_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34538474e5733-wk-Fact-E2BFDEA035DA508FB0A5726BC0845D09"
          xlink:to="TextSelection-BCA6746A65F6E1E3BC29801F8319AE4E-0-wk-Footnote-BCA6746A65F6E1E3BC29801F8319AE4E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4561-wk-Fact-E2D26B3B9514260520BAD85DDAA659BB"
          xlink:label="d34529301e4561-wk-Fact-E2D26B3B9514260520BAD85DDAA659BB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4561-wk-Fact-E2D26B3B9514260520BAD85DDAA659BB"
          xlink:to="TextSelection-E7F3635D42C128620B81801F83359F7E-0-wk-Footnote-E7F3635D42C128620B81801F83359F7E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2750-wk-Fact-E2FFF18A87ED82A265A1801F8065BD9A"
          xlink:label="d34661879e2750-wk-Fact-E2FFF18A87ED82A265A1801F8065BD9A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2750-wk-Fact-E2FFF18A87ED82A265A1801F8065BD9A"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105"
          xlink:label="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105"
          xlink:to="TextSelection-46CE04D433F70815976D801F83495E62-0-wk-Footnote-46CE04D433F70815976D801F83495E62_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105"
          xlink:to="TextSelection-697888E8EFDD5D34484F801F8349796F-0-wk-Footnote-697888E8EFDD5D34484F801F8349796F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e3590-wk-Fact-E315CC35FB7793A9FC31801F8156B105"
          xlink:to="TextSelection-82EE3756CFF71A790C97801F83494E2E-0-wk-Footnote-82EE3756CFF71A790C97801F83494E2E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10111-wk-Fact-E31F7F0602F984C69606801F822B89AD"
          xlink:label="d34661879e10111-wk-Fact-E31F7F0602F984C69606801F822B89AD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10111-wk-Fact-E31F7F0602F984C69606801F822B89AD"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4986-wk-Fact-E33B08E22E8C41C41495801F7F33C2F5"
          xlink:label="d34545404e4986-wk-Fact-E33B08E22E8C41C41495801F7F33C2F5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4986-wk-Fact-E33B08E22E8C41C41495801F7F33C2F5"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4986-wk-Fact-E33B08E22E8C41C41495801F7F33C2F5"
          xlink:to="TextSelection-7E85253EA18FEE6FA163801F8311BDD7-0-wk-Footnote-7E85253EA18FEE6FA163801F8311BDD7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21905-wk-Fact-E34AFABD364472579390801F7DF5BC3B"
          xlink:label="d34661879e21905-wk-Fact-E34AFABD364472579390801F7DF5BC3B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21905-wk-Fact-E34AFABD364472579390801F7DF5BC3B"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7302-wk-Fact-E385705FB7C3A2995158801F82A7D035"
          xlink:label="d34594690e7302-wk-Fact-E385705FB7C3A2995158801F82A7D035"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7302-wk-Fact-E385705FB7C3A2995158801F82A7D035"
          xlink:to="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2920-wk-Fact-E3D918CD118292C5AA27801F802986E2"
          xlink:label="d34430544e2920-wk-Fact-E3D918CD118292C5AA27801F802986E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2920-wk-Fact-E3D918CD118292C5AA27801F802986E2"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e8816-wk-Fact-E3E97336ACA652838D81F531EE99F43B"
          xlink:label="d34496162e8816-wk-Fact-E3E97336ACA652838D81F531EE99F43B"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e1546-wk-Fact-E3E97336ACA652838D81F531EE99F43B"
          xlink:label="d34423000e1546-wk-Fact-E3E97336ACA652838D81F531EE99F43B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e8816-wk-Fact-E3E97336ACA652838D81F531EE99F43B"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1546-wk-Fact-E3E97336ACA652838D81F531EE99F43B"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3255-wk-Fact-E3F086AF3830512484E4717330E2CA08"
          xlink:label="d34428379e3255-wk-Fact-E3F086AF3830512484E4717330E2CA08"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3255-wk-Fact-E3F086AF3830512484E4717330E2CA08"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11277-wk-Fact-E3F7F347B26B1F422343801F81F13EF8"
          xlink:label="d34661879e11277-wk-Fact-E3F7F347B26B1F422343801F81F13EF8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11277-wk-Fact-E3F7F347B26B1F422343801F81F13EF8"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2785-wk-Fact-E3FD9DF1F7065B2BAFE310C3379623D1"
          xlink:label="d34423000e2785-wk-Fact-E3FD9DF1F7065B2BAFE310C3379623D1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2785-wk-Fact-E3FD9DF1F7065B2BAFE310C3379623D1"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:label="d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:label="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9611-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2653-wk-Fact-E4C56A431CBCEBC307F5801F821F5808"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e3103-wk-Fact-E4D712528036514CA1CCFB0C4C138D8D"
          xlink:label="d34529301e3103-wk-Fact-E4D712528036514CA1CCFB0C4C138D8D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3103-wk-Fact-E4D712528036514CA1CCFB0C4C138D8D"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e3103-wk-Fact-E4D712528036514CA1CCFB0C4C138D8D"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2196-wk-Fact-E54EE12FB1C1E89110A9CB2DE5B4B413"
          xlink:label="d34458032e2196-wk-Fact-E54EE12FB1C1E89110A9CB2DE5B4B413"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2196-wk-Fact-E54EE12FB1C1E89110A9CB2DE5B4B413"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e9051-wk-Fact-E562078593EEE80AC567801F8179DDAD"
          xlink:label="d34586122e9051-wk-Fact-E562078593EEE80AC567801F8179DDAD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e9051-wk-Fact-E562078593EEE80AC567801F8179DDAD"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10209-wk-Fact-E5C179E74FC2148A9039801F81F8B818"
          xlink:label="d34661879e10209-wk-Fact-E5C179E74FC2148A9039801F81F8B818"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10209-wk-Fact-E5C179E74FC2148A9039801F81F8B818"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e7897-wk-Fact-E60F964DE99E4B40AE50801F7ECFCAC9"
          xlink:label="d34545404e7897-wk-Fact-E60F964DE99E4B40AE50801F7ECFCAC9"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e7897-wk-Fact-E60F964DE99E4B40AE50801F7ECFCAC9"
          xlink:to="TextSelection-E1A9118C3F4F47C9E597801F831276DB-0-wk-Footnote-E1A9118C3F4F47C9E597801F831276DB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7188-wk-Fact-E6122F9BEB87535189F2629012724D92"
          xlink:label="d34586122e7188-wk-Fact-E6122F9BEB87535189F2629012724D92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7188-wk-Fact-E6122F9BEB87535189F2629012724D92"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34519344e1883-wk-Fact-E658F74A5A8852C19F682FC523E87C64"
          xlink:label="d34519344e1883-wk-Fact-E658F74A5A8852C19F682FC523E87C64"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e2075-wk-Fact-E658F74A5A8852C19F682FC523E87C64"
          xlink:label="d34423000e2075-wk-Fact-E658F74A5A8852C19F682FC523E87C64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34519344e1883-wk-Fact-E658F74A5A8852C19F682FC523E87C64"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2075-wk-Fact-E658F74A5A8852C19F682FC523E87C64"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e3950-wk-Fact-E6A475BF77FF3BDAAABB801F825FD297"
          xlink:label="d34545404e3950-wk-Fact-E6A475BF77FF3BDAAABB801F825FD297"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3950-wk-Fact-E6A475BF77FF3BDAAABB801F825FD297"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e9110-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC"
          xlink:label="d34496162e9110-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34423000e1880-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC"
          xlink:label="d34423000e1880-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e9110-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1880-wk-Fact-E6E2236184E3570EAC658AE1E59CC5EC"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e5482-wk-Fact-E6EDC6EB8DF84B60CE5A801F80D3642D"
          xlink:label="d34594690e5482-wk-Fact-E6EDC6EB8DF84B60CE5A801F80D3642D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e5482-wk-Fact-E6EDC6EB8DF84B60CE5A801F80D3642D"
          xlink:to="TextSelection-C075792364F3F1E4361D801F8348FF26-0-wk-Footnote-C075792364F3F1E4361D801F8348FF26_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2710-wk-Fact-E6FC35E4FFF354B58F58E4CFFF29DCB8"
          xlink:label="d34428379e2710-wk-Fact-E6FC35E4FFF354B58F58E4CFFF29DCB8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2710-wk-Fact-E6FC35E4FFF354B58F58E4CFFF29DCB8"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1756-wk-Fact-E70CA54923CC1FAD4F80801F7E7CC351"
          xlink:label="d34458036e1756-wk-Fact-E70CA54923CC1FAD4F80801F7E7CC351"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1756-wk-Fact-E70CA54923CC1FAD4F80801F7E7CC351"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4441-wk-Fact-E71BAB60F8F54CE72E1EAB460A620A61"
          xlink:label="d34458036e4441-wk-Fact-E71BAB60F8F54CE72E1EAB460A620A61"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4441-wk-Fact-E71BAB60F8F54CE72E1EAB460A620A61"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8699-wk-Fact-E7318B73FA0358F7AAB3343146AFB749"
          xlink:label="d34586122e8699-wk-Fact-E7318B73FA0358F7AAB3343146AFB749"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8699-wk-Fact-E7318B73FA0358F7AAB3343146AFB749"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19617-wk-Fact-E73373912ABEFE585146801F81629B0E"
          xlink:label="d34661879e19617-wk-Fact-E73373912ABEFE585146801F81629B0E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19617-wk-Fact-E73373912ABEFE585146801F81629B0E"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0"
          xlink:label="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0"
          xlink:to="TextSelection-14911E1F7380E49081C7801F83395965-0-wk-Footnote-14911E1F7380E49081C7801F83395965_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24238-wk-Fact-E7417561E2B6F9418798801F8137CAF0"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3125-wk-Fact-E756524CD9B052E3BC12448706C676DB"
          xlink:label="d34501946e3125-wk-Fact-E756524CD9B052E3BC12448706C676DB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3125-wk-Fact-E756524CD9B052E3BC12448706C676DB"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21594-wk-Fact-E7F460C957BC5FCAA01E801F7E03BE66"
          xlink:label="d34661879e21594-wk-Fact-E7F460C957BC5FCAA01E801F7E03BE66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21594-wk-Fact-E7F460C957BC5FCAA01E801F7E03BE66"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4269-wk-Fact-E826CDDD3780AEBA80B0CB2DE5D9E519"
          xlink:label="d34458032e4269-wk-Fact-E826CDDD3780AEBA80B0CB2DE5D9E519"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4269-wk-Fact-E826CDDD3780AEBA80B0CB2DE5D9E519"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3104-wk-Fact-E83DC31A66C95716944B69D6571C0712"
          xlink:label="d34458036e3104-wk-Fact-E83DC31A66C95716944B69D6571C0712"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3104-wk-Fact-E83DC31A66C95716944B69D6571C0712"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:label="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:label="d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:label="d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-DE2259FCD19CACB4B98B801F82F8563D-0-wk-Footnote-DE2259FCD19CACB4B98B801F82F8563D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1848-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e2780-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5781-wk-Fact-E85B78972C0E5DABBEF43A7A4FA7F961"
          xlink:to="TextSelection-FC1178D68801DCD3E4F2801F83138A99-0-wk-Footnote-FC1178D68801DCD3E4F2801F83138A99_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e7614-wk-Fact-E880D275F9E61ED56A76801F7EE80BBC"
          xlink:label="d34661879e7614-wk-Fact-E880D275F9E61ED56A76801F7EE80BBC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e7614-wk-Fact-E880D275F9E61ED56A76801F7EE80BBC"
          xlink:to="TextSelection-758394BD7E17E2CDEDC7801F83398A31-0-wk-Footnote-758394BD7E17E2CDEDC7801F83398A31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10373-wk-Fact-E89A524C2D8E94D7B82F801F820D0235"
          xlink:label="d34661879e10373-wk-Fact-E89A524C2D8E94D7B82F801F820D0235"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10373-wk-Fact-E89A524C2D8E94D7B82F801F820D0235"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5071-wk-Fact-E89AA763E81D428EDA17801F811E14C7"
          xlink:label="d34545404e5071-wk-Fact-E89AA763E81D428EDA17801F811E14C7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5071-wk-Fact-E89AA763E81D428EDA17801F811E14C7"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2315-wk-Fact-E8B4FB59DE0025523471801F82937FF6"
          xlink:label="d34458036e2315-wk-Fact-E8B4FB59DE0025523471801F82937FF6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2315-wk-Fact-E8B4FB59DE0025523471801F82937FF6"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3406-wk-Fact-E8C1F0E054CC0BFAC98F801F7EA87952"
          xlink:label="d34458036e3406-wk-Fact-E8C1F0E054CC0BFAC98F801F7EA87952"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3406-wk-Fact-E8C1F0E054CC0BFAC98F801F7EA87952"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23798-wk-Fact-E8F433CDF6DA732D6EF5801F7E697BF0"
          xlink:label="d34661879e23798-wk-Fact-E8F433CDF6DA732D6EF5801F7E697BF0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23798-wk-Fact-E8F433CDF6DA732D6EF5801F7E697BF0"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3124-wk-Fact-E90985269B2154239A430851FD659027"
          xlink:label="d34661879e3124-wk-Fact-E90985269B2154239A430851FD659027"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3124-wk-Fact-E90985269B2154239A430851FD659027"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3339-wk-Fact-E926E550228AFBDF79A3801F7EAA2096"
          xlink:label="d34458036e3339-wk-Fact-E926E550228AFBDF79A3801F7EAA2096"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3339-wk-Fact-E926E550228AFBDF79A3801F7EAA2096"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4422-wk-Fact-E9440844908157FB84B59804D5572F92"
          xlink:label="d34458036e4422-wk-Fact-E9440844908157FB84B59804D5572F92"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4422-wk-Fact-E9440844908157FB84B59804D5572F92"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8306-wk-Fact-E9743691F65857D4AA21DEFCE49F0F66"
          xlink:label="d34586122e8306-wk-Fact-E9743691F65857D4AA21DEFCE49F0F66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8306-wk-Fact-E9743691F65857D4AA21DEFCE49F0F66"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8532-wk-Fact-E97AA6E5D4FA5F64AFB7FBD507DC3DB7"
          xlink:label="d34586122e8532-wk-Fact-E97AA6E5D4FA5F64AFB7FBD507DC3DB7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8532-wk-Fact-E97AA6E5D4FA5F64AFB7FBD507DC3DB7"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8532-wk-Fact-E97AA6E5D4FA5F64AFB7FBD507DC3DB7"
          xlink:to="TextSelection-D8B69C079A73D284D968801F8350B2AF-0-wk-Footnote-D8B69C079A73D284D968801F8350B2AF_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2193-wk-Fact-E9E2C2D229FB5FD08F618AA417F7A246"
          xlink:label="d34529301e2193-wk-Fact-E9E2C2D229FB5FD08F618AA417F7A246"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2193-wk-Fact-E9E2C2D229FB5FD08F618AA417F7A246"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8645-wk-Fact-EA467189B34B25F5663DDE209D44E894"
          xlink:label="d34586122e8645-wk-Fact-EA467189B34B25F5663DDE209D44E894"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8645-wk-Fact-EA467189B34B25F5663DDE209D44E894"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3354-wk-Fact-EA60695FBD38F2408E8C801F7EC802D2"
          xlink:label="d34458032e3354-wk-Fact-EA60695FBD38F2408E8C801F7EC802D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3354-wk-Fact-EA60695FBD38F2408E8C801F7EC802D2"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2721-wk-Fact-EAC2A8EBA0265A18879BA13F53119C66"
          xlink:label="d34423000e2721-wk-Fact-EAC2A8EBA0265A18879BA13F53119C66"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2721-wk-Fact-EAC2A8EBA0265A18879BA13F53119C66"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4999-wk-Fact-EADEAA54DF8A5541A925A32BD98FDB78"
          xlink:label="d34661879e4999-wk-Fact-EADEAA54DF8A5541A925A32BD98FDB78"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4999-wk-Fact-EADEAA54DF8A5541A925A32BD98FDB78"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e25527-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:label="d34661879e25527-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e26050-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:label="d34661879e26050-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e24057-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:label="d34661879e24057-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e25527-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26050-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24057-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e25527-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e26050-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24057-wk-Fact-EAE26AAB2C1914749716801F81E7B60A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1917-wk-Fact-EB399C3D7F4B5217B1ECA17E1450C7CB"
          xlink:label="d34458036e1917-wk-Fact-EB399C3D7F4B5217B1ECA17E1450C7CB"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1917-wk-Fact-EB399C3D7F4B5217B1ECA17E1450C7CB"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1917-wk-Fact-EB399C3D7F4B5217B1ECA17E1450C7CB"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4140-wk-Fact-EB4AB9F6D4F4A8E5149B801F8025CB18"
          xlink:label="d34661879e4140-wk-Fact-EB4AB9F6D4F4A8E5149B801F8025CB18"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4140-wk-Fact-EB4AB9F6D4F4A8E5149B801F8025CB18"
          xlink:to="TextSelection-C5969C6B6BC2D667FD76801F8337988D-0-wk-Footnote-C5969C6B6BC2D667FD76801F8337988D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10313-wk-Fact-EBE912A2B8B787111E58801F81ECF50B"
          xlink:label="d34661879e10313-wk-Fact-EBE912A2B8B787111E58801F81ECF50B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10313-wk-Fact-EBE912A2B8B787111E58801F81ECF50B"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5604-wk-Fact-EC03DB407E47C12F595C02108AD6FC21"
          xlink:label="d34545404e5604-wk-Fact-EC03DB407E47C12F595C02108AD6FC21"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5604-wk-Fact-EC03DB407E47C12F595C02108AD6FC21"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5604-wk-Fact-EC03DB407E47C12F595C02108AD6FC21"
          xlink:to="TextSelection-C247591C8487C01B6A5A021628C00FB8-0-wk-Footnote-C247591C8487C01B6A5A021628C00FB8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5008-wk-Fact-EC11057FA838BD75D525801F824F6767"
          xlink:label="d34458032e5008-wk-Fact-EC11057FA838BD75D525801F824F6767"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5008-wk-Fact-EC11057FA838BD75D525801F824F6767"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2089-wk-Fact-EC38E965C828B3438D45801F82AD8435"
          xlink:label="d34458036e2089-wk-Fact-EC38E965C828B3438D45801F82AD8435"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2089-wk-Fact-EC38E965C828B3438D45801F82AD8435"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e1942-wk-Fact-EC3C848AE6A9CBDEC522801F7E7CD417"
          xlink:label="d34460716e1942-wk-Fact-EC3C848AE6A9CBDEC522801F7E7CD417"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e1942-wk-Fact-EC3C848AE6A9CBDEC522801F7E7CD417"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19481-wk-Fact-EC53E968779C6028ED9C801F7EC737F6"
          xlink:label="d34661879e19481-wk-Fact-EC53E968779C6028ED9C801F7EC737F6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19481-wk-Fact-EC53E968779C6028ED9C801F7EC737F6"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3903-wk-Fact-ECAA0C7EF7645E87A5DF7782CF068255"
          xlink:label="d34468079e3903-wk-Fact-ECAA0C7EF7645E87A5DF7782CF068255"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3903-wk-Fact-ECAA0C7EF7645E87A5DF7782CF068255"
          xlink:to="TextSelection-98CCDF57DA0F470C9D50801F8304F63B-0-wk-Footnote-98CCDF57DA0F470C9D50801F8304F63B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5348-wk-Fact-ECECA9DC935CC99E3524801F82146F62"
          xlink:label="d34506804e5348-wk-Fact-ECECA9DC935CC99E3524801F82146F62"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5348-wk-Fact-ECECA9DC935CC99E3524801F82146F62"
          xlink:to="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5710-wk-Fact-ED209CAAD0144B632B7B801F7DF7158B"
          xlink:label="d34458032e5710-wk-Fact-ED209CAAD0144B632B7B801F7DF7158B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5710-wk-Fact-ED209CAAD0144B632B7B801F7DF7158B"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3209-wk-Fact-ED884752BC3FCC09AA86801F82ADF8F8"
          xlink:label="d34458036e3209-wk-Fact-ED884752BC3FCC09AA86801F82ADF8F8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3209-wk-Fact-ED884752BC3FCC09AA86801F82ADF8F8"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e3324-wk-Fact-EDB5A19EC991587EA94D6F34F8FC39F7"
          xlink:label="d34428379e3324-wk-Fact-EDB5A19EC991587EA94D6F34F8FC39F7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e3324-wk-Fact-EDB5A19EC991587EA94D6F34F8FC39F7"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e8566-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0"
          xlink:label="d34594690e8566-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34458036e4157-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0"
          xlink:label="d34458036e4157-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e8566-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4157-wk-Fact-EDBFD82226585614A23C7C8070B2F2E0"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5182-wk-Fact-EDC9BC9984C3F470119D801F8127899E"
          xlink:label="d34545404e5182-wk-Fact-EDC9BC9984C3F470119D801F8127899E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5182-wk-Fact-EDC9BC9984C3F470119D801F8127899E"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24442-wk-Fact-EDDE1FED2572278FFC6B801F7EC0F70A"
          xlink:label="d34661879e24442-wk-Fact-EDDE1FED2572278FFC6B801F7EC0F70A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24442-wk-Fact-EDDE1FED2572278FFC6B801F7EC0F70A"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20601-wk-Fact-EDE6AA3E50AC798E1DBE801F7DF2E87B"
          xlink:label="d34661879e20601-wk-Fact-EDE6AA3E50AC798E1DBE801F7DF2E87B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20601-wk-Fact-EDE6AA3E50AC798E1DBE801F7DF2E87B"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22641-wk-Fact-EDF3B6B8EE0203C0AE3F801F80E9D531"
          xlink:label="d34661879e22641-wk-Fact-EDF3B6B8EE0203C0AE3F801F80E9D531"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22641-wk-Fact-EDF3B6B8EE0203C0AE3F801F80E9D531"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8384-wk-Fact-EE402418A54D574CB441079C7682C003"
          xlink:label="d34545404e8384-wk-Fact-EE402418A54D574CB441079C7682C003"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8384-wk-Fact-EE402418A54D574CB441079C7682C003"
          xlink:to="TextSelection-FCA6242FB8EA38781CF1801F831387AE-0-wk-Footnote-FCA6242FB8EA38781CF1801F831387AE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4329-wk-Fact-EE63D6A60A1762912BF4801F8259FD6E"
          xlink:label="d34458032e4329-wk-Fact-EE63D6A60A1762912BF4801F8259FD6E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4329-wk-Fact-EE63D6A60A1762912BF4801F8259FD6E"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e6292-wk-Fact-EE6CC8909F1494988B7A801F7DF1C8F7"
          xlink:label="d34458032e6292-wk-Fact-EE6CC8909F1494988B7A801F7DF1C8F7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6292-wk-Fact-EE6CC8909F1494988B7A801F7DF1C8F7"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e6292-wk-Fact-EE6CC8909F1494988B7A801F7DF1C8F7"
          xlink:to="TextSelection-7D4E9A400D1244513FA3801F82F86069-0-wk-Footnote-7D4E9A400D1244513FA3801F82F86069_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7325-wk-Fact-EE8C91D96F98673768FF801F82A21974"
          xlink:label="d34594690e7325-wk-Fact-EE8C91D96F98673768FF801F82A21974"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7325-wk-Fact-EE8C91D96F98673768FF801F82A21974"
          xlink:to="TextSelection-1634DE21A50EAFCE7634801F834A9F29-0-wk-Footnote-1634DE21A50EAFCE7634801F834A9F29_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10748-wk-Fact-EEAFCF15A92A73FE4BC1801F820BA9BC"
          xlink:label="d34661879e10748-wk-Fact-EEAFCF15A92A73FE4BC1801F820BA9BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10748-wk-Fact-EEAFCF15A92A73FE4BC1801F820BA9BC"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24481-wk-Fact-EEDDB06313F61B23BAEB801F7EC79AC8"
          xlink:label="d34661879e24481-wk-Fact-EEDDB06313F61B23BAEB801F7EC79AC8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24481-wk-Fact-EEDDB06313F61B23BAEB801F7EC79AC8"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10353-wk-Fact-EF1120B81FCABC3479FE801F81EE2ED4"
          xlink:label="d34661879e10353-wk-Fact-EF1120B81FCABC3479FE801F81EE2ED4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10353-wk-Fact-EF1120B81FCABC3479FE801F81EE2ED4"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5346-wk-Fact-EF43F96DEFFEE9BA1C18801F82C1C357"
          xlink:label="d34458036e5346-wk-Fact-EF43F96DEFFEE9BA1C18801F82C1C357"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5346-wk-Fact-EF43F96DEFFEE9BA1C18801F82C1C357"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5346-wk-Fact-EF43F96DEFFEE9BA1C18801F82C1C357"
          xlink:to="TextSelection-713D661705EED646E0A2CB5EFDA7E01B-0-wk-Footnote-713D661705EED646E0A2CB5EFDA7E01B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6700-wk-Fact-EF6483D67C1CC41F73AB801F8280AE16"
          xlink:label="d34545404e6700-wk-Fact-EF6483D67C1CC41F73AB801F8280AE16"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6700-wk-Fact-EF6483D67C1CC41F73AB801F8280AE16"
          xlink:to="TextSelection-C59E08D2F6D28A6880AF801F83115199-0-wk-Footnote-C59E08D2F6D28A6880AF801F83115199_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e5943-wk-Fact-EFC8C046FEC7E568BE67801F803C6F71"
          xlink:label="d34458032e5943-wk-Fact-EFC8C046FEC7E568BE67801F803C6F71"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e5943-wk-Fact-EFC8C046FEC7E568BE67801F803C6F71"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2002-wk-Fact-EFFB4E372D675AF89AAD0163ED875CE2"
          xlink:label="d34428379e2002-wk-Fact-EFFB4E372D675AF89AAD0163ED875CE2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2002-wk-Fact-EFFB4E372D675AF89AAD0163ED875CE2"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21944-wk-Fact-F02B4A8F59412D2599F9801F7EBEBAF8"
          xlink:label="d34661879e21944-wk-Fact-F02B4A8F59412D2599F9801F7EBEBAF8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21944-wk-Fact-F02B4A8F59412D2599F9801F7EBEBAF8"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8773-wk-Fact-F0DD6FB9D7D65FF7A33085989120CCED"
          xlink:label="d34586122e8773-wk-Fact-F0DD6FB9D7D65FF7A33085989120CCED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8773-wk-Fact-F0DD6FB9D7D65FF7A33085989120CCED"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e1923-wk-Fact-F0E9225B40E6D9F21243801F7E9BDD39"
          xlink:label="d34460716e1923-wk-Fact-F0E9225B40E6D9F21243801F7E9BDD39"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e1923-wk-Fact-F0E9225B40E6D9F21243801F7E9BDD39"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3067-wk-Fact-F1667F5FCAC154B8954BDD808EA7CF01"
          xlink:label="d34501946e3067-wk-Fact-F1667F5FCAC154B8954BDD808EA7CF01"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3067-wk-Fact-F1667F5FCAC154B8954BDD808EA7CF01"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e4063-wk-Fact-F16E0A41BA8953F7AFA1ACB2D90C1AB8"
          xlink:label="d34471435e4063-wk-Fact-F16E0A41BA8953F7AFA1ACB2D90C1AB8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e4063-wk-Fact-F16E0A41BA8953F7AFA1ACB2D90C1AB8"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e28318-wk-Fact-F1841F95F4C2B39FD6AF1B677F253E82"
          xlink:label="d34661879e28318-wk-Fact-F1841F95F4C2B39FD6AF1B677F253E82"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e28318-wk-Fact-F1841F95F4C2B39FD6AF1B677F253E82"
          xlink:to="TextSelection-244B470B077332C11F811732546782CD-0-wk-Footnote-244B470B077332C11F811732546782CD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19680-wk-Fact-F1A609A7255A0AC15A90801F8171F6C4"
          xlink:label="d34661879e19680-wk-Fact-F1A609A7255A0AC15A90801F8171F6C4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19680-wk-Fact-F1A609A7255A0AC15A90801F8171F6C4"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3767-wk-Fact-F1DA5A74EBBE5412A2A5D4960C73D7D2"
          xlink:label="d34586122e3767-wk-Fact-F1DA5A74EBBE5412A2A5D4960C73D7D2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3767-wk-Fact-F1DA5A74EBBE5412A2A5D4960C73D7D2"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:label="d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:label="d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:label="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e1690-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e4322-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2039-wk-Fact-F21DF57D0EF65156A5D3F3B4870592BC"
          xlink:to="TextSelection-BD7930C49C417519DB99801F830FA1B0-0-wk-Footnote-BD7930C49C417519DB99801F830FA1B0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e1916-wk-Fact-F2276591896D5AF8B95530B8937AAC4D"
          xlink:label="d34428379e1916-wk-Fact-F2276591896D5AF8B95530B8937AAC4D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e1916-wk-Fact-F2276591896D5AF8B95530B8937AAC4D"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e6882-wk-Fact-F23CE49E146AE8ABD01E801F80CDC5E3"
          xlink:label="d34545404e6882-wk-Fact-F23CE49E146AE8ABD01E801F80CDC5E3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e6882-wk-Fact-F23CE49E146AE8ABD01E801F80CDC5E3"
          xlink:to="TextSelection-347B74D4E8ADB0A5A09B801F83115191-0-wk-Footnote-347B74D4E8ADB0A5A09B801F83115191_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3751-wk-Fact-F2E147AA2E8654AB8038D339B5F38F4E"
          xlink:label="d34468079e3751-wk-Fact-F2E147AA2E8654AB8038D339B5F38F4E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3751-wk-Fact-F2E147AA2E8654AB8038D339B5F38F4E"
          xlink:to="TextSelection-9F1C5BA30F71444460BD801F8304F73E-0-wk-Footnote-9F1C5BA30F71444460BD801F8304F73E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2461-wk-Fact-F2F4F04B9714562C8431CD66A86B0259"
          xlink:label="d34468079e2461-wk-Fact-F2F4F04B9714562C8431CD66A86B0259"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2461-wk-Fact-F2F4F04B9714562C8431CD66A86B0259"
          xlink:to="TextSelection-7151E0C2E96574AE07F1801F83056081-0-wk-Footnote-7151E0C2E96574AE07F1801F83056081_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e2262-wk-Fact-F2F93F5F2FC3C51352FB801F80F4AFFE"
          xlink:label="d34471435e2262-wk-Fact-F2F93F5F2FC3C51352FB801F80F4AFFE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2262-wk-Fact-F2F93F5F2FC3C51352FB801F80F4AFFE"
          xlink:to="TextSelection-21F0A0AC843355FD3BFC801F830DCEA2-0-wk-Footnote-21F0A0AC843355FD3BFC801F830DCEA2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e2463-wk-Fact-F35741687D18E3B4878F801F81982A44"
          xlink:label="d34594690e2463-wk-Fact-F35741687D18E3B4878F801F81982A44"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e2463-wk-Fact-F35741687D18E3B4878F801F81982A44"
          xlink:to="TextSelection-2265D82290BC1789F587801F834812F7-0-wk-Footnote-2265D82290BC1789F587801F834812F7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9114-wk-Fact-F3755FEC2162588F811E0BE706D54E9C"
          xlink:label="d34458032e9114-wk-Fact-F3755FEC2162588F811E0BE706D54E9C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9114-wk-Fact-F3755FEC2162588F811E0BE706D54E9C"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e4019-wk-Fact-F3866D134A97F71188EB801F7E1851F4"
          xlink:label="d34458032e4019-wk-Fact-F3866D134A97F71188EB801F7E1851F4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e4019-wk-Fact-F3866D134A97F71188EB801F7E1851F4"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e4837-wk-Fact-F3A34AC6947D589C87DC5D125305250F"
          xlink:label="d34529301e4837-wk-Fact-F3A34AC6947D589C87DC5D125305250F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e4837-wk-Fact-F3A34AC6947D589C87DC5D125305250F"
          xlink:to="TextSelection-A05EE50531B9FA56C7F6D82B712DA107-0-wk-Footnote-A05EE50531B9FA56C7F6D82B712DA107_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10767-wk-Fact-F3A9A889D5F803CEA915801F81FC88F0"
          xlink:label="d34661879e10767-wk-Fact-F3A9A889D5F803CEA915801F81FC88F0"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10767-wk-Fact-F3A9A889D5F803CEA915801F81FC88F0"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3603-wk-Fact-F3F4B1BA315C571D94BD569F67709BC4"
          xlink:label="d34586122e3603-wk-Fact-F3F4B1BA315C571D94BD569F67709BC4"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3603-wk-Fact-F3F4B1BA315C571D94BD569F67709BC4"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20582-wk-Fact-F412DE60776769E48B4D801F8102E063"
          xlink:label="d34661879e20582-wk-Fact-F412DE60776769E48B4D801F8102E063"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20582-wk-Fact-F412DE60776769E48B4D801F8102E063"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34594690e7272-wk-Fact-F46555EB6318EAAE369C801F8291F711"
          xlink:label="d34594690e7272-wk-Fact-F46555EB6318EAAE369C801F8291F711"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34594690e7272-wk-Fact-F46555EB6318EAAE369C801F8291F711"
          xlink:to="TextSelection-AE0E862113F128878157801F834A188B-0-wk-Footnote-AE0E862113F128878157801F834A188B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e4023-wk-Fact-F48375E1B07289C166E7801F7E895D8F"
          xlink:label="d34545404e4023-wk-Fact-F48375E1B07289C166E7801F7E895D8F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4023-wk-Fact-F48375E1B07289C166E7801F7E895D8F"
          xlink:to="TextSelection-51BF103FD30FA18AEA03801F8312B160-0-wk-Footnote-51BF103FD30FA18AEA03801F8312B160_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e4023-wk-Fact-F48375E1B07289C166E7801F7E895D8F"
          xlink:to="TextSelection-6D16B9A6002EB0A37025801F8310D828-0-wk-Footnote-6D16B9A6002EB0A37025801F8310D828_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e9848-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2"
          xlink:label="d34661879e9848-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e3002-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2"
          xlink:label="d34661879e3002-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9848-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3002-wk-Fact-F4A677627BF7ACD07178801F81FAAEF2"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10047-wk-Fact-F507F3DBBA00388E5CD9801F820B8A6C"
          xlink:label="d34661879e10047-wk-Fact-F507F3DBBA00388E5CD9801F820B8A6C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10047-wk-Fact-F507F3DBBA00388E5CD9801F820B8A6C"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e3221-wk-Fact-F510E0B5E23456BCA1F3AB0787E1A55F"
          xlink:label="d34586122e3221-wk-Fact-F510E0B5E23456BCA1F3AB0787E1A55F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e3221-wk-Fact-F510E0B5E23456BCA1F3AB0787E1A55F"
          xlink:to="TextSelection-563532A8DDC99D75A36C801F834F4E25-0-wk-Footnote-563532A8DDC99D75A36C801F834F4E25_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e3712-wk-Fact-F538ACACF4943B2112FE801F7FAADCE2"
          xlink:label="d34661879e3712-wk-Fact-F538ACACF4943B2112FE801F7FAADCE2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e3712-wk-Fact-F538ACACF4943B2112FE801F7FAADCE2"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e8684-wk-Fact-F57AC8E1967F55269DC8AFBFE79580C5"
          xlink:label="d34496162e8684-wk-Fact-F57AC8E1967F55269DC8AFBFE79580C5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e8684-wk-Fact-F57AC8E1967F55269DC8AFBFE79580C5"
          xlink:to="TextSelection-00B1F244805F23E229ECE4C97135F977-0-wk-Footnote-00B1F244805F23E229ECE4C97135F977_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e24814-wk-Fact-F588B19D0C5C6EC9C734801F7FE99D83"
          xlink:label="d34661879e24814-wk-Fact-F588B19D0C5C6EC9C734801F7FE99D83"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e24814-wk-Fact-F588B19D0C5C6EC9C734801F7FE99D83"
          xlink:to="TextSelection-1FF08D06D8E01114C18A801F833D069C-0-wk-Footnote-1FF08D06D8E01114C18A801F833D069C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e1993-wk-Fact-F590D4C627155C828C90476F227A1511"
          xlink:label="d34430544e1993-wk-Fact-F590D4C627155C828C90476F227A1511"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34471435e2580-wk-Fact-F590D4C627155C828C90476F227A1511"
          xlink:label="d34471435e2580-wk-Fact-F590D4C627155C828C90476F227A1511"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e1993-wk-Fact-F590D4C627155C828C90476F227A1511"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e2580-wk-Fact-F590D4C627155C828C90476F227A1511"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8867-wk-Fact-F5C4DA82D51CF805497FDE20A789D463"
          xlink:label="d34586122e8867-wk-Fact-F5C4DA82D51CF805497FDE20A789D463"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8867-wk-Fact-F5C4DA82D51CF805497FDE20A789D463"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e3164-wk-Fact-F60C602F8EF1574C98B984D666B6FDE3"
          xlink:label="d34423000e3164-wk-Fact-F60C602F8EF1574C98B984D666B6FDE3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e3164-wk-Fact-F60C602F8EF1574C98B984D666B6FDE3"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e2175-wk-Fact-F6552983FEE057A7B0758F714B47B201"
          xlink:label="d34468079e2175-wk-Fact-F6552983FEE057A7B0758F714B47B201"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e2175-wk-Fact-F6552983FEE057A7B0758F714B47B201"
          xlink:to="TextSelection-D8566474AE21E37301E8801F8304D0E0-0-wk-Footnote-D8566474AE21E37301E8801F8304D0E0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e9332-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
          xlink:label="d34545404e9332-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34428379e2996-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
          xlink:label="d34428379e2996-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9332-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
          xlink:to="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2996-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
          xlink:to="TextSelection-24C996E2B0C4C9CA8E1C801F82F7F813-0-wk-Footnote-24C996E2B0C4C9CA8E1C801F82F7F813_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e9332-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2996-wk-Fact-F6AD2F260FDC5710AB5EBF1AC1BCE85C"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11569-wk-Fact-F6AEFE5F18DC80AFD6EE801F81742ECC"
          xlink:label="d34586122e11569-wk-Fact-F6AEFE5F18DC80AFD6EE801F81742ECC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11569-wk-Fact-F6AEFE5F18DC80AFD6EE801F81742ECC"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e10096-wk-Fact-F6B75BABBAB55FA999FDCDEA743AF12B"
          xlink:label="d34586122e10096-wk-Fact-F6B75BABBAB55FA999FDCDEA743AF12B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e10096-wk-Fact-F6B75BABBAB55FA999FDCDEA743AF12B"
          xlink:to="TextSelection-B1C4F0498B1BFCD37408801F8352D0A7-0-wk-Footnote-B1C4F0498B1BFCD37408801F8352D0A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e21517-wk-Fact-F6CAFC8B9758DAA23D9B801F80F1603E"
          xlink:label="d34661879e21517-wk-Fact-F6CAFC8B9758DAA23D9B801F80F1603E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e21517-wk-Fact-F6CAFC8B9758DAA23D9B801F80F1603E"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14952-wk-Fact-F6F791A5DBF42B041441801F7F0A62EE"
          xlink:label="d34661879e14952-wk-Fact-F6F791A5DBF42B041441801F7F0A62EE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14952-wk-Fact-F6F791A5DBF42B041441801F7F0A62EE"
          xlink:to="TextSelection-B868DCE5CE239678E3C3801F8338A980-0-wk-Footnote-B868DCE5CE239678E3C3801F8338A980_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e20932-wk-Fact-F7341069EEF19CA78430801F7ECE7A09"
          xlink:label="d34661879e20932-wk-Fact-F7341069EEF19CA78430801F7ECE7A09"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20932-wk-Fact-F7341069EEF19CA78430801F7ECE7A09"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e20932-wk-Fact-F7341069EEF19CA78430801F7ECE7A09"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e5332-wk-Fact-F774D66B39E3548293A7768C17FCC7C8"
          xlink:label="d34586122e5332-wk-Fact-F774D66B39E3548293A7768C17FCC7C8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e5332-wk-Fact-F774D66B39E3548293A7768C17FCC7C8"
          xlink:to="TextSelection-AD02D966550AA38B95DE801F835016C0-0-wk-Footnote-AD02D966550AA38B95DE801F835016C0_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e2711-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
          xlink:label="d34661879e2711-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34661879e9649-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
          xlink:label="d34661879e9649-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2711-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9649-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e2711-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e9649-wk-Fact-F78BA68FB841DEBCA8D1801F8212444F"
          xlink:to="TextSelection-8EB736916E696A166217801F83374EA7-0-wk-Footnote-8EB736916E696A166217801F83374EA7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2993-wk-Fact-F7A1A47C403158F4A0050A07FD1FD932"
          xlink:label="d34458036e2993-wk-Fact-F7A1A47C403158F4A0050A07FD1FD932"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2993-wk-Fact-F7A1A47C403158F4A0050A07FD1FD932"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e9424-wk-Fact-F7BF280E6470537B8D74D0E1C2349E3E"
          xlink:label="d34458032e9424-wk-Fact-F7BF280E6470537B8D74D0E1C2349E3E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e9424-wk-Fact-F7BF280E6470537B8D74D0E1C2349E3E"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8625-wk-Fact-F7DF3FA519E05ABBB36AF2BDC1C1D5E2"
          xlink:label="d34586122e8625-wk-Fact-F7DF3FA519E05ABBB36AF2BDC1C1D5E2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8625-wk-Fact-F7DF3FA519E05ABBB36AF2BDC1C1D5E2"
          xlink:to="TextSelection-33ACFD0C39C088E9BC1E801F8350AA5F-0-wk-Footnote-33ACFD0C39C088E9BC1E801F8350AA5F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2187-wk-Fact-F7E834DB2C365543A0147187D74A1E82"
          xlink:label="d34430544e2187-wk-Fact-F7E834DB2C365543A0147187D74A1E82"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34523018e1635-wk-Fact-F7E834DB2C365543A0147187D74A1E82"
          xlink:label="d34523018e1635-wk-Fact-F7E834DB2C365543A0147187D74A1E82"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2187-wk-Fact-F7E834DB2C365543A0147187D74A1E82"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e1635-wk-Fact-F7E834DB2C365543A0147187D74A1E82"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e1718-wk-Fact-F7E8D2F6BA545C88B2145BBF4BB71213"
          xlink:label="d34458036e1718-wk-Fact-F7E8D2F6BA545C88B2145BBF4BB71213"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e1718-wk-Fact-F7E8D2F6BA545C88B2145BBF4BB71213"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5478-wk-Fact-F803761CFD33D77A1C43801F82624A72"
          xlink:label="d34458036e5478-wk-Fact-F803761CFD33D77A1C43801F82624A72"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5478-wk-Fact-F803761CFD33D77A1C43801F82624A72"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5478-wk-Fact-F803761CFD33D77A1C43801F82624A72"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2552-wk-Fact-F8064D62E55D3D14B6F5801F82AA72CC"
          xlink:label="d34458036e2552-wk-Fact-F8064D62E55D3D14B6F5801F82AA72CC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2552-wk-Fact-F8064D62E55D3D14B6F5801F82AA72CC"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11791-wk-Fact-F82E69C6D1AF9AB5F0E1801F7E7C93ED"
          xlink:label="d34586122e11791-wk-Fact-F82E69C6D1AF9AB5F0E1801F7E7C93ED"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11791-wk-Fact-F82E69C6D1AF9AB5F0E1801F7E7C93ED"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2763-wk-Fact-F84C8C614DC11C920600801F81CCF916"
          xlink:label="d34586122e2763-wk-Fact-F84C8C614DC11C920600801F81CCF916"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2763-wk-Fact-F84C8C614DC11C920600801F81CCF916"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34509238e2046-wk-Fact-F86E93B23C3F1D21812D801F7FA074B1"
          xlink:label="d34509238e2046-wk-Fact-F86E93B23C3F1D21812D801F7FA074B1"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34509238e2046-wk-Fact-F86E93B23C3F1D21812D801F7FA074B1"
          xlink:to="TextSelection-1B6D1520B957E6708C32801F8318DAAD-0-wk-Footnote-1B6D1520B957E6708C32801F8318DAAD_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23778-wk-Fact-F8768CC4E46B6B99211A801F7EE08C5B"
          xlink:label="d34661879e23778-wk-Fact-F8768CC4E46B6B99211A801F7EE08C5B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23778-wk-Fact-F8768CC4E46B6B99211A801F7EE08C5B"
          xlink:to="TextSelection-9443D7C26CB3D86A39EA801F8339764A-0-wk-Footnote-9443D7C26CB3D86A39EA801F8339764A_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23778-wk-Fact-F8768CC4E46B6B99211A801F7EE08C5B"
          xlink:to="TextSelection-C8B3BEA4E19574EFF302801F83390BFE-0-wk-Footnote-C8B3BEA4E19574EFF302801F83390BFE_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5329-wk-Fact-F887DA1F92BAA8B8385A801F81DC8EFC"
          xlink:label="d34506804e5329-wk-Fact-F887DA1F92BAA8B8385A801F81DC8EFC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5329-wk-Fact-F887DA1F92BAA8B8385A801F81DC8EFC"
          xlink:to="TextSelection-3E18A1B7552781D3BF6E801F83026505-0-wk-Footnote-3E18A1B7552781D3BF6E801F83026505_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e2421-wk-Fact-F8A9B839E0BCBA875A7D801F82AD2263"
          xlink:label="d34458036e2421-wk-Fact-F8A9B839E0BCBA875A7D801F82AD2263"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e2421-wk-Fact-F8A9B839E0BCBA875A7D801F82AD2263"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2919-wk-Fact-F917EC74CAF8798A2465D083C001D773"
          xlink:label="d34586122e2919-wk-Fact-F917EC74CAF8798A2465D083C001D773"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2919-wk-Fact-F917EC74CAF8798A2465D083C001D773"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e4883-wk-Fact-F926238DB44A5C97B1224C96A9C8141E"
          xlink:label="d34661879e4883-wk-Fact-F926238DB44A5C97B1224C96A9C8141E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e4883-wk-Fact-F926238DB44A5C97B1224C96A9C8141E"
          xlink:to="TextSelection-E057FF6A36F39CAAA0D0801F833D46B3-0-wk-Footnote-E057FF6A36F39CAAA0D0801F833D46B3_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2712-wk-Fact-F98321594AC5D5415DB0801F825F0776"
          xlink:label="d34458032e2712-wk-Fact-F98321594AC5D5415DB0801F825F0776"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2712-wk-Fact-F98321594AC5D5415DB0801F825F0776"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E"
          xlink:label="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e3473-wk-Fact-F98358A8C0B973270FE3AB460A656F1E"
          xlink:to="TextSelection-ADD7FA9B7202217F06F8801F82F8FA31-0-wk-Footnote-ADD7FA9B7202217F06F8801F82F8FA31_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e4557-wk-Fact-F9953003974753B0A6C247B19A717620"
          xlink:label="d34458036e4557-wk-Fact-F9953003974753B0A6C247B19A717620"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e4557-wk-Fact-F9953003974753B0A6C247B19A717620"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458036e5242-wk-Fact-F99E6C3DC2CC5F62AF63CD1ED043A574"
          xlink:label="d34458036e5242-wk-Fact-F99E6C3DC2CC5F62AF63CD1ED043A574"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5242-wk-Fact-F99E6C3DC2CC5F62AF63CD1ED043A574"
          xlink:to="TextSelection-1A2ED62D03E0259A6F17801F82F94777-0-wk-Footnote-1A2ED62D03E0259A6F17801F82F94777_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458036e5242-wk-Fact-F99E6C3DC2CC5F62AF63CD1ED043A574"
          xlink:to="TextSelection-646678D7FC41D9A6F9CFCB5E7319A63D-0-wk-Footnote-646678D7FC41D9A6F9CFCB5E7319A63D_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34523018e2597-wk-Fact-F9C9FEE2CCBF5BBAB626316FA2913D2A"
          xlink:label="d34523018e2597-wk-Fact-F9C9FEE2CCBF5BBAB626316FA2913D2A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34523018e2597-wk-Fact-F9C9FEE2CCBF5BBAB626316FA2913D2A"
          xlink:to="TextSelection-5CDC97EC44C9DE188E94801F834D03A5-0-wk-Footnote-5CDC97EC44C9DE188E94801F834D03A5_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5519-wk-Fact-F9D55A1BA8C4FB2C64FC801F7F4A5D64"
          xlink:label="d34545404e5519-wk-Fact-F9D55A1BA8C4FB2C64FC801F7F4A5D64"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5519-wk-Fact-F9D55A1BA8C4FB2C64FC801F7F4A5D64"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e11752-wk-Fact-FA19F775D49E5417994497ED45F8B1B7"
          xlink:label="d34586122e11752-wk-Fact-FA19F775D49E5417994497ED45F8B1B7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e11752-wk-Fact-FA19F775D49E5417994497ED45F8B1B7"
          xlink:to="TextSelection-7AF969DFE04882A7A6D4801F8350E892-0-wk-Footnote-7AF969DFE04882A7A6D4801F8350E892_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34506804e5578-wk-Fact-FA33375103F0D9AB7DC6801F81DED8EA"
          xlink:label="d34506804e5578-wk-Fact-FA33375103F0D9AB7DC6801F81DED8EA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34506804e5578-wk-Fact-FA33375103F0D9AB7DC6801F81DED8EA"
          xlink:to="TextSelection-6EE01BB95F5B0EFA0920801F8303FDC8-0-wk-Footnote-6EE01BB95F5B0EFA0920801F8303FDC8_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e3862-wk-Fact-FA5370553D0E753807A4801F800C2D97"
          xlink:label="d34458032e3862-wk-Fact-FA5370553D0E753807A4801F800C2D97"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3862-wk-Fact-FA5370553D0E753807A4801F800C2D97"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e3862-wk-Fact-FA5370553D0E753807A4801F800C2D97"
          xlink:to="TextSelection-CD5590C54E00CAC0A807801F82F8EF24-0-wk-Footnote-CD5590C54E00CAC0A807801F82F8EF24_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e2958-wk-Fact-FA6F8F4B8C07145CBB9E801F8194C1D3"
          xlink:label="d34586122e2958-wk-Fact-FA6F8F4B8C07145CBB9E801F8194C1D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e2958-wk-Fact-FA6F8F4B8C07145CBB9E801F8194C1D3"
          xlink:to="TextSelection-FC07D67233DC28EADC5C801F834FE74B-0-wk-Footnote-FC07D67233DC28EADC5C801F834FE74B_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7972-wk-Fact-FA8027A58E5CA9651A05801F82B7CF8D"
          xlink:label="d34586122e7972-wk-Fact-FA8027A58E5CA9651A05801F82B7CF8D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7972-wk-Fact-FA8027A58E5CA9651A05801F82B7CF8D"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7972-wk-Fact-FA8027A58E5CA9651A05801F82B7CF8D"
          xlink:to="TextSelection-E2B3F0DA55A186A98B13801F83505AE9-0-wk-Footnote-E2B3F0DA55A186A98B13801F83505AE9_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11077-wk-Fact-FAED8312CB6DE3371555801F822F66EF"
          xlink:label="d34661879e11077-wk-Fact-FAED8312CB6DE3371555801F822F66EF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11077-wk-Fact-FAED8312CB6DE3371555801F822F66EF"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34501946e3028-wk-Fact-FB08398EDEE850A395E7D7BAD4CE39AD"
          xlink:label="d34501946e3028-wk-Fact-FB08398EDEE850A395E7D7BAD4CE39AD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34501946e3028-wk-Fact-FB08398EDEE850A395E7D7BAD4CE39AD"
          xlink:to="TextSelection-F036D64E776E56A4DFEC801F831646B2-0-wk-Footnote-F036D64E776E56A4DFEC801F831646B2_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34468079e3856-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
          xlink:label="d34468079e3856-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34468079e1910-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
          xlink:label="d34468079e1910-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3856-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
          xlink:to="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1910-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
          xlink:to="TextSelection-13B5F01039B0051B8C7A801F83041E59-0-wk-Footnote-13B5F01039B0051B8C7A801F83041E59_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e3856-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
          xlink:to="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34468079e1910-wk-Fact-FB096382AB9A56C08DF1A5971885A3D3"
          xlink:to="TextSelection-3C0AD1684977A8C460BF801F8304853F-0-wk-Footnote-3C0AD1684977A8C460BF801F8304853F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e10723-wk-Fact-FB2A542C8BE81796CCFD801F824281CD"
          xlink:label="d34661879e10723-wk-Fact-FB2A542C8BE81796CCFD801F824281CD"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e10723-wk-Fact-FB2A542C8BE81796CCFD801F824281CD"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34524436e1765-wk-Fact-FB3538E362BC65E9A4AD801F8283AB6A"
          xlink:label="d34524436e1765-wk-Fact-FB3538E362BC65E9A4AD801F8283AB6A"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34524436e1765-wk-Fact-FB3538E362BC65E9A4AD801F8283AB6A"
          xlink:to="TextSelection-02E52614EBB7CDE55C93801F8347287F-0-wk-Footnote-02E52614EBB7CDE55C93801F8347287F_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e1837-wk-Fact-FB53920211195F4191C78C4B2EA1ECDE"
          xlink:label="d34471435e1837-wk-Fact-FB53920211195F4191C78C4B2EA1ECDE"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e1837-wk-Fact-FB53920211195F4191C78C4B2EA1ECDE"
          xlink:to="TextSelection-5963023ACE684CB3772A801F830ACC32-0-wk-Footnote-5963023ACE684CB3772A801F830ACC32_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2750-wk-Fact-FB5AEC684D9BF5EB4428801F8178F643"
          xlink:label="d34428379e2750-wk-Fact-FB5AEC684D9BF5EB4428801F8178F643"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2750-wk-Fact-FB5AEC684D9BF5EB4428801F8178F643"
          xlink:to="TextSelection-897507A0451D09412949801F82F71600-0-wk-Footnote-897507A0451D09412949801F82F71600_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2750-wk-Fact-FB5AEC684D9BF5EB4428801F8178F643"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e5748-wk-Fact-FBAE50428F678875E52F801F7F51C451"
          xlink:label="d34545404e5748-wk-Fact-FBAE50428F678875E52F801F7F51C451"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e5748-wk-Fact-FBAE50428F678875E52F801F7F51C451"
          xlink:to="TextSelection-01B53D5755B805F2EA3C801F83129BBA-0-wk-Footnote-01B53D5755B805F2EA3C801F83129BBA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e2518-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31"
          xlink:label="d34423000e2518-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34519344e2012-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31"
          xlink:label="d34519344e2012-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e2518-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34519344e2012-wk-Fact-FBCE4F7A44495F72B128CAC7EEDA4D31"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34430544e2103-wk-Fact-FC65E982593353C58EDD19521634B9BF"
          xlink:label="d34430544e2103-wk-Fact-FC65E982593353C58EDD19521634B9BF"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34545404e3114-wk-Fact-FC65E982593353C58EDD19521634B9BF"
          xlink:label="d34545404e3114-wk-Fact-FC65E982593353C58EDD19521634B9BF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34430544e2103-wk-Fact-FC65E982593353C58EDD19521634B9BF"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e3114-wk-Fact-FC65E982593353C58EDD19521634B9BF"
          xlink:to="TextSelection-870012ED3DA7909620EF801F82F771DA-0-wk-Footnote-870012ED3DA7909620EF801F82F771DA_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e14700-wk-Fact-FC73D9D20F903DB9A545801F7F1031E7"
          xlink:label="d34661879e14700-wk-Fact-FC73D9D20F903DB9A545801F7F1031E7"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e14700-wk-Fact-FC73D9D20F903DB9A545801F7F1031E7"
          xlink:to="TextSelection-4EE053CBD765CA91DD91801F8338910E-0-wk-Footnote-4EE053CBD765CA91DD91801F8338910E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34423000e1527-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6"
          xlink:label="d34423000e1527-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6"
          xlink:type="locator"/>
        <link:loc
          xlink:href="#d34496162e8797-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6"
          xlink:label="d34496162e8797-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34423000e1527-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e8797-wk-Fact-FC7766C192B65D888CAD3CA1DC9C30C6"
          xlink:to="TextSelection-494CFE7D07A641A6F9C5801F82F6FA14-0-wk-Footnote-494CFE7D07A641A6F9C5801F82F6FA14_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e7876-wk-Fact-FD3ADF5E45AC5ABC941EDCA88225428B"
          xlink:label="d34586122e7876-wk-Fact-FD3ADF5E45AC5ABC941EDCA88225428B"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e7876-wk-Fact-FD3ADF5E45AC5ABC941EDCA88225428B"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e7323-wk-Fact-FD92DBC7FD8183249D6D801F80213CFC"
          xlink:label="d34458032e7323-wk-Fact-FD92DBC7FD8183249D6D801F80213CFC"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e7323-wk-Fact-FD92DBC7FD8183249D6D801F80213CFC"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34496162e5495-wk-Fact-FE5FA64237140370947E0C1E584B0DA8"
          xlink:label="d34496162e5495-wk-Fact-FE5FA64237140370947E0C1E584B0DA8"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34496162e5495-wk-Fact-FE5FA64237140370947E0C1E584B0DA8"
          xlink:to="TextSelection-E0FF5C1CA4536A1C3DAD023DF7A9774E-0-wk-Footnote-E0FF5C1CA4536A1C3DAD023DF7A9774E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e23999-wk-Fact-FE6953A187622C643914801F80E89DAA"
          xlink:label="d34661879e23999-wk-Fact-FE6953A187622C643914801F80E89DAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e23999-wk-Fact-FE6953A187622C643914801F80E89DAA"
          xlink:to="TextSelection-8919DE19DDCE826AE30E801F833CF4E4-0-wk-Footnote-8919DE19DDCE826AE30E801F833CF4E4_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e22931-wk-Fact-FE7BED24ED2F7DF891B2801F80642BB5"
          xlink:label="d34661879e22931-wk-Fact-FE7BED24ED2F7DF891B2801F80642BB5"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e22931-wk-Fact-FE7BED24ED2F7DF891B2801F80642BB5"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19177-wk-Fact-FF00362B6AD5984309B1801F80812477"
          xlink:label="d34661879e19177-wk-Fact-FF00362B6AD5984309B1801F80812477"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19177-wk-Fact-FF00362B6AD5984309B1801F80812477"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e2481-wk-Fact-FF2092BE1BF7CB316625801F7E1E3368"
          xlink:label="d34458032e2481-wk-Fact-FF2092BE1BF7CB316625801F7E1E3368"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e2481-wk-Fact-FF2092BE1BF7CB316625801F7E1E3368"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34586122e8120-wk-Fact-FF2D62AF2B56AC1092D2DE1ACB8DAAEA"
          xlink:label="d34586122e8120-wk-Fact-FF2D62AF2B56AC1092D2DE1ACB8DAAEA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34586122e8120-wk-Fact-FF2D62AF2B56AC1092D2DE1ACB8DAAEA"
          xlink:to="TextSelection-9D41BEEA5A0076284C66801F8350345C-0-wk-Footnote-9D41BEEA5A0076284C66801F8350345C_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34529301e2174-wk-Fact-FF4615007CC653C7B1758F53F75C3121"
          xlink:label="d34529301e2174-wk-Fact-FF4615007CC653C7B1758F53F75C3121"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34529301e2174-wk-Fact-FF4615007CC653C7B1758F53F75C3121"
          xlink:to="TextSelection-588F9BD8F2106BF35766801F8335FADB-0-wk-Footnote-588F9BD8F2106BF35766801F8335FADB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34471435e4082-wk-Fact-FF50DEB8A335501E80F11891D08A50FF"
          xlink:label="d34471435e4082-wk-Fact-FF50DEB8A335501E80F11891D08A50FF"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34471435e4082-wk-Fact-FF50DEB8A335501E80F11891D08A50FF"
          xlink:to="TextSelection-3A2F3BA4BA7BD14CDFB8801F830DB9A7-0-wk-Footnote-3A2F3BA4BA7BD14CDFB8801F830DB9A7_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34545404e8119-wk-Fact-FF8055EC7C995980A43AA0986DC6DBB3"
          xlink:label="d34545404e8119-wk-Fact-FF8055EC7C995980A43AA0986DC6DBB3"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34545404e8119-wk-Fact-FF8055EC7C995980A43AA0986DC6DBB3"
          xlink:to="TextSelection-FC2FFDBE1F8668460B3A801F831375CB-0-wk-Footnote-FC2FFDBE1F8668460B3A801F831375CB_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34458032e8745-wk-Fact-FFA1CCE628C152E085CCD1B102488E00"
          xlink:label="d34458032e8745-wk-Fact-FFA1CCE628C152E085CCD1B102488E00"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34458032e8745-wk-Fact-FFA1CCE628C152E085CCD1B102488E00"
          xlink:to="TextSelection-011F88228CBADE14622D801F82F8E851-0-wk-Footnote-011F88228CBADE14622D801F82F8E851_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e19080-wk-Fact-FFA28E99A41E4CCC026F801F803FFF5D"
          xlink:label="d34661879e19080-wk-Fact-FFA28E99A41E4CCC026F801F803FFF5D"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e19080-wk-Fact-FFA28E99A41E4CCC026F801F803FFF5D"
          xlink:to="TextSelection-A8A744685EF9A7F8D940801F8338794E-0-wk-Footnote-A8A744685EF9A7F8D940801F8338794E_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34661879e11115-wk-Fact-FFA2D2947052B95B9E66801F822852A2"
          xlink:label="d34661879e11115-wk-Fact-FFA2D2947052B95B9E66801F822852A2"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34661879e11115-wk-Fact-FFA2D2947052B95B9E66801F822852A2"
          xlink:to="TextSelection-66DD5BE2DF5D16FCD3A1801F83381314-0-wk-Footnote-66DD5BE2DF5D16FCD3A1801F83381314_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34428379e2909-wk-Fact-FFE4B8C9C5A45A3BB02F23579673DDAA"
          xlink:label="d34428379e2909-wk-Fact-FFE4B8C9C5A45A3BB02F23579673DDAA"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34428379e2909-wk-Fact-FFE4B8C9C5A45A3BB02F23579673DDAA"
          xlink:to="TextSelection-93772A9C90BB81014352801F82F8AB38-0-wk-Footnote-93772A9C90BB81014352801F82F8AB38_lbl"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#d34460716e2346-wk-Fact-FFFCC0F0F24614B44437801F828D0336"
          xlink:label="d34460716e2346-wk-Fact-FFFCC0F0F24614B44437801F828D0336"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="d34460716e2346-wk-Fact-FFFCC0F0F24614B44437801F828D0336"
          xlink:to="TextSelection-D09113F7E2B9D811DF76801F8315D250-0-wk-Footnote-D09113F7E2B9D811DF76801F8315D250_lbl"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R107.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7035824272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Plant and Equipment (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">$ 30,756<span></span>
</td>
<td class="nump">$ 29,977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: Accumulated depreciation</a></td>
<td class="nump">16,789<span></span>
</td>
<td class="nump">16,591<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment</a></td>
<td class="nump">13,967<span></span>
</td>
<td class="nump">13,385<span></span>
</td>
<td class="nump">$ 13,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember', window );">Land [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">516<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">10,068<span></span>
</td>
<td class="nump">9,920<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember', window );">Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">12,281<span></span>
</td>
<td class="nump">11,871<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">4,930<span></span>
</td>
<td class="nump">4,693<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, plant and equipment before accumulated depreciation</a></td>
<td class="nump">$ 2,960<span></span>
</td>
<td class="nump">$ 2,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">33 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Furniture, fixtures and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">50 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Machinery and equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">20 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Furniture, fixtures and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Useful lives (years)</a></td>
<td class="text">12 years 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LandMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_MachineryAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040023424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows (Parenthetical)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit', window );">Tax benefits associated with the enactment of the TCJA</a></td>
<td class="nump">$ 323,000,000<span></span>
</td>
<td class="nump">$ 10,660,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsAndJobsActIncomeTaxBenefit', window );">Tax benefits associated with the enactment of the TCJA</a></td>
<td class="nump">325,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="nump">8,233,000,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount', window );">Deconsolidation gain</a></td>
<td class="nump">2,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="nump">138,000,000<span></span>
</td>
<td class="nump">999,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pfe_U.K.PoundDenominatedDebtMember', window );">U.K. Pound Denominated Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainLossOnExchangeOfDebt', window );">Loss on exchange of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">747,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Senior Unsecured U.K. Pound Debt, 2.735%, Due 2043 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.735%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="nump">$ 8,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure', window );">Equity method investments</a></td>
<td class="nump">$ 15,700,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationNetAssetsContributed', window );">Deconsolidation net assets contributed</a></td>
<td class="nump">7,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountCashConveyed', window );">Deconsolidation, cash conveyed</a></td>
<td class="nump">$ 146,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountCashConveyed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Cash Conveyed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountCashConveyed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfCashConveyed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationNetAssetsContributed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Net Assets Contributed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationNetAssetsContributed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Deconsolidation, Gain (Loss), Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectiveIncomeTaxRateReconciliationDeconsolidationGainLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainLossOnExchangeOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) On Exchange Of Debt</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainLossOnExchangeOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsAndJobsActIncomeTaxBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts And Jobs Act, Income Tax Benefit</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsAndJobsActIncomeTaxBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of investments accounted under the equity method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117311354&amp;loc=d3e32014-111567<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_U.K.PoundDenominatedDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_U.K.PoundDenominatedDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredU.K.PoundDebtTwoPointSevenThreeFivePercentDue2043Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952859888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Inventories</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Finished goods</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,262</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Work in process</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,743</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,701</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Raw materials and supplies</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>790</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>546</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Inventories</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,283</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,508</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent inventories not included above</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>714</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>618</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The change from </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;"> reflects increases for certain products, including inventory build for new product launches, supply recovery and market demand, partially offset by a decrease due to foreign exchange and the write off of rivipansel inventory previously expected to be sold (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2E</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:Arial;font-size:7pt;">. There are no recoverability issues associated with these amounts.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -URI http://asc.fasb.org/topic&amp;trid=2126998<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R139.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953226688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Restricted Stock Unit Activity (Detail) - Restricted Stock Units [Member]<br> shares in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>Employee </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="nump">27,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares</a></td>
<td class="nump">7,478<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares</a></td>
<td class="num">(10,644)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod', window );">Reinvested dividend equivalents, shares</a></td>
<td class="nump">911<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares</a></td>
<td class="num">(1,614)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="nump">23,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 33.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted-average grant-date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">43.17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">31.66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue', window );">Reinvested dividend equivalents, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">39.64<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">38.82<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 37.54<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of shares modified to accelerate vesting</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,400<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Number of employees affected by accelerated vesting | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends In Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Reinvested Dividends in Period, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsReinvestedDividendsinPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of grantees affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953001808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingencies and Certain Commitments</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Contingencies and Certain Commitments</span><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, including tax and legal contingencies. For a discussion of our tax contingencies, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5D.</span><span style="font-family:Arial;font-size:8pt;"> For a discussion of our legal contingencies, see below.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Legal Proceedings</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our legal contingencies include, but are not limited to, the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Patent litigation, which typically involves challenges to the coverage and/or validity of patents on various products, processes or dosage forms. We are the plaintiff in the majority of these actions. An adverse outcome in actions in which we are the plaintiff could result in loss of patent protection for a drug, a significant loss of revenues from that drug or impairment of the value of associated assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Product liability and other product-related litigation, which can include personal injury, consumer, off-label promotion, securities, antitrust and breach of contract claims, among others, often involves highly complex issues relating to medical causation, label warnings and reliance on those warnings, scientific evidence and findings, actual, provable injury and other matters.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Commercial and other matters, which can include merger-related and product-pricing claims and environmental claims and proceedings, can involve complexities that will vary from matter to matter.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Government investigations, which often are related to the extensive regulation of pharmaceutical companies by national, state and local government agencies in the U.S. and in other jurisdictions.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain of these contingencies could result in losses, including damages, fines and/or civil penalties, which could be substantial, and/or criminal charges.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We believe that our claims and defenses in matters in which we are a defendant are substantial, but litigation is inherently unpredictable and excessive verdicts do occur. We do not believe that any of these matters will have a material adverse effect on our financial position. However, we could incur judgments, enter into settlements or revise our expectations regarding the outcome of certain matters, and such developments could have a material adverse effect on our results of operations in the period in which the amounts are accrued and/or our cash flows in the period in which the amounts are paid.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have accrued for losses that are both probable and reasonably estimable. Substantially all of our contingencies are subject to significant uncertainties and, therefore, determining the likelihood of a loss and/or the measurement of any loss can be complex. Consequently, we are unable to estimate the range of reasonably possible loss in excess of amounts accrued. Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but the assessment process relies heavily on estimates and assumptions that may prove to be incomplete or inaccurate, and unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for legal and environmental contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The principal pending matters to which we are a party are discussed below. In determining whether a pending matter is a principal matter, we consider both quantitative and qualitative factors in order to assess materiality, such as, among other things, the amount of damages and the nature of any other relief sought in the proceeding, if such damages and other relief are specified; our view of the merits of the claims and of the strength of our defenses; whether the action purports to be, or is, a class action and, if not certified, our view of the likelihood that a class will be certified by the court; the jurisdiction in which the proceeding is pending; whether related actions have been transferred to multidistrict litigation; any experience that we or, to our knowledge, other companies have had in similar proceedings; whether disclosure of the action would be important to a reader of our financial statements, including whether disclosure might change a reader&#8217;s judgment about our financial statements in light of all of the information that is available to the reader; the potential impact of the proceeding on our reputation; and the extent of public interest in the matter. In addition, with respect to patent matters in which we are the plaintiff, we consider, among other things, the financial significance of the product protected by the patent(s) at issue. As a result of considering qualitative factors in our determination of principal matters, there are some matters discussed below with respect to which management believes that the likelihood of possible loss in excess of amounts accrued is remote.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A1</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Legal Proceedings&#8211;&#8211;Patent Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Like other pharmaceutical companies, we are involved in numerous suits relating to our patents, including but not limited to, those discussed below. Most of the suits involve claims by generic drug manufacturers that patents covering our products, processes or dosage forms are invalid and/or do not cover the product of the generic drug manufacturer. Also, counterclaims, as well as various independent actions, have been filed alleging that our assertions of, or attempts to enforce, patent rights with respect to certain products constitute unfair competition and/or violations of antitrust laws. In addition to the challenges to the U.S. patents on a number of our products that are discussed below, patent rights to certain of our products are being challenged in various other jurisdictions. We are also party to patent damages suits in various jurisdictions pursuant to which generic drug manufacturers, payers, governments or other parties are seeking damages from us for allegedly causing delay of generic entry. Additionally, our licensing and collaboration partners face challenges by generic drug manufacturers to patents covering products for which we have licenses or co-promotion rights. </span><span style="font-family:Arial;font-size:8pt;">We also are often involved in other proceedings, such as inter partes review, post-grant review, re-examination or opposition proceedings, before the U.S. Patent and Trademark Office, the European Patent Office, or other foreign counterparts relating to our intellectual property or the intellectual property rights of others.</span><span style="font-family:Arial;font-size:8pt;"> Also, if one of our patents is found to be invalid by such proceedings, generic or competitive products could be introduced into the market resulting in the erosion of sales of our existing products. For example, several of the patents in our pneumococcal vaccine portfolio were challenged in inter partes review and post-grant review proceedings in the U.S. In October 2017, the Patent Trial and Appeal Board (PTAB) refused to initiate proceedings as to </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> patents. In June 2018, the PTAB ruled on another patent, holding that </span><span style="font-family:Arial;font-size:8pt;"><span>one</span></span><span style="font-family:Arial;font-size:8pt;"> claim was valid and that all other claims were invalid. The party challenging that patent has appealed the decision. In November 2019, the U.S. Court of Appeals for the Federal Circuit vacated the PTAB&#8217;s ruling and requested that the PTAB redecide the challenge.</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:8pt;">In March and June 2019, an additional patent was found invalid in separate proceedings by the PTAB. We have appealed. Challenges to other patents remain pending in jurisdictions outside the U.S.</span><span style="font-family:Arial;font-size:8pt;color:#1f497d;"> </span><span style="font-family:Arial;font-size:8pt;">The invalidation of all of the patents in our pneumococcal portfolio could potentially allow a competitor pneumococcal vaccine into the marketplace. In the event that any of the patents are found valid and infringed, a competitor pneumococcal vaccine might be prohibited from entering the market or required to pay Pfizer a royalty. We are also subject to patent litigation pursuant to which one or more third parties seeks damages and/or </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">injunctive relief to compensate for alleged infringement of its patents by our commercial or other activities. For example, our Hospira subsidiaries are involved in patent and patent-related disputes over their attempts to bring generic pharmaceutical and biosimilar products to market. </span><span style="font-family:Arial;font-size:8pt;">If one of our marketed products is found to infringe valid patent rights of a third party, such third party may be awarded significant damages, or we may be prevented from further sales of that product. Such damages may be enhanced as much as three-fold in the event that we or one of our subsidiaries, like Hospira, is found to have willfully infringed valid patent rights of a third party.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Actions In Which We Are The Plaintiff</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In July 2010, King, which we acquired in 2011 and is a wholly-owned subsidiary, brought a patent-infringement action against Sandoz in the U.S. District Court for the District of New Jersey in connection with Sandoz&#8217;s abbreviated new drug application filed with the FDA seeking approval to market an epinephrine injectable product. Sandoz is challenging patents, which expire in 2025, covering the next-generation autoinjector for use with epinephrine that is sold under the EpiPen brand name.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Precedex Premix</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in 2014, several generic manufacturers filed separate abbreviated new drug applications with the FDA, seeking approval to market their generic versions of our subsidiary Hospira&#8217;s premix version of Precedex prior to the expiration of </span><span style="font-family:Arial;font-size:8pt;"><span>one</span></span><span style="font-family:Arial;font-size:8pt;"> or more patents covering the product. </span><span style="font-family:Arial;font-size:8pt;"><span>One</span></span><span style="font-family:Arial;font-size:8pt;"> of those patents expired in March 2019, while others do not expire until 2032. Beginning in 2014, Hospira brought suit against these generic manufacturers, in some cases joined by Orion Corporation (co-owner of certain of our Precedex premix patents). To date, </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> of the actions have been settled or dismissed on terms not material to Pfizer: (i) the action filed against Ben Venue Laboratories, Inc., which was sued along with Hikma Pharmaceuticals PLC (together, succeeded by Eurohealth International Sarl) and West-Ward Pharmaceuticals Corp (collectively, the Ben Venue case); and (ii) the action filed against Baxter Healthcare Corporation. The remaining actions continue as described below. </span></div><div style="line-height:120%;text-align:justify;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2015, Hospira filed suit against Amneal Pharmaceuticals LLC (Amneal) in the U.S. District Court for the District of Delaware asserting the validity and infringement of </span><span style="font-family:Arial;font-size:8pt;"><span>four</span></span><span style="font-family:Arial;font-size:8pt;"> patents relating to the Precedex premix formulations and their use, all of which expire in 2032. In January 2018, the District Court ruled that </span><span style="font-family:Arial;font-size:8pt;"><span>one</span></span><span style="font-family:Arial;font-size:8pt;"> of the </span><span style="font-family:Arial;font-size:8pt;"><span>four</span></span><span style="font-family:Arial;font-size:8pt;"> patents was valid and infringed, and that the other </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> patents were invalid. In February and March 2018, respectively, each of Amneal and Hospira appealed the District Court decision to the U.S. Court of Appeals for the Federal Circuit. In January 2019, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2015, Fresenius Kabi USA LLC (Fresenius) notified Hospira that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Hospira&#8217;s premix version of Precedex and containing allegations that certain patents relating to the Precedex premix formulations and their use, all of which expire in 2032, were invalid or not infringed. In January 2016, Hospira filed suit against Fresenius in the U.S. District Court for the Northern District of Illinois, asserting the validity and infringement of those patents. In December 2018, the District Court ruled that the asserted claims of </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> patents were invalid. Hospira appealed the District Court&#8217;s decision as to </span><span style="font-family:Arial;font-size:8pt;"><span>one</span></span><span style="font-family:Arial;font-size:8pt;"> of the patents to the U.S. Court of Appeals for the Federal Circuit. In January 2020, the U.S. Court of Appeals for the Federal Circuit affirmed the District Court&#8217;s decision. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Separate actions in which Hospira sued Par Sterile Products LLC, Gland Pharma Limited, and Jiangsu Hengrui Medicine Co., Ltd., each in response to such generic manufacturer&#8217;s filing of a separate abbreviated new drug application with the FDA, seeking approval to market their generic versions of our subsidiary Hospira&#8217;s premix version of Precedex prior to the expiration of </span><span style="font-family:Arial;font-size:8pt;">one</span><span style="font-family:Arial;font-size:8pt;"> or more patents covering the product, were stayed pending the outcome of the case against Fresenius described above. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Xeljanz (tofacitinib)</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in 2017, we brought patent-infringement actions against several generic manufacturers that filed separate abbreviated new drug applications with the FDA, seeking approval to market their generic versions of tofacitinib tablets in </span><span style="font-family:Arial;font-size:8pt;">one</span><span style="font-family:Arial;font-size:8pt;"> or both of 5 mg and 10 mg dosage strengths, and in both immediate and extended release forms. To date, actions against the following generic manufacturers have been settled on terms not material to Pfizer: (i) MicroLabs USA Inc. and MicroLabs Ltd.; (ii) Sun Pharmaceutical Industries Ltd.; (iii) Prinston Pharmaceutical Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Huahai US Inc. and Solco Healthcare US, LLC; and (iv) Breckenridge Pharmaceutical Inc., Pensa Pharma S.A. and Laboratorios Del Dr. Esteve, S.A. The remaining actions continue as described below.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2017, we brought a patent-infringement action against Zydus Pharmaceuticals (USA) Inc. and Cadila Healthcare Ltd. (collectively, Zydus) in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> patents: the patent covering the active ingredient expiring in December 2025, the patent covering an enantiomer of tofacitinib expiring in 2022, and the patent covering a polymorphic form of tofacitinib expiring in 2023, which Zydus challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2018, we brought a separate patent infringement action against Teva Pharmaceuticals USA, Inc. (Teva) in the U.S. District Court for the District of Delaware asserting the infringement and validity of our patent covering extended release formulations of tofacitinib that was challenged by Teva in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 11 mg extended release tablets.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2019, we brought a separate patent infringement action against Ajanta Pharma Ltd. and Ajanta Pharma USA Inc. (collectively, Ajanta) in the U.S. District Court for the District of Delaware asserting the infringement and validity of </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> patents: the patent covering the active ingredient that expires in December 2025 and the patent covering a polymorphic form of tofacitinib that expires in 2023, each of which Ajanta challenged in its abbreviated new drug application seeking approval to market a generic version of tofacitinib 5 mg tablets. In August 2019, in response to a similar challenge by Ajanta relating the tofacitinib 10 mg tablets, we brought another patent infringement action against Ajanta in the U.S. District Court for the District of Delaware.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Inlyta (axitinib)</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, Apotex Inc. notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Apotex Inc. asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In May </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018, we filed suit against Apotex Inc. in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In May 2019, Glenmark Pharmaceuticals Limited (Glenmark) notified us that it had filed an abbreviated new drug application with the FDA seeking approval to market a generic version of Inlyta. Glenmark asserts the invalidity and non-infringement of the crystalline form patent for Inlyta that expires in 2030. In June 2019, we filed suit against Glenmark in the U.S. District Court for the District of Delaware, asserting the validity and infringement of the crystalline form patent for Inlyta.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Kerydin (tavaborole)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2018, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Kerydin. The generic companies</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span><span style="font-family:Arial;font-size:8pt;">assert the invalidity and non-infringement of methods of use and formulation patents for tavaborole that expire in 2026 and 2027, including pediatric exclusivity. In October 2018, Anacor, our wholly-owned subsidiary</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">,</span><span style="font-family:Arial;font-size:8pt;"> filed infringement lawsuits against each of the generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Ibrance (palbociclib)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2019, several generic companies notified us that they had filed abbreviated new drug applications with the FDA seeking approval to market generic versions of Ibrance. The generic companies assert the invalidity and non-infringement of </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> composition of matter patents and a method of use patent covering palbociclib, each of which expire in 2023. In April 2019, we brought patent infringement actions against each of the generic filers in various federal courts, asserting the validity and infringement of the patents challenged by the generic companies.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Chantix (varenicline) </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In January 2020, we brought a patent infringement action against Viwit Pharmaceutical Co. Ltd. (Viwit) in the U.S. District Court for the District of Delaware, asserting the validity and infringement of </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> patents challenged by Viwit in its abbreviated new drug application seeking approval to market a generic version of varenicline, 0.5 mg &#160;and 1.0 mg tablets.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Matter Involving Our Collaboration/Licensing Partners</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Eliquis</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February, March, and April 2017, </span><span style="font-family:Arial;font-size:8pt;"><span>twenty-five</span></span><span style="font-family:Arial;font-size:8pt;"> generic companies sent BMS Paragraph-IV certification letters informing BMS that they had filed abbreviated new drug applications seeking approval of generic versions of Eliquis, challenging the validity and infringement of one or more of the </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> patents listed in the Orange Book for Eliquis. </span><span style="font-family:Arial;font-size:8pt;"><span>One</span></span><span style="font-family:Arial;font-size:8pt;"> of the patents expired in December 2019 and the remaining patents currently are set to expire in 2026 and 2031. Eliquis has been jointly developed and is being commercialized by BMS and Pfizer. In April 2017, BMS and Pfizer filed patent-infringement actions against all generic filers in the U.S. District Court for the District of Delaware and the U.S. District Court for the District of West Virginia, asserting that each of the generic companies&#8217; proposed products would infringe each of the patent(s) that each generic filer challenged. Some generic filers challenged only the 2031 patent, some challenged both the 2031 and 2026 patent, and one generic company challenged all </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> patents. We and BMS have settled with certain of the generic companies on terms not material to Pfizer, and we and BMS may settle with other generic companies in the future. </span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;">Action In Which We Are The Defendant</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Inflectra (infliximab-dyyb)</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2015, Janssen and New York University, together, brought a patent-infringement action in the U.S. District Court for the District of Massachusetts against Hospira, Celltrion Healthcare Co. Ltd. and Celltrion Inc. alleging that infliximab-dyyb, to be marketed by Hospira in the U.S. under the brand name Inflectra, would infringe </span><span style="font-family:Arial;font-size:8pt;"><span>six</span></span><span style="font-family:Arial;font-size:8pt;"> patents relating to infliximab, its manufacture and use. Claims with respect to </span><span style="font-family:Arial;font-size:8pt;"><span>four</span></span><span style="font-family:Arial;font-size:8pt;"> of the patents were dismissed by the plaintiffs, leaving </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> patents at issue: the infliximab antibody patent and a patent relating to cell culture media. In January 2018, the antibody patent was declared invalid by the Court of Appeals for the Federal Circuit. In July 2018, the U.S. District Court for the District of Massachusetts granted defendants&#8217; motion for summary judgment and ruled that the patent relating to cell culture media was not infringed. Janssen appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Federal Circuit. </span></div><div style="line-height:120%;padding-top:9px;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A2. Legal Proceedings&#8211;&#8211;Product Litigation</span></div><div style="line-height:120%;text-align:justify;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Like other pharmaceutical companies, we are defendants in numerous cases, including but not limited to those discussed below, related to our pharmaceutical and other products. Plaintiffs in these cases seek damages and other relief on various grounds for alleged personal injury and economic loss.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Asbestos</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Between 1967 and 1982, Warner-Lambert owned American Optical Corporation (American Optical), which manufactured and sold respiratory protective devices and asbestos safety clothing. In connection with the sale of American Optical in 1982, Warner-Lambert agreed to indemnify the purchaser for certain liabilities, including certain asbestos-related and other claims. Claims against American Optical and numerous other defendants are pending in various federal and state courts seeking damages for alleged personal injury from exposure to asbestos and other allegedly hazardous materials. Warner-Lambert was acquired by Pfizer in 2000 and is a wholly owned subsidiary of Pfizer. Warner-Lambert is actively engaged in the defense of, and will continue to explore various means of resolving, these claims.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Numerous lawsuits are pending against Pfizer in various federal and state courts seeking damages for alleged personal injury from exposure to products allegedly containing asbestos and other allegedly hazardous materials sold by Pfizer and certain of its previously owned subsidiaries.</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">There also&#160;are a small number of lawsuits pending in various federal and state courts seeking damages for alleged exposure to asbestos in facilities owned or formerly owned by Pfizer or its subsidiaries.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Effexor</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in May 2011, actions, including purported class actions, were filed in various federal courts against Wyeth and, in certain of the actions, affiliates of Wyeth and certain other defendants relating to Effexor XR, which is the extended-release formulation of Effexor. The plaintiffs in each of the class actions seek to represent a class consisting of all persons in the U.S. and its territories who directly purchased, indirectly purchased or reimbursed patients for the purchase of Effexor XR or generic Effexor XR from any of the defendants from June 14, 2008 until the time the defendants&#8217; allegedly unlawful conduct ceased. The plaintiffs in all of the actions allege delay in the launch of generic Effexor XR in the U.S. and its territories, in violation of federal antitrust laws and, in certain of the actions, the antitrust, consumer protection and various other laws of certain states, as the result of Wyeth fraudulently obtaining and improperly listing certain patents for Effexor XR in the Orange Book, enforcing certain patents for Effexor XR and entering into a litigation settlement agreement with a generic drug manufacturer with respect to Effexor XR. Each of the plaintiffs seeks treble damages (for itself in the individual actions or on behalf of the putative class in the purported class actions) for alleged price overcharges for Effexor XR or generic Effexor XR in the U.S. and its territories since June 14, 2008. All of these actions have been consolidated in the U.S. District Court for the District of New Jersey. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2014, the District Court dismissed the direct purchaser plaintiffs&#8217; claims based on the litigation settlement agreement, but declined to dismiss the other direct purchaser plaintiff claims. In January 2015, the District Court entered partial final judgments as to all settlement agreement claims, including those asserted by direct purchasers and end-payer plaintiffs, which plaintiffs appealed to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Lipitor</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Antitrust Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in November 2011, purported class actions relating to Lipitor were filed in various federal courts against, among others, Pfizer, certain affiliates of Pfizer, and, in most of the actions, Ranbaxy, Inc. (Ranbaxy) and certain affiliates of Ranbaxy. The plaintiffs in these various actions seek to represent nationwide, multi-state or statewide classes consisting of persons or entities who directly purchased, indirectly purchased or reimbursed patients for the purchase of Lipitor (or, in certain of the actions, generic Lipitor) from any of the defendants from March 2010 until the cessation of the defendants&#8217; allegedly unlawful conduct (the Class Period). The plaintiffs allege delay in the launch of generic Lipitor, in violation of federal antitrust laws and/or state antitrust, consumer protection and various other laws, resulting from (i) the 2008 agreement pursuant to which Pfizer and Ranbaxy settled certain patent litigation involving Lipitor, and Pfizer granted Ranbaxy a license to sell a generic version of Lipitor in various markets beginning on varying dates, and (ii) in certain of the actions, the procurement and/or enforcement of certain patents for Lipitor. Each of the actions seeks, among other things, treble damages on behalf of the putative class for alleged price overcharges for Lipitor (or, in certain of the actions, generic Lipitor) during the Class Period. In addition, individual actions have been filed against Pfizer, Ranbaxy and certain of their affiliates, among others, that assert claims and seek relief for the plaintiffs that are substantially similar to the claims asserted and the relief sought in the purported class actions described above. These various actions have been consolidated for pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re Lipitor Antitrust Litigation MDL-2332</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District</span><span style="font-family:Arial;font-size:8pt;color:#0000ff;"> </span><span style="font-family:Arial;font-size:8pt;">Court for the District of New Jersey. </span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2013 and 2014, the District Court dismissed with prejudice the claims by direct purchasers. In October and November 2014, the District Court dismissed with prejudice the claims of all other Multi-District Litigation plaintiffs. All plaintiffs have appealed the District Court&#8217;s orders dismissing their claims with prejudice to the U.S. Court of Appeals for the Third Circuit. In addition, the direct purchaser class plaintiffs appealed the order denying their motion to amend the judgment and for leave to amend their complaint to the U.S. Court of Appeals for the Third Circuit. In August 2017, the U.S. Court of Appeals for the Third Circuit reversed the District Court&#8217;s decisions and remanded the claims to the District Court.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Also, in January 2013, the State of West Virginia filed an action in West Virginia state court against Pfizer and Ranbaxy, among others, that asserts claims and seeks relief on behalf of the State of West Virginia and residents of that state that are substantially similar to the claims asserted and the relief sought in the purported class actions described above.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A number of individual and multi-plaintiff lawsuits have been filed against us in various federal and state courts alleging that the plaintiffs developed type 2 diabetes purportedly as a result of the ingestion of Lipitor. Plaintiffs seek compensatory and punitive damages. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February 2014, the federal actions were transferred for consolidated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re Lipitor (Atorvastatin Calcium) Marketing, Sales Practices and Products Liability Litigation (No. II) MDL-2502</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the District of South Carolina. Since 2016, certain cases in the Multi-District Litigation were remanded to certain state courts. In January 2017, the District Court granted our motion for summary judgment, dismissing substantially all of the remaining cases pending in the Multi-District Litigation. In January 2017, the plaintiffs appealed the District Court&#8217;s decision to the U.S. Court of Appeals for the Fourth Circuit. In June 2018, the U.S. Court of Appeals for the Fourth Circuit affirmed the District Court&#8217;s decision.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Viagra</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Since April 2016, a Multi-District Litigation has been pending in the U.S. District Court for the Northern District of California (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In Re: Viagra (Sildenafil Citrate) Products Liability Litigation, MDL-2691</span><span style="font-family:Arial;font-size:8pt;">), in which plaintiffs allege that they developed melanoma and/or the exacerbation of melanoma purportedly as a result of the ingestion of Viagra. Additional cases filed against Lilly with respect to Cialis have also been consolidated in the Multi-District Litigation </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">(In re: Viagra (Sildenafil Citrate) and Cialis (Tadalafil) Products Liability Litigation, MDL-2691</span><span style="font-family:Arial;font-size:8pt;">). In January 2020, the District Court granted our and Lilly&#8217;s motion to exclude all of plaintiffs&#8217; general causation opinions. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Intravenous Solutions</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in November 2016, purported class actions were filed in the U.S. District Court for the Northern District of Illinois against Hospira, Hospira Worldwide, Inc. and certain other defendants relating to intravenous saline solution. Plaintiffs seek to represent a class consisting of all persons and entities in the U.S. who directly purchased intravenous saline solution sold by any of the defendants from January 1, 2013 until the time the defendants&#8217; allegedly unlawful conduct ceases. Plaintiffs allege that the defendants&#8217; conduct restricts output and artificially fixes, raises, maintains and/or stabilizes the prices of intravenous saline solution sold throughout the U.S. in violation of federal antitrust laws. </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plaintiffs seek treble damages (for themselves and on behalf of the putative classes) and an injunction against defendants for alleged price overcharges for intravenous saline solution in the U.S. since January 1, 2013. All of these actions have been consolidated in the U.S. District Court for the Northern District of Illinois. In July 2018, the District Court granted defendants&#8217; motions to dismiss the consolidated amended complaint without prejudice. Plaintiffs filed a second amended complaint in September 2018. On February 3, 2017, we completed the sale of our global infusion systems net assets, HIS, which includes intravenous saline solution, to ICU Medical. The litigation is the subject of cross-claims for indemnification by both Pfizer and ICU Medical under the purchase agreement.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Hormone Therapy Consumer Class Action</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A certified consumer class action is pending against Wyeth in the U.S. District Court for the Southern District of California based on the alleged off-label marketing of its hormone therapy products. The case was originally filed in December 2003. The class consists of California consumers who purchased Wyeth&#8217;s hormone-replacement products between January 1995 and January 2003 and who do not seek personal injury damages therefrom. The class seeks compensatory and punitive damages, including a full refund of the purchase price.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">EpiPen</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Beginning in February 2017, purported class actions were filed in various federal courts by indirect purchasers of EpiPen against Pfizer, and/or its affiliates King and Meridian, and/or various entities affiliated with Mylan, and Mylan Chief Executive Officer, Heather Bresch. The plaintiffs in these actions seek to represent U.S. nationwide classes comprising persons or entities who paid for any portion of the end-user purchase price of an EpiPen between 2009 until the cessation of the defendants&#8217; allegedly unlawful conduct. In August 2017, a similar lawsuit brought in the U.S. District Court for the District of New Jersey on behalf of a purported class of direct purchaser plaintiffs against Pfizer, King, Meridian and Mylan was voluntarily dismissed without prejudice. In February 2020, a similar lawsuit was filed in the U.S. District Court for the District of Kansas against Pfizer, King, Meridian and the Mylan entities on behalf of a purported U.S. nationwide class of direct purchaser plaintiffs who purchased EpiPen devices directly from the defendants (the 2020 lawsuit). Against Pfizer and/or its affiliates, plaintiffs in these actions generally allege that Pfizer&#8217;s and/or its affiliates&#8217; settlement of patent litigation regarding EpiPen delayed market entry of generic EpiPen in violation of federal antitrust laws and various state antitrust laws. At least </span><span style="font-family:Arial;font-size:8pt;"><span>one</span></span><span style="font-family:Arial;font-size:8pt;"> lawsuit also alleges that Pfizer and/or Mylan violated the federal Racketeer Influenced and Corrupt Organizations Act. Plaintiffs also filed various federal antitrust, state consumer protection and unjust enrichment claims against, and relating to conduct attributable solely to, Mylan and/or its affiliates regarding EpiPen. Plaintiffs seek treble damages for alleged overcharges for EpiPen since 2009. In August 2017, all of these actions, except for the 2020 lawsuit, were consolidated for coordinated pre-trial proceedings in a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re: EpiPen (Epinephrine Injection, USP) Marketing, Sales Practices and Antitrust Litigation, MDL-2785</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the District of Kansas with other EpiPen-related actions against Mylan and/or its affiliates to which Pfizer, King and Meridian are not parties.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nexium 24HR and Protonix</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A number of individual and multi-plaintiff lawsuits have been filed against Pfizer, certain of its subsidiaries and/or other pharmaceutical manufacturers in various federal and state courts alleging that the plaintiffs developed kidney-related injuries purportedly as a result of the ingestion of certain proton pump inhibitors. The cases against Pfizer involve Protonix and/or Nexium 24HR and seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement. In August 2017, the federal actions were ordered transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re: Proton-Pump Inhibitor Products Liability Litigation</span><span style="font-family:Arial;font-size:8pt;"> (No. II)) in the U.S. District Court for the District of New Jersey. On July&#160;31, 2019, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. As part of the joint venture transaction, the joint venture has agreed to assume, and to indemnify Pfizer for, liabilities arising out of such litigation to the extent related to Nexium 24HR.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Docetaxel&#160;</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Personal Injury Actions</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A number of lawsuits have been filed against Hospira and Pfizer in various federal and state courts alleging that plaintiffs who were treated with Docetaxel developed permanent hair loss. The significant majority of the cases also name other defendants, including the manufacturer of the branded product, Taxotere. Plaintiffs seek compensatory and punitive damages.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2016, the federal cases were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re Taxotere (Docetaxel) Products Liability Litigation, MDL-2740</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the Eastern District of Louisiana.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Mississippi Attorney General Government Investigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2018, the Attorney General of Mississippi filed a complaint in Mississippi state court against the manufacturer of the branded product and </span><span style="font-family:Arial;font-size:8pt;"><span>eight</span></span><span style="font-family:Arial;font-size:8pt;"> other manufacturers including Pfizer and Hospira, alleging, with respect to Pfizer and Hospira, a failure to warn about a risk of permanent hair loss in violation of the Mississippi Consumer Protection Act. The action seeks civil penalties and injunctive relief.&#160;</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Array Securities Litigation</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In November 2017, </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> purported class actions were filed in the U.S. District Court for the District of Colorado alleging that Array, which we acquired in July 2019 and is our wholly owned subsidiary, and certain of its former officers violated federal securities laws in connection with certain disclosures made, or omitted, by Array regarding the NRAS-mutant melanoma program. In March 2018, the actions were consolidated into a single proceeding. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Zantac </span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A number of lawsuits have been filed against Pfizer in various federal courts alleging that plaintiffs developed various types of cancer, or face an increased risk of developing cancer, purportedly as a result of the ingestion of Zantac. The significant majority of these cases also name other defendants that have historically manufactured and sold Zantac. Pfizer has not sold Zantac since 2006. Plaintiffs seek compensatory and punitive damages and, in some cases, treble damages, restitution or disgorgement.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February 2020, these federal actions were transferred for coordinated pre-trial proceedings to a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re Zantac/Ranitidine NDMA Litigation, MDL-2924</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the Southern District of Florida. </span></div><div style="line-height:120%;padding-top:9px;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A3</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Legal Proceedings&#8211;&#8211;Commercial and Other Matters</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Monsanto-Related Matters</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 1997, Monsanto Company (Former Monsanto) contributed certain chemical manufacturing operations and facilities to a newly formed corporation, Solutia Inc. (Solutia), and spun off the shares of Solutia. In 2000, Former Monsanto merged with Pharmacia &amp; Upjohn Company to form Pharmacia. Pharmacia then transferred its agricultural operations to a newly created subsidiary, named Monsanto Company (New Monsanto), which it spun off in a two-stage process that was completed in 2002. Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with its spin-off that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities related to Pharmacia&#8217;s former agricultural business. New Monsanto has defended and/or is defending Pharmacia in connection with various claims and litigation arising out of, or related to, the agricultural business, and has been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with its spin-off in 1997, Solutia assumed, and agreed to indemnify Pharmacia for, liabilities related to Former Monsanto&#8217;s chemical businesses. As the result of its reorganization under Chapter 11 of the U.S. Bankruptcy Code, Solutia&#8217;s indemnification obligations relating to Former Monsanto&#8217;s chemical businesses are primarily limited to sites that Solutia has owned or operated. In addition, in connection with its spinoff that was completed in 2002, New Monsanto assumed, and agreed to indemnify Pharmacia for, any liabilities primarily related to Former Monsanto&#8217;s chemical businesses, including, but not limited to, any such liabilities that Solutia assumed. Solutia&#8217;s and New Monsanto&#8217;s assumption of, and agreement to indemnify Pharmacia for, these liabilities apply to pending actions and any future actions related to Former Monsanto&#8217;s chemical businesses in which Pharmacia is named as a defendant, including, without limitation, actions asserting environmental claims, including alleged exposure to polychlorinated biphenyls. Solutia and/or New Monsanto are defending Pharmacia in connection with various claims and litigation arising out of, or related to, Former Monsanto&#8217;s chemical businesses, and have been indemnifying Pharmacia when liability has been imposed or settlement has been reached regarding such claims and litigation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Environmental Matters</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2009, we submitted to the U.S. Environmental Protection Agency (EPA) a corrective measures study report with regard to Pharmacia&#8217;s discontinued industrial chemical facility in North Haven, Connecticut. In September 2010, our corrective measures study report was approved by the EPA, and we commenced construction of the site remedy in late 2011 under an Updated Administrative Order on Consent with the EPA. In September 2019, the EPA acknowledged that construction of the site remedy has been completed.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Also, in 2009, we submitted a revised site-wide feasibility study with regard to Wyeth Holdings Corporation&#8217;s (formerly, American Cyanamid Company) discontinued industrial chemical facility in Bound Brook, New Jersey. In July 2011, Wyeth Holdings Corporation finalized an Administrative Settlement Agreement and Order on Consent for Removal Action (the 2011 Administrative Settlement Agreement) with the EPA with regard to the Bound Brook facility. In May 2012, we completed construction of an interim remedy to address the discharge of impacted groundwater from that facility to the Raritan River. In September 2012, the EPA issued a final remediation plan for the Bound Brook facility&#8217;s main plant area, which is generally in accordance with one of the remedies evaluated in our revised site-wide feasibility study. In March 2013, Wyeth Holdings Corporation (now Wyeth Holdings LLC) entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the main plant area and to perform a focused feasibility study for </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> adjacent lagoons. In September 2015, the U.S., on behalf of the EPA, filed a complaint and consent decree with the federal District Court for the District of New Jersey that allows Wyeth Holdings LLC to complete the design and to implement the remedy for the main plant area. In December 2015, the consent decree (which supersedes the 2011 Administrative Settlement Agreement) was entered by the District Court. In September 2018, the EPA issued a final remediation plan for the </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> adjacent lagoons, which is generally in accordance with one of the remedies evaluated in our focused feasibility study, and in September 2019, Wyeth Holdings LLC entered into an Administrative Settlement Agreement and Order on Consent with the EPA to allow us to undertake detailed engineering design of the remedy for the lagoons. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have accrued for the estimated costs of the site remedies for the North Haven and Bound Brook facilities.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are a party to a number of other proceedings brought under the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended, and other state, local or foreign laws in which the primary relief sought is the cost of past and/or future remediation.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2017, a number of United States service members, civilians, and their families brought a complaint in the U.S. District Court for the District of Columbia against a number of pharmaceutical and medical devices companies, including Pfizer and certain of its subsidiaries, alleging that the defendants violated the United States Anti-Terrorism Act. The complaint alleges that the defendants provided funding for terrorist organizations through their sales practices pursuant to pharmaceutical and medical device contracts with the Iraqi Ministry of Health, and seeks monetary relief. In July 2018, the U.S. Department of Justice requested documents related to this matter, which are being provided.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Allergan Complaint for Indemnity</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2018, Pfizer was named as a defendant in a third-party complaint for indemnity, along with King, filed by Allergan Finance LLC (Allergan) in a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re National Prescription Opiate Litigation MDL 2804</span><span style="font-family:Arial;font-size:8pt;">) in the U.S. District Court for the Northern District of Ohio. The lawsuit asserted claims for indemnity related to Kadian, which was owned for a short period by King in 2008, prior to Pfizer's acquisition of King in 2010. In December 2018, the District Court dismissed the lawsuit. In February 2019, Allergan filed a similar complaint in the Supreme Court of the State of New York, asserting claims for indemnity related to Kadian.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:justify;font-size:9pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Breach of Contract</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Xalkori</span></div><div style="line-height:120%;padding-bottom:12px;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer is a defendant in a breach of contract action brought by New York University (NYU) in the Supreme Court of the State of New York (Supreme Court). NYU alleges that it is entitled to royalties on Pfizer&#8217;s sales of</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"> </span><span style="font-family:Arial;font-size:8pt;">Xalkori under the terms of a Research and License Agreement between NYU and Sugen, Inc. Sugen, Inc. was acquired by Pharmacia in August 1999, and </span><span style="font-family:Arial;font-size:8pt;color:#212529;">Pharmacia was acquired by Pfizer in 2003 and is a wholly owned subsidiary of Pfizer.</span><span style="font-family:Arial;font-size:8pt;"> The action was originally filed in 2013. In December 2015, the Supreme Court dismissed the action and in May 2017, the New York State Appellate Division reversed the decision and remanded the proceedings to the Supreme Court. In January 2020, the Supreme Court denied both parties&#8217; summary judgment motions.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A4. Legal Proceedings&#8211;&#8211;Government Investigations</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Like other pharmaceutical companies, we are subject to extensive regulation by government agencies in the U.S., other developed markets and multiple emerging markets in which we operate. Criminal charges, substantial fines and/or civil penalties, limitations on our ability to conduct business in applicable jurisdictions, corporate integrity or deferred prosecution agreements, as well as reputational harm and increased public interest in the matter could result from government investigations in the U.S. and other jurisdictions in which we do business. In addition, in a qui tam lawsuit in which the government declines to intervene, the relator may still pursue a suit for the recovery of civil damages and penalties on behalf of the government.</span><span style="font-family:Arial;font-size:8pt;"> Among the investigations by government agencies are the matters discussed below.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Phenytoin Sodium Capsules</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2012, Pfizer sold the U.K. Marketing Authorisation for phenytoin sodium capsules to a third party, but retained the right to supply the finished product to that third party. In May 2013, the U.K. Competition &amp; Markets Authority (CMA) informed us that it had launched an investigation into the supply of phenytoin sodium capsules in the U.K. market. In August 2015, the CMA issued a Statement of Objections alleging that Pfizer and Pfizer Limited, a U.K. subsidiary, engaged in conduct that violates U.K. and EU antitrust laws. In December 2016, the CMA imposed a </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;84.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> fine on Pfizer and Pfizer Limited. Pfizer appealed the CMA decision to The Competition Appeal Tribunal in February 2017</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span><span style="font-family:Arial;font-size:8pt;">On June 7, 2018, the Competition Appeal Tribunal overturned the CMA decision as well as the associated fine. The CMA appealed the judgment to the Court of Appeal.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Greenstone Investigations</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">U.S. Department of Justice Antitrust Division Investigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Since July 2017, the U.S. Department of Justice's Antitrust Division has been investigating our Greenstone generics business. We believe this is related to an ongoing broader antitrust investigation of the generic pharmaceutical industry. The government has been obtaining information from Greenstone.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">State Attorneys General Generics Antitrust Litigation</span></div></td></tr></table><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, Greenstone received requests for information from the Antitrust Department of the Connecticut Office of the Attorney General. In May 2019, Attorneys General of more than 40 states plus the District of Columbia and Puerto Rico filed a complaint against a number of pharmaceutical companies, including Greenstone and Pfizer. The matter has been consolidated with a Multi-District Litigation (</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">In re: Generic Pharmaceuticals Pricing Antitrust Litigation MDL No. 2724)</span><span style="font-family:Arial;font-size:8pt;"> in the Eastern District of Pennsylvania. As to Greenstone and Pfizer, the complaint alleges anticompetitive conduct in violation of federal and state antitrust laws and state consumer protection laws.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Subpoena relating to Manufacturing of Quillivant XR</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2018, we received a subpoena from the U.S. Attorney&#8217;s Office for the Southern District of New York (SDNY) seeking records relating to our relationship with another drug manufacturer and its production and manufacturing of drugs including, but not limited to, Quillivant XR. We have produced records pursuant to the subpoena.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Government Inquiries relating to Meridian Medical Technologies </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In February 2019, we received a civil investigative demand from the U.S. Attorney&#8217;s Office for the SDNY. The civil investigative demand seeks records and information related to alleged quality issues involving the manufacture of auto-injectors at our Meridian site. In August 2019, we received a HIPAA subpoena from the U.S. Attorney&#8217;s Office for the Eastern District of Missouri seeking similar records and information. We are producing records in response to these requests. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">U.S. Department of Justice/SEC Inquiry relating to Russian Operations</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In June 2019, we received an informal request from the U.S. Department of Justice&#8217;s FCPA Unit seeking documents relating to our operations in Russia. In September 2019, we received a similar request from the SEC&#8217;s FCPA unit. We are producing records pursuant to these requests. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Contracts with Iraqi Ministry of Health</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16A3. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Legal Proceedings&#8211;&#8211;Commercial and Other Matters&#8211;&#8211;Contracts with Iraqi Ministry of Health</span><span style="font-family:Arial;font-size:8pt;"> above for information regarding U.S. government investigations related to contracts with the Iraqi Ministry of Health.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Docetaxel</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Mississippi Attorney General Government Investigation</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16A2. </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:normal;text-decoration:none;">Contingencies and Certain Commitments</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">: Legal Proceedings</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Product Litigation</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Docetaxel</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Mississippi Attorney General Government Investigation</span><span style="font-family:Arial;font-size:8pt;"> above for information regarding a government investigation related to Docetaxel marketing practices.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Guarantees and Indemnifications</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the ordinary course of business and in connection with the sale of assets and businesses and other transactions, we often indemnify our counterparties against certain liabilities that may arise in connection with the transaction or that are related to events and activities prior to or following a transaction. If the indemnified party were to make a successful claim pursuant to the terms of the indemnification, we may be required to reimburse the loss. These indemnifications are generally subject to various restrictions and limitations. Historically, we have not paid significant amounts under these provisions and, as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, the estimated fair value of these indemnification obligations was not significant. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition, in connection with our entry into certain agreements, our counterparties agree to indemnify us. For example, our collaboration agreement with EMD Serono, Inc. to co-promote Rebif in the U.S. expired at the end of 2015 and included certain indemnity provisions. Patent litigation brought by Biogen Idec MA Inc. against EMD Serono Inc. and Pfizer is pending in the U.S. District Court for the District of New Jersey and the United States Court of Appeals for the Federal Circuit. EMD Serono Inc. has acknowledged that it is obligated to satisfy any award of damages.</span></div><div style="line-height:120%;padding-bottom:10px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pfizer Inc. has also guaranteed the long-term debt of certain companies that it acquired and that now are subsidiaries of Pfizer.</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Certain Commitments</span></div><table cellpadding="0" cellspacing="0" style="padding-top:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had agreements totaling </span><span style="font-family:Arial;font-size:8pt;"><span>$2.5 billion</span></span><span style="font-family:Arial;font-size:8pt;"> to purchase goods and services that are enforceable and legally binding and include amounts relating to advertising, information technology services, employee benefit administration services, and potential milestone payments deemed reasonably likely to occur, as well as obligations to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">seven</span><span style="font-family:Arial;font-size:8pt;">-year period in connection with the U.S. and EU approvals for Besponsa (</span><span style="font-family:Arial;font-size:8pt;"><span>$412 million</span></span><span style="font-family:Arial;font-size:8pt;">) and an obligation to make guaranteed fixed annual payments over an </span><span style="font-family:Arial;font-size:8pt;">eight</span><span style="font-family:Arial;font-size:8pt;">-year period for Bosulif (</span><span style="font-family:Arial;font-size:8pt;"><span>$217 million</span></span><span style="font-family:Arial;font-size:8pt;">), both associated with R&amp;D arrangements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, in connection with the TCJA, we have an estimated </span><span style="font-family:Arial;font-size:8pt;"><span>$15 billion</span></span><span style="font-family:Arial;font-size:8pt;"> repatriation tax liability on accumulated post-1986 earnings of foreign subsidiaries for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. With respect to the aforementioned repatriation tax liability, it is reported in current </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Income taxes payable</span><span style="font-family:Arial;font-size:8pt;"> (approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$600 million</span></span><span style="font-family:Arial;font-size:8pt;"> due in April 2020) and the remaining liability is reported in noncurrent </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable </span><span style="font-family:Arial;font-size:8pt;">in our consolidated balance sheet as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. The first installment of </span><span style="font-family:Arial;font-size:8pt;"><span>$750 million</span></span><span style="font-family:Arial;font-size:8pt;"> was paid in April 2019. Our obligations may vary as a result of changes in our uncertain tax positions and/or availability of attributes such as foreign tax and other credit carryforwards. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:6px;padding-top:6px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Contingent Consideration for Acquisitions</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We may be required to make contingent consideration payments to sellers for certain prior business combinations. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1D</span><span style="font-family:Arial;font-size:8pt;">. The estimated fair value of contingent consideration as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$711 million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$160 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$551 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">. The estimated fair value of contingent consideration as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$988 million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$280 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$708 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">. The decrease in the contingent consideration balance from prior year is primarily due to payments made upon the achievement of certain milestones.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>R131.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039222896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Narrative (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for award</a></td>
<td class="nump">518,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember', window );">2019 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Number of additional shares authorized</a></td>
<td class="nump">400,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee', window );">Maximum shares available per individual during the plan period</a></td>
<td class="nump">20,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | 2019 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Portfolio Performance Shares [Member] | 2019 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member] | 2019 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member] | 2019 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember', window );">Performance Total Shareholder Return Unit (PTSRUs) [Member] | 2019 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member] | 2019 Stock Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee', window );">Number of shares counted toward maximum</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Maximum Number of Awards Granted Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardMaximumNumberofAwardsGrantedPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Shares Counted Toward Maximum Number of Awards Granted Per Employee</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesCountedTowardMaximumNumberofAwardsGrantedPerEmployee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pfe_A2019StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PerformanceTotalShareholderReturnUnitPTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>R135.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7185974320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Total Shareholder Return Units Activity (Details) - Total Shareholder Return Units (TSRUs) [Member] - $ / shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="nump">138,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares</a></td>
<td class="nump">39,246<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares</a></td>
<td class="num">(47,710)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares</a></td>
<td class="num">(7,826)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="nump">122,654<span></span>
</td>
<td class="nump">138,945<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">$ 6.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, weighted-average grant-date fair value per share (in dollars per share)</a></td>
<td class="nump">8.52<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="nump">$ 6.23<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">5.92<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">7.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share)</a></td>
<td class="nump">7.53<span></span>
</td>
<td class="nump">6.48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice', window );">Outstanding, beginning of period, weighted-average exercise price per share (in dollars per share)</a></td>
<td class="nump">33.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice', window );">Granted, weighted-average exercise price per share (in dollars per share)</a></td>
<td class="nump">43.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice', window );">Forfeited, weighted-average exercise price per share (in dollars per share)</a></td>
<td class="nump">30.70<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice', window );">Expired, weighted-average exercise price per share (in dollars per share)</a></td>
<td class="nump">38.90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice', window );">Outstanding, end of period, weighted-average exercise price per share (in dollars per share)</a></td>
<td class="nump">$ 38.01<span></span>
</td>
<td class="nump">$ 33.44<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNonvestedWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPriceAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsForfeitedinPeriodWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsGrantsinPeriodWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangements by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementsbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedinPeriodWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>128
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952955376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Equity</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Equity</span><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. Common Stock</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We purchase our common stock through privately negotiated transactions or in open market purchases as circumstances and prices warrant. Purchased shares under each of the share-purchase plans, which are authorized by our Board of Directors, are available for general corporate purposes. On October 23, 2014, we announced that the Board of Directors had authorized an </span><span style="font-family:Arial;font-size:8pt;"><span>$11 billion</span></span><span style="font-family:Arial;font-size:8pt;"> share repurchase program, which was exhausted in the first quarter of 2017. In December 2015, the Board of Directors authorized a new </span><span style="font-family:Arial;font-size:8pt;"><span>$11 billion</span></span><span style="font-family:Arial;font-size:8pt;"> share repurchase program, which was exhausted in the third quarter of 2018. In December 2017, the Board of Directors authorized an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$10 billion</span></span><span style="font-family:Arial;font-size:8pt;"> share repurchase program, which was exhausted in the first quarter of 2019. In December 2018, the Board of Directors authorized a new </span><span style="font-family:Arial;font-size:8pt;"><span>$10 billion</span></span><span style="font-family:Arial;font-size:8pt;"> share repurchase program to be utilized over time and share repurchases commenced thereunder in the first quarter of 2019. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">February&#160;2, 2017</span><span style="font-family:Arial;font-size:8pt;">, we entered into an accelerated share repurchase agreement with Citibank to repurchase </span><span style="font-family:Arial;font-size:8pt;"><span>$5 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of our common stock. Pursuant to the terms of the agreement, on February 6, 2017, we paid </span><span style="font-family:Arial;font-size:8pt;"><span>$5 billion</span></span><span style="font-family:Arial;font-size:8pt;"> to Citibank and received an initial delivery of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>126 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from Citibank at a price of </span><span style="font-family:Arial;font-size:8pt;"><span>$31.73</span></span><span style="font-family:Arial;font-size:8pt;"> per share, which represented, based on the closing price of our common stock on the NYSE on February 2, 2017, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>80%</span></span><span style="font-family:Arial;font-size:8pt;"> of the notional amount of the accelerated share repurchase agreement. On May 16, 2017, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:Arial;font-size:8pt;"><span>24 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from Citibank on May 19, 2017. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:Arial;font-size:8pt;"><span>$33.31</span></span><span style="font-family:Arial;font-size:8pt;"> per share. The common stock received is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Treasury Stock</span><span style="font-family:Arial;font-size:8pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">March&#160;12, 2018</span><span style="font-family:Arial;font-size:8pt;">, we entered into an accelerated share repurchase agreement with Citibank to repurchase </span><span style="font-family:Arial;font-size:8pt;"><span>$4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of our common stock. Pursuant to the terms of the agreement, on </span><span style="font-family:Arial;font-size:8pt;">March&#160;14, 2018</span><span style="font-family:Arial;font-size:8pt;">, we paid </span><span style="font-family:Arial;font-size:8pt;"><span>$4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> to Citibank and received an initial delivery of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>87 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from Citibank at a price of </span><span style="font-family:Arial;font-size:8pt;"><span>$36.61</span></span><span style="font-family:Arial;font-size:8pt;"> per share, which represented, based on the closing price of our common stock on the NYSE on </span><span style="font-family:Arial;font-size:8pt;">March&#160;12, 2018</span><span style="font-family:Arial;font-size:8pt;">, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>80%</span></span><span style="font-family:Arial;font-size:8pt;"> of the notional amount of the accelerated share repurchase agreement. On September 5, 2018, the accelerated share repurchase agreement with Citibank was completed, which, per the terms of the agreement, resulted in Citibank owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:Arial;font-size:8pt;"><span>21 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from Citibank on September 7, 2018. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:Arial;font-size:8pt;"><span>$36.86</span></span><span style="font-family:Arial;font-size:8pt;"> per share. The common stock received is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Treasury stock</span><span style="font-family:Arial;font-size:8pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">February&#160;7, 2019</span><span style="font-family:Arial;font-size:8pt;">, we entered into an accelerated share repurchase agreement with </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> to repurchase approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$6.8 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of our common stock. Pursuant to the terms of the agreement, on </span><span style="font-family:Arial;font-size:8pt;">February&#160;12, 2019</span><span style="font-family:Arial;font-size:8pt;">, we paid approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$6.8 billion</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> and received an initial delivery of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>130 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;">, which represented, based on the closing price of our common stock on the NYSE on February 7, 2019, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>80%</span></span><span style="font-family:Arial;font-size:8pt;"> of the notional amount of the accelerated share repurchase agreement. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">August&#160;1, 2019</span><span style="font-family:Arial;font-size:8pt;">, the accelerated share repurchase agreement with </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> was completed, which, per the terms of the agreement, resulted in </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> owing us a certain number of shares of Pfizer common stock. Pursuant to the agreement&#8217;s settlement terms, we received an additional </span><span style="font-family:Arial;font-size:8pt;"><span>33.5 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock from </span><span style="font-family:Arial;font-size:8pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:8pt;"> on </span><span style="font-family:Arial;font-size:8pt;">August&#160;5, 2019</span><span style="font-family:Arial;font-size:8pt;">. The average price paid for all of the shares delivered under the accelerated share repurchase agreement was </span><span style="font-family:Arial;font-size:8pt;"><span>$41.42</span></span><span style="font-family:Arial;font-size:8pt;"> per share. The common stock received is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Treasury stock</span><span style="font-family:Arial;font-size:8pt;">. This agreement was entered into pursuant to our previously announced share repurchase authorization.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Open market purchases totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$2.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$8.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> under our publicly announced share-purchase plans.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our accelerated share repurchase agreements:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(SHARES IN MILLIONS, DOLLARS IN BILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares of common stock purchased</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of purchase</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt">(</sup></span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Represents shares purchased pursuant to the accelerated share repurchase agreement with</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:7pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:7pt;"> entered into on </span><span style="font-family:Arial;font-size:7pt;">February&#160;7, 2019</span><span style="font-family:Arial;font-size:7pt;">, as well as other share repurchases. See above for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on </span><span style="font-family:Arial;font-size:7pt;">March&#160;12, 2018</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">, as well as other share repurchases. See above for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"> </span><span style="font-family:Arial;font-size:7pt;">February&#160;2, 2017</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">. See above for additional information.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">After giving effect to the accelerated share repurchase agreement, as well as other share repurchases through </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, our remaining share-purchase authorization was approximately&#160;</span><span style="font-family:Arial;font-size:8pt;"><span>$5.3 billion</span></span><span style="font-family:Arial;font-size:8pt;"> at </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Preferred Stock</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The Series A convertible perpetual preferred stock (</span><span style="font-family:Arial;font-size:8pt;"><span>7,500</span></span><span style="font-family:Arial;font-size:8pt;"> shares designated) is held by an employee stock ownership plan (Preferred ESOP) Trust and provides dividends at the rate of </span><span style="font-family:Arial;font-size:8pt;"><span>6.25%</span></span><span style="font-family:Arial;font-size:8pt;">, which are accumulated and paid quarterly. The per-share stated value is </span><span style="font-family:Arial;font-size:8pt;"><span>$40,300</span></span><span style="font-family:Arial;font-size:8pt;"> and the preferred stock ranks senior to our common stock as to dividends and liquidation rights. Each share is convertible, at the holder&#8217;s option, into </span><span style="font-family:Arial;font-size:8pt;"><span>2,574.87</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock with equal voting rights. The conversion option is indexed to our common stock and requires share settlement, and, therefore, is reported at the fair value at the date of issuance. We may redeem the preferred stock at any time or upon termination of the Preferred ESOP, at our option, in cash, in shares of common stock, or a combination of both at a price of </span><span style="font-family:Arial;font-size:8pt;"><span>$40,300</span></span><span style="font-family:Arial;font-size:8pt;"> per share.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Employee Stock Ownership Plans</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> employee stock ownership plans (collectively, the ESOPs), the Preferred ESOP and another that holds common stock of the Company (Common ESOP).</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Allocated shares held by the Common ESOP, including reinvested dividends, are considered outstanding for EPS calculations and the eventual conversion of allocated preferred shares held by the Preferred ESOP are assumed in the diluted EPS calculation. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, the Preferred ESOP held preferred shares convertible into approximately </span><span style="font-family:Arial;font-size:8pt;"><span>1 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock, and the Common ESOP held approximately </span><span style="font-family:Arial;font-size:8pt;"><span>47 million</span></span><span style="font-family:Arial;font-size:8pt;"> shares of our common stock. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, all shares of preferred and common stock held by the ESOPs have been allocated to the Pfizer U.S. defined contribution plan participants. The compensation cost related to the Common ESOP was </span><span style="font-family:Arial;font-size:8pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$19 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$11 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>R116.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039051696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Expected to be Amortized into Net Periodic Benefit Costs (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear', window );">Actuarial losses</a></td>
<td class="nump">$ 1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear', window );">Prior service credits and other</a></td>
<td class="nump">172<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear', window );">Total</a></td>
<td class="nump">$ 172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanExpectedAmortizationTerm', window );">Amortization period</a></td>
<td class="text">9 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear', window );">Actuarial losses</a></td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear', window );">Prior service credits and other</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear', window );">Total</a></td>
<td class="num">$ (121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanExpectedAmortizationTerm', window );">Amortization period</a></td>
<td class="text">19 years 4 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear', window );">Actuarial losses</a></td>
<td class="num">$ (127)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear', window );">Prior service credits and other</a></td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear', window );">Total</a></td>
<td class="num">$ (124)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanExpectedAmortizationTerm', window );">Amortization period</a></td>
<td class="text">24 years 10 months 24 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan [Member] | United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear', window );">Actuarial losses</a></td>
<td class="num">$ (14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear', window );">Prior service credits and other</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear', window );">Total</a></td>
<td class="num">$ (14)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanExpectedAmortizationTerm', window );">Amortization period</a></td>
<td class="text">24 years 6 months<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanExpectedAmortizationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Expected Amortization, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanExpectedAmortizationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost (credit) included in accumulated other comprehensive (income) loss expected to be recognized in net periodic benefit cost (credit) for fiscal year following most recent annual statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (s)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedAmortizationNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount included in accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan expected to be recognized in net periodic benefit (cost) credit for fiscal year following most recent annual statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (s)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedAmortizationOfGainLossNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount included in accumulated other comprehensive (income) loss for prior service cost (credit) expected to be recognized in net periodic benefit cost (credit) for fiscal year following most recent annual statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (s)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedAmortizationOfPriorServiceCostCreditNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>130
<FILENAME>R112.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952776096">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Expected Annual Amortization Expense (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths', window );">2020</a></td>
<td class="nump">$ 3,477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo', window );">2021</a></td>
<td class="nump">3,391<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree', window );">2022</a></td>
<td class="nump">3,151<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour', window );">2023</a></td>
<td class="nump">2,851<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive', window );">2024</a></td>
<td class="nump">$ 2,602<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for assets, excluding financial assets and goodwill, lacking physical substance with a finite life expected to be recognized during the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>131
<FILENAME>R94.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952725120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Investments - Unrealized Gains and Losses Related to Equity Securities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains recognized during the period on investments in equity securities</a></td>
<td class="nump">$ 454<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="nump">$ 224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss', window );">Less: Net gains recognized during the period on equity securities sold during the period</a></td>
<td class="num">(25)<span></span>
</td>
<td class="num">(109)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss', window );">Net unrealized gains during the reporting period on equity securities still held at the reporting date</a></td>
<td class="nump">$ 429<span></span>
</td>
<td class="nump">$ 477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiUnrealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>132
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040076896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Restructuring Accruals (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">$ 1,252<span></span>
</td>
<td class="nump">$ 1,105<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="num">(691)<span></span>
</td>
<td class="num">(636)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">933<span></span>
</td>
<td class="nump">1,252<span></span>
</td>
<td class="nump">1,105<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Termination Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="nump">239<span></span>
</td>
<td class="nump">459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="num">(555)<span></span>
</td>
<td class="num">(295)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">887<span></span>
</td>
<td class="nump">1,203<span></span>
</td>
<td class="nump">1,039<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember', window );">Asset Impairment Charges [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="num">(81)<span></span>
</td>
<td class="num">(290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember', window );">Exit Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveRollForward', window );"><strong>Restructuring Reserve [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Beginning balance</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Provision</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment', window );">Utilization and other</a></td>
<td class="num">(55)<span></span>
</td>
<td class="num">(51)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Ending balance</a></td>
<td class="nump">$ 46<span></span>
</td>
<td class="nump">$ 49<span></span>
</td>
<td class="nump">$ 66<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments for Restructuring, Other Restructuring And Restructuring Translation Adjustment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsforRestructuringOtherRestructuringAndRestructuringTranslationAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=pfe_AssetImpairmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_OtherRestructuringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>133
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7008028688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - R &amp; D and Collaborative Arrangements (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2016</div></th>
<th class="th"><div>Jan. 31, 2016</div></th>
<th class="th"><div>Apr. 01, 2018</div></th>
<th class="th"><div>Apr. 02, 2017</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2013</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,650,000,000<span></span>
</td>
<td class="nump">$ 8,006,000,000<span></span>
</td>
<td class="nump">$ 7,683,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,750,000,000<span></span>
</td>
<td class="nump">53,647,000,000<span></span>
</td>
<td class="nump">52,546,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(10,219,000,000)<span></span>
</td>
<td class="num">(11,248,000,000)<span></span>
</td>
<td class="num">(11,228,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14,350,000,000)<span></span>
</td>
<td class="num">(14,455,000,000)<span></span>
</td>
<td class="num">(14,804,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income/(deductions)&#8212;net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,578,000,000)<span></span>
</td>
<td class="num">(2,116,000,000)<span></span>
</td>
<td class="num">(1,416,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundVL.P.Member', window );">NovaQuest Co-Investment Fund V, L.P. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount', window );">Maximum funding amount</a></td>
<td class="nump">$ 200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed', window );">Percentage of costs to be reimbursed</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred', window );">Reduction to research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000,000<span></span>
</td>
<td class="nump">58,000,000<span></span>
</td>
<td class="nump">72,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale', window );">Charge primarily for inventory manufactured for expected future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_RPIFinanceTrustMember', window );">RPI Finance Trust [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount', window );">Maximum funding amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed', window );">Percentage of costs to be reimbursed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred', window );">Reduction to research and development expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,000,000<span></span>
</td>
<td class="nump">99,000,000<span></span>
</td>
<td class="nump">76,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure', window );">Research and development, contingent payments, maximum exposure</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99,000,000<span></span>
</td>
<td class="nump">162,000,000<span></span>
</td>
<td class="nump">222,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,313,000,000<span></span>
</td>
<td class="nump">4,409,000,000<span></span>
</td>
<td class="nump">3,533,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(351,000,000)<span></span>
</td>
<td class="num">(296,000,000)<span></span>
</td>
<td class="num">(329,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(173,000,000)<span></span>
</td>
<td class="num">(90,000,000)<span></span>
</td>
<td class="num">(54,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income/(deductions)&#8212;net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">362,000,000<span></span>
</td>
<td class="nump">281,000,000<span></span>
</td>
<td class="nump">249,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementUpfrontAndMilestonePayments', window );">Upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Eli Lilly &amp; Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">67,000,000<span></span>
</td>
<td class="nump">98,000,000<span></span>
</td>
<td class="nump">147,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized', window );">Deferred milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Merck KGaA [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrepaymentsandPaymentstoCollaborators', window );">Collaborative arrangement sales based milestones payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">140,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Mylan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Merck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage', window );">Collaborator's revenue and expense ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage', window );">Company's revenue and expense ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Merck [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementMilestonePaymentReceivable', window );">Milestone payment due to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 40,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized', window );">Deferred milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Other Noncurrent Liabilities [Member] | Merck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementDeferredMilestonePayment', window );">Deferred milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember', window );">Collaborative Arrangement [Member] | Deferred Revenue [Member] | Eli Lilly &amp; Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Proceeds received from upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 200,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=pfe_CollaborativeArrangementUpfrontCashPaymentMember', window );">Collaborative Arrangement, Upfront Cash Payment [Member] | Merck KGaA [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementUpfrontAndMilestonePayments', window );">Upfront payments and milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 850,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Collaborative Arrangement [Member] | Merck [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized', window );">Deferred milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Collaborative Arrangement [Member] | Other Noncurrent Liabilities [Member] | Merck [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementDeferredMilestonePayment', window );">Deferred milestone payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member', window );">Revenues [Member] | Difference between Revenue Guidance in Effect before and after Topic 606 [Member] | Collaborative Arrangement [Member] | Deferred Revenue [Member] | Eli Lilly &amp; Company [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized', window );">Deferred milestone revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 107,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=us-gaap_ProductMember', window );">Product [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 664,000,000<span></span>
</td>
<td class="nump">571,000,000<span></span>
</td>
<td class="nump">606,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_CopromotionMember', window );">Co-promotion [Member] | Collaborative Arrangement, Transaction with Party to Collaborative Arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,648,000,000<span></span>
</td>
<td class="nump">$ 3,838,000,000<span></span>
</td>
<td class="nump">$ 2,927,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge primarily for inventory manufactured for expected future sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Collaborator's Revenue and Expense Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementCollaboratorsRevenueandExpenseOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Company's Revenue and Expense Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementCompanysRevenueandExpenseOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementContingentPaymentsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Contingent Payments, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementContingentPaymentsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementDeferredMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Deferred Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementDeferredMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Deferred Milestone Revenue Recognized</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementDeferredMilestoneRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementMilestonePaymentReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Milestone Payment, Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementMilestonePaymentReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementUpfrontAndMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to our partners for payments made upfront as part of a collaborative arrangement and the payments upon the achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementUpfrontAndMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrepaymentsandPaymentstoCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Prepayments and Payments to Collaborators</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrepaymentsandPaymentstoCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Contingent Payments, Maximum Exposure</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementContingentPaymentsMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Funding to Offset Costs Incurred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementFundingtoOffsetCostsIncurred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementMaximumFundingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Maximum Funding Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementMaximumFundingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Percentage of Costs to be Reimbursed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementPercentageofCoststobeReimbursed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundVL.P.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundVL.P.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_RPIFinanceTrustMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_RPIFinanceTrustMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_EliLillyCompanyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_MerckKGaAMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_MerckKGaAMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_MylanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_MylanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_MerckMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_MerckMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=us-gaap_OtherNoncurrentLiabilitiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_DeferredRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_DeferredRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=pfe_CollaborativeArrangementUpfrontCashPaymentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=pfe_CollaborativeArrangementUpfrontCashPaymentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InitialApplicationPeriodCumulativeEffectTransitionAxis=us-gaap_DifferenceBetweenRevenueGuidanceInEffectBeforeAndAfterTopic606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_ProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_ProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementTransactionWithPartyToCollaborativeArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_CopromotionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_CopromotionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>R90.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7032761744">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis - Footnotes (Details) - Recurring [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNIRestrictedCurrent', window );">Short-term equity securities held in trust</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent', window );">Long-term equity securities held in trust</a></td>
<td class="nump">$ 176<span></span>
</td>
<td class="nump">$ 132<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNIRestrictedCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restricted, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNIRestrictedCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNIRestrictedNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Restricted, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNIRestrictedNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>135
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952861568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes - Royalty Income (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th">
<div>Jun. 30, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromLegalSettlements', window );">Proceeds from legal settlements</a></td>
<td class="nump">$ 82<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromLegalSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for the settlement of litigation during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromLegalSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>136
<FILENAME>R98.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7021206656">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5<span></span>
</td>
<td class="num">$ (5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(43)<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,955<span></span>
</td>
<td class="nump">32,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,462<span></span>
</td>
<td class="nump">$ 4,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 34,820<span></span>
</td>
<td class="nump">$ 32,558<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting', window );">Net fair value adjustments related to hedging and purchase accounting</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,305<span></span>
</td>
<td class="nump">479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet', window );">Net unamortized discounts, premiums and debt issuance costs</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="num">(176)<span></span>
</td>
<td class="num">(136)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLongTermDebt', window );">Other long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt, carried at historical proceeds, as adjusted</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">35,955<span></span>
</td>
<td class="nump">32,909<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1,462<span></span>
</td>
<td class="nump">4,776<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2020 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2021 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,153<span></span>
</td>
<td class="nump">$ 4,459<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2022 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">1.00%<span></span>
</td>
<td class="nump">0.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,624<span></span>
</td>
<td class="nump">$ 1,145<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2023 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,892<span></span>
</td>
<td class="nump">$ 2,892<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2024 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">4.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 2,250<span></span>
</td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2026-2029 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 7,453<span></span>
</td>
<td class="nump">5,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2034 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 750<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2036-2040 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">5.80%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 8,566<span></span>
</td>
<td class="nump">$ 7,796<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2043-2044 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 3,568<span></span>
</td>
<td class="nump">$ 3,509<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Unsecured Debt, Due 2046-2049 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">4.10%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentCarryingAmount', window );">Total principal amount of long-term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 4,565<span></span>
</td>
<td class="nump">$ 3,315<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="4"></td></tr>
<tr><td colspan="4"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Fair Value Adjustments, Hedging and Purchase Accounting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtInstrumentFairValueAdjustmentsHedgingandPurchaseAccounting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentCarryingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but is not limited to, notes payable, bonds payable, commercial loans, mortgage loans, convertible debt, subordinated debt and other types of debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentCarryingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unamortized debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2023Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2023Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20262029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20262029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2034Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue2034Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20362040Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20362040Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20432044Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20432044Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20462049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtDue20462049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>137
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039959520">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent', window );">Accounts receivable, allowance for doubtful accounts</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 527<span></span>
</td>
<td class="nump">$ 541<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Short term borrowings, current portion of long term debt</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 1,462<span></span>
</td>
<td class="nump">$ 4,776<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">431<span></span>
</td>
<td class="nump">478<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">$ 0.05<span></span>
</td>
<td class="nump">$ 0.05<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">12,000,000,000<span></span>
</td>
<td class="nump">12,000,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">9,369,000,000<span></span>
</td>
<td class="nump">9,332,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockShares', window );">Treasury stock, shares at cost</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3,835,000,000<span></span>
</td>
<td class="nump">3,615,000,000<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Amounts may not add due to rounding.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of allowance for credit loss on accounts receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5074-111524<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118955202&amp;loc=SL82895884-210446<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllowanceForDoubtfulAccountsReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt, classified as current. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of common and preferred shares that were previously issued and that were repurchased by the issuing entity and held in treasury on the financial statement date. This stock has no voting rights and receives no dividends.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>138
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7019579552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Income - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 51,750<span></span>
</td>
<td class="nump">$ 53,647<span></span>
</td>
<td class="nump">$ 52,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAndExpensesAbstract', window );"><strong>Costs and expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of sales</a></td>
<td class="nump">10,219<span></span>
</td>
<td class="nump">11,248<span></span>
</td>
<td class="nump">11,228<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, informational and administrative expenses</a></td>
<td class="nump">14,350<span></span>
</td>
<td class="nump">14,455<span></span>
</td>
<td class="nump">14,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="nump">8,650<span></span>
</td>
<td class="nump">8,006<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction', window );">Amortization of intangible assets</a></td>
<td class="nump">4,610<span></span>
</td>
<td class="nump">4,893<span></span>
</td>
<td class="nump">4,758<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">(Gain) on completion of Consumer Healthcare JV transaction</a></td>
<td class="num">(8,086)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="nump">3,578<span></span>
</td>
<td class="nump">2,116<span></span>
</td>
<td class="nump">1,416<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="nump">17,682<span></span>
</td>
<td class="nump">11,885<span></span>
</td>
<td class="nump">12,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="nump">1,384<span></span>
</td>
<td class="nump">706<span></span>
</td>
<td class="num">(9,049)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest', window );">Income from continuing operations</a></td>
<td class="nump">16,298<span></span>
</td>
<td class="nump">11,179<span></span>
</td>
<td class="nump">21,353<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract', window );"><strong>Discontinued operations:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax', window );">Income from discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax', window );">Gain on disposal of discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax', window );">Discontinued operations&#8211;&#8211;net of tax</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="nump">16,302<span></span>
</td>
<td class="nump">11,188<span></span>
</td>
<td class="nump">21,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest', window );">Less: Net income attributable to noncontrolling interests</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">36<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net income attributable to Pfizer Inc.</a></td>
<td class="nump">$ 16,273<span></span>
</td>
<td class="nump">$ 11,153<span></span>
</td>
<td class="nump">$ 21,308<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAbstract', window );"><strong>Earnings per common share&#8211;&#8211;basic:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 2.92<span></span>
</td>
<td class="nump">$ 1.90<span></span>
</td>
<td class="nump">$ 3.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">2.92<span></span>
</td>
<td class="nump">1.90<span></span>
</td>
<td class="nump">3.57<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDilutedAbstract', window );"><strong>Earnings per common share&#8211;&#8211;diluted:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare', window );">Income from continuing operations attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">2.87<span></span>
</td>
<td class="nump">1.86<span></span>
</td>
<td class="nump">3.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare', window );">Discontinued operations&#8211;&#8211;net of tax (in dollars per share)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net income attributable to Pfizer Inc. common shareholders (in dollars per share)</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="nump">$ 1.87<span></span>
</td>
<td class="nump">$ 3.52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average shares&#8211;&#8211;basic</a></td>
<td class="nump">5,569<span></span>
</td>
<td class="nump">5,872<span></span>
</td>
<td class="nump">5,970<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average shares&#8211;&#8211;diluted</a></td>
<td class="nump">5,675<span></span>
</td>
<td class="nump">5,977<span></span>
</td>
<td class="nump">6,058<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of amortization that is not associated with a single function. Amounts associated in a single function are included in Cost of sales, Selling, information and administrative expenses and Research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AmortizationOfIntangibleAssetsNotAssociatedWithSingleFunction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.2(a),(d))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of gain (loss) not previously recognized resulting from the disposal of a discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationGainLossOnDisposalOfDiscontinuedOperationNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from operations classified as a discontinued operation. Excludes gain (loss) on disposal and provision for gain (loss) until disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DiscontinuedOperationIncomeLossFromDiscontinuedOperationDuringPhaseOutPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=117327953&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from continuing operations including portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) from continuing operations per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868656-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) derived from continuing operations during the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1252-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-03(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868656-224227<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of income (loss) from a discontinued operation including the portion attributable to the noncontrolling interest. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721525-107759<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e957-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721523-107759<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1012-107759<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per basic share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1278-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerBasicShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per diluted share amount, after tax, of income (loss) from the day-to-day business activities of the discontinued operation and gain (loss) from the disposal of the discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1337-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 5.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355146-122828<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=SL5780133-109256<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1278-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromDiscontinuedOperationsNetOfTaxPerDilutedShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of Net Income (Loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=68048583&amp;loc=d3e3636-108311<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=117326831&amp;loc=d3e1448-109256<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>139
<FILENAME>R154.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6950929232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Commitments and Contingent Consideration for Acquisitions) (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermPurchaseCommitmentAmount', window );">Long-term purchase commitment, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForRepatriationTax', window );">Payment for repatriation tax</a></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent', window );">Contingent consideration liability, current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">280<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent', window );">Contingent consideration liability, noncurrent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 551<span></span>
</td>
<td class="nump">$ 708<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BesponsaMember', window );">Besponsa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Research and development arrangement, aggregate payment obligation, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Research arrangement, fixed payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 412<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_BosulifMember', window );">Bosulif [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm', window );">Research and development arrangement, aggregate payment obligation, term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">8 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation', window );">Research arrangement, fixed payment obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 217<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember', window );">Income Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability', window );">Repatriation tax liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForRepatriationTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Repatriation Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForRepatriationTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Aggregate Payment Obligation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementAggregatePaymentObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research and Development Arrangement, Aggregate Payment Obligation, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ResearchandDevelopmentArrangementAggregatePaymentObligationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination, expected to be settled beyond one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermPurchaseCommitmentAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The minimum amount the entity agreed to spend under the long-term purchase commitment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermPurchaseCommitmentAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax liability from transition tax on accumulated earnings of controlled foreign corporation deemed repatriated pursuant to Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017TransitionTaxForAccumulatedForeignEarningsLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BesponsaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BesponsaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>140
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952817680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Revenue from Segments to Consolidated</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="37"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Earnings</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Depreciation and Amortization</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>39,419</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>37,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>35,530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>24,517</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>23,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>22,194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>958</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>10,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12,484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>13,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>6,785</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>8,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>9,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>105</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>49,653</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>50,042</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>48,977</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>31,301</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>32,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>31,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>1,063</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>2,098</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>3,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>3,472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,723</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,283</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,302</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,859</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,383</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,299</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(4,333</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(4,786</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(4,758</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>4,347</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>4,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>4,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(185</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(318</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(456</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Certain significant items</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>2,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(3,719</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(2,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>51,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>53,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>52,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>17,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>11,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>6,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>6,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>6,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. Biopharma&#8217;s earnings</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> include d</span><span style="font-family:Arial;font-size:7pt;">ividend income from our investment in ViiV of </span><span style="font-family:Arial;font-size:7pt;"><span>$220 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$253 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$266 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. </span></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$758 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$543 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$495 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$415 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) a pre-tax gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$8.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$138 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (viii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: an upfront license fee payment of </span><span style="font-family:Arial;font-size:7pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:7pt;"> to Akcea, which was recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses, </span><span style="font-family:Arial;font-size:7pt;">charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$112 million</span></span><span style="font-family:Arial;font-size:7pt;"> recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a </span><span style="font-family:Arial;font-size:7pt;"><span>$337 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:7pt;"> related to our acquisition of Therachon, a </span><span style="font-family:Arial;font-size:7pt;"><span>$99 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">related to rivipansel, primarily for inventory manufactured for expected future sale and charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$240 million</span></span><span style="font-family:Arial;font-size:7pt;">, primarily in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A, Note 2A, Note 2C</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2D,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$977 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) net charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$157 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$3.1 billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$63 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$586 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$4 million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$343 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a </span><span style="font-family:Arial;font-size:7pt;"><span>$119 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge, in the aggregate, in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:7pt;"> for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">, Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$204 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$237 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$379 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$71 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$224 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$999 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$756 million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a charitable contribution to the Pfizer Foundation of </span><span style="font-family:Arial;font-size:7pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:7pt;">, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$195 million</span></span><span style="font-family:Arial;font-size:7pt;"> in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales,</span><span style="font-family:Arial;font-size:7pt;"> an </span><span style="font-family:Arial;font-size:7pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:7pt;"> loss related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>49%</span></span><span style="font-family:Arial;font-size:7pt;"> equity share in Hisun Pfizer, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net,</span><span style="font-family:Arial;font-size:7pt;"> charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$55 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>40%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:Arial;font-size:7pt;"><span>60%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership interest, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2C,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock', window );">Reconciliation of Operating Profit (Loss) from Segments to Consolidated</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="37"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Earnings</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Depreciation and Amortization</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>39,419</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>37,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>35,530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>24,517</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>23,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>22,194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>958</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>10,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12,484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>13,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>6,785</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>8,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>9,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>105</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>49,653</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>50,042</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>48,977</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>31,301</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>32,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>31,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>1,063</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>2,098</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>3,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>3,472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,723</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,283</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,302</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,859</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,383</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,299</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(4,333</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(4,786</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(4,758</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>4,347</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>4,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>4,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(185</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(318</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(456</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Certain significant items</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>2,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(3,719</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(2,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>51,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>53,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>52,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>17,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>11,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>6,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>6,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>6,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. Biopharma&#8217;s earnings</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> include d</span><span style="font-family:Arial;font-size:7pt;">ividend income from our investment in ViiV of </span><span style="font-family:Arial;font-size:7pt;"><span>$220 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$253 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$266 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. </span></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$758 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$543 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$495 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$415 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) a pre-tax gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$8.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$138 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (viii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: an upfront license fee payment of </span><span style="font-family:Arial;font-size:7pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:7pt;"> to Akcea, which was recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses, </span><span style="font-family:Arial;font-size:7pt;">charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$112 million</span></span><span style="font-family:Arial;font-size:7pt;"> recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a </span><span style="font-family:Arial;font-size:7pt;"><span>$337 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:7pt;"> related to our acquisition of Therachon, a </span><span style="font-family:Arial;font-size:7pt;"><span>$99 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">related to rivipansel, primarily for inventory manufactured for expected future sale and charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$240 million</span></span><span style="font-family:Arial;font-size:7pt;">, primarily in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A, Note 2A, Note 2C</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2D,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$977 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) net charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$157 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$3.1 billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$63 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$586 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$4 million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$343 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a </span><span style="font-family:Arial;font-size:7pt;"><span>$119 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge, in the aggregate, in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:7pt;"> for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">, Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$204 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$237 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$379 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$71 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$224 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$999 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$756 million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a charitable contribution to the Pfizer Foundation of </span><span style="font-family:Arial;font-size:7pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:7pt;">, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$195 million</span></span><span style="font-family:Arial;font-size:7pt;"> in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales,</span><span style="font-family:Arial;font-size:7pt;"> an </span><span style="font-family:Arial;font-size:7pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:7pt;"> loss related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>49%</span></span><span style="font-family:Arial;font-size:7pt;"> equity share in Hisun Pfizer, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net,</span><span style="font-family:Arial;font-size:7pt;"> charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$55 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>40%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:Arial;font-size:7pt;"><span>60%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership interest, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2C,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock', window );">Reconciliation Of Depreciation And Amortization From Segments To Consolidated</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.20634920634922%;border-collapse:collapse;text-align:left;"><tr><td colspan="37"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/></tr><tr><td colspan="37" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides selected income statement information by reportable segment:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Earnings</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Depreciation and Amortization</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reportable Segments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>39,419</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>37,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>35,530</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>24,517</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>23,738</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>22,194</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>958</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>953</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>881</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>10,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12,484</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>13,447</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>6,785</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>8,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>9,348</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>105</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>112</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>125</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Total reportable segments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>49,653</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>50,042</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>48,977</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>31,301</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>32,374</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>31,542</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>1,063</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,006</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other business activities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>2,098</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>3,605</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>3,472</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,723</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,283</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,302</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>108</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>142</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Reconciling Items:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Corporate and other unallocated</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,859</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,383</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,299</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>503</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>465</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Purchase accounting adjustments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(4,333</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(4,786</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(4,758</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>4,347</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>4,620</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>4,565</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(185</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(318</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(456</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Certain significant items</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>2,481</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(3,719</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(2,423</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>51,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>53,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>52,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>17,682</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>11,885</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>12,305</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>6,010</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>6,384</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>6,269</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;">Income from continuing operations before provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:7pt;">. Biopharma&#8217;s earnings</span><span style="font-family:Arial;font-size:7pt;text-align:center;"> include d</span><span style="font-family:Arial;font-size:7pt;">ividend income from our investment in ViiV of </span><span style="font-family:Arial;font-size:7pt;"><span>$220 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$253 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$266 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain production facilities are shared. Depreciation is allocated based on estimates of physical production. Amounts here relate solely to the depreciation and amortization associated with continuing operations.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain significant items are substantive and/or unusual, and in some cases recurring, items (as noted above) that, either as a result of their nature or size, would not be expected to occur as part of our normal business on a regular basis. </span></div></td></tr></table><div style="line-height:120%;padding-top:1px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$758 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$543 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.8 billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$495 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$415 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) a pre-tax gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$8.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> associated with the completion of the GSK Consumer Healthcare joint venture transaction, (vii) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$138 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (viii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: an upfront license fee payment of </span><span style="font-family:Arial;font-size:7pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:7pt;"> to Akcea, which was recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses, </span><span style="font-family:Arial;font-size:7pt;">charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$112 million</span></span><span style="font-family:Arial;font-size:7pt;"> recorded in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> representing our pro rata share of primarily restructuring and business combination accounting charges recorded by the GSK Consumer Healthcare joint venture, a </span><span style="font-family:Arial;font-size:7pt;"><span>$337 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:7pt;"> related to our acquisition of Therachon, a </span><span style="font-family:Arial;font-size:7pt;"><span>$99 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:7pt;">related to rivipansel, primarily for inventory manufactured for expected future sale and charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$240 million</span></span><span style="font-family:Arial;font-size:7pt;">, primarily in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">, for external incremental costs, such as transaction costs and costs to separate our Consumer Healthcare business into a separate legal entity associated with the formation of the GSK Consumer Healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A, Note 2A, Note 2C</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2D,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$977 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) net charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$157 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$3.1 billion</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$63 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$586 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$4 million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$343 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> associated with our transaction with Bain Capital to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and pre-clinical stage neuroscience assets primarily targeting disorders of the central nervous system, a </span><span style="font-family:Arial;font-size:7pt;"><span>$119 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge, in the aggregate, in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:7pt;"> for a special, one-time bonus paid to virtually all Pfizer colleagues, excluding executives, which was one of several actions taken by us after evaluating the expected positive net impact of the December 2017 enactment of the TCJA, and a non-cash </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the contribution of our allogeneic CAR T cell therapy development program assets in connection with our contribution agreement entered into with Allogene. For additional information, see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">, Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4.</span></div><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For Earnings in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, certain significant items includes: (i) restructuring charges and implementation costs associated with our cost-reduction initiatives that are not associated with an acquisition of </span><span style="font-family:Arial;font-size:7pt;"><span>$204 million</span></span><span style="font-family:Arial;font-size:7pt;">, (ii) charges for certain legal matters of </span><span style="font-family:Arial;font-size:7pt;"><span>$237 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iii) certain asset impairment charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$379 million</span></span><span style="font-family:Arial;font-size:7pt;">, (iv) charges for business and legal entity alignment of </span><span style="font-family:Arial;font-size:7pt;"><span>$71 million</span></span><span style="font-family:Arial;font-size:7pt;">, (v) net gains of </span><span style="font-family:Arial;font-size:7pt;"><span>$224 million</span></span><span style="font-family:Arial;font-size:7pt;"> recognized during the period on equity securities, (vi) net losses on early retirement of debt of </span><span style="font-family:Arial;font-size:7pt;"><span>$999 million</span></span><span style="font-family:Arial;font-size:7pt;"> and (vii) other charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$756 million</span></span><span style="font-family:Arial;font-size:7pt;">, which includes, among other things: a charitable contribution to the Pfizer Foundation of </span><span style="font-family:Arial;font-size:7pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:7pt;">, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Selling, informational and administrative expenses,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$195 million</span></span><span style="font-family:Arial;font-size:7pt;"> in inventory losses, overhead costs related to the period in which our Puerto Rico plants were not operational, and incremental costs, all of which resulted from hurricanes in Puerto Rico in 2017 and are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales,</span><span style="font-family:Arial;font-size:7pt;"> an </span><span style="font-family:Arial;font-size:7pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:7pt;"> loss related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>49%</span></span><span style="font-family:Arial;font-size:7pt;"> equity share in Hisun Pfizer, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net,</span><span style="font-family:Arial;font-size:7pt;"> charges of </span><span style="font-family:Arial;font-size:7pt;"><span>$55 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">representing adjustments to amounts previously recorded to write down the HIS net assets to fair value less costs to sell and a net loss of </span><span style="font-family:Arial;font-size:7pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the sale of our former </span><span style="font-family:Arial;font-size:7pt;"><span>40%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership investment in Teuto, including the extinguishment of a put option for the remaining </span><span style="font-family:Arial;font-size:7pt;"><span>60%</span></span><span style="font-family:Arial;font-size:7pt;"> ownership interest, which is included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;">. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B, Note 2C,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock', window );">Revenue from External Customers by Geographic Areas</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As described in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides revenues by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>23,852</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>25,329</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>26,026</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Europe</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,701</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,508</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Rest of World</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,465</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,612</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging Markets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>12,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12,651</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,399</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>51,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>53,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>52,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span><span style="font-family:Arial;font-size:7pt;"> Revenues denominated in euros were </span><span style="font-family:Arial;font-size:7pt;"><span>$7.0 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$7.3 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$6.8 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span><span style="font-family:Arial;font-size:7pt;"> </span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Long-lived Assets by Geographic Areas</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:64%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides long-lived assets by geographic area:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">United States</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,606</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,089</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,971</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Europe</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,304</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed Rest of World</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>490</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>632</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Emerging Markets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,603</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,917</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Property, plant and equipment, net</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>13,967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,385</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,865</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Developed Europe region includes the following markets: Western Europe, Scandinavian countries and Finland.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;padding-left:12px;"><div style="line-height:120%;text-align:left;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Developed Rest of World region includes the following markets: Japan, Canada, South Korea, Australia and New Zealand.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;text-indent:-12px;"><span style="font-family:Arial;font-size:7pt;">Emerging Markets region includes, but is not limited to, the following markets: Asia (excluding Japan and South Korea), Latin America, Eastern Europe, Africa, the Middle East, Central Europe and Turkey.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock', window );">Schedule of Significant Product Revenues</a></td>
<td class="text"><div style="line-height:120%;padding-bottom:4px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As described in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:8pt;">, acquisitions impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, the contribution of our Consumer Healthcare business to the GSK Consumer Healthcare joint venture impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and divestitures impacted our results of operations in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides detailed revenue information for several of our major products:</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">TOTAL REVENUES</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>51,750</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>53,647</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>52,546</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PFIZER BIOPHARMACEUTICALS GROUP (BIOPHARMA)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>39,419</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>37,558</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>35,530</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Internal Medicine</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>9,119</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8,869</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8,229</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Eliquis alliance revenues and direct sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Nonvalvular Atrial fibrillation, deep vein thrombosis, pulmonary embolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,220</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,434</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,523</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Chantix/Champix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">An aid to smoking cessation treatment in adults 18 years of age or older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,107</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>997</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Premarin family</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Symptoms of menopause</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>734</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>832</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>977</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">BMP2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Development of bone and cartilage</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>287</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>279</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Toviaz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Overactive bladder</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>250</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>271</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>257</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Internal Medicine</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,521</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,969</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,213</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Oncology</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>9,014</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>7,471</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>6,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Ibrance</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Metastatic breast cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,961</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>4,118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,126</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Sutent</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Advanced and/or metastatic RCC, adjuvant RCC, refractory GIST (after disease progression on, or intolerance to, imatinib mesylate) and advanced pancreatic neuroendocrine tumor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>936</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,049</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,081</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xtandi alliance revenues</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Non-metastatic and metastatic castration-resistant prostate cancer and non-metastatic castration-sensitive prostate cancer</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>838</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>699</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>590</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xalkori</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">ALK-positive and ROS1-positive advanced NSCLC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>530</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>524</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>594</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Inlyta</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Advanced RCC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>477</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>339</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bosulif</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Philadelphia&#160;chromosome&#8211;positive&#160;chronic myelogenous leukemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>365</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>233</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Retacrit</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anemia</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>225</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Mektovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">In combination with Braftovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>49</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Braftovi</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">In combination with Mektovi for metastatic melanoma for patients who test positive for a BRAF genetic mutation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>48</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Oncology</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>585</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>274</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Hospital</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7,772</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>7,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8,369</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Sulperazon</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>684</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>613</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>471</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Medrol</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anti-inflammatory glucocorticoid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>469</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>493</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>540</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Vfend</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>346</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>392</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>421</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zithromax</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>336</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>326</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">EpiPen</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Epinephrine injection used in treatment of life-threatening allergic reactions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>303</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fragmin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Treatment/prevention of venous thromboembolism</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>253</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>293</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zyvox</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>251</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>236</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zosyn/Tazocin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>200</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>230</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>195</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Tygacil</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Bacterial infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>197</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Diflucan</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fungal infections</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>190</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>180</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Panzyga</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Primary humoral immunodeficiency</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>183</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pfizer CentreOne</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>810</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>755</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>706</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Anti-infectives</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,041</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,237</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Hospital</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,436</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,797</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,182</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6,504</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>6,332</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>6,001</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Prevnar 13/Prevenar 13</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pneumococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>5,847</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,802</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,601</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Nimenrix</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>230</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>86</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">FSME/IMMUN-TicoVac</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Tick-borne encephalitis disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>184</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Trumenba</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Meningococcal disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>135</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>88</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Vaccines</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Inflammation &amp; Immunology (I&amp;I)</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,733</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>4,720</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>4,386</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xeljanz</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">RA, PsA, UC</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,242</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,774</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Enbrel (Outside the U.S. and Canada)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">RA, juvenile idiopathic arthritis, PsA, plaque psoriasis, pediatric plaque psoriasis, ankylosing spondylitis and nonradiographic axial spondyloarthritis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,699</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,112</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,452</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Inflectra/Remsima</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(c), (g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Crohn&#8217;s Disease, Pediatric Crohn&#8217;s Disease, UC, Pediatric UC, RA in combination with methotrexate, Ankylosing Spondylitis, PsA and Plaque Psoriasis</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>625</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>642</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>419</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Eucrisa</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Mild-to-moderate atopic dermatitis (eczema) in adults and children 2 years of age and older</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>138</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>67</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other I&amp;I</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>29</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="15"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:44%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRODUCT</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">PRIMARY INDICATION OR CLASS</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,278</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,240</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Genotropin</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Replacement of human growth hormone</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>498</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">BeneFIX</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hemophilia B</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>488</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>554</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>604</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:24px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Vyndaqel/Vyndamax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">ATTR-Cardiomyopathy and Polyneuropathy</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>473</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>148</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>124</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Refacto AF/Xyntha</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hemophilia A</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>426</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>551</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Somavert</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Acromegaly</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>264</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>267</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Rare Disease</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>129</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>170</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>176</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Upjohn</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>10,233</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>12,484</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>13,447</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Lyrica </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;padding-left:6px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Epilepsy, post-herepetic neuralgia and diabetic peripheral neuropathy, fibromyalgia, neuropathic pain due to spinal cord injury</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>3,321</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>4,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,065</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Lipitor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Reduction of LDL cholesterol</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,973</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,062</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,915</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Norvasc</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>950</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,029</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>932</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Celebrex</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Arthritis pain and inflammation, acute pain</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>719</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>686</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>775</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Viagra</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Erectile dysfunction</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>497</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>636</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Effexor</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>336</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>311</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>297</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Zoloft</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Depression and certain anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>298</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>291</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xalatan/Xalacom</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Glaucoma and ocular hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>281</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>318</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Xanax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Anxiety disorders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>198</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>223</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>225</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Revatio</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Pulmonary arterial hypertension</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:18px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">All other Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,519</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>1,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,158</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Consumer Healthcare Business</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>2,098</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,605</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,472</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Alliance revenues</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,927</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Biosimilars</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Various</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>911</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>769</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="3" style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Total Sterile Injectable Pharmaceuticals</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>5,035</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,214</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>5,673</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We reclassified certain products from the LEP category, including Premarin family products, and certain other products from the legacy Peri-LOE category, including Pristiq, to the Internal Medicine category and reclassified Lyrica from the Internal Medicine category to the Upjohn business to conform 2018 and 2017 product revenues to the current presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We performed certain reclassifications in the All other Oncology category to conform 2018 and 2017 product revenues to the current presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biosimilars are highly similar versions of approved and authorized biological medicines and primarily include revenues from Inflectra/Remsima and Retacrit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Hospital is a business unit that commercializes our global portfolio of sterile injectable and anti-infective medicines. We performed certain reclassifications, primarily from the legacy SIP category (Sulperazon, Medrol, Fragmin, Tygacil, Zosyn/Tazocin and Precedex, among other products), the LEP category (Epipen and Zithromax), and the legacy Peri-LOE category (Vfend and Zyvox) to the Hospital category to conform 2018 and 2017 product revenues to the current presentation. Hospital also includes Pfizer CentreOne</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span><span style="font-family:Arial;font-size:7pt;">. All other Hospital primarily includes revenues from legacy SIP products (that are not anti-infective products) and, to a much lesser extent, solid oral dose products (that are not anti-infective products). SIP anti-infective products that are not individually listed above are recorded in &#8220;All other Anti-infectives&#8221;.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2018 and 2017 revenues for Medrol and Zithromax may not agree to previously disclosed revenues because revenues for those products were previously split between LEP and the legacy SIP categories. All revenues for these products are currently reported in the Hospital category.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Pfizer CentreOne includes revenues from our contract manufacturing and active pharmaceutical ingredient sales operation, including sterile injectables contract manufacturing, and revenues related to our manufacturing and supply agreements, including with Zoetis Inc. In the fourth quarter of 2017, we sold our equity share in Hisun Pfizer. As a result, effective in the first quarter of 2018, Hisun Pfizer-related revenues, previously reported in emerging markets within legacy All Other LEP and legacy All Other SIP, are reported in emerging markets within Pfizer CentreOne.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We reclassified Inflectra/Remsima from the legacy Biosimilars category to the Inflammation &amp; Immunology category to conform 2018 and 2017 product revenues to the current presentation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(h)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">On July 31, 2019, Pfizer&#8217;s Consumer Healthcare business, an over-the-counter medicines business, was combined with GSK&#8217;s consumer healthcare business to form a new consumer healthcare joint venture. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(i)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Represents HIS revenues through February 2, 2017, which includes Medication Management Systems products composed of infusion pumps and related software and services, as well as IV Infusion Products, including large volume IV solutions and their associated administration sets. On February 3, 2017, we completed the sale of HIS to ICU Medical. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1A </span><span style="font-family:Arial;font-size:7pt;">and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(j)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Sterile Injectable Pharmaceuticals represents the total of all branded and generic injectable products in the Hospital business, including anti-infective sterile injectable pharmaceuticals.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reconciliation Of Depreciation And Amortization From Segments To Consolidated [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ReconciliationOfDepreciationAndAmortizationFromSegmentsToConsolidatedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph b<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of profit (loss) from reportable segments to the consolidated income (loss) before income tax expense (benefit) and discontinued operations. Includes, but is not limited to, reconciliation after income tax if income tax is allocated to the reportable segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfOperatingProfitLossFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of all significant reconciling items in the reconciliation of total revenues from reportable segments to the entity's consolidated revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8924-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfRevenueFromSegmentsToConsolidatedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of revenue from external customers by geographic areas attributed to the entity's country of domicile and to foreign countries from which the entity derives revenue.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 41<br> -Subparagraph a<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9038-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromExternalCustomersByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of entity-wide revenues from external customers for each product or service or each group of similar products or services if the information is not provided as part of the reportable operating segment information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 40<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e9031-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEntityWideInformationRevenueFromExternalCustomersByProductsAndServicesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>141
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7004867296">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - ROU Assets and Liabilities Presented in Balance Sheet (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="nump">$ 1,313<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities (short-term)</a></td>
<td class="nump">276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities (long-term)</a></td>
<td class="nump">$ 1,048<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>142
<FILENAME>R150.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952693680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Data Related to All Stock Option Activity (Detail) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per stock option (in dollars per share)</a></td>
<td class="nump">$ 5.98<span></span>
</td>
<td class="nump">$ 5.06<span></span>
</td>
<td class="nump">$ 4.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value on exercise</a></td>
<td class="nump">$ 261<span></span>
</td>
<td class="nump">$ 625<span></span>
</td>
<td class="nump">$ 331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Cash received upon exercise</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions', window );">Tax benefits realized related to exercise</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="nump">95<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost related to nonvested stock options not yet recognized, pre-tax</a></td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which stock option compensation cost is expected to be recognized (years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">9 months 18 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromExerciseOfStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>143
<FILENAME>R158.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7041126976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Geographic Area (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 51,750<span></span>
</td>
<td class="nump">$ 53,647<span></span>
</td>
<td class="nump">$ 52,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">23,852<span></span>
</td>
<td class="nump">25,329<span></span>
</td>
<td class="nump">26,026<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">8,701<span></span>
</td>
<td class="nump">9,116<span></span>
</td>
<td class="nump">8,508<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember', window );">Developed Rest Of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,465<span></span>
</td>
<td class="nump">6,551<span></span>
</td>
<td class="nump">6,612<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 12,733<span></span>
</td>
<td class="nump">$ 12,651<span></span>
</td>
<td class="nump">$ 11,399<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>144
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036715936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Summarized Financial Information of Equity Method Investee (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">2 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,505<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets', window );">Noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">38,575<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46,081<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities', window );">Noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,536<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,776<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital', window );">Equity/(deficit) attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35,199<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">105<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity', window );">Total net equity</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,304<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue', window );">Net Sales</a></td>
<td class="nump">$ 2,161<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales', window );">Cost of sales</a></td>
<td class="num">(803)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss', window );">Gross profit</a></td>
<td class="nump">1,358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems', window );">Income from continuing operations</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss', window );">Net income</a></td>
<td class="nump">152<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders', window );">Income attributable to shareholders</a></td>
<td class="nump">$ 148<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV Healthcare Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets', window );">Current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,839<span></span>
</td>
<td class="nump">$ 3,381<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets', window );">Noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,437<span></span>
</td>
<td class="nump">3,664<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets', window );">Total assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,276<span></span>
</td>
<td class="nump">7,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities', window );">Current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,904<span></span>
</td>
<td class="nump">2,725<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities', window );">Noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,860<span></span>
</td>
<td class="nump">6,636<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities', window );">Total liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,765<span></span>
</td>
<td class="nump">9,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital', window );">Equity/(deficit) attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,489)<span></span>
</td>
<td class="num">(2,316)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract', window );"><strong>Equity Method Investment, Summarized Financial Information, Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue', window );">Net Sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,139<span></span>
</td>
<td class="nump">6,219<span></span>
</td>
<td class="nump">$ 5,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales', window );">Cost of sales</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(516)<span></span>
</td>
<td class="num">(462)<span></span>
</td>
<td class="num">(381)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss', window );">Gross profit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,623<span></span>
</td>
<td class="nump">5,757<span></span>
</td>
<td class="nump">5,123<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems', window );">Income from continuing operations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss', window );">Net income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">2,154<span></span>
</td>
<td class="nump">1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders', window );">Income attributable to shareholders</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,398<span></span>
</td>
<td class="nump">$ 2,154<span></span>
</td>
<td class="nump">$ 1,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Summarized Financial Information, Balance Sheet [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentSummarizedFinancialInformationBalanceSheetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Method Investment, Summarized Financial Information, Net Income (Loss) Attributable To Shareholders</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLossAttributableToShareholders</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of the cost of sales reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of current liabilities reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity, including noncontrolling interest, reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.g)<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity, excluding noncontrolling interest, attributable to the equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationEquityOrCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of gross profit (loss) reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationGrossProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations reported by an equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeLossFromContinuingOperationsBeforeExtraordinaryItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationIncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity attributable to noncontrolling interests of an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationMinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent assets reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of noncurrent liabilities reported by an equity method investment of the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33912-111571<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=75031198&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue from sale of product and rendering of service reported by equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentSummarizedFinancialInformationRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>145
<FILENAME>R143.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952951920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Data Related to All Portfolio Performance Shares Activity (Details) - Portfolio Performance Shares [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested</a></td>
<td class="nump">$ 136<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
<td class="nump">$ 131<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to nonvested awards not yet recognized, pre-tax</a></td>
<td class="nump">$ 87<span></span>
</td>
<td class="nump">$ 102<span></span>
</td>
<td class="nump">$ 94<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which nonvested award cost is expected to be recognized (years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>146
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036264240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Medivation, Inc. (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">15 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 28, 2016</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,861<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,653<span></span>
</td>
<td class="nump">53,411<span></span>
</td>
<td class="nump">55,952<span></span>
</td>
<td class="nump">$ 55,952<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Assumed contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">711<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember', window );">Medivation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share)</a></td>
<td class="nump">$ 81.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, cash portion</a></td>
<td class="nump">$ 14,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="nump">13,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationConsiderationTransferredAmountPayable', window );">Acquisition consideration, amount payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 365<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">12,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">6,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Assumed contingent consideration</a></td>
<td class="nump">259<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities', window );">Contingent consideration paid</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 51<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles', window );">Reduction in identifiable intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets', window );">Decrease in amortization of intangible assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Medivation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired intangible assets, useful life</a></td>
<td class="text">12 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Medivation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationConsiderationTransferredAmountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Consideration Transferred, Amount Payable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationConsiderationTransferredAmountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combination, Provisional Information, Initial Accounting Incomplete, Adjustment, Increase (Decrease) in Amortization of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIncreaseDecreaseinAmortizationofIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116859824&amp;loc=d3e6819-128478<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents the amount of any measurement period adjustment (as defined) realized during the reporting period to intangibles acquired in connection with a business combination for which the initial accounting was incomplete.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=SL65897772-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationProvisionalInformationInitialAccountingIncompleteAdjustmentIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow, made soon after acquisition date of business combination, to settle contingent consideration liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentForContingentConsiderationLiabilityInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_MedivationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>147
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040021216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Future Minimum Rental Commitments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths', window );">Next one year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo', window );">1-2 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree', window );">2-3 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">220<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour', window );">3-4 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">180<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive', window );">4-5 years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive', window );">Thereafter</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total undiscounted lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,530<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: Imputed interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of minimum lease payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,324<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Less: Current portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Operating leases, rent expense, net</a></td>
<td class="nump">$ 301<span></span>
</td>
<td class="nump">$ 314<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract', window );"><strong>Operating Leases, Future Minimum Payments Due, Fiscal Year Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">252<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">210<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="nump">248<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">After 2023</a></td>
<td class="nump">$ 2,040<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=pfe_OfficeBuildingInNewYorkCityMember', window );">Office Building In New York City [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract', window );"><strong>Lessee, Operating Lease, Liability, Payment, Due, Rolling Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Term of corporate headquarters lease agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">20 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Future minimum commitment for corporate headquarters lease</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due after fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fifth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in fourth rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in third rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in second rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueInRollingYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments for operating lease, due in next rolling twelve months following latest statement of financial position date. For interim and annual periods when interim periods are reported on a rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextRollingTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueRollingMaturityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=pfe_OfficeBuildingInNewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=pfe_OfficeBuildingInNewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>148
<FILENAME>R147.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7037823216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Stock Option Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="nump">1,181,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award vesting period</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term (years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod', window );">Holding period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions', window );">Exercise period in the event of a divestiture or restructuring</a></td>
<td class="text">3 months<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_TitleOfIndividualAxis=srt_ManagementMember', window );">Management [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted, shares</a></td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exercise period for options held by employees in the event of a divestiture or restructuring.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExercisePeriodSpecialConditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The required period of time for holding award before any vesting occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardHoldingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_ManagementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_ManagementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>149
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7008349440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Reconciliation of Unrecognized Tax Benefits, Excluding Amounts Pertaining to Examined Tax Returns [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, beginning</a></td>
<td class="num">$ (6,259)<span></span>
</td>
<td class="num">$ (6,558)<span></span>
</td>
<td class="num">$ (5,826)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition', window );">Acquisitions</a></td>
<td class="num">(44)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition', window );">Acquisitions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions', window );">Increases based on tax positions taken during a prior period</a></td>
<td class="num">(36)<span></span>
</td>
<td class="num">(192)<span></span>
</td>
<td class="num">(49)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Decreases based on tax positions taken during a prior period</a></td>
<td class="nump">1,109<span></span>
</td>
<td class="nump">561<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Decreases based on settlements for a prior period</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">123<span></span>
</td>
<td class="nump">35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases based on tax positions taken during the current period</a></td>
<td class="num">(383)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
<td class="num">(753)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation', window );">Impact of foreign exchange</a></td>
<td class="nump">25<span></span>
</td>
<td class="nump">56<span></span>
</td>
<td class="num">(121)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther', window );">Other, net</a></td>
<td class="nump">107<span></span>
</td>
<td class="nump">121<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Balance, ending</a></td>
<td class="num">$ (5,381)<span></span>
</td>
<td class="num">$ (6,259)<span></span>
</td>
<td class="num">$ (6,558)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Increase (Decrease) Resulting from Foreign Currency Translation</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsIncreaseDecreaseResultingfromForeignCurrencyTranslation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Period Increase (Decrease), Other</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsPeriodIncreaseDecreaseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=SL37586934-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from acquisitions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromAcquisition</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>150
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7041674192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes - Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">$ 2,770<span></span>
</td>
<td class="nump">$ 3,100<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">131<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Multi-Antigen Vaccine For Spinal Fusion Surgery [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">117<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AMPharmaBVMember', window );">AM Pharma BV [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount', window );">Impairment of investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">2,639<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Hospira [Member] | Sterile Injectable Pain Reliever [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Hospira [Member] | Generic Injectable Pain Reliever [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | NextWave [Member] | Treatment Of Attention Hyperactivity Disorder [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Biopharma Segment [Member] | Anacor [Member] | Eucrisa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Biopharma Segment [Member] | Anacor [Member] | Treatment For Toenail Fungus [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Operating Segments [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Operating Segments [Member] | Biopharma Segment [Member] | Anacor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Operating Segments [Member] | Biopharma Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | Operating Segments [Member] | Biopharma Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">242<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | InnoPharma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">10<span></span>
</td>
<td class="nump">17<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Biopharma Segment [Member] | AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Operating Segments [Member] | Biopharma Segment [Member] | Hospira [Member] | Generic Sterile Injectable Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">Pfizer's Worldwide Research, Development And Medical [Member] | In Process Research and Development [Member] | Gene Therapies [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill', window );">Intangible asset impairments</a></td>
<td class="nump">$ 90<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Intangible Assets [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative impairment loss on investment in equity security without readily determinable fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117539-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesWithoutReadilyDeterminableFairValueImpairmentLossCumulativeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of an intangible asset (excluding goodwill) to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MultiAntigenVaccineForSpinalFusionSurgeryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AMPharmaBVMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AMPharmaBVMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GenericSterileInjectableProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GenericSterileInjectableProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SterileInjectablePainRelieverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SterileInjectablePainRelieverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GenericInjectablePainRelieverMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GenericInjectablePainRelieverMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_NextWaveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_NextWaveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TreatmentOfAttentionHyperactivityDisorderMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TreatmentOfAttentionHyperactivityDisorderMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_AnacorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EucrisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EucrisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TreatmentForToenailFungusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TreatmentForToenailFungusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_InnoPharmaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_InnoPharmaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GeneTherapiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GeneTherapiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>151
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039477632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Provision for Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (1,641)<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
<td class="nump">$ 1,267<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="num">(166)<span></span>
</td>
<td class="nump">9<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred income taxes:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">1,258<span></span>
</td>
<td class="num">(1,663)<span></span>
</td>
<td class="num">(2,064)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="num">(304)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations', window );">Total U.S. tax benefit</a></td>
<td class="num">(274)<span></span>
</td>
<td class="num">(970)<span></span>
</td>
<td class="num">(1,055)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EffectofTaxCutsandJobsActAbstract', window );"><strong>TCJA</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit', window );">Current income taxes</a></td>
<td class="num">(135)<span></span>
</td>
<td class="num">(3,035)<span></span>
</td>
<td class="nump">13,135<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit', window );">Deferred Income taxes</a></td>
<td class="num">(187)<span></span>
</td>
<td class="nump">2,439<span></span>
</td>
<td class="num">(23,795)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit', window );">Total TCJA tax benefit</a></td>
<td class="num">(323)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
<td class="num">(10,660)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InternationalIncomeTaxesAbstract', window );"><strong>International</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CurrentForeignTaxExpenseBenefit', window );">Current income taxes</a></td>
<td class="nump">2,900<span></span>
</td>
<td class="nump">2,831<span></span>
</td>
<td class="nump">2,709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit', window );">Deferred income taxes</a></td>
<td class="num">(919)<span></span>
</td>
<td class="num">(558)<span></span>
</td>
<td class="num">(42)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations', window );">Total international tax provision</a></td>
<td class="nump">1,981<span></span>
</td>
<td class="nump">2,273<span></span>
</td>
<td class="nump">2,667<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Provision/(benefit) for taxes on income</a></td>
<td class="nump">$ 1,384<span></span>
</td>
<td class="nump">$ 706<span></span>
</td>
<td class="num">$ (9,049)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Domestic Income Tax Expense (Benefit), Continued Operations</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DomesticIncomeTaxExpenseBenefitContinuedOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EffectofTaxCutsandJobsActAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Effect of Tax Cuts and Jobs Act [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EffectofTaxCutsandJobsActAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InternationalIncomeTaxesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>International Income Taxes [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InternationalIncomeTaxesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Current Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax Cuts and Jobs Act of 2017, Deferred Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_TaxCutsandJobsActof2017DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentForeignTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentForeignTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredForeignIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred foreign income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredForeignIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current and deferred foreign income tax expense (benefit) attributable to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignIncomeTaxExpenseBenefitContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109238882&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>152
<FILENAME>R160.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7041212448">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Long-Lived Assets By Geographic Region (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 13,967<span></span>
</td>
<td class="nump">$ 13,385<span></span>
</td>
<td class="nump">$ 13,865<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">7,606<span></span>
</td>
<td class="nump">7,089<span></span>
</td>
<td class="nump">6,971<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember', window );">Developed Europe [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">4,304<span></span>
</td>
<td class="nump">4,204<span></span>
</td>
<td class="nump">4,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember', window );">Developed Rest Of World [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">490<span></span>
</td>
<td class="nump">632<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember', window );">Emerging Markets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems', window );"><strong>Revenues from External Customers and Long-Lived Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, net</a></td>
<td class="nump">$ 1,603<span></span>
</td>
<td class="nump">$ 1,602<span></span>
</td>
<td class="nump">$ 1,917<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedEuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_DevelopedRestOfWorldMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=pfe_EmergingMarketsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=pfe_EmergingMarketsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>153
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7189784048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests - Footnotes (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest', window );">Foreign currency translation income (loss) attributable to noncontrolling interests</a></td>
<td class="num">$ (11)<span></span>
</td>
<td class="num">$ (20)<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax</a></td>
<td class="nump">$ 978<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to noncontrolling interests.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>154
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953079024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests</a></td>
<td class="text">Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests<div style="line-height:100%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the changes, net of tax, in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net Unrealized Gain/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Prior Service (Costs)/ Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,659</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(131</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,473</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(11,036</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(129</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,180</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,262</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(9,321</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss) due to the adoption of new accounting standards</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(416</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(637</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(913</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(893</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(1,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,075</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,027</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>728</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(11,275</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(146</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(144</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(6,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>584</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(11,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:Arial;font-size:7pt;"><span>$11 million</span></span><span style="font-family:Arial;font-size:7pt;"> loss in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:7pt;"> loss in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$14 million</span></span><span style="font-family:Arial;font-size:7pt;"> income in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. Amounts in 2019 include after-tax gains of approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$978 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2C</span><span style="font-family:Arial;font-size:7pt;">), partially offset by the strengthening of the U.S. dollar against the euro and the Australian dollar, and the results of our net investment hedging program.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we estimate that we will reclassify into 2020 income the following pre-tax amounts currently held in</span><span style="font-family:Arial;font-size:11pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss:</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$179 million</span></span><span style="font-family:Arial;font-size:8pt;"> of unrealized pre-tax net </span><span style="font-family:Arial;font-size:8pt;">gains</span><span style="font-family:Arial;font-size:8pt;"> on derivative financial instruments (which are expected to be offset primarily by net </span><span style="font-family:Arial;font-size:8pt;">losses</span><span style="font-family:Arial;font-size:8pt;"> from foreign currency exchange-denominated forecasted intercompany inventory sales upon the sale of the inventory to a third party); </span><span style="font-family:Arial;font-size:8pt;"><span>$265 million</span></span><span style="font-family:Arial;font-size:8pt;"> of actuarial losses related to benefit plan obligations and plan assets and other benefit plan items; and </span><span style="font-family:Arial;font-size:8pt;"><span>$178 million</span></span><span style="font-family:Arial;font-size:8pt;"> of prior service credits, primarily related to benefit plan amendments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -URI http://asc.fasb.org/topic&amp;trid=2134417<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>155
<FILENAME>R101.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7035972288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Derivative Financial Instruments and Hedging Activities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="nump">$ 476<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="num">$ (10)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="nump">421<span></span>
</td>
<td class="nump">688<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">664<span></span>
</td>
<td class="num">(27)<span></span>
</td>
<td class="nump">$ 520<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeGainLossOnDerivativeNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="num">(172)<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember', window );">Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="num">(1)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">808<span></span>
</td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="nump">339<span></span>
</td>
<td class="nump">80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="num">(313)<span></span>
</td>
<td class="nump">175<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged Item</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(5)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">525<span></span>
</td>
<td class="num">(182)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gains/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Interest rate contracts [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="nump">900<span></span>
</td>
<td class="num">(348)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1', window );">Hedged Item</a></td>
<td class="num">(900)<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="nump">34<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency short-term borrowings [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax', window );">Amount of Gains/(Losses) Recognized in OCI</a></td>
<td class="nump">36<span></span>
</td>
<td class="nump">149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Foreign currency long-term debt [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax', window );">Amount of Gain/(Losses) Reclassified from OCI into OID and COS</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="nump">136<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Cash Flow Hedging [Member] | Foreign exchange contracts [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="nump">140<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign exchange contracts [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="nump">188<span></span>
</td>
<td class="nump">77<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member] | Net Investment Hedging [Member] | Foreign exchange contracts [Member] | Other (Income) Deductions And Cost Of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax', window );">Amount excluded from effectiveness testing</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">68<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember', window );">Not Designated as Hedging Instrument [Member] | Foreign exchange contracts [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsGainLossLineItems', window );"><strong>Derivative Instruments, Gain (Loss) [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet', window );">Amount of Gains/(Losses) Recognized in OID</a></td>
<td class="num">$ (172)<span></span>
</td>
<td class="nump">$ 136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivative Net Investment Hedge, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativeNetInvestmentHedgeGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Gain (Loss), Before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), Reclassification, Before Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Comprehensive Income (Loss), Non-Derivatives And Derivatives, Other, Gain (Loss), before Reclassification and Tax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherComprehensiveIncomeLossNonDerivativesAndDerivativesOtherGainLossbeforeReclassificationandTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from the increase (decrease) in fair value of derivative and nonderivative instruments designated as fair value hedging instruments recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnFairValueHedgingInstruments1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the increase (decrease) in fair value of the hedged item in a fair value hedge recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 25<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109977999&amp;loc=d3e76258-113986<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInUnrealizedGainLossOnHedgedItemInFairValueHedge1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeGainLossOnDerivativeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the fair value of derivatives recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeGainLossOnDerivativeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized and unrealized gain (loss) of derivative instruments not designated or qualifying as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CC<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998890-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsNotDesignatedAsHedgingInstrumentsGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative instrument designated and qualifying cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification of gain (loss) from accumulated other comprehensive income (AOCI) for derivative instrument designated and qualifying as cash flow hedge included in assessment of hedge effectiveness.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossCashFlowHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of adjustments from accumulated other comprehensive income (AOCI) for gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e689-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseAdjustmentsBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and adjustments, of gain (loss) from increase (decrease) in value of excluded component of derivative designated and qualifying as hedge. Adjustments include, but are not limited to, reclassifications for sale and settlement, and amounts recognized under systematic and rational method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (dd)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109974929&amp;loc=SL110061190-113977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossDerivativeExcludedComponentIncreaseDecreaseBeforeAdjustmentsAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax and reclassification, of gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossBeforeReclassificationAndTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of reclassification from accumulated other comprehensive income (AOCI) for gain (loss) from derivative designated and qualifying as net investment hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4CCC<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL109998896-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetInvestmentHedgeGainLossReclassificationBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeDeductionsAndCostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyShortTermBorrowingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=pfe_ForeignCurrencyLongTermDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_CashFlowHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsGainLossByHedgingRelationshipAxis=us-gaap_NetInvestmentHedgingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>157
<FILENAME>R105.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036748400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Credit Risk (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_FinancialServicesSectorMember', window );">Bank sector [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure', window );">Maximum exposure, amount</a></td>
<td class="nump">$ 1.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount of loss due to credit risk that, based on the gross fair value of the financial instrument, the entity would incur if parties to the financial instruments that make up the concentration failed completely to perform according to the terms of the contracts and the collateral or other security, if any, for the amount due proved to be of no value to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRiskFinancialInstrumentMaximumExposure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_FinancialServicesSectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesByIndustryAxis=us-gaap_FinancialServicesSectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>158
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952866592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract', window );"><strong>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock', window );">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements, and Research and Development and Collaborative Arrangements</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Acquisitions</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Array BioPharma Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">July&#160;30, 2019</span><span style="font-family:Arial;font-size:8pt;">, we acquired Array, a commercial stage biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule medicines to treat cancer and other diseases of high unmet need, for </span><span style="font-family:Arial;font-size:8pt;"><span>$48</span></span><span style="font-family:Arial;font-size:8pt;"> per share in cash. The total fair value of the consideration transferred for Array was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$11.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$10.9 billion</span></span><span style="font-family:Arial;font-size:8pt;">, net of cash acquired). In addition, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$157 million</span></span><span style="font-family:Arial;font-size:8pt;"> in payments to Array employees for the fair value of previously unvested stock options was recognized as post-closing compensation expense and recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs </span><span style="font-family:Arial;font-size:8pt;">in the consolidated statement of income in the third quarter of 2019</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:8pt;">). We financed the majority of the transaction with debt and the balance with existing cash. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Array&#8217;s portfolio includes the approved combined use of Braftovi (encorafenib) and Mektovi (binimetinib) for the treatment of BRAF</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600E</sup></span><span style="font-family:Arial;font-size:8pt;">- or BRAF</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">V600K</sup></span><span style="font-family:Arial;font-size:8pt;">-mutant unresectable or metastatic melanoma. The combination therapy has significant potential for long-term growth via expansion into additional areas of unmet need and is currently being investigated in over 30 clinical trials across several solid tumor indications, including in BRAF-mutant mCRC, through collaborations with third parties. In December 2019, the FDA accepted and granted priority review to our supplemental new drug application for Braftovi in combination with Erbitux (cetuximab) (Braftovi Doublet) in BRAF-mutant mCRC. Pfizer has exclusive rights to commercialize Braftovi and Mektovi in the U.S. and Canada. In addition to the combination therapy for BRAF-mutant metastatic melanoma, Array brings a broad pipeline of targeted cancer medicines in different stages of R&amp;D, as well as a portfolio of out-licensed medicines, which may generate milestones and royalties over time.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with this acquisition, we provisionally recorded: (i) </span><span style="font-family:Arial;font-size:8pt;"><span>$7.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">, consisting of </span><span style="font-family:Arial;font-size:8pt;"><span>$1.8 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"> with a useful life of </span><span style="font-family:Arial;font-size:8pt;"><span>16 years</span></span><span style="font-family:Arial;font-size:8pt;color:#0000ff;">,</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$4.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">IPR&amp;D </span><span style="font-family:Arial;font-size:8pt;">and </span><span style="font-family:Arial;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Licensing agreements </span><span style="font-family:Arial;font-size:8pt;">(</span><span style="font-family:Arial;font-size:8pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> for technology in development</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">indefinite-lived licensing agreements and </span><span style="font-family:Arial;font-size:8pt;"><span>$340 million</span></span><span style="font-family:Arial;font-size:8pt;"> for developed technology</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">finite-lived licensing agreements with a useful life of </span><span style="font-family:Arial;font-size:8pt;"><span>10 years</span></span><span style="font-family:Arial;font-size:8pt;">), (ii) </span><span style="font-family:Arial;font-size:8pt;"><span>$5.4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;">, (iii) </span><span style="font-family:Arial;font-size:8pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of net deferred tax liabilities and (iv) </span><span style="font-family:Arial;font-size:8pt;"><span>$451 million</span></span><span style="font-family:Arial;font-size:8pt;"> of assumed long-term debt, which was paid in full in the third quarter of 2019. The allocation of the consideration transferred to the assets acquired and the liabilities assumed has not yet been finalized.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Therachon Holding AG</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On July 1, 2019, we acquired all the remaining shares of Therachon, a privately-held clinical-stage biotechnology company focused on rare diseases, with assets in development for the treatment of achondroplasia, a genetic condition and the most common form of short-limb dwarfism, for </span><span style="font-family:Arial;font-size:8pt;"><span>$340 million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront, plus potential milestone payments of up to </span><span style="font-family:Arial;font-size:8pt;"><span>$470 million</span></span><span style="font-family:Arial;font-size:8pt;"> contingent on the achievement of key milestones in the development and commercialization of the lead asset. In 2018, we acquired approximately </span><span style="font-family:Arial;font-size:8pt;"><span>3%</span></span><span style="font-family:Arial;font-size:8pt;"> of Therachon&#8217;s outstanding shares for </span><span style="font-family:Arial;font-size:8pt;"><span>$5 million</span></span><span style="font-family:Arial;font-size:8pt;">. We accounted for the transaction as an asset acquisition since the lead asset represented substantially all the fair value of the gross assets acquired. The total fair value of the consideration transferred for Therachon was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$322 million</span></span><span style="font-family:Arial;font-size:8pt;">, which consisted of </span><span style="font-family:Arial;font-size:8pt;"><span>$317 million</span></span><span style="font-family:Arial;font-size:8pt;"> of cash and our previous </span><span style="font-family:Arial;font-size:8pt;"><span>$5 million</span></span><span style="font-family:Arial;font-size:8pt;"> investment in Therachon. Therachon is a wholly-owned subsidiary of Pfizer. In connection with this asset acquisition, we recorded a charge of </span><span style="font-family:Arial;font-size:8pt;"><span>$337 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">AstraZeneca&#8217;s Small Molecule Anti-Infectives Business</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On December 22, 2016, which fell in the first fiscal quarter of 2017 for our international operations, we acquired the development and commercialization rights to AstraZeneca&#8217;s small molecule anti-infectives business, primarily outside the U.S., including the commercialization and development rights to the marketed products Zavicefta&#8482; (ceftazidime-avibactam), Merrem&#8482;/Meronem&#8482; (meropenem) and Zinforo&#8482;&#160;(ceftaroline fosamil), and the clinical development assets ATM-AVI and CXL (ceftaroline fosamil-AVI). In 2017, under the terms of the agreement, we made payments of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$605 million</span></span><span style="font-family:Arial;font-size:8pt;"> to AstraZeneca related to the transaction. We made an additional milestone payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$125 million</span></span><span style="font-family:Arial;font-size:8pt;"> in our first fiscal quarter of 2018, we made a deferred payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$175 million</span></span><span style="font-family:Arial;font-size:8pt;"> to AstraZeneca in January 2019, and we made an additional milestone payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:8pt;"> in our third fiscal quarter of 2019. We may make payments of up to </span><span style="font-family:Arial;font-size:8pt;"><span>$600 million</span></span><span style="font-family:Arial;font-size:8pt;"> to AstraZeneca if sales of Zavicefta&#8482; exceed certain thresholds prior to January 1, 2026, as well as tiered royalties on sales of Zavicefta&#8482; and ATM-AVI in certain markets for a period ending on the later of 10 years from first commercial sale or the loss of patent protection or loss of regulatory exclusivity. The total royalty payments are unlimited during the royalty term and the undiscounted payments are expected to be in the range of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$315 million</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span>$542 million</span></span><span style="font-family:Arial;font-size:8pt;">. The total fair value of consideration transferred for AstraZeneca&#8217;s small molecule anti-infectives business was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> inclusive of cash paid of </span><span style="font-family:Arial;font-size:8pt;"><span>$555 million</span></span><span style="font-family:Arial;font-size:8pt;"> and the fair value of contingent consideration of </span><span style="font-family:Arial;font-size:8pt;"><span>$485 million</span></span><span style="font-family:Arial;font-size:8pt;"> (which is composed of the fair values of the deferred payment, the </span><span style="font-family:Arial;font-size:8pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment made in the second quarter of 2017, the </span><span style="font-family:Arial;font-size:8pt;"><span>$125 million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment made in our first fiscal quarter of 2018, the </span><span style="font-family:Arial;font-size:8pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment made in the third quarter of 2019, and the future expected milestone and royalty payments). In connection with this acquisition, we recorded </span><span style="font-family:Arial;font-size:8pt;"><span>$894 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">, consisting of </span><span style="font-family:Arial;font-size:8pt;"><span>$728 million</span></span><span style="font-family:Arial;font-size:8pt;"> in</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$166 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">IPR&amp;D</span><span style="font-family:Arial;font-size:8pt;">. We also recorded </span><span style="font-family:Arial;font-size:8pt;"><span>$92 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current assets</span><span style="font-family:Arial;font-size:8pt;"> related to the economic value of inventory which was retained by AstraZeneca for sale on our behalf, </span><span style="font-family:Arial;font-size:8pt;"><span>$73 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$19 million</span></span><span style="font-family:Arial;font-size:8pt;"> of net deferred tax liabilities. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Medivation, Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On September 28, 2016, we acquired Medivation for </span><span style="font-family:Arial;font-size:8pt;"><span>$81.50</span></span><span style="font-family:Arial;font-size:8pt;"> per share. The total fair value of consideration transferred for Medivation was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$14.3 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in cash (</span><span style="font-family:Arial;font-size:8pt;"><span>$13.9 billion</span></span><span style="font-family:Arial;font-size:8pt;">, net of cash acquired). Of this consideration, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$365 million</span></span><span style="font-family:Arial;font-size:8pt;"> was not paid as of December 31, 2016, and was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities.</span><span style="font-family:Arial;font-size:8pt;"> The remaining consideration was paid as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2017</span><span style="font-family:Arial;font-size:8pt;">. Medivation is a wholly-owned subsidiary of Pfizer. Medivation is focused on developing and commercializing small molecules for oncology. Medivation&#8217;s portfolio includes Xtandi (enzalutamide). Xtandi is FDA-approved for the treatment of non-metastatic and metastatic castration-resistant </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">prostate cancer as well as metastatic castration sensitive prostate cancer. Xtandi is being developed and commercialized through a collaboration with Astellas. Astellas has exclusive commercialization rights for Xtandi outside the U.S. The Medivation portfolio also includes talazoparib, which was approved by the FDA in October 2018, under the trade name Talzenna, for the treatment of adults with germline BRCA-mutated HER2-negative locally advanced or metastatic breast cancer and is currently in development for other types of cancer. In connection with this acquisition, we recorded </span><span style="font-family:Arial;font-size:8pt;"><span>$12.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">, primarily consisting of </span><span style="font-family:Arial;font-size:8pt;"><span>$8.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"> with an average useful life of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>12</span></span><span style="font-family:Arial;font-size:8pt;"> years and </span><span style="font-family:Arial;font-size:8pt;"><span>$4.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">IPR&amp;D, </span><span style="font-family:Arial;font-size:8pt;">and recorded </span><span style="font-family:Arial;font-size:8pt;"><span>$6.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Goodwill,</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$4.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of net income tax liabilities, and </span><span style="font-family:Arial;font-size:8pt;"><span>$259 million</span></span><span style="font-family:Arial;font-size:8pt;"> of assumed contingent consideration of which </span><span style="font-family:Arial;font-size:8pt;"><span>$51 million</span></span><span style="font-family:Arial;font-size:8pt;"> has been paid through December 31, 2019. In 2017 and 2016, we recorded measurement period adjustments to the estimated fair values initially recorded in 2016, which resulted in a reduction in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;"> of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> with a corresponding change to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;"> and net income tax liabilities. The measurement period adjustments were recorded to better reflect market participant assumptions about facts and circumstances existing as of the acquisition date. The 2017 results included a decrease of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$38 million</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:8pt;"> which reflected the cumulative pre-tax impact of the measurement period adjustments to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;"> that were amortized to the income statement since the acquisition date. The measurement period adjustments did not result from intervening events subsequent to the acquisition date. The final allocation of the consideration transferred to the assets acquired and the liabilities assumed has been completed.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Divestitures</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Sale of Hospira Infusion Systems Net Assets to ICU Medical, Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On October 6, 2016, we announced that we entered into a definitive agreement under which ICU Medical, a global device manufacturer, agreed to acquire all of our global infusion systems net assets, HIS, for approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in cash and ICU Medical common stock. HIS includes IV pumps, solutions, and devices. As a result of the performance of HIS relative to ICU Medical&#8217;s expectations, on January 5, 2017 we entered into a revised agreement with ICU Medical under which ICU Medical would acquire HIS for up to approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$900 million</span></span><span style="font-family:Arial;font-size:8pt;">, composed of cash and contingent cash consideration, ICU Medical common stock and seller financing. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The revised transaction closed on February 3, 2017. At closing, we received </span><span style="font-family:Arial;font-size:8pt;"><span>3.2 million</span></span><span style="font-family:Arial;font-size:8pt;"> newly issued shares of ICU Medical common stock (as originally agreed), which we initially valued at approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$428 million</span></span><span style="font-family:Arial;font-size:8pt;"> (based upon the closing price of ICU Medical common stock on the closing date less a discount for lack of marketability) and which were reported as equity securities at fair value in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span><span style="font-family:Arial;font-size:8pt;"> on the consolidated balance sheet as of December 31, 2017. Upon the sale of these shares in 2018, we realized a full gain of </span><span style="font-family:Arial;font-size:8pt;"><span>$302 million</span></span><span style="font-family:Arial;font-size:8pt;"> on these securities, although our income statement only reflects a gain of </span><span style="font-family:Arial;font-size:8pt;"><span>$47 million</span></span><span style="font-family:Arial;font-size:8pt;"> as the balance of the previously unrealized gain was recorded as a cumulative effect adjustment upon the adoption of a new accounting standard. We also received a promissory note in the amount of </span><span style="font-family:Arial;font-size:8pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:8pt;">, which was repaid in full as of December 31, 2017, and net cash of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:8pt;"> before customary adjustments for net working capital, which was reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other investing activities, net</span><span style="font-family:Arial;font-size:8pt;"> on the consolidated statement of cash flows for the year-ended December 31, 2017. In addition, we are entitled to receive a contingent amount of up to an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$225 million</span></span><span style="font-family:Arial;font-size:8pt;"> in cash based on ICU Medical&#8217;s achievement of certain cumulative performance targets for the combined company through December 31, 2019. The amount of contingent payment we will receive, if any, will be determined during the first half of 2020. We recognized a pre-tax gain of </span><span style="font-family:Arial;font-size:8pt;"><span>$1 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and a pre-tax loss of </span><span style="font-family:Arial;font-size:8pt;"><span>$55 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net, </span><span style="font-family:Arial;font-size:8pt;">representing adjustments to amounts previously recorded in 2016 to write down the HIS net assets to fair value less costs to sell. </span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The sale of the HIS net assets was fully completed in all jurisdictions as of year-end 2018.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with the sale transaction, we entered into certain transitional agreements designed to facilitate the orderly transition of the HIS net assets to ICU Medical. These agreements primarily related to administrative services, and were provided for a period of 24 months after the closing date. We will also manufacture and supply certain HIS products for ICU Medical and ICU Medical will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of five years. These agreements are not material to Pfizer and none confers upon us the ability to influence the operating and/or financial policies of ICU Medical subsequent to the sale.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Contribution Agreement Between Pfizer and Allogene Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, Pfizer and Allogene announced that the two companies entered into a contribution agreement for Pfizer&#8217;s portfolio of assets related to allogeneic CAR T therapy, an investigational immune cell therapy approach to treating cancer. Under this agreement, Allogene received from Pfizer rights to pre-clinical and clinical CAR T assets, all of which were previously licensed to Pfizer from French cell therapy company, Cellectis, beginning in 2014 and French pharmaceutical company, Servier, beginning in 2015. Allogene assumed responsibility for all potential financial obligations to both Cellectis and Servier. Pfizer continues to participate financially in the development of the CAR T portfolio through an ownership stake in Allogene. Separately, Pfizer continues to maintain its approximate </span><span style="font-family:Arial;font-size:8pt;"><span>7%</span></span><span style="font-family:Arial;font-size:8pt;"> ownership stake in Cellectis that was obtained in 2014 as part of the licensing agreement in which Pfizer obtained exclusive rights to pursue the development and commercialization of certain Cellectis CAR T therapies in exchange for an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$80 million</span></span><span style="font-family:Arial;font-size:8pt;">, as well as potential future development, regulatory and commercial milestone payments and royalties. In connection with the Allogene transaction, Pfizer recognized a non-cash </span><span style="font-family:Arial;font-size:8pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:8pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">in the second quarter of 2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">,</span><span style="font-family:Arial;font-size:8pt;"> representing the difference between the </span><span style="font-family:Arial;font-size:8pt;"><span>$127 million</span></span><span style="font-family:Arial;font-size:8pt;"> fair value of the equity investment received and the book value of assets transferred (including an allocation of goodwill) (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2018, Allogene consummated an initial public offering of new shares of its common stock, which resulted in Pfizer&#8217;s preferred stock converting into common stock and a decrease in our ownership percentage from approximately </span><span style="font-family:Arial;font-size:8pt;"><span>25%</span></span><span style="font-family:Arial;font-size:8pt;"> to approximately </span><span style="font-family:Arial;font-size:8pt;"><span>18%</span></span><span style="font-family:Arial;font-size:8pt;"> as of December 31, 2018. The closing price on the day of the initial public offering was </span><span style="font-family:Arial;font-size:8pt;"><span>$25</span></span><span style="font-family:Arial;font-size:8pt;"> per share. Beginning as of the date of the initial public offering, our investment in Allogene is being measured at fair value with changes in fair value recognized in net income (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Sale of Phase 2b Ready AMPA Receptor Potentiator for CIAS to Biogen Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, we sold our Phase 2b ready AMPA receptor potentiator for CIAS to Biogen. We received </span><span style="font-family:Arial;font-size:8pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront and have the opportunity to receive up to </span><span style="font-family:Arial;font-size:8pt;"><span>$515 million</span></span><span style="font-family:Arial;font-size:8pt;"> in total development and commercialization milestones, as well as tiered royalties in the low-to-mid-teen percentages. We recognized the </span><span style="font-family:Arial;font-size:8pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront payment in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> in the second quarter of 2018 (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">). In the fourth quarter of 2018, we recognized an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$10 million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">4</span><span style="font-family:Arial;font-size:8pt;">).</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">We will record the other milestones and royalties to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> when due, or earlier if we have sufficient experience to determine such amounts are not probable of significant reversal.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Divestiture of Neuroscience Assets</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2018, we and Bain Capital entered into a transaction to create a new biopharmaceutical company, Cerevel, to continue development of a portfolio of clinical and preclinical stage neuroscience assets primarily targeting disorders of the central nervous system including Parkinson&#8217;s disease, epilepsy, Alzheimer&#8217;s disease, schizophrenia and addiction. These assets were part of the neuroscience discovery and early development efforts, which we announced we were ending in January 2018. In connection with this transaction, we out-licensed the portfolio to Cerevel in exchange for a </span><span style="font-family:Arial;font-size:8pt;"><span>25%</span></span><span style="font-family:Arial;font-size:8pt;"> ownership stake in Cerevel&#8217;s parent company, Cerevel Therapeutics, Inc., and potential future regulatory and commercial milestone payments and royalties. Bain Capital has committed to invest </span><span style="font-family:Arial;font-size:8pt;"><span>$350 million</span></span><span style="font-family:Arial;font-size:8pt;"> to develop the portfolio, with the potential for additional funding as the assets advance. In connection with the transaction, we recognized a non-cash </span><span style="font-family:Arial;font-size:8pt;"><span>$343 million</span></span><span style="font-family:Arial;font-size:8pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">in the third quarter of 2018, representing the fair value of the equity investment received as the assets transferred</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">had a book value of </span><span style="font-family:Arial;font-size:8pt;"><span>$0</span></span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">). Our investment in Cerevel Therapeutics, Inc. is reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments </span><span style="font-family:Arial;font-size:8pt;">on the consolidated balance sheets as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Equity-Method Investments and </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Assets and Liabilities Held for Sale</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Formation of a New Consumer Healthcare Joint Venture</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we completed the transaction in which we and GSK combined our respective consumer healthcare businesses into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name. In exchange for contributing our Consumer Healthcare business to the joint venture, we received a </span><span style="font-family:Arial;font-size:8pt;"><span>32%</span></span><span style="font-family:Arial;font-size:8pt;"> equity stake in the new company and GSK owns the remaining </span><span style="font-family:Arial;font-size:8pt;"><span>68%</span></span><span style="font-family:Arial;font-size:8pt;">. Upon the closing of the transaction, we deconsolidated our Consumer Healthcare business and recognized a pre-tax gain of </span><span style="font-family:Arial;font-size:8pt;"><span>$8.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$5.4 billion</span></span><span style="font-family:Arial;font-size:8pt;">, net of tax) in our fiscal third quarter of 2019 in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">(Gain) on completion of Consumer Healthcare JV transaction</span><span style="font-family:Arial;font-size:8pt;"> for the difference in the fair value of our </span><span style="font-family:Arial;font-size:8pt;"><span>32%</span></span><span style="font-family:Arial;font-size:8pt;"> equity stake in the new company and the carrying value of our Consumer Healthcare business. We may record additional adjustments to the gain in future periods, which we do not expect to have a material impact on our consolidated financial statements.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In valuing our investment in GSK Consumer Healthcare, we used discounted cash flow techniques. Some of the more significant estimates and assumptions inherent in this approach include: the amount and timing of the projected net cash flows, which include the expected impact of competitive, legal or regulatory forces on the products; the long-term growth rate, which seeks to project the sustainable growth rate over the long term; the discount rate, which seeks to reflect our best estimate of the various risks inherent in the projected cash flows; and the tax rate, which seeks to incorporate the geographic diversity of the projected cash flows. As part of the joint venture transaction, we agreed to indemnify GSK with respect to certain tax matters related to periods prior to closing of the transaction as well as certain potential environmental or other legal liabilities associated with the previous operation of our Consumer Healthcare business. We recognized a liability of </span><span style="font-family:Arial;font-size:8pt;"><span>$45 million</span></span><span style="font-family:Arial;font-size:8pt;"> with respect to the tax matters indemnification. The value of the environmental and legal indemnifications was not considered to be material.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are accounting for our interest in GSK Consumer Healthcare as an equity-method investment. The carrying value of our investment in GSK Consumer Healthcare is approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$17.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> and it is reported as a private equity investment in the </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Equity-method investments </span><span style="font-family:Arial;font-size:8pt;">line in our consolidated balance sheet as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. Our consolidated statement of income for 2019 includes revenues and expenses associated with Pfizer&#8217;s Consumer Healthcare business through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. We record our share of earnings from the Consumer Healthcare joint venture on a quarterly basis on a one-quarter lag in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> commencing from August 1, 2019. Therefore, we recorded our share of two months of the joint venture&#8217;s earnings generated in the third quarter of 2019 totaling </span><span style="font-family:Arial;font-size:8pt;"><span>$47 million</span></span><span style="font-family:Arial;font-size:8pt;"> in our operating results in the fourth quarter of 2019. As of the July 31, 2019 closing date, we estimated that the fair value of our investment in GSK Consumer Healthcare was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$15.7 billion</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>32%</span></span><span style="font-family:Arial;font-size:8pt;"> of the underlying equity in the carrying value of the net assets of GSK Consumer Healthcare was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$11.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> resulting in an initial basis difference of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$4.5 billion</span></span><span style="font-family:Arial;font-size:8pt;">. In the fourth quarter of 2019, we preliminarily completed the allocation of the basis difference, which resulted from the excess of the initial fair value of our investment over the underlying equity in the carrying value of the net assets of the joint venture, primarily to inventory, definite-lived intangible assets, indefinite-lived intangible assets, related deferred tax liabilities and equity method goodwill within the investment account. We recorded the amortization of basis differences allocated to inventory, definite-lived intangible assets and related deferred tax liabilities in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> commencing August 1, 2019. The amortization of these basis differences for two months of the third quarter of 2019 totaling approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$31 million</span></span><span style="font-family:Arial;font-size:8pt;"> is included in our operating results in the fourth quarter of 2019. Amortization of basis differences on inventory and related deferred tax liabilities will be completely recognized by the first quarter of 2020. Basis differences on definite-lived intangible assets and related deferred tax liabilities are being amortized over approximately </span><span style="font-family:Arial;font-size:8pt;"><span>17 years</span></span><span style="font-family:Arial;font-size:8pt;">. The increase in the value of our investment from the closing date to December 31, 2019 is primarily due to foreign currency translation adjustments (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 6</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">While we have received our full </span><span style="font-family:Arial;font-size:8pt;"><span>32%</span></span><span style="font-family:Arial;font-size:8pt;"> interest in GSK Consumer Healthcare as of the </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> closing and transferred control of our Consumer Healthcare business to GSK Consumer Healthcare, the contribution of the business was not completed in certain non-U.S. jurisdictions due to temporary regulatory or operational constraints. In these jurisdictions, we have continued to operate the business for the net economic benefit of GSK Consumer Healthcare, and we are indemnified by GSK Consumer Healthcare against risks associated with such operations during the interim period, subject to our obligations under the definitive transaction agreements. We expect the contribution of our </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Consumer Healthcare business in these jurisdictions to be fully completed by the first half of 2021. As such, and as we and GSK Consumer Healthcare are contractually obligated to complete the transaction, we have treated these jurisdictions as sold for accounting purposes.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with the contribution of our Consumer Healthcare business, we entered into certain transitional agreements designed to facilitate the orderly transition of the business to GSK Consumer Healthcare. These agreements primarily relate to administrative services, which are generally to be provided for a period of up to </span><span style="font-family:Arial;font-size:8pt;"><span>24 months</span></span><span style="font-family:Arial;font-size:8pt;"> after the closing date. We will also manufacture and supply certain consumer products for GSK Consumer Healthcare and GSK Consumer Healthcare will manufacture and supply certain retained Pfizer products for us after closing, generally for a term of up to </span><span style="font-family:Arial;font-size:8pt;"><span>six years</span></span><span style="font-family:Arial;font-size:8pt;">. These agreements are not material to Pfizer.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets and liabilities associated with our Consumer Healthcare business were reclassified as held for sale in the consolidated balance sheet as of December 31, 2018. The Consumer Healthcare business assets held for sale are reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Assets held for sale</span><span style="font-family:Arial;font-size:8pt;"> and Consumer Healthcare business liabilities held for sale are reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Liabilities held for sale </span><span style="font-family:Arial;font-size:8pt;">in the consolidated balance sheet as of December 31, 2018. This includes the Consumer Healthcare business tax assets and liabilities related to fully dedicated consumer healthcare subsidiaries.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Assets Held for Sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PP&amp;E</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Identifiable intangible assets, less accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Consumer Healthcare assets held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,678</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other assets held for sale</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Assets held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Liabilities Held for Sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrued compensation and related items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>870</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Consumer Healthcare liabilities held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,890</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other assets held for sale consist of PP&amp;E.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a part of Pfizer, pre-tax income on a management business unit basis for the Consumer Healthcare business was </span><span style="font-family:Arial;font-size:8pt;"><span>$654 million</span></span><span style="font-family:Arial;font-size:8pt;"> through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$977 million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2018 and </span><span style="font-family:Arial;font-size:8pt;"><span>$863 million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2017.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the two months ending September 30, 2019, the most recent period available, is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,505</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38,575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>46,081</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,241</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,536</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>10,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity attributable to shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35,199</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total net equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For the Two Months Ending</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">September 30,</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,161</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,358</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Investment in ViiV Healthcare Limited</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">In 2009, we and GSK created ViiV, which is focused on research, development and commercialization of human immunodeficiency virus (HIV) medicines. We own approximately </span><span style="font-family:Arial;font-size:8pt;"><span>11.7%</span></span><span style="font-family:Arial;font-size:8pt;"> of ViiV, and we have historically accounted for our investment in ViiV under the equity method due to the significant influence that we have over the operations of ViiV through our board representation and minority veto rights. We suspended application of the equity method to our investment in ViiV in 2016 when the carrying value of our investment was reduced to </span><span style="font-family:Arial;font-size:8pt;"><span>zero</span></span><span style="font-family:Arial;font-size:8pt;"> due to the recognition of cumulative equity method losses and dividends. Since 2016, we have recognized dividends from ViiV as income in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> when earned, including dividends of </span><span style="font-family:Arial;font-size:8pt;"><span>$220 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$253 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$266 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Summarized financial information for our equity method investee, ViiV, as of December 31, 2019 and 2018 and for the years ending December 31, 2019, 2018, and 2017 is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,839</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,381</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,437</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,276</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,904</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,765</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total net equity/(deficit) attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,489</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,139</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,219</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,504</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(381</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,623</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,757</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,398</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,867</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,398</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,867</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,867</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Investment in Hisun Pfizer Pharmaceuticals Company Limited</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2012, we and Hisun, a leading pharmaceutical company in China, formed a new company, Hisun Pfizer, to develop, manufacture, market and sell pharmaceutical products, primarily branded generic products, predominately in China. Hisun Pfizer was established with registered capital of </span><span style="font-family:Arial;font-size:8pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:8pt;">, of which our portion was </span><span style="font-family:Arial;font-size:8pt;"><span>$122.5 million</span></span><span style="font-family:Arial;font-size:8pt;">. As a result of the contributions from both parties, Hisun Pfizer holds a broad portfolio of branded generics covering cardiovascular disease, infectious disease, oncology, mental health and other therapeutic areas.</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We accounted for our interest in Hisun Pfizer as an equity-method investment, due to the significant influence we had over the operations of Hisun Pfizer through our board representation, minority veto rights and </span><span style="font-family:Arial;font-size:8pt;"><span>49%</span></span><span style="font-family:Arial;font-size:8pt;"> voting interest. Our investment in Hisun Pfizer was reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span><span style="font-family:Arial;font-size:8pt;">, and our share of Hisun Pfizer&#8217;s net income was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On November 10, 2017, we sold our </span><span style="font-family:Arial;font-size:8pt;"><span>49%</span></span><span style="font-family:Arial;font-size:8pt;"> equity share in Hisun Pfizer to Sapphire I (HK) Holdings Limited, an investment fund managed by Hillhouse Capital, for a total of </span><span style="font-family:Arial;font-size:8pt;"><span>$286 million</span></span><span style="font-family:Arial;font-size:8pt;"> in cash which included our carrying value of </span><span style="font-family:Arial;font-size:8pt;"><span>$270 million</span></span><span style="font-family:Arial;font-size:8pt;"> in cash plus </span><span style="font-family:Arial;font-size:8pt;"><span>$16 million</span></span><span style="font-family:Arial;font-size:8pt;"> to cover certain taxes incurred on the transaction.&#160;As a result of the sale transaction, we recognized a loss of </span><span style="font-family:Arial;font-size:8pt;"><span>$81 million</span></span><span style="font-family:Arial;font-size:8pt;"> in the fourth quarter of 2017 for the recognition in earnings of the currency translation adjustment associated with our investment. After the sale transaction, Hisun Pfizer changed its name but retained its current rights to manufacture, sell and distribute all of Hisun Pfizer&#8217;s currently marketed and pipeline products in China. We are providing technical, manufacturing and regulatory services in connection with a technology transfer process being run by Hisun Pfizer to support Hisun Pfizer&#8217;s objective that the products that we had previously licensed to Hisun Pfizer, will in the future, be manufactured locally in China.&#160;We continue to supply certain products to Hisun Pfizer for a period of time, after the sale transaction, to facilitate a smooth transition.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Investment in Laborat&#243;rio Teuto Brasileiro S.A.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We entered into an agreement on June 30, 2017 to exit our investment in Teuto, a </span><span style="font-family:Arial;font-size:8pt;"><span>40%</span></span><span style="font-family:Arial;font-size:8pt;">-owned generics company in Brazil, and sell our </span><span style="font-family:Arial;font-size:8pt;"><span>40%</span></span><span style="font-family:Arial;font-size:8pt;"> interest in Teuto to the majority shareholders. As part of the agreement, we waived our option to acquire the remaining </span><span style="font-family:Arial;font-size:8pt;"><span>60%</span></span><span style="font-family:Arial;font-size:8pt;"> of Teuto, and Teuto&#8217;s other shareholders have waived their option to sell their </span><span style="font-family:Arial;font-size:8pt;"><span>60%</span></span><span style="font-family:Arial;font-size:8pt;"> stake in the company to us. As a result, in the second quarter of 2017, we recognized a net loss of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">), which included the impairment of our equity-method investment in Teuto, the reversal of a contingent liability associated with the majority shareholders&#8217; option to sell their </span><span style="font-family:Arial;font-size:8pt;"><span>60%</span></span><span style="font-family:Arial;font-size:8pt;"> stake in the company to us, and the recognition in earnings of the currency translation adjustment associated with the Teuto investment. The transaction closed on August 16, 2017.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Licensing Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Akcea Therapeutics, Inc.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In October 2019, we entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with certain cardiovascular and metabolic diseases, with Akcea, a majority-owned affiliate of Ionis. The transaction closed in November 2019 and we made an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:8pt;"> to Akcea and Ionis, which was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses </span><span style="font-family:Arial;font-size:8pt;">in our fiscal fourth quarter of 2019. Under the terms of the agreement, Akcea and Ionis will split equally the </span><span style="font-family:Arial;font-size:8pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront license fee. We may be required to make development, regulatory and sales milestone payments of up to </span><span style="font-family:Arial;font-size:8pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:8pt;"> and tiered, double-digit royalties on annual worldwide net sales upon marketing approval of AKCEA-ANGPTL3-LRx and these payments will also be split equally between Akcea and Ionis. Pfizer is responsible for all development and regulatory activities and costs beyond those associated with the ongoing Phase 2 study.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Shire International GmbH</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2016, we out-licensed PF-00547659, an investigational biologic being evaluated for the treatment of moderate-to-severe inflammatory bowel disease, including ulcerative colitis and Crohn&#8217;s disease, to Shire for an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$90 million</span></span><span style="font-family:Arial;font-size:8pt;">, up to </span><span style="font-family:Arial;font-size:8pt;"><span>$460 million</span></span><span style="font-family:Arial;font-size:8pt;"> in development and sales-based milestone payments and potential future royalty payments on commercialized products. The </span><span style="font-family:Arial;font-size:8pt;"><span>$90 million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront payment was initially deferred and recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> ratably through December 2017. In the first quarter of 2018, we recognized </span><span style="font-family:Arial;font-size:8pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of ulcerative colitis, and in the third quarter of 2018, we recognized </span><span style="font-family:Arial;font-size:8pt;"><span>$35 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> for a milestone payment received from Shire related to their first dosing of a patient in a Phase 3 clinical trial of the compound for the treatment of Crohn&#8217;s disease (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">BionTech AG</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2018, a multi-year R&amp;D arrangement went into effect between BionTech AG (BionTech), a privately held company, and Pfizer to develop mRNA-based vaccines for prevention of influenza (flu). In September 2018, we made an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:8pt;"> to BionTech, which was recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses, </span><span style="font-family:Arial;font-size:8pt;">and BionTech became eligible to receive up to an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$325 million</span></span><span style="font-family:Arial;font-size:8pt;"> in future development and sales based milestones and future royalty payments associated with worldwide sales. As part of the transaction, we also purchased </span><span style="font-family:Arial;font-size:8pt;"><span>169,670</span></span><span style="font-family:Arial;font-size:8pt;"> newly-issued ordinary shares of BionTech for </span><span style="font-family:Arial;font-size:8pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:8pt;"> in the third quarter of 2018, which are reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments </span><span style="font-family:Arial;font-size:8pt;">in the consolidated balance sheets as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and December 31, 2018.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Research and Development and Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Research and Development Arrangement with NovaQuest Co-Investment Fund V, L.P.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2016, Pfizer entered into an agreement with NovaQuest under which NovaQuest would fund up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">in development costs related to certain Phase 3 clinical trials of Pfizer&#8217;s rivipansel compound and Pfizer would use commercially reasonable efforts to develop and obtain regulatory approvals for such compound. NovaQuest&#8217;s development funding was expected to cover up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>100%</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">of the development </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">costs and was received over approximately 13 quarters from 2016 through the second quarter of 2019 after which Pfizer would be responsible for the remaining development costs. As there was a substantive and genuine transfer of risk to NovaQuest, the development funding was recognized by us as an obligation to perform contractual services and therefore a reduction of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"> as incurred. The funding cap was reached in 2019.</span><span style="font-family:Arial;font-size:8pt;"> The reduction to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and Development expenses </span><span style="font-family:Arial;font-size:8pt;">totaled </span><span style="font-family:Arial;font-size:8pt;"><span>$24 million</span></span><span style="font-family:Arial;font-size:8pt;"> for 2019, </span><span style="font-family:Arial;font-size:8pt;"><span>$58 million</span></span><span style="font-family:Arial;font-size:8pt;"> for 2018 and </span><span style="font-family:Arial;font-size:8pt;"><span>$72 million</span></span><span style="font-family:Arial;font-size:8pt;"> for 2017.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:11pt;"><span style="font-family:Arial;font-size:8pt;">In August 2019, we announced that the Phase 3 RESET (Rivipansel Evaluating Safety, Efficacy and Time to Discharge)</span><span style="font-family:Arial;font-size:11pt;"> </span><span style="font-family:Arial;font-size:8pt;">pivotal study did not meet its primary or key secondary efficacy endpoints. The objective of the trial was to evaluate the efficacy and safety of rivipansel in patients aged six and older with sickle cell disease who were hospitalized for a vaso-occlusive crisis and required treatment with IV opioids. As a result, in 2019, we recorded a </span><span style="font-family:Arial;font-size:8pt;"><span>$99 million</span></span><span style="font-family:Arial;font-size:8pt;"> charge in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales </span><span style="font-family:Arial;font-size:8pt;">related to rivipansel</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">,</span><span style="font-family:Arial;font-size:8pt;"> primarily for inventory manufactured for expected future sale</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">, </span><span style="font-family:Arial;font-size:8pt;">as well as </span><span style="font-family:Arial;font-size:8pt;"><span>$15 million</span></span><span style="font-family:Arial;font-size:8pt;"> of anticipated clinical development program close-out costs, which were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development costs </span><span style="font-family:Arial;font-size:8pt;">in the consolidated statement of income. In January 2020, we discontinued development of rivipansel resulting in the termination of the R&amp;D arrangement with NovaQuest. No payments have been or are expected to be received from or paid to NovaQuest as part of the termination of the arrangement.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Research and Development Arrangement with RPI Finance Trust</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In January 2016, Pfizer entered into an agreement with RPI, a subsidiary of Royalty Pharma, under which RPI would fund up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$300 million</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">in development costs related to certain Phase 3 clinical trials of Pfizer&#8217;s Ibrance (palbociclib) product primarily for adjuvant treatment of hormone receptor positive early breast cancer (the Indication). RPI&#8217;s development funding is expected to cover up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>100%</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">of the costs primarily for the applicable clinical trials until the first quarter of 2020 after which Pfizer will be responsible for the remaining cost of the trials. As there is a substantive and genuine transfer of risk to RPI, the development funding is recognized by us as an obligation to perform contractual services and therefore is a reduction of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"> as incurred. The reduction to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"> totaled</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$63 million</span></span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$99 million</span></span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$76 million</span></span><span style="font-family:Arial;font-size:8pt;"> for </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span><span style="font-family:Arial;font-size:8pt;"> If successful and upon approval of Ibrance in the U.S. or certain major markets in the EU for the Indication based on the applicable clinical trials, RPI will be eligible to receive a combination of approval-based fixed milestone payments of up to</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;"><span>$250 million</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">dependent upon results of the clinical trials and royalties on certain Ibrance sales over approximately seven years. Fixed milestone payments due upon approval will be recorded as intangible assets and amortized to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:8pt;"> over the estimated commercial life of the Ibrance product and sales-based royalties will be recorded as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"> when incurred. </span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Collaborative Arrangements</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the normal course of business, we enter into collaborative arrangements with respect to in-line medicines, as well as medicines in development that require completion of research and regulatory approval. Collaborative arrangements are contractual agreements with third parties that involve a joint operating activity, typically a research and/or commercialization effort, where both we and our partner are active participants in the activity and are exposed to the significant risks and rewards of the activity. Our rights and obligations under our collaborative arrangements vary. For example, we have agreements to co-promote pharmaceutical products discovered by us or other companies, and we have agreements where we partner to co-develop and/or participate together in commercializing, marketing, promoting, manufacturing and/or distributing a drug product.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">&#8212;Revenues</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>664</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>606</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenue</span><span style="font-family:Arial;font-size:8pt;">s&#8212;Alliance revenues</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,927</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total revenues from collaborative arrangements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(351</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(296</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(329</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(173</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(54</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other income/(deductions)&#8212;net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents sales to our partners of products manufactured by us.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in each of the periods presented reflect increases in alliance revenues from Eliquis and Xtandi.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$15 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. There were </span><span style="font-family:Arial;font-size:7pt;">no</span><span style="font-family:Arial;font-size:7pt;"> upfront and milestone payments in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">. Our collaboration with Lilly (see below) also includes reimbursements of </span><span style="font-family:Arial;font-size:7pt;"><span>$67 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$98 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$147 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to royalties from our collaboration partners. </span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The amounts disclosed in the above table do not include transactions with third parties other than our collaboration partners, or other costs associated with the products under the collaborative arrangements.</span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition, in connection with our collaborative arrangements, we paid post-approval milestones of </span><span style="font-family:Arial;font-size:8pt;"><span>$80 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$140 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"> related to our collaboration with Merck KGaA (see below). These payments were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights. </span><span style="font-family:Arial;font-size:8pt;">We did not pay post-approval milestones to collaboration partners in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">. We also recorded milestones earned related to (i) our collaboration with Mylan Pharmaceuticals Inc. related to the FDA&#8217;s approval and launch of Wixela Inhub&#174;, a generic of Advair Diskus&#174; (fluticasone propionate and salmeterol inhalation powder) of </span><span style="font-family:Arial;font-size:8pt;"><span>$78 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">) and (ii) our </span></div><div style="line-height:120%;padding-top:8px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">collaboration with Merck (see below) of </span><span style="font-family:Arial;font-size:8pt;"><span>$40 million</span></span><span style="font-family:Arial;font-size:8pt;"> in 2018 in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">and </span><span style="font-family:Arial;font-size:8pt;"><span>$150 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">, substantially all of which was included in the adjustment to increase the opening balance of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"> upon the adoption of a new accounting standard for revenue recognition, effective January 1, 2018.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Collaboration with Merck &amp; Co., Inc.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Under a worldwide collaboration agreement, except for Japan, we collaborated with Merck on the clinical development of ertugliflozin and ertugliflozin-containing fixed-dose combinations with metformin and Januvia (sitagliptin) tablets, which were approved by the FDA in December 2017 and the EC in March 2018 as Steglatro, Segluromet and Steglujan. Merck exclusively promotes Steglatro and the two fixed-dose combination products and we share revenues and certain costs with Merck on a </span><span style="font-family:Arial;font-size:8pt;"><span>60%</span></span><span style="font-family:Arial;font-size:8pt;">/</span><span style="font-family:Arial;font-size:8pt;"><span>40%</span></span><span style="font-family:Arial;font-size:8pt;"> basis, with Pfizer having the </span><span style="font-family:Arial;font-size:8pt;"><span>40%</span></span><span style="font-family:Arial;font-size:8pt;"> share. </span></div><div style="line-height:120%;padding-bottom:6px;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the first quarter of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2017</span><span style="font-family:Arial;font-size:8pt;">, we received a </span><span style="font-family:Arial;font-size:8pt;"><span>$90 million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment from Merck upon the FDA&#8217;s acceptance for review of the NDAs for ertugliflozin and two fixed-dose combinations (ertugliflozin plus Januvia (sitagliptin) and ertugliflozin plus metformin), which, as of December 31, 2017, was deferred and primarily reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities, </span><span style="font-family:Arial;font-size:8pt;">and through December 31, 2017, was being recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> over a multi-year period. As of December 31, 2017, we were due a </span><span style="font-family:Arial;font-size:8pt;"><span>$60 million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment from Merck, which we received in the first quarter of 2018, in conjunction with the approval of ertugliflozin by the FDA. As of December 31, 2017, the </span><span style="font-family:Arial;font-size:8pt;"><span>$60 million</span></span><span style="font-family:Arial;font-size:8pt;"> due from Merck was deferred and primarily reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">. In the first quarter of 2018, in connection with the approval of ertugliflozin in the EU, we recognized a </span><span style="font-family:Arial;font-size:8pt;"><span>$40 million</span></span><span style="font-family:Arial;font-size:8pt;"> milestone payment from Merck in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">). We are eligible for additional payments associated with the achievement of future commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard for revenue recognition, as of January 1, 2018, the </span><span style="font-family:Arial;font-size:8pt;"><span>$60 million</span></span><span style="font-family:Arial;font-size:8pt;"> of deferred income and approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$85 million</span></span><span style="font-family:Arial;font-size:8pt;"> of the </span><span style="font-family:Arial;font-size:8pt;"><span>$90 million</span></span><span style="font-family:Arial;font-size:8pt;"> of deferred income associated with the above-mentioned milestone payments were recorded as a cumulative effect adjustment to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Collaboration with Eli Lilly &amp; Company</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In 2013, we entered into a collaboration agreement with Lilly to jointly develop and globally commercialize Pfizer&#8217;s tanezumab, which provides that Pfizer and Lilly will equally share product-development expenses as well as potential revenues and certain product-related costs. We received a </span><span style="font-family:Arial;font-size:8pt;"><span>$200 million</span></span><span style="font-family:Arial;font-size:8pt;"> upfront payment from Lilly in accordance with the collaboration agreement between Pfizer and Lilly, which was deferred and primarily reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities, </span><span style="font-family:Arial;font-size:8pt;">and through December 31, 2017, was being recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> over a multi-year period beginning in the second quarter of 2015. Pfizer and Lilly resumed the Phase 3 chronic pain program for tanezumab in July 2015. Under the collaboration agreement with Lilly, we are eligible to receive additional payments from Lilly upon the achievement of specified regulatory and commercial milestones. In the first quarter of 2018, in connection with the adoption of a new accounting standard for revenue recognition, as of January 1, 2018, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$107 million</span></span><span style="font-family:Arial;font-size:8pt;"> of deferred income associated with the above-mentioned upfront payment was recorded as a cumulative effect adjustment to </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;">. Approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$9 million</span></span><span style="font-family:Arial;font-size:8pt;"> of the upfront payment continues to be deferred, and is reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. This amount is being recognized in</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> over the remaining development period for the product in 2020.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Collaboration with Merck KGaA</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In November 2014, we entered into a collaborative arrangement with Merck KGaA, to jointly develop and commercialize avelumab, currently approved as Bavencio for metastatic MCC in the U.S., the EU, Japan and select other markets, in combination with Inlyta for the first-line treatment of patients with advanced RCC in the U.S., the EU, Japan and select other markets, as well as for the second-line treatment of patients with locally advanced or metastatic urothelial carcinoma in the U.S. and select other markets. Avelumab is also in development as a potential treatment for multiple other types of cancer. We and Merck KGaA are exploring the therapeutic potential of this novel anti-PD-L1 antibody as a single agent as well as in various combinations with our and Merck KGaA&#8217;s broad portfolio of approved and investigational oncology therapies. Also, as part of the agreement, we gave Merck KGaA certain co-promotion rights for Xalkori in the U.S. and several other key markets. Under the terms of the agreement, in the fourth quarter of 2014, we made an upfront payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$850 million</span></span><span style="font-family:Arial;font-size:8pt;"> to Merck KGaA and Merck KGaA is eligible to receive regulatory and commercial milestone payments of up to approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$2.0 billion</span></span><span style="font-family:Arial;font-size:8pt;">. During 2017, we made </span><span style="font-family:Arial;font-size:8pt;"><span>$140 million</span></span><span style="font-family:Arial;font-size:8pt;"> in milestone payments to Merck KGaA, which were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights, </span><span style="font-family:Arial;font-size:8pt;">for approvals of avelumab received in 2017 for the MCC indication in the U.S., the EU and Japan, and for the metastatic urothelial carcinoma indication in the U.S. </span><span style="font-family:Arial;font-size:8pt;">Both companies jointly fund the majority of development and commercialization costs, and split equally any profits related to net sales generated from selling any products containing avelumab from this collaboration.</span><span style="font-family:Arial;font-size:8pt;"> In December 2018, both companies amended the collaborative agreement such that Pfizer will be solely responsible for the development and commercialization of its anti PD-1 antibody. Under the terms of the amended agreement, we paid Merck KGaA an up-front payment and we will make a potential milestone and tiered royalty payments should the Pfizer anti PD-1 antibody achieve regulatory and commercial success. We made </span><span style="font-family:Arial;font-size:8pt;"><span>$80 million</span></span><span style="font-family:Arial;font-size:8pt;"> in milestone payments to Merck KGaA, which were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights,</span><span style="font-family:Arial;font-size:8pt;"> for the U.S. and the EU approvals received in 2019 related to the use of Bavencio in combination with Inlyta for the first-line treatment of patients with advanced RCC.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Disposal Groups, Including Discontinued Operations, Collaborative Arrangements, Equity and Cost Method Investments Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDisposalGroupsIncludingDiscontinuedOperationsCollaborativeArrangementsEquityandCostMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>159
<FILENAME>R109.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952546624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets - Footnotes (Details) - Array [Member]<br> $ in Millions</strong></div></th>
<th class="th">
<div>Jul. 30, 2019 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">$ 7,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Licensing Agreements, Developed Technology [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">340<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">4,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Licensing Agreements, Technology In Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsLineItems', window );"><strong>Schedule of Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 1,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>[Line Items] for Intangible Assets [Table]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsDevelopedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsDevelopedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsTechnologyInDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsTechnologyInDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>160
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952933056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock', window );">Schedule Providing Components of Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges/(credits):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>239</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(181</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset impairments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Transaction costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Integration costs and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>317</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>747</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit costs recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;</sup></span><span style="font-family:Arial;font-size:8pt;">recorded in our consolidated statements of income as follows</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Implementation costs recorded in our consolidated statements of income as follows</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,434</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>805</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The asset impairment charges for </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> are largely associated with cost reduction initiatives not associated with acquisitions. The asset impairment charges for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are primarily associated with abandoned assets. See (b) below for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5B</span><span style="font-family:Arial;font-size:7pt;">). In 2018, restructuring charges were primarily related to employee termination costs and asset write downs. The employee termination costs for 2019 and 2018 were primarily associated with our improvements to operational effectiveness as part of the realignment of our organizational structure, and for 2019, also includes employee termination costs associated with the Transforming to a More Focused Company initiative. In </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, restructuring charges were primarily associated with our acquisitions of Hospira and Medivation, partially offset by credits associated with cost-reduction and productivity initiatives not associated with acquisitions that mostly related to the reversal of previously recorded accruals for employee termination costs resulting from revisions of our severance benefit estimates. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span></div></td></tr></table><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biopharma (</span><span style="font-family:Arial;font-size:7pt;"><span>$118 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); Upjohn (</span><span style="font-family:Arial;font-size:7pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$180 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:18px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate 2018 and 2017 restructuring charges with the new individual segments.</span></div><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities for </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total reportable segments (</span><span style="font-family:Arial;font-size:7pt;"><span>$207 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$575 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge). </span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:24px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total reportable segments (</span><span style="font-family:Arial;font-size:7pt;"><span>$89 million</span></span><span style="font-family:Arial;font-size:7pt;"> credit); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$119 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services. In 2019, transaction costs relate to our acquisition of Array. In 2017, transaction costs were directly related to our acquisitions of Hospira, Anacor and Medivation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, integration costs and other mainly related to our acquisitions of Array (including </span><span style="font-family:Arial;font-size:7pt;"><span>$157 million</span></span><span style="font-family:Arial;font-size:7pt;"> in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">)) and Hospira. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, integration costs and other mostly related to our acquisition of Hospira. In 2017, integration costs primarily related to our acquisitions of Hospira and Medivation, as well as a net gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$12 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2018, primarily represents the net pension curtailments and settlements included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">upon the adoption of a new accounting standard in the first quarter of 2018. In 2017, mainly represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock', window );">Schedule of Restructuring Reserve by Type of Cost</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Termination</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impairment</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, January 1, 2018 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,039</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Utilization and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(295</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(290</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, December 31, 2018</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Provision</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>239</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Utilization and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance, December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes adjustments for foreign currency translation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$823 million</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$428 million</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5D</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other current liabilities </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;"><span>$714 million</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;"><span>$219 million</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of costs incurred for restructuring including, but not limited to, exit and disposal activities, remediation, implementation, integration, asset impairment, and charges against earnings from the write-down of assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB TOPIC 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringAndRelatedCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's restructuring reserve that occurred during the period associated with the exit from or disposal of business activities or restructurings for each major type of cost. This element may also include a description of any reversal and other adjustment made during the period to the amount of an accrued liability for restructuring activities. This element may be used to encapsulate the roll forward presentations of an entity's restructuring reserve by type of cost and in total, and explanation of changes that occurred in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestructuringReserveByTypeOfCostTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>161
<FILENAME>R126.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7037640544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Long-term Target Asset Allocations Ranges and the Percentage of the Fair Value of Plan Assets (Detail)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember', window );">Cash and Cash Equivalents [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember', window );">Equity Securities [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember', window );">Fixed Income Securities [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember', window );">Other Investments [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Equity Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">21.50%<span></span>
</td>
<td class="nump">22.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Fixed Income Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">46.90%<span></span>
</td>
<td class="nump">46.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Other Investments [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">29.20%<span></span>
</td>
<td class="nump">27.90%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Cash and Cash Equivalents [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Other Investments [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">95.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Foreign Plan [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Foreign Plan [Member] | Equity Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Foreign Plan [Member] | Fixed Income Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Foreign Plan [Member] | Other Investments [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Cash and Cash Equivalents [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Other Investments [Member] | Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Foreign Plan [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Foreign Plan [Member] | Equity Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Foreign Plan [Member] | Fixed Income Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Foreign Plan [Member] | Other Investments [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">2.50%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Equity Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">31.80%<span></span>
</td>
<td class="nump">31.30%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Fixed Income Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">48.70%<span></span>
</td>
<td class="nump">47.10%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Other Investments [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations', window );">Equity and debt securities, percentage of plan assets</a></td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">18.20%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Minimum [Member] | United States [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Minimum [Member] | United States [Member] | Equity Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Minimum [Member] | United States [Member] | Fixed Income Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Minimum [Member] | United States [Member] | Other Investments [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Maximum [Member] | United States [Member] | Cash and Cash Equivalents [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Maximum [Member] | United States [Member] | Equity Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">55.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Maximum [Member] | United States [Member] | Fixed Income Securities [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Maximum [Member] | United States [Member] | Other Investments [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage', window );">Equity and debt securities, target allocation percentage</a></td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of target investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlanAssetsTargetAllocationPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of actual investment allocation to total plan assets. Includes, but is not limited to, percentage on weighted-average basis if more than one plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanWeightedAverageAssetAllocations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanCashAndCashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_DefinedBenefitPlanEquitySecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_FixedIncomeSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanByPlanAssetCategoriesAxis=us-gaap_OtherInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>162
<FILENAME>R122.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7025102704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Amounts Recognized in Accumulated Other Comprehensive (Loss)/Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Actuarial losses</a></td>
<td class="num">$ (76)<span></span>
</td>
<td class="num">$ (202)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (costs)/credits</a></td>
<td class="nump">830<span></span>
</td>
<td class="nump">994<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total</a></td>
<td class="nump">754<span></span>
</td>
<td class="nump">792<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Actuarial losses</a></td>
<td class="num">(2,921)<span></span>
</td>
<td class="num">(2,372)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (costs)/credits</a></td>
<td class="num">(21)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total</a></td>
<td class="num">(2,942)<span></span>
</td>
<td class="num">(2,372)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Actuarial losses</a></td>
<td class="num">(4,812)<span></span>
</td>
<td class="num">(5,061)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (costs)/credits</a></td>
<td class="num">(2)<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total</a></td>
<td class="num">(4,814)<span></span>
</td>
<td class="num">(5,060)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan [Member] | United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax', window );">Actuarial losses</a></td>
<td class="num">(484)<span></span>
</td>
<td class="num">(370)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax', window );">Prior service (costs)/credits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax', window );">Total</a></td>
<td class="num">$ (485)<span></span>
</td>
<td class="num">$ (370)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive income (loss) for gain (loss) of defined benefit plan, that has not been recognized in net periodic benefit (cost) credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetGainsLossesBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of accumulated other comprehensive (income) loss for cost (credit) of benefit change attributable to participants' prior service from plan amendment or plan initiation of defined benefit plan, that has not been recognized in net periodic benefit cost (credit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAccumulatedOtherComprehensiveIncomeNetPriorServiceCostCreditBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>163
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039968464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in </span><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Note 1E</span><span style="font-family:Arial;font-size:7.5pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financial assets measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as equity securities with readily determinable fair values:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,583</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>9,609</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>9,609</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>811</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>811</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>15,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>15,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>7,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>7,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>16,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>16,674</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>413</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>413</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as equity securities with readily determinable fair values</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>521</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>266</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>266</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>526</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>526</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>11,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>9,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>20,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>18,850</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financial liabilities measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>378</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>378</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>604</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>604</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, long-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$176 million</span></span><span style="font-family:Arial;font-size:7pt;"> are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. </span><span style="font-family:Arial;font-size:7pt;text-align:center;">As of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;">, short-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$11 million</span></span><span style="font-family:Arial;font-size:7pt;"> and long-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$132 million</span></span><span style="font-family:Arial;font-size:7pt;"> are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4</span><span style="font-family:Arial;font-size:7pt;">).</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock', window );">Financial Liabilities Not Measured at Fair Value on a Recurring Basis</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:bold;">Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Long-term debt, excluding the current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>35,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>40,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>40,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>32,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>35,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>35,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesTextBlock', window );">Summary of Investments</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table represents our investments by classification type:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities with readily determinable fair values</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,003</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Total Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,525</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>17,694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities with readily determinable fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Private equity securities at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>756</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Total Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,014</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17,133</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term investments and equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>20,147</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,767</span></span></div></td><td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Contractual Maturities of Available-for-sale and Held-to-maturity Securities</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">December 31, 2019</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,895</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(38</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>9,754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>9,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,120</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>811</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Corporate and other</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,014</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>498</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>798</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>8,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>8,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>16,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>16,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily issued by a diverse group of corporations.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of Available-for-sale Securities Reconciliation</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">December 31, 2019</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,895</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(38</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>9,754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>9,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,120</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>811</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Corporate and other</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,014</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>498</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>798</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>8,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>8,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>16,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>16,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily issued by a diverse group of corporations.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesTextBlock', window );">Held-to-maturity Securities</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">December 31, 2019</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,895</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(38</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>9,754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>9,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,120</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>811</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Corporate and other</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,014</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>498</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>798</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>8,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>8,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>16,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>16,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily issued by a diverse group of corporations.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock', window );">Schedule of Gains and Losses on Investment Securities</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table presents the net unrealized (gains) and losses for the period that relate to equity securities, excluding equity method investments, still held at the reporting date, calculated as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net gains recognized during the period on equity securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(454</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(586</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net gains recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(109</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unrealized gains during the reporting period on equity securities still held at the reporting date</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(429</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The net gains on equity securities are reported in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net.</span><span style="font-family:Arial;font-size:7pt;"> For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShortTermDebtTextBlock', window );">Schedule of Short-term Borrowings</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Short-term borrowings include:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Commercial paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>13,915</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current portion of long-term debt, principal amount</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,458</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other short-term borrowings, principal amount</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>860</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>966</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total short-term borrowings, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,233</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,847</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span><span style="font-family:Arial;font-size:8pt;">, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7D</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7F</span><span style="font-family:Arial;font-size:7pt;">.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-term Debt Instruments</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the first quarter of 2019, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.800% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;11, 2022</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>500</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.950% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2024</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.450% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2029</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.900% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2039</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4.000% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2049</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt issued in the first quarter of 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The weighted-average effective interest rate for the notes at issuance was </span><span style="font-family:Arial;font-size:7pt;"><span>3.57%</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2019 and 2018 by maturity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2020 (1.2%)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2021 (0.7% and 3.4%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,153</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2022 (1.0% and 0.3%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,624</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2023 (3.7% and 3.8%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2024 (3.9% and 4.4%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,250</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2026-2029 (3.3%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,718</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2034 (6.5%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2036-2040 (5.8% and 6.0%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,566</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,796</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2043-2044 (3.5%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,568</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,509</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2046-2049 (4.1% and 4.2%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,565</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>34,820</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>32,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,305</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>479</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(176</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>32,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, the debt issuances have been reclassified to the current portion of long-term debt.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock', window );">Schedule of Derivative Financial Instruments</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>25,193</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>591</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>22,984</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,645</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>909</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>968</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>19,623</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><span style="font-family:Arial;font-size:7pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:Arial;font-size:7pt;"><span>$5.9 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$5.8 billion</span></span> as of December 31, 2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock', window );">Schedule of Derivative Assets at Fair Value</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>25,193</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>591</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>22,984</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,645</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>909</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>968</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>19,623</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><span style="font-family:Arial;font-size:7pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:Arial;font-size:7pt;"><span>$5.9 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$5.8 billion</span></span> as of December 31, 2018<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock', window );">Schedule of Derivative Liabilities at Fair Value</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>25,193</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>591</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>22,984</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,645</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>909</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>968</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>19,623</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><span style="font-family:Arial;font-size:7pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:Arial;font-size:7pt;"><span>$5.9 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$5.8 billion</span></span> as of December 31, 2018<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock', window );">Schedule of Gains/(Losses) Incurred to Hedge or Offset Operational Foreign Exchange or Interest Rate Risk</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>339</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>525</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(182</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>136</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>900</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(348</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(900</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(313</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>188</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency short-term borrowings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency long-term debt</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(172</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(172</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>688</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">OID = Other (income)/deductions&#8212;net,</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#160;</span><span style="font-family:Arial;font-size:7pt;">included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:7pt;"> COS = Cost of Sales, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other comprehensive income/(loss)&#8211;&#8211;Unrealized holding gains/(losses) on derivative financial instruments, net</span><span style="font-family:Arial;font-size:7pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other comprehensive income/(loss)&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The amounts reclassified from OCI into COS were a net </span><span style="font-family:Arial;font-size:7pt;">gain</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$247 million</span></span><span style="font-family:Arial;font-size:7pt;"> in 2019 and a net </span><span style="font-family:Arial;font-size:7pt;">loss</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$13 million</span></span><span style="font-family:Arial;font-size:7pt;"> in 2018. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </span><span style="font-family:Arial;font-size:7pt;">gain</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$145 million</span></span><span style="font-family:Arial;font-size:7pt;"> within the next 12 months into </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales. </span><span style="font-family:Arial;font-size:7pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:Arial;font-size:7pt;"><span>$1.8 billion</span></span><span style="font-family:Arial;font-size:7pt;"> U.K. pound debt maturing in 2043. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">These amounts were reclassified from OCI into OID. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Short-term borrowings include foreign currency short-term borrowings with carrying values of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.0 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, which are used as hedging instruments in net investment hedges.</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Value Hedging Adjustment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase/(Decrease) to <br/>Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedging</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Fair Value Hedges</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Value Hedging Adjustment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase/(Decrease) to <br/>Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedging</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock', window );">Schedule of Amounts Recorded In Balance Sheet Related to Cumulative Adjustments for Cash Flow Hedges</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Value Hedging Adjustment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase/(Decrease) to <br/>Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedging</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Trading, And Equity Securities, FV-NI [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesTradingAndEquitySecuritiesFVNITableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information about investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of marketable securities. This may consist of investments in certain debt and equity securities, short-term investments and other assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information pertaining to carrying amount and estimated fair value of short-term and long-term debt instruments or arrangements, including but not limited to, identification of terms, features, and collateral requirements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCarryingValuesAndEstimatedFairValuesOfDebtInstrumentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for cash flow hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28541-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21506-112644<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(e),(f))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21521-112644<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21538-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative assets at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeAssetsAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the location and amount of derivative instruments and nonderivative instruments designated as hedging instruments reported before netting adjustments, and the amount of gain (loss) on derivative instruments and nonderivative instruments designated and qualified as hedging instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4E<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624181-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5618551-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsGainLossInStatementOfFinancialPerformanceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information about a derivative or group of derivatives on a disaggregated basis, such as for individual instruments, or small groups of similar instruments. May include a combination of the type of instrument, risks being hedged, notional amount, hedge designation, related hedged item, inception date, maturity date, or other relevant item.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624163-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41678-113959<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41641-113959<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of derivative liabilities at fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDerivativeLiabilitiesAtFairValueTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=117815213&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for fair value hedging instruments of (a) the location and amount of gains and losses reported in the statement of financial performance and (b) the location and fair value amounts of the instruments reported in the statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4C<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624171-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueHedgingInstrumentsStatementsOfFinancialPerformanceAndFinancialPositionLocationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShortTermDebtTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of short-term debt arrangements (having initial terms of repayment within one year or the normal operating cycle, if longer) including: (1) description of the short-term debt arrangement; (2) identification of the lender or type of lender; (3) repayment terms; (4) weighted average interest rate; (5) carrying amount of funds borrowed under the specified short-term debt arrangement as of the balance sheet date; (6) description of the refinancing of a short-term obligation when that obligation is excluded from current liabilities in the balance sheet; and (7) amount of a short-term obligation that has been excluded from current liabilities in the balance sheet because of a refinancing of the obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShortTermDebtTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>164
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7038971552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Net Periodic Benefit Costs</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="49" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the annual (credit)/cost and changes in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">&#160;for our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="47" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Qualified</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Service cost</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>269</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>125</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>629</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>215</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(890</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,040</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,005</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(317</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(360</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(345</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial losses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>147</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service cost/(credit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(173</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(178</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(182</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>230</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit cost/(credit) reported in income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(189</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>115</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(146</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Credit)/cost reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(246</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(189</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>570</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(301</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Credit)/cost recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(129</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>215</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(86</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the </span><span style="font-family:Arial;font-size:7pt;"><span>$156 million</span></span><span style="font-family:Arial;font-size:7pt;"> net pension benefit obligation and recorded a pretax settlement gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$41 million</span></span><span style="font-family:Arial;font-size:7pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net </span><span style="font-family:Arial;font-size:7pt;">(see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Effective January 1, 2018, we froze </span><span style="font-family:Arial;font-size:7pt;"><span>two</span></span><span style="font-family:Arial;font-size:7pt;"> significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We adopted an accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> on the consolidated statements of income. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock', window );">Schedule of Amounts in Accumulated Other Comprehensive Income/(Loss) Expected to be Amortized into 2014 Net Periodic Benefit Costs</a></td>
<td class="text"><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">&#160;expected to be amortized into 2020 net periodic benefit costs:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.<br/>Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial (losses)/gains</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service credits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for </span><span style="font-family:Arial;font-size:7pt;">2020</span><span style="font-family:Arial;font-size:7pt;"> are </span><span style="font-family:Arial;font-size:7pt;"><span>24.9</span></span><span style="font-family:Arial;font-size:7pt;"> years for our U.S. qualified plans, </span><span style="font-family:Arial;font-size:7pt;"><span>24.5</span></span><span style="font-family:Arial;font-size:7pt;"> years for our U.S. supplemental (non-qualified) plans, </span><span style="font-family:Arial;font-size:7pt;"><span>19.4</span></span><span style="font-family:Arial;font-size:7pt;"> years for our international plans, and </span><span style="font-family:Arial;font-size:7pt;"><span>9.2</span></span><span style="font-family:Arial;font-size:7pt;"> years for our postretirement plans.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock', window );">Schedule of Assumptions Used</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average actuarial assumptions of our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">(PERCENTAGES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Weighted-average assumptions used to determine benefit obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate of compensation increase:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Weighted-average assumptions used to determine net periodic benefit cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected return on plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate of compensation increase:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#8217; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock', window );">Schedule of Health Care Cost Trend Rates</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Healthcare cost trend rate assumed for next year (up to age 65)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Healthcare cost trend rate assumed for next year (age 65 and older)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate to which the cost trend rate is assumed to decline</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year that the rate reaches the ultimate trend rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2037</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2037</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the effects as of December 31, 2019 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decrease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect on total service and interest cost components</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect on postretirement benefit obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock', window );">Schedule of Effect of One-Percentage-Point Change in Assumed Health Care Cost Trend Rates</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the effects as of December 31, 2019 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decrease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect on total service and interest cost components</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect on postretirement benefit obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock', window );">Schedule of Analysis of the Changes in the Benefit Obligations, Plan assets and Accounting Funded Status of Pension and Postretirement Benefit Plans</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Change in benefit obligation</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit obligation, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16,702</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>9,952</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,870</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>125</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>629</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>215</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(56</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Changes in actuarial assumptions and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,001</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,219</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,224</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(87</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(122</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange impact</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(457</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions/divestitures/other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(36</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(692</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(70</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(72</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(373</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit obligation, ending</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,870</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Change in plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>14,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,215</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>469</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actual gain/(loss) on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,760</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(796</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>873</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(77</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Company contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>230</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>137</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange impact</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(380</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions/divestitures, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(692</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(70</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(72</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(373</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets, ending</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,215</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>519</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,103</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The PBO represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases. The ABO is similar to the PBO but does not factor in future compensation increases. For the U.S. qualified and supplemental (non-qualified) pension plans, the benefit obligation is the PBO, which is also equal to the ABO. Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#8217; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was </span><span style="font-family:Arial;font-size:7pt;"><span>$10.6 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$9.5 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">. For the postretirement plans, the benefit obligation is the ABO.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock', window );">Schedule of Amounts Recognized in Balance Sheet</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information as to how the funded status is recognized in our consolidated balance sheets:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement<br/>Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(189</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(167</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(30</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(24</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,162</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,113</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,526</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Funded status</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,103</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Accrued compensation and related items</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of December 31, 2019, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Pension benefit obligations, net</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Postretirement benefit obligations</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net, </span><span style="font-family:Arial;font-size:7pt;">as appropriate. In 2018, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Pension benefit obligations, net</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Postretirement benefit obligations</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net</span><span style="font-family:Arial;font-size:7pt;">, as well as in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Liabilities held for sale</span><span style="font-family:Arial;font-size:7pt;"> (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;">)</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">, as </span><span style="font-family:Arial;font-size:7pt;">appropriate.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock', window );">Schedule of Amounts Recognized in Accumulated Other Comprehensive Income (Loss)</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the pre-tax components of cumulative amounts recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement<br/>Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial losses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4,812</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5,061</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(484</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(370</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,921</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,372</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(76</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(202</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service (costs)/credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>994</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(485</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(370</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,942</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>754</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our PBO, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:7pt;"> and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the average life expectancy of plan participants for frozen plans, primarily using the corridor approach.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information related to the funded status of selected benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension plans with an ABO in excess of plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,843</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ABO</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,960</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension plans with a PBO in excess of plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,947</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PBO</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock', window );">Schedule of Accumulated Benefit Obligations in Excess of Fair Value of Plan Assets</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information related to the funded status of selected benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension plans with an ABO in excess of plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,843</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ABO</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,960</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension plans with a PBO in excess of plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,947</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PBO</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock', window );">Schedule of Allocation of Plan Assets</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Target</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Allocation Percentage</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Percentage of Plan Assets</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">(PERCENTAGES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-10%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">35-55%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>31.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fixed income securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">28-53%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>48.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5-20%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-10%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">20-40%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>21.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fixed income securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">35-60%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>46.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>46.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10-35%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">U.S. postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-5%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">95-100%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="41"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="41" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">The following table provides the components of plan assets:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair Value</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair Value</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As of<br/>December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Assets Measured at NAV</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of<br/>December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Assets Measured at NAV</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>363</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>284</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>443</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Global equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>3,464</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>3,406</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>57</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,179</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>819</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>5,292</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>5,281</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>4,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>4,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,799</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,799</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other investments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Partnership investments</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,212</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,212</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other commingled funds</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,075</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>3,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>8,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>2,638</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>7,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>221</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>187</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Global equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,548</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>374</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>463</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>796</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>796</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>727</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>727</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,200</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,200</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,305</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,305</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>2,201</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,031</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,171</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,770</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,007</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other investments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Partnership investments</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>944</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d), (f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,524</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>398</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,043</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,473</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,020</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>8,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>4,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,342</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>2,652</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>8,215</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>4,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">U.S. postretirement plans</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>519</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>519</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:7pt;"/></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 1E</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span><span style="font-family:Arial;font-size:7pt;"/></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Mostly includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations are inclusive of repurchase agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock', window );">Schedule of Effect of Significant Unobservable Inputs, Changes in Plan Assets</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International Pension Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>684</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>468</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actual return on plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets held, ending</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Purchases, sales, and settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Transfer into/(out&#160;of) Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>247</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exchange rate changes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value, ending</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock', window );">Schedule of Expected Future Cash Flow Information</a></td>
<td class="text"><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the expected future cash flow information related to our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:center;">U.S. Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:center;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected employer contributions:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,276</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected benefit payments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,089</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2025&#8211;2029</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>435</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>642</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For the U.S. qualified plans, we plan to make a </span><span style="font-family:Arial;font-size:7pt;"><span>$1.25 billion</span></span><span style="font-family:Arial;font-size:7pt;"> voluntary contribution in the second half of 2020.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in the benefit obligation, fair value of plan assets, and funded status of pension plans or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangesInProjectedBenefitObligationsFairValueOfPlanAssetsAndFundedStatusOfPlanTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets of defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the major categories of plan assets of pension plans and/or other employee benefit plans.  This information may include, but is not limited to, the target allocation of plan assets, the fair value of each major category of plan assets, and the level within the fair value hierarchy in which the fair value measurements fall.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAllocationOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income (loss) expected to be recognized as components of net periodic benefit cost over the next fiscal year, including the net gain (loss), net prior service cost or credit, and net transition asset or obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (s)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsInAccumulatedOtherComprehensiveIncomeLossToBeRecognizedOverNextFiscalYearTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts that are recognized in the balance sheet (or statement of financial position) for pension plans and/or other employee benefit plans, showing separately the assets and current and noncurrent liabilities (if applicable) recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAmountsRecognizedInBalanceSheetTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAssumptionsUsedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assumption used to determine benefit obligation and net periodic benefit cost of defined benefit plan. Includes, but is not limited to, discount rate, rate of compensation increase, expected long-term rate of return on plan assets and interest crediting rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAssumptionsUsedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefit obligation and plan assets for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfBenefitObligationsInExcessOfFairValueOfPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in plan assets and benefit obligations recognized in other comprehensive income (loss) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDefinedBenefitPlanAmountsRecognizedInOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of a one-percentage-point increase and the effect of a one-percentage-point decrease in the assumed health care cost trend rates on the aggregate of the service and interest cost components of net periodic postretirement health care benefit costs and the accumulated postretirement benefit obligation for health care benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectOfOnePercentagePointChangeInAssumedHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the effect of fair value measurements using significant unobservable inputs (Level 3) on changes in plan assets of pension plans and/or other employee benefit plans for the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(02)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectOfSignificantUnobservableInputsChangesInPlanAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of benefits expected to be paid by pension plans and/or other employee benefit plans in each of the next five fiscal years and in the aggregate for the five fiscal years thereafter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfExpectedBenefitPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the assumed health care cost trend rates for the next year used to measure the expected cost of benefits covered by the plans, including the ultimate trend rate(s) and when that rate is expected to be achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfHealthCareCostTrendRatesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amounts related to pension plans and/or other employee benefit plans in accumulated other comprehensive income or loss that have not yet been recognized as components of net periodic benefit cost, such as the net gain (loss), net prior service cost or credit, and net transition asset or obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNetPeriodicBenefitCostNotYetRecognizedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>165
<FILENAME>R118.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952990096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Healthcare Cost Trend Rate Assumptions (Details) - Postretirement Benefits Plan [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge', window );">Healthcare cost trend rate assumed for next year (up to age 65)</a></td>
<td class="nump">5.60%<span></span>
</td>
<td class="nump">5.80%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver', window );">Healthcare cost trend rate assumed for next year (age 65 and older)</a></td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1', window );">Rate to which the cost trend rate is assumed to decline</a></td>
<td class="nump">4.50%<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, 65 Years of Age and Over</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRate65YearsofAgeandOver</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Ultimate Health Care Cost Trend Rate, Under 65 Years of Age</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanUltimateHealthCareCostTrendRateUnder65YearsofAge</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ultimate trend rate for health care cost for defined benefit postretirement plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanUltimateHealthCareCostTrendRate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>166
<FILENAME>R114.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7037812256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 42<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">75<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(33)<span></span>
</td>
<td class="num">(37)<span></span>
</td>
<td class="num">(36)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of actuarial losses</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="nump">31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits/(credits)</a></td>
<td class="num">(173)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
<td class="num">(182)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="num">(19)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">2<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs/(income) reported in Income</a></td>
<td class="num">(146)<span></span>
</td>
<td class="num">(111)<span></span>
</td>
<td class="num">(75)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">(Income)/cost reported in Other comprehensive income/(loss)</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">105<span></span>
</td>
<td class="num">(8)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">(Credit)/cost recognized in Comprehensive income</a></td>
<td class="num">(107)<span></span>
</td>
<td class="num">(6)<span></span>
</td>
<td class="num">(83)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">125<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="nump">171<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">215<span></span>
</td>
<td class="nump">212<span></span>
</td>
<td class="nump">204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(317)<span></span>
</td>
<td class="num">(360)<span></span>
</td>
<td class="num">(345)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of actuarial losses</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">101<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits/(credits)</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs/(income) reported in Income</a></td>
<td class="nump">115<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">(Income)/cost reported in Other comprehensive income/(loss)</a></td>
<td class="nump">570<span></span>
</td>
<td class="nump">84<span></span>
</td>
<td class="num">(301)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">(Credit)/cost recognized in Comprehensive income</a></td>
<td class="nump">685<span></span>
</td>
<td class="nump">168<span></span>
</td>
<td class="num">(154)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">269<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">629<span></span>
</td>
<td class="nump">598<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="num">(890)<span></span>
</td>
<td class="num">(1,040)<span></span>
</td>
<td class="num">(1,005)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of actuarial losses</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">120<span></span>
</td>
<td class="nump">393<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits/(credits)</a></td>
<td class="num">(3)<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">13<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">4<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs/(income) reported in Income</a></td>
<td class="nump">116<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="nump">382<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">(Income)/cost reported in Other comprehensive income/(loss)</a></td>
<td class="num">(246)<span></span>
</td>
<td class="nump">361<span></span>
</td>
<td class="nump">141<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">(Credit)/cost recognized in Comprehensive income</a></td>
<td class="num">(129)<span></span>
</td>
<td class="nump">171<span></span>
</td>
<td class="nump">523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan [Member] | United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanServiceCost', window );">Service cost</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">24<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanInterestCost', window );">Interest cost</a></td>
<td class="nump">47<span></span>
</td>
<td class="nump">55<span></span>
</td>
<td class="nump">54<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets', window );">Expected return on plan assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses', window );">Amortization of actuarial losses</a></td>
<td class="nump">11<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit', window );">Amortization of prior service credits/(credits)</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments', window );">Curtailments</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Settlements</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">26<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod', window );">Special termination benefits</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">10<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs/(income) reported in Income</a></td>
<td class="nump">100<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="nump">166<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax', window );">(Income)/cost reported in Other comprehensive income/(loss)</a></td>
<td class="nump">115<span></span>
</td>
<td class="num">(189)<span></span>
</td>
<td class="nump">23<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax', window );">(Credit)/cost recognized in Comprehensive income</a></td>
<td class="nump">$ 215<span></span>
</td>
<td class="num">$ (86)<span></span>
</td>
<td class="nump">$ 189<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized in net periodic benefit cost (credit) and other comprehensive (income) loss.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmountRecognizedInNetPeriodicBenefitCostAndOtherComprehensiveIncomeLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfGainsLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of prior service cost (credit) recognized in net periodic benefit cost (credit) of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(5)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanAmortizationOfPriorServiceCostCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost of providing special or contractual termination benefits payable from defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanCostOfProvidingSpecialOrContractualTerminationBenefitRecognizedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expected return (loss) recognized in net periodic benefit (cost) credit, calculated based on expected long-term rate of return and market-related value of plan assets of defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedReturnOnPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanInterestCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost recognized for passage of time related to defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanInterestCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from event reducing expected years of future service of present employees or eliminating accrual of defined benefits for some or all future services of present employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToCurtailments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanServiceCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for actuarial present value of benefits attributed to service rendered by employee for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanServiceCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, after reclassification adjustment, of (increase) decrease in accumulated other comprehensive income for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (i-k)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossPensionAndOtherPostretirementBenefitPlansAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>167
<FILENAME>R110.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952947168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Intangible Assets Percentage of Total Intangibles (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Biopharma Segment [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">99.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Biopharma Segment [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Biopharma Segment [Member] | Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">98.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Upjohn Segment [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Upjohn Segment [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member] | Upjohn Segment [Member] | Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member] | Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member] | Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember', window );">Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member] | Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">1.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member] | Operating Segments [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">42.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member] | Operating Segments [Member] | Upjohn Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">58.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member] | Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member] | Operating Segments [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">95.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member] | Operating Segments [Member] | Upjohn Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">IPR&amp;D [Member] | Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">Licensing Agreements And Other [Member] | Operating Segments [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">Licensing Agreements And Other [Member] | Operating Segments [Member] | Upjohn Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">Licensing Agreements And Other [Member] | Pfizer's Worldwide Research, Development And Medical [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet', window );">Percentage of intangible asset amortized cost by segment</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intangible Assets, Net, Percentage of Intangible Assets, Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IntangibleAssetsNetPercentageofIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsegmentsAxis=pfe_PfizersWorldwideResearchDevelopmentAndMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>169
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7037642080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text">The consolidated financial statements include our parent company and all subsidiaries, and are prepared in accordance with accounting principles generally accepted in the United States of America (U.S. GAAP). <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">The decision of whether or not to consolidate an entity requires consideration of majority voting interests, as well as effective economic or other control over the entity. Typically, we do not seek control by means other than voting interests. For subsidiaries operating outside the U.S., the financial information is included as of and for the year ended November 30 for each year presented. Pfizer's fiscal year-end for U.S. subsidiaries is as of and for the year ended December 31 for each year presented. Substantially all unremitted earnings of international subsidiaries are free of legal and contractual restrictions. All significant transactions among our businesses have been eliminated. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Adoption of New Accounting Standards in 2019</a></td>
<td class="text"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Adoption of New Accounting Standards in 2019</span><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On January 1, 2019, we adopted </span><span style="font-family:Arial;font-size:8pt;"><span>four</span></span><span style="font-family:Arial;font-size:8pt;"> new accounting standards.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Leases</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;On January 1, 2019, we adopted a new accounting standard for leases and changed our lease policies accordingly. Under the new standard, the most significant change is the requirement of balance sheet recognition of ROU assets and lease liabilities by lessees for those leases classified as operating leases. We adopted the new accounting standard utilizing the modified retrospective method using a simplified transition approach, and, therefore, no adjustments were made to our prior period financial statements. We have elected the package of practical expedients for transition which are permitted in the new standard. Accordingly, we did not reassess whether (i) any expired or existing contracts are or contain leases under the new standard, (ii) classification of leases as operating leases or capital leases would be different under the new standard, or (iii) any initial direct costs would have met the definition of initial direct costs under the new standard. Additionally, we did not elect to use hindsight in determining the lease term for existing leases as of January 1, 2019. We recorded noncurrent ROU assets of </span><span style="font-family:Arial;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> and current and noncurrent operating lease liabilities of </span><span style="font-family:Arial;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> as of January 1, 2019. We also recorded the cumulative effect of adopting the standard as an adjustment to increase the opening balance of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span><span style="font-family:Arial;font-size:8pt;"> by </span><span style="font-family:Arial;font-size:8pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:8pt;"> on a pre-tax basis (</span><span style="font-family:Arial;font-size:8pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:8pt;"> after-tax), relating to previously deferred sale-leaseback gains that can be recognized under the new rules.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adopting the standard related to leases impacted our prior period consolidated balance sheet as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As Previously Reported Balance at</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect of Change</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher/(Lower)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance at</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,461</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,460</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,913</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,149</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>258</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11,011</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,060</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,910</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>89,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>89,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adoption of the standard related to leases did not have a material impact on our consolidated statements of income or consolidated statements of cash flows in</span><span style="font-family:Arial;font-size:8pt;text-align:center;"> 2019</span><span style="font-family:Arial;font-size:8pt;">. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1T</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Amortization Period for Certain Callable Debt Securities Held at a Premium</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which shortens the amortization period for certain callable debt securities held at a premium. The new guidance requires the premium to be amortized to the earliest call date. We do not have any investments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Accounting for Certain Financial Instruments with Characteristics of Liabilities and Equity and Accounting for Certain Financial Instruments with Down Round Features</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which changes the accounting for warrants or convertible instruments that include a down round feature. We do not have any financial instruments with features subject to this standard and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Accounting for Share-Based Payments to Nonemployees</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We prospectively adopted the standard, which simplifies the accounting for share-based payments to nonemployees by aligning it with the accounting for share-based payments to employees, with certain exceptions. Under the guidance, the measurement of equity-classified nonemployee awards will be fixed at the grant date. We do not have any share-based awards issued to nonemployees and, therefore, there was no impact to our consolidated financial statements from the adoption of this new standard.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Estimates and Assumptions</a></td>
<td class="text">Estimates and Assumptions<div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In preparing the consolidated financial statements, we use certain estimates and assumptions that affect reported amounts and disclosures, including amounts recorded and disclosed in connection with acquisitions. These estimates and underlying assumptions can impact all elements of our financial statements. For example, in the consolidated statements of income, estimates are used when accounting for deductions from revenues (such as rebates, chargebacks, sales allowances and sales returns), determining the cost of inventory that is sold, allocating cost in the form of depreciation and amortization, and estimating restructuring charges and the impact of contingencies, as well as determining provisions for taxes on income. On the consolidated balance sheets, estimates are used in determining the valuation and recoverability of assets, such as accounts receivable, investments, inventories, deferred tax assets, fixed assets and intangible assets (including acquired IPR&amp;D assets), and estimates are used in determining the reported amounts of liabilities, such as taxes payable, benefit obligations, accruals for contingencies, rebates, chargebacks, sales allowances and sales returns, and restructuring reserves, all of which also impact the consolidated statements of income.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our estimates are often based on complex judgments and assumptions that we believe to be reasonable, but that can be inherently uncertain and unpredictable. If our estimates and assumptions are not representative of actual outcomes, our results could be materially impacted.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As future events and their effects cannot be determined with precision, our estimates and assumptions may prove to be incomplete or inaccurate, or unanticipated events and circumstances may occur that might cause us to change those estimates and assumptions. We are subject to risks and uncertainties that may cause actual results to differ from estimated amounts, such as changes in the healthcare environment, competition, litigation, legislation and regulations. We regularly evaluate our estimates and assumptions using historical experience and expectations about the future. We adjust our estimates and assumptions when facts and circumstances indicate the need for change.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Acquisitions</a></td>
<td class="text">Acquisitions<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our consolidated financial statements include the operations of acquired businesses after the completion of the acquisitions. We account for acquired businesses using the acquisition method of accounting, which requires, among other things, that most assets acquired and liabilities assumed be recognized at their estimated fair values as of the acquisition date and that the fair value of acquired IPR&amp;D be recorded on the balance sheet. Transaction costs are expensed as incurred. Any excess of the consideration transferred over the assigned values of the net assets acquired is recorded as goodwill. When we acquire net assets that do not constitute a business, as defined in U.S. GAAP, no goodwill is recognized and acquired IPR&amp;D is expensed.</span></div><div style="line-height:120%;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Contingent consideration in a business combination is included as part of the acquisition cost and is recognized at fair value as of the acquisition date. Fair value is generally estimated by using a probability-weighted discounted cash flow approach. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16D</span><span style="font-family:Arial;font-size:8pt;">. Any liability resulting from contingent consideration is remeasured to fair value at each reporting date until the contingency is resolved. These changes in fair value are recognized in earnings in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div>Amounts recorded in connection with an acquisition can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value</a></td>
<td class="text">Fair Value<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We are often required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, we use fair value extensively in the initial recognition of net assets acquired in a business combination, when measuring certain impairment losses and when accounting for and reporting of certain financial instruments. We estimate fair value using an exit price approach, which requires, among other things, that we determine the price that would be received to sell an asset or paid to transfer a liability in an orderly market. The determination of an exit price is considered from the perspective of market participants, considering the highest and best use of non-financial assets and, for liabilities, assuming that the risk of non-performance will be the same before and after the transfer. </span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">When estimating fair value, depending on the nature and complexity of the asset or liability, we may use one or all of the following techniques:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income approach, which is based on the present value of a future stream of net cash flows. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost approach, which is based on the cost to acquire or construct comparable assets, less an allowance for functional and/or economic obsolescence.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our fair value methodologies depend on the following types of inputs:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Quoted prices for identical assets or liabilities in active markets (Level 1 inputs).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means (Level 2 inputs).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Unobservable inputs that reflect estimates and assumptions (Level 3 inputs).</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div>A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock', window );">Foreign Currency Translation</a></td>
<td class="text">Foreign Currency Translation<div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For most of our international operations, local currencies have been determined to be the functional currencies. We translate functional currency assets and liabilities to their U.S. dollar equivalents at exchange rates in effect as of the balance sheet date and we translate functional currency income and expense amounts to their U.S. dollar equivalents at average exchange rates for the period. The U.S. dollar effects that arise from changing translation rates are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">. The effects of converting non-functional currency monetary assets and liabilities into the functional currency are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">. For operations in highly inflationary economies, we translate monetary items at rates in effect as of the balance sheet date, with translation adjustments recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;">, and we translate non-monetary items at historical rates.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue and Collaborative Arrangements</a></td>
<td class="text"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Revenues and Trade Accounts Receivable</span><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We recorded direct product sales and/or alliance revenues of more than </span><span style="font-family:Arial;font-size:8pt;"><span>$1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> for each of </span><span style="font-family:Arial;font-size:8pt;">eight</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, for each of </span><span style="font-family:Arial;font-size:8pt;">ten</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and for each of </span><span style="font-family:Arial;font-size:8pt;">nine</span><span style="font-family:Arial;font-size:8pt;"> products in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. In the aggregate, these direct products sales and/or alliance product revenues represent </span><span style="font-family:Arial;font-size:8pt;"><span>49%</span></span><span style="font-family:Arial;font-size:8pt;"> of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>51%</span></span><span style="font-family:Arial;font-size:8pt;"> of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>46%</span></span><span style="font-family:Arial;font-size:8pt;color:#ffffff;"> </span><span style="font-family:Arial;font-size:8pt;">of our revenues in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">. See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17C </span><span style="font-family:Arial;font-size:8pt;">for additional information. The loss or expiration of intellectual property rights can have a significant adverse effect on our revenues as our contracts with customers will generally be at lower selling prices due to added competition and we generally provide for higher sales returns during the period in which individual markets begin to near the loss or expiration of intellectual property rights. Our Consumer Healthcare business, which was combined with GSK&#8217;s Consumer Healthcare business into a new consumer healthcare joint venture that operates globally under the GSK Consumer Healthcare name on July 31, 2019, included OTC brands with a focus on dietary supplements, pain management, gastrointestinal and respiratory and personal care. We sell biopharmaceutical products after patent expiration, and under patent, and, to a much lesser extent, through July 31, 2019, we sold consumer healthcare products worldwide to developed and emerging market countries.</span></div><div style="line-height:120%;padding-bottom:4px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenue Recognition</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;We record revenues from product sales when there is a transfer of control of the product from us to the customer. We determine transfer of control based on when the product is shipped or delivered and title passes to the customer.</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Customers</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Our biopharmaceutical products are sold principally to wholesalers but we also sell directly to retailers, hospitals, clinics, government agencies and pharmacies, and, in the case of our vaccine products in the U.S., we primarily sell directly to the CDC, wholesalers, individual provider offices, retail pharmacies and integrated delivery networks. Customers for our consumer healthcare business, which were part of the business that was combined with GSK&#8217;s Consumer Healthcare business into a new consumer healthcare joint venture on July 31, 2019, included retailers and, to a lesser extent, wholesalers and distributors.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;padding-left:12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharmaceutical products that ultimately are used by patients are generally covered under governmental programs, managed care programs and insurance programs, including those managed through PBMs, and are subject to sales allowances and/or rebates payable directly to those programs. Those sales allowances and rebates are generally negotiated, but government programs may have legislated amounts by type of product (e.g., patented or unpatented). </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Our Sales Contracts</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Sales on credit are typically under short-term contracts. Collections are based on market payment cycles common in various markets, with shorter cycles in the U.S. Sales</span><span style="font-family:Arial;font-size:8pt;color:#ff0000;"> </span><span style="font-family:Arial;font-size:8pt;">are adjusted for sales allowances, chargebacks, rebates and sales returns and cash discounts. Sales returns occur due to loss of exclusivity, product recalls or a changing competitive environment. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Deductions from Revenues</span><span style="font-family:Arial;font-size:8pt;">&#8211;&#8211;Our gross product revenues are subject to a variety of deductions, which generally are estimated and recorded in the same period that the revenues are recognized. Such variable consideration represents chargebacks, rebates, sales allowances and sales returns. These deductions represent estimates of the related obligations and, as such, knowledge and judgment is required when estimating the impact of these revenue deductions on gross sales for a reporting period. </span></div></td></tr></table><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Specifically:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the U.S., we sell our products to distributors and hospitals under our sales contracts. However, we also have contracts with managed care or pharmacy benefit managers and legislatively mandated contracts with the federal and state governments under which we provide rebates to them based on medicines utilized by the lives they cover. We record provisions for Medicare, Medicaid, and performance-based contract pharmaceutical rebates based upon our experience ratio of rebates paid and actual prescriptions written during prior quarters. We apply the experience ratio to the respective period&#8217;s sales to determine the rebate accrual and related expense. This experience ratio is evaluated regularly to ensure that the historical trends are as current as practicable. We estimate discounts on branded prescription drug sales to Medicare Part D participants in the Medicare &#8220;coverage gap,&#8221; also known as the &#8220;doughnut hole,&#8221; based on the historical experience of beneficiary prescriptions and consideration of the utilization that is expected to result from the discount in the coverage gap. We evaluate this estimate regularly to ensure that the historical trends and future expectations are as current as practicable. For performance-based contract rebates, we also consider current contract terms, such as changes in formulary status and rebate rates.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Outside the U.S., the majority of our pharmaceutical sales allowances are contractual or legislatively mandated and our estimates are based on actual invoiced sales within each period, which reduces the risk of variations in the estimation process. In certain European countries, rebates are calculated on the government&#8217;s total unbudgeted pharmaceutical spending or on specific product sales thresholds and we apply an estimated allocation factor against our actual invoiced sales to project the expected level of reimbursement. We obtain third-party information that helps us to monitor the adequacy of these accruals.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provisions for pharmaceutical chargebacks (primarily reimbursements to U.S. wholesalers for honoring contracted prices to third parties) closely approximate actual amounts incurred, as we settle these deductions generally within two to five weeks of incurring the liability.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provisions for pharmaceutical sales returns are based on a calculation for each market that incorporates the following, as appropriate: local returns policies and practices; historical returns as a percentage of sales; an understanding of the reasons for past returns; estimated shelf life by product; an estimate of the amount of time between shipment and return or lag time; and any other factors that could impact the estimate of future returns, such as loss of exclusivity, product recalls or a changing competitive environment. Generally, returned products are destroyed, and customers are refunded the sales price in the form of a credit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We record sales incentives as a reduction of revenues at the time the related revenues are recorded or when the incentive is offered, whichever is later. We estimate the cost of our sales incentives based on our historical experience with similar incentives programs to predict customer behavior.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amounts recorded for revenue deductions can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Taxes collected from customers relating to product sales and remitted to governmental authorities are excluded from </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">.</span></div>Collaborative Arrangements<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Payments to and from our collaboration partners are presented in our consolidated statements of income based on the nature of the arrangement (including its contractual terms), the nature of the payments and applicable accounting guidance. Under co-promotion agreements, we record the amounts received from our collaboration partners as alliance revenues, a component of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues,</span><span style="font-family:Arial;font-size:8pt;"> when our collaboration partners are the principal in the transaction and we receive a share of their net sales or profits. Alliance revenues are recorded as we perform co-promotion services for the collaboration and the collaboration partners sell the products to their customers within the applicable period. The related expenses for selling and marketing these products are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses.</span><span style="font-family:Arial;font-size:8pt;"> In collaborative arrangements where we manufacture a product for our collaboration partners, we record revenues when we transfer control of the product to our collaboration partners. In collaboration arrangements where we are the principal in the transaction, we record amounts paid to collaboration partners for their share of net sales or profits earned, and all royalty payments to collaboration partners as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;">. Royalty payments received from collaboration partners are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reimbursements to or from our collaboration partners for development costs are recorded net in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">. Upfront payments and pre-approval milestone payments due from us to our collaboration partners in development stage collaborations are recorded as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">. Milestone payments due from us to our collaboration partners after regulatory approval has been attained for a medicine are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets&#8212;Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. Upfront and pre-approval milestone payments earned from our collaboration partners by us are recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;"> over the development period for the collaboration products, when our performance obligations include providing R&amp;D services to our collaboration partners. Upfront, pre-approval and post-approval milestone payments earned by us may be recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;"> immediately when earned or over other periods depending upon the nature of our performance obligations in the applicable collaboration. Where the milestone event is regulatory approval for a medicine, we generally recognize milestone payments due to us in the transaction price when regulatory approval in the applicable jurisdiction has been attained. We may recognize milestone payments due to us in the transaction price earlier than the milestone event in certain circumstances when recognition of the income would not be probable of a significant reversal.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReceivablesPolicyTextBlock', window );">Trade Accounts Receivable</a></td>
<td class="text"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Trade Accounts Receivable</span><span style="font-family:Arial;font-size:8pt;">&#8212;Trade accounts receivable are stated at their net realizable value. The allowance against gross trade accounts receivable reflects the best estimate of probable losses inherent in the receivables portfolio determined on the basis of historical experience, specific allowances for known troubled accounts and other current information. Trade accounts receivable are written off after all reasonable means to collect the full amount (including litigation, where appropriate) have been exhausted.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Cost of Sales and Inventories</a></td>
<td class="text">Cost of Sales and Inventories<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We carry inventories at the lower of cost or net realizable value. The cost of finished goods, work in process and raw materials is determined using average actual cost. We regularly review our inventories for impairment and reserves are established when necessary.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock', window );">Selling, Informational and Administrative Expenses</a></td>
<td class="text">Selling, Informational and Administrative Expenses<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div>Selling, informational and administrative costs are expensed as incurred. Among other things, these expenses include the internal and external costs of marketing, advertising, shipping and handling, information technology and legal defense.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text">Research and Development Expenses<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">R&amp;D costs are expensed as incurred. These expenses include the costs of our proprietary R&amp;D efforts, as well as costs incurred in connection with certain licensing arrangements. Before a compound receives regulatory approval, we record upfront and milestone payments made by us to third parties under licensing arrangements as expense. Upfront payments are recorded when incurred, and milestone payments are recorded when the specific milestone has been achieved. Once a compound receives regulatory approval, we record any milestone payments in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:8pt;"> and, unless the asset is determined to have an indefinite life, we amortize the payments on a straight-line basis over the remaining agreement term or the expected product life cycle, whichever is shorter.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment</a></td>
<td class="text"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Property, plant and equipment, less accumulated depreciation</span><span style="font-family:Arial;font-size:8pt;">&#8212;These assets are recorded at cost and are increased by the cost of any significant improvements after purchase. Property, plant and equipment assets, other than land and construction in progress, are depreciated on a straight-line basis over the estimated useful life of the individual assets. Depreciation begins when the asset is ready for its intended use. For tax purposes, accelerated depreciation methods are used as allowed by tax laws.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Intangible Assets and Goodwill</a></td>
<td class="text"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Specifically:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For finite-lived intangible assets, such as developed technology rights, and for other long-lived assets, such as property, plant and equipment, whenever impairment indicators are present, we calculate the undiscounted value of the projected cash flows associated with the asset, or asset group, and compare this estimated amount to the carrying amount. If the carrying amount is found to be greater, we record an impairment loss for the excess of book value over fair value. In addition, in all cases of an impairment review, we reevaluate the remaining useful lives of the assets and modify them, as appropriate.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For indefinite-lived intangible assets, such as Brands and IPR&amp;D assets, when necessary, we determine the fair value of the asset and record an impairment loss, if any, for the excess of book value over fair value. In addition, in all cases of an impairment review other than for IPR&amp;D assets, we re-evaluate whether continuing to characterize the asset as indefinite-lived is appropriate.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For goodwill, when necessary, we determine the fair value of each reporting unit and compare that value to its book value. If the carrying amount is found to be greater, we then determine the implied fair value of goodwill by subtracting the fair value of all the identifiable net assets other than goodwill from the fair value of the reporting unit and record an impairment loss, if any, for the excess of the book value of goodwill over the implied fair value.</span></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:8pt;">&#8212;These acquired assets are recorded at fair value. Intangible assets with finite lives</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">are amortized on a straight-line basis over their estimated useful lives. Intangible assets with indefinite lives that are associated with marketed products are not amortized until a useful life can be determined.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;">&#8212;Goodwill represents the excess of the consideration transferred for an acquired business over the assigned values of its net assets. Goodwill is not amortized.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization expense related to finite-lived acquired intangible assets that contribute to our ability to sell, manufacture, research, market and distribute products, compounds and intellectual property is included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Amortization of intangible assets</span><span style="font-family:Arial;font-size:8pt;"> as these intangible assets benefit multiple business functions. Amortization expense related to intangible assets that are associated with a single function and depreciation of property, plant and equipment are included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses,</span><span style="font-family:Arial;font-size:8pt;"> as appropriate.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentImpairment', window );">Property, Plant and Equipment, Impairment</a></td>
<td class="text"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We review all of our long-lived assets for impairment indicators throughout the year. We perform impairment testing for indefinite-lived intangible assets and goodwill at least annually and for all other long-lived assets whenever impairment indicators are present. When necessary, we record charges for impairments of long-lived assets for the amount by which the fair value is less than the carrying value of these assets.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock', window );">Restructuring Charges and Certain Acquisition-Related Costs</a></td>
<td class="text">Restructuring Charges and Certain Acquisition-Related Costs<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We may incur restructuring charges in connection with acquisitions when we implement plans to restructure and integrate the acquired operations or in connection with our cost-reduction and productivity initiatives. Included in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span><span style="font-family:Arial;font-size:8pt;"> are all restructuring charges, as well as certain other costs associated with acquiring and integrating an acquired business. If the restructuring action results in a change in the estimated useful life of an asset, that incremental impact is classified in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate. Termination costs are generally recorded when the actions are probable and estimable. Transaction costs, such as banking, legal, accounting and other similar costs incurred in connection with a business acquisition are expensed as incurred</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div>Amounts recorded for restructuring charges and other associated costs can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash Equivalents</a></td>
<td class="text"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash equivalents include items almost as liquid as cash, such as certificates of deposit and time deposits with maturity periods of three months or less when purchased. If items meeting this definition are part of a larger investment pool, we classify them as </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term investments</span><span style="font-family:Arial;font-size:8pt;">.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesReportingOfDerivativeActivity', window );">Statement of Cash Flows</a></td>
<td class="text"><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash flows associated with financial instruments designated as fair value or cash flow hedges may be included in operating, investing or financing activities, depending on the classification of the items being hedged. Cash flows associated with financial instruments designated as net investment hedges are classified according to the nature of the hedge instrument. Cash flows associated with financial instruments that do not qualify for hedge accounting treatment are classified according to their purpose and accounting nature.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentPolicyTextBlock', window );">Investments</a></td>
<td class="text">Investments and Derivative Financial Instruments<div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our investments are comprised of the following: public equity securities with readily determinable fair values, available-for-sale debt securities, held-to-maturity debt securities (when we have both the positive intent and ability to hold the investment to maturity), private equity securities </span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">without readily determinable fair values and equity-method investments. The classification of an investment can depend on the nature of the investment, our intent and ability to hold the investment, and the degree to which we may exercise influence.</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Public equity securities with readily determinable fair values are carried at fair value, with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities are carried at fair value, with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss) </span><span style="font-family:Arial;font-size:8pt;">until realized.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities are carried at amortized cost.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Private equity securities without readily determinable fair values and where we have no significant influence are measured at cost minus any impairment and plus or minus changes resulting from observable price changes in orderly transactions for the identical or a similar investment of the same issuer.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For equity investments in common stock or in-substance common stock where we have significant influence over the financial and operating policies of the investee, we use the equity-method of accounting. Under the equity-method, we record our share of the investee&#8217;s income and expenses in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;">. The excess of the cost of the investment over our share of the underlying equity in the net assets of the investee as of the acquisition date is allocated to the identifiable assets and liabilities of the investee, with any remaining excess amount allocated to goodwill. Such investments are initially recorded at cost, which is the fair value of consideration paid and typically does not include contingent consideration.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Realized gains or losses on sales of investments are determined by using the specific identification cost method.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We regularly evaluate all of our financial assets for impairment. For investments in debt and equity, when a decline in fair value, if any, is determined, an impairment charge is recorded and a new cost basis in the investment is established.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativesPolicyTextBlock', window );">Derivative Financial Instruments</a></td>
<td class="text"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative financial instruments are carried at fair value in various balance sheet categories (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7A</span><span style="font-family:Arial;font-size:8pt;">), with changes in fair value reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Net income</span><span style="font-family:Arial;font-size:8pt;"> or, for derivative financial instruments in certain qualifying hedging relationships, in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss) </span><span style="font-family:Arial;font-size:8pt;">(see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7F</span><span style="font-family:Arial;font-size:8pt;">). </span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Tax Assets and Liabilities and Income Tax Contingencies</a></td>
<td class="text">Tax Assets and Liabilities and Income Tax Contingencies<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Tax Assets and Liabilities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current tax assets primarily includes (i) tax effects associated with intercompany transfers of inventory within our combined group, which are recognized in the consolidated statements of income when the inventory is sold to a third party, as well as (ii) income tax receivables that are expected to be recovered either as refunds from taxing authorities or as a reduction to future tax obligations.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Deferred tax assets and liabilities are recognized for the expected future tax consequences of differences between the financial reporting and tax bases of assets and liabilities using enacted tax rates and laws, including the impact of the TCJA enacted in December 2017. We provide a valuation allowance when we believe that our deferred tax assets are not recoverable based on an assessment of estimated future taxable income that incorporates ongoing, prudent and feasible tax-planning strategies, that would be implemented, if necessary, to realize the deferred tax assets. All deferred tax assets and liabilities within the same tax jurisdiction are presented as a net amount in the noncurrent section of our consolidated balance sheet. Amounts recorded for valuation allowances can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For information about the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other non-current tax assets </span><span style="font-family:Arial;font-size:8pt;">primarily represent our estimate of the potential tax benefits in one tax jurisdiction that could result from the payment of income taxes in another tax jurisdiction. These potential benefits generally result from cooperative efforts among taxing authorities, as required by tax treaties to minimize double taxation, commonly referred to as the competent authority process. The recoverability of these assets, which we believe to be more likely than not, is dependent upon the actual payment of taxes in one tax jurisdiction and, in some cases, the successful petition for recovery in another tax jurisdiction.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other taxes payable</span><span style="font-family:Arial;font-size:8pt;"> in our consolidated balance sheet as of December 31, 2019 includes liabilities for uncertain tax positions and the noncurrent portion of the repatriation tax liability on the deemed repatriated accumulated post-1986 foreign earnings recorded in connection with the TCJA for which we elected, with the filing of our 2018 U.S. Federal Consolidated Income Tax Return, payment over eight years through 2026. For additional information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5D</span><span style="font-family:Arial;font-size:8pt;"> for uncertain tax positions and </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 5A</span><span style="font-family:Arial;font-size:8pt;"> for the repatriation tax liability.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Income Tax Contingencies</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We account for income tax contingencies using a benefit recognition model. If we consider that a tax position is more likely than not to be sustained upon audit, based solely on the technical merits of the position, we recognize the benefit. We measure the benefit by determining the amount that is greater than 50% likely of being realized upon settlement, presuming that the tax position is examined by the appropriate taxing authority that has full knowledge of all relevant information.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Under the benefit recognition model, if our initial assessment fails to result in the recognition of a tax benefit, we regularly monitor our position and subsequently recognize the tax benefit: (i) if there are changes in tax law, analogous case law or there is new information that sufficiently raise the likelihood of prevailing on the technical merits of the position to &#8220;more likely than not&#8221;; (ii) if the statute of limitations expires; or (iii) if there is a completion of an audit resulting in a favorable settlement of that tax year with the appropriate agency. We regularly re-evaluate our tax positions based on the results of audits of federal, state and local and foreign income tax filings, statute of limitations expirations, changes and clarification in tax law or receipt of new information that would either increase or decrease the technical merits of a position relative to the </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">more-likely-than-not standard. Liabilities associated with uncertain tax positions are classified as current only when we expect to pay cash within the next 12 months. Interest and penalties, if any, are recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Provision/(benefit) for taxes on income</span><span style="font-family:Arial;font-size:8pt;"> and are classified on our consolidated balance sheet with the related tax liability.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div>Our assessments are based on estimates and assumptions that have been deemed reasonable by management, but our estimates of unrecognized tax benefits and potential tax benefits may not be representative of actual outcomes, and variation from such estimates could materially affect our financial statements in the period of settlement or when the statutes of limitations expire, as we treat these events as discrete items in the period of resolution. Finalizing audits with the relevant taxing authorities can include formal administrative and legal proceedings, and, as a result, it is difficult to estimate the timing and range of possible changes related to our uncertain tax positions, and such changes could be significant. <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementPlansPolicy', window );">Pension and Postretirement Benefit Plans</a></td>
<td class="text">Pension and Postretirement Benefit Plans<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The majority of our employees worldwide are covered by defined benefit pension plans, defined contribution plans or both. In the U.S., we have both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans, as well as other postretirement benefit plans consisting primarily of medical insurance for retirees and their eligible dependents. We recognize the overfunded or underfunded status of each of our defined benefit plans as an asset or liability on our consolidated balance sheet. The obligations are generally measured at the actuarial present value of all benefits attributable to employee service rendered, as provided by the applicable benefit formula. Our pension and other postretirement obligations may include assumptions such as expected employee turnover and participant mortality. For our pension plans, the obligation may also include assumptions as to future compensation levels. For our other postretirement benefit plans, the obligation may include assumptions as to the expected cost of providing medical insurance benefits, as well as the extent to which those costs are shared with the employee or others (such as governmental programs). Plan assets are measured at fair value. Net periodic pension and postretirement benefit costs other than the service costs are recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div>Amounts recorded for pension and postretirement benefit plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Legal and Environmental Contingencies</a></td>
<td class="text">Legal and Environmental Contingencies<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We and certain of our subsidiaries are subject to numerous contingencies arising in the ordinary course of business, such as patent litigation, product liability and other product-related litigation, commercial litigation, environmental claims and proceedings, government investigations and guarantees and indemnifications. We record accruals for these contingencies to the extent that we conclude that a loss is both probable and reasonably estimable. If some amount within a range of loss appears to be a better estimate than any other amount within the range, we accrue that amount. Alternatively, when no amount within a range of loss appears to be a better estimate than any other amount, we accrue the lowest amount in the range. We record anticipated recoveries under existing insurance contracts when recovery is assured.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div>Amounts recorded for contingencies can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-Based Payments</a></td>
<td class="text">Share-Based Payments<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our compensation programs can include share-based payments. Generally, grants under share-based payment programs are accounted for at fair value and these fair values are generally amortized on a straight-line basis over the vesting terms into </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales, Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"> and/or </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;">, as appropriate.</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div>Amounts recorded for share-based compensation can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-bottom:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On January&#160;1, 2019, we adopted a new accounting standard for leases. For further information, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1B</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We lease real estate, fleet, and equipment for use in our operations. Our leases generally have lease terms of </span><span style="font-family:Arial;font-size:8pt;"><span>1</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span>30</span></span><span style="font-family:Arial;font-size:8pt;"> years, some of which include options to terminate or extend leases for up to </span><span style="font-family:Arial;font-size:8pt;"><span>5</span></span><span style="font-family:Arial;font-size:8pt;"> to </span><span style="font-family:Arial;font-size:8pt;"><span>10</span></span><span style="font-family:Arial;font-size:8pt;"> years or on a month-to-month basis. We include options that are reasonably certain to be exercised as part of the determination of lease terms. We may negotiate termination clauses in anticipation of any changes in market conditions, but generally these termination options are not exercised. Residual value guarantees are generally not included within our operating leases with the exception of some fleet leases. In addition to base rent payments, the leases may require us to pay directly for taxes and other non-lease components, such as insurance, maintenance and other operating expenses, which may be dependent on usage or vary month-to-month. Variable lease payments amounted to </span><span style="font-family:Arial;font-size:8pt;"><span>$328 million</span></span><span style="font-family:Arial;font-size:8pt;"> for the year ended </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">. We have elected the practical expedient in the new standard to not separate non-lease components from lease components in calculating the amounts of ROU assets and lease liabilities for all underlying asset classes.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We determine if an arrangement is a lease at inception of the contract in accordance with guidance detailed in the new standard and we perform the lease classification test as of the lease commencement date. ROU assets represent our right to use an underlying asset for the lease term and lease liabilities represent our obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As most of our leases do not provide an implicit rate, we use our estimated incremental borrowing rate based on the information available at commencement date in determining the present value of future payments.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6052-115624<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 450<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491354&amp;loc=d3e6049-115624<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=68068213&amp;loc=d3e12565-110249<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting.  The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.3A-02)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355033-122828<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.3A-03)<br> -URI http://asc.fasb.org/extlink&amp;oid=116822174&amp;loc=d3e355100-122828<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=d3e5614-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and reporting costs associated with exiting, disposing of, and restructuring certain operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostsAssociatedWithExitOrDisposalActivitiesOrRestructuringsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for its derivative instruments and hedging activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41620-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41638-113959<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=d3e41675-113959<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativesReportingOfDerivativeActivity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for derivatives entered into for trading purposes and those entered into for purposes other than trading including where and when derivative financial instruments and derivative commodity instruments and their related gains or losses are reported in the entity's statements of financial position, cash flows, and results of operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579240-113959<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(n)(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativesReportingOfDerivativeActivity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for (1) transactions denominated in a currency other than the reporting enterprise's functional currency, (2) translating foreign currency financial statements that are incorporated into the financial statements of the reporting enterprise by consolidation, combination, or the equity method of accounting, and (3) remeasurement of the financial statements of a foreign reporting enterprise in a hyperinflationary economy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionsAndTranslationsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116657188&amp;loc=SL116659661-227067<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32247-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e32280-109318<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4556-108314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6361739&amp;loc=d3e7789-107766<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e543-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116847112&amp;loc=d3e4492-108314<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment in financial asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918666-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementPlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for pension and other postretirement benefit plans. This accounting policy may address (1) the types of plans sponsored by the entity, and the benefits provided by each plan (2) groups that participate in (or are covered by) each plan (3) how plan assets, liabilities and expenses are measured, including the use of any actuaries and (4) significant assumptions used by the entity to value plan assets and liabilities and how such assumptions are derived.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66047640&amp;loc=d3e39622-114963<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 80<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=65877416&amp;loc=d3e29149-114947<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6412939&amp;loc=d3e15145-114933<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementPlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentImpairment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for assessing and recognizing impairments of its property, plant and equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2921-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentImpairment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReceivablesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for receivable. Includes, but is not limited to, accounts receivable and financing receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118936363&amp;loc=d3e5033-111524<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10178-111534<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10149-111534<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84159169&amp;loc=d3e10133-111534<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReceivablesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -URI http://asc.fasb.org/topic&amp;trid=49130388<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for inclusion of significant items in the selling, general and administrative (or similar) expense report caption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpensesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>170
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952557184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders</a></td>
<td class="text">Earnings Per Common Share Attributable to Pfizer Inc. Common Shareholders<div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the detailed calculation of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Earnings per common share</span><span style="font-family:Arial;font-size:8pt;">&#160;(EPS)</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(IN MILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Basic</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,298</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,179</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net income attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,269</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Preferred stock dividends&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,268</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,142</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,305</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Discontinued operations&#8211;&#8211;net of tax, attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,272</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,152</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,307</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Numerator&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,269</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,143</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,306</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued operations&#8211;&#8211;net of tax, attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income attributable to Pfizer Inc. common shareholders and assumed conversions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,153</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21,308</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">EPS Denominator</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Basic</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,569</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,872</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,970</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Common-share equivalents: stock options, stock issuable under employee compensation plans, convertible preferred stock and accelerated share repurchase agreements</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>106</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>89</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average number of common shares outstanding&#8211;&#8211;Diluted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,675</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,977</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,058</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Stock options that had exercise prices greater than the average market price of our common stock issuable under employee compensation plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>36</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash dividends declared per share</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.46</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.30</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017 includes the effect of the modification for a commitment to pay </span><span style="font-family:Arial;font-size:7pt;"><span>15.2 million</span></span><span style="font-family:Arial;font-size:7pt;"> common-share equivalents that were scheduled for near-term settlement. These common share equivalents were paid in the first quarter of 2018.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">These common stock equivalents were outstanding for the periods presented, but were not included in the computation of diluted EPS for those periods because their inclusion would have had an anti-dilutive effect.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI http://asc.fasb.org/topic&amp;trid=2144383<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>171
<FILENAME>R133.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7190063520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Total Shareholder Return Units Narrative (Details) - Total Shareholder Return Units (TSRUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>trading_day</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage', window );">Trading day average used to calculate the conversion</a></td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement', window );">Age of eligible unit holder which can elect to exercise and convert TSRUs when vested into PTUs</a></td>
<td class="text">55 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1', window );">Award requisite service period</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term (years)</a></td>
<td class="text">5 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Contractual term (years)</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Age Requirement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationAgeRequirement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Plan Modification, Value Conversion, Trading Day Average</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardPlanModificationValueConversionTradingDayAverage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Estimated period over which an employee is required to provide service in exchange for the equity-based payment award, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardRequisiteServicePeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>172
<FILENAME>R137.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952581968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Data Related to All Total Shareholder Return Units (Details) - Total Shareholder Return Units (TSRUs) [Member] - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average grant-date fair value per stock option (in dollars per share)</a></td>
<td class="nump">$ 8.52<span></span>
</td>
<td class="nump">$ 7.42<span></span>
</td>
<td class="nump">$ 6.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to nonvested awards not yet recognized, pre-tax</a></td>
<td class="nump">$ 229<span></span>
</td>
<td class="nump">$ 246<span></span>
</td>
<td class="nump">$ 232<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which nonvested award cost is expected to be recognized (years)</a></td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 7 months 6 days<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>173
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952743920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Identifiable Intangible Assets and Goodwill</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Identifiable Intangible Assets and Goodwill</span><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;"> </span><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Identifiable Intangible Assets</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Balance Sheet Information</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:30%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gross</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accumulated</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Identifiable</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intangible</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets, less</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accumulated</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Gross</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Carrying</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Amount</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Accumulated</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Identifiable</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Intangible</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Assets, less</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Accumulated</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:right;">Amortization</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Finite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>88,730</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(63,106</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>25,625</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>89,430</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(58,895</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>30,535</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>922</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(741</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>181</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>923</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(708</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>215</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,772</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,191</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>582</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,436</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,140</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>296</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>91,425</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(65,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>26,387</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>91,788</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(60,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>31,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Indefinite-lived intangible assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,991</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,919</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,919</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,073</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,983</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,983</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,165</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Identifiable intangible assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100,408</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(65,037</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35,370</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>95,954</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(60,743</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>35,211</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The increase in the gross carrying amount of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">I</span><span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets </span><span style="font-family:Arial;font-size:7pt;text-align:right;">mainly reflects the impact of the acquisition of Array, including the addition of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.8 billion</span></span><span style="font-family:Arial;font-size:7pt;text-align:right;"> of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$340 million</span></span><span style="font-family:Arial;font-size:7pt;"> of</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">finite-lived </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreements, </span><span style="font-family:Arial;font-size:7pt;"><span>$4.0 billion</span></span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">IPR&amp;D</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> of indefinite-lived </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreement</span><span style="font-family:Arial;font-size:7pt;">s</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">(see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">), partially offset by intangible asset impairment charges, primarily for Eucrisa in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:7pt;">. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </span><span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Reflects acquired licensing agreements for technology in development.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The increase in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">I</span><span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:7pt;text-align:right;">, </span><span style="font-family:Arial;font-size:7pt;">is mostly due to the additions noted in (a) above, partially offset by amortization and intangible asset impairment charges, primarily for Eucrisa in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:7pt;">. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </span><span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other, indefinite-lived</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Developed Technology Rights</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed technology rights represent the amortized cost associated with developed technology, which has been acquired from third parties and which can include the right to develop, use, market, sell and/or offer for sale the product, compounds and intellectual property that we have acquired with respect to products, compounds and/or processes that have been completed. We possess a well-diversified portfolio of hundreds of developed technology rights across therapeutic categories, representing the commercialized products included in our biopharmaceutical businesses. The more significant components of developed technology rights are the following (in order of significance): Xtandi, Prevnar 13/Prevenar 13 Infant, Braftovi/Mektovi, Eucrisa, Premarin, Prevnar 13/Prevenar 13 Adult, and, to a lesser extent Tygacil, Zavicefta, Pristiq, Refacto AF and Bosulif. Also included in this category are the post-approval milestone payments made under our alliance agreements for certain biopharmaceutical products.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Brands</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands represent the amortized or unamortized cost associated with tradenames and know-how, as the products themselves do not receive patent protection. The more significant components of indefinite-lived brands are the following (in order of significance): Xanax, Medrol and Depo-Medrol. The more significant components of finite-lived brands are the following (in order of significance): Depo-Provera and Zavedos.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">IPR&amp;D</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">IPR&amp;D assets represent R&amp;D assets that have not yet received regulatory approval in a major market. The significant components of IPR&amp;D at December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;"> include IPR&amp;D assets acquired in connection with the Array acquisition and the program for the oral PARP inhibitor for the treatment of patients with germline BRCA-mutated advanced breast cancer acquired as part of the Medivation acquisition. IPR&amp;D assets are required to be classified as indefinite-lived assets until the successful completion or the abandonment of the associated R&amp;D effort. Accordingly, during the development period after the date of acquisition, these assets will not be amortized until approval is obtained in a major market, typically either the U.S. or the EU, or in a series of other countries, subject to certain specified conditions and management judgment. At that time, we will determine the useful life of the asset, reclassify the asset out of IPR&amp;D and begin amortization. If the associated R&amp;D effort is abandoned, the related IPR&amp;D assets will likely be written-off, and we will record an impairment charge.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For IPR&amp;D assets, the risk of failure is significant and there can be no certainty that these assets ultimately will yield successful products. The nature of the biopharmaceutical business is high-risk and, as such, we expect that many of these IPR&amp;D assets will become impaired and be written off at some time in the future.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Licensing Agreements</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements for developed technology and licensing agreements for technology in development primarily relate to out-licensing arrangements acquired from third parties, including the Array acquisition. These intangible assets represent the amortized or unamortized cost associated with the license, where Pfizer has acquired the right to future royalties and/or milestones upon development or commercialization by the licensing partner. A significant component of the licensing arrangements at </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> are for out-licensing arrangements with a number of partners for oncology technology in varying stages of development that have not yet received regulatory approval in a major market. Accordingly, during the development period after the date of acquisition, each of these assets is classified as indefinite-lived intangible assets and will not be amortized until approval is obtained in a major market. At that time we will determine the useful life of the asset, reclassify the respective licensing arrangement asset to finite-lived intangible asset and begin amortization. If the development effort is abandoned, the related licensing asset will likely be written-off, and we will record an impairment charge.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;text-decoration:underline;">Amortization</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The weighted-average life for each of our total finite-lived intangible assets and the largest component, developed technology rights, is approximately </span><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;"><span>9</span></span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;">years.</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:8pt;">Total amortization expense for finite-lived intangible assets was </span><span style="font-family:Arial;font-size:8pt;"><span>$4.7 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;color:#000000;text-decoration:none;"><span>$5.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$4.8 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the annual amortization expense expected for the years 2020 through 2024:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Goodwill</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior to 2019, we managed our commercial operations through </span><span style="font-family:Arial;font-size:8pt;"><span>two</span></span><span style="font-family:Arial;font-size:8pt;"> distinct business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). At the beginning of our 2019 fiscal year, we reorganized our commercial operations and our businesses have been managed through </span><span style="font-family:Arial;font-size:8pt;"><span>three</span></span><span style="font-family:Arial;font-size:8pt;"> different operating segments&#8211;&#8211;Biopharma, Upjohn and through </span><span style="font-family:Arial;font-size:8pt;">July&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, Pfizer&#8217;s Consumer Healthcare business (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17</span><span style="font-family:Arial;font-size:8pt;"> for further information). Our Consumer Healthcare business was classified as held for sale as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;"> (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:8pt;"> for further information). Additionally, upon closing of the transaction during the third quarter of 2019, we deconsolidated our Consumer Healthcare business and derecognized Consumer Healthcare goodwill.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a result of the reorganization of our commercial operations, our remaining goodwill was required to be reallocated amongst the then new Biopharma and Upjohn operating segments by determining the fair value of each reporting unit under our old and new management structure and the portions being transferred. We completed this re-allocation based on relative fair value in the second quarter of 2019 and have retrospectively presented goodwill according to the new operating structure.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>43,359</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,600</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,993</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55,952</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(432</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(116</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,993</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,541</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>42,927</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,484</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>53,411</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Additions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,411</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,411</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(136</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>48,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>10,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>58,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily reflects the reclassification of our Consumer Healthcare business as</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">held for sale (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;">), the impact of foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biopharma additions relate to our acquisition of Array (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily reflects the impact of foreign exchange.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -URI http://asc.fasb.org/topic&amp;trid=2144416<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>174
<FILENAME>R156.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7038289104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 51,750<span></span>
</td>
<td class="nump">$ 53,647<span></span>
</td>
<td class="nump">$ 52,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="nump">17,682<span></span>
</td>
<td class="nump">11,885<span></span>
</td>
<td class="nump">12,305<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">6,010<span></span>
</td>
<td class="nump">6,384<span></span>
</td>
<td class="nump">6,269<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">49,653<span></span>
</td>
<td class="nump">50,042<span></span>
</td>
<td class="nump">48,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="nump">31,301<span></span>
</td>
<td class="nump">32,374<span></span>
</td>
<td class="nump">31,542<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">1,063<span></span>
</td>
<td class="nump">1,065<span></span>
</td>
<td class="nump">1,006<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,098<span></span>
</td>
<td class="nump">3,605<span></span>
</td>
<td class="nump">3,472<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="num">(5,723)<span></span>
</td>
<td class="num">(5,283)<span></span>
</td>
<td class="num">(5,302)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">108<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">142<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember', window );">Corporate [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="num">(5,859)<span></span>
</td>
<td class="num">(6,383)<span></span>
</td>
<td class="num">(6,299)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">503<span></span>
</td>
<td class="nump">465<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">39,419<span></span>
</td>
<td class="nump">37,558<span></span>
</td>
<td class="nump">35,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">39,419<span></span>
</td>
<td class="nump">37,558<span></span>
</td>
<td class="nump">35,530<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="nump">24,517<span></span>
</td>
<td class="nump">23,738<span></span>
</td>
<td class="nump">22,194<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">958<span></span>
</td>
<td class="nump">953<span></span>
</td>
<td class="nump">881<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember', window );">Upjohn Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">10,233<span></span>
</td>
<td class="nump">12,484<span></span>
</td>
<td class="nump">13,447<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="nump">6,785<span></span>
</td>
<td class="nump">8,636<span></span>
</td>
<td class="nump">9,348<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="nump">125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_PurchaseAccountingAdjustmentsMember', window );">Purchase Accounting Adjustments [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="num">(4,333)<span></span>
</td>
<td class="num">(4,786)<span></span>
</td>
<td class="num">(4,758)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">4,347<span></span>
</td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">4,565<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_BusinessCombinationsAcquisitionRelatedCostsMember', window );">Acquisition-Related Costs [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="num">(185)<span></span>
</td>
<td class="num">(318)<span></span>
</td>
<td class="num">(456)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">39<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_CertainSignificantItemsMember', window );">Certain Significant Items [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Earnings</a></td>
<td class="nump">2,481<span></span>
</td>
<td class="num">(3,719)<span></span>
</td>
<td class="num">(2,423)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and Amortization</a></td>
<td class="nump">$ 36<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_CorporateNonSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_PurchaseAccountingAdjustmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_PurchaseAccountingAdjustmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_BusinessCombinationsAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_BusinessCombinationsAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherSegmentReconcilingItemsAxis=pfe_CertainSignificantItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherSegmentReconcilingItemsAxis=pfe_CertainSignificantItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>175
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953333776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of share-based compensation expense and the associated tax benefit:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>294</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>302</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>221</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">RSUs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>275</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>301</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PPSs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PSAs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>28</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>62</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>47</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Stock options </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Directors&#8217; compensation</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Share-based payment expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>949</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>840</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax benefit for share-based compensation expense</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(137</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(180</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(163</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Share-based payment expense, net of tax</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>769</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>677</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)&#160;&#160;&#160;&#160;</sup></span><span style="font-family:Arial;font-size:7pt;">Includes expense for PTSRUs, described in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 13C</span><span style="font-family:Arial;font-size:7pt;"> below, which is not significant for all years presented.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average assumptions used in the valuation of TSRUs:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected dividend yield</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.27</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.69</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Risk-free interest rate</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.60</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.98</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected stock price volatility</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>18.34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>20.00</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>18.39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Contractual term (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.13</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.12</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.11</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using a constant dividend yield during the expected term of the TSRU.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using the interpolated yield on U.S. Treasury zero-coupon issues.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using implied volatility, after consideration of historical volatility.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Appreciation Rights Award Activity</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="12"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all TSRU activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant-Date</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>138,945</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33.44</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39,246</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8.52</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.35</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(47,710</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.92</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>30.70</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(7,826</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.63</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38.90</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>122,654</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.53</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38.01</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:41%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes TSRU and PTU information as of December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">TSRUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PTUs</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant&#160;Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per TSRU</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Remaining Contractual Term (Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate Intrinsic Value (Millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Outstanding</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>179,999</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35.33</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,415</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>57,345</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>31.04</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>775</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs Expected to vest</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>118,618</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37.23</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,096</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">TSRUs exercised and converted to PTUs</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,299</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>0.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>51</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, we settled </span><span style="font-family:Arial;font-size:7pt;"><span>7,953,671</span></span><span style="font-family:Arial;font-size:7pt;"> TSRUs with a weighted-average grant price of </span><span style="font-family:Arial;font-size:7pt;"><span>$27.33</span></span><span style="font-family:Arial;font-size:7pt;"> per unit.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>2,173,131</span></span><span style="font-family:Arial;font-size:7pt;"> TSRUs with a weighted-average grant price of </span><span style="font-family:Arial;font-size:7pt;"><span>$30.68</span></span><span style="font-family:Arial;font-size:7pt;"> per unit were converted into </span><span style="font-family:Arial;font-size:7pt;"><span>844,871</span></span><span style="font-family:Arial;font-size:7pt;"> PTUs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The number of TSRUs expected to vest takes into account an estimate of expected forfeitures.</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:63%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all TSRU activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT PER TSRU AMOUNTS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average grant-date fair value per TSRU</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8.52</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7.42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.23</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested TSRU grants not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>229</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which TSRU cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock', window );">Schedule of Nonvested Restricted Stock Units Activity</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:66%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all RSU activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Grant-Date Fair Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>27,276</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33.70</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,478</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.17</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(10,644</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>31.66</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Reinvested dividend equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>911</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39.64</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,614</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38.82</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>23,407</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37.54</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all RSU activity:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>454</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>584</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested RSU awards not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>241</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>256</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>254</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which RSU cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">2017 includes the modification for a commitment to pay approximately </span><span style="font-family:Arial;font-size:7pt;"><span>6.4 million</span></span><span style="font-family:Arial;font-size:7pt;"> RSUs to approximately </span><span style="font-family:Arial;font-size:7pt;"><span>9,900</span></span><span style="font-family:Arial;font-size:7pt;"> employees, including senior and key management employees, for </span><span style="font-family:Arial;font-size:7pt;"><span>6.6 million</span></span><span style="font-family:Arial;font-size:7pt;"> RSUs. These shares were paid in the first quarter of 2018.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock', window );">Schedule of Nonvested Performance-based Units Activity</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:65%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="8" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all PPS activity during 2019, with the shares representing the maximum award that could be achieved:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>19,261</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>43.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,212</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.35</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(6,882</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>42.89</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(897</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39.93</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17,694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Vested and non-vested shares outstanding, but not paid as of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> were </span><span style="font-family:Arial;font-size:7pt;"><span>32.0 million</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;text-align:left;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides data related to all PPS activity:</span></div></td></tr><tr><td rowspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>136</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>169</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>131</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested PPS awards not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>87</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which PPS cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="8"/></tr><tr><td style="width:58%;"/><td style="width:1%;"/><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/></tr><tr><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;">The following table summarizes all PSA activity during 2019, with the shares granted representing the maximum award that could be achieved:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares&#160;</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Nonvested, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,282</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>43.65</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,716</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.35</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,481</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>42.89</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(456</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>41.91</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Nonvested, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,061</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>39.18</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:61%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;background-color:#ffffff;">The following table provides data related to all PSA activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total fair value of shares vested</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>64</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>58</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested PSA grants not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>34</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which PSA cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;font-size:7.5pt;"><span style="font-family:Arial;font-size:7pt;">2017 </span><span style="font-family:Arial;font-size:7.5pt;">includes the modification </span><span style="font-family:Arial;font-size:7pt;">for a commitment to pay</span><span style="font-family:Arial;font-size:7.5pt;"> </span><span style="font-family:Arial;font-size:7.5pt;"><span>1.1 million</span></span><span style="font-family:Arial;font-size:7.5pt;"> PSAs to approximately </span><span style="font-family:Arial;font-size:7.5pt;"><span>90</span></span><span style="font-family:Arial;font-size:7.5pt;"> employees, including senior and key management employees, for </span><span style="font-family:Arial;font-size:7.5pt;"><span>1.1 million</span></span><span style="font-family:Arial;font-size:7.5pt;"> PSAs. These shares were paid in the first quarter of 2018.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Valuation Assumptions</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.40476190476191%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average assumptions used in the valuation of stock options:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected dividend yield</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.27</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.73</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.69</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Risk-free interest rate</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.66</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.85</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected stock price volatility</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>18.34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>20.02</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>18.39</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected term (years)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.75</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using a constant dividend yield during the expected term of the option.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using the interpolated yield on U.S. Treasury zero-coupon issues.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using implied volatility, after consideration of historical volatility.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Determined using historical exercise and post-vesting termination patterns.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Share-based Compensation, Stock Options, Activity</a></td>
<td class="text"><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="14"/></tr><tr><td style="width:39%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="14" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes all stock option activity during 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Thousands)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exercise Price</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Per Share</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Remaining Contractual Term</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Years)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Intrinsic Value</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Millions)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Outstanding, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>103,791</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>27.69</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Granted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,181</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>43.35</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercised</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(15,964</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>24.84</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Forfeited</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37.67</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Expired</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(353</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>31.12</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Outstanding, December 31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>88,600</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>28.39</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>960</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Vested and expected to vest, December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b</sup></span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>88,469</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>28.37</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>960</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Exercisable, December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>85,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>28.04</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>951</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Market price of our underlying common stock less exercise price.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The number of options expected to vest takes into account an estimate of expected forfeitures.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:73%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table summarizes data related to all stock option activity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year&#160;Ended December&#160;31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS, EXCEPT PER STOCK OPTION AMOUNTS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average grant-date fair value per stock option</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.98</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.06</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.01</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Aggregate intrinsic value on exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>625</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>331</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash received upon exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>394</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,259</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>862</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Tax benefits realized related to exercise</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>95</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total compensation cost related to nonvested stock options not yet recognized, pre-tax</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-average period over which stock option compensation cost is expected to be recognized (years)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>0.8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of Share-based Payment Award, Stock Appreciation Rights, Valuation Assumptions [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ScheduleofSharebasedPaymentAwardStockAppreciationRightsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested performance-based units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedPerformanceBasedUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock units.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNonvestedRestrictedStockUnitsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average exercise prices (or conversion ratios) for stock appreciation rights awards that were outstanding at the beginning and end of the year, and the number of stock appreciation rights awards that were granted, exercised or converted, forfeited, and expired during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockAppreciationRightsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>176
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7041196016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Impact of Lease Standard Adoption (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Jan. 01, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">$ 2,600<span></span>
</td>
<td class="nump">$ 2,460<span></span>
</td>
<td class="nump">$ 2,461<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">1,913<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">4,450<span></span>
</td>
<td class="nump">4,149<span></span>
</td>
<td class="nump">2,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">11,083<span></span>
</td>
<td class="nump">11,011<span></span>
</td>
<td class="nump">10,753<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">6,317<span></span>
</td>
<td class="nump">6,910<span></span>
</td>
<td class="nump">5,850<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">$ 97,670<span></span>
</td>
<td class="nump">89,574<span></span>
</td>
<td class="nump">$ 89,554<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems', window );"><strong>New Accounting Pronouncements or Change in Accounting Principle [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(11)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">258<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,060<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsOrChangeInAccountingPrincipleLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>177
<FILENAME>R152.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040147040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Action In Which We Are the Plaintiff) (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="8">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jan. 31, 2020 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jun. 30, 2018 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Jan. 31, 2018 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Oct. 31, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Aug. 31, 2015 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Apr. 30, 2017 </div>
<div>Defendant </div>
<div>Patents</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>Patents</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber', window );">Number of patents without court proceedings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember', window );">Patent Infringement [Member] | Judicial Ruling [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber', window );">Number of patents infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_PfizerVersusAjantaMember', window );">Pfizer Versus Ajanta [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember', window );">Pfizer Versus Generic Companies [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_PrecedexPremixMember', window );">Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber', window );">Number of patents allegedly not infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_PrecedexPremixMember', window );">Precedex Premix [Member] | Hospira Versus Amneal Pharmaceuticals LLC [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber', window );">Number of patents infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019', window );">Number of patents not infringed upon expired March 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber', window );">Number of patents found not infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_PrecedexPremixMember', window );">Precedex Premix [Member] | Hospira Versus Fresenius Kabj USA LLC [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber', window );">Number of patents found not infringed upon</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber', window );">Number of patents found not infringed upon subsequently appealed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_PrecedexPremixMember', window );">Precedex Premix [Member] | Hospira Versus Par [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber', window );">Number of patents allegedly not infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_XeljanzMember', window );">Xeljanz [Member] | Pfizer Versus Zydus [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=pfe_EliquisMember', window );">Eliquis [Member] | Pfizer and BMS Versus Several Generic Manufacturers [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyNumberofDefendants', window );">Number of defendants | Defendant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019', window );">Number of patents allegedly infringed upon due to expire In December 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Pfizer Versus Viwit Pharmaceutical Co. Ltd. [Member] | Patent Infringement [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingenciesLineItems', window );"><strong>Gain Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber', window );">Number of patents allegedly infringed upon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyNumberofDefendants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Number of Defendants</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyNumberofDefendants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Allegedly Infringed Upon, Number Due To Expire In December 2019</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyInfringedUponNumberDueToExpireInDecember2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly not infringed upon.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Allegedly Not Infringed Upon, Number Due to Expire March 2019</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsAllegedlyNotInfringedUponNumberDuetoExpireMarch2019</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Found Not Infringed Upon, Subsequently Appealed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsFoundNotInfringedUponSubsequentlyAppealedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainContingencyPatentsWithoutCourtProceedingsNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain Contingency, Patents Without Court Proceedings, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainContingencyPatentsWithoutCourtProceedingsNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsAllegedlyInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsFoundInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity was found to have infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsFoundInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of entity's patents that another entity was found not to have infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyPatentsFoundNotInfringedUponNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingenciesByNatureAxis=pfe_PatentInfringementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_JudicialRulingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusAjantaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusAjantaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusGenericCompaniesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrecedexPremixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrecedexPremixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_HospiraVersusAmnealPharmaceuticalsLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_HospiraVersusFreseniusKabjUSALLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_HospiraVersusFreseniusKabjUSALLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_HospiraVersusParMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_HospiraVersusParMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusZydusMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerandBMSVersusSeveralGenericManufacturersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerVersusViwitPharmaceuticalCo.Ltd.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>178
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6897002496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Other Supplemental Lease Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating leases weighted-average remaining contractual lease term</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease weighted-average discount rate</a></td>
<td class="nump">3.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="nump">$ 346<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleAndLeasebackTransactionGainLossNet', window );">(Gains)/losses on sale and leaseback transactions, net</a></td>
<td class="num">(29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">ROU assets obtained in exchange for new operating lease liabilities</a></td>
<td class="nump">$ 326<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleAndLeasebackTransactionGainLossNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale and leaseback transaction from transfer of asset accounted for as sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 40<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888430&amp;loc=SL77919786-209982<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleAndLeasebackTransactionGainLossNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>179
<FILENAME>R96.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953379856">
<tr>
<th class="tl" colspan="2" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt, New Issuances (Details) - Senior Notes [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">3.57%<span></span>
</td>
<td class="nump">3.56%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Unsecured Debt, 2.800% Notes, Due 2022 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.80%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Unsecured Debt, 2.950% Notes, Due 2024 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">2.95%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Unsecured Debt, 3.450% Notes, Due 2029 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.45%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Unsecured Debt, 3.900% Notes, Due 2039 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">3.90%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Unsecured Debt, 4.000% Notes, Due 2049 [Member]</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="th" style="border-bottom: 0px;"><sup>[1]</sup></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="th" style="border-bottom: 0px;"><sup></sup></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr><td colspan="3"></td></tr>
<tr><td colspan="3"><table class="outerFootnotes" width="100%"><tr class="outerFootnote">
<td style="vertical-align: top; width: 12pt;" valign="top">[1]</td>
<td style="vertical-align: top;" valign="top"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.</span></div></td>
</tr></table></td></tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointEightPercentDue2022Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtTwoPointNineFivePercentDue2024Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtThreePointFourFivePercentDue2029Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtThreePointNinePercentDue2039Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtFourPercentDue2049Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredDebtFourPercentDue2049Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>180
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7035310352">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Equity (Parenthetical)<br> shares in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_OncologyVaccinesStartUpMember', window );">Oncology Vaccines Start Up [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_OncologyVaccinesStartUpMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_OncologyVaccinesStartUpMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>181
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039122880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (226)<span></span>
</td>
<td class="num">$ (333)<span></span>
</td>
<td class="num">$ (391)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,574<span></span>
</td>
<td class="nump">1,316<span></span>
</td>
<td class="nump">1,270<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestRevenueExpenseNet', window );">Net interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,348<span></span>
</td>
<td class="nump">983<span></span>
</td>
<td class="nump">879<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyIncomeNonoperating', window );">Royalty-related income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(648)<span></span>
</td>
<td class="num">(495)<span></span>
</td>
<td class="num">(499)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnDispositionOfAssets1', window );">Net (gains)/losses on asset disposals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(31)<span></span>
</td>
<td class="num">(71)<span></span>
</td>
<td class="nump">45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Net gains recognized during the period on investments in equity securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(454)<span></span>
</td>
<td class="num">(586)<span></span>
</td>
<td class="num">(224)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesRealizedGainLoss', window );">Net realized (gains)/losses on sales of investments in debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">141<span></span>
</td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights', window );">Income from collaborations, out-licensing arrangements and sales of compound/product rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(168)<span></span>
</td>
<td class="num">(488)<span></span>
</td>
<td class="num">(217)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent', window );">Net periodic benefit costs/(credits) other than service costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64<span></span>
</td>
<td class="num">(288)<span></span>
</td>
<td class="nump">101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Certain legal matters, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="nump">157<span></span>
</td>
<td class="nump">240<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Certain asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
<td class="nump">3,115<span></span>
</td>
<td class="nump">395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessAlignmentCosts', window );">Business alignment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Net losses on early retirement of debt</a></td>
<td class="nump">$ 999<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">999<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization', window );">Income (Loss) from Equity Method Investments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(17)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherNonoperatingIncomeExpenseNet', window );">Other, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(388)<span></span>
</td>
<td class="num">(417)<span></span>
</td>
<td class="num">(328)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,578<span></span>
</td>
<td class="nump">$ 2,116<span></span>
</td>
<td class="nump">$ 1,416<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessAlignmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Alignment Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessAlignmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Collaborations, Licensing Agreements And Sales Of Compound/Product Rights</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromCollaborationsLicensingAgreementsAndSalesOfCompoundProductRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income (Loss) From Equity Method Investments, Net Excess Basis Amortization</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_IncomeLossFromEquityMethodInvestmentsNetExcessBasisAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherNonoperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Nonoperating Income (Expense), Net</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherNonoperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnDispositionOfAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of assets, including but not limited to property plant and equipment, intangible assets and equity in securities of subsidiaries or equity method investee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnDispositionOfAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestRevenueExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest revenue (income derived from investments in debt securities and on cash and cash equivalents) net of interest expense (cost of borrowed funds accounted for as interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestRevenueExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (reversal of expense) for net periodic benefit cost components, excluding service cost component, of defined benefit plan. Amount includes, but is not limited to, interest cost, expected (return) loss on plan asset, amortization of prior service cost (credit), amortization of (gain) loss, amortization of transition (asset) obligation, settlement (gain) loss, curtailment (gain) loss and certain termination benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=SL108413299-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetPeriodicDefinedBenefitsExpenseReversalOfExpenseExcludingServiceCostComponent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyIncomeNonoperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ancillary revenue earned during the period from the consideration paid to the entity for the use of its rights and property by another party. Examples include licensing the use of copyrighted materials and leasing the extraction of natural resources.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyIncomeNonoperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>182
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040027360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SeveranceCosts1', window );">Employee terminations</a></td>
<td class="nump">$ 239<span></span>
</td>
<td class="nump">$ 459<span></span>
</td>
<td class="num">$ (181)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringAssetImpairmentCharges', window );">Asset impairments</a></td>
<td class="nump">81<span></span>
</td>
<td class="nump">290<span></span>
</td>
<td class="nump">190<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessExitCosts1', window );">Exit costs</a></td>
<td class="nump">53<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="nump">21<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Total restructuring charges/(credits)</a></td>
<td class="nump">373<span></span>
</td>
<td class="nump">782<span></span>
</td>
<td class="nump">30<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts', window );">Transaction costs</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="nump">4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationIntegrationRelatedCosts', window );">Integration costs</a></td>
<td class="nump">311<span></span>
</td>
<td class="nump">260<span></span>
</td>
<td class="nump">317<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts', window );">Restructuring charges and certain acquisition-related costs</a></td>
<td class="nump">747<span></span>
</td>
<td class="nump">1,044<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our consolidated statements of income as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="nump">158<span></span>
</td>
<td class="nump">194<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts', window );">Total costs associated with acquisitions and cost-reduction/productivity initiatives</a></td>
<td class="nump">967<span></span>
</td>
<td class="nump">1,434<span></span>
</td>
<td class="nump">805<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost', window );">Net periodic benefit costs recorded in Other (income)/deductions&#8211;&#8211;net</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">146<span></span>
</td>
<td class="nump">136<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</a></td>
<td class="nump">27<span></span>
</td>
<td class="nump">48<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our consolidated statements of income as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="nump">63<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">118<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, Informational and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our consolidated statements of income as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">72<span></span>
</td>
<td class="nump">71<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringChargesAbstract', window );"><strong>Restructuring charges:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringReserveAcceleratedDepreciation', window );">Additional depreciation - asset restructuring, virtually all of which is recorded in Cost of sales</a></td>
<td class="nump">8<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCostAbstract', window );"><strong>Implementation costs recorded in our consolidated statements of income as follows:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ImplementationCosts', window );">Implementation costs</a></td>
<td class="nump">$ 22<span></span>
</td>
<td class="nump">$ 39<span></span>
</td>
<td class="nump">$ 38<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents external costs directly related to effecting a business combination which costs have been expensed during the period. Such costs include advisory, legal, accounting, valuation, and other similar services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationAcquisitionRelatedCostsTransactionCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCostAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation Cost [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCostAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Implementation costs represent external, incremental costs directly related to Implementing cost-reduction initiatives, and primarily include expenditures related to system and process standardization and the expansion of shared services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring, Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges, Acquisition Related Costs and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAcquisitionRelatedCostsandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesAndAcquisitionRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This element represents (i) restructuring charges, which are amounts charged against earnings in the period for incurred and estimated costs associated with exit from or disposal of business activities or restructurings pursuant to a program that is planned and controlled by management, and materially changes either the scope of a business undertaken by an entity, or the manner in which that business is conducted; and (ii) acquisition-related costs, which are costs incurred to effect a business combination which costs have been expensed during the period. Such costs can include transaction costs such as banking, legal, accounting and other costs directly related to effect a business combination as well as external, incremental costs of integration planning that are directly related to a business combination, including costs associated with preparing for systems and other integration activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesAndAcquisitionRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationIntegrationRelatedCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Costs incurred to effect a business combination which have been expensed during the period. Such costs could include business integration costs, systems integration and conversion costs, and severance and other employee-related costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationIntegrationRelatedCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessExitCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Includes, but is not limited to, one-time termination benefits, termination of an operating lease or other contract, consolidating or closing facilities, and relocating employees, and termination benefits associated with an ongoing benefit arrangement. Excludes expenses associated with special or contractual termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessExitCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of net periodic benefit cost (credit) for defined benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserveAcceleratedDepreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accelerated depreciation charged against earnings associated with exit from or disposal of business activities or restructuring plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserveAcceleratedDepreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeveranceCosts1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses for special or contractual termination benefits provided to current employees involuntarily terminated under a benefit arrangement associated exit or disposal activities pursuant to an authorized plan. Excludes expenses related to one-time termination benefits, a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeveranceCosts1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>183
<FILENAME>R92.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952624144">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Total Short-term and Long-term Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestmentsAbstract', window );"><strong>Short-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values(a)</a></td>
<td class="nump">$ 705<span></span>
</td>
<td class="nump">$ 1,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent', window );">Available-for-sale debt securities</a></td>
<td class="nump">6,687<span></span>
</td>
<td class="nump">15,091<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesCurrent', window );">Held-to-maturity debt securities</a></td>
<td class="nump">1,133<span></span>
</td>
<td class="nump">1,003<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Total Short-term investments</a></td>
<td class="nump">8,525<span></span>
</td>
<td class="nump">17,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestmentsAbstract', window );"><strong>Long-term investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_EquitySecuritiesFVNINoncurrent', window );">Equity securities with readily determinable fair values</a></td>
<td class="nump">1,902<span></span>
</td>
<td class="nump">1,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent', window );">Available-for-sale debt securities</a></td>
<td class="nump">315<span></span>
</td>
<td class="nump">491<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesNoncurrent', window );">Held-to-maturity debt securities</a></td>
<td class="nump">42<span></span>
</td>
<td class="nump">59<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PrivateEquityInvestments', window );">Private equity securities at cost</a></td>
<td class="nump">756<span></span>
</td>
<td class="nump">763<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Total Long-term investments</a></td>
<td class="nump">3,014<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="nump">17,133<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LongtermInvestmentsAndEquityMethodInvestments', window );">Total long-term investments and equity-method investments</a></td>
<td class="nump">20,147<span></span>
</td>
<td class="nump">2,767<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldToMaturityCashEquivalents', window );">Held-to-maturity cash equivalents</a></td>
<td class="nump">$ 163<span></span>
</td>
<td class="nump">$ 199<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_EquitySecuritiesFVNINoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity Securities, FV-NI, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_EquitySecuritiesFVNINoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldToMaturityCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held-To-Maturity Cash Equivalents</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldToMaturityCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LongtermInvestmentsAndEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Long-term Investments And Equity Method Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LongtermInvestmentsAndEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PrivateEquityInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Private Equity Investments</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PrivateEquityInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity), classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>184
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953095136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Income (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</a></td>
<td class="nump">$ 366<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, before tax</a></td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax', window );">Other comprehensive income (loss), foreign currency transaction and translation adjustment, net of tax</a></td>
<td class="nump">$ 978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="nump">32.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax, after reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 35<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118948100&amp;loc=d3e30304-110892<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669646-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (b,c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>185
<FILENAME>R115.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036729680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Footnotes (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 02, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2018 </div>
<div>pension_plan</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen', window );">Number of pension plans frozen | pension_plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember', window );">Hospira [Member] | Pension Plan [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost', window );">Net pension benefit obligation</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax', window );">Pretax settlement gain</a></td>
<td class="nump">41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | Hospira [Member] | Pension Plan [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems', window );"><strong>Defined Benefit Plans and Other Postretirement Benefit Plans Table Text Block [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost', window );">Net pension benefit obligation</a></td>
<td class="nump">$ 156<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Actuarial Loss and Prior Service Costs, Immediate Recognition as Component in Net Periodic Benefit Cost</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanActuarialLossandPriorServiceCostsImmediateRecognitionasComponentinNetPeriodicBenefitCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Net Periodic Benefit Cost (Credit), Gain (Loss) Due to Settlement, Pretax</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanNetPeriodicBenefitCostCreditGainLossDuetoSettlementPretax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DefinedBenefitPlanNumberofPensionPlansFrozen">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Defined Benefit Plan, Number of Pension Plans Frozen</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DefinedBenefitPlanNumberofPensionPlansFrozen</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlansAndOtherPostretirementBenefitPlansTableTextBlockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>186
<FILENAME>0000078003-20-000014-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0000078003-20-000014-xbrl.zip
M4$L#!!0    ( .%Q6U"W*OZ^[R,  *4Q   =    861J9&EL=71E9&5P<RUN
M;VYG86%P,C Q.2YJ<&?M>@M0$UN7;B,H*D@$! 24J BH@%%Y*6"B<A01,:("
M1WED%!4!$1$1T)!6$<)#P.,#%)0<!43ED:.\%#$1".0H>B(O$53RX" OD6Y
M:)).]VWOG?K_^H].U<R=J:D[M_Y0F^I>Z;UZK;777M^WNH._PR7 W&U;W+8
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M4U*&:]9S&^S9I:^EP]M\P[QLXP(L6J-L0B>,7_^VXPO?0H PIY/N*;?DFBS
M@;T3O-I:<=8@>A,M&8X=%=?4B*HDK[R#DF,S)M*V^V^>?F&"ML]+[PGOX?"Z
M=;(J3[8=-]3R'8HA%HH3Z!'D-90M%)XF?[X&RJPC&\!Y=B-JJ#-'"C:. ,Q-
MB(V,/KN? ]UH.@.K>B'M)IP\WQC&UN9>R*];OUUGI#;ZX5"N+4RZ<!0S\8]I
MJI=__,2_?;H)>\^;P5->I1IA;=T&4%":\^90.'U(&I3(,V+:,Q#7<;Y^*'\N
MMCIFR!4)DHC5 T(-NH3HXM.'^*AY]BOOKJJ+KDF4FN7Z\<'1,G^#G1WE4[;E
M;3C@7$Y!S.G#;G<1DFPBK0#=I^10%X@4FYB'&3KH:206*I.*!2( 78-D0:)-
M'9AM:$:^QLA,IDM+3924HH<>:J>:(Z=)J=@BZ!/W4'$ :H)$2W#@G(M_6TG8
M5X[QH/C7;B="IR7337GK&*8V))PXU&H;C01#[S<^@C)SH"!!%5_#JL93$FXH
M+ XX\I:E^P1N3_B##;UES#["TB/XT;D[T+/NA!YQ0O>B\JS&;@/813P08-0Z
M+KY*_5-20U?$#6:3"=:IC_"W*6\Q05D87?($Z; 87E[P#N$_=P39F&;A<VN;
M.FP1G)F-4=_:&5.T8JH:3*R@PM1RSGQT.31<.&'5;0[5G,Z\+5.(V+L'LKQ#
M)_L2F&YWB?A33>!C*<=R7&$J.S\F=5OHD.4M1[C\8^2.RO:C1B/T9^G&3<97
M@J-G/2ZK3K',V5M5ZQQL=2P/;O4EBLQ19M@CB!/OK"<1)3& +RPR@[D3Q@&A
M*(,\P]D?&I)M9\S&*&C V](:PS#HI5B0*N4FG>)18'8=P0M-%D !-^VX:LR?
M.E W<B.77,(5T%)T!X,+.Y%ME,YG5B'N=X.'BI]=S'[\L-PH/_N@S]S@EI!-
MW;2J]1<<(OW\&PY.LB+W"2.=.[3?7V^)/7C5Z;?I\F5WSL[^V^#.YTPD(X9A
M\"GRV3+4&[)BS"\UO=@ #:,N!W@6H3?*'>#M1C[OG%^M?!8AW5H 'ZIBFWAU
M?&$NU^PVKVI=^N9 W,8-ZW-38*)%:B&KL)9S%H)U3Y%GD*)Q%O3Z)C(:IM%@
MY#_,3Q@.O.)]=K"ZXN4'ZW)'#;]^D\7EJ0(WJVJUCEP3>/I-QYM9CB9%>H4Y
MZ!9E-7A0G&"B!X'I:"S,KY63S]7$253@W754^_>E(3S26YYQQ46C.TBW6"#7
M3WMPY#BR?_SI=;NM7\\T*4+=;%\8['0S$MF<)94L*QXV]6[].FSI\78\Y][(
MR6>!]$?MMN]_CT\J_6QG_#/7JC10)_^$VN/*W.67W(S6^J@T^ZZP/:)*)-R_
M^?AL2DBLZ16LF:JJ)"JIY!$9VLY)X6B7,-UBI46T3I\)>7,!NZXZZN[](N-G
M 6.2T_OFE3]K*[^GN;CD@X>I__WM]V<^O\4G<*M^Y-LC:[D!U9% ?I(T PL/
M'<_5A4 !YMAD=NLX6RT(=;GFHN<SW8KE&Q\%P0W-"2NN'5DW1NG>G1"RZW)E
M2D0<_17RM)&A$4.R2W=M=(Z\=/Q+N)79@I,G4)'!Y]44]:3[WM<T-[&7\J.\
M"V8W7^ 6%=I5=TR8IZ"G<( MQH2<\97,*((.D.O):#>!&R2^,H/6[X<,$<2"
MEDB;>L:]BP/)1^$^+(UA0!A908!74!-1SE\ATW' U?<"#>H9P($=* X4%6&"
M9D:Z&"*HZKLQ+$&4SD=<D$ <R.FB22=QX&&?4H-(#(@-$>%S* <%E3%C.+"%
MFTK@=A<.3*TB;G0#TL#2JV:"4F$K=FL*!WQ\E,EW^ OY/YK_??".?&?J?AS0
MM9$8*!<>(UA%?4:ATFD,*^4J=#>SG'X\_T<QT>GL$2F->$0:U!.\X\]ZS#SH
M.47N^('@$&PR71[=I_1G_$="FH>9E0DY<CLFP0P2"9+Q@HUN%YUEC$<])OB"
M%I4S/B*25_,_>^@APS^<3085)N";)S Q=2:H"8Z=<47=@S)HXR$('P?F$*3F
M"@FYP0'X_4/'V=B".-J F/,U"GR7;0F__]%<*I'IWYZ)1?9PL;G8?!SX-)&!
M9(I,P/YV&,2,"2/-R; -505L?BLEH6OE8"N?-DA0U8>V/CU5/YX=1^R86!S8
MU"=DH(O1U3CP>I@,6^<2US47$5P M>=CVVFRP\QI.)!74D=&(L9QH) %MA/$
M], 1KC#\API^E%<R7V?BLCP?HB5%PD#T.OC?F9>\><IKW\H"2+A!)(9A3.IS
M@HK:<I/>&@D3G5<Y[[W7U$,A'9&OOY"]O[VX/'QE2YR3H+KM4;?&4V1^@UG-
MZJEIKKKZ#"LY#@S/4NQCB1B/GG$3*%1G='LSC^S2X^\Y+B)9*^]6W/_P01@:
M5= 5(O_:RV&//PL8<87"$P^_'?_VH&O!T*H!3 NZX%AZBY9L]WJ-T]!NAT_.
MGG5,M]J]S_S8*:-'3[G<?%.PZ=G1IZL+/D?LZ9<%/WAW^G)A])'V@F5_:,D;
M[K(*ZC[XUON%7VF6:>G^<7S=A'M244#"@J:51<._55CN?^#H-=!8<*UWVYWC
MV967O9^,']*3.48/FT&Z/L@]CEHY/U5,^DI*:>FT'J?.> 3;YT26?C!%3G4T
M3GO[=N;AF&,5GI+W0V1#:G)8Q,H*<OQ(<8V7>6ZN277\KC,!ZY2W>>I,6U@4
M3S5$<$!6=18E]XPD[7[W'G&J8RV"S6_='3K]9W5E<2ZY>7/%-<%+V/R9;-T2
MJ(-=4&/_&Q(O:&F0OM9W5Y[XZ;?P7&K2Q#9+(=-0L9&I@R3#JHVTV2@)=G^.
MK4"2)>IMN@W=<]^@+OOOA69;]G?EG];B5>E?VM88*>7/]5!GU] G+*J)/18H
ML*G]%8E7V/R<;6DQL>*[7SVYO(%S2<!!SM%HT7:?'J' F+20Z:<L<SW[E7Z6
M8\#300T0?W@C\XR$M"#&0JI_)?I79J2R((IV(9IEU H>&4FAZ7R.VE,%3=:#
M%[R-^E#3 /TW!UO"F1$]?'),T/:.&M_[ [QI$"<!M99QWJ6$9^94'?7H_&,X
M[U1<Y,5/9VDZX&%*9U8#:QW17/E+1M+ LD\ETI%IS%D$)$4BKA-.2)8T/,71
MX<((NAR.E(G8*$.R\/!RYNK]@0^&)DP<(5("0^K1D60[HB-V"9<J#Y!3[.UW
M"N.*7&3#%O78+6A$XM 0YCZQF=#GQWK%6@LY)-F*-9'(6K(*:=@_K\G\^ENY
M-P=2E>PQ6=*"&2#5:[\4I@RYPW1AF/IS(WJRK<*\S?;UF0UO*D;F#+I%W!GR
M64)_>^G!F@W E<L;5"W:>NY/VOY+Q/.><\\E)Y^/]Z0O SS/JC-V/W_A?#GB
MW.43.P!#9Q^+GCA*0[6075KLK"LKHLQ $O<6=W<P^- KZLK*BD3+>W_6)(\[
MI?G^E-);.NSM>_#JH+:QSR6_%=L#1W-*[IREI= 0RI9S,'D3X<19L-;)%&'#
MZMO@\3%41?E(*X>:)7$"55?F_A+"F976Y3&'G^S\4]7PR4.5RWJ'O3O#KD^_
M5KI ""T$/6B5&?4CT]#MA)INL':U,P76K>V>#XL2/RE_X4MN&T0>H5HWVXKG
M!NOX^_JAFOH='H4AF9/V)9%'#Y^JY+Q<\_SSP83F1JF<@P.:'HI%8/-#ICJ!
M(GLE(YB7SR2]N6D@L)XZ&](RO6"3KB>*O.EU;)&P3[OQT..;TZT<"R[6]2(Q
MS<<%?]BMSS?1VG7%_=K]_(H=1&?(=V/<(<U#>F36)K8O'E<M>K'J*A)N]<*$
M9%/WR>[ARDIU@QL'+/SI&COV/+O:DW%QO_&8Q0Z?C^2Z]7K*#V"]+NMW\OA1
MA@I1WM[&..' M3T_D'DI1M ]3N=H_6=E8M3Z!5$&H[\&]8)]8J10G0PV"P@D
M6/0'DS\@RE'4B*0F*=@7FC29?Y DMZ=\>[D1ZKP0!UX^^*%,=OL#D:P_J>L3
ML'N,C@--_"*:)0?>H45 25XR@08;;TZ!K1R'R5C.?\3B/6"#RV-=+$G+FL#>
M#T3$LT!OE@]-=G,! 2:NN@0@Q*\;)6"&&OYEC';AM*7B,8&^YLI+M/YWO&_O
M38JA:!Q8<>_?$*:PCULHYRX@R'S"$QH.K,2*T5*P8>U:!99N0<#"C,A> FR8
MXH^?P)GC/I,1/UAOSQ_+]+0D=/FBM54$<IP ,7_EWBD_XF['(R:5"W80G*5.
MLZ\)NSG%?_H*T^[G?NG!YN=,;"#B=.#;NZ[$LEHQ^B#OA[(5"Y]SQC=$A&/Z
M?Q* ^U1>-OH$!^9)>D;D:V\2Q.6"H2A+N6X,C+Z!FC8S/@K1U0Z?SQ&HUP"1
M"0X1%,^?\G+]H>S[I(C$EM<*Q>,1:PGV,M.&0Y%'?L)&;!#7._RG&<B!\$Y5
M+"U50L.,1.K@Z(,?2>Y%3P.;51KXB.\5@K*-#(I>]J&[XS/X_3*"O\P-HC+&
M^UXKNX.@C,U@-!D2B!^I*XT-GH.H7:X6#O1Z_4@$[_RBA@-W5%-!J,J"D(C;
M.==$_ZVI2TR#-C&FUHHNTB9^(MC6;K%F1S\%U?-]WNW4;A=^KGL=PH"X/03C
M$8230C3NQ#CU6'R>HIQG[@7S0N0< 3]!_I531TNEJ?,6U5I<J/&%W@NK,Q++
MQ?,Z8ZH$O_G'1-;FFD%&^X8<.\X.U[@JGYV1!T$C$W&(,93JQ>N@ZJ.+D7!H
M[.<V@EI]+G'= P7%EU.T&.+@\Y\L:_='117L]?58S^F2)/9]'K79W->PX&GT
MG5^&/C]X]T&E]G?1%*ITG<$_1[U$7=;+6X5<N0[SO#(#3UPT<5CY<M7QVL-Z
MR[P$=;&G9N3JY_<ZVQ:X->;_VJOA=._I>OJX3?^8-."01)2X+FC:X<Z[ZFL;
M)9&:[XV=3_GO>&9E);W>8Y9\P51S>Z#7MIN'FNS;<WS2V;+)>A<X7D8?]H+J
M79$>A2TR)%6/QV;$E#A'YW'KN!?>FDI]&FE=?!_$(%K*3\*!\N@TZG*7HE6M
MK/E'W&4C2>0Y+*V8K9UTF5A_B.6:@2T= @\P5&,"/628#7.9\FZ4J(O>R#'
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M+FIP9YV2>5335Q;'WR\K@3 80M@F$"$@4<1*$C9! UH" 5-9.B@@H\@:F<B
MH&%I3X A5AH6BZ*B[(M8D )A":@UR%:5Q0A"",4!V901@0BQH)4&.VW_F3]F
MYK[S??>>>^]Y[WW>>QNRC0FPQ8/)8@((@L!QU0 ;DX#GRN.$ \!F@QT  #6
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M)=A08".Z/D,.>$$SL3;K[@\@K\=0\E_\@,D=]#YJ;?]Z6=E).X!I Y7'VKA
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MHG)L^6EP\D$VIF.%J6R7 TZ*2(@<N'2'B Z;3B2S^R:EX2H0_U![&$EOE*>
MY(D&8GCKVWD;AHEJ-E0K 6'),+F$E+ &8E<K2.C:/K0NCW[]#KLUC&<,&W)
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MW:ET;V4,TCTY/+<;W2^[ANDS_>#F2Y4ND*=8&\>H9/+B,-+24?Y2.T.D3UH
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ML>O'D1]G[X#6+G_;ZM.B\#!WXJ^[AE+^?E!I,NS/^U<0UW4_]5#&/0M%U^5
MG;+03H)%E5(C4-S#:>(MKI1</?#-DD4$>]9=!4=X%S$SQAL.Z@ NLP"__DM_
MZ[7^CWU.?\QNH[S=^#_:%U5F@R>4X4)<51X;5Y$#%"W+E.^S\*3REP.78G[\
M%H_&EYA+L!@MRSA362]?%L'!KKV%\F4!A&S,EB3;KC[W@SY9"SMQ\Y;^IIFT
M G#IM-W4R_:Y1CD018#_(9U&UO_]:/;?]E(M^=,-4<!_'?U/<'3U,,*=U,CX
M6TX\,+\UU]@))D2P(\Y\B.#^3I 4B(GH=2(1?#<MH<CVA45(\#;PTAO6*L;<
M$@+JZ6OQA?R9UEG _B/+9TS-< P\IX"]>L*?/7X;4QO$FRR:WQ0X\1T.-@4^
M^#XKV["#=?REJ]Z?;?\[(@6_[S6L^S-@$!W]OG7P.Y"\PFU5#1&2;H,?Y\%*
M>&K?<_W*)\-^F$M\ BAU@$E8/ASPF;<41]EE[H),\N"_P ;U4[[L!S>7?DX_
M=>XSF*+W]^KX TD:_OLG)JNF5LG4P!N V9_<,")NQSJ(Q4]E>79ZU=!'9NCW
M#1\!?,/:7L]$4&0CN\4R!FMRD:M6TD-%^<&RB^2DA?%BPA:!-5O*Z;7T,1U3
MD386DG_*&%\F2SW)R0*A(6V<"QZ"U?YD>#M.2=:]LEOW+Y!UY("HB80SU'Z<
ML]Z XE^(6%@)*+A#Q:[=P_$*1Z3:CV1T-%AZ/ E M>  =*D*SOMLRWB8D (*
M[X*0!U$S^)FW=X]3P2BG[*AG]P2--AAULR<O371.HLK/(%W/U/AMJ$#]:#=J
M?^_[XX!6"*P^P(=)X_QOW9Y3^@Z1U[=Q$I^4T(Y![QTYHB=3JW7/!NYO"MU@
M$=@>O4]C^$!>8HKU6>']Z\<6U6]R6GO-#EQ6<W1],M=3,UG$6EEW/+CCAA=R
M>8_CC6ZNU^-/;ZU+"P[5-.5XI:95;6\Z</U!7VI(F1S@$)%X>RDNN+-QVZ-S
M0#&U#YPLRBU']7+FMC]L1K?* 533=,($!^=799@1CHN[2_"<F:WHGEKM^ VM
M\."/AFN!K>ZU'"3J+9,_0GJ] N_IC^)KMSM>!13;7C\/=A"OD6],]!ABB[PA
MJH3SBK,$W0?3QW&J5[1(]NVR<8#MG5^X$*1EY27M#MP8GAECXM4L)?442_>H
MYJUA ]TGP<,V8F->\.W:TXDV#V8IV.H6&9XMGQ&R,)^*I$D'T-&"F:'=+6?)
MJK26SYA^:TFADE/YS2^!%F^U78O;2CZ?Z""="C/]=O_9D[C^WNWT,+W&EW,O
MEJ^+S.@K2,Y/;K9YMK60B'N!!^ ?W%":O5'-F=I[NAPS['%,D^W\9O@-[[<3
MSI(#R+-V!&2#)[9.AKM@/7*-A%AY2L.C#^?%2R7X&N8Z6"ROL]F<-QYSDJO1
M\MLSP88?$)\;C(\.5U?\4G0O?@W_[B,3IG==RA'8<;E%9_KY+X'M7H'M=2,E
M/SXWC3F4+C+0<O%Z>UJZ/[WT<?OA';F/2[_^1S+QFV2870\BH<ERH.T@6?B,
M@]S!63PSA/C_1I('X&"QC2];9X^IK)<#B;^!W[IPY:1V!IS=%X]JN<L!]5_E
MP&0AMP=7>C '6RG&A=P- K(Q#S/&A<N0MR.ZO0X7*1N(T!$*ZFHO!YK*^"=,
M[A+J_>3 @E_.R('M?U@11IQDQK]0P!)#F'-SWQ^&;F(ZP@U2/V0>S*[C0 >;
MD8U+?$V0>U",2 Y<J70P2)X[99E[I:([L=(R;Z3W5MLX16 :5]J.]81N*BX/
M3HZ+?M^@3MED;RH'[,-NW_^<;A4WE6+U(R1-S0VTUDKQ"\D-G#5/.4;+&;;V
MR/!?7AV0-UP1<GFKU&.KQY,U]B&TX 4>T.Z"E6[W3?;/0Z;_Q.'L?W:56JRQ
M7TE"_F>'V?\<&];O.*1=E@/_'"+R/\6F=&Z3 \#"M=(_A2CPGX/3/5:G,0]I
M_O_38A'V/6#K2@D+T>WP3/+9 61#.*JU:9JH@IC6L=8\\>;W)505^'YF$3O"
MO ^]8&.:OWR[.6[[X/C/:AG9&ZT6RUH>S9R[F1Y;^#9ENK1J_,9X95?:S?#3
M=:'!8<&AZH(S(:'TS95;^IJ7L#5:WK!7/MW1L.;9I@4*$$6HA"XO]L*3@B1L
MJ.4L!:O=^<(GK[G,G0@%DM3/]M(X99/>PP4%2'EUA'%"V+KV\6:!3DI54O^(
M>^$#H_.7]R]J:32R(A[]LU7TS<BE]6[-//8@4*KEY9&:T^,UW'OB=F[O3K\\
M6F]42N6Y,@\M+8^G=2$! 0'!2SRZRLI@1\7*98Y+-CT(?&3>\I\Q#_X?+ ;M
M!DHFT.626J(2^41SK[IX*)8OS!^ #EO!5C7-%_&^@V6(A%FR^\X43<5W,PE"
MXE(&9Z^/1RM+I\^R*[TW+NT4J;!K\$-NV>9ZXX2RZ>EQ;6R1;&M.]K#7)1P9
MY "R,?TUF/O.=V_!W"_+'\UX_-KTY@%SHUN)Q24U)?T+0M;;D=D]-[C#7EFQ
M1</IK-+[P5Y17U(?!\Z6WBC+R0GJ]<@),<O*S@V*"!MS[QD8GI&&N@1'^H<O
MZ>KV:&M< #MI7(D;.].@0=/8>]5!=^.9!MU'CKIK8G?OWJ_IIJ%X:/_\AP
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M4UOZ)J[1K3SNJZ'B>[>CCM#+B'6_+SE^VU$M7JF4)6T]TB6^8E3K5A!?>\8
M3!!TYUE;/O3$U6I'\(%\@WW7'[7E)]ZPOCY$.'?ZCK^.0^G:]L"N^$50EE;I
M2E?MV.>AJHF"CMB@%9?M'&ZT<G>5KM]S=J2UD**B>_U1^QT_DX.7LK?MV^!&
M*^#\!TJ X=CRY]/GY(#40Y9.&2N%Y( GI(S(YGYBM8*]_68\F(H:\4O)=73$
MNY_<;M?WX'.O)VKHY9BH=E$T\)3AVCY'G-O7N&=.@Q_06>IS8G*<))TP)^4&
M_D]?'R98(,6P^8#(,>8C?#!K*=S,YOIW55J*JK2K^6IG-6"E9)N=7$:Y[Q/H
M"]O?7_&#-/4^[=SZR(<-X46,C#K=_HLBTN+/YWK9"4Q*T;#7ULSP<.)O,U3(
MC1BO+$**IKB7Y,!*U$628B>17J 8,(V@B7@;S4@)/ZZ,^&SPJ>BMNH15+*:=
MLEMUA+'E2#NZ"920%NZ\6RTD:#,:/)%84G*)":J<,WIE]FY;E43Z"%^8<7UQ
M<S3+!&H>*Q3S%S"TQ=C+T'NT"/ R&A;^\$@/(T!@%=%YC2$Y!(W7L6,J07J(
MY!VZ3E9(%^K)PJMYQE!3BK@QDW04)L0S[7-HX;H+\Z%,]I@;W%W-TD<B"U #
MJ&%L#AIM8!D@>G/[6$VLU5!]%>PI,:XCJOHR0,E,$JH#K^9MI:*43DR/$=G
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M<,+?UH9C_=F>Q3_2FU,!BO\@?CW=AT/\H7(=4;YCS%02/E.(+:C!D1PA)LX
M]&T*H'W/5P$)#L8\F<G@I MLB17!(0-\O!N\:(?ZL5<,;5S&]\W!L@9NX;)G
M6?/D_3]_W7W=:"3]0W%YW2\]NEF7RXOL][F9]2\]N/S:"C5/@&%*I_+@;*R+
MK1XETM\VXV.=9P;;"K<P%OBC ,Q&-<:J,0.8?):^4L):,'RH,\9I*2*0L0C8
M6R?'+CH!#J#) MD!_%9N<<0:Z9<7?(-<F_%+EQB=!'@<8_=W96,,4BAY$1F1
M2<D-<JN=B.T]2I^NO("*Z=** Y!"J>A=IC2+A6U"=;*)22)"F4J@D20KH\S3
MU\%J38G8[:T/&7(>MA,DG& HT?VJX$WY9PJ0ES*O[#?]TW/WG6.='LVX[R7[
M$I=WTBH5B/[7M5AB4R.JV8SMX>"=ZY%&-3CM>:^K?X*!QZ0&K^(?AR8$,^H.
MR@K@=G<) _29(>(,,5M $(Q<>2Z8(&]5 -J5QQ1 )D=J++_Z?0PK[,1C)G G
M6?_M.XA_JAV.QVEQF*NJ,B;LUL'RS"B+?&:XX/0$2;XZ1P+VG<3+"L;"_DB1
M9V6PTT KCYUV#'.TR1Q,;)QIT<^ZA9['H7;$17/OK/^WQLY8ABE:;[YR$.%\
MTY153)!_)S:ZU9&^FS@YX;X9;F!/_S8TT=AU!%?+NP@LP4@L7(C=L:LZ-8%]
M.B;X:E$-OM/640"[O4DU'YHQU\,*8&91G0(8'$S4W!=8./_'LI?/7S10B!O?
MI@#FB'$OED,$^5FG%0I@R/@,F8W@B;!&6$>:,42R%, !I'2</!_\.$2+5 #'
M!"HX:Y\->HSO<P$O]L\<^E&Z_W%HS>UT:G+::O0B)^EK.;M7H-PL?S-?_%WP
MK'&Z.3/::]^>EY=>?DG:L?-CR,6Y1X?NUE\RO;K_\.P;&Q9&)JWX^:WRUY1H
M:%A<GB(+G*UJZ27_C>ZB+T3<#@;N::P!(>?>)3NC5?>KFNYOCTHN>7 CK2ZS
MCT8Y\/3IVS4=UESJ*&5THZ>WL-6=&GW$"/213;,_@\W?.)^+W<ITWQ2%&5>3
MWZG(\%QI$WY%KC5\C=A(>B<=EMDT//VIHMVJ3Q@-60F[XZ=&:J!WP^II"9%2
M\B):3YU?[_D@IV)MRZ-[V:UTG<4!^565+7N*K"'['0.2->=]4FG$X/7N-Z[J
MKLT_[KX\^85A<=+>68[_%^'_G1&NV;S0V?2#-65VPZC5[H-'#U]UOWP[9.6<
M([,L A(7+C@*K+ESG[4XU(Z4&F4>(G1:V38Z$:%<9W<H_^9P;&!W%K>]+#WH
M9;R]=]N7O5KFU+C@2,>RH67NJ3ZS?A.?);PD:P7@\+ N.PT9E MTZ!2Q0!G]
M^5$'>DPB4J,;(H,S!VB6XH)2R1K8G)5HR5A)8]60%CCX%* ;(./:8HYF>*=N
M%+C8P:6 9BLI*+T;?AH[Q+OKQEB5,V%9TZ<*L<\ZV-RA.5=C^BVHJ21^R8?N
M,#_MA,*>P>QC%]>XK_[-.2QB>>BJ;*G[ XO"DUTZ/MY>T=%F758>IMBI,!*T
MBW3.CWJN,DSLSUE.W]-U Q9=X.NBAIT.+B7;H"+4Y]B,/=U<MUW7N-I<Z5 ;
M8VG8J3 #[<XRD3JEFWRQ\O0U;_07V(;/B8R)AG7U#S4[MUNSVHI-[0/MWG36
M-O3I>9CJT2+,1LUE.R-&(R)DAR-&2R1;BS07;T_1W+!BP?+0NS< D]E-_S>Y
M_ALGU]_'_B7*^Y7;9=];J5YCN'0B-9S5=[&-!<^ 8S<QZ[^?(^5P_DJ/S"@
M;.$O+\'P*NJB0LS$:]84\=OHO9FN?NS'C@;P$::&$[-B: 9[88:SU8/C!)C2
M<$ !2$V1E'P%<$7@B!.ZZ=H6]\M#I VN/SZ"BY2PD/<*X!]V5?QM(X2*4_.T
M F"2:=Q_4B_'?]SR#OIFB:[257Y-^NAX,X8XOO31_0WD+[C&'F['9WJ-FN@U
MO#F>" ^"@\_9[\\.(KQOUF75@ZS**G^$631UIX_=1YX9 -/_#B3F/L]_.Z?7
M-H,KJ7@"?"/X;L'8O[HC?5#^20'PF<A;I?][\K_3R2*"5SWX^^U_"_[*J,:^
MH&+4N3VN+6.X@_$3J$_^T[I3(%BWQAM6:GSW$RBM@ M/*0#G/24!C+_A_ZDO
M%4U[2)R<FXAK'<UF*,;*:\:#B".?_K>T_X>-/UK=)]]/@G_;[74K\\?NH(L_
M<#V[N1032+KZS/^Z "S\&,MZ_;>*,8^,4*BSZ#A25Q"2'1OE"V.N?E< :<2O
MQQV<%<!CRQ1PPBN-Y (EDI#4O.6#"L#F7^J# C#W&CR?>F(<^ZH 1,YHZ-]3
MX4?-L/N?%\*V*=]4'HA$[\X*_8LMQ-^;)V_(<UFC6Z ^ M-(QA[5F7'\;K"F
MM=)# 2SH'Q'"]IB6;5V*X'%)M =Y9 &ZUYJT^$S>LG:P#&NY-TC^B5P>&#;]
MLRB4-9+S,_H-S_/- OEJ9TQE+:Z^GX/?.[M&ZC5G(<T*0.T4.+V+B6I[*P"-
M2PK@6TD^MER*I_A5 F)6B!FO5 #]_N12S;W*8EX:27R6K(R>N4]*IE,4P%PE
M!7#^(5(<>*6[[Z4G.4#^6,H7Q'EX68V4-SD(5'A+(]#W]-L#!6Z.A[,_"Z3Z
MA/?-&"L!6W@5GP(8H0#>5 AN#)E^N%F'>B;F>Q"2I X*0)5Y<WY;_O:DR.O[
M\EW_6+*W<-=5A]UA;85S-?/GNVY(=5]U^1N2L42R.S#VR7VR"O395"/H]KVN
MNJ,;'1Y4Q7:$6(1UE/@]T(Y>U_Y'U>";7W^[L^9#3@0/111 G1VQE"TG*J-:
MI@I@"=:C '*C;03B7LOW3:Z@!"_!XB+R&3<T;RX/7D^>7EW8A8O>3L'-A:3F
M3ZU<!>#_I!1+S5NE (1?*#BR]S%V-LIWB9NG5VW&6[CZ2/XK[ 9Z&>4P7A"A
M[:+S"F Y-@<)D?JD@1$"9.UMO\E'4LM4W<"7H2"76U60;4[7ARF-#.56>DXD
MU"J^W[@3ZD@@N_>K.WX+>&-TP?V3<2L(JS%'^A6 &R[5Y^["YR\HQR,12!;8
MK4FXB5#V,-V@+^EW0NT\*WF1VPI"*Z+SKA8Z;[H9%UE$;M*Z>F'39,NKN+M]
M@:+>YY=-/_3U!@3N#CKSZ3(W](<IO'\RA=3^8)$"N.6<*( -7CH(A@@OB,TL
MU/GFS!8%T *!-?L%L.6HX'O7@<M@386@M'))O0.)1T2U-JZ]<6VMY"KIN-XQ
M6D&2R[5E^YBU(\6-AF;)PJO1B[9HR>?N<Y;VF84WIVZ^7'"_K3G2-;O--<_R
MX*VY-0&Z][OF0X_#.RG,QQ<Z2G[)KNFU.<:Y_%\ I$\S<3?#"K?B#S)VY2;N
MI-]P)WTDH<.A_T^ 749"M]3C!64=$?+U0O?@&?^FG(5$XAVW]0!)_)B-_,'$
M$13!>(V3N8L* .K'2<CMNV#-,1*\A:  [+I)DC>6"L!]+YXB+T'IKT0LFCNS
MP05@6!$1HTS6]Y<_)G%7 >1\='Q.'/>@](O>VV(+TJ2D#%(IL9IPD6&&?[
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M1,V[;C^4)LB9(Y)LD?E%:#)S'/'*RG:6\Q#Q-HP%\97K=G9E1LB[).74C1>
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M6? -2%B @*+%M3/M%H%29:G)9R1+[80CSYDSD+P":6CL1>'G5 /Q43G#+O
M<FU50?QPV 5G[H(Z&.$7VX@E &-TX[I^K7USVC?K5[FZ.28VRAGB^^,O"BT*
M6!5NG:]?CW5L\CV-HJ#B\L^RY9[,*H9"';63C,"2 9[\^OI^4M7WG?FPA79[
MWV;[.TWEX>KM7 Z._89KVI9#\OX]]]<]KHI.T5?\J]UP'\(!Q _TV],1:JK1
M=MOYSJ\#I%8V-I;'6'O*E:O"$08/>3FM^.0'05224W3]5+\F>(\KW,Y #!*
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M@T4F=M+I6A76/@X5D5I/ZK9HF%09SU<W:P+HW6^4#54>L!F \L="O-%4I)M
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M/"OFE0$"WID1"N\J<0 &#C,M4-?X$$2DPZC]BOT,TW/>*^>_<#B^'&(N_M;
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M\LP]S'&%LOZJ(^/".9[2#S18)$J+S%R()Y)9>/%< 2]<J&'LV#,0.W"7_"
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M!XM;,E(U[M3PH(3S3])21CI@LX1$L<!-<97"&,/E6XA[NC93.B(4/T60I\Y
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MHE%Q$#@'Q_D'['9 ";3-N(,T>;_=S2R;9*4+.Q[USZ^\S+AR9U;6Z1/-Q41
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M0'_[\C_]&\S_+7IW=T@T[")'.27:&*;_E[^L_%\GJK/%_P%02P,$%     @
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MZZJ:)42K45I/KU4$VGPNQVMUU\;S9^P%D_MGVN%QC?*A+W! 1AH#XPS=%2H
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M_I@Q'LNTOGA^5O#&42R%DQ1 Q+ MO.5&=%H+/8X>O3@*.MPGAT<'$1[3 P#
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M,<?TZD.?%J/=.M*RTYXRD<,+79"P6RQI,&=L.O=*^(%ZO866S@6S3"CUYW\
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MV,P\43-:;J#/#,@Z_+V*$;WZ%U!+ P04    " #A<5M0(_TQF&1!  !]2@
M&@   &QO<F5T=&%S:6=N871U<F5Q-#(P,3DN:G!G[+ME4%S!GRY\A@$&=W<R
M0W""NR;!0K $]^"N 08?($" P88 P=V#N[L'"1 @6- 0(+@-"2$W_]W::[5[
M=^_>JO?>#V^?>CZ=KJ[S].F?/-W]^[/T9P,@>::DJ@2 0"# XN\#_-D$J!3A
M#K8 H*K*!>  _]+^K !/ !QL; @V%@X$ L'%Q<$CH" DP,<GH"4C)Z9@I&-F
M8J1C8&"!\;&S/."!,C!PB''R\ L("PLSLTO(B M*\PD)"_YC$! N+BX!/@$-
M(2&-("L#J^#_=OO3"Y#B +_!I&#0 P"#% 0F!?T9!)@! (0%^J?V+Y\,P@!C
M8F%#<'#Q\/]V:"(!,$!@, 8F& L+$_/OVZ"_[P%,4BPR5@$%;'+M5Y ''A2"
MH4GY.-#'=7V4+SZ=PH0L/<-P\:BH:6CIV!ZR<W!R"8N(BHE+2#YYJJBDK*+Z
M[*6.KIZ^@:&1E;6-K9V]@Z/7:V\?7[B??_B;B,BHM]$QJ.1W*:EI[],S"@J+
MBDM*R\HKZAL:FYI;6MO:^P<&AX9'1L?&9^?F/R\L+GU9WMS:WMG]MO=]_^#L
M_.+RZOH&??OS'[Q  !CT+^U?Y47ZEQ<&)B88$_(/7B ,WW]T(,7$8A7 )E/0
MAKSR('\@&(I#\3@IOZX/%RKTXI32TO,3'A5,>)/M[!_4_HG9?XQ8V'^*V7\E
M]M]X+0,$8-#?GP<F!>2 FY\<!0B\_Q__.7!^6!K!W)FGIA8P?L(V. MS?UI<
ME#2% 1J#_?20I[*O9KK9RGW#T\2M+N,-K^'CV\$)ZS/:HUUKD35P1NEPX*=.
M/*+YUO;K)%I6B,KCJT&@U/SZE\ZR-3[M5(-OF(UY#\(^1HA&)#LBOHS*^2!D
M+&-VI?&WU33IX3Z\S^0>X*,T<ZW3,/1;;K_HAP!Q?9Z"V 'Z^O)8%-K_%S#B
MDN<):2OZ.JVEY)%T*$^FK:ZWEB,0'N,-4&@K_B>A;KLL-+)E#U(=TFMKCUG
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M1U_=TUU?2; G7U[F0;05*8#_#8"R*P]2_9G290O+3$9<'#!.4@V)\>3281N
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M*&_E1\$20S[&2E[R%)>_\&5$9Z6,Z0U<7 HAUOQ*4,4QV*8R&*6YY;A!DT=
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M$4_YK$S(V\)V0A,I/,9<Q0F4IN*J';I9ZXR/'M[C3^CU?L6W<^B5,O#6ZX-
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MO1_ @:<$8B&/&RAU)U8LB.$ _F=42,8==6?;+^H+WGH\A !UEBJZ('FV]R@
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M' $ ) "CP)!G#A2=M!F"]_6)0\5!4M&YBNYVK& CP/=CM!*5MP,:UM@<!K&
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M=GJNM*L/4#JOQ$!CM^D#X/U403,UQX0@3))5KV[QAX(%Y_X2NNS($)S+O2K
MT&J.,-X+K3_60][YI%3][)FZUX#8N2J/)K[(U&?[R4$#4.'].6'T/(F*^.A0
MD&+UOL!A!MNW-.&+ <I56TY8N.OOJ!-0FX&GH*3O-@2[E9GVCF;&>XV,0]@)
M_KIR1?S92J-VF6K"1(+X1D,6GY@=U(/=]QDPVOE)E@\]R\I4[E<"#QX<HT['
MZA&T85!ATS/=<V>QP*5.891@+SIMZ7>!#!C%.J;QRM95JC8MGVAQ_;*9VGZ
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M8<#/H'?1EN=K,#>ZCRP!B+HRBZ_>H43*XWO2"*JN%+FW_DSI>;C_YU7-_W?
M5;76OV(T(12--QPQ^M3.&91#J0#[!6C651*L>$P;G?\!8G)@C?C4;S*-PI6[
MNJ)=4>?PG4%75'Z$[Z.?75,? C\FA@D-J[!@I$5>ZI_Y)JP,&C5U9\/\G807
M[G4+;C^>I^)BK5AA.'D_Q9+,Y_+T2CZL -AI1ISU'D4T.@C+$2XY7*A8M\60
MN-I<&&F*^D@5!TV.K>[&:]8H&%M8(J@R>AG 5Z6Z,DK77S7FCMVJ=TB-5Y[.
M/=M578X1' $GA^;\_:<+='&Y;^7LI29(G8K&"+,/38-*X!Z>YXJ.K.=)"5K5
M^-M@+#$[!/>JU7?_BVDHH]-@,+8#RDERY&VG]^N#AYTY*E3B\11"]1.L?9C;
M;!@7<S[*SVZP3 MIV0_EB?Z=/.C_58!JLJSISB9E.E6W'L6FD9FQ)V^VF:DG
MCHZN^R]-UO'+KQ>9B >*2B%K:PSF^=2KXH9Z^3DCV1-I=\\+:6AOOT(<?V8Q
M$+G[ZV??L<4<?W2D\KUGO!_M<C)6&]O-\!(9VD'=YA<GO=_UM)+K$.?R]9^!
ME"H)).5<_G2L_H1,?J9*TSL)0 4P :&,L]RX=8ZV=%YI2*EA=(UW F=Z-H)&
M<)-40_FC*;_J!G&U<C$\=_"G>82PH;>,F0=CNP76D[2D>/>83NLLYM%D!"[3
MJ]-?_:GK;&?%(X/XZ4SWZ[M4 ?!CUD %SX]>= VDWW >5T0+-":?;Y0"3/F;
M,GS;BJ?5:<5K)K3'/$>%D:KB.V7#V,"&%1@J#I:07C@2\<_QE/+XMRHU_M\'
M=MNP^%T0]T PXWH"=J#"0J,<B=.)UP='ZFA'LEW:[$]07H)ARUUY&Y<"N?1Z
M+8_1&D^;-62RB7Y\-_WW;HE(JJZO+F6/BU]UO>&[C\*[918,O["*1T/961A3
MS_')&[$8%H6VB9F^=V,WQZB;[@F:V/TX5:#U8UO6$16*H%DEAMEE69^94.47
MW-E@?)5O6."QJ8MG1QZ,Z\*2-'RB?6T&$! .N;=D'ST52@)9NL\4QP]S2;T-
MJT^6GI(M+,B7)7&,Q=UKQZMB/A0(\R4;1!!Y3@SX+PZON</3#,'*G_+-_\N4
M^#6];4ZM\^3>\5BY[-IDQB+#[4WL>U[\BNWK7Q;]\E?IKJA;T<M.+.P1$$F?
MMV?R/$^;29ZV6=G:W+76_MLW;O'7NW=/M4OEI+5@B%9?\07&L /'US]W8)!8
M.@B*67*Q)F20LGM"==^450O=1;90K4T!PNS_;P( 4$L#!!0    ( .%Q6U!2
M<2^;W X  ,@/   0    ;6%R:V5T9W)O=W1H+FIP9YU7>3A4_=L_UA%9(_%D
M"]E"DWV2"<]8\DA#]NW)DJW-,@R-ID(4HFQ1R%)##)%=3.')'A.9(DHFVY1E
MEFQCSGMZWN7W_O&[?M?O?>]SW>>ZSO5=SOVY/_?]/9\#?@"_ &*GK&RM "XN
M+B 7N@!P"K $!&$P 1B_H(" @)"@H)#( 3$186$1.:G]X@>4%515#BD<4CJL
M9:1[6$-?0^G047.XOLEQ,S,S59W?;2U-;8Q.F!W_M0F7H)"0B+#(03&Q@\?5
M#ZD?_S\;^ H0%P R@4P>KD, MS@7CS@7V ,H   7']??!OR7<7'S\/+QPP3V
M" I!$QK% &XN'AYN7AX^/EY>:#0>&@=XQ?DDE.#F_/O0YV"'PB6/W;A7(J!L
M4?=:RI&\IJ+G%W%SC^!^Z0,RLJJ'U=0U-/4-#(V,31"6OZ.LK&UL3SF==79Q
M=7/W\ \(/!\4'!(:&86)CL'&QB4D)MU*3KE]YWY6=DYNWH/\@M*R\B=/"165
MS^I?-#0V-;>TMG5U]_SUIK>O?^#=V/C["<J'CY.S7^>HW^87%I>6U^D,)NOG
MQN;6]B]<7  /UW_;/\4E#N'BYN7EX87]PL7%'?-K@C@OGQ*<7\(<#3L7ON_0
ML1L"DA;W2NI>[U'6<UR3\HL@"^Y7T9]57?\%[6]D_QZPF_\O9/\#[!^X)H&]
M/%P0>3SB !+X&:I>>EU0O?J'OU<]6?OE5*59A)E-7B[^,:<1G9I5_RG_[=$,
M_<)[96X(0EI#^M$'[+E(=8Z V85XAU.S&-+^4$1_\&!\T50#O(BT*@\" \]I
MXV5YK J.=5+*,*M1BH&G8O(^B[$T;N^_TGVA\/9O4PS3:SFWP[]JGU\PN_0D
M,F'\2)(U%>X^[EHB*%FRUD/7]*L:WRSO]UB>?>L1Z[;3JJ_]ONM@-;V2)8)"
MH<("S@WM%!ARE"8NUGT+=544N5%^!*GL&>TKUF@L('VE.ZKCK2&<;:WP)"+*
MQ:GD%%X2W6'J'(??F[_<YIO&3+>I/N\4!N?L:8$MQKFPL($7%XNTQJ,<ZZJV
M?D[/9JXAIT^0<F)9]9R&SWVLYUOM'56Z!2"@/!%</?V;=QU%FSWH?G39#/MP
M50T$/&<:J@:SO;R?M*Y:A#^*+5VY>4>]4EV]]$7CL)_</ONKE5=&-OPRD/'M
M@A5_]=.)_8_F!%KM IS7U6XKCEZ\#MC%*.Y^<@>!WHQF1NV1EQTMXSI%\\LN
MN:XF1_!YSTM_TN?.M-]?GK=4J3]8AQQ<.D,9/;=&+E/0H\(?]/L%3FH%2*)1
MF(/F*,DS7+_<R?WC"#Y&CE@OG6N9)"4<@SC1X",^ZNO6<?+R)>D+\*+'\@G;
MQ:%O&GV#Y(RNRAV(,YOP6)*JNF:M^FS)R,. YN%=(<)OJ3'PG,5?2<%F*-PU
M->W;D79NH$9/@\ $LJ1&G%P6G3Y>I='-;<*?(WLWY(VOQ*=J>RG[2DNW#M(@
MU2XD-OQ<1)YA?8-CR<#S6O3:R.T2"G' 6-S[#3)6'JN\,_B#736@&6;7^OU2
M65M39N^1(,TN@GAR>O!67L(;!V'D"LNZ&>W>)M(HTOKTR3C6'39X!/_I\AJ3
MJ+FUA/J+WC%2FSAG7&E]7C46F6KP@A@ZY']ARCP[,=J,N D"1UPQ<]IGE@IX
M2PU[FM4&'"ZPD+EXN(^SSU-?Z[@,*M:D4VD)%4<:52^]P\K@A>[ ?WI-""*J
MH(D@G'U!<N!3W7>8"N?L0[2K?YI7>6GS>4H"4WU5[:+CCE!@"$-B6BX9F;D<
MFGP;0Z%@#+,#/'OI7<G/66;S[8673W86VR38O),]H'WF&N.JV,B/5RPJA8L8
M'!,GU649Y>]_:,4EC2H[6^(H%1K97(OZ*/]4,_V4I+,Q$=&YRKZW/^N90]DR
MW.=DK"5#!XM9$8[JU'[W9?S"W+K\ R.49L:)DTL<"M-@.,3#^TT=+C>Z'?>&
M]]M;@*<CAG-@C5-5MC71?-_3WA]12+ZEDL!4+CDHB\U_\RA[;"/O]**;9B01
M9E^+87T' >*(?FGC2_NR]'UN5P,N]-#F4<N26:^WQ5 !E  5@I3J"]/ES!P3
M8[NHBUA73X1.=<WW:\.&$N<6CQO-<@QHBM2 "&%L8%SQ38QEQ:+Z?</ 1C.G
MN'ML-?K<6JW>T;+2BLZ@YFP_N6GI99+3@\TD7-"$7X,P?<JZ#P1"6I%/)ZDT
MZQXCA9!U/G9KG]YSV(>#HJ,NF)C19%7U'GJX\XDGL79#$"D?%@3_/HP@=SYO
MM3?-.=E"1* FKZN O_C9Y(QWJ(1-G:?_RL$__[SO\,T5_X(M! +F&J35IR#P
M-:S(+:72^&-[M'7 T<ALR:W[I!C_;$]:U]RNSC428Y2"7I?F(*OQM!L<#.QV
ME+#NZ;'J6F9_('8!Q[V@=$,&]KB2<PAJ1U;&[A7DVSJGM.4N-,,H:N%4DMLP
M"&@XO/*EZZGM1N"_N6^___$N+&:@V8E/6@20D#?S]Y#G!H%[^4A:%@AH]E.0
MU.-X$/ 5!8$26;+*NBA9QK8Q,9V4S[$AJ-3_,55^K[##C3H67-IV5ZRF:I:U
MWDR1'V_NCY0!\ TO,\8P$8UXBY8=G0Y_PRO[H_I_JL&8!CG8R+%L^[7W)PJ#
M!X<JKTRM!.)739!$:X<6[SP)PH97QD2^AW::SRQ*TDD,C;+W2U7=;4/<<LDQ
MA[7TE4]GJL;XR6J],S7_ZGD1=F:_Y:D[Z&^W]@IX!9GZRX^OBF+O3/5(UWO(
MZ:A;]'AEW1I1]#^P4:-+=,@JSG)P&MM.UPWYWE';L3B4P0\"?8U$$*#H@<!C
MV3FMYK7'/.:45P< 0QB;KRJ%J X"$H1G[+0ZY.LGBR"@]V(=QKZ-4'B/9.[[
M8S,5!!0FD*Q7((# IR"IMJ.<2FB7@J >WTU.'0C4P+8H!@IWY>N/PQ6Z*I>X
MBZ^3J.<=MJG0YZ0>,[(E\AEZ;3<(+%HUON2##N1C>(H:QSFK!M\7#0*<3@40
ML# 84]A(7KRK@6_M93O04;+J4'X5"593JM8<&H\]P:J=>I:SSGW=,Z]Q!_\B
M;&/='SC=(^H7@;1T9[W'6=0?#0N?3MK2\9=!_M"%,:>\B/X6.&:9KC+.&1GD
M@68(JM?T=K5%W\>97'T6ZE(<3 ]4W.A*<GK%MD<T2ADS]#4EO4/H!/^[5;)X
M=B(13ZO'P[U]?X[<A$(65MM=0VX^\Y58*L#D3*2'G[N@N*]O#T_+P#TV3;?:
MF][2&$E8SDU]=+Z0V%QI]U64G18& CXT]K#=&HUC"944I14$1G-+-Q,@X++0
M8QN46T<V @0RH?2P5O!,U6K?G>*^:7Q?[[SG6BW[^DMSYN5=B)&:SUTD.O<Z
MC$QB[J\YU%3"MF63E(NEV+(^&8SC2#%\7U;)KA/40/HC*:3U77\0\!)E$#83
M.+\7BBX7;^]YBD.!0 9-8?L+OC 2O3E+4WXASM8LRM38%.)8!4"<.;"KU+R@
M,'Z P"X.R4D,\_Q'DR 6V,F708 V"P),96\X"&"OI7S-VWF$[P$!%73I':V*
MKX(=)5.[5=YUR3+"B*!%$8>ELV$5F_B 2P;SK<K4IK1'(-#P270,F1/H@<O^
MIHPS0(9XP!D(DNQ2$'I4!4LY-EEL$/]JIYN^L%9[I#9261F6&=:/<RJ5DW:-
M@@*W?JB[ARE'60,!009]>Q)QF1JWU2DW[>*3P817-8PBJ87+4/;(4'B\-3IM
MJT++V_KR<NWO6':W$ATTU$+A SGHU\"VZWD-([[ >/3"GU[.UD,_HC9,9%=-
MG3FUW:1574[_6<[@%]UM 2_\9UT0Z''$%GN]JZ&^R^V*+CAN/5B8=I3_$X;G
MA);,\'CE;ZBE>,H]\NF",BO<6&I'4\RRZ[_@DRCGLOJZ8/A#6_OX888AWY;$
MR:/(+V;,'X=W7K>I#GYR7Y98#?@04Y[HKP@",9/UD7C7G[B:G]\O5?;2KDT5
M&79LH/""4+,*]2A80:7CT7*'AM,FAACF3N8TE1VWR+-_+="K>%/TY)58PF[>
M*U^F6 L(=/J"0 JQS.AT^:HTL<G'VG3IV7@(_:TF97JJ @3^>:T\Q9:YD%?T
MPWX3UOGVU#-(#GU#D!^1J65W=ARG4*-_;.;SD+S^)'=96OPU)[?N I%CX5<'
M"9&E!%44(C3T9X:W_J>>-6EV6C^T5_&6RVFHRI6F0&![$[\K0/%^\FE3UZ9#
M.KHM<>9/1Q+"QDJ4S=\R[8A=:?1L_6IRUS8_>TZ&]Y&K_>$%]X%A+8RU'/89
M%MN=;Q3-C-$DHZ0F8F=]RK[$:S?L[@F\%ZY-9HA6^,XJY"'3K\P<('MZOK]_
M&/9]'<=0N.S02UCP:0+.0+)^5)#^0G!2,VS^:JN5W/3$M12/(0K3#3-L\*.\
MJ\\LN)Q#PR<30\@^9P.^CN<N=!A;A8?G#JT+M;M_OU3>U)H&29J]3TMK7=:1
MMY0HCR6L7+3Z>ON5%KMW"%-;KGG>'B.!$3\I<'W'-U<&IJL6KVRF3&3DTXV'
M#JZ-<5:M4"A)5]L>2-(!_]NEM!L;*'GPJ:DW 9"J0\^DAH6LZDC,S!CFNHM(
MG8T(&V/KSF(;U'%+3?VQBMTMBPD[9>RPA^(IZ0>V"A_\H;*N-W:ING5V5T);
MR-XSJOO49_UW^%C2JVCB*?7:HNQ'Y=0-LTZQ=..*WE]:TO:<>\'$#?\:S^^M
M]O456X?1#-W-C-"QTF?'PF-2QV]WZ64<R2%3XSXGL>3$4VV*,)W8(GCOW)(;
M:R6 GU=,X(1YS=6S:U99%2]L)0S*"2^14;NNA&]W6,'S0J&I\UCCM)(9IB]$
M=?ZW!E>G>*@K79I5IO1=@Q$7+Z9OR2,]>EK(!IY>6Y.8 :[/ RK7XK5&DT(C
M-P-B#8Z^KV2C V4UW&5$9$X5A]^1DGDK9:=P4L_CP1Z4=S.TJ#H6@1E,^#Q@
MS-YVF<[KWO7YDA!!]B#$#[>2E'II[J<;C7&.1H1;1*?95),X"AD'KZ!=D%5G
M5^$8I@E"FW$%*PTDGB7$U3V'75YFQSS\S9J,[S4@ Y)\9P >0.3]PL30_G'*
M$/0S8-E!0][7TW<0_;!XYF*S/?WYUOPYAM&F:.AXZ1WZ$PW;&0>GF43ETZ9U
M+I H/YN+!S_^!U!+ P04    " #A<5M0E!FS[, /  !D$   #@   &UI8W)O
M<V-O<&4N:G!GG9=G5-/=EH?_H8-*;RH0!50DA"(=!$0EM L($D)'Z56E=^(K
M(D6*=$6*$#H$!$('XTN1)DU": J&WDL@=)+!.S/W?ID/,_,[G\[>>YVUGK/+
M.H<R3OD-L.K M&$ " 0"TLX70)D"'@!,]/0,]'1,# P,%YB8+C#SLC)?NL3,
MS\7-QBL$OB$L"!:\?A,B+W'SMLSMZX*2ZE(RBLJJJJHWQ!]J/[BK):^BJOSG
M$!#3A0O,EYCY6%GYE$4$193_SZ)\!=@8@'? .VJ0($#%!J)F U$Z #  @&A!
M_Q3P7P)14=/0TM$S,#)=. ^H906H0-345#34M+0T-.?>T',_0,-&RWY=2IV.
MP_ IO: GYYV_$G,9A.Y7_<UE-+PM+&WK]8J1B9N']_*5&S=OB=P6E9&5DU=0
M5'KP4 .FJ:6M\]@8;H(P-3.WLW=P=')V<?7V\?7S#P@,"G\=\28R*CHF*3DE
M-2W]_8>,/%1^06%1<4EI=0VFMJZ^H;&IK;VC\UM7=T_OCQ'<*'YL?&*2,#LW
MO["XM+RRND/<W2/M'QP>'?_A @'4H/_6_\C%=LY%14-#34/_APM$Y?\G@(V&
M]KH4';NZ(?U33P[!.W\Q<-Y/S*WZFU%(VFB;R]9KF(E;6(9P8^</VC_)_G=@
MK_Y?9/\"^S?7)'"1&G2>/&HV0 W8=Q7)>\DD4KYA9UD]#&V9*E'U4M5*3T-^
M(M<:ODVN_OEA0#)!)BL19:I4%(N)DWQ_.N<M0F90=0\UT"'X8KE=E7J<^T*S
MIS!2V=@M 0K0^WD-ATHG%9,U(Z+Z2;5<N\AYW_095M+M:.X7[>Y9T5>G=N^&
MI49[SD(=EU2?%7B'X\0B-.>ES'"(7";.W.T.HJAM&>XPO\=\E3!@'FAZTB@#
M'6WC*R>6D)@U-#3<[)]^/\F0(U_'>U0MN"*N,?^5+Z8F9.%GPUJKP,#SHMVG
M=4!.ZE037.#E8_(X5P?):=AZ%QZ$O/AAM<DF=B].J]SQL9L4F;&!?CG(A!3@
MX+&<#<'Y&%65'>W_(KS;5ONE@DT-)%63,3/=I,]'S:UE$AD40 CO7/[KJE75
M&/2TSTQR537@X]8M"F QC2GK2[&T*FC<NN^9&9BW^2I&I$1$)*^FMM^6GT,O
MN.3%X(%M@EIH,U-Q9P\1W9,YQ]"H:P_?N15];<CC):#K?^WLIQD%Z$JHWZT4
M:VEMP(EG+ZZ:I"$4Q9#IG_/VB7./FI-6%Q\(5_-5J?6M/!H;>KH]C )+STN]
M[[%UF(38<QIJ^/*I:W ^HBJM^0RG?9\)T)NO>:CRSPRZ5QOX<K7$2B^DBFGB
M1DXY\F#4;O6'6M=H.IMSA<K"P(,K9E>VHL5K]> 53S.T;&-GN4R$ /_CC+DL
MG=2;!.W)*>S0WNT?!3I))5;6)U#,IKN+.3P^VE<E,FI]Z&TFP[.HWE!J)&,Y
M!> X-%W^ZQEZD7VB=PIQ:]$(=N_@&%^1,'?5X_[,B7R'% IUD3'J-P5H409[
MFI'%AV_^0-4[/UO(T;<-R?<7$U1YH6S'#Q'1R4.[-,L?J.EW:9@.IUUN<ET)
MR2!MQMO&B%0^W.E!2XB+B1LMXDUBC!5-N%95+^_(*)$:-:D@#5U;0H,TR,#0
M\XQIZ+GXJ\3A_$U^\"[$+I@BY(18K@SO*K\(Z"$4G4T7[Z]"Y-7QN6,RN*:$
M"]>.'!).XL@"J04V*B(-7Q"-I.U,)RZ1]8[*6SN.=;YHLUB/C\YWWL5WC6+!
M"S&;+0ZE_-+W4F#C:?-'VAO91<3!14AO&:YO><OP-(%>OD-%I!)Q3,MI:%WU
M.X+3\!ZM:T"P1K(E[L<OKRJ)?FD*X(OLP+M+]GC>><#.DS@N6KRJ77DOB["M
M]N:U5*H'; E[8C4XY%<11+(TB@V[57^4]5Z'[:-WR787DGB4<M<-K<GI\FGE
M4.LIH%=?Q,^SO67I &E6KFGF=E04SM;.7T/H)!4P&SM$58J.\LV<WH&Z-(4<
M%YR:^*VEOR.MHQI5VYIF^"PM)ESDE/CT[0/N5PD3.:GHPFK1!!4J/;!.<&&T
M.=FG&Z$PJ2Q1CZ4 Y@W\SR[I\.N;C KY-"2^90^2'SI&B#F6C0VO@#NS?A2(
MB?/ RP^(-HN]Y\7GG_W(4(,35$NP<E]NJFZN.I$9UX[\M#X3>3A6'IZ8V"U+
M2%T-8QQE1GW*TYI(PQWIK6INY_0EM+64M\7'Y!UE[QM&^?O8E)[IV\UR[>28
MQ0S)]WF A<X*Y\D?W9+18-:?H44=/,2E:P-?P4]>J*F;C<[<YTM!<?1T&N^G
M+DA(YL5 [#)%\F* ]3 !TP?07Z-[+Z6GBMD2[GLG']OM5 1;CCKA9;6?%?;N
MUK)2 *KX5[4AO+)NP=%;Y=".(5A#UN6ZK:V7H<C!H*F680R2UT)V/U7T[\!1
M7*P]!< HAVJN60=GNHQYI4VZC9-0.O#/5:]E@IJ1\AE;=H-K9=OZK^K]Z>$M
MCZ >\0A_V-.998CJ2)MY^7'U>+^;L.C5@Z1$8@2)/A<]R.LZM%(G=1BLUR;Z
MB8-M ME,4C&@ -88].-LW$JKS>_8SSBX,KX<$]_7?(>TQ6UMM6;C_+DAB??)
MC:>3GLVXQ!FUWGJ?5J_V3CQVPKQ#)UTX)%[A9RABZ 21\P.%>581"T^99PVD
M*S4U52C@OS+QH?TJ7*_7O*AIV=FM"?HMLE@6,W,'G*$HU5YYB/<-8G38R0F?
M>$^-=%M6BV(Y>Q^&U=E=+>7B&S$Z3)N?+?Z6F9*[W0<GVUP[O]U/\TRK7\ V
M5T,]-W1#TJ7>T9_H=I_)(R"(/4A"]1I>V@GD](\<VQ?(!V:(2!7%AS.7'D_@
M8UMZTR]]6420=Y./<3XG$1.>HDC?[C.7U+SQSLWSFI&B-1U9=\15YM:\=-2V
MH%9IU4.4>#PKK&G4?1MXT>N;5[FR4>KZ1L-<W_?&.N5*=FM-0A8S/XL!C>Z=
MD %ZA<VP? J0G:HG8]HB3\!NF&W>J,=-T4'CXO+WC)0$E!8K5L(D?Y!,40F6
M;T267D9J7_;*CY\;&I.>C0NL[=>J9H?F];85C32'Z@5B<HW(_66^SQLW$&4:
M$FX\H5"N\2\4@+76KXZ(5_9)SDVY/;B0B9 2JS: ]$'2$P<6S_MMQ+GBT"A"
M+<*46#I69O*3V'H^\-$7]<L(I#7U"I6*,-VH08&U[C-I4[(@YH0E2L+C:UMY
M04JP@.:R:U=X.)ASPF.ML69OTMM@I_(T+AV[/T@!--!>4"F#_K"BD!PY1IM\
M]$'9>^/SL9X)TH^KTTDXP]-]U(_S[RXYFZ4%ZB7<]BF X]C6[#<@*TJ@8S[L
M3<U:Z6&$_1/\7/,%HN6W.\A):Y:5ND;S;Z^/5F#6L,/2L $,:I'3T$* ;WMG
MAV8$)OYCIO=1X-6W3D/VR$R3Y,RG B[N3OJ9I=KW(29VPU;84X@W!5!WH !8
MM;-4B5.(+7)1%'NP1 &J*YY7/"(__[Y.'NA$2LQBOQ.6*^;(7%7@72Z;DUT*
M,&&$;*M7V^/^SXTAJ1?<?Q2Y[P<Y0G*1G=@TM+U9)BH<PH.P:0O^$@_"8V/B
MFT8:OXYFO8JY/=0IO"LLF1O(MP$W[)&A6X)O[_<4XAU:A.;K8V//&_$G4@PO
M@ W</_,CSLLM!&H])G?_#GN)L/-=.)1O4W,P 3]OZA8&SPHE[U''[*[.Y9[T
M)I6-V ?Q%JP[MT5:S911@)?G9><G$ #?8)[9,-^(5>AV&5&[YX7405EIMI\(
M>5;*]H!O8.R7S@I_AWTX+1,=F2^Z?950<J(SG/!A]'!,5RG^+Z%OC>?CJVR3
M?AJ<KA81Z!#\X3+OW7!KW=DLUN6FYCR)X[L3 0:?-K&1AXB<=/SP"%)HK'][
M<[5Z#YD;=^^&OOJU$T.-H*)7$N\IP,SS@:)JG'BY^%Q3?6J:UH#Z(/C!!GQE
MNQW:T7-1"I.DV%8:F^0B@RZ>G<^H6\JE&[GK6R2QI=I7W-$*6D >%I#A7:Y-
MW&6H;@V<OMT@>^X-EKFI'?04"^ :PTZH1&'>\Q7_(PD;5=&N7S?Z29TYU_>Y
MOX!4<Y]HU]KX6.K&G#IY$V&%[<D^&'6*T1Y]&]M\0-),,+1N]R3T7UEXJUOX
MU91TW6^)6-A)R&*GNYCA?AD\;34S@"$/1]0YVHR3GN\(]<EL"%( >(JFDSLQ
MJ$X2M1J$>.Y0N!+&6'/BERO:']+.P%,YK+DK.SRMCIR/PO1 T6]4=V$6X'L*
M%3 *\#6H8#[!4ZZ,OV.I)0:&%!A-[B@]UK>LVAC]*,;W>7(D0:9YQ8&H:&5G
MTHBOG-[\32*P"K %@XQ=.\DYOH56LNB?,$6>JF7-8I5.1*4)DR@DW:ZM>''Q
MY\'J>9(-0=:HWZ%0S!FC0Z(G='B7I=B&<)ZPN!?3O,,6%J-)-^G7=T)VP<\-
MNHJ6K.N 1^</^2$F8@W3I*C;8G CC/\7/BS*_/O8GJEOO^Q&?ENWJG,^>0T9
MB789MC:VG\6E+;4JP#P]T[[O7&@V6W^67]<8VR7F=+$PK])D1^W-];%/[# 3
M2'=7S_7E]I.BJ2-$NI7YH(/7_IB4C-&W%[V_RI9?'$;A$SX0%;[S;8^0MV :
M5I'MW5#R1&#@;:MMF-S2H?J P<KQ&%C#Q20'$QZWX7U1Q<8.;ER[[K+:1,XM
ML=%6_J55:KK^T)9+\PGMXQ/?I=,S/0J O*2N8?[:MCR1O411U9%TZ]]V\+,6
M"I!3@MTB%(L4]39S](O/4X!_V4J@)(_[DPX95WM2<?/\\^14HQC+JE"Z(N'-
M#[\"JK5\;1A=CLO<.9)0X:NJ3X]B",YY>7$2#@(6&;.0D\#=6J?S(<',!:W%
MC*5+34U]LT][$&$X_=;-94N<?7I:+LV,F<O8RVWD5((0@!$)6:GK";S6WK <
M?H(Z=;L+$Y2Q6W1[W6; H2*WVI<-'A8<PHS6_T,&O:MWZ^#C*;TK+B_F:$6[
M5]_ >XW ,!(3ZW?^QC5.X_J =N966OC2ES(EFI#D +Y# :+VT4JBJ%L\ :U:
MF4(*Q!XK 4WTH8WA,"\F>LEB*7J.+TPU-<%Z\=X3=2 <=V6IUH#&1>FM3**0
MN4YP^X'!:%"8::5)_).ZXB].X5&]_%L:ISE'V18:OO(S+"0W+[T:#;_P0OSX
M3.(<J5PWC@->.YA59/F)_S1/<^E'*X-)D=H;S>3'E\QS.KD-\U(3WQ%22@YX
M<PTS"<95>]2R)2]3X%.A'/"FKN0BRP:54U3"8(''1(C:Z":#/)2KU/_GU$<B
M7UAMRMKCR$ZAH #7457>FG1T*$_[E?BZO_,2>NL'I;LEL9$E%6NZVZK)19^3
M'-QZ- .K,*$\I]Y6K*![< "0!#:L0]W_]M +&;1@25&>KCD2DGZX?18?03?E
M,P-AR78$2R-?[J-U1"I%C5*RYDDJR_=EYOJX_GP;M)TH$_\!4$L#!!0    (
M .%Q6U#AQMB;HR,  ( O   :    ;F5T8V%S:&9L;W=F<F]M;W!S,C Q.2YJ
M<&?M>@E4$UN7;B$"*D)D%A"BHJ(B1@5$$1-G%,1<)[B"DJNH3 )R08D:4CA
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M/P/[%UPMP%1-#=QYF@8 !4#1^9E)P'^;XW:'CM6I@'LQ/8,Z<E$-*:552_T
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MQ]"07Z'R1IX3-)Q]?\]GO\Z>W."E70V^!>J6MRJ-=E(6!DB>4^!TE,"7MF,
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M(D:$ 999?Y%P,\?BUV, >5G_CQYR;MOH2, ;,$CIK)YXF _K@:2^DS&M/L?
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ML49<=%S<&W(D/+0W)\GR:;C&LRU3E_8V_]]^D?C?.+"/_P!02P,$%     @
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M[%Z'BY,L03YSGUC6L91)_79=^B[=U<ZHL["IF^#F_C>O?3C/A-Z15@!.T1-
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M^_= I6N>W6HR$%2=(IY-*AK=@I^%G"%4';B![;/.>5Q6\:L*[MP\OXVS#:3
M-ZY9*05$,11M*>"[M$>2E[VL)"]R#?A'%FA_?+UX9+FLPK<L^'\OP, _G\(]
M<]1H[X4-JK_-)%_J)<)]??E$J[8#IBUQI4KY&B"\EJ?<T%5?_[/DDY\1$+FY
M[[TU3@HLPNJ"KUJPDKP!W1RE?S0XZ*:'.5RY4&SQZ+'*4U_;$$EN<)6+R0*G
MT%#KPP_R/_RD(K_ET%R%78G+@;P_OV1AUE\,OZ(\E(LH\)TR".TV$RZR),Q<
M11Q9[E0#\&D,ER74J%XK!6X:6$5NMEJ>%ZGH.$2-F][;;FD_B7L>N0D_!VPJ
MJ4!MZ9>(FX3/>!\]39TO!6C>)$ECBP8XS']?^?P'I/A6A$J\4$L*W*N(94TM
M:[M;5()O9'V2(0F5R.B3O4%Z?_(ADW1TE$O]^Z7 ?2^V%)@Y"UN$6/Q)2+#*
M_,KD=]<FFASXE,X#A4  ;L9>+GCJ-[*)9)L44$(_*>LL!=IU3 I13+7\FTN%
M0$!C*..KHGY&?;9S7WU7I[L9 QW1O184K/,&1U;P T=^U'V)+\K?)U4X0YR,
MXI,14U[F\.A5% 2(+E".HHJR!F>2R,<BK<+^A,_?KX"0>?/IU\XO#%VT??9@
MJ];NIKSTW=M7/0X=)B1) ;V?8<M:?#]]%\* W3A[D"JAC6@OS&%CE1!COA^;
MHS622:IGO>KG&^;RZ;T<GL\EB-'(5(_S*G\ .XV-PR[\H*;8B9"[*#Y@6R:6
M1H"#3DG%5%/R>A\D; :77+U!1FBMH^9D';IRB[5?[$*34ST!&R=VZ"RXE&VS
M_Q?)MEE.N;(*9=03O9+GY>E@^1RD &(W$72LE^:.$)2I9HBO@-9Y%'DX^,;7
M!:D:Q,6K(3M%:SM*B]7KJ8NZ*!8Y9#;W7<F50>S\(<ER2"N!URM2N!G8YW1^
M\NWC=HL@O&O;)E8,YX%3DO52A?&X/)$,4CB(0:?*/*JEO^'L-MMYPP/6/<Q%
MHN!VD?&@MSH>=F4UFJ7ZJ*+:364N>H64L[<C#!*?H40.*BW&-O7)I=^^(\+A
M-"=OFY9A=4N*BP!JOHF\KN[D])5?)#ME1*<2/4734B#J)/DHTT"D"W/J3#@Q
MV4H(@8]%1]47G>-B-"W9IF!3]B+$%U;W*.^P-N;KDQ*HL^A\OWB*QV $U@7&
MQ%&<<H9G)J+1B::&1(VBGI@:;*:%Z%K;\9=;X[2>W*9&[U88!$4+U*7 <M3!
MH\Z#O7._>E13G<5,%30JV68FASIB 8\F7C/<A=!0VWSIIFYNE@*S+XM9XQ:D
M..S<HFH=JO+(6F?&,$=71+B-9)F'P/28AH)/Y!T?N(YI!<]NX_7ZRQI_&3!/
M[>MZE[EQ*JGL_)+'XAPDU):%AAILE& X<Q,62B#[II7XW&X1J&1E*\1=9]EG
MAW&#<S N>?>KI0 Z<5O-'-%H,?Y%"JS_Y9P$!44Y/BEH<.B?D/@MESUVJ1*;
M*]E/^X#$2<Z'64HP)-;TKS?6(W$*DJ5AEO928.W?WK.LP\*CQ:A$O7R:V/I@
MCX=/.&]365M0T738B<MLB1I=+=VLV&>12@@Q920W>*[EXO*MCU=Z;_'54R\-
ML07CP2'M?) K0(/UM>= [U_C++'QLPAE8,L3?33$5W!$+_=\PV2.<J:)?@N,
M$<^:)(D,.>#G34YT/G9&;HB#V*!)X/WIR W^121</6Y2J8T%A:-1^;=WAM]Q
M\AO,$$5Z2>H&]%#+77<L>5#]I7$?L=#^\++K-]  &HB<^:6;L22(79]I9U=6
M.B=65W!WPUA>^LF2GXS^A:7J+?'D2)R"W"5HS24%AOOKNW*_&:/DV-PR#K*S
M;*OY&^,7:-;TLYL7YUD]9WX@T^A5'7YLUF]C#>Q%"5MCW-0VG;XEPVD[,/#M
M -8_B"GST,'W>U&_$W.W_ O-E&_8R/]&S"WZYFZ6WXI*^U9,X/A?X<2IEO#)
M&"%(:O3PDHNUWC8G;96O^QBJ04]IKNV&:W,#['2GJIZ^21O;/>Z7$CQWOTZR
M6IZ3(EFEYN=)YK^L07._3U FYWN.]>RZS1V?.7&QR-KAM*]2\<":4-247O61
M=^^WSF_,6S=FX+;7>_\&N3.+@_]U!>O],:\^^=95B7;7??3BD@0!E?;J_ ._
MG2^K:E"4 E R<CQHJ[G"NM4U*4\N^(6O.UZG<%)EYI_!L=##POUBTJB-[8#I
MA;M](Z&6EW77/=JGT>>:>$=SE4O"M?.*>>MT'@SMEG'0^-^7SZ9PH2U%K9-J
MU"\Z^ 0YS!72X\LKE*C9RS.V1PZXW&W02B(1^?I55//1"8UA0;9!ZY@Y0].G
M]R"9MKVCM-D;Y])ENBKMJ6V3 T#QS@%KK:3 $8P2<K?1<%,K[IC9!4_W9 I8
M0/[L &<DC%NO22@AQ^U"Z$&W/"GVT7L[,WD?CX*Z7H%]18:+'SL;577R.\OD
M'CTZ?.[4^X,(B&:<&7$B4Q-Q;Z+.14*%ZRF+H- 8YC(GW@%12-Z0K7KY_5)X
M):+_4X871!*<=]:+&-#J/AKD91=^KICCTGDAM#M(\[<]+MA7I;OEL;&B];P)
M!?^PT-CJ%7D!5 -(<DFFHL,\2*NQW[7C^.& G[/:^UYV;\REO<CV.+'L9/;/
M7]2:3ZU_9OY@>_\O>[9@4>^"3N)%N0R)(IH=?UXV*@7V8>?TC$RP&=/SJ]'R
MX4A&+&Z27>C^3ONO9=9.F=XV!PU@[^_(-?WW7/:3S'.RO<0FA"74M]XC!0J3
M,D=-TJ X4=@H*-A SI<">&V+[F_-AUX*QH.$::!"'%.-9OS;&U*^@M[OR^WO
M/R-SL(PE2NUCB!,'L%*@HR+A[NWO(V^G3.=7_O9\>\G\"50M\?TN</W0B#L]
M\T.1]3@"E&QEHF3N7T95N0>O[KYGBYS&=]<90Y2[B[1DUI@?"D/VD.;UX \V
MQ4F!MT:#9D+=052S7FQSF8X_X?,'OA$..K%F2X'G:+[DYA $6T^PIM9"*=02
M$>JQEY30"+6"["L%=EJ%4/> M;6X3[$L9+FV^.)UAG@GQ8APEZ7">KL5(H@3
M?710A:ED;3'(^LJA43#.7G0[X&\=GP6%%W"#/6@1</]A W:&_+CDP6/<]P7)
MC[KYWECN/]CSQ\;FCY5&9>8[%..\/=L%CKFA^%.25>VZQ<#U>X6BUX*F[VKX
M]]::: 4&QJ"%A<P-U/3S-#M:?_"Q'PH-DPRT<GUK@A9DNJM94QIH^?.CWMW7
MHLQ-ST&:)8UD*3"E!;WX6NJ@=K==A^HH&R=VJ%Z_Q<#F3YC\_:(H^PH/D>GU
M4J <6X_O#:VS58,"1PASCD G"O@3\\A-#7H5,1)CI(K'20F2:+W!I*)^.?G,
MW"1+H9Z@2%E[:I"N2=[[R;]D8G498X'( J;'EI29*01J65E4)-A.,UIP?0H"
M)_C+N!Q<P=-.KG8HHJQO+\5'$=3-20ET)=L5_IF6\<$M-% EJ)2C3ED%&R=0
ML>0P2=_; '<]0L-FC#R9Q?M *VOLGA1KNR-^@TDL922)UY-8,E8<LE@F ;87
M\) KPDT45]B<4.I7\T2;C0/V<4/'C>$)-DO=UH#B4H6FCA3KM5PIT$MTA#@)
M%'^6CD@6Y!+F^C.U23H(L3Z]ASFODZ([R# 83J<N<B'(D=/?M^SIFGSA2%$.
MERA:GH+>#TRP.1H2C?XACI:U/30J<$>2($:-IW8*6M/B8>^F\0CX>8?@# *B
M?G$ ]LG-/<#.1])JI("6!4UEF*4:DH+;V1U,0QS*F@E:R+'^O>'A8L7V@0JA
M);4+9UA&I[$PK(!1L-<6[)4"@YPZ5A)=5F0'0G7]@TN;&JNP,6BHISCP6C!D
MPO9JN"BZ)LSAQ1-F965/DH67]P;_D(GYGM>?3E[-\]:S4;@.XT3J&?4LC?0/
MC70-R5+DQ,2@\07) LE3)H X\_$89)>(O&]K%^A+HI732UDQMHN0:'98]IW5
M)T)PB3B-X"QY,WV$Z,PJ+X<^1)6219MYK/F<$>W03%$-UI\BB\!F#2FA@QGL
M%M6AL]EZR'6A%05_#R' ZCL[+'2GO!5V/X(5V 09T4$(3!2M!4/]#E-FL G5
M&%C=/JNH3/] F;(ZX2$L'V.= 0V7]Y7G3T90G@EM*/*=MIID&AIQZCE:HWIG
M*^#U@BL(HY"R%W[6MO!)-)MJB%>FF"+AT)E:JC+4(TA*$KY9SY8H(:0;+\*+
M1K2ZW3,G$D)(\P/S=[47G3AN?AUS<T@6 B5*,%S%?8E.KMFH\T9%DG$N2 7$
MW@,31;J=I;] #1GU6(4WY(0I%[PN^?")TLY6;O>-+NSNBG!B_/L'+O8A&A>?
MZ=>7%#B--;%?A&XCR""K-MPOD$5+K(S8C9+V^R@N4LD:/L6Y-35;]:(=+HT#
MG<3&6=N0T/'.?AV/4YLS=)^ .=^3EO1J,LMF=?W$(%:1=.V$VZM=#^Y?:MZ^
M1.6WAB2M]ZR#M@;]7E@9\JKK9-S;O5"+Z'XR^)L"?I+P:>.0'!!,Z)_!BN6#
M&2)=#Q">P55,XF;F#1.0=0]0?YG*%7B1IK]$2T1-J/;:_GC3*@\*)&@XM\LR
MD0+R;@01]>+HC"%&M"NX)$YRY.M]*;4Y2 K80B#GJA1 ,NV)0=$2F@(*E%:A
ML9KO+QL'93_.=PHJBNLJ;3#ET]6>YI8I62S%NCW^^="\P97-L7LW'ET892=?
M21\78R315NZ2>44L1'R$[#CPNF_4(TJ6IHG\.J\!"P1^V8@-S1GW)O0&L3X,
M8(2?T;RCOD57"ORS!*-]PX!_1'J_) *=]:RU4@ V__9.ABYFY:((UV\'BG"O
M9$@!;+X01$7.>7D%1;@F9A*<)_9HN12@DW$3OX$BUV]N #\I0!H")W7;6=#1
MHU*@:4C":94"0^L+0.YSM(2G=<?]442G;^1=8)E<]D+/6_FRC=?.LY(N:##(
MV_%9JGI]IOWCFE]_76FRWC QY^%\&8O.[\8856],%XSFKM6"9,7%/";EJA"Y
M[C0[8N""VIR)_Y^K]'MYWQ_J,3\\:+IWW]V J W0RVB=,[=Z@U97,A)T?[&D
M1STOB8E<<NNH:4IS=O]8.>?SA()X&@4^"24^2N$@XFJQ7VBM[Q0S*2_[G 9D
M>=7G7/H$7Y2/.+F^=;=\T_\)VOD?\H8&Q/)@6QZ4$>N;YM;>OJTUN" XR/&9
MQP&/K8H/KM6Z*<3NE=EW<<O"Q.'O^$GC5H6?A>)B=?IKG%O-+^/3#)V%\W2-
MW[W-OC%EG/8BF//_=<7\0XYPRO/CXWS;V]SWWEXN1VGU[F:+]%(NS8FK&UBR
MY3>*%+CB\B#'&'BX\L.9Y39FW_'XP&(T_-0=\AHE,D!2?1TMO#J-A1+)5[FB
M)^MD9B+#(IWP_R(R_HO8]/$3A8-M:;OA<Q%>+GN,$XPNKPO17VB X^E ?2?V
M?>!EA%E=7B=KLH)M(M/WC?06OPUI"3[L@5.#N)LIKCK8Q[3S*%1@Q:8J-(\X
MV]ZX?&Y9I 7K&[8FP6\CO?T?PU+^'V]RYDF!;\R _4;:5J%IA4A8*P6HOV?N
M;^]F/2FY?7/@Z9&'G:M*"GY:9WZVY^SGI_/G%SRW-[FW^[><^_IV"_V6'!,[
M7F3KOEFPQ\A7=WO7+IMU.0M.;A3<_K\K3O^GK3@M9RSIDEB+%K3:+AKF*%HP
MXB7J';:+ N\&"'#S? +OL2DG+'0G^X.,7!]?8;4&BXD^U]T[,MB96KFAQ&+R
MI1/;,C5C\]6V#\F,!KNCYE=RXE4(6*F3,BAXE]]0!54YM5/L8!-'@KI_RQT*
MKG5J5-E]?^L42>_ TD%OLB^^V_R)DD=G:?.30)/EI%+Q:HF@MZ"\+'T_Q(GB
M5)B-Q0D=+%/<N;1Q=>@NWP,YPQNR]AA\R"-I]!',+E2O/4UJ8,5;? DY;_[&
MD#16[-+<N5HWZ-> +T5+&DH; -OBO.HX;D932S18"D9E\"UK6/%,;22?>ZRK
M3%G9>A\/M<>XC9ZKUPZO8YW'C:H^Y7D8/]0^R^<N/)I2,,>+?)3@DX-I1)'P
M1F/);K3^EILE!1ZHH^Y\FW:!.!7*ZQ'%^WQMJ;BPL3.'.^Y^2OJK.U[&AE /
M6_%[%\-E^QL,&M-6 N^LO]^%<N49\EU[ZL=)E_;]NL1C'/K74SG6F"F/(78N
M#?SQ,\ /3?_.'E.T1#$JORL%CE2@D6]RG!\(C/C_R3:_/VE>]*SE,J;51692
MX)"RL138?J@D^\?Y\&/WZ2"3)046$;XVZ)ZA^KE5F'#WU@]38M9C&LKB4Z=&
M@F ]&IIO5<02"W]T=V!XZ._L2L38<Q)%[LBC3'H=J;\$HR=I"4N]/YCB/HBK
M9\3UX<=QPB4B.PB,#S'0;]#6ZJL8>\/U9P62(JE&$5;KN01URCHDZ";9N"%[
M4T_!(]BREJ$WA)7CL+]<%&U&[MZL2#S!"EQ1I7V20JF9CSFIKQ\Y.?M.NJQ,
MXNV%5_8"M@"RSS8N O6:N>*RR?;T4%*$T$K2D)YQT>70@&/AZBLEDFY"GR#(
MHN%![\C#X;/9"R&DJU@M_-GDW8@S#MX[3 Z4N5H?/$JF.2.A@S@%20^H@?,/
M<FEDJB'N,*8AS*EFU-7+J5L$HMEF_C!.D:E&+*SIBQ!DE8BLA=B4:HNC?+,4
M3RG0@%$U3C!/2MKL4;VTR+\O2SQ#)CN?(^0]TC7^]5>5P@5A\[CA%V5LAE;.
M,?K5\-$1S/LY1I#-QN$&@!(AU!CF:)H38GV6MU(7DX6-H";%-$_D"CMDU- 2
M0/7C;BW\C&2JO/--)'0WE,6I=TZ]GG>0F#F0P%>:T"$[.<&Q^7D!89S4:E5>
MRUQR1[TJAY@IR"T: 0_O20;I[\/HM_,B<3(L+I.@8KOD%5B[#"2)J4(T<*18
MT#",VO&]T]6J(5S2A0TSV\K5D6;V,0/=LA1<37?VBM3NMF.QRTL&N]WW7?1J
M,FUX^^":'KZ/$5=Y[.: +.1AN/B)K$35;!YD+M; 3,L$2($IC$V8T,]_>@NC
M>>*O3>=;LNY"DY^D0&ZJ4 H Y@2)>YOXRAVPM0DU::0>ZNXFHU^WTTB>=^&&
M?)E2H$99&T5=DW$[NM: _'SF$/B.[8 3THIG?D]@NQ6RR/M<.[/[#_3SE5[5
M(?GU\5M?#7TXL[KXM.[+4?E-9](7SL_Y=>6=2(4]WXTR0ON^RQFY!GQ0AI_1
MF6!!L@Y2X%T$MM>S4#POE(/(H)GU$_/W33QCQ?LDL9LG1$ ;.$UP$KC=E@+V
M!E\D@#]+Q/A]3\Q_1SCP:"!]<BT'Y,HG28'G,P-YD=8?&O5.W,@T6H]$?;(3
MW^6UW2\R/[ENP*A]OY?)H>)?CBR8-WXD9^/1Y]GYWXW7A?T^3OVS6/I_0SL]
M%O+7;X-UA^\8"\1#IWC%<K^Q#K4UKRN_S5]SR^Y>GZ;BPUEW=).RQK;F$.Q_
M[.R3_G4%^S-64(PY7)F&X-F[LA<^2='?VI[86*ZWZ:=]1U7F:]T[MLA)_]JU
MZ_I7+[L&@]\R</=/0,[_F"/^Y\K!V/28OW$.P<V1A^5&M6'EY_GZRMBU]Z"*
M!/TP?H/=TOWY;/F#FTY6M<T9QGU+:_\/O7>9Z.^X'/J.PZF_[0W\ELWOR/Z^
M!_1;-FG?:.OW'8C?:NS[:=0]==+'%KG.)<5>)!^M#N#3,>03HTT^J]LEAF3%
M)D*/^0M%DCYE6\]XB#Y+A:S.WAM8H54^0TNT0":SM@R'_;17/^E"Z>-?S*[,
M+LK1"IGFL*T,[_--"?5]]6%NT06!5MV%IAEQQ5/ACR;%*Y]';!6X!)DYM9E-
M>3OR3(/>^:\R[S>I$O9&>?9ZOO9VG;?N%&=>R%T"=F@=,E@G6=9]$_J0K!+-
M3U'\L >J0L[LK6H3V7%I<T=FO%_F\SCJ9- 95HF.6!KSCM57&D%R;B^+L-I/
M#,+O*F6F\C7YU9J0L!&G:FW/:TEBZ8VGN:;MI->"JK:J%(/JCJ)5%'?A9G*=
M%. YWN>""5:8).9"$0Z)XV/E*4<[0U90O/ASCE0EUE:;Y*Y*,;S0-U8^XYZP
M\ L.<^H6N?Y,4T+>@LMX0RWHJ:[Q$K'SLLA5_PQ;'<VZ,EY:O+2Q^ PE1C'^
M6%D';_^1Y]O.CYL>NG@/*.D^?6'MTM,R>L%_9_U%X_\N>_X#RYZ[MR_(QLU\
M "*<N2H?$D5HZ1YU!ZREX'ZF(\LRGT$/:DM8 6;]VCY:E:%1N*,3,>[/;B&Q
M')^N-PM;T_BICPL]1]>*;$H["S-?'? '>_M:ZFTB3HSKLR7*U0^SIC;OQO2]
M(:\/9*JLO+SQ]UY+JN5%Q\*OO99V#3?5VWX.\][9'=L_^[)<<.V5!)GS1K=F
MJ]G$CV#N,_A$7H5(W4FB9(?B#7]X($[HCE8'+E+@.":9 .$)2B,*^_&]+0(?
M\=6R%*]:GW6([^K"7,)(.9H=XX-=2&ILA>AFKU?UF44^&[JM/>#K];.<2[-.
M?^")KV1E78X(-1.I3TA4MHK3+GR2-.,@-WH,KAQW(9BGV5"!PN1^/][Q2E)\
MR/+QQ*(P?[CI%7,9$CO"/W#ZP1L4 2O9;[YUENAW[-H6W)U*DVF/-(GB5U34
M)D[/W X&,9#%RY[ )/8,Y6@9-@$MGEGUSM4AA66_S-+.<"N'5*Y* =TIAWBO
M<QW65HU5O+3W_ TN6R[/GI("%[!0B+%([6%CWVL?%:2+03DK3JT.N[DY?&*N
MI ,WNWI/KK-OV/.&_*IN*K:B7GG]KO+/VLU>+\A#ISXS?XJQ_P607!IB9%!G
M2?K!^VB!YA1 .H<BYP[Z+*JY.,_B8B]E(U+ Y6B,;JCJ.9FT&Q)DW7W&5][
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M0,M!HD,9=R[."+AX4V#N9>[1Y+6^A^$$T&,N12]DL$GIE!N1'_5.BLTA#NQ
MUI375;S$<E04%7!B]MT1/H Q.E7LU[?%.H0%SZJBV YH:?"9,0XMK\A81!#8
M79;T."M=<FC"!>;18NA\E7Y;02! 2C:^F+$..4Z%"4@UDE\8U&BP6:3\L5S
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MR'U7M88,THZO=ZTG_I#[ALH7@%#SZ!2A='[J@NB*F"PZR;Z338I$]@E'A5<
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M.W7B?-'J0UZ3%T_$FOGWI(P(4X+[CXV/CE9'>45^S2DON^86<??-Z!0>IIN
M_V@,5LOI(4H).B>5O_VHO*+0Q]+<14"<NBPZ)0[H#@RVOV =90)3?JF"N@ E
M^^KQ/F</O$/UKK0C>Y,_XS>XC=Q9F'EP#>;F,)"N>"!Y4*MMQXRBPGD<D[<<
MO:5LT%YD0(VD H?H411%W,"9;??;"IQ"P5RO9\\ZIM[?^AAQA/L]PZ$7_;#J
MEX')*Q=NWQEWQ/7AI IVEQ^.IRWPQ)K>SEV6CAX!FH$?H'"1FO2-^ZJ;&*#5
MA[Q7XY2!)3[>:INKY\"!('_^4WY-!7.O?W15ST7PT/4M W,;$A#BTB[<.>3
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MSZ EL[AF]AHVORT4-9L*&SXC-9F&8<5:%_?G)H3DWA!SB" :HR;I=8E@/XE
M@JQF-!3DV2(Q#I<JVBPBXI^?642\B:7_1=LUG'=H[CQ#NH :.?CW(0,3_\K"
MK+\VFXO2K:+^4/D;^[,6P 61"SIEQ+!)J[_]3L*;W&DW. =G@^@Z5E0G--E
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MYOUJTOR*J GYN?M(F(!'XI9)-Y-714GEVH#$9HHN>.IYH93#7DZF#N,2AXP
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M$O_K&()PC7IP<J K>*!1(39.I^#I2[5=)^'@MH@VWG#,ZXY0BVX[%/PA<4:
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M33R]# BR,A3'!H2L+*6QI\)S:7$XZM2#BJV%;&C:>P=>K3.^!(_*>)#IY]
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M%"HFS^G=".K>9[@YVC$>GN,OGJR&2)F(XM%79^-8T2=+-U(_PV<L\L=37W+
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M)ZU_1T[P\L/(0@@U=T8LM55\J,:1\ABM;6>&M4.VYLA]TH\ /:V=S_;3_N%
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MGAY.1T]0,-F[8S2WW!QEF)S^""<.,'GBP&$^;5AJ*VKE@8X2D6E(2? 4EQY
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M+HTG &\P%TVXU'$$V&?0=2PKU^ W,B;-5UCY@-W=L/'+]B4 ^6<,X,LX<;#
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M\3"#;LZVB[EF:V1\0M[<-U<+@O-[2#5>^]A5,=T?[G'HMH,)]((@UAZ%KX3
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M!-?'V=9SCCKS< 0[I@&,J 0CJG9,TY09KLNQ@60N1XX-PQD4;H2V8PE4<&P
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M=[4.@VB ?%+(P40Z(1PEEC/N=96WGA4)ZWG<D++;\MFA%O@ (Y+F5$EZTQ<
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M5XVUZN)!8'=1@D"T1'O !J(3?2C:.[J]Y\?TP4=FL/9?P01B'X"V-^6O*EA
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MRC=@MI)P!!\50)390%Z3F[8AF0";MB&Q0!$>4>3Q;N]I;-,VM(:%/=A4N+.
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MXN'9HH,4#V4%<M7MU(38=9N!I/IW24(<F3EWID3U*R2SF &$[4VUU\<RZ:<
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M61EXGT>?ZXN\2G7Z5SE./]NKG(!6RG;5OO!5*U_BJKU:W2UOUQ__^O.KB;_
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M0VKE2^,G$&?XM>*E"U:F45U_;K6\N7LW7__G?'9]^_9JMIY_GKH<?M\T=&9
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MGOKV[_'U\@KNW^V;_69U-=L9H'N_'6IS*/SS/4A$ZZ3[DDK]B0/9GZ#4CPC
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M!N8)]=$BXNZ?#8<@(D,E"(7PGMM ?.0>B^@\-;C#1&%X27L0#AV?"(0,WCM
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M%,%"F/HD"$:"HPM2*\Y)BC4[Z?T6$AGW$1PZ/@4$-WC!]09W'A=,$BZ<M\S
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M<)M"43R+_RMP\SA!,5K+M1+6HD"B,>!5.\5TL::&@#<M*68^&$RB@V_HNM?
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M_+]RSD<NX0)- S"<]ASUU1+@V>PSZJ'CTT*0H;RXUSM"B,,$W"[.?4+3FFA
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M0R@X>!-<$6-3\3J/EGAK.[TT3+G]*.O0\:D@V#6C*)XCZ"3X"PP%F6)<R#+
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MJ(Y,%0M@ZQS<V2^F8=G"5GQ_.:(8@K?<J]1;XUPT+*)4B>B;.WB\GX?GID3
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MITEM.JT,:$+X7 @:N+VBT582!/1(1B3ZD4911?!J]F5PX/A$$.RK=;3(C3'
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M=-M>,=E!T K*K0N1<R&=8G!3N1B-C@3C<AM&'?MR2SN;3X%@G:YQGVT"'7U
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MX9S3-&[Q?A^!T@SHFB&4",&-,5]E =I\ZL#0YUH9\3']%W#_9Q"ZY%@[+<'
M&J-BP%W#,DFUL44(@T-4&Q(,D4P+E]8@L&U-)C^ <.CX1"!D DDLYFE$PP."
M&&&IE0UI!Z, &NG41CH0]?![Q1O4HY2< <9);-H>A7WL:Y$ $,+W;]"AXU-!
M<-,C17'6?4# N= IV(>MX%:G%:[&@/UF/-ULKMAM6VF/5+>R0Q.<(4@#)<"4
M20P<.P&/J)#G D<3P-,I%L'2JI>>G +!.I:>%$)C(E7Y/B HM-6*:K @E#,'
M5-ENF"0XVU$7:5"=N;Y3(FB%H3$"_P$:#WR>&LGC-EK(U#Z"0\<G@N V6RH0
MR2"47$9!0&D1"MQ&2;LD@>%!RV+"N>IL*4"X<Q,J0:/UP*DI<DY$Y#:-J9BF
M@'1Q"%"=$':]>03 RA$$^</,:BF-HJG2H5M)'R,!AM-Z\XZNG, R%\* $ ,+
MG<+<(J;4?5?-'@Q0W_*@<):VV&HP!(&R:"7EM@O[4^VLV(=PZ/B90EB:T7P:
M"*N<T=P/\V)9SIX0(@/F$6.9<O=I@U;G]],TQ[9M3"ATB.K,'H-GJG#DG!L$
MWH,$2]+MTZ#$,=4FRAV?R:<S-2:1,>TM ^N+K-<XJ Y!(HWC;3_W45HME<P1
M5. B,(N9MUA:JW5GCBE/;;%%! W08^\0XQ@\1L*9,7TM#1:8[;MV0\<G@F W
MB@KGZ[D!04<X0*4U*#(WQC'!P8G6!/XARNNYZQQ%M5V-3.7#I Q"A6'*,>8)
M!FW&!''3782I JR8[*M3C;>V1"J10>BM8AKK(!%0M=0CU77<,.UT*.MQE1!N
M2^BR<?6$(1T"$%X/;!!1T"ELNQ(ZL"2FN$T0+#7!(BV.8E: ;T&"]=O6;8[W
MPX1#QZ>%($-YK@_NI8@B=YXP&C7V:8/"O7-LTXBY8K"_SAG#'8)\YR)DPED"
M<#%M4WS&*(F]IY[9F,;_%^O9N9,(#*RB5AK00BEMEX2C'%FP2/L5= /'IX)@
MW]B3APF!7@0#/$.JM%G#*D$BYBY*N V%5VV\Z_,A6'=SV0D0K+-VZ:$8.RM!
M)$R9U%R65L(SD 8#UV!7>>,TET5&6&<Q=A=G%23/&S,#SAXF,D9P6H07AG3E
M[$X*1XLYNSKCK*=$4'H6-'P4>4Q8JE>,AO:0""3T_D4X<'PB"'8#O,"U%SF"
M06H*/"9R@R+@ACM":+A5LCC BUA+#:)!* Y>M1%I>E7'\#0R>K\K9>CXF2)8
MR!MS0;)L"7/4(\T#<8ZZ2$A@&!'P3(1GP!4?V:%5<=[X) @ZL.)<8Z=82@7#
M\33=##PWN.D0BG:_?F;H^%00[%?'D*P $>0B>@U$A[ @!$>JFTV&P,\CHMS6
M4\4$V=(2LKQ#E/ (@F$IHPXX+U;.: G&TEB!D;>D&)RI>@R?!'+[@*! A#IM
M,">,2LEP3$D[;(BR.%5,-@2/W(-IC&"&(!.2>LU4HFC(&&38ALT !_:BV-0#
MTLITVL^C K&.6J;ZED^,F*'[E9A#QR>"8#]$#N?E,X(IAY45P&*X),3 /26B
M!+ 57(6JO->WRC%\'1^D/*\&%MP;KP-"5FL-G UW5?J82V8>2==IJ12X$R%Z
MSSVP=<7Z":UI7>;^,L:AXV>*X $?/"&"BH1 )1<N1HE3H;[KEI<!)&!<]T,+
M0\?/%,$#&22:(IRVTN9:+"WX!\(:>$#P[73DTGHE''<1&5<,\Z>T@##"@/FA
M4H4@B.M+LH2G!_.[AHY/!<%.!H7.&#7X65)Y!#>\=%C+$+KY])AIY\I#5^K6
MXE,@6(<6%_QBJK*I-40B0:V4T:1N:^U3X]$F6:>Q<>5T)S="$<R9"%@$93SQ
MIH\ZPU5ZT)DW=/Q,$2SRP1,@:"TB8(-$*G.PZ;\>DQX2:=%^F'_H^$00["M9
M4_@N0]!A(+D.! &DP@5&B;/$!QX5^+!%!.N,L/9>'>.97RPI""8-6FGEM7?@
MTC%X1(U!'$WDY2A_E5Y=UYE#*,IED!D6J) J]0_CH WU@3AIN(]I1E3Q'E38
M">"1U$>I6' B4K)MM=%D7XN'CI\I@J6)N%AF,6HIC#*4)Q/,D8Y JRVP:4.M
MLQ'81YN(^UP("O"R@07)Z!CV^KZB+:81MS+E+P7=]XN'CD\+0:+1+H*!J0C?
MX+C53 M&,652.\.D<VVX^M&"?L10EC"&)R$$ :H(3 >Q5(ENOSGVX/X5(:RS
M,:?/N6N,LO(M:5,S'4L%+%BD8E>]Z6U"\+M4%N-;=4*X'=6 <VOL/"+@&02N
MJ7;8"Z<W,59BB2CW*-8Y<J'CU/<7U0."03-J*74R$*R0#WY3Y8QD],062V?J
MY-3][CN5VQ*X\81%%'06<W@D@T$$[]?NI 'UO'@1UH%@H0".R[PM1Q$$;AR.
M-BH>C3121" ='B[#Y,(4,\;8,L>!$8<H*/?)-?1:&IUZ!B@8^'T^,W3\3!$L
M%&&>!,$ZBC +)80G0;#.$L)^\A1!/!O>HY@ Z4B)-,0]1MHA!">UCMC E56<
M?Q: /$;D#><&*V&TLEW1$N6(F[!?OC5T?"(0;KOK>!:F5L8J$27RQ'E&%;;=
M+(1D5:PH!A?J["GI"2%76;I.>9^&+O@(P'HN5< 4=#BU>@A-;+'973*09$(9
M(5)'Y&3J;>P9G@AH/TP]=/Q,$2PL7SX)@I52ZLT *9"#S*T#"RF5-0Q$ Y %
M-T0%I#&!JQ!95M;B2@=(=>$9CO-[,$9F++>$6$Z#(;1K. *O+JV-J3L\4Z#4
M#.6]=>!ZL/O!R,SPP*+5" 4"&AVEXZ(\-H7>QYEI\"HZIR4X@W'+3Y".^Y1Z
MZ/B9(EB@U"=!L&I*?1($ZZ34_411FO<U)1,,+- ((;B45'NXKH1T47NJQ",-
M$9CC@!P)6J0JI8!D[ @>X@*I_=#"T/&)(+B=.T-P9HS3'EIIF 3U$L[?C_W=
M4&IROQ>Y[AAK<73/*2"L<_I1/UM]9ZRMEAP1H70TC*?^.@)Z9D&+'<&8X*)G
M7+4U/@F"55OCDR!8J37N/&.1^W7:.2PX4X$$SE+QEA3$8F0(7/O6EA?15AU;
M. 6"M<86[F<?44RSA"<P/^Q2?%JD<=36 #6,W+B #08PB^FZ.F<?]>V)B.(<
M0;B(0A()N/^D!R'L"OI1U!(5R]&K;O!4.P7]!J%4*LZ9T4#8HF8T&K NWJ.
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ML$\5'0 M6#%[S9U/79:.,9<R^Z#VNG.NF4?@"ASL@'W\^$00["HA"<,9!<7
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M_-FP\4D]*(,L5S.#3@+.O6;B0B7%H10:5)$I_+8-0K6P)"ZNM[F''MWNZ:&
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M2("LNE,^-H4B4+:](;R'KMNO_M'U':MSP)1REVIJI;N->JB2&9$.-]^>M%]
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M!&]=[_ E"-ZCWF'#"476BI$V6Z%BA1Z#\\ T0U&M8^TU]?R'2+][\&"N9:@
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M5/"(;\>(:Q[<2C!GLTT1GI-/5\=? ?D#K^#_X\N836A]IGW$'H\WI.ZONB_
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M/9C#CKUB7%JLS=1OG84Z!K7NK[F5%LM<3#+\>6\1O"=[?6]O78>/*T3WJ!W
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MUI  2DM0I]:M50^X^5,"^^_'7P3!4VTGX)([+"45(ZVS>\&OH#JB#G,9[FY
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M]\F)1"T8\90S)VS914-\7K7&FY;OE@@IX4W>^TQI.9(47 X?N- VI_JX.4%
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M)]AOIM47ISD3$PD$QHE02D4 YZ9&%3QJPVI9^X;E.R+"^ER1V@:)>I:61!'
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M1OP)80Q$-$E(%Z3S 5RB%(/#PPJ(J4Q[D7DG4Z?U 8CFS? S6A9]T!!T0DC
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M?[_]/I_/1HOA*[1O0P#AY]G@XL6&O=/H\W").X(M5]RYE)3W3G%PG2G51I.
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M'L^BM$7W(?O>D>INN&;M+%&A.9Z1"L]C8JVOMV)>]?"'6_YJ6M$X/CZJUUM
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M4F2E(=R-A(.%616.PK$9<[=3@(RG)[,;1H&714!4MO)":Z30ZOP@V+A43Y-
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M!J,U<EMV%8#1TV?(]K=86Z!!M8D3HSA?W;8?O)M5CPMX,W!<-BDA<R5;&WF
MK(EK<=0VL=#IDR/VCB(T^2N6KR'+"ZO7_K+BCEB)A!?D=R6TB9+AE:W^!@.
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MW<MQ0VD<26A=0N8S<GM[F/Z&L0_=/[5W=V:7S%GNM!\_!A"-^WIL](QPH \
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MKCG;A>\'=RRAH: $\AS9([4>%J>.HV+K"6N3,#AA*:X7I0/R=6"($<=8%*1
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MB8:E,0?Q[^FCJ-C%8?H.3A2I_*7!V@(,B*X4;\+$_><L6G0X% 5)!\.GDEM
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MB7,'U?X2720_5PU9W2LG-=$G]M4$M\$B7A?K ^7-I]H>JKT=9,1 ";4?>%C
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M$?N?JENF(:P ##G=A=>8+^) _4\U&YC:(NH-DLV$J.$,%&W-PA-6)\;76>S
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M KQ='ZE.SMLS,R&>VM5MVVYP_]GH^O-RD987!Q7A H'UE:&SYJ1=/.P4Z7V
M**@9"XJ-?Z8]%R^@ D>91G36LC=RX803)&YWBF% (<<%T(Q30'H9,RC \!%
MPBI1^1NQJISHJ)L[5XV!_P&%WAM$R(K,5Y':4_?PKF]9:LZE5MA75P$ Y@V8
M3(,0ZF\1=T8R^BZN^L#J--U@I1;6J9\TO^$<Y(7#\8 [XK'B6>%1P3PY&F4I
MS5U&\O%IK\=7E##I)K0+M \N^JZ2',G2NH&* H,!5E?%VU?W<(O:7<>@+\X#
M_%J.@,O"92KBDQ;=#+ PYPY]E8X")W 0L^^D \H / /DJQ]X(!B.T>EHF1N)
M@'F@T'? 'LCIF\F??<'P<$[@UW.U$=CUD2QHQV2L^'XV!6X7"3"Y:FM??'7C
M[^(<Z$80K=AIX#__HUFKUCYN:F4:I*ZM5++:JI#>9U&90 (H$A..&+9]L/?W
M7:6#;< KX!!*"Y5]UT.=)>_\)ED80>G\K(5@]5V[QT&;9FPPC,=!'P1)FRR=
M$/5S[/B.)]V14"[A>R\0?I @R"+'507RBT0A]Q%=]9H$?]0RG^N#>--3,S..
MB1XPJ5"T<) *1P'*N31K)FEH5V1%7*!P[;"]34?B[(L_\&60[/*BA!P BXS1
MV$:235_!"]DRC;2/HA72"11&>@I0A@X*A"5X:@9A9R[9W/WTI<_&TC]>OUT4
M?)][?4;;SVN(^#D_OH\TQBOD#U2UA6 IZ\A#UI I8PA0\H'K\_)DF@3F"TY,
MH&_8/')4;619"J1BA['ZQ?PQHQIG1A9X!*_BO][5WRVVJ? <M>9AP08S9: Y
M>.C76NTH]^N/S38CM]?SU-,F;QP<G-1[!XN3-VB ]:B,#D8Y.#@\.>[S;V,&
MIF[@]3(+_(7OS#-]/.OQL)ED]GQ6/+U-I+X4CP\38?*,:<<.;,H<]Q305IU7
M3G%A&A'_=QAEQ'*@]KJ@UW[?DZ"N1K](;RPG,2+U,-)4?*EX/KED3)<Y03&,
M5/^_WOU'W#X[.NN<'1P=GAV>-DX.6JV#VM%QO7Y^4#OL'+>KYTN:,Z>F^?6V
M=?JY(Z[.1?OJRVWGR^V-/3U9/*,'&-BFI9:YHNZ7@ 2!0+1!; G(% @0=P[Z
MC$]*\TT"7Y!];\,2*$XLJD>;&JZU4HV0>2/M;TS\;Y,D-$ KMS9OM(&TH&T%
M!,B1F]"Q;FJR#5_/9[(L7F=*%(U?_:C_T?K#9VL)7E%_T(K@*F_/D^^0RJ^X
MD@SDORI407=3=[%TZDAU^W,O_JMRZ&8#:Y/KW&.8+E %_1U%V;+VTLE,IMMZ
M7!MEDX#3&H.U_4-GMDQY&=0]FE_1 MS3JLY>5\;P(3/HD\:&'AD<:7%6EZ.G
M8[N,M61X,DY$'T3_B9*1MN*/>5[4*?5+=E% WOL2]+6<+\7#X=G2W)N;*8D.
M#IK+AP/,YMI?%;WR5J$9/\9#CJ6*N%5W$K:<^LX0]6R[W)Q9]G=7#B(YG1QZ
M!K \ZL(^@"X<[PN=X/1LB:5L+L5!X?;A>:/SZ[G1-MT>HN'_OC Y:=':)07?
M?X&;T)NH'>R+&\VX66^4W>!.63OYW&EH)#<SV8UP^WFOVM9;K3>,PG]81,D\
M*HR%; RU3I<>&S&FSY'NIUO )IWX=D"W#=@:@!0OR2[:"\;^6$9D%I< 1LY0
M^[L\=':S0P7>K,*+49 .AOBAL0Z2E;;-,X7Y*$A]T;_T=S4!'7GO,YJ6-=MZ
M:7="O+K)=8.K6&"RG36P/1=>OBQ5N*4L)9,:Q=15!S_%>4Q"DIO.X;$1R4W>
M)&/^, XY:Y21GX $9)(!DHS5+@X)S6IO5@JT;!DYQ#"GB@FUA+=T5.05\)2^
M%9Z9J\>K[F[#0KW4]N9L?8,45%P\?N29>)*PXKXWRPP2'3"#?Q="*/HV?<U>
M?<^-G31&0:JKL+;-)F#8!+2](HLSFVM/FON']>/&7]:R*%>/?VA2KC;_LMB@
MO/BGVN%JK]57>NV!GU9;_J[,]>BBA$]BQB=#ERWS]%BSZO%R;(4??W]Y\?GS
MQ=67&S0&GEU]_MSZ>O-A6TIC/G0.VU2IJ]Q\N?ER\SNW^8S=5]]M_B16H_F;
M\#W.<]9JF\Q78UL ^?A2V_0N=$SGYFKWSN[W>4OW;L59QR^&<=M+47X$)D^Q
M_Z>_<#3QG,EUPD2+XZU;S5F6%=[?%@ ^@I*_@8M_/#M_"BC8*A;T3R4CT:'\
M(^N#JE<K:W'XI^7@VTLRROV5^ROW5^YO$YRIMC5ZY@8BA.?PG;RK9'FI;#WS
MZ,HW-\?O5P+F!O;ZE+!'H+9*'^X2FDIHF@]-QZ\)FAY5/62+K&YK7@^'UZWF
MA%_7FM)]:6O*]AK0%Y_JL^]\NF[/AJ-S3#1FG1#R4G)C _I0"/(L@62;@63#
M0'$I_PRB+$U>QT@34%!L$OVUH&!:"16;A(J7@H$Y*M!/J^[WE:AXU?IAJ>&5
M2+A%2+AC. ?*R'&)8B6*E2CVA"C6;,S+)W^=*/;&; &K]<';C"W *6T!KT#-
M6UO7UWT+%^91;,B8L(JKI 2CUP)&"ZP#3P13I9EA19?$\XIB3^1VK=0.5G&&
M;:<\4\+LSL'LNU_KE6:C5H)H":+;#*(G!]6= =$WIA5>1U@(^%\OHQ;V2K7P
M%<CS&_?^1<ZP=/J^M6LO%:VW(A',4;0.2Q&V!-BM!=AWOQ[OCOQ:PN<.PF>U
M7M\9 'VD@E5(-:Q34>T4ZQ]M7V;\FG>K2TF^C :F5M? ?GA#NTYIU@#>UR[,
M%VJ;EK"SV["S<<5O<V.O*@1MWR%OI93T),>T37II\V2-M,L'9).M%+Q*I"B1
M8EY(7WT-%WB) R4.[  .'*]CH'QM.+"P^]-2!8;S%XJ)@_DE31<<%K-KFUL:
M&*'@G3W\9>P%Q</\01^J G#JXLJ/A9?FFFIWHU!I;#458:G-+KVW;[ZGL'XV
M-I$<N['"WI6J5Q%8[;]V\-$6;://U8_"]7O8/E,MZIC"/=GG^7X*@%@"WW,!
M7W>+@:_U(AUF2MC<%MATMA@V5TN@:!K-DYY=H_L'+^+9FB")$BFV!2EZ6XP4
M2Q%L;J]M>LL;2(0[3_O22=)(84^T*1JN^]91E%I&ZJ?@/8LI*FGYUH"MVF*P
MO=UD<[>*& ]=@#_=J3TV#>2I/];QQUB  .(3>H2JY\H$H3O?FX;:N8/^IZCP
M*+Z,S8:"'K[!Z2^+VOH4EHM_PQG@O>M&8C%\.X*=#V-N6,;U5VH'/T22QYW\
M#G3-/'7AD0'<Q_SBXSMR#N]^Q69/7;-7TP"IHB$6R(0X!:I[?O&/BOBJJ"=<
M1?QC H C*^)4WF%3+/CF.E)WOHQ$M?[S-37;H[^YUZC?C90GWH^5@5C]39 F
ML=M3&<12.UWIRY[\4!'2BY3L3:C+)?7<&DG^8("\GR);J!2D%0)EV$SLPH9E
M%(OWTHL#[ >EHHC;=<E8]P3;0^E&[SO^L&I_OHM\(ZT8>P'FIQ\'J=?CZ;EY
M'9QU$+D#U\>67+/'+F2(#<I@I2D@?)0=S77:!:@4ORGI 9N\4=&="\.UG&1?
MM"Q2>Y.*H2]B*'.#R=R6(P4'UL7F68D8IL"=@ 0%8QAT&$1 $!23'+MD;K8%
M"P5Q<NCC<B=FM17Q2?E!$@6AZU?XM;&<NX7S\[-V:VM[4:XYVVGNOB6P@+QP
M8B]X!-0=) AB '!.U%*VJY0O>M@S,@CQD@#ZZ>1\!-.N$D-8(LC<>G#\$L]2
M@X^7C8WXH*(131C+O@(^@&.I/C:R=/A#-JL?" >. %DJ##Y2T@<<[Z>>Z+E]
M?>?4RH)'JH@PC:A)6B1"@ '?F>R+_(YI3.)+^&N"_=A@H0$.11O8^U<*]!0'
MHAZ9>PXJ*0#$*@(4<.^X4?GL,0%8=X%(W+G4N]RCSM7 AH?88M[V1F5(@U_X
MI.V:U#V(A/E6NZZOYR/69QKOPKD RKJ(E[0!&<=RH$RGN%:[Q2U J\#$ 8$B
M.5+C(/I.LQ.BV^EIOKC ?($L<)HJ8Z1-6:4NX3$9((CSQWHU2&=EF@ .NO_6
M3?SZ3"#LKN BXA2QEMJ.@N2,*R6)&):@@8?$%<>#G>S%H7*PE2FUQU,>P5YQ
M2+N!>)D.D2^%FS^R=<^?#G204$:):93;!4')1Q-FG$0 60, 2V!+B+6.#(GS
M_QMO(N 6YM39,4$[IYMC%3FEQ,5VD$#RQJ BX+_X4J[A(EX*$-N1BJA/(<RI
M_ %(7!6\0HWX4P_!RO,WE,.'FV!D83,/%DQWE6E;C3C-7%:+G "*U PQ G[]
M!1$NF8R0E2?2 <2NB/]V(]E5=_!5>L]=+'%%MY'\-R@Q1>O8Q_Q8V0@\JCN:
M_V+GVT?ZX>(>H+&2_6YGIE_MY&AIH":4/^+'"WT;*[;@O'DSS71SY'M%H2?.
MFY9F^\V^,#$Q7T_//J\1Z6-;>2YJ*I%[?4:KWK)>GD 60'#@Y0&K"<P7['JF
M;]@,<51M9"[7E7I]UM\MMEWHYIO-PX*M8\H0<O#0K[7:4>[7'YM'1FZOYZFG
M<<_WX%E%CMN3>N]I7=%68ST\.>[/BUBZ[L.C$=!H9ZELJJ<X'AIDSOFL>'J;
M:.E2/#ZNJY_1K!T[L/4#>7\(;=5Y>3$+XP?XO\,H(Y8#M0<"OOR^)_MPM[](
M#T5[1.IAI*GX4C8^^5@#G]T8GZ 8@JK[7^_^(VZ?'9UUS@Z.#L\.3QLG!ZW6
M0>WHN%X_/Z@==H[;U?,E[8A3T_QZVSK]W,&&L>VK+[>=+[<W]O1D\8P>8&";
M9I]_J,RHDC/*DR4^4JA )$;K!"W![;FL6?Z,"I!#'</[VC:*O=)!Z$79&;6_
M>1:E??'9_:XP:D"+S$8"KN2M_"0,QDI]QW'8I)^7=BMV/EPXZ,B@Z0!RHO8\
M $4/M+YT.IQ@&W69)[%77N25W)T\@W>_7OE6!QJA8N\!7"2FZ3TK;0"7D?X&
MK1BH-3E!ZB>1J^)9DZ/+%GE/.M^I+7R_CZ+MG2*3@8>Z3HJ6!]3>HV22=ZNB
M+HWS9?#]C>Q=15L#@C-;XR/4+R()D\L!_#TB*';)'H?.A8DB\ :T((M*C+8A
M6KP[(J,0^<C@\8$7='E%9B&P[/F+)28#ZSI'XW]F^7?]/@J?^*F"\SR!UK,O
M3K6BO14*SR<,E/3I!+^R=H[GAE=S':$9M0W  E<#I[CY]5J\I<"^Y5=/3+VG
MG("!&A0'7Y'1/@?(OHL4\"99M5_FDVZ "9.%SFL-G<^D>:)@X/;^ZUU\U#H\
M;=;/CPZ/CYJ-\X/6*?Q[T&G4VV?'YX>'M>J[/"=^B((55+8CX_A],C&K?75Y
MW;F]N+VX^O)X*IO7/.NU==?X(@XI33\4V]2=P$<BR]Y]I'9^K+Q)YOJY8\$A
M %'2-W9S;8B#=[3!=W]%R]"E]"?&@!B"7.1$;DA & XE$%)'I:0=9$X<$JCR
M;BGCL4(X15MU),F="W391#3THG00BRF++YGV$A"2$^L$Z('\)/%4@LA$5R*K
M6]5[A;[N,')]QPUA [@^\B(4U\YF1.-.J%C/ "X$GTY)I",S)@A@EH7B]>W#
M#$$Z&#+'5M*?&?Y.HJ%T%(#D:.W7:)D-B%_CJ-9FBRF](?#(GAHQP69YDZ73
M5&57I*_!Q?@3-%'2[?3) F>L]PX."-<B/2][SYQ#!GQ+R)(%G#MXC3AGKB6(
M8GOK%.HKQD'D]<;(;P#\%0;4Z%!>@-8I),!!I ]W!W R@M-5D7TG^XU5C%$0
M*9;@.+0ADB&- G?DI'SW!CT(#C*S.&)+,39H7_QA4$[QZ+SR;$I"IEE-P\OA
M;0[?%N!9T1D7Q(H?QY.8$!"-J$*IE0G?"LF^15Z<1VM)5( ](@[>LT%N@ULV
M,";FZT9RZ*-'RIL@5KN^']R1@Q!43?8,H,_$!;T39#D.760W1_'V8G@G[D]$
M"N)>PNX3 $I?J5YL':Q:;K+@EI.P 8X0$]0(H#IV2:<P*\$_8_9IQ[BC[,HI
MA++K>AX\L]=#,RG"#/I$C-#^]3_E*/QX-N,KLJ1-J\+T/! V/Y8DYL I=0&.
MX>?8'?@<OZ #ZI!VH4<I3SA#-R1''V^BN 2+A+T H-H/X*A @F%4(70RSL"/
MY$R"^W7]E Z=Q\$Q^FE$2/58 FS\M,B]7<8?^#AAG"D<1N8\]M68H,!R-D1L
M8Q#06@\-.N10"+Q4'&6OJ\AS1Q8)EY0KN!]8I'NGK1(@,R#:,QU@P$#O.I:)
M$-_]8.RI7N;][0+AZ;OL) 9%*OX>F]UEGGP+#DD0]*P?+_4IY8'NRBRE J+"
M)(;7I$\FC(F*-'UC;<[LA1W \ YOFV)7S-[UE="BE3^4QFT=1 ,@</\V"F>!
M_5+89<;A9JEU/_4-H&7Q/DX01#V,4,$/<1J&0918=1?&AX_DM9>.DZ(7U=/Q
M!B"0\YEJNXW&MQ'<61$NM(D(L#X!#3=Z.V3RBFT3=,86)70LB(/*/K%$9XA\
MTQ_@<QQ#,T(#!GZTVC]<+@#SM#2%M]B#4XVL]&L471+-$(1 RT62H/EEAN6)
M_$X2&@^+Z((X#;<+>-J384*C:$JIPY@RN"O*:6&$U,O1H1TJ27 '"LBQN7"&
M#(YH(M),J^D"[5)WRCJT.;($EH7#VXWM>4H2E$:!1]YB=1=XA.*X*")BTAGR
MW&1XZ;D1( 2H:WNPW3BEZ7MDT8_)?4_V&DUNB1RR+ M(RB8:C'=C_'0D\[&^
MH@ .P$Y^U' 9!=#-Q\&A'1D.YP\Z#F$BEA'@L1%C4J\7T<DQO4#N"2@H@:=H
MDROB&C[0E1'(Q6@H8A,JT3?%0]P120",[DE<>496XDF,5AD *W^ QQN11)Y'
M;'U)N6W&@9<6-8N=QTT GSLX9B+M%I:M?7PFRA!I+\ .TS1MA\O%-=FQV/ZF
M[D$"\%0^4'+^V%.J8B:3VP'SI-HNF/AX/KQ7 :N<A"S ZO0\'^^' X;P*9.D
M%_HJ'05.X+#X[O^9#C!ESPX->E%  B^:$=%70PO,)?&A 3*)C67>"':X.T(T
MTM19'B0<Y;A-+<?LJ+6>P4EK+_&4^A+GK1L%G<48!C()"B$MIY<5)4@2QA9.
M,J4??2+6@2&BVD^,ND\\/Z6"'C AZH4Y341=;DWZN8K.80XP'*V'JA$I6  O
M+A'J/^'^*;)A@=4D+_%X7F$GB <VDJ_OR1%;KP5)U<"40.;BP%2R ?D.?Y@3
M>SG09U 0*D?R'B;ZMY:FB"B"#(>Q]\ $8URS&P-N&2SJNR#P(3MA_<-@$>*X
MC++HJQ"67_ 3F(/.G00;?:;NC8[[1[/9T;4^$V?"%+P[/](2#XIR#! ?QT-D
MJW<2IL25$(O!LT>L-3I2JLF*%<[A/;2M >QXJ*_H@%-/6=4*)&;#M%!@\8H@
M6C1O%<P-Y-_7;AW<YVL(2'P2)]ZE].5 81@\D,BKG(BU1/;!"_/A#=<30Q,E
MRGBIX34C?40DI^1C;C'DG6*JI3;#:).??B9O+!Z!6)F&1MG+R3T,?J$']&E?
MM%":!.+ *%,_.! CUO)%J(+0*\X.&J1VW:$@;_BW%L%<U#U)/B/[!:Q_7YQI
MP9N9*6B&>G\+7Q'O2V_=Z_36F221]1UU/W" ?:CDB*BQA^1=%LQR4"]#NY+1
MB&*=(Z"0$)/]P9I+):D,;LPPBL*)!<<\]!L-A\;&A!)RU(R0F2(,+ZM%Y,C'
MZ[:KWY*6T/=23O_IB\OV54R4"H3X2)$1?2H(0/0RPH GB=?HIY11F+=NX2ML
MV[(78E0[G .H%]O)8M &1>*.*!,!Q;*\XA[G,E$0&%""8P,%H%<@^@H$B8K
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M(?0#R8(FVL2_CU.RG?W:8PIO$,!R\Z6TWPN>D>R[E(VM 29DA)("L'U5<C8
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M[KUK=J#W_GM@8P6Z^ALI=S\HEY46%XU1UJ7NTJSC7P\.4^=\8\#Q9].V&B?
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MA8-232Y<0E[;B6]SV@(@/?6PF#4])LC,&"HA$-?0P;SUKAR_&[&N;P L3.D
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M<4RH>(<0RT*=R!V&-V.[<\W:__B<2-[2+N%VTBT _Q: ?PO OP7@?Z+_<@O
M_TP _D^W'+Q?&D=_S<$-. 74DY9&7LG[HK48X1^J:1=*\*#U?:FJ6>"QP;7?
MY-++J;X6X^UX*1GEY@A4$YW#4;&X8*AP2J/ %TO=#*'N'X1L.4/#JZ;3)//"
M^19-J[&#1[%;45%P)=P<R9D//Y)!K,C('9 \FS1S2_L@D5TBGQ$S&$X^,2(B
M-J.3H^K!;%2>+OE-)64F=_M>/CSD4E9S4ISZH&563I:H$$@'-S\54@JMJ9XS
MF3!9LK8N+KO8!>LU/W,! VBZ?^"KWLER^9BHBX""Y"4$J4M'51,C(%].D##H
M5Q:,U7P4Q4$\[TPW2-ZW;R98F%*'FX9!'XDBB,C1"A(EIO0C>FG.PZAYJ:S%
MH=\F+-8F+ X==?"1YU;[DAD*/ZB4\,T$\#:! "<%:XQ(C8@"/H;D.AN25(K%
M5T,1$%&V"((OZX4C5,9F'L$.LU"7MK*OLZ=A!+(@_U0Z)%);^"1N(+=0#";?
MGI'=_%5)Z9F<GUY[7)25DJN/"Z-Y#L(N\HG[]<.?[CU?^W$PL2'\.^0IW+6;
MIW.F]4C4($%4-060QH)N;[D-4B]3\UD3X")2&]]S.<'H)8R#C8X-Z<!0*<I)
M"[D8HHR<\^^M,-)4Q?LP =-8^]0G-(F<J%+-$7GQGO$M-BV<=S*[Q.Q9<C]M
M@-+ZJN;0;5%I)NO:FB_H[I>0FI?\<-)+$CM(^&.*4>B\^ KH__Y\?\:1YJV_
MRA:,/_\8;\XY-U5<7-=C7&GU_/!+YT[RKZ !Z=JX+[^V_J,??GF>ZY8\E!1G
M+#D>NRK4<#PV8?9#)("O;Z'_S[4]BFU!C/ZDS2>%C;LC0\T):@X\O_#*_GI[
MF*P,*24+,@SS1G+%H\M8#OT^/=6$M59@2;28$*VL9.\I'F)/GPM007893-?T
MYX3>&FHL3:4MSTH(F4+@]T3CHM<R#7YM8/&8KU"! DUKHAD2LD3]#A]=J:?0
MJUML\!:3RHRA9?.Q]8X*:%>XXB4^DH!HK11Z[#&;9H[\']X1?!PGJCDJO*1#
M"*I1UXBS0$$A3_3E6G<7KJ-J/KAY4&"#161L$NB1F",^\,VEE_+$\C8FV1%T
M$)VV*%^AGX3^LYPH#F?H(FNC,A>J) F>>R5T5<3TB _&7O-DGS47O<2%.9*:
M/E YS 38)RR0C#U2RC,)FJ7H'ZOQ@3$M!JG!M\6K%3<PNN>A$S\\NZ 'GB\G
MI\4B>P/6=^!'K**OS=E*QQ:N+HN=YA $?O]XF(U4:QC_%NC ^P5YQF,RX=OL
M7-/2XW<Q-8IUB"5-\W:K+5C_ #XK]S5'5]TK@!<5*E$+*RM:A1'<JK*/^TK$
M R\H8$N?1@QVOMUBUHSYY8X9##N!,R*#0X4ZK 5 1F+-DO,=PEFKR;,D;\;(
MD#8N?*1%6+J(?D]V]])5IRV!LZ8O8)5E%?&!YB4DQ),LW+NPK62Y&,Q$TE1X
MS@7J15*OADIZGEVT# >KLS\HQ@HH5 =2DVLD4!E10[W0FZ\^4D IL3%DLZ/9
M,)NK%QI'6CC(:Z4#[A33)XUDA:9T/K0-[0:&_.<%Y;!,SI!)LXC0#TH*CWM?
MREK^N\X#:B9"A&1L])65Z.]W8X$%X+:(IFZB')AEA+;6,>I-=*<<5*>/"W.=
M@E@<?1.L=&6*JNF!F(2(TIUL8WMCNF4MB.^@C<I[IA997#UC0GGV(]59 2/+
M:> /'G_:)85Q1P47@+U8AFNH?+\(J?YP.SMB=/L+**1\'4SU>)U[[O7\E:3T
MV9!VGO7A_-$8A$5-VQ*L$J:P N-4&7VIZ?TXP1KK ?QPVLI6$TV]EPPJWI>=
M+"=89\UW]'YK=Q S%-9ES*T/HT!).)GC ).%NN; 5(F1S">.T%(4E$M"GB?H
MK^F9,Z]RZRJ5$[8WQ)"@,O4^;Y(]DB3\(@@$B8J.M)(G%"EDD2H^0J7XH*HC
MXHXB6>>R8')8.T,9!^95-S;E#M/VSU6L*R@9"^4L48\#C3:2"_ISODG$PRQ*
M&:3IUT3=C7[7@AEE,9I>VEN(>!F6I?\&_DN7YB7S.Y0"8:'WU50%U[9:*(1P
M+T)528NARJ!I3@]B.Y:@;:.COV&YE[ZI',H8SP\Z\:4"'#2F1T6*1'+ 'Z#\
M]^]B>6LS=60'NG%W^&V=M)R>_XOLY7<:.'/V.[8H3--%YZ4AU=C&]1S8P,B5
M;Z5'I^"%LQ(L.KBTUD@+LC,-HG%Q$KG*:H'>I("7R8&EM\!!XH<%T&R3I2*?
M8@K1R&B4"2K>*2J=O'JT#YJI5]X5E=&L8+@<&6S*&L3 )1U3(GP6.',W&(X8
M]^JC>,8656+4\+ S.;BT@-5*49_?AKB MJ(GQ0Q%U9[/MAV*8?&UK?AU[/LU
M7)J0_D,=#YE ?AW\6$[M) 1@6@-F9;#5,KTSI8-L4DIG;X8H1*K1I_0_\Q1-
M>IK7FGQ103TK/A?U60Z28ZNPB4Z<IW] N-F6IPV(Q$;E9&*A9+P#A^P4YBAZ
MOOB4DNZ-WM]O1$]0VPUXY<<UF^ADP3L-0 LI?4&7RSL.?(P[G5%#3 <V9_3I
M<E4+\BID1[#D[$*NSW2BB&,V(H4*Q.G6BC[!*SK8V;TH.'.@G8RT+*3'OSLK
MI]@V$J;E+%NG,-5BBQ;YEOI>%M#P(UT(9D-O8/JW]CGB-3H MUA,&3=I6VY$
MT5]+;,^7<-,DGEFWB-M1KJ/BN),UGLZ)J=Z&4&O6T RA<W? ,XS G@Q D6-R
MO5G@^PTTL!07NYA$-WB JSKC-US$IGF^:B ]#S>4 %VZ.-,4:-!V('?8Q!G*
M5 Z (V9:2TKT-RGSTYK?O29/D2?1:\"RS(I<0<H-CSX77Q:;5T5NHL@.O7.H
M'MXD\,5GWNUW3FA597%>>-%T=5)%5!&)9<MQ1_8.5<MP^W3":%]:GK+"5;Q#
M,?Z@ZM0=J9DG$QUU5^@N.W(*D1]!AR4"H KD_>\,H95/SILQ'Y@2W%5+1W@4
M1B=)#G!WV%[H;?2!LRBA97IE*++LU=+$R"].%8^0DS%U;YYR3M)/\NA0),_7
M[QK3]K^ *BO.FPKZ@["/R'%7S2A%P8?T"SD%DVZ<ST5A*,Z;/K#C4AW8WQ;%
M^*SFY@-K< \U#!,\U 0Y_BZLD9HC_,,RFEK9T-.5\Z:NZ7Q+I;2CB$BGCAFZ
MXV_A][?P^UOX_2W\_A/!>;?P^\^$WS^ZA=]_:?C]9_IKR'T""8XZL'C6J+[P
M$2W.%@?:'#]3W#I)>&,YP2=:@W 5#(J@9S6W84OLHR6M2LBSN"%>I.XIY!''
M+FV?CVZ>@OBB>P2O[$(@A2CDHO<>M^,:]VG9@24*GD5(2PX$7#)N3BDZA_>?
ML]<@;ORRX]IVGZ4RD,B([)[_H.)$+1PB?YE^,OM3\WNRA&],E/ W0[17-) _
MH_&[+9Q,G2=!*!0'HS1=J[CEBA>:5I<@U[C6Q9=0D],]B+Z#CQ^_.'""X,#'
MFG1XNHZ0"U,I3Y.TLO4;JYOQ!PAS("^YK+42A7VF@EGV/*&XJ\SOO18-FP4I
M[!?<7>$XIBOEAD(BK*QIEP*8H+*?+<L,VJ8-E=2 Q1WN# V*4W8^0QO'>YF=
MAM:)=EEI:7JW&!<@",&!K94M! T[93M>EHMLAW8OTGW#.8\YJ&QE+\HI[53[
M6GDUX;-U2_*D>)^3@=S.AO_)KX:T^^&70 E7QM873H'F++HHZ54D??TJ30K4
M@6>GY"H6)-%4M9 IRP03WA51RJ!%AM480"Q@7;:+%"1^<58H$<&ZH4GZK2OF
M>1M%YH2<8\&0$1E0'5+=*LO,K$?(H*"@17&E]K5P0AMXI]4'4-YC3KF$Q ^>
MH:P5,]-;81S:R^<\ (G>91X"XT?L3N<EHOYR6BR-^>'BO;"X="G0H'A/KQGO
M8.GIC@)+GPF[T=9IK"3)-57.&BU17].-X[EX:.AEEXCYTN2@ZXP1;"_I79T7
MK3 #3)=0?J#]6=%V#Z; A@$<Q ?Q<<;-(\A,298S\5B $7&^8Y4C2  ;2+[R
MNS[71+P50K:4-A!\?3:%.*9QQ'(:+>?BG]2J Q@H4E<L\O<ZU4S!PFP2X5F=
M753C:X;JBD][>]2N/VK!X+'3M.UR+EU"5S-MX*+:.1P&>HQ.#+8A?D..69K@
M:"D'9/BY\?)$Y@].[:*_;A# A5H<40Y6EQZ7'4*KD&9L':!UD. [%[1@R,#P
MZ4*W:=@U1;$+93-0@=J? @HOD_P<.W^SN8@TCH1<FI\#_Q67WJAM<@&@9N2Q
MSH-+B[E1?I4N;285TD*%DJ1XAZGA(5&XG($EQ'2,MC.AR(["1@GT+] L\?L=
MA_<;\'$IC>?M]MBD"L"2\2BQCB^ONC?TT%$<1\<@X0Y^$/3HZ8R4OKVI4E6=
M@HLF+JG0&ZHGO,)!%%2B:72@ W ]IK)VO+<R=*EU\,?,_@A<U<=TB!HHDM.\
M>S4@_6[3BO8J%N!&A:"^<'VOHW6'IICV;5WF:,!!OZW.-(C.[NS0GE$*%O[/
M6$R? =G9Z('/ >4_*?IC.,S]@2K9,_*2SYJ@U-2,:,U$U9)E\JPY.<TB7Z(=
MVN+"<)G@M,'>8A!W\MHL,M77P? 6+EAR3>%,%*<YI>V>T7J*%0Q[*I+@J#N&
MCS(DB;J4>JYLTUNS>FSM^KH%@[W2Q-TOU*M?TG2!IU<I0YUF#+_3UBJIW8)B
M^KJIM^Q>7B)WH!$SWV-"I_QIH<JW\Z7#NS*B(#F;OTTS\U<JN+Q9+K@F*2'0
M.AF7*]F[.- _/9#O%6O$6.M:NJ3;<*HZ.ZAJ:B'&5D9+/J^Y_!F/Y\:_2?:-
MOLL)_?B1ZZ4!A'7T,W5T]MY*)-FG.Y4JO_*,<<M'<0X1"<O3'% H@D8V9!)A
MU" W-@E,D[OHLFDY3T._#!]F&ISMO<UVUGUN<(JY_0$LIXB1['?BH@9BC'FU
ME :CO65+7B7-PAX=&N0DC[,A155QE0WH<&C!DKH_+BKD>^C_7I7%^(PY>Q=%
M6>N)NFY@@X YU@AY[V XL @*I.PU(^/J4PKHS3%/VS4DV.<9E\-:02==Q .T
M^5QQOK'B'4 6IQKJAU>5C]M&>ZMH5@!2D7_Q2'2#S69-39.'Y#*/HQ;(E&2L
MO\M-!N&OG3.*@2V'$LR5)BW)7:1_:F@>B BCNQ1@@3&UUL,'6A0/IG7Q7'NJ
M]P!5^T*^>INQ?>:"<X/-E+M_2F2#.)]/7X1+ QL9O,RT329PV2!II,UN()$>
M<%U#4B>8 "3#0IO.1+,)XOD*<;'^Q7>J1@G74OO")ASH5:+HJEHC+B!T+8#L
MSH6Y"_42OD:/WU=&YP\2!5I<RN>O[5D/%%]T:-C'7@_2G=<'Y"</F \'.B-F
M.S3RW$\F;H<,Q;@4S.Q+>I^- 1BS._L[+^_:))R!9)BWO<S!*>C+VX1:*'TC
M@(1@G$SZPYS,A=6.C)));4J,%[8EP<N,QM8FH6P^(#(VT+/J8@5R\L@>;2^3
M;(#R,%M0H&V:3>L[L\([[[0+SXB?!?_+CYN2O7]_1N.?^3Q7N:3# ^$6Q]YO
M2N%@YE-#&.3-I:<76S6-42YQ%*0':R*\?"FG#E_3I;K+FH%*LL1R>KWD'0&\
M*.\V[@P7=L2@+6A(J+[$P&LC]/4Y&$>KZ['7BRLB=BHO9()->>WYJ6FU<(*)
MEYZZ#0$=K=Z#W$H>!%,8'U? BLAM=<DJ0QS:%T))7!,MO<H!FD_.M077[CVN
M\JYSNAV>TOV[/?A>KJ#60NI,0!SBL*,44H(1QKGHU@4;5TYP1,AXY:&H7$S6
M&FZ3#[,H01,=\7-+!M*J,!?Q8'C7EA= CB,Z'VLOI"H9 +\:4U2X)?-$2$:^
M+4SV4<P&_0M^2A(-EZI!OM-6HF21DLT;R.'GS=PZ0[U$CS U%WK?U=F[C74V
M<9&),:(M?EI"F_)*H4X?YW3%/&4O7**E&=[[RCBEZ6H8P9\B&+THI/HH3J=J
M4H@BPA0)9UZYUIRCN7S>5#.ZQB1:1;-P*C"J(?4TAE5N+6_SO\-NE'@N=+-O
M(G5W^PLJH6DPLT[7-&AH2067ZY->ZPJYLQRDX/(9($X"W><N&212N34Q".QY
MS[BS.GF0/7+5\BCKFGC8,4=H>DC:Q*@-U]*F'QJAXO78YV/?WY@0#=ICF28=
M5V&\FEU"5:91F/H)\Y5UD8SQ/-<$24JBSS539G2P!Q/-L]#K$;J>T/K@6S_:
M53V>K\2@W *0;P'(MP#D;PE/>PM _@H!R(]O <A?&H#\3;'U7M%3WE&T1DQE
MK;!23,HIF'P6:[+Y4@'ZU_; <K3J3>WD=3ZA?QXWY(YF_VHXLV_$26O3H.J@
M#0)U1]KURG*!BV:+#'2C'<W2]BG>KY:<U:$-&9Z 106<)($B(FC.61&G/0UU
M .OC\H1PJ\QIQ@\GO71I@WC$V1I[76R*3Q.&#G&VIM4N@;,)4D\SP]K]IJ P
MWUE^U=+2U7X6"?\D3F'P1@YP12'9 7[P+:5;3PGW/D(#G=+J<:)HO.2_"H:3
MLQ1*P/OA'CX6$FU:SI,C*1"8!5<T?DU0''#G@?$S?X3+RIB:-4TBJ&')#HL6
MDZ8;*%RJ$1I&0 R?0 ;*=YS+@I]@-'^*A;H[")V(H:Q 05Q4A(\]]5CKYTU%
MN\%ZJ^DC[5W\C,IC;-!4)C(W,[0/QF?HM$0$5HX+%]IH7[*"X;+""GUA_K59
M6S @Q<*:)]Q;M+*9QX9U)@7(05D*58]-F];U$%)F&@$&*^19)A9@0U7NT<#,
M8-H($:CVE85J?V,VW?/T?8SGC=9+Z"/F(ID0Z 0@<=S40AH74-KQ'<-HEVCP
M"9967[(L&"BG"A4\KL:&QX!?Q7LR*NW(N%D_-EJQN9QS#V(=H5X$,*=!J4'_
MD4TK%F@TL4=.C4^:BUII"5*R#\=2ITAS1K9=UOE,J!$YW>Y1TX&"JD<$8K4A
MIN'[R,/,E7VX1^W)IYSPY_5*!DSYQ9LA%.-OU[JW=\:RJ.R'?(KQ"V4C+E(G
M"6V*3RXIP.GU*AJ1/_V]::N)4K=D;]Q5LCN_OWQS=Q!H'Y//^. ,8(F=AEZ8
MHU#=C3FX@7$46[+)<\'VS/=:9MA %,/I2LE6S:7!B,LXO,0N^[E.5*^C%BT]
MA6-R+-X7[:)/>++AUDF1E>G/-/4GO"6GI3'V@H"Q=XXF-37EMX#PH-9\$WK-
MO.6N0*T-=+K1NB)O^27RN=4K]\\3_LUPP"3R[$X5!^4OTQ[XCC>3*\/:*R[J
M\[)MZM#]8>8\8=ZP_C'T]I1*M:UZQY'TLD^+FG^8U^'.RY/A70..P)RB(4-.
MI'S"O*U!9,&YY>%BL*R0]J[R93T^V\[V0D.-09?UZE(D\,'!I!A+SP^6#$A9
MV>/ 4]*X8@@D?4 X \KNW7;V^UE9I?&+P[3(EV6"&3 L@#.+-:7G,#O,Q^_R
MTV) L003;VG;3F>($3IC\;G.[U-T97%JVY].4]HMN6"CA6R+CT04!>5@#N0;
M/:@(^JMH15GU9-R6Z#$*09&<X <Y)&61>3^DARJ73#F2O2LNS>( JJ(R1C0Y
M#+#J=(-E%!=V9B(#6V8,*%:ZD_C0NP!/BM%;76"2^6L36&Y7%56Y[DX9B,FA
M+64M5OG%=UH/%%B6!OEXB?E"<%<'9I(/);0YDA+O\X8]I#N'!X='S^\R7V:!
M $5P2PYGDW"T"_S-&'^CBA=-_6N*/T-CI>$P0 %YV@AZ!M$?4 Q+6J^\-0RL
MZ"\U(;\GXEA#0V#TK"B0XO 0$:VYI\#G)7V':D&D/!4#G:E0.0I!3[' 098H
M_G0!YN=IH]@PE" $S'NB,)$J,/K3"T-@"@VW]?VI XX93QXYTH\+-J1MWN/?
M-$O_>/ XL(TG!'>AT2UT(ZXE(_\N]\+',W\"D#.;?&@9FR^9]XNH2J_$K0DQ
MYN-MT<T,K(@QH7-Z+*2HA$= /HF\8=8[J5XPKD9&VB?8UD@J: _&*F<KHC%K
MMYP(/U0$2&YGOZY3?<"/(@2S M\ETQ#^IYB$WA'VYB57$ZCB5FBQ9'4KJFZU
MC5.<1!M;$.4"/3?.+0YMQU+*E_+TJ4 KE0=/+F/'>YH>C& ILC\TPRO]O79X
MGO,I[AFF^:T"NDD&Y#]%W2G$,_Y2CW;:KO]>@FVSD4Y729.L\\7D[=  )'!@
M=,Q2"+>Z9MF:$5OKQ6E+<[<<,=IREE??IXG ?I.3"KLNH%'<&Z^+TV;A.-T3
MB >?*JFI?G;/S[B@[.[P9#/59ST6US>\B+MV' 0L;E*!$*?Q%6T896P=+<MJ
M @#+XWL&X:MHI4^X8WGB!-)MU'I.,"@8JX7=R&WS 0Q"W3G^"HG@)FEG=93+
M+/W<;%6:R^2^J[A?0.,8;A^M!7>F,D4K^VV8/'%0!1NKDSI(\[YA5\#P3'J\
M=-[U_O>2ST^D+D>.ZLUE8),Q346A]+R4%NX%* /$GQ&_W46/B;U!HF&K8HM9
M]*ZI*=%X689\UO2BYTKZ<=9T<SY\M![QU7*M?OZ>0O_$=+HUA_N9,<0CH-,?
M&FY^5)SF=>I9YA]+JM_Y/SM[=P,PT2,$C4V1;VT78;)./C-T'6\Y"I^@)",[
M8*!\Y_14PNW#&".84DX>R28!07L']% A-2X)8142.2H;_A6-%0XJ"#$P$(0E
MT7/%B70G4NQCKEH*Q&H^D_#Q74O;4,@7&B8$1!GT;[2S04Y7,/73%$Z242RT
M1D5S1MYK-B^K!B<8>F0E)(LM.IL*%-F=WYX?W@6$GD9J+K!$_9;4>? HFS55
M,5Y6TL@J\X7CBS^^?U]I&?TAR![U6R6[*+ODCN!A'6">\05[W8%UA&E2R</I
MSA @ M86PTM.3%G_@-H<&YP^I$2,I\N<3MY%(3&#WNJ"C'?1:@;9*2(@")[$
M?'"ODSYH [%_!JKZE#(VO#4<^C"(O)3H>O1N-K5$F GVF7D4Z>+&BM')9U89
MO_9C_S/O]G;^1W-6:\>&B-/:%,:MIWN*SQO:];SBILO*<,K3LJ7?&8FVK<BE
M6\"\NT+$2Z\24&5LK1[AT%.C0C8Y,2CP(,$IOD@8IFEG\,CJA; >.R/0%QQ?
M/T:_I%+>G["JM&_&/35?1/0AV.=!+4+_)!Z"9<Q5M6MJ;>2A1L?Y/3K^)//^
M[+'HEB$'WCD72CN<9%^!."#N4:7G-9NQ(A+!;H)6>L0\GP&0T,G9;[. 5QK
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MH+25A"T 4WH43],LF!P5Z+[&T9&?TZ&*E;5H-KT+K>A%Y(@\J!9U&12:#A4
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M8% QT:Y-])O*:?^I$_!YF_^GK-Q\O0(KVG#&6\$+!NJV:JHBJF>MVV6:)!)
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M&-41H.O>MU:IG+O;8!2DF>KLLD,1(5EZO;>4,+?K8XW3)0S+P/=IQF.41)S
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M=_4MP8AN<5=?(>[JP2WNZD;CKC[ZAD/>XK>][/#H#4M>?ZOUO(@ LYJ_B$D
M:#$6P(&I(;2]?MN2JU&F9NV\*LZC1<<T!O-<-C#7NN"\K=:]1!:B[X -5I*7
M@Y#4(\^UJ-S?1V6CTAF;5"6TN  )[DG9%8&U?VP-/5U0WT#[*!P_9!@!O!#.
M&AEI+-_ &XXW =[D3TT+DB\QP"O:IHN)?15=T)"N>%]VB\2G3G4HPI<]RZ?K
MHTPJCLO:0_-LFII1U]!%QIP3V(Z4QG&\FF@I-*9J>'5P2:KDA^ S2M("*J.L
M 6X8(BLSK)N#7(+L\[PMFV7'B*E3>1(W^NWL6,-;"91P?]3*)+!#.MU"MR2P
M@THQ_\$)AV@J7K6G-89"*:G]-&#)S0Z:?X\*2_0F8E)%BX2V#WHI^#0R\C&I
M"_= ]12C*[_]9;8WW"L)*64?.94/S?/%+!Q7.C\V4"X&\_<DW]BGJ8KMX+KI
MUE]:HCX4F#E7R^6A=J%@,Y^3"UP ].]IN="Q;V>_EVC/"H0E:P+5#<^D#R$#
M4.$>53N1--6DX'2G)6C=;(W:GK7MI(J)^/7?RW+\CF7J3F2?T)ZM.)\@FB!X
M17[#J%++FLPSESFQ$4,^$:F%;)33]9O3?JH[2<&L3W--BBJ_E&2-:/882'*E
MBA72DC7M0Y^6E'00@(J:&=#RELMFA.SZRF1WHLV5Z!?QA?AX9#O'U@N#HW,(
M)+@\#IJB']N$[E=OB8H=HR)4")V.G7S"0$6 8 (OH6C G >YLI).XW.>?1M"
M+]FZ7T\YH]_F> ,^F;OZJ)(J<M2D!E#9K[/C8KZPY.;])P/C\16SVBW+E%%G
MEPZAEMV#'9J<1>A+W,L[+G_%CUE\HZCK[K*B)RWSD&K_9W-6=_2T_TU/\7/X
MUYU_XM__O,O O^)42INTJ?3/85.%2G%HG\SM(&RTR$@[.SECC.>#ODT'$M2T
MCHH9+<!)<17D&]O8Y7Q#7,0ZH1^PT8_G"^YIO?_D)VZX7,Y_N=H LCLEO?KR
M?3G+1W>S\[*I@#LN*$QBI2G&4[7+CL_JB^_E*/NH)[^[=[CW>G?O]0Y%(*^S
M?^W];[;_>NO5_NOOP:]GAIN6/>I)V7(E+QR+(@Q%.T[P_Z'.1'MW)D<EW>D?
M]\E TE<4LE#D9*Y9#XU'N*8^[YU/3C#\C^/)\>0S(3_M,M92/AI8MIH[Z^?L
M/=!7:HJ4*VDVEVK-C_2_LWGYGL\O=M&C,RGP-W4)K[;#?GKV7U?<FNJK+YH%
M$-XZH3075[O>5?MUN75ZWUSE>%JV@/3K& V+^4?CS[U"\'4*S7"-.O25457,
M(I;'RDZK5;P[C&*14YY^<G>@)/&=E+ <4DG9=E0ASB#T,=@HS9F)-5MN# C5
M-NB32'T:>)O@KB0"<M*A ;("?)6/@$G#V'5TWBA\ALZ'*6/<>46F")(0>*V/
M:]W#(1P%3LFP* "]R'$<U!@&)BJ'HJW$.K3& ?TA+V<@FT\>"_X 1Y^B'Q 4
MARVVY 8#>+1:K+? /"W6:[V9?N?JO)]2'M;*BV"N(K0 2\K6@9M^7\QG\*D&
M@NK"FC^1EI('!JA+"TAY;XRCHJ-U3E$L?VCP)(20@(B&L%"FQ=8O+U.%!(C"
M8/2->EY5KS4GM^7M4 -=L5@(!G*0G13G>7;8PUB^/1X.D(2V<'FR'C?P6YF?
MMG^J7-ZKB^^2#QH\MEZA[#NJP:?5P0\N]@#VC>TSFLU"EQ0[4)*A,0>9-^U<
ML*;TP;OB,HFC9-$XI&/2OM45Q5^@YG!-$FY7.TZN0[KA<XZS6*>@J1=LA;SU
MX8KW8DVI$>8M9M^]>08]FD9D'RJ5UL,E,^B*TT$ITPKSFHI"?0:9, 906E>5
M!J#X4#Z:]G6N(\?)-^5Y?M0C/]H[WAL>[;Q$-]+NWF][K]X<'NR]/B''_+>]
MXQ/^SV]R8H0@'\T90&X)\55DNV,@3S[E1L_@ 'C+DV1Q>3'W?NMLTK+3),=*
MYG@@X)."_1*.I"V*-Q@LU_U:.AT79^'8=;V4;UQ6I,+I.^-P$WW@=(;69<<G
MGJ1F>*&C+00=@ U=;LIL12;!S+Y#@6Q+';V/#V(MTN=/Q.$I-D%\;RR.,E+U
M,6.>7-)EZJ^UIP4P+VNR9['A,;ZA-)E&MY0.B$F %*V=;NU#F$S8 R3_=4:/
M)'C_BBY03*Q55Q)+:0Y)V\D%KUR4"Y'P;IOEZ9FI=E79$=(DNP(SDL\2,\8O
MW%%6#U(9(O'B BC(VHUIC;2Y@B8#5JIL)])KP@OAI?4,C_(JE[0?Z@&,(50U
M;<<XS5.CC<WZ3@RS.B&G&7N!USY+*I\)R6I;T+?KD#Q;P<=J>EAR;]KVX%!;
M?F=X@'>+/FI:/I-&=7R"XZH]-O+(\%AK'!EM/H=WQ_LF3[*6<K9(#C(XJJ[<
MI"1YO4W;T8:A9W)">OQ7>XV<6IXV%'++"F[JTR9E[\;8?!7-EYJ,,B%<;JKK
M-*D;]1<I_6$AW%?F0'&C.5"+]$:[>:,$FR@RZ?[Z/G)+/_PR##:5^YO93-C4
MNN4=:0I;H\$+.>-1(=,X9C^4O$2$!*-B<<%I\VZ,($L;=C3)S_]P[6YR'_..
M@9W(? L7+5_V/T44/"S6KCC5GL)0!Z68"ZKMIT5#H<?\#%A)B<HT'83BI@<(
M<F.5LPZ)BOJ&ACHAW74<^!9@EG..CPOGP_%!P*$O@EC>7+%X)WT=G94^LGPA
M+3[T"[:CJ!J*C2XM#,9<+J"PB_Q\KKN47P)J)E8II&U]RA?B8=)$S#)#CN,J
M#@SMWG!LP&O""HC >Y]<#V>-;NQ^#8&]TRY))^2.#7=4*-^ _/B,WC9-[>2R
MSF?A=9%+&>5$;0AGRW9222:"75S!DTOR0=:E.UANSN:]5E"/ !W<86".3B'G
MORK:QP/5";PA/T'S1S_LA/U>RL?TLB<"_;:V,RW=V(]0':JJ=$LX XVF7?#F
M< N&'0W<N*K[12D:NE LDMOIN:EMDFH<:O*"MOCUAUMKF"$4&&[DMAKM,G(4
M=UCBD@&Q@TZWN1QU[O!.:IP!;XLS_I8,\!:4>@M*O06EWH)2_V90ZL-;4.J-
M!J5^96FZY_MOCO</]E\-C[[5"OEP1 O^7-2]I#@TSQ=GO.Q#7LSWA'F(*8+H
MD"=(1-1]6#6@B((C/.G6[SK.5IA4S0X#K[(IA2#%1=.^PRVEPFKWQ$U2R?;]
MI'-)& R4L4N)4>3N23_;-,&5,9_(M&@5K:4P* HF$YCMVC_#;URM#X_[#<]2
M?'9W'"BD>,$.<UXO>O54J8YJ&1"-CFT14AKB@0I]6*]BI]@ !GEU(5?B,%T]
MI-V,JUY[2ZZ*Y*$D*9FD7D5;^M &V40BA="H'*L%;5*8EC$NZ&>G17+;;Y.H
M3."C;<A QX9""X1%F]B#**U>*\+D7: /U"9H_]-0D/%KUMHCL9-"E(T]LRB*
M.8*8O,Y2;#,O)0-6Z[OTM"QQ#6JS+B>9Z5W.*Y/[6]\][^!U",]X6] JU@$*
M]]':!T(F) Q^#?H0J[$%SA3PW!P$>/Q3X9U8SD&(U=_0^FP&H_9$AQC<N:7Z
MA;*0%[/_^9UB^W1[@+G;6@NA&V3SL\N..8< 5J21HO F-($06$JV>R\7'A@T
MA*J*WV!#6X7K<!& @AK^K.S@+G&F)5#,LP&M0:YQ=SL[+A2X?)U55@]W/S1;
M=[5J)5Z7S#_S:YVOB8:_!0OPYVM\QR=O=_?W/L&#N.:DSY=-.>WVR-9HMQ1Y
M2V=\MUA.)!/#."9P=^DQ[VL7 #,9.P0@U WG?,9L26.I(:'Q<*3*$1'$UXU^
M0><%'(6])ZT\"0\HIW:0YIHR1:C6J+H$&JX.1A](0[8319R\%G?''I;':<P7
MB7/"M$--SK_A$B%82V)A+5@QEV)V3LZF9Y"I<Z4JX!<3X$;@W4+9!$1KZ328
MI;8JIU2[N*CCZ$-0Z4RS_R%?C%3=C)X"4V[Z9P-%>?N3J")[*>EROP"D,F!]
M$?:\Z1D(S'R7S*FZF)CK^)C@FUVT*'%RS2)25RUX\3).;3D!E:O<I6%V[Z[A
MA.2E.U@%V:8ES7@4#K+1$A,BQU?=K!**9\V<B:\KF\=0",']T8>%DZ";<[9>
MBJ^2E*2] Z\S(#PD:3J1EQJRG/1]!FGPT"5]"7\Z3I7'Q;<X1FD_%K4^D3 5
M\K/*P^'-N/0GG]Y:QC0&WYMBUOY:8[]/ ?31:W#*#E^MX9?]IHX^48M-([Y&
ME')CN,)+U$&/I#8^)A^,?:>E5>9-Q%"JLH(F-89/KOG3?S8SH.RL09$9\ZSY
M)-08M&-'VB_8AXFDHDJ=FF)5USNU&@ '-*!5CMASY]U-%FP2*N;A<YC9": $
M GC5CP+<UFQ2J$0B8$I8_:(Q;Z:#/@BB:3V25J.%M9 8FF<FE10P^K+F"6'(
M<"?I>T>TB@O*XW:7%#W,K&Y.KW0K?H]-:]G-E^CJ'-96J^^*,)?]&JBS$X::
MN3G%ML^\VP'G0>B=M6CAL13("IS8X[[1]OK>'!P]]@I7"N?S2VD=@2QUA)I1
M=2OT3$WHD&XO0\.0UO/F4=$:5(9Y+'#Y5E)AVW7>D?+M\G@QSMZ3.;\"77F^
M*K@Z#:[ZJ_U[TV5E1SDX.K7_-'PS*51*75"_ZV>PYWBAHKXX PH(+%5\$//W
M>2Q3]&E)E(Q,2'^4F!&ATE'4MCLN2^6]LE#3F1CP949"SF# G!&P"VI!Q"4#
M$BPO:*QZP^K-S:A("6_/EU5=M)8"$Q8T+*<8/X)2S>Q""7N@V)LVJ?>O-=)"
M:WQIO$6S4O5,U-%C\R1<UV"T-C7:[6S/O8H+(6%="!B9O$'.W6'1%N=-=<[/
MNK)B#*J0=FLCNJ3GE'D<A'G=\+"J(F%LR79M=L/7&JU/]VIND(GZJ!=S?+BW
MLS]\=?*_V>'+X='!<&?O[<G^SO#5M^K&',\+7C),BMIGBJ:E'!LL'&U"RY\@
M]SDMMA9G0.G4NN>-0D&^?CGG2U6Z<;H9&Y+8<3-OYN9%B-]N1DH)865_LGU4
M-(S!*LZQQ]8/FU-WLQ%D&0U(5+:QMY;!-,;<JA"<7$,T\:!HS,JBL+ZO3?J=
MT?F0JRRNYW2.E LR(=UBRQ,/^V.%L:>:^P2DGB'V3:O4$8%?0Z"?1DZFQ,6>
M ][1]M;1_'*\O?'-EH&7&E;*MP%9TG",M\J02^Y%LB- $GGD I:G,Q@G->4"
MI6H4;8OS,]P\2'H'5&/H((O$[<%OC?#%T"FO+_]#/,SABG2XS3-:LXN T?39
M!GWY1NH/&SZ"#]*TCBZ?O^F4"T0+]/E!4H)9@6&O#EBOX6!ZP-YUT?MTQV=H
M#LM<GU2_U_X[-<G:H9L=#%^_?3'<.7E[M/_ZUT%V/'RU=XSN@8/AT;_V3NB/
M&110OLE9^N&7W7(Z98\'Z3A>L)+Q*6L'+W0YHH$1PK0NM$HR&6D6(R#'?6K/
MXL;N;+G8FC078&S@,F6W:.9S;5UDJU:^ V&]I9YD;%+PF[3Y12Y\Z'P8<!FA
MH'#9-#_0"4F;KUW.P\UB6R3?:/QNJUE*@R?%819MLTV+P-;8*@J5(.\N 1=.
MOICXQ\*4RN9BLFD^4<&11)9Q=)K/MV@L:^<;!30D<;$M!_4Y6DY1 :H[4:M2
MZ0UZ3T+XZ2&^1KND#J]\BTTD:B+L;,>Z;MJ=9O/N.)-^UNR@97 OLZ"IH#.N
M?$1-S=;'.F]Q-!C[ADQDX&8//4U\$2A02Z)2G4J[ !Q@23]/6&J!?R8@0^'L
MW#"RP-115L)1HAHBGF7#;FK7#DN6<^I-3,=8*D7_H0]<%PNL7(4Y(]MZJ=(=
MOQX<)B02H7<YR72$0T9%!.4LNB/G3,Z5:44,M/GXG<Q7FTO_H.^*=R^!SM6R
M%J60,[Q,<XVX VAQ>??GU=ZP6Q3E+8KR%D7Y+8$";U&47R&*\J=;%.4-1U&*
M9B02I^ZLU8RJ)19<TXZKWO3E67/RD^D;=R*%W=FR99:%FEW8(F\79^2;O-/J
MQ[1JFDEW5QSO>@NU?:;\XL1KYR^2MYV R.B#MFD92I@O%N0[T(^5*YZ\>2O
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MA@/ED\Q&>=W_LG["27[4**R?6TJ1OC]+P3^!1FF]@(_EXP:N7A 2MX9@04*
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M*0FZT@UD!(+.^^;Q&'G$>^1(KBV8P40+&(Q<LO-T(DO%-Y.!)JUG0CR-),+
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M;@V&(&_L#JQN(I><&@_BYOK/2/0!OB']M/&SZ&G3I]8L@R,\M4%Q@CV9) N
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M]0L1I7+%N!/MJ$OG<E]T2C+9_EA(]LF)*7J(YN\"5/:\>$W$2Y7E(C_%H0S
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M,V'B41R96/?4)J!$!I6&MLLCX<E"Q1)OZF!YZ:*;B-L!8S;%)]!*4AVI]5+
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M3";?%P&6/A3X:C("I-"L((.G9,N::#$'-)85)6I/U"C8JZ\%_R;.G@G?,%R
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MH;-V'6R38B7 (];I%GLA&Z*O#B%@4&&>&! 5&/3*#%)8*IR199#,&"3F3SJ
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MBZ\=J_^CV^IM;[%FD2DO>JBY3FL/DSGG\7[0RA?,.@OPOV,G8$8*ZR@SKTJ
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M/I,U3S^\@\\/*,!Q=<HH#1?%#3S!WXG5$K^3E4YD+<R)NVY7WRC;8#EM3 +
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M@DSQ#):RYBBE6_6*1PNVQ"TV[K]X,6N"1KKE9]VP1VRZ8=(=C>+5M.'XB1M
MQ]^UZS+ [ML9>WSGLI *OH*9Z8>J*2VH:AC_.$F@=,0FY%R:@JO:&3:/3KKE
M^E>7V34#UL.D/2YQ(_AC8PSPLSMOC\*ZE?IK8R0(?<2!,C4^-%GW"II%?Y\D
M(+IA0A%Q@UIM+6^E_]Q840/B KBS-DC$;>"/DZ1Q1P3$D@.T'UNIQ;J5^NLD
M:6\B@2AE0D&"HKAPN21TRG2)+(-U^^=X\1[CJ:,,]I^CI;/:K'^WY&R)N2#2
MG$IM@A2 .<?37][('<I)O!7Y'Q?Y;^4^(*Z1@Y^U*M0J)9NXH:]HN$YPC"'
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ML**JS13^V)S"BJH6&*JNW&4SGWA('R+K]%HJEA4J(E_YQ;(>I;:-;'6<&72
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M6<$IE]%3CHCE'I%<$T\H;Q"C@5L=,4 Y^0>Y.A"$CC$:SE58V<7U##R;#09
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MC!^ X3<I17](UPY+2"$PV!:8,)0PUTB;F"LL48Q ^)FAE'N1&BGQ?F8E'\4
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MMH5_["+<U_H"]R<3N;\L:/M."^^T 1HUDH)S)+ &*]JXL'V0Q>C$IY\NUJ'
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M%+Q;G/:(^Q#T[IPM?(X7507"$QL4'A^&M-O;V4/-HLNR?M @+OPD<#NMLLU
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M!-YZDIQ@'&V+2IT#5=_O<>*?)H?VA>I0(;8WMW?S\FN,VYJB^]D E+8QG+<
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M7T_5L/^\_9/B+?[U+_\%4$L#!!0    ( .%Q6U!4"H#)H\(! &_&%P 4
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M\W@^2>/9F_EUEM^5ZW/##5J=3B.N)0$ %,6W*8?"4DWXUCK4I$5@TNMS;?<
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M6-#"=GN_"/O:/Y*OCSZ  ,@\_#C9V">'[QR=U$^PJ#64+.#JN*-0$,6\K;#
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M.<]*K(:L0WEVO7:!4$-%NEGZ-IW-'DQV=Q_/'PXJ<N>S$51(0X(P]44]$:<
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MZW6P]PYSQSRJ\HF\'-^)+-K7383#%D0!9PP(&$JF!8+5%(V8U2W"0U^G6WP
MD/MFT&;R# S/;N;IO_>&VS3O,-+$8J^)88(QXHD%BE7;%,1-BQPP\'7ZQ@>%
MNW,[J]D!<^/^(L$4] A@(1A5V!!$F*W$15ZTR,;].CWE0Z+]2*[_^.T%T$&
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MIQ;2D(7L3#@'(5"_SR?;(,]LXKZ/4\W$0PD C>8+R0]*E9,LA:YC$O4076K
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MFOK^M.YZGK;-K^<5TYJ!U!_KEUD1-\A3^/[3D\$J2ITCS$:J""$2&E6^*@[
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M.!$!,XXS2LJ[ B.E[--W- @): >GF@SWV6@Q_3R=39<_/BY7DT?'UY<\KN<
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M:9\[TB=\_^,!$!C7*"RVW"L$D).(EHN5E@^P,U8;R.>M(U/S;>ZE,"924CC
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MKM-$.2M@LV!KRVV!MQ\Y:3@)B&-Z1YNE^X1/M'DL&6Y>:J^U94A#9@! .TD
MET4WV.E/AQY0C'?*_6-]3]?C]3)W3P5CD;3 B,A0;#E(U_YJ*X?AUG3/U!HA
MF;"_2KLC,4&^RJZ>\/LO)U-7-DUCJNMW]:8PQZWZ5M]M,EXN/6V%(92N,#0
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M9BSS$.%H#%T[4AQ]15! *9).PH8Q9ZCQ6#?L5L3Z[DZN[#D(I1$D)ZX#D^6
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M)W.)>F&-89QJX@C!FD"TS>/'CEO;/9)], ]_9E7W!^52,I<0Q!@BJ"6'E@-
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MK4L/$>BGL):EJSLA]-IX4&1X0 GJO\0P3QA/# HP!K&VT$(BG62[]5'8[K>
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MOR]FWR)>\_^MKNU\M9GZAV7U;7[W32TV39W?K%9WJ>"BJ5>GPLE[OCE "IE
MT$#%2/S.$,2P^<@PB%9Z9ZZQPKDV#8!C$FYK0YT@S_:I$$]@*(7,,ZTY)LHI
MHDDC!W&PNZ.:7Q 1NH$QB6.J6^?DMJ\(EFIA)1042A1IK8VT36 %=EATMR/%
MA=!A(*2FN+=J[G)^F_TU_W;W8!.;V??X7]8_6]YHG7I-X%@R)8#AW$3[.C4:
M![NE,)5 ZLP9>2&<&1"MKLZ2.*.ZY8SL7?6YWH3A5/^:KV_FB_>+ZO]5LT.Q
M33E>';R-'P]PP""-L!3 2[4SUQP /:Y'0>&<F0C"*=>?CU4".,K4=P4Z_*(
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MKNZ^W6W"-!_[";MQYL#+@E+*&^0PLXP1[QVPLH$;.02ZWUM/6W1S !;E0;
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M/&IZWC(R"RQCJ?W3>K;>6 W-0:.9]8GKZJ/C O8XQ38Z1276S"B02I_>VTM
MD!Y]0P>*Z,N]N0^!TFB,N)_BZ3;UCY\+"'#IE6-(>@.)(]C"1A9H*"H\BC^3
MGIYK/P-"EZWUHO;WDI2=Y8I$S^OO-[/EM]GVMX]>A.Q_.!",H>0BOI@A""42
M%,*T*W'!(.S3L7.X!D?=@*XS0]%19[]__W=]LVBCL#U/!L8B*9'&*(I)B4/
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M=/?/@-FX##BZBA]Z/(+#(49.,<(I 8 "+V@CD8?:E;R[]U/146WW0N<UZ+W
MS7IZ=4_C!'A14/[DX?_ B,"E8LX!@C2"RCNI,&N.Q(QX-6J-O]/;>W\UU4/
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MNM78(*BGBEF,%-?&>JSA S($C7KGT#_+JK5.ZF%A*LK(E( *[ 62CJHX=PL
M8<W4I>A1%FF*5,@N&LX+4-=4XWJYKO[Z^:UZL[CZK^,)QR^?#-1P+1BC %MI
M4W]+I8##$0LG!;8]RIA-D0O918?]01DQ^=@+[J"',IY7@&%<6X7(O=O/.*](
M]U*TV<-/!])6+SS&\I,WX9/O%Y]FR:SXD)K[+-<_/]S.[JV)[P>B$\][0>"(
M,J6E!C"%FAC/&$?-C3C0I'L<XF">\B'N]P<!:]P8]><6Y\X?\B&>AE."Q==C
M01^MWQ&H)CR"R^,_G6&4.DT;6P-QZKN70!\LEV4(P@R%U[2<^5C-;J.I>?WP
M.30Q76=3Y_"KDD5CH2>$NU1MWCD@0>-619:R@LR%\1F4#;:QB/3;?!%-U_7/
M-ZD.;!1BSR>@?WZ8+8]O5F>\)5BBE--( B8 D#3^V3W@($7W2X7!TF>&H,]P
MB$V96O7[8OGL SBY\)QZ05 *(<>TLE QS70J6Z$W]IWV3DK9/4I]L%R<X9:;
MS&!-'79LZMO;^^/S_$?U.+A^Z@CC@Q-3B^MW=91H_W_^'/^TFMW+^;9%2'+.
MGPF*& V$<D2;>& ETJ:SU?V5!X*2M8JO&@;-!^=J!H';-ZK/]6,AGBN5X9)Y
M[>-1DU,H[?;:D%H>__^(9ZRCD=/3T*DN#/^BH[3O5\-=J^BWB2NGZU@=&158
M5%,T*ZV4F@ODF8L+O2, 0J\4%Z.&RG6L934^3UYD!^2"=[Q*!GMG?+*"T=%Q
M@6#) <54<681!O&4(O165H.LE67>\F;58CMF],+K=7.DJ)O=<JDQ#24.9"ZZ
MO[Y'( ]?0IPS/ "$$=&66"U1/+,::[!*DL<I6<O9J"T6VQ[7LFCR>?7\_&"-
M19,)V@L+&S'V\>QJO<54$(*VQB9UDNGN%O; X> %&3'#P5T [09N"^L)-%9"
M"RG7Q#(*(6@P=Q2BPDM\#J+YGOUANR'Z#].*-)\ND6#3$,O.5[M"26T[#Q\8
M$ACP''H#.=$X&J:>(J4:"2$U!347'%R'SUL.YX%LHH.8GMVFTGF?;JIJ'8T#
M=7V]4=#L-HJ5_%5WRRI^5LVUX2_+^N[[_V?O2YO;2)(L_]%NW,='CZM;9E6E
M6DG5;;M?TE!DBL(,"+ !4%WJ7[^1(!*D2 +((S(S0$Z/38FB\O+G+R(\//S8
MQ$<L[JN3A.J:7:&9^_)ZWY\I6@[MW$<#?4#!I5(B@,2:2621]PKM(]UX" K&
M/!>^5",N2TV-.'DVEZ/1ZMSQB84F6/L(D=8(6^F( ELO8D$&3_*V!W,CT<O9
M>T2E_ ]YG^.4I8GY3CF;)(CX]ZJE,_GS4SF[_@&__@Z?RJOR+NKT]]4V0CFO
MU!NB\?4!/I\,,V[[F (X(XP&A(W6Q!EKHM55"V<IC%K0HYF!.K@:5Z/!.<F\
MMC/@YU_GC0XMS]Q9."<$LY'*VG+&D?0!V0.HDG7?"K>/ [M4<S$MQ!E0JMVB
M^-J]A<(,$:.%(#+^/WBFB*MEIDK1O&VW9!IMSI1>N+T/SF1I,N5+E0PH\O"7
MN)Q_-3^JE)#?5MO75_DF_KG.CRTX0P(Q#5(JC005OFJ8_1!$A233&?KP$FK_
M%*^&!7+(='E;5>8JUW>S]?;'F8H<KUU:.,8D!^UL56A8.V^"IK4DT; 7G2G1
M/ISYTLR>1)@.R8Y/Y=U]51)_4Q[Z)#S_XI-U%1K?7^"X=47!!HG!2*LTB^+6
M,FL%F9Y9]E?A:CRPW@=1LC)N,N5'$C_-KS\6L^.U4Y]=42C%P'BC./82.'.,
M8.$90L8A@ER/[?$@I3,&@'J5 I>.JOK\;;X^G93_Y(HB&B".4^V1M@9[#XPI
M.' 3A.VLJD%J8 RKJNZX=!U5T83Y[].CZO&* AO'$!B$F5!<:8&%JT7"DK#N
M/LM!2ET,/*HZXS+6EFY?5/?1ACSC<GSU^H(2+IUD0E@@&(/R"M>9+-B,VZKI
MTBSNE,".19J7^,Q>A^1\K>IV3RH4<!)EESJ.(*RM-"+8&@^.3>:NQYXZ?E["
M>A3L_H=365GOET&E:2CTR_RJ0F]Y<UC*SY/EZ#U%G,6) J$0]Y0IB;FTII91
M!Y]AV9_!M+@:!K.Q>'%L;3]+CM,W%L$816RHN@XX@@-XI7DM+3*JN^MYL#H_
M8S$D*7!CT>3W]>JJ+*_W[5AK 5;K4^;PT7L*3(+G6@H2AX-$F -EM8PD[LTR
M[&.?16Y[*D"[!OH\>?WC-/<H[+' GC.W%50A:1E8QS4Q5F+JT.'C.>^10C[8
M5#$I&P; =)(STM/Q3S]U,6UZ/MKBD070N.6D2GN#L<684G>89XDF/5K #%9&
M+(LY:"2\QV+D\T)I.V5^_/H\?^0$ 1L^H>#.,2,5-]P)1XVP]G""0!A%W0VB
MP>J.9<&W8>"=OO+4[>U\6X-YZ-U\E4%WVPKLGS[HEP:5I([?5'!$!!,N;G:X
MD,I[<%#'/"NB>*. @Y$D/5?;Z?4;"B.U!V4#$3185P7I,K67D =)Q]P,GZS/
ME$))SW>[*1#)NF+2+U$I-[L5K,H.N#^7Z_;:Y87#07"!C:'*6D$1DT[7<$1;
MG8U(D%8G 'VU^\(UTAN;\;QE/W_JV2#/UV\HG/(:^SBF#%BN75!"[RL^<R&P
M8GF[Y/LI[(SV>R'TUGB0I1L]!_5/Y.V*QE:<]!Z_^:PW],@=A2?86AEHY1M$
MR!)-7;VP1A,U=.^6,)BGJZ^BGONLD@ S9"C<[^M59:)_7'\NU]_G5Z<B:E^[
MM)"6,H*-\][K$'A<&!VK)3%8=T]X'+AX4*+5/1$N(VBXVFKM/_#X1'[R^H(!
MDLXC4H6@*ZY  MD[,:KVD";CJ-=^*GJIZV3@O W%9[6 9Z+O)(<.MER4?Z[+
MOTYWE?KIHL(:K;A6)@@ %/^TPM7YLC*N8)G%KB8 >)4(BM',ZN=+C_GQ6[0U
MUKM8L_K7/\YMM1L_I)" (@H<HNVJF36$1S@/0#+2/>EEX-(PJ3?@0R$V#6_V
M'W]^3W;\KD)*QFV<#H-BP)S%A A9RRGBD,MS01]2H2<YDP*\MTN6K(R "^%(
MFLB$6574XM?9=ENN3Q<9>7%A8:7P6DKKK4% E>6>'5S?5NONV1/#[=!3P+U*
M",H$WKARNWTX#=@7-&[FDGM^5R&TQE7> 7+<0=#,*UXG$ROF6(:!2$,<XB0#
M:.ICU>>GPMW/4E^=9IX__I<3)Z,GKR\$TQXY0YSSRA(M,6@@PK& @W*Z61/5
M1I_\F,3Q_&..'78VN*O )A!KJO(.WL?M1-R66+7__$B4,*8[^]43ST3@KX9"
M).L3S\_W?^Y?=^ZP\]F5A>/6Q@DC2,PPEE!%G=$:!!'"F.W6&VVSDBKV>1^B
M7MB,M:(^^<JSEO&+:PNBD,5>86FHDMP1@N4!&XF"R'OSU%E#QS7="Y>WH?,L
M]T#3J3K-]F9G!VW^N8IKP[_GU^6G<E/&1WUSY?=RL=KUEH;E]:_E]?QJMCB]
M_VG_I")N(7B4RH%VAL7=@*$,[T7$@,9MN=/,1NZAIM686(TUXL=OJ!*WH=0S
M"XHKRI4!+$B--U;"C1G2/[DE,!QN&?!GX'X58+1E5B@9ART8:03&OL:#!JOR
MMC &T7S/QA7=$/T?IF5IUUPBP:8AUG[1+J^_E%??EJO%ZN9'TP8II^\L@M8J
M6&<P0MA2#=(A>\"56I.?>3281I^G"B5%[C(3Y9'!EDFID3)> \',$;&7D0AE
M,ZK--#8[4F$V%B\^+'=)EYM-O0^(QO^3K<!9CC2ZO^!&&ZRT1R9H(A'$76H]
M2Y,JOW?$2(7,^#($?D/&GCUN)_R_[N?;'[^6VV^K"-'W<K-+_'KYV[(\4]"U
MSR,+I+5UBLM $%CJF!"<'T85^.S:(PVQ)1L9Q"'I=>PS3\8WGKZI0"P08 %)
MIKA7*G /H9:.$YUIMLIX2ET-C.1;XTM6>Z9+I$D2[S'\^ONWV?IV9OYQTC7\
M_++"8>*T0%QP)H7$!H*O?9D$0DZ!,2F17B5#9#S#=(]R;P]ORR<5'DL6I3<,
MF6AV:>2]1GL\J-"V>W+30"UTAO3R#HM=)EQJZ8/K\+2"HZIV+%!N'5:6<2"R
M=@I03FGF9\J#L: =VQ(B^S_,J_')RIIY"X1[RWX<SX2FFH$*2!/!K79PD%T2
M/68H5$,_SJ :[N3+:8?AD)NGJI+5:C&_W@7)[H((3[;=>>WBP@47+<;XX4X:
M::UU!IF#-("[F],#-=X9RO^2!)YQE7URCWSL\D)P%0>$(1AC$1QXYP3;2\2P
MH)F>7:=0T4EM]T+G+>@]*SLB%W5/8POL2Q4N;S[OP\7.KOY'[BBP#$$&+3V/
M0E'L/4/UJ0:31F5T"IQ&3:LA8!DM O;0Y_M^,U]&,^1SPWCW4_<5FNQ*0 N&
MC?%:(T:%K&5ELD>CJX'Z? P:_9X0J=%8\?")YV.BGUY7<$\,]<@R%X X0CB%
M.IF$>6]LGJM\8CT]UWX"A"Y;ZUFM\3DI.\F)AIFO[G:>^?V[3YYKO'YQP;"'
M8 "90!&E,O[/UT$F/'Y^AJUQ.P*]2@S%6 .S)BE<_>M^_E#V]\SR?.2.@GFE
M.#%,>NTM\=&4];7/BTO#NQ]3R,M;F--@-"4'JA_7Y7D7\-E["^J=%$%Y;8QV
MB,9!@P\R:XTS#7=(ILD&S$B!U_O@2I8+?GX421/0L)Q=K4[7^7AZ26$$,LB;
MJGXE(AP)!;ZV;#@H+?-;ZA,"O4H"2E=-;;;KV?\KE^75[+2ZGE]72,Z1UM0I
MZ:5$%@A8O?\\ 8R[SCH;+&YZ()WU1*:CXCXLEZN'X)>3>GM^60% +0'NC0L:
MQ8T$8%2;)4))U7U?-%CX\C!JZPE,1ZW]?;6YFZ]/J^RG:XHHCT&"*G :* B+
M-3U\5M,Z).,V)1E&7WU0Z:BLW\J_MO^<?3_=YOOGBXK@'',$0& $SG 7E_##
MV+>R1UIM^S/$2=75"Y8ASY#ZUI)6P"@CE'C$*#'86@.NED1XTMW,5*T5/.DA
M<0)P1E!S@KK"4C.("X.PG&HNI4=.RH-,A&3:L[F_BAH5&.X&SMM0?%8;RDST
MG63=]?=7Z_GFM)'TTS6%T1B8ET%1L(B C*9!?8@IF2(74TZZ,;RK-$AT5-#?
MXF[GR[=R/;N;E\</Y(]<63COB [ !78V[H^$4+9FI"0(9;1Q3*^L_GCT4-EZ
M?O5Y&_^[*#\L_ZN\VE9K_UZ\LTH\>V]!I8^F' J4XT =,H';.AA%:@FXLUJ3
M;RR'46MJA#HJ^M>XVLYAN9W?E,M_S*ZNHFT?5NO/=_/E;!'NJS7D\_WZIES_
M.*GRED\IE/&>@1:!FB@A-<38^H!J-Q?ELTM-K_QAL>I(@R_K<K9+F(N?\F55
M+F?S^"W+F_O3T_69NPIDL11(*E3U/@=%/%4'!IM@NL=0)=_=IE=S6FPZJO7E
M#!/%^50NYN7W,W6U&]Q9<"I=4,$IRH)%U#G*ZZ)[2F/5O=9R^_BHT=6;'I^^
M(_?C5]A69;\CE'^O=OI5P][O\^T/-]_L8&TVDIL]I0C"!@\T,.(Q%\QK;>NP
M0B4][6Z4M3^!GVYD#X)5/X.MPTAO<&>!0\"6LV \CM8F$I&]M<=',=:C8F1[
M+]94QEI"?$9+C+J]F\W7#TQ][LGS?^T;O?]MM;K^]_RQYO9K"5)MGE. HHAA
MJY0/5$E&942@QD*%'FDQR3?7:8N*CX'66,QYR+W_7%[=KZ,6RLT_Y]MOJ_OM
MIW)V/5_\<&5<_&ZCO1KE"E'6?\P6]^6CV+N&!O>W]XN'/O*WJ_OE]@2[DK^K
MD(8!-U%S7%,N.??*U*:51MYEY#$8AH%3(_K(TLF:1I3K<K-]N&;?^.)TYXC]
MYP[[5751DAY=+%+53ES/O^_T^\N)AA<GKB[BTFFM<@:4]5)Q9$@0DCE+ 3"5
MOM$0&UJV8_TPCEQ96!]M J]PG(J5C./-DCCF=C+I8'0/CU2B'AA)]/&BHF,?
M#&8Y=[WX>WE]$U=:5V[F-\M9@VCCUV\HB&):&2 T.*Q FS@5TQH2+>B8#9];
MM1KLK-K5 +",9;B\_-BSH:+';BFP-PA(1$T(;(2TRL>U;R\ALMCE>9*;2FUG
M6= +I;?(AZP.>'.CP33JK[^SO(;-_M,_+#=QB6I4&*3!W04+7"@G->=:(NLX
M$]4V[D%NH5E&1\GI5/C"AD@-TWCTJ)?(QP_^--_\]QE#X=1MA<4&26I857Q'
M* 6,";2WQ!!3NGL8R$"-,E*;"PG!&9\&51_&RHW[);[_[$)QZK8('P@'"#PU
ME%.'$;&ZEE0K[?,V'M(H\2@SDN'UEAF2I3F1'S&F(418K<NXZ/F_KK[-EC>'
M[SYK4IR\KT#*<>^Y1MH;&Q1VR-%:5A+_EI\QD49USQN4) 1IM+.6@W>O N!L
M6=;G%Q>4>Q*76(8!NSB :% (#E@A/F8XU"1F0V](IE&TC6;OS6H]_\_.D&Y0
M:O#<S05W&@@C/"#@W%$>&)C:DR>-)WD;#GW4>)(1";%Z+TS)TH#(BR!369-_
M;A]/YQJX(5Y>7A!F)=,TRL H""68X:26C"DTJO78M!QI.G6],"![(S2-[N'[
M;+[8'<2NUI]GB_)3.5O,_U->5X>PC1EQZB&%Y@("\4I2;\ S!50>( U>CSI)
MM#4I4QQO#0346'3Y6T2L^KR/R]=V7M7Y\N_K<CO[ZP19FCZB4%K90 SCC,BJ
M?Z"4B.T1($*A[A6.!\O03TF5@6#*:U[YVSE_1=.'%!1KK3 !+>+*S5%<O7&]
MUR<4A^YD&:PNP/CS2@>@QJ++KEIW>;T)$:;JDS]^?2[$HWB5L"=(T_91!3A@
M(+0"BUE@B*NJ=UP]@&3H[N48K$1!2NH,#-?4L5>?5C]FB^V/^I)I8JYVKHCA
M7OO[PUX'EM>_K^("46[GZX<JC.4R/F_[^V*VW.SJW\>'E]<[]]7\S_OJ+;M_
MRO6['F+]-E6\W-6VO/ZR,E7XWWI;364?EMM5M03&@;"ZGE_MGVCC:S((9MN)
M\T1(-]]4T4CWZX;A;0WN+W0T":OP1P"I@5,C>;!8>!6WK-Y1TL@_-XS\C]4:
M7DJR>11E<RX<KM5S"HL]&"60=,$P!X1K)_9X:&*:!0".$RR75+O/2Z4.B%G6
MP76?#I-+)>J7V5]5*=K[<^6V3]P5ESDK!8N+702? !BB,*_! 8O&;-;3R@$^
M$ 560R$WEH5YY(O/GIF>O*]P%AONF*RJ"VD9]^E,D+VL@+Q'>7O'DVBQ&3-Z
MX?6V.9*E7SP_:DQ#B?]S'_?.7^?E=?7)9UWCKUQ="%^50#4<"*&::$RJ/?=>
M+JIZ5-P:S..92$^KU-B,I?/?5LM_M5+[ZS<4Q!&,D54T L,X#\A!J*4CS'4O
M"SN8 W,8S2>!9YHUX/-=U<AF_4NEF_,9&V?O+82F0+#Q(#PXHPTA1NYE-EB[
M[DT!!H[&G,*J[(]?%IQI:3V\>G=!(H+2<QG!Q(0H[3SQM=Q">'Q)=F8OO;9A
M3"_LW@]W+L#^S(TR$YVIK6[+S79^U<@F>7EQH6A@2BG$G#.V*H6KL:ZE"L2/
MVG^XBSW24U?/S\SZ M1,[9L:ADUY];]N5M__]U7EU5[_J-0NZ[]4&I=/-+[_
M=?''YU<T_/B/!41Y0]R,505OJ17$D^#V'VR1U=WKH P73=$#]55/^4<.QFXT
M3%]<&\UBI+CVRON@E/1,"%[/:U9& SGW74/:4=H7GXE<1^=CKE^_H3!,4LQ!
M(<RTXY)Y:6K/OW5Q-(P8QY#]!J$C:--1HJTC\3%UP8NJPF8@. A&*='2:55+
M2!2$2[+_VZOM+ MZH?06^7 !-OUT-)@HQ.D!I8<)\:<Y\JR1<.[6PE/%G1(!
MM##&5#U$$.PE=C*X,6N"=/,T=E#>\SBFM!B-Q8K/]W=W#P?FLX6_O5NL?I3E
MS]BTY$JW!U:YDI($H3A!WCOJ$#DX8QTPV3TN>RQ?=7\&C8+<6+S:A:(=#[MJ
M2:H.3RN0",960:5>*- 4&Z5K.]T)@3.,R$W.J.%A&R^<^[E17X?E[4/R=GN]
MCU_KJ/6J?U*(5O]L\7_+V>EDHCX/+IQ"@<=MG^$2@F7!<E4//F^E&[7)2=/8
MW2$#P$:%,S?R_;Z>K^KF,54HJ%V7U_-M<BHV>4U!J-+*:5Q5WQ7*<I"V/BOU
MVNON=7@&3%[)@9@#@)L731/3\1DR&)D # 6J'+)0U2)P>U\JIX#LF.ZC"Z)=
M+Q#/T^O5 NG-ONQ+N;Y]A2/M'E P6_5TE48'Z[%2429>"\2\LMU/  ?,<!F"
M%8/"-G"F2YIDBD_EU>IF^9!! 5=7#W65R^N=H6I7MW?K\EOUGN]E91PT29IY
M*_D4U'E*@&'/@\(D!.R%= IC+#00A1H%YKRE? J-//+ #78@P'%$XQ9WCX<4
M@8T9M)H@GZ*Q=GOE4[3#[)WE4R#NJ%"(8Q0T5.UF@@&GXL3-XF1-S9B)_P,>
M;#6F0(M\BG;(77:LO&#.5B?"1G/0M++O/=W)*N*^5-#,RQ0FT6*KH/EN>+UM
MCES"V5<&U)B&$OWS*9 G$CGIP!OM-,>>VAU:@6/+XS2;G\LOD9X:Y%.TP^;2
M\BD\YDCI@((A3$09-9$N2J>( "/"Y>53=-5\$GBRB&_NG4_AD!7 !2!N$0Z.
MA5!!N+.W%/&\^S8EJWR*-%9E?_RRX$R2F'BC, ],ZT =118(6 FUW$$2>4EV
M9B^]=@B.[X;=^^'.!=B?N5%FH@.;GOD45:M.IXC5RBF!1;# ?5QPA<;.4\1'
M#<)+%ZG=6%?G\RG: 91!/D5E?%DJN"!:DQ"1\('5LO-H5.6GT3ZHO\RG:"?_
M9>136()8< Z<\)J!89C+>E[3(80+S:?H.DK[XG-I^11<6ZT%-IJ9(! -@2I2
M2X<1[[Y89Y5/D<CMW VT2XR?%R'.<IIA9KG1*." 'TF/XQ[ZDNS_]FIK&DC?
M#:6WR(<+L.FGH\$TZA\RGX* %-10[!U8)H%88GTML:$RP[#2_LIKFT_1#J/W
MED\AF'(@JPY G&)+B22:UQ$'E/:H1SE^/D57!HV"W/O)I[!864&0)8PJ&BU^
M;X.N<8GS?/<Z8N/G4W1EU/"P31<K?#(:[R$2[[=R6\7M;ZK8O')CRJ]Q+_?E
M9*^%E*\IJH+BPJ&JL *RGGJKB3\,3-MC*S5QKD77X+ )P<V=IJ]'\0_)V#-O
M+ 2F-,2%A7I)C?<!A*\]6[M"]OFMQWF2-RW.6?-X,+H^HD4#5A0[81T6\6<1
MS1U4HX6<Z.Z;G#A=8U16=H4S\X#]Y6SQ8S/??/QJ=UU'-Q^6G^<WR_G7^=5L
MN7UL7K;YQVQQ7U[_L9DO;YY<\,=R]><F#M/*/?AA>7?_7OHB"&IEE1>FD P&
M2<:!4R(<\\'%7_I&E1#>4AP_ULHXQPT-@C%CC)3"[_&H*C&-6?PO01Q_8^WV
MBN-OA]D%Q?$GC[Z2@?*XFT*:&<81XL39&BCLJ!V17 ,>KC2F0_OHJU;XO9T(
M&JI-,")*37&@V#!"):GE%ICI2SI]Z:77#J$TW;![/]RY@).:W"ASB5$=P#VE
MAE.G;!6C0D%)V,MDM#$91NHDU=39J(YV^%Q:5(<3 ,R*8*D,%IBI IUJZ<"8
M-U)&/XWAT1&T2SS%QY)K(90D%E'+XT2J#*HE=(:22[(KVJNMZ7%^-Y3>(A\N
MP%:8C@9O+ZH#<R.Y 6V5HK3R3"(G:XF]Z-%0?/RHCL;*:QO5T0ZCT6S%V7R]
M\W.:'X<?_SXOU_']WW[\4GXO%V?LB&8/*+C6P<;_D4 0=U@3D'POO<6:CNF/
MS]"N& 3$T2GT:SFKL-CYSE^*<7:Q:?6<0B/BN(IFO3$0IVZ"):ZW=98%I?*V
M2%(K_!B?!H3R?=,K2P/GHE@U,9L>CNYVH-#S7I+C=Q4T>$VXYAXCH; &ZDE]
M<F(%QR8_VV<@/1YC2V_,IHME,#]V)^6;3;FULVUYLUK/RW.EFEH\I0@\CCUG
M=;0'L0H\&!M4C8,*/9H6MB\?F*%5-!R2H^VY7G[MV77JZ#V%("&.%*UD'"."
M6X>,JK<F#FF7>6K](-I\O@E+C-W;Y$F6MDO>]&A+BU<+TWY8QDEQMJS"^Y;;
M]>QJNSEJ>)RZO !-5#3AL!*$@D6&\&C)[3^6>-:] O9@%D<"X%?)@1DUP0%N
M;M;E315L]R3 K%DVPXE;"Q64P2YPRA$QW@2-5'VL%7_;HP7Z8,&WZ:@P$$C3
M69L/X8@?E@?+^>/7 UI[^[FJ,KR\FB_FN[/-3ZO%(JS6_YZMKUL9I'U>5!A$
M,8'@A<#1K*L./57MQ_0R&O/YS3[#1L!-"N]T9'U5N%8L?/4)!:5&(H$4,*O!
M4RV5JT]CO+-RU'SAKO0:AP!G>9@"X"GS"+;WL\6G<GN_7GY</@H ?VYVBWXK
MKIU[6 % O/%.,!Y 1C.2!E6;#IYKF^%"FBWM$F.='P,_;^>+Q=_+1;M%]^S3
M"H0L VZU,YAC)BT*I+93O'"7,?6E4WYGGG4%=#JB_7Z_OOHVVY2;S[-%6:6N
M?"ZWVX>@]G9+ZJD'%4Y3S+0)UCNL(6"B*-NC$8SFW6/*1TR)RF2*2XCS=*S[
M$O?0FZ_E>F/*[;_+<OGD-&"'9#OJG7U:03DPS(T7AG.N)+*>UUZ;H%@8T]E]
MZ?Q+#?:$4]\!O7VDK;U?K\OEU8^=B(L=AG5+O79388L'%U54L-'2 $8^1"O8
M@*UMXN"4[%[XGK\[:@Z(>]YII>\C"]00K;A#1!)@6AL.UFENN).*"1;HN\L"
M-89$@]8YZW'0(!GR$N_QH'%,C>F+3Y %VEB[O;) VV%V05F@*;HY>= $,QL"
M<@HIKC"/2_@>'.=@S%#: 4,"&E.@13>G=LA-%'6?J%,/MV UDU2BP$-<+T%Q
M>\#/!IMW*$ 2+;9JV=,-K[?-D2S# /*CQC24Z-_-R5B"C52!!J !4\ 8TUHN
M:T3^E3:[ZJE!-Z=VV(RE\U3=G )XK 3%4GDC)/.&5M%W.^E8$'[,',Y)-9\$
MGBSR^WO7$XFS)2.:2A\W^AH39)DYR"RPZ>[@R"JM-XU5V1^_+#B3I":$<L2
M5T3J.$E2%L=="+7<W@IV279F+[UV* [1#;OWPYT+L#]SH\Q$7ON>W9RJ;HS>
M6D:\1F 8<D!$+15%.,/RMDEU=;Z;4SN FJE]T&Y.V"J,$3*2DVH7%K21]4Z,
M<^Y&W5IV[N;4&/67W9S:R3]:;ENONC_1OHZ?CHD%88+TT>C6M>^7"R\OM)M3
MUU':%Y^)7$?=Z_ZXN!/FHJI0X(,7Q E7F\Z<(6ATKI-_?GXBMW,WT*:C1/<Z
M+TP0L$$+&HC#(#7RW!\D)()>DOW?7FU-"[YT0^DM\N$";/KI:#"-^H>L^\/
MX,",L#8 %H1+9* ^+\9296@']E=>V[H_[3 :BQ6Y='/R'#1E2DOGL"00-]>T
M]L0+CZ#[A#)^-Z>N#!H%N5&3'2?MYD00Q)E<8\ZHB=LT@S3E-2X:6/?3C_&[
M.75EU/"P31<P^J1#2JM@MB?W%9YZ+75@P3ADJ,4:R&%*!N&ZGX9,G,+8-7PK
M)5K3,>/#<EO&G=ZV-36>WE@@I(.R0)WGPCDIHJ"U5T@(Z[H']$W<SB@=-WK
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M/M5Z #EAA:0X$5=3\^K[_+KJRACMR?EL\7%=%P*[GRV^E.O;^7(WB>]O?,3
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MUW))Y#/L2IE(3PVJ/[7#9BR=)ZO^A)'!4CC.7!1+8@?2U=(%T!=7_:FKYI/
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M1(VFO"3/+XBCGEAMJ)<@#7/4U9:&(2'0[O$$$U>Z'XN.*5"=<,&]K?S>/\7
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M_X;# ;QR.&XN5?!2$"\">G #:NDB<*/V^TO1=K:QGAHT'&Z'S5@Z3]5P&+'
MI<=F5T#.2NJXWHT3KS0WPG4O!CI1P^&NFD\"SS1K0.J&PZ!"W(LCBK'5SAOF
M(]]K>ROBT#U[)*N&PVFLRO[X9<&9)$UCA7&$RR@H.!&EI9CH/:(1#+#FDNS,
M7GKMT#VV&W;OASL78'_F1IF)3@5Z-AS&1/B O)82J,6.0O"5M:6]\-QPGF%M
MDZ2Z.M]PN!U S=0^:,-A*T%)A9P,3FA'!""B:]F-4*,.[<X-AQNC_K+A<#OY
MQQJG_1H.<Q\(#8@Z1SP8:Y2C!SXCHS/L<3+D*.V+SW3QIAU#TDW 02EM F
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M/@D\TZP!J4M. I7!6LPEL2$$4$@Z5-M;1/6H#9!5R<DT5F5__++@3)*R@31
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M"1*HU2I8[L#4N&!*NC-JL CFY(P:'K;I@IB?1^(]!N#]L:D27.UL<76_B%O
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MB:D*3WRXO9O-U]5<M!?L%4TVO+-P5"ANB8\V$:%$$B94+8(6S&483YE4L\/
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M[&':2:H)Y;;212CT-+Z:6F_ACTB@BXZAB.3LU_M_%;>+)H2]\F0&O;%&>$.
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MS?R/F)VO/I\Y0Y&G"BK&=3#.L3 6[%#27MOX@M'T9-:3-3B[0&XHJ7@RRK)
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MGH 6]?S'Y4SL!:ZATU8^+,K>21^N/RZ+^WRY_OYQ/ME6G+MOF+=2_P&9=!P
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M<G>(7SKNN_>391DI^9J?V4W7Q ];YV9JXL;U*&B\7  B&64<"5E&?# "2!I
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M5#N"H4&650.SN,759#("ET@K+*)O$_G)=%VHZ__^OEC?UNLHKSZ;408@X11
MQJUFTILPU-TPD;2ZQ2DV L=(%Y#$YM.'47_-ET<NEC][*$/>!5,%E.4^./>2
M>5UE@TD$/8J_6DY&X 5IA45+Q?))JXR35,F#[V6>: 4QU(Y93I3WUC*P'[Y2
M+8K:C,!!TC4\D>S^_'TYF];OF4\?R9BU-!B9-&A$@@1=UF-CJT%Q(^(S3,@(
MG"8MD(BE9W8_"P#6\_/TF<PR[K57/@PFS,1CJYBLAF6@C\_L)B-PD;2!(C;4
M62R_3E;UP;-GSV3A*%420.PHM,"#<B25YHKPT^;N)S,T L](&R@B&3+Y//]M
MF1^I9OCLH4Q@3 C6FK-PC%K(C*^Z0$E,G8OWW=,1^#5:81%K:<TF-\OZ<^CI
M(QE#P4)71CN/E $0 40JEW5YBS?>>4]'X*YH@42L__?Z.O]VY!QZ]DSFMTE?
MG@@KRG(LG(O*@X)5T&KB"1J!JZ(-%-&7).;%=;TE]?21S#"NF&9E!I!RWC*H
M]Z8Y1ES%NY+H"-P4+9"(#1]/YI/U9%'^,BWNZJ/(KSR: 1=.1$^"QFDX+LO_
M(E3I,AB&<S.>KA&X*#I ))JVQ9$[L$^>R"3D!"@MD(<HS))8N8^CAM_H%H?2
M"'P3\4!$^_V^EB&7(_Z^)\]DB%(DE0Q#"Z8!( XI7VDRQ(D62:%T! Z'-E"T
M=!UM^Y"<Y#5Z[94L[-+04\VX"^N="F?L/BV2(&U;K*\1.!\Z1";6D.JH Q,2
MLDQ90)CP<-(2(;0@U6##OM'"N!J!BZ(C5"(I_/N[SXV6X0_/9513@S$ODTN4
MDLHBO0]>$R1<BRK7(_!:M(4C-LFW6$_F52W2?5>G:?ZPGDTG\WH&&[V;:04H
MQ4!:YSESU(5_P7X:IL6%038"/T<?$+5A.@QA-;N;S2?+!M3^\'#F.=:>*2X1
M+WUJS#-<18.(1S8^G,)&X!+I!),VY'U>Y\O9/'^W^%<^79>]MSZ>NEB;?4*&
MN2,4<<@M#-H;(YY6!;\EA0;')]:Q$3A6^@/J./?==/9]TL@MJ +KY62Z_N=L
M?5LU<W/?IO.'J]GB1JU6>?CGZLODVRM"T^+3,FZ5AD%+-$Q*A)S >N]TIU"T
M\/STUF/VU(YX/\\6^;MU?K?*//&80 W+K%CI9=D^D59S]4JRES(V'*Z/\O8_
M__8"TC#\WS=_\<K/=Y_Q#-X__OCCK_>;J]1_G19W?]L@N^OO^%->W"PG][>S
M:5A_VWCS=F9/@-QT"EP]'UT>$%U<Y5?5$-N,)"S.7$\"2!\GWS<])P?\*CM9
M3S[E\\DZ4%2$H_YCOMS,.QSXFX?5'Y/EU>KC:K*R^7HRFQ\:6__[PN/837%W
MGR]6D^WJ6DX6-]OVV-]_F-YF]'MAK]DFVG]X!C5#&&D,N#+.$E,Z# 1 @&-J
M!%6--,6>D-MWSCPZS=6A>6[60!V 77U'YI0-QQYT4'+#B*,<$KS#42/DXV],
MGK[[3N;SPWOND"+SLG?[F<#>;,DE6E?K_S&=%^$3_^LOZ^5#_OC#<!2$+<'-
M-]_]7W]9;3?90:1\.ZLPS@,-<5]]+N-<>$,(PU@[""'6VE44:&)YO*OE=&F+
M[(8[F @4W>$XE"X9C\WC[!97'^>3Q?O)7;Y5R]N<(A%?ETEC:=#.A:&8:"N$
M 62/+%9:I=F$MZ64O-SPT@'V372[0_@\(OL,BHN2V/-(ZDN3X; GY\@;&;!!
M&](4F#+ AGVP2B6M]"%-5;SGIC?#^[PT%WW FLP&=P@Y]^^'V?K[N\5JO:E8
ML5YMS/8OMY/%A_OR(U;_R%?!G'VW"'C,BJN-1\Q/9LM_3.8/M2;,60:4&>H!
M)9@00!'03$HH2,4.57;03;(CH>_1\AD#1T.M('=W/R^^Y_G.;?PZ-N^+Q=?-
MU+:>G,W$GOZ]*5;K]\7Z_^;K3_FTN%G,_I-?/7[2]J676-4LHK.-J>PD*0V"
MWC/NH3'4:2]W'%ENVA0ROL!U-!::1K^4MMN)+Y:['Y7/P7.LGU<'DG'@RMKQ
MB$IJ(;'>>+AG0_(V)9/>%LVPW RJMOUV'/_??E!XI]-\GB_+2$-YULX6-^\?
MCM@)G7]7AA1"PF@#)<#*J'"B$U!A"A")=RYWGB2<@+R?&_[D+9'2;ONEN)I=
MSZ;;M;^9Y8?K:J-8J>NRZ&\9NNO>ZFC\Y9GE$F)+&5"(6.PLAAA6J&NJXPLN
M=)YTG8K0I\1';.F 8XOWMP.+]W5+:?VHPKW/)\LO^?)NM[0/9.P,]OV9!D8+
M1BER$BAB$31([.!T0+OXXA2=YZR?4;Q3IJ3O3(_C20_%<GU=S&?%#QXT599L
M#W-_2WZH%T<M,?4><R&H,("B8-:I#>'$"VQY(\_M6_)#GCE69DF7U7:!=Q)Y
M83W?X<@])_%)Y.DE/S06F?Z2'TX"^P*3'QCE%GNLO- .*RT$]Z0"@ (T9*K-
MN9(?FHI ;?+#:3@F8]:,((+LF?=.<<X 4UA!1\O6H#MD(1!^3,D/C:5DB%!R
M'+!OHML=PB-(?AB5Q'9B-1^V!&JOIQQ[+2NO0L&RMB.RG!#BC X6T4[94;1%
M/]1Q938TYK#H#=MDMK _27H##2O,*4,Q](HZRB5CE88E$$)#)M@.YYV)MFW&
MP-'H8[*C3&^@!F#@&7 &>>R4L&+G\ L<6>E:="Z]P'4T%II&OY023V]@##M"
MF: 88,BDM8*8'1L2!47D(M,;DELT77#SEM[0)+Y.!*3 486A,!X9!96V%:8>
MM.DV<H'R?F[XD[=$1I+>X)1G%C+M ?" 6RFII7O4@W5_D>D-@UL8??%Q]N#O
MI["$E[-RY)_7Q?3W7\-W/(_ZO@5]#\B@41Y:;2R WA&B&,!N8S8R@[7GJE&U
MN;>@;YY)8F!8M*YL^5+F U%.S0Y'A1B,K]J77M"WL<CT%O0]#>P+#/HBIBA"
M93]$8+$1BF$@*P"<,$->LCM3T+>Q"-0&?4_#,1EE;P21,R<Y$E@@0@3C#&(G
MD:XV"06A&%/0M[&4#!%"BP/V372[0W@$0=]12>QY)/45DV'UZ?.O1^^]U[Z7
M<4\,@N'\,4AB$JPG8E0U5T[UH+)SQAAQ8\I_J$C7';C);'E_DB QX 0;PP0"
M6'#F >(2[=@Q%CDV0M'OT18: T>CCVR-,DB,-+6*"LR9A5 S0H.A4W'DO8N/
M=Z4<)(Y=1V.A:?1+*?$@L2 BZ+G<4DVY=-YR0/<;&U0T7N]*.4B<W*+I@INW
M('&3*"4%TG/+$5) &,J-=MOX3(FI)BQ>WE,.$K=2MLX(?_*6R$B"Q(9";+E2
M7FJ@()/*FLKG:Y0%EWD'?G +HR\^WN[ '[MPC9G#@F'/N1?2,LE<Y32QPLD6
MK4TN2+Q3IN3L:1 ;I]EV*F_I#XW$SQ(@F=8;J;,6* SQYC(+<XY"8=Q;^D.S
M<"P"@A&L#?'06.<=U$3M<"0,H?B]*[WTA\8BTUOZPVE@7V#Z@Y768ZH, 8(X
MAH73CNXIP'Q(5_.9TA\:BT!M^L-I."9CQHP@AAST RHQ,08JI"&WAGI=(>LT
M@V-*?V@L)4,$D^. ?1/=[A >0?K#J"3VS(&"1Y/A:.K#P7<R(12%5 $.C#52
MHK(C735'"5J4;QM7VD-CJ@\YY%L"F\PV=PB[G9G]4WAPO:IBU/_,9S>W9:#A
M:[Z<W.2;OPR6;=YKKD/<2#*%!4348NRE4L)X80C?\<&(A?$NR)23'*(MGJ3)
M&<MB<=^"@3%;Y:MG.1WO%NOE+)R-T[Y72).OSR K>^H$_!62FA*)/2,5\E:*
MR\Q9.->RZ(&1H=;"QV4QS?.K5=ER]LEAMY]278#IZ+N9MM8'\S>L?F^TIU)8
M)ZLYAR,YOD!/RDD L5+8-9Q)9;A\F7S3^2)0N=YV3MY.Z</UTXFV35YI\AU9
M4/HL\$B6E" A&"-HCZ%TC\W(+RI.'RN2YX(]*=&-R;LY1QY6)HCEGC!D/$3<
M&%^F>.\PYERVZ/&;<C2^5]$>@(;1BWKB>8B2*8&\I5H++Z2BW'A4L1'^B:_P
ME'(,/[E%T04W9P_F;V:Z>>RVF <9^)2O'Y:+S968MTKV]0()G'!*,XD(+S58
MY+3=59.D-)@_C=R1;U']/#.68@6@1L &-!TR<GNV!!R)5F;(MI9]1_4;BTQO
M4?W3P+[ J+[C #)N$99*.4ZY5;L6MP$ ;M"0]77/%-5O+ *U4?W3<$S&#3J"
MT"CC7DF#*6&8@, 5\*Q"ED(NW)BB^HVE9(@8:1RP;Z+;'<(CB.J/2F([R7VO
M,0&^?/[T:WT]^V8O9\@$I0=HZG#0>2C"VH&]XF,-'..U[5[Y+'I&.)E-+?H&
M>@+1_:['F"%(O/"2>VP4-A 9*-1>/)@8TA(:SJ\3;1.-E+;1.T<?/VE$]0XT
MEA 83ZS2F& C!!%@QQ'C',?G&Z:<.Q"[M,9"T^B74N)Q!@6L$\C3LO.=])S*
M0$?%AJ,M$BY33G5(;M%TP<W@<89W=_>3Z?K#XGV^?K<(S^5O5P1KI8X*[#UP
MCE$+G076!F7>86:$L18'(7P+)C2\LD0\ @$_*!P->")",=_AJ"SC0S:1ZCN8
MT%AD^KLB>!+820<3*D/]2"SAZ6,9=X@KZ!FR-AP1X5?(J^EKJN"0WJYS71!L
M*@ OTP+C81PLB;2I(_6%BX=0IX$BFD,& 49EMHRK9J,\2KPD<1PQ!]AMA<C8
M>4[2U7T.>COQ4:OR)YODRTWAF#J/]&N/9D!)1@7%KFPU C&0E&B')0I#=AB\
M;.">@F<M%N6B4R2&6H61-_25,\'H<9AXKIUV5NA* S)>L/BHPNE.G9$=P&UP
M3"9V,(* J*06 <RLHEQ1Z1CW8=WND,58@K2U@4@I&2(R&@?LF^AVAW"2"LZ(
M)78TL7PB&$ 06J45<<J%T<O]1 1B)CU=ZKQ\GA[+/PWAH3:U?GI9,&Z$4U9X
M!0*.3$EE;.7%T@#$:^;G"\P-(4U]@!NYYWPLENOK8CXK/N;+ZV)Y-UGLHA_U
MN\VQUS(*'?!.(VH!Y!I:'2S4:O <&CG"Z--0^TS'V [FBVDL0$?>R* H.TW8
M@!NUF(AP[@M4S0\2$']#ZGPW8H?<5;J!=9Q5ABC0FA,%44 ->BBX]V*_-+R-
M5V_.=^-T2-'I"MC(P\C.EODT$+)Z"D7M.53S1J8I!L%N$)(CCZ2&BI)]B(VY
M%LK)^2Y:#G4$=0=KK%KRN(<=5KL_'K>*3OZ<C!EE&1;22.:44,Q N#]<D;?Q
M;DE^\5+3-]B#^;/G&UJ?9KP]1=9]*W];EQ'1[ ,R#Y7BM,S]UMX[%!95Z<W?
MS-XAC<98$J^_Q(=>,$TJ!_%YV9+3)*Z;+\@L]L2%I0@(1\'<)([;RN3T#HKX
M@ATI)]K&2N19,$]K#WR?KS]<ARFVW@NK#\J\LYP:)XE$#H6#QY/*Z>& )"@^
M!2SEK-5^]\1(; ?/.GT_"9BM9U_?LDWKI44+3)4E5IF@A0/&C"06&.6Y !0C
MV\BU]I9MFF=,&40)TV$9<"LEA4S*'8X(43AD**3O;-/&(M-;MNEI8">=;1J7
M[J*<4P0IH4'8W+F@95^&"@!!_9!)3&=*=VDL K7I+J?A^)8ST-SD-\!# 8(Z
M&M00YP6VSO@=LE@#1L>4[M)82@8I[Q\%[)OH=H?P"-)=1B6QEY3#8 BBBE%M
M& G_\9*6P;#=7 'U@Y8].6=CBJ:4GY3#<!JXB>4P$%>F55M%'=&:,L 1H'M(
M*(BOZ#"N[)93):,';,>7PR TE<2'3=P3IZD(B'E>S0]C.D8_UI"[2C>P)IR'
M&>QNJP$'7!O($&.0*K2;"/%6Q<=^QI7C$K.W](+PZ.+41&CGN*7,0&ZHI@1R
M4$U/6(6C!6A<F2Y1AU//8(\S=<I8IQVT5G+!'#3&(5NY9XAZVF;[LM-E8D^L
MKH =^NKL*7?FH<.00U4&J;!@DH5E0??+0)/XI-[17-F+]6&V@#'UN]1 4RQ*
M++1PDB!IJ7;5;("T/&VW81PQ]9>JXQ 9.\])^MC.06\GBF7;._.H'(PHDTD(
M5HH3'<ZQ*N)'^:#]S^/NS#=&^=B=^=.02,;K?N@<>O]0SNK#M;JZVE"S4U]7
MZF%]6RR/M'KJ\5LS[,H>@AIIPYG0!D-,*P<V-9;'YXZEG,T8'5A/AHC(_2EZ
M K],OLWN'NZV\RBNMZ7T-G59-\7R*C7ZP%[7]]=FDB'/#-*08:VT@M*@/:'!
M,HCO,)%R!N2I4IP@$T.+\7;5F>)AL6G&=$;)CA])1J!1U("R-HTAR'.@"=M!
MS 1LT:HZY63+085],')&H[?LCJNOD]F\M*A]L=S,O4^EY<!7!GN 0>8]A="%
M?XEB2%2N'F:PBX_OI=QY]6P:2S<L#)Z5_.%AO5I/%E>SQ4U-X$%-U[.OL_7W
MM[9[]=(G.*,8$JHD"+)G$>(,.2RI!]8AI!J9I6^YRWD&B/%0,BM!T(TXU=H1
MO\/1"([C/;'IY2XW%IG><I=/ _L"<Y>-5$!#++DT2ADDG= 5 !:1%D;1:'*7
M&XM ;>[R:3@FH]*-( %4E"7T,376$R<]U\:":I.PWO!1Y2XWEI(A,D'C@'T3
MW>X03C*N,F*)'4V*F$/,""0,1UKJ8/&'&9AJ(EK)(;LAG#,AHS&?IZ>(G89P
M;(K8LKB>K3??79\"]O*YS##(?5 YN,/4.X6"O<ZKX;F@"8_0%SV4 +0%,YD#
M[*!7I=BUW?JQ(=ZCPV+K>NG%M=;\ZS.@&76&&B,@@!YYHIBK##B [666.8FV
M6M-CI$UHY;>:F?SV_?&1XRT>UX^-YIY,Z+7^CA^7LVEME.5L@\J8 E!H1CAB
MGAM')9&R MXK=YF-#$]="J/C*?G#XFC3U,.@?,I+,0D_-\5BO9Q,UP^3^9=\
MV8^?N(]Q9@0BXP3QU#&%-%.4:%UQR:"ZS"#GX,=/ M0-N@SK]B9]TM[T!"-U
M<[/,;R;K_%T 8A8L\>FF1_$3Z(ZMNC,-*T,60V LE8YB)JP2NBPM5#+E,$3\
M,D.IK1;9.)A*3O?[QZ8!ZS:6/+B.]_3+,^D%,A0#(37#A H*2@@W0!*I6W2E
M.M\%K+'I<BWX2$.PO[R<RYGMF>;CR30WDD$)D.(& E6JQ:R"N\S:&^%UL5&(
M?V\4I;$B?EC=+>R1E(:7<6615MXZ3C2SUFN#2$4&MU!'KY?SU94>Q7H9BK&+
MM3ZVJ*5D>&Q'E&FH.>04EO>QN21&"RHJ?@AKD;TL+FA%C8NDY,Z@LH1N6=MH
M793S.1A/&7X0&8!(Z[+.N0T"@;0GG,#][N1$? :@O"#I3YZ7Q 4^G?!*PW%E
M4@H#K<5.>*<Y YRH76C+40A<BS*KX&U=G)6K<2V50VIE6@OGT"@S)#U6# B@
MK<+>8ZN9WU-#6I0O@Y<4M!\_<\DMJ@/:Y',L!E]$C4:5*:@\D I3AP53!! .
M304](*3%HGD+[Y^3J>06R>=\O9Z?+0KR[-LSC+$E' M(*66>2R8DV$.I0(OL
MKDN*KZ?+R+F%^Z4[83>7LUD>IXXGX\@IZA07F"/L58#<[>$F#K38]2\I]CTF
MCI+/YSJ<Z^F^Y<OI;-53$:#C7YM1C8164@NKM:?>24/Q#FDF*8@/<\!+"HLG
M2,6YSX%7S)_M1%8I.:&.#2ESA!A,O":N+#K,K8>25Z!S"%I4R7N+BY^-IJ'7
MQN'5O:L3\^M]L0B&?YC6TPO07:V#$[\^4]P[([T+NXW#H#QI:76ZLJ"%QB?_
MP;?8]B"4)!^[5M-I/@]K.$RTM-\;7VWJ\KLR!S4W,!RDQ!+EE6&85NDT#"L<
M7W$=O@6<N\<_>25^4Z*TN)I=SZ:;5ZHZ254!L)6ZOM[XK/I0Y1M_>8:\0T!H
MKC2!0GHO<+FE;%%'B+:XGGY)@>9D"1F\7M;+SBW;^G8?5Y.W&ED-9<^6ES"1
ME@QJIBGS2A @  +,,R-ELT*Z;S6R\HPAB<.)(0SA6 D)9#@Q=C@&LQCX >\=
M]UTCJ['(]-??]R2P+[!&EO#(,L\]=08HI[7D1E4 6 F'++A^KMX8346@MD;6
M:3@FH^6-H-!0X(<1BJED5FDNPA]<M4EHA&'BC3HBI62(BD-QP+Z);G<(GT=D
M3ZJ1-2J)/8^D=MA]4W'+(=%"8L44M@(A5.E#D,D$NY^<E^:FW3=/@C69#2ZZ
M9L'[TJ%:7F/X5,SGOEB6+_5A^T4-)&,6025*=X"CE!'C@(45&XZ8^!N8*:=H
M1ELZ*7-S02NEOY)CIXXA4P2Y  0P%GG$$<;"[SF $+2X"I#<^NA92(=?2U$4
MCG\9;8)YJW>+< #/BO,<-<^'D'DLB,) HH"VHY #J<6. 2L-B->DTDMIOI1%
MU(K!\:^A[<73LZZAYT/(>%##L;2662NDI5XZ+2L&L$'Q!U%Z&=*7LH9:,3C^
M-12(N<YGYUY&/XPB*ZN86&^\<@8S&0P!J"I!L653U^B5E%ZJ]:6LI+8DCG\Q
M[8EZ?B4I&9_"P6&5_B/!'=.P]%0B:P 2IF(*RA9NU_24OU%X&+IBZF+75$H+
M*<.*2!F4;U;F!1NH!=7[?4Y),&2/KG0.JPY$^-SK[D1BQ[_8GAN4":RXN@%E
M BD%J9;&<R6#BJ$EX3MVG$,D/NTGO4/K,I==A^R.?^T]-T036'MU \J8U%@@
M8K!0SFLG+;*5[N2D\O&- L?LZ1C3VNN0W?&OO9WI^K#,5PDLO(.CR3#R6GA'
M =<28H4Y(*[BQ1,;KVB.V2LRIE77%;4))?N_GP1<UK.O^5NV?[V[ 7**";9$
M8\;+6AW:!=D4$CJNG16BT:VRMVS_/$,<>.2I(=91!"S%2O$=CD9;,63*5]_9
M_HU%IK=L_]/ OL!L?Z>< IPJX:$4!H69VXH"PW2+ZO>CR?9O+ *UV?ZGX9B,
M2CF"E&FED*;<(!*4&TJ\T8!6_%B*K!]3MG]C*1DB=SH.V#?1[0[A$63[CTIB
MQY[MSSVD#B+@"30TF$F $%C-C[6JP#:J;/_&-#?,]C\-UDBQ62W73T0F_.FE
MN(0?99]*6 [H9\_^/H,*8,8<]=IK;JG  *)JS$;X^&H%ISO_1Z*7M<&O=\X/
M;@DOGL@H%8QH8B$TV'E.D2.Z,HF$]2!-;2<2^Y?,M<)@/!PF=>P/2]UPE/T2
MX+M[N*LE[=DS&990.&#"X0"I4D K[&0U=@9AB^I?79^^T:@7W<R]5]XFWX[S
M]O29C"H.*- 02 ,5(8Q9:ZJQE[]))T[>"6\MYCYX^;_-Y9?B^I=\LBIC K^N
MRL+E-E_GR[O98JNDA>>+A\X+X3?_YK)%>MCJC R*1M QK#22BPI"R."@1MI@
MN8&G>E[3)&-H>7XRTFHNZNI?#YM[7OGZW6):W.759+>!Y\Z+VD<,(4.$,F@\
M$3[HTL 18"0+H/JR*:"0+/Y@2R^1Z$P2WC\K*8JZ?5AN/JZ:TSED_>48,BHY
MDL93S#T6DECE.&!" :6]Q\3$IWJGE[F3L+"WI"49)W.M]VI7U7,[0_B*]/?Q
M-9G13@NN Z" !;JM,=KNN/:<N_C"].DER700*3X?\D/OV$>KB5<'T-8WZB;+
M1?B ?#D-STYN\N+Z72D1D[DZ<)$GG<%EFIBP:TB+/&4$6<S#SK(G(EA T4L@
MY=8,@^[QY^3KG,E?7XKU9+YYXK:8!Y'XE*\?EHM?P[>\)8(U%512]NG (MAM
M!#!+7.DWW+#MI":N61;G6R)8GB%/#)+A7\>XT3!8!I;O<)0.DR'+OO2="-98
M9/I+!#L)["$3P1IY3;_,UB4*[Q97LZ^SJX>P\1X.,K[Z;%;6I''*6.N]4E(8
M*HVK ("(#BEMYPHX-A6!HELL^_2F_S"^?\[6MY_R^0::U>WL_DOA%NNREOFA
M!)F(3\F4=P)Q;Q2WS!-NE9!J-__P5XBD&\1LR6>=9/2"V9]/=I(+GJ8K,L.)
MBB["+OKAVLZ6^330L3*WDUFI4-=&\>I?RC#D 'D#K'4$ !4,AETH.LR..=:B
M2TT?8;W>N"MZ BS2/?'3LGBX_QA,OME5.#W-[2R_U@^KH,BM5A^NKV?38!,N
M?3"F\N7S)S]NK+!WBT7Q=6-$_3V?S->W!^6CKZ_*B(:\O/*GB#58,NNU+7/!
M1%DC SL:G^_>2["X;ZE*!.:AW+UQ5R2\I\(S:"DP#EF,E*+[=86A'+)XS$@T
MXRYP3"8$,((\<TS"BO<&(V8Q4]:[@'2%K%( I:EOMY22(1+.XX!]$]WN$$Y*
MW;\ B>U$"6SD,/_XY?.G7P_?A8CZG$Q;BZ56B"!L*0>>.5"=1%I8-\92\;VR
M7 P'=C*[7H(Q>QTT7P:L<H 1"#T'7.L*2<C1H!GA@P4LHYWZYT,^>1D^VCZY
M#XD^^J4!98"U#0<?IEIIP0 58(>RD1!?9GW-P>6[:QX&3P>O'_]JMJO6M.EL
MWWE&^"E?GD'*&%6:"DX]MUXX!RMNC68^WOF8<A;AJ0*=+!^I"O;F3W:RSOUD
MMCQ4@.M,(\DP1\:KL&UX*JE' "E3:7N&<A>_AZ><5YBDR+<F9_@,JF*YOB[F
ML^*'*]AOO;*;"6)Y<0N38,DQP .M6"JPZ:K(D246^T:WD-Z2IL)" >$T\( [
MC+FVP"$#^ Y'+) 9,GS<=])48Y'I+6GJ-+ OL'H65)LF*EHI#;B25$#J*PH0
M^S/TRFXL K6AH=-P3,9*'X%_'0B A65(*A+T&:N\HJA"5F*!QQ0::BPE0SC:
MXX!]$]WN$!Y!:&A4$MM-:.B@)5 ?"3KR6D: =IYA:"$/X\82<;,?/ <MVC>.
M*_#3F,.B-VR3V<(NM!LV]!0IQS%2E!A'.<(4[]B@EN/XRE\IQXJB;9F4N;F@
ME9)0-VR@H/!"D[*9,E/ \[)2T8X#IEB\GS*]]=&SD)ZM&_9I%(Y_&:77#3OL
ML49BI040CB'-F%*N8D!#'5]$(+V [:4LHE8,CG\-I=<-FWGI@9#&".DP11@!
M;RH&!!+QA</2BQ%?RAIJQ>#XUU"JW;"U1E"6-4=!V+B8,KJL_;SE@0&A+RGT
M?"DKJ2V)XU],X^V&#8,0,4 1LX0QJ0%37%1,&8?=!2E_H_ P=,74Q:ZIE!92
M9KS@EE,J(7>> L68KI2&8,O"06^L)'-8=2#"YUYW)Q([_L4VKF[8W@O#'$80
M6"PM!Y0Q6[$C ;BD0^LREUV'[(Y_[8VK&[9V7$ MH$&X+#2O,=U''3D Z))J
MZE[FVNN0W?&OO;%TPR:"&"2"Z@$T1!P:%=21BA=O<7P/^C%[1<:TZKJB=M E
M5W>Q01^XV*"FTWR>+R>!G]WURV;QXBZ_*\-44VR]PHARZIVQSL$*4VA9? '#
M] ZICKP:9X0_^5.DS+OZI;B:7<^FFU>VL_QP[>[NY\7W/%^IZ^M\VM.%V\9?
MGG%DA%1>$:B$=P*6&U^%.E8H/EDHO3/BC*Z\OOA(?A4\4Q_5XLI]N]_,\TM1
M_NC#PWJUGBRN&N_W PPA@Y8+!:UA% $/'8((5F$(X4B+*QDIUX8??$7TRTI"
M]Q??JKXW%$'D#1<,,*LT",JLM!C+P#)%UIG _-L%QH87JJ@.=H$2$AGL ('.
M0 ]W.$J!>'PWP_0N,#86F=XN,)X&]@5>8.2<(F^!@0!Q2BW"6JL= ,IS-*2T
MG>D"8V,1J+W >!J.R>A]([@%YK2WTB+#PD9AK JZ@Z![9#WE8[K V%A*AK@.
M%@?LF^AVA_ (+C".2F*3OL (%1 &,&J%+-LU"T)DI>QHP%O$K\=U@;$QAZ=<
M8#P-V\@MK%$CA$\E-C6]=_9_7P(A%?0" R&]1Q3;/1!:61%?$G(T5<5/U;S:
MX-<[Y[6=+IX\D3&NO2 &8$>1D9!:2UTU;D^H2E.?B<3^)7.M,!@/ATD=[,-2
M-QQEOP3X[A[N:DE[]DRF9!D)=H12YHPV4$%2;3B&0)E0#8%HU(MNYMXK;Y-O
MQWE[^DS&G26*8*$XY-A(NTE8V8T=.!#OI.BE9TMKWEK,/1GKK%8S_)3_^V&V
MFJWSS_GRZVR:]UV,^\#W94I :1"CPA)/, YZ(V(5MLR00;?QP4)%T4[7!"@8
MAWB?I\0\$<9S&^QSBK$AG#A*\0Y)6S:%2F>3'+TPMT)^Z-K$?Z*V\-0AY9CE
M99$DZI3!2.Q.6X^@!?&U/U/. #MU"8R6K\&3 CZ%9;Z<E5D-G]?%]/>R/<KS
M:L9ON0 '9-)1*1G#B%(DH8-06+0I"LH\14*"1IG+;[D >19@TQ(J[XDC4'"O
M$; ['*%S/KY*2WJY (U%IK=<@-/ OL!<  F$4Q@(CRQV6%L@L*D D,;_"8H9
M-Q:!VER TW!,QJ8904!52X^MP5@)JJA16@BT1Y8CE:COO*64#!%9C0/V372[
M0SBID,$%2.QY)/45DV'UZ?.O!WW=C=[+'!%(<VD<0UAZI)UVI-*-B"'Q%P''
ME3K0F/*B/W"3V?(2]$ ZQP0E##NGM-&:&^[W2,* [@C%M$>[Y7S()R_#(R_@
M[9E2G%#CG)%4 ZFA0#LVL!/^DBJ5G'$=#,'-!:V4A IX>\Y@.,2Y)1Q;3[DD
M?,\!;9/YEMXYT;.0GJV ]VD4CG\9I5? FVLMA7+(EJJO"'JP ;IBP#CQ5L [
MO474BL'QKZ'T"G@;J83'VD-"-=: 46WW# 1])M[AG5Z\^%+64"L&DTN]^)3/
M=JC;V=?95;ZXJCMCSC:63$EN%"7<4H49IH3(_]_>M36WD2OG]_P:W"\OJ6K<
M]CBUNW+9WIQ'%"V-;"8RZ4-2/M[\^F!(#B79(C6<*X96);7'DC@<X.NO@49W
MHYM6YTN& VI>6B>_*B/#*,I41#G]72?7DO?(.F":.%TFO03KJ#;5RL64ILV;
M1^17IN12]IZV0IR^,AT$]<]B_NES6?GE6[&:?2I^;EB?C6/NG)%&A;T '-(!
ME@50@(6T]+ X>M[\4)6?03@)SUV/PON5E#%S#8R!2&".(02!*@LR"'Z0G ??
M/&]WR@[!?KB?H0Z?*?[I*^Y3/U">VGOF&*-Q)#C-D!:,!$LA\;&RA#@$WOR$
M.&5WY,15N%\.3%^/G_JB\M3C,\<8O726>UG>,M7*.(MTT)4,+8A?TR4Z<3WN
MEP-3<*K.6^AHOH,M$^(XD5PK3YW3G&)LQ%Y0@N" &ROKE-VRO2KKQ9!A^KOO
MH^8*>6Z]YPPP<J(X<TH*PT&D)1=IJ&Z>",QL\R/PE-W!$]]W>R3 H.I[:JW+
MNB.(=((@0R47H#!U%DM1A1"27=/"F,UO?^S(G3LB_-GO2!/I"(*8+6MUBD M
M]42G_RJH4%>F19W)_':2$6,8?<EC\"('VRLQNPWKM;A!+:XA#L9A(;1PAG.A
M.#;;WEUIE3,>N*VC8*_%#8HHD?8).>J%)L9)(C'R>QS+6X:U<)Q(<8/:E.FM
MN,%Y8%]@<0-F7'#$IUTA;0E<<\L5.P!@Z9!=NT<J;E"; B>+&YR'8S9&W01N
MB!.C!0N:(29,.O$I(AVMD$7.N2D5-ZC-DB&NBC<#]I6ZW2$\@>(&DV+L.$RM
MSC:/C@PO%C8X^DP,E'&)&1?<.:1E63+15C:1D/)7*6I06]3+?H#-9IE[H=/@
MHY:"/>>6GGQA%,@Q,(Q8Z9D7/CC&1(4N(F3(4\MP[I7&YY<<9#!!AO?>3?7G
M!IU<>(<8H9P&[M(62-@^_@"JK#,^Y/FH;UYW1*[^N-Y()%.A^=.LLM]6RW4O
M_KKC;XO:8,=UL,R5?<FE29OE 5?I]"5=G<Z3ZNV%,AC92^OJS7I]7]RX^]6A
MXLYV=H]=YVO_O5A=S]>G@S]G?UEDS@/%VH!2'%'0FG)R0 7;YD9R?NEX/5&U
M;\RGLNP^2D;H\R;D\;=%1K%@1 ?%" 'GE>2"'K8SAIN7!\LO&I_GLMM>*%,A
MN__^=;[:/C,$V9]Y6Z326R^T40:D# (A(6"/J_,$FML8^47A\R1[>Z%,A>R[
M]&Y8W*0I;U,./BS+7PUYG*P[A$@2^BA@2'305'DBA:P<"4Y?:FF\L;PG/4EE
MXGJQ-_3*D.A8>O'3$*(BBFF&'5.4!TN(T;R*/C@IH7DF?WYV?K9ZT58J4]&+
M1_K_0UIR=09ZNYI?;W.K;X?TLM<<3-3&2DX(5PY3(U%PR%<6A5-<-]]#\CM'
MC*\KO<OGPK1F?%5)%G?P0H) ,G@PAEJ#*ZKXM,=/L='\B"0=1Y_.%&(V2G0T
M E[G2GEGBM3=*&)::866W 5L+?8J",%P)0>:%N$+.K!DJ$RC"7(R"E5-<G2=
M.FL@$?G O#%@0ME/!H.ULK*L/4]_O*#SS@35JD]93D:SGO&6CZ5;9PXE<NDU
MUL(K1X$Z86Q0%7&"#* OZ(0T0>WJ5YJ3T:]G'/3C[5UG#24Z9KTLPPA*>QX,
M%T;+2B+&\TNZ8CE!_>I7FMGH5VOG_TANC'8#BUKJP! !+L HAKU,LJJDI4.+
MFC?YZ=[XWK]!935QS7H4/LA+LVH.+'JN.#!PP6&K-%>,0D6RX!WEC35+O&K6
MN++*OEK,BU;&NZ(D1/J]72XVJ]GUYGYV]Z%8?2$OJ=.PHXG@)=>&2TU,.@,S
MZYS7E5PX1[*Q#LE+U:&L!305Q3E[GSX&T(N]8K,89 R0!*:9P<YB&HA!#/8F
MNT;:F>9JIE[5+!^Y35S[CN_E&6E?@T&FDSTI;R4%RJV0DIM L*BDR)EO'A/3
MK]J7C]RF<AQ[M Z]21.>+];SZ]Z*?K[TSD@PI]IJ%H+'C!+B[+Z;?,+8@VV^
M,V%TJ<J1@1RFPO67MV+X]&E5?)IMBL%TH?&88MK^DYB\=M@P668>FX?U2#C7
M0E?RRU0:7U>&DM/$=>G1QIJ-+KT\ILB,E8$J($)K0JF'H/;%O326Q#?OOX+S
M2U3*5I<ZEU/V)Z LRCQ[K[A"AEL3)..>,V9#A2GF;0I)YI=--.*!I"/\QZQP
M^^=L54:&OQ6[$K?KIR-[K7'[4$\Y6<W(*":!8P*,,H*VY)+,:4\$JJ-2/2$W
MJ1JW(:WOO"R\J7E025V-"6R/HU1>M-B6SUZ9^JYQ6YLRO=6X/0_L(6O<KE>;
M1PQ//_W([O2K^&&^*5%XDVSQ;_.;^]G=D?JV1S\;*0LH$&RD%9;1=.I-:W %
M@-"^>01W,C5N:U-@V2V6#0VU9KSXYWSS^5UQMTMQ^CS_^F'I%YNR;ONQVI\-
MOB4RH)Z <@*CLA:FDXR2:OXLH9)G-=H.Y'F*&;U@]NMQ9QS.'"D'FS=EAJ/*
M'[/%;+?&'BWJ^MS'HM0JD""#=H0'+I#10N]GH #YYF5].G?B]2J?96<0#77H
M;U9''\EDY FG) T$L Q"!UK-A;7I.7B^GVDB-D87.&;C5)U ,7+M+ 0D*<4>
M"8,)*T\B>V2U]Y.JHU^;)4-4)6\&["MUNT,X*\/I A@[#E.[K:,OF7#4.8F)
M ,2Q5AK" ? VU6RG54>_MJAKU]$_#]ALEKGLRR\K 4J590&EY-X@0H-UE:-0
M8MS\=FK.4?_&WM'1!9 ]L;?_>5?\ZWZ^GF^*]\7JV_RZV,WWQ83*KM\7%1%6
M.Q>DU0A+):Q%U?:GJ6P1B\PY##\XN3L40?8A]H?KK/4*V7;QCNBXDL@3PZ@%
MQ2U.-IRO,+2 +[,>82L:CP#[R]3]>EML^8C)GHWI%RVU[A_+NYM#&?5GN-CQ
M&R(72'/KRW;N7!)D%?65[RR=+$*M2/1$:EDT9^*XH(_"P\-]R%T]_Z_%]7QV
M9Y>+FZV<G[-I>W]G! 7:!,4]<I8[(BUAE6$%0M7K##RYN^G#<[5;,0R>C[3U
M(A]+/=J/I-L7+C>SN^VO/R<M+U;OBLW]:O%7^NKUTY;?K_E0QTC.P%@CK!-(
M )*<,T?QCE+48:MKV4.O^5!EK14%"E-!K.&@A6!(\#V.%O$P9(9*W_E0M2G3
M6S[4>6 /F0\U4*R24!2"#P81+ZF X"7H"@ @5 S(MI%BE;4I<#)6>1Z.V3B,
M)A#P <LQMTP+#2#3V<\8C"ID=1!B2K'*VBP9(O+3#-A7ZG:'\ 1BE9-B;"=G
M[A-'@0_OW_VU/AJ'K/]PM*!TPL])#HIQH%HX5QD^6B,V)#%&#$C6EN>R9X2S
M6=2.@>C_=9^.H&\6ZV1N;M&^VGPN5A\^SQ;[(-:?R\6W[8V[GCM_-QI(I$)9
M&8 ):30(XTLKJY*&1.*2^BUT<+K)6387I"G]M;8Z=PQ1466T54%9KH/"0GJ[
MSY>DZ5]LB@DJ(Y%T>%UJ),+IJ]'3K(E1M.CI$"(1$AM#@1OB2&! ;#"5!)"'
MYM9V?GD%EZ)$K20X?1W:U4@858>>#B$R36FB0C"L+$&ND-6(5!)0#"ZIF?JE
MZ% K"4Y?A_:M(D96HY]&$5&@4F'DK$#>H60!.%X1)7 @S=.#\DO*N!1-:BO$
M[//D?A3'#V41M[NQFVV*,)NOMK5XX.-Z6Q^QCX2ZQH.)&BQ7'ANG0".JN>('
M,R$8A"^S0W8K;T+.\IG^%E0?HG&=#2\.+RHE5! :.*4!@)D@U4%R*)!<_=*9
MTGMX7T37$IZ^;IYL?YF)@IXYQNBQLLP83Q#%"*0/L.O&)!E#F-+FMX/ZW?]^
M=2WM5\S35]6G!]D\5?7,,4:=SN'8XN 15>"8HE:A2H;E%<E,_2F_NJKV*^;I
MJ^JC_IQYZNDY XQ>E9<WN$4686 AZ&0A5=)+=(1,736_NI+V*.,VUW5.B>7C
ML5MNS\YU\S#7XYUDMG/==CP[X:S)9W"1$XV4E)R!#=(:Y@7!AZ4R'4LRW1&'
M==Y,5E[9*<[)E>Y8M\FQAQ0= J, $XY(B3L\G-(9UD%D5#!NBDP=1,DZEW)?
MJK5N/,7=@79^PDINI6"]#RP213 1A%K&@5G!?0CD( #+FI>>[MR1<NEJEINL
M\U.VW9$T0V6K.;"(F')>&YP.$90+29"PMA) 0"BC>AFORC:LK/-3MD,F0(;Z
M5G]L$05AT@G#6$2\9A(#8J$2@U0MNE!V[MAX5;G!Q9U]MDH6C9."#8%CD6ST
MX!0(S9F%/:9$$YR1"DTYUZ0C^+-WK)?WW_Y8WLQOY]?;1W:SO+JM*FRNX?9V
MVRRM#Z=Y[9='S[T0G":T%>,NE)<95(4ZUZ%Y@#GG(CV#7]?J2Q[#5^LY?B7S
MM9M83?89@9&W95TH(817WDDMD84@65F6@M1J]/I:/:>(Z:#A%)'!D02?M%08
M8O<X:L9Q&-!SVG?UG-J4Z:UZSGE@7V#U'(&0],R#-IPJ);G5/%0 ^-"B\N)D
MJN?4IL#)ZCGGX9B-F3>!$B1"6:$T@'92(AJ\4^D86R'+!9M2]9S:+!FB%DDS
M8%^IVQW"XU#VK.HYDV)L)T[9(:KG.*2)YL:C9 $QA FVA.\G ICHC*+C><CS
M_.HYYR'<<%&KU7+O78G0B2ZOA[]'Z0.CX(24V**@/&*A,H<!N!KR^O]$;+$V
M^/4N\Y,=%A]](AHK#%<&><09\09)@7$U;JXXSM/":8C]CY)KA<%T9)C55C^L
MZ(83V1\)OB_W7TZW-GW\F2B<!97^CU$7M)3 "%0[D $?!JUO^')?TT:H+[N9
M>Z]RFWU_66Z//Q,A$958PJC7Q!J6S =.JK$[U"*HU7G>4R=R:S'W[(.DH[2^
M03Z9&!II3@T*C-M2!RH,B2,9Z7T.[M:18!\Z%?O'<-;VWH4MLV!7Y7;Z834K
M\R_<[.]]XD+7>=?GOC^ZX*T(PB JK8($+'>F@M,KF5'VYX@LSEDD8S,</A7;
M!FNK8A>FZ)?/3]\6+5"F');8I TL$(] B@JJM$8T;Z23\SV:4=G;2@#9.'XG
MT2(R>+ X8":UXCK9U40;V&-K%>'-KTWGG'75RL 86039TWLBF5>T;,IIE&5<
M2A,XD^S@>+62MF@JF7/FU>#$[TL>@V=>E0;5;M+K]?V7?;+S[:,^W>M=WM5K
MVM6QI+^T9SN2ECBBD)6$!D^WC7#+^PI.J%K-ME[3KHHHJ//.!F,#HH%+CKAR
M>QRE,+;Y62J_M*O:E.DO[>HLL"\P[8H00$XGY"W&D Z*P7A< : ]^Q72KNI2
MX'33LK-PS,;&FT#N"@D^2/#!!">Q!J.3C5,A:Q"A>08E6[)DB"269L"^4K<[
MA+.*Q5X 8\=A:G74>716.!I ?/&92!/ A$I5%K0(6(+31%1SY!*&-/_&S,BJ
M+>IE/\!FL\P=P^ZAK-C#>=5__[H]:[OYM_E-.I>^FVUZJ1E7]]U1:PR,,:V5
M-TX2;AQAE8&/?(NX4,[1S<:GFLS$,4D5>#=?_V]8%<6;=!!;%>O-D"KPW+NC
M=0(\8$Z#X,27K7@PJ3 G;50@Y]!H%BK0@3@FJ0*5ZO_W\BY]S=U\\_<8^\#3
MMT>II **A$C';2>$8VC7_#;AKH-US?.D<HZQ9J$&G0@D^^2M4S/_4*R^O!AX
M[>6E4<I@.1*(" J<4T[XKNC"%F6'FZ_^.4=?6]$^!SED$GPZ<</D-19UDH&@
M,*:*.124PX)Q*^R.@9YR1$RMV.]K+*J(7.AT"&>2I/^G5%-APDYM//%*FB$=
M6'W'HFI3IK=8U'E@7V LRA)-C''.&DV0TLQ@V(N !,],\UHYDXE%U:; R5C4
M>3AF<\:9@$,?,V*11!J $I<.C B0JI U6&9Z0:XE2X;P[#<#]I6ZW2$\@5C4
MI!C;27[]$"4 +"5&,TI\T%Y2HKT'4QD^E*%:Y;(R\]'W*L_S2P"<AW VB]JD
M(T].2.^) .\8<A0H B,JS(U$0Q8O&\[QTO@,DYDX)JD"V46>C$J'!HU,6>P2
MA/)I:W$5YH#LD%4\?C$5Z$ <DU2!+"-/@3 M$N28FR 1<"F@PEWH@$EC-<@Y
M\I2%&G0BD-?(4\.(1UES"@,6&!&KL:"(Z0IE+N1E5EMO1?L<Y-!SY.G#[/L?
MLTW:E(Y5C]Z_NY-7N.*V6*T2#K/OQ?ITT>K>7AN6R\UBN7GI_?TO+V\6::A%
M&I/_/OLR7\SV\WLQ&';RN8A].JXBB9-9+0Q26"3.[\*:1#@0M3SFP\WWI;C5
MT6>B$$9)9[DV$)0O6XIPLY\G8YAE$X?J2%K+?G#).F1D9G>SQ77Q_G-1;'Y?
M[LL$G(X>'7LD<JEI$ R7)4/!,">2T;V'A6/#_(!T.2N0U(&@E[U -)01]MQP
M7W27'W\H,BJ"Y9B)H$E 93D4ABJ-8X!<WO&:]L*KP8962%TJ+[(,AN1$ATZB
M&W\N%]?WR51;;![9;,F0+C9K6-QLNW<]?.3PIY,QCS9?&:WD915@:R665'AG
ME&:'_=GQ(?,/:AZ9NI#@<A3TNJ3,[_/9Q]*],"\:D..GAR/7&M.MIYHP+JEW
M7-%J(IS2YL9F;W[3(6C0%J>& O^9B.OU\GI>MC?[YWSS^:_%JKA>?EJDPV#Y
M$5,L$O";]=77L@/:?/'I]^5Z;6>KU=^WR]4V +BXL>G;YIO'OSQ"ER%>':T&
M297$E@K G"'I9&782>D'S;"K2;9NSSB9 CV48?.\@ITP:IY_('IDI. *B).$
M8,IU8+B:'2"98:RGGZ-R)_ ,YH3;81 2-C:=O.>+^\3F/:V7B[4I$G>+MZOE
MMWEI'X;E:NO2NEKL'AO.HY9-Y[D#9W9P?2H6UW^?Y41[[KEH2%"8E#TPA17.
MH+0MIO=;BJE0"B1DX$1[-.[:3K0?GXD2"^>QX,$*9 BA07.WGZ<P#F536*@C
M:1USHK7$Y==QHB$4G ,EE48A,$82V!4L L20EDDS)UIS0==VHIT%T62=)88R
M+JPQ 21S1A/0=C_+9#FYS/N>M1?>&5Z31DA=*B\FYD0;G@X7Z41S5FJ.:'#)
M4$<N[=1&035IC6GS8MJC.-'J2K K)]IYZ+7WJ3PZ)/U9;![&=9(?M9^/6"<3
MS2 39#I[">6%%H?I".^;7SH8Q976@ Q]0=50\@?;J%B_G?U=&D4G!7WLXY$8
MX<%Q*8(NN\50)>4!"F=I\P!K;SEU'<NU(V0:BG&[B-26XI%/1Y.6%(J,D9JE
M'4YS:GVUXZFR*'-^&6(="[$;8(8RW_Y:W,S7F]7\X_VFN/&SU2*=;=97MV&Y
M*N:?%N_O/Z[G-_/9ZK3[L/Z71%962B!@)-5$I%.W2(2N4+!TT(;<Y[H4.W4<
M] 990^4_X@[WWZ_O[LL>,%72^9'5H.[C408.@+7DW$I'?;D-\?UD-#A2RRTV
MDDNY$_GW"-:@L;!.HUM1E@%%HSQER2I!5#*F0C513UN8][WM_-VS8A#HAMM6
MGAUMQ>PJVK#=)LO,YL7ZE/>YP;=%S8T5C&,.0FX[_Q@N*UPT$AG62.IKH^D;
MNQPY!=?7J_N3O6(:?%O$(C O46#.<H6=!7QP]2;(<FS^,CZGFF'7K153#6SY
MS,#2;U;%;%VX8O>_;Q;;/\SNSK-T&KTBEM6'?3K-.>R0Y]0YI4P%2MK\F]\G
M%M,@U,B #K5R'6;P+LUT<3V_F^^3L+^_+S:;74BO5J3YU/,1P/C@M<24.P"I
M ?1AU08>FKM/Y#3(U"=:PV7N5(P^IA;K=^GOR\7LX]W?;Y?K]?QTW+[1]T7A
M#>= F$_:8ZR4X ZN"K!)JQHS24V+24.@-UA:4 8I/T>'T$$NT$N>Z=]/9/0<
M^VC$VH!52#B?V*.E-](S$C0Q%(A-!ZTF23PO#?18*LYS'XLH6>G!!VX%XD@Q
MJP/7^P%B8\B0[K1GLV_:(_N\>[S)['^9'!MCO5&.6(,MTT%QJI&L8&%I$<HM
MQZ:=;.NFU9R'RE33)VB@%GM*J,?,<\.#H?8P2\;,1--J:@NO?AY%,Z0NE1?3
M2JL9@0Y91<H#=<I0I@3CGH*AZ>3"J]V3(#=HV<760=;:R->)E)^'S%#:7!Y,
M[K>9.O^U_+B&Z\W5;?JDW,[BZUVQ*>#Z>GF_/;E\6,V2<NP/K,E.3G^Y_W)_
M5X8!]L'!*EIXL*9G=U46R-\G%H?!QA"1YH)JHAC26"I9%B1QE0PDV(S8V9EY
MFCO((Q/]CW1*OE]MS>I=^WJX^9_[]:;\^=&-G6WP87^T/I_(Y[\C4D^-9T !
MRL)1&)"'4&%H%&]>I+3S8/101.T=Q)&)6%_I6BRI#5X2I4IFBR1$<5:ZK9UD
MCNQ1I)BYC'+?AJ)B_R@V-.+VE;K2(-X57V>;U<&]?,2*._KY*+  1"T"+0V1
MSDC$^<-P;:WF]L/$J#OUXW0%2$/Y[?DV._!M>72/_NUN^7%V]V:QF2T^E;[=
MWY?_+N=_LX/BT;[\3$;N<PO'D*^/6!EK';@@*%?")0O!5G8U#98V+U'9>;2Z
M4W9EBF^W9#VQ3Y^>5'NB=OKJJ)FU&!E5)L<*Z;E7[@ B,JCY6:'S"/@0)!T3
MVVX)VC<+&\"13D@RV05IYD(1QP,X12LX*-;-DPP[CX\/0;7> 6S()W][6UR7
MH<"','XR^9Z&\EWYTWIY-[_9_OA;PK(LUP%?RG7]"(]:?V]$#'@(2%#&-( P
MH/S!N 2JFE?#Z#PJWBE_A@8NJZ0<ESZRWLROVR;G5-\3-1)E#K?PP+RG) %!
MT!X+9@AN?KU59TNB(8#J<;%Y4UJ-Y=BV/UW=7JT^S1;S_]O^-+M[OUG=7V_2
MGMW9(M3H?9$1200*@ 77.C!=)KE4< 7J6G0F0=D2*R=$1UZU_ER6"3)I'N56
MOG?0I6G/YJMRWN6L3E[@:O&M43H.Q@:P#!@1AC'G3843LRV*1.'\W?W#X=;.
M.G_PK1U&?-S/7NNYR!QF CM)!0W<>NQ"&6BS-B "E$-S[P+.UWG>!S)="79G
MU:=?ORD1W2;3K>O'5MI^9<3<,(RILS0MFSQXP:6HV(RAS2J0KP-[8- Z9DIM
M]WHW+&K[NI@TR22I)#/06XP522A5TF&6^!89+'E[RS,!M"OV[8([]G/9 ^7-
M8F^O/>=N:$F[MN^)6C/LC$4421>",1(\KN 1T*;DS"3\YZ,AV2W13KNY.N%8
MHU>DXX6RM*S'XM+9 @4G'*] X5RWB,[@27B^QP"Q6P_W#PKQ*%K4B%6MOSYB
M6J8^FN M 5(Z9#VJ#JP<&]?"!)ND@[MO +LUQYX+3]98<LM[25_FFT<U1-KR
M<,2!162=#!B4=]IKK(25X2  +Z#%EINWBWURT&?!_8?-8E<O(Q/FGS^LZ DW
MR>+6+-@RX3FM-:ZZZ\*5U2T29O.-"DP0^&XMT\YR@CLQ8OL>3608.T)PLM&\
M9T);H8,X0.U(\P %R3M ,0V\QTZEZ\1D[NRU$3,I0%C$&0O&!245JW*:>7F$
M;4[6?&,:&0+;/RL[\)=W]IIH67EW25MC*2)8@G'@*W 08\W++I!)A%3& G+D
MT.WC'.A# <AJH3\_9GORZZ)CX$@2"T]6?N#4>V&K5!QA.&_N=2+YAFD&!*S'
M-)0R:GRU<,7'C?]>:L+]?/UYVS"\;;[)Z2^.6GLKL;+(<2:Y)[9L<50! +)%
MW[J\PRZ#0]>0.Z$H]C=@CW#@X0/1B)#F[X(!+3BPA(FMKDT+CV2+#2;OD$9C
M" 8KSO.45U>WOZT2M8X4'1JN7L\YHPK+Y6:QW!0O#&^J[;PXM08)0JC57"6>
M>$&UIYH'ZKQ1N)9K<KCY-F_GI0-HSK#1EC.%R\*,S.SG:;ES0]:.:='.J[:T
M:K?S.@^77Z;4$%!P90],X9 T.!BM@Z]@,5@TOT$]6CNOVH*N6W?H/(@F6U_&
MJ'32*J.Q%GE'53IXD?TLG4!"3+3N4&WAG5%HIA%2E\J+<?C0M.[0"'3HY)#0
M5=TA;ZU$,@U.$:^5Q\(;5PT64=.\2L$H=8?J(E^G[M!YR#04HSVGW]KS'XZ.
M2^FI!RJLQQ1;I9WW3$E'I9:.9]C3N6,1=H)+0P'FUE:/864(6.& 42&0TCS-
M?H^?TB'#OAL=DV% ]+JDS*.N;^>3XZ>'HQ'"(\0=,]P%;*A%"A\6K^":^X7&
MZ-G5&0W:XM10X-VT82/ <0!.M&<:44^=5-4QQC,?FI>6Z:U51<<B[0:8H<SN
M^EV67G@BXJ# <:4M,V#*?_( U?R@C>!':K#6U)73#3Z#.8"WSH<A?+K/!C*&
M<RE_V)=]+V5[=;M54KO\\G55?"[/9E6TI0RLC.U'3@C=S=;K^>U\?P \E&*Y
MNM]<W3Y*SCDVBS(TM)I_V\6JZ[B@^WIE]-R&0$!H3APQ7G&,,$K6K2*,2FQJ
M&?W#H%QWHB]YN%M];Z0D;?+)IO.:2X$=8.G]'B\B.!JR"?E)+_CXA%F.!WO6
M3O8'2:S#<O5G\>^''):WJ^4B_?-Z5_#B!<_[6=\3"09I7=E8'J?CK G..%H!
M",H/Z6T[RQT_$&V6PV$[E.'X(;TM076S_%KB=O2H<.KC$5OGE5.<<TH]]M88
M:0_*3@G)VW??DQ1_+%+:'7"71(TLW?<9,V(<)CS,__UFMKB9K6[6?WV]20MK
M^KQ"Y$5JU'H^6DP8QQ@4I.67(@O,0C5W'EB&K;W;B?#'W:0'D'(@B$"X%4$.
MSR>CTE <F U4)(0Q=@K1 [+>-/<V]Q9Z&(P@34$:BB"G#NJE6_SC>K.:79^J
MVE_S&R(!1C12A#!'F$TKLW)B/W]FO=;YK2+9'<+Z@3H'JNVSLW<AO.N_MQ>F
M[GX _<.SA=@[_/:() <PPO*@TQK.$VI>5K@%;(;,D:M)T<X9<0;C^D$U!S;:
MV?ISN%O^^Q_%S:=#]4!3W*8)_[@F-"?E>2^)("FS"#-D1& 4.609'"0(K/GR
MV=L>.R8W>P4W6XKV3,YGD7."!ZN"H>E(91 JNRSOD>,65/-;)+TE&F1'R_:P
MM@E('QGI<=NG1!2N[)O-\ET9R%D\5*-HOHF/.)J(&0#E%!OD')) E"&\@IH@
MW=P3TEN.1%\,GHX4LEV!X793K'I>AH^](S+.I,-E\3_LA%+"N(3E'D-,M&K,
MY-Y20[);BSO"=FQ^ECD2L[LR0^(?R[N;\E+_?GY7B_?%]?UJF_L$J_DZ_<FE
M'Q>?=EU)FC&UQ=NBQ@)D@M$89(E0@7I3A7BX(*ZY;['S8GEC<W8XE,=F[^F]
M)NSWFK2SO)_=%5>W#[-OOM V?5UDC@(EE! 9/,)*:XDJGV%9J+!YA:?.2_.-
MS=\!81[4'DXC3B.\6CSH9ZF890F+N_N;LFS*CR91UR9PDP%$!%XZXR1F! 7M
MK!8Z[ $51K4H2=)Y0;Y\K=X!@,]A*89OL_E=F8^QU\TNUMN3WQF),< $!8%%
MDB&ACH<J5")$,,U]79U7S<MA4>T2R['YYDJI%3?[I-ZW=^FT^&>Q^6LQ^[)<
M;2H-VTZZ*^.UY1NC4XKC0)BWAG$P2;L/L9QD:.$6-^<Z+W\W-EF'A7IL*M>S
M=][N4E^J.TEOEPG[8C/?M8I\C-0VX653(=2GI=M\2-%C#9931!E03(@RV[;A
M.PEIAUI4#;C("%I&LNC!9'YH_M9B7K<U:#_.0*)G1K.R'KWSN"Q;I %79Q+)
MO&O1MV1R(;E)2""3*,DSNR!<;^YGJ_GL;GM^&"Y$4F<H40!5I=V(/%68.>]H
MJ XL$A'</,+7?0.HL6F>B0QZ(/I>26<O*NGN9G4[DWV\P<2R.+X3WDCBC$;!
M&T<J1ZFDT.9^T,5% [.10D.Z_ZQXN^J.V^)XN^NE\\4I -*4GFCJ:0.EK]=%
M6Z:2 DTG?"LU8<%ZA0Y@&=]B?9Y<V"\CG$<DY=ND1JOWQ>K;_+JP22OM*CVT
MJ>RK?AGZXKNC\:HLL(LH%0&P<YJKPU:F*6V1!CRYB%^NH.?@.8'=5M'-L?AY
M@%IXKP<97 Q&&R4P%67#V;3"(!$.VZ"WIL7*?I'!Q2RETH,M;N]790&%IZ?I
MVZ?3?-DJNSU;,[(85UG."T- U@'!3F@7I#1[^!4'U<+??G&1RQP%DJ\3YL<9
MKG=3'-<=<V)0,5#PC!OO2JB1UT!"=:]"86M;7,N<7)AT<M+(P45SQ&P<S4MS
MSG@B=J#!22!>6!R,X4 .<"/IFD>:NN\Z-C;Y<Q)$#D>+VI;@HW^_2=^T_%;L
ML]5W+40:'AZZ>GU4!$EL$0E**03E11&H>*(\E\UO*W;?RRR'X\%(N.? ^.8G
MW:WCRZ0C#D/**$FM=$005#D/-(!N7GBP^^YE.?#L?,A>K$6X_W7YGX^S=?&?
M__'_4$L#!!0    ( .)Q6U#H\V?5,:@" *F7)0 4    <&9E+3(P,3DQ,C,Q
M7VQA8BYX;6SDO6F3W+AV)OQ]?@7?.S$1W1&E;B[@ H?M"0 $KV6K)86DOIYY
M.QP9K$Q6%=U9R3*9I9;\ZX=K9E95+MB)ZGO#X=92(I[S'. Y!\ !\(__^]O]
MVOE:U$U9;?[I+]Y/[E^<8K.L5N7F]I_^\NOG-^@S>?OV+__[G__'/_Y_;][\
M'_SIG9-6R\?[8K-U2%WDVV+E_%%N[YQ_7Q7-[\Y-7=T[_U[5OY=?\S=OAG_D
M]+]8EYO?_Z'[?]=Y4SC?FO(?FN5=<9^_JY;YMF_[;KM]^(>??_[CCS]^^G9=
MKW^JZMN??=<-?M[]JY,_T?WNS?1C;[H_>N/Y;P+OIV_-ZB].:^&FZ=MF:&3Z
M\6\O?OZ/H/]I#T+X<_^WNQ]MRF,_V'[6^_G__/+N<V_GFW+3;//-LOC+/_\/
MQQGHJ*MU\:FX<;K__OKI[4ET\.?N)W[>%+<=WQ^+NJQ6G[=YO7V77Q?K%D;_
MM;NZN#G^B75=/_E"QQ#L&/*BCJ'_>>'#V^\/Q3_]I2GO']8M/3]+X!< O'T)
M5A>ZGH3W(B#/L?K\@XKQ?FF';J$6\<M/*L8\=#2Z6>GHO\\_JQB[6LA:>T:U
MS=>*>\:+3Y[$O.Y^ZEW[J_$'NZ^?D=^^\5%4#SY<?-L6FU6QZD7SR:>=<O5/
M?VE_M5@5Y8)4;01#U\VVSI?;1>H&+O)IG"$WC=+032G$!&5!&A#LD00O^@\L
MBLV;7S]/S?5_)/K!O_#8^)*]NFBJQWHYA)X621=Y!W#_W.-P'O+;XJ=__'D/
M] D;U?*%>YNV_;[MIEC^=%M]_;FUJ<7@P>X7;[I?O'&],3[^SQ?V/N>D6DIP
M,IBX[J)\58\]Y(DC4;UTJGI5U&WV,?VCO%Y>X'+\B9^751M2'[9OGM#:92'2
MN"O9WC!8W@(]9O63[DLWVW);%LV7_'I=+"@,8S=- S?R,S>,DS#VD_'[*8DP
M6FQW^GRV#_-]E:</;T\$B#,=>0+C_-;#^8^3O5F6G,MC6Q\O?&.;F1(5 _R)
MT2<&N!@Q\P]P0=R5;)=@&^"/S9O;/']8M'GUMNCF362=-\V'F\_;:OD[^E8V
M"Q=0%R*/1+$;9VX&LBSPQO8H3+*49<#+MZ)9 'H\3G7C](B<WSI,C"J@@,'S
MJF"6/,X,@(NW(U(Q*<5-WESW2$9K![DHUMMF^I/GNG&1EB,ZHH[*>75%H1V5
MZD[&ISN'S:35?5YN%E[FM9J6QA["<9;%*0()FAI"<4)Y!$?@\X:59D#%J34B
MK+&)C&;"Y-3E$E=:].4E(V>$18(^.Q1%QH!*65?BU)#J_K[:].W\4MQ?%_4"
M(Q2G29+@&,9N%M*0>F#7CD>Y<A;^K^M6D![0-"8&3+SZP<\8HWQH)8MW=8*'
M)SW:\9R.<](A3)TERB&._[EP2#)Q23<>;HK%^VI;-.ECX;NMK3^YKCNVY&*?
MI"E.(R\B8=LB25)_;"FC"&(6Y9#YOF;MZ&$Y+2ZG W;E]-#^%Z>*2/%W7D=,
M4<>G)/.SMAIW-?O-R-G9>X)&ED5N:6ZM[/76\T>U/6/V$;U50=*\BJO$@DI=
MEQ%27=_]R0^GEOP(A$& 81P%243]+$)X6M/* A1& JK+]7V3JNMW/;^%)JD?
M?/QQJ:XVZB14=Q;6A%17&WL*5)>#14[1/;3ZLN@*<625Z(I9<%QT)=C@%-W8
M.Y!W"+(0$TBC* TBDGD9(=-.898FOB\@NES?-RFZ\97C*4C:^/CC$EUMU$F(
M[BRL"8FN-O84B"X'BYRB>VCU9=$5XL@JT16SX+CH2K#!7#3Q_>WFIJKO^[[S
MKMP4;[?%?;. 'D& QC ",(Z1#[,@@U-C$4(>5P6%6!,FRBF^.P?0G-\Z<$Z/
MCK>Z0I#%\^IKD$ ^ 1;E3ED9QE%"SM5DR#%H28&&I!'/JS54<,(B,U.U^Y?V
M7RQHFD6$!MV::)* .*8N&'=74M?%@&G7@_NCFJ5D5\[?@6$7#CY>+DN%-DKX
MQ(&-#152<&CPB<$OQ,G\PUT,=B79%_B'--IL'O/UI^*AJK<+Z,81R&@0XSB+
M  #$Q6';#,Q FD0DS'B'-M?'30WQ 90SH.(?ZWR$L8]Y;5P)CGTVFE2*P"$#
M%\1 B"Q[1$$,_A%QD."!1R1VATK2?%LL4@C;Z8M/PP @GR+B!5$PB1%%$=/F
MI?C73<G$@,II83D=+GZAX"2-72GT\24H%:Q4J12+)R1<4 LQPNR1"T'\1_1"
MA@FNB4*=;YJRFY:,VD02-PG<((T"2CSD$]A.2W9-8<JT"BS5@+$)Q Z8<(;!
M3Q['S$(G;Z*S#&;*E$XYGC%Q:?HA2IP],B)NPK%IB1P?[(N;6;DNWC_VZZ?$
MA1&.B1>%(060D#C&[M1$YF.7;TF3X\-F%C([0,Z B'?MDH<DUA5+3?P(K5.R
M4*-N:7)O^=D%20&"YA<#<>@O%A^%[6<?_)^*V[([<;K9OL_OVX0E1-BE <0P
M#7 ",PS2*6'Q@$\X!8#SXV9$8 _*Z5#Q"@$O8:QBH)$K(4%@I4F=*#QEX*PP
M"))EBSB(PG\A$%(\\&Q_+JNZS4'Z;9#^9!FI'C?;^CNI5L6B34MBC\1>$&:(
M@C1"28:G5@EUF5<K5+1E:D/T ..5TZ-L^XTS(G4ZJ/R;HU(<L^^2FJ)7<+M4
M@EF56Z=G6+JPAZJ"7UN$2I$U1W95U;'$+F-?\F]O5^W,JKPIA]O =KD521&%
M7AQ#X@<D21#V=^T!-^03,-%6S$A7B\YY"D]P0B1,)JM2F>!12*/X*50G3"=(
M.2M)LD3:(D;2=KR0(37,L L06JW:[M6,_WE7;@IO$20H0#1. 8H0#1.249A.
M;;G$B_G$1Z0%,\(S0KJ:?N%TX)P/&^Y$28A$5M'1S9^0X/!3ITYPCA!R5FQD
M"+1%:*1L>"$R\HQP"PQI?_FA_E+]L5G$6:M8:>2'*$C=-"(PP%-=BQ>'! K)
M"\?W#8M+AZR;+W38!(6%ASQ.6='$FYRH,%&F7%#V5+#(B0!QEHF)B 6GI$28
M#6XAZ:=F'^J/=?6U;.U=N*F;I#A%4=HF1!G,(H].J] >AC004A/>1@Q+RFX-
M8@(HJ"O<7'**BTX:Y12&G4'E,O.,%!:M$>71,L$1-N.4ZLCQPBT]'ZMFFZ__
M__*A7Q+"81QFGN=C2M,P"C(8N^'8F!^['N>^E% 3AF5G .>TZ(26D\58Y)0<
M?03*"0XK=\KEY@DA+&(CQJ!E4B-HQ"FAD>&$16:Z] G51=Y_/L9!MY'N)\1U
MLPSX, 39[O,13%B%A>NCFJ6DS^@[,)S*P4?,9:W0Q@F?.C#2H>2"\P.+3PQ_
M(5+F'_!BL"O)SL ^J+L'7M8?[ZK-KF &@-CW$0$A"F%&H->MW8Y-P- GK .;
M^\.:!W>/Q^D!<>_<\)-T>9!KY8=OH'-0HV*P/[?\Q( 7)FC^02\.O5+00=@'
M_^=B^5BW^N+YUU_*[;I8! C0U/=) CP/$QJ%,?%W3;09!.O@Y_ZPYL'?@^@N
MTO7\'ZY_="9X[ K S]1E!=!*$I\"\/*C0@:>FW]"!H19FE\&Q*%7"GH)NPQ\
MJ?/N0;G/W^^OJ_4BIFEK9Q@0#R44NS2)PZD8S@^2D#FSY_NJ;@$8P#@#&O9Q
MSTG-Y4&OCQ7.$<]&B(J!_L3D$Z-<C);YA[@@[DJV0_#'>/IM>==V@&(H>(VH
MEX4^S%SBXS#-8)PF4S/4A\S[$4(?USS4)TS.!(JS7%V,,/9PKXTK/@'@I$EE
MQ#]DX$+4%R)K?EF0@W\D^DOPP+Z#\._%>OUOF^J/S><B;]IYQ^IMTSRV$P^4
M>7$<18F+7!_2)$C=8%IU") ?<M9"B+9B9A^A0_?F]PZ>,^%S!H"\.PG";+)N
M)I@@4F@_08!#=3L*)U@YNZD@R^3\@J/(CA=;"VJ889>@OU7KQ\TVK_LC?'6S
M() D4>)1 $*4^AY$$9@F.P'UV"<C8E\W(SD[5,X BU=HN#EC%1B== D)"S-3
MZN3D&0=G9424+UOD0QC_"]F08X)=+LAC71>;[7#0OYM%;?/M8[,($^)A$D38
M]W"<())FT:ZYB&:<)^L$&S$C'B,X9X?.&>#QBH@HDZQ:8H!$(4GAYD^=M!RG
MY*S"2+)HB]#(FO%";Y3PPG.NMQVP^7);?BW2?)N/K2\RG]+4RVB<M?\_HV'4
M'8(9F_/;J1GO@5ZA1LS(S@&X[F:M?!I'_*=WQ9ADE1T#) K)#C=_*L_H'J/D
MK.Q(LFB+[,B:<>0XK@)>^"X<JDF^+6ZK^OL"9R1QN^5BFF8ICA+D[6XV"7#@
M _X[A]B_;49D>DS.!$KDYB$.ME@511]10D+"R)':*XAV]I]5#3&F;!$+0?1'
M[R(298%=&C[?Y^LU?FS*3=$T"^1BF*5^1),,!#1,,YI-Q^2"T*><5=]\WS8C
M#3TF9P+%*PV<;+%*@SZBA*2!D2-UTO#$_K/2(,:4+=(@B/Z%-,BPP"X-]+ZH
M;]LYT5_KZH_M':GN'_+-]X5/^TN/PLCS09*$<=(V-+8&O(1P'I\7:\.,5$S8
MG &<,Z+CU0Q!&EFU0S^#0AK"2YXZ,3E*R%E1D:/0%G&1M.*%R*A@A2,/N2O6
MZZF1I/U0$(;$BT'H9V'J)3&8&DECR'RULL"G#64A'2110>&CBCD'T<626 K"
M1)#"#.3 ^O,)B A-MDB$&/B7Z8<X!^R"\/'Q>ETNLW65;Q>4M"D-!'$[T?$Q
M2J'?O:D\MD%2WDM2>;YL1@X&1$X/B5<-N'AB%0-=% EI 1,[ZJ3@P/:S2B#"
MD2U"((3]A0Z(,\"Q45O=WW<W%E;+WS_?Y6UG^?"X;;;YIBM]7= XIM1U41J'
M'DB""/K13GLBROX$@X*F#&W:]A"='N.5,Z!T#F!R;]Y*L<N\A6N*6+&-7%%.
M%6[HGB'H_+:N"F9M$24UQKS<XE7'$<][,<W^RM5BA;]_*FZ*NFB9^%)\V^+6
M\-\70>0#/W+=. Z3  $O\^-IDQD@Z#(_9ZNN1<TBM@/J'")UKKN[ST>L_$_+
M*.#YLH[-0S&?G#&PZ_S6 75ZI'H?Q&4F[(2\J2=\?I738-.15VQ4,\:1JK6M
MU_GZ[695?/NWXOL"AU'HT\!U0P2[FZ5]ZNVUU<6<^\R\7S>4D VHG!Z6T^+B
MSL!X26-.NC3R)99G,5.E,+%Z2L+Y7$J0L/F%11+_RXQ)B@FF&X&&@I>L;);Y
M^O\6>3V]WY>EV,N" "59X@+H@1!%T_6*813YS+M+P@UHEHVI:G0 YG3(!-[C
M%*?OLGH888Y/0(1(4W*[T DN3NB(-'7S2XF\"97"KL0_Z]JWE;5_TBR\U U;
MU4HQ2!'*$$CIOB4/1,R7$HE^W]",ZLG0Z)'Q3Z2XJ6.?-NED36R2Q$&8RNG0
M,R(N3'Y$:9M?1J0M.#*QD6.#7T2&AX6'ML+ !5%"2.CZ80IHZJ5PJKX+$Q!S
MOP_.WX)A(1G?OY:2$BX"><5$%W=R<L)$FWI!.2"#25)$R+--5(1L."DKXHRP
M" MJ&UKUC:WSVX7G^X$?)R$A('1A@C./3*]MA0%DK[_G^ZIF =F!<3HT[)+!
M2<UEF=#'"I\T,!*B0@R>F'Q" ,1HF7_0"^*N9#L$V^!^;-[<YOG#XE/1;.O'
MY?:Q+C>W:+/Z5*R[Y5?4G? IMV71H.ONU=#E=I&@*,1! B./0IJ@V(>!G[B^
M&R<I1BY%%WJX^@;UC8 G&)V\G;"/*)T]3.>W"2C7?L0T0F[RYKK'./(R#)-B
MO6VF/WD^7K@)/#*>]#EAWO&FT:Y*=_?E&Z^?EW?%ZG%=?+@Y@814S;;YDE^O
MBT4<0X@!BE&$$<A"ZF< C@A(%).()5SK:%=S0)^@=I=[GA[)/5[GMQ[QZ1&L
MWP=LJCD7_7RZJ9)Y+=K)0>,9]=3A##OT4XMEE?ZNS*>A.&][[;+X?%<4V^[*
MZ>XY3_2M;!8T"=KL*O)\G$4HAEX:>?'87.JG*=,=D=*-:%;'$9?3 W,F9&TV
MTV+CU$%Q'ME$SPB%? HGQIX6+3O%SAGADB;4#I62-Z-2W-'D]2>M[O-RLXB\
M" 91[(((MVV[. E!,C9(:4J8EFL5-#.3!@WH%*@0*YOB.J2!2#5*=(E#8UHT
M .%4(TY:[=4C7D,8%$F(&U9-^K"]*^IQV_M=F5^7ZWXV^TO1O\,1(!#X((RC
M,(UP^XO(]]*QS2R. %Y\+>KKBE68Y-KB&5*'L)A'5@]O=TO: 4#GMP$BIT!)
M4LNF4>8XY9,I"3*U*-59GLZ(E1I^[= K1;94.GJ@@&J];ZT^U6P", T]/Z'0
MBZ($IS"F=&H6XPSQY%/2C6G.JH:AM@>H2KJD^.50+U/4B@B8**OZ-.P,6Y=D
M3 71%BF9$G..B9DZGH1VX[IUL'Y5K"GJK\6[<E.\W1;WS0+ $/H$41J!A/C
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ML-/P:N]NKOKK3__VT\?J<=-/6C^7WSY6Y6:;E5^+CT7;B3;;'DZ0C'"H&R!
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M^5\W+<]1^'^+O&ZJ&]05S<>Q3T+H^7%(B)_Z?H2GS102A7[,>@&; 2B:=7/
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M1RW-]E6F>K-T=+NP2;QP(QQ#G&0P2^(0QUX8I=XNS&8>T]M"&ILW52CS5F6
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M<O&NN,W7=+,MM]_[Q>0D]*,HC",/9Z%/:>)'-!A; "%B>\Q(Y+NZ2R$Z.,Z
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MS=K\ $[O \1^A .>&A;A1K37I PXG+*'Q7NN1)0YMM(1(Z3QA;D])&? U-6
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MC[^/V:%E#B1GC6-X1',V^;DJU_F:X>#+ROU.)(.]+&J.FZ/*FT5,0I3B#.$
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MJTRQHZE/_6%A_I('#&(_=K(P(P%%28B'-AV<80,*)=C2A!JE6 1'BU<MG;)
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M;#Y>K4.WLJZ.P[0M57U/CTN?IEI.7?4]-EMM-6#:964UQ9_!<]X#@B_+8KU
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MUL24Q#)AJCG?A#KRFI$S,J)!WSQ41,> REA74EUP^E24^<=M_M LO"0(HS2
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M/JQ/;_N-[2IS2FW?2[8$^P@Y]^6 ?<;*_2;7F@*NY[_WH^.:=BK(N0EF1>I
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M"/TX2!.:(@>%$:1=<[Z#@RB5D0'E1BQKP@'7%2A[9&#90I-],$R513&U&(5
M.>DXYFX !=!Y[BP]#?8V-V=$19O.>2B,OAFO'@(SPHN\]G2G]A:)DR&*(]_-
M8M>)<(8QC(=F^&5(N?5NZ8^WOM!]0-05 585&5&Z9,7% D^JHM*=]YU*23HB
MA!1$DK.Y*8<L_).*H<2#O%(<'=E:D,P)G2R)J)_%B 11Z"*O;\OU8XA5Y4*F
MC3$U8]/C>E+5#2GR9,7#%FO*"O+I(EV65>2($2$I46%P;GJB9,-)45%G1'CE
M8W6?KW>;_/KV?$V&]CKT]_SG-F5V_^^"HM!),X>F,8UX0A2P;R2.Y\0)<8@+
M7:E%$CL0;*^G]*AY65N=XB6C>D5P;69ZAT@NX\CYHB_9 #ATT&(?>^E'B>!S
MJT1V/38/D;5MY,NUIS$XE9?I[OV(?/VQW+(A4+"VN\SS@"#-LC3 0<!:C3SJ
M>2ZO7=$A<,/8%;I\9:/=$049K==%OR3SL;RMZH?N@2=T4^VVX&#!<*ERL$U5
MI WX1%:9QW6'NAP/.-]@?3XJ?)%,(>DUYY*YZ:U!RTZ*K&GV1,Y$?,V;;;U;
M;7<U$_7^.1Y4KM'JG[NB:06D?R"L?5)BV(?(,A2Z)(R"T".!%\$0ISY&;NHF
M?@@SH8>ZK#5N66.?81Y>HFKOK!_!_G5X7:\%KG"%QXY;SBOL+#PB)[/OV1GB
MYT(F=XK:V1$KSA$Y6*+"UXG#)U:IG_Z BEWSJI&ZL.0\@G7C]C6>X=6D;_E=
M]TH]/W68X"3"01H@WPL2%*9IECA]FX&/HD!JYJ#5DNVY0H]%Z@2P(0X%,_W1
MZ)/,[069LY.QGR/E7(YNA,R99.5F;'F9AQMD2%B+NB;Z@WT1"B.??R"*W<A'
M3N+[<&@#,C&4TAZI3QY-:Z3.VRJR)*@NU@A259-+W-C1DV,:SNF'$ETST0LU
M["_U08,!H1=KB^J1)48/R[ZA/@E"T/?=./!\"M/(IUE$(]PW% 81%3J$I_'Q
MEI5ACPKTL!2F9ZK$79X-C\"9G%A,29?$J[7V:5-\M5:>/J%W:]^T]\2,4I.<
MZ>>,N@94QCJ*N+;^_O@_U7WYHA62$NI"W_-"Y&<T=FGB#:VDCBM\^4OELRVK
M:@=)0R.4^+JLI[:IDA/3:5@2EU';;*EIJ"QK(@+ZAJ4GU%.'D^FE4PM]9:9G
MB(EF4V\7N"J;:E.LV_[1UCYI9\*IAX((PQ@EF(1NX&,:#3/AT(V@T J9QL=;
MELYGJ+JZ/E(K9#K$G1?0D3B3TU %ND2FL<S6HRDL^]/+Z>MI,MX0#@/,3:L=
M)@RHC/4B'07I9\^QD]$$QHZ#"(TIA&D"PZ&ID/U$74,$&YA"1:36OO3H4U$2
M"\P9T!(3BV**:G)R3<P(?W-4%%D3SFJ*$A_"+W,.YQ"'Y=,^"Z)9"FD:01P%
M,/3<P"'[UB*:95(WUU7;L*PM>UA##JYZI5V90[$%]C'HDQ,8%>;L/*SY-C5G
MEM]UR9S'0KRV%2_?T#3"BJCF_'W)1FNQW'S-N;G%AI^"YD(W/.3D1Y"2.,SB
MS$$P3) ;'1KUH51=6<VFQMG. T?HAG"M)$2ZQ(KIT8B<*NT JM!I19W.$W5&
MI PQ/ ^M,F5,9:47RBG76Z>O%F$8X"@- QBY"732F'I>MF\J]*2J>R@U8%FE
MGA\_7+6@P(=5G:^+K>1=-#7^Q&3).G5R8O3FH<UQ]><M1LZHCA:!\] :/1,J
M@QU*3E>&DU*X>K@IRG;J]RU_7+*<+-\\?3U4LJV79;-<\1\W_8TQ?OCS4]6P
M+PZ_MO!\WW$S)G@T13"F<8#PL(0=(>H+%:&=")IE+?M2-5NPVE1-*V75 P?:
M+9/D'>BV/M_C\JF;U6PK@.IZ^03RA\=-]93G3?OSVV51@Q_+S:Z]EO18YS^*
M:M=LGL"N_,$Z3;X&S;9:_2^H'EL^Y#1R[+X@IJXS[@9RNCP8 HXLN0('6\ !
M)3BVY@H,]H!EN0:=14>_/*ZTFW7'F: PD=_G$4ZF,KZ:Q=B3+2MSRT"N^TKK
M7]B8.S3Y.=_^MBQ*CH3L\N_5MWR[W;1'A!MW00F)<.+3+,D0=/T@2E#,X'@I
M\1P_0E+3?6L@+(<E#@RP(-0<,(U=:$6-N#/*8=T7\] (^V:^JN@R"J^BX_Y+
MS4L9;)\XD"V3&_K/7?'(6T0W+'UF<K1@C4'JDCAU(M9L0F,GSOA=6R8V 28H
M$LQ ]!NREU0,V*Y BZ[-$/;XP!\#PI'7GRXR=F;TFF-['L/4H#V5K7YI:."1
MHN$SG%U]5$G$B4(/QBC"KN-A$H19%/@#!!;W8[GR;D:;EAF52E7?S@Y.N;F9
M6<XU=<\VV28E\( 5_#%9D0X9)E6D4<<A,U=)+=-$!5.?/_')RLU1:WNACOP@
M#%WL![Z3I!@&+LJ0PUI&"8H<-Q:OXZCTZ?;&)@?T; A.E)"\3<S9.806D_,8
M5+I&O,K_#7 B7RLL*\IBFW\J?KQ15H?77EJ$,:0H<E.:(3^#D.%Q80\@"=-8
ML528=K.VM_"/ZE-U6']MP9ZL425[9=>@ \34:R+N);?ZS=%NN1[8)1+/J)\%
M3\Q#$6T8=K(8F&'NA ]6\D*/>%?7++$Y*KW;'T]P0@P=-X0DBSPORPCA9\2[
M-F'J4J%SVV9:LGW(LBVANNK0[:MN%Y.]E'.6K'/G!HV0/(_A9\B6EV<(#3(D
M<B>"32/6N]7VNOZ6US^*5=Y5%Z$A'[MQEB1!0(CKIBGMFT%NZ(6B]R&4/MSV
MWG6'J9U9]["D;U2ID78^<1B%+^G%"%FJC-U_>(N*-X1%F[7I[SWHP:\,]1YI
MQ>";HGU#P]V*S,,H\7%"W8#0U(&)0[.A+09#Z,",7@M3:(?T/2H- H4EQ#)W
M!G1DM)M4)QDY+R<:#,Y&4W1L>"TLVHR(E,;X^].FVB[KNS[A@6G(YA$1]>+$
M3TB61>S_0P.,%*';W0H?:UE'!C0*11YD^3FO&):ID9.)$5D1KWIAD1VU@A?B
M+(F4NGANWAN*J,'!] 4N5(%7VOZ7J+-6-;M-<=M_OD\"[,<P\%V4II&7I9C)
M:O?Y*?52H11*_E,MRUT/1J4XF!PYE\7.'B]R6C<:)1)ETJQ1HU@=390BH9IH
MQ\:=D#DU J97.47<E:[K)30N;QZKLED.#?C8]1"%6<I/T%$FH=0=&L@"(K2\
MI/"QME6N1Z,RIB7Y$= Y>]1("MUXK$A(G3UV%+5.F"4AL7MFWBFU4^-@!G*G
M"+S2]K_<UA7=\1,ZR_+WDO6$OJ7,25,W@!"2+*9QG"$G=/J6, D0E3M J-*"
M3%]6.B=(?U>\=J_$UWDE'(LH.4D<T( 6SD0[>&]0<F;?3H? >>S6:5E0F>M.
M<AIR9M?]4U'F[57]A4<SU_5#$K,&2>B$81;Z0],9^X',+KB1!BTG6I=.JG"@
M7<4*204RP[:8)(U.M)Q&F>#8BFZ)\'9&R(S2/@]E,VM29;&;2CT#F+/?NU^6
M:Y+_R#=5=Q6DKAF"]B(6NKNK\[OE-O_273*_OMD4=VW._3VO'Q:AAP,2!QG*
M,B]TTR1-H;=78S^1>1'0*@[+2CG ;W?>U@<#P/)@P158#C8,-_9!M;?B"K!F
M'Z3>IK/KN,M3WSGY3$YTG[GK"#M Q^[:PP<]?G!]Y*[O\W*7U*N"LW&;\@.#
M=MTG^-B@#HTG%@O&<L[TJPNC65J-W_5'B;^+./("B*@7T-C%-(4)A<$^&\B0
M\!:630R6X^YAC"\?JAT/J+?@;K=DR+<YRZ=OBY_LG\NRW"TWSZKDW.3@8;G.
M05$"UE7+O*U" ?XLMO>@%@CEH^C^9?]:#=%&73MV>)Z)@T8)RD8=-55 GBH4
MFP_#PNYXUR%8W$HSX5>250/+?I_S[0)1!T+/IQA'04J]S/-1W#=*TCB5>A18
MLZEQEOHV[3)4<5B&6K8 KT"92Y8>T&56>W'/-*DFE_6NP.<S?(Z]G,>PJ"WD
MR5 \^R4\*6/$%^_D.3(R;1AN-#VENZ=JMT5M=KQ((A_&*4G2*/$QQ&[LD6'O
MA&0N%'Y3U%+SEC7NT^[A$32[A_WJ&Z^-.5SQ>P(W+52#F:.B#PQD]?;IMY'0
M[U&##C;+&%O@T[O$8!YOWS4V4WAI%QE)W]_D3#5SUW/ .TC:-0V4R==-<&DD
MW/$J@AFC:0^(_N3/@^R*YI[_>!%[7N1Z%#LHH#Y#11("]Q$8XT#L.- H4*R?
M&_I<E;^NELT]N.-5/'GGZD,?V!XJLAK47&W?& B(8SK%1FAL"ZYR XX4^+D)
M<W*8P7 YIN-L!DX-!QH)H1=X5 VFIMSS#L*J,5-E JQ9?D4NG7\OMKP*S<=R
M7?PHUKOEIKW<[OE^0A$F),L0@@D.(:91 EU*(>N(H=#S>NJ?;GE>V(+B.T<'
M6-*%*A1I.Q_:QF%,+EXID&7L@OF;7+PA7?J\37^Q7!-_9:H':2C'?Q?;^Z_Y
MI@VGS7WQ^+VBY99I6'^E'64T\>(,HYA$61 3E$#4(V _\H3?$S?=[A1J(UW:
MPCC9"DHT(L\&-&JT,AB2/(GJER&V9ZALIBP[IWE&V1-1P[1:UNOK6U+4^8HQ
MW>#[95$_+(=;#+X;.UZ&'4)HX#@HBQ+7&QJ,:"1<P4>S&<M:UZ+C W&/#PP
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M!>Y$Y?-+7:WR?-WP0O6\R>O;ER .\#C8!2(H0!%,$':#+'#"!$?)7L7C3.H
M@O'&+4OI@+=[>*65TNH6+"\*K)R6FG>)F*).Z@TY77WNB&^](P34=EQYE67T
MC,A:<\X\I-:>>=5(G5Q:=A_S>OOTA77K+2K7_/!9^W[(]_SG-F7,_.\"ADE*
MW,1U<<2$/R".#]/$\9PX]+(XBZ3N\AMHSK*T?EO=Y^M=-X[Y";ZJ;/<_V9\&
M[&QBR=&W3_7L\4LKJS;KPEHZ)N'2ZGF:4?#'=SX8  <*6J0C;_=<INZ\3)KB
M?3;":,R@UU)HEBOA$Z[#"=KNE5W6]/!$4KM!M6QV=;Z^+K]R(:Z+\H[]PN>J
MK(<_ILNF:/C?;[?)O^>K^[+XYRYOVGZ[2!%-4R>C?D)#ZB _P#&E/@RSP(/\
M8KO4 =DI@=H^7[L_QP]Z2]K1_[%\W#'=Y9*P1PX.T'MUD-PRG];A8HK];GPM
MI_66W&SGB+5%%YP[H3T'S\\CVLR#BI?GPV<!2BW"I4_[+_]6Y#5_+_#I$W\M
ML#V9ZCC$01E,*4Q8?*5.%..H;YR'6:D#5X::'"_J[,&U*O09_4/I3+HIIB6#
MQ'@D*\N]-+]V-?TL8R+J;(;RF>FL(:-.*:9)SJ2U[RC?:%[#Z!_OBI +W0B3
M.*+8\0,OCD,\8 @B7^X^F]&6)U5"I?/SAIF7E,3123>IC),<LY>B3D0BC;I@
M9DIIUK93@FF!06G=[.9FK4R[PV-B(4S<,"70CV 2TX#]+QA:)-2!2BJIT(YE
M36RQ %?Q8+X6@9)B9YD[56F[ZB?V5T"82KO*]IHG$1W38'=FJJ5CR2F-TF9'
M1Y&\OD4W\'V8I33)O##A=P8P@4.+<2A6<M-$.Z,HDF=0D80)5%<D&]R94B0!
M*D=3)$])D639G:\B25LBH$AJ[.@HDM^W")$71S[V_,!!@4M0F'K[V:SC8*2K
M2*+MC*)(OD%%$B9079%L<&=*D02H'$V1?"5%DF5WOHHD;8F (JFQ,_%>]J>B
MS#]N\X=F03WBQDX:!"2E"#H1)%'2P\8ICJ0.K4\.=J9[VMP T%HPCXUM">]/
MNKEMQ_'C;'"+^/P][7+O?3'^3K=\-YA9!)J<CG%VO%7])!P+B[+8YI^*'_GZ
M8[EE@[2XV?0F["TB1;/:5-R !?)(A#S*J[G%*2*$PB3L01#JP5 JLIEMVG*<
M.D $RQ;C?_Y'XKGN?_7_(CQMJ1[S-=ARWU6;ZNX)U,7=_5;R)H%IAP@&F^E\
M(1DZ6J"_;CA2<.23#NO54:E;<, [<K"0XO*<]-MQRDR$W))Q+V79)H?B=>?6
M^>UI(/3G:K-;LR#P6U6M_RPVF[>0I1F$B0<#[(1QDB;8R3QG0!9#@N4*T]G'
M,ZT<?_SR]3^7#X__162KV8W@*#%%GIN/Y&3Z@/Z45(,/>Q/ 8,,OL]!O \R?
M$?4Q_3H/I1_5XE?%^L9F6^2!&)%(A#')4!9D:9CX+HT=A&&PCT0D=A9;_L#Z
M>;TWU9:4EN]A"8M%^U2\^ L81M@[+\)3$"<KL)JIKQU:Q1\"&9M>M8<[3,\P
MWGQ70VV68)K$Z=^M,&I-9:>K22;^#X^L+=[MKF\OQIZ%%R2(AEZ"28(IC'V,
M]R="2)RPT?4CKV\JX23?:-LR0^T8IOA(V\.53-G-4BR8G$_&K624V./DM[+%
M<O"1DVT9)L^EU58\,I,$VHYM+U-EBPR*ZB6N'AZ*KHPZ*M?\51'69EZN>&&'
MO5:CFZ9];&21>K'OA1EBRAUE"&*70A13AR9A%#NN+UK[U&RC]@;S$<YVC^P9
MTJ-<!/PQ@!UYETR*R#-CV8Y#YC&6+=E6C=&EY<8RKR_XK.7N\F;LNR'&+O%1
MXF-"0B=VX-"8GT"I(U^*3=@^[<7K\CT?G$HW\%4)%%.]$;B3DS<%VJRHV-O$
MG)$K32;GH4NZ1E1&>Y>FTAPVS3/V^9$;QI'G1G%"/-<-O+Y!! ,2::F->#,3
M*,XGU?-1.FPJ2H\=(O7E1X3#<33HD\!)(0.TSE2+% RYI$>JW(AK4GGW/:\?
MOK#N=K]L\D-&AAZJ7;E=1"0F,/!AYL$,Q4D6)UXZ-)O!5.IZH'9CUO6IO/N5
M_;T'\-@C!*L]Q"NP;$'*JI0NOZ):-2*ULHHUL#J  _B(572>54NZ=9ZML^IE
MB.BY:)@I<UXIF5&>1+8KO^9-SN]2+\MU?\RM;>[P3C.ZNZO;UR#Z1YJO;S;%
M7;<%1$CB$QI3CTFL[R(?QM@=T.#0(6)KVK916%_='L"#Y0'O%;@M?N9K\-@_
M]%[M\6KM)FGP=&*7:0SFI]]]&L7*:MS^+)>SI+N&944\47JX*<JVI7W.M&5?
M-06CO_WV<+3Y:0&3-'!)%OLPQ6[D09R&PXPNA3"+Y/:L;""P/K;;#>$?[89P
M=<L2FP$O__( >-Q K$#DF=ALTRWS"-=6+:S&Z^36!SS>U37[X2+T28(CC&.8
M1 ',@C@(Z0 H<RB1F;Y8A&%Y8H-/#':P&8!>@54'56YZ8],S8A.?F3A%;DHT
M@ 9'J*_ D9>> ;\"GPYNPA?<-!>9[G&:56M9S[U;T98V5%^[U;BU*.&?&;L]
MIB0.B4L\"DD$4S=.'$SB 9-+ ]>RBDL@F8&0EWNTUK5<QD76Y-R2=T93],^7
M_34743] -:OK"BY\M]*N8JN^NBLS+'YW;%4]Y-^7/^G/Y4,/JMM,C:(TB0D.
M88JRA"9Q'(;M0P\1]H+ #7S)XZ+*[=@_&MI" PP;. *G=JA"@TXQH1V'1SD1
M5230TNVJ$_R<.]RIS>D\5,V ':_N-YEA1D>-#ENI+D7(=V*7DB!*G<2-HB#L
MVXP(BJ3V-/5:LIPNGAI0(@<&;/"J+DUV*#4C3R)LCJ91>Z(D=4J>X/EJE8(M
M GJERI#(UB7);W.6G:U9BWU=EJ:I5@5_N/Z_B^W][[P 2W57\@=;V:^D>9G?
M%MOF^K%-\\J[]MC(LJZ?;JOZSV6]YH=IV:<5V^-O+C!$L9_$+O8CY(:!$Y-X
MD%J6 *9"=55G ]:R<G[-U[M5.[P9(+ [,@ELV?B_Z8P2O[4X"\X$;I/. J<]
M"1_,:T6\OUQTL!!P$\&QC>WO#59>@;V=H#N&=V040/RJ0VOKL^^_MRXB?C-V
M%GAENHK:U=H9=1F18Q5C>.7$^8M9=8CI#VK,BXYJI@-7;EYW!/VH;-V".FD<
MA0GR2.QYKA_"+'"'QI 32QV?5VS"<C[R.=^"]:!$/ /9+_C+3>!4"12;N8W
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MYVR;3@-^M,#EM'.F- I*\TS1VU/^UII?;[@YX-AD<&0SN'D"Q[_7VPU:PZ]
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M$SINBGAT[I%Q)V1.CH#Y54X2=S75]?P:]PM;/G^Y+>K\OBS&4V22$2^E,(P
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M>E*^ZC1#.5G&>Y\H]+%0FO'ULE%?A?=F/A5W>=F^EXNK3=?M8)>OOQ3UG;>
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MED[C*B-3ES^J9?_8E=N'S\5R5Y?;LFCH;^_?LI74MB[;75&\JVN&9P&)%[H
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M011Q-O^FB"I#*N7S2:;9\&&87\MUT6RK3?%K_KV\V]WUUQ-0E%$/!BFB'@X
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MN-ZMWY5,@>,XBC!(7) Q4:590#.0#$-C$D*A!KY*!C2C<.ON.7QZ3^"5L^N
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MHIY[:/0Q?$;';?"K'=' "B:>7I]C R8%D>E]?E<, 3$,$I"E7A9&/DB#A&#
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MN8=!V%<2 *E/,S]#%*>!F^Q3*8]D2.29%_QJS<_]B*:1?/A%B>(3 (T<B8G
M"&0F(7C,PQDQD"3,#D&0!5\IF31BPO!KOKPM-T7]<)Q^#"/&E#(_QC1+TR3!
M40C<!.\77 &(151BRCB:)6,/K<O"B\/FJY2 3"*43TU,<2DF+8]IS/AIU*(T
M9S@Z(SLJF+5#@Y184JF?=V+J1'?UIMSNZH*-2,OO[4_-,&":PBBA$,?$2S#U
ML(?W<D@(3#P1<9HPC&9MVB.[<JX'8-WC56UOBUI2H::0RB=0AO@4TZ<]J([
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MFU/EX]%H2>^Y/ACMC3GR:=-^N#7(.;+(HG"DP"-<X<BDYVT+1T9M/QF.S'N
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M"2M/R88Q5D4*MG__<-WK#XRH&SJ)DX89#AV$LR >*AZAYR?"F^#%/]%PCLB
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MURBW%?H19UYT^D)L=C(')XP+L,=O<[WJEC;!3[\-?B+GYHKF3[V(4RQZZ,6
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M8HU&J]4VUFEF7>0(($?65@\BR-Z>BJ AP2Y*W="G7@S]@(7&80-@XI,H%3T
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M(8L_$25.%L(HH,-I2Y0$%)I3?$5 IK<K=XCXCH?"BN2KNL6$ZEOPB 7AYU:
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M:O-<\&V2'_C%49NF7/XC7S\57ZKUFE8U_XB%&P8X<D(O(D$4):D3(1C'CN=
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M1'61M_\Q?RC0][)9P,R#R*611PCQ8O9?%\+,CW",21HB5VI[BM0'&Z[Z<"R
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M\SZ/-%2W4971OBHG?,/BZ'51/Y?+XGT(7_/O:;$I;LN6,G+> T=\&F11AIP
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MV_*QZDWY9U'>W;/_(C;MR>^*7]E'MR1O"YJ7]3_R]5-Q<-/<(G:S"+F4Q$Y
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M-:]OIM'(DNBP;'<H_586+%'@LL]?%>.[*88B+R8H\I,X=-W 9RH0QEYL#UI
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M@]B\ 3L^MK ?^3T8X@0D$GUMTB $TT7G'LY%$9B4]O-5B 4Q+E>D&$ #<OR
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M%XE)T'A&+(UX8QFZ:<:TES>-F>-/GYK^EK$DM440>Q8*K00GR U";-L0>G!
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MF 0QC"TO\88$RK:10U=?L^JV%-GSN "P,B/SV"[Q =K9!9Y8>.@OV]\RL[O
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M>FT[I9D&&)163W[71AR&86+;R$<VCFG $D\?#DU8"?%E;L*0^F I[9._"F/
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M)/3O_%QA? 3=M' ^R?&$P#YQV\Z8ME4Q^D+*GCU8RZ;K^=VM%WHI^$9O]&@
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M;!*N7)]PQ4V=P,TR/XA3Z*:>8\5HVA_OI3[,%'8-+.J' 2T$1Z5!NZ>"9R+
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MF[+MFO+KCF3&K&Z*\J;">5/1(VU7MA]CC*P(94%H91B'<>COIP01$N]Q5@5
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M??-AWI8M_%&V*QC#-(OMR$9.ZB4N2A'N)^A#QXD=&W+-;<O:TCPG<X0)]*#
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MR*M^;+3KVDHI(0@C1@0AE D(8)SL!T8X#53#AGD+CB-%#<QKD>T']SL#N1I
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MF_U^'[+'^I_WVX_Y,B_NJ@5/*&>)GP3$CT#  Q^!?LTP$Q J[<)SB\"UG!]
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M[?>LO+TM-E_7^4K<;U:[#D\"$^I'%$>^C(MA%$EH08='8 13>]%I" K'P>H
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MFX.8F8%\#L-?VNHCFMN,R:8JBLUUOJR*A_V9JC",<"I2Q",?10 B'/IIWU8
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M?[)C99: ABB) 5.7%=@M27JR.SX_ZO+JEB<S3=7C2T5&?[#RA'::LS&]8 [
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MY9CY?IU5^>HLO)+F!U/>/^3;=Q*K*'9RV/1?>;9]!A\R/X*$A7Y,$HQ3C%G
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M+]?O\JI?;=0%F7J@]JZL_BNO#A"?3YP3E"8)\!,?A#!B3"3H,%6$X\1,M9U
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M?)3B?18-F*MR@#J ,90U<*6LZC3;5E8G_#I75HEZWLK:TVI%6;5]]-J45=]
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M[!U#GG!.Y3R7JE,MECPR#\5U8MFYB1FK[*D,=M[>WK4EU?UEJ?LEN;(%""/
M(UI?/<V9P)STC24Q]%7G8P8TX;JT\P39"SF2_$/YT\VN7!>KYE7=R8]VIP9*
MP6QS)RF]WG6Y7I??5%?\#R7^\H3,2)SK:>(SNINPH[#&WRIUZI,E(U%H-AEB
M2*7*"/NTW2=&TQ:(FG[D;,.(TFKG&:+ANX7/PH3 ,*98P"!(ZZ72J&]%H'"
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M"J>2_$)[&&+#WT_&XOI"5*ZS,ZD^W:;9(J>"3K,L_2??K*DOSN'*.I.CT@[
MX8+=M2_W0]C@4XSPJR[8RJ19H_96)'TSB?,SA"3'\,UL,9K=).'3QE[Y/4TG
M_R330Z=\1];29\O=M_MX'*9@-9LM"RL]6R3_+LX'\E]F\XH#6$=OZQ.)0+MD
M$;\- VYHWN3-;!)?/W[SLERKJ#1Y\V 1.G)]T&<3^L2L_'>K*.RHM$^Y7OYT
M%6?CW&7M)OYP70S6CP^TRX &+^X3GR,-P(:U]BE9)4.D5EWM2#&;+[,BSMR!
M%KY\KJ6W?PV"I]EAG^<M3[;=@HK4VUF@[?948\ZNYUMI3;$>6?DIV7BR+)Q&
MYN_CQ8%&'2K6:=NJJ;%BZ4Y;NIEPM][U45_2Y2*_UY%DN\R:FC*V]MX3HM-,
MRT?5W9.4.;XVF=^G\]%T7EAKFZ7:FUF];<9N7]H/+@=",#2&H&K]?4F[U15M
MW)[*J[^A'XGK+16;5MN;;$6 R]4S1^T0M%)W7U(>N6/5H,9^)/J8/HRFBX?R
MD59DVE=GIU)5,B.K%6ZEG5?YY8CBHM95.E]D\2+8&;FJ=3R+KY/%U714G'C9
M?*LB+@:HPCDP%"E^.B!(2[4/0=*U#T"Y"?@YU?%Z"["PR]*@GK":3])),E[7
MF%]IJ]@'!]&V :'\,1ZG-[-5\P_&,SYF8!A*\P:!=;"S'XHKF^8VM[-"2Y]<
MUGPRZA?^"Y,_\^@A3Q[X<Y9^F<?9U]4NR?VR+ZYWW.HA:*87( <H=SF K4)+
ME#<JCUYG]MR*(2!WY(%%1V\;!!++V61ULV_Y;)S>>4NZ'\0:MFH(R/X1!Y/Y
M=CS*BLOZG[-X-OD8VAU6=,N[^R.N@/7=C"%@5Y[X?QYE-_&B6 2KZ72=/6?^
ML9C(\KJ?G <]\5?-JSABIW&0;1V"%HX\U^KH;4- XL.7:7*S4FAXZNGHU LT
ME5\_"*QF\2/7K](DMS+'61ZTY$-FX]6G-[,=PU(_<+;8PB$@OBY>?'XS<]_&
M\7S^>F3I&-0C&S$(W'I&:,A85-IH:_4=0Y#ZKSBYN<U]U+[&61@+U'BQ'&6K
M2PJ]&FG'MZ,=]++T/LX6#WD;\B"F^9E9$=#TD+2'RG7;NHHJJ5B\V[96ZU?5
M2K?2TH]Q[F@;")9?K3&WN=&ZB5E:;',&SJ7C)%]A_94L;I^&C2B.W.:+C^4>
M>VAV\>EKDA\-A&<*\^V0L/TUX$SP>K*Y?'+HMK3EG%!\L=,R##AW-.I,<'VQ
M+#LYI#O:<R9H/GO#\Q#1)T>V0MO.&>6AC0W'-/),<*]D[/3=C%:P^Q3?Y/;8
M[W%ZDXWN;XMP1D6+/\9?X]GR:3CF ^+7J*EO"2IUD-KU]2W-<?V^><5]RY?O
M/Z\NR11["_KAL=#'^*8#=1[YPK[Q.,Y@:5YQW_*MOWF&N\KB4=OB5GO/4*3O
MK)<?^<+3X;&>##L$8/L;^I:XDI%1N[YVI,G#_NG1/)Y<C1ZJ1%#;7:"C]MC1
M8K0)R*&FTZLX*P I#M3SJ(;_C++)_&H^JKC_V>(;^I(XS1;7Z31)7S9LO@[X
M]-":Y,>^J2<$"D,\&1>!G=/QWW\& _IY@QI+7OD-/4E<M.)#L9_>LJ0':^Y)
MPG7LA$W4T8]Q6&?-<N!;Z\C57]&1S.MT0;/W\>*IL^C1@AVHIZ/6'VF>5BW?
M46L_+!?S/"%36*KOT7O3$;/16SJ2?/=\U53:HVON7<(C'7_:J+I[&?<PJTUY
M:[RF*]D[LW"&8M'L;D=SC1Y==4<RMF^EG=HJ:\\*.Y75]>2]C8E6H:Z.I*BV
MD#Y0K*NV=6=L#,;"Z')"&LXLE/LYKT(S//HR?;A^POJ*&U:-*^Y5OH.+I);$
MK?R>5J3_//KV;K18'$Z8\OK!EM^?)SG*LK B'7VK>HFG6N$NVWGDK:,C:VFY
MY:LEL<_2NU68A658G'VX7^<3FNLX&$7Q599^3>;%45A6M.W#[)C;I=V\K&4<
MCAR*#Q=LN7VMZ>!$^.Y\;6W@CZZQ98GR"VNS<3)-"O9^N/X]2^=%5.SR'EMX
M=.T7?/1(T*#N$TI9>^!KXR4MRUW):M[U>.MM^99?27F.TK$85ZFD_787O7(1
MWP4;YG4<@%5WS:,!U!"F7LVU)/SV)9O^FF8WOR$ Y$K(67R3[Y2_'7V)7]AX
MV\I-L^Q9L5_RBGZ!Z!?("L&VU=9R2]_'BW8;^[+"EMN[BLSA9BU#O+W:3MK^
M:3'*6L9\5\4MM_]SZ&%QNRU_767;;2YRIK?;YE=5MM?F&L18O&YF11;</\D]
M_S9\L7X^KW?O2'XPB(O[-IXN\^.</!U ?MDIG8::;\JP7R]&W?C;(LZOM/Z<
MMZQLVS0=;P.A .!Z-/]2H+"<_W(S&MW_EL\&O\73Q;S\II@??@'PE_4,L?XZ
M6D4%5%_FBVPTWEQ7FN9H_>OG\,IH^X.11=98Y252PGO/M%;."H  %T 3#^ES
M@8K;WVFVQKI;B;9,;^^#%?0Y@*K#&__>(^.AHI%77C#'&3.$ DR] %244GN*
M=!6IGW),9>.?TFP29__Z&?[\4_AEM:Q]NVK:CJZ!5YQ;O!HH1MGX%5.?%UP_
M\=M]D5O[E_%M,IV4I:_#8K,=E:>=HAID*/OL;UL[[0"Z\U9;Z@QZM7.>$F&]
MDX($[ 7T #@LJ<?:A[\K\;L;B?:JY-&(+587>^0]IIJ("PD\QEX2[R7SBCIE
M2C1,P.BB>WME*J2](?S8\SOFVK-$F._C?X),>=RVT,.OLG06/HY70675MV2^
MCVS'U!,)Q2$RT'!  -'0 J_6@!N C!*7Q;9N:/*2BQTJH"\R?@YO^W"M)FEQ
MPO$NOOL29WLXM^WQ2%-+-(;00.H\L$$ZL9%,$7YA UE'6D];![JW\6PC_Z?<
MJ2SW//KS/@\9%IYG ![D5*7R$8+"J] ;/9;<"A;TAE@I.[#FPFSC9NI_/6>V
M#O 0R!6,^$;DVI2/K'3>T? WY090J#VS;BT[=%J2!N1"WS&YZ@+<%[GRF%[%
M6+TR3G,C(9U5L+SVEHL8EP8A)R *, JB#">\E%5A!BZ+3+U86FT"WA>Y7C35
MIG>C9+:'5%N?CS@)ZR&/ !/8<RP II9M9*,47]:TUY*>T_:1[7&^.]2=JLQY
MU>J(K'56&PW#L*P=I,@(CDH,,&&\3W9]C;,O:2^;$+69</Q>1"V<3\"US]EH
M-I^N=+A9WQQ#M#T51,Q#BXA$ E, $5<8\K+?(@9<$^MJ@&-8!ZS8S;OV8#\!
MZ?)\];EM\#Y>E&',_X@G-_%5@?,Q[*M24X0"R@!P%?"FE"FO&=S@88EH,MB=
MIUW6'@T[P/\$? RMSWV=1M-5\/,R54,IW#&$K%15!#$""#@CF%;<8R>,4B4B
M1'C;@)'X.V=D%PHX 277 4R?A37=C/.%C*,RDTX=FM:N/D)0 X.TQ1(Z!PBW
M0KL-<IZJ!M0EWSEU^U+* .E\E25I]BG.OB;C(@JX"11(CK($FKPA<DP!":%1
MP"'(O'<:;88#P$T34M,?I.Y++P-:JN=]\VV0N_"/;>XWL*DJ<@:IT*$I,("R
MH!')[,:6HE T65*=I^70PFENMSKHC94?S!NU6(4[S_'XG*Z,\-#'/ESGON?I
M=.K3+ \0L(^0U6N)O#'<,P*H"O:]P!9@!-<XA/_R)E;L>2[O:]+D)1\[4T%_
MQROI^._5/<GY:N=M[YG*RX<C((F00AD(@7=..:-@.>QCRDVO^T;W.SR^6Z=7
M%UI_=9K2$.J^"+2O@Y6 Y($C<MUNP6P/VQK6'"DA.03( L<%< (#1\M.C272
M35Q>CMY+ZF/CO ]:]JN3OCAL5K-%D,9=7\?C(,8+EZ%D-D[N\VR?JTLECP?S
M^SS):U<:(265]$PCK)'CS@@@;8F2E:K)+N@0+<<>>-N;,LYEWM8.0T,Q,X!8
MRVF80/@&2*U!$U?3H_>&[K?>,SM'FC4&^AQN-NR_5'P.5QPHI1I@ @4-%I2S
MQ @(F1,(6F>D0*>[XO!I?!M/EM/XP_6JR>_BQ6WZ9&O\X.6&:A5$""E,J=70
MRC A2P"1P9!#224DD+(+\UBIJ_Z7G;L+;&O.%_-L\815X:^7C I?'6SPZV_C
M^/WH+M[A6=>TR@@S;H#P7".&",?>T3"LYLAH#+VE%^9CT#9=TI-HH4M^[FKF
M3C>\PX4B1QR4"$GF";3,<@ 464L7@(87<L^A/Q*D'2%_F%>O(EJ$+Z+?/_UG
MGN]\>1=GC[EH=YX]'2@1.>&H]RZ89CK, DHIQ.RJR=)#X,WED*4MW:5= -O;
MFNG0B%SE&*AZ)1&PAA*,J*">08"EL=2LA_: #FAB90W0F:FC^:YSW$^]41K6
MG'%R,S/+H,O9^*'P%AP5J;S4;+OOX-Z-MNV+MAK;K+VT*T),0F"AT((&]7OC
ME.>E,4Z#?7X90W"7)*ZX0SM$=9ZZZ^6['?5QJ7ET4?^%$<BO93F@+/-*4Z>M
M [[@A-+20.2^LPFEN\[2JY[.8<]O?YC(,]CS$UQK"\,8I("&P0R5@+#UP)1O
MS58R]4_JHM1J6!/LB1$>!ZO<,,\(%,"1-1I<.'0AJ^2F5&@2UN0XA,_[,BV"
M%!/GPZ@'PN(. N,H*F651EW8;G(W-#CJ,NUQ@)_795I)!!4,$F(I1)( SF!I
M07)OT87LR;2LYTJ7:8]#]O+OFH6A7DOLJ+;*A56+<)24?5, P?UE,:TA)QK>
M*SL.ZP'>>CC9)1[#I<P/*(/-PK&&!$CN2^2$:714.\ U7V<L[4L! Z3NB2_L
M$"F<A4%A3C.*J$9*FS5^$EG3A, #=&8[&8%;U,'W<#G'2X<E )H1+9&AEDGH
M2D0XI=]S *"Z:Y:.==";,_!3(Z:<"SZG.L\&,1W-Y\EU$D_^2A:WR>SS/_'T
M:_PNG2UN]Y&S9HV1@1@++9G%"#E&)&- ;_ !$EZ6@=H=?5[Z O>BCG/8U=V6
MB.4,]G(9#298?G8LD:1$AOF+FB)8.")6&5II][)K#X-C1MPJ<>D;UAR18']@
M8U58=AEI,$/,EY@Y#>&%;:O4)<Q.GX,^0.]EQ C S)-5)L@D/TA+%LM0UXX#
M-C6;J/D\+CZ\349?DFDH&L__B*<3'XS-T31^&ZS-@,'L1F79:'83E\4^AO8%
M>6[#1QM_C:?I??Y+^,N$(6CT)5T=)CTM5&,4VNHAII>A.?%\'C3T)9F-UJ+.
MQZL<>D%]FQ1Z>=N2^7TZ'TU_S]+E_7QGV\*3NQ#:/7B=KC&1=UI1I:%$0(+<
MJ4829QQSX1^/!*KEX'X,V$_$"'UC-05M%WNGE"L11SEAYHM7DN:53=-YH.Z^
ML7-@+8P ]-!Z9#R5*@Q"/)@LJ%0+ (9=QAA\#KQ/+X$@W_=\D7]^T$EZ?SO*
M[D9!1_4]$W[,(SOZDZ06($6L(-00"0-$UEL!L($@OXQ^0J>)1\NLA.8I5?7#
MD[^J7YFJ5E6$<+ FP_)/.^$QA+G7 %^C @GT%W)N= ZTVVFN=Z+)OC:@WH0!
MZSJ9)8LP6G[- ^,M GA):.]J;-4/[T;_G68FWZHXX+9Q9$T1T)98[B0AR@O)
M'*0.K/'(;T%7RN@V?&9W3Y>T3S4,A):/,NR]PM6@MDA"HBE7NO"&L%!+XV6)
M"V7B0@;>SEES'#M;T$1_#+W*TG'HQ]NMR8,GGI7*1P(9:0D%CDGM+;#8LPW.
MA#8*47Q^+&S&CE=,;!__OKCWN+"YR>*5I7.0;SO+1,@$[+" H1\3C01D!I4S
M#=**]1JZZ+(XUA;F->^O;GG]YWA\.TNGZ<W#FUF5T:I.-5$P5(QTQ@LO.#&:
M0&O96CA,7;5<O>?CA-$'H7I00WL<6[<D3RU>-N]8?NVL(C*>"VTD)L'(<%Q*
M03 JA;*^D8// ,-,GY!;;:F@KSG1M[*(/:*6B#MO!5/!X(66.(:%"#ULC8.L
M>#)\/O-F;PO8[E0P "H>N7 ]LJ:($B<DL4)9@XS"H?<+4^+!72-3;H#+A4Z8
M4IV-+6B@+T9N&<P_)C>W%98-!TI&D%*N(<7,$F:I$)0[O9:7" ^;W!(^+\8U
M8T/:)>I]L6S+Q'!@NMU1(O)(8D>P\EQQ&I;<GL-R4YY !B\L#TYO4VL[<)^2
M3OG'8*$>G#@/EHTD54R1(*@//8E#BS@I,22>N L+4M]8\Q68U 3?FJO/XEQ^
M[^+RR1,1)[EXDDI P@*862TL+)LDN;T0EY@.5)2V@6=_&_.Y@^3FKNO;7(V'
M9Z(]I2+ .-50>L(]- X X%R)$W5$-CD*&N">0X\GE6U!?F)J53A_W%,N4C2,
MO4Q K8Q64D&DN"IEM>;2AJ56M%Z-2;7PK3D3?8SGBVPY7BRS9'9C;D?935QX
MJ#UVEH]QX=&=^^?M7G;5K2H"2@/KE0H+ R>P)=2K<M>/(GQYQ]6M*#SM%?03
MVLUO*]QJW%<L@L:$KD@ ]8A+2!"@4I22$@EU WH-,!'>*1=D=3$_(;L^A>X2
M7V7)>)_GX]YR$40$Y-TT]")(*'3,L/*LBFIT:7X.[:C],)=J ]P7F:Y&#ZN#
MS'2]-"F%B.>_9^E\WW!UJ&@D)5=.L?!F'>36(BQSRQU?)@3H-;MW'QF9.B%5
MRR@/@%=%W,3\5N[ZEWU)#X^I)G*:><><(C2_>X>ATZCL84P%N^.R]BS[9EM3
MO/N>'I]XL7^* Z3!=)P^?(S'Z<TL#_OR),#GW'V[CV?SPMS,KW7&\\?'*LRG
M[;PH IYB*D,'%AP#K;7P;M./G95-1LL![G%T.@&?1",GY/=CF]], O;)=3+:
MG(J5O?7Y':WPV_+N]1%:<=GY\^UH]GN:3OY)IM/CZ-]=.R)I,0#(*<@XY%Q:
M&UA1ZB*L )MX'0UP^=-7[QB,POJ+0;02:L\Q\E]Q?LX;Y XFX^@F_G,>7R^G
M;Y/K_=%XZU<;,9F[A3%JB$9<2:OI9ND:IE/>9.!GWPFU>\3_O(?Y*MM/+;\Q
M0L)1R*G WDECL$/:(2N0%XAH:$"3C5'^W2P#AZ&<T_OO51J.JQ2/G%?".J"<
MDUXP! W$Y=DI,XHV\9L2W\FPVP'.?3&L@H&[,664!%H&XQ\IQIE'%HE@_J\D
MX$@TVAJ5WPE3:F)YCI.M7:OS\^C;DQ][FG>WOSQ2PB JL0726Q?49@$K^R#'
M%#3R2@;?"84'IZ9S[!QY9,(BP\[BR6]OT]G-YSB[L_&7?6$!>VU'Q+P%@2?,
M2DJI(L9A7F[^<&)]DXSI\'L[$!NBQK[S<$IY[)5_Q[-X//H12*GUB#;*Y/$?
MG<\3@8$P=$LCE7%*64<Y,[*2KT8W8_DI REQ:CTG@F HG3#>*DMXB0IDK(D'
MRX &U'.@7=- 2L=I<B 1:SH,I,2=$4A[PQ#%Q&LEA:-K/ 3B^,)<_[JC2\-
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MS:A%(J_D.JETDG.@9 084$)CA /-F:,8*U/N\1%C59,]]*.#!7V_YDPWVAH
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M7X=U3*".55&39^_C99;.QTD<!N-5.,>]?-KU>!2Z!$;,6 $Q=8XZ@$MK1#%
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MHF"D:!)#].AMBPNA7V?HGY:#?P8S()L^)+.;,OMBL#17D8>.IN*>NB**@(7
ML@" 0L ([D#IX,4PL$T\HP88V.MD?&Q/!:>EI4VN@T+CV3C6\>*?.)Z949;E
M8JU60VHV>2GIT6P]_A7!-.8*8^2]H@)1*0R1Y=$"0U+TFM3E@DG<N69:716[
M;^-X/M>C>9(OU;-%\N]]N;2.JB.B6G ("&18.&H1=U:7UT<YQ*91P.4!IG Y
MR6*X'>S[H-15G"7II UBK6J* ,3$>QNLE0"BP(!27+J1<BF;A9K_OHX8^M%
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MK66( 8X8Y%JK4C;"T<7>%S_YG-6&.OJBVFM\1MLA.1@H[\B:(F(E=@Q+2&!
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M'*+"^NH\I5![=K;_BO.MYR!WL-M&-WE&G.OE]&URO6]]TZ3:2!)K@+7<6@L
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ML"H4X0,2'IDU<LHY?G&9\;HFV,M@-_WKJ.<UT./L=<"$V/I\9!02TG)#,,,
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MB)+>2LT@) QC9 $$:YP$<>K"$A8/DH$O\\/WILV3V$7[)<D3[N:GB^%?^:G
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M"!H9R*#P(NI> "@45:5M)[U6,,?N'M!%_DY$G@OF&=TVR:5UNL>F:A4@$TP
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M8-5FM$@SZUE.?=:+-6[;X5VF*,Y,O'I)TX^U#3ABR"SGRL5M'UDC#=^,F4B
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MKJSW9%P-B-G\I4$KS+RF(!4TM<I+2'WEOV&4JAP_QQ!#WOHQ(/H018^KYUJ
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MB3.*0$$H< :8*LB'4L8N7%UKS) F"EL&[@-5V1JQ\J2WAFB,$VL<DXZDPAB
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M:ON#?<!T-)ME@KTL*W<O#13;%-0S7 I&I"><4+=?NH'+L0,'F,TZ#&JVPW[
M#'VSF-]T0=*']P;!J846.6G3I3$N@+'U>:>&CN3DC@PPA788/&T-?R]IC'$K
M>S?Y7/W\RXU3#E?U1%E5-W_[O/CVOVZKZ?T<B7]X.C7B7X7M#Y[(('SV3+
M X4<3\73F(V.G8L[D?+88J.A$8WJC!7Y=!?5O#Z1 _CLF>#26:"U&##D >6"
M<B1VGVX-RRHX/:!09X;*%F60ZZWR3%3#-BQA9I/5ZNVG#^O%S7_.M=L^-B8
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MG=5G?4!699=[1QZBG9J6?CJKCE9N.O18,$ RS0UDE#HB36KF"^J/]RBKB/Z
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M _I]-=LJ-A4+3XF547O5MI50>KP.X>D?AU[6))V^OX\(ED.E!--22A)-7*1
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M]5O\4A# ::F%QY93QQF"Z7)U<O4Q%=IEQ>7AKW>L>5WM7"\0<PF3N_[)5":
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M?N1TZ?E# 7/#O#8ZI;Y2(G#T&VG]8129D>7_ME;+HA" V9H]>OASZ+&@%>)
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M,1'*<4HAKL70WH*1W4Z[$@46W6JE$W*=C/%>,CQ88 PDJ=DSH8!KC!F M3"
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MGZS/)1N=&!F<P#9%>CADWG)MI8.U1<:X!SD7OBZ.Q_?1+B=;[P=X5 [?ZZQ
M9K)<_IC./ZN[Q69^JE#9J6$!2H29=0I[[M*JC:@&M:3.L9RTTHL#^"^5287
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M2(.O5)'/HF+ 7B/?MV&B;P R9;]@AHC$@'MIXC:^DP3&.9*3*S;X6A7Y%,F
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M(W@'N_,ZOLWK^P^S?Y<KLYBMUR>LIS/>$HQT'J;(0J\Q92CZG9)6.& !<C;
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M+EX=O(T3#SA@D$98"N"E.EBI#H"LL (P6;Y="/Y+KGN?BW3;%67*7?F.OR@
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M'(1D'0)]2:KMS\L?HCU;>)V-WQ8$Y1%PK1F@&G,K(:"DPD7KK!:,8[KO')2
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M'4K3_%:6UW_-%XM?OZM1+$,W.V3U ?%;GGY>JIN[*%.YG :'E&>])TC.M,(
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M\9].CN@/;PO: ^X@YBPZ)PP[Z:./LL=&R>B[3LNRZ8DWK<_JV^IAL#2(1\W
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MJS(=Q>P*%1V-8._R1X**:*02AQI IBB(P!M3 2.):W0V>H2#XJUP\.)J&:P
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ML$IVBU!.8=+7Q\(\=CQC8O?X#\6]P\:C[P]__'T>G:THQOW[),2I]HV-7A
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MK>^K&Y#?5N7=[3J^8G&7#B?3,]OB$G?%];Z=3-Q$SG.#>_J 0+D0S"L.)>'
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M?1*@EF,Y8+>]!9VEA/0/LTV$L[ZXP+,'@^',2<Z-,QJHZ 121RKC6Q@I<Q(
M1L^&EJHJ.P3T8IO6^P9A1,<'!0H0(\QRH^-&+)Q35AVD1(+F;$HCO,+I>U-J
MB^L%#MR*S6:QO9_:'U,W.W5[.BHP*6%*G@ V'6%+X@2MSK0%L61BH3I=*/SX
M 5PFN&.XQ'MZ#SG5FSL'N2"2.>,TPA9 1"U#S!(/?4H ;%14M5D6X"&,\2FT
MQV[D&HP*4'MD="HLX5STQ*)'9\3A\R.]IC5KN])EV1? 0RW_7^[^7!<WNROV
M>K?VR9/!4F/B:N0Y)!!RE0*W<"4/\WXB_:$[U>S3;A!9B%Z (2=]TV?/!B2
M@4Y KK'@U"(49U8E$P<^QY@<$4NR-7J<&:UP;.ML;O?V];_*U>+ZK_EU\3GB
M'E_UW18_BT6Y;6P95\L/Q77J9%[OC9[_IA"=,AJELDI:3:)_I3&!>Q&A E-K
ML)"AXG)(G(=:9H:O@L\YP8X8):C 5&@%&:KPAH+9B02"][F!]8?V"%C7<SE[
MI:4AA@D>)[O27#,(784']F^HU'A[IF26LS]/ X,E'NQ6[N+Z:W'U?5DNRIO[
MIE7MZT<&+Z7PQFH( #18*FZ!.>"*C7XSC,MCP]-,@4Y1?YTY]D!#0SB70&@G
M%8+$HLI=1DR8B50:&II97>$]%*?>+;>Y7NMU981&R_.1'7J27XW&!ZJEAD(Z
MH+U$'*CH7E6[ THIB=.Z,A^*:WU@WV?4UH-%^W*+\N=_6Q0G"G/FO#( *8T5
ME'L$E,&6,$;I848J-Y%>&GWX$@-#WR<ICWUF;3QA_:  B$>*>,")H$X(3YWR
ME704R8D<RP]'@K(GY%N>N*D/G[[/5C]F^I^UQVE/'PL6(BL9H(P2SCC4RKOJ
M# <I/Y70CBZU5':&YG#VU'7QK9-3L3/?E*Z_2)1>$Z#CCB^!<Q+L\<!,FIQ4
MB!%%@/1Y,M8OXB-AX)DG9"W>%BA(I3L5IL9"80A5B%?>,Z883^SZJ#?6G,?.
M#C3QG*&3T4(>.J_<[TK%+LK%_'JKQFV44VVK@Y<>#M;;N,5BCBS7W!AC-= 5
M5ES!'-ME1,T.^O*5.@%U6(K4^C_''@^,BCB--((0,F^5LY:1O40$,CR1"Y(N
M5%K+CE9H#F5@?*RZM7_97X6?/"0\,B) [CWWDCL:A<+0.0*J@R_"M9C(Y48W
M*B[[@'2P<*1#!\N[]7P9=\XO#</7ZL:%N*VFXJ2,0*V=E(!@QBM9"<]J@3*B
MHNB]!K-UB.]@7-I]XNFPML?/!>J0Q@X88KU"%B&*E:ID<4Y/Y.RE8[T^94L&
MHBV/VO2\O-T>^^Q_N_; [>6' X%.>:VB'8X!QCS^SU47;S1^_D1LDDPEE1W#
M.-1J4!%<7?WW;KZKHG9B3SDR(A G!$6:<">=02[:;J[RRRG7-.?\;$1EE?O<
M3;I!]I+,27]<%:=/Q4Z.#=A9SKQP4FMI 8Y3#1YDEA).Y JH,\TW8%(.OFTO
M>I:SJ[(^@_?Q(T$SH('3J1H/0!0PH5RUL5(E9*-LHM>M])9**CL!M*V64_[0
M_RN6Q=6L7M5/GPN<4B EMH([SH%12!FY_SRF"+73"J'J2=^9J+94^KOELMQ=
M*-;J_.EC02ELD*).6R]!M)\5!-7>R 07.7[$B&)&^E5Y)J@M-?Y[N;Z=K^K5
M_<LS(<JC <-"6:FP8@9*?/@L*\E$;E3[U74.HBT5_4?Q]^9?LY_U/3=_?2AX
M:XE%2C$(E-741I/EL.88GI56,J+KC7Y5G05IGY<;N54$A2*8((P<(!AI:(Q6
MMI*$.91CRXOQD*.ONZ\.(!V '!V4$N22J+B-,4.QI)P[8#D_R(301)H@YJNT
M42G!\\!LN5.XNZO5?%UO$OSR3- 2*N*X%U@9@!2/FUEUO<*)0!.IU=61:LIN
M4&RIW-^B3_'U>[&:W<Z+XU>41YX,UEDDO:(,6A.]$,:$J=C,(Y(3<>VZ5W0^
MEAGJ7LVOOD2PYHOBW?+?Q=4F[5E[\4X2X.38@+F+A@OPF$*/+=">FNIJGTNN
M)M2SNWM*=(UN2Y)\N%MLYFJYF=\4RW_.KJZB%>S+U9?;^7*V\-$H+I=?[E8W
MQ>J^OI'[>6\)0CM'E&0>ZR@AUDB;ZN9DNP9.PX_LGCC]XMR20E]7Q6R;VA _
MY6M9+&?S^"W+F[OZ+>;$J  ,Y QP 5)_5"60P^+ ?NUU3B3,B/S/[BG2+:XM
M*?%\98OB?"X6\^+GB?J?#48&BKGUPEN!B3< 6XMI58Y&2"AR*O.-*,JE>VIT
MCVWNBO'QF]JD\J11";_?I_BMJ\W\YWQS;^?KK4*:K2#-WA(\,]XI[ ERD#+B
MI#158)G@#N<8L".ZSNYQ1>D%YSSCML4*TV!D@-Y#0XG7#D;+'+#(_.I41Q"2
M5<-I1.=;O1FV'6+;^C+KU\.Z]S6UA&N?#XS(*+I&UCIAD.10R2I>2&1>><CQ
M4*&/H\XN<1TL5>S'[6R^VBUV3[_=_;WOG_I;65[_-5\L7N!2J_<$)3 @T CA
M/!:<8!XG0H6%\%FI)",Z0^N(#T]3CWI$>BC6[9*#OQ17=ZOY9EZL_S7??"_O
M-I^+V?5\<6^+J),?T<6+<ODHZS]GB[OB0>QMY>:['W>+77O6'^7=BTW%>_NM
MP#515$?-48DII]0)77D4$C@[Z,%@W&;^+%\5?R^MCP>.7[2V=A'?O=D]LR]C
M/-4"VY!X %E41&H8KQR"<1L5  $.N26N61QD3YO?7@VF7&_69G8[W\P649/7
M=?O<D2&!, TY<0)II+4R*4*:5E)"R2:2R-2URI^EU7:"[CBF>%4 9;*5\X%2
M&CGAHUE!G2<P+KJ:$VNPDB[N!HV<QGXDMM$I^[G=(DXUNW[R9# N^GY.P&@O
M"1ZW-8/BUK:3R6N9=</S^J9Q8P4_JZV8 ^I01NCOQ?5--)5ML9[?+&<-TD9>
M'A"0(%)HA;"W4"BIHS6$*^DDPQ-K0-M:MV4/8%Z.*B?S0XX-"=!IH%!$C3&H
M&3?"1:-U+R$P,,=[&"%=<M5\DC6M4!V*-]5W%M=JO?_T=\NXN-XU*JS98'0@
MGC)AN:14<F L)2RY^3NYF203B4;J3OW/=JJN(1Z.6M4Z_/#!G^?K_YS8P^J&
M!0,UX%B35(2(":$(86 GJ0)$R)SPQ1%%/'6]DW4(Z?#D22W0DJWW-?[^R3VM
M;EB$3S&K@')88XHM!,C(2E(I9$[\_ A7HFZ4?I1)V?@.Q21?KHJX@KJ_K[[/
MEC>'[SZYM]6."T!8ZAR50#IMO( 66%S)BN*_395+.6I_VE6A0X 'NXPZG)DD
M $X6QWSZ<(A>*HJK-H$*VCCYL!= '; "="+AF5WO7]E 7H8>)EIM-^5J_K];
M536H4G]J<*!6*D00]4!1:C'U1.V/.Q3DVN64J!_AJI.C]EH&=8#M<';0GYN'
MFZ@&#MGSQP,BAA.)HPP$*R88T115DA$!)F;W=*GJ9]9/-KK#V\_O&_3L?N'I
MP!TP1EBMA'%<4*"19Y5<F+N<4Z 1!83WYVJU1?(R*XOZ.9LOME?:Y>K+;%%\
M+G;W6NDZN_%Z4_>2("E3'CG!L=/*$:$P/TPZ[^0P>Y?<\6E9W*03E:\#TJH%
M'6I7GPZQ'HIQOT5O(7W>Q^5+OFFZF_RT*C:SOVOXUO0504AA/-*$$L13:S?.
M =DC@)@ .3V$FQ\4_<JV5T.TGD >U\+VVZF#I*8O"1A**2!2DD7#E()HG,+J
M+ 5AF-6N>M0^W5 K6@N0AZ+:ML1Z<;WV$:;TR1^_/17B0;PD; WASGU54%81
MQ:10!A)/ !6I.5<U^;C/.8$:M7V63[N>H1Y#;,_G\GZVV-Q7CTPSNL=S;PA0
MPCHG&(+2&J(<EM&=BQL1DHW"&OI?%]['W7_QI=AL%KM.BPW7@*?# @8<6H\0
M%I1I2R@T$#GL**.: ,@G$I'>M>IKIGXFPA><YEL7=7KS61%M"%)4,*)$5"W4
M>!>3*2Q0$C4RI/J1^"$/9RO"'^6RK$K;_Q(@O57,UZ@*';_C/S5(M'MA<"KN
M<AXXS1W3"B@2_Z)"R$+YMF+_&M/E:87P(; ?R@)]E"&V34%XWE7H/#J>?$O0
MWFMB"(FR,^002IF#>QP@Y5G182,,P>B=@UT#/L"V]"DUCXZ*6UY_*B,.Q29^
M_[:.?[$LOLTWGQ:SY7K;;>I;--6OM_>Z\S_OTJ]L_]/%]BU3_DCJV[%N>?WY
M\.%VOKY:E.N[5=%@$SOC+5%UQ#O$+7)<$0*%I,!M54?COQ#4J*I_3Q;J08=;
MAK^HR/6#1$T6D;:O#- "##DW7 (-,!%6(E*AI"F;2$VZ7OGSU,P=1A7C7VMV
M^7?KM&Y?I0/_4J>4O-4FG2O%%;=,9YG%:EY>SZ_V;]PF]ES:8QY^I1+6*,*=
M45X2Z3"B3EG(G("62*3%!5>JAZURK^3'JG^09'TJC^:L]P0#G=*" 6[CYFL5
MHM*R!SRR;C]?^9K4F"E'39[N\1_*VGX )GWUU]G?J8?1W:D&836C@K*&1]O1
M*LTI2LE, M)*3F7 Q-K0]L2!LB^\+\RKD^'.M>."-7'/MH2G"MF2*T<(0WM9
M%7!N8C&JG6B]&9-:X3L4E_Z_N]EB_FU>7*=//ADP]L+3@;G4!T=3A1"62$*4
MKMOV<F&154K\]?#F7!V77>,Z%%_^*)?_/8LR+P\(R"((@1$X D,H]< J7TF'
MB,WI*S3"<Z%^6-,)M)?9M+[<INZQJ_=)KZ<3E4^.#4QBA:!VBD7[4DN-D.9[
MF364-J<AX@CI= G#*!_U43#M3"/IQ=$!102YHSR""1$2TCKD*KD9<Q.[6.F0
M!^<PK!76@T6-E3^*]69^U6@+?/YP$-@3(00@UFJ3VM%(*"NI/'(3<^0ZU?/3
MJ+!<<)M19EUQ9EU<_<]-^?/_7*6CPM5]H@RO_B6QA3]BR_ZOPS^^O,".A_\8
M5)371Y\CU6/$)EW;^.J0Q #3K/#,ZV%#CL;*3.P&3B-MM#P\>S9:<$!0Z81S
M7@CN"&.T6D\-C[;<M*R9/E>'7&PO=*1S.EOTY0%!$XXA50) (BWEQ'%M*NEL
MG$G3BBZ^R %A.Z@O1Z1SCP4?4K4=2UU*/(*>$8R1Y%:*2D(D5$ZH^@BWI5PU
MGV1-*U0'BTW?W9SN9LXOD^GD_G5J:'!84"N85Y)IK5-;3*#V$EON[<0*BN4K
M_N7K^:[P'2S6[.[V=A<K.UNX'[>+\KXH?L7F3)ZU>V$J7L*19X(BX)S%%J##
M<9A5A.=D$H[>F.J ?8.@/A0GC\>WM%GX6KPM .:U25E(C@DE,=1"5N:G90Q.
M+/VK<S;V#_EP>8=/+=8'@_5]HR3\!N.#=$2D.N)*<:DHUISZRGJ)LQ+EG%2.
M,.UK&'^@#^0OQ[HJV&T?Z+;5\L=O55)O:H#MHW2SQ?\M9O6E1')>'*P GD;_
M6U.NO"'>4%%M%\YP.VA09Y\M"'KBT$F&]JB,L5'WTVI>5EV<4WBFB7J?;SHG
M<I.?"0@+*:R$J4T2$X8J;JJ;72>=S*EFVK:NP!!5+,; [1[T,RZF=\SH)\A
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M%"PQ0Q$*%Z>=7_]6D80VBR2 PD8HDTDL40"(^]RGJF[=NDL8K=Z7<CO#4F(
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MX[K6A?9?Y^JVA/5P\YJ9;>[4ZB;^X_ZY6WR?+0.TF\LV=*T'99)JJ#'12C/
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M;;'7BC@HL54>H!(71L1[J;;=E'?=0SZM<@'2.DRD@%IJ"9DF1N'2L@R?X90
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M4@78>\EC URL*/2:(J;V37$Y$,+*D4:T===(E5A&@7*&1=N#,&QM^.& AW0
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M=ZKA@=%P]PY!*I$E'!(K[;'5-O**D4K69M]G;"D1PL^:C%.A8Z('-$Q*02S
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MX-HT@GZSR;<?[A]FB_7YDC:G+\XLQI9J1!CQWDCN*'6^?%&@D_+\1^A(:H\
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M4FGO\9U>]K0]<6I9Y;:,:F>4DLY2'MX?0@>4*5\>&#&QM*Y.U?NZ,E][L'?
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MX7_9\95C>6,T';*TI;NB"V ;<N&7+_\OUN?9W>?KI_<XRX4S=V34B&C7A]%
MD58H_.O5WGAC6%&0U!-E9)9R!UQH#]B&7##Y.H:%7"HD_W1-YAET '/@F?<J
M/HSP,L;).812(I)'9@UWH.\4*)LZ2I;+XC9?G1_@+R_*&!4:,4.APA0&:PK3
M?>[%_L40)1.)&>U(QTE8-E3R7Q>;W>K7??V'7_>UH>?Y;KN8SY8;4WS<GE_H
M*]V;*>T<Q&$W;K45,IC>(AZ[QTRF( G7*9O@$1U-=T2)+B"NG.LUHO..CN =
M(JMVK,TXH),<66H(H9!!S8S"I4O% R123',Q'B(-$4+2)N[]A4\V:<9A(.>2
M6>B0\!8"H0@O-[D^#)BI58=I1Z]GFW'40[2IA[N%9AQA?\&QD9X0)\(PH8X\
M6BO>4SRQF/N&2KK<C*,>C .E_^C9<K::YU_N\GR[C\^]V>?'S99/W9PW^D?X
MY:'8S):_K(O=PR8\XE!R,EYS*-27WSS5Z:N7I];1"P23VUH-L0S_[SSC #MY
M]*(H0#A*(;$<(8F'2WD;AP+[&CZUY#CKCT]\8J:="K:L(-:%Y8E8+V7IA5;0
M&Y8263["67ILI'M='+(7)39U#'SX<G[S7_X]HU)([($1DCCF8@ZT?'P=@&E*
M[/D(.=6YTHITC+N-STQOWH05)YPCYH0$CDKNC3FZ+Q5"$";E_8+Q4::_(,T6
MT.Z7.\VZ-S&*G:$L&-G*$ !1K)I;2@2YF] I8JI*JW1OJH=F7S93>]V;-$$L
M-@Z)XP<: 9'W_"@?%LY,Q"G1CHHK=F^J!VE?E.FJ>Q.A7#AH#/7Q; V&5;@,
M>E;8!CRG<U#=.H%:1;9GWV>G+7BLP5PAZH6CS"!,@O2RE!SPM#CR$<U*@[C;
MV\>_/S];&4MVV+K:Q??%3;ZZ.<.V4[=DU&B'PG"2#$BH4, //$J(45+YIC$2
MK%6E_^2\:@7CACOQW\)WKW?S[6X=Y#)WL_5MOIFM;C[</RSW;HV]D#'=_53-
MR.H/R""%EA"I-0,*F+#1A+X4B$ BIE:+MPO2=(IX7Q/1+V'1CVUU?LN7806_
M^5I\7&P7M_O7_I)OMP<ISLQ*E>[/F#;"*ZR\XDZ&+0S$R)>RQZ)"TX@(ZV6*
MZ@+PIG%CL6QBH/ILL=[G@1SH7[:0.?YZ*IRLRKT99H3#8!)X9KTD9%\A[2@&
ME5JE[.A&%&76^2S5!=A-3Z"/)^AJN;A=';*'3J]G;U^<:>$L$-)2R2$5#O!]
M64X+L!=*4Y\23SRB0+/.6=$*NGVM4X>8L"_Y/*RTVT6^\=\_+<JI\,SR=.ZV
MC$@ (CA.8PP-I5@#6!+>8I8RN]2.J.NRW6XOZU*+2/=V6AM]%4]ND/BVG]?Q
M?=5]3&D\=RI[_LXLS)R&AZ'#&5;">XC$WF\+"(!8^J2Z7F/,S>N25^U"W:=9
MO8EOF6\^K]R?$97=8G,78?K\S>9_7#*IS]Z;>8L@ET8)&H2E D/VM%(CRU)2
MSZM'<,H#O5;Y;;1#KY=@;</=V[E)M-T>_?8OZG5^RL_QZ_R-F="$&1>F96JU
M)!YC6];A4Y0RDG+*7STTZB6YOE[W%-8JX WM[E]G/_9U%8KU4VVHI])3)^SO
M\S=E"L2I%A(M)0QO+<.Z?LSPCY71:%+3GC&>[G=EB+<*<U_3S]FRT4]MQV-3
MA:#"#ZM?U\4\;#;B'N/,W)3PU$R&#8KPTB+%(7/<8P'XP1(05B*8XF2J?])R
M]?9\?YIHFI>Z=UL\K!?WL_5B^2.(OEA]#Z]8K'_<SU:[;[/HE<UO8E?P\-+S
ML(Q\V\5/-K,W>^6F/C*+C9R5= P1C9#G!"CM#D)KHTQ2^AM\3R[U'I70D'FO
MMB3!9LS7J]DR+.SK@]-_N?>DG-Q%UGY&IJ@!%%)OE"8&8.*0.8CU_]E[U^VV
MD21;^%W. \SD_;+6^9.WZ/'YNFPOEVMZOO,'BT5!-J<DTDU2'KN?_B0H@I9D
M\88$@03,F2Y760+(S-@[,B,B(R,P8T3YI#RH7R6 ?FFI-UW&%O?5DKH9SS:F
MOQG#VVIXY?1A4PG]_LO=XGM9KNQB_K O6'K^!Q76.LRHT4Y2;;CEGB-;6YZ"
MHR1:_4KQ]8N+OFD9CVW\#:(HW&*^7L[^?-C@5)?NVD.EH^\5FC@E-4@@6G$*
MG@6WLTD%F)00//Z58O!M2[HKZ[\:L]NDP7\JY]/OU5^C"5@N9XM#*2P'WBJ0
M,P$34!8'C0A%3MK=/(E-*RR>T?WV3FSW]N3<N*+(":=[+\Z=//=* U0'3=0$
M3:U%NX$IEW2JA\\.F@_6?4L6;((W-EM7Z7Q/E[&MNWC W=K[3B&]"DHH9D$[
M<%PZ6C7V#+ZZ4R,E2O*G<JQ3<$E_JBTI-R3'F]J!^T<<2>D7_S.O<@^BCGTN
M)S>'EHCC+Q9@ N,D: 40[7*DJKR7JMD+0=H 0TD-!'*\RGLIFK0NZJXSV-[-
MJQY [V[?+Q=?RN7Z^_N[R6.EQB\GIK =_H!"!XD0<ZPJZ0C.1JN]RE+V/ J:
MJ&!3HMWD]&CWF$[=6A=ZM\DH+ZN"OON?>53_S[,OT=*:5BA_>FWC._LS"N4D
M1T&HZH\@H[3))J;%JX)_.$!2H?%?+<'[4E+OI<# V\7ZU=O(/W2K?OQ0*DNS
M3RRH0,)%P6L9;4JGF7""UAFFDN&4:L#D5PEW=XM!OZOCAW)R-_M7>7,6.<_]
MJ((0'65.G&%((\F]))@_:FU@0MJ4TJ/D]$#Y6#;I"XN_L^NBL_DB&K7?WU1M
M"N(D7EGN[??W&W$?X.(9GU+X8)P%J[W"Q&IN0 3W6*>1&&UU4@OB7R6P?GFY
M_^#?__[WGT0>!_[7YE>O_F;[.3])\<NF@N>_31?WC[+?2N9OY>+3<O+E\VQ:
M)]U_**.[]5 ^E=1B_NGOLZ_ES29;?V6__WCI0_DI/N#+]61V]WP*Y;=U.;\I
M;_Y7]Y=ES9]5H][I(979]TI1-1"GDEEDD3/62VT44X@@8;GA^K0*T1>:Y>[^
MZA:A36B^/BAT#ZOUXC[2+\+X J_-5=9#LDCZX *BMRVELT2&*G=:2Z;=3F+6
MC:021GO$>7E5N$OI7[*RRJ[&U8_587)WJ,7,ON<+YQP2R$F!K+4!:6>$J>?D
M$"1E[V7(J(X(L&A?]!>ET\O]:7)WL%+/WN<+0ZU7)O HG # N+!,;^<4]12/
MY!9Z2[@NVI?H:2Q9U319E=-_^[3X^N_3*M-E^;UBBJS_4A%%/B'*]L?%'[^_
MPHH?ORR"9: L"^ 4T9JC@,#6 ^;.CJ27;TN@+1+%USAW;9/+6=Z$ARKB>K#R
MWZO/%I0B@A7QG,6M%[A F*-ZF"#PB(KDM(=R6]),!;TJ5_#N]A^+Y=WAA@_[
M7R@B)[4P<2_T*A F=,""[*9.=4J>1D:9B!>$/U6D#3D0HGGS*9K2OTV6?Y4'
MBJSM?;; 6#@ 0BT-7AN'#::A'B9B:$0M7]I%O@UI=G>KXRSC^.\G5,EJ^I'1
MYK9$8,.<4UYZ! ZS6BV<1$D)]1EM-#TY*!VCTQ5_GQTCQ^'O3I(/7XD\]%I!
M* \,$2*]5EI:YR'4FNH,94F)2#GFI5V>$HN+23^OD.[;R;(ZN_M:CBAT:Q%'
MU)$0G*::A0"2.DD)(CJZO$Z?%(B\=.CVY-*#)\5KSRADB#$SR)H@,6<"(4",
MU;*)0AM)#*0]BNP-TEY*Y%UM0VXQKXZF'@_N/\Q6?]GO'^, CO0^.?!6 0@Y
MIJS0'"',K-6(B.T\G7%A)+&53IBPN)34>V-7-=ZCG40.O%6@X)$/G%JMHC^"
ME0%9:ZP3?BR5LUM%_!B+&DNWL[S9G0'ST]B/UM$^^FZ!+6<X:$>-)51HT$#T
M3HXR)%W&'P"CFJ#_,D.V91EWMCIM787S677DS<)S2;&W1FH%G <*R.[F2Z1,
M6:4R# A<@E/M2KA':\J6\^GG^\GRK_--JF>O%@S; !X+*UC@GE$?/<WMC#VV
M?B2]Z3.QJU)$WQ_9ZD&?;V&]>+7@1+L0JKQR!SQ$7\A1J&>,#!I9RD5[!#C*
MK"0Y=QQ;WUWUCJ[R/V;KS_6:?'1[/.G]@E?J&?<&QY 603(' M=SEURD9$ /
M@F--J?!Z7+Q587=%-#/=9!6L/I33<O:U6L2/<FO?*T4T,JI;?A"4I-PAHK14
M]0RMXDF9S#D&OR]&J)8D/(S<0B4 %*:^.M9D'$GL?&V?AN#%V.K]=V!5M2GO
M8204<LZQDI8(@KD4+@"J.F8_SDF'I)4GHXVL)5Q/2B@\3Z(-\TS>+N9_S&?K
M\F8SJ\-Y)J\^6X!G#$6K4((64@A1=4G?39K(I(Y9F0&?#M6B76EFD$5*K3:(
MV& L1\8AI$F@]8 )5DD72\<*?V/Q=8#W_WE_ .__\[[0<8VCA)-H_R#PUFL.
MM1<8K#0I)UL9V0J7P?ML\76 MWM[ &_WM@!&M%"&&^YH=)V(-J&V?( ;E;*\
M#R:-L"G>9XOODJ;>;Y/_7BQ_) ;M]Q-^?K"@C"H9C!0>41:7*$88J6<!&H^$
M!%T[",F"OB1=WD[NHP">#?&@9[#W^4(P*^.>YI W00&1C@9>S\E+/Y(TFU1
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M.JDG4X[I7KU; IU#ECW1CUXH>EN%JJO+0Q\6=W>P6%8O74(I&@VD$)Y@HZJ
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MD81/>^3 P32&\Z2?C2LV@#0&JX%Z1ZE1W'!GK%)D)UE)S$B.@1)9U44:PWE
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M+(@ GK':W;"(D)'Y9EW2L2U-:!._ 6K'Y2[Y[?NN@HO@$2/1]0;NHXU)V/9
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MOO,4P"*<$@S-\32AYV!HSMB.:.,[*J)^]\2CPRN4$@J$-CPNE\8P"U+MD$-
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MXUI;'$=K.9882(6J\0MF9Y;AK!,FE/WC/)3Z^E-_$S3'GR6E8KV]=(:K\78
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M-@^WNZAN=+8&MOI>((@C!KR"C$KIB4PI_"JX/+995]W ?+DY):&,O';^6:9
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M-_M(4!P3 R !FGF"@06&J),$%9E9[/>8O.Y5,).E=\_$?A8YRZ@WPFNLA-,
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MUTA(>_Q%^L_[Q;;XO__G_P-02P,$%     @ XG%;4)KE%__J P  OPX  !D
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M'=NN\8-.L_TZ!>#!<OO3)>')-X6?R^WKD0K/@^T@W.4.>^&2V?\&4$L#!!0
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M:(.W('P<IZ@H((7>G!%LHX(\V?H#-\F=5</>M'<3^Q= [Q]02P,$%     @
MXG%;4%V<[T<$"   :"4  !H   !P9F4M97AH,S$Q>#$R,S$R,#$Y,3!K+FAT
M;>5:VW(;-Q)]MK\"8<I9J8IW2K)$T:K2A:JHUAN[%*:\^X@9]'!0P@ ,@"'%
M?/UV8X;4\.*U*#E;B?0@B@ :0%\.3C=F./CAZM/EZ#^?ARSUF6*??[OX>'/)
M:HU6ZTOOLM6Z&EVQGT?_^L@.FNT.&UFNG?32:*Y:K>$O-59+O9_T6ZW9;-:<
M]9K&CENCVQ8M==!2QCAH"B]J9V\'U'7V]LT@!2[P_YO!#XT&NS)QGH'V++;
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MHKW[6S4\P&.I"_5X[LVBHWBD$GIF4OBT?W+2/&X?MH^.N]TC=,3QX;O3".D
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MB/&Q97OHYQ@0.*4S+^ZCE*LQ^/+DII HT>WQ5O=P#_;]T.YA7+;*IJ#J296
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M<^0M?)K/#$=>GB!IV"$^+!"[8,0\JU8B%N;;M6;N2E;YQ,<]KD1Z)LNU^[*
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M)RH0(\4J1"R/B%*%2Q?BJT301:CZWT/QE^3N@!%\IQM+H#!:8Y>!O=W93"\
M<YDN*%?1TJ5I:0IZ.>A)%=#8I0Z1JI"T/))JEE7A9TE>7U7:714!;_Y/A7Q+
M*SM:OXFU[_K84_(UZ=[/@(@7QY5CLTS@LC<2K"?ZGB]8P+]7"%@> 4^^ZJR$
MJF-#"41,@/?26?(BY?7Y$?7UY<4],\R1D+K>/9G/%R3.O0MXSQ'QW^E?^J?G
MOTO]GK-4B\I23FT%':WUH= P:S5^_C#[0;+89D-O+L=(3F?2B*SDTK7A6_H]
M/8'KH0<A<_9-? >&I%U1R5;S])>=Q@[]#F"PHM]S 'HG1T)1#8 ;;\3=Z=6.
M.*8FZ>7Q,/"B/V@LH;\\2#L8OC\ZVMUO'+4/.C]'R  7P>%C)=Y'/\QX '9B
M<@*OX'']LM/>*28V9J+VSQ]V9BZ-?M8J?M1)'CTE'2M$?'HE!>W#Y?#^,/)_
M/&C4Z'F.#=^W&LTCE@0[WXBQYP?_^JFYW_@P^V_VBFQLF=@I>':Z^41/PW0C
M9^#!5'W'>W@_E#;<LISK6;0YZ0Z%+X/9+Y;?W\89Y2*ZJ\\U9U7KQ<C'S+CS
M42Y#K/6_0S^AH -1[_F"?ZOS/M#;]]QYX!.%EWWH&]H^CV G.UB2]9C7-=\H
MN$ES9@,VOM1T]'[.E4_?]GLI'LJLI=2M-K9%%!9URF384]*6W)\8^Z*<CA3>
MGF/X4;ETL]'8-']N[Q4SX?8<WIU^EAX\-?53,(LEU+!I3F+.OP.C;)*I+*",
M<X39I:Y!+(I7]R#G'K06WH/6'&'TX/!YI-$7;=[QW*K:_ 849P3KM(/PI9N
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M)6M+;^HEUH)<GS,7D?S$4Y2NJKBS/G=V58R\HC +*$RSUF@=511F*RG,VIS
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M$?>_"5T]%$'D<!6P/G F# ( 6"-<'O2\L-7HHWA1P+4 S"(-'@>'MWQ!RQH
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M+T+K]5GZ0+\E%=4D2) .RP<#4&% )1&@D=NB+X!RH'HPI6>!\BK0Z  *ERU
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M9(9R"3/:0ZTK<F40Y=>[?Q46/6/]/3K/=5Z*[(&:56O@$07^6&F4N5'JPZ2
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M:(4XAVNH:14?MRF%65^TKO!BIVMEJ$ME;54)IBGD2::%?A&(@Z2#!H+F%$+
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ME4!8+.Z+B]@6\_N^J.:O2%:9TMAB5(KS5N]T^[ 4O25%L$MP*;HO TNQ$!V
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M'LV<_*>ME,N?K,>I 1<;U7%35]+$'B#X_D]=V'EU4MX'7N+'&/&A5 ^5V:'
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M/Z/)C]N>TX']#>7"@=M*L[N@R[^7*&&_*%W1SW>NYC(*Q="C8B!* PP\+WB
M;=Q.R8Z,"QQ,WO_%%O,^*Y/N%]+;),G QO:]7 22\3.0*2'-AUPVL02?TXCR
M=.'OTS^#<<G<S$9)8N<!4IH<YC<]JI)+C2"AP/EY<)@8V ?^H,0S*C/Z].C9
M_G:2Y0W=UY;N;P*$1D*4O2A*)D)6L$RFGM#U*T!+A>@Y66!_/G/P.?)FK)Z)
MRN0X7TR+T4'RB#:G[895!B^$)UT6==$M][H45PF64N>/)U-@301CLQ]E4N),
M(7V$Z(G913;,*9=T!YGSH@QSWOI2GL^VD0\#M%=M"<Z5:9,"+!Q:OPG;B\<.
M_I3+C<Z5B<'YAJ7-D4JS=B,"A0T'9/I:3SM.R%@F<E9E$YX]HI(M4*D"!#):
M%K=;X?F4Y5M@=*4JV\RRY%8C-W-]B9JU*LH-)5BKS1:_5 (3K$++%X/TK&.L
MMA7I(O4?5:V'N["&I--ZE<U_7W^\:9V;'KE$74K?&(]#H4&:(O5B(RP.3%BD
M&JR?8W0?*WS0RZ546:D8ECR;R?8_F_4NKZFLEKMMP"B/$M%/:>3$'1)QF8$:
MW4!5L:(R HH,5[2#U%'(O*HZA<4 X9#P4[U'RZ/08\@E-#-UM0$\!WX7\T"J
MLZVZ#+_M.[^]_^&,L2J$/,>1U)\'3#8DA2?NX.2?MB]+1T$B6]^ROH8L;27^
MT+X/0J*0E#WS-<TEF;75[&S(K @D+*/M'&JM9EBM=OGQV$5J0;G'46Y!**+$
MHS7G/270"U1B@%C0JLYN-,$I4]0@4T<LX0 (CBYD8;'@=@5FTS,']($)C%QJ
M9"$%LPR)]'><@RD&)S8BDXPDD# (ER2.8IO=.17)B6[SO%N2'Q4D!@]N?=N:
M'\-6B%H!/RA * :>+.\--H7[+Q:8Z&\S,%&Q/VQ)A2^6RH?2CV-1"G26":_R
M<6,&UH>C'H\$,))UV6H1WQ\C<  \0_( D+T?^">_7EU]S9C/$V%CVY7HU1QD
MZ6=U<9J&_8DOMH[U^[A3ZJN2G4[+=S&^G&[<Q?B=&+D^X;!)"=!03NP^;(F/
M"#KV"'^>L:\_@4DP</%-NKBHP1A9&G*'#?7W4_>K8.!\=D=@T<L)@TX%LSU@
M\ 'D*P?E#J>1*S<GV:Z,$6R!2U*++SP6$:Z=&XW9UP!*0.>5=9QYUBO"CU/J
M2".O=JGDI3D_H9XF7I4=&0%PD<L"R^3XI3-+I-91^7?[V:5>Z-2@_CZ,EZ2'
M2'K-XJ&(4.3\2S/C2.,G>B@,IA_;'MQ0$BBCVRL+QRU391K6$)0]U?H9)8*'
M</I*RZ/EQW 1PQ46X,,\(Y?PBFK6T#M \D3N)C6AB<@ZT?UWI"\)MG="/CT6
M0M*UQ6A-Y(0>2JPTO<?9G?HE8US+6VTNT"<+6W;4 >T$Q6D&(7$)*_%I 8KT
MOV&4H2M###I"6Q"ID#.<!A%E$*?Q+?AM=E6:_#CR5A+$1!^%+G^)2DB(FIH<
M LZ D)WIQU$H!+="QX\(^I6ZZ)GEI#6A(F]1KMD1$[8K1\L]56B+$C]M;R3W
MRPVS/8C40T1VOX8<)L@T2<X$#!K+-PQ_K&BSU,0)SYO8@A]<DAVJ1W6A3U74
M-*&>QW,S!:,K@#68RJF**J=*G0G+(C I(>]FV53Q$,H534W<P< 3]8=$*%<5
M)6?W//1;LK]T5355K>8%I26>=9JG&Z7 5TH2:]2%;RMK]?;==^L3R>F7X6UG
MAJW7(-SG(,QR.[2-7.S3B[*YV"_!YR])TC?E$K$/A*I^ZC0[79FB?=HM15 O
MF;*^X>R_L,F.?4OL:&Q]>#&=9E!>[CUO444=2;C=5E6.G:>K' ^EVF N9K:F
M4_^B(EW]19SZI2)O'YZT@,)\^K?RYX'U!$?S"<4 +(+BE(X0V7>,XU7*&[52
MAK7U8$?9)%ENBI/Z7;6+-9-(5S30@B1T?%"1(S6RW#ACXX&.T1?X*O*;BX'*
M -39XP6/?MJSKGWC?.D)3U:"TKK.C+LH=8KGW=\KOF?.M2RGDB;E+?,LL^^]
MU[2>I@O"T'55&B8YQ#5Y"*H?5!21.B;=6$RD*VUA4C4E#BPCD]?6L?L*Y9X.
MKY+/5O<1E_LBGZ%2$]'_FEV%QHPW%YUT222SJ*;8C1TH"?%]Q0\WBMGMCQBY
M8H +Q4WLCET8"(=%,K[%$]55FF;;8"\D4AI'OY@>\7)7HN.&]RYVX=7N4XPU
MQ ]"I/YB>)=T]5)\047AEN>19O:JP-39,(=4YURF.:+4#GN57%M*(,%$4IT>
M^W06:;X#ZEKIHT\.J'8II>:TK7\(O=QI:T+HJX70#;MLBUV<'6*76:KOD])'
MF 0<5\E2()QL_.4K5.@&8DCGO1WIY&X/%1QJ8)=,<CR50U1JI-_?W5*WGBN=
M7Y#Y337R*?C)G@2P;O_1\54X:6Q_Y")!VRDR^RI5'@NQG9J%)_I,K,*Q49]A
M]8^JTOK"<^'^2+;?$R%)'U07)/=SIS&I@W 7@"",Y/&8R0$)A8WR2?V0EU:4
M!POSC")ZJ=(!M03(OA=^3+64F4E-]*3\(.;\DFA,,7>LI0-% 04)[7 #FY"
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MTDC6"'QFF3T/M=!;CSQ[Z_J^;SG6_MW^(?$5*&3QT;5AZFY<LE1L!SCX5L5
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M@%'B\B<WBA*6@OB@N_?71&)]X;FP_2P9.*=R8C_B>:).5*9;$4Y#$2OMQ?%
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ML+_![N[[S]9"I)B2%<$O?2*<-]?TC*@;CC_=?OQX"YHHJITW7SY^O/IV]^K
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M12@'11C_$R73)62PY/W=:7ST]MA&/T\R+2'*5Z"RRM02IKKW/QPO&<!^VI,
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M3?RA?0],!I*OY'*[0'8.M6) 0$^@9M1.0/<=B0UVHMT\L_HOM!.G)7=B3^3
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M]OGT1]7=,[]G6V=FFT\-2U#\9>FSE.\L^4+5C*GDW27?VOVYY"0=[%.,;<'
M1"N]PFL?0)=2IJ3ZO!U1.S'L>64%PYG.,FLIU 5D>U Z]G__UV6G<UY;Y9@O
MMW--RYP%#@A&_D-_ TMSY>O*N@W_[=JCD+OJ?GS$%G)OZ.]*;31#4CM'4K,
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MW?BV[) R U['#54-2ND:7BAI!FTD^PL\DC=\ 'R5!\ 5' !?0NM*'0#?,@?
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MI 5##KWZ7Q,9[9N"KC#SPNWRMRQJQ,0["AU]$HX_A"[C@\(5&//39RY7CR*
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MM%_VX$TO<!(GW9,QZ33C6ON6-+<#F  ^%T,.#[4?*DNPOO!@LJR)/\W'ZGC
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MNLW3//$;!%V"[LZA>Y['4J\'<DME3ZUK+*7,I"@$^N>#.(7^+=E+F]G)Q%*
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MI>?@C^'?_L#;-'G$+!W$/'92Y<]-)9%)$)D$D4D0F419@FV(3(+()'8N&^6
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M(H/%'.]&%C/&4$E,W8=_A=8A_!@_;U@P0+O#U#[Y3H@I_-Q2" (+%!.?XLW
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M*VS=4[^9G.K*[0M(RC<Q *5SZ1=!@5!BM_[B?I'@D> 5Y__?"$1S'1"4[@R
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M\XJS8H5*"3,:? AM>(IFP14!UP%48K'/5U=I0H>&^>WFCP;[G6.M9A2$(ZR
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MRRBZU0Y;7"Z[(+1]X;'/EX: B/"_*_Q;)<9_M:/'EN/_5^%AJK<U:)  [%0
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M<]9_E+!PZ$-C!E+9&>JZ2+*CPWR.KH1LZ.K^BDWYL29[ $M(7,(BLB%MDEO
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M%K5O!X NBO>A&Q^]R.F)KH+3)'8PPG-I0^@F%]B!Y8U&RB<1).4X?!S:UA#
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MY^Q,HOE/'$64>$_B<*:/]__*/'H>  XQ[\/KQLKMD:]S$HN-C]"GI69]GY^
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MO!K(PAHBLT(]53B>E9P7D_ 8\C43!<$F:UTJ"F)9^V3Z'K0Q$S[5#S2]X=%
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M&")[ B@Q^"'JXG8LN*2U">0:.DN!U*6N<FR%7GDR1[D/H.=XOA9-S]\* E(
M#^L9#9UTJM28L J$.\0_:5&,BJ.U:3N8&3X-@E9+ZT6S$Z@E)L7IQLYSEZ$D
MD7S9LYT(_YOHMO!2$0PQNQ9Y)T:ND_T37NC+M-L]B"<TDG^@^)@H&-.B/=Z
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MSH_HP>226*>4/P+=F!B+A$?"Y,!$LQH&0L/\>Y&ODU+B%(4@PC@"G9"3RJO
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M[<AS#_7IN7J(:*"<I$HMNFG&9*%3L^*<*M4'+A,&,_>:X-K>Y"$ 3V!P]&I
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M36S,6%;P<_KQKN>/8-G3^]QLZ%W5]A%+.8[Y]9]'C2/Z#).RXL\9:_+='JE
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MWA?QC?@N ;X;9C6/52^LU8!X+3=>*RVCWM%)6(C\&/%=!GR;IM%JZ>2\.Q*
M2TO]*J30\^EU^3?5C:6RZJ^?\UJ&9.I]<[=7%^QM\3W=H"?R=+MS<V=6U4S)
M7A.+N6[\Z[_/JF?R.PS32KZOF)[OS@CLZ*_LB3SX([I$0$^.'0[?=CN7-;-1
MZS3;\=\WR9H#0;ATS-G;Y,/2A)Q-O1\SXC'/UCM'5(N-^IMW9TOP4[^96C]U
MLGYA0=KJ[K$ML[K'QMH;/;7G"((MBJ:5O49?F08_92UF=RO!O#P,G9G2JZ1G
M 8MGP:Z"K%8U5^VM'#2PYOB07Q!PFR<&;A52]2'BH 1Q3JZMT)DXH7/R^7_K
M.6S:%6RLQSZ^DUE+S?W/;)C7MMN?LV&U+IO;<:SD@<J7V[N[V_NOC^3^$_EX
M?W=W_?"(P4]ED5N9>%+^\_#Q2S(CVSWYWSP:KYDJ&,B[)>_#['D 'V#/$4B+
MQKN[IY>GK)CEHI&*CI:*/G_[>" B0BI"*LJ4BO(E%&DE'8I4<J05) <D!PUR
MN/&#L1_0D,G4=\J%(%?Z#X^ZKF^)K'<'HI8)$@L22Z&(Y;L?4O>8X'A,)TH?
MV(1YT:EZ.S,?7ZYK]<L.@\ 3XRAN\AQ?)D9GD:CB@%X)?9)!TQ_I">EI\?:Z
MT6CO<(@'J0FI":EI>GM7YYPUDA*2$I+2LF!JMG0.FA>3FH[)+7+C\U"D >;4
M/57?2(G3-Z#/ 0&5*:!*51X7H51D*)F&V44X(9RR2GO5U#DNC&!",*WD39U&
MJ;*H%<KDF&LCG_*+C\QUH0F#.%Y?'-05::RH*X-0J#UR/(>'(K?5A!'V<\P\
MCK9+^6BP@0P=P905F!!*"*6L=(.V5J8PA!/":55F+J-6;2"<$$X9F<%&M7.<
M*7M+L%GRP#BC@364=HC-)LSUQR.P>= (*2LYU8QZ"\T0A%-F^]QF$W5'A%-6
MIDA;)X,@@@G!M ),G89.BF $$X)II1G2K)=*T!V3&7(]\J'G_]"DA+OCA=0;
M.")I*>6<A6B&E(V<,(X+ 86 0D 5%U -]&$CEI Y(:"*"*AR,:="F2)[B.5Z
M8#P,(BN, FB(6$,:#!B76R@6#)LZ'J'6WY'#'6'/7 3,%4F% (X<#9G242*R
M=@04 @H!A8!"0"&@$% (J), 5'%-FCS*KE<^@]%R+NJE6_YH[+)D'^;&]W@T
M8@'YC5$W'%HT8.3W/TD84(]32]R%M(BTB,P= 86 0D AH!!0""@$% *J>( J
ME#VSX_2KH@T5QP-CA9U?V<R.I"W"Y;J8[^)_/!8B996,LBH-G:-@R_._RT"R
M@"B6]"L=\G0.)B#P$'@['XEIEDF/0"P5&4NM;@?!A&#**C]=J<"D64FZ/OY)
M;#\21TWV64HZ]RV=6VD=755<G_-ST@_\$6#1"QTO$C%K_I@%\K0-)SW6]P-&
MQH$_<3A<N:KTF,?Z3@A/^0$)Z4_&Q<Z0,K?T4U[O=[Z+2N:Y3$;.FG'-:#1W
MJ!SP^EC+K3XCODN.[[IA-G1$'>(;\5T"?->ULG6].M#"6@V(UW+CM=(R:MT=
M:JL@/T9\%QK?IFFTJCJI2XX$X-)2OPHI]'QZ7?Z5EXC%7#?NYK_/JF?R.[S#
M2KZO:/N[,P(C]2M[(@_^B'KOR#(\YST#3XX=#M_6&FKX\>1O[$B R9R?M!=J
MNXMIF,.@&<_Y=O.X<W'YN+;\]@7'Q.NW&NT68VO+V__S\/%+O*4>#AEY^#]T
M-'[W49ZG^\)LT95I.D("JTL'S":]9^)' 1&/$C\84"_.'F*0IZ%C#8G#R8!Y
M+*"N^TP"QL>^QV4^$>'3")*LA^/ _\&LD,NKXGT?''\\I,&(DK$?A'W?=7P2
M>:'CBEO]_@7\W_(]BXU#T0*UA@Z;0&]$5Z'KGO*8B.A8>?1/>%K"H<_9K*'0
M%S>2S]\^SG5;/CCVN>JC!3,LARV/%/JC$0LLF+AT@L;+Z31QF!F!+IB:9^&D
M<2.;D6C<#V"6Y0M@YAD/?0]Z09_%LVJXCA<"84&G(BI'-X9EAZD2J\HOR7?H
MY-+D$NIRGPPIG\VHXSKPE'A?<O216PZ#&;KH41[/C"_WZ\<N#47F^PO.@HEC
M":=2ZM4\63CIAX(1P*" :5TP,;/,&GI3&  X84)G[YV^+I[:"0T</^+3^4FF
MWB#0[R<8LOA7W/@?/W#M)]%6@C+QTD?:9S"B0>!'XZ1/ +TH$"T,:4B^]0&Y
M0=)/  &\D8?T+S;T7>#."T$(:D'$\HQAG&+R#3*<!5/';PG@JL*=Y7!Q"ZP4
M7)0=4G<3&@&20(XZ;*&%)P=^C<.VU;Q$8S%S-H6OJ6(#PH<GAATX_"_UYMC/
MQT6.'1\ )@ZIRK?-AB@B*SCAOAHZ//Y,+"#M$0R7T+% 32"> V1:TGDH/85#
M_TF^_TE0!*Q*!.NE7BF[W'X'9"QF'-@(OWQ-/LC+RA*0'U>+*@MFE@6O\:GE
M!Y;E1.KY.;9=7?#1BN_I!CPQS^Z<O#6KBM-G)M86>CNBP<#Q5/< 'GYR04E_
M>47)N6[WLE7MUMO--XD* ?J52\><O4T^O%N4^S.1.=7%ZF?K)63<4/U-2IXN
M"-OU/S5G/VTD?//VT&>@YLEO3PH:/6 ,\'RM:G;))\>CGF3F#TR(&"6/E__.
MDT6NL6Q[K$!:,"LC;X#%Q*;4OFT+E*[H5;:(W*3%L_<K*P>LU>#5WV$P8Z$#
MT 0"1O^ZH'U@N&^I^T2?N:#V81 S]\TTR^9V(VZN<R%MUAHHZ5LU)^]?0?-I
M<I\X[$FG+UID'8OP6\^Z5&I-U...[=#@F=R K@!ZUV)N[^(LPZF*:;-:S5M
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MWM_=73\\ZFP8EGW=];?]<F:P&6SNG;U7G)-(%\)7W[OX?'W]C5S;/R(.S/5
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MF(<A?C"D2D!<H1X E_D92FV CYGE]!V+.&)O2GQ2HQ=OFG*B2_)EIAGTF.O
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ME<0W@<HJIT;TE,&LA,^"X.%]PC@_-Y0.)4;*)M2-Y$Q)/1CNAY5W;!BIL 6
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M+[K5=?JB1=;?^O Y$%[_2VG=/48][M@.!=%\(\,XG,4*SL59AE,5TV:UFK>
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MI='H9E/Z(![S:>I]6YZ*R(!S_ 8]8<$TZ".=(GC&3?P^$4=ZH-V^B,"<L%E
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M4XWR:"S4.MG@<@H<>+EP!*8Z_IVZ_S#/HVM8(YVK=BVG0JBP4ZT2Y*3'^RP
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M0DN7[$9"-BHS"NJ;JK6R,FKP,YG6*E,&9[=CT9CZ]N4'K+BRLSH'T&8+[&6
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MI8[=IHYDY,3H4]:1QO; =_O "1@=->*"RE#56A3ATP] D\VH!@3!%^F?]ZB
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M@*>3F?\TG2ZV&;WE-J,W+S"_EJWGQ[^$U@<Q *T-UM[MVM;1X=&A;3T(<EO
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M;@LB!-+C/ &ZET\!W,7$L1()G.S/0MF16CQIC:2VSKU\';9/B]\7CE1_FE]
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M"*IT'FK3;('"JX7OYUZ!FUU<=$X/+X[7CRQZ\4A)YR/0HKW-((NN,U! ?RT
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MUM**9R715K BD,,<E7C'JX2I"^N0<)*DE#LPM*>P'28!XEC*N-- (@_X!#&
MP?B[T.?XTPB4:@P5R28"%%7S:/JZ_HZAX61(\Q_]_E=5WSD6Z2CR& Z/8F$2
M/=N .C>V(Q^O"IYAK]G2\RAS2US$AE-Q56X'*5LS>8GM^3_[^1;,MR8P3BB
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MV'Q?#B+;ZCXOI"Z[55^W3GUM^'Q;@;S6[04!W<_N,A 56!_SA'PVL*&:\LC
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ME!-/HA\H*D-P,>[@G.<VC+(8&PUCDIM"B@&9'&<3&71-1M@V^(Y?E:21^X/
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M,4XTB#'48%OCR-.F*Y=6@,WK>]KCF40R:SNO?2RW:I)5#U_A-TC<7W/G* J
M/N+J>D21ESC5/EK>8.<X6*"71Q_^R<1_J03+-=Q8GL0W@44>($'XSW[KX]^[
M"T#T-10>&[GH;J(D9D.-K7(LJ:*A">+"3A7 <\[PJ\'#2XB_&N.;51(&A=:8
MIQ.)>8KWR1\/LCAAO00O#'E\S3M(#1*T;+&UO#'@KY<2,^_0Q*,K%V7I030\
MF$3N#PI_($(:JD9C? ,6?YC5M/@:6$Q>Q$]_Z5*& G1&7NF CFH8P^,-CL5
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ME&J45Q!;4[*Q2X4;]Q1 208P>I04]L$$/'5^6GZ29*V"OK?L3;,4(/$8R"[
M0C:)I1YK%&GF3++PC6W(O%!&XPHA):GBMX1 0@? ;Q#Q11#XIZ/2)@;8WHX>
M0)6/?W" @)P$+A5*3[;L%HP\QT0[?61 ?RB!FEIRWB]R+B7L2%]'451J=CK'
M2TFE#6T!0TM8YN.%;KJ<CJBB;\0O,41K-M:UA@':EDJ<5P-F#0U'H1K%$Z#%
M97F[Q[R&&LT2^ <#OHT(TC@<2N]^O!  54N3.T63!0]KX#PH?Z[JQ6RFARE^
M5B#=W(O]-/8_:(AF3Q4J6I8.Y_PML\EB,D&&'..$\DHHK,*)J9)WQG6N<L:D
M,L$M+:0:PMV]Y7U1"@EP[2CA.A=]Q11N/FC@<5[9DELI<),GL=!1ZJ&9\28K
M<[]?_MH';=UQ92#YZ+![UEZO_;I>92\D&TAHJ4FK"K6*@#K\@7XZB@*!Q6L8
MZN"^, ;XO<-]GMD"IJ28U&&L3TP8,5R7JFM92VO[16MY?Y# 5 \8)$"AM$ZH
M![@KTV,RY&-#X:=Y"HG*URV%MF4!)+ X3%X/"X3&ZG"HD['<*!PB*B_E5,GW
MI^(NEDU+\*=YQDH-P,OZ<%GGNXN6=7'1.>J>KQ_3LE<+TO)B#F#6_+O3*$(6
M?_ 41M;:(0:K$05/YT+!-3VARO=O$A&RN/^U^>$L+EE=,,^M6]HJ8*HM4N73
MKVN1*ENDRA:ILHH5MDB5+5+EWMA.V,:#LGHI,CT@4TDF]E,>4""=.VC0, );
M%"8C?V(-1/H@A&H#_S^=0E:E#.1?_U8$GQPY]UQEH-U*VJ!*A!.[(S/@2Z/D
MA2.RDXF1.^H;+S??6&J8HGH543X*&W/2%FM+A_>3YN?XIF;Z;NF$$]D#B_I.
M^PS^J'+A-3TJ"DN=X1!KN%S=.*>0_&&2)Y7T<'LO?([:1F,,C<*Q3.X2WA)N
M#"57,>QJCIQ:!:T48Y^;6.0YQJ!79$F*75Y33/V/O9;@6X)_G."1._Z!38<M
MA :C$JH\\DOT?,"@I)HO.W'LR(RDEKSVC+P>#QF5*BM*T2,-4E,5@K-+< K5
MSV@]0/;?*T%A%9H>YF/1XU*]"!B+=H+4+Z,-7#\(O_0G01M1V#>*+FK%!F-4
M^JBJ/;+S8A];,T-;B]QB'W6LBV4 4*-SUA.AX[DS*?8.R_"N4/Y9 K:H!%!$
M/4'$JM (:Y650D'A#Y6.*OF]C&L?Z$P,G;@CDO2 ,S?N8B%T);5"A\:K<A=$
M V-;S 7*MLS*+B@'H8TK*0<9:@^4JAFDQ:JU%Q/N8 K1 ^E&0TK;S0;I, O4
M+4[,E#>%,?1.6PLS(./W$7*5P(C7R)B[EQ'N= G:19XFYIQ07$EV&.1TU%84
M[B'C0$W+()*<(^0U@53-6'%/)(GEM5WIB'KH8:X'ENE$0*VZ,^ATCM3#.ZVQ
M61ZB./!L>0&9QNGQ,5*XDQ<R1Y25[[3$NF?$>A='#X0Z)6NUN<Z6RW=:6M@O
M6C"8EN$:PZJ-.^W2NQ.(;C(9 =\:^S];L.,](Y$RV'$,-),(TV!RO#\RJ?B
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MQ5'_Y+#;O^A>X&^<@E1X=D&T=6_K=CMG2V)\J)]4,*A/U.8:570=PV$FA4;
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MNNE@\B)>]9?GGWT^Y^LCK2 >\;V>'FTRQ/O+?_GC.RN)W?]^Y03 T],!,(G
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M)I#"4*!%</]\< .E I)(B>,\.*>@P-N3S Y.H$XCU3EQ2>*2P^$24G$)%D(
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M_6GP<]B'Y=46YVKQXU_D*#R?3A>3Z2++(?@YB,NG;)SE4OJ2DR"["!.$N/3
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MR1'4GF GA*&$^@.B@AV<Z[1*!5U#? +XT0*\ENO&%=! !UAC0IGPQM-BPHI
M#',,#@G@.ZB%$6F.YEZ1?NTSG[<&_VPY6PQ&X^+UY$,E'^IA7N6U?#G'O,'4
M$>\]ID13X:EPQ(0?D;1&-\XA-I485I1Z?IU2'TXP/K^'4O=<K9.<I^0\';%M
MQ6L9;D!I RA1VO+P#R=:0"T8AH!3[H!I/+WN>3E@!WY3.B)*T#Y :->RTKRF
MRADFB)4ZN$PZOJEH%Q [\1!\&-#>A<=T<M ^IMRUU&G@%/R8AWB.BRH=S4KD
MB/)26T@] P(+B($U3BC&A78[*X5L?$R^7_<EM3,^%9AW#<U-P2NKAN3*"VJ
MH@AQ%+X A9$RA$*ME97<JFZ#=P>]C%.S@831#F!4U'+-(.520\"%,!SCH%;5
MJM> T#0X%MW&:#>GWJ<REM1 H!O%>2?>0$ 05&628,UX(#2L!:.2&66HXY+(
M^,5AO#$=Y4EU?'O(%;LW")(Z"*0CDF<GGX/BF,:4PFJ4X@F4'"A-E:>*4DV<
M M1AKBU7 K7;06 /.6?WN2Z@U6JYU$(@$<6Q$X6HB$(JKYE5CL5QTAP@+J7,
M"WJ<%4:VW+QH#[EK]Q)%ZC6RA^,;V$VG+9?)(%TUH>R-<JE\_=-X.I__W.\5
M[GQO,?B>6//(SWD>HD@)JO[WWCNB QD:J@A56&N /,*42\:QM4H])@]XS_W:
M6,HI2P[3(8>+'\0IJG"*@;)0"F08A%0AJ7 P:IC05"IG-7G4Y+L]5\OT"6W3
MB>D:(!/^#A5_#\&/5/ S3$++!';::"DP8+:8;\\]9)PRW1;\VNOCW"?L1 9#
M[M-.WT.A2A",WM5L^L<HGNN]_NE+X8S^W(LE_0^9^:OU>RP:EE=WK&T<NCD.
M/O'+B\+B@ C\N?;W]&KQXJ\_9?&ZRZMT:GWLCL5#A,FK'!3L#<!4,:L0I\I#
M:;E#S#/C-='^<;T$=GUL ]ML>9^RN[J,P:Y!K2FR:BW%/%,V^.@,>&LHA_$8
MQ&D/E8':.$%;0%9KIQ>TU;3P!* $H&U]:0Q@-49-8FL-E%A (;QT "CN\MPK
M()2$N 4$M5]@T6ZTZS!\Z&Z9_KL.T:\B](/Q>%J6J"^FO;#?4;IFTW$PP[^&
MOUADLVR^F)\F3>W_N/,N:ZY#^3)_>H[DHBX>$6][(((!J1P7YCWU#G'M':62
M6@TX%,H)A3&#SM+'*(=WV>+]^;[.0S!G*?LL':8<#+,^6S; +OBRR[38F 59
MQ8(:,XRX @:*X%Y"J8C!U'K.H18Z^)PML> N3ILD;S6<<_R9,(G=$KL=/KL]
M1&ZB*FZFGE"N) "24NP!T1SRXC!/(\8V)Y!M26XMGN5Q#-*LH.<LLNH27QW!
M\YW$F=GV"BD=(758)+LF>4\0M"1/29Z.0IXZ58"]AQPA<\LQ0CH_> :[ZLFJ
M^AF/ )X0XN]@]A&&M>PC!"&1Q'H'-:-:2N&44EAH0BEPPFQ,<KJ]G"MW[,)/
MXV5\_@^QR?ETHA:+V>C+<C'X,LX^3]]=@]?;$ET[S5:B?8E:C?0G:_,(B*AS
M,:5GMV*:D49]5B-T&E%F9" /:K'6T@M &+&42V HWC]IM#>;L8]@FR,-$C4D
M:CAV:D"P/L:54VPD%81"HH7@,2,@;_N+ ?-H8SKS[JFAO<)QW >BS1.SY 3N
MR0G\-9O/W_1N=04'-:%*7N#VT>=]MOGJHD^%<&U"O;#8$$\Y)XHRSB3!S H&
M'7'.<_H8G^K9?:@VT]*W%I)D1!T Q+N&Y*; I56ZN\,>"*8\%AA0B(@@CG#(
M,08.&07$[H';FA\#]YGBF/"9\+DS?')2*59,A=><6,*0(1)8%!R-/!W%0.+T
M1L9Q^_ALS9EHMR5+5_'9V-&X_@0X/,%PNHPF^5.D][&>2-WOV-G9TTV'X\-Y
M^(-9+TCGJR?O_)[6K4MAGITLP"&?53VT'L=VF!4LM:HB!1A+K ">*T>14%+!
MH!X8DN&[\/)&ZY][],.N#Z; [ARKQVQZ9RVW1&R[6(#.!;@;/V6WC52,*B/5
M64T5E,Y(":G@3DEBF<?$"V^P]$\DH18/NJ#<*P<EJDE4DZCFZ51#*JI15D+'
MPJXSC;VT&$I>EF<X(:A[C#^\ZX,SM+NFRUWBFMSA?9T[=^O7\Z^%OW>6C<>E
M6/WE!7B1_QP^XVSU\RVW\'ETF<U[[[)OO8_3R\'DE][FO5QWL+^-AHN+PG]]
ML5[/QOYX$/[KBW=/3[,HM=>H 137?*S4/ZVGVJ#LJ?9X^HL?_R+'V_ETNIA,
M%UD.ML]!7#YEXRR7TN!3:&*A-E1Z1"35R H'F?7"8,\8A2^+D;?E!SSX]G^.
MOXPC6(JW?YS&V[I8+*[>O'[][=NW5]^_S,:OIK.OKQ$ ^/4L_/KUZKTO>M\O
MQV_&@R@JV>3E/SX]:I\>L2T\?WO9S[TWFO2B[Q/#%^/E,.L->E\'X;7I>6]P
M=36;?@\07V3C'[W'-M3C-<K[TT.<1ZN2-!T<N;"41CO!H#2 :.0A<\Q# H$U
M&S'Z^TK2_'06%FQBEK-9-CG[\7DVF,R+.U"38?[3.$\/K@8//]RX^9_SV>*?
MG\XNLN%RG+T_=_]>CA8_?LL6%]/AV\D?6?$QFZ]FV;MPV^K[:/[/J_/LGW_[
M]%]F.IDO+[/9W[/!>'%Q-IAEOV677[+9/80LUH0L[W= 7VVR<>_+:#P.W]Q@
MY<=M9R^L\LO%X'OOIYV*0VW"":=!T2G.@:#"6A&D / @#AH@$VQNMI&*UJXX
M/!@M>$YI:.P)\$T_H'?9AC0,SA>Q.G+P_>?>+ MKEPUCQ/.\6.;>6;G.O46U
MM+W!>FWG&Z'2Z7+6R_*UZEWFBQ5(:;6&D:?"UO;"4O56:]6K%JOWK^DHO.F/
M\,YE^.FG>99M\TS%3_&];T:+H$3.XE.^BXH#F>W6Z.=^[VH0M-)@'#AT>GX^
MSQ:]+S_R1XGS"2=?PW>3F(D2"#>^^(]7GUX%:V<\'LQZ@\C$\T7^>K:<37N#
MR3#_084EG(7;"S=2O+6__M4LFR_'86W#Q\7EG&2+^B(&.?T:+Q:(_>ML</FJ
M]S9G?]'?BMYO6RW?<//[\=:V6]*PHK,@V;/PCO"XYU&1S[=;T'[X[7^]ZEW%
MP%F^@N8B:-EY7,7)Y6CR9=0O%X@?QP)]RP:_;[\X\1=F,!D,*[F[>:11,[5N
M,YB3D;PK(_G+;HUDX0AC$$&,M"8 .A6LWF)&:_!%N?4WC.2'WMZFD9QKYM%D
MF0W5XM&W#7=K8P>LYZCYD05\99-AT(\V.\OU>@_#?FYX]_-W-->90;O5T7TV
M'LSGH_-1%I5ET*%MT=1/?PMLD+?:CHWZQEE^(X$U;M.]__N_B]LMK;GM2*O4
M[V$W\[/MW)B8+\(_N>(*5UZ=KX8U*+7<BL7RH_UH2)3W&!7?;??Y93F/]#Z/
MMD9.9@_:$=]&BXMH<KQJS9C8;G$^95EK.UN:,UL]4GB !C+-'RG3NY/BHM7D
M3X7H_/PZW.PRE]%Y.7(YFD>[%=<Z5G.9/9]-+PMK)9CN*VF-UGNXT:<X50_X
M5*0VZ<@H8RF0" M)G+52"HZ*KJ\::&;039_J=J_F_;=)-IM?C*X^9+.S\//@
M:W;#37I;!!G;\9%^'7R9S@:+Z6PT_9PM%U,]&\Q'XVPVW?"3@ON3OU"Y2FCM
M*;U$][I*9+.YS)^?YB)-5ZMTPY?)GV%M5NU9%B"IE7I1S@T6("A*SBP$3IE"
M%H*V=(9U4A;^/IHO)T5BS8>+0=C-L[":T::9F^FOBV&K$K$YR/AI$O$R2L3P
M7C\W?[PR<>A5;P?<O]V=)V._&\9^1'=I] [6\-["\'U]XW/^^M/9;KT(*RAE
MR'FDN),T'F-1O+HKA;&^X44\]/:#";5_/$#[)FJFMNXR#H"-VBUJN?F6>O1>
M>VM>&5RO<@,U0C2NPV <7B[8/?<-@MU9'GL<HLVYLSWI;[DI\[95$_=)R>0K
M]!0EP]M0,C\-=QQ1DIP"K@"AT ))8)PQMR+W<$%P,Z+TP-N?0Q?P;73!W>S4
MS^$489 '*$R=Z?QH,IB<A<_K?5IS7EO *VDIQQ_46YJ&K=& #EY=3N<?@K\<
M/8DB6A"8[U.0K4#79X-@)*NSLTCC,9+](2S2V2B;O^FIX?1J%0**P*Z]*:S:
M9#B8#5?'W6)[KS^Z:/DG5'OR,;N:SA:)N;IA'J^'\.V(N1 Q4C*'-##A.Z.$
M@V9M6PN(;S#70V\_&"OV;N9ZU;XA0%U%*<WP=/^F2<PY4M)(H+6  !),4;D+
M0FDL;FS:0V_?WZ;=E;38K)O"5BIJE1ET.?C1"[<<-[TW7.8G]'F)0;C\O5S7
M]'$@ :O;+^ 7(T?9[*E9EI\>I47[O6\7H[.+_%PE7"7V@_@Z"^^(A_;E^<(\
MJWD:-YX\_U+D"E8_W[< #1ZW]N<;9%K?[/AS_?,G$8_CZTM<$G!KRN:&KKD<
MS+Z.)L7M#9:+Z>J%(BLZ?Z70/E*^0E!P^N=5;N=9/#^^FF=O5M_\<C.+L])C
MZQ)9_.)NM55<)US@Q0;+%[]"=_]*XNIWC31B2RGCY5H4+SQ4UGG+73P)*?E/
M]8*L6Y4A(QL"OZL;NO7ZVRGQ?523-G[6S23C;9O+=N[1&A;ZY0FF-^WEQV17
M%U\O9A4O?LU>?IEE@]]?YCEH;P;C;X,?\XCABUG)PH/<#)@S[X!U6#ME6>Q:
MI1ECQ ,AK0/8*!G_9M"8OC=M[:9+<W=B></KH4=>#]V^%]<THAX$2^0LZWVZ
MR+*;/9!V8DH6;Z_51!>NW?++?#0<#68_\B9.@\DHV^IF]K,G]ZGPU2<>HPZ'
M .Q:?6-RMY+&N-GOZA]>N_3]%2?[* $KMYA>L]#;KP9[@$1OL5B;2/H=A34'
M).<M";%\4(CY/4(,M_L5:/T3GWRQ/?<8?,0DGBZ57A[[PZ]AP7= L/<^]M8]
M<=J),J@\2%W/?'O^/IQMM0EBK^CCEF3U!S_]]O;77]^^?_>IWW/_S[@/GWL?
M/CKO/GYTMO?I\WOS7[VWGS[](_R@WMG>!_>Q9][_]MO[=[U/?U<?7<^JS^I$
MI_+M=$3*UF*QFZXOT1D\IAY823P/5SQS:13')(V=F@VX)X_GM![U%'W:M,/'
M_MB=:EG_))V2?]@P.XO5"J/IY,UR$C1%C'WD7L-\(\[:&0'OBE2WVDN^8XN0
M-OE(GO5X^.K%7\U@?I&?PYS%;V)ERA^#<3W%\+1DN'T/YX#;S1Y--UD<W+(,
M$E%U&E)8$PF)AAP9&CLZ,2RU%(9YC3T5F],  CK49!C_<15&U,(,9K,?X=G_
M>S!>WE;V)O\/::.I;!^#-H<3'5[+V$0MC\!8FFAV'PU04$U(E0@@@003D!@J
M#)',*HNM- X IX1JBP9$2S0 \69):II1]JP&U*>+Z6SQ<I'-+FN5O"=J/36?
M9W*\(\-*DD$5R7C#.6,&2J09M4(($SC&*&B--!ALEMGG$O4Y"%15%3_?F6DA
M^A0ET^)4<-<U>#5%$V&U.5Y.<HR9,HI1)+"P GJ*H7-2>H+UEFAJ24/S/I-'
M,6+XF%3TY]D@-K<M2@+S\N\LF&Y?QEF_-XXMH0;C -4\%S9L;=YN>G&^'*__
MX$W>JZLLE?Q38/9?\B+ ]0L$)M8Y<6W/X9J?L!%">JP0,( &]:XI5YA;:[ V
MU'A[DY_*2M7YQ[54OLL619O:FT/*VM3Z'+5)4TGK=QE_78-94U1)L$85%4I:
M*A'AR%&BC(8":JV<U$9"!S:F(3P25>UH?]$'K=K22?FWH/RCV3>)K>-NEI4D
MFC@U-<U@-4XND MVA$"GG:&"*8$,,$1BXP@PW,N;A+(2HQ^!1W:HEH-#D]3R
MB>"M:[!JBB)<[R#)+/)<0">"NH9<&>*HP(HA0B4'&\[X RAJ1PWS/FUU F-2
MPVWD&12V5R\.$!FD3*BDC2&C55=BP@W#7%%HG*/. P$L%-HXJ+%PW*[/X:[.
MLV+*2YSRG4O1KCUEW ]WG%3RB8"N:]AJ"B5>9;9P(ZEWA&J &.7(2!/^H8"R
M8-A*@L4V4&I'+P<H\10;[YA>+CJ6GI7:.6GFI)DSR &N$N68,!@'HQX"2!7@
MV@,D&-<LD X3FWYR+D_[4<VHS\!FS_ZDFH\3=5T#5U,LH6J>(74*$R2I TI1
M:WGXRK"F"!,#K=0;1T.-L-2.;D9]PF#2S=W2S<76]RZR\3 _F8[]NA-+[$\W
M=ZQXOAG?D"KQ#"%O$&4>24FIHDH9$GP!2"0*7YC:F)]:R-O[<SN:7TV#L/TM
M+.35VWPV<%B9\.IZW-K[JZRH<-NYCF^3E.X4CLY6="=H'W)_@6: 955N&X&>
M<:B%P-12Z9U@&&F$++4 4,<V,D5;!6P[AH3L\W;S2;L*S4X9&M>NP:Z^/U5R
M/T\7@W&*"J2H0)VH9.7): 0E"_]Y2AW%3 H+K!)(6@]=8"Q^.U'M/%:/^@*D
M\_-305S7@-401P)6R:)">!$L=*4%)!09HP0CED@E,#'<F4?CJ!T=3F1?(I:B
M =V*!A23,5]N3(U,BOG$%;/ E0<AC:8>&*>HA50YH@CF '-DF04<8M]LI.ON
MRLT@[T.<5/2I8*]K$&N**%HEB@)OXH1L AR'5&J@ Z*<\-XP;R%0;GM$M51R
M)E+<OF.:^M=IO)U4$9ZT=)U31%7-XIA#"#,HB,.4Q['KC KEH*/2&.K,34Z)
M K6O@G#<!S EO)T*[+J&KJ9@DE7N*!9:<($!M%I2KI'D%C$0=#52ED*XT<.E
M&9C:.E:G(CG2'5//'V;3JW#O/_J]JW$<*!N[W\7&=U=1%E8EX6=GR\OE.!^4
M-,RN9F%#\^.31">GK<4EJHI?E-'!"<!$8(6I%T)(0Z)S0 R2Q&]6>J_D[D.4
M.C49NI7,[;*D#.*^9#SI\Q,!8-=PUA16I,HXY9X[0!B@R N*")8:*2 $\0!)
MP\"&<?Q(6+7D=>,^%JG6NV.:_6V<-S8Z'^53Q$:3Q6#R=12_+0ZP;U'M@\MI
M>-3_)-6>5#N4K"JB(<APAAVTWB'JO1,2"@4AEQ2!X&[ S;K6E:P5)W2!>MSW
M,@WG;]/I\-MH/-Z=QT[[F*=$^%,!8M?PUA1>HDI,!5+[X*D[P9"C&FLAF4.>
MQ\8+1BJX83EO":^6RM9H'\$48^^8JE]M>R*+D];: >555AISCG)+H'124$"U
M%AP9ZS&W2AG+T4U:V;EFIJ+/:#KM/A6P=0U332&$JX0T+J4!S&!N#*.: >&,
MC0T9%/00&D > :%VM"_%?9*T;]>T[[OI9)4</LS.L_#=L-;9)8^H3_/"\DGU
MQM3Y)>GLDG!HE;"F-,1,,,4@492 X&@[:C53-$;6D7#U=A6V%+5UQXK@!ZC)
M\'H7BTHT=UAX#F2;<QB25N\R'+N&NJ8@X[26;T*%YP%@2@B*#)2>">0-1=@)
M;AAI%V1M#3N1K;8H3GJ_M6XQ-:6>%'HJ2G^8BR"H<M^TL$Q38P0PE"HB%70.
M0P*-T98JLY%/6VN"L0?53OJ$[B64WMFZU@3<8R\Y1Q#6.B\J@H@D5$/F*#!"
M,B20#GAR/':-V#AM;PK'MO+G>+N6=E=1URDCX=HU6JLF/V53H7V6::97<)#P
M.,]FG#U:Q ]S[NSVC_^<YA&I^)@SB!76CFL<_#-*!(]DRBUV4B-I-CIJ%U2\
MN_1!QOM$["78T9KD)I.H"P3UC#RTL^FUS\HN3<FDEL:DO21,$4RD"U1"M2(*
M(JB4C5D72F[.HKJ+3%H*Z5#9)PCMS)[K$F<\JT%WDSPN"IU$KYERA\$CW7W4
MM1>)]QG^Z>YZI*T_ZL?NE(?Z)$6:?UA02M.B(]Z; ,QL-AY-LO!!OXX&7T;C
MT6*4%:?8135_1P6^*V&R0SZPWIK1TJ%MET6R:Y+W!$$[31.V98<PGP)>].0(
M/L-L^BU<>][OC5:]4M>]+J]B05#PJJ;GO?&ZC<<P^[*X/@4:]@E#U^= DS[G
M[#1AN;_PYG%'+[L8G$2BJGB.$WA]K'4FG%"NM(8&66 1<I81P3:R0VW S:Z;
M?D+6A[+5CL-)L1\!@QQB>+$#T4-<'_U#H:90"200IX@CQ0WEV! "M&?8/Q+M
M;8W8%CAE@W?,N/H\&PRS6%>=CUSO70U^Q +LTR2RDW":FU$)JJC$&N.A"?:"
M HA*3<+_A*9,8>R]<D)L'$24LO2A$*5=VQ"DCU JH#X5Y'4-8$WQ1*I*1P,L
MP!9)RV/2) 62.$D"M)RRQA.P/9Y::B#>9VG29]>TM!W],0HP'"8%G11T02BL
MUI%!*60I =XZ3+$-'K[WQC$62 51R\"&K;\2ICUI:-2'('4E/17H=0UA30$E
MJKI&&JL<M;<4:4I5T-- (X0UL1H9!M'&W-SF@&HKLQJ0-ML")A7=1O^RR=GT
M,HN5TEG2TDE+YZ1":N.",+10<@6YQ)AZ%?B%*:X-M< RXM1&@Y//49#VI*&E
M2![TJ8"N:]AJ"B5<E2%:;Z@)OT"*XF#W4NV$D\(RY(UB0<EN!Z6V2I\12[U%
M.Z:;U=G9;)E%D%Q>99-YGCJ6IXC-LJ*7Z&B179YH>5/2UFN*J4T.XD@: )&R
M@7BHU4YCQ:1@1CCL@=_TJ=WEU7CZ(\L^%@)52T7<O7?-4_S[9$#8-:PUA1:O
M$E$X%P!:;"B7@!IA)/9*:X*<(EH9M]&?=QMHM>5G8YG\[([I\J*-R2KE;UQ)
M0V*.$U??M;E"U@ I(%0"4T"Q1!H+ )RSCB&NO-DHGLN%:H]*&\(^$*FYZ*E@
MKVL0:X@H"JMR5*^-(YXK0HBDGB,-D3#*\  J12S>T-K-$=62WPWZO-5VO4E9
MMS%-LU:2=9&-AW$'>_-!BHR?NK*FM:%!S+#@9B/OK =4<:.L@D [Z8PWC-L-
M95T3JO?G=C2_F@:)^EM8K:NWJY*0\&KDF=%DF0W?7V5%L6![VOP_V6PZ',PO
MXF[G!21)DY\(,+N&OZ9P8U7^F440>^$8UC;XWTYKAPF4C'%N!<6 [Q!N;878
MA6PSXI4T_>X:AR4_O0L-1^,[#J/;**U-&B(:4@F4=8)KRH05Q@@CF <ZL)3Q
M&S'X/?KOF/?Q?G+:MMO!9!)TVR1X-EPVA"$#538<,(YJ9JT"F%&C@62.4*(1
MD%Y*@3>:_N[1Z<?!%*"B_9Y4'4-;ZD=U[(^:^E&EK4_]J XSQ'FMTTA'Q;DK
MMM+1QS49K_P7B8Q7SBIH$:<F?"\IL9[;&.A4FF[Z+T&2/@=!BK7X>QB7@&E?
MTM1\XU2@US6$-064K'DB% *A'27> 8HDE)8)C9%FA#$MK=\:4"UY(Z@O09OM
MMD_3X6A9/W_()O,H5U^R278^6O2F7\)'YP'J>;\WR9+&/G&-S5%5H^.404HX
MK0!B5$$AN-0*8D\QA-(PMMDUYWPTR8:Z$*U2TCZ,!Y-:#&0/FISV&6XU"I(4
M>8<1V37@-<49J17P(.4A"\:QXCK@#&NKB33<0H%X@.#&H(PGXZRE><;]P!9)
MOW=,OT_GBUFV&,VRRWC0F-1\4O.WT@^K_ BK)7  40BYH\YQ!3Q'X5]M,62(
M;]!/GLMX7<YN,-+>53[LPU8GK":5WV5T=@V$33$G:F.,L;?!18>> T8UTLH[
M#('!F$N&L+T]?[@MS+65=X1;-;.3^F]!_5?['K:TF'X=>W"DA*.D^E<T)&#E
M>0!KK%- >>\E=58*Y#663JGPKY%$W>)YY#)5='?Y//A>IYQLERX]Y<FE/Q4(
M=@UI38&%JHH[R91PTH&@U345%"MH@>"(8@TUPV!#OS\>6"T%Z?L<I.3ACBGQ
MHJ8WM<Y*2KOB%EIU#( 82N@A"OZ#IMQI81UA$EL<>(5+<&<B\ \_G?UC<A86
M<#":!(H)[L0HCPCMPT%'P4-G28.?"!Z[!KNF*.-5&9Z0'"%D%&!84X*%5B#8
MQ8X9"+CA>N/PZVDH:\DE)WV.4XN.3JKS2>69)V?\.:M_RE<.HP!(R*KG *>>
M.T$4P)!3X( BTG.NL7*>4,8?[#FP!S7/^N'>]E@']/B]3%9 MZV YP1I0TQ*
M6"6U,NL1!Y( ;Q@5DBAJE(0Z3I5R&J.G8;*M8WI!6^V(UU7H=<IFN':-UNJ'
MD^60+(>F+%6;L4-)'%5%E3564X2MI Y3+JGP& 6GAMY3L[B[B  @?4#:S!]*
MQL(A _;0<-D4AJS*IX6&*>D18!"Z@$"I'*?,<P0$\%C ^UJ-[,PZD+3/6*NI
M,UT%6RH;/O9'367#:>M3V?!!QDC-]/)RM(AI;?-\$H&9QOY97[/)67)UCN;P
MLYG)A &N/!<NI!74&FVI4<HKPT6PEJ#G3AKF]49N<DV.U&1X38J:>3+?YZ,W
MD]$X//ILF:UM*'##AIKF'S59A">ZRW+:TN1/YYI=AMJA(HK6BHU,  ]Q'"FD
M;6PP9A@O$*4X!VRC:OAQB+K%*7EN1"6'(UF=SVUU)H?C9+?^B![[F!R.#[-5
M><1\,3W[O=^;3'M7@UGOC\%XF?5[@T5X/9^%EK_P2P_QWOQB,,N">[)<7$QG
MX9.&O_1&\_DR&[[I15NR['U-,/PE_BQ6/\?$]4Z"I2M&U<'X+UL>Q6"(*O.+
M46614-8IAJAS6FO,(%98$(BX5QL5%VLY_13%]+^C,.[N2&8OJ1O)D>D YKH&
MK:9(PE6)!9(60^,55XQ2X+12C'D:1Z8I"#C;2+UHAJ26$C%3WZ..Z?OHQDXG
M*V7_)_ *T$K?_]*#J!\$K*&*EWW,Y#4E'U[!*%'.B:MY5M5H> 8, \@+YR'E
MQ$BAI2"6,::9MP[?%F693O:@XPE+=92G@KBN :LICD15A6&(0"@P+-,24."E
M]LH HYGFP%*A-I1\ QRUH^$)2W46'5/Q*EPM[L-@'#3[:/AR-.F=#:Y&B\$X
M\<1I:V8$JBH*J%%PMDG,@T04"Z6MX(8;*"!1P9W88)1*JCX$H7H[,85([4Q!
M"]XG*.GH4\%>UR#6%%&HJH'@&CM',/):QZQB*9E15")F#84V_+@]HMI1U8+U
M49J%VC5M_7F6#>;+V8^52[YRO1=!#.:+:_XV[@M,K_G;N,\@3<QRY%K]IX=(
MB%:. F7(,B\\) )0;;6"SFGJ#&>.*D8WRK57XK>/L#H$?0'@/E3ZIJP^96^?
M#O-;MO;G!-N#- @>!&.M=P+GA,-@8$O@&#6":@"05$YSB(WP=*/>J!$8VQJ,
M#H/N:+,>LFN8NQUBQV0Z?,QB;XULV,L&LTFX;DH0/G9+X"'ND=6QH*!,&0&5
M,<Y0 ,,WUBG$(,+&6>HVYC.NA,F5LJ3.SI:7RW',_8@=5L]&N^N6('F?\59+
MLY.KWV$8=@UM#<&%814\0SK8U-!88[&CAG/AM!3!V+8 0\#H1O+P5N!JR>N7
M?4K;+&Q,7G\;,?I* 'K3O"_2V?3R:I9=Q"$6?V2]\72>M/D>M7DG.QL\Y&I@
M4KD:C#DG@XZW2!I*%)'4"TN$UXAR!^QF\+$2P+P7BZF+7]%]]=<@@^^RQ?OS
MSX/O3]/]\[!2X;4'H@-]1O9B!&SEJ+15SIV"!UTU,;K01.%!Q#-<ZZ( %1$V
M_,]K*CT1Q%@FM<<(0FS1AH'_=,0_PB!IB'C$VYPT>FC /H (Q;5KM-:^Z<-Y
M>&76"T+WJCCON BTELWF^:D&_Z67_7LY6OQ(''?:T0PLJFB&\40'>B,<&D\5
MX\I"['Q,@8($,K31ZSF/H)92Y7)IVEVO1]R'I,UCU12]Z#+LNH:NAF BM=0?
MJX)W0"VEW%@*'9'"8>2$EY@#9?!&ZD\C,+43K0A@(B!E%'8L6E%L>F^P6,Q&
M7Y:+.(BAMYCFK9S#.V?3\3C<3&\4)&*6S1<I<''J@8N'N A77HSUQ'#+%=0&
M4A-=&:2,-5($A0\EW&AL\MMH,@U;\^-M*6P[4^L8[$6G=[9-7$+LX8<3'L(A
MK1H,8>6XDTI0RQGE BN(B1-:@F!=4\PV4A4:X+"ER4RTU8RAKL*M4^;";KS^
MY-4GXZ !*?$JHYH(!H!$V"--*"%<.&D!"\8!9AYR:1YV5-Y.SL;+N"P?IK-X
M-54S83]/WUTS8'=N4D3GAJ2Q$ GJQVU5R&JDNHI92-1(PB"DA#,I(-:&4XNM
M=AYM6!4[ W!KT0E.6ZU)ZBI.]VR.7%\''-9A.%W&*$.SA=B-O5(;,I'W8GUF
M^^61:[1GUFN?Z9KIMD?+2MM&S9]VD9K06 ,\YO&?T:BCJ-()4#*N"4!6:$<9
M(\) [RP75$JAL;ESH&" H9H,]WBP QGO$]%F!YO=R_2!&FRGQFW/2&';,5;7
MB:DI#Q%:)<@S$Z@H3C:5CCJ A1(X6*N8, TE 1L=Z+;@H99*=:CL$]3JA*#.
MTDUN=[[.K?OUZ_G7\.SGT^EB,EUD^:9^#O?T*1MG^5*\))(8[[@%7#$"%?/2
MT-C,62#/O(+D9=%XL/R !]_^S_&7<=R2XNT?I_&Q+A:+JS>O7W_[]NW5]R^S
M\:OI[.MK! !^'9R/[/7JO2]ZWR_';\:#R=>_O,@F+__QZ?I*!B\E>UEV*84(
M_/F7NY>6/PX$Q=O595 NBWGO<O"C%VZG%U#:&R[SP[I<[03(OKJQZK6%O?]6
MZQ3 0 !\[=[/LNAZ/17"G[*L]R[<QSS>KYE.<E\H3Y'VH\E@<A;^IO<I=B/-
MNW#W>]\N1F<7O<$L"^9Y?OKX=9;W/)DM>M/SWN(BFV>]^?K]-QX\_U)(X>KG
M6^2]?+#FN[BQ$BN!K_W]-96Q7LG1)*BRXN?Z!2:1&,;75A^"(L91',2>9>-Q
M^=N\G7C\.3SHV>KG6Y;_\^@R+/*[[%OOX_1RL*$_+P>SKZ-)<7N#Y6*Z>J'0
MU_DKWT;#Q<4;*5\Q(#&G?UY12C!KQH.K>?9F]<V&A+]8^Y6UUL%W>YWEA?"?
M?WFQ06[%[]#=OZ+5KQYV:,/*[CJXOAL+/!J\-81\S*ZFLT5ASVQ^W0#!KO1Q
MI_MC/XO!V)Z E6#+/^31,<!;[JI=B6QRQ1=_9;?UK;A3_1=?+V85A7[-7O[_
M[+U[<R))DB_Z5;">,WM[S*CN>#^J[QVS>.[4GNZJ.E6U<^_>?\:02+4X@T"3
M0%?5?OH3F2 E$I) *$%)IO=8]TB0(O$,__W\$1[N9WDV^.>;P44BW+>#\=?!
M]UF!]LM\1>Z#TE&8<><=0H+@:#$/@FKM6?+[(C?I!QYM\3>#.U;A*:K?77/N
M/ZO'/9\=[T>>>3_R,%W<,:R5.2U,9G@@P[7;E]NO]_A:&7"18/N\.)N-AJ-!
M_KU7%*</)ALSCW;Q3VZ2J?3ZH2[P)V2&ES8,(W1HZTK9XR:4/F%YU]];__ F
MS@00#VI#?:R_A;F>\#:?$1.<K!(G1Y'=^>=E*LW$5ITF_'&]Q8^_]002GOBK
M_=YZ EG[?> QO_P37C<\*+A7PQ7@I.1:Y[A\^O5PQ06/!AJEH=A[<UH\SS<4
M6\.KYCZ$URHUH6);6=F60H,7[&(\4SDV$F1[J<?'^.[_#Y]Z[]Z[GWJ?_V8^
MA;]]^-6'3Y]?>P>KR4HB?S@L<AI(%@]&):^!E4/#X7:*5[DOU<VL6YL7>#6V
M!5;W=9(*1W1N.K..+43I;2]GP"G@%-81UA'6$=:QMMV%7<KQ#V$TC[S(/_[V
M[M=?WWUX_[F_?!SA_W/AXY?>QT\AAD^?@E_&^Y\[V@*M.2[3_2J1O1;[<SGM
MHDTG9YJ(T*:>@#M!?5T.0R][\X/6MDIKVZ:IP*SMT]$6,^O'00ZT"BI[2BIK
MAL-5Q])[DU4/"I/1\,V[R='NY_:>' N@;"XH6P9$\'5:J*,M-AQN.IN#MH*V
MGH:VWHZ9"_N/F0/5!=5]#0^]F'FQ>?#W4+<KYVH<SS6?7EW_U/MUOTE1 $@
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M7L+U?+U>>[7U__./XZ1B?^GW)MF\-[WHS0??H!J@L]3=6<$ADP"K#]COIN"
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MCYC$<Q_-S1_\^-N[7W]]]^']YWV.!!_#\A\+&"^=,;G/L]BYJGU/S7\D*#[
MC,7&'HL!%7T-ZJY)?TMU50=0UV8>*@!=;KLNR\[H\IYQQTEG#[HEZEH6KDMB
M=TA46.&VB]K%%7Y5RU1[SJO\P*+R,B_+'-\N)LD9*++%Z:,^7!<'SXIZ*7,^
M'_U1GK=HJ,HW1<\/W"3AP,KP0+S?:*)KRJJ?Q.+"6C;&4H%YVEUIWV?SFR-^
M9]G%M"AX'(^GJ[-\3QQ+Z*::UR[?HP;M^*9HKXXS+V@H\PK9]>VG"$2&N69K
M?6.8$@%S*S'E5#OKN70!2\Z+R?1Z8PK=QWQZ,9K_.IW-'F@@H,L& G7,AA=]
MBC;/_[^@_<M+M1!RK0W@DH/;BGT8H@%$L"/N!:[ZCUC.J%?62R(05\98HX15
MRC"L#5(X/@OWJC;<XSY6=0Y^!'@#O#L#;[H&[_1240"NM9462V4L%65[H4A1
M0%H\"]ZR+G@3W*>\SM&*W=Q=NB_GG7N(ZWMGX\2==.;>*FB&_WNQ/.-9GC#+
MB[/6YZ-QUIOL&5^5[Z6_/2_*[Z_SZ1^CX?(,Y/0V:SBXS1J^[2;%[KY;76?:
M\!7BEOW;IX)CWV"U;*+VO4#90*<@O_I*^57<W 2K+SJ[G8^JWER#JZ*#\'^7
M+W1<F=MNMW<*3"16MX%)E$%Y$H4UG'&GE"68<6LCLU9B@F_G2%Y?9&_7%2O]
M/,[*EJ>3H5G3K]NNU7XT*]S,T621#5?[SN5?W7["X.X?'C)]*?H(USHG#)R<
M!F.XB5#=%9FT:B>$E=064V28,IQ@H[$EW!AI&*5,8?^:R*PMP2CZ5+$V)"
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MFJV2U<9J9S;.>FZ2S9IV'7C_EA]E0F$3;3\XXJUR!K8!E*T-5*&,**.53&Z
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M;R3!U]]ZY9#YWI]0^4^]OO[J9L45FW=J:LI=HFH6$8W&82\]YLAS3X6FFJ=
M@1F+,.-RHQEATE*7E/3C2D?M]_^<%8,]JX*Z6S4]Z&%/TN>JUIEY^RK-?@H
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MW_1<>F4T6:0P_TW#1']>:N@QY:#'4(Z?YX.$U9O7G[<$#^"N_,_RY9O?']>
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M^IH1-)HGU069^/DS4.??B3B/-J\+V!OX;$?U0I]&]M'D4#' ]X\TM9##NXO
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MXF_^<E&XL]$_LMO"'2X^CG%=Y:5Q^&V>S(K$8UO<13/9I69R]M1,\O7Z)8_
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M8>!N$?3V]?JU2B]F;6\^%>X^6JV@#.>39,';*(@MD:H]D?[Q3VF1Q[."+6-
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M2,J\RSL'VW:K98\>D]V;5-\@*OE9VYP#=/RSA :>:_0HSZ:,AE <CNJ'@<P
M!V+6Y0+?7R8;1]61@52<QK/X#NNGEBA(I\ ;)+>XA,.3XE9B)Q-O1[FEH3B:
MKB>*9E;550&F(1F@DUP/P4%<7^%-GA5-"1W#656.?U -X\?Q1R&3;Y([LA/V
MR9$NO_1O_JUZAL3[/Z(R14)N9$9<P;9C=L0CF! @&]_\NGC,=J&G'6C-CE(L
M11DN2L$&1\W6];-4!JIGV0-!A/"T:.GM^[^_(W'*GP@+E-QXGN*!\.]@E;@M
M/@LG&Z=.-D0@\!1,'!B/4<H>A,*$TMTDNR6[+5\.*4.;-#^KK^F0S7,(-=7P
MCT(96,&T(B @QPA5!RA)CSS;,US+LVU#/H::UK _>J.F^QRS6'JEIS4R(@0N
MY1?^'TXP7IK-[V.8V3!94D2ZD'Z#0YU+;\N_O!M(?\[_RNY9W.@XX?"/Y>2)
MA84%HDRW]PS:"@2NJ]705,6L<V:MD8;/R5.D2PRQ+]?2OQ)F0N3)0XIN\AR5
MY15O^LT?:QAVF(_"=#0O4L]RX)GT?^FO_1<AE'>;;44(BM5M"Z]!G)2S')10
M1#%/P4$?J4/!W::I?LCP&B/)I[4Z[Z(C97.K9!WWJN%)@BPB9Z^X3\".J$Q$
ML#DF8%N =<GJ3_I:8;BAFKWK*IEGA9135LDL<_)]Y[4PW#,3VUK-X:LQP/P5
M_N!$N%\(K58'Q:)HVQ+<R &:EZ 1=?<&Y/.0(\>A=+]#;PR_AOXEF]=K/9[W
MFST59\ =X:;/YY"Q0ZX0;-\)K1-=KI#PPDCV-573(@L1!4S;L7U?M113MZ+
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MWE2>(Y_,KD-.H'SI\NJ* U]PLTTT/*PH8-"@>U1%R"886);>HEM( "P\TZP
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MG6L\BBV(*R^C6B#;:[!EV-)NDUDR!@,HNP7M21N%IS8<YLMXP@YGY42[$O"
M'T"=C."W)'\@.@$:@1GSCL_8W%.8'?OPYTYCHM6\$.):R.F].\'QJ-*:^*Y]
MO1&\/L-6<%,XNW3&IA<O%YGX@%TOT">L YGC7*N*;1G'M8S;W3'.V-P$;4LO
M.4=K;Y#6'H2&C>WI[H7O!?M@%QQFRRSZO8AH&>#-KY:\T1#I>T*MXQ^.NMO?
M\?24*;1^5R \UQ]^:7M><*'W4@L]L49@^UV2U/^]SRNY> <N:9[$7Z^HQ^G/
M\>0Q?BJ0A^_S/:1P->,#^]<9QQGHBGK8</1\RX9BB)\""'Y=IU4[?%-JMV=S
M(SZ-X>=<>C\;7I.*OEG>%NDHQ:XZ?@9*>+96P'(^![1-*?^ #5KWULI']W#=
MK9 U?;/:U;3]_M;:LW17R])>-?0^<-6KJ1/\_(WYMQ9JZB^+8H?,7#50=P=/
M[ A&<L(@L$/'4?Q(D56UC'[(EGNE;0V>[/RZ_J:7$,Z)8S ?P?5ONDP9*)J9
MQ.*@&<8?T/G_)OVU'-TQ/Z(U]O&8@&\T2<&!YW=OH+2*;,:]IN6BT6*;3A_>
M-7F2,#>+!5=8Z *<[%$ZI&.^EMZST,3FL O.%X.X.3KG!;R1^JF3HPI.$RB(
M;+E CP=<)GP1/+.<P K 9YV,<"+B3AXF(IK='G#K<&PJ 3B,2[QVD3#LL2C#
M RFLF"))%+/!Y=TFI0.+D10, U$PHJ#0P_8MFL9/%#\0YT(N()SH@A(+0),.
MA\L<OCG 7Y>@6$'&I'/2L[5I#=-\N)QB-!J]57QGAM]CISK%+8&Y8JAL2>J:
MW6_!7[.UZ%1M;A2&QR.LW3KE:?%5A+$X92S8Q04.!..R8?CQB@.%+XY2V+.<
MQ9'$B*5[7_GSXN:-1W?NDWBRN!_B))+90YIG,Z3Q 5%]LDA9; =C G<\SC-)
M[M)B4@^1W"W9KVPY[/<<""IAL91DQ_DL"W3M[],"8R0@W:7D&]Z0)]09$.,9
MW_"2)^;T?ILMF9//*(?M(*4_[AB&PF_C>-AZGJ#28>A%PEO=)_QVGK;J^?AA
M0^;/_O<<1XX?$3^4R2HH_#;O9TMD%C?OB_\/EV6Y[&^Z-F_V>LV.,=PCLV..
MG87T)?XF_1XO0'@5/^,O+'#YGF4V$;/Z['R1"SX"Y7->.N+N]_ENLX*NMUD>
M<GU2%. QW )%T)(_ 9$,G]INMMPPBHP@4F4M\CQ##APU=,A&T&15LT*O=K.E
M1JH=^*9NZ*IK@4V"/^*C5N0KAAEMOP_:.<[:S99;NXPX]C)KG]&/F?S^AI1U
M&-E8W^$RZ^->=\LB100E4U;R%C./>!3]EE,BBCB,,/ (,ED(M33'YJW3O\J+
M?U(4;2]C:FWEJ](T 9-@Q"8@;H)$EH+(XQJ@TH;OLD8LBWM,Y!UP_8_W,N*B
M0 R*DGE23Q!"*9V,F TZS.YFE #&<@#2O&8;C&/X%94T?:EEI90KP*TRGD-0
M?:>QB]5=!!^5[O(R9F,T;F*NI2]Y/"MX[C->-#$K%M7\C%(/Z-BP(G-T+;FS
M)\J1*,KIX:&G(WZ4T@+?Q:]4T"]C*RBPG0!\PM?&OSE+UO<NK=\\%M)=EHTP
M=0).&,V%QT0\6?\R[05/GL#9@)6TQ&TJ3W_ KJ_&9*R"GOSS^N9:^LUU/PTP
M/T*,(<86YX/Z=7T[X2&Q,YT,D><->W5B95]<&"U6#A=]HG)3D2>%JL!=X:Q-
MQS:/\T4;^=(U)EVH%2NL4"/CS91_+4758_ *F"),#7VEBH=NGSBG8X9F=LMO
M"KD"3=A5-O(Y_%@F*DOQ')Z-A_?7TDWOZ<!FT#5M&7E-R)$G[EG0134:*<.-
MAX1;RU.4*%.HOK4+*8E)LF$<&-]% @7%WD0P,[\K?&(O GG^@'S/KO5KODK]
MK7E#L&%: B]WP)_[VDV&S_.671B^^ZFZJ6]:JR 7NN[WJ_$K^K!]5$H&;Z:*
MM"6'S)H" 'YGA,RH."ZC.06ZF,3YM;@..9?K(8FF(T[>([T7! &XSP^P\*VN
MTO7Z;DNKKE;EUW+_OR@RS+40T8Z-+S]%18%_@*;IN;JD>SS_F?/XPJZ>#ZJ4
M?Z(<^[U*ZV2>#_L7^<*;9,.O;8Z0;GIJX*JFK9J!806!XH4!9Q/9-Y2Z(R3+
MJN7XBA^IGJSJIFTX 7M442U%\\.MOL3.<=8<(=*4M*YCW:!]QCYFZN?E!O7,
M/SR>R$+8W*$@K<PU=)G)5\LV:O@.==-H("4I:<'EG*PQ>(1"CJ1ZF7.4LZSG
MY6T!8U$7F"K!+<LKQ;^22,?3"FM*';8!C%R6RLU#DZT#CMO-^$V6XH#%_=CJ
M*1.-KQ^CW6E..=63C'E_L_8</1;D% 8,IJSQ5[26$Y!O**1U?8'<2L24[W0!
MMF**X4UN!Q[@ 3[6(N&\X ??Q/XFHOHL%XT=?$'I=/S \4Q@W:P<B+M.L'.5
MU4?7$!+=A<%!3./\*WEL]]6HL3B'YE+2HK0+T;,4.=W@<XL<??P.>R'9ZQ1D
MI\BT^)[PE^^!.Q)NN-_B#T@J>/# W=6>5P0\H&-J)*^1@F3OBRNU*EX"DR+-
MBSZI2)2GL@$0U/ SYK0S-5O& \1>'6*T;>;L9[[I[D6N(&/4TCOK0F*4@']*
MJ8G<WY]1+0TSE)BYQ9,GN7/.Z+ D.A('>+-!YSRC:QF>W\?R3S%+D XS&=[/
M4I SQ<_-C3CH?KT>+M5%M'3#?;NT?J';=O>M\$P;?L%]2(+909>;:_D(!Y\C
M>BVJ>7 NTHY9]DQL/#B^*AU!Q)27LKS4$6\\:]$H8;N#-$[BJ5 658'P*ONN
MWZM?*.E%4=+O3-]LHR2ADE"+U1M@U[TS4F?\P445O<1XPT,V>:":,,P)HNM+
M2H$&ZR*/:_G;306UFG]\(<,S(\.C(YK%=J(KRS' #A,19HYR0.GNZQ2$%^]%
M08:<2)HGLV>\G TYS@#0[D]H9,-;LBDXI-EMD<&7AGB3OI/B7HTE@Q='-;.<
M7<ADD^P.W1]FRH@3JED>3_.$UP_,EXN+^7%>W-HSA?S/,L.X&]<(R&25<&\5
MY^0U,1^'*8E">OLA 5=64CC!O+M(_-=.0T4*C\?YOA1$V6C_V4*)^[Q24",K
MSN2I@FR< 4M^0^(LPPRPP.:(Y?=&H*"&F*U(7ZI^N\5Z+);B6+VN^A;X] _L
M;3/T]O'F#$VI =-U>9[=8FB5;M$&M9<)4VL4+V*\8,-'$YYR!M]DTYTF8(<)
M/E,O?/8Z^>S/68ULZO27)V.,"&])8..DH^U-.N=\0]?W-4P/87J\L9,PZ#FI
M!43!A*H97Y?KN5-?SSWO==SS7;]%G:_?LAR&F+$63<.G6BY2X<Y&].NDGHZX
M]3I.46S7"FS-M&4KC$(C-")1N^#+JJ+6KN-\S30,T_<4+[)");1L1W987J+N
M!:IM;KW3VCG.^G4<6Z8DUBG55G;L!=T>L_DQ[XP[)TU/.;("9J"G6%;&;DG0
M2BN3#L&!S]!N8[T&A@3NAL@[MTDRJQ<WL"(%EN%>NO;5E^A^:<$/L^V9ITU7
M>PP!#F0OI:.-L/@K)S AD,5,EBXPU8X5+N0DS#"UAD%Z5$E2C62^*D'P<=>L
M.):CR.B?%4D)/;#/S&*$8;A+5F=(:!#LGBG-6-Y0\RV\CH3;I&G!<Z[I)>39
M5WS!7RG2BT2*2;\)1:C@\N2>W77R3?GI+5Y!ONN:1X1K%NMDB!IDEL'BZ,:L
MY2RFV2Q98,'F!E(!&LXVD.#3B??GE E7R*JU+&"8.UXUTH7SF)$ [@F/GR4,
M_:8BZG+3TD4R)9H\A$DX[E>=W.(*M?N'W-#!.N,CP:WO4ZVVA[;LK-*+.H)_
MB#';P&,O)<CMP""F[&BG1P9QMA0;;X$&,;X/,LA&?(;3()"W C2PDN/U?S>R
M:=]M4PX'R'@Y3;U.36"<V>@ENRK;U\[UY% T^XSXYE=+N6"([![N@B%RP1 Y
MH0*_8(A<,$0.QQ#1C\,0,?:^]#AUQ/&W0YVD@T>HLM,Z138_,^S0*,^F6%&'
M$/+_ I?3!Q\3_+]\CW"FINBR'+FN;?BRI46Z8KDBI*_ \=2K"P+75$)/=B-9
MUE5/,^"\/'I45MU UZVMI[YSG+5PYNDV_;- 7$4U]"6/1XE U"_ .A:0GB4K
MK49.]V23?59\S(:=%TYQ_S4-97B$73UCJ24&,P2,*$M\BB>3E#?$X&>*&>>8
MS$U7V]V"'*QET]]V]&S23:5D#<_S U_S'<4T(L.2==_T%1;IUU37L3S!M_-Q
M\C,P*MH0C"X_I\575N/V9A//_[O(%__^Q!;_,;])\H=TF%!3-WC;O[]D\Q!/
M@3]0L YN9;^WM<&\)R^9#>_QMKW1&.X&=Y4S!G_7!SCCW:_[\C1/&F_BWUY[
M=&=O.:?L..5L[VN]UFQ*NDV!#K*R$U"G4Z>X,I6N @EU>P7Q0\?1.7EWKF=E
M?G[7J-[Q:U\DG1HQ];5RN^/@J *.7_P,6.5[KM[J&AY_S[(>X[N[/+FCD/6"
MJK";,K?8('2%2"Z%;PE)=I3DW25XG<HFB6PC"B+%-L+(T!S9D4.-0[]HGFD'
MVJK!M":5/B4Y?A#?)<KKD\ @6.F#2@BKI0P&^V*;$-:=-2G\7\>)7WZ76M+2
M=Y&#)R7;JL>C[.E>I%F&;.NNHAJ:K/DN(UM/5O3 .I)L[?W(]DLR>UU$:ZR;
M#F=$M,>HL!/2K2%;549+8/NR%BF!I1L@8*,0'F%T&WFAH?M'TJVU']W^ 13V
MN@A7-WLE7-XV=4S_0Q+J1CY]$G]G"Z9_-!W+[[B,\<8>H"QA S,^)"J)GZ=Y
M65.-R4,3]/H1VQ,LJGF2(Q0/FA2L?PUOI8KX5NDX'6(_KWCTD.2%2 $1757+
M@\"D!(:51B$AWN]NR*-"O%-8A6QT2Z@]D^PQR:ETG'5?H6SPT9(@5&%5R:B.
M#RK2 *J74+N6$2M0HFKNO-G; UY55GOS;IA +[Q,:C9*X<NX 2)]_3:Y0TB
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MTU]\6]@BG[S?><NZ%3S_MDYW/Q$T%O7%$YWU5I@'AQ"#H\. O[?VS!.O:6[
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M:<T6PX9WZ#Y+X/I-4.B1_X%A?I@*.H )=^EX@S$*0JZTA/\=7P++'/"?TM%
MA*D%UNL5&U&L1UIQ.,7\V%,$>4P=Q:IN9"1T4415OELJ&G?P.X>D&.:IZ#B6
MIPN$8>:7'7,03PCI$Z,)R7O(S.<3MM*U47@(!:/N'#Z7R;<R#,$H@H+8=3A@
M-C71D9VK'R:S>=DU"GS>5:0Q(G[&.[:)KFXY<T>365%>6#" WK*><Y$G>,]
MUF?!:X2I$'9.=Y-#UL:P#HE<6I5X]'1-00A!U<9)HWQY5RU/'*ST">,U00,[
M6"C4\AF2"O(O1"Q8+7X7SP?TF?(+XQ+43C-J:W]?/CU"!WX&7C(&5,K'&UA]
M[=WI@!(8(PVI<J5Y^@S]MJZLN0IE1,[;U^"6\L/ WHLLH%<!HN#S8L/*"%UM
M<6QK19^]!9VKV.A#CQ"3WSBV2J/CWO:CQ9KJ+3Q6&B)"3(DM*5]8/HI4W-ZG
M$%^.2WDB8;.L!SY:"XHOCL/+5ZT?EXLBY9V]F'[%GZ;Q7T#5S$8G/=L4\>O6
M<%[IS"4#5=N@!0D8=JU5;"DD^/<1#S8=)L+$1H5)[6F I)GXKI#>0?\SW59"
MDY.-7T(3D%;@-C(, .H.NV!1EJ8 H ^7>,<=SZJ;RD$C'@A+'BZYO<Y>6*GI
M4H\L,@R++F>W8*DGA/VVLF<EN'>.;RFX_;IR[;>X![$%\I,+DD>AV^)9W1>:
M( 0*0]2%#4/[_2Y&['S:V?8M!-D%(S$G[#ZI!.6$P+M(%Z?3VV5>)"R$ /(P
MNZ7=@:W/1U>H+IX:6$XD ^^3R;S@EX[3;)8N.(Y(/ (G!2VDTA'AFO0B8UZ?
MC/G4-#%7&*/F<$MOJYNP!CT2?5%\L'Y;0VDQV2QC#2FX^*FA+F:,=IFIDQ3O
MI.$D*^CJ R&%OS'USME%1.Q%RSSRQ,G56. M]V+5MZ_B%%PX+1[)V!RCB?F8
M)%\YS"V^3?CF)5+_A0<N/-"B4,O(<4,CENJ'Y+THJQ HZF3XSL"3FV<L :H!
MN$Q43-0^1YV8_,S!L\1(<RQF+*^RF3V:%+\TD&;$I# +95ZFFB)UTZQ_0=U$
MKBHV@1[QWB[,A<+&[7R]<;$0K_JEILH*4"!C8(QQ0M>03!?^4E=W9;\+8E#Z
M+:7V(HM'1/S"[!1V*T^V+ Y UD=\1\_]PMS*V1-'.V7ZDE^&LN[M/&)6LQ,8
MO"*SX?F<*WNZSSC];T*(#/@X)+QJ&0VC!#/(GA+NA%?9ABRX.5Z2U\=BH4A!
MO(>,@-W.IZR= [OO.:G4,2]2YPRE3A7F8?214CXU18.(GW.AT)@%*"+GC!N(
MS^K!ZK70.FM.FU=I8^7[T1G/QN.$-"F9ZAAEPT_Q57DSE%&B^'-O8VVNI3#$
MO[;'$-B](@=RKGVUO*8G QCC&XN2C4"(W,</:;::K=92XM\-W*H[ (;]<O$O
M'.=:5>S3XU<9G>"KG T0&)LYNE?,"_;!+M2+D\,)M:,'J1OS=_N>4.OXWQ/]
M:2.^TV%2>AUII"MPU]DM[1C@M LJU>[A+JA4%U2J$VKE"RK5!97J<%0JXSA4
M*O-YO:$^ (;4[4V35=51 L5U3-TS'<]QM- 37U<UT[R2W[2X#A\I:L_"XXU+
M^.K:3US&-RZB6<H ]W"J9_>Y1FQD.>U.;FI)9F07'LEQ9=*[\(!,I8;\;YJ&
M:?F!HH>.$3FJ&T6^',IV9)NVYOE*'0_H,UNG.QL%8KXNV^"5"NGW#)!B"X*.
MO2>"CG%MG0A#A\%A=_MRD RI9)K)#%$@T;THOJ^JX--2C5JC&L/#Y 3#MR+#
M4&37]0P@'D_S35<);$OO3#5V3U2CGQW5M$%QM])11W"%E6A+)Y"^F^%],EI.
MDH]C.J%D]*&"W?^""G K0)^N@!YR7-^Q3#4(#=.P3)TK)L]1';D&T*<XBNJH
MMN\&0#".%X6V&3& /B/RPE!?0]CKIL]^0-.R)[O1V6DW6LIFV[#CG[8$@/H?
M;+^OM5JVSK-8MB>, +SY]4NS 2@1(T]E+#;TAFIV?1A.XJ*@5-]:]E<MH>#G
M39;PULC=]W(->M[=S3#SSXC[?H1G=$IWJ,Y(U@Y&XDO@RUQ?19>-ZD85FZX"
M#J,+E[2_T-I8&7L,EYQB=[J+(?/ZP$"0^,+;W]]_^/#^XQ\WTL=("CY^^.!^
MOGGWW;CF/!A#_6$8XW2-/#J0P*YMZ44C=#[YMO8\%\(^/6&?DG:;<'8]DNIW
MH\9G-M+:O:O5I+GNQ_,YP0:Z29F+VT^HI$5D,73U6*"KYR6Z^H"@+:I 'L42
M1]GR=C%>3LHOO$ZYT/OZ,'9ZE\..CJYXZ7EBX/\]\WWJW[I(A$U3_\XBKF5Y
M>Z%IVK)>QFML758#53,-TW<,P]5LPW9LUW5"4PW]P(R.B1*7\)0><U!OT#_]
MP%/Q&_B5HO5!U?E@)U*[648,S>U([0/56(\TK\0*^R"&BY7R TFCDP89NLB8
M[VXM[2<Y5*V4'&ZH*(9BA)$6!H9C1;9KZ[[C6*'G*X$1=;]?LL]'<MAVCY+C
M=1J.W^EN_W4M=>_4CIVFS,O8C\O1O^AEORA/>,V*;[O_YTW<>>UZK6=Z9Z^Y
MZ3>T70J= Q^="_-\5[GYTH7EN1SRC[[6;F)1.<][<)ZG(E+P7CGI[HS.]RF?
MSC%FY6A5!QA--^W0T3S+\!5#-2W7T0W;<15P/+7 \)VZY\G)B#N@Q\:I2 W[
M3 O7,JAZ<SDU<#F-2[#JE3#MN?'FOJQHF"4KJI;I&EHHJY&B&7IDV)$:!5K@
MR;(3*H87'L2*!P5^GH$5Y5<<_3E3JX#Y02*5[2)?7KE18%?MCQ53BYPH\D$0
M:8:K.(X9NH9E:XHA!YYEF75)1%3$ ]!G;Q,8]GK'P(M%\#(Y]MP8<S\^U&2Y
M*@ PK< -7$LU30,M@\#6'<W57,4/ ]_3_/ 0/CPK@\#0^N3#'\P<^+'CQ:]K
MJ3]&4/-R]"\]U/E*+X-.W)>BQ59F3A'HI2WW0V?&$N=B<+UT%TF3K<I%LEU=
M,U79]G15,:+ L#W/55W9=D)?TU7GJ(KP ^VT/TIB/8FI9EZ"J*^%@\^-4??E
M2Z=RF2S54VU3=V19\PU5-1S-TH- UAQ=5D-3]I\GD^X9^%)SG%?E0C5+2;3Y
M-ZHNF"3?J1"P6STRX;3'S=M8!DM_;"SVNVS/.257G&0#-JJK[U5UW6*Z=*K"
MV+59QY1IG%.)Y5[Z0ZEAMKA:Y&NJ)WN>+!N!97I.$$:ZXU@1:1/U1$@_>UMC
M ]/N4^YW)X0?L\KT(B9/(B:_&P;%283?.<NX?46:YI0B+?(B%SXP9=<-#/C1
MBU3;\=7052W#-37S1#!4^XLT736?5:2=I>1J 5 \D"Y:7MS M]H'@W /$,%M
M&(2N[NBF%FJV;BJ1%:B^%FGBZT!I*F$0UO9W8_-./)P2UO^(Q,=I6:?, ./'
MU+5]K2WI,)XU>K;%U#=AD@!U(,@[ 9J(-J@%1PL2C=8>V&<S;%7/NSHM1%L+
M]M[)DW2?Q _862:;U;M/87N(HEA.6;LYUHBM'98(^TLA;GZ1#:DE/,.<W_BJ
M <P[Z:D*G,'\2HJ_@IVV[1B/%7%=@8V[>67Q-^K+26W&D4:0 JIV%X1XF2)^
M5+;2,(OA84ZQ0R1U_:LZ<Z&7MUS<8Q^SE/<LH)X=(_'ZOH[FN#[*J[T'VOH*
M[+'KUF&[;FTZXTYH?%6Q8O$).\H\;47?,RT[<B,ULAP]T'0GM(THXNA[@88I
M,)4G8*NN'82>I[JJX\&SJAD1@JP5Z4%DALI!Z'L]7UP(( 91L2E5NW!$1VWU
MEXWP#JR3]H*U@".1E.;2+$%4UQ@[8>(CV,*2.I,F-1@(@4C!NCXO-KX_3\9X
M1JR'T"T(MD9#'."[6WH,.^ 0=AMHUZ3JIUF]"/L*Y8LQ4$*MJVK9.^\V+J@Y
M2'LCCT'5&:\&2(LJ@[4<7>1D2(RJ!52A&W%=5!/?L!5;MU/TELW&8XG@XW%4
MWKF('IHF\8S@U;EL8IUUEA/1,4QZF\Y0J*!PPN@B:^:-/4^2/*FW7GK'.@O?
M8M.BY-M]#+(M&742YWVQ^JIELM_HSF&C.VTQ 3+I1F@/T&[]3.VC<$QX\]^O
MI3ULI#V,G*-L).7-KSZ"6-[2%.'<W#S'/JH<2'^]'<R*##UV^LK>LJPO:CBA
M<O\4/Y5-_*@]+FI?;.4SK+886W/&^6(FFEMA$V!$PANA>&'/UMH;%&53 ]YE
M+YLFS4[#LY@L0]$\K#J].L.FBZH7.#8!I-:Y[P8M+YB+)9"1-Y]/6-]>(5?P
M97=+F!Q(JVOI3VK</<RN@/FG&;,B[_*$39A:^/*F3%5?,R&8DCUVAQ!^4I+L
MHB/3@%O+V2QA/=+ZMFT&W50:ZPRUXZAI?W,XE71.?4M9\RDXL(+[U;P3*M\A
M6&IQ'Y='PW4@LP8S:@D_3K&SN[NZ2<VV5:R](\=*;QX6XCBE0NVPYE3UR>-T
MUC\MET3-Z=F:JN;T;**502N:1MXG=6IBO6V9^E[I-LXF@^]&6L,IL Z *>LM
M623-QG&,QAGW]$4+-VSP05V_\M;H\0A4/*AS+BS%G*\[4@WVYFU(WQK_%ERU
M/F*7XMD2&_HAG\:E7X#[M)GBZNQ7$@91Z2,GNC'Q+@B%;%)R/W\U'.3F-U^O
M3!LII77:^]!\?9I"0LP1_Y];(BUTQXD5R*QDCS;&D)(8^PRRAH)D[&1/\63Q
M5(FXS4, S_1%3#[O]T;3Z^@Y29]7I]X4HEMDSBGX@Z4MO67:Z-U/56B#&_9P
M&@?8>_4HC%+"?_<7M?V\UE\7:&27[B% .>P8G;&FF]BU;T6N(LWUN*F(JA?G
MV'H3R+4^M) Q76GGSSDL%M[3T.Q@=5R1S0Y^E 1?!_\'5&KUS&B9L#UB':^W
M[!1L07VV!?5,;3R[KH_.?L]^/V9'F'N5)W?8RS;+>1=FW.A[6#OY1?$"(W<\
M1!B#[S5*A_![<Z-Z)*[WB*4/OB8IWW2VP'ZM9-6!@[L0;!NP#<3P4C*\GV63
M[.Y)HEN$HVEO'Y)CXGHG9]X^X0F(C;J;P7#/+=PZ*GL,V)'ZJU,JLX0V&&#"
MTAE4YF6MYXV4W4ZX&UX(.<\1Y]%8^OQ_XNG\EZ R\G8H=7Y6@^9!T<F!\-OG
MZ-C13.,G(/(?[G32*7(A6*+8Z1QWFR\*C2P\.!9Y8<<%TB ! 4/;O)RO.6+;
MSVG5%FZ<Q[7T+[*>\)EJHRGLCSUEVX1*4X20/57U;"]/89.0!Z)8%FV^".NP
M3#O1-NKZ.OY:YFF!;6?QVVN2CAKA(FD<.R,XEDE*C!3/VK<)C%-V,R(-TWRX
MG&*[[J$P?OGPM0X+PJM^I";9LVR!U%O& *FM= &V"#5FF"W(EL[!F#NS</9Y
MQ+3>LYC6X8'U]S,\.Z"P/<+JFN=HNJRKBNE%8:18FNI;HJF-HKA&+:RN!;HI
MVYYOA;[O^J;N*+K,FMHXCF^9SM;8V<YQUJ+RPM:_*6]LQ+HHH7\E#'E@*&V/
MZ9PGT75MZ#T$K_()N+/<0=&O>Y(]HD >\U[:V^X&1+?M,7KM]R#.[S(0WR D
ML_PK2@K@\R%!2>/M6OPHX1T SJ= :5L+Z2\+BD8 ZZ-YRZ-H^'*2:TQ YB1O
M']+DD31 ?>(HH],I^+4Y*7UVET<HVOR^KL"[>#9#$E.S!*<5YT\7,=,B9O[1
M5<SPR,YO3#^ZLY';B.>$W&W8YV[/T\+0L$(O4$(;.%/Q#(,'ME5'ELWZW9X9
M1:X=&(H>R6JH!IZI:NQN3XU\!0MKMPBAG>.L":$R>O5^+7K57*T4EE[2<9)I
MGSD>LT3UV05;5S8[5;?.?;9H_ZAE%<S@?C(YY2DK( !+S9UF(.R8P8O1V[MB
MP$.O98Q6N!O,?@(Q*8:":;-?V" @>LOP[0#F05E4!?U2W*?SN8CQ@C$W6IM]
MW0_%AR;)';QXE(QQ#M?KAP3T7;Z_FJIHWTFFZS>ZY05!?<*VC)HF5Y!7EJX'
M2N"I3JA%BJVY8(FX='(*,+\M:ZL2JK8$SIYO-@NWH[LRJM?KR7#]=&7LZ/.U
MM63LWLAS<-IC5HSRF&4E<!S'\'TOU,&R5&0G<IBAJ5JAZD2=CMGNZYBUZW4$
MA',\YHY]-DDXG/2D:^CILJ9:AND$FJ>ZH:X$KF993)MK?N0[=J>3ME[L2=.Y
M6EWCAY]8  R/9+O2JMU5<K63QZ,TDQ;I- 'E!8KT 8X 50I\P-H^S^-A0B[
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MV!&,Y(1!8(>.H_B1(JLJ3P"(=-ERL0A^2[!DY]>MO2,3IXY7?: [J-)MP^C
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M,$*<Y^DJF,> 0Z]3M@*E+M1BJRQG\GLWHK[47+QPVG9WQJ#.CGXI))?<8T^
M!]&-]*>WF#O\KB-B#8. 81T1]T"ON+# BV*!O^\*L:XP0 4=1 TM+]3RJJCE
MT\:X^$'&[R.UK19A^UG6A$44=B61WC2)BV5>@UF$=V)+]]G3:H_4^61)R0/L
M 2&76282 1=0K_A;;*1*DV(=HFORF_PXF'JMC715/<J*06#OJ<JU3'ZKF>3<
M\B[B*0($%,NU]AD7[GCAW($)9IPSZC=IE!$YG6;XIFSXE2557Q7+6]9KO/G'
M)FNT\T59[E-=H5,^GL@TD.9XCYM6%<=L-@GK+K,L6+YWTP-%#[.\&;^6_J3F
M0VN/U4NMT:TL[N-5GS-)R)ZV?BE$KW36Z;/LYO2<!GW75G)?6M#$BL6Z<\V.
M8FTGV+4\5;"5],"<]%H567/3, 5#5.;6<F0Q:DO%JI-)-A3H3&O%:;6*\DG*
M_/OVTZ=LW-E3K4"=KY(7VC6&$>5EU](-IGJM7@ZS#/]&_C&7T;R9$,Y[O22N
M"<L&$IRWXWN:,Z@,:90E#%%-)**Q,- =A3WJ7SX*:&TSZ_\ 92*?N;$NW<4I
MJ]) !R"A'E&45,^PQIKG5>L_11W'1/%CV>1+D-2PRC3G&+MGFYMZY#XVNK&7
MQ>4U+*6:@&V#4A*E@@U93P9T%>+C%;0Q-N@D -"&IU@5?#8ZA U6:D-9VC7#
M3A:\AJ$\$"B/[* 8K"@7,S4!Q5 W1+_XEP#Q54MBW"-?R?9#18ULW0M<2]=,
MQS$#2\2:0\VK(WL%1N#*;J2IFNI$AA$:>F2R?"7+<]7H6;-R:\E+[7ER&^,2
M2 ,/<9YF2ZSCF)"% 4>?8,QXD=QEE(+_MO<$=LOMIFO?/7L<Y0]*=$2;H6,9
M49:S\NS1KC-"PX]7@O%41I&OB?^EDC0T5^[3>3'X$2)%)Z":J"/5'-)*MW^Y
MU0W!K5N(4L!KBFH45$TU#J'BP4L5_<LIMZF^?NJ$X4_=$X91EGR)O^VA?RU+
ML=10MR(GBBS;1SP_153%F&84U?2O:D>!'C@FW@BK1J"9=JCPJI@PT"-WZYWR
MSG'6\H5A_KSC#Q'<AYKC1"!+S'G%IWSA@ S3XWL^[S/18];Y@NKAMQ'OYM,[
M?\;N5KB"M;&8J P+Y\[(/ >!F:,DYJXR&';I.WHB&8^384O5.>8!Y(3%,WLJ
M,=%+=W%&O9KQ00R'4I7_])8\1H[HQ_QZT:'A;D9.*'<ZAO4\LZ+,+F/O)EXJ
MRY.KL;#7,"4A9*"FJO[73XUR^K<IK(J_ Q?'&DRCCU_#I2Z;&S.,()S?0X*!
MXR3E=:KPV9A@P!E83_R-BF^6X.#R&#;A%\(\*E@#!#%GFA''S<"+NF,VVP^@
M/CKZ'1PCOT9FJV&EE>.OD(KX =1V#&D"W&",6K+:P!3H,F>_WB:+QX031&4_
M5VA)%!6"=]R6R''MTV&1C&06L]-'^BBM".S_,^#<(>(='-V !\>^^/]PRR\#
M)0= 6]-;H!?0?A;#0LZSAW2$9A0+$) M@V40Y%J) H3;9(+MT!D](NN,VG:2
M]]_@Q$FQNUMJ%440&O1848C;A JZH=I1WJ2%L0+';<CR><:6G,WN,JHTF^?+
MD;@7&2=Q08B"\/4KQ *AN!]A*B1W5&9!+WK,EL"'MS7@$ Q#I.,Z]A=AB%#H
MB6<(K2WQ6G*!9UO7OG)L7,J45R;XZ%]+, U'Z; JYV2HI;RW$PN?<D@P'E#-
M&&C C.XL1:X4$UTU<=1PA G^?KW0O>5TSZ:8_6)+/[\PW.Q9 ]%=#=?5<3=7
MME+B93<3HM^ZO\=JFC"##T4D"476Y8'=6\Y:N(?WU$">KM,OO2E^$B*F4JHL
M]!+/.+C=RNOH1J2H3Z*<0!V&I!IGF/';*$1M&0/A+NB. 47PFMX=,-TL$&]8
MYS8J[TQ9!CMBP$Q1Z(RR)1=D,0,795=G-+:0.!EOCD&,FK"L1S[6$\KR(:'I
M?+E/*BG,\B%70-L'5=IC*=O)LIAF.;9>^HK<2R" L&<\?(OYF#C@<IZ5."S4
M9J3:\7*K6T\-N)4B006>"D&F#IB$7 YQWHC? VMB5T,,G(.6\+3U[%X9=[(=
MABU'7=DQQ%>:OYMT"+^N*ZT%31E(5,)26N)U78='5>H UMXP$WA=(MVVILG(
M JJ*O4$NQ(N<]U*AKH9I2;,SKHA!88^J!UD5=-FP;8Y878ICFS@1. !0-7&.
M5D!- [; ]I3F$4Z_9 ;R1-$T*)\9IQ,J6&=Z%W;!EOZ\O@&EE>!-W:19@%)S
MJS\GH">!B4ONP+M4H@]J1%%VIX!7JB;3@0)6F *MI3H\@5(S@HZ4L^NH^YUE
MQZ![:;-O)JV7*36V110V!WQ>X$;0W2=/^. M74KW>EA?/7>OXK*O%/?\6 ?6
M;)1,")GEL>JWQEWR!NVC>FS3FURE%LL"V05!ZOXO>]_^W"B2I?NO$+4[&]41
MMAM(DD?UO1W!<\:S]>JJZIF[^\L$EI#-M"0T()7+\]??<S(32$GH#;9LL_=.
MM6TA2#)/GE=^YSMH.6,(UL"D\L@(5$<RKC0=:Z+ 8%B8?:MA%.6#*H *"TXY
M9RX?.(OE!)I,_CLZ'.7!:QDBEMT)6(!5E'S#?-14_5/Y%DB#GO"C''$>SX8/
MWL.<1U 7+(!93/A]8^ZQK\Y+\B.N3N79PVOJMU5GZ8'?Y0Z)2!809_TQS>['
MC!A#T!9#2)%\%V"A4CN^S)W\YM<:HK11-%G\RLM?&%9%#K!'<3HN63'1;14!
MI7P/QB,D>=M"N$K  'B>Z3SC\)]J05''([2+93WF AQ3"Z-TMW<L69<R^<TY
MV%$Z!!7=BQ$($(^S6SS-17\0_Z9PY9TS/  " .3(D E(L1B-$ #&!Q"G O'%
MQ#:]RSC<"T03X>\2U\RNS86SQ8!XZB]-FYE]I/WRB\C7"3CD/)XO>!0S!B=^
M+HA%DQ\S\/:+7_!=X')Y(A#M)*)LJ?:)Z00)S<FH+D?Q]XQG4>H]QP<=\\@,
M_0BI38FTLV+4;P],*=0K*K<8P%5=-M]5ID;P<#+*31P=#HW]-.(>SP5/?_*4
M1S80\+S2]Y(T+?><BHNMLQ2+P+T4#I8^@/'62)U:7!0>$R3IC,U#HW#P1(_(
MBI;-RA5VGBU^WB0+<2T)_/":QT1X>2NT&.7>7Z^UW1_'^:J*<QWGRE0=TCUG
MAK.E#'<+:09]&LZ,C<P%[)(6XLX]J MX,>[ZOQO-8[O#/(8ZHM6JZ.V%S^O;
M<]/+'5[M_'BD+.PFNVJ^U]:U<Y*6?9[XYE>+]NP:NQ_7LVOT[!H=&O">7:-G
MUSB<7<,^C5W#V8M=8P^@T4DX)=(M@!H#U$L>H%YB@'J)V28LN!K&^?!J&>VU
M<GBZ,7V[PC,*$;E(V+,CJ!()P'$0:!MF\0.GB)7.NJ<P2XJF"[)C;(T!VBXI
M1 EC L$^/Q(KRP)*L$7><ON,SXAJ*."]?GXK\A$_\:PP.SW)RC#U^$X+J].5
M[3Q2J>+TJA']V22DSXW-?Y_=A82>=;Z+BV^5PM@($"@SC$BGF;#6:N)H*2XR
M7LQ[\Z" R0/_CV<X;Q;+Y]4L4["82@"AI?-J)N;-1]G(+H.[E*&WQ%$X3S*P
MXD1VDIHMYBB6HG<NUCGP*6*'SHR1O!X'/_W&GW->IQ8S4-Q*88^$5!-;E!.3
MLP8E4E8IK^%K(EM3-">U!'2-GV"+(^42"U(HV&LW3^8EA?/:(^&UL_&"G[FC
M.SE._\TSP,.*05UL$9[H;8"Q<>PWKYUCN9_Q:A\5EIC"UA[\0#P9\BP4.WT6
M"#C,;H$68OEO1&VE TR2@E*K< DL2Y1.2JA6SKK.8%XQ*SC>J"[!'I<EA3CU
M&]3KA4B=#NI:D$$)29+*8/O&#L\0:?[;L4CSSUB]DDW=Z9"=[7_.0(23><H[
M%7W&OE8<@MZ$/%=5S0I<4(J^'JF69GL&5<N.)[9N^#)AO:=&X!^ID1'9MA4:
M6A@)PGK5MXV(;/5T=CYG#7DNWHI)W_(K*9XXRF#O=BK4?)^1G?)B+PAJ_N97
M1 1-XG_R8S:!94@FLW'VD"!:,<O'PWL& V6\V!Q:S(X.1_SP3BS<3*PM:[IV
M47V,TYRG-XMY]1E:%"2L9NV245<A9N)BF<OZ^HM_R2O'4E'Q62QF IT)ROLM
M M&JSW]:'PM[#N].M6D82T!K#B":+8OD\MW8*2]O8E CUV"ZP$E@IP7IM%CD
MS*GC^"2\35*A7%*84X@1F7FHX%*%.(61S\E8+(<J9*@P0,6P^I49WZ)J-2M6
M:L.K%U6;,U8D+>-F=F%$41XDP/=*RRV9EJ0">J%<E9#5Y7:RM?LSY_///"FT
MID+"$$[Z'?E(<IR3/.&&6$"/Y:-AT';<"Q,OBE9O,8ZO%'3W9I)B:5Q+^85$
MHT'F)L@.8-G7I<)S5V-$N X#Z3 G+L:@/YVA$X*<0#%STAE*)Y.&(H1LOC2;
M[-GQN,@:!Q 7$NZ>H?BF!?_:&)NL%?5#=LMKXY,W/W0)QUY2/O!50(E?%_)R
M89>V$;_+7-#*<^04N&=%(G5O8WP1P]JAJR8Y$Z^%1;IB)6YQTJ=BT\-H;O-X
M4OQTQ8R$#"V7A5+NQXX5K]S#!,LKR\B&F>.CE-H<,Z=7"&C]"LLE(.?/ZM$'
MD(?9]D:4_![B(PS%62#GUR>^Q]*?>[3PY?CNSA,(QIE 80<W&<:V1Z5JZ$61
MX;IF:*F^[FFV&ZA:F3>EU#9EI@AB.;[J>%9D.GID6VX4V#Q>T#5/#;?'"SN?
MLQ8OO&>A.DI?./V>YEEI"EJM2]UG6*>\U8L*%OZ>+'4:%DYH49ZXE55R\(=_
MBESP%)>%H;B6T)5P;2'@3,Q1P<95>&(W@/L5S'TL6Z?6#?=F,7,M,'M]*_#/
MHO6RY.%*+B#_K&J!+'\/ZR>0SCD>+_TY61*SP3A.)T79XKE.%]5N2=G9K/*5
MX=);\(?!-RR=?SR<FTPKS%+M\^<,JYY#%%.1[17)RBQ5GAGWJ1B*B5W#_3@!
M.$5J"TQ7L=!IJ>MME;U\D!O@7H]XG85 >XHD?5QGLM@-P>?F8'2&5$4<[!RQ
MH%(:#)VPZ4/9#G7I9LRJX.U88,?>LQPNNP[+Y>!N4Y:6&Y=<0=.LBS$M#R&!
M.]VS<X>E>CKVG*6UF7(O?\Z2P"SP9:A@!KY,?HA0L':(68098^DQ>Y6Z0(49
M5O1.>S_L0+79Z(<M;Y#>V>J=K>.<K:_'.EM?,8#U\#S)ET+T3VRUP/NZGB*0
M [3:CBQMX(>F&E#7LB/=]SU"2%3R<_F$Z*[D==FF;3JJ9QJF:D34B2S=]T26
MEJAD1Y9VYW/6O"[V@I?L#97/O$3I9"=KGU&<\A(ORLGZQ DHZO1/F?I8.N%B
MB91+?K I*LG N?ASF:D#-P7=D-)B-5Q=WQ9=-E$3([3L,K.:2&(6ZQT.ZL1@
MS8^-VHZ5V>.$7#+J/T[25]&WEMU@L?@$CP+!G+>EX'R1NV)LD!<*B-!8M*"M
M=+$(*5:.!DNBUN,/_G^&>6OK-;[ 9,<YNKTLB0T^4C9C:W;:,/DI9UT-T+LD
M!RJ91I=$WEM+^[;W3H[R3IYAFO,\?)IOQ_HT[R'.3I+W6 2S3\9();II6"[L
M"A+JND4<S?;\P#5,R]==S54EW\7T0L/7#=T*[-"U/=VVX2*X- R(I5&R'=&W
M\SD-&:.X.#TEM,=SSTG &KIQM]TC>:K\-8;YRA\X&E04_?/(>IC-6.$]J[J2
MNHR7H$.F(\=L8?@)UFB1BQJL+BO9-:]S/=+R+/\]X=/$RFH9>_$\N5!&XR01
MW<F0*H2[ :S:GO4BX^>!,T$-7O#S4#[;DG?&CM;YS;G3!9;GN.GY/_Q+RVH&
MM]"0&%1SB&$DQ*&T4@"J#M:4!,2W I5ZD6G[NDY\+71LU?8-1VM619]*2G^V
MH;_!D#^-?)%A>;.LU:ZY5OM'D<__\06S..Z/M&"_?4#ZE,7D V.J>,,A8:!C
M4EBT(AF\&RYR+)-\\ZNV45\<Y0H>Z<WN.[5.C=X)(J(YCF%03Z>ZH]HJ,4)#
M#8AJ4X=0M\NIC7_L-;5$;7=N&3_&!4]?@@@+NGT1$64EDC-31 ^6.3M69NG3
M8;DIV-:9=;Q*)JE6*=(H+(YI18Y!:. $CAD&FN^J5A#J-K&-<I5FHZ1QA7AF
MX5L6LK? ]7JSR:R?L ?H<]H#IE7-KD\LDX:N%A@>H8:G>9JO^JKEF<0!\^W:
M'<_NGMM ZV(;,,0$QMH,4L]Z6>$//-AFJ>RUC5%R1DKG A4FE:74RR:70W[>
MDE=T@55;H[(T73(FG&$"0<S);3;G_ W2Q8-QO"A*FBV15*_JVQ_DVO])G/^1
ML&87PQ(;BRCKVHSQ),322$H8BV 8K%[@2H$8.ATB=IHG,>1SF:7,A=1R8RAS
M@-9M983FJ#$K/P;)K'P'IHN8D:Z<G.MI1=C#YI7;=,RXB#P-1^>(V^+,"18P
ML.EE_<00?AT@C4%=G% ?;2'^C2\ !I39E-^S/">K#B4N%.QV H+-3BCJK]=O
M5J832M(O',N-!%%# 5L4\2W3H]_Q@&Y9V*Z4OR'Z"\^;^'C*-Q3'*QS]?(HJ
M^$^A"Z*<=Z9:4P:65BD#P[5HZ-DFT<R VGX(L49HN(87(HVR'EJK!K$<.],$
MF#G:N/??0!2>\K\NBN$;I R @'A<_-\WE^8;!4(0?"5S20.\FRXFPVPNK@13
MJ-NE$BC?Y5<%7G\,/YRF#4I2(T;ZD#"PX#%W:F(?*'F^N-M?DGT=VUWH[P+C
M*:BT> 4 FPL$EZ$L#M-$XKB$>*(*(O H&2N9$M!*J&&:M@#/LJS]%2F^XO$
M2<&6B6Z8&_SET^]+5)WLVZLD9HAEE)H;<60E*_))#J'$E2L!.PC3_BXUN^&%
M5*#JV,EFV1(E%N_'"51K)29XC)D3R!3U /-;G.@5M=[M(N6_P?WC=%R3'R^M
M$6MQQXHZ<!_4.FZUJ_.<G;]6-"O5@DV0()<-%9&I5_+2+'-$LC))% F,@> M
MUY:FW!*UE=JPN,OWE?"22+\8_[&NU@1NH2*59)]#U+5L+-:D:C.-,*.K7'GU
M9<J5-63MRIBJO'K]ME>*B\13/!>>U1'AD.^BBMJ7-=O!GFES1AY<]4F3"YN&
MG"Q%@")NLCS/[AGYT]I EU**98O9YA=D_8*6R:?67E.D0JO#C5:X5HZOQ[9?
M;CFVXUSIFMT]G0H]BDW%V5"1_4AL%_P/NXJP.V>W:":S,#<:G[8'U/C\IR0C
MV4@W<I@I72]\/Y9'YNQ>[10>GYXDI2=).9,%ZDE2>I*4GB3E0):3_0^!,37*
M.PJYTZ'$#\+3I=]PZ-OK!R)=-5S-M$T:6E%H>![Q_<"UG$@GCN,%TFFPI3F&
MYAI19%JA[='(5<T +XU,SR)4,P_J-+G9+#Y#I=#2CK=VN^!;=KRVQ3W?XKIO
M^=JVCZR]OM:H7:P=VD5,H= =ZZKA[+TTWE-]-0/-T\8[4@MUZYB]R/Q'&39]
M*=YMTEU;8ZV7SIS8OU__?N?Q?I7JTSMPK'80=[8=;WI"!\5-0>:NM=Q7Z1Z]
M"DU(U8.TX7D9'_/JP!"M_,+;#]?OWU]_^OA5^10IP:?W[]TO7W]ZG9OOG)>[
M%<[D<D=^95Z!OW1:\SJ7?+>^Q6Q?%VO_R,IX_827*4#YF+?%S7#^VOL9A 9U
M / Z]^93KE];FW %L5SU5RR95?OU;?'];N+!']C(>3K$K$J6O_N/(?N_1SYG
M^<]C%.JFH9^?)5F";FZ :QD:,:ILH$,BW]"LP Q-2C73]XA)*'%=W]##2(_,
M5;C6,G+S"S[[T^CW(F')RV;H<@NX+>V":&0-N;6"V&IC17O;V()M?+^&\'E;
MW&7Y_!*Q)GWX\K+L96DLI>4^DQDXNVAE7W-RQI'*?O;%K.V+[VI4<QU-U0.5
M!I9JVY$>A@;QJ!\YAKU6!;EL7\J3L >?2UEG!D9'$$]O7E:#1P+!H^A[_8R.
M;1KLSSC#$1YI?IYD3L[)/CVU4#Q6P'>:#7L-8K*_D=LU&2_?"CIUE:B)1:*>
MJ4=!I(/A<^U =8F._W,LQW'7JD0W6,&/E:AV&&FIQGJ-S FF\&@Y>%I;N0P7
M.K!HJIEG1:X\/)(A0I1([<8#46)3VZ T=$-7)9'JN9'C!ZX-(;ZEVZXMX8$\
MWPN,B*B$&@%17;B,$KS4=DW=4*.PQP.=B >B._% MGI.P![Z\H$]R,\PS["4
MIJQ[*GG%SPJ-<P*T\OFG,\[WY3O%@1SPVIW[.?^#Q:PA%K,>;_D/?)$S#82?
M6LOU")(GBUU>"**@!Q.<L3NR4KB,[LCKW*/]L?/+/78F>LT2HJFZZ^C4UBP5
MJ9E\SU -QU8M.R!&2'VR/2'2-4V(H?6G <]%=ZYPW[Q>U=F?/U:*QGC&=$2]
MGCE//?,5L]8QH_N4>Y/W.N:HL.'YZZ"WNY20:=8DH8Y/J4<-';P;&OJ1%_BA
MI4:FIZ-J"L*U]A9"UJZ9J'7JZ=#.SGJ.6/1:RD]9]4X<^*:<R:L"57Q;29?W
M!^1G,@'/.<(]&21P;E9AEU%P+(F'P=2-, JL@!I4A8^B2'6#D!!-TWW+5#>>
M_G9I#RQ5[0__&[E"]CSU[LEQ#CD:U]2=9^/&D5P91QZI[W=NWM)'6\A]=AW2
M:^HK.*5G^+QB,9N-2^9+F=U2\$7SEN?\T!X&=P;']N?K@/3OUS+RH.TB\+\S
MI9\,+UUX0:3\_I(@?3@>#97](9!-G2.<D2E?>8N'],5/G,KW.4S9<Y>7<Y*.
M("U8JQ_E"_+Y'BL"YXG4>.V"^S)11CVHZ'R<LAY4U)5YZ8J7Y("U?@Y,)?WZ
MG_=)QROAI7D%8MIC'U^2P+ZD<_45[.,K)0]X/,#.&:4[=IVB-+<>-*A=-W:T
M7"\,;5.CAJE35U,=774#W0Y-D_I$\W;@",MX6H335:ZEZLJI;:JSW-AET+RR
M=[09[ 6[&\$^6S'>=!A(G5J.O< //-\)_#"*:!AIGA?IKNOYMA9884CH07)<
M9H4P*?0YR0?[U M/%[Q]9GUF2*HCPTM].XKMJE402:L@D5;R!>W(Q)]>IP+8
MNQM%QU;NZ2;AK+RUI6>8*V?/E_B'$_TY/R[NE%F<\I;S98_'JK>K:%DX ;6U
MX/WLZF9Z$OU&TRG>*]@LKW.#O(*%?1IP_IE-PJM9Y-[4G8.I:RTQ,4"3AE,H
MFANOMH1YG=+^.B7\%2QL;ZM>P2*WCRAXQC#T%X8RMS1:\WL'EN-%GF&$=D@]
MW[)=0]?5R/!5S=',2-^>6/HLVGYW6@1I],76S\4G>OOG.)T6/_T\S@KL9 ^B
M5\3871Y;X*&\X.PK\SR>%GPABPMEFKS2>NS>=+[0A>W]HWZ17Q*;PJY*9LNL
MR4(=AU(O4HW \!P:1;I#5<,S@H"J>F09[GHE,Y@'[&A<&H=OM6U 4_(>[,C'
MM;XAA[L7!<P1_&T[Q;MSMJ=4C^LB/_]2YLX/,:3VOMG-' 25GUPD/P9W\?0V
M84<;T^1^-1/4$XAW7!_]:BWJ:Q"-,^66/[-9ZL7D/,7D'!-!ME8383DJ,8CE
MT5#UD&#/\U3J4,,QJ$DHPHQ6/;>5UFZ?A!F\GH;""$99OJ%-0;>46:UFBUX$
M0<%AODUWW0E 3I(-(O$AGB_@-1]V=RYP7<>C6F ;1+5L3:>FHP=^X#I:1%4_
M\JC4N8!JOJZ&;D"=4#4-PXPTU\1++<-0(\]SN!RFTT4R=.<'/T<[MO%!3P'1
M;G<$ZS@&B&WD$"<0+[R"[@C?[A*%"]9- G9=R1/81X-T+*@60!D*@"E$1?+9
M. 1%C(HAS8LY_/L]41 37;#T,.^VD(W8%7E5U,XOF&?LSUNB*3:&7 *0P8C8
MO,8XB!O1.KU@K=-9&;125H$H90'(2<00Y[6J?>'F(X)UGON[/E,9/TIS?8:Y
MR8ZI*W_NB_R22_QD*!8G/GG?8IJM+^OK9"=^A-LIV92[ .6['ABH%(O9AGG
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M$7TXQ]V',4?&*"1('<DFZT*)66%"DK/0HIA#T*;<I-F,3> @63#G"R^!)SV
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M/UVB]RVE:7];(;ZQT5CLT)FK#NJ*!\L"X&^PT%^3,8>F7=J^;8<N"2,U"J+
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M010ZV!"+LQ6X)(@VL9"T5K-^ (%<!XO=69._"B3,H"5E-G$51^-4;,1L7U?
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ML[SIB.EQQ/7H?NB=H<,E9EY)U2Z8VRJ)SP7HYUM,K.)9^[(HX4!@#M"9%-+
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ML5;0G"WFEW61&Q(5UM5:6;FJZY4L'8+:L*BD;E&/$#;5"%73,D++L%02"8)
MVW7\P#T)U(:-=U7M$OX5",7J>U))"IL N3Y4>$LM5;RPVY\WH+&Q/HN-NX;&
M@HYGO7V7M4%#72TO05\KF3FE2F9)FV%',_QV.A<EJAR@U64\@[)4-VGT7(]
MY.+J)/1,WW0,1Q  6=2*EILTUK558%7</,?M-6$<76+\M23Q&IFZ%,MEMK4A
ML^+\9FSG[L+9$I/5F22W%UM]2$!=,8_G&VB?,XVT9"^ .P'M42YW5E/$_#5F
M:Y;5_D5=9R;M4M3Y=7)@M.!61U#=EAT'A]]QBC>6K:V:GD>O5--5O3[Q"GW=
M<HW 4M4H-'R-1)I@Z@K"$.MNCN=OWF!<GG1'MB&*!NG+VY9'+C*!X%CE:XG
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MV5BKS%O7,(;;8>/@X?&LIQ/COZM!VK-%CG1*AY1%M;P2QVOIEFJPF@C^FJ+
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M%KF?%6.8Y5J\7:N\*_;<.'&*H!H3/>(SQ*4G!!.$^-(+2:A-5<DY1EXK-5U
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MQ_M\UR==;<R.A2IK-R9HKSY<3U8X< 8H;R1K4QL[B#'NN91Z$0\=)EP_<H(
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M6O=1<\JYA(%(JUK3*RP0[*#BQ<ITCJBQN60* #Z'@A;/]H.(LI#C@-I5X7"
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M,?WQK\D(IE_#@$]=M C#EQLCK?78Z>F4YWJ(<C7G>6Y,\H?&OB_CGHYC#MW
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M!T+M <0!\X>TEVCF!T:J6&ZN&6LIH$JVG=?^ET[Z7COGJ3J$95W8NFD3RV=
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MD(9_B!,9R, -,/2)!%Q"X6(.0HF9Q) L123V0(/:8C#T?S'1BV"X]U,Z6+9
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M,'-10=V<LLPA!2Z1KFG=AA'P)1*R##,'/I:AZ<FY)DJ]\7;T9IM1$%\)"/S
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ML,<(K53>9Y1[,?S7*_U[9@I+G5OY?3&]S)-AH@UB/4BM)8R3Q7.-I[-!KU6
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M\1_S_)!03I@;8A$BPE2A'V-?,.+:&ZM>%QSH*0/9$K?)COI<UI<+Z7-#[MY
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M]+.CH5[R2A^"EV;I#S,MH,YNY4"=WRM"3Z P8-)Q:2@5QA@D0'&6%7G(7DF
MV2 '_E$OTV>S2FH^MZ?,P,=K#I9;=VVP_",5CQ;"NX<-]-+Z9ZPUZ@385,&
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M 7!826Q+!Y>.1Y_YTCTY_CH)"Z!+^]4Y)7MTGB<Z=X&3U:F".'21D @3YI*
MA,P1"I7@%(@P=G)P/LHR6,'D:NO6WC1XTDPC8RI\^8_H;O*S;Y*)!ED\3*8F
MX^@N&L^N89MF&0S(*LFH46R_9SPO1W_?J4!PTG"RAXX;>*%ONS[UJ./X87F
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M[Z=D!U*S@TD&2,R2VFH"/1YF%3<RZ&HU?<Y$#KEKKC_HW"5@++,LTWE.AO\
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MTRKRC3W*5TK@/4J8MA2K<_I(> ^D<["E&>(UD@(AE>(.#03V;2("7^$223C
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M;-C4P8H\B=AHQTJR<5_#N0=<;R6=E97TR.7^+9Y:.@4X,DWL1VF>O]>-FP?
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M"2Q<'TIQ$*C;(K!MQPT950X7"!7F@.>!E;#2Z6H#L/SX<&#QM@0A7LW6?X;
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MT?.KP#3=:]5FE"HNCT/UILSBG-9LM52OI'IK^]<81*9*V(( #@!*I?GT&YD
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M,95\I!0,))I,X$1F(RN%R -18F<E;N[(I]Y]L3DT>8Y5L+LFOYN*JZDK4BF
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M>C'<[[EX_"G7=D1D>U^Z?.R#N/S #_]Z\\LO;]Z]?3]XEP;AW2^_V-_>8ZF
M_4_]QJ</ME[R:97[ZB]S7S\T<E\;I8X'6\S^0T^DL^>#<-EV?=F&_$2^YD6:
M[:<ZE/1F,E_,+FZ))>%JQ=7ZG*O5?AV.QJ7GX67&[<OWPW$Q>%^<7LRJ5"]<
MJKA4.[143Q<7P_)OE=D\?XK=C*L45^F.5FE5A'>PJL([^*'JX?&/'P>K-AY5
M4L>V;1=PU>*JW1E;[P^6OUE5A_JEE>I0'5JZ':WRO+W3<#C.)D=Q,OC/X>2B
M3!NC)V7^MSI.J6U]?#N?OVV*272"(/?7BQ"2*"H+JAI%I 4XJ50BWGKEF',Z
M&K%,(-&1*6+7TET6T],_/T_'&23S^-\7H\7W&R4BWN2%+O^WN&IL=96_N7QW
M2;3IY+;V5Y?H:SB8:O]2^UWSY(D$<RA]\[9>$$?JE$7D[!DY#Q&G45^:1&J#
MME:#!@H)./?+5#QFM1!BK4+-[HE36K*E3O6V6/CA_'/*Z_2?Q=D?Q:_#V:/1
M<P]QN&BSNA;:&8B/WN#C08VE47':<8A*)D4"TU[8&*Q=]@I-DK/$GT%CR=RH
MTTG>7-5]N<3*#CK^<HJ:"Z*G&Q/5<_1DM%RAQQKKN%/$  .F.#.7Q:^RZI+
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M"'L/0EZ#,"H3K);.:2J ,*-Y)#8HZJ4J(S=KS1X/%X3]-W)[HQ0^:TI VRD
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M$*4PUAHB%3$A2BU)FZEM70^%MI$I 2?$M'IN_"'R(& 0,-T#C*IS9VFT@1"
MJ$2I,RGMI0*BC4[6::O:K)S1P1@&&H[(*^15YWG5R/4OZV8P*91QV<:C/+G$
MK+>4TVST.2T/)#>LQ\8=ZEC/'VN]>YQ;">F'Z6(X'LS+%?YRD9?X8%2O<<0U
M>NVV]MI16O?+*P,6C*4,=+ VQ2ALHI77CG&M3+JR=,\_%:\KV"ZNPS;^=3J^
M*)_(/XOQV8?IOX:+DNS?CST,JTZX8>AKP] #0FQ7$.-UTRDM7<:5=)3JZ#*W
M.*1E4SS&=,:;/S"(H5F-4$0H(A2W@"+4>77@&+.,)) B6JZ#ROK<$HJ42<[2
MD4#Q &QW5!;1#_F,?L@.N!JIJKFEE3!!*")%<B"B,9QS1GT$!5&(N!-E[AB"
ML/)$[M5!B+Q 7NR,%X8WNH>:"-IK)ZR&I*13B6DN#+&!>U/7^#X07O3)^+N)
MH'UFGR%^$#^[P@]K' '0/,-'\) H-T AF&Q?A9AM+@&42&*/!#\'8&:5&I 2
MQX"@_D1!;W&$O"OK[0[*Q5'U!9W/BZ,/A_)]-J7JV$,XVH'C[./LX^PCX'LR
MUKZ/#^>R/^,[FKGLCR'QXN>0Q_XUF\=?BY71\!H7+VH.QS9PG'V<?9Q]!'Q/
MQMKW\>%<]F=\1S.7G;(:KEVCA>9_;R:+8E;,%X.J 6 9FBL#2<<>@7@P$-SS
M!C!<-"I:!A42M\1HT Y 2QU]I,Q8 S%%D=8J6M:6J:T,4[^,;3TUO[8*E*V^
M:_G%-V*T]77K$K^_C>9_7ON6R_7^6U[N?K7:NQ_KA58[LQQ<YY4^J^_(G$OF
M0",-Q5DC0DPVBBB!ZV0D!*(("2FY:-Q:4?0>,:=/&7,[/2Z%&$.,=1%CC2*2
M(7KC==1>E&VGG#*69Z01S7U,*I*U@KJ(L4/(O#MR;>R8:-4U*&W*H$;Q1Q()
MMT9YPQ@%X.6)<@+*6A$""<#6:AUMSJ!'Y>T>L_EFVCPI@%Q +FS-A4;-1AFL
M=)J3I(D"B$9KXX(0W,G\%W!K-1M[Q 4TL1 UB)H=HZ91;K&LVF"8-L"S&<03
MLX$F&:VC0F>EQ#W!#.HM:@[ #.J'5M/KZ%Z:SHK\Y8/BK]//P\D?&.!#+]4*
MS[)1-#%&HF5,P>MD@7GOA*(I:F]$I%+PPW*VKY9\7*WXPS$2!3UNMQ)ZQX^"
M.XTZASX!4!U(<DR"M=9P(YER*G/'Q[3>^;A?W$$C%$F&)#M@DC6*$W*P.CFB
M7)0!K.0V,X@'(!*(4R%:)-F!VKC'KI0=$[&Z!J9-.=0H-BB8YYHZ8H)Q6;6R
MQBIJJ N):Q(D76M:V6E'V^%:<JH7GC%DP^&SH5%8,+C@RBZVAH+/;&".:YMD
M"HZ1()@^+"<\6EL8\D/:=(PVJI' #9PHGSCG1#H(DFG)5%9"&$1"0Z(,:7.H
M%E$_E)M.A?V>*)S+SFI3+"2(W3?:='!E7M=E8<NT=6.D,40"R&!I .Z-)M9S
M2ASIBH.KB\"4@,TPT)6.F-H5ID#5B6;4>BL2(]9)()(:IX0@SG!#58BB,T>5
MT3!%\"'X$'Q/ Y^J4[B\C]X9HX1-!APD$R/AX!+C5H&!SJ12'(F-C"H?.OJ>
MJZ'(LW%L4VR9&EN,AHRHE*07'DP()K+ HV):"QF=[8R7L(.,@;WV_D"4($JZ
MAQ)-ZV320)A.B7FB#0<?C(W$1!E(5 0X3[&#*$'3#^&$<.HMG)J9[H$;20SG
MU'F@1CE"E>3 \HO,4-DG.!V >8:J4Y_BG[>X3WZ9EO=7S+X,1G63P"-'-)9(
M/\*!X^SC[./L(^![,M:^CP_GLC_C.YJY?%9+XHF&O!\/Y_/1IU%Q-AC.!]DD
M'2V^#^97O<H'WT:+SX-9,3S+7Y$MS=*D&$V&'\?%X%,V50=?2UOURK!XK _A
MXOR.YY6?QT_CT:1X^7EIU5!&_M[X/)PO7OS\P_ ?^;H7Y^AYZE *01>S!(PA
M=5(^5<8QB(GR"(%P2\NBZDQK0X./?.UX8*P$XOV5/*2O;T?;I@B<?RK^J[3+
M2QEZ4UOEW?<6T1-#6!?"^9WU9/?9?$#0; @:08BI:XL20B&_8")P*,N,$B)D
M4@!)4I]ITRG0]"D,M\8N+5LM8(#L0G;UD5VL/NKB07F9K([)&?"):QKS,RA3
MDI@TUJZ=DSY(=AU E(X;!!<:<3M+'WC^# %!1.. G0/"F129/1JB229(JIE/
MQ$?O%5FKQKXA=39*#SA@TXRI?:HW" .$P<Y@(.MC;#)F:THYYK4NTX6,-B18
MXYF2QD%:+R?WK##HM?G$!/(%^=(+ONB:+TJ CL0E57:$\D0[7V(%$K?16V+7
M6D(=)%\.P<0AQP"7_J0:W@P8#K\.1^,R'/@R3_++>9[QO H^+AH1Q-='#EO,
M/#K"@>/LX^SC["/@>S+6OH\/Y[(_XSN:N>R447'M&BVT;?N/\DE.OE1U'"?9
MTOBC-%!7YVJSL?CR]U?O7QWY^C[V]B."B;J_IE54,0Z6B62 &6>%MU%8PR.A
MB=(U?XZ]M%O3=/8^6ZVU9R=D\[7^[;!R_>HWCR;YOO*CKDOZWE;.MY:RZZ/N
MZ"'X@XM0]UF_1PY=<4B21DMQZBGEC"0E@'%FI1/@I(@^) VP5GZQ<QSJ:BP+
MT89H0[3M'6VJSF@VA+L0+'C#+,043;#><E#&9>!IW5^T[3J,AFCK%MJ.B6!=
M ]6F7#(UEPA/VEMK6.04G(M:4$&<-"I:31.X%KG4X5S"YX?(C<B^:;/"$+("
M6;$M*SBM<XQ-%%5O6E\J,EP3)R)E@5)I2.!,Z\ZS LTS; F'^#DH_#1Z"+%
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MUVP8&F<<UYDN4!Z)HD(3HV3R@BC:W90+-!415@BK(X 5;V3D<QE "^T<EP9
M< M"ZN1TX%0Z%3;K07>8L#H <PY5JT?$6:\/C^<1G$TO/HZ+)\GRLP1BGQ9W
M?9;GT*7BSCMY +OU=;3CS/O;+A[6@Z[/+NZ$VWHZN6@<5J/!.V64T80&XEFD
MEN4?DV9>!<?X1EOC _[-#NXYBK9YZG_[Y=7-W6CWXH141BHCE:]36=8'6G1@
MUD.,%J+6G@H:A5]2V23'83.#97,JHR<$.8^<1\XCY_?!>5US7JD8*:.)@(I
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MX;H_TXR5]Q]YAD'QSE47BT_VK:)FL(%NKWN]4;<WRG(N_!(HYG/6R7(R/@=
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MQVX62TS&T/P\,K^!N ;B&HAK(&[W$(=*B+,:8JH<Q5Q "IS7@"N.H]JFN;,
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M4PP\X)89#9DC%E),B #FT$E*?WPN.4M%IIH#]\K@%YY!!%ZT@_R4#_\:!'B
M #.A[M1@8CA SE*D  (62ITC@- 00;$N NPEHV>7L- <FC68<)*8L-0Y)&;"
MA )" (R05P(Y%=! !$N-<8TH@]8Y5<?\ESWJ"GO)]*NCWV@!<349,"\:59:
MB@"EIJ%!4"X,4A0"A@E'UFI<@ HE'%)SH%R1_=H8L,K#\4:?:#B_MIP_$W6,
M(!$<"HP #:RO@)741QN#"8: ]ZY6B15[Q ,!88,&#1J\!#0@,\8%MMAS%2"
M"FXE(]R(' VLA,C9C=.L=IV#L$=@P)6>!#7 T !#;8&!E1'[F&ME."5 *0@D
M0<9*&X$AF K.>NIJ$['?^!^;*+CJ^;V.;+TJ%\]&KGK/+028*"Z)-,1(#QTQ
MX5-*-<+K1JY6'0B_3RE^)D 3"]]P:5VX5(*22RE&0=(:;KDU0!B(-/0YEQI
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MTZF0SEAE)2:.(H'P*@BZ3H)2%>!9:<.U1L%L(GVVQ\\#PN2.4+'NX+<:UA$
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M*V72V;G^7G-^BV\?VC'"8<&AX*Q#9/M4?%II]M.R_=[_@6 U!' X0^+$@.Y
M6[H9?-49I58&)38;.Q_;>P (%-94.2D=M,!)8*S4L??@EJ DJ@(E*JJLD'14
MV+,8:E;VY>Q='V:/U6&VO3;\/AL.WR9;Z,1QNQ9<^S(Q?(NNBX^$]TYJ*>]5
M01-E)J;SW'/JA=":4&9(4-"<)I XJX@5\Y65%V'AIYE0U%TK:JC2 *Y*];1&
M%:L3&]>-6U=E3@QFTJ2M5XX;#RVFU&,L&%5(J' MXE!071%S5J:P0" /K;#4
M4">)GJ1:%"[?N<;RX>%Q8:&VS.@?Y2'>LUK+DL._N@1HU@P9#Q"A>JKNNO5S
MBT_9GX=Q62$.!4V18@NI88Y"K31'C""EH8Q-.<Q<A^Y%$NEA[M+./7NH2IFT
M/6D<A?E=D;[9P&YM$P/VYCRL3U+ +I5V6D*DH]A)1PU4P%+*A0",6,6<<L@K
M!FQE$%F9VD[X7@L1'Q42/J/T+\H:6!2$/ F$38MU/:Z\@D?#WR1F&&X7"HQ6
M&@4A@C'#K7-4$FDI)!A.'L,9]W+)*);>CDXIQV*.)A=\LGT>AB,02J:E\MI0
M"@B@#-SO;.R\_C /8]GEU>9A5$#7%1$F>I8P%6*&<"PHAX:Q\!=G8GJ[85*?
M@_TFE7R9! 47IOU"\ST=3 WV+$;U)NM&YO"I_IE?^[8]"J-OA5=_' 7M+'G=
M[K9ZM]G/;ZZRJW&^1FN'_O")3B<0A+],_JEJD&%M+C8;3^)[@R3B1IQ3V@DK
M5TCL\-=96-ZLLG7\$-F5;#;(!0E"2Y%D>1+1K_\WS3EGJ+0D'AE"G=-4.RJT
M H0AISR.9<Y,%&/I3*[,$MY;@7F>%4T>2!AX%@DOD)7"!WB:W!Z,8*>6\MY<
MTLC3S"C78T:YR$9[+N_(7"2?;P)+GG_)!K>)[@T&><S_-NE'4_WU<^LFL&(G
M^WB=OR&^(&8E/9MH%#>764JBUT!IB"F#9+HSCA(^DVB$H?,:!=3T"GB#%!$N
MWT3N%21>VF>W<.E[-DXT>B+N\XC2C KU4,J+L"!4<%S\W'5"$2>5Y_B ?284
MK?:RHTDHVM(V*C!E%#'E\AY3@NB**3[95MDXI^X9.H'YW1,VKU.3ZKD,T(T(
M6PUC;O0T 2'!\*Q)+:M9:ED]:!_7 M0W\XY5P2H+3@HV3"]KJ.)TJ.+54TE:
MM8K@W'**IG<;#*56^"KI!PMBD+Q,HJ\^.'ZGE;OKE 6T[WKU548-/'$B%ML>
M$9A!PM&]">^IEPAJ*#%GE&HD%'+":*R,18YY]MBC4#+6[Y&O=E:0'N(S"7<;
M3WK4-><;<*K3.>2I9NXL Q()2R A2E!$(79"4V&LBIF$QD'!-69B/OIH.9!4
M4TP/GT&P@]+O-8.+D]+=QH-!T'.3/*XT$%TP]CN].,+HRKK*+D=G27_0[K;:
M_:#=I;<!TD=-AOD!#:KUDW:V:"M51WTJ@%[9IE<*([A%6J%X#D4% @P3P 1T
M0AE*9PO$O0]4/9H<R4R(OFP Y*:UF#YDH_O^/^KJ?\:30DR?\D).5U]Z?\NN
MOK;SPG*_CP>MFW28J58K,D7X<'?JV1FAE1:@/[IN:B^)@^O&J*OR)2[M'*W"
M1Q0J88"E0'NI%$!<:V\0YQ:P@_-E-=H..>,"5LB7C4)3@4)31,<,%YW'U465
MN6Q4F4:5B9!)Y3UD<FWS=!)B,:'04>F%-=X3R@VB#L''%EU.YO=Q)F4<R\Z4
M$,$J->P:%:3&G%<W!EN5G[@HN\\+A"QV@A(:F0D+QRR@"L18*>_D7/#6&OQ4
MC?(@694U31K586%>[Y94]Z4W"JK"FKI$@RF[E^9'=PK$ )Z!)A7[NWLB#:6&
M8<&%)C((?4ABJ/T#KT6.2%/S*.\/M3LO SM#&#>'0 VS'EFIYU59$)4."J,E
M!L8[;#2D1@"IL&3 .<8P8$"AM5FPHJ9L9X+L( .Q9HQ6*Y5A2\J+A3ZNT_8@
M^18]4TE:NJ8FQ?^O8O7_F\([E;<+Z$_\4TEZ[Z!JP.AE^P$8*9.F)30&.T.M
MIX9JA*25GC#&D,.8<3;7XOM==S@:C"/%+?*/3MRBZ5Z/*_822-*H"37@S+HQ
MX)3?GJI2<,]PK"PMQ@G'B#N#E4=4:*F!U-)S+ %PV J^4X9;0VT8AC4*G^V-
M\^9I<IO-?1&%4"O0)<:!V&(D1E[;M#W,22?W-62W[?'M,-<@8E1&WLHN[;:R
M0%/#T;#!J1/7()8BFBR-&TF5L+'WJD> <L6EQD!X[Z5@D@ P5RSQ(:K]45*@
MG1#@[P7UJ>Y5?NF$\DPDO$"S.],CR%Z<$77#N04D\-)3BP[1[:<.:@J')5,#
M[J0D2$K')>78"TB0M5@H)*"EV.V>J2MJMUQEP,2J&U\7WMY2AWD9M5.+0Y=-
M(C.*O^*U99&/A8G99Y/,[.B3:2T+@-TL1B0V9AP,VEE>NO6F/1SU!G%#@R;7
M:V7951A".IRXB[)-"M$W%07W4\CU1#*NUJ_6><(I67S&WV:I1!Y3+P@G05G6
M&AID@47(648$(XODZB1,<9<G<5!6ZD7;>/OK>8+0@.,A%J!V25U55%2MP<$D
MG_%&*@IU#)Q& G&*.%+<!&W?$ *T9]BO"4>5G4KBW6GM"[;ML">3BZJ9'E>M
MTN<J=Y7O/X+ZG-O7WE2< HVA1<8J*#A07JMIW3,OO']4>W/9Y=76WGQNGRHN
M5[G7FHK<5E94\;F"B8]+#!\7DRZOVKA*S;YM2OX=6RG?R_5*^6X/'@)PCA4P
M7E$:%DU":Z:5;[F.X40/P6/9Y?LNW+LU 52,0<]DYL1@VMMT$.Z=ULQ+6NGP
M)LE++H9KT\[%?LO"<K_#NK!+JL ^N1^SZNR]YZTZ%3R6-"ZLZ>SJ/ T,DW[-
MDNSZ.I+3M\ ?L1I2-APE@[ CL>)QZW'9G]YX-!REW=RM]CVZM_K]0>]'V-A1
M%C9VTURK%31H 4N#GGH7E&4I1= DF;88.3(IDRH-EGJNT?*#6JU_GTQ?%;-_
M-YGRIS3RX")K_\_)8_Y\6/+UKI^I'^WA_;>/ZB_\EA?3FU'-@\:=?U!JY^1>
M.8^%L9]S%EQ(-*><__1(.U]OS:-KLG>]X89-2P46*(WA63);!FW=@72O=DHW
MJ.R%JQ"D@ )F@%3.6B%%0,JBO"[R$J@*Z4;4@6[0!:D_W8C-GO4(A0^(J:HF
MG'06D#VY2:]BU&DV',:@U#3\B"<M&X^O8+%_7<9C9*:$M7+&6F^PYD$Y<1(9
M21VQVA$OA"5S28[OPVY]O#:#+$C]\(!VISVZ^RT-$F5<9FB9-"KWH[LE^/SP
M(0^8;/8M!8=5Q)V/'2[RGC?E\Y ^[_M-+MN=3OAE._YL=Y,_+CY?)(/L6Z_S
M+3_]RF>=7!?K$KL6A%4<MH=YC\% &>F.:8.442L$">JMHM8SI#4@F 6ZL 8P
M!<*GLG:T\?"$/;^K?YT]>IC[T6_'KH\((%(+VII/+ZB&M"84=)=DDQE'8HNS
MSF5XNG[WB_7HJ$S\1-#%%B, *4TI 5YQ%.E((ZN"8%=S/>WK2D>/*>ASUA_E
M-X9%!;4@I?F2-#LDI?OI1Z("09S=M%LWR6UZEUQFR7A8Y%D,Q_UXC!\,D<&\
M=5):FQ?)N^Z]*1GOBZU5EP'C6?[43A9[20R#* T64;!NOK6OPJO',3!SUCC=
M*;'3,BHH4+K30COHJ?0!+S6UUA%'*+3!QE=S2NNAB+V*K *\ +IN*Y**42W,
M-;5BV\_BKP6%[78G2[.5."FH =Y231'DC'H@ VQY1+PRE/L')7/":'LK[J(=
M9U]Z.89D?V^/;MK=C]WL'UGZ1"W1P^TN6( FE>QN#B)9\CV??-+K9LE=F/Y%
M\O$ZLOTPFVC!<Q2PTXUG92E'S23G! .JE5: >0TTC_**"QS$%YKS5RQBX4_9
M;=KNAET_1JU8K*P57^Q*+_X>K/4PP%R,U,7WL=23F']<'&1.K=R5W;E/E3:?
MN7W.WU^SKCVWZ>!KNUL,+QV/>M,/BO",_)/[QCX("DZW:^B#7SU]OE.\AS[=
M$ <]_97$BYOE/'UL44WLRF0MB@^6A?8L&$6U@5L+3V>D>-*-4_6 %KY_LR/I
M6B4:S4= B T#BVHWM35Z<"2^W4V[N2GP*>_'N$[H1_'S9E#BXM?L_'*0I7^=
MI]<!1-^FG>_IW3#R\,W@81<_C[2R'D/'%: 6!]G/9?@7*T0,EX3&>]*5X?O!
M<>@Z*T.?BGE9[6T0K?>Z_/H%.Q'/U7+'H^EU<[#)L^/+K?D\"A_D292;C'(C
M[^SOU^'W0; &6Q>YF^+S^'+8OFJG@[LPR-OPJ&#W;3*8?6S0<]+\")OPK2S.
M(0"[EN3XF=9\&*_VW<+&=\NZX50JVE>)V7T<LSK9?_H@BZ/Z\-4E8/M8LUVA
M1_'R#J7/-CA%0 "''4=2*8(1D60:N2&X,'3]!J?E6NRZH:F]6-M86?L=L49O
MT3#5;I 0L_;KDKT)@(V%X@9O>V[&$1:G*7C5MJ)]Z%T>/MN,%@8[R6.IO&4<
M81M+(DP#A@1#U,\TH_42.T@\U-)CH@V,IS3Y:;DC!!(CGV4W X"QW &JG+
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M13"=KZ.S6[$<;>59D8P/+I(;@7P" IE<@$8@UQ&4ZS/QG0MDT@CD'05OG;S
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M[?Z2S(_NH1K^O7TUNGD+)]0^6>&5M?; .Z]R"IX=?D["7\*Z?LXZ6;Z=YP8
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M>.2%>-TF,)YX)U0VNK1\967=_!"]@7*^X>6K<@E5T-BF[+$S"BPJ/'CMYEQ
MOPM&/U2VE*?8>IRC#O9B:CD1.)%(6RQB2#EC8#GZ%6?,K@SUJ(0!\@+D!<@[
M-\@C4Y"'<&R81HFA@";6:FLTB;GBAD(NE5P.>5-'CJ\,]QA#5XU[ =ZVX/,J
MB@CN EHGQJ9-H8CQ"10QQ(PQ!"2<.WL3*(%-@B6F"I'8*FOVL#W%!:,10C=2
MD H!*>!.P)V+QQW!2MR!B6,@ED!E)'6:D(1"&,VQA#KFW)_OW-KJNV2\832
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M9F5.-$P$E)A"K&)+@;0:"<2$BAE@S@S%=$\'="WDE 3R&&ZAW>C@U$IJP(.
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M @D5<Z>1*\2575)?+AM7-CEWC(FXNG/' 70N0^L)AU0ODR;K1GKAD.J9$U0
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M O2:MBT#DITUD@7 VH)S3]5'\.3.I(W !<'RI&;,?9]5A43,!;7"G[#DAD*
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MS-$U_7;VQ^VX9VRQ5-_]Z;J'M#$8]AWTMU*O^A<-9=TMPV8:.2G[Z*X=^M9
MSXV^+XR=YVGPO[D-?>YE[K[\:O=H/YE6^M 8=OR#(T>IXZWOO13#]EOOGI?V
M(_^HGW>1ROQ-NU3:GN];M*X'Z'8;=%/TY/WNEO.[6Z]IXG0C=K]EZ?I=RW?
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M7N>^;^=\#O!BCOD1(E@**2J/GA/!;9)P28$5 L4TL3;/!.1)(J6T<T7.EL8
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M!O\*PC.]X8J0Y;Q?7/MV1%YG/%M3KBF[8W;V2P=%01:G*%+-BUWN7[^9 $A
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M8Q1S32EEB%?&D'$0T1<:0P4"74_R^Q&\;6(0I F#$@8E##HP#!)U16Y!E"4
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M'3N>:+!%'\ZG>SR>;,?A8BWX4E9(XB-=CLJ=</7?1V&X;9?/UCZ[H_5)MM[
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MA)0[<>\27D.E<% J1I$QCBM!C' >51'#R%IH#L%KT!FHW"@ F.ZN"DGRRB:
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M*E85ZE;YODMH;+-S6@-D*Q=<_TXOM1C;L<VS%IO:TNT>[-F+I=>^\.2%OR"
MP%U_X1VGX(>7=-?;NXW0LC>VG+^M\R!>W43:I5UT1]/A*W0SW4XL'O,*/I.,
M52[UXB U2<;CDM$Y%K%?A-BR#VD["K*]5XJ=/],KL/C"V__\^,LO'S_]^CG[
MY#/[Z9=?U.^?MTFA.X(,N8U5X)67OAU C-$(!0U>1H^G53^-5<^:U78+$7C[
M:R#:2SE(ZG\"@O QWF34*P_/7]E>3LN^MV6_FVC[J#6\9[[8JD-@F6V0O2US
M+'YZ'Q-]MB3D;25VGJ9RM?Y^K?"&O14<V-D+[:_8  OC6#KRL;+,$TT4@0PC
M;X%F96D6R#W49*6W^6I8LZL\6ZH1B/KI:I&^=O<,XEYZS\?R&.0DTBDW:V/>
M9@6MK2H3O)XVGJB-FO#T\/$4-?"4,L =Q@8ZQ;W0L?1K4;S%$1W^N%*\Y3#Q
MM,NM838"VC:KQ2:<33B;<'8?.$OJ]'4CD>6 ,8Y$K"_BC7>JL%L1(EC!E>[C
MKXRSAU5,&R5X3/"8X+%C\+@.'1O%/22@P'AIF9&22PB,EF4)08>--&ZE5<L>
MT7&?U0*?PKCV:P2^3-1;;Z_RJ@[?EE7ZM[OE=(H"264&=A&K=9J0O3SF0*]P
MS-$%P!,UX&%A.+680@Z1)0II;F )>,@AYE;:M&X*>/?K&I6UN;I!P@_$J;F[
M:JP= ML$-T</-[!Q:B*\LU9Z+PCF6 ,?C*RR>!HD$G"UDM5Q#'!S\#Z_A$,)
MAXX!AZ!<XA C"'BD<;!R@! !@AB'E1=, ,>W/FW8"PX=E$\L63$)/8X"/7"-
M'EXR310@ C'**:'<&U)YB; 0@G0&/;K680)R= IPL&7BQ)Z:[;3L8OHRCJ'3
M'>FSTS'0W/\$=.Z X$@:#3'(:OP'$&-H/).6"B2TC85B2Q8K..)2;H?_W6"K
M'7".[>V$]4AZ%"6D?95VQ0=U3ML&#+_Z0>Y:C!8U1D=.+XG%,I94#21?(BU*
M&YTJ9\5!8W27/8K["A[<#78?5OA, O9D0A^0"8U@?1"DB7%(44>)UY((&5 9
M5^'>B',+.@'/G7&T/FD1[^Y\)EG$"3@3<+ZZZQGA&C<IT@RS>&SEE7).QACN
MRJQE4EB]=]P\)1?S Q+TNC[FNY4]GREZZTO:'U9#DO7%2S>IG_F2\IOHKC1T
MOBW*DYV65]H9M- H!4!D-+#0:&>,")R<R&H&L60>PWN-4M9=WFZCE!;D9YT
MM%R_R];MF8IB-E65[3MEOYO%WJK^35F^[ P6&S6M= ?;6W>G27X5I_:E79U:
M;=F4?7GZ[:=5(<KE@^)L;-<1)1:OW+(U3.S:U4+OMD6-Y?L&1Z-1KX;4$! 8
M&O;2>\ITN"2V;%- ,(LI?KIUVT/&QI=\<O- N]*RK/.!'W#<;R)W.9]$N0QK
M3<[E:LN8.V;),T6@E/<H?>/YY$%=/-NEB#229J 3AF+F@19<,^^8)3:(B "
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MI!: 8.JUDA'\:)4CB+BG+XJ@ZC2-/-P _'8Q.?'+XT*OKH'4AI@$05T12T@
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M,_&PXO_(]CUY-:>=Q:I_.<:&53YK<4UV/A1&=45>;3A"DF/F<*3*ZTB0KI+
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M!HN9F8B*CM*"0S:3GD&A_V*#U1N@D1DAI2#21FF<1Q)+M3MJ;T)\.CYZ&>5
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M;CR_8AD<,W)# Y"@_SKC(#)HC0Q+I161(RX1LM&J]*%J+QQ+$WG[DQP(:(&
MEHR\/3>G;NS#?"]CHO)">)W<*T0>&)(XTEV8*G&JP9&8-H?]/OHP)!)I)6;E
M(G7C>#9:%\MO54J;T:=MMT,0R^!%R5Y]^&B"5Q039X4/E$K,.:_RX4<A0H,
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M/R)]KE-'MEE&"+3.T%@R!*W#:^I0@V643GIME*,V6DI5I74H0EB<6.OD$II
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MU_&ATMT=T-ZOB(+3]TET',3#7JH^@H71.G"JI#*1>V/1#@^*"*4ST1Q]W/^
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M)#F7<Z,(:)0!:12)ZQ3LPG 6&5+<&X2HU]3[*EN'2?^_0;:.HVF4P<$B-R8
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M ]*G%VP9@/11]8%=8U54E!B*'2,!(X9$M8V&!6=-,G,<1_IT8<=>G6D.*S/
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MR%0^KS+(J1QI5QN\II=V8F SNKYY_HH$%:TVC#QPDCBGE:V^-[[V(GH$+WI
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M35WDAVZE["YW>7'/(N/]:RDO?OEI_/=TW<N+Q^P1#L8HLP-4%FO8 VE\OE8
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M@D0G".O<M!8"I%N3AH!"0&%W40@U'?MID[F97N-!5["ZIB/B6CKOD(H\^C0
M4V6J3#M1>=EBBMO'QO3#6G*#$9*="0XG(H$O>?!%T3I5A=52>4JI)U@Y:@Q'
M;%=)"&G-N\876._-4=0#K@!7C\95^G_UDBR1'#LK=>!.<"DQBE4E$V%-9!GD
M]((EV>=36&WN4 &R %F/1Q:ID84X,LX;518K841X&HFHEDV-ES*#!#JP;/I,
M"54!5X"KX^(*JC.V&50LKL<4BZ>'%/];:<SS$D.C\?Q\-/Y2S"=_C1:?TBUL
M\ >AQ?W=>&@H)D0=GL>H0IRA2$4@9?;U]*EJN88()+7/9P_V'Q]_7Q;CU>7R
M+U@+OEZJ4;::Q:5[FU"P8SH,<*DZ>$0+D:R>1"8)"L$&Q=$NEHX0ZKH%+EAD
MSC*U'H 00)@E""FJ-_25\5$JYB+EC%E.L.#;?,H^<$;4X$ (R]<@"H&% V(A
MJ5DHG# L<HQ$\ AQ39S5VX.R5GL1,SIL=AH6#G5='$0A@+!'((1XXG[:9&ZF
MUWC(%76\'XDT8JH=1TI0+)Q#0FW78:R17F043PP+R'?/%:B&Z#R 2QYP476H
MB]:..BV)"8HI$8W2D6WADI 3VESD/0%<8)$W2ST/L )8/1I6#.%:"4F%"$$:
M"81,))8JX;=;Z=A+2KJEA& A%L05\*I_O"(UKQ"R$@FF$[9X< 0%YJMRYD$3
M*?#0> 6+I2"N %8010Q1Q#]?JT$VN:J<-_I<ELX#?^OM5D-#&;$706PQ#H'3
M@!%RVG#-3(S5"4IC0L@HJ=W&IM]N3!I6@*^5UX8-4M@@[2ZUAK1!"L;:<6-M
M-L3RO1!/32VAS%)"L2MW6VTT:+NR2 E"IL65Q5,,L;"T"*,V@!! V!2$>_&=
M5#H2M(C((6&5#5QY5X%0ZD#-X$ (:Y80X DD' H)61UVAP7!E)4K+<H+10EF
MSFXW;Y(^I/%JU>7B<W$+!<UL72SG"0I_))C\4:S6I?.N<F(C@&R((!L2KW+#
M4F,*[07_EO7HE%>,ESC2C"A!777V4 :K,\J>!\RY<Q:IVYQ& EH +8]'RU[H
M;V1E@3B!I!12Z,"4954T'2(!"=HMM$#L;Y8*"6@%M'HTK<1>[&_PY6XW#65J
M3JE5P'Y;Y5+Z2(*2=G"T&NH*/= *:)4GK?8B?S'%EA&N$>?>,<P9PG@7LL,#
MRZA& RRC ZV 5@.D%4-UBE*KB,1!&A2XH2[R@*I#H$Y93\PQE[IAV0F6G8X1
M%HZ.$Q;^1-_\L$ZM'TUK-WDS<+S24^XY9O80!MMPZ'WH?>C]838<>A]Z/[?>
M;UGDP;3Y</_VH*U];Q_T97_:!WW9G_9!7_:G?<_:ER>2/<^;U^&)C?IUO%S/
MB^7JZ_1B?]ENU\R'KLQ?7MSQ"%(+?YY-Y\7+K]NP=4S0W_:^SR_6+W[Y:?+W
M=-W+BZ%K2SBGH&1]8LNS])IBEBE+2,2&>X6JK6:)&6XQR=1C3R6LENO_VO.C
MM^EGE\F18)-FF[R.8#+H(PF#6.\ 9BE=GVI :7B3T7*JD_$'3YVE_S][9][<
M.(XD^J_"J-UYT1-ANW$?U;$3 >*85R]ZJGO;-;NQ?TW0$FUK6I8T.JJZ]M,_
M@*1$VO(AR91-2>B8<=D23R#SA\Q$(I%6J<> "--B,M]^F163CCN9&!,9&!GX
MQ@R,]7&BL!Z,L&XV8$O<6"O$,8& 26L=E%IQ07#E9.B0-M:!$G1O-F#'3-8X
M8$<&G@H#:9W3KRC!FJ60*H:A,$[2M-J'B4E"*>EB08@8>HFAEQ@5/NA$?<EK
M!'&,4J<Y%5(8S;CQV*F6%2$ 6-J!19 1.,\"!S)Z##GYD2M'P!59+P#"R$&0
M$J$H=5!99C%8EC]5VOMWA\*5&(_MI'L7.14YM2NG( "RWGW>L=3;0%!KYT@J
MM01HN16N9I1VH&3-FW$JEG^(G(J<ZA*G4,TI!;4U!'#B%'3&<45=6449(&0=
M1R?$J1@NCYR*G.H2IXBHR]0HG#*)F-/$6::<DUJ4G/(6%2"@BX4?8H3I%"),
MW=H,\)6*^6DT6TRS42\OM"#T2MS@[\1G%B'@=3JDQHQ0I9D'L468F!2FJ'1K
MH</4MNC6[CJ/Z > ?ZRD6"^%.#*W8&ZK=78.;Q(QID*<!K!DG0XF#=508N.T
M=9!2@U)%R_D"*JSDYD" %:<+.NG>1@1&!'82@?Z_1H57G4KB +9$8@N%XLR5
MKC.C*94=6';W5@@\U9F(: 9&!IX@ W&#@5P02PAS,@68 &\+6EYMD48=HQW8
M+/*M&!AG.:(9&!%X\ @\I55\IR2371.]C0=;7N=H.@804TY PHTU*3,VK9;@
M*2.!Z,"6$C%(_)QWT.9*DPB5")7=H2+J1"4M!==AJQIK);4IXLBQ:E<M9P!I
M<5WO7J$2 [F=M. CIB*F=L84 G6>$I4IM(P*"2'FJ50 ,E/:/D:B--6G@ZD8
M;(WF5.14ISB%:DYA JW@ &"A' O,LLMY<>P,-(?BH\6 :#2G(J8.!5.[!RU/
M-+OWE>U=[N'6&]_=^9L,\WYRO1CUWZDB=#]6A-YH3F(\[>?3Y9O R1_);#P<
M])-_ \5_!SUGL:&5TJ@8K1@3WD+1VDH)4FZ@Y*2:MD5$B0Y47PU62J%F>J5E
M+BC9B1H5:XL\ &]SD<?.VM%9@R1.Q$;H!>@U2DY[ @+B)'.8,T,@@H;)$GH6
M4HC%P4 OQKH[Z9Q%B$:('B5$,:S7?5! (:)"6X>XM,H2"2K+42";LHXD/;\-
M1&,DOC!&961H9&ADZ L,;912)Q(1RP156&FEN$T-L\5<IC.,*]EB;9CN,S3.
M$D1#-$(T0G0SB#9KL3,$"1:I$5H8XJ"3IBJ$#%DJ$.MB+?88U'PAJ,E:74!W
M=!B,M*M[KVM0VYAAS6+N$D!%I04I,T*ES%JLJF01#C3N2%);)-8SQ$+P#8D5
MP13!M#\P-:K!4RZIU(0(RW4J4V69@R68B"2ZS1V%]PRF.%5RD!YJ!%T$W9OF
MP46!C +Y;B,O:=0-3XTQ&F.=(J4)0 1KOBP$B22'+1;4Z/[(&V/#<>2-H#LF
MT#4*CW,4HA]8*"BMTAAJ!>2R\#C&QG:Q\'B,AL1HR.YK%]IA5LN%R;^,Y]GP
M-'&\A?!A+WS]\>)JF+^*P:^><6AGLNW?]]$>+\X^'MID(^&-73(XHS)E4C(B
M$92<85;NCHB@M1"WN*JS.;5XJN,(.:-B?Q.!V\AN9ZWA8TZ(B%R.7'Z.RY+7
M3@14.E4<<L=#U@<#7*W6L0$F]U1^-$XJM(5Z?$;:K9D<21])'TE_)*2GD#=J
M7VKEM$@EI\(HA;"1:45Z+U_8=I;T<9%(07IQ1NC^@D.1])'TD?0'3'K,5J0W
M2!$G);+>T'?>/$2.RW(&5&O'=8L%25LF_:E.5SX,WT3*1\I'RD?*KU.>TCK/
M!3 )4B0A38731$%$=6G/(\A3_&;+=TX4TNB,81%!'6<X6^;Q7N>J]T+9 TF=
MH;QFIY,<I*F0EH;]5TWJ+>-RXT%$B*,4["='\$1)"?$9>-O(121B)&(DXLM$
ME'4]2\L=84!+RE--G58*P+*BA@4XM8SMAXAQ'K"]>4#(<61L9&QD;*<8RV!=
M/A/3L!9! (D5QZD#-C5E#AS " /08OG,EAD;9^ *QO(S)$ED;&1L9&RW&(MK
MQ@JBG;+""(2TA,8Z@DQ5HE@))$AG&1OGODH[-O(U\C7RM5M\I77E32$!3 FU
MEDELH***H+3*+7 \A>E;+3H\43RB,RI.(Y1Z/$L$BXOY'AQ/"^'\N!CY)@^[
M$OD+?1I5"C$>9<-D4@I0,@D2=)K#QFJ%-WYIA?=^LT JQ0CGO*@5G1I9CS@Y
M)LI&E(TH&U$VHFQ$V8BRT0W9."41.()W/?;WBWUY/.\7^_)XWB_VY?&\W\GT
MY8XA2-#!&.2'O^AL=IMD(]]]X9?\7XO!UVP8HN^G*<2MO]\AKZ,ZMF520M2+
M867*28I%FBHMH23:I 9590\(H5W8L_CI<X+.JE$__&-KA=TZ46"5=C">^L8<
M=7-BJ]W"EP>W5NJ88RR1M4?,6@GJ9546$^54:C CA"/*)99%@BLWCJ8:IP?/
MVG=9KW (^,:MYFU%>D=Z1WJ_";U136]#(40\)1[6B&&+&,.PLI0U0:3%1;&'
M2^_M5T(< KV],$1\1WQ'?!\<ODF]@M<!E!(E')4$(H.HE*ZJ^I7:5+G##W2\
MRR*+3N)[K]L;17I'>D=ZO^[U7K&-XL&I7]2R+<3MO98BO;.*;&S/B'HEIY0,
MI]  A*Q584-W[)9;NS/&]9YJ-,6)FVTG;DB;VP]$RD7*'3OE$ #U>DJ64DA3
M CDS"CMHB>!5W26)B:/\X"D7ITR>FC*1D9N1FY&;6W 3P;J6DJ8 ,X$4YIPA
M[4U%6TY60,(1HSIR\U@G*Q!HL^QR!&<$Y_&#D]3@A$BF6E'K+4RL"2#<.+'<
M-3PU.!J<<9H@<C-R\\BYN7N _MT$_ZA6HP1\S[\GL[RW\(W@R?_Q-%6]*\O/
MN\N[8W[QV/NQ]V/OG^:+Q]Z/O=^UWF_9R#MA%^YDULC'OCRJ=SWV]XM]>3SO
M%_OR>-[O7?ORC<R>'0-XHI,O^=?A^"H;%G5D[L7Q3EQ\T5N:\UU<DH20X'62
M!A<ZI<HQ2IQRT&F8%INQ<)<BS8!]_R5)D^O\D>/+Z/3E2JA+88^3@L>W>.$D
M8@P12AC4!:$4P0QR+BD@,,4@!50O=S!1#J@6=SI]!RC%;-O(N<BYT^5<HYP'
M,(8#2[%,!7?(I1YWNLR0A2@%UITZYXXD.S9R+G+N]#A':LZE"FF0XI0R[VPB
M20REJMJY7BM 3MZ>B\FLD7.1<UWC7*P0<9PRV371VWA$%74E*4($(EH0CJGV
M7W#%257&U3+$>(N5I'9=(G)Z8=N'B^#B4H[(C2YP@X!&Q1;DD$%2A%HME'*F
M@2NG>RS7UN .5&R)D=6(HHBB8T41JLNJ<$8%"*#@5$K)H".*+G?],(S#4T=1
M#'Y&%D46[9%%I&:1AX^16",G)2".&8Y37F;!.&6X[$"IDAB@C"R*+#H\%IW.
M*O9N)L%6J]A[X[L[?]=AWD^N%Z-^S($]WK#]AJ-_<_]!12WC#AO!')>I,#"M
M/!&;&L[)H4Q/EG_KE:B[(.G',7(_W WE3*(V@QJ'-V$39Q=/ E.TL74?4H1:
MA"7F*;0 IT I66:+,6<@4\>$J1C*C4D5$7NGBSU43W5#9JC&.$782.:0%%:Q
M<LH*"L!!Q-Y1AHW7##Y*VJPI&\D7R==-\C6VBU/>L+,6<:<ID5 1*4%E\%')
M,&BQ#NQ1D"\&J2/V(O8.%'NLSE%*&0086T I%= $I[><C!- ,YVJ56ZCA\\C
MR%/#>3X=>1W_ZMGP-9_-@_+.#@>$!TJMASNG<'+2V#HE.G4-0ALSI[&3'=)*
MIBZEV"&G4V <U; J@P&Y=?)0$@!.AS#P3/"XK5U$22=0PAK;Q2'(*7<,*>L
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MC!598R6UB$EJM+;:&2&XDDZ4%I-0SJ#T_5==G01$'KINB!_#8H4(BX.'!09
MKF#!,,&<<N6(0HQ@8+@JR^08 [1NLR+AV\ B1L7C,LR(GV[C!XD:/X@8"4--
M"THX54#[X\I).4 QU0=GJ\3(=31_(G\ZSA]2\P<+9JS@T!G+ #86> 2MHLN,
MN!/D3XPN1_Q$_.P1/XRO\ ,$L0P9RI"C)H46<E--W",*.4R[6(7B)((W1TF/
M]\U0OW=1]C AG;T^'_VO@52C("9)-NHGV4T^ZGU/QE?^S0II6^6E;ZO5B\D3
MS>5;XZ>AE[?SVW(F""+PI\;Y=#+_\)<?\C_[^RXF$><G/O6'@:PW DD!XE1@
M!X4T_H=B&M%E,JHPND6[\[43?7^__#+-L]EB^OW8&+]611$!<-(3?3$%X20X
M!"%N),5KHAG# BDM'3886E-MQ68<QAW8D&@+#L78?TQ@B%P[7:[A>K&/D- P
MRX7&7 DBE#)L.:^ %7?ZU+AVG),*T62+:#L-M%'4F#*ET@I)=&J94]*E'*K2
M9 -.*]7BE.EAH"W.5T2N1:X=*-=X<RL3"P#!$C$% '/&<BBJS0*4=T99E[/A
MCS=(%K%TJ@'YKD%F8Z;(FBE4Z!1@*;&V6N.4(6"K] YC+<$MNH&OG4T]7H*L
M^6P8T&.838VL.'Q6(%@OFT&2 <X5X8(SIHTPVE93<LC_CYN#8D4,A1]U)D=D
MSQ&P!]6K<%+H_.=$6FHPL$X*!2KV,("MZL VCC%<'4V?B)]CP@^I\4/\7PHQ
MPRF5%&.H=56( %+") "GAI\84H[LB>S9(WM88P6.X\@JBK#&Q&";IMK!J@@*
MUUJB+J? 'V_0YBC1T>$*[?O(A[^W%6-OM1]H<ATV!(UD/?&I-]2HT:X,,P!0
M33FPC&M+"9%EF)PQ"FB'LD +F?Y4B/2Q(?>!LXC.?'.=]&1;S $X"1#A1HUV
M"045E DML=1<68Y%51'/:L!EBX[H6X H!N%C%D$$V^F"K5&AG9(TQ9PXBB%C
MR!M9&, JP@853UN<7#P0L!UKA!_@:+1%MAT_VQH5VJ6T0"H#!;;"XPUH+?BR
MWJC K$,[?+T1V^+T001;!-N!@JU1GYU2P*CA&$FG@?:0 PQ7&6'<4&2ZG)%^
M.H$R> ;Y:=M<IT2@KH%F8ZXT"K0;:RW23 )+C53,TR2M"K0S"C%EW4FW."6*
M<-[F4N((BPB+G6%!0#,WRP"K" 54:<LL8=06)0*Y,QQ)3@X+%C$D?M09%A$^
M1P"?1GEV@:B2B'CY3 &2QF"=5N6AI(!*=VA-3 Q;ORYL#6)Y]LB?;O"G49X=
M2F59Z@ Q0FNJ!+>VJG4"D;(8G1Q_8F@YPB?"9X_P:11G3QD R$ FK *0<B.4
M<U4R$L*6[37\&P,W&V\LP] QP&/'W'2PG]ST5^K:+W/_]LF@%ON/)XY+_);S
M:AUKA)-]\=C[L?=C[Y_FB\?>C[W?M=YOV<B+;O#+_7L$[WKL[Q?[\GC>+_;E
M\;Q?[,OC>;]W[<LW,GO>M[C$*U_JUVPZ'^73V>U@T@S;O<^&B;VX86+,Q0^3
M,1S4BXRT=09QKJ4Q'%#!K:#53KG:@K3-C;IWS;R?3>?_:.C1)W_9J5>DHYQT
M8>RD$^Y/(G81^<-1G;//(,-<8Z<,5-"F5F/)JEUWD!5M9J+LES\Q 3<N;XQ(
M.UVDX7IE 4X%X9!:"$V*>9IRAZMUV] Z[? )(>TXTWIQ)%HDVM$3C3;*Z#NM
M0ODPQ4%J9 HY1* RTE*/H0Y4V7DSHL5$X8BTB+0#11JO5T XP9G0FEC"4I9*
MB>!RMU<+A*9I%VM0G%0D[+2-K%,"3]?XLC%.9(T3*QS!6!O'C.(8&68=K4I/
M2)ZZ#NST<4KPH''1961$)Q@A8+WN20NH' ,40^&,LMQ*56[$#,.>96F+&\SO
MEQ$QU!V76T;L=!L[F-7A: @!M,!0);U-(C5!J5SNU<Q@VN(,?^>Q<YSA:!*I
M$ZG3">K0FCJI2@4TB@@)#)""IT5.4:!.:B'A]H2H$T/&$3L1.WO$#J>UL8,$
M!00+QCFAS%A!397.:!W!BG:QML1)16;:#.L>6E&);N2D?QK-%M-LU,L+"0Z]
M\$[YZ-<Q'SW.RP6 2X : $\M4AJK%%%AE+<54U5MZ&,H!/+]4PW\T/&/E0[I
MI0H=):WA&4!MAM(/;QXN9@:<!H%0O2)&.9P*3#UVA*+*06 (* E$..7F4 @4
MH_0QURD2[72)1D!CC9_B4#J9<DL84$QJ7J5OZE0+<4)$.\X) -%FI<9(M$BT
M;A*-U413 @FFL6&I<JEW%Q6DI SS&6 E@Z=#M".97'A -$G:G-2,2(M(ZR;2
M>+W&1AK!*0K5L"61R' J""R--"6,L+*+">FG% H[:1Z=$G:Z1I>-82)KF#C+
M),7*?\,0THQ@"2O[R II5(M;1^\ZZ7E"Z.!4'L.D9V3$P3.">'VM#0YA-2)0
M X)$:H"R$.BJ3($W/-(6?:B],B+&N6."5J1.MZF#ZT4P2"N&A,#0>SK <" E
M0LO9-0-U!Q;!Q%CTJXR=F(T>J=,-ZM":.E99Q)1*D8;>$^)$<LA*ZEB>,G H
M_E",%S]5+4!$[$3L= ,[O+'T3DJL)<#$4T<#;!B Z7+I'9:ND]GH)Q28:3.F
M&W/1=U&I8D/#]\D^[__Y+(DIZ!O.Q(VG_7RZ?!,X^2.9C8>#?O)OH/CO^&?J
M" 2X3CY(4ZZA=V&]Y8B9@I)!4QJ3$*;:=:!D\?*<0KW4S<TTO_$']!NCR''R
M_(RB5O,&=A7[SAJ0,:\@TBS0#-4+;DA*C+=9K>8"*"PQT\B64X5$8H%:K%SU
M9C2+4P)ODOH>Z1CI>)1T)/5B(*:Y D1PHPRR&G#JI*P23;%07=B>XCWH>)Q3
M%^VFT4<Z1CH>)1U934>I:$C!3[4DR$BEH!*NFE;!!KL6B_P<$AV/<XH%2Q'Q
M&/$8\?@"'D6]2@D3I*&A2'(JE$5"<E?5F$\=X8AT,:7_9$.'@+1:<?[H^!8Q
M5O=>UVBU*9P0J.'$C<1.>T01+0TE&'!2%6B$G%#2@928DT41X6^)HDB<2)S]
M$0<V]D5D&&-"+%-: :,<H;I<X6BLM=QT8(^,.--PD#,-D6"18/LC&&[L\L,)
MY)1!BU+F) E'+'?PX%IU89>?.!O0VD*&5E=\1X)%@KT;P6A-, X$ARYUB&O,
MA25<FZJ\JM%(0G::!#O2B/V;3FA&A$6$[0]AO%[+)8"1H9PA].XCD C;E/,J
MJJXA<GO=N36&LK:N'PU.@4$[+L)H!T9/O^=.&OEE/,^&I\G9+80/>^'KCQ=7
MP_Q5<'WU/% [<YO_OH_V>'&R]]#F=C'@C44@P@F,%(::( L! :P8A02"C!)(
M]Y/Z<AS#@CB3E.UM6-A&$CMKM!YS-DFD;*3L<Y1%]0)JSPD@)4<$*@DM=UJ;
MJD:5ARVB+88KFI2-LSI/113V-R\=J1VI':E]P-0F-;6-]816@@A,D="I=%*6
MU#8."\GWM-]$G,EZ:G_H,XG:K$ :P1W!'<%]-.!FM#$[J%*I+,&I0 H'V]N8
M:J,@!E(J.@ONXYS @V>8[&\*+X([@CN"^X#!+4@])TI8BAA&/+66:4D4!F4T
M&@)DF!-OM=+H.+B+SAB-W(V3?6WC=:_3MGN!YH&DAQ!0HY! R*T#UE&NM30,
M05=MWVN=Q:#%->GBZ, GSA"D;PF^R+?(M\BWE_F&ZNJ30A/C"):2  <X$"EU
M5?J;X*G_<C]\BU-B3P57]Y??%GD9>1EYN1,O25W?TIHP'64-HAPA+IS3K*K!
MKH'C^]KZ(4Y&/3D9)<";3D9%9$9D1F2^C$Q6(U-3XYA( 9#"&Y2(2$.J N<<
M<$Q:+'K9,C*/=1H(L.B51V1&9'8,F:*NA&F]F9D"AB%V#*8(I\HNK4PNE=[K
M!,SQQ2'1&0:GX5>_Z\*Q5VE)T4B^Q\;30K8^+D:^B<.N._Y"?[^XO$@FX]E\
MNA*E9!+DY7VV^KF)N_R$Q</XI<7#)YM+<<0O'GL_]G[L_=-\\=C[L?=C[T?C
M[DC>]=C?+_;E\;Q?[,OC>;_8E\?S?B?3EQL'%K><<P#M-$7+TQ"K#>N+Z'BQ
M8WU7IE^Z)!1Q45%<5/3\G!:'=8DKZ$S8WQP [!@S4#( 8+GWI36I WM:QK]-
M6<7)=?Z/E>KKI>9O-YU5E&3\]=Y<1>/>^YKAHC"NR-^SZD5(1T@?*:1Q76N%
M4_\%-5PQQ#703 M&RL0#B1#$^$ @O??U!>_%_;?;%R5B/V(_8O^8L4]K[ N8
M.DD(%UA:3W[.!:Q2="$P<%^56KJ(_>>7241S/W(_<C]ROYO<7YF$$0$1 1$!
M$0$1 7$")BX >F\UW=0A$[ N.^2H$"F4!FBJF=52<US&X9R5TH@6XW"[[D%U
MN),EA,45XQ&/$8^=P>,>C9:H?%'YHO*U8)O0NIZ#P(PQ@BCA."7">K.$X6H7
M'4*IZL"VY3%8',V=2-Q(W(,F+D>-W2&IU=8:@(AR$$ %E2ZGYRA,@>.G0]SG
M2_*<9%9&!&X$;@3NJ?F7Q8*,'^>9?YC5Y\7/XJ.DEP^'53O_QP=OD8>__35Z
MR[\?>80O@[M\EGS.OR6_C>^RT4_)^K/<7P#R;="?WWZ$5?]5[;GQ>A$O#?<;
M[YFZ*Z$;[^D**.^Y[;C[NKHOV8.Z+UO>?0OI"X_SH; 0KL?C^6@\SPOSX(L7
MK\M\F!=#RKD2BA/"!+5.*NZ$D:2L3(^QMR"(/0>%_5!=X,7#_S&\&H91K3S\
MMW%XK-OY?/+QQQ^_??MV\<?5='@QGM[\B # /T[]US\NC_V0_'$W_.C'4R]:
M^>C\[Y=;]>O6W1C,@N1KL MF23;-_0 ]SZ=W81Q/KK*9_^F-J?!U5II5A>V0
M]"ISY7_]]]DL*6R)!)XE*!E/$YS\,,OS7;JU_"L<^W$P]WW7\\^7? []!>UN
M8O+GBP>"TA""QU0_JON^U/VJ6^JN18I3JXB%DG)BG<, 5?HK0>H>JOM+AQ^,
MNFO?5MD@*/*JDETRO\WFA>[?Y9GW.8).SY//ZK^223Y-9K?AFQ^\7@_\H?F_
M%@-/ W_:GY/;[&N>^%=(KO)\E/2&V6PVN![XL_WEO:.07*_(DMPNW9*+Y(O_
M)EP[NQLOPLTGTWSF+[<\;> ?I]#!<->!_WS4]U_-Q^%9[@;S9)I[)ZLW& Y*
M'HVOG[Q5."E\MWXC[VL4W\S''C+^PD7%//\6A=LR*VJA>:H%ER[2HR/TZ%7T
MV-YYV(@&DA!LN$9,I]@(IK"T:JG>G!'U@ 8O'7XP-/B;1\'PN]>SWG#1]Q+8
MI()7Q\G4*[MOL*#U\^]GJ[_[^=7<_^5-]T&O^C(9#KQZ>N6:9-/Y*)_.;@>3
MV5F2C?IG01&S9)A[C9HFOMG]U<^\'GO5\_<*E_,')5_]IQX]WK*8A*$_*EY'
M%*^_7\6#1$(8-J3& E@B@8":+S6)2D8?*-Y+AQ^.XHUG\X;BG15C4EF8LQY]
MSA[JXVW>O_&#W6+4GVVL6>6EPTA:U+ =C\*0]\P]'BIFXYY1*3NBE/E^E5(3
M[JB1,DTM)B[EF*9TJ64Z9?"A;?S"X0>CE'\-T<Y140\W2'YVDX]ZWY.Q'^5N
M"LV954:IU]G9P-N^WOB<YI.%-S:]H^P/G^9%2#SJ25?TY'J_>B(DE,9[A,9H
M*Q!380/#2O"U(Y8\T).7#C\8/;G,<^\M#<??BJ$E"P[;8ICYW_S8\GWF/;C*
M*_-Z,;HIK,HJ0H3O#3:%O]9/O"Z-;I*9;W7O/?8RKWR+T?C*CVA?"[TH(TY;
MJE3X/DS&#49EW.K0E.S!XS\B>PA3@$BH^Z$UYYJF2E<!"4*I]H83+*<C_27R
MOIIO?3HZ,%6_>4[5UZ2A#<O5.2 ,8$98 "$D&HJE#^@_E?JAY?K"X>TJ?POR
MLYT ;-W?O^77X5%FCQ6B7YFFWVX'O=O$=^MD//5C<A+^J:(^XT5E+Y?GAMA5
M/W1A6<G^$5P\$("M 5)<J)P]*GY=_GBR@1JS5[T0=YHVVD"43=8X?4V#BM,'
MH[X_M?B[>?U1F"P?WIL)A)76M<:Y!YB[RZ8W@U'Y>-EB/EY^4$X<%Y^4X)/R
M D'!Z9^6LWV]\7"836;YQ^4O/SV<UZL1VB@ ]S0QR_OX&WQ84^3R*_3T5Q+7
MWVT$XY9FU:NV*#^ DS^2V7@XZ#\Q[_G(4ZR)SJ;:)AY;V/0H[R $][5FCT_T
MZ /L9J7M(^OAZ8GG%]YU?=Y9[)CST+E7VTBP/OPEU"1(W&"4C7K^^.2W/#![
MFPGW\N?MM ;C37Y^-<VSW\^S:T_1C]GP6_9]%I3X=KH!AN\9"MN\('TJ86"S
MNWD#<*O;%<<_TJ!A^G,6 CTZ[!;DH9&%*&O=PI<A4E,8U+L\Y0Z=_N$OOU[[
MWZ?)IU'OHG"4+Q=7LT%_D$V_^X>\\Y<:Y#L]S%MTT'.C\M*>/\9A&0*P[Q$9
MDZ?'78PW^ZYY\3>N!ELU3M%K+PS0#[/BJOZG_BK[3)![@9D/+=27G0 K%;)4
M*ZJ(3!6TFC!9.0$,.F1#BN8S3N2+I_,/R[S<SXL[_[*]^QFRIBQ@\S]?S,.,
MV\O>;=Y?#/-?KNWUM;_;+]>7=7S@[XWP0)G+JLM PZ=1G8S[)7P;'C<=CGN_
M?WCDY8D"-&78IIPZI[0P$INE!P0%748Y0\(P$<8XX+S;QB$65C,FRD.! 919
MK[GYK)=-PO Z7>0;.TX'R)N68 +YR_8]>YH8<*>O1-L7C/=ZXJQ'*>[[?)OL
MT'4&=]X<_O"7D-QR[?5@_"W$-$LEG$S'7P=A<CT$-IZ.D(: QMUXFM^+A.X:
M+OWX_IL9OF(X?<\D\V-_^5H=Z3NHXQ;MLD'X;#O=_)\\FR:V2"<S>:]8G))@
M>):\OZH<NS:<L,#O6:8_W4OKJ/;^37YM;N8:Q?HHWV\EUN]A5>U=JMO8+R1V
M<J<[N5A+VM[6.._M+K"++:.7RQ-^^-NGGW_^],OGR^07EYA??OY9_7;YYQ,7
M=W0PING#!97M3:*\>GGE^EOL]HKOO>[YE 2[54ZW()N%*(H=.BU*4P>D*6(R
M8O*X!'O7K(C(R,[$ 5J.N-?+U\^2J_QF,!KYFY^F^K3^?J\N4=T.YG>JHO(6
M-<;;>;V-ZE=1BNJM'ZVRB"F5(@TE))Q(#EE9O\KRE $5ZU>5]:LN)R%E:OKS
MN%=$2.]?;3SUO5 D#&Q7 ZL*LNZSQ" 3I,V*5P=7:#ZRN"V[NXT1=A?\=MF1
MV)BXI+&/HV(<2(6T4<0:*!S#JB(N!B[5[1&71^*^ W$) NW7&(P.Y.%3-UK
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MSQ4[))0=W1@RUMJ@-$UFBZMPTJ2T8GP[S+U].KL=3()"E!;%30!*P8;5XQ^
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MD.[*M[T>3&?S,$$QG1?1C" !_"+Y-$I,WBNBV.$3>O:4!#1[/P1;]BP =3(
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M>V7ZNO6%$&U9!P@]KO2A9DY1[$Z'DKV^^XL!L:; JB+PV]7MK*9,/HUZ98'
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M1B7O\%$YZM$<6W<8^<W49C<;L$3[GSWU;Q46?IZ- 4(&!WV>[_>QH3#'B&[
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M_+F/]2'-^5,_U(R!@:TJO;XJ-QT?>?8>((@%W_#=;^ $Z/Q)N_,H'4']?K]
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MV2_$@[_EQ"I6*+G=]+VB)=BEEU)'!+U]=X,SC;A>H/>P2;W%U+>"T+,#'+B
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M.\=<&DR2%6"R+/ Z21 Q:9\>A3JZ"\H.$93]4X7^74QV@;#X?ATNBCH5Y?#
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MK9EH<,53;'D>M4*7,8C<1>A17%HSV\7(>@UK=L890-8G767AI2+(Z;SX260
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M[>8T3RYEV0%=BXY+1SFU$I3LNLTN]I'E^'9HA\3GGLLI"VD)2JY)^2+=_*F
MTLK&V\<")6QV='<=]G38LP7V-%I\VXBI+M^^%U+"G ";0E,58-]RA-=>Q]RV
ML6=EJ^]C88_%VW2(WF8XW?8RE JO!PWAA#_RHKGX-*E*#/02E&I##Q\6QF,L
MCZN:SO=DHZVK(OK9H747$E]62"QP3?D7!-QT+0MS']/0L0G#W"XM@.U@O& !
M@K*KWK7N1K;<(,RK>!0NYTHIF]_+)E6?T^)?,>!OI6_UE?1)SPW$H>M]=K(
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M_?CAP\/#0__G33;JI]G=!X(0_9#!UQ^J8]\9/\>CCZ-(BG \N?KSNAWYV4X
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M@,@\4Z6GT/D"*"VX5X/[>#B3H=AR!&R@4RZW 6ODS//96'_V79H N93ECN#
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M!M:Y;K3>==/+S&/(3*D_G&]JANJ%KNX$$19JQ7[$2[5LV['UW2O 'RTSZ^$
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MN/)3,?N?#%!:\-OJGOS_XL_]%]WIZ_TT\W_D5?W7>C6-7/B8L>EOCY8!78J
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MUYP<9VE5%:"F(@/"C]FL6@P<+,FUG@]?%A\N1AM9!!<C:X)MSLIL3!2RS*Q
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M$_]76$.D$9;*+=.(<U!)A)F#)DXEAR_0ZMRCP\#^18CNRZU!]+QS77,/WT3
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MS 3FTL%^0(IAG[W=U9*-LC%ZMC*16\\5F;KMH)QN(=R2A\1BN\%BSS<C3S<
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M+*E@34 BO83;[\)>QT[7^^]L_&<Z^0\&B8#0 &4G^>7;DTD=<JB!DH@DK\_
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M%3W()&6?N:IIAC9J^#GUA[Q' IRQ5D#HU 95@&<L\LU0JO0JF]TKPS$0';
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M'.%D,5\CQ*Z PN0&ZV1]-L)Z0NGJ3-^0='KX4*G3$5OSFZ_I*!WCQX<^ZP4
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M[W+D?5S]&35#N()#RSE$L'-;("C6_^=7X"H*[8:-85A3V!NF2(_!@O)OL34
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MH9=$Z'LR[S38"0MJGPV6FXULF)K *RQ.-+QD,;:\#YOCN[1%SILTQ'DY>B'
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M!KOI/P9=N@B#_C]%_3\-G^(NH&C$[10,D._Z1/G4$! C;H[E+9D/5"X6K=!
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M&U7W2@ *D*=5$RA(W0"AD!=;* -0];2%[I[ET*E2;K;M[)(9>U#*(U#*T["
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M5"B(@Q#Y/B*0AT"$(BA:* 2>"V7KR.1^V5!/$SYN]WQ(EW55PS'),:/#,8+
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MS7M$4SV&_-7U7R,GB^.#1K3-''QO[&7R>L/@;AC3VURBP0WJRPTZZ]<-"CW
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MG(BU=RU>1U:U/TBTT0B4A('B! .$4%&!'BJ!NJ,8V)VFK7>#$8'> @''03'
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M6GKTYL9?5OK9USMU_[X-N6Z;]&;HMH>.3E480,];'!O2_L/2YO]" 7"NUFW
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M_^C=,^E7&U&GVC@HW:!T!RN=K!T Z!/,52@QPAP2!0261<6@Q+Z'6UR*G3L
M/6^!I,LFZ(,_T*T_L,9.]CANP=G@%@QN@<9$"$7#$%&^ L!7U*,^]EUMB'@Y
M)G*!F/_ ;D$?S:T)[;0EZ^ 9'+'J'IN&[JJ0F#=Z)P,9!-27OA]P@$,%H5LH
MI$>5:C'T]NL9]**0LLM.6X/>#7IWL-[1NEK=#0)/4)<&(,12**"U#Q9ZYS+1
M;GW:KW/0A]XQC$Y![T[*/]CD#'T<QV \. 9=5 N<ON,@2!U,"44  ZHT:!)
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MK6(3.SKB(!-2RB6/J>;06"BL,2*6\8'V\'8J/-8^$.4#4NMF_(,@&K R8&7
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M8E=DH%4A19- ?T2)(ZDH51HH"HA)C&1 )$DL67-4NU?(P&0@W@$ 6@, O (
MQ #"6BI($<&<$YBPQ%BHD(@AT_&!ZB7N0KQ[!0!4UIE(-]#PP]'P=/S'M,B/
M$_P:G](Z=L'?_>_+V73-BSU__OSQ!&Y]LMF=_G"BW^F6#$-;;=Q1$&4.Y)4U
MY,80H+$&%D,*.!'(6F.1MII8P?B!K.%.1'F%2UTU?SCDD3\6T&@C-NP*!:C*
MYZ$4PEQ@A6P"*.&.#%,$:&(Q2'PYI08+B7<<"E"=YS"#Q@>-?Y+&DTKCA0",
M0I:(V"D\-E1HP<N0<6,M([3!RN$=UWC9"XWO/_=].QE?+M+C!+O&9[3. /#/
M.C#;P&RY<U^OC)N.K9%"<&29H<HP@1.:,*H3R4&B;9,'HDO4Z:AM(SQ4!#\6
MS&@C-.R(! )4)1,I=%A@.:=)0JD0)@:&&VTUX.X#'C=8$;S32(!D. H=%+XU
M"H_0UG$*CKC2,<3,"(FAT_IX?11:6*!I@T>ANZSP&/<BIJ/_M#:>SI?C_.PX
MP:[Q*:UA C^=Y^-TE(UGYWFZZNOPW('3=.[@Z+_^0R (?]OL[U9?3_)A='&9
M.<S()M/E/!IGRS^RB_Q(ES<",;YF';?2:%)G'0GD$G'#*;8VCF,(.(J9^X<Z
MCMP<,5[C5E?-(Z.!&1\):+01&W:% E[E#$H,5B:AEE"EJ8JU)- :K81SIBE!
M(FZ.&7<;"I#L1<:@H/']T'A9:3R53L<),93"&))8:9LD*VK,!<--4N..:SSN
M7<6SQHG40;CQYVR1#MV8/+8V6?7"?:N3E<7)AJ$X6<>YN9H$4AU(M;>K$E>[
MS4H ([@@B,:46FYB8"6**1' &5P,#F17=R'5&\#KJF%%@54?"VJT$1QVQ0):
M;3\I&3-?O0M8YV<K311&AFCG:6MK8]OD$>..8X% ??"Q@\;W0^-YI?&),_^(
M*RHLU4HR"A6@ZV1>7"?"-,>J.Z[QK,Y@LQ:SZDYGWGZ?_;&8?@LGB!N8SUIB
MX!VR7)SFDS+%5O3=X5 4%^F9GU*OFMLIO"ZR<3J97J3EYS/WD4>!Z/OY-%ID
M\T5T=>;8?YU&\6>51%^S25;>NER4+SA.*0G$><MT"@"VBCK21 L28X(U5!@*
M9S^Y3\<1,PA,C YT!FD7XKR&M8Y:SEH3WP;:W&;,:",T[(H$6P5L3$(,-XP8
M3)3[UTB@6(D$BDEA%&Z.-G<,"?Z=N8ZD\W,O7@)!]%L??.B@\/U0>%(I/%.,
MDD1# CG74C'"I2H5/K%$$R.;8\U!X9M7^)Z3Y@W%.DZHZR5K7J-&(,V!-!^"
M-(NJ<E3, 39*$I1P;DWB/&<)O>74Q%I.;(-9NS:PUA73>9,UAWS6QP(:;<2&
M':$ @NW249;&F@!)L*)N6!@S'#C_623&P0,]4)J#G4*X.P8%O?2B@\;W0^-1
MI?%)@@Q#*D$Q9<H7>T8&E<8_%D:I0QG_G4*X@\8WK_']#^%6XW$T7;AAB38R
M=)S U_CLUC"7?TN+?+H\TII?@>!>LW&TJM_$N,9<:4RYUI0+*Q325BH#J0()
M/51UQ%T([D<//!O<65_5V1H-(L16'PN$M!$I=@6&K>HME!.&4&PD4X9J"036
M3*A8PP3AV)@#)2_8A>[V"1@(".>7@_ZW1O]EI?]84&MBQW8!B36S2#$!5I'6
MTFJD#E0I?1?RVR?]1[QW":RO% 4_Y&M/BU%6;-0 SGY$\^DX'T7_ <K_:@*-
M]5O\/;=?\1A.C:YQ:OXX->1WN^N_3^>S?)&.'WM&>O/V?4](T_*(]"@<D7Y.
MV;S7;7^"B!Z"0_[G <;K05[]LW';:W@:YM@(\ZTCRS'%,5 )0)!*3B04-HD!
M$0+CA.H#)?]9<^R?6\0- +7'(O(!YW6>/MQ;,FO1RN!I=P&8&\3?P\!MVU%U
M5Q"E50PK-@@A@R3&1%%HC22<:PH, R3AB3AL;O'N@:BDM:XX/@2B 2L#5@:L
M;!0KM[)-QI)A8K V%"8Z@2CFB8]:].7&D,7D0&NWO)M8*0:8U7J$KY-8V?]@
MAI/E>)85Z;^/-<B[\5FMXRR'T\[,?Q?ED[.LU-00T1 B&@0&E?&SDA.'Z#!A
M5%!NB%+(&;]$6R(3D+ #)87:):*A0J"==BO:9RJ9J'.W(H0QM!DWV@@/NZ(!
MJN*;*$9*^'(+@ $:)UQ)$ /$C#0::\$.M(VY2QA#]]$ ]B(3<U#Z?B@]J90>
M.IO/'0?6T"J C6"6,D=]@4@42VQ"FHM=Z+S2$P[[H/3]I[OOLU$Q?71@04W)
MU[,06=!QIJTFB_RE(]GC],)!P;2XC+Z.E\/IT(/4<)J/6M+SMAK2XV#= FTM
M.3N#:YB(N2 40Q(38"T B&)K$DM$D]GE/!!VU=S6NS0=&'>+,:.-T+ C$A!0
MI<S@5)J$B41 J:C$0BJB- ":&9@PJ!M,RMYM))"!;0>%;XW"HZT<.198%2M%
M@9$L232FP&\T XDA@(HTF).]TPI/">B#PO>?:?_M+)L<*1]J?$)KF+YD.?D:
M-I0#M;UNW[8B3R7FB9!2(&X-Q7$B.<:Q!I8JI!%GAPW?_ZE]*Y&GH^8-DSI/
MO@9FVV;(:",R[ H$O-I6PI0)Q)3FC%B:0!6[*PR#,<34*,D/&X+>7R"0H=A8
MT/?6Z+NL])USD7"64$P$8S%QQI[$);%EC"0F/E#&QUV(;9?UG:"P@]P)7OL/
M)[M.E-,?81,Y4.L0KAW8=6WLFF*T':ZM%+/4D$31A!&5Q#R)C5]#UMC$O#EV
M?85__W#_WU%CBW%@V<<"'6U$B%T!@5;;22JA "O+$*&$(F9C@#F3RCKR+65"
M#Q2\N0O+[@4@H)!P+NA]:_2>5WH/,16:2XDM(II#JS'4)=N697;:!MEV'_0>
MR3H#R0+K/ACKMK/\4Q:.*'>6\[KYFV2S\\+]=*SWGRO6&RT= +D_HT61I0NO
MV-'T+!KG9]E+!RWNHVSBFAFEXW%6?,V'D?LHL.7 EE=&DFT=;C: 65^[%R.+
M*09&&DR!3K"O6Z(IILVQY15N==0Z8E!G<&6@R6W&C#9"PZY(L'6P.>$FP8FB
M4%I 51S'F/E*149##0VUJ#F:')"@>3\Y*'P_%'[K4+-5A'$H9(Q)C&A"&<.F
MY,>&$"MD@X>:.ZWP2(8PZTX08S<[7R_RP(P[RXR_;+COZUGAL:D$/$>#W:_3
MY3PJU]A.ITZOI^-\?M&2<6BK43L.YBNJ8IPRD7'B/%XB+:%2Q()0K6EBL*!:
M@*3!0F5K8.JJ_:.!^AX+:+01&W:% BDK3YAC*&+NV"_ 5"1<J1AC@B%A/GB$
MR.:H;\>A(!PQ#AK?&HWGL-)X23$%V !#G>+'R!"%@.>^"@C(]*$JJ.S"?;NM
M\;@?Y0?[3W[_<?EM^N,XL:[Q"0V!T('@'HC@<KI5<%<#P(@1,D&"QL8(Y1Q:
M+E%L08*Q.-#Z[DZ!T!Y\.FKA$*WSM%&@MVV&C#8BPZY P'&ULPN,84DL?9P'
M31R]Q1@(*H7T,1[:'BB?SDX!T%T&@EI/0@1]#_K^)'V7>"N_2,*%T.X[#HCE
M5+.XW-A5.#$\U@>*Y-@I\+G+^B[",>-N4-OI_'+R^DOZ[^DP[.X&BMO]V0P4
M=]O2"22N+)T0UA"IC$ (4XJ2V&ICC<8<$14KKAJDN!Z$UAC458,'Z@QD"DRW
MS<C11H#8%0\(KTXS&  59@)*"ZD 2"5Q BU'B47.\:4-)M3J Q[@7@0V!K7O
MA]JS2NT3JHE1 AD*=2( )9(G)>'E0AK"<(.$M_MJ#V6=A=\#[ST8[_UR^34=
MYN/CA+S&IS0PWL!X#\1X):BR6Q&&G$-KC$(^O86*90R0Q IA"ZTD^D#E1W=A
MO&OXZ:R5XX'L'@EHM!$;=H6"[3(IF)#82!4GC%-?H3S1":9 )1092^"!*J3M
M0G:[#06(]"*S3=#X?F@\J31>0(P8L5PC(14UU.JX+(RDG!\ !3K0.85=>&['
M-9[U8F6K_Q37Y&?CY3 -N[J=Y;BA.%(@N+=M'*\24A&N,4I83"0!FE&=4 B]
MC4MLK&4"&SR6NP&?CAHY6&M>BL!PVXP:;02'7;%@JUZ*H@P*Y_ *C+'@CNL"
M[#.X0H 9MT V>"ZWZU@@ L4-*M\2E9< 5BI/1,)!8AC"C#(CN7 N0*GR0FH;
MTP9CESNO\H'C=H+C?DHG_[[\FAXGW#4^I75,8.$TKKB,SI<7T\)SW8N+Y60Z
MRL[R89Y-AI<MZ7E;#=DQ,%X)MNJ36,H0X()*;*T50&G*N  P$9!+8]2!CN?M
MPGC74-19BQ<241T+:+01&W:% E[EI*.24I-0# %"EBD.D"8E%"!%D,('6OS:
MA?!V&PIPH+M!X5NC\')+X9,$\D12(B2U%"E*@3^JBV)I0&Q-@W2W8PK_[\QU
M))V?>_$2"*+?^J#P1T!VS]Q?1:3=W!?9QTG64&7@LU 9N..D^V]ID4^783<Y
M<&L)$=^*F (Q3 P@G#&*I%8BT0:Z'U@(;,B!\CSNQ*U+Y+L"OJ[8V1N.M1O?
MP+&/!#S:B!&[0@*I DP89Y@F1B=<*.K 00BD'<%.J#8&2'.@^N [<>Q>0 *G
MO3@O&#2_'YK/*LU7*"%$,B:)<?H>:X.!+LFV5A0+=J"%]IW(=C\T/R1_[@;K
M5N-Q-%VX88G49)&_7 ?C?LN.E#XU/LF!_P;^6Q__=3:GXK^.C$*4,&D8I!)@
M*335UEI@'",F318Y^NCQQ\-/A3X=-7MP "$)+/A((*2-2+$K,*!JXXDX)SB1
MD$(+&/4!)YB86%EB84P92AH,K>X3, #2BYRQ0?_[H?\$;"V,2T*!!(HDB24
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M!N"JT"TUF$I-A+6 8Y-P+;59[^L[!P$?* O33OOZ_<( U@L(>.;,_P^E &B
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MY7<N 0Q<N!-<^,.T^);.A\<)?(U/:0T3^/OES#4_F\R=BK6DEVTU7\?!?=U
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M(@D'ADA!E=*Q8!;XK0%B8D9MT\M3?8%O!&NMQ_<@? >4#KYY .+6 _%620=
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M1G1/]J,&7-"]H'L=TSWX"M=::23H7M"]H'L[[CR 5R <TVH[W7XBNPX9Y$+
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M_XE>B>@T=X,]G>SW!"\$0R>^J?LWG<_]7I'#QKPH[:R3FZ%W6D=UBLK'A9?
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M9!Y37^6E#]5D_]$RT19Y1^"SKPH?,S,MVNP%QG3>H)LF4A&0"$@$) (2 8F
M1$ B("MC'UZ#!<C5>C0N.A_J+UJ&; L@Z_AST9L'?;"DP*O2V_JC LO6VEV
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MR&-3I\2U\IX:D*@S<C4SKMH%XJH8::5R[RV&A^YB>)"C@QH]95HM./KR]N-
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M6(:"</[5C!1 A0NF1JK%.G%$DX9SGO!QCH!(A8(NBYA5S<QQWL"^L0(+G#F
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ME!DY@ O'A38CP=H!31BTN>4(OM4<N,+.U)UE^<1+"@\ZV##LT]$QJP/5R/
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MD+78?4M3S76Q4D &?@T$:L91U;= A([*L)!:P:T#'B8\$+8@NEHI8;\185F
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MI?)Q<H-A)@MH*.Z*)'F"D7D8F3<A@W+)"R:CK22"Z+X!VW*>@X\Z+TR9$HZ
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M;C>%/6B1/5?T"IZ A1D6/O,PM+MG3M>.K(?Z (J8K 'YW2ZH'[/*/W@@0\5
MGU_+O.#JJ=Z&M1!%(P0,IO@N,6ZQG5>83(')%.NP1]3:<:'1%KIZHJOG-Q#I
MJ<A-$37RQO6?I^S#]Y( (LN(4%4A"/U.F0C*82[M]\.,62^Q5H>6.>MJD[D$
M0DET;GTC"/ 1LVE6:3U1DNSX^G85XP 4\5:=+[+1SB5_B6T$1&Q-LLEFA]H
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MF&XP)1!*HFWFST2\1J*#\/H]=IY1']D9)@I*L(L\<C4Q*(,742!S80@"!AT
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MSR=H5*O W=%3N_"E]H\M[I=[NKZS='U^)7&%)+7-B8?DQE6QCL0O&"X:@_Q
M_0(NSE7PR(I_XK2>,!U TD88>XBO$(%$VWB__XO8U."94H%7.E]DBKH&1WM)
ME><N=NU5>X_-R]3G,F;2Z,QY>5>J++1-?NXCYU>GM5J#R3OU(U*1>@N3?":&
M4320BGV#S1O,?RDSH8DOZ;26 H*@'(PS@QJ8;'#56CN19BW-\$(]#V=@OMC*
MK'ACKV$NWYU$ F(RQ-K&V&;_NG^)W'+7%)NCN-#Q*)U33G:0_CMN:S"1HK%;
M5GZ2(U5?]SPLMN>6Z8HZS*[UASZXMYCOA@B:L&*-7Y$\@'XE%@+=U 2S"E_L
M7^7V]%H7!&D/OK<5\P$U-J<P[/C&?LU /9SP:L(K\:8-O937=U+"MZ.[=>^A
M''HHW4:-^2<EJ3CT44Y2XL!#.<4X=]Q#R7^&Y7'3J9@G=8T)-:1S[/:Z0(]U
M]097UQ'9TC/SP;!6(&NNG<0]5;H3^[I<;QXNB5GKV.0X4Y([UT[%CF@Q'36E
M&5!8G%!MJ5$\#!/.:13O@MX4S':0-C[2X<3JX=*2X,,8FK>'Y$(Z^* ZU@%Q
MAQ5\-ZE]*E2J PX;AR4;_D[:G1TK2!S98]6,'+ M$7HG/%42T\L0H,5B$U@\
M(U/O8+K/4-=K@UK#-1!P'NME50P?0X#!BKJ0(G;&GH'GH]ZY&58MSBFM6:HA
M/*/M)&GW.=A & V2O<P=XN#=F.+,?Y@6TD9)\[M0H3?7'##M=U7Z11R#RB\4
M1Y]5S%9QT8(1=I3W9!N[4C(A_/(RTVM3<3TVVWZ]V\B<=IP-]\5;>*E@YXJL
M*]SE"4#SQT3A=>^2%8!8$ ?WR5;WP/(TPPYK,)6WUP1QOQ4N)W'P15>+U-XP
M+@P^(5YMX0@G_1/@P=,7MS0P^$HGJFOTEKH';$1,5A<BTP665VAO4<$9W+BN
M+H>/CA9A"IB"80ISAHM$=B2@#LK#R+[!948D"^!6"VU036U7!6OI5=(\F\K5
MJ69(>L>Y'&);XF7/VZ8C\,''MG1KC?V@6_61@*3IXH1B)9A&;*J0E13 &H^4
MB4$I%\'RZ\2V#+GC5#:FW(&D -T4%9H?&,;NHB88D=U>B;LOQ&<$*[0.H7"U
M=-RF=FH<Q026R4GR!:+$*69+-B_1@ 1S2P3.*22APV);X,]1^D>PV&7X;LM^
M.":;Y_Y'OK\]KQ*#\Z++IJNE^:B7SH@W?::MH,77I+K)4 7A3IZW "*$"HE(
M;Z3B3[-&0VR"F6AVV,2K>VF:CX)ZW,#DHJ9X5K7@1HXP[EIMO"97;8@1XP3#
ME--X.DTT.I^:.]6OM01IUC6](4- ;^K&6XH&C.*582%A#<)->Y@;]X#WOV=A
MXIBIU"P-6+!:*W-3,XL,@!^Q2)83+DCV&*_\I3:,A[+HK ;M'$YHAG2E (_Y
MK7X](3J23Q6&] @S:$.<"6\#%MS:,DB<X$IS%JK!!C:X"N8A%(.":#)X-AP\
MS+7SUM'+1QP;2&YJ@/6V\SSL36F-5FQAP"('*00DQ,-_(XA.FLT%2=>4#1FU
M M@ 4$4AOBFI"Z6S]3-UW)%O/6"R[!'(H _P/+JMW$33T2FJA&L4<*B$FT;@
M[-@86&GBF>"4>Z+GJK;DK%R)>.U2@\+R;XH6>: $*6+$XYZ A2IR@*UD;Q=L
M>2WP9>1\5+K69KDD%'UJPW4'2=HXE5=@<H/,I?3/E:1T8!^')<-X]7PK@2^V
M&^TLLF-T.+D -M@:QUNFS*QQRVI2O@XZM/P*-EB\Q9BDE@83=8;B5AG-A1CQ
MV:#^S]X.YDW2@'V%BF$KBM>,S822,46$\X]YN0+C28WNXN0FLFB8REZUG7QN
MH[4ZS:NH=EPM:NV\Z Y9V].,,&>\IOT."WO\N+GGFZ!"N5 !W*JM_<TA?0OV
M#I]N61FD16DD(@R'2_?1@.VT_S&+4Y^&Q>^Y(7JCOG_F5[U'_8:T.WZ@HUY_
M VD&&RT >>^L=_C4V<,I?[S;"P0[UU7NF)J%Q 9EXFGO^,#709!9LC?*H$ D
M_GY8H!%RRF:$1F9P]_+L(Z*+E-QV#NLYBZZX$L5JT&V.0I#71[.*LOE]>OD=
M"9:W8U")A+$ZIV;U$E]F/TC)03%I%2\.=F/,2 <,U4?(&@:,Z :HQJ*U*^>B
M0^=O$J!).C%K6<Q)PB2])M!T FB5CAR("6Y:.8PL2[*HOF$\V2M;E-Y3_1^5
MZK&>^%)*#$S_!@QZD9NH%O!>B:&!M#9)WN.7I=:_=&02D2[8-!VI;F'Q@K#Y
M%T#[]U1W5ZF.FH68MF2"P$8*\*0Z$0 8WL*LFS?<XP,-KB8>4WO$*3 "BXNZ
ML ^E-HZ4RRI+9GLP3@ ZBB+N$'@IT(Y]-M"@#/2IV-QG/H$>.O$$"]B;,-O8
MZ,,GG**_O^/:_8.7-CG#2Y(;QI.#,/)^#T9V.L$*-6F?#DC5%1^8_J23KN4F
M;N2GQS8,G// >H$)]$O)&#=Z$]1 ]/)PC[,]4J,E>4O;*F1)M;"CS@=1YWV"
M\>\AU<\0"$@G'Z4SJ%F-:<-K=&:9LM^8*DVII9X/?&QCDTRE. DS4 B_Z:UT
MMO%^4ZMZ/[8]JE@YH^2;SSFSJKSB8'QTQK%%$_=B#/]U5CM[G#R\=9?(C>+"
M]%\ZBDFQSD?1*DQ?"7Z&MD=!J9.M1C^YS7G$#B_66V4=59(E[O:H-[\#,#9-
M21>B.=4+RHRYCY/\3HR$#MDE"BTL&I&$2^G0N<&!AR6*.GS1:U258)V$Z?."
M#,%U2\-X.Q^MZ;G+QGHI*)'$BJ0YKC<#83F&+'><*=.?80N%'ZJ4[ZKLYQOC
MA=SME3QX^=/0<2I=+7!FEA&.\D4YM8+6KBU8/]',:L4!<5(/C$<V&PRF8)"?
MN4402NW% @&.VV%?#_/BJFLM(+%K34:%,)S?W<L'*?QSV;NL*(BCN+5DDJNF
MV:<<3"'LK"4F5?0.DP8R+8%3P1L>!]DU-X= :&.TT<<&([L&1>C<)>?1PUFQ
M4ED=M*S#8^#$. =:JA&3-+%UV>:E(O7ZW8M3/6N]AF@C<R(X:0QPUP1QPT<_
M?!)N9I>8"*?7E-9*$\-=&-!\G 9D"5,_Q^_6"M508[0I]L:A62B:X\2N!KYJ
M1NNQC05MC8#YW,\Y#-^YPK;HYH71Y)20"98<;LG\)D6FUA[?*L$)4V]%2BA3
MV^WC<&>7)D7X->_-;J\ )BS]3YDT3%H)=Z6L2M.9$_'?C?-!%C8:3)K6H4VJ
M;[^?T;W7]NYX$HSGDV+NQ-Y\Z4 YXJ+S6]6JM'EI-A71M/[!=(VTT_<NT7N2
MLFE)FZ"_IB4C%)FF(QLWQC/?($X-$)%M?FI0\2>H[I[8[HF-FQ?Z#2.F6-25
M9'=/3O?DY#(QG 9NM&;C>^O7I&&W'?AQQX JE)S!U/9-0&UK;=/:3&M/Z41)
MD.#WD9V[38!<OH?03M1M%"6H,=M,UF+?_L/TV+I;M0G5,S95?DD&.N5/^M"8
MA'_0U0),>1N+KT]LD)7M''*O2R8PN@IT2KF:?K-$U?M)>'.-V>ZUT^G_ -TM
M8UW"[$M*C7D"JH9YC[U0E181#)&Z"&G$]!!"+Q1:9X3 Y_K1]AQ-VVTUHQB9
MM^YI[I,XIU19<068!'*D#=HUPZE$<(YZA/;1Z96UMM)7:C_-A*5$Q4U[9DNF
M9ERQ95)\0T?<COL/L"OYJ&G=-Z/'_7E>3SDN%1ED $@[8Z]DUWAJ?.<B-C)&
M;\[CQW^ACI0C3D5_ CZ14,4+38%R!762JUI2:7LB)^X9?#+V'D:OLJ!H>'1X
MRKBOLP5UO**8*&<FXA@._$)*H;'RR?-XC2W(]1G;CU9YUVQM@5QQ2'AT8D*,
M7@0(S0G%Q@?W5CIQ69(BF)5LE7,M)B!2!2AM</IC)V[;/6&\(M[N+[Z1E]C7
M7_%,81Y)5J8"9%EVN0EGN?G>I][=&:7!IS-,GIOI.;<\=PR&<I),#S(5_=RE
M"U=.D=3<G-*/G7$ HM2;:UE$?YC0Y_TE^:->DK7TER,A0F3O-W$-+LM8W!B5
M)(P4HQP)P$7,AYX&U=IFEP%7UFGX2_L+ZKMX;_/==<H$?4FG?560OJ$(GJ"O
M]D-9<9_>RJI\Z"=!>.3GZ1S;D#O&5"JJ>;+90GT/R"TT)5')MS:3K$=\/IQV
M6T<H.UP<SAF-W V53B;(\YWIOI;?L^) I:?B"%5^B3(XEC+0,B@Z)9F%=J1%
M!2);4W%SXPU'B@<FC@"_4Z#WEXZJ2\?,9J_.:<Q02D E9>-;"+=/8&'C;9LU
M%D8[VW45)5F== 5N <SD>72OT-X-CJCZ[HE>6'(>BP#MX1'U6D8SF2624%+;
M6^XQQWYL"M,?X'[A]_>.V+M-@M;=7WG)-RP2'8.S^6/HM 6J287;8<H,IPQS
M@A;0&LD2!_8PRMH]@7L+1>I[IXA0775GL)VI3KKR!&X<Z-M4$-:: EF!J/FD
MZP1AE<0'1;7+DM8'YP'BIY[ !S3ITY1['TNU;V402+VL,9'-,0PC<MF7UP)5
M8"<)ND!3E9(6FNJB!*:"<O#:[AWOO'M^0B,""T0L:(8%H]CHI#5%!8*CU0I>
M$,AU#>3&"HC%'1) _TS ZJAF0*>FSHYR: N=;D(LV$!;0( L/@([".XYC@P[
M0_5TJZH,?V,SZ4=]U S8N.N^7VFY[B>92VD)JCKH:R,!A(G_=2.P P%,5W\C
MFY9C-0838LTO<(F!8\HG&98S3#@W)6">*U;R,[V$0 )J]S"R>PHK24N2DH.7
MQY+ZSJ4+J%CB^=FP@07;5#;.B>OI7&+\]<X3?3Z_?9H?Z)]P27''_F.S&O-+
M;7N]3]#/?A-ZQE #'+O!+"/@SM1N5(S?%1I(&QWWG/U..(I-57"]#'8+X;"A
M S"8, I&:MT]Z%6_[)U),0,^<EDAG]@8=\S0&>.Y80A<)$C9#]ITCZB*#@@V
M#C+93 ,HB<R!B4$! KF[2.(Z':9-8]=.X/Q4SB,?]H(C 0"-,9PIVA/4 GV)
M9_Y7T!B-[O;[:HS'7_VQ-<:UMK6#]BZE?)GZMV=K0JZ?V/9KFR#WQ+/CQ..
M$6;:Y@]L>M@QA.FU$7PO8;3(X^J,T_AM>O\8FV;3V?Q,6W=B:J/<P310E=O@
M2[O/MTBVR]DG-]NP)W*L1T\.7_P'Q?R%9Z+@]78BU=9[HF3MJ!Z#]<=0,T1U
M4O1(BU[EZY$LHF"PK!2;!>/JC0:91I:DT2MMX::G *XPP2QEK*M<>8T%O%F2
M^Y*"U41.F1BN_SF%;D)UVI&XXG^9/V95NGGYIV\?+=LB?_G_ 5!+ P04
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MG(9ZB*Q?(#L4@/RBZ*<N4(A4>BM%/3%/ZZE?(OS'$G#]*0)^"* D)HQ) T"
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M4%)"E #%"%"< "4(\)!'4I+ (RE(@$($*$R (@1(:'LHB9" H!@/>$MYP&G
M(\8CSB/!(\D#FD90D$=0B$=0F$=0A >\Q2"3H#@/.!^$0%YPEH"3!)P_HN!4
M F<".&G N7#UNOAU10E%41%A11$Q!5$!(4D)!44103EY404A(7#JR']?%XY*
M?W\&;]A[@/[*[SON^VJA8^WVH_J][F3/1G#E4A;0[X\ E.!<K-A_H.W_D?OX
MIX_O][8^=M8N_ZF'^L[F ;/Q]+%PMY:S!1_??^98^?]SZ3TLO/^)[/_4]?V_
MD_U'&ZB=A8NM-1B2\/_21IK_;_=&FO\?W#]IT"=ZVGLZ6<L25)=S\OQOQPX_
M;0>VEW("A0'-P_OC6)Q=]B^_B?PNEI.][/<"..1/^?Z4!2Q9_1F!_'\BV]\D
MXO\W41(A_.+_$7\=!G_\OZ(_L,;VOY!^#_)[D-^#_![D]R"_!_FOI#]W-ZQ=
MK&2X?+@@LOAA0!X@^M?3D3\3\:]TV,G?>(C^2OT7$^%[+2*>(R3$1#0_O]?Z
M#+ >?@9XA/@O'W*24Y"1DAPE/G:$"#@.,I2>!(X0$9,0$1,?#GF$[*@7T1%B
M$AK24V3GR6G9 0I!.CDACM-'M:Z?L> 4IM=VNW?6,N*"?$KAVD41]V/G/G:*
M<DWJB-U?CWRKH.NAJ"2N#+VDIV_ 4/2I:VK#ZH%GU$/KU.+Z[NG+$C:;7MR2
M4C=4;AH:W;:ULW?P]O'U\__C4<CC)T]?1L?$OHJ+3TO/R,S*SBDI+2NOJ*SZ
MW-"(;&INZ>GMZQ\8')J9G9M?0"UN;>^@=_?V#_4"-2(C_O,3,[!&2D),?H2"
MZ"APC* 7S:%>AU]YD9*0D)"1D3J#>M&0G#]%*D@&L-/*:9$+6="Y45R_QQ%Q
M6CO%\HSPT4+.CYWR[FOTD_=%+D3JG(4JK+\MNBAZ3E=,T8KKF,>#*"7/0Z7T
MK+WTQ1_^0=!J\S+#R[22P\^]HK]_[W5)V<!&XM<G7W]^<7;#T,[W\:NLBJ:!
MA5U)%2-[OR=QV97-@Z@];JF;MQW\G\;G5+4,+>X3OJ^3^_OG8>/3XU5H,_1*
M;7\MIL!K-7AI-.!_#:%FU-995M8 &5TQ;;@_W).\4?RZ]9:E_5XMPK_N;9*L
M9W+']- 2<['[R,Q:V6A=P!/XHTM#\A@ZVD[]I;IO 700K=I5L1AO/- @W?D9
ML:HM%#[?&3PR+APLN*S)/7,UP+F_F?4E15F7%1H6/3VMH.,<3YG'OR)^;)F]
M,;@JSYV\&E9<-[L2KXZX;-*8$9>@0$?^Y4D<(\N=(\%Z2"VR/73LCG#L]K,.
M-Z=T-Q/CHRZ+RB\<[6;5]DY]U&3HRGR+!RHA<?/7+6LB)M[+A%1QF5Z_?.>S
MI9L$BD(U/R<TPX7GH</&2<0:S6,@P968NFRU6EEFU-YQ:;FN5_ICQ(Q;LD)H
M2F,P1#.1G7=IM6V9;XS9.R_3KRZJ*5=0\5PC=U<[YVD)7-->O&O6N62<XS9)
M\YE^E!V4".%0+%-K9MD*1]N(LY:SK9<EH_1'DM=F'*%HHU![YX[73[8-\SY@
MPS89\$ -U=O1_E6LL(-Z^+"HN7+25FGPP'3Y;7B[SD'1\3E$/%?3,:S;E/>J
MT1U+ML<S(4>3FO33^]6'G![-Q3QO*;^"TR#?KM@1+,(4;= QW%YR'<F$"5@]
MH<.I4EALKF(N]SA78/=K1VJHRAC%D'9)BG>2E,]N"IF\E$W=0K;7DE0FSQW=
M0'!W\01%D[$?E139?9Y<S'84TZA'TZL[P;UQZ=1'WX2>^VT!A>P)YA8R>:44
MQK$,!BSN)B:LW-8*.2']D].?7J7!*[$K6!S"5G=>K_P)@E(LQE&MG_*K]/U7
MK"S74O+4Y7D*6B&1@WKPRI6Q^I#;5:R3"8\*CEU[$=E Q?3U[ !K5ZMEZEWE
M0N:"TN"1H8C)#9LQ^Z3=& W631V]X#OKFPLT0>A[Z"*L.1)]U??V?8C&9,I4
M8 TK5<C7T'!N3]:9@.+*HD_F4[65@X,0J;=M!_+!*SGC0AF)Q_E'9JTVN.W/
MD.V4%R](BD<M'\'R<SL7HB;?]I&F!UVZGTC*%]2&YG*UW<<#KN7-VU2KIW"H
M1?)CBR_[7J7[*^G#3@R;GH\O]W3A;BYY>*K79L/K% E)M!QGJ<:0;N'[VLH=
M9ZKNTNM5YX=Y.Z_<YK$C_T;\YN"@X0N]^V[YU>692-=WZAP,_KJ%(BA^+9XH
M%<[N&QNM5TJ*6CE$(E4X0XUF(@9B?+S%.2-59+_HZ9WDOG2,%#@+4 &>6APU
M4><XW;L$.2,=5"0YHR(UXV2X<IKQ@!_K*@ ^14'#_>\N37:YY&+]<(AU66PW
MJBNPMZ=3HU372Y0N6M <J:4J\D*3)6M,O)-'+?)BUD!VX<PIV:1M3JTO>4Q9
M>>>F*$A8FP[V#6 B?1L\7V\V7YIHN<'^]M%#JSO=WY8X9>XA!._#)JO[?: '
M^]+CT$IAD21S^A?(68S_P$$2A,.^=CEK>.E;75"";47G]+)^AP;#6_F;724Y
M\0:IPRY6<U?4X:J(L8:<Z$[I=[==\\[J1XML%6CV)%_ *4VTYT*"T1K\C^_=
MINH<VRJLNL9/Z:Y(Y<81<VGUD\ 5J*/QH,+!LV9Q/7KIY-)FY%3IW?4I.<&)
M@T9_VL& S!7G1T[8AG'+R;7QT4OG?8^0E+#Y,WE6-,(%^.,2?,=9-QCAZIFF
MB-">Z7*V;134K:)P\%:?]9G:K6?W[MS@I)?M"+#VAAA$.2'WKW7B@=XRC4=B
MK+[A 6)KTM1NZ#.2N-Y(V'Y-)+QP]O,6]R0\8;YMA"I\BG'8SF7YA#?CLP*Q
M4O&7CA$ES=CNM\,DQR7,-:+2R<5[#/G]T%X[58MU9/UNSN;HT<\9R9O1Z3BO
MJ6!=UF5$ !X(Y"G!:NS9^FFBM]..FTOO'B?/$U0CFM=6EBD]V+G:R@0U175A
M#2IIR.(TAO-'$Z[;Y^83^PE)\LY3NJB>=U32'<PE2TECA*.-9NV]F(OC^">Y
M0AX7JI%C6CX%!6*%0YLP!N.Q2>>[,4M1WN]>2.SRRE1*!XZN !OYEQOO&I#9
MVL)E@^/S[&+?5_$7E659DA24> S;!BD?%<Q+P+:R("(5:"-/O!2[EW4DB.5#
M0NPH]%4*R;)TIS4D\VFDG D>D$=N[*TC.[*-K3%K&\\[Y1#N&M..9K(D[T?N
MA:.PER615.?2W3H_#"2W%4S$[-I=GEDYZJVAY.86/EZMZCFA?QYU8KZM_FF3
ML]W-V"-MYA[-]$ $LTM2?4!RZ9)%Z]0<S>Z;&/&"@3]B='#K/1^+@N:QL6,U
M(M(]3O.P>@^2SN[E%QS7(?-<&PNK3GQ3BV8]Z;?'BKZM(+XQV&@WFL;6B.'F
M:%"L%<5\K.<-UU1I)CL_50F<O\L6[I:/:L6L-,W)S-M4E<!5WOKB 9O2T^1-
MH:Q\&;RQ\7ZV<>RT[FB!@7'%)9)U58RG\*UP 3MEXJ_AWU)35VI71P,* M!F
M2V/8_BHTPNN_@L!__5]<IJ^MH/=(NX)<;9[Y>;MT?=;7&>]XJI;FIS9R6[&]
MY@R3E3 ['@@?F%F3W!$8E"1.E'S,X710ZB/"^[&%+A0/M V**.,!AD71N0)?
M;-Y,*K<'OXQS'_KRNL*%4^VR ^?7+^*!'+^-A3>KFG/6W8;R/(SB3JLGUK4?
M+F1',I@6/'I%1?:TYD'O'%T"W)&%!X*\Q^<T[IWO5MN%:9^UA9Z;(K*?85W6
M48,7F14BXG!8EL%EFQN5MI8CY49(,NZ8]^4#&_2O@KVGWR;6X($XA+MUS0LG
M[+NB,F>1AR^SDABP;:\>FJ".ZAEIR3^Q2-LOO77J1L7[Z9%W)4%#DK+=JBN8
MO.69!X])SX.*E-[J"FZ&PPS17Y*#"]S1_*?XC&>Q!4YWUVR,^#+,;UXM<4U.
M=&X+S*Y_6UQ=IW_P="Q)*V%Y=)).**9?Y6X37T^JI\<73=72J<]R(M?<TNNI
MW8.[EVW+$\22W\Y>$9I^<#/I:E!*AM#)8,O$:R/UZ/OHU/CCN"TTO;OA4*FJ
MGVP$A:PBKP*W<O.]!41?O_Z,P\6\)GT] WV-AOEWN5DQ.1FV$(,8O]'9B"<'
MD9J%WP3J8:? ?^2QIZ2WZ*C?'R/J4?;P\@BX.C)FHB+:&E]<?<9&-OU5I.:0
MOS,L>V=MLLNFE>5]^?0HTCBJ-6M^$X<<.]CO_(0SO2.[VFLPR6P)RT9/SW8[
MK[,4JFRQ+F&&UA?SUG!!=V"9U2PEKU46KP;)#+@MIH9KI4N+[X^OLZS.]B'.
M8:3NY+AH[L_CV +0&EDI*%%#7]@V8MH<7$GFN_Y ">K##3@6QP\_8GF"=DDV
MBRHE?X##/ M8GY+RA2>G854FPM=AZ"093,_6QM9';;C!_CQV8GB\RD^YOLL_
M:Q/W&0]\'4//=B_-=I.J3"+Z(:N!\-J  LUPOE=S!W@@'S(ETUL3HOIVNEM1
M;@8/U.TG.V_=(;O<K:VO]U5/T4A>3TO12).]55-/1>1EK\!-A,KYI#,JEEX'
MI]G"G9L95!F5V<F4/I+HTFR2DZ>[JG#R%=5S<.8X'(ND@+ +42MUY\)?(=N"
MX_T5!L?/H[%F4L]NRC\8JZ2HIB8K.;BB51\V+F [E9)QB8=4\(]4SI?<(YAP
M<82#3,UX?0).K]0HX=FG#/*";+N;NG@@(R]P42JVTG8,#WA5WOE<#;MJ5G+\
MD^2 "5)S\K@KYS%(%RJ31KXW9IO^X))PF2M,76XLZ$*Q^.BIZ*=.J^;610&T
MDDP&IGI>9W,K1BN<\@R)$"YG&A7ZF?+"LF#!F/=.44M1L9*/IH8TSG/IQ5U9
M.!?(I;4I>QX36$0?C=L]0,(F&]I>YSGZL!!%C@Z19V8KKT=T-)V]MZ<CUM %
MAH83F6ZEO&3RA4O[,%?=EXKU/A<Y, 5*#/N<$>5A4N\DWZ/L(YJZ>HUNVI_3
M*#A;_,=#OY !N%O9"7?E4EYLUH%^WA3KWN>/%[FP/$ZR@5<B7N>A7^YDQM5(
MI(^9.]<X>)MQ/83,"\7>I=[JRN80F5:]^M%VS3CUM'+2L&2NQM3'&4O:Z4T)
MGF@6\].F1SF/9FU([.5<6GS+&9SFS3)UY9EC@F1:676Y;_[)SNB>=\0+>G<Y
M-IDU8LJ]R[\J>UE[,/7E<^>',AOZ/]*68[5 #0\S7_HO.%L$OO/_G9/5NO)N
MP<TS:D;(J^35XC'#+Z5ZI;TGN[1U%"C(5!8=6"0L0D])VA GNWPD0>LHPYR/
M-U^-Y\[B^;P/<*M@R%565GEY>#-JZJK"&"4:3&>L%;06OWSF#H]C\]0.H)Z'
M()_?[=9NJ,H<E[RA]M1.[ +W7$I?#>]FE*9\N=7SD=OK>BT?CJ/VS6[/KD*#
MZL<_W<1H#PS%^XR*/X+/GSPA $&E:FU.J[G-0VHSBT:2NH8;OO!6NQPW[WXO
M)]7CBO6V6W[,Q1PER&3_*0WZ'A)7AFN.R_:?AMX12Q>D?!8U(GJ:,8'?D5FX
MN_N#X-D<21CV"3373#;C0.,J^6BR15DGO^!J++W[>N?)D\B=4X'*%ILZYY9H
M_9"KD^WT<ZHN-V:ORE01W^-M%>T91T4;?'Q"W1QCL;-WRAF[P55=S=.2@"PJ
M5U(*<YTR4>1U^S21R()6_CA)R_SD):D8Z:1-.?T,)GZ'&B;)%5,BUM'J7?BE
M)"VTCO-M4F1SOMR> +/EJ@2F>R53>O?)EYI-N&AQW_NT)!(25@Z2(Q*:&;?B
M+6N/<&(U"Y.3M1Y_VOX0,*[+) 4ZF7=81^K=Y-WDX WF@/Y<S2UTZ5*PJ07H
M^;P*D5G(S97ZC$;C7#7X&'EU&+/SQK5#7[CKMJ2YEO0>@S!C(C<,[\$#!:O(
M<+6]I/?-VZQ+ 45[V_H3Y(:,*%S]6 =-?^PDM(\,;=$7HG51-@J'V5R9;\W)
M5PVJY>*.1^,!8_"500<>O(7:0HGK!]?@X%-^>, ?78C,[+\+NE#?<I"^R@LN
ML.A"T!-V!:>MP0?P0"-BK!:S[KFXYYF<#5DU7[7!86?\?5U1$&TP1 $[@,&#
M4=OG6&U5%A\TX0$+W/:J[3W4[ ;J?MHZ#G'@ G89O-3U1S.S4 L<]$IC!2MY
MR%0*14VU;?(H'.MZ\7)=+#7?JTS0RQ:B4^]U/9R0LLZ"K$*Q$[0K(>EN?IYM
M@J!4=7B U5.&-U0GXTEX/Q:^&[X[7I7,%]THX<FU3=V4O[6+?N6$ONE=AEYR
MV+N@XL@Q+#G4HJ:O%]6H)_R*W,_5:)?H#XA#6?Q;X127FN/DZ!7#V16;!R@T
M-GYL4>"2M )I+);CP,[=/9=*\SK.: YG-WLERJO5>+OW95K/XY$_''2FPR^S
M?:A_1TD)?5>V.X\'CC$L)V9>(*.>)3>RJ%8^EB3![=-A^M0TKFXR5"CNW9+W
MR+?A*VZ]ITEXZ)!$]&RQ4VWAKSO1MH,%)+%,Z=4J]A :NMX8_A=4$#WRMAKH
MQE8+GP9F:+7OXA47[T%H7=D'8>.N<W<W;4)QH2'[5R:HDX3?QS9"YJC7^6>_
MT'WU1#M9Y(@[?=USD.KWC"B]RO \FC*JL=J69UTU(2Q",B;S](4@!K,QQ_55
M!K_B81?WF3+OL1V?,]>FP-NE38O:?[9FT&Q%@=SU;Y5514-?[&W3^,&#0L<C
M=&#\*!-JX7WGV,P$!5/R=4_/VGM2$?^"@\-W_8_[-D^CJY!9M+R7^8CV;'FT
M[&2[SJ,3Y6)VX6Y6G[-8UG0U-45\G;RN60-(/0/BY]>&1C!1?M AEL"Y BIC
M];B\;\98AJGWZ3+7V)JFYQ[7,_G?\\.L\BZ3E]?)U$U_00547X WY&9[\"H&
M&$4_I!%5/-8JXOS"7N-=:Q$8UBG?F</-A>2*E7%9=0IZ/A.-OUSI<_36>+D6
MJ4BAW-TW$?W;BCRG%R%4P74;]#%URZ\1UI,=7S!IY=V4KZ9S!0,_WE'+E3EW
MFV-CZ5CEZFIO>T)!N'T3$\*Y]';\/>FMJLITUY8TWAJK,.[.$:*9T9.)VT,R
M3P9%X7YUZ(RI4:%WL4]YRC0R_!GTQ:="&)C=!K:V6=5HE,JYPC0KERQG@TUG
M*P*9GUF7EVI?4K,C%M^WW1U?MN'*E9MKA\^[^%702X^WB5<_O-MS--U& 0_$
MN^DJGVW^Q![ZVO;-WO.0XLT9J:-\Q.*&FK5A)0]$EXZS%E2O,?NB(88)*!RB
MEBIWGFZI('C)5'E_$^N'+D864!5"^D=C0\QD32T\<-LX]&IP4,#]J#[BE?J<
MS%/^'^:7<,.C!U7]9V2480',]IMI7H^QU-7;179'E^BKMCH,F?;#,3 7?JJL
M$3C?>P1F%8T(WEP*I%U>(H9_#JA8DK\G<RU+3 =7"/H@// <4SC=JW,7):D+
MU\,#>8AA:M"K@*%D81WBFR8&>:"+&4!=0XGJCX=O(\;(#V"C(9I44=OJ'^?7
ML7 Q// 4D[4I(RVEV2N^B < ..0K_//X&%;*%^117L*5'C;1K-WWW%^7X5HT
MCH%\947GRRRLH;:G<05\K[@U#S0Q7UE7H6-50;+GNZ4SL0MX  Q@&9\L--)T
M\\J!#NA0R/(JS_*,RQW]6)B_-/E-^KNH> \\H BO<97YNE4DB,RP[^#"EF-@
MGC(\<N';08DB&KZ0;_"IY'66!7^CLZ@D#]R.,J;_0&<L_.8TLY!N,GK\FS*"
M7R,I+J8HYWY^4MVCG+=/J\+><K=(M:BD9>2DO<N(N)B9G9[U1Z0=-UL<,4<V
M92@1"<VJTQ-V:7<VNX&3<J=):%[(?23_PI)5)*VMS*/1RETJ1_;PI ,%!]M3
M79KZ=T]V0PZV9(T.8($V \O<]1LZN9?C)1@9$46E CM\%Y_<T!:0>6E1T-S[
MJA]UQH8IQUZ+21W8IH D!MV=6;&E-5V^##Z8DKW''AQG17V\E;K\&+DH[_6B
MY@'ZU7S=+8%!F'OP[J !@ZTEWTGX]:G0QJ3()^21T>>6'%=#(%\>3)6WC9@(
M;E\\"&$=$-0Z5C-^:Q5"-O[-2?DIC:ACMZ5UTFW3[M"W9E;YGS5-54]R7_!]
MO7 VH'UL8-/G_!>DWW"K<T-6.8W>I--7O6S#@3W.>V?WC@CW>0; 5U8Y R*.
M/ _Q.%I%^FZH3:'B]K%XWAL1R@F?395$3[IUKJ-9O;C^8_]BCN_^'_%50B[,
MK>5E,=RIDE7"K_)J0])(>JPV1;<&%B_5\DS>?IM_(U5(*J7K;HRCX9&@O.&=
MT7KOJC"D8V',U/HNIT,[<N.6NHPFT7RG_G;=MYK*\HYJ#[)EF'69TM7T),6G
M@O?MLYM.BX@P:;Z0,>APP@."8]7#%]_1]U;<K/O0TFAVNJT_;BU ^QQ9^D;]
M[+/=/A-E]H&<>E6ZIUZ<,[?W2%O@/GR6(Y\-3#K]$X)24M;Z(MN5P<MTUB;/
M-ZISY(86*^+C(9'>M&[E&'BI2LT*]XWUF5[2MZ]G':3]L@+O*^0*%44T%F,T
M9_F]=_:R,T896XK"2;6/B?4.WUZ[ZO-I!%NK>($SV2/FL6 %!I7S&I[S'K!"
M7 DP;99.F50I_=:$;L6%BR^VF=_Z<OD<Z()N/IA%YE*CCZ^2KI17VOA*/HB_
M\,PN,.A"GO-R"1XXSLZL0PWI]]-LOWNK%O.BZH^JA83C&+0QL\7% PSB]I3_
M)^1X2(&!$U +A:[4YX7U%AA2UR:5/'BR= Y\#<M;K0\QDX05Y_,Y(9;6\<!I
M/."++NP+SS0,6LK;OKL!6VZO =T4^*2%!S/;KP%+M*P^S,ZN:=OG$,2CX;IF
M[POG1T-N3^$!6X('K/;?SI3(-,3V9R!94EE4=E;5H[0U#8V75N7?R5Z2(KB[
MX0>M.:_YU:/5&Q#C<'-T"N@1G97(5:IB)G"RB%6N\5K_(&5*S[AWCE$=??78
MRDI">-5U;[;+)3L?B0W'-*-=F*7?EJ#N9^?#^R'KXGC &>9UEEFJ$B6CW8_8
M3487XP$Z%G1WZV=HQK$,T.\4X %&=%VR7'AY&E8^N&"=+0C>"$949EN^8<F:
M9J\<C*-VIT$V,_A4T%(Z3>A6AR#6?(D(AQRV3;VD3!7G0$U^ )*ZT^7#U3R2
M"VI99[O2SS$+M?M!EJC141Y@A!41"G^WC$J";H,1%AKA*1O$(W</5Y"LMID$
M&88W!/6LHTR@S"(:\#'E P/<E97,=+<P9L&>),U=^&?S,:2!#%<.=3\6/8<'
MUEE&F$7\[X"QF_DZJ(D+/#F#FB75LC@NL?Q5X\J)ZMB6.\(##HM.28SB?Q3D
M-%BO2W)+QKP-/Q_:?*N-U)G4BW.A@*Y02H7QKNY]_N7JQVQ5CXP=7VFK^FCG
MYA)?N?R1,N/-?0$Y.IE+)145)4F,[U3&KF0-"%4)ZNN?H\REX)9K8KLO-<@_
M07UP23Y@^^"52\%>M6;$-^<8E@36\%6F"^QM P$V"6J>"YCIHZI,;K 14RE@
M0[_[<?'-=QQ5,]9>>@T=;K(K,8QWD[UF](T=1Z(<D%LFZ]B+D$'!";H^/N#L
M7=$O,,>Z+>.8X:UA\8JG:.^S>C5R1M-,$".RBUJ?J[JT(A5RKS%Z;B.MM]&N
M3C7TEE[>&\/5:.C*;<6\3RY!!2_36RT=)UTX%;/3?4[V=K50>M%MD"3%6]O-
M*D08*3&O!)A-%YMUE*V4:1N/?[9K6M2[AZ$^Z7N?FR*%Y(%9<8+#Z$[;SJ=A
MK\'5J<KAC-MI$>^M.9:9*"9:['1[!$AHNJ:'J$+]_WUDUO-_X^VZS'U@INGO
M7;M7F%$5A8RV)S3K^^>N6*0^F>DRLD?%*)WJ[6VA6WATP<]*FCL*6:R>:CU:
MCFG:P<:ZQ,]M5W Z&';W=!]+;7OU!XN5I]R7FM[6P,32MEH/#;2S16GFN8M>
MUS1/YAQ]5WEPZ5YBV&F5Q:* V+W(+IU2#<8TL=T"+UZ:L82R>#N[)K)&$]EA
M([;<5T()::5%U_3^B(\+J8F;&:_V[*(H\!MW7>L/[[XF!RM2R=(-[!/H9>(D
MSSV&EE_M<#Z:[+B3:DTKP!GD-564.7PBBWM9*]IO2(I&Z5Z(7@BB^BI\)\RH
MV!CC;2,NZEW)0O0BY^+3AZJ9S6?XZ2F>,3Z]5_(,J4EWPSG ?$SC&U-AZT&!
M'4_9B0Q&PTM74@+B7Q^O?%>Y5RVXMWVW9KIC9':%;,I'PVWN2@*F*K*.(_BU
MUQ3[$WNZFW97H8JL?"^2.JHH?MG6< 0'&<84A<N6?PC<_ZP>4IM4EOIEC=F"
M:W,UR,Y'W/ 53F; RQ8,ND"$B:;^KD$^\6C5F^TEQH0$N.;AN^-2T&6Q'>38
M\,=XF=1BM 8JPI!#N5P,9RRV.)/SAW6CMIZ 9?O;<>,(;%#T"N-8:PDP7+;J
MZ%"29Q,C@3QPCOVZ!2_:*!#QX!!R7^4='Z\081\:LV^2H$N[,=B$34VY'CY5
MWK2(.18<\XWSXGD!S&BMT7,&JKM$DJ?3C_/G!@]NA_E.# A#JLQ&A^^;OR[;
MC/=N ;T44V]X,G62LCS&_$X0JH9-<3EFC;NJ>GF,!XK=I97<#>:3^)AJ)C_-
MVA3J&I'CKUEL:AGQUD.QN-B/7WNQI_5 +*R@F?H-;FI,B ?65+V#FPT(<DM3
M;D^PXS2HFA+! ^%%7P_"@DTY:W>$QXQE;&".Z*[3)8EG/)H_5;(PR!BPGES>
MF_&DL?7NFQG6.6:*+-\,"$ZO>[E7HQ?,[;&]KVBJ21(2#0G_N,-;.%*VW$Q9
M[75 3[/?N#B]D\V1A0>\!\7SPN1@-<OT^E&L]=+:"N.%O9JQ*I_\N(96GCXB
M-Z3N'T7J:0HO]5W<QZQ/]C+-)4(]K"'+M;MNBS5$,LH031<69BW%&TO$+)H(
MJII!:(\/9-W<A2IGL$O*]AV\ ,.*3B+'?$!/=C](FS4.(KP&UV*Z,WMLTQIT
M-C0/SN*!S]3H9.\MU#9*\M9(.>A;W<!H&QG"DF2^#7^0<2P&=/%W(>MRJV/7
M/!>WDK-<-'=-\$#9&19L=^M\-ZEJ$+SOD!HDF\JZB)'2[!%G7>[ 6%B ?2@_
M06TS"_0P1H$!/@MYNB 55T;<\",\< H^]6!8.?7&'^1JT;R@[P_"89*]P'"X
MFVGY(QZ KBJ'WXP-5^N. *-I<*2:$Y!U6537YPDIV]=KX&KR3".>&W3[X9@/
MY55;A4"F.FUR 08&OI6'>\E<T0#'*U^$+!TJY<WL5[.OJ9O<BQO&3HVORXZ8
M\\7#9,%E:QM^%UP;IT>1L6K)LG%6$/,=R"KQ6(>!7+=5)G85QS7LW+6P?S69
M'/XJI$GS'N.NBUE.ARP4:ITS$17L1369DQ,+A=U6(&(QNJS;-'"BE41:>S:K
MESN%^Y2<C&1DT@U,$K9J=@P^C$OP?J"X3SQIPL;"H[Q\8*?9P.B=Q*&J]3!]
MN:-RI&.Y;JK<6+2]MG+ MZ]=Y9'6IY*#4T1K3;7U]WI*=>KPP,?Q).R)S>'<
M6'!,ZP4T%0O#V0#J7(_(;N5:*32_83%%=E')^VKE%Y]F.--?3F]XHC/RGE!@
ML[L<?%V)D_S(@V>8OP[ 3BZ6NZL)YP5*OO3+ECZKZR@_DK:7K2]S80</C+B8
MHAGM&<.:91-> NK$$5.?&BONR%X0D>(TZR-N?L"=F'PG+*3V;PX:W_O?<>FB
M<\6^SI7/<MM6*/.O'@U!7G>XLE'IT!(8+!MVFNV<@\-BVE,*[9GCQ<>C8 6E
M^OH&"=$]8L9!N5%C-^RR&6*]9>_IGH*?[PQ&52T'L(Q[5:U>#3V38'4\1\7&
M*TS$7-_GO&Y09IA4;OX:#OK*Q&#TCA2$GF4B7_MK<VTYJ:BZ+!6QC7Z@&$V;
MF#P7>^2Q-FW[*7WS39WSY&-J&Y#1EIW53XCY@%08.8TS+?%E,&2,]&&GUE-W
MDMO]&O:>?S090=9;'J34L2P[QN_2(%=7H6](W_2*3<KJY;YT'<,12'&TNG].
M$'J@>KK8PWV%=Z^RJ#KARODHA4&&^VM:R"N.#D[6E)92E'IG\A7H.AM.0A31
MT0'T?-\"BZT2O.O+%)WM+M]ZP*,D>I6AN'PK,:XNR*,^H7(\01+M%14PA]T'
M@T,W2[NN4CTBT2MTEA&?HR<BN-DVF-FQB9ZG_[8;DO_D/7KB2A^R(-80CAS=
M[U/9VW[R?!<]N=0[3'QCB0:RRO)-:N@Y>V8N)_@X80H7<[@=_#^/=X^%%!A[
M:-.GVJ^C)\?MT,-RKS+^$ O^)'3;>?9UQJN&VT\X%$4"8&<SSFUV?U[X\-[7
M_G1T=*8!$:56!V[-'7D^I#BB;0ZK9OQ9T> TF6W38R;+T)F3UT\W-87;RBZ;
M8%90S]SO"Y9MA.6.M><I U^?V57?GKQ'0IO-3G+:7O[$Q?&J=Q/H:UZ!NJ6G
ME@W+YR9#Y%N3QR]3V05]&BSMG$@2'=ZZPE2OJZ!3>]W-S_!NT!27:,!P1TW[
M1F-U2N'P\)$K#LAPI9>LIW,$1B<UUXYUYT=@X&C]G0<OIN_;SFZ/ED>GB--_
M4!\1UKT;GAE*'"W+>*,B-U317YRNIZ?'<ZU+J_NCBJHF0P.IJ(C61TV2&SP1
M]90W"Y$,X6]N 6A:%<ZH&QMM'-*Y#BJ<D4$JDERY3^]3\*:$C0W1A9$ W%G'
M<L@!NEN ]%VZ!:XQ9CS0%7"DL+ :45*F07LI5-M)=V_Q\D;)#*/9NW/*%]2#
MV",I3G#:'24A_KC#/21Y/%%\0;&]LY6^V)@FA$9 'A<]0 IK2DI=L4+[#%-I
M58J9(#L23//61 1%%KH*]GU?E#R6=7K#P"K?E0K=,3??,249Y+U74[:RDIIN
MUU6X9G3S]IX=YTMAQ3/7XR^?T)<UTE/1C>.P.3)A/&B#;@W  [SM,<,['6[V
MPD=T;X:FW)VZ%9'^89/[!C/+1OG5C9"K0ZI!+=*MUA7#2M<\2++/AR8=4237
MM;I[@RKG1A,=2N]%XW315A1THX3.2.K8'Y>U%%^DWR^+]&3+5LG.@<:<T[TO
M1YEFB+E27EE1$LU5FCB5J"[/<=IBYZ0<:ZPR.D8_X'E-3,(?:3I#$JF<3_-#
M98Z]9PLO\52O=IP01[:W9^0EGROKSROG7.+0F1>34@Y[>_-^YF='L4(\$(Q5
MYX]I8Z\_P;-Q_)X0;9;J0?9J.<2]YT5Z^Y0/<^6-7!]1[\RD.$3I";4C7Q8A
M=]>6&&L_8=(Q<AT")JW0HN>Q_JXW.RQ)[!A>]3OBIHOZ>6C8O4\?T;OX-D)6
M(=#R&RQ,<G?!1T_:3[TX*LEN9VR[ <FUYM3T7"W964C2STWR\>2VBHH@+\KF
MR>SSP!"16@3Z2FQM_7O[LDI*XY<W*?M6E)\PNVG-<EI-2!T\((%FYEM@ZK_Y
M2 8(5B'M$=>+OT45GNDO))YH4T/=<;!\15FBX7A?*TVNX.V0GSCZ?)+,=:]L
MKEPAUC?@:K?2(KW?[4J<R^.++NZ+.BVC#,NLILJ1V&90>L^U3XT>7Y5=G>VK
M*)1-%-"#<"WM@6^9T]C5\2HO)7\-/02X#,YCPQ&>*3+^:KVBI? R/!"IV('I
MJ/;;VMA*3*R K"*0X^$O4+.H1^EUB*7#+Z?4]W!UV/GNUFY2\)5N9WR="^S+
MUS,I!UX 60V117?=ZSX!+ND?B' [8TO=2_4R@FHCV.#[X"N6IK^TE,')R6YU
MN0EJ</E8]=D97&@FI<^0.@P0ZO8WP07?%'*V0ZTX&7P;-L>&0-99%@+W]<ZB
M8MR=<0C,8"5:OJOG'''&DP[,..1P6[[D'+/P%S_P+93P\OP8;1;#%7NXF.\2
MMMR?H#5EH_F)" '&9SS0!(8MV JI3A3D%GQ,$S/:41T6!PU[Q6V\A./"*2]W
MR,;)B-STA2S!:Y."%K8VJ!(N@+J/PPN6RU">T(QF37(L_' /WS;%8WJU*7]T
MMW (XU@EI>S=NWQBN^RBVPG=:[I0C[-546>;G=N:G[[$9GBXV)P/O:#(\R&;
MN^B\2FJ8 O4F*]_R_R'MO:.:"K\WWR@@5E 41%I4D%Y4I)> "(B D:8(2A$$
MI/<6( (*@D(H2H<@O??>E1*J"*$'"!U"@% 3("2YP>_OSLR:-7/OW'7_87%"
MWG/RGG.RG^>S]WX/',BJZ8W&F82D+IWH7S]"Z=462K+F0_O9@I2976L?XMYD
M-AGA&J\L*M<]<58S^'[R%/MKJ)4)'GW#[/SQ5>I746Q%;Q3=#RH /@A_I@"?
M@0C&!#%,K]<4?+C7/J9/<UDNU[;O15>F6+E;]34I5*\F6%4$4^#_3L9ZM;;>
M!.68-NOX^Y9&\ON46-K]PX\]ZCDL!ASJYSC[PC]C7E6WK#F8+&V0Y97-T&8O
M1$6PV[$P)MGE#+>V';VIR9]V(@2V _Z#_YZ*&OO_J.3NSQHI@)55(_?5V4U2
MRS;^'#FTC\:\W,#F?MVS['UHZU<IIH$;;H^7UK-RF$;6'\<<B@*GD=U</6YB
MTH?L(7.Y3A-LH1W14%U5"N!3E\U3[D^P;'X/L;#'S>]:F^"^6T_PB'6\0V*\
MS^J-@H0[+G-*B\!%\0@E9HFB!W9Q!;K@<S\;<D1G<25_MDYJ=S@)==8%&2'6
M\;=JUC3_;A;==U"Z''"/Q^;;/+M&7L* /M9LMPQP>6"92V4Y\FG5L?]71_W$
MSUQ66TG@_=UK1J]D;SZCB<I4<%V=+O66(<SX([ ^K;X^(@9AX5.R"#M&X,8\
M;83^(VH8,'SQZ-,9);>)OKSV_U4!PAA[B1WN=3;5&WZGO<C> :<NO=Y>92OO
M^QO<Z)'-%NG;A=C9:B^NST_'7@#!?1=\RS9-BAGG8;^?>G6*BM40 T+ 6RG]
MU<G@]R.9'<0TYK&[ ]91:W&<+;N _;^7)%P#N2F 6&9FUDX<7[-3A:9'KU^F
M-&D]4XL ")Y+>2E=%RQR?Y/\":*^3C._"I^!;54")5 3D(@MU9_D4IGQ#Y9M
MP>X954ES9E]=;=[!OLW9.?T5Y&TPLK6UI8J_K*RW@(# [?"DN+@D_KF<G)P@
MB?"+OMYW]<-9[X2=S>"_6  X.[O=J\&3I,&;I.:3&F;%$Z,AP1,;H]'#QW,P
M<OYVT-AYA^*?3S<SE?+"SQ84A L6A-,9_'MBI?(XVU2OE@>GB<H= ["JLK*V
MPGN']_KY8$T-#<WK8#T#/?FB<A4P+?^?K0[!/)YD1DC(+4?>\-GSB:N>%PO2
MXZPLE-(OQVBDT_ <&"<G0X3LOO;U# L]C4Z=Z39X\N)U8L)?P3S:&&T ;5H>
M;-GIS\SHQ)%62??ZF^* 46R21@&_H'C=47;&(,XC7!=F:#MTI^3WG.#9*3;#
M2=XT)J.L*7#M5YGF(KR4[3+*^"TN6<2B887OS*?G-*H..B\:7"N>@:Y'&1A?
MBT1?JU<@?"1.N-'+HM&[M;7Q>PXG\>R/'.3M=1>.0SX??"R]TJA7<4]P]PZO
MA?JV1?$D:R43U2EH\"[%'O&M@YN^G(5;&QHNQ3YV&RH\U*BO59LY$AES=DA<
M#]H2;G<X(=$R/178E?.LB,O0*AC[':^QT/6+<38G_;&F5FE7,O&K/P;E.=".
M"K#T[V&IV3XL?W V7[#L0M;13;[V1PLEZO#7=(2WLX29^-D_ZC"+N&<FTR2%
M#MOGB2(SAGU%E^]'O.IB/C21L-=MMJ_')9,\5T]O7LR%27^WZD9KRU4\PRX"
M$?5KZZ+ A_<-:K8V@NZQZG%=?7>E<WHM!-T':#]R/N2O$WS*EU+;+Y<KB'O)
MOC4H$XFGORP]%+J@?O:'.O-++K,C-JZ@ILV>9,8ZCO)&5_A#HPLUC77A*5=T
MJN7N?8MR[[NNL^C$>[::F5[_3\_$I&(E&M5N9G7>+W)H^I8\![)@+;*<O\!$
MUO8P7N]'\!W-#.]?4A=NMRH>A_4USM0^V#!^3K(1</)RC#FSDOWQ'GB K2#
M[*!MUGW9;DMC9?;=,F?'V)Y34\S9D73G;X^[Z;19G@QC5]68!Y^R2/$0%5@Y
MZ0Q'TLKJ"3C%&N=TWX- &!'1&%EU_\+Z%9778"*.,/VOVC,^F+6I28*B_*&Y
MXZ15=(._ND9#[3$)5$IT]-]P_ZE*KU%0NX#&E?A0W3->UL>OP2S?D?%T-(0
M!XMI,8M09<K?K8<*XL3Q7'7J-N*8 -JD !;22,C>A_0:ZW'UM40H7IXXV::@
MF!FJ92 "@6/W*8!WWE0)Y\(B%W,T8.,GVJT++>NS;T6_6.>$A]2#<"U-$*?,
M,Q]E+?+L8LE$V.%XLP\77#GX/W6@8C(!T<!U6G@>D%DEM9[HD;EGP)H6'+XV
M*20JA./D(3_GA[. HDF\ITB[H[S5\E98.2VQ@#V83,3B5&#/_!K HU(G&A2
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M:5?7E @!5135;'V%_6DEU#F?4 "V44'1395_UI!RC8_2]LXN^ZA/ICVO;ZY
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M$$!K&I/J:)B?&TU&  X4+^''/ZJ'J3/4Z!(B4RU#3?\?%X4\^7B!AQH:8LT
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MKU+CJMWW\I@51AV%/'%$UM%-@?G8$X;V0 4[]H,E(@;&4*<9)Z'  &1O($%
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MN_K#['Q>=Y>:FBSCTC^(JK[LUS"MHO#8[5]/* VIM89U_\/%;:S8]DGH! 7
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MFDZ]CLZ,.O.8Y)G*$4N#&L^7HE3[8HO1464+93;<U:N*B$I:!PHA . %@!:
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M)[]S:7^B<\Y_QQ_%,JDW +P_DC_=>[P]TGRY;JLNE[2#T^FK)T^ZE*X'^?4
MC.:JF@X&\<)1U//?;I1@"G72.%HX,Z1B&.&IF!&,;;CN/1?PYO#_Q  V^0*B
M']:%0+V^91LP+:T^6R^L';/FL^'/)\-O[S+E.B:6\ >R0W ;1U,N7=.)S8Z>
MU"]+]G<L6!(>KT5\ML#C#M62C;D'5'O:@S8_B]LP/]T_B&G)+LW.6_HY$!Y.
M/I<M,K\0Q=4.S^C]P/F%G.[N].*,UF;9"YC[TSL<)4;#0ZZ_,[UT0L?K!5UK
MGZ>(,60%]BU7OYO'5^D;47/E)J%NH$YB"2O.CJQ.(7XV8E^L+K?Z<1?W]G+
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M%&F25CKO5.L1A4L</%%.^?(TS6F3]6GVI, >+QGHQTF_W[#"MQA.7J60G!N
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MYQWG*X^\&I4WIDM6U3N&)\W-"H'B'6&7&YMV'8B@C:%*HX4!]8WTS.M,S9:
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MIC 2B2C*!69_#W<^4I:,L<U\,);4Y-JDY$06.-1T ]!V[X$?G;N8;2$2WER
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M<2=)QH6.'3$V7R70KESU1NUUR>MPNU=6&'M?6YUD^M.KFJO\7L):,C7LW$%
MZ#:J"O9O).BL6MIR,**5FUS?2EZWSW \ V85Q^GGNKQAN;X1Y9U\&U'<$]_]
M,4<I4.PVW305(+0)[P_I^[JIQG0X/Z>7*)_RA<ZSVL" ._[O'2S=PZX>2^A
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MA)B'+6R.=C]K)7B35M5Y#Y*E&U(;I'^93<VJ,GS18+W*<O=N''U9CM"[90#
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M+JD?O&Y[5FY+B%%PPIW.UE\2N_=#3T:5\=.6PFX*MZM9V'039/$A9N=P[T@
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MB"%TDPNHWR%X!.53+63Z.16PSZT-^6:&<R)+GOR[\.KNIP,J;,.G&$!*.;)
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M;GRB6/G]_+>:9X_%O#@C+_ZNR\0NX_:N>8S/^C,,3H"%I^J\D9RT^:2UUW$
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M:Q.2IQE2.D\JY[$1'!>LK3O0BUL(+B2<.20")SH M":+-IRXAA M$H8ON?R
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M8(S3ML\3[Q'YP=5"T"O@1Y9%?(+PI93<]0Y#D;281EKC[UO 2]0=L2A8"U-
MF$)VIR?H2>WZ-S;R2=G78&(Y>3DB(7Z(4YQF7@P%A'8BK0LO2:26\]0]1!H6
MZ'41:Q(K6C2[]\>" ?P1 ,(LB@.*-,M@ACEV!C--QY\TQQF5Z@L RX'CSH\%
M,;/WIZFV*Y#X+ (Y#+F0_OX8ETG2&.!\/$T<NV!FQ )4*/!Y6G1Q<X6<N[.
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MW7$'IZY@I/G-O*^>/!/,HYD$PZ)V19)"S5]=$D3P0H=&*N_HL[N;S9P@%9A
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MBA L<!$)N(BU)$<LWI*+JD/=$.606^2R\'+=\+?]O\>F V1*GT.5K32 ORB
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MG^=S>-V<Q70-]2J9:PF9&YX"'J 3^6SX?;Q:ZQV^!._0JJ@5&)4 JT/CP=T
MB"'0M3PM?O]W+I.LI$?"L'_#M__K1H11J9D(3V\P:U@\<\+:AU)QE[$.-%J(
MJ"P,MT3Y"@A?KP14+E>"$R<@;,#& ,D/H)1#$ 67(0,<^@<S!?2NC_K*&Y&"
MT_0LKG_Q99JV\2?#2X1&T72Z7HUD;^/;3>FI3JE4?5&, 3S-L-6X0'Q(M!^O
M\;4DY5"<?V<;W\O)T*>P1/$$LAUJ4 AJE%@!7/CW4+M4I\25,,V^]/<9E@HY
MZP"5$:)J8V<J") 5PAJI1M+N?88_H+MA*!9AJIZ)0.['JW:>E!+I[H_;_'L
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MS>!\(:R1!0JK@@9R315L';[%  U +@P"M):%6+<_60E*^@?4HD"*X"5@"(A
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M=3./\;ZQU1U?>N<#1^5]D \JA2 I[76#RBV$7G[%-X8,HL-.Y!MFW-UH"-&
MZS6,4W\VF+GZ)?/+^5^_KPUFWXX?8>?+X$S[_+8?R']T;NA@3;F/^3M8+-;*
MY*$0Y%RA3!.OUL"YK5 K7Z)R$<O;O79D9'9<R#^NP3*9PE\'!]%=!7DA%[JD
M6L^FUJ;:9T4G.9 \CG@JM,8JQ!KT_?UW3 H\YU"?! VUHL!?EN6ZDR3_P!R-
M_J0/$T!6H&P!I_\[:XL!9H7 (VV8\3@ RD\I0@!+_6 =L+9,(<B;8<ZD3D)-
MLG*YJ]YL#5$P!XW@(7Q.RER+S>3^H\0YEMN@NS[6-0I0@W&,FT^)[> EJEP[
M\(5#5L3&]"FF.K2^*PJ'!\E<S!J.R;%FYIDHF\BG<C$<\B3#]O+FL)^IL^E"
M$(9%P/%0P+U]1:K]A"BK#M ?"HB?0O/ZMCH+079"$%$469*E0J%92+56M3G1
MJKLUT0/T ^R?47\F3V 0R$CD;_P#]$=UB6+^3"-U) SP D1SQIAU:8[=>T4B
M<%) YM-$YB@=8[9*J;];* &(_6%83C+V]^P!QT=]!5#S5^1%'PCX$@*M17&C
M.*(9$1D\S6<(+BU]57]4:21IM Y9%*]%/<OAMJ!;G"Y4*Y[1DI*Q3VJ?5?R4
MT3SUQ1\NO2/A>LFG1G_F^XL78SK-S6$:;_?)1=T=BGJB,/+8:%^=J9%&_KN/
MQY-?;0.)I('$><0=;V_-CIYOWMOU?1;_R _O:%S>MEE?X<>F_HI0%X&>O8;6
MS90=%8$.O:%A0_O"I+-&T_J/.Y,[VV_17WI/I@7KZ=O@LXK_UJJ*K8^3-E0F
MTJ6H1]-=.?/OKG@WOAS?H*M-9>J4R[C/YCO<-"O>]3( _!V!N:)&GZ1;7ERS
ME+)Q6PIY;$*KS=?48'[=E%+V8^!+GD!EH,E>"C4)0>U0OS9=.E9W@7"B$G_D
MI25RF3 V7HDMBO(@=L.;]U28%X>;=AS<,:YWR5@W5L["AM=<[,YK6*W@3]DL
M"F1)]]WYB:&-".FD^QM3M[JZ"DMFNFHECOC-OWA<'Y1:/U76,?9.C/KYZ"7P
MJ8?Q8==8@:DN[IYI\>'-GIZIE>=L##TF71T_-2QUEKYJF?"Q2CFIFY2GDO36
M7/.$5GC"\?U64U&[];I#PNG%=%SQ\5I\=:P[]I)+P-E%:.J%/?KK<0,WAN\.
M+;&[AP:M6S9_<'@3DY]Q\O ?^4\^ACX1PY)=N;#_KP;D7P7"GO^Y(?E7).@-
M><SW,P_JU>^IU31\66:^THW>.[6Z1D6LR:4:'C/OJ<MU_HA[KJ)B=JVG:_>L
M#%2K,\!S-6B6-LB10?NE#+""-#S,8A;Z&DZM6FR&_O'70D3R%9O$*P2/5.>Y
MJ(1AGD>82L?3KQIBIZ[H@5]T%^2U?=:$*?R S,R_Q2&6OJT0$#L.%UL[T?!\
M37/GDWL,#YQ+;?LSKZVGZ;#C;1\2<:"TNK8_@]>F9<C[.7K]6,E\&J[)#@SS
MVF>_%"MVT]%.Z= 1L></6>'IL\B6,\4'I_W8M4ANX!7NZ687].*;F2TQUPZ8
M)Q^73Z>\AQO*X+OQQ.[U&V^6HFM&:Z^DN&"S6@=Z^#_'VFX]*=VA-=>"MQ,[
M<STR!@J3.\F_%M)F9S.O93Y'0^7.CM&WQQC$P_3_1AF?(!Y#5=RQ/_L9EJ99
M-H_S]A*@/P0[4%LC72T?]N]XCJJ?O][=2AN<09]3W]RI+\CD5X%7M!K7%G9C
M"YVQ_%Q4'88]4$D(L_6&6J5@-Z"\KR(+X"+R-\P !2B/$:V$QA919!ZX%81Y
M"@9135""8Q&Q\)A+3+^<9:R>T\V;IAWTQLWF=G>37W\&W<.$R8/TCRA;_M5Q
MS9RNL*KIK;PR7S1-W?66&E9F9;$M"O.9/:=PLH"9J%&UX#)JKMOXI+]ZB'KB
MB,_VU)!9B2N,J(X/0QTV%$1VYV@TX21K]P$AR/W G77X.,-S_4'PA7?!D/CP
MS;'MWB_5UML_2J?RR[)'5A<>LJ47/']WINOV7<IE \]<F%ACTS[PV4!(ZJ)'
MWU]?#U "EC:-I*(ZQ+8$%2@&[K^6>Z2XQB;]6H4ULI^M+.DW%^84<]7AA=*[
MC1GO/0:A7Z,A:> EVB8M_KWN8T/K<G''XNI#7GO+RT9N"U*QG&EV=9TUP_VM
M/K!.]0Y!U?TF[JI>Q#WR=KM/K7=8M?9\+]1XV+/Q @I@.792(<UDFBQJ!K>&
MQ<,]C\"W4B&?A"!'(4B2#R7X3YB&UKQ<E02TMQWSUF$$W(%ZNET4>$%P3*$&
MIHJL/?I/-D09NK@2<)Q!PA'U%_* 8\$C&3^E]&U5%-T(*9!E]7^/Z]NJ0)@G
M%QBGF8LM4?^,$P5=@)\0+2K4.%^R3_H$89Z/YA_4I.)/6O$13^7)=JAQU'C7
M/&![6 : YQ%KGT>H87*+5/JDCPM!,:@F%!9OB>U7_UT3\#E$07W[D;ZMQRN!
M^VS QE]36%"MU-F4KR(3=(EQS1+K(UJ++EI$&2":4[U)Y/_S! B1\:F2,4G/
M[.V=.<_JJ^HPW^D,E;,]#S.9_L(D#I L^MJ&';#963GZBHHG8JK,=,ZT+&A2
MQB\[!CO'F%[:=Z81))ZG(%:D=[BT]?#^E0L=<T_-]C2N@[9 !]5+=KT2& M!
M'1(SNS.+FI@O;Q0&=+J\C1H:*W<LRCT2[7Y $5*;?%+QZK::V$?%M$NR^W..
M/9&QR^K?ORJ%3Q_UFZN:)2?0*:CN);UH:.Y UG6)F)V**>OW>Q_,HFHY-1_Z
M)]LEE/#QJ:B,<3#VCIUXPWV7(ROYW[^G!^^K):,QRZE:.5\/GNEJ+5X:DT&_
MT[T[/Y3V0'M7T_";R>OE.\-FVW>,+_R\(QGP"Z;S+&5F%TA]PO@AKXLAI25_
MN."+CKO4IC/S37%+?]4XWOCE>%((.F'@AQT3=RA;IE]I3YJK>_^PR2OC0'US
M3/F/Z;D,R895?''X&G(E<HJM8<)4TU\\6Y.<-Y!0 'G3T'*WSL^?^B;\<#.G
M0U4O<.X8<_2XD4>N=-*3[8>F.2J/L9<>WTM7.,>HE#IM_=PYRPUI<9QXD)^?
M69@Z&W9]9MPP\OMLM&UYF9M)3;;3@X55K;Q[H<D_IFD]L>P#"[;_UZC_'V-&
MO?]K$_"O J/@PA-2OM.GSZ5&[([L>E!RKESKQNZ4CUEMCJ?S1N].%'XL?H.P
M3K)"FO>\%X*@;DI>]$*O8S4EU;&'LBY9ZIZD(LW?ATMTR,;:6UG1 ^(&O2SN
MW+-J*PN:U8E5$V^-^68!/O87M9Q7NFX<:KND7-OJ0=U!,*3K-Y8<MVA)5E2M
MBS<^(#>PV%&=^_%-[%7T8+-1)"SK<6O==!LY*!TUJ'%2[<KTV!F+\+@W!N),
M9P,5A;7L/?PT!XXFL@N/G>LZ2'.J2'4<.X@USRO<C/YCH-?\#_3$TX\'IIO+
ME4=1;9*S$O;(?I2]8<755/&MSJ\\N<R1U$+8QS-$<\^B%DU-Z3#-<ST/W;.]
M/YHB9_24D#/!$L'+D^,6R)+%E16IQC?UX5;?O#NGWTK8?1%+TYK3HOHQ(GW;
M2ZP9 =L;OCW8V22>JJVRW5XGVM5J?5?!C5# >W@ 3[_S.>UUB9IS<_N6&$MP
M#9L.\^YKDZO(.S7=UDL\F'3K_LT8JJ[%GWO^.N$]7(E/159*V:C2O .]-^[<
M*MED;RO?O1'UUP2B68D3OQX93^]$G_=02Y"":R;^72=/[! W[[ML\B;\KR/=
MT>^B3"%Y$%J<@/65[=ISTFZOW>=RH_KG$APRD<9 VNBS%H@;LK2X4?"9F@M.
MA@;N*EWUOB/HJV)Z,]A$[\7RU"!G5VK['WE06^UG"#^CXMX7LCFRTT*0/X=,
MG:\<[:\N3''>'W78N7J/T2T3=$KIRXV"K[+9.(=JL\<1M:&O2^K4EZ*X1B=S
M=ECT5[U3:XT]AG$'G=>SJ>#-DFR;_WU3<*K T[8XY-!< J^9^+/\0#&N8>EG
M6?/Y:L7C33T5@3Y'W^XI4-*BCE[J5N'&;"-S=[U%DBN41^N'/6'JE*KZ6,,$
M(<C#7V_]0*;N!G>:,=Z2C#X?TE4_DI52I%KUH!1:+M64*)L1G T3O(??58;Q
MC82@AA7!8$@*M[E;_15+G#O"YS"Y(1S+OZ#MN6@5M7G^:RWF+4I_Y&R?<R(?
MO98NCM^O>>I6S=M5B5; ]^!Y=]589F__6^9&K&AQ^AO TQ/'^R^ ?*A[XT96
M11E)$-1)?8#]9-%$ H=1B?T#P=JF3V@1.0CN;/@6X$^!(FHJG6:7;L5])D\6
MQ:<V4,U=>']N]F6XJ*;@M#=< =M_JB77U(BO2</&(P"'85K VP#LAM;KWZ9!
M%C(.F789KT%:$G//&P*=*A3*%8A>&8+E4+!_"#;$+1>^L2P;</%C2^Q8N%I+
M_=!X$G4)XEGU*,#9 ?U(!F$07)END?[,#>:^$_YKX'C?GLM;OD7-IU^YFE@>
M-9_L,1$?]"G^-N:]P>V(7[#N!@?V:GHUIL$SXCV#_B!LSYFSQS;F[G^1Z&S!
M6400"<OIA"0>8Y$6X@)GH?0<3SSD+2*='>P:Q_W=.BXEK1RZVEI*[7@D(>:3
M/?R=+?\J,I37YJ=++M9,^<GP>>]S-/0 FN>*,D']E.P;:R?["T$^E9!=1FQN
MN\?S%=.YJ0>" >5>R.H'5,H@%R:0[%QF/,"?O5')@3IQFDV5((^CB]J4[WFD
MI!V]Y=3@0;$,O-[$\ D4^V2S4^W/).\P7MOCBBE9S81>DM>KY?OU%S/Y99D-
M0E#^D0UN6K4W/6V)/6!J*^"N^B?YFI*A6X4@U]TK>AOS<K/]>']RLT0T679!
MT)7%M2RJZ2Z[ONUM=/]P4LH.P?5+N_+/\Q*7R#YSMN9M+PORD\-3[49#7E36
M>\QY/42&L'EP>,J+6-V3!(IIC10_/QH[;C=3;SI[>4/+9K;]JH9)V1W%6E1.
M;+J<$%3AV+VT".G&_!],VOX7"PC_?=GZ_Z&]N.#"II/'K&H^R"Y\>U!Y8G^Y
MO\6#U;6V,\UGB\[HIGP(T]WV1G^@<?F'GE;?L-VXYVIV_XO1S[;*XE')!Y!O
MLW:OR\9X'?(:J[5N=ZRQNO'X(3 J_#)^1 F2#^^#)"V\"@C\5;-F/Y23D\7R
MYHB=-KWW 7O7^71%TI-JA8U4[RW%0Y]?.,+%I!\PN;YTJT$^AW/!L?M9&+<6
MOJ%VLH2T%%<!2+@K*(R)\@7^ /+]W.,SV'A4X%AYR&+6HU/VDQ$U@Z$$O=D&
M&<LNH-ZQX4!>2GH6H^V54F'/Y%4I-QV30Y1IZS1BA;NKOW6CRNVK=AR0=;/]
M4#W+=.?6#HTLB8*1-KV16]GBZYT#6H^E1HTEI]K;-#;:-U1LOTH,W9UTPOY,
MF/]DN>Z'.FLWNO:%?+7E2TA YL/97 I[I]W04+!,9DIA6V_7^Y]S*G#I,T^>
M*;SZ[G0R.[-QRNZ#]'USIT*?2[M]9#FIXV'V\^-F(Q5>=H:Y,VH.^@EFVZYG
MG#//KRWX@WYHQZV3E_W/\JKXH\&EP_6AXU?0J>EM5HG>CSS'QW7?227</-L7
M- T_?=CIZOL_Y"\6*9Z='S\'3TW[G;:U-L['@9T^UD4O!,2K^XN1R_>*)]K[
M!L&539.Y+C](7<X/89-9.0$S3UM(PZFG]1D,I3.>B>8=O86/-.\.*J([8GHU
MFP4C;B.,2D,2T<5S>_M1YJV^6G"KMF8H-T0\=+;V$-+;^.O/ZM#Q];&0B,#9
M014?OY X)<NDHMXFF.F;E&;0H.\:&(IT&PZ@(5/=1@(B[]E8C[3L065'_:'\
M2\8'BARE5T>$C@?RV$5+K+[*/2ALBFX,8?HV0N<B>5HP$K<4AC..'%#6[@M(
MY$=PA2![N,(\D29Q)]T'TBA*F!NF.0!(Z:_4,P!N6W@,MMAXC<^F&?6(X]=$
M&T>1N#R2Q3912 A"XC_Y[RS>.B?:)P.'-=[,I!Z.^[T"'LF'X "=;:[^?!45
M11@7@J:>A/0CD# 2VB3=.Q?,($S5 VQ5M%P$+D"A10)=G?XF\GA2823X]<?B
M-LN^/67,RU1]FKO"_;,W+_;UM%]\OFD-ME3M_/)/5Y=X4Y7&+R")L@_^^>,#
M(<E[3@=9ZT,WFUAA/F^+ZXD<0FT->\"&1+&]FXT9[::WKT6>4KY'#S7>/91Y
M]YKTZ,!5F8@S#G!W0,(;GN*>J]+SX8C'L&LB!9XC/2V3*]/.0E"0KK/ SOYL
M1*UE>?V4]T'CL=9#'V+2=WC.WF0)>OIA+\.4H7;1)YH$M\ =4H@U>Y7/ 5!K
M6-]>(HP0 O:L>)4&#\9F#I9ZAZ:IXWHR@_;?#\M;W%R-G,"7?>X[,EI\=C#X
MAIC@J_/N4SQM;%>>FBOO<TAY]2.UJT;EL> K=+E)ZLTMSN 'UALU5\> A]S:
M-@Y'>=\909VH^+GW]#AN-^FJQ*GJ#0I55MVSH;K41F_IT *\XJSOMX.H<KK&
MF!;3XG11@!TL :J;[A2-<=,ML5Q<$1_IRRM%=JEMZ>8)0>K:,I>+ZG8>#[NN
M+ZN(K)=$IH'32P77P9O9=[$8A+)[X&;KF..WKQ)"90@O$ZY]\H?UP,>ONCR<
MR*GJSS"@D.^H^57<.40G!W7YX%A*$3V#V)AH)<_UY!1SA<5K6K:&AY3''$=D
M*F_0C_%\WOGNZ9S$SE30)#>Q:\%I*OV1@ 65>#TFQXYE>;=$9P_?/0B6SNDB
M>G1HW8!_>B-018XE87_0@\>V[]D1[Z$MSX=6-03-%_N165'D9)SSZZI/\0F0
M]>9L1W L2]G#;LQ/02G(\\NO^!=U!=\:3_9.1U"K7"7F^-*X!UHOT_ZO"OO_
MS0A0WW_%&ORG!=VNH^0%&G]/@#W77@A*-N<W \RA'!."6OQ1OD+0LW[ "]4@
MCV$XR\C*96^UQ"4(JJ4 JO6S^C&GA<%/Y!*$H./D_$B*0&*I'+TM78%"LCV%
MJRC#:?_T%N"$(/-@-%>42;VEQXB%&H91ZE17"B8$11J:YLN\/&MX$<X!U;"7
MFBN@HW(.!;FLH#()S&IL*_M.D(#,/XW8&$=::Y KY_IQ[#)>AR=6L)6K,!#&
MF#K- AMNZ*%[UV%1%PQ@-?C'I% AZ$E&21B=3UM.02J34']-LJJ+@MR:\TDE
M:9)(BA"T4Z\81??F::%\YW-Z9H0@;<C7^I&EB%%D)5D(JNZ"I)!6$7!WXD(/
M77M$""(-1_):N+B,B(@!6I&OK>9[+#;^= I+RHNPK.*&&@.3["5-IGFU#=D7
MC.SSK+E3Y3FG>NS&4(M%PP6\1$''3H!/$.#?1D!Z!C"3UG,K?-(RQI*\MH$H
M$PP464R--ZO:D\*ZQNUKZG>LH>ZL.)3UKP6M=.UZ<@C-'3&% BU .%U(6:E/
MG.@\G;EB&I]SF;G52YD^/WJ#/R"XR@Z3^(6>)C_@@'V+&),"&9Z=Q'Y,/[4?
MU81_Y1E6>0/I_6+*\N E4XSFW2+$-CL!?462$Q@U"=,ZFS)0;^UK$ :G*"G$
MK3)%X8^&X?38(@WN<P#2_[P*RE,/@K7GXG 8#IHBD*6Q6;XY^&U!.*;$ABZ&
M]TV0* 0]%W#&A"!QP1QJMQ"DHCS"KR2C8H6@KVD' 4%;P[))#3E:)2A=@S()
MVM-3*76V&CKN6(W3!L$K"Y:N_-LKTUSR.,HH96'YDL_%G$+?;/=9:Y=/+:ZH
M!J"WQ0A!*,+0*&&T=>,&[Y,@'(Y,U%(N$;U = I"+>="L)_Q'.YB&);>167L
M(DO1+F\P@Y%I.]E=K&B^,F  !@B1M=^X$A%M*1N"4?]';.B&"J#U(0QQWM5A
MP3#6DC/-BY]=12ZL!$-Z<(M(TDN!)J1TDA#'\5S<5XWZ)@ECDON'S5".TS[8
M#<A%'%A]>8FJ.PR9,,W@V[/R:Z"\F G?_C?\LZ>-]RX16VHSOY'(3 F)!##X
MV5IZGI+@'6$H>WEMH\=U%4GF,2]2*]+L:S,M<,8XWV:@!VZ63>BW%Q?LYM43
MXB&6&_'9Z@EL[[4=K+,I2%W4*'J\3O$RB>FZ0;&>PEM!+$1+V.W =''>,7L4
M=B.1UR!X0Z@+Z+&?Y4$8'-[:)20AM7.:%>2_KBD+\0U;$1"0Y#HAJ# =G([.
MZYEM^;8X;6#YLZP3D1P@L29="WF,,MNP5Y:D:$";K(.$H+P&B_Q@TRJLA<YG
M0D_B\A"D)X(CN0;!MO._"QC 8!&"GNY+T<",,7[9K^WC["?P2EO7^^DG1PDA
M09D<0M^:$+2\A*B2F.[:"8G7LC4*@=(A(,$4%YJSNJRAJ6'#YT2K$S3MX)3
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M7^[__WU_8H;^YRW^B1M4\._TCX_P7V_M;QOWCVWY+_; ?_$&NO[4?058 0[
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M?(N-3! M[ON(X;UYJN)&_OG;L8-_F5F:[DL&WAO@QQ>Z@/^)\=Z(VU:$M>Z
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M]MK:N(M>3N^SY"3XP5M;UUG*6:8(6:%7H:#JE@.Y"XS@[&;YI@P/==C/WB?
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MAPK,^M4AXW$G;Y\R3)_4PYMSI,LZ8K ?*2&6!\5#*<?/UX3T_DTD.@!ID)'
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M@B8I%>$MI9;."@\,_I6]50E3V:GSL9U^$31>V%M^;T%C+JX*H:\=&DHKKC_
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M4K)06;24%N4<OJ&+>#12BD:G!XED\V67S>],E%Y*8O< RCR2 %, P(&RJCL
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M510Y(:;;8M$GF"ZNN6MB^RA_+_0$(YIML)?;W(G0X<TPPV/>B9S!EI7*7;L
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MKM#/!%8%.%13)<G(RI=D.BO!53M(\+27WW>"FT_U;&N]YW$$&#1U'P5>I=Z
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M6=PGBK>@:79>:G3T()4G-D<BZ'BPPP'%A3!R_ZF1I10E0ZBM*B%V*+$_,:"
M22/TH^AJ'@F"+F^:QQ(Z&.4&5UM#+$+ 'C$T]'HG3T-MFR.1G#N)-MFH:F,
M#(6^\">U'$-E.012DBQ01[W))_OS)+=]9DM\RBCPJ%GRVV'&E0_@D HOM#.M
M"^719)&=+G1B81':2\;?9Z'=FT@SX7LJYB_,U0:_)3+%Y2%+^:#<-.1/%. 5
M9H-$DBRG1(*M$*0Y!Z]'W_MR5(K1&%;M"2,RKV46$@I0BXI01#^D(WJX?MOK
M]3HS_SQ"8T5X,OQP55AF;<#':F:3-VJC)8B$]ML6E1,QU1&[; 3)9&PPX-@^
M!0I;)^]:5J^UOZ]\EYN1WIQC@*G"1\WI+ "'C"+OE&XG-7Z$;LLI+@\]EZI1
M0 $*ZHM[UBI>&:EIX.3V)D9T1H_8OA!=&]-/,,E9/#&-*08E])*'?-QO/-VG
M')YW3S#1:T\"?)C>2.8XL1H!=-8N,5681M\KC3(4S<:G288$'TBL!-4,/.R9
MDIDC^?NC85':?P@U+Y;"ZY;&+%AU2QZ)30_&.<0:J,)/,)&/;5D&0/7%M!X&
MK*6T638T7?/X74HVUC;&F@!3U1%P#GY>UR@SG:BL^*<199X_.+R6EI<6X3SC
M._V6L?T^X>2KW&(CDAN"MWF59N"SN$-I1[Q/Z=NN-V '1^!V]M/7IR\[WG.:
M;\!,TO- OHC76?O2&] ?]OD&1N!$B[#=_6YW[#EU2)U3QNR.LSDSR2ZSK'G"
MB5V>Q*S.,L=XO5IRSXJ*E#\Z/3[6: D?C/U \>,/)931>/<A>]ZGR8[5S_I;
M-<ZN2UE/HH[F^+D][.H)<-D&M2U'&M,:-[?5$(<RM@W08.(6'147/T[//<Z"
MYC(93HT#GQ?.$C.T>%S5J'# A+!/7(T<%5YC46MNJ4>I'6EPSN+X@JQLX@=K
MESIYQ3;.;6N.6\CEND5QS6G XB6,92;H/6D" SD'K6 _XX([^&0[BO!&HA"'
MA$[^?-DPI+^*T?YZ%[9BL-YUF]=\N\+HXLAK@CT*,A[*H4!DC/V+K/#X99UK
MS0EV^][4&9,VTHER%,ZU0H"ZCA'C*%+?GE&,-UJB@[QDGH1. N@/CE/Z4@T,
MV\ED2E1OX==XZ0Z3C1WB>,3FZRB#J]/47"8CDI]Q5*Y^ZWD>@S.SYE.P=.-^
M_(XR*U>9(S6G'(7HA1MI5-/&419Y@_T9QY/?OSL@0Y?O8WW.\4]S*4*WM_F&
MS19"5S;^/)2@;"*7KPS?7K3FC-!1*R?2I[MCS?JVA:AFX?#+[-%%H PY3&J_
M(LX[/-\)?'N=&=8Y=Q\J,__F1E+\<Q9%:9-($EI@Q%&_WX'N*?$<ZE1'-'-D
M<,UA<[.JA \)HU%9]#/3B03T[WRK?,4;-&G29X$!7*HQ@;+L -W7QC9Y0K.L
M,Q8.0VK%V(>@VKOF6V-DPA\:G+:\NP_<P"DI#.Y.5;9;E*S=TR09H[8Z7SQ4
MH<39TH>KF#< 4>!BV7'U[@+GI7@3SQ!*KKBP39CX.I1[E.%6XK&>W<=32L]7
M36?K@KKV3G](7=4491KE3MHB+;G([IX[.3H:IM(IFE]E>]]8SZ<IT&SM.X@$
MTOJA($(7G&S+6N6F94=#4#]\W3 KY@@^&8MW0(%1CH/H]E[PCGRDS_K6\L3I
M!<)><YVE;R2>>]K@MQ7I-#=H7QJ,3Y*D-A$*1(D-OZX2US1_"N,+?#&.83::
M<ZR]P.37>I;A-L>MT75RZ"N,9PF!/-N0&<U9(U[;%VV5C6CU446_+(ZS[WSJ
MH-^K2X+S:W"W4$DG<R:=CU8_5914$;[_KHRY*Z&7/7%AYMG96U?+:"4[[4FP
M;T?/.(C-'T GWZ0.DA_MV:.*@30&QB%-YK/[G:8F"M^\2D=NI"ZEO71JH,KP
M\#XDTTYR)@#$K#X&%6(<#*:E;>*L6TKYHS(HN:9N'*& X=V%0,>%@32/4Q@J
MWB4]CGQAMCV<EEO43Q3)'-+BTOGOGFNOORSEEG8HDCXXXS]<9?F;A/.I&_ K
M_52?">L;^@D* DUPF*_D[H'IS7EUM9E24?3P  WM3O=#Z!#=2Y<&HT:A2JS:
M*B;<&\R(A(S0WP"J)U162N$& ?EEGUU;OG%IO2J" 'F<5J'XDJF'3\S 0])1
M+N\^+-8U YI_=4+:^SZ+I>,:X5A'6XAOM,DG]><C92CGM(@U@^!N&398]'3>
M1 MT<AZ"T6DXA4R8\A$[3O(O=:O^0H5(G6I+V4[YDSA8XFAOF!MZ2WRJ->T\
M$'\@H:4M C<36L/M^T/)G%<%OF[?VDD=^\?S==HNODA^4Z7V\!RD_,Z)^-P7
MMY+T)+86B1 9\EU$U8^K9ZOVR4@O<OE.JPU\G7;<C2:<;\ 5VN\&&%=K6]V-
M1G&JM;4A@>L2[TVSZ35>:V?I\"7;._$:^97*!6IW'H^;\8RG%)P"]&;JCH0P
MK# >I@09_>T"9!.5.Q"98@#/WAEZ\, ^"W7UWD'4OR9H$PUB5AA7),<0%)G$
M1('3XSS\]O*X>$NH).04WSW8R?V+KM5:Q?SY=ENU=$E!LY.K9.O'+90P6\)X
M)3(A%X> G(=2";;[OA%]IH0:>F*37<25*+G8YM'"Z"A3$ZLK<H/INFR4)1VF
M[V4H1H\>5)V$G<@^6/PS3O=[3OM[:S.#XFVM&LA94[YN(420KE)9+$2]BGE/
MPTU59P37->P([0W?<:)BSQ4$!O4D4%0[-4D:U3^3IV6A LV5=O?QZ$/0J072
M?'O4>U80H4S5U3;W,$Y,,;9GHRO^8K)XS21T4S(_ BD!R&">UQ6G)RI7^YAA
MBU.'^VLN5S(7Q8RE:]H^E;CL2;A-K^NS4]T@-*BUY_5"P@4F?,9^1VIQ7 :@
MN+2+.@J C%!OK(!+==U0PN/:SQ0T&7JF0GZA:"A=/<D_MF)N]X<BZ%)%UAWL
M%K+8HQ^4AO9.EU'FD/YY52PD_N,A<_X,SKVBH,')A.I>I5A-4PWZR*2<%YKH
M10BR6.#G;Q[;(V62C2FGP6:KO0W#I[@U_L-SRC97\)RSLXWS+\L48I<0S9HT
ML!)SSW;PDE>WK7'G)O:0@;W/>N>K7U33.S:,L61JQN'V RGN2O*'!)E/_,@5
MG52';#5".YW(09']5())6H>B3Y',VXR3STU^1N$956!^),'=WT[0,.0'K4>@
MF0J>36$SO*)!-KY_ SKQOM;@L5OLR^YDV:[1D <FJ1+NZ\M]3* "5T5@K0=@
M2>+(8LK4X0)YK5K<0Z^TMN+L:<L#$NA)C!LFZ67O:>?-6</C_%]0?1'K;"EF
MD6.L^H:QD9E ^<F+8U DA2SSPEK;#K"6Z4+"N\[<':*HR,3@.'^CH!8_G.,3
M-:I4"[!Y2F:68SL>4W1T."4)G)>UM9QM=EX8IX% ]*SO[F\7;DMB/ZHI8A05
M5A:K[Y).-8:7&V/WEQ%>V?/N1,+9#O?71%B1IWMZ0C_JT0\J'.7!$5#IVZU[
MYW;52982QWMH8X8ONISN4MCBLJM(0:E(*/NG07T]X&GY@4; =A/!VE_4UF*G
M&\LHKA,N6<:#6NR3BF5<@8Y*'M?V,K+BM<:C2&^UB@;NU%B:F'R"[1/*16',
M'T^-KD@JJIZH!"%BVP*27FP6J<VR2,-EF90SU+'R!MAT:EE(DLJ6J.Z1YVUO
M97'IC-09*OE$.L5A8RJ6?'=- L!BR,+; L.)<_/(DL^R5G^LGI7%)I?QZ+"U
M@T^R%H>?9RNFFF)CQB3_.MJ5A X%@2L6&G6FZ. [WV3G;]P:WCPW'\UN;%RX
MDHCI.YU7:0S$)J/"WM91"%0FJT7%N;7__=# . $>EC&6:#?<.N"22[<OT\2I
M4@;?EZ!6O&2IK"=.LKF?/B9@4IM/U09?&^KK!,*^$F9:@>5@#1?&5Z-_-.@=
MX]@0 .M 6T<DRJGFBQ%/J"]($3WWK+6+IW^W,$G:R;QM6H.ML?*Z%^&I27>6
M=(TZW^J6JJ[^!0&.!63LN)IP(GF<-VF<O!8F#\T4(M1LX:1'-E2)LC^_/\HM
MT(O81V2:(@%R@<-* 5DFGV&V3Q#V"^6WQWN.3$[Z17IL.:T+4EMX\"N#&"_6
MJ)VNY!CM$($0.9+68'F#-DGGK]Y$]GB"R:=T&>-+>A"8[X>^W:D!2J!8<S<&
M20)LN@I,J$Q?:T-X4/4T%A/'.EN0R2?9E8OG.DOND99'XP!N>-13^ T@O=D7
MX=ZPOM3-V#3)JR+"&+N_8US6=EN,8J:UO;EU;/F"P>UUKZSHYF$N*TMHXHZG
M(Z9V0.'^8&'A-%-?Y^C@IDC-%"O7V3*5W:2^7N#!)G=Z<*Z;3+AJ:*[S.2MZ
MYYZH)K6X=[N4G K]0[PC#'*-;WW_L"#)N<EGN62(WD3IXC*E!QX5ZA/8":PX
M@H*EB@9,=O>7%Y.4C#TON/4U.>GI-5L)*"",:%E= 7^F5-%-D?BDF?"DJ6/"
M;!%CA3:\S;RQ.1'%L/Q,,+A>,2M1.^_33/NFY;;3MT%5;$F*$MI$E(A[E:W:
M)?U"M;B1:03R-\!YVO-#N*+D3 H*#\50C#B&4T,53GIYTUR ]L<;V9ONPYQT
M/^UBD/#739[TMES9#LB-F(H.@S('"<P!^E(8F89L @$F*;=.!S&ML!+6^GO_
MI65V6IZ!"Y>NI,Y$Q#N J0/M1K5B =81;?&*MN&&_R&>7$.M*: >:JWL8!QC
M-MEH*C1F1*FE]K []TN^C@XX^&K8[%)_7\E'\+"8.)IO?L'(:2E;  _'&J+>
ML0G)V<77J^F"80Z8*&EL[%_.L2+(-(@4!RK'R9<"7ZXOPPA[+-LB?[E'K,Y*
M&V!.Z+2G2.<K:NP$X<BNBKG BETY:,."#*B"%380O2U0>]2,2.].B!CSX"2A
MU5A^==<,8+!M-PHH);IWXSQ"7OWM>V6[O;N'=%F6[BGB2/S2NCKJMZSM-41'
M;NZ8\"XM/CZ+567)JTO\IIR3='9W93\\ESL=QJIHU6U'<86NF,P-0$*LSC#R
MBHO;*?ZM29@5]@"E&]/$KV4-<?6:&*K>$,%H@:-WX643$CD3I2Q%E^JG&YP^
MW[(<*_D)7] ],IV7IP<:2@'"1WR.@^BE:_<-(&^JT7#X0M;63"^>^HE:_*E)
M^'D=4V_6Y@VHOW=RMVF-0PA,CI#W2=PJAN8WX-R%>M"B>XX>*=WB)8^V4_Y4
MKZ34B9A"/.VA3#FM>>0\_D%?J >F.+12NXB<.#7THW*\3 S")3H'(R(/D37]
M\;J+!7I@8/O,ZP<]<+%0W<-O@N0J/A*L9#:\]?K./,Z-?4MI40Y]R.O:G_B(
MUU1&2<L554#A@/,"'Y)2))0QL!(!^U>95DK_KPX2,9>4R02!$NB,^#^)53LG
M:IE%K@J.%98D9TO$1<,)_)=L4X<)UM+%5U*SU(?*W@4;4@PN*/W+DK.8@@CS
MSA8K28FU'K]W\$6?BXNK?R66XP$#Q7EQ^8HZX[(&FWHS1(=*3?T4^/B/P[#4
M,FSGTH(5'J08Y1#_G #'!8,V^6HFF2K+QB^N4.'KRK;7^>7'2%-0O;+[[FM0
MCG7!EWK6VL4Y_,@.VC97%:T#?2X>8V9<BXHD4J:CBW!M+D=?K=)+<\]UFC5%
M%VUJ"]&*:T]*#8MK2_%%9 RA@X-O";B0M6B_Q0QB:\PI )0 O@^8#YA,PKGF
M7JQD84JF"5FB@32J:ZP\JGP([XWW2SZER?>>)H_P/6+2='\'Z'TI"YXJ,"D3
MDX@$L& H^<K1X8_$>-]OW"\Z!1$]!_?Z)X[Z?NZ8#1J;S_6.2*[D>XO%$%4I
ML9VV 0MM2#96*;&QNQ>/R ^]9AW4WH6QMO+SC_ZO%\L2E,\&^G)6!WU/E!L?
MMK$$X2&X&QZG,>J'J16?/ZD4DNZ@,4*N^JV+6_EUU%E>K#R]6J0-:MC>1?Y\
MD*0C4;S-DQ*_<JRZW_J19.9DMPH==[.V;\<D(D[RQ0<O!&F>6KODM\"<N7AP
M256=G.& 2T=6,NB]:X6:NBK*LMCT56Q%VH@ &.)+R: 8CO$8#[2O,@J <I2W
M:+>[M9+V6:#9I,#B="\>;*CV V6GM(!45,@<ZVF[Z(&]>TB=DVB-M3Q57%.3
M 5>YG509S3.X[2W70;<\V*AZQ;?I.L@(C5HA]K%E#J$\L:%XZ#BG\3AJ2N(8
ML!QE21(0*:(OD+F(FF2IDA\31J5.)2E2R.;B+BD^R[+_$C8'9V^<#FB* "V-
M!%$5A 5^ 0!D"<R$3M'KDJMA>N5A"TOQO#4JQA*YR,LPU>>"&-P YK,12-2/
M_@O( ;8K>%;&(KV7T)$%6?7N[D\,JYYY(=\>K2!R1XDO4>4UTXF8*SY\S@89
M0O#8>HK9\+[WW>3?LQ))[D@SRH26=<&F QH"JGP0H[]G7QK(HSJR\S6\-*W;
MP>R:6(^CG-3VH%1%%KC]R"Y>WE>)C71PP))O]A--5=+@$QSFT<E5)2P5YA 1
M!%%%,VV[V.2\,W+&DS>7(W*2R HCSM$6U5?P"#_-1U?N!D&<+RTA?<EQETAK
M5<?T'#C'*!-?#3;Z"(V@>J4DUH?2$VB),E=>23E3S20FB'CH^. [!J_;XZ$S
M?S)0,VE991B!%F9K(9DVB"LS/3YKMG1@,<](AL$,[9.BKE/B"RU(31D_DAPP
M%;A*OVR%>&(%0Q(J+F,FH+N^^OXACY!'>T5UY4Q0,I/5'5*0RV_K)/B]G+G!
M;H0V":_TE2QL9M P]TA>>5:A5*HXGSTZ,OH<TT>)L]NNK-3EJ\59K"M.3&&M
MEU(ZZWBD3E<L)8DJ7J_ZMB)WD+Y>I3B!\2@6#"YL,IH$HGWZ/G=IANJ<JO+P
MC^D53KHH_X;5)[?9F9JPD(^!N_9R)>1FB"VXZ;(  *%07)H+^12U%K&^[KD<
MO>$^2V+%/)M*'5JN( )SZ <]S)_.-'=3(4E6U\8;>;[0>9<YH-A\$<BY(=3F
M$)<\+$^KB=JSQQ?^5<YH;ZU/V)FHN;?.K9X4_(D;1 4LLHO$<B=KS<3-8].1
MI;HMSO)+S:H8KQ^Q\RN.4?1BGW(7@FQ5K6Z.:8-GQQE-<:ZB=U*L^]&2YWZL
M6BB]0)DE.DFZ/^26DF,6;TG[QQ$E=-PF6GLMSI=Y\O2,'LCLB#OJTGTS[KXM
M[-Y1_C!;'%(J2I\R==TRPT;T":$'OVCW !&JY><BQ\9GKO0H*Z>2CLBS6)R/
M[!>,8L%8A^KPQ4&Q98QF_E=H7;;#Y_(@9Q>NZY;I#.X\?LW#EY?#C@C%[9'+
M!9%.*"EZ[!&[,>96EP/*^5']L&8NHF8"5!WYS3(KHG?(5!586 CH%G>?TG2:
M="KM9/N%059(G7Z$&\%ARB5(@)^E#G-8>?7@#R-UZ=O4KO^X_[!N^B',B6AT
M!Z.TC+>Z&S35GE'[=F@,Y.<D&F,)2$L$B[M]N]<PWP]A>P%K](VOFK!M*]WV
MCHXDBZ%A;9-RZ&*DH>+<'W)KY&LE*@X$6AHE]V9%;6_=B&T+T65WOIJK*KFA
M8L*Y-\)A.#'0*\.0K8/5F6TQ5P:8&XTL8W0AED;&2V*@?>"17M+!LLS7&3^;
M/+A75,I5ZF#J*:<<!4655P0OD^JKH_L4/)^BP76/<G[@Y/P#:Y5SE&B9H!.5
M!L_FQ7ZM%C=/5PK4K[2+6P@;NDK,*2660ZGFU##T4XOOE8FVTQ*:9YQUL. @
M[1<4YH9VCVX114U2;/8/&#4:^4J<6)=P7\XW#7P07\\XL Z:O."LQ&Z#>L:&
M>D>T@\#];\3Q1=23%(M8E 7NG4XGEW6;UM-67$KLDX:A%1ZZC0) >7TS7>=F
MLP2K/L@57/"DKAL2?GS=$6[#G-6L71A(;2[\0K)7+$I2$#J3*[;I-2AN-.S7
M77U/_+PUZVG__[1QUD]1.."W7DJD&Z4EE52ZNSN7#DG)74*Z.Z066+J1[ER6
MI20DI7OID$9ID/I^[LR]<^?.W/,_G#G/\\/[/B_>U/B>;3\OP).J%LE L]@7
MU[G_W P.CGPQ4Q7X5_S_;,RZ<(T'?W&V.^B97&>N+$>[M_^1O9D43A9'3LO*
MBZ?WMO_1+\5%QC&!Q_*!+ZHIP81J^5LLE^LS?>KDHE(S;]?O!;58(^=3 ..P
MF.&R5N!;5]H_# J=DNB[I.^B?MHOQW90=?+3K.\_Q.=DN$LW-WK3&,;KPJJD
M[VT0C*7=F%/&/PG"6TJ@_#Q!@PANKI%E@\"A26/25>&[Q2E]4OO&([\=">M+
ML'+,>0+G))IV_<LBY$LV<'1,R,P2Z(U=T3&*U<U,IK=='$<%RAL2CE"\/ )&
M9A=7,4P#"NE0>AW1>IQ;ZBY&KR&Q3 7$ZLJS11\D)^BV7P#E^CG6-<=ILCO5
M[_TMM%X GG=3*TM[M,NX60ZYC??XYH-AM*R?J^4%/@4G7_3!W3-C0)^]&-O3
M5!MX-U9[]F]7,W?]^BW!U'I_C]V.X/_LC\KO:3WGRA[4>H/&3_6$*XDS*$S@
M7RKW#Q6"/U(^D<6N!0Q ]]3=_@-FM71"GPU*:X4Z?QJ34X*3"V4628IB1S65
MZ0[V?S>%1SJ]\E@'+*(:>=BB5^O(!I9+X;R)#GU1)\]8S>/Q>:8 &07I.\DA
M4\$NSO7VKL96KQKW&:=C6%[O_B&R7 ES<T;M]27W(WX(=I/EX@[!8OO!D(E%
M5(F[*0P?TX+55R?J!?#FF,:OI%4"S?A;? -9];&%+X\6RNHFROUU0]1P 9Z'
M ?Q@!W-_?DRH//$%L*Q)W;!&)"??O!3'(0I/0^\JAB;V9=6D6[DT*EHM,:^>
M,  L\4L6 ^7_N/$&KW">=_ </6F->&T1Y&H7J'P\FO84>\I8V;>[*;=T68PO
M'1=:R@=>Y+L=KQ)4.=C<W9]/ 6X;1UD:W5$CXRD[+A2M15!L\@M?$1S=^.]<
M2@1EQ5#]Z7(GIY<BHGD!?"=< @AR%YW*@G%H,K)6>125__SQT[L?!/T',J4I
MEM<>%W&2Z])==-QK9K5-G[/;?)RU((M7(+#-L:OBXSJ5/OHS9%,X#W,901'T
MZ#ZHBBC;T^<EFMZO4:XJ$IWA>(J)K)![QTS(+=;79_D0,1",E>.-.0"@A]_*
MMTO:W&Q:6?MIIB 2V?"#<BWB]P^.E.;NH\O9CK.?UI&,#_(; JO-?92S: GY
MKDH5U_MTT!A?@V*C->5=ZXKM5S4%(\[Y:A]#>%]I7T*;.UQ0A][C>H1@:=J(
M^=4<G4:WXVK=CY&459R]>T?S''Y8*&MY>MD!RU]&/M%HKYD/)+T R.8H=1^7
MP@NJ=8G6GG:[NDZ]GM:#*I3/[^"[,05489&<B_>S+4[71\5BV-L[B2;N^)0Y
M'%\<IMF'LP]3F5*X1^''SK0"F@>_UD"TPJ)RW])6")_6Y5)$QM+PMHCCH;=)
M[<K(P S/M#9L]\L"F7G-C\"T_"8Q'6:,X5TE/2;/12WYTV]-,[>3'8:/&.=N
M;2YO+GVQ,/SB7Q^),X.QN)AL8RBOV;*84;IX^#U:2DSFJB)BR@PRB5H=NW'9
MYO79!",2T(L9'PD;\,C1-1:8DZ'HR.1G7B)49_%B#*2V_6RW*@/(/:/.)A]4
M:><X/.]5/2SO>#K02%9-1RORCR!Q@H.<R%G@F8T>+Z]>OK6)+$I$+N]37UFD
ME294BS:%T*T(-;LFW>MF]99L5T&CV=8Y'DD[O.2L,3 BH/FNA<,&789%V.HX
M65U/ZC\'PB-<ZLV66U7S\&:K3&R*^^"Q8>\]VR3Z'KSDLDJU7IJ&,Y!CO<A8
M ..(ZN&%;VO2_]## &H3! [?I)XU=R#&N+M@SH9P=QCXA_S%/]<!]L,?V,E^
M#+%!0.J1:K@#S7()2.:F;*_N4_$J#W^W(!UW]?1Q*GG6OK)Y9KN94+L"NY+H
MJ]J8)5*O<[EDXF)($#.06\F\#,_[K84;3?ODWGFFF/-M?3(BCR&>R@O0&4^J
MMQ@6YCCP%_7[Q2RP0SSMMN>+R_C9\<2*U4Z_=2US>U;D-N_K+9G3F2+'<:GB
MBNUQF<3WBOLKP9R+319X;JND_FT[UH/!ND4F#*FZWD3'_-#D8,#)829V(2RC
MKA-4J8?\:3O:9$M$FM#@=O;197W3OR@'D2WPF*A8MOVF_!4&F0W9GA[4D&BR
MO#0&)>K[_K+"[>#9V8]34Y>:PP<#G",CTY\$XY$VWI$Q^[,<N/&4:5Q,6LJR
M%:5GES]JX/GE#L*S>-*UWNG5<R2%2%;NT>\F*$59ZK^6Z,L_&[4#&=1\S WS
MB@^;&+AZ<6-GU750BU-C3^L1)N ORWM>B0<(\O3%-RS;%$MTFK4EB8*)"H K
MH+6" C@U_)6MN+C:8O='$&(#+BS>LQH8F>B<<)T7T@1OD1$'*[-D^Y1%&H9R
M4OJ2RUD,[%#(>QY_H&F4;/O">]%Y:1_1\"N)3I%B1 ?2O,<RIEU4K'6)S2:F
MW=(DUZ#R/>M;.[%PZJ":63S&">TIB4E2CW@=L@WLCBS&6?[GV&A,) HOE0F+
MGI4]ATRA]6;_G6)OZBJYO?2SV6XTB_2,;SG^GD&!(0!1:"VR:B(PEA(KC--G
MB,#/%SG,WS8E*'/MK@R-Z@KD;)MVLK2S3E9F.(T/"#_,O,X42RJHFU?9\GT%
M!.,,+E-OV\:EU,Y<L+$)G7Z47 ;]V1,M@:R] /+ZGTWH0.?\,"4[H )N+77*
M%+LJT #UF]:OF2*=\N9;Z=,>M"4U09<7@.V9M']&9]S7+OSAQ(LB!>5"V!%7
M^M67F!1#=@9/88</'-?]SCIO5;_Y"%+15#1!PH:FZCGPXC-9OKIXR?VR;TO>
M.V6%,:?;3H$^H[T&@!>E)#U@!#?5[53-(DS'84Z+1-D+#0.!'X*KY.Y\'<U%
M29HQP0^2R%\54_^\]>^&LVU+6=V$'@>'_^Z)->&+!=P==4K<&]FX!"27;*>#
M.AO;,^B*3Q]<N7NJD#PX*6I*R0,;S3O5/_MR,4%;?PBO -/EI__QXL32O4L_
MQ]<"9A^9 B&7(9D7@/%L4K4VY*%/L. T_\CE*0]]3;_=U/Z+Q32\RY(]SGT'
M3%.)64#R=TJ1:/6K[@$6:C9[T)(8"F1/0@J<RL.G<_#?Z-*-O:NI$%'62QT1
M$%!D3'/@+B?\P(X;<T-KZT[E_LZJ[1T4^!A#8/;PAU2\IU\"!\L5_[PS/J((
M':FPBGNZNQ\3JBF \0LH8CIRDW':O8] I'#.PT^6_<$)F10BH:C_/$MP],38
M"3=!IK2OY5054^M$HXOC."'*_SF"= =66=QKABP=>5*=#T1,*4HA.BS9-A]0
M5    -6K$OFLO*RU6'='Y6UEL1$)IB-020*#7!P3#F4( #4$I1> "0!L O;J
M7Z;^"$<1.9ME\)@+^<C"C%-]6_1CY$5#-&;8+)'Z^$HL2T/2.Z2S0-Y@KZS>
MH#55KB6X>G];@_!P@O[9!*N/;P>KY56U'M&F-.7]XH:[P-B&_Y"]:7ZL&YP]
MQX_6U@H*?>L;+553/J@D(3+U3:+@_C\>ZA1!YJ"*\1<E>?P,WI*\/6BT#O9V
M"N(>NNKTQHRV/QJ8J29L3>>BUM0@&QNPS'PWM)\7IDS&[?-X$#>&)04 "D?P
M">^+M^QXW.?6@?Y\-?N6@XB&AB2*L'IQSK YS;0>T@'X'%PL I<#2]I<J2SH
M&KE/;9-:XM"M^=;4&*3R7*0URM\UZ_XAJ; =[38WO-<,B.LTHM]AI\<R=#),
M#(_V.46B$\HH:*A[=_T1T#(7=V-Z5WA"!6$:.]":+45V+QO>W!*XQ39VI&R.
MN=HZT$A9J51%WOM\K3"G(QX:4GOC^]1G@^AO/[G%UQFEX@;;M1WB:HR'L(_0
M^\%HRWFTN[%+^K65_1DLNT?!_[[N*":^/SO\UK'VMU:Q2A)1'_;[I\<9UIED
M_^$_S[,D6LR5K3J[2Z\Q9CFI@O(H!!UY!;M=M])6@/,>O2>-W3 A4YXC@.5B
MP6HU8JU"@* #_O8@:!-9K^XAWC=6-KN44RV6,"O>E9:?=0$=*B>XKLD^\6>%
M@1!9Z[1KSO=S7=#?^B@\253VR 7X"Z!DZ'W_9%0]7472XLQ"Q8^Q\7R*;ZE&
M/0P,N[2*DS84<Y]SH9KO/AJ%FK)#;0&;#-IH!@R45RC$T86OHU8R0,NGEVT"
M^#,_6@)Y96TIDMV_-Q'H6SZQ=W<[^%]V*KJ*COTGP=3KI;4+^I8X^JVPD&?S
MI<5G,&E NZ_KHMU6DK@S]:>$;KZJ';;6D:>G*Y)88=]#904N$]YZ>H;<KT[N
MG]14;+!;$)%J#**Q:?AY:*;UGJ+BMFO"?R]L/&[)&Y:90G7X%#"^LQDE:>_+
M:4F@[90S(H?@N?6P'/')5R1?C&RXFIID9E3Y4AC9I)I>[VB%GX1SQ#N-%T1U
M!+.)S_. /[B>+%"F#O&KZ'%&Z6!<C<<SM?3?@HVEE(OX%CX==+-JL6%FV"Q[
M4)VC) ,(M!>%D9/@M_@;9_YFT^!<.*(C3)B,7$X>VT:6PJ^>\HJW5BSSN../
M9I?+SGI@>/+IT]ELXY!UW>_(O10*6V_/,&F>G[)_#WF^@S1%"B\7Z;:^B#KG
M<BC2/Q_OQ'7-K\OJ-'W<F!P>Y7:C76DPFH3:31FBA RWZWO*5G;WL=![;WQ&
MEIV5VSO[5RQIKE",?3,\B>ABIRQYQ?//TWI^&_TSP??CR)O+,X./IX>"6GVG
M[!SQ][K@A4ME!A[.GMJ9ZNG-GW:<8S'4!ZS"BAM@CNB'F*'@0YJ,AU]\P2>1
M,,E%G#\'Q=-LDKX2=Y)W#G'/^3MWK2$/9WN%+P#7N^,GQJ87@&_I\[")QQ.X
M^SGNX\[\QK]4</!CZV"PIMNC\998ZJWKJ%ABWRW'IX>W>JR-,)MM*F6-/G5U
M1(IRO,V)S7;-E/*62G2BG#4*!NQ:7C8:6==C]>""?*#[NGVK)OR04WF* TV4
M2]!K_CD=Q>PS[]<1?8Q2MH\PO_/.\'P(+EAZ(RKQLV_V'8,12Y11MA3D%_6@
M5!!IZNSKC:IQ,4^T]C\CJUV#WT; F7%]AD,31.JY5Z39F)!JXQ(2+2"32R+U
M&Q !D;KL6QT@,Y'7DIJEO,W 3R+OV^X^I%G? +7$7M,U@^X\=9R?;61,N9ZF
M[(QF##VD JT:P"?D58+(V6_VCP>Y)*413HP2V]M@G)Y9ORH6WJZZ!C@"H2ER
M3)EK6$PY55]ZQ"B*=5ED=\:;2&))2XWF>4Y^S:GNG,(7U2-V>04A\JM>Z)%C
M/PY[4NMZ/]B*%ZQ]2Q<R.Z9H$8OX^\GSCCQAV>+P4'/W[DC.E:XSE=H9XJWH
M]-LTAI33R:N6JH"8V!Y:\JQ9^;' @!+?+#WPE@=WW'IXG#NR^LJ[FO"@U %A
MF-'1"9)_S7Q?!OQ-!&Q?J$\F.E,S%0J*=@UPH!;D@B&]5[C(%[:%;Q4.L\_>
M.5J%<:-F^_#%7S3J[LPTPE+1ADP3KYYV3/*?9YS4(QLX&Q=Q7[]YXY'39IS4
MDOS=5:%.N-YD'/J@U!\53E8ML'ZA86"9X8$^'@5L?"].P,ZERCL+Q?(YJ&3:
MP'/AX55GF7)5_:Y;J# .D4?8S-$1VUY-BR>MM,?3KN>XG.;H#1EFFI',F'^8
M* W4G5-.D;(?S$VWPM2E034R>VJ_-;^$K3_\?C:=T#(=9"K>:E>!M =+8:!8
M1<05)C+K)1A>?=@K(95X,G*57&41>@$H<VRLVW]Y =C0P)[;+8+ER1-[GA0%
MZY]-_I>.%]RU4%Z>V31<8'[:Q1UQ *VEK3W[*D<3_2(WZU=JJX2!Z=X03WLS
ML%<ML+"FX*5RWQ Q2$^)\VFXX#7;-GM-4#E;KW;5YM*C$:*X*W]QQP28+6?.
M#AQ0GPG<C=Q^##@SN\Z,M>X9,<U2866VUJJ"_"QMAR;RR^GX3"N4_8%-PC!V
M,@3(WSCE.*@$TVXS81X+N+UK3NVL&=3"Y,_^Q"5-UAF7INW]?L6NIDU8A4WH
M8P1EXL5M#QGR&VNC(2QQWW>X@,ET = ?T3R;@<]*)BN)ZJ=U;1]V,WOJ(;D>
MG]<6+$JZ(-X2ICF0G\=CEB;)1PZE=@PR>E^4^#$3=28QU#4.R%:>Z.A*:LR!
M[F)>8I @P_+J%3, U"<<[DH[D,+R6^0_7:&0!VH- 3TU;$FY$ZW?6FNR0X=_
M7PAF.;?NK-K447>F"%?STI'L8K[#0 TADP+@J4]@HD6MW#E[;2#O#FH_M4%>
M;T5QS\1\&T893W$TBN485^7F4!95Z*1$'K],\^=?!EA!ZM<9A&4-/Q?/(XJ)
M/$T3[0Y#GFC72*?BV9LU.C^_8F<G)9'+NHV5J^RP GC<"JMUB';5W*+BK,I/
M@IM(4 (=)_EK@QZY_$JE_TTKJ<YF*>-A,%I7^#QMBZ<A?H*<\*^W.+]9\;#3
MM,E^#P[KB$65YM5-T42M 9:2*TG9U0SSX82Z$9S]^C<DOR]SCZ=@9DN=^P+
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M!;T $#>'CM?&YV(MDW75-=F]ZK"RC-GJD(7KI$8[M3%>YGIK2KSN%P"?Y?N
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M]SQXW@<9B@SQ008>-+NH>]#&S1T1\*,-:!\_?L)(Z[C1<;V#6GI&NOI&QPT
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M(99ZE(P<33/Q8'#LH/.71 KMSI&F>=FKCXW/U:D6]O31='2*,\GY9$I_^<P
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ML<9::\ZOS-_7UEPA3Y.7 )?UM'2U %145(!PR@$@+P-N:((]W0$  P. *
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M%L< W%G]'V^?B/_Q)PGUDC5LF#BZ%J:O$E)5555H]3B25497MIK*W,SONRZ
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M>-3(?=9 ["1-=,0H8^&X?CA<;NX''MJ%8B1HHLD IBWNWC2*[RE.6YX>M;?
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M6\',QPO/$D;2J6J/Y2L.LZ2.O'_[9LF9G3X)IVM]LN4@@I'"-</1_-UA>^?
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M->H<8.N8/"N(SV@L+/TA&=>\Y;>;N%"4+M: ,.'RYKBB.GYJ:*@6O&+>*:F
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M=%AX&/0FX=8.:BG&W2>S0/QVV<>[P,[?&@+-YIM:D', T85T*\1!-Z%STGE
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M54S+^EH@./Q!YD@^)SI+ >.D(Y<K&*3\9*$1F#Q,,E=N.]29TRG<B'RFQ3,
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M;KF\!14DQ"A$W4A:7M 5/'&9,;7OM3MEZW&FZ Q513>X*0=8D-/R]AJ!]><
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M&@88>T>HX<LA@L]?+O45+G9X7IX3OBK\2-M#8\ +[?&K\UG*79>_SL^?Q\0
MRY?;6M\1RT=C5UK,J>+1@<YSPNI@N_!"&VL]=\%H506^(&BEVT?IP4N<QK]3
M\$F += +<_37+-7-%SY%C>INGI[),<H)5YV1[HB#:<J!>LMQL;5;XL]S@(.M
MQ-<_1_)35H8(EDN:*667A?^?I:SR_E_^'P_EQAATR=Y#/>#T4L-]I:/C"FQL
M]!I$OY <<=2+]-+,R?U^998:M*4)#A3-S[!6Y!&;C:N7[7]6#_NOZP@8$34I
M?1D@#,=*PN4=<_7;N,CPXX1+\F-.4]F"31&+K]Q86 VZ=?,I[*W=BO:#WCU"
M[N< VEFL(;),(Q@=Y]VSQ)Y?_<7(B2M&?JJIKMI#XX\F:Y>@(B#"A'[Y@_CF
MHZ#1L.3'/M,"35D*/:#W9T ,#;81W:[</(57MNFL.^0<FQ%*N<(F_).]ZGYH
MHSRMZU:67?D[TEMR5CZA8T4\Y(G@)T'69M[;M?5UCA"5TH+:YF695T/LB;I-
M%!<W "N [@;#4>N\<5QCX=(WBM\O@7=8%;S5,(5^)RB[)J,HJOGYBL$;843#
M9+/63]Z==<2C)P_+:TV%:)-K7[S-ROHLT[T(:U-7!;XKWV8-<.A>8E>ER]\V
MUSX(8>L(.@=,'XV)\P_V1CQP1&3_4'@V#0#0; (<%P;4$1JC/1=P_7A?[ F&
M)O>EY0YHULQ_5NX< !ZM=;V/*9>7%(.X'KY.#S03^D O%M"KR-U.T"$*;L(8
M57T6Q9JGFE^C$]AUW"93J3,\OAG\((?1#N(A]D.'V\7KD9MJ[/+G$&\UI[LZ
M"_X/C\T<$BF3@I7P"*"+&J-.)>XV_G=!7^Z"_$#!>H(W_^\_J39EX=D*O(8<
MOP!*6AOQP4.,)*51R%WL8D=[*MZS+W?K+,C)R?5^I#E"MS.8SXXIA5OUU>K4
MHT!+C3%V'X1AVR39*-L%N/PM2# "362.;+D%>8U%1DP^%[:\E++B%]$^H]<7
MK]H]=HM53ZSJ:F'3_G7HWUGI^&:9Y1 1HC&.]C.!T:QZLLPAN$V^:QQ?\B?'
M,<G4[_.#@Y=8*INX!M=5C:]A,?5_VSQV^B/0'.6.]!;M:I$;(=$5D!'6$S4+
M CU^0S4@F]O-&K\,%91H%&G1P]<)"/PE@@I7I_N<_HIH-R.O?B^)4?A$#Z60
M/E.^MYKMH%_Z\P*Q9.!*T?>59?,9J#+!%;44;2D7!(NJ8>+JM(281(W.O:B*
M/N#X_ _-QT3=*S3W!F4_A("-]$<Q1\'TDA(85&U=7=R;:&YC'3[=O NF.H +
MK32A6BIW&UH&I+]5M$,/GEG9*!SL6E,][XXX79?E,WLNEA-4N/OSVZ8^'2%+
MG@_YY#5_;F&W)]DLY[6KK>9OZK%$F%*!>(4S^#KHB1 QL_XG6+D&;7(U*V5L
M@8OG#^OSB$U")#Z2( AL9X(^B)7+"#E4BGZDOL>]+!A23P8/@O>D9R.?CAXS
MA\WF3O \>VV,E0'>[\MB:B&(8@<@*J!. 3&/"D&A0:5[Y5XOGCQ1LUL 9O^D
ME&*)G\3MT]W5?/<U#A CQT9[\]2 2.HEYFFV4SC&FYW*>HJVS+Q!MG]X4N]$
MO'Q_WVA9?#OA Q!KI&\5[.C+S/MTBNW7 OF;^\V7:+P_7R7>^L(V>(U)U+QQ
MN)9^;W=/N+8A4N5V7%W5ZC6/D#8A'-P;9X0Y70D!H3#Q::_9@Z#E:X'^C=&H
M=%RK3,6]_'@])2JCFT3J4[,23SO!R"EJZ-6&"0,V#LZUYD:IF%1GCL4V:WSR
MV7S'^NQC3?*L_B#Y-\=>R%,VU'YKIFGL.:!= =657(CFD[Y[AGU)/'"6(Q>H
M\\^K+Q&>U%Q:Z!GPB$:FKR"5COF?H,U_)ZWO!5:XV;L.28SR"'\^2U5-/OX)
MQC@'[)AD_<YFO$@_9B4ZM_:V!;WF1-!B2-SH>E-P]_<"<G ?!]0FN1/5"+QH
MJ<_V]:,UI]DH?QV80YU20BZKZ*) C]!LBSPYE\J#R\'+9GGRK:R@ $AO*1,6
MP+'0Q'@K/E8F]DA)H+Y\:3H9#<U=!D;AE=G36/5^['@%,C%6BE^)5+&@>V-X
MX7BH-B0=9]56MW2-P@^^;C"Z%W$P\\7SQ(K'1*T-,#79+]Y'.!3.?AV97_SF
MI@_&/4I\IB9E;!^<H\('=6@[+?,P+5'^<MNAG,*Y.VON![:1MH>^&3',X$2D
MY_G.XBK-Z"KYG6I)Q7<.6LQ@FMIZI3\F8WXL!B2;(G[]0F3L[6VU:[&#&[XE
MO!+?<?]7W7$J3VLBC7%9<3]M[C'AZ=_>I;7]VW%E-?B:"F3!>6J7&<LJR$QX
M$=!A'&YE/,$><Z\5EM<QYG$";:#LJ1D\(U<#P9E(^FVO //V0W+V*8#H>W#-
M\LKA6E&>7=)"=8]JPJ8A!^I*SLV^O$Z(GH"#N*)&Z7[)R.:<Y<QF(@%YS5/$
M(<O>7;AW[4^>[UW)!TLVHT8&\NYV,X+Z!'^L&$=B+G8H\G%DY+MHKF2<HN39
MI$M.+;Q#<4\UAZ#G0YY6N^75['E2AT;"Y4\/B[<1E@MSUK8VUK;6]RX49&L*
MU2GR""=WF5=84I3-"J2>-M$97K,2A:_]21S1;%=^;CV]^W1-JMP"ZN\P+5@'
MZP1=(J"7\WL>3\A)/B*[O?;E/.@^%$M=789T++8 J:Z#B%7\$4B1MRMY'J?P
MY\>XNX/]\=0XD<*-(KPEZ'S\.#\EZQ^\XRKW7]6&7IS];VE;NDLM'\B)YP!'
M79*Z)$FZ1#90=JAN]/G)ZUXEVN.VFP_/IH9J;Y>-:OCR)<I*_&S[##?6>6H^
MZ@%G?5-EW<T]+S[A.*4GV@B;W(CLY!$1E&_K9_QDZ1/R?'/D3.,EC$65R0G'
MV\Z58;!"6=^B9XK].E?-[/D2RE4]I>J$5?[#&Q,QY@ONOU=^9_6G*LVQ>%AV
M\\1^&(5YO)D%Q5RYG3;PTR9P0/3K7ROGSP >X%.*//DTLMCH7FNWK]W>>+2;
M=+!\L/PA,+YRVO1)&?:@>LU-:DY%):2G"\9#X9Z'W,&M3:;=KPQ_^;LFDF*I
M'0CJX1[PJCWFPF"D$LAA!<)9.[9.,AS$=@F^C3E%LOC:+,5DA528:I4QWF&<
MY&FXTZ?F0AHYW7L=^:+T#\O<V;!X%4$("S0E[*\,[0[<UP?[AM.FL1D27MH-
MWN?:E\'3;.M8HL'!*'BGC3X*%"?A^UL*)+4]</ B)_4M,)#;WT21'!2-.YAY
MG2K&S)U9Y/LWN1IAQ3>NI#15,U>,S^E 3HNVMC#5A->*!T(T0GBNCMGTFJFB
MO\?IVK0,-.W8=%*D"<'80&C[U"(7]C368;<7V]H*J[\'>T) K, Q*6BC*(2)
M1-#'#(&L_E^6TPVQF$&HD_JA@-K#'N[5C3\\,0^,A _T]D&EYCA&L?YS@&_R
M:Z%W^(Q:R@YB>V9/7SY79Z&CC8H;+'/RZ\X!-?X=_1LS5!KL$!GD<)+F&';X
MYJ(6VGUFOQ7)[=.=NJ\S9@\NF$^;C*X<V&W7(B[%Z]1"W:?J*1U+UVNE:2&F
M8T=T]:D&S):?6X=EW[W^\L%,BS\^0'&;^5=%<U&G,T^VB*+$$/-5RSAM8OYB
M]-:2D<JFDZ9BG%.)[_>R(TJ%]U(-<G?L)W1H\4;"R4#(CR493H261VL\!,%/
M<V&KC0_7*P "_4#63GTL)UD0U0,2'6P&[)RG?B%\ EH\=);ISZZ3MN%1: I?
MWI=UU7K8!W"ZU.P,W+#G6\8K]*/:W.IQ(@V>A>" @G&1;F3LO!SV47NRY;ZF
M(;F09=)7<[%U_H\1RG96_1\"'?#@#N'Y.>#B9QA._K1 *Y@'^.FEM<!5;HM7
M:-&+;O:C[D,H6/I(Y #*,"/L@]\.C$"WY4^Z XH\!QS][XERL/9P NP<\"@A
M'(BUH#L'L($RY,SSS@$L^M2=ARS$J7/ +7<R@OD4WW(.H%[!BW01>^$<D*[9
MGD.0"#L'1!4!=XG+6E1*T,Z+\I"9(DHQ4VZU<)!3U-D07?NQ&:ZQE:EC+E:8
MM"(^[N$/[+B$]%\RFT8%(05$$X@Y*"SGDJ]XKX5=2[U1Y<R%J;\>#V_ JAK<
MVULV;@[]^DJJJW#XU-Z==1,ZB#?W&PF\/7_TJ[[^Q8\=0X:[D'/ 8X@:47OZ
MY1:,I_:KW+2KY&[>@6H])M'D]E^6Y/?-OL)9_@.>[%NWG3*]964%\K.2#>#K
M\VZWY'%LY1Q_"D0PLWOX4T%^$^M1KSTJ3:TP^=_2H;+B_S1S* V$.!&%H<.B
MW76? _Q-/I,;!Z?I;1J':K(.Q[_5JYY=/Y5JE/Y87(+L=+WIXRY+U,2(KV&&
MGI)F>A3GLHCV+:5AA[O:%E\?^;B-9QB*E[@?[OJ_\GR>9ZIXO. /U"A=AQ/N
M@';U7Q-U ^[OV%8:27=9RL=^&"])./K.8P46:+[H OMMVT_-=!D]\:I<_ 41
M^3[$+H8#[KYG0@#%WE7O?2LHT\B>J@I*G%=\+J?6R)5>S][N9,@;-!.H#@9=
M_!0A?O74DI(!+1KVO*0?/O"+K<U.Z+\_\;-/:&/L5_*9ZW/=$PJP#__K)11[
M_Y[BC01C9]7UWQT4AIN^*)6A67AG'(K#M/KPT8++.<#,[>$_)DBLVLS)H"*<
M>5O\[$2Z2]60\UN@5D^ZJ$-CX^]T2I #-T=8]T2[]A/K).<=!P=P7@4U'BET
M+M4 .U6 5PC/#5QUS!K[$^N%/;3IF21B UY8Q^9X (3?PXR [ZB&=6OI/85K
M>FY;0#VQ&5SQ2F6NTM%GSN_H91N3B&QLKU^6PRMX_U(8DLMW*!3(*H?D"'##
MSCHWOFC7_1K7=V-SI)XB_/JS3NZN!WC+:':.PG"*AB<T>FU2N Y)S+DU8@CM
M2<BBK=*S9A[M*YX;-VC;A(J56@F+4OV')->@ )=&9_:WO[=$[7,RETRKS':\
MCZ" @7ISB?;Q[O6C;]:/+==BS&.,2HP>CRTTG0H69$3&J#-2^HW+FZ=@S,W,
MZ[%E%\I=;(V1TO3UDK%V[X/>_!B!N2Q]H"BWV#R8ZZ$P-F9L?AJE&[\)4LS^
MYWVGF^BP-RAL5,5(2%965J9?1DGX+,-II05&N2DI*N!<7ZQT4D7*=,>IE]BJ
M37YL<'SUO?@<(&T5E)^V#%TF477QP9'$2SAT59VR9:L>]=7_-"V2EY=3^:1L
M6OTURXH2;WR5D*]Z[:D.T9G2K7Z#'-LB GOK;!*"U!E7T"MP=LPTV[L7>$5I
M[M;J)9"'SJ66;]0+/H0N!E4DKWQ30"E\JJB0%V<R#,F0&)/Q'VN-,'=$L%'*
MOCPL):E\O7J/;EP0:RX=AH>QP^RDKRWI70]!MG?)@_6>K.5-M^K2$4>J$WKQ
M<*Z[?[W5^09S4]"%&T]<;_O-5OL9@,!JDW-G.7HY;T]%N3WF#_]6)1799KCI
M"7\;;3+\,[CSX@3(91 \M0LDT@0DXR=Q_"M;)WCE!Z'YO<4_07_;]80D[G,J
M:ESY^W#;#P[*%.)8_@T>A[W-F6WJ%*QB[G(DZ>66+&@)VR\2C9(>?5[JA(57
M9ET+-&N[061EW@V<]ZQN,W@W(%9WXE8!/P75'K5L',*9^B4C[/361[QR88&B
M#NZI=48^9;O0\G_;&WVP@/ 0. I[)'LB72$&Q8\;4L\!H#G?)*7>J,@O7W<?
M.= D!4V!@XDF)%:"1>-(LRL5ENLY9MI9M?VT*KTI*,5PL[=;9BS6?)4.HT#T
M)6F32VJ5D*A;4R*(D1FD;][+:DT[[D'M5;J36)EOHYQ*6Z%= 7N>H*_/L'."
M<;9S"EUZ?4>6<^M'Q)1$HKUH]]-J29@9BD3+SCF:&G<Z(TZ::P(&J:H1+2%\
MA%*80((=.N'B-H(K;DW'?FHXK5Z48,I-ZIFFL89U+Q%NG[0AXRQ--T@F=;:"
MXQ7F)T$1L3]&=4%9#[H$GO,E?^OU)OP#9#5DB/6%C^P3A!"8F15W+D+W$,KH
M4X7P1!FZIJ%^#%XA+.UYS4BBC#;;XI\H7>&D^W0/Q0>&%+EXDUXO L4[GPQ/
M/L$[2;K[YAU5[GGT1)WZL[[)2]FHU[7-J[&IJ#C2*_*#CQ0UX(8PX<1; 3%X
M)4+^HL DC[O$WN>APFV9W)?[J$'9>+]&+(^7A^[JA\L''@HX$!R)M1*,F%2_
M2TZPGRJ,@RZ@0K1G@P.!4686G'2@W,,+/25AL\@;XD?Q]$,E]C-O/3E:%!$\
M@;4.L SP.E1A!<0PBB)MOWRJ0IY/^N)>JK>D3<IPNLC^#/0*&O2_I7EIPK38
M+TQ"KA$:BB',A&_YA$S]Q+S&,?NK+WP2@5&Z>_2877&\+/X1^4<9S G^H1'T
M27)!"ZMQ*9>>.#S8_. A!:_ ;,]!2,R*)D92Z(N9HWE7M%LFPY$HCI<R$$&5
M*].G#_ +)]Z4 :C3BJ%F9.?:07>3=OZ#D G\Z1'0&0N*]@R06.1Q>9ZB7%[$
M,3*W<NH+U"L]0%,8>\X!M+W5.)V. ?V5DS ?/&6^\C=XP8_>3G#KFO(MN2RO
MO_POR#P#T'#(*X)[1<#V.< HV6 R?RRWSCU;_DU#WUK]3H^=#7/"ZL@N11#,
MM"(MO.DYW4_.W8"5WONH<DBP1^94S;][*A\P7G1H,V5'- G7>YZR A-971VQ
MB<30 ".EU!4"JHSHRV)0Q?)6$6-A^(^]<YZ4066'+#O5*4%0)75T^E'B]+_/
M;S_\1E,NXZ@3)N&*2.PZZ#<$H_9^_OB<-Z6>Y6#97'"(R'P2S3U:3K\;'Q]J
MO&&^<>GU\C%9!M;&!GRK#YQ1P#-@8]T=\# 60ON"JD:Y;B]MN<3V=<7I,QT>
M+9IQMOFIF!S[!+I'6$+!CW, ,+$_IC-8T:GA.=Z8ZJ;\T"%0E8D4E5/2UZC+
M3PF]L)]0?5&Y%"@1W>"8^^Y:U^$_Q ^</-V[ +J\'236)&&F!U68*Q+GC0M&
M9>>H1<FHU;:4N_73W&U[)"1\E_85_!GH"PQKFT 0K\C%-77Y@^A:!+;3KL,^
MR@562*KJR3<7"$_LO:E/97/KM#MA$&)"Y*5?"K"%28,W/" J()Z+()YG"[N-
M<QNG?#Y8KY*&[;Z<B92ACISW0,30Q[<35U.P/2O9:6*UE>,W(\9,'*L_]%87
MVCZ@I>FX1'OUH_GJ$HGCD$+/*+B[AK+17_%O"V_YC4W-+@P!=50W65L[R5RM
MUKC9W\=P_,[+1MMP7=#_$+8,[T'R0 >ARI4XT0\0K9( [Y=C&_J?UJNSOOM9
MO^>'[L9$O#(-I97]YYX!3!^$U3\'S.484,46!^WC%+A3CZB-L45(YA.2C8RO
M>-J(Q75*&>VMFEW]CG?QD\\68HSI6RT=S4Q1F2DZ@_<E*_O>&\J6P@'3@L2W
MI0D2@KM.7+M:1$]"9D>0#7P&(EWF.EG#8>RG Y91^N29L- K_)!.R_08G@;>
M^S6!MOSBW.,DGEVK=%=+SY=*\.KN_)]EE__<3IBG-?&K.)U=69RK+^8?UTG+
MR!3WXME?\\D/1>*U;QKQ8C_2C+NIUY)%(!P$1#[)GV":&]#TJ"%^Y^F4*^NV
MJ.:W_(1TYL9?8B%=L#N^1"JDO30[%W F/0/O9 7'B9)NFH"2<R^W+34QKG,?
M]J0T^1NM+(!XNP)#E)Z=_1G5FYL\!ZP&!H9S'Q -B[8DP0$@4Z($15]A;W73
MR,Y"[FZ'YU0M-"A@(Q!TF[((PYH*,E+^I)IG,$=>'^JDJ,=KNDUJ9>[.6KF8
M+7ET\*"Z6:[JT;+6R^_":G5Z1,C?D/;,[(0^/+E:;VQZ5OPH./*6H@9^\8]1
M'1C;C\H)/1Z:!:&S4W([/&]/-J"9C'5N_^VLYDHY%*X(7N:TVV4"!-%%J:M"
M L@-JJ:>]HU%<:HV<DLJ6Y:/O<CQM(,7[CVB=<Y37.Q0SS\NED(N9RX)RHG[
M4=%ZN.?*NWL)LKX->B(D#KX&]59[I /, 3:#[@!6<W5( MM;."OC)P='+M3G
MO#K<7V]EDBM3/T0@-=[? W L#M.A]ML$"7?2NH=FV+J!,U.S=;4_+;<.Z.&J
M:BN@!\^X^0+M!LB[M%<SZ7FZ-;9 Y3E5HAAO5,X<+\H%*H3=C7/W9*3WE7Q@
M?RE$V<7!SF[_[G:%XNM-#9I$,A+V6HT.WT6P\:=$N;NB71\LY&A/_!/^6;'O
MFNY2%YO />^:;QU9&P?[E,L31"UG8)4@QK>PXL>AA9-ERA1> .DJ>H$CQWZ=
M/^/NO9F=]QT-WYGGH\42(N6)1IP!03TO?J6[2?B*!^R5K]DF:6_S&*W0EW8N
M&].MP#"5Q+>D)[7D0M)K<"[I,:X[N7#:>:JNTNKESHD9]E;!?.O%Q\F.%_Q"
M8ST &-LWR%ID-\)4:,6_ZQ;SC026I<-S0*)X&F&@#!G3(D<H(7KZC?N6-J2)
M J'^KW=V0,-&'9+L >XH9.31&J]9AT%='0UW=V\*K   989U6$&HV.U')H[J
MA@SBYX#_:I.(Z!XZNXMD1V)_(/_M74@D:P'^;:9(^Y!0@):.%J GA$K'JNJM
MN+,8.(38IPZ5.;,MU(C9??FE*<[Z_;-L?#W'B<U_-"(Q/>97\Q6'29XYR+^)
M!JRXNUK^0>6YH^3,$+$3CW_]ZE[A]=^*OO-/VO]O:?E1A>A#T&P8/F/X'/!.
M,'*$D-GY(*@+$S9/_JI5V,67[':0GZ:8.&SG\E3Y6&A;33* XT"4Q!F*1+.Y
MPG:E@$?Q>Y7E"AR^"]*_\R#R\LK1]U6\J5R3#4L)*[: QY 8<4:HO9206^T9
M0Y]\.!*>1NLH:B4YOONB_1++"%!)HI,_8NVM:/I2;,;'LMBB2ZX'.B&IC)6-
M.I<X[U8*!TXGDN2ZLL]M)9*2OW6=?]ZRH//DRM8',Q%W"2E&3B_ W/SR"UBM
MUK]?TM&2=,@YS6S+OX-V#";D=]1TGB!]L[XR:%TL2O=H_1"+NY&29Z_=P7*0
M]=EOX6#.:B9P"S8&D\U0<%+?0JR!H?XD9CB@]WN(^/I^5)#PTB^%W04<8U<=
M5)&:[F+E'6JB)( H\8GXDKH3K>:OM'H?&:[KI4&5PVF/*H K_KOG )S@,G+W
MU!?':T#(P;&]("2BR&J^W[3;SP%67-<YYGY$2>5R0HT3^J>%Z7]>^\"U3I<1
M#[;Y7=-T? Z0*OBYV%_ZN\6,M!<BB0M;T>IIA],,E5L1O$&XQ\,#5S2-1LI)
MQ ;:I+)W$_?O_^3U#KHH6B0_Z: (SX"Y2L=Q913M,G/%061*G"U59X='X*X5
MY:+!5A_C5[:G4^;C&KSB7[PWU!!*M,BI$^V>=D,Z[E\FW6\F) IV"#(-%!C!
M V*>&[SA%SAP[#@UF\3:Z'TK&Z6S-V7H8O_6D5MNWDBL/1&>8="K>%>;3%Q(
M*&%PVR&]2!^ Q!&E2![5V 3,NS*(T@A%9 "GV>9_QAXTF1[B7=Y58>MT G)Z
M>1L1_&7U[F(LR\FU>QH\-Q9K1TEZ1$?H: Z+BU6/P'TL_+VZP(+FCQD=5)P1
M46KEQ/@@;+YF5*RZ,?=5WOJSUE.CO_IK0?(3H-5OR'OKYN"2*N+$.4!H\QS
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MNBCXFL'!2'GU4ZFHF;6;B6KI^)XK1B3SCX4#(JS9]<B9G5?@*K<7?U^DG3,
M,@6##7!D6<"UE),ROC[,PGT?>E(>.&.>\P<B.XRGN;MT,3'89$RB@3$-<-_>
M"9P^-P#1\"B)=>H>$:?Z,QQ'T0 GS0>S]"FOJS]\"*1#CT?=.-#D3T@(#? C
MX,#K($'ET\>QP_/=OA"?:.4GR8PB\3HL;X.O))V67X;AC'=B#'%(@BPQ*+<7
MF.'3>"_H^0T>(;T]5<;]VTXXI/-G]JQP _H79!+/+"$OUA8]7[!:=&>$U%2A
M&ZIK7"5M W_DV;?XG'C[^;'32WO%:-C")Q!CLQA'MR>NNZVRV)_D@IPV?N#G
M*FV,<9C4!@3+T#%]X0.0@?R$#PMF\U?U^YXPT3RFU#,@:/"9!E!:![/#6N^@
M%Y+F<;G-ER,PD.C#S.BBS^N%;B/565T<]M;WE&]W++#?EA<PCUYA5/;V/:XS
MKY%2$0 ;UU<U)KK6-B9^25>X;*ES\J9&!\=U1GPJ]4PD'0^H/:#S;H,'FR5Q
MS4QE(G!?2,J\8[V9Z+6$0,D[.HR%5Q"-$H30L6W53:L_46/W71^N;?A=OO]#
M>$/B:)S8NBB'X^Y$7'SJBQ>$E]A;BY$J^GZ [D@<>A*$\1?G)"EO47P>W)+]
MZMTQSPXKE"4M1.VH[Q@VWOWS1D13Z2*#L<V(I5&E*_7:HK;?N3^ZKM[628;V
MXS6RA0Z*Y#VMJ&*YOR6@#+#_9Q;8,P4W0(ZY0@.\A*U=:YSZ;Y7;__5RWBMK
M?K#E4WS;,VED9]JDR9U]09W)@UAEUG-I\\"C[?.)YAU"''&4O96.OMU"7!%W
M=^]\ZV)7U63*VOU.]FP9.5"-X#/.W-C0CIZ;94U1]=?F3P6SA#\GYBIVPH'V
M'JS67DX:YM6PF3NP#P?(G\T6&/"66M6DXPIIH\YD.\-R=S(4\9D8T;:CT!VF
MWWMH=@"%Y%"L>S=YJZ>V2WQ#?*^F+&WHI.NH]RC+6\1+$+/S]492BQ0##YY1
M\PJ,;L:__EOJ8';IG[9TFXC*PZV6"/RTG6U3?OIX>SK\35PWFT\[D7-^M"G"
M@WU2>,$;@>_M'E<(S1O6=7*"K#9J[5;G??KLC7WUG&@YAP+B.A&O_4_[STK/
M2:@:6)'KA;6/'I[[&'2X[7G(?E;MEG53DB>\[MN;P,2#5&.W2;%#1&KPRVZX
M-,KV%55"?W?](BD(]DH)$0_B4E,D29*5HV^QW@HQ.5*!(IA_#I]7#648J:#H
MK=)#5")0(& ^R6;#P9-3O!UPEJG:>O<))H6Y2"TE!#N$2B-^()WQA'&1;7U+
M/:AJUN770$)LU[>B5(7855^ CBF>""#N@1Z<_,L70VT%4VI1=?!*J.RO@@,U
MP<O#;5T_;SUZ]<? %2O3\ S^<8'<&WV[,,*-$XRX(&7WT14;,=1(FMLZLHD_
M+J$*1-Z@ 3X,@<A<,,(4:''B-@WP>QU(94&3O*#V-,#Y2+K#K?'1 &(Q-( (
ME$Y,+\C&H->$:0!1Q!%0?-P1)[-DAV"A"J\?Y]  );>[N5H'[C=WN%(NE4%_
M(YAL%V3@PK]_%5!*_MCD#WR\LNO;\"D0.S.K$# 0NNB)B<A6%.Y+*6SP&$HO
M7I]$RDW!0O9_!MM-,_0;[CTJ$NRW!XFY'>;NYV+<7EDNT2E_F:U!3&]RS5E[
M0M],.3Z&+IPC&,!906//W<>K;&=T?@]X8_ECVUD3SIW66(@G"1,$*?E>9-/%
M3=AI3^ZSY\J>H.Q3?\ PN^>5'L*:<Q." ((A99 I2\*-*F)+84_9TZ#SZRK+
MD8<_U\+?5"6==4J#$%XH;ZN.[^OR^?P]/B?M]X"?K7ZI4^_U67"3S8%AB^ Z
M(AZ7'4 M<=IT4<['&!EM6 1N(7(M1I^-H<#G1M+3*\'_KL\7+UQT^13WG7$F
MD] #6T" SS]IM!KU=[_0^+/.[>GQBA;T;DLJP8<2?97H7FZ[.2?4&/-H5"II
M,^RI)DF]B0: B9S84G4&J)]I!;Y;=N!:)<XX/QW]O-Y&W<\K3=D8#YKJ7OM0
M%_M!@8]U8ZBX6']*1Z7V6&RZOVI2XWRP83,;KDIKR)D&L"Z8U#Y+N9M K<'!
ML0%+]61[DB;QU5-[D>@I\QH=!ZI-%(0<?!/Y#>2.F!(S)HHM-'WAQ_67S]R(
M'IHXWU=^Y^A]H#DKN[H?<RCYJ+DIA;IM_34PQ?UCCW"=Q3^-)"B<75N'9PW.
MQ"R2)5/]MY;3FXO%>T *68&[&A)M'[\VX^6K,C=^6IKL><W6K.18"N?$2QPU
M4SK^!J"&12P+IN-XM":JU$NT<_BU-F.YYS;Z-9!%DLH5;#'VB\O4_ZIY?08U
M5%$2QM8Q_H;:#3LKM<\FC>EJ[)IXDL@R]8&9I669:B4\,HXFVG8=6R8^=O=O
M^N$]&(K](9RBS)S]>?R@X%4SQ[?WQM@$.UB(Z2)Z$@ZS/ +^0EWW->U8@E7Y
M[!Y>Q=N68-?>Z+:/@::934B2(._)E2,2-*+YHQM>?H\=&XFG8DS'O=5D\V:\
MOKUDM2PM$'*;.0<Z@4[RG 2YPQ)NX!#?.:IORQ#R"4]JC#;"ZA:3P>P#/N//
MJRMEU5($^KJ+Y#>#<SN-$BZ91Z7E2SF/:P^&'[HM*/]2[@SC@8R3HP>UN8AG
M=A?_2?!P[2MNF> DVF%\X<I+GA&A/5\]0Z[NNNGQ*C_^$8X5AG]_I5XR]F,W
M=#);6DF%[88^ 35U[5AL8JW=<<4FIT!@<J^?Z\#M#6CA0[EHNN'9#HPK*(CM
M -G'WAP+>YC6O@'&&0-C%80/81-!V;]GDQ$D[*664DN&U?H@]X>0H8'=9VM%
M:4M/#MX<>03;6PWY-QST6TS]'%-(_[-K'BTB8#_Q@OF/Y\P^@BAFF;033\E9
MU:QTH+KT5K&W/H2/M6 (H91X?\BKXQ2/PW'#LLWDR!7]P2.?:;>B>SVJ%5U+
MT!>64(/%.4@\DLLFZ[5,27JZ_;,ZR+)GS$]?SI1'B1F!H0.O_:-P=9'^TY<<
MW_#=7W*:7KG#OHO\A9B2Z4Q'*1%[2CW2_233#QUTNDS?!K;R(D8-(ZQ)+M3A
M=-BYYALABW3/O(:_]#F:>S<K:$(8TMRGJR/\0F4/@6ROV8?><'OGME59JFIH
M.F:QAG5N>43^U;S)R=VK(Z!( US)B9\C.BZH(N-0&D/[$@_G7+^H=%G!>N4V
M^HG7Q7#('[A],8=2=U/+=YEZ09![P;?>I)K85FW0 $0Q2!MH"\@T%UR^(55G
M,QRB,!TC<4+0F'RFZH!%XBR5Y08^_;Z,__QI]T,.G9_1V^3<"V]_F@AK?"YZ
MHEN/S%OVDEF4:>^?%RU/^SQ).:'+2P,<H%7($\143!@B3D-U5+ZW]&@JK=T@
MDGQVT!+WD'D17(]/>^JLS"29'7GXI^5/DY3M40MW\O[[(TGI2TK!WH<4*,'Q
MKT%I[EW]5\90QU=;12DSA.OB)5<E0) <Y+, [#LRJ@[(189Y/BZ>=TDX&C=.
MXKA%%6/$(^O)7(L28,9@FV[]*O/[DDNG;\T<B.%%,O= =&W<:@/9(N$:U;7L
M,E7Y^@V>9;!?$?DB+*2AFO0<KG\@<RXXO;NS\9'#>MVM65N]M^79N4F:RU!Y
MBN;B/$NW9*NDH3EIL@2UKFH-^T (<6"?&%Y-WSFNB,',/F^G 4ZI290%%Q^K
MAEU_MN29]>$[ X+QX!KZ,@W@#I]2M:;D484]>.?R1=Y Y(=[/9^!_::OLGS1
M'331\5&Q'$;@+(VG]J@<- "'6/LG#DP@(K\^PS1%X<@UZS.<>D)V.+(1)8#<
MVF$+MG>\.0]& J%AL !8%NA=\U-,QGL,K/);"F54;,?6W0#9\XS.)Z!Y4(Z_
MM$* *8)^UR?I].>5HQX^\$_W$G>'Q"5X6\6W+(.A/W8*Y;I"ULQ/F1UI "G0
M#(D,(G/H$N[A#K&:^%0S%%[WV#5U8>US$_67!*GI2,3MM AHKS^0PY)8R8"Y
M0FT(1M\;0:IQA100 X_'M48<&+D^C:3#W.-_8QB:/Z\W01SKSWVJ1_Y0NXNQ
M7ORZ6\JWDEHG5S,H7[E7-5K6Z &[2]1=+%/SDD>X7EA]!4GA#>M7GYTMS:PT
M#D+%)$.GYFMWZ/S^"3RZS3V=;^>\@X[3D%SP>XD^7;YIH)\H1@KNF I. %^F
MR@7#"2^(<; E^,4-#@_>\L\S%4M*YR,F<AWB>%<9=!N415*/SV# Q*O(6*@P
M,0EC,8Z2-R[QL#3Z=<AMPWB_HTKVK6S0]YD^GYNGC)A<V(F*2TXT@/P3&?(U
M.)TK6+*?_M,LDVJZF@8-K23F]\@TN.?LC&9G )?M(!T!:4J+ FIJ&CS/VZ$[
M<Z.$K5J0\G7DX  Q9@IV+'$!MB@'.Q*/I%L&R8B9G!:+QF6"R&E@3SH5 <:@
M5VD JI[,+DB!!HA5[T3OGZ4!4NE6E )2OA6I'8BH-FX[163"5W4XG//2(ED1
MH5M3E&^:RR'$AT'/9J9#]V<\L3)$,>8M)MPFH9&2 I%N-BR8U2QK+[73/%7B
MY./8$'6BZ^[""I]@4LQEI2[/L7YBQIF,A5QX49"1H75^67;1Y#29#,_^$:P(
MS'(U_5EH(_\X/T L?VEK='1TITYK#U,FL+E_=BF&?%ZW(S-\2&]AGF]=Y>.#
M(X,(ASD#G<0(UN0X1F!$/'M-R->ROS*,./O5J:<.UT\#]-<=\F;/L(/GA/#'
M>T,--V<"DL?L!CNT0^= F;JY"3AT'&[8)YW#F*R00AIVZQ&+W+0?V.K%+9&6
M5K',"S0 NSM>;IPWO>1$,KR)MSZ$AR0N 6Q#?<;)D,]7+44W%-]MW&Y9M&?I
MA.^(QEM[KQKGA7'9XM]:SH$KC<F<-,!W4.6Y+-8I]2P/0>'=66GYIN^\&P])
M0>*8U\;)/KD%RB(IQE$=#L(N[VX.%;Q&5!<.ZTFEUB:VE"V7#Q31O_VT;+/#
M;2[?_5E>$_<Z*3Z]DKRZ)GOK#2!GL[$GC@98M&@H<=#C5\ATR)+;;?I47)Q<
MH4PN.<)L>.Z74%D.:0 FP- RKFRU#7UJPV1N;EX)#FZJ\QJ<[BBX-FO%S^T*
MT)!]P9)M#,RL+X>=];,A/N!Z8.Z_M%$]%#;YC!H$DY!%=@N*M&'V>*WX1=ZE
MG1SV- _RS#N>%(7=I).. V'<[[]5,GYF$>[7Q>3GH7TT *,\^Y08YESJ8M9)
MK[I'S T9S%[-5Q+[(AH8\:6WE.+];^C76#[M5)A/4<%9J=0WXMI-_B* ],Z]
M"$/ZLN51XI]!A26I:GCS-X:.GK=ASCH8OJ])VC#%-18G@3UPGL.CH[# Q/JN
M6UT2B4.B.,36YD*$L";W^?70B,3&5N\H/>EB0,_4&;$DO1U[2\+LET$:H%IC
MD'VB&2W79W>ZS4EY0)]JM!1^7.Z5^,F5,CTE44D#*#;M@5!$X.NGRY==U"0Y
M5BO],H+&EY'.P1#L(LF8"".<HF3(#W")*(P=EJ)=AJ6$K[+U#T=/J?L G#X&
M"M:0MZ CP&JC!I)9N.\X&;)T-B;ST+K![9[K[/(]#2N,X,^7NHO@._18[X*&
MN,.>[4Q9+(WK-P;BW%YG&TC=,GN;(96,"H?5U/AFOY?'8R/<SJT8G-4T2SE<
M0:=L0;]$MN_J?OA[2 LR3_75?U2N2LS#'M.))20!O9!#O8WGCB%S%@<'&8ZJ
MJ1=(Y[1;95HYUFM=,2P>[+[*]BN$YY K+127S_PHM])>[]T[\Y6*!3/+V<QN
M,M\;DLEZAB>_!B_N5U[9M78I=*Q4VL7G>\";N4Y)[6I)*A@449D>+EK"??'I
M1=[ACDO&)X-E#)U(!(.X (F)&-(MG1(^J*Q4R.XOW"V[7WE0$O6L*7=\7MI1
M\M'T@@Q@$WR1[)E/#&IO]!JK*/>TO.'NY/(L*[\^[1?7'6K!B]MZ $[P"-U)
MN@GFPS3 8]!$2;L&:V/FF&J98/\!FQ^.7^?0S]4V9@86963&2;XND4UYA5YX
M!SY# RP@'"[!28R&]I".:>I@P)*A@](RRNUT#ZDJ09/'TH?K5KM )UP>!R-S
M0^A3RO<4O#R*.DT6'LT=T9CA'>_4N%+U5NXL4+>RSK<]?5TX"7"D*5(!3NUV
M$G?CRHUN%_OQ:1J61;FP.E:*YS!;K#BB8Q:3"J4$MEB%]D+P!\_-N5\;]):F
MMN<R,RY7O@CQ=9K\-O3\E[/\@ID)..QN@KMIHM)66L:/@R]<%W/HBU;&\J_6
MH/]<?CI#W\Q[9?D!*G^RP&!8*S_Z\3K:2V;*8\Q+_Q28F6CL12V08*QT8U6K
M9P!V=$NMOY8?B.^X&R7VZ.N/7WDC3OW".W2:=!5)YF0!1FJ<ID>!3CBWU1%4
M8E1JM?Y;M/:?L3E'GCA4&8\K%BX[A=;;D)"X[K^I5(;%)/%<T>3WS<%:C; "
M &N I7SDCUL34^^+?Y72(TF&TY]-\P#1OFXM1KO[7)9BZB7?AJH/ADO';HV7
M $W-R/)YE/3Y_F18B-@# E>9G<Z_O3_EV@-W@8GBD#8:X 603UZ&D5@4KE<P
MM_[LC=2N52G!N=GDYZV*/D2@-@V0'J%)OJ/Q+@<%;J;C?P=U() 0?0]?-MH.
M,$X3C('RD,)_OQP8:P8O[9"YI]N.S3@U%\!,F[R=W>D_,VR:B]Q.Z)&E5KJ<
MW1SR7@UFW^KR VB\IH^3#!VK!57"MU:*[73]BY80Y[6N(7)L2Z"XG[TU!=V'
M3RQFC!]@!3JA3^D>>(T&<..#3YTE- SNE%]QKP:=:MRT>9UTNW0-YGM9HTSZ
MG&JQ8KYO4!WB$F@A'UTM7F& Y B.)[$4\;[?JGX33@/,WVQKV @1.7#UACT&
M/0%.[.E2$J!LML30KGNH422/W29OK.%7 H8'4Y_(_#-W6&37$!#&5%8:J##8
MSE+J>_?+!;/'XB]?,!EJAX_334J72 ,LP2>S",^J\9:O(>G=%K7C94).(A)R
MSSMZI8FS5H]+'KOQ"!=>6?C-//3.\@^LS9@H0VG3X]=0P['>OBH<\2?2W_S=
M8[?SAA^7EVF ,IZ3YT+'ZX.?4\]&X!1M:_:D"_ 6233 WL\=O9EN*KDY\N S
M^S<)YB5+>/5\5/:),36]4CM=S_RU]!0'._UN!O.+'R.,[ZBF,(5G8=B)TK!6
M!'N,O<9 E\U^UADMKP)=5I>F$RYI/!%WLS]M+B*G8Z@L(1B9:06FWY@:\%FB
MNC,'F_B4DUQ&DL:FL30WE/WJB2AF9M8[<@P+#E=1*&(%7M@,55>3$D8)/5XZ
M[(D+NN7FFOR"<5AL%[G&3(C ,9(EB-QTP&/KI39I#6*?Y:^"5.X5SQ-Q\KA#
M,@<W]4QW83#+.O1Z,,DP9>!AYJDW=X?*<SO>Z@IAPSX\W"W]J5^<?<=5Q$]B
M7__?O*P3+UTKI%,'WP$V1TAHF:/M50;S0&%$W:)R#7>;$.OIG5L]GT\-_G-L
M]O^/I)]X"V5CG= O[&_2W5#".JWMUTBHG'K]59X&L"CK;@&8-#=Z-D4G-[C*
M"W"]P>SP6Y-!N/X_^6%"I8&#ET^D1EY= QRG,&/LB'WVDE*7+9&B/-H*TY.B
M#2@^]D<M]P?SD#=411IK0T#83_@WU M@5F1,J>MT1/%5V32U[@N8@V7+GKSE
ML>XDLF, 9H=KWF/\F8U!T5F \:S#"R@C%QS<^C&D,TUV:RRX#B<3*%%I&SZW
M1:U?%!2,-LEH/X=2+$4$T@#:W_Z6S.B._&M[DV B21'ZFXVD'IQ)>F0OXM&U
M.Z.YDH40=N51>%Y1-?R5*4R1K+:.IP&$]&$+\W1X'?_I;SGMC!)R.S+B>HSC
M.G+_.F57$5H75&*($,OT,3)\OR0H<=D@T[L'Y2Y5;7,M8R'"FDZJU%*IK]_3
M #@O&F#*';:X6@G[G8(@TH4C5GXWC6L+UO%D"7U,C_0]5VF ']DPLI:&  V
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MZ]FFEB"O;$72@_ GJ4MHN,NN,V2KB7-Y6LPILA?QG/P"J9P33]7KVV.IWWJ
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MLJ3N)<]DM?C$B;^.IZ<T\W_+*/XC65Q>53J]IO(_V'OOJ*:V[FTT5E1 I(F
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MLQ!%@$,[?&)KP.CA'99A4'K4JN#%%>L75L-ID\T:?\1V% 3;;GD__QQ')\$
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MT9-CP("T:^"CP[K:-4)-#OK CV#O, 2B=P9/C1I#2A %A9;)R_XLEG=]H/$
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M]^U/.F[@V*V7]X92TOXL;JI\_0H9,U_#LO2YKXEG>&,0QG6H&$<UQBY6GR3
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M_]IZMDT=KA]J<*XNMK%9. &_UR^A(SFN:#EWV>UV&O&^EU#"5M:T:0,SEQ7
MC24]@!S@1M'Z.S#[^U3C3C!KZZG0W=8T$8EY8<FNWH7,Q-+6Z"5SA"G-Q=/[
M^)T$9>$CJ4YI</7@)D+9S8^1//=,]DHZ1P3)K=X!(;I'>)(< 2:BC22]?X 3
MP(RR8(34*"[DJL)\/N0(3LC05VCB+M]PHI8.5G/)+[$OQQI<>)/00ZL0'Y$C
M*!>H9"5PH#T0ZNI/?ID3^>NQ4Y_W8Q;AK%[]92WCSGS]B\_.?0^A"\E8<_X
M"+81R@KZ-%]&.E\8* F(5*5'P&D+LV,<R#%9/-GU<YI^1;#D2S7$,7A:OY)O
MJKK8X<&#\I;=_5%3IQ# Z:[-Y:6RGZUC[:O)"LJ#IN?]5Y3V"YM2;#X/P^4%
M^K<=RF!%)%"5P%S_A8J26FS(2@L^$:-<=>8QZKN;V-CWOAKCJ=@)J"QDNO!_
M_CB .^HRCSZ3VT.^O#DV:@AO7>#3=;GDTQ%50[(3%YN>.VCZ>H5DB/MFG9ZM
M\LAXTL VXQNLJ3BO=THCUY(9&Z=G%2PGK\.&W4R\RI@KJTD6L?MUVQW:D-S2
MZ_GH*E'YX]FB@\7'4^4RMF98<<#' UC(=)FA)K93>S]_PV)(>]Y$.3!F<Q =
MD",P,B*>8Q,J_J9U?;E:-;9WB%[L=>G[69,A@I/9,407YCGO%&#+#N!$#+=8
MTU;)YNU$,>!34.^DU!*5\.1ABZMGE=G^;.&7HX[>>+>KM.^^L\Z'XET.RJC^
M>OXNRZ^JWNT1;TFII<"]M-5M6WF3!!R8A__!ZB;:[;>F*6(0^K'"V</HB5WK
MA1'_Y?OD1.NT7D5]JGUL^(#H#/RKDZ !^# G6.>9F&33HYS[(RTB;Q>V(S,X
M4-$AZEQ9E9^^M=XW@491D\J)R;ZL-:5G!G[PR==6<0/O%%*G(4]?<*3_]71:
M(!W^*P>6B"SH0.]UD[:K&_5^MN1DD=+S-46 /';FR_E/5]:L+W7,*MTGF@-1
M;!-D+^_$2P:E@PMI,U5!R'9,VXFXVE";(V4Q=*>5FXM?K6=@%G:Z5L56WTM"
MA<Z:+(Z\+(E,MPX-;:7T7O)4&8YH96N2OK%U:%#Z#*.'*MWIUZ):"\OI@,FB
M0MXOOE^8DAO>,!(1*6GC]BXZ9C:NN?I]G9:>#-6X>,4@37P.IX-EC2.>[X :
M271Y&%.Z6\H0W(Z-1@LQ&IL%W<TE;BP@D.0W']._W5[W]K-M.527^=CI='?S
MZQ@F9B+P&E.UG93",V#&?G+BF0".,Z--9%L22T-!H. N0Z0S-'9Y02AK3'-O
M9HC:;$QCVK3[SU^74W7.G1'-O@ FLUGZ?$%# 4Z-=6*2IF08Q+K:Q0+!(-)>
M(-V*,4+[1I0#HI5QK ^M=5=>"(9IOW&^Z>K\M7GB;ICJ0665UR&V&W"(,F6;
MG0 5RDKS"VX=X7'ALY$DIC1K$_!AU J#_,>FM')O,%5>&)O!BA?0AT8WW.Y/
MV&U9DA\M:\*5F]['Z>S5#)2X>-[KO+?W43#C!H9<:_<,^JXLWCA@.K=\H^ (
M,J6;8L,P=_J0%VQ[ZU90P] UB^ORU\9$31TO7+3J0^V V#!_,B*98U',<6<\
MA#98MD,3QQ3VG)F7)<6@Y=R7WBV)VORQ5DBO],/Z!$K<=/VE3R/$/_CTZX'1
ML[=DDPFZ73>F09L.8Y\!#M#T<TL7\I6!0"H"<(6(ZDY>X/0*VGJ_X?4/T5^N
M8%ZZV6(,A>E]"2_ZGG2'A65IYQ$6B/DAT##COHBO$U#W;9<Y#!_/)YQ)GCAR
M1W?!?IXR<KV+J#G(YPGLMK5YUNBVY&;\QA([)M'>[=;-U(<U?T@Y^KZ:U^I[
MFT[E6+5YG7NR [)%YK)6@3M42!1: G@RI8F]P^C!*B5H"W]Y^],-YIA_/.V.
M5MWX^'B79E_G4\GQM%/9J9ZIKT]=4?S#%RMQTI3WJQS)B!EH<HLYHY^663%-
MD43J=,B&Y-'LA %]=J=H;C.4;IGVS=)'@J#T+D,@**D]*4$Y31\9!:C&[( \
ML0D%NXP/L/60$TZYM+%_ZE9H"CFZU'D$D+.L8ZJ0IBF E=ZNT/M%=FG?.3;'
M L01D''-WVF*)TZC<&>CK]JN(NYL0?0=3]\<>C]$3*"'F\92#* ,^X)G9,PG
M5TP\.1:KH0O=8UN#/6Q;L9A),,2P'A0^LJUH:$U #KJJB7DT='VU_+T16=4'
MXQSF-J"/\7X0CS.EL%2ZYYV&48[J7H,<8@9-1,3?]-BPIF;IX?L?]<G/CUP=
M7:UCGJM(>NG1?#P!R*(=6*[7I=0W9-90Y2 I[A<^,,?^76-++QGDZS.&9=%E
M8?*MK&SA+F"HYF&-PN# B89=?7W5VNQLI7N>7JG-JQ-0U@/F6 ]D0GUF'S8:
M/WG]&W*"]=^PL7K9$ESHG5]?I34&DOIP\^)#L5UJ\(^_RI=_MEWX_C@@):>Y
M8<&W;+WYQRLR"PU-)% _KD(%,=/%!0>(>D!-$%0(2'0B$IN&'FTDG^JEPEU&
M*9V-(=6%87\KYAJL&BZ[S9O5A6VJ5VG]OF?7@Q'DQXOP/_1=C )6#!!?@0H$
MLAFAM@Q<W.I?-WD<6JRU)[;EK >\@DPV"XC_V_7AX[!R1W5C/[)/H/GQ*'/K
M(LZ6+<\Y#HTO$.7]*U!@0Q,A?U_O+#A@/FE!W0%)($6L&?^J3*O_UQ2TC2HG
M_Z^U1)G.*;_P=NK"WIQ\O?)W?3XF69?TYU5\_E;UH['R/P-+R=]5?XS9FVSB
MS3MM7#_&QU\I6:MJ$CUMWY6WJ1]5@MUM!%CNZ_@+&&DOT#K!S>1N6K,RY*>]
M[P7=Y.>E/\WS#_QZ?VC_A^!Z_A_=W[Y\=#^P[</R_N2='Y[-7Q;CNO;X0]VL
M[.S=W3O7/4J=L+9_<G[._+2PZ)-JOVWN);?4W[5<]_EA^-N''PX_KC]B\<?X
MX=SL\"MZ[^5>V=H'3#Z\:^ZZ[C5[-R9:16051R_M_:QVDC,Z\XEJTM0&;>FI
M'W=';M5OBO\0]EXB>]?YUIK"2J#'.^/Y_U@OSIBU;O+#VW>##K^]9CYKYJQ;
MKQ[=,^\Z\79W:\MT7Q$7,>MCE_N-_O:5[!>I$?N[W$[NA_F#SA\OLS]D/=R:
M69/^H+]3CG/GQDM_&(5=5!I+YB8]NZ4^\])G@;5;S*-:>&4V6QDIJ;1>_KYF
M?OKZ68E!87EW=2Y]VK3_W/,7)QX$NHJ(P$Z. ^,D CLGCXH$.K". ,QS^\_J
MCLO[T^=SO(R7,_7OO/#2_F-L=I2+G/S.JRH[9[F)"7BK;+Q]7-JR3^6S:GF^
M;LAN@8B-H0==?>KT7V]8NO%NH*NH,WP"]>$?Q=]V%>X/[Q^]+U7QV_M2S7SQ
M&@=OE>M;Q7?-2MOKK3%+.X3CW4DAMW7_&72\NB)O=N@<F=3%\$[C*/30A:Z!
M7HD Q?;_;P( 4$L#!!0    ( .)Q6U#.4"@3]!$  +L3   .    <&AA<FUA
M<&%C:RYJ<&>UEW=4D]NRP#]Z$2D*J"A$0*0J4J4F1Q%",2 U%$..($H+14":
M$!M(%1$ITHNA!8) 0$(1%44$::&'9F@"47HH 9*+YYUWWSMGO;7N?6^M-_NO
M67N^V>NW9[Z9V8QAQC> W]C R !@8F("4@X6P!@%] !N#@Y.#G9N3D[.0]S<
MAWB/\_,>/LPK*B0L<%P2)'5& B0A?E;^HN)96559<8D+EY14-;7!8+#4^2M&
M>CJ&%W7!VK^<,'$?.L1[F/<4/_\I;1D)&>W_M3#> 0*<P#/@&0N3!, LP,0B
MP,3X"(  @(F-Z0\!_A0F9A96-G8.3B[N0P<&-?P ,Q,+"S,K"QL;*^O!;MC!
M/L JP'9$7.D2^U'S&QP2OH+*#Q+S."4O5[X7LNA=.:/B=.<A%[?PL>,G1*3.
M2LO(RJFJJ5_4T-32NZ)O #4T,K:TLK:!V]K9.]]TN77;U<W=SS_@;F!0<,BC
MQQ&13Z*B8YXGO4A.24U[F9Y?\ I36%1<4EI5C:^I?5-'J/_0\O%3Z^>V+^W$
MOOZ!P:'A$1)Y:GIF=N[[_,+BZMKZ!G5S:WN']HN+"6!A^D_Y'[D$#KB865E9
M6#E^<3$Q!_XR$&!E$U=B/W+)G..&[U$)Y0><@I<3\RK?<TFJ6*P(.=WIY18^
MHTJ66OV%]@?9OP?V\/]$]D^P_^(B 3PL3 ?!8Q$ (,"FNTS^?6Z9LI_.UZMZ
MSS6.EH#O@ U34]"Y]!KSV*2JL9==%Q)4LQ(+;+6*XO#Q%]+VIOUDZ)Q@SS S
M8W) L["[UA?7CK#L4;Q2=O.R& -H?TWI+TBE%M.A$5&=U!JA=?1,0.HD/U4V
M6MBGQ3,K^N3HNDYX<K3OU+E;W\%>&+]'_0H1T!DENWYX'K=@WLK'-3DG;/_V
MJR_VB^0N^V#;78+JN8$/I\K62JB\^OKZ'C=O?-U-5Z>+#Z(J9]WAIWD?O%*
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M;&(6F\E'B)!YMQH&T.S, &(+Z +G).F1&<C=3<AV/;C:I&$W9X>C'WL7&<(
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M1Z?(XON=DK?>[&G^I34A("T;SE,29"/KB#>G?+3@2E<@\8KZM(@_<X(*8EE
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M$OX<Z4!NXZT,,UJ "^IS E:QI/R>8@X6(#>Q\Z7CK@MC*V"/SR^]G@7@.EG
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M(,S%+:VV][>S6![W(!&9DW=X#QHDYY1]W">K;DT6O72]CT],3F/ZV,8O:/]
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M+.;2I$;+A4@4K"G12>5577>9.@W5JNS5-U;'#)MS,_ASZU<QKLJMA;;4G="
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M5#MVEXU?)G;SQNRLW^0?:_5N9NE ;*'7C.'&^@W0AXLROGY02]C&OO3R ]O
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M2QGI>7I\_I8Y";%W_EF-_W]V4+"W_P)02P,$%     @ XG%;4$0;>=NF<@
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MSDW*#W/% (O7\[%SBVCAW@WN#+Q=8LJ91T\DK&=X#4@)'L*$,*B$:Y\4IX^
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M,('V".,3M:7D)0TD2 S<+(YD+(9:( <GCV.R>*:) )^$7<5 2BE8J*(M6L5
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MX6<XQY>./KCC<.'#/<37@(T.ZALDJ$K\4L0-7GLVA&'E7^=I .TYR3>HMYB
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MT1Z3[9+V6\]SZ<#2GLCO%,G!MZ$\ZST&^A:CZ;J+Z.<SW5V.6=BD^7?-WV7
MK$JRI7R&?:M#Z >&<#INV,4V_."3Y_-Y.35%1EC4B&^W+SHXUNG<Y)5%B0M8
MB9@__]]^=,7_V8MP!(ZH-X95^>,@XKZW4%_<:5"ZZ,<9_X0/3/'VOK7Z-F,^
M8AN<,_"O/5S\GOY(E!= 3.$C:C&U1+96YMME-&,-\URIKR:FI*GP UVS??J/
M-P:RPD?=)+'D,?LPBI7EV&"!R^:JSRXU^_B2)0O/$:<@Y9DK8Y6"BJ^=WBZK
M,IU:O)ISZBJ^S ]_6ALN?4?9;-0JM7,J<Q1;_VTQ^I7B^%;C8_I=[)@")!+*
MI2[J;MKB$5N%P41O^EX<>G#*J9THR--KX#I0.X4#W!N %?EC0XXMJSB=2$AZ
M[OI\Z-C.Y7UOK,RZE#$*[JUH?ZCQES\%AP2^IXV:!=R;=CGJ>E'[N!%CN,)J
MF"+IFG[MJHI!?92NZK'-KC(+RLC(T*<_7Y*4.>=- ZUM4G"-.JK/=*_,7CH6
M>O&Z_87/;78ERE]?3:I0C6?5)9QV<\T[-WQ;R8ED49KR@F/$1B()6'@-:7 G
MR[Q**E[Y1S0&Q_%,2W$9T*"U6]=BA<S&].#YW+TGPL*"KUU33+/1N1!\%U_T
MP;A1[7,W=KRZ)0(.R)=2]@JPGN*XL%8+U">;.+$>%)HJ?(%D7P!]K8O:G(K/
M])0W\T''(^QG&XN-8I[W3PT?-BH.+7_1Z5?W^:6-*#2>K8>5H2GP#@,1+7W)
M1/$<5DXR) 5:3EG7LRRI O.Y,[=KD:E1FHE-E@\7I,A[BKDF&(DF+&M1D$'0
M M::IY"28#1#V]G%;S# @OV2Y_(4=[J]3D9+<&+(5B0FZNZ?G:=)W>_693..
M/?PIY<<%FD-[#F]ZSV.>,U];:J9M^-X*I"E\^,@[#73>[DM:XIF'L*_NTQ0=
M"Q@E/4VW'C4;]?%3MTZKJJ"^CWVK<2 7QWM(!7%,(%0Z35*.SK[79/BMJ!XC
MHTNX61I([-)?2G-:,#G (B87'KK<C6%;HTH>^-A(8W>L/I@Q5-JQY2M2>JX6
MXT5Z>WUX<8<KDCP6>FXIV^H)P;R#9H3S9G\-AZ@AOJ)#W=K!S]YUQ+@:HB,R
ML$YM#<^TU[X3/%(>13:&K9M230(;'F>>A\JOEJ<+V <%G.Y?O1GO5E=:XC>>
M^G.EC[,K]&9OM>COCP]L-_/>'WK'78-35E#D23^6?]0ZC*+KUVI]TLEZ(+7:
MR<G&H?$FQC5^RDZT5!!G?2+?([?I\OW'7U:=K(QUKS_^/5^([+6JR!*)OO>S
M_"H7FT0,=,%[<]15EUOHVPA:X"M68177$^X;/91.&^%?V'*^OP2+SQ$TAP@H
MF)"C=U1Q%9G[DEJV,)V-UH_8EGQ$\@PCX(E+;?FD-MG*)J&?3LH^AQY^3!,
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M=R=34Q+51*OV%>!:3Z9EZ=IDA2I6^,3$ONR[,[ES *V,QW [&211W3=7T1B
MF,P3K]#-3Y4<GY,__H[*PY36EI=75GVHR"XRO#UVP,XV[<W/1UX9J<W85&*T
M('GH#;:&D%>&_VG4))H3')N;0=F4XPF#2< R*YXF&\?9T4QMH]ZA'0/DXX#!
MT]RE]H-6I\84 512.>\H&S?H #C%4TUB8O2HG I'J+O]W<2L45!&10<T2'Z.
M:K,9U^?XC*:LUFP5Y,&R+3Z.3;J#EB ,]..4G0'R8L#FL0G0H<DPFD/=C5<
M;[.:M6UHW.G;1(ZPM"=7.1Z9UN3-CO90FNEL_)HP5;&7HY\0&%03P$>,S!\3
MR ;J>4I>X=RIH\"?&.!^ !%(([;J;#3=;I*]<@>,J64N7IU2X6 5>W5O#-;/
MJ1VZX_QG%UW.2L)VVQD)6\%/2)[4*%NY'9F.JNK-8B/CB<@F#ZY:^P5\(+"S
M5CD)+_EH$HQSME+J/,>-UV_,?/^^4W$!)I6?G[F[2W[C!-PY?;=)!CKW"89@
M/.&CDN'/6[ :OVIWW@Z!83OC2(I? K=!J?<L6(C=RK=V4U?L7IN:^6F9"GY2
MVS!O91:314&7UH6$%[UR76$F)]^&1))&JE9#@,KY2U-)::7?V NM9$7)'6^^
M1^9EOAIG]A!48V0,PMJOJ?(1KLO6AWM#W]IU Y%1C-^NLF9.9PJJ5DIJ>N8_
M,[09[W[@<=0G:*P'U!OG]+5Z[J]YE6@94!:,O'IS76I9Q>)AH;!JK\JC+*2*
MHEU1QWRDDQWR2*/K,>J,:JV<:ZUJ36:IH57)B]"@&FI%5M_<GHO#JA?GSM25
M#B;H3"Z>4E6AZV4_UOIPXNNNC5(AC"VF@VY"DX9ZZ37,EFCL7IX8S"<.LN%F
M[ NWX\M#^$@O3@N[(OHBV,O<71M\)Y?:;FK).@&,E.X89?Q13!M:+>,CDE[P
M?B,YRS33&8;G<X-OE1,.5]#3*HBGGY;W(-LFD.#1G(R5I23LBYS8()H"N&\<
M.[:^1@#= *)'X>BIT4?57)$J%FK">.W"%F4IO$)CA[Q/<P*4OHD!<WZNC>7E
MM8WB[;UBC&,R3,^0?JF$]:@!I#V.-P+]'N'UP4[6DB".R:8E;1)<Q\$,4T$G
M'#68&(@:UV=@#M:\5_>16OYX]<G$J?YPF]VXI+:UM5'7K[<K%VY":""F8J2>
MO:BGMW7O\2VTW%8*\0I6EM!K1Q@P(F?@SY0L1)#E:<;C>._!F@7D?IX]F![.
M6M1#Q6(%(7%SMBF6H]EAA77ESK0)F[W!)@SX"W,6':?.6YDQ+\:.=S/0^ZN>
MUPVH0YS'*0@U.+\F\EHGCW+KO]SE+K46BKS3#9; D3W F-+W5VFH=^4E0[HQ
MKAN6>4H9O:UO1'T:7H:;J^W[J4U-[-WHB(134>:T[DG\A%K/G'V"?X.C]^VW
M?A>>?BH=+KW=-M!^JL!\9_$C0[L+>:EV%Z[U&,M?"\L>[ U-&U6NL+OA=Z7A
MIKY&F>N]U-)SA?K"3L)&]X<&X_(5'-ZH6K1W*0XZ8>[T@9>6QI?>]O&T,1UO
M@WN)[)]&C*[U$H>CG%:3-H5 MS;:[JU[Z)]P]AU&.RO81/%9++*F6SB L;%X
MOY% +6::AT4-N##'SF^O&]U5F?#X^OZ==E$I&W2!=X13V70'KG)'VE1;.47@
M_K2AGDOVP.MIL;>'G03LI8TR2V5U\?K5]]H<\B_*!KP)*NGIV5\VOLXC,S#;
MOP4+5>,)P=DS+D]\G% YENH%LN$FBBJ#E./6!R47#P$KI3U]><+[QZTZL^T&
MUJK.AL7]^$ECK1DLD<ZYJG$SUXJ6S:=(7THWK7B!8(E><SB7Q*8D-AD#G,&U
MM!$^PI<D,8[;M^3")2<T.7'I:U'-X&&VAW*GO/#P)?0.KGX20<J_4)E+2;\\
M[#NT>I!^)\03%]:Z04TTP>PD/9L?A[N9Z](7U*8#7@/L!Z*GT'=H(F >ARD!
M#:%>R%.(;*8HCC)5WU&!?.TJ_1HY-KHV#E!231RF2*E$\4\C33Y/_":/#Q,T
M9N_BO-MRE>-KT@78E&3=]".MW:_'6V+=^L3YB-,W; 59S#8;\&CG(FI*,RF'
M*/0(G&,-LOD(J3E7IY3P;ERX32JT"Z#'$M3\Z;4Y;<'C5 Y,RY!XL;+Q.:)4
MDQAG8DEN;O(G8 >E(R;"H1XTIN <;42O3HJ.?L5[<=3E:*U@Q*8H+J<%M8^V
M'?S<Y,;V4Z=)$OI1P 7-=*//!1D/2ELB*N>8=>0V9C+!%)C.##"^+3/O*1'7
M,>Y#3:X,1H[5&O>H6J8;JZR%8LX^_9\R?]?T=L8QQ#WOZXAY"SN$_*?1Y6'E
MUZ@,)9<[X&FN4)S.VUU S]HN/]E8@]E?MCNM:)^)CM2+=%/:Z*QZ=*Y^Q#1'
MOS;,G=8][I9SSY*SEK'^I1SG,G+FM/%&?5V%(VFXN5[SA2U^<N+]<EA8^Y=2
M-=>)5TS*G]@J3'S3!59?W&B4>6J3:1GHZT \B$M9O;%X[8W;WH[JE_4#4GOO
M;G]](O%*BD/&+]^JTE]C5*C4JX^;/EQ3=?[@@'>?VF\I9N=P=)='AX;-U66]
M+TT3OI3;K9T"<0P66\5Z?Y1MR8$W'P9L'5^].+?4=8A*(JCQ), 2/R[SW%8Q
M36 >C6C@9BVU/@%5N-*OF1(E7*4<-ED2U#_/M:9,D04"7%&I38>?+#0R$TPL
M6?1]"]#Q#,YXL! N]2SW6@+G59E*[^VGL^.>3_D(KPONG1? 4JX;M)O(5>BD
M[>3N)*':J$D1-%CW TEK,P"Y8\L?%C">1_J;C".X@FMOP()--,_1:":VR3@H
M@F/\!T^.E4SXZ2H?(;S(PW#D/&=<AO HW<)7T94?P5CFA9IA8TP&"K!!)<OK
M;3WBA6^:XXPY0J(+1M3VD"FB,$ZCCT/N1-Y^9_4X /5BB8&ZE;MBM-2&B=5?
M(VA5C=Y@BN$UWO$<BF,21UW>A=-%;)[A[#V>U[YJ>CYZPV8TY9C \N::\E8J
M#-27>["=ZW8!GM)#*S^>$W!B*XLF/Y==*%O-O2Q@C1U;9BWPC(</4+B4.TU8
MS@&=&#>/5T.K).'W"_+J7#2UQ"^'Z#T<OFB]8A&N/"O\'QW__[_^SU^"_+'_
M 5!+ P04    " #B<5M0NJ.*<T%Z  !-C0  &@   ')E=F)Y;F%T;&UR:W0R
M,#$W+3(P,3DN:G!GU+I[/%3]OS<\I1)BDE,'3*5R;BHDDKE*$6)"#A'3R3E)
MR%1C5@GC/%<)19D+(4E3(269&(?*I7&>4ADSDYRS)HP5:];<J[WW?3_W[W==
M^]G[OO?KN9_GF5[KC_FNM3[?[^?T?K\_(^D'Z2!FI8.MO2UFT2(,9A'Z#R/]
MA+%!O_W7/K^,_%=M+)*^QB@OQ\POEI=9M!&S6'F1C/(B:1,&AYYSZ;\^@/FW
MSZ+%,DN6+I-=+B>O@#Y0O1*S>)&,S.(E,DN7+EF"WHU%[V.6*"]=M6'[WF4J
M+B=D-T:H[KAZO6"YSKXG#6JNG> FDY/GX^3DU356KUF[>8NNGKZ!J=E.\UT6
MEC;[#]C:';1W<#OB[N'I==3[U&G_@,"@X)#(J.@+,>2+EZ[%)R32DI)3;F3>
MS,K.N74[M[#H7G%)Z?VR!T\KJZJ?U3Q_4=O(;FIN:7WS]EU7=T]O'_?#QWZ^
M0/AUZ-OPR.B8Z,?TS*QX#OHY_\NO11B9_^'ZW_JEC/JU>,D2F26RO_Q:M#CF
MUP/*2Y9NV+YLU5X7V1,1*AMW7%VNNN]ZP9,&.1T35U#MY/E.>?5-IOS-HE^N
M_8MG_SG'XOZW//L?COU??O5C5L@L0I,GHXPA8!!$KS %\_^G"XZ0% .#]T@X
M9"VU/]],\CMU*=(NQ6"HF^S!87$(%+YPD%S:PM.48LY<6S Y$%,,[Q/5- '+
MFOGA"J/3E&50<>F8=T:N%(/=PJKMF=T3<Z#[^#6W9*;?>[W]E6+<"L+@4\:3
MK:\6ME+?,:JXK?B4?%5)3A@K%+?<EUS48+T$JA'LWL\]DVG3QV#[;:U_SNHR
M/FOT%0+XD[$;XF$OUK7]H%I?U@,(\'K1:_JFNFUWR ]"?S>RO $,% ]+'@+!
M^#1<%3>1NA;B\4M;<!\8?,^)7G#@F]/2LX@9107*' 22>.I6@66P%W11D.ZX
M/YO7,!_G W'9"B5^099O:ON*._%5>+5@KO;JVOPV5X@G),'*#/%'J/L>98DH
M/-W:E/K>SPQJXTLQ'QC-/)!(IX.D4*#:LV'J6OT>R,:\*92QDNPH>)_#QWZD
MM["656-7DND>X,/D4Z)3X@A1E10#%EF1'KRY[A7B[9](+^*<7;30<)_:#SS]
MEE5*[C[28VT"[>O_Q!]N!>2H?^;CTWE'0B4X82O];)U.X" CT>E>:XEU^64!
M09V0 >L0:-V'GM8_[GUHUN;D^FX^;/O9K8."*!:DQYNPJ( =H#80L)>46JN&
M$%:Q M&L0-/-./6ZS8',NGE&_ PIX=SM>KUCV8XV@4PBR-6V:](R;^1Z?RL;
M+.?2B2+C[-NQ&WUJ&MG(<BDFO!3A\181@B856FL/E$Y\ 7D-K*7P"1%VT.A9
M_U 38B5Y*,7X,^+SMTGRI9@ 3MKC+R&9H3?VED(V@U(,?6M8]&HSDFK(VI[\
MC5 T^'[^&[#2L>19T0G1<",#VH!K 6A^&Z \_DLI)@6WO,X3Y+ 1K!03EW 4
M:=<V%>'2 #2NE"-=%*>%J!%@9=3Y>CTH\A'%MTYR&UGM UER!+9/BLG#S3P%
MZ[6AWG,MEV/-]W.K[^JP$8.J6(_?L-QP>2FFP8LU> ?9!<XUT]7(-N(ZR$*P
M1V8PAAVF(<0V:SD>Y.*9)\":1@G%2W%WZXY[EC[$<G+DI'=Q8L[]$&T<S8-N
MR]WJ]EN?+:."ULW]9!6Z$$)]QU/:!'7BZ/66% )X3I)O)0-*,0):RVW8OMR^
MZ".\!\0W!U=?#D^<%[^,O1RJR,@2AGY1<.NN,_<_L>=[^8.Q<^P2'Z\]DMF$
M:HZ 2R<,TDC*UNLI9AW(FF.P-Q3)3]^!AM^E$&@P?!2MJ&(KTOID(\K;)VIE
M<S0_49RKN[X^[C[Q$@JU+AZ\W??]?6@;7OU][<VT9\J.FYX^(C81(!W6Y/6%
M_=!E\2L1L961+L54OJ>)&.)X$ >K/ U?NA>,<8:$110+L+2)\0$K"*=;19\H
M@LK=I)CX:VQ@5351!K:MYIK>/UOGSE<,;Z2:@L^>W/<=0[2[SDQ1UA7XC0_B
M*LP!T&WJPY;N0<XUA(#MC^$W2S%L+(Y<V:2]!$QD%K8]&I__]D)(6G[4;XRZ
M'<QB7JDRQKI"-%RRE49Q,#>7E6[JR)3[-&:MW+4^S*<I>S[@3J>O/78R;.$R
M66,0"ZOP!*VPJ@K?N":1%<3$D'&#;Z'VP20KO)!LRED!'^HHS7'R-5\P:9FG
MT@5)#XV813U6[/MVA2&N/E:K]IHEW=U\D&6\#ED^+1)@KU*UDGRH;?,YK0O,
M_D^"\,D#PMUMI'02Z(*7':_=R13R$FIU&PVUB/SPR9?!HD]-O&J/JR)K+MM:
MO5,'H@F=?'ZK SDM>[1WD^3)J:\M]U]2RV8!8MDF%J3+FUPC<D.6?Q'P(%U&
M4W@_W@&J7+ E<\34'JKJ.*L*EQ$E.<NQ[:VS*2/'AXAS:JL\7$+JM_1$\12#
M!-V-SVI[9\S]-HO,ZM-#F>1D)6;9F,]OUAE0M!2S=(_D&J(?E&/)BY-B@J?B
MD0TU7?5&,!Y283Y+9QX+V39"4D=,VC?G-$[)AZ@TEQJP0T4*1VKJNJT4!&_W
M4Q5%8;WW1$'UZVMOF*=;YX-VK;@$GDHT,347QV:N'M7>T5>_C"P8YN<T&RIJ
M/2K6QD*T8+ZO0DN,ME+OUJ]5&6^K7Y*4( 9[/GVV(KUY2GPIY%F'7Y5&?E@5
M\!Z8=%N0I1P%<UX3(#V@E?,)U]1/RJ  (D>QKX3!\I_Z^*D1]SCF-2E]P*BW
M:C)4?$(4GD+5I:*THCI+HM7ZEJ92[")$;I[0SP=D6[@_^''IE7JU$>_-);<)
M=-V.[^'5Y;@^'K29,S$N4AC$3K@,:ID(3V^W6W"DA-6+6),F"ZX#>5X/OV\E
M!/'Z;9K6TINQR=D:V>*'XNM23*/&?7(<AS^4MO.0^$(MX5K5N*/YC8$!W>/8
M]\#'4XC2*A W>6#! FEG:$01KVIHKX;R1)?%,"2[L)+B N'+89OG"^&-E[']
M!E/-,8"2]:Z@@0W/074&H0F_!&(T^FGYAK/EZ[7 ]@S6@[V"V,5<D@?8U)\P
M-2*N1I-V"@6PV%%O9NN4X@>D"X7?.G<A[F/I:Y(:HD-Q P/CF6>K&2N]R<!@
MPL,<G&H!*(R]@;9W=N7@[>X%\Z9^NX3J"N\I=FW1.J=84U;E@'W83\7!<,A<
MV.HG#W)@92G&MQNEB]T.$&MA"7EJL(O:;6<7KF$'CHO3H:,@2<!-M=Y*(<2U
MO//=C/\JFF)KA393-SR%8LL@FG-W0:JCB)5J^FG2>:!1<8?L9)V)%+.$+*F$
MW1><8%/H[<(!I!NG9+UQ%%B!LA:D%WX5X.L_Z;/>]1EB-=<O11]4%(0K0"8N
MW8A*:/]52 ;T$/+/: RL V>GV+QK5$T021>\--8>;LG7$;&2K1PCE1@K90=8
M3YFP6NE@S*2/!INE30[U@%!:NXKLE"29D3[I'!.9TQ&C!I1>DP'%20I>9%RO
M39[>B^)=FQ2S_",42@3-V9_R8ATXS3R-XU"6=4*HH'WK]+[NJ'2B[4KH$>DX
M",!JGH@<3\A)H&Z%/O+#^X6#WXK!EZ^U=X"R5RC1@F_<[U7C^&7D3$%)>5@A
MO)/6[)'[[.X)5%38BWIGNX!&0T&L#[$*?%;CKS90=JJBO?@#R<^'NGN$!>XC
M]LL*L WI.GR-5GH&83ELV>\)*PNXB%QLN(!T;3Z<;E:@_1)52DD=UGKP1J@X
MNH#\GK/7Z=1OKT#@&L4L4.38J!+2I_ PU)RZL2,J4B/QT>246X_U%J!A"^$,
MH9_F A6C]9<#75\P&)5BUE+7^Z&LM0?1/@KA!TL3Z_6"24O"K&6I*+Y6JR"=
M]08]=7MUTXUGPU=!J0)24WDZR;O35'%#E._NQGRY3F,4'(D/QSO\?$/%ZW%E
MN218=4J\M*]>AOQ2G-M-"&'$<X$E5G)"/LALIEK0O5]ZF=*3;[2=4&.P?YKJ
M1XW [I'"/>[1OCO';< OB==BRL?GHR4E987]O-'*XH]\RE*TQ+="CBB;W);D
MU"O"2S/9A-76*D@W4#DWN5GTT@::X@,:1,G=>P/(>]9*Z[44JSXK%32-Q:TT
M]3&AVXL^2DR9]WBI6V^5L4^C=VGB4!>S:EW9U.;+N!OU^D##3E1E;NXEG*&K
MP8NA*7"Z82UW4@O=4Q[27_!B%[0_HAP&[>#-O"7P(M#\-:! B03MFG%JUIJC
M%Z08%:H21&M9.Q4OQ=1,4G4H:U_4BK0R\DJ/CHC&^LZ1KWEG=.=+KA &;S T
M":=9&6CI6QN0IP5 XY3Z*$E!@'8N72N U]A-.93GUON($$;*(,@B6\D'JM@B
M#'3->QODBET,T1Q$1@,&(DZRV7AYWMTMT/B ;EU];_CDE3UNK:C0\Y)B%"EZ
MJ*G;L*LDKGXCK!TKP^>RB1^?S0F+6R>UZZTT=L[YZ71;JY"9PKMS[#P.C</7
M6Y8[S ]D,Y+SMU2*Y*$6T5F5!L^.^DSE/(K5U(0[ZO];2$O4)C:KDSP"0MO7
ML0F/>[93._W,)'?/6./(-0+%J:;T2$\1,<%J-Y^G9A-^[T !A#L@4JI^]'G$
M<F*^I.*/(*I:#X=VQC1O7&)S>&<$T8Q%0\ML+S"8C%-AG>&E =6<9CP6/@X&
M7CEKO6=,BGD<[R?;HP9[A@D(*Z#=@X'74!J^!E3-T:(_I>_>7YM0@6R%5TD*
MZUSX=*Q/<.87'Y[STZ/D;*>U[]SK?7O1 !RA?L0IS3!5@J08&60/Q1 <CJ><
M0%W1D3"!$"E&@[+=Z;*0SE;4:>8M 8+"%?O)E_F,."9B0%%[#I:VA"N2:8.]
MO5FLI&K24K).$X(#/9M=EE@KB\Q3P^JLUWR6F6D[@FZ3BS1>NE #AC=V4+M)
M"M6 &M+IMP+,H2,RY)C]O<SJ=AM!:X+51<$ZM @AQV/@I9':@,+:C*S[4*E3
M76<X<^\!<+:YNJE^HY/!@,9-LA0S@8KFI2<D=UG!S(]LOF<+D%2_!:TUDB;4
M*O;,%+,@.OCRJ*BJ=I;9 ,3U(1O[*&:$]+I(X3A#$0JTZ;0RWBQ.OBC)>0CE
M\]BKQLM#R]X6C7(?!YM/LW\08!5'9/F"R%.L Z6"&BW:5E FV-:JSD#;:C"W
MWE22& ,%=#?_/A8SH"O2F 2$I/YEGUJ\3X;F'E,.'EC[$KSPHC"H/Y]A/#/?
M7)ID%%B5,&MLL-K,AT5'EJ'9K 54J0I("Z AQ9R*51!? :F9?&P_3VS=5:]-
M[;&\LPJ28IIRU%$@X362DH(%0!RPMG[ULQ>A@52J>HC?LN>9?,]F?,*6N==]
M16Q$$WQ6SE^D5+;EI1C$]G#2 ? 8 =*M:<1=05F-%=2.%V[)$[GQ2YMP_9ZO
M"4]G+K'8(\RS]\"8C+J3XOY'%??16#KT&D5),<H0R0X,OW*:(=A:'A[Q1SMS
MG*J!M+\ ,](?I8<24<H^-O%]<FHRC!FV2<7[2X-B;]6#U7)AWW6._O&[K/NY
M3<F=K_T]%ETYKG0 ,$,U:@.:R1!%N\&:-,HA9+LDKPK7O^ JJ2:<Y/7S[)Z'
M:U,_HL6%K"$G(<V>SXP'6?*4PU#U@@WLA.(LVR_LPONP\WKA5GN*@I3)=OLM
ML7$/,X]V5X7N.<N9=Z]:\/P8AGPV;N;'J409'TK\<.Q6SV>%R&U'#RT.-WF[
MXZIN5B496WO%R.6 *N;_Q!5_^O@PN GWY\K@2U'_CTS_E=67R\Y4O=KW7:L^
MNCI]LLFG96AZ?75NT-Q66\]+6VU_?8)D;%/@?K31]E%[6*HH*$*ZV GFPF$X
MR%J3H(+@R3H^7-B/LKFHA@9;1BL26I'MX&?<QTN[!\843\F*+]#\ZTTN6B_0
M+<_<_]V6<:_J_TC@_OER/7MXWPT9[=_>O)4IDREK-J8N13ZA=4D(Q=. &N[$
M+!\;1WI&2+-R$>&$^!;.%464SQ4A &3RVZ?8=%FD)1_7%_7*1-P!32]X_9KM
MN4DPI59G[]9R*4:>)_"X+0Q/O!Z<;XA.4)[\UJM6^@+>2E:RV9K7!,H/N?4K
M#[:@@;QT.GK-9.X.BZ\1#5_/1=S!.2^W$ELPARK%WI):UIFIM=0>H%*W28&1
MVL^@P[@%"@4%SKA:6*N+X,_#!6LO!YELX&HVZW%?M7 Y*V"<IQA:OPJZ1-6%
M3KF^JH;"[H_@-"DV N9*ROY4WWJ(5C+F#23.++3KV%=?0 ??1Z@QQA=J$P[T
M^')^NF52I"$NA1:A2+>V"M(/+T<X+ 5&RS;*&DC;%/>1Z *U12R8PUM$2K?1
M9K7,Y./94HP6Q5%D=]6($APH8*XBIWH]S6E>VY)9]N60E>YON)['ZZ_L7:(=
MKWEM9N.3.ML+(VN[M5/OC=%^=']WHNY#NU83[5I2$J%*-P&E>/PBB"O0;2:E
MU6(G. L^H:3ER$J8!$V";^M7PF=$W(;V<#Z!C4VIEV<(:N(8KQDK_.G-M;^)
M^@I*?4+G "48^X#,:-1I[/]6S8\E>+ZLNS$\*VSB_<"',L2RO<#,EVBGD*[O
M';@&+KS*!U$RA98NK$7/L)O@S_G(: 8J62V<U1"=;QY7/2GK(=)-C&;2=M8J
ME4=<%*FTY/X@EK ?CHO["U]G]]>M-/]D'/9U6I!S)F#/#?MY8[1J@I _23,A
MA"HBHDJ2 WX6,P=E!J48.),D)\5P[\XA^=4.,P\DPP:#UNN:_2^>-7BF7E=^
M\CRLOK'<JVZ_6SE)T:'"MK#DIMN=>UWVF^YFO^.U'>6EU)VX^KXR31VG=BT#
M)YO[;9>#<O:RM.*UN\[X>YL6Z9M=-'.^XY;9YSPYQOG.139V2FZQ1GJ ( :L
M5[]*BIEVM(,/%"UL!SKO(YT$R(6R68KYELV*?V#(0C8,*T@Q'5MTI!B%[028
M,1LS%(Y'-J)"$UWU0V\MU[MX\2(5_T*"]GB3-Z%20[*6/HDJM@2-1A(2C-9@
M4A40@)\WP_7KHK6.CV?!75PPZP!.A-U%0JYNQT%'DZ68KU),.<L0)]* N$@<
M2(+VVK2UM8EB_Y?.BHJFI(N-4LR,7!(ZQ/U)E&)T);X_43V5Q&IAS6B@0W"C
MO+:?'RGU.W"!)5*G3Z"*V+9H8;\4PS\ YD@QN=XD*-5&?+(%X-\$@AX&KD&;
MD<;?:3+*@.PO_3"$?#JKPGR:O%LR^9,RAU[U54\"1[JK]F!MNX^'WK7S[*M.
M_6#Z1=>A>Y+[+7_!M>=LQ<,S_"47:TR:M6TGZ"/=C3S0D9'H[4Z;B 6[!;*-
MQ-4?R9G[)"5 ,'TYTLM2KPL.%LGPAZ_6ZY H6R19=7M$/_"T7%SJ<,=D'IL@
M4T77"-;> NV]1['K^.-%;UULY*]Q)]\*/#U'O9 :'/@MP$JGX47@4Z^T+?KO
M'H8ZV:Y^]]XA7SMM_$B>:X5"Z9NRENUG7<M<=QY+.4][D1F!!N4VKX9\R,]W
M]>'LM7<>N+]V.YQUS'ECNGQ49H)%E63.X_R-M W.*M]NW"Q80WV.9O8HKW(+
M*I'9NDCG9=9+*49.MO$,0@)O!.3]JFCJGUX<> >:]XS;_SUJ4HR.,55AM'Z=
MY 9*X>HP#FI%%;(\PLZ-N5*O2U&%F@LIEM#U$X74KES\Q'4!/8.D5&\$;R.J
MC +JULO(G$.OH&)PJ@E9!!D*PC6"YI7*@F,JR'8"9R83UA=-7!]!-EO6VDV3
M)L,7C)H'.3(A^5L@%3"PR96RI</JH@@GH*4B6T*5&RF.@[PE%!L1CH9]S8FW
MS,HN?X!5WT-K9%[S,X3V,F'/GN.=LPKA\K K-%X*^;36]C$>?0R^<)YOD_#<
MMB+D2&#VJ?N6S!LF%6GE\A31G=$>FODSJ,A5/L?X56EU;K%EU+<7SI])ZR*^
MK\,F-;FU_TCS9I=:N+*'WD7[ZLJK!1_Y&M7M4F9;]/#3G-KR!>_(<CES[.CT
M_T(+]O]M7?L,L01X$5.R=) %QM%R<G($"XPOS+\Q08=2[<0GI9@B%TDA !9"
MCE),NS$@=\1%BEDYC6+IB(HRVJRW& AQ_N6/)V@R@71@!(\*RGA5J[HZEL9G
M9!(0&.,^IB+I=F*T51M3^7@IQK0*^&NSAT(.A72(=@>]_]LM.FS4),7\ 'IY
M6>@1X% I9B\9#Z\O&!H:@NJ'YT+_!@C_0"&VGU"Y<@E:9WI(I]5BX.M)R/$#
M:M\&7XT>.7V.)$%GI [%OP,/A>;O9F'XBL$:1^3 S+^>7(IQ8J2S0&]./&&)
M%6[!#&H]"FT7V7E72XI9@9RE2 <55]E535S:',U_I=#RQ.C9I67/N;4/#Q,?
M?DQL[ND/Y90^P3V_W?#F)P@TM! 6867$,5 ?\8\^JA9#\MY3$ .KRB ':?"J
M/*23 :*B^6 1<YTD"][.5PQM #2C@^K4P$Q!3$O%8A[_*TNQ'@>'BOP9"?"Z
MR,'R5\2F,%%D\[-M8WX[H<LE$*UI8&W54S#KCH>&]9:,,!5V+IKUNJ,G2@9\
M1\HO%DLQ^T'S*_FK3M5M>_.<9?W&Q.H"88WVH6./?WXWEW5V-QR>W9&K]L#R
MUF=KK%P">]^1$&&$RAW]#K8K,^E&9FH:RKU"TCULZ@>B:B15\4WD1.FBJ^P6
MM7.\HV_./7_;HOJ<FA&>5+R4*)?4+'BR*WE?M9&VMO+-<4&H"[NYP<F!T,&$
M]Y\"57[E93<<^GH,>$;5&HPEBH?,6(-"PI60C&$Q&>K]H?,"]XFD]&/?!@H6
MRH^1H5=0O<GE@[@)9F$(H,T*=%("$J_#MGFM5--J,+OHX3&(<TS$32SD6FT'
M?5IQ<F8L#/1N.3;Q-&0&LM@U#,VI^AWCVIMK4>1V!_MHI6.6<23>9_(%+\"*
M$,Q)K.5=I81&E#/9BI[\'#9#M;\=V_ARC^ON W4]L"'_[CK;[DD\O-\XG%GR
M&+I:/NKIK9%&N5@0>LI9M.SV ZAQ#=,T==TZR3;[J7-35_T6B=0-,M3I"A'+
M%I,?FG//&9IR(C6UCE&5CFQ[?L>,8BP7L*,\*=$@_9A3B"O[04>ZIOK&8N^;
M7_Z _71$O%$9MI>%8%Q$5/RVG7WR1-R?ZNZ_#T;<_ $?B]B5MG5+XM:Z<]N+
M:-EK*S3-#%+JRIS=G\SH=Y>:?N;-Q50@'^M7=9KB$VMGZA5%!YIPJY#5Y-T"
M*F.)N??&MI+1^NW=+07!)233FB0Z$+Q&^?/;,Z>K8[ZMT?0TEV(4AP8;Y;07
MBZ[*E"T$TAY;ET[.@DPZ\/4N]1T@_C4V$V;7><_@$^NQ8$8IWVF1687Y;WG>
M(M\YNJ"FJC?OB+:12.M1>I&1GS:=_ZHWZZOESJSH,,'J[Y/A_J+UU71/5OK#
M29QKXLY*W!5^W4YP3H']P8J[_9W)"B>'7M'-DL<?$TWN/MQS*#:8F#EN.EA$
ME+MZ?VAS4&M63[E!5%;(C!1SN0G*$VS!)SVY[>QSQQ\*B=H&K>V8?T^*^TI4
M(QK?^Z,$K X8<M/(B#^A<='>\6.7NZ'ED1")R[]X]IX@B!/1]A"ZK?9PNB6$
MW!D@D5'MF8ALYI$S6HD@,RFJ%1R.GR6I?[8'(NX=S-E9Z_;IWK/?8[/'7&MV
MY"5LKRHXL<CG<MP!RH:2(#2]2@E\^RICPX-]T4ZKN.RY^<3K]SZ-/1GO[_TZ
MH)GR;HKMMRU[ZNV3W+DF0,4_(<KMU%;CNG7A%9]-L\4>K6VC0, KW2,=L+\H
MT*G/J+_U<.H@*^5;+F]N&7[K],*6'_V7[8W]\[M"UY5?%#Q_DM]U<3*@^H9N
M3>[!=T^FH53V]T5L<&JEX =<BKO2OJ-.]UFQX[I;)]W)K JWPN%9[UNWW[DD
M6+C>M7=F/*7W!=U_3QG-SU&$:()E.LGD2-E;PZM74-WR3JG)9YT[2E7KO$DM
M-WB'\RE-B#]AT9/@U9UF</GH0[,8/9NLTG&4=9>J@SJ%NZ!(X3DMY=?F VO?
M*!5<(8BVCYFDQ,!6;J]9,\Z4,"GFZ@ Z!0\E4!WV(H78>3X627'(9EE(,4>>
M$N=ERU! 5Y-B?A+&D&P)3A+.(8QL82 J'3^DF%(J<6I!BCG*X@OR48XHC!2&
MPTH@3XHQ0N47+86L@21S4,C=S0;@Q\RWN7K_9K'\ET46:G#J7=N_V2/^I!4,
M23'.,&. TQ<.D4NO B-W('2JDJE#2[M-GO"7'0Q_!*00>HTRD:MCOS1;^+\R
M%E(SS)A1(9;"[/]^OL!Q\[]ZBH>MB*]?$?C'()XU(^S?[-78U':?B4[?.7>T
M\ZM(*2OX0H[YO&I,Y6BI9TV"G\WQ.7%G6V3HBN_WMYZN<;_U2:XHPR<F(A+;
M,3>@U?T]FAZ_ W)DXQ2BRZ>2/2[1:;/Z$S-W4:+EMS.3PBCV\G_V>5N7/^@?
MFW>NYH=COWQX*[@=L"UX[MS!K57WOQ?F^N[S"_EL?KWCCHZ1UH62DE[BPYXC
MW:7.T0'WOAP1MCG?O/?)?O<CGV)S(A/;].+[QE4W(VZ&R[DY,WK+:M.=BPU<
M;IZ\_Z,MM_A@RSM/OSESPRA)Z4< %!$62S&=%B(6L@P*EV*R51F@B/BO2S7_
MMJ0F>G^M#%;GPN[""D03?)1W[]C8I9W7^4Y;PG8?T[C$2C2>8:T<S>%2%9YU
M;ZIU)"3[Z8FV@R6EI15_=A[M__B%Z+\D-2S\4@ :["1KV1[8)+2(J!Y_LL-T
M?!T>^YG\0.:L&-DBLHV6FZUPAU_>/EN(ABK4]Y0]6-W<7EU14EP(G3L6?,,W
MX<7O@43:#_W>(X%Q31UYZ1:;?91=Y8_-]'Q>+ZDHW67^=I?MI./M\I8=$;5W
M;!C[,BN(6C3F\MH4OY8$_7?6[POC[NZ_7^I\]V!S3_SPZ6[[?M>4G)&:OZ8=
M]S_Y+TO^%_]_FAQ A>R#H[H2F5Y4SJ3P_F6H.8N;95E),7_DQA*^:=-R)+M_
M )<)_X4R;YWGY0,=3M:,::Q-&W+W)^$5XR'OKX<QPH&'I9C%[58KL32JF9L5
M^-L:)L4\(7CH8%;2VL2#KH._6[S>]8VUV: ]!P9&>6+E;E0(/I4GC67;HR)K
M%A5T-?^J![V+FC\*;WKV!8]U23$Q!0.$F:FWD@DD;Z0P!?Y=<N7_[F<<['HZ
MR;GZ)UV(@S8-3[0)<?W=S:1G#_.-)*6PL:B[99[)OBS%:(20L(009CH/:Z4K
MV+.;;]&U[C6RJJ].@8]5';5>TTM1O/>VJ'4WV1)Y-[SW96V/6?G+///:OFBY
M4LFNPBO6*R!/*6;)!TDF51'I1'0D]V'%08ZJ-WRPKQJ;4CN06AR*4Z%N@#+Y
M=#9)&;[46U5Q6=B:8KV2LH5;=P  T;8*3+8V#;74SKP/V_=1UA0$QU WYG=>
MS^WOGSY<\_)SK1031Z7^.<?"2C$AG,0<ZS6B?1!)W 8UE%'(T ?3J22J64?U
M)TY*SCSI2M0;JZ.#4ZIDP*NKSFY087(-LAHR/-+!XJOVS,QV5:>OP0^V?3[6
MBN^?.2S[GE I.U$!IHIMP645O\ZAE9-RC];L9\I%-D-23 MA95T,.MBD$%2L
MM\#VHD/>L:PD"B#2$1#H9K&1S?4[1'ZE_O>"YGU"O.N+])YV5L7J[.]>_[0K
MJLUP5VS;/_SFX).5+L#_7!1*$,OWH&F.^Y901'R,$V2"B9>CH##^@<MYIT\$
MQF9=3G*AP<[5SO*5B;(?KOI=%Y<3?RY423&ORP'$@C0R*<4L@V -D)%"&$SG
M/<ZHN;^Y[&4=1!(DWGH[R$FHS;O!TJC?=-_XL@!+FW]?OOVUC+EE_-=%">LC
M2$]YX'MD&3*4@ZSCQ 'P6/ELG6SRD<=>*Y04ARA3<M<:^1>1%WK3$K\$2RNX
M7':S]EGGL^[ZWN)O%U["6#,PX-&IW("C<>^+[4]-KSAKYC:?8+%@EMK4PWS[
M7@2>_^JN>?'.QJ$VJM= &TQ!>H.E&,(%!J2&]D&KWH)[*2SI!P;=65*,)E.\
M0HI)C '-YXQ8X  %U?_#[G:P">LJZX4_>F-ZD"'%6#X81P&HU Y)P/V,Q2,G
M=A$$R_JDF(()%OC%L0TIL0[_/DUHY4QZ,*;GT)VN>D@Q\'EZM3? ^5**+/61
M8D3OI)CC'"@0D '.MZ&*8[B!@$0? =B[H74+V20HW%H.'<H>%"$;[^+F58&A
M&=;/^/^WMN@WA(YG6PSVK(\+.IT1%) XORL@,>CNZ10O_XS3-_1/7O<X^#4]
M2QCM:>MQV*Z[?J6D6HH)8BU&!>"*&9(BY43OY"2B3#G>1[6 U@K=>DZ*C"=I
M3=B59$\V(M=;TO-59-;R)%2 5_P"D=C9M5;U2MPS4_!.\25:TO'LQH.4 ^5V
M$4@%XQ\KX_Y?$G34760BZZO7]V:TUT'LOITR&FE[..OF8RSYG4NL<$M^VBB;
M;'+KA&9Q@N",L[;;D&O4N8B2H;9=1])_FIA1C[;L\"U>THF@6+CR5_^JPH=%
M&HTHZJB228.O<JY2%7CV,8- G/8R<"<='!^L?NA=FE)A=4JXVX<C"WG,=XV)
MZC>.[SR'SXBVF"TSN^OI$->V[VF/:;N&?>>$*3+G*GF%H'TF3]6E;!>M("G"
M>P$1T1.JC"FGN/6:MO5!>040(.1F4&1%.D+SJ[!Y;*C ,5S^$YG4BNR @@>_
MN$Y6$^3&:I&K82> (LCM6&?4W<##5<#L[O]$H39 M&PS!_SZXK9]#E$Y7-V%
M%Y&U&:C(/0F5[AQRF?*8//+-N=459.QV:SIR[&B*6W,S6QE_OTLRH;6K<^@&
MTE%CI/_(P7Y3F1[3_\T$1S1C?N'>C7!CN4TWJ+WA/;,HB]QDA*#MSWA)A.51
M-A!F(0W_8;9\&2+5$724+I)B\.AT^:?N;33R.VLDV%_G'O,CS6Z?!F)N(];
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MQUO M.YLX! PL3,%L6()MA)IN)E3+'26 B$R =6HEH2_6^NA&J#(ZT2$]1N
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M0@<E&8B)'*9FN9!R67])%.&O,2M?,R7!.*+?M[%@%F=Z@BT)?@.,G,#!NLW
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M$U=ME,W=KB&Y6KTRSB=88$1,JGZX=)5M<7)#XR/[!D%=)7\J@W(9+&VQ)&7
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M1AJ?9LO(2AL?+L!M[5[ZO.0I,%(>>ZE_60LC</:U$WBEWKYO4U!-"6-.8K1
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M)/]<?9P8'&4:F<<@_?==OB^U*R>G N[QZ&%+40S*&!1E+@&,7X.%_]?)T/-
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M;$D-G\-%;"XE098;ZU'<@,XN.I&]LQM8,W(I$P9<&@ U#,,&#9V%6U<:8BC
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M8*+K46*$<Q5'7?1X8@E&#"]M:50=QQ:2='I_,!;8U@SKDMKB7\7?\O)*+4#
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M>BZU''8OL][0^^!]UF8(II*]VD;!=(HD>P?C6LFK&4UL6&FA<??Q(D](LG>
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M:Q(:6.PV5"\X>X#VLKXI8:+B&?P N/:&>7^C/.Q7"]P@6X(X:WE#R,F9..V
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MO?5-[:_2YZ=^+L[0>$Z?_9NIEW9P/TU'IR\OOOJ@%OI%D,UYAT4FW3H<X6U
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M@L]V\(,(%A/AI(0G]GL-HW9#'Q&)1/'FUBB*.;W ^!Z=N!^X;R%(BF?O67L
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M=&L6YSM#\X0T'?[VCFW6]T0*\U:88TX:\.2KE717R<QCW[ZPX,=N7[E\8)2
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M'5%I2DDN>A$!(=([$9$2$!$1B!(2I86>*XHH"!$!Z42D"DB$!+ ATJ4()-@
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M.1"1WF$)8#RV80G^&*CY.T/U$$!*-[<K6<3L0*KQK_\TWF@^_MSG25PWA$O
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M$L*@U<K%M(*!0:0D@)W1/54B\ *#YI7 ^'GS%Y([SDMM+/__)@!02P,$%
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MF#2F<O!CDGX/<SWD(,"VHA*UF0T"=+K9&%[U/HA[V2GO*B"DD#>ELRU'5/&
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M9;ZU[U-NB#I(].XOUNI)UD\LUJ[\@'C56P@G_DI>^Y,3U1.3EO]Y^9ZJ\P8
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MX>L;NNKB?YS^%7O)R/T!2CA7\O >*@L;R$V28*" (OC\4S#CYFY3B#.?!_T
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M('AGR,UI1D^. =_2OP,.@\P!VQO\!<RM&O><G3ZP<'%_)+$NK;:<Q+SSX:^
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MV9G7OGI&+_WB$%9LN[TKB_459'ZBH142Y K=B!:THE5&16U4/);=ZE:S4U"
MD4?IEI&&O<-S@1M> $0SJA*37(.KN9/D?[CIUECG?C8M !Y==&#RN@BKX::'
MK._A: T*S6P!5$;GN0XA*&8#;?VJHMA.($K6&M?5@;&>%5A&)D2_^3.A#WS;
M!"P&^)X)"W :#\N9G<_L_J?!SNJ9V1^JND\;!6B!1CG6#(CNRL";/\%DD+^%
M_<$IN6HC'6_V<.(DU=Z,QSH"KB J5Z#6G*,:42=C!Q176$P=LQPL_IV @_"5
M:NDZYETYR3E5?$13[37^O41<!TA<C+;CS)SWOC;##HC>UI/2@/Z"_UR)Z6)
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M<%9-%#G!C$M7P8%SOQ<<A@M+71\[99T<0 ZJ6P]-G7BVU/3P!A&--UU<BT2
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M)F8/+M^4+EZN>*5%E.I^\]K?1%8'/Q/QG8%ML=YI0BV1[6_<K3!^?;TD7/;
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MP,<!) %)S"!)@(D/Q,P'8G0 X@  8@7]-N!O S$QL["RL7,<X>0Z'(#G!9A
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M*;EDFQ3?$ <<="4N5..",\H#IUWK5-#S_?.*[X(<89<7EN+YW6N)'3?<:T@
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M0 R*( G:#<71X9]4$8(X7Q]]K5%6^^?TW>*@V],FORO,3R//_=C*.QXT.&_
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M"Z56-PG">YL4"8X9<WI!:N<O&G7BES>;6F"^>W=^%F7+"KP"#$Z?+!P(Z"I
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M#AVE^7*Y?/D&8W\J@@>8U=8E<8$[2_&T1::RA\A5;-DZP9V:B>J?)2FIT%R
MU$X$L15SOXG+[3@AFL9#0IB,2=B-O/30U4/7-59J2M14JCX>Y!3\YT&Y0%8
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M/<2;@>6#+9\\GB?I$&!O]F_M- 6^]0X+%,J,7Q6T2TK4E3F0)S: VR<L>K/
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MLF"+3!V%KP[L0U(F^S9Y32Q+)'<0LVW14%ALD?#B\!@X_?'F0869=4I7*QU
ML-S&16_/Y[=ZB,QO)7C]@@;\UE'(O<E[Q[SSWBX5$;3"-&KG!3\((3-8-)@:
M+H?" 3NX$^(;H [\7^<3+DQ)EN:^[:WCTSP\,?B)Y2*O:\]C?LZ?/WZ>!BLR
M(*QLYRIN=K,[U$U 13@A^ZG%(YYOA689)R=]^^ Y8TP;?V\"@G<8IC&#\&VV
MA<;SB\+^,F]R2O?EBNNU5",K[5T%G>>I9QN\SESU8K*I/H9#$A=<")EWN322
M+;H?&S5FYA;[;[MIC5@/MLL."/:*>Q]802[;F-S>[)1!WVF0TRF;PF9L[0<Y
MPW_C<%UV'KRWNWAOMWX5B+LJ]NWU*P O@(F3?9D.J$9L-,[/XD;F+WV=CPL:
MNZ*B.>R"GD0$YTUM'@D]Q'(U._SI?>^V%TD#]N\@:.&8"#J )-W(\,YUH'G*
M+ <=\,>2!&/P/7F6IHMZVTJ"M9L'#:&T4F1CZEPM\N#Y<3NI;\H# N=E5'?S
MY1T_\Z4[1=,8UYVC6GK"B=A/F/Y=-C84]\39HN\>I10F\4WT_L'XN#?MMQOT
MA\5,)6Q^FGO/H.']0R<[YBGPC57NFREV)( >0C5H-NH _ YS!25?,,=D@957
MED[AT>[F#ZE(G>1.[.+) +"!]:O)H?]BTT=9EZGOX,(VFD\M]-@L50M6KGPX
ML:6BC3BFBO]1U>ME#VD[&2H"F?([B,/LYX4@PY2GOO_0=W'K26:9T:1Y9R""
MPNKV0+P(9U ,[G"3@<VN%BO)\@-?\1X:[OO%UU_\:K?2\O!LK#AAX#T:I;9.
MU")*4&,;Y,E\%,G*X?U)2[<$5JM[^>9C%^P&FS[N-BN:1H'/OWD%$)'0!78/
MDH2VPVUW$C;7"?B!.=%XGE54A";<+=BEC'%A^=]!MC1\2(6?="]NW E1K-?3
MT,D=M>X4/9*"[&&_W6TXUV,;%] DT!E\D*O(+E*LWV/L5IEZ!UM1,52A4FR^
M79H3X;R0SO4QYT-=!,3H]GVFL+,+9S"W$',5R')(!,)I^_*?+#E"7,-=?22^
M.$H2)5>0ZG[92BR"[<$76].(%XTG>+V\0.;%<V"2=!?E Y*AW,==8=3+;DLA
M=[L@V5F&N?IZFOY&UMR502B1\L,L&8=:*S S7GPLS"<O*6:=H__J!F7$I32M
M#]'2!-J#@+88"@-]<*P!S< 08 F4T4'R&\0F%?[!)"".#A"Z)O"W8]F(MQP!
M1M.F *GMC'\J0?_></3X;\;\;3,2J4&6#)!O$)FW+%@DO2Z[YWWS\NSX^]M=
M66VT(#2ETDC-G " _01?<L/R7]NY&%'H5KEIX='G;[#-DQITV^'GUIW3KJ3#
M#@ML-$UPQBWK-AG^M<05PAR*(%8,Z;T0;(N?,+47\#SS3W)SI_AA[%[XG^7
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MK]G4MHHW\=QD?-=_H_4RY+]3+BY+J@;XZH;1V\\V1>M:3F8ZU/6'6670B,Z
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M>V&EH?FZ/PRT]]BT>0LH0MJ3M).3!52W_QOB:2*_=M/'7+3[?F"]P"XN,DR
M@=,Q9?F+-%';U?D K'BG@57EY\+ILIJ"1%A]9>6N#K NF>3/,$Q2U-R_CV+!
M%=O4Q3MZ,+55JB?D:" _:EQA#P0<)-X;S*H5 T5@7-0E M(H'(3*=EQ[<$._
MR..Z1NML$9G6+9F?^PP=#"0K!]@ ^6E#_">'/+__<K,1&-G(F[ISOM>'6P%Q
M1KYK7OW21X>HOB))EPZAO?K4@6[I##46H*S87@2ST+>-8IT?@1,=&B#Q;HQ)
M I:%)(S8$,BF]6+.^C;ZF(Q\178='U1,0ZT'+\NZ]-X,DQ2@S9DJO5!VG$Z*
M^Q)Z7X/]".Z2!NG".\6T]^PF8?(3=ZU9R2E:B?,O/K.KGCDO=CM,=_0 5A]<
M _=&M#@AGK.<#S!NUMDQ;C/SJ[OV!5UNX3KF-_1N<_MM3O@GL5B)K^6UL6>8
M1#X,IB%:SB 6MT-TZ(#GH8.TE'$L%DBP8&1-*)C6.@8ZOHW]20<0[O_M3,W&
MF!H?1HS7R)//&,>AHN9B=5$B(OS.Q=L./<-'4+ DRXK-]5ZO6M"5[V[,IT^K
MZ\A5Z8/3%#U3*S!9]94'19CS#%C-P>R& MDP&Q*(?0O(5BZ<G1%,.@B&;A!"
MC)LS2*4*)= */.(RHP-0"+(O^-OQ SK@9RK#-T,1Q&Y@.;(<34GG:$62K^PG
M4&]&--YLF"4J,&+D <F8<0)PAE[*,<#F0);34LE+T!W=/:?-IR*4F.^,'XZD
M)89%WRJ[\OL\A:':PW[1?BM"KX&<4PCRF6V(5I4YJT=#A4>>TA/W4QZN?V?E
M''Q08;<-6>] J$*Y*;K2L4UW BHA:3F)'L9/&^K]$ U/DNIYR7O08I)NRDCI
M)]..?NA$AV5W#T,-O7!;AC/MOQHHMJV(5CJOWU.%5/S\+ F=[0'Z<,R@S5-_
M?QWQIXF-Y)1+,=JQR8 5!B39W'^9K>'#Z3N\J>_WN.B%Z@33 $]1H<%M7:=M
M[GZ"?\07 O2M;R/_;S'<JH+7Q -VOU<?OF@T;S;SFB6'G G]C.W;J>P8\YBN
MEXI68]N'KOPX'CSOM<PAT"OZ[/:0;K*4TYA1306L&+9EIOLH%L$; OH%%W9F
M<[&Y.535Z*^7D5J-J=9]%W6 FXN-[RHH=;ZNZVRD-&07+W^^*/O\%R\ WZM\
M0QO=0A'V,_O6=_F/<T\K&@KU;634E$I6[]:7DYC(]@S.FZ$PYJR\#4('#$\4
M'T02&3HPS)>B1#I!H ,>8D$5I10=?#%9&R8T6GW+3"L\\Z1'F&SRNPMSK*EJ
MXP2FQ</_X\,,R)'O)B*$(XS?Y&IZRJ0?)OHU9O.(+)5- OO4+RXIJ9HA/N%E
MY'XOZ=NLNU)*!_Q=CZ$:9>MY&W^*][1HS)5D)><9'GX.TH><5<+XK"LV(6=M
M^X*MT=:#"'-[=^]E6^'3"1+_T %^&-UB//1OJX9TCK^M&KS^MFH07Z.07WF;
MWEJI4LM RR[!7?*S*53#XY483FZEK&L=9.>\>?9;385YU=;U(.&A94:^W&/A
MMU*D2"1<T!&0+Z(FF+R^XQ4?\C-7:77O! MU9Q8]CD##-B_/5AQN-.)A[);)
MM+%X5J?<L#OJ6)D)'KO:)ZD"M0]4L&U0PCWPD3CP,F;C"D-09:<WRM*8-_%1
M$K3S 2R:1C,V7TM[ YI9/GYZ=DMVD*JHAI&B TR1#K[E(9[?AVTV/O-8#X?!
MMK5)^NR#Q4LTSEX>INU6>0&.B;IX&82(I!K+6X0=;**'#B#V47.K!B_TO_2M
M.:S0*7!3;%M)$?=5R0WY3-EJORX"DHO65L5N*;8!PYOX2;)SO2 6$E2G<L@W
MF+W=C+A:[3/]Z<!1:>E38G 2-!-(@&V'VS;L8-K[O<.HV>#R[^4/XQ\,"F[-
MEM;1DH]A5C:BC@?%CD@#_=^K0OFZ59FTY<3-$;\@]=,$&I#E0\EHQ]WJ)>G
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MY%V]MLGI@+:7,P5#GV]71+TRW\.RZ6#Y'CUAN7#_&$@[-T@'"*L0!FG-Y72
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MJ/[W@?D!)$J R6F?L)2(!-2QO"\%^<]3_,W8(S[49"R%I1WA12.JUM0%M1.
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M@2SJ"+Z]N&3,)/?GC]R7KB!6RI"1V/2YJS@0 <(L95KD:)1GESK0\G5'F3P
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M".-QV8MTH[=LR9A]A0]@>=PSFNT-?T>]M<''B(.'RW)SHR7U\![E5VHC34X
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M,;VOS#+!1KTPC4LDQ)F''?0Q3HQM<'()&P^\*:N?<=\KT:]4ZR.7&V_!8D\
M59!->#ZR%<9EW6^#==;5&;I!\HSY*GH$%WC6%?]*=3/TKU[%.\97>^DW@TM(
M,(3(K]>P+6Y,F"J=N8JMC9[;!$2F>H*C\[FF[5D\[ ,*9R0Y"5:G8!IE'-)Q
M$86EWD[-(Q@G!R\Q#87&6(V+ F_-F?)V/S_^#OP0>^X5^ FNC^,3Q6O]X,X,
MKS#29HM7MLQ/>=]28BN#"(GRYN.B]AQ/ ^U*7'038XH=0*2I+N4"IY\C!.A(
MW[X]]8(K2<,15H[9C,E>3UYNL7)*YAVJ%3_H]M](#-./F:1DLL=LWYT4;O!G
M@\FBF@2I=+/D"Y0H66\/<Y^7!Q V2UV,A?F/.JM3HE\>G%<)>!8N='V7\9(/
MQWX#TJFUI*5P]-*WRJ75^*)*B@JF*H8$H>OF% NY(.9/*<CE<]JI3-RKP/C#
M_8+8]:VX]N?5V1^?^O]RP !_%H?)7 )\UW'@, XO=5>X:T[7]/M,L5 P4!I"
M6AJ=_4//'K.\O8Q 49(JBI1Z6<J=KCV2LY0#'*6]>-O%8H O#Z4O8#A^Q/HS
M\VW/U]&4<KC]FJ 3&8.*P9/]X_JD?[A>==39JY+><W4TMG(9.4I_OZ"C,.R_
M[X-=E:/\A6+;37^.[)W%/9F$C6_,C83-,\)"L"YZ-Q58/"@UR]Q)O!.:_EC[
ME[8?\=5S3^VJD+30U&2SK?)L3L])NPS'0K <R;.6RX*F3Z9YC5][("IP@> Q
M!;W3KJE#1/4<#_RYR.ZP(D@HSW+!7F,/GM3HL#V]X^($WU5=0(=.:>HR?7N-
MOY)[]6M6!D0KVP;3[5\[0[6-V@\V"_076H09(#1%9'0?.CA*#PT0/V>S;<*)
M_+"6=*(65<F)*I!P]Q<1_G#WN2(I;DI^&'RX?2>$S(#5 2W#B +"+7'SDN.>
M>HXFA+Z%3X^<XI_??BCUG!VHUTF+FF^A0TJ]1?#/#IS048/S12\S?%;<R>?#
M3=%SIS KC8KM]58>T$2C*Y\;S<#DY%6"0G"2X_=7R\S./(,TEEE5 3L21W=A
MB**SK4V+?1,[AF7A$.G)EBNO'+0#=[<!/<(+?,:&U-7/''O:<2NKZ=E.Y(?X
MUMG+JC>=9J[73!.BW!^G4?^"3$O_Z$.W>(+28QVI@5VW=>D#LH-@=B*(+<P"
M"F0_'MBQ8H3';/7J^2I\.0+Q[^@QTO)>IWE_AFZ],B)TV72-L.9\FN6R_X_^
M^U]/ &BK[PQ[?1.35(8"5Y(>F;T1YXP-1,WSH@W2N"0D4)6JHXV*4]IE]N\_
MF3Y>]<+MKS1JQCJ^7>KQ)B(9.[]"HV]^ B(EUO;TUBL:2YV0J_W/Z^\O,#VZ
M9J(S%C$8Z^H4R[!6(.?!/O(IZ3>J=+7#&V5W HCVE8P2ZN=L!8XUN@O&U))N
M>\5RALI3T%%UARR)7WF51L=H&0;=W.0)0)9&$B1@U"5,GX]@&S3!<:-'$2;V
MTS&?.($8T.G<TW;P).A)%"YW*K8H=KU04869QU[<D^NF+]"VVHWP$QRB,**(
MDAJS1]FP(W?4H:#&+,Z*@MW30>VNTC!(AXR+?>1XP>8[1H;RUP_4:@<5 J9J
M$1+#ZO5. /? 1X)@ZE\4-MH E7U'62> (QK!.11$,.+3%SQ&V\'AC3?Q1KL^
M4*L;0_98[ZKM2T?1)AK,Y^X'L/,P XH]31WKT5:-ABT^GN9W('20^$[3NLZU
MO9?XO6)0C[NW1L(SZ"?U:0F3(M36$&9/%4V)HJ%VKJH2Y7T15-,HHHV/=<K$
M0:%,FOO^(^VJ#Z>M.Y?RF)($ML[&P>R),"IC'2[78##0<8(EJKS@VSEB[ 3C
MQSUJ=]@]Q4.C#5B<=*=1MN]<CZ*P2,>0QX9A^<RVQ.B!.:QW].[+1'19865X
MRZ^"'KK2V)6JS)D9:%7,<17^#)5Q$;>J41)'9<6>)]99U ,V.=/4H^IX7/="
MXANQPJLP#NKHWSU39ROL4EPSIRS-B=;-HX"L9..X&KJ!8XB(X!)?P6X&==MI
MY<@F?T!5SPK:Y//HM&.1*#1VO',:H_N[P:#&M(K/WC1>0:?!_-[VEP^&!Y5%
M/@K60R< :\D)@SZ"-O$$D$/<W6A!X3YH9]U3,C>E8#>?"23(1_R47.Y,Y:]N
MG\GBB70G9-*B2!L)O!)] E@>/P%,>1QEBGW,C^U,7N]1- ?]=!(E3E@,Z(RN
MQ Y:BB5;FO;%X3V=XW]Y(RY::57YN;6M;V*\KAQ+Y-:CFNYC7;JQD]T+P6B,
M]F=4LY3]E[6 9L93*$)_==?V[L[NXG+5S47X::E.3%J.[Q!N-E@.S$T,[M/N
MWR?U&#X9$KPT:6;6/-"CG!:>_SD6&7^<?0(XNT!CM2 SA%PZ!(]M(YE;0EI9
MX],Z6K+?C=2ZOU*;8HU/T!\_9VVUW"N_MW*GTKQE[-:@KT#156%/BL1.XQ;5
MW@X:MY*J'1T/"S?P2ITHM:K4MIH4/'+TWB%?'J32J),[/MA?84&A39G+644H
M,O'_:N\]@YJ WG[!8 ,L% $!*5%I0H!([T14P(B(U-"CTGN3#HF*@"!%@H#2
MHO0>Z2T0Z=*E]RY%()!0 X2P\7WW[LS.?KQW[L[._C/S)%\R2<XYS_F5G/(H
M&H4JNL2;<TR7]2@6XQZP<R9-2.#VNP9'05>,Y]_)+X2Q,G=P.[)9/;\'./\&
ML'0NRW"RYCS '8!71ZH2:9D6RYTUJUM5V%O8*F!'A\'!HDE[20R$61;!EL"K
MDO5(UO0=!,(BL7L4_UE7W4_H]T56W?O_5P1]/'E-'0J1VZ<5JO=,2740[NZ%
MKQE#5D/+52ZWX*(I/..*U6F<EL +3 %V*H4;!:#!KMT@2S/XAKSP3E^O9>?:
MX4 .[GQ[?PT2W.>.T^O)WQVJ\\$F%MKY59P!6'9]*;>I!KV@EFJYJ\\ /O_N
MN P)&K!]*-268]]RK:N18[)'Z0UBU#V80.UY-?5@,/F1*]7??(LEHX#D""*<
M>(D$H?P[T94-ISPE(1?ZR4P?%]!AVZ]JB.P?L+J+<-'EXI',TNJDB7?G!2$S
MGVX>+RT(-<'IR72$K !@R!Z/TOTAIBT)TXZPA#K7N#Y3C0ZNU/AM"W6V^94@
M]:^V(N-=@\GX0'"M"8)VQ#KU=KSU=HI8BT9J?;:_6;44MGC9'?.ODO$W-$&G
M!NDZ!;Y<Z%< OV+N9[(5*3\4NFXN\#/<';2BH7:)M6DZH)J'[E@R\D]W.;?&
M>69NR^OFY=&;FVDER0'2H[U[*MQ+0DTK-0KS$H35;"4+B\*)G$IM&=OX@?0K
M)^<I+;\I+>GG1_>\B?SI0BEFC68=-;+G>JTNOSWW?I=?-2MM^H^[1'^#KOHS
M"!#.]2$1Q"+NT&VTF7#L7(0[MU-4>"5QX?;;IH>)J6P9)3.5C?BJ_6!C6 ^R
M,I=\';V PVL53CM]J%9E)JIW@F6_YV1\V9HZ&7J @*ET"VL(%=X\]HS$UDNW
MS8,"@W@TZ7WA\68R?_8D^R25+SF%^YFWH_(9>IU/<NL0#CD(&"F30L>^U VU
MIK01.]Y[TW5,RY6:FR2NUCQ*XO8:WNUHT%Y DVYI1KLNQY[8=:2S_WA8[5]6
ME;Z).?S!K9[J$:,17+@O$GD")$504T((7 ';[N:B&)$9^W"+].[HBM4#R6I7
M?[-=W&(0[M\J=).H,A?US<T0UH=%3I9WB(^>8^F]%,P"[0W'G)Q#)3TU-/LV
M%>;/2<&?ZZH'^=@DORK=;RR-2DD]J,=/F#W"QAT+:L7-2Z9*-BT/)RCZ-B3Y
MCE3[S'XTFE*>.D@]C2>SGYCY<=@CP$.3;K>2RANK7_*LI*]RVJ-I.7]V?3+\
M(<EP2?4"*9:*!Y>)-CFYMPFQ,4%*>2;E\3<WF'KM1)W&6:YW<<0^9Y=?DWI[
M'*$>< 1F7ZDU4$F\GEM++A9LA$TM6ZV2DEJFPU7R\;N7Y?*KI<VBBE=&*;!G
M,XR]\'<XPOV3UI&%&E+XDA:DM%T-U7T_>B+W8'?%<!*"_RHT51R<MN@V'KXP
MBSN1F@D2JAZP&@P"*5MUWPAG:9*_G?CG\838O1?T=GV;+Y:A;!N?]7KE<;(=
MP]'FZG9;THN)$3+E9>OU]65E$$;/JSG13SB>*E8^6A("=7:!7T\UQA8866JN
MWD!3VW8E18.8EC8-9%F,?U95"^WJ_,Z6XEB%QSXS2 7(>6S$C!PKJ;-UIQ)O
MO$S>40Y^YJHU]:BZ\D"K3*G&+60G*M3 Q!!LAQ==WGX"J\03Y9PL\-/D8P*,
MS.38WS1WO:+8B7+#>Z0M+"E?/: *.7XY'LKM2<O\%?'[_JM+<D=^_4J!L#4Q
M5H-5;K4OMJBHTGV%:=?$"-.3S:1%. ,A43].P[TK[T1&-K7A[Q.\"U'.9794
M^?#@VVF*,N0$%@0<5@8N"KRNKFL='=,%V/ZH,=_\*C5M_0X289+4$!1/T*?0
M)>0%7255?B/50TE-'FPKH7Y)C^\0QJ.S[R/\NKER.%Z+YHJH7?53 6U'@LRK
M(\J5&7B-GXJ9Z2=LW\CDWRJB\..]&Z*D8N@[O<QME!&*X3*F/LNHSQDC:6,M
M=V?[G6:;X)*4:1SAJ0X]92+Y?<">[Y"?63M3ZRW%STST&0WJ)X7*)A9M ;17
M.1@8YED9<_(P$+$>HO'E#9:0E/=CAD?2>TZ=:P$3?="WO3_*FFRE1YZX96X/
MY!0-[6I+[80=4N@$B HR%HD4<0)WE<(9P()_S*,[!KG\Y6UX+G%L /X#1[X.
MHG#J+\ZF+!7;M:,<)]L3X[-N&-UH5,=LO_)+Z?$1R.(R_W2NA$-XE0-3>1>3
MUZ.LUE?ZQ?]EP;!YF;:2.B@W$U8-!P$9/Y,T6Q1\Q#DF6<U2;WYV4Y!.]M4&
M;=C-KJ911H'E>Y!*N<W313!-;P$T(P?[Z6W )_K>>G5EK_QQ$]]S P"-A2;E
M2 )P/)Q"+P/<]"+^\.O2X84N:L8T.\GCV35NW.>47>X^VK$&, (8'BLLT6Z*
M@)J;/2Z]#&L:[EXSJ!1)6C'ZV#"H8U12H64;F]<CKRG<OF)0'F3(Z[A7E"GN
M #*IJM!6GZC:?WHW(Y(8FZ4J?/H#,A]#H(S *QBJEWY1;D,7#L>N3VM93W)@
MF2ON:5XR))-(H)NI;//Q_;G#Z/+59@X*#9F%T!_RLC%>7X=A7-/NH/K#(]?+
M^\%OTKZAW"7=Y3LW+!+8-I=J0NZUOW28+V53R!^J%JDP+"JJA,KE)%<%S<*:
M%9Y9Q!9_G5_;&2WV5?""SFY_79MZLFUQ7?7?9MAWR";5A=-Z9ZQ(\6)^D)C'
M@EW=W:5G[/GN2>=X?F*^<E[@T*?U6)]^S:=U0'L:_OTT7)FV>&UC$:JL(UL=
M5!WK[GPQN9WMW$7ZE<?!4*7:7_-6Z(","(]++W;V$^K0M:8[$[XKL]-3&S5+
MS29/O7S3"^!X,9/^9#///++<,DG/C,KEEA)[=KUG@"IV,LN5A6V\!U*P7'+:
MSZH-!0 :#0WH3/ZXITR*[1:D)9[#_';]>:Y1@4B=I$J+/&D+%HSMZ5>&Q7;<
M#YM7>G^= ;SY/B.71HZ+U8-]]#M,^N#0Y]^-"&;" J  N0)+6.G15O""+X/M
M_BR([<&( /;;M-FN@_V<S\B<URYX(9S,!(0E'PLK.RSA92<GW*U#U"O]_\0/
MT]O0L>,$N')U=+ X.\B$5Q.DK#H$4JK,E=GQDKO&J3"?\:LO8DG>(5NYBCH:
MAIV3 'G,@XQ:KQ+17J_')\HV1DOD?/Y&![?=VC7WN?"C&^H0IZ3G3P*]9)?!
M\2Z3IRY.^Y<+2^Q]$((#KGLS#T:YIJZ0+&=79JT9N8DU(K]^$M0NO%-9'V';
MC8M_MG9"KP[U[+;:11^\I8[<M99"4AA5\"U@(O$5]4KO+*2+'>5>5ZE&N*=\
MP7RSYJ?IEG'G9:.^D9:L43]\;@,A23!".\5]%=4>^?-E>T=9EY$<B'8\A64T
MKH='<.Z+6'8:/ILQUT<&5^[[0L3:_*2:$X@,]=^6?'TYNIY O/<LH=GC1V[S
MM.3K\ 7<S]A+ZZ-+>-/#B,IHQ6"5_>ZUWPV?$F6CDR?!]<PMW@(I59O703UG
M !LTZ<Y^Q^;AR7T_9'L2CNGV2#%9R7-,PK0IBX-WN:HLSU;RA]KN.7>N'/D^
MS5E66 *O9)^8B2+^Q-#!0LC;MJBD8<3VH'1;JR6=V[.E2]X&^&+[B@)(*=?7
MMC9M<!06<-&6A&N:U&EEO&9I?[R29E?H8/K>%I2BE?>^]&ENJ7X'B=?I2>V_
MXU)<02 "8W/I!N+>:/%K'A&GS^5:']^TF<(Z#8_4E$.MA@#"0@!8_\*"D3??
M3?I:N);EX4Y5M6H]NUZHHF2Z0/8553O0W:GB[>SZZ2/@XBJ9*7.A/\K;'Z,,
M6KP6V+0A(7;PH##/M&V-2<$$<.# 12AQ:X(3[H.O_3U<H]PA11<[CJY/V%><
MBBM=LEF*[N>?)2\U!"_,]_.N(9DKC/?!C!LW+6MS.Z.K9=FA'LS]$']ZMF*X
M0<W&!_N6]6UF 1<9:/>V4PI1E<&2W3WF3D9;!SUM,$PT*^.4C_,NE:T7T5-+
M!S8$VLU"*B\.$P_BYV<NCST^\7(H[7;W$IO9C=:@6A5_D$T*0 +P*3.59K!1
MEYH7M_ZBYBA3JLZ.;<X55SJS;K&$BK$BPWLVQD8;="A7#$^<UGB5!J@B.[21
M=;AXW\HA +P_56ARX9,&,<P8'Q(5]J+'@GCXY%N?+PV.^K4<I"O>66NJ8J38
MP"OJ#,75ZD.<29>,!ZK[YO>GL(^^Q4AQQ4PCWH;F?VAR=Q5L?#&GXC.Y@I-:
MT8V<LXA')*-15OGSNV!F@M_3#(D#8^,VU4>U,+[4F>*<F"?@DTE71 1LM?_=
MOYW@LHT,I.BLC8>+H6UMZ4EY;0%BC.'-W7<T;WD 4P[>G6>2J+>5ZIL=.;ZF
MCM#]3+ST,E$CRUU&@4U+V($]T'(JETK$D,!^DJ9PW_(3_S2P_5_9I6VH23U\
MP?%PV6SN148DJ%WUT]&_/034-IV$'VQ5$#*J(_\0*B@W C-BI!<"DJZXWYZ^
M?%2:<*NY1D%%AX=NZ/0M[N7:&> E[IQ3LB(I48>EMWBN>&F:B\:V]&+4K?OI
MUN_3Z85\/7ZVZS3H6O90D=H_H"M-9[K8WX67/#65$NRKZJK,][E#SG\]FS(X
MDGJ472T2VX* APJ4+N$JSP";:O-S4SHMD]ZYD68&E=B!H*6<.>-I?T_3KSYN
M1\:2]]S$)#F]0N=C*HG V'_72,P*5-8G8$%+> ;*^1Z'@DDM^XU-4X@T,._\
MWTF<3EX)&1U5'E26G!E:N 4N&W2 6XA7C%G<5&Z\0U@-WZWK9XG]'A S]MDL
M*BTA87/0Q\@T-^,QN9B01&:2ZCA,<JP[C,8"<YKJDWYHI8R=C_&I>R U%G7
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M%-1X[W(F*C@T6(9PGD)W1$0OQ9M-S]J7DH0>IUQUW1^]UV.P/^5*D^2C>,F
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M3_PG_A/_B?_$_^_B_-G$_P%02P,$%     @ XG%;4*Q>>X0T$P  ^Q,   @
M  !T96%M+FIP9YV79U333;/ _Q%X*$J5" @2 4&*$&G2B:"A"AAZ1RQ4)0J$
M#D&0(@@8%%$0$"FA140@(%6*!"G2.T@W&'IO(;EYWG/+<\^Y'^Z]LV<^[)DY
MN^>WLS,[2QVES@ <!CKZ.@ (! +>T 9 G0!N "R,C$R,?[$P,3&=9F$YS<;+
MP<;*RG8!?(Z35P0B>DD8(BPD)J4$%9-0D! 2OJHEJZ"BIJFI*2IS4_^&NIZ2
MAJ;:WXN 6$Z?9F-E$^#@$% 3%Q97^S\+]1O R01@  P=2!@XQ0FBXP116P$(
M ( 80/\2X-\%=(J.GN$O1B9FEM,TATH.X!2(CNX4/1T# ST]S1I*LP/TG Q<
M0K):?YU%.#,*/^&6>XK)9A+1+FL"F_9M7)*_ZQW!S'*.AY?OO*C897$)207%
M:TK**JHW;L)U=/7T#<S,+2RMK&UL[]U_X.+JYN[AXXOR\P\(#(I\%A4=$_L\
M+OG5ZY0WJ6_?I7W,R<W+QQ84%GTIKZC$5U5_K6EN:?W>1FC_T=$_,#@T/#(Z
M-CX[-[^P^)NX](>TN;6]L[NW?W!X]#<7"* #_8?\CUR<-*Y3]/1T](Q_<X%.
M^?_MP$G/("3[%Y<6@M'YR5EAN:=,W-J8[+(F9A%YTPWP7>\^EG.7%&9%-_]&
M^Q?9_PXLXO]%]I]@_\4U#IRA ]&"1\<)P( ]#_&/X2SB1>?QY0\^3@3N>\_#
MGC!>(8Z:O;#/P,B]OO,U=R5^-Z8HH%&OOU-G@._WA7LQOPF#.^#FY4SHH&)$
MGPB_IQD5N)*C_ID*N.U3+"(=<0*-.-TM]2LZR%)I\#9Z 34RS:G(_-Q.+>#1
M0!DRH[%EI\0PB<O3ZN9A6@9!0UNSZ5!&2BYN1TC[];7G"^;?1PHW]9/KI[IB
MH$^D(/YB&"\OCD57C$F!MZ2JE)T(F^MD;Z33L'39HH?51;;P=NLP'?S#AHND
M7@Z9>]%_@I-K>2DB2?U?/:14;F-A<>+CO&F#%#[Y0=\> 7>>E;*N;E>)5>A4
MS_$43-WJ)M,=/KV+6TSKCGRVXTK/41<XOT4XR9TA]^IW9&&SCZRR[*!V VB1
MX9;?JVJ63@I!NV!,=D RP2%^7WKQ9PZ4+NMM<!)BW79WT8 K<C%Y<#_;5%&D
MF]&7&P'7=X9SWP;!P3=LAC[T^?Z1(2XD<LIW5CD;RWK[W>PPX/1^TUX\!^6T
M6SJ7_999YCZD)EXCM*<R\,')R4^LW[Z5][M+8<0/@N%^W$[3DQ[^R0Y3>H[Z
M[)KA0>P>I4XWHEMT7H3T8-KNB<:FNNUHP;FM$,VT/8%_JB;S(OZ=6(1.XDT5
M2[,(UB!D5(B58"5DS,N/$!3Y8<9 0[>Q@ J(=/[9Z!:M^Z$@T]<>X_WE/8=G
M%F=,@MO8&FI6UJ?%>-FK8/^\%$_+^2//FL<N0EX?F[LB1XY;1H>'0G9F9B_S
M>86&JF(*&917FN/$"Q18MK)XEK,F5 NMTZ_A#_4:QW>1A$.00T_\KEG>DES%
M([Q[3PK?FOP@Q>9$JD-JN'-I'4%.HE-JU1 G#%&>TBA* D!P7S]!YD&91U%#
M"V76UP.["+\) U5S<".EIY>3Q5X9#N*0S;LL3?HG>N1NGSHC[M4N5,DY(4)Z
MZM'.Y&(!MOL,?EM=7H?&<J;DJE:^E0Y1Q$CMZL<X<>!?6KF#/$VR'=V6GK>>
M813TQ;*$971[4(%FEF3*VH!]>=I\G8/L(1?:H-DZ[K;?0U(T6[W>MHZJ0 ;8
MQZP?Z1N?);QWEE_0?-=2\,-^$:KB?NZG1'<=1,@72Y?$R.(?'TEE#OD&H6/F
M:*[,G",*>(6C^T*KA,*M\RK<<I_7V TV2#OHF*/"VOZ%SY@O>]B%'E_8C,^1
M5?I;1%WHQZ5@&V.A-J_XL542J@(!#R#T93[99#OH+FYQX5^H2KJ$KI@^N2.5
MC(-R3H86MUIM$6$-#QC' B =Y9Y_"FXDO[X;8BR)K2B5"(SRS60<F*D9RJVM
M 5H>0-ZUS_L_/%&!1?F@!@_8?D.KIMS+KPTV/"O8%U$/@Q<]D2Z2*PL0Y8E-
M4MJ=V)1#37DOVS<$YOEQ1(04E#>S;^XJ&O_<(YI\M4O73Y.PRI$X82_ DFQ1
M;2FAHAD=L[T;P5=7="LM;P;>MYXW72.P%,GIXX1XO6W5> =3G#PF2[M]2C?U
M8JPW=I-B[[W0E8=(WE';A60S"K95;_:<JH5PM"HX,5J[;7T^-D\._"*NP7B)
MDLO^;=@_XDKR?BN&CUMNHC"=<? .^V#D@94B7P'B=8W41.]JZP#JB6S,N+O3
M2*'70-/>\!O#T#FI]3*=:3_P,148R;K#>BL-&KG+<VY/M:YO$L;\^Q0(MB'*
M=^3RF6Q8V%FT[,]5>P'S-5&40HHD'% 44XP5BHS5^]--.N^Z.B:H>&NGN?M/
M40%,#F[)*@@\&KWPEQ5?HL7Q)QAA/+N_I+$"96<GIW=6#QQ+8D3WUU3G/_*?
M722,-P260!9\1EA /\C,X,XE_V+LLF6JUV-,AU(67!W2FU9@_K[P!^RYPUG+
M!&6+2"?Z$BK0S?]+?MA!!OUYQ03CZI'M<'L^\-O,,;N)_8AX27O3ZY0[WDS*
MPC4F_'],QSVA(<4UX^MG/JF RMHIC0D^%M8/(/>_HO.-%7N6N8A_JK W\ -K
MZ=\=P?7E]9H/%N,",09AVX_UR $73W2#YCS+-Q9KW3)Y!E'!I5,G^1HO)4A3
MU\D_(.'=3U)X@R6Z=3VI0$MJ?"W6J&<.WY#:*^7?E-K6V8J?]^,*:?YU^.=H
M[G/AAL'P/F?7>P4OWE"M;E_S)'6!X/>OBU11(HI]F?-P,\I@.17(;,P#;PLD
MKX0V5L3XM*TY==6D'*UYHVT3LU17,N&49<S1@!3)DM!<W_Q&15#BG-YH3O:9
M$BP]YR\\66D6/_Q+GYBZLG<5C4O-#YXY2S#&5GI4/5?7^%B5FN,N]438MSHU
M,51+!=;Q.0,=G,RR0L)&UUD8)"\ZJ)%?MH?<<T4_Q/\2'H /_WRE\]=ZYPM(
M-L0@* ![O5\KE$?'686>68P"(5RB")COXRW#% =^YF E6XIN-C8\>X^D AI)
M,Z%%2XX7(DWPJB.Q/#\B1-ZN+@A\7<608]!81[7;B_Y&L,5&L[Z&RQG>%2/Z
M-H](/K91)\/8 %JEYDFA @#C'49GJSIHD=BK4JTG$JW2;Q<TP_?);.RS=DGS
MCY00F)PA7_/D4WI6]/)%>\O32W#S877I,_C"PH. ^JD2[%^B#.\T,]KWU..F
MQR]#7$W5"_\L>!^?RULMZ,G A5#FH#P!8<&LVG9+(G(V]DIOOUP68EZ(3,R<
MMOV&QV=NH2)^77YCI6RAE>P9-N T0KYZ[N?<V45PQPWOF*<K090+DJV9L#KK
ML8<[QW8NSIV R4%8Q:SD9I*D@:,_6,\9JR2A3ZBI6K ;Q*C+SC2N8!\CD>F^
M<6Q^1#[R5>#H=W7:Q".>5M6V#\GVXY,5J?0N[K>C$"23ZQJ-DN/OR(JSUXYA
M8^A*Z,!Z^;Q'%N%B&)!E9L9<9-#YZ]6(=M$ :EI^7^@"F K@;-)S AKL^&$K
M)]ICR)*R\*0A7:R&;EEQ\:<#S:&$[_@8^2X5BY>L7\G63P\M"A2-E-H^X]/1
M+#8.I=>^2/S4B#GP+\'!FI2V2%_LIB6J*JM4DL.Z8&,:VT?^.R737VKWGG_?
MM9HF=X\,2X/U"W&O/)&-=Z/KY]2Z@Q[(WU7F^*ULOJ'14[A?DK:Z1KZ79ZNG
M,.$@QH]3Y:SP$J'?O\CA<[!;D'6C+\307;0MW*AR\IZTI] W6 _D]I,=G+.-
M69QIS!4T[F=0M;_MH[:/KVMP#6M$?KA4CLY*8IZ-,2]G!*NH7Z9[\4G1]'8O
MQ26N]"0SU(0(O^=V07U(U[,W--VQ(8;WM-K\DK'NDD<4"L)QI:&G-#Z\4;I+
MJYS2.T,)#T-U#N3(!#U)Q2B_#5;M3WHW2EH;1X;[=BHWF.##MK1AL9#TH])%
M^]?71GA.B]R@3XY-]7EMZI=DMB15O(DDQU$@5.#3:2KP05J0F0J\-&ZD H[+
MM.D/^PI2L"I;*/)H= UG.''WGGZM%+2#*(\E\:@ZS#F,ZYG>)+\-@B L*W%A
MQP[O[M<\,-?:@@MJES8.EXM_(AC+V \/;J?8%*BZ_QF=V&@+5RRN2IXEUTHY
MU[C^E%_-G&+7*+8\;EN^G]_9LO=R8@)[6L+1;I*=Y&UTY>9HB*SKBY<CKSA:
M@[S&T3<)\_8_T_,=/$;N#G?3M9M7709 ]L]U2O)4TR\CI54SULRRF<QR-O4=
M&FI6$DN-AE9#[-Q/,+@4PZY72&^ 3S/+R2MFV1 ;X#'28BB#*]5+O/A0Z_QV
MW9[RFHGS1.'>G)[;9&3* Q@&[')LWC!(;L1/J5-,5XT(6"K@-(U3BDE99;:%
MHBB.N00^?A^+A-]X-'&)EO?-34/?E[N*F9\F==)!631S&!7]#(V@;7[R]J/7
MI16MHXFQ@I<H,9KU/L-?[4(EMXC&U8/"+_B#[](GO$?MX" ,M_H"BGHE+FKN
MWE%+P!X]-<@3UY'QK7A"J91\(UQ"/(_:?5%[N*LCZ"BAW*$*R::W'*("\2@'
MW5N&S+FWPYVG=,Z;["=HS;F]@7 Y%>ULQX>%4 ';SD\IO(.(=$=7_A0#N13E
M1C%]UHI]-7+L_=1.TYXR_?$&[ 4&AXW=A3?G=]_WE2%^%S6H%2J+;.%H58@*
M%-)V6 ZG F/%J0.-"Z*TPN[PZC N1M-?6;&*E "&N11:F%A2 3&C3U2@'8V@
M J6%Z!UY\QR=9'B"CDTLW;(5:OJ0G03;W852HCU&HJXD[#^_,N!EJ;1M-PJ%
M]=!M%ILNYG6/\56KC"PX.)&"H&21-^@%A.V.U<]@FWU-PJ@IQ2Q]\^=;Y(Z(
MNN>[1_Q=@K7H>#*:9>MH_]IMDD6XI Z3QG)[B&Z.YO-B?62$,S+SG,8@%4#T
MU]]JJ!S(I^@^3Y\=3RZIY^MC-6D^PD=A;4FI/C=$<[6N%2G=!M2C1"IM!J#D
M"[E-*-:&' G#RM-B!Y.;$<J'Z'%%XH[5C69XL8^:'P7S7:#9O=!;9QE7N3JY
M3"',P(Z8[:G -)0*M"+V8" JT&M I!RB*<)?620;:$>1Z80FG]*L;B1.AJT?
M7 XNS7L6!CSU_7'>3DMI;:KIQV&ZQO7UM(Z#8%K#?);68]2B%?/=PZ#1!'B\
M84V_<'VBV*7 Q*O>^DOF1VE5R/D$S7X3N8D6RUY-V1H5L+&&'-?7DPSK@0Q%
M_JEZK\3I1]HH]V$?@Q_N+MZI69O'L!-?)!%A91WBG%M^#LEBPV6L+ZI"!0@2
ML%F9/BJP9/:%/$ %8C^EF!99+I 1WR45^)'CI5]I:7YREJ)/*:.%&/9QV"J2
M"BQXT":!C3MG[9CGBWEQOW[!6"=RY03J/(6CD 5CD;=BVFH>U15?$>2IC(,?
M?THLTNU]5B)M.V"?Q9.V@O)Q/BQL=-^8R%D/^W[B,=&T7CQ9>;*S.<5S,E>$
M!Q&^I.7\]X/#69))01G?_R1U;F?Y=1$A"18XH6@/R6UT8,*MA_83YG-#Q^@F
M#3J#0?4+.;CF<9(<YG&V4XA7 !';N6[N'/GMLY% 9Z']6D+DF>)=QI..>3?L
M+MSO\%<#>H-^<S6W_KWOA"[E <XV8 T5/Q%KY^L]J;<TVJ9U5^O3R.ROMW?Q
M66:8QRZ:]KHGF$%* +DX;D#AL-)(FU^9L4?JGL9K_\M+4J,KJ\)EY='#G+&S
MUXL/+'E)<=Q#BB-;JE]J9/)<;>V@W:_ZX."Y+#UPTIP#BX:_D>P9Z=9 -_L]
MS9C1X>_@V^G/7N=\!4NTY=J+EJNKNMVO>C?[CD7O6;$4&^U?@0TH;RXN(>S5
M7B\,BEP2%8R9[J6UC+^]OU_BJC/-N13[N*.%_OS1%8V X81A(F%NXU6+<8_7
MBT?<" ?&BP@X-_!/O0VZ!,@9 5R/5<3J&9L%.:Y%*4H;P*91T><H['M)C57(
MTEN>E@F\VWI++<[8V*PK8<@R_Z8& 4I[^;%%Q]TMU +DT*5QZNAHQ @.WJZ4
M-,A]GQN:<!Z1P\"T$A$G7M*M'2?^X529NM9LL(:?W$*@TO60<O'EE99J7(WD
MK(JV?5_0NT$L"V8QK48=:=F[OF-35]NN9QIFP_,:F4W)\-2L;W:[6_T\.U/A
MS37>^ZAV6)1W#;9EF3^YWWU;,2=K1L0;'5MJF^C,DV?$GM7Z0#Z^G@<U44A4
ML%S<CT1U"J-[NYO9Y\/7>V9'=DILG-\P2EQ!\K,5D;1*M16%8%&36ZX&>4KN
M^=&T4+@XPR5%])H0AK)+P ^<)Y3%T[\UT(]+!WN0?\BXW+-H)M$FN>4GPTU4
M<BM^!W8U&4 J&CYE>,\JM4^ [U^N]!MW;2FX]^"568T\Y[!X@-/WFJS^FF5#
M*4\F^FLO+\DFS6HET3+E,:W]5+UA&50=DI\[15IJ/$O7DLF*[[\VY;!:72<0
M298]T3"I]QU$.,(-D@MEW.67W!%1O%M--@S<")NT*&[$=89_ZNWAQ@4!*D L
M^QA7':+WL_1;C_@0>@0ZC[!&$]J/SHN7YCF!-KTI$B1-7EJZHF=@N$<(>,@B
M<DY^Y3'M\8E%P,&8ZG_<!1!U[-\ 4$L#!!0    ( .)Q6U =%.8$\!$  $,3
M   -    =&5S='1U8F5S+FIP9YU79U13V[K=-($@(AZJ@A$!*1'IHK2(""A<
MI!>I%U 1$)$F12 V0)&B B*A20D8 E($1%I40E.07J1%I >1D!!:RK[;\\ZY
M[]P[WAWCO;?VV#_66&NO]<WUS6_.O< Q\!NPW]3X@C' QL8&/(<> )P # $8
M-S</]QX8#P\/'PS&MT]L_SY^_GV2PB*"8M)P69FC\*-2QQ!:RL<4-!2DCJH8
MJ&J<UM'7UY<]<>Z"H>YY+3U]G5^+L,'X^/;Q[Y/8OU]"1_ZHO,[_N8'O 4$>
MX GPA(/M*, NR,8AR 82 #@ L'&Q_=Z /QH;.P<GUQYN'EX8'S2A=C_ SL;!
MP<[)P<7%R0F-1D/C *<@UP$I58,]OUEY<!\-%%*[^S2?1_ILU0=AZWZRC+IG
MT#U>F(BHF/A!V6-R\@J*&IHGM4Z=UC8\9V1L<OZ"J8VMG;V#XR4GK\M7KGI?
M\_$-#@F]%18>$7G_06Q<_,-'"<]2T]*?9[S(1!<4%F&*2UYA2ZO?U-36O:U_
MU_"QE=#6WM'9]6E@<&AX9'3LZ_C,]]FY^87%I672.H6Z0=O<VM[9_86+#>!@
M^[/]C[@$(5SLG)P<G-R_<+&QA_V:(,C)):6ZYX"!%;='X&]'U>[R")U]FE_U
M@5=:W9HL[!G4#Q.1T9B17?\%[7=D_SM@]_Y?R/X)[+]QC0-[.=B@Y'$( DA@
MTU>^X Y,OFS5RZ6Z7ZEI JL?I'\^XSGJ):O6ZG%J]63F%Y44C9RGA8[:)8DU
M22HO&+/!\BP>_>O1%J8SH7@17^VN:Y^C<R=J5'/Q:X=!X%/ERE!A!NT5RR3V
M80^M5IB*F@O-(.ZG*3P2N=EZ/>?1H0FJ;DSZH\#O2E<7]6]@@N\/'8\UF5.]
M-.20#Q/*)Q,HBIZXH>VB+B?2S!>G"$?Z.PVEX8\2910L;9^1D9'?98]N.OHD
M2VK$OVK>U^'(OKM%QY'2SK?<]]>>XA&]V1K2_.6D*L,$C@D*L;?)-T4)637K
MVD6B]F:2&MP3-Y+.EUVU\5-E\=9S+T7:T\*O^"_E(H9"K*MP.YM3,T_(R"D]
M?'H$K9I50^RD5>XT-N.4T2 @/7*M;.J0:]6H$N/S)162?GC6FAP(.$_7X#ZG
MN;ABWJV=#<R.*/AY+T$>*R]?\*:VQU/R-_/;V)N]6YXIR.A&V*NV+DIY5_8L
MSSNSRW;K<H^.]/G? <S"CC G+X% 1\I;:L7QIN;ZH1.Y"R3[YPZGCZ,R*@LV
M*;.6C<]("X8RU1)5R,_+EJ-]'N3^0KCZG.J++L\KXXC+0E9&H1(&1D*6;']Y
M.4<R,D1$%8+]$$:*$C@8#;YW&RT9.5EX5WC2:^OIXCUD4POQ4U-!<4UC;CM)
M!^>S-Z@]J R1)1B?=&TGIU[W,GF0M69[.U0XZ^6*Y0K:U]4D]DE4=0>S'00$
M3 <J<M-<W!&3N]L7U1/2;GDZI&Z_<=8>*6L_V5,C?M[$BT1,H;2%N:D-[\M\
M:2I]W2PHJFBSUV;'FRH\;T>ZLA$&,>)^UO?#:0XX)GO#6KQ\.6[RC?SQRJBB
M9!-I3)#F6-0I$'A23F3>!(&OL;>^@\!=Z9[WJ*;W_>^VXR5KA_HD5;,^/4W5
M#W.1B+3KX6OW*2>97:X[=L"VCGKB9^[8ZQ@DU_3*@4FB23"GCRPAR_!RKD0R
MT;3YY?:-Q5:67"UU(<$.K7 RK5>,8W3%1;TD=LX7*=S4:Y]^/1@KJAS;\MGK
MQ;J:3(PTWM:R5/84\'?[E#M6[H0[U7$(/N'.I?"%-PP;B F:(, ,U<20Z2QC
M=1!P.;23\ /+6J'HCILQ:U&/:5JA G!,7'[@M9"1X+VQ6A%C7W0VL"$HB>+R
M4D-/C<V'G\X3%Q;%.#<Z:F^RI$#@:1P(L!KQ5)P;/]0I[B41=WG+9!\4O*(Z
M.\?$VP9NQS^T7!C8_!HF.7M^0%G(E:=/7LKQCFJ75>I%LJZ/7(+2UBO_TA]J
MZO?O]QP^]6N%1>80"/09Z;S'4S0,6+,@L'2L#D]79C;N2BPK5X# !!$[2)K6
M-E>VR24LKTK%5N%[VL-[_V83TGOX& 9K<%5C(;&;'A;QKF,F82[*&<)KM$6'
M5C$0ZN4#@<[/'B#@&NM9F1:=HEG[=BE$-T9Z12)[/-CYRF3C;(WMND:6[8FE
MH>Q])9)^.:]3._ 4=20SR&+>92IT!@3NPPU[VU%-%L-9;L(C7Q[C$(WP-^8/
M7D3NZ]E&)45VGA:7N.\F[E;R+<>2I V32<KTMTB;+D+Q,NH9B'B5PH)7+=ZX
M-$_)*5$2WN;%=FR4]XAG#3]EPJ03!'S>(8O'YU9,"%IPGW4NQKM.]4KN,0F!
M/OO0L+YX67D")=!.#Q-AUHVHW X$ 2EG_"X4SAO8[,J_]A/=R3)^=T @XFZO
MKZC#?E+&8V%"5<4X/#:(>UJSZEL$)J]-L&:@Z<&Y[1.$S3(E&];9T3S:% AL
M2#N[L4.'GXE<204!1;MGFP)]*JM,7T0O33Z\A&7L!P*[)#^SF2U&HC>K7HLJ
MG/4];T<<2L8*MEPYGDA1S=O]1NRVA1(7NB-JQMR!:*0690B=/<0)9AAJT;[I
M$-0QSQO&;_QF]Y\&G,R84[LQ<98@<-O]._.";N"OD5XZ%@1>)H3=1<U=N\_L
M@)AAKM4!IVA,@D!#WBY/2;@HR_@A<A+%Y!Q!47E!X 8KCDB%@T! #"9 !,IW
M?S1K^Q>=U#^" $5M##7JX:HT4CA#UPNS,7<B]*J^$(Z^VSY5F!QI;80-OT5U
M&/0:N+Y7_?$3LQT/?1>)9 %-6%ESAC)B O6T,!\>T/NEHN>M:W<%9!&=W2!
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MK?!;M%(-D_?*TT"E?JK *_<9> 8RZ>:T6+^S\_"S8]P_UJ.H\ "+CI)%MSK
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M0[4G%F=GHAUB4[ PJ7HB*L[LW5IP?]>=>Q9:X6/7PS,2:]P"49/1-^'B!8W
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M5[UY,5R4 P?VG'0KK/.Q^Z49"ODY;H.5X[-CD;_M\/LL0&.]1J^0!2L;I1#
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M=;;\0CKMO/N;%M]O@4&)@6RIBV416@4SVCT'JFCJZ&HY1T118NJ+\>4P1T0
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M07"Q-2F1ON/^(4%S5*A0G8BD#S^\80FZ)=<FRR4RTT3\&SA%?*>4R6^UJA+
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M>N(^9VE_T__K7_3_%X/X\&]02P,$%     @ XG%;4.-(J49#0@  ;T8  !8
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M5@$M\P9!B4Y9(QX1Z%^P*L&;N( 6[3YZO8@=WP2,8JLA@@-[GO*@^2I9^<<
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M@K+L/U/A@ FG9]$GEG,0J?DO7<84#>?O!HWB5\G*=L]"+09.A5((IY/<H:0
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M*8LWK^OLA#AA<:6$5\#+O%@&G>P>&!W]W;=K'=9X3?05U5.V&DA^K\RL1ST
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M?\MWW-)O6&3A3T2R-&6 5WZ,7%Y*JL%91^("Z@U5M'W;ZAZ_";,\'$@]\VX
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MEE@HFMNS-5AD-D@R",?Q-[Y<WE]H,6B:Y]Q" 6@_,8I@5 *U=#RX*;Z:#N^
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MD(,H0+4XHB=>>!P75HQ3^NF/)U25Q7Z\DG#BM>;._ZPI0^LP%P#U@$-/)&N
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M=]$_!&%/#DX!G7%564='OB=8.DL'13@UG>@\F/B!<PLQL X[Q9 MH!%C4WK
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M)/2N5L$#W)FNX8C[8V7AHZ-KU2Z=>W?!78LI#FM,R*6G;8&J/J4I 3RWFD*
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M01X*=7H%;!CJ.)J243US"]$ TV=;&PHT\AMC4%;CZ?(L/B&)(F=ESZ/L$IX
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MYO2="Y^^\1WSNX\9SGEM$7LMO=5=RG92<!&"7Q5=HLC<4KIZ41E>/EXV(?-
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M1[((\T0,9$WZ5IW4!Z&O$T]?SC;_*VK8._CCK1F^!"!%+X [5HF&*<0*U>1
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MG^3"W#-%=-F3S#Q,$64C_K<W1GN!0P J'O7ET0?7O?^/0G8O_!=02P,$%
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MF]&O(6:I7GYL%-NBA[WB_9GQBGQ,CI6%"*_1Z3LNM8T1?M"I8EK1Y1,EBMA
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M]7C:OB;DYKQ2%9M'R([MZ0&/0_VX-K<W4BQ;2K$]$KOYCI[%R8=$W^P#XXU
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MM0MUE &"$N\T&\R@$,6M:X=CH5)32S,,+-L?68N.NUEM#"37+?,$/%$.;L:
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M;K>+R#Y9_V5-U.M6V2&7CF)8%'N5>"$_Z7997*]+SO-H3$CM :M*J]C4]BF
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M&JJTP4:0D"&Y"]%ST.-!<E@@C#TG=?9DX#>]5.35G#WFTEF,9[HRJ=:%MOX
M,7K(38AY4([^4KXSJA[Y#*1-5-!Q@DLYTD'=W6&\/*,,!8H!03&'RKVS5<@>
M1/7FE_>1\Z,IBM(NA],/-TJ=#UG]9E:>L:RJ8?QSL_83V4KZ5AWQH?FV-CO6
M4[F3#TPG8WW@UI*A1P9)^=I6FW,M[#"/Y$/2?=O:B1*,3N<M_U- 2F7F:[AA
M[8?!<*OO(RAFDBS-+M+10(W?:WOO;JP#%6.UC&6:KZ"OK>'8V TX#*@ERI(R
M*>5?V%D_W1I1.@7L6N-7/7&JF, -@Z7#WH:#6GZ=8$TL)-W1T-UK=,@-7/!1
MBNEJ@QHJ85%@PN)N6%R&+$,9#GH*&!)8NS&L!SU^G!I-C3//C,EO/6OD/'F.
M@^[H90,Y8Q.F.+BBH0\PO9DQL@R<[^,XY]J"+H&RG\Z:AVK4F0"7SXJ"@*M_
M4<S;O42.WX;A2][7_CEE&:I]<$&64]<-='YG16B$QD#7J_>V2DOY61$07C +
MA=,XGN6)N^=W6LJ\^H'?:GE22 M'CHJ?:F#_\2AI)O/D'2JI=<*T)N!SY//X
M*/9+/?^L&(:V$;(*FNH,"\<EJ*3 =V=W5Z<]]J68RL\+3$"?E<4N'9?47OV/
M7OX 39@JSPM,0?]1'7P%_2-//%\7.3O/F/J/DJ(YY)^))O!-OB_%=BU4R=N'
M:;(+(J!@6-%IKUWL(6R_5_7&([R98PXQFF^G]GI406]B,YZQ*1,S;9OO-I;"
MO,\=02_9#%_#5BE7>!<QK\J9AD;<CX5\KKMCWZQ&HFN>J,B]+925W=AF4;%*
MW5V)-\7C2E++<'(CC54FTR/4VM!<B$OPN)",5@_O"% SONY#P'SUN=D7][">
MIO8,6\"_&O$$LK9J%3(I[;-ON?V/_\7<>T8UN;5[OSRZ[$M=TA&$)56Z@'2!
M)0H(2)!> F'1I04(TMM21!>$(C52 E(#"2120@@0(B U%.F$)""$7D+O[<7G
MV?M]SSECCS/&<_;^<.:G.9+<<\XQRS6OW_S/7+<<PUFOWE_IB'?VC0 F.2;.
M;P:9Q*^W<)N*[F TTKJLT!H@BO]4BKOT#[-\BZG6\;#:$7.*F^A.F+B36NG:
M;B\C[/Y?1?O$U]O'EC"G1D4]7*+?6P)OY$T!?T%*3<&&&NR34^_7_P^KE\?
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MV-M36=%.V<[-YO.0Q^/NJB%)*_")S96CA]_7=%C"W11/JQ S"E/ZV2HK]4F
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M6O9]&Q[ID\)W'()C2Q[;*;LE<#^Y54L2UM4U@/]>$ZABZEVRAZ=F/<6% AT
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MMYTQP=X&N',N&MGQ0-^V*WO0R)[/MD'DB2]&2_%^["0>O03:H>O0CE2\203
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MN:RRY[?Z+?+)TZ?M6"K/KT'C;9WO>/,<:#PRE7/)V:N#'X89-'"\D:87Q$*
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M=<$XOF=\.$14:FEG;9NN^LWBUYGI/P8?X8.#62#$O3MFL+Y.:7BQ6]:?)YX
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M:)J_;J]E]I6Z)NZMIHP9YB:3"E%.+\KOM_!/?=-ZGUD^&.*?%')J_^MBY=7
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MRN)X]MN>(&$QNXCY9;'^6WK&R6$\[O(#O<H#J>,L]?EO><$9)P,1KT>%]OB
M);0E9ZRI1S+O/4=G@FD6KM[]0>\;F_%B$N9=VJ<:1<T1A(7.!%32$>+T]92V
MD9!/#D<%!FX\W A#0"-%BH:34U- 885]-G7,NQ-%U#0TP:"<?;D)%8(//FB/
M#:J<3.CX@KN:>7A=]V&KM/[*IWQ1V%&1B2%FEA90H25NR"-6^/K!7*3BXVM2
M3L9_^[#I\!K')2C*LE8Z\KS[^_*H,$DMHMV=S$;X9,-&??)^CF\H>RC6*A$M
M<T6D2V0V:>-YP[_13-J;^V_P"_%,T!E@WBH;EJ"Y+G@*/E\/L]J9@P/'O&<
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MUP"'#W]BY.1=1)SS@=]P4*EIO!'%I'A[X;\IB,Z?\&CY&>(A3;?>Z*?:L.#
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MG#7W(BPOVT:8O&W0B7!(MOL_Y+UW4%O)T@>JO4YKX[ .@,G71 ,&#":+L Z
M 0,F!Q%,-A)1!)&Y#AB3#4*PY#481!(R8"&$$%HR(IH@@H3 Y"B1,Q(/[[WU
MOOM5O7^^O]^4ZJA*ZNHST]/GUS,]?;J3XQBFN#*UJ><,8S-5'2A+$/'TR[@
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M%!!_"N"LU3SV8WH&[1^+*>WK:TT-/PTR/3@V9+;O'Q>Q[ZG-FY\"HJ0USK2
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MSH'L/U_&3&EG\:YU@1RLNFLB9#ZH6- GXR,[@'HM<5$!J+Y\:"<]Q'5Z5/7
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MCV4M8[T97DO'"R<)0<RTEYV'H0UJ <KEPW_DI*"?E;PX!31K/&3^=H!JK@_
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M&*S$D=1?L%;G57[)O?Y9(HY7Y$!F-*[%*=P[*S?F\7(_)U31RGX!N(9[N:J
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M=&]4OX09H'$MN"X#VD0MTMZ:9[AS8+4$$H/P$0XS0R,\PSJ01P/C7QGRW,
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M&4T3?2,NPGOAF]*DL?@>G<5X+FX=F.F=(F%;REI[T"O$]*^9J3&M(+P8,$]
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M[69GJ?IORT3Y%2X71UU0U/Y/RM"E>@0V9D]SFWS<V\8"A0'Z\C-9.CVLB^>
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M<?CUR6Q&7Q=DIM<'A7$+PD) 9W(T%\PNYK)\X@Y!;+&J%/IQ?72Y0LN!QYR
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M$,^)'.SO'JU#^VJDKO=U$;72LF;,H-"T(QI%[6'YC_G54&[EOGM[K@N3T<B
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M9/G"OX0]7,7C"GJ/Q2B2^R&P&>;@U8!-*B3JJ2LH?!GDL/&$L2KD;RO=D+J
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M]\PE_._^![Q UZZ*Q*T=<03?_%.#R*M4[^#4I]E<7CD5NVW0DWWJV"1G'#8
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MBJK?(2H1<FU;N-MBV@$<XI@ZB:\<+?;NT4-HUAL1A%BW@.%33;^63"7T_0$
M0/79S@!(E@0+JNC#T)):^OED/L]8YQ ;%II:':R0)<'.8$H4/NA.EJNVP7\
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M11H_G'^H<&G-%#BY1RNS6J@PNL )\HCRG-+4,JJ*;0>1?#<>]#T?QTMCQ;3
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MU_IYIZM_)BWWI-==-JA77S*MTSZ/I2_RD2BY0 C=I9H;.0^3%#2=#@46U-:
M0*<RKVN\O(+7!+@S/KXO!_N9O;OS#^0QTY.S_(EWA#\C;1@,Q@+#H:>7"-WS
M7B+2B&IJ)M#D\F)Q X*X0=T_#:3N<VIM*K4S,6KV?P7CIU6V89Q^TDIIVGV3
MT[]@)K'G@%O?F\?)-['CRKC/9:4Q3?K.G:S[*=ND9A !A\='S!#U=Y_:I]_+
M%S?6/?0[=:"Y;.<U/V?"2:.A2W"K8>O1;6^[9(<YB+F3UQG S-L$(6RP-K/)
M/8FX'OMUQJ,YOGE&;LB/.R?<#2WYO74.K&N"5&<"@5Y*GDVM<NH8/1R;'IT.
MZFXGIJ>*/<S&IBR(]9K_= OSR7BJ2E5T-/)U-/@"^W5"M!O-N^E*RHO??F**
M .<D)WI$=%,XX)Q> R-OFF5VF-XSD=?XMYMJ,T?K462RD7VS+IYY>S6P%LM5
MG7FUI"L#]_AVZ0(_C^VNYY\G%D7^LR4MJVO 1Q9!1B3233P))'3-FI#K;]?1
MF=I!LJKH4-630]:*&ZZJF4/G#-4:%.\F?(YHA8F1LKNXM!^32R:H!QE^.&\0
M.4C>6D3-9+=#CU/&'/<N@I.*K%FR8%?2?K[F35(4)V\3.,&!M,6!;UEIO-Z3
M;M$Q2S>L'__N7/*FB]WE>LQ00&)A:F=,!5,W2'](TY89Z^=C.(!=-VUTS$6+
M'TO\V!*?<V+/.]IHX;$ND)X),@#;C60GL',$24^W@W-?5>KS--Q" ]$,$[7]
MIH;V!LG-R;+Q"*,NB,-T&D8*BH\/Z@[-R\)$PS,6P'7TTC3LB&GL'#:URDFO
M0*E? @9S-NY9AD> E1D)!?:M YOTK.4W,!^_GQJKMHZ+V#KD2BR%ED G!!+@
MX+\GXZUF2.GEKBVH03^TLBKT>!@U<K!M0;Z/:VQ-K9S$>9M:]^^>.)66@&N-
M36V:K+P?:I$KG9=>?*GM+ =:->KS)D22U:M@:D"S.)-*(/"@K%1 8?<JTT)F
M/J(X=$TO<-P*)F-HD9./_PGU*:E)Z<:#BDS>WZ<RB\:PL2C;A*?2=N^\J6_V
M]*X;BH=].#I'UYI[7?]^"Q09YMA?OG[25=L_LHGTZO[F;#-O/[Y7'F>V3[A6
M]L-6".(F?T,"QX7C/1]$&LI[4J#_9!I8$V1%GU8O"L@E(B5'#P*[4DEF/DN3
MQ,[KH&FC%"%Q,VU>\CYKF#F?( T.?/E84#!!1RN5.F!(YO0>+8-&+.M)SN84
M\G0\.NXSU53C[:E\]#320-J39EIN5SVE-O>*>83;K-+D/[>G&;VQUYA&DP\<
M+<(&V)3IK*=C]L(-1,>O>1X#"_?ZGFQY[4R/KK>$N]Q+@8:=D +GKLB%I:OA
M1K44S8950C2Z*O=]'+:WU*OV1A3SA_TLRMXPYB=1EZ:S%F2>F1;PJ1=+_0JG
MP(]%K?:Y WWUJ*?)P5$[J?-K%\!$Z_D'-(42YL/W+P=:EBV#G(=?[?1 25.E
M$UT?IR?X(^K"-<=VH8CS3\X R_:^+%%F,>T*M$2O,!',;[:Y:-I;R]+G=7*@
M>*&B1<EBS/RVR3%LJ6."E4QJ+$QD&!A84VX'*C$GS>M/0QI^&V#SX;4  "Z&
M'^\=BLC>/;R./MA_VQY:1_G]>0'E2_-O%0'*1*'@4@LQ/[$=IX/R\.;2$G5N
M$B4.XSS<?B1F'3C&54S.Y1=Z-3V9^: D"!782@7'M%73@))=E>L9DZJ&<OB#
M#27<\@J\RVXJXUCC1N#7 :]2!X.-$)6!%+3)M2XLH\4Z[J5DU<RW[[&3.TG1
MT'NFM;C0,\#XA7M[:0D@U&8Z/+8@UAW3AOIQGH$>_4&)"SZ)NO<C5E]V\" F
MO87KB$7)IN*O<I:6SZZY[1GG*\2-XDZ4M43R6""5+-+O*ARQA><BAD;EN5;;
M;CTUC<W;>?Q64I+W'.=:D.N<SXT>HD,.?8F[Z5*GN4^CGCC^],/11I5\X-4N
M&]5GJ;2N42$([1Y:O-=;[WK,)C390!:LP7G"L0F[/K,>]]"]R3+3RF%/[%9F
M[Z,NH![:GX;\@M<X=M,5T]&W1=NM)"'%2$Q1K=P@V0UCXY\^XO0TJ4O!SV'9
M!INO^X%24W4M<LCCQ\3!?,.:>83H#PU0M=PQO-H7/UR9G@J9=CR4);03-QU3
MP\P1OPEJ_S,<PS'OC_;_>0X' +ANOE^T0=CQH#QFB DZATMSI<@C"SL42W5'
M^/V3RO45N_O4[Q=Z6K6L*ZW4&0B0[6@U%I)3\80K;*^/GJ\AYGKX5_G=&(%>
M5\)M!I+G_&^;A02&+;RH$V'IML:DT7OTCN968?2&V82@($;6*Q[<6MQ8BR\V
M:]"3>>/ FZ&K(M8B]:&G$TB^F"4DDHGY\9\'\R&,^6<5C1)C4VK%A#PL;K<?
MY88/@F)L*;$)'OWN-K(CJ%_+$ $O=\MIV*?T [3<TY6=ZUS##:.V)/"Y(-N$
MZ8UJ_EBDC,SPK@W^]"/I/,=Z7<][A/O(85HV.1 R3>_;KT1%5GN5'$@>5";'
M6>,9L=4I^5@!K2:+=^>4!_Y)*+Q@X:W^JG(/DV1(;,"466)9 5=Q*>#!?@?=
MWH=CN#$^QI?%Z6WQ[$ZUSV,9\T=&M/W"K+B^R:3."O+C2PWF.*7MTE90KF"U
M2\4A>+:UH=YRE@5)HVA^W%!H3/C?00*-NQ1KT]-;-,$S0)K#*"M(N4D,9GVX
MDGSLB&G4Z>;5/X@974(=[?G<:M,O^0_*L*.F_1 [;P^II]"PO#. )JE1:0^U
M#3)F_9)PP,TM9LU2[F1=]]_=>C"VWEO_<Y=;9P KS"FW.F&[JXLR[17"02*<
M;.9OP$$YW40L(MKEV/7G(KP'<HG+_SJ7;O-NN?:GT7C*B)/@MGW[[ZZKA,T]
MZPWMDZ)K-QL0L>6L2=:>SA\=PLX;   M??GT#% \^ VSM7T&(,DJY%T@G@&Z
MO=8/\G=C]3]-Y+<=G '0)WR]74E"F2F 0)'#XE.YL&I6]<DZ*P!?X,,\ \SR
M"?X(0ERX^>LRJ%7E# #)7\E$7H"$/0?\0K68^?W3-<&#%[-6B6Q!(\86K7EL
M7[MXPK!Y*\%3"B-@Q[P0\18V>TZF0[R!6RI2)\OZY]ZK'W1K,?45C;D?)T.W
MUHWF8<*CVK\197]S1\I/IZ)<)HZS'X"<[W<*E6C]-[NI?SUE!HSMF 9>DW^0
M:!WH-D5_*DJO(FX\J4Q.#-XWIM\NAUG[%^I1L]T#/@\[[14>:5Y?I!M$4;NC
MDK$/9%3L['Q/>_VCY@.^-Y&2IE,K7?6IBF> AICT?6,;@>[%KX!S7P9W7;?P
M\EH3)J4*=[V"9>^J67.8]2LQPU+G6SUL"5J=#?JX;9'Z[@I=3[F&;+M<]0)B
MOP]IX]GDI"$N31K/ZAY=$'Z9FRZZXZE]90"4R74Z\&A>6M/C_^'8Q$->GY&+
M/42W31<'Y  N+C;#/VBBJGFQ<XF_=4BN-QZ"?B'R^EY-@L^X<Q$25%.ZY[9>
M6 \<Q,S7 >M5963*\FU3:J&%Y?</&JZEQW\Y ]2X:Q*9TO+2.\6?)]//ZX-*
M']T*6RZ%HM\<I*MTJM#'E3X" +RXO7O#GB]/*J>#P'["E4.JI@]/H.6&Z^F=
M[D$]VMQI]BHM560Y;34NGX&];C)7(9!3^JAF2,8E:/_F[]2"CF'I7;\%WB ?
MPY3-@R/!NM@)D[[5TP&I>1C\V;"L1+WTY94H=FL9NLOCLH9K7=M")MX&Q[>E
M'SN6S/PK0QEA K\2/^X;D@N3_=7VV\*F&I^,>?7>3E5\YV 6<HR+6.EC #:9
M/S&SF-L1U!,%KO*1;&O[4/=ZVGMEQ^\KW:=D%H6%1K(KE[Y&/.U.<!+0S9P@
M"GK)Z#89+<2^6LGI<IF.[J1OFC\9+VIUE9F;EKQNUP$RZ4[-%>)9KT'""Y<_
M4 1B((4"6^UMA$0.7>CU5,U< _4(C\-/W:UI HXT T6&)_WO"3K-=0Z4%[60
MT]8- -P\W%A09L9^H]SVEW^*EW+\82(<.)ZF%.W:WESP'.V:CL5]CM[>:(_N
MUP!JB6\L>IP!B,'H*[59:Q*.#^(QZ0/$$YG3-L$-.VT=<DIO:+X[OC*@>!@Z
M/S5XE"MN6VYDEG]ML!1.SF$3^7>ZX$;ZO],% Y?^#UT@;-^.!5_A]O(55KU&
M_M9'\?@IK]2X+/C#DZXV.$]=T$&6PP8Z2IJ9A#K9,\#=2M-R9$09SF/IM"K^
M/,$4XZDL;0!_<1YZ?)BR2CU<-#;],^M\A7W#C6$?/4K,3ECV1D17N@CXNL78
M9'TL1=[U*QLD._^?ISM7,399=?C/_+\+SA?8$#'L$BSO&A]ZJ]2@Z#P+ZBG8
MC&%QNB\IN"+D=Q+H]:"O]FK"2]=,=#6FFX_T?1>V102WUB'*EY9N'B:7G@$D
M*%]ME;A./^4/0*)/WE%&MMAN)K7_U(F_W+GV/$(3G<)P"F>(SZYC2UYE528G
MA,7IZ[5!V?WO9I 5)=;?>K5<$]#G(9;2QA;\@68"GQ?#EX]MB2X^BT>_\=]-
M30\ZH9Q.T5[<.NVAJ^@WUJ)Z?,<P>S FR19.\H-TQ1!\ T[";("^( >21A)X
MQ^!%,;!%'&=9W&HF?%GYGX^#KT*VQ8[N'%J?VA.[3L:\+Q"8^3N)A)^&8P,Q
M4L'=1J9\[UT[ VRTHEF%87^I$;:W:P  OL1FQ!PBAI*#Y#TTC54W[CFA#FG_
M-7URJ\^T&I$7JK^5)SO#S/T@FGEMX/F_S<N!B=GDBA^&9_WDO5]5!^C)8)!Q
MZ4;7Y/@+7YO8D/O+.RY9^^I#."JO65F\?\Z'? Z-7%*1 XV'Q1GE61:2&50^
M'!R2',=[F(P1X+NF4D_@R"VLP6D.AHN!3;Y2D@89LJ)#E?<W"@]R+,T=[ -T
M1.75)#/CD"=XPZXU5VBZMRN4D\'<]78D::Q.5(EY*C44;7<NR.KH+)=,^JV.
MMU1=]0K^;$,XS]T"-8LQ$%DS>':R]9).7WCIV-N53$P/I5>:F.:@E!GBZL%X
MZDL4\$1,Y?>PH8?[]PO$=4+63AZ]>4O:O'QKB;_CH/.9668^\[#M4D>#[::6
M>NB2EH)55U>[&H1NK<_'8WFM>\[*"F49YK_Z;."]W7IUJ:SN<O[Y;Z<;HWE3
MS#14Q(T2/>-BY#5PR+6N7,WE0:*L#_MOKW=(-0C)X^E/LY,Q:0(<^]FPL31A
M1VJ@D_BTU=^#/XYJ-WX8^8[<K?^I\)!MI'7A"*C_&JHML%S=T,&]Z+%T+<<9
MP*VAC60# =U!.JN9-522]6\P@(L+$>P?8K K U-O:DY34RMI,=:XJZT%I_BJ
M49V(EG$G$ OO:3WJMGKB0Z/QHSV!;?T[='K#/,LA=7QC?RQ2 :.R)>SI4A9Q
MPQCX1TP4!GJYFBRU:YTR>S]=8=CQ^%;%^?"H LJ^X< ;Y+8F1V=!0U.-?EG9
M71,IHE _T!+SFT/B8J6.N%57DG#V*K--,#OG2AU4,R-<HSZ]OJ["0$,]]&@-
M"3R8N!$:VP\:S^]DV XN^O@,#@-OG#LJ'FV@U&\J\D+P-2?J'7 9NA81T='4
M==CSY8AC(C\&[IU?5]F:R8,O'.0R+7:Y(4/C#Q^M=,4$:JY22[D[Z@':0L][
M77!Q[#XONXVW#G+AUY-Z7TH%Z.[(C67Y@T@J^FH5($,<3&/V<_ZUHB/?*MGE
MVVF^<M96QL=5A//,%'HAQS8^(=9\2"X@5T,(V)MNPJD4/5E[^I' I4;)$J]F
MT^B=3)Z&&9."NTD4.:+7^"3J_AHC-'SFRTOIEY  *([<8\1)B]XPC1K*_Y-
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M[\,;7!G'P.$;/ =.RHT3BS$)]O(*[A-_6TO E%P.'102;_[XR86"GR[Z+U-
MQ1628/MT-8?.V@9=^CA"TP>3,;;_MW2A_1'KF"Q8>,6&\R5S&2PDJJUB(GEX
M<, [<S>Q^J]?9H \,0L20F8<0&#HO7MA0*#UCP\?;F#.=Q=Z2#3H2(?%T8L9
M:X&,"'TOM)(F"M;KT$SL+)M?P560!,N;%F!J?$='I^K]92@=H(^ECLF';/<Q
M>+AW>';)HK3YFC)_;=_>J  :LT 4I^1_.SF%V<,B'/:%["<3PZT4 GD':LX
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M0$V6=O=V0&]*,XXO_4V&U_% 4\ )D8Q4;5@R#Q5!TC!:$,*4D0?P!%<EV*4
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MT8Q>SDG/7+0BUAL3\.EB9][(X;;*G^-,[*$059KK<4XH],7[*^G ^\,KNY1
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M%C'R#X3X?0K^[<N;>F,^$SD?J?8G /V?<@:E2>.U/:$6A=O>,!TG[?32V(3
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MV5)9#_3:+%]3Z9Y^GSEHVRV!*@X"Q6U2[E@6[BSCWYJRYVM(Y(>[&/3G(DX
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M_UE*T6JJ*VXJG)QO^-KN&@HY@G*>R-5]-.<K2,TN$E<1-S#S3RT2 U%_55)
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MG?&$<0 [7[&'K#\X)[PK\J7$7I?JMP.2Q,]L,L=(E$$;Y^;I=?)GYQSU3:9
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M/+_<&BZ_GXP%_\ 8_9Y@E>#^+?70N"OF,^ 7(?P(-P>0I<&(X@!>>P0>:'(
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MX]Y(W6]< 51+<?7H1Z33SG&/U]SR^]&!X5VN%'$^:5.E4'OZ-KUQQN#4QO?
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M8W<2SU)!A+3G('-^*_]YC4A0#3RFM6(=*^:M%R-F/00-MQG&N52NP8NX1CO
MZ K"!"X=.XF[$ML:!U<0"[QN#*M[CN"!SIT.<"7MK(^[1E_,/\S?#\\T[# H
M"^G8F7L9Z[*M&#*ZC*ETN=2B-:.KD*%JL>X3_62>'C@(]7I9?IXBNA( %) :
M.Y1)6:P]',N0N"?,]226C' ]\K:2KAQ0U^IJY*5<DS+55I(N,$=HC':2;BR=
MBT[X<6:19G"+'U/^J(#>(O(\'RRK^U<'N-R-[&E6#?RE7;V%?)XR\"#WJN(7
MX5=E\0G#.IG87=7IW3B8+ZORW0XT?O-H@'/K(>I5B:\.FJN5_=NI2\R^\QS
M\0GN8^Z?_=X%Q&++'VP<C.!?564H.<J=5'XK]EM2&4EKM1+61GU?:9H!QBQ]
M[!P=*2AC\G"!5\E[(N2!]#7",$:=S'"9(=X\?6O"]H_T!YAK'Q$]L5_:7?]1
MY?_#=];<0QR 'W$G:/\FRUDSGR$-NQ*[S0;[&;0JL#&9';?94NVL$K$<AZU!
MLOA7174AO<GH'Y4^2AB3LVU ^%.(\X"6<ETV3Z'3]II@\^C$RUA!.>",'ZUE
MHZ!M_^"LS1W*86*PM;;W/2J,;0$4P:][V0GN-^[@(UQ9 N9#C33G1,R>V31B
MS+:Z<PG7'A<!W;T?GBT/'IX\M348T[_89/>VY5AZX]XQ@DQ2U+!];4!D.R1I
MMOJB/&0T:I/N_G'(OZD\8S%M(XJ4>_KCDJ-ZE=E:99_]D5#3, <T5FOWHP"S
M"T_;.G,<:JVLF4-41KO0G(&=5-<[.:4C/X\92QBREVD):%=)_006DHI*%>P:
M0E%>:M1X'B% ;[_"#)N" H@B]$BK98$QK5W6>SK!VS2Q/NW% -=9-M=(UEZI
MXIK*F["I84V:&?@]ZP\&O&.<I9!!\0J;E!K=XW+K/M>'.O=;[^J!ZMWDW)H.
MX2I@?4>383+?:R&V:PK]H:%!V0^W=+PQ6(FA903=?U*=0$/7**+W5EY)K"5"
M\V8"L']Q /8:G]V5ZLP4NS%LMRU9>;?>L/U<A.?S/[\CH_U@"48/--DML@'&
M1ZO0;_  ]3]2/R8['D @$2*6V,-L)<T'[>W7Q)(\20;K2$?6*ZEUG0HW1+&3
MGQ,W;3%*:!$VFBRV;[2_#WVNZ=^Q:MKP^@O3Y<.F_@>7&L)?WU%)1G5&WU;\
M4,&/7!++W>]567B%YLJ7*V3U$$-S]C!]=J[^^:4^2XA)B\+(U</U5:24U)9,
M"]?$1\3?2TJ;(9OR#,?OR=C8SB*\3O9>78;EJ_F?FODK_^3&89".[W8KW)_J
M/E8X],19M-CO6]!:BFNRGHU(>J<2_OC"DGTH=\7.0='?[42<VB)IASWPP.*@
MD(!+C5!\Y 6^#]OK$C&C7'L\/Y)7EU@>^6PX< 9U?9HZXTFHL@CIB"-4#W51
MG[,N.I5OZYZ_"P!(1*U(F(8S/6@5\%2\?'">LNT'6Y#L2#14[+'*J+'*HK^U
M;HZ;P+(=\+/_U/#PJ-X>TA%8:WPW*9\@E_0"[]R+@_I4)J:NVM>D+](LGUC(
MDAT?SFC%/J(R6EHC7EA)=?XSX\X]GL-S1WMNB9&R$>$^]\9!(^=+)?OY+C]E
M$:PU!S2SL&]1^F(^:9><AU9?TW,%OFBC[N_I #%1Z][6.J$V71T=,%D+4UJ^
M_V'OL(Y=[/!QUIS"E%OZ*A 4B6RNUQ5N)H2V%*S,;M@"6P)T(./NYR'",>TU
M6KRC/AT!.PURFW@94+RHN3:FIS@3=JSEH8P,!E=1[K3[-&G\Z\A5I$FMBIZ=
M5523E&'?@6)YS.)KOF"7P0T5CY9Q[CG=J:YE,!]+OK$ZA$]#D1Y-)]U/KUI-
M!MH/^BA8-5;0QF%-2B$UX/P2G-3ZAI*+ULHOG;NT#+5J\?J<^M-C;\^H9$E"
MW-\:HZN[&QP?^X#!M\9LD)%%,/N8NQQ ]1\>D5_ZI2YNU]\K#YVV"V)A$Z>,
M9<'EEMQG6Z@7?#@ '_=YM'H]KO?O2(J(R(19@PO=[M;J3CFU;?"+"DTZZF0H
M$UX(TAUK'?8'8^S][-"N+Q9VV,>LF_>%'_F1% =:RF1B3^APM52K1\8%^$:F
M(U?@-7QT.T)LR) CFR@ZTT53?DKAYR_M4^K*KNY<O0F-VU9!H!2'F8BAA,!U
MPKN!:T:1^Q2SI)Q%4=JJTP6Y21^0OZ?1CCW*071M[2/MSN)X2ZC5;IR@YJ(V
M[])&QDIUC>,MHAA%H ZF,K8P-3:H4*SWI<G!\FRKV"E8"R+HT<:F:8-;Q,:L
MCP!?E&*X0P=H&%?[4,/"G4 *]3;>.CEX33,]%W_1_D?]4A-*EN_()_X\X1(
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M0$?=RW?%H!V><IV='\NI,'7^:N<T%:45EV0Z16[Y0#ZXG.)Y;.E%[FM) 5U
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M$-=]NMZW@KGT@:H?:L93\J>+SBE%HSYBX1(WS5U': 4S^:[.\/I;GQ00\=Y
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M]%.-0&75+_.J(HZM)GY:@6B6SKG03+52E^"%M+#)PUOS3H]F4*0.1PWK9K
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M4L86A7 JRL(_J>A\MN^0=W&LX^&0OQ'^YI]#_F%WCPID%!K6I&R)YS0";A1
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MLVK8B4QL-=/GUMR%IZ4\3;@6LXD^_"GLP1";)--3^4/XYASPMU6+VYW_+$#
MR# [>R.,Y4+'"YH_XG_$?3O#(DMZ(\+2!7;,N0>(]"6+_RKH<&W&+'Y_D-S1
M'>H0JZB@QQDQ)3N[A=S-D'/^;XZW(SFO58O&H%8,^XM,_RLYXY*+FF6,\A\Z
M-8QD_?^D;S.?DVX*W)$_XMH,G63^%&[0KN5X2-BE]6V]'UCGD]F7TVA:<=U\
M0A_'5?DW2IF,K/NX?#Q)V]#T=[NL.9;ZQLBWZEU2ZA>7B+0;6]&' ;*)D_"<
MC .4JS)["V:"N.G*+68#FA3R"[(NX[P$43('GUZBN,X'>_WMKJ5]XRE[+X/D
M1T[<P?)I(IH@T&_SKC=RPU*?[2A-%W2"!:(WID-SP:R/.(V"(H^]N/>!&3%*
MM79%*UMVCK0"VT,^83-;Y9W!=(2L'Z_3W!\U!XS'7D3M1V#8_&1<Z?".;:(T
M6NY+08[DJ9RGE5*DFC+0,=%9C#=(P@[$5OQ.<#V983-5N@+^M45[BG=:/IB0
M_?GJ7M$,\B:AOI5=EG3@2)+G$\_ VMIN?L<>FH=ED@?/NPF%)#\1QPF,QAV)
MMC\_PW Z%8$!*?&2)3R5^D*=_ZM*]?^\<-C5IBKL]'3U"L""1&$,P]J-<!GG
M;LR/G&RDE7+B;P\KFC"2S4:WTCTDFWHEN,K'Z"._1RJ'OGRPZ6:0-MO$XK[!
MO#$04[6L(Q&=V'BW>0P85Y6 Y-_<R>^"0V1RQQTX-7/G&O#F?=F;91X^(7(M
M!$/]M3+=.=MYDOGXHE-9['ROSH6X;6!K1W@QUMV\;VP_JG_$5>;HS7J><@A]
M,38<G>CL:]O44K4XJ) M'*L#W3;Q*[3])JRC,#UP2RX(6:UK1<YQLB=M/+@X
M&%6)#<1HTA)'&> !PLIR90A<&#AHNL:>G'&J[:=-J+S^%+BW1O#&@DI7AQ2#
M09ACJ\*=?GSW(Z>8FJC/C).XV<:M%_/0T<41>,J8>X<)<J7O>B7<E-LI%5+B
M@3H'7#EZWK37+RS4B-1.A"'[3J+E55)KZPP80=Y];54!L%2)PCJHYB]9=8G\
MK0/O",AM&R5PT#[.7[ME(O@T9&^Q;#97JHV9^7%SAC9_U&,(5QY(RH-//FL\
M)38>1#2<5"DG^8?Z=X:I;LIPKQ5<:$&F548*2[3EZO?-!!UOI8=)P.G^T^*)
M1)!&<%)&79VMKOU4G9IAH\$P*\AUTG*E_!S0D+C/,C?$8I11SWDTOCRG(>*\
MCRY;;S72=&[-'\X*</#C]XV J.E*8*]X2=F:NMJ@!DF3N\P?]G)R?H?&T/F5
M,:SQPR$NT-@P8FFR-3-U-H9X8L0797L.,. Z!V0$1%]C*K-_C3%3C7E?1[R:
M8+(RP<3]B"\"E$F;N(485KW6M>5J@2Y:Z\XL<EV.+B?CZ<N>/#&FD:"]U;15
M=;NQ9&"E1N8]>-"(XY1BJGQ;3S*X<MIQ;N%J/ZQ ]8F/3F+^L%S,'SELV:=G
M]D7EDR]T>59# Q>0H665NJ7P6ZTQ17MY#F;^'Y85&$%"W3+./Q*8!]D592^A
M]0WOE.GKB[LI_2[THV/,<MSM1D/. 36(!#Q*K4(3O",RJ./XK:J#H.;>*_=+
MS@M>.;=,UJ@ZHQ;$*X:*+>''NU$%[\,J894HD$9;Z(L(1 Y<FLD[$X7LGR9Y
M&Y.TYT!GX>S:5?"^)]"?FWOC U,IEBG>? [8L1O<O'_4Z1R?OW#-@A;M0'*=
M.HR6GPL^>S0I&C3'[S'LJWE-TZN#, P_[E+.^L/3KW(N(<KM)G5I86:X@Q ;
M<<@_47(I.C,P,.;#L*[[_LY6.YM8=JE"/D,#/:09JK8<,<DT@0>;F8Y7L9:0
M/<T@-&%=5:-K*V?R<$-,,/:J3[-$[XV3XXW7H+5)=:+PJ\K(QZH(6"B']*;@
M@<E$M?$-UU[])N*@050]E)MA<-"JLLPIMJO\-"IE+_?_=?CXZ<+67^< VZ"A
M3?OE5O"B=FAFY.,2]*Z=/.2[*[PJRYYE)C=ZE_)#*'M.7(J-C@2A"SVCL1*_
MW4WDU[Q=JV6:(9"4PG@$Z2'(X_'@*T^ZVO$>ZM1Z=PJ_!<9@_C=NXUFS#&?I
MM+)7"OFN R3Y11?BE0]K-W%2TGTA1<!*EL#0[7/ O//1Q7/ &/?;N9/VI;ES
M@&':UCF@-0I]IJ=[VJ^[/%RP*_R]*E)P]OXY8!!^QCG\(H:M\!)X#JB2^[[9
M#Q,^&L:< WI\S@%A/JQC5AR)V.=Q#HC2W?N^?1-$$3X'/''ECUF_DA/#%C)D
M[S%B=GG/ ;,.YP =W=L'X-T/YX Y<]:TLOSE8R??G>XO:$$U[E#BO_L8+/TO
M&@;_U'EBG!SX9Z@;0YC72!C!YV*0?$+;XEV:6/YO]F[N>;[.0PDK,\2?=3:O
M/AQ"57NMO5RSK(UF+7.*IJ>F 6W$25$-P(@!>"G-G./G(=F)O'XHC=O,QCCW
M>YM\'Q(T@AC_NQT>\@,/2_8F+6NU@K;E3'1M)>[HOQ]OS!/Q0 .K@QQ3']@)
MUQ+E^2.H(U9^(]K7.?MFY^(Q5S7'N9\?\$@9VKW)@>>"'8E =! $^_4<8"W>
M(N-Z(>X _CC_TWW_5-@@(?3.:*0$/(9K%T$PX,[K/"G7/Q[--8\_!R#CAMQ.
M[D/,O[<@[1QP>@=:<#0]4W"XQ'$T>@[HU!!>ZYTCGDV0=%OBSM1[-; -\ )-
MK1$,Y4XVU1!IR;Q:%D';<+Z'3%65J##0SI\%]B2E52*EM:\[HMP:\LH,"]9D
M&M2N _U:HSH/&ZL\35LCBQF245GHB_WQ:_<+#'4^'3@4[PM73L> 8^2OS3CC
M.MTRYH2O@-.<CWGK._/;6/49V9A\SR4"OVDAH6XXZ6NM VQ.[C!4(L20.M!=
MYJ&PARLXLA5;4HB9:NF<^?XR! *<5R]@-2Q,-4S*TXSK]NY^QU Z K>ORC (
MF7&;7FY17.;'DUT^MW<OS<>#EFRZ3[AED'Q_!I]Z+16S1$%Z7>> @'/ 32WO
M>OC0.A_?)GY6W4$V^E]T')*A?@+-FEDB=U@Y!A^@PL?-]?>7BPRN /TSD$KO
MDT[)K5%?YBSRQ:/=2,%9VR^/>V<:)^L@2'R@+L\0_>.<4+II\M2)T\:1/X@\
M?A^ENTY^1>4;&/1CK_1:+V"$/DS5BS+-2.44HX:ED8+2OT0?_W")ZQ%'\\O[
MPQ!NWI?S;UNF%4ZXE%GQS9-O&!%V =/KO89V14 BMQ[X"E+TT+'@VDJ0J<WZ
M]JH66W3C'%#Y?)I,EKY%R-)%VH-9&64DJ,E,66BI_)Q7=M'95[.%Z'N4<+N
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M4L)"I%^D1DM;^J*#=)V9\!I "#NP<:NO)9 .=)E\+4V7AY1>A,Q4^7$&.LX
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M">S&0ZZ#4 9FTJVS5_F+>L:VE43+$.Z#TR6/EG_O+=DP,]H6B=MD+W,AWX'
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M;>+%M&FL9EK=YLS4A@Y?.E,@[_3:"J'&NL1A5SNZ%&->=H5#PG*@OFS^ 66
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MO:6>DXVSZ-5&C?)%7P!RK^PK_#:3#U7L!T450X*^)B:+&$G&B" 65_F>P]3
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M<)DS[&J"*?1< '92?2NGU#)2@#6DF15-V<>'&@+-.[L5?N:3_VPG>N>,!KJ
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MU<E,@365>@X#03<B5+8HY%D-45VYLV:5P%[GO.HS$GS:,C,.MLC?%7M])S-
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M&.$JUKCS]!CMM? ,UR[!,-+^;>S*D)*Q^R*H7\57KXM\>.'+5+[^DY;O(MU
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M#,MHM]8D8+<@3A1^+0FMAMF1AK6A0@>;B+"/=/FN>J3SX#YV.(KWI(&P;X;
M#I9-;0:#+Z@67-K]]^3S/X$7;P)<6RUW'&$>DRM1\P5)K'!!B8!@BP"J(^WN
MMJ>.-LR4M7*4VCTVUOU=^(JJU(4:#X_TB<;XLH,;HNEM=U6^NU:Y>/\$.::Y
M](<*6QHY-]8B:RI;#=BIHOO%.)%$_\WBU<W810R'/JL+]W>4/"[P\R%<_TG#
M.AD=Y'#"RF*HO1-*[Z)%NYH-HAK+7<S<X%1YI5F& >3S*U[]X3(K(F9V,\Q?
MS%*.4*NK@CKG6Q5UO]>UK5NITELXMI '6%!2(PBN4[Y0KM//S]25P9G-6%W9
MDN\3*#5SQ)$Z)4#_U>JARN'XK0A<T\Z3CIG&?;1)ZE2"J)H%(I-$T1)U'B9+
MENIKXT7'[2-"IIW'<B!FK@$1HB:/Y:./T"C:K.@)F/7-_TQFODD'M"'E%C!6
MZ9[^H6$ >NU@;6ZCSZ3+A40ZC0V<V/#FMC8S-2O=YV(ITOF/#2"GJ[[.N327
MV2;W[RS@VV6X",(<XE2'# Z,3PM J4R2KX0HR&7 S.TKI3SP$_Z"_^(,3G!,
M*/R!WCX"'-=^\B6=R$"IK@8,I;&QYQDU/8SK.GZ^>-GKUXJD'C'*0'-WW%Q;
M0CAWN?+Y/;TJ0F>3RAX]V,]3;X)U2S.S8!^-?_,FXQKQ]JLE;1;^93$'O-^$
MTN<8HHU04!\@&;'/D\@N"..9?"QCTP:;%71!V^-=80OI!)B NQRA/0C?+M$7
MN<:,JHTL&0VF*DE*WGHRO'MX"NR4%@(Z>1RI<^Y696#Z$SXDE HLS0H<_!DE
MG]:6W>.A*>P2.-OK"7?I\:A^%M;GQ3FF]_BRFV_J+\CP_,R7J7U;3KKV3%*"
M0(#?0U$)10&5_Z="M]WY'Z7Q9-),EPN4E*3U%9=@(':@ZEZ/56!Z)5Z7K&#6
M)BC'A$_U*(0_=E<' T*<%LE9^JXZ6:ST.NT ,VB3H&?PH.QG"-((<UE#WD3?
M?4:3K#Y=\X.O88(HH@LB^FI</TIJ2Z4>?_S(8UJGP\1_"5H8#E0-6,W GH@G
MO*+0,CP5;0"N?QQI=W5P4MP!IF%:(3)5S6ED1D=_7>E4P:,7\GV#O<V( >G=
MTHLE3#,5\?:\/G<=?0Q%$H#HPC5_0?_F+0F05JSQZ(5.-3R\W@<B>7V.D$GN
MHH[P,FN^C)H\&<I)J=A%W*P*:=S?!Q<4NG696@V_.JL9:1UA3PS=NJ'VB]*-
M@8JE@LS3Q-?(G1UUI$ UI:Y4 :J?;N,<"<?U:<O#_S4J<V*7^;1^,+-1:]ET
M*EEK3E5Q<"=6=6OHQIHE:E8LNF&.5"8/-3196(,T="_NW*JK""Y_V]4 #8ST
MN7+-KF5:/_J6+Z=_FH8[2XI-TB<B5@,@5P1;$2MO([=-L1.YIO^:;>Y[.MD$
MC'(=K5.9L,)\3UQLXFKM:Q/W0-CO;H/MK@\=/K]L*JDK7KO/3!G7NAIUO?+Y
M2\U2?P.C"Y(0P:3*^/>C$!.<(Z#ZT1J]O-32XE^]#-+EHY*@IAT$W(K3$SG*
M->NU7D[W_CYN,G+O_E5)P0<CWX@K6<YCZ\ WQR[(/XB?C>^[I>Z:=B+_^5^U
M).6PX4/8=GK;BC[ <TL);E)3(>4:6>"[2WFNRI;G78^)ZN17V1SI%\Z%1 NM
MMXM5*E1L=2+I0S)K3^.5A=@.$3E?T9';'!Y^ZQ4G;QH;YBI,5667,/&^>=Z2
MMSDL&X1-88#/7Z?RB<1B# ?@4%/U6[!S12+#0%>GS3<#:K)F.D#'"PTMML49
M&'.&V:5_"[W1)2KG5DH>PDVLFY"@J34-'[]$]3#1@]X!+;C/H-(2S_Q%#P>=
M(?F'D*E[ GYA8U5N]P[C!61RE.S"3KM3J[QAQ.M*Y@-OP=_I+FG1]CO?"CDS
M9%E.8QYG0%%6P27-#&^= #@G:3I$PKI9^NB:J>+/5"WW'IB=Q>SVJN6:F^T$
MIZ/>BE =V;I#J7YUPH3M:\R6\:[ Y1LCG0]E576WI?^65)676O.2^8@>N2,O
MM%,ELG0YN'-AV:W[8'LV'(6O)'Z9? _@7PER=ZLJG_\\[3<-3^J[&16>N-#7
M7SO*,;?@AADE2@WYE+0'N[:LB(Y@5!\4F,Q#;B4LT[7H]ZFGH,7^'WP&[5._
M_SL2]1^"B/R0C;7&Z<Q6R*@[PL#F&[?.EF=K4N3GKKIM"+7L:3\'7AH2TWT)
M:,&_]$P:@$< 6[[CQ'!KRC6J/_BFL:67L6O#C2C7?2%5VV1-5Y4#P 4W#9\J
M:T6MBF__O/J =LH[&B E/$:]]%-V'EQ8ON35#79SF,=T81$W,H .R7\?*9J'
M/X\K_L$G_7&C;U'1OG/+.S%+OS>=70)VG)U_X^!+%C7;_P345J65,NH>AM_9
MQ_2\""NLV:WHF:(.V.>@T[3AV:EE\);&"(%QACH3XJ^:BUVD)JMO_Y&S5(K0
M^D8?2^%%HZ1[.D;"G5X';F#Q!QTJ\KQ4!"G!GYZ3<7*<EK#(F<*(V]E4%YDL
M67$,8$;UXVJ+*DY%)GBD<OH4!>;U&[#^!IE0G!-:# 6.'A PO^8)PI@UODX;
M9B;]4FRY YDT IR%%8">D^A:)VQV=2>6IB)\U>,=$!DY-O%@E88T\(C9S-(A
M4$(V/.)@:^[=3XR0.J:_,K\E):/$/3N0OU!6O!358Z3]@T_\2KB:@J?B9$S?
M5 ^P9PHW7;5R49\_);P1MS#6C,L6V%+'!TRN@DJC*ACOCR4Q"9>Z#DJ^'3B(
M&NW98%,F9ZU<H#5'0?.D*U^ R:86<THA.,!VJ94/9(@""X"_36O$O%PI'+K3
M'-S2FM[Q-0@: C&E^6;S_GIM#BU&3#<WD^6U%]PS'2VB(,P&LTT)LGT0YA[F
MJ"C<IEQ9VS,PH):L?+B:C6B&']R_[><V4FX+4&8F/S:01T>LV?YM7RK'R^M\
M'[GOX9_O##=^69K.J*UK*IL*K$L-<\:!V'"!:5N\P&SD^Y-@=,>7B.C%;D1:
ME5)*F1FM27FDAB!V_&[ ,E,[+\;IK\II=)^SRU2L6ANN]O(/"W94>S*[2@]3
M-A2][NYFL=_M,?9XET+0QEO8H->P=FE;5K2VQ(&S(>X4U0+AZSHR1#ZF6S5L
M;HF")"P/2M$!$?2ZY 7_ ZV,P_J5NXB?<\'_^_!_*Y!K"5EH4SH036\)8YM?
MH^(1Z)I 2-O]JTD((8O52O+KJ5?5F.IX,5YY/M%%VFP#6F2AE3TS7@.B(8$F
M!$RAKV/P4_FG"9JVX&Z*N=JNAD/"OI&8-19P<Q"MO*56P<SSV0X7V2\UH7Y/
M'HH6LY'_(*%Z&+UNNA3YQ7?G>F+@HM2\2BW#R1)UITM7N="[,1=[_Z5:CX2U
M=.+7ACZ,'-SLN2ETLDF(S%/W4]<H61@ @NM>LW!_ [S.MM96V'2ZN=+L&_0M
M;SYG\4S'_*]/NY)I1(Y))>U)[B9(_G;VCI2XL/"D"5UB;D3_;MAPDK-HI0/O
M"23(=08"XO2U2[_-%AR$UTI%KG3WY/4\;WFXW=V,94]GQ9KV@ER=]'/"06M'
M#6:3A$ 5W]O#.F2OE 3LED]]9@'NDM<+K3E$W.)">-/(SIWK)(JDJF)M*CHE
M-VSH2I6PT+8CO-H/:N$4>:HVE[Z5L!IQ4^;@Q<+_S8[5\?Z"]OA\</A9++=_
M\@>?Y6[05;L[V6^*JQP!"CEA&N](T:9%6<1TPQH6P2R!-6HZB',P2J>O#]1A
M6E".YR<Z*IJS4X6T6T<DS3E#:=.-@_#I6YTH^?#GO(47J\VS-D4T^J?EX,>;
M.ZJ;,0E@,3@8TVP1OZ#5)93+P2XT!+YM_,65F5I8HP8XO)I7TR]&_-!CRLSR
MI+ZS .R="#SN34QM4&\\2<Q<[Y*VV?38=A)J^_O#._OT,#<8;J:>>J/+WU5D
MI*,S$1VC,@)0-?V<EF$O12\FNC3T&Z]X-U".;Y%37%F]UFC8T]BRU5LYQ\L.
MRPJ3)".K3V^G>[HJ/I^N#?-$+_9Y!DPH.UH#LBCG]6^]H[%ZV1H"D)6QHF3:
M6-KT6J;DUOH;TDO0?O7H6/F[K:T-ST67KNZ$_,>3W;_&+RN8X86JP_UEGJSW
MM_@;W^2B_1:@U[HH((KNJ\0[%RGFE@=WN[1/O_R.S<S;2MMV^9)LNV0QXFSN
MXMCGTT15NI;J&C^R=9=E\C%Q=Z9L D_\'?_3T,28MH55IM6H4SEY<)JC)"KI
MY7/L-9*2F_(BM!8"1T>)KX33*0I!8\3?3+0*39>C6PS;>[@IB&!_3F3?E[Y>
M;*H@A+K@<CQC</=09S)1[WL:2HS]:+&_A)?YS30P)5M$93U&,F?T($PWU-L]
MJ$9Z36^&XE:O%PPPY/I9&!QC>NV.S%.>01FYZP3@,N#/L/?3:[Y(NBHC>W=5
M+]TY\_O!R#QLEUKOZ*XS'B-[=XM@QJXVQ;6$[U.SA(6UCW8C^0T?[#EU,#R[
MW$U3?FG)!F*M!>^Z%/PB-ZX2FC*0M?$/:GOHK0]J?1#U3K3\B^V;]J4&*;E7
M,PF=V>?;G?B-W?_PJ-?5QP4ZO)I5O[D7_#1/<=Q0VJT:QRD9H]8UZ\<435K-
M++  [HX8^0M8$4I54*;JW^7#\=NX<CG,L_7P\=::YJ15@"TK]!J@ 394!Q!J
MF":DTI>?,(,*7PTR8,SNM11!V&E#7H;;@-D/O@6!O?H??+NPC@:N_H4??.0>
M;VV56.GC?!(KWVIYGINZ&'?*+E[YP>?C;=5=MVTRW1QP\J5;:>E)+.1XZ)7O
M[()&<"*K(!,%!Q<L]09B!R<-KU\WB*0=M"\4"+]B>XVCG2#M--0KZK.9XE#7
M!9U]SX:^?MPL+*P\BR2CY3 K0'\G$'GUD98DB[@0CH:#.'T(@L3>3*YZE(_;
M;+O7_<W(2^9!RP#Y>73TL0HS#S;*&S*?=,P @[7U,I\N=(%ZFT[ZXTH':/WI
M24W;9"'3- V/S1*[_V/!?>2GP]^AK.2F=**GG6@18I-&+S?9&PDY6E?<NL!H
MWRU->0/.XH#MVC08:9D^4I,M2E&\]21^RF&9XBFJ$C^Z\#2VEG0E8@W  Q-4
M<<;&/ 7CK6=*/%VUH"F;M"U?I3<([]SQ *XSCHJZX20ON8+G\0I&(,IV_N$Z
MK3Y"L\O'09:BWM^,PZQ^Z7K8B];?3A&=TW$:Q&E*FF&_(V9C60,6DK$?R4O!
MA^X;==E?2RC@D@<95.76$/4]/QG^%98]IX$VAO!;Y/W@LTVOJYALXLX--.D_
M<\R%*8)_"8*IO"K*P( *(X#5&%\D64)QK3/OMEIU,\F('\J4L Q<Q-WTVF[Q
M]&J'O-O3T\7UELJ]^#[JKK. @7K>4@/(;XGW[FVWN%"\8$@M'C)<S^H![BD)
MO\K*-R_>7S!Y"-.93 Y&^2P/.G*: :+'[(9R]C1(]3<URIIE5V0E,&%!8,@Z
M9JQF'B^K4UVD.%XA-C_;5A+7)I"[I;NY=KWLWR#S_PS.B89VO/,+K)KLTIL9
M!@MN<I/J'O>&O]/V>9X*&.@ AKLO$(T8,JG;EH3YVDSY?K:+ONC5N/*O5:/9
M:< GD:T,UM>I,.1'W.]3+ I20B5;Y@=?^&0S36X;*XL,L*F#XLG\^O1(5>VC
MFG<GDX* LYIBGYQZNTEG80MCN:NE>RVYU[*<1Y)<D"HL1$]K28:W4@AO'.09
M_% FY5>/G7^A=]!/2J^&-,L+O5 M%BW]X*3B,ZP-(/B-?E7W(Z"B6@??+^EB
M"5/EL>&2]%:QRF3??=/-U+-L;5.V]BF09P\M>;GE5%"S:%Y#2UD%XA;'%8#Q
M$3(/U5RF!T_B. ^G&F^MC /$V(EE9W?G76PR0>,Q<GBX<.F@[DUHXI-04?G[
MM6:W.B_.;<I/'6=&%/?)3T>4#P4HZ7#23<9<K;,2I E;R@&?E]7'I-Y,LS('
MY/V2]@+@CQ^9:G(>6"WJHE!M>LAVVO'2[(CD1HYQ;'02JV$VVE>[QNF"!6'B
MP&^Y[D9L:;4YD(;4--IK1OURNI13W%@^01^QPIC;MN5]'W=X5T:0T'LT0-B5
ME-P4BI/41.9'##5'#5!WM+QB$^N5#G'>%@1Y-^);R^8(-)+3*.^XKWDIH;8S
MT /:8Y-@"0D!]R09"ZX(H*NOB4DX/GJ!/ 9+AM*V[UPR36]+O6"2\X]WD<A]
M6,VGXD62?T?J7G-+2*68V71-DJ!UPGXW9(S+>KOBD! 7+%><79/BF2+09M%R
M"L]KB$!5%[U2Z_50-U87# 95WUV<5%OJ5-\OU(8/ %,',.%9W*-]X<<@7&V6
M$^/\V4G>Y-94UJT2(F%,LVCABC-] #ZYU$!4W,P0GPJ(DSV]RLO='FI,GVTB
M5A'/P8,&9VT/8-X#QG<4=XY:[&M%K3XUUJR6:[B>IR3U_)^C*\!;=6AS'!!E
M$*:+D"T,53OR%:0OD^ %>.A&RMG1VAP"AX KPR7BQ[4<^/EO5WK>[3%7*9>W
M'[_?>S^G:#[[XY#H;@O@;:L)PIN$TG 7KCUXP6XU3D/]X+N$GSP-![)%]*\(
MP@.'WJ.6<![VQVG*]9-/]2&:$"V%66E\&GLT61E#\ "Q]!QPR[\? <Y?)E]I
MS;\)N^^(<.I[+/SJV[BL$.,P0C^ 'BC_<5&5J'_'W!':ET*O/S-GA%/7&WD'
M+%[*WTXRIR)+0MOTP^7_8%7CV!"XJM4$L:DKB1FGPFS&3.KHWTE+K:$9+73?
MTN[_^H (723RXZ%NY?L>UB7?:764^O?P2#T%CQ+BLDO\D>#+#+CL/D!'[K3*
M@#W&",I-'ZGS_&.Q@:/7)V'=+<92XJ1(YK1@S5HU1?+_^!_WS'\0;XV;C#^@
M(G[?N9#F&=_;9C??DC0H18?27C0HJJBHR:,S4>JNFWVR9O3G4Z[(_D#:L$?)
M*L<!8GE[*NHY+YA8P/03ZKT_&GS15&/'-Z5BUUWI5;!9M>KX(Q!$88]D7O?P
MK#(\):J1^ITA?\G)=$2USZK;;,Q0AYX'8UD"!)<A.U[%%":27FVN3NM"G^\_
M5!]B^70(!9%NNR [7'.OF1?[AV\"W^E6]7"RNY[=^NJ^-2&2WGH[U:9V<G?>
MJBJUK)49Q5WW3ZK7)!M96V1J8=E=;9-J%G,D.',+%&"59Q^&[]$41J:3)Z='
MN'+8FLVFT4 -6ZI.1;/SYL&VZM:<,S"1!?ULMQ*K*\/;X-:UVK$W[H0XM8/O
M-2>--<[&U#26^ U64K6HYAM+NTCX8JU*THC4\\;P]]_U1BMH89CYG'68;ZO1
MVX#=XV)79CC GMM-%9X=VS,;ZJU>QQ8MV:HG^>SW]_?<K=A,=RS&"6N<NL(N
MBPY11 2?(XLY;IRD:PP2NN#30E^/;=X2!KU7LO(5)4.OE%;:\JWY6&)E,:F\
MHZ8\F6[YV</HH<*'/U_FN9:UWWS6:S?Z*3C@""*ZRGE7H01;8KZAC;SK3"4W
M<?8M- I;G11[J-?/BWK#NO5P$Z%C<X@SAZ65"V$+F)-<4I2)A$?IW=)=E3):
MALU%E$DY*GSCDL6CFL#5_:IGG7_2+"H6 S@F0A.."I)X5&],V:"9(V=9H2W>
M+W?H;;ZV^XGM5EO*0:8.0;7G9_Z)P^O2SYQY[- +SY,ONXBM&$1Y,?S<LP6T
MBZDW(":)XG;5=H[B])G]YFAJ'>!V7FOA,GNAZ[3$L(%!LKZ@"I!K407A=$2_
MK5O[J3<_9HKK>S\VW2KV/YQ,3Y+,S@Y5  =#S.\5^S&Q203'M<Z^6Q+"O_\W
M\_MB*.],9CZB^UM$J<1ON>BD7F"5]ZV>5N-MAAI0>?S7G7<8I5J@Q$X"R:&*
M<D5KHY#1^J4M,5?<"TECJI7P4,Q 4'YTN:D"K;\CS[5YK$"IP?OS*[188W=+
M,2;$01Q9^EK<E'_2NN0$B*&$? Y8$%8;1"\-^'INAD:AKE_Q<T- 75X;]K=(
M+;Z-@3NMTY9UK/NNW8_0'.]9\-.J!7K_NA/I9^](L)0<=(?\??A+%]5(MB+L
M.^@=;7QT#H3[6#;)'@!W4[[]X)OS8Y0TFI=7QSQ=P0M#CU!/6_<J%ZR78R8.
MJK]:84#CO?/>;63O[)XETXN3;4W/Z?_<-H[5%LTS8PO> ,:-(O)0_2(=[(_9
M3[;JK+U"]I+RS=-<N_K3)A)J/ EK9H86XJW>P2\EWP?SBX6&-ED]XF>%MXQR
M_CIG]VV(,HU&5G%FXG_MTIEZ-[%K.-M_US4VT8NRR3."KCN69^^&II/^IZ7T
MG\/G#>.3C-BN%$'*Y=0*X&'DD()-$%K+W2&_CCQ02&J:(&PUF#0IB!)'WPT"
M3?0+S?@OF"2P>(6+9T/KH?#3X]A"5HIC-@R,MJY;Y>4$)FP=KP74YBQRY7LT
M+X3%<]_J6TPE600^*[ B(R4=/H.-7=J$35B,$&,IQ=";UBLF]!3M]S+4C=2-
M--,F,YG  ID4!'4CG %:I@XZ!.8MJSDX'%3D>IL]OMME>_?D!Y^Y;49>,3,]
MV'_'[\-R@W9!]4'T?*S.<<QVL !^O:HYE1%2+>S?!_:K$DAVI.JLV2-VP_0_
MZ$I0S:]&^38)J1,T@N,?VPKO,VW[N::OZJL&7MH=,YJ'F[&R70\0T<%1[5MY
M7"W>2%/1;F%26ICC<!"W'QD-V;O31*RN!'?C$B]:1%-\!6_;NR\<;VBYU..4
MA)P#CVYZE6QPP\7!!FQ5%&M;8X9=(-\0B77X[,$^!CPK,_O@!<_5GA AS#ZX
MFB"/DJP<#K\U7&,"FG:LB&C.>0+5\^(?\+:> GK<UN9&NS$FNR(E=4V+SO<=
ME\+4*9C[9W<'W%A1EAJ2'M <'(Y,0)US:>3"KXYCHB1&9T><N6A8Z8>6Y]56
MCJ_\M38'1^LX<BT-24G'\@=ON4\6C\^LN%G53N;S%D/=W]69<>(00 _=WJ.Z
MYQ&ML.'E_0C7[L%Q17G8 X9W-_= (B[&T&9?_&7.%6TY+"*GI.A:Y;L"(;=2
M*^PZ:EE0,K)Q0,NL\.F1P'H?Z[AJ.3BX3^MK/10G%&\QUYPW7P"TSNDBR]X_
M40.1[C8QTVSKM7;]__L?R40<]B_3R5'7= M<]X'?5*#2M4Z,>UDS>CNT^'M7
MD_P1L\GJUE=T9BRZ;2!62F(I[3L$Y<>>@^[L3I.)Y7P1?F4-4#2I5GV/8Q2N
M9)<3G9>WR;7 $,ZTF3_XY,/3P3?GTS,P!C-$&!>71F(Y-Q0VP;LBJ6U-I_<-
M6P?]9892MIUN124#_"_/A/]9-L^FZK]<:)$*#>R:\OLR$9&PU:"HSL3W-+$O
MY9[+[8_03$X8\[#3$!UQ*%FU+1(0U?(/7+F5##:<?DU!;Z$%(8PJZY/'1\/,
M]!]\LL&;%16$5=!H$2U7T&L=(('9[T.\V7%KZW8YQA_I1.8HAMS?E^TX::9%
M['>+F&H$: ^EL$+64N_=YEG:N75377]>#^X,=+V]214UO)*OQT(X--MZU0[H
M?^C[>[]'#37N6]TFHKZ_+TOX*W*;8]9M@[Z*#H/&0Z,MM=KS$R2E!AW>+SJG
M8;(K2MHVE[^-WS_03+O^8>E_V"3_,?SM5TCHD$+4T[.'M(Z<0=.E^ZKG#EG\
MU5AL4Y5+VL:1<3Y <J)L,@J0"Q:S$-EU^NM^(+GQ^JG(WU92GI\]]:-1 C_2
M":NG 'XG(7>3UJ>1,YZNR]9X89>*2DOUHUGN$)N&<.P9X>[Y<YH9OO915_M7
MZ&L:<T,]Q0$COC5Y:CI-3]O;KK=8+UY7/8R%+ Q8BZ8G.*=(/QB2AFW:I1X0
M)>V?061/8IJKXW:SLRBV]<,+BE_*UC*'1=ZG-CC5*:'D&X'&,.UICK<-CIP_
M)YOTHB=XMMG<1%%K]7N"SW3.W$6'G0#KGY N]:(I+<UT4?_OO"JB@NO;.D2&
M"SDA!3B(P(@Y])AH)"7 D_HR((^M;*9^\#4Y'MI]"%6+CFR,0!^3KY9L>3A?
M;/#=F@QV15W.B>9+G5M;VJ@.=/\<D"(9T6VGX#.86G/"&LP]6*U>D6C^N1@T
M7&_H0LVE57%+R_23Z;YD^0N(NE<ITVR/H"F2!/_W^)2.@)O'C,RYNL9]J]<K
MZ62P0](M,T>'73S=B\'PRF1,'@#;.];:T O^:AJP*/%22WM58O9VWY<!^7<'
M5DG9I!]\3M<[3RR NZI56?D&8XZL!H#8*9+0NI&K-)LVM3/@1A']\ 7D/!Q6
M0_A':UL"<P"#H9"?SM<I&+20!<$M"?7F V1>KV18)PV&(</&'71JI0WE]5O$
M^_^<U!=@X4L=9PI*N\WSP>+))=MP4XYX[^RHQ@A1#=Q&!Q9;+K]NA%AO+;^O
M!XL-0X_T>"EOHX7%L5UBCCNZ\A1>G8N F=29RJ1EM)K!OK(2NM="H\A&*.D1
M \UE'67NL$+#L8Z80$051<MQ5+I78 %23_Y9R+0[U6'!$1Y-9DH^YK0.T'F.
MLRE6N:]?_&96C$?"YYO#@N:6P(UL1- <0PYSTPRQLGS=X[^=Y<L6NW?9+Z>[
MV KV/>X:#LI?ORQ4C[UCB^["'ASQ5ES+7Z0YD6P9H>)BJ5_&U=<1I"]E%3'#
M&1]E=;1+<'8@$6BZ=7MADH*\L&)7*OMK((^*B:@L^I.9:<)"3YR!N(>73RY3
MEKS3(JS?GVQ\FLSDNL=K3N:J02@'=3!<GZ%N)>5Y.4.%RMD-1,GV/M,N8HGS
MKSJOH)V?,\UW!0URU;]5/0YAI<AA!7<C_+M"E>S"X;I_Y>H8*P4Y%T&TW$E
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MWLM(K8ZSV.%%65N9(A#3+ \]#><Y[]J;H8B>0M^0D(M8DXSCWT98]9KV=0I
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M\07HFYMU:[E4F JXIS-*E1RUFY"5:'<GE"[ #6K]>2"SJ:>A0Y-1L#><I%N
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ML7$M\1G#(-%;5R9JX%$2*8G:"'D*DRST6GQ#1NEK/TK+, 71P0J>4-EQG@=
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MC)0Q=W[:O0.W*M'.8U5 Y9!V>;-.86S>8J!LEL9OL59O+G2@/F.D5V4P4CI
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M<TDXK<HBO!?/1^*F/ @CN#[%A86:NO<R=,JUBT^^SR6NBVYWU.6;U+&&?3;
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MQC>S- 8ZZ5VNY?8W&=:Q(B$WBC49?C3>/P6X>E0QKR[4)80(%VHZ2GT1N?:
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M#/DIR%E 57M^^%6@S83\-S77'/;XJ&MC)Z319H*>^>QMQ?6?YJ1?# FOM5/
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M4M5F0<E#%7WUZ1]^FHE_-6YYPXOVN91#+<<#7FQ2A:<7G-W>T$LXWVVD/6
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M$0_%*R^;.I/(TA$I%W(7]WQ;!YJ 5D,E"->*%TY7ZUZ02H!6(77'?9\G6^K
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MZ%X2AIN=<=2WJ3O.7$K$Q*UD[$,R2*C=T>@4\'W*SO]"E7_)R*;1MI;7BYH
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M>8UK-OFW.KR<J9&'3Z9FK5H+V5A_5'K:Y[ K:[K @?@VD(E51&M'&D!NC=(
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MJ77"M";@<^3S^"CV2SW_K!B&MA&R"IKJ# O'):BDP'=G=U>G/?:EF,K/"TQ
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MVTLA7E55./7UKL,<2C,AS?]1X73I50M8!L04=^G036R?ESML3]HA@&)X[$S
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MIN(M9"T*@.:S/1IV+70']Z;=[ 5@1A+&[-G:,_>]YS=O#%R6$ (S9D9<(?*
M@(J5$I\-(P($$A;>J(>H2KR:6!=9K:^R6C]V).U%P2IRB0=NR=IV*6X[2W@H
M_*CU!8L+ZZ[O)P,:-J;W&A4YO&M\#S')X_F^[$UNZV:)H2/FIW[QJU:P2OD4
M44UG;-7B>J=J_UUT@'FUIU;8KKV[6(Y^Q*')Z/;?AB_'#OCBODQG;4IM4SIU
M@[3UTC$J?B>Q!NOO!,D?0XV61]T8W#7;"0M3I\)#Q4/FM@GUM<8I4\"/X18;
M*>!8#/\U<PNI)K%L?P;^ASEW.A;?,+"1SP/J 8?9**,-6A;!4=)/0T:SF ,@
MX JI>R,>3I#:I1ZM+D&U'KP!U ,O_-[[$X.@MA<H IZ7&O.&05JQOBWL@<O7
M+/%VVT#D:]]WN2MFARP1MBK.O(ER2UN#$^P; [.3O*/:O6:+5A9^Y73C&=FR
MP??^'[R1<OBKIWV#9I#Q0-3HM8,DN(@,ZL_S"03VH"3V\8!O9F"8P]!=?;C]
MY6Y6M'MJ9:@SQ>JR[ZF^VG5ZKG:;=C<#^U2WMY"&\;,=9 D=Q#$WMV+O<X6.
MCNL?@$=]0T.]'+T-%-Q7"ES$-"SC<<-#^6E"$32Q%+L(W##8UI 4HTB0"WG;
M^M7B2)6V/-"SBL:"+3=RGA7)QZB2\II-4I;>2X[W5Y\QA=(6"5? 4BMQE[=8
MVKQ2OO4&46I3%!;7',3UJ(P/%21NSAZ,)LG0WO^8HB;_VLV9^Y<TL RR/&''
M[=.PG_6H%&@5?=C$$!YHHUI6OW\!@R5Y1<9VO 4YJ55/(R[OUT.@K[V*>%6'
MQWL,JVA-W60RP^+A]#%5O\?(R<$&L@E>GQIN-F<(-2O:*R$+LUKI$YR?>_FN
M/:;0'FM2,9J'5>!L20(_71D(]0) =92AV O?L1E--8%"G@'#@'<)CH*@,;1F
MKK1]J)KR_5;;P547&#5<EMG8LKZ 9?I;E_XT[M%AJ@A MGH&.<IQ+<R';B:Q
M,Y9SM S/&&%HODP/:!M2__7XFL;[5;Q4C W6[CW7G2@W]3MX/@)U:O"!]^CX
M&5,?S2*YDDQDW8VOF?"31H!ZM+X"&UN61DF;%FP.Q17"+-=RO+YY+C8N'5*-
M5,SQ=D+(I XD)KFLLN>W^BWRR=.G[5@JSZ]!XVV=[WCS'&@\,I5SR=FK@Q^&
M&31PO)&F%\1"@'-%=0!6 A=X[6*WRH[*>!Q'%8>9IZ2%5."SWGCAW(<GT!K
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M2"2WIWUS<,J[W;FGLUS ?1'X2*)<,+""\8%R;%#54+6G$.T_-KBC[S8S7=B
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M0 [I^-BM%",X1[E5OLVOI(I<VC7)G>=)WYL0CPQOQW,>%18=)"*V>A;W;1G
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M]L7A++/V5NG7)4.@*CDL$K5AN@J4"E$;3N6N0COJS;\-&HP]&*\7K@W-K9J
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MTDW>!PYZV2P/RDF*OJ[S'Z^MM:GP%SX$C_\OVMXSH*EL;1O.'$?1L0TBO<V
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M<I(R8X'LSI/'+"WE\BK/;M\U 7!D;._)U7E1Y%(KG%#UJSTF=(U3-V_C)HM
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MVFG:?#WB?[5ZZCQW!E!H_L/%L <NZ R_< ;H_FU;=9'1.+ ^L^GT\%JR-A
MN-X%0\X<V:OIG0& FL<UN\JSH?DGA'.B%WT&L*H+X2\_@2<>X;_TKF&%E#-_
M^_].UDN-X7UAFCC:8B*'+$_$<WS:*XJPS'J'K[Y4 #D7Q<]=X>J/E39<&*O,
MUE"WW=D,(;1U$A$KNGP:B+CA\6JJS3IAUUHE!9YR^,E"SL;@$%*N&K34@)<
MZTK@92Q5',7]"^2/2M<(.L&A7E+2W%H;ZW*KW5\-BA?0++P-_48180S3CXU
ME:GJ<FU^SP@FY,J'T9U#J4M?8SIG=S^$8F1)GAJ@M+A 4VY844)DG^2>5P=[
M5CJBFPBA)%7YF:M(\&JW=Q/Z"9$N_)WV;4WL8H:W3.(*B&:%=R;<J\^5B%NM
M*HO2L]ZF4@\+;\KB>/;;GB!A,;N(^66Q_EMZQLEA/.[R [W* ZGC+/7Y;WG!
M&2<#$:]'A?;X@"6T)6>LJ4<R[SU'9X)I%J[>_4'O&YOQ8A+F7=JG&D7-$82%
MS@14TA'B]/64MI&03PY'!09N/-P(0T C18J&DU-30&&%?39US+L31=0T-,&@
MG'VY"16"#SYHCPVJG$SH^(*[FGEX7?=AJ[3^RJ=\4=A1D8DA9I864*$E;L@C
M5OCZP5RDXN-K4D[&?_NPZ? :QR4HRK)6.O*\^_ORJ#!)+:+=G<Q&^&3#1GWR
M?HYO*'LHUBH1+7-%I$MD-FGC><._T4S:F_MO\ OQ3- 98-XJ&Y:@N2YX"CY?
M#[/:F8,#Q[QG %OX7JO2$[)"W#FY/J%?/ >]S-_@BA,#.WF/?@G!,[V6S@!?
MJYF7QS/H07!U)<X=^\2O-<9%EQ5;_Q/]"'BA\R'/Q0,$A,1]-%0)U91T76DQ
M<'T>\/:IV"BTY0Y),>BW35 )![<5->:.A1',0LI7DH?D$G6/GET74@H-8(&M
MYBF.HR1 >$.YL!.$PIQD?+BX;WP#6OSNY(L'8RN"(RY_DOCY'2B(X*9-&?*K
M\5SP-:&5%E3*\/:C;O>R=I,@:LXO%'8HK:$3RO*KMUTIAG80?Z )=R+5!O*K
M3\8?FJ^,!H ?I3U@*[HM6U<(-L2YV73^'L\:![%Y%TFHDV9Y2K:QK^)]C+H6
MKM+KSJ45GJF[FTIE=$.]3<)L/8=*UJ::8L-6#WFS YRG>D=K7(FJ*0%S]$\1
ML#CI+V&*ZU_$'HEKBXL\_CMCP3\L02R^8TMC[3 )@A'X6]?:JV"EYL9&33UW
MJ0U3O)*6E#;>O7;DBU6I=>=F75Y4.ROL2J4A??4,D*K>.[+SJTRE9RB"A\\C
MN4-OLNPTN:':B+3-.[.'KM,45N7^^,(NRM#;1;6_J36^1\YP3R5C2KNMRC:
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M/@BP3I>CGR@@;Z>7\^%T[YQ&R.B]50(^;_!5OB6N#"O(V]F+ 8++.*OY]&Z
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M?>T22YV\=6>D7MZO0:OU#JLVNG]H6YJ)S8G>J^#CYM4,G+<-.F^A-C&MWY2
M8^]J\;X"-3B)SK<0]56%EX&LQGDV$N&_[L0W3[IW$8O*N:9\LO4S%#.B>UQS
MU=_]2Y5=V**KY]L,HS@PUYM>?%D9YQ$;L^];"_;@4M-2Q(8H>#G5!$H,5R>
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MX;M-L$,,1M^DY#VV,\&ZAK6T Q&:E6"V%;)8:KCF]CXH/:=62AN=KC!N#U?
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MAS(5(Z33:JD^C[Y8?<V<5!H?75-T6[/A=Y1:S:@P.*<N7#<FV/E[A\QG)[$
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M\O+36SU2(@Q+'V"E@V2- #R&M[PY3.+@<=SSV_<^SO7F.JWO\F7/\9B/3 6
MVT\Z%B8U[2$12C)A$<+Q=+&.\E!,^$7+TLJE.<LNW#M'#;N[RT/),9F2.8=^
MZ/$95UZ9YWS9;<O;=+"*E/^VW)?Z.M-D!(\M[D1^MJ_\C8[CGM'&.P6^=.>J
MG,^E]0'/XNRB/KG5B"@\5Q<)=*%4@>2-S.$'4[/9$K 3U:"(MW5YQ<>?$V;6
MC2[=DP8OJ)K/VFN8H8BPBW5A!PGKS_ERNQ,*DWU,VJ!S=%?%V>8<M25[6Y9,
MK'XR_LW[\+:UVX\DK0E_A:]0%6V2;"C]4HZI%PV&9G*/BS^?C^4Y$BQ08BB
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M;#/7W;/XAA&US0-DB3&=!I:"D)LLS953P*5'U7,?%UP!?+J1'E$O'!X0*XC
M4T"N5$GV<=1!S*6#OQ.QU6=L)I[9*>31@O-C:OY=P)&=IC^U[O@5LO8U7MK?
MB"+[?:Y\ME;*1\S_6G9'VQ]MM&87UE/Q)U;2@Q$]AMK!O =YHT=0W$W3TI8H
M_G9SI+/H39SK8%6J@:H\V?3'TJ#K'L,6HP =SG%K,"V<*3DXB>G]?V>-WV91
MMC>,=T$]24>AUQR2M8"VP%4:QB5I&9:4F/XAQK<FM:Z3MGA98>IR>-4X%99^
M?Q8NT)2#R<$)5?-^?LIIOB4FX)WAKN65]WO;+$1E;"VM6CBS4\C*G=%953V5
M1.BBG\C/J[<4//E#:F3W2QW(BZDL4^>SK$,78-_P37I!H299RP_YSX.6PV]'
M>1EA,I8RWAW[",3GH*_>#SN;DI@;!)^=^?XHQ9,0YGJM)WYP?<?4_2!(9S6E
MZ(;M*6!H06?+36!5&/PRY3P0 +@<$<:[SAF4?$W.AK;*CUR:S=CG<V=G*PI(
M?G<9T;K*4Z%/62AX>B<357"D4%)Y4&4Y/5H >4>V1T#.X;[V8K@C8 8U0=YI
M%=/ 6H&N82G0[+J2RI*D/;$\2)N1F2+!>C!2[0DR+[>H!%6E-3YC3!&T.N"1
MHK.=WPU\ 8!6(UFUWAGTU8-E&-\>;'[/L\NF]+,?0Z(MR),GR>972N7:KCDI
M?K2J/UW)14Y.=I.<2(=P*<3>0TOKT-&>V$O^@>BV^B<6&U[&<RX&FM(]//L1
MP-3"+7IQ3I9779.>7XO=RGKDP%H2Y22PSF4=G'%4&!OC510F.F//SDSJX3'<
M7<AZZZ']"'<?E".GEK_5G]E0.[E(PSDX1621%ZII((-V57#]AXS$/,.YCM4#
MI+Z@PBJ/S3BJ;]F;8B'8*WELDSA>VT*?'*>/I'XC$%RUH?J]! G@Z%PC96Z)
MP'R8>.]*XQ]E]<ML];3I2>;,Q*U16*0^HJ3+7EM>DM?SM=+. VKYK)ZX+1Q!
M3;/S#S!K?S?QQ_^D=:-U8'WP_-2F?0R+=TM,)G4BV,8:[/0P&[$X1J+;FH,*
MFLPK,WD4F,FZ)67MC>4C^E9'O:PYRX[;$JH/]O.'^G+K4?83>.D)6>P30_\:
M;NT1T,*!;R)^/=[4+)H42=+5G3#%#SE47'-VG'/VK)RWQV=792?BK1]YA]R]
M.<^OYA[&H7:[=A7:PSD)N5LN;74WH5'R59NS?]T#Q-6^VX^>%)O>S&BCOF4I
MB2<2STD9=SJOFX=C4$-8&PO2G2I<3QAO7%Q),0'J5_UP2RPVXS*E"Z-TN=FC
MW3C-3H1+:Z!4-,NC#-F4'=[<VSKL)P7FCJ#"-GRHB=TP*9(AYSWY(JYF8V^Y
MA(*A!+A'<9;[4H[8($ (=M0TM:U]"I")VGQ@0-01V$MFH<\@P,#I%/!ZD7F&
M!BCBD2-/@5=6.P!P-6/S%-"5]V*S\$+WM[KBH8= ,:F5@U[5OL4[J4J/RAW+
MYL0(*=F@M6=>+Q:TJA7O,LKQR[+V!S;P"M.GT_LQ/CM2VQG%M(F;L*_?5K<:
M*C ;=MEQ">937G5,L>NF 281?,;IQO31H'TC2 #3K7T@JV-X-^&YL[Z(TL(8
MA@O7.W:<75.6X#U2FV'V)Z(OMH5[/EUW+M7C2_C0B_WN!]6$0=T'J2KVA\)A
M9-M]0E?9SX;$)CC?+6D3N5.2.I=1=;?Y[Z)Q.$-#5*,4MA<[,[YD]NUOO;A$
M7P6)AAF.^6:[H=();\85&HIX)]D4$G/)ZS-;==2;U,+0+[T''>J0FPJ]#G&!
M1G$2X3<R@)=NF[;@D6".Z;"+3-R3.>%RKF:]U'C[]MP;1'VRPK7;)E45'DJ5
MSBM_8#\'D<<T,JFXR^)/_"*O2XG&]@2SS2-N/&P('3V\U0(>G-P(XD-N!?&7
M57T:FI -!/<JZB$"[ ]\CT787DY6Y+)7/>BO3 K[,RS#+'>*/C])]9&D/% M
M^D*S#WHPI6*=[:%MU![T)1<77"\^(/[%IV6H(UCV>(@:[M7M]V3R1Y5,N3LH
M^0)OME^\?]P":O)]81#_S15$/8D*?V35UA[P?STE!'A>U/3U-O_K %1Z$%)H
MA:^86768H-8S?@.M];@%2L&!_DJ6VBT&5VH]+3@@7/J&)%W:*BA)>P1<3:SH
MOANRY^\SOZ\IA+.I<(X2?%DS9PWY$;T:-,QWB&SVUWNX-3KPSM"[9MDWQ6^7
M#_^-U>&X9_E[VJ;?/7^Q56L),YP__^ZX79)4<1WUVSQTMF&5#)6RL5,\(O=&
M<;U/^H\MX4UN#:\A^/H(@1M*V\=+OP*3\N'Q8G'U?8NCF3<Y@,$]")<PKJ@;
MB.+]4:S=ZKAZ"&_;46BNZ"R58K@Z %5DX3SLAZ!>=7T:DFUZ,G3W2[I/]!-<
MX.H:O9,\[QR]/0VHM3+= C;-]4AO_;C(6^]GFPQIG5BV3^$BE^4/X2V;89U2
M#EW\UP=4"LW<2:,4O[*)OIO;<F&JDP.)B!U%]<ANZD#_,5[\?.SY)$^(4WE!
M[MV1KH]@T\BU-69T_=9>^Y]'R&3-MP$%>+!^&:WMZ+7",#SBD4DT*%[S=V8)
M0Q%.BXA&KB?>"[#IQNQ3#9"2G#\F9*SAS NM1RZ#_K73T%@#H?Q^?I?_7>)0
M",A0F<_&=7RBM6>YZ8K,-"J2QMX"V=W645CZ1JU>B-0;!YYT'N4>]P"$;%=N
MKS^']4#7.&7$4_.K^E>0TF-0C 76H+L$9% JK?A 58^C;M,T_S)M7F?@8OG%
MR2RF_?Z(73<-[>Y%I8$$= C"19Q6\ZYES?-'2%T0=M.F UR*A*YXV>FICJP>
M7+[R] TYZK+>%:%^*.OFL_LQ_[Z:GPA^-+Y]>_-=4M2S28U-_K<'MS 3HAEQ
MV8_^(5B@4^4VQGSG^DQ'$%BPQ@62)!NSA^Z:&?U)OO'S;<2NB-TR2)R=A8^;
M 2B2:L':=6?I_:;Y.#>=(O IM^1[4$7A0$HBT@;FO-;9D'N2?!B&U9S0 >;=
M)_TX=RZ"A!/8"9F)W+1OF$PR_>0]?;#.S6#D]O;V'1^.D4L6</1L\U:'Y!^$
MF_U:]J5D3H6CB.^:_/O *W-DOZ^.:J6G@+8B'I\% M!GSFA>Z%(%'^U0?(Q@
M2,8%+*R,2KT"'<KH]FWMCW*3#XZS#<B^?J_,3R0\_QQ45X\IPUU@*PDM1VB9
M_(S9-Z+R6D.?_1%1J7S16_+'(8Y'TX!<V^>2G@Y51L97MVOJ=BCVA*("U\&$
MI.[PB4-.23NJ, >D,(6/"VUD?#S)DQ&,.G<QPL8MM<CKVX&^8  L?T75&4*[
M;YB4JL2^A,74C/-AT^G#]#I(]MN7#6D(D:O "'UNM6"T4AF,QB?"E@XW?U,#
M!<+/GF_!$(9L=Q5T"L$S/';LH/2O[SR6B;XF"O1P0[<JD7QB4>P ;E.#J[8;
M=R&1;KY[;\VA-?OAFL9H^AB]D5>F ZFDB(-Q)D^E;@VAN<ME,6:'>B6#,F7T
M[6N[D[EZ"P^.=@A2.O_H1EFNPV14RLSEM]PCVBK]EMUI81:;@S[\%DY!; \K
MZEBRY%J^+BU_XU=!>JVRX+J/>67Q)P%!0>R86X(%^V:K.PK&H3XFJOLSD11:
M4^URE#$)XQ@6>AM6S-)&!6@&+,^$1FGA#;SY=ZW(TAWEG#K-Q+35[IY4JQ'X
M?JD#3&@=Z_ /8]'Z:Z3_.<[]]>1X="NLJ,>W_]IP]91ADN8CDLI*R1RT/CR!
M,8()X1]VF*'9\T:"E@]PHEH'@N%N^477&@OCRQCQ50=(92=JY!):<66?W-6_
M7XQ5#_'N4*.Q.8]E+6.]&5Y+QPLG"4',M)>=AZ$-:@'*Y<-_Y*2@GY6\. 4T
M:SQD_G: :JX/P(S4&@100!I!8E763FI[2X=!$RB('<UV>7.D1M)R=D?Q_+.E
MX6<*(%INTZ'!A(&E64)]%0LC:3'U#NN4_FJT7H\OZD%VN,%2$*<'2VLOYLGW
M1?X$=$D[<YC,34B;U.KLGKILM\5Z+EPG[&J<E-#P[T'_LMD00P2?@ J]PA/K
MYS)CR?(-'$\=^Z:@L'H)Y24!X"SJAD4]>=40K&7/P<0MA@DY2>9\# I53,E'
MKXP=26=<\G_9A><)FJ6GY4I,O;=4T=U(,/5YJQK1@O8(<WC:/6%#;H/H-5<!
ML:YK">PV^O0BF<)?*^7@QK8V_\SNG^BH"OFE)_Q=#_!)N1R^K\7]/B6RK)=?
MZ/9MP<_H'Y"NDE%=RU_>(&W2#,T8_O_4@K69&U1[\6&B:VK[^"E_S2;'NSXM
M2_//KJBTA31-U,TK-O#6^<I[-.Y'?B9B/WQN4##DLAZ_#E8HPWJ9<*#$9GDL
M"MD\ML'BC6)LA*G&T*==80FIF\FM>>Y;0_XGPS.$*'+'[%P%WIZ>82WN<10!
ME#%S3>@S$$(,4C,KH$UZ-6)XQ[N+<B+.PF%JBL<,T7'Z0N8N,W)7QD!3HE5<
M<C1KXSVX)(-J:/@PT=S5 D[*_48WW& 4HP]J(+,C;5@!3<%Y9V=^&3A.596T
MN8R]( DO]$M^X3*,#-?;Z]B<;1NKPK-7F*FANA52X+J=H#S5;]]GI 6K.NEB
M5BDCFUG-3Y8&G*LK:^"&B\A>89^=[%_P,5/J\T01M?NVH9&3X1SJF?(+Q&G&
M!H)RT#&-Z5X/M#-R)Y3M4+\"W=E"]J6D3 ,ZXKLZWX)O3;.277>?](HW1_$Q
M9-8),D6> <VMT7]O:Q-#_#\J3^4&J(UR0VM+$R<")G:\O"8L])1@3YVDYTOA
M[;;1 W9MKDOJ74=[Y23>#?R!M&'Y:#WU.,::0D&A((\[\Q0+/3;2PDT7N<2L
M^F[-WR<I$^\$\.1#EH =V@3LOJA" TIBZ^"S JG2]#U"Y')'CCM'$2?ID_,V
MO/7D%/#AY/BKGZ'VW#C*FVQS;,3O.=C\B?AJL'J($B.@4/SHH&YKK#RMXF7]
MR!YF!%RO+:@E#,8_I7]@M3(4AVK0UG&83"Z@-<<0.B/TLHK(T64QKI8=.=T3
MW:QPQK[7HS!+@@^]?!OF*\(>QKUJ!O,TP'"*D QO): F-E;>I=K)Q7[H=TBF
M<_W6?G_,$F-T$_GP<*C9ZM@\M8]'JYLZ'SZ#JPQ[%9-<1E1XF[+VC!XF,I&=
M$-TYK[W710@]!5SPNQ2Q?VENWU,!^!4A!T556(71]@<TJ]Q[HY3ZW(T,P]RW
M\O$4@_B4E=86_(/NO/F$>CHQ[Q205K<Q.TOJ2R,O8_\" -Z? G#"#2D+4[BD
MP[8)('H.VS-9Z,[9G)4NP$,5([5];@'NZU8KSB/N.V[>35P5RTKOS9RZ%CH0
M&% V"N.YM[83$$D-<N<$32@YQB=^*LH,@F["*%MF)G:F.6OM70DF4/@T=QGW
MM_5P3-_R_M"CQU1%;S?76;V[BHX"&*ME/,.@\8\GG/,1729@65N7H5)BOL\4
M6%IPXU@@;DKIHZP:<N[1C[@P(**KW-UVX 'AYM;L 94G\E>:A17?0%*/5:R<
M:0%P\/#YEXC .-KH>C%Q@J=F<*?#_Y*'Z&!UKK2#_:W.-(<[A^7&D;;!@2&I
M>BXM:XM( HX*XMCU,@<-*V7'>>\@O,8B9=L3,B[B@(/VGG4[AW[P-[7^YU+/
M[-+#^ G-]A<W$(UB4"R???L(!C.S.Y&WVJ[")>1$:=GB1R5C4_]"@:Y;H*S\
MRWG_P'L?ZV[!7(\EYGQ>)%,2YQ%5^WW746!HTE5&>]^S<#&GN31W\YGIYKDH
MG5\WBUXX3UY+B24&78],#KJ9'H&7(R1*^'W0*L&!"C=,9\%1?^;46<3844>7
M3]S&U-O_Y)0CKVXR_X0&W^I@@KRNV-@&SG/>[[:SX,L(FJ5=2<1V7,&D+M^5
M>N?8-8J2<>_1KL9^\E -V@_2K!99)A.>*ZVLFUDJ1'!JQ1]4S#HTC IL#D77
MU>)\M\X6/!6$+P<[/D5 &PTLBA2N5.VWIK5Q"KC-EB$,7^SH?Y?Q[DO$^\Q?
M@PW^+YD&?[;1&!QG]#>UEA^K"@_-)=IZ;(-ZDMK:QJW5[[L07<E9:XW)T.'<
MBF0NK):%J$*?/^C"@:3>HK 7 MU#2V%$,"B,NHGNM#Q*KQ\6<5VFR/('\0ZN
MJ]OK6]F\MVF<G:&4]I0I(;%CW; 9D:OQ&VC4P)3PQF] I2L_O"TM_\+5Z+M?
MJ'I*SF"ODE*QRVIYCX2B22X/#T,5-T,\#5:#>XH?W;.WR=@<Y[Y-LJ#S8,2<
MQ<J]B_[(Y4TAE.RIE\5]+/&2;CM6L;@'3U2>Z,!=N-\EI=PE9YY0,'HQRZ.X
M3J&-6Z2KC=34A8O.]@ZJ>3"1)OW$H]TWAR?A\_WZ,T(#7?DL#V1KE8KA_Q)(
M1#Z?#UZ 8[W>1QBLQ)'47[!6YU5^R;W^62*.5^1 9C2NQ2G<.RLWYO%R/R=4
MT<I^ ;B&>[FJ@!)B<QB4"S#04P_F"A(#STSON'-RD"&Z$B,RS;H*;7R3E G5
MO*$)96"^=GY&V?*A1;64?J(JW<! W+BL;:C8&"7",7.@&'3.-U\2TC#?VA#2
M75\X,*;Q.]D/Q&>EKMTMK=K613_NO^:Q]@P\U>3*I0#\-?]\WJ6"B(MY6,/)
M7DIVO)(WF&U_DO\9':LG?I_X ;*C=&](F?7A.9/#TVZJ>)V>6[PN=8^U,>PG
M-1F'LN7-Z  ;,>BV)EC-@:;"M.OO=_]>] 3R'8;\"VZVU4%BVKN-N]1/?3HA
M_PN!?14(283?( &E5>A8ZUY(^;B.I8-QW,>**+/E#;'KT8'V P_7)4R":XM:
M,GC\PJ]>+GG:W4_T8?@81,0^XK\^?/@?V8KACLJ5'=(WC+*W&0&=)\1T'D.%
M*@V-,8O&VQ_KO%^O_;7[S#H"Q)7I##-$:<44A(>F%#;L2^)DZ1%]=QS&\3!F
MV]Z+HJI" ^DU)G9JX8D (]5']A?Z?TW>_U]<L/_3(HMOJ&2-/ J.R+#M=O$%
M7B>D=2P^5.E1I]Y=:^14B,5>.[$'<7XJ%;98<O$;+>^0O_ULCW2G I)54A)G
M#:7A1^;=ULQ0AE*Z"F9#9A[(IN(Z>0NY-&'DQ>&A,L@[ ^CKM>V]C]L+R#JE
MF/H,X85%E(#<:_BC1%P_USF()03;('4%KH,U*;+[6MO($]DR]D[LMO4=7TNL
M5)E?^6 !P9%Q2)6C'.UL2B%WV?+#JT\!OU,/0'M-(S)M7[ZP4K*^73,'4\)]
M])F"FE='ES*222(=\V4;BA^#9_& WZ;W4:P<W/K"5+(F8:\W(]2.%>=Y"KC>
MR83*?U[-/PKO9+UH8;HDZMWZ9\PKP"^2 J]. 4NS/5']GOF=!L]&I\J)B[69
M)VG$&\%4Y%[(V1S;3&VMG@+,.I2^/AN,^M=UKJU+N0%&/,%PGP7^9_@M"JLT
M.6# Y,/S[-0Q?T7.@1:(E561OTF[@T)([P=AUOG7E>E:GL:=>T<1N=]VO=;K
MJFI'XJ]7],0.D$:+)SBY:-FVGW\E$SF;92NRC%IA/%%TUICG&FT9YQVP/!:T
M4I"U2O#;P#H-AC/L<H4$+K1#P3?3TCC"T[> *2?(^=QWZ2&2@LM;*KIVEI?>
MO?5PB!["_"&69VM8CFX2/ 7<3&ROADGF#@C7.&Y9(>SDT5#Z.V?/W-NOO*A
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MGUAEC1JR"9]"!_X%^(6G!:X;X)A,#8NZIF[[(B=1ZB/*_\_@"-.D244H%26
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MNW__9Y\$/^HB"W]7@%MO?4UYS.E?1]RU/G 1\'/?,*%:3B)5?:9']3*!9+3
MR^4@:W>^V<]L[!),&WR3(@<--74J8/+M*_NIGO_>R$\%D>Z>-O+?&'#1:K.^
MY?CA*9U%T#&/*ICYD7-B=80N.P< .D^O7>- G@/X/:,N$8Z/;ON%+#O_)"0N
M"FG+2A!T.%I<G-W$/8B;H;!"!P^UT0->CI,M[9BSVJB"Q-/;7?O_<5P*SQV/
M"WU?[W19E[]YA*+]IACL<'@B?2C$LKP8.ZO;,1X%.0? A2]YI"J$ @ 0XWW$
M.6!X==[V*.P<,).5/?C;]#E@237DU/RXH_@[W7SA-&J,=</;LYNMKP>@F7HZ
MS/K4;!=EAP@Y!V@Z6*@=G .V;]S<TM)]&_LZ2'Z!_QR -]_O([W%Z]P' &8D
M,$P\EXON:5E0S9/.7O?.I OH#S-'OA*J7@_Q-'D'#'<*Z;*7F-YK5<H$1=5?
M*M"FW1U,(G<J?VE2^ E%U!PH?&IFTF7(U&E91+38]O29D8_\D)%\G,D>W-O
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M+M"E:-<]NJ>$1-OE @%X$(3/$87'$D2=*^(>>DPN5:@7<VS\J7U!;:<13D\
M?5&.^*G%I^J<N@;S3:R*LR%M0$E&J_DQ8Z06:(<OAAK6%_1^97_X/3!"JC]0
M1G7 K\I925,,U JVX0M[U?MEK@KH@KZR^J15?UNE_ @L'9V3N]V[W[YKK08,
M."Y?/CQB5217+"?#E/C0 R2H::N%=QW\'E'O8>&M@EKAB)B@J:F!H+374?@
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M$).M^9A'=OR);>WH?"\H<U68_3'6Y<[/'5K7Y1$%UU(1PZ0<2D_D=WC$^!G
M@!=QZ'/AU+,_#DX]O;JV?@:XZDE95FD_EXW0UO@OP"\=?"HLE0/T87L_)>4
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MV1->6[=-.UZP'!E<QL'E%QZ? =[@3TB@K6>O*5I]WKK5<,=/WE$"V0<3@:A
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MU&"TV\-[I:-0GT5[?*ZD6L,EH#!:7(F[ ^/^)4B&0O/N1];L,7":C^\YO)1
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M<U?4\T 1GKQ99>L74YG&996ZT#5=M<"SSJ@P2<GI*/7=/O\?S/6YHX[@X1+
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MA-@@1-$[EYP^SW9HAM6LQ9J=;M;]&L1(50S.]DIW;6>']<:A22%>H.I+5<-
M\>NJ0-8"K$S;UQ]M\9]4=@/GADB[;;<R(U9RZ6</ML?SS$C<RMW5$O9]/;E&
M/_ =CBWY<O!Z2]E260_TVBQ?4^F>?I\Y:-LM@2H. L5M4NY8%NXLX]^:LN=K
M2.2'NQCTYR). *-%%P=)(9)XMZ'?+5\9V1\6#?&"%8A "Z!@C?()@#;6ME+I
MV[3; 7JF?\>G*7;77Y\=.7PE)1A']W/Q(++CM%4VL%:4H<7U6=.0;1V=V./2
MG1- J2=-\SPKO'I++9-!(B1:P-?@4O@LFK' @P;3Y?#6H4#[T1$>@\%ZP2,X
M?6&0!4R".HMBF8;Q]U3%KPJ3V@& 1Y(4> I'<N/W.??/.:)M+W;=?2K$O\Q%
M=A5G 6M\OTK6(T.. SN2(Q_I,@H.+1'YV #H:/B9%WQ?!YV4GL35&4I$G  T
M=VPCZ_8-)PWH4^[F1)FE4"2.U-INB+QA@KW,$_GYH"9$!K7?U<04M_$U:KQJ
M&=%7_N1[=Z+_AHZ( [X&E'KA:2\*6J%@;++%%N-A59$R4Q.+"9:40<2LWZ]W
ML01_-R0/HML;0C<K4<!'NCC+F2_Q=MJ3X=_WWM1RQZUVE0C)7&N-PO>%JW"L
M:7GL-_G?#I>!:G?V[BPRU@A(MM^HU16A3>7\#2;',)J,%ALA!;Y?]L;_+\ 9
M=N^@7!,FG8Z0%BP;W[Z7I_?-@_YC9/='QFI\ D4^G;N48:8WZ\NYQS^T0EH>
MYY@EWGC>E*$HT!K>&%+>:DA*L.^*WML/:-KZ_6A;1E_;.=XPI']<.^&PMD;2
MK$(YZ16D"XC8\A9+\F'B.*2^'T[KM7T9(N<<8P7WK_$)>4W\;)*WG*MPP_?P
M &]6%V]DUTA/2_:VU3?9)J.$4YZQ]_A:$F,MD)?H,JN@>O4\8201,5_FL2..
M=\,H-RK7YFGEF /-++D7+EOUV^WSS1-13E&9V/X4H?X1C_*UU17?T.7A@QK[
M*VV@E ,5!1=+CSF08,Z"@9)O>QC0/!6+JO;X$W &:7(['+'7U6%L.88-C)QG
MM77U=0I_G-\VZSQD'?7=T8?H6!3?_/P?=/EHYN7P>X(K_7V^U+3UM.4EX5"X
MMN?D4[4U GE8>2*Q>&G2XFL6+!DW OM5?DJJ3TGQ'DW6UQ%.-I#>91FH'5LS
MIG6.'QQ7(H]"15KOW)_=#RAOEKB+@1IT0:X9MM92YU15Q)7W],/CPD+!N^/S
MIX"WFZFW=R<D;P7<B!^K=V/B]P?;9!_BFL!,L/7AO<EY-AV&].92Y&1@!GY<
M,7'C::3-T=QQSZ!6ZPE@ZW,(WRK]!#!#ZAL[1=2[(;*5EHF2QX>4ON.E@A/
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MO#Q%'!PKVHF (&(K*I#)^IBIX">LE$ 6L_JRJ1<A.'+YX/2/I@'W?N*^7[R
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MF<H=;RE^M E#6Y)_8YI=&XMF%%I:*EU2Q #48S-N>!>+2G@\,4F"^>OHZ%B
M$Y\.;OA[\M1[%4$X-F2_-\]AB^[TRENXE_1HGP ,9@+4=%&(%]Q%\1XZ^$ .
M4&L#3WH%.25NM5>F,M6YKCAOC+J<(:)]]6A#B;=8@;UHWR<674YC'_M=F;Z&
MC($+5;A>^S)Z[.M!E'O9D?YMTL)X2:3M(:RF#X:P1/QX9*5-B30@)6@>9I9X
M>>D>\V9%FC<H\7S<7$('0!]0PV-HGX5+-RE>Q3\;E%:Z=+M:JS_O)@]M^M\I
M$FB[QZ#0*!O+[83:G"[SS=0R7:HP&3)>^&4WL(VRVQS6:H ^EIX+/QOVGJ(O
M]=+#%B0@DA3-CNMBISQ2'I%,J.:Q7&UQY"QR.Q3]S+[34U ?0!RS'MEF=NOK
M#&"@QG(1>ST5T;).<9D1EW,.G>IL.4)&$W0'AQ57']P &K3I8'M"BZ"&W6_A
M<6Z<'4&%L*(L8.E]:63ZGZ4VYW=['+LKOY^3TGFTGNYN-SKK#3P FK*^OK40
M !FOP]J%)0.]J8]W,%ZD2N@X[D[S$-"N<$ _E#P5)[' Y@-FJV-]-Q;0Y#JL
MK+%JE?MU*<PGH/BPUK9JR%(YMG3*LR^^V3JM'.A15?OE_F")]0TL#O:>2,/
M L,7"2:#LJ,_4F8C167Y.T]#]&@#]\CO#Z@X"M<;E852KR[&%K\O<:?1+N?!
MA4&>BZ9=[:E-L\5#V=+Z>^J[4@2R"-!J(+AG+:]+R\821R"E&6J8-U]OC_8
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M<M91*+]/6@K-5K0#366,.^GY#L?2RO+T."E/SQBY<[6/F(#;=%=W(%,K7.S
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M$YUSWG8=<S"XM+-\L-2[C JJ/,=:]Z&*MP/6A6Z%@8UGV M7M2]HZ6'MYH!
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M$Y'FR:&&.*$#;W.43B@L(?:WT*2"Y<OM)J87+)1-30IO1N4'+&=K//%:C2'
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M@]-4Q!ZHHVFP\/K?!*V6VE/"0 I(PO@W2\D01),?";$>:J(Z+OG8[_/D8P#
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MNZV1C]8U02VGA'M:/!Y?JO;6N2QI*?32BVR:O_J4)(LH/P4Y@K2YI;LY&J
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MAD/?_6WUNN+OR0*'(X9%<%L7U3T_T1WNY02M;KK<B(@OW4&B*^,'0&VK <[
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M>?7&6AX&JG18RIRIZTY2\]HLJOB_7SDXO\/T!3T%<'E>D[Z-SL][ES*A\EY
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M977?_(IIME#*DAZV4-'#\9TG TI537_F,@3X-\<?#[ AW_?HX%==RWPC1$D
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M@?Q2=K?S&@+\#+RS3>'S?FO(+)R(7+9B8WI]Z'UW\UZEBM7E"05HU&3ZUA.
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MA20_$<<)C,8=B;8_/\-P.A6! 2GQDB4\E?I"G?^K2O7_O'#8U:8J[/1T]0K
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M1&I(T6Z8?91>7Y]>$^6+JG"6VPN] "22+@#,U?/O0!> A\7'['^V;6I= (9
MYU>[Y\\#O]WU[V)]Z[JAT?%/,=\AQM[V>'8M>Q^(P3VJEH#00^[UZ N I*\\
M$%G+]LH=/T(HS6U/P8\VQN)>OI2?O#(94N]^;G[(>I/M=\0F5ZLY(HQM4<P2
M6VXF'&&A/N*]G&B'@M]&+^3;59K88!>E3<919>CW\T$*>\ _1D00C2$1TAL4
M>)J\7R4U*A:,-KV!<LO7L=D>QSOL.9&6]O#/TZ,G76,D7_Q&9=;(\0@$;M]S
M]]U05SO[X;#AZ&E4^"-?9+ZO96:X56HIW5-0JH*?;/CQ^-4HC7 <Z!F@-Y5V
MDWA#]9Z&XD!MEE5JF0Q.QIS7)+C0,=LCR[P*V24><]V_65TG+_#Z/G^:@G5%
M/@2H$?=A:8]%UP^-T&]>H>*T,$99YRLQ&=Y>ZOEM @WNZY1!E3"HG:;&^S(D
MX:'/H'B2N?U!*F:X7L^$,E$82?X:(6V.</FA#:_,C/%]RRX\4/]A"7_3!!\H
M"$??:"%_'=]7H:-&$[K2'/ NYD!II9/Y3?>_?B.XZ,#V;V>0<PJ2NNZQ8^-_
M_S#XQP2,7]Z,\3?!UN+G:*:3*^GI=GIF]K//[O2Y&8]B::!&%'&+T65/:6:M
M%VC<V MMNR*0 5MHBY:M <FII+H&FF861 AAW.\:RRI[TL3^38CX-V7+#T&:
MN "(R&O<64SR(N.0&@+@HZ01J[9H[@+<7:I9C;G=3\L"Q-1TT1MO;[#/;!+O
MV4Z*3HHVVM5WO_CS]CA"QNIZ1OO5<:&&-AUWWP8BQK"TE$>]]^G6RF/596^8
MALTL5%!-"6W+8,QKD*@6G$+YB.:-_/#B ENTE^WBDYI?-5MK#"RMY+/!?'R:
M0OF[?M2"<T,1LE_N!< "5%Z2-Q[:'K%RO$8XT&G:J7O%>SP'BHG+@!?OY)R6
MX,=8'CM'VL=X?%DY*)SX:_P<?"J=QK$\$BVLC>@8Q43-/WJ M/B&LJ$;F.A6
MZRSL5<2TQ9.N8[%.[XX+@$R\4/ASY][]N'='OE%-.&#7@XW<<V2N>7&Z'IAA
M4T9;%^XO! !XYNG$/[MT6LZP?A< 5-#L!:#P5"K4E<7]&3K,0<X[F#HH9[&P
M9+Z@/%90WN:1GN;I:303C]7/HWK78GNH@< 2EM[4DCT^J';CD+&6G.9SI&$R
MWER+EFMRTIYG1I]K3L*.X@<N ,H;#G9!87%RC/6#0!.$'C2UC$*FF!S6C#=#
MD 47@*][%X"SM@O []\"<EB:=A;R[;+P K B=@'X/CS^_QJM0\5?H!YBPJV?
MM) S;::_S;"F)%**B36M"CW7'8L3]-Z*SC@HV3F0J(.>#WC4O=3B''LM#RN\
M0Z5?>6D]VXTA4 R/IQJD7_[E/CWN#S'3>9.-];A_8B7@\>ZN-J(Y0!9M=,V@
M3!Y^_#G"7[T>@;&&>RX'WBRPLDJK?9,.E,@,QPS^B!K,Y;,ZD490,^L"'X6$
M:8!L,;[@6C+:Y7HVXU<^1Y1<CPA?K>T+]9[+T;OZDP8W?^SN]KL[88BK>IWT
M.35"R7QS&;Y96&_<0@L/Z%1L.6F9YY]7#7;$^?9433?<_3@D7G:W1_)NC]S]
MS"^9$%X([Y<T?=;@EMD%0.'<IW;P H N&<,/^F@JZAS$'#JS%N>/E1YKQ.R(
M$;N>M..#AL[V:&N<1F8T(F9V=JQ1 P?\JVN;Y#<8<"[#/K8%#\YY3W:4H.\:
MH<L84U%AMD2(7[]UJMK.?#GT='?^E[GX;% R.UC1/0KTC#T<6SU; LT[&A0S
M'4);&''E'VF/!7B;374]#+]E;<,:[0"IJW7P$P^^=>U^B=ZQDE*]QBK0;JII
M?_[!_NQY2;6T=X3Y:ABCX=AZB.->[>%[3T\4<9JK[>=2W*9EU0RN\'&4.RB5
MG$RJ/)<:"SY,[WK >-M2=T1&UP[@[X:'33KK.:NAK2M\[(:ZD3JQ"G^SB#V1
M2L"^@ W2S# TL!JW<5H8/1$#:<Y0.=Z+\M>?3O16(XT^5K':@)S3,N2],3<H
MHJF;<(,MC3#54[M6I0W^D,ZVE(S4+4CC-LL$>L?S6O4AI/ROQ8_OPU/+6VUK
MN=B_;P:6S*=5(/&J#^+Y5Q>\2.(C)N\;1>*NT=H": ?^DP(2]V>5#+/^E.PQ
M1+[H^('YZ6/D8V(@)\$;%6]RRC56"YX(N5W_(O]Q>)WU?H;G 4;?F1Q\.@"A
M%(9_;R0]J'"K9NE<1=)EU&%V^W0YPMJX9^P=^ESY(ZDOHK*S8975M!:,/Q<?
M-7F!&FUGP"#MD2?<%J*H8!UN[.JV:7O7(L)4F5>3.4\!UBXY1? -=K%&+)P(
M,HZ+NV'R ;'.\5P3-P&FUN9"Z&;L"BE?O:/S#,0Y'CH(7!Z*+QL=LQN$Q\%7
M#_)&AT='1L<-TG<(Y^S#SM#M[F]);>?7HEE,)CNQJ@3+_*B'YUB,D2L</K%)
MDQNGMPAPSJ@T8W ]S*YL^*MCN#;X(T)B;'6A_F2T8S[;Q=N6D%6-L&#<>\CN
MV<#'EM0APL^X-=!#^T"E?%8(AG\P:O&%YE2_Z(/1$)"\*Y!-"<6DV\3R5D Z
M;RO:$4,(/W1E'"[#-312,@W"K)C$=+^2.W69@O>33C1\ F=#/?Q:(KCF"<N^
M_+ZM-1^#XTUF^RCACTSS:WS&+4.RW25E3E_2SK#T+4Q&TW$X$O2DSW@7H:$(
M28M6=B@2,Z %3*J6F6E<ZWV6729S 0AT^:C[1]*PQ9NOW_A1,*^U_W@7_^P@
M9-@OKRZ6]P)P![<ZQ& >9#CGX<ICG!^&^[9 R\;=M**?*CZ@S"$SDNNVS7CW
M"0:4)7I"GW&]VK/VOQ9J4.++V@CRNWI,T*F>!K]H6"/<984$MPZ<G_2?;8)?
MVRTCN-G9E)CZ]#NU5 R^D_Z$TGP\'63U87-"'?235C+IYP6&LVE.L[/&E0B'
MLGS[Y;"D'[R#\&^;"A W2KC?IE?XVD;+9^0XUB M0.U$)X96Y(./,U3?CUTR
M8U B3,/S>HTMO\T=[3)F/:PPRI8&X79Z?P%HVC#ZFZ+(0/1,5E2[/4)8]?3B
MY'\D&#E"^E']SL&Y7*VTA.J#]?82OHXT<MJ>DS1/0.&O+QVC7]T&D03G-#[5
MZPC<>7L&Y4--*OK=/7J7\*)76U#VJYSYJ$FMY!\U?9D/8VXO9%B83N[_$B$*
M7!ID] \T%01)(:Q][;QOU&RV5TZ4V%##"ZS"P\N6+!"A_FZ^!1H/O)Z'N3Y?
M\LD-QAPZF?,KTAOD?UQK+KR=5H4C!YA<S[ TUYTDQ%YA?B-J;XXEMB%_L //
MI,_AZTKDSK4SX3A/Q/QL4;?7^1[K C"ZA5]A(RCKT<#4^*VB;VG*&Q<*BB!L
M70"BVZ74D2>U##&[@8/V\Z;5(\1V\/HZFYB/T)ZJWJ_0I!AV60!17=O"H5[;
M(-)\6ES;'T=!R@RH[=KI%H&(B'?J8YPAT>A*W0W*1R0P:NJ/DT_]7)J#>]Z*
M&V\VHRL==FGN5D;@_J^-1[PVI-5=0<VLE1"MFFLZXUIEYW>LC.^DQ:H."N]Q
MD6?;F?V36QNG\-.&*B<S6)WW%?/:"/$3<][2.JA4=NE$F:#LK:Y3!$ZGJ"4H
M0'$Q3:1(_, *$NWMN^0W!A^:Z@G<E!O/7!60,3:YG>WYE][BM%%$SZK_W-<2
M\=WUY(P=UO73WJ[<C]XA1UXP TE3+:)MKWD+^%M:6(TP&0@K$,?Z=D^ 0WYY
MB+5S!'.>4.E4Q=$ZR3T=@9]U8'[)O@(V$$WRRT+JZ@1+:&NJJXGLTCTAF=&H
MH592H\[F!Q?DU']4?IE:OS@0TLKV<Y"'9[>%2?XCV2ZBEW*R\8BJXA0/@FGO
MDX./Q;OLD+N: AO4<!J?A[%\DU>?2]>;07]-DA;/N'6Z0LQ]VS+)L#'YQ7C4
MW%SM$0;ZKY6"IMTN 9V&D"@!I:C<TOS%94.55,7!#V:$M-#DU&K)[5//M=L!
M 5N.(SBZF<7>QR8US:_4YLU%XQZ*_$'A*NQ0U[FU=R!LO:!0I/1X^#^1:Y,$
M_I>Y]L%S)L:QP5==P?"7IJM5O2K&ABHF2?=;[^=^G_M]J\33#N&M&VR!_:8K
M2_.<=_%:P)79EC/2@<2AV3%HZ#S<>MH7,<OJ9YL.L$$_'Q]'8/:YOV%H4>HV
M8T:C_<SHW)K)WN[FF"U%M;;X?W-:IPTT2CZH=H#=+$]9WC_@DQ\FI_X\#4R]
M /Q\2D#.6@Q88*($68(@, >Z?(1PTR@;6SV+7M;6I1Y%*=>BUWH[-!X9\H8(
M!>_-4^T.KRW72PQ8D"\ J]!9)^G[_J"W7:785F+\.!<>OS$OS1IE/QEB0\/B
MPMESZ-EM%O)Q4POP?,48L<J0WB?@(]2Y%^)K63DJF'^^ZT#V**8ET.Z?#YM:
MMBIV6V=@/$TT+6A!1B7'47/R>C.<4O9J%JH@AM'U;+_V:%"+/SKV E!/1^<>
MI=>PE+&EV4BP>^O^P]O/_U>C06I32\@6Y=3S1_TQ>G:7I6\',8D^1?B0V6A[
M=IYPIMK #-/,>$_JBO*\SJ1Q14(V=AIV1C#TFSYCS\>H/.9:7JY:VRO=AT'*
M%_F^^A[%]@5_Y9/6"8%@,@;;7'()[G1CR"@N_3#M@W97G6O5QP=9>T2DA=RJ
MJ&HVN+8I=CM?:O4"X&LA>^+*NEF)_?-EP<.!087W*ZW[@I4S$E4C1^Z-^7<8
M'$Z$2*]\X1!LV35-.[R@YM XH(GXF'D!")-Q9PBXH&I,DCY)5OAT??90)N*^
M%(W*66P_N4?G-B9.S,#:4!7VZ?C27@RDVVS.<G>C)QYA]=6VCK4'D=?>5:N(
MKMCT'-3DH$PC.0FRY1A8&N/ ILVJV]QV\'+^I*#(9S/AK+)\9EE&7/:#BMH6
M+"UM@S=UL]]6-<5<$6BF9D-FECZ$DOIZB JQ;\WG]/^185V4P0V;**6I+>17
M>],3I2\AR_=F3Q*_&_]'5U*(^RW6> UK\;%&$U5J5--A3;W&&\._EZPA/%(X
M%G@9-D/$[L7],*[&TU AM([;^BQ/X7-I4C*ZNJ1OL[5Y<ARAT2(0W3A5&V],
M999<_;@"[MEBQ)GE'H3-N[!W*^[!I=>@?H>+?H3QP\@!^'N,Z<QX!R?AX&@1
M=-TZS;?ZIU+A@N\!@*L_1SD-!*X$W=>JS:1YKZQM<A+>F[XL:!.;LN]U@@O8
M((G 0>(M/V'+(NLO1*+UEX!://7*4F_?^*%2<4'K"9S2,[C3Z!Q1,@JWCM<J
M'6$$1@4!%S><<E09#:@J9W@)YZ;D\C14[:T35 5I<C =K'M+K^*?C2T+SB9W
MZ!> HP1>^?T[J M JPU&?JBR7L;9PL=@]&R\.:A$?.=-^6H<G]C/-LF!\5]/
M?F)%Y4H^2BDY 5X[!?UL5<$7\46DTVI9[%MSCEBV=4_N'?#\RWV47&YSZ>HA
MQ_?&NKGG%9UCF]@*'^@_\UZ6HTO*)@G_S&;9HEC7E2*^</XB*OL$KL;]JZ.U
ML>/\44K1>>MJ3VZ%N2>A:(J9C'KWZ^A)G/(F\@U13C#H$_!RU!^C%P!)][1(
ML2AB I'*/K7]]$A1^EEF.[,NIW:3ECJM:V@HXQX!:ZEK&EHZ44F'E=F)!9HS
MF,<^1X\=*"'N6:)PS.!(>TD#K1&MB1]<L#3MJ>CN/[5K0@S/(6Y_#HMM6[!
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MF'K&ISF>DZ*_:UT"%;X$ J?V4> 4J#OQ-6>=]B[T-MH>?M;NOSW\+YWU4(<
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MM^JK3\B_N6MISY$P>?$]9Y=/"_YXA3>7IJC5-MLD#$"@-:OGO!EHZSG12 !
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M=5X O,24[ZU8X"\ MW8$._!S'1FDL/*O<78Y#A*9FX1<44J%>:47N\'2.2*
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M*U=Y;TH<<S+%,1B]'C,E/==+;6KQCEY8S"BZ?(5T =# :41L^5P "F=./2X
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M@6T2DU%(**3X3@59CIF_;[<\!\,GILPL9/KJ/C,%CQO_-H7\K<9T>%?V5"K
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M:420&%2ATE\2[C&3HJBF#;VFQ Z 3WXVT-40]=$[95E;-!, LEU+7)79F"0
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M+W5R\FD"FQVA1WYX_0.6D>HUT6*_>+5D,:39R9=2J^<2(3LH:J$^6+^L[;0
MB.</TVM5E7GWU)1@.:YG!TG8H4-W=>_%5UA/AO6'E?=5].,'88TU="7KZK/
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M.L)4'9!L?F%52QD\N"'1B5*_7[P*U>N,"ILE.L4 BQ>XJU:$"6;IL'1TO7M
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M,0F7N@Y*OATXB!KMV6!3)F>M7* U1T'SI"M?@,FF%G-*(3C =JF5#V2( @N
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M&*5:H,1. LFABG)%:Z.0T?JE+3%7W M)8ZJ5\%#,0%!^=+FI JV_(\^U>:Q
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M$=VU<\WZA9=/"X[VA."E? YP!6G%5HF^/5XGLEL4G_/6?OKGL9E-RE'7M).
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MXY*/:XCE"LTRQZCAHV%\8K.PC.S3#R[PGV25/G]U_=F;&J#AA>6ER(896F9
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M=U%>A'%USOB@E0_3&LG_<O/5UQ-EI.(/6Y(?!H'?9K7R#;Z>>#BO"\74M)O
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MX6&-1(+G809U1HDNU"=OO-Z7=&TYHKR<E4H#ZVLY'M6$N?1GMIG7^^07PG=
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MV\T^!,.Q!:3GH#W8!W)W E$A_G:GK+ $81])KBH)AA$S1@88=#'30V1+.UQ
M9:YW6?=(*,7V_IDC84#9JA"-ZF*\>_1,UA$?R88"H2^W:'MJ#7\^&WTOWUQ[
MG*23ZS'P6K&EYV!M@:6@2NSM[^0XK51Q9GD@T[V4(D?2ZG'**V[ ^9DD!T[7
M^0K70J)]OZ%KY0V$_SX$H/"*TSK6:8GRGMA$2_B!&,24+M)XU/S0A![3K5;
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MM^MZW I5]_H--D]'11/?K9\1K-3OC I*HP.\X'5Y19$F_D-U\@Z.#7#U^3"
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M_+2CGEWR!.EC9W ?*>MG^N2&XM*P4OJ;#\'/?&^\^H._K?B/916;=^?Y],D
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MK(2/43S#Q^5I@M\D\]5?G\H %0<1_RO=70;$R[V@D>;+AZC=2;4>.,V1E]:
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MDH_<>A9RPVL3V.Y^8T0&_'#</8G[B?J!FTN$UU/WTN:W/2-@1'H;7M-<9V7
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M7/_P8_D-/;<#6]U?5/Q\^\#$<^7Y')R\G45Z9<#> 2%5BL(L&6!B@*.HA!&
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MS_<H:9R_VO"1R !LV=E7H/]SVO(\S,!YP2SQV\0C2>]G[/L]HN!3;(4,>%D
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M\^D7C2]2^BIF&B'B!.FA0PX25L=7KE$"0R"VD-;,778"W=UI;>H[M!W9"#\
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MG2*&K_1)K17VMD>+<Z.4OX"^=XRB4_K,6AFVJ<?4$UX,;8$KHE Y2-QDJ9_
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MM^ ,9C. W!%43*2%PL6:-:=RF6_XZJ@F9#+@A91E#:(@/)G ]2E2>7%)'53
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MN<N3O) U01A'A+N@)P#?)@82,^XMQQ'TJ+%3?XK-7YXG"(R.B%&3_60DSL,
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M:"$#=EG;/$1;_GGA9"N5XVL<K52 OX\MV#5C"WSO_SZ#_ZU@8V_$N<C!67
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M_/:1/[:M*"#X;.(7']FZ=>=LZHO6S1B6RQ_[>Y:LEQ9\3U(KV\[7T)$!<Z_
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M3IS<%D&7?/M;U?^[=R)=_#@^@S* #$U,J24=_?%:X]^27X'0,2\#XLG4JK\
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M[[7_ U!+ 0(4 Q0    ( .%Q6U"W*OZ^[R,  *4Q   =              "
M 0    !A9&ID:6QU=&5D97!S+6YO;F=A87 R,#$Y+FIP9U!+ 0(4 Q0    (
M .%Q6U RZI^YX08  )X'   ?              "  2HD  !A;&)E<G1B;W5R
M;&%S:6=N871U<F5Q-#(P,3DN:G!G4$L! A0#%     @ X7%;4'S=,,P\2P
MIUP  "               ( !2"L  &)I;W!H87)M<F5V:6YC<F5A<V4R,#$X
M+3(P,3DN:G!G4$L! A0#%     @ X7%;4)A;Q^TR2   *ED  "
M     ( !PG8  &)I;W!H87)M<F5V:6YC<F5A<V4R,#$X=C(P,3<N:G!G4$L!
M A0#%     @ X7%;4,R S(_".   VSL  !@              ( !,K\  &9R
M86YK<VEG;F%T=7)E<30R,#$Y+FIP9U!+ 0(4 Q0    ( .%Q6U! O2T)D!8
M "$7   )              "  2KX  !G;&]B92YJ<&=02P$"% ,4    " #A
M<5M0F>Z3BYH'  !O"   %P              @ 'A#@$ :W!M9W-I9VYA='5R
M97$T,C Q.2YJ<&=02P$"% ,4    " #A<5M0(_TQF&1!  !]2@  &@
M        @ &P%@$ ;&]R971T87-I9VYA='5R97$T,C Q.2YJ<&=02P$"% ,4
M    " #A<5M04G$OF]P.  #(#P  $               @ %,6 $ ;6%R:V5T
M9W)O=W1H+FIP9U!+ 0(4 Q0    ( .%Q6U"4&;/LP \  &00   .
M      "  59G 0!M:6-R;W-C;W!E+FIP9U!+ 0(4 Q0    ( .%Q6U#AQMB;
MHR,  ( O   :              "  4)W 0!N971C87-H9FQO=V9R;VUO<',R
M,#$Y+FIP9U!+ 0(4 Q0    ( .%Q6U"!XV.2AYP  )C0   6
M  "  1V; 0!P965R9W)O=7!G<F%P:#(P,3DN:G!G4$L! A0#%     @ X7%;
M4'/CX\*;, , 0U4I !D              ( !V#<" '!F92TQ,C,Q,C Q.7@Q
M,&MS:&5L;"YH=&U02P$"% ,4    " #A<5M0>847G8$^  "K3 , $
M        @ &J: 4 <&9E+3(P,3DQ,C,Q+GAS9%!+ 0(4 Q0    ( .%Q6U"P
MEMH[SV$  'F"!  4              "  5FG!0!P9F4M,C Q.3$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( .%Q6U!4"H#)H\(! &_&%P 4              "
M 5H)!@!P9F4M,C Q.3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( .)Q6U#H\V?5
M,:@" *F7)0 4              "  2_,!P!P9F4M,C Q.3$R,S%?;&%B+GAM
M;%!+ 0(4 Q0    ( .)Q6U#;MGWIYQ$" "!.'  4              "  9)T
M"@!P9F4M,C Q.3$R,S%?<')E+GAM;%!+ 0(4 Q0    ( .)Q6U":Y1?_Z@,
M +\.   9              "  :N&# !P9F4M97@Q,#$U>#$R,S$R,#$Y>&LN
M:'1M4$L! A0#%     @ XG%;4$.QQ4E( P  71   !H              ( !
MS(H, '!F92UE>&@Q,#(Y>#$R,S$R,#$Y>#$N:'1M4$L! A0#%     @ XG%;
M4%V<[T<$"   :"4  !H              ( !3(X, '!F92UE>&@S,3%X,3(S
M,3(P,3DQ,&LN:'1M4$L! A0#%     @ XG%;4/U3A3T3"   Z"4  !H
M         ( !B)8, '!F92UE>&@S,3)X,3(S,3(P,3DQ,&LN:'1M4$L! A0#
M%     @ XG%;4(E90A0L!0  "!D  !H              ( !TYX, '!F92UE
M>&@S,C%X,3(S,3(P,3DQ,&LN:'1M4$L! A0#%     @ XG%;4/:\7E-6!0
MT1@  !H              ( !-Z0, '!F92UE>&@S,C)X,3(S,3(P,3DQ,&LN
M:'1M4$L! A0#%     @ XG%;4$SH;B+/KP@ \SJ" !H              ( !
MQ:D, '!F92UE>&AI8FET,3-X,3(S,3(P,3DN:'1M4$L! A0#%     @ XG%;
M4$(5J&$]'P  ?^0# !H              ( !S%D5 '!F92UE>&AI8FET,C%X
M,3(S,3(P,3DN:'1M4$L! A0#%     @ XG%;4+=X!UY=!0  #B4  !H
M         ( !07D5 '!F92UE>&AI8FET,C-X,3(S,3(P,3DN:'1M4$L! A0#
M%     @ XG%;4"!#I5?>"   +#<  !H              ( !UGX5 '!F92UE
M>&AI8FET,C1X,3(S,3(P,3DN:'1M4$L! A0#%     @ XG%;4)B@!]93/0
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M>F5R;&]G;S(X,38N:G!G4$L! A0#%     @ XG%;4-0^N>K!B0$ A:<! !D
M             ( !6(X7 '!F:7IE<G!I<&5L:6YE,C R,&$P,BYJ<&=02P$"
M% ,4    " #B<5M0SE H$_01  "[$P  #@              @ %0&!D <&AA
M<FUA<&%C:RYJ<&=02P$"% ,4    " #B<5M0V#* 3Z8-   ##P  #@
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M+3(P,3DN:G!G4$L! A0#%     @ XG%;4+JCBG-!>@  38T  !H
M     ( !D-X9 ')E=F)Y;F%T;&UR:W0R,#$W+3(P,3DN:G!G4$L! A0#%
M  @ XG%;4-?Y&.S_2   04T  "               ( !"5D: ')E=F)Y;W!S
M96=M96YT+6=E;V=R87!H>3(P,3<N:G!G4$L! A0#%     @ XG%;4*%/F(=:
M0@  X48  "               ( !1J(: ')E=F)Y;W!S96=M96YT+6=E;V=R
M87!H>3(P,3@N:G!G4$L! A0#%     @ XG%;4&.ZE<VZ0   2$4  "
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M;F=E+FIP9U!+ 0(4 Q0    ( .)Q6U![VG$6!?@  $H: 0 -
M  "  7NZ&P!T86=L:6YE7S$N:G!G4$L! A0#%     @ XG%;4*Q>>X0T$P
M^Q,   @              ( !J[(< '1E86TN:G!G4$L! A0#%     @ XG%;
M4!T4Y@3P$0  0Q,   T              ( !!<8< '1E<W1T=6)E<RYJ<&=0
M2P$"% ,4    " #B<5M0U1- 6P0D   ),P  $               @ $@V!P
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M;FQO9V]A,#(N:G!G4$L! A0#%     @ XG%;4-=HW86A30  'UX  !X
M         ( !0] C '5P:F]H;G)E=F1E8W)E87-E,C Q."TR,#$Y+FIP9U!+
M 0(4 Q0    ( .)Q6U#O=M?FAD@  #Y:   >              "  2 >) !U
M<&IO:&YR979D96-R96%S93(P,3AV,C Q-RYJ<&=02P4&     #< -P"P#@
&XF8D

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>187
<FILENAME>R111.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7037224672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Narrative (Details)<br> $ in Billions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Operating_Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Operating_Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Operating_Segment</a></td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember', window );">Finite-Lived Intangible Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AmortizationOfIntangibleAssets', window );">Amortization expense for finite-lived intangible assets | $</a></td>
<td class="nump">$ 4.7<span></span>
</td>
<td class="nump">$ 5.0<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16225-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_FiniteLivedIntangibleAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>188
<FILENAME>R119.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952681680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - One-Percentage-Point Increase or Decrease in the Healthcare Cost Trend Rate (Details) - Postretirement Benefits Plan [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents', window );">Effect on total service and interest cost components, increase</a></td>
<td class="nump">$ 2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1', window );">Effect on total service and interest cost components, decrease</a></td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation', window );">Effect on postretirement benefit obligation, increase</a></td>
<td class="nump">38<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1', window );">Effect on postretirement benefit obligation, decrease</a></td>
<td class="num">$ (27)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in accumulated postretirement benefit obligation from one-percentage-point decrease in assumed health care cost trend rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnAccumulatedPostretirementBenefitObligation1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in service and interest cost components of net periodic postretirement benefit cost from one-percentage-point decrease in assumed health care cost trend rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointDecreaseOnServiceAndInterestCostComponents1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in accumulated postretirement benefit obligation from one-percentage-point increase in assumed health care cost trend rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnAccumulatedPostretirementBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in service and interest cost components of net periodic postretirement benefit cost from one-percentage-point increase in assumed health care cost trend rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (m)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEffectOfOnePercentagePointIncreaseOnServiceAndInterestCostComponents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>189
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7008841280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insurance<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InsuranceCoverageAbstract', window );"><strong>Insurance Coverage [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InsuranceCoverageDisclosureTextBlock', window );">Insurance</a></td>
<td class="text">Insurance<div style="line-height:120%;padding-top:4px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our insurance coverage reflects market conditions (including cost and availability) existing at the time it is written, and our decision to obtain insurance coverage or to self-insure varies accordingly. Depending upon the cost and availability of insurance and the nature of the risk involved, the amount of self-insurance may be significant. The cost and availability of coverage have resulted in self-insuring certain exposures, including product liability.</span><span style="font-family:Arial;font-size:8pt;color:#1f497d;"> </span><span style="font-family:Arial;font-size:8pt;">If we incur substantial liabilities that are not covered by insurance or substantially exceed insurance coverage and that are in excess of existing accruals, there could be a material adverse effect on our cash flows or results of operations in the period in which the amounts are paid and/or accrued (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 16</span><span style="font-family:Arial;font-size:8pt;">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InsuranceCoverageAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Coverage [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InsuranceCoverageAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InsuranceCoverageDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Insurance Coverage Disclosure [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InsuranceCoverageDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>190
<FILENAME>R132.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7038038400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Impact on Net Income (Detail) - 2019 Stock Plan [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expense</a></td>
<td class="nump">$ 718<span></span>
</td>
<td class="nump">$ 949<span></span>
</td>
<td class="nump">$ 840<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense', window );">Tax benefit for share-based compensation expense</a></td>
<td class="num">(137)<span></span>
</td>
<td class="num">(180)<span></span>
</td>
<td class="num">(163)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax', window );">Share-based payment expense, net of tax</a></td>
<td class="nump">581<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">677<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember', window );">Total Shareholder Return Units (TSRUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expense</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">302<span></span>
</td>
<td class="nump">221<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expense</a></td>
<td class="nump">275<span></span>
</td>
<td class="nump">286<span></span>
</td>
<td class="nump">301<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember', window );">Portfolio Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expense</a></td>
<td class="nump">114<span></span>
</td>
<td class="nump">276<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expense</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">62<span></span>
</td>
<td class="nump">47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expense</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">12<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember', window );">Directors' compensation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based payment expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 10<span></span>
</td>
<td class="nump">$ 7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of expense for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpenseNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of tax benefit for recognition of expense of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=pfe_A2019StockPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=pfe_A2019StockPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_DirectorsCompensationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_DirectorsCompensationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>191
<FILENAME>R136.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036119344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Outstanding Total Shareholder Return Units Activity (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember', window );">Total Shareholder Return Units (TSRUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, Share Units</a></td>
<td class="nump">179,999,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice', window );">Outstanding, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 35.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 1,415<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares', window );">Vested, Share Units</a></td>
<td class="nump">57,345,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice', window );">Vested, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 31.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms', window );">Vested, Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">1 year 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Vested, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 775<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber', window );">Expected to vest, Share Units</a></td>
<td class="nump">118,618,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice', window );">Expected to vest, Weighted-Average Grant Price Per Share Unit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 37.23<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm', window );">Expected to vest, Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">3 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest', window );">Expected to vest, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 1,096<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares', window );">Settled, Share Units</a></td>
<td class="nump">7,953,671<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice', window );">Settled, Weighted-Average Grant Price Per Share Per Unit (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 27.33<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Exercised during period, Share Units</a></td>
<td class="nump">2,173,131<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice', window );">Exercised during period, Weighted-Average Grant Price (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 30.68<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_ProfitUnitsMember', window );">Profit Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber', window );">Outstanding, Share Units</a></td>
<td class="nump">1,299,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">Outstanding, Weighted-Average Remaining Contractual Term (Years)</a></td>
<td class="text">8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">Outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion', window );">Converted awards</a></td>
<td class="nump">844,871<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instrument Other Than Options, Settled, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentOtherThanOptionsSettledWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other Than Options, Vested, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Aggregate Intrinsic Value, Expected to Vest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsAggregateIntrinsicValueExpectedtoVest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Exercises, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExercisesWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Expected to Vest, Weighted Average Remaining Contractual Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsExpectedtoVestWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Outstanding, Weighted Average Grant Price</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsOutstandingWeightedAverageGrantPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Settled, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsSettledShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested, Weighted Average Remaining Contractual Terms</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsVestedWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Granted Upon Conversion</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardNonOptionEquityInstrumentsGrantedUponConversion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of equity instruments other than options outstanding, including both vested and non-vested instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of vested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_TotalShareholderReturnUnitsTSRUsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_ProfitUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_ProfitUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>192
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953057376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Retirement Benefits [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Pension and Postretirement Benefit Plans and Defined Contribution Plans</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Pension and Postretirement Benefit Plans and Defined Contribution Plans</span><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The majority of our employees worldwide are eligible for retirement benefits provided through defined benefit pension plans, defined contribution plans or both. In the U.S., we sponsor both IRC-qualified and supplemental (non-qualified) defined benefit plans and defined contribution plans. A qualified plan meets the requirements of certain sections of the IRC, and, generally, contributions to qualified plans are tax deductible. A qualified plan typically provides benefits to a broad group of employees with restrictions on discriminating in favor of highly compensated employees with regard to coverage, benefits and contributions. A supplemental (non-qualified) plan provides additional benefits to certain employees. In addition, we provide medical insurance benefits to certain retirees and their eligible dependents through our postretirement plans. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. Components of Net Periodic Benefit Costs and Changes in Other Comprehensive Income/(Loss)</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="49"/></tr><tr><td style="width:22%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="49" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the annual (credit)/cost and changes in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">&#160;for our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="47" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="35" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Qualified</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Service cost</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>269</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>24</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>125</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>42</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>629</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>215</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>204</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>90</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected return on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(890</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,040</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,005</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(317</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(360</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(345</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(37</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(36</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization of:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial losses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>147</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>120</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>393</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>116</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>31</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service cost/(credit)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(173</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(178</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(182</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(17</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(19</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>230</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>75</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>26</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(10</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit cost/(credit) reported in income</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>116</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(189</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>166</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>115</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(146</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(111</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(75</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Credit)/cost reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(246</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>361</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>141</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>115</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(189</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>570</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>84</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(301</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(8</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Credit)/cost recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Comprehensive income</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(129</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>171</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>523</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>215</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(86</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>685</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>168</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(107</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(83</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">In the second quarter of 2017, we settled the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. We purchased a group annuity contract on behalf of the remaining plan participants with a third-party insurance provider. As a result, we were relieved of the </span><span style="font-family:Arial;font-size:7pt;"><span>$156 million</span></span><span style="font-family:Arial;font-size:7pt;"> net pension benefit obligation and recorded a pretax settlement gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$41 million</span></span><span style="font-family:Arial;font-size:7pt;">, partially offset by the recognition of actuarial losses and prior service costs upon plan settlement of approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$30 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8212;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net </span><span style="font-family:Arial;font-size:7pt;">(see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 3</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Effective January 1, 2018, we froze </span><span style="font-family:Arial;font-size:7pt;"><span>two</span></span><span style="font-family:Arial;font-size:7pt;"> significant defined benefit pension plans to future benefit accruals in the U.S. and U.K. and as a result, service costs for those plans are eliminated. In addition, due to the plan freeze, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans was extended to the expected life expectancy of the plan participants, whereas the average amortization period in prior years utilized the expected future service period of plan participants.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">We adopted an accounting standard on January 1, 2018 that requires the net periodic pension and postretirement benefit costs other than service costs be presented in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> on the consolidated statements of income. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-left:4px;text-align:left;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;padding-left:4px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:23%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">&#160;expected to be amortized into 2020 net periodic benefit costs:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#160;&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.<br/>Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial (losses)/gains</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(127</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service credits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(124</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(14</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(121</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Due to the U.S. Pfizer Consolidated Pension Plan freeze effective for January 1, 2018, the average amortization period for the U.S. qualified plans and U.S. supplemental (non-qualified) plans reflect the expected life expectancy of the plan participants, whereas prior years utilized the expected future service period of plan participants. The average amortization periods to be utilized for </span><span style="font-family:Arial;font-size:7pt;">2020</span><span style="font-family:Arial;font-size:7pt;"> are </span><span style="font-family:Arial;font-size:7pt;"><span>24.9</span></span><span style="font-family:Arial;font-size:7pt;"> years for our U.S. qualified plans, </span><span style="font-family:Arial;font-size:7pt;"><span>24.5</span></span><span style="font-family:Arial;font-size:7pt;"> years for our U.S. supplemental (non-qualified) plans, </span><span style="font-family:Arial;font-size:7pt;"><span>19.4</span></span><span style="font-family:Arial;font-size:7pt;"> years for our international plans, and </span><span style="font-family:Arial;font-size:7pt;"><span>9.2</span></span><span style="font-family:Arial;font-size:7pt;"> years for our postretirement plans.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Actuarial Assumptions</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the weighted-average actuarial assumptions of our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">(PERCENTAGES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Weighted-average assumptions used to determine benefit obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate of compensation increase:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Weighted-average assumptions used to determine net periodic benefit cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discount rate:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected return on plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.7</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7.3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate of compensation increase:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. non-qualified pension plans</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:36px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International pension plans</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1.4</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2.6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#8217; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The assumptions above are used to develop the benefit obligations at fiscal year-end and to develop the net periodic benefit cost for the subsequent fiscal year. Therefore, the assumptions used to determine net periodic benefit cost for each year are established at the end of each previous fiscal year, while the assumptions used to determine benefit obligations are established at each fiscal year-end.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The net periodic benefit cost and the benefit obligations are based on actuarial assumptions that are reviewed on at least an annual basis. We revise these assumptions based on an annual evaluation of long-term trends, as well as market conditions that may have an impact on the cost of providing retirement benefits.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The weighted-average discount rate for our U.S. defined benefit plans is determined annually and evaluated and modified to reflect at year-end the prevailing market rate of a portfolio of high-quality fixed income investments, rated AA/Aa or better that reflect the rates at which the pension benefits could be effectively settled. For our international plans, the discount rates are set by benchmarking against investment grade corporate bonds rated AA/Aa or better, including, when there is sufficient data, a yield curve approach. These rate determinations are made consistent with local requirements. Overall, the yield curves used to measure the benefit obligations at year-end </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;"> resulted in lower discount rates as compared to the prior year.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the healthcare cost trend rate assumptions for our U.S. postretirement benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Healthcare cost trend rate assumed for next year (up to age 65)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5.6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.8</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Healthcare cost trend rate assumed for next year (age 65 and older)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6.0</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Rate to which the cost trend rate is assumed to decline</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4.5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year that the rate reaches the ultimate trend rate</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2037</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2037</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:76%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the effects as of December 31, 2019 of a one-percentage-point increase or decrease in the healthcare cost trend rate assumed for postretirement benefits:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Decrease</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect on total service and interest cost components</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect on postretirement benefit obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(27</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial and other assumptions for pension and postretirement plans can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Obligations and Funded Status</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:28%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides an analysis of the changes in our benefit obligations, plan assets and funded status of our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Change in benefit obligation</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit obligation, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>16,702</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,495</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>9,952</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,607</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,870</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Service cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>125</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>37</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>629</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>598</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>47</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>215</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>212</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>75</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Plan amendments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>18</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(56</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Changes in actuarial assumptions and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,001</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,219</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(152</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,224</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(169</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(87</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(122</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange impact</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(33</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(457</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions/divestitures/other, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(55</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(36</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Curtailments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(692</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(70</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(72</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Special termination benefits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(373</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefit obligation, ending</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11,059</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,667</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,870</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Change in plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>14,284</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,215</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,863</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>469</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>494</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actual gain/(loss) on plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,760</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(796</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>873</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(77</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(22</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Company contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>230</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>209</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>137</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee contributions</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>84</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>102</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange impact</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(380</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Acquisitions/divestitures, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(16</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Settlements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(692</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(391</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(70</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(72</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(34</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Benefits paid</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(544</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(546</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(74</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(360</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(373</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(221</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(249</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets, ending</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,215</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>519</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>469</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Funded status&#8212;Plan assets less than benefit obligation</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,103</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The PBO represents the present value of the benefit obligation earned through the end of the year and factors in future compensation increases. The ABO is similar to the PBO but does not factor in future compensation increases. For the U.S. qualified and supplemental (non-qualified) pension plans, the benefit obligation is the PBO, which is also equal to the ABO. Effective January 1, 2018, we froze the defined benefit plans to future benefit accruals in the U.S. and members&#8217; accrued benefits to that date no longer increase in line with future compensation increases. The rate of compensation increase is therefore no longer an assumption used to determine the benefit obligation and net periodic benefit cost. For the international pension plans, the benefit obligation is the PBO. The ABO for our international pension plans was </span><span style="font-family:Arial;font-size:7pt;"><span>$10.6 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$9.5 billion</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">. For the postretirement plans, the benefit obligation is the ABO.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information as to how the funded status is recognized in our consolidated balance sheets:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement<br/>Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(189</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(167</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(30</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(28</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(24</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(29</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,088</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,162</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,113</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,526</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,111</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,124</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,371</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Funded status</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,949</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,089</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,103</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,738</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,401</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent assets</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Accrued compensation and related items</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of December 31, 2019, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Pension benefit obligations, net</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Postretirement benefit obligations</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net, </span><span style="font-family:Arial;font-size:7pt;">as appropriate. In 2018, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Pension benefit obligations, net</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Postretirement benefit obligations</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net</span><span style="font-family:Arial;font-size:7pt;">, as well as in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Liabilities held for sale</span><span style="font-family:Arial;font-size:7pt;"> (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;">)</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">, as </span><span style="font-family:Arial;font-size:7pt;">appropriate.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="33"/></tr><tr><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="33" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the pre-tax components of cumulative amounts recognized in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="31" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S.&#160;Supplemental<br/>(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement<br/>Plans</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actuarial losses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4,812</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5,061</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(484</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(370</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,921</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,372</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(76</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(202</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Prior service (costs)/credits</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>830</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>994</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(4,814</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5,060</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(485</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(370</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(2,942</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,372</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>754</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>792</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The accumulated actuarial losses primarily represent the impact of changes in discount rates and other assumptions that result in cumulative changes in our PBO, as well as the cumulative difference between the expected return and actual return on plan assets. These accumulated actuarial losses are recognized in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:7pt;"> and are amortized into net periodic benefit costs primarily over the average remaining service period for active participants for plans that are not frozen or the average life expectancy of plan participants for frozen plans, primarily using the corridor approach.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information related to the funded status of selected benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Supplemental (Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension plans with an ABO in excess of plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,843</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,514</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ABO</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,960</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,286</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension plans with a PBO in excess of plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value of plan assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,947</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PBO</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,535</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,141</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,280</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,503</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,571</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All of our U.S. plans and many of our international plans were underfunded as of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. Plan Assets</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="41"/></tr><tr><td style="width:19%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:3%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="41" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:10px;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">The following table provides the components of plan assets:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair Value</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair Value</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">As of<br/>December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Assets Measured at NAV</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of<br/>December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Assets Measured at NAV</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>363</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>80</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>284</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>443</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>390</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Global equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>3,464</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>3,406</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>57</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,156</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,119</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>37</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,179</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>819</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>360</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>933</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>634</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>299</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>5,292</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>10</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>5,281</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>4,654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>4,650</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,799</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,799</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,391</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>96</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other investments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Partnership investments</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,212</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,212</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,165</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>196</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>192</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other commingled funds</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,075</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,066</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,021</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>14,586</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>3,496</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>8,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>2,638</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>13,051</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,173</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>7,294</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2,581</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:3px double #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>221</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>187</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>246</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>208</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Global equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,922</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,548</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>374</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,876</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,413</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>463</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>796</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>796</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>727</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>727</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,200</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,200</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,305</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,305</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed income commingled funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>2,201</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,031</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,171</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,770</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,007</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>762</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other investments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Partnership investments</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>66</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>53</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>944</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>759</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>74</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>684</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d), (f)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,524</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>398</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,043</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,473</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,020</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>8,956</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>4,929</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,342</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>2,652</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>8,215</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>40</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>4,809</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,065</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2,300</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;text-decoration:underline;">U.S. postretirement plans</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>519</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>519</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>469</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span><span style="font-family:Arial;font-size:7pt;"/></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fair values are determined based on valuation inputs categorized as Level 1, 2 or 3 (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 1E</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span><span style="font-family:Arial;font-size:7pt;"/></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Certain investments that are measured at NAV per share (or its equivalent) have not been classified in the fair value hierarchy. The NAV amounts presented in this table are intended to permit reconciliation of the fair value hierarchy to the amounts presented for the total pension benefits plan assets.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Mainly includes investments in private equity, private debt, public equity limited partnerships, and, to a lesser extent, real estate and venture capital.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Mostly includes, for U.S. plan assets, investments in hedge funds and, to a lesser extent, real estate and, for international plan assets, investments in real estate and hedge funds.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency obligations are inclusive of repurchase agreements.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">See below for a tabular analysis of the changes in Level 3 investments valued using significant unobservable inputs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Reflects postretirement plan assets, which support a portion of our U.S. retiree medical plans.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:56%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides an analysis of the changes in our more significant investments valued using significant unobservable inputs:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International Pension Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Insurance contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value, beginning</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>684</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>420</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>382</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>468</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Actual return on plan assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Assets held, ending</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>50</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Purchases, sales, and settlements, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(40</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>188</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Transfer into/(out&#160;of) Level 3</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>247</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>107</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exchange rate changes</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(31</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(20</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair value, ending</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>944</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>684</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>382</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A single estimate of fair value can result from a complex series of judgments about future events and uncertainties and can rely heavily on estimates and assumptions. For a description of our general accounting policies associated with developing fair value estimates, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1E.</span><span style="font-family:Arial;font-size:8pt;"> For a description of the risks associated with estimates and assumptions, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 1C.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities, Fixed income securities and Other investments may each be combined into commingled funds. Most commingled funds are valued to reflect the interest in the fund based on the reported year-end NAV. Partnership and Other investments are valued based on year-end reported NAV (or its equivalent), with adjustments as appropriate for lagged reporting of up to three months.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following methods and assumptions were used to estimate the fair value of our pension and postretirement plans&#8217; assets:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents: Level 1 investments may include cash, cash equivalents and foreign currency valued using exchange rates. Level 2 investments may include short-term investment funds which are commingled funds priced at a stable NAV by the administrator of the funds.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 1 and Level 2 investments may include commingled funds that have a readily determinable fair value based on quoted prices on an exchange or a published NAV derived from the quoted prices in active markets of the underlying securities. Level 3 investments may include individual securities that are unlisted, delisted, suspended, or illiquid and are typically valued using their last available price.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fixed income securities: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include commingled funds that have a readily determinable fair value based on observable prices of the underlying securities. Level 2 investments may include corporate bonds, government and government agency obligations and other fixed income securities valued using bid evaluation pricing models or quoted prices of securities with similar characteristics. Level 3 investments may include securities that are valued using alternative pricing sources, such as investment managers or brokers, which use proprietary pricing models that incorporate unobservable inputs.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments: Level 1 investments may include individual securities that are valued at the closing price or last trade reported on the major market on which they are traded. Level 2 investments may include Insurance contracts which invest in interest bearing cash, U.S. government securities and corporate debt instruments.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain investments are authorized to include derivatives, such as equity or bond futures, swaps, options and currency futures or forwards for managing risks and exposures.</span></div><div style="line-height:120%;padding-top:6px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:48%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-top:8px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the long-term target asset allocations ranges and the percentage of the fair value of plan assets for benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Target</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Allocation Percentage</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="5" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Percentage of Plan Assets</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6pt;"><span style="font-family:Arial;font-size:6pt;">(PERCENTAGES)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">U.S. qualified pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-10%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">35-55%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>31.8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>31.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fixed income securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">28-53%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>48.7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>47.1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">5-20%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>18.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">International pension plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-10%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3.0</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">20-40%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>21.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>22.9</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fixed income securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">35-60%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>46.9</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>46.3</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">10-35%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>29.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>27.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;text-decoration:underline;">U.S. postretirement plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">0-5%</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">95-100%</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">%</span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Global plan assets are managed with the objective of generating returns that will enable the plans to meet their future obligations, while seeking to manage net periodic benefit costs and cash contributions over the long-term. We utilize long-term asset allocation ranges in the management of our plans&#8217; invested assets. Our long-term return expectations are developed based on a diversified, global investment strategy that takes into account historical experience, as well as the impact of portfolio diversification, active portfolio management, and our view of current and future economic and financial market conditions. As market conditions and other factors change, we may adjust our targets accordingly and our asset allocations may vary from the target allocations.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our long-term asset allocation ranges reflect our asset class return expectations and tolerance for investment risk within the context of the respective plans&#8217; long-term benefit obligations. These ranges are supported by analysis that incorporates historical and expected returns by asset class, as well as volatilities and correlations across asset classes and our liability profile. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Each pension plan is overseen by a local committee or board that is responsible for the overall investment of the pension plan assets. In determining investment policies and associated target allocations, each committee or board considers a wide variety of factors. As such, the target asset allocation for each of our international pension plans is set on a standalone basis by the relevant board or committee. The target asset allocation ranges shown for the international pension plans seek to reflect the combined target allocations across all such plans, while also showing the range within which the target allocations for each plan typically falls.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The investment managers of certain separately managed accounts, commingled funds and private equity funds may be permitted to use repurchase agreements and derivative securities, including U.S. Treasury and equity futures contracts as described in each respective investment management, subscription, partnership or other governing agreement.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Cash Flows</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">It is our practice to fund amounts for our qualified pension plans that are at least sufficient to meet the minimum requirements set forth in applicable employee benefit laws and local tax laws.</span></div><div style="line-height:120%;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:27%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:14%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the expected future cash flow information related to our benefit plans:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">U.S. Qualified</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:center;">U.S. Supplemental</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-align:center;">(Non-Qualified)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">International</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement Plans</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected employer contributions:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,276</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>172</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>147</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Expected benefit payments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>189</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>355</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,089</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>113</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>358</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,048</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>115</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>364</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>137</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,046</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>110</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>366</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,028</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>103</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>375</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>134</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2025&#8211;2029</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,759</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>435</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>642</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="padding-top:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For the U.S. qualified plans, we plan to make a </span><span style="font-family:Arial;font-size:7pt;"><span>$1.25 billion</span></span><span style="font-family:Arial;font-size:7pt;"> voluntary contribution in the second half of 2020.</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The above table reflects the total U.S. and international plan benefits projected to be paid from the plans or from our general assets under the current actuarial assumptions used for the calculation of the benefit obligation and, therefore, actual benefit payments may differ from projected benefit payments.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">F. Defined Contribution Plans</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We have defined contribution plans in the U.S. and several other countries. For the majority of the U.S. defined contribution plans, employees may contribute a portion of their salaries and bonuses to the plans, and we match, in cash, a portion of the employee contributions. Beginning on January 1, 2011, for newly hired non-union employees, rehires and transfers to the U.S. or Puerto Rico, we no longer offer a defined benefit pension plan and, instead, offer a Retirement Savings Contribution (RSC) in the defined contribution plan. The RSC is an annual non-contributory employer contribution (that is not dependent upon the participant making a contribution) determined based on each employee&#8217;s eligible compensation, age and years of service. Beginning on January 1, 2018, all non-union employees in the U.S. and Puerto Rico defined benefit plans transitioned to the RSC in the defined contribution plans. We recorded charges related to the employer contributions to global defined contribution plans of </span><span style="font-family:Arial;font-size:8pt;"><span>$659 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2019</span><span style="font-family:Arial;font-size:8pt;">, </span><span style="font-family:Arial;font-size:8pt;"><span>$622 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$380 million</span></span><span style="font-family:Arial;font-size:8pt;"> in </span><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>193
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7188389232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Impact of Adoption of Accounting Standard Updates</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:2px;padding-top:2px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Adopting the standard related to leases impacted our prior period consolidated balance sheet as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As Previously Reported Balance at</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Effect of Change</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Higher/(Lower)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance at</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">January 1, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,461</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,460</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,924</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,913</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,799</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,351</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,149</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,753</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>258</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>11,011</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,850</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,060</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,910</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Retained earnings</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>89,554</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>89,574</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Information About Balance Sheet Classification of Accruals</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:71%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information about the balance sheet classification of these accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Reserve against </span><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,257</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,288</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;font-weight:bold;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrued rebates</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,285</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,208</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other accruals</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>581</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>531</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>565</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>399</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total accrued rebates and other accruals</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,689</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,426</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetsAndLiabilitiesLesseeTableTextBlock', window );">ROU Assets and Liabilities Presented in Condensed Consolidated Balance Sheets</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:54%;"/><td style="width:1%;"/><td style="width:25%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For operating leases, the ROU assets and liabilities are presented in our consolidated balance sheet as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance at</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance Sheet Classification</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ROU assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,313</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease liabilities (short-term)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease liabilities (long-term)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Total Lease Costs and Other Supplemental Information</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:80%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our total lease costs are as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Year Ended</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>416</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Variable lease cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>328</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Sublease income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total lease cost</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>700</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:44%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/><td style="width:17%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other supplemental information includes the following:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average Remaining Contractual Lease Term (Years) as of</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Weighted-Average Discount Rate as of</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6.8</span></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3.5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating cash flows from operating leases</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>346</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">(Gains)/losses on sale and leaseback transactions, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(29</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">ROU assets obtained in exchange for new operating lease liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>326</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:23%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The table below reconciles the undiscounted cash flows for the first five years and total of the remaining years to the operating lease liabilities recorded in the consolidated balance sheet as of December 31, 2019:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Operating Lease Liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Next one year</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>323</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">1-2 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>286</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2-3 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>220</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3-4 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>180</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4-5 years</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>97</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Thereafter</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>424</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total undiscounted lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,530</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Imputed interest</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>206</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Present value of minimum lease payments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,324</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Current portion</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>276</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,048</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Reflects lease payments due within 12 months subsequent to the balance sheet date.</span><span style="font-family:Arial;font-size:8pt;"> </span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rental Payments for Operating Leases</a></td>
<td class="text"><div style="line-height:120%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:11%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31, 2018, the future minimum rental commitments under non-cancelable operating leases follow:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">After 2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Lease commitments</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>300</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>252</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>210</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>267</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>248</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,040</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetsAndLiabilitiesLesseeTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets And Liabilities, Lessee [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetsAndLiabilitiesLesseeTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of changes in accounting principles, including adoption of new accounting pronouncements, that describes the new methods, amount and effects on financial statement line items.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22499-107794<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e765-108305<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.10-01.(b)(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=27015980&amp;loc=d3e46468-122699<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=116846552&amp;loc=d3e725-108305<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22583-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfNewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>194
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952903296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Total Lease Cost (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="nump">328<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(45)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 700<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>195
<FILENAME>R157.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7010864320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="5">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 29, 2019</div></th>
<th class="th"><div>Jul. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 02, 2017</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
<th class="th"><div>Nov. 10, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (554)<span></span>
</td>
<td class="num">$ (157)<span></span>
</td>
<td class="num">$ (240)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessAlignmentCosts', window );">Business alignment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">338<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain associated with Bain Capital transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">454<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of Consumer Healthcare JV transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,086<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,650<span></span>
</td>
<td class="nump">8,006<span></span>
</td>
<td class="nump">7,683<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationExternalIncrementalCostsAmount', window );">External incremental costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">152<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposition of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(60)<span></span>
</td>
<td class="num">(52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesandImplementationCosts', window );">Restructuring charges and implementation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">758<span></span>
</td>
<td class="nump">977<span></span>
</td>
<td class="nump">204<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossRelatedToLitigationSettlement', window );">Litigation settlement income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(543)<span></span>
</td>
<td class="num">(157)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetImpairmentChargesAndOtherCharges', window );">Certain asset impairments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,800<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">379<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessAlignmentCosts', window );">Business alignment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">495<span></span>
</td>
<td class="nump">63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain associated with Bain Capital transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">415<span></span>
</td>
<td class="nump">586<span></span>
</td>
<td class="nump">224<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">138<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">999<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherOperatingIncomeExpenseNet', window );">Other income (charges)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="nump">756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus', window );">One-time bonus paid to all Pfizer colleagues excluding executives</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyLossInPeriod', window );">Other legal matters, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">237<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AlignmentCosts', window );">Alignment costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember', window );">HIS [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Income (Loss) on sale of HIS net assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="num">(55)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV Healthcare Limited [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember', window );">ViiV Healthcare Limited [Member] | Biopharma Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentIncomeDividend', window );">Dividend income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 220<span></span>
</td>
<td class="nump">253<span></span>
</td>
<td class="nump">266<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of Consumer Healthcare JV transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeconsolidationGainOrLossAmount', window );">Gain on completion of Consumer Healthcare JV transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationExternalIncrementalCostsAmount', window );">External incremental costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember', window );">Allogene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainLossFromContributionAgreement', window );">Gain from contribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember', window );">Allogene [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainLossFromContributionAgreement', window );">Gain from contribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember', window );">Hisun Pfizer Pharmaceuticals Co. Ltd [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposition of property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Equity method investment, ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal', window );">Loss on disposal of equity method investment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundVL.P.Member', window );">NovaQuest Co-Investment Fund V, L.P. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale', window );">Charge primarily for inventory manufactured for expected future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundVL.P.Member', window );">NovaQuest Co-Investment Fund V, L.P. [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale', window );">Charge primarily for inventory manufactured for expected future sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BainCapitalMember', window );">Bain Capital [Member] | Cerevel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain associated with Bain Capital transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_BainCapitalMember', window );">Bain Capital [Member] | Cerevel [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain associated with Bain Capital transaction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Licensing Agreements [Member] | Akcea And Ionis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForLicensingArrangement', window );">Payment for licensing arrangement</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeExpenseMember', window );">Other Income (Expense) [Member] | GSK Consumer Healthcare [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RestructuringChargesandImplementationCosts', window );">Restructuring charges and implementation costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, General and Administrative Expenses [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CharitableContributionExpense', window );">Charitable contribution expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember', window );">Cost of Sales [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InventoryWriteDownAndOverheadCosts', window );">Inventory losses and overhead costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember', window );">Therachon Asset Acquisition [Member] | Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost', window );">Research and development expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember', window );">Laboratorio Teuto Brasilero [Member] | Laboratorio Teuto Brasilero [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AlignmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Alignment Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AlignmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetImpairmentChargesAndOtherCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of impairment loss recognized in the period resulting from the write-down of the carrying amount of intangible assets, other than goodwill, to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetImpairmentChargesAndOtherCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessAlignmentCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Alignment Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessAlignmentCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charge primarily for inventory manufactured for expected future sale</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_Chargeprimarilyforinventorymanufacturedforexpectedfuturesale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CharitableContributionExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Charitable Contribution Expense</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CharitableContributionExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Compensation Related Costs, Non-Executive Employees, Bonus</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CompensationRelatedCostsNonExecutiveEmployeesBonus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationExternalIncrementalCostsAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, External Incremental Costs, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationExternalIncrementalCostsAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainLossFromContributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Contribution Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainLossFromContributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InventoryWriteDownAndOverheadCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Inventory Write Down And Overhead Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InventoryWriteDownAndOverheadCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForLicensingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Licensing Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForLicensingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RestructuringChargesandImplementationCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Restructuring Charges and Implementation Costs</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RestructuringChargesandImplementationCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeconsolidationGainOrLossAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) from deconsolidation of subsidiary and derecognition of group of assets constituting transfer of business or nonprofit activity, excluding conveyance of oil and gas mineral rights and transfer of good or service in contract with customer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4582445-111684<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeconsolidationGainOrLossAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of an equity method investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(7)(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(b)(9)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentRealizedGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossRelatedToLitigationSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in settlement of litigation and insurance claims. Excludes claims within an insurance entity's normal claims settlement process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossRelatedToLitigationSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyLossInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of loss pertaining to the specified contingency that was charged against earnings in the period, including the effects of revisions in previously reported estimates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyLossInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingIncomeExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of other operating income and expenses, the components of which are not separately disclosed on the income statement, from items that are associated with the entity's normal revenue producing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingIncomeExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The costs incurred in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, excluding in-process research and development acquired in a business combination consummated during the period. Excludes software research and development, which has a separate concept.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_ViivHealthcareLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_HisunPfizerPharmaceuticalsCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundVL.P.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_NovaQuestCoInvestmentFundVL.P.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BainCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BainCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_OtherIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_CostOfSalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_LaboratorioTeutoBrasileroMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>196
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952935360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock', window );">Summary of Common Stock Purchases</a></td>
<td class="text"><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:46%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:15%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the number of shares of our common stock purchased and the cost of purchases under our publicly announced share purchase plans, including our accelerated share repurchase agreements:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(SHARES IN MILLIONS, DOLLARS IN BILLIONS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">c)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Shares of common stock purchased</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>213</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>307</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>150</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of purchase</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8.9</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>12.2</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5.0</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt">(</sup></span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Represents shares purchased pursuant to the accelerated share repurchase agreement with</span><span style="font-family:Arial;font-size:8pt;"> </span><span style="font-family:Arial;font-size:7pt;">GS&amp;Co.</span><span style="font-family:Arial;font-size:7pt;"> entered into on </span><span style="font-family:Arial;font-size:7pt;">February&#160;7, 2019</span><span style="font-family:Arial;font-size:7pt;">, as well as other share repurchases. See above for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"><sup style="vertical-align:top;line-height:120%;background-color:#ffffff; font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on </span><span style="font-family:Arial;font-size:7pt;">March&#160;12, 2018</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">, as well as other share repurchases. See above for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">Represents shares purchased pursuant to the accelerated share repurchase agreement with Citibank entered into on</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;"> </span><span style="font-family:Arial;font-size:7pt;">February&#160;2, 2017</span><span style="font-family:Arial;font-size:7pt;background-color:#ffffff;">. See above for additional information.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfTreasuryStockByClassTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of treasury stock, including, but not limited to, average cost per share, description of share repurchase program, shares repurchased, shares held for each class of treasury stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23309-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23285-112656<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfTreasuryStockByClassTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>197
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7019715760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Basis of Presentation and Significant Accounting Policies - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1">18 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares</div>
</th>
<th class="th">
<div>Jul. 01, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>USD ($) </div>
<div>Accounting_standard</div>
</th>
<th class="th">
<div>Dec. 22, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Nov. 30, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($) </div>
<div>Operating_Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Operating_Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jul. 02, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Jun. 28, 2020</div></th>
<th class="th">
<div>Feb. 03, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Operating_Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NumberOfAccountingStandardsAdopted', window );">Number of accounting standards adopted | Accounting_standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,861<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,313<span></span>
</td>
<td class="nump">1,313<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities (long-term)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_RebatesAndDiscountsAccrual', window );">Accruals for Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances, cash discounts and sales returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,689<span></span>
</td>
<td class="nump">5,689<span></span>
</td>
<td class="nump">5,426<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="nump">3,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VariableLeaseCost', window );">Variable lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">328<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, cash portion</a></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="nump">$ 10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember', window );">AstraZeneca [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, cash portion</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 555<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ICUMedicalMember', window );">ICU Medical [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash received for disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue [Member] | Top Eight Products [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConcentrationRiskAmount', window );">Concentration risk, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue [Member] | Top Nine Products [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConcentrationRiskAmount', window );">Concentration risk, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember', window );">Revenue [Member] | Top Ten Products [Member] | Product Concentration Risk [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ConcentrationRiskAmount', window );">Concentration risk, amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member', window );">Accounting Standards Update 2016-02 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">ROU assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities (long-term)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1', window );">Cumulative effect on retained earnings, before tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1', window );">Cumulative effect on retained earnings, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member] | Akcea And Ionis [Member] | Licensing Agreements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForLicensingArrangement', window );">Payment for licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember', window );">Therachon Asset Acquisition [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum', window );">Maximum potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetAcquisitionConsiderationTransferred', window );">Fair value of consideration transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LesseeOperatingLeaseOptionToExtendTerm', window );">Operating lease term, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">30 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LesseeOperatingLeaseOptionToExtendTerm', window );">Operating lease term, option to extend</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Upjohn And Mylan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByParent', window );">Noncontrolling interest, ownership percentage by parent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Mylan [Member] | Upjohn And Mylan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners', window );">Noncontrolling interest, ownership percentage by noncontrolling owners</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">43.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionConsiderationTransferred">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionConsiderationTransferred</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Milestone Payments, Maximum</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionConsiderationTransferredMilestonePaymentsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Acquisition, Consideration Transferred, Upfront Payment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionConsiderationTransferredUpfrontPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ConcentrationRiskAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Concentration Risk, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ConcentrationRiskAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LesseeOperatingLeaseOptionToExtendTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lessee, Operating Lease, Option To Extend, Term</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LesseeOperatingLeaseOptionToExtendTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NumberOfAccountingStandardsAdopted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number Of Accounting Standards Adopted</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NumberOfAccountingStandardsAdopted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForLicensingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Licensing Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForLicensingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_RebatesAndDiscountsAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Medicare rebates, Medicaid and related state program rebates, performance-based contract rebates, chargebacks, sales allowances and sales returns and cash discounts</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_RebatesAndDiscountsAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 720<br> -SubTopic 35<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420018&amp;loc=d3e36677-107848<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=116859721&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6351-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13531-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13537-108611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6404-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings before related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 50<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=116651436&amp;loc=d3e122869-111746<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsBeforeTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cumulative effect on retained earnings net of related income tax effect.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22663-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOnRetainedEarningsNetOfTax1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The equity interest of noncontrolling shareholders, partners or other equity holders in consolidated entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByNoncontrollingOwners</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterestOwnershipPercentageByParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The parent entity's interest in net assets of the subsidiary, expressed as a percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterestOwnershipPercentageByParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VariableLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI http://asc.fasb.org/extlink&amp;oid=77888399&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VariableLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_AstraZenecaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ICUMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ICUMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueProductLineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TopEightProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TopEightProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_ProductConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TopNineProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TopNineProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TopTenProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TopTenProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetAcquisitionAxis=pfe_TherachonAssetAcquisitionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pfe_UpjohnAndMylanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pfe_UpjohnAndMylanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_MylanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_MylanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>198
<FILENAME>R153.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7021244496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingencies and Certain Commitments (Action In Which We Are The Defendant) (Details)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="5">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Oct. 31, 2018 </div>
<div>manufacturer</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>lagoon</div>
</th>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>class_action</div>
</th>
<th class="th">
<div>Mar. 31, 2015 </div>
<div>Patents</div>
</th>
<th class="th">
<div>Mar. 31, 2013 </div>
<div>lagoon</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>lawsuit</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>GBP (&#163;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyClassActionsFiledNumber', window );">Number of class actions filed | class_action</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member', window );">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents allegedly infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member', window );">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber', window );">Number of patents allegedly infringed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member', window );">Janssen and New York University Versus Hospira, Celltrion Healthcare and Celltrion Inc. [Member] | Inflectra [Member] | Settled Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyClaimsDismissedNumber', window );">Number of claims dismissed</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember', window );">Pfizer And Hospira And Various Other Manufacturers Versus Mississippi Attorney General [Member] | Docetaxel [Member] | Pending Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant', window );">Number of defendants other than main defendant | manufacturer</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember', window );">Environmental Remediation Litigation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FeasibilityStudyNumberOfLagoons', window );">Feasibility study, number of lagoons | lagoon</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ViolationofAntitrustLawsMember', window );">Violation of Antitrust Laws [Member] | Phenytoin Sodium Capsules [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingencyEstimateOfPossibleLoss', window );">Imposed fine | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 84.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Epi Pen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LossContingencyNumberOfLawsuits', window );">Number of lawsuits | lawsuit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FeasibilityStudyNumberOfLagoons">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Feasibility Study, Number Of Lagoons</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FeasibilityStudyNumberOfLagoons</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyClassActionsFiledNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Class Actions Filed, Number</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyClassActionsFiledNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Defendants Other Than Main Defendant</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyNumberOfDefendantsOtherThanMainDefendant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LossContingencyNumberOfLawsuits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Loss Contingency, Number Of Lawsuits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LossContingencyNumberOfLawsuits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyClaimsDismissedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of claims dismissed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyClaimsDismissedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyEstimateOfPossibleLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reflects the estimated amount of loss from the specified contingency as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14435-108349<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14557-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118943654&amp;loc=d3e12021-110248<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyEstimateOfPossibleLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyPatentsAllegedlyInfringedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of another entity's patents that the entity has allegedly infringed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyPatentsAllegedlyInfringedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_JanssenandNewYorkUniversityVersusHospiraCelltrionHealthcareandCelltrionInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InflectraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InflectraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_SettledLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=pfe_PfizerAndHospiraAndVariousOtherManufacturersVersusMississippiAttorneyGeneralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_DocetaxelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_DocetaxelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_EnvironmentalRemediationLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ViolationofAntitrustLawsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_ViolationofAntitrustLawsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PhenytoinSodiumCapsulesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PhenytoinSodiumCapsulesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>199
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7033794528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsAbstract', window );"><strong>Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 1,305<span></span>
</td>
<td class="nump">$ 1,139<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShortTermInvestments', window );">Short-term investments</a></td>
<td class="nump">8,525<span></span>
</td>
<td class="nump">17,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Trade accounts receivable, less allowance for doubtful accounts: 2019&#8212;$527; 2018&#8212;$541</a></td>
<td class="nump">8,724<span></span>
</td>
<td class="nump">8,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">8,283<span></span>
</td>
<td class="nump">7,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_OtherTaxAssetsCurrent', window );">Current tax assets</a></td>
<td class="nump">3,344<span></span>
</td>
<td class="nump">3,374<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other current assets</a></td>
<td class="nump">2,600<span></span>
</td>
<td class="nump">2,461<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent', window );">Assets held for sale</a></td>
<td class="nump">21<span></span>
</td>
<td class="nump">9,725<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">32,803<span></span>
</td>
<td class="nump">49,926<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity-method investments</a></td>
<td class="nump">17,133<span></span>
</td>
<td class="nump">181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermInvestments', window );">Long-term investments</a></td>
<td class="nump">3,014<span></span>
</td>
<td class="nump">2,586<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, plant and equipment, less accumulated depreciation</a></td>
<td class="nump">13,967<span></span>
</td>
<td class="nump">13,385<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable intangible assets, less accumulated amortization</a></td>
<td class="nump">35,370<span></span>
</td>
<td class="nump">35,211<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">58,653<span></span>
</td>
<td class="nump">53,411<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent', window );">Noncurrent deferred tax assets and other noncurrent tax assets</a></td>
<td class="nump">2,099<span></span>
</td>
<td class="nump">1,924<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other noncurrent assets</a></td>
<td class="nump">4,450<span></span>
</td>
<td class="nump">2,799<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">167,489<span></span>
</td>
<td class="nump">159,422<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract', window );"><strong>Liabilities and Equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtCurrent', window );">Short-term borrowings, including current portion of long-term debt: 2019&#8212;$1,462; 2018&#8212;$4,776</a></td>
<td class="nump">16,195<span></span>
</td>
<td class="nump">8,831<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Trade accounts payable</a></td>
<td class="nump">4,220<span></span>
</td>
<td class="nump">4,674<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DividendsPayableCurrent', window );">Dividends payable</a></td>
<td class="nump">2,104<span></span>
</td>
<td class="nump">2,047<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxesPayableCurrent', window );">Income taxes payable</a></td>
<td class="nump">980<span></span>
</td>
<td class="nump">1,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation and related items</a></td>
<td class="nump">2,720<span></span>
</td>
<td class="nump">2,397<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">11,083<span></span>
</td>
<td class="nump">10,753<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation', window );">Liabilities held for sale</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,890<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">37,304<span></span>
</td>
<td class="nump">31,858<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long-term debt</a></td>
<td class="nump">35,955<span></span>
</td>
<td class="nump">32,909<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent', window );">Pension benefit obligations, net</a></td>
<td class="nump">5,638<span></span>
</td>
<td class="nump">5,272<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent', window );">Postretirement benefit obligations, net</a></td>
<td class="nump">1,124<span></span>
</td>
<td class="nump">1,338<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Noncurrent deferred tax liabilities</a></td>
<td class="nump">5,578<span></span>
</td>
<td class="nump">3,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent', window );">Other taxes payable</a></td>
<td class="nump">12,126<span></span>
</td>
<td class="nump">14,737<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other noncurrent liabilities</a></td>
<td class="nump">6,317<span></span>
</td>
<td class="nump">5,850<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">104,042<span></span>
</td>
<td class="nump">95,664<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, no par value, at stated value; 27 shares authorized; issued: 2019&#8212;431; 2018&#8212;478</a></td>
<td class="nump">17<span></span>
</td>
<td class="nump">19<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.05 par value; 12,000 shares authorized; issued: 2019&#8212;9,369; 2018&#8212;9,332</a></td>
<td class="nump">468<span></span>
</td>
<td class="nump">467<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">87,428<span></span>
</td>
<td class="nump">86,253<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TreasuryStockValue', window );">Treasury stock, shares at cost: 2019&#8212;3,835; 2018&#8212;3,615</a></td>
<td class="num">(110,801)<span></span>
</td>
<td class="num">(101,610)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Retained earnings</a></td>
<td class="nump">97,670<span></span>
</td>
<td class="nump">89,554<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(11,640)<span></span>
</td>
<td class="num">(11,275)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total Pfizer Inc. shareholders&#8217; equity</a></td>
<td class="nump">63,143<span></span>
</td>
<td class="nump">63,407<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MinorityInterest', window );">Equity attributable to noncontrolling interests</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">351<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Total equity</a></td>
<td class="nump">63,447<span></span>
</td>
<td class="nump">63,758<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and equity</a></td>
<td class="nump">$ 167,489<span></span>
</td>
<td class="nump">$ 159,422<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Net, And Other Tax Assets, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsNetAndOtherTaxAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_OtherTaxAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other Tax Assets, Current</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_OtherTaxAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130549-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4428-111522<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=118952595&amp;loc=d3e4531-111522<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e637-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders. Includes adjustments to additional paid in capital. Some examples of such adjustments include recording the issuance of debt with a beneficial conversion feature and certain tax consequences of equity instruments awarded to employees. Use this element for the aggregate amount of additional paid-in capital associated with common and preferred stock. For additional paid-in capital associated with only common stock, use the element additional paid in capital, common stock. For additional paid-in capital associated with only preferred stock, use the element additional paid in capital, preferred stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of, expected to be disposed of within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2473-110228<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperationCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of short-term debt and current maturity of long-term debt and capital lease obligations due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31931-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit pension plan, classified as noncurrent. Excludes other postretirement benefit plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPensionPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DividendsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of dividends declared but unpaid on equity securities issued by the entity and outstanding. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DividendsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109237563&amp;loc=d3e33749-111570<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8813-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 330<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=116846819&amp;loc=d3e3927-108312<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.6(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as liabilities attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after unamortized (discount) premium and debt issuance costs of long-term debt classified as noncurrent and excluding amounts to be repaid within one year or the normal operating cycle, if longer. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of investments that are intended to be held for an extended period of time (longer than one operating cycle).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.12)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MinorityInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which is directly or indirectly attributable to that ownership interest in subsidiary equity which is not attributable to the parent (that is, noncontrolling interest, previously referred to as minority interest).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MinorityInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6904-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=118951113&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability, recognized in statement of financial position, for defined benefit other postretirement plan, classified as noncurrent. Excludes pension plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1731-114919<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109237824&amp;loc=d3e1703-114919<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherPostretirementDefinedBenefitPlanLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investments including trading securities, available-for-sale securities, held-to-maturity securities, and short-term investments classified as other and current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(g))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568740-111683<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4590271-111686<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4568447-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable for statutory income, sales, use, payroll, excise, real, property and other taxes. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount allocated to treasury stock. Treasury stock is common and preferred shares of an entity that were issued, repurchased by the entity, and are held in its treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=6405834&amp;loc=d3e23315-112656<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29,30)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6405813&amp;loc=d3e23239-112655<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>200
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7008642208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br> $ in Billions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Feb. 25, 2020</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">1-3619<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">PFIZER INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">13-5315170<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">235 East 42nd Street<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New York<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">NY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">10017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">212<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">733-2323<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 241<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,547,639,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:653px;border-collapse:collapse;text-align:left;"><tr><td colspan="2"/></tr><tr><td style="width:532px;"/><td style="width:121px;"/></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Portions of the 2019 Annual Report to Shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Parts&#160;I,&#160;II&#160;and&#160;IV</span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Portions of the Proxy Statement for the 2020 Annual Meeting of Shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Part III</span></div></td></tr></table></div><span style="font-family:inherit;font-size:10pt;"><br/></span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0000078003<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $.05 par value<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20200.000Member', window );">Notes Due 2020, 0.000% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.000% Notes due 2020<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE20A<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member', window );">Notes Due 2022, 0.250% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">0.250% Notes due 2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member', window );">Notes Due 2027, 1.000% [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInformationLineItems', window );"><strong>Entity Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">1.000% Notes due 2027<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">PFE27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NYSE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 20-F, 40-F<br> -Number 240<br> -Section 15<br> -Subsection d-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1-<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20200.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20200.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20220.250Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=pfe_NotesDue20271.000Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>201
<FILENAME>R97.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7042546416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Long-Term Debt Narrative (Details)<br> &#163; in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="2"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2"></th>
<th class="th" colspan="2"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2019 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>GBP (&#163;)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>EUR (&#8364;)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="nump">$ 999,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 999,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member', window );">Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="nump">846,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member', window );">Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on early retirement of debt</a></td>
<td class="nump">$ 153,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 138,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.57%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.56%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Senior Unsecured U.K. Pound Debt, 6.50%, Due 2038 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased debt | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 197<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption value | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 1,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ExtinguishmentOfDebtAmount', window );">Amount of debt exchanged</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 833<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount | &#163;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#163; 470<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes [Member] | Senior Unsecured Euro Debt, 5.75%, Due 2021 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchaseAmount', window );">Repurchased debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,300,000,000<span></span>
</td>
<td class="nump">&#8364; 1,100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 834,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="nump">5.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentRepurchasedFaceAmount', window );">Redemption value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,500,000,000<span></span>
</td>
<td class="nump">&#8364; 1,300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount | &#8364;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8364; 1,200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument, face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,065,000,000.000<span></span>
</td>
<td class="nump">&#8364; 4,000,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.20%<span></span>
</td>
<td class="nump">1.30%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
<td class="nump">0.23%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Principal amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,800,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember', window );">Unsecured Debt [Member] | Senior Notes Due 2047 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtWeightedAverageInterestRate', window );">Weighted average interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">4.20%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28551-108399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchaseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value amount of debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchaseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentRepurchasedFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of the original debt instrument that was repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentRepurchasedFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtWeightedAverageInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average interest rate of debt outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtWeightedAverageInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ExtinguishmentOfDebtAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross amount of debt extinguished.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ExtinguishmentOfDebtAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12355-112629<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=117329964&amp;loc=d3e12317-112629<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after unamortized (discount) premium and debt issuance costs, of long-term debt. Includes, but not limited to, notes payable, bonds payable, debentures, mortgage loans and commercial paper. Excludes capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109500613&amp;loc=SL6031897-161870<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=119400593&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredU.K.PoundDebtSixPointFivePercentDue2038Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorUnsecuredEuroDebtFivePointSevenFivePercentDue2021Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_UnsecuredDebtMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2047Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=pfe_SeniorNotesDue2047Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>202
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7019547536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net income before allocation to noncontrolling interests</a></td>
<td class="nump">$ 16,302<span></span>
</td>
<td class="nump">$ 11,188<span></span>
</td>
<td class="nump">$ 21,355<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">6,010<span></span>
</td>
<td class="nump">6,384<span></span>
</td>
<td class="nump">6,269<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AssetWriteOffsAndAssetImpairmentCharges', window );">Asset write-offs and impairments</a></td>
<td class="nump">2,953<span></span>
</td>
<td class="nump">3,398<span></span>
</td>
<td class="nump">634<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit', window );">TCJA impact</a></td>
<td class="num">(323)<span></span>
</td>
<td class="num">(596)<span></span>
</td>
<td class="num">(10,660)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="num">(8,233)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Deferred taxes from continuing operations</a></td>
<td class="nump">614<span></span>
</td>
<td class="num">(2,205)<span></span>
</td>
<td class="num">(2,410)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">949<span></span>
</td>
<td class="nump">840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense', window );">Benefit plan contributions in excess of expense/income</a></td>
<td class="num">(336)<span></span>
</td>
<td class="num">(1,095)<span></span>
</td>
<td class="num">(961)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other adjustments, net</a></td>
<td class="num">(1,086)<span></span>
</td>
<td class="num">(1,269)<span></span>
</td>
<td class="nump">399<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Other changes in assets and liabilities, net of acquisitions and divestitures:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Trade accounts receivable</a></td>
<td class="num">(742)<span></span>
</td>
<td class="num">(644)<span></span>
</td>
<td class="nump">259<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(1,050)<span></span>
</td>
<td class="num">(717)<span></span>
</td>
<td class="num">(357)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets', window );">Other assets</a></td>
<td class="nump">795<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade', window );">Trade accounts payable</a></td>
<td class="num">(564)<span></span>
</td>
<td class="nump">431<span></span>
</td>
<td class="nump">46<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities', window );">Other liabilities</a></td>
<td class="nump">267<span></span>
</td>
<td class="nump">98<span></span>
</td>
<td class="num">(67)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable', window );">Other tax accounts, net</a></td>
<td class="num">(2,737)<span></span>
</td>
<td class="num">(78)<span></span>
</td>
<td class="nump">1,446<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash provided by operating activities</a></td>
<td class="nump">12,588<span></span>
</td>
<td class="nump">15,827<span></span>
</td>
<td class="nump">16,802<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Investing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property, plant and equipment</a></td>
<td class="num">(2,176)<span></span>
</td>
<td class="num">(2,042)<span></span>
</td>
<td class="num">(1,956)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireShortTermInvestments', window );">Purchases of short-term investments</a></td>
<td class="num">(6,835)<span></span>
</td>
<td class="num">(11,677)<span></span>
</td>
<td class="num">(14,596)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments', window );">Proceeds from redemptions/sales of short-term investments</a></td>
<td class="nump">9,183<span></span>
</td>
<td class="nump">17,581<span></span>
</td>
<td class="nump">10,302<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromShortTermInvestments', window );">Net (purchases of)/proceeds from redemptions/sales of short-term investments with original maturities of three months or less</a></td>
<td class="nump">6,925<span></span>
</td>
<td class="num">(3,917)<span></span>
</td>
<td class="nump">2,058<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of long-term investments</a></td>
<td class="num">(201)<span></span>
</td>
<td class="num">(1,797)<span></span>
</td>
<td class="num">(3,537)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments', window );">Proceeds from redemptions/sales of long-term investments</a></td>
<td class="nump">232<span></span>
</td>
<td class="nump">6,244<span></span>
</td>
<td class="nump">3,579<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisitions of businesses, net of cash acquired</a></td>
<td class="num">(10,861)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireIntangibleAssets', window );">Acquisitions of intangible assets</a></td>
<td class="num">(418)<span></span>
</td>
<td class="num">(154)<span></span>
</td>
<td class="num">(261)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities', window );">Other investing activities, net</a></td>
<td class="nump">205<span></span>
</td>
<td class="nump">288<span></span>
</td>
<td class="nump">671<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by/(used in) investing activities</a></td>
<td class="num">(3,945)<span></span>
</td>
<td class="nump">4,525<span></span>
</td>
<td class="num">(4,740)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Financing Activities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromShortTermDebt', window );">Proceeds from short-term borrowings</a></td>
<td class="nump">16,455<span></span>
</td>
<td class="nump">3,711<span></span>
</td>
<td class="nump">8,464<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfShortTermDebt', window );">Principal payments on short-term borrowings</a></td>
<td class="num">(8,378)<span></span>
</td>
<td class="num">(4,437)<span></span>
</td>
<td class="num">(9,947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess', window );">Net (payments on)/proceeds from short-term borrowings with original maturities of three months or less</a></td>
<td class="nump">2,551<span></span>
</td>
<td class="num">(1,617)<span></span>
</td>
<td class="nump">1,422<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="nump">4,942<span></span>
</td>
<td class="nump">4,974<span></span>
</td>
<td class="nump">5,274<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Principal payments on long-term debt</a></td>
<td class="num">(6,806)<span></span>
</td>
<td class="num">(3,566)<span></span>
</td>
<td class="num">(6,154)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Purchases of common stock</a></td>
<td class="num">(8,865)<span></span>
</td>
<td class="num">(12,198)<span></span>
</td>
<td class="num">(5,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfOrdinaryDividends', window );">Cash dividends paid</a></td>
<td class="num">(8,043)<span></span>
</td>
<td class="num">(7,978)<span></span>
</td>
<td class="num">(7,659)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">394<span></span>
</td>
<td class="nump">1,259<span></span>
</td>
<td class="nump">862<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities', window );">Other financing activities, net</a></td>
<td class="num">(736)<span></span>
</td>
<td class="num">(588)<span></span>
</td>
<td class="num">(611)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash used in financing activities</a></td>
<td class="num">(8,485)<span></span>
</td>
<td class="num">(20,441)<span></span>
</td>
<td class="num">(13,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of exchange-rate changes on cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="num">(32)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
<td class="nump">53<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase/(decrease) in cash and cash equivalents and restricted cash and cash equivalents</a></td>
<td class="nump">125<span></span>
</td>
<td class="num">(205)<span></span>
</td>
<td class="num">(1,235)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, at beginning of period</a></td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
<td class="nump">2,666<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents and restricted cash and cash equivalents, at end of period</a></td>
<td class="nump">1,350<span></span>
</td>
<td class="nump">1,225<span></span>
</td>
<td class="nump">1,431<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtConversionConvertedInstrumentAmount1', window );">Exchange of $1.1 billion net book value 6.50% U.K. pound denominated bonds maturing in 2038 for $1.8 billion of new 2.735% U.K. pound denominated bonds maturing in 2043, resulting in a debt extinguishment loss of $747 million</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,848<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock', window );">Receipt of ICU Medical common stock</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">428<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable', window );">Promissory note from ICU Medical</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Cash paid (received) during the period for:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes</a></td>
<td class="nump">3,664<span></span>
</td>
<td class="nump">3,655<span></span>
</td>
<td class="nump">2,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest</a></td>
<td class="nump">1,587<span></span>
</td>
<td class="nump">1,311<span></span>
</td>
<td class="nump">1,518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InterestPaidInterestRateHedges', window );">Interest rate hedges</a></td>
<td class="num">(42)<span></span>
</td>
<td class="num">(38)<span></span>
</td>
<td class="num">(199)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember', window );">GSK Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net income before allocation to noncontrolling interests to net cash provided by operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed', window );">Gain on completion of Consumer Healthcare JV transaction, net of cash conveyed</a></td>
<td class="num">(8,200)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment', window );">Equity investment in exchange for Pfizer's assets</a></td>
<td class="nump">15,711<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelTherapeuticsMember', window );">Cerevel Therapeutics [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment', window );">Equity investment in exchange for Pfizer's assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember', window );">Allogene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract', window );"><strong>Supplemental Cash Flow Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment', window );">Equity investment in exchange for Pfizer's assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 92<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AssetWriteOffsAndAssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Asset Write-Offs And Asset Impairment Charges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AssetWriteOffsAndAssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeconsolidationGainLossAmountNetOfCashConveyed">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deconsolidation, Gain (Loss), Amount, Net Of Cash Conveyed</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeconsolidationGainLossAmountNetOfCashConveyed</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets. Includes the amount of expense from discontinued operations, that reflects the allocation of the cost of tangible and intangible assets over the assets' useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DepreciationDepletionAndAmortizationIncludingDiscontinuedOperationDepreciationandAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InterestPaidInterestRateHedges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Interest Paid, Interest Rate Hedges</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InterestPaidInterestRateHedges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Divestiture, Amount of Consideration Received, Common Stock</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Divestiture, Amount of Consideration Received, Note Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NoncashorPartNoncashDivestitureAmountofConsiderationReceivedNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Noncash or Part Noncash Divestiture, Contribution Agreement, Equity Investment</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_NoncashorPartNoncashDivestitureContributionAgreementEquityInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash or cash equivalents contributed during the reporting period by the entity to fund its pension plans and its non-pension postretirement benefit plans less the amount of pension and other postretirement benefit costs/income recognized during the period for defined benefit plans (periodic benefit costs/income include the following components: service cost, interest cost, expected return on plan assets, gain or loss on assets, prior service cost or credit, transition asset or obligation, and gain or loss due to settlements or curtailments).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PensionAndOtherPostretirementBenefitContributionsNetOfPensionAndOtherPostretirementBenefitExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalCashFlowElementsAndSupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtConversionConvertedInstrumentAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The value of the financial instrument(s) that the original debt is being converted into in a noncash (or part noncash) transaction. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtConversionConvertedInstrumentAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=116825942&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid during the current period to foreign, federal, state, and local authorities as taxes on income, net of any cash received during the current period as refunds for the overpayment of taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableTrade">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in recurring obligations of a business that arise from the acquisition of merchandise, materials, supplies and services used in the production and sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableTrade</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedTaxesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period of all taxes owed but not paid, including income, property and other taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedTaxesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherOperatingLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherOperatingLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromOtherInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash (inflow) outflow from investing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromOtherInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForProceedsFromShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount paid (received) by the reporting entity through acquisition or sale and maturities of short-term investments with an original maturity that is three months or less which qualify for treatment as an investing activity based on management's intention and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3098-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForProceedsFromShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfOrdinaryDividends">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow in the form of ordinary dividends to common shareholders, preferred shareholders and noncontrolling interests, generally out of earnings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfOrdinaryDividends</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to acquire asset without physical form usually arising from contractual or other legal rights, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireShortTermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for securities or other assets acquired, which qualify for treatment as an investing activity and are to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireShortTermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromPaymentsForOtherFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e24072-122690<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromPaymentsForOtherFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing net of the cash outflow from repayment of a borrowing having initial term of repayment within three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3098-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfShortTermDebtMaturingInThreeMonthsOrLess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, beyond the current operating cycle.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfLongtermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from sales, maturities, prepayments, calls and collections of all investments, including securities and other assets, having ready marketability and intended by management to be liquidated, if necessary, within the current operating cycle. Includes cash flows from securities classified as trading securities that were acquired for reasons other than sale in the short-term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleMaturityAndCollectionOfShorttermInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591551-111686<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3000-108585<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI http://asc.fasb.org/extlink&amp;oid=116874947&amp;loc=SL4591552-111686<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfShortTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing having initial term of repayment within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfShortTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) from effect of Tax Cuts and Jobs Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCutsAndJobsActOf2017IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_GSKConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>203
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6951987872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes - Interest (Income) Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherIncomeAndExpensesAbstract', window );"><strong>Other Income and Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestCostsCapitalized', window );">Interest costs capitalized</a></td>
<td class="nump">$ 88<span></span>
</td>
<td class="nump">$ 73<span></span>
</td>
<td class="nump">$ 72<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest capitalized during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherIncomeAndExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherIncomeAndExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>204
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7039024016">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives - Costs - Footnotes (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="nump">$ 373<span></span>
</td>
<td class="nump">$ 782<span></span>
</td>
<td class="nump">$ 30<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember', window );">Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">207<span></span>
</td>
<td class="num">(89)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="nump">180<span></span>
</td>
<td class="nump">575<span></span>
</td>
<td class="nump">119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="nump">118<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember', window );">Upjohn Segment [Member] | Operating Segments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charge (credit)</a></td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember', window );">Restructuring Charges And Acquisition-Related Costs [Member] | Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Post closing compensation expense for payments to Array employees for fair value of previously unvested stock options</a></td>
<td class="nump">157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | Qualified Plan [Member] | United States [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Gain on settlements</a></td>
<td class="num">$ (230)<span></span>
</td>
<td class="num">(113)<span></span>
</td>
<td class="num">$ (75)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember', window );">Pension Plan [Member] | Qualified Plan [Member] | United States [Member] | Hospira [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1', window );">Gain on settlements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) recognized in net periodic benefit (cost) credit from irrevocable action relieving primary responsibility for benefit obligation and eliminating risk related to obligation and assets used to effect settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)(7)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanRecognizedNetGainLossDueToSettlements1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140864-122747<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6394359&amp;loc=d3e17939-110869<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=115931487&amp;loc=d3e140904-122747<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_OperatingSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_HospiraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>205
<FILENAME>R93.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7021184304">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Investments (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAmortizedCostBasis', window );">Debt securities, amortized cost</a></td>
<td class="nump">$ 8,380<span></span>
</td>
<td class="nump">$ 16,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain', window );">Debt securities, gross unrealized gains</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss', window );">Debt securities, gross unrealized losses</a></td>
<td class="num">(47)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue', window );">Debt securities maturities, within 1 year, fair value</a></td>
<td class="nump">7,984<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue', window );">Debt securities maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">322<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue', window );">Debt securities maturities, over 5 years, fair value</a></td>
<td class="nump">35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity', window );">Debt Securities, Available-for-sale and Held-to-maturity, fair value</a></td>
<td class="nump">8,340<span></span>
</td>
<td class="nump">16,842<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember', window );">Government and agency debt - non-U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">4,895<span></span>
</td>
<td class="nump">9,754<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gain</a></td>
<td class="nump">6<span></span>
</td>
<td class="nump">7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized loss</a></td>
<td class="num">(38)<span></span>
</td>
<td class="num">(58)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">4,863<span></span>
</td>
<td class="nump">9,703<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">4,863<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">4,863<span></span>
</td>
<td class="nump">9,703<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="nump">803<span></span>
</td>
<td class="nump">592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">798<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government and agency - U.S. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">1,120<span></span>
</td>
<td class="nump">3,804<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized loss</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(23)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">3,782<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">303<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">3,782<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract', window );"><strong>Debt Securities, Available-for-sale, Fair Value to Amortized Cost [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Available-for-sale debt securities, amortized cost</a></td>
<td class="nump">1,027<span></span>
</td>
<td class="nump">2,101<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Available-for-sale debt securities, gross unrealized gain</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Available-for-sale debt securities, gross unrealized loss</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Available-for-sale Securities, Debt Maturities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Available-for-sale securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">1,014<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Available-for-sale securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Available-for-sale securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Available-for-sale securities, debt maturities</a></td>
<td class="nump">1,025<span></span>
</td>
<td class="nump">2,097<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember', window );">Time deposits and other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecurities', window );">Held-to-maturity securities, amortized cost</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">668<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain', window );">Held-to-maturity securities, gross unrealized gains</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss', window );">Held-to-maturity securities, gross unrealized losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesFairValue', window );">Held-to-maturity securities, fair value</a></td>
<td class="nump">535<span></span>
</td>
<td class="nump">$ 668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract', window );"><strong>Debt Securities, Held-to-maturity, Maturity, Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Held-to-maturity securities, debt maturities, within 1 year, fair value</a></td>
<td class="nump">498<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">Held-to-maturity securities, debt maturities, over 1 to 5 years, fair value</a></td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue', window );">Held-to-maturity securities, debt maturities, over 5 years, fair value</a></td>
<td class="nump">$ 30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Available-for-sale Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_AvailableforsaleSecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Gain</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Accumulated Gross Unrealized Loss</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAccumulatedGrossUnrealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities, Amortized Cost Basis</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Next Twelve Months, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesNextTwelveMonthsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Debt Securities Maturities, Year Two Through Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DebtSecuritiesMaturitiesYearTwoThroughFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Held-to-maturity Securities, Debt Maturities, After Year Five, Fair Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HeldtomaturitySecuritiesDebtMaturitiesAfterYearFiveFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27198-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=118942338&amp;loc=SL82898722-210454<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesFairValueToAmortizedCostBasisAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity) and investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAndHeldToMaturity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118954083&amp;loc=d3e26610-111562<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrecognized gain on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated unrealized loss on investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year through fifth fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity), with single maturity date and allocated without single maturity date, maturing in next fiscal year following latest fiscal year. Excludes interim and annual periods when interim period is reported on rolling approach, from latest statement of financial position date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HeldToMaturitySecuritiesFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at amortized cost (held-to-maturity).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=118939692&amp;loc=d3e27232-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HeldToMaturitySecuritiesFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_ForeignGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_BankTimeDepositsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>206
<FILENAME>R142.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7028708384">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Portfolio Performance Shares Activity (Details)<br> shares in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of period, shares</a></td>
<td class="nump">88,469<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember', window );">Portfolio Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, beginning of period, shares</a></td>
<td class="nump">19,261<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares</a></td>
<td class="nump">6,212<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shares</a></td>
<td class="num">(6,882)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited, shares</a></td>
<td class="num">(897)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Nonvested, end of period, shares</a></td>
<td class="nump">17,694<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, beginning of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 43.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue', window );">Granted, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">43.35<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue', window );">Vested, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">42.89<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue', window );">Forfeited, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">39.93<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue', window );">Nonvested, end of period, weighted-average grant date fair value per share (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 39.18<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest, end of period, shares</a></td>
<td class="nump">32,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award forfeited under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award granted under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedIntrinsicValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average intrinsic value of award vested under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=pfe_PortfolioPerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>207
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7007840480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Divestitures (Details) - USD ($)<br> $ / shares in Units, shares in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">3 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Apr. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Jul. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
<th class="th"><div>Feb. 03, 2017</div></th>
<th class="th"><div>Oct. 06, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain representing difference between fair value of equity investment and book value of assets transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 454,000,000<span></span>
</td>
<td class="nump">$ 586,000,000<span></span>
</td>
<td class="nump">$ 224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values(a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">705,000,000<span></span>
</td>
<td class="nump">1,600,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember', window );">Disposal Group, Held-for-sale, Not Discontinued Operations [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,725,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,725,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember', window );">Disposed of by Sale, Not Discontinued Operations [Member] | Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash and common stock to be received for disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue', window );">Maximum amount of milestone payments to be received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 515,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ICUMedicalMember', window );">ICU Medical [Member] | Disposal Group, Held-for-sale, Not Discontinued Operations [Member] | HIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash and common stock to be received for disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_CounterpartyNameAxis=pfe_ICUMedicalMember', window );">ICU Medical [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | HIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash and common stock to be received for disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares', window );">Shares of common stock received for disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests', window );">Value of common stock received for disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 428,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiRealizedGain', window );">Gain from sale of shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">302,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain representing difference between fair value of equity investment and book value of assets transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable', window );">Consideration receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromDivestitureOfBusinesses', window );">Cash proceeds from disposal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration', window );">Maximum contingent consideration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CellectisMember', window );">Cellectis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentsToCollaborators', window );">Upfront payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 80,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember', window );">Allogene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="nump">18.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainLossFromContributionAgreement', window );">Gain from contribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember', window );">Cerevel [Member] | Bain Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain representing difference between fair value of equity investment and book value of assets transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember', window );">Cerevel [Member] | Bain Capital [Member] | Disposal Group, Disposed of by Means Other than Sale, Not Discontinued Operations [Member] | Neuroscience Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount', window );">Committed investment from collaborator</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">350,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation', window );">Assets held for sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | Allogene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNi', window );">Equity securities with readily determinable fair values(a)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">127,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=pfe_AllogeneMember', window );">Allogene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price (in dollars per share)</a></td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember', window );">Other Nonoperating Income (Expense) [Member] | Disposed of by Sale, Not Discontinued Operations [Member] | Phase 2b Ready AMPA Receptor Potentiator For CIAS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration', window );">Cash and common stock to be received for disposition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone', window );">Milestone payment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_OwnershipAxis=pfe_CerevelTherapeuticsMember', window );">Cerevel Therapeutics [Member] | Cerevel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_InvestmentOwnershipPercentage', window );">Ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain representing difference between fair value of equity investment and book value of assets transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 415,000,000<span></span>
</td>
<td class="nump">586,000,000<span></span>
</td>
<td class="nump">224,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | HIS [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal', window );">Income (loss) on sale of assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="num">$ (55,000,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Allogene [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_GainLossFromContributionAgreement', window );">Gain from contribution agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember', window );">Segment Reconciling Items [Member] | Cerevel [Member] | Bain Capital [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquitySecuritiesFvNiGainLoss', window );">Gain representing difference between fair value of equity investment and book value of assets transferred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 343,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Committed Investment From Collaborator, Amount</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_CollaborativeArrangementCommittedInvestmentFromCollaboratorAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration, Note Receivable</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationNoteReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterests</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Consideration Transferred, Equity Interests, Shares</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationConsiderationTransferredEquityInterestsShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Contingent Consideration</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationContingentConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationMilestone">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Milestone</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationMilestone</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disposal Group, Including Discontinued Operation, Milestone, Maximum, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DisposalGroupIncludingDiscontinuedOperationMilestoneMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_GainLossFromContributionAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gain (Loss) From Contribution Agreement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_GainLossFromContributionAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_InvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment, Ownership Percentage</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_InvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentsToCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payments To Collaborators</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentsToCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount classified as assets attributable to disposal group held for sale or disposed of.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=d3e1107-107759<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsOfDisposalGroupIncludingDiscontinuedOperation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of gain (loss) recognized on the sale or disposal of a disposal group. Excludes discontinued operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2443-110228<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupNotDiscontinuedOperationGainLossOnDisposal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNi">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -URI http://asc.fasb.org/extlink&amp;oid=99377092&amp;loc=SL75136599-209740<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNi</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrealized and realized gain (loss) on investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquitySecuritiesFvNiRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain from sale of investment in equity security measured at fair value with change in fair value recognized in net income (FV-NI).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 321<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116654751&amp;loc=SL75117546-209714<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquitySecuritiesFvNiRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromDivestitureOfBusinesses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromDivestitureOfBusinesses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupHeldforsaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfBySaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_Phase2bReadyAMPAReceptorPotentiatorForCIASMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ICUMedicalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ICUMedicalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_HISMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CellectisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CellectisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_AllogeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=pfe_CerevelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BainCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BainCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisposalGroupClassificationAxis=us-gaap_DisposalGroupDisposedOfByMeansOtherThanSaleNotDiscontinuedOperationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_NeuroscienceAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=pfe_NeuroscienceAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=pfe_AllogeneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=pfe_AllogeneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_OwnershipAxis=pfe_CerevelTherapeuticsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_OwnershipAxis=pfe_CerevelTherapeuticsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ConsolidationItemsAxis=us-gaap_MaterialReconcilingItemsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>208
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036835152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements - Array BioPharma Inc (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jul. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,861<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,653<span></span>
</td>
<td class="nump">$ 53,411<span></span>
</td>
<td class="nump">$ 55,952<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionSharePrice', window );">Business acquisition, per share in cash (in dollars per share)</a></td>
<td class="nump">$ 48<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesGross', window );">Payments to acquire businesses, cash portion</a></td>
<td class="nump">$ 11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Cash payments for acquisition, net of cash acquired</a></td>
<td class="nump">10,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">7,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">5,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities', window );">Net deferred tax liabilities</a></td>
<td class="nump">1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt', window );">Assumed long-term debt</a></td>
<td class="nump">$ 451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember', window );">Array [Member] | Restructuring Charges And Acquisition-Related Costs [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized', window );">Post closing compensation expense for payments to Array employees for fair value of previously unvested stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 157<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member] | Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife', window );">Acquired intangible assets, useful life</a></td>
<td class="text">16 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 1,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member] | Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember', window );">Licensing Agreements [Member] | Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">1,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsTechnologyInDevelopmentMember', window );">Licensing Agreements, Technology In Development [Member] | Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsDevelopedTechnologyMember', window );">Licensing Agreements, Developed Technology [Member] | Array [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles', window );">Identifiable intangible assets</a></td>
<td class="nump">$ 340<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife', window );">Finite-lived intangible asset, useful life</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average amortization period of finite-lived intangible assets acquired either individually or as part of a group of assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AcquiredFiniteLivedIntangibleAssetsWeightedAverageUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionSharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks paid or offered to be paid in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionSharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=116821951&amp;loc=d3e31917-109318<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedDeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of intangible assets, excluding goodwill, acquired at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable intangible assets recognized as of the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 55<br> -Paragraph 37<br> -URI http://asc.fasb.org/extlink&amp;oid=116868840&amp;loc=d3e2207-128464<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedIntangibles</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt due after one year or the normal operating cycle, if longer, assumed at the acquisition date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=116869197&amp;loc=d3e4845-128472<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentLiabilitiesLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expenses and losses recorded for each transaction with the acquiree that was recognized separately from the acquisition of assets and assumptions of liabilities in the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=79982066&amp;loc=d3e1392-128463<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationSeparatelyRecognizedTransactionsExpensesAndLossesRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of finite-lived intangible assets, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=99380562&amp;loc=d3e13770-109266<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of business during the period. The cash portion only of the acquisition price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118932676&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=pfe_ArrayMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=pfe_RestructuringChargesAndAcquisitionRelatedCostsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsTechnologyInDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsTechnologyInDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsDevelopedTechnologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsDevelopedTechnologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>209
<FILENAME>R146.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7044301920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Payments - Data Related to All Performance Share Awards (PSAs) (Details) - Performance Shares [Member]<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Employee </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of shares vested | $</a></td>
<td class="nump">$ 64<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="nump">$ 58<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions', window );">Total compensation cost related to nonvested awards not yet recognized, pre-tax | $</a></td>
<td class="nump">$ 34<span></span>
</td>
<td class="nump">$ 41<span></span>
</td>
<td class="nump">$ 34<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period over which nonvested award cost is expected to be recognized (years)</a></td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
<td class="text">1 year 9 months 18 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber', window );">Number of shares modified to accelerate vesting | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected', window );">Number of employees affected by plan modification | Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting', window );">Number of shares scheduled for near-term vesting | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Near-Term Vesting</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_SharebasedCompensationArrangementbySharebasedPaymentAwardEquityInstrumentsOtherthanOptionsNearTermVesting</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost to be recognized for nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of grantees affected by modification of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=116856206&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationNumberOfEmployeesAffected</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares for which recognition of cost was accelerated for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAcceleratedVestingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>210
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7021011040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements  - Licensing Arrangements (Details) - Licensing Agreements [Member] - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Apr. 01, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ProceedsFromLicensingArrangement', window );">Proceeds from licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Akcea And Ionis [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForLicensingArrangement', window );">Payment for licensing arrangement</a></td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LicensingArrangementMilestoneMaximumValue', window );">Licensing arrangement, maximum potential milestones</a></td>
<td class="nump">$ 1,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Shire [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LicensingArrangementMilestoneMaximumValue', window );">Licensing arrangement, maximum potential milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 460<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ProceedsFromLicensingArrangement', window );">Proceeds from licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="nump">$ 110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">Shire [Member] | Other Nonoperating Income (Expense) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_ProceedsFromLicensingArrangement', window );">Proceeds from licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 90<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">BionTech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LicensingArrangementMilestoneMaximumValue', window );">Licensing arrangement, maximum potential milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 325<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember', window );">BionTech [Member] | Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_PaymentForLicensingArrangement', window );">Payment for licensing arrangement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember', window );">Long-term Investments [Member] | BionTech [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems', window );"><strong>Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LicensingArrangementNumberOfSharesPurchased', window );">Number of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">169,670<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_LicensingArrangementValueOfSharesPurchased', window );">Value of shares purchased</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LicensingArrangementMilestoneMaximumValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Arrangement, Milestone, Maximum, Value</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LicensingArrangementMilestoneMaximumValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LicensingArrangementNumberOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Arrangement, Number Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LicensingArrangementNumberOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_LicensingArrangementValueOfSharesPurchased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Licensing Arrangement, Value Of Shares Purchased</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_LicensingArrangementValueOfSharesPurchased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_PaymentForLicensingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment For Licensing Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_PaymentForLicensingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_ProceedsFromLicensingArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Licensing Arrangement</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_ProceedsFromLicensingArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=us-gaap_LicensingAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_AkceaAndIonisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_ShireMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_ShireMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_OtherNonoperatingIncomeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=pfe_BionTechMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=pfe_BionTechMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_LongtermInvestmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>211
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040841248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Narrative (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries', window );">Unremitted earnings of international subsidiaries</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 29,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsExcludingInterest', window );">Unrecognized tax benefits excluding associated interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,200<span></span>
</td>
<td class="nump">$ 5,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits', window );">Deferred tax assets associated with unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense', window );">Unrecognized tax benefits, interest on income taxes expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">564<span></span>
</td>
<td class="num">(103)<span></span>
</td>
<td class="num">$ (208)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">485<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual', window );">Unrecognized accrued interest decrease as a result of cash payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13<span></span>
</td>
<td class="nump">16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxSettlements', window );">Effective Income Tax Rate Reconciliation, Tax Settlement, Amount</a></td>
<td class="num">$ (1,400)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible, amount of unrecorded benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember', window );">Noncurrent Deferred Tax Assets And Other Noncurrent Tax Assets [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits', window );">Deferred tax assets associated with unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_DeferredTaxLiabilitiesNetNoncurrentMember', window );">Deferred Tax Liabilities, Net, Noncurrent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits', window );">Deferred tax assets associated with unrecognized tax benefits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">109<span></span>
</td>
<td class="nump">128<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember', window );">Income Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember', window );">Other Taxes Payable [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxContingencyLineItems', window );"><strong>Income Tax Contingency [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued', window );">Unrecognized tax benefits, interest on income taxes accrued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 465<span></span>
</td>
<td class="nump">$ 1,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Associated With Unrecognized Tax Benefits</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_DeferredTaxAssetsAssociatedWithUnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsExcludingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Excluding Interest</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsExcludingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Interest on Income Taxes Accrued, Increase (Decrease) In Accrual</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_UnrecognizedTaxBenefitsInterestonIncomeTaxesAccruedIncreaseDecreaseInAccrual</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxContingencyLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxContingencyLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxSettlements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to income tax settlements. Including, but not limited to, domestic tax settlement, foreign tax settlement, state and local tax settlement, and other tax settlements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxSettlements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarningsOfForeignSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of undistributed earnings of foreign subsidiaries intended to be permanently reinvested outside the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6487024&amp;loc=d3e29054-158556<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=117330534&amp;loc=d3e28200-109314<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6479915&amp;loc=d3e66715-112838<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarningsOfForeignSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense accrued for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of interest expense for an underpayment of income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_NoncurrentDeferredTaxAssetsAndOtherNoncurrentTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_DeferredTaxLiabilitiesNetNoncurrentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_DeferredTaxLiabilitiesNetNoncurrentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_IncomeTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BalanceSheetLocationAxis=pfe_OtherTaxesPayableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>212
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7047312864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other (Income)/Deductions - Net - Footnotes - Commitments and Contingencies (Details) - Pending Litigation [Member]<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Patent Matter [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="nump">$ 79<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember', window );">Celebrex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LossContingenciesLineItems', window );"><strong>Loss Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationSettlementExpense', window );">Litigation settlement expense</a></td>
<td class="nump">$ 94<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationSettlementExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationSettlementExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=us-gaap_PendingLitigationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentMatterMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingenciesByNatureOfContingencyAxis=pfe_PatentMatterMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_CelebrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_CelebrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>213
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952873984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Tax Matters - Income from Continuing Operations Before Provision for Taxes on Income (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic', window );">United States</a></td>
<td class="nump">$ 7,931<span></span>
</td>
<td class="num">$ (4,403)<span></span>
</td>
<td class="num">$ (6,879)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign', window );">International</a></td>
<td class="nump">9,751<span></span>
</td>
<td class="nump">16,288<span></span>
</td>
<td class="nump">19,184<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Income from continuing operations before provision/(benefit) for taxes on income</a></td>
<td class="nump">$ 17,682<span></span>
</td>
<td class="nump">$ 11,885<span></span>
</td>
<td class="nump">$ 12,305<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to domestic operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=116634182&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637232&amp;loc=SL114874131-224263<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109234566&amp;loc=d3e22694-107794<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=116637391&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of earnings or loss from continuing operations before income taxes that is attributable to foreign operations, which is defined as Income or Loss generated from operations located outside the entity's country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(1)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>214
<FILENAME>R161.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7034521312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment, Geographic and Other Revenue Information - Revenues By Products (Detail) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 51,750<span></span>
</td>
<td class="nump">$ 53,647<span></span>
</td>
<td class="nump">$ 52,546<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember', window );">Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">39,419<span></span>
</td>
<td class="nump">37,558<span></span>
</td>
<td class="nump">35,530<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember', window );">Biopharma, Upjohn And Consumer Healthcare Segments [Member] | HIS Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">97<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember', window );">Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Alliance Biopharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,648<span></span>
</td>
<td class="nump">3,838<span></span>
</td>
<td class="nump">2,927<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember', window );">Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Biosimilars [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">911<span></span>
</td>
<td class="nump">769<span></span>
</td>
<td class="nump">531<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember', window );">Biopharma, Upjohn And Consumer Healthcare Segments [Member] | Total Sterile Injectable Pharmaceuticals [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,035<span></span>
</td>
<td class="nump">5,214<span></span>
</td>
<td class="nump">5,673<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,119<span></span>
</td>
<td class="nump">8,869<span></span>
</td>
<td class="nump">8,229<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma Segment [Member] | Eliquis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,220<span></span>
</td>
<td class="nump">3,434<span></span>
</td>
<td class="nump">2,523<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma Segment [Member] | Chantix Champix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,107<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
<td class="nump">997<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma Segment [Member] | Premarin Family [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">734<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="nump">977<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma Segment [Member] | BMP2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">287<span></span>
</td>
<td class="nump">279<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma Segment [Member] | Toviaz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">250<span></span>
</td>
<td class="nump">271<span></span>
</td>
<td class="nump">257<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember', window );">Internal Medicine [Member] | Biopharma Segment [Member] | All Other Internal Medicine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,521<span></span>
</td>
<td class="nump">2,969<span></span>
</td>
<td class="nump">3,213<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">9,014<span></span>
</td>
<td class="nump">7,471<span></span>
</td>
<td class="nump">6,304<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Ibrance [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,961<span></span>
</td>
<td class="nump">4,118<span></span>
</td>
<td class="nump">3,126<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Sutent [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">936<span></span>
</td>
<td class="nump">1,049<span></span>
</td>
<td class="nump">1,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Xtandi Alliance Revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">838<span></span>
</td>
<td class="nump">699<span></span>
</td>
<td class="nump">590<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Xalkori [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">530<span></span>
</td>
<td class="nump">524<span></span>
</td>
<td class="nump">594<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Inlyta [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">477<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">339<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Bosulif [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">365<span></span>
</td>
<td class="nump">296<span></span>
</td>
<td class="nump">233<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Retacrit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">225<span></span>
</td>
<td class="nump">82<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Mektovi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">49<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Braftovi [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">48<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember', window );">Oncology [Member] | Biopharma Segment [Member] | Other Oncology Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">406<span></span>
</td>
<td class="nump">274<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">7,772<span></span>
</td>
<td class="nump">7,955<span></span>
</td>
<td class="nump">8,369<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Sulperazon [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">684<span></span>
</td>
<td class="nump">613<span></span>
</td>
<td class="nump">471<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Medrol [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">493<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Vfend [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">346<span></span>
</td>
<td class="nump">392<span></span>
</td>
<td class="nump">421<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Zithromax Zmax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">326<span></span>
</td>
<td class="nump">299<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Epi Pen [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">303<span></span>
</td>
<td class="nump">303<span></span>
</td>
<td class="nump">290<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Fragmin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">253<span></span>
</td>
<td class="nump">293<span></span>
</td>
<td class="nump">306<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Zyvox [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">251<span></span>
</td>
<td class="nump">236<span></span>
</td>
<td class="nump">281<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Zosyn / Tazocin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">200<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Tygacil [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">197<span></span>
</td>
<td class="nump">249<span></span>
</td>
<td class="nump">260<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Diflucan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="nump">180<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Panzyga [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">183<span></span>
</td>
<td class="nump">39<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Pfizer CentreOne [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">810<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="nump">706<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Other Anti-infectives [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,114<span></span>
</td>
<td class="nump">1,041<span></span>
</td>
<td class="nump">1,237<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember', window );">Hospital [Member] | Biopharma Segment [Member] | Other Hospital Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,436<span></span>
</td>
<td class="nump">2,797<span></span>
</td>
<td class="nump">3,182<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">6,504<span></span>
</td>
<td class="nump">6,332<span></span>
</td>
<td class="nump">6,001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma Segment [Member] | Prevenar 13/Prevnar 13 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">5,847<span></span>
</td>
<td class="nump">5,802<span></span>
</td>
<td class="nump">5,601<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma Segment [Member] | Nimenrix [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">230<span></span>
</td>
<td class="nump">140<span></span>
</td>
<td class="nump">86<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma Segment [Member] | FSME/IMMUN-TicoVac [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">220<span></span>
</td>
<td class="nump">184<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma Segment [Member] | Trumenba [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">135<span></span>
</td>
<td class="nump">116<span></span>
</td>
<td class="nump">88<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember', window );">Vaccines [Member] | Biopharma Segment [Member] | Other Vaccines Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">73<span></span>
</td>
<td class="nump">90<span></span>
</td>
<td class="nump">91<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">4,733<span></span>
</td>
<td class="nump">4,720<span></span>
</td>
<td class="nump">4,386<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Biopharma Segment [Member] | Xeljanz [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,242<span></span>
</td>
<td class="nump">1,774<span></span>
</td>
<td class="nump">1,345<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Biopharma Segment [Member] | Enbrel [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,699<span></span>
</td>
<td class="nump">2,112<span></span>
</td>
<td class="nump">2,452<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Biopharma Segment [Member] | Inflectra/Remsima [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">625<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="nump">419<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Biopharma Segment [Member] | Eucrisa [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">138<span></span>
</td>
<td class="nump">147<span></span>
</td>
<td class="nump">67<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember', window );">Inflammation and Immunology [Member] | Biopharma Segment [Member] | All Other Inflammation and Immunology Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">29<span></span>
</td>
<td class="nump">45<span></span>
</td>
<td class="nump">103<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">2,278<span></span>
</td>
<td class="nump">2,211<span></span>
</td>
<td class="nump">2,240<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma Segment [Member] | Genotropin [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">498<span></span>
</td>
<td class="nump">558<span></span>
</td>
<td class="nump">532<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma Segment [Member] | BeneFIX [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">488<span></span>
</td>
<td class="nump">554<span></span>
</td>
<td class="nump">604<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma Segment [Member] | Vyndaqel/Vyndamax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">473<span></span>
</td>
<td class="nump">148<span></span>
</td>
<td class="nump">124<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma Segment [Member] | ReFacto AF Xyntha [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">426<span></span>
</td>
<td class="nump">514<span></span>
</td>
<td class="nump">551<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma Segment [Member] | Somavert [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">264<span></span>
</td>
<td class="nump">267<span></span>
</td>
<td class="nump">254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember', window );">Rare Disease [Member] | Biopharma Segment [Member] | All Other Rare Disease Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">129<span></span>
</td>
<td class="nump">170<span></span>
</td>
<td class="nump">176<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">10,233<span></span>
</td>
<td class="nump">12,484<span></span>
</td>
<td class="nump">13,447<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Lyrica [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">3,321<span></span>
</td>
<td class="nump">4,970<span></span>
</td>
<td class="nump">5,065<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Lipitor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,973<span></span>
</td>
<td class="nump">2,062<span></span>
</td>
<td class="nump">1,915<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Norvasc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">950<span></span>
</td>
<td class="nump">1,029<span></span>
</td>
<td class="nump">932<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Celebrex [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">719<span></span>
</td>
<td class="nump">686<span></span>
</td>
<td class="nump">775<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Viagra [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">497<span></span>
</td>
<td class="nump">636<span></span>
</td>
<td class="nump">1,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Effexor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">336<span></span>
</td>
<td class="nump">311<span></span>
</td>
<td class="nump">297<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Zoloft [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">294<span></span>
</td>
<td class="nump">298<span></span>
</td>
<td class="nump">291<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Xalatan Xalacom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">281<span></span>
</td>
<td class="nump">318<span></span>
</td>
<td class="nump">335<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Xanax [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">198<span></span>
</td>
<td class="nump">223<span></span>
</td>
<td class="nump">225<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | Revatio [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">144<span></span>
</td>
<td class="nump">227<span></span>
</td>
<td class="nump">252<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember', window );">Upjohn Reporting Unit [Member] | Upjohn Segment [Member] | All Other Upjohn Products [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">1,519<span></span>
</td>
<td class="nump">1,725<span></span>
</td>
<td class="nump">2,158<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember', window );">Consumer Healthcare Reporting Unit [Member] | Consumer Healthcare [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems', window );"><strong>Revenue from External Customer [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenues</a></td>
<td class="nump">$ 2,098<span></span>
</td>
<td class="nump">$ 3,605<span></span>
</td>
<td class="nump">$ 3,472<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EntityWideInformationRevenueFromExternalCustomerLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130543-203045<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=118956577&amp;loc=SL49130545-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_BiopharmaUpjohnAndConsumerHealthcareSegmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_HISProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_HISProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalAllianceBiopharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalBiosimilarsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TotalSterileInjectablePharmaceuticalsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_InternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EliquisMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EliquisMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ChantixChampixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ChantixChampixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PremarinFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PremarinFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BMP2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BMP2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ToviazMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ToviazMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherInternalMedicineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_OncologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_OncologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_IbranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_IbranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SutentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SutentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XtandiAllianceRevenuesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XalkoriMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XalkoriMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InlytaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InlytaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BosulifMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BosulifMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RetacritMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RetacritMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MektoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MektoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BraftoviMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BraftoviMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherOncologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_HospitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_HospitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SulperazonMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SulperazonMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_MedrolMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_MedrolMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VfendMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VfendMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZithromaxZmaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EpiPenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EpiPenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FragminMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FragminMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZyvoxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZyvoxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZosynTazocinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZosynTazocinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TygacilMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TygacilMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_DiflucanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_DiflucanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PanzygaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PanzygaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PfizerCentreOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PfizerCentreOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherAntiinfectivesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherHospitalProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_VaccinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_VaccinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_PrevnarPrevenarFamilyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_NimenrixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_NimenrixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_FSMEIMMUNTicoVacMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_TrumenbaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_TrumenbaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_OtherVaccinesProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_InflammationandImmunologyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XeljanzMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XeljanzMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EnbrelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EnbrelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_InflectraRemsimaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EucrisaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EucrisaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherInflammationandImmunologyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_RareDiseaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_GenotropinMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_GenotropinMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_BeneFIXMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_BeneFIXMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_VyndaqelMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_VyndaqelMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ReFactoAfXynthaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_SomavertMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_SomavertMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherRareDiseaseProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_UpjohnReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_UpjohnSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_LyricaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_LyricaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_LipitorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_LipitorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_NorvascMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_NorvascMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_CelebrexMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_CelebrexMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ViagraMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ViagraMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_EffexorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_EffexorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_ZoloftMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_ZoloftMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XalatanXalacomMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XalatanXalacomMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_XanaxMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_XanaxMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_RevatioMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_RevatioMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=pfe_AllOtherUpjohnProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=pfe_AllOtherUpjohnProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReportingUnitAxis=pfe_ConsumerHealthcareReportingUnitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=pfe_ConsumerHealthcareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=pfe_ConsumerHealthcareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>215
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7040914832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Jan. 01, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 63,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="num">(365)<span></span>
</td>
<td class="num">$ (1,041)<span></span>
</td>
<td class="nump">$ 1,715<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">63,143<span></span>
</td>
<td class="nump">63,407<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated Other Comprehensive Income/(Loss) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(11,275)<span></span>
</td>
<td class="num">(9,321)<span></span>
</td>
<td class="num">(11,036)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Other comprehensive income/(loss) due to the adoption of new accounting standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (913)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(11,640)<span></span>
</td>
<td class="num">(11,275)<span></span>
</td>
<td class="num">(9,321)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign Currency Translation Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(6,075)<span></span>
</td>
<td class="num">(5,180)<span></span>
</td>
<td class="num">(6,659)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">123<span></span>
</td>
<td class="num">(893)<span></span>
</td>
<td class="nump">1,479<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(5,952)<span></span>
</td>
<td class="num">(6,075)<span></span>
</td>
<td class="num">(5,180)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember', window );">Derivative Financial Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">167<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="nump">348<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="num">(146)<span></span>
</td>
<td class="nump">198<span></span>
</td>
<td class="num">(378)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">20<span></span>
</td>
<td class="nump">167<span></span>
</td>
<td class="num">(30)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Available-For-Sale Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(68)<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="num">(131)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="nump">33<span></span>
</td>
<td class="num">(53)<span></span>
</td>
<td class="nump">532<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(35)<span></span>
</td>
<td class="num">(68)<span></span>
</td>
<td class="nump">401<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember', window );">Actuarial Gains/(Losses) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(6,027)<span></span>
</td>
<td class="num">(5,262)<span></span>
</td>
<td class="num">(5,473)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="num">(231)<span></span>
</td>
<td class="num">(128)<span></span>
</td>
<td class="nump">211<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(6,257)<span></span>
</td>
<td class="num">(6,027)<span></span>
</td>
<td class="num">(5,262)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember', window );">Prior Service (Costs)/Credits and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">728<span></span>
</td>
<td class="nump">750<span></span>
</td>
<td class="nump">879<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Other comprehensive income/(loss)</a></td>
<td class="num">(144)<span></span>
</td>
<td class="num">(166)<span></span>
</td>
<td class="num">(129)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 584<span></span>
</td>
<td class="nump">$ 728<span></span>
</td>
<td class="nump">$ 750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member] | Foreign Currency Translation Adjustments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Other comprehensive income/(loss) due to the adoption of new accounting standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member', window );">Accounting Standards Update 2016-01 [Member] | Available-For-Sale Securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Other comprehensive income/(loss) due to the adoption of new accounting standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(416)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member', window );">Reclassification of Certain Tax Effects from AOCI [Member] | Derivative Financial Instruments [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Other comprehensive income/(loss) due to the adoption of new accounting standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member', window );">Reclassification of Certain Tax Effects from AOCI [Member] | Actuarial Gains/(Losses) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Other comprehensive income/(loss) due to the adoption of new accounting standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(637)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member', window );">Reclassification of Certain Tax Effects from AOCI [Member] | Prior Service (Costs)/Credits and Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Income (Loss) [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption', window );">Other comprehensive income/(loss) due to the adoption of new accounting standards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) to equity or (increase) decrease to net assets, resulting from the cumulative effect adjustment of a new accounting principle applied in the period of adoption.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CumulativeEffectOfNewAccountingPrincipleInPeriodOfAdoption</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669625-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569643-111683<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669619-108580<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=108774443&amp;loc=SL4569616-111683<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedGainLossNetCashFlowHedgeParentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetUnamortizedGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedDefinedBenefitPlansAdjustmentNetPriorServiceCostCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201601Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201802Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>216
<FILENAME>R108.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7036817872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill - Finite-lived and Indefinite-lived Intangible Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">$ 91,425<span></span>
</td>
<td class="nump">$ 91,788<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(65,037)<span></span>
</td>
<td class="num">(60,743)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, less accumulated amortization</a></td>
<td class="nump">26,387<span></span>
</td>
<td class="nump">31,045<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total indefinite-lived intangible assets</a></td>
<td class="nump">8,983<span></span>
</td>
<td class="nump">4,165<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill', window );">Intangible assets, gross carrying amount</a></td>
<td class="nump">100,408<span></span>
</td>
<td class="nump">95,954<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IntangibleAssetsNetExcludingGoodwill', window );">Identifiable Intangible Assets, less Accumulated Amortization</a></td>
<td class="nump">35,370<span></span>
</td>
<td class="nump">35,211<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total indefinite-lived intangible assets</a></td>
<td class="nump">1,991<span></span>
</td>
<td class="nump">1,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember', window );">In Process Research and Development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total indefinite-lived intangible assets</a></td>
<td class="nump">5,919<span></span>
</td>
<td class="nump">2,171<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems', window );"><strong>Indefinite-lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Total indefinite-lived intangible assets</a></td>
<td class="nump">1,073<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember', window );">Developed Technology Rights [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">88,730<span></span>
</td>
<td class="nump">89,430<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(63,106)<span></span>
</td>
<td class="num">(58,895)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, less accumulated amortization</a></td>
<td class="nump">25,625<span></span>
</td>
<td class="nump">30,535<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember', window );">Brands [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">922<span></span>
</td>
<td class="nump">923<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(741)<span></span>
</td>
<td class="num">(708)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, less accumulated amortization</a></td>
<td class="nump">181<span></span>
</td>
<td class="nump">215<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember', window );">Licensing Agreements And Other [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsLineItems', window );"><strong>Finite-Lived Intangible Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsGross', window );">Finite-lived intangible assets, gross carrying amount</a></td>
<td class="nump">1,772<span></span>
</td>
<td class="nump">1,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization', window );">Finite-lived intangible assets, accumulated amortization</a></td>
<td class="num">(1,191)<span></span>
</td>
<td class="num">(1,140)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsNet', window );">Finite-lived intangible assets, less accumulated amortization</a></td>
<td class="nump">$ 582<span></span>
</td>
<td class="nump">$ 296<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated amount of amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsAccumulatedAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 928<br> -SubTopic 340<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6473545&amp;loc=d3e61844-108004<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after amortization of assets, excluding financial assets and goodwill, lacking physical substance with a finite life.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsGrossExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated amortization of intangible assets, excluding goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsGrossExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IntangibleAssetsNetExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts of all intangible assets, excluding goodwill, as of the balance sheet date, net of accumulated amortization and impairment charges.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph ((a)(1),(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388964&amp;loc=d3e16212-109274<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IntangibleAssetsNetExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_InProcessResearchAndDevelopmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_DevelopedTechnologyRightsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_TradeNamesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=pfe_LicensingAgreementsAndOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>217
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952647376">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_FinancialInstrumentsAbstract', window );"><strong>Financial Instruments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsDisclosureTextBlock', window );">Financial Instruments</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Financial Instruments</span><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">A. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Fair Value Measurements</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Financial Assets and Liabilities Measured at Fair Value on a Recurring Basis</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:42%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">The following table presents the financial assets and liabilities measured at fair value using a market approach on a recurring basis by balance sheet categories and fair value hierarchy level as defined in </span><span style="font-family:Arial;font-size:7.5pt;font-style:italic;">Note 1E</span><span style="font-family:Arial;font-size:7.5pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financial assets measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as equity securities with readily determinable fair values:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Money market funds</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Equity</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>29</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,583</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>9,609</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>9,609</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>811</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>811</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>3,437</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,013</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>2,045</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>15,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>15,091</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>7,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>7,392</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>16,691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>17</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>16,674</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>97</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>413</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>413</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>477</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>465</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>574</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as equity securities with readily determinable fair values</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>39</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,273</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Classified as available-for-sale debt securities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>94</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Government and agency&#8212;U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>345</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Corporate and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>52</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>2,216</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>354</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,764</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,243</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>521</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative assets:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>266</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>266</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>335</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>261</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>232</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total derivative assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>526</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>526</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>566</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Insurance contracts</span><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>515</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,102</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,082</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>11,176</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1,863</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>9,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>20,110</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>18,850</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Financial liabilities measured at fair value on a recurring basis:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>78</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>114</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Derivative liabilities:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>378</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>378</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>604</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>604</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>564</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>604</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>942</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, long-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$176 million</span></span><span style="font-family:Arial;font-size:7pt;"> are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans. </span><span style="font-family:Arial;font-size:7pt;text-align:center;">As of </span><span style="font-family:Arial;font-size:7pt;text-align:center;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;">, short-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$11 million</span></span><span style="font-family:Arial;font-size:7pt;"> and long-term equity securities of </span><span style="font-family:Arial;font-size:7pt;"><span>$132 million</span></span><span style="font-family:Arial;font-size:7pt;"> are held in restricted trusts for benefits attributable to various U.S. non-qualified employee benefit plans.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other noncurrent assets include life insurance policies held in restricted trusts attributable to the funding of various U.S. non-qualified employee benefit plans. The underlying invested assets in these insurance contracts are marketable securities, which are carried at fair value, with changes in fair value recognized in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Financial Assets and Liabilities Not Measured at Fair Value on a Recurring Basis</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:36%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table presents the financial liabilities not measured at fair value on a recurring basis, including the carrying values and estimated fair values using a market approach:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Estimated Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Carrying Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Estimated Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Level 2</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-style:italic;font-weight:bold;">Financial Liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Long-term debt, excluding the current portion</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>35,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>40,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>40,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>32,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>35,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><span>35,260</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The differences between the estimated fair values and carrying values of held-to-maturity debt securities, restricted stock and private equity securities, and short-term borrowings not measured at fair value on a recurring basis were not significant as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> or </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">. The fair value measurements of our held-to-maturity debt securities and our short-term borrowings are based on Level 2 inputs. The fair value measurements of our private equity securities, which represent investments in the life sciences sector, are based on Level 3 inputs using a market approach.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In addition, as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, we had long-term receivables whose fair value is based on Level 3 inputs. As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, the differences between the estimated fair values and carrying values of these receivables were not significant.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Total Short-Term and Long-Term Investments and Equity-Method Investments</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table represents our investments by classification type:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities with readily determinable fair values</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>705</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,600</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,687</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,091</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,133</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,003</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Total Short-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,525</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>17,694</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities with readily determinable fair values</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,902</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,273</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>315</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>491</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>59</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Private equity securities at cost</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>756</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Total Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,014</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,586</span></span></div></td><td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;font-weight:bold;">Equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>17,133</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>181</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term investments and equity-method investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>20,147</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;background-color:;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,767</span></span></div></td><td style="vertical-align:bottom;background-color:;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Held-to-maturity cash equivalents</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>163</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>199</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">As of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:7pt;">, equity securities with readily determinable fair values included money market funds primarily invested in U.S. Treasury and government debt.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Fair Value Methodology</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following inputs and valuation techniques were used to estimate the fair value of our financial assets and liabilities:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Available-for-sale debt securities&#8212;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data and credit-adjusted interest rate yield curves. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity securities with readily determinable fair values&#8212;quoted market prices and observable net asset value prices.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative assets and liabilities&#8212;third-party matrix-pricing model that uses significant inputs derived from or corroborated by observable market data. Where applicable, these models discount future cash flow amounts using market-based observable inputs, including interest rate yield curves, and forward and spot prices for currencies. The credit risk impact to our derivative financial instruments was not significant.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Money market funds&#8212;observable net asset value prices.</span></div></td></tr></table><div style="line-height:120%;padding-bottom:10px;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We periodically review the methodologies, inputs and outputs of third-party pricing services for reasonableness. Our procedures can include, for example, referencing other third-party pricing models, monitoring key observable inputs (like LIBOR interest rates) and selectively performing test-comparisons of values with actual sales of financial instruments.</span></div><div style="line-height:120%;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">B. Investments</span></div><div style="line-height:120%;padding-top:10px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Debt Securities</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="45"/></tr><tr><td style="width:20%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:5%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:4%;"/><td style="width:1%;"/></tr><tr><td colspan="45" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At December 31, 2019, the investment securities portfolio consisted of debt securities that were virtually all investment-grade. Information on investments in debt securities at December 31, 2019 and December 31, 2018 is as follows, including, as of December 31, 2019, the contractual maturities, or as necessary, the estimated maturities, of the available-for-sale and held-to-maturity debt securities:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="28" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">December 31, 2019</span></div></td><td colspan="15" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="12" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Maturities (in Years)</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="6" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gross Unrealized</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:justify;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Within 1</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 1<br/>to 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Over 5</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Amortized Cost</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Gains</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Losses</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Fair Value</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Available-for-sale debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,895</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(38</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4,863</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>9,754</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(58</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>9,703</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,120</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(6</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,114</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>811</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>303</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,804</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(23</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>3,782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Corporate and other</span><span style="font-family:Arial;font-size:6.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,027</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(2</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,025</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>1,014</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>11</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,101</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(4</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>2,097</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:middle;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;text-decoration:underline;">Held-to-maturity debt securities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Time deposits and other</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>535</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>498</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>30</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>668</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-6px;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Government and agency</span><span style="font-family:Arial;font-size:6.5pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:6.5pt;">non-U.S.</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>798</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>4</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>592</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">Total debt securities</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>8,380</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>6</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>(47</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>8,340</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>7,984</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>322</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;font-weight:bold;"><span>35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>16,920</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>8</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>(85</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;"><span>16,842</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily issued by a diverse group of corporations.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Equity Securities</span></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table presents the net unrealized (gains) and losses for the period that relate to equity securities, excluding equity method investments, still held at the reporting date, calculated as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net gains recognized during the period on equity securities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(454</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(586</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Less: Net gains recognized during the period on equity securities sold during the period</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#e5e5e5;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(25</span></span></div></td><td style="vertical-align:bottom;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(109</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unrealized gains during the reporting period on equity securities still held at the reporting date</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#e5e5e5;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(429</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#e5e5e5;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The net gains on equity securities are reported in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions</span><span style="font-family:Arial;font-size:7pt;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">net.</span><span style="font-family:Arial;font-size:7pt;"> For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:7pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">C. Short-Term Borrowings</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Short-term borrowings include:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Commercial paper </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>13,915</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,100</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current portion of long-term debt, principal amount</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,458</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,781</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other short-term borrowings, principal amount</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>860</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>966</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total short-term borrowings, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,233</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,847</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(43</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(11</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span><span style="font-family:Arial;font-size:8pt;">, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>16,195</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>8,831</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7D</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other short-term borrowings primarily include cash collateral. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 7F</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The weighted-average effective interest rate on commercial paper outstanding was approximately </span><span style="font-family:Arial;font-size:8pt;"><span>1.92%</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>2.42%</span></span><span style="font-family:Arial;font-size:8pt;"> as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had access to a total of </span><span style="font-family:Arial;font-size:8pt;"><span>$15 billion</span></span><span style="font-family:Arial;font-size:8pt;"> in U.S. revolving credit facilities consisting of a </span><span style="font-family:Arial;font-size:8pt;"><span>$7 billion</span></span><span style="font-family:Arial;font-size:8pt;"> facility expiring in 2024 and an </span><span style="font-family:Arial;font-size:8pt;"><span>$8 billion</span></span><span style="font-family:Arial;font-size:8pt;"> facility expiring in September 2020, which may be used to support our commercial paper borrowings. In addition to the U.S. revolving credit facilities, our lenders have provided us an additional </span><span style="font-family:Arial;font-size:8pt;"><span>$537 million</span></span><span style="font-family:Arial;font-size:8pt;"> in lines of credit, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$508 million</span></span><span style="font-family:Arial;font-size:8pt;"> expire within one year. Of these total lines of credit, </span><span style="font-family:Arial;font-size:8pt;"><span>$15.5 billion</span></span><span style="font-family:Arial;font-size:8pt;"> were unused as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">D. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Long-Term Debt</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;"> </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">New Issuances</span></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:99.8015873015873%;border-collapse:collapse;text-align:left;"><tr><td colspan="7"/></tr><tr><td style="width:62%;"/><td style="width:1%;"/><td style="width:18%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:16%;"/><td style="width:1%;"/></tr><tr><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In the first quarter of 2019, we issued the following senior unsecured notes:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Principal</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest Rate</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Maturity Date</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">As of December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.800% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;11, 2022</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>500</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2.950% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2024</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.450% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2029</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">3.900% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2039</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">4.000% notes</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">March&#160;15, 2049</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,250</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt issued in the first quarter of 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,000</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Fixed rate notes may be redeemed by us at any time, in whole, or in part, at varying redemption prices plus accrued and unpaid interest.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The weighted-average effective interest rate for the notes at issuance was </span><span style="font-family:Arial;font-size:7pt;"><span>3.57%</span></span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In September 2018, we completed a public offering of </span><span style="font-family:Arial;font-size:8pt;"><span>$5.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> aggregate principal amount of senior unsecured notes with a weighted-average effective interest rate of </span><span style="font-family:Arial;font-size:8pt;"><span>3.56%</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In March 2017, we completed a public offering of </span><span style="font-family:Arial;font-size:8pt;"><span>$1.065 billion</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of senior unsecured notes due 2047 with an interest rate of </span><span style="font-family:Arial;font-size:8pt;"><span>4.20%</span></span><span style="font-family:Arial;font-size:8pt;">, and also in March 2017, we completed a public offering of &#8364;</span><span style="font-family:Arial;font-size:8pt;"><span>4.0 billion</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of senior unsecured notes with a weighted-average effective interest rate of </span><span style="font-family:Arial;font-size:8pt;"><span>0.23%</span></span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Retirements</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In January 2019, we repurchased all </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;1.1 billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$1.3 billion</span></span><span style="font-family:Arial;font-size:8pt;">, at exchange rates on settlement) principal amount outstanding of the </span><span style="font-family:Arial;font-size:8pt;"><span>5.75%</span></span><span style="font-family:Arial;font-size:8pt;"> euro-denominated debt that was due June 2021 before the maturity date at a redemption value of </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;1.3 billion</span></span><span style="font-family:Arial;font-size:8pt;"> (</span><span style="font-family:Arial;font-size:8pt;"><span>$1.5 billion</span></span><span style="font-family:Arial;font-size:8pt;">, at exchange rates on settlement). As a result, in the first quarter of 2019, we recorded a net loss of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$138 million</span></span><span style="font-family:Arial;font-size:8pt;">, which included the related termination of cross-currency swaps, and is reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:8pt;">in the consolidated statements of income (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2017, we exchanged approximately </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;833 million</span></span><span style="font-family:Arial;font-size:8pt;"> and repurchased </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;197 million</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of the outstanding </span><span style="font-family:Arial;font-size:8pt;"><span>6.50%</span></span><span style="font-family:Arial;font-size:8pt;"> debt before the maturity date at a redemption value of </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;1.7 billion</span></span><span style="font-family:Arial;font-size:8pt;">, leaving </span><span style="font-family:Arial;font-size:8pt;"><span>&#163;470 million</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of the </span><span style="font-family:Arial;font-size:8pt;"><span>6.50%</span></span><span style="font-family:Arial;font-size:8pt;"> debt due 2038 outstanding. Also, in December 2017, we repurchased approximately </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;834 million</span></span><span style="font-family:Arial;font-size:8pt;"> principal amount of the outstanding </span><span style="font-family:Arial;font-size:8pt;"><span>5.75%</span></span><span style="font-family:Arial;font-size:8pt;"> debt before the maturity date at a redemption value of </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;1.0 billion</span></span><span style="font-family:Arial;font-size:8pt;">, leaving approximately </span><span style="font-family:Arial;font-size:8pt;"><span>&#8364;1.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> of the </span><span style="font-family:Arial;font-size:8pt;"><span>5.75%</span></span><span style="font-family:Arial;font-size:8pt;"> euro-denominated debt due 2021 outstanding as of December 31, 2017. As a result, we recorded a net loss of approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$846 million</span></span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$153 million</span></span><span style="font-family:Arial;font-size:8pt;"> upon the exchange and early retirement of the U.K. pound-denominated debt and the early retirement of the euro-denominated debt, respectively, for a net loss on early retirement of debt of </span><span style="font-family:Arial;font-size:8pt;"><span>$999 million</span></span><span style="font-family:Arial;font-size:8pt;">, which included the related termination of cross-currency swaps, and that were recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> in the consolidated statement of income (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of our senior unsecured long-term debt, including the weighted-average stated interest rate for 2019 and 2018 by maturity:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2020 (1.2%)</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,474</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2021 (0.7% and 3.4%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,153</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2022 (1.0% and 0.3%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,624</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2023 (3.7% and 3.8%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,892</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2024 (3.9% and 4.4%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,250</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,500</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2026-2029 (3.3%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,453</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,718</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2034 (6.5%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>750</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2036-2040 (5.8% and 6.0%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,566</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,796</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2043-2044 (3.5%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,568</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,509</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notes due 2046-2049 (4.1% and 4.2%)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,565</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,315</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt, principal amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>34,820</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>32,558</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net fair value adjustments related to hedging and purchase accounting</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,305</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>479</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net unamortized discounts, premiums and debt issuance costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(176</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(136</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total long-term debt, carried at historical proceeds, as adjusted</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35,955</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>32,909</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current portion of long-term debt, carried at historical proceeds (not included above (1.2% and 1.3%))</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,462</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">At December 31, </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, the debt issuances have been reclassified to the current portion of long-term debt.</span></div></td></tr></table><div style="line-height:120%;padding-left:12px;text-indent:-12px;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our long-term debt, provided in the above table, is generally redeemable by us at any time at varying redemption prices plus accrued and unpaid interest.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">E. Other Noncurrent Liabilities</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Mylotarg (gemtuzumab ozogamicin)</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In April 2018, the EU approved Mylotarg for the treatment of acute myeloid leukemia. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">ten</span><span style="font-family:Arial;font-size:8pt;">-year period aggregating </span><span style="font-family:Arial;font-size:8pt;"><span>$301 million</span></span><span style="font-family:Arial;font-size:8pt;"> related to an R&amp;D arrangement. We recorded the estimated net present value of </span><span style="font-family:Arial;font-size:8pt;"><span>$240 million</span></span><span style="font-family:Arial;font-size:8pt;"> as a liability and an intangible asset in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;"> as of the approval date. In June 2018, we entered into a transaction with the obligee to buyout the remaining liability for the fixed annual payments for a lump sum payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$224 million</span></span><span style="font-family:Arial;font-size:8pt;">. As a result of the buyout transaction, the liability was extinguished and we recognized a non-cash </span><span style="font-family:Arial;font-size:8pt;"><span>$17&#160;million</span></span><span style="font-family:Arial;font-size:8pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> in the second quarter of 2018 (see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 4</span><span style="font-family:Arial;font-size:8pt;">).</span></div><div style="line-height:120%;padding-bottom:6px;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Bosulif (bosutinib)</span></div><div style="line-height:120%;padding-bottom:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In December 2017, the FDA approved Bosulif for the treatment of patients with newly-diagnosed chronic-phase Ph+ CML. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">ten</span><span style="font-family:Arial;font-size:8pt;">-year period aggregating </span><span style="font-family:Arial;font-size:8pt;"><span>$416 million</span></span><span style="font-family:Arial;font-size:8pt;"> related to an R&amp;D arrangement. We recorded the estimated net present value of </span><span style="font-family:Arial;font-size:8pt;"><span>$364 million</span></span><span style="font-family:Arial;font-size:8pt;"> as of the approval date as an intangible asset in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. In August 2018, we entered into a transaction with the obligee to buyout a portion of the remaining liability for the fixed annual payments for a lump sum payment of </span><span style="font-family:Arial;font-size:8pt;"><span>$71 million</span></span><span style="font-family:Arial;font-size:8pt;">. As a result of the buyout transaction, the liability was reduced and we recognized a non-cash </span><span style="font-family:Arial;font-size:8pt;"><span>$9 million</span></span><span style="font-family:Arial;font-size:8pt;"> pre-tax gain in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"> in the third quarter of 2018</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:8pt;"> The present value of the remaining future payments as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$191 million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$22 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$169 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Besponsa (inotuzumab ozogamicin)</span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In August 2017, the FDA approved Besponsa and in June 2017, the EU approved Besponsa as monotherapy for the treatment of adults with relapsed or refractory CD22-positive B-cell precursor acute lymphoblastic leukemia. In connection with the U.S. approval, we incurred an obligation to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">nine</span><span style="font-family:Arial;font-size:8pt;">-year period aggregating </span><span style="font-family:Arial;font-size:8pt;"><span>$296 million</span></span><span style="font-family:Arial;font-size:8pt;"> related to an R&amp;D arrangement. We recorded the estimated net present value of </span><span style="font-family:Arial;font-size:8pt;"><span>$248 million</span></span><span style="font-family:Arial;font-size:8pt;"> as of the approval date as an intangible asset in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. The present value of the remaining future payments as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$242 million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$7 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$235 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">. In connection with the EU approval, we incurred an obligation to make guaranteed fixed annual payments over a </span><span style="font-family:Arial;font-size:8pt;">nine</span><span style="font-family:Arial;font-size:8pt;">-year period aggregating </span><span style="font-family:Arial;font-size:8pt;"><span>$148 million</span></span><span style="font-family:Arial;font-size:8pt;"> related to an R&amp;D arrangement. We recorded the estimated net present value of </span><span style="font-family:Arial;font-size:8pt;"><span>$123 million</span></span><span style="font-family:Arial;font-size:8pt;"> as of the approval date as an intangible asset in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:8pt;">. The present value of the remaining future payments as of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> is </span><span style="font-family:Arial;font-size:8pt;"><span>$122 million</span></span><span style="font-family:Arial;font-size:8pt;">, of which </span><span style="font-family:Arial;font-size:8pt;"><span>$3 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;"><span>$119 million</span></span><span style="font-family:Arial;font-size:8pt;"> is recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:8pt;">.</span></div><div style="line-height:120%;text-align:left;font-size:5pt;"><span style="font-family:Arial;font-size:5pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;"> and </span><span style="font-family:Arial;font-size:8pt;">2018</span><span style="font-family:Arial;font-size:8pt;">, the differences between&#160;the estimated fair values, using a market approach in the Level 2 fair value hierarchy, and carrying values of these obligations were not significant.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">F</span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">. </span><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">Derivative Financial Instruments and Hedging Activities</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Foreign Exchange Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">A significant portion of our revenues, earnings and net investments in foreign affiliates is exposed to changes in foreign exchange rates. We manage our foreign exchange risk, in part, through operational means, including managing same-currency revenues in relation to same-currency costs and same-currency assets in relation to same-currency liabilities. We also manage our foreign exchange risk, depending on market conditions, through fair value, cash flow, and net investment hedging programs through the use of derivative financial instruments and foreign currency debt. These financial instruments serve to protect net income against the impact of remeasurement into another currency, or against the impact of translation into U.S. dollars of certain foreign exchange-denominated transactions.</span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All derivative financial instruments used to manage foreign currency risk are measured at fair value and are reported as assets or liabilities on the consolidated balance sheet. The derivative financial instruments primarily hedge or offset exposures in the </span><span style="font-family:Arial;font-size:8pt;">euro, U.K. pound, Japanese yen, Chinese renminbi and Swedish krona</span><span style="font-family:Arial;font-size:8pt;">. Changes in fair value are reported in earnings or in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;">, depending on the nature and purpose of the financial instrument (hedge or offset relationship) and the effectiveness of the hedge relationships, as follows: </span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Generally, we recognize the gains and losses on foreign exchange contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach. We also recognize the offsetting foreign exchange impact attributable to the hedged item in earnings.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Generally, we record in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;"> gains or losses on foreign exchange contracts that are designated as cash flow hedges and reclassify those amounts, as appropriate, into earnings in the same period or periods during which the hedged transaction affects earnings. For certain foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-bottom:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We record in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:8pt;"> the foreign exchange gains and losses related to foreign exchange-denominated debt and foreign exchange contracts designated as a hedge of our net investments in foreign subsidiaries and reclassify those amounts into earnings upon the sale or substantial liquidation of our net investments. For foreign exchange contracts, we exclude an amount from the assessment of hedge effectiveness and recognize that excluded amount through an amortization approach.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For certain foreign exchange contracts not designated as hedging instruments, we recognize the gains and losses on foreign currency exchange contracts that are used to offset the same foreign currency assets or liabilities immediately into earnings along with the earnings impact of the items they generally offset. These contracts essentially take the opposite currency position of that reflected in the month-end balance sheet to counterbalance the effect of any currency movement.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As a part of our cash flow hedging program, we designate foreign exchange contracts to hedge a portion of our forecasted </span><span style="font-family:Arial;font-size:8pt;">euro, Japanese yen, Chinese renminbi, Canadian dollar, U.K. pound and Australian dollar</span><span style="font-family:Arial;font-size:8pt;">-denominated intercompany inventory sales expected to occur no more than </span><span style="font-family:Arial;font-size:8pt;"><span>two years</span></span><span style="font-family:Arial;font-size:8pt;"> from the date of each hedge. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For 2017, any ineffectiveness was recognized immediately into earnings. There was no significant ineffectiveness for 2017.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Interest Rate Risk</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our interest-bearing investments and borrowings are subject to interest rate risk. With respect to our investments, we strive to maintain a predominantly floating-rate basis position, but our strategy may change based on prevailing market conditions. We currently borrow primarily on a long-term, fixed-rate basis. From time to time, depending on market conditions, we will change the profile of our outstanding debt by entering into derivative financial instruments like interest rate swaps. We entered into derivative financial instruments to hedge or offset the fixed interest rates on the hedged item, matching the amount and timing of the hedged item. The derivative financial instruments primarily hedge U.S. dollar fixed-rate debt.</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;padding-bottom:4px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All derivative contracts used to manage interest rate risk are measured at fair value and reported as assets or liabilities on the consolidated balance sheet. Changes in fair value are reported in earnings, as follows:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:6px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We recognize the gains and losses on interest rate contracts that are designated as fair value hedges in earnings upon the recognition of the change in fair value of the hedged risk. We also recognize the offsetting earnings impact of fixed-rate debt attributable to the hedged risk in earnings.</span></div></td></tr></table><div style="line-height:120%;font-size:10pt;"><span style="font-family:Arial;font-size:8pt;">For 2017, any ineffectiveness was recognized immediately into earnings. There was no significant ineffectiveness for 2017.</span><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the fair value of the derivative financial instruments and the related notional amounts presented between those derivatives that are designated as hedging instruments and those that are not designated as hedging instruments:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December&#160;31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Fair Value</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Notional</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Liability</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>25,193</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>591</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>22,984</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>654</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>586</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,645</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>318</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>11,145</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>432</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>383</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>909</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>662</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,085</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>968</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Derivatives not designated as hedging instruments:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>19,623</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>82</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>15,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>992</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>718</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,140</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,024</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The notional amount of outstanding foreign currency forward-exchange contracts hedging our intercompany forecasted inventory sales was </span><span style="font-family:Arial;font-size:7pt;"><span>$5.9 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$5.8 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of December 31, 2018.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:34%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides information about the gains/(losses) incurred to hedge or offset operational foreign exchange or interest rate risk:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of<br/>Gains/(Losses)<br/>Recognized in OID</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of Gains/(Losses)<br/>Recognized in OCI</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount of Gains/(Losses)<br/>Reclassified from<br/>OCI into OID and COS</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a), (b)</sup></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="23" style="vertical-align:middle;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:top;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Cash Flow Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#160;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>339</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>80</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>525</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(182</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amount excluded from effectiveness testing recognized in earnings based on an amortization approach</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>136</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>140</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>140</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>153</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Fair Value Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Interest rate contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>900</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(348</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(900</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedged item </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(313</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>175</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:18px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The portion on foreign exchange contracts excluded from the assessment of hedge effectiveness</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>188</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>77</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>144</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Non-Derivative Financial Instruments in Net Investment Hedge Relationships:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency short-term borrowings</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>34</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>68</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign currency long-term debt</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>36</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>149</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Derivative Financial Instruments Not Designated as Hedges:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Foreign exchange contracts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(172</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All other net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">&#8212;</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">&#8212;</span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(172</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>421</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>688</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>808</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>41</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">OID = Other (income)/deductions&#8212;net,</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">&#160;</span><span style="font-family:Arial;font-size:7pt;">included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8212;net</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span><span style="font-family:Arial;font-size:7pt;"> COS = Cost of Sales, included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:7pt;"> in the consolidated statements of income. OCI = Other comprehensive income/(loss), included in the consolidated statements of comprehensive income</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">For derivative financial instruments in cash flow hedge relationships, the gains and losses are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other comprehensive income/(loss)&#8211;&#8211;Unrealized holding gains/(losses) on derivative financial instruments, net</span><span style="font-family:Arial;font-size:7pt;">. For derivative financial instruments in net investment hedge relationships and for foreign currency debt designated as hedging instruments, the gains and losses are included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other comprehensive income/(loss)&#8211;&#8211;Foreign currency translation adjustments, net.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">The amounts reclassified from OCI into COS were a net </span><span style="font-family:Arial;font-size:7pt;">gain</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$247 million</span></span><span style="font-family:Arial;font-size:7pt;"> in 2019 and a net </span><span style="font-family:Arial;font-size:7pt;">loss</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$13 million</span></span><span style="font-family:Arial;font-size:7pt;"> in 2018. The remaining amounts were reclassified from OCI into OID. Based on year-end foreign exchange rates that are subject to change, we expect to reclassify a pre-tax </span><span style="font-family:Arial;font-size:7pt;">gain</span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;"><span>$145 million</span></span><span style="font-family:Arial;font-size:7pt;"> within the next 12 months into </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Cost of sales. </span><span style="font-family:Arial;font-size:7pt;">The maximum length of time over which we are hedging future foreign exchange cash flow relates to our </span><span style="font-family:Arial;font-size:7pt;"><span>$1.8 billion</span></span><span style="font-family:Arial;font-size:7pt;"> U.K. pound debt maturing in 2043. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">These amounts were reclassified from OCI into OID. </span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Short-term borrowings include foreign currency short-term borrowings with carrying values of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, which are used as hedging instruments in net investment hedges. Long-term debt includes foreign currency long-term borrowings with carrying values of </span><span style="font-family:Arial;font-size:7pt;"><span>$2.0 billion</span></span><span style="font-family:Arial;font-size:7pt;"> as of </span><span style="font-family:Arial;font-size:7pt;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:7pt;">, which are used as hedging instruments in net investment hedges.</span></div></td></tr></table><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:99.0079365079365%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:24%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts recorded in our consolidated balance sheet related to cumulative basis adjustments for fair value hedges:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, 2018</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Value Hedging Adjustment</span></div><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Increase/(Decrease) to <br/>Carrying Amount</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cumulative Amount of Fair Value Hedging Adjustment Increase/(Decrease) to <br/>Carrying Amount</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Hedging</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Carrying Amount of Hedged Assets/Liabilities</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Active Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Discontinued Hedging Relationships</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term investments</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>45</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>45</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,499</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(5</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Long-term debt</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,092</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>266</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>690</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(45</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>129</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7.5pt;padding-left:0px;"><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Carrying amounts exclude the cumulative amount of fair value hedging adjustments.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Certain of our derivative financial instruments are covered by associated credit-support agreements that have credit-risk-related contingent features designed to reduce both counterparties&#8217; exposure to risk of defaulting on amounts owed by the other party. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, the aggregate fair value of these derivative financial instruments that are in a net liability position was </span><span style="font-family:Arial;font-size:8pt;"><span>$449 million</span></span><span style="font-family:Arial;font-size:8pt;">, for which we have posted collateral of </span><span style="font-family:Arial;font-size:8pt;"><span>$470 million</span></span><span style="font-family:Arial;font-size:8pt;"> in the normal course of business. If there had been a downgrade to below an A rating by S&amp;P or the equivalent rating by Moody&#8217;s, we would not have been required to post any additional collateral to our counterparties. </span></div><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we received cash collateral of </span><span style="font-family:Arial;font-size:8pt;"><span>$835 million</span></span><span style="font-family:Arial;font-size:8pt;"> from various counterparties. The collateral primarily supports the approximate fair value of our derivative contracts. With respect to the collateral received, the obligations are reported in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Short-term borrowings, including current portion of long-term debt.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:9pt;"><span style="font-family:Arial;font-size:9pt;font-weight:bold;text-decoration:underline;">G. Credit Risk</span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">On an ongoing basis, we review the creditworthiness of counterparties to our foreign exchange and interest rate agreements and do not expect to incur a significant loss from failure of any counterparties to perform under the agreements. There are no significant concentrations of credit risk related to our financial instruments with any individual counterparty. For additional information about concentrations of credit risk related to certain significant customers, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17C</span><span style="font-family:Arial;font-size:8pt;">. As of </span><span style="font-family:Arial;font-size:8pt;text-align:center;">December&#160;31, 2019</span><span style="font-family:Arial;font-size:8pt;">, we had amounts due from a well-diversified, high quality group of banks (</span><span style="font-family:Arial;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:Arial;font-size:8pt;">) from around the world. For details about our investments, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7B </span><span style="font-family:Arial;font-size:8pt;">above</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">. </span></div><div style="line-height:120%;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In general, there is no requirement for collateral from customers. However, derivative financial instruments are executed under credit-support agreements that provide for the ability to request to receive cash collateral, depending on levels of exposure, our credit rating and the credit rating of the counterparty, see </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 7F</span><span style="font-family:Arial;font-size:8pt;"> above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_FinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Financial Instruments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_FinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments. This disclosure includes, but is not limited to, fair value measurements of short and long term marketable securities, international currencies forward contracts, and auction rate securities. Financial instruments may include hedging and non-hedging currency exchange instruments, derivatives, securitizations and securities available for sale at fair value. Also included are investment results, realized and unrealized gains and losses as well as impairments and risk management disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>218
<FILENAME>R100.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7042797056">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Financial Instruments - Fair Value of Derivative Financial Instruments and Related Notional Amounts (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">$ 992<span></span>
</td>
<td class="nump">$ 1,140<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">718<span></span>
</td>
<td class="nump">1,024<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember', window );">Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">909<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">968<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">25,193<span></span>
</td>
<td class="nump">22,984<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">591<span></span>
</td>
<td class="nump">654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">662<span></span>
</td>
<td class="nump">586<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign exchange contracts [Member] | Not Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">19,623<span></span>
</td>
<td class="nump">15,154<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">82<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">55<span></span>
</td>
<td class="nump">55<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember', window );">Interest rate contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">6,645<span></span>
</td>
<td class="nump">11,145<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeAssets', window );">Derivative asset</a></td>
<td class="nump">318<span></span>
</td>
<td class="nump">432<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLiabilities', window );">Derivative liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">383<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_HedgedItemAxis=us-gaap_SalesMember', window );">Sales [Member] | Foreign exchange contracts [Member] | Designated as Hedging Instrument [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNotionalAmount', window );">Derivative, notional amount</a></td>
<td class="nump">$ 5,900<span></span>
</td>
<td class="nump">$ 5,800<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial asset or other contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes assets not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset. Includes liabilities not subject to a master netting arrangement and not elected to be offset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=51824906&amp;loc=SL20225862-175312<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=118260190&amp;loc=d3e13433-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 20<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99393222&amp;loc=SL20226008-175313<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNotionalAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Nominal or face amount used to calculate payment on derivative.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1B<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5580258-113959<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5579245-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNotionalAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_DesignatedAsHedgingInstrumentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_HedgingDesignationAxis=us-gaap_NondesignatedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_InterestRateContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_HedgedItemAxis=us-gaap_SalesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_HedgedItemAxis=us-gaap_SalesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>219
<FILENAME>R104.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7190454080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Financial Instruments - Narrative (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2019 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue', window );">Derivatives in a net liability position</a></td>
<td class="nump">$ 449<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollateralAlreadyPostedAggregateFairValue', window );">Collateral posted</a></td>
<td class="nump">470<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SecuritiesReceivedAsCollateral', window );">Cash collateral received</a></td>
<td class="nump">$ 835<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember', window );">Foreign Exchange Contract [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeLineItems', window );"><strong>Derivative [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeTermOfContract', window );">Derivative term of contract</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollateralAlreadyPostedAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value of assets that are already posted, at the end of the reporting period, as collateral for derivative instruments with credit-risk-related contingent features.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollateralAlreadyPostedAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeNetLiabilityPositionAggregateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate fair value amounts of derivative instruments that contain credit-risk-related contingent features that are in a net liability position at the end of the reporting period. For nonderivative instruments that are designated and qualify as hedging instruments, the fair value amounts are the carrying value of the nonderivative hedging instrument, including the adjustment for the foreign currency transaction gain (loss) on that instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4H<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109980867&amp;loc=SL5624258-113959<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeNetLiabilityPositionAggregateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period the derivative contract is outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SecuritiesReceivedAsCollateral">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the assets received as collateral against securities loaned to other broker-dealers. Borrowers of securities generally are required to provide collateral to the lenders of securities, commonly cash but sometimes other securities or standby letters of credit, with a value slightly higher than that of the securities borrowed. In instances where the entity is permitted to sell or re-pledge these securities, the entity reports the fair value of the collateral received and the related obligation to return the collateral as a liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (b)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109249958&amp;loc=SL6224234-111729<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 860<br> -SubTopic 10<br> -Section 05<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=109246787&amp;loc=d3e93645-111703<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SecuritiesReceivedAsCollateral</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_ForeignExchangeContractMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>220
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952577648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</a></td>
<td class="text"><span style="font-family:Arial;font-size:11pt;font-weight:bold;text-decoration:underline;">Restructuring Charges and Other Costs Associated with Acquisitions and Cost-Reduction/Productivity Initiatives</span><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We incur significant costs in connection with acquiring, integrating and restructuring businesses and in connection with our global cost-reduction/productivity initiatives. For example:</span></div><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with acquisition activity, we typically incur costs associated with executing the transactions, integrating the acquired operations (which may include expenditures for consulting and the integration of systems and processes), and restructuring the combined company (which may include charges related to employees, assets and activities that will not continue in the combined company); and</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="padding-top:4px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In connection with our cost-reduction/productivity initiatives, we typically incur costs and charges associated with site closings and other facility rationalization actions, workforce reductions and the expansion of shared services, including the development of global systems.</span></div></td></tr></table><div style="line-height:120%;padding-top:6px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">All of our businesses and functions may be impacted by these actions, including sales and marketing, manufacturing and R&amp;D, as well as groups such as information technology, shared services and corporate operations. </span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">2017-2019 Initiatives and Organizing for Growth</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">During 2018, we determined that at the start of our 2019 fiscal year, we would begin operating under our new commercial structure, which reorganized our operations into three businesses</span><span style="font-family:Arial;font-size:8pt;font-style:italic;">&#8211;&#8211;</span><span style="font-family:Arial;font-size:8pt;">Biopharma,</span><span style="font-family:Arial;font-size:8pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:8pt;">a science-based innovative medicines business; Upjohn, a global, primarily off-patent branded and generic established medicines business; and through July 31, 2019, a Consumer Healthcare business (See </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Note 17</span><span style="font-family:Arial;font-size:8pt;">). To operate effectively in this structure and position ourselves for future growth, we focused on creating a simpler, more efficient operating structure within each business as well as the functions that support them. Beginning in the fourth quarter of 2018, we reviewed previously planned initiatives and new initiatives to ensure that there was alignment around our new structure and combined the 2017-2019 initiatives with our Organizing for Growth initiatives to form one cohesive plan. Initiatives for the combined program included activities related to the optimization of our manufacturing plant network, the centralization of our corporate and platform functions, and the simplification and optimization of our operating business structure and functions that support them. From 2017 through December 31, 2019, we incurred approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$921 million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with manufacturing optimization, approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.2 billion</span></span><span style="font-family:Arial;font-size:8pt;"> associated with other activities, and have substantially completed this program.</span></div><div style="line-height:120%;padding-top:10px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Transforming to a More Focused Company</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">With the formation of the GSK Consumer Healthcare venture and the pending combination of Upjohn with Mylan, Pfizer is transforming itself into a more focused, global leader in science-based innovative medicines.&#160;As a result, we began in the fourth quarter of 2019, to identify and undertake efforts to ensure our cost base aligns appropriately with our Biopharmaceutical revenue base as a result of both the completed Consumer Healthcare and expected Upjohn transactions.&#160;While certain direct costs have transferred or will transfer to the Consumer Healthcare joint venture and to the Upjohn entities, there are indirect costs which are not expected to transfer. In addition, we are taking steps to restructure our organizations to appropriately support and drive the purpose of the three core functions of our focused innovative medicines business: R&amp;D, Manufacturing and Commercial.</span></div><div style="line-height:120%;padding-top:9px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">We expect the costs associated with this multi-year effort to continue through 2022 and to total approximately </span><span style="font-family:Arial;font-size:8pt;"><span>$1.4 billion</span></span><span style="font-family:Arial;font-size:8pt;"> on a pre-tax basis and approximately </span><span style="font-family:Arial;font-size:8pt;"><span>10%</span></span><span style="font-family:Arial;font-size:8pt;"> of this to be non-cash. Actions may include, among others, changes in location of certain activities, expanded use and co-location of centers of excellence and shared services, and increased use of digital technologies. The associated actions and the specific costs are currently in development but will include severance and benefit plan impacts, exit costs as well as associated implementation costs.</span></div><div style="line-height:120%;padding-top:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Current-Period Key Activities</span></div><div style="line-height:120%;padding-top:9px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">In </span><span style="font-family:Arial;font-size:8pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:8pt;">, we incurred costs of </span><span style="font-family:Arial;font-size:8pt;"><span>$967 million</span></span><span style="font-family:Arial;font-size:8pt;"> composed of </span><span style="font-family:Arial;font-size:8pt;"><span>$695 million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with 2017-2019 Initiatives and Organizing for Growth, </span><span style="font-family:Arial;font-size:8pt;"><span>$288 million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the integration of Array, </span><span style="font-family:Arial;font-size:8pt;"><span>$94 million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the integration of Hospira, and </span><span style="font-family:Arial;font-size:8pt;"><span>$87 million</span></span><span style="font-family:Arial;font-size:8pt;"> associated with the Transforming to a More Focused Company initiative, partially offset by income of </span><span style="font-family:Arial;font-size:8pt;"><span>$197 million</span></span><span style="font-family:Arial;font-size:8pt;">, primarily due to the reversal of certain accruals upon the effective favorable settlement of a U.S. IRS audit for multiple tax years and other acquisition-related initiatives.</span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:68%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of costs associated with acquisitions and cost-reduction/productivity initiatives:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31, </span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges/(credits):</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee terminations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>239</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(181</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset impairments</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>190</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exit costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>21</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:28px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Restructuring charges</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>30</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Transaction costs</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Integration costs and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>311</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>260</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>317</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:18px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Restructuring charges and certain acquisition-related costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>747</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,044</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>351</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net periodic benefit costs recorded in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>23</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>146</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>136</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:6px;text-indent:-6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Additional depreciation&#8211;&#8211;asset restructuring</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">&#160;</sup></span><span style="font-family:Arial;font-size:8pt;">recorded in our consolidated statements of income as follows</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>27</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>48</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total additional depreciation&#8211;&#8211;asset restructuring</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>50</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>91</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Implementation costs recorded in our consolidated statements of income as follows</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup></span><span style="font-family:Arial;font-size:8pt;">:</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>63</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>83</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>118</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>73</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>72</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>71</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:20px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>22</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>38</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;text-indent:24px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total implementation costs</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>158</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>194</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>227</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total costs associated with acquisitions and cost-reduction/productivity initiatives</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>967</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,434</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>805</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The asset impairment charges for </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> are largely associated with cost reduction initiatives not associated with acquisitions. The asset impairment charges for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are largely associated with our acquisitions of Hospira and Medivation. The asset impairment charges included in restructuring charges for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are primarily associated with abandoned assets. See (b) below for additional information.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2019, restructuring charges mainly represent employee termination costs associated with cost-reduction and productivity initiatives, partially offset by the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5B</span><span style="font-family:Arial;font-size:7pt;">). In 2018, restructuring charges were primarily related to employee termination costs and asset write downs. The employee termination costs for 2019 and 2018 were primarily associated with our improvements to operational effectiveness as part of the realignment of our organizational structure, and for 2019, also includes employee termination costs associated with the Transforming to a More Focused Company initiative. In </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">, restructuring charges were primarily associated with our acquisitions of Hospira and Medivation, partially offset by credits associated with cost-reduction and productivity initiatives not associated with acquisitions that mostly related to the reversal of previously recorded accruals for employee termination costs resulting from revisions of our severance benefit estimates. Employee termination costs are generally recorded when the actions are probable and estimable and include accrued severance benefits, pension and postretirement benefits, many of which may be paid out during periods after termination.</span></div></td></tr></table><div style="line-height:120%;padding-top:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biopharma (</span><span style="font-family:Arial;font-size:7pt;"><span>$118 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); Upjohn (</span><span style="font-family:Arial;font-size:7pt;"><span>$75 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$180 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge).</span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;text-align:left;padding-left:18px;text-indent:-6px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">At the beginning of fiscal 2019, we revised our operating segments and are unable to directly associate 2018 and 2017 restructuring charges with the new individual segments.</span></div><div style="line-height:120%;padding-bottom:1px;padding-left:12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities for </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="padding-bottom:1px;font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total reportable segments (</span><span style="font-family:Arial;font-size:7pt;"><span>$207 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$575 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge). </span></div></td></tr></table><div style="line-height:120%;padding-bottom:1px;padding-top:1px;padding-left:24px;text-indent:-12px;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The restructuring activities for </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;"> are associated with the following:</span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:18px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:12px;"><span style="font-family:Arial;font-size:7pt;">&#8226;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Total reportable segments (</span><span style="font-family:Arial;font-size:7pt;"><span>$89 million</span></span><span style="font-family:Arial;font-size:7pt;"> credit); and Other (</span><span style="font-family:Arial;font-size:7pt;"><span>$119 million</span></span><span style="font-family:Arial;font-size:7pt;"> charge).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Transaction costs represent external costs for banking, legal, accounting and other similar services. In 2019, transaction costs relate to our acquisition of Array. In 2017, transaction costs were directly related to our acquisitions of Hospira, Anacor and Medivation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Integration costs and other represent external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs. In </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2019</span><span style="font-family:Arial;font-size:7pt;">, integration costs and other mainly related to our acquisitions of Array (including </span><span style="font-family:Arial;font-size:7pt;"><span>$157 million</span></span><span style="font-family:Arial;font-size:7pt;"> in payments to Array employees for the fair value of previously unvested stock options that was recognized as post-closing compensation expense (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">)) and Hospira. In </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;">, integration costs and other mostly related to our acquisition of Hospira. In 2017, integration costs primarily related to our acquisitions of Hospira and Medivation, as well as a net gain of </span><span style="font-family:Arial;font-size:7pt;"><span>$12 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to the settlement of the Hospira U.S. qualified defined benefit pension plan (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">In 2018, primarily represents the net pension curtailments and settlements included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net </span><span style="font-family:Arial;font-size:7pt;">upon the adoption of a new accounting standard in the first quarter of 2018. In 2017, mainly represents the net pension curtailments and settlements, partially offset by net periodic benefit credits, excluding service costs, related to our acquisition of Hospira, both of which were reclassified to </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other (income)/deductions&#8211;&#8211;net</span><span style="font-family:Arial;font-size:7pt;"> as a result of the retrospective adoption of a new accounting standard in the first quarter of 2018. These credits included a net settlement gain, partially offset by accelerated amortization of actuarial losses and prior service costs upon the settlement of the remaining obligation associated with the Hospira U.S. qualified defined benefit pension plan. For additional information, see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 11</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Additional depreciation&#8211;&#8211;asset restructuring represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(g)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Implementation costs represent external, incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.</span></div></td></tr></table><div style="line-height:120%;text-align:left;padding-left:12px;text-indent:-12px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:52%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of and changes in our restructuring accruals:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Employee</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Termination</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Asset</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Impairment</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Charges</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Exit Costs</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrual</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, January 1, 2018 </span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,039</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>66</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,105</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Provision</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>459</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>290</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>782</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Utilization and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(295</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(290</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(51</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, December 31, 2018</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,203</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>49</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,252</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Provision</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>239</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>81</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>53</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>373</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Utilization and other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(555</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(81</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(55</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(691</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance, December 31, 2019</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>887</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>933</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes adjustments for foreign currency translation.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other current liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$823 million</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent liabilities</span><span style="font-family:Arial;font-size:7pt;"> (</span><span style="font-family:Arial;font-size:7pt;"><span>$428 million</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Includes the reversal of certain accruals related to our acquisition of Wyeth upon the effective favorable settlement of a U.S. IRS audit for multiple tax years. See </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 5D</span><span style="font-family:Arial;font-size:7pt;"> for additional information.</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Included in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other current liabilities </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;"><span>$714 million</span></span><span style="font-family:Arial;font-size:7pt;">) and </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Other noncurrent liabilities </span><span style="font-family:Arial;font-size:7pt;">(</span><span style="font-family:Arial;font-size:7pt;"><span>$219 million</span></span><span style="font-family:Arial;font-size:7pt;">).</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 420<br> -URI http://asc.fasb.org/topic&amp;trid=2175745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>221
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6952732944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Identifiable Intangible Assets and Goodwill (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Finite-Lived Intangible Assets</a></td>
<td class="text"><span style="font-family:Arial;font-size:8pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The increase in the gross carrying amount of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">I</span><span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets </span><span style="font-family:Arial;font-size:7pt;text-align:right;">mainly reflects the impact of the acquisition of Array, including the addition of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.8 billion</span></span><span style="font-family:Arial;font-size:7pt;text-align:right;"> of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$340 million</span></span><span style="font-family:Arial;font-size:7pt;"> of</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">finite-lived </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreements, </span><span style="font-family:Arial;font-size:7pt;"><span>$4.0 billion</span></span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">IPR&amp;D</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> of indefinite-lived </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreement</span><span style="font-family:Arial;font-size:7pt;">s</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">(see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">), partially offset by intangible asset impairment charges, primarily for Eucrisa in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:7pt;">. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </span><span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Reflects acquired licensing agreements for technology in development.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The increase in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">I</span><span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:7pt;text-align:right;">, </span><span style="font-family:Arial;font-size:7pt;">is mostly due to the additions noted in (a) above, partially offset by amortization and intangible asset impairment charges, primarily for Eucrisa in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:7pt;">. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </span><span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other, indefinite-lived</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock', window );">Schedule of Indefinite-Lived Intangible Assets</a></td>
<td class="text"><span style="font-family:Arial;font-size:8pt;"><br/></span><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The increase in the gross carrying amount of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">I</span><span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets </span><span style="font-family:Arial;font-size:7pt;text-align:right;">mainly reflects the impact of the acquisition of Array, including the addition of </span><span style="font-family:Arial;font-size:7pt;"><span>$1.8 billion</span></span><span style="font-family:Arial;font-size:7pt;text-align:right;"> of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights,</span><span style="font-family:Arial;font-size:7pt;"> </span><span style="font-family:Arial;font-size:7pt;"><span>$340 million</span></span><span style="font-family:Arial;font-size:7pt;"> of</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">finite-lived </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreements, </span><span style="font-family:Arial;font-size:7pt;"><span>$4.0 billion</span></span><span style="font-family:Arial;font-size:7pt;"> of </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">IPR&amp;D</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$1.1 billion</span></span><span style="font-family:Arial;font-size:7pt;"> of indefinite-lived </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Licensing agreement</span><span style="font-family:Arial;font-size:7pt;">s</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">(see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">), partially offset by intangible asset impairment charges, primarily for Eucrisa in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:7pt;">. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </span><span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Reflects acquired licensing agreements for technology in development.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">The increase in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">I</span><span style="font-family:Arial;font-size:7pt;font-style:italic;text-align:right;">dentifiable intangible assets, less accumulated amortization</span><span style="font-family:Arial;font-size:7pt;text-align:right;">, </span><span style="font-family:Arial;font-size:7pt;">is mostly due to the additions noted in (a) above, partially offset by amortization and intangible asset impairment charges, primarily for Eucrisa in </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Developed technology rights</span><span style="font-family:Arial;font-size:7pt;">. See</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 4 </span><span style="font-family:Arial;font-size:7pt;">for additional information on intangible asset impairments.</span></div></td></tr></table><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="10"/></tr><tr><td style="width:55%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="10" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Our identifiable intangible assets are associated with the following, as a percentage of total identifiable intangible assets, less accumulated amortization:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="8" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">December&#160;31, 2019</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">WRDM</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Developed technology rights</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Brands, indefinite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>42</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>58</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">IPR&amp;D</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>95</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>5</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other, finite-lived</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>98</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>1</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Licensing agreements and other, indefinite-lived</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>100</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;">%</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock', window );">Schedule of Expected Amortization Expense</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="21"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/></tr><tr><td colspan="21" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the annual amortization expense expected for the years 2020 through 2024:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2020</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2021</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2022</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2023</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2024</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:top;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Amortization expense</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,477</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,391</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,151</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,851</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,602</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfGoodwillTextBlock', window );">Schedule of Goodwill</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="17"/></tr><tr><td style="width:40%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="17" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the components of and changes in the carrying amount of </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Goodwill</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Biopharma</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Upjohn</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Consumer Healthcare</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, January 1, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>43,359</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,600</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,993</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>55,952</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(432</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(116</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(1,993</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,541</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>42,927</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>10,484</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>53,411</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Additions</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,411</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,411</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Other</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(136</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(169</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>48,202</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>10,451</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>&#8212;</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>58,653</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily reflects the reclassification of our Consumer Healthcare business as</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> </span><span style="font-family:Arial;font-size:7pt;">held for sale (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2C</span><span style="font-family:Arial;font-size:7pt;">), the impact of foreign exchange and the contribution of the allogeneic CAR T developmental program assets and operations to Allogene that constituted a business for accounting purposes (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2B</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Biopharma additions relate to our acquisition of Array (see </span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 2A</span><span style="font-family:Arial;font-size:7pt;">).</span></div></td></tr></table><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div><div style="line-height:120%;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily reflects the impact of foreign exchange.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance with a finite life, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfGoodwillTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of goodwill by reportable segment and in total which includes a rollforward schedule.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=108376223&amp;loc=d3e13854-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfGoodwillTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets, excluding financial assets and goodwill, lacking physical substance and exist in perpetuity, by either major class or business segment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b),(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfIndefiniteLivedIntangibleAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the amount of amortization expense expected to be recorded in succeeding fiscal years for finite-lived intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleofFiniteLivedIntangibleAssetsFutureAmortizationExpenseTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>222
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp6953032896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisitions, Divestitures, Equity-Method Investments and Assets and Liabilities Held for Sale, Licensing Arrangements and Research and Development and Collaborative Arrangements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract', window );"><strong>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock', window );">Summary of Assets and Liabilities Held For Sale</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:84%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:13%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The amounts associated with the Consumer Healthcare business, as well as other assets classified as held for sale consisted of the following:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">December 31, <br/>2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Assets Held for Sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cash and cash equivalents</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>32</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Trade accounts receivable, less allowance for doubtful accounts</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Inventories</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>538</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">PP&amp;E</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>675</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Identifiable intangible assets, less accumulated amortization</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,763</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Goodwill</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,972</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent deferred tax assets and other noncurrent tax assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>54</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>57</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Consumer Healthcare assets held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,678</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other assets held for sale</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>46</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Assets held for sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,725</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;text-decoration:underline;">Liabilities Held for Sale</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Trade accounts payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>406</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income taxes payable</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Accrued compensation and related items</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>93</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>353</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Pension benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>39</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Postretirement benefit obligations, net</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>33</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent deferred tax liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>870</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Other noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>56</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total Consumer Healthcare liabilities held for sale</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,890</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Other assets held for sale consist of PP&amp;E.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsTextBlock', window );">Summarized Financial Information of Equity Method Investments</a></td>
<td class="text"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="9"/></tr><tr><td style="width:74%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:10%;"/><td style="width:1%;"/></tr><tr><td colspan="9" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-bottom:13px;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Summarized financial information for our equity method investee, ViiV, as of December 31, 2019 and 2018 and for the years ending December 31, 2019, 2018, and 2017 is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">As of December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,839</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,381</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,437</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,664</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,276</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>7,045</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,904</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,725</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,860</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,636</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>8,765</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>9,361</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total net equity/(deficit) attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(1,489</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(2,316</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr></table></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:67%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>6,139</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>6,219</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,504</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(516</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(462</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(381</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,623</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,757</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>5,123</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,398</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,867</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,398</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,154</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,867</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>3,398</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,154</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>1,867</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td colspan="5" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Summarized financial information for our equity method investee, GSK Consumer Healthcare, as of and for the two months ending September 30, 2019, the most recent period available, is as follows:</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">September 30, <br/>2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>7,505</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>38,575</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total assets</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>46,081</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Current liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,241</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Noncurrent liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,536</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:6px;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total liabilities</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>10,776</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:5px;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity attributable to shareholders</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35,199</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Equity attributable to noncontrolling interests</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>105</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total net equity</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>35,304</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="5"/></tr><tr><td style="width:77%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:20%;"/><td style="width:1%;"/></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">For the Two Months Ending</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">September 30,</span></div><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net Sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>2,161</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Cost of sales</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(803</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Gross profit</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>1,358</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income from continuing operations</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Net income</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>152</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Income attributable to shareholders</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>148</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div><span style="font-family:Arial;font-size:8pt;"><br/></span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions</a></td>
<td class="text"><div style="line-height:120%;text-align:left;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="13"/></tr><tr><td style="width:70%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/></tr><tr><td colspan="13" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the amounts and classification of payments (income/(expense)) between us and our collaboration partners:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Year Ended December 31,</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">2019</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2018</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">2017</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenues</span><span style="font-family:Arial;font-size:8pt;">&#8212;Revenues</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>664</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>571</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>606</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Revenue</span><span style="font-family:Arial;font-size:8pt;">s&#8212;Alliance revenues</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>4,648</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,838</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>2,927</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">Total revenues from collaborative arrangements</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>5,313</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>4,409</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>3,533</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Cost of sales</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(351</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(296</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(329</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:3px double #000000;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Selling, informational and administrative expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>(173</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(90</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>(54</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Research and development expenses</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>99</span></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>162</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>222</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-style:italic;">Other income/(deductions)&#8212;net</span><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;font-weight:bold;"><span>362</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>281</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:8pt;"><span style="font-family:Arial;font-size:8pt;"><span>249</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents sales to our partners of products manufactured by us.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Substantially all relates to amounts earned from our partners under co-promotion agreements. The increases in each of the periods presented reflect increases in alliance revenues from Eliquis and Xtandi.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:7pt;padding-left:0px;"><span style="font-family:Arial;font-size:7pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(c)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:left;font-size:7pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to amounts paid to collaboration partners for their share of net sales or profits earned in collaboration arrangements where we are the principal in the transaction, and cost of sales associated with inventory purchased from our partners.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(d)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Represents net reimbursements to our partners for selling, informational and administrative expenses incurred.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(e)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to upfront payments and pre-approval milestone payments earned by our partners as well as net reimbursements. The upfront and milestone payments were as follows: </span><span style="font-family:Arial;font-size:7pt;"><span>$50 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$15 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. There were </span><span style="font-family:Arial;font-size:7pt;">no</span><span style="font-family:Arial;font-size:7pt;"> upfront and milestone payments in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">. Our collaboration with Lilly (see below) also includes reimbursements of </span><span style="font-family:Arial;font-size:7pt;"><span>$67 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$98 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$147 million</span></span><span style="font-family:Arial;font-size:7pt;"> in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">.</span></div></td></tr></table><div style="line-height:120%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(f)</sup>&#160;</span></div><div style="line-height:120%;text-align:justify;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Primarily relates to royalties from our collaboration partners. </span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business Combinations, Discontinued Operations And Disposal Groups, Collaborative Arrangements And Equity Method Investments [Abstract]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">pfe_BusinessCombinationsDiscontinuedOperationsAndDisposalGroupsCollaborativeArrangementsAndEquityMethodInvestmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>pfe_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of equity method investments including, but not limited to, name of each investee or group of investments, percentage ownership, difference between recorded amount of an investment and the value of the underlying equity in the net assets, and summarized financial information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=SL51724579-110230<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1474-107760<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5D<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721677-107760<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=109222160&amp;loc=SL51721533-107759<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721659-107760<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721665-107760<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=109226691&amp;loc=d3e2941-110230<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5C<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721675-107760<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=d3e1361-107760<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721671-107760<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 5B<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721673-107760<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4A<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721663-107760<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDisposalGroupsIncludingDiscontinuedOperationsIncomeStatementBalanceSheetAndAdditionalDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>223
<FILENAME>R127.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7037784352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Expected Future Cash Flow Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember', window );">Postretirement Benefits Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions in 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract', window );"><strong>Expected benefit payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">153<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">136<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2025-2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">642<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Voluntary contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="nump">$ 145<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions in 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">172<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract', window );"><strong>Expected benefit payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">355<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">358<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">364<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">366<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">375<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2025-2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Voluntary contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="nump">209<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions in 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,276<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract', window );"><strong>Expected benefit payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,048<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,046<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,028<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2025-2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Voluntary contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="nump">500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan [Member] | United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanDisclosureLineItems', window );"><strong>Defined Benefit Plan Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear', window );">Expected contributions in 2019</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract', window );"><strong>Expected benefit payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths', window );">2020</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo', window );">2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree', window );">2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour', window );">2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive', window );">2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">103<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter', window );">2025-2029</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Voluntary contribution</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 144<span></span>
</td>
<td class="nump">$ 129<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember', window );">Forecast [Member] | Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract', window );"><strong>Expected benefit payments:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanContributionsByEmployer', window );">Voluntary contribution</a></td>
<td class="nump">$ 1,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanContributionsByEmployer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contribution received by defined benefit plan from employer which increases plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(01)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2709-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanContributionsByEmployer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanEstimatedFutureEmployerContributionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in five fiscal years after fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsFiveFiscalYearsThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in fifth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in fourth fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in third fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of benefits for defined benefit plan expected to be paid in second fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureBenefitPaymentsYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of contributions expected to be received by defined benefit plan from employer in next fiscal year following latest fiscal year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanExpectedFutureEmployerContributionsNextFiscalYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_OtherPostretirementBenefitPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementScenarioAxis=srt_ScenarioForecastMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementScenarioAxis=srt_ScenarioForecastMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>224
<FILENAME>R123.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7041970672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Pension and Postretirement Benefit Plans and Defined Contribution Plans - Pension Plans in Excess of Plan Assets (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2019</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember', window );">Foreign Plan [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with an ABO in excess of plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">$ 5,843<span></span>
</td>
<td class="nump">$ 4,514<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">ABO</a></td>
<td class="nump">7,960<span></span>
</td>
<td class="nump">6,286<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with a PBO in excess of plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">5,947<span></span>
</td>
<td class="nump">5,432<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">PBO</a></td>
<td class="nump">8,503<span></span>
</td>
<td class="nump">7,571<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember', window );">Qualified Plan [Member] | United States [Member] | Pension Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with an ABO in excess of plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">14,586<span></span>
</td>
<td class="nump">13,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">ABO</a></td>
<td class="nump">16,535<span></span>
</td>
<td class="nump">15,141<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with a PBO in excess of plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets', window );">Fair value of plan assets</a></td>
<td class="nump">14,586<span></span>
</td>
<td class="nump">13,051<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">PBO</a></td>
<td class="nump">16,535<span></span>
</td>
<td class="nump">15,141<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember', window );">Nonqualified Plan [Member] | United States [Member] | U.S. Supplemental (Non-Qualified) Pension Plans [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with an ABO in excess of plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation', window );">ABO</a></td>
<td class="nump">1,351<span></span>
</td>
<td class="nump">1,280<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract', window );"><strong>Pension plans with a PBO in excess of plan assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation', window );">PBO</a></td>
<td class="nump">$ 1,351<span></span>
</td>
<td class="nump">$ 1,280<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of projected benefit obligation for defined benefit pension plan with projected benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlanWithProjectedBenefitObligationInExcessOfPlanAssetsProjectedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated benefit obligation for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateAccumulatedBenefitObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of plan asset for defined benefit plan with accumulated benefit obligation in excess of plan assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118257860&amp;loc=d3e4179-114921<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118255775&amp;loc=d3e2417-114920<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPensionPlansWithAccumulatedBenefitObligationsInExcessOfPlanAssetsAggregateFairValueOfPlanAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedBenefitPlanPlansWithBenefitObligationsInExcessOfPlanAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=us-gaap_ForeignPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_PensionPlansDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_QualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanSponsorLocationAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanSponsorLocationAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTaxStatusAxis=us-gaap_NonqualifiedPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetirementPlanTypeAxis=us-gaap_SupplementalEmployeeRetirementPlanDefinedBenefitMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>225
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.3.a.u2</span><table class="report" border="0" cellspacing="2" id="idp7008680272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accumulated Other Comprehensive Loss, Excluding Noncontrolling Interests (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2019</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Changes in Accumulated Other Comprehensive Loss, Net of Tax</a></td>
<td class="text"><div style="line-height:100%;text-align:left;padding-left:0px;text-indent:0px;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;border-collapse:collapse;text-align:left;"><tr><td colspan="25"/></tr><tr><td style="width:31%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:8%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:7%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:6%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:9%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:1%;"/><td style="width:12%;"/><td style="width:1%;"/></tr><tr><td colspan="25" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="font-size:8pt;"><span style="font-family:Arial;font-size:8pt;">The following table provides the changes, net of tax, in </span><span style="font-family:Arial;font-size:8pt;font-style:italic;">Accumulated other comprehensive loss</span><span style="font-family:Arial;font-size:8pt;">:</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="11" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Net Unrealized Gain/(Losses)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:center;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Benefit Plans</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">&#160;</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:6.5pt;"><span style="font-family:Arial;font-size:6.5pt;">(MILLIONS OF DOLLARS)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Foreign Currency Translation Adjustments </span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Derivative Financial Instruments</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Available-For-Sale Securities</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Actuarial Gains/(Losses)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Prior Service (Costs)/ Credits and Other</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Accumulated Other Comprehensive Income/(Loss)</span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, January 1, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,659</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>348</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(131</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,473</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>879</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">$</span></div></td><td style="vertical-align:bottom;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(11,036</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,479</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(378</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>532</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>211</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(129</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>1,715</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, December 31, 2017</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,180</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(30</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>401</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(5,262</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>750</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(9,321</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss) due to the adoption of new accounting standards</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(b)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(2</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(1</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(416</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(637</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>144</span></span></div></td><td style="vertical-align:bottom;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(913</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(893</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>198</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(53</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(128</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(166</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(1,041</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">Balance, December 31, 2018</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,075</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>167</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(68</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(6,027</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>728</span></span></div></td><td style="vertical-align:bottom;border-top:1px solid #000000;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;"><span>(11,275</span></span></div></td><td style="vertical-align:bottom;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;">)</span></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="padding-left:12px;text-indent:-12px;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">Other comprehensive income/(loss)</span><span style="font-family:Arial;font-size:7.5pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(a)</sup></span></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>123</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(146</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>33</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(231</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(144</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td colspan="2" style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(365</span></span></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr><tr><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">Balance, December 31, 2019</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(5,952</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;border-top:1px solid #000000;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>20</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(35</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(6,257</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>584</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;"><div style="text-align:left;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;"><br/></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><span style="font-family:inherit;font-size:10pt;">&#160;</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#dddddd;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">$</span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-top:2px;padding-bottom:2px;"><div style="text-align:right;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;"><span>(11,640</span></span></div></td><td style="vertical-align:bottom;border-bottom:3px double #000000;background-color:#dddddd;padding-right:2px;padding-top:2px;padding-bottom:2px;"><div style="text-align:left;font-size:7.5pt;"><span style="font-family:Arial;font-size:7.5pt;font-weight:bold;">)</span></div></td></tr></table></div></div><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(a)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts do not include foreign currency translation adjustments attributable to noncontrolling interests of </span><span style="font-family:Arial;font-size:7pt;"><span>$11 million</span></span><span style="font-family:Arial;font-size:7pt;"> loss in </span><span style="font-family:Arial;font-size:7pt;">2019</span><span style="font-family:Arial;font-size:7pt;">, </span><span style="font-family:Arial;font-size:7pt;"><span>$20 million</span></span><span style="font-family:Arial;font-size:7pt;"> loss in </span><span style="font-family:Arial;font-size:7pt;text-align:center;">2018</span><span style="font-family:Arial;font-size:7pt;"> and </span><span style="font-family:Arial;font-size:7pt;"><span>$14 million</span></span><span style="font-family:Arial;font-size:7pt;"> income in </span><span style="font-family:Arial;font-size:7pt;">2017</span><span style="font-family:Arial;font-size:7pt;">. Amounts in 2019 include after-tax gains of approximately </span><span style="font-family:Arial;font-size:7pt;"><span>$978 million</span></span><span style="font-family:Arial;font-size:7pt;"> related to foreign currency translation adjustments attributable to our equity method investment in GSK Consumer Healthcare (see</span><span style="font-family:Arial;font-size:7pt;font-style:italic;"> Note 2C</span><span style="font-family:Arial;font-size:7pt;">), partially offset by the strengthening of the U.S. dollar against the euro and the Australian dollar, and the results of our net investment hedging program.</span></div></td></tr></table><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman; font-size:10pt;"><tr><td style="width:12px;"/><td/></tr><tr><td style="vertical-align:top"><div style="line-height:100%;font-size:8pt;padding-left:0px;"><span style="font-family:Arial;font-size:8pt;"><sup style="vertical-align:top;line-height:120%;font-size:5pt">(b)</sup>&#160;</span></div></td><td style="vertical-align:top;"><div style="line-height:100%;text-align:left;font-size:8pt;"><span style="font-family:Arial;font-size:7pt;">Amounts represent the cumulative effect adjustments as of January 1, 2018 from the adoption of new accounting standards related to (i) financial assets and liabilities and (ii) the reclassification of certain tax effects from AOCI. For additional information, see Notes to Consolidated Financial Statements&#8211;&#8211;</span><span style="font-family:Arial;font-size:7pt;font-style:italic;">Note 1B. Basis of Presentation and Significant Accounting Policies: Adoption of New Accounting Standards in 2018 </span><span style="font-family:Arial;font-size:7pt;">in our 2018 Financial Report.</span></div></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=118930883&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
